The P07162146A0000 DT O
application P07162146A0000 NN O
of P07162146A0000 IN O
ultrafiltration P07162146A0000 NN O
to P07162146A0000 TO O
sample P07162146A0000 VB O
preparation P07162146A0000 NN O
in P07162146A0000 IN O
the P07162146A0000 DT O
detection P07162146A0000 NN O
and P07162146A0000 CC O
quantification P07162146A0000 NN O
of P07162146A0000 IN O
ethylene P07162146A0000 NN O
glycol P07162146A0000 NN O
in P07162146A0000 IN O
plasma P07162146A0000 NN O
by P07162146A0000 IN O
gas P07162146A0000 NN O
chromatography P07162146A0000 NN O
is P07162146A0000 VBZ O
described P07162146A0000 VBN O
. P07162146A0000 . O
. . O O

The P09933641A0241 DT O
missing P09933641A0241 VBG O
5 P09933641A0241 CD O
' P09933641A0241 '' O
sequences P09933641A0241 NNS O
were P09933641A0241 VBD O
obtained P09933641A0241 VBN O
by P09933641A0241 IN O
5'-rapid P09933641A0241 JJ O
amplification P09933641A0241 NN O
of P09933641A0241 IN O
cDNA P09933641A0241 NN O
ends P09933641A0241 NNS O
and P09933641A0241 CC O
by P09933641A0241 IN O
analysis P09933641A0241 NN O
of P09933641A0241 IN O
an P09933641A0241 DT O
NHE5 P09933641A0241 NNP I-UN
genomic P09933641A0241 JJ I-UN
clone P09933641A0241 NN I-UN
, P09933641A0241 , O
and P09933641A0241 CC O
the P09933641A0241 DT O
missing P09933641A0241 VBG O
3 P09933641A0241 CD O
' P09933641A0241 '' O
sequences P09933641A0241 NNS O
were P09933641A0241 VBD O
obtained P09933641A0241 VBN O
by P09933641A0241 IN O
3'-rapid P09933641A0241 JJ O
amplification P09933641A0241 NN O
of P09933641A0241 IN O
cDNA P09933641A0241 NN O
ends P09933641A0241 NNS O
. P09933641A0241 . O
. . O O

Cluster P08670853A0000 NNP O
formation P08670853A0000 NN O
of P08670853A0000 IN O
E-cadherin P08670853A0000 NNP I-UN
on P08670853A0000 IN O
the P08670853A0000 DT O
cell P08670853A0000 NN O
surface P08670853A0000 NN O
is P08670853A0000 VBZ O
believed P08670853A0000 VBN O
to P08670853A0000 TO O
be P08670853A0000 VB O
of P08670853A0000 IN O
major P08670853A0000 JJ O
importance P08670853A0000 NN O
for P08670853A0000 IN O
cell-cell P08670853A0000 JJ O
adhesion P08670853A0000 NN O
. P08670853A0000 . O
. . O O

Reye P02762198T0001 NNP O
's P02762198T0001 POS O
syndrome P02762198T0001 NN O
: P02762198T0001 : O
reports P02762198T0001 NNS O
of P02762198T0001 IN O
7 P02762198T0001 CD O
cases P02762198T0001 NNS O
in P02762198T0001 IN O
the P02762198T0001 DT O
period P02762198T0001 NN O
1982-1987 P02762198T0001 JJ O
. P02762198T0001 . O
. . O O

The P09228202A0581 DT O
selective P09228202A0581 JJ O
5-HT3 P09228202A0581 JJ I-UN
receptor P09228202A0581 NN I-UN
antagonists P09228202A0581 NNS O
ramosetron P09228202A0581 VBP O
( P09228202A0581 ( O
YM060 P09228202A0581 NNP O
) P09228202A0581 ) O
, P09228202A0581 , O
YM114 P09228202A0581 NNP O
( P09228202A0581 ( O
KAE-393 P09228202A0581 NNP O
) P09228202A0581 ) O
, P09228202A0581 , O
granisetron P09228202A0581 NN O
and P09228202A0581 CC O
ondansetron P09228202A0581 NN O
, P09228202A0581 , O
and P09228202A0581 CC O
the P09228202A0581 DT O
substituted P09228202A0581 VBN O
benzamides P09228202A0581 NNS O
( P09228202A0581 ( O
5-HT4 P09228202A0581 JJ I-UN
receptor P09228202A0581 NN I-UN
agonist P09228202A0581 NN O
/ P09228202A0581 IN O
5-HT3 P09228202A0581 JJ I-UN
receptor P09228202A0581 NN I-UN
antagonists P09228202A0581 NNS O
) P09228202A0581 ) O
cisapride P09228202A0581 VBP O
mosapride P09228202A0581 JJ O
and P09228202A0581 CC O
SC-53116 P09228202A0581 JJ O
dose-dependently P09228202A0581 RB O
enhanced P09228202A0581 JJ O
gastric P09228202A0581 JJ O
emptying P09228202A0581 VBG O
in P09228202A0581 IN O
normal P09228202A0581 JJ O
rats P09228202A0581 NNS O
. P09228202A0581 . O
. . O O

An P09804836A0000 DT O
approximately P09804836A0000 RB O
37-kDa P09804836A0000 JJ O
cytoplasmic P09804836A0000 JJ O
protein P09804836A0000 NN O
is P09804836A0000 VBZ O
rapidly P09804836A0000 RB O
tyrosine-phosphorylated P09804836A0000 JJ O
in P09804836A0000 IN O
the P09804836A0000 DT O
response P09804836A0000 NN O
of P09804836A0000 IN O
mouse P09804836A0000 NN O
BAC1.2F5 P09804836A0000 NNP O
macrophages P09804836A0000 VBZ O
to P09804836A0000 TO O
colony P09804836A0000 VB I-UN
stimulating P09804836A0000 VBG I-UN
factor-1 P09804836A0000 JJ I-UN
( P09804836A0000 ( O
CSF-1 P09804836A0000 NNP I-UN
) P09804836A0000 ) O
. P09804836A0000 . O
pp37 P09804836A0000 NN I-UN
was P09804836A0000 VBD O
purified P09804836A0000 VBN O
from P09804836A0000 IN O
the P09804836A0000 DT O
cytosolic P09804836A0000 JJ O
fraction P09804836A0000 NN O
by P09804836A0000 IN O
anti-Tyr P09804836A0000 JJ I-UN
( P09804836A0000 ( I-UN
P P09804836A0000 NNP I-UN
) P09804836A0000 ) I-UN
affinity P09804836A0000 NN O
chromatography P09804836A0000 NN O
, P09804836A0000 , O
size P09804836A0000 NN O
exclusion P09804836A0000 NN O
chromatography P09804836A0000 NN O
, P09804836A0000 , O
and P09804836A0000 CC O
C4 P09804836A0000 NNP O
reverse P09804836A0000 VB O
phase P09804836A0000 NN O
high P09804836A0000 JJ O
pressure P09804836A0000 NN O
liquid P09804836A0000 NN O
chromatography P09804836A0000 NN O
. P09804836A0000 . O
. . O O

The P10715325A0834 DT O
AtERF P10715325A0834 NNP I-UN
genes P10715325A0834 NNS I-UN
were P10715325A0834 VBD O
differentially P10715325A0834 RB O
regulated P10715325A0834 VBN O
by P10715325A0834 IN O
ethylene P10715325A0834 NN O
and P10715325A0834 CC O
by P10715325A0834 IN O
abiotic P10715325A0834 JJ O
stress P10715325A0834 NN O
conditions P10715325A0834 NNS O
, P10715325A0834 , O
such P10715325A0834 JJ O
as P10715325A0834 IN O
wounding P10715325A0834 NN O
, P10715325A0834 , O
cold P10715325A0834 NN O
, P10715325A0834 , O
high P10715325A0834 JJ O
salinity P10715325A0834 NN O
, P10715325A0834 , O
or P10715325A0834 CC O
drought P10715325A0834 NN O
, P10715325A0834 , O
via P10715325A0834 IN O
ETHYLENE-INSENSITIVE2 P10715325A0834 NNP I-UN
( P10715325A0834 ( O
EIN2 P10715325A0834 NNP I-UN
) P10715325A0834 ) O
-dependent P10715325A0834 NN O
or P10715325A0834 CC O
-independent P10715325A0834 NN O
pathways P10715325A0834 NNS O
. P10715325A0834 . O
. . O O

Control P09481826T0000 NN O
of P09481826T0000 IN O
fatty P09481826T0000 JJ O
liver P09481826T0000 JJ O
syndrome P09481826T0000 NN O
in P09481826T0000 IN O
a P09481826T0000 DT O
Jersey P09481826T0000 NNP O
herd P09481826T0000 NN O
by P09481826T0000 IN O
a P09481826T0000 DT O
change P09481826T0000 NN O
of P09481826T0000 IN O
diet P09481826T0000 NN O
and P09481826T0000 CC O
the P09481826T0000 DT O
use P09481826T0000 NN O
of P09481826T0000 IN O
recombinant P09481826T0000 JJ O
bovine P09481826T0000 NN O
somatotrophin P09481826T0000 NN I-UN
. P09481826T0000 . O
. . O O

The P09368097T0000 DT O
pen P09368097T0000 NN O
can P09368097T0000 MD O
heal P09368097T0000 VB O
. P09368097T0000 . O
. . O O

Triton-disrupted P08334304A0473 JJ O
cells P08334304A0473 NNS O
retained P08334304A0473 VBN O
capacity P08334304A0473 NN O
for P08334304A0473 IN O
activation P08334304A0473 NN O
of P08334304A0473 IN O
the P08334304A0473 DT O
pathway P08334304A0473 NN O
by P08334304A0473 IN O
both P08334304A0473 DT O
peptide P08334304A0473 JJ O
growth P08334304A0473 NN O
factors P08334304A0473 NNS O
and P08334304A0473 CC O
by P08334304A0473 IN O
addition P08334304A0473 NN O
of P08334304A0473 IN O
GTP-loaded P08334304A0473 NNP O
p21 P08334304A0473 NN I-UN
rasVal12 P08334304A0473 NN I-UN
. P08334304A0473 . O
. . O O

Dopamine P09763470A0000 NNP I-UN
beta-hydroxylase P09763470A0000 NN I-UN
( P09763470A0000 ( O
DBH P09763470A0000 NNP I-UN
) P09763470A0000 ) O
catalyzes P09763470A0000 VBZ O
the P09763470A0000 DT O
conversion P09763470A0000 NN O
of P09763470A0000 IN O
dopamine P09763470A0000 NN O
to P09763470A0000 TO O
noradrenaline P09763470A0000 VB O
and P09763470A0000 CC O
is P09763470A0000 VBZ O
selectively P09763470A0000 RB O
expressed P09763470A0000 VBN O
in P09763470A0000 IN O
noradrenergic P09763470A0000 NN O
and P09763470A0000 CC O
adrenergic P09763470A0000 JJ O
neurons P09763470A0000 NNS O
and P09763470A0000 CC O
neuroendocrine P09763470A0000 JJ O
cells P09763470A0000 NNS O
. P09763470A0000 . O
. . O O

Adverse P01774093T0000 JJ O
foetal P01774093T0000 JJ O
outcome P01774093T0000 NN O
in P01774093T0000 IN O
specific P01774093T0000 JJ O
IgM P01774093T0000 NNP I-UN
positive P01774093T0000 JJ O
Chlamydia P01774093T0000 NNP O
trachomatis P01774093T0000 NN O
infection P01774093T0000 NN O
in P01774093T0000 IN O
pregnancy P01774093T0000 NN O
. P01774093T0000 . O
. . O O

Patients P10585311A0494 NNS O
with P10585311A0494 IN O
types P10585311A0494 NNS O
I P10585311A0494 PRP O
and P10585311A0494 CC O
III P10585311A0494 NNP O
MPGN P10585311A0494 NNP O
did P10585311A0494 VBD O
not P10585311A0494 RB O
differ P10585311A0494 VB O
in P10585311A0494 IN O
age P10585311A0494 NN O
at P10585311A0494 IN O
apparent P10585311A0494 JJ O
onset P10585311A0494 NN O
, P10585311A0494 , O
age P10585311A0494 NN O
at P10585311A0494 IN O
diagnosis P10585311A0494 NN O
, P10585311A0494 , O
or P10585311A0494 CC O
interval P10585311A0494 NN O
from P10585311A0494 IN O
apparent P10585311A0494 JJ O
onset P10585311A0494 NN O
of P10585311A0494 IN O
symptoms P10585311A0494 NNS O
to P10585311A0494 TO O
diagnosis P10585311A0494 VB O
( P10585311A0494 ( O
biopsy P10585311A0494 NN O
) P10585311A0494 ) O
. P10585311A0494 . O
. . O O

Furthermore P10521447A1190 RB O
, P10521447A1190 , O
overexpression P10521447A1190 NN O
of P10521447A1190 IN O
AML3 P10521447A1190 NNP I-UN
/ P10521447A1190 NNP O
CBFalpha1 P10521447A1190 NNP I-UN
could P10521447A1190 MD O
rescue P10521447A1190 VB O
the P10521447A1190 DT O
AML1-ETO P10521447A1190 JJ O
repression P10521447A1190 NN O
. P10521447A1190 . O
. . O O

One P09671576A0900 CD O
is P09671576A0900 VBZ O
to P09671576A0900 TO O
act P09671576A0900 VB O
within P09671576A0900 IN O
the P09671576A0900 DT O
visceral P09671576A0900 JJ O
endoderm P09671576A0900 NN O
to P09671576A0900 TO O
promote P09671576A0900 VB O
proper P09671576A0900 JJ O
streak P09671576A0900 JJ O
morphogenesis P09671576A0900 NN O
. P09671576A0900 . O
. . O O

Although P09931435A0357 IN O
both P09931435A0357 DT O
transcripts P09931435A0357 NNS O
share P09931435A0357 NN O
the P09931435A0357 DT O
first P09931435A0357 JJ O
nine P09931435A0357 CD O
exons P09931435A0357 NNS O
, P09931435A0357 , O
exon P09931435A0357 VBP O
10 P09931435A0357 CD O
of P09931435A0357 IN O
ZIS-2 P09931435A0357 NNP I-UN
is P09931435A0357 VBZ O
lacking P09931435A0357 VBG O
in P09931435A0357 IN O
ZIS-1 P09931435A0357 NNP I-UN
, P09931435A0357 , O
and P09931435A0357 CC O
instead P09931435A0357 RB O
, P09931435A0357 , O
exon P09931435A0357 VBZ O
11 P09931435A0357 CD O
( P09931435A0357 ( O
10th P09931435A0357 CD O
exon P09931435A0357 NN O
) P09931435A0357 ) O
of P09931435A0357 IN O
ZIS-1 P09931435A0357 NNP I-UN
is P09931435A0357 VBZ O
larger P09931435A0357 JJR O
in P09931435A0357 IN O
size P09931435A0357 NN O
, P09931435A0357 , O
leading P09931435A0357 VBG O
to P09931435A0357 TO O
the P09931435A0357 DT O
longer P09931435A0357 JJR O
3'-UTR P09931435A0357 JJ O
. P09931435A0357 . O
. . O O

Methoxyflurane P05837169T0001 NNP O
and P05837169T0001 CC O
renal P05837169T0001 JJ O
function P05837169T0001 NN O
. P05837169T0001 . O
. . O O

The P07592647A0797 DT O
single-stranded P07592647A0797 JJ O
DNA P07592647A0797 NNP O
Pur P07592647A0797 NNP I-UN
alpha P07592647A0797 POS I-UN
recognition P07592647A0797 NN I-UN
element P07592647A0797 NN I-UN
disrupts P07592647A0797 VBZ O
these P07592647A0797 DT O
complexes P07592647A0797 NNS O
. P07592647A0797 . O
. . O O

No P01675763A1389 DT O
such P01675763A1389 JJ O
benefits P01675763A1389 NNS O
were P01675763A1389 VBD O
seen P01675763A1389 VBN O
for P01675763A1389 IN O
children P01675763A1389 NNS O
with P01675763A1389 IN O
CD4+ P01675763A1389 NNP I-UN
counts P01675763A1389 NNS O
below P01675763A1389 IN O
0.2 P01675763A1389 CD O
x P01675763A1389 NNS O
10 P01675763A1389 CD O
( P01675763A1389 ( O
9 P01675763A1389 CD O
) P01675763A1389 ) O
per P01675763A1389 IN O
liter P01675763A1389 NN O
at P01675763A1389 IN O
entry P01675763A1389 NN O
. P01675763A1389 . O
. . O O

For P03563399A0534 IN O
signal P03563399A0534 JJ O
durations P03563399A0534 NNS O
less P03563399A0534 JJR O
than P03563399A0534 IN O
10 P03563399A0534 CD O
ms P03563399A0534 NN O
, P03563399A0534 , O
however P03563399A0534 RB O
, P03563399A0534 , O
the P03563399A0534 DT O
SoNo P03563399A0534 NNP O
and P03563399A0534 CC O
S P03563399A0534 NNP O
pi P03563399A0534 VBP O
No P03563399A0534 NNP O
threshold P03563399A0534 JJ O
functions P03563399A0534 NNS O
converged P03563399A0534 VBD O
and P03563399A0534 CC O
the P03563399A0534 DT O
masking-level P03563399A0534 JJ O
difference P03563399A0534 NN O
decreased P03563399A0534 VBN O
. P03563399A0534 . O
. . O O

Here P09443978A0262 RB O
we P09443978A0262 PRP O
report P09443978A0262 VBP O
that P09443978A0262 IN O
in P09443978A0262 IN O
cultured P09443978A0262 JJ O
cells P09443978A0262 NNS O
from P09443978A0262 IN O
Drosophila P09443978A0262 NNP O
melanogaster P09443978A0262 NN O
human P09443978A0262 JJ I-UN
Sp1 P09443978A0262 NNP I-UN
efficiently P09443978A0262 RB O
activates P09443978A0262 VBZ O
transcription P09443978A0262 NN O
from P09443978A0262 IN O
synthetic P09443978A0262 JJ O
promoters P09443978A0262 NNS O
containing P09443978A0262 VBG O
TATA P09443978A0262 NNP O
boxes P09443978A0262 NNS O
, P09443978A0262 , O
but P09443978A0262 CC O
not P09443978A0262 RB O
from P09443978A0262 IN O
promoters P09443978A0262 NNS O
that P09443978A0262 WDT O
contain P09443978A0262 VBP O
an P09443978A0262 DT O
initiator P09443978A0262 NN O
instead P09443978A0262 RB O
of P09443978A0262 IN O
a P09443978A0262 DT O
TATA P09443978A0262 NNP O
box P09443978A0262 NN O
. P09443978A0262 . O
. . O O

Myogenic P01315706A0000 JJ O
differentiation P01315706A0000 NN O
can P01315706A0000 MD O
be P01315706A0000 VB O
inhibited P01315706A0000 VBN O
by P01315706A0000 IN O
the P01315706A0000 DT O
adenovirus P01315706A0000 NN O
E1a P01315706A0000 NNP I-UN
protein P01315706A0000 NN I-UN
in P01315706A0000 IN O
the P01315706A0000 DT O
rat P01315706A0000 NN O
L6 P01315706A0000 NNP O
muscle P01315706A0000 NN O
cell P01315706A0000 NN O
line P01315706A0000 NN O
. P01315706A0000 . O
. . O O

However P11226228A0899 RB O
, P11226228A0899 , O
plasmids P11226228A0899 NNS O
carrying P11226228A0899 VBG O
the P11226228A0899 DT O
yeast P11226228A0899 NN I-UN
TyrRS P11226228A0899 NNP I-UN
gene P11226228A0899 NN I-UN
could P11226228A0899 MD O
not P11226228A0899 RB O
be P11226228A0899 VB O
stably P11226228A0899 RB O
maintained P11226228A0899 VBN O
in P11226228A0899 IN O
E. P11226228A0899 NNP O
coli P11226228A0899 NNS O
. P11226228A0899 . O
. . O O

The P10393251A0283 DT O
PAC P10393251A0283 NNP O
clone P10393251A0283 NN O
with P10393251A0283 IN O
an P10393251A0283 DT O
insert P10393251A0283 JJ O
size P10393251A0283 NN O
of P10393251A0283 IN O
120kb P10393251A0283 CD O
was P10393251A0283 VBD O
isolated P10393251A0283 VBN O
and P10393251A0283 CC O
mapped P10393251A0283 VBN O
by P10393251A0283 IN O
restriction P10393251A0283 NN O
analysis P10393251A0283 NN O
. P10393251A0283 . O
. . O O

The P06791500A0622 DT O
evaluation P06791500A0622 NN O
of P06791500A0622 IN O
amniotic P06791500A0622 JJ O
fluid P06791500A0622 NN O
delta P06791500A0622 NN O
OD450 P06791500A0622 NNP O
is P06791500A0622 VBZ O
considered P06791500A0622 VBN O
to P06791500A0622 TO O
be P06791500A0622 VB O
the P06791500A0622 DT O
cornerstone P06791500A0622 NN O
of P06791500A0622 IN O
clinical P06791500A0622 JJ O
management P06791500A0622 NN O
. P06791500A0622 . O
. . O O

Experience P06217859T0000 NN O
with P06217859T0000 IN O
the P06217859T0000 DT O
tensor P06217859T0000 NN O
fasciae P06217859T0000 NN O
latae P06217859T0000 VBD O
free P06217859T0000 JJ O
flap P06217859T0000 NN O
. P06217859T0000 . O
. . O O

Fifty-six P11736792A0204 JJ O
semen P11736792A0204 NNS O
samples P11736792A0204 NNS O
were P11736792A0204 VBD O
included P11736792A0204 VBN O
in P11736792A0204 IN O
this P11736792A0204 DT O
study P11736792A0204 NN O
; P11736792A0204 : O
18 P11736792A0204 CD O
were P11736792A0204 VBD O
subnormal P11736792A0204 JJ O
( P11736792A0204 ( O
G1 P11736792A0204 NNP O
) P11736792A0204 ) O
and P11736792A0204 CC O
38 P11736792A0204 CD O
were P11736792A0204 VBD O
normal P11736792A0204 JJ O
( P11736792A0204 ( O
G2 P11736792A0204 NNP O
) P11736792A0204 ) O
based P11736792A0204 VBN O
on P11736792A0204 IN O
World P11736792A0204 NNP O
Health P11736792A0204 NNP O
Organization P11736792A0204 NNP O
criteria P11736792A0204 NNS O
, P11736792A0204 , O
except P11736792A0204 IN O
for P11736792A0204 IN O
morphology P11736792A0204 NN O
, P11736792A0204 , O
which P11736792A0204 WDT O
was P11736792A0204 VBD O
evaluated P11736792A0204 VBN O
according P11736792A0204 VBG O
to P11736792A0204 TO O
strict P11736792A0204 JJ O
criteria P11736792A0204 NNS O
. P11736792A0204 . O
. . O O

The P01408137A0974 DT O
sequence P01408137A0974 NN O
of P01408137A0974 IN O
this P01408137A0974 DT O
region P01408137A0974 NN O
shows P01408137A0974 VBZ O
high P01408137A0974 JJ O
G+C P01408137A0974 NNP O
content P01408137A0974 NN O
( P01408137A0974 ( O
62 P01408137A0974 CD O
% P01408137A0974 NN O
) P01408137A0974 ) O
, P01408137A0974 , O
which P01408137A0974 WDT O
is P01408137A0974 VBZ O
particularly P01408137A0974 RB O
emphasized P01408137A0974 VBN O
in P01408137A0974 IN O
the P01408137A0974 DT O
200 P01408137A0974 CD O
bp P01408137A0974 NN O
upstream P01408137A0974 NN O
from P01408137A0974 IN O
the P01408137A0974 DT O
mRNA P01408137A0974 JJ O
start P01408137A0974 NN O
( P01408137A0974 ( O
80 P01408137A0974 CD O
% P01408137A0974 NN O
G+C P01408137A0974 NNP O
) P01408137A0974 ) O
. P01408137A0974 . O
. . O O

Insulin P10329736A1106 NNP I-UN
stimulation P10329736A1106 NN O
promoted P10329736A1106 VBD O
the P10329736A1106 DT O
association P10329736A1106 NN O
of P10329736A1106 IN O
mIRS3 P10329736A1106 NN I-UN
with P10329736A1106 IN O
p85 P10329736A1106 NN I-UN
, P10329736A1106 , O
SHP2 P10329736A1106 NNP I-UN
, P10329736A1106 , O
Nck P10329736A1106 NNP I-UN
, P10329736A1106 , O
and P10329736A1106 CC O
Shc P10329736A1106 NNP I-UN
. P10329736A1106 . O
. . O O

A P11255252A0961 DT O
minimal P11255252A0961 JJ O
ER3 P11255252A0961 NNP O
sequence P11255252A0961 NN O
of P11255252A0961 IN O
DNA P11255252A0961 NNP O
was P11255252A0961 VBD O
further P11255252A0961 RB O
demonstrated P11255252A0961 VBN O
to P11255252A0961 TO O
function P11255252A0961 VB O
as P11255252A0961 IN O
a P11255252A0961 DT O
FXR P11255252A0961 NNP I-UN
HRE P11255252A0961 NNP I-UN
and P11255252A0961 CC O
was P11255252A0961 VBD O
bound P11255252A0961 VBN O
in P11255252A0961 IN O
vitro P11255252A0961 NN O
by P11255252A0961 IN O
FXR-expressing P11255252A0961 NNP O
yeast P11255252A0961 NN O
extracts P11255252A0961 NNS O
. P11255252A0961 . O
. . O O

Far-infrared P10002245T0000 JJ O
hopping P10002245T0000 VBG O
conductivity P10002245T0000 NN O
in P10002245T0000 IN O
the P10002245T0000 DT O
CuO P10002245T0000 NNP O
chains P10002245T0000 NNS O
of P10002245T0000 IN O
a P10002245T0000 DT O
single-domain P10002245T0000 JJ O
YBa2Cu3O7- P10002245T0000 JJ O
delta P10002245T0000 NN O
crystal P10002245T0000 NN O
. P10002245T0000 . O
. . O O

A P11313249T0000 DT O
novel P11313249T0000 JJ O
myeloid-restricted P11313249T0000 JJ O
zebrafish P11313249T0000 NN O
CCAAT P11313249T0000 NNP I-UN
/ P11313249T0000 NNP I-UN
enhancer-binding P11313249T0000 JJ I-UN
protein P11313249T0000 NN I-UN
with P11313249T0000 IN O
a P11313249T0000 DT O
potent P11313249T0000 JJ O
transcriptional P11313249T0000 JJ O
activation P11313249T0000 NN O
domain P11313249T0000 NN O
. P11313249T0000 . O
. . O O

In P10959838A0153 IN O
invertebrates P10959838A0153 NNS O
, P10959838A0153 , O
Fhit P10959838A0153 NNP I-UN
is P10959838A0153 VBZ O
encoded P10959838A0153 VBN O
as P10959838A0153 IN O
a P10959838A0153 DT O
fusion P10959838A0153 NN O
protein P10959838A0153 NN O
with P10959838A0153 IN O
Nit P10959838A0153 NNP I-UN
, P10959838A0153 , O
a P10959838A0153 DT O
member P10959838A0153 NN O
of P10959838A0153 IN O
the P10959838A0153 DT O
nitrilase P10959838A0153 JJ I-UN
superfamily P10959838A0153 RB I-UN
. P10959838A0153 . O
. . O O

These P01603088A1121 DT O
results P01603088A1121 NNS O
indicate P01603088A1121 VBP O
that P01603088A1121 IN O
baculovirus-expressed P01603088A1121 JJ O
TR P01603088A1121 NNP I-UN
mediates P01603088A1121 VBZ O
transcriptional P01603088A1121 JJ O
activation P01603088A1121 NN O
and P01603088A1121 CC O
repression P01603088A1121 NN O
in P01603088A1121 IN O
a P01603088A1121 DT O
promoter-specific P01603088A1121 JJ O
manner P01603088A1121 NN O
in P01603088A1121 IN O
vitro P01603088A1121 NN O
. P01603088A1121 . O
. . O O

Nitrogen P06782869A0263 NNP O
balance P06782869A0263 NN O
was P06782869A0263 VBD O
compared P06782869A0263 VBN O
, P06782869A0263 , O
and P06782869A0263 CC O
metabolic P06782869A0263 JJ O
complications P06782869A0263 NNS O
were P06782869A0263 VBD O
monitored P06782869A0263 VBN O
by P06782869A0263 IN O
evaluating P06782869A0263 VBG O
BUN P06782869A0263 NNP O
, P06782869A0263 , O
serum P06782869A0263 NN O
creatinine P06782869A0263 NN O
, P06782869A0263 , O
creatinine P06782869A0263 JJ O
clearance P06782869A0263 NN O
, P06782869A0263 , O
serum P06782869A0263 NN O
CO2 P06782869A0263 NNP O
, P06782869A0263 , O
SGOT P06782869A0263 NNP I-UN
, P06782869A0263 , O
SGPT P06782869A0263 NNP I-UN
, P06782869A0263 , O
serum P06782869A0263 NN I-UN
LDH P06782869A0263 NNP I-UN
, P06782869A0263 , O
and P06782869A0263 CC O
serum P06782869A0263 JJ I-UN
alkaline P06782869A0263 NN I-UN
phosphatase P06782869A0263 NN I-UN
. P06782869A0263 . O
. . O O

Analysis P10446910A0147 NN O
of P10446910A0147 IN O
the P10446910A0147 DT O
E2F1 P10446910A0147 NNP I-UN
gene P10446910A0147 NN I-UN
promoter P10446910A0147 NN I-UN
showed P10446910A0147 VBD O
that P10446910A0147 IN O
the P10446910A0147 DT O
-146 P10446910A0147 NN O
to P10446910A0147 TO O
-54 P10446910A0147 VB O
region P10446910A0147 NN O
was P10446910A0147 VBD O
required P10446910A0147 VBN O
for P10446910A0147 IN O
E2-responsiveness P10446910A0147 NNP O
in P10446910A0147 IN O
transient P10446910A0147 JJ O
transfection P10446910A0147 NN O
assays P10446910A0147 NNS O
, P10446910A0147 , O
and P10446910A0147 CC O
subsequent P10446910A0147 JJ O
deletion P10446910A0147 NN O
/ P10446910A0147 NNP O
mutation P10446910A0147 NN O
analysis P10446910A0147 NN O
showed P10446910A0147 VBD O
that P10446910A0147 IN O
a P10446910A0147 DT O
single P10446910A0147 JJ O
upstream P10446910A0147 JJ O
GC-rich P10446910A0147 NNP O
and P10446910A0147 CC O
two P10446910A0147 CD O
downstream P10446910A0147 NN O
CCAAT-binding P10446910A0147 NN O
sites P10446910A0147 NNS O
were P10446910A0147 VBD O
required P10446910A0147 VBN O
for P10446910A0147 IN O
transactivation P10446910A0147 NN O
by P10446910A0147 IN O
E2 P10446910A0147 NNP I-UN
. P10446910A0147 . O
. . O O

Below P03964489A1195 IN O
50 P03964489A1195 CD O
% P03964489A1195 NN O
decrease P03964489A1195 NN O
of P03964489A1195 IN O
PaO2 P03964489A1195 NNP O
, P03964489A1195 , O
NADH P03964489A1195 NNP O
was P03964489A1195 VBD O
reduced P03964489A1195 VBN O
largely P03964489A1195 RB O
. P03964489A1195 . O
. . O O

Ectopic P10073940A0335 NNP O
expression P10073940A0335 NN O
of P10073940A0335 IN O
d-axin P10073940A0335 NN I-UN
inhibited P10073940A0335 JJ O
Wingless P10073940A0335 NNP I-UN
signaling P10073940A0335 NN O
. P10073940A0335 . O
. . O O

Chronic P02843694T0001 JJ O
E-B P02843694T0001 NNP O
virus P02843694T0001 NN O
infection P02843694T0001 NN O
terminated P02843694T0001 VBN O
in P02843694T0001 IN O
malignant P02843694T0001 JJ O
lymphoma P02843694T0001 NN O
: P02843694T0001 : O
a P02843694T0001 DT O
case P02843694T0001 NN O
report P02843694T0001 NN O
. P02843694T0001 . O
. . O O

Expression P02330041A0335 NN O
, P02330041A0335 , O
cellular P02330041A0335 JJ O
localization P02330041A0335 NN O
and P02330041A0335 CC O
in P02330041A0335 IN O
vitro P02330041A0335 JJ O
transcription P02330041A0335 NN O
studies P02330041A0335 NNS O
establish P02330041A0335 VB O
that P02330041A0335 DT O
cloned P02330041A0335 VBD I-UN
hUBF P02330041A0335 NN I-UN
encodes P02330041A0335 VBZ O
a P02330041A0335 DT O
nucleolar P02330041A0335 JJ O
factor P02330041A0335 NN O
that P02330041A0335 WDT O
binds P02330041A0335 VBZ O
specifically P02330041A0335 RB O
to P02330041A0335 TO O
the P02330041A0335 DT O
upstream P02330041A0335 JJ O
control P02330041A0335 NN O
element P02330041A0335 NN O
and P02330041A0335 CC O
core P02330041A0335 NN O
of P02330041A0335 IN O
the P02330041A0335 DT O
rRNA P02330041A0335 NN O
gene P02330041A0335 NN O
promoter P02330041A0335 NN O
to P02330041A0335 TO O
activate P02330041A0335 VB O
transcription P02330041A0335 NN O
in P02330041A0335 IN O
a P02330041A0335 DT O
binding P02330041A0335 JJ O
site-dependent P02330041A0335 JJ O
manner P02330041A0335 NN O
. P02330041A0335 . O
. . O O

Solution P10218109T0000 NN O
structure P10218109T0000 NN O
and P10218109T0000 CC O
mechanism P10218109T0000 NN O
of P10218109T0000 IN O
the P10218109T0000 DT O
MutT P10218109T0000 NNP I-UN
pyrophosphohydrolase P10218109T0000 NN I-UN
. P10218109T0000 . O
. . O O

The P08148756A0358 DT O
degree P08148756A0358 NN O
of P08148756A0358 IN O
lung P08148756A0358 NN O
destruction P08148756A0358 NN O
, P08148756A0358 , O
reflected P08148756A0358 VBN O
by P08148756A0358 IN O
interstitial P08148756A0358 JJ O
hemorrhage P08148756A0358 NN O
was P08148756A0358 VBD O
assessed P08148756A0358 VBN O
by P08148756A0358 IN O
measuring P08148756A0358 VBG O
hemoglobin P08148756A0358 NN I-UN
content P08148756A0358 NN O
in P08148756A0358 IN O
the P08148756A0358 DT O
fluid P08148756A0358 NN O
of P08148756A0358 IN O
the P08148756A0358 DT O
lavaged P08148756A0358 JJ O
lungs P08148756A0358 NNS O
. P08148756A0358 . O
. . O O

Autonomic P03466730A0210 JJ O
dysfunctions P03466730A0210 NNS O
were P03466730A0210 VBD O
restricted P03466730A0210 VBN O
to P03466730A0210 TO O
tonic P03466730A0210 VB O
pupils P03466730A0210 NNS O
. P03466730A0210 . O
. . O O

Williams P00337102T0058 NNP O
, P00337102T0058 , O
2 P00337102T0058 CD O
August P00337102T0058 NNP O
1977 P00337102T0058 CD O
. P00337102T0058 . O
. . O O

The P08987225A0675 DT O
most P08987225A0675 RBS O
common P08987225A0675 JJ O
risk P08987225A0675 NN O
factor P08987225A0675 NN O
reported P08987225A0675 VBD O
for P08987225A0675 IN O
both P08987225A0675 DT O
recent P08987225A0675 JJ O
and P08987225A0675 CC O
all P08987225A0675 DT O
other P08987225A0675 JJ O
hepatitis P08987225A0675 NN O
C P08987225A0675 NNP O
cases P08987225A0675 NNS O
was P08987225A0675 VBD O
a P08987225A0675 DT O
history P08987225A0675 NN O
of P08987225A0675 IN O
injecting P08987225A0675 VBG O
drug P08987225A0675 NN O
use P08987225A0675 NN O
, P08987225A0675 , O
although P08987225A0675 IN O
the P08987225A0675 DT O
proportion P08987225A0675 NN O
of P08987225A0675 IN O
cases P08987225A0675 NNS O
with P08987225A0675 IN O
that P08987225A0675 DT O
history P08987225A0675 NN O
was P08987225A0675 VBD O
different P08987225A0675 JJ O
in P08987225A0675 IN O
NT P08987225A0675 NNP O
from P08987225A0675 IN O
ACT P08987225A0675 NNP O
and P08987225A0675 CC O
Queensland P08987225A0675 NNP O
. P08987225A0675 . O
. . O O

L-735,524 P07667195A0146 JJ O
free P07667195A0146 JJ O
base P07667195A0146 NN O
or P07667195A0146 CC O
sulfate P07667195A0146 NN O
salt P07667195A0146 NN O
was P07667195A0146 VBD O
administered P07667195A0146 VBN O
orally P07667195A0146 RB O
as P07667195A0146 IN O
suspension P07667195A0146 NN O
, P07667195A0146 , O
solution P07667195A0146 NN O
or P07667195A0146 CC O
in P07667195A0146 IN O
solid P07667195A0146 JJ O
dosage P07667195A0146 NN O
forms P07667195A0146 NNS O
to P07667195A0146 TO O
fasted P07667195A0146 VB O
or P07667195A0146 CC O
fed P07667195A0146 VB O
Beagle P07667195A0146 NNP O
dogs P07667195A0146 NNS O
. P07667195A0146 . O
. . O O

The P02027839A0250 DT O
muscles P02027839A0250 NNS O
from P02027839A0250 IN O
the P02027839A0250 DT O
ischemic P02027839A0250 JJ O
group P02027839A0250 NN O
had P02027839A0250 VBD O
significantly P02027839A0250 RB O
lower P02027839A0250 JJR O
( P02027839A0250 ( O
P P02027839A0250 NNP O
less P02027839A0250 JJR O
than P02027839A0250 IN O
.05 P02027839A0250 NN O
) P02027839A0250 ) O
values P02027839A0250 NNS O
for P02027839A0250 IN O
capillary P02027839A0250 JJ O
density P02027839A0250 NN O
and P02027839A0250 CC O
capillary P02027839A0250 JJ O
to P02027839A0250 TO O
fiber P02027839A0250 VB O
ratio P02027839A0250 NN O
and P02027839A0250 CC O
significantly P02027839A0250 RB O
higher P02027839A0250 JJR O
intercapillary P02027839A0250 JJ O
distance P02027839A0250 NN O
than P02027839A0250 IN O
those P02027839A0250 DT O
from P02027839A0250 IN O
the P02027839A0250 DT O
normal P02027839A0250 JJ O
group P02027839A0250 NN O
. P02027839A0250 . O
. . O O

The P10076007A0656 DT O
MSY2 P10076007A0656 NNP I-UN
associated P10076007A0656 JJ O
kinase P10076007A0656 NN O
is P10076007A0656 VBZ O
not P10076007A0656 RB O
casein P10076007A0656 JJ I-UN
kinase P10076007A0656 NN I-UN
2 P10076007A0656 CD I-UN
, P10076007A0656 , O
the P10076007A0656 DT O
kinase P10076007A0656 NN O
believed P10076007A0656 VBD O
to P10076007A0656 TO O
phosphorylate P10076007A0656 VB O
mRNP3+4 P10076007A0656 NN I-UN
in P10076007A0656 IN O
oocytes P10076007A0656 NNS O
, P10076007A0656 , O
but P10076007A0656 CC O
a P10076007A0656 DT O
yet P10076007A0656 RB O
unidentified P10076007A0656 JJ O
kinase P10076007A0656 NN O
. P10076007A0656 . O
. . O O

A P04263748T0042 DT O
medical-geographical P04263748T0042 JJ O
review P04263748T0042 NN O
. P04263748T0042 . O
. . O O

Replacement P02863747T0000 NN I-UN
variant P02863747T0000 NN I-UN
histone P02863747T0000 NN I-UN
genes P02863747T0000 NNS I-UN
contain P02863747T0000 VBP O
intervening P02863747T0000 JJ O
sequences P02863747T0000 NNS O
. P02863747T0000 . O
. . O O

For P10860196A0876 IN O
an P10860196A0876 DT O
unsupervised P10860196A0876 JJ O
program P10860196A0876 NN O
, P10860196A0876 , O
the P10860196A0876 DT O
costs P10860196A0876 NNS O
were P10860196A0876 VBD O
estimated P10860196A0876 VBN O
at P10860196A0876 IN O
$ P10860196A0876 $ O
311 P10860196A0876 CD O
for P10860196A0876 IN O
the P10860196A0876 DT O
first P10860196A0876 JJ O
year P10860196A0876 NN O
and P10860196A0876 CC O
$ P10860196A0876 $ O
73 P10860196A0876 CD O
for P10860196A0876 IN O
all P10860196A0876 DT O
additional P10860196A0876 JJ O
years P10860196A0876 NNS O
. P10860196A0876 . O
. . O O

Fourteen P09152656A0149 JJ O
patients P09152656A0149 NNS O
with P09152656A0149 IN O
New P09152656A0149 NNP O
York P09152656A0149 NNP O
Heart P09152656A0149 NNP O
Association P09152656A0149 NNP O
class P09152656A0149 NN O
II P09152656A0149 NNP O
congestive P09152656A0149 JJ O
heart P09152656A0149 NN O
failure P09152656A0149 NN O
were P09152656A0149 VBD O
enrolled P09152656A0149 VBN O
in P09152656A0149 IN O
a P09152656A0149 DT O
double-blind P09152656A0149 JJ O
, P09152656A0149 , O
cross-over P09152656A0149 JJ O
study P09152656A0149 NN O
. P09152656A0149 . O
. . O O

In P11368901A0327 IN O
contrast P11368901A0327 NN O
the P11368901A0327 DT O
human P11368901A0327 JJ O
and P11368901A0327 CC O
mouse P11368901A0327 NN I-UN
BCNT P11368901A0327 NNP I-UN
proteins P11368901A0327 VBZ I-UN
contain P11368901A0327 VB O
one P11368901A0327 CD O
repeat P11368901A0327 NN O
unit P11368901A0327 NN O
and P11368901A0327 CC O
lack P11368901A0327 VB O
the P11368901A0327 DT O
RTE-1-derived P11368901A0327 JJ O
portion P11368901A0327 NN O
. P11368901A0327 . O
. . O O

Induction P10347197A0502 NN O
of P10347197A0502 IN O
the P10347197A0502 DT O
urokinase P10347197A0502 JJ I-UN
promoter P10347197A0502 NN I-UN
by P10347197A0502 IN O
HGF P10347197A0502 NNP I-UN
/ P10347197A0502 NNP O
SF P10347197A0502 NNP I-UN
via P10347197A0502 IN O
the P10347197A0502 DT O
Met P10347197A0502 NNP I-UN
receptor P10347197A0502 NN I-UN
was P10347197A0502 VBD O
blocked P10347197A0502 VBN O
by P10347197A0502 IN O
co-expression P10347197A0502 NN O
of P10347197A0502 IN O
a P10347197A0502 DT O
dominant-negative P10347197A0502 JJ O
Grb2 P10347197A0502 NNP I-UN
and P10347197A0502 CC O
Sos1 P10347197A0502 NNP I-UN
expression P10347197A0502 NN O
construct P10347197A0502 NN O
. P10347197A0502 . O
. . O O

Finally P10855796A1160 RB O
, P10855796A1160 , O
in P10855796A1160 IN O
situ P10855796A1160 JJ O
RNA P10855796A1160 NNP O
hybridization P10855796A1160 NN O
studies P10855796A1160 NNS O
revealed P10855796A1160 VBD O
a P10855796A1160 DT O
very P10855796A1160 RB O
specific P10855796A1160 JJ O
pattern P10855796A1160 NN O
of P10855796A1160 IN O
EphA8 P10855796A1160 NNP I-UN
gene P10855796A1160 NN I-UN
expression P10855796A1160 NN O
restricted P10855796A1160 VBN O
to P10855796A1160 TO O
the P10855796A1160 DT O
rostral P10855796A1160 JJ O
region P10855796A1160 NN O
of P10855796A1160 IN O
midbrain P10855796A1160 NN O
tectum P10855796A1160 NN O
during P10855796A1160 IN O
embryonic P10855796A1160 JJ O
development P10855796A1160 NN O
. P10855796A1160 . O
. . O O

The P11870646A0668 DT O
utility P11870646A0668 NN O
of P11870646A0668 IN O
such P11870646A0668 JJ O
analyses P11870646A0668 NNS O
in P11870646A0668 IN O
the P11870646A0668 DT O
design P11870646A0668 NN O
of P11870646A0668 IN O
ceramic P11870646A0668 JJ O
/ P11870646A0668 NN O
substrate P11870646A0668 NN O
bilayer P11870646A0668 NN O
systems P11870646A0668 NNS O
for P11870646A0668 IN O
optimal P11870646A0668 JJ O
resistance P11870646A0668 NN O
to P11870646A0668 TO O
lifetime-threatening P11870646A0668 JJ O
damage P11870646A0668 NN O
is P11870646A0668 VBZ O
discussed P11870646A0668 VBN O
. P11870646A0668 . O
. . O O

Research P03441587A0000 NN O
was P03441587A0000 VBD O
carried P03441587A0000 VBN O
out P03441587A0000 RP O
on P03441587A0000 IN O
the P03441587A0000 DT O
rheumatoid P03441587A0000 JJ I-UN
factors P03441587A0000 NNS I-UN
in P03441587A0000 IN O
the P03441587A0000 DT O
serum P03441587A0000 NN O
of P03441587A0000 IN O
917 P03441587A0000 CD O
patients P03441587A0000 NNS O
by P03441587A0000 IN O
means P03441587A0000 NNS O
of P03441587A0000 IN O
two P03441587A0000 CD O
tests P03441587A0000 NNS O
( P03441587A0000 ( O
one P03441587A0000 CD O
using P03441587A0000 VBG O
polystyrene P03441587A0000 NN O
and P03441587A0000 CC O
one P03441587A0000 CD O
with P03441587A0000 IN O
erythrocytes P03441587A0000 NNS O
) P03441587A0000 ) O
and P03441587A0000 CC O
the P03441587A0000 DT O
results P03441587A0000 NNS O
obtained P03441587A0000 VBD O
were P03441587A0000 VBD O
compared P03441587A0000 VBN O
using P03441587A0000 VBG O
a P03441587A0000 DT O
method P03441587A0000 NN O
of P03441587A0000 IN O
reference P03441587A0000 NN O
. P03441587A0000 . O
. . O O

This P09488713A0886 DT O
resulted P09488713A0886 VBD O
in P09488713A0886 IN O
a P09488713A0886 DT O
complete P09488713A0886 JJ O
inhibition P09488713A0886 NN O
of P09488713A0886 IN O
Site-1 P09488713A0886 NNP O
cleavage P09488713A0886 NN O
that P09488713A0886 WDT O
was P09488713A0886 VBD O
restored P09488713A0886 VBN O
by P09488713A0886 IN O
concomitant P09488713A0886 JJ O
overexpression P09488713A0886 NN O
of P09488713A0886 IN O
full-length P09488713A0886 JJ O
SCAP P09488713A0886 NNP I-UN
. P09488713A0886 . O
. . O O

The P07647570A0713 DT O
most P07647570A0713 RBS O
likely P07647570A0713 JJ O
explanation P07647570A0713 NN O
for P07647570A0713 IN O
this P07647570A0713 DT O
is P07647570A0713 VBZ O
that P07647570A0713 IN O
gold P07647570A0713 NN O
principally P07647570A0713 RB O
accumulates P07647570A0713 VBZ O
in P07647570A0713 IN O
the P07647570A0713 DT O
Kupffer P07647570A0713 NNP O
cells P07647570A0713 NNS O
and P07647570A0713 CC O
renal P07647570A0713 JJ O
cortex P07647570A0713 NN O
and P07647570A0713 CC O
these P07647570A0713 DT O
cells P07647570A0713 NNS O
do P07647570A0713 VBP O
not P07647570A0713 RB O
express P07647570A0713 VB O
Type P07647570A0713 NNP I-UN
I P07647570A0713 PRP I-UN
deiodinase P07647570A0713 VBP I-UN
. P07647570A0713 . O
. . O O

Breast-fed P10231862A1117 NNP O
newborn P10231862A1117 JJ O
infants P10231862A1117 NNS O
synthesize P10231862A1117 VB O
n-6 P10231862A1117 JJ O
long-chain P10231862A1117 NN O
polyunsaturated P10231862A1117 VBD O
fatty P10231862A1117 JJ O
acids P10231862A1117 NNS O
already P10231862A1117 RB O
during P10231862A1117 IN O
the P10231862A1117 DT O
first P10231862A1117 JJ O
week P10231862A1117 NN O
of P10231862A1117 IN O
life P10231862A1117 NN O
, P10231862A1117 , O
but P10231862A1117 CC O
the P10231862A1117 DT O
contribution P10231862A1117 NN O
of P10231862A1117 IN O
endogenous P10231862A1117 JJ O
synthesis P10231862A1117 NN O
to P10231862A1117 TO O
the P10231862A1117 DT O
total P10231862A1117 JJ O
plasma P10231862A1117 JJ O
long-chain P10231862A1117 NN O
polyunsaturated P10231862A1117 JJ O
pool P10231862A1117 NN O
is P10231862A1117 VBZ O
small P10231862A1117 JJ O
. P10231862A1117 . O
. . O O

Nuclear P09914500A0000 JJ I-UN
factor P09914500A0000 NN I-UN
kappa P09914500A0000 NN I-UN
B P09914500A0000 NNP I-UN
( P09914500A0000 ( O
NF-kappaB P09914500A0000 NNP I-UN
) P09914500A0000 ) O
is P09914500A0000 VBZ O
an P09914500A0000 DT O
important P09914500A0000 JJ O
transcription P09914500A0000 NN O
factor P09914500A0000 NN O
for P09914500A0000 IN O
the P09914500A0000 DT O
genes P09914500A0000 NNS O
of P09914500A0000 IN O
many P09914500A0000 JJ O
pro-inflammatory P09914500A0000 JJ O
proteins P09914500A0000 NNS O
and P09914500A0000 CC O
is P09914500A0000 VBZ O
strongly P09914500A0000 RB O
activated P09914500A0000 VBN O
by P09914500A0000 IN O
the P09914500A0000 DT O
cytokines P09914500A0000 NNS O
interleukin-1 P09914500A0000 JJ I-UN
and P09914500A0000 CC O
tumor P09914500A0000 JJ I-UN
necrosis P09914500A0000 NN I-UN
factor P09914500A0000 NN I-UN
( P09914500A0000 ( I-UN
TNF P09914500A0000 NNP I-UN
) P09914500A0000 ) I-UN
alpha P09914500A0000 NN I-UN
under P09914500A0000 IN O
various P09914500A0000 JJ O
pathological P09914500A0000 JJ O
conditions P09914500A0000 NNS O
. P09914500A0000 . O
. . O O

The P07498791A0680 DT O
second P07498791A0680 JJ O
mutation P07498791A0680 NN O
present P07498791A0680 NN O
in P07498791A0680 IN O
the P07498791A0680 DT O
original P07498791A0680 JJ O
mutant P07498791A0680 NN O
proved P07498791A0680 VBD O
to P07498791A0680 TO O
be P07498791A0680 VB O
an P07498791A0680 DT O
allele P07498791A0680 NN O
of P07498791A0680 IN O
a P07498791A0680 DT O
known P07498791A0680 VBN O
gene P07498791A0680 NN O
, P07498791A0680 , O
PBS2 P07498791A0680 NNP I-UN
, P07498791A0680 , O
which P07498791A0680 WDT O
encodes P07498791A0680 VBZ O
a P07498791A0680 DT O
putative P07498791A0680 JJ O
protein P07498791A0680 NN O
kinase P07498791A0680 NN O
that P07498791A0680 WDT O
functions P07498791A0680 NNS O
in P07498791A0680 IN O
the P07498791A0680 DT O
high P07498791A0680 JJ O
osmolarity P07498791A0680 NN O
stress P07498791A0680 NN O
pathway P07498791A0680 NN O
. P07498791A0680 . O
. . O O

The P06321770A1353 DT O
expression P06321770A1353 NN O
of P06321770A1353 IN O
chloramphenicol P06321770A1353 NN I-UN
acetyltransferase P06321770A1353 NN I-UN
was P06321770A1353 VBD O
detected P06321770A1353 VBN O
within P06321770A1353 IN O
1 P06321770A1353 CD O
h P06321770A1353 NN O
after P06321770A1353 IN O
infection P06321770A1353 NN O
of P06321770A1353 IN O
cells P06321770A1353 NNS O
with P06321770A1353 IN O
recombinant P06321770A1353 JJ O
virus P06321770A1353 NN O
, P06321770A1353 , O
reflecting P06321770A1353 VBG O
the P06321770A1353 DT O
early P06321770A1353 JJ O
nature P06321770A1353 NN O
of P06321770A1353 IN O
the P06321770A1353 DT O
promoters P06321770A1353 NNS O
used P06321770A1353 VBN O
. P06321770A1353 . O
. . O O

The P02830214A0000 DT O
effect P02830214A0000 NN O
of P02830214A0000 IN O
acetazolamide P02830214A0000 NN O
( P02830214A0000 ( O
ACZ P02830214A0000 NNP O
) P02830214A0000 ) O
on P02830214A0000 IN O
HCO3- P02830214A0000 NNP O
and P02830214A0000 CC O
Cl- P02830214A0000 NNP O
activities P02830214A0000 NNS O
in P02830214A0000 IN O
inner P02830214A0000 JJ O
ear P02830214A0000 JJ O
fluid P02830214A0000 NN O
was P02830214A0000 VBD O
investigated P02830214A0000 VBN O
by P02830214A0000 IN O
ion-selective P02830214A0000 JJ O
microelectrode P02830214A0000 NN O
methods P02830214A0000 NNS O
. P02830214A0000 . O
. . O O

The P08668124A0744 DT O
Dox-A2 P08668124A0744 NNP I-UN
ORF P08668124A0744 NNP I-UN
driven P08668124A0744 VBN O
by P08668124A0744 IN O
the P08668124A0744 DT O
TDH3 P08668124A0744 NNP I-UN
promoter P08668124A0744 NN I-UN
complemented P08668124A0744 VBD O
the P08668124A0744 DT O
phenotype P08668124A0744 NN O
of P08668124A0744 IN O
a P08668124A0744 DT O
strain P08668124A0744 NN O
deleted P08668124A0744 VBN O
for P08668124A0744 IN O
sun2 P08668124A0744 NN I-UN
. P08668124A0744 . O
. . O O

A P01128985A0000 DT O
clinically P01128985A0000 RB O
useful P01128985A0000 JJ O
diagnostic P01128985A0000 JJ O
method P01128985A0000 NN O
has P01128985A0000 VBZ O
been P01128985A0000 VBN O
developed P01128985A0000 VBN O
for P01128985A0000 IN O
detecting P01128985A0000 VBG O
and P01128985A0000 CC O
quantitating P01128985A0000 VBG O
periods P01128985A0000 NNS O
of P01128985A0000 IN O
apnea P01128985A0000 NN O
in P01128985A0000 IN O
pediatric P01128985A0000 JJ O
patients P01128985A0000 NNS O
. P01128985A0000 . O
. . O O

We P07890599A0132 PRP O
have P07890599A0132 VBP O
screened P07890599A0132 VBN O
the P07890599A0132 DT O
mouse P07890599A0132 NN O
cDNA P07890599A0132 NN O
library P07890599A0132 NN O
of P07890599A0132 IN O
an P07890599A0132 DT O
MIN6 P07890599A0132 NNP O
cell P07890599A0132 NN O
line P07890599A0132 NN O
, P07890599A0132 , O
derived P07890599A0132 VBD O
from P07890599A0132 IN O
pancreatic P07890599A0132 JJ O
beta P07890599A0132 NN O
cells P07890599A0132 NNS O
, P07890599A0132 , O
for P07890599A0132 IN O
its P07890599A0132 PRP$ O
novel P07890599A0132 JJ O
isoform P07890599A0132 NN O
and P07890599A0132 CC O
have P07890599A0132 VBP O
identified P07890599A0132 VBN O
a P07890599A0132 DT O
cDNA P07890599A0132 NN O
encoding P07890599A0132 VBG O
a P07890599A0132 DT O
593-amino P07890599A0132 JJ O
acid P07890599A0132 NN O
protein P07890599A0132 NN O
having P07890599A0132 VBG O
63 P07890599A0132 CD O
, P07890599A0132 , O
53 P07890599A0132 CD O
, P07890599A0132 , O
and P07890599A0132 CC O
30 P07890599A0132 CD O
% P07890599A0132 NN O
identity P07890599A0132 NN O
with P07890599A0132 IN O
munc-18 P07890599A0132 JJ I-UN
/ P07890599A0132 JJ I-UN
n-Sec1 P07890599A0132 JJ I-UN
/ P07890599A0132 NN I-UN
rbSec1 P07890599A0132 NN I-UN
, P07890599A0132 , O
Caenorhabditis P07890599A0132 NNP I-UN
elegans P07890599A0132 VBZ I-UN
unc18 P07890599A0132 JJ I-UN
, P07890599A0132 , O
and P07890599A0132 CC O
Saccharomyces P07890599A0132 NNP I-UN
cerevisiae P07890599A0132 NN I-UN
Sec1p P07890599A0132 NNP I-UN
, P07890599A0132 , O
respectively P07890599A0132 RB O
. P07890599A0132 . O
. . O O

( P10454568A0815 ( O
i P10454568A0815 NN O
) P10454568A0815 ) O
Complete P10454568A0815 NNP O
Grb10 P10454568A0815 NNP I-UN
expression P10454568A0815 NN O
from P10454568A0815 IN O
cDNA P10454568A0815 NN O
with P10454568A0815 IN O
an P10454568A0815 DT O
ecdysone-regulated P10454568A0815 JJ O
transient P10454568A0815 NN O
expression P10454568A0815 NN O
system P10454568A0815 NN O
stimulated P10454568A0815 VBD O
PDGF-BB- P10454568A0815 NNP O
, P10454568A0815 , O
IGF-I P10454568A0815 NNP I-UN
, P10454568A0815 , O
and P10454568A0815 CC O
insulin- P10454568A0815 NNS O
but P10454568A0815 CC O
not P10454568A0815 RB O
epidermal P10454568A0815 JJ I-UN
growth P10454568A0815 NN I-UN
factor P10454568A0815 NN I-UN
( P10454568A0815 ( O
EGF P10454568A0815 NNP I-UN
) P10454568A0815 ) O
-induced P10454568A0815 VBD O
DNA P10454568A0815 NNP O
synthesis P10454568A0815 NN O
in P10454568A0815 IN O
an P10454568A0815 DT O
ecdysone P10454568A0815 NN O
dose-responsive P10454568A0815 JJ O
fashion P10454568A0815 NN O
. P10454568A0815 . O
. . O O

Since P10788320A1034 IN O
proteins P10788320A1034 NNS O
containing P10788320A1034 VBG O
TPR P10788320A1034 NNP O
elements P10788320A1034 NNS O
are P10788320A1034 VBP O
typically P10788320A1034 RB O
involved P10788320A1034 VBN O
in P10788320A1034 IN O
multiple P10788320A1034 JJ O
protein-protein P10788320A1034 JJ O
interactions P10788320A1034 NNS O
, P10788320A1034 , O
we P10788320A1034 PRP O
suggest P10788320A1034 VBP O
that P10788320A1034 IN O
the P10788320A1034 DT O
102kD P10788320A1034 CD O
protein P10788320A1034 NN O
interacts P10788320A1034 NNS O
within P10788320A1034 IN O
the P10788320A1034 DT O
tri-snRNP P10788320A1034 NN O
with P10788320A1034 IN O
both P10788320A1034 DT O
the P10788320A1034 DT O
U5 P10788320A1034 NNP I-UN
and P10788320A1034 CC O
U4 P10788320A1034 NNP I-UN
/ P10788320A1034 NNP O
U6 P10788320A1034 NNP I-UN
snRNPs P10788320A1034 NN O
, P10788320A1034 , O
thus P10788320A1034 RB O
bridging P10788320A1034 VBG O
the P10788320A1034 DT O
two P10788320A1034 CD O
particles P10788320A1034 NNS O
. P10788320A1034 . O
. . O O

IgM P10773951A0000 NNP I-UN
and P10773951A0000 CC O
IgG P10773951A0000 NNP I-UN
anti P10773951A0000 VBP I-UN
A P10773951A0000 NNP I-UN
and P10773951A0000 CC O
anti P10773951A0000 NN I-UN
B P10773951A0000 NNP I-UN
antibody P10773951A0000 NN I-UN
status P10773951A0000 NN O
of P10773951A0000 IN O
100 P10773951A0000 CD O
antenatal P10773951A0000 JJ O
O P10773951A0000 NNP O
group P10773951A0000 NN O
mothers P10773951A0000 NNS O
( P10773951A0000 ( O
who P10773951A0000 WP O
had P10773951A0000 VBD O
non P10773951A0000 CC O
O P10773951A0000 NNP O
group P10773951A0000 NN O
husbands P10773951A0000 NNS O
) P10773951A0000 ) O
were P10773951A0000 VBD O
studied P10773951A0000 VBN O
. P10773951A0000 . O
. . O O

Regression P08299896A0880 NNP O
line P08299896A0880 NN O
slopes P08299896A0880 NNS O
of P08299896A0880 IN O
IBDQ P08299896A0880 NNP O
scores P08299896A0880 NNS O
were P08299896A0880 VBD O
significantly P08299896A0880 RB O
different P08299896A0880 JJ O
in P08299896A0880 IN O
patients P08299896A0880 NNS O
who P08299896A0880 WP O
deteriorated P08299896A0880 VBD O
from P08299896A0880 IN O
those P08299896A0880 DT O
who P08299896A0880 WP O
remained P08299896A0880 VBD O
stable P08299896A0880 JJ O
( P08299896A0880 ( O
[ P08299896A0880 JJ O
b P08299896A0880 NN O
] P08299896A0880 NNP O
< P08299896A0880 NNP O
0.15 P08299896A0880 CD O
; P08299896A0880 : O
P P08299896A0880 NNP O
< P08299896A0880 NNP O
0.0001 P08299896A0880 CD O
) P08299896A0880 ) O
. P08299896A0880 . O
. . O O

Venkatesan P01690703A0285 NNP O
, P01690703A0285 , O
and P01690703A0285 CC O
D P01690703A0285 NNP O
. P01690703A0285 . O
. . O O

After P11204897A0797 IN O
allowing P11204897A0797 VBG O
time P11204897A0797 NN O
for P11204897A0797 IN O
absorption P11204897A0797 NN O
, P11204897A0797 , O
participants P11204897A0797 NNS O
completed P11204897A0797 VBD O
a P11204897A0797 DT O
bridge P11204897A0797 NN O
simulator P11204897A0797 NN O
task P11204897A0797 NN O
. P11204897A0797 . O
. . O O

Among P02510242A0313 IN O
100 P02510242A0313 CD O
cases P02510242A0313 NNS O
of P02510242A0313 IN O
post-transfusion P02510242A0313 NN O
hepatitis P02510242A0313 NN O
, P02510242A0313 , O
10 P02510242A0313 CD O
are P02510242A0313 VBP O
due P02510242A0313 JJ O
to P02510242A0313 TO O
the P02510242A0313 DT O
hepatitis P02510242A0313 NN O
B P02510242A0313 NNP O
virus P02510242A0313 NN O
( P02510242A0313 ( O
despite P02510242A0313 IN O
systematic P02510242A0313 JJ O
search P02510242A0313 NN O
for P02510242A0313 IN O
HBs P02510242A0313 NNP I-UN
Ag P02510242A0313 NNP I-UN
) P02510242A0313 ) O
, P02510242A0313 , O
89 P02510242A0313 CD O
are P02510242A0313 VBP O
due P02510242A0313 JJ O
to P02510242A0313 TO O
one P02510242A0313 CD O
of P02510242A0313 IN O
the P02510242A0313 DT O
non-A P02510242A0313 JJ O
non-B P02510242A0313 JJ O
viruses P02510242A0313 NNS O
( P02510242A0313 ( O
not P02510242A0313 RB O
detectable P02510242A0313 JJ O
by P02510242A0313 IN O
specific P02510242A0313 JJ O
serological P02510242A0313 JJ O
tests P02510242A0313 NNS O
) P02510242A0313 ) O
and P02510242A0313 CC O
1 P02510242A0313 CD O
to P02510242A0313 TO O
several P02510242A0313 JJ O
viruses P02510242A0313 NNS O
, P02510242A0313 , O
specially P02510242A0313 RB O
CMV P02510242A0313 NNP O
. P02510242A0313 . O
. . O O

Our P11074003A0741 PRP$ O
results P11074003A0741 NNS O
indicate P11074003A0741 VBP O
that P11074003A0741 IN O
Shh P11074003A0741 NNP I-UN
can P11074003A0741 MD O
drive P11074003A0741 VB O
continued P11074003A0741 JJ O
cycling P11074003A0741 NN O
in P11074003A0741 IN O
immature P11074003A0741 NN O
, P11074003A0741 , O
proliferating P11074003A0741 VBG O
CGNPs P11074003A0741 NNP O
. P11074003A0741 . O
. . O O

Two P09519757A0482 CD O
rare P09519757A0482 JJ O
novel P09519757A0482 JJ O
mutations P09519757A0482 NNS O
, P09519757A0482 , O
D811N P09519757A0482 NNP O
in P09519757A0482 IN O
exon P09519757A0482 CC O
20 P09519757A0482 CD O
and P09519757A0482 CC O
R835C P09519757A0482 NNP O
in P09519757A0482 IN O
exon P09519757A0482 JJ O
21 P09519757A0482 CD O
, P09519757A0482 , O
were P09519757A0482 VBD O
identified P09519757A0482 VBN O
in P09519757A0482 IN O
the P09519757A0482 DT O
first P09519757A0482 JJ O
nucleotide-binding P09519757A0482 JJ O
fold P09519757A0482 NN O
( P09519757A0482 ( O
NBF P09519757A0482 NNP O
) P09519757A0482 ) O
, P09519757A0482 , O
a P09519757A0482 DT O
functionally P09519757A0482 RB O
important P09519757A0482 JJ O
region P09519757A0482 NN O
of P09519757A0482 IN O
SUR1 P09519757A0482 NNP I-UN
, P09519757A0482 , O
in P09519757A0482 IN O
one P09519757A0482 CD O
patient P09519757A0482 NN O
each P09519757A0482 DT O
, P09519757A0482 , O
both P09519757A0482 DT O
heterozygotes P09519757A0482 NNS O
. P09519757A0482 . O
. . O O

The P11376119A0346 DT O
first P11376119A0346 JJ O
exon P11376119A0346 NN O
( P11376119A0346 ( O
exon P11376119A0346 JJ O
1A P11376119A0346 CD O
) P11376119A0346 ) O
that P11376119A0346 WDT O
corresponded P11376119A0346 VBD O
to P11376119A0346 TO O
the P11376119A0346 DT O
5'-untranslated P11376119A0346 JJ O
region P11376119A0346 NN O
of P11376119A0346 IN O
the P11376119A0346 DT O
GHR P11376119A0346 NNP I-UN
1A P11376119A0346 CD I-UN
mRNA P11376119A0346 NN I-UN
was P11376119A0346 VBD O
15,250 P11376119A0346 CD O
bp P11376119A0346 JJ O
upstream P11376119A0346 NN O
from P11376119A0346 IN O
exon P11376119A0346 JJ O
2 P11376119A0346 CD O
in P11376119A0346 IN O
the P11376119A0346 DT O
GHR P11376119A0346 NNP I-UN
gene P11376119A0346 NN I-UN
. P11376119A0346 . O
. . O O

Probable P01546522A0000 JJ O
progressive P01546522A0000 JJ O
multifocal P01546522A0000 JJ O
leukoencephalopathy P01546522A0000 NN O
( P01546522A0000 ( O
PML P01546522A0000 NNP O
) P01546522A0000 ) O
was P01546522A0000 VBD O
diagnosed P01546522A0000 VBN O
on P01546522A0000 IN O
the P01546522A0000 DT O
basis P01546522A0000 NN O
of P01546522A0000 IN O
clinical P01546522A0000 JJ O
picture P01546522A0000 NN O
and P01546522A0000 CC O
magnetic P01546522A0000 JJ O
resonance P01546522A0000 NN O
imaging P01546522A0000 NN O
in P01546522A0000 IN O
a P01546522A0000 DT O
63-year-old P01546522A0000 JJ O
man P01546522A0000 NN O
with P01546522A0000 IN O
a P01546522A0000 DT O
complete P01546522A0000 JJ O
remission P01546522A0000 NN O
of P01546522A0000 IN O
a P01546522A0000 DT O
non-Hodgkin P01546522A0000 JJ O
's P01546522A0000 POS O
lymphoma P01546522A0000 NN O
. P01546522A0000 . O
. . O O

Expression P07629150A0155 NN O
of P07629150A0155 IN O
the P07629150A0155 DT O
CYP11A1 P07629150A0155 NNP I-UN
gene P07629150A0155 NN I-UN
is P07629150A0155 VBZ O
increased P07629150A0155 VBN O
by P07629150A0155 IN O
hormones P07629150A0155 NNS O
, P07629150A0155 , O
such P07629150A0155 JJ O
as P07629150A0155 IN O
adrenocorticotropin P07629150A0155 NN I-UN
and P07629150A0155 CC O
luteinizing P07629150A0155 VBG I-UN
hormone P07629150A0155 NN I-UN
, P07629150A0155 , O
as P07629150A0155 RB O
well P07629150A0155 RB O
as P07629150A0155 IN O
by P07629150A0155 IN O
a P07629150A0155 DT O
number P07629150A0155 NN O
of P07629150A0155 IN O
growth P07629150A0155 NN O
factors P07629150A0155 NNS O
, P07629150A0155 , O
suggesting P07629150A0155 VBG O
that P07629150A0155 IN O
its P07629150A0155 PRP$ O
promoter P07629150A0155 NN O
may P07629150A0155 MD O
contain P07629150A0155 VB O
regulatory P07629150A0155 JJ O
elements P07629150A0155 NNS O
that P07629150A0155 WDT O
respond P07629150A0155 VBP O
to P07629150A0155 TO O
multiple P07629150A0155 VB O
signal P07629150A0155 JJ O
transduction P07629150A0155 NN O
pathways P07629150A0155 NNS O
. P07629150A0155 . O
. . O O

Antidepressant-like P09798263T0000 JJ O
properties P09798263T0000 NNS O
of P09798263T0000 IN O
some P09798263T0000 DT O
serotonin P09798263T0000 NN I-UN
receptor P09798263T0000 NN I-UN
ligands P09798263T0000 NNS O
and P09798263T0000 CC O
calcium P09798263T0000 NN O
channel P09798263T0000 NN O
antagonists P09798263T0000 NNS O
measured P09798263T0000 VBD O
with P09798263T0000 IN O
the P09798263T0000 DT O
forced P09798263T0000 JJ O
swimming P09798263T0000 NN O
test P09798263T0000 NN O
in P09798263T0000 IN O
mice P09798263T0000 NN O
. P09798263T0000 . O
. . O O

Molecular P10721726T0000 JJ O
cloning P10721726T0000 NN O
of P10721726T0000 IN O
mouse P10721726T0000 NN I-UN
thioredoxin P10721726T0000 NN I-UN
reductases P10721726T0000 NNS I-UN
. P10721726T0000 . O
. . O O

Petrous P00933251T0000 JJ O
meningioma P00933251T0000 NN O
en P00933251T0000 IN O
plaque P00933251T0000 NN O
presenting P00933251T0000 NN O
as P00933251T0000 IN O
a P00933251T0000 DT O
right P00933251T0000 JJ O
middle P00933251T0000 NN O
ear P00933251T0000 JJ O
tumor P00933251T0000 NN O
. P00933251T0000 . O
. . O O

CONCLUSIONS P10371097A0963 NN O
: P10371097A0963 : O
Turbutest P10371097A0963 NNP O
is P10371097A0963 VBZ O
a P10371097A0963 DT O
valuable P10371097A0963 JJ O
tool P10371097A0963 NN O
in P10371097A0963 IN O
asthmatic P10371097A0963 JJ O
patients P10371097A0963 NNS O
' P10371097A0963 POS O
training P10371097A0963 NN O
, P10371097A0963 , O
allowing P10371097A0963 VBG O
identification P10371097A0963 NN O
and P10371097A0963 CC O
improvement P10371097A0963 NN O
of P10371097A0963 IN O
an P10371097A0963 DT O
inadequate P10371097A0963 JJ O
inhalation P10371097A0963 NN O
technique P10371097A0963 NN O
with P10371097A0963 IN O
Turbuhaler P10371097A0963 NNP O
. P10371097A0963 . O
. . O O

A P02511430A0000 DT O
215-base-pair P02511430A0000 JJ O
( P02511430A0000 ( O
bp P02511430A0000 NN O
) P02511430A0000 ) O
region P02511430A0000 NN O
of P02511430A0000 IN O
the P02511430A0000 DT O
mouse P02511430A0000 NN I-UN
MOPC P02511430A0000 NNP I-UN
41 P02511430A0000 CD I-UN
kappa P02511430A0000 VBD I-UN
light-chain P02511430A0000 JJ I-UN
immunoglobulin P02511430A0000 NN I-UN
gene P02511430A0000 NN I-UN
enhancer P02511430A0000 NN I-UN
has P02511430A0000 VBZ O
been P02511430A0000 VBN O
analyzed P02511430A0000 VBN O
for P02511430A0000 IN O
specific P02511430A0000 JJ O
binding P02511430A0000 NN O
of P02511430A0000 IN O
lymphoid P02511430A0000 NN O
and P02511430A0000 CC O
nonlymphoid P02511430A0000 JJ O
nuclear P02511430A0000 JJ O
factors P02511430A0000 NNS O
. P02511430A0000 . O
. . O O

Oxidative P05806615T0001 JJ O
degradation P05806615T0001 NN O
of P05806615T0001 IN O
adrenaline P05806615T0001 JJ O
solutions P05806615T0001 NNS O
: P05806615T0001 : O
study P05806615T0001 NN O
of P05806615T0001 IN O
the P05806615T0001 DT O
intermediate P05806615T0001 JJ O
stages P05806615T0001 NNS O
and P05806615T0001 CC O
their P05806615T0001 PRP$ O
analytic P05806615T0001 JJ O
value P05806615T0001 NN O
for P05806615T0001 IN O
the P05806615T0001 DT O
control P05806615T0001 NN O
of P05806615T0001 IN O
this P05806615T0001 DT O
solute P05806615T0001 NN O
. P05806615T0001 . O
. . O O

Of P11340525A0737 IN O
the P11340525A0737 DT O
patients P11340525A0737 NNS O
in P11340525A0737 IN O
each P11340525A0737 DT O
regimen P11340525A0737 NNS O
who P11340525A0737 WP O
reached P11340525A0737 VBD O
study P11340525A0737 NN O
end P11340525A0737 NN O
points P11340525A0737 NNS O
, P11340525A0737 , O
17 P11340525A0737 CD O
of P11340525A0737 IN O
29 P11340525A0737 CD O
( P11340525A0737 ( O
59 P11340525A0737 CD O
% P11340525A0737 NN O
) P11340525A0737 ) O
were P11340525A0737 VBD O
in P11340525A0737 IN O
regimen P11340525A0737 NNS O
A P11340525A0737 NNP O
, P11340525A0737 , O
11 P11340525A0737 CD O
of P11340525A0737 IN O
20 P11340525A0737 CD O
( P11340525A0737 ( O
55 P11340525A0737 CD O
% P11340525A0737 NN O
) P11340525A0737 ) O
were P11340525A0737 VBD O
in P11340525A0737 IN O
regimen P11340525A0737 NNS O
B P11340525A0737 NNP O
, P11340525A0737 , O
and P11340525A0737 CC O
28 P11340525A0737 CD O
of P11340525A0737 IN O
43 P11340525A0737 CD O
( P11340525A0737 ( O
65 P11340525A0737 CD O
% P11340525A0737 NN O
) P11340525A0737 ) O
were P11340525A0737 VBD O
in P11340525A0737 IN O
regimen P11340525A0737 NNS O
C P11340525A0737 NNP O
met P11340525A0737 VBD O
the P11340525A0737 DT O
treatment P11340525A0737 NN O
success P11340525A0737 NN O
criterion P11340525A0737 NN O
. P11340525A0737 . O
. . O O

METHODS P09366456A0234 NN O
: P09366456A0234 : O
Total P09366456A0234 JJ O
muscle P09366456A0234 NN O
paralysis P09366456A0234 NN O
was P09366456A0234 VBD O
induced P09366456A0234 VBN O
under P09366456A0234 IN O
general P09366456A0234 JJ O
anesthesia P09366456A0234 NN O
in P09366456A0234 IN O
a P09366456A0234 DT O
group P09366456A0234 NN O
of P09366456A0234 IN O
obese P09366456A0234 JJ O
persons P09366456A0234 NNS O
( P09366456A0234 ( O
n P09366456A0234 JJ O
= P09366456A0234 VBZ O
9 P09366456A0234 CD O
; P09366456A0234 : O
body P09366456A0234 NN O
mass P09366456A0234 NN O
index P09366456A0234 NN O
, P09366456A0234 , O
32 P09366456A0234 CD O
+ P09366456A0234 NN O
/ P09366456A0234 NNP O
- P09366456A0234 : O
3 P09366456A0234 CD O
kg P09366456A0234 NN O
[ P09366456A0234 NNP O
-2 P09366456A0234 NNP O
] P09366456A0234 NNP O
) P09366456A0234 ) O
and P09366456A0234 CC O
in P09366456A0234 IN O
a P09366456A0234 DT O
group P09366456A0234 NN O
of P09366456A0234 IN O
nonobese P09366456A0234 JJ O
persons P09366456A0234 NNS O
( P09366456A0234 ( O
n P09366456A0234 JJ O
= P09366456A0234 VBZ O
9 P09366456A0234 CD O
; P09366456A0234 : O
body P09366456A0234 NN O
mas P09366456A0234 FW O
index P09366456A0234 NN O
, P09366456A0234 , O
21 P09366456A0234 CD O
+ P09366456A0234 NN O
/ P09366456A0234 NNP O
- P09366456A0234 : O
2 P09366456A0234 CD O
kg P09366456A0234 NN O
[ P09366456A0234 NNP O
-2 P09366456A0234 NNP O
] P09366456A0234 NNP O
) P09366456A0234 ) O
. P09366456A0234 . O
. . O O

These P09402088A2250 DT O
defects P09402088A2250 VBZ O
no P09402088A2250 DT O
doubt P09402088A2250 NN O
impair P09402088A2250 VBZ O
the P09402088A2250 DT O
folding P09402088A2250 NN O
and P09402088A2250 CC O
configuration P09402088A2250 NN O
necessary P09402088A2250 JJ O
for P09402088A2250 IN O
normal P09402088A2250 JJ O
processing P09402088A2250 NN O
of P09402088A2250 IN O
the P09402088A2250 DT O
AVP P09402088A2250 NNP I-UN
gene P09402088A2250 NN I-UN
precursor P09402088A2250 NN I-UN
. P09402088A2250 . O
. . O O

Measurements P05684081T0001 NNS O
of P05684081T0001 IN O
activity P05684081T0001 NN O
with P05684081T0001 IN O
the P05684081T0001 DT O
radioprotective P05684081T0001 JJ O
chamber P05684081T0001 NN O
VA-K-254 P05684081T0001 NNP O
of P05684081T0001 IN O
the P05684081T0001 DT O
osimeter P05684081T0001 JJ O
VA-J18 P05684081T0001 NNP O
. P05684081T0001 . O
. . O O

With P01895370A0199 IN O
stepwise P01895370A0199 NN O
reductions P01895370A0199 NNS O
in P01895370A0199 IN O
flow P01895370A0199 NN O
, P01895370A0199 , O
the P01895370A0199 DT O
peak P01895370A0199 NN O
( P01895370A0199 ( O
S P01895370A0199 NNP O
) P01895370A0199 ) O
and P01895370A0199 CC O
trough P01895370A0199 $ O
( P01895370A0199 ( O
D P01895370A0199 NNP O
) P01895370A0199 ) O
points P01895370A0199 NNS O
of P01895370A0199 IN O
the P01895370A0199 DT O
maximum P01895370A0199 JJ O
shifted-frequency P01895370A0199 JJ O
envelope P01895370A0199 NN O
fell P01895370A0199 VBD O
in P01895370A0199 IN O
parallel P01895370A0199 NN O
in P01895370A0199 IN O
a P01895370A0199 DT O
linear P01895370A0199 JJ O
fashion P01895370A0199 NN O
until P01895370A0199 IN O
D P01895370A0199 NNP O
reached P01895370A0199 VBD O
zero P01895370A0199 NN O
. P01895370A0199 . O
. . O O

By P08665853A0228 IN O
using P08665853A0228 VBG O
interleukin-3-dependent P08665853A0228 JJ O
cells P08665853A0228 NNS O
that P08665853A0228 WDT O
ectopically P08665853A0228 RB O
express P08665853A0228 VBP O
the P08665853A0228 DT O
three P08665853A0228 CD O
ErbB P08665853A0228 NNP I-UN
proteins P08665853A0228 NNS I-UN
or P08665853A0228 CC O
their P08665853A0228 PRP$ O
combinations P08665853A0228 NNS O
, P08665853A0228 , O
we P08665853A0228 PRP O
found P08665853A0228 VBD O
that P08665853A0228 IN O
ErbB-3 P08665853A0228 NNP I-UN
is P08665853A0228 VBZ O
devoid P08665853A0228 CD O
of P08665853A0228 IN O
any P08665853A0228 DT O
biological P08665853A0228 JJ O
activity P08665853A0228 NN O
but P08665853A0228 CC O
both P08665853A0228 DT O
ErbB-1 P08665853A0228 NNP I-UN
and P08665853A0228 CC O
ErbB-2 P08665853A0228 NNP I-UN
can P08665853A0228 MD O
reconstitute P08665853A0228 VB O
its P08665853A0228 PRP$ O
extremely P08665853A0228 RB O
potent P08665853A0228 JJ O
mitogenic P08665853A0228 JJ O
activity P08665853A0228 NN O
. P08665853A0228 . O
. . O O

In P10671224A0254 IN O
the P10671224A0254 DT O
present P10671224A0254 JJ O
study P10671224A0254 NN O
we P10671224A0254 PRP O
have P10671224A0254 VBP O
investigated P10671224A0254 VBN O
the P10671224A0254 DT O
regulatory P10671224A0254 JJ O
mechanism P10671224A0254 NN O
for P10671224A0254 IN O
CD95L P10671224A0254 NNP I-UN
expression P10671224A0254 NN O
. P10671224A0254 . O
. . O O

DNA-STAT P08642285A1548 JJ I-UN
complexes P08642285A1548 NNS I-UN
were P08642285A1548 VBD O
detected P08642285A1548 VBN O
in P08642285A1548 IN O
all P08642285A1548 DT O
Bcr P08642285A1548 NNP I-UN
/ P08642285A1548 NNP O
Abl-transformed P08642285A1548 NNP O
cell P08642285A1548 NN O
lines P08642285A1548 NNS O
and P08642285A1548 CC O
they P08642285A1548 PRP O
were P08642285A1548 VBD O
supershifted P08642285A1548 VBN O
by P08642285A1548 IN O
antibodies P08642285A1548 NNS O
against P08642285A1548 IN O
STAT1 P08642285A1548 NNP I-UN
and P08642285A1548 CC O
STAT5 P08642285A1548 NNP I-UN
. P08642285A1548 . O
. . O O

Functional P10967361A0000 NNP O
magnetic P10967361A0000 JJ O
resonance P10967361A0000 NN O
imaging P10967361A0000 NN O
( P10967361A0000 ( O
fMRI P10967361A0000 NN O
) P10967361A0000 ) O
has P10967361A0000 VBZ O
been P10967361A0000 VBN O
increasingly P10967361A0000 RB O
used P10967361A0000 VBN O
in P10967361A0000 IN O
studying P10967361A0000 VBG O
human P10967361A0000 JJ O
brain P10967361A0000 NN O
function P10967361A0000 NN O
given P10967361A0000 VBN O
its P10967361A0000 PRP$ O
non-invasive P10967361A0000 JJ O
feature P10967361A0000 NN O
and P10967361A0000 CC O
good P10967361A0000 JJ O
spatial P10967361A0000 JJ O
resolution P10967361A0000 NN O
. P10967361A0000 . O
. . O O

Thus P09144195A1051 RB O
, P09144195A1051 , O
the P09144195A1051 DT O
association P09144195A1051 NN O
of P09144195A1051 IN O
PS1 P09144195A1051 NNP I-UN
fragments P09144195A1051 NNS I-UN
may P09144195A1051 MD O
be P09144195A1051 VB O
maintained P09144195A1051 VBN O
during P09144195A1051 IN O
cycles P09144195A1051 NNS O
of P09144195A1051 IN O
phosphorylation P09144195A1051 NN O
/ P09144195A1051 NNP O
dephosphorylation P09144195A1051 NN O
of P09144195A1051 IN O
the P09144195A1051 DT O
PS1 P09144195A1051 NNP I-UN
CTF P09144195A1051 NNP I-UN
. P09144195A1051 . O
. . O O

Amplification P08732665A0000 NN O
and P08732665A0000 CC O
overexpression P08732665A0000 NN O
of P08732665A0000 IN O
the P08732665A0000 DT O
c-erbB-2 P08732665A0000 JJ I-UN
gene P08732665A0000 NN I-UN
in P08732665A0000 IN O
21MT-2 P08732665A0000 JJ O
and P08732665A0000 CC O
21MT-1 P08732665A0000 JJ O
human P08732665A0000 JJ O
breast P08732665A0000 NN O
carcinoma P08732665A0000 NN O
cells P08732665A0000 NNS O
results P08732665A0000 NNS O
in P08732665A0000 IN O
progressively P08732665A0000 RB O
elevated P08732665A0000 JJ O
levels P08732665A0000 NNS O
of P08732665A0000 IN O
constitutively P08732665A0000 RB O
tyrosine-phosphorylated P08732665A0000 JJ I-UN
p185erbB-2 P08732665A0000 NN I-UN
and P08732665A0000 CC O
is P08732665A0000 VBZ O
associated P08732665A0000 VBN O
with P08732665A0000 IN O
progressive P08732665A0000 JJ O
insulin-like P08732665A0000 JJ I-UN
growth P08732665A0000 NN I-UN
factor P08732665A0000 NN I-UN
( P08732665A0000 ( O
IGF P08732665A0000 NNP I-UN
) P08732665A0000 ) O
and P08732665A0000 CC O
combined P08732665A0000 VBN O
IGF P08732665A0000 NNP I-UN
/ P08732665A0000 NNP O
epidermal P08732665A0000 JJ I-UN
growth P08732665A0000 NN I-UN
factor P08732665A0000 NN I-UN
( P08732665A0000 ( O
EGF P08732665A0000 NNP I-UN
) P08732665A0000 ) O
independence P08732665A0000 NN O
in P08732665A0000 IN O
culture P08732665A0000 NN O
. P08732665A0000 . O
. . O O

A P10229668A0560 DT O
cdc33-1 P10229668A0560 JJ I-UN
strain P10229668A0560 NN O
expressing P10229668A0560 VBG O
either P10229668A0560 CC O
stable P10229668A0560 JJ O
Cln3p P10229668A0560 NNP I-UN
( P10229668A0560 ( O
Cln3-1p P10229668A0560 NNP I-UN
) P10229668A0560 ) O
or P10229668A0560 CC O
a P10229668A0560 DT O
hybrid P10229668A0560 JJ O
UBI4 P10229668A0560 NNP I-UN
5'-CLN3 P10229668A0560 JJ I-UN
mRNA P10229668A0560 NN O
, P10229668A0560 , O
whose P10229668A0560 WP$ O
translation P10229668A0560 NN O
displays P10229668A0560 NNS O
decreased P10229668A0560 VBD O
dependence P10229668A0560 NN O
on P10229668A0560 IN O
eIF4E P10229668A0560 NN I-UN
, P10229668A0560 , O
arrested P10229668A0560 VBD O
randomly P10229668A0560 RB O
in P10229668A0560 IN O
the P10229668A0560 DT O
cell P10229668A0560 NN O
cycle P10229668A0560 NN O
. P10229668A0560 . O
. . O O

Armed P02005547A0121 VBN O
with P02005547A0121 IN O
a P02005547A0121 DT O
clear P02005547A0121 JJ O
understanding P02005547A0121 NN O
of P02005547A0121 IN O
the P02005547A0121 DT O
pathophysiologic P02005547A0121 NN O
pathways P02005547A0121 VBZ O
that P02005547A0121 WDT O
may P02005547A0121 MD O
cause P02005547A0121 VB O
and P02005547A0121 CC O
/ P02005547A0121 VB O
or P02005547A0121 CC O
contribute P02005547A0121 VB O
to P02005547A0121 TO O
the P02005547A0121 DT O
development P02005547A0121 NN O
of P02005547A0121 IN O
unconjugated P02005547A0121 JJ O
hyperbilirubinemia P02005547A0121 NN O
and P02005547A0121 CC O
the P02005547A0121 DT O
associated P02005547A0121 JJ O
jaundice P02005547A0121 NN O
, P02005547A0121 , O
the P02005547A0121 DT O
practitioner P02005547A0121 NN O
will P02005547A0121 MD O
be P02005547A0121 VB O
successful P02005547A0121 JJ O
in P02005547A0121 IN O
helping P02005547A0121 VBG O
the P02005547A0121 DT O
family P02005547A0121 NN O
understand P02005547A0121 VBP O
their P02005547A0121 PRP$ O
child P02005547A0121 NN O
's P02005547A0121 POS O
illness P02005547A0121 NN O
. P02005547A0121 . O
. . O O

Three P08550425A1401 CD O
of P08550425A1401 IN O
these P08550425A1401 DT O
subunits P08550425A1401 NNS O
are P08550425A1401 VBP O
also P08550425A1401 RB O
homologous P08550425A1401 JJ O
to P08550425A1401 TO O
the P08550425A1401 DT O
dimeric P08550425A1401 JJ O
POR P08550425A1401 NNP I-UN
from P08550425A1401 IN O
a P08550425A1401 DT O
mesophilic P08550425A1401 JJ O
archaeon P08550425A1401 NN O
, P08550425A1401 , O
Halobacterium P08550425A1401 NNP O
halobium P08550425A1401 NN O
( P08550425A1401 ( O
21 P08550425A1401 CD O
% P08550425A1401 NN O
identity P08550425A1401 NN O
) P08550425A1401 ) O
. P08550425A1401 . O
. . O O

No P03976323A0821 DT O
consistent P03976323A0821 JJ O
correlation P03976323A0821 NN O
between P03976323A0821 IN O
blood P03976323A0821 NN O
pressure P03976323A0821 NN O
change P03976323A0821 NN O
and P03976323A0821 CC O
SCR-change P03976323A0821 NN O
was P03976323A0821 VBD O
seen P03976323A0821 VBN O
. P03976323A0821 . O
. . O O

Weight P10453371A0640 NNP O
and P10453371A0640 CC O
height P10453371A0640 VBD O
z-scores P10453371A0640 NNS O
were P10453371A0640 VBD O
significantly P10453371A0640 RB O
associated P10453371A0640 VBN O
with P10453371A0640 IN O
BMD P10453371A0640 NNP O
z-scores P10453371A0640 NNS O
. P10453371A0640 . O
. . O O

Comparison P03110678A0702 NNP O
of P03110678A0702 IN O
beta P03110678A0702 NN I-UN
2-microglobulin P03110678A0702 JJ I-UN
removal P03110678A0702 NN O
using P03110678A0702 VBG O
the P03110678A0702 DT O
same P03110678A0702 JJ O
polysulphone P03110678A0702 NN O
membrane P03110678A0702 NN O
for P03110678A0702 IN O
haemodialysis P03110678A0702 NN O
and P03110678A0702 CC O
haemofiltration P03110678A0702 NN O
shows P03110678A0702 NNS O
that P03110678A0702 WDT O
beta P03110678A0702 VBP I-UN
2-microglobulin P03110678A0702 JJ I-UN
is P03110678A0702 VBZ O
more P03110678A0702 RBR O
effectively P03110678A0702 RB O
removed P03110678A0702 VBN O
by P03110678A0702 IN O
convection P03110678A0702 NN O
than P03110678A0702 IN O
by P03110678A0702 IN O
diffusion P03110678A0702 NN O
when P03110678A0702 WRB O
both P03110678A0702 DT O
treatment P03110678A0702 NN O
modes P03110678A0702 NNS O
are P03110678A0702 VBP O
matched P03110678A0702 VBN O
for P03110678A0702 IN O
blood P03110678A0702 NN O
flow P03110678A0702 NN O
and P03110678A0702 CC O
urea P03110678A0702 JJ O
clearance P03110678A0702 NN O
. P03110678A0702 . O
. . O O

Thus P10523647A1001 RB O
, P10523647A1001 , O
CHOP P10523647A1001 NNP I-UN
not P10523647A1001 RB O
only P10523647A1001 RB O
is P10523647A1001 VBZ O
a P10523647A1001 DT O
negative P10523647A1001 JJ O
or P10523647A1001 CC O
a P10523647A1001 DT O
positive P10523647A1001 JJ O
regulator P10523647A1001 NN O
of P10523647A1001 IN O
C P10523647A1001 NNP I-UN
/ P10523647A1001 NNP I-UN
EBP P10523647A1001 NNP I-UN
target P10523647A1001 NN O
genes P10523647A1001 NNS O
but P10523647A1001 CC O
also P10523647A1001 RB O
, P10523647A1001 , O
when P10523647A1001 WRB O
tethered P10523647A1001 VBN O
to P10523647A1001 TO O
AP-1 P10523647A1001 NNP I-UN
factors P10523647A1001 NNS I-UN
, P10523647A1001 , O
can P10523647A1001 MD O
activate P10523647A1001 VB O
AP-1 P10523647A1001 NNP I-UN
target P10523647A1001 NN O
genes P10523647A1001 NNS O
. P10523647A1001 . O
. . O O

Angiotensin P00676790T0000 NNP I-UN
effect P00676790T0000 NN O
in P00676790T0000 IN O
the P00676790T0000 DT O
human P00676790T0000 JJ O
kidney P00676790T0000 NN O
. P00676790T0000 . O
. . O O

Characterization P10691972T0000 NN O
of P10691972T0000 IN O
the P10691972T0000 DT O
5'-flanking P10691972T0000 JJ O
region P10691972T0000 NN O
of P10691972T0000 IN O
the P10691972T0000 DT O
human P10691972T0000 JJ I-UN
multidrug P10691972T0000 NN I-UN
resistance P10691972T0000 NN I-UN
protein P10691972T0000 NN I-UN
2 P10691972T0000 CD I-UN
( P10691972T0000 ( O
MRP2 P10691972T0000 NNP I-UN
) P10691972T0000 ) O
gene P10691972T0000 NN O
and P10691972T0000 CC O
its P10691972T0000 PRP$ O
regulation P10691972T0000 NN O
in P10691972T0000 IN O
comparison P10691972T0000 NN O
withthe P10691972T0000 JJ O
multidrug P10691972T0000 NN I-UN
resistance P10691972T0000 NN I-UN
protein P10691972T0000 NN I-UN
3 P10691972T0000 CD I-UN
( P10691972T0000 ( O
MRP3 P10691972T0000 NNP I-UN
) P10691972T0000 ) O
gene P10691972T0000 NN O
. P10691972T0000 . O
. . O O

Isolation P01709933T0000 NN O
and P01709933T0000 CC O
characterization P01709933T0000 NN O
of P01709933T0000 IN O
the P01709933T0000 DT O
rat P01709933T0000 NN O
chromosomal P01709933T0000 JJ O
gene P01709933T0000 NN O
for P01709933T0000 IN O
a P01709933T0000 DT O
polypeptide P01709933T0000 NN O
( P01709933T0000 ( O
pS1 P01709933T0000 NN I-UN
) P01709933T0000 ) O
antigenically P01709933T0000 RB O
related P01709933T0000 VBN O
to P01709933T0000 TO O
statin P01709933T0000 VB I-UN
. P01709933T0000 . O
. . O O

Patients P10452306A0502 NNS O
were P10452306A0502 VBD O
assessed P10452306A0502 VBN O
for P10452306A0502 IN O
cardiac P10452306A0502 JJ O
MIBG P10452306A0502 NNP O
uptake P10452306A0502 NN O
, P10452306A0502 , O
circulating P10452306A0502 VBG O
norepinephrine P10452306A0502 JJ O
concentration P10452306A0502 NN O
, P10452306A0502 , O
LVEF P10452306A0502 NNP O
, P10452306A0502 , O
peak P10452306A0502 NN O
Vo2 P10452306A0502 NNP O
, P10452306A0502 , O
x-ray P10452306A0502 JJ O
cardiothoracic P10452306A0502 NN O
ratio P10452306A0502 NN O
, P10452306A0502 , O
M-mode P10452306A0502 NNP O
echographic P10452306A0502 JJ O
end-diastolic P10452306A0502 JJ O
diameter P10452306A0502 NN O
and P10452306A0502 CC O
right-sided P10452306A0502 JJ O
heart P10452306A0502 NN O
catheterization P10452306A0502 NN O
parameters P10452306A0502 NNS O
. P10452306A0502 . O
. . O O

Of P01420579A0292 IN O
the P01420579A0292 DT O
serum P01420579A0292 NN I-UN
neutralizing P01420579A0292 NN I-UN
( P01420579A0292 ( I-UN
SN P01420579A0292 NNP I-UN
) P01420579A0292 ) I-UN
antibody P01420579A0292 NN I-UN
negative P01420579A0292 JJ O
calves P01420579A0292 NNS O
89.7 P01420579A0292 CD O
% P01420579A0292 NN O
( P01420579A0292 ( O
26 P01420579A0292 CD O
/ P01420579A0292 RB O
29 P01420579A0292 CD O
) P01420579A0292 ) O
and P01420579A0292 CC O
92.8 P01420579A0292 CD O
% P01420579A0292 NN O
( P01420579A0292 ( O
90 P01420579A0292 CD O
/ P01420579A0292 RB O
97 P01420579A0292 CD O
) P01420579A0292 ) O
developed P01420579A0292 VBD O
SN P01420579A0292 NNP I-UN
antibody P01420579A0292 NN I-UN
1 P01420579A0292 CD O
month P01420579A0292 NN O
after P01420579A0292 IN O
intranasal P01420579A0292 NN O
and P01420579A0292 CC O
intramuscular P01420579A0292 JJ O
vaccination P01420579A0292 NN O
, P01420579A0292 , O
respectively P01420579A0292 RB O
. P01420579A0292 . O
. . O O

High P07500953A0305 JJ O
ADR1 P07500953A0305 NNP I-UN
gene P07500953A0305 NN I-UN
dosage P07500953A0305 NN O
increased P07500953A0305 VBD O
the P07500953A0305 DT O
transcription P07500953A0305 NN O
of P07500953A0305 IN O
genes P07500953A0305 NNS O
encoding P07500953A0305 VBG O
peroxisomal P07500953A0305 JJ O
proteins P07500953A0305 NNS O
as P07500953A0305 IN O
compared P07500953A0305 VBN O
to P07500953A0305 TO O
one P07500953A0305 CD O
copy P07500953A0305 NN O
of P07500953A0305 IN O
the P07500953A0305 DT O
ADR1 P07500953A0305 NNP I-UN
gene P07500953A0305 NN I-UN
. P07500953A0305 . O
. . O O

G-CSF P08977235A0134 NNP I-UN
activates P08977235A0134 VBZ O
multiple P08977235A0134 JJ O
signaling P08977235A0134 VBG O
molecules P08977235A0134 NNS O
, P08977235A0134 , O
including P08977235A0134 VBG O
the P08977235A0134 DT O
JAK1 P08977235A0134 NNP I-UN
and P08977235A0134 CC O
JAK2 P08977235A0134 NNP I-UN
kinases P08977235A0134 NNS I-UN
and P08977235A0134 CC O
the P08977235A0134 DT O
STAT P08977235A0134 NNP I-UN
transcription P08977235A0134 NN O
factors P08977235A0134 NNS O
. P08977235A0134 . O
. . O O

The P02247072A0794 DT O
SUP44 P02247072A0794 NNP I-UN
suppressor P02247072A0794 NN I-UN
mutation P02247072A0794 NN I-UN
occurs P02247072A0794 VBZ O
near P02247072A0794 IN O
a P02247072A0794 DT O
region P02247072A0794 NN O
of P02247072A0794 IN O
the P02247072A0794 DT O
protein P02247072A0794 NN O
that P02247072A0794 WDT O
corresponds P02247072A0794 VBZ O
to P02247072A0794 TO O
the P02247072A0794 DT O
known P02247072A0794 VBN O
positions P02247072A0794 NNS O
of P02247072A0794 IN O
alterations P02247072A0794 NNS O
in P02247072A0794 IN O
E. P02247072A0794 NNP I-UN
coli P02247072A0794 NNS I-UN
S5 P02247072A0794 NNP I-UN
ram P02247072A0794 NN I-UN
mutations P02247072A0794 NNS I-UN
. P02247072A0794 . O
. . O O

Characterization P02034655T0000 NN O
of P02034655T0000 IN O
the P02034655T0000 DT O
alpha P02034655T0000 NN I-UN
4 P02034655T0000 CD I-UN
integrin P02034655T0000 JJ I-UN
gene P02034655T0000 NN I-UN
promoter P02034655T0000 NN I-UN
. P02034655T0000 . O
. . O O

Removal P09675896A0959 NN O
of P09675896A0959 IN O
the P09675896A0959 DT O
carboxyl P09675896A0959 JJ O
region P09675896A0959 NN O
severely P09675896A0959 RB O
reduced P09675896A0959 VBD O
transcriptional P09675896A0959 JJ O
activation P09675896A0959 NN O
. P09675896A0959 . O
. . O O

We P10653693A0429 PRP O
have P10653693A0429 VBP O
addressed P10653693A0429 VBN O
these P10653693A0429 DT O
issues P10653693A0429 NNS O
by P10653693A0429 IN O
reconstituting P10653693A0429 VBG O
and P10653693A0429 CC O
characterizing P10653693A0429 VBG O
the P10653693A0429 DT O
KRAB P10653693A0429 NNP I-UN
: P10653693A0429 : O
KAP-1-RBCC P10653693A0429 JJ O
interaction P10653693A0429 NN O
using P10653693A0429 VBG O
purified P10653693A0429 JJ O
components P10653693A0429 NNS O
. P10653693A0429 . O
. . O O

A P07759094A0634 DT O
polymorphic P07759094A0634 JJ O
dinucleotide P07759094A0634 NN O
( P07759094A0634 ( O
GT P07759094A0634 NNP O
/ P07759094A0634 NNP O
CA P07759094A0634 NNP O
) P07759094A0634 ) O
n P07759094A0634 RB O
repeat P07759094A0634 NN O
contained P07759094A0634 VBN O
in P07759094A0634 IN O
the P07759094A0634 DT O
NHE5 P07759094A0634 NNP O
cosmid P07759094A0634 NN O
was P07759094A0634 VBD O
identified P07759094A0634 VBN O
and P07759094A0634 CC O
developed P07759094A0634 VBN O
into P07759094A0634 IN O
a P07759094A0634 DT O
microsatellite P07759094A0634 JJ O
PCR P07759094A0634 NNP O
marker P07759094A0634 NN O
. P07759094A0634 . O
. . O O

We P11278855A0205 PRP O
confirmed P11278855A0205 VBD O
the P11278855A0205 DT O
interaction P11278855A0205 NN O
between P11278855A0205 IN O
TLS P11278855A0205 NNP I-UN
and P11278855A0205 CC O
p65 P11278855A0205 NN I-UN
by P11278855A0205 IN O
the P11278855A0205 DT O
pull-down P11278855A0205 JJ O
assay P11278855A0205 NN O
in P11278855A0205 IN O
vitro P11278855A0205 NN O
and P11278855A0205 CC O
by P11278855A0205 IN O
a P11278855A0205 DT O
coimmunoprecipitation P11278855A0205 NN O
experiment P11278855A0205 NN O
followed P11278855A0205 VBN O
by P11278855A0205 IN O
Western P11278855A0205 JJ O
blot P11278855A0205 NN O
of P11278855A0205 IN O
the P11278855A0205 DT O
cultured P11278855A0205 VBN O
cell P11278855A0205 NN O
in P11278855A0205 IN O
vivo P11278855A0205 NN O
. P11278855A0205 . O
. . O O

4 P09279813A1389 CD O
. P09279813A1389 . O
. . O O

Amino P01350780A0184 NNP O
acid P01350780A0184 VBD O
sequence P01350780A0184 NN O
comparison P01350780A0184 NN O
revealed P01350780A0184 VBD O
significant P01350780A0184 JJ O
homology P01350780A0184 NN O
between P01350780A0184 IN O
the P01350780A0184 DT O
yeast P01350780A0184 NN I-UN
and P01350780A0184 CC I-UN
Escherichia P01350780A0184 NNP I-UN
coli P01350780A0184 VBP I-UN
gamma-glutamyl P01350780A0184 NN I-UN
kinases P01350780A0184 NNS I-UN
throughout P01350780A0184 IN O
their P01350780A0184 PRP$ O
lengths P01350780A0184 NNS O
. P01350780A0184 . O
. . O O

Disrupted P00342623A0228 VBN O
vaccines P00342623A0228 NNS O
and P00342623A0228 CC O
whole-virus P00342623A0228 JJ O
vaccines P00342623A0228 NNS O
containing P00342623A0228 VBG O
type P00342623A0228 NN I-UN
B P00342623A0228 NNP I-UN
antigen P00342623A0228 NN I-UN
only P00342623A0228 RB O
did P00342623A0228 VBD O
not P00342623A0228 RB O
cause P00342623A0228 VB O
significant P00342623A0228 JJ O
reactivity P00342623A0228 NN O
. P00342623A0228 . O
. . O O

Twenty-eight P01567649A0139 NNP O
( P01567649A0139 ( O
7.0 P01567649A0139 CD O
% P01567649A0139 NN O
) P01567649A0139 ) O
infants P01567649A0139 NNS O
without P01567649A0139 IN O
periventricular P01567649A0139 JJ O
hemorrhage P01567649A0139 NN O
were P01567649A0139 VBD O
revealed P01567649A0139 VBN O
as P01567649A0139 IN O
having P01567649A0139 VBG O
spastic P01567649A0139 JJ O
cerebral P01567649A0139 JJ O
palsy P01567649A0139 NN O
by P01567649A0139 IN O
neurodevelopmental P01567649A0139 JJ O
evaluation P01567649A0139 NN O
in P01567649A0139 IN O
later P01567649A0139 JJ O
infancy P01567649A0139 NN O
. P01567649A0139 . O
. . O O

Pathogenetic P06873504T0000 JJ O
relationships P06873504T0000 NNS O
between P06873504T0000 IN O
renal P06873504T0000 JJ O
tubular P06873504T0000 JJ O
acidosis P06873504T0000 NN O
and P06873504T0000 CC O
sodium P06873504T0000 NN O
metabolism P06873504T0000 NN O
alterations P06873504T0000 NNS O
in P06873504T0000 IN O
liver P06873504T0000 JJ O
cirrhosis P06873504T0000 NN O
. P06873504T0000 . O
. . O O

A P00602622A0362 DT O
one-week P00602622A0362 JJ O
ulcer P00602622A0362 JJ O
therapy P00602622A0362 NN O
with P00602622A0362 IN O
atropine P00602622A0362 NN O
and P00602622A0362 CC O
Vikalin P00602622A0362 NNP O
( P00602622A0362 ( O
Roter P00602622A0362 NNP O
) P00602622A0362 ) O
led P00602622A0362 VBD O
to P00602622A0362 TO O
a P00602622A0362 DT O
significant P00602622A0362 JJ O
( P00602622A0362 ( O
p P00602622A0362 NN O
less P00602622A0362 JJR O
than P00602622A0362 IN O
0.01 P00602622A0362 CD O
) P00602622A0362 ) O
reduction P00602622A0362 NN O
of P00602622A0362 IN O
the P00602622A0362 DT O
nocturnal P00602622A0362 JJ O
proteolytic P00602622A0362 JJ O
activity P00602622A0362 NN O
. P00602622A0362 . O
. . O O

It P06454625A0000 PRP O
has P06454625A0000 VBZ O
been P06454625A0000 VBN O
shown P06454625A0000 VBN O
in P06454625A0000 IN O
an P06454625A0000 DT O
animal P06454625A0000 JJ O
experiment P06454625A0000 NN O
that P06454625A0000 IN O
alterations P06454625A0000 NNS O
of P06454625A0000 IN O
the P06454625A0000 DT O
renal P06454625A0000 JJ O
vasculature P06454625A0000 NN O
and P06454625A0000 CC O
parenchyma P06454625A0000 NN O
after P06454625A0000 IN O
hemostasis P06454625A0000 NN O
performed P06454625A0000 VBN O
by P06454625A0000 IN O
Infrared-Contact-Coagulation P06454625A0000 NNP O
are P06454625A0000 VBP O
best P06454625A0000 JJS O
shown P06454625A0000 VBN O
by P06454625A0000 IN O
intravital P06454625A0000 JJ O
magnification P06454625A0000 NN O
angiography P06454625A0000 NN O
( P06454625A0000 ( O
magnification P06454625A0000 NN O
factor P06454625A0000 NN O
2.22 P06454625A0000 CD O
) P06454625A0000 ) O
. P06454625A0000 . O
. . O O

The P07903670A1202 DT O
mutant P07903670A1202 JJ O
allele P07903670A1202 NN O
of P07903670A1202 IN O
the P07903670A1202 DT O
alpha P07903670A1202 JJ I-UN
1-tubulin P07903670A1202 JJ I-UN
gene P07903670A1202 NN I-UN
was P07903670A1202 VBD O
designated P07903670A1202 VBN O
tua1-1 P07903670A1202 NN I-UN
. P07903670A1202 . O
. . O O

Formalin P01881595A0476 NNP O
activated P01881595A0476 VBD O
both P01881595A0476 DT O
SNO P01881595A0476 NNP O
NS P01881595A0476 NNP O
and P01881595A0476 CC O
NnS P01881595A0476 NNP O
neurones P01881595A0476 NNS O
, P01881595A0476 , O
but P01881595A0476 CC O
, P01881595A0476 , O
when P01881595A0476 WRB O
they P01881595A0476 PRP O
responded P01881595A0476 VBD O
, P01881595A0476 , O
NS P01881595A0476 NNP O
neurones P01881595A0476 NNS O
( P01881595A0476 ( O
n P01881595A0476 JJ O
= P01881595A0476 NNP O
5 P01881595A0476 CD O
) P01881595A0476 ) O
showed P01881595A0476 VBD O
only P01881595A0476 RB O
the P01881595A0476 DT O
first P01881595A0476 JJ O
phase P01881595A0476 NN O
of P01881595A0476 IN O
activity P01881595A0476 NN O
while P01881595A0476 IN O
NnS P01881595A0476 NNP O
neurones P01881595A0476 NNS O
showed P01881595A0476 VBD O
either P01881595A0476 CC O
one P01881595A0476 CD O
( P01881595A0476 ( O
n P01881595A0476 JJ O
= P01881595A0476 NNP O
13 P01881595A0476 CD O
) P01881595A0476 ) O
or P01881595A0476 CC O
two P01881595A0476 CD O
phases P01881595A0476 NNS O
( P01881595A0476 ( O
n P01881595A0476 JJ O
= P01881595A0476 NNP O
6 P01881595A0476 CD O
) P01881595A0476 ) O
. P01881595A0476 . O
. . O O

Furthermore P09238850A0785 RB O
, P09238850A0785 , O
ICER P09238850A0785 NNP I-UN
negatively P09238850A0785 RB O
autoregulates P09238850A0785 VBZ O
the P09238850A0785 DT O
alternative P09238850A0785 JJ O
promoter P09238850A0785 NN O
, P09238850A0785 , O
thus P09238850A0785 RB O
generating P09238850A0785 VBG O
a P09238850A0785 DT O
feedback P09238850A0785 NN O
loop P09238850A0785 NN O
. P09238850A0785 . O
. . O O

The P08649403A0963 DT O
growth P08649403A0963 NN O
defect P08649403A0963 NN O
of P08649403A0963 IN O
a P08649403A0963 DT O
reg1 P08649403A0963 NN I-UN
reg2 P08649403A0963 NN I-UN
double P08649403A0963 JJ I-UN
mutant P08649403A0963 NN I-UN
is P08649403A0963 VBZ O
alleviated P08649403A0963 VBN O
by P08649403A0963 IN O
a P08649403A0963 DT O
loss-of-function P08649403A0963 JJ O
mutation P08649403A0963 NN O
in P08649403A0963 IN O
the P08649403A0963 DT O
SNF1-encoded P08649403A0963 JJ I-UN
protein P08649403A0963 NN I-UN
kinase P08649403A0963 NN I-UN
. P08649403A0963 . O
. . O O

Consistent P10607566A0880 JJ O
with P10607566A0880 IN O
this P10607566A0880 DT O
finding P10607566A0880 NN O
, P10607566A0880 , O
beta-catenin P10607566A0880 NN I-UN
interacted P10607566A0880 VBN O
directly P10607566A0880 RB O
with P10607566A0880 IN O
the P10607566A0880 DT O
RA P10607566A0880 NNP I-UN
receptor P10607566A0880 NN I-UN
( P10607566A0880 ( O
RAR P10607566A0880 NNP I-UN
) P10607566A0880 ) O
in P10607566A0880 IN O
a P10607566A0880 DT O
retinoid-dependent P10607566A0880 JJ O
manner P10607566A0880 NN O
, P10607566A0880 , O
but P10607566A0880 CC O
not P10607566A0880 RB O
with P10607566A0880 IN O
the P10607566A0880 DT O
retinoid P10607566A0880 NN I-UN
X P10607566A0880 NNP I-UN
receptor P10607566A0880 NN I-UN
( P10607566A0880 ( O
RXR P10607566A0880 NNP I-UN
) P10607566A0880 ) O
, P10607566A0880 , O
and P10607566A0880 CC O
RAR P10607566A0880 NNP I-UN
competed P10607566A0880 VBD O
with P10607566A0880 IN O
TCF P10607566A0880 NNP I-UN
for P10607566A0880 IN O
beta-catenin P10607566A0880 JJ I-UN
binding P10607566A0880 NN O
. P10607566A0880 . O
. . O O

The P10449072A0560 DT O
second P10449072A0560 JJ O
goal P10449072A0560 NN O
was P10449072A0560 VBD O
to P10449072A0560 TO O
ascertain P10449072A0560 VB O
the P10449072A0560 DT O
somatotopic P10449072A0560 NN O
arrangement P10449072A0560 NN O
of P10449072A0560 IN O
the P10449072A0560 DT O
GPi P10449072A0560 NNP O
in P10449072A0560 IN O
PD P10449072A0560 NNP O
. P10449072A0560 . O
. . O O

Facioscapulohumeral P08733123A0000 NNP O
muscular P08733123A0000 JJ O
dystrophy P08733123A0000 NN O
( P08733123A0000 ( O
FSHD P08733123A0000 NNP O
) P08733123A0000 ) O
is P08733123A0000 VBZ O
an P08733123A0000 DT O
autosomal P08733123A0000 JJ O
dominant P08733123A0000 NN O
, P08733123A0000 , O
neuromuscular P08733123A0000 JJ O
disorder P08733123A0000 NN O
characterized P08733123A0000 VBN O
by P08733123A0000 IN O
progressive P08733123A0000 JJ O
weakness P08733123A0000 NN O
of P08733123A0000 IN O
muscles P08733123A0000 NNS O
in P08733123A0000 IN O
the P08733123A0000 DT O
face P08733123A0000 NN O
, P08733123A0000 , O
shoulder P08733123A0000 NN O
and P08733123A0000 CC O
upper P08733123A0000 JJ O
arm P08733123A0000 NN O
. P08733123A0000 . O
. . O O

Genomic P02030910A0000 NNP O
clones P02030910A0000 NNS O
encompassing P02030910A0000 VBG O
the P02030910A0000 DT O
human P02030910A0000 JJ I-UN
ETS1 P02030910A0000 NNP I-UN
gene P02030910A0000 NN I-UN
were P02030910A0000 VBD O
isolated P02030910A0000 VBN O
and P02030910A0000 CC O
utilized P02030910A0000 JJ O
to P02030910A0000 TO O
define P02030910A0000 VB O
its P02030910A0000 PRP$ O
molecular P02030910A0000 JJ O
organization P02030910A0000 NN O
. P02030910A0000 . O
. . O O

Practical P03382772A0319 JJ O
interest P03382772A0319 NN O
of P03382772A0319 IN O
such P03382772A0319 JJ O
studies P03382772A0319 NNS O
is P03382772A0319 VBZ O
limited P03382772A0319 JJ O
since P03382772A0319 IN O
the P03382772A0319 DT O
pharmacokinetic P03382772A0319 JJ O
parameters P03382772A0319 NNS O
are P03382772A0319 VBP O
systematically P03382772A0319 RB O
evaluated P03382772A0319 VBN O
in P03382772A0319 IN O
man P03382772A0319 NN O
during P03382772A0319 IN O
phase P03382772A0319 NN O
I P03382772A0319 PRP O
trials P03382772A0319 NNS O
. P03382772A0319 . O
. . O O

Two P01659685T0000 CD O
independent P01659685T0000 JJ O
promoters P01659685T0000 NNS O
as P01659685T0000 RB O
well P01659685T0000 RB O
as P01659685T0000 IN O
5 P01659685T0000 CD O
' P01659685T0000 POS O
untranslated P01659685T0000 JJ O
regions P01659685T0000 NNS O
regulate P01659685T0000 VBP O
Dd P01659685T0000 NNP I-UN
ras P01659685T0000 NNS I-UN
expression P01659685T0000 NN O
in P01659685T0000 IN O
Dictyostelium P01659685T0000 NNP O
. P01659685T0000 . O
. . O O

Coexisting P10991648T0000 VBG O
vertical P10991648T0000 JJ O
and P10991648T0000 CC O
horizontal P10991648T0000 JJ O
one P10991648T0000 CD O
and P10991648T0000 CC O
a P10991648T0000 DT O
half P10991648T0000 JJ O
syndromes P10991648T0000 NNS O
. P10991648T0000 . O
. . O O

In P09243505A1194 IN O
addition P09243505A1194 NN O
, P09243505A1194 , O
the P09243505A1194 DT O
DNA-binding P09243505A1194 JJ O
experiments P09243505A1194 NNS O
show P09243505A1194 VBP O
that P09243505A1194 IN O
either P09243505A1194 DT O
one P09243505A1194 CD O
of P09243505A1194 IN O
the P09243505A1194 DT O
two P09243505A1194 CD O
MADS P09243505A1194 NNP I-UN
domains P09243505A1194 NNS I-UN
of P09243505A1194 IN O
a P09243505A1194 DT O
dimer P09243505A1194 NN O
can P09243505A1194 MD O
be P09243505A1194 VB O
sufficient P09243505A1194 JJ O
to P09243505A1194 TO O
confer P09243505A1194 VB O
a P09243505A1194 DT O
particular P09243505A1194 JJ O
DNA-binding P09243505A1194 JJ O
specificity P09243505A1194 NN O
to P09243505A1194 TO O
the P09243505A1194 DT O
complex P09243505A1194 NN O
and P09243505A1194 CC O
that P09243505A1194 IN O
sequences P09243505A1194 NNS O
outside P09243505A1194 IN O
the P09243505A1194 DT O
amino-terminal P09243505A1194 JJ O
basic P09243505A1194 JJ O
region P09243505A1194 NN O
of P09243505A1194 IN O
the P09243505A1194 DT O
MADS P09243505A1194 NNP I-UN
domain P09243505A1194 NN O
can P09243505A1194 MD O
, P09243505A1194 , O
in P09243505A1194 IN O
some P09243505A1194 DT O
cases P09243505A1194 NNS O
, P09243505A1194 , O
contribute P09243505A1194 NN O
to P09243505A1194 TO O
the P09243505A1194 DT O
DNA-binding P09243505A1194 NNP O
specificity P09243505A1194 NN O
of P09243505A1194 IN O
the P09243505A1194 DT O
proteins P09243505A1194 NNS O
. P09243505A1194 . O
. . O O

Subsequently P11094075A0257 RB O
, P11094075A0257 , O
we P11094075A0257 PRP O
show P11094075A0257 VBP O
that P11094075A0257 IN O
the P11094075A0257 DT O
reexpression P11094075A0257 NN O
of P11094075A0257 IN O
the P11094075A0257 DT O
r-PTPeta P11094075A0257 JJ I-UN
gene P11094075A0257 NN I-UN
in P11094075A0257 IN O
highly P11094075A0257 RB O
malignant P11094075A0257 JJ O
rat P11094075A0257 NN O
thyroid P11094075A0257 NN O
cells P11094075A0257 NNS O
transformed P11094075A0257 VBN O
by P11094075A0257 IN O
retroviruses P11094075A0257 NNS O
carrying P11094075A0257 VBG O
the P11094075A0257 DT O
v-mos P11094075A0257 JJ I-UN
and P11094075A0257 CC O
v-ras-Ki P11094075A0257 JJ I-UN
oncogenes P11094075A0257 NNS I-UN
suppresses P11094075A0257 VBZ O
their P11094075A0257 PRP$ O
malignant P11094075A0257 JJ O
phenotype P11094075A0257 NN O
. P11094075A0257 . O
. . O O

Disruption P08570615T0000 NN O
of P08570615T0000 IN O
RB P08570615T0000 NNP I-UN
/ P08570615T0000 NNP O
E2F-1 P08570615T0000 NNP I-UN
interaction P08570615T0000 NN O
by P08570615T0000 IN O
single P08570615T0000 JJ O
point P08570615T0000 NN O
mutations P08570615T0000 NNS O
in P08570615T0000 IN O
E2F-1 P08570615T0000 JJ I-UN
enhances P08570615T0000 NNS O
S-phase P08570615T0000 NNP O
entry P08570615T0000 NN O
and P08570615T0000 CC O
apoptosis P08570615T0000 NN O
. P08570615T0000 . O
. . O O

The P07565685A0420 DT O
peptide P07565685A0420 NN O
sequences P07565685A0420 VBZ O
reveal P07565685A0420 NN O
that P07565685A0420 IN O
the P07565685A0420 DT O
factor P07565685A0420 NN O
consists P07565685A0420 VBZ O
of P07565685A0420 IN O
GABP P07565685A0420 NNP I-UN
alpha P07565685A0420 NN I-UN
and P07565685A0420 CC O
GABP P07565685A0420 NNP I-UN
beta P07565685A0420 VBD I-UN
1 P07565685A0420 CD I-UN
with P07565685A0420 IN O
Ets P07565685A0420 NNP I-UN
and P07565685A0420 CC O
Notch P07565685A0420 NNP I-UN
motifs P07565685A0420 NNS I-UN
, P07565685A0420 , O
respectively P07565685A0420 RB O
. P07565685A0420 . O
. . O O

Nevertheless P10556751A0758 RB O
, P10556751A0758 , O
in P10556751A0758 IN O
view P10556751A0758 NN O
of P10556751A0758 IN O
the P10556751A0758 DT O
potential P10556751A0758 JJ O
transmission P10556751A0758 NN O
rates P10556751A0758 NNS O
of P10556751A0758 IN O
HGV P10556751A0758 NNP O
and P10556751A0758 CC O
the P10556751A0758 DT O
lack P10556751A0758 NN O
of P10556751A0758 IN O
effective P10556751A0758 JJ O
immunization P10556751A0758 NN O
, P10556751A0758 , O
HGV P10556751A0758 NNP O
should P10556751A0758 MD O
be P10556751A0758 VB O
regarded P10556751A0758 VBN O
as P10556751A0758 IN O
a P10556751A0758 DT O
potential P10556751A0758 JJ O
occupational P10556751A0758 JJ O
hazard P10556751A0758 NN O
for P10556751A0758 IN O
medical P10556751A0758 JJ O
and P10556751A0758 CC O
dental P10556751A0758 JJ O
staff P10556751A0758 NN O
. P10556751A0758 . O
. . O O

We P01697611A0738 PRP O
speculate P01697611A0738 VBP O
that P01697611A0738 IN O
these P01697611A0738 DT O
tumors P01697611A0738 NNS O
may P01697611A0738 MD O
represent P01697611A0738 VB O
congenital P01697611A0738 JJ O
hamartomatous P01697611A0738 JJ O
growths P01697611A0738 NNS O
. P01697611A0738 . O
. . O O

The P08706662A1125 DT O
results P08706662A1125 NNS O
also P08706662A1125 RB O
imply P08706662A1125 VBP O
that P08706662A1125 IN O
the P08706662A1125 DT O
absence P08706662A1125 NN O
of P08706662A1125 IN O
perforin P08706662A1125 JJ I-UN
expression P08706662A1125 NN O
in P08706662A1125 IN O
non-cytotoxic P08706662A1125 JJ O
cells P08706662A1125 NNS O
may P08706662A1125 MD O
be P08706662A1125 VB O
due P08706662A1125 JJ O
to P08706662A1125 TO O
the P08706662A1125 DT O
suppression P08706662A1125 NN O
of P08706662A1125 IN O
the P08706662A1125 DT O
induction P08706662A1125 NN O
of P08706662A1125 IN O
the P08706662A1125 DT O
killer-cell-specific P08706662A1125 JJ O
trans-acting P08706662A1125 JJ O
factor P08706662A1125 NN O
NF-P2 P08706662A1125 NNP I-UN
. P08706662A1125 . O
. . O O

We P11113179A0541 PRP O
show P11113179A0541 VBP O
that P11113179A0541 IN O
in P11113179A0541 IN O
contrast P11113179A0541 NN O
to P11113179A0541 TO O
SRC1 P11113179A0541 NNP I-UN
, P11113179A0541 , O
direct P11113179A0541 JJ O
binding P11113179A0541 NN O
of P11113179A0541 IN O
CBP P11113179A0541 NNP I-UN
to P11113179A0541 TO O
the P11113179A0541 DT O
estrogen P11113179A0541 NN I-UN
receptor P11113179A0541 NN I-UN
is P11113179A0541 VBZ O
weak P11113179A0541 JJ O
, P11113179A0541 , O
suggesting P11113179A0541 VBG O
that P11113179A0541 IN O
SRC1 P11113179A0541 NNP I-UN
functions P11113179A0541 NNS O
primarily P11113179A0541 RB O
as P11113179A0541 IN O
an P11113179A0541 DT O
adaptor P11113179A0541 NN O
to P11113179A0541 TO O
recruit P11113179A0541 VB O
CBP P11113179A0541 NNP I-UN
and P11113179A0541 CC O
p300 P11113179A0541 NN I-UN
. P11113179A0541 . O
. . O O

Immunohistochemical P02811378A0379 JJ O
studies P02811378A0379 NNS O
revealed P02811378A0379 VBD O
positive P02811378A0379 JJ O
staining P02811378A0379 NN O
for P02811378A0379 IN O
S100 P02811378A0379 NNP I-UN
protein P02811378A0379 NN I-UN
in P02811378A0379 IN O
all P02811378A0379 PDT O
the P02811378A0379 DT O
granular P02811378A0379 JJ O
cell P02811378A0379 NN O
tumors P02811378A0379 NNS O
of P02811378A0379 IN O
the P02811378A0379 DT O
adult P02811378A0379 NN O
but P02811378A0379 CC O
in P02811378A0379 IN O
none P02811378A0379 NN O
of P02811378A0379 IN O
the P02811378A0379 DT O
congenital P02811378A0379 JJ O
granular P02811378A0379 NN O
cell P02811378A0379 NN O
epulides P02811378A0379 NNS O
. P02811378A0379 . O
. . O O

Rainbow P00970839A0118 NN O
trout P00970839A0118 NN O
were P00970839A0118 VBD O
obtained P00970839A0118 VBN O
from P00970839A0118 IN O
a P00970839A0118 DT O
commercial P00970839A0118 JJ O
trout P00970839A0118 NN O
farm P00970839A0118 NN O
, P00970839A0118 , O
kept P00970839A0118 VBD O
in P00970839A0118 IN O
running P00970839A0118 VBG O
water P00970839A0118 NN O
and P00970839A0118 CC O
feeding P00970839A0118 NN O
in P00970839A0118 IN O
experimental P00970839A0118 JJ O
pellets P00970839A0118 NNS O
for P00970839A0118 IN O
4 P00970839A0118 CD O
to P00970839A0118 TO O
8 P00970839A0118 CD O
weeks P00970839A0118 NNS O
. P00970839A0118 . O
. . O O

Many P09575217A0000 JJ O
cytokine P09575217A0000 NN O
receptors P09575217A0000 NNS O
employ P09575217A0000 VBP O
Janus P09575217A0000 NNP I-UN
protein P09575217A0000 NN I-UN
tyrosine P09575217A0000 NN I-UN
kinases P09575217A0000 NNS I-UN
( P09575217A0000 ( O
Jaks P09575217A0000 NNP I-UN
) P09575217A0000 ) O
and P09575217A0000 CC O
signal P09575217A0000 JJ I-UN
transducers P09575217A0000 NNS I-UN
and P09575217A0000 CC I-UN
activators P09575217A0000 NNS I-UN
of P09575217A0000 IN I-UN
transcription P09575217A0000 NN I-UN
( P09575217A0000 ( O
Stats P09575217A0000 NNP I-UN
) P09575217A0000 ) O
for P09575217A0000 IN O
nuclear P09575217A0000 JJ O
signaling P09575217A0000 NN O
. P09575217A0000 . O
. . O O

The P10496553A1004 DT O
healing P10496553A1004 VBG O
rate P10496553A1004 NN O
in P10496553A1004 IN O
HIV-positive P10496553A1004 JJ O
patients P10496553A1004 NNS O
was P10496553A1004 VBD O
66 P10496553A1004 CD O
percent P10496553A1004 NN O
after P10496553A1004 IN O
14 P10496553A1004 CD O
weeks P10496553A1004 NNS O
and P10496553A1004 CC O
100 P10496553A1004 CD O
percent P10496553A1004 NN O
after P10496553A1004 IN O
32 P10496553A1004 CD O
weeks P10496553A1004 NNS O
; P10496553A1004 : O
the P10496553A1004 DT O
corresponding P10496553A1004 JJ O
figures P10496553A1004 NNS O
for P10496553A1004 IN O
patients P10496553A1004 NNS O
with P10496553A1004 IN O
acquired P10496553A1004 JJ O
immunodeficiency P10496553A1004 NN O
syndrome P10496553A1004 NN O
were P10496553A1004 VBD O
0 P10496553A1004 CD O
and P10496553A1004 CC O
50 P10496553A1004 CD O
percent P10496553A1004 NN O
. P10496553A1004 . O
. . O O

Prior P09324720A0317 RB O
to P09324720A0317 TO O
meals P09324720A0317 NNS O
2 P09324720A0317 CD O
to P09324720A0317 TO O
3 P09324720A0317 CD O
times P09324720A0317 NNS O
daily P09324720A0317 RB O
, P09324720A0317 , O
1-2 P09324720A0317 JJ O
tablespoons P09324720A0317 NNS O
of P09324720A0317 IN O
Alzoon P09324720A0317 NNP O
are P09324720A0317 VBP O
recommended P09324720A0317 VBN O
. P09324720A0317 . O
. . O O

Evaluation P01895555T0001 NN O
of P01895555T0001 IN O
left P01895555T0001 JJ O
ventricular P01895555T0001 JJ O
function P01895555T0001 NN O
using P01895555T0001 VBG O
gated P01895555T0001 VBN O
planar P01895555T0001 JJ O
myocardial P01895555T0001 JJ O
imaging P01895555T0001 VBG O
with P01895555T0001 IN O
Tc-99m-MIBI P01895555T0001 NNP O
. P01895555T0001 . O
. . O O

Wild P09852136A0507 JJ O
type P09852136A0507 JJ O
HA-p190 P09852136A0507 NNP O
induced P09852136A0507 VBD O
a P09852136A0507 DT O
phenotype P09852136A0507 NN O
of P09852136A0507 IN O
rounded P09852136A0507 JJ O
cells P09852136A0507 NNS O
with P09852136A0507 IN O
long P09852136A0507 JJ O
, P09852136A0507 , O
beaded P09852136A0507 VBD O
extensions P09852136A0507 NNS O
similar P09852136A0507 JJ O
to P09852136A0507 TO O
that P09852136A0507 DT O
seen P09852136A0507 VBN O
when P09852136A0507 WRB O
Rho P09852136A0507 NNP I-UN
function P09852136A0507 NN O
is P09852136A0507 VBZ O
disrupted P09852136A0507 VBN O
by P09852136A0507 IN O
ADP-ribosylation P09852136A0507 NNP O
. P09852136A0507 . O
. . O O

The P10857262A0186 DT O
protein P10857262A0186 NN O
encoded P10857262A0186 VBN O
by P10857262A0186 IN O
the P10857262A0186 DT O
fruA P10857262A0186 NN I-UN
transcript P10857262A0186 NN I-UN
is P10857262A0186 VBZ O
well P10857262A0186 RB O
conserved P10857262A0186 VBN O
with P10857262A0186 IN O
the P10857262A0186 DT O
D. P10857262A0186 NNP I-UN
melanogaster P10857262A0186 NN I-UN
type P10857262A0186 NN I-UN
A P10857262A0186 NNP I-UN
protein P10857262A0186 NN I-UN
, P10857262A0186 , O
particularly P10857262A0186 RB O
the P10857262A0186 DT O
BTB P10857262A0186 NNP I-UN
protein-protein-binding P10857262A0186 NN O
domain P10857262A0186 NN O
, P10857262A0186 , O
which P10857262A0186 WDT O
is P10857262A0186 VBZ O
encoded P10857262A0186 VBN O
by P10857262A0186 IN O
exons P10857262A0186 NNS O
I P10857262A0186 PRP O
and P10857262A0186 CC O
II P10857262A0186 NNP O
and P10857262A0186 CC O
is P10857262A0186 VBZ O
100 P10857262A0186 CD O
% P10857262A0186 NN O
conserved P10857262A0186 VBN O
. P10857262A0186 . O
. . O O

The P01304515A0178 DT O
obtained P01304515A0178 VBN O
results P01304515A0178 NNS O
were P01304515A0178 VBD O
compared P01304515A0178 VBN O
with P01304515A0178 IN O
control P01304515A0178 NN O
group P01304515A0178 NN O
( P01304515A0178 ( O
10 P01304515A0178 CD O
female P01304515A0178 NN O
volunteers P01304515A0178 NNS O
) P01304515A0178 ) O
. P01304515A0178 . O
. . O O

This P02115118A0565 DT O
Mr P02115118A0565 NNP O
is P02115118A0565 VBZ O
similar P02115118A0565 JJ O
to P02115118A0565 TO O
those P02115118A0565 DT O
of P02115118A0565 IN O
the P02115118A0565 DT O
purified P02115118A0565 JJ I-UN
smg P02115118A0565 NN I-UN
p25A P02115118A0565 NN I-UN
GDI P02115118A0565 NNP I-UN
estimated P02115118A0565 VBN O
by P02115118A0565 IN O
sodium P02115118A0565 NN O
dodecyl P02115118A0565 NN O
sulfate-polyacrylamide P02115118A0565 JJ O
gel P02115118A0565 NN O
electrophoresis P02115118A0565 NN O
and P02115118A0565 CC O
sucrose P02115118A0565 JJ O
density P02115118A0565 NN O
gradient P02115118A0565 NN O
ultracentrifugation P02115118A0565 NN O
, P02115118A0565 , O
which P02115118A0565 WDT O
are P02115118A0565 VBP O
about P02115118A0565 IN O
54,000 P02115118A0565 CD O
and P02115118A0565 CC O
65,000 P02115118A0565 CD O
, P02115118A0565 , O
respectively P02115118A0565 RB O
. P02115118A0565 . O
. . O O

Our P09585253A1147 PRP$ O
data P09585253A1147 NNS O
showed P09585253A1147 VBD O
that P09585253A1147 IN O
activation P09585253A1147 NN O
of P09585253A1147 IN O
the P09585253A1147 DT O
raf-ERK P09585253A1147 JJ O
pathway P09585253A1147 NN O
led P09585253A1147 VBD O
to P09585253A1147 TO O
activation P09585253A1147 NN O
of P09585253A1147 IN O
TF P09585253A1147 NNP I-UN
expression P09585253A1147 NN O
in P09585253A1147 IN O
breast P09585253A1147 NN O
carcinoma P09585253A1147 NN O
cells P09585253A1147 NNS O
and P09585253A1147 CC O
suggested P09585253A1147 VBD O
that P09585253A1147 IN O
constitutive P09585253A1147 JJ O
activation P09585253A1147 NN O
of P09585253A1147 IN O
this P09585253A1147 DT O
pathway P09585253A1147 NN O
leads P09585253A1147 VBZ O
to P09585253A1147 TO O
high P09585253A1147 VB O
TF P09585253A1147 NNP I-UN
expression P09585253A1147 NN O
in P09585253A1147 IN O
MDA-MB-231 P09585253A1147 NNP O
cells P09585253A1147 NNS O
. P09585253A1147 . O
. . O O

GCD10 P07542616A0313 NNP I-UN
was P07542616A0313 VBD O
first P07542616A0313 RB O
identified P07542616A0313 VBN O
genetically P07542616A0313 RB O
as P07542616A0313 IN O
a P07542616A0313 DT O
translational P07542616A0313 JJ O
repressor P07542616A0313 NN O
of P07542616A0313 IN O
GCN4 P07542616A0313 NNP I-UN
. P07542616A0313 . O
. . O O

Here P08088513A0419 RB O
, P08088513A0419 , O
we P08088513A0419 PRP O
present P08088513A0419 VBP O
genetic P08088513A0419 JJ O
evidence P08088513A0419 NN O
in P08088513A0419 IN O
Saccharomyces P08088513A0419 NNP O
cerevisiae P08088513A0419 NN O
for P08088513A0419 IN O
a P08088513A0419 DT O
functional P08088513A0419 JJ O
interaction P08088513A0419 NN O
between P08088513A0419 IN O
the P08088513A0419 DT O
DEAH P08088513A0419 NNP I-UN
protein P08088513A0419 NN I-UN
Prp16 P08088513A0419 NNP I-UN
, P08088513A0419 , O
and P08088513A0419 CC O
the P08088513A0419 DT O
U6 P08088513A0419 NNP I-UN
and P08088513A0419 CC O
U2 P08088513A0419 NNP I-UN
spliceosomal P08088513A0419 JJ I-UN
snRNAs P08088513A0419 NN I-UN
. P08088513A0419 . O
. . O O

The P08139542A1229 DT O
mutations P08139542A1229 NNS O
did P08139542A1229 VBD O
not P08139542A1229 RB O
affect P08139542A1229 VB O
the P08139542A1229 DT O
repression P08139542A1229 NN O
of P08139542A1229 IN O
CPA1 P08139542A1229 NNP I-UN
by P08139542A1229 IN O
arginine P08139542A1229 NN O
. P08139542A1229 . O
. . O O

METHODS P07864709A0324 NN O
: P07864709A0324 : O
Ten P07864709A0324 CD O
influenza P07864709A0324 VBZ O
A P07864709A0324 NNP O
( P07864709A0324 ( O
H3N2 P07864709A0324 NNP O
) P07864709A0324 ) O
viruses P07864709A0324 VBZ O
isolated P07864709A0324 JJ O
during P07864709A0324 IN O
the P07864709A0324 DT O
outbreaks P07864709A0324 NNS O
were P07864709A0324 VBD O
examined P07864709A0324 VBN O
for P07864709A0324 IN O
resistance P07864709A0324 NN O
to P07864709A0324 TO O
amantadine P07864709A0324 VB O
and P07864709A0324 CC O
rimantadine P07864709A0324 VB O
by P07864709A0324 IN O
means P07864709A0324 NNS O
of P07864709A0324 IN O
an P07864709A0324 DT O
enzyme P07864709A0324 JJ O
immunoassay P07864709A0324 NN O
and P07864709A0324 CC O
by P07864709A0324 IN O
sequencing P07864709A0324 VBG O
of P07864709A0324 IN O
the P07864709A0324 DT O
viral P07864709A0324 JJ O
nucleic P07864709A0324 NN O
acid P07864709A0324 NN O
that P07864709A0324 WDT O
encodes P07864709A0324 VBZ O
the P07864709A0324 DT O
transmembrane P07864709A0324 NN O
domain P07864709A0324 NN O
of P07864709A0324 IN O
the P07864709A0324 DT O
M2 P07864709A0324 NNP I-UN
protein P07864709A0324 NN I-UN
. P07864709A0324 . O
. . O O

They P08626540A1007 PRP O
were P08626540A1007 VBD O
found P08626540A1007 VBN O
to P08626540A1007 TO O
stimulate P08626540A1007 VB O
at P08626540A1007 IN O
nanomolar P08626540A1007 JJ O
concentrations P08626540A1007 NNS O
the P08626540A1007 DT O
turnover P08626540A1007 NN O
of P08626540A1007 IN O
biosynthetically P08626540A1007 RB O
labeled P08626540A1007 VBN O
ceramide P08626540A1007 NN O
, P08626540A1007 , O
glucosylceramide P08626540A1007 NN O
, P08626540A1007 , O
and P08626540A1007 CC O
lactosylceramide P08626540A1007 RB O
. P08626540A1007 . O
. . O O

In P02078570A0287 IN O
all P02078570A0287 DT O
cases P02078570A0287 NNS O
, P02078570A0287 , O
high-level P02078570A0287 JJ O
expression P02078570A0287 NN O
of P02078570A0287 IN O
the P02078570A0287 DT O
truncated P02078570A0287 JJ I-UN
avian P02078570A0287 JJ I-UN
integrins P02078570A0287 NNS I-UN
was P02078570A0287 VBD O
obtained P02078570A0287 VBN O
. P02078570A0287 . O
. . O O

Neonatal P02518645T0001 NNP O
Chagas P02518645T0001 NNP O
disease P02518645T0001 NN O
: P02518645T0001 : O
laboratory P02518645T0001 JJ O
diagnosis P02518645T0001 NN O
during P02518645T0001 IN O
the P02518645T0001 DT O
first P02518645T0001 JJ O
year P02518645T0001 NN O
of P02518645T0001 IN O
life P02518645T0001 NN O
. P02518645T0001 . O
. . O O

Mapping P02521674T0000 NN O
of P02521674T0000 IN O
RNA- P02521674T0000 NNP O
temperature-sensitive P02521674T0000 JJ I-UN
mutants P02521674T0000 NNS I-UN
of P02521674T0000 IN I-UN
Sindbis P02521674T0000 NNP I-UN
virus P02521674T0000 NN I-UN
: P02521674T0000 : I-UN
complementation P02521674T0000 NN I-UN
group P02521674T0000 NN I-UN
F P02521674T0000 NNP I-UN
mutants P02521674T0000 NNS I-UN
have P02521674T0000 VBP O
lesions P02521674T0000 NNS O
in P02521674T0000 IN O
nsP4 P02521674T0000 NN I-UN
. P02521674T0000 . O
. . O O

It P03232410A1467 PRP O
has P03232410A1467 VBZ O
been P03232410A1467 VBN O
calculated P03232410A1467 VBN O
that P03232410A1467 IN O
600,000 P03232410A1467 CD O
new P03232410A1467 JJ O
cases P03232410A1467 NNS O
of P03232410A1467 IN O
lung P03232410A1467 NN O
cancer P03232410A1467 NN O
occur P03232410A1467 VBP O
worldwide P03232410A1467 IN O
every P03232410A1467 DT O
year P03232410A1467 NN O
, P03232410A1467 , O
most P03232410A1467 JJS O
of P03232410A1467 IN O
them P03232410A1467 PRP O
due P03232410A1467 JJ O
to P03232410A1467 TO O
smoking P03232410A1467 VBG O
. P03232410A1467 . O
. . O O

Setting P06931124A0109 VBG O
takes P06931124A0109 VBZ O
place P06931124A0109 NN O
through P06931124A0109 IN O
complex P06931124A0109 JJ O
formation P06931124A0109 NN O
of P06931124A0109 IN O
( P06931124A0109 ( O
NH4Mg P06931124A0109 NNP O
PO4.6H2O P06931124A0109 NNP O
) P06931124A0109 ) O
n P06931124A0109 NN O
, P06931124A0109 , O
excess P06931124A0109 JJ O
reactants P06931124A0109 NNS O
, P06931124A0109 , O
and P06931124A0109 CC O
water P06931124A0109 NN O
. P06931124A0109 . O
. . O O

In P02001033A1907 IN O
summary P02001033A1907 JJ O
, P02001033A1907 , O
at P02001033A1907 IN O
equianesthetic P02001033A1907 JJ O
concentrations P02001033A1907 NNS O
, P02001033A1907 , O
desflurane P02001033A1907 NN O
and P02001033A1907 CC O
isoflurane P02001033A1907 NN O
produced P02001033A1907 VBD O
similar P02001033A1907 JJ O
hemodynamic P02001033A1907 JJ O
effects P02001033A1907 NNS O
; P02001033A1907 : O
however P02001033A1907 RB O
, P02001033A1907 , O
in P02001033A1907 IN O
the P02001033A1907 DT O
absence P02001033A1907 NN O
of P02001033A1907 IN O
drugs P02001033A1907 NNS O
that P02001033A1907 WDT O
inhibit P02001033A1907 VBP O
autonomic P02001033A1907 JJ O
reflexes P02001033A1907 NNS O
, P02001033A1907 , O
desflurane P02001033A1907 NN O
had P02001033A1907 VBD O
less P02001033A1907 RBR O
negative P02001033A1907 JJ O
inotropic P02001033A1907 NN O
activity P02001033A1907 NN O
and P02001033A1907 CC O
produced P02001033A1907 VBD O
less P02001033A1907 JJR O
decrease P02001033A1907 NN O
in P02001033A1907 IN O
arterial P02001033A1907 JJ O
pressure P02001033A1907 NN O
. P02001033A1907 . O
. . O O

Immediately P10487307A0768 RB O
before P10487307A0768 IN O
surgery P10487307A0768 NN O
patients P10487307A0768 NNS O
received P10487307A0768 VBD O
either P10487307A0768 RB O
intravenous P10487307A0768 JJ O
hydrocortisone P10487307A0768 NN O
100 P10487307A0768 CD O
mg P10487307A0768 NN O
or P10487307A0768 CC O
placebo P10487307A0768 NN O
in P10487307A0768 IN O
random P10487307A0768 NN O
, P10487307A0768 , O
double-blind P10487307A0768 JJ O
order P10487307A0768 NN O
. P10487307A0768 . O
. . O O

Apparent P08572616A0000 JJ O
loss P08572616A0000 NN O
of P08572616A0000 IN O
differentiation P08572616A0000 NN O
markers P08572616A0000 NNS O
characterizes P08572616A0000 VBP O
advanced P08572616A0000 JJ O
malignant P08572616A0000 JJ O
neoplasms P08572616A0000 NNS O
. P08572616A0000 . O
. . O O

The P09129147A0644 DT O
Jem P09129147A0644 NNP I-UN
peptide P09129147A0644 NN O
sequence P09129147A0644 NN O
shows P09129147A0644 VBZ O
a P09129147A0644 DT O
'leucine-zipper P09129147A0644 JJ O
' P09129147A0644 POS O
dimerisation P09129147A0644 NN O
motif P09129147A0644 NN O
with P09129147A0644 IN O
limited P09129147A0644 JJ O
homology P09129147A0644 NN O
to P09129147A0644 TO O
Fos P09129147A0644 NNP I-UN
/ P09129147A0644 NNP O
Jun P09129147A0644 NNP I-UN
and P09129147A0644 CC O
ATF P09129147A0644 NNP I-UN
/ P09129147A0644 NNP O
CREB P09129147A0644 NNP I-UN
proteins P09129147A0644 NNS O
and P09129147A0644 CC O
several P09129147A0644 JJ O
putative P09129147A0644 JJ O
phosphorylation P09129147A0644 NN O
sites P09129147A0644 NNS O
. P09129147A0644 . O
. . O O

A P07500950A0000 DT O
tobacco P07500950A0000 NN O
homologue P07500950A0000 NN O
( P07500950A0000 ( O
trolC P07500950A0000 NN I-UN
) P07500950A0000 ) O
of P07500950A0000 IN O
the P07500950A0000 DT O
rolC P07500950A0000 JJ I-UN
gene P07500950A0000 NN I-UN
of P07500950A0000 IN I-UN
the P07500950A0000 DT I-UN
Agrobacterium P07500950A0000 NNP I-UN
rhizogenes P07500950A0000 NNS I-UN
Ri-plasmid P07500950A0000 NNP I-UN
was P07500950A0000 VBD O
cloned P07500950A0000 VBN O
and P07500950A0000 CC O
sequenced P07500950A0000 VBN O
from P07500950A0000 IN O
Nicotiana P07500950A0000 NNP O
tabacum P07500950A0000 NNP O
L. P07500950A0000 NNP O
cv P07500950A0000 NN O
. P07500950A0000 . O
. . O O

This P01742341A0499 DT O
study P01742341A0499 NN O
confirms P01742341A0499 VBZ O
, P01742341A0499 , O
although P01742341A0499 IN O
individual P01742341A0499 JJ O
reaction P01742341A0499 NN O
is P01742341A0499 VBZ O
remarkably P01742341A0499 RB O
different P01742341A0499 JJ O
, P01742341A0499 , O
transportation P01742341A0499 NN O
as P01742341A0499 IN O
a P01742341A0499 DT O
potent P01742341A0499 NN O
stressor P01742341A0499 NN O
for P01742341A0499 IN O
Beagle P01742341A0499 NNP O
dogs P01742341A0499 NNS O
. P01742341A0499 . O
. . O O

Taxonomically P04579436T0000 RB O
significant P04579436T0000 JJ O
colour P04579436T0000 NN O
changes P04579436T0000 NNS O
in P04579436T0000 IN O
Brevibacterium P04579436T0000 NNP O
linens P04579436T0000 VBZ O
probably P04579436T0000 RB O
associated P04579436T0000 VBN O
with P04579436T0000 IN O
a P04579436T0000 DT O
carotenoid-like P04579436T0000 JJ O
pigment P04579436T0000 NN O
. P04579436T0000 . O
. . O O

Autotransplantation P03829848T0001 NN O
of P03829848T0001 IN O
a P03829848T0001 DT O
vein P03829848T0001 NN O
segment P03829848T0001 NN O
with P03829848T0001 IN O
valve P03829848T0001 NN O
in P03829848T0001 IN O
the P03829848T0001 DT O
treatment P03829848T0001 NN O
of P03829848T0001 IN O
deep P03829848T0001 JJ O
vein P03829848T0001 NN O
valvular P03829848T0001 JJ O
insufficiency P03829848T0001 NN O
of P03829848T0001 IN O
the P03829848T0001 DT O
lower P03829848T0001 JJR O
extremity P03829848T0001 NN O
. P03829848T0001 . O
. . O O

Instead P09170159A0348 RB O
, P09170159A0348 , O
they P09170159A0348 PRP O
contained P09170159A0348 VBD O
dendritic P09170159A0348 JJ O
cells P09170159A0348 NNS O
that P09170159A0348 IN O
express P09170159A0348 NN O
melanogenic P09170159A0348 JJ O
marker P09170159A0348 NN O
proteins P09170159A0348 NNS O
such P09170159A0348 JJ O
as P09170159A0348 IN O
tyrosinase P09170159A0348 NN I-UN
and P09170159A0348 CC O
tyrosinase-related P09170159A0348 JJ I-UN
protein P09170159A0348 NN I-UN
1 P09170159A0348 CD I-UN
. P09170159A0348 . O
. . O O

( P06131378A0818 ( O
iii P06131378A0818 NN O
) P06131378A0818 ) O
The P06131378A0818 DT O
mRNA P06131378A0818 NN O
is P06131378A0818 VBZ O
not P06131378A0818 RB O
efficiently P06131378A0818 RB O
polyadenylated P06131378A0818 VBN O
at P06131378A0818 IN O
sequences P06131378A0818 NNS O
in P06131378A0818 IN O
the P06131378A0818 DT O
3 P06131378A0818 CD O
' P06131378A0818 POS O
end P06131378A0818 NN O
of P06131378A0818 IN O
the P06131378A0818 DT O
DHFR P06131378A0818 NNP I-UN
cDNA P06131378A0818 NN I-UN
but P06131378A0818 CC O
rather P06131378A0818 RB O
uses P06131378A0818 VBZ O
polyadenylation P06131378A0818 NN O
signals P06131378A0818 NNS O
downstream P06131378A0818 VBP O
from P06131378A0818 IN O
the P06131378A0818 DT O
DHFR P06131378A0818 NNP I-UN
cDNA P06131378A0818 NN I-UN
. P06131378A0818 . O
. . O O

Strikingly P09572491A1044 RB O
, P09572491A1044 , O
these P09572491A1044 DT O
cells P09572491A1044 NNS O
contain P09572491A1044 VBP O
a P09572491A1044 DT O
missense P09572491A1044 JJ O
mutation P09572491A1044 NN O
of P09572491A1044 IN O
the P09572491A1044 DT O
p53 P09572491A1044 NN I-UN
gene P09572491A1044 NN I-UN
at P09572491A1044 IN O
codon P09572491A1044 $ O
242 P09572491A1044 CD O
( P09572491A1044 ( O
p53 P09572491A1044 NN I-UN
( P09572491A1044 ( O
242 P09572491A1044 CD O
) P09572491A1044 ) O
) P09572491A1044 ) O
, P09572491A1044 , O
which P09572491A1044 WDT O
substitutes P09572491A1044 VBZ O
alanine P09572491A1044 NN O
for P09572491A1044 IN O
glycine P09572491A1044 NN O
. P09572491A1044 . O
. . O O

Whole P07737024A1003 JJ O
bowel P07737024A1003 NN O
irrigation P07737024A1003 NN O
is P07737024A1003 VBZ O
a P07737024A1003 DT O
recently P07737024A1003 RB O
described P07737024A1003 VBN O
technique P07737024A1003 NN O
to P07737024A1003 TO O
enhance P07737024A1003 VB O
the P07737024A1003 DT O
passage P07737024A1003 NN O
of P07737024A1003 IN O
drugs P07737024A1003 NNS O
already P07737024A1003 RB O
beyond P07737024A1003 IN O
the P07737024A1003 DT O
pylorus P07737024A1003 NN O
. P07737024A1003 . O
. . O O

An P01340470A0000 DT O
RNA-binding P01340470A0000 JJ I-UN
protein P01340470A0000 NN I-UN
gene P01340470A0000 NN I-UN
( P01340470A0000 ( O
rbp1 P01340470A0000 NN I-UN
) P01340470A0000 ) O
from P01340470A0000 IN O
Drosophila P01340470A0000 NNP O
melanogaster P01340470A0000 NN O
, P01340470A0000 , O
encoding P01340470A0000 VBG O
an P01340470A0000 DT O
RNA P01340470A0000 NNP O
recognition P01340470A0000 NN O
motif P01340470A0000 NN O
and P01340470A0000 CC O
an P01340470A0000 DT O
Arg-Ser P01340470A0000 NNP O
rich P01340470A0000 NN O
( P01340470A0000 ( O
RS P01340470A0000 NNP O
) P01340470A0000 ) O
domain P01340470A0000 NN O
, P01340470A0000 , O
has P01340470A0000 VBZ O
been P01340470A0000 VBN O
characterized P01340470A0000 VBN O
. P01340470A0000 . O
. . O O

In P08093642A0600 IN O
addition P08093642A0600 NN O
, P08093642A0600 , O
a P08093642A0600 DT O
microsatellite P08093642A0600 JJ O
repeat P08093642A0600 NN O
polymorphism P08093642A0600 NN O
with P08093642A0600 IN O
a P08093642A0600 DT O
heterozygosity P08093642A0600 NN O
of P08093642A0600 IN O
71 P08093642A0600 CD O
% P08093642A0600 NN O
at P08093642A0600 IN O
the P08093642A0600 DT O
RET P08093642A0600 NNP I-UN
locus P08093642A0600 NN I-UN
and P08093642A0600 CC O
a P08093642A0600 DT O
restriction P08093642A0600 NN O
fragment P08093642A0600 NN O
length P08093642A0600 NN O
polymorphism P08093642A0600 NN O
with P08093642A0600 IN O
a P08093642A0600 DT O
heterozygosity P08093642A0600 NN O
of P08093642A0600 IN O
42 P08093642A0600 CD O
% P08093642A0600 NN O
detected P08093642A0600 VBN O
by P08093642A0600 IN O
a P08093642A0600 DT O
lambda P08093642A0600 JJ O
clone P08093642A0600 NN O
from P08093642A0600 IN O
the P08093642A0600 DT O
D10S94 P08093642A0600 NNP I-UN
locus P08093642A0600 NN I-UN
have P08093642A0600 VBP O
been P08093642A0600 VBN O
developed P08093642A0600 VBN O
for P08093642A0600 IN O
high-resolution P08093642A0600 NN O
genetic P08093642A0600 JJ O
linkage P08093642A0600 NN O
mapping P08093642A0600 NN O
and P08093642A0600 CC O
predictive P08093642A0600 JJ O
diagnostic P08093642A0600 JJ O
testing P08093642A0600 NN O
. P08093642A0600 . O
. . O O

The P11006331A0319 DT O
variable P11006331A0319 JJ O
phenotype P11006331A0319 NN O
of P11006331A0319 IN O
the P11006331A0319 DT O
allotetraploids P11006331A0319 NNS O
could P11006331A0319 MD O
not P11006331A0319 RB O
be P11006331A0319 VB O
explained P11006331A0319 VBN O
by P11006331A0319 IN O
cytological P11006331A0319 JJ O
abnormalities P11006331A0319 NNS O
. P11006331A0319 . O
. . O O

Histological P09354349A0338 NNP O
slides P09354349A0338 NNS O
of P09354349A0338 IN O
one P09354349A0338 CD O
biopsy P09354349A0338 NN O
of P09354349A0338 IN O
each P09354349A0338 DT O
patient P09354349A0338 NN O
( P09354349A0338 ( O
formalin-fixed P09354349A0338 JJ O
and P09354349A0338 CC O
paraffin-embedded P09354349A0338 JJ O
) P09354349A0338 ) O
were P09354349A0338 VBD O
stained P09354349A0338 VBN O
with P09354349A0338 IN O
a P09354349A0338 DT O
Modified P09354349A0338 NNP O
Giemsa P09354349A0338 NNP O
( P09354349A0338 ( O
MG P09354349A0338 NNP O
) P09354349A0338 ) O
, P09354349A0338 , O
the P09354349A0338 DT O
Warthin-Starry P09354349A0338 NNP O
( P09354349A0338 ( O
WS P09354349A0338 NNP O
) P09354349A0338 ) O
, P09354349A0338 , O
and P09354349A0338 CC O
an P09354349A0338 DT O
immunohistochemical P09354349A0338 JJ O
method P09354349A0338 NN O
( P09354349A0338 ( O
IMM P09354349A0338 NNP O
) P09354349A0338 ) O
using P09354349A0338 VBG O
purified P09354349A0338 JJ O
polyclonal P09354349A0338 JJ O
H. P09354349A0338 NNP O
pylori P09354349A0338 NN O
antiserum P09354349A0338 NN O
( P09354349A0338 ( O
DAKO P09354349A0338 NNP O
B471 P09354349A0338 NNP O
) P09354349A0338 ) O
. P09354349A0338 . O
. . O O

After P03451761A0215 IN O
a P03451761A0215 DT O
baseline P03451761A0215 NN O
study P03451761A0215 NN O
, P03451761A0215 , O
WPW P03451761A0215 NNP O
syndrome P03451761A0215 NN O
was P03451761A0215 VBD O
simulated P03451761A0215 VBN O
by P03451761A0215 IN O
stimulation P03451761A0215 NN O
at P03451761A0215 IN O
seven P03451761A0215 CD O
different P03451761A0215 JJ O
sites P03451761A0215 NNS O
around P03451761A0215 IN O
the P03451761A0215 DT O
base P03451761A0215 NN O
of P03451761A0215 IN O
the P03451761A0215 DT O
ventricles P03451761A0215 NNS O
, P03451761A0215 , O
and P03451761A0215 CC O
RNV P03451761A0215 NNP O
's P03451761A0215 POS O
were P03451761A0215 VBD O
obtained P03451761A0215 VBN O
. P03451761A0215 . O
. . O O

Tumor P07628389A0145 NN I-UN
necrosis P07628389A0145 NN I-UN
factor-alpha P07628389A0145 NN I-UN
( P07628389A0145 ( O
TNF P07628389A0145 NNP I-UN
alpha P07628389A0145 RB I-UN
) P07628389A0145 ) O
, P07628389A0145 , O
a P07628389A0145 DT O
proinflammatory P07628389A0145 NN O
cytokine P07628389A0145 NN O
, P07628389A0145 , O
inhibits P07628389A0145 VBZ O
cAMP-stimulated P07628389A0145 JJ O
testosterone P07628389A0145 NN O
production P07628389A0145 NN O
in P07628389A0145 IN O
mouse P07628389A0145 NN O
Leydig P07628389A0145 NNP O
cells P07628389A0145 NNS O
. P07628389A0145 . O
. . O O

These P01310154A0879 DT O
results P01310154A0879 NNS O
indicate P01310154A0879 VBP O
that P01310154A0879 IN O
both P01310154A0879 DT O
N- P01310154A0879 NNP O
and P01310154A0879 CC O
C-terminal P01310154A0879 JJ O
mutations P01310154A0879 NNS O
are P01310154A0879 VBP O
required P01310154A0879 VBN O
to P01310154A0879 TO O
inhibit P01310154A0879 VB O
transrepression P01310154A0879 NN O
by P01310154A0879 IN O
FBR P01310154A0879 NNP I-UN
protein P01310154A0879 NN I-UN
and P01310154A0879 CC O
that P01310154A0879 IN O
multiple P01310154A0879 JJ O
structural P01310154A0879 JJ O
mutations P01310154A0879 NNS O
accompanied P01310154A0879 VBN O
by P01310154A0879 IN O
posttranslational P01310154A0879 JJ O
protein P01310154A0879 NN O
modification P01310154A0879 NN O
alter P01310154A0879 NN O
gene P01310154A0879 NN O
regulation P01310154A0879 NN O
by P01310154A0879 IN O
FBR P01310154A0879 NNP I-UN
protein P01310154A0879 NN I-UN
. P01310154A0879 . O
. . O O

In P03931293A0437 IN O
the P03931293A0437 DT O
absence P03931293A0437 NN O
of P03931293A0437 IN O
other P03931293A0437 JJ O
stabilizers P03931293A0437 NNS O
, P03931293A0437 , O
increased P03931293A0437 VBD O
sucrose P03931293A0437 RB O
can P03931293A0437 MD O
provide P03931293A0437 VB O
increased P03931293A0437 VBD O
thermoresistance P03931293A0437 NN O
to P03931293A0437 TO O
the P03931293A0437 DT O
virus P03931293A0437 NN O
in P03931293A0437 IN O
2.5 P03931293A0437 CD O
% P03931293A0437 NN O
albumin P03931293A0437 NN I-UN
. P03931293A0437 . O
. . O O

Recombinant P08925545T0001 JJ I-UN
erythropoietin P08925545T0001 NN I-UN
( P08925545T0001 ( O
r-HuEPO P08925545T0001 JJ I-UN
) P08925545T0001 ) O
in P08925545T0001 IN O
the P08925545T0001 DT O
treatment P08925545T0001 NN O
of P08925545T0001 IN O
anemia P08925545T0001 NN O
in P08925545T0001 IN O
multiple P08925545T0001 JJ O
myeloma P08925545T0001 NN O
. P08925545T0001 . O
. . O O

Four P01620781A0611 CD O
of P01620781A0611 IN O
these P01620781A0611 DT O
five P01620781A0611 CD O
subjects P01620781A0611 NNS O
also P01620781A0611 RB O
performed P01620781A0611 VBD O
mixed P01620781A0611 JJ O
sequences P01620781A0611 NNS O
under P01620781A0611 IN O
conditional P01620781A0611 JJ O
control P01620781A0611 NN O
of P01620781A0611 IN O
the P01620781A0611 DT O
words P01620781A0611 NNS O
( P01620781A0611 ( O
e.g. P01620781A0611 NN O
, P01620781A0611 , O
A1 P01620781A0611 NNP O
-- P01620781A0611 : O
-- P01620781A0611 : O
B2 P01620781A0611 NNP O
-- P01620781A0611 : O
-- P01620781A0611 : O
A3 P01620781A0611 NNP O
-- P01620781A0611 : O
-- P01620781A0611 : O
B4 P01620781A0611 NNP O
-- P01620781A0611 : O
-- P01620781A0611 : O
A5 P01620781A0611 NNP O
and P01620781A0611 CC O
its P01620781A0611 PRP$ O
reversal P01620781A0611 NN O
) P01620781A0611 ) O
, P01620781A0611 , O
verifying P01620781A0611 VBG O
that P01620781A0611 IN O
the P01620781A0611 DT O
stimuli P01620781A0611 NN O
which P01620781A0611 WDT O
occupied P01620781A0611 VBD O
the P01620781A0611 DT O
same P01620781A0611 JJ O
position P01620781A0611 NN O
in P01620781A0611 IN O
each P01620781A0611 DT O
sequence P01620781A0611 NN O
were P01620781A0611 VBD O
members P01620781A0611 NNS O
of P01620781A0611 IN O
the P01620781A0611 DT O
same P01620781A0611 JJ O
class P01620781A0611 NN O
. P01620781A0611 . O
. . O O

We P08288596A0663 PRP O
found P08288596A0663 VBD O
that P08288596A0663 IN O
T3 P08288596A0663 NNP O
( P08288596A0663 ( O
10 P08288596A0663 CD O
( P08288596A0663 ( O
-8 P08288596A0663 NN O
) P08288596A0663 ) O
M P08288596A0663 NNP O
) P08288596A0663 ) O
selectively P08288596A0663 RB O
stimulates P08288596A0663 VBZ O
transcription P08288596A0663 NN O
from P08288596A0663 IN O
rGH-TRE- P08288596A0663 JJ O
and P08288596A0663 CC O
TREpal- P08288596A0663 JJ O
, P08288596A0663 , O
but P08288596A0663 CC O
not P08288596A0663 RB O
ME-TRE- P08288596A0663 NNP O
and P08288596A0663 CC O
F2-TRE- P08288596A0663 NNP O
, P08288596A0663 , O
containing P08288596A0663 VBG O
templates P08288596A0663 NNS O
in P08288596A0663 IN O
which P08288596A0663 WDT O
these P08288596A0663 DT O
TREs P08288596A0663 NNP O
are P08288596A0663 VBP O
linked P08288596A0663 VBN O
in P08288596A0663 IN O
front P08288596A0663 NN O
of P08288596A0663 IN O
the P08288596A0663 DT O
rGH P08288596A0663 NN I-UN
minimal P08288596A0663 JJ I-UN
promoter P08288596A0663 NN I-UN
containing P08288596A0663 VBG O
only P08288596A0663 RB O
the P08288596A0663 DT O
TATA P08288596A0663 NNP I-UN
box P08288596A0663 NN I-UN
binding P08288596A0663 VBG I-UN
protein P08288596A0663 NN I-UN
, P08288596A0663 , O
but P08288596A0663 CC O
not P08288596A0663 RB O
any P08288596A0663 DT O
other P08288596A0663 JJ O
proximal P08288596A0663 JJ O
binding P08288596A0663 VBG O
protein P08288596A0663 NN O
, P08288596A0663 , O
sequence P08288596A0663 NN O
. P08288596A0663 . O
. . O O

Thus P09153348A0647 RB O
, P09153348A0647 , O
an P09153348A0647 DT O
increase P09153348A0647 NN O
in P09153348A0647 IN O
plasma P09153348A0647 JJ I-UN
TBG P09153348A0647 NNP I-UN
and P09153348A0647 CC O
a P09153348A0647 DT O
shift P09153348A0647 NN O
from P09153348A0647 IN O
adrenal P09153348A0647 JJ O
androgen P09153348A0647 NN O
and P09153348A0647 CC O
mineralocorticoid P09153348A0647 JJ O
steroid P09153348A0647 NN O
secretion P09153348A0647 NN O
towards P09153348A0647 NNS O
cortisol P09153348A0647 VBP O
secretion P09153348A0647 NN O
may P09153348A0647 MD O
be P09153348A0647 VB O
endocrine P09153348A0647 JJ O
markers P09153348A0647 NNS O
for P09153348A0647 IN O
progression P09153348A0647 NN O
of P09153348A0647 IN O
the P09153348A0647 DT O
disease P09153348A0647 NN O
in P09153348A0647 IN O
patients P09153348A0647 NNS O
with P09153348A0647 IN O
HIV-infection P09153348A0647 NNP O
. P09153348A0647 . O
. . O O

There P07942448A1227 EX O
were P07942448A1227 VBD O
9 P07942448A1227 CD O
patients P07942448A1227 NNS O
in P07942448A1227 IN O
NYHA P07942448A1227 NNP O
class P07942448A1227 NN O
III P07942448A1227 NNP O
and P07942448A1227 CC O
8 P07942448A1227 CD O
in P07942448A1227 IN O
class P07942448A1227 NN O
IV P07942448A1227 NNP O
. P07942448A1227 . O
( P07942448A1227 ( O
ABSTRACT P07942448A1227 NNP O
TRUNCATED P07942448A1227 NNP O
AT P07942448A1227 NNP O
250 P07942448A1227 CD O
WORDS P07942448A1227 NNP O
) P07942448A1227 ) O
. P07942448A1227 . O
. . O O

A P09505733A0246 DT O
review P09505733A0246 NN O
of P09505733A0246 IN O
studies P09505733A0246 NNS O
published P09505733A0246 VBN O
between P09505733A0246 IN O
1983 P09505733A0246 CD O
and P09505733A0246 CC O
1995 P09505733A0246 CD O
shows P09505733A0246 NNS O
that P09505733A0246 IN O
there P09505733A0246 EX O
are P09505733A0246 VBP O
some P09505733A0246 DT O
common P09505733A0246 JJ O
factors P09505733A0246 NNS O
as P09505733A0246 IN O
regards P09505733A0246 NNS O
the P09505733A0246 DT O
psychological P09505733A0246 JJ O
distress P09505733A0246 NN O
and P09505733A0246 CC O
social P09505733A0246 JJ O
and P09505733A0246 CC O
functional P09505733A0246 JJ O
limitations P09505733A0246 NNS O
this P09505733A0246 DT O
group P09505733A0246 NN O
of P09505733A0246 IN O
patients P09505733A0246 NNS O
has P09505733A0246 VBZ O
to P09505733A0246 TO O
deal P09505733A0246 VB O
with P09505733A0246 IN O
. P09505733A0246 . O
. . O O

SM P10400785A0912 NNP I-UN
is P10400785A0912 VBZ O
also P10400785A0912 RB O
shown P10400785A0912 VBN O
to P10400785A0912 TO O
be P10400785A0912 VB O
associated P10400785A0912 VBN O
in P10400785A0912 IN O
vivo P10400785A0912 NN O
with P10400785A0912 IN O
other P10400785A0912 JJ O
components P10400785A0912 NNS O
of P10400785A0912 IN O
the P10400785A0912 DT O
CRM P10400785A0912 NNP I-UN
1 P10400785A0912 CD I-UN
export P10400785A0912 NN O
pathway P10400785A0912 NN O
, P10400785A0912 , O
including P10400785A0912 VBG O
the P10400785A0912 DT O
small P10400785A0912 JJ I-UN
GTPase P10400785A0912 NNP I-UN
Ran P10400785A0912 NNP I-UN
and P10400785A0912 CC O
the P10400785A0912 DT O
nucleoporin P10400785A0912 NN O
CAN P10400785A0912 NNP I-UN
/ P10400785A0912 NNP O
Nup214 P10400785A0912 NNP I-UN
. P10400785A0912 . O
. . O O

The P09822647A0000 DT O
rat P09822647A0000 NN I-UN
aldolase P09822647A0000 NN I-UN
C P09822647A0000 NNP I-UN
gene P09822647A0000 NN I-UN
encodes P09822647A0000 VBZ O
a P09822647A0000 DT O
glycolytic P09822647A0000 JJ O
enzyme P09822647A0000 NN O
strongly P09822647A0000 RB O
expressed P09822647A0000 VBN O
in P09822647A0000 IN O
adult P09822647A0000 NN O
brain P09822647A0000 NN O
. P09822647A0000 . O
. . O O

The P11580301A1161 DT O
diagnosis P11580301A1161 NN O
of P11580301A1161 IN O
HCV P11580301A1161 NNP O
arthritis P11580301A1161 NN O
in P11580301A1161 IN O
patients P11580301A1161 NNS O
with P11580301A1161 IN O
positive P11580301A1161 JJ O
rheumatoid P11580301A1161 NN I-UN
factor P11580301A1161 NN I-UN
and P11580301A1161 CC O
chronic P11580301A1161 JJ O
inflammatory P11580301A1161 NN O
polyarthritis P11580301A1161 NN O
may P11580301A1161 MD O
be P11580301A1161 VB O
difficult P11580301A1161 JJ O
. P11580301A1161 . O
. . O O

The P02022920A0334 DT O
C4BP P02022920A0334 NNP I-UN
alpha P02022920A0334 NN I-UN
gene P02022920A0334 NN I-UN
is P02022920A0334 VBZ O
organized P02022920A0334 VBN O
as P02022920A0334 IN O
follows P02022920A0334 VBZ O
: P02022920A0334 : O
the P02022920A0334 DT O
first P02022920A0334 JJ O
exon P02022920A0334 NN O
codes P02022920A0334 NNS O
for P02022920A0334 IN O
the P02022920A0334 DT O
first P02022920A0334 JJ O
198 P02022920A0334 CD O
nucleotides P02022920A0334 NNS O
of P02022920A0334 IN O
the P02022920A0334 DT O
5 P02022920A0334 CD O
' P02022920A0334 POS O
UTR P02022920A0334 NNP O
. P02022920A0334 . O
. . O O

A P07798217T0095 DT O
role P07798217T0095 NN O
for P07798217T0095 IN O
glycogen P07798217T0095 JJ I-UN
synthase P07798217T0095 NN I-UN
kinase-3 P07798217T0095 NN I-UN
in P07798217T0095 IN O
the P07798217T0095 DT O
control P07798217T0095 NN O
of P07798217T0095 IN O
gene P07798217T0095 NN O
expression P07798217T0095 NN O
. P07798217T0095 . O
. . O O

RESULTS P10973400A0664 NN O
: P10973400A0664 : O
No P10973400A0664 DT O
significant P10973400A0664 JJ O
deformation P10973400A0664 NN O
in P10973400A0664 IN O
vertebral P10973400A0664 JJ O
artery P10973400A0664 NN O
flow P10973400A0664 NN O
was P10973400A0664 VBD O
noted P10973400A0664 VBN O
in P10973400A0664 IN O
the P10973400A0664 DT O
flexion-distraction P10973400A0664 NN O
Stage P10973400A0664 NN O
I P10973400A0664 PRP O
injuries P10973400A0664 VBP O
within P10973400A0664 IN O
the P10973400A0664 DT O
physiologic P10973400A0664 JJ O
range P10973400A0664 NN O
of P10973400A0664 IN O
cervical P10973400A0664 JJ O
flexion P10973400A0664 NN O
. P10973400A0664 . O
. . O O

These P00423649A0259 DT O
techniques P00423649A0259 NNS O
have P00423649A0259 VBP O
been P00423649A0259 VBN O
used P00423649A0259 VBN O
by P00423649A0259 IN O
many P00423649A0259 JJ O
people P00423649A0259 NNS O
for P00423649A0259 IN O
many P00423649A0259 JJ O
years P00423649A0259 NNS O
and P00423649A0259 CC O
no P00423649A0259 DT O
claim P00423649A0259 NN O
is P00423649A0259 VBZ O
being P00423649A0259 VBG O
made P00423649A0259 VBN O
for P00423649A0259 IN O
any P00423649A0259 DT O
innovation P00423649A0259 NN O
in P00423649A0259 IN O
this P00423649A0259 DT O
regard P00423649A0259 NN O
. P00423649A0259 . O
. . O O

The P08516324A0000 DT O
11 P08516324A0000 CD O
; P08516324A0000 : O
22 P08516324A0000 CD O
chromosomal P08516324A0000 JJ O
translocation P08516324A0000 NN O
specifically P08516324A0000 RB O
linked P08516324A0000 VBN O
to P08516324A0000 TO O
Ewing P08516324A0000 NNP O
sarcoma P08516324A0000 NN O
and P08516324A0000 CC O
primitive P08516324A0000 JJ O
neuroectodermal P08516324A0000 JJ O
tumor P08516324A0000 NN O
results P08516324A0000 NNS O
in P08516324A0000 IN O
a P08516324A0000 DT O
chimeric P08516324A0000 JJ O
molecule P08516324A0000 NN O
fusing P08516324A0000 VBG O
the P08516324A0000 DT O
amino-terminal-encoding P08516324A0000 JJ O
portion P08516324A0000 NN O
of P08516324A0000 IN O
the P08516324A0000 DT O
EWS P08516324A0000 NNP I-UN
gene P08516324A0000 NN I-UN
to P08516324A0000 TO O
the P08516324A0000 DT O
carboxyl-terminal P08516324A0000 JJ O
DNA-binding P08516324A0000 NNP O
domain P08516324A0000 NN O
encoded P08516324A0000 VBN O
by P08516324A0000 IN O
the P08516324A0000 DT O
FLI1 P08516324A0000 NNP I-UN
gene P08516324A0000 NN I-UN
. P08516324A0000 . O
. . O O

The P08987009A0400 DT O
patient P08987009A0400 NN O
's P08987009A0400 POS O
role P08987009A0400 NN O
, P08987009A0400 , O
organized P08987009A0400 VBN O
by P08987009A0400 IN O
the P08987009A0400 DT O
prerequisites P08987009A0400 NNS O
of P08987009A0400 IN O
expressive P08987009A0400 JJ O
freedom P08987009A0400 NN O
, P08987009A0400 , O
is P08987009A0400 VBZ O
counter P08987009A0400 RB O
posed P08987009A0400 VBN O
with P08987009A0400 IN O
the P08987009A0400 DT O
psychoanalyst P08987009A0400 NN O
's P08987009A0400 POS O
, P08987009A0400 , O
which P08987009A0400 WDT O
is P08987009A0400 VBZ O
structured P08987009A0400 VBN O
to P08987009A0400 TO O
empower P08987009A0400 VB O
listening P08987009A0400 NN O
and P08987009A0400 CC O
understanding P08987009A0400 NN O
. P08987009A0400 . O
. . O O

Furthermore P09372924A0758 RB O
, P09372924A0758 , O
both P09372924A0758 DT O
rhHR23 P09372924A0758 VBP I-UN
proteins P09372924A0758 NNS I-UN
function P09372924A0758 VBP O
in P09372924A0758 IN O
a P09372924A0758 DT O
defined P09372924A0758 JJ O
NER P09372924A0758 NNP O
system P09372924A0758 NN O
reconstituted P09372924A0758 VBD O
with P09372924A0758 IN O
purified P09372924A0758 JJ O
proteins P09372924A0758 NNS O
, P09372924A0758 , O
indicating P09372924A0758 VBG O
direct P09372924A0758 JJ O
involvement P09372924A0758 NN O
of P09372924A0758 IN O
hHR23 P09372924A0758 NN I-UN
proteins P09372924A0758 NNS I-UN
in P09372924A0758 IN O
the P09372924A0758 DT O
DNA P09372924A0758 NNP O
repair P09372924A0758 NN O
reaction P09372924A0758 NN O
via P09372924A0758 IN O
interaction P09372924A0758 NN O
with P09372924A0758 IN O
XPC P09372924A0758 NNP I-UN
. P09372924A0758 . O
. . O O

Feline P08828142A0000 NNP O
leukemia P08828142A0000 NN O
viruses P08828142A0000 NNS O
( P08828142A0000 ( O
FeLVs P08828142A0000 NNP O
) P08828142A0000 ) O
, P08828142A0000 , O
which P08828142A0000 WDT O
are P08828142A0000 VBP O
replication-competent P08828142A0000 JJ O
oncoretroviruses P08828142A0000 NNS O
of P08828142A0000 IN O
the P08828142A0000 DT O
domestic P08828142A0000 JJ O
cat P08828142A0000 NN O
species P08828142A0000 NNS O
, P08828142A0000 , O
are P08828142A0000 VBP O
contagiously P08828142A0000 RB O
transmitted P08828142A0000 VBN O
in P08828142A0000 IN O
natural P08828142A0000 JJ O
environments P08828142A0000 NNS O
. P08828142A0000 . O
. . O O

For P02228615A0974 IN O
85Sr P02228615A0974 CD O
, P02228615A0974 , O
larger-than-expected P02228615A0974 JJ O
distribution P02228615A0974 NN O
coefficients P02228615A0974 NNS O
were P02228615A0974 VBD O
obtained P02228615A0974 VBN O
in P02228615A0974 IN O
the P02228615A0974 DT O
desorption P02228615A0974 NN O
experiments P02228615A0974 NNS O
, P02228615A0974 , O
an P02228615A0974 DT O
indication P02228615A0974 NN O
of P02228615A0974 IN O
the P02228615A0974 DT O
irreversible P02228615A0974 JJ O
formation P02228615A0974 NN O
of P02228615A0974 IN O
metal-oxyhydroxides P02228615A0974 NNS O
during P02228615A0974 IN O
a P02228615A0974 DT O
slow P02228615A0974 JJ O
reaction P02228615A0974 NN O
. P02228615A0974 . O
. . O O

The P02334972A0145 DT O
examination P02334972A0145 NN O
was P02334972A0145 VBD O
focused P02334972A0145 VBN O
on P02334972A0145 IN O
assessment P02334972A0145 NN O
of P02334972A0145 IN O
different P02334972A0145 JJ O
types P02334972A0145 NNS O
of P02334972A0145 IN O
drusen P02334972A0145 NN O
, P02334972A0145 , O
on P02334972A0145 IN O
evaluation P02334972A0145 NN O
of P02334972A0145 IN O
the P02334972A0145 DT O
development P02334972A0145 NN O
and P02334972A0145 CC O
incidence P02334972A0145 NN O
of P02334972A0145 IN O
risk P02334972A0145 NN O
factors P02334972A0145 NNS O
leading P02334972A0145 VBG O
to P02334972A0145 TO O
complications P02334972A0145 NNS O
and P02334972A0145 CC O
loss P02334972A0145 NN O
of P02334972A0145 IN O
central P02334972A0145 JJ O
vision P02334972A0145 NN O
. P02334972A0145 . O
. . O O

BSE P07475793T0000 NNP O
and P07475793T0000 CC O
farmworkers P07475793T0000 NNS O
. P07475793T0000 . O
. . O O

As P09300323A1182 IN O
a P09300323A1182 DT O
result P09300323A1182 NN O
, P09300323A1182 , O
the P09300323A1182 DT O
subendocardial P09300323A1182 JJ O
/ P09300323A1182 NNP O
subepicardial P09300323A1182 JJ O
blood P09300323A1182 NN O
flow P09300323A1182 NN O
ratio P09300323A1182 NN O
( P09300323A1182 ( O
ENDO P09300323A1182 NNP O
/ P09300323A1182 NNP O
EPI P09300323A1182 NNP O
) P09300323A1182 ) O
increased P09300323A1182 VBD O
from P09300323A1182 IN O
0.44 P09300323A1182 CD O
+ P09300323A1182 NNS O
/ P09300323A1182 SYM O
- P09300323A1182 : O
0.09 P09300323A1182 CD O
during P09300323A1182 IN O
control P09300323A1182 NN O
stenosis P09300323A1182 NN O
to P09300323A1182 TO O
0.85 P09300323A1182 CD O
+ P09300323A1182 NNS O
/ P09300323A1182 SYM O
- P09300323A1182 : O
0.13 P09300323A1182 CD O
after P09300323A1182 IN O
ITF P09300323A1182 JJ O
1129 P09300323A1182 CD O
( P09300323A1182 ( O
10 P09300323A1182 CD O
micrograms P09300323A1182 NNS O
/ P09300323A1182 VBP O
kg P09300323A1182 JJ O
/ P09300323A1182 NNP O
min P09300323A1182 NN O
i.v P09300323A1182 NN O
. P09300323A1182 . O
) P09300323A1182 ) O
and P09300323A1182 CC O
to P09300323A1182 TO O
0.81 P09300323A1182 CD O
+ P09300323A1182 NNS O
/ P09300323A1182 SYM O
- P09300323A1182 : O
0.12 P09300323A1182 CD O
after P09300323A1182 IN O
NTG P09300323A1182 NNP O
. P09300323A1182 . O
. . O O

In P03668003T0000 IN O
vivo P03668003T0000 JJ O
epiluminescence P03668003T0000 NN O
microscopy P03668003T0000 NN O
of P03668003T0000 IN O
pigmented P03668003T0000 JJ O
skin P03668003T0000 JJ O
lesions P03668003T0000 NNS O
. P03668003T0000 . O
. . O O

These P07919540A0240 DT O
genetic P07919540A0240 JJ O
alterations P07919540A0240 NNS O
do P07919540A0240 VBP O
not P07919540A0240 RB O
affect P07919540A0240 VB O
synthesis P07919540A0240 NN O
of P07919540A0240 IN O
the P07919540A0240 DT O
major P07919540A0240 JJ O
c-myc P07919540A0240 JJ I-UN
protein P07919540A0240 NN I-UN
, P07919540A0240 , O
p64 P07919540A0240 NN I-UN
, P07919540A0240 , O
which P07919540A0240 WDT O
is P07919540A0240 VBZ O
initiated P07919540A0240 VBN O
from P07919540A0240 IN O
the P07919540A0240 DT O
first P07919540A0240 JJ O
AUG P07919540A0240 NNP O
codon P07919540A0240 NN O
in P07919540A0240 IN O
exon P07919540A0240 JJ O
2 P07919540A0240 CD O
. P07919540A0240 . O
. . O O

The P08622596A0189 DT O
men P08622596A0189 NNS O
self-selected P08622596A0189 VBD O
a P08622596A0189 DT O
prescribed P08622596A0189 JJ O
diet P08622596A0189 NN O
at P08622596A0189 IN O
home P08622596A0189 NN O
emphasizing P08622596A0189 NN O
saturated P08622596A0189 VBD O
fat P08622596A0189 JJ O
as P08622596A0189 IN O
the P08622596A0189 DT O
visible P08622596A0189 JJ O
fat P08622596A0189 NN O
for P08622596A0189 IN O
1 P08622596A0189 CD O
week P08622596A0189 NN O
. P08622596A0189 . O
. . O O

A P08812490A0000 DT O
1.8-kb P08812490A0000 JJ O
cDNA P08812490A0000 NN O
clone P08812490A0000 NN O
( P08812490A0000 ( O
designed P08812490A0000 VBN O
hKID P08812490A0000 NN I-UN
, P08812490A0000 , O
gene P08812490A0000 NN I-UN
symbol P08812490A0000 NN I-UN
AQP2L P08812490A0000 NNP I-UN
) P08812490A0000 ) O
with P08812490A0000 IN O
homology P08812490A0000 NN O
to P08812490A0000 TO O
the P08812490A0000 DT O
aquaporins P08812490A0000 NNS I-UN
was P08812490A0000 VBD O
isolated P08812490A0000 VBN O
from P08812490A0000 IN O
a P08812490A0000 DT O
human P08812490A0000 JJ O
kidney P08812490A0000 NN O
cDNA P08812490A0000 NN O
library P08812490A0000 NN O
. P08812490A0000 . O
. . O O

We P08858463A0853 PRP O
conclude P08858463A0853 VBP O
that P08858463A0853 DT O
, P08858463A0853 , O
in P08858463A0853 IN O
AIDS P08858463A0853 NNP O
patients P08858463A0853 NNS O
with P08858463A0853 IN O
cryptococcosis P08858463A0853 NN O
, P08858463A0853 , O
tolerance P08858463A0853 NN O
to P08858463A0853 TO O
ILd-AmB P08858463A0853 NNP O
was P08858463A0853 VBD O
acceptable P08858463A0853 JJ O
when P08858463A0853 WRB O
the P08858463A0853 DT O
daily P08858463A0853 JJ O
dosage P08858463A0853 NN O
did P08858463A0853 VBD O
not P08858463A0853 RB O
exceed P08858463A0853 VB O
1 P08858463A0853 CD O
mg P08858463A0853 JJ O
/ P08858463A0853 NNP O
kg P08858463A0853 NN O
, P08858463A0853 , O
but P08858463A0853 CC O
the P08858463A0853 DT O
higher P08858463A0853 JJR O
1.5 P08858463A0853 CD O
mg P08858463A0853 NNS O
/ P08858463A0853 JJ O
kg P08858463A0853 JJ O
daily P08858463A0853 JJ O
dosage P08858463A0853 NN O
was P08858463A0853 VBD O
associated P08858463A0853 VBN O
with P08858463A0853 IN O
an P08858463A0853 DT O
unacceptable P08858463A0853 JJ O
rate P08858463A0853 NN O
of P08858463A0853 IN O
nephrotoxicity P08858463A0853 NN O
. P08858463A0853 . O
. . O O

These P07225300A0968 DT O
results P07225300A0968 NNS O
show P07225300A0968 VBP O
that P07225300A0968 IN O
the P07225300A0968 DT O
neonate P07225300A0968 JJ O
differs P07225300A0968 NNS O
from P07225300A0968 IN O
the P07225300A0968 DT O
adult P07225300A0968 NN O
in P07225300A0968 IN O
respect P07225300A0968 NN O
of P07225300A0968 IN O
both P07225300A0968 DT O
the P07225300A0968 DT O
nature P07225300A0968 NN O
of P07225300A0968 IN O
effects P07225300A0968 NNS O
of P07225300A0968 IN O
the P07225300A0968 DT O
drug P07225300A0968 NN O
and P07225300A0968 CC O
sensitivity P07225300A0968 NN O
to P07225300A0968 TO O
it P07225300A0968 PRP O
. P07225300A0968 . O
. . O O

The P01782424A0278 DT O
existence P01782424A0278 NN O
of P01782424A0278 IN O
threshold P01782424A0278 JJ O
concentrations P01782424A0278 NNS O
, P01782424A0278 , O
above P01782424A0278 IN O
which P01782424A0278 WDT O
certain P01782424A0278 JJ O
phenomena P01782424A0278 NNS O
may P01782424A0278 MD O
occur P01782424A0278 VB O
, P01782424A0278 , O
strengthens P01782424A0278 VBZ O
the P01782424A0278 DT O
role P01782424A0278 NN O
of P01782424A0278 IN O
sentinels P01782424A0278 NNS O
. P01782424A0278 . O
. . O O

Using P10487759A0630 VBG O
transgenic P10487759A0630 JJ O
Xenopus P10487759A0630 NN O
embryos P10487759A0630 NN O
, P10487759A0630 , O
we P10487759A0630 PRP O
demonstrate P10487759A0630 VBP O
that P10487759A0630 IN O
the P10487759A0630 DT O
integrity P10487759A0630 NN O
of P10487759A0630 IN O
these P10487759A0630 DT O
two P10487759A0630 CD O
sequences P10487759A0630 NNS O
is P10487759A0630 VBZ O
necessary P10487759A0630 JJ O
for P10487759A0630 IN O
correct P10487759A0630 JJ O
spatial P10487759A0630 JJ O
expression P10487759A0630 NN O
of P10487759A0630 IN O
a P10487759A0630 DT O
Xbra2 P10487759A0630 NNP I-UN
promoter-driven P10487759A0630 JJ I-UN
reporter P10487759A0630 NN I-UN
gene P10487759A0630 NN I-UN
. P10487759A0630 . O
. . O O

At P01372365A1202 IN O
some P01372365A1202 DT O
sites P01372365A1202 NNS O
, P01372365A1202 , O
% P01372365A1202 NN O
T P01372365A1202 NNP O
is P01372365A1202 VBZ O
greatly P01372365A1202 RB O
increased P01372365A1202 VBN O
by P01372365A1202 IN O
Cl- P01372365A1202 NNP O
concentrations P01372365A1202 NNS O
up P01372365A1202 RB O
to P01372365A1202 TO O
1 P01372365A1202 CD O
M P01372365A1202 NNP O
, P01372365A1202 , O
while P01372365A1202 IN O
at P01372365A1202 IN O
other P01372365A1202 JJ O
sites P01372365A1202 NNS O
% P01372365A1202 NN O
T P01372365A1202 NNP O
is P01372365A1202 VBZ O
reduced P01372365A1202 VBN O
or P01372365A1202 CC O
unaffected P01372365A1202 VBN O
by P01372365A1202 IN O
these P01372365A1202 DT O
conditions P01372365A1202 NNS O
. P01372365A1202 . O
. . O O

The P11023074A1105 DT O
cost P11023074A1105 NN O
per P11023074A1105 IN O
test P11023074A1105 NN O
is P11023074A1105 VBZ O
less P11023074A1105 RBR O
than P11023074A1105 IN O
those P11023074A1105 DT O
for P11023074A1105 IN O
CC P11023074A1105 NNP O
, P11023074A1105 , O
kEIA P11023074A1105 NN O
and P11023074A1105 CC O
PACE2 P11023074A1105 NNP O
. P11023074A1105 . O
. . O O

In P07794556A0000 IN O
the P07794556A0000 DT O
Center P07794556A0000 NNP O
for P07794556A0000 IN O
Human P07794556A0000 NNP O
Genetics P07794556A0000 NNP O
in P07794556A0000 IN O
Leuven P07794556A0000 NNP O
, P07794556A0000 , O
predictive P07794556A0000 JJ O
DNA-testing P07794556A0000 NN O
for P07794556A0000 IN O
Huntington P07794556A0000 NNP O
's P07794556A0000 POS O
disease P07794556A0000 NN O
is P07794556A0000 VBZ O
available P07794556A0000 JJ O
as P07794556A0000 IN O
a P07794556A0000 DT O
clinical P07794556A0000 JJ O
service P07794556A0000 NN O
since P07794556A0000 IN O
November P07794556A0000 NNP O
1987 P07794556A0000 CD O
, P07794556A0000 , O
initially P07794556A0000 RB O
by P07794556A0000 IN O
DNA-linkage P07794556A0000 NNP O
and P07794556A0000 CC O
since P07794556A0000 IN O
mid P07794556A0000 NN O
1993 P07794556A0000 CD O
by P07794556A0000 IN O
direct P07794556A0000 JJ O
mutation P07794556A0000 NN O
analysis P07794556A0000 NN O
. P07794556A0000 . O
. . O O

Deglutition P10687945A0000 NN O
is P10687945A0000 VBZ O
considered P10687945A0000 VBN O
to P10687945A0000 TO O
be P10687945A0000 VB O
immature P10687945A0000 NN O
in P10687945A0000 IN O
infants P10687945A0000 NNS O
and P10687945A0000 CC O
to P10687945A0000 TO O
mature P10687945A0000 VB O
postnatally P10687945A0000 RB O
. P10687945A0000 . O
. . O O

The P10928179A0101 DT O
optimum P10928179A0101 NN O
technique P10928179A0101 NN O
for P10928179A0101 IN O
the P10928179A0101 DT O
pathological P10928179A0101 JJ O
examination P10928179A0101 NN O
of P10928179A0101 IN O
sentinel P10928179A0101 NN O
lymph P10928179A0101 NN O
nodes P10928179A0101 NNS O
( P10928179A0101 ( O
SLNs P10928179A0101 NNP O
) P10928179A0101 ) O
is P10928179A0101 VBZ O
still P10928179A0101 RB O
under P10928179A0101 IN O
debate P10928179A0101 NN O
. P10928179A0101 . O
. . O O

An P02707909A0209 DT O
alternative P02707909A0209 JJ O
method P02707909A0209 NN O
of P02707909A0209 IN O
UKM P02707909A0209 NNP O
is P02707909A0209 VBZ O
proposed P02707909A0209 VBN O
based P02707909A0209 VBN O
on P02707909A0209 IN O
collecting P02707909A0209 VBG O
a P02707909A0209 DT O
small P02707909A0209 JJ O
fraction P02707909A0209 NN O
of P02707909A0209 IN O
spent P02707909A0209 JJ O
dialysate P02707909A0209 NN O
flow P02707909A0209 NN O
for P02707909A0209 IN O
3 P02707909A0209 CD O
consecutive P02707909A0209 JJ O
dialyses P02707909A0209 NNS O
. P02707909A0209 . O
. . O O

These P10085088A0918 DT O
results P10085088A0918 NNS O
indicate P10085088A0918 VBP O
that P10085088A0918 IN O
the P10085088A0918 DT O
p33 P10085088A0918 JJ I-UN
subunit P10085088A0918 NN I-UN
of P10085088A0918 IN O
eIF3 P10085088A0918 NN I-UN
plays P10085088A0918 NNS O
an P10085088A0918 DT O
important P10085088A0918 JJ O
role P10085088A0918 NN O
in P10085088A0918 IN O
the P10085088A0918 DT O
initiation P10085088A0918 NN O
phase P10085088A0918 NN O
of P10085088A0918 IN O
protein P10085088A0918 JJ O
synthesis P10085088A0918 NN O
and P10085088A0918 CC O
that P10085088A0918 IN O
its P10085088A0918 PRP$ O
RNA-binding P10085088A0918 NNP O
domain P10085088A0918 NN O
is P10085088A0918 VBZ O
required P10085088A0918 VBN O
for P10085088A0918 IN O
optimal P10085088A0918 JJ O
activity P10085088A0918 NN O
. P10085088A0918 . O
. . O O

This P09849965A0000 DT O
study P09849965A0000 NN O
utilizes P09849965A0000 VBZ O
the P09849965A0000 DT O
mammalian P09849965A0000 JJ O
two-hybrid P09849965A0000 JJ O
system P09849965A0000 NN O
to P09849965A0000 TO O
examine P09849965A0000 VB O
the P09849965A0000 DT O
role P09849965A0000 NN O
of P09849965A0000 IN O
ligand P09849965A0000 NN O
in P09849965A0000 IN O
the P09849965A0000 DT O
dimerization P09849965A0000 NN O
of P09849965A0000 IN O
human P09849965A0000 JJ I-UN
progesterone P09849965A0000 NN I-UN
receptor P09849965A0000 NN I-UN
( P09849965A0000 ( O
hPR P09849965A0000 NN I-UN
) P09849965A0000 ) O
. P09849965A0000 . O
. . O O

The P09770686A0484 DT O
most P09770686A0484 RBS O
frequent P09770686A0484 JJ O
risk P09770686A0484 NN O
factor P09770686A0484 NN O
for P09770686A0484 IN O
ischaemic P09770686A0484 NN O
was P09770686A0484 VBD O
hypertension P09770686A0484 NN O
. P09770686A0484 . O
. . O O

Three P08686381A0527 CD O
ORFs P08686381A0527 NNP O
( P08686381A0527 ( O
9765orfR002 P08686381A0527 CD O
, P08686381A0527 , O
9765orfR011 P08686381A0527 CD O
and P08686381A0527 CC O
9765orfR013 P08686381A0527 CD O
) P08686381A0527 ) O
were P08686381A0527 VBD O
found P08686381A0527 VBN O
to P08686381A0527 TO O
be P08686381A0527 VB O
homologous P08686381A0527 JJ O
with P08686381A0527 IN O
Schizosaccharomyces P08686381A0527 NNP O
pombe P08686381A0527 NN O
polyadenylate P08686381A0527 NN I-UN
binding P08686381A0527 NN I-UN
protein P08686381A0527 NN I-UN
, P08686381A0527 , O
Escherichia P08686381A0527 NNP O
coli P08686381A0527 VBZ O
hypothetical P08686381A0527 JJ O
38.1-kDa P08686381A0527 JJ O
protein P08686381A0527 NN O
in P08686381A0527 IN O
the P08686381A0527 DT O
BCR P08686381A0527 NNP I-UN
5 P08686381A0527 CD O
' P08686381A0527 POS O
region P08686381A0527 NN O
, P08686381A0527 , O
and P08686381A0527 CC O
transcription P08686381A0527 NN O
regulatory P08686381A0527 JJ O
protein P08686381A0527 NN O
Swi3 P08686381A0527 NNP I-UN
, P08686381A0527 , O
respectively P08686381A0527 RB O
. P08686381A0527 . O
. . O O

Bacteria P10205933A0699 NNS O
can P10205933A0699 MD O
also P10205933A0699 RB O
cause P10205933A0699 VB O
a P10205933A0699 DT O
labyrinthitis P10205933A0699 NN O
acting P10205933A0699 VBG O
directly P10205933A0699 RB O
on P10205933A0699 IN O
the P10205933A0699 DT O
inner P10205933A0699 JJ O
ear P10205933A0699 NN O
: P10205933A0699 : O
among P10205933A0699 IN O
these P10205933A0699 DT O
, P10205933A0699 , O
Treponemas P10205933A0699 NNP O
Pallidum P10205933A0699 NNP O
, P10205933A0699 , O
a P10205933A0699 DT O
spirochaete P10205933A0699 NN O
which P10205933A0699 WDT O
causes P10205933A0699 VBZ O
syphilis P10205933A0699 NN O
and P10205933A0699 CC O
Borrelia P10205933A0699 NNP O
Burgdorferi P10205933A0699 NNP O
, P10205933A0699 , O
a P10205933A0699 DT O
spirochaete P10205933A0699 NN O
that P10205933A0699 WDT O
causes P10205933A0699 VBZ O
Lyme P10205933A0699 NNP O
Disease P10205933A0699 NNP O
, P10205933A0699 , O
must P10205933A0699 MD O
be P10205933A0699 VB O
mentioned P10205933A0699 VBN O
. P10205933A0699 . O
. . O O

Finally P07565736A2134 RB O
, P07565736A2134 , O
we P07565736A2134 PRP O
demonstrate P07565736A2134 VBP O
that P07565736A2134 IN O
C P07565736A2134 NNP I-UN
/ P07565736A2134 NNP I-UN
EBP P07565736A2134 NNP I-UN
alpha P07565736A2134 NN I-UN
can P07565736A2134 MD O
also P07565736A2134 RB O
active P07565736A2134 JJ O
the P07565736A2134 DT O
GM-CSF P07565736A2134 NNP I-UN
receptor P07565736A2134 NN I-UN
alpha P07565736A2134 NN I-UN
promoter P07565736A2134 NN O
in P07565736A2134 IN O
nonmyeloid P07565736A2134 JJ O
cells P07565736A2134 NNS O
. P07565736A2134 . O
. . O O

Far P09267306A0381 RB O
from P09267306A0381 IN O
this P09267306A0381 DT O
being P09267306A0381 VBG O
the P09267306A0381 DT O
case P09267306A0381 NN O
, P09267306A0381 , O
however P09267306A0381 RB O
, P09267306A0381 , O
the P09267306A0381 DT O
measurement P09267306A0381 NN O
of P09267306A0381 IN O
apo P09267306A0381 NN I-UN
B P09267306A0381 NNP I-UN
has P09267306A0381 VBZ O
met P09267306A0381 VBN O
every P09267306A0381 DT O
reasonable P09267306A0381 JJ O
standard P09267306A0381 NN O
of P09267306A0381 IN O
laboratory P09267306A0381 NN O
precision P09267306A0381 NN O
and P09267306A0381 CC O
reliability P09267306A0381 NN O
to P09267306A0381 TO O
allow P09267306A0381 VB O
its P09267306A0381 PRP$ O
widespread P09267306A0381 JJ O
introduction P09267306A0381 NN O
in P09267306A0381 IN O
clinical P09267306A0381 JJ O
laboratories P09267306A0381 NNS O
. P09267306A0381 . O
. . O O

Elimination P08447005T0001 NN O
of P08447005T0001 IN O
Haemophilus P08447005T0001 NNP O
influenzae P08447005T0001 NN O
type P08447005T0001 NN O
b P08447005T0001 NN O
meningitis P08447005T0001 NN O
after P08447005T0001 IN O
introduction P08447005T0001 NN O
of P08447005T0001 IN O
vaccination P08447005T0001 NN O
. P08447005T0001 . O
. . O O

Further P07094905A0644 RB O
, P07094905A0644 , O
intracerebroventricular P07094905A0644 JJ O
injections P07094905A0644 NNS O
of P07094905A0644 IN O
KA P07094905A0644 NNP O
resulted P07094905A0644 VBD O
in P07094905A0644 IN O
the P07094905A0644 DT O
substantial P07094905A0644 JJ O
loss P07094905A0644 NN O
of P07094905A0644 IN O
pyramidal P07094905A0644 JJ O
cells P07094905A0644 NNS O
in P07094905A0644 IN O
the P07094905A0644 DT O
whole P07094905A0644 JJ O
CA3 P07094905A0644 NNP O
field P07094905A0644 NN O
of P07094905A0644 IN O
the P07094905A0644 DT O
hippocampus P07094905A0644 NN O
. P07094905A0644 . O
. . O O

We P10982825A0363 PRP O
show P10982825A0363 VBP O
here P10982825A0363 RB O
that P10982825A0363 IN O
this P10982825A0363 DT O
difference P10982825A0363 NN O
is P10982825A0363 VBZ O
due P10982825A0363 JJ O
to P10982825A0363 TO O
the P10982825A0363 DT O
presence P10982825A0363 NN O
of P10982825A0363 IN O
a P10982825A0363 DT O
Mot3 P10982825A0363 NNP I-UN
binding P10982825A0363 NN I-UN
site P10982825A0363 NN I-UN
in P10982825A0363 IN O
OpA P10982825A0363 NNP I-UN
. P10982825A0363 . O
. . O O

In P10454557A0000 IN O
the P10454557A0000 DT O
budding P10454557A0000 NN O
yeast P10454557A0000 NN O
, P10454557A0000 , O
Saccharomyces P10454557A0000 NNP O
cerevisiae P10454557A0000 NN O
, P10454557A0000 , O
replicators P10454557A0000 NNS O
can P10454557A0000 MD O
function P10454557A0000 VB O
outside P10454557A0000 IN O
the P10454557A0000 DT O
chromosome P10454557A0000 NN O
as P10454557A0000 IN O
autonomously P10454557A0000 RB O
replicating P10454557A0000 VBG O
sequence P10454557A0000 NN O
( P10454557A0000 ( O
ARS P10454557A0000 NNP O
) P10454557A0000 ) O
elements P10454557A0000 NNS O
; P10454557A0000 : O
however P10454557A0000 RB O
, P10454557A0000 , O
within P10454557A0000 IN O
chromosome P10454557A0000 NN O
III P10454557A0000 NNP O
, P10454557A0000 , O
certain P10454557A0000 JJ O
ARSs P10454557A0000 NNP O
near P10454557A0000 IN O
the P10454557A0000 DT O
transcriptionally P10454557A0000 RB O
silent P10454557A0000 JJ O
HML P10454557A0000 NNP I-UN
locus P10454557A0000 NN I-UN
show P10454557A0000 NN O
no P10454557A0000 DT O
replication P10454557A0000 NN O
origin P10454557A0000 NN O
activity P10454557A0000 NN O
. P10454557A0000 . O
. . O O

A P01253191T0000 DT O
note P01253191T0000 NN O
on P01253191T0000 IN O
the P01253191T0000 DT O
phase-plane P01253191T0000 NN O
technique P01253191T0000 NN O
representation P01253191T0000 NN O
of P01253191T0000 IN O
cardiac P01253191T0000 JJ O
action P01253191T0000 NN O
potentials P01253191T0000 NNS O
. P01253191T0000 . O
. . O O

JNK P09006914A0812 NNP I-UN
and P09006914A0812 CC O
p38 P09006914A0812 NN I-UN
are P09006914A0812 VBP O
constitutively P09006914A0812 RB O
present P09006914A0812 JJ O
in P09006914A0812 IN O
the P09006914A0812 DT O
nucleus P09006914A0812 NN O
, P09006914A0812 , O
and P09006914A0812 CC O
DNA-bound P09006914A0812 NNP O
c-JUN P09006914A0812 NN I-UN
and P09006914A0812 CC O
ATF-2 P09006914A0812 NNP I-UN
are P09006914A0812 VBP O
stably P09006914A0812 RB O
contacted P09006914A0812 VBN O
by P09006914A0812 IN O
JNK P09006914A0812 NNP I-UN
and P09006914A0812 CC O
p38 P09006914A0812 NN I-UN
, P09006914A0812 , O
respectively P09006914A0812 RB O
. P09006914A0812 . O
. . O O

About P10393422A0476 IN O
20 P10393422A0476 CD O
kb P10393422A0476 NNS O
upstream P10393422A0476 NN O
of P10393422A0476 IN O
LAMB2 P10393422A0476 NNP I-UN
we P10393422A0476 PRP O
found P10393422A0476 VBD O
a P10393422A0476 DT O
gene P10393422A0476 NN O
encoding P10393422A0476 VBG O
a P10393422A0476 DT O
transcribed P10393422A0476 NN O
, P10393422A0476 , O
non-processed P10393422A0476 JJ O
LAMB2-like P10393422A0476 JJ I-UN
pseudogene P10393422A0476 NN I-UN
( P10393422A0476 ( O
LAMB2L P10393422A0476 NNP I-UN
) P10393422A0476 ) O
. P10393422A0476 . O
. . O O

Alternative P09188863A0954 JJ O
splicing P09188863A0954 NN O
of P09188863A0954 IN O
CDC25B P09188863A0954 NNP I-UN
may P09188863A0954 MD O
therefore P09188863A0954 VB O
contribute P09188863A0954 NN O
to P09188863A0954 TO O
the P09188863A0954 DT O
control P09188863A0954 NN O
of P09188863A0954 IN O
cell P09188863A0954 NN O
proliferation P09188863A0954 NN O
. P09188863A0954 . O
. . O O

The P08618433A0000 DT O
novel P08618433A0000 JJ O
hematopoietic P08618433A0000 JJ I-UN
growth P08618433A0000 NN I-UN
factor P08618433A0000 NN I-UN
FLT3 P08618433A0000 NNP I-UN
ligand P08618433A0000 NN I-UN
( P08618433A0000 ( O
FL P08618433A0000 NNP I-UN
) P08618433A0000 ) O
is P08618433A0000 VBZ O
the P08618433A0000 DT O
cognate P08618433A0000 NN O
ligand P08618433A0000 NN O
for P08618433A0000 IN O
the P08618433A0000 DT O
FLT3 P08618433A0000 NNP I-UN
, P08618433A0000 , O
tyrosine P08618433A0000 JJ I-UN
kinase P08618433A0000 NN I-UN
receptor P08618433A0000 NN I-UN
( P08618433A0000 ( O
R P08618433A0000 NNP I-UN
) P08618433A0000 ) O
, P08618433A0000 , O
also P08618433A0000 RB O
referred P08618433A0000 VBD O
to P08618433A0000 TO O
as P08618433A0000 IN O
FLK-2 P08618433A0000 NNP I-UN
and P08618433A0000 CC O
STK-1 P08618433A0000 NNP I-UN
. P08618433A0000 . O
. . O O

Each P08293992A0432 DT O
repeat P08293992A0432 NN O
consists P08293992A0432 VBZ O
of P08293992A0432 IN O
12 P08293992A0432 CD O
nt P08293992A0432 NNS O
, P08293992A0432 , O
coding P08293992A0432 VBG O
for P08293992A0432 IN O
the P08293992A0432 DT O
reiterated P08293992A0432 JJ O
sequence P08293992A0432 NN O
, P08293992A0432 , O
K P08293992A0432 NNP O
/ P08293992A0432 NNP O
NPAG P08293992A0432 NNP O
. P08293992A0432 . O
. . O O

Saturable P09154797A0777 JJ O
spermidine P09154797A0777 NN O
transport P09154797A0777 NN O
in P09154797A0777 IN O
stk2 P09154797A0777 NN I-UN
: P09154797A0777 : O
:lacZ P09154797A0777 JJ O
mutants P09154797A0777 NNS I-UN
had P09154797A0777 VBD O
an P09154797A0777 DT O
approximately P09154797A0777 RB O
fivefold-lower P09154797A0777 JJ O
affinity P09154797A0777 NN O
and P09154797A0777 CC O
twofold-lower P09154797A0777 NN O
Vmax P09154797A0777 NNP O
than P09154797A0777 IN O
in P09154797A0777 IN O
the P09154797A0777 DT O
parental P09154797A0777 JJ O
strain P09154797A0777 NN O
. P09154797A0777 . O
. . O O

Analysis P08921387A1182 NN O
of P08921387A1182 IN O
one P08921387A1182 CD O
cDNA P08921387A1182 NN O
revealed P08921387A1182 VBD O
an P08921387A1182 DT O
unusual P08921387A1182 JJ O
splicing P08921387A1182 NN O
event P08921387A1182 NN O
involving P08921387A1182 VBG O
EZH1 P08921387A1182 NNP I-UN
and P08921387A1182 CC O
a P08921387A1182 DT O
tandemly P08921387A1182 NN O
linked P08921387A1182 VBN O
gene P08921387A1182 NN O
GPR2 P08921387A1182 NNP I-UN
and P08921387A1182 CC O
suggests P08921387A1182 VBZ O
a P08921387A1182 DT O
potential P08921387A1182 JJ O
mechanism P08921387A1182 NN O
for P08921387A1182 IN O
modifying P08921387A1182 VBG O
the P08921387A1182 DT O
EZH1 P08921387A1182 NNP I-UN
protein P08921387A1182 NN I-UN
in P08921387A1182 IN O
the P08921387A1182 DT O
conserved P08921387A1182 JJ O
C-terminal P08921387A1182 JJ O
domain P08921387A1182 NN O
. P08921387A1182 . O
. . O O

Dermal P02361575T0000 NNP O
toxicity P02361575T0000 NN O
and P02361575T0000 CC O
carcinogenicity P02361575T0000 NN O
of P02361575T0000 IN O
4-vinyl-1-cyclohexene P02361575T0000 JJ O
diepoxide P02361575T0000 NN O
in P02361575T0000 IN O
Fischer P02361575T0000 NNP O
rats P02361575T0000 NNS O
and P02361575T0000 CC O
B6C3F1 P02361575T0000 NNP O
mice P02361575T0000 NN O
. P02361575T0000 . O
. . O O

Furthermore P09199318A1147 RB O
, P09199318A1147 , O
p150 P09199318A1147 JJ I-UN
suppresses P09199318A1147 NNS O
actin P09199318A1147 JJ I-UN
gelation P09199318A1147 NN O
, P09199318A1147 , O
which P09199318A1147 WDT O
is P09199318A1147 VBZ O
induced P09199318A1147 VBN O
by P09199318A1147 IN O
smooth P09199318A1147 JJ I-UN
muscle P09199318A1147 NN I-UN
alpha-actinin P09199318A1147 NN I-UN
. P09199318A1147 . O
. . O O

In P09237862A0782 IN O
all P09237862A0782 DT O
experimental P09237862A0782 JJ O
eyes P09237862A0782 NNS O
, P09237862A0782 , O
there P09237862A0782 EX O
was P09237862A0782 VBD O
a P09237862A0782 DT O
marked P09237862A0782 JJ O
reduction P09237862A0782 NN O
, P09237862A0782 , O
but P09237862A0782 CC O
never P09237862A0782 RB O
a P09237862A0782 DT O
complete P09237862A0782 JJ O
absence P09237862A0782 NN O
of P09237862A0782 IN O
adrenergic P09237862A0782 JJ O
nerves P09237862A0782 NNS O
in P09237862A0782 IN O
the P09237862A0782 DT O
iris P09237862A0782 NN O
. P09237862A0782 . O
. . O O

This P03531317A0930 DT O
means P03531317A0930 VBZ O
that P03531317A0930 IN O
the P03531317A0930 DT O
loss P03531317A0930 NN O
of P03531317A0930 IN O
recessives P03531317A0930 NNS O
must P03531317A0930 MD O
be P03531317A0930 VB O
calculated P03531317A0930 VBN O
by P03531317A0930 IN O
using P03531317A0930 VBG O
a P03531317A0930 DT O
hypergeometric P03531317A0930 NN O
and P03531317A0930 CC O
not P03531317A0930 RB O
a P03531317A0930 DT O
binomial P03531317A0930 JJ O
model P03531317A0930 NN O
as P03531317A0930 IN O
Fisher P03531317A0930 NNP O
did P03531317A0930 VBD O
. P03531317A0930 . O
. . O O

To P09886843A0339 TO O
evaluate P09886843A0339 VB O
whether P09886843A0339 IN O
the P09886843A0339 DT O
human P09886843A0339 JJ O
gene P09886843A0339 NN O
is P09886843A0339 VBZ O
also P09886843A0339 RB O
a P09886843A0339 DT O
target P09886843A0339 NN O
of P09886843A0339 IN O
thyroid P09886843A0339 JJ O
hormone P09886843A0339 NN O
we P09886843A0339 PRP O
have P09886843A0339 VBP O
searched P09886843A0339 VBN O
for P09886843A0339 IN O
T3-responsive P09886843A0339 JJ O
elements P09886843A0339 NNS O
in P09886843A0339 IN O
NRGN P09886843A0339 NNP I-UN
cloned P09886843A0339 VBD O
genomic P09886843A0339 JJ O
fragments P09886843A0339 NNS O
spanning P09886843A0339 VBG O
the P09886843A0339 DT O
whole P09886843A0339 JJ O
gene P09886843A0339 NN O
. P09886843A0339 . O
. . O O

Telomerase P11433024A0260 NNP I-UN
is P11433024A0260 VBZ O
a P11433024A0260 DT O
ribonucleoprotein P11433024A0260 NN O
complex P11433024A0260 NN O
that P11433024A0260 WDT O
synthesizes P11433024A0260 VBZ O
telomeric P11433024A0260 JJ O
DNA P11433024A0260 NNP O
onto P11433024A0260 IN O
chromosomes P11433024A0260 NNS O
using P11433024A0260 VBG O
its P11433024A0260 PRP$ O
RNA P11433024A0260 NNP O
component P11433024A0260 NN O
as P11433024A0260 IN O
template P11433024A0260 NN O
. P11433024A0260 . O
. . O O

The P08182171A0000 DT O
efficacy P08182171A0000 NN O
of P08182171A0000 IN O
a P08182171A0000 DT O
Propionibacterium P08182171A0000 NNP O
acnes P08182171A0000 NNS O
product P08182171A0000 NN O
for P08182171A0000 IN O
treatment P08182171A0000 NN O
of P08182171A0000 IN O
coliform P08182171A0000 NN O
mastitis P08182171A0000 NN O
was P08182171A0000 VBD O
evaluated P08182171A0000 VBN O
following P08182171A0000 VBG O
intramammary P08182171A0000 JJ O
infusion P08182171A0000 NN O
of P08182171A0000 IN O
Escherichia P08182171A0000 NNP O
coli P08182171A0000 NN O
. P08182171A0000 . O
. . O O

Changes P03930894T0000 NNS O
in P03930894T0000 IN O
muscarinic P03930894T0000 JJ I-UN
acetylcholine P03930894T0000 NN I-UN
receptors P03930894T0000 NNS I-UN
in P03930894T0000 IN O
guinea-pig P03930894T0000 JJ O
lung P03930894T0000 NN O
: P03930894T0000 : O
effects P03930894T0000 NNS O
of P03930894T0000 IN O
aging P03930894T0000 VBG O
, P03930894T0000 , O
inhalation P03930894T0000 NN O
of P03930894T0000 IN O
an P03930894T0000 DT O
allergen P03930894T0000 NN O
, P03930894T0000 , O
administration P03930894T0000 NN O
of P03930894T0000 IN O
drugs P03930894T0000 NNS O
, P03930894T0000 , O
and P03930894T0000 CC O
vagotomy P03930894T0000 NN O
. P03930894T0000 . O
. . O O

Functional P10082554T0000 JJ O
domains P10082554T0000 NNS O
of P10082554T0000 IN O
c-myc P10082554T0000 JJ I-UN
promoter P10082554T0000 NN I-UN
binding P10082554T0000 VBG I-UN
protein P10082554T0000 JJ I-UN
1 P10082554T0000 CD I-UN
involved P10082554T0000 VBN O
in P10082554T0000 IN O
transcriptional P10082554T0000 JJ O
repression P10082554T0000 NN O
and P10082554T0000 CC O
cell P10082554T0000 NN O
growth P10082554T0000 NN O
regulation P10082554T0000 NN O
. P10082554T0000 . O
. . O O

Salazopyrine P08098882T0001 NNP O
desensitization P08098882T0001 NN O
. P08098882T0001 . O
. . O O

The P11323716A0413 DT O
UBA P11323716A0413 NNP I-UN
domains P11323716A0413 NNS I-UN
of P11323716A0413 IN O
RAD23 P11323716A0413 NNP I-UN
and P11323716A0413 CC O
DDI1 P11323716A0413 NNP I-UN
are P11323716A0413 VBP O
required P11323716A0413 VBN O
for P11323716A0413 IN O
these P11323716A0413 DT O
interactions P11323716A0413 NNS O
. P11323716A0413 . O
. . O O

Hybrid-selection P06141764A0339 NN O
experiments P06141764A0339 NNS O
against P06141764A0339 IN O
total P06141764A0339 JJ O
PB-inducible P06141764A0339 JJ O
RNA P06141764A0339 NNP O
were P06141764A0339 VBD O
performed P06141764A0339 VBN O
with P06141764A0339 IN O
plasmid P06141764A0339 JJ O
DNA P06141764A0339 NNP O
derived P06141764A0339 VBD O
from P06141764A0339 IN O
clones P06141764A0339 NNS O
enriched P06141764A0339 VBN O
in P06141764A0339 IN O
PB-inducible P06141764A0339 JJ O
information P06141764A0339 NN O
. P06141764A0339 . O
. . O O

It P07876210A0275 PRP O
is P07876210A0275 VBZ O
now P07876210A0275 RB O
recognized P07876210A0275 VBN O
that P07876210A0275 IN O
essentially P07876210A0275 RB O
all P07876210A0275 DT O
eukaryotic P07876210A0275 JJ O
and P07876210A0275 CC O
prokaryotic P07876210A0275 JJ O
genes P07876210A0275 NNS O
whose P07876210A0275 WP$ O
5'-flanking P07876210A0275 JJ O
regions P07876210A0275 NNS O
are P07876210A0275 VBP O
known P07876210A0275 VBN O
and P07876210A0275 CC O
that P07876210A0275 IN O
encode P07876210A0275 JJ O
barbiturate-inducible P07876210A0275 JJ O
proteins P07876210A0275 NNS O
contain P07876210A0275 VBP O
the P07876210A0275 DT O
Barbie P07876210A0275 NNP O
box P07876210A0275 NN O
element P07876210A0275 NN O
. P07876210A0275 . O
. . O O

METHODS P11580757A0304 NNS O
: P11580757A0304 : O
We P11580757A0304 PRP O
retrospectively P11580757A0304 RB O
selected P11580757A0304 VBD O
13 P11580757A0304 CD O
TFCD P11580757A0304 NNP O
patients P11580757A0304 NNS O
who P11580757A0304 WP O
underwent P11580757A0304 VBP O
surgery P11580757A0304 NN O
for P11580757A0304 IN O
intractable P11580757A0304 JJ O
epilepsy P11580757A0304 NN O
with P11580757A0304 IN O
the P11580757A0304 DT O
aim P11580757A0304 NN O
of P11580757A0304 IN O
removing P11580757A0304 VBG O
the P11580757A0304 DT O
magnetic P11580757A0304 JJ O
resonance P11580757A0304 NN O
( P11580757A0304 ( O
MR P11580757A0304 NNP O
) P11580757A0304 ) O
-detectable P11580757A0304 JJ O
lesion P11580757A0304 NN O
and P11580757A0304 CC O
/ P11580757A0304 NN O
or P11580757A0304 CC O
the P11580757A0304 DT O
epileptogenic P11580757A0304 JJ O
zone P11580757A0304 NN O
defined P11580757A0304 VBN O
by P11580757A0304 IN O
stereoelectroencephalographic P11580757A0304 JJ O
recordings P11580757A0304 NNS O
. P11580757A0304 . O
. . O O

At P06816609A0639 IN O
43 P06816609A0639 CD O
% P06816609A0639 NN O
blood P06816609A0639 NN O
pressure P06816609A0639 NN O
reduction P06816609A0639 NN O
, P06816609A0639 , O
PCO2 P06816609A0639 NNP O
fell P06816609A0639 VBD O
by P06816609A0639 IN O
0.53 P06816609A0639 CD O
kPa P06816609A0639 NNS O
, P06816609A0639 , O
a P06816609A0639 DT O
decrease P06816609A0639 NN O
which P06816609A0639 WDT O
could P06816609A0639 MD O
not P06816609A0639 RB O
explain P06816609A0639 VB O
the P06816609A0639 DT O
observed P06816609A0639 JJ O
CBF P06816609A0639 NNP O
fall P06816609A0639 NN O
of P06816609A0639 IN O
27 P06816609A0639 CD O
% P06816609A0639 NN O
. P06816609A0639 . O
. . O O

The P08011166A0207 DT O
complete P08011166A0207 JJ O
gene P08011166A0207 NN O
organization P08011166A0207 NN O
was P08011166A0207 VBD O
obtained P08011166A0207 VBN O
by P08011166A0207 IN O
combining P08011166A0207 VBG O
the P08011166A0207 DT O
results P08011166A0207 NNS O
of P08011166A0207 IN O
the P08011166A0207 DT O
sequence P08011166A0207 NN O
of P08011166A0207 IN O
these P08011166A0207 DT O
clones P08011166A0207 NNS O
and P08011166A0207 CC O
those P08011166A0207 DT O
of P08011166A0207 IN O
the P08011166A0207 DT O
characterization P08011166A0207 NN O
of P08011166A0207 IN O
polymerase P08011166A0207 NN O
chain P08011166A0207 NN O
reaction-amplified P08011166A0207 JJ O
genomic P08011166A0207 JJ O
segments P08011166A0207 NNS O
. P08011166A0207 . O
. . O O

Similar P10385384A0654 JJ O
results P10385384A0654 NNS O
were P10385384A0654 VBD O
obtained P10385384A0654 VBN O
with P10385384A0654 IN O
xylitol P10385384A0654 NNP O
, P10385384A0654 , O
an P10385384A0654 DT O
activator P10385384A0654 NN O
of P10385384A0654 IN O
the P10385384A0654 DT O
pentose P10385384A0654 JJ O
phosphate P10385384A0654 NN O
pathway P10385384A0654 NN O
. P10385384A0654 . O
. . O O

The P02160622A0000 DT O
antinociceptive P02160622A0000 JJ O
properties P02160622A0000 NNS O
, P02160622A0000 , O
as P02160622A0000 IN O
measured P02160622A0000 VBN O
by P02160622A0000 IN O
the P02160622A0000 DT O
tail-flick P02160622A0000 JJ O
and P02160622A0000 CC O
hot-plate P02160622A0000 JJ O
tests P02160622A0000 NNS O
, P02160622A0000 , O
and P02160622A0000 CC O
the P02160622A0000 DT O
motor P02160622A0000 NN O
effects P02160622A0000 NNS O
of P02160622A0000 IN O
an P02160622A0000 DT O
intrathecally-administered P02160622A0000 JJ O
benzodiazepine P02160622A0000 NN O
agonist P02160622A0000 NN O
midazolam P02160622A0000 NN O
, P02160622A0000 , O
alone P02160622A0000 RB O
, P02160622A0000 , O
and P02160622A0000 CC O
in P02160622A0000 IN O
combination P02160622A0000 NN O
with P02160622A0000 IN O
morphine P02160622A0000 NN O
, P02160622A0000 , O
was P02160622A0000 VBD O
examined P02160622A0000 VBN O
in P02160622A0000 IN O
rats P02160622A0000 NNS O
. P02160622A0000 . O
. . O O

An P11036938A1162 DT O
increase P11036938A1162 NN O
in P11036938A1162 IN O
hypothalamic P11036938A1162 JJ O
expression P11036938A1162 NN O
of P11036938A1162 IN O
at P11036938A1162 IN O
least P11036938A1162 JJS O
two P11036938A1162 CD O
of P11036938A1162 IN O
the P11036938A1162 DT O
erbB P11036938A1162 NN I-UN
receptors P11036938A1162 NNS I-UN
is P11036938A1162 VBZ O
initiated P11036938A1162 VBN O
before P11036938A1162 IN O
the P11036938A1162 DT O
pubertal P11036938A1162 JJ O
augmentation P11036938A1162 NN O
of P11036938A1162 IN O
gonadal P11036938A1162 JJ O
steroid P11036938A1162 JJ O
secretion P11036938A1162 NN O
and P11036938A1162 CC O
is P11036938A1162 VBZ O
completed P11036938A1162 VBN O
on P11036938A1162 IN O
the P11036938A1162 DT O
day P11036938A1162 NN O
of P11036938A1162 IN O
the P11036938A1162 DT O
first P11036938A1162 JJ O
preovulatory P11036938A1162 NN O
surge P11036938A1162 NN O
of P11036938A1162 IN O
gonadotropins P11036938A1162 NNS I-UN
. P11036938A1162 . O
. . O O

Among P06342141A0226 IN O
these P06342141A0226 DT O
are P06342141A0226 VBP O
: P06342141A0226 : O
( P06342141A0226 ( O
1 P06342141A0226 CD O
) P06342141A0226 ) O
Is P06342141A0226 VBZ O
there P06342141A0226 JJ O
sufficient P06342141A0226 JJ O
understanding P06342141A0226 NN O
of P06342141A0226 IN O
family P06342141A0226 NN O
pathophysiology P06342141A0226 NN O
, P06342141A0226 , O
of P06342141A0226 IN O
the P06342141A0226 DT O
sensitivity P06342141A0226 NN O
and P06342141A0226 CC O
specificity P06342141A0226 NN O
of P06342141A0226 IN O
diagnostic P06342141A0226 JJ O
techniques P06342141A0226 NNS O
and P06342141A0226 CC O
of P06342141A0226 IN O
the P06342141A0226 DT O
safety P06342141A0226 NN O
and P06342141A0226 CC O
efficacy P06342141A0226 NN O
of P06342141A0226 IN O
therapeutic P06342141A0226 JJ O
modalities P06342141A0226 NNS O
to P06342141A0226 TO O
make P06342141A0226 VB O
true P06342141A0226 JJ O
family P06342141A0226 NN O
health P06342141A0226 NN O
care P06342141A0226 NN O
possible P06342141A0226 JJ O
? P06342141A0226 . O
( P06342141A0226 ( O
2 P06342141A0226 CD O
) P06342141A0226 ) O
If P06342141A0226 IN O
this P06342141A0226 DT O
type P06342141A0226 NN O
of P06342141A0226 IN O
care P06342141A0226 NN O
is P06342141A0226 VBZ O
possible P06342141A0226 JJ O
, P06342141A0226 , O
how P06342141A0226 WRB O
are P06342141A0226 VBP O
the P06342141A0226 DT O
needs P06342141A0226 NNS O
of P06342141A0226 IN O
the P06342141A0226 DT O
family P06342141A0226 NN O
and P06342141A0226 CC O
its P06342141A0226 PRP$ O
individual P06342141A0226 JJ O
members P06342141A0226 NNS O
met P06342141A0226 VBD O
, P06342141A0226 , O
or P06342141A0226 CC O
value P06342141A0226 NN O
judgements P06342141A0226 NNS O
made P06342141A0226 VBN O
about P06342141A0226 IN O
their P06342141A0226 PRP$ O
relative P06342141A0226 JJ O
importance P06342141A0226 NN O
? P06342141A0226 . O
and P06342141A0226 CC O
( P06342141A0226 ( O
3 P06342141A0226 CD O
) P06342141A0226 ) O
What P06342141A0226 WP O
are P06342141A0226 VBP O
the P06342141A0226 DT O
consequences P06342141A0226 NNS O
for P06342141A0226 IN O
the P06342141A0226 DT O
health P06342141A0226 NN O
care P06342141A0226 NN O
delivery P06342141A0226 NN O
system P06342141A0226 NN O
of P06342141A0226 IN O
this P06342141A0226 DT O
type P06342141A0226 NN O
of P06342141A0226 IN O
care P06342141A0226 NN O
? P06342141A0226 . O
An P06342141A0226 DT O
extensive P06342141A0226 JJ O
literature P06342141A0226 NN O
review P06342141A0226 NN O
is P06342141A0226 VBZ O
used P06342141A0226 VBN O
in P06342141A0226 IN O
an P06342141A0226 DT O
attempt P06342141A0226 NN O
to P06342141A0226 TO O
answer P06342141A0226 VB O
these P06342141A0226 DT O
queries P06342141A0226 NNS O
, P06342141A0226 , O
from P06342141A0226 IN O
which P06342141A0226 WDT O
questions P06342141A0226 NNS O
for P06342141A0226 IN O
further P06342141A0226 JJ O
study P06342141A0226 NN O
are P06342141A0226 VBP O
posed P06342141A0226 VBN O
. P06342141A0226 . O
. . O O

The P09763446A1234 DT O
GEF P09763446A1234 NNP I-UN
and P09763446A1234 CC O
GAP P09763446A1234 NNP I-UN
activities P09763446A1234 NNS O
for P09763446A1234 IN O
Ypt1p P09763446A1234 NNP I-UN
localize P09763446A1234 NN O
to P09763446A1234 TO O
particulate P09763446A1234 VB O
cellular P09763446A1234 JJ O
fractions P09763446A1234 NNS O
. P09763446A1234 . O
. . O O

Thus P01418834A0987 RB O
, P01418834A0987 , O
chronic P01418834A0987 JJ O
hematocrit P01418834A0987 NN O
decrease P01418834A0987 NN O
induced P01418834A0987 VBN O
by P01418834A0987 IN O
H P01418834A0987 NNP O
or P01418834A0987 CC O
P P01418834A0987 NNP O
resulted P01418834A0987 VBD O
in P01418834A0987 IN O
a P01418834A0987 DT O
significant P01418834A0987 JJ O
fall P01418834A0987 NN O
in P01418834A0987 IN O
blood P01418834A0987 NN O
pressure P01418834A0987 NN O
compared P01418834A0987 VBN O
to P01418834A0987 TO O
control P01418834A0987 VB O
( P01418834A0987 ( O
201 P01418834A0987 CD O
+ P01418834A0987 NN O
/ P01418834A0987 NNP O
- P01418834A0987 : O
3 P01418834A0987 CD O
v P01418834A0987 NN O
175 P01418834A0987 CD O
+ P01418834A0987 NN O
/ P01418834A0987 NNP O
- P01418834A0987 : O
4 P01418834A0987 CD O
, P01418834A0987 , O
167 P01418834A0987 CD O
+ P01418834A0987 NN O
/ P01418834A0987 NNP O
- P01418834A0987 : O
4 P01418834A0987 CD O
mm P01418834A0987 NN O
Hg P01418834A0987 NNP O
, P01418834A0987 , O
respectively P01418834A0987 RB O
; P01418834A0987 : O
P P01418834A0987 NNP O
< P01418834A0987 NNP O
.05 P01418834A0987 NNP O
) P01418834A0987 ) O
. P01418834A0987 . O
. . O O

Sibling P09467707T0000 VBG O
aggregation P09467707T0000 NN O
of P09467707T0000 IN O
low- P09467707T0000 JJ I-UN
and P09467707T0000 CC I-UN
high-density P09467707T0000 JJ I-UN
lipoprotein P09467707T0000 NN I-UN
cholesterol P09467707T0000 NN I-UN
and P09467707T0000 CC O
apolipoproteins P09467707T0000 VBZ I-UN
B P09467707T0000 NNP I-UN
and P09467707T0000 CC I-UN
A-I P09467707T0000 NNP I-UN
levels P09467707T0000 NNS O
in P09467707T0000 IN O
black P09467707T0000 JJ O
and P09467707T0000 CC O
white P09467707T0000 JJ O
children P09467707T0000 NNS O
: P09467707T0000 : O
the P09467707T0000 DT O
Bogalusa P09467707T0000 NNP O
Heart P09467707T0000 NNP O
Study P09467707T0000 NNP O
. P09467707T0000 . O
. . O O

And P01608239T0001 CC O
the P01608239T0001 DT O
natural P01608239T0001 JJ O
barriers P01608239T0001 NNS O
? P01608239T0001 . O
. P01608239T0001 . O
. . O O

Echinococcus P01954835A0000 NNP O
granulosus P01954835A0000 NN O
was P01954835A0000 VBD O
diagnosed P01954835A0000 VBN O
by P01954835A0000 IN O
fine-needle P01954835A0000 JJ O
aspiration P01954835A0000 NN O
cytology P01954835A0000 NN O
of P01954835A0000 IN O
a P01954835A0000 DT O
lung P01954835A0000 NN O
cyst P01954835A0000 NN O
in P01954835A0000 IN O
a P01954835A0000 DT O
6-yr-old P01954835A0000 JJ O
white P01954835A0000 JJ O
female P01954835A0000 NN O
in P01954835A0000 IN O
central P01954835A0000 JJ O
Missouri P01954835A0000 NNP O
. P01954835A0000 . O
. . O O

Most P02254418A0641 JJS O
strains P02254418A0641 NNS O
( P02254418A0641 ( O
95 P02254418A0641 CD O
% P02254418A0641 NN O
) P02254418A0641 ) O
of P02254418A0641 IN O
S. P02254418A0641 NNP O
lugdunensis P02254418A0641 NN O
produced P02254418A0641 VBD O
a P02254418A0641 DT O
delta P02254418A0641 JJ I-UN
hemolysin P02254418A0641 NN I-UN
like P02254418A0641 IN O
that P02254418A0641 DT O
seen P02254418A0641 VBN O
with P02254418A0641 IN O
nine P02254418A0641 CD O
other P02254418A0641 JJ O
species P02254418A0641 NNS O
of P02254418A0641 IN O
CNS P02254418A0641 NNP O
. P02254418A0641 . O
. . O O

There P02667259A0331 EX O
were P02667259A0331 VBD O
3 P02667259A0331 CD O
/ P02667259A0331 JJ O
32 P02667259A0331 CD O
( P02667259A0331 ( O
9.4 P02667259A0331 CD O
per P02667259A0331 IN O
cent P02667259A0331 NN O
) P02667259A0331 ) O
adverse P02667259A0331 JJ O
reactions P02667259A0331 NNS O
( P02667259A0331 ( O
ADRs P02667259A0331 NNP O
) P02667259A0331 ) O
, P02667259A0331 , O
and P02667259A0331 CC O
one P02667259A0331 CD O
case P02667259A0331 NN O
each P02667259A0331 DT O
of P02667259A0331 IN O
nausea P02667259A0331 NN O
, P02667259A0331 , O
dizziness P02667259A0331 NN O
and P02667259A0331 CC O
increased P02667259A0331 VBD O
menstrual P02667259A0331 JJ O
flow P02667259A0331 NN O
. P02667259A0331 . O
. . O O

Identification P10400794T0000 NN O
of P10400794T0000 IN O
a P10400794T0000 DT O
spliced P10400794T0000 JJ O
gene P10400794T0000 NN O
from P10400794T0000 IN O
Kaposi P10400794T0000 NNP O
's P10400794T0000 POS O
sarcoma-associated P10400794T0000 JJ O
herpesvirus P10400794T0000 NN O
encoding P10400794T0000 VBG O
a P10400794T0000 DT O
protein P10400794T0000 NN O
with P10400794T0000 IN O
similarities P10400794T0000 NNS O
to P10400794T0000 TO O
latent P10400794T0000 VB I-UN
membrane P10400794T0000 NN I-UN
proteins P10400794T0000 NNS I-UN
1 P10400794T0000 CD I-UN
and P10400794T0000 CC I-UN
2A P10400794T0000 CD I-UN
of P10400794T0000 IN I-UN
Epstein-Barr P10400794T0000 NNP I-UN
virus P10400794T0000 NN I-UN
. P10400794T0000 . O
. . O O

In P09235618A0000 IN O
a P09235618A0000 DT O
series P09235618A0000 NN O
of P09235618A0000 IN O
patients P09235618A0000 NNS O
with P09235618A0000 IN O
neuroinfection P09235618A0000 NN O
, P09235618A0000 , O
Lyme P09235618A0000 NNP O
disease P09235618A0000 NN O
, P09235618A0000 , O
Guillain P09235618A0000 NNP O
Barre P09235618A0000 NNP O
syndrome P09235618A0000 NN O
, P09235618A0000 , O
demyelinization P09235618A0000 NN O
, P09235618A0000 , O
partial P09235618A0000 JJ O
or P09235618A0000 CC O
generalized P09235618A0000 VBN O
, P09235618A0000 , O
epilepsy P09235618A0000 RB O
, P09235618A0000 , O
we P09235618A0000 PRP O
have P09235618A0000 VBP O
investigated P09235618A0000 VBN O
antiphospholipid P09235618A0000 JJ O
antibodies P09235618A0000 NNS O
of P09235618A0000 IN O
IgG P09235618A0000 NNP I-UN
and P09235618A0000 CC O
IgM P09235618A0000 NNP I-UN
subtypes P09235618A0000 NNS O
, P09235618A0000 , O
together P09235618A0000 RB O
with P09235618A0000 IN O
anticoagulant P09235618A0000 JJ O
factors P09235618A0000 NNS O
, P09235618A0000 , O
member P09235618A0000 NN O
of P09235618A0000 IN O
thrombocytes P09235618A0000 NNS O
, P09235618A0000 , O
sedimentation P09235618A0000 NN O
rate P09235618A0000 NN O
of P09235618A0000 IN O
erythrocytes P09235618A0000 NNS O
. P09235618A0000 . O
. . O O

We P01331057A0000 PRP O
have P01331057A0000 VBP O
cloned P01331057A0000 VBN O
and P01331057A0000 CC O
sequenced P01331057A0000 VBN O
COX12 P01331057A0000 NNP I-UN
, P01331057A0000 , O
the P01331057A0000 DT O
nuclear P01331057A0000 JJ O
gene P01331057A0000 NN O
for P01331057A0000 IN O
subunit P01331057A0000 JJ I-UN
VIb P01331057A0000 NNP I-UN
of P01331057A0000 IN O
Saccharomyces P01331057A0000 NNP I-UN
cerevisiae P01331057A0000 VBP I-UN
cytochrome P01331057A0000 JJ I-UN
c P01331057A0000 JJ I-UN
oxidase P01331057A0000 NN I-UN
. P01331057A0000 . O
. . O O

Such P03910310A0666 JJ O
a P03910310A0666 DT O
concept P03910310A0666 NN O
is P03910310A0666 VBZ O
crucial P03910310A0666 JJ O
to P03910310A0666 TO O
our P03910310A0666 PRP$ O
understanding P03910310A0666 NN O
of P03910310A0666 IN O
the P03910310A0666 DT O
pathology P03910310A0666 NN O
of P03910310A0666 IN O
ageing P03910310A0666 VBG O
in P03910310A0666 IN O
general P03910310A0666 JJ O
. P03910310A0666 . O
. . O O

The P08794547A0648 DT O
rCBF P08794547A0648 NN O
and P08794547A0648 CC O
vasomotion P08794547A0648 NN O
were P08794547A0648 VBD O
recorded P08794547A0648 VBN O
by P08794547A0648 IN O
laser-doppler P08794547A0648 JJ O
fluxmetry P08794547A0648 NN O
. P08794547A0648 . O
. . O O

The P09650180A1130 DT O
general P09650180A1130 JJ O
recombination P09650180A1130 NN O
at P09650180A1130 IN O
a P09650180A1130 DT O
polarizing P09650180A1130 JJ O
voltage P09650180A1130 NN O
of P09650180A1130 IN O
300 P09650180A1130 CD O
V P09650180A1130 NNP O
is P09650180A1130 VBZ O
less P09650180A1130 JJR O
than P09650180A1130 IN O
2 P09650180A1130 CD O
% P09650180A1130 NN O
for P09650180A1130 IN O
dose-rates P09650180A1130 NNS O
up P09650180A1130 RB O
to P09650180A1130 TO O
about P09650180A1130 IN O
100 P09650180A1130 CD O
mGy P09650180A1130 JJ O
min-1 P09650180A1130 NN O
. P09650180A1130 . O
. . O O

METHODS P10193950A0478 NN O
: P10193950A0478 : O
Between P10193950A0478 NNP O
August P10193950A0478 NNP O
1991 P10193950A0478 CD O
and P10193950A0478 CC O
June P10193950A0478 NNP O
1994 P10193950A0478 CD O
, P10193950A0478 , O
198 P10193950A0478 CD O
men P10193950A0478 NNS O
with P10193950A0478 IN O
clinical P10193950A0478 JJ O
T2 P10193950A0478 NNP O
or P10193950A0478 CC O
T3 P10193950A0478 NNP O
classified P10193950A0478 VBD O
( P10193950A0478 ( O
TNM P10193950A0478 NNP O
) P10193950A0478 ) O
prostate P10193950A0478 NN O
carcinoma P10193950A0478 NN O
( P10193950A0478 ( O
bone P10193950A0478 JJ O
scan P10193950A0478 JJ O
negative P10193950A0478 NN O
) P10193950A0478 ) O
who P10193950A0478 WP O
were P10193950A0478 VBD O
at P10193950A0478 IN O
high P10193950A0478 JJ O
risk P10193950A0478 NN O
of P10193950A0478 IN O
lymph P10193950A0478 JJ O
node P10193950A0478 JJ O
involvement P10193950A0478 NN O
underwent P10193950A0478 VBD O
a P10193950A0478 DT O
111In-capromab P10193950A0478 JJ O
pendetide P10193950A0478 NN O
scan P10193950A0478 JJ O
prior P10193950A0478 RB O
to P10193950A0478 TO O
staging P10193950A0478 VBG O
lymphadenectomy P10193950A0478 NN O
. P10193950A0478 . O
. . O O

This P03138449A0759 DT O
suggested P03138449A0759 VBD O
that P03138449A0759 IN O
delta P03138449A0759 NN O
6 P03138449A0759 CD O
and P03138449A0759 CC O
delta P03138449A0759 JJ O
5 P03138449A0759 CD O
desaturation P03138449A0759 NN O
activities P03138449A0759 NNS O
are P03138449A0759 VBP O
normal P03138449A0759 JJ O
in P03138449A0759 IN O
these P03138449A0759 DT O
conditions P03138449A0759 NNS O
with P03138449A0759 IN O
this P03138449A0759 DT O
C18:2w6 P03138449A0759 NNP O
supply P03138449A0759 NN O
. P03138449A0759 . O
. . O O

We P10974541A0389 PRP O
screened P10974541A0389 VBD O
a P10974541A0389 DT O
K562 P10974541A0389 NNP O
cDNA P10974541A0389 NN O
library P10974541A0389 NN O
and P10974541A0389 CC O
identified P10974541A0389 VBD O
novel P10974541A0389 JJ O
transcripts P10974541A0389 NNS O
, P10974541A0389 , O
MZF1B P10974541A0389 NNP I-UN
and P10974541A0389 CC O
MZF1C P10974541A0389 NNP I-UN
. P10974541A0389 . O
. . O O

Their P09549632A1189 PRP$ O
use P09549632A1189 NN O
resulted P09549632A1189 VBD O
in P09549632A1189 IN O
a P09549632A1189 DT O
sensitivity P09549632A1189 NN O
of P09549632A1189 IN O
73 P09549632A1189 CD O
% P09549632A1189 NN O
and P09549632A1189 CC O
a P09549632A1189 DT O
specificity P09549632A1189 NN O
of P09549632A1189 IN O
74 P09549632A1189 CD O
% P09549632A1189 NN O
with P09549632A1189 IN O
regard P09549632A1189 NN O
to P09549632A1189 TO O
predictability P09549632A1189 NN O
of P09549632A1189 IN O
ALT P09549632A1189 NNP I-UN
levels P09549632A1189 NNS O
increasing P09549632A1189 VBG O
during P09549632A1189 IN O
the P09549632A1189 DT O
trial P09549632A1189 NN O
. P09549632A1189 . O
. . O O

The P10687862A1980 DT O
CCAAT P10687862A1980 NNP O
core P10687862A1980 NN O
sequence P10687862A1980 NN O
mutants P10687862A1980 NNS O
in P10687862A1980 IN O
which P10687862A1980 WDT O
both P10687862A1980 DT O
CIII P10687862A1980 NNP O
and P10687862A1980 CC O
CI P10687862A1980 NNP O
/ P10687862A1980 NNP O
CII P10687862A1980 NNP O
were P10687862A1980 VBD O
abolished P10687862A1980 VBN O
, P10687862A1980 , O
also P10687862A1980 RB O
increased P10687862A1980 VBD O
the P10687862A1980 DT O
promoter P10687862A1980 NN O
activity P10687862A1980 NN O
. P10687862A1980 . O
. . O O

The P11874637A0212 DT O
use P11874637A0212 NN O
of P11874637A0212 IN O
highly P11874637A0212 RB O
active P11874637A0212 JJ O
antiretroviral P11874637A0212 JJ O
therapy P11874637A0212 NN O
( P11874637A0212 ( O
HAART P11874637A0212 NNP O
) P11874637A0212 ) O
has P11874637A0212 VBZ O
resulted P11874637A0212 VBN O
in P11874637A0212 IN O
significant P11874637A0212 JJ O
improvements P11874637A0212 NNS O
in P11874637A0212 IN O
the P11874637A0212 DT O
treatment P11874637A0212 NN O
of P11874637A0212 IN O
HIV P11874637A0212 NNP O
infection P11874637A0212 NN O
, P11874637A0212 , O
including P11874637A0212 VBG O
a P11874637A0212 DT O
decrease P11874637A0212 NN O
in P11874637A0212 IN O
the P11874637A0212 DT O
incidence P11874637A0212 NN O
and P11874637A0212 CC O
severity P11874637A0212 NN O
of P11874637A0212 IN O
several P11874637A0212 JJ O
acquired P11874637A0212 VBN O
immune P11874637A0212 JJ O
deficiency P11874637A0212 NN O
syndrome P11874637A0212 NN O
( P11874637A0212 ( O
AIDS P11874637A0212 NNP O
) P11874637A0212 ) O
-related P11874637A0212 VBD O
malignancies P11874637A0212 NNS O
. P11874637A0212 . O
. . O O

Studies P08586874T0000 NNS O
on P08586874T0000 IN O
the P08586874T0000 DT O
life P08586874T0000 NN O
cycle P08586874T0000 NN O
of P08586874T0000 IN O
Haplorchis P08586874T0000 NNP O
pumilio P08586874T0000 NN O
( P08586874T0000 ( O
Looss P08586874T0000 NNP O
, P08586874T0000 , O
1896 P08586874T0000 CD O
) P08586874T0000 ) O
Looss P08586874T0000 NNP O
, P08586874T0000 , O
1899 P08586874T0000 CD O
with P08586874T0000 IN O
morphological P08586874T0000 JJ O
redescription P08586874T0000 NN O
of P08586874T0000 IN O
larval P08586874T0000 NN O
and P08586874T0000 CC O
adult P08586874T0000 NN O
stages P08586874T0000 NNS O
. P08586874T0000 . O
. . O O

These P08246984A0923 DT O
results P08246984A0923 NNS O
demonstrate P08246984A0923 VBP O
the P08246984A0923 DT O
existence P08246984A0923 NN O
of P08246984A0923 IN O
different P08246984A0923 JJ O
PI P08246984A0923 NNP I-UN
3-kinase P08246984A0923 JJ I-UN
isoforms P08246984A0923 NNS I-UN
and P08246984A0923 CC O
define P08246984A0923 VB O
a P08246984A0923 DT O
family P08246984A0923 NN O
of P08246984A0923 IN O
genes P08246984A0923 NNS O
encoding P08246984A0923 VBG O
distinct P08246984A0923 JJ O
PI P08246984A0923 NNP I-UN
3-kinase P08246984A0923 NNP I-UN
catalytic P08246984A0923 JJ I-UN
subunits P08246984A0923 NNS I-UN
that P08246984A0923 WDT O
can P08246984A0923 MD O
associate P08246984A0923 VB O
with P08246984A0923 IN O
p85 P08246984A0923 NN I-UN
. P08246984A0923 . O
. . O O

Since P03810361A0576 IN O
the P03810361A0576 DT O
integrated P03810361A0576 VBN O
13h00-16h00 P03810361A0576 JJ O
plasma P03810361A0576 NN O
cortisol P03810361A0576 NN O
estimation P03810361A0576 NN O
is P03810361A0576 VBZ O
cheaper P03810361A0576 JJR O
and P03810361A0576 CC O
simpler P03810361A0576 JJR O
than P03810361A0576 IN O
the P03810361A0576 DT O
mean P03810361A0576 JJ O
13h00-16h00 P03810361A0576 JJ O
plasma P03810361A0576 NN O
cortisol P03810361A0576 NN O
estimation P03810361A0576 NN O
, P03810361A0576 , O
we P03810361A0576 PRP O
recommend P03810361A0576 VBP O
it P03810361A0576 PRP O
as P03810361A0576 IN O
an P03810361A0576 DT O
adjunct P03810361A0576 NN O
in P03810361A0576 IN O
the P03810361A0576 DT O
diagnosis P03810361A0576 NN O
of P03810361A0576 IN O
Cushing P03810361A0576 NNP O
's P03810361A0576 POS O
syndrome P03810361A0576 NN O
. P03810361A0576 . O
. . O O

Thyroid P00728718T0000 NNP O
disease P00728718T0000 NN O
and P00728718T0000 CC O
pregnancy P00728718T0000 NN O
. P00728718T0000 . O
. . O O

Alanine P07557276A0526 NNP I-UN
aminotransferase P07557276A0526 NN I-UN
( P07557276A0526 ( O
ALT P07557276A0526 NNP I-UN
) P07557276A0526 ) O
levels P07557276A0526 NNS O
had P07557276A0526 VBD O
been P07557276A0526 VBN O
elevated P07557276A0526 VBN O
for P07557276A0526 IN O
six P07557276A0526 CD O
months P07557276A0526 NNS O
in P07557276A0526 IN O
all P07557276A0526 DT O
patients P07557276A0526 NNS O
and P07557276A0526 CC O
hepatitis P07557276A0526 NN O
B P07557276A0526 NNP O
viral P07557276A0526 JJ O
infection P07557276A0526 NN O
was P07557276A0526 VBD O
replicative P07557276A0526 JJ O
. P07557276A0526 . O
. . O O

In P10475972A0269 IN O
the P10475972A0269 DT O
face P10475972A0269 NN O
of P10475972A0269 IN O
the P10475972A0269 DT O
outbreak P10475972A0269 NN O
, P10475972A0269 , O
there P10475972A0269 EX O
was P10475972A0269 VBD O
a P10475972A0269 DT O
delay P10475972A0269 NN O
before P10475972A0269 IN O
vaccination P10475972A0269 NN O
was P10475972A0269 VBD O
able P10475972A0269 JJ O
to P10475972A0269 TO O
stop P10475972A0269 VB O
deaths P10475972A0269 NNS O
. P10475972A0269 . O
. . O O

Studies P05172320T0001 NNS O
on P05172320T0001 IN O
the P05172320T0001 DT O
hereditary P05172320T0001 JJ O
nature P05172320T0001 NN O
of P05172320T0001 IN O
sole P05172320T0001 JJ O
prints P05172320T0001 NNS O
-- P05172320T0001 : O
with P05172320T0001 IN O
special P05172320T0001 JJ O
reference P05172320T0001 NN O
to P05172320T0001 TO O
interdigital P05172320T0001 JJ O
and P05172320T0001 CC O
triradii P05172320T0001 NN O
. P05172320T0001 . O
. . O O

Chimeras P09371622A0779 NNP O
containing P09371622A0779 VBG O
IE1 P09371622A0779 NNP I-UN
peptides P09371622A0779 NNS I-UN
dramatically P09371622A0779 RB O
activated P09371622A0779 VBN O
transcription P09371622A0779 NN O
of P09371622A0779 IN O
the P09371622A0779 DT O
basal P09371622A0779 NN O
promoter P09371622A0779 NN O
only P09371622A0779 RB O
when P09371622A0779 WRB O
lac P09371622A0779 NN I-UN
operator P09371622A0779 NN I-UN
sequences P09371622A0779 NNS I-UN
were P09371622A0779 VBD O
present P09371622A0779 JJ O
. P09371622A0779 . O
. . O O

( P08995681A0518 ( O
ii P08995681A0518 NN O
) P08995681A0518 ) O
ICP27 P08995681A0518 NNP I-UN
binds P08995681A0518 VBZ O
preferentially P08995681A0518 RB O
to P08995681A0518 TO O
less P08995681A0518 JJR O
modified P08995681A0518 JJ O
forms P08995681A0518 NNS O
of P08995681A0518 IN O
ICP4 P08995681A0518 NNP I-UN
, P08995681A0518 , O
a P08995681A0518 DT O
protein P08995681A0518 NN O
that P08995681A0518 WDT O
is P08995681A0518 VBZ O
extensively P08995681A0518 RB O
modified P08995681A0518 VBN O
posttranslationally P08995681A0518 RB O
. P08995681A0518 . O
. . O O

We P07862092A0302 PRP O
have P07862092A0302 VBP O
attempted P07862092A0302 VBN O
to P07862092A0302 TO O
clone P07862092A0302 VB O
two P07862092A0302 CD O
recessive P07862092A0302 JJ O
extragenic P07862092A0302 JJ O
suppressors P07862092A0302 NNS O
of P07862092A0302 IN O
such P07862092A0302 JJ O
ts P07862092A0302 JJ O
mutants P07862092A0302 NNS O
( P07862092A0302 ( O
sdp1 P07862092A0302 NN I-UN
for P07862092A0302 IN O
mutation P07862092A0302 NN I-UN
pol3-14 P07862092A0302 NN I-UN
and P07862092A0302 CC O
sdp5-1 P07862092A0302 NN I-UN
for P07862092A0302 IN O
mutation P07862092A0302 NN I-UN
pol3-11 P07862092A0302 NN I-UN
) P07862092A0302 ) O
by P07862092A0302 IN O
transforming P07862092A0302 VBG O
thermoresistant P07862092A0302 JJ O
haploid P07862092A0302 JJ O
strains P07862092A0302 NNS O
pol3-14 P07862092A0302 JJ I-UN
sdp1 P07862092A0302 NN I-UN
and P07862092A0302 CC O
pol3-11 P07862092A0302 JJ I-UN
sdp5-1 P07862092A0302 NN I-UN
with P07862092A0302 IN O
wild-type P07862092A0302 JJ O
genomic P07862092A0302 JJ O
libraries P07862092A0302 NNS O
in P07862092A0302 IN O
singlecopy P07862092A0302 NN O
or P07862092A0302 CC O
multicopy P07862092A0302 NN O
vectors P07862092A0302 NNS O
. P07862092A0302 . O
. . O O

Tumor P08119149A0000 NN I-UN
necrosis P08119149A0000 NN I-UN
factor-alpha P08119149A0000 NN I-UN
( P08119149A0000 ( O
TNF P08119149A0000 NNP I-UN
alpha P08119149A0000 NN I-UN
) P08119149A0000 ) O
is P08119149A0000 VBZ O
one P08119149A0000 CD O
of P08119149A0000 IN O
several P08119149A0000 JJ O
autocrine P08119149A0000 JJ O
/ P08119149A0000 JJ O
paracrine P08119149A0000 NN O
factors P08119149A0000 NNS O
known P08119149A0000 VBN O
to P08119149A0000 TO O
exert P08119149A0000 VB O
potent P08119149A0000 JJ O
inhibitory P08119149A0000 JJ O
effects P08119149A0000 NNS O
on P08119149A0000 IN O
bone P08119149A0000 NN O
. P08119149A0000 . O
. . O O

Heterodimers P01850096A0662 NNS O
of P01850096A0662 IN O
myogenin P01850096A0662 NN I-UN
and P01850096A0662 CC O
E12 P01850096A0662 NNP I-UN
( P01850096A0662 ( O
or P01850096A0662 CC O
MyoD P01850096A0662 NNP I-UN
and P01850096A0662 CC O
E12 P01850096A0662 NNP I-UN
) P01850096A0662 ) O
specifically P01850096A0662 RB O
bound P01850096A0662 IN O
a P01850096A0662 DT O
restriction P01850096A0662 NN O
fragment P01850096A0662 NN O
extending P01850096A0662 VBG O
from P01850096A0662 IN O
-200 P01850096A0662 NN O
to P01850096A0662 TO O
-103 P01850096A0662 VB O
relative P01850096A0662 JJ O
to P01850096A0662 TO O
the P01850096A0662 DT O
start P01850096A0662 NN O
of P01850096A0662 IN O
cardiac P01850096A0662 JJ I-UN
alpha-actin P01850096A0662 JJ I-UN
transcription P01850096A0662 NN O
. P01850096A0662 . O
. . O O

Cranio-caudal P10231513T0000 JJ O
differences P10231513T0000 NNS O
in P10231513T0000 IN O
granulation P10231513T0000 NN O
tissue P10231513T0000 NN O
formation P10231513T0000 NN O
: P10231513T0000 : O
an P10231513T0000 DT O
experimental P10231513T0000 JJ O
study P10231513T0000 NN O
in P10231513T0000 IN O
the P10231513T0000 DT O
rat P10231513T0000 NN O
. P10231513T0000 . O
. . O O

Changes P00564032A0724 NNS O
in P00564032A0724 IN O
ionic P00564032A0724 JJ O
content P00564032A0724 NN O
of P00564032A0724 IN O
the P00564032A0724 DT O
mucous P00564032A0724 JJ O
suggest P00564032A0724 NN O
that P00564032A0724 IN O
cholinergic P00564032A0724 JJ O
mechanisms P00564032A0724 NNS O
affect P00564032A0724 JJ O
pressure P00564032A0724 NN O
in P00564032A0724 IN O
the P00564032A0724 DT O
excretory P00564032A0724 JJ O
duct P00564032A0724 NN O
of P00564032A0724 IN O
the P00564032A0724 DT O
gland P00564032A0724 NN O
. P00564032A0724 . O
. . O O

To P03980386A0000 TO O
assess P03980386A0000 VB O
the P03980386A0000 DT O
effects P03980386A0000 NNS O
of P03980386A0000 IN O
alveolar P03980386A0000 JJ O
hypoxia P03980386A0000 NN O
and P03980386A0000 CC O
angiotensin P03980386A0000 NN I-UN
II P03980386A0000 NNP I-UN
infusion P03980386A0000 NN O
on P03980386A0000 IN O
distribution P03980386A0000 NN O
of P03980386A0000 IN O
blood P03980386A0000 NN O
flow P03980386A0000 NN O
to P03980386A0000 TO O
the P03980386A0000 DT O
lung P03980386A0000 NN O
we P03980386A0000 PRP O
performed P03980386A0000 VBD O
perfusion P03980386A0000 NN O
lung P03980386A0000 NN O
scans P03980386A0000 NNS O
on P03980386A0000 IN O
anesthetized P03980386A0000 VBN O
mechanically P03980386A0000 RB O
ventilated P03980386A0000 JJ O
lambs P03980386A0000 NNS O
. P03980386A0000 . O
. . O O

The P03001645A0785 DT O
pet56 P03001645A0785 NN I-UN
and P03001645A0785 CC O
his3 P03001645A0785 NN I-UN
genes P03001645A0785 NNS I-UN
are P03001645A0785 VBP O
transcribed P03001645A0785 VBN O
divergently P03001645A0785 RB O
from P03001645A0785 IN O
initiation P03001645A0785 NN O
sites P03001645A0785 NNS O
that P03001645A0785 WDT O
are P03001645A0785 VBP O
separated P03001645A0785 VBN O
by P03001645A0785 IN O
only P03001645A0785 RB O
192 P03001645A0785 CD O
bp P03001645A0785 NN O
. P03001645A0785 . O
. . O O

Thin-layer P06643612A0000 NNP O
chromatographic P06643612A0000 JJ O
methods P06643612A0000 NNS O
were P06643612A0000 VBD O
up-dated P06643612A0000 JJ O
for P06643612A0000 IN O
pharmacokinetic P06643612A0000 JJ O
studies P06643612A0000 NNS O
of P06643612A0000 IN O
imipramine P06643612A0000 NN O
in P06643612A0000 IN O
plasma P06643612A0000 NN O
and P06643612A0000 CC O
urine P06643612A0000 NN O
. P06643612A0000 . O
. . O O

The P07835088A0238 DT O
HSD3B1 P07835088A0238 NNP I-UN
and P07835088A0238 CC O
HSD3B2 P07835088A0238 NNP I-UN
genes P07835088A0238 NNS I-UN
encoding P07835088A0238 VBG O
the P07835088A0238 DT O
types P07835088A0238 NNS I-UN
I P07835088A0238 PRP I-UN
and P07835088A0238 CC I-UN
II P07835088A0238 NNP I-UN
3 P07835088A0238 CD I-UN
beta-HSD P07835088A0238 NN I-UN
isoenzymes P07835088A0238 NNS I-UN
, P07835088A0238 , O
respectively P07835088A0238 RB O
, P07835088A0238 , O
have P07835088A0238 VBP O
been P07835088A0238 VBN O
previously P07835088A0238 RB O
assigned P07835088A0238 VBN O
by P07835088A0238 IN O
in P07835088A0238 IN O
situ P07835088A0238 JJ O
hybridization P07835088A0238 NN O
to P07835088A0238 TO O
the P07835088A0238 DT O
chromosome P07835088A0238 NN O
1p13.1 P07835088A0238 CD O
region P07835088A0238 NN O
. P07835088A0238 . O
. . O O

The P08905819A0531 DT O
majority P08905819A0531 NN O
of P08905819A0531 IN O
the P08905819A0531 DT O
cases P08905819A0531 NNS O
with P08905819A0531 IN O
0-I P08905819A0531 JJ O
or P08905819A0531 CC O
0-III P08905819A0531 JJ O
components P08905819A0531 NNS O
were P08905819A0531 VBD O
sm P08905819A0531 NNS O
. P08905819A0531 . O
cancer P08905819A0531 NN O
. P08905819A0531 . O
. . O O

Thus P09175858A1449 RB O
, P09175858A1449 , O
the P09175858A1449 DT O
B-S P09175858A1449 NNP O
mutant P09175858A1449 NN O
does P09175858A1449 VBZ O
not P09175858A1449 RB O
mimic P09175858A1449 VB O
efficiently P09175858A1449 RB O
the P09175858A1449 DT O
chloroplastic P09175858A1449 JJ I-UN
GAPDHs P09175858A1449 NNP I-UN
, P09175858A1449 , O
and P09175858A1449 CC O
long-range P09175858A1449 NN O
and P09175858A1449 CC O
/ P09175858A1449 NN O
or P09175858A1449 CC O
second-layer P09175858A1449 JJ O
effects P09175858A1449 NNS O
, P09175858A1449 , O
not P09175858A1449 RB O
easily P09175858A1449 RB O
predictable P09175858A1449 JJ O
from P09175858A1449 IN O
visual P09175858A1449 JJ O
inspection P09175858A1449 NN O
of P09175858A1449 IN O
three-dimensional P09175858A1449 JJ O
structures P09175858A1449 NNS O
, P09175858A1449 , O
need P09175858A1449 VBP O
to P09175858A1449 TO O
be P09175858A1449 VB O
taken P09175858A1449 VBN O
into P09175858A1449 IN O
account P09175858A1449 NN O
for P09175858A1449 IN O
designing P09175858A1449 VBG O
a P09175858A1449 DT O
true P09175858A1449 JJ O
`` P09175858A1449 `` O
chloroplastic-like P09175858A1449 JJ O
'' P09175858A1449 '' O
mutant P09175858A1449 NN O
of P09175858A1449 IN O
cytosolic P09175858A1449 JJ I-UN
GAPDH P09175858A1449 NNP I-UN
. P09175858A1449 . O
. . O O

Titration P08823187A1020 NN O
of P08823187A1020 IN O
the P08823187A1020 DT O
human P08823187A1020 JJ O
and P08823187A1020 CC O
porcine P08823187A1020 JJ O
proteins P08823187A1020 NNS O
with P08823187A1020 IN O
2-nitro-5-thiosulfabenzoate P08823187A1020 JJ O
indicates P08823187A1020 NNS O
that P08823187A1020 IN O
membrane P08823187A1020 NN I-UN
dipeptidase P08823187A1020 NN I-UN
additionally P08823187A1020 RB O
possesses P08823187A1020 VBZ O
two P08823187A1020 CD O
intrachain P08823187A1020 NN O
disulfide P08823187A1020 JJ O
bonds P08823187A1020 NNS O
. P08823187A1020 . O
. . O O

There P00209664A0836 EX O
was P00209664A0836 VBD O
no P00209664A0836 DT O
correlation P00209664A0836 NN O
between P00209664A0836 IN O
serum P00209664A0836 NN I-UN
LH P00209664A0836 NNP I-UN
and P00209664A0836 CC O
chronological P00209664A0836 JJ O
or P00209664A0836 CC O
bone P00209664A0836 JJ O
age P00209664A0836 NN O
in P00209664A0836 IN O
this P00209664A0836 DT O
age P00209664A0836 NN O
group P00209664A0836 NN O
, P00209664A0836 , O
which P00209664A0836 WDT O
suggests P00209664A0836 VBZ O
that P00209664A0836 IN O
the P00209664A0836 DT O
correlation P00209664A0836 NN O
found P00209664A0836 VBD O
is P00209664A0836 VBZ O
not P00209664A0836 RB O
due P00209664A0836 JJ O
to P00209664A0836 TO O
age-related P00209664A0836 JJ O
parallel P00209664A0836 JJ O
phenomena P00209664A0836 NN O
. P00209664A0836 . O
. . O O

The P02970061A0271 DT O
RAD18 P02970061A0271 NNP I-UN
gene P02970061A0271 NN I-UN
open P02970061A0271 JJ I-UN
reading P02970061A0271 NN I-UN
frame P02970061A0271 NN I-UN
encodes P02970061A0271 VBZ O
a P02970061A0271 DT O
protein P02970061A0271 NN O
of P02970061A0271 IN O
487 P02970061A0271 CD O
amino P02970061A0271 NN O
acids P02970061A0271 NNS O
, P02970061A0271 , O
with P02970061A0271 IN O
a P02970061A0271 DT O
calculated P02970061A0271 JJ O
molecular P02970061A0271 JJ O
weight P02970061A0271 NN O
of P02970061A0271 IN O
55,512 P02970061A0271 CD O
. P02970061A0271 . O
. . O O

Use P08079268T0028 NNP O
of P08079268T0028 IN O
Medi-Jector P08079268T0028 NNP O
EZ P08079268T0028 NNP O
dermojet P08079268T0028 NN O
for P08079268T0028 IN O
anesthesia P08079268T0028 NN O
in P08079268T0028 IN O
minor P08079268T0028 JJ O
surgery P08079268T0028 NN O
. P08079268T0028 . O
. . O O

Platelet P02648646A0216 NNP I-UN
activating P02648646A0216 VBG I-UN
factor P02648646A0216 NN I-UN
was P02648646A0216 VBD O
given P02648646A0216 VBN O
in P02648646A0216 IN O
six P02648646A0216 CD O
doses P02648646A0216 NNS O
at P02648646A0216 IN O
15 P02648646A0216 CD O
minute P02648646A0216 NN O
intervals P02648646A0216 NNS O
and P02648646A0216 CC O
airway P02648646A0216 JJ O
response P02648646A0216 NN O
measured P02648646A0216 VBD O
as P02648646A0216 IN O
change P02648646A0216 NN O
in P02648646A0216 IN O
partial P02648646A0216 JJ O
expiratory P02648646A0216 NN O
flow P02648646A0216 NN O
at P02648646A0216 IN O
30 P02648646A0216 CD O
% P02648646A0216 NN O
of P02648646A0216 IN O
vital P02648646A0216 JJ O
capacity P02648646A0216 NN O
( P02648646A0216 ( O
Vp30 P02648646A0216 NNP O
) P02648646A0216 ) O
. P02648646A0216 . O
. . O O

In P07274505A0660 IN O
controls P07274505A0660 NNS O
, P07274505A0660 , O
only P07274505A0660 RB O
modest P07274505A0660 JJ O
differences P07274505A0660 NNS O
were P07274505A0660 VBD O
observed P07274505A0660 VBN O
. P07274505A0660 . O
. . O O

Here P11095981A0254 RB O
, P11095981A0254 , O
we P11095981A0254 PRP O
identified P11095981A0254 VBD O
three P11095981A0254 CD O
cis-elements P11095981A0254 NNS O
required P11095981A0254 VBN O
for P11095981A0254 IN O
replication P11095981A0254 NN O
within P11095981A0254 IN O
the P11095981A0254 DT O
200 P11095981A0254 CD O
bp P11095981A0254 NN O
promoter P11095981A0254 NN O
, P11095981A0254 , O
using P11095981A0254 VBG O
autonomously P11095981A0254 RB O
replicating P11095981A0254 VBG O
plasmids P11095981A0254 NNS O
carrying P11095981A0254 VBG O
various P11095981A0254 JJ O
mutations P11095981A0254 NNS O
and P11095981A0254 CC O
deletions P11095981A0254 NNS O
. P11095981A0254 . O
. . O O

In P10363517A0401 IN O
this P10363517A0401 DT O
paper P10363517A0401 NN O
, P10363517A0401 , O
such P10363517A0401 JJ O
lesions P10363517A0401 NNS O
in P10363517A0401 IN O
two P10363517A0401 CD O
cases P10363517A0401 NNS O
were P10363517A0401 VBD O
evaluated P10363517A0401 VBN O
by P10363517A0401 IN O
ultrasonography P10363517A0401 NN O
. P10363517A0401 . O
. . O O

Its P02712246T0042 PRP$ O
clinical P02712246T0042 JJ O
and P02712246T0042 CC O
histopathologic P02712246T0042 JJ O
characteristics P02712246T0042 NNS O
. P02712246T0042 . O
. . O O

Molecular P09988682T0033 JJ O
cloning P09988682T0033 NN O
of P09988682T0033 IN O
human P09988682T0033 JJ O
cDNA P09988682T0033 NN O
encoding P09988682T0033 VBG O
a P09988682T0033 DT O
novel P09988682T0033 JJ O
beta1,6-N-acetylglucosaminyltransferase P09988682T0033 JJ I-UN
forming P09988682T0033 NN O
core P09988682T0033 NN O
2 P09988682T0033 CD O
and P09988682T0033 CC O
core P09988682T0033 VBD O
4 P09988682T0033 CD O
. P09988682T0033 . O
. . O O

We P09228042A0109 PRP O
have P09228042A0109 VBP O
separated P09228042A0109 VBN O
a P09228042A0109 DT O
dermatan P09228042A0109 JJ O
sulfate P09228042A0109 NN O
proteoglycan P09228042A0109 NN O
, P09228042A0109 , O
epiphycan P09228042A0109 JJ O
, P09228042A0109 , O
from P09228042A0109 IN O
decorin P09228042A0109 NN I-UN
and P09228042A0109 CC O
biglycan P09228042A0109 JJ O
by P09228042A0109 IN O
using P09228042A0109 VBG O
dissociative P09228042A0109 JJ O
extraction P09228042A0109 NN O
of P09228042A0109 IN O
bovine P09228042A0109 JJ O
fetal P09228042A0109 JJ O
epiphyseal P09228042A0109 NN O
cartilage P09228042A0109 NN O
, P09228042A0109 , O
followed P09228042A0109 VBN O
by P09228042A0109 IN O
sequential P09228042A0109 JJ O
ion-exchange P09228042A0109 NN O
, P09228042A0109 , O
gel P09228042A0109 JJ O
permeation P09228042A0109 NN O
, P09228042A0109 , O
hydrophobic P09228042A0109 NN O
, P09228042A0109 , O
and P09228042A0109 CC O
Zn2+ P09228042A0109 NNP O
chelate P09228042A0109 VBP O
chromatographic P09228042A0109 JJ O
steps P09228042A0109 NNS O
. P09228042A0109 . O
. . O O

Overexpression P09892021A0712 NN O
of P09892021A0712 IN O
PTTG P09892021A0712 NNP I-UN
in P09892021A0712 IN O
transfected P09892021A0712 JJ O
NIH P09892021A0712 NNP O
3T3 P09892021A0712 CD O
cells P09892021A0712 NNS O
also P09892021A0712 RB O
stimulated P09892021A0712 VBD O
expression P09892021A0712 NN O
and P09892021A0712 CC O
secretion P09892021A0712 NN O
of P09892021A0712 IN O
basic P09892021A0712 JJ I-UN
fibroblast P09892021A0712 NN I-UN
growth P09892021A0712 NN I-UN
factor P09892021A0712 NN I-UN
, P09892021A0712 , O
a P09892021A0712 DT O
human P09892021A0712 JJ I-UN
pituitary P09892021A0712 JJ I-UN
tumor P09892021A0712 NN I-UN
growth-regulating P09892021A0712 JJ I-UN
factor P09892021A0712 NN I-UN
. P09892021A0712 . O
. . O O

The P11260468A1179 DT O
results P11260468A1179 NNS O
presented P11260468A1179 VBD O
here P11260468A1179 RB O
show P11260468A1179 VBP O
that P11260468A1179 IN O
AR1 P11260468A1179 NNP I-UN
of P11260468A1179 IN O
the P11260468A1179 DT O
promoter-proximal P11260468A1179 JJ O
CAP P11260468A1179 NNP I-UN
subunit P11260468A1179 NN I-UN
was P11260468A1179 VBD O
required P11260468A1179 VBN O
for P11260468A1179 IN O
papBA P11260468A1179 JJ I-UN
transcription P11260468A1179 NN O
even P11260468A1179 RB O
in P11260468A1179 IN O
the P11260468A1179 DT O
absence P11260468A1179 NN O
of P11260468A1179 IN O
the P11260468A1179 DT O
histone-like P11260468A1179 JJ I-UN
protein P11260468A1179 NN I-UN
H-NS P11260468A1179 NNP I-UN
. P11260468A1179 . O
. . O O

Immunelectrophoretic P04890336T0001 JJ O
pattern P04890336T0001 NN O
of P04890336T0001 IN O
Wassermann P04890336T0001 NNP O
reagin P04890336T0001 NN O
and P04890336T0001 CC O
comparison P04890336T0001 NN O
of P04890336T0001 IN O
the P04890336T0001 DT O
appearance P04890336T0001 NN O
time P04890336T0001 NN O
between P04890336T0001 IN O
RPCF P04890336T0001 NNP I-UN
and P04890336T0001 CC O
FTA P04890336T0001 NNP I-UN
antibodies P04890336T0001 NNS I-UN
. P04890336T0001 . O
. . O O

These P07596558A0824 DT O
results P07596558A0824 NNS O
suggest P07596558A0824 VBP O
that P07596558A0824 IN O
low P07596558A0824 JJ O
concentrations P07596558A0824 NNS O
of P07596558A0824 IN O
IL-1 P07596558A0824 NNP I-UN
beta P07596558A0824 NN I-UN
may P07596558A0824 MD O
be P07596558A0824 VB O
useful P07596558A0824 JJ O
for P07596558A0824 IN O
nonsurgical P07596558A0824 JJ O
treatment P07596558A0824 NN O
of P07596558A0824 IN O
human P07596558A0824 JJ O
vitreous P07596558A0824 JJ O
hemorrhage P07596558A0824 NN O
. P07596558A0824 . O
. . O O

In P02166825A0198 IN O
order P02166825A0198 NN O
to P02166825A0198 TO O
characterize P02166825A0198 VB O
the P02166825A0198 DT O
functional P02166825A0198 JJ O
elements P02166825A0198 NNS O
of P02166825A0198 IN O
the P02166825A0198 DT O
promoter P02166825A0198 NN O
that P02166825A0198 WDT O
in P02166825A0198 IN O
some P02166825A0198 DT O
way P02166825A0198 NN O
must P02166825A0198 MD O
respond P02166825A0198 VB O
to P02166825A0198 TO O
these P02166825A0198 DT O
regulatory P02166825A0198 JJ O
signals P02166825A0198 NNS O
, P02166825A0198 , O
a P02166825A0198 DT O
number P02166825A0198 NN O
of P02166825A0198 IN O
promoter P02166825A0198 NN O
mutations P02166825A0198 NNS O
were P02166825A0198 VBD O
constructed P02166825A0198 VBN O
, P02166825A0198 , O
including P02166825A0198 VBG O
a P02166825A0198 DT O
set P02166825A0198 NN O
of P02166825A0198 IN O
linker-scanning P02166825A0198 JJ O
mutations P02166825A0198 NNS O
across P02166825A0198 IN O
the P02166825A0198 DT O
entire P02166825A0198 JJ O
promoter P02166825A0198 NN O
region P02166825A0198 NN O
. P02166825A0198 . O
. . O O

Surprisingly P01398140A0488 RB O
, P01398140A0488 , O
the P01398140A0488 DT O
Xenopus P01398140A0488 NNP I-UN
U7 P01398140A0488 NNP I-UN
gene P01398140A0488 NN I-UN
contains P01398140A0488 NNS O
two P01398140A0488 CD O
adjacent P01398140A0488 JJ O
octamer-binding P01398140A0488 JJ O
motifs P01398140A0488 NNS O
located P01398140A0488 VBN O
only P01398140A0488 RB O
12 P01398140A0488 CD O
and P01398140A0488 CC O
24 P01398140A0488 CD O
bp P01398140A0488 NN O
upstream P01398140A0488 NN O
from P01398140A0488 IN O
the P01398140A0488 DT O
PSE P01398140A0488 NNP I-UN
, P01398140A0488 , O
instead P01398140A0488 RB O
of P01398140A0488 IN O
the P01398140A0488 DT O
usual P01398140A0488 JJ O
location P01398140A0488 NN O
around P01398140A0488 IN O
150-200 P01398140A0488 JJ O
bp P01398140A0488 NN O
upstream P01398140A0488 NN O
. P01398140A0488 . O
. . O O

In P09040011A1316 IN O
summary P09040011A1316 JJ O
, P09040011A1316 , O
p56 P09040011A1316 NN I-UN
( P09040011A1316 ( O
lck P09040011A1316 JJ I-UN
) P09040011A1316 ) O
activity P09040011A1316 NN O
stimulates P09040011A1316 VBZ O
G1 P09040011A1316 NNP O
/ P09040011A1316 NNP O
S P09040011A1316 NNP O
transition P09040011A1316 NN O
in P09040011A1316 IN O
immature P09040011A1316 NN O
thymoblasts P09040011A1316 NNS O
and P09040011A1316 CC O
maintains P09040011A1316 NNS O
cell P09040011A1316 VBP O
viability P09040011A1316 NN O
via P09040011A1316 IN O
transduction P09040011A1316 NN O
of P09040011A1316 IN O
constitutive P09040011A1316 JJ O
activation P09040011A1316 NN O
signals P09040011A1316 NNS O
downstream P09040011A1316 VBP O
to P09040011A1316 TO O
components P09040011A1316 NNS O
of P09040011A1316 IN O
the P09040011A1316 DT O
Ras P09040011A1316 NNP I-UN
/ P09040011A1316 NNP O
Raf P09040011A1316 NNP I-UN
/ P09040011A1316 NNP O
MAPK P09040011A1316 NNP I-UN
pathway P09040011A1316 NN O
. P09040011A1316 . O
. . O O

The P01159822A0353 DT O
bronchial P01159822A0353 JJ O
epithelia P01159822A0353 NN O
of P01159822A0353 IN O
all P01159822A0353 DT O
smoke-exposed P01159822A0353 JJ O
animals P01159822A0353 NNS O
were P01159822A0353 VBD O
hyperplastic P01159822A0353 JJ O
, P01159822A0353 , O
and P01159822A0353 CC O
their P01159822A0353 PRP$ O
ultrastructure P01159822A0353 NN O
showed P01159822A0353 VBD O
invaginations P01159822A0353 NNS O
, P01159822A0353 , O
tilt P01159822A0353 NN O
of P01159822A0353 IN O
nuclear P01159822A0353 JJ O
axes P01159822A0353 NNS O
, P01159822A0353 , O
an P01159822A0353 DT O
increase P01159822A0353 NN O
in P01159822A0353 IN O
the P01159822A0353 DT O
number P01159822A0353 NN O
and P01159822A0353 CC O
size P01159822A0353 NN O
of P01159822A0353 IN O
lysosomes P01159822A0353 NNS O
and P01159822A0353 CC O
multivesiculated P01159822A0353 JJ O
bodies P01159822A0353 NNS O
, P01159822A0353 , O
and P01159822A0353 CC O
increased P01159822A0353 VBD O
numbers P01159822A0353 NNS O
of P01159822A0353 IN O
enlarged P01159822A0353 JJ O
intramitochondrial P01159822A0353 JJ O
granules P01159822A0353 NNS O
. P01159822A0353 . O
. . O O

Latanoprost P09154283A0307 NNP O
produces P09154283A0307 VBZ O
an P09154283A0307 DT O
additional P09154283A0307 JJ O
reduction P09154283A0307 NN O
of P09154283A0307 IN O
intraocular P09154283A0307 JJ O
pressure P09154283A0307 NN O
( P09154283A0307 ( O
IOP P09154283A0307 NNP O
) P09154283A0307 ) O
when P09154283A0307 WRB O
used P09154283A0307 VBN O
in P09154283A0307 IN O
combination P09154283A0307 NN O
with P09154283A0307 IN O
timolol P09154283A0307 NN O
, P09154283A0307 , O
pilocarpine P09154283A0307 NN O
, P09154283A0307 , O
acetazolamide P09154283A0307 RB O
and P09154283A0307 CC O
dipivefrin P09154283A0307 NN O
. P09154283A0307 . O
. . O O

Also P10628971A1165 RB O
in P10628971A1165 IN O
the P10628971A1165 DT O
spectrum P10628971A1165 NN O
of P10628971A1165 IN O
mutants P10628971A1165 NNS O
with P10628971A1165 IN O
TGN P10628971A1165 NNP O
sorting P10628971A1165 VBG O
defects P10628971A1165 NNS O
are P10628971A1165 VBP O
isolates P10628971A1165 VBZ O
with P10628971A1165 IN O
mutations P10628971A1165 NNS O
in P10628971A1165 IN O
the P10628971A1165 DT O
following P10628971A1165 NN O
: P10628971A1165 : O
RIC1 P10628971A1165 NNP I-UN
, P10628971A1165 , O
encoding P10628971A1165 VBG O
a P10628971A1165 DT O
product P10628971A1165 NN O
originally P10628971A1165 RB O
proposed P10628971A1165 VBN O
to P10628971A1165 TO O
participate P10628971A1165 VB O
in P10628971A1165 IN O
ribosome P10628971A1165 JJ O
biogenesis P10628971A1165 NN O
; P10628971A1165 : O
LUV1 P10628971A1165 NNP I-UN
, P10628971A1165 , O
encoding P10628971A1165 VBG O
a P10628971A1165 DT O
product P10628971A1165 NN O
potentially P10628971A1165 RB O
involved P10628971A1165 VBN O
in P10628971A1165 IN O
vacuole P10628971A1165 NN O
and P10628971A1165 CC O
microtubule P10628971A1165 NN O
organization P10628971A1165 NN O
; P10628971A1165 : O
and P10628971A1165 CC O
INP53 P10628971A1165 NNP I-UN
, P10628971A1165 , O
encoding P10628971A1165 VBG O
a P10628971A1165 DT O
synaptojanin-like P10628971A1165 JJ I-UN
inositol P10628971A1165 NN I-UN
polyphosphate P10628971A1165 NN I-UN
5-phosphatase P10628971A1165 NN I-UN
. P10628971A1165 . O
. . O O

The P11893767A0356 DT O
mass-specific P11893767A0356 JJ O
resting P11893767A0356 NN O
minute P11893767A0356 NN O
ventilation P11893767A0356 NN O
( P11893767A0356 ( O
E P11893767A0356 NNP O
) P11893767A0356 ) O
and P11893767A0356 CC O
the P11893767A0356 DT O
ventilatory P11893767A0356 NN O
equivalent P11893767A0356 NN O
( P11893767A0356 ( O
VE P11893767A0356 NNP O
/ P11893767A0356 NNP O
( P11893767A0356 ( O
O P11893767A0356 NNP O
( P11893767A0356 ( O
2 P11893767A0356 CD O
) P11893767A0356 ) O
) P11893767A0356 ) O
) P11893767A0356 ) O
were P11893767A0356 VBD O
approximately P11893767A0356 RB O
the P11893767A0356 DT O
same P11893767A0356 JJ O
at P11893767A0356 IN O
the P11893767A0356 DT O
two P11893767A0356 CD O
ages P11893767A0356 NNS O
, P11893767A0356 , O
with P11893767A0356 IN O
a P11893767A0356 DT O
breathing P11893767A0356 NN O
pattern P11893767A0356 NN O
significantly P11893767A0356 RB O
deeper P11893767A0356 JJR O
and P11893767A0356 CC O
slower P11893767A0356 JJR O
at P11893767A0356 IN O
day P11893767A0356 NN O
1 P11893767A0356 CD O
. P11893767A0356 . O
. . O O

Transcription P09917391A0380 NN O
readthrough P09917391A0380 NN O
into P09917391A0380 IN O
the P09917391A0380 DT O
inverted P09917391A0380 JJ O
repeats P09917391A0380 NN O
has P09917391A0380 VBZ O
little P09917391A0380 JJ O
effect P09917391A0380 NN O
on P09917391A0380 IN O
this P09917391A0380 DT O
event P09917391A0380 NN O
. P09917391A0380 . O
. . O O

In P06350092A0916 IN O
the P06350092A0916 DT O
posthospital P06350092A0916 JJ O
phase P06350092A0916 NN O
of P06350092A0916 IN O
AMI P06350092A0916 NNP O
, P06350092A0916 , O
as P06350092A0916 RB O
well P06350092A0916 RB O
as P06350092A0916 IN O
in P06350092A0916 IN O
CCHD P06350092A0916 NNP O
, P06350092A0916 , O
the P06350092A0916 DT O
occurrence P06350092A0916 NN O
of P06350092A0916 IN O
high-grade P06350092A0916 JJ O
VPBs P06350092A0916 NNP O
usually P06350092A0916 RB O
indicates P06350092A0916 VBZ O
more P06350092A0916 RBR O
advanced P06350092A0916 JJ O
degrees P06350092A0916 NNS O
of P06350092A0916 IN O
both P06350092A0916 DT O
coronary P06350092A0916 JJ O
and P06350092A0916 CC O
left P06350092A0916 VBD O
ventricular P06350092A0916 JJ O
disease P06350092A0916 NN O
as P06350092A0916 RB O
well P06350092A0916 RB O
as P06350092A0916 IN O
the P06350092A0916 DT O
possibility P06350092A0916 NN O
of P06350092A0916 IN O
cardiac P06350092A0916 NN O
and P06350092A0916 CC O
/ P06350092A0916 NN O
or P06350092A0916 CC O
sudden P06350092A0916 JJ O
death P06350092A0916 NN O
. P06350092A0916 . O
. . O O

The P08937989A1365 DT O
results P08937989A1365 NNS O
suggest P08937989A1365 VBP O
that P08937989A1365 IN O
, P08937989A1365 , O
although P08937989A1365 IN O
both P08937989A1365 DT O
the P08937989A1365 DT O
N- P08937989A1365 NNP O
and P08937989A1365 CC O
C-terminal P08937989A1365 JJ O
regions P08937989A1365 NNS O
of P08937989A1365 IN O
talin P08937989A1365 NN I-UN
bind P08937989A1365 NN O
actin P08937989A1365 NN I-UN
, P08937989A1365 , O
the P08937989A1365 DT O
properties P08937989A1365 NNS O
of P08937989A1365 IN O
these P08937989A1365 DT O
two P08937989A1365 CD O
regions P08937989A1365 NNS O
of P08937989A1365 IN O
the P08937989A1365 DT O
protein P08937989A1365 NN O
are P08937989A1365 VBP O
distinct P08937989A1365 JJ O
. P08937989A1365 . O
. . O O

It P03045725A0872 PRP O
is P03045725A0872 VBZ O
concluded P03045725A0872 VBN O
that P03045725A0872 IN O
suppression P03045725A0872 NN O
of P03045725A0872 IN O
elevated P03045725A0872 JJ O
prolactin P03045725A0872 NN I-UN
levels P03045725A0872 NNS O
in P03045725A0872 IN O
progressive P03045725A0872 JJ O
metastatic P03045725A0872 JJ O
breast P03045725A0872 NN O
cancer P03045725A0872 NN O
patients P03045725A0872 NNS O
is P03045725A0872 VBZ O
not P03045725A0872 RB O
effective P03045725A0872 JJ O
in P03045725A0872 IN O
restoring P03045725A0872 VBG O
tumor P03045725A0872 NN O
sensitivity P03045725A0872 NN O
to P03045725A0872 TO O
chemotherapy P03045725A0872 VB O
. P03045725A0872 . O
. . O O

The P02149566A0478 DT O
ratio P02149566A0478 NN O
of P02149566A0478 IN O
P-31 P02149566A0478 NNP O
NMR-S P02149566A0478 NNP O
derived P02149566A0478 VBD O
inorganic P02149566A0478 JJ O
phosphates P02149566A0478 NNS O
[ P02149566A0478 VBP O
Pi P02149566A0478 NNP O
] P02149566A0478 NNP O
to P02149566A0478 TO O
phosphocreatine P02149566A0478 VB O
[ P02149566A0478 NNP O
PCr P02149566A0478 NNP O
] P02149566A0478 NNP O
was P02149566A0478 VBD O
significantly P02149566A0478 RB O
greater P02149566A0478 JJR O
at P02149566A0478 IN O
rest P02149566A0478 NN O
in P02149566A0478 IN O
LVH P02149566A0478 NNP O
baboons P02149566A0478 NNS O
[ P02149566A0478 VBP O
0.53 P02149566A0478 CD O
+ P02149566A0478 NNP O
/ P02149566A0478 NNP O
- P02149566A0478 : O
0.06 P02149566A0478 CD O
versus P02149566A0478 NN O
controls P02149566A0478 NNS O
= P02149566A0478 VBP O
0.41 P02149566A0478 CD O
+ P02149566A0478 NNP O
/ P02149566A0478 NNP O
- P02149566A0478 : O
0.17 P02149566A0478 CD O
; P02149566A0478 : O
P P02149566A0478 NNP O
less P02149566A0478 JJR O
than P02149566A0478 IN O
0.05 P02149566A0478 CD O
] P02149566A0478 NN O
. P02149566A0478 . O
. . O O

Differentiation P08552093A0657 NN O
was P08552093A0657 VBD O
not P08552093A0657 RB O
observed P08552093A0657 VBN O
after P08552093A0657 IN O
cellular P08552093A0657 JJ O
expression P08552093A0657 NN O
of P08552093A0657 IN O
GTPase-deficient P08552093A0657 JJ O
forms P08552093A0657 NNS O
of P08552093A0657 IN O
alpha P08552093A0657 JJ I-UN
i2 P08552093A0657 NN I-UN
or P08552093A0657 CC O
alpha P08552093A0657 NN I-UN
0 P08552093A0657 CD I-UN
, P08552093A0657 , O
indicating P08552093A0657 VBG O
selectivity P08552093A0657 NN O
for P08552093A0657 IN O
the P08552093A0657 DT O
Gq P08552093A0657 NNP I-UN
family P08552093A0657 NN I-UN
of P08552093A0657 IN O
G P08552093A0657 NNP I-UN
proteins P08552093A0657 NNS I-UN
. P08552093A0657 . O
. . O O

To P09686603A0124 TO O
further P09686603A0124 RBR O
understand P09686603A0124 VB O
the P09686603A0124 DT O
role P09686603A0124 NN O
of P09686603A0124 IN O
cis-acting P09686603A0124 JJ O
elements P09686603A0124 NNS O
in P09686603A0124 IN O
these P09686603A0124 DT O
regulatory P09686603A0124 JJ O
mechanisms P09686603A0124 NNS O
, P09686603A0124 , O
we P09686603A0124 PRP O
have P09686603A0124 VBP O
characterized P09686603A0124 VBN O
a P09686603A0124 DT O
transcriptional P09686603A0124 JJ O
promoter P09686603A0124 NN O
that P09686603A0124 WDT O
drives P09686603A0124 VBZ O
germline P09686603A0124 JJ O
expression P09686603A0124 NN O
of P09686603A0124 IN O
TCR P09686603A0124 NNP I-UN
beta P09686603A0124 NN I-UN
gene P09686603A0124 NN I-UN
segments P09686603A0124 NNS I-UN
in P09686603A0124 IN O
vivo P09686603A0124 NN O
. P09686603A0124 . O
. . O O

The P07665605A1127 DT O
plasmin-derived P07665605A1127 JJ I-UN
D P07665605A1127 NNP I-UN
( P07665605A1127 ( I-UN
approximately P07665605A1127 RB I-UN
105-kDa P07665605A1127 JJ I-UN
) P07665605A1127 ) I-UN
product P07665605A1127 NN I-UN
, P07665605A1127 , O
however P07665605A1127 RB O
, P07665605A1127 , O
could P07665605A1127 MD O
be P07665605A1127 VB O
cross-linked P07665605A1127 JJ O
into P07665605A1127 IN O
DD P07665605A1127 NNP O
dimers P07665605A1127 NNS O
. P07665605A1127 . O
. . O O

Amongst P09592208A0470 NNP O
other P09592208A0470 JJ O
qualities P09592208A0470 NNS O
, P09592208A0470 , O
the P09592208A0470 DT O
book P09592208A0470 NN O
's P09592208A0470 POS O
importance P09592208A0470 NN O
lies P09592208A0470 VBZ O
in P09592208A0470 IN O
the P09592208A0470 DT O
fact P09592208A0470 NN O
that P09592208A0470 IN O
it P09592208A0470 PRP O
associates P09592208A0470 VBZ O
an P09592208A0470 DT O
elaborate P09592208A0470 JJ O
theoretical P09592208A0470 JJ O
construction P09592208A0470 NN O
with P09592208A0470 IN O
the P09592208A0470 DT O
empirical P09592208A0470 JJ O
data P09592208A0470 NNS O
, P09592208A0470 , O
working P09592208A0470 VBG O
within P09592208A0470 IN O
the P09592208A0470 DT O
possibilities P09592208A0470 NNS O
provided P09592208A0470 VBN O
by P09592208A0470 IN O
late P09592208A0470 JJ O
19th-century P09592208A0470 JJ O
moral P09592208A0470 JJ O
statistics P09592208A0470 NNS O
. P09592208A0470 . O
. . O O

Oncogenic P11101847A0159 JJ O
signalling P11101847A0159 NN O
by P11101847A0159 IN O
E2F1 P11101847A0159 NNP I-UN
has P11101847A0159 VBZ O
recently P11101847A0159 RB O
been P11101847A0159 VBN O
linked P11101847A0159 VBN O
to P11101847A0159 TO O
stabilization P11101847A0159 NN O
and P11101847A0159 CC O
activation P11101847A0159 NN O
of P11101847A0159 IN O
the P11101847A0159 DT O
tumour P11101847A0159 NN O
suppressor P11101847A0159 NN O
p53 P11101847A0159 NN I-UN
( P11101847A0159 ( O
refs P11101847A0159 VB O
1,3,4 P11101847A0159 CD O
) P11101847A0159 ) O
. P11101847A0159 . O
. . O O

The P11472696A0387 DT O
differences P11472696A0387 NNS O
in P11472696A0387 IN O
the P11472696A0387 DT O
CPIgG P11472696A0387 NNP I-UN
, P11472696A0387 , O
CRP P11472696A0387 NNP I-UN
, P11472696A0387 , O
and P11472696A0387 CC O
fibrinogen P11472696A0387 NN I-UN
levels P11472696A0387 NNS O
in P11472696A0387 IN O
patients P11472696A0387 NNS O
who P11472696A0387 WP O
were P11472696A0387 VBD O
diagnosed P11472696A0387 VBN O
with P11472696A0387 IN O
ACS P11472696A0387 NNP O
versus P11472696A0387 VBP O
those P11472696A0387 DT O
who P11472696A0387 WP O
were P11472696A0387 VBD O
not P11472696A0387 RB O
( P11472696A0387 ( O
non-ACS P11472696A0387 JJ O
) P11472696A0387 ) O
were P11472696A0387 VBD O
evaluated P11472696A0387 VBN O
. P11472696A0387 . O
. . O O

Current P07888156T0000 JJ O
status P07888156T0000 NN O
of P07888156T0000 IN O
telepathology P07888156T0000 NN O
. P07888156T0000 . O
. . O O

Orthop P00726581T0122 NNP O
. P00726581T0122 . O
. . O O

These P03768208A0879 DT O
results P03768208A0879 NNS O
indicate P03768208A0879 VBP O
that P03768208A0879 IN O
during P03768208A0879 IN O
pregnancy P03768208A0879 NN O
there P03768208A0879 EX O
are P03768208A0879 VBP O
increases P03768208A0879 NNS O
in P03768208A0879 IN O
bone P03768208A0879 NN O
formation P03768208A0879 NN O
rates P03768208A0879 NNS O
contributing P03768208A0879 VBG O
to P03768208A0879 TO O
the P03768208A0879 DT O
increases P03768208A0879 NNS O
in P03768208A0879 IN O
skeletal P03768208A0879 JJ O
mass P03768208A0879 NN O
. P03768208A0879 . O
. . O O

A P10101159A0742 DT O
mutation P10101159A0742 NN O
linked P10101159A0742 VBN O
to P10101159A0742 TO O
the P10101159A0742 DT O
SOC1 P10101159A0742 NNP I-UN
gene P10101159A0742 NN I-UN
, P10101159A0742 , O
previously P10101159A0742 RB O
defined P10101159A0742 VBN O
by P10101159A0742 IN O
recessive P10101159A0742 JJ O
mutations P10101159A0742 NNS O
that P10101159A0742 WDT O
suppress P10101159A0742 VBP O
cbp1 P10101159A0742 JJ I-UN
ts P10101159A0742 NN I-UN
alleles P10101159A0742 NNS I-UN
and P10101159A0742 CC O
stabilize P10101159A0742 VB O
many P10101159A0742 JJ O
mitochondrial P10101159A0742 JJ O
mRNAs P10101159A0742 NN O
, P10101159A0742 , O
was P10101159A0742 VBD O
also P10101159A0742 RB O
isolated P10101159A0742 VBN O
. P10101159A0742 . O
. . O O

We P09675154A0690 PRP O
then P09675154A0690 RB O
studied P09675154A0690 VBD O
four P09675154A0690 CD O
unrelated P09675154A0690 JJ O
Japanese P09675154A0690 JJ O
families P09675154A0690 NNS O
with P09675154A0690 IN O
GSD-Ib P09675154A0690 NNP O
, P09675154A0690 , O
and P09675154A0690 CC O
found P09675154A0690 VBD O
three P09675154A0690 CD O
novel P09675154A0690 JJ O
mutations P09675154A0690 NNS O
: P09675154A0690 : O
a P09675154A0690 DT O
four-base P09675154A0690 JJ O
deletion P09675154A0690 NN O
/ P09675154A0690 IN O
two-base P09675154A0690 JJ O
insertion P09675154A0690 NN O
, P09675154A0690 , O
a P09675154A0690 DT O
point P09675154A0690 NN O
mutation P09675154A0690 NN O
within P09675154A0690 IN O
a P09675154A0690 DT O
consensus P09675154A0690 NN O
splicing P09675154A0690 VBG O
donor P09675154A0690 JJ O
site P09675154A0690 NN O
, P09675154A0690 , O
and P09675154A0690 CC O
a P09675154A0690 DT O
missense P09675154A0690 JJ O
mutation P09675154A0690 NN O
( P09675154A0690 ( O
W118R P09675154A0690 NNP O
) P09675154A0690 ) O
. P09675154A0690 . O
. . O O

ICA P11523446A0523 NNP O
in P11523446A0523 IN O
the P11523446A0523 DT O
reference P11523446A0523 NN O
solution P11523446A0523 NN O
was P11523446A0523 VBD O
characterised P11523446A0523 VBN O
by P11523446A0523 IN O
LC P11523446A0523 NNP O
and P11523446A0523 CC O
time-of-flight P11523446A0523 JJ O
( P11523446A0523 ( O
TOF P11523446A0523 NNP O
) P11523446A0523 ) O
MS P11523446A0523 NNP O
and P11523446A0523 CC O
quantified P11523446A0523 VBN O
by P11523446A0523 IN O
LC P11523446A0523 NNP O
chemiluminescent P11523446A0523 NN O
nitrogen P11523446A0523 NN O
detection P11523446A0523 NN O
( P11523446A0523 ( O
LC-CLND P11523446A0523 NNP O
) P11523446A0523 ) O
. P11523446A0523 . O
. . O O

Double-blind P02865502T0000 NNP O
randomised P02865502T0000 VBD O
trial P02865502T0000 NN O
of P02865502T0000 IN O
intravenous P02865502T0000 JJ O
tissue-type P02865502T0000 JJ I-UN
plasminogen P02865502T0000 NN I-UN
activator P02865502T0000 NN I-UN
versus P02865502T0000 NN O
placebo P02865502T0000 NN O
in P02865502T0000 IN O
acute P02865502T0000 JJ O
myocardial P02865502T0000 JJ O
infarction P02865502T0000 NN O
. P02865502T0000 . O
. . O O

Immunologically P06346427A0000 RB O
reactive P06346427A0000 JJ O
insulin P06346427A0000 NN I-UN
levels P06346427A0000 NNS O
were P06346427A0000 VBD O
determined P06346427A0000 VBN O
in P06346427A0000 IN O
freely-moving P06346427A0000 JJ O
normal P06346427A0000 JJ O
rats P06346427A0000 NNS O
offered P06346427A0000 VBD O
three P06346427A0000 CD O
different P06346427A0000 JJ O
test-meals P06346427A0000 NNS O
. P06346427A0000 . O
. . O O

Our P08709245A1521 PRP$ O
studies P08709245A1521 NNS O
also P08709245A1521 RB O
excluded P08709245A1521 VBD O
the P08709245A1521 DT O
possibility P08709245A1521 NN O
that P08709245A1521 IN O
the P08709245A1521 DT O
phosphorylation P08709245A1521 NN O
of P08709245A1521 IN O
Ser-2 P08709245A1521 NNP O
, P08709245A1521 , O
Ser-123 P08709245A1521 NNP O
, P08709245A1521 , O
or P08709245A1521 CC O
Ser-210 P08709245A1521 NNP O
, P08709245A1521 , O
had P08709245A1521 VBD O
roles P08709245A1521 NNS O
in P08709245A1521 IN O
the P08709245A1521 DT O
trans-suppression P08709245A1521 NN O
activity P08709245A1521 NN O
of P08709245A1521 IN O
the P08709245A1521 DT O
large P08709245A1521 JJ I-UN
HDAg P08709245A1521 NNP I-UN
, P08709245A1521 , O
in P08709245A1521 IN O
the P08709245A1521 DT O
assembly P08709245A1521 NN O
of P08709245A1521 IN O
empty P08709245A1521 JJ O
virus-like P08709245A1521 JJ I-UN
HDAg P08709245A1521 NNP I-UN
particle P08709245A1521 NN I-UN
, P08709245A1521 , O
and P08709245A1521 CC O
in P08709245A1521 IN O
the P08709245A1521 DT O
nuclear P08709245A1521 JJ O
transport P08709245A1521 NN O
of P08709245A1521 IN O
HDAgs P08709245A1521 NNP I-UN
. P08709245A1521 . O
. . O O

Thus P03591464A0840b RB O
, P03591464A0840b , O
a P03591464A0840b DT O
negative P03591464A0840b JJ O
test P03591464A0840b NN O
is P03591464A0840b VBZ O
compatible P03591464A0840b JJ O
with P03591464A0840b IN O
low P03591464A0840b JJ O
disease P03591464A0840b NN O
activity P03591464A0840b NN O
and P03591464A0840b CC O
/ P03591464A0840b NN O
or P03591464A0840b CC O
efficacy P03591464A0840b NN O
of P03591464A0840b IN O
calcium P03591464A0840b JJ O
antagonist P03591464A0840b NN O
treatment P03591464A0840b NN O
. P03591464A0840b . O
. . O O

One P01446132A0328 CD O
air P01446132A0328 NN O
embolism P01446132A0328 NN O
occurred P01446132A0328 VBD O
; P01446132A0328 : O
this P01446132A0328 DT O
was P01446132A0328 VBD O
the P01446132A0328 DT O
only P01446132A0328 JJ O
filter- P01446132A0328 JJ O
or P01446132A0328 CC O
retrieval-related P01446132A0328 JJ O
complication P01446132A0328 NN O
. P01446132A0328 . O
. . O O

Five P09891707A0000 CD O
different P09891707A0000 JJ O
subtypes P09891707A0000 NNS O
of P09891707A0000 IN O
spondyloarthropathy P09891707A0000 NN O
( P09891707A0000 ( O
SpA P09891707A0000 NNP O
) P09891707A0000 ) O
are P09891707A0000 VBP O
now P09891707A0000 RB O
recognized P09891707A0000 VBN O
. P09891707A0000 . O
. . O O

The P02495745T0000 DT O
thrombolytic P02495745T0000 JJ O
effects P02495745T0000 NNS O
of P02495745T0000 IN O
native P02495745T0000 JJ O
tissue-type P02495745T0000 JJ I-UN
plasminogen P02495745T0000 NN I-UN
activator P02495745T0000 NN I-UN
( P02495745T0000 ( O
AK-124 P02495745T0000 NNP I-UN
) P02495745T0000 ) O
on P02495745T0000 IN O
experimental P02495745T0000 JJ O
canine P02495745T0000 NN O
coronary P02495745T0000 JJ O
thrombosis P02495745T0000 NN O
. P02495745T0000 . O
. . O O

At P01509798A0520 IN O
rest P01509798A0520 JJS O
AFF P01509798A0520 NNP O
was P01509798A0520 VBD O
significantly P01509798A0520 RB O
higher P01509798A0520 JJR O
in P01509798A0520 IN O
UT P01509798A0520 NNP O
( P01509798A0520 ( O
29 P01509798A0520 CD O
% P01509798A0520 NN O
) P01509798A0520 ) O
as P01509798A0520 IN O
compared P01509798A0520 VBN O
to P01509798A0520 TO O
AT P01509798A0520 NNP O
( P01509798A0520 ( O
25 P01509798A0520 CD O
% P01509798A0520 NN O
) P01509798A0520 ) O
and P01509798A0520 CC O
UEA P01509798A0520 NNP O
( P01509798A0520 ( O
25 P01509798A0520 CD O
% P01509798A0520 NN O
) P01509798A0520 ) O
. P01509798A0520 . O
. . O O

Using P08939891A0285 VBG O
the P08939891A0285 DT O
yeast P08939891A0285 JJS O
one-hybrid P08939891A0285 JJ O
screen P08939891A0285 NN O
with P08939891A0285 IN O
integrated P08939891A0285 JJ O
NRE P08939891A0285 NNP O
and P08939891A0285 CC O
flanking P08939891A0285 VBG O
DNA P08939891A0285 NNP O
as P08939891A0285 IN O
bait P08939891A0285 NN O
, P08939891A0285 , O
the P08939891A0285 DT O
predominant P08939891A0285 NN O
clone P08939891A0285 NN O
obtained P08939891A0285 VBN O
was P08939891A0285 VBD O
bovine P08939891A0285 JJ I-UN
Nrl P08939891A0285 NNP I-UN
. P08939891A0285 . O
. . O O

Sequencing P08817324A1070 VBG O
of P08817324A1070 IN O
the P08817324A1070 DT O
16p P08817324A1070 CD O
11.1 P08817324A1070 CD O
/ P08817324A1070 NN O
Xq28 P08817324A1070 NNP O
duplication P08817324A1070 NN O
breakpoints P08817324A1070 NNS O
has P08817324A1070 VBZ O
revealed P08817324A1070 VBN O
the P08817324A1070 DT O
presence P08817324A1070 NN O
of P08817324A1070 IN O
repetitive P08817324A1070 JJ O
immunoglobulin-like P08817324A1070 JJ I-UN
CAGGG P08817324A1070 NNP I-UN
pentamer P08817324A1070 NN I-UN
sequences P08817324A1070 NNS I-UN
at P08817324A1070 IN O
or P08817324A1070 CC O
near P08817324A1070 IN O
the P08817324A1070 DT O
paralogy P08817324A1070 NN O
boundaries P08817324A1070 NNS O
. P08817324A1070 . O
. . O O

A P09726987T0000 DT O
human P09726987T0000 JJ O
SPT3-TAFII31-GCN5-L P09726987T0000 JJ O
acetylase P09726987T0000 NN I-UN
complex P09726987T0000 JJ O
distinct P09726987T0000 NN O
from P09726987T0000 IN O
transcription P09726987T0000 NN I-UN
factor P09726987T0000 NN I-UN
IID P09726987T0000 NNP I-UN
. P09726987T0000 . O
. . O O

In P07583562A1826 IN O
men P07583562A1826 NNS O
with P07583562A1826 IN O
BMI P07583562A1826 NNP O
< P07583562A1826 NNP O
30 P07583562A1826 CD O
, P07583562A1826 , O
the P07583562A1826 DT O
OR P07583562A1826 NNP O
was P07583562A1826 VBD O
1.83 P07583562A1826 CD O
for P07583562A1826 IN O
postprandial P07583562A1826 JJ O
TG P07583562A1826 NNP O
( P07583562A1826 ( O
P P07583562A1826 NNP O
= P07583562A1826 NNP O
.041 P07583562A1826 NNP O
) P07583562A1826 ) O
and P07583562A1826 CC O
2.77 P07583562A1826 CD O
for P07583562A1826 IN O
postprandial P07583562A1826 JJ O
RP P07583562A1826 NNP O
( P07583562A1826 ( O
P P07583562A1826 NNP O
= P07583562A1826 NNP O
.032 P07583562A1826 NNP O
) P07583562A1826 ) O
in P07583562A1826 IN O
models P07583562A1826 NNS O
that P07583562A1826 WDT O
included P07583562A1826 VBD O
fasting P07583562A1826 VBG O
TG P07583562A1826 NNP O
, P07583562A1826 , O
LDL-C P07583562A1826 NNP I-UN
, P07583562A1826 , O
and P07583562A1826 CC O
hypertension P07583562A1826 NN O
. P07583562A1826 . O
. . O O

In P08441411A1260 IN O
mitogen-stimulated P08441411A1260 JJ O
splenocytes P08441411A1260 NNS O
, P08441411A1260 , O
Gfi-1 P08441411A1260 NNP I-UN
expression P08441411A1260 NN O
begins P08441411A1260 VBZ O
to P08441411A1260 TO O
rise P08441411A1260 VB O
at P08441411A1260 IN O
12 P08441411A1260 CD O
h P08441411A1260 NN O
after P08441411A1260 IN O
stimulation P08441411A1260 NN O
and P08441411A1260 CC O
reaches P08441411A1260 VBZ O
very P08441411A1260 RB O
high P08441411A1260 JJ O
levels P08441411A1260 NNS O
after P08441411A1260 IN O
50 P08441411A1260 CD O
h P08441411A1260 NN O
, P08441411A1260 , O
suggesting P08441411A1260 VBG O
that P08441411A1260 IN O
it P08441411A1260 PRP O
may P08441411A1260 MD O
be P08441411A1260 VB O
functionally P08441411A1260 RB O
involved P08441411A1260 VBN O
in P08441411A1260 IN O
events P08441411A1260 NNS O
occurring P08441411A1260 VBG O
after P08441411A1260 IN O
the P08441411A1260 DT O
interaction P08441411A1260 NN O
of P08441411A1260 IN O
IL-2 P08441411A1260 NNP I-UN
with P08441411A1260 IN O
its P08441411A1260 PRP$ O
receptor P08441411A1260 NN O
, P08441411A1260 , O
perhaps P08441411A1260 RB O
during P08441411A1260 IN O
the P08441411A1260 DT O
transition P08441411A1260 NN O
from P08441411A1260 IN O
the P08441411A1260 DT O
G1 P08441411A1260 NNP O
to P08441411A1260 TO O
the P08441411A1260 DT O
S P08441411A1260 NNP O
phase P08441411A1260 NN O
of P08441411A1260 IN O
the P08441411A1260 DT O
cell P08441411A1260 NN O
cycle P08441411A1260 NN O
. P08441411A1260 . O
. . O O

However P09087430A1046 RB O
, P09087430A1046 , O
the P09087430A1046 DT O
same P09087430A1046 JJ O
U1A P09087430A1046 NNP I-UN
peptide P09087430A1046 NN I-UN
, P09087430A1046 , O
when P09087430A1046 WRB O
conjugated P09087430A1046 VBN O
to P09087430A1046 TO O
BSA P09087430A1046 NNP I-UN
, P09087430A1046 , O
inhibits P09087430A1046 VBZ O
vertebrate P09087430A1046 NN I-UN
PAP P09087430A1046 NNP I-UN
. P09087430A1046 . O
. . O O

In P10393201A0654 IN O
a P10393201A0654 DT O
reconstituted P10393201A0654 JJ O
human P10393201A0654 JJ O
DNA P10393201A0654 NNP O
repair P10393201A0654 NN O
system P10393201A0654 NN O
containing P10393201A0654 VBG O
DNA P10393201A0654 NNP I-UN
polymerase P10393201A0654 NN I-UN
beta P10393201A0654 NN I-UN
and P10393201A0654 CC O
DNA P10393201A0654 NNP I-UN
ligase P10393201A0654 VBD I-UN
III-XRCC1 P10393201A0654 NNP O
, P10393201A0654 , O
accurate P10393201A0654 JJ O
rejoining P10393201A0654 NN O
of P10393201A0654 IN O
a P10393201A0654 DT O
3 P10393201A0654 CD O
' P10393201A0654 POS O
mismatched P10393201A0654 JJ O
base P10393201A0654 NN O
residue P10393201A0654 NN O
at P10393201A0654 IN O
a P10393201A0654 DT O
single-strand P10393201A0654 JJ O
break P10393201A0654 NN O
is P10393201A0654 VBZ O
dependent P10393201A0654 JJ O
on P10393201A0654 IN O
addition P10393201A0654 NN O
of P10393201A0654 IN O
the P10393201A0654 DT O
exonuclease P10393201A0654 NN O
. P10393201A0654 . O
. . O O

Several P00131739T0001 JJ O
demographic P00131739T0001 JJ O
indices P00131739T0001 NNS O
of P00131739T0001 IN O
isolated P00131739T0001 JJ O
populations P00131739T0001 NNS O
in P00131739T0001 IN O
Uzbekistan P00131739T0001 NNP O
. P00131739T0001 . O
. . O O

Expression P08132667T0000 NN O
of P08132667T0000 IN O
the P08132667T0000 DT O
dibasic P08132667T0000 JJ O
proprotein P08132667T0000 NN O
processing P08132667T0000 VBG O
enzyme P08132667T0000 JJ O
furin P08132667T0000 NN I-UN
is P08132667T0000 VBZ O
directed P08132667T0000 VBN O
by P08132667T0000 IN O
multiple P08132667T0000 JJ O
promoters P08132667T0000 NNS O
. P08132667T0000 . O
. . O O

Tolerance P11340516A0509 NN O
to P11340516A0509 TO O
ADAL-2 P11340516A0509 NNP O
was P11340516A0509 VBD O
similar P11340516A0509 JJ O
to P11340516A0509 TO O
that P11340516A0509 DT O
of P11340516A0509 IN O
Vicryl P11340516A0509 NNP O
suture P11340516A0509 NN O
and P11340516A0509 CC O
tolerance P11340516A0509 NN O
to P11340516A0509 TO O
ADAL-2 P11340516A0509 NNP O
was P11340516A0509 VBD O
superior P11340516A0509 JJ O
to P11340516A0509 TO O
that P11340516A0509 DT O
to P11340516A0509 TO O
Tisuacryl P11340516A0509 NNP O
. P11340516A0509 . O
. . O O

What P09022632T0000 WP O
's P09022632T0000 VBZ O
new P09022632T0000 JJ O
in P09022632T0000 IN O
gynecologic P09022632T0000 NN O
and P09022632T0000 CC O
obstetrical P09022632T0000 JJ O
surgery P09022632T0000 NN O
. P09022632T0000 . O
. . O O

This P03610663A0201 DT O
approach P03610663A0201 NN O
enables P03610663A0201 VBZ O
the P03610663A0201 DT O
sources P03610663A0201 NNS O
of P03610663A0201 IN O
error P03610663A0201 NN O
in P03610663A0201 IN O
the P03610663A0201 DT O
calculation P03610663A0201 NN O
of P03610663A0201 IN O
nutrient P03610663A0201 JJ O
utilization P03610663A0201 NN O
to P03610663A0201 TO O
be P03610663A0201 VB O
readily P03610663A0201 RB O
identified P03610663A0201 VBN O
, P03610663A0201 , O
and P03610663A0201 CC O
their P03610663A0201 PRP$ O
effect P03610663A0201 NN O
on P03610663A0201 IN O
precision P03610663A0201 NN O
to P03610663A0201 TO O
be P03610663A0201 VB O
assessed P03610663A0201 VBN O
in P03610663A0201 IN O
different P03610663A0201 JJ O
nutritional P03610663A0201 JJ O
and P03610663A0201 CC O
metabolic P03610663A0201 JJ O
states P03610663A0201 NNS O
. P03610663A0201 . O
. . O O

They P09649437A1140 PRP O
also P09649437A1140 RB O
indicate P09649437A1140 VBP O
that P09649437A1140 IN O
direct P09649437A1140 JJ O
interactions P09649437A1140 NNS O
between P09649437A1140 IN O
C P09649437A1140 NNP I-UN
/ P09649437A1140 NNP I-UN
EBPs P09649437A1140 NNP I-UN
and P09649437A1140 CC O
specific P09649437A1140 JJ O
Ets P09649437A1140 NNP I-UN
family P09649437A1140 NN O
members P09649437A1140 NNS O
, P09649437A1140 , O
together P09649437A1140 RB O
with P09649437A1140 IN O
GATA-1 P09649437A1140 NNP I-UN
, P09649437A1140 , O
are P09649437A1140 VBP O
important P09649437A1140 JJ O
for P09649437A1140 IN O
eosinophil P09649437A1140 JJ O
lineage P09649437A1140 NN O
determination P09649437A1140 NN O
. P09649437A1140 . O
. . O O

Symptoms P11003807A0303 NNS O
, P11003807A0303 , O
however P11003807A0303 RB O
, P11003807A0303 , O
appear P11003807A0303 VBP O
to P11003807A0303 TO O
correlate P11003807A0303 VB O
poorly P11003807A0303 RB O
with P11003807A0303 IN O
oesophagitis P11003807A0303 NN O
; P11003807A0303 : O
hence P11003807A0303 NN O
, P11003807A0303 , O
severe P11003807A0303 JJ O
symptoms P11003807A0303 NNS O
do P11003807A0303 VBP O
not P11003807A0303 RB O
indicate P11003807A0303 VB O
there P11003807A0303 EX O
is P11003807A0303 VBZ O
greater P11003807A0303 JJR O
oesophageal P11003807A0303 JJ O
damage P11003807A0303 NN O
. P11003807A0303 . O
. . O O

This P06473252A1073 DT O
experiment P06473252A1073 NN O
was P06473252A1073 VBD O
conducted P06473252A1073 VBN O
to P06473252A1073 TO O
determine P06473252A1073 VB O
if P06473252A1073 IN O
the P06473252A1073 DT O
sex P06473252A1073 NN O
or P06473252A1073 CC O
actual P06473252A1073 JJ O
egg P06473252A1073 NN O
production P06473252A1073 NN O
was P06473252A1073 VBD O
the P06473252A1073 DT O
important P06473252A1073 JJ O
factor P06473252A1073 NN O
. P06473252A1073 . O
( P06473252A1073 ( O
ABSTRACT P06473252A1073 NNP O
TRUNCATED P06473252A1073 NNP O
AT P06473252A1073 NNP O
250 P06473252A1073 CD O
WORDS P06473252A1073 NNP O
) P06473252A1073 ) O
. P06473252A1073 . O
. . O O

A P11450776T0000 DT O
rare P11450776T0000 JJ O
case P11450776T0000 NN O
of P11450776T0000 IN O
primary P11450776T0000 JJ O
group P11450776T0000 NN O
A P11450776T0000 NNP O
streptococcal P11450776T0000 JJ O
peritonitis P11450776T0000 NN O
. P11450776T0000 . O
. . O O

Our P07981246A0112 PRP$ O
previous P07981246A0112 JJ O
study P07981246A0112 NN O
suggested P07981246A0112 VBD O
that P07981246A0112 IN O
pertussis P07981246A0112 NN I-UN
toxin P07981246A0112 NN I-UN
( P07981246A0112 ( O
IAP P07981246A0112 NNP I-UN
) P07981246A0112 ) O
-sensitive P07981246A0112 VBP O
GTP-binding P07981246A0112 JJ I-UN
protein P07981246A0112 NN I-UN
( P07981246A0112 ( I-UN
s P07981246A0112 PRP I-UN
) P07981246A0112 ) I-UN
( P07981246A0112 ( O
G-protein P07981246A0112 NNP I-UN
) P07981246A0112 ) O
is P07981246A0112 VBZ O
involved P07981246A0112 VBN O
in P07981246A0112 IN O
the P07981246A0112 DT O
process P07981246A0112 NN O
of P07981246A0112 IN O
differentiation P07981246A0112 NN O
by P07981246A0112 IN O
hormones P07981246A0112 NNS O
/ P07981246A0112 NNP O
IBMX P07981246A0112 NNP O
, P07981246A0112 , O
accompanied P07981246A0112 VBN O
by P07981246A0112 IN O
c-fos P07981246A0112 JJ I-UN
induction P07981246A0112 NN O
. P07981246A0112 . O
. . O O

In P08195233A0147 IN O
addition P08195233A0147 NN O
, P08195233A0147 , O
this P08195233A0147 DT O
kinase P08195233A0147 NN O
is P08195233A0147 VBZ O
well P08195233A0147 RB O
conserved P08195233A0147 VBN O
evolutionarily P08195233A0147 RB O
, P08195233A0147 , O
ubiquitously P08195233A0147 RB O
expressed P08195233A0147 VBN O
, P08195233A0147 , O
and P08195233A0147 CC O
its P08195233A0147 PRP$ O
genes P08195233A0147 NNS O
map P08195233A0147 VBP O
to P08195233A0147 TO O
a P08195233A0147 DT O
position P08195233A0147 NN O
on P08195233A0147 IN O
human P08195233A0147 JJ O
chromosome P08195233A0147 NN O
1 P08195233A0147 CD O
frequently P08195233A0147 RB O
deleted P08195233A0147 VBN O
in P08195233A0147 IN O
the P08195233A0147 DT O
late P08195233A0147 JJ O
stages P08195233A0147 NNS O
of P08195233A0147 IN O
tumorigenesis P08195233A0147 NN O
. P08195233A0147 . O
. . O O

The P03200488A0439 DT O
results P03200488A0439 NNS O
presented P03200488A0439 VBD O
suggest P03200488A0439 JJS O
that P03200488A0439 IN O
TIQ P03200488A0439 NNP O
reduces P03200488A0439 VBZ O
the P03200488A0439 DT O
turnover P03200488A0439 NN O
rate P03200488A0439 NN O
of P03200488A0439 IN O
the P03200488A0439 DT O
nigrostriatal P03200488A0439 JJ O
dopamine P03200488A0439 NN O
neurons P03200488A0439 NNS O
after P03200488A0439 IN O
repeated P03200488A0439 VBN O
administration P03200488A0439 NN O
for P03200488A0439 IN O
a P03200488A0439 DT O
long P03200488A0439 JJ O
period P03200488A0439 NN O
in P03200488A0439 IN O
mice P03200488A0439 NN O
. P03200488A0439 . O
. . O O

Kinetics P08380896A0938 NNS O
of P08380896A0938 IN O
the P08380896A0938 DT O
inhibition P08380896A0938 NN O
indicated P08380896A0938 VBD O
that P08380896A0938 IN O
this P08380896A0938 DT O
polymerase P08380896A0938 NN O
domain P08380896A0938 NN O
can P08380896A0938 MD O
inhibit P08380896A0938 VB O
viral P08380896A0938 JJ O
replication P08380896A0938 NN O
only P08380896A0938 RB O
during P08380896A0938 IN O
the P08380896A0938 DT O
preinitiation P08380896A0938 NN O
stage P08380896A0938 NN O
. P08380896A0938 . O
. . O O

When P00641395A0441 WRB O
blood P00641395A0441 NN O
samples P00641395A0441 NNS O
of P00641395A0441 IN O
patients P00641395A0441 NNS O
with P00641395A0441 IN O
hyperbilirubinemia P00641395A0441 NN O
were P00641395A0441 VBD O
analyzed P00641395A0441 VBN O
, P00641395A0441 , O
direct P00641395A0441 JJ O
measurement P00641395A0441 NN O
of P00641395A0441 IN O
ZPP P00641395A0441 NNP O
by P00641395A0441 IN O
this P00641395A0441 DT O
fluorimeter P00641395A0441 NN O
yielded P00641395A0441 VBD O
significantly P00641395A0441 RB O
higher P00641395A0441 JJR O
levels P00641395A0441 NNS O
than P00641395A0441 IN O
did P00641395A0441 VBD O
an P00641395A0441 DT O
alternate P00641395A0441 NN O
extraction P00641395A0441 NN O
method P00641395A0441 NN O
. P00641395A0441 . O
. . O O

NE P01518849A0165 NNP I-UN
and P01518849A0165 CC O
PR3 P01518849A0165 NNP I-UN
assist P01518849A0165 NN O
in P01518849A0165 IN O
the P01518849A0165 DT O
destruction P01518849A0165 NN O
of P01518849A0165 IN O
phagocytosed P01518849A0165 JJ O
microorganisms P01518849A0165 NNS O
, P01518849A0165 , O
cleave P01518849A0165 VBP O
the P01518849A0165 DT O
important P01518849A0165 JJ O
connective-tissue P01518849A0165 NN I-UN
protein P01518849A0165 NN I-UN
elastin P01518849A0165 NN I-UN
, P01518849A0165 , O
and P01518849A0165 CC O
generate P01518849A0165 VB O
chemotactic P01518849A0165 JJ O
activities P01518849A0165 NNS O
by P01518849A0165 IN O
forming P01518849A0165 VBG O
alpha P01518849A0165 JJ I-UN
1-proteinase P01518849A0165 JJ I-UN
inhibitor P01518849A0165 NN I-UN
complexes P01518849A0165 NNS I-UN
and P01518849A0165 CC O
elastin P01518849A0165 NN I-UN
peptides P01518849A0165 NNS I-UN
. P01518849A0165 . O
. . O O

In P09582350A0165 IN O
patients P09582350A0165 NNS O
with P09582350A0165 IN O
type P09582350A0165 JJ O
IA P09582350A0165 NNP O
maple P09582350A0165 NN O
syrup P09582350A0165 NN O
urine P09582350A0165 JJ O
disease P09582350A0165 NN O
, P09582350A0165 , O
the P09582350A0165 DT O
E1alpha P09582350A0165 NNP I-UN
subunit P09582350A0165 NN I-UN
is P09582350A0165 VBZ O
affected P09582350A0165 VBN O
, P09582350A0165 , O
resulting P09582350A0165 VBG O
in P09582350A0165 IN O
the P09582350A0165 DT O
loss P09582350A0165 NN O
of P09582350A0165 IN O
E1 P09582350A0165 NNP I-UN
and P09582350A0165 CC O
branched-chain P09582350A0165 JJ I-UN
ketoacid P09582350A0165 NN I-UN
dehydrogenase P09582350A0165 NN I-UN
catalytic P09582350A0165 JJ O
activities P09582350A0165 NNS O
. P09582350A0165 . O
. . O O

The P05901778T0000 DT O
effect P05901778T0000 NN O
of P05901778T0000 IN O
feeding P05901778T0000 VBG O
patterns P05901778T0000 NNS O
on P05901778T0000 IN O
fat P05901778T0000 JJ O
deposition P05901778T0000 NN O
in P05901778T0000 IN O
mice P05901778T0000 NN O
. P05901778T0000 . O
. . O O

The P11568988A0960 DT O
best P11568988A0960 JJS O
regression P11568988A0960 NN O
model P11568988A0960 NN O
for P11568988A0960 IN O
predicting P11568988A0960 VBG O
changes P11568988A0960 NNS O
in P11568988A0960 IN O
the P11568988A0960 DT O
WCXR P11568988A0960 NNP O
included P11568988A0960 VBD O
time P11568988A0960 NN O
to P11568988A0960 TO O
first P11568988A0960 RB O
positive P11568988A0960 JJ O
culture P11568988A0960 NN O
and P11568988A0960 CC O
antibody P11568988A0960 NN O
titer P11568988A0960 NN O
for P11568988A0960 IN O
Pa P11568988A0960 NNP I-UN
elastase P11568988A0960 NN I-UN
. P11568988A0960 . O
. . O O

The P09696819A0450 DT O
resulting P09696819A0450 VBG O
mutants P09696819A0450 NNS O
were P09696819A0450 VBD O
coexpressed P09696819A0450 VBN O
with P09696819A0450 IN O
gE P09696819A0450 NN I-UN
in P09696819A0450 IN O
the P09696819A0450 DT O
vaccinia P09696819A0450 JJ O
virus-based P09696819A0450 JJ O
vTF7-3 P09696819A0450 NN O
system P09696819A0450 NN O
, P09696819A0450 , O
and P09696819A0450 CC O
the P09696819A0450 DT O
formation P09696819A0450 NN O
and P09696819A0450 CC O
endoplasmic P09696819A0450 JJ O
reticulum P09696819A0450 NN O
( P09696819A0450 ( O
ER P09696819A0450 NNP O
) P09696819A0450 ) O
-to-Golgi P09696819A0450 VBP O
transport P09696819A0450 NN O
of P09696819A0450 IN O
the P09696819A0450 DT O
hetero-oligomeric P09696819A0450 JJ O
complex P09696819A0450 NN O
were P09696819A0450 VBD O
monitored P09696819A0450 VBN O
. P09696819A0450 . O
. . O O

Electronic P03371806A0000 NNP O
data P03371806A0000 NNS O
processing P03371806A0000 NN O
( P03371806A0000 ( O
EDP P03371806A0000 NNP O
) P03371806A0000 ) O
latex P03371806A0000 VBP O
immunoassay P03371806A0000 JJ O
using P03371806A0000 VBG O
anti-human P03371806A0000 JJ I-UN
seminal P03371806A0000 JJ I-UN
acid P03371806A0000 NN I-UN
phosphatase P03371806A0000 NN I-UN
( P03371806A0000 ( O
anti-HSAP P03371806A0000 JJ I-UN
) P03371806A0000 ) O
immune P03371806A0000 NN O
serum P03371806A0000 NN O
was P03371806A0000 VBD O
applied P03371806A0000 VBN O
for P03371806A0000 IN O
the P03371806A0000 DT O
species P03371806A0000 NNS O
and P03371806A0000 CC O
organ P03371806A0000 JJ O
identification P03371806A0000 NN O
of P03371806A0000 IN O
human P03371806A0000 JJ O
seminal P03371806A0000 JJ O
stains P03371806A0000 NNS O
. P03371806A0000 . O
. . O O

MBI P10656161A0316 NNP O
and P10656161A0316 CC O
MMBI P10656161A0316 NNP O
showed P10656161A0316 VBD O
similar P10656161A0316 JJ O
Cmax P10656161A0316 NNP O
values P10656161A0316 NNS O
, P10656161A0316 , O
but P10656161A0316 CC O
the P10656161A0316 DT O
former P10656161A0316 JJ O
disappeared P10656161A0316 VBD O
slower P10656161A0316 JJR O
in P10656161A0316 IN O
the P10656161A0316 DT O
serum P10656161A0316 NN O
than P10656161A0316 IN O
the P10656161A0316 DT O
latter P10656161A0316 JJ O
and P10656161A0316 CC O
resulted P10656161A0316 VBD O
in P10656161A0316 IN O
its P10656161A0316 PRP$ O
larger P10656161A0316 JJR O
AUC P10656161A0316 NNP O
values P10656161A0316 NNS O
. P10656161A0316 . O
. . O O

Oligodeoxynucleotides P08551572A0155 NNS O
antisense P08551572A0155 VBP O
to P08551572A0155 TO O
the P08551572A0155 DT O
predicted P08551572A0155 VBN O
translation P08551572A0155 NN O
initiation P08551572A0155 NN O
regions P08551572A0155 NNS O
of P08551572A0155 IN O
ICP4 P08551572A0155 NNP I-UN
and P08551572A0155 CC O
pp38 P08551572A0155 VB I-UN
mRNAs P08551572A0155 NN I-UN
inhibited P08551572A0155 JJ O
proliferation P08551572A0155 NN O
of P08551572A0155 IN O
MSB1 P08551572A0155 NNP O
cells P08551572A0155 NNS O
but P08551572A0155 CC O
not P08551572A0155 RB O
MDCC-CU91 P08551572A0155 NNP O
( P08551572A0155 ( O
CU91 P08551572A0155 NNP O
) P08551572A0155 ) O
reticuloendotheliosis P08551572A0155 NN O
virus-transformed P08551572A0155 JJ O
cells P08551572A0155 NNS O
. P08551572A0155 . O
. . O O

In P11278286A0456 IN O
SN-48 P11278286A0456 NNP O
neuronal P11278286A0456 JJ O
cells P11278286A0456 NNS O
that P11278286A0456 IN O
express P11278286A0456 NN O
MR P11278286A0456 NNP I-UN
, P11278286A0456 , O
GR P11278286A0456 NNP I-UN
, P11278286A0456 , O
and P11278286A0456 CC O
5-HT1A P11278286A0456 JJ I-UN
receptors P11278286A0456 NNS I-UN
, P11278286A0456 , O
deletion P11278286A0456 NN O
or P11278286A0456 CC O
inactivation P11278286A0456 NN O
of P11278286A0456 IN O
the P11278286A0456 DT O
nGRE P11278286A0456 NN O
( P11278286A0456 ( O
negative P11278286A0456 JJ O
GRE P11278286A0456 NNP O
) P11278286A0456 ) O
eliminated P11278286A0456 VBD O
negative P11278286A0456 JJ O
regulation P11278286A0456 NN O
of P11278286A0456 IN O
the P11278286A0456 DT O
rat P11278286A0456 NN I-UN
5-HT1A P11278286A0456 JJ I-UN
or P11278286A0456 CC O
heterologous P11278286A0456 JJ O
promoters P11278286A0456 NNS O
by P11278286A0456 IN O
corticosteroids P11278286A0456 NNS O
, P11278286A0456 , O
whereas P11278286A0456 IN O
its P11278286A0456 PRP$ O
inclusion P11278286A0456 NN O
conferred P11278286A0456 VBD O
corticosteroid-induced P11278286A0456 JJ O
inhibition P11278286A0456 NN O
to P11278286A0456 TO O
a P11278286A0456 DT O
heterologous P11278286A0456 JJ O
promoter P11278286A0456 NN O
. P11278286A0456 . O
. . O O

Functional P07615541T0000 JJ O
analysis P07615541T0000 NN O
of P07615541T0000 IN O
DNase-I P07615541T0000 NNP I-UN
hypersensitive P07615541T0000 JJ O
sites P07615541T0000 NNS O
at P07615541T0000 IN O
the P07615541T0000 DT O
mouse P07615541T0000 NN I-UN
porphobilinogen P07615541T0000 NN I-UN
deaminase P07615541T0000 NN I-UN
gene P07615541T0000 NN I-UN
locus P07615541T0000 NN I-UN
. P07615541T0000 . O
. . O O

The P08296434A1141 DT O
Harleco P08296434A1141 NNP O
apparatus P08296434A1141 NN O
is P08296434A1141 VBZ O
a P08296434A1141 DT O
simple P08296434A1141 JJ O
, P08296434A1141 , O
useful P08296434A1141 JJ O
, P08296434A1141 , O
cost-effective P08296434A1141 JJ O
adjunct P08296434A1141 NN O
to P08296434A1141 TO O
the P08296434A1141 DT O
diagnosis P08296434A1141 NN O
and P08296434A1141 CC O
treatment P08296434A1141 NN O
of P08296434A1141 IN O
this P08296434A1141 DT O
life-threatening P08296434A1141 JJ O
condition P08296434A1141 NN O
. P08296434A1141 . O
. . O O

It P07916983A0623 PRP O
is P07916983A0623 VBZ O
concluded P07916983A0623 VBN O
that P07916983A0623 IN O
CT P07916983A0623 NNP O
should P07916983A0623 MD O
be P07916983A0623 VB O
routinely P07916983A0623 RB O
employed P07916983A0623 VBN O
in P07916983A0623 IN O
patients P07916983A0623 NNS O
with P07916983A0623 IN O
N1-N3 P07916983A0623 NNP O
neck P07916983A0623 NN O
disease P07916983A0623 NN O
to P07916983A0623 TO O
determine P07916983A0623 VB O
the P07916983A0623 DT O
proper P07916983A0623 JJ O
electron-energy P07916983A0623 JJ O
prescription P07916983A0623 NN O
. P07916983A0623 . O
. . O O

Ras-GRF1 P10681520A0525 NNP O
transiently P10681520A0525 RB O
expressed P10681520A0525 VBD O
with P10681520A0525 IN O
v-Src P10681520A0525 NN I-UN
was P10681520A0525 VBD O
tyrosine-phosphorylated P10681520A0525 JJ O
and P10681520A0525 CC O
showed P10681520A0525 VBD O
significant P10681520A0525 JJ O
GEF P10681520A0525 NNP I-UN
activity P10681520A0525 NN O
toward P10681520A0525 IN O
Rac P10681520A0525 NNP I-UN
, P10681520A0525 , O
but P10681520A0525 CC O
not P10681520A0525 RB O
Rho P10681520A0525 NNP I-UN
and P10681520A0525 CC O
Cdc42 P10681520A0525 NNP I-UN
, P10681520A0525 , O
which P10681520A0525 WDT O
was P10681520A0525 VBD O
comparable P10681520A0525 JJ O
with P10681520A0525 IN O
that P10681520A0525 DT O
induced P10681520A0525 VBN O
by P10681520A0525 IN O
Gbetagamma P10681520A0525 NNP I-UN
. P10681520A0525 . O
. . O O

Histamine P04056256A0416 NNP O
reactivity P04056256A0416 NN O
was P04056256A0416 VBD O
significantly P04056256A0416 RB O
reduced P04056256A0416 VBN O
after P04056256A0416 IN O
the P04056256A0416 DT O
nifedipine P04056256A0416 JJ O
aerosol P04056256A0416 NN O
, P04056256A0416 , O
the P04056256A0416 DT O
geometric P04056256A0416 JJ O
mean P04056256A0416 NN O
provocative P04056256A0416 JJ O
concentration P04056256A0416 NN O
causing P04056256A0416 VBG O
a P04056256A0416 DT O
35 P04056256A0416 CD O
% P04056256A0416 NN O
fall P04056256A0416 NN O
in P04056256A0416 IN O
specific P04056256A0416 JJ O
airway P04056256A0416 NN O
conductance P04056256A0416 NN O
, P04056256A0416 , O
rising P04056256A0416 VBG O
from P04056256A0416 IN O
5.0 P04056256A0416 CD O
to P04056256A0416 TO O
10.9 P04056256A0416 CD O
mg P04056256A0416 NNS O
/ P04056256A0416 JJ O
ml P04056256A0416 NN O
of P04056256A0416 IN O
histamine P04056256A0416 NN O
( P04056256A0416 ( O
p P04056256A0416 NN O
less P04056256A0416 JJR O
than P04056256A0416 IN O
0.05 P04056256A0416 CD O
) P04056256A0416 ) O
. P04056256A0416 . O
. . O O

An P09370276A0781 DT O
open P09370276A0781 JJ O
reading P09370276A0781 NN O
frame P09370276A0781 NN O
of P09370276A0781 IN O
2862 P09370276A0781 CD O
bp P09370276A0781 NN O
encoding P09370276A0781 VBG O
a P09370276A0781 DT O
954 P09370276A0781 CD O
amino P09370276A0781 NN O
acid P09370276A0781 NN O
protein P09370276A0781 NN O
was P09370276A0781 VBD O
identified P09370276A0781 VBN O
. P09370276A0781 . O
. . O O

Prognostic P10493203T0000 JJ O
value P10493203T0000 NN O
of P10493203T0000 IN O
a P10493203T0000 DT O
treadmill P10493203T0000 NN O
exercise P10493203T0000 NN O
score P10493203T0000 NN O
in P10493203T0000 IN O
symptomatic P10493203T0000 JJ O
patients P10493203T0000 NNS O
with P10493203T0000 IN O
nonspecific P10493203T0000 JJ O
ST-T P10493203T0000 JJ O
abnormalities P10493203T0000 NNS O
on P10493203T0000 IN O
resting P10493203T0000 VBG O
ECG P10493203T0000 NNP O
. P10493203T0000 . O
. . O O

This P11164078A0833 DT O
animal P11164078A0833 JJ O
model P11164078A0833 NN O
of P11164078A0833 IN O
dystonia P11164078A0833 NN O
appears P11164078A0833 VBZ O
to P11164078A0833 TO O
be P11164078A0833 VB O
a P11164078A0833 DT O
model P11164078A0833 NN O
of P11164078A0833 IN O
NAD P11164078A0833 NNP O
in P11164078A0833 IN O
man P11164078A0833 NN O
from P11164078A0833 IN O
the P11164078A0833 DT O
viewpoint P11164078A0833 NN O
of P11164078A0833 IN O
treatment-response P11164078A0833 NN O
. P11164078A0833 . O
. . O O

However P09817190A0074 RB O
, P09817190A0074 , O
the P09817190A0074 DT O
use P09817190A0074 NN O
of P09817190A0074 IN O
cyclosporin P09817190A0074 NN O
A P09817190A0074 NNP O
is P09817190A0074 VBZ O
associated P09817190A0074 VBN O
with P09817190A0074 IN O
an P09817190A0074 DT O
increased P09817190A0074 JJ O
prevalence P09817190A0074 NN O
of P09817190A0074 IN O
hypertension P09817190A0074 NN O
in P09817190A0074 IN O
kidney P09817190A0074 NN O
transplant P09817190A0074 NN O
recipients P09817190A0074 NNS O
. P09817190A0074 . O
. . O O

Progression P10375107A1138 NN O
after P10375107A1138 IN O
first-line P10375107A1138 JJ O
chemotherapy P10375107A1138 NN O
was P10375107A1138 VBD O
associated P10375107A1138 VBN O
with P10375107A1138 IN O
significantly P10375107A1138 RB O
worse P10375107A1138 JJR O
survival P10375107A1138 NN O
for P10375107A1138 IN O
patients P10375107A1138 NNS O
with P10375107A1138 IN O
metastasis P10375107A1138 NN O
. P10375107A1138 . O
. . O O

The P11478627A0573 DT O
desirability P11478627A0573 NN O
function P11478627A0573 NN O
is P11478627A0573 VBZ O
based P11478627A0573 VBN O
on P11478627A0573 IN O
the P11478627A0573 DT O
search P11478627A0573 NN O
for P11478627A0573 IN O
a P11478627A0573 DT O
global P11478627A0573 JJ O
optimum P11478627A0573 NN O
[ P11478627A0573 NNP O
D P11478627A0573 NNP O
= P11478627A0573 NNP O
f P11478627A0573 NN O
( P11478627A0573 ( O
Y1 P11478627A0573 NNP O
, P11478627A0573 , O
Y2 P11478627A0573 NNP O
, P11478627A0573 , O
... P11478627A0573 : O
, P11478627A0573 , O
Yn P11478627A0573 NNP O
) P11478627A0573 ) O
] P11478627A0573 NN O
by P11478627A0573 IN O
the P11478627A0573 DT O
transformation P11478627A0573 NN O
of P11478627A0573 IN O
the P11478627A0573 DT O
measured P11478627A0573 JJ O
property P11478627A0573 NN O
to P11478627A0573 TO O
a P11478627A0573 DT O
dimensionless P11478627A0573 NN O
scale P11478627A0573 NN O
for P11478627A0573 IN O
each P11478627A0573 DT O
criterion P11478627A0573 NN O
. P11478627A0573 . O
. . O O

The P09165039A0728 DT O
monkey P09165039A0728 NN I-UN
LHR P09165039A0728 NNP I-UN
cDNA P09165039A0728 NN I-UN
displayed P09165039A0728 VBD O
83-94 P09165039A0728 CD O
% P09165039A0728 NN O
overall P09165039A0728 JJ O
sequence P09165039A0728 NN O
homology P09165039A0728 NN O
with P09165039A0728 IN O
the P09165039A0728 DT O
other P09165039A0728 JJ O
mammalian P09165039A0728 JJ I-UN
LHR P09165039A0728 NNP I-UN
cDNAs P09165039A0728 NN I-UN
. P09165039A0728 . O
. . O O

Interestingly P10068637A1320 RB O
, P10068637A1320 , O
Csx P10068637A1320 NNP I-UN
/ P10068637A1320 NNP O
Nkx2 P10068637A1320 NNP I-UN
. P10068637A1320 . O
. . O O

Influence P11086872A0000 NN O
of P11086872A0000 IN O
oil P11086872A0000 NN O
emulsions P11086872A0000 NNS O
and P11086872A0000 CC O
diphenyl P11086872A0000 VB O
on P11086872A0000 IN O
post-harvest P11086872A0000 JJ O
physiconutritional P11086872A0000 JJ O
changes P11086872A0000 NNS O
in P11086872A0000 IN O
Kagzi P11086872A0000 NNP O
limes P11086872A0000 NNS O
( P11086872A0000 ( O
Citrus P11086872A0000 NNP O
aurantifolia P11086872A0000 RB O
) P11086872A0000 ) O
was P11086872A0000 VBD O
studied P11086872A0000 VBN O
. P11086872A0000 . O
. . O O

Like P01176905A0094 IN O
pineal P01176905A0094 NN O
melatonin P01176905A0094 NN O
, P01176905A0094 , O
serum P01176905A0094 NN O
melatonin P01176905A0094 NN O
was P01176905A0094 VBD O
high P01176905A0094 JJ O
at P01176905A0094 IN O
mid-dark P01176905A0094 JJ O
and P01176905A0094 CC O
low P01176905A0094 JJ O
at P01176905A0094 IN O
mid-light P01176905A0094 NN O
. P01176905A0094 . O
. . O O

Antenatal P00350465T0000 JJ O
diagnosis P00350465T0000 NN O
of P00350465T0000 IN O
haematological P00350465T0000 JJ O
disorders P00350465T0000 NNS O
-- P00350465T0000 : O
'1978 P00350465T0000 POS O
' P00350465T0000 POS O
. P00350465T0000 . O
. . O O

Analysis P08294429A0153 NN O
of P08294429A0153 IN O
the P08294429A0153 DT O
intact P08294429A0153 JJ O
hGH P08294429A0153 JJ I-UN
gene P08294429A0153 NN I-UN
or P08294429A0153 CC O
hGH P08294429A0153 VB I-UN
5'-flanking P08294429A0153 JJ I-UN
DNA P08294429A0153 NNP I-UN
( P08294429A0153 ( I-UN
5'-FR P08294429A0153 JJ I-UN
) P08294429A0153 ) I-UN
coupled P08294429A0153 VBN O
to P08294429A0153 TO O
the P08294429A0153 DT O
hGh P08294429A0153 NN I-UN
cDNA P08294429A0153 NN I-UN
or P08294429A0153 CC O
chloramphenicol P08294429A0153 JJ I-UN
acetyltransferase P08294429A0153 NN I-UN
or P08294429A0153 CC O
luciferase P08294429A0153 NN I-UN
genes P08294429A0153 NNS I-UN
, P08294429A0153 , O
indicated P08294429A0153 VBD O
that P08294429A0153 IN O
cAMP P08294429A0153 NN O
primarily P08294429A0153 RB O
stimulated P08294429A0153 VBD O
hGH P08294429A0153 JJ I-UN
promoter P08294429A0153 NN I-UN
activity P08294429A0153 NN O
. P08294429A0153 . O
. . O O

Thirty P01379032A0495 NNP O
percent P01379032A0495 NN O
of P01379032A0495 IN O
patients P01379032A0495 NNS O
were P01379032A0495 VBD O
tapered P01379032A0495 VBN O
off P01379032A0495 RP O
all P01379032A0495 DT O
steroids P01379032A0495 NNS O
, P01379032A0495 , O
and P01379032A0495 CC O
the P01379032A0495 DT O
average P01379032A0495 JJ O
steroid P01379032A0495 NN O
dose P01379032A0495 NN O
in P01379032A0495 IN O
the P01379032A0495 DT O
group P01379032A0495 NN O
who P01379032A0495 WP O
received P01379032A0495 VBD O
steroids P01379032A0495 NNS O
was P01379032A0495 VBD O
8.6 P01379032A0495 CD O
mg P01379032A0495 NN O
of P01379032A0495 IN O
prednisone P01379032A0495 NN O
per P01379032A0495 IN O
day P01379032A0495 NN O
. P01379032A0495 . O
. . O O

Auditory-visual P02257899T0000 JJ O
interaction P02257899T0000 NN O
in P02257899T0000 IN O
the P02257899T0000 DT O
generation P02257899T0000 NN O
of P02257899T0000 IN O
saccades P02257899T0000 NNS O
in P02257899T0000 IN O
man P02257899T0000 NN O
. P02257899T0000 . O
. . O O

We P07713421A1435b PRP O
show P07713421A1435b VBP O
that P07713421A1435b IN O
these P07713421A1435b DT O
three P07713421A1435b CD O
gain-of-function P07713421A1435b NN O
mutants P07713421A1435b NNS O
differ P07713421A1435b VBP O
considerably P07713421A1435b RB O
in P07713421A1435b IN O
their P07713421A1435b PRP$ O
ability P07713421A1435b NN O
to P07713421A1435b TO O
bypass P07713421A1435b VB O
the P07713421A1435b DT O
sex P07713421A1435b NN O
determination P07713421A1435b NN O
signal P07713421A1435b NN O
, P07713421A1435b , O
with P07713421A1435b IN O
SxlM4 P07713421A1435b NNP I-UN
being P07713421A1435b VBG O
the P07713421A1435b DT O
strongest P07713421A1435b JJS O
and P07713421A1435b CC O
SxlM1 P07713421A1435b NNP I-UN
the P07713421A1435b DT O
weakest P07713421A1435b JJS O
. P07713421A1435b . O
. . O O

In P10490662A0819 IN O
fact P10490662A0819 NN O
, P10490662A0819 , O
SPT P10490662A0819 NNP I-UN
activity P10490662A0819 NN O
in P10490662A0819 IN O
the P10490662A0819 DT O
fly P10490662A0819 NN O
expressing P10490662A0819 VBG O
epitope-tagged P10490662A0819 JJ O
Lace P10490662A0819 NNP I-UN
was P10490662A0819 VBD O
absorbed P10490662A0819 VBN O
by P10490662A0819 IN O
epitope-specific P10490662A0819 JJ O
antibody P10490662A0819 NN O
. P10490662A0819 . O
. . O O

Effect P08276762T0000 NN O
of P08276762T0000 IN O
single P08276762T0000 JJ O
base P08276762T0000 NN O
substitutions P08276762T0000 NNS O
at P08276762T0000 IN O
glycine-870 P08276762T0000 JJ O
codon P08276762T0000 NN O
of P08276762T0000 IN O
gramicidin P08276762T0000 NN I-UN
S P08276762T0000 NNP I-UN
synthetase P08276762T0000 NN I-UN
2 P08276762T0000 CD I-UN
gene P08276762T0000 NN I-UN
on P08276762T0000 IN O
proline P08276762T0000 JJ O
activation P08276762T0000 NN O
. P08276762T0000 . O
. . O O

( P05892712T0034 ( O
3 P05892712T0034 CD O
) P05892712T0034 ) O
. P05892712T0034 . O
. . O O

High-resolution P08823163T0000 NN O
structure P08823163T0000 NN O
of P08823163T0000 IN O
the P08823163T0000 DT O
diphtheria P08823163T0000 NN I-UN
toxin P08823163T0000 NN I-UN
repressor P08823163T0000 NN I-UN
complexed P08823163T0000 VBN O
with P08823163T0000 IN O
cobalt P08823163T0000 NN O
and P08823163T0000 CC O
manganese P08823163T0000 JJ O
reveals P08823163T0000 NNS O
an P08823163T0000 DT O
SH3-like P08823163T0000 JJ I-UN
third P08823163T0000 JJ O
domain P08823163T0000 NN O
and P08823163T0000 CC O
suggests P08823163T0000 VBZ O
a P08823163T0000 DT O
possible P08823163T0000 JJ O
role P08823163T0000 NN O
of P08823163T0000 IN O
phosphate P08823163T0000 NN O
as P08823163T0000 IN O
co-corepressor P08823163T0000 NN O
. P08823163T0000 . O
. . O O

Results P01098179A0167 NNS O
obtained P01098179A0167 VBD O
for P01098179A0167 IN O
chloramphenicol-containing P01098179A0167 JJ O
preparations P01098179A0167 NNS O
are P01098179A0167 VBP O
presented P01098179A0167 VBN O
, P01098179A0167 , O
and P01098179A0167 CC O
both P01098179A0167 DT O
dissolution P01098179A0167 NN O
curves P01098179A0167 NNS O
and P01098179A0167 CC O
cup-plate P01098179A0167 JJ O
assays P01098179A0167 NNS O
demonstrate P01098179A0167 VBP O
that P01098179A0167 IN O
chloramphenicol P01098179A0167 NN O
has P01098179A0167 VBZ O
far P01098179A0167 RB O
superior P01098179A0167 JJ O
release P01098179A0167 NN O
( P01098179A0167 ( O
and P01098179A0167 CC O
hence P01098179A0167 RB O
activity P01098179A0167 NN O
) P01098179A0167 ) O
from P01098179A0167 IN O
creams P01098179A0167 JJR O
than P01098179A0167 IN O
from P01098179A0167 IN O
ophthalmic P01098179A0167 JJ O
ointments P01098179A0167 NNS O
. P01098179A0167 . O
. . O O

In P07980440A0138 IN O
H4IIE P07980440A0138 NNP O
rat P07980440A0138 NN O
hepatoma P07980440A0138 NN O
cells P07980440A0138 NNS O
, P07980440A0138 , O
glucocorticoids P07980440A0138 NNS O
, P07980440A0138 , O
retinoic P07980440A0138 NN O
acid P07980440A0138 NN O
and P07980440A0138 CC O
cyclic P07980440A0138 JJ O
AMP P07980440A0138 NNP O
( P07980440A0138 ( O
cAMP P07980440A0138 NN O
) P07980440A0138 ) O
increase P07980440A0138 NN O
PEPCK P07980440A0138 NNP I-UN
gene P07980440A0138 NN I-UN
transcription P07980440A0138 NN O
whereas P07980440A0138 IN O
insulin P07980440A0138 NN I-UN
and P07980440A0138 CC O
phorbol P07980440A0138 NN O
esters P07980440A0138 NNS O
have P07980440A0138 VBP O
the P07980440A0138 DT O
opposite P07980440A0138 JJ O
effect P07980440A0138 NN O
. P07980440A0138 . O
. . O O

Selected P09156883A0294 VBN O
parameters P09156883A0294 NNS O
: P09156883A0294 : O
heart P09156883A0294 NN O
rate P09156883A0294 NN O
( P09156883A0294 ( O
HR P09156883A0294 NNP O
) P09156883A0294 ) O
, P09156883A0294 , O
arterial P09156883A0294 JJ O
blood P09156883A0294 NN O
pressure P09156883A0294 NN O
( P09156883A0294 ( O
ABP P09156883A0294 NNP O
) P09156883A0294 ) O
and P09156883A0294 CC O
arterial P09156883A0294 JJ O
O2 P09156883A0294 NNP O
saturation P09156883A0294 NN O
( P09156883A0294 ( O
SaO2 P09156883A0294 NNP O
) P09156883A0294 ) O
monitored P09156883A0294 VBN O
by P09156883A0294 IN O
pulsoximetry P09156883A0294 NN O
were P09156883A0294 VBD O
measured P09156883A0294 VBN O
during P09156883A0294 IN O
the P09156883A0294 DT O
procedure P09156883A0294 NN O
. P09156883A0294 . O
. . O O

These P08906056A1290 DT O
patients P08906056A1290 NNS O
appear P08906056A1290 VBP O
to P08906056A1290 TO O
have P08906056A1290 VB O
slightly P08906056A1290 RB O
better P08906056A1290 JJR O
pulmonary P08906056A1290 JJ O
function P08906056A1290 NN O
and P08906056A1290 CC O
nutritional P08906056A1290 JJ O
status P08906056A1290 NN O
; P08906056A1290 : O
yet P08906056A1290 RB O
, P08906056A1290 , O
they P08906056A1290 PRP O
seem P08906056A1290 VBP O
to P08906056A1290 TO O
have P08906056A1290 VB O
a P08906056A1290 DT O
higher P08906056A1290 JJR O
degree P08906056A1290 NN O
of P08906056A1290 IN O
health P08906056A1290 NN O
care P08906056A1290 NN O
utilization P08906056A1290 NN O
. P08906056A1290 . O
. . O O

The P09667482A0978 DT O
report P09667482A0978 NN O
highlights P09667482A0978 VBZ O
the P09667482A0978 DT O
possible P09667482A0978 JJ O
contribution P09667482A0978 NN O
of P09667482A0978 IN O
stress P09667482A0978 JJ O
factors P09667482A0978 NNS O
in P09667482A0978 IN O
the P09667482A0978 DT O
context P09667482A0978 NN O
of P09667482A0978 IN O
therapy P09667482A0978 NN O
resistant P09667482A0978 JJ O
periodontal P09667482A0978 JJ O
disease P09667482A0978 NN O
, P09667482A0978 , O
and P09667482A0978 CC O
the P09667482A0978 DT O
results P09667482A0978 NNS O
seem P09667482A0978 VBP O
to P09667482A0978 TO O
be P09667482A0978 VB O
understandable P09667482A0978 JJ O
within P09667482A0978 IN O
the P09667482A0978 DT O
context P09667482A0978 NN O
of P09667482A0978 IN O
a P09667482A0978 DT O
stress P09667482A0978 NN O
system P09667482A0978 NN O
disorder P09667482A0978 RBR O
perspective P09667482A0978 NN O
. P09667482A0978 . O
. . O O

Unilateral P09915118T0000 JJ O
naris P09915118T0000 JJ O
occlusion P09915118T0000 NN O
and P09915118T0000 CC O
the P09915118T0000 DT O
rat P09915118T0000 NN O
accessory P09915118T0000 JJ O
olfactory P09915118T0000 NN O
bulb P09915118T0000 NN O
. P09915118T0000 . O
. . O O

FOG P09230307A0329 NNP I-UN
is P09230307A0329 VBZ O
coexpressed P09230307A0329 VBN O
with P09230307A0329 IN O
GATA-1 P09230307A0329 NNP I-UN
during P09230307A0329 IN O
embryonic P09230307A0329 JJ O
development P09230307A0329 NN O
and P09230307A0329 CC O
in P09230307A0329 IN O
erythroid P09230307A0329 NN O
and P09230307A0329 CC O
megakaryocytic P09230307A0329 JJ O
cells P09230307A0329 NNS O
. P09230307A0329 . O
. . O O

Saunders P11740806X0810 NNS O
Company P11740806X0810 NNP O
. P11740806X0810 . O
. . O O

In P10209119A0076 IN O
budding P10209119A0076 VBG O
yeast P10209119A0076 NN O
, P10209119A0076 , O
the P10209119A0076 DT O
protein P10209119A0076 NN O
Skp1p P10209119A0076 NNP I-UN
, P10209119A0076 , O
the P10209119A0076 DT O
cullin-family P10209119A0076 JJ I-UN
member P10209119A0076 NN I-UN
Cdc53p P10209119A0076 NNP I-UN
, P10209119A0076 , O
and P10209119A0076 CC O
the P10209119A0076 DT O
F-box P10209119A0076 NNP O
/ P10209119A0076 NNP O
WD-repeat P10209119A0076 NNP O
protein P10209119A0076 NN O
Cdc4p P10209119A0076 NNP I-UN
form P10209119A0076 VBZ O
the P10209119A0076 DT O
SCFCdc4p P10209119A0076 NNP I-UN
ubiquitin P10209119A0076 JJ I-UN
ligase P10209119A0076 NN I-UN
complex P10209119A0076 NN O
, P10209119A0076 , O
which P10209119A0076 WDT O
targets P10209119A0076 VBZ O
the P10209119A0076 DT O
cyclin-dependent P10209119A0076 JJ I-UN
kinase P10209119A0076 NN I-UN
( P10209119A0076 ( O
Cdk P10209119A0076 NNP I-UN
) P10209119A0076 ) O
inhibitor P10209119A0076 NN O
Sic1p P10209119A0076 NNP I-UN
for P10209119A0076 IN O
proteolysis P10209119A0076 NN O
[ P10209119A0076 $ O
3 P10209119A0076 CD O
] P10209119A0076 NNP O
[ P10209119A0076 VBD O
4 P10209119A0076 CD O
] P10209119A0076 NNP O
[ P10209119A0076 VBD O
5 P10209119A0076 CD O
] P10209119A0076 NNP O
[ P10209119A0076 VBD O
6 P10209119A0076 CD O
] P10209119A0076 NNP O
[ P10209119A0076 VBD O
7 P10209119A0076 CD O
] P10209119A0076 NNP O
[ P10209119A0076 VBD O
8 P10209119A0076 CD O
] P10209119A0076 NN O
. P10209119A0076 . O
. . O O

OBJECTIVE P09925120A0074 NN O
: P09925120A0074 : O
This P09925120A0074 DT O
meta-analysis P09925120A0074 NN O
of P09925120A0074 IN O
67 P09925120A0074 CD O
controlled P09925120A0074 JJ O
trials P09925120A0074 NNS O
was P09925120A0074 VBD O
performed P09925120A0074 VBN O
to P09925120A0074 TO O
quantify P09925120A0074 VB O
the P09925120A0074 DT O
cholesterol-lowering P09925120A0074 JJ O
effect P09925120A0074 NN O
of P09925120A0074 IN O
major P09925120A0074 JJ O
dietary P09925120A0074 JJ O
fibers P09925120A0074 NNS O
. P09925120A0074 . O
. . O O

Endonuclease P10882850A0000 NNP I-UN
III P10882850A0000 NNP I-UN
( P10882850A0000 ( O
Nth P10882850A0000 NNP I-UN
) P10882850A0000 ) O
of P10882850A0000 IN O
Escherichia P10882850A0000 NNP O
coli P10882850A0000 NN O
is P10882850A0000 VBZ O
a P10882850A0000 DT O
DNA P10882850A0000 NN I-UN
glycosylase P10882850A0000 NN I-UN
essential P10882850A0000 JJ O
for P10882850A0000 IN O
the P10882850A0000 DT O
removal P10882850A0000 NN O
of P10882850A0000 IN O
oxidised P10882850A0000 JJ O
pyrimidine P10882850A0000 NN O
base P10882850A0000 NN O
residues P10882850A0000 NNS O
from P10882850A0000 IN O
DNA P10882850A0000 NNP O
. P10882850A0000 . O
. . O O

Restriction P08188606A1034 NN O
analysis P08188606A1034 NN O
and P08188606A1034 CC O
Southern P08188606A1034 NNP O
hybridization P08188606A1034 NN O
revealed P08188606A1034 VBD O
the P08188606A1034 DT O
presence P08188606A1034 NN O
of P08188606A1034 IN O
Tn5422 P08188606A1034 NNP I-UN
in P08188606A1034 IN O
all P08188606A1034 PDT O
the P08188606A1034 DT O
plasmid-mediated P08188606A1034 JJ O
cadmium-resistant P08188606A1034 JJ O
L. P08188606A1034 NNP O
monocytogenes P08188606A1034 NNS O
strains P08188606A1034 NNS O
tested P08188606A1034 VBN O
but P08188606A1034 CC O
not P08188606A1034 RB O
in P08188606A1034 IN O
strains P08188606A1034 NNS O
encoding P08188606A1034 VBG O
cadmium P08188606A1034 NN O
resistance P08188606A1034 NN O
on P08188606A1034 IN O
the P08188606A1034 DT O
chromosome P08188606A1034 NN O
. P08188606A1034 . O
. . O O

Human P10079173A0000 JJ I-UN
neuronal P10079173A0000 JJ I-UN
Elav-like P10079173A0000 JJ I-UN
proteins P10079173A0000 NNS I-UN
contain P10079173A0000 VBP O
three P10079173A0000 CD O
RNP-type P10079173A0000 JJ O
RNA P10079173A0000 NNP O
recognition P10079173A0000 NN O
motifs P10079173A0000 NNS O
( P10079173A0000 ( O
RRMs P10079173A0000 NNP O
) P10079173A0000 ) O
. P10079173A0000 . O
. . O O

Simian P10400712A0000 JJ O
parainfluenza P10400712A0000 NN O
virus P10400712A0000 NN O
5 P10400712A0000 CD O
( P10400712A0000 ( O
SV5 P10400712A0000 NNP O
) P10400712A0000 ) O
is P10400712A0000 VBZ O
a P10400712A0000 DT O
prototype P10400712A0000 NN O
of P10400712A0000 IN O
the P10400712A0000 DT O
Paramyxoviridae P10400712A0000 NNP O
family P10400712A0000 NN O
of P10400712A0000 IN O
nonsegmented P10400712A0000 JJ O
negative-sense P10400712A0000 JJ O
RNA P10400712A0000 NNP O
viruses P10400712A0000 NNS O
. P10400712A0000 . O
. . O O

The P01863768A0649 DT O
protein P01863768A0649 NN O
encoded P01863768A0649 VBN O
by P01863768A0649 IN O
ORF113 P01863768A0649 NNP I-UN
contains P01863768A0649 VBZ O
a P01863768A0649 DT O
transmembrane P01863768A0649 NN O
domain P01863768A0649 NN O
. P01863768A0649 . O
. . O O

Nuclear P08395004A0558 JJ O
localization P08395004A0558 NN O
and P08395004A0558 CC O
protein P08395004A0558 NN O
sequence P08395004A0558 NN O
similarities P08395004A0558 NNS O
suggested P08395004A0558 VBD O
that P08395004A0558 IN O
the P08395004A0558 DT O
SPT2 P08395004A0558 NNP I-UN
/ P08395004A0558 NNP O
SIN1 P08395004A0558 NNP I-UN
protein P08395004A0558 NN O
may P08395004A0558 MD O
be P08395004A0558 VB O
related P08395004A0558 VBN O
to P08395004A0558 TO O
the P08395004A0558 DT O
nonhistone P08395004A0558 NN I-UN
chromosomal P08395004A0558 JJ I-UN
protein P08395004A0558 NN I-UN
HMG1 P08395004A0558 NNP I-UN
. P08395004A0558 . O
. . O O

Results P02251119A0319 NNS O
have P02251119A0319 VBP O
surprisingly P02251119A0319 RB O
revealed P02251119A0319 VBN O
the P02251119A0319 DT O
presence P02251119A0319 NN O
of P02251119A0319 IN O
three P02251119A0319 CD O
U14 P02251119A0319 NNP I-UN
snRNA-homologous P02251119A0319 JJ I-UN
regions P02251119A0319 NNS I-UN
positioned P02251119A0319 VBD O
within P02251119A0319 IN O
introns P02251119A0319 NNS O
5 P02251119A0319 CD O
, P02251119A0319 , O
6 P02251119A0319 CD O
, P02251119A0319 , O
and P02251119A0319 CC O
8 P02251119A0319 CD O
of P02251119A0319 IN O
the P02251119A0319 DT O
mouse P02251119A0319 NN O
cognate P02251119A0319 NN O
hsc70 P02251119A0319 NN I-UN
heat P02251119A0319 NN O
shock P02251119A0319 NN O
gene P02251119A0319 NN O
. P02251119A0319 . O
. . O O

Unaided P08712799A0123 VBN O
attempts P08712799A0123 NNS O
to P08712799A0123 TO O
quit P08712799A0123 VB O
smoking P08712799A0123 NN O
are P08712799A0123 VBP O
generally P08712799A0123 RB O
unsuccessful P08712799A0123 JJ O
. P08712799A0123 . O
. . O O

The P01709486A0000 DT O
murine P01709486A0000 NN I-UN
mutation P01709486A0000 NN I-UN
dominant P01709486A0000 JJ I-UN
white P01709486A0000 JJ I-UN
spotting P01709486A0000 NN I-UN
( P01709486A0000 ( O
W P01709486A0000 NNP I-UN
) P01709486A0000 ) O
is P01709486A0000 VBZ O
in P01709486A0000 IN O
the P01709486A0000 DT O
proto-oncogene P01709486A0000 JJ O
, P01709486A0000 , O
c-kit P01709486A0000 JJ I-UN
. P01709486A0000 . O
. . O O

During P10623758A0947 IN O
latency P10623758A0947 NN O
, P10623758A0947 , O
more P10623758A0947 JJR O
than P10623758A0947 IN O
1 P10623758A0947 CD O
% P10623758A0947 NN O
of P10623758A0947 IN O
neurons P10623758A0947 NNS O
in P10623758A0947 IN O
ganglia P10623758A0947 NN O
that P10623758A0947 WDT O
innervate P10623758A0947 VBP O
the P10623758A0947 DT O
footpad P10623758A0947 NN O
expressed P10623758A0947 VBD O
beta-galactosidase P10623758A0947 NN I-UN
, P10623758A0947 , O
with P10623758A0947 IN O
the P10623758A0947 DT O
number P10623758A0947 NN O
of P10623758A0947 IN O
positive P10623758A0947 JJ O
cells P10623758A0947 NNS O
remaining P10623758A0947 VBG O
constant P10623758A0947 JJ O
for P10623758A0947 IN O
at P10623758A0947 IN O
least P10623758A0947 JJS O
5 P10623758A0947 CD O
months P10623758A0947 NNS O
. P10623758A0947 . O
. . O O

A P02806916A0000 DT O
genomic P02806916A0000 JJ O
DNA P02806916A0000 NNP O
clone P02806916A0000 NN O
encoding P02806916A0000 VBG O
oryzacystatin P02806916A0000 NN I-UN
( P02806916A0000 ( O
Oc P02806916A0000 NNP I-UN
) P02806916A0000 ) O
, P02806916A0000 , O
a P02806916A0000 DT O
cysteine P02806916A0000 JJ I-UN
proteinase P02806916A0000 NN I-UN
inhibitor P02806916A0000 NN O
( P02806916A0000 ( O
cystatin P02806916A0000 NN I-UN
) P02806916A0000 ) O
of P02806916A0000 IN O
rice P02806916A0000 NN O
, P02806916A0000 , O
was P02806916A0000 VBD O
isolated P02806916A0000 VBN O
from P02806916A0000 IN O
a P02806916A0000 DT O
lambda P02806916A0000 JJ O
EMBL3 P02806916A0000 NNP O
phage P02806916A0000 NN O
library P02806916A0000 NN O
constructed P02806916A0000 VBD O
with P02806916A0000 IN O
Sau3AI P02806916A0000 NNP I-UN
partial P02806916A0000 JJ O
digests P02806916A0000 NNS O
of P02806916A0000 IN O
rice P02806916A0000 NN O
chromosomal P02806916A0000 NN O
DNA P02806916A0000 NNP O
, P02806916A0000 , O
by P02806916A0000 IN O
screening P02806916A0000 VBG O
with P02806916A0000 IN O
an P02806916A0000 DT O
oc P02806916A0000 JJ I-UN
cDNA P02806916A0000 NN I-UN
as P02806916A0000 IN O
a P02806916A0000 DT O
probe P02806916A0000 NN O
. P02806916A0000 . O
. . O O

A P07831310A0000 DT O
genetic P07831310A0000 JJ O
complementation P07831310A0000 NN O
system P07831310A0000 NN O
was P07831310A0000 VBD O
developed P07831310A0000 VBN O
in P07831310A0000 IN O
which P07831310A0000 WDT O
tobacco P07831310A0000 NN I-UN
etch P07831310A0000 NN I-UN
virus P07831310A0000 NN I-UN
( P07831310A0000 ( I-UN
TEV P07831310A0000 NNP I-UN
) P07831310A0000 ) I-UN
polymerase P07831310A0000 NN I-UN
( P07831310A0000 ( O
NIb P07831310A0000 NNP I-UN
) P07831310A0000 ) O
-expressing P07831310A0000 VBG O
transgenic P07831310A0000 JJ O
plants P07831310A0000 NNS O
or P07831310A0000 CC O
protoplasts P07831310A0000 NNS O
were P07831310A0000 VBD O
inoculated P07831310A0000 VBN O
with P07831310A0000 IN O
NIb-defective P07831310A0000 JJ O
TEV P07831310A0000 NNP I-UN
mutants P07831310A0000 NNS I-UN
. P07831310A0000 . O
. . O O

Studies P05441564T0001 NNS O
on P05441564T0001 IN O
the P05441564T0001 DT O
pathogenicity P05441564T0001 NN O
of P05441564T0001 IN O
ECHO P05441564T0001 NNP O
9 P05441564T0001 CD O
( P05441564T0001 ( O
HILL P05441564T0001 NNP O
) P05441564T0001 ) O
virus P05441564T0001 NN O
and P05441564T0001 CC O
its P05441564T0001 PRP$ O
mutants P05441564T0001 NNS O
for P05441564T0001 IN O
suckling P05441564T0001 VBG O
mice P05441564T0001 NN O
. P05441564T0001 . O
. . O O

Unlike P09111059A0327 IN O
the P09111059A0327 DT O
MAR-binding P09111059A0327 NNP O
domain P09111059A0327 NN O
, P09111059A0327 , O
the P09111059A0327 DT O
homeodomain P09111059A0327 NN I-UN
when P09111059A0327 WRB O
isolated P09111059A0327 JJ O
binds P09111059A0327 NNS O
poorly P09111059A0327 RB O
and P09111059A0327 CC O
with P09111059A0327 IN O
low P09111059A0327 JJ O
specificity P09111059A0327 NN O
to P09111059A0327 TO O
DNA P09111059A0327 NNP O
. P09111059A0327 . O
. . O O

Chimaeric P09519828A0809 JJ O
VP16-E2 P09519828A0809 NNP O
molecules P09519828A0809 NNS O
suggest P09519828A0809 VBP O
that P09519828A0809 IN O
the P09519828A0809 DT O
epithelial P09519828A0809 JJ O
specific P09519828A0809 JJ O
transcriptional P09519828A0809 JJ O
activation P09519828A0809 NN O
of P09519828A0809 IN O
the P09519828A0809 DT O
BPV-4 P09519828A0809 NNP I-UN
LCR P09519828A0809 NNP I-UN
promoter P09519828A0809 NN I-UN
is P09519828A0809 VBZ O
mediated P09519828A0809 VBN O
by P09519828A0809 IN O
the P09519828A0809 DT O
E2 P09519828A0809 NNP I-UN
transactivation P09519828A0809 NN I-UN
domain P09519828A0809 NN I-UN
. P09519828A0809 . O
. . O O

Cleavage P01398106A0754 NN O
by P01398106A0754 IN O
the P01398106A0754 DT O
intron-encoded P01398106A0754 JJ O
enzyme P01398106A0754 NN O
( P01398106A0754 ( O
I-CreI P01398106A0754 NNP I-UN
) P01398106A0754 ) O
occurs P01398106A0754 VBZ O
5 P01398106A0754 CD O
bp P01398106A0754 NN O
and P01398106A0754 CC O
1 P01398106A0754 CD O
bp P01398106A0754 NN O
3 P01398106A0754 CD O
' P01398106A0754 '' O
to P01398106A0754 TO O
the P01398106A0754 DT O
intron P01398106A0754 NN O
insertion P01398106A0754 NN O
site P01398106A0754 NN O
( P01398106A0754 ( O
in P01398106A0754 IN O
the P01398106A0754 DT O
3'-exon P01398106A0754 JJ O
) P01398106A0754 ) O
in P01398106A0754 IN O
the P01398106A0754 DT O
top P01398106A0754 JJ O
( P01398106A0754 ( O
/ P01398106A0754 JJ O
) P01398106A0754 ) O
and P01398106A0754 CC O
bottom P01398106A0754 NN O
( P01398106A0754 ( O
, P01398106A0754 , O
) P01398106A0754 ) O
strands P01398106A0754 VBZ O
, P01398106A0754 , O
respectively P01398106A0754 RB O
, P01398106A0754 , O
resulting P01398106A0754 VBG O
in P01398106A0754 IN O
4-nt P01398106A0754 JJ O
single-stranded P01398106A0754 JJ O
overhangs P01398106A0754 NNS O
with P01398106A0754 IN O
3'-OH P01398106A0754 JJ O
termini P01398106A0754 NN O
. P01398106A0754 . O
. . O O

The P02971957A0287 DT O
absorbable P02971957A0287 JJ O
perisplenic P02971957A0287 JJ O
mesh P02971957A0287 NN O
is P02971957A0287 VBZ O
an P02971957A0287 DT O
important P02971957A0287 JJ O
improvement P02971957A0287 NN O
, P02971957A0287 , O
and P02971957A0287 CC O
in P02971957A0287 IN O
some P02971957A0287 DT O
cases P02971957A0287 NNS O
it P02971957A0287 PRP O
may P02971957A0287 MD O
replace P02971957A0287 VB O
other P02971957A0287 JJ O
techniques P02971957A0287 NNS O
for P02971957A0287 IN O
arresting P02971957A0287 VBG O
splenic P02971957A0287 JJ O
bleeding P02971957A0287 NN O
. P02971957A0287 . O
. . O O

Transcriptional P08754802T0000 NNP O
control P08754802T0000 NN O
of P08754802T0000 IN O
a P08754802T0000 DT O
nuclear P08754802T0000 JJ O
gene P08754802T0000 NN O
encoding P08754802T0000 VBG O
a P08754802T0000 DT O
mitochondrial P08754802T0000 JJ O
fatty P08754802T0000 JJ O
acid P08754802T0000 JJ O
oxidation P08754802T0000 NN O
enzyme P08754802T0000 NN O
in P08754802T0000 IN O
transgenic P08754802T0000 JJ O
mice P08754802T0000 NN O
: P08754802T0000 : O
role P08754802T0000 NN O
for P08754802T0000 IN O
nuclear P08754802T0000 JJ O
receptors P08754802T0000 NNS O
in P08754802T0000 IN O
cardiac P08754802T0000 NN O
and P08754802T0000 CC O
brown P08754802T0000 JJ O
adipose P08754802T0000 JJ O
expression P08754802T0000 NN O
. P08754802T0000 . O
. . O O

The P07798207A0759 DT O
deduced P07798207A0759 JJ O
amino P07798207A0759 NN O
acid P07798207A0759 JJ O
sequences P07798207A0759 NNS O
of P07798207A0759 IN O
each P07798207A0759 DT O
of P07798207A0759 IN O
the P07798207A0759 DT O
W3A1 P07798207A0759 NNP I-UN
ETF P07798207A0759 NNP I-UN
subunits P07798207A0759 VBZ I-UN
exhibit P07798207A0759 NN O
only P07798207A0759 RB O
approximately P07798207A0759 RB O
30 P07798207A0759 CD O
% P07798207A0759 NN O
identity P07798207A0759 NN O
with P07798207A0759 IN O
the P07798207A0759 DT O
corresponding P07798207A0759 VBG O
subunits P07798207A0759 NNS O
of P07798207A0759 IN O
the P07798207A0759 DT O
ETF P07798207A0759 NNP I-UN
from P07798207A0759 IN O
human P07798207A0759 JJ O
, P07798207A0759 , O
rat P07798207A0759 NN O
, P07798207A0759 , O
and P07798207A0759 CC O
Paracoccus P07798207A0759 NNP O
denitrificans P07798207A0759 NNS O
, P07798207A0759 , O
which P07798207A0759 WDT O
as P07798207A0759 IN O
a P07798207A0759 DT O
group P07798207A0759 NN O
are P07798207A0759 VBP O
greater P07798207A0759 JJR O
than P07798207A0759 IN O
50 P07798207A0759 CD O
% P07798207A0759 NN O
identical P07798207A0759 JJ O
. P07798207A0759 . O
. . O O

Estrogen P01533760T0000 NNP O
replacement P01533760T0000 NN O
therapy P01533760T0000 NN O
and P01533760T0000 CC O
risk P01533760T0000 NN O
of P01533760T0000 IN O
breast P01533760T0000 NN O
cancer P01533760T0000 NN O
: P01533760T0000 : O
results P01533760T0000 NNS O
of P01533760T0000 IN O
two P01533760T0000 CD O
meta-analyses P01533760T0000 NNS O
. P01533760T0000 . O
. . O O

S1 P02529378A0536 NNP I-UN
nuclease P02529378A0536 JJ I-UN
analysis P02529378A0536 NN O
of P02529378A0536 IN O
RNA P02529378A0536 NNP O
prepared P02529378A0536 VBD O
after P02529378A0536 IN O
transfection P02529378A0536 NN O
of P02529378A0536 IN O
these P02529378A0536 DT O
HIV P02529378A0536 NNP O
constructs P02529378A0536 NNS O
into P02529378A0536 IN O
HeLa P02529378A0536 NNP O
cells P02529378A0536 NNS O
infected P02529378A0536 VBN O
with P02529378A0536 IN O
wild-type P02529378A0536 JJ O
adenovirus P02529378A0536 NN O
indicated P02529378A0536 VBD O
that P02529378A0536 IN O
the P02529378A0536 DT O
enhancer P02529378A0536 NN O
, P02529378A0536 , O
SP1 P02529378A0536 NNP I-UN
, P02529378A0536 , O
TATA P02529378A0536 NNP O
, P02529378A0536 , O
and P02529378A0536 CC O
a P02529378A0536 DT O
portion P02529378A0536 NN O
of P02529378A0536 IN O
the P02529378A0536 DT O
transactivation-responsive P02529378A0536 JJ O
element P02529378A0536 NN O
were P02529378A0536 VBD O
each P02529378A0536 DT O
required P02529378A0536 VBN O
for P02529378A0536 IN O
complete P02529378A0536 JJ O
E1A P02529378A0536 NNP I-UN
/ P02529378A0536 NNP O
E1B-mediated P02529378A0536 JJ O
activation P02529378A0536 NN O
of P02529378A0536 IN O
the P02529378A0536 DT O
HIV P02529378A0536 NNP I-UN
LTR P02529378A0536 NNP I-UN
. P02529378A0536 . O
. . O O

The P10828591A0080 DT O
transcript P10828591A0080 NN O
was P10828591A0080 VBD O
initially P10828591A0080 RB O
identified P10828591A0080 VBN O
as P10828591A0080 IN O
a P10828591A0080 DT O
partial P10828591A0080 JJ O
cDNA P10828591A0080 NN O
sequence P10828591A0080 NN O
in P10828591A0080 IN O
the P10828591A0080 DT O
course P10828591A0080 NN O
of P10828591A0080 IN O
constructing P10828591A0080 VBG O
a P10828591A0080 DT O
transcript P10828591A0080 NN O
map P10828591A0080 NN O
of P10828591A0080 IN O
the P10828591A0080 DT O
region P10828591A0080 NN O
between P10828591A0080 IN O
markers P10828591A0080 NNS O
D11S1765 P10828591A0080 NNP I-UN
and P10828591A0080 CC O
uteroglobin P10828591A0080 JJ I-UN
known P10828591A0080 VBN O
to P10828591A0080 TO O
encompass P10828591A0080 VB O
the P10828591A0080 DT O
gene P10828591A0080 NN O
causing P10828591A0080 VBG O
Best P10828591A0080 NNP O
disease P10828591A0080 NN O
. P10828591A0080 . O
. . O O

Clinical P05028628T0001 JJ O
and P05028628T0001 CC O
angiographic P05028628T0001 JJ O
examinations P05028628T0001 NNS O
in P05028628T0001 IN O
occlusion P05028628T0001 NN O
disease P05028628T0001 NN O
of P05028628T0001 IN O
the P05028628T0001 DT O
great P05028628T0001 JJ O
intestinal P05028628T0001 JJ O
arteries P05028628T0001 NNS O
. P05028628T0001 . O
. . O O

12 P10376446A0000 CD O
healthy P10376446A0000 JJ O
women P10376446A0000 NNS O
( P10376446A0000 ( O
age P10376446A0000 NN O
18-38 P10376446A0000 CD O
years P10376446A0000 NNS O
) P10376446A0000 ) O
were P10376446A0000 VBD O
examined P10376446A0000 VBN O
using P10376446A0000 VBG O
the P10376446A0000 DT O
2-hour P10376446A0000 CD O
's P10376446A0000 POS O
method P10376446A0000 NN O
of P10376446A0000 IN O
passive P10376446A0000 JJ O
leg P10376446A0000 NN O
rising P10376446A0000 VBG O
( P10376446A0000 ( O
PLR P10376446A0000 NNP O
) P10376446A0000 ) O
in P10376446A0000 IN O
follicular P10376446A0000 NN O
( P10376446A0000 ( O
FP P10376446A0000 NNP O
) P10376446A0000 ) O
and P10376446A0000 CC O
luteal P10376446A0000 JJ O
( P10376446A0000 ( O
LP P10376446A0000 NNP O
) P10376446A0000 ) O
phases P10376446A0000 VBZ O
of P10376446A0000 IN O
normal P10376446A0000 JJ O
ovulatory P10376446A0000 JJ O
cycle P10376446A0000 NN O
. P10376446A0000 . O
. . O O

Radioligand P07745008A0892 NNP O
binding P07745008A0892 NN O
was P07745008A0892 VBD O
indistinguishable P07745008A0892 JJ O
for P07745008A0892 IN O
both P07745008A0892 DT O
transiently P07745008A0892 RB O
expressed P07745008A0892 VBN O
constructs P07745008A0892 NNS O
. P07745008A0892 . O
. . O O

Here P08986770A0268 RB O
we P08986770A0268 PRP O
report P08986770A0268 VBP O
that P08986770A0268 DT O
expression P08986770A0268 NN O
of P08986770A0268 IN O
the P08986770A0268 DT O
I-POU P08986770A0268 NNP I-UN
/ P08986770A0268 NNP O
tI-POU P08986770A0268 JJ I-UN
message P08986770A0268 NN O
is P08986770A0268 VBZ O
maximal P08986770A0268 JJ O
late P08986770A0268 RB O
in P08986770A0268 IN O
the P08986770A0268 DT O
embryonic P08986770A0268 JJ O
phase P08986770A0268 NN O
of P08986770A0268 IN O
Drosophila P08986770A0268 NNP O
development P08986770A0268 NN O
, P08986770A0268 , O
and P08986770A0268 CC O
I-POU P08986770A0268 NNP I-UN
is P08986770A0268 VBZ O
the P08986770A0268 DT O
preferred P08986770A0268 JJ O
splice P08986770A0268 NN O
variant P08986770A0268 NN O
. P08986770A0268 . O
. . O O

Similar P11553704A0674 JJ O
data P11553704A0674 NNS O
were P11553704A0674 VBD O
also P11553704A0674 RB O
obtained P11553704A0674 VBN O
when P11553704A0674 WRB O
either P11553704A0674 DT O
dominant P11553704A0674 JJ O
negative P11553704A0674 JJ O
EGFR-CD533 P11553704A0674 NN O
or P11553704A0674 CC O
dominant P11553704A0674 JJ I-UN
negative P11553704A0674 JJ I-UN
Ras P11553704A0674 NNP I-UN
N17 P11553704A0674 NNP I-UN
were P11553704A0674 VBD O
used P11553704A0674 VBN O
to P11553704A0674 TO O
block P11553704A0674 VB O
MAPK P11553704A0674 NNP I-UN
activation P11553704A0674 NN O
. P11553704A0674 . O
. . O O

Copyright P10673335X0782 JJ O
2000 P10673335X0782 CD O
Academic P10673335X0782 NNP O
Press P10673335X0782 NNP O
. P10673335X0782 . O
. . O O

This P07369458A0606 DT O
relatively P07369458A0606 RB O
simple P07369458A0606 JJ O
and P07369458A0606 CC O
easily P07369458A0606 RB O
performed P07369458A0606 VBD O
technique P07369458A0606 NN O
of P07369458A0606 IN O
measuring P07369458A0606 VBG O
deep P07369458A0606 JJ O
muscle P07369458A0606 NN O
temperature P07369458A0606 NN O
appears P07369458A0606 VBZ O
to P07369458A0606 TO O
be P07369458A0606 VB O
a P07369458A0606 DT O
useful P07369458A0606 JJ O
adjunct P07369458A0606 NN O
in P07369458A0606 IN O
choosing P07369458A0606 VBG O
the P07369458A0606 DT O
amputation P07369458A0606 NN O
level P07369458A0606 NN O
. P07369458A0606 . O
. . O O

The P07673154A0688 DT O
tyrosine-phosphorylated P07673154A0688 JJ O
state P07673154A0688 NN O
of P07673154A0688 IN O
CAK P07673154A0688 NNP I-UN
beta P07673154A0688 NN I-UN
was P07673154A0688 VBD O
not P07673154A0688 RB O
reduced P07673154A0688 VBN O
on P07673154A0688 IN O
trypsinization P07673154A0688 NN O
, P07673154A0688 , O
nor P07673154A0688 CC O
enhanced P07673154A0688 VBD O
in P07673154A0688 IN O
response P07673154A0688 NN O
to P07673154A0688 TO O
plating P07673154A0688 VBG O
3Y1 P07673154A0688 CD O
cells P07673154A0688 NNS O
onto P07673154A0688 IN O
fibronectin P07673154A0688 NN I-UN
. P07673154A0688 . O
. . O O

A P07168531T0001 DT O
new P07168531T0001 JJ O
Onchocerca P07168531T0001 NNP O
species P07168531T0001 NNS O
, P07168531T0001 , O
a P07168531T0001 DT O
parasite P07168531T0001 NN O
of P07168531T0001 IN O
domestic P07168531T0001 JJ O
cattle P07168531T0001 NNS O
, P07168531T0001 , O
in P07168531T0001 IN O
Senegal P07168531T0001 NNP O
. P07168531T0001 . O
. . O O

This P08226780A0160 DT O
motif P08226780A0160 NN O
has P08226780A0160 VBZ O
been P08226780A0160 VBN O
shown P08226780A0160 VBN O
to P08226780A0160 TO O
mediate P08226780A0160 VB O
protein P08226780A0160 JJ O
interactions P08226780A0160 NNS O
in P08226780A0160 IN O
the P08226780A0160 DT O
case P08226780A0160 NN O
of P08226780A0160 IN O
ankyrin P08226780A0160 NN I-UN
as P08226780A0160 RB O
well P08226780A0160 RB O
as P08226780A0160 IN O
several P08226780A0160 JJ O
other P08226780A0160 JJ O
repeat-bearing P08226780A0160 JJ O
proteins P08226780A0160 NNS O
. P08226780A0160 . O
. . O O

E. P09857038A1374 NNP O
, P09857038A1374 , O
Scott P09857038A1374 NNP O
, P09857038A1374 , O
J P09857038A1374 NNP O
. P09857038A1374 . O
. . O O

Because P09265642A0668 IN O
the P09265642A0668 DT O
biosynthetic P09265642A0668 JJ O
pathway P09265642A0668 NN O
to P09265642A0668 TO O
the P09265642A0668 DT O
vacuole P09265642A0668 JJ O
intersects P09265642A0668 NNS O
with P09265642A0668 IN O
the P09265642A0668 DT O
endocytic P09265642A0668 JJ O
pathway P09265642A0668 NN O
, P09265642A0668 , O
internalization P09265642A0668 NN O
of P09265642A0668 IN O
a P09265642A0668 DT O
bulk P09265642A0668 NN O
membrane P09265642A0668 NN O
endocytic P09265642A0668 JJ O
marker P09265642A0668 NN O
FM P09265642A0668 NNP O
4-64 P09265642A0668 CD O
was P09265642A0668 VBD O
assayed P09265642A0668 VBN O
in P09265642A0668 IN O
the P09265642A0668 DT O
sop P09265642A0668 NN I-UN
mutants P09265642A0668 NNS I-UN
. P09265642A0668 . O
. . O O

All P10499121A0542 DT O
were P10499121A0542 VBD O
experienced P10499121A0542 VBN O
hearing P10499121A0542 VBG O
aid P10499121A0542 NN O
users P10499121A0542 NNS O
who P10499121A0542 WP O
wore P10499121A0542 VBP O
linear P10499121A0542 JJ O
Class P10499121A0542 NNP O
D P10499121A0542 NNP O
instruments P10499121A0542 NNS O
with P10499121A0542 IN O
input P10499121A0542 JJ O
compression P10499121A0542 NN O
limiting P10499121A0542 VBG O
at P10499121A0542 IN O
the P10499121A0542 DT O
time P10499121A0542 NN O
of P10499121A0542 IN O
their P10499121A0542 PRP$ O
enrollment P10499121A0542 NN O
in P10499121A0542 IN O
this P10499121A0542 DT O
study P10499121A0542 NN O
. P10499121A0542 . O
. . O O

In P02466414A0000 IN O
10 P02466414A0000 CD O
pentobarbitalized P02466414A0000 JJ O
dogs P02466414A0000 NNS O
, P02466414A0000 , O
plasma P02466414A0000 JJ O
viscosity P02466414A0000 NN O
( P02466414A0000 ( O
Ep P02466414A0000 NNP O
) P02466414A0000 ) O
was P02466414A0000 VBD O
raised P02466414A0000 VBN O
fourfold P02466414A0000 RB O
while P02466414A0000 IN O
apparent P02466414A0000 JJ O
blood P02466414A0000 NN O
viscosity P02466414A0000 NN O
( P02466414A0000 ( O
Ea P02466414A0000 NNP O
) P02466414A0000 ) O
increased P02466414A0000 VBD O
about P02466414A0000 IN O
twofold P02466414A0000 VBN O
by P02466414A0000 IN O
two P02466414A0000 CD O
steps P02466414A0000 NNS O
of P02466414A0000 IN O
exchange P02466414A0000 NN O
transfusion P02466414A0000 NN O
of P02466414A0000 IN O
200 P02466414A0000 CD O
ml P02466414A0000 NN O
of P02466414A0000 IN O
plasma P02466414A0000 NN O
with P02466414A0000 IN O
plasma P02466414A0000 NN O
containing P02466414A0000 VBG O
high P02466414A0000 JJ O
molecular P02466414A0000 JJ O
weight P02466414A0000 NN O
dextran P02466414A0000 NN O
( P02466414A0000 ( O
mol P02466414A0000 JJ O
wt P02466414A0000 NN O
500,000 P02466414A0000 CD O
, P02466414A0000 , O
20 P02466414A0000 CD O
% P02466414A0000 NN O
wt P02466414A0000 NN O
/ P02466414A0000 NNP O
vol P02466414A0000 NN O
) P02466414A0000 ) O
. P02466414A0000 . O
. . O O

We P10679190A0693 PRP O
present P10679190A0693 JJ O
evidence P10679190A0693 NN O
that P10679190A0693 IN O
the P10679190A0693 DT O
upstream P10679190A0693 JJ O
open P10679190A0693 JJ O
reading P10679190A0693 NN O
frame P10679190A0693 NN O
( P10679190A0693 ( O
uORF P10679190A0693 JJ O
) P10679190A0693 ) O
represses P10679190A0693 VBZ O
the P10679190A0693 DT O
translation P10679190A0693 NN O
of P10679190A0693 IN O
the P10679190A0693 DT O
downstream P10679190A0693 NN O
major P10679190A0693 JJ O
open P10679190A0693 JJ O
reading P10679190A0693 NN O
frame P10679190A0693 NN O
( P10679190A0693 ( O
mORF P10679190A0693 NN O
) P10679190A0693 ) O
. P10679190A0693 . O
. . O O

Analysis P03015953T0000 NN O
of P03015953T0000 IN O
glucocorticoid P03015953T0000 JJ O
unresponsive P03015953T0000 JJ O
cell P03015953T0000 NN O
variants P03015953T0000 NNS O
using P03015953T0000 VBG O
a P03015953T0000 DT O
mouse P03015953T0000 NN I-UN
glucocorticoid P03015953T0000 NN I-UN
receptor P03015953T0000 NN I-UN
complementary P03015953T0000 JJ O
DNA P03015953T0000 NNP O
clone P03015953T0000 NN O
. P03015953T0000 . O
. . O O

Indeed P07559555A0557 RB O
, P07559555A0557 , O
ERM P07559555A0557 NNP I-UN
and P07559555A0557 CC O
c-Jun P07559555A0557 JJ I-UN
synergistically P07559555A0557 RB O
activated P07559555A0557 VBD O
the P07559555A0557 DT O
EBS-CRE P07559555A0557 NNP O
without P07559555A0557 IN O
making P07559555A0557 VBG O
an P07559555A0557 DT O
apparent P07559555A0557 JJ O
ternary P07559555A0557 NN O
complex P07559555A0557 NN O
. P07559555A0557 . O
. . O O

Epithelial P09088737T0000 JJ O
and P09088737T0000 CC O
corneal P09088737T0000 JJ O
thickness P09088737T0000 NN O
measurements P09088737T0000 NNS O
by P09088737T0000 IN O
in P09088737T0000 IN O
vivo P09088737T0000 JJ O
confocal P09088737T0000 JJ O
microscopy P09088737T0000 NN O
through P09088737T0000 IN O
focusing P09088737T0000 NN O
( P09088737T0000 ( O
CMTF P09088737T0000 NNP O
) P09088737T0000 ) O
. P09088737T0000 . O
. . O O

Not P11626110T0000 RB O
Available P11626110T0000 NNP O
. P11626110T0000 . O
. . O O

The P02832149A1009 DT O
lack P02832149A1009 NN O
of P02832149A1009 IN O
change P02832149A1009 NN O
in P02832149A1009 IN O
the P02832149A1009 DT O
ratio P02832149A1009 NN O
of P02832149A1009 IN O
the P02832149A1009 DT O
two P02832149A1009 CD O
spliced P02832149A1009 VBD O
products P02832149A1009 NNS O
expressed P02832149A1009 VBN O
from P02832149A1009 IN O
either P02832149A1009 CC O
the P02832149A1009 DT O
normal P02832149A1009 JJ O
or P02832149A1009 CC O
the P02832149A1009 DT O
5'-rearranged P02832149A1009 JJ I-UN
myb P02832149A1009 NN I-UN
further P02832149A1009 RBR O
indicates P02832149A1009 VBZ O
that P02832149A1009 IN O
the P02832149A1009 DT O
insertion P02832149A1009 NN O
of P02832149A1009 IN O
the P02832149A1009 DT O
unique P02832149A1009 JJ O
121 P02832149A1009 CD O
amino P02832149A1009 NN O
acids P02832149A1009 NNS O
in P02832149A1009 IN O
the P02832149A1009 DT O
larger P02832149A1009 JJR O
myb P02832149A1009 NN I-UN
transcripts P02832149A1009 NNS I-UN
is P02832149A1009 VBZ O
not P02832149A1009 RB O
a P02832149A1009 DT O
consequence P02832149A1009 NN O
of P02832149A1009 IN O
tumor-specific P02832149A1009 JJ O
activation P02832149A1009 NN O
of P02832149A1009 IN O
the P02832149A1009 DT O
mouse P02832149A1009 NN I-UN
myb P02832149A1009 NN I-UN
oncogene P02832149A1009 NN I-UN
. P02832149A1009 . O
. . O O

The P11158337A0000 DT O
gonadotrope-specific P11158337A0000 JJ O
and P11158337A0000 CC O
regulated P11158337A0000 JJ O
expression P11158337A0000 NN O
of P11158337A0000 IN O
the P11158337A0000 DT O
GnRH P11158337A0000 NNP I-UN
receptor P11158337A0000 NN I-UN
( P11158337A0000 ( O
GnRH-R P11158337A0000 NNP I-UN
) P11158337A0000 ) O
gene P11158337A0000 NN O
is P11158337A0000 VBZ O
dependent P11158337A0000 JJ O
on P11158337A0000 IN O
multiple P11158337A0000 JJ O
transcription P11158337A0000 NN O
factors P11158337A0000 NNS O
that P11158337A0000 IN O
interact P11158337A0000 NN O
with P11158337A0000 IN O
the P11158337A0000 DT O
noncanonical P11158337A0000 JJ I-UN
GnRH-R P11158337A0000 NNP I-UN
activating P11158337A0000 NN I-UN
sequence P11158337A0000 NN I-UN
( P11158337A0000 ( O
GRAS P11158337A0000 NNP I-UN
) P11158337A0000 ) O
, P11158337A0000 , O
the P11158337A0000 DT O
activator P11158337A0000 NN I-UN
protein-1 P11158337A0000 NN I-UN
( P11158337A0000 ( O
AP-1 P11158337A0000 NNP I-UN
) P11158337A0000 ) O
element P11158337A0000 NN O
, P11158337A0000 , O
and P11158337A0000 CC O
the P11158337A0000 DT O
steroidogenic P11158337A0000 JJ I-UN
factor-1 P11158337A0000 NN I-UN
( P11158337A0000 ( O
SF-1 P11158337A0000 NNP I-UN
) P11158337A0000 ) O
binding P11158337A0000 VBG O
site P11158337A0000 NN O
. P11158337A0000 . O
. . O O

From P02733116T0000 IN O
the P02733116T0000 DT O
National P02733116T0000 NNP O
Institutes P02733116T0000 NNPS O
of P02733116T0000 IN O
Health P02733116T0000 NNP O
. P02733116T0000 . O
. . O O

From P07638517A0000 NN O
May P07638517A0000 NNP O
1985 P07638517A0000 CD O
to P07638517A0000 TO O
May P07638517A0000 NNP O
1989 P07638517A0000 CD O
, P07638517A0000 , O
126 P07638517A0000 CD O
necropsies P07638517A0000 NNS O
were P07638517A0000 VBD O
performed P07638517A0000 VBN O
at P07638517A0000 IN O
the P07638517A0000 DT O
Sao P07638517A0000 NNP O
Paulo P07638517A0000 NNP O
City P07638517A0000 NNP O
Morgue P07638517A0000 NNP O
on P07638517A0000 IN O
cadavers P07638517A0000 NNS O
of P07638517A0000 IN O
individuals P07638517A0000 NNS O
AIDS P07638517A0000 NNP O
victims P07638517A0000 NNS O
whose P07638517A0000 WP$ O
unnatural P07638517A0000 JJ O
deaths P07638517A0000 NNS O
had P07638517A0000 VBD O
prompted P07638517A0000 VBN O
police P07638517A0000 JJ O
investigations P07638517A0000 NNS O
. P07638517A0000 . O
. . O O

Goodpasture's-like P08000112T0000 JJ O
syndrome P08000112T0000 NN O
and P08000112T0000 CC O
effect P08000112T0000 NN O
of P08000112T0000 IN O
extracorporeal P08000112T0000 JJ O
membrane P08000112T0000 NN O
oxygenator P08000112T0000 NN O
support P08000112T0000 NN O
. P08000112T0000 . O
. . O O

One P08504932A0123 CD O
enigmatic P08504932A0123 JJ O
aspect P08504932A0123 NN O
of P08504932A0123 IN O
GATA P08504932A0123 NNP I-UN
factor P08504932A0123 NN I-UN
expression P08504932A0123 NN O
is P08504932A0123 VBZ O
that P08504932A0123 IN O
several P08504932A0123 JJ O
GATA P08504932A0123 NNP I-UN
proteins P08504932A0123 NNS I-UN
, P08504932A0123 , O
which P08504932A0123 WDT O
ostensibly P08504932A0123 RB O
share P08504932A0123 NN O
the P08504932A0123 DT O
same P08504932A0123 JJ O
DNA-binding P08504932A0123 NNP O
site P08504932A0123 NN O
specificity P08504932A0123 NN O
, P08504932A0123 , O
are P08504932A0123 VBP O
coexpressed P08504932A0123 VBN O
in P08504932A0123 IN O
erythroid P08504932A0123 JJ O
cells P08504932A0123 NNS O
. P08504932A0123 . O
. . O O

Echosismography P06876006A0930 NN O
enables P06876006A0930 NNS O
to P06876006A0930 TO O
improve P06876006A0930 VB O
the P06876006A0930 DT O
diagnosis P06876006A0930 NN O
when P06876006A0930 WRB O
compared P06876006A0930 VBN O
with P06876006A0930 IN O
classical P06876006A0930 JJ O
sonography P06876006A0930 NN O
in P06876006A0930 IN O
about P06876006A0930 RB O
20 P06876006A0930 CD O
% P06876006A0930 NN O
of P06876006A0930 IN O
cases P06876006A0930 NNS O
. P06876006A0930 . O
. . O O

Demographic P08085228A0000 JJ O
characteristics P08085228A0000 NNS O
and P08085228A0000 CC O
risk P08085228A0000 NN O
factor P08085228A0000 NN O
data P08085228A0000 NNS O
for P08085228A0000 IN O
76,672 P08085228A0000 CD O
clients P08085228A0000 NNS O
were P08085228A0000 VBD O
studied P08085228A0000 VBN O
to P08085228A0000 TO O
characterize P08085228A0000 VB O
the P08085228A0000 DT O
distribution P08085228A0000 NN O
of P08085228A0000 IN O
infection P08085228A0000 NN O
with P08085228A0000 IN O
human P08085228A0000 JJ O
immunodeficiency P08085228A0000 NN O
virus P08085228A0000 NN O
( P08085228A0000 ( O
HIV P08085228A0000 NNP O
) P08085228A0000 ) O
and P08085228A0000 CC O
the P08085228A0000 DT O
use P08085228A0000 NN O
of P08085228A0000 IN O
counseling P08085228A0000 NN O
and P08085228A0000 CC O
testing P08085228A0000 VBG O
facilities P08085228A0000 NNS O
in P08085228A0000 IN O
Houston P08085228A0000 NNP O
, P08085228A0000 , O
Tex P08085228A0000 NNP O
. P08085228A0000 . O
. . O O

Northern P03838797A0903 NNP O
blotting P03838797A0903 VBG O
with P03838797A0903 IN O
a P03838797A0903 DT O
unique P03838797A0903 JJ O
17-mer P03838797A0903 JJ O
oligonucleotide P03838797A0903 NN O
demonstrated P03838797A0903 VBD O
the P03838797A0903 DT O
absence P03838797A0903 NN O
of P03838797A0903 IN O
the P03838797A0903 DT O
mutant P03838797A0903 JJ O
sequence P03838797A0903 NN O
in P03838797A0903 IN O
the P03838797A0903 DT O
mRNA P03838797A0903 NN O
from P03838797A0903 IN O
which P03838797A0903 WDT O
the P03838797A0903 DT O
cDNA P03838797A0903 NN O
library P03838797A0903 NN O
giving P03838797A0903 VBG O
rise P03838797A0903 NN O
to P03838797A0903 TO O
the P03838797A0903 DT O
mutant P03838797A0903 JJ O
cDNA P03838797A0903 NN O
was P03838797A0903 VBD O
constructed P03838797A0903 VBN O
. P03838797A0903 . O
. . O O

Several P09434160A0767 JJ O
PTPases P09434160A0767 NNS I-UN
were P09434160A0767 VBD O
expressed P09434160A0767 VBN O
abundantly P09434160A0767 RB O
in P09434160A0767 IN O
the P09434160A0767 DT O
5-FU-treated P09434160A0767 JJ O
bone P09434160A0767 NN O
marrow P09434160A0767 NN O
stem P09434160A0767 NN O
cells P09434160A0767 NNS O
. P09434160A0767 . O
. . O O

The P03820222A0203 DT O
in P03820222A0203 IN O
vitro P03820222A0203 JJ O
antibacterial P03820222A0203 JJ O
potency P03820222A0203 NN O
is P03820222A0203 VBZ O
greatest P03820222A0203 JJS O
when P03820222A0203 WRB O
the P03820222A0203 DT O
1-substituent P03820222A0203 JJ O
is P03820222A0203 VBZ O
2,4-difluorophenyl P03820222A0203 JJ O
and P03820222A0203 CC O
the P03820222A0203 DT O
7-substituent P03820222A0203 JJ O
is P03820222A0203 VBZ O
a P03820222A0203 DT O
3-amino-1-pyrrolidinyl P03820222A0203 JJ O
group P03820222A0203 NN O
. P03820222A0203 . O
. . O O

The P03595418A0688 DT O
nucleotide P03595418A0688 JJ O
sequences P03595418A0688 NNS O
of P03595418A0688 IN O
the P03595418A0688 DT O
human P03595418A0688 JJ I-UN
and P03595418A0688 CC I-UN
murine P03595418A0688 JJ I-UN
ornithine P03595418A0688 NN I-UN
decarboxylase P03595418A0688 NN I-UN
mRNAs P03595418A0688 NN I-UN
share P03595418A0688 NN O
an P03595418A0688 DT O
85 P03595418A0688 CD O
% P03595418A0688 NN O
homology P03595418A0688 NN O
, P03595418A0688 , O
even P03595418A0688 RB O
in P03595418A0688 IN O
their P03595418A0688 PRP$ O
3'-noncoding P03595418A0688 JJ O
regions P03595418A0688 NNS O
. P03595418A0688 . O
. . O O

Vitrectomy P11787746A0374 NNP O
and P11787746A0374 CC O
removal P11787746A0374 NN O
of P11787746A0374 IN O
retained P11787746A0374 JJ O
lens P11787746A0374 NNS O
fragments P11787746A0374 NNS O
restores P11787746A0374 NNS O
good P11787746A0374 JJ O
visual P11787746A0374 JJ O
acuity P11787746A0374 NN O
and P11787746A0374 CC O
reduces P11787746A0374 NNS O
secondary P11787746A0374 JJ O
glaucoma P11787746A0374 NN O
in P11787746A0374 IN O
the P11787746A0374 DT O
majority P11787746A0374 NN O
of P11787746A0374 IN O
patients P11787746A0374 NNS O
. P11787746A0374 . O
. . O O

CES4 P09443973A1028 NNP I-UN
on P09443973A1028 IN O
a P09443973A1028 DT O
multicopy P09443973A1028 NN O
plasmid P09443973A1028 NN O
was P09443973A1028 VBD O
unable P09443973A1028 JJ O
to P09443973A1028 TO O
suppress P09443973A1028 VB O
tif1-A79V P09443973A1028 NN I-UN
. P09443973A1028 . O
. . O O

Here P11566996A1391 RB O
we P11566996A1391 PRP O
suggest P11566996A1391 VBP O
that P11566996A1391 IN O
uvrA P11566996A1391 NN I-UN
and P11566996A1391 CC O
the P11566996A1391 DT O
nucleotide P11566996A1391 JJ O
excision P11566996A1391 NN O
repair P11566996A1391 NN O
pathway P11566996A1391 NN O
are P11566996A1391 VBP O
involved P11566996A1391 VBN O
in P11566996A1391 IN O
the P11566996A1391 DT O
repair P11566996A1391 NN O
of P11566996A1391 IN O
acid-induced P11566996A1391 JJ O
DNA P11566996A1391 NNP O
damage P11566996A1391 NN O
and P11566996A1391 CC O
are P11566996A1391 VBP O
associated P11566996A1391 VBN O
with P11566996A1391 IN O
successful P11566996A1391 JJ O
adaptation P11566996A1391 NN O
of P11566996A1391 IN O
S. P11566996A1391 NNP O
mutans P11566996A1391 NNS O
to P11566996A1391 TO O
low P11566996A1391 JJ O
pH P11566996A1391 NN O
. P11566996A1391 . O
. . O O

The P03863231A0530 DT O
M-3 P03863231A0530 NNP O
subtype P03863231A0530 NN O
was P03863231A0530 VBD O
an P03863231A0530 DT O
adverse P03863231A0530 JJ O
prognostic P03863231A0530 JJ O
factor P03863231A0530 NN O
. P03863231A0530 . O
. . O O

Our P09364440A2206 PRP$ O
study P09364440A2206 NN O
reveals P09364440A2206 NNS O
that P09364440A2206 IN O
the P09364440A2206 DT O
modular P09364440A2206 JJ O
structure P09364440A2206 NN O
of P09364440A2206 IN O
the P09364440A2206 DT O
FSH P09364440A2206 NNP I-UN
receptor P09364440A2206 NN I-UN
gene P09364440A2206 NN O
generates P09364440A2206 NNS O
motifs P09364440A2206 VBP O
that P09364440A2206 IN O
allows P09364440A2206 VBZ O
coupling P09364440A2206 VBG O
to P09364440A2206 TO O
different P09364440A2206 JJ O
effectors P09364440A2206 NNS O
. P09364440A2206 . O
. . O O

The P01708774A0203 DT O
DNA P01708774A0203 NNP O
sequence P01708774A0203 NN O
conferring P01708774A0203 VBG O
AP-1 P01708774A0203 JJ I-UN
activity P01708774A0203 NN O
was P01708774A0203 VBD O
located P01708774A0203 VBN O
in P01708774A0203 IN O
the P01708774A0203 DT O
proximal P01708774A0203 JJ O
promoter P01708774A0203 NN O
region P01708774A0203 NN O
. P01708774A0203 . O
. . O O

In P02493644A0588 IN O
resting P02493644A0588 VBG O
3T3 P02493644A0588 CD O
cells P02493644A0588 NNS O
, P02493644A0588 , O
jun-D P02493644A0588 NN I-UN
is P02493644A0588 VBZ O
expressed P02493644A0588 VBN O
at P02493644A0588 IN O
a P02493644A0588 DT O
higher P02493644A0588 JJR O
level P02493644A0588 NN O
compared P02493644A0588 VBN O
to P02493644A0588 TO O
c-jun P02493644A0588 JJ I-UN
and P02493644A0588 CC O
jun-B P02493644A0588 JJ I-UN
, P02493644A0588 , O
and P02493644A0588 CC O
its P02493644A0588 PRP$ O
transcription P02493644A0588 NN O
is P02493644A0588 VBZ O
stimulated P02493644A0588 VBN O
only P02493644A0588 RB O
slightly P02493644A0588 RB O
by P02493644A0588 IN O
serum P02493644A0588 JJ O
growth P02493644A0588 NN O
factors P02493644A0588 NNS O
. P02493644A0588 . O
. . O O

Interestingly P07745685A1442 RB O
, P07745685A1442 , O
virions P07745685A1442 NNS O
also P07745685A1442 RB O
contained P07745685A1442 VBD O
smaller P07745685A1442 JJR O
proteins P07745685A1442 NNS O
that P07745685A1442 WDT O
reacted P07745685A1442 VBD O
with P07745685A1442 IN O
antibodies P07745685A1442 NNS O
specific P07745685A1442 VBP O
for P07745685A1442 IN O
the P07745685A1442 DT O
accessory P07745685A1442 JJ O
proteins P07745685A1442 NNS O
as P07745685A1442 RB O
well P07745685A1442 RB O
as P07745685A1442 IN O
SN P07745685A1442 NNP I-UN
and P07745685A1442 CC O
CAT P07745685A1442 NNP I-UN
fusion P07745685A1442 NN I-UN
partners P07745685A1442 NNS O
. P07745685A1442 . O
. . O O

Cell P03600633A1069 NNP O
. P03600633A1069 . O
. . O O

Each P10202006A0546 DT O
recombinant P10202006A0546 JJ O
product P10202006A0546 NN O
was P10202006A0546 VBD O
a P10202006A0546 DT O
fusion P10202006A0546 NN O
protein P10202006A0546 NN O
with P10202006A0546 IN O
a P10202006A0546 DT O
B P10202006A0546 NNP O
domain P10202006A0546 NN O
of P10202006A0546 IN O
Staphylococcal P10202006A0546 NNP I-UN
protein P10202006A0546 NN I-UN
A P10202006A0546 NNP I-UN
( P10202006A0546 ( O
SPA P10202006A0546 NNP I-UN
) P10202006A0546 ) O
. P10202006A0546 . O
. . O O

Our P11112417A1126 PRP$ O
data P11112417A1126 NNS O
show P11112417A1126 VBP O
that P11112417A1126 IN O
multiple P11112417A1126 JJ O
MLSN1 P11112417A1126 NNP I-UN
transcripts P11112417A1126 NNS I-UN
, P11112417A1126 , O
both P11112417A1126 DT O
constitutively P11112417A1126 RB O
expressed P11112417A1126 VBN O
and P11112417A1126 CC O
inducible P11112417A1126 JJ O
, P11112417A1126 , O
are P11112417A1126 VBP O
present P11112417A1126 JJ O
in P11112417A1126 IN O
cultured P11112417A1126 JJ O
pigmented P11112417A1126 JJ O
melanoma P11112417A1126 NN O
cells P11112417A1126 NNS O
, P11112417A1126 , O
and P11112417A1126 CC O
suggest P11112417A1126 VBP O
that P11112417A1126 IN O
MLSN1 P11112417A1126 NNP I-UN
expression P11112417A1126 NN O
can P11112417A1126 MD O
be P11112417A1126 VB O
regulated P11112417A1126 VBN O
at P11112417A1126 IN O
the P11112417A1126 DT O
level P11112417A1126 NN O
of P11112417A1126 IN O
both P11112417A1126 DT O
transcription P11112417A1126 NN O
and P11112417A1126 CC O
mRNA P11112417A1126 NN O
processing P11112417A1126 NN O
. P11112417A1126 . O
. . O O

T4 P00096241A0087 NNP O
and P00096241A0087 CC O
FT4I P00096241A0087 NNP O
followed P00096241A0087 VBD O
parallel P00096241A0087 JJ O
courses P00096241A0087 NNS O
in P00096241A0087 IN O
both P00096241A0087 DT O
groups P00096241A0087 NNS O
; P00096241A0087 : O
during P00096241A0087 IN O
the P00096241A0087 DT O
first P00096241A0087 JJ O
45 P00096241A0087 CD O
days P00096241A0087 NNS O
, P00096241A0087 , O
however P00096241A0087 RB O
, P00096241A0087 , O
the P00096241A0087 DT O
values P00096241A0087 NNS O
were P00096241A0087 VBD O
significantly P00096241A0087 RB O
lower P00096241A0087 JJR O
in P00096241A0087 IN O
premature P00096241A0087 JJ O
infants P00096241A0087 NNS O
under P00096241A0087 IN O
34 P00096241A0087 CD O
weeks P00096241A0087 NNS O
' P00096241A0087 POS O
EGA P00096241A0087 NNP O
than P00096241A0087 IN O
in P00096241A0087 IN O
term P00096241A0087 NN O
infants P00096241A0087 NNS O
( P00096241A0087 ( O
P P00096241A0087 NNP O
less P00096241A0087 JJR O
than P00096241A0087 IN O
0.001 P00096241A0087 CD O
) P00096241A0087 ) O
. P00096241A0087 . O
. . O O

Our P06634712A0557 PRP$ O
results P06634712A0557 NNS O
demonstrate P06634712A0557 VB O
the P06634712A0557 DT O
importance P06634712A0557 NN O
of P06634712A0557 IN O
phosphate P06634712A0557 NN O
and P06634712A0557 CC O
calcium P06634712A0557 NN O
in P06634712A0557 IN O
influencing P06634712A0557 VBG O
the P06634712A0557 DT O
secretion P06634712A0557 NN O
of P06634712A0557 IN O
PTH P06634712A0557 NNP I-UN
and P06634712A0557 CC O
CT P06634712A0557 NNP I-UN
in P06634712A0557 IN O
uremia P06634712A0557 NN O
. P06634712A0557 . O
. . O O

The P07659085A1520 DT O
ubiquitous P07659085A1520 JJ O
transcription P07659085A1520 NN O
factor P07659085A1520 NN O
Oct-1 P07659085A1520 NNP I-UN
forms P07659085A1520 NNS O
complexes P07659085A1520 VBP O
with P07659085A1520 IN O
an P07659085A1520 DT O
octamer P07659085A1520 NN O
motif P07659085A1520 NN O
present P07659085A1520 NN O
within P07659085A1520 IN O
FPIV P07659085A1520 NNP O
by P07659085A1520 IN O
gel P07659085A1520 NN O
shift P07659085A1520 NN O
analysis P07659085A1520 NN O
with P07659085A1520 IN O
liver P07659085A1520 NN O
and P07659085A1520 CC O
kidney P07659085A1520 NN O
extracts P07659085A1520 NNS O
, P07659085A1520 , O
making P07659085A1520 VBG O
Oct-1 P07659085A1520 NNP I-UN
an P07659085A1520 DT O
intriguing P07659085A1520 JJ O
candidate P07659085A1520 NN O
for P07659085A1520 IN O
partnership P07659085A1520 NN O
in P07659085A1520 IN O
androgen P07659085A1520 NN O
regulation P07659085A1520 NN O
. P07659085A1520 . O
. . O O

Canine P04796997T0000 JJ O
reproduction P04796997T0000 NN O
: P04796997T0000 : O
effects P04796997T0000 NNS O
of P04796997T0000 IN O
a P04796997T0000 DT O
single P04796997T0000 JJ O
injection P04796997T0000 NN O
of P04796997T0000 IN O
medroxyprogesterone P04796997T0000 NN O
acetate P04796997T0000 NN O
on P04796997T0000 IN O
the P04796997T0000 DT O
reproductive P04796997T0000 JJ O
organs P04796997T0000 NNS O
of P04796997T0000 IN O
the P04796997T0000 DT O
bitch P04796997T0000 NN O
. P04796997T0000 . O
. . O O

Innervation P00198510T0000 NN O
of P00198510T0000 IN O
the P00198510T0000 DT O
ventral P00198510T0000 JJ O
diaphragm P00198510T0000 NN O
of P00198510T0000 IN O
the P00198510T0000 DT O
locust P00198510T0000 NN O
( P00198510T0000 ( O
Locusta P00198510T0000 NNP O
migratoria P00198510T0000 NN O
) P00198510T0000 ) O
. P00198510T0000 . O
. . O O

Study P05850652T0001 NN O
of P05850652T0001 IN O
the P05850652T0001 DT O
alterations P05850652T0001 NNS O
of P05850652T0001 IN O
intestinal P05850652T0001 JJ O
absorption P05850652T0001 NN O
, P05850652T0001 , O
by P05850652T0001 IN O
means P05850652T0001 NNS O
of P05850652T0001 IN O
I-131-triolein P05850652T0001 NNP O
, P05850652T0001 , O
in P05850652T0001 IN O
the P05850652T0001 DT O
whole P05850652T0001 JJ O
body P05850652T0001 NN O
irradiated P05850652T0001 JJ O
rat P05850652T0001 NN O
. P05850652T0001 . O
. . O O

The P11152070A0573 DT O
actA P11152070A0573 JJ I-UN
gene P11152070A0573 NN I-UN
is P11152070A0573 VBZ O
present P11152070A0573 JJ O
as P11152070A0573 IN O
a P11152070A0573 DT O
single P11152070A0573 JJ O
copy P11152070A0573 NN O
in P11152070A0573 IN O
the P11152070A0573 DT O
genome P11152070A0573 NN O
of P11152070A0573 IN O
A. P11152070A0573 NNP O
chrysogenum P11152070A0573 NN O
; P11152070A0573 : O
and P11152070A0573 CC O
its P11152070A0573 PRP$ O
expression P11152070A0573 NN O
level P11152070A0573 NN O
, P11152070A0573 , O
opposite P11152070A0573 RB O
to P11152070A0573 TO O
pcbC P11152070A0573 VB I-UN
and P11152070A0573 CC O
cefEF P11152070A0573 VB I-UN
cephalosporin P11152070A0573 JJ I-UN
biosynthetic P11152070A0573 JJ I-UN
genes P11152070A0573 NNS I-UN
, P11152070A0573 , O
was P11152070A0573 VBD O
steady P11152070A0573 JJ O
during P11152070A0573 IN O
cephalosporin P11152070A0573 JJ O
fermentation P11152070A0573 NN O
, P11152070A0573 , O
showing P11152070A0573 VBG O
a P11152070A0573 DT O
single P11152070A0573 JJ O
1.4-kb P11152070A0573 JJ O
transcript P11152070A0573 NN O
. P11152070A0573 . O
. . O O

Detection P10557008T0000 NN O
of P10557008T0000 IN O
poisoning P10557008T0000 NN O
by P10557008T0000 IN O
Impila P10557008T0000 NNP O
( P10557008T0000 ( O
Callilepis P10557008T0000 NNP O
laureola P10557008T0000 NN O
) P10557008T0000 ) O
in P10557008T0000 IN O
a P10557008T0000 DT O
mother P10557008T0000 NN O
and P10557008T0000 CC O
child P10557008T0000 NN O
. P10557008T0000 . O
. . O O

55 P04024685A0650 CD O
+ P04024685A0650 JJ O
/ P04024685A0650 NNP O
- P04024685A0650 : O
11 P04024685A0650 CD O
% P04024685A0650 NN O
) P04024685A0650 ) O
, P04024685A0650 , O
all P04024685A0650 DT O
other P04024685A0650 JJ O
parameters P04024685A0650 NNS O
showed P04024685A0650 VBD O
a P04024685A0650 DT O
significant P04024685A0650 JJ O
increase P04024685A0650 NN O
: P04024685A0650 : O
RS P04024685A0650 NNP O
index P04024685A0650 NN O
5.4 P04024685A0650 CD O
+ P04024685A0650 NN O
/ P04024685A0650 NNP O
- P04024685A0650 : O
1.4 P04024685A0650 CD O
mVolt P04024685A0650 NN O
to P04024685A0650 TO O
6.0 P04024685A0650 CD O
+ P04024685A0650 NNS O
/ P04024685A0650 SYM O
- P04024685A0650 : O
1.7 P04024685A0650 CD O
mVolt P04024685A0650 NN O
( P04024685A0650 ( O
p P04024685A0650 NN O
less P04024685A0650 JJR O
than P04024685A0650 IN O
0.01 P04024685A0650 CD O
) P04024685A0650 ) O
; P04024685A0650 : O
EDD P04024685A0650 $ O
6.3 P04024685A0650 CD O
+ P04024685A0650 NNP O
/ P04024685A0650 NNP O
- P04024685A0650 : O
0.7 P04024685A0650 CD O
to P04024685A0650 TO O
6.8 P04024685A0650 CD O
+ P04024685A0650 NNS O
/ P04024685A0650 SYM O
- P04024685A0650 : O
0.9 P04024685A0650 CD O
cm P04024685A0650 NN O
( P04024685A0650 ( O
p P04024685A0650 NN O
less P04024685A0650 JJR O
than P04024685A0650 IN O
0.001 P04024685A0650 CD O
) P04024685A0650 ) O
; P04024685A0650 : O
HV P04024685A0650 NNP O
1017 P04024685A0650 CD O
+ P04024685A0650 NNP O
/ P04024685A0650 NNP O
- P04024685A0650 : O
151 P04024685A0650 CD O
ml P04024685A0650 NN O
to P04024685A0650 TO O
1099 P04024685A0650 CD O
+ P04024685A0650 NNP O
/ P04024685A0650 NNP O
- P04024685A0650 : O
261 P04024685A0650 CD O
ml P04024685A0650 NN O
( P04024685A0650 ( O
p P04024685A0650 NN O
less P04024685A0650 JJR O
than P04024685A0650 IN O
0.01 P04024685A0650 CD O
) P04024685A0650 ) O
; P04024685A0650 : O
EDV P04024685A0650 $ O
371 P04024685A0650 CD O
+ P04024685A0650 NNP O
/ P04024685A0650 NNP O
- P04024685A0650 : O
131 P04024685A0650 CD O
ml P04024685A0650 NN O
to P04024685A0650 TO O
441 P04024685A0650 CD O
+ P04024685A0650 NNS O
/ P04024685A0650 SYM O
- P04024685A0650 : O
175 P04024685A0650 CD O
ml P04024685A0650 NN O
( P04024685A0650 ( O
p P04024685A0650 NN O
less P04024685A0650 JJR O
than P04024685A0650 IN O
0.001 P04024685A0650 CD O
) P04024685A0650 ) O
; P04024685A0650 : O
RBV P04024685A0650 $ O
117 P04024685A0650 CD O
+ P04024685A0650 NNP O
/ P04024685A0650 NNP O
- P04024685A0650 : O
57 P04024685A0650 CD O
ml P04024685A0650 NN O
to P04024685A0650 TO O
151 P04024685A0650 CD O
+ P04024685A0650 NNS O
/ P04024685A0650 SYM O
- P04024685A0650 : O
77 P04024685A0650 CD O
ml P04024685A0650 NN O
( P04024685A0650 ( O
p P04024685A0650 NN O
less P04024685A0650 JJR O
than P04024685A0650 IN O
0.001 P04024685A0650 CD O
) P04024685A0650 ) O
. P04024685A0650 . O
. . O O

Although P03228518A0339 IN O
not P03228518A0339 RB O
consistently P03228518A0339 RB O
identified P03228518A0339 VBN O
in P03228518A0339 IN O
all P03228518A0339 DT O
samples P03228518A0339 NNS O
, P03228518A0339 , O
secondary P03228518A0339 JJ O
Academic P03228518A0339 NNP O
, P03228518A0339 , O
Personal P03228518A0339 NNP O
Responsibility P03228518A0339 NNP O
, P03228518A0339 , O
and P03228518A0339 CC O
Community P03228518A0339 NNP O
/ P03228518A0339 NNP O
Vocational P03228518A0339 NNP O
dimensions P03228518A0339 NNS O
were P03228518A0339 VBD O
also P03228518A0339 RB O
identified P03228518A0339 VBN O
. P03228518A0339 . O
. . O O

AIMS P08750173A0000 NNP O
/ P08750173A0000 NNP O
METHODS P08750173A0000 NNP O
: P08750173A0000 : O
Reticuloendothelial P08750173A0000 JJ O
system P08750173A0000 NN O
function P08750173A0000 NN O
, P08750173A0000 , O
as P08750173A0000 IN O
assessed P08750173A0000 VBN O
by P08750173A0000 IN O
clearance P08750173A0000 NN O
of P08750173A0000 IN O
radiolabelled P08750173A0000 JJ O
bacteria P08750173A0000 NNS O
, P08750173A0000 , O
was P08750173A0000 VBD O
evaluated P08750173A0000 VBN O
in P08750173A0000 IN O
acute P08750173A0000 JJ O
liver P08750173A0000 JJ O
injury P08750173A0000 NN O
induced P08750173A0000 VBN O
by P08750173A0000 IN O
D-galactosamine P08750173A0000 NNP O
in P08750173A0000 IN O
rats P08750173A0000 NNS O
, P08750173A0000 , O
and P08750173A0000 CC O
compared P08750173A0000 VBN O
with P08750173A0000 IN O
that P08750173A0000 DT O
after P08750173A0000 IN O
70 P08750173A0000 CD O
% P08750173A0000 NN O
liver P08750173A0000 JJ O
resection P08750173A0000 NN O
model P08750173A0000 NN O
. P08750173A0000 . O
. . O O

Deterministic P11281201T0000 JJ O
effects P11281201T0000 NNS O
. P11281201T0000 . O
. . O O

In P10997863A0753 IN O
the P10997863A0753 DT O
TLE P10997863A0753 NNP O
patients P10997863A0753 NNS O
the P10997863A0753 DT O
NAA P10997863A0753 NNP O
: P10997863A0753 : O
Cr P10997863A0753 JJ O
ratios P10997863A0753 NNS O
were P10997863A0753 VBD O
reduced P10997863A0753 VBN O
in P10997863A0753 IN O
the P10997863A0753 DT O
seizure P10997863A0753 NN O
focus P10997863A0753 NN O
, P10997863A0753 , O
while P10997863A0753 IN O
in P10997863A0753 IN O
the P10997863A0753 DT O
FLE P10997863A0753 NNP O
patients P10997863A0753 NNS O
they P10997863A0753 PRP O
were P10997863A0753 VBD O
not P10997863A0753 RB O
always P10997863A0753 RB O
reduced P10997863A0753 VBN O
in P10997863A0753 IN O
the P10997863A0753 DT O
seizure P10997863A0753 NN O
focus P10997863A0753 NN O
. P10997863A0753 . O
. . O O

The P01850105A1093 DT O
effects P01850105A1093 NNS O
of P01850105A1093 IN O
c-myc P01850105A1093 NN I-UN
were P01850105A1093 VBD O
further P01850105A1093 RB O
dissected P01850105A1093 VBN O
by P01850105A1093 IN O
showing P01850105A1093 VBG O
that P01850105A1093 IN O
c-myc P01850105A1093 NN I-UN
can P01850105A1093 MD O
inhibit P01850105A1093 VB O
differentiation P01850105A1093 NN O
independently P01850105A1093 RB O
of P01850105A1093 IN O
Id P01850105A1093 NNP I-UN
, P01850105A1093 , O
a P01850105A1093 DT O
negative P01850105A1093 JJ O
regulator P01850105A1093 NN O
of P01850105A1093 IN O
muscle P01850105A1093 NN O
differentiation P01850105A1093 NN O
. P01850105A1093 . O
. . O O

We P10895417A0000 PRP O
have P10895417A0000 VBP O
shown P10895417A0000 VBN O
that P10895417A0000 IN O
the P10895417A0000 DT O
epidural P10895417A0000 JJ O
( P10895417A0000 ( O
EPI P10895417A0000 NNP O
) P10895417A0000 ) O
delivery P10895417A0000 NN O
of P10895417A0000 IN O
morphine P10895417A0000 NN O
encapsulated P10895417A0000 VBN O
in P10895417A0000 IN O
multivesicular P10895417A0000 JJ O
liposomes P10895417A0000 NNS O
( P10895417A0000 ( O
DepoFoam P10895417A0000 NNP O
drug P10895417A0000 NN O
delivery P10895417A0000 NN O
system P10895417A0000 NN O
) P10895417A0000 ) O
produces P10895417A0000 VBZ O
a P10895417A0000 DT O
sustained P10895417A0000 JJ O
clearance P10895417A0000 NN O
of P10895417A0000 IN O
morphine P10895417A0000 NN O
and P10895417A0000 CC O
a P10895417A0000 DT O
prolonged P10895417A0000 JJ O
analgesia P10895417A0000 NN O
. P10895417A0000 . O
. . O O

We P08387519A0000 PRP O
have P08387519A0000 VBP O
previously P08387519A0000 RB O
reported P08387519A0000 VBN O
that P08387519A0000 DT O
high P08387519A0000 JJ O
level P08387519A0000 NN O
human P08387519A0000 JJ I-UN
desmin P08387519A0000 NN I-UN
expression P08387519A0000 NN O
depends P08387519A0000 VBZ O
on P08387519A0000 IN O
a P08387519A0000 DT O
280-base P08387519A0000 JJ O
pair P08387519A0000 NN O
muscle-specific P08387519A0000 JJ O
enhancer P08387519A0000 NN O
which P08387519A0000 WDT O
can P08387519A0000 MD O
function P08387519A0000 VB O
not P08387519A0000 RB O
only P08387519A0000 RB O
in P08387519A0000 IN O
myotubes P08387519A0000 NNS O
, P08387519A0000 , O
but P08387519A0000 CC O
can P08387519A0000 MD O
also P08387519A0000 RB O
activate P08387519A0000 VB O
gene P08387519A0000 NN O
expression P08387519A0000 NN O
in P08387519A0000 IN O
myoblasts P08387519A0000 NNS O
. P08387519A0000 . O
. . O O

Natural P10485353T0000 JJ O
Haemophilus P10485353T0000 NNP O
influenzae P10485353T0000 NN O
type P10485353T0000 NN O
b P10485353T0000 NN O
capsular P10485353T0000 JJ O
polysaccharide P10485353T0000 NN O
antibodies P10485353T0000 NNS O
in P10485353T0000 IN O
412 P10485353T0000 CD O
infants P10485353T0000 NNS O
and P10485353T0000 CC O
children P10485353T0000 NNS O
from P10485353T0000 IN O
West P10485353T0000 NNP O
Africa P10485353T0000 NNP O
( P10485353T0000 ( O
Burkina-Faso P10485353T0000 NNP O
) P10485353T0000 ) O
and P10485353T0000 CC O
France P10485353T0000 NNP O
: P10485353T0000 : O
a P10485353T0000 DT O
cross-sectional P10485353T0000 JJ O
serosurvey P10485353T0000 NN O
. P10485353T0000 . O
. . O O

Conformational P11419938T0000 JJ O
changes P11419938T0000 NNS O
of P11419938T0000 IN O
the P11419938T0000 DT O
ferric P11419938T0000 JJ I-UN
uptake P11419938T0000 JJ I-UN
regulation P11419938T0000 NN I-UN
protein P11419938T0000 NN I-UN
upon P11419938T0000 IN O
metal P11419938T0000 JJ O
activation P11419938T0000 NN O
and P11419938T0000 CC O
DNA P11419938T0000 NNP O
binding P11419938T0000 NN O
; P11419938T0000 : O
first P11419938T0000 JJ O
evidence P11419938T0000 NN O
of P11419938T0000 IN O
structural P11419938T0000 JJ O
homologies P11419938T0000 NNS O
with P11419938T0000 IN O
the P11419938T0000 DT O
diphtheria P11419938T0000 NN I-UN
toxin P11419938T0000 NN I-UN
repressor P11419938T0000 NN I-UN
. P11419938T0000 . O
. . O O

These P02775136A1151 DT O
results P02775136A1151 NNS O
suggest P02775136A1151 VBP O
that P02775136A1151 IN O
HAPE-S-S P02775136A1151 NNP O
are P02775136A1151 VBP O
prone P02775136A1151 NN O
to P02775136A1151 TO O
irregular P02775136A1151 JJ O
nocturnal P02775136A1151 JJ O
breathing P02775136A1151 NN O
patterns P02775136A1151 NNS O
at P02775136A1151 IN O
high P02775136A1151 JJ O
altitude P02775136A1151 NN O
, P02775136A1151 , O
which P02775136A1151 WDT O
is P02775136A1151 VBZ O
associated P02775136A1151 VBN O
with P02775136A1151 IN O
the P02775136A1151 DT O
development P02775136A1151 NN O
of P02775136A1151 IN O
AMS P02775136A1151 NNP O
, P02775136A1151 , O
but P02775136A1151 CC O
it P02775136A1151 PRP O
was P02775136A1151 VBD O
not P02775136A1151 RB O
possible P02775136A1151 JJ O
to P02775136A1151 TO O
determine P02775136A1151 VB O
whether P02775136A1151 IN O
these P02775136A1151 DT O
abnormal P02775136A1151 JJ O
breathing P02775136A1151 NN O
patterns P02775136A1151 NNS O
are P02775136A1151 VBP O
a P02775136A1151 DT O
cause P02775136A1151 NN O
or P02775136A1151 CC O
an P02775136A1151 DT O
effect P02775136A1151 NN O
of P02775136A1151 IN O
AMS P02775136A1151 NNP O
. P02775136A1151 . O
. . O O

An P09572990A0630 DT O
association P09572990A0630 NN O
between P09572990A0630 IN O
hSIE P09572990A0630 NN I-UN
and P09572990A0630 CC O
Stat-3 P09572990A0630 NNP I-UN
after P09572990A0630 IN O
MHC-I P09572990A0630 NNP I-UN
ligation P09572990A0630 NN O
was P09572990A0630 VBD O
directly P09572990A0630 RB O
demonstrated P09572990A0630 VBN O
by P09572990A0630 IN O
precipitating P09572990A0630 VBG O
Stat-3 P09572990A0630 NNP I-UN
from P09572990A0630 IN O
nuclear P09572990A0630 JJ O
extracts P09572990A0630 NNS O
with P09572990A0630 IN O
biotinylated P09572990A0630 JJ O
hSIE P09572990A0630 NN I-UN
probe P09572990A0630 NN O
and P09572990A0630 CC O
avidin-coupled P09572990A0630 JJ O
agarose P09572990A0630 NN O
. P09572990A0630 . O
. . O O

Pargyline P02062116A0688 NNP O
, P02062116A0688 , O
a P02062116A0688 DT O
monoamine P02062116A0688 JJ I-UN
oxidase P02062116A0688 NN I-UN
inhibitor P02062116A0688 NN O
, P02062116A0688 , O
reduces P02062116A0688 VBZ O
peak P02062116A0688 JJ O
3 P02062116A0688 CD O
transiently P02062116A0688 RB O
( P02062116A0688 ( O
max P02062116A0688 NN O
. P02062116A0688 . O
. . O O

The P07337609A0531 DT O
geometric P07337609A0531 JJ O
mean P07337609A0531 JJ O
hemagglutination-inhibition P07337609A0531 NN O
antibody P07337609A0531 NN O
titers P07337609A0531 NNS O
( P07337609A0531 ( O
GMT P07337609A0531 NNP O
) P07337609A0531 ) O
of P07337609A0531 IN O
non-immunized P07337609A0531 JJ O
, P07337609A0531 , O
once-immunized P07337609A0531 JJ O
, P07337609A0531 , O
and P07337609A0531 CC O
twice-immunized P07337609A0531 JJ O
chickens P07337609A0531 NNS O
were P07337609A0531 VBD O
compared P07337609A0531 VBN O
at P07337609A0531 IN O
2-week P07337609A0531 JJ O
intervals P07337609A0531 NNS O
following P07337609A0531 VBG O
primary P07337609A0531 JJ O
immunization P07337609A0531 NN O
, P07337609A0531 , O
secondary P07337609A0531 JJ O
immunization P07337609A0531 NN O
, P07337609A0531 , O
and P07337609A0531 CC O
challenge P07337609A0531 NN O
. P07337609A0531 . O
. . O O

Early P11341349T0000 JJ O
indicators P11341349T0000 NNS O
of P11341349T0000 IN O
the P11341349T0000 DT O
effect P11341349T0000 NN O
of P11341349T0000 IN O
a P11341349T0000 DT O
breast P11341349T0000 NN O
cancer P11341349T0000 NN O
screening P11341349T0000 VBG O
program P11341349T0000 NN O
for P11341349T0000 IN O
low-income P11341349T0000 JJ O
women P11341349T0000 NNS O
. P11341349T0000 . O
. . O O

The P07854130T0000 DT O
pilE P07854130T0000 JJ I-UN
gene P07854130T0000 NN I-UN
product P07854130T0000 NN I-UN
of P07854130T0000 IN I-UN
Pseudomonas P07854130T0000 NNP I-UN
aeruginosa P07854130T0000 NN I-UN
, P07854130T0000 , O
required P07854130T0000 VBN O
for P07854130T0000 IN O
pilus P07854130T0000 JJ O
biogenesis P07854130T0000 NN O
, P07854130T0000 , O
shares P07854130T0000 NNS O
amino P07854130T0000 VBP O
acid P07854130T0000 JJ O
sequence P07854130T0000 NN O
identity P07854130T0000 NN O
with P07854130T0000 IN O
the P07854130T0000 DT O
N-termini P07854130T0000 NNP O
of P07854130T0000 IN O
type P07854130T0000 NN I-UN
4 P07854130T0000 CD I-UN
prepilin P07854130T0000 NN I-UN
proteins P07854130T0000 NNS I-UN
. P07854130T0000 . O
. . O O

Trinipatch P09922856A0459 NN O
is P09922856A0459 VBZ O
a P09922856A0459 DT O
small P09922856A0459 JJ O
, P09922856A0459 , O
transparent P09922856A0459 JJ O
, P09922856A0459 , O
matricial P09922856A0459 JJ O
, P09922856A0459 , O
monolayer P09922856A0459 JJ O
patch P09922856A0459 NN O
with P09922856A0459 IN O
an P09922856A0459 DT O
absorption P09922856A0459 NN O
promoter P09922856A0459 NN O
, P09922856A0459 , O
marketed P09922856A0459 VBN O
in P09922856A0459 IN O
two P09922856A0459 CD O
dose-strengths P09922856A0459 NNS O
( P09922856A0459 ( O
5 P09922856A0459 CD O
mg P09922856A0459 NN O
/ P09922856A0459 VBD O
24 P09922856A0459 CD O
h P09922856A0459 NN O
and P09922856A0459 CC O
10 P09922856A0459 CD O
mg P09922856A0459 NN O
/ P09922856A0459 VBD O
24 P09922856A0459 CD O
h P09922856A0459 NN O
) P09922856A0459 ) O
by P09922856A0459 IN O
Laboratoires P09922856A0459 NNP O
Synthelabo P09922856A0459 NNP O
. P09922856A0459 . O
. . O O

Mitochondria-lytic P01526690T0000 JJ O
action P01526690T0000 NN O
of P01526690T0000 IN O
warfarin P01526690T0000 NN O
in P01526690T0000 IN O
lymphocytes P01526690T0000 NNS O
. P01526690T0000 . O
. . O O

Disruption P01545797A0587 NN O
mutations P01545797A0587 NNS O
have P01545797A0587 VBP O
been P01545797A0587 VBN O
constructed P01545797A0587 VBN O
in P01545797A0587 IN O
the P01545797A0587 DT O
SLK1 P01545797A0587 NNP I-UN
gene P01545797A0587 NN I-UN
. P01545797A0587 . O
slk1 P01545797A0587 JJ I-UN
null P01545797A0587 JJ I-UN
mutants P01545797A0587 NNS I-UN
can P01545797A0587 MD O
not P01545797A0587 RB O
grow P01545797A0587 VB O
at P01545797A0587 IN O
37 P01545797A0587 CD O
degrees P01545797A0587 NNS O
C P01545797A0587 NNP O
, P01545797A0587 , O
but P01545797A0587 CC O
many P01545797A0587 JJ O
cells P01545797A0587 NNS O
can P01545797A0587 MD O
grow P01545797A0587 VB O
at P01545797A0587 IN O
30 P01545797A0587 CD O
, P01545797A0587 , O
24 P01545797A0587 CD O
, P01545797A0587 , O
and P01545797A0587 CC O
17 P01545797A0587 CD O
degrees P01545797A0587 NNS O
C P01545797A0587 NNP O
. P01545797A0587 . O
. . O O

Progressive P11513121T0000 NNP O
study P11513121T0000 NN O
and P11513121T0000 CC O
robustness P11513121T0000 JJ O
test P11513121T0000 NN O
of P11513121T0000 IN O
QSAR P11513121T0000 NNP O
model P11513121T0000 NN O
based P11513121T0000 VBN O
on P11513121T0000 IN O
quantum P11513121T0000 JJ O
chemical P11513121T0000 NN O
parameters P11513121T0000 NNS O
for P11513121T0000 IN O
predicting P11513121T0000 VBG O
BCF P11513121T0000 NNP O
of P11513121T0000 IN O
selected P11513121T0000 VBN O
polychlorinated P11513121T0000 JJ O
organic P11513121T0000 JJ O
compounds P11513121T0000 NNS O
( P11513121T0000 ( O
PCOCs P11513121T0000 NNP O
) P11513121T0000 ) O
. P11513121T0000 . O
. . O O

Sixteen P11321187A0355 NNP O
out P11321187A0355 IN O
of P11321187A0355 IN O
52 P11321187A0355 CD O
seropositive P11321187A0355 JJ O
MS P11321187A0355 NNP O
patients P11321187A0355 NNS O
( P11321187A0355 ( O
30.8 P11321187A0355 CD O
% P11321187A0355 NN O
) P11321187A0355 ) O
showed P11321187A0355 VBD O
intrathecal P11321187A0355 JJ O
synthesis P11321187A0355 NN O
of P11321187A0355 IN O
C. P11321187A0355 NNP I-UN
pneumoniae-specific P11321187A0355 JJ I-UN
IgG P11321187A0355 NNP I-UN
but P11321187A0355 CC O
only P11321187A0355 RB O
one P11321187A0355 CD O
of P11321187A0355 IN O
43 P11321187A0355 CD O
seropositive P11321187A0355 JJ O
controls P11321187A0355 NNS O
( P11321187A0355 ( O
2.3 P11321187A0355 CD O
% P11321187A0355 NN O
) P11321187A0355 ) O
. P11321187A0355 . O
. . O O

ACTH P03036933A0774 NNP I-UN
release P03036933A0774 NN O
is P03036933A0774 VBZ O
transiently P03036933A0774 RB O
suppressed P03036933A0774 VBN O
in P03036933A0774 IN O
some P03036933A0774 DT O
children P03036933A0774 NNS O
after P03036933A0774 IN O
exogenous P03036933A0774 JJ O
ACTH P03036933A0774 NNP I-UN
treatment P03036933A0774 NN O
. P03036933A0774 . O
. . O O

This P10207092A0924 DT O
phosphorylation P10207092A0924 NN O
can P10207092A0924 MD O
be P10207092A0924 VB O
catalyzed P10207092A0924 VBN O
by P10207092A0924 IN O
a P10207092A0924 DT O
break-ended P10207092A0924 JJ O
double-stranded P10207092A0924 JJ O
DNA-activated P10207092A0924 JJ O
protein P10207092A0924 NN O
kinase P10207092A0924 NN O
activity P10207092A0924 NN O
from P10207092A0924 IN O
the P10207092A0924 DT O
sea P10207092A0924 NN O
urchin P10207092A0924 JJ O
nucleus P10207092A0924 NN O
in P10207092A0924 IN O
vitro P10207092A0924 NN O
. P10207092A0924 . O
. . O O

Hierarchy P10825200T0000 NNP O
of P10825200T0000 IN O
protein P10825200T0000 NN I-UN
tyrosine P10825200T0000 NN I-UN
kinases P10825200T0000 NNS I-UN
in P10825200T0000 IN O
interleukin-2 P10825200T0000 NN I-UN
( P10825200T0000 ( O
IL-2 P10825200T0000 NNP I-UN
) P10825200T0000 ) O
signaling P10825200T0000 NN O
: P10825200T0000 : O
activation P10825200T0000 NN O
of P10825200T0000 IN O
syk P10825200T0000 JJ I-UN
depends P10825200T0000 NNS O
on P10825200T0000 IN O
Jak3 P10825200T0000 NNP I-UN
; P10825200T0000 : O
however P10825200T0000 RB O
, P10825200T0000 , O
neither P10825200T0000 CC O
Syk P10825200T0000 NNP I-UN
nor P10825200T0000 CC O
Lck P10825200T0000 NNP I-UN
is P10825200T0000 VBZ O
required P10825200T0000 VBN O
for P10825200T0000 IN O
IL-2-mediated P10825200T0000 JJ O
STAT P10825200T0000 NNP I-UN
activation P10825200T0000 NN O
. P10825200T0000 . O
. . O O

Aryl P09211913A0000 NNP I-UN
hydrocarbon P09211913A0000 NN I-UN
receptor P09211913A0000 NN I-UN
nuclear P09211913A0000 JJ I-UN
translocator P09211913A0000 NN I-UN
( P09211913A0000 ( O
ARNT P09211913A0000 NNP I-UN
) P09211913A0000 ) O
is P09211913A0000 VBZ O
a P09211913A0000 DT O
component P09211913A0000 NN O
of P09211913A0000 IN O
the P09211913A0000 DT O
transcription P09211913A0000 NN O
factors P09211913A0000 NNS O
, P09211913A0000 , O
aryl P09211913A0000 JJ I-UN
hydrocarbon P09211913A0000 NN I-UN
receptor P09211913A0000 NN I-UN
( P09211913A0000 ( O
AhR P09211913A0000 NNP I-UN
) P09211913A0000 ) O
and P09211913A0000 CC O
hypoxia-inducible P09211913A0000 JJ I-UN
factor P09211913A0000 NN I-UN
1 P09211913A0000 CD I-UN
, P09211913A0000 , O
which P09211913A0000 WDT O
transactivate P09211913A0000 VBP O
their P09211913A0000 PRP$ O
target P09211913A0000 NN O
genes P09211913A0000 NNS O
, P09211913A0000 , O
such P09211913A0000 JJ O
as P09211913A0000 IN O
CYP1A1 P09211913A0000 NNP I-UN
and P09211913A0000 CC O
erythropoietin P09211913A0000 NN I-UN
, P09211913A0000 , O
in P09211913A0000 IN O
response P09211913A0000 NN O
to P09211913A0000 TO O
xenobiotic P09211913A0000 JJ O
aromatic P09211913A0000 JJ O
hydrocarbons P09211913A0000 NNS O
and P09211913A0000 CC O
to P09211913A0000 TO O
low P09211913A0000 VB O
O2 P09211913A0000 NNP O
concentration P09211913A0000 NN O
, P09211913A0000 , O
respectively P09211913A0000 RB O
. P09211913A0000 . O
. . O O

Much P10805738A0799 JJ O
evidence P10805738A0799 NN O
indicates P10805738A0799 VBZ O
that P10805738A0799 IN O
p38 P10805738A0799 NN I-UN
is P10805738A0799 VBZ O
an P10805738A0799 DT O
activator P10805738A0799 NN O
of P10805738A0799 IN O
MyoD P10805738A0799 NNP I-UN
: P10805738A0799 : O
( P10805738A0799 ( O
i P10805738A0799 NN O
) P10805738A0799 ) O
p38 P10805738A0799 NN I-UN
kinase P10805738A0799 NN I-UN
activity P10805738A0799 NN O
is P10805738A0799 VBZ O
required P10805738A0799 VBN O
for P10805738A0799 IN O
the P10805738A0799 DT O
expression P10805738A0799 NN O
of P10805738A0799 IN O
MyoD-responsive P10805738A0799 NNP O
genes P10805738A0799 NNS O
, P10805738A0799 , O
( P10805738A0799 ( O
ii P10805738A0799 NN O
) P10805738A0799 ) O
enforced P10805738A0799 VBD O
induction P10805738A0799 NN O
of P10805738A0799 IN O
p38 P10805738A0799 NN I-UN
stimulates P10805738A0799 VBZ O
the P10805738A0799 DT O
transcriptional P10805738A0799 JJ O
activity P10805738A0799 NN O
of P10805738A0799 IN O
a P10805738A0799 DT O
Gal4-MyoD P10805738A0799 JJ O
fusion P10805738A0799 NN O
protein P10805738A0799 NN O
and P10805738A0799 CC O
allows P10805738A0799 VBZ O
efficient P10805738A0799 JJ O
activation P10805738A0799 NN O
of P10805738A0799 IN O
chromatin-integrated P10805738A0799 JJ O
reporters P10805738A0799 NNS O
by P10805738A0799 IN O
MyoD P10805738A0799 NNP I-UN
, P10805738A0799 , O
and P10805738A0799 CC O
( P10805738A0799 ( O
iii P10805738A0799 NN O
) P10805738A0799 ) O
MyoD-dependent P10805738A0799 NNP O
myogenic P10805738A0799 JJ O
conversion P10805738A0799 NN O
is P10805738A0799 VBZ O
reduced P10805738A0799 VBN O
in P10805738A0799 IN O
mouse P10805738A0799 NN O
embryonic P10805738A0799 JJ O
fibroblasts P10805738A0799 NNS O
derived P10805738A0799 VBN O
from P10805738A0799 IN O
p38alpha P10805738A0799 NN I-UN
( P10805738A0799 ( I-UN
- P10805738A0799 : I-UN
/ P10805738A0799 SYM I-UN
- P10805738A0799 : I-UN
) P10805738A0799 ) I-UN
embryos P10805738A0799 NN O
. P10805738A0799 . O
. . O O

We P08626065A0000 PRP O
have P08626065A0000 VBP O
cloned P08626065A0000 VBN O
and P08626065A0000 CC O
sequenced P08626065A0000 VBD O
a P08626065A0000 DT O
3574-bp P08626065A0000 JJ O
Bacillus P08626065A0000 NN O
subtilis P08626065A0000 NNS O
( P08626065A0000 ( O
Bs P08626065A0000 NNP O
) P08626065A0000 ) O
DNA P08626065A0000 NNP O
fragment P08626065A0000 NN O
located P08626065A0000 VBN O
between P08626065A0000 IN O
the P08626065A0000 DT O
nrdA P08626065A0000 NN I-UN
and P08626065A0000 CC O
citB P08626065A0000 NN I-UN
genes P08626065A0000 NNS I-UN
at P08626065A0000 IN O
about P08626065A0000 IN O
169 P08626065A0000 CD O
degrees P08626065A0000 NNS O
on P08626065A0000 IN O
the P08626065A0000 DT O
chromosome P08626065A0000 NN O
. P08626065A0000 . O
. . O O

Troubled P10132730T0000 JJ O
CareNetwork P10132730T0000 NNP O
gets P10132730T0000 VBZ O
pact P10132730T0000 NN O
from P10132730T0000 IN O
largest P10132730T0000 JJS O
teacher P10132730T0000 NN O
union P10132730T0000 NN O
in P10132730T0000 IN O
Wis P10132730T0000 NNP O
. P10132730T0000 . O
. . O O

None P03237446A0377 NN O
had P03237446A0377 VBD O
a P03237446A0377 DT O
past P03237446A0377 JJ O
history P03237446A0377 NN O
of P03237446A0377 IN O
opportunistic P03237446A0377 JJ O
infections P03237446A0377 NNS O
; P03237446A0377 : O
neither P03237446A0377 CC O
did P03237446A0377 VBD O
any P03237446A0377 DT O
have P03237446A0377 VB O
lymphopenia P03237446A0377 NN O
. P03237446A0377 . O
. . O O

In P01385462A0151 IN O
general P01385462A0151 JJ O
, P01385462A0151 , O
two P01385462A0151 CD O
separate P01385462A0151 JJ O
high-performance P01385462A0151 NN O
liquid P01385462A0151 NN O
chromatographic P01385462A0151 JJ O
runs P01385462A0151 NNS O
were P01385462A0151 VBD O
performed P01385462A0151 VBN O
, P01385462A0151 , O
one P01385462A0151 CD O
for P01385462A0151 IN O
the P01385462A0151 DT O
gamma-aminobutyric P01385462A0151 JJ O
acid P01385462A0151 NN O
determination P01385462A0151 NN O
and P01385462A0151 CC O
one P01385462A0151 CD O
for P01385462A0151 IN O
the P01385462A0151 DT O
determination P01385462A0151 NN O
of P01385462A0151 IN O
the P01385462A0151 DT O
monoamines P01385462A0151 NNS O
. P01385462A0151 . O
. . O O

Terazosin P02884860A0329 NNP O
, P02884860A0329 , O
a P02884860A0329 DT O
structural P02884860A0329 JJ O
analog P02884860A0329 NN O
of P02884860A0329 IN O
prazosin P02884860A0329 NN O
, P02884860A0329 , O
also P02884860A0329 RB O
inhibits P02884860A0329 VBZ O
alpha P02884860A0329 RB I-UN
1 P02884860A0329 CD I-UN
adrenoceptors P02884860A0329 NNS I-UN
and P02884860A0329 CC O
is P02884860A0329 VBZ O
recommended P02884860A0329 VBN O
as P02884860A0329 IN O
once P02884860A0329 RB O
or P02884860A0329 CC O
twice-daily P02884860A0329 JJ O
therapy P02884860A0329 NN O
. P02884860A0329 . O
. . O O

The P03109954A0945 DT O
results P03109954A0945 NNS O
suggest P03109954A0945 VBP O
that P03109954A0945 IN O
the P03109954A0945 DT O
greater P03109954A0945 JJR O
estrogenic P03109954A0945 JJ O
influence P03109954A0945 NN O
associated P03109954A0945 VBN O
with P03109954A0945 IN O
the P03109954A0945 DT O
ethinyl P03109954A0945 JJ O
estradiol-containing P03109954A0945 JJ O
OC P03109954A0945 NNP O
resulted P03109954A0945 VBD O
in P03109954A0945 IN O
inhibition P03109954A0945 NN O
of P03109954A0945 IN O
coronary P03109954A0945 JJ O
artery P03109954A0945 NN O
atherosclerosis P03109954A0945 NN O
despite P03109954A0945 IN O
a P03109954A0945 DT O
pronounced P03109954A0945 JJ O
progestin-induced P03109954A0945 JJ O
lowering P03109954A0945 NN O
of P03109954A0945 IN O
plasma P03109954A0945 NN O
HDL P03109954A0945 NNP I-UN
cholesterol P03109954A0945 NN I-UN
concentration P03109954A0945 NN O
and P03109954A0945 CC O
, P03109954A0945 , O
further P03109954A0945 RB O
, P03109954A0945 , O
that P03109954A0945 IN O
hormonal P03109954A0945 JJ O
balance P03109954A0945 NN O
may P03109954A0945 MD O
have P03109954A0945 VB O
a P03109954A0945 DT O
marked P03109954A0945 JJ O
influence P03109954A0945 NN O
on P03109954A0945 IN O
the P03109954A0945 DT O
relationship P03109954A0945 NN O
between P03109954A0945 IN O
plasma P03109954A0945 NN O
lipids P03109954A0945 NNS O
and P03109954A0945 CC O
atherogenesis P03109954A0945 NN O
. P03109954A0945 . O
. . O O

Ig-alpha P08454858A0285 JJ I-UN
and P08454858A0285 CC O
Ig-beta P08454858A0285 JJ I-UN
contain P08454858A0285 NN O
extended P08454858A0285 VBD O
cytoplasmic P08454858A0285 JJ O
structure P08454858A0285 NN O
( P08454858A0285 ( O
61 P08454858A0285 CD O
and P08454858A0285 CC O
48 P08454858A0285 CD O
amino P08454858A0285 NN O
acids P08454858A0285 NNS O
, P08454858A0285 , O
respectively P08454858A0285 RB O
) P08454858A0285 ) O
and P08454858A0285 CC O
associate P08454858A0285 JJ O
with P08454858A0285 IN O
cytoplasmic P08454858A0285 JJ O
effectors P08454858A0285 NNS O
indicating P08454858A0285 VBG O
that P08454858A0285 IN O
they P08454858A0285 PRP O
are P08454858A0285 VBP O
directly P08454858A0285 RB O
involved P08454858A0285 VBN O
in P08454858A0285 IN O
signal P08454858A0285 JJ O
transduction P08454858A0285 NN O
. P08454858A0285 . O
. . O O

DMCM P06340643A0598 NNP O
also P06340643A0598 RB O
permits P06340643A0598 VBZ O
extension P06340643A0598 NN O
of P06340643A0598 IN O
the P06340643A0598 DT O
possibilities P06340643A0598 NNS O
of P06340643A0598 IN O
obtaining P06340643A0598 VBG O
and P06340643A0598 CC O
transplanting P06340643A0598 VBG O
donor P06340643A0598 JJ O
organs P06340643A0598 NNS O
. P06340643A0598 . O
. . O O

Genomic P11121118T0000 NNP O
organization P11121118T0000 NN O
of P11121118T0000 IN O
the P11121118T0000 DT O
human P11121118T0000 JJ O
phosphodiesterase P11121118T0000 NN I-UN
PDE11A P11121118T0000 NNP I-UN
gene P11121118T0000 NN I-UN
. P11121118T0000 . O
. . O O

A P11313946T0000 DT O
novel P11313946T0000 JJ O
potential P11313946T0000 JJ O
effector P11313946T0000 NN O
of P11313946T0000 IN O
M-Ras P11313946T0000 NNP I-UN
and P11313946T0000 CC O
p21 P11313946T0000 VB I-UN
Ras P11313946T0000 NNP I-UN
negatively P11313946T0000 RB O
regulates P11313946T0000 VBZ O
p21 P11313946T0000 JJ I-UN
Ras-mediated P11313946T0000 JJ O
gene P11313946T0000 NN O
induction P11313946T0000 NN O
and P11313946T0000 CC O
cell P11313946T0000 NN O
growth P11313946T0000 NN O
. P11313946T0000 . O
. . O O

The P08034708A0000 DT O
molecular P08034708A0000 JJ O
basis P08034708A0000 NN O
for P08034708A0000 IN O
commitment P08034708A0000 NN O
of P08034708A0000 IN O
progenitors P08034708A0000 NNS O
to P08034708A0000 TO O
the P08034708A0000 DT O
eosinophil P08034708A0000 JJ O
lineage P08034708A0000 NN O
and P08034708A0000 CC O
mechanisms P08034708A0000 NNS O
by P08034708A0000 IN O
which P08034708A0000 WDT O
eosinophil-specific P08034708A0000 JJ O
genes P08034708A0000 NNS O
are P08034708A0000 VBP O
expressed P08034708A0000 VBN O
and P08034708A0000 CC O
regulated P08034708A0000 VBN O
during P08034708A0000 IN O
differentiation P08034708A0000 NN O
is P08034708A0000 VBZ O
unknown P08034708A0000 JJ O
. P08034708A0000 . O
. . O O

Since P01469042A0355 IN O
CENP-B P01469042A0355 NNP I-UN
gene P01469042A0355 NN I-UN
is P01469042A0355 VBZ O
conserved P01469042A0355 VBN O
in P01469042A0355 IN O
mammalian P01469042A0355 JJ O
species P01469042A0355 NNS O
and P01469042A0355 CC O
CENP-B P01469042A0355 NNP I-UN
boxes P01469042A0355 NNS I-UN
are P01469042A0355 VBP O
found P01469042A0355 VBN O
also P01469042A0355 RB O
in P01469042A0355 IN O
mouse P01469042A0355 NN O
centromere P01469042A0355 EX O
satellite P01469042A0355 JJ O
DNA P01469042A0355 NNP O
( P01469042A0355 ( O
minor P01469042A0355 JJ O
satellite P01469042A0355 NN O
) P01469042A0355 ) O
, P01469042A0355 , O
this P01469042A0355 DT O
sequence-specific P01469042A0355 JJ O
DNA-protein P01469042A0355 NNP O
interaction P01469042A0355 NN O
may P01469042A0355 MD O
be P01469042A0355 VB O
important P01469042A0355 JJ O
for P01469042A0355 IN O
some P01469042A0355 DT O
kind P01469042A0355 NN O
of P01469042A0355 IN O
common P01469042A0355 JJ O
centromere P01469042A0355 JJ O
function P01469042A0355 NN O
. P01469042A0355 . O
. . O O

The P06402480A0373 DT O
susceptibility P06402480A0373 NN O
of P06402480A0373 IN O
the P06402480A0373 DT O
PPNG P06402480A0373 NNP O
strains P06402480A0373 VBZ O
to P06402480A0373 TO O
clinically P06402480A0373 VB O
relevant P06402480A0373 JJ O
antibiotics P06402480A0373 NNS O
varied P06402480A0373 VBD O
with P06402480A0373 IN O
the P06402480A0373 DT O
plasmid P06402480A0373 NN O
pattern P06402480A0373 NN O
; P06402480A0373 : O
this P06402480A0373 DT O
stresses P06402480A0373 VBZ O
the P06402480A0373 DT O
necessity P06402480A0373 NN O
of P06402480A0373 IN O
permanent P06402480A0373 JJ O
surveillance P06402480A0373 NN O
of P06402480A0373 IN O
gonococcal P06402480A0373 JJ O
infections P06402480A0373 NNS O
and P06402480A0373 CC O
of P06402480A0373 IN O
regular P06402480A0373 JJ O
evaluation P06402480A0373 NN O
of P06402480A0373 IN O
the P06402480A0373 DT O
recommendations P06402480A0373 NNS O
for P06402480A0373 IN O
antimicrobial P06402480A0373 JJ O
treatment P06402480A0373 NN O
. P06402480A0373 . O
. . O O

In P09840932A0365 IN O
this P09840932A0365 DT O
study P09840932A0365 NN O
we P09840932A0365 PRP O
provide P09840932A0365 VBP O
evidence P09840932A0365 NN O
that P09840932A0365 IN O
B-Myb P09840932A0365 NNP I-UN
is P09840932A0365 VBZ O
a P09840932A0365 DT O
direct P09840932A0365 JJ O
physiological P09840932A0365 JJ O
target P09840932A0365 NN O
for P09840932A0365 IN O
cyclin P09840932A0365 NN I-UN
A P09840932A0365 NNP I-UN
/ P09840932A0365 NNP O
Cdk2 P09840932A0365 NNP I-UN
. P09840932A0365 . O
. . O O

Protein P07689154A0168 NNP O
phosphorylation P07689154A0168 NN O
appears P07689154A0168 VBZ O
to P07689154A0168 TO O
play P07689154A0168 VB O
a P07689154A0168 DT O
critical P07689154A0168 JJ O
role P07689154A0168 NN O
in P07689154A0168 IN O
uPA P07689154A0168 JJ I-UN
gene P07689154A0168 NN I-UN
expression P07689154A0168 NN O
in P07689154A0168 IN O
these P07689154A0168 DT O
cells P07689154A0168 NNS O
; P07689154A0168 : O
protein P07689154A0168 VB I-UN
kinase P07689154A0168 VB I-UN
C-activating P07689154A0168 NNP O
phorbol P07689154A0168 NN O
esters P07689154A0168 NNS O
cooperate P07689154A0168 VBP O
with P07689154A0168 IN O
pp60v-src P07689154A0168 NN I-UN
to P07689154A0168 TO O
synergistically P07689154A0168 RB O
increase P07689154A0168 VB O
uPA P07689154A0168 JJ I-UN
mRNA P07689154A0168 NN I-UN
, P07689154A0168 , O
whereas P07689154A0168 WP O
cyclic P07689154A0168 JJ I-UN
AMP P07689154A0168 NNP I-UN
( P07689154A0168 ( I-UN
cAMP P07689154A0168 NN I-UN
) P07689154A0168 ) I-UN
-dependent P07689154A0168 NN I-UN
protein P07689154A0168 JJ I-UN
kinase-activating P07689154A0168 JJ O
agents P07689154A0168 NNS O
( P07689154A0168 ( O
e.g. P07689154A0168 NN O
, P07689154A0168 , O
8-bromo P07689154A0168 JJ O
cAMP P07689154A0168 NN O
) P07689154A0168 ) O
repress P07689154A0168 NN O
uPA P07689154A0168 JJ I-UN
mRNA P07689154A0168 NN I-UN
levels P07689154A0168 NNS O
. P07689154A0168 . O
. . O O

DESIGN P11910310A0279 NN O
: P11910310A0279 : O
Prospective P11910310A0279 JJ O
, P11910310A0279 , O
randomized P11910310A0279 VBN O
, P11910310A0279 , O
double-blind P11910310A0279 NN O
, P11910310A0279 , O
controlled P11910310A0279 VBN O
trial P11910310A0279 NN O
. P11910310A0279 . O
. . O O

Alveolar P03000489A0822 JJ O
lymphocytes P03000489A0822 NNS O
were P03000489A0822 VBD O
surprisingly P03000489A0822 RB O
increased P03000489A0822 VBN O
in P03000489A0822 IN O
most P03000489A0822 JJS O
patients P03000489A0822 NNS O
with P03000489A0822 IN O
AIDS P03000489A0822 NNP O
( P03000489A0822 ( O
mean P03000489A0822 JJ O
26.1 P03000489A0822 CD O
+ P03000489A0822 NN O
/ P03000489A0822 NNP O
- P03000489A0822 : O
21.9 P03000489A0822 CD O
% P03000489A0822 NN O
; P03000489A0822 : O
range P03000489A0822 VB O
1-76 P03000489A0822 CD O
% P03000489A0822 NN O
) P03000489A0822 ) O
and P03000489A0822 CC O
CGL P03000489A0822 NNP O
( P03000489A0822 ( O
mean P03000489A0822 JJ O
26.6 P03000489A0822 CD O
+ P03000489A0822 NN O
/ P03000489A0822 NNP O
- P03000489A0822 : O
22.6 P03000489A0822 CD O
% P03000489A0822 NN O
; P03000489A0822 : O
range P03000489A0822 VB O
3-76 P03000489A0822 CD O
% P03000489A0822 NN O
) P03000489A0822 ) O
with P03000489A0822 IN O
criteria P03000489A0822 NNS O
of P03000489A0822 IN O
activation P03000489A0822 NN O
contrasting P03000489A0822 VBG O
with P03000489A0822 IN O
the P03000489A0822 DT O
blood P03000489A0822 NN O
lymphopenia P03000489A0822 NN O
. P03000489A0822 . O
. . O O

A P07798217T0000 DT O
secondary P07798217T0000 JJ O
phosphorylation P07798217T0000 NN O
of P07798217T0000 IN O
CREB341 P07798217T0000 NNP I-UN
at P07798217T0000 IN O
Ser129 P07798217T0000 NNP O
is P07798217T0000 VBZ O
required P07798217T0000 VBN O
for P07798217T0000 IN O
the P07798217T0000 DT O
cAMP-mediated P07798217T0000 JJ O
control P07798217T0000 NN O
of P07798217T0000 IN O
gene P07798217T0000 NN O
expression P07798217T0000 NN O
. P07798217T0000 . O
. . O O

Control P08617800A0150 NN O
of P08617800A0150 IN O
transcription P08617800A0150 NN O
of P08617800A0150 IN O
the P08617800A0150 DT O
erbB-2 P08617800A0150 JJ I-UN
gene P08617800A0150 NN I-UN
is P08617800A0150 VBZ O
an P08617800A0150 DT O
important P08617800A0150 JJ O
determinant P08617800A0150 NN O
of P08617800A0150 IN O
receptor P08617800A0150 NN O
expression P08617800A0150 NN O
. P08617800A0150 . O
. . O O

Human P09693035T0000 NNP I-UN
ULK1 P09693035T0000 NNP I-UN
, P09693035T0000 , O
a P09693035T0000 DT O
novel P09693035T0000 JJ O
serine P09693035T0000 NN I-UN
/ P09693035T0000 NNP I-UN
threonine P09693035T0000 NN I-UN
kinase P09693035T0000 NN I-UN
related P09693035T0000 VBN O
to P09693035T0000 TO O
UNC-51 P09693035T0000 JJ I-UN
kinase P09693035T0000 NN I-UN
of P09693035T0000 IN O
Caenorhabditis P09693035T0000 NNP O
elegans P09693035T0000 NNS O
: P09693035T0000 : O
cDNA P09693035T0000 NN O
cloning P09693035T0000 NN O
, P09693035T0000 , O
expression P09693035T0000 NN O
, P09693035T0000 , O
and P09693035T0000 CC O
chromosomal P09693035T0000 JJ O
assignment P09693035T0000 NN O
. P09693035T0000 . O
. . O O

In P10987301A0332 IN O
this P10987301A0332 DT O
regard P10987301A0332 NN O
, P10987301A0332 , O
we P10987301A0332 PRP O
have P10987301A0332 VBP O
recently P10987301A0332 RB O
observed P10987301A0332 VBN O
that P10987301A0332 IN O
a P10987301A0332 DT O
constitutively P10987301A0332 RB O
active P10987301A0332 JJ O
G P10987301A0332 NNP I-UN
protein-coupled P10987301A0332 JJ I-UN
receptor P10987301A0332 NN I-UN
( P10987301A0332 ( O
GPCR P10987301A0332 NNP I-UN
) P10987301A0332 ) O
encoded P10987301A0332 VBN O
by P10987301A0332 IN O
the P10987301A0332 DT O
Kaposi P10987301A0332 NNP O
's P10987301A0332 POS O
sarcoma-associated P10987301A0332 JJ O
herpes P10987301A0332 NNS O
virus P10987301A0332 NN O
( P10987301A0332 ( O
KSHV P10987301A0332 NNP O
) P10987301A0332 ) O
/ P10987301A0332 VBP O
human P10987301A0332 JJ O
herpes P10987301A0332 NNS O
virus P10987301A0332 NN O
8 P10987301A0332 CD O
is P10987301A0332 VBZ O
oncogenic P10987301A0332 JJ O
and P10987301A0332 CC O
stimulates P10987301A0332 NNS O
angiogenesis P10987301A0332 NN O
by P10987301A0332 IN O
increasing P10987301A0332 VBG O
the P10987301A0332 DT O
secretion P10987301A0332 NN O
of P10987301A0332 IN O
vascular P10987301A0332 JJ I-UN
endothelial P10987301A0332 JJ I-UN
growth P10987301A0332 NN I-UN
factor P10987301A0332 NN I-UN
( P10987301A0332 ( O
VEGF P10987301A0332 NNP I-UN
) P10987301A0332 ) O
, P10987301A0332 , O
which P10987301A0332 WDT O
is P10987301A0332 VBZ O
a P10987301A0332 DT O
key P10987301A0332 JJ O
angiogenic P10987301A0332 JJ O
stimulator P10987301A0332 NN O
and P10987301A0332 CC O
a P10987301A0332 DT O
critical P10987301A0332 JJ O
mitogen P10987301A0332 NN O
for P10987301A0332 IN O
the P10987301A0332 DT O
development P10987301A0332 NN O
of P10987301A0332 IN O
Kaposi P10987301A0332 NNP O
's P10987301A0332 POS O
sarcoma P10987301A0332 NN O
. P10987301A0332 . O
. . O O

The P06520418A0325 DT O
results P06520418A0325 NNS O
obtained P06520418A0325 VBN O
were P06520418A0325 VBD O
as P06520418A0325 IN O
follows P06520418A0325 VBZ O
: P06520418A0325 : O
The P06520418A0325 DT O
mitral P06520418A0325 JJ O
valve P06520418A0325 NN O
orifice P06520418A0325 NN O
area P06520418A0325 NN O
( P06520418A0325 ( O
MVA P06520418A0325 NNP O
) P06520418A0325 ) O
was P06520418A0325 VBD O
significantly P06520418A0325 RB O
smaller P06520418A0325 JJR O
in P06520418A0325 IN O
patients P06520418A0325 NNS O
with P06520418A0325 IN O
type P06520418A0325 JJ O
III P06520418A0325 NNP O
of P06520418A0325 IN O
the P06520418A0325 DT O
LVIT P06520418A0325 NNP O
flow P06520418A0325 NN O
velocity P06520418A0325 NN O
pattern P06520418A0325 NN O
than P06520418A0325 IN O
in P06520418A0325 IN O
patients P06520418A0325 NNS O
with P06520418A0325 IN O
type P06520418A0325 NN O
I P06520418A0325 PRP O
( P06520418A0325 ( O
p P06520418A0325 NN O
less P06520418A0325 JJR O
than P06520418A0325 IN O
0.001 P06520418A0325 CD O
) P06520418A0325 ) O
. P06520418A0325 . O
. . O O

Stems P08529630A0840 NNP O
contain P08529630A0840 VBP O
distinctly P08529630A0840 RB O
less P08529630A0840 JJR O
P P08529630A0840 NNP I-UN
protein P08529630A0840 NN I-UN
mRNA P08529630A0840 NN I-UN
and P08529630A0840 CC O
the P08529630A0840 DT O
relative P08529630A0840 JJ O
level P08529630A0840 NN O
in P08529630A0840 IN O
roots P08529630A0840 NNS O
is P08529630A0840 VBZ O
very P08529630A0840 RB O
low P08529630A0840 JJ O
but P08529630A0840 CC O
still P08529630A0840 RB O
clearly P08529630A0840 RB O
detectable P08529630A0840 JJ O
. P08529630A0840 . O
. . O O

This P10688639A1310 DT O
repression P10688639A1310 NN O
does P10688639A1310 VBZ O
not P10688639A1310 RB O
require P10688639A1310 VB O
the P10688639A1310 DT O
PU.1 P10688639A1310 NNP I-UN
transactivation P10688639A1310 NN O
or P10688639A1310 CC O
PEST P10688639A1310 NNP O
domains P10688639A1310 NNS O
and P10688639A1310 CC O
can P10688639A1310 MD O
not P10688639A1310 RB O
be P10688639A1310 VB O
reversed P10688639A1310 VBN O
by P10688639A1310 IN O
p300 P10688639A1310 JJ I-UN
expression P10688639A1310 NN O
. P10688639A1310 . O
. . O O

Identification P01876836T0000 NN O
of P01876836T0000 IN O
Ets- P01876836T0000 NNP O
and P01876836T0000 CC O
notch-related P01876836T0000 JJ O
subunits P01876836T0000 NNS O
in P01876836T0000 IN O
GA P01876836T0000 NNP I-UN
binding P01876836T0000 VBG I-UN
protein P01876836T0000 NN I-UN
. P01876836T0000 . O
. . O O

A P08535537A0000 DT O
survey P08535537A0000 NN O
is P08535537A0000 VBZ O
given P08535537A0000 VBN O
of P08535537A0000 IN O
the P08535537A0000 DT O
pharmacological P08535537A0000 JJ O
backgrounds P08535537A0000 NNS O
that P08535537A0000 WDT O
are P08535537A0000 VBP O
relevant P08535537A0000 JJ O
for P08535537A0000 IN O
the P08535537A0000 DT O
drug P08535537A0000 NN O
treatment P08535537A0000 NN O
of P08535537A0000 IN O
essential P08535537A0000 JJ O
hypertension P08535537A0000 NN O
in P08535537A0000 IN O
the P08535537A0000 DT O
elderly P08535537A0000 JJ O
. P08535537A0000 . O
. . O O

We P09790986A0689 PRP O
also P09790986A0689 RB O
raised P09790986A0689 VBD O
a P09790986A0689 DT O
polyclonal P09790986A0689 JJ O
antibody P09790986A0689 NN O
against P09790986A0689 IN O
the P09790986A0689 DT O
glutathione P09790986A0689 NN I-UN
S-transferase P09790986A0689 NNP I-UN
fusion P09790986A0689 NN I-UN
protein P09790986A0689 NN I-UN
containing P09790986A0689 VBG O
the P09790986A0689 DT O
NH2-terminal P09790986A0689 JJ O
86 P09790986A0689 CD O
amino P09790986A0689 JJ O
acids P09790986A0689 NNS O
of P09790986A0689 IN O
human P09790986A0689 JJ I-UN
NRAMP2 P09790986A0689 NNP I-UN
. P09790986A0689 . O
. . O O

The P10870043A0621 DT O
administration P10870043A0621 NN O
of P10870043A0621 IN O
the P10870043A0621 DT O
GnRH P10870043A0621 NNP I-UN
agonist P10870043A0621 NN O
reduced P10870043A0621 VBD O
the P10870043A0621 DT O
bone P10870043A0621 NN O
mineral P10870043A0621 JJ O
density P10870043A0621 NN O
in P10870043A0621 IN O
the P10870043A0621 DT O
whole P10870043A0621 JJ O
femur P10870043A0621 NN O
to P10870043A0621 TO O
91.0 P10870043A0621 CD O
% P10870043A0621 NN O
of P10870043A0621 IN O
that P10870043A0621 DT O
in P10870043A0621 IN O
the P10870043A0621 DT O
control P10870043A0621 NN O
group P10870043A0621 NN O
. P10870043A0621 . O
. . O O

The P07461848A0230 DT O
mean P07461848A0230 JJ O
values P07461848A0230 NNS O
of P07461848A0230 IN O
the P07461848A0230 DT O
concentrations P07461848A0230 NNS O
of P07461848A0230 IN O
the P07461848A0230 DT O
components P07461848A0230 NNS O
due P07461848A0230 JJ O
to P07461848A0230 TO O
tobacco P07461848A0230 VB O
smoke P07461848A0230 NN O
are P07461848A0230 VBP O
: P07461848A0230 : O
CO P07461848A0230 NNP O
= P07461848A0230 VBZ O
1.1 P07461848A0230 CD O
ppm P07461848A0230 NN O
, P07461848A0230 , O
NO P07461848A0230 NNP O
= P07461848A0230 NNP O
32 P07461848A0230 CD O
ppb P07461848A0230 NN O
, P07461848A0230 , O
NO2 P07461848A0230 NNP O
= P07461848A0230 VBZ O
24 P07461848A0230 CD O
ppb P07461848A0230 NN O
, P07461848A0230 , O
nicotine P07461848A0230 JJ O
= P07461848A0230 VBP O
0.9 P07461848A0230 CD O
micrograms P07461848A0230 NNS O
/ P07461848A0230 JJ O
m3 P07461848A0230 NN O
, P07461848A0230 , O
particulate P07461848A0230 VBP O
matter P07461848A0230 NN O
= P07461848A0230 $ O
133 P07461848A0230 CD O
micrograms P07461848A0230 NNS O
/ P07461848A0230 JJ O
m3 P07461848A0230 NN O
. P07461848A0230 . O
. . O O

However P08252067A0917 RB O
, P08252067A0917 , O
limited P08252067A0917 JJ O
comparisons P08252067A0917 NNS O
reveal P08252067A0917 VBP O
domains P08252067A0917 NNS O
in P08252067A0917 IN O
the P08252067A0917 DT O
NH2 P08252067A0917 NNP O
and P08252067A0917 CC O
COOH P08252067A0917 NNP O
termini P08252067A0917 VBP O
that P08252067A0917 WDT O
have P08252067A0917 VBP O
a P08252067A0917 DT O
high P08252067A0917 JJ O
degree P08252067A0917 NN O
of P08252067A0917 IN O
similarity P08252067A0917 NN O
suggesting P08252067A0917 VBG O
functional P08252067A0917 JJ O
conservation P08252067A0917 NN O
. P08252067A0917 . O
. . O O

By P07862165A0184 IN O
treating P07862165A0184 VBG O
monkey P07862165A0184 JJ O
COS P07862165A0184 NNP O
cells P07862165A0184 NNS O
with P07862165A0184 IN O
oligonucleotides P07862165A0184 NNS O
linked P07862165A0184 VBN O
to P07862165A0184 TO O
psoralen P07862165A0184 VB O
, P07862165A0184 , O
we P07862165A0184 PRP O
have P07862165A0184 VBP O
generated P07862165A0184 VBN O
targeted P07862165A0184 JJ O
mutations P07862165A0184 NNS O
in P07862165A0184 IN O
a P07862165A0184 DT O
simian P07862165A0184 JJ O
virus P07862165A0184 NN O
40 P07862165A0184 CD O
( P07862165A0184 ( O
SV40 P07862165A0184 NNP O
) P07862165A0184 ) O
vector P07862165A0184 NN O
contained P07862165A0184 VBD O
within P07862165A0184 IN O
the P07862165A0184 DT O
cells P07862165A0184 NNS O
via P07862165A0184 IN O
intracellular P07862165A0184 JJ O
triple P07862165A0184 JJ O
helix P07862165A0184 NN O
formation P07862165A0184 NN O
. P07862165A0184 . O
. . O O

( P07061350A0042 ( O
1980 P07061350A0042 CD O
) P07061350A0042 ) O
: P07061350A0042 : O
Science P07061350A0042 NN O
210 P07061350A0042 CD O
, P07061350A0042 , O
77-72 P07061350A0042 CD O
) P07061350A0042 ) O
that P07061350A0042 IN O
stimulating P07061350A0042 VBG O
the P07061350A0042 DT O
crossed P07061350A0042 JJ O
olivocochlear P07061350A0042 JJ O
bundle P07061350A0042 NN O
( P07061350A0042 ( O
COCB P07061350A0042 NNP O
) P07061350A0042 ) O
can P07061350A0042 MD O
change P07061350A0042 VB O
the P07061350A0042 DT O
magnitude P07061350A0042 NN O
of P07061350A0042 IN O
the P07061350A0042 DT O
distortion P07061350A0042 NN O
product P07061350A0042 NN O
( P07061350A0042 ( O
f2-f1 P07061350A0042 JJ O
) P07061350A0042 ) O
in P07061350A0042 IN O
the P07061350A0042 DT O
ear-canal P07061350A0042 JJ O
sound P07061350A0042 NN O
pressure P07061350A0042 NN O
. P07061350A0042 . O
. . O O

A P07934331T0037 DT O
simple P07934331T0037 JJ O
registration P07934331T0037 NN O
as P07934331T0037 IN O
an P07934331T0037 DT O
incentive P07934331T0037 NN O
for P07934331T0037 IN O
improvement P07934331T0037 NN O
. P07934331T0037 . O
. . O O

Drug P02360336A0574 NN O
and P02360336A0574 CC O
personnel P02360336A0574 NNS O
costs P02360336A0574 NNS O
were P02360336A0574 VBD O
reduced P02360336A0574 VBN O
when P02360336A0574 WRB O
batch P02360336A0574 NN O
manufacturing P02360336A0574 NN O
with P02360336A0574 IN O
40-mL P02360336A0574 JJ O
multidose P02360336A0574 JJ O
vials P02360336A0574 NNS O
was P02360336A0574 VBD O
compared P02360336A0574 VBN O
with P02360336A0574 IN O
extemporaneous P02360336A0574 JJ O
compounding P02360336A0574 VBG O
with P02360336A0574 IN O
unit-dose P02360336A0574 JJ O
vials P02360336A0574 NNS O
. P02360336A0574 . O
. . O O

Nursing P06656249T0000 NNP O
home P06656249T0000 NN O
discharges P06656249T0000 NNS O
in P06656249T0000 IN O
clinical P06656249T0000 JJ O
practice P06656249T0000 NN O
. P06656249T0000 . O
. . O O

Current P11123701A0442 JJ O
evidence P11123701A0442 NN O
for P11123701A0442 IN O
this P11123701A0442 DT O
type P11123701A0442 NN O
of P11123701A0442 IN O
DNA P11123701A0442 NNP O
supercoiling-dependent P11123701A0442 JJ O
transcriptional P11123701A0442 JJ O
coupling P11123701A0442 NN O
, P11123701A0442 , O
based P11123701A0442 VBN O
largely P11123701A0442 RB O
on P11123701A0442 IN O
the P11123701A0442 DT O
in P11123701A0442 IN O
vivo P11123701A0442 JJ O
activities P11123701A0442 NNS O
of P11123701A0442 IN O
promoters P11123701A0442 NNS O
contained P11123701A0442 VBN O
in P11123701A0442 IN O
engineered P11123701A0442 JJ O
DNA P11123701A0442 NNP O
constructs P11123701A0442 NNS O
, P11123701A0442 , O
suggests P11123701A0442 VBZ O
that P11123701A0442 IN O
the P11123701A0442 DT O
transcription P11123701A0442 NN O
complex P11123701A0442 NN O
must P11123701A0442 MD O
be P11123701A0442 VB O
physically P11123701A0442 RB O
hindered P11123701A0442 VBN O
to P11123701A0442 TO O
generate P11123701A0442 VB O
DNA P11123701A0442 NNP O
supercoils P11123701A0442 NNS O
and P11123701A0442 CC O
to P11123701A0442 TO O
prevent P11123701A0442 VB O
their P11123701A0442 PRP$ O
diffusion P11123701A0442 NN O
throughout P11123701A0442 IN O
the P11123701A0442 DT O
DNA P11123701A0442 NN O
duplex P11123701A0442 NN O
. P11123701A0442 . O
. . O O

However P09765285A0998 RB O
, P09765285A0998 , O
changing P09765285A0998 VBG O
the P09765285A0998 DT O
half-site P09765285A0998 JJ O
to P09765285A0998 TO O
the P09765285A0998 DT O
consensus P09765285A0998 NN O
sequence P09765285A0998 NN O
AGGTCA P09765285A0998 NNP O
( P09765285A0998 ( O
IRper-1 P09765285A0998 NNP O
) P09765285A0998 ) O
increased P09765285A0998 VBD O
binding P09765285A0998 NN O
of P09765285A0998 IN O
AaEcR.AaUSP P09765285A0998 NNP I-UN
10-fold P09765285A0998 JJ O
over P09765285A0998 IN O
IRhsp-1 P09765285A0998 NNP O
and P09765285A0998 CC O
, P09765285A0998 , O
at P09765285A0998 IN O
the P09765285A0998 DT O
same P09765285A0998 JJ O
time P09765285A0998 NN O
, P09765285A0998 , O
reduced P09765285A0998 VBD O
the P09765285A0998 DT O
stringency P09765285A0998 NN O
of P09765285A0998 IN O
the P09765285A0998 DT O
spacer P09765285A0998 NN O
length P09765285A0998 NN O
requirement P09765285A0998 NN O
, P09765285A0998 , O
with P09765285A0998 IN O
IRper-0 P09765285A0998 NNP O
to P09765285A0998 TO O
IRper-5 P09765285A0998 NNP O
showing P09765285A0998 VBG O
detectable P09765285A0998 JJ O
binding P09765285A0998 NN O
. P09765285A0998 . O
. . O O

In P10919971A0606 IN O
addition P10919971A0606 NN O
to P10919971A0606 TO O
its P10919971A0606 PRP$ O
effect P10919971A0606 NN O
in P10919971A0606 IN O
augmenting P10919971A0606 VBG O
the P10919971A0606 DT O
neutrophil P10919971A0606 JJ O
response P10919971A0606 NN O
to P10919971A0606 TO O
eccentric P10919971A0606 JJ O
exercise P10919971A0606 NN O
, P10919971A0606 , O
vitamin P10919971A0606 NN O
E P10919971A0606 NNP O
causes P10919971A0606 VBZ O
a P10919971A0606 DT O
greater P10919971A0606 JJR O
increase P10919971A0606 NN O
in P10919971A0606 IN O
circulating P10919971A0606 VBG O
creatine P10919971A0606 JJ I-UN
kinase P10919971A0606 NN I-UN
activity P10919971A0606 NN O
, P10919971A0606 , O
perhaps P10919971A0606 RB O
indicating P10919971A0606 VBG O
increased P10919971A0606 VBN O
skeletal P10919971A0606 JJ O
muscle P10919971A0606 NN O
repair P10919971A0606 NN O
. P10919971A0606 . O
. . O O

The P11704380A1608 DT O
event P11704380A1608 NN O
rate P11704380A1608 NN O
in P11704380A1608 IN O
patients P11704380A1608 NNS O
with P11704380A1608 IN O
chronic P11704380A1608 JJ O
Irr-rMFP P11704380A1608 JJ O
or P11704380A1608 CC O
Un-nrMFP P11704380A1608 NNP O
was P11704380A1608 VBD O
markedly P11704380A1608 RB O
higher P11704380A1608 JJR O
than P11704380A1608 IN O
it P11704380A1608 PRP O
was P11704380A1608 VBD O
in P11704380A1608 IN O
those P11704380A1608 DT O
with P11704380A1608 IN O
Rev-rMFP P11704380A1608 NNP O
or P11704380A1608 CC O
Sta-nrMFP P11704380A1608 NNP O
. P11704380A1608 . O
. . O O

We P09862343A0225 PRP O
now P09862343A0225 RB O
show P09862343A0225 VBP O
that P09862343A0225 IN O
gp200-MR6 P09862343A0225 JJ O
ligation P09862343A0225 NN O
can P09862343A0225 MD O
also P09862343A0225 RB O
mimic P09862343A0225 VB O
IL-4 P09862343A0225 NNP I-UN
and P09862343A0225 CC O
have P09862343A0225 VBP O
an P09862343A0225 DT O
anti-proliferative P09862343A0225 JJ O
pro-maturational P09862343A0225 JJ O
influence P09862343A0225 NN O
within P09862343A0225 IN O
the P09862343A0225 DT O
immune P09862343A0225 NN O
system P09862343A0225 NN O
, P09862343A0225 , O
causing P09862343A0225 VBG O
up-regulation P09862343A0225 NN O
of P09862343A0225 IN O
co-stimulatory P09862343A0225 JJ O
molecules P09862343A0225 NNS O
on P09862343A0225 IN O
B P09862343A0225 NNP O
lymphocytes P09862343A0225 NNS O
. P09862343A0225 . O
. . O O

Twenty P07565031A0454 CD O
food P07565031A0454 NN O
products P07565031A0454 NNS O
were P07565031A0454 VBD O
contaminated P07565031A0454 VBN O
with P07565031A0454 IN O
V. P07565031A0454 NNP O
cholerae P07565031A0454 NN O
O1 P07565031A0454 NNP O
, P07565031A0454 , O
Ogawa P07565031A0454 NNP O
, P07565031A0454 , O
toxigenic P07565031A0454 NN O
and P07565031A0454 CC O
not P07565031A0454 RB O
toxigenic P07565031A0454 JJ O
strains P07565031A0454 NNS O
: P07565031A0454 : O
yoghurt P07565031A0454 NN O
, P07565031A0454 , O
cream P07565031A0454 NN O
cheese P07565031A0454 NN O
, P07565031A0454 , O
apricot P07565031A0454 JJ O
marmelade P07565031A0454 NN O
, P07565031A0454 , O
hip P07565031A0454 NN O
rose P07565031A0454 VBD O
marmelade P07565031A0454 NN O
, P07565031A0454 , O
mayonnaise P07565031A0454 NN O
, P07565031A0454 , O
italian P07565031A0454 JJ O
pasta P07565031A0454 NN O
for P07565031A0454 IN O
`` P07565031A0454 `` O
empanadas P07565031A0454 JJ O
'' P07565031A0454 '' O
, P07565031A0454 , O
`` P07565031A0454 `` O
dulce P07565031A0454 NN O
de P07565031A0454 FW O
leche P07565031A0454 NN O
'' P07565031A0454 '' O
, P07565031A0454 , O
meat P07565031A0454 NN O
sausage P07565031A0454 NN O
, P07565031A0454 , O
meat P07565031A0454 NN O
and P07565031A0454 CC O
spinach P07565031A0454 NN O
ravioli P07565031A0454 NN O
, P07565031A0454 , O
margarine P07565031A0454 NN O
, P07565031A0454 , O
milk P07565031A0454 NN O
dessert P07565031A0454 NN O
( P07565031A0454 ( O
made P07565031A0454 VBN O
with P07565031A0454 IN O
cocoa P07565031A0454 NN O
, P07565031A0454 , O
milk P07565031A0454 NN O
confiture P07565031A0454 NN O
, P07565031A0454 , O
starch P07565031A0454 NN O
and P07565031A0454 CC O
additives P07565031A0454 NNS O
) P07565031A0454 ) O
, P07565031A0454 , O
lettuce P07565031A0454 UH O
, P07565031A0454 , O
tuna P07565031A0454 JJ O
fish P07565031A0454 NN O
, P07565031A0454 , O
ricotta P07565031A0454 NN O
and P07565031A0454 CC O
sterilized P07565031A0454 VBN O
milk P07565031A0454 NN O
. P07565031A0454 . O
. . O O

This P08565548A0196 DT O
study P08565548A0196 NN O
determined P08565548A0196 VBD O
the P08565548A0196 DT O
arthritogenic P08565548A0196 JJ O
potential P08565548A0196 NN O
of P08565548A0196 IN O
silicone P08565548A0196 NN O
gel P08565548A0196 NN O
by P08565548A0196 IN O
either P08565548A0196 DT O
mixing P08565548A0196 VBG O
it P08565548A0196 PRP O
with P08565548A0196 IN O
bovine P08565548A0196 NN I-UN
collagen P08565548A0196 NN I-UN
II P08565548A0196 NNP I-UN
( P08565548A0196 ( O
BII P08565548A0196 NNP I-UN
) P08565548A0196 ) O
or P08565548A0196 CC O
by P08565548A0196 IN O
injecting P08565548A0196 VBG O
silicone P08565548A0196 NN O
gel P08565548A0196 NN O
alone P08565548A0196 RB O
in P08565548A0196 IN O
DA P08565548A0196 NNP O
rats P08565548A0196 NNS O
. P08565548A0196 . O
. . O O

Thus P09389669A1009 RB O
, P09389669A1009 , O
dpp P09389669A1009 NN I-UN
and P09389669A1009 CC O
omb P09389669A1009 JJ I-UN
promote P09389669A1009 NN O
both P09389669A1009 DT O
dorsal P09389669A1009 VBP O
leg P09389669A1009 NN O
cell P09389669A1009 NN O
fate P09389669A1009 NN O
as P09389669A1009 RB O
well P09389669A1009 RB O
as P09389669A1009 IN O
transdetermination-competent P09389669A1009 JJ O
leg P09389669A1009 NN O
disc P09389669A1009 NN O
cells P09389669A1009 NNS O
. P09389669A1009 . O
. . O O

MS P11108548A0710 NNP O
characteristics P11108548A0710 NNS O
of P11108548A0710 IN O
coumarins P11108548A0710 NNS O
, P11108548A0710 , O
psoralens P11108548A0710 NNS O
and P11108548A0710 CC O
polymethoxylated P11108548A0710 VBN O
flavones P11108548A0710 NNS O
with P11108548A0710 IN O
different P11108548A0710 JJ O
substitution P11108548A0710 NN O
patterns P11108548A0710 NNS O
were P11108548A0710 VBD O
determined P11108548A0710 VBN O
on P11108548A0710 IN O
the P11108548A0710 DT O
basis P11108548A0710 NN O
of P11108548A0710 IN O
the P11108548A0710 DT O
response P11108548A0710 NN O
obtained P11108548A0710 VBN O
with P11108548A0710 IN O
the P11108548A0710 DT O
APcI P11108548A0710 NNP O
interface P11108548A0710 NN O
. P11108548A0710 . O
. . O O

Defects P08406497A0000 NNS O
of P08406497A0000 IN O
fibrillin P08406497A0000 NN I-UN
( P08406497A0000 ( O
FBN1 P08406497A0000 NNP I-UN
) P08406497A0000 ) O
, P08406497A0000 , O
a P08406497A0000 DT O
glycoprotein P08406497A0000 JJ O
component P08406497A0000 NN O
of P08406497A0000 IN O
the P08406497A0000 DT O
extracellular P08406497A0000 JJ O
microfibril P08406497A0000 NN O
, P08406497A0000 , O
cause P08406497A0000 NN O
Marfan P08406497A0000 NNP O
syndrome P08406497A0000 NN O
. P08406497A0000 . O
. . O O

Expression P09539746A0781 NN O
of P09539746A0781 IN O
Bcl-XL P09539746A0781 NNP I-UN
inhibited P09539746A0781 VBD O
the P09539746A0781 DT O
association P09539746A0781 NN O
of P09539746A0781 IN O
Apaf-1 P09539746A0781 NNP I-UN
with P09539746A0781 IN O
caspase-9 P09539746A0781 NN I-UN
in P09539746A0781 IN O
mammalian P09539746A0781 JJ O
cells P09539746A0781 NNS O
. P09539746A0781 . O
. . O O

The P11162666A0442 DT O
glucose P11162666A0442 JJ O
/ P11162666A0442 NNP O
insulin P11162666A0442 NN I-UN
stimulation P11162666A0442 NN O
was P11162666A0442 VBD O
inhibited P11162666A0442 VBN O
by P11162666A0442 IN O
the P11162666A0442 DT O
addition P11162666A0442 NN O
of P11162666A0442 IN O
polyunsaturated P11162666A0442 JJ O
fatty P11162666A0442 JJ O
acids P11162666A0442 NNS O
. P11162666A0442 . O
. . O O

The P02423533A1314 DT O
levels P02423533A1314 NNS O
of P02423533A1314 IN O
both P02423533A1314 DT O
MAP1-specific P02423533A1314 NNP I-UN
and P02423533A1314 CC I-UN
MAP2-specific P02423533A1314 NNP I-UN
mRNAs P02423533A1314 NNP I-UN
decline P02423533A1314 NN O
in P02423533A1314 IN O
the P02423533A1314 DT O
postnatal P02423533A1314 JJ O
developing P02423533A1314 NN O
brain P02423533A1314 NN O
; P02423533A1314 : O
the P02423533A1314 DT O
level P02423533A1314 NN O
of P02423533A1314 IN O
MAP1-specific P02423533A1314 NNP I-UN
mRNA P02423533A1314 NN I-UN
also P02423533A1314 RB O
increases P02423533A1314 VBZ O
slightly P02423533A1314 RB O
in P02423533A1314 IN O
rat P02423533A1314 NN O
PC12 P02423533A1314 NNP O
cells P02423533A1314 NNS O
upon P02423533A1314 IN O
exposure P02423533A1314 NN O
to P02423533A1314 TO O
nerve P02423533A1314 VB I-UN
growth P02423533A1314 NN I-UN
factor P02423533A1314 NN I-UN
. P02423533A1314 . O
. . O O

The P11030066A0142 DT O
major P11030066A0142 JJ O
neurological P11030066A0142 JJ O
manifestations P11030066A0142 NNS O
of P11030066A0142 IN O
brain P11030066A0142 NN O
injury P11030066A0142 NN O
in P11030066A0142 IN O
these P11030066A0142 DT O
babies P11030066A0142 NNS O
are P11030066A0142 VBP O
spastic P11030066A0142 JJ O
motor P11030066A0142 NN O
deficits P11030066A0142 NNS O
. P11030066A0142 . O
. . O O

To P08986214A0000 TO O
evaluate P08986214A0000 VB O
the P08986214A0000 DT O
hepatic P08986214A0000 JJ O
regenerative P08986214A0000 JJ O
response P08986214A0000 NN O
in P08986214A0000 IN O
patients P08986214A0000 NNS O
with P08986214A0000 IN O
alcoholic P08986214A0000 JJ O
liver P08986214A0000 NN O
disease P08986214A0000 NN O
, P08986214A0000 , O
sera P08986214A0000 NN O
from P08986214A0000 IN O
263 P08986214A0000 CD O
patients P08986214A0000 NNS O
with P08986214A0000 IN O
severe P08986214A0000 JJ O
alcoholic P08986214A0000 JJ O
hepatitis P08986214A0000 NN O
and P08986214A0000 CC O
/ P08986214A0000 NN O
or P08986214A0000 CC O
cirrhosis P08986214A0000 NN O
were P08986214A0000 VBD O
analyzed P08986214A0000 VBN O
for P08986214A0000 IN O
hepatocyte P08986214A0000 NN I-UN
growth P08986214A0000 NN I-UN
factor P08986214A0000 NN I-UN
( P08986214A0000 ( O
HGF P08986214A0000 NNP I-UN
) P08986214A0000 ) O
and P08986214A0000 CC O
alpha-fetoprotein P08986214A0000 JJ I-UN
( P08986214A0000 ( O
AFP P08986214A0000 NNP I-UN
) P08986214A0000 ) O
. P08986214A0000 . O
. . O O

A P00378735A0000 DT O
randomized P00378735A0000 JJ O
clinical P00378735A0000 JJ O
trial P00378735A0000 NN O
in P00378735A0000 IN O
sixty-two P00378735A0000 JJ O
adult P00378735A0000 NN O
patients P00378735A0000 NNS O
suffering P00378735A0000 VBG O
from P00378735A0000 IN O
typhoid P00378735A0000 JJ O
fever P00378735A0000 NN O
, P00378735A0000 , O
proved P00378735A0000 VBN O
by P00378735A0000 IN O
blood P00378735A0000 NN O
and P00378735A0000 CC O
marrow P00378735A0000 JJ O
culture P00378735A0000 NN O
, P00378735A0000 , O
showed P00378735A0000 VBD O
that P00378735A0000 IN O
amoxycillin P00378735A0000 NN O
in P00378735A0000 IN O
a P00378735A0000 DT O
dosage P00378735A0000 NN O
schedule P00378735A0000 NN O
of P00378735A0000 IN O
1 P00378735A0000 CD O
g P00378735A0000 JJ O
8-hourly P00378735A0000 JJ O
orally P00378735A0000 RB O
for P00378735A0000 IN O
fourteen P00378735A0000 JJ O
days P00378735A0000 NNS O
was P00378735A0000 VBD O
better P00378735A0000 JJR O
than P00378735A0000 IN O
chloramphenicol P00378735A0000 NN O
with P00378735A0000 IN O
regard P00378735A0000 NN O
to P00378735A0000 TO O
clinical P00378735A0000 JJ O
and P00378735A0000 CC O
temperature P00378735A0000 JJ O
response P00378735A0000 NN O
and P00378735A0000 CC O
in P00378735A0000 IN O
respect P00378735A0000 NN O
of P00378735A0000 IN O
carriers P00378735A0000 NNS O
and P00378735A0000 CC O
relapse P00378735A0000 NN O
rates P00378735A0000 NNS O
. P00378735A0000 . O
. . O O

These P07615634A0535 DT O
transcripts P07615634A0535 NNS O
have P07615634A0535 VBP O
a P07615634A0535 DT O
unique P07615634A0535 JJ O
5'untranslated P07615634A0535 CD O
region P07615634A0535 NN O
and P07615634A0535 CC O
NH2-terminal P07615634A0535 JJ O
sequence P07615634A0535 NN O
and P07615634A0535 CC O
encode P07615634A0535 VB O
a P07615634A0535 DT O
predicted P07615634A0535 JJ O
protein P07615634A0535 NN O
of P07615634A0535 IN O
121 P07615634A0535 CD O
kD P07615634A0535 NNS O
. P07615634A0535 . O
. . O O

For P09293006A1412 IN O
higher P09293006A1412 JJR O
expression P09293006A1412 NN O
of P09293006A1412 IN O
lipA P09293006A1412 NN I-UN
in P09293006A1412 IN O
S. P09293006A1412 NNP O
lividans P09293006A1412 NNS O
, P09293006A1412 , O
the P09293006A1412 DT O
gene P09293006A1412 NN O
was P09293006A1412 VBD O
cloned P09293006A1412 VBN O
next P09293006A1412 JJ O
to P09293006A1412 TO O
the P09293006A1412 DT O
strong P09293006A1412 JJ O
aphII P09293006A1412 NN I-UN
promoter P09293006A1412 NN I-UN
. P09293006A1412 . O
. . O O

Interleukin-6 P09452444A0000 NNP I-UN
( P09452444A0000 ( O
IL-6 P09452444A0000 NNP I-UN
) P09452444A0000 ) O
is P09452444A0000 VBZ O
a P09452444A0000 DT O
pleiotropic P09452444A0000 JJ O
cytokine P09452444A0000 NN O
, P09452444A0000 , O
which P09452444A0000 WDT O
is P09452444A0000 VBZ O
involved P09452444A0000 VBN O
in P09452444A0000 IN O
inflammatory P09452444A0000 NN O
and P09452444A0000 CC O
immune P09452444A0000 JJ O
responses P09452444A0000 NNS O
, P09452444A0000 , O
acute P09452444A0000 JJ O
phase P09452444A0000 NN O
reactions P09452444A0000 NNS O
, P09452444A0000 , O
and P09452444A0000 CC O
hematopoiesis P09452444A0000 NN O
. P09452444A0000 . O
. . O O

The P08820642A0173 DT O
harpin-encoding P08820642A0173 JJ O
hrpZ P08820642A0173 NN I-UN
gene P08820642A0173 NN I-UN
is P08820642A0173 VBZ O
located P08820642A0173 VBN O
in P08820642A0173 IN O
an P08820642A0173 DT O
operon P08820642A0173 NN O
that P08820642A0173 WDT O
also P08820642A0173 RB O
encodes P08820642A0173 VBZ O
Hrp P08820642A0173 NNP I-UN
secretion P08820642A0173 NN I-UN
pathway P08820642A0173 NN I-UN
components P08820642A0173 NNS I-UN
and P08820642A0173 CC O
is P08820642A0173 VBZ O
part P08820642A0173 NN O
of P08820642A0173 IN O
the P08820642A0173 DT O
functional P08820642A0173 JJ O
cluster P08820642A0173 NN O
of P08820642A0173 IN O
hrp P08820642A0173 NN I-UN
genes P08820642A0173 NNS I-UN
carried P08820642A0173 VBD O
on P08820642A0173 IN O
cosmid P08820642A0173 NN O
pHIR11 P08820642A0173 NN O
that P08820642A0173 WDT O
enables P08820642A0173 VBZ O
saprophytic P08820642A0173 JJ O
bacteria P08820642A0173 NNS O
like P08820642A0173 IN O
Escherichia P08820642A0173 NNP O
coli P08820642A0173 NNS O
and P08820642A0173 CC O
Pseudomonas P08820642A0173 NNP O
fluorescens P08820642A0173 VBZ O
to P08820642A0173 TO O
elicit P08820642A0173 VB O
the P08820642A0173 DT O
HR P08820642A0173 NNP O
in P08820642A0173 IN O
tobacco P08820642A0173 NN O
leaves P08820642A0173 NNS O
. P08820642A0173 . O
. . O O

Increased P07524265T0000 VBN O
granulocyte-colony P07524265T0000 JJ I-UN
stimulating P07524265T0000 NN I-UN
factor P07524265T0000 NN I-UN
( P07524265T0000 ( O
G-CSF P07524265T0000 NNP I-UN
) P07524265T0000 ) O
levels P07524265T0000 NNS O
in P07524265T0000 IN O
neonates P07524265T0000 NNS O
with P07524265T0000 IN O
perinatal P07524265T0000 JJ O
complications P07524265T0000 NNS O
. P07524265T0000 . O
. . O O

AB004534 P10620777A1399 NNP I-UN
. P10620777A1399 . O
. . O O

CONCLUSION P10950415A0866 NN O
: P10950415A0866 : O
Vitrectomy P10950415A0866 NN O
for P10950415A0866 IN O
vitreous P10950415A0866 JJ O
hemorrhage P10950415A0866 NN O
in P10950415A0866 IN O
Terson P10950415A0866 NNP O
syndrome P10950415A0866 NN O
is P10950415A0866 VBZ O
a P10950415A0866 DT O
safe P10950415A0866 JJ O
and P10950415A0866 CC O
effective P10950415A0866 JJ O
procedure P10950415A0866 NN O
, P10950415A0866 , O
offering P10950415A0866 VBG O
a P10950415A0866 DT O
rapid P10950415A0866 JJ O
and P10950415A0866 CC O
prolonged P10950415A0866 JJ O
improvement P10950415A0866 NN O
in P10950415A0866 IN O
vision P10950415A0866 NN O
. P10950415A0866 . O
. . O O

Regulation P11114521A0282 NN O
of P11114521A0282 IN O
RhoA P11114521A0282 NNP I-UN
is P11114521A0282 VBZ O
required P11114521A0282 VBN O
to P11114521A0282 TO O
maintain P11114521A0282 VB O
adhesion P11114521A0282 NN O
in P11114521A0282 IN O
stationary P11114521A0282 JJ O
cells P11114521A0282 NNS O
, P11114521A0282 , O
but P11114521A0282 CC O
is P11114521A0282 VBZ O
also P11114521A0282 RB O
critical P11114521A0282 JJ O
for P11114521A0282 IN O
cell P11114521A0282 NN O
spreading P11114521A0282 NN O
and P11114521A0282 CC O
migration P11114521A0282 NN O
[ P11114521A0282 VBP O
3 P11114521A0282 CD O
] P11114521A0282 NN O
. P11114521A0282 . O
. . O O

This P07772036A1000 DT O
region P07772036A1000 NN O
binds P07772036A1000 VBZ O
two P07772036A1000 CD O
ubiquitous P07772036A1000 JJ O
nuclear P07772036A1000 JJ O
factors P07772036A1000 NNS O
, P07772036A1000 , O
USF P07772036A1000 NNP I-UN
/ P07772036A1000 NNP O
MLTF P07772036A1000 NNP I-UN
and P07772036A1000 CC O
the P07772036A1000 DT O
CAAT-binding P07772036A1000 JJ I-UN
transcription P07772036A1000 NN I-UN
factor P07772036A1000 NN I-UN
/ P07772036A1000 JJ O
nuclear P07772036A1000 JJ I-UN
factor P07772036A1000 NN I-UN
1 P07772036A1000 CD I-UN
( P07772036A1000 ( O
CTF P07772036A1000 NNP I-UN
/ P07772036A1000 NNP O
NF1 P07772036A1000 NNP I-UN
) P07772036A1000 ) O
. P07772036A1000 . O
. . O O

Lower P02808232A0681 JJR O
limits P02808232A0681 NNS O
( P02808232A0681 ( O
to P02808232A0681 TO O
10 P02808232A0681 CD O
micrograms P02808232A0681 NNS O
/ P02808232A0681 NNP O
kg P02808232A0681 NN O
) P02808232A0681 ) O
were P02808232A0681 VBD O
detectable P02808232A0681 JJ O
, P02808232A0681 , O
but P02808232A0681 CC O
with P02808232A0681 IN O
lower P02808232A0681 JJR O
reliability P02808232A0681 NN O
( P02808232A0681 ( O
60 P02808232A0681 CD O
% P02808232A0681 NN O
) P02808232A0681 ) O
. P02808232A0681 . O
. . O O

PROCEDURE P11592315A0325 NN O
: P11592315A0325 : O
Cannulas P11592315A0325 NNS O
were P11592315A0325 VBD O
surgically P11592315A0325 RB O
positioned P11592315A0325 VBN O
in P11592315A0325 IN O
the P11592315A0325 DT O
abomasal P11592315A0325 NN O
body P11592315A0325 NN O
and P11592315A0325 CC O
pyloric P11592315A0325 JJ O
antrum P11592315A0325 NN O
of P11592315A0325 IN O
each P11592315A0325 DT O
calf P11592315A0325 NN O
. P11592315A0325 . O
. . O O

A P01294345A0591 DT O
statistically P01294345A0591 RB O
significant P01294345A0591 JJ O
improvement P01294345A0591 NN O
due P01294345A0591 JJ O
to P01294345A0591 TO O
the P01294345A0591 DT O
administration P01294345A0591 NN O
of P01294345A0591 IN O
Bromergon P01294345A0591 NNP O
was P01294345A0591 VBD O
observed P01294345A0591 VBN O
in P01294345A0591 IN O
symptoms P01294345A0591 NNS O
associated P01294345A0591 VBN O
with P01294345A0591 IN O
overreactiveness P01294345A0591 NN O
to P01294345A0591 TO O
normal P01294345A0591 JJ O
prolactin P01294345A0591 NN I-UN
levels P01294345A0591 NNS O
, P01294345A0591 , O
i.e P01294345A0591 NN O
. P01294345A0591 . O
abdominal P01294345A0591 JJ O
tension P01294345A0591 NN O
, P01294345A0591 , O
edema P01294345A0591 NN O
, P01294345A0591 , O
weight P01294345A0591 VBD O
gain P01294345A0591 NN O
and P01294345A0591 CC O
breast P01294345A0591 NN O
tenderness P01294345A0591 NN O
. P01294345A0591 . O
. . O O

Immunofluorescence P11160896A0713 NN O
studies P11160896A0713 NNS O
in P11160896A0713 IN O
C2C12 P11160896A0713 NNP O
myotubes P11160896A0713 NNP O
show P11160896A0713 VBP O
that P11160896A0713 IN O
Smad2 P11160896A0713 NNP I-UN
and P11160896A0713 CC O
MEF2A P11160896A0713 NNP I-UN
co-localise P11160896A0713 NN O
in P11160896A0713 IN O
the P11160896A0713 DT O
nucleus P11160896A0713 NN O
of P11160896A0713 IN O
multinuclear P11160896A0713 JJ O
myotubes P11160896A0713 NNS O
during P11160896A0713 IN O
differentiation P11160896A0713 NN O
. P11160896A0713 . O
. . O O

Familial P04764049T0001 NNP O
juvenile P04764049T0001 NN O
nephronophthisis P04764049T0001 NN O
. P04764049T0001 . O
. . O O

Purification P09514272A0482 NN O
of P09514272A0482 IN O
MvaT P09514272A0482 NNP I-UN
enriched P09514272A0482 VBD O
for P09514272A0482 IN O
two P09514272A0482 CD O
polypeptides P09514272A0482 NNS O
of P09514272A0482 IN O
approximate P09514272A0482 JJ O
molecular P09514272A0482 JJ O
mass P09514272A0482 NN O
15 P09514272A0482 CD O
kDa P09514272A0482 NN O
and P09514272A0482 CC O
16 P09514272A0482 CD O
kDa P09514272A0482 NN O
, P09514272A0482 , O
designated P09514272A0482 VBN O
P15 P09514272A0482 NNP I-UN
and P09514272A0482 CC O
P16 P09514272A0482 NNP I-UN
. P09514272A0482 . O
. . O O

Lipiodol P07789396A0504 NNP O
was P07789396A0504 VBD O
covalently P07789396A0504 RB O
conjugated P07789396A0504 VBN O
with P07789396A0504 IN O
EDTB P07789396A0504 NNP O
. P07789396A0504 . O
. . O O

These P00485615A0935 DT O
data P00485615A0935 NNS O
confirm P00485615A0935 VBP O
the P00485615A0935 DT O
existence P00485615A0935 NN O
of P00485615A0935 IN O
hyperlipemic P00485615A0935 JJ O
abdominal P00485615A0935 JJ O
crisis P00485615A0935 NN O
as P00485615A0935 IN O
a P00485615A0935 DT O
distinct P00485615A0935 JJ O
entity P00485615A0935 NN O
and P00485615A0935 CC O
testify P00485615A0935 VB O
to P00485615A0935 TO O
the P00485615A0935 DT O
importance P00485615A0935 NN O
of P00485615A0935 IN O
recognizing P00485615A0935 VBG O
this P00485615A0935 DT O
syndrome P00485615A0935 NN O
in P00485615A0935 IN O
order P00485615A0935 NN O
to P00485615A0935 TO O
avoid P00485615A0935 VB O
the P00485615A0935 DT O
occurrence P00485615A0935 NN O
of P00485615A0935 IN O
acute P00485615A0935 JJ O
pancreatitis P00485615A0935 NN O
and P00485615A0935 CC O
the P00485615A0935 DT O
performance P00485615A0935 NN O
of P00485615A0935 IN O
unnecessary P00485615A0935 JJ O
and P00485615A0935 CC O
potentially P00485615A0935 RB O
harmful P00485615A0935 JJ O
surgery P00485615A0935 NN O
. P00485615A0935 . O
. . O O

All P08160054A0224 DT O
patients P08160054A0224 NNS O
with P08160054A0224 IN O
deterioriation P08160054A0224 NN O
in P08160054A0224 IN O
mental P08160054A0224 JJ O
status P08160054A0224 NN O
showed P08160054A0224 VBD O
a P08160054A0224 DT O
marked P08160054A0224 JJ O
increase P08160054A0224 NN O
in P08160054A0224 IN O
liver P08160054A0224 JJ O
enzymes P08160054A0224 NNS O
( P08160054A0224 ( O
aspartate P08160054A0224 NN I-UN
and P08160054A0224 CC I-UN
alanine P08160054A0224 JJ I-UN
aminotransaminases P08160054A0224 NNS I-UN
) P08160054A0224 ) O
and P08160054A0224 CC O
severe P08160054A0224 JJ O
coagulopathy P08160054A0224 NN O
. P08160054A0224 . O
. . O O

We P09557678A0140 PRP O
previously P09557678A0140 RB O
demonstrated P09557678A0140 VBD O
that P09557678A0140 IN O
acute P09557678A0140 JJ O
expression P09557678A0140 NN O
of P09557678A0140 IN O
the P09557678A0140 DT O
bovine P09557678A0140 NN O
papillomavirus P09557678A0140 NN O
type P09557678A0140 NN O
1 P09557678A0140 CD O
( P09557678A0140 ( O
BPV1 P09557678A0140 NNP O
) P09557678A0140 ) O
E2 P09557678A0140 NNP I-UN
protein P09557678A0140 NN I-UN
in P09557678A0140 IN O
HeLa P09557678A0140 NNP O
and P09557678A0140 CC O
HT-3 P09557678A0140 NNP O
cervical P09557678A0140 JJ O
carcinoma P09557678A0140 NN O
cell P09557678A0140 NN O
lines P09557678A0140 NNS O
greatly P09557678A0140 RB O
reduced P09557678A0140 VBD O
cellular P09557678A0140 JJ O
proliferation P09557678A0140 NN O
by P09557678A0140 IN O
imposing P09557678A0140 VBG O
a P09557678A0140 DT O
specific P09557678A0140 JJ O
G1 P09557678A0140 NNP O
/ P09557678A0140 NNP O
S P09557678A0140 NNP O
phase P09557678A0140 NN O
growth P09557678A0140 NN O
arrest P09557678A0140 NN O
. P09557678A0140 . O
. . O O

To P11169149A0097 TO O
the P11169149A0097 DT O
best P11169149A0097 JJS O
of P11169149A0097 IN O
our P11169149A0097 PRP$ O
knowledge P11169149A0097 NN O
, P11169149A0097 , O
SNTCS P11169149A0097 NNP O
is P11169149A0097 VBZ O
highly P11169149A0097 RB O
malignant P11169149A0097 JJ O
. P11169149A0097 . O
. . O O

Transcription P07537851A0000 NN O
of P07537851A0000 IN O
the P07537851A0000 DT O
vascular P07537851A0000 NN I-UN
cell P07537851A0000 NN I-UN
adhesion P07537851A0000 NN I-UN
molecule P07537851A0000 NN I-UN
1 P07537851A0000 CD I-UN
( P07537851A0000 ( O
VCAM-1 P07537851A0000 NNP I-UN
) P07537851A0000 ) O
gene P07537851A0000 NN O
in P07537851A0000 IN O
endothelial P07537851A0000 JJ O
cells P07537851A0000 NNS O
is P07537851A0000 VBZ O
induced P07537851A0000 VBN O
by P07537851A0000 IN O
lipopolysaccharide P07537851A0000 NN O
and P07537851A0000 CC O
the P07537851A0000 DT O
inflammatory P07537851A0000 JJ O
cytokines P07537851A0000 NNS I-UN
interleukin-1 P07537851A0000 JJ I-UN
beta P07537851A0000 NN I-UN
and P07537851A0000 CC O
tumor P07537851A0000 NN I-UN
necrosis P07537851A0000 NN I-UN
factor P07537851A0000 NN I-UN
alpha P07537851A0000 NN I-UN
( P07537851A0000 ( O
TNF-alpha P07537851A0000 NNP I-UN
) P07537851A0000 ) O
. P07537851A0000 . O
. . O O

In P10463057A0534 IN O
vitro P10463057A0534 JJ O
expression P10463057A0534 NN O
levels P10463057A0534 NNS O
of P10463057A0534 IN O
the P10463057A0534 DT O
different P10463057A0534 JJ O
plasmids P10463057A0534 NNS O
differed P10463057A0534 VBN O
by P10463057A0534 IN O
as P10463057A0534 RB O
much P10463057A0534 JJ O
as P10463057A0534 IN O
tenfold P10463057A0534 NN O
. P10463057A0534 . O
. . O O

Thereafter P07757315A1227 RB O
, P07757315A1227 , O
the P07757315A1227 DT O
aggregation P07757315A1227 NN O
rose P07757315A1227 VBD O
to P07757315A1227 TO O
the P07757315A1227 DT O
initial P07757315A1227 JJ O
100 P07757315A1227 CD O
% P07757315A1227 NN O
value P07757315A1227 NN O
4 P07757315A1227 CD O
h P07757315A1227 NN O
after P07757315A1227 IN O
drug P07757315A1227 NN O
application P07757315A1227 NN O
and P07757315A1227 CC O
remained P07757315A1227 VBD O
at P07757315A1227 IN O
this P07757315A1227 DT O
level P07757315A1227 NN O
during P07757315A1227 IN O
the P07757315A1227 DT O
observation P07757315A1227 NN O
period P07757315A1227 NN O
. P07757315A1227 . O
( P07757315A1227 ( O
ABSTRACT P07757315A1227 NNP O
TRUNCATED P07757315A1227 NNP O
AT P07757315A1227 NNP O
250 P07757315A1227 CD O
WORDS P07757315A1227 NNP O
) P07757315A1227 ) O
. P07757315A1227 . O
. . O O

The P10544089A1208 DT O
RNA P10544089A1208 NNP O
transcripts P10544089A1208 NNS O
structurally P10544089A1208 RB O
equivalent P10544089A1208 JJ O
to P10544089A1208 TO O
I P10544089A1208 PRP I-UN
( P10544089A1208 ( I-UN
2 P10544089A1208 CD I-UN
) P10544089A1208 ) I-UN
sgRNAs P10544089A1208 NN I-UN
of P10544089A1208 IN O
TMV P10544089A1208 NNP I-UN
U1 P10544089A1208 NNP I-UN
and P10544089A1208 CC O
crTMV P10544089A1208 NN O
, P10544089A1208 , O
but P10544089A1208 CC O
containing P10544089A1208 VBG O
a P10544089A1208 DT O
hairpin P10544089A1208 NN O
structure P10544089A1208 NN O
( P10544089A1208 ( O
H P10544089A1208 NNP O
) P10544089A1208 ) O
immediately P10544089A1208 RB O
upstream P10544089A1208 NN O
of P10544089A1208 IN O
IRES P10544089A1208 NNP I-UN
( P10544089A1208 ( I-UN
MP,75 P10544089A1208 NNP I-UN
) P10544089A1208 ) I-UN
( P10544089A1208 ( I-UN
HIRES P10544089A1208 NNP I-UN
( P10544089A1208 ( I-UN
MP P10544089A1208 NNP I-UN
) P10544089A1208 ) I-UN
, P10544089A1208 , I-UN
( P10544089A1208 ( I-UN
75 P10544089A1208 CD I-UN
) P10544089A1208 ) I-UN
( P10544089A1208 ( I-UN
CR P10544089A1208 NNP I-UN
) P10544089A1208 ) I-UN
-MP-CP-3'UTR P10544089A1208 VBP I-UN
; P10544089A1208 : O
HIRES P10544089A1208 NNP I-UN
( P10544089A1208 ( I-UN
MP,75 P10544089A1208 NNP I-UN
) P10544089A1208 ) I-UN
( P10544089A1208 ( I-UN
U1 P10544089A1208 NNP I-UN
) P10544089A1208 ) I-UN
-MP-CP-3'UTR P10544089A1208 NN I-UN
) P10544089A1208 ) O
, P10544089A1208 , O
were P10544089A1208 VBD O
able P10544089A1208 JJ O
to P10544089A1208 TO O
express P10544089A1208 VB O
the P10544089A1208 DT O
MP P10544089A1208 NNP I-UN
gene P10544089A1208 NN I-UN
in P10544089A1208 IN O
vitro P10544089A1208 NN O
. P10544089A1208 . O
. . O O

On P10972688A1272 IN O
long-term P10972688A1272 JJ O
follow-up P10972688A1272 NN O
, P10972688A1272 , O
there P10972688A1272 EX O
was P10972688A1272 VBD O
no P10972688A1272 DT O
significant P10972688A1272 JJ O
difference P10972688A1272 NN O
in P10972688A1272 IN O
the P10972688A1272 DT O
incidence P10972688A1272 NN O
of P10972688A1272 IN O
hospitalizations P10972688A1272 NNS O
( P10972688A1272 ( O
1 P10972688A1272 CD O
per P10972688A1272 IN O
2.1 P10972688A1272 CD O
vs P10972688A1272 NN O
. P10972688A1272 . O
. . O O

Diet P09412079T0001 NNP O
therapy P09412079T0001 NN O
with P09412079T0001 IN O
soy P09412079T0001 JJ O
proteins P09412079T0001 NNS O
for P09412079T0001 IN O
chronic P09412079T0001 JJ O
stomach P09412079T0001 NN O
ulcers P09412079T0001 NNS O
. P09412079T0001 . O
. . O O

Biochemical P02022188A0112 JJ O
analysis P02022188A0112 NN O
demonstrates P02022188A0112 VBZ O
that P02022188A0112 IN O
the P02022188A0112 DT O
BJ1 P02022188A0112 NNP I-UN
protein P02022188A0112 NN I-UN
is P02022188A0112 VBZ O
associated P02022188A0112 VBN O
with P02022188A0112 IN O
nucleosomes P02022188A0112 NNS O
and P02022188A0112 CC O
is P02022188A0112 VBZ O
released P02022188A0112 VBN O
from P02022188A0112 IN O
chromatin P02022188A0112 NN O
by P02022188A0112 IN O
agents P02022188A0112 NNS O
which P02022188A0112 WDT O
intercalate P02022188A0112 VBP O
into P02022188A0112 IN O
DNA P02022188A0112 NNP O
, P02022188A0112 , O
as P02022188A0112 IN O
previously P02022188A0112 RB O
shown P02022188A0112 VBN O
for P02022188A0112 IN O
the P02022188A0112 DT O
high P02022188A0112 JJ I-UN
mobility P02022188A0112 NN I-UN
group P02022188A0112 NN I-UN
proteins P02022188A0112 VBZ I-UN
( P02022188A0112 ( O
HMGs P02022188A0112 NNP I-UN
) P02022188A0112 ) O
. P02022188A0112 . O
. . O O

A P09003617A0000 DT O
cohort P09003617A0000 NN O
of P09003617A0000 IN O
Swedish P09003617A0000 JJ O
children P09003617A0000 NNS O
was P09003617A0000 VBD O
monitored P09003617A0000 VBN O
from P09003617A0000 IN O
6 P09003617A0000 CD O
months P09003617A0000 NNS O
to P09003617A0000 TO O
11 P09003617A0000 CD O
years P09003617A0000 NNS O
of P09003617A0000 IN O
age P09003617A0000 NN O
. P09003617A0000 . O
. . O O

Doxorubicin P11703558A0000 NNP O
( P11703558A0000 ( O
DOX P11703558A0000 NNP O
) P11703558A0000 ) O
is P11703558A0000 VBZ O
commonly P11703558A0000 RB O
used P11703558A0000 VBN O
for P11703558A0000 IN O
the P11703558A0000 DT O
treatment P11703558A0000 NN O
of P11703558A0000 IN O
hematological P11703558A0000 JJ O
and P11703558A0000 CC O
solid P11703558A0000 JJ O
tumors P11703558A0000 NNS O
. P11703558A0000 . O
. . O O

In P04063732A0509 IN O
controls P04063732A0509 NNS O
, P04063732A0509 , O
most P04063732A0509 JJS O
of P04063732A0509 IN O
the P04063732A0509 DT O
output P04063732A0509 NN O
from P04063732A0509 IN O
the P04063732A0509 DT O
conduit P04063732A0509 NN O
occurred P04063732A0509 VBD O
during P04063732A0509 IN O
type P04063732A0509 NN O
I P04063732A0509 PRP O
activity P04063732A0509 NN O
( P04063732A0509 ( O
73 P04063732A0509 CD O
+ P04063732A0509 NN O
/ P04063732A0509 NNP O
- P04063732A0509 : O
14 P04063732A0509 CD O
% P04063732A0509 NN O
) P04063732A0509 ) O
. P04063732A0509 . O
. . O O

Oligonucleotide P08264628A0418 IN O
competitors P08264628A0418 NNS O
were P08264628A0418 VBD O
used P08264628A0418 VBN O
to P08264628A0418 TO O
evaluate P08264628A0418 VB O
the P08264628A0418 DT O
accessibility P08264628A0418 NN O
of P08264628A0418 IN O
the P08264628A0418 DT O
TATA-binding P08264628A0418 NNP O
site P08264628A0418 NN O
in P08264628A0418 IN O
TIF-IB P08264628A0418 NNP I-UN
, P08264628A0418 , O
TFIID P08264628A0418 NNP I-UN
, P08264628A0418 , O
and P08264628A0418 CC O
TFIIIB P08264628A0418 NNP I-UN
. P08264628A0418 . O
. . O O

A P02548683T0001 DT O
brief P02548683T0001 JJ O
account P02548683T0001 NN O
of P02548683T0001 IN O
the P02548683T0001 DT O
1988 P02548683T0001 CD O
seminar P02548683T0001 NN O
in P02548683T0001 IN O
Shanghai P02548683T0001 NNP O
on P02548683T0001 IN O
viral P02548683T0001 JJ O
hepatitis P02548683T0001 NN O
A P02548683T0001 NNP O
. P02548683T0001 . O
. . O O

Cardiac P09035612T0000 NNP I-UN
endothelin P09035612T0000 NN I-UN
release P09035612T0000 NN O
and P09035612T0000 CC O
infarct P09035612T0000 NN O
size P09035612T0000 NN O
, P09035612T0000 , O
myocardial P09035612T0000 JJ O
blood P09035612T0000 NN O
flow P09035612T0000 NN O
, P09035612T0000 , O
and P09035612T0000 CC O
ventricular P09035612T0000 JJ O
function P09035612T0000 NN O
in P09035612T0000 IN O
canine P09035612T0000 JJ O
infarction P09035612T0000 NN O
and P09035612T0000 CC O
reperfusion P09035612T0000 NN O
. P09035612T0000 . O
. . O O

Cytomegalovirus P11179272T0000 NNP O
, P11179272T0000 , O
Chlamydia P11179272T0000 NNP O
pneumoniae P11179272T0000 NN O
, P11179272T0000 , O
and P11179272T0000 CC O
Helicobacter P11179272T0000 NNP O
pylori P11179272T0000 VBP O
IgG P11179272T0000 NNP I-UN
antibodies P11179272T0000 NNS I-UN
and P11179272T0000 CC O
restenosis P11179272T0000 NN O
after P11179272T0000 IN O
stent P11179272T0000 JJ O
implantation P11179272T0000 NN O
: P11179272T0000 : O
an P11179272T0000 DT O
angiographic P11179272T0000 JJ O
and P11179272T0000 CC O
intravascular P11179272T0000 JJ O
ultrasound P11179272T0000 NN O
study P11179272T0000 NN O
. P11179272T0000 . O
. . O O

Moreover P01895393A0745 RB O
, P01895393A0745 , O
promoters P01895393A0745 NNS O
containing P01895393A0745 VBG O
a P01895393A0745 DT O
TATA P01895393A0745 NNP O
box P01895393A0745 NN O
in P01895393A0745 IN O
the P01895393A0745 DT O
absence P01895393A0745 NN O
of P01895393A0745 IN O
Sp1 P01895393A0745 NNP I-UN
sites P01895393A0745 NNS I-UN
or P01895393A0745 CC O
Sp1 P01895393A0745 NNP I-UN
sites P01895393A0745 NNS I-UN
in P01895393A0745 IN O
the P01895393A0745 DT O
absence P01895393A0745 NN O
of P01895393A0745 IN O
a P01895393A0745 DT O
TATA P01895393A0745 NNP O
box P01895393A0745 NN O
were P01895393A0745 VBD O
equally P01895393A0745 RB O
inducible P01895393A0745 JJ O
in P01895393A0745 IN O
vitro P01895393A0745 NN O
, P01895393A0745 , O
as P01895393A0745 IN O
was P01895393A0745 VBD O
an P01895393A0745 DT O
RNA P01895393A0745 NNP I-UN
polymerase P01895393A0745 NN I-UN
III P01895393A0745 NNP I-UN
promoter P01895393A0745 NN I-UN
. P01895393A0745 . O
. . O O

By P08492290A0306 IN O
applying P08492290A0306 VBG O
the P08492290A0306 DT O
potentiometric P08492290A0306 JJ O
method P08492290A0306 NN O
, P08492290A0306 , O
in P08492290A0306 IN O
aqueous P08492290A0306 JJ O
medium P08492290A0306 NN O
of P08492290A0306 IN O
ionic P08492290A0306 JJ O
strength P08492290A0306 NN O
mu P08492290A0306 NN O
= P08492290A0306 NN O
0.2 P08492290A0306 CD O
, P08492290A0306 , O
the P08492290A0306 DT O
stability P08492290A0306 NN O
constants P08492290A0306 NNS O
, P08492290A0306 , O
log P08492290A0306 NN O
beta P08492290A0306 NN O
1 P08492290A0306 CD O
= P08492290A0306 NN O
4.42 P08492290A0306 CD O
and P08492290A0306 CC O
log P08492290A0306 JJR O
beta P08492290A0306 NN O
2 P08492290A0306 CD O
= P08492290A0306 NN O
8.57 P08492290A0306 CD O
were P08492290A0306 VBD O
obtained P08492290A0306 VBN O
. P08492290A0306 . O
. . O O

The P09405380A0800 DT O
existence P09405380A0800 NN O
of P09405380A0800 IN O
these P09405380A0800 DT O
two P09405380A0800 CD O
categories P09405380A0800 NNS O
of P09405380A0800 IN O
strains P09405380A0800 NNS O
offers P09405380A0800 NNS O
a P09405380A0800 DT O
new P09405380A0800 JJ O
genetic P09405380A0800 JJ O
system P09405380A0800 NN O
in P09405380A0800 IN O
which P09405380A0800 WDT O
the P09405380A0800 DT O
properties P09405380A0800 NNS O
of P09405380A0800 IN O
a P09405380A0800 DT O
potential P09405380A0800 JJ O
invertebrate P09405380A0800 NN O
retrovirus P09405380A0800 NN O
can P09405380A0800 MD O
be P09405380A0800 VB O
tested P09405380A0800 VBN O
. P09405380A0800 . O
. . O O

Eleven P00846559A0000 NNP O
strains P00846559A0000 NNS O
of P00846559A0000 IN O
Fusarium P00846559A0000 NNP O
poae P00846559A0000 NN O
and P00846559A0000 CC O
F. P00846559A0000 NNP O
sporotrichioides P00846559A0000 NNS O
from P00846559A0000 IN O
the P00846559A0000 DT O
U.S.S.R. P00846559A0000 NNP O
and P00846559A0000 CC O
7 P00846559A0000 CD O
strains P00846559A0000 NNS O
of P00846559A0000 IN O
these P00846559A0000 DT O
species P00846559A0000 NNS O
and P00846559A0000 CC O
one P00846559A0000 CD O
of P00846559A0000 IN O
F. P00846559A0000 NNP O
sporotrichioides P00846559A0000 NNS O
var P00846559A0000 NN O
. P00846559A0000 . O
tricinctum P00846559A0000 NN O
from P00846559A0000 IN O
U.S.A. P00846559A0000 NNP O
and P00846559A0000 CC O
France P00846559A0000 NNP O
have P00846559A0000 VBP O
been P00846559A0000 VBN O
compared P00846559A0000 VBN O
as P00846559A0000 IN O
to P00846559A0000 TO O
their P00846559A0000 PRP$ O
capacity P00846559A0000 NN O
to P00846559A0000 TO O
yield P00846559A0000 VB O
T-2 P00846559A0000 NNP I-UN
toxin P00846559A0000 NN I-UN
. P00846559A0000 . O
. . O O

Effect P07298523T0000 NN O
of P07298523T0000 IN O
indomethacin P07298523T0000 NN O
and P07298523T0000 CC O
prostaglandin P07298523T0000 NN O
F2 P07298523T0000 NNP O
alpha P07298523T0000 NN O
on P07298523T0000 IN O
parturition P07298523T0000 NN O
in P07298523T0000 IN O
swine P07298523T0000 NN O
. P07298523T0000 . O
. . O O

The P10342511A0909 DT O
coefficient P10342511A0909 NN O
of P10342511A0909 IN O
determination P10342511A0909 NN O
, P10342511A0909 , O
r2 P10342511A0909 NN O
, P10342511A0909 , O
of P10342511A0909 IN O
the P10342511A0909 DT O
other P10342511A0909 JJ O
scores P10342511A0909 NNS O
ranged P10342511A0909 VBD O
from P10342511A0909 IN O
0.56 P10342511A0909 CD O
to P10342511A0909 TO O
0.61 P10342511A0909 CD O
. P10342511A0909 . O
. . O O

For P11822790A0907 IN O
instance P11822790A0907 NN O
, P11822790A0907 , O
a P11822790A0907 DT O
total P11822790A0907 JJ O
SIP P11822790A0907 NNP O
score P11822790A0907 NN O
of P11822790A0907 IN O
an P11822790A0907 DT O
individual P11822790A0907 JJ O
patient P11822790A0907 NN O
of P11822790A0907 IN O
28.3 P11822790A0907 CD O
% P11822790A0907 NN O
( P11822790A0907 ( O
which P11822790A0907 WDT O
is P11822790A0907 VBZ O
taken P11822790A0907 VBN O
as P11822790A0907 IN O
an P11822790A0907 DT O
example P11822790A0907 NN O
, P11822790A0907 , O
being P11822790A0907 VBG O
the P11822790A0907 DT O
mean P11822790A0907 NN O
score P11822790A0907 NN O
in P11822790A0907 IN O
the P11822790A0907 DT O
study P11822790A0907 NN O
population P11822790A0907 NN O
) P11822790A0907 ) O
should P11822790A0907 MD O
decrease P11822790A0907 VB O
by P11822790A0907 IN O
at P11822790A0907 IN O
least P11822790A0907 JJS O
9.26 P11822790A0907 CD O
% P11822790A0907 NN O
or P11822790A0907 CC O
approximately P11822790A0907 RB O
13 P11822790A0907 CD O
items P11822790A0907 NNS O
, P11822790A0907 , O
before P11822790A0907 IN O
any P11822790A0907 DT O
improvement P11822790A0907 NN O
beyond P11822790A0907 IN O
reproducibility P11822790A0907 NN O
noise P11822790A0907 NN O
can P11822790A0907 MD O
be P11822790A0907 VB O
detected P11822790A0907 VBN O
. P11822790A0907 . O
. . O O

Moreover P02176209A0954 RB O
, P02176209A0954 , O
radiolabeled P02176209A0954 VBD O
EFI P02176209A0954 NNP I-UN
, P02176209A0954 , O
NF-Y P02176209A0954 NNP I-UN
, P02176209A0954 , O
or P02176209A0954 CC O
CBF P02176209A0954 NNP I-UN
DNAs P02176209A0954 NNP I-UN
give P02176209A0954 VBP O
rise P02176209A0954 NN O
to P02176209A0954 TO O
identical P02176209A0954 JJ O
gel P02176209A0954 NN O
retardation P02176209A0954 NN O
patterns P02176209A0954 NNS O
in P02176209A0954 IN O
extracts P02176209A0954 NNS O
from P02176209A0954 IN O
a P02176209A0954 DT O
variety P02176209A0954 NN O
of P02176209A0954 IN O
different P02176209A0954 JJ O
cell P02176209A0954 NN O
types P02176209A0954 NNS O
. P02176209A0954 . O
. . O O

Thin P03401060A0000 NNP O
melanomas P03401060A0000 NN O
can P03401060A0000 MD O
metastasize P03401060A0000 VB O
and P03401060A0000 CC O
be P03401060A0000 VB O
lethal P03401060A0000 VBN O
. P03401060A0000 . O
. . O O

Ca2+ P08645219A1377 NNP O
decreased P08645219A1377 VBD O
Zn2+ P08645219A1377 NNP O
binding P08645219A1377 VBG O
in P08645219A1377 IN O
S100 P08645219A1377 NNP I-UN
beta P08645219A1377 NN I-UN
but P08645219A1377 CC O
it P08645219A1377 PRP O
did P08645219A1377 VBD O
not P08645219A1377 RB O
influence P08645219A1377 VB O
binding P08645219A1377 VBG O
to P08645219A1377 TO O
MRP14 P08645219A1377 NNP I-UN
, P08645219A1377 , O
suggesting P08645219A1377 VBG O
that P08645219A1377 IN O
the P08645219A1377 DT O
Zn2+ P08645219A1377 NNP O
binding P08645219A1377 NN O
site P08645219A1377 NN O
was P08645219A1377 VBD O
distinct P08645219A1377 JJ O
from P08645219A1377 IN O
and P08645219A1377 CC O
independent P08645219A1377 JJ O
of P08645219A1377 IN O
the P08645219A1377 DT O
two P08645219A1377 CD O
Ca2+ P08645219A1377 NNP O
binding P08645219A1377 NN O
domains P08645219A1377 NNS O
. P08645219A1377 . O
. . O O

The P08692892A0330 DT O
Pro-258 P08692892A0330 NNP O
-- P08692892A0330 : O
> P08692892A0330 JJ O
Leu P08692892A0330 NNP O
( P08692892A0330 ( O
P258L P08692892A0330 NNP O
) P08692892A0330 ) O
mutation P08692892A0330 NN O
caused P08692892A0330 VBD O
constitutive P08692892A0330 JJ O
receptor P08692892A0330 NN O
signaling P08692892A0330 VBG O
that P08692892A0330 WDT O
was P08692892A0330 VBD O
equivalent P08692892A0330 JJ O
to P08692892A0330 TO O
about P08692892A0330 RB O
45 P08692892A0330 CD O
% P08692892A0330 NN O
of P08692892A0330 IN O
the P08692892A0330 DT O
maximum P08692892A0330 JJ O
level P08692892A0330 NN O
observed P08692892A0330 VBN O
in P08692892A0330 IN O
wild-type P08692892A0330 JJ O
cells P08692892A0330 NNS O
stimulated P08692892A0330 VBN O
with P08692892A0330 IN O
alpha-factor P08692892A0330 NN I-UN
. P08692892A0330 . O
. . O O

Hepatitis P06092588T0000 NN O
B P06092588T0000 NNP O
virus P06092588T0000 NN O
and P06092588T0000 CC O
hepatoma P06092588T0000 NN O
. P06092588T0000 . O
. . O O

Isolation P02204621T0000 NN O
of P02204621T0000 IN O
a P02204621T0000 DT O
temperature-sensitive P02204621T0000 JJ O
mutant P02204621T0000 NN O
with P02204621T0000 IN O
an P02204621T0000 DT O
altered P02204621T0000 JJ O
tRNA P02204621T0000 NN I-UN
nucleotidyltransferase P02204621T0000 NN I-UN
and P02204621T0000 CC O
cloning P02204621T0000 NN O
of P02204621T0000 IN O
the P02204621T0000 DT O
gene P02204621T0000 NN I-UN
encoding P02204621T0000 VBG I-UN
tRNA P02204621T0000 JJ I-UN
nucleotidyltransferase P02204621T0000 NN I-UN
in P02204621T0000 IN I-UN
the P02204621T0000 DT I-UN
yeast P02204621T0000 NN I-UN
Saccharomyces P02204621T0000 NNP I-UN
cerevisiae P02204621T0000 NN I-UN
. P02204621T0000 . O
. . O O

In P09511724A0483 IN O
all P09511724A0483 DT O
cells P09511724A0483 NNS O
, P09511724A0483 , O
the P09511724A0483 DT O
accumulation P09511724A0483 NN O
of P09511724A0483 IN O
high P09511724A0483 JJ O
Dsg P09511724A0483 NNP I-UN
protein P09511724A0483 NN I-UN
levels P09511724A0483 NNS O
required P09511724A0483 VBN O
calcium P09511724A0483 NN O
and P09511724A0483 CC O
was P09511724A0483 VBD O
not P09511724A0483 RB O
observed P09511724A0483 VBN O
in P09511724A0483 IN O
low P09511724A0483 JJ O
calcium P09511724A0483 NN O
( P09511724A0483 ( O
0.05-0.07 P09511724A0483 JJ O
mM P09511724A0483 NN O
) P09511724A0483 ) O
media P09511724A0483 NNS O
. P09511724A0483 . O
. . O O

Its P09227799A0254 PRP$ O
potential P09227799A0254 JJ O
as P09227799A0254 IN O
a P09227799A0254 DT O
diagnostic P09227799A0254 JJ O
tool P09227799A0254 NN O
for P09227799A0254 IN O
epidemiological P09227799A0254 JJ O
surveillance P09227799A0254 NN O
was P09227799A0254 VBD O
assessed P09227799A0254 VBN O
in P09227799A0254 IN O
comparison P09227799A0254 NN O
with P09227799A0254 IN O
three P09227799A0254 CD O
other P09227799A0254 JJ O
diagnostic P09227799A0254 JJ O
tests P09227799A0254 NNS O
: P09227799A0254 : O
stool P09227799A0254 NN O
examination P09227799A0254 NN O
, P09227799A0254 , O
ELISA P09227799A0254 NNP O
with P09227799A0254 IN O
soluble P09227799A0254 JJ I-UN
egg P09227799A0254 NN I-UN
antigen P09227799A0254 NN I-UN
( P09227799A0254 ( O
SEA P09227799A0254 NNP I-UN
) P09227799A0254 ) O
and P09227799A0254 CC O
the P09227799A0254 DT O
circumoval P09227799A0254 NN O
precipitin P09227799A0254 NN I-UN
test P09227799A0254 NN O
( P09227799A0254 ( O
COPT P09227799A0254 NNP O
) P09227799A0254 ) O
. P09227799A0254 . O
. . O O

As P01083321X0000 IN O
stands P01083321X0000 NNS O
shifted P01083321X0000 VBN O
in P01083321X0000 IN O
dominance P01083321X0000 NN O
from P01083321X0000 IN O
pine P01083321X0000 NN O
to P01083321X0000 TO O
fir P01083321X0000 VB O
with P01083321X0000 IN O
age P01083321X0000 NN O
, P01083321X0000 , O
subalpine P01083321X0000 JJ O
fir P01083321X0000 NN O
appeared P01083321X0000 VBD O
to P01083321X0000 TO O
maintain P01083321X0000 VB O
gradually P01083321X0000 RB O
increasing P01083321X0000 VBG O
rates P01083321X0000 NNS O
of P01083321X0000 IN O
whole-forest P01083321X0000 JJ O
productivity P01083321X0000 NN O
until P01083321X0000 IN O
stands P01083321X0000 NNS O
were P01083321X0000 VBD O
approximately P01083321X0000 RB O
400 P01083321X0000 CD O
years P01083321X0000 NNS O
old P01083321X0000 JJ O
. P01083321X0000 . O
. . O O

Each P08676383A0518 DT O
half P08676383A0518 NN O
molecule P08676383A0518 NN O
contains P08676383A0518 VBZ O
four P08676383A0518 CD O
disulfide P08676383A0518 NN O
linkages P08676383A0518 NNS O
and P08676383A0518 CC O
four P08676383A0518 CD O
cis P08676383A0518 NN O
peptides P08676383A0518 NNS O
. P08676383A0518 . O
. . O O

The P03559193A0000 DT O
present P03559193A0000 JJ O
investigation P03559193A0000 NN O
sought P03559193A0000 VBD O
to P03559193A0000 TO O
identify P03559193A0000 VB O
the P03559193A0000 DT O
principal P03559193A0000 JJ O
dimensions P03559193A0000 NNS O
of P03559193A0000 IN O
the P03559193A0000 DT O
Framingham P03559193A0000 NNP O
Type P03559193A0000 NNP O
A P03559193A0000 NNP O
scale P03559193A0000 NN O
( P03559193A0000 ( O
FTAS P03559193A0000 NNP O
) P03559193A0000 ) O
and P03559193A0000 CC O
then P03559193A0000 RB O
to P03559193A0000 TO O
examine P03559193A0000 VB O
their P03559193A0000 PRP$ O
physiological P03559193A0000 JJ O
and P03559193A0000 CC O
psychological P03559193A0000 JJ O
correlates P03559193A0000 NNS O
. P03559193A0000 . O
. . O O

Azygos P06600533T0000 NNP O
vein P06600533T0000 NN O
abutting P06600533T0000 VBG O
the P06600533T0000 DT O
posterior P06600533T0000 JJ O
wall P06600533T0000 NN O
of P06600533T0000 IN O
the P06600533T0000 DT O
right P06600533T0000 NN O
main P06600533T0000 JJ O
and P06600533T0000 CC O
upper P06600533T0000 JJ O
lobe P06600533T0000 NN O
bronchi P06600533T0000 NN O
: P06600533T0000 : O
a P06600533T0000 DT O
normal P06600533T0000 JJ O
CT P06600533T0000 NNP O
variant P06600533T0000 NN O
. P06600533T0000 . O
. . O O

Aviators P03178626A0137 NNS O
from P03178626A0137 IN O
the P03178626A0137 DT O
Light P03178626A0137 NNP O
Attack P03178626A0137 NNP O
Wing P03178626A0137 NNP O
, P03178626A0137 , O
Pacific P03178626A0137 NNP O
were P03178626A0137 VBD O
surveyed P03178626A0137 VBN O
and P03178626A0137 CC O
the P03178626A0137 DT O
results P03178626A0137 NNS O
were P03178626A0137 VBD O
categorized P03178626A0137 VBN O
by P03178626A0137 IN O
aircraft P03178626A0137 NN O
type P03178626A0137 NN O
. P03178626A0137 . O
. . O O

To P02300541A0000 TO O
determine P02300541A0000 VB O
the P02300541A0000 DT O
effects P02300541A0000 NNS O
on P02300541A0000 IN O
the P02300541A0000 DT O
pulmonary P02300541A0000 JJ O
barrier P02300541A0000 NN O
of P02300541A0000 IN O
several P02300541A0000 JJ O
surface P02300541A0000 NN O
active P02300541A0000 JJ O
agents P02300541A0000 NNS O
, P02300541A0000 , O
a P02300541A0000 DT O
series P02300541A0000 NN O
of P02300541A0000 IN O
metered P02300541A0000 VBN O
dose P02300541A0000 JJ O
inhalers P02300541A0000 NNS O
( P02300541A0000 ( O
MDIs P02300541A0000 NNP O
) P02300541A0000 ) O
was P02300541A0000 VBD O
prepared P02300541A0000 VBN O
and P02300541A0000 CC O
used P02300541A0000 VBN O
to P02300541A0000 TO O
dose P02300541A0000 VB O
aerosolized P02300541A0000 JJ O
surfactant P02300541A0000 NN O
to P02300541A0000 TO O
the P02300541A0000 DT O
airways P02300541A0000 NNS O
of P02300541A0000 IN O
isolated P02300541A0000 JJ O
perfused P02300541A0000 JJ O
rat P02300541A0000 NN O
lungs P02300541A0000 NNS O
. P02300541A0000 . O
. . O O

PBSX P02125016A0145 NNP I-UN
is P02125016A0145 VBZ O
induced P02125016A0145 VBN O
by P02125016A0145 IN O
agents P02125016A0145 NNS O
which P02125016A0145 WDT O
elicit P02125016A0145 VBP O
the P02125016A0145 DT O
SOS P02125016A0145 NNP O
response P02125016A0145 NN O
. P02125016A0145 . O
. . O O

Furthermore P08356792A1275 RB O
, P08356792A1275 , O
a P08356792A1275 DT O
p21X P08356792A1275 NN I-UN
protein P08356792A1275 NN I-UN
lacking P08356792A1275 VBG O
the P08356792A1275 DT O
N-terminus P08356792A1275 NNP O
of P08356792A1275 IN O
Rex1 P08356792A1275 NNP I-UN
was P08356792A1275 VBD O
expressed P08356792A1275 VBN O
at P08356792A1275 IN O
high P08356792A1275 JJ O
levels P08356792A1275 NNS O
; P08356792A1275 : O
our P08356792A1275 PRP$ O
data P08356792A1275 NNS O
indicate P08356792A1275 VBP O
that P08356792A1275 IN O
p21X P08356792A1275 NN I-UN
is P08356792A1275 VBZ O
translated P08356792A1275 VBN O
from P08356792A1275 IN O
the P08356792A1275 DT O
1.6-kb P08356792A1275 JJ O
mRNA P08356792A1275 NN O
which P08356792A1275 WDT O
is P08356792A1275 VBZ O
derived P08356792A1275 VBN O
primarily P08356792A1275 RB O
from P08356792A1275 IN O
deleted P08356792A1275 VBN O
proviruses P08356792A1275 NNS O
. P08356792A1275 . O
. . O O

A P11181531A0464 DT O
major P11181531A0464 JJ O
mechanism P11181531A0464 NN O
by P11181531A0464 IN O
which P11181531A0464 WDT O
estrogens P11181531A0464 VBZ O
prevent P11181531A0464 NN O
osteoporosis P11181531A0464 NN O
seems P11181531A0464 VBZ O
to P11181531A0464 TO O
be P11181531A0464 VB O
repression P11181531A0464 NN O
of P11181531A0464 IN O
transcription P11181531A0464 NN O
of P11181531A0464 IN O
NF-kappa P11181531A0464 NNP I-UN
B P11181531A0464 NNP I-UN
target P11181531A0464 NN I-UN
genes P11181531A0464 NNS I-UN
, P11181531A0464 , O
such P11181531A0464 JJ O
as P11181531A0464 IN O
the P11181531A0464 DT O
osteoclast-activating P11181531A0464 JJ O
cytokines P11181531A0464 NNS O
interleukin-6 P11181531A0464 JJ I-UN
and P11181531A0464 CC O
interleukin-1 P11181531A0464 JJ I-UN
. P11181531A0464 . O
. . O O

Recruitment P11158288T0000 NN O
of P11158288T0000 IN O
an P11158288T0000 DT O
RNA P11158288T0000 NNP I-UN
polymerase P11158288T0000 NN I-UN
II P11158288T0000 NNP I-UN
complex P11158288T0000 NN I-UN
is P11158288T0000 VBZ O
mediated P11158288T0000 VBN O
by P11158288T0000 IN O
the P11158288T0000 DT O
constitutive P11158288T0000 JJ O
activation P11158288T0000 NN O
domain P11158288T0000 NN O
in P11158288T0000 IN O
CREB P11158288T0000 NNP I-UN
, P11158288T0000 , O
independently P11158288T0000 RB O
of P11158288T0000 IN O
CREB P11158288T0000 NNP I-UN
phosphorylation P11158288T0000 NN O
. P11158288T0000 . O
. . O O

This P07964459A0845 DT O
motif P07964459A0845 NN O
is P07964459A0845 VBZ O
similar P07964459A0845 JJ O
to P07964459A0845 TO O
but P07964459A0845 CC O
distinct P07964459A0845 JJ O
from P07964459A0845 IN O
the P07964459A0845 DT O
LIM P07964459A0845 NNP I-UN
domain P07964459A0845 NN I-UN
and P07964459A0845 CC O
the P07964459A0845 DT O
RING P07964459A0845 NNP I-UN
finger P07964459A0845 NN I-UN
family P07964459A0845 NN I-UN
, P07964459A0845 , O
and P07964459A0845 CC O
is P07964459A0845 VBZ O
reminiscent P07964459A0845 JJ O
of P07964459A0845 IN O
known P07964459A0845 VBN O
metal-binding P07964459A0845 JJ O
regions P07964459A0845 NNS O
. P07964459A0845 . O
. . O O

Extracellular-regulated P10747099A0507 JJ I-UN
kinase P10747099A0507 NN I-UN
( P10747099A0507 ( O
ERK P10747099A0507 NNP I-UN
) P10747099A0507 ) O
activation P10747099A0507 NN O
and P10747099A0507 CC O
molecular P10747099A0507 JJ O
coupling P10747099A0507 NN O
of P10747099A0507 IN O
the P10747099A0507 DT O
adaptor P10747099A0507 NN O
proteins P10747099A0507 VBZ O
p130 P10747099A0507 JJ I-UN
Crk-associated P10747099A0507 JJ I-UN
substrate P10747099A0507 NN I-UN
( P10747099A0507 ( O
CAS P10747099A0507 NNP I-UN
) P10747099A0507 ) O
and P10747099A0507 CC O
c-CrkII P10747099A0507 JJ I-UN
( P10747099A0507 ( O
Crk P10747099A0507 NNP I-UN
) P10747099A0507 ) O
represent P10747099A0507 VBP O
two P10747099A0507 CD O
distinct P10747099A0507 JJ O
pathways P10747099A0507 NNS O
that P10747099A0507 WDT O
induce P10747099A0507 VBP O
cell P10747099A0507 NN O
invasion P10747099A0507 NN O
and P10747099A0507 CC O
protect P10747099A0507 VBP O
cells P10747099A0507 NNS O
from P10747099A0507 IN O
apoptosis P10747099A0507 NN O
in P10747099A0507 IN O
a P10747099A0507 DT O
three-dimensional P10747099A0507 JJ O
collagen P10747099A0507 NN I-UN
matrix P10747099A0507 NN O
. P10747099A0507 . O
. . O O

Mapping P02677666A0356 VBG O
results P02677666A0356 NNS O
suggested P02677666A0356 VBD O
that P02677666A0356 IN O
the P02677666A0356 DT O
complementation P02677666A0356 NN O
group P02677666A0356 NN O
identified P02677666A0356 VBN O
by P02677666A0356 IN O
these P02677666A0356 DT O
mutants P02677666A0356 NNS O
is P02677666A0356 VBZ O
allelic P02677666A0356 JJ O
to P02677666A0356 TO O
the P02677666A0356 DT O
ag P02677666A0356 NN I-UN
alpha P02677666A0356 VBZ I-UN
1 P02677666A0356 CD I-UN
mutation P02677666A0356 NN O
identified P02677666A0356 VBD O
previously P02677666A0356 RB O
. P02677666A0356 . O
. . O O

Two P08255341A0554 CD O
patients P08255341A0554 NNS O
were P08255341A0554 VBD O
treated P08255341A0554 VBN O
successfully P08255341A0554 RB O
with P08255341A0554 IN O
a P08255341A0554 DT O
combination P08255341A0554 NN O
of P08255341A0554 IN O
metronidazole P08255341A0554 NN O
( P08255341A0554 ( O
a P08255341A0554 DT O
tissue P08255341A0554 NN O
amoebicide P08255341A0554 NN O
) P08255341A0554 ) O
and P08255341A0554 CC O
diloxanide P08255341A0554 NN O
( P08255341A0554 ( O
a P08255341A0554 DT O
lumenal P08255341A0554 JJ O
amoebicide P08255341A0554 NN O
) P08255341A0554 ) O
. P08255341A0554 . O
. . O O

Treatment P04048245A0331 NN O
with P04048245A0331 IN O
oxyphenylbutazone P04048245A0331 NN O
and P04048245A0331 CC O
hydrocortisone P04048245A0331 NN O
failed P04048245A0331 VBD O
to P04048245A0331 TO O
inhibit P04048245A0331 VB O
the P04048245A0331 DT O
raised P04048245A0331 VBN O
serum P04048245A0331 NN I-UN
CPN P04048245A0331 NNP I-UN
levels P04048245A0331 NNS O
. P04048245A0331 . O
. . O O

As P00429949A0000 IN O
authorized P00429949A0000 VBN O
by P00429949A0000 IN O
the P00429949A0000 DT O
World P00429949A0000 NNP O
Health P00429949A0000 NNP O
Organization P00429949A0000 NNP O
29th P00429949A0000 CD O
Expert P00429949A0000 NNP O
Committee P00429949A0000 NNP O
on P00429949A0000 IN O
Biological P00429949A0000 NNP O
Standardization P00429949A0000 NNP O
, P00429949A0000 , O
the P00429949A0000 DT O
preparation P00429949A0000 NN O
of P00429949A0000 IN O
human P00429949A0000 JJ I-UN
prolactin P00429949A0000 NN I-UN
in P00429949A0000 IN O
ampoules P00429949A0000 NNS O
coded P00429949A0000 VBD O
75 P00429949A0000 CD O
/ P00429949A0000 NN O
504 P00429949A0000 CD O
has P00429949A0000 VBZ O
been P00429949A0000 VBN O
established P00429949A0000 VBN O
as P00429949A0000 IN O
the P00429949A0000 DT O
International P00429949A0000 NNP O
Reference P00429949A0000 NNP O
Preparation P00429949A0000 NNP O
( P00429949A0000 ( O
IRP P00429949A0000 NNP O
) P00429949A0000 ) O
of P00429949A0000 IN O
human P00429949A0000 JJ I-UN
prolactin P00429949A0000 NN I-UN
for P00429949A0000 IN O
immunoassay P00429949A0000 NN O
. P00429949A0000 . O
. . O O

At P11489597A0379 IN O
termination P11489597A0379 NN O
( P11489597A0379 ( O
gd P11489597A0379 JJ O
20 P11489597A0379 CD O
) P11489597A0379 ) O
, P11489597A0379 , O
confirmed-pregnant P11489597A0379 JJ O
females P11489597A0379 NNS O
( P11489597A0379 ( O
21 P11489597A0379 CD O
to P11489597A0379 TO O
25 P11489597A0379 CD O
per P11489597A0379 IN O
group P11489597A0379 NN O
) P11489597A0379 ) O
were P11489597A0379 VBD O
evaluated P11489597A0379 VBN O
for P11489597A0379 IN O
clinical P11489597A0379 JJ O
status P11489597A0379 NN O
and P11489597A0379 CC O
gestational P11489597A0379 JJ O
outcome P11489597A0379 NN O
; P11489597A0379 : O
live P11489597A0379 JJ O
fetuses P11489597A0379 NNS O
were P11489597A0379 VBD O
examined P11489597A0379 VBN O
for P11489597A0379 IN O
external P11489597A0379 JJ O
, P11489597A0379 , O
visceral P11489597A0379 JJ O
, P11489597A0379 , O
and P11489597A0379 CC O
skeletal P11489597A0379 JJ O
malformations P11489597A0379 NNS O
. P11489597A0379 . O
. . O O

Nuclear-encoded P01542565T0000 JJ I-UN
chloroplast P01542565T0000 NN I-UN
ribosomal P01542565T0000 JJ I-UN
protein P01542565T0000 NN I-UN
L12 P01542565T0000 NNP I-UN
of P01542565T0000 IN I-UN
Nicotiana P01542565T0000 NNP I-UN
tabacum P01542565T0000 NN I-UN
: P01542565T0000 : O
characterization P01542565T0000 NN O
of P01542565T0000 IN O
mature P01542565T0000 NN O
protein P01542565T0000 NN O
and P01542565T0000 CC O
isolation P01542565T0000 NN O
and P01542565T0000 CC O
sequence P01542565T0000 NN O
analysis P01542565T0000 NN O
of P01542565T0000 IN O
cDNA P01542565T0000 NN O
clones P01542565T0000 NNS O
encoding P01542565T0000 VBG O
its P01542565T0000 PRP$ O
cytoplasmic P01542565T0000 JJ O
precursor P01542565T0000 NN O
. P01542565T0000 . O
. . O O

M. P09079928A0525 NNP I-UN
leprae P09079928A0525 VBD I-UN
OxyR P09079928A0525 NNP I-UN
was P09079928A0525 VBD O
overproduced P09079928A0525 VBN O
and P09079928A0525 CC O
purified P09079928A0525 VBN O
, P09079928A0525 , O
and P09079928A0525 CC O
its P09079928A0525 PRP$ O
binding P09079928A0525 NN O
to P09079928A0525 TO O
the P09079928A0525 DT O
oxyR-ahpC P09079928A0525 JJ O
intergenic P09079928A0525 JJ O
region P09079928A0525 NN O
of P09079928A0525 IN O
M. P09079928A0525 NNP O
leprae P09079928A0525 NN O
was P09079928A0525 VBD O
demonstrated P09079928A0525 VBN O
. P09079928A0525 . O
. . O O

Effects P11305129T0000 NNS O
of P11305129T0000 IN O
a P11305129T0000 DT O
booster P11305129T0000 NN O
dose P11305129T0000 NN O
of P11305129T0000 IN O
tetanus P11305129T0000 NN O
toxoid P11305129T0000 NN O
after P11305129T0000 IN O
different P11305129T0000 JJ O
primary P11305129T0000 JJ O
courses P11305129T0000 NNS O
of P11305129T0000 IN O
vaccination P11305129T0000 NN O
: P11305129T0000 : O
implications P11305129T0000 NNS O
on P11305129T0000 IN O
the P11305129T0000 DT O
use P11305129T0000 NN O
of P11305129T0000 IN O
immune P11305129T0000 JJ I-UN
globulin P11305129T0000 NN I-UN
. P11305129T0000 . O
. . O O

Normal P04661961T0001 JJ O
values P04661961T0001 NNS O
for P04661961T0001 IN O
the P04661961T0001 DT O
peripheral P04661961T0001 JJ O
blood P04661961T0001 NN O
and P04661961T0001 CC O
bone P04661961T0001 NN O
marrow P04661961T0001 NN O
of P04661961T0001 IN O
the P04661961T0001 DT O
grey P04661961T0001 NN O
( P04661961T0001 ( O
Armenian P04661961T0001 JJ O
) P04661961T0001 ) O
hamster P04661961T0001 NN O
. P04661961T0001 . O
. . O O

Endostatin P10828022A0877 NNP O
treatment P10828022A0877 NN O
for P10828022A0877 IN O
10 P10828022A0877 CD O
minutes P10828022A0877 NNS O
or P10828022A0877 CC O
24 P10828022A0877 CD O
hours P10828022A0877 NNS O
induced P10828022A0877 JJ O
tyrosine P10828022A0877 JJ O
phosphorylation P10828022A0877 NN O
of P10828022A0877 IN O
Shb P10828022A0877 NNP I-UN
and P10828022A0877 CC O
formation P10828022A0877 NN O
of P10828022A0877 IN O
multiprotein P10828022A0877 NN O
complexes P10828022A0877 NNS O
. P10828022A0877 . O
. . O O

Upstream P08562688A0968 NN O
of P08562688A0968 IN O
-37 P08562688A0968 NN O
, P08562688A0968 , O
the P08562688A0968 DT O
5 P08562688A0968 CD O
' P08562688A0968 POS O
untranslated P08562688A0968 JJ O
sequences P08562688A0968 NNS O
of P08562688A0968 IN O
the P08562688A0968 DT O
isolates P08562688A0968 NNS O
differ P08562688A0968 VBP O
in P08562688A0968 IN O
both P08562688A0968 DT O
length P08562688A0968 NN O
and P08562688A0968 CC O
sequence P08562688A0968 NN O
. P08562688A0968 . O
. . O O

The P03680791A0230 DT O
histologic P03680791A0230 NN O
grade P03680791A0230 NN O
for P03680791A0230 IN O
the P03680791A0230 DT O
same P03680791A0230 JJ O
anatomic P03680791A0230 JJ O
site P03680791A0230 NN O
varied P03680791A0230 VBD O
among P03680791A0230 IN O
hearts P03680791A0230 NNS O
and P03680791A0230 CC O
among P03680791A0230 IN O
different P03680791A0230 JJ O
anatomic P03680791A0230 JJ O
sites P03680791A0230 NNS O
in P03680791A0230 IN O
the P03680791A0230 DT O
same P03680791A0230 JJ O
heart P03680791A0230 NN O
. P03680791A0230 . O
. . O O

Remarkably P07937132A0819 RB O
, P07937132A0819 , O
U21 P07937132A0819 NNP I-UN
contains P07937132A0819 VBZ O
a P07937132A0819 DT O
long P07937132A0819 JJ O
stretch P07937132A0819 NN O
( P07937132A0819 ( O
13 P07937132A0819 CD O
nt P07937132A0819 RB O
. P07937132A0819 . O
) P07937132A0819 ) O
of P07937132A0819 IN O
complementarity P07937132A0819 NN O
to P07937132A0819 TO O
a P07937132A0819 DT O
highly P07937132A0819 RB O
conserved P07937132A0819 VBN O
sequence P07937132A0819 NN O
in P07937132A0819 IN O
28S P07937132A0819 CD I-UN
rRNA P07937132A0819 NN I-UN
. P07937132A0819 . O
. . O O

Secondly P10510295A0606 RB O
, P10510295A0606 , O
an P10510295A0606 DT O
ethanol P10510295A0606 JJ O
repression P10510295A0606 NN O
autoregulation P10510295A0606 NN O
( P10510295A0606 ( O
ERA P10510295A0606 NNP O
) P10510295A0606 ) O
/ P10510295A0606 VBD O
twelve-fold P10510295A0606 JJ O
TA P10510295A0606 NNP O
repeat P10510295A0606 NN O
( P10510295A0606 ( O
TAB P10510295A0606 NNP O
) P10510295A0606 ) O
repressor P10510295A0606 NN O
element P10510295A0606 NN O
was P10510295A0606 VBD O
identified P10510295A0606 VBN O
within P10510295A0606 IN O
the P10510295A0606 DT O
promoter P10510295A0606 NN O
region P10510295A0606 NN O
of P10510295A0606 IN O
the P10510295A0606 DT O
GLK1 P10510295A0606 NNP I-UN
gene P10510295A0606 NN I-UN
. P10510295A0606 . O
. . O O

In P08139539A0446 IN O
Rat P08139539A0446 NNP O
1a P08139539A0446 CD O
cells P08139539A0446 NNS O
, P08139539A0446 , O
m1R P08139539A0446 JJ I-UN
stimulation P08139539A0446 NN O
of P08139539A0446 IN O
phospholipase P08139539A0446 NN I-UN
C P08139539A0446 NNP I-UN
beta P08139539A0446 NN I-UN
and P08139539A0446 CC O
the P08139539A0446 DT O
marked P08139539A0446 JJ O
rise P08139539A0446 NN O
in P08139539A0446 IN O
intracellular P08139539A0446 JJ O
calcium P08139539A0446 NN O
stimulated P08139539A0446 VBD O
cyclic P08139539A0446 JJ O
AMP P08139539A0446 NNP O
( P08139539A0446 ( O
cAMP P08139539A0446 NN O
) P08139539A0446 ) O
synthesis P08139539A0446 NN O
, P08139539A0446 , O
resulting P08139539A0446 VBG O
in P08139539A0446 IN O
the P08139539A0446 DT O
activation P08139539A0446 NN O
of P08139539A0446 IN O
protein P08139539A0446 NN I-UN
kinase P08139539A0446 NN I-UN
A P08139539A0446 NNP I-UN
. P08139539A0446 . O
. . O O

The P11265853A0000 DT O
Novacor P11265853A0000 NNP O
Left P11265853A0000 NNP O
Ventricular P11265853A0000 NNP O
Assist P11265853A0000 NNP O
System P11265853A0000 NNP O
( P11265853A0000 ( O
LVAS P11265853A0000 NNP O
) P11265853A0000 ) O
( P11265853A0000 ( O
Novacor P11265853A0000 NNP O
Corp P11265853A0000 NNP O
, P11265853A0000 , O
Oakland P11265853A0000 NNP O
, P11265853A0000 , O
CA P11265853A0000 NNP O
) P11265853A0000 ) O
was P11265853A0000 VBD O
initially P11265853A0000 RB O
console-based P11265853A0000 JJ O
and P11265853A0000 CC O
has P11265853A0000 VBZ O
been P11265853A0000 VBN O
available P11265853A0000 JJ O
since P11265853A0000 IN O
1993 P11265853A0000 CD O
in P11265853A0000 IN O
a P11265853A0000 DT O
wearable P11265853A0000 JJ O
configuration P11265853A0000 NN O
. P11265853A0000 . O
. . O O

In P09519830A0282 IN O
order P09519830A0282 NN O
to P09519830A0282 TO O
examine P09519830A0282 VB O
the P09519830A0282 DT O
potential P09519830A0282 JJ O
role P09519830A0282 NN O
of P09519830A0282 IN O
transcriptional P09519830A0282 JJ O
silencing P09519830A0282 NN O
during P09519830A0282 IN O
productive P09519830A0282 JJ O
HSV-1 P09519830A0282 NNP O
infection P09519830A0282 NN O
, P09519830A0282 , O
recombinant P09519830A0282 JJ O
viruses P09519830A0282 NNS O
were P09519830A0282 VBD O
generated P09519830A0282 VBN O
in P09519830A0282 IN O
which P09519830A0282 WDT O
wild-type P09519830A0282 NN I-UN
or P09519830A0282 CC I-UN
mutant P09519830A0282 JJ I-UN
ICP34.5 P09519830A0282 NNP I-UN
promoters P09519830A0282 NNS I-UN
controlling P09519830A0282 VBG O
the P09519830A0282 DT O
expression P09519830A0282 NN O
of P09519830A0282 IN O
a P09519830A0282 DT O
chloramphenicol P09519830A0282 JJ I-UN
acetyltransferase P09519830A0282 NN I-UN
reporter P09519830A0282 NN I-UN
gene P09519830A0282 NN I-UN
were P09519830A0282 VBD O
inserted P09519830A0282 VBN O
into P09519830A0282 IN O
the P09519830A0282 DT O
thymidine P09519830A0282 JJ I-UN
kinase P09519830A0282 NN I-UN
gene P09519830A0282 NN I-UN
of P09519830A0282 IN O
the P09519830A0282 DT O
viral P09519830A0282 JJ O
genome P09519830A0282 NN O
. P09519830A0282 . O
. . O O

Thus P07851643A1365 RB O
, P07851643A1365 , O
these P07851643A1365 DT O
studies P07851643A1365 NNS O
indicate P07851643A1365 VBP O
that P07851643A1365 IN O
the P07851643A1365 DT O
104-kDa P07851643A1365 JJ O
isoform P07851643A1365 NN O
is P07851643A1365 VBZ O
required P07851643A1365 VBN O
for P07851643A1365 IN O
normal P07851643A1365 JJ O
proliferation P07851643A1365 NN O
of P07851643A1365 IN O
female P07851643A1365 JJ O
germline P07851643A1365 NN O
cells P07851643A1365 NNS O
and P07851643A1365 CC O
perhaps P07851643A1365 RB O
for P07851643A1365 IN O
oocyte P07851643A1365 JJ O
differentiation P07851643A1365 NN O
. P07851643A1365 . O
. . O O

The P02679804A2000 DT O
products P02679804A2000 NNS O
of P02679804A2000 IN O
genes P02679804A2000 NNS O
ura10 P02679804A2000 NNS I-UN
and P02679804A2000 CC O
ura3 P02679804A2000 NNS I-UN
are P02679804A2000 VBP O
proposed P02679804A2000 VBN O
to P02679804A2000 TO O
participate P02679804A2000 VB O
in P02679804A2000 IN O
the P02679804A2000 DT O
channeling P02679804A2000 NN O
of P02679804A2000 IN O
orotidine P02679804A2000 JJ O
monophosphate P02679804A2000 NN O
. P02679804A2000 . O
. . O O

In P10485470A0242 IN O
this P10485470A0242 DT O
study P10485470A0242 NN O
, P10485470A0242 , O
we P10485470A0242 PRP O
identified P10485470A0242 VBD O
Sp1 P10485470A0242 NNP I-UN
and P10485470A0242 CC O
Sp3 P10485470A0242 NNP I-UN
as P10485470A0242 IN O
major P10485470A0242 JJ O
factors P10485470A0242 NNS O
binding P10485470A0242 VBG O
to P10485470A0242 TO O
the P10485470A0242 DT O
Sp1 P10485470A0242 NNP I-UN
sites P10485470A0242 NNS I-UN
of P10485470A0242 IN O
the P10485470A0242 DT O
p21 P10485470A0242 NN I-UN
/ P10485470A0242 NNP O
WAF1 P10485470A0242 NNP I-UN
/ P10485470A0242 NNP O
Cip1 P10485470A0242 NNP I-UN
promoter P10485470A0242 NN O
in P10485470A0242 IN O
MG63 P10485470A0242 NNP O
cells P10485470A0242 NNS O
through P10485470A0242 IN O
electrophoretic P10485470A0242 JJ O
mobility P10485470A0242 NN O
shift P10485470A0242 NN O
assays P10485470A0242 NNS O
and P10485470A0242 CC O
showed P10485470A0242 VBD O
that P10485470A0242 IN O
TSA P10485470A0242 NNP O
treatment P10485470A0242 NN O
did P10485470A0242 VBD O
not P10485470A0242 RB O
change P10485470A0242 VB O
their P10485470A0242 PRP$ O
binding P10485470A0242 NN O
activities P10485470A0242 NNS O
. P10485470A0242 . O
. . O O

The P04038702A0768 DT O
results P04038702A0768 NNS O
indicate P04038702A0768 VBP O
that P04038702A0768 IN O
: P04038702A0768 : O
1 P04038702A0768 CD O
) P04038702A0768 ) O
the P04038702A0768 DT O
initial P04038702A0768 JJ O
response P04038702A0768 NN O
to P04038702A0768 TO O
tethering P04038702A0768 VBG O
varies P04038702A0768 NNS O
according P04038702A0768 VBG O
to P04038702A0768 TO O
previous P04038702A0768 JJ O
penning P04038702A0768 NN O
and P04038702A0768 CC O
handling P04038702A0768 VBG O
experience P04038702A0768 NN O
, P04038702A0768 , O
2 P04038702A0768 CD O
) P04038702A0768 ) O
although P04038702A0768 IN O
the P04038702A0768 DT O
circadian P04038702A0768 JJ O
rhythm P04038702A0768 NN O
of P04038702A0768 IN O
cortisol P04038702A0768 NN O
was P04038702A0768 VBD O
either P04038702A0768 RB O
altered P04038702A0768 JJ O
or P04038702A0768 CC O
disrupted P04038702A0768 VBN O
during P04038702A0768 IN O
estrus P04038702A0768 NN O
, P04038702A0768 , O
such P04038702A0768 JJ O
disruptions P04038702A0768 NNS O
were P04038702A0768 VBD O
not P04038702A0768 RB O
influenced P04038702A0768 VBN O
by P04038702A0768 IN O
type P04038702A0768 NN O
of P04038702A0768 IN O
penning P04038702A0768 NN O
and P04038702A0768 CC O
3 P04038702A0768 CD O
) P04038702A0768 ) O
tether P04038702A0768 NN O
stalls P04038702A0768 NNS O
may P04038702A0768 MD O
chronically P04038702A0768 RB O
increase P04038702A0768 VB O
cortisol P04038702A0768 NN O
concentrations P04038702A0768 NNS O
in P04038702A0768 IN O
gilts P04038702A0768 NNS O
. P04038702A0768 . O
. . O O

Responses P08281740A0000 NNS O
to P08281740A0000 TO O
the P08281740A0000 DT O
Plowright P08281740A0000 NNP O
Rinderpest P08281740A0000 NNP O
vaccine P08281740A0000 NN O
by P08281740A0000 IN O
43 P08281740A0000 CD O
calves P08281740A0000 NNS O
and P08281740A0000 CC O
70 P08281740A0000 CD O
adult P08281740A0000 NN O
cattle P08281740A0000 NNS O
in P08281740A0000 IN O
Uganda P08281740A0000 NNP O
in P08281740A0000 IN O
1990 P08281740A0000 CD O
, P08281740A0000 , O
through P08281740A0000 IN O
the P08281740A0000 DT O
production P08281740A0000 NN O
of P08281740A0000 IN O
IgG P08281740A0000 NNP I-UN
antibodies P08281740A0000 NNS I-UN
, P08281740A0000 , O
were P08281740A0000 VBD O
monitored P08281740A0000 VBN O
for P08281740A0000 IN O
4 P08281740A0000 CD O
weeks P08281740A0000 NNS O
using P08281740A0000 VBG O
the P08281740A0000 DT O
ELISA P08281740A0000 NNP O
assay P08281740A0000 NN O
. P08281740A0000 . O
. . O O

Time P06822645T0039 NNP O
shifts P06822645T0039 JJ O
increase P06822645T0039 NN O
growth P06822645T0039 NN I-UN
hormone P06822645T0039 NN I-UN
release P06822645T0039 NN O
. P06822645T0039 . O
. . O O

We P08412662A0333 PRP O
have P08412662A0333 VBP O
isolated P08412662A0333 VBN O
a P08412662A0333 DT O
cosmid P08412662A0333 JJ O
containing P08412662A0333 NN O
DNA P08412662A0333 NN O
that P08412662A0333 WDT O
corresponds P08412662A0333 VBZ O
to P08412662A0333 TO O
the P08412662A0333 DT O
site P08412662A0333 NN O
of P08412662A0333 IN O
transposon P08412662A0333 JJ O
insertion P08412662A0333 NN O
in P08412662A0333 IN O
257DH4 P08412662A0333 CD O
and P08412662A0333 CC O
have P08412662A0333 VBP O
localized P08412662A0333 VBN O
Tn5 P08412662A0333 NNP I-UN
on P08412662A0333 IN O
an P08412662A0333 DT O
8.0 P08412662A0333 CD I-UN
kb P08412662A0333 NN I-UN
EcoRI P08412662A0333 NNP I-UN
fragment P08412662A0333 NN I-UN
. P08412662A0333 . O
. . O O

Forty P10684097A0175 NNP O
4-month P10684097A0175 JJ O
old P10684097A0175 JJ O
SD P10684097A0175 NNP O
female P10684097A0175 NN O
rats P10684097A0175 NNS O
were P10684097A0175 VBD O
randomly P10684097A0175 RB O
divided P10684097A0175 VBN O
into P10684097A0175 IN O
four P10684097A0175 CD O
groups P10684097A0175 NNS O
, P10684097A0175 , O
namely P10684097A0175 RB O
sham P10684097A0175 JJ O
operation P10684097A0175 NN O
, P10684097A0175 , O
bilateral P10684097A0175 JJ O
ovariectomy P10684097A0175 NN O
, P10684097A0175 , O
ovariectomy P10684097A0175 JJ O
plus P10684097A0175 CC O
supplementary P10684097A0175 JJ O
ethinyl P10684097A0175 NN O
estradiol P10684097A0175 NN O
( P10684097A0175 ( O
0.2 P10684097A0175 CD O
microgram P10684097A0175 NN O
/ P10684097A0175 NN O
100 P10684097A0175 CD O
g P10684097A0175 NN O
B P10684097A0175 NNP O
. P10684097A0175 . O
. . O O

The P09187371A0450 DT O
1.1- P09187371A0450 JJ O
and P09187371A0450 CC O
1.3-kb P09187371A0450 JJ O
mRNA P09187371A0450 NN O
species P09187371A0450 NNS O
were P09187371A0450 VBD O
found P09187371A0450 VBN O
only P09187371A0450 RB O
in P09187371A0450 IN O
the P09187371A0450 DT O
heart P09187371A0450 NN O
, P09187371A0450 , O
and P09187371A0450 CC O
the P09187371A0450 DT O
2.6-kb P09187371A0450 JJ O
species P09187371A0450 NNS O
was P09187371A0450 VBD O
found P09187371A0450 VBN O
in P09187371A0450 IN O
the P09187371A0450 DT O
heart P09187371A0450 NN O
, P09187371A0450 , O
kidney P09187371A0450 NN O
and P09187371A0450 CC O
brain P09187371A0450 NN O
, P09187371A0450 , O
but P09187371A0450 CC O
not P09187371A0450 RB O
in P09187371A0450 IN O
skeletal P09187371A0450 JJ O
muscle P09187371A0450 NN O
or P09187371A0450 CC O
liver P09187371A0450 NN O
. P09187371A0450 . O
. . O O

QBMDs P08597108A0642 NNP O
for P08597108A0642 IN O
a P08597108A0642 DT O
5 P08597108A0642 CD O
% P08597108A0642 NN O
change P08597108A0642 NN O
in P08597108A0642 IN O
response P08597108A0642 NN O
( P08597108A0642 ( O
QBMD05 P08597108A0642 NNP O
) P08597108A0642 ) O
were P08597108A0642 VBD O
6-fold P08597108A0642 JJ O
lower P08597108A0642 JJR O
, P08597108A0642 , O
on P08597108A0642 IN O
average P08597108A0642 NN O
, P08597108A0642 , O
than P08597108A0642 IN O
the P08597108A0642 DT O
corresponding P08597108A0642 JJ O
NOAEL P08597108A0642 NNP O
. P08597108A0642 . O
. . O O

Compared P11273995A1148 VBN O
with P11273995A1148 IN O
normal P11273995A1148 JJ O
control P11273995A1148 NN O
subjects P11273995A1148 NNS O
, P11273995A1148 , O
all P11273995A1148 DT O
74 P11273995A1148 CD O
TOF P11273995A1148 NNP O
patients P11273995A1148 NNS O
had P11273995A1148 VBD O
decreased P11273995A1148 VBN O
systolic P11273995A1148 JJ O
and P11273995A1148 CC O
diastolic P11273995A1148 JJ O
myocardial P11273995A1148 JJ O
velocities P11273995A1148 NNS O
and P11273995A1148 CC O
a P11273995A1148 DT O
longer P11273995A1148 RBR O
isovolumic P11273995A1148 JJ O
relaxation P11273995A1148 NN O
time P11273995A1148 NN O
. P11273995A1148 . O
. . O O

Analysis P09272108A1295b NN O
of P09272108A1295b IN O
the P09272108A1295b DT O
5 P09272108A1295b CD O
' P09272108A1295b POS O
flanking P09272108A1295b JJ O
region P09272108A1295b NN O
of P09272108A1295b IN O
the P09272108A1295b DT O
gene P09272108A1295b NN O
also P09272108A1295b RB O
revealed P09272108A1295b VBD O
the P09272108A1295b DT O
presence P09272108A1295b NN O
of P09272108A1295b IN O
multiple P09272108A1295b JJ O
TATA P09272108A1295b NNP O
and P09272108A1295b CC O
CAAT P09272108A1295b NNP O
sequences P09272108A1295b NNS O
. P09272108A1295b . O
. . O O

There P09765754A1727 EX O
was P09765754A1727 VBD O
a P09765754A1727 DT O
trend P09765754A1727 NN O
in P09765754A1727 IN O
all P09765754A1727 DT O
studies P09765754A1727 NNS O
favouring P09765754A1727 VBG O
PVI P09765754A1727 NNP O
. P09765754A1727 . O
. . O O

The P09880512A1251 DT O
data P09880512A1251 NN O
indicate P09880512A1251 NN O
that P09880512A1251 IN O
Bmp2 P09880512A1251 NNP I-UN
is P09880512A1251 VBZ O
directly P09880512A1251 RB O
regulated P09880512A1251 VBN O
by P09880512A1251 IN O
retinoic P09880512A1251 JJ O
acid-bound P09880512A1251 JJ O
receptors P09880512A1251 NNS O
and P09880512A1251 CC O
Sp1 P09880512A1251 NNP I-UN
. P09880512A1251 . O
. . O O

Five P02119626A0471 CD O
of P02119626A0471 IN O
10 P02119626A0471 CD O
scars P02119626A0471 NNS O
studied P02119626A0471 VBD O
decreased P02119626A0471 VBN O
at P02119626A0471 IN O
least P02119626A0471 JJS O
50 P02119626A0471 CD O
% P02119626A0471 NN O
in P02119626A0471 IN O
linear P02119626A0471 JJ O
dimensions P02119626A0471 NNS O
. P02119626A0471 . O
. . O O

Alternatively P07896846T0000 RB O
processed P07896846T0000 JJ O
isoforms P07896846T0000 NNS O
of P07896846T0000 IN O
cellular P07896846T0000 JJ I-UN
nucleic P07896846T0000 JJ I-UN
acid-binding P07896846T0000 JJ I-UN
protein P07896846T0000 NN I-UN
interact P07896846T0000 NN O
with P07896846T0000 IN O
a P07896846T0000 DT O
suppressor P07896846T0000 NN O
region P07896846T0000 NN O
of P07896846T0000 IN O
the P07896846T0000 DT O
human P07896846T0000 JJ I-UN
beta-myosin P07896846T0000 JJ I-UN
heavy P07896846T0000 NN I-UN
chain P07896846T0000 NN I-UN
gene P07896846T0000 NN I-UN
. P07896846T0000 . O
. . O O

Evaluation P04813394T0000 NN O
of P04813394T0000 IN O
1,10-phenanthroline P04813394T0000 JJ O
as P04813394T0000 IN O
a P04813394T0000 DT O
reagent P04813394T0000 NN O
for P04813394T0000 IN O
sialic P04813394T0000 JJ O
acid P04813394T0000 JJ O
determinations P04813394T0000 NNS O
. P04813394T0000 . O
. . O O

Northern P07913926A0878 NNP O
analysis P07913926A0878 NN O
of P07913926A0878 IN O
RNA P07913926A0878 NNP O
samples P07913926A0878 NNS O
isolated P07913926A0878 VBD O
from P07913926A0878 IN O
ammonium-grown P07913926A0878 JJ O
cultures P07913926A0878 NNS O
of P07913926A0878 IN O
the P07913926A0878 DT O
ntcA P07913926A0878 NN I-UN
mutant P07913926A0878 NN I-UN
showed P07913926A0878 VBD O
reduced P07913926A0878 JJ O
amounts P07913926A0878 NNS O
of P07913926A0878 IN O
glnA P07913926A0878 JJ I-UN
message P07913926A0878 NN I-UN
and P07913926A0878 CC O
the P07913926A0878 DT O
absence P07913926A0878 NN O
of P07913926A0878 IN O
a P07913926A0878 DT O
1.7-kb P07913926A0878 JJ O
transcript P07913926A0878 NN O
. P07913926A0878 . O
. . O O

Mutants P08977235A0588 NNS O
lacking P08977235A0588 VBG O
any P08977235A0588 DT O
tyrosine P08977235A0588 NN O
residues P08977235A0588 NNS O
in P08977235A0588 IN O
the P08977235A0588 DT O
cytoplasmic P08977235A0588 JJ O
domain P08977235A0588 NN O
maintain P08977235A0588 VBP O
their P08977235A0588 PRP$ O
ability P08977235A0588 NN O
to P08977235A0588 TO O
activate P08977235A0588 VB O
STAT5 P08977235A0588 NNP I-UN
and P08977235A0588 CC O
STAT1 P08977235A0588 NNP I-UN
but P08977235A0588 CC O
can P08977235A0588 MD O
not P08977235A0588 RB O
activate P08977235A0588 VB O
STAT3 P08977235A0588 NNP I-UN
, P08977235A0588 , O
implying P08977235A0588 VBG O
that P08977235A0588 IN O
STAT5 P08977235A0588 NNP I-UN
and P08977235A0588 CC O
STAT1 P08977235A0588 NNP I-UN
activation P08977235A0588 NN O
does P08977235A0588 VBZ O
not P08977235A0588 RB O
require P08977235A0588 VB O
receptor P08977235A0588 NN O
tyrosine P08977235A0588 JJ O
phosphorylation P08977235A0588 NN O
. P08977235A0588 . O
. . O O

Blood P01410071T0000 NN O
levels P01410071T0000 NNS O
of P01410071T0000 IN O
melatonin P01410071T0000 NN O
, P01410071T0000 , O
serotonin P01410071T0000 NN O
, P01410071T0000 , O
cortisol P01410071T0000 NN O
, P01410071T0000 , O
and P01410071T0000 CC O
prolactin P01410071T0000 NN I-UN
in P01410071T0000 IN O
relation P01410071T0000 NN O
to P01410071T0000 TO O
the P01410071T0000 DT O
circadian P01410071T0000 JJ O
rhythm P01410071T0000 NN O
of P01410071T0000 IN O
platelet P01410071T0000 NN O
serotonin P01410071T0000 NN O
uptake P01410071T0000 NN O
. P01410071T0000 . O
. . O O

As P09405685A0113 IN O
a P09405685A0113 DT O
sequence-specific P09405685A0113 JJ O
DNA P09405685A0113 NN O
binding P09405685A0113 VBG O
transcription P09405685A0113 NN O
factor P09405685A0113 NN O
, P09405685A0113 , O
p53 P09405685A0113 NN I-UN
specifically P09405685A0113 RB O
binds P09405685A0113 VBZ O
to P09405685A0113 TO O
a P09405685A0113 DT O
20-bp P09405685A0113 JJ O
consensus P09405685A0113 NN O
motif P09405685A0113 VBZ O
5'-PuPuPuC P09405685A0113 JJ O
( P09405685A0113 ( O
A P09405685A0113 DT O
/ P09405685A0113 NNP O
T P09405685A0113 NNP O
) P09405685A0113 ) O
( P09405685A0113 ( O
T P09405685A0113 NNP O
/ P09405685A0113 NNP O
A P09405685A0113 NNP O
) P09405685A0113 ) O
GPyPyPyPuPuPuC P09405685A0113 NNP O
( P09405685A0113 ( O
A P09405685A0113 NNP O
/ P09405685A0113 NNP O
T P09405685A0113 NNP O
) P09405685A0113 ) O
( P09405685A0113 ( O
T P09405685A0113 NNP O
/ P09405685A0113 NNP O
A P09405685A0113 NNP O
) P09405685A0113 ) O
GPyPyPy-3 P09405685A0113 NNP O
' P09405685A0113 POS O
. P09405685A0113 . O
. . O O

The P11145562A0468 DT O
P69 P11145562A0468 NNP O
cell P11145562A0468 NN O
line P11145562A0468 NN O
was P11145562A0468 VBD O
derived P11145562A0468 VBN O
by P11145562A0468 IN O
immortalization P11145562A0468 NN O
of P11145562A0468 IN O
human P11145562A0468 JJ O
primary P11145562A0468 JJ O
prostate P11145562A0468 NN O
epithelial P11145562A0468 JJ O
cells P11145562A0468 NNS O
with P11145562A0468 IN O
simian P11145562A0468 JJ I-UN
virus-40 P11145562A0468 JJ I-UN
T P11145562A0468 NNP I-UN
antigen P11145562A0468 NN I-UN
and P11145562A0468 CC O
is P11145562A0468 VBZ O
rarely P11145562A0468 RB O
tumorigenic P11145562A0468 JJ O
. P11145562A0468 . O
. . O O

The P08530105A0308 DT O
minimal P08530105A0308 JJ O
region P08530105A0308 NN O
of P08530105A0308 IN O
overlap P08530105A0308 NN O
of P08530105A0308 IN O
Langer-Giedion P08530105A0308 NNP O
syndrome P08530105A0308 JJ O
deletions P08530105A0308 NNS O
, P08530105A0308 , O
previously P08530105A0308 RB O
identified P08530105A0308 VBN O
by P08530105A0308 IN O
analysis P08530105A0308 NN O
of P08530105A0308 IN O
15 P08530105A0308 CD O
patients P08530105A0308 NNS O
, P08530105A0308 , O
was P08530105A0308 VBD O
placed P08530105A0308 VBN O
on P08530105A0308 IN O
the P08530105A0308 DT O
map P08530105A0308 NN O
by P08530105A0308 IN O
analysis P08530105A0308 NN O
of P08530105A0308 IN O
2 P08530105A0308 CD O
patients P08530105A0308 NNS O
whose P08530105A0308 WP$ O
deletions P08530105A0308 NNS O
define P08530105A0308 VBP O
the P08530105A0308 DT O
endpoints P08530105A0308 NNS O
. P08530105A0308 . O
. . O O

Paf1p P08552095A1115 NNP I-UN
may P08552095A1115 MD O
therefore P08552095A1115 RB O
be P08552095A1115 VB O
required P08552095A1115 VBN O
for P08552095A1115 IN O
both P08552095A1115 DT O
positive P08552095A1115 JJ O
and P08552095A1115 CC O
negative P08552095A1115 JJ O
regulation P08552095A1115 NN O
of P08552095A1115 IN O
subsets P08552095A1115 NNS O
of P08552095A1115 IN O
yeast P08552095A1115 NN O
genes P08552095A1115 NNS O
. P08552095A1115 . O
. . O O

The P07445971A0241 DT O
same P07445971A0241 JJ O
response P07445971A0241 NN O
occurs P07445971A0241 VBZ O
whether P07445971A0241 IN O
acrylamide P07445971A0241 NN O
is P07445971A0241 VBZ O
given P07445971A0241 VBN O
immediately P07445971A0241 RB O
after P07445971A0241 IN O
nerve P07445971A0241 JJ O
ligation P07445971A0241 NN O
or P07445971A0241 CC O
1 P07445971A0241 CD O
week P07445971A0241 NN O
later P07445971A0241 RB O
. P07445971A0241 . O
. . O O

Directives P04543036T0001 NNS O
concerning P04543036T0001 VBG O
medical P04543036T0001 JJ O
care P04543036T0001 NN O
. P04543036T0001 . O
. . O O

These P08554540A1480 DT O
regions P08554540A1480 NNS O
overlap P08554540A1480 VBP O
with P08554540A1480 IN O
the P08554540A1480 DT O
HIT P08554540A1480 NNP I-UN
protein P08554540A1480 NN I-UN
similarity P08554540A1480 NN I-UN
regions P08554540A1480 NNS I-UN
. P08554540A1480 . O
. . O O

Sensory P04019066A0000 JJ O
evoked P04019066A0000 VBD O
field P04019066A0000 NN O
potentials P04019066A0000 NNS O
were P04019066A0000 VBD O
recorded P04019066A0000 VBN O
from P04019066A0000 IN O
the P04019066A0000 DT O
mesencephalic P04019066A0000 JJ O
reticular P04019066A0000 JJ O
formation P04019066A0000 NN O
( P04019066A0000 ( O
MRF P04019066A0000 NNP O
) P04019066A0000 ) O
, P04019066A0000 , O
central P04019066A0000 JJ O
gray P04019066A0000 NN O
( P04019066A0000 ( O
CG P04019066A0000 NNP O
) P04019066A0000 ) O
and P04019066A0000 CC O
somatosensory P04019066A0000 JJ O
cortex P04019066A0000 NN O
( P04019066A0000 ( O
SCX P04019066A0000 NNP O
) P04019066A0000 ) O
, P04019066A0000 , O
following P04019066A0000 VBG O
incremental P04019066A0000 JJ O
doses P04019066A0000 NNS O
of P04019066A0000 IN O
halothane P04019066A0000 NN O
in P04019066A0000 IN O
freely-moving P04019066A0000 JJ O
rats P04019066A0000 NNS O
. P04019066A0000 . O
. . O O

During P01545523A0000 IN O
the P01545523A0000 DT O
1980 P01545523A0000 CD O
's P01545523A0000 POS O
, P01545523A0000 , O
quantifications P01545523A0000 NNS O
of P01545523A0000 IN O
immunoserological P01545523A0000 JJ O
testings P01545523A0000 NNS O
, P01545523A0000 , O
especially P01545523A0000 RB O
C P01545523A0000 NNP I-UN
reactive P01545523A0000 JJ I-UN
protein P01545523A0000 NN I-UN
, P01545523A0000 , O
rheumatoid P01545523A0000 JJ I-UN
factor P01545523A0000 NN I-UN
and P01545523A0000 CC O
antistreptolysin P01545523A0000 NN I-UN
O P01545523A0000 NNP I-UN
, P01545523A0000 , O
progressed P01545523A0000 VBD O
rapidly P01545523A0000 RB O
. P01545523A0000 . O
. . O O

Two P09111004A0732 CD O
predominant P09111004A0732 JJ O
effects P09111004A0732 NNS O
were P09111004A0732 VBD O
noted P09111004A0732 VBN O
: P09111004A0732 : O
( P09111004A0732 ( O
i P09111004A0732 NN O
) P09111004A0732 ) O
the P09111004A0732 DT O
Xaa P09111004A0732 NNP O
residue P09111004A0732 NN O
in P09111004A0732 IN O
the P09111004A0732 DT O
dual P09111004A0732 JJ O
phosphorylation P09111004A0732 NN O
motif P09111004A0732 RB O
Thr-Xaa-Tyr P09111004A0732 NNP O
as P09111004A0732 RB O
well P09111004A0732 RB O
as P09111004A0732 IN O
the P09111004A0732 DT O
length P09111004A0732 NN O
of P09111004A0732 IN O
L12 P09111004A0732 NNP O
influence P09111004A0732 NN O
p38 P09111004A0732 NN I-UN
substrate P09111004A0732 NN O
specificity P09111004A0732 NN O
, P09111004A0732 , O
and P09111004A0732 CC O
( P09111004A0732 ( O
ii P09111004A0732 NN O
) P09111004A0732 ) O
the P09111004A0732 DT O
length P09111004A0732 NN O
of P09111004A0732 IN O
L12 P09111004A0732 NNP O
plays P09111004A0732 VBZ O
a P09111004A0732 DT O
major P09111004A0732 JJ O
role P09111004A0732 NN O
in P09111004A0732 IN O
controlling P09111004A0732 VBG O
autophosphorylation P09111004A0732 NN O
. P09111004A0732 . O
. . O O

Taken P10074903A0915 VBN O
together P10074903A0915 RB O
, P10074903A0915 , O
these P10074903A0915 DT O
results P10074903A0915 NNS O
are P10074903A0915 VBP O
consistent P10074903A0915 JJ O
with P10074903A0915 IN O
the P10074903A0915 DT O
possibility P10074903A0915 NN O
that P10074903A0915 IN O
p202 P10074903A0915 VBZ I-UN
protein P10074903A0915 RB I-UN
contributes P10074903A0915 NNS O
to P10074903A0915 TO O
the P10074903A0915 DT O
cell P10074903A0915 NN O
growth P10074903A0915 NN O
retardation P10074903A0915 NN O
activity P10074903A0915 NN O
of P10074903A0915 IN O
the P10074903A0915 DT O
IFNs P10074903A0915 NNP I-UN
, P10074903A0915 , O
at P10074903A0915 IN O
least P10074903A0915 JJS O
in P10074903A0915 IN O
part P10074903A0915 NN O
, P10074903A0915 , O
by P10074903A0915 IN O
modulating P10074903A0915 VBG O
p21 P10074903A0915 JJ I-UN
protein P10074903A0915 NN I-UN
levels P10074903A0915 NNS O
. P10074903A0915 . O
. . O O

Additionally P02123877A1452 RB O
, P02123877A1452 , O
although P02123877A1452 IN O
c-fos P02123877A1452 JJ I-UN
and P02123877A1452 CC O
egr-1 P02123877A1452 JJ I-UN
mRNAs P02123877A1452 NNS I-UN
are P02123877A1452 VBP O
expressed P02123877A1452 VBN O
at P02123877A1452 IN O
elevated P02123877A1452 JJ O
levels P02123877A1452 NNS O
in P02123877A1452 IN O
stimulated P02123877A1452 VBN O
liver P02123877A1452 NN O
cells P02123877A1452 NNS O
, P02123877A1452 , O
fos-B P02123877A1452 JJ I-UN
, P02123877A1452 , O
fra-1 P02123877A1452 JJ I-UN
, P02123877A1452 , O
and P02123877A1452 CC O
egr-2 P02123877A1452 NNS I-UN
are P02123877A1452 VBP O
not P02123877A1452 RB O
, P02123877A1452 , O
which P02123877A1452 WDT O
suggests P02123877A1452 VBZ O
that P02123877A1452 IN O
factors P02123877A1452 NNS O
in P02123877A1452 IN O
addition P02123877A1452 NN O
to P02123877A1452 TO O
the P02123877A1452 DT O
serum P02123877A1452 NN I-UN
response P02123877A1452 NN I-UN
factor P02123877A1452 NN I-UN
participate P02123877A1452 NN O
in P02123877A1452 IN O
the P02123877A1452 DT O
regulation P02123877A1452 NN O
of P02123877A1452 IN O
immediate-early P02123877A1452 JJ I-UN
gene P02123877A1452 NN I-UN
induction P02123877A1452 NN O
. P02123877A1452 . O
. . O O

RPS14 P03785212A1128 NNP I-UN
introns P03785212A1128 NNS O
3 P03785212A1128 CD O
and P03785212A1128 CC O
4 P03785212A1128 CD O
both P03785212A1128 DT O
contain P03785212A1128 NN O
Alu P03785212A1128 NNP I-UN
sequences P03785212A1128 NNS O
. P03785212A1128 . O
. . O O

RESULTS P10811079A0555 NN O
: P10811079A0555 : O
Abnormal P10811079A0555 JJ O
color P10811079A0555 NN O
perception P10811079A0555 NN O
was P10811079A0555 VBD O
found P10811079A0555 VBN O
in P10811079A0555 IN O
32 P10811079A0555 CD O
% P10811079A0555 NN O
of P10811079A0555 IN O
the P10811079A0555 DT O
epilepsy P10811079A0555 NN O
patients P10811079A0555 NNS O
treated P10811079A0555 VBN O
with P10811079A0555 IN O
vigabatrin P10811079A0555 JJ O
monotherapy P10811079A0555 NN O
and P10811079A0555 CC O
28 P10811079A0555 CD O
% P10811079A0555 NN O
of P10811079A0555 IN O
the P10811079A0555 DT O
epilepsy P10811079A0555 NN O
patients P10811079A0555 NNS O
treated P10811079A0555 VBN O
with P10811079A0555 IN O
carbamazepine P10811079A0555 JJ O
monotherapy P10811079A0555 NN O
. P10811079A0555 . O
. . O O

This P02218094A0395 DT O
last P02218094A0395 JJ O
includes P02218094A0395 VBZ O
tissue P02218094A0395 NN O
O2 P02218094A0395 NNP O
transfer P02218094A0395 NN O
( P02218094A0395 ( O
Ft P02218094A0395 NNP O
' P02218094A0395 POS O
) P02218094A0395 ) O
and P02218094A0395 CC O
mitochondrial P02218094A0395 JJ O
O2 P02218094A0395 NNP O
utilization P02218094A0395 NN O
( P02218094A0395 ( O
Fm P02218094A0395 NNP O
' P02218094A0395 POS O
) P02218094A0395 ) O
. P02218094A0395 . O
. . O O

By P11352663A0138 IN O
comparison P11352663A0138 NN O
, P11352663A0138 , O
in P11352663A0138 IN O
nontumorigenic P11352663A0138 JJ O
Ad5 P11352663A0138 NNP O
cells P11352663A0138 NNS O
, P11352663A0138 , O
class P11352663A0138 NN O
I P11352663A0138 PRP O
expression P11352663A0138 VBP O
is P11352663A0138 VBZ O
high P11352663A0138 JJ O
due P11352663A0138 JJ O
to P11352663A0138 TO O
negligible P11352663A0138 JJ O
binding P11352663A0138 NN O
of P11352663A0138 IN O
COUP-TF P11352663A0138 NNP I-UN
and P11352663A0138 CC O
strong P11352663A0138 JJ O
binding P11352663A0138 NN O
of P11352663A0138 IN O
NF-kappaB P11352663A0138 NNP I-UN
. P11352663A0138 . O
. . O O

In P10751398A1135 IN O
addition P10751398A1135 NN O
, P10751398A1135 , O
the P10751398A1135 DT O
transcription P10751398A1135 NN O
of P10751398A1135 IN O
c-IAP2 P10751398A1135 JJ I-UN
promoter P10751398A1135 NN I-UN
was P10751398A1135 VBD O
strongly P10751398A1135 RB O
up-regulated P10751398A1135 JJ O
when P10751398A1135 WRB O
CD40 P10751398A1135 NNP I-UN
or P10751398A1135 CC O
Epstein-Barr P10751398A1135 NNP I-UN
virus P10751398A1135 NN I-UN
latent P10751398A1135 NN I-UN
membrane P10751398A1135 NN I-UN
protein P10751398A1135 VBD I-UN
1 P10751398A1135 CD I-UN
was P10751398A1135 VBD O
overexpressed P10751398A1135 VBN O
. P10751398A1135 . O
. . O O

The P06784123A0771 DT O
1.9-kb P06784123A0771 JJ O
C P06784123A0771 NNP I-UN
mu P06784123A0771 NN I-UN
RNA P06784123A0771 NNP O
contains P06784123A0771 VBZ O
the P06784123A0771 DT O
3 P06784123A0771 CD O
' P06784123A0771 POS O
sequence P06784123A0771 NN O
characteristic P06784123A0771 NN O
of P06784123A0771 IN O
secreted P06784123A0771 JJ O
mu P06784123A0771 NN I-UN
chain P06784123A0771 NN I-UN
, P06784123A0771 , O
whereas P06784123A0771 IN O
the P06784123A0771 DT O
longer P06784123A0771 JJR O
species P06784123A0771 NNS O
bear P06784123A0771 VBP O
that P06784123A0771 IN O
of P06784123A0771 IN O
membrane-bound P06784123A0771 JJ O
mu P06784123A0771 NN I-UN
chin P06784123A0771 NN O
. P06784123A0771 . O
. . O O

By P08264582A0750 IN O
using P08264582A0750 VBG O
the P08264582A0750 DT O
full-length P08264582A0750 JJ O
cytoplasmic P08264582A0750 JJ O
domain P08264582A0750 NN O
and P08264582A0750 CC O
mutants P08264582A0750 NNS O
with P08264582A0750 IN O
progressive P08264582A0750 JJ O
carboxy-terminal P08264582A0750 JJ O
deletions P08264582A0750 NNS O
, P08264582A0750 , O
internal P08264582A0750 JJ O
deletions P08264582A0750 NNS O
, P08264582A0750 , O
or P08264582A0750 CC O
point P08264582A0750 NN O
mutations P08264582A0750 NNS O
, P08264582A0750 , O
we P08264582A0750 PRP O
identified P08264582A0750 VBD O
the P08264582A0750 DT O
first P08264582A0750 JJ O
150 P08264582A0750 CD O
amino P08264582A0750 NN O
acid P08264582A0750 NN O
residues P08264582A0750 NNS O
of P08264582A0750 IN O
LIFR P08264582A0750 NNP I-UN
as P08264582A0750 IN O
the P08264582A0750 DT O
minimal P08264582A0750 JJ O
region P08264582A0750 NN O
necessary P08264582A0750 JJ O
for P08264582A0750 IN O
signaling P08264582A0750 VBG O
. P08264582A0750 . O
. . O O

The P10761263A1108 DT O
'Newcastle P10761263A1108 NNP O
' P10761263A1108 POS O
model P10761263A1108 NN O
, P10761263A1108 , O
which P10761263A1108 WDT O
is P10761263A1108 VBZ O
based P10761263A1108 VBN O
on P10761263A1108 IN O
Hotelling P10761263A1108 NNP O
's P10761263A1108 POS O
T2 P10761263A1108 NNP O
statistic P10761263A1108 NN O
, P10761263A1108 , O
proved P10761263A1108 VBD O
to P10761263A1108 TO O
be P10761263A1108 VB O
more P10761263A1108 RBR O
sensitive P10761263A1108 JJ O
and P10761263A1108 CC O
diagnosed P10761263A1108 VBD O
a P10761263A1108 DT O
systematic P10761263A1108 JJ O
displacement P10761263A1108 NN O
for P10761263A1108 IN O
three P10761263A1108 CD O
prostate P10761263A1108 NN O
patients P10761263A1108 NNS O
. P10761263A1108 . O
. . O O

Antibodies P03282232A0743 NNS O
made P03282232A0743 VBN O
against P03282232A0743 IN O
fusion P03282232A0743 NN O
protein P03282232A0743 NN O
produced P03282232A0743 VBN O
by P03282232A0743 IN O
the P03282232A0743 DT O
DP1A P03282232A0743 NNP I-UN
clone P03282232A0743 NN O
reacted P03282232A0743 VBD O
specifically P03282232A0743 RB O
with P03282232A0743 IN O
DP-I P03282232A0743 NNP I-UN
and P03282232A0743 CC I-UN
-II P03282232A0743 NNP I-UN
on P03282232A0743 IN O
immunoblots P03282232A0743 NNS O
. P03282232A0743 . O
. . O O

The P05410590T0000 DT O
role P05410590T0000 NN O
of P05410590T0000 IN O
ascorbic P05410590T0000 JJ O
acid P05410590T0000 NN O
in P05410590T0000 IN O
the P05410590T0000 DT O
prevention P05410590T0000 NN O
of P05410590T0000 IN O
bladder P05410590T0000 NN O
tumor P05410590T0000 NN O
formation P05410590T0000 NN O
. P05410590T0000 . O
. . O O

We P07891720A0818 PRP O
show P07891720A0818 VBP O
here P07891720A0818 RB O
that P07891720A0818 IN O
the P07891720A0818 DT O
binding P07891720A0818 NN O
of P07891720A0818 IN O
C1F P07891720A0818 NNP I-UN
in P07891720A0818 IN O
vitro P07891720A0818 NN O
is P07891720A0818 VBZ O
sensitive P07891720A0818 JJ O
to P07891720A0818 TO O
the P07891720A0818 DT O
concentration P07891720A0818 NN O
of P07891720A0818 IN O
calcium P07891720A0818 NN O
ions P07891720A0818 NNS O
. P07891720A0818 . O
. . O O

The P07559356T0000 DT O
hypBFCDE P07559356T0000 NN I-UN
operon P07559356T0000 NN I-UN
from P07559356T0000 IN O
Rhizobium P07559356T0000 NNP O
leguminosarum P07559356T0000 NN O
biovar P07559356T0000 NN O
viciae P07559356T0000 NN O
is P07559356T0000 VBZ O
expressed P07559356T0000 VBN O
from P07559356T0000 IN O
an P07559356T0000 DT O
Fnr-type P07559356T0000 JJ I-UN
promoter P07559356T0000 NN I-UN
that P07559356T0000 WDT O
escapes P07559356T0000 VBZ O
mutagenesis P07559356T0000 NN O
of P07559356T0000 IN O
the P07559356T0000 DT O
fnrN P07559356T0000 JJ I-UN
gene P07559356T0000 NN I-UN
. P07559356T0000 . O
. . O O

In P01682542A0690 IN O
a P01682542A0690 DT O
country P01682542A0690 NN O
where P01682542A0690 WRB O
general P01682542A0690 JJ O
HIV P01682542A0690 NNP O
prevalence P01682542A0690 NN O
is P01682542A0690 VBZ O
low P01682542A0690 JJ O
, P01682542A0690 , O
the P01682542A0690 DT O
strategy P01682542A0690 NN O
is P01682542A0690 VBZ O
cost-effective P01682542A0690 JJ O
for P01682542A0690 IN O
location P01682542A0690 NN O
and P01682542A0690 CC O
counselling P01682542A0690 NN O
of P01682542A0690 IN O
unknowingly P01682542A0690 RB O
seropositive P01682542A0690 JJ O
individuals P01682542A0690 NNS O
. P01682542A0690 . O
. . O O

Examination P01982997A1104 NN O
of P01982997A1104 IN O
immediate-early P01982997A1104 JJ I-UN
transcription P01982997A1104 NN I-UN
factor P01982997A1104 NN I-UN
expression P01982997A1104 NN O
during P01982997A1104 IN O
the P01982997A1104 DT O
MDI P01982997A1104 NNP O
regimen P01982997A1104 NNS O
revealed P01982997A1104 VBD O
that P01982997A1104 IN O
RA P01982997A1104 NNP O
mediated P01982997A1104 VBD O
an P01982997A1104 DT O
elevated P01982997A1104 VBN O
, P01982997A1104 , O
prolonged P01982997A1104 JJ O
expression P01982997A1104 NN O
of P01982997A1104 IN O
c-Jun P01982997A1104 JJ I-UN
mRNA P01982997A1104 NNS I-UN
accompanied P01982997A1104 VBN O
by P01982997A1104 IN O
diminished P01982997A1104 JJ O
expression P01982997A1104 NN O
of P01982997A1104 IN O
c-Fos P01982997A1104 JJ I-UN
and P01982997A1104 CC O
Jun-B P01982997A1104 JJ I-UN
mRNAs P01982997A1104 NN I-UN
. P01982997A1104 . O
. . O O

An P02076816T0000 DT O
RME1-independent P02076816T0000 JJ O
pathway P02076816T0000 NN O
for P02076816T0000 IN O
sporulation P02076816T0000 NN O
control P02076816T0000 NN O
in P02076816T0000 IN O
Saccharomyces P02076816T0000 NNP O
cerevisiae P02076816T0000 NN O
acts P02076816T0000 VBZ O
through P02076816T0000 IN O
IME1 P02076816T0000 NNP I-UN
transcript P02076816T0000 NN I-UN
accumulation P02076816T0000 NN O
. P02076816T0000 . O
. . O O

After P11530684A0667 IN O
nerve P11530684A0667 JJ O
injury P11530684A0667 NN O
, P11530684A0667 , O
the P11530684A0667 DT O
nociceptive P11530684A0667 JJ O
responses P11530684A0667 NNS O
through P11530684A0667 IN O
type P11530684A0667 NN O
I P11530684A0667 PRP O
neurons P11530684A0667 NNS O
, P11530684A0667 , O
which P11530684A0667 WDT O
are P11530684A0667 VBP O
polymodal P11530684A0667 JJ O
C-fibers P11530684A0667 NNS O
and P11530684A0667 CC O
drive P11530684A0667 JJ O
NK1-receptor P11530684A0667 NNP I-UN
mechanisms P11530684A0667 NN O
in P11530684A0667 IN O
spinal P11530684A0667 JJ O
pain P11530684A0667 NN O
transmission P11530684A0667 NN O
, P11530684A0667 , O
were P11530684A0667 VBD O
completely P11530684A0667 RB O
lost P11530684A0667 VBN O
, P11530684A0667 , O
but P11530684A0667 CC O
without P11530684A0667 IN O
changes P11530684A0667 NNS O
in P11530684A0667 IN O
type P11530684A0667 NN O
II P11530684A0667 NNP O
ones P11530684A0667 NNS O
, P11530684A0667 , O
which P11530684A0667 WDT O
are P11530684A0667 VBP O
polymodal P11530684A0667 JJ O
C-fibers P11530684A0667 NNS O
and P11530684A0667 CC O
drive P11530684A0667 JJ O
NMDA P11530684A0667 NNP I-UN
receptor-mechanisms P11530684A0667 NN O
, P11530684A0667 , O
while P11530684A0667 IN O
type P11530684A0667 JJ O
III P11530684A0667 NNP O
ones P11530684A0667 NNS O
, P11530684A0667 , O
which P11530684A0667 WDT O
are P11530684A0667 VBP O
capsaicin-insensitive P11530684A0667 JJ O
( P11530684A0667 ( O
possibly P11530684A0667 RB O
A-fibers P11530684A0667 NNP O
) P11530684A0667 ) O
and P11530684A0667 CC O
drive P11530684A0667 JJ O
NMDA-receptor P11530684A0667 NNP I-UN
mechanisms P11530684A0667 NNS O
, P11530684A0667 , O
were P11530684A0667 VBD O
markedly P11530684A0667 RB O
enhanced P11530684A0667 VBN O
. P11530684A0667 . O
. . O O

Four P02603923A0220 CD O
full-thickness P02603923A0220 JJ O
skin P02603923A0220 NN O
incisions P02603923A0220 NNS O
were P02603923A0220 VBD O
made P02603923A0220 VBN O
in P02603923A0220 IN O
the P02603923A0220 DT O
back P02603923A0220 NN O
of P02603923A0220 IN O
10 P02603923A0220 CD O
female P02603923A0220 JJ O
pigs P02603923A0220 NNS O
that P02603923A0220 WDT O
treated P02603923A0220 VBD O
twice P02603923A0220 RB O
a P02603923A0220 DT O
day P02603923A0220 NN O
for P02603923A0220 IN O
14 P02603923A0220 CD O
days P02603923A0220 NNS O
with P02603923A0220 IN O
2 P02603923A0220 CD O
ml P02603923A0220 NNS O
of P02603923A0220 IN O
epidermal P02603923A0220 JJ I-UN
growth P02603923A0220 NN I-UN
factor P02603923A0220 NN I-UN
( P02603923A0220 ( O
300 P02603923A0220 CD O
ng P02603923A0220 RB O
/ P02603923A0220 NNP O
ml P02603923A0220 NN O
) P02603923A0220 ) O
or P02603923A0220 CC O
2 P02603923A0220 CD O
ml P02603923A0220 NN O
of P02603923A0220 IN O
Ringer P02603923A0220 NNP O
's P02603923A0220 POS O
lactate P02603923A0220 JJ O
solution P02603923A0220 NN O
in P02603923A0220 IN O
a P02603923A0220 DT O
single-blind P02603923A0220 NN O
, P02603923A0220 , O
randomized P02603923A0220 VBN O
fashion P02603923A0220 NN O
. P02603923A0220 . O
. . O O

Our P08065901A0997 PRP$ O
results P08065901A0997 NNS O
indicate P08065901A0997 VBP O
that P08065901A0997 IN O
the P08065901A0997 DT O
KRAB P08065901A0997 NNP I-UN
domain P08065901A0997 NN I-UN
present P08065901A0997 NN O
in P08065901A0997 IN O
the P08065901A0997 DT O
non-finger P08065901A0997 JJ O
region P08065901A0997 NN O
of P08065901A0997 IN O
many P08065901A0997 JJ O
ZFP P08065901A0997 NNP I-UN
genes P08065901A0997 NNS I-UN
quenches P08065901A0997 NNS O
transcription P08065901A0997 NN O
possibly P08065901A0997 RB O
due P08065901A0997 JJ O
to P08065901A0997 TO O
specific P08065901A0997 JJ O
protein-protein P08065901A0997 JJ O
interactions P08065901A0997 NNS O
between P08065901A0997 IN O
the P08065901A0997 DT O
KRAB-A P08065901A0997 NNP I-UN
domain P08065901A0997 NN I-UN
and P08065901A0997 CC O
components P08065901A0997 NNS O
of P08065901A0997 IN O
the P08065901A0997 DT O
proximal P08065901A0997 JJ O
transcriptional P08065901A0997 JJ O
apparatus P08065901A0997 NN O
. P08065901A0997 . O
. . O O

In P07592072A0217 IN O
Trial P07592072A0217 NNP O
1 P07592072A0217 CD O
, P07592072A0217 , O
eight P07592072A0217 CD O
sows P07592072A0217 NNS O
were P07592072A0217 VBD O
allowed P07592072A0217 VBN O
to P07592072A0217 TO O
farrow P07592072A0217 VB O
naturally P07592072A0217 RB O
( P07592072A0217 ( O
d P07592072A0217 JJ O
114 P07592072A0217 CD O
, P07592072A0217 , O
NF P07592072A0217 NNP O
sows P07592072A0217 VBZ O
) P07592072A0217 ) O
and P07592072A0217 CC O
eight P07592072A0217 CD O
sows P07592072A0217 NNS O
were P07592072A0217 VBD O
induced P07592072A0217 VBN O
to P07592072A0217 TO O
farrow P07592072A0217 VB O
( P07592072A0217 ( O
IF P07592072A0217 NNP O
sows P07592072A0217 VBZ O
) P07592072A0217 ) O
prematurely P07592072A0217 RB O
by P07592072A0217 IN O
injection P07592072A0217 NN O
of P07592072A0217 IN O
prostaglandin P07592072A0217 NN O
F2 P07592072A0217 NNP O
alpha P07592072A0217 NN O
on P07592072A0217 IN O
d P07592072A0217 JJ O
112 P07592072A0217 CD O
of P07592072A0217 IN O
gestation P07592072A0217 NN O
. P07592072A0217 . O
. . O O

IgG P01098592A0567 NNP I-UN
levels P01098592A0567 NNS O
of P01098592A0567 IN O
1 P01098592A0567 CD O
/ P01098592A0567 NNS O
100 P01098592A0567 CD O
were P01098592A0567 VBD O
present P01098592A0567 JJ O
in P01098592A0567 IN O
only P01098592A0567 RB O
four P01098592A0567 CD O
out P01098592A0567 IN O
of P01098592A0567 IN O
ten P01098592A0567 JJ O
samples P01098592A0567 NNS O
obtained P01098592A0567 VBD O
150 P01098592A0567 CD O
days P01098592A0567 NNS O
after P01098592A0567 IN O
the P01098592A0567 DT O
clinical P01098592A0567 JJ O
onset P01098592A0567 NN O
. P01098592A0567 . O
. . O O

Toxicity P06199132A0179 NN O
was P06199132A0179 VBD O
significant P06199132A0179 JJ O
in P06199132A0179 IN O
selected P06199132A0179 JJ O
cases P06199132A0179 NNS O
; P06199132A0179 : O
three P06199132A0179 CD O
patients P06199132A0179 NNS O
developed P06199132A0179 VBD O
WBC P06199132A0179 NNP O
counts P06199132A0179 VBZ O
less P06199132A0179 JJR O
than P06199132A0179 IN O
1,000 P06199132A0179 CD O
/ P06199132A0179 JJ O
mm3 P06199132A0179 NN O
and P06199132A0179 CC O
one P06199132A0179 CD O
of P06199132A0179 IN O
these P06199132A0179 DT O
patients P06199132A0179 NNS O
died P06199132A0179 VBD O
with P06199132A0179 IN O
sepsis P06199132A0179 NN O
. P06199132A0179 . O
. . O O

Absorption P05806936T0000 NN O
of P05806936T0000 IN O
electrolytes P05806936T0000 NNS O
from P05806936T0000 IN O
the P05806936T0000 DT O
colon P05806936T0000 NN O
in P05806936T0000 IN O
cases P05806936T0000 NNS O
of P05806936T0000 IN O
ulcerative P05806936T0000 JJ O
colitis P05806936T0000 NN O
and P05806936T0000 CC O
in P05806936T0000 IN O
control P05806936T0000 NN O
subjects P05806936T0000 NNS O
. P05806936T0000 . O
. . O O

T. P08900164A0188 NNP O
, P08900164A0188 , O
Patel P08900164A0188 NNP O
, P08900164A0188 , O
S P08900164A0188 NNP O
. P08900164A0188 . O
. . O O

Elevated P09858581A0183 JJ O
expression P09858581A0183 NN O
of P09858581A0183 IN O
a P09858581A0183 DT O
previously P09858581A0183 RB O
uncharacterized P09858581A0183 JJ O
gene P09858581A0183 NN O
, P09858581A0183 , O
SPP381 P09858581A0183 NNP I-UN
, P09858581A0183 , O
efficiently P09858581A0183 RB O
suppresses P09858581A0183 VBZ O
the P09858581A0183 DT O
growth P09858581A0183 NN O
and P09858581A0183 CC O
splicing P09858581A0183 VBG O
defects P09858581A0183 NNS O
of P09858581A0183 IN O
a P09858581A0183 DT O
temperature-sensitive P09858581A0183 JJ O
( P09858581A0183 ( O
Ts P09858581A0183 NNP O
) P09858581A0183 ) O
mutant P09858581A0183 VBD I-UN
prp38-1 P09858581A0183 NN I-UN
. P09858581A0183 . O
. . O O

The P09765372A0669 DT O
high P09765372A0669 JJ O
density P09765372A0669 NN O
of P09765372A0669 IN O
tegumental P09765372A0669 JJ O
spines P09765372A0669 NNS O
on P09765372A0669 IN O
posterior P09765372A0669 JJ O
half P09765372A0669 NN O
of P09765372A0669 IN O
the P09765372A0669 DT O
body P09765372A0669 NN O
and P09765372A0669 CC O
the P09765372A0669 DT O
distribution P09765372A0669 NN O
of P09765372A0669 IN O
type P09765372A0669 NN O
II P09765372A0669 NNP O
papillae P09765372A0669 NN O
on P09765372A0669 IN O
dorsal P09765372A0669 NN O
surface P09765372A0669 NN O
are P09765372A0669 VBP O
considered P09765372A0669 VBN O
to P09765372A0669 TO O
be P09765372A0669 VB O
characteristic P09765372A0669 JJ O
of P09765372A0669 IN O
C. P09765372A0669 NNP O
armatus P09765372A0669 NN O
. P09765372A0669 . O
. . O O

Deformities P06451557A0777 NNS O
of P06451557A0777 IN O
the P06451557A0777 DT O
tip P06451557A0777 NN O
of P06451557A0777 IN O
the P06451557A0777 DT O
olecranon P06451557A0777 NN O
and P06451557A0777 CC O
of P06451557A0777 IN O
the P06451557A0777 DT O
coronoid P06451557A0777 NN O
process P06451557A0777 NN O
are P06451557A0777 VBP O
also P06451557A0777 RB O
described P06451557A0777 VBN O
( P06451557A0777 ( O
De P06451557A0777 NNP O
Palma P06451557A0777 NNP O
1956 P06451557A0777 CD O
, P06451557A0777 , O
Jordan P06451557A0777 NNP O
1958 P06451557A0777 CD O
, P06451557A0777 , O
Ahlberg P06451557A0777 NNP O
1965 P06451557A0777 CD O
, P06451557A0777 , O
Weseloh P06451557A0777 NNP O
1973 P06451557A0777 CD O
) P06451557A0777 ) O
. P06451557A0777 . O
. . O O

Although P08583783A0870 IN O
ANP P08583783A0870 NNP I-UN
induced P08583783A0870 VBD O
systemic P08583783A0870 JJ O
capillary P08583783A0870 JJ O
filtration P08583783A0870 NN O
, P08583783A0870 , O
in P08583783A0870 IN O
the P08583783A0870 DT O
calf P08583783A0870 NN O
, P08583783A0870 , O
filtration P08583783A0870 NN O
was P08583783A0870 VBD O
reduced P08583783A0870 VBN O
with P08583783A0870 IN O
ANP P08583783A0870 NNP I-UN
. P08583783A0870 . O
. . O O

The P08768374A0765 DT O
P-wr P08768374A0765 NNP I-UN
and P08768374A0765 CC O
P-rr P08768374A0765 NNP I-UN
cDNA P08768374A0765 NN I-UN
sequences P08768374A0765 NNS I-UN
are P08768374A0765 VBP O
very P08768374A0765 RB O
similar P08768374A0765 JJ O
in P08768374A0765 IN O
their P08768374A0765 PRP$ O
5 P08768374A0765 CD O
' P08768374A0765 POS O
regions P08768374A0765 NNS O
. P08768374A0765 . O
. . O O

Although P08990168A0688 IN O
p48 P08990168A0688 JJ I-UN
gene P08990168A0688 NN I-UN
induction P08990168A0688 NN O
is P08990168A0688 VBZ O
dependent P08990168A0688 JJ O
on P08990168A0688 IN O
STAT1 P08990168A0688 NNP I-UN
and P08990168A0688 CC O
JAK1 P08990168A0688 NNP I-UN
, P08990168A0688 , O
activated P08990168A0688 VBD O
STAT1 P08990168A0688 NNP I-UN
does P08990168A0688 VBZ O
not P08990168A0688 RB O
bind P08990168A0688 VB O
to P08990168A0688 TO O
GATE P08990168A0688 NNP I-UN
. P08990168A0688 . O
. . O O

The P07835886A0894 DT O
kallistatin P07835886A0894 NN I-UN
gene P07835886A0894 NN I-UN
was P07835886A0894 VBD O
localized P07835886A0894 VBN O
by P07835886A0894 IN O
in P07835886A0894 IN O
situ P07835886A0894 JJ O
hybridization P07835886A0894 NN O
to P07835886A0894 TO O
human P07835886A0894 JJ O
chromosome P07835886A0894 NN O
14q31-q32.1 P07835886A0894 CD O
, P07835886A0894 , O
close P07835886A0894 RB O
to P07835886A0894 TO O
the P07835886A0894 DT O
serpin P07835886A0894 NN I-UN
genes P07835886A0894 NNS I-UN
encoding P07835886A0894 VBG O
alpha P07835886A0894 JJ I-UN
1-antichymotrypsin P07835886A0894 JJ I-UN
, P07835886A0894 , O
protein P07835886A0894 JJ I-UN
C P07835886A0894 NNP I-UN
inhibitor P07835886A0894 NN I-UN
, P07835886A0894 , O
alpha P07835886A0894 JJ I-UN
1-antitrypsin P07835886A0894 CD I-UN
, P07835886A0894 , O
and P07835886A0894 CC O
corticosteroid-binding P07835886A0894 JJ I-UN
globulin P07835886A0894 NN I-UN
. P07835886A0894 . O
. . O O

During P08098914A0400 IN O
exercise P08098914A0400 NN O
, P08098914A0400 , O
the P08098914A0400 DT O
Pes-Ves P08098914A0400 NNP O
relation P08098914A0400 NN O
was P08098914A0400 VBD O
shifted P08098914A0400 VBN O
toward P08098914A0400 IN O
the P08098914A0400 DT O
left P08098914A0400 NN O
and P08098914A0400 CC O
the P08098914A0400 DT O
slope P08098914A0400 NN O
[ P08098914A0400 VBZ O
end-systolic P08098914A0400 JJ O
elastance P08098914A0400 NN O
( P08098914A0400 ( O
Ees P08098914A0400 NNP O
) P08098914A0400 ) O
] P08098914A0400 VBP O
increased P08098914A0400 VBN O
from P08098914A0400 IN O
7.7 P08098914A0400 CD O
+ P08098914A0400 NNS O
/ P08098914A0400 SYM O
- P08098914A0400 : O
2.8 P08098914A0400 CD O
to P08098914A0400 TO O
12.7 P08098914A0400 CD O
+ P08098914A0400 NNS O
/ P08098914A0400 SYM O
- P08098914A0400 : O
4.2 P08098914A0400 CD O
( P08098914A0400 ( O
SD P08098914A0400 NNP O
) P08098914A0400 ) O
mmHg P08098914A0400 NN O
/ P08098914A0400 JJ O
ml P08098914A0400 NN O
( P08098914A0400 ( O
P P08098914A0400 NNP O
< P08098914A0400 NNP O
0.05 P08098914A0400 CD O
) P08098914A0400 ) O
. P08098914A0400 . O
. . O O

In P10022850A0929 IN O
contrast P10022850A0929 NN O
, P10022850A0929 , O
an P10022850A0929 DT O
amino-terminal P10022850A0929 JJ O
fragment P10022850A0929 NN O
containing P10022850A0929 VBG O
the P10022850A0929 DT O
C P10022850A0929 NNP O
/ P10022850A0929 NNP O
H1 P10022850A0929 NNP O
domain P10022850A0929 NN O
was P10022850A0929 VBD O
sufficient P10022850A0929 JJ O
for P10022850A0929 IN O
coactivation P10022850A0929 NN O
of P10022850A0929 IN O
Zta P10022850A0929 NNP I-UN
transcription P10022850A0929 NN O
and P10022850A0929 CC O
viral P10022850A0929 JJ O
reactivation P10022850A0929 NN O
function P10022850A0929 NN O
. P10022850A0929 . O
. . O O

Analysis P02298741A0809 NN O
with P02298741A0809 IN O
additional P02298741A0809 JJ O
anti-peptide P02298741A0809 JJ O
antibodies P02298741A0809 NNS O
specific P02298741A0809 VBP O
for P02298741A0809 IN O
alpha P02298741A0809 NN I-UN
, P02298741A0809 , I-UN
beta P02298741A0809 NN I-UN
, P02298741A0809 , I-UN
or P02298741A0809 CC I-UN
gamma P02298741A0809 VB I-UN
PKC P02298741A0809 NNP I-UN
indicated P02298741A0809 VBD O
that P02298741A0809 IN O
all P02298741A0809 DT O
three P02298741A0809 CD O
types P02298741A0809 NNS O
of P02298741A0809 IN O
PKC P02298741A0809 NNP I-UN
are P02298741A0809 VBP O
expressed P02298741A0809 VBN O
in P02298741A0809 IN O
JK P02298741A0809 NNP O
cells P02298741A0809 NNS O
; P02298741A0809 : O
however P02298741A0809 RB O
, P02298741A0809 , O
JKPE P02298741A0809 NNP O
cells P02298741A0809 NNS O
lost P02298741A0809 VBD O
a P02298741A0809 DT O
major P02298741A0809 JJ O
approximately P02298741A0809 RB O
82 P02298741A0809 CD O
kDa P02298741A0809 NNS O
immunoreactive P02298741A0809 JJ O
cytosolic P02298741A0809 JJ O
protein P02298741A0809 NN O
detectable P02298741A0809 JJ O
with P02298741A0809 IN O
anti-PKC P02298741A0809 JJ I-UN
alpha P02298741A0809 NN I-UN
antibody P02298741A0809 NN I-UN
. P02298741A0809 . O
. . O O

The P01358758A0000 DT O
distal P01358758A0000 JJ O
portion P01358758A0000 NN O
of P01358758A0000 IN O
the P01358758A0000 DT O
rat P01358758A0000 NN I-UN
insulin P01358758A0000 NN I-UN
I P01358758A0000 PRP I-UN
gene P01358758A0000 NN I-UN
5'-flanking P01358758A0000 JJ I-UN
DNA P01358758A0000 NNP I-UN
contains P01358758A0000 VBZ O
two P01358758A0000 CD O
sequence P01358758A0000 NN O
elements P01358758A0000 NNS O
, P01358758A0000 , O
the P01358758A0000 DT O
Far P01358758A0000 NNP O
and P01358758A0000 CC O
FLAT P01358758A0000 NNP O
elements P01358758A0000 NNS O
, P01358758A0000 , O
that P01358758A0000 WDT O
can P01358758A0000 MD O
function P01358758A0000 VB O
in P01358758A0000 IN O
combination P01358758A0000 NN O
, P01358758A0000 , O
but P01358758A0000 CC O
not P01358758A0000 RB O
separately P01358758A0000 RB O
, P01358758A0000 , O
as P01358758A0000 IN O
a P01358758A0000 DT O
beta-cell-specific P01358758A0000 JJ O
transcriptional P01358758A0000 JJ O
enhancer P01358758A0000 NN O
. P01358758A0000 . O
. . O O

Anti-B P08107167A0222 NNP I-UN
. P08107167A0222 . I-UN
burgdorferi P08107167A0222 NN I-UN
, P08107167A0222 , O
anti-B P08107167A0222 NN I-UN
. P08107167A0222 . I-UN
turicatae P08107167A0222 NN I-UN
and P08107167A0222 CC O
anti-B P08107167A0222 NN I-UN
. P08107167A0222 . I-UN
parkeri P08107167A0222 NN I-UN
antibodies P08107167A0222 NNS I-UN
, P08107167A0222 , O
tested P08107167A0222 VBN O
by P08107167A0222 IN O
the P08107167A0222 DT O
indirect P08107167A0222 JJ O
immunofluorescent P08107167A0222 NN O
assay P08107167A0222 NN O
( P08107167A0222 ( O
IFA P08107167A0222 NNP O
) P08107167A0222 ) O
, P08107167A0222 , O
were P08107167A0222 VBD O
detected P08107167A0222 VBN O
in P08107167A0222 IN O
10.8 P08107167A0222 CD O
, P08107167A0222 , O
16.1 P08107167A0222 CD O
and P08107167A0222 CC O
8.2 P08107167A0222 CD O
% P08107167A0222 NN O
of P08107167A0222 IN O
the P08107167A0222 DT O
serum P08107167A0222 NN O
samples P08107167A0222 NNS O
tested P08107167A0222 VBN O
, P08107167A0222 , O
and P08107167A0222 CC O
confirmed P08107167A0222 VBN O
by P08107167A0222 IN O
IFA-ABS P08107167A0222 NNP O
in P08107167A0222 IN O
1.3 P08107167A0222 CD O
, P08107167A0222 , O
1.3 P08107167A0222 CD O
and P08107167A0222 CC O
1.0 P08107167A0222 CD O
% P08107167A0222 NN O
, P08107167A0222 , O
respectively P08107167A0222 RB O
. P08107167A0222 . O
. . O O

Based P07768898A0492 VBN O
on P07768898A0492 IN O
the P07768898A0492 DT O
estimated P07768898A0492 VBN O
values P07768898A0492 NNS O
of P07768898A0492 IN O
divergence P07768898A0492 NN O
of P07768898A0492 IN O
apobec1 P07768898A0492 JJ I-UN
sequences P07768898A0492 NNS I-UN
in P07768898A0492 IN O
terms P07768898A0492 NNS O
of P07768898A0492 IN O
the P07768898A0492 DT O
numbers P07768898A0492 NNS O
of P07768898A0492 IN O
synonymous P07768898A0492 JJ O
and P07768898A0492 CC O
non-synonymous P07768898A0492 JJ O
suhstitutions P07768898A0492 NNS O
per P07768898A0492 IN O
site P07768898A0492 NN O
, P07768898A0492 , O
we P07768898A0492 PRP O
found P07768898A0492 VBD O
that P07768898A0492 IN O
apobec1 P07768898A0492 NN I-UN
is P07768898A0492 VBZ O
a P07768898A0492 DT O
fairly P07768898A0492 RB O
rapidly P07768898A0492 RB O
evolving P07768898A0492 VBG O
protein P07768898A0492 NN O
. P07768898A0492 . O
. . O O

Seventy-one P00401521A0138 CD O
percent P00401521A0138 NN O
of P00401521A0138 IN O
patients P00401521A0138 NNS O
treated P00401521A0138 VBN O
with P00401521A0138 IN O
ticarcillin P00401521A0138 NN O
alone P00401521A0138 RB O
responded P00401521A0138 VBD O
favorably P00401521A0138 RB O
. P00401521A0138 . O
. . O O

Isolation P03117046T0000 NN O
and P03117046T0000 CC O
characterization P03117046T0000 NN O
of P03117046T0000 IN O
a P03117046T0000 DT O
vinculin P03117046T0000 NN I-UN
cDNA P03117046T0000 NN I-UN
from P03117046T0000 IN I-UN
chick-embryo P03117046T0000 JJ I-UN
fibroblasts P03117046T0000 NNS I-UN
. P03117046T0000 . O
. . O O

The P02549036A0000 DT O
Bacillus P02549036A0000 NNP I-UN
subtilis P02549036A0000 NNS I-UN
phage P02549036A0000 NN I-UN
phi P02549036A0000 VBP I-UN
105 P02549036A0000 CD I-UN
repressor P02549036A0000 NN I-UN
, P02549036A0000 , O
a P02549036A0000 DT O
lambda P02549036A0000 JJ I-UN
repressor-like P02549036A0000 JJ O
transcriptional P02549036A0000 JJ O
regulatory P02549036A0000 JJ O
protein P02549036A0000 NN O
, P02549036A0000 , O
was P02549036A0000 VBD O
overproduced P02549036A0000 VBN O
in P02549036A0000 IN O
Escherichia P02549036A0000 NNP O
coli P02549036A0000 NN O
and P02549036A0000 CC O
purified P02549036A0000 VBD O
to P02549036A0000 TO O
near P02549036A0000 IN O
homogeneity P02549036A0000 NN O
in P02549036A0000 IN O
order P02549036A0000 NN O
to P02549036A0000 TO O
examine P02549036A0000 VB O
its P02549036A0000 PRP$ O
in P02549036A0000 IN O
vitro P02549036A0000 JJ O
DNA-binding P02549036A0000 JJ O
properties P02549036A0000 NNS O
. P02549036A0000 . O
. . O O

Nrf2 P11274184A0000 NNP I-UN
regulates P11274184A0000 VBZ O
expression P11274184A0000 NN O
of P11274184A0000 IN O
genes P11274184A0000 NNS O
encoding P11274184A0000 VBG O
enzymes P11274184A0000 NNS O
with P11274184A0000 IN O
antioxidant P11274184A0000 NN O
( P11274184A0000 ( O
e.g P11274184A0000 NN O
. P11274184A0000 . O
heme P11274184A0000 JJ I-UN
oxygenase-1 P11274184A0000 JJ I-UN
( P11274184A0000 ( O
HO-1 P11274184A0000 NNP I-UN
) P11274184A0000 ) O
) P11274184A0000 ) O
or P11274184A0000 CC O
xenobiotic P11274184A0000 JJ O
detoxification P11274184A0000 NN O
( P11274184A0000 ( O
e.g P11274184A0000 NN O
. P11274184A0000 . O
. . O O

Foveating P02219751A0517 VBG O
saccades P02219751A0517 NNS O
, P02219751A0517 , O
therefore P02219751A0517 RB O
, P02219751A0517 , O
can P02219751A0517 MD O
be P02219751A0517 VB O
distinguished P02219751A0517 VBN O
from P02219751A0517 IN O
other P02219751A0517 JJ O
FEMs P02219751A0517 NNP O
on P02219751A0517 IN O
the P02219751A0517 DT O
basis P02219751A0517 NN O
of P02219751A0517 IN O
speed P02219751A0517 NN O
. P02219751A0517 . O
. . O O

The P08599946A0999 DT O
evidence P08599946A0999 NN O
presented P08599946A0999 VBD O
here P08599946A0999 RB O
suggests P08599946A0999 VBZ O
that P08599946A0999 IN O
the P08599946A0999 DT O
p40 P08599946A0999 NN I-UN
complex P08599946A0999 NN I-UN
is P08599946A0999 VBZ O
a P08599946A0999 DT O
ribonucleoprotein P08599946A0999 NN O
complex P08599946A0999 JJ O
containing P08599946A0999 VBG O
L1Hs P08599946A0999 NNP I-UN
RNA P08599946A0999 NNP I-UN
( P08599946A0999 ( I-UN
s P08599946A0999 NN I-UN
) P08599946A0999 ) I-UN
and P08599946A0999 CC O
that P08599946A0999 IN O
protein-protein P08599946A0999 JJ O
interactions P08599946A0999 NNS O
in P08599946A0999 IN O
which P08599946A0999 WDT O
alpha-helix P08599946A0999 JJ O
structures P08599946A0999 NNS O
participate P08599946A0999 VB O
, P08599946A0999 , O
for P08599946A0999 IN O
example P08599946A0999 NN O
coiled-coils P08599946A0999 NNS O
, P08599946A0999 , O
may P08599946A0999 MD O
occur P08599946A0999 VB O
in P08599946A0999 IN O
the P08599946A0999 DT O
complex P08599946A0999 NN O
. P08599946A0999 . O
. . O O

No P11528500A0571 DT O
mutation P11528500A0571 NN O
of P11528500A0571 IN O
the P11528500A0571 DT O
NRL P11528500A0571 NNP I-UN
gene P11528500A0571 NN I-UN
was P11528500A0571 VBD O
found P11528500A0571 VBN O
in P11528500A0571 IN O
any P11528500A0571 DT O
of P11528500A0571 IN O
the P11528500A0571 DT O
two P11528500A0571 CD O
families P11528500A0571 NNS O
. P11528500A0571 . O
. . O O

Cost-effectiveness P11028131T0000 NN O
of P11028131T0000 IN O
interferon P11028131T0000 JJ I-UN
beta-1b P11028131T0000 NN I-UN
in P11028131T0000 IN O
slowing P11028131T0000 VBG O
multiple P11028131T0000 JJ O
sclerosis P11028131T0000 NN O
disability P11028131T0000 NN O
progression P11028131T0000 NN O
. P11028131T0000 . O
. . O O

The P10841537A0669 DT O
experimentally P10841537A0669 RB O
mapped P10841537A0669 JJ O
regions P10841537A0669 NNS O
of P10841537A0669 IN O
RPB5 P10841537A0669 NNP I-UN
involved P10841537A0669 VBN O
in P10841537A0669 IN O
these P10841537A0669 DT O
interactions P10841537A0669 NNS O
correspond P10841537A0669 VBP O
to P10841537A0669 TO O
distinct P10841537A0669 VB O
and P10841537A0669 CC O
surface-exposed P10841537A0669 JJ O
alpha-helical P10841537A0669 JJ O
structures P10841537A0669 NNS O
. P10841537A0669 . O
. . O O

We P11778044A0000 PRP O
derive P11778044A0000 VBP O
joint P11778044A0000 JJ O
probability P11778044A0000 NN O
density P11778044A0000 NN O
distributions P11778044A0000 NNS O
for P11778044A0000 IN O
three P11778044A0000 CD O
key P11778044A0000 NN O
uncertain P11778044A0000 JJ O
properties P11778044A0000 NNS O
of P11778044A0000 IN O
the P11778044A0000 DT O
climate P11778044A0000 NN O
system P11778044A0000 NN O
, P11778044A0000 , O
using P11778044A0000 VBG O
an P11778044A0000 DT O
optimal P11778044A0000 JJ O
fingerprinting P11778044A0000 NN O
approach P11778044A0000 NN O
to P11778044A0000 TO O
compare P11778044A0000 VB O
simulations P11778044A0000 NNS O
of P11778044A0000 IN O
an P11778044A0000 DT O
intermediate P11778044A0000 JJ O
complexity P11778044A0000 NN O
climate P11778044A0000 NN O
model P11778044A0000 NN O
with P11778044A0000 IN O
three P11778044A0000 CD O
distinct P11778044A0000 JJ O
diagnostics P11778044A0000 NNS O
of P11778044A0000 IN O
recent P11778044A0000 JJ O
climate P11778044A0000 NN O
observations P11778044A0000 NNS O
. P11778044A0000 . O
. . O O

The P08756556A0406 DT O
cDNA P08756556A0406 NN O
encoded P08756556A0406 VBD O
a P08756556A0406 DT O
mature P08756556A0406 NN O
protein P08756556A0406 NN O
of P08756556A0406 IN O
240 P08756556A0406 CD O
amino P08756556A0406 NN O
acids P08756556A0406 NNS O
, P08756556A0406 , O
including P08756556A0406 VBG O
a P08756556A0406 DT O
29-amino P08756556A0406 JJ O
acid P08756556A0406 JJ O
signal P08756556A0406 JJ O
sequence P08756556A0406 NN O
. P08756556A0406 . O
. . O O

The P02142993A0176 DT O
clinical P02142993A0176 JJ O
picture P02142993A0176 NN O
of P02142993A0176 IN O
the P02142993A0176 DT O
disease P02142993A0176 NN O
was P02142993A0176 VBD O
significantly P02142993A0176 RB O
different P02142993A0176 JJ O
from P02142993A0176 IN O
anthropogenic P02142993A0176 JJ O
cutaneous P02142993A0176 JJ O
leishmaniasis P02142993A0176 NN O
caused P02142993A0176 VBN O
by P02142993A0176 IN O
L. P02142993A0176 NNP O
tropica P02142993A0176 NN O
but P02142993A0176 CC O
similar P02142993A0176 JJ O
to P02142993A0176 TO O
cutaneous P02142993A0176 JJ O
patterns P02142993A0176 NNS O
caused P02142993A0176 VBN O
by P02142993A0176 IN O
L. P02142993A0176 NNP O
infantum P02142993A0176 NN O
which P02142993A0176 WDT O
was P02142993A0176 VBD O
a P02142993A0176 DT O
prevalent P02142993A0176 JJ O
pattern P02142993A0176 NN O
in P02142993A0176 IN O
the P02142993A0176 DT O
southern P02142993A0176 JJ O
France P02142993A0176 NNP O
. P02142993A0176 . O
. . O O

However P08704240A1111 RB O
, P08704240A1111 , O
in P08704240A1111 IN O
TF-1 P08704240A1111 NNP O
cells P08704240A1111 NNS O
grown P08704240A1111 VBN O
on P08704240A1111 IN O
GM-CSF P08704240A1111 NNP I-UN
before P08704240A1111 IN O
starvation P08704240A1111 NN O
, P08704240A1111 , O
CREB P08704240A1111 NNP I-UN
phosphorylation P08704240A1111 NN O
was P08704240A1111 VBD O
observed P08704240A1111 VBN O
10 P08704240A1111 CD O
minutes P08704240A1111 NNS O
after P08704240A1111 IN O
PIXY321 P08704240A1111 NNP I-UN
stimulation P08704240A1111 NN O
. P08704240A1111 . O
. . O O

It P10851745A0624 PRP O
brings P10851745A0624 VBZ O
about P10851745A0624 IN O
fatigue P10851745A0624 NN O
, P10851745A0624 , O
negative P10851745A0624 JJ O
moods P10851745A0624 NNS O
, P10851745A0624 , O
and P10851745A0624 CC O
impaired P10851745A0624 JJ O
health P10851745A0624 NN O
, P10851745A0624 , O
sleep P10851745A0624 NN O
, P10851745A0624 , O
safety P10851745A0624 NN O
, P10851745A0624 , O
and P10851745A0624 CC O
working P10851745A0624 VBG O
capacity P10851745A0624 NN O
. P10851745A0624 . O
. . O O

The P08508861A0294 DT O
patients P08508861A0294 NNS O
were P08508861A0294 VBD O
divided P08508861A0294 VBN O
into P08508861A0294 IN O
ischaemia P08508861A0294 NN O
and P08508861A0294 CC O
non-ischaemia P08508861A0294 JJ O
groups P08508861A0294 NNS O
on P08508861A0294 IN O
the P08508861A0294 DT O
basis P08508861A0294 NN O
of P08508861A0294 IN O
the P08508861A0294 DT O
change P08508861A0294 NN O
in P08508861A0294 IN O
lactate P08508861A0294 JJ O
extraction P08508861A0294 NN O
ratio P08508861A0294 NN O
during P08508861A0294 IN O
balloon P08508861A0294 NN O
inflation P08508861A0294 NN O
. P08508861A0294 . O
. . O O

Approximately P02324104A0151 RB O
65 P02324104A0151 CD O
% P02324104A0151 NN O
of P02324104A0151 IN O
the P02324104A0151 DT O
total P02324104A0151 JJ O
cAMP-dependent P02324104A0151 JJ I-UN
phosphotransferase P02324104A0151 NN I-UN
activity P02324104A0151 NN O
is P02324104A0151 VBZ O
recovered P02324104A0151 VBN O
in P02324104A0151 IN O
particulate P02324104A0151 JJ O
fractions P02324104A0151 NNS O
of P02324104A0151 IN O
homogenates P02324104A0151 NNS O
prepared P02324104A0151 VBN O
from P02324104A0151 IN O
asynchronous P02324104A0151 JJ O
populations P02324104A0151 NNS O
of P02324104A0151 IN O
C. P02324104A0151 NNP O
elegans P02324104A0151 NNS O
. P02324104A0151 . O
. . O O

Type P08445792A0469 NNP O
II P08445792A0469 NNP O
could P08445792A0469 MD O
be P08445792A0469 VB O
divided P08445792A0469 VBN O
further P08445792A0469 RB O
into P08445792A0469 IN O
two P08445792A0469 CD O
forms P08445792A0469 NNS O
( P08445792A0469 ( O
IIA P08445792A0469 NNP O
and P08445792A0469 CC O
IIB P08445792A0469 NNP O
) P08445792A0469 ) O
that P08445792A0469 WDT O
may P08445792A0469 MD O
represent P08445792A0469 VB O
two P08445792A0469 CD O
underscribed P08445792A0469 JJ O
species P08445792A0469 NNS O
or P08445792A0469 CC O
developmental P08445792A0469 JJ O
stages P08445792A0469 NNS O
of P08445792A0469 IN O
the P08445792A0469 DT O
same P08445792A0469 JJ O
species P08445792A0469 NNS O
. P08445792A0469 . O
. . O O

Evaluation P05693602T0001 NN O
of P05693602T0001 IN O
automatic P05693602T0001 JJ O
blood P05693602T0001 NN O
cell P05693602T0001 NN O
counters P05693602T0001 NNS O
. P05693602T0001 . O
. . O O

Moreover P08934533A0784 RB O
, P08934533A0784 , O
the P08934533A0784 DT O
same P08934533A0784 JJ O
mutations P08934533A0784 NNS O
alter P08934533A0784 VBP O
the P08934533A0784 DT O
structure P08934533A0784 NN O
of P08934533A0784 IN O
junB P08934533A0784 NN I-UN
5 P08934533A0784 CD O
' P08934533A0784 '' O
flanking P08934533A0784 VBG O
DNA P08934533A0784 NNP O
within P08934533A0784 IN O
chromatin P08934533A0784 NN O
. P08934533A0784 . O
. . O O

Morphological P04975676T0000 NNP O
and P04975676T0000 CC O
functional P04975676T0000 JJ O
alterations P04975676T0000 NNS O
noted P04975676T0000 VBD O
after P04975676T0000 IN O
baboon P04975676T0000 JJ O
renal P04975676T0000 JJ O
allotransplantation P04975676T0000 NN O
. P04975676T0000 . O
. . O O

Clinical P03098018A0139 JJ O
findings P03098018A0139 NNS O
were P03098018A0139 VBD O
: P03098018A0139 : O
height P03098018A0139 NN O
183 P03098018A0139 CD O
cm P03098018A0139 NN O
, P03098018A0139 , O
weight P03098018A0139 VBD O
62 P03098018A0139 CD O
kg P03098018A0139 NN O
, P03098018A0139 , O
increased P03098018A0139 VBD O
length P03098018A0139 NN O
of P03098018A0139 IN O
lower P03098018A0139 JJR O
limbs P03098018A0139 NN O
, P03098018A0139 , O
P2-A2 P03098018A0139 NNP O
pilosity P03098018A0139 NN O
and P03098018A0139 CC O
micropenis P03098018A0139 NN O
. P03098018A0139 . O
. . O O

Multi P07234308A0121 NNP O
drug P07234308A0121 NN O
regimens P07234308A0121 NNS O
like P07234308A0121 IN O
C-MOPP P07234308A0121 NNP O
, P07234308A0121 , O
CHOP P07234308A0121 NNP O
and P07234308A0121 CC O
BACOP P07234308A0121 NNP O
led P07234308A0121 VBD O
to P07234308A0121 TO O
high P07234308A0121 JJ O
remission P07234308A0121 NN O
rates P07234308A0121 NNS O
and P07234308A0121 CC O
in P07234308A0121 IN O
some P07234308A0121 DT O
cases P07234308A0121 NNS O
probably P07234308A0121 RB O
also P07234308A0121 RB O
to P07234308A0121 TO O
a P07234308A0121 DT O
cure P07234308A0121 NN O
of P07234308A0121 IN O
the P07234308A0121 DT O
disease P07234308A0121 NN O
. P07234308A0121 . O
. . O O

A P10453721A0445 DT O
limited P10453721A0445 JJ O
sampling P10453721A0445 NN O
strategy P10453721A0445 NN O
was P10453721A0445 VBD O
used P10453721A0445 VBN O
based P10453721A0445 VBN O
on P10453721A0445 IN O
a P10453721A0445 DT O
bayesian P10453721A0445 JJ O
parameter P10453721A0445 NN O
estimation P10453721A0445 NN O
algorithm P10453721A0445 NN O
that P10453721A0445 WDT O
is P10453721A0445 VBZ O
part P10453721A0445 NN O
of P10453721A0445 IN O
the P10453721A0445 DT O
ADAPT P10453721A0445 NNP O
II P10453721A0445 NNP O
software P10453721A0445 NN O
package P10453721A0445 NN O
. P10453721A0445 . O
. . O O

A P09325278A0458 DT O
data P09325278A0458 NN O
base P09325278A0458 NN O
homology P09325278A0458 NN O
search P09325278A0458 NN O
revealed P09325278A0458 VBD O
that P09325278A0458 IN O
the P09325278A0458 DT O
predicted P09325278A0458 JJ O
ER1 P09325278A0458 NNP I-UN
amino P09325278A0458 NN O
acid P09325278A0458 NN O
sequence P09325278A0458 NN O
contains P09325278A0458 NNS O
three P09325278A0458 CD O
regions P09325278A0458 NNS O
of P09325278A0458 IN O
similarity P09325278A0458 NN O
to P09325278A0458 TO O
the P09325278A0458 DT O
rat P09325278A0458 NN O
and P09325278A0458 CC O
human P09325278A0458 JJ O
proteins P09325278A0458 NNS O
encoded P09325278A0458 VBN O
by P09325278A0458 IN O
the P09325278A0458 DT O
metastasis-associated P09325278A0458 JJ O
gene P09325278A0458 NN O
, P09325278A0458 , O
mta1 P09325278A0458 NN I-UN
, P09325278A0458 , O
and P09325278A0458 CC O
two P09325278A0458 CD O
regions P09325278A0458 NNS O
of P09325278A0458 IN O
similarity P09325278A0458 NN O
to P09325278A0458 TO O
the P09325278A0458 DT O
Caenorhabditis P09325278A0458 NNP O
elegans P09325278A0458 VBZ O
sequence P09325278A0458 NN O
that P09325278A0458 WDT O
is P09325278A0458 VBZ O
similar P09325278A0458 JJ O
to P09325278A0458 TO O
mta1 P09325278A0458 VB I-UN
. P09325278A0458 . O
. . O O

Whereas P11278290A1220 NNP O
Smad2 P11278290A1220 NNP I-UN
was P11278290A1220 VBD O
rapidly P11278290A1220 RB O
phosphorylated P11278290A1220 VBN O
by P11278290A1220 IN O
TGF-beta P11278290A1220 NNP I-UN
and P11278290A1220 CC O
involved P11278290A1220 VBN O
in P11278290A1220 IN O
the P11278290A1220 DT O
initial P11278290A1220 JJ O
activation P11278290A1220 NN O
of P11278290A1220 IN O
Agc P11278290A1220 NNP I-UN
expression P11278290A1220 NN O
in P11278290A1220 IN O
confluent P11278290A1220 NN O
cells P11278290A1220 NNS O
, P11278290A1220 , O
Smad2 P11278290A1220 NNP I-UN
activation P11278290A1220 NN O
was P11278290A1220 VBD O
not P11278290A1220 RB O
required P11278290A1220 VBN O
for P11278290A1220 IN O
maintaining P11278290A1220 VBG O
the P11278290A1220 DT O
high P11278290A1220 JJ O
level P11278290A1220 NN O
of P11278290A1220 IN O
Agc P11278290A1220 NNP I-UN
expression P11278290A1220 NN O
. P11278290A1220 . O
. . O O

Identification P08189498T0000 NN O
of P08189498T0000 IN O
an P08189498T0000 DT O
immediate-early P08189498T0000 JJ I-UN
gene P08189498T0000 NN I-UN
in P08189498T0000 IN O
the P08189498T0000 DT O
Marek P08189498T0000 NNP O
's P08189498T0000 POS O
disease P08189498T0000 NN O
virus P08189498T0000 NN O
long P08189498T0000 JJ O
internal P08189498T0000 JJ O
repeat P08189498T0000 NN O
region P08189498T0000 NN O
which P08189498T0000 WDT O
encodes P08189498T0000 VBZ O
a P08189498T0000 DT O
unique P08189498T0000 JJ O
14-kilodalton P08189498T0000 JJ O
polypeptide P08189498T0000 NN O
. P08189498T0000 . O
. . O O

CONCLUSIONS P11067797A1306 NN O
: P11067797A1306 : O
EBCT P11067797A1306 NNP O
technology P11067797A1306 NN O
allows P11067797A1306 VBZ O
minimally P11067797A1306 RB O
invasive P11067797A1306 JJ O
evaluation P11067797A1306 NN O
of P11067797A1306 IN O
intramyocardial P11067797A1306 JJ O
microcirculatory P11067797A1306 NN O
function P11067797A1306 NN O
and P11067797A1306 CC O
permits P11067797A1306 VBZ O
assessment P11067797A1306 NN O
of P11067797A1306 IN O
microvascular P11067797A1306 JJ O
BV P11067797A1306 NNP O
distribution P11067797A1306 NN O
in P11067797A1306 IN O
different P11067797A1306 JJ O
functional P11067797A1306 JJ O
components P11067797A1306 NNS O
. P11067797A1306 . O
. . O O

Among P03755673A0054 IN O
them P03755673A0054 PRP O
, P03755673A0054 , O
26 P03755673A0054 CD O
cases P03755673A0054 NNS O
were P03755673A0054 VBD O
benign P03755673A0054 JJ O
and P03755673A0054 CC O
34 P03755673A0054 CD O
malignant P03755673A0054 NN O
. P03755673A0054 . O
. . O O

Increased P09541280A0404 VBN O
plasma P09541280A0404 NN O
IgE P09541280A0404 NNP I-UN
was P09541280A0404 VBD O
also P09541280A0404 RB O
confirmed P09541280A0404 VBN O
in P09541280A0404 IN O
the P09541280A0404 DT O
NC P09541280A0404 NNP O
mice P09541280A0404 NN O
, P09541280A0404 , O
and P09541280A0404 CC O
treatment P09541280A0404 NN O
with P09541280A0404 IN O
FK506 P09541280A0404 NNP O
ointment P09541280A0404 NN O
reduced P09541280A0404 VBD O
the P09541280A0404 DT O
plasma P09541280A0404 NN O
IgE P09541280A0404 NNP I-UN
level P09541280A0404 NN O
. P09541280A0404 . O
. . O O

Serum P10710742T0000 NNP O
leptin P10710742T0000 NN I-UN
concentrations P10710742T0000 NNS O
in P10710742T0000 IN O
women P10710742T0000 NNS O
during P10710742T0000 IN O
gonadotropin P10710742T0000 JJ I-UN
stimulation P10710742T0000 NN O
cycles P10710742T0000 NNS O
. P10710742T0000 . O
. . O O

Diagnosis P07064923T0000 NN O
of P07064923T0000 IN O
phenylalanine P07064923T0000 JJ I-UN
hydroxylase P07064923T0000 NN I-UN
deficiency P07064923T0000 NN O
( P07064923T0000 ( O
phenylketonuria P07064923T0000 NN O
) P07064923T0000 ) O
. P07064923T0000 . O
. . O O

These P10049357A0608 DT O
results P10049357A0608 NNS O
show P10049357A0608 VBP O
that P10049357A0608 IN O
Ski P10049357A0608 NNP I-UN
is P10049357A0608 VBZ O
a P10049357A0608 DT O
component P10049357A0608 NN O
of P10049357A0608 IN O
the P10049357A0608 DT O
HDAC P10049357A0608 NNP I-UN
complex P10049357A0608 NN I-UN
and P10049357A0608 CC O
that P10049357A0608 DT O
Ski P10049357A0608 NNP I-UN
is P10049357A0608 VBZ O
required P10049357A0608 VBN O
for P10049357A0608 IN O
the P10049357A0608 DT O
transcriptional P10049357A0608 JJ O
repression P10049357A0608 NN O
mediated P10049357A0608 VBN O
by P10049357A0608 IN O
this P10049357A0608 DT O
complex P10049357A0608 NN O
. P10049357A0608 . O
. . O O

Notably P08663310A0157 RB O
, P08663310A0157 , O
SRF P08663310A0157 NNP I-UN
has P08663310A0157 VBZ O
been P08663310A0157 VBN O
found P08663310A0157 VBN O
to P08663310A0157 TO O
be P08663310A0157 VB O
a P08663310A0157 DT O
key P08663310A0157 JJ O
regulator P08663310A0157 NN O
of P08663310A0157 IN O
members P08663310A0157 NNS O
of P08663310A0157 IN O
a P08663310A0157 DT O
class P08663310A0157 NN O
of P08663310A0157 IN O
cellular P08663310A0157 JJ O
response P08663310A0157 NN O
genes P08663310A0157 NNS O
termed P08663310A0157 VBD O
immediate-early P08663310A0157 JJ I-UN
genes P08663310A0157 NNS I-UN
( P08663310A0157 ( O
IEGs P08663310A0157 NNP I-UN
) P08663310A0157 ) O
, P08663310A0157 , O
many P08663310A0157 JJ O
of P08663310A0157 IN O
which P08663310A0157 WDT O
are P08663310A0157 VBP O
believed P08663310A0157 VBN O
to P08663310A0157 TO O
be P08663310A0157 VB O
involved P08663310A0157 VBN O
in P08663310A0157 IN O
regulating P08663310A0157 VBG O
cell P08663310A0157 NN O
growth P08663310A0157 NN O
and P08663310A0157 CC O
differentiation P08663310A0157 NN O
. P08663310A0157 . O
. . O O

The P08595658A0961 DT O
DNA P08595658A0961 NN O
sequences P08595658A0961 VBZ O
upstream P08595658A0961 NN O
of P08595658A0961 IN O
these P08595658A0961 DT O
termini P08595658A0961 JJ O
exhibit P08595658A0961 NN O
homology P08595658A0961 NN O
to P08595658A0961 TO O
plant P08595658A0961 NN O
mitochondrial-processing P08595658A0961 NN O
sites P08595658A0961 NNS O
, P08595658A0961 , O
therefore P08595658A0961 IN O
the P08595658A0961 DT O
proximal P08595658A0961 JJ O
5 P08595658A0961 CD O
' P08595658A0961 POS O
ends P08595658A0961 NNS O
are P08595658A0961 VBP O
most P08595658A0961 RBS O
probably P08595658A0961 RB O
generated P08595658A0961 VBN O
by P08595658A0961 IN O
RNA P08595658A0961 NNP O
processing P08595658A0961 NN O
. P08595658A0961 . O
. . O O

The P09005979A0841 DT O
GHR P09005979A0841 NNP I-UN
mRNA P09005979A0841 NN I-UN
: P09005979A0841 : O
GHBP P09005979A0841 NNP I-UN
mRNA P09005979A0841 VBD I-UN
ratio P09005979A0841 NN O
was P09005979A0841 VBD O
1.1 P09005979A0841 CD O
+ P09005979A0841 JJ O
/ P09005979A0841 NNP O
- P09005979A0841 : O
0.12 P09005979A0841 CD O
and P09005979A0841 CC O
remained P09005979A0841 VBD O
unchanged P09005979A0841 JJ O
during P09005979A0841 IN O
differentiation P09005979A0841 NN O
. P09005979A0841 . O
. . O O

Based P09171389A0549 VBN O
on P09171389A0549 IN O
the P09171389A0549 DT O
occurrence P09171389A0549 NN O
of P09171389A0549 IN O
several P09171389A0549 JJ O
transcription P09171389A0549 NN O
signals P09171389A0549 NNS O
in P09171389A0549 IN O
the P09171389A0549 DT O
Thermus P09171389A0549 NNP I-UN
pyr P09171389A0549 NN I-UN
promoter P09171389A0549 NN I-UN
region P09171389A0549 NN I-UN
and P09171389A0549 CC O
strong P09171389A0549 JJ O
amino P09171389A0549 NN O
acid P09171389A0549 NN O
sequence P09171389A0549 NN O
identities P09171389A0549 NNS O
( P09171389A0549 ( O
about P09171389A0549 IN O
60 P09171389A0549 CD O
% P09171389A0549 NN O
) P09171389A0549 ) O
between P09171389A0549 IN O
Thermus P09171389A0549 NNP I-UN
PyrR P09171389A0549 NNP I-UN
and P09171389A0549 CC O
the P09171389A0549 DT O
PyrR P09171389A0549 NNP I-UN
attenuation P09171389A0549 NN I-UN
proteins P09171389A0549 NNS I-UN
of P09171389A0549 IN O
two P09171389A0549 CD O
Bacillus P09171389A0549 NNP O
sp. P09171389A0549 NNS O
, P09171389A0549 , O
we P09171389A0549 PRP O
propose P09171389A0549 VBP O
a P09171389A0549 DT O
regulatory P09171389A0549 JJ O
mechanism P09171389A0549 NN O
involving P09171389A0549 VBG O
transcriptional P09171389A0549 JJ O
attenuation P09171389A0549 NN O
to P09171389A0549 TO O
control P09171389A0549 VB O
pyr P09171389A0549 JJ I-UN
gene P09171389A0549 NN I-UN
expression P09171389A0549 NN O
in P09171389A0549 IN O
Thermus P09171389A0549 NNP O
. P09171389A0549 . O
. . O O

Nip7p-depleted P09891085A0815 JJ O
cells P09891085A0815 NNS O
exhibited P09891085A0815 VBD O
the P09891085A0815 DT O
same P09891085A0815 JJ O
defects P09891085A0815 NNS O
as P09891085A0815 IN O
Nop8p-depleted P09891085A0815 JJ O
cells P09891085A0815 NNS O
, P09891085A0815 , O
except P09891085A0815 IN O
that P09891085A0815 IN O
they P09891085A0815 PRP O
accumulated P09891085A0815 VBD O
27S P09891085A0815 CD I-UN
precursors P09891085A0815 NNS I-UN
. P09891085A0815 . O
. . O O

The P07568116A0902 DT O
hydropathy P07568116A0902 NN O
plot P07568116A0902 NN O
revealed P07568116A0902 VBD O
a P07568116A0902 DT O
rather P07568116A0902 RB O
hydrophilic P07568116A0902 JJ O
N-terminal P07568116A0902 JJ O
region P07568116A0902 NN O
and P07568116A0902 CC O
the P07568116A0902 DT O
absence P07568116A0902 NN O
of P07568116A0902 IN O
a P07568116A0902 DT O
hydrophobic P07568116A0902 JJ O
signal P07568116A0902 JJ O
peptide P07568116A0902 NN O
. P07568116A0902 . O
. . O O

Toxicity P09708450A0648 NN O
during P09708450A0648 IN O
the P09708450A0648 DT O
therapeutic P09708450A0648 JJ O
period P09708450A0648 NN O
was P09708450A0648 VBD O
not P09708450A0648 RB O
significant P09708450A0648 JJ O
in P09708450A0648 IN O
the P09708450A0648 DT O
study P09708450A0648 NN O
group P09708450A0648 NN O
compared P09708450A0648 VBN O
with P09708450A0648 IN O
the P09708450A0648 DT O
historical P09708450A0648 JJ O
control P09708450A0648 NN O
, P09708450A0648 , O
treated P09708450A0648 VBN O
with P09708450A0648 IN O
the P09708450A0648 DT O
same P09708450A0648 JJ O
regimen P09708450A0648 NNS O
without P09708450A0648 IN O
G-CSF P09708450A0648 NNP I-UN
. P09708450A0648 . O
. . O O

Groups P10125354T0000 NNP O
dicker P10125354T0000 NN O
for P10125354T0000 IN O
price P10125354T0000 NN O
breaks P10125354T0000 NNS O
as P10125354T0000 IN O
anesthetic P10125354T0000 JJ O
gas P10125354T0000 NN O
goes P10125354T0000 VBZ O
multi-source P10125354T0000 NN O
. P10125354T0000 . O
. . O O

Furthermore P09541721A0894 RB O
, P09541721A0894 , O
in P09541721A0894 IN O
the P09541721A0894 DT O
ischemia P09541721A0894 NN O
/ P09541721A0894 JJ O
angiotension P09541721A0894 NN I-UN
II-induced P09541721A0894 NNP O
AHF P09541721A0894 NNP O
model P09541721A0894 NN O
, P09541721A0894 , O
NIC P09541721A0894 NNP O
decreased P09541721A0894 VBD O
left P09541721A0894 VBD O
ventricular P09541721A0894 JJ O
end-diastolic P09541721A0894 JJ O
pressure P09541721A0894 NN O
( P09541721A0894 ( O
LVEDP P09541721A0894 NNP O
) P09541721A0894 ) O
. P09541721A0894 . O
. . O O

Immediate-early P07707544T0000 JJ O
transcription P07707544T0000 NN O
from P07707544T0000 IN O
the P07707544T0000 DT O
channel P07707544T0000 NN O
catfish P07707544T0000 JJ O
virus P07707544T0000 NN O
genome P07707544T0000 NN O
: P07707544T0000 : O
characterization P07707544T0000 NN O
of P07707544T0000 IN O
two P07707544T0000 CD O
immediate-early P07707544T0000 JJ I-UN
transcripts P07707544T0000 NNS I-UN
. P07707544T0000 . O
. . O O

The P08083963A0795 DT O
LTR-binding P08083963A0795 JJ O
activities P08083963A0795 NNS O
of P08083963A0795 IN O
VBP P08083963A0795 NNP I-UN
, P08083963A0795 , O
a1 P08083963A0795 NN I-UN
/ P08083963A0795 NNP I-UN
EBP P08083963A0795 NNP I-UN
, P08083963A0795 , O
and P08083963A0795 CC O
B-cell P08083963A0795 NNP I-UN
nuclear P08083963A0795 JJ I-UN
extract P08083963A0795 NN I-UN
protein P08083963A0795 NN I-UN
were P08083963A0795 VBD O
compared P08083963A0795 VBN O
and P08083963A0795 CC O
mapped P08083963A0795 VBN O
by P08083963A0795 IN O
gel P08083963A0795 NN O
shift P08083963A0795 NN O
, P08083963A0795 , O
DNase P08083963A0795 NNP I-UN
I P08083963A0795 PRP I-UN
footprinting P08083963A0795 VBP O
, P08083963A0795 , O
and P08083963A0795 CC O
methylation P08083963A0795 NN O
interference P08083963A0795 NN O
assays P08083963A0795 NNS O
. P08083963A0795 . O
. . O O

Routine P08284337A0825 NNP O
psychometric P08284337A0825 JJ O
screening P08284337A0825 NN O
of P08284337A0825 IN O
IHD P08284337A0825 NNP O
patients P08284337A0825 NNS O
may P08284337A0825 MD O
provide P08284337A0825 VB O
a P08284337A0825 DT O
cost-effective P08284337A0825 JJ O
means P08284337A0825 NNS O
of P08284337A0825 IN O
alerting P08284337A0825 VBG O
cardiologists P08284337A0825 NNS O
and P08284337A0825 CC O
internists P08284337A0825 NNS O
to P08284337A0825 TO O
the P08284337A0825 DT O
relatively P08284337A0825 RB O
high P08284337A0825 JJ O
levels P08284337A0825 NNS O
of P08284337A0825 IN O
distress P08284337A0825 NN O
among P08284337A0825 IN O
their P08284337A0825 PRP$ O
patients P08284337A0825 NNS O
. P08284337A0825 . O
. . O O

Brain P02761008X0000 NNP I-UN
cholinesterase P02761008X0000 NN I-UN
activity P02761008X0000 NN O
of P02761008X0000 IN O
nestling P02761008X0000 VBG O
great P02761008X0000 JJ O
egrets P02761008X0000 NNS O
, P02761008X0000 , O
snowy P02761008X0000 JJ O
egrets P02761008X0000 NNS O
and P02761008X0000 CC O
black-crowned P02761008X0000 JJ O
night-herons P02761008X0000 NNS O
. P02761008X0000 . O
inhibition P02761008X0000 NN O
of P02761008X0000 IN O
brain P02761008X0000 NN I-UN
cholinesterase P02761008X0000 NN I-UN
( P02761008X0000 ( O
ChE P02761008X0000 NNP I-UN
) P02761008X0000 ) O
activity P02761008X0000 NN O
in P02761008X0000 IN O
birds P02761008X0000 NNS O
is P02761008X0000 VBZ O
often P02761008X0000 RB O
used P02761008X0000 VBN O
to P02761008X0000 TO O
diagnose P02761008X0000 VB O
exposure P02761008X0000 NN O
or P02761008X0000 CC O
death P02761008X0000 NN O
from P02761008X0000 IN O
organophosphorus P02761008X0000 NN O
or P02761008X0000 CC O
carbamate P02761008X0000 NN O
pesticides P02761008X0000 NNS O
. P02761008X0000 . O
. . O O

We P07713421A1435a PRP O
show P07713421A1435a VBP O
that P07713421A1435a IN O
these P07713421A1435a DT O
three P07713421A1435a CD O
gain-of-function P07713421A1435a NN O
mutants P07713421A1435a NNS O
differ P07713421A1435a VBP O
considerably P07713421A1435a RB O
in P07713421A1435a IN O
their P07713421A1435a PRP$ O
ability P07713421A1435a NN O
to P07713421A1435a TO O
bypass P07713421A1435a VB O
the P07713421A1435a DT O
sex P07713421A1435a NN O
determination P07713421A1435a NN O
signal P07713421A1435a NN O
, P07713421A1435a , O
with P07713421A1435a IN O
SxlM4 P07713421A1435a NNP I-UN
being P07713421A1435a VBG O
the P07713421A1435a DT O
strongest P07713421A1435a JJS O
and P07713421A1435a CC O
SxlM1 P07713421A1435a NNP I-UN
the P07713421A1435a DT O
weakest P07713421A1435a JJS O
. P07713421A1435a . O
. . O O

In P07609037A0775 IN O
addition P07609037A0775 NN O
, P07609037A0775 , O
depletion P07609037A0775 NN O
of P07609037A0775 IN O
Oct-1 P07609037A0775 NNP I-UN
from P07609037A0775 IN O
the P07609037A0775 DT O
nuclear P07609037A0775 JJ O
extract P07609037A0775 NN O
by P07609037A0775 IN O
using P07609037A0775 VBG O
Oct-1-specific P07609037A0775 JJ O
antiserum P07609037A0775 NN O
or P07609037A0775 CC O
a P07609037A0775 DT O
sequence-specific P07609037A0775 JJ O
DNA P07609037A0775 NNP O
affinity P07609037A0775 NN O
resin P07609037A0775 NN O
decreased P07609037A0775 VBN O
in P07609037A0775 IN O
vitro P07609037A0775 JJ O
transcription P07609037A0775 NN O
from P07609037A0775 IN O
the P07609037A0775 DT O
wild-type P07609037A0775 JJ O
MMTV P07609037A0775 NNP O
promoter P07609037A0775 NN O
to P07609037A0775 TO O
a P07609037A0775 DT O
level P07609037A0775 JJ O
identical P07609037A0775 JJ O
to P07609037A0775 TO O
that P07609037A0775 DT O
obtained P07609037A0775 VBN O
from P07609037A0775 IN O
a P07609037A0775 DT O
promoter P07609037A0775 NN O
in P07609037A0775 IN O
which P07609037A0775 WDT O
all P07609037A0775 DT O
three P07609037A0775 CD O
octamer-related P07609037A0775 JJ O
sequences P07609037A0775 NNS O
were P07609037A0775 VBD O
mutated P07609037A0775 VBN O
. P07609037A0775 . O
. . O O

Conservation P02157882T0000 NN O
of P02157882T0000 IN O
function P02157882T0000 NN O
of P02157882T0000 IN O
Drosophila P02157882T0000 NNP I-UN
melanogaster P02157882T0000 NN I-UN
abl P02157882T0000 NN I-UN
and P02157882T0000 CC O
murine P02157882T0000 VB I-UN
v-abl P02157882T0000 JJ I-UN
proteins P02157882T0000 NNS I-UN
in P02157882T0000 IN O
transformation P02157882T0000 NN O
of P02157882T0000 IN O
mammalian P02157882T0000 JJ O
cells P02157882T0000 NNS O
. P02157882T0000 . O
. . O O

Our P09268661A1405 PRP$ O
results P09268661A1405 NNS O
indicate P09268661A1405 VBP O
that P09268661A1405 IN O
the P09268661A1405 DT O
retroplasmid P09268661A1405 JJ O
reverse P09268661A1405 NN I-UN
transcriptase P09268661A1405 NN I-UN
is P09268661A1405 VBZ O
uniquely P09268661A1405 RB O
adapted P09268661A1405 VBN O
to P09268661A1405 TO O
initiate P09268661A1405 VB O
cDNA P09268661A1405 NN O
synthesis P09268661A1405 NN O
by P09268661A1405 IN O
recognizing P09268661A1405 VBG O
a P09268661A1405 DT O
3 P09268661A1405 CD O
' P09268661A1405 POS O
CCA P09268661A1405 NNP O
sequence P09268661A1405 NN O
. P09268661A1405 . O
. . O O

Initial P10215811A0635 JJ O
control P10215811A0635 NN O
of P10215811A0635 IN O
bleeding P10215811A0635 NN O
is P10215811A0635 VBZ O
similar P10215811A0635 JJ O
, P10215811A0635 , O
but P10215811A0635 CC O
eradication P10215811A0635 NN O
is P10215811A0635 VBZ O
achieved P10215811A0635 VBN O
in P10215811A0635 IN O
fewer P10215811A0635 JJR O
sessions P10215811A0635 NNS O
with P10215811A0635 IN O
EVL P10215811A0635 NNP O
. P10215811A0635 . O
. . O O

In P01626631A0557 IN O
the P01626631A0557 DT O
Rett P01626631A0557 NNP O
syndrome P01626631A0557 NN O
we P01626631A0557 PRP O
, P01626631A0557 , O
therefore P01626631A0557 RB O
, P01626631A0557 , O
suspect P01626631A0557 VB O
there P01626631A0557 EX O
are P01626631A0557 VBP O
disturbances P01626631A0557 NNS O
in P01626631A0557 IN O
the P01626631A0557 DT O
brain P01626631A0557 NN O
stem P01626631A0557 NN O
functions P01626631A0557 NNS O
especially P01626631A0557 RB O
in P01626631A0557 IN O
the P01626631A0557 DT O
ascending P01626631A0557 VBG O
reticular P01626631A0557 JJ O
activating P01626631A0557 NN O
system P01626631A0557 NN O
which P01626631A0557 WDT O
is P01626631A0557 VBZ O
related P01626631A0557 VBN O
to P01626631A0557 TO O
elevation P01626631A0557 NN O
of P01626631A0557 IN O
the P01626631A0557 DT O
conscious P01626631A0557 JJ O
level P01626631A0557 NN O
. P01626631A0557 . O
. . O O

METHODS P09047252A0209 NNS O
: P09047252A0209 : O
Fifty-eight P09047252A0209 JJ O
patients P09047252A0209 NNS O
who P09047252A0209 WP O
underwent P09047252A0209 VBP O
a P09047252A0209 DT O
curative P09047252A0209 JJ O
hepatic P09047252A0209 JJ O
resection P09047252A0209 NN O
for P09047252A0209 IN O
HCC P09047252A0209 NNP O
and P09047252A0209 CC O
whose P09047252A0209 WP$ O
preoperative P09047252A0209 JJ O
AFP P09047252A0209 NNP I-UN
levels P09047252A0209 NNS O
were P09047252A0209 VBD O
> P09047252A0209 RB O
100 P09047252A0209 CD O
ng P09047252A0209 JJ O
/ P09047252A0209 NNP O
ml P09047252A0209 NN O
, P09047252A0209 , O
were P09047252A0209 VBD O
selected P09047252A0209 VBN O
for P09047252A0209 IN O
this P09047252A0209 DT O
study P09047252A0209 NN O
. P09047252A0209 . O
. . O O

PABP P11287654A0150 NNP I-UN
is P11287654A0150 VBZ O
a P11287654A0150 DT O
modular P11287654A0150 JJ O
protein P11287654A0150 NN O
, P11287654A0150 , O
with P11287654A0150 IN O
four P11287654A0150 CD O
N-terminal P11287654A0150 JJ O
RNA-binding P11287654A0150 NNP O
domains P11287654A0150 NNS O
and P11287654A0150 CC O
an P11287654A0150 DT O
extensive P11287654A0150 JJ O
C P11287654A0150 NNP O
terminus P11287654A0150 NN O
. P11287654A0150 . O
. . O O

In P09294161A0650 IN O
contrast P09294161A0650 NN O
to P09294161A0650 TO O
the P09294161A0650 DT O
wild-type P09294161A0650 JJ O
protein P09294161A0650 NN O
, P09294161A0650 , O
expression P09294161A0650 NN O
of P09294161A0650 IN O
p45 P09294161A0650 JJ I-UN
NF-E2 P09294161A0650 JJ I-UN
lacking P09294161A0650 NN O
this P09294161A0650 DT O
activation P09294161A0650 NN O
domain P09294161A0650 NN O
in P09294161A0650 IN O
an P09294161A0650 DT O
NF-E2 P09294161A0650 JJ I-UN
null P09294161A0650 NN O
cell P09294161A0650 NN O
line P09294161A0650 NN O
fails P09294161A0650 VBZ O
to P09294161A0650 TO O
support P09294161A0650 VB O
enhancer-dependent P09294161A0650 JJ O
transcription P09294161A0650 NN O
in P09294161A0650 IN O
transient P09294161A0650 NN O
assays P09294161A0650 NNS O
. P09294161A0650 . O
. . O O

Instead P11285235A0466 RB O
, P11285235A0466 , O
TRPS1 P11285235A0466 NNP I-UN
potently P11285235A0466 RB O
and P11285235A0466 CC O
specifically P11285235A0466 RB O
represses P11285235A0466 VBZ O
transcriptional P11285235A0466 JJ O
activation P11285235A0466 NN O
mediated P11285235A0466 VBN O
by P11285235A0466 IN O
other P11285235A0466 JJ O
GATA P11285235A0466 NNP I-UN
factors P11285235A0466 NNS I-UN
. P11285235A0466 . O
. . O O

Potency P00646193T0000 NN O
of P00646193T0000 IN O
enflurane P00646193T0000 NN O
in P00646193T0000 IN O
dogs P00646193T0000 NNS O
: P00646193T0000 : O
comparison P00646193T0000 NN O
with P00646193T0000 IN O
halothane P00646193T0000 NN O
and P00646193T0000 CC O
isoflurane P00646193T0000 NN O
. P00646193T0000 . O
. . O O

OBJECTIVE P10479492A0000 NN O
: P10479492A0000 : O
1998 P10479492A0000 CD O
Surveillance P10479492A0000 NNP O
, P10479492A0000 , O
Epidemiology P10479492A0000 NNP O
, P10479492A0000 , O
and P10479492A0000 CC O
End P10479492A0000 NNP O
Results P10479492A0000 NNP O
( P10479492A0000 ( O
SEER P10479492A0000 NNP O
) P10479492A0000 ) O
data P10479492A0000 NN O
estimate P10479492A0000 NN O
an P10479492A0000 DT O
83.1 P10479492A0000 CD O
% P10479492A0000 NN O
5-year P10479492A0000 JJ O
survival P10479492A0000 NN O
rate P10479492A0000 NN O
for P10479492A0000 IN O
corpus P10479492A0000 NN O
uteri P10479492A0000 JJ O
adenocarcinoma P10479492A0000 NN O
FIGO P10479492A0000 NNP O
stage P10479492A0000 NN O
II P10479492A0000 NNP O
. P10479492A0000 . O
. . O O

Because P10171173A0955 IN O
of P10171173A0955 IN O
concerns P10171173A0955 NNS O
regarding P10171173A0955 VBG O
blood P10171173A0955 NN O
transfusion-related P10171173A0955 JJ O
communicable P10171173A0955 JJ O
disease P10171173A0955 NN O
( P10171173A0955 ( O
eg P10171173A0955 JJ O
, P10171173A0955 , O
acquired P10171173A0955 VBD O
immune P10171173A0955 JJ O
deficiency P10171173A0955 NN O
syndrome P10171173A0955 NN O
and P10171173A0955 CC O
non-A P10171173A0955 JJ O
, P10171173A0955 , O
non-B P10171173A0955 JJ O
hepatitis P10171173A0955 NN O
) P10171173A0955 ) O
, P10171173A0955 , O
there P10171173A0955 EX O
has P10171173A0955 VBZ O
been P10171173A0955 VBN O
increasing P10171173A0955 VBG O
research P10171173A0955 NN O
effort P10171173A0955 NN O
into P10171173A0955 IN O
postoperative P10171173A0955 JJ O
hemorrhage P10171173A0955 NN O
related P10171173A0955 VBN O
to P10171173A0955 TO O
cardiopulmonary P10171173A0955 JJ O
bypass P10171173A0955 NN O
with P10171173A0955 IN O
extracorporeal P10171173A0955 JJ O
circulation P10171173A0955 NN O
. P10171173A0955 . O
. . O O

Accordingly P10219091A0246 RB O
, P10219091A0246 , O
we P10219091A0246 PRP O
designated P10219091A0246 VBD O
this P10219091A0246 DT O
gene P10219091A0246 NN I-UN
CTL1 P10219091A0246 NNP I-UN
( P10219091A0246 ( O
capping P10219091A0246 VBG I-UN
enzyme P10219091A0246 RB I-UN
RNAtriphosphatase-like P10219091A0246 NNP I-UN
1 P10219091A0246 CD I-UN
) P10219091A0246 ) O
. P10219091A0246 . O
. . O O

Following P10708243A0000 VBG O
the P10708243A0000 DT O
observation P10708243A0000 NN O
that P10708243A0000 IN O
non-organ-specific P10708243A0000 JJ O
antibodies P10708243A0000 NNS O
are P10708243A0000 VBP O
related P10708243A0000 VBN O
with P10708243A0000 IN O
pregnancy P10708243A0000 NN O
loss P10708243A0000 NN O
and P10708243A0000 CC O
preeclampsia P10708243A0000 NN O
, P10708243A0000 , O
the P10708243A0000 DT O
role P10708243A0000 NN O
of P10708243A0000 IN O
organ-specific P10708243A0000 JJ O
antibodies P10708243A0000 NNS O
is P10708243A0000 VBZ O
currently P10708243A0000 RB O
being P10708243A0000 VBG O
extensively P10708243A0000 RB O
investigated P10708243A0000 VBN O
. P10708243A0000 . O
. . O O

An P10068418A1194 DT O
increase P10068418A1194 NN O
in P10068418A1194 IN O
bone P10068418A1194 JJ O
mineral P10068418A1194 JJ O
density P10068418A1194 NN O
at P10068418A1194 IN O
the P10068418A1194 DT O
spine P10068418A1194 NN O
, P10068418A1194 , O
total P10068418A1194 JJ O
hip P10068418A1194 NN O
, P10068418A1194 , O
and P10068418A1194 CC O
total P10068418A1194 JJ O
body P10068418A1194 NN O
has P10068418A1194 VBZ O
been P10068418A1194 VBN O
reported P10068418A1194 VBN O
with P10068418A1194 IN O
raloxifene P10068418A1194 NN O
but P10068418A1194 CC O
seems P10068418A1194 VBZ O
to P10068418A1194 TO O
be P10068418A1194 VB O
less P10068418A1194 JJR O
than P10068418A1194 IN O
that P10068418A1194 DT O
seen P10068418A1194 VBN O
with P10068418A1194 IN O
estrogen P10068418A1194 NN O
or P10068418A1194 CC O
alendronate P10068418A1194 JJ O
therapy P10068418A1194 NN O
. P10068418A1194 . O
. . O O

We P08719155A0105 PRP O
report P08719155A0105 VBP O
here P08719155A0105 RB O
the P08719155A0105 DT O
molecular P08719155A0105 JJ O
cloning P08719155A0105 NN O
of P08719155A0105 IN O
a P08719155A0105 DT O
putative P08719155A0105 JJ O
adhesive P08719155A0105 JJ O
molecule P08719155A0105 NN O
from P08719155A0105 IN O
P. P08719155A0105 NNP O
falciparum P08719155A0105 NN O
that P08719155A0105 WDT O
shares P08719155A0105 NNS O
both P08719155A0105 DT O
sequence P08719155A0105 NN O
and P08719155A0105 CC O
structural P08719155A0105 JJ O
similarities P08719155A0105 NNS O
with P08719155A0105 IN O
a P08719155A0105 DT O
sporozoite P08719155A0105 JJ O
surface P08719155A0105 NN O
molecule P08719155A0105 NN O
from P08719155A0105 IN O
Plasmodium P08719155A0105 NNP O
termed P08719155A0105 VBD O
the P08719155A0105 DT O
thrombospondin-related P08719155A0105 JJ I-UN
anonymous P08719155A0105 JJ I-UN
protein P08719155A0105 NN I-UN
( P08719155A0105 ( O
TRAP P08719155A0105 NNP I-UN
) P08719155A0105 ) O
and P08719155A0105 CC O
, P08719155A0105 , O
to P08719155A0105 TO O
a P08719155A0105 DT O
lesser P08719155A0105 JJR O
extent P08719155A0105 NN O
, P08719155A0105 , O
with P08719155A0105 IN O
the P08719155A0105 DT O
circumsporozoite P08719155A0105 NN I-UN
( P08719155A0105 ( I-UN
CS P08719155A0105 NNP I-UN
) P08719155A0105 ) I-UN
protein P08719155A0105 NN I-UN
. P08719155A0105 . O
. . O O

A P02909528A1081 DT O
second P02909528A1081 JJ O
promoter P02909528A1081 NN O
activity P02909528A1081 NN O
was P02909528A1081 VBD O
identified P02909528A1081 VBN O
in P02909528A1081 IN O
the P02909528A1081 DT O
region P02909528A1081 NN O
between P02909528A1081 IN O
the P02909528A1081 DT O
two P02909528A1081 CD O
major P02909528A1081 JJ O
transcriptional P02909528A1081 JJ O
start P02909528A1081 NN O
sites P02909528A1081 NNS O
. P02909528A1081 . O
. . O O

Despite P10681679A0220 IN O
resolution P10681679A0220 NN O
of P10681679A0220 IN O
the P10681679A0220 DT O
solid P10681679A0220 JJ O
portion P10681679A0220 NN O
of P10681679A0220 IN O
the P10681679A0220 DT O
tumor P10681679A0220 NN O
, P10681679A0220 , O
serial P10681679A0220 JJ O
MRI P10681679A0220 NNP O
showed P10681679A0220 VBD O
enlargement P10681679A0220 NN O
of P10681679A0220 IN O
a P10681679A0220 DT O
bilobar P10681679A0220 NN O
tumor P10681679A0220 NN O
cyst P10681679A0220 NN O
3 P10681679A0220 CD O
years P10681679A0220 NNS O
after P10681679A0220 IN O
the P10681679A0220 DT O
original P10681679A0220 JJ O
diagnosis P10681679A0220 NN O
. P10681679A0220 . O
. . O O

Mutational P01400217T0000 JJ O
analysis P01400217T0000 NN O
of P01400217T0000 IN O
essential P01400217T0000 JJ O
IncP P01400217T0000 NNP O
alpha P01400217T0000 NN O
plasmid P01400217T0000 NN O
transfer P01400217T0000 NN O
genes P01400217T0000 NNS O
traF P01400217T0000 NNS I-UN
and P01400217T0000 CC O
traG P01400217T0000 NN I-UN
and P01400217T0000 CC O
involvement P01400217T0000 NN O
of P01400217T0000 IN O
traF P01400217T0000 NN I-UN
in P01400217T0000 IN O
phage P01400217T0000 NN O
sensitivity P01400217T0000 NN O
. P01400217T0000 . O
. . O O

It P07274428A0000 PRP O
has P07274428A0000 VBZ O
been P07274428A0000 VBN O
shown P07274428A0000 VBN O
in P07274428A0000 IN O
experiments P07274428A0000 NNS O
in P07274428A0000 IN O
vitro P07274428A0000 NN O
that P07274428A0000 IN O
the P07274428A0000 DT O
hepatotrophic P07274428A0000 JJ O
organic P07274428A0000 JJ O
anions P07274428A0000 NNS O
, P07274428A0000 , O
the P07274428A0000 DT O
radiographic P07274428A0000 JJ O
contrast P07274428A0000 NN O
agent P07274428A0000 NN O
( P07274428A0000 ( O
RCA P07274428A0000 NNP O
) P07274428A0000 ) O
bilignost P07274428A0000 NN O
used P07274428A0000 VBN O
in P07274428A0000 IN O
cholecystography P07274428A0000 NN O
and P07274428A0000 CC O
Bengal P07274428A0000 NNP O
pink P07274428A0000 VBP O
, P07274428A0000 , O
have P07274428A0000 VBP O
an P07274428A0000 DT O
affinity P07274428A0000 NN O
, P07274428A0000 , O
unlike P07274428A0000 IN O
the P07274428A0000 DT O
urographic P07274428A0000 JJ O
RCA P07274428A0000 NNP O
triombrin P07274428A0000 NN O
and P07274428A0000 CC O
renotrophic P07274428A0000 JJ O
dye P07274428A0000 NN O
indigo-carmine P07274428A0000 NN O
, P07274428A0000 , O
for P07274428A0000 IN O
the P07274428A0000 DT O
plasmatic P07274428A0000 JJ O
membranes P07274428A0000 NNS O
( P07274428A0000 ( O
PM P07274428A0000 NNP O
) P07274428A0000 ) O
of P07274428A0000 IN O
liver P07274428A0000 NN O
cells P07274428A0000 NNS O
. P07274428A0000 . O
. . O O

Perfusion P11146961T0000 NN O
technique P11146961T0000 NN O
for P11146961T0000 IN O
perfusion-assisted P11146961T0000 JJ O
direct P11146961T0000 JJ O
coronary P11146961T0000 JJ O
artery P11146961T0000 NN O
bypass P11146961T0000 NN O
( P11146961T0000 ( O
PADCAB P11146961T0000 NNP O
) P11146961T0000 ) O
. P11146961T0000 . O
. . O O

W P03629973A0240 NNP O
. P03629973A0240 . O
. . O O

The P11014465A0479 DT O
mean P11014465A0479 JJ O
day P11014465A0479 NN O
of P11014465A0479 IN O
diagnosis P11014465A0479 NN O
of P11014465A0479 IN O
periventricular P11014465A0479 JJ O
echodensities P11014465A0479 NNS O
was P11014465A0479 VBD O
3 P11014465A0479 CD O
+ P11014465A0479 JJ O
/ P11014465A0479 NNP O
- P11014465A0479 : O
2 P11014465A0479 CD O
days P11014465A0479 NNS O
( P11014465A0479 ( O
range P11014465A0479 VB O
1-11 P11014465A0479 JJ O
days P11014465A0479 NNS O
) P11014465A0479 ) O
, P11014465A0479 , O
and P11014465A0479 CC O
of P11014465A0479 IN O
cystic P11014465A0479 JJ O
PVL P11014465A0479 NNP O
21 P11014465A0479 CD O
+ P11014465A0479 NNP O
/ P11014465A0479 NNP O
- P11014465A0479 : O
8 P11014465A0479 CD O
days P11014465A0479 NNS O
( P11014465A0479 ( O
range P11014465A0479 VB O
2-47 P11014465A0479 JJ O
days P11014465A0479 NNS O
) P11014465A0479 ) O
. P11014465A0479 . O
. . O O

A P10471743A0000 DT O
cDNA P10471743A0000 NN O
encoding P10471743A0000 VBG O
a P10471743A0000 DT O
putative P10471743A0000 JJ O
RNA P10471743A0000 NNP I-UN
and P10471743A0000 CC I-UN
/ P10471743A0000 NNP I-UN
or P10471743A0000 CC I-UN
DNA P10471743A0000 NNP I-UN
helicase P10471743A0000 NN I-UN
has P10471743A0000 VBZ O
been P10471743A0000 VBN O
isolated P10471743A0000 VBN O
from P10471743A0000 IN O
Arabidopsis P10471743A0000 NNP O
thaliana P10471743A0000 NN O
cDNA P10471743A0000 NN O
libraries P10471743A0000 NNS O
. P10471743A0000 . O
. . O O

These P01620118A0470 DT O
mutant P01620118A0470 JJ O
proteins P01620118A0470 NNS O
retained P01620118A0470 VBD O
the P01620118A0470 DT O
ability P01620118A0470 NN O
to P01620118A0470 TO O
competitively P01620118A0470 RB O
inhibit P01620118A0470 VB O
kappa P01620118A0470 JJ I-UN
B-mediated P01620118A0470 JJ O
transcriptional P01620118A0470 JJ O
activation P01620118A0470 NN O
of P01620118A0470 IN O
the P01620118A0470 DT O
human P01620118A0470 JJ I-UN
immunodeficiency P01620118A0470 NN I-UN
virus P01620118A0470 NN I-UN
long P01620118A0470 JJ I-UN
terminal P01620118A0470 JJ I-UN
repeat P01620118A0470 NN I-UN
but P01620118A0470 CC O
failed P01620118A0470 VBD O
to P01620118A0470 TO O
efficiently P01620118A0470 RB O
transform P01620118A0470 VB O
chicken P01620118A0470 NN O
lymphoid P01620118A0470 NN O
cells P01620118A0470 NNS O
both P01620118A0470 DT O
in P01620118A0470 IN O
vitro P01620118A0470 NN O
and P01620118A0470 CC O
in P01620118A0470 IN O
vivo P01620118A0470 NN O
. P01620118A0470 . O
. . O O

A P02850971A0180 DT O
17-mer P02850971A0180 JJ O
oligodeoxynucleotide P02850971A0180 NN O
, P02850971A0180 , O
corresponding P02850971A0180 VBG O
to P02850971A0180 TO O
a P02850971A0180 DT O
region P02850971A0180 NN O
of P02850971A0180 IN O
the P02850971A0180 DT O
VtHb P02850971A0180 NNP I-UN
amino P02850971A0180 NN I-UN
acid P02850971A0180 NN I-UN
sequence P02850971A0180 NN I-UN
was P02850971A0180 VBD O
used P02850971A0180 VBN O
as P02850971A0180 IN O
a P02850971A0180 DT O
hybridization P02850971A0180 NN O
probe P02850971A0180 NN O
to P02850971A0180 TO O
screen P02850971A0180 VB O
a P02850971A0180 DT O
Vitreoscilla P02850971A0180 NNP O
genomic P02850971A0180 JJ O
library P02850971A0180 NN O
constructed P02850971A0180 VBN O
in P02850971A0180 IN O
broad-host-range P02850971A0180 NN O
cosmid P02850971A0180 NN O
vector P02850971A0180 NN O
pVK102 P02850971A0180 NN O
. P02850971A0180 . O
. . O O

However P11590364A1056 RB O
, P11590364A1056 , O
the P11590364A1056 DT O
beta5L P11590364A1056 NN O
splice P11590364A1056 NN O
variant P11590364A1056 NN O
was P11590364A1056 VBD O
found P11590364A1056 VBN O
only P11590364A1056 RB O
in P11590364A1056 IN O
the P11590364A1056 DT O
retina P11590364A1056 NN O
. P11590364A1056 . O
. . O O

The P08814651A0000 DT O
importance P08814651A0000 NN O
of P08814651A0000 IN O
temporal P08814651A0000 JJ O
factors P08814651A0000 NNS O
on P08814651A0000 IN O
the P08814651A0000 DT O
presence P08814651A0000 NN O
and P08814651A0000 CC O
severity P08814651A0000 NN O
of P08814651A0000 IN O
ethanol P08814651A0000 NN O
withdrawal P08814651A0000 NN O
signs P08814651A0000 NNS O
in P08814651A0000 IN O
the P08814651A0000 DT O
rat P08814651A0000 NN O
was P08814651A0000 VBD O
quantified P08814651A0000 VBN O
using P08814651A0000 VBG O
rating P08814651A0000 NN O
scale P08814651A0000 NN O
, P08814651A0000 , O
tremor P08814651A0000 NN O
, P08814651A0000 , O
and P08814651A0000 CC O
acoustic P08814651A0000 JJ O
startle P08814651A0000 NN O
paradigms P08814651A0000 NN O
. P08814651A0000 . O
. . O O

The P08509430A0372 DT O
first P08509430A0372 JJ O
involved P08509430A0372 JJ O
complementation P08509430A0372 NN O
of P08509430A0372 IN O
a P08509430A0372 DT O
nonphotosynthetic P08509430A0372 JJ O
mutant P08509430A0372 NN O
of P08509430A0372 IN O
Chlamydomonas P08509430A0372 NNP O
, P08509430A0372 , O
CC-2341 P08509430A0372 NNP O
( P08509430A0372 ( O
ac-u-g-2.3 P08509430A0372 NN O
) P08509430A0372 ) O
, P08509430A0372 , O
which P08509430A0372 WDT O
has P08509430A0372 VBZ O
a P08509430A0372 DT O
frameshift P08509430A0372 JJ O
mutation P08509430A0372 NN O
in P08509430A0372 IN O
the P08509430A0372 DT O
psaB P08509430A0372 NN I-UN
gene P08509430A0372 NN I-UN
, P08509430A0372 , O
and P08509430A0372 CC O
selection P08509430A0372 NN O
of P08509430A0372 IN O
photosynthetic P08509430A0372 JJ O
transformants P08509430A0372 NNS O
on P08509430A0372 IN O
minimal P08509430A0372 JJ O
medium P08509430A0372 NN O
. P08509430A0372 . O
. . O O

The P03545955A1378 DT O
serum P03545955A1378 JJ I-UN
insulin P03545955A1378 NN I-UN
response P03545955A1378 NN O
can P03545955A1378 MD O
not P03545955A1378 RB O
. P03545955A1378 . O
. . O O

These P02645431A1562 DT O
data P02645431A1562 NNS O
suggest P02645431A1562 VBP O
that P02645431A1562 IN O
hypocitraturia P02645431A1562 NN O
in P02645431A1562 IN O
type P02645431A1562 NN O
I P02645431A1562 PRP O
renal P02645431A1562 VBP O
tubular P02645431A1562 JJ O
acidosis P02645431A1562 NN O
may P02645431A1562 MD O
be P02645431A1562 VB O
due P02645431A1562 JJ O
to P02645431A1562 TO O
a P02645431A1562 DT O
defect P02645431A1562 NN O
in P02645431A1562 IN O
proximal P02645431A1562 JJ O
tubule P02645431A1562 NN O
function P02645431A1562 NN O
. P02645431A1562 . O
. . O O

CREST P10934751T0001 NNP O
syndrome P10934751T0001 NN O
; P10934751T0001 : O
a P10934751T0001 DT O
changing P10934751T0001 VBG O
clinical P10934751T0001 JJ O
significance P10934751T0001 NN O
. P10934751T0001 . O
. . O O

ID-PaGIA P10878944A0000 JJ O
diphtheria P10878944A0000 NN I-UN
toxin P10878944A0000 NN I-UN
polymer P10878944A0000 NN O
particle P10878944A0000 NN O
diagnostic P10878944A0000 JJ O
agent P10878944A0000 NN O
manufactured P10878944A0000 VBN O
by P10878944A0000 IN O
DiaMed P10878944A0000 NNP O
AG P10878944A0000 NNP O
, P10878944A0000 , O
Switzerland P10878944A0000 NNP O
, P10878944A0000 , O
was P10878944A0000 VBD O
tried P10878944A0000 VBN O
at P10878944A0000 IN O
bacteriological P10878944A0000 JJ O
laboratory P10878944A0000 NN O
of P10878944A0000 IN O
Institute P10878944A0000 NNP O
of P10878944A0000 IN O
Childhood P10878944A0000 NNP O
Infections P10878944A0000 NNP O
in P10878944A0000 IN O
St P10878944A0000 NNP O
. P10878944A0000 . O
. . O O

Although P06788388A0000 IN O
the P06788388A0000 DT O
mechanism P06788388A0000 NN O
of P06788388A0000 IN O
action P06788388A0000 NN O
of P06788388A0000 IN O
ICRF-159 P06788388A0000 NNP O
and P06788388A0000 CC O
187 P06788388A0000 CD O
has P06788388A0000 VBZ O
not P06788388A0000 RB O
been P06788388A0000 VBN O
clearly P06788388A0000 RB O
defined P06788388A0000 VBN O
, P06788388A0000 , O
it P06788388A0000 PRP O
is P06788388A0000 VBZ O
evident P06788388A0000 JJ O
from P06788388A0000 IN O
both P06788388A0000 DT O
preclinical P06788388A0000 JJ O
and P06788388A0000 CC O
early P06788388A0000 JJ O
clinical P06788388A0000 JJ O
studies P06788388A0000 NNS O
that P06788388A0000 IN O
these P06788388A0000 DT O
compounds P06788388A0000 NNS O
are P06788388A0000 VBP O
of P06788388A0000 IN O
interest P06788388A0000 NN O
. P06788388A0000 . O
. . O O

By P07600986A0605 IN O
in P07600986A0605 IN O
vitro P07600986A0605 JJ O
immunoprecipitations P07600986A0605 NNS O
and P07600986A0605 CC O
gel P07600986A0605 JJ O
shift P07600986A0605 NN O
assays P07600986A0605 NNS O
, P07600986A0605 , O
we P07600986A0605 PRP O
identified P07600986A0605 VBD O
two P07600986A0605 CD O
classes P07600986A0605 NNS O
of P07600986A0605 IN O
high P07600986A0605 JJ O
affinity P07600986A0605 NN O
Engrailed-binding P07600986A0605 NNP I-UN
sites P07600986A0605 VBZ I-UN
upstream P07600986A0605 NN O
of P07600986A0605 IN O
each P07600986A0605 DT O
of P07600986A0605 IN O
the P07600986A0605 DT O
two P07600986A0605 CD O
polyhomeotic P07600986A0605 JJ O
transcription P07600986A0605 NN O
units P07600986A0605 NNS O
. P07600986A0605 . O
. . O O

The P11161793A1033 DT O
presence P11161793A1033 NN O
of P11161793A1033 IN O
truncated P11161793A1033 JJ O
receptor P11161793A1033 NN O
isoforms P11161793A1033 NNS O
in P11161793A1033 IN O
diverse P11161793A1033 JJ O
species P11161793A1033 NNS O
suggests P11161793A1033 VBZ O
that P11161793A1033 IN O
these P11161793A1033 DT O
proteins P11161793A1033 NNS O
may P11161793A1033 MD O
have P11161793A1033 VB O
important P11161793A1033 JJ O
functional P11161793A1033 JJ O
roles P11161793A1033 NNS O
in P11161793A1033 IN O
regulating P11161793A1033 VBG O
EGFR P11161793A1033 NNP I-UN
activity P11161793A1033 NN O
. P11161793A1033 . O
. . O O

The P08488700A0283 DT O
strategies P08488700A0283 NNS O
by P08488700A0283 IN O
which P08488700A0283 WDT O
hepatitis P08488700A0283 NN O
B P08488700A0283 NNP O
and P08488700A0283 CC O
hepatitis P08488700A0283 NN O
D P08488700A0283 NNP O
can P08488700A0283 MD O
be P08488700A0283 VB O
diminished P08488700A0283 VBN O
and P08488700A0283 CC O
eventually P08488700A0283 RB O
eliminated P08488700A0283 VBN O
are P08488700A0283 VBP O
: P08488700A0283 : O
immunization P08488700A0283 NN O
, P08488700A0283 , O
measures P08488700A0283 NNS O
to P08488700A0283 TO O
prevent P08488700A0283 VB O
exposure P08488700A0283 NN O
to P08488700A0283 TO O
infective P08488700A0283 VB O
blood P08488700A0283 NN O
or P08488700A0283 CC O
blood P08488700A0283 NN O
derivatives P08488700A0283 NNS O
and P08488700A0283 CC O
education P08488700A0283 NN O
( P08488700A0283 ( O
in P08488700A0283 IN O
particular P08488700A0283 JJ O
awareness P08488700A0283 NN O
that P08488700A0283 WDT O
hepatitis P08488700A0283 NN O
B P08488700A0283 NNP O
is P08488700A0283 VBZ O
a P08488700A0283 DT O
sexually P08488700A0283 RB O
transmitted P08488700A0283 JJ O
disease P08488700A0283 NN O
) P08488700A0283 ) O
. P08488700A0283 . O
. . O O

Homozygous P10326221A0531 JJ O
mutation P10326221A0531 NN O
in P10326221A0531 IN O
two P10326221A0531 CD O
children P10326221A0531 NNS O
led P10326221A0531 VBD O
to P10326221A0531 TO O
amputation P10326221A0531 NN O
of P10326221A0531 IN O
legs P10326221A0531 NNS O
due P10326221A0531 JJ O
to P10326221A0531 TO O
purpura P10326221A0531 VB O
fulminans P10326221A0531 NNS O
. P10326221A0531 . O
. . O O

Anti-HBc P01916632A0431 JJ I-UN
production P01916632A0431 NN O
of P01916632A0431 IN O
PBMC P01916632A0431 NNP O
was P01916632A0431 VBD O
enhanced P01916632A0431 VBN O
remarkably P01916632A0431 RB O
in P01916632A0431 IN O
this P01916632A0431 DT O
case P01916632A0431 NN O
. P01916632A0431 . O
. . O O

To P01560021A0379 TO O
determine P01560021A0379 VB O
the P01560021A0379 DT O
genetic P01560021A0379 JJ O
basis P01560021A0379 NN O
for P01560021A0379 IN O
the P01560021A0379 DT O
differences P01560021A0379 NNS O
between P01560021A0379 IN O
the P01560021A0379 DT O
cardiac P01560021A0379 NN O
and P01560021A0379 CC O
brain P01560021A0379 NN I-UN
AE3 P01560021A0379 NNP I-UN
variants P01560021A0379 NNS I-UN
, P01560021A0379 , O
we P01560021A0379 PRP O
isolated P01560021A0379 VBD O
and P01560021A0379 CC O
characterized P01560021A0379 VBD O
the P01560021A0379 DT O
rat P01560021A0379 NN O
gene P01560021A0379 NN O
. P01560021A0379 . O
. . O O

The P07490278A0799 DT O
latter P07490278A0799 JJ O
domain P07490278A0799 NN O
appears P07490278A0799 VBZ O
to P07490278A0799 TO O
be P07490278A0799 VB O
involved P07490278A0799 VBN O
in P07490278A0799 IN O
targeting P07490278A0799 VBG O
Num1p P07490278A0799 NNP I-UN
to P07490278A0799 TO O
the P07490278A0799 DT O
mother P07490278A0799 NN O
cell P07490278A0799 NN O
cortex P07490278A0799 NN O
. P07490278A0799 . O
. . O O

Three P02900760A0073 CD O
sequence P02900760A0073 NN O
elements P02900760A0073 NNS O
are P02900760A0073 VBP O
shown P02900760A0073 VBN O
to P02900760A0073 TO O
be P02900760A0073 VB O
required P02900760A0073 VBN O
for P02900760A0073 IN O
accurate P02900760A0073 NN O
and P02900760A0073 CC O
efficient P02900760A0073 JJ O
transcription P02900760A0073 NN O
termination P02900760A0073 NN O
by P02900760A0073 IN O
RNA P02900760A0073 NNP I-UN
polymerase P02900760A0073 NN I-UN
I P02900760A0073 PRP I-UN
( P02900760A0073 ( O
pol P02900760A0073 IN I-UN
I P02900760A0073 PRP I-UN
) P02900760A0073 ) O
assayed P02900760A0073 VBD O
both P02900760A0073 DT O
in P02900760A0073 IN O
a P02900760A0073 DT O
cell-free P02900760A0073 JJ O
transcription P02900760A0073 NN O
system P02900760A0073 NN O
and P02900760A0073 CC O
in P02900760A0073 IN O
vivo P02900760A0073 NN O
after P02900760A0073 IN O
transfection P02900760A0073 NN O
of P02900760A0073 IN O
rDNA P02900760A0073 NN O
minigene P02900760A0073 NN O
constructs P02900760A0073 VBZ O
into P02900760A0073 IN O
3T6 P02900760A0073 CD O
cells P02900760A0073 NNS O
. P02900760A0073 . O
. . O O

Using P09573374A0687 VBG O
Southern P09573374A0687 NNP O
blot P09573374A0687 NN O
analysis P09573374A0687 NN O
and P09573374A0687 CC O
restriction P09573374A0687 NN O
mapping P09573374A0687 NN O
of P09573374A0687 IN O
genomic P09573374A0687 JJ O
YAC P09573374A0687 NNP O
( P09573374A0687 ( O
yeast P09573374A0687 JJ O
artificial P09573374A0687 JJ O
chromosome P09573374A0687 NN O
) P09573374A0687 ) O
and P09573374A0687 CC O
cosmid P09573374A0687 JJ O
clones P09573374A0687 NNS O
, P09573374A0687 , O
we P09573374A0687 PRP O
located P09573374A0687 VBD O
the P09573374A0687 DT O
human P09573374A0687 JJ I-UN
RIL P09573374A0687 NNP I-UN
gene P09573374A0687 NN I-UN
240-260 P09573374A0687 JJ O
kb P09573374A0687 NNS O
telomeric P09573374A0687 JJ O
to P09573374A0687 TO O
the P09573374A0687 DT O
IRF1 P09573374A0687 NNP I-UN
gene P09573374A0687 NN I-UN
and P09573374A0687 CC O
characterized P09573374A0687 VBD O
its P09573374A0687 PRP$ O
genomic P09573374A0687 JJ O
structure P09573374A0687 NN O
. P09573374A0687 . O
. . O O

Urinary P00521732T0000 JJ O
excretion P00521732T0000 NN O
of P00521732T0000 IN O
oestrone P00521732T0000 NN O
, P00521732T0000 , O
oestradiol-17 P00521732T0000 JJ O
beta P00521732T0000 NN O
and P00521732T0000 CC O
oestriol P00521732T0000 NN O
in P00521732T0000 IN O
pregnancies P00521732T0000 NNS O
complicated P00521732T0000 VBN O
by P00521732T0000 IN O
steroid P00521732T0000 JJ I-UN
sulphatase P00521732T0000 NN I-UN
deficiency P00521732T0000 NN O
. P00521732T0000 . O
. . O O

Adhesion P03721594A0000 NN O
, P03721594A0000 , O
phagocytosis P03721594A0000 NN O
, P03721594A0000 , O
chemotactic P03721594A0000 JJ O
and P03721594A0000 CC O
random P03721594A0000 JJ O
migration P03721594A0000 NN O
, P03721594A0000 , O
nitroblue P03721594A0000 JJ O
tetrazolium P03721594A0000 NN O
dye P03721594A0000 NN O
reduction P03721594A0000 NN O
of P03721594A0000 IN O
peritoneal P03721594A0000 JJ O
exudate P03721594A0000 NN O
neutrophils P03721594A0000 NNS O
and P03721594A0000 CC O
macrophages P03721594A0000 NNS O
, P03721594A0000 , O
fibrinogen P03721594A0000 NN I-UN
level P03721594A0000 NN O
, P03721594A0000 , O
gelation P03721594A0000 NN O
of P03721594A0000 IN O
soluble P03721594A0000 JJ O
fibrin P03721594A0000 NN I-UN
and P03721594A0000 CC O
serial P03721594A0000 JJ O
dilution P03721594A0000 NN O
protamine P03721594A0000 NN O
sulfate P03721594A0000 JJ O
test P03721594A0000 NN O
were P03721594A0000 VBD O
investigated P03721594A0000 VBN O
in P03721594A0000 IN O
115 P03721594A0000 CD O
New P03721594A0000 NNP O
Zealand P03721594A0000 NNP O
white P03721594A0000 JJ O
rabbits P03721594A0000 NNS O
with P03721594A0000 IN O
experimentally P03721594A0000 RB O
induced P03721594A0000 VBN O
Shwartzman P03721594A0000 NNP O
phenomenon P03721594A0000 NN O
in P03721594A0000 IN O
the P03721594A0000 DT O
colon P03721594A0000 NN O
, P03721594A0000 , O
and P03721594A0000 CC O
in P03721594A0000 IN O
control P03721594A0000 NN O
animals P03721594A0000 NNS O
. P03721594A0000 . O
. . O O

Various P01564653A0307 JJ O
companies P01564653A0307 NNS O
produce P01564653A0307 VBP O
this P01564653A0307 DT O
type P01564653A0307 NN O
of P01564653A0307 IN O
lens P01564653A0307 NNS O
. P01564653A0307 . O
. . O O

Intravenous P08209051T0000 JJ O
antibiotic P08209051T0000 JJ O
therapy P08209051T0000 NN O
in P08209051T0000 IN O
cystic P08209051T0000 JJ O
fibrosis P08209051T0000 NN O
: P08209051T0000 : O
in P08209051T0000 IN O
hospital P08209051T0000 NN O
or P08209051T0000 CC O
at P08209051T0000 IN O
home P08209051T0000 NN O
? P08209051T0000 . O
. P08209051T0000 . O
. . O O

These P01753317A0879 DT O
results P01753317A0879 NNS O
strongly P01753317A0879 RB O
suggest P01753317A0879 VBP O
that P01753317A0879 IN O
locally-applied P01753317A0879 JJ O
TTC P01753317A0879 NNP O
in P01753317A0879 IN O
combination P01753317A0879 NN O
with P01753317A0879 IN O
FDBA P01753317A0879 NNP O
enhances P01753317A0879 VBZ O
new P01753317A0879 JJ O
bone P01753317A0879 NN O
formation P01753317A0879 NN O
in P01753317A0879 IN O
experimental P01753317A0879 JJ O
alveolar P01753317A0879 JJ O
bone P01753317A0879 NN O
defects P01753317A0879 NNS O
. P01753317A0879 . O
. . O O

The P02310261A0115 DT O
abscess P02310261A0115 NN O
was P02310261A0115 VBD O
debrided P02310261A0115 VBN O
and P02310261A0115 CC O
the P02310261A0115 DT O
septum P02310261A0115 NN O
was P02310261A0115 VBD O
patched P02310261A0115 VBN O
with P02310261A0115 IN O
a P02310261A0115 DT O
single P02310261A0115 JJ O
layer P02310261A0115 NN O
of P02310261A0115 IN O
autologous P02310261A0115 JJ O
pericardium P02310261A0115 NN O
. P02310261A0115 . O
. . O O

The P10690866A0783 DT O
variations P10690866A0783 NNS O
were P10690866A0783 VBD O
caused P10690866A0783 VBN O
by P10690866A0783 IN O
opposite P10690866A0783 JJ O
shifts P10690866A0783 NNS O
in P10690866A0783 IN O
TSH P10690866A0783 NNP I-UN
frequency P10690866A0783 NN O
distribution P10690866A0783 NN O
in P10690866A0783 IN O
mothers P10690866A0783 NNS O
and P10690866A0783 CC O
neonates P10690866A0783 NNS O
. P10690866A0783 . O
. . O O

RESULTS P09582953A1097 NN O
: P09582953A1097 : O
Horses P09582953A1097 VBZ O
with P09582953A1097 IN O
colic P09582953A1097 NN O
had P09582953A1097 VBD O
significantly P09582953A1097 RB O
higher P09582953A1097 JJR O
fibrinogen P09582953A1097 NN I-UN
concentration P09582953A1097 NN O
, P09582953A1097 , O
greater P09582953A1097 JJR O
alpha P09582953A1097 NN I-UN
2AP P09582953A1097 CD I-UN
and P09582953A1097 CC O
protein P09582953A1097 VB I-UN
C P09582953A1097 NNP I-UN
activities P09582953A1097 NNS O
, P09582953A1097 , O
and P09582953A1097 CC O
longer P09582953A1097 JJR O
PT P09582953A1097 NNP O
and P09582953A1097 CC O
APTT P09582953A1097 NNP O
than P09582953A1097 IN O
did P09582953A1097 VBD O
healthy P09582953A1097 JJ O
horses P09582953A1097 NNS O
. P09582953A1097 . O
. . O O

A P01460772T0001 DT O
case P01460772T0001 NN O
of P01460772T0001 IN O
chronic P01460772T0001 JJ O
hepatitis P01460772T0001 NN O
C P01460772T0001 NNP O
with P01460772T0001 IN O
primary P01460772T0001 JJ O
hypothyroidism P01460772T0001 NN O
manifested P01460772T0001 VBD O
during P01460772T0001 IN O
interferon P01460772T0001 NN I-UN
treatment P01460772T0001 NN O
. P01460772T0001 . O
. . O O

Efficacy P11248626T0000 NN O
of P11248626T0000 IN O
first-generation P11248626T0000 NN O
Cavermap P11248626T0000 NNP O
to P11248626T0000 TO O
verify P11248626T0000 VB O
location P11248626T0000 NN O
and P11248626T0000 CC O
function P11248626T0000 NN O
of P11248626T0000 IN O
cavernous P11248626T0000 JJ O
nerves P11248626T0000 NNS O
during P11248626T0000 IN O
radical P11248626T0000 JJ O
prostatectomy P11248626T0000 NN O
: P11248626T0000 : O
a P11248626T0000 DT O
multi-institutional P11248626T0000 JJ O
evaluation P11248626T0000 NN O
by P11248626T0000 IN O
experienced P11248626T0000 JJ O
surgeons P11248626T0000 NNS O
. P11248626T0000 . O
. . O O

We P07969181A0313 PRP O
have P07969181A0313 VBP O
recently P07969181A0313 RB O
detected P07969181A0313 VBN O
high P07969181A0313 JJ O
levels P07969181A0313 NNS O
of P07969181A0313 IN O
CKB P07969181A0313 NNP I-UN
mRNA P07969181A0313 NN I-UN
in P07969181A0313 IN O
HeLa P07969181A0313 NNP O
cells P07969181A0313 NNS O
and P07969181A0313 CC O
, P07969181A0313 , O
in P07969181A0313 IN O
this P07969181A0313 DT O
study P07969181A0313 NN O
, P07969181A0313 , O
have P07969181A0313 VBP O
tested P07969181A0313 VBN O
whether P07969181A0313 IN O
this P07969181A0313 DT O
may P07969181A0313 MD O
be P07969181A0313 VB O
due P07969181A0313 JJ O
to P07969181A0313 TO O
the P07969181A0313 DT O
extremely P07969181A0313 RB O
low P07969181A0313 JJ O
amounts P07969181A0313 NNS O
of P07969181A0313 IN O
p53 P07969181A0313 NN I-UN
protein P07969181A0313 NN I-UN
present P07969181A0313 NN O
in P07969181A0313 IN O
HeLa P07969181A0313 NNP O
cells P07969181A0313 NNS O
. P07969181A0313 . O
. . O O

Since P07251564A0569 IN O
only P07251564A0569 RB O
58 P07251564A0569 CD O
% P07251564A0569 NN O
of P07251564A0569 IN O
our P07251564A0569 PRP$ O
sample P07251564A0569 NN O
could P07251564A0569 MD O
be P07251564A0569 VB O
adequately P07251564A0569 RB O
classified P07251564A0569 VBN O
with P07251564A0569 IN O
one P07251564A0569 CD O
diagnosis P07251564A0569 NN O
, P07251564A0569 , O
we P07251564A0569 PRP O
expect P07251564A0569 VBP O
that P07251564A0569 IN O
the P07251564A0569 DT O
ASDC P07251564A0569 NNP O
nosology P07251564A0569 NN O
will P07251564A0569 MD O
need P07251564A0569 VB O
to P07251564A0569 TO O
evolve P07251564A0569 VB O
further P07251564A0569 RB O
. P07251564A0569 . O
. . O O

Treatment P11865218A0069 NN O
for P11865218A0069 IN O
this P11865218A0069 DT O
condition P11865218A0069 NN O
often P11865218A0069 RB O
involves P11865218A0069 VBZ O
use P11865218A0069 NN O
of P11865218A0069 IN O
a P11865218A0069 DT O
wax P11865218A0069 JJ O
softening P11865218A0069 NN O
or P11865218A0069 CC O
dispersing P11865218A0069 VBG O
agent P11865218A0069 NN O
( P11865218A0069 ( O
cerumenolytic P11865218A0069 JJ O
) P11865218A0069 ) O
before P11865218A0069 IN O
syringing P11865218A0069 VBG O
. P11865218A0069 . O
. . O O

Before P01168956A0552 IN O
this P01168956A0552 DT O
date P01168956A0552 NN O
, P01168956A0552 , O
the P01168956A0552 DT O
drug P01168956A0552 NN O
directly P01168956A0552 RB O
inhibits P01168956A0552 VBZ O
fetal P01168956A0552 JJ O
weight P01168956A0552 NN O
gain P01168956A0552 NN O
, P01168956A0552 , O
whereas P01168956A0552 IN O
the P01168956A0552 DT O
sensitivity P01168956A0552 NN O
of P01168956A0552 IN O
the P01168956A0552 DT O
placenta P01168956A0552 NN O
is P01168956A0552 VBZ O
only P01168956A0552 RB O
transient P01168956A0552 JJ O
at P01168956A0552 IN O
day P01168956A0552 NN O
16 P01168956A0552 CD O
resulting P01168956A0552 VBG O
in P01168956A0552 IN O
maximum P01168956A0552 JJ O
weight P01168956A0552 JJ O
decrease P01168956A0552 NN O
of P01168956A0552 IN O
this P01168956A0552 DT O
organ P01168956A0552 JJ O
24 P01168956A0552 CD O
h P01168956A0552 NN O
later P01168956A0552 RB O
. P01168956A0552 . O
. . O O

The P06687953T0000 DT O
mucosal P06687953T0000 NN O
defence P06687953T0000 NN O
capacity P06687953T0000 NN O
against P06687953T0000 IN O
proteolytic P06687953T0000 JJ O
leukocyte P06687953T0000 NN O
enzymes P06687953T0000 NNS O
. P06687953T0000 . O
. . O O

We P09230894A0422 PRP O
further P09230894A0422 VBP O
found P09230894A0422 VBD O
that P09230894A0422 IN O
KmMig1p P09230894A0422 NNP I-UN
is P09230894A0422 VBZ O
fully P09230894A0422 RB O
functional P09230894A0422 JJ O
when P09230894A0422 WRB O
expressed P09230894A0422 VBN O
in P09230894A0422 IN O
S. P09230894A0422 NNP O
cerevisiae P09230894A0422 NN O
. P09230894A0422 . O
. . O O

N. P09582326A0151 NNP O
, P09582326A0151 , O
and P09582326A0151 CC O
Fanning P09582326A0151 NNP O
, P09582326A0151 , O
E P09582326A0151 NNP O
. P09582326A0151 . O
. . O O

These P10611225A1127 DT O
data P10611225A1127 NNS O
indicate P10611225A1127 VBP O
that P10611225A1127 IN O
the P10611225A1127 DT O
interaction P10611225A1127 NN O
of P10611225A1127 IN O
eIF4A P10611225A1127 NN I-UN
with P10611225A1127 IN O
the P10611225A1127 DT O
middle P10611225A1127 JJ O
region P10611225A1127 NN O
of P10611225A1127 IN O
eIF4GI P10611225A1127 NN I-UN
is P10611225A1127 VBZ O
necessary P10611225A1127 JJ O
for P10611225A1127 IN O
translation P10611225A1127 NN O
, P10611225A1127 , O
whereas P10611225A1127 IN O
the P10611225A1127 DT O
interaction P10611225A1127 NN O
of P10611225A1127 IN O
eIF4A P10611225A1127 NN I-UN
with P10611225A1127 IN O
the P10611225A1127 DT O
C-terminal P10611225A1127 JJ O
region P10611225A1127 NN O
plays P10611225A1127 VBZ O
a P10611225A1127 DT O
modulatory P10611225A1127 JJ O
role P10611225A1127 NN O
. P10611225A1127 . O
. . O O

Histological P11306845A0168 JJ O
examination P11306845A0168 NN O
showed P11306845A0168 VBD O
lichenoid P11306845A0168 JJ O
changes P11306845A0168 NNS O
, P11306845A0168 , O
acantholytic P11306845A0168 JJ O
blister P11306845A0168 NN O
formation P11306845A0168 NN O
and P11306845A0168 CC O
apoptotic P11306845A0168 JJ O
keratinocytes P11306845A0168 NNS O
. P11306845A0168 . O
. . O O

Electrophoretic P08207232A0503 JJ O
mobility P08207232A0503 NN O
shift P08207232A0503 NN O
analysis P08207232A0503 NN O
indicates P08207232A0503 VBZ O
that P08207232A0503 IN O
NF-IL-6 P08207232A0503 NNP I-UN
, P08207232A0503 , O
as P08207232A0503 RB O
well P08207232A0503 RB O
as P08207232A0503 IN O
other P08207232A0503 JJ O
related P08207232A0503 JJ O
members P08207232A0503 NNS O
of P08207232A0503 IN O
this P08207232A0503 DT O
family P08207232A0503 NN O
, P08207232A0503 , O
bind P08207232A0503 RB O
specifically P08207232A0503 RB O
to P08207232A0503 TO O
the P08207232A0503 DT O
NF-IL-6 P08207232A0503 NNP I-UN
site P08207232A0503 NN O
in P08207232A0503 IN O
the P08207232A0503 DT O
IL-8 P08207232A0503 NNP I-UN
promoter P08207232A0503 NN I-UN
. P08207232A0503 . O
. . O O

157 P01695314A0762 CD O
+ P01695314A0762 JJ O
/ P01695314A0762 NNP O
- P01695314A0762 : O
16 P01695314A0762 CD O
mg P01695314A0762 NN O
/ P01695314A0762 NNP O
dl P01695314A0762 NN O
; P01695314A0762 : O
NS P01695314A0762 NNP O
) P01695314A0762 ) O
, P01695314A0762 , O
glucose P01695314A0762 JJ O
levels P01695314A0762 NNS O
, P01695314A0762 , O
and P01695314A0762 CC O
basal P01695314A0762 NN O
( P01695314A0762 ( O
17 P01695314A0762 CD O
+ P01695314A0762 NN O
/ P01695314A0762 NNP O
- P01695314A0762 : O
4 P01695314A0762 CD O
vs P01695314A0762 NN O
. P01695314A0762 . O
. . O O

Similarly P03572706A0329 RB O
, P03572706A0329 , O
actuarial P03572706A0329 JJ O
interpretations P03572706A0329 NNS O
for P03572706A0329 IN O
the P03572706A0329 DT O
second P03572706A0329 JJ O
protocols P03572706A0329 NNS O
were P03572706A0329 VBD O
not P03572706A0329 RB O
more P03572706A0329 RBR O
frequently P03572706A0329 RB O
selected P03572706A0329 VBN O
by P03572706A0329 IN O
therapists P03572706A0329 NNS O
as P03572706A0329 IN O
more P03572706A0329 RBR O
valid P03572706A0329 JJ O
, P03572706A0329 , O
regardless P03572706A0329 RB O
of P03572706A0329 IN O
treatment P03572706A0329 NN O
condition P03572706A0329 NN O
and P03572706A0329 CC O
elevation P03572706A0329 NN O
of P03572706A0329 IN O
the P03572706A0329 DT O
F P03572706A0329 NNP O
and P03572706A0329 CC O
F-K P03572706A0329 NNP O
indices P03572706A0329 NNS O
on P03572706A0329 IN O
the P03572706A0329 DT O
first P03572706A0329 JJ O
MMPI P03572706A0329 NNP O
profile P03572706A0329 NN O
. P03572706A0329 . O
. . O O

Alternative P07994021A1223 JJ O
splicing P07994021A1223 NN O
of P07994021A1223 IN O
the P07994021A1223 DT O
cytoplasmic P07994021A1223 JJ O
tail P07994021A1223 NN O
appears P07994021A1223 VBZ O
to P07994021A1223 TO O
generate P07994021A1223 VB O
multiple P07994021A1223 JJ O
PECAM-1 P07994021A1223 JJ I-UN
isoforms P07994021A1223 NNS I-UN
that P07994021A1223 WDT O
may P07994021A1223 MD O
regulate P07994021A1223 VB O
phosphorylation P07994021A1223 NN O
, P07994021A1223 , O
cytoskeletal P07994021A1223 JJ O
association P07994021A1223 NN O
, P07994021A1223 , O
and P07994021A1223 CC O
affinity P07994021A1223 NN O
modulation P07994021A1223 NN O
of P07994021A1223 IN O
the P07994021A1223 DT O
mature P07994021A1223 NN O
protein P07994021A1223 NN O
. P07994021A1223 . O
. . O O

It P07169630A0983 PRP O
was P07169630A0983 VBD O
suggested P07169630A0983 VBN O
that P07169630A0983 IN O
the P07169630A0983 DT O
absence P07169630A0983 NN O
of P07169630A0983 IN O
pronounced P07169630A0983 JJ O
differences P07169630A0983 NNS O
between P07169630A0983 IN O
conditions P07169630A0983 NNS O
may P07169630A0983 MD O
have P07169630A0983 VB O
been P07169630A0983 VBN O
due P07169630A0983 JJ O
to P07169630A0983 TO O
the P07169630A0983 DT O
complexity P07169630A0983 NN O
of P07169630A0983 IN O
the P07169630A0983 DT O
task P07169630A0983 NN O
or P07169630A0983 CC O
the P07169630A0983 DT O
type P07169630A0983 NN O
of P07169630A0983 IN O
prompts P07169630A0983 NNS O
employed P07169630A0983 VBN O
. P07169630A0983 . O
. . O O

The P10438924T0000 DT O
B P10438924T0000 NNP I-UN
cell P10438924T0000 NN I-UN
antigen P10438924T0000 NN I-UN
receptor P10438924T0000 NN I-UN
activates P10438924T0000 VBZ O
the P10438924T0000 DT O
Akt P10438924T0000 NNP I-UN
( P10438924T0000 ( O
protein P10438924T0000 JJ I-UN
kinase P10438924T0000 NN I-UN
B P10438924T0000 NNP I-UN
) P10438924T0000 ) O
/ P10438924T0000 VBP O
glycogen P10438924T0000 JJ I-UN
synthase P10438924T0000 NN I-UN
kinase-3 P10438924T0000 JJ I-UN
signaling P10438924T0000 VBG O
pathway P10438924T0000 NN O
via P10438924T0000 IN O
phosphatidylinositol P10438924T0000 JJ I-UN
3-kinase P10438924T0000 JJ I-UN
. P10438924T0000 . O
. . O O

Thus P03652083A0720 RB O
in P03652083A0720 IN O
this P03652083A0720 DT O
region P03652083A0720 NN O
of P03652083A0720 IN O
the P03652083A0720 DT O
vessel P03652083A0720 NN O
pyridinoline P03652083A0720 NN O
represents P03652083A0720 VBZ O
the P03652083A0720 DT O
major P03652083A0720 JJ O
stabilising P03652083A0720 VBG O
crosslink P03652083A0720 NN O
of P03652083A0720 IN O
collagen P03652083A0720 NN I-UN
. P03652083A0720 . O
. . O O

4 P01426109A1837 CD O
. P01426109A1837 . O
. . O O

Null P09334330A0252 JJ O
mutations P09334330A0252 NNS O
in P09334330A0252 IN O
daf-3 P09334330A0252 JJ I-UN
suppress P09334330A0252 NN O
mutations P09334330A0252 NNS O
in P09334330A0252 IN O
genes P09334330A0252 NNS O
encoding P09334330A0252 VBG O
this P09334330A0252 DT O
TGF-beta P09334330A0252 JJ I-UN
signal P09334330A0252 NN O
, P09334330A0252 , O
its P09334330A0252 PRP$ O
receptors P09334330A0252 NNS O
, P09334330A0252 , O
and P09334330A0252 CC O
associated P09334330A0252 VBD O
Smad P09334330A0252 NNP I-UN
signal P09334330A0252 JJ I-UN
transduction P09334330A0252 NN I-UN
proteins P09334330A0252 NNS I-UN
. P09334330A0252 . O
daf-3 P09334330A0252 JJ I-UN
encodes P09334330A0252 VBZ O
a P09334330A0252 DT O
Smad P09334330A0252 NNP I-UN
protein P09334330A0252 NN I-UN
that P09334330A0252 WDT O
is P09334330A0252 VBZ O
most P09334330A0252 RBS O
closely P09334330A0252 RB O
related P09334330A0252 VBN O
to P09334330A0252 TO O
mammalian P09334330A0252 JJ I-UN
DPC4 P09334330A0252 NNP I-UN
, P09334330A0252 , O
and P09334330A0252 CC O
is P09334330A0252 VBZ O
expressed P09334330A0252 VBN O
throughout P09334330A0252 IN O
development P09334330A0252 NN O
in P09334330A0252 IN O
many P09334330A0252 JJ O
of P09334330A0252 IN O
the P09334330A0252 DT O
tissues P09334330A0252 NNS O
that P09334330A0252 WDT O
are P09334330A0252 VBP O
remodeled P09334330A0252 VBN O
during P09334330A0252 IN O
dauer P09334330A0252 NN O
development P09334330A0252 NN O
. P09334330A0252 . O
. . O O

It P07780738A0091 PRP O
acts P07780738A0091 VBZ O
on P07780738A0091 IN O
Cdks P07780738A0091 NNP I-UN
in P07780738A0091 IN O
the P07780738A0091 DT O
G1 P07780738A0091 NNP O
and P07780738A0091 CC O
S P07780738A0091 NNP O
phases P07780738A0091 NNS O
of P07780738A0091 IN O
the P07780738A0091 DT O
cell P07780738A0091 NN O
cycle P07780738A0091 NN O
, P07780738A0091 , O
and P07780738A0091 CC O
also P07780738A0091 RB O
binds P07780738A0091 VBZ O
to P07780738A0091 TO O
proliferating P07780738A0091 VBG I-UN
cell P07780738A0091 NN I-UN
nuclear P07780738A0091 JJ I-UN
antigen P07780738A0091 NN I-UN
( P07780738A0091 ( O
PCNA P07780738A0091 NNP I-UN
) P07780738A0091 ) O
, P07780738A0091 , O
blocking P07780738A0091 VBG O
DNA P07780738A0091 NNP O
replication P07780738A0091 NN O
in P07780738A0091 IN O
vitro P07780738A0091 NN O
. P07780738A0091 . O
. . O O

Baseline P10320177A0487 NNP O
electrocorticography P10320177A0487 NN O
over P10320177A0487 IN O
the P10320177A0487 DT O
surface P10320177A0487 NN O
of P10320177A0487 IN O
the P10320177A0487 DT O
temporal P10320177A0487 JJ O
lobe P10320177A0487 NN O
and P10320177A0487 CC O
depth P10320177A0487 NN O
electrode P10320177A0487 NN O
recordings P10320177A0487 NNS O
in P10320177A0487 IN O
the P10320177A0487 DT O
amygdala P10320177A0487 NN O
and P10320177A0487 CC O
hippocampus P10320177A0487 NN O
were P10320177A0487 VBD O
obtained P10320177A0487 VBN O
, P10320177A0487 , O
followed P10320177A0487 VBN O
by P10320177A0487 IN O
10 P10320177A0487 CD O
min P10320177A0487 NNS O
of P10320177A0487 IN O
recording P10320177A0487 VBG O
before P10320177A0487 IN O
and P10320177A0487 CC O
after P10320177A0487 IN O
the P10320177A0487 DT O
i.v P10320177A0487 NN O
. P10320177A0487 . O
administration P10320177A0487 NN O
of P10320177A0487 IN O
both P10320177A0487 DT O
alfentanil P10320177A0487 JJ O
50 P10320177A0487 CD O
microg P10320177A0487 NN O
/ P10320177A0487 NNP O
kg P10320177A0487 NN O
and P10320177A0487 CC O
fentanyl P10320177A0487 $ O
10 P10320177A0487 CD O
microg P10320177A0487 NN O
/ P10320177A0487 NNP O
kg P10320177A0487 NN O
. P10320177A0487 . O
. . O O

RESULTS P08937112A0561 NN O
: P08937112A0561 : O
The P08937112A0561 DT O
age P08937112A0561 NN O
distribution P08937112A0561 NN O
was P08937112A0561 VBD O
28 P08937112A0561 CD O
to P08937112A0561 TO O
83 P08937112A0561 CD O
years P08937112A0561 NNS O
old P08937112A0561 JJ O
( P08937112A0561 ( O
mean P08937112A0561 NN O
was P08937112A0561 VBD O
54.1 P08937112A0561 CD O
years P08937112A0561 NNS O
) P08937112A0561 ) O
. P08937112A0561 . O
. . O O

With P03340726A1103 IN O
histology P03340726A1103 NN O
and P03340726A1103 CC O
Evans P03340726A1103 NNP O
blue P03340726A1103 JJ O
injections P03340726A1103 NNS O
, P03340726A1103 , O
blood-brain P03340726A1103 JJ O
barrier P03340726A1103 NN O
alterations P03340726A1103 NNS O
were P03340726A1103 VBD O
seen P03340726A1103 VBN O
as P03340726A1103 RB O
early P03340726A1103 JJ O
as P03340726A1103 IN O
4 P03340726A1103 CD O
days P03340726A1103 NNS O
after P03340726A1103 IN O
a P03340726A1103 DT O
dose P03340726A1103 NN O
of P03340726A1103 IN O
50 P03340726A1103 CD O
Gy P03340726A1103 NNP O
. P03340726A1103 . O
. . O O

Most P10531360A0958 RBS O
important P10531360A0958 JJ O
, P10531360A0958 , O
infection P10531360A0958 NN O
of P10531360A0958 IN O
the P10531360A0958 DT O
cells P10531360A0958 NNS O
with P10531360A0958 IN O
an P10531360A0958 DT O
adenoviral P10531360A0958 JJ O
construct P10531360A0958 NN O
expressing P10531360A0958 VBG O
this P10531360A0958 DT O
mutant P10531360A0958 NN O
inhibited P10531360A0958 VBD O
the P10531360A0958 DT O
induction P10531360A0958 NN O
of P10531360A0958 IN O
VEGF P10531360A0958 NNP I-UN
mRNA P10531360A0958 FW I-UN
under P10531360A0958 IN O
conditions P10531360A0958 NNS O
that P10531360A0958 WDT O
mimic P10531360A0958 VBP O
hypoxia P10531360A0958 NN O
. P10531360A0958 . O
. . O O

For P10444813A0448 IN O
symptomatic P10444813A0448 JJ O
relief P10444813A0448 NN O
and P10444813A0448 CC O
inhibition P10444813A0448 NN O
of P10444813A0448 IN O
the P10444813A0448 DT O
growth P10444813A0448 NN O
of P10444813A0448 IN O
the P10444813A0448 DT O
metastases P10444813A0448 NNS O
interferon-a P10444813A0448 JJ I-UN
and P10444813A0448 CC O
somatostatin P10444813A0448 JJ I-UN
analogues P10444813A0448 NNS O
can P10444813A0448 MD O
be P10444813A0448 VB O
employed P10444813A0448 VBN O
. P10444813A0448 . O
. . O O

Radionuclide P03622571A0208 NNP O
study P03622571A0208 NN O
and P03622571A0208 CC O
endomyocardial P03622571A0208 JJ O
biopsy P03622571A0208 NN O
revealed P03622571A0208 VBD O
remarkable P03622571A0208 JJ O
degeneration P03622571A0208 NN O
of P03622571A0208 IN O
myocardium P03622571A0208 NN O
. P03622571A0208 . O
. . O O

The P02766330A0779 DT O
author P02766330A0779 NN O
gives P02766330A0779 VBZ O
an P02766330A0779 DT O
account P02766330A0779 NN O
of P02766330A0779 IN O
antipsychotic P02766330A0779 JJ O
, P02766330A0779 , O
analgetic P02766330A0779 JJ O
, P02766330A0779 , O
myorelaxing P02766330A0779 VBG O
and P02766330A0779 CC O
vasodilatating P02766330A0779 VBG O
effects P02766330A0779 NNS O
of P02766330A0779 IN O
some P02766330A0779 DT O
calcium P02766330A0779 NN O
antagonists P02766330A0779 NNS O
, P02766330A0779 , O
and P02766330A0779 CC O
their P02766330A0779 PRP$ O
clinical P02766330A0779 JJ O
application P02766330A0779 NN O
is P02766330A0779 VBZ O
discussed P02766330A0779 VBN O
. P02766330A0779 . O
. . O O

The P11089911A1267 DT O
non-homologous P11089911A1267 JJ O
sequences P11089911A1267 NNS O
in P11089911A1267 IN O
the P11089911A1267 DT O
5 P11089911A1267 CD O
' P11089911A1267 POS O
untranslated P11089911A1267 JJ O
regions P11089911A1267 NNS O
might P11089911A1267 MD O
be P11089911A1267 VB O
acquired P11089911A1267 VBN O
at P11089911A1267 IN O
or P11089911A1267 CC O
after P11089911A1267 IN O
transcription P11089911A1267 NN O
during P11089911A1267 IN O
retrotransposition P11089911A1267 NN O
of P11089911A1267 IN O
the P11089911A1267 DT O
ATLN P11089911A1267 NNP O
elements P11089911A1267 NNS O
. P11089911A1267 . O
. . O O

Fentanyl P02869125A0120 NNP O
, P02869125A0120 , O
a P02869125A0120 DT O
prototypic P02869125A0120 JJ O
mu-opiate P02869125A0120 JJ I-UN
receptor P02869125A0120 NN I-UN
agonist P02869125A0120 NN O
, P02869125A0120 , O
has P02869125A0120 VBZ O
been P02869125A0120 VBN O
previously P02869125A0120 RB O
shown P02869125A0120 VBN O
to P02869125A0120 TO O
produce P02869125A0120 VB O
a P02869125A0120 DT O
syndrome P02869125A0120 JJ O
characterized P02869125A0120 VBN O
by P02869125A0120 IN O
marked P02869125A0120 JJ O
analgesia P02869125A0120 NN O
and P02869125A0120 CC O
locomotor P02869125A0120 NN O
stimulation P02869125A0120 NN O
as P02869125A0120 RB O
well P02869125A0120 RB O
as P02869125A0120 IN O
tachycardia P02869125A0120 NN O
, P02869125A0120 , O
tachypnoea P02869125A0120 NN O
and P02869125A0120 CC O
behavioural P02869125A0120 JJ O
arousal P02869125A0120 NN O
. P02869125A0120 . O
. . O O

Based P08471796A1654 VBN O
on P08471796A1654 IN O
these P08471796A1654 DT O
results P08471796A1654 NNS O
, P08471796A1654 , O
a P08471796A1654 DT O
new P08471796A1654 JJ O
model P08471796A1654 NN O
for P08471796A1654 IN O
the P08471796A1654 DT O
regulation P08471796A1654 NN O
of P08471796A1654 IN O
nif P08471796A1654 JJ I-UN
/ P08471796A1654 NNP O
fix P08471796A1654 NN I-UN
gene P08471796A1654 NN O
expression P08471796A1654 NN O
in P08471796A1654 IN O
A. P08471796A1654 NN O
caulinodans P08471796A1654 NNS O
is P08471796A1654 VBZ O
proposed P08471796A1654 VBN O
. P08471796A1654 . O
. . O O

Lipid P08958137A0534 NNP O
hydroperoxide P08958137A0534 NN O
levels P08958137A0534 NNS O
in P08958137A0534 IN O
plasma P08958137A0534 NN O
and P08958137A0534 CC O
LDL P08958137A0534 NNP I-UN
remained P08958137A0534 VBD O
unchanged P08958137A0534 JJ O
throughout P08958137A0534 IN O
the P08958137A0534 DT O
study P08958137A0534 NN O
. P08958137A0534 . O
. . O O

Taken P10855690A0870 VBN O
together P10855690A0870 RB O
, P10855690A0870 , O
these P10855690A0870 DT O
results P10855690A0870 NNS O
indicate P10855690A0870 VBP O
that P10855690A0870 IN O
MAP P10855690A0870 NNP I-UN
kinase P10855690A0870 VB I-UN
stimulates P10855690A0870 VBZ O
the P10855690A0870 DT O
hPL-B P10855690A0870 JJ I-UN
enhancer P10855690A0870 NN I-UN
by P10855690A0870 IN O
an P10855690A0870 DT O
NF-IL-6-dependent P10855690A0870 JJ O
pathway P10855690A0870 NN O
. P10855690A0870 . O
. . O O

ECG-gated P10466306A0000 JJ O
myocardial P10466306A0000 JJ O
Technetium-99m P10466306A0000 NNP O
sestamibi P10466306A0000 NN O
SPECT P10466306A0000 NNP O
is P10466306A0000 VBZ O
a P10466306A0000 DT O
useful P10466306A0000 JJ O
technique P10466306A0000 NN O
to P10466306A0000 TO O
measure P10466306A0000 VB O
myocardial P10466306A0000 JJ O
perfusion P10466306A0000 NN O
and P10466306A0000 CC O
function P10466306A0000 NN O
simultaneously P10466306A0000 RB O
. P10466306A0000 . O
. . O O

This P08497269A0999 DT O
sequence P08497269A0999 NN O
similarity P08497269A0999 NN O
raises P08497269A0999 VBZ O
the P08497269A0999 DT O
possibility P08497269A0999 NN O
that P08497269A0999 IN O
GCN1 P08497269A0999 NNP I-UN
interacts P08497269A0999 VBZ O
with P08497269A0999 IN O
ribosomes P08497269A0999 NNS O
or P08497269A0999 CC O
tRNA P08497269A0999 NN O
molecules P08497269A0999 NNS O
and P08497269A0999 CC O
functions P08497269A0999 NNS O
in P08497269A0999 IN O
conjunction P08497269A0999 NN O
with P08497269A0999 IN O
GCN2 P08497269A0999 NNP I-UN
in P08497269A0999 IN O
monitoring P08497269A0999 VBG O
uncharged P08497269A0999 JJ O
tRNA P08497269A0999 NN O
levels P08497269A0999 NNS O
during P08497269A0999 IN O
the P08497269A0999 DT O
process P08497269A0999 NN O
of P08497269A0999 IN O
translation P08497269A0999 NN O
elongation P08497269A0999 NN O
. P08497269A0999 . O
. . O O

The P09920982A0253 DT O
aim P09920982A0253 NN O
of P09920982A0253 IN O
the P09920982A0253 DT O
present P09920982A0253 JJ O
study P09920982A0253 NN O
was P09920982A0253 VBD O
to P09920982A0253 TO O
examine P09920982A0253 VB O
the P09920982A0253 DT O
antimicrobial P09920982A0253 JJ O
susceptibility P09920982A0253 NN O
to P09920982A0253 TO O
10 P09920982A0253 CD O
currently P09920982A0253 RB O
used P09920982A0253 VBN O
antimicrobial P09920982A0253 JJ O
agents P09920982A0253 NNS O
of P09920982A0253 IN O
50 P09920982A0253 CD O
strains P09920982A0253 NNS O
of P09920982A0253 IN O
P. P09920982A0253 NNP O
acnes P09920982A0253 NNS O
isolated P09920982A0253 VBD O
from P09920982A0253 IN O
acne P09920982A0253 JJ O
lesions P09920982A0253 NNS O
and P09920982A0253 CC O
identified P09920982A0253 VBD O
using P09920982A0253 VBG O
a P09920982A0253 DT O
Rap P09920982A0253 NNP O
ID P09920982A0253 NNP O
ANA P09920982A0253 NNP O
II P09920982A0253 NNP O
panel P09920982A0253 NN O
. P09920982A0253 . O
. . O O

AF154055 P10641037A1371 NNP I-UN
. P10641037A1371 . O
. . O O

Glucagon P10215594A1728 NNP I-UN
also P10215594A1728 RB O
induced P10215594A1728 VBD O
LUC P10215594A1728 NNP I-UN
activity P10215594A1728 NN O
very P10215594A1728 RB O
strongly P10215594A1728 RB O
when P10215594A1728 WRB O
the P10215594A1728 DT O
CRE1 P10215594A1728 NNP O
and P10215594A1728 CC O
CRE2 P10215594A1728 NNP O
sites P10215594A1728 NNS O
were P10215594A1728 VBD O
combined P10215594A1728 VBN O
; P10215594A1728 : O
induction P10215594A1728 NN O
of P10215594A1728 IN O
the P10215594A1728 DT O
( P10215594A1728 ( O
CRE1 P10215594A1728 NNP O
) P10215594A1728 ) O
3 P10215594A1728 CD O
( P10215594A1728 ( O
CRE2 P10215594A1728 NNP O
) P10215594A1728 ) O
2SV40-LUC P10215594A1728 JJ O
constructs P10215594A1728 NNS O
was P10215594A1728 VBD O
positively P10215594A1728 RB O
modulated P10215594A1728 VBN O
by P10215594A1728 IN O
the P10215594A1728 DT O
pO2 P10215594A1728 NN O
. P10215594A1728 . O
. . O O

The P02155017A1106 DT O
possible P02155017A1106 JJ O
benefits P02155017A1106 NNS O
of P02155017A1106 IN O
LMW P02155017A1106 NNP O
heparin P02155017A1106 NN O
( P02155017A1106 ( O
reduced P02155017A1106 JJ O
frequency P02155017A1106 NN O
of P02155017A1106 IN O
bleeding P02155017A1106 NN O
, P02155017A1106 , O
alleviation P02155017A1106 NN O
of P02155017A1106 IN O
hypertriglyceridemia P02155017A1106 NN O
) P02155017A1106 ) O
were P02155017A1106 VBD O
not P02155017A1106 RB O
, P02155017A1106 , O
however P02155017A1106 RB O
, P02155017A1106 , O
apparent P02155017A1106 JJ O
, P02155017A1106 , O
possibly P02155017A1106 RB O
because P02155017A1106 IN O
of P02155017A1106 IN O
the P02155017A1106 DT O
short P02155017A1106 JJ O
observation P02155017A1106 NN O
period P02155017A1106 NN O
and P02155017A1106 CC O
the P02155017A1106 DT O
low P02155017A1106 JJ O
incidence P02155017A1106 NN O
of P02155017A1106 IN O
hemorrhagic P02155017A1106 JJ O
complications P02155017A1106 NNS O
in P02155017A1106 IN O
routine P02155017A1106 JJ O
dialyses P02155017A1106 NNS O
. P02155017A1106 . O
. . O O

Anatomy P00232456T0000 NNP O
of P00232456T0000 IN O
the P00232456T0000 DT O
RNA P00232456T0000 NNP O
and P00232456T0000 CC O
gene P00232456T0000 NN O
products P00232456T0000 NNS O
of P00232456T0000 IN O
MC29 P00232456T0000 NNP O
and P00232456T0000 CC O
MH2 P00232456T0000 NNP O
, P00232456T0000 , O
two P00232456T0000 CD O
defective P00232456T0000 JJ O
avian P00232456T0000 JJ O
tumor P00232456T0000 NN O
viruses P00232456T0000 NNS O
causing P00232456T0000 VBG O
acute P00232456T0000 JJ O
leukemia P00232456T0000 NN O
and P00232456T0000 CC O
carcinoma P00232456T0000 NN O
: P00232456T0000 : O
evidence P00232456T0000 NN O
for P00232456T0000 IN O
a P00232456T0000 DT O
new P00232456T0000 JJ O
class P00232456T0000 NN O
of P00232456T0000 IN O
transforming P00232456T0000 VBG O
genes P00232456T0000 NNS O
. P00232456T0000 . O
. . O O

Fas P08972182A0527 NNP I-UN
has P08972182A0527 VBZ O
been P08972182A0527 VBN O
shown P08972182A0527 VBN O
to P08972182A0527 TO O
require P08972182A0527 VB O
ICE P08972182A0527 NNP I-UN
( P08972182A0527 ( O
interleukin-1 P08972182A0527 JJ I-UN
beta-converting P08972182A0527 NN I-UN
enzyme P08972182A0527 NN I-UN
) P08972182A0527 ) O
family P08972182A0527 NN O
proteases P08972182A0527 VBZ O
to P08972182A0527 TO O
induce P08972182A0527 VB O
apoptosis P08972182A0527 NN O
from P08972182A0527 IN O
studies P08972182A0527 NNS O
utilizing P08972182A0527 VBG O
the P08972182A0527 DT O
cowpox P08972182A0527 NN O
ICE P08972182A0527 NNP I-UN
inhibitor P08972182A0527 NN I-UN
protein P08972182A0527 NN I-UN
CrmA P08972182A0527 NNP I-UN
, P08972182A0527 , O
the P08972182A0527 DT O
synthetic P08972182A0527 JJ O
tetrapeptide P08972182A0527 NN O
ICE P08972182A0527 NNP I-UN
inhibitor P08972182A0527 NN O
YVAD-CMK P08972182A0527 NNP I-UN
, P08972182A0527 , O
and P08972182A0527 CC O
the P08972182A0527 DT O
tripeptide P08972182A0527 JJ O
pan-ICE P08972182A0527 JJ O
inhibitor P08972182A0527 NN O
Z-VAD-FMK P08972182A0527 NNP I-UN
. P08972182A0527 . O
. . O O

( P10464250A0275 ( O
1998 P10464250A0275 CD O
) P10464250A0275 ) O
FASEB P10464250A0275 NNP O
J P10464250A0275 NNP O
. P10464250A0275 . O
. . O O

A P11306463A0383 DT O
mutation P11306463A0383 NN O
in P11306463A0383 IN O
the P11306463A0383 DT O
C P11306463A0383 NNP O
domain P11306463A0383 NN O
of P11306463A0383 IN O
Rb P11306463A0383 NNP I-UN
, P11306463A0383 , O
L901Q P11306463A0383 NNP O
, P11306463A0383 , O
has P11306463A0383 VBZ O
been P11306463A0383 VBN O
identified P11306463A0383 VBN O
that P11306463A0383 IN O
completely P11306463A0383 RB O
abolishes P11306463A0383 VBZ O
cdk4 P11306463A0383 JJ I-UN
/ P11306463A0383 NNP O
D1 P11306463A0383 NNP I-UN
phosphorylation P11306463A0383 NN O
of P11306463A0383 IN O
the P11306463A0383 DT O
isolated P11306463A0383 JJ O
C P11306463A0383 NNP O
domain P11306463A0383 NN O
. P11306463A0383 . O
. . O O

This P07693372A0115 DT O
agent P07693372A0115 NN O
, P07693372A0115 , O
isolated P07693372A0115 VBN O
from P07693372A0115 IN O
the P07693372A0115 DT O
fungus P07693372A0115 NN O
Streptomyces P07693372A0115 NNP O
tsukubaensis P07693372A0115 NN O
, P07693372A0115 , O
has P07693372A0115 VBZ O
a P07693372A0115 DT O
mechanism P07693372A0115 NN O
of P07693372A0115 IN O
action P07693372A0115 NN O
similar P07693372A0115 JJ O
to P07693372A0115 TO O
that P07693372A0115 DT O
of P07693372A0115 IN O
cyclosporine P07693372A0115 NN O
. P07693372A0115 . O
. . O O

Biochemical P01679124A1368 JJ O
studies P01679124A1368 NNS O
revealed P01679124A1368 VBD O
the P01679124A1368 DT O
expected P01679124A1368 JJ O
loss P01679124A1368 NN O
of P01679124A1368 IN O
ChAT P01679124A1368 NNP I-UN
activity P01679124A1368 NN O
in P01679124A1368 IN O
the P01679124A1368 DT O
dorsal P01679124A1368 NN O
and P01679124A1368 CC O
ventral P01679124A1368 JJ O
hippocampi P01679124A1368 NN O
of P01679124A1368 IN O
lesioned P01679124A1368 JJ O
animals P01679124A1368 NNS O
along P01679124A1368 IN O
with P01679124A1368 IN O
elevated P01679124A1368 JJ O
levels P01679124A1368 NNS O
of P01679124A1368 IN O
norepinephrine P01679124A1368 NN O
( P01679124A1368 ( O
NE P01679124A1368 NNP O
) P01679124A1368 ) O
in P01679124A1368 IN O
the P01679124A1368 DT O
dorsal P01679124A1368 NN O
hippocampus P01679124A1368 NN O
of P01679124A1368 IN O
MS P01679124A1368 NNP O
/ P01679124A1368 NNP O
HSI P01679124A1368 NNP O
animals P01679124A1368 NNS O
. P01679124A1368 . O
( P01679124A1368 ( O
ABSTRACT P01679124A1368 NNP O
TRUNCATED P01679124A1368 NNP O
AT P01679124A1368 NNP O
250 P01679124A1368 CD O
WORDS P01679124A1368 NNP O
) P01679124A1368 ) O
. P01679124A1368 . O
. . O O

Regulation P07623821T0000 NN O
of P07623821T0000 IN O
Gax P07623821T0000 NNP I-UN
homeobox P07623821T0000 NN I-UN
gene P07623821T0000 NN I-UN
transcription P07623821T0000 NN O
by P07623821T0000 IN O
a P07623821T0000 DT O
combination P07623821T0000 NN O
of P07623821T0000 IN O
positive P07623821T0000 JJ O
factors P07623821T0000 NNS O
including P07623821T0000 VBG O
myocyte-specific P07623821T0000 JJ I-UN
enhancer P07623821T0000 NN I-UN
factor P07623821T0000 NN I-UN
2 P07623821T0000 CD I-UN
. P07623821T0000 . O
. . O O

Furthermore P08529662A0507 RB O
, P08529662A0507 , O
we P08529662A0507 PRP O
have P08529662A0507 VBP O
identified P08529662A0507 VBN O
a P08529662A0507 DT O
soluble P08529662A0507 JJ O
form P08529662A0507 NN O
of P08529662A0507 IN O
ERp57 P08529662A0507 NNP I-UN
/ P08529662A0507 NNP O
GRP58 P08529662A0507 NNP I-UN
by P08529662A0507 IN O
Western P08529662A0507 JJ O
blotting P08529662A0507 NN O
and P08529662A0507 CC O
biosynthetic P08529662A0507 JJ O
labeling P08529662A0507 NN O
. P08529662A0507 . O
. . O O

When P07061263A0293 WRB O
vascular P07061263A0293 JJ O
pressure P07061263A0293 NN O
( P07061263A0293 ( O
Pvas P07061263A0293 NNP O
) P07061263A0293 ) O
was P07061263A0293 VBD O
raised P07061263A0293 VBN O
abruptly P07061263A0293 RB O
from P07061263A0293 IN O
-5 P07061263A0293 NN O
to P07061263A0293 TO O
+25 P07061263A0293 VB O
cmH2O P07061263A0293 NN O
by P07061263A0293 IN O
air P07061263A0293 NN O
inflation P07061263A0293 NN O
for P07061263A0293 IN O
60 P07061263A0293 CD O
min P07061263A0293 NN O
, P07061263A0293 , O
Px P07061263A0293 NNP O
( P07061263A0293 ( O
f P07061263A0293 NN O
) P07061263A0293 ) O
became P07061263A0293 VBD O
abruptly P07061263A0293 RB O
less P07061263A0293 RBR O
negative P07061263A0293 JJ O
, P07061263A0293 , O
then P07061263A0293 RB O
remained P07061263A0293 VBD O
stable P07061263A0293 JJ O
. P07061263A0293 . O
. . O O

This P11123089A0362 DT O
article P11123089A0362 NN O
reviews P11123089A0362 VBZ O
recent P11123089A0362 JJ O
information P11123089A0362 NN O
on P11123089A0362 IN O
the P11123089A0362 DT O
frequency P11123089A0362 NN O
, P11123089A0362 , O
characteristics P11123089A0362 NNS O
, P11123089A0362 , O
and P11123089A0362 CC O
possible P11123089A0362 JJ O
pathogenic P11123089A0362 JJ O
mechanisms P11123089A0362 NNS O
of P11123089A0362 IN O
the P11123089A0362 DT O
vasculitides P11123089A0362 NNS O
occurring P11123089A0362 VBG O
in P11123089A0362 IN O
patients P11123089A0362 NNS O
with P11123089A0362 IN O
the P11123089A0362 DT O
main P11123089A0362 JJ O
connective P11123089A0362 JJ O
tissue P11123089A0362 NN O
diseases P11123089A0362 NNS O
. P11123089A0362 . O
. . O O

In P01619114A0383 IN O
an P01619114A0383 DT O
ongoing P01619114A0383 JJ O
study P01619114A0383 NN O
the P01619114A0383 DT O
performance P01619114A0383 NN O
of P01619114A0383 IN O
the P01619114A0383 DT O
SMSP P01619114A0383 NNP O
is P01619114A0383 VBZ O
being P01619114A0383 VBG O
compared P01619114A0383 VBN O
with P01619114A0383 IN O
that P01619114A0383 DT O
of P01619114A0383 IN O
the P01619114A0383 DT O
Mini P01619114A0383 NNP O
Speech P01619114A0383 NNP O
Processor P01619114A0383 NNP O
( P01619114A0383 ( O
MSP P01619114A0383 NNP O
) P01619114A0383 ) O
. P01619114A0383 . O
. . O O

When P11861092A0730 WRB O
a P11861092A0730 DT O
plateau P11861092A0730 NN O
of P11861092A0730 IN O
enhancement P11861092A0730 NN O
was P11861092A0730 VBD O
reached P11861092A0730 VBN O
, P11861092A0730 , O
a P11861092A0730 DT O
single P11861092A0730 JJ O
lesion P11861092A0730 NN O
in P11861092A0730 IN O
each P11861092A0730 DT O
patient P11861092A0730 NN O
was P11861092A0730 VBD O
imaged P11861092A0730 VBN O
using P11861092A0730 VBG O
five P11861092A0730 CD O
different P11861092A0730 JJ O
continuous P11861092A0730 JJ O
scanning P11861092A0730 VBG O
modes P11861092A0730 NNS O
, P11861092A0730 , O
fundamental P11861092A0730 JJ O
grey P11861092A0730 NN O
scale P11861092A0730 NN O
( P11861092A0730 ( O
FGS P11861092A0730 NNP O
) P11861092A0730 ) O
; P11861092A0730 : O
fundamental P11861092A0730 JJ O
colour P11861092A0730 NN O
Doppler P11861092A0730 NNP O
( P11861092A0730 ( O
FCD P11861092A0730 NNP O
) P11861092A0730 ) O
; P11861092A0730 : O
fundamental P11861092A0730 JJ O
power P11861092A0730 NN O
Doppler P11861092A0730 NNP O
( P11861092A0730 ( O
FPD P11861092A0730 NNP O
) P11861092A0730 ) O
; P11861092A0730 : O
second P11861092A0730 JJ O
harmonic P11861092A0730 JJ O
grey P11861092A0730 NN O
scale P11861092A0730 NN O
( P11861092A0730 ( O
HGS P11861092A0730 NNP O
) P11861092A0730 ) O
; P11861092A0730 : O
and P11861092A0730 CC O
pulse P11861092A0730 VB O
inversion P11861092A0730 NN O
mode P11861092A0730 NN O
( P11861092A0730 ( O
Pim P11861092A0730 NNP O
) P11861092A0730 ) O
using P11861092A0730 VBG O
an P11861092A0730 DT O
HDI5000 P11861092A0730 NNP O
scanner P11861092A0730 NN O
and P11861092A0730 CC O
C5-2 P11861092A0730 NNP O
probe P11861092A0730 NN O
( P11861092A0730 ( O
ATL P11861092A0730 NNP O
, P11861092A0730 , O
Bothell P11861092A0730 NNP O
, P11861092A0730 , O
WA P11861092A0730 NNP O
) P11861092A0730 ) O
. P11861092A0730 . O
. . O O

Two P08647091A0592 CD O
overlapping P08647091A0592 VBG O
clones P08647091A0592 NNS O
contained P08647091A0592 VBD O
the P08647091A0592 DT O
complete P08647091A0592 JJ O
Adh-2 P08647091A0592 NNP I-UN
gene P08647091A0592 NN I-UN
composed P08647091A0592 VBD O
of P08647091A0592 IN O
nine P08647091A0592 CD O
exons P08647091A0592 NNS O
in P08647091A0592 IN O
a P08647091A0592 DT O
12-kb P08647091A0592 JJ O
region P08647091A0592 NN O
, P08647091A0592 , O
with P08647091A0592 IN O
the P08647091A0592 DT O
placement P08647091A0592 NN O
of P08647091A0592 IN O
introns P08647091A0592 NNS O
matching P08647091A0592 VBG O
that P08647091A0592 DT O
observed P08647091A0592 VBN O
in P08647091A0592 IN O
other P08647091A0592 JJ O
mammalian P08647091A0592 JJ I-UN
ADH P08647091A0592 NNP I-UN
genes P08647091A0592 NNS I-UN
. P08647091A0592 . O
. . O O

Therefore P10597222A1371 RB O
, P10597222A1371 , O
we P10597222A1371 PRP O
propose P10597222A1371 VBP O
that P10597222A1371 IN O
p27 P10597222A1371 NN I-UN
represents P10597222A1371 VBZ O
a P10597222A1371 DT O
crucial P10597222A1371 JJ O
molecule P10597222A1371 NN O
in P10597222A1371 IN O
HMBA P10597222A1371 NNP O
signaling P10597222A1371 VBG O
that P10597222A1371 WDT O
can P10597222A1371 MD O
not P10597222A1371 RB O
be P10597222A1371 VB O
replaced P10597222A1371 VBN O
by P10597222A1371 IN O
p21 P10597222A1371 NN I-UN
. P10597222A1371 . O
. . O O

The P10385395A0000 DT O
high P10385395A0000 JJ I-UN
density P10385395A0000 NN I-UN
lipoprotein P10385395A0000 NN I-UN
( P10385395A0000 ( I-UN
HDL P10385395A0000 NNP I-UN
) P10385395A0000 ) I-UN
receptor P10385395A0000 NN I-UN
mediates P10385395A0000 VBZ O
the P10385395A0000 DT O
uptake P10385395A0000 NN O
of P10385395A0000 IN O
cholesterol P10385395A0000 NN O
and P10385395A0000 CC O
cholesteryl P10385395A0000 NN O
esters P10385395A0000 NNS O
, P10385395A0000 , O
substrates P10385395A0000 NNS O
for P10385395A0000 IN O
steroidogenesis P10385395A0000 NN O
, P10385395A0000 , O
from P10385395A0000 IN O
an P10385395A0000 DT O
HDL P10385395A0000 NNP I-UN
particle P10385395A0000 NN O
in P10385395A0000 IN O
the P10385395A0000 DT O
adrenal P10385395A0000 JJ O
gland P10385395A0000 NN O
and P10385395A0000 CC O
gonads P10385395A0000 NNS O
. P10385395A0000 . O
. . O O

Postglucose P03552363A0568 NNP O
serum P03552363A0568 JJ I-UN
insulin P03552363A0568 NN I-UN
levels P03552363A0568 NNS O
showed P03552363A0568 VBD O
no P03552363A0568 DT O
significant P03552363A0568 JJ O
correlations P03552363A0568 NNS O
with P03552363A0568 IN O
systolic P03552363A0568 JJ O
or P03552363A0568 CC O
diastolic P03552363A0568 JJ O
blood P03552363A0568 NN O
pressure P03552363A0568 NN O
levels P03552363A0568 NNS O
in P03552363A0568 IN O
men P03552363A0568 NNS O
, P03552363A0568 , O
but P03552363A0568 CC O
in P03552363A0568 IN O
female P03552363A0568 JJ O
diabetic P03552363A0568 JJ O
and P03552363A0568 CC O
non-diabetic P03552363A0568 JJ O
subjects P03552363A0568 NNS O
significant P03552363A0568 JJ O
correlations P03552363A0568 NNS O
were P03552363A0568 VBD O
found P03552363A0568 VBN O
in P03552363A0568 IN O
particular P03552363A0568 JJ O
with P03552363A0568 IN O
systolic P03552363A0568 JJ O
blood P03552363A0568 NN O
pressure P03552363A0568 NN O
level P03552363A0568 NN O
. P03552363A0568 . O
. . O O

The P02627159A0899 DT O
antigen-specific P02627159A0899 JJ I-UN
IgG4 P02627159A0899 NNP I-UN
antibody P02627159A0899 NN I-UN
seems P02627159A0899 VBZ O
to P02627159A0899 TO O
be P02627159A0899 VB O
an P02627159A0899 DT O
index P02627159A0899 NN O
in P02627159A0899 IN O
evaluating P02627159A0899 VBG O
immunotherapy P02627159A0899 NN O
objectively P02627159A0899 RB O
. P02627159A0899 . O
. . O O

Both P10362652A0350 DT O
carbachol P10362652A0350 NN O
( P10362652A0350 ( O
100 P10362652A0350 CD O
microM P10362652A0350 NN O
) P10362652A0350 ) O
and P10362652A0350 CC O
EGF P10362652A0350 NNP I-UN
( P10362652A0350 ( O
10 P10362652A0350 CD O
nM P10362652A0350 NN O
) P10362652A0350 ) O
induced P10362652A0350 VBD O
Ras P10362652A0350 NNP I-UN
activation P10362652A0350 NN O
. P10362652A0350 . O
. . O O

The P08538702A0214 DT O
encoded P08538702A0214 JJ O
polypeptide P08538702A0214 NN O
is P08538702A0214 VBZ O
similar P08538702A0214 JJ O
in P08538702A0214 IN O
sequence P08538702A0214 NN O
to P08538702A0214 TO O
the P08538702A0214 DT O
ABA-1 P08538702A0214 NNP I-UN
allergen P08538702A0214 NN I-UN
of P08538702A0214 IN I-UN
Ascaris P08538702A0214 NNP I-UN
, P08538702A0214 , O
the P08538702A0214 DT O
gp15 P08538702A0214 NN I-UN
/ P08538702A0214 VBZ I-UN
400 P08538702A0214 CD I-UN
'ladder P08538702A0214 NN I-UN
' P08538702A0214 '' I-UN
protein P08538702A0214 NN I-UN
of P08538702A0214 IN I-UN
Brugia P08538702A0214 NNP I-UN
malayi P08538702A0214 NN I-UN
, P08538702A0214 , I-UN
Brugia P08538702A0214 NNP I-UN
pahangi P08538702A0214 NN I-UN
and P08538702A0214 CC I-UN
Wuchereria P08538702A0214 NNP I-UN
bancrofti P08538702A0214 NN I-UN
, P08538702A0214 , O
and P08538702A0214 CC O
a P08538702A0214 DT O
15-kDa P08538702A0214 JJ I-UN
antigen P08538702A0214 NN I-UN
of P08538702A0214 IN I-UN
Dirofilaria P08538702A0214 NNP I-UN
immitis P08538702A0214 NN I-UN
. P08538702A0214 . O
. . O O

The P10649449A0413 DT O
sequences P10649449A0413 NNS O
showed P10649449A0413 VBD O
extensive P10649449A0413 JJ O
homologies P10649449A0413 NNS O
with P10649449A0413 IN O
squalene P10649449A0413 JJ I-UN
synthase P10649449A0413 NN I-UN
genes P10649449A0413 NNS I-UN
and P10649449A0413 CC O
enzymes P10649449A0413 NNS O
from P10649449A0413 IN O
a P10649449A0413 DT O
number P10649449A0413 NN O
of P10649449A0413 IN O
other P10649449A0413 JJ O
organisms P10649449A0413 NNS O
and P10649449A0413 CC O
extreme P10649449A0413 JJ O
amino P10649449A0413 NN O
acid P10649449A0413 NN O
conservation P10649449A0413 NN O
within P10649449A0413 IN O
the P10649449A0413 DT O
binding P10649449A0413 NN O
and P10649449A0413 CC O
catalytic P10649449A0413 JJ O
domains P10649449A0413 NNS O
. P10649449A0413 . O
. . O O

Diverse P10663558T0000 NNP O
endogenous P10663558T0000 JJ O
light P10663558T0000 NN O
chains P10663558T0000 NNS O
contribute P10663558T0000 VBP O
to P10663558T0000 TO O
basement P10663558T0000 VB O
membrane P10663558T0000 NN O
reactivity P10663558T0000 NN O
in P10663558T0000 IN O
nonautoimmune P10663558T0000 JJ O
mice P10663558T0000 NN O
transgenic P10663558T0000 NN O
for P10663558T0000 IN O
an P10663558T0000 DT O
anti-laminin P10663558T0000 JJ I-UN
Ig P10663558T0000 NNP I-UN
heavy P10663558T0000 NN I-UN
chain P10663558T0000 NN I-UN
. P10663558T0000 . O
. . O O

In P11538437A0568 IN O
such P11538437A0568 JJ O
conditions P11538437A0568 NNS O
, P11538437A0568 , O
the P11538437A0568 DT O
following P11538437A0568 JJ O
kinetic P11538437A0568 JJ O
reactions P11538437A0568 NNS O
have P11538437A0568 VBP O
been P11538437A0568 VBN O
studied P11538437A0568 VBN O
: P11538437A0568 : O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
A P11538437A0568 NNP O
) P11538437A0568 ) O
+ P11538437A0568 NN O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
A P11538437A0568 NNP O
) P11538437A0568 ) O
-- P11538437A0568 : O
> P11538437A0568 JJ O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
C P11538437A0568 NNP O
, P11538437A0568 , O
B P11538437A0568 NNP O
, P11538437A0568 , O
V P11538437A0568 NNP O
' P11538437A0568 POS O
) P11538437A0568 ) O
+ P11538437A0568 FW O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
X P11538437A0568 NNP O
) P11538437A0568 ) O
, P11538437A0568 , O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
A P11538437A0568 NNP O
) P11538437A0568 ) O
+ P11538437A0568 NN O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
X P11538437A0568 NNP O
, P11538437A0568 , O
V P11538437A0568 NNP O
> P11538437A0568 NNP O
5 P11538437A0568 CD O
) P11538437A0568 ) O
-- P11538437A0568 : O
> P11538437A0568 JJ O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
X P11538437A0568 NNP O
) P11538437A0568 ) O
+ P11538437A0568 VBP O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
B P11538437A0568 NNP O
, P11538437A0568 , O
V P11538437A0568 NNP O
' P11538437A0568 POS O
) P11538437A0568 ) O
in P11538437A0568 IN O
pure P11538437A0568 JJ O
N2 P11538437A0568 NNP O
post-discharges P11538437A0568 NNS O
and P11538437A0568 CC O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
A P11538437A0568 NNP O
) P11538437A0568 ) O
+ P11538437A0568 NN O
CH4 P11538437A0568 NNP O
-- P11538437A0568 : O
> P11538437A0568 JJ O
products P11538437A0568 NNS O
, P11538437A0568 , O
C P11538437A0568 NNP O
+ P11538437A0568 NNP O
N P11538437A0568 NNP O
+ P11538437A0568 NNP O
M2 P11538437A0568 NNP O
-- P11538437A0568 : O
> P11538437A0568 JJ O
CN P11538437A0568 NNP O
( P11538437A0568 ( O
B P11538437A0568 NNP O
, P11538437A0568 , O
V P11538437A0568 NNP O
' P11538437A0568 POS O
) P11538437A0568 ) O
+ P11538437A0568 FW O
M2 P11538437A0568 NNP O
, P11538437A0568 , O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
X P11538437A0568 NNP O
, P11538437A0568 , O
V P11538437A0568 NNP O
> P11538437A0568 NNP O
4 P11538437A0568 CD O
) P11538437A0568 ) O
+ P11538437A0568 NN O
CN P11538437A0568 NNP O
-- P11538437A0568 : O
> P11538437A0568 JJ O
N2 P11538437A0568 NNP O
( P11538437A0568 ( O
X P11538437A0568 NNP O
) P11538437A0568 ) O
+ P11538437A0568 VBP O
CN P11538437A0568 NNP O
( P11538437A0568 ( O
B P11538437A0568 NNP O
, P11538437A0568 , O
A P11538437A0568 NNP O
, P11538437A0568 , O
V P11538437A0568 NNP O
' P11538437A0568 POS O
) P11538437A0568 ) O
, P11538437A0568 , O
in P11538437A0568 IN O
N2-1 P11538437A0568 NNP O
% P11538437A0568 NN O
CH4 P11538437A0568 NNP O
post-discharges P11538437A0568 NNS O
. P11538437A0568 . O
. . O O

Immunoglobulin P02489032A0000 NNP I-UN
light P02489032A0000 NN I-UN
chain P02489032A0000 NN I-UN
( P02489032A0000 ( O
IgL P02489032A0000 NNP I-UN
) P02489032A0000 ) O
diversity P02489032A0000 NN O
is P02489032A0000 VBZ O
generated P02489032A0000 VBN O
in P02489032A0000 IN O
the P02489032A0000 DT O
chicken P02489032A0000 NN O
by P02489032A0000 IN O
recombination P02489032A0000 NN O
between P02489032A0000 IN O
the P02489032A0000 DT O
single P02489032A0000 JJ O
functional P02489032A0000 JJ O
variable P02489032A0000 NN O
( P02489032A0000 ( O
VL P02489032A0000 NNP I-UN
) P02489032A0000 ) O
and P02489032A0000 CC O
joining P02489032A0000 VBG O
( P02489032A0000 ( O
JL P02489032A0000 NNP I-UN
) P02489032A0000 ) O
gene P02489032A0000 NN O
segments P02489032A0000 NNS O
and P02489032A0000 CC O
subsequent P02489032A0000 JJ O
somatic P02489032A0000 JJ O
diversification P02489032A0000 NN O
of P02489032A0000 IN O
the P02489032A0000 DT O
rearranged P02489032A0000 JJ O
VL P02489032A0000 NNP I-UN
region P02489032A0000 NN O
. P02489032A0000 . O
. . O O

RVEF P02838319A0527 NNP O
and P02838319A0527 CC O
LVEF P02838319A0527 NNP O
both P02838319A0527 DT O
increased P02838319A0527 VBN O
by P02838319A0527 IN O
about P02838319A0527 RB O
14 P02838319A0527 CD O
% P02838319A0527 NN O
( P02838319A0527 ( O
p P02838319A0527 NN O
less P02838319A0527 JJR O
than P02838319A0527 IN O
0.05 P02838319A0527 CD O
and P02838319A0527 CC O
p P02838319A0527 RB O
less P02838319A0527 JJR O
than P02838319A0527 IN O
0.01 P02838319A0527 CD O
) P02838319A0527 ) O
. P02838319A0527 . O
. . O O

BACKGROUND P11465518A0000 NN O
: P11465518A0000 : O
There P11465518A0000 EX O
is P11465518A0000 VBZ O
increasing P11465518A0000 VBG O
interest P11465518A0000 NN O
on P11465518A0000 IN O
the P11465518A0000 DT O
part P11465518A0000 NN O
of P11465518A0000 IN O
investigators P11465518A0000 NNS O
and P11465518A0000 CC O
the P11465518A0000 DT O
public P11465518A0000 NN O
at P11465518A0000 IN O
large P11465518A0000 JJ O
in P11465518A0000 IN O
finding P11465518A0000 VBG O
ways P11465518A0000 NNS O
to P11465518A0000 TO O
study P11465518A0000 VB O
and P11465518A0000 CC O
improve P11465518A0000 VB O
treatments P11465518A0000 NNS O
for P11465518A0000 IN O
the P11465518A0000 DT O
seriously P11465518A0000 RB O
mentally P11465518A0000 RB O
ill P11465518A0000 VB O
without P11465518A0000 IN O
exposing P11465518A0000 VBG O
such P11465518A0000 JJ O
individuals P11465518A0000 NNS O
to P11465518A0000 TO O
unnecessary P11465518A0000 JJ O
risks P11465518A0000 NNS O
. P11465518A0000 . O
. . O O

The P09326727T0000 DT O
regurgitation P09326727T0000 NN O
of P09326727T0000 IN O
large P09326727T0000 JJ O
vitreous P09326727T0000 JJ O
injections P09326727T0000 NNS O
. P09326727T0000 . O
. . O O

A P08232304A1166 DT O
series P08232304A1166 NN O
of P08232304A1166 IN O
5'-deletions P08232304A1166 NNS O
revealed P08232304A1166 VBD O
that P08232304A1166 IN O
the P08232304A1166 DT O
fragment P08232304A1166 NN O
-218 P08232304A1166 NN O
to P08232304A1166 TO O
+4 P08232304A1166 VB O
from P08232304A1166 IN O
the P08232304A1166 DT O
TSS P08232304A1166 NNP O
had P08232304A1166 VBD O
the P08232304A1166 DT O
highest P08232304A1166 JJS O
promoter P08232304A1166 NN O
activity P08232304A1166 NN O
, P08232304A1166 , O
nearly P08232304A1166 RB O
1000-fold P08232304A1166 JJ O
greater P08232304A1166 JJR O
than P08232304A1166 IN O
the P08232304A1166 DT O
promoterless P08232304A1166 NN O
chloramphenicol P08232304A1166 NN I-UN
acetyltransferase P08232304A1166 NN I-UN
construct P08232304A1166 NN I-UN
. P08232304A1166 . O
. . O O

Here P09472608A0253 RB O
we P09472608A0253 PRP O
have P09472608A0253 VBP O
examined P09472608A0253 VBN O
the P09472608A0253 DT O
ability P09472608A0253 NN O
of P09472608A0253 IN O
the P09472608A0253 DT O
cellular P09472608A0253 JJ O
protein P09472608A0253 NN O
YB-1 P09472608A0253 NNP I-UN
to P09472608A0253 TO O
modulate P09472608A0253 VB O
transcription P09472608A0253 NN O
of P09472608A0253 IN O
the P09472608A0253 DT O
HIV-1 P09472608A0253 NNP I-UN
promoter P09472608A0253 NN I-UN
in P09472608A0253 IN O
a P09472608A0253 DT O
human P09472608A0253 JJ O
astrocytic P09472608A0253 JJ O
cell P09472608A0253 NN O
line P09472608A0253 NN O
( P09472608A0253 ( O
U-87MG P09472608A0253 NNP O
) P09472608A0253 ) O
, P09472608A0253 , O
a P09472608A0253 DT O
neuronal P09472608A0253 JJ O
cell P09472608A0253 NN O
line P09472608A0253 NN O
( P09472608A0253 ( O
SK-N-MC P09472608A0253 NNP O
) P09472608A0253 ) O
and P09472608A0253 CC O
lymphoid P09472608A0253 JJ O
cells P09472608A0253 NNS O
( P09472608A0253 ( O
Jurkat P09472608A0253 NNP O
) P09472608A0253 ) O
by P09472608A0253 IN O
transfection P09472608A0253 NN O
assay P09472608A0253 NN O
. P09472608A0253 . O
. . O O

METHODS P10658445A0208 NN O
: P10658445A0208 : O
The P10658445A0208 DT O
former P10658445A0208 JJ O
group P10658445A0208 NN O
included P10658445A0208 VBD O
patients P10658445A0208 NNS O
who P10658445A0208 WP O
had P10658445A0208 VBD O
been P10658445A0208 VBN O
treated P10658445A0208 VBN O
with P10658445A0208 IN O
at P10658445A0208 IN O
least P10658445A0208 JJS O
four P10658445A0208 CD O
PGE1 P10658445A0208 NNP O
alpha-ciclodestrina P10658445A0208 NN O
, P10658445A0208 , O
short-term P10658445A0208 JJ O
treatment P10658445A0208 NN O
cycles P10658445A0208 NNS O
per P10658445A0208 IN O
year P10658445A0208 NN O
while P10658445A0208 IN O
the P10658445A0208 DT O
latter P10658445A0208 NN O
was P10658445A0208 VBD O
a P10658445A0208 DT O
historical P10658445A0208 JJ O
reference P10658445A0208 NN O
group P10658445A0208 NN O
managed P10658445A0208 VBD O
without P10658445A0208 IN O
prostaglandins P10658445A0208 NNS O
. P10658445A0208 . O
. . O O

Overall P09242375A1313 JJ O
, P09242375A1313 , O
these P09242375A1313 DT O
findings P09242375A1313 NNS O
demonstrate P09242375A1313 VBP O
that P09242375A1313 IN O
mutations P09242375A1313 NNS O
E768D P09242375A1313 NNP O
and P09242375A1313 CC O
V804L P09242375A1313 NNP O
are P09242375A1313 VBP O
gain-of-function P09242375A1313 JJ O
mutations P09242375A1313 NNS O
that P09242375A1313 WDT O
confer P09242375A1313 VBP O
to P09242375A1313 TO O
the P09242375A1313 DT O
long P09242375A1313 JJ I-UN
RET P09242375A1313 NNP I-UN
isoform P09242375A1313 NN I-UN
the P09242375A1313 DT O
capacity P09242375A1313 NN O
to P09242375A1313 TO O
exert P09242375A1313 VB O
a P09242375A1313 DT O
biological P09242375A1313 JJ O
effect P09242375A1313 NN O
, P09242375A1313 , O
although P09242375A1313 IN O
these P09242375A1313 DT O
mutations P09242375A1313 NNS O
are P09242375A1313 VBP O
more P09242375A1313 RBR O
weakly P09242375A1313 JJ O
activating P09242375A1313 NN O
than P09242375A1313 IN O
the P09242375A1313 DT O
MEN2A P09242375A1313 NNP I-UN
and P09242375A1313 CC O
MEN2B P09242375A1313 NNP I-UN
mutations P09242375A1313 NNS O
. P09242375A1313 . O
. . O O

Pet-1 P09468386A0594 NN I-UN
can P09468386A0594 MD O
bind P09468386A0594 VB O
specifically P09468386A0594 RB O
to P09468386A0594 TO O
a P09468386A0594 DT O
PEA3 P09468386A0594 NNP I-UN
ETS P09468386A0594 NNP I-UN
DNA-binding P09468386A0594 NNP O
motif P09468386A0594 NN O
and P09468386A0594 CC O
can P09468386A0594 MD O
modulate P09468386A0594 VB O
transcription P09468386A0594 NN O
of P09468386A0594 IN O
synthetic P09468386A0594 JJ O
promoter P09468386A0594 NN O
constructs P09468386A0594 NNS O
in P09468386A0594 IN O
a P09468386A0594 DT O
sequence-specific P09468386A0594 JJ O
manner P09468386A0594 NN O
. P09468386A0594 . O
. . O O

The P01826003A0694 DT O
gene P01826003A0694 NN O
is P01826003A0694 VBZ O
1,139 P01826003A0694 CD O
base P01826003A0694 NN O
pairs P01826003A0694 NN O
( P01826003A0694 ( O
bp P01826003A0694 NN O
) P01826003A0694 ) O
long P01826003A0694 RB O
, P01826003A0694 , O
and P01826003A0694 CC O
, P01826003A0694 , O
like P01826003A0694 IN O
other P01826003A0694 JJ O
members P01826003A0694 NNS O
of P01826003A0694 IN O
the P01826003A0694 DT O
SIG P01826003A0694 NNP I-UN
family P01826003A0694 NN I-UN
, P01826003A0694 , O
the P01826003A0694 DT O
beta P01826003A0694 NN I-UN
TG P01826003A0694 NNP I-UN
gene P01826003A0694 NN I-UN
is P01826003A0694 VBZ O
divided P01826003A0694 VBN O
into P01826003A0694 IN O
3 P01826003A0694 CD O
exons P01826003A0694 NNS O
. P01826003A0694 . O
. . O O

Role P04704137T0001 NNP O
of P04704137T0001 IN O
histoclinical P04704137T0001 JJ O
studies P04704137T0001 NNS O
in P04704137T0001 IN O
the P04704137T0001 DT O
prophylaxis P04704137T0001 NN O
of P04704137T0001 IN O
spontaneous P04704137T0001 JJ O
abortions P04704137T0001 NNS O
. P04704137T0001 . O
. . O O

Filter P08964172A0221 NNP O
and P08964172A0221 CC O
cytocentrifuge P08964172A0221 JJ O
preparations P08964172A0221 NNS O
of P08964172A0221 IN O
the P08964172A0221 DT O
urine P08964172A0221 NN O
were P08964172A0221 VBD O
studied P08964172A0221 VBN O
and P08964172A0221 CC O
all P08964172A0221 DT O
cases P08964172A0221 NNS O
displayed P08964172A0221 VBD O
numerous P08964172A0221 JJ O
scattered P08964172A0221 JJ O
aggregates P08964172A0221 NNS O
or P08964172A0221 CC O
single P08964172A0221 JJ O
tumor P08964172A0221 NN O
cells P08964172A0221 NNS O
in P08964172A0221 IN O
an P08964172A0221 DT O
inflammatory P08964172A0221 NN O
background P08964172A0221 NN O
. P08964172A0221 . O
. . O O

Forty-five P07282444A0075 JJ O
cases P07282444A0075 NNS O
were P07282444A0075 VBD O
surgically P07282444A0075 RB O
by P07282444A0075 IN O
direct P07282444A0075 JJ O
approach P07282444A0075 NN O
to P07282444A0075 TO O
the P07282444A0075 DT O
tumour P07282444A0075 NN O
, P07282444A0075 , O
while P07282444A0075 IN O
two P07282444A0075 CD O
cases P07282444A0075 NNS O
were P07282444A0075 VBD O
treated P07282444A0075 VBN O
only P07282444A0075 RB O
with P07282444A0075 IN O
a P07282444A0075 DT O
shunt P07282444A0075 NN O
. P07282444A0075 . O
. . O O

However P07598303A1728 RB O
, P07598303A1728 , O
the P07598303A1728 DT O
few P07598303A1728 JJ O
studies P07598303A1728 NNS O
that P07598303A1728 WDT O
address P07598303A1728 VBP O
antimicrobial P07598303A1728 JJ O
prophylaxis P07598303A1728 NN O
in P07598303A1728 IN O
bone P07598303A1728 NN O
marrow P07598303A1728 NN O
transplantation P07598303A1728 NN O
have P07598303A1728 VBP O
not P07598303A1728 RB O
always P07598303A1728 RB O
shown P07598303A1728 VBN O
a P07598303A1728 DT O
survival P07598303A1728 JJ O
benefit P07598303A1728 NN O
. P07598303A1728 . O
. . O O

Although P11340048A0432 IN O
there P11340048A0432 EX O
was P11340048A0432 VBD O
a P11340048A0432 DT O
high P11340048A0432 JJ O
correlation P11340048A0432 NN O
between P11340048A0432 IN O
sap P11340048A0432 JJ O
flux P11340048A0432 NN O
densities P11340048A0432 NNS O
registered P11340048A0432 VBN O
by P11340048A0432 IN O
the P11340048A0432 DT O
old P11340048A0432 JJ O
and P11340048A0432 CC O
new P11340048A0432 JJ O
sensors P11340048A0432 NNS O
, P11340048A0432 , O
significant P11340048A0432 JJ O
differences P11340048A0432 NNS O
in P11340048A0432 IN O
sap P11340048A0432 JJ O
flux P11340048A0432 NN O
densities P11340048A0432 NNS O
between P11340048A0432 IN O
the P11340048A0432 DT O
duplicated P11340048A0432 JJ O
sensors P11340048A0432 NNS O
were P11340048A0432 VBD O
detected P11340048A0432 VBN O
. P11340048A0432 . O
. . O O

Surprisingly P08164661A0414 RB O
, P08164661A0414 , O
TFIIIC P08164661A0414 NNP I-UN
alpha P08164661A0414 NN I-UN
has P08164661A0414 VBZ O
no P08164661A0414 DT O
homology P08164661A0414 NN O
to P08164661A0414 TO O
any P08164661A0414 DT O
of P08164661A0414 IN O
the P08164661A0414 DT O
yeast P08164661A0414 NN I-UN
TFIIIC P08164661A0414 NNP I-UN
subunits P08164661A0414 VBZ I-UN
already P08164661A0414 RB O
cloned P08164661A0414 VBN O
, P08164661A0414 , O
suggesting P08164661A0414 VBG O
a P08164661A0414 DT O
significant P08164661A0414 JJ O
degree P08164661A0414 NN O
of P08164661A0414 IN O
evolutionary P08164661A0414 JJ O
divergence P08164661A0414 NN O
for P08164661A0414 IN O
RNA P08164661A0414 NNP I-UN
polymerase P08164661A0414 NN I-UN
III P08164661A0414 NNP I-UN
factors P08164661A0414 NNS I-UN
. P08164661A0414 . O
. . O O

Seven P03421425A0878 CD O
patients P03421425A0878 NNS O
( P03421425A0878 ( O
8.3 P03421425A0878 CD O
percent P03421425A0878 NN O
) P03421425A0878 ) O
had P03421425A0878 VBD O
latent P03421425A0878 JJ O
hypothyroidism P03421425A0878 NN O
only P03421425A0878 RB O
discovered P03421425A0878 VBN O
by P03421425A0878 IN O
hormonal P03421425A0878 JJ O
determinations P03421425A0878 NNS O
. P03421425A0878 . O
. . O O

Mutation P08386319A1229 NN O
of P08386319A1229 IN O
the P08386319A1229 DT O
presumptive P08386319A1229 JJ O
phosphorylated P08386319A1229 JJ O
tyrosine P08386319A1229 NN O
and P08386319A1229 CC O
threonine P08386319A1229 NN O
residues P08386319A1229 NNS O
of P08386319A1229 IN O
Mpk1p P08386319A1229 NNP I-UN
individually P08386319A1229 RB O
to P08386319A1229 TO O
phenylalanine P08386319A1229 VB O
and P08386319A1229 CC O
alanine P08386319A1229 VB O
, P08386319A1229 , O
respectively P08386319A1229 RB O
, P08386319A1229 , O
severely P08386319A1229 RB O
impaired P08386319A1229 JJ O
Mpk1p P08386319A1229 NNP I-UN
function P08386319A1229 NN O
. P08386319A1229 . O
. . O O

Plasma P06152670T0000 NNP I-UN
secretin P06152670T0000 NN I-UN
, P06152670T0000 , O
pancreozymin P06152670T0000 NN I-UN
, P06152670T0000 , O
and P06152670T0000 CC O
somatostatin-like P06152670T0000 JJ I-UN
hormone P06152670T0000 NN I-UN
in P06152670T0000 IN O
chronic P06152670T0000 JJ O
renal P06152670T0000 JJ O
failure P06152670T0000 NN O
patients P06152670T0000 NNS O
. P06152670T0000 . O
. . O O

Experience P05884183T0001 NN O
with P05884183T0001 IN O
the P05884183T0001 DT O
restoration P05884183T0001 NN O
of P05884183T0001 IN O
agglutination P05884183T0001 NN O
properties P05884183T0001 NNS O
of P05884183T0001 IN O
non-agglutinating P05884183T0001 JJ O
dysenterial P05884183T0001 JJ O
cultures P05884183T0001 NNS O
with P05884183T0001 IN O
the P05884183T0001 DT O
use P05884183T0001 NN O
of P05884183T0001 IN O
Rzhaninov P05884183T0001 NNP O
's P05884183T0001 POS O
method P05884183T0001 NN O
. P05884183T0001 . O
. . O O

Of P06290859A0426 IN O
115 P06290859A0426 CD O
hepatitis P06290859A0426 NN O
B P06290859A0426 NNP O
patients P06290859A0426 NNS O
seen P06290859A0426 VBN O
at P06290859A0426 IN O
12 P06290859A0426 CD O
months P06290859A0426 NNS O
, P06290859A0426 , O
6 P06290859A0426 CD O
% P06290859A0426 NN O
had P06290859A0426 VBD O
chronic P06290859A0426 JJ O
hepatitis P06290859A0426 NN O
Bs P06290859A0426 NNP O
antigenaemia P06290859A0426 NN O
, P06290859A0426 , O
60 P06290859A0426 CD O
% P06290859A0426 NN O
had P06290859A0426 VBD O
developed P06290859A0426 VBN O
anti-HBs P06290859A0426 JJ I-UN
antibodies P06290859A0426 NNS I-UN
, P06290859A0426 , O
and P06290859A0426 CC O
7.3 P06290859A0426 CD O
% P06290859A0426 NN O
still P06290859A0426 RB O
had P06290859A0426 VBD O
abnormal P06290859A0426 JJ O
liver P06290859A0426 NN O
function P06290859A0426 NN O
. P06290859A0426 . O
. . O O

We P09495283A0000 PRP O
have P09495283A0000 VBP O
examined P09495283A0000 VBN O
reporter P09495283A0000 NN O
gene P09495283A0000 NN O
( P09495283A0000 ( O
beta-gal P09495283A0000 JJ I-UN
) P09495283A0000 ) O
expression P09495283A0000 NN O
directed P09495283A0000 VBN O
by P09495283A0000 IN O
human P09495283A0000 JJ I-UN
heat P09495283A0000 NN I-UN
shock P09495283A0000 NN I-UN
transcription P09495283A0000 NN I-UN
factors P09495283A0000 NNS I-UN
1 P09495283A0000 CD I-UN
and P09495283A0000 CC I-UN
2 P09495283A0000 CD I-UN
( P09495283A0000 ( O
HSF1 P09495283A0000 NNP I-UN
and P09495283A0000 CC O
HSF2 P09495283A0000 NNP I-UN
) P09495283A0000 ) O
in P09495283A0000 IN O
HeLa P09495283A0000 NNP O
cells P09495283A0000 NNS O
and P09495283A0000 CC O
in P09495283A0000 IN O
yeast P09495283A0000 NN O
( P09495283A0000 ( O
Saccharomyces P09495283A0000 NNP O
cerevisiae P09495283A0000 NN O
) P09495283A0000 ) O
. P09495283A0000 . O
. . O O

Chloroplast P08776901A0000 NNP I-UN
mutator P08776901A0000 NN I-UN
( P08776901A0000 ( O
chm P08776901A0000 NN I-UN
) P08776901A0000 ) O
of P08776901A0000 IN O
Arabidopsis P08776901A0000 NNP O
is P08776901A0000 VBZ O
a P08776901A0000 DT O
recessive P08776901A0000 JJ O
nuclear P08776901A0000 JJ O
mutation P08776901A0000 NN O
that P08776901A0000 WDT O
causes P08776901A0000 VBZ O
green P08776901A0000 JJ O
and P08776901A0000 CC O
white P08776901A0000 JJ O
variegation P08776901A0000 NN O
in P08776901A0000 IN O
leaves P08776901A0000 NNS O
and P08776901A0000 CC O
is P08776901A0000 VBZ O
inherited P08776901A0000 VBN O
in P08776901A0000 IN O
a P08776901A0000 DT O
non-Mendelian P08776901A0000 JJ O
fashion P08776901A0000 NN O
. P08776901A0000 . O
. . O O

Furthermore P11256944A1144 RB O
, P11256944A1144 , O
the P11256944A1144 DT O
soluble P11256944A1144 JJ O
forms P11256944A1144 NNS O
of P11256944A1144 IN O
ATF6 P11256944A1144 NNP I-UN
and P11256944A1144 CC O
the P11256944A1144 DT O
G13 P11256944A1144 NNP I-UN
gene P11256944A1144 NN I-UN
product P11256944A1144 NN I-UN
are P11256944A1144 VBP O
unable P11256944A1144 JJ O
to P11256944A1144 TO O
bind P11256944A1144 VB O
to P11256944A1144 TO O
several P11256944A1144 JJ O
point P11256944A1144 NN O
mutants P11256944A1144 NNS O
of P11256944A1144 IN O
the P11256944A1144 DT O
cis-acting P11256944A1144 JJ O
ER P11256944A1144 NNP O
stress P11256944A1144 NN O
response P11256944A1144 NN O
element P11256944A1144 NN O
in P11256944A1144 IN O
vitro P11256944A1144 NN O
that P11256944A1144 WDT O
hardly P11256944A1144 RB O
respond P11256944A1144 VBP O
to P11256944A1144 TO O
ER P11256944A1144 NNP O
stress P11256944A1144 NN O
in P11256944A1144 IN O
vivo P11256944A1144 NN O
. P11256944A1144 . O
. . O O

Overexpression P09032267A0850 NN O
of P09032267A0850 IN O
the P09032267A0850 DT O
bZip P09032267A0850 NN O
interaction P09032267A0850 NN O
domain P09032267A0850 NN O
of P09032267A0850 IN O
CBP P09032267A0850 NNP I-UN
specifically P09032267A0850 RB O
abolishes P09032267A0850 VBZ O
the P09032267A0850 DT O
positive P09032267A0850 JJ O
cross P09032267A0850 NN O
talk P09032267A0850 NN O
between P09032267A0850 IN O
TR P09032267A0850 NNP I-UN
and P09032267A0850 CC O
p45 P09032267A0850 JJ I-UN
/ P09032267A0850 NNP O
NF-E2 P09032267A0850 NNP I-UN
. P09032267A0850 . O
. . O O

Adult P06740919A0162 NNP O
Amblyomma P06740919A0162 NNP O
lepidum P06740919A0162 NN O
ticks P06740919A0162 NNS O
fed P06740919A0162 VBN O
as P06740919A0162 IN O
nymphs P06740919A0162 NN O
on P06740919A0162 IN O
this P06740919A0162 DT O
goat P06740919A0162 NN O
transmitted P06740919A0162 VBD O
heartwater P06740919A0162 NN O
to P06740919A0162 TO O
a P06740919A0162 DT O
Friesian P06740919A0162 NNP O
( P06740919A0162 ( O
Bos P06740919A0162 NNP O
taurus P06740919A0162 NN O
) P06740919A0162 ) O
calf P06740919A0162 NN O
. P06740919A0162 . O
. . O O

In P01655713A0294 IN O
this P01655713A0294 DT O
study P01655713A0294 NN O
, P01655713A0294 , O
we P01655713A0294 PRP O
have P01655713A0294 VBP O
cloned P01655713A0294 VBN O
a P01655713A0294 DT O
region P01655713A0294 NN O
that P01655713A0294 WDT O
complements P01655713A0294 VBZ O
the P01655713A0294 DT O
exoenzyme P01655713A0294 JJ I-UN
S-deficient P01655713A0294 JJ O
phenotype P01655713A0294 NN O
of P01655713A0294 IN O
strain P01655713A0294 NN O
388 P01655713A0294 CD O
exs1 P01655713A0294 NN I-UN
: P01655713A0294 : O
:Tn1 P01655713A0294 NN O
, P01655713A0294 , O
a P01655713A0294 DT O
chromosomal P01655713A0294 JJ I-UN
Tn1 P01655713A0294 NNP I-UN
insertional P01655713A0294 JJ I-UN
mutation P01655713A0294 NN I-UN
. P01655713A0294 . O
. . O O

A P02335713A0905 DT O
poor P02335713A0905 JJ O
correlation P02335713A0905 NN O
was P02335713A0905 VBD O
also P02335713A0905 RB O
observed P02335713A0905 VBN O
between P02335713A0905 IN O
PbB P02335713A0905 NNP O
and P02335713A0905 CC O
ALAD P02335713A0905 NNP I-UN
activity P02335713A0905 NN O
of P02335713A0905 IN O
the P02335713A0905 DT O
stearate P02335713A0905 JJ O
workers P02335713A0905 NNS O
. P02335713A0905 . O
. . O O

Curiously P07949205A0286 RB O
, P07949205A0286 , O
testololactone P07949205A0286 NN O
was P07949205A0286 VBD O
earlier P07949205A0286 JJR O
and P07949205A0286 CC O
more P07949205A0286 RBR O
widely P07949205A0286 RB O
used P07949205A0286 VBN O
than P07949205A0286 IN O
aminoglutethimide P07949205A0286 RB O
in P07949205A0286 IN O
treating P07949205A0286 VBG O
advanced P07949205A0286 JJ O
breast P07949205A0286 NN O
carcinoma P07949205A0286 NN O
. P07949205A0286 . O
. . O O

Mouse P10687855T0000 NNP I-UN
growth P10687855T0000 NN I-UN
hormone P10687855T0000 NN I-UN
transcription P10687855T0000 NN I-UN
factor P10687855T0000 NN I-UN
Zn-16 P10687855T0000 JJ I-UN
: P10687855T0000 : O
unique P10687855T0000 JJ O
bipartite P10687855T0000 NN O
structure P10687855T0000 NN O
containing P10687855T0000 VBG O
tandemly P10687855T0000 RB O
repeated P10687855T0000 VBN O
zinc P10687855T0000 NN O
finger P10687855T0000 NN O
domains P10687855T0000 VBZ O
not P10687855T0000 RB O
reported P10687855T0000 VBN O
in P10687855T0000 IN O
rat P10687855T0000 NN I-UN
Zn-15 P10687855T0000 NNP I-UN
. P10687855T0000 . O
. . O O

A P07268828A0000 DT O
fluoroimmunoassay P07268828A0000 NN O
for P07268828A0000 IN O
the P07268828A0000 DT O
determination P07268828A0000 NN O
of P07268828A0000 IN O
serum P07268828A0000 NN O
of P07268828A0000 IN O
plasma P07268828A0000 NN O
levels P07268828A0000 NNS O
of P07268828A0000 IN O
propranolol P07268828A0000 NN O
was P07268828A0000 VBD O
developed P07268828A0000 VBN O
using P07268828A0000 VBG O
antibodies P07268828A0000 NNS O
to P07268828A0000 TO O
propranolol P07268828A0000 VB O
coupled P07268828A0000 VBN O
to P07268828A0000 TO O
magnetizable P07268828A0000 VB O
solid-phase P07268828A0000 JJ O
particles P07268828A0000 NNS O
and P07268828A0000 CC O
fluorescein-labeled P07268828A0000 JJ O
propranolol P07268828A0000 NN O
as P07268828A0000 IN O
tracer P07268828A0000 NN O
. P07268828A0000 . O
. . O O

Muscle P02489895T0001 NNP O
action P02489895T0001 NN O
potential P02489895T0001 NN O
and P02489895T0001 CC O
masticatory P02489895T0001 JJ O
rhythm P02489895T0001 NN O
of P02489895T0001 IN O
anterior P02489895T0001 JJ O
temporal P02489895T0001 JJ O
and P02489895T0001 CC O
masseter P02489895T0001 JJ O
muscles P02489895T0001 NNS O
in P02489895T0001 IN O
children P02489895T0001 NNS O
and P02489895T0001 CC O
adults P02489895T0001 NNS O
. P02489895T0001 . O
. . O O

To P09335298A2129 TO O
examine P09335298A2129 VB O
the P09335298A2129 DT O
basis P09335298A2129 NN O
for P09335298A2129 IN O
the P09335298A2129 DT O
apparent P09335298A2129 JJ O
differences P09335298A2129 NNS O
in P09335298A2129 IN O
postsegregational P09335298A2129 JJ O
killing P09335298A2129 NN O
between P09335298A2129 IN O
the P09335298A2129 DT O
two P09335298A2129 CD O
E. P09335298A2129 NNP O
coli P09335298A2129 NNS O
strains P09335298A2129 NNS O
, P09335298A2129 , O
transformation P09335298A2129 NN O
assays P09335298A2129 NNS O
were P09335298A2129 VBD O
carried P09335298A2129 VBN O
out P09335298A2129 IN O
to P09335298A2129 TO O
determine P09335298A2129 VB O
the P09335298A2129 DT O
relative P09335298A2129 JJ O
sensitivities P09335298A2129 NNS O
of P09335298A2129 IN O
the P09335298A2129 DT O
strains P09335298A2129 NNS O
to P09335298A2129 TO O
the P09335298A2129 DT O
ParE P09335298A2129 NNP I-UN
toxin P09335298A2129 NN I-UN
protein P09335298A2129 NN I-UN
. P09335298A2129 . O
. . O O

Angina P11415952A0369 NNP O
( P11415952A0369 ( O
Q P11415952A0369 NNP O
) P11415952A0369 ) O
persistence P11415952A0369 NN O
showed P11415952A0369 VBD O
marked P11415952A0369 JJ O
associations P11415952A0369 NNS O
with P11415952A0369 IN O
previous P11415952A0369 JJ O
myocardial P11415952A0369 JJ O
infarction P11415952A0369 NN O
, P11415952A0369 , O
diagnosed P11415952A0369 VBD O
angina P11415952A0369 NN O
, P11415952A0369 , O
electrocardiogram P11415952A0369 JJ O
ischemia P11415952A0369 NN O
, P11415952A0369 , O
and P11415952A0369 CC O
subsequent P11415952A0369 JJ O
major P11415952A0369 JJ O
ischemic P11415952A0369 JJ O
heart P11415952A0369 NN O
disease P11415952A0369 NN O
events P11415952A0369 NNS O
from P11415952A0369 IN O
Q5 P11415952A0369 NNP O
onward P11415952A0369 NN O
. P11415952A0369 . O
. . O O

The P06539738T0000 DT O
toxicological P06539738T0000 JJ O
evaluation P06539738T0000 NN O
of P06539738T0000 IN O
chlorofluorocarbon P06539738T0000 NN O
22 P06539738T0000 CD O
( P06539738T0000 ( O
CFC P06539738T0000 NNP O
22 P06539738T0000 CD O
) P06539738T0000 ) O
. P06539738T0000 . O
. . O O

These P10692374A1873 DT O
results P10692374A1873 NNS O
suggest P10692374A1873 VBP O
that P10692374A1873 IN O
the P10692374A1873 DT O
M. P10692374A1873 NNP O
jannaschii P10692374A1873 NN O
as P10692374A1873 RB O
well P10692374A1873 RB O
as P10692374A1873 IN O
related P10692374A1873 JJ O
archaeal P10692374A1873 NN I-UN
20S P10692374A1873 CD I-UN
proteasomes P10692374A1873 NNS I-UN
require P10692374A1873 VBP O
a P10692374A1873 DT O
nucleotidase P10692374A1873 NN O
complex P10692374A1873 NN O
such P10692374A1873 JJ O
as P10692374A1873 IN O
PAN P10692374A1873 NNP I-UN
to P10692374A1873 TO O
mediate P10692374A1873 VB O
the P10692374A1873 DT O
energy-dependent P10692374A1873 JJ O
hydrolysis P10692374A1873 NN O
of P10692374A1873 IN O
folded-substrate P10692374A1873 JJ O
proteins P10692374A1873 NNS O
and P10692374A1873 CC O
that P10692374A1873 IN O
the P10692374A1873 DT O
N-terminal P10692374A1873 JJ O
73 P10692374A1873 CD O
amino P10692374A1873 NN O
acid P10692374A1873 NN O
residues P10692374A1873 NNS O
of P10692374A1873 IN O
PAN P10692374A1873 NNP I-UN
are P10692374A1873 VBP O
not P10692374A1873 RB O
absolutely P10692374A1873 RB O
required P10692374A1873 VBN O
for P10692374A1873 IN O
this P10692374A1873 DT O
reaction P10692374A1873 NN O
. P10692374A1873 . O
. . O O

V P00240016T0033 NNP O
. P00240016T0033 . O
. . O O

Finally P03078268A0529 RB O
, P03078268A0529 , O
the P03078268A0529 DT O
pathophysiological P03078268A0529 JJ O
aspects P03078268A0529 NNS O
of P03078268A0529 IN O
urinary P03078268A0529 JJ O
acidification P03078268A0529 NN O
are P03078268A0529 VBP O
discussed P03078268A0529 VBN O
, P03078268A0529 , O
focusing P03078268A0529 VBG O
on P03078268A0529 IN O
renal P03078268A0529 JJ O
tubular P03078268A0529 JJ O
acidosis P03078268A0529 NN O
models P03078268A0529 NNS O
( P03078268A0529 ( O
induced P03078268A0529 VBN O
by P03078268A0529 IN O
maleate P03078268A0529 NN O
and P03078268A0529 CC O
amphotericin P03078268A0529 NN O
B P03078268A0529 NNP O
treatment P03078268A0529 NN O
) P03078268A0529 ) O
and P03078268A0529 CC O
their P03078268A0529 PRP$ O
cellular P03078268A0529 JJ O
mechanisms P03078268A0529 NNS O
, P03078268A0529 , O
as P03078268A0529 RB O
well P03078268A0529 RB O
as P03078268A0529 IN O
the P03078268A0529 DT O
role P03078268A0529 NN O
of P03078268A0529 IN O
adrenal P03078268A0529 JJ O
steroids P03078268A0529 NNS O
in P03078268A0529 IN O
urinary P03078268A0529 JJ O
acidification P03078268A0529 NN O
. P03078268A0529 . O
. . O O

In P09703021A0000 IN O
insects P09703021A0000 NNS O
, P09703021A0000 , O
arylalkylamine P09703021A0000 JJ I-UN
N-acetyltransferases P09703021A0000 NNP I-UN
( P09703021A0000 ( O
AANATs P09703021A0000 NNP I-UN
) P09703021A0000 ) O
have P09703021A0000 VBP O
been P09703021A0000 VBN O
implicated P09703021A0000 VBN O
in P09703021A0000 IN O
several P09703021A0000 JJ O
physiological P09703021A0000 JJ O
processes P09703021A0000 NNS O
, P09703021A0000 , O
including P09703021A0000 VBG O
sclerotization P09703021A0000 NN O
, P09703021A0000 , O
inactivation P09703021A0000 NN O
of P09703021A0000 IN O
certain P09703021A0000 JJ O
neurotransmitters P09703021A0000 NNS O
, P09703021A0000 , O
and P09703021A0000 CC O
, P09703021A0000 , O
similar P09703021A0000 JJ O
to P09703021A0000 TO O
the P09703021A0000 DT O
function P09703021A0000 NN O
in P09703021A0000 IN O
vertebrates P09703021A0000 NNS O
, P09703021A0000 , O
catalysis P09703021A0000 NN O
of P09703021A0000 IN O
the P09703021A0000 DT O
rate-limiting P09703021A0000 JJ O
step P09703021A0000 NN O
in P09703021A0000 IN O
melatonin P09703021A0000 JJ O
biosynthesis P09703021A0000 NN O
. P09703021A0000 . O
. . O O

This P00267764A0651 DT O
report P00267764A0651 NN O
has P00267764A0651 VBZ O
reviewed P00267764A0651 VBN O
some P00267764A0651 DT O
of P00267764A0651 IN O
the P00267764A0651 DT O
reasons P00267764A0651 NNS O
for P00267764A0651 IN O
treatment P00267764A0651 NN O
failures P00267764A0651 NNS O
and P00267764A0651 CC O
has P00267764A0651 VBZ O
presented P00267764A0651 VBN O
a P00267764A0651 DT O
philosophy P00267764A0651 NN O
for P00267764A0651 IN O
their P00267764A0651 PRP$ O
management P00267764A0651 NN O
. P00267764A0651 . O
. . O O

Fermentation P09324922T0065 NNP O
process P09324922T0065 NN O
after P09324922T0065 IN O
supplementation P09324922T0065 NN O
of P09324922T0065 IN O
nitrate P09324922T0065 NN O
, P09324922T0065 , O
nitrite P09324922T0065 RB O
, P09324922T0065 , O
lactic P09324922T0065 JJ O
acid P09324922T0065 NN O
bacteria P09324922T0065 NNS O
and P09324922T0065 CC O
formic P09324922T0065 JJ O
acid P09324922T0065 NN O
. P09324922T0065 . O
. . O O

The P09524267A1023 DT O
plant P09524267A1023 NN O
protein P09524267A1023 NN O
maintains P09524267A1023 VBZ O
all P09524267A1023 PDT O
the P09524267A1023 DT O
functional P09524267A1023 JJ O
domains P09524267A1023 NNS O
found P09524267A1023 VBN O
in P09524267A1023 IN O
the P09524267A1023 DT O
other P09524267A1023 JJ O
proteins P09524267A1023 NNS O
, P09524267A1023 , O
including P09524267A1023 VBG O
nuclear P09524267A1023 JJ O
localization P09524267A1023 NN O
signal P09524267A1023 NN O
, P09524267A1023 , O
DNA-binding P09524267A1023 NNP O
domain P09524267A1023 NN O
and P09524267A1023 CC O
helicase P09524267A1023 NN I-UN
motifs P09524267A1023 NNS I-UN
, P09524267A1023 , O
suggesting P09524267A1023 VBG O
that P09524267A1023 IN O
it P09524267A1023 PRP O
might P09524267A1023 MD O
also P09524267A1023 RB O
act P09524267A1023 VB O
as P09524267A1023 IN O
part P09524267A1023 NN O
of P09524267A1023 IN O
the P09524267A1023 DT O
RNA P09524267A1023 NNP O
transcription P09524267A1023 NN O
apparatus P09524267A1023 NN O
, P09524267A1023 , O
as P09524267A1023 RB O
well P09524267A1023 RB O
as P09524267A1023 IN O
nucleotide P09524267A1023 JJ O
excision P09524267A1023 NN O
repair P09524267A1023 NN O
in P09524267A1023 IN O
plant P09524267A1023 NN O
cells P09524267A1023 NNS O
. P09524267A1023 . O
. . O O

The P10983344A0000 DT O
article P10983344A0000 NN O
deals P10983344A0000 NNS O
with P10983344A0000 IN O
the P10983344A0000 DT O
diagnosing P10983344A0000 NN O
and P10983344A0000 CC O
correction P10983344A0000 NN O
of P10983344A0000 IN O
reversible P10983344A0000 JJ O
ischemia P10983344A0000 NN O
of P10983344A0000 IN O
the P10983344A0000 DT O
intestine P10983344A0000 NN O
. P10983344A0000 . O
. . O O

No P11687517A1619 DT O
ISREs P11687517A1619 NNP I-UN
could P11687517A1619 MD O
be P11687517A1619 VB O
identified P11687517A1619 VBN O
in P11687517A1619 IN O
the P11687517A1619 DT O
mouse P11687517A1619 NN O
promoter P11687517A1619 NN O
. P11687517A1619 . O
. . O O

Molecular P11323419T0000 JJ O
cloning P11323419T0000 NN O
, P11323419T0000 , O
genomic P11323419T0000 JJ O
mapping P11323419T0000 NN O
, P11323419T0000 , O
and P11323419T0000 CC O
expression P11323419T0000 NN O
of P11323419T0000 IN O
two P11323419T0000 CD O
secretor P11323419T0000 NN I-UN
blood P11323419T0000 NN I-UN
group P11323419T0000 NN I-UN
alpha P11323419T0000 NN I-UN
( P11323419T0000 ( I-UN
1,2 P11323419T0000 CD I-UN
) P11323419T0000 ) I-UN
fucosyltransferase P11323419T0000 NN I-UN
genes P11323419T0000 NNS I-UN
differentially P11323419T0000 RB O
regulated P11323419T0000 VBN O
in P11323419T0000 IN O
mouse P11323419T0000 NN O
uterine P11323419T0000 JJ O
epithelium P11323419T0000 NN O
and P11323419T0000 CC O
gastrointestinal P11323419T0000 JJ O
tract P11323419T0000 NN O
. P11323419T0000 . O
. . O O

Confirming P09235424A1200 VBG O
measures P09235424A1200 NNS O
made P09235424A1200 VBN O
by P09235424A1200 IN O
nurses P09235424A1200 NNS O
and P09235424A1200 CC O
additionally P09235424A1200 RB O
, P09235424A1200 , O
ABPM P09235424A1200 NNP O
for P09235424A1200 IN O
women P09235424A1200 NNS O
, P09235424A1200 , O
seem P09235424A1200 VBP O
to P09235424A1200 TO O
lessen P09235424A1200 VB O
this P09235424A1200 DT O
effect P09235424A1200 NN O
. P09235424A1200 . O
. . O O

Furthermore P11278848A1316 RB O
, P11278848A1316 , O
SB203580 P11278848A1316 NNP O
inhibited P11278848A1316 VBD O
LPS-induced P11278848A1316 NNP O
activation P11278848A1316 NN O
of P11278848A1316 IN O
Sp1 P11278848A1316 NNP I-UN
, P11278848A1316 , O
as P11278848A1316 RB O
well P11278848A1316 RB O
as P11278848A1316 IN O
the P11278848A1316 DT O
promoter P11278848A1316 NN O
activity P11278848A1316 NN O
in P11278848A1316 IN O
cells P11278848A1316 NNS O
transfected P11278848A1316 VBN O
with P11278848A1316 IN O
a P11278848A1316 DT O
plasmid P11278848A1316 NN O
containing P11278848A1316 VBG O
the P11278848A1316 DT O
Sp1 P11278848A1316 NNP I-UN
consensus P11278848A1316 NN O
sequence P11278848A1316 NN O
. P11278848A1316 . O
. . O O

Low P09814637A1214 JJ O
PbrO2 P09814637A1214 NNP O
readings P09814637A1214 NNS O
, P09814637A1214 , O
however P09814637A1214 RB O
, P09814637A1214 , O
could P09814637A1214 MD O
be P09814637A1214 VB O
caused P09814637A1214 VBN O
by P09814637A1214 IN O
local P09814637A1214 JJ O
microhemorrhages P09814637A1214 NNS O
, P09814637A1214 , O
undetectable P09814637A1214 JJ O
on P09814637A1214 IN O
CT P09814637A1214 NNP O
or P09814637A1214 CC O
MRI P09814637A1214 NNP O
. P09814637A1214 . O
. . O O

Closure P07558263T0000 NN O
of P07558263T0000 IN O
an P07558263T0000 DT O
open P07558263T0000 JJ O
high P07558263T0000 JJ O
below-knee P07558263T0000 JJ O
guillotine P07558263T0000 NN O
amputation P07558263T0000 NN O
wound P07558263T0000 IN O
using P07558263T0000 VBG O
a P07558263T0000 DT O
skin-stretching P07558263T0000 JJ O
device P07558263T0000 NN O
. P07558263T0000 . O
. . O O

Pulmonary P01756539A0354 JJ O
hypertension P01756539A0354 NN O
, P01756539A0354 , O
with P01756539A0354 IN O
or P01756539A0354 CC O
without P01756539A0354 IN O
coronary P01756539A0354 JJ O
arterial P01756539A0354 JJ O
narrowing P01756539A0354 NN O
, P01756539A0354 , O
is P01756539A0354 VBZ O
the P01756539A0354 DT O
major P01756539A0354 JJ O
condition P01756539A0354 NN O
leading P01756539A0354 VBG O
to P01756539A0354 TO O
isolated P01756539A0354 VBN O
atrial P01756539A0354 JJ O
infarction P01756539A0354 NN O
. P01756539A0354 . O
. . O O

Pharmacokinetic P00417166T0000 NNP O
profile P00417166T0000 NN O
of P00417166T0000 IN O
clonazepam P00417166T0000 NN O
in P00417166T0000 IN O
rhesus P00417166T0000 NN O
monkeys P00417166T0000 NNS O
. P00417166T0000 . O
. . O O

Implication P09131139T0000 NN O
of P09131139T0000 IN O
PAF P09131139T0000 NNP I-UN
and P09131139T0000 CC O
acetylhydrolase P09131139T0000 NN I-UN
( P09131139T0000 ( O
PAF-AH P09131139T0000 NNP I-UN
) P09131139T0000 ) O
activity P09131139T0000 NN O
in P09131139T0000 IN O
periodontal P09131139T0000 JJ O
disease P09131139T0000 NN O
. P09131139T0000 . O
. . O O

The P07749461A0632 DT O
2 P07749461A0632 CD O
kb P07749461A0632 NN O
of P07749461A0632 IN O
5'-flanking P07749461A0632 JJ O
region P07749461A0632 NN O
and P07749461A0632 CC O
the P07749461A0632 DT O
1.1 P07749461A0632 CD O
kb P07749461A0632 NN O
of P07749461A0632 IN O
the P07749461A0632 DT O
entire P07749461A0632 JJ O
sGTH P07749461A0632 NN I-UN
alpha P07749461A0632 NN I-UN
subunit P07749461A0632 NN I-UN
coding P07749461A0632 VBG O
region P07749461A0632 NN O
were P07749461A0632 VBD O
sequenced P07749461A0632 VBN O
from P07749461A0632 IN O
the P07749461A0632 DT O
genomic P07749461A0632 JJ O
clone P07749461A0632 NN O
, P07749461A0632 , O
sGTH P07749461A0632 JJ I-UN
alpha-G1 P07749461A0632 NN I-UN
. P07749461A0632 . O
. . O O

Insertion P08151787A0355 NN O
of P08151787A0355 IN O
short P08151787A0355 JJ O
oligonucleotides P08151787A0355 NNS O
encoding P08151787A0355 VBG O
the P08151787A0355 DT O
basic P08151787A0355 JJ O
amino P08151787A0355 NN O
acid P08151787A0355 JJ O
motifs P08151787A0355 NNS O
726-GRKRKSP-732 P08151787A0355 CD O
from P08151787A0355 IN O
IE175 P08151787A0355 NNP I-UN
and P08151787A0355 CC O
500-VRPRKRR-506 P08151787A0355 JJ O
from P08151787A0355 IN O
IE110 P08151787A0355 NNP I-UN
into P08151787A0355 IN O
deleted P08151787A0355 VBN O
cytoplasmic P08151787A0355 JJ O
forms P08151787A0355 NNS O
of P08151787A0355 IN O
the P08151787A0355 DT O
two P08151787A0355 CD O
proteins P08151787A0355 NNS O
restored P08151787A0355 VBD O
the P08151787A0355 DT O
karyophilic P08151787A0355 JJ O
phenotype P08151787A0355 NN O
and P08151787A0355 CC O
confirmed P08151787A0355 VBD O
that P08151787A0355 IN O
these P08151787A0355 DT O
motifs P08151787A0355 NNS O
are P08151787A0355 VBP O
both P08151787A0355 DT O
necessary P08151787A0355 JJ O
and P08151787A0355 CC O
sufficient P08151787A0355 JJ O
for P08151787A0355 IN O
proper P08151787A0355 JJ O
nuclear P08151787A0355 JJ O
localization P08151787A0355 NN O
. P08151787A0355 . O
. . O O

Evolutionary P02573829T0000 JJ O
conservation P02573829T0000 NN O
of P02573829T0000 IN O
homeodomain-binding P02573829T0000 NN O
sites P02573829T0000 NNS O
and P02573829T0000 CC O
other P02573829T0000 JJ O
sequences P02573829T0000 NNS O
upstream P02573829T0000 RB O
and P02573829T0000 CC O
within P02573829T0000 IN O
the P02573829T0000 DT O
major P02573829T0000 JJ O
transcription P02573829T0000 NN O
unit P02573829T0000 NN O
of P02573829T0000 IN O
the P02573829T0000 DT O
Drosophila P02573829T0000 NNP I-UN
segmentation P02573829T0000 NN I-UN
gene P02573829T0000 NN I-UN
engrailed P02573829T0000 VBD I-UN
. P02573829T0000 . O
. . O O

The P01824713A0964 DT O
12S P01824713A0964 CD I-UN
E1A P01824713A0964 NNP I-UN
product P01824713A0964 NN I-UN
does P01824713A0964 VBZ O
not P01824713A0964 RB O
activate P01824713A0964 VB O
a P01824713A0964 DT O
TRE P01824713A0964 NNP O
sequence P01824713A0964 NN O
, P01824713A0964 , O
but P01824713A0964 CC O
cotransfection P01824713A0964 NN O
with P01824713A0964 IN O
c-jun P01824713A0964 JJ I-UN
circumvents P01824713A0964 NNS O
this P01824713A0964 DT O
lack P01824713A0964 NN O
of P01824713A0964 IN O
stimulation P01824713A0964 NN O
. P01824713A0964 . O
. . O O

The P08514766A0732 DT O
GTPase P08514766A0732 NNP I-UN
activity P08514766A0732 NN O
of P08514766A0732 IN O
CDC42Ce P08514766A0732 NNP I-UN
is P08514766A0732 VBZ O
moderately P08514766A0732 RB O
stimulated P08514766A0732 VBN O
by P08514766A0732 IN O
human P08514766A0732 JJ I-UN
n-chimaerin P08514766A0732 JJ I-UN
, P08514766A0732 , O
a P08514766A0732 DT O
GTPase-activating P08514766A0732 JJ I-UN
protein P08514766A0732 NN I-UN
for P08514766A0732 IN O
the P08514766A0732 DT O
related P08514766A0732 JJ O
p21 P08514766A0732 NN I-UN
rac1 P08514766A0732 NN I-UN
. P08514766A0732 . O
. . O O

( P06070072T0052 ( O
3 P06070072T0052 CD O
) P06070072T0052 ) O
. P06070072T0052 . O
. . O O

Cognate P09042911A0626 NNP O
promoter P09042911A0626 NN O
elements P09042911A0626 NNS O
implicated P09042911A0626 VBN O
in P09042911A0626 IN O
glucocorticoid- P09042911A0626 JJ O
and P09042911A0626 CC O
cAMP-mediated P09042911A0626 JJ O
regulation P09042911A0626 NN O
as P09042911A0626 RB O
well P09042911A0626 RB O
as P09042911A0626 IN O
in P09042911A0626 IN O
liver- P09042911A0626 JJ O
, P09042911A0626 , O
myeloid- P09042911A0626 JJ O
, P09042911A0626 , O
and P09042911A0626 CC O
lymphocyte-specific P09042911A0626 JJ O
expression P09042911A0626 NN O
are P09042911A0626 VBP O
located P09042911A0626 VBN O
within P09042911A0626 IN O
the P09042911A0626 DT O
5 P09042911A0626 CD O
' P09042911A0626 POS O
flanking P09042911A0626 JJ O
sequence P09042911A0626 NN O
. P09042911A0626 . O
. . O O

We P07517869A0411 PRP O
observed P07517869A0411 VBD O
that P07517869A0411 DT O
dephosphorylation P07517869A0411 NN O
severely P07517869A0411 RB O
inhibits P07517869A0411 VBZ O
the P07517869A0411 DT O
DNA-binding P07517869A0411 JJ O
ability P07517869A0411 NN O
of P07517869A0411 IN O
C P07517869A0411 NNP I-UN
/ P07517869A0411 NNP I-UN
EBP-delta P07517869A0411 NNP I-UN
and P07517869A0411 CC O
its P07517869A0411 PRP$ O
transactivating P07517869A0411 VBG O
potential P07517869A0411 JJ O
increases P07517869A0411 NNS O
in P07517869A0411 IN O
the P07517869A0411 DT O
presence P07517869A0411 NN O
of P07517869A0411 IN O
cellular P07517869A0411 JJ O
phosphatase P07517869A0411 NN O
inhibitors P07517869A0411 NNS O
, P07517869A0411 , O
such P07517869A0411 JJ O
as P07517869A0411 IN O
okadaic P07517869A0411 JJ O
acid P07517869A0411 NN O
and P07517869A0411 CC O
sodium P07517869A0411 NN O
orthovanadate P07517869A0411 NN O
. P07517869A0411 . O
. . O O

These P09294161A1103 DT O
findings P09294161A1103 NNS O
suggest P09294161A1103 VBP O
one P09294161A1103 CD O
potential P09294161A1103 JJ O
mechanism P09294161A1103 NN O
for P09294161A1103 IN O
direct P09294161A1103 JJ O
recruitment P09294161A1103 NN O
of P09294161A1103 IN O
distal P09294161A1103 JJ O
regulatory P09294161A1103 JJ O
regions P09294161A1103 NNS O
of P09294161A1103 IN O
the P09294161A1103 DT O
globin P09294161A1103 NN I-UN
loci P09294161A1103 NN I-UN
to P09294161A1103 TO O
the P09294161A1103 DT O
individual P09294161A1103 JJ O
promoters P09294161A1103 NNS O
. P09294161A1103 . O
. . O O

In P09388199A0948 IN O
an P09388199A0948 DT O
effort P09388199A0948 NN O
to P09388199A0948 TO O
separate P09388199A0948 VB O
domains P09388199A0948 NNS O
of P09388199A0948 IN O
FadR P09388199A0948 NNP I-UN
required P09388199A0948 VBD O
for P09388199A0948 IN O
DNA P09388199A0948 NNP O
binding P09388199A0948 NN O
, P09388199A0948 , O
dimerization P09388199A0948 NN O
, P09388199A0948 , O
and P09388199A0948 CC O
ligand P09388199A0948 NN O
binding P09388199A0948 NN O
, P09388199A0948 , O
chimeric P09388199A0948 JJ O
protein P09388199A0948 NN O
fusions P09388199A0948 NNS O
between P09388199A0948 IN O
the P09388199A0948 DT O
DNA P09388199A0948 NNP O
binding P09388199A0948 VBG O
domain P09388199A0948 NN O
of P09388199A0948 IN O
LexA P09388199A0948 NNP I-UN
and P09388199A0948 CC O
different P09388199A0948 JJ O
regions P09388199A0948 NNS O
of P09388199A0948 IN O
FadR P09388199A0948 NNP I-UN
were P09388199A0948 VBD O
constructed P09388199A0948 VBN O
. P09388199A0948 . O
. . O O

Although P08794547A1403 IN O
basal P08794547A1403 NN O
vessels P08794547A1403 NNS O
may P08794547A1403 MD O
constrict P08794547A1403 VB O
distal P08794547A1403 JJ O
parenchymal P08794547A1403 JJ O
vessels P08794547A1403 NNS O
tend P08794547A1403 VBP O
to P08794547A1403 TO O
dilate P08794547A1403 VB O
after P08794547A1403 IN O
SAH P08794547A1403 NNP O
. P08794547A1403 . O
. . O O

Regional P10483124T0000 JJ O
insertional P10483124T0000 JJ O
mutagenesis P10483124T0000 NN O
of P10483124T0000 IN O
specific P10483124T0000 JJ O
genes P10483124T0000 NNS O
on P10483124T0000 IN O
the P10483124T0000 DT O
CIC5F11 P10483124T0000 NNP I-UN
/ P10483124T0000 NNP O
CIC2B9 P10483124T0000 NNP I-UN
locus P10483124T0000 NN O
of P10483124T0000 IN O
Arabidopsis P10483124T0000 NNP O
thaliana P10483124T0000 NNP O
chromosome P10483124T0000 NN O
5 P10483124T0000 CD O
using P10483124T0000 VBG O
the P10483124T0000 DT O
Ac P10483124T0000 NNP I-UN
/ P10483124T0000 NNP O
Ds P10483124T0000 NNP I-UN
transposon P10483124T0000 NN O
in P10483124T0000 IN O
combination P10483124T0000 NN O
with P10483124T0000 IN O
the P10483124T0000 DT O
cDNA P10483124T0000 NN O
scanning P10483124T0000 VBG O
method P10483124T0000 NN O
. P10483124T0000 . O
. . O O

Various P02164588A0266 JJ O
mutant P02164588A0266 JJ I-UN
HN P02164588A0266 NNP I-UN
genes P02164588A0266 NNS I-UN
were P02164588A0266 VBD O
constructed P02164588A0266 VBN O
to P02164588A0266 TO O
examine P02164588A0266 VB O
the P02164588A0266 DT O
role P02164588A0266 NN O
of P02164588A0266 IN O
residues P02164588A0266 NNS O
flanking P02164588A0266 VBG O
the P02164588A0266 DT O
signal-anchor P02164588A0266 NN O
domain P02164588A0266 NN O
, P02164588A0266 , O
including P02164588A0266 VBG O
the P02164588A0266 DT O
cytoplasmic P02164588A0266 JJ O
tail P02164588A0266 NN O
, P02164588A0266 , O
on P02164588A0266 IN O
assembly P02164588A0266 NN O
and P02164588A0266 CC O
intracellular P02164588A0266 JJ O
transport P02164588A0266 NN O
of P02164588A0266 IN O
the P02164588A0266 DT O
HN P02164588A0266 NNP I-UN
glycoprotein P02164588A0266 NN I-UN
. P02164588A0266 . O
. . O O

PATIENTS P11387351A0092 NNS O
AND P11387351A0092 CC O
METHODS P11387351A0092 NNP O
: P11387351A0092 : O
Between P11387351A0092 NNP O
June P11387351A0092 NNP O
1991 P11387351A0092 CD O
and P11387351A0092 CC O
December P11387351A0092 NNP O
1996 P11387351A0092 CD O
, P11387351A0092 , O
we P11387351A0092 PRP O
administered P11387351A0092 VBD O
the P11387351A0092 DT O
nucleoside P11387351A0092 JJ O
analog P11387351A0092 NN O
2-chlorodeoxyadenosine P11387351A0092 JJ O
( P11387351A0092 ( O
2-CDA P11387351A0092 JJ O
) P11387351A0092 ) O
to P11387351A0092 TO O
73 P11387351A0092 CD O
children P11387351A0092 NNS O
with P11387351A0092 IN O
primary P11387351A0092 JJ O
AML P11387351A0092 NNP O
and P11387351A0092 CC O
20 P11387351A0092 CD O
children P11387351A0092 NNS O
with P11387351A0092 IN O
secondary P11387351A0092 JJ O
AML P11387351A0092 NNP O
or P11387351A0092 CC O
myelodysplastic P11387351A0092 JJ O
syndrome P11387351A0092 NN O
( P11387351A0092 ( O
MDS P11387351A0092 NNP O
) P11387351A0092 ) O
. P11387351A0092 . O
. . O O

U4 P09328476A0068 NNP I-UN
/ P09328476A0068 NNP O
U6 P09328476A0068 NNP I-UN
snRNP P09328476A0068 NN O
is P09328476A0068 VBZ O
one P09328476A0068 CD O
of P09328476A0068 IN O
four P09328476A0068 CD O
essential P09328476A0068 JJ O
small P09328476A0068 JJ O
nuclear P09328476A0068 JJ O
ribonucleoprotein P09328476A0068 NN O
( P09328476A0068 ( O
snRNP P09328476A0068 NN O
) P09328476A0068 ) O
particles P09328476A0068 NNS O
( P09328476A0068 ( O
U1 P09328476A0068 NNP I-UN
, P09328476A0068 , O
U2 P09328476A0068 NNP I-UN
, P09328476A0068 , O
U5 P09328476A0068 NNP I-UN
and P09328476A0068 CC O
U4 P09328476A0068 NNP I-UN
/ P09328476A0068 NNP O
U6 P09328476A0068 NNP I-UN
) P09328476A0068 ) O
present P09328476A0068 NN O
in P09328476A0068 IN O
the P09328476A0068 DT O
spliceosome P09328476A0068 NN O
. P09328476A0068 . O
. . O O

The P02796216A0063 DT O
disease P02796216A0063 NN O
ran P02796216A0063 VBD O
an P02796216A0063 DT O
atypical P02796216A0063 JJ O
course P02796216A0063 NN O
; P02796216A0063 : O
with P02796216A0063 IN O
early P02796216A0063 JJ O
jaundice P02796216A0063 NN O
syndrome P02796216A0063 NN O
, P02796216A0063 , O
severe P02796216A0063 JJ O
enterorrhagia P02796216A0063 NN O
and P02796216A0063 CC O
late P02796216A0063 JJ O
appearance P02796216A0063 NN O
of P02796216A0063 IN O
roseola P02796216A0063 NN O
. P02796216A0063 . O
. . O O

Three P06584416A0157 CD O
radiologists P06584416A0157 NNS O
without P06584416A0157 IN O
knowledge P06584416A0157 NN O
of P06584416A0157 IN O
patients P06584416A0157 NNS O
' P06584416A0157 POS O
data P06584416A0157 NNS O
and P06584416A0157 CC O
treatment P06584416A0157 NN O
analyzed P06584416A0157 VBD O
30 P06584416A0157 CD O
angiograms P06584416A0157 NNS O
with P06584416A0157 IN O
and P06584416A0157 CC O
30 P06584416A0157 CD O
examinations P06584416A0157 NNS O
without P06584416A0157 IN O
PGF P06584416A0157 NNP O
. P06584416A0157 . O
. . O O

Clinically P09043534A1600 RB O
meaningful P09043534A1600 JJ O
decreases P09043534A1600 NNS O
due P09043534A1600 JJ O
to P09043534A1600 TO O
alkalinization P09043534A1600 VB O
alone P09043534A1600 RB O
within P09043534A1600 IN O
30 P09043534A1600 CD O
minutes P09043534A1600 NNS O
are P09043534A1600 VBP O
unlikely P09043534A1600 JJ O
. P09043534A1600 . O
. . O O

SETTING P01736651A0104 NN O
-- P01736651A0104 : O
Women P01736651A0104 NNP O
, P01736651A0104 , O
Infants P01736651A0104 NNP O
, P01736651A0104 , O
and P01736651A0104 CC O
Children P01736651A0104 NNP O
clinics P01736651A0104 NNS O
in P01736651A0104 IN O
Minneapolis P01736651A0104 NNP O
, P01736651A0104 , O
Minn P01736651A0104 NNP O
. P01736651A0104 . O
. . O O

We P09268652A0116 PRP O
describe P09268652A0116 VBP O
a P09268652A0116 DT O
novel P09268652A0116 JJ O
zinc P09268652A0116 NN I-UN
finger P09268652A0116 NN I-UN
protein P09268652A0116 NN I-UN
, P09268652A0116 , O
dsRBP-ZFa P09268652A0116 JJ I-UN
, P09268652A0116 , O
isolated P09268652A0116 VBN O
by P09268652A0116 IN O
screening P09268652A0116 VBG O
an P09268652A0116 DT O
expression P09268652A0116 NN O
library P09268652A0116 NN O
with P09268652A0116 IN O
dsRNA P09268652A0116 NN O
. P09268652A0116 . O
. . O O

We P08523031A0737 PRP O
failed P08523031A0737 VBD O
to P08523031A0737 TO O
find P08523031A0737 VB O
these P08523031A0737 DT O
data P08523031A0737 NNS O
to P08523031A0737 TO O
be P08523031A0737 VB O
useful P08523031A0737 JJ O
in P08523031A0737 IN O
predicting P08523031A0737 VBG O
the P08523031A0737 DT O
time P08523031A0737 NN O
of P08523031A0737 IN O
onset P08523031A0737 NN O
of P08523031A0737 IN O
initial P08523031A0737 JJ O
seizures P08523031A0737 NNS O
after P08523031A0737 IN O
acute P08523031A0737 JJ O
ischemic P08523031A0737 JJ O
stroke P08523031A0737 NN O
and P08523031A0737 CC O
recurrence P08523031A0737 NN O
. P08523031A0737 . O
. . O O

Human P09028942A0000 JJ I-UN
granulocyte-macrophage P09028942A0000 JJ I-UN
colony-stimulating P09028942A0000 NN I-UN
factor P09028942A0000 NN I-UN
( P09028942A0000 ( O
hGM-CSF P09028942A0000 JJ I-UN
) P09028942A0000 ) O
activates P09028942A0000 VBZ O
a P09028942A0000 DT O
set P09028942A0000 NN O
of P09028942A0000 IN O
genes P09028942A0000 NNS O
such P09028942A0000 JJ O
as P09028942A0000 IN O
c-fos P09028942A0000 NN I-UN
, P09028942A0000 , O
jun P09028942A0000 NN I-UN
, P09028942A0000 , O
myc P09028942A0000 NN I-UN
, P09028942A0000 , O
and P09028942A0000 CC O
early P09028942A0000 RB I-UN
growth P09028942A0000 NN I-UN
response P09028942A0000 NN I-UN
gene P09028942A0000 NN I-UN
1 P09028942A0000 CD I-UN
( P09028942A0000 ( O
egr-1 P09028942A0000 NN I-UN
) P09028942A0000 ) O
. P09028942A0000 . O
. . O O

Thus P09786932A1042 RB O
, P09786932A1042 , O
IRF-7 P09786932A1042 NNP I-UN
exhibits P09786932A1042 VBZ O
functional P09786932A1042 JJ O
similarity P09786932A1042 NN O
to P09786932A1042 TO O
IRF-3 P09786932A1042 NNP I-UN
; P09786932A1042 : O
however P09786932A1042 RB O
, P09786932A1042 , O
the P09786932A1042 DT O
preferential P09786932A1042 JJ O
expression P09786932A1042 NN O
of P09786932A1042 IN O
IRF-7 P09786932A1042 NNP I-UN
in P09786932A1042 IN O
lymphoid P09786932A1042 JJ O
cells P09786932A1042 NNS O
( P09786932A1042 ( O
the P09786932A1042 DT O
cell P09786932A1042 NN O
type P09786932A1042 NN O
that P09786932A1042 WDT O
expresses P09786932A1042 VBZ O
IFNA P09786932A1042 NNP I-UN
) P09786932A1042 ) O
suggests P09786932A1042 VBZ O
that P09786932A1042 IN O
IRF-7 P09786932A1042 NNP I-UN
may P09786932A1042 MD O
play P09786932A1042 VB O
a P09786932A1042 DT O
critical P09786932A1042 JJ O
role P09786932A1042 NN O
in P09786932A1042 IN O
regulating P09786932A1042 VBG O
the P09786932A1042 DT O
IFNA P09786932A1042 NNP I-UN
gene P09786932A1042 NN I-UN
expression P09786932A1042 NN O
. P09786932A1042 . O
. . O O

There P02331361A0268 EX O
was P02331361A0268 VBD O
a P02331361A0268 DT O
gradual P02331361A0268 JJ O
increase P02331361A0268 NN O
in P02331361A0268 IN O
the P02331361A0268 DT O
myocyte P02331361A0268 NN O
diameter P02331361A0268 NN O
according P02331361A0268 VBG O
to P02331361A0268 TO O
age P02331361A0268 NN O
in P02331361A0268 IN O
the P02331361A0268 DT O
biopsy P02331361A0268 NN O
and P02331361A0268 CC O
autopsy P02331361A0268 NN O
specimens P02331361A0268 NNS O
. P02331361A0268 . O
. . O O

The P10383764A1809 DT O
results P10383764A1809 NNS O
of P10383764A1809 IN O
these P10383764A1809 DT O
studies P10383764A1809 NNS O
support P10383764A1809 VBP O
a P10383764A1809 DT O
model P10383764A1809 NN O
in P10383764A1809 IN O
which P10383764A1809 WDT O
VirB4 P10383764A1809 NNP I-UN
dimers P10383764A1809 NNS I-UN
or P10383764A1809 CC O
homomultimers P10383764A1809 NNS O
contribute P10383764A1809 VBP O
structural P10383764A1809 JJ O
information P10383764A1809 NN O
for P10383764A1809 IN O
the P10383764A1809 DT O
assembly P10383764A1809 NN O
of P10383764A1809 IN O
a P10383764A1809 DT O
transenvelope P10383764A1809 NN O
channel P10383764A1809 NN O
competent P10383764A1809 NN O
for P10383764A1809 IN O
bidirectional P10383764A1809 JJ O
DNA P10383764A1809 NNP O
transfer P10383764A1809 NN O
, P10383764A1809 , O
whereas P10383764A1809 IN O
an P10383764A1809 DT O
ATP-dependent P10383764A1809 JJ O
activity P10383764A1809 NN O
is P10383764A1809 VBZ O
required P10383764A1809 VBN O
for P10383764A1809 IN O
configuring P10383764A1809 VBG O
this P10383764A1809 DT O
channel P10383764A1809 NN O
as P10383764A1809 IN O
a P10383764A1809 DT O
dedicated P10383764A1809 JJ O
export P10383764A1809 NN O
machine P10383764A1809 NN O
. P10383764A1809 . O
. . O O

A P07413242A0000 DT O
16-year P07413242A0000 JJ O
follow-up P07413242A0000 JJ O
study P07413242A0000 NN O
of P07413242A0000 IN O
69 P07413242A0000 CD O
paraplegics P07413242A0000 NNS O
with P07413242A0000 IN O
complete P07413242A0000 JJ O
lesions P07413242A0000 NNS O
from P07413242A0000 IN O
T1-L3 P07413242A0000 NNP O
is P07413242A0000 VBZ O
presented P07413242A0000 VBN O
. P07413242A0000 . O
. . O O

The P10534048A0297 DT O
first P10534048A0297 JJ O
algorithm P10534048A0297 NN O
, P10534048A0297 , O
FOREPROJ P10534048A0297 NNP O
, P10534048A0297 , O
is P10534048A0297 VBZ O
a P10534048A0297 DT O
fast-forward P10534048A0297 JJ O
projection P10534048A0297 NN O
algorithm P10534048A0297 NN O
that P10534048A0297 WDT O
allows P10534048A0297 VBZ O
calculation P10534048A0297 NN O
of P10534048A0297 IN O
the P10534048A0297 DT O
3-D P10534048A0297 JJ O
attenuation P10534048A0297 NN O
correction P10534048A0297 NN O
factors P10534048A0297 NNS O
( P10534048A0297 ( O
ACF P10534048A0297 NNP O
's P10534048A0297 POS O
) P10534048A0297 ) O
directly P10534048A0297 RB O
from P10534048A0297 IN O
a P10534048A0297 DT O
two-dimensional P10534048A0297 JJ O
( P10534048A0297 ( O
2-D P10534048A0297 JJ O
) P10534048A0297 ) O
transmission P10534048A0297 NN O
scan P10534048A0297 JJ O
, P10534048A0297 , O
without P10534048A0297 IN O
first P10534048A0297 JJ O
reconstructing P10534048A0297 VBG O
the P10534048A0297 DT O
attenuation P10534048A0297 NN O
map P10534048A0297 NN O
and P10534048A0297 CC O
then P10534048A0297 RB O
performing P10534048A0297 VBG O
a P10534048A0297 DT O
3-D P10534048A0297 JJ O
forward P10534048A0297 NN O
projection P10534048A0297 NN O
. P10534048A0297 . O
. . O O

Retinal P07392519T0001 JJ O
changes P07392519T0001 NNS O
in P07392519T0001 IN O
pigmentary P07392519T0001 JJ O
retinopathy P07392519T0001 NN O
in P07392519T0001 IN O
children P07392519T0001 NNS O
. P07392519T0001 . O
. . O O

In P09425036A0649 IN O
addition P09425036A0649 NN O
, P09425036A0649 , O
a P09425036A0649 DT O
catalytically P09425036A0649 RB O
inactive P09425036A0649 JJ O
version P09425036A0649 NN O
of P09425036A0649 IN O
the P09425036A0649 DT O
Src P09425036A0649 NNP I-UN
family P09425036A0649 NN I-UN
member P09425036A0649 NN O
, P09425036A0649 , O
Lck P09425036A0649 NNP I-UN
( P09425036A0649 ( O
lymphoid P09425036A0649 JJ I-UN
cell P09425036A0649 NN I-UN
kinase P09425036A0649 NN I-UN
) P09425036A0649 ) O
, P09425036A0649 , O
was P09425036A0649 VBD O
expressed P09425036A0649 VBN O
, P09425036A0649 , O
purified P09425036A0649 VBN O
, P09425036A0649 , O
and P09425036A0649 CC O
evaluated P09425036A0649 VBD O
as P09425036A0649 IN O
a P09425036A0649 DT O
Csk P09425036A0649 NNP I-UN
substrate P09425036A0649 NN O
. P09425036A0649 . O
. . O O

While P11029700A0295 IN O
Pt P11029700A0295 NNP I-UN
; P11029700A0295 : I-UN
cycH P11029700A0295 NN I-UN
; P11029700A0295 : I-UN
1 P11029700A0295 CD I-UN
and P11029700A0295 CC O
Os P11029700A0295 NNP I-UN
; P11029700A0295 : I-UN
cycH P11029700A0295 NN I-UN
; P11029700A0295 : I-UN
1 P11029700A0295 CD I-UN
were P11029700A0295 VBD O
expressed P11029700A0295 VBN O
in P11029700A0295 IN O
all P11029700A0295 DT O
tissues P11029700A0295 NNS O
examined P11029700A0295 VBN O
, P11029700A0295 , O
the P11029700A0295 DT O
transcripts P11029700A0295 NNS O
accumulated P11029700A0295 VBN O
abundantly P11029700A0295 RB O
in P11029700A0295 IN O
dividing P11029700A0295 VBG O
cells P11029700A0295 NNS O
. P11029700A0295 . O
. . O O

Thus P11438651A1365 RB O
, P11438651A1365 , O
replication P11438651A1365 NN O
fork P11438651A1365 NN O
movement P11438651A1365 NN O
near P11438651A1365 IN O
HML P11438651A1365 NNP I-UN
pauses P11438651A1365 VBZ O
at P11438651A1365 IN O
a P11438651A1365 DT O
silent P11438651A1365 JJ O
origin P11438651A1365 NN O
which P11438651A1365 WDT O
is P11438651A1365 VBZ O
competent P11438651A1365 NN O
for P11438651A1365 IN O
replication P11438651A1365 NN O
initiation P11438651A1365 NN O
but P11438651A1365 CC O
kept P11438651A1365 VBD O
silent P11438651A1365 JJ O
through P11438651A1365 IN O
Orc2p P11438651A1365 NNP I-UN
, P11438651A1365 , O
a P11438651A1365 DT O
component P11438651A1365 NN O
of P11438651A1365 IN O
the P11438651A1365 DT O
replication P11438651A1365 NN O
initiator P11438651A1365 NN O
. P11438651A1365 . O
. . O O

This P09031639A0474 DT O
0.74 P09031639A0474 CD O
kb P09031639A0474 NN O
cDNA P09031639A0474 NN O
contains P09031639A0474 VBZ O
an P09031639A0474 DT O
open P09031639A0474 JJ O
reading P09031639A0474 NN O
frame P09031639A0474 NN O
( P09031639A0474 ( O
ORF P09031639A0474 NNP O
) P09031639A0474 ) O
of P09031639A0474 IN O
477 P09031639A0474 CD O
bp P09031639A0474 NN O
encoding P09031639A0474 VBG O
a P09031639A0474 DT O
polypeptide P09031639A0474 NN O
of P09031639A0474 IN O
159 P09031639A0474 CD O
amino P09031639A0474 JJ O
acids P09031639A0474 NNS O
( P09031639A0474 ( O
aa P09031639A0474 NN O
) P09031639A0474 ) O
which P09031639A0474 WDT O
differs P09031639A0474 VBZ O
at P09031639A0474 IN O
only P09031639A0474 RB O
one P09031639A0474 CD O
position P09031639A0474 NN O
( P09031639A0474 ( O
position P09031639A0474 NN O
65 P09031639A0474 CD O
) P09031639A0474 ) O
from P09031639A0474 IN O
the P09031639A0474 DT O
human P09031639A0474 JJ I-UN
U1-C P09031639A0474 NNP I-UN
protein P09031639A0474 NN I-UN
. P09031639A0474 . O
. . O O

Among P10430883A0000 IN O
mucus-secreting P10430883A0000 JJ O
cells P10430883A0000 NNS O
, P10430883A0000 , O
the P10430883A0000 DT O
gastric P10430883A0000 JJ O
gland P10430883A0000 NN O
mucous P10430883A0000 JJ O
cells P10430883A0000 NNS O
, P10430883A0000 , O
Brunner P10430883A0000 NNP O
's P10430883A0000 POS O
glands P10430883A0000 NNS O
, P10430883A0000 , O
accessory P10430883A0000 JJ O
glands P10430883A0000 NNS O
of P10430883A0000 IN O
pancreaticobiliary P10430883A0000 JJ O
tract P10430883A0000 NN O
, P10430883A0000 , O
and P10430883A0000 CC O
pancreatic P10430883A0000 JJ O
ducts P10430883A0000 NNS O
exhibiting P10430883A0000 VBG O
gastric P10430883A0000 JJ O
metaplasia P10430883A0000 NN O
are P10430883A0000 VBP O
unique P10430883A0000 JJ O
in P10430883A0000 IN O
that P10430883A0000 DT O
they P10430883A0000 PRP O
express P10430883A0000 VBP O
class P10430883A0000 NN I-UN
III P10430883A0000 NNP I-UN
mucin P10430883A0000 NN I-UN
identified P10430883A0000 VBN O
by P10430883A0000 IN O
paradoxical P10430883A0000 JJ O
Con P10430883A0000 NNP I-UN
A P10430883A0000 NNP I-UN
staining P10430883A0000 VBG O
composed P10430883A0000 VBN O
of P10430883A0000 IN O
periodate P10430883A0000 NN O
oxidation P10430883A0000 NN O
, P10430883A0000 , O
sodium P10430883A0000 NN O
borohydride P10430883A0000 NN O
reduction P10430883A0000 NN O
, P10430883A0000 , O
Con P10430883A0000 NNP I-UN
A P10430883A0000 NNP I-UN
, P10430883A0000 , O
and P10430883A0000 CC O
horseradish P10430883A0000 JJ I-UN
peroxidase P10430883A0000 NN I-UN
reaction P10430883A0000 NN O
. P10430883A0000 . O
. . O O

METHODS P11342479A0430 NNP O
AND P11342479A0430 CC O
RESULTS P11342479A0430 NNP O
: P11342479A0430 : O
Palmaz-Schatz P11342479A0430 JJ O
stents P11342479A0430 NNS O
were P11342479A0430 VBD O
dip-coated P11342479A0430 JJ O
with P11342479A0430 IN O
paclitaxel P11342479A0430 NN O
( P11342479A0430 ( O
0 P11342479A0430 CD O
, P11342479A0430 , O
0.2 P11342479A0430 CD O
, P11342479A0430 , O
15 P11342479A0430 CD O
, P11342479A0430 , O
or P11342479A0430 CC O
187 P11342479A0430 CD O
microgram P11342479A0430 NNS O
/ P11342479A0430 JJ O
stent P11342479A0430 NN O
) P11342479A0430 ) O
by P11342479A0430 IN O
immersion P11342479A0430 NN O
in P11342479A0430 IN O
ethanolic P11342479A0430 JJ O
paclitaxel P11342479A0430 NN O
and P11342479A0430 CC O
evaporation P11342479A0430 NN O
of P11342479A0430 IN O
the P11342479A0430 DT O
solvent P11342479A0430 NN O
. P11342479A0430 . O
. . O O

The P08071982T0000 DT O
newly P08071982T0000 RB O
recognised P08071982T0000 VBN O
skeletogenital P08071982T0000 JJ O
syndrome P08071982T0000 NN O
. P08071982T0000 . O
. . O O

The P08634423A0498 DT O
frequency P08634423A0498 NN O
of P08634423A0498 IN O
integrations P08634423A0498 NNS O
that P08634423A0498 WDT O
led P08634423A0498 VBD O
to P08634423A0498 TO O
transcription P08634423A0498 NN O
of P08634423A0498 IN O
the P08634423A0498 DT O
lacZ P08634423A0498 JJ I-UN
gene P08634423A0498 NN I-UN
was P08634423A0498 VBD O
estimated P08634423A0498 VBN O
to P08634423A0498 TO O
be P08634423A0498 VB O
0.5 P08634423A0498 CD O
% P08634423A0498 NN O
of P08634423A0498 IN O
all P08634423A0498 DT O
integrations P08634423A0498 NNS O
, P08634423A0498 , O
of P08634423A0498 IN O
which P08634423A0498 WDT O
14 P08634423A0498 CD O
% P08634423A0498 NN O
were P08634423A0498 VBD O
downregulated P08634423A0498 VBN O
on P08634423A0498 IN O
differentiation P08634423A0498 NN O
of P08634423A0498 IN O
32D P08634423A0498 CD O
cells P08634423A0498 NNS O
towards P08634423A0498 NNS O
neutrophils P08634423A0498 NNS O
. P08634423A0498 . O
. . O O

Theory P07221354T0000 NN O
and P07221354T0000 CC O
applications P07221354T0000 NNS O
of P07221354T0000 IN O
pulse P07221354T0000 JJ O
dosing P07221354T0000 NN O
: P07221354T0000 : O
a P07221354T0000 DT O
summary P07221354T0000 NN O
of P07221354T0000 IN O
the P07221354T0000 DT O
symposium P07221354T0000 NN O
. P07221354T0000 . O
. . O O

Manganese P10708424A0800 JJ O
ions P10708424A0800 NNS O
were P10708424A0800 VBD O
found P10708424A0800 VBN O
to P10708424A0800 TO O
be P10708424A0800 VB O
essential P10708424A0800 JJ O
for P10708424A0800 IN O
autophosphorylation P10708424A0800 NN O
of P10708424A0800 IN O
BGLF4 P10708424A0800 NNP I-UN
, P10708424A0800 , O
and P10708424A0800 CC O
magnesium P10708424A0800 NN O
can P10708424A0800 MD O
stimulate P10708424A0800 VB O
the P10708424A0800 DT O
activity P10708424A0800 NN O
. P10708424A0800 . O
. . O O

The P01531086A0127 DT O
cDNA P01531086A0127 NN O
has P01531086A0127 VBZ O
an P01531086A0127 DT O
open P01531086A0127 JJ O
reading P01531086A0127 NN O
frame P01531086A0127 NN O
of P01531086A0127 IN O
900 P01531086A0127 CD O
amino P01531086A0127 JJ O
acids P01531086A0127 NNS O
capable P01531086A0127 JJ O
of P01531086A0127 IN O
encoding P01531086A0127 VBG O
a P01531086A0127 DT O
97-kDa P01531086A0127 JJ O
protein P01531086A0127 NN O
. P01531086A0127 . O
. . O O

CONCLUSIONS P08205827A0940 NN O
: P08205827A0940 : O
Translocation P08205827A0940 NN O
of P08205827A0940 IN O
bacteria P08205827A0940 NNS O
or P08205827A0940 CC O
endotoxin P08205827A0940 NN O
from P08205827A0940 IN O
the P08205827A0940 DT O
gastrointestinal P08205827A0940 JJ O
tract P08205827A0940 NN O
into P08205827A0940 IN O
the P08205827A0940 DT O
bloodstream P08205827A0940 NN O
has P08205827A0940 VBZ O
been P08205827A0940 VBN O
noted P08205827A0940 VBN O
in P08205827A0940 IN O
animal P08205827A0940 JJ O
experiments P08205827A0940 NNS O
; P08205827A0940 : O
however P08205827A0940 RB O
, P08205827A0940 , O
translocation P08205827A0940 NN O
was P08205827A0940 VBD O
not P08205827A0940 RB O
detected P08205827A0940 VBN O
in P08205827A0940 IN O
our P08205827A0940 PRP$ O
patients P08205827A0940 NNS O
with P08205827A0940 IN O
hemorrhagic P08205827A0940 JJ O
shock P08205827A0940 NN O
. P08205827A0940 . O
. . O O

These P11554469A1386 DT O
analyses P11554469A1386 VBZ O
re-open P11554469A1386 VBP O
the P11554469A1386 DT O
question P11554469A1386 NN O
whether P11554469A1386 IN O
all P11554469A1386 PDT O
the P11554469A1386 DT O
CesA P11554469A1386 NNP I-UN
genes P11554469A1386 NNS I-UN
encode P11554469A1386 VBP O
cellulose P11554469A1386 JJ I-UN
synthases P11554469A1386 NNS I-UN
or P11554469A1386 CC O
whether P11554469A1386 IN O
some P11554469A1386 DT O
of P11554469A1386 IN O
the P11554469A1386 DT O
sub-class P11554469A1386 JJ O
members P11554469A1386 NNS O
may P11554469A1386 MD O
encode P11554469A1386 VB O
other P11554469A1386 JJ O
non-cellulosic P11554469A1386 JJ I-UN
( P11554469A1386 ( I-UN
1 P11554469A1386 CD I-UN
-- P11554469A1386 : I-UN
> P11554469A1386 JJ I-UN
4 P11554469A1386 CD I-UN
) P11554469A1386 ) I-UN
beta-glycan P11554469A1386 JJ I-UN
synthases P11554469A1386 NNS I-UN
in P11554469A1386 IN O
plants P11554469A1386 NNS O
. P11554469A1386 . O
. . O O

Cotransfection P09528987A1348 NN O
analyses P09528987A1348 NNS O
of P09528987A1348 IN O
the P09528987A1348 DT O
T P09528987A1348 NNP I-UN
/ P09528987A1348 NNP I-UN
EBP P09528987A1348 NNP I-UN
promoter-reporter P09528987A1348 JJ I-UN
constructs P09528987A1348 NNS I-UN
with P09528987A1348 IN O
a P09528987A1348 DT O
T P09528987A1348 NNP I-UN
/ P09528987A1348 NNP I-UN
EBP P09528987A1348 NNP I-UN
expression P09528987A1348 NN O
vector P09528987A1348 NN O
into P09528987A1348 IN O
human P09528987A1348 JJ O
HepG2 P09528987A1348 NNP O
cells P09528987A1348 NNS O
, P09528987A1348 , O
which P09528987A1348 WDT O
do P09528987A1348 VBP O
not P09528987A1348 RB O
express P09528987A1348 VB O
T P09528987A1348 NNP I-UN
/ P09528987A1348 NNP I-UN
EBP P09528987A1348 NNP I-UN
, P09528987A1348 , O
suggested P09528987A1348 VBD O
that P09528987A1348 IN O
autoregulation P09528987A1348 NN O
may P09528987A1348 MD O
be P09528987A1348 VB O
involved P09528987A1348 VBN O
in P09528987A1348 IN O
controlling P09528987A1348 VBG O
both P09528987A1348 DT O
rat P09528987A1348 NN O
and P09528987A1348 CC O
human P09528987A1348 JJ I-UN
T P09528987A1348 NNP I-UN
/ P09528987A1348 NNP I-UN
EBP P09528987A1348 NNP I-UN
gene P09528987A1348 NN I-UN
expression P09528987A1348 NN O
. P09528987A1348 . O
. . O O

M-66 P09514962A0841 NNP I-UN
identified P09514962A0841 VBD O
the P09514962A0841 DT O
14-kDa P09514962A0841 JJ O
protein P09514962A0841 NN O
in P09514962A0841 IN O
another P09514962A0841 DT O
MMTV P09514962A0841 NNP O
bearing P09514962A0841 VBG O
T-cell P09514962A0841 NNP O
lymphoma P09514962A0841 NN O
, P09514962A0841 , O
EL-4 P09514962A0841 NNP O
. P09514962A0841 . O
. . O O

Arterial P01869968A0000 JJ O
radioactivity P01869968A0000 NN O
content P01869968A0000 NN O
after P01869968A0000 IN O
the P01869968A0000 DT O
intravenous P01869968A0000 JJ O
administration P01869968A0000 NN O
of P01869968A0000 IN O
HMPAO P01869968A0000 NNP O
in P01869968A0000 IN O
seven P01869968A0000 CD O
human P01869968A0000 JJ O
subjects P01869968A0000 NNS O
was P01869968A0000 VBD O
analyzed P01869968A0000 VBN O
. P01869968A0000 . O
. . O O

The P01473207A0582 DT O
major P01473207A0582 JJ O
pathological P01473207A0582 JJ O
findings P01473207A0582 NNS O
of P01473207A0582 IN O
the P01473207A0582 DT O
placenta P01473207A0582 NN O
were P01473207A0582 VBD O
prematuration P01473207A0582 NN O
and P01473207A0582 CC O
hypoplasia P01473207A0582 NN O
. P01473207A0582 . O
. . O O

Stereotactic P09225686A0683 JJ O
radiofrequency P09225686A0683 NN O
lesioning P09225686A0683 NN O
of P09225686A0683 IN O
the P09225686A0683 DT O
hamartoma P09225686A0683 NN O
resulted P09225686A0683 VBD O
in P09225686A0683 IN O
seizure P09225686A0683 NN O
remission P09225686A0683 NN O
without P09225686A0683 IN O
complications P09225686A0683 NNS O
20 P09225686A0683 CD O
months P09225686A0683 NNS O
after P09225686A0683 IN O
surgery P09225686A0683 NN O
. P09225686A0683 . O
. . O O

The P06723849A0197 DT O
pyramidal P06723849A0197 JJ O
tract P06723849A0197 NN O
and P06723849A0197 CC O
Mesencephalic P06723849A0197 NNP O
Reticular P06723849A0197 NNP O
Formation P06723849A0197 NNP O
( P06723849A0197 ( O
MRF P06723849A0197 NNP O
) P06723849A0197 ) O
were P06723849A0197 VBD O
stimulated P06723849A0197 VBN O
before P06723849A0197 IN O
and P06723849A0197 CC O
after P06723849A0197 IN O
the P06723849A0197 DT O
transection P06723849A0197 NN O
. P06723849A0197 . O
. . O O

Hypoglycemic P03607961T0001 NNP O
action P03607961T0001 NN O
of P03607961T0001 IN O
`` P03607961T0001 `` O
he P03607961T0001 PRP O
xiang P03607961T0001 VBD O
zhuang P03607961T0001 NNP O
qi P03607961T0001 NN O
gong P03607961T0001 NN O
'' P03607961T0001 '' O
and P03607961T0001 CC O
its P03607961T0001 PRP$ O
mechanism P03607961T0001 NN O
on P03607961T0001 IN O
diabetes P03607961T0001 NNS O
mellitus P03607961T0001 NNS O
. P03607961T0001 . O
. . O O

In P09067577A0307 IN O
cell P09067577A0307 NN O
lines P09067577A0307 NNS O
transformed P09067577A0307 VBN O
by P09067577A0307 IN O
BCR P09067577A0307 NNP I-UN
/ P09067577A0307 NNP O
ABL P09067577A0307 NNP I-UN
, P09067577A0307 , O
CRKL P09067577A0307 NNP I-UN
was P09067577A0307 VBD O
tyrosine P09067577A0307 JJ O
phosphorylated P09067577A0307 VBN O
, P09067577A0307 , O
while P09067577A0307 IN O
CRK P09067577A0307 NNP I-UN
was P09067577A0307 VBD O
not P09067577A0307 RB O
. P09067577A0307 . O
. . O O

The P11092770A0238 DT O
extraction P11092770A0238 NN O
was P11092770A0238 VBD O
subsequently P11092770A0238 RB O
rated P11092770A0238 VBN O
as P11092770A0238 IN O
'easy P11092770A0238 NNP O
' P11092770A0238 POS O
or P11092770A0238 CC O
'difficult'.Taking P11092770A0238 VBG O
Pell-Gregory P11092770A0238 JJ O
class P11092770A0238 NN O
C P11092770A0238 NNP O
as P11092770A0238 IN O
a P11092770A0238 DT O
predictor P11092770A0238 NN O
of P11092770A0238 IN O
a P11092770A0238 DT O
'difficult P11092770A0238 NN O
' P11092770A0238 POS O
extraction P11092770A0238 NN O
, P11092770A0238 , O
specificity P11092770A0238 NN O
was P11092770A0238 VBD O
88 P11092770A0238 CD O
% P11092770A0238 NN O
but P11092770A0238 CC O
sensitivity P11092770A0238 NN O
was P11092770A0238 VBD O
low P11092770A0238 JJ O
at P11092770A0238 IN O
15 P11092770A0238 CD O
% P11092770A0238 NN O
. P11092770A0238 . O
. . O O

The P06935514A0000 DT O
Authors P06935514A0000 NNS O
have P06935514A0000 VBP O
proposed P06935514A0000 VBN O
to P06935514A0000 TO O
develop P06935514A0000 VB O
this P06935514A0000 DT O
research P06935514A0000 NN O
employing P06935514A0000 VBG O
a P06935514A0000 DT O
preparation P06935514A0000 NN O
containing P06935514A0000 VBG O
exclusively P06935514A0000 RB O
a P06935514A0000 DT O
cortisonic P06935514A0000 NN O
, P06935514A0000 , O
the P06935514A0000 DT O
desametazone P06935514A0000 NN O
, P06935514A0000 , O
in P06935514A0000 IN O
order P06935514A0000 NN O
to P06935514A0000 TO O
evaluate P06935514A0000 VB O
the P06935514A0000 DT O
alterations P06935514A0000 NNS O
of P06935514A0000 IN O
the P06935514A0000 DT O
dentinogenesis P06935514A0000 NN O
to P06935514A0000 TO O
be P06935514A0000 VB O
attributed P06935514A0000 VBN O
to P06935514A0000 TO O
such P06935514A0000 JJ O
component P06935514A0000 NN O
. P06935514A0000 . O
. . O O

This P01767060A0000 DT O
study P01767060A0000 NN O
was P01767060A0000 VBD O
aimed P01767060A0000 VBN O
at P01767060A0000 IN O
assessing P01767060A0000 VBG O
whether P01767060A0000 IN O
c-DDP P01767060A0000 JJ O
administration P01767060A0000 NN O
immediately P01767060A0000 RB O
before P01767060A0000 IN O
radiotherapy P01767060A0000 NN O
could P01767060A0000 MD O
increase P01767060A0000 VB O
frequency P01767060A0000 NN O
and P01767060A0000 CC O
duration P01767060A0000 NN O
of P01767060A0000 IN O
objective P01767060A0000 JJ O
responses P01767060A0000 NNS O
, P01767060A0000 , O
as P01767060A0000 RB O
well P01767060A0000 RB O
as P01767060A0000 IN O
survival P01767060A0000 NN O
, P01767060A0000 , O
in P01767060A0000 IN O
patients P01767060A0000 NNS O
affected P01767060A0000 VBN O
with P01767060A0000 IN O
locally P01767060A0000 RB O
advanced P01767060A0000 JJ O
stages P01767060A0000 NNS O
of P01767060A0000 IN O
squamous P01767060A0000 JJ O
carcinomas P01767060A0000 NN O
of P01767060A0000 IN O
the P01767060A0000 DT O
head P01767060A0000 NN O
and P01767060A0000 CC O
neck P01767060A0000 NN O
. P01767060A0000 . O
. . O O

EXAFS P11512925A0000 NN O
measurements P11512925A0000 NNS O
around P11512925A0000 IN O
the P11512925A0000 DT O
Ge-K P11512925A0000 NNP O
edge P11512925A0000 NN O
have P11512925A0000 VBP O
been P11512925A0000 VBN O
carried P11512925A0000 VBN O
out P11512925A0000 RP O
for P11512925A0000 IN O
liquid P11512925A0000 JJ O
Ge-Si P11512925A0000 NNP O
alloys P11512925A0000 NN O
for P11512925A0000 IN O
the P11512925A0000 DT O
first P11512925A0000 JJ O
time P11512925A0000 NN O
to P11512925A0000 TO O
investigate P11512925A0000 VB O
the P11512925A0000 DT O
local P11512925A0000 JJ O
structure P11512925A0000 NN O
around P11512925A0000 IN O
a P11512925A0000 DT O
Ge P11512925A0000 NNP O
atom P11512925A0000 NN O
. P11512925A0000 . O
. . O O

We P08221251A0239 PRP O
suggest P08221251A0239 VBP O
that P08221251A0239 IN O
CT P08221251A0239 NNP O
scan P08221251A0239 JJ O
be P08221251A0239 VB O
preferable P08221251A0239 JJ O
in P08221251A0239 IN O
diagnosis P08221251A0239 NN O
of P08221251A0239 IN O
tumors P08221251A0239 NNS O
in P08221251A0239 IN O
that P08221251A0239 DT O
area P08221251A0239 NN O
. P08221251A0239 . O
. . O O

Similarly P10839470A1148 RB O
, P10839470A1148 , O
comparison P10839470A1148 NN O
of P10839470A1148 IN O
percentage P10839470A1148 NN O
reductions P10839470A1148 NNS O
of P10839470A1148 IN O
heart P10839470A1148 NN O
rate P10839470A1148 NN O
at P10839470A1148 IN O
supine P10839470A1148 NN O
, P10839470A1148 , O
sitting P10839470A1148 VBG O
and P10839470A1148 CC O
exercise P10839470A1148 NN O
by P10839470A1148 IN O
repeated P10839470A1148 JJ O
measure P10839470A1148 NN O
analysis P10839470A1148 NN O
showed P10839470A1148 VBD O
the P10839470A1148 DT O
Malays P10839470A1148 NNPS O
to P10839470A1148 TO O
have P10839470A1148 VB O
significantly P10839470A1148 RB O
higher P10839470A1148 JJR O
change P10839470A1148 NN O
compared P10839470A1148 VBN O
to P10839470A1148 TO O
the P10839470A1148 DT O
Chinese P10839470A1148 NNP O
( P10839470A1148 ( O
p P10839470A1148 JJ O
= P10839470A1148 NNP O
0.040 P10839470A1148 CD O
) P10839470A1148 ) O
. P10839470A1148 . O
. . O O

Reagent P02609112A0000 JJ O
strips P02609112A0000 NNS O
are P02609112A0000 VBP O
frequently P02609112A0000 RB O
used P02609112A0000 VBN O
in P02609112A0000 IN O
the P02609112A0000 DT O
practice P02609112A0000 NN O
of P02609112A0000 IN O
laboratory P02609112A0000 JJ O
medicine P02609112A0000 NN O
as P02609112A0000 RB O
well P02609112A0000 RB O
as P02609112A0000 IN O
outside P02609112A0000 IN O
the P02609112A0000 DT O
professional P02609112A0000 JJ O
laboratories P02609112A0000 NNS O
. P02609112A0000 . O
. . O O

Nucleotide P11264177T0000 NNP O
sequence P11264177T0000 NN O
, P11264177T0000 , O
transcription P11264177T0000 NN O
map P11264177T0000 NN O
, P11264177T0000 , O
and P11264177T0000 CC O
mutation P11264177T0000 NN O
analysis P11264177T0000 NN O
of P11264177T0000 IN O
the P11264177T0000 DT O
13q14 P11264177T0000 CD O
chromosomal P11264177T0000 JJ O
region P11264177T0000 NN O
deleted P11264177T0000 VBN O
in P11264177T0000 IN O
B-cell P11264177T0000 NNP O
chronic P11264177T0000 JJ O
lymphocytic P11264177T0000 JJ O
leukemia P11264177T0000 NN O
. P11264177T0000 . O
. . O O

Sequencing P01406688A0898 VBG O
analysis P01406688A0898 NN O
has P01406688A0898 VBZ O
shown P01406688A0898 VBN O
that P01406688A0898 IN O
each P01406688A0898 DT O
rap1t P01406688A0898 NN I-UN
allele P01406688A0898 NN I-UN
contains P01406688A0898 VBZ O
a P01406688A0898 DT O
nonsense P01406688A0898 JJ O
mutation P01406688A0898 NN O
within P01406688A0898 IN O
a P01406688A0898 DT O
discrete P01406688A0898 JJ O
region P01406688A0898 NN O
between P01406688A0898 IN O
amino P01406688A0898 NN O
acids P01406688A0898 NNS O
663 P01406688A0898 CD O
and P01406688A0898 CC O
684 P01406688A0898 CD O
. P01406688A0898 . O
. . O O

A P06782612A0142 DT O
convenient P06782612A0142 JJ O
measure P06782612A0142 NN O
of P06782612A0142 IN O
this P06782612A0142 DT O
impairment P06782612A0142 NN O
may P06782612A0142 MD O
be P06782612A0142 VB O
obtained P06782612A0142 VBN O
using P06782612A0142 VBG O
the P06782612A0142 DT O
ratio P06782612A0142 NN O
of P06782612A0142 IN O
urine P06782612A0142 JJ O
volume P06782612A0142 NN O
( P06782612A0142 ( O
V P06782612A0142 NNP O
) P06782612A0142 ) O
divided P06782612A0142 VBN O
by P06782612A0142 IN O
lithium P06782612A0142 JJ O
clearance P06782612A0142 NN O
( P06782612A0142 ( O
CLi P06782612A0142 NNP O
) P06782612A0142 ) O
. P06782612A0142 . O
. . O O

In P10991383A0289 IN O
the P10991383A0289 DT O
lattice P10991383A0289 NN O
, P10991383A0289 , O
23 P10991383A0289 CD O
% P10991383A0289 NN O
of P10991383A0289 IN O
the P10991383A0289 DT O
sites P10991383A0289 NNS O
are P10991383A0289 VBP O
occupied P10991383A0289 VBN O
, P10991383A0289 , O
95 P10991383A0289 CD O
% P10991383A0289 NN O
of P10991383A0289 IN O
the P10991383A0289 DT O
atoms P10991383A0289 NNS O
are P10991383A0289 VBP O
in P10991383A0289 IN O
the P10991383A0289 DT O
lowest P10991383A0289 JJS O
energy P10991383A0289 NN O
magnetic P10991383A0289 JJ O
sublevel P10991383A0289 NN O
, P10991383A0289 , O
and P10991383A0289 CC O
37 P10991383A0289 CD O
% P10991383A0289 NN O
are P10991383A0289 VBP O
in P10991383A0289 IN O
the P10991383A0289 DT O
lowest P10991383A0289 JJS O
3D P10991383A0289 CD O
vibrational P10991383A0289 JJ O
state P10991383A0289 NN O
. P10991383A0289 . O
. . O O

Molecular P02405393T0000 JJ O
and P02405393T0000 CC O
functional P02405393T0000 JJ O
characterization P02405393T0000 NN O
of P02405393T0000 IN O
the P02405393T0000 DT O
promoter P02405393T0000 NN O
of P02405393T0000 IN O
ETS2 P02405393T0000 NNP I-UN
, P02405393T0000 , O
the P02405393T0000 DT O
human P02405393T0000 JJ O
c-ets-2 P02405393T0000 JJ I-UN
gene P02405393T0000 NN O
. P02405393T0000 . O
. . O O

Recurrence P00857024A0888 NN O
of P00857024A0888 IN O
bladder P00857024A0888 NN O
tumors P00857024A0888 NNS O
among P00857024A0888 IN O
the P00857024A0888 DT O
original P00857024A0888 JJ O
9 P00857024A0888 CD O
cases P00857024A0888 NNS O
has P00857024A0888 VBZ O
occurred P00857024A0888 VBN O
only P00857024A0888 RB O
among P00857024A0888 IN O
the P00857024A0888 DT O
5 P00857024A0888 CD O
whose P00857024A0888 WP$ O
properdin P00857024A0888 NN I-UN
levels P00857024A0888 NNS O
remained P00857024A0888 VBN O
below P00857024A0888 IN O
the P00857024A0888 DT O
median P00857024A0888 NN O
. P00857024A0888 . O
. . O O

The P11811825A0972 DT O
results P11811825A0972 NNS O
of P11811825A0972 IN O
our P11811825A0972 PRP$ O
ten-fold P11811825A0972 JJ O
cross-validation P11811825A0972 NN O
experiments P11811825A0972 NNS O
show P11811825A0972 VBP O
that P11811825A0972 IN O
, P11811825A0972 , O
on P11811825A0972 IN O
the P11811825A0972 DT O
average P11811825A0972 NN O
, P11811825A0972 , O
the P11811825A0972 DT O
system P11811825A0972 NN O
increases P11811825A0972 VBZ O
the P11811825A0972 DT O
specificity P11811825A0972 NN O
from P11811825A0972 IN O
0.19 P11811825A0972 CD O
( P11811825A0972 ( O
0.35 P11811825A0972 CD O
) P11811825A0972 ) O
to P11811825A0972 TO O
0.69 P11811825A0972 CD O
( P11811825A0972 ( O
0.74 P11811825A0972 CD O
) P11811825A0972 ) O
at P11811825A0972 IN O
a P11811825A0972 DT O
sensitivity P11811825A0972 NN O
level P11811825A0972 NN O
of P11811825A0972 IN O
1.0 P11811825A0972 CD O
( P11811825A0972 ( O
0.95 P11811825A0972 CD O
) P11811825A0972 ) O
. P11811825A0972 . O
. . O O

An P08549706T0000 DT O
epidemic P08549706T0000 NN O
of P08549706T0000 IN O
hepatitis P08549706T0000 NN O
B P08549706T0000 NNP O
virus P08549706T0000 NN O
infection P08549706T0000 NN O
among P08549706T0000 IN O
intravenous P08549706T0000 JJ O
drug P08549706T0000 NN O
users P08549706T0000 NNS O
in P08549706T0000 IN O
Iceland P08549706T0000 NNP O
. P08549706T0000 . O
. . O O

METHODS P11155096A0222 NN O
: P11155096A0222 : O
Thyroid P11155096A0222 NN O
status P11155096A0222 NN O
was P11155096A0222 VBD O
measured P11155096A0222 VBN O
at P11155096A0222 IN O
baseline P11155096A0222 NN O
( P11155096A0222 ( O
1990-93 P11155096A0222 JJ O
) P11155096A0222 ) O
, P11155096A0222 , O
through P11155096A0222 IN O
assessment P11155096A0222 NN O
of P11155096A0222 IN O
serum P11155096A0222 NN O
antibodies P11155096A0222 NNS O
to P11155096A0222 TO O
thyroid P11155096A0222 VB I-UN
peroxidase P11155096A0222 NN I-UN
( P11155096A0222 ( O
TPO-Abs P11155096A0222 NNP I-UN
, P11155096A0222 , O
positive P11155096A0222 JJ O
: P11155096A0222 : O
> P11155096A0222 JJ O
10 P11155096A0222 CD O
IU P11155096A0222 NNP O
/ P11155096A0222 NNP O
ml P11155096A0222 NN O
) P11155096A0222 ) O
, P11155096A0222 , O
serum P11155096A0222 JJ I-UN
TSH P11155096A0222 NNP I-UN
levels P11155096A0222 NNS O
, P11155096A0222 , O
and P11155096A0222 CC O
when P11155096A0222 WRB O
TSH P11155096A0222 NNP I-UN
was P11155096A0222 VBD O
abnormal P11155096A0222 JJ O
( P11155096A0222 ( O
< P11155096A0222 JJ O
0.4 P11155096A0222 CD O
or P11155096A0222 CC O
> P11155096A0222 VB O
4.0 P11155096A0222 CD O
mU P11155096A0222 NN O
/ P11155096A0222 NNP O
l P11155096A0222 NN O
) P11155096A0222 ) O
, P11155096A0222 , O
serum P11155096A0222 JJ I-UN
thyroxin P11155096A0222 NN I-UN
levels P11155096A0222 NNS O
( P11155096A0222 ( O
T4 P11155096A0222 NNP O
) P11155096A0222 ) O
. P11155096A0222 . O
. . O O

Overexpression P11030744A0763 NN O
of P11030744A0763 IN O
Trdpm1 P11030744A0763 NNP I-UN
in P11030744A0763 IN O
a P11030744A0763 DT O
dpm1 P11030744A0763 NN I-UN
( P11030744A0763 ( I-UN
+ P11030744A0763 JJ I-UN
) P11030744A0763 ) I-UN
: P11030744A0763 : O
:his7 P11030744A0763 JJ O
/ P11030744A0763 NN I-UN
dpm1 P11030744A0763 NN I-UN
( P11030744A0763 ( I-UN
+ P11030744A0763 NNP I-UN
) P11030744A0763 ) I-UN
S.pombe P11030744A0763 NNP O
diploid P11030744A0763 NN O
resulted P11030744A0763 VBD O
in P11030744A0763 IN O
a P11030744A0763 DT O
4-fold P11030744A0763 JJ O
increase P11030744A0763 NN O
in P11030744A0763 IN O
specific P11030744A0763 JJ O
DPM P11030744A0763 NNP I-UN
synthase P11030744A0763 NN I-UN
activity P11030744A0763 NN O
. P11030744A0763 . O
. . O O

The P01644814A0068 DT O
virus P01644814A0068 NN O
encodes P01644814A0068 VBZ O
a P01644814A0068 DT O
40-kDa P01644814A0068 JJ O
protein P01644814A0068 NN O
, P01644814A0068 , O
tax P01644814A0068 NN I-UN
, P01644814A0068 , O
that P01644814A0068 WDT O
is P01644814A0068 VBZ O
important P01644814A0068 JJ O
for P01644814A0068 IN O
the P01644814A0068 DT O
immortalization P01644814A0068 NN O
of P01644814A0068 IN O
T P01644814A0068 NNP O
cells P01644814A0068 NNS O
. P01644814A0068 . O
. . O O

SIN-1 P08222384A0455 NNP O
had P08222384A0455 VBD O
no P08222384A0455 DT O
influence P08222384A0455 NN O
on P08222384A0455 IN O
either P08222384A0455 CC O
the P08222384A0455 DT O
ischemic P08222384A0455 JJ O
parameters P08222384A0455 NNS O
in P08222384A0455 IN O
the P08222384A0455 DT O
surface P08222384A0455 NN O
electrocardiogram P08222384A0455 NN O
( P08222384A0455 ( O
ECG P08222384A0455 NNP O
) P08222384A0455 ) O
or P08222384A0455 CC O
the P08222384A0455 DT O
intracoronary P08222384A0455 JJ O
ECG P08222384A0455 NNP O
. P08222384A0455 . O
. . O O

There P08543173A0314 EX O
is P08543173A0314 VBZ O
no P08543173A0314 DT O
TATA P08543173A0314 NNP O
box P08543173A0314 NN O
around P08543173A0314 IN O
the P08543173A0314 DT O
transcriptional P08543173A0314 JJ O
start P08543173A0314 NN O
points P08543173A0314 NNS O
( P08543173A0314 ( O
tsp P08543173A0314 NN O
) P08543173A0314 ) O
, P08543173A0314 , O
as P08543173A0314 IN O
determined P08543173A0314 VBN O
by P08543173A0314 IN O
primer P08543173A0314 JJ O
extension P08543173A0314 NN O
analysis P08543173A0314 NN O
. P08543173A0314 . O
. . O O

A P01396583A0204 DT O
cDNA P01396583A0204 JJ O
library P01396583A0204 NN O
of P01396583A0204 IN O
tumour P01396583A0204 NN O
cells P01396583A0204 NNS O
was P01396583A0204 VBD O
screened P01396583A0204 VBN O
with P01396583A0204 IN O
an P01396583A0204 DT O
interleukin P01396583A0204 JJ I-UN
2 P01396583A0204 CD I-UN
gene-specific P01396583A0204 JJ O
probe P01396583A0204 NN O
. P01396583A0204 . O
. . O O

Prognosis P02458080T0000 NN O
of P02458080T0000 IN O
asymptomatic P02458080T0000 JJ O
multiple P02458080T0000 JJ O
myeloma P02458080T0000 NN O
. P02458080T0000 . O
. . O O

Employing P10360947A1113 VBG O
fluorescence P10360947A1113 NN O
spectroscopy P10360947A1113 NN O
and P10360947A1113 CC O
circular P10360947A1113 JJ O
dichroism P10360947A1113 NN O
, P10360947A1113 , O
we P10360947A1113 PRP O
showed P10360947A1113 VBD O
that P10360947A1113 IN O
the P10360947A1113 DT O
binding P10360947A1113 NN O
of P10360947A1113 IN O
Ca2+ P10360947A1113 NNP O
to P10360947A1113 TO O
ALG-2 P10360947A1113 NNP I-UN
induced P10360947A1113 JJ O
significant P10360947A1113 JJ O
conformational P10360947A1113 JJ O
changes P10360947A1113 NNS O
in P10360947A1113 IN O
both P10360947A1113 DT O
the P10360947A1113 DT O
N-terminal P10360947A1113 JJ O
and P10360947A1113 CC O
C-terminal P10360947A1113 JJ O
domains P10360947A1113 NNS O
of P10360947A1113 IN O
the P10360947A1113 DT O
protein P10360947A1113 NN O
. P10360947A1113 . O
. . O O

The P08601284A0000 DT O
5 P08601284A0000 CD O
' P08601284A0000 POS O
external P08601284A0000 JJ O
transcribed P08601284A0000 NNS O
spacer P08601284A0000 NN O
( P08601284A0000 ( O
ETS P08601284A0000 NNP O
) P08601284A0000 ) O
region P08601284A0000 NN O
of P08601284A0000 IN O
the P08601284A0000 DT O
pre-rRNA P08601284A0000 NN O
in P08601284A0000 IN O
Saccharomyces P08601284A0000 NNP O
cerevisiae P08601284A0000 NN O
contains P08601284A0000 VBZ O
a P08601284A0000 DT O
sequence P08601284A0000 NN O
with P08601284A0000 IN O
10 P08601284A0000 CD O
bp P08601284A0000 NN O
of P08601284A0000 IN O
perfect P08601284A0000 JJ O
complementarity P08601284A0000 NN O
to P08601284A0000 TO O
the P08601284A0000 DT O
U3 P08601284A0000 NNP I-UN
snoRNA P08601284A0000 NN I-UN
. P08601284A0000 . O
. . O O

CONCLUSIONS P11037823A1134 NN O
: P11037823A1134 : O
LSCC P11037823A1134 NNP O
malformation P11037823A1134 NN O
, P11037823A1134 , O
like P11037823A1134 IN O
other P11037823A1134 JJ O
inner P11037823A1134 JJ O
ear P11037823A1134 JJ O
malformations P11037823A1134 NNS O
such P11037823A1134 JJ O
as P11037823A1134 IN O
large P11037823A1134 JJ O
vestibular P11037823A1134 JJ O
aqueduct P11037823A1134 NN O
and P11037823A1134 CC O
X-linked P11037823A1134 JJ O
mixed P11037823A1134 JJ O
deafness P11037823A1134 NN O
with P11037823A1134 IN O
perilymph P11037823A1134 NN O
gusher P11037823A1134 NN O
, P11037823A1134 , O
can P11037823A1134 MD O
be P11037823A1134 VB O
associated P11037823A1134 VBN O
with P11037823A1134 IN O
CHL P11037823A1134 NNP O
, P11037823A1134 , O
SNHL P11037823A1134 NNP O
, P11037823A1134 , O
or P11037823A1134 CC O
normal P11037823A1134 JJ O
hearing P11037823A1134 NN O
. P11037823A1134 . O
. . O O

Cochlear P09693306T0000 NNP O
microphonic P09693306T0000 JJ O
potentials P09693306T0000 NNS O
in P09693306T0000 IN O
patients P09693306T0000 NNS O
with P09693306T0000 IN O
vestibular P09693306T0000 JJ O
schwannomas P09693306T0000 NN O
. P09693306T0000 . O
. . O O

Laser P07941174T0001 NNP O
therapy P07941174T0001 NN O
of P07941174T0001 IN O
penile P07941174T0001 JJ O
carcinoma P07941174T0001 NN O
. P07941174T0001 . O
. . O O

The P07862533A0000 DT O
Wilms P07862533A0000 NNP I-UN
' P07862533A0000 POS I-UN
tumour P07862533A0000 NN I-UN
suppressor P07862533A0000 NN I-UN
protein P07862533A0000 NN I-UN
( P07862533A0000 ( O
WT1 P07862533A0000 NNP I-UN
) P07862533A0000 ) O
is P07862533A0000 VBZ O
a P07862533A0000 DT O
putative P07862533A0000 JJ O
transcriptional P07862533A0000 JJ O
regulatory P07862533A0000 JJ O
protein P07862533A0000 NN O
with P07862533A0000 IN O
four P07862533A0000 CD O
zinc P07862533A0000 NN O
fingers P07862533A0000 NNS O
, P07862533A0000 , O
the P07862533A0000 DT O
last P07862533A0000 JJ O
three P07862533A0000 CD O
of P07862533A0000 IN O
which P07862533A0000 WDT O
have P07862533A0000 VBP O
extensive P07862533A0000 JJ O
sequence P07862533A0000 NN O
homology P07862533A0000 NN O
to P07862533A0000 TO O
the P07862533A0000 DT O
early P07862533A0000 JJ I-UN
growth P07862533A0000 NN I-UN
response-1 P07862533A0000 NN I-UN
( P07862533A0000 ( O
EGR-1 P07862533A0000 NNP I-UN
) P07862533A0000 ) O
protein P07862533A0000 NN O
. P07862533A0000 . O
. . O O

Fetal P09570030T0000 JJ O
growth P09570030T0000 NN O
retardation P09570030T0000 NN O
as P09570030T0000 IN O
a P09570030T0000 DT O
cause P09570030T0000 NN O
of P09570030T0000 IN O
impaired P09570030T0000 JJ O
ovarian P09570030T0000 JJ O
development P09570030T0000 NN O
. P09570030T0000 . O
. . O O

Transient P01321332A0970 JJ O
transfection P01321332A0970 NN O
assays P01321332A0970 NNS O
showed P01321332A0970 VBD O
that P01321332A0970 IN O
site P01321332A0970 NN O
A P01321332A0970 DT O
is P01321332A0970 VBZ O
necessary P01321332A0970 JJ O
and P01321332A0970 CC O
sufficient P01321332A0970 JJ O
for P01321332A0970 IN O
RXR P01321332A0970 NNP I-UN
alpha-mediated P01321332A0970 JJ O
transactivation P01321332A0970 NN O
of P01321332A0970 IN O
the P01321332A0970 DT O
apoAI P01321332A0970 JJ I-UN
gene P01321332A0970 NN I-UN
basal P01321332A0970 NN I-UN
promoter P01321332A0970 NN I-UN
in P01321332A0970 IN O
human P01321332A0970 JJ O
hepatoma P01321332A0970 NN O
HepG2 P01321332A0970 NNP O
cells P01321332A0970 NNS O
in P01321332A0970 IN O
the P01321332A0970 DT O
presence P01321332A0970 NN O
of P01321332A0970 IN O
RA P01321332A0970 NNP O
and P01321332A0970 CC O
that P01321332A0970 IN O
this P01321332A0970 DT O
transactivation P01321332A0970 NN O
is P01321332A0970 VBZ O
abolished P01321332A0970 VBN O
by P01321332A0970 IN O
increasing P01321332A0970 VBG O
amounts P01321332A0970 NNS O
of P01321332A0970 IN O
cotransfected P01321332A0970 JJ O
ARP-1 P01321332A0970 NNP I-UN
. P01321332A0970 . O
. . O O

A P09533109A0449 DT O
possible P09533109A0449 JJ O
decrease P09533109A0449 NN O
in P09533109A0449 IN O
theophylline P09533109A0449 NN O
's P09533109A0449 POS O
volume P09533109A0449 NN O
of P09533109A0449 IN O
distribution P09533109A0449 NN O
at P09533109A0449 IN O
4 P09533109A0449 CD O
days P09533109A0449 NNS O
, P09533109A0449 , O
but P09533109A0449 CC O
not P09533109A0449 RB O
immediately P09533109A0449 RB O
, P09533109A0449 , O
after P09533109A0449 IN O
administration P09533109A0449 NN O
of P09533109A0449 IN O
chloroquine P09533109A0449 NN O
was P09533109A0449 VBD O
suggested P09533109A0449 VBN O
, P09533109A0449 , O
although P09533109A0449 IN O
this P09533109A0449 DT O
just P09533109A0449 RB O
failed P09533109A0449 VBN O
to P09533109A0449 TO O
achieve P09533109A0449 VB O
statistical P09533109A0449 JJ O
significance P09533109A0449 NN O
( P09533109A0449 ( O
p P09533109A0449 JJ O
= P09533109A0449 NNP O
0.055 P09533109A0449 CD O
) P09533109A0449 ) O
. P09533109A0449 . O
. . O O

Induction P01695378A1406 NN O
of P01695378A1406 IN O
Jurkat P01695378A1406 NNP O
leukemic P01695378A1406 JJ O
T P01695378A1406 NNP O
cells P01695378A1406 NNS O
with P01695378A1406 IN O
phorbol P01695378A1406 JJ O
12-myristate P01695378A1406 JJ O
13-acetate P01695378A1406 JJ O
and P01695378A1406 CC O
ionomycin P01695378A1406 NN O
did P01695378A1406 VBD O
not P01695378A1406 RB O
affect P01695378A1406 VB O
the P01695378A1406 DT O
level P01695378A1406 NN O
of P01695378A1406 IN O
FKBP P01695378A1406 NNP I-UN
mRNA P01695378A1406 NN I-UN
. P01695378A1406 . O
. . O O

Here P02201901A0229 RB O
, P02201901A0229 , O
we P02201901A0229 PRP O
have P02201901A0229 VBP O
used P02201901A0229 VBN O
specific P02201901A0229 JJ O
antibody P02201901A0229 NN O
to P02201901A0229 TO O
identify P02201901A0229 VB O
and P02201901A0229 CC O
characterize P02201901A0229 VB O
the P02201901A0229 DT O
SSN6 P02201901A0229 NNP I-UN
protein P02201901A0229 NN I-UN
. P02201901A0229 . O
. . O O

This P10920186A0528 DT O
enabled P10920186A0528 VBD O
the P10920186A0528 DT O
formation P10920186A0528 NN O
of P10920186A0528 IN O
stem-loop P10920186A0528 JJ O
templates P10920186A0528 NNS O
with P10920186A0528 IN O
the P10920186A0528 DT O
fusion P10920186A0528 NN O
point P10920186A0528 NN O
of P10920186A0528 IN O
the P10920186A0528 DT O
chimeric P10920186A0528 JJ O
transcript P10920186A0528 NN O
in P10920186A0528 IN O
the P10920186A0528 DT O
loop P10920186A0528 NN O
and P10920186A0528 CC O
the P10920186A0528 DT O
use P10920186A0528 NN O
of P10920186A0528 IN O
MLL P10920186A0528 NNP I-UN
primers P10920186A0528 NNS O
in P10920186A0528 IN O
two-sided P10920186A0528 JJ O
PCR P10920186A0528 NNP O
. P10920186A0528 . O
. . O O

The P10369775A0178 DT O
studied P10369775A0178 JJ O
protein P10369775A0178 NN O
fragments P10369775A0178 NNS O
consist P10369775A0178 NN O
of P10369775A0178 IN O
residues P10369775A0178 NNS O
Arg183-His267 P10369775A0178 NNP O
of P10369775A0178 IN O
the P10369775A0178 DT O
human P10369775A0178 JJ I-UN
ER P10369775A0178 NNP I-UN
and P10369775A0178 CC O
residues P10369775A0178 VBZ O
Lys438-Gln520 P10369775A0178 NNP O
of P10369775A0178 IN O
the P10369775A0178 DT O
rat P10369775A0178 NN O
GR P10369775A0178 NNP I-UN
. P10369775A0178 . O
. . O O

Here P01682509A0539 RB O
we P01682509A0539 PRP O
present P01682509A0539 JJ O
evidence P01682509A0539 NN O
that P01682509A0539 IN O
major P01682509A0539 JJ I-UN
IE P01682509A0539 NNP I-UN
proteins P01682509A0539 VBZ I-UN
IE86 P01682509A0539 NNP I-UN
, P01682509A0539 , O
IE72 P01682509A0539 NNP I-UN
, P01682509A0539 , O
and P01682509A0539 CC O
IE55 P01682509A0539 NNP I-UN
are P01682509A0539 VBP O
capable P01682509A0539 JJ O
of P01682509A0539 IN O
trans-activating P01682509A0539 VBG O
the P01682509A0539 DT O
HIV P01682509A0539 NNP I-UN
LTR P01682509A0539 NNP I-UN
in P01682509A0539 IN O
a P01682509A0539 DT O
T-cell P01682509A0539 NNP O
line P01682509A0539 NN O
, P01682509A0539 , O
HUT-78 P01682509A0539 NNP O
. P01682509A0539 . O
. . O O

The P09705497A0227 DT O
yeast P09705497A0227 NN I-UN
MMS2 P09705497A0227 NNP I-UN
gene P09705497A0227 NN I-UN
was P09705497A0227 VBD O
cloned P09705497A0227 VBN O
by P09705497A0227 IN O
its P09705497A0227 PRP$ O
ability P09705497A0227 NN O
to P09705497A0227 TO O
complement P09705497A0227 VB O
the P09705497A0227 DT O
methyl P09705497A0227 NN O
methanesulfonate P09705497A0227 NN O
sensitivity P09705497A0227 NN O
of P09705497A0227 IN O
the P09705497A0227 DT O
mms2-1 P09705497A0227 JJ I-UN
mutant P09705497A0227 NN I-UN
and P09705497A0227 CC O
was P09705497A0227 VBD O
later P09705497A0227 RB O
shown P09705497A0227 VBN O
to P09705497A0227 TO O
be P09705497A0227 VB O
involved P09705497A0227 VBN O
in P09705497A0227 IN O
DNA P09705497A0227 NNP O
post-replication P09705497A0227 NN O
repair P09705497A0227 NN O
. P09705497A0227 . O
. . O O

Continued P08409284A0262 JJ O
absorption P08409284A0262 NN O
of P08409284A0262 IN O
amino P08409284A0262 NN O
acids P08409284A0262 NNS O
by P08409284A0262 IN O
the P08409284A0262 DT O
NBB P08409284A0262 NNP O
carrier P08409284A0262 NN O
( P08409284A0262 ( O
for P08409284A0262 IN O
neutral P08409284A0262 JJ O
amino P08409284A0262 NN O
acids P08409284A0262 NNS O
) P08409284A0262 ) O
, P08409284A0262 , O
the P08409284A0262 DT O
Y+ P08409284A0262 NNP O
system P08409284A0262 NN O
( P08409284A0262 ( O
for P08409284A0262 IN O
dibasic P08409284A0262 NN O
amino P08409284A0262 NN O
acids P08409284A0262 NNS O
) P08409284A0262 ) O
, P08409284A0262 , O
and P08409284A0262 CC O
the P08409284A0262 DT O
PHE P08409284A0262 NNP O
carrier P08409284A0262 NN O
were P08409284A0262 VBD O
operative P08409284A0262 JJ O
even P08409284A0262 RB O
during P08409284A0262 IN O
the P08409284A0262 DT O
actively P08409284A0262 RB O
purging P08409284A0262 JJ O
stage P08409284A0262 NN O
of P08409284A0262 IN O
watery P08409284A0262 NN O
diarrhoea P08409284A0262 NN O
due P08409284A0262 JJ O
to P08409284A0262 TO O
cholera P08409284A0262 VB O
. P08409284A0262 . O
. . O O

In P07579164A0409 IN O
comparison P07579164A0409 NN O
of P07579164A0409 IN O
cDNA P07579164A0409 NN O
and P07579164A0409 CC O
genomic P07579164A0409 JJ O
sequences P07579164A0409 NNS O
four P07579164A0409 CD O
RNA P07579164A0409 NNP O
editing P07579164A0409 VBG O
events P07579164A0409 NNS O
were P07579164A0409 VBD O
found P07579164A0409 VBN O
in P07579164A0409 IN O
both P07579164A0409 DT O
atp9 P07579164A0409 JJ I-UN
genes P07579164A0409 NNS I-UN
. P07579164A0409 . O
. . O O

The P07525548A1380 DT O
results P07525548A1380 NNS O
revealed P07525548A1380 VBD O
a P07525548A1380 DT O
hierarchy P07525548A1380 NN O
of P07525548A1380 IN O
ligand P07525548A1380 NN O
affinities P07525548A1380 NNS O
that P07525548A1380 WDT O
mirrored P07525548A1380 VBD O
their P07525548A1380 PRP$ O
adhesive P07525548A1380 JJ O
activity P07525548A1380 NN O
( P07525548A1380 ( O
rsVCAM-1 P07525548A1380 JJ I-UN
> P07525548A1380 NNP O
fibronectin P07525548A1380 NN I-UN
variants P07525548A1380 NNS I-UN
containing P07525548A1380 VBG O
CS1 P07525548A1380 NNP I-UN
> P07525548A1380 NNP O
> P07525548A1380 NNP O
other P07525548A1380 JJ O
fibronectin P07525548A1380 JJ I-UN
variants P07525548A1380 NNS I-UN
) P07525548A1380 ) O
. P07525548A1380 . O
. . O O

By P11181516A0119 IN O
analyzing P11181516A0119 VBG O
5'-deletion P11181516A0119 JJ O
insulin P11181516A0119 NN I-UN
promoter-reporter P11181516A0119 NN I-UN
constructs P11181516A0119 NNS I-UN
in P11181516A0119 IN O
transient P11181516A0119 JJ O
transfections P11181516A0119 NNS O
of P11181516A0119 IN O
clonal P11181516A0119 JJ O
INS-1 P11181516A0119 NNP I-UN
beta-cells P11181516A0119 NNS O
, P11181516A0119 , O
we P11181516A0119 PRP O
located P11181516A0119 VBD O
activating P11181516A0119 VBG O
Hh-responsive P11181516A0119 JJ O
regions P11181516A0119 NNS O
within P11181516A0119 IN O
the P11181516A0119 DT O
rat P11181516A0119 NN I-UN
insulin P11181516A0119 NN I-UN
I P11181516A0119 PRP I-UN
promoter P11181516A0119 VBP I-UN
that P11181516A0119 WDT O
include P11181516A0119 VBP O
the P11181516A0119 DT O
glucose-response P11181516A0119 JJ O
elements P11181516A0119 NNS O
Far P11181516A0119 NNP O
( P11181516A0119 ( O
E2 P11181516A0119 NNP O
) P11181516A0119 ) O
and P11181516A0119 CC O
Flat P11181516A0119 NNP O
( P11181516A0119 ( O
A2 P11181516A0119 NNP O
/ P11181516A0119 NNP O
A3 P11181516A0119 NNP O
) P11181516A0119 ) O
. P11181516A0119 . O
. . O O

SPP P09182707A0254 NNP I-UN
also P09182707A0254 RB O
induced P09182707A0254 VBD O
transient P09182707A0254 JJ O
tyrosine P09182707A0254 JJ O
phosphorylation P09182707A0254 NN O
of P09182707A0254 IN O
focal P09182707A0254 JJ I-UN
adhesion P09182707A0254 NN I-UN
kinase P09182707A0254 NN I-UN
( P09182707A0254 ( O
p125 P09182707A0254 NN I-UN
( P09182707A0254 ( O
FAK P09182707A0254 NNP I-UN
) P09182707A0254 ) O
) P09182707A0254 ) O
, P09182707A0254 , O
a P09182707A0254 DT O
cytosolic P09182707A0254 JJ I-UN
tyrosine P09182707A0254 NN I-UN
kinase P09182707A0254 NN I-UN
that P09182707A0254 WDT O
localizes P09182707A0254 VBZ O
in P09182707A0254 IN O
focal P09182707A0254 JJ O
adhesions P09182707A0254 NNS O
, P09182707A0254 , O
and P09182707A0254 CC O
of P09182707A0254 IN O
the P09182707A0254 DT O
cytoskeleton-associated P09182707A0254 JJ I-UN
protein P09182707A0254 NN I-UN
paxillin P09182707A0254 NN I-UN
. P09182707A0254 . O
. . O O

Commonly P07053251A0666 RB O
observed P07053251A0666 JJ O
systemic P07053251A0666 JJ O
toxic P07053251A0666 NN O
effects P07053251A0666 NNS O
( P07053251A0666 ( O
bone P07053251A0666 NN O
marrow P07053251A0666 NN O
, P07053251A0666 , O
gastrointestinal P07053251A0666 JJ O
tract P07053251A0666 NN O
, P07053251A0666 , O
and P07053251A0666 CC O
heart P07053251A0666 NN O
) P07053251A0666 ) O
were P07053251A0666 VBD O
not P07053251A0666 RB O
seen P07053251A0666 VBN O
in P07053251A0666 IN O
this P07053251A0666 DT O
study P07053251A0666 NN O
. P07053251A0666 . O
. . O O

We P08432137A0000 PRP O
compared P08432137A0000 VBN O
the P08432137A0000 DT O
parameters P08432137A0000 NNS O
pleural P08432137A0000 JJ I-UN
adenosine P08432137A0000 JJ I-UN
deaminase P08432137A0000 NN I-UN
( P08432137A0000 ( O
PADA P08432137A0000 NNP I-UN
, P08432137A0000 , O
determined P08432137A0000 VBD O
in P08432137A0000 IN O
405 P08432137A0000 CD O
patients P08432137A0000 NNS O
) P08432137A0000 ) O
, P08432137A0000 , O
the P08432137A0000 DT O
PADA P08432137A0000 NNP I-UN
/ P08432137A0000 NNP O
serum P08432137A0000 VBD I-UN
ADA P08432137A0000 NNP I-UN
ratio P08432137A0000 NN O
( P08432137A0000 ( O
P P08432137A0000 NNP I-UN
/ P08432137A0000 NNP O
SADA P08432137A0000 NNP I-UN
; P08432137A0000 : O
276 P08432137A0000 CD O
cases P08432137A0000 NNS O
) P08432137A0000 ) O
, P08432137A0000 , O
pleural P08432137A0000 JJ I-UN
lysozyme P08432137A0000 NN I-UN
( P08432137A0000 ( O
PLYS P08432137A0000 NNP I-UN
, P08432137A0000 , O
276 P08432137A0000 CD O
cases P08432137A0000 NNS O
) P08432137A0000 ) O
, P08432137A0000 , O
the P08432137A0000 DT O
PLYS P08432137A0000 NNP I-UN
/ P08432137A0000 NNP O
serum P08432137A0000 NN I-UN
LYS P08432137A0000 NNP I-UN
ratio P08432137A0000 NN O
( P08432137A0000 ( O
P P08432137A0000 NNP I-UN
/ P08432137A0000 NNP O
SLYS P08432137A0000 NNP I-UN
; P08432137A0000 : O
276 P08432137A0000 CD O
cases P08432137A0000 NNS O
) P08432137A0000 ) O
, P08432137A0000 , O
and P08432137A0000 CC O
pleural P08432137A0000 JJ I-UN
interferon P08432137A0000 NN I-UN
gamma P08432137A0000 NN I-UN
( P08432137A0000 ( O
IFN P08432137A0000 NNP I-UN
, P08432137A0000 , O
145 P08432137A0000 CD O
cases P08432137A0000 NNS O
) P08432137A0000 ) O
regarding P08432137A0000 VBG O
their P08432137A0000 PRP$ O
ability P08432137A0000 NN O
to P08432137A0000 TO O
differentiate P08432137A0000 VB O
tuberculous P08432137A0000 JJ O
pleural P08432137A0000 JJ O
effusions P08432137A0000 NNS O
from P08432137A0000 IN O
others P08432137A0000 NNS O
. P08432137A0000 . O
. . O O

Replacement P08219227A0830 NN O
of P08219227A0830 IN O
the P08219227A0830 DT O
CRE P08219227A0830 NNP O
with P08219227A0830 IN O
a P08219227A0830 DT O
second P08219227A0830 JJ O
copy P08219227A0830 NN O
of P08219227A0830 IN O
the P08219227A0830 DT O
AP-1 P08219227A0830 NNP I-UN
site P08219227A0830 NN I-UN
results P08219227A0830 NNS O
in P08219227A0830 IN O
a P08219227A0830 DT O
level P08219227A0830 NN O
of P08219227A0830 IN O
transcriptional P08219227A0830 JJ O
activity P08219227A0830 NN O
comparable P08219227A0830 JJ O
with P08219227A0830 IN O
that P08219227A0830 DT O
of P08219227A0830 IN O
the P08219227A0830 DT O
wild-type P08219227A0830 JJ O
sequence P08219227A0830 NN O
, P08219227A0830 , O
but P08219227A0830 CC O
replacement P08219227A0830 NN O
of P08219227A0830 IN O
the P08219227A0830 DT O
AP-1 P08219227A0830 NNP I-UN
site P08219227A0830 NN I-UN
with P08219227A0830 IN O
a P08219227A0830 DT O
CRE P08219227A0830 NNP O
abolishes P08219227A0830 VBZ O
activity P08219227A0830 NN O
. P08219227A0830 . O
. . O O

The P08444345A0403 DT O
deduced P08444345A0403 JJ O
bovine P08444345A0403 NN O
EFIA P08444345A0403 NNP I-UN
# P08444345A0403 # I-UN
1 P08444345A0403 CD I-UN
amino P08444345A0403 NN O
acid P08444345A0403 NN O
( P08444345A0403 ( O
aa P08444345A0403 NN O
) P08444345A0403 ) O
sequence P08444345A0403 NN O
is P08444345A0403 VBZ O
98 P08444345A0403 CD O
% P08444345A0403 NN O
identical P08444345A0403 JJ O
to P08444345A0403 TO O
rat P08444345A0403 VB O
EFIA P08444345A0403 NNP I-UN
and P08444345A0403 CC O
100 P08444345A0403 CD O
% P08444345A0403 NN O
identical P08444345A0403 JJ O
to P08444345A0403 TO O
human P08444345A0403 JJ O
EFIA P08444345A0403 NNP I-UN
/ P08444345A0403 NNP O
DbpB P08444345A0403 NNP I-UN
/ P08444345A0403 NNP O
YB-1 P08444345A0403 NNP I-UN
family P08444345A0403 NN O
member P08444345A0403 NN O
DNA-binding P08444345A0403 NNP I-UN
protein P08444345A0403 NN I-UN
B P08444345A0403 NNP I-UN
( P08444345A0403 ( O
DbpB P08444345A0403 NNP I-UN
) P08444345A0403 ) O
. P08444345A0403 . O
. . O O

This P07651400A0335 DT O
inhibition P07651400A0335 NN O
can P07651400A0335 MD O
be P07651400A0335 VB O
overcome P07651400A0335 VBN O
by P07651400A0335 IN O
mutating P07651400A0335 VBG O
either P07651400A0335 CC O
the P07651400A0335 DT O
exon P07651400A0335 NN O
's P07651400A0335 POS O
5 P07651400A0335 CD O
' P07651400A0335 '' O
or P07651400A0335 CC O
3 P07651400A0335 CD O
' P07651400A0335 '' O
splice P07651400A0335 NN O
site P07651400A0335 NN O
to P07651400A0335 TO O
make P07651400A0335 VB O
it P07651400A0335 PRP O
correspond P07651400A0335 VB O
more P07651400A0335 RBR O
closely P07651400A0335 RB O
to P07651400A0335 TO O
the P07651400A0335 DT O
relevant P07651400A0335 JJ O
consensus P07651400A0335 NN O
sequence P07651400A0335 NN O
. P07651400A0335 . O
. . O O

The P01731979A1408 DT O
tissue P01731979A1408 NN O
specificity P01731979A1408 NN O
of P01731979A1408 IN O
gene P01731979A1408 NN O
expression P01731979A1408 NN O
was P01731979A1408 VBD O
identical P01731979A1408 JJ O
to P01731979A1408 TO O
that P01731979A1408 DT O
described P01731979A1408 VBD O
previously P01731979A1408 RB O
for P01731979A1408 IN O
the P01731979A1408 DT O
CaMV P01731979A1408 NNP I-UN
35S P01731979A1408 CD I-UN
domain P01731979A1408 NN I-UN
B P01731979A1408 NNP I-UN
enhancer P01731979A1408 NN I-UN
element P01731979A1408 NN I-UN
. P01731979A1408 . O
. . O O

The P05501347T0001 DT O
effect P05501347T0001 NN O
of P05501347T0001 IN O
low P05501347T0001 JJ O
dosage P05501347T0001 NN O
radiation P05501347T0001 NN O
on P05501347T0001 IN O
metabolism P05501347T0001 NN O
and P05501347T0001 CC O
function P05501347T0001 NN O
of P05501347T0001 IN O
the P05501347T0001 DT O
rat P05501347T0001 NN O
kidney P05501347T0001 NN O
damaged P05501347T0001 VBN O
by P05501347T0001 IN O
ischemia P05501347T0001 NN O
. P05501347T0001 . O
. . O O

OBJECTIVE P10839593A0000 NN O
: P10839593A0000 : O
To P10839593A0000 TO O
determine P10839593A0000 VB O
the P10839593A0000 DT O
efficacy P10839593A0000 NN O
and P10839593A0000 CC O
safety P10839593A0000 NN O
of P10839593A0000 IN O
amphotericin P10839593A0000 NN O
B P10839593A0000 NNP O
oral P10839593A0000 JJ O
suspension P10839593A0000 NN O
( P10839593A0000 ( O
ABOS P10839593A0000 NNP O
) P10839593A0000 ) O
for P10839593A0000 IN O
the P10839593A0000 DT O
treatment P10839593A0000 NN O
of P10839593A0000 IN O
fluconazole P10839593A0000 JJ O
refractory P10839593A0000 JJ O
oral P10839593A0000 JJ O
candidiasis P10839593A0000 NN O
in P10839593A0000 IN O
persons P10839593A0000 NNS O
with P10839593A0000 IN O
HIV P10839593A0000 NNP O
infection P10839593A0000 NN O
. P10839593A0000 . O
. . O O

Substitutions P01731107A0928 NNS O
introduced P01731107A0928 VBN O
at P01731107A0928 IN O
bases P01731107A0928 NNS O
surrounding P01731107A0928 VBG O
the P01731107A0928 DT O
ICR2 P01731107A0928 NNP I-UN
motif P01731107A0928 NN I-UN
yielded P01731107A0928 VBN O
levels P01731107A0928 NNS O
of P01731107A0928 IN O
pRNA P01731107A0928 NN O
replication P01731107A0928 NN O
that P01731107A0928 WDT O
differed P01731107A0928 VBD O
, P01731107A0928 , O
depending P01731107A0928 VBG O
on P01731107A0928 IN O
the P01731107A0928 DT O
maintenance P01731107A0928 NN O
of P01731107A0928 IN O
a P01731107A0928 DT O
putative P01731107A0928 JJ O
5 P01731107A0928 CD O
' P01731107A0928 POS O
stem-loop P01731107A0928 JJ O
structure P01731107A0928 NN O
in P01731107A0928 IN O
the P01731107A0928 DT O
positive P01731107A0928 JJ O
strand P01731107A0928 NN O
of P01731107A0928 IN O
the P01731107A0928 DT O
viral P01731107A0928 JJ O
genome P01731107A0928 NN O
. P01731107A0928 . O
. . O O

The P01991521A0481 DT O
results P01991521A0481 NNS O
strengthen P01991521A0481 VBP O
the P01991521A0481 DT O
conclusion P01991521A0481 NN O
that P01991521A0481 WDT O
predominantly P01991521A0481 RB O
dynamic P01991521A0481 VBZ O
activity P01991521A0481 NN O
increases P01991521A0481 VBZ O
the P01991521A0481 DT O
G4 P01991521A0481 NNP I-UN
content P01991521A0481 NN O
of P01991521A0481 IN O
mature P01991521A0481 NN O
innervated P01991521A0481 VBN O
fast P01991521A0481 JJ O
muscles P01991521A0481 NNS O
. P01991521A0481 . O
. . O O

Immunocytochemical P08632015A1226 JJ O
analysis P08632015A1226 NN O
demonstrated P08632015A1226 VBD O
the P08632015A1226 DT O
presence P08632015A1226 NN O
of P08632015A1226 IN O
DREF P08632015A1226 NNP I-UN
polypeptide P08632015A1226 NN I-UN
in P08632015A1226 IN O
nuclei P08632015A1226 NN O
after P08632015A1226 IN O
the P08632015A1226 DT O
eighth P08632015A1226 JJ O
nuclear P08632015A1226 JJ O
division P08632015A1226 NN O
cycle P08632015A1226 NN O
, P08632015A1226 , O
suggesting P08632015A1226 VBG O
that P08632015A1226 IN O
nuclear P08632015A1226 JJ O
accumulation P08632015A1226 NN O
of P08632015A1226 IN O
DREF P08632015A1226 NNP I-UN
is P08632015A1226 VBZ O
important P08632015A1226 JJ O
for P08632015A1226 IN O
the P08632015A1226 DT O
coordinate P08632015A1226 NN O
zygotic P08632015A1226 JJ O
expression P08632015A1226 NN O
of P08632015A1226 IN O
DNA P08632015A1226 NNP O
replication-related P08632015A1226 JJ O
genes P08632015A1226 NNS O
carrying P08632015A1226 VBG O
DRE P08632015A1226 NNP O
sequences P08632015A1226 NNS O
. P08632015A1226 . O
. . O O

An P02644735A0427 DT O
FP P02644735A0427 NNP I-UN
mutant P02644735A0427 NN I-UN
, P02644735A0427 , O
AcFP875-2 P02644735A0427 NNP I-UN
, P02644735A0427 , O
had P02644735A0427 VBD O
a P02644735A0427 DT O
1.6-kbp P02644735A0427 JJ O
insertion P02644735A0427 NN O
of P02644735A0427 IN O
S. P02644735A0427 NNP O
frugiperda P02644735A0427 NNP O
DNA P02644735A0427 NNP O
near P02644735A0427 IN O
the P02644735A0427 DT O
5 P02644735A0427 CD O
' P02644735A0427 POS O
end P02644735A0427 NN O
of P02644735A0427 IN O
these P02644735A0427 DT O
transcripts P02644735A0427 NNS O
which P02644735A0427 WDT O
by P02644735A0427 IN O
S1 P02644735A0427 NNP I-UN
analysis P02644735A0427 NN O
were P02644735A0427 VBD O
shown P02644735A0427 VBN O
to P02644735A0427 TO O
initiate P02644735A0427 VB O
within P02644735A0427 IN O
the P02644735A0427 DT O
host P02644735A0427 NN O
cell P02644735A0427 NN O
sequence P02644735A0427 NN O
. P02644735A0427 . O
. . O O

Vascular P10865838A0000 JJ I-UN
endothelial P10865838A0000 JJ I-UN
growth P10865838A0000 NN I-UN
factor P10865838A0000 NN I-UN
( P10865838A0000 ( O
VEGF P10865838A0000 NNP I-UN
) P10865838A0000 ) O
, P10865838A0000 , O
a P10865838A0000 DT O
potent P10865838A0000 JJ O
agonist P10865838A0000 NN O
secreted P10865838A0000 VBN O
by P10865838A0000 IN O
virtually P10865838A0000 RB O
all P10865838A0000 DT O
cells P10865838A0000 NNS O
, P10865838A0000 , O
controls P10865838A0000 NNS O
migration P10865838A0000 NN O
and P10865838A0000 CC O
division P10865838A0000 NN O
of P10865838A0000 IN O
vascular P10865838A0000 JJ O
endothelial P10865838A0000 JJ O
cells P10865838A0000 NNS O
. P10865838A0000 . O
. . O O

We P07628451A0114 PRP O
show P07628451A0114 VBP O
here P07628451A0114 RB O
that P07628451A0114 IN O
RA P07628451A0114 NNP O
and P07628451A0114 CC O
E1A P07628451A0114 NNP I-UN
induce P07628451A0114 VBP O
phosphorylation P07628451A0114 NN O
of P07628451A0114 IN O
the P07628451A0114 DT O
E1A-associated P07628451A0114 JJ I-UN
300 P07628451A0114 CD I-UN
kDa P07628451A0114 NN I-UN
protein P07628451A0114 NN I-UN
( P07628451A0114 ( O
p300 P07628451A0114 NN I-UN
) P07628451A0114 ) O
during P07628451A0114 IN O
the P07628451A0114 DT O
differentiation P07628451A0114 NN O
of P07628451A0114 IN O
F9 P07628451A0114 NNP O
cells P07628451A0114 NNS O
. P07628451A0114 . O
. . O O

Human P02243093A0000 JJ O
T-cell P02243093A0000 NNP O
leukemia P02243093A0000 NN O
virus P02243093A0000 NN O
type P02243093A0000 NN O
I P02243093A0000 PRP O
( P02243093A0000 ( O
HTLV-I P02243093A0000 NNP O
) P02243093A0000 ) O
encodes P02243093A0000 VBZ O
a P02243093A0000 DT O
40-kDa P02243093A0000 JJ O
nuclear P02243093A0000 JJ O
protein P02243093A0000 NN O
, P02243093A0000 , O
Tax P02243093A0000 NNP I-UN
, P02243093A0000 , O
which P02243093A0000 WDT O
stimulates P02243093A0000 VBZ O
transcription P02243093A0000 NN O
from P02243093A0000 IN O
three P02243093A0000 CD O
21-base P02243093A0000 JJ O
pair P02243093A0000 NN O
( P02243093A0000 ( O
bp P02243093A0000 NN O
) P02243093A0000 ) O
repeats P02243093A0000 VBZ O
in P02243093A0000 IN O
its P02243093A0000 PRP$ O
U3 P02243093A0000 NNP O
region P02243093A0000 NN O
. P02243093A0000 . O
. . O O

The P09321406T0000 DT O
pheromone P09321406T0000 NN O
response P09321406T0000 NN O
pathway P09321406T0000 NN O
activates P09321406T0000 VBZ O
transcription P09321406T0000 NN O
of P09321406T0000 IN O
Ty5 P09321406T0000 NNP I-UN
retrotransposons P09321406T0000 NNS I-UN
located P09321406T0000 VBD O
within P09321406T0000 IN O
silent P09321406T0000 JJ O
chromatin P09321406T0000 NN O
of P09321406T0000 IN O
Saccharomyces P09321406T0000 NNP O
cerevisiae P09321406T0000 NN O
. P09321406T0000 . O
. . O O

Diffuse P07677836A1356 NNP O
white P07677836A1356 JJ O
matter P07677836A1356 NN O
injury P07677836A1356 NN O
can P07677836A1356 MD O
be P07677836A1356 VB O
attributed P07677836A1356 VBN O
to P07677836A1356 TO O
radiation P07677836A1356 NN O
and P07677836A1356 CC O
associated P07677836A1356 VBN O
with P07677836A1356 IN O
neurological P07677836A1356 JJ O
deficits P07677836A1356 NNS O
, P07677836A1356 , O
but P07677836A1356 CC O
leukoencephalopathy P07677836A1356 JJ O
is P07677836A1356 VBZ O
rarely P07677836A1356 RB O
observed P07677836A1356 VBN O
in P07677836A1356 IN O
the P07677836A1356 DT O
absence P07677836A1356 NN O
of P07677836A1356 IN O
chemotherapy P07677836A1356 NN O
. P07677836A1356 . O
. . O O

Regarding P10992983T0000 VBG O
`` P10992983T0000 `` O
the P10992983T0000 DT O
relation P10992983T0000 NN O
between P10992983T0000 IN O
sexual P10992983T0000 JJ O
orientation P10992983T0000 NN O
and P10992983T0000 CC O
penile P10992983T0000 NN O
size P10992983T0000 NN O
, P10992983T0000 , O
'' P10992983T0000 '' O
by P10992983T0000 IN O
A P10992983T0000 DT O
. P10992983T0000 . O
. . O O

Chem P10617613A1192 NNP O
. P10617613A1192 . O
. . O O

Cases P11244733A0782 NNS O
of P11244733A0782 IN O
lung P11244733A0782 NN O
cancer P11244733A0782 NN O
with P11244733A0782 IN O
intramedullary P11244733A0782 JJ O
metastasis P11244733A0782 NN O
are P11244733A0782 VBP O
rare P11244733A0782 JJ O
, P11244733A0782 , O
especially P11244733A0782 RB O
those P11244733A0782 DT O
diagnosed P11244733A0782 VBN O
before P11244733A0782 IN O
death P11244733A0782 NN O
. P11244733A0782 . O
. . O O

Despite P02332018A0538 IN O
the P02332018A0538 DT O
absence P02332018A0538 NN O
of P02332018A0538 IN O
exercise-induced P02332018A0538 JJ O
asthma P02332018A0538 NN O
( P02332018A0538 ( O
EIA P02332018A0538 NNP O
) P02332018A0538 ) O
while P02332018A0538 IN O
breathing P02332018A0538 VBG O
WH P02332018A0538 NNP O
air P02332018A0538 NN O
, P02332018A0538 , O
asthmatic P02332018A0538 JJ O
patients P02332018A0538 NNS O
still P02332018A0538 RB O
had P02332018A0538 VBD O
significantly P02332018A0538 RB O
higher P02332018A0538 JJR O
mean P02332018A0538 JJ O
GH P02332018A0538 NNP O
increments P02332018A0538 NNS O
than P02332018A0538 IN O
normal P02332018A0538 JJ O
subjects P02332018A0538 NNS O
( P02332018A0538 ( O
9.2 P02332018A0538 CD O
vs P02332018A0538 RB O
2.3 P02332018A0538 CD O
ng P02332018A0538 JJ O
/ P02332018A0538 NNP O
ml P02332018A0538 NN O
, P02332018A0538 , O
P P02332018A0538 NNP O
less P02332018A0538 JJR O
than P02332018A0538 IN O
0.05 P02332018A0538 CD O
) P02332018A0538 ) O
. P02332018A0538 . O
. . O O

These P09653182A1298 DT O
data P09653182A1298 NNS O
show P09653182A1298 VBP O
that P09653182A1298 IN O
heterologous P09653182A1298 JJ O
virus P09653182A1298 NN O
RNAs P09653182A1298 NNP O
( P09653182A1298 ( O
BSMV P09653182A1298 NNP O
) P09653182A1298 ) O
can P09653182A1298 MD O
serve P09653182A1298 VB O
as P09653182A1298 IN O
primer P09653182A1298 NN O
donors P09653182A1298 NNS O
for P09653182A1298 IN O
MStV P09653182A1298 NNP O
mRNA P09653182A1298 NN O
capped P09653182A1298 VBD O
RNA-primed P09653182A1298 NNP O
transcription P09653182A1298 NN O
in P09653182A1298 IN O
doubly P09653182A1298 RB O
infected P09653182A1298 JJ O
plants P09653182A1298 NNS O
. P09653182A1298 . O
. . O O

We P11308851A0333 PRP O
find P11308851A0333 VBP O
that P11308851A0333 IN O
our P11308851A0333 PRP$ O
response P11308851A0333 NN O
function P11308851A0333 NN O
is P11308851A0333 VBZ O
well P11308851A0333 RB O
approximated P11308851A0333 VBN O
by P11308851A0333 IN O
the P11308851A0333 DT O
GSER P11308851A0333 NNP O
only P11308851A0333 RB O
within P11308851A0333 IN O
a P11308851A0333 DT O
particular P11308851A0333 JJ O
frequency P11308851A0333 NN O
range P11308851A0333 NN O
determined P11308851A0333 VBN O
by P11308851A0333 IN O
the P11308851A0333 DT O
material P11308851A0333 NN O
parameters P11308851A0333 NNS O
of P11308851A0333 IN O
both P11308851A0333 DT O
the P11308851A0333 DT O
bead P11308851A0333 NN O
and P11308851A0333 CC O
the P11308851A0333 DT O
network P11308851A0333 NN O
. P11308851A0333 . O
. . O O

Purified P09705352A0879 NNP O
Hsk1 P09705352A0879 NNP I-UN
phosphorylates P09705352A0879 VBZ O
the P09705352A0879 DT O
Cdc19 P09705352A0879 NNP I-UN
( P09705352A0879 ( O
Mcm2 P09705352A0879 NNP I-UN
) P09705352A0879 ) O
subunit P09705352A0879 NN O
of P09705352A0879 IN O
the P09705352A0879 DT O
six-member P09705352A0879 JJ I-UN
minichromosome P09705352A0879 JJ I-UN
maintenance P09705352A0879 NN I-UN
protein P09705352A0879 NN I-UN
complex P09705352A0879 JJ I-UN
purified P09705352A0879 VBN O
from P09705352A0879 IN O
fission P09705352A0879 NN O
yeast P09705352A0879 NN O
. P09705352A0879 . O
. . O O

We P10995751A0093 PRP O
have P10995751A0093 VBP O
recently P10995751A0093 RB O
discovered P10995751A0093 VBN O
that P10995751A0093 IN O
CCAAAT P10995751A0093 NNP I-UN
/ P10995751A0093 VBD I-UN
enhancer-binding P10995751A0093 JJ I-UN
protein-beta P10995751A0093 NN I-UN
( P10995751A0093 ( O
C P10995751A0093 NNP I-UN
/ P10995751A0093 NNP I-UN
EBP-beta P10995751A0093 NNP I-UN
) P10995751A0093 ) O
induces P10995751A0093 VBZ O
gene P10995751A0093 NN O
transcription P10995751A0093 NN O
through P10995751A0093 IN O
a P10995751A0093 DT O
novel P10995751A0093 JJ O
IFN P10995751A0093 NNP I-UN
response P10995751A0093 NN I-UN
element P10995751A0093 NN I-UN
called P10995751A0093 VBD O
the P10995751A0093 DT O
gamma-IFN-activated P10995751A0093 JJ I-UN
transcriptional P10995751A0093 JJ I-UN
element P10995751A0093 NN I-UN
. P10995751A0093 . O
. . O O

Transcriptional P07708497A0000 JJ O
activation P07708497A0000 NN O
by P07708497A0000 IN O
thyroid P07708497A0000 JJ O
hormone P07708497A0000 NN O
( P07708497A0000 ( O
T3 P07708497A0000 NNP O
) P07708497A0000 ) O
requires P07708497A0000 VBZ O
interactions P07708497A0000 NNS O
between P07708497A0000 IN O
the P07708497A0000 DT O
T3 P07708497A0000 NNP I-UN
receptor P07708497A0000 NN I-UN
( P07708497A0000 ( O
TR P07708497A0000 NNP I-UN
) P07708497A0000 ) O
and P07708497A0000 CC O
T3 P07708497A0000 NNP O
response P07708497A0000 NN O
elements P07708497A0000 NNS O
( P07708497A0000 ( O
TREs P07708497A0000 NNP O
) P07708497A0000 ) O
composed P07708497A0000 VBD O
of P07708497A0000 IN O
two P07708497A0000 CD O
copies P07708497A0000 NNS O
of P07708497A0000 IN O
sequences P07708497A0000 NNS O
related P07708497A0000 VBN O
to P07708497A0000 TO O
AGGTCA P07708497A0000 NNP O
. P07708497A0000 . O
. . O O

Cytoplasmic P07929559A0000 NNP I-UN
dynein P07929559A0000 NN I-UN
is P07929559A0000 VBZ O
a P07929559A0000 DT O
multisubunit P07929559A0000 NN O
, P07929559A0000 , O
microtubule-dependent P07929559A0000 JJ O
mechanochemical P07929559A0000 JJ O
enzyme P07929559A0000 NN O
that P07929559A0000 WDT O
has P07929559A0000 VBZ O
been P07929559A0000 VBN O
proposed P07929559A0000 VBN O
to P07929559A0000 TO O
function P07929559A0000 NN O
in P07929559A0000 IN O
a P07929559A0000 DT O
variety P07929559A0000 NN O
of P07929559A0000 IN O
intracellular P07929559A0000 JJ O
movements P07929559A0000 NNS O
, P07929559A0000 , O
including P07929559A0000 VBG O
minus-end-directed P07929559A0000 JJ O
transport P07929559A0000 NN O
of P07929559A0000 IN O
organelles P07929559A0000 NNS O
. P07929559A0000 . O
. . O O

Derepression P09057841T0000 NN O
of P09057841T0000 IN O
gene P09057841T0000 NN O
expression P09057841T0000 NN O
mediated P09057841T0000 VBN O
by P09057841T0000 IN O
the P09057841T0000 DT O
5 P09057841T0000 CD O
' P09057841T0000 POS O
upstream P09057841T0000 JJ O
region P09057841T0000 NN O
of P09057841T0000 IN O
the P09057841T0000 DT O
isocitrate P09057841T0000 JJ I-UN
lyase P09057841T0000 NN I-UN
gene P09057841T0000 NN I-UN
of P09057841T0000 IN I-UN
Candida P09057841T0000 NNP I-UN
tropicalis P09057841T0000 NN I-UN
is P09057841T0000 VBZ O
controlled P09057841T0000 VBN O
by P09057841T0000 IN O
two P09057841T0000 CD O
distinct P09057841T0000 JJ O
regulatory P09057841T0000 JJ O
pathways P09057841T0000 NNS O
in P09057841T0000 IN O
Saccharomyces P09057841T0000 NNP O
cerevisiae P09057841T0000 NN O
. P09057841T0000 . O
. . O O

During P04002131A0506 IN O
a P04002131A0506 DT O
disease P04002131A0506 NN O
remission P04002131A0506 NN O
there P04002131A0506 EX O
was P04002131A0506 VBD O
an P04002131A0506 DT O
increase P04002131A0506 NN O
in P04002131A0506 IN O
GAG P04002131A0506 NNP O
secretion P04002131A0506 NN O
with P04002131A0506 IN O
urine P04002131A0506 JJ O
, P04002131A0506 , O
linked P04002131A0506 VBN O
with P04002131A0506 IN O
hyperheparinuria P04002131A0506 NNS O
( P04002131A0506 ( O
13.1-fold P04002131A0506 JJ O
, P04002131A0506 , O
P P04002131A0506 NNP O
less P04002131A0506 JJR O
than P04002131A0506 IN O
0.001 P04002131A0506 CD O
) P04002131A0506 ) O
. P04002131A0506 . O
. . O O

The P05389125T0000 DT O
exploratory P05389125T0000 JJ O
behaviour P05389125T0000 NN O
in P05389125T0000 IN O
normal P05389125T0000 JJ O
and P05389125T0000 CC O
aggressive P05389125T0000 JJ O
mice P05389125T0000 NN O
. P05389125T0000 . O
. . O O

The P10766556T0000 DT O
somatoform P10766556T0000 NN O
conundrum P10766556T0000 NN O
: P10766556T0000 : O
a P10766556T0000 DT O
question P10766556T0000 NN O
of P10766556T0000 IN O
nosological P10766556T0000 JJ O
valves P10766556T0000 NNS O
. P10766556T0000 . O
. . O O

In P07883167A0157 IN O
yeast P07883167A0157 NN O
, P07883167A0157 , O
the P07883167A0157 DT O
products P07883167A0157 NNS O
of P07883167A0157 IN O
the P07883167A0157 DT O
UPF1 P07883167A0157 NNP I-UN
and P07883167A0157 CC O
UPF3 P07883167A0157 NNP I-UN
genes P07883167A0157 NNS I-UN
are P07883167A0157 VBP O
required P07883167A0157 VBN O
for P07883167A0157 IN O
this P07883167A0157 DT O
decay P07883167A0157 NN O
pathway P07883167A0157 NN O
, P07883167A0157 , O
and P07883167A0157 CC O
in P07883167A0157 IN O
this P07883167A0157 DT O
report P07883167A0157 NN O
we P07883167A0157 PRP O
focus P07883167A0157 VBP O
on P07883167A0157 IN O
the P07883167A0157 DT O
identification P07883167A0157 NN O
and P07883167A0157 CC O
characterization P07883167A0157 NN O
of P07883167A0157 IN O
additional P07883167A0157 JJ O
factors P07883167A0157 NNS O
required P07883167A0157 VBN O
for P07883167A0157 IN O
rapid P07883167A0157 JJ O
decay P07883167A0157 NN O
of P07883167A0157 IN O
nonsense-containing P07883167A0157 JJ O
mRNAs P07883167A0157 NN O
. P07883167A0157 . O
. . O O

The P02685331A0523 DT O
R. P02685331A0523 NNP I-UN
meliloti P02685331A0523 NN I-UN
nifH P02685331A0523 NN I-UN
promoter P02685331A0523 NN I-UN
but P02685331A0523 CC O
not P02685331A0523 RB O
the P02685331A0523 DT O
K. P02685331A0523 NNP I-UN
pneumoniae P02685331A0523 NN I-UN
nifH P02685331A0523 NN I-UN
promoter P02685331A0523 NN I-UN
showed P02685331A0523 VBD O
sigma P02685331A0523 JJ I-UN
54-dependent P02685331A0523 JJ O
methylation P02685331A0523 NN O
protection P02685331A0523 NN O
of P02685331A0523 IN O
guanine P02685331A0523 NN O
residues P02685331A0523 NNS O
at P02685331A0523 IN O
-14 P02685331A0523 NN O
, P02685331A0523 , O
-25 P02685331A0523 NNP O
and P02685331A0523 CC O
-26 P02685331A0523 NNP O
, P02685331A0523 , O
the P02685331A0523 DT O
most P02685331A0523 RBS O
conserved P02685331A0523 JJ O
nucleotides P02685331A0523 NNS O
characteristic P02685331A0523 JJ O
of P02685331A0523 IN O
sigma P02685331A0523 JJ I-UN
54-dependent P02685331A0523 JJ I-UN
promoters P02685331A0523 NNS I-UN
. P02685331A0523 . O
. . O O

Interdomain P10455143T0000 NNP O
signaling P10455143T0000 VBG O
in P10455143T0000 IN O
a P10455143T0000 DT O
two-domain P10455143T0000 JJ O
fragment P10455143T0000 NN O
of P10455143T0000 IN O
the P10455143T0000 DT O
human P10455143T0000 JJ I-UN
glucocorticoid P10455143T0000 NN I-UN
receptor P10455143T0000 NN I-UN
. P10455143T0000 . O
. . O O

OBJECTIVES P11687083A0218 NN O
: P11687083A0218 : O
The P11687083A0218 DT O
objective P11687083A0218 NN O
of P11687083A0218 IN O
this P11687083A0218 DT O
review P11687083A0218 NN O
was P11687083A0218 VBD O
to P11687083A0218 TO O
assess P11687083A0218 VB O
the P11687083A0218 DT O
effects P11687083A0218 NNS O
of P11687083A0218 IN O
prophylactic P11687083A0218 JJ O
prostaglandin P11687083A0218 NN O
use P11687083A0218 NN O
in P11687083A0218 IN O
the P11687083A0218 DT O
third P11687083A0218 JJ O
stage P11687083A0218 NN O
of P11687083A0218 IN O
labour P11687083A0218 NN O
. P11687083A0218 . O
. . O O

Since P01927845A0107 IN O
the P01927845A0107 DT O
morphology P01927845A0107 NN O
of P01927845A0107 IN O
the P01927845A0107 DT O
lesions P01927845A0107 NNS O
can P01927845A0107 MD O
mimic P01927845A0107 VB O
that P01927845A0107 DT O
of P01927845A0107 IN O
other P01927845A0107 JJ O
cutaneous P01927845A0107 JJ O
disorders P01927845A0107 NNS O
, P01927845A0107 , O
Bowen P01927845A0107 NNP O
's P01927845A0107 POS O
disease P01927845A0107 NN O
is P01927845A0107 VBZ O
often P01927845A0107 RB O
not P01927845A0107 RB O
recognized P01927845A0107 VBN O
initially P01927845A0107 RB O
. P01927845A0107 . O
. . O O

A P03653226A0833 DT O
careful P03653226A0833 JJ O
, P03653226A0833 , O
radiolabelled P03653226A0833 VBD O
tissue-distribution P03653226A0833 NN O
study P03653226A0833 NN O
is P03653226A0833 VBZ O
warranted P03653226A0833 VBN O
to P03653226A0833 TO O
elucidate P03653226A0833 VB O
the P03653226A0833 DT O
complicated P03653226A0833 JJ O
metabolic P03653226A0833 JJ O
fate P03653226A0833 NN O
of P03653226A0833 IN O
perhexiline P03653226A0833 NN O
. P03653226A0833 . O
. . O O

The P07835888A0402 DT O
locus P07835888A0402 NN O
encoding P07835888A0402 VBG O
the P07835888A0402 DT O
XD P07835888A0402 NNP I-UN
gene P07835888A0402 NN I-UN
( P07835888A0402 ( O
designated P07835888A0402 VBN O
Xd P07835888A0402 NNP I-UN
) P07835888A0402 ) O
was P07835888A0402 VBD O
mapped P07835888A0402 VBN O
to P07835888A0402 TO O
the P07835888A0402 DT O
distal P07835888A0402 JJ O
part P07835888A0402 NN O
of P07835888A0402 IN O
mouse P07835888A0402 NN O
chromosome P07835888A0402 NN O
17 P07835888A0402 CD O
by P07835888A0402 IN O
haplotype P07835888A0402 JJ O
analysis P07835888A0402 NN O
of P07835888A0402 IN O
114 P07835888A0402 CD O
interspecific P07835888A0402 JJ O
backcross P07835888A0402 NN O
mice P07835888A0402 NN O
. P07835888A0402 . O
. . O O

Finally P11390663A1400 RB O
, P11390663A1400 , O
profiling P11390663A1400 VBG O
of P11390663A1400 IN O
a P11390663A1400 DT O
gcn4Delta P11390663A1400 NN I-UN
mutant P11390663A1400 NN I-UN
uncovered P11390663A1400 VBD O
an P11390663A1400 DT O
alternative P11390663A1400 JJ O
induction P11390663A1400 NN O
pathway P11390663A1400 NN O
operating P11390663A1400 VBG O
at P11390663A1400 IN O
many P11390663A1400 JJ O
Gcn4p P11390663A1400 NNP I-UN
target P11390663A1400 NN I-UN
genes P11390663A1400 NNS I-UN
in P11390663A1400 IN O
histidine-starved P11390663A1400 JJ O
cells P11390663A1400 NNS O
. P11390663A1400 . O
. . O O

A P11380370A0000 DT O
patient P11380370A0000 NN O
is P11380370A0000 VBZ O
described P11380370A0000 VBN O
with P11380370A0000 IN O
skin P11380370A0000 JJ O
lesions P11380370A0000 NNS O
resembling P11380370A0000 VBG O
Kaposi P11380370A0000 NNP O
's P11380370A0000 POS O
sarcoma P11380370A0000 NN O
( P11380370A0000 ( O
KS P11380370A0000 NNP O
) P11380370A0000 ) O
. P11380370A0000 . O
. . O O

We P02832744A0403 PRP O
detected P02832744A0403 VBD O
mos P02832744A0403 NNS I-UN
transcripts P02832744A0403 NNS I-UN
by P02832744A0403 IN O
Northern P02832744A0403 NNP O
( P02832744A0403 ( O
RNA P02832744A0403 NNP O
) P02832744A0403 ) O
analyses P02832744A0403 VBZ O
in P02832744A0403 IN O
RNA P02832744A0403 NNP O
prepared P02832744A0403 VBD O
from P02832744A0403 IN O
chicken P02832744A0403 NN O
and P02832744A0403 CC O
quail P02832744A0403 NN O
ovaries P02832744A0403 NNS O
and P02832744A0403 CC O
testes P02832744A0403 NNS O
. P02832744A0403 . O
. . O O

This P01347664A1026 DT O
mutation P01347664A1026 NN O
also P01347664A1026 RB O
results P01347664A1026 NNS O
in P01347664A1026 IN O
markedly P01347664A1026 RB O
decreased P01347664A1026 JJ O
levels P01347664A1026 NNS O
of P01347664A1026 IN O
CAD P01347664A1026 NNP I-UN
mRNA P01347664A1026 NN I-UN
and P01347664A1026 CC O
protein P01347664A1026 NN O
in P01347664A1026 IN O
the P01347664A1026 DT O
mutant P01347664A1026 NN O
. P01347664A1026 . O
. . O O

Second P08501030A0456 JJ O
, P08501030A0456 , O
nitrate P08501030A0456 JJ O
induction P08501030A0456 NN O
of P08501030A0456 IN O
aeg-46.5 P08501030A0456 JJ I-UN
operon P08501030A0456 NN I-UN
expression P08501030A0456 NN O
is P08501030A0456 VBZ O
substantially P08501030A0456 RB O
enhanced P08501030A0456 VBN O
in P08501030A0456 IN O
narL P08501030A0456 JJ I-UN
null P08501030A0456 JJ O
strains P08501030A0456 NNS O
( P08501030A0456 ( O
M.H P08501030A0456 NNP O
. P08501030A0456 . O
. . O O

The P11908529A0553 DT O
results P11908529A0553 NNS O
are P11908529A0553 VBP O
given P11908529A0553 VBN O
as P11908529A0553 IN O
: P11908529A0553 : O
flux P11908529A0553 NN O
, P11908529A0553 , O
number P11908529A0553 NN O
of P11908529A0553 IN O
stars P11908529A0553 NNS O
per P11908529A0553 IN O
cm3 P11908529A0553 NN O
, P11908529A0553 , O
charge P11908529A0553 NN O
of P11908529A0553 IN O
the P11908529A0553 DT O
ions P11908529A0553 NNS O
, P11908529A0553 , O
comparison P11908529A0553 NN O
with P11908529A0553 IN O
other P11908529A0553 JJ O
detectors P11908529A0553 NNS O
( P11908529A0553 ( O
plastics P11908529A0553 NNS O
, P11908529A0553 , O
AgCl P11908529A0553 NNP O
crystals P11908529A0553 NNS O
, P11908529A0553 , O
LiF P11908529A0553 NNP O
) P11908529A0553 ) O
, P11908529A0553 , O
energy P11908529A0553 NN O
loss P11908529A0553 NN O
, P11908529A0553 , O
hit P11908529A0553 JJ O
region P11908529A0553 NN O
in P11908529A0553 IN O
the P11908529A0553 DT O
biological P11908529A0553 JJ O
objects P11908529A0553 NNS O
. P11908529A0553 . O
. . O O

Leukocyte P07278104T0001 NNP O
enzyme P07278104T0001 NN O
activity P07278104T0001 NN O
and P07278104T0001 CC O
blood P07278104T0001 NN O
lymphocyte P07278104T0001 NN O
blast P07278104T0001 NN O
transformation P07278104T0001 NN O
in P07278104T0001 IN O
chronic P07278104T0001 JJ O
bronchitis P07278104T0001 NN O
. P07278104T0001 . O
. . O O

An P07571766A0122 DT O
abnormally P07571766A0122 RB O
high P07571766A0122 JJ O
percentage P07571766A0122 NN O
of P07571766A0122 IN O
hypertensive P07571766A0122 JJ O
patients P07571766A0122 NNS O
( P07571766A0122 ( O
approximately P07571766A0122 RB O
30 P07571766A0122 CD O
% P07571766A0122 NN O
) P07571766A0122 ) O
undergoing P07571766A0122 NN O
cardiac P07571766A0122 JJ O
catheterization P07571766A0122 NN O
because P07571766A0122 IN O
of P07571766A0122 IN O
anginal P07571766A0122 JJ O
pain P07571766A0122 NN O
and P07571766A0122 CC O
/ P07571766A0122 NN O
or P07571766A0122 CC O
exercise-induced P07571766A0122 JJ O
ST-segment P07571766A0122 JJ O
depressions P07571766A0122 NNS O
has P07571766A0122 VBZ O
angiographically P07571766A0122 RB O
normal P07571766A0122 JJ O
coronary P07571766A0122 JJ O
arteries P07571766A0122 NNS O
. P07571766A0122 . O
. . O O

Estral P04247472T0001 JJ O
cycle P04247472T0001 NN O
in P04247472T0001 IN O
white P04247472T0001 JJ O
rats P04247472T0001 NNS O
in P04247472T0001 IN O
the P04247472T0001 DT O
low P04247472T0001 JJ O
and P04247472T0001 CC O
high P04247472T0001 JJ O
mountains P04247472T0001 NNS O
of P04247472T0001 IN O
Kirghizia P04247472T0001 NNP O
. P04247472T0001 . O
. . O O

A P01539996A0588 DT O
comparison P01539996A0588 NN O
of P01539996A0588 IN O
the P01539996A0588 DT O
amino P01539996A0588 NN O
acid P01539996A0588 JJ O
sequence P01539996A0588 NN O
of P01539996A0588 IN O
the P01539996A0588 DT O
T. P01539996A0588 NNP O
thermophilus P01539996A0588 CC O
enzyme P01539996A0588 NN O
with P01539996A0588 IN O
that P01539996A0588 DT O
of P01539996A0588 IN O
the P01539996A0588 DT O
Escherichia P01539996A0588 NNP O
coli P01539996A0588 NN O
enzyme P01539996A0588 NN O
showed P01539996A0588 VBD O
( P01539996A0588 ( O
i P01539996A0588 NN O
) P01539996A0588 ) O
a P01539996A0588 DT O
37 P01539996A0588 CD O
% P01539996A0588 NN O
overall P01539996A0588 JJ O
similarity P01539996A0588 NN O
; P01539996A0588 : O
( P01539996A0588 ( O
ii P01539996A0588 NN O
) P01539996A0588 ) O
the P01539996A0588 DT O
conservation P01539996A0588 NN O
of P01539996A0588 IN O
the P01539996A0588 DT O
Ser P01539996A0588 NNP O
residue P01539996A0588 NN O
, P01539996A0588 , O
which P01539996A0588 WDT O
is P01539996A0588 VBZ O
known P01539996A0588 VBN O
to P01539996A0588 TO O
be P01539996A0588 VB O
phosphorylated P01539996A0588 VBN O
in P01539996A0588 IN O
the P01539996A0588 DT O
E. P01539996A0588 NNP O
coli P01539996A0588 NNS O
enzyme P01539996A0588 NN O
, P01539996A0588 , O
and P01539996A0588 CC O
of P01539996A0588 IN O
the P01539996A0588 DT O
surrounding P01539996A0588 VBG O
sequence P01539996A0588 NN O
; P01539996A0588 : O
and P01539996A0588 CC O
( P01539996A0588 ( O
iii P01539996A0588 NN O
) P01539996A0588 ) O
the P01539996A0588 DT O
presence P01539996A0588 NN O
of P01539996A0588 IN O
141 P01539996A0588 CD O
extra P01539996A0588 JJ O
residues P01539996A0588 NNS O
at P01539996A0588 IN O
the P01539996A0588 DT O
C P01539996A0588 NNP O
terminus P01539996A0588 NN O
of P01539996A0588 IN O
the P01539996A0588 DT O
T. P01539996A0588 NNP O
thermophilus P01539996A0588 NN O
enzyme P01539996A0588 NN O
. P01539996A0588 . O
. . O O

The P08070393A0631 DT O
maximal P08070393A0631 JJ O
effect P08070393A0631 NN O
was P08070393A0631 VBD O
seen P08070393A0631 VBN O
at P08070393A0631 IN O
100 P08070393A0631 CD O
ng P08070393A0631 JJ O
/ P08070393A0631 NNP O
ml P08070393A0631 NN O
EGF P08070393A0631 NNP I-UN
, P08070393A0631 , O
with P08070393A0631 IN O
a P08070393A0631 DT O
time P08070393A0631 NN O
lag P08070393A0631 NN O
of P08070393A0631 IN O
about P08070393A0631 IN O
5 P08070393A0631 CD O
h P08070393A0631 NN O
. P08070393A0631 . O
. . O O

During P08071356A0232 IN O
transcript P08071356A0232 JJ O
elongation P08071356A0232 NN O
, P08071356A0232 , O
the P08071356A0232 DT O
sizes P08071356A0232 NNS O
of P08071356A0232 IN O
the P08071356A0232 DT O
DNA P08071356A0232 NNP O
footprint P08071356A0232 NN O
and P08071356A0232 CC O
the P08071356A0232 DT O
single-stranded P08071356A0232 JJ O
transcription P08071356A0232 NN O
bubble P08071356A0232 JJ O
vary P08071356A0232 JJ O
markedly P08071356A0232 RB O
among P08071356A0232 IN O
transcription P08071356A0232 NN O
complexes P08071356A0232 NNS O
halted P08071356A0232 VBN O
at P08071356A0232 IN O
different P08071356A0232 JJ O
template P08071356A0232 NN O
positions P08071356A0232 NNS O
. P08071356A0232 . O
. . O O

Human P07494303A0000 NNP I-UN
immunodeficiency P07494303A0000 NN I-UN
virus P07494303A0000 NN I-UN
type P07494303A0000 NN I-UN
1 P07494303A0000 CD I-UN
Vpr P07494303A0000 NNP I-UN
is P07494303A0000 VBZ O
a P07494303A0000 DT O
virion-associated P07494303A0000 JJ O
, P07494303A0000 , O
regulatory P07494303A0000 JJ O
protein P07494303A0000 NN O
that P07494303A0000 WDT O
is P07494303A0000 VBZ O
required P07494303A0000 VBN O
for P07494303A0000 IN O
efficient P07494303A0000 JJ O
viral P07494303A0000 JJ O
replication P07494303A0000 NN O
in P07494303A0000 IN O
monocytes P07494303A0000 NNS O
/ P07494303A0000 JJ O
macrophages P07494303A0000 NNS O
. P07494303A0000 . O
. . O O

The P10400760A0663 DT O
results P10400760A0663 NNS O
of P10400760A0663 IN O
these P10400760A0663 DT O
analyses P10400760A0663 NNS O
indicate P10400760A0663 VBP O
that P10400760A0663 IN O
the P10400760A0663 DT O
proteinase P10400760A0663 NN O
cleaves P10400760A0663 VBZ O
at P10400760A0663 IN O
amino P10400760A0663 NN O
acid P10400760A0663 NN O
residues P10400760A0663 VBZ O
E960-A961 P10400760A0663 NNP O
, P10400760A0663 , O
E1071-S1072 P10400760A0663 NNP O
, P10400760A0663 , O
E1345-T1346 P10400760A0663 NNP O
, P10400760A0663 , O
and P10400760A0663 CC O
E1419-G1420 P10400760A0663 NNP O
; P10400760A0663 : O
however P10400760A0663 RB O
, P10400760A0663 , O
the P10400760A0663 DT O
cleavage P10400760A0663 NN O
efficiency P10400760A0663 NN O
is P10400760A0663 VBZ O
varied P10400760A0663 VBN O
. P10400760A0663 . O
. . O O

Factors P05020660T0000 NNS O
affecting P05020660T0000 VBG O
the P05020660T0000 DT O
inhibition P05020660T0000 NN O
of P05020660T0000 IN O
phagocytosis P05020660T0000 NN O
by P05020660T0000 IN O
chlorpromazine P05020660T0000 NN O
. P05020660T0000 . O
. . O O

Mental P11162278A0629 JJ O
rotation P11162278A0629 NN O
of P11162278A0629 IN O
paired P11162278A0629 JJ O
figures P11162278A0629 NNS O
engendered P11162278A0629 VBN O
activation P11162278A0629 NN O
in P11162278A0629 IN O
the P11162278A0629 DT O
left P11162278A0629 NN O
superior P11162278A0629 JJ O
parietal P11162278A0629 JJ O
lobule P11162278A0629 NN O
and P11162278A0629 CC O
the P11162278A0629 DT O
right P11162278A0629 JJ O
frontal P11162278A0629 JJ O
medial P11162278A0629 JJ O
gyrus P11162278A0629 NN O
. P11162278A0629 . O
. . O O

A P00221136A0984 DT O
similar P00221136A0984 JJ O
phenomenon P00221136A0984 NN O
has P00221136A0984 VBZ O
been P00221136A0984 VBN O
reported P00221136A0984 VBN O
in P00221136A0984 IN O
a P00221136A0984 DT O
few P00221136A0984 JJ O
humans P00221136A0984 NNS O
. P00221136A0984 . O
. . O O

Thirty P07431059A0000 NNP O
cadaver P07431059A0000 NN O
brains P07431059A0000 NNS O
were P07431059A0000 VBD O
examined P07431059A0000 VBN O
under P07431059A0000 IN O
X P07431059A0000 $ O
6 P07431059A0000 CD O
to P07431059A0000 TO O
16 P07431059A0000 CD O
magnification P07431059A0000 NN O
in P07431059A0000 IN O
order P07431059A0000 NN O
to P07431059A0000 TO O
define P07431059A0000 VB O
the P07431059A0000 DT O
microsurgical P07431059A0000 JJ O
anatomy P07431059A0000 NN O
of P07431059A0000 IN O
the P07431059A0000 DT O
pineal P07431059A0000 JJ O
region P07431059A0000 NN O
, P07431059A0000 , O
particularly P07431059A0000 RB O
the P07431059A0000 DT O
relationship P07431059A0000 NN O
of P07431059A0000 IN O
the P07431059A0000 DT O
pineal P07431059A0000 NN O
body P07431059A0000 NN O
, P07431059A0000 , O
posterior P07431059A0000 JJ O
cerebral P07431059A0000 JJ O
artery P07431059A0000 NN O
, P07431059A0000 , O
superior P07431059A0000 JJ O
cerebellar P07431059A0000 JJ O
artery P07431059A0000 NN O
, P07431059A0000 , O
vein P07431059A0000 NN O
of P07431059A0000 IN O
Galen P07431059A0000 NNP O
, P07431059A0000 , O
basal P07431059A0000 NN O
vein P07431059A0000 NN O
of P07431059A0000 IN O
Rosenthal P07431059A0000 NNP O
, P07431059A0000 , O
internal P07431059A0000 JJ O
cerebral P07431059A0000 JJ O
vein P07431059A0000 NN O
, P07431059A0000 , O
straight P07431059A0000 JJ O
sinus P07431059A0000 NN O
, P07431059A0000 , O
bridging P07431059A0000 VBG O
vein P07431059A0000 NN O
, P07431059A0000 , O
the P07431059A0000 DT O
size P07431059A0000 NN O
of P07431059A0000 IN O
the P07431059A0000 DT O
tentorial P07431059A0000 JJ O
notch P07431059A0000 NN O
, P07431059A0000 , O
and P07431059A0000 CC O
the P07431059A0000 DT O
third P07431059A0000 JJ O
and P07431059A0000 CC O
the P07431059A0000 DT O
fourth P07431059A0000 JJ O
cranial P07431059A0000 JJ O
nerves P07431059A0000 NNS O
. P07431059A0000 . O
. . O O

Polypeptide P07576178A0000 NNP O
growth P07576178A0000 NN O
factors P07576178A0000 NNS O
and P07576178A0000 CC O
cytokines P07576178A0000 NNS O
mediate P07576178A0000 VBP O
their P07576178A0000 PRP$ O
biochemical P07576178A0000 JJ O
functions P07576178A0000 NNS O
through P07576178A0000 IN O
their P07576178A0000 PRP$ O
responsive P07576178A0000 JJ O
receptors P07576178A0000 NNS O
. P07576178A0000 . O
. . O O

HBx P07937954A0612 NNP I-UN
strongly P07937954A0612 RB O
elevates P07937954A0612 VBZ O
levels P07937954A0612 NNS O
of P07937954A0612 IN O
GTP-bound P07937954A0612 NNP O
Ras P07937954A0612 NNP I-UN
, P07937954A0612 , O
activated P07937954A0612 VBD O
and P07937954A0612 CC O
phosphorylated P07937954A0612 VBD O
Raf P07937954A0612 NNP I-UN
, P07937954A0612 , O
and P07937954A0612 CC O
tyrosine-phosphorylated P07937954A0612 JJ O
and P07937954A0612 CC O
activated P07937954A0612 JJ O
MAP P07937954A0612 NNP I-UN
kinase P07937954A0612 NN I-UN
. P07937954A0612 . O
. . O O

Moreover P09356645A0672 RB O
, P09356645A0672 , O
in P09356645A0672 IN O
one P09356645A0672 CD O
patient P09356645A0672 NN O
with P09356645A0672 IN O
a P09356645A0672 DT O
sarcoma P09356645A0672 NN O
who P09356645A0672 WP O
underwent P09356645A0672 VBD O
a P09356645A0672 DT O
leg-sparing P09356645A0672 JJ O
procedure P09356645A0672 NN O
, P09356645A0672 , O
no P09356645A0672 DT O
sciatic P09356645A0672 JJ O
nerve P09356645A0672 NN O
enlargement P09356645A0672 NN O
was P09356645A0672 VBD O
seen P09356645A0672 VBN O
postoperatively P09356645A0672 RB O
. P09356645A0672 . O
. . O O

A P11208017A0070 DT O
cDNA P11208017A0070 NN O
clone P11208017A0070 NN O
encoding P11208017A0070 VBG O
C2H2-type P11208017A0070 NNP I-UN
zinc P11208017A0070 NN I-UN
finger P11208017A0070 NN I-UN
protein P11208017A0070 NN I-UN
, P11208017A0070 , O
SCOF-1 P11208017A0070 NNP I-UN
, P11208017A0070 , O
was P11208017A0070 VBD O
isolated P11208017A0070 VBN O
from P11208017A0070 IN O
soybean P11208017A0070 NN O
. P11208017A0070 . O
. . O O

Our P11408604A1440 PRP$ O
results P11408604A1440 NNS O
indicate P11408604A1440 VBP O
that P11408604A1440 IN O
D P11408604A1440 NNP O
( P11408604A1440 ( O
4 P11408604A1440 CD O
) P11408604A1440 ) O
and P11408604A1440 CC O
D P11408604A1440 NNP O
( P11408604A1440 ( O
2L P11408604A1440 CD O
) P11408604A1440 ) O
receptors P11408604A1440 NNS O
activate P11408604A1440 VBP O
the P11408604A1440 DT O
ERK P11408604A1440 NNP I-UN
kinase P11408604A1440 NN I-UN
cascade P11408604A1440 NN O
by P11408604A1440 IN O
first P11408604A1440 JJ O
mobilizing P11408604A1440 VBG O
signaling P11408604A1440 NN O
by P11408604A1440 IN O
the P11408604A1440 DT O
PDGF P11408604A1440 NNP I-UN
receptor P11408604A1440 NN I-UN
, P11408604A1440 , O
followed P11408604A1440 VBN O
by P11408604A1440 IN O
the P11408604A1440 DT O
subsequent P11408604A1440 JJ O
activation P11408604A1440 NN O
of P11408604A1440 IN O
ERK1 P11408604A1440 NNP I-UN
/ P11408604A1440 NNP I-UN
2 P11408604A1440 CD I-UN
by P11408604A1440 IN O
pathways P11408604A1440 NNS O
associated P11408604A1440 VBN O
with P11408604A1440 IN O
this P11408604A1440 DT O
receptor P11408604A1440 NN I-UN
tyrosine P11408604A1440 NN I-UN
kinase P11408604A1440 NN I-UN
. P11408604A1440 . O
. . O O

Vertebrate P08627354A0000 NNP I-UN
synapsins P08627354A0000 NNS I-UN
constitute P08627354A0000 VBP O
a P08627354A0000 DT O
family P08627354A0000 NN O
of P08627354A0000 IN O
synaptic P08627354A0000 JJ O
proteins P08627354A0000 NNS O
that P08627354A0000 WDT O
participate P08627354A0000 VBP O
in P08627354A0000 IN O
the P08627354A0000 DT O
regulation P08627354A0000 NN O
of P08627354A0000 IN O
neurotransmitter P08627354A0000 JJ O
release P08627354A0000 NN O
. P08627354A0000 . O
. . O O

Apoptosis P10597317A1156 NN O
of P10597317A1156 IN O
small P10597317A1156 JJ O
cells P10597317A1156 NNS O
is P10597317A1156 VBZ O
still P10597317A1156 RB O
observed P10597317A1156 VBN O
after P10597317A1156 IN O
co-transfection P10597317A1156 NN O
of P10597317A1156 IN O
JBD P10597317A1156 NNP I-UN
and P10597317A1156 CC O
LMP1 P10597317A1156 NNP I-UN
but P10597317A1156 CC O
in P10597317A1156 IN O
addition P10597317A1156 NN O
a P10597317A1156 DT O
few P10597317A1156 JJ O
apoptotic P10597317A1156 JJ O
HD-MyZ P10597317A1156 NNP O
cells P10597317A1156 NNS O
with P10597317A1156 IN O
large P10597317A1156 JJ O
fused P10597317A1156 JJ O
nuclear P10597317A1156 JJ O
masses P10597317A1156 NNS O
are P10597317A1156 VBP O
identified P10597317A1156 VBN O
suggesting P10597317A1156 VBG O
that P10597317A1156 IN O
specific P10597317A1156 JJ O
inhibition P10597317A1156 NN O
of P10597317A1156 IN O
JNK P10597317A1156 NNP I-UN
leads P10597317A1156 VBZ O
also P10597317A1156 RB O
to P10597317A1156 TO O
apoptosis P10597317A1156 NN O
of P10597317A1156 IN O
LMP1 P10597317A1156 NNP I-UN
induced P10597317A1156 VBD O
RS P10597317A1156 NNP O
cells P10597317A1156 NNS O
. P10597317A1156 . O
. . O O

B P08871635A0000 NNP I-UN
cell P08871635A0000 NN I-UN
antigen P08871635A0000 NN I-UN
receptor P08871635A0000 NN I-UN
( P08871635A0000 ( O
BCR P08871635A0000 NNP I-UN
) P08871635A0000 ) O
-induced P08871635A0000 VBD O
apoptosis P08871635A0000 NN O
in P08871635A0000 IN O
the P08871635A0000 DT O
WEHI-231 P08871635A0000 NNP O
B P08871635A0000 NNP O
lymphoma P08871635A0000 NN O
cell P08871635A0000 NN O
line P08871635A0000 NN O
can P08871635A0000 MD O
be P08871635A0000 VB O
prevented P08871635A0000 VBN O
by P08871635A0000 IN O
engaging P08871635A0000 VBG O
CD40 P08871635A0000 NNP I-UN
. P08871635A0000 . O
. . O O

Their P09283828A0484 PRP$ O
circadian P09283828A0484 JJ O
responses P09283828A0484 NNS O
to P09283828A0484 TO O
both P09283828A0484 DT O
photic P09283828A0484 JJ O
and P09283828A0484 CC O
non-photic P09283828A0484 JJ O
cues P09283828A0484 NNS O
were P09283828A0484 VBD O
then P09283828A0484 RB O
tested P09283828A0484 VBN O
. P09283828A0484 . O
. . O O

Underestimations P07395750A0294 NNS O
by P07395750A0294 IN O
as P07395750A0294 RB O
much P07395750A0294 JJ O
as P07395750A0294 IN O
35 P07395750A0294 CD O
% P07395750A0294 NN O
may P07395750A0294 MD O
occur P07395750A0294 VB O
due P07395750A0294 JJ O
to P07395750A0294 TO O
the P07395750A0294 DT O
problems P07395750A0294 NNS O
in P07395750A0294 IN O
the P07395750A0294 DT O
existing P07395750A0294 VBG O
methodologies P07395750A0294 NNS O
. P07395750A0294 . O
. . O O

There P08435885A0787 EX O
was P08435885A0787 VBD O
a P08435885A0787 DT O
positive P08435885A0787 JJ O
correlation P08435885A0787 NN O
between P08435885A0787 IN O
pyridinium P08435885A0787 NN O
cross-link P08435885A0787 NN O
excretion P08435885A0787 NN O
and P08435885A0787 CC O
thyroid P08435885A0787 VB O
hormone P08435885A0787 NN O
concentrations P08435885A0787 NNS O
. P08435885A0787 . O
. . O O

The P10727426A1280 DT O
kinase P10727426A1280 NN O
activity P10727426A1280 NN O
of P10727426A1280 IN O
PfPK6 P10727426A1280 NNP I-UN
is P10727426A1280 VBZ O
sensitive P10727426A1280 JJ O
to P10727426A1280 TO O
CDK P10727426A1280 NNP I-UN
inhibitors P10727426A1280 NNS O
such P10727426A1280 JJ O
as P10727426A1280 IN O
olomoucine P10727426A1280 NN O
and P10727426A1280 CC O
roscovitine P10727426A1280 NN O
. P10727426A1280 . O
. . O O

Papers P03407843T0000 NNS O
of P03407843T0000 IN O
the P03407843T0000 DT O
Society P03407843T0000 NNP O
for P03407843T0000 IN O
Clinical P03407843T0000 NNP O
Vascular P03407843T0000 NNP O
Surgery P03407843T0000 NNP O
. P03407843T0000 . O
. . O O

We P10469140A0336 PRP O
have P10469140A0336 VBP O
tested P10469140A0336 VBN O
the P10469140A0336 DT O
function P10469140A0336 NN O
of P10469140A0336 IN O
two P10469140A0336 CD O
potential P10469140A0336 JJ O
NF-kappaB-like P10469140A0336 JJ I-UN
sites P10469140A0336 NNS I-UN
present P10469140A0336 JJ O
in P10469140A0336 IN O
the P10469140A0336 DT O
PAI-2 P10469140A0336 NNP I-UN
proximal P10469140A0336 JJ I-UN
promoter P10469140A0336 NN I-UN
for P10469140A0336 IN O
responsiveness P10469140A0336 NN O
to P10469140A0336 TO O
TNFalpha P10469140A0336 NNP I-UN
using P10469140A0336 VBG O
chloramphenicol P10469140A0336 NN I-UN
acetyl P10469140A0336 JJ I-UN
transferase P10469140A0336 NN I-UN
reporter P10469140A0336 NN I-UN
gene P10469140A0336 NN I-UN
deletion P10469140A0336 NN O
and P10469140A0336 CC O
mutation P10469140A0336 NN O
analyses P10469140A0336 NNS O
. P10469140A0336 . O
. . O O

Inhibition P11525640A0560 NN O
of P11525640A0560 IN O
JNK1 P11525640A0560 NNP I-UN
and P11525640A0560 CC O
ERK P11525640A0560 NNP I-UN
kinase P11525640A0560 NNP O
activities P11525640A0560 NNS O
either P11525640A0560 CC O
by P11525640A0560 IN O
expression P11525640A0560 NN O
of P11525640A0560 IN O
the P11525640A0560 DT O
dominant P11525640A0560 JJ O
negative P11525640A0560 JJ O
mutant P11525640A0560 NN O
JNK1 P11525640A0560 NNP I-UN
or P11525640A0560 CC O
by P11525640A0560 IN O
treatment P11525640A0560 NN O
with P11525640A0560 IN O
a P11525640A0560 DT O
selective P11525640A0560 JJ O
chemical P11525640A0560 NN O
inhibitor P11525640A0560 NN O
of P11525640A0560 IN O
ERK P11525640A0560 NNP I-UN
( P11525640A0560 ( O
PD098059 P11525640A0560 NNP O
) P11525640A0560 ) O
substantially P11525640A0560 RB O
abrogates P11525640A0560 VBZ O
the P11525640A0560 DT O
UV P11525640A0560 NNP O
induction P11525640A0560 NN O
of P11525640A0560 IN O
the P11525640A0560 DT O
GADD45 P11525640A0560 NNP I-UN
promoter P11525640A0560 NN I-UN
. P11525640A0560 . O
. . O O

Vancomycin P10801244A0578 NNP O
data P10801244A0578 NNS O
were P10801244A0578 VBD O
analyzed P10801244A0578 VBN O
according P10801244A0578 VBG O
to P10801244A0578 TO O
a P10801244A0578 DT O
one-compartment P10801244A0578 JJ O
open P10801244A0578 JJ O
model P10801244A0578 NN O
with P10801244A0578 IN O
use P10801244A0578 NN O
of P10801244A0578 IN O
NONMEM P10801244A0578 NNP O
population P10801244A0578 NN O
pharmacokinetic P10801244A0578 JJ O
software P10801244A0578 NN O
. P10801244A0578 . O
. . O O

In P09234713A0754 IN O
this P09234713A0754 DT O
study P09234713A0754 NN O
, P09234713A0754 , O
we P09234713A0754 PRP O
tested P09234713A0754 VBD O
this P09234713A0754 DT O
notion P09234713A0754 NN O
by P09234713A0754 IN O
using P09234713A0754 VBG O
ligation-mediated P09234713A0754 JJ O
PCR P09234713A0754 NNP O
to P09234713A0754 TO O
assess P09234713A0754 VB O
the P09234713A0754 DT O
formation P09234713A0754 NN O
of P09234713A0754 IN O
recombination-activating P09234713A0754 JJ I-UN
gene P09234713A0754 NN I-UN
( P09234713A0754 ( O
RAG P09234713A0754 NNP I-UN
) P09234713A0754 ) O
-dependent P09234713A0754 VBD O
double-strand P09234713A0754 NN O
breaks P09234713A0754 NNS O
( P09234713A0754 ( O
DSBs P09234713A0754 NNP O
) P09234713A0754 ) O
at P09234713A0754 IN O
RSSs P09234713A0754 NNP O
3 P09234713A0754 CD O
' P09234713A0754 '' O
of P09234713A0754 IN O
Ddelta3 P09234713A0754 NNP I-UN
and P09234713A0754 CC O
5 P09234713A0754 CD O
' P09234713A0754 '' O
of P09234713A0754 IN O
Jdelta1 P09234713A0754 NNP I-UN
. P09234713A0754 . O
. . O O

A P10430583A0000 DT O
new P10430583A0000 JJ O
DNA P10430583A0000 NNP I-UN
repair P10430583A0000 NN I-UN
gene P10430583A0000 NN I-UN
from P10430583A0000 IN O
Schizosaccharomyces P10430583A0000 NNS O
pombe P10430583A0000 VBP O
with P10430583A0000 IN O
homology P10430583A0000 NN O
to P10430583A0000 TO O
RecA P10430583A0000 NNP I-UN
was P10430583A0000 VBD O
identified P10430583A0000 VBN O
and P10430583A0000 CC O
characterized P10430583A0000 VBN O
. P10430583A0000 . O
. . O O

The P03690262A0428 DT O
maximum P03690262A0428 JJ O
amplitude P03690262A0428 NN O
of P03690262A0428 IN O
evoked P03690262A0428 JJ O
responses P03690262A0428 NNS O
in P03690262A0428 IN O
the P03690262A0428 DT O
cervical P03690262A0428 JJ O
sympathetic P03690262A0428 JJ O
trunk P03690262A0428 NN O
was P03690262A0428 VBD O
obtained P03690262A0428 VBN O
when P03690262A0428 WRB O
the P03690262A0428 DT O
T2 P03690262A0428 NNP O
white P03690262A0428 JJ O
ramus P03690262A0428 NN O
was P03690262A0428 VBD O
stimulated P03690262A0428 VBN O
and P03690262A0428 CC O
decreased P03690262A0428 VBN O
gradually P03690262A0428 RB O
when P03690262A0428 WRB O
followed P03690262A0428 VBN O
by P03690262A0428 IN O
the P03690262A0428 DT O
stimulation P03690262A0428 NN O
of P03690262A0428 IN O
T1 P03690262A0428 NNP O
, P03690262A0428 , O
T3 P03690262A0428 NNP O
, P03690262A0428 , O
T4 P03690262A0428 NNP O
and P03690262A0428 CC O
T5 P03690262A0428 NNP O
white P03690262A0428 JJ O
rami P03690262A0428 NN O
. P03690262A0428 . O
. . O O

In P01301171A0979 IN O
7 P01301171A0979 CD O
of P01301171A0979 IN O
9 P01301171A0979 CD O
cases P01301171A0979 NNS O
, P01301171A0979 , O
the P01301171A0979 DT O
enhancer P01301171A0979 NN O
is P01301171A0979 VBZ O
fused P01301171A0979 VBN O
to P01301171A0979 TO O
the P01301171A0979 DT O
c-myc P01301171A0979 JJ I-UN
bearing P01301171A0979 NN I-UN
sequences P01301171A0979 NNS I-UN
of P01301171A0979 IN O
chromosome P01301171A0979 NN O
8 P01301171A0979 CD O
. P01301171A0979 . O
. . O O

We P10674395A0262 PRP O
have P10674395A0262 VBP O
previously P10674395A0262 RB O
demonstrated P10674395A0262 VBN O
that P10674395A0262 IN O
expression P10674395A0262 NN O
of P10674395A0262 IN O
the P10674395A0262 DT O
gene P10674395A0262 NN O
for P10674395A0262 IN O
the P10674395A0262 DT O
reproductive P10674395A0262 JJ O
neuropeptide P10674395A0262 NN O
, P10674395A0262 , O
GnRH P10674395A0262 NNP I-UN
, P10674395A0262 , O
is P10674395A0262 VBZ O
repressed P10674395A0262 VBN O
by P10674395A0262 IN O
the P10674395A0262 DT O
glutamate P10674395A0262 NN O
/ P10674395A0262 VBZ O
NO P10674395A0262 NNP O
/ P10674395A0262 NNP O
cyclic P10674395A0262 JJ O
GMP P10674395A0262 NNP O
( P10674395A0262 ( O
cGMP P10674395A0262 NN O
) P10674395A0262 ) O
signal P10674395A0262 NN O
transduction P10674395A0262 NN O
pathway P10674395A0262 RB O
through P10674395A0262 IN O
cGMP-dependent P10674395A0262 JJ I-UN
protein P10674395A0262 NN I-UN
kinase P10674395A0262 NN I-UN
in P10674395A0262 IN O
the P10674395A0262 DT O
hypothalamic P10674395A0262 JJ O
GnRH-secreting P10674395A0262 NNP O
neuronal P10674395A0262 JJ O
cell P10674395A0262 NN O
line P10674395A0262 NN O
GT1-7 P10674395A0262 NNP O
. P10674395A0262 . O
. . O O

A P08538052A0000 DT O
human P08538052A0000 JJ O
recombinant P08538052A0000 NN O
cDNA P08538052A0000 NN O
clone P08538052A0000 NN O
that P08538052A0000 WDT O
encoded P08538052A0000 VBD O
253 P08538052A0000 CD O
amino P08538052A0000 NN O
acids P08538052A0000 NNS O
residues P08538052A0000 NNS O
of P08538052A0000 IN O
a P08538052A0000 DT O
zinc-finger P08538052A0000 JJ I-UN
protein P08538052A0000 NN I-UN
( P08538052A0000 ( O
THZif-1 P08538052A0000 NNP I-UN
) P08538052A0000 ) O
was P08538052A0000 VBD O
cloned P08538052A0000 VBN O
by P08538052A0000 IN O
screening P08538052A0000 VBG O
a P08538052A0000 DT O
cDNA P08538052A0000 NN O
library P08538052A0000 NN O
prepared P08538052A0000 VBD O
from P08538052A0000 IN O
human P08538052A0000 JJ O
promyelocytic P08538052A0000 JJ O
leukemia P08538052A0000 NN O
HL60 P08538052A0000 NNP O
cells P08538052A0000 NNS O
with P08538052A0000 IN O
synthetic P08538052A0000 JJ O
oligodeoxynucleotide P08538052A0000 NN O
probes P08538052A0000 NNS O
that P08538052A0000 WDT O
corresponded P08538052A0000 VBD O
to P08538052A0000 TO O
the P08538052A0000 DT O
amino P08538052A0000 NN O
acid P08538052A0000 JJ O
sequences P08538052A0000 NNS O
of P08538052A0000 IN O
tryptic P08538052A0000 JJ O
peptides P08538052A0000 NNS O
derived P08538052A0000 VBN O
from P08538052A0000 IN O
the P08538052A0000 DT O
DNA-binding P08538052A0000 NNP O
protein P08538052A0000 NN O
specific P08538052A0000 NN O
for P08538052A0000 IN O
the P08538052A0000 DT O
nuclease-hypersensitive P08538052A0000 JJ I-UN
element P08538052A0000 NN I-UN
( P08538052A0000 ( O
NHE P08538052A0000 NNP I-UN
) P08538052A0000 ) O
of P08538052A0000 IN O
the P08538052A0000 DT O
human P08538052A0000 JJ I-UN
c-myc P08538052A0000 JJ I-UN
gene P08538052A0000 NN I-UN
. P08538052A0000 . O
. . O O

Although P08043523A0000 IN O
elevated P08043523A0000 VBN O
serum P08043523A0000 NN O
levels P08043523A0000 NNS O
of P08043523A0000 IN O
antibodies P08043523A0000 NNS O
to P08043523A0000 TO O
the P08043523A0000 DT O
nicotinic P08043523A0000 JJ I-UN
acetylcholine P08043523A0000 NN I-UN
receptor P08043523A0000 NN I-UN
( P08043523A0000 ( O
nAChR P08043523A0000 NN I-UN
) P08043523A0000 ) O
have P08043523A0000 VBP O
been P08043523A0000 VBN O
reported P08043523A0000 VBN O
in P08043523A0000 IN O
neuroleptic P08043523A0000 JJ O
treated P08043523A0000 VBD O
patients P08043523A0000 NNS O
with P08043523A0000 IN O
tardive P08043523A0000 JJ O
dyskinesia P08043523A0000 NN O
, P08043523A0000 , O
such P08043523A0000 JJ O
antibodies P08043523A0000 NNS O
have P08043523A0000 VBP O
not P08043523A0000 RB O
been P08043523A0000 VBN O
determined P08043523A0000 VBN O
in P08043523A0000 IN O
comparable P08043523A0000 JJ O
nondyskinetic P08043523A0000 JJ O
patients P08043523A0000 NNS O
. P08043523A0000 . O
. . O O

The P11773168A0915 DT O
5-year P11773168A0915 JJ O
overall P11773168A0915 JJ O
survival P11773168A0915 NN O
( P11773168A0915 ( O
OS P11773168A0915 NNP O
) P11773168A0915 ) O
and P11773168A0915 CC O
progression-free P11773168A0915 JJ O
survival P11773168A0915 NN O
( P11773168A0915 ( O
PFS P11773168A0915 NNP O
) P11773168A0915 ) O
rates P11773168A0915 NNS O
were P11773168A0915 VBD O
58.9 P11773168A0915 CD O
% P11773168A0915 NN O
and P11773168A0915 CC O
55.4 P11773168A0915 CD O
% P11773168A0915 NN O
for P11773168A0915 IN O
arm P11773168A0915 NN O
A P11773168A0915 NNP O
and P11773168A0915 CC O
44.5 P11773168A0915 CD O
% P11773168A0915 NN O
and P11773168A0915 CC O
41.3 P11773168A0915 CD O
% P11773168A0915 NN O
for P11773168A0915 IN O
arm P11773168A0915 NN O
B P11773168A0915 NNP O
( P11773168A0915 ( O
P P11773168A0915 NNP O
=.007 P11773168A0915 NNP O
and P11773168A0915 CC O
P P11773168A0915 NNP O
=.02 P11773168A0915 NNP O
) P11773168A0915 ) O
, P11773168A0915 , O
respectively P11773168A0915 RB O
. P11773168A0915 . O
. . O O

The P06625058A0666 DT O
population P06625058A0666 NN O
of P06625058A0666 IN O
between P06625058A0666 IN O
75,000 P06625058A0666 CD O
and P06625058A0666 CC O
100,000 P06625058A0666 CD O
was P06625058A0666 VBD O
largely P06625058A0666 RB O
unstable P06625058A0666 JJ O
, P06625058A0666 , O
and P06625058A0666 CC O
cost P06625058A0666 NN O
per P06625058A0666 IN O
capita P06625058A0666 NN O
was P06625058A0666 VBD O
$ P06625058A0666 $ O
0.95 P06625058A0666 CD O
to P06625058A0666 TO O
$ P06625058A0666 $ O
1.21 P06625058A0666 CD O
. P06625058A0666 . O
. . O O

These P08187085A0086 DT O
rearrangements P08187085A0086 NNS O
result P08187085A0086 VBP O
in P08187085A0086 IN O
the P08187085A0086 DT O
formation P08187085A0086 NN O
of P08187085A0086 IN O
chimeric P08187085A0086 JJ O
genes P08187085A0086 NNS O
showing P08187085A0086 VBG O
the P08187085A0086 DT O
tyrosine P08187085A0086 JJ I-UN
kinase P08187085A0086 NN I-UN
domain P08187085A0086 NN I-UN
of P08187085A0086 IN O
ret P08187085A0086 NNS I-UN
fused P08187085A0086 VBN O
with P08187085A0086 IN O
the P08187085A0086 DT O
5 P08187085A0086 CD O
' P08187085A0086 POS O
end P08187085A0086 NN O
sequences P08187085A0086 NNS O
of P08187085A0086 IN O
different P08187085A0086 JJ O
genes P08187085A0086 NNS O
. P08187085A0086 . O
. . O O

( P10938109A1361 ( O
iii P10938109A1361 NN O
) P10938109A1361 ) O
In P10938109A1361 IN O
these P10938109A1361 DT O
cells P10938109A1361 NNS O
, P10938109A1361 , O
PKCbeta P10938109A1361 NNP I-UN
plays P10938109A1361 VBZ O
a P10938109A1361 DT O
unique P10938109A1361 JJ O
Ras-independent P10938109A1361 JJ O
role P10938109A1361 NN O
in P10938109A1361 IN O
mediating P10938109A1361 VBG O
insulin P10938109A1361 NN I-UN
but P10938109A1361 CC O
not P10938109A1361 RB O
EGF P10938109A1361 NNP I-UN
or P10938109A1361 CC O
other P10938109A1361 JJ O
growth P10938109A1361 NN O
factor P10938109A1361 NN O
mitogenic P10938109A1361 JJ O
signals P10938109A1361 NNS O
. P10938109A1361 . O
. . O O

This P09751166A1460 DT O
and P09751166A1460 CC O
previous P09751166A1460 JJ O
results P09751166A1460 NNS O
suggest P09751166A1460 VBP O
that P09751166A1460 IN O
the P09751166A1460 DT O
CRE P09751166A1460 NNP O
and P09751166A1460 CC O
Sp1 P09751166A1460 NNP I-UN
site P09751166A1460 NN I-UN
may P09751166A1460 MD O
synergistically P09751166A1460 RB O
activate P09751166A1460 VB O
TH P09751166A1460 NNP I-UN
transcription P09751166A1460 NN O
in P09751166A1460 IN O
a P09751166A1460 DT O
promoter P09751166A1460 NN O
context-dependent P09751166A1460 JJ O
manner P09751166A1460 NN O
. P09751166A1460 . O
. . O O

A P08015850A1076 DT O
more P08015850A1076 RBR O
complete P08015850A1076 JJ O
analysis P08015850A1076 NN O
of P08015850A1076 IN O
dose P08015850A1076 JJ O
response P08015850A1076 NN O
, P08015850A1076 , O
time P08015850A1076 NN O
and P08015850A1076 CC O
mode P08015850A1076 NN O
of P08015850A1076 IN O
Ga P08015850A1076 NNP O
administration P08015850A1076 NN O
( P08015850A1076 ( O
preinjury P08015850A1076 NN O
or P08015850A1076 CC O
postinjury P08015850A1076 NN O
) P08015850A1076 ) O
, P08015850A1076 , O
and P08015850A1076 CC O
availability P08015850A1076 NN O
of P08015850A1076 IN O
Ga P08015850A1076 NNP O
across P08015850A1076 IN O
the P08015850A1076 DT O
blood-brain P08015850A1076 NN O
barrier P08015850A1076 NN O
is P08015850A1076 VBZ O
needed P08015850A1076 VBN O
to P08015850A1076 TO O
further P08015850A1076 RBR O
evaluate P08015850A1076 VB O
the P08015850A1076 DT O
efficacy P08015850A1076 NN O
of P08015850A1076 IN O
this P08015850A1076 DT O
compound P08015850A1076 NN O
. P08015850A1076 . O
. . O O

Following P09288848A0780 VBG O
2.5 P09288848A0780 CD O
Gy P09288848A0780 NNP O
, P09288848A0780 , O
HbO2 P09288848A0780 NNP I-UN
changes P09288848A0780 NNS O
were P09288848A0780 VBD O
minimal P09288848A0780 JJ O
. P09288848A0780 . O
. . O O

CASE P09739913A0194 JJ O
REPORT P09739913A0194 NNP O
: P09739913A0194 : O
We P09739913A0194 PRP O
observed P09739913A0194 VBD O
a P09739913A0194 DT O
congenital P09739913A0194 JJ O
skin P09739913A0194 NN O
defect P09739913A0194 NN O
located P09739913A0194 VBN O
exclusively P09739913A0194 RB O
on P09739913A0194 IN O
the P09739913A0194 DT O
trunk P09739913A0194 NN O
. P09739913A0194 . O
. . O O

The P07622058A0411 DT O
PEBP2 P07622058A0411 NNP I-UN
alpha P07622058A0411 NN I-UN
proteins P07622058A0411 VBZ I-UN
contain P07622058A0411 VB O
a P07622058A0411 DT O
128-amino-acid P07622058A0411 JJ O
( P07622058A0411 ( O
aa P07622058A0411 NN O
) P07622058A0411 ) O
region P07622058A0411 NN O
highly P07622058A0411 RB O
homologous P07622058A0411 JJ O
to P07622058A0411 TO O
the P07622058A0411 DT O
Drosophila P07622058A0411 NNP I-UN
melanogaster P07622058A0411 NN I-UN
segmentation P07622058A0411 NN I-UN
gene P07622058A0411 NN I-UN
runt P07622058A0411 NN I-UN
. P07622058A0411 . O
. . O O

These P09312025A0373 DT O
effects P09312025A0373 NNS O
were P09312025A0373 VBD O
abrogated P09312025A0373 VBN O
by P09312025A0373 IN O
co-expression P09312025A0373 NN O
of P09312025A0373 IN O
kinase-deficient P09312025A0373 JJ I-UN
PKC P09312025A0373 NNP I-UN
zeta P09312025A0373 NN I-UN
and P09312025A0373 CC O
inhibition P09312025A0373 NN O
of P09312025A0373 IN O
phosphatidylinositol P09312025A0373 JJ I-UN
3-kinase P09312025A0373 JJ I-UN
p85alpha-p110 P09312025A0373 NN O
by P09312025A0373 IN O
wortmannin P09312025A0373 NN O
, P09312025A0373 , O
LY294002 P09312025A0373 NNP O
and P09312025A0373 CC O
a P09312025A0373 DT O
dominant-negative P09312025A0373 JJ O
mutant P09312025A0373 NN O
of P09312025A0373 IN O
p85alpha P09312025A0373 NN I-UN
. P09312025A0373 . O
. . O O

Postprandial P06735247A0803 JJ O
plasma P06735247A0803 NN I-UN
enteroglucagon P06735247A0803 NN I-UN
concentration P06735247A0803 NN O
after P06735247A0803 IN O
90 P06735247A0803 CD O
minutes P06735247A0803 NNS O
in P06735247A0803 IN O
untreated P06735247A0803 JJ O
patients P06735247A0803 NNS O
correlated P06735247A0803 VBD O
positively P06735247A0803 RB O
to P06735247A0803 TO O
the P06735247A0803 DT O
faecal P06735247A0803 JJ O
fat P06735247A0803 NN O
excretion P06735247A0803 NN O
( P06735247A0803 ( O
r P06735247A0803 JJ O
= P06735247A0803 NN O
0.58 P06735247A0803 CD O
, P06735247A0803 , O
p P06735247A0803 NN O
less P06735247A0803 JJR O
than P06735247A0803 IN O
0.02 P06735247A0803 CD O
) P06735247A0803 ) O
. P06735247A0803 . O
. . O O

Investigated P07068887A0000 VBN O
the P07068887A0000 DT O
reliability P07068887A0000 NN O
, P07068887A0000 , O
validity P07068887A0000 NN O
and P07068887A0000 CC O
dimensionality P07068887A0000 NN O
of P07068887A0000 IN O
scores P07068887A0000 NNS O
obtained P07068887A0000 VBN O
by P07068887A0000 IN O
acute P07068887A0000 JJ O
psychiatric P07068887A0000 JJ O
inpatients P07068887A0000 NNS O
( P07068887A0000 ( O
N P07068887A0000 NNP O
= P07068887A0000 NNP O
120 P07068887A0000 CD O
) P07068887A0000 ) O
on P07068887A0000 IN O
the P07068887A0000 DT O
Michigan P07068887A0000 NNP O
Alcoholism P07068887A0000 NNP O
Screening P07068887A0000 NNP O
Test P07068887A0000 NNP O
adapted P07068887A0000 VBD O
to P07068887A0000 TO O
assess P07068887A0000 VB O
lifetime P07068887A0000 NN O
and P07068887A0000 CC O
current P07068887A0000 JJ O
symptomatology P07068887A0000 NN O
. P07068887A0000 . O
. . O O

Hydrophobicity P02045366A1149 NNP O
analysis P02045366A1149 NN O
indicated P02045366A1149 VBD O
that P02045366A1149 IN O
the P02045366A1149 DT O
KlaA P02045366A1149 NNP I-UN
and P02045366A1149 CC O
KlaB P02045366A1149 NNP I-UN
polypeptides P02045366A1149 NNS I-UN
are P02045366A1149 VBP O
likely P02045366A1149 JJ O
to P02045366A1149 TO O
be P02045366A1149 VB O
soluble P02045366A1149 JJ O
, P02045366A1149 , O
whereas P02045366A1149 IN O
the P02045366A1149 DT O
KlaC P02045366A1149 NNP I-UN
polypeptide P02045366A1149 NN I-UN
was P02045366A1149 VBD O
predicted P02045366A1149 VBN O
to P02045366A1149 TO O
have P02045366A1149 VB O
four P02045366A1149 CD O
potential P02045366A1149 JJ O
membrane-spanning P02045366A1149 NN O
domains P02045366A1149 NNS O
. P02045366A1149 . O
. . O O

There P08461946A0386 EX O
was P08461946A0386 VBD O
either P08461946A0386 CC O
no P08461946A0386 DT O
change P08461946A0386 NN O
or P08461946A0386 CC O
an P08461946A0386 DT O
improvement P08461946A0386 NN O
in P08461946A0386 IN O
renographic P08461946A0386 JJ O
findings P08461946A0386 NNS O
( P08461946A0386 ( O
t1 P08461946A0386 JJ O
/ P08461946A0386 $ O
2 P08461946A0386 CD O
time P08461946A0386 NN O
and P08461946A0386 CC O
/ P08461946A0386 NN O
or P08461946A0386 CC O
split P08461946A0386 NN O
function P08461946A0386 NN O
) P08461946A0386 ) O
in P08461946A0386 IN O
40 P08461946A0386 CD O
patients P08461946A0386 NNS O
( P08461946A0386 ( O
93 P08461946A0386 CD O
% P08461946A0386 NN O
) P08461946A0386 ) O
. P08461946A0386 . O
. . O O

Using P07635312A0692 VBG O
mutagenesis P07635312A0692 NN O
, P07635312A0692 , O
we P07635312A0692 PRP O
have P07635312A0692 VBP O
identified P07635312A0692 VBN O
two P07635312A0692 CD O
mutations P07635312A0692 NNS O
of P07635312A0692 IN O
the P07635312A0692 DT O
second P07635312A0692 JJ O
actin-binding P07635312A0692 JJ I-UN
domain P07635312A0692 NN I-UN
that P07635312A0692 WDT O
can P07635312A0692 MD O
also P07635312A0692 RB O
suppress P07635312A0692 VB O
the P07635312A0692 DT O
act1 P07635312A0692 JJ I-UN
mutations P07635312A0692 NNS O
of P07635312A0692 IN O
interest P07635312A0692 NN O
. P07635312A0692 . O
. . O O

Repression P08289341A1202 NN O
is P08289341A1202 VBZ O
alleviated P08289341A1202 VBN O
when P08289341A1202 WRB O
the P08289341A1202 DT O
two P08289341A1202 CD O
( P08289341A1202 ( O
for P08289341A1202 IN O
E2 P08289341A1202 NNP I-UN
) P08289341A1202 ) O
or P08289341A1202 CC O
three P08289341A1202 CD O
( P08289341A1202 ( O
for P08289341A1202 IN O
E2-C P08289341A1202 NNP I-UN
) P08289341A1202 ) O
promoter-proximal P08289341A1202 JJ O
copies P08289341A1202 NNS O
of P08289341A1202 IN O
E2-RS P08289341A1202 NNP O
are P08289341A1202 VBP O
mutated P08289341A1202 VBN O
. P08289341A1202 . O
. . O O

Gabapentin P11401105T0000 NNP O
for P11401105T0000 IN O
opiod-related P11401105T0000 JJ O
myoclonus P11401105T0000 NN O
in P11401105T0000 IN O
cancer P11401105T0000 NN O
patients P11401105T0000 NNS O
. P11401105T0000 . O
. . O O

Regulation P02174861A0736 NN O
of P02174861A0736 IN O
irgA P02174861A0736 NN I-UN
by P02174861A0736 IN O
iron P02174861A0736 NN O
in P02174861A0736 IN O
V. P02174861A0736 NNP O
cholerae P02174861A0736 NN O
occurs P02174861A0736 VBZ O
at P02174861A0736 IN O
the P02174861A0736 DT O
transcriptional P02174861A0736 JJ O
level P02174861A0736 NN O
, P02174861A0736 , O
and P02174861A0736 CC O
there P02174861A0736 EX O
is P02174861A0736 VBZ O
an P02174861A0736 DT O
interrupted P02174861A0736 JJ O
dyad P02174861A0736 NN O
symmetric P02174861A0736 JJ O
sequence P02174861A0736 NN O
in P02174861A0736 IN O
the P02174861A0736 DT O
vicinity P02174861A0736 NN O
of P02174861A0736 IN O
the P02174861A0736 DT O
promoter P02174861A0736 NN O
that P02174861A0736 WDT O
is P02174861A0736 VBZ O
homologous P02174861A0736 JJ O
to P02174861A0736 TO O
Fur P02174861A0736 NNP I-UN
binding P02174861A0736 VBG I-UN
sites P02174861A0736 NNS I-UN
of P02174861A0736 IN O
E. P02174861A0736 NNP O
coli P02174861A0736 NNS O
. P02174861A0736 . O
. . O O

Heterogeneous P09275159T0000 JJ I-UN
nuclear P09275159T0000 JJ I-UN
ribonucleoprotein P09275159T0000 NN I-UN
A1 P09275159T0000 NNP I-UN
binds P09275159T0000 VBZ O
to P09275159T0000 TO O
the P09275159T0000 DT O
transcription-regulatory P09275159T0000 JJ O
region P09275159T0000 NN O
of P09275159T0000 IN O
mouse P09275159T0000 NN O
hepatitis P09275159T0000 NN O
virus P09275159T0000 NN O
RNA P09275159T0000 NNP O
. P09275159T0000 . O
. . O O

We P07601445A0207 PRP O
now P07601445A0207 RB O
show P07601445A0207 VBP O
that P07601445A0207 IN O
the P07601445A0207 DT O
BAT1 P07601445A0207 NNP I-UN
translation P07601445A0207 NN I-UN
product P07601445A0207 NN I-UN
is P07601445A0207 VBZ O
the P07601445A0207 DT O
homolog P07601445A0207 NN O
of P07601445A0207 IN O
the P07601445A0207 DT O
rat P07601445A0207 NN I-UN
p47 P07601445A0207 NN I-UN
nuclear P07601445A0207 JJ I-UN
protein P07601445A0207 NN I-UN
, P07601445A0207 , O
the P07601445A0207 DT O
WM6 P07601445A0207 NNP I-UN
Drosophila P07601445A0207 NNP I-UN
gene P07601445A0207 NN I-UN
product P07601445A0207 NN I-UN
, P07601445A0207 , O
and P07601445A0207 CC O
probably P07601445A0207 RB O
also P07601445A0207 RB O
Ce08102 P07601445A0207 NNP I-UN
of P07601445A0207 IN O
Caenorhabditis P07601445A0207 NNP O
elegans P07601445A0207 NNS O
, P07601445A0207 , O
all P07601445A0207 DT O
members P07601445A0207 NNS O
of P07601445A0207 IN O
the P07601445A0207 DT O
DEAD P07601445A0207 NNP I-UN
protein P07601445A0207 VBP I-UN
family P07601445A0207 NN I-UN
of P07601445A0207 IN O
ATP-dependent P07601445A0207 NNP I-UN
RNA P07601445A0207 NNP I-UN
helicases P07601445A0207 NNS I-UN
. P07601445A0207 . O
. . O O

Here P02505087A1037 RB O
, P02505087A1037 , O
we P02505087A1037 PRP O
alter P02505087A1037 VBP O
the P02505087A1037 DT O
dimerization P02505087A1037 NN O
specificity P02505087A1037 NN O
of P02505087A1037 IN O
Fos P02505087A1037 NNP I-UN
by P02505087A1037 IN O
precisely P02505087A1037 RB O
replacing P02505087A1037 VBG O
its P02505087A1037 PRP$ O
leucine P02505087A1037 NN O
zipper P02505087A1037 NN O
with P02505087A1037 IN O
that P02505087A1037 DT O
from P02505087A1037 IN O
GCN4 P02505087A1037 NNP I-UN
. P02505087A1037 . O
. . O O

Eight P09268578A0225 CD O
induced P09268578A0225 VBN O
cDNA P09268578A0225 NN O
sequences P09268578A0225 NNS O
were P09268578A0225 VBD O
identified P09268578A0225 VBN O
and P09268578A0225 CC O
designated P09268578A0225 VBN O
message P09268578A0225 NN I-UN
up-regulated P09268578A0225 JJ I-UN
during P09268578A0225 IN I-UN
death P09268578A0225 NN I-UN
( P09268578A0225 ( I-UN
mud P09268578A0225 NN I-UN
) P09268578A0225 ) I-UN
-1-8 P09268578A0225 NN I-UN
. P09268578A0225 . O
. . O O

T2 P08306834A0866 NN O
cancers P08306834A0866 NNS O
should P08306834A0866 MD O
not P08306834A0866 RB O
be P08306834A0866 VB O
excluded P08306834A0866 VBN O
from P08306834A0866 IN O
the P08306834A0866 DT O
benefit P08306834A0866 NN O
of P08306834A0866 IN O
preoperative P08306834A0866 JJ O
irradiation P08306834A0866 NN O
. P08306834A0866 . O
. . O O

A P03311954A0000 DT O
multicentre P03311954A0000 NN O
study P03311954A0000 NN O
involving P03311954A0000 VBG O
9 P03311954A0000 CD O
Italian P03311954A0000 JJ O
institutions P03311954A0000 NNS O
was P03311954A0000 VBD O
carried P03311954A0000 VBN O
out P03311954A0000 IN O
to P03311954A0000 TO O
compare P03311954A0000 VB O
the P03311954A0000 DT O
efficacy P03311954A0000 NN O
and P03311954A0000 CC O
safety P03311954A0000 NN O
of P03311954A0000 IN O
ranitidine P03311954A0000 NN O
150 P03311954A0000 CD O
mg P03311954A0000 NN O
b.i.d P03311954A0000 NN O
. P03311954A0000 . O
and P03311954A0000 CC O
ranitidine P03311954A0000 VB O
300 P03311954A0000 CD O
mg P03311954A0000 NN O
nocte P03311954A0000 NN O
in P03311954A0000 IN O
the P03311954A0000 DT O
treatment P03311954A0000 NN O
of P03311954A0000 IN O
reflux P03311954A0000 NN O
oesophagitis P03311954A0000 NN O
. P03311954A0000 . O
. . O O

The P02705296A0231 DT O
predicted P02705296A0231 JJ O
molecular P02705296A0231 JJ O
weight P02705296A0231 NN O
of P02705296A0231 IN O
the P02705296A0231 DT O
polyprotein P02705296A0231 NN O
encoded P02705296A0231 VBN O
by P02705296A0231 IN O
ORF1 P02705296A0231 NNP O
is P02705296A0231 VBZ O
33 P02705296A0231 CD O
kilodaltons P02705296A0231 NNS O
( P02705296A0231 ( O
kDa P02705296A0231 NN O
) P02705296A0231 ) O
. P02705296A0231 . O
. . O O

Regressing P08587075T0000 VBG O
microaneurysms P08587075T0000 NNS O
in P08587075T0000 IN O
5 P08587075T0000 CD O
cases P08587075T0000 NNS O
of P08587075T0000 IN O
hepatitis P08587075T0000 NN O
B P08587075T0000 NNP O
virus P08587075T0000 NN O
related P08587075T0000 VBN O
polyarteritis P08587075T0000 NN O
nodosa P08587075T0000 NN O
. P08587075T0000 . O
. . O O

Practical P03836777T0001 JJ O
use P03836777T0001 NN O
and P03836777T0001 CC O
interpretation P03836777T0001 NN O
of P03836777T0001 IN O
viral P03836777T0001 JJ O
hepatitis P03836777T0001 NN O
B P03836777T0001 NNP O
markers P03836777T0001 NNS O
and P03836777T0001 CC O
hepatic P03836777T0001 JJ O
biopsy P03836777T0001 NN O
in P03836777T0001 IN O
HBs P03836777T0001 NNP I-UN
Ag P03836777T0001 NNP I-UN
carriers P03836777T0001 NNS O
and P03836777T0001 CC O
at P03836777T0001 IN O
the P03836777T0001 DT O
chronic P03836777T0001 JJ O
hepatitis P03836777T0001 NN O
stage P03836777T0001 NN O
. P03836777T0001 . O
. . O O

During P08588852A0236 IN O
the P08588852A0236 DT O
following P08588852A0236 JJ O
pregnancy P08588852A0236 NN O
ultrasonographic P08588852A0236 JJ O
studies P08588852A0236 NNS O
of P08588852A0236 IN O
the P08588852A0236 DT O
male P08588852A0236 NN O
fetus P08588852A0236 NN O
in P08588852A0236 IN O
the P08588852A0236 DT O
16th P08588852A0236 CD O
week P08588852A0236 NN O
of P08588852A0236 IN O
gestation P08588852A0236 NN O
revealed P08588852A0236 VBN O
severe P08588852A0236 JJ O
micrognathia P08588852A0236 NN O
, P08588852A0236 , O
short P08588852A0236 JJ O
and P08588852A0236 CC O
wide P08588852A0236 JJ O
thumbs P08588852A0236 NN O
, P08588852A0236 , O
and P08588852A0236 CC O
big P08588852A0236 JJ O
toes P08588852A0236 NNS O
, P08588852A0236 , O
and P08588852A0236 CC O
bowed P08588852A0236 VBD O
tibiae P08588852A0236 NNS O
. P08588852A0236 . O
. . O O

Rep63A P10322022A0263 NNP I-UN
( P10322022A0263 ( I-UN
513 P10322022A0263 CD I-UN
amino P10322022A0263 NN I-UN
acids P10322022A0263 NNS I-UN
[ P10322022A0263 VBP I-UN
aa P10322022A0263 JJ I-UN
] P10322022A0263 NN I-UN
) P10322022A0263 ) I-UN
, P10322022A0263 , O
encoded P10322022A0263 VBN O
by P10322022A0263 IN O
the P10322022A0263 DT O
largest P10322022A0263 JJS O
ORF P10322022A0263 NN O
, P10322022A0263 , O
displayed P10322022A0263 VBN O
strong P10322022A0263 JJ O
similarity P10322022A0263 NN O
( P10322022A0263 ( O
40 P10322022A0263 CD O
% P10322022A0263 NN O
identity P10322022A0263 NN O
) P10322022A0263 ) O
to P10322022A0263 TO O
the P10322022A0263 DT O
replication P10322022A0263 NN O
proteins P10322022A0263 VBZ O
from P10322022A0263 IN O
plasmids P10322022A0263 NNS O
pAMbeta1 P10322022A0263 NN O
, P10322022A0263 , O
pIP501 P10322022A0263 NN O
, P10322022A0263 , O
and P10322022A0263 CC O
pSM19035 P10322022A0263 NN O
, P10322022A0263 , O
indicating P10322022A0263 VBG O
that P10322022A0263 IN O
the P10322022A0263 DT O
pAW63 P10322022A0263 NN O
replicon P10322022A0263 NN O
belongs P10322022A0263 NNS O
to P10322022A0263 TO O
the P10322022A0263 DT O
pAMbeta1 P10322022A0263 JJ O
family P10322022A0263 NN O
of P10322022A0263 IN O
gram-positive P10322022A0263 JJ O
theta-replicating P10322022A0263 JJ O
plasmids P10322022A0263 NNS O
. P10322022A0263 . O
. . O O

( P09235995A0339 ( O
1996a P09235995A0339 CD O
) P09235995A0339 ) O
Biochemistry P09235995A0339 NN O
35 P09235995A0339 CD O
, P09235995A0339 , O
1589-1598 P09235995A0339 JJ O
] P09235995A0339 NN O
. P09235995A0339 . O
. . O O

Differential P11118440T0000 NNP O
association P11118440T0000 NN O
of P11118440T0000 IN O
products P11118440T0000 NNS O
of P11118440T0000 IN O
alternative P11118440T0000 JJ O
transcripts P11118440T0000 NNS O
of P11118440T0000 IN O
the P11118440T0000 DT O
candidate P11118440T0000 NN O
tumor P11118440T0000 NN I-UN
suppressor P11118440T0000 NN I-UN
ING1 P11118440T0000 NNP I-UN
with P11118440T0000 IN O
the P11118440T0000 DT O
mSin3 P11118440T0000 NN I-UN
/ P11118440T0000 NNP O
HDAC1 P11118440T0000 NNP I-UN
transcriptional P11118440T0000 JJ O
corepressor P11118440T0000 NN O
complex P11118440T0000 NN O
. P11118440T0000 . O
. . O O

The P07949137A0532 DT O
pretransplant P07949137A0532 JJ O
regimen P07949137A0532 NNS O
consisted P07949137A0532 VBD O
of P07949137A0532 IN O
cyclophosphamide P07949137A0532 NN O
( P07949137A0532 ( O
120 P07949137A0532 CD O
mg P07949137A0532 NN O
/ P07949137A0532 NNP O
kg P07949137A0532 NN O
) P07949137A0532 ) O
and P07949137A0532 CC O
total P07949137A0532 JJ O
body P07949137A0532 NN O
irradiation P07949137A0532 NN O
. P07949137A0532 . O
. . O O

In P08543595A1093 IN O
summary P08543595A1093 JJ O
, P08543595A1093 , O
the P08543595A1093 DT O
efficacies P08543595A1093 NNS O
of P08543595A1093 IN O
adjuvant P08543595A1093 JJ O
carboplatin P08543595A1093 NN O
and P08543595A1093 CC O
of P08543595A1093 IN O
abdominal P08543595A1093 JJ O
radiotherapy P08543595A1093 NN O
seem P08543595A1093 VBP O
to P08543595A1093 TO O
be P08543595A1093 VB O
identical P08543595A1093 JJ O
. P08543595A1093 . O
. . O O

These P03049570A1242 DT O
similarities P03049570A1242 NNS O
suggest P03049570A1242 VBP O
that P03049570A1242 IN O
these P03049570A1242 DT O
E2 P03049570A1242 NNP I-UN
proteins P03049570A1242 NNS I-UN
are P03049570A1242 VBP O
structurally P03049570A1242 RB O
and P03049570A1242 CC O
evolutionarily P03049570A1242 RB O
related P03049570A1242 VBN O
. P03049570A1242 . O
. . O O

To P03673881A0000 TO O
evaluate P03673881A0000 VB O
the P03673881A0000 DT O
relative P03673881A0000 JJ O
accuracy P03673881A0000 NN O
of P03673881A0000 IN O
continuous P03673881A0000 JJ O
wave P03673881A0000 NN O
( P03673881A0000 ( O
CW P03673881A0000 NNP O
) P03673881A0000 ) O
and P03673881A0000 CC O
high P03673881A0000 JJ O
pulse P03673881A0000 NN O
repetition P03673881A0000 NN O
frequency P03673881A0000 NN O
( P03673881A0000 ( O
HPRF P03673881A0000 NNP O
) P03673881A0000 ) O
Doppler P03673881A0000 NNP O
for P03673881A0000 IN O
estimating P03673881A0000 VBG O
aortic P03673881A0000 JJ O
transvalvular P03673881A0000 JJ O
pressure P03673881A0000 NN O
gradients P03673881A0000 NNS O
, P03673881A0000 , O
Doppler P03673881A0000 NNP O
examinations P03673881A0000 NNS O
with P03673881A0000 IN O
both P03673881A0000 DT O
devices P03673881A0000 NNS O
were P03673881A0000 VBD O
obtained P03673881A0000 VBN O
in P03673881A0000 IN O
87 P03673881A0000 CD O
consecutive P03673881A0000 JJ O
patients P03673881A0000 NNS O
with P03673881A0000 IN O
aortic P03673881A0000 JJ O
valve P03673881A0000 NN O
disease P03673881A0000 NN O
. P03673881A0000 . O
. . O O

Epileptiform P06713200A0630 NN O
activity P06713200A0630 NN O
recorded P06713200A0630 VBN O
from P06713200A0630 IN O
superficial P06713200A0630 JJ O
laminae P06713200A0630 NN O
bordering P06713200A0630 VBG O
layer P06713200A0630 NN O
4 P06713200A0630 CD O
, P06713200A0630 , O
and P06713200A0630 CC O
into P06713200A0630 IN O
which P06713200A0630 WDT O
layer P06713200A0630 VBD O
4 P06713200A0630 CD O
's P06713200A0630 POS O
primary P06713200A0630 JJ O
projections P06713200A0630 NNS O
terminate P06713200A0630 NN O
, P06713200A0630 , O
is P06713200A0630 VBZ O
suppressed P06713200A0630 VBN O
preferentially P06713200A0630 RB O
by P06713200A0630 IN O
phenytoin P06713200A0630 NN O
. P06713200A0630 . O
. . O O

In P11238447A0524 IN O
vitro P11238447A0524 JJ O
binding P11238447A0524 NN O
studies P11238447A0524 NNS O
demonstrate P11238447A0524 VBP O
that P11238447A0524 IN O
eIF-5A P11238447A0524 NN I-UN
is P11238447A0524 VBZ O
required P11238447A0524 VBN O
for P11238447A0524 IN O
efficient P11238447A0524 JJ O
interaction P11238447A0524 NN O
of P11238447A0524 IN O
Rev-NES P11238447A0524 NNP O
with P11238447A0524 IN O
CRM1 P11238447A0524 NNP I-UN
/ P11238447A0524 NNP O
exportin1 P11238447A0524 NN I-UN
and P11238447A0524 CC O
that P11238447A0524 IN O
eIF-5A P11238447A0524 JJ I-UN
interacts P11238447A0524 NNS O
with P11238447A0524 IN O
the P11238447A0524 DT O
nucleoporins P11238447A0524 NNS O
CAN P11238447A0524 NNP I-UN
/ P11238447A0524 NNP O
nup214 P11238447A0524 RB I-UN
, P11238447A0524 , O
nup153 P11238447A0524 RB I-UN
, P11238447A0524 , O
nup98 P11238447A0524 UH I-UN
, P11238447A0524 , O
and P11238447A0524 CC O
nup62 P11238447A0524 RB I-UN
. P11238447A0524 . O
. . O O

Large P10046849T0000 JJ O
scale P10046849T0000 JJ O
electronic P10046849T0000 JJ O
structure P10046849T0000 NN O
calculations P10046849T0000 NNS O
. P10046849T0000 . O
. . O O

Duch P10516072A0146 NNP O
, P10516072A0146 , O
and P10516072A0146 CC O
F P10516072A0146 NNP O
. P10516072A0146 . O
. . O O

Air P08458660A0855 NNP O
lead P08458660A0855 NN O
was P08458660A0855 VBD O
not P08458660A0855 RB O
a P08458660A0855 DT O
significant P08458660A0855 JJ O
explanatory P08458660A0855 NN O
variable P08458660A0855 NN O
. P08458660A0855 . O
. . O O

After P09714835A0345 IN O
that P09714835A0345 DT O
report P09714835A0345 NN O
, P09714835A0345 , O
carboxypeptidase P09714835A0345 NN I-UN
D P09714835A0345 NNP I-UN
( P09714835A0345 ( O
CPD P09714835A0345 NNP I-UN
) P09714835A0345 ) O
was P09714835A0345 VBD O
subsequently P09714835A0345 RB O
purified P09714835A0345 VBN O
from P09714835A0345 IN O
bovine P09714835A0345 NN O
pituitary P09714835A0345 JJ O
and P09714835A0345 CC O
characterized P09714835A0345 VBN O
as P09714835A0345 IN O
a P09714835A0345 DT O
novel P09714835A0345 JJ O
carboxypeptidase P09714835A0345 NN I-UN
E P09714835A0345 NNP I-UN
( P09714835A0345 ( O
CPE P09714835A0345 NNP I-UN
) P09714835A0345 ) O
-like P09714835A0345 IN O
enzyme P09714835A0345 NN O
, P09714835A0345 , O
with P09714835A0345 IN O
many P09714835A0345 JJ O
characteristics P09714835A0345 NNS O
in P09714835A0345 IN O
common P09714835A0345 JJ O
with P09714835A0345 IN O
duck P09714835A0345 NN O
gp180 P09714835A0345 NN I-UN
( P09714835A0345 ( O
Song P09714835A0345 NNP O
, P09714835A0345 , O
L. P09714835A0345 NNP O
, P09714835A0345 , O
Fricker P09714835A0345 NNP O
, P09714835A0345 , O
L.D. P09714835A0345 NNP O
, P09714835A0345 , O
1995 P09714835A0345 CD O
. P09714835A0345 . O
. . O O

End-tidal P07592220A0846 JJ O
PO2 P07592220A0846 NNP O
and P07592220A0846 CC O
the P07592220A0846 DT O
ratio P07592220A0846 NN O
of P07592220A0846 IN O
minute P07592220A0846 NN O
ventilation P07592220A0846 NN O
to P07592220A0846 TO O
oxygen P07592220A0846 VB O
consumption P07592220A0846 NN O
( P07592220A0846 ( O
VE P07592220A0846 NNP O
/ P07592220A0846 NNP O
VO2 P07592220A0846 NNP O
) P07592220A0846 ) O
were P07592220A0846 VBD O
lower P07592220A0846 JJR O
while P07592220A0846 IN O
PETCO2 P07592220A0846 NNP O
was P07592220A0846 VBD O
higher P07592220A0846 JJR O
for P07592220A0846 IN O
Hyp P07592220A0846 NNP O
( P07592220A0846 ( O
P P07592220A0846 NNP O
< P07592220A0846 NNP O
or P07592220A0846 CC O
= P07592220A0846 VB O
0.01 P07592220A0846 CD O
) P07592220A0846 ) O
. P07592220A0846 . O
. . O O

The P11447490A0598 DT O
amount P11447490A0598 NN O
of P11447490A0598 IN O
drained P11447490A0598 JJ O
effusion P11447490A0598 NN O
was P11447490A0598 VBD O
measured P11447490A0598 VBN O
, P11447490A0598 , O
and P11447490A0598 CC O
fluid P11447490A0598 NN O
was P11447490A0598 VBD O
sent P11447490A0598 VBN O
for P11447490A0598 IN O
diagnostic P11447490A0598 JJ O
assessment P11447490A0598 NN O
. P11447490A0598 . O
. . O O

However P10090125A0750 RB O
, P10090125A0750 , O
with P10090125A0750 IN O
the P10090125A0750 DT O
alpha1 P10090125A0750 JJ O
antagonist P10090125A0750 NN O
prazosin P10090125A0750 NN O
( P10090125A0750 ( O
5 P10090125A0750 CD O
x P10090125A0750 RB O
10 P10090125A0750 CD O
( P10090125A0750 ( O
-8 P10090125A0750 NN O
) P10090125A0750 ) O
-5 P10090125A0750 VBZ O
x P10090125A0750 $ O
10 P10090125A0750 CD O
( P10090125A0750 ( O
-7 P10090125A0750 NN O
) P10090125A0750 ) O
M P10090125A0750 NNP O
) P10090125A0750 ) O
, P10090125A0750 , O
no P10090125A0750 DT O
relaxation P10090125A0750 NN O
occurred P10090125A0750 VBD O
. P10090125A0750 . O
. . O O

The P03296212A0603 DT O
future P03296212A0603 NN O
of P03296212A0603 IN O
research P03296212A0603 NN O
with P03296212A0603 IN O
interferon P03296212A0603 NN I-UN
may P03296212A0603 MD O
be P03296212A0603 VB O
divided P03296212A0603 VBN O
into P03296212A0603 IN O
three P03296212A0603 CD O
areas P03296212A0603 NNS O
: P03296212A0603 : O
Efforts P03296212A0603 NNS O
must P03296212A0603 MD O
be P03296212A0603 VB O
made P03296212A0603 VBN O
to P03296212A0603 TO O
determine P03296212A0603 VB O
how P03296212A0603 WRB O
best P03296212A0603 JJS O
to P03296212A0603 TO O
translate P03296212A0603 VB O
the P03296212A0603 DT O
in P03296212A0603 IN O
vitro P03296212A0603 NN O
synergy P03296212A0603 NN O
into P03296212A0603 IN O
clinically P03296212A0603 RB O
meaningful P03296212A0603 JJ O
terms P03296212A0603 NNS O
; P03296212A0603 : O
in P03296212A0603 IN O
order P03296212A0603 NN O
to P03296212A0603 TO O
exploit P03296212A0603 VB O
the P03296212A0603 DT O
fullest P03296212A0603 JJS O
potential P03296212A0603 NN O
of P03296212A0603 IN O
IFN P03296212A0603 NNP I-UN
, P03296212A0603 , O
research P03296212A0603 NN O
is P03296212A0603 VBZ O
moving P03296212A0603 VBG O
toward P03296212A0603 IN O
using P03296212A0603 VBG O
this P03296212A0603 DT O
agent P03296212A0603 NN O
earlier P03296212A0603 RBR O
in P03296212A0603 IN O
disease P03296212A0603 NN O
either P03296212A0603 CC O
as P03296212A0603 IN O
an P03296212A0603 DT O
adjuvant P03296212A0603 NN O
after P03296212A0603 IN O
tumor P03296212A0603 NN O
debulking P03296212A0603 NN O
or P03296212A0603 CC O
after P03296212A0603 IN O
initial P03296212A0603 JJ O
diagnosis P03296212A0603 NN O
; P03296212A0603 : O
the P03296212A0603 DT O
medical P03296212A0603 JJ O
community P03296212A0603 NN O
must P03296212A0603 MD O
rethink P03296212A0603 VB O
the P03296212A0603 DT O
natural P03296212A0603 JJ O
history P03296212A0603 NN O
of P03296212A0603 IN O
some P03296212A0603 DT O
diseases P03296212A0603 NNS O
, P03296212A0603 , O
because P03296212A0603 IN O
the P03296212A0603 DT O
fullest P03296212A0603 JJS O
potential P03296212A0603 NN O
of P03296212A0603 IN O
the P03296212A0603 DT O
biologic P03296212A0603 NN O
agents P03296212A0603 NNS O
will P03296212A0603 MD O
most P03296212A0603 RBS O
likely P03296212A0603 JJ O
manifest P03296212A0603 JJS O
itself P03296212A0603 PRP O
when P03296212A0603 WRB O
these P03296212A0603 DT O
agents P03296212A0603 NNS O
are P03296212A0603 VBP O
used P03296212A0603 VBN O
together P03296212A0603 RB O
. P03296212A0603 . O
. . O O

Evidence P11760796A0698 NN O
suggests P11760796A0698 VBZ O
that P11760796A0698 IN O
PHACES P11760796A0698 NNP O
syndrome P11760796A0698 NN O
is P11760796A0698 VBZ O
not P11760796A0698 RB O
a P11760796A0698 DT O
random P11760796A0698 JJ O
association P11760796A0698 NN O
but P11760796A0698 CC O
a P11760796A0698 DT O
true P11760796A0698 JJ O
phakomatosis P11760796A0698 NN O
; P11760796A0698 : O
further P11760796A0698 JJ O
studies P11760796A0698 NNS O
are P11760796A0698 VBP O
awaited P11760796A0698 VBN O
to P11760796A0698 TO O
shed P11760796A0698 VB O
light P11760796A0698 NN O
on P11760796A0698 IN O
a P11760796A0698 DT O
possible P11760796A0698 JJ O
genetic P11760796A0698 JJ O
background P11760796A0698 NN O
. P11760796A0698 . O
. . O O

Most P11197288A0855 JJS O
patients P11197288A0855 NNS O
harboring P11197288A0855 VBG O
metronidazole- P11197288A0855 JJ O
and P11197288A0855 CC O
clarithromycin-resistant P11197288A0855 JJ O
strains P11197288A0855 NNS O
were P11197288A0855 VBD O
eradicated P11197288A0855 VBN O
at P11197288A0855 IN O
an P11197288A0855 DT O
equal P11197288A0855 JJ O
rate P11197288A0855 NN O
by P11197288A0855 IN O
each P11197288A0855 DT O
of P11197288A0855 IN O
the P11197288A0855 DT O
three P11197288A0855 CD O
regimens P11197288A0855 NNS O
. P11197288A0855 . O
. . O O

Protein P07658262A0944 NNP I-UN
S P07658262A0944 NNP I-UN
levels P07658262A0944 NNS O
were P07658262A0944 VBD O
virtually P07658262A0944 RB O
undetectable P07658262A0944 JJ O
at P07658262A0944 IN O
the P07658262A0944 DT O
time P07658262A0944 NN O
of P07658262A0944 IN O
admission P07658262A0944 NN O
and P07658262A0944 CC O
failed P07658262A0944 VBD O
to P07658262A0944 TO O
respond P07658262A0944 VB O
to P07658262A0944 TO O
infusions P07658262A0944 NNS O
of P07658262A0944 IN O
fresh P07658262A0944 JJ O
frozen P07658262A0944 JJ O
plasma P07658262A0944 NN O
, P07658262A0944 , O
despite P07658262A0944 IN O
correction P07658262A0944 NN O
of P07658262A0944 IN O
other P07658262A0944 JJ O
procoagulant P07658262A0944 NN O
and P07658262A0944 CC O
anticoagulant P07658262A0944 JJ O
factors P07658262A0944 NNS O
. P07658262A0944 . O
. . O O

Here P10827952A0158 RB O
, P10827952A0158 , O
it P10827952A0158 PRP O
is P10827952A0158 VBZ O
shown P10827952A0158 VBN O
that P10827952A0158 IN O
TAFII250 P10827952A0158 NNP I-UN
, P10827952A0158 , O
the P10827952A0158 DT O
largest P10827952A0158 JJS O
subunit P10827952A0158 NN O
of P10827952A0158 IN O
TFIID P10827952A0158 NNP I-UN
, P10827952A0158 , O
contains P10827952A0158 VBZ O
two P10827952A0158 CD O
tandem P10827952A0158 NN O
bromodomain P10827952A0158 NN O
modules P10827952A0158 NNS O
that P10827952A0158 WDT O
bind P10827952A0158 VBP O
selectively P10827952A0158 RB O
to P10827952A0158 TO O
multiply P10827952A0158 VB O
acetylated P10827952A0158 JJ O
histone P10827952A0158 NN I-UN
H4 P10827952A0158 NNP I-UN
peptides P10827952A0158 NNS I-UN
. P10827952A0158 . O
. . O O

Endovascular P11583880T0000 JJ O
aneurysm P11583880T0000 NNS O
repair P11583880T0000 NN O
with P11583880T0000 IN O
the P11583880T0000 DT O
AneuRx P11583880T0000 NNP O
stent-graft P11583880T0000 NN O
is P11583880T0000 VBZ O
safe P11583880T0000 JJ O
, P11583880T0000 , O
but P11583880T0000 CC O
is P11583880T0000 VBZ O
it P11583880T0000 PRP O
effective P11583880T0000 JJ O
? P11583880T0000 . O
. P11583880T0000 . O
. . O O

Rss1p P08898365A0274 NNP I-UN
encodes P08898365A0274 VBZ O
a P08898365A0274 DT O
novel P08898365A0274 JJ O
essential P08898365A0274 JJ O
protein P08898365A0274 NN O
of P08898365A0274 IN O
538 P08898365A0274 CD O
amino P08898365A0274 NN O
acids P08898365A0274 NNS O
, P08898365A0274 , O
which P08898365A0274 WDT O
contains P08898365A0274 VBZ O
an P08898365A0274 DT O
extended P08898365A0274 JJ O
predicted P08898365A0274 VBD O
coiled-coil P08898365A0274 NN O
domain P08898365A0274 NN O
and P08898365A0274 CC O
is P08898365A0274 VBZ O
located P08898365A0274 VBN O
both P08898365A0274 DT O
at P08898365A0274 IN O
nuclear P08898365A0274 JJ O
pore P08898365A0274 NN O
complexes P08898365A0274 NNS O
( P08898365A0274 ( O
NPCs P08898365A0274 NNP O
) P08898365A0274 ) O
and P08898365A0274 CC O
in P08898365A0274 IN O
the P08898365A0274 DT O
cytoplasm P08898365A0274 NN O
. P08898365A0274 . O
. . O O

To P07723247A0187 TO O
study P07723247A0187 VB O
the P07723247A0187 DT O
mechanisms P07723247A0187 NN O
as P07723247A0187 RB O
well P07723247A0187 RB O
as P07723247A0187 IN O
magnitude P07723247A0187 NN O
of P07723247A0187 IN O
the P07723247A0187 DT O
transmembrane P07723247A0187 NN O
transfer P07723247A0187 NN O
of P07723247A0187 IN O
bacterial P07723247A0187 JJ O
products P07723247A0187 NNS O
from P07723247A0187 IN O
the P07723247A0187 DT O
dialysate P07723247A0187 NN O
, P07723247A0187 , O
we P07723247A0187 PRP O
developed P07723247A0187 VBD O
a P07723247A0187 DT O
computerized P07723247A0187 VBN O
in P07723247A0187 IN O
vitro P07723247A0187 JJ O
dialysis P07723247A0187 NN O
model P07723247A0187 NN O
which P07723247A0187 WDT O
provides P07723247A0187 VBZ O
continuous P07723247A0187 JJ O
pressure P07723247A0187 NN O
recording P07723247A0187 VBG O
from P07723247A0187 IN O
the P07723247A0187 DT O
arterial P07723247A0187 JJ O
, P07723247A0187 , O
venous P07723247A0187 JJ O
, P07723247A0187 , O
dialysate P07723247A0187 JJ O
inflow P07723247A0187 NN O
and P07723247A0187 CC O
outflow P07723247A0187 JJ O
ports P07723247A0187 NNS O
. P07723247A0187 . O
. . O O

Our P09448574A0964 PRP$ O
findings P09448574A0964 NNS O
suggest P09448574A0964 VBP O
that P09448574A0964 IN O
striatal P09448574A0964 JJ O
FDG P09448574A0964 NNP O
and P09448574A0964 CC O
particularly P09448574A0964 RB O
RACLO P09448574A0964 NNP O
are P09448574A0964 VBP O
sensitive P09448574A0964 JJ O
and P09448574A0964 CC O
effective P09448574A0964 JJ O
measures P09448574A0964 NNS O
of P09448574A0964 IN O
striatal P09448574A0964 JJ O
function P09448574A0964 NN O
and P09448574A0964 CC O
may P09448574A0964 MD O
help P09448574A0964 VB O
characterizing P09448574A0964 VBG O
patients P09448574A0964 NNS O
with P09448574A0964 IN O
multiple P09448574A0964 JJ O
system P09448574A0964 NN O
atrophy P09448574A0964 NN O
. P09448574A0964 . O
. . O O

Changes P07379334A0503 NNS O
in P07379334A0503 IN O
immunologic P07379334A0503 JJ O
reactivity P07379334A0503 NN O
in P07379334A0503 IN O
subjects P07379334A0503 NNS O
receiving P07379334A0503 VBG O
transfer P07379334A0503 NN I-UN
factor P07379334A0503 NN I-UN
could P07379334A0503 MD O
not P07379334A0503 RB O
be P07379334A0503 VB O
distinguished P07379334A0503 VBN O
from P07379334A0503 IN O
those P07379334A0503 DT O
in P07379334A0503 IN O
subjects P07379334A0503 NNS O
receiving P07379334A0503 VBG O
placebo P07379334A0503 NN O
. P07379334A0503 . O
. . O O

Comparison P02324102A1157 NNP O
of P02324102A1157 IN O
transmembrane P02324102A1157 NN O
and P02324102A1157 CC O
cytoplasmic P02324102A1157 JJ O
domains P02324102A1157 NNS O
to P02324102A1157 TO O
a P02324102A1157 DT O
third P02324102A1157 JJ O
cell-surface P02324102A1157 JJ O
proteoglycan P02324102A1157 NN O
, P02324102A1157 , O
48K5 P02324102A1157 CD I-UN
from P02324102A1157 IN O
human P02324102A1157 JJ O
lung P02324102A1157 NN O
fibroblasts P02324102A1157 NNS O
( P02324102A1157 ( O
Marynen P02324102A1157 NNP O
, P02324102A1157 , O
P. P02324102A1157 NNP O
, P02324102A1157 , O
Zhang P02324102A1157 NNP O
, P02324102A1157 , O
J. P02324102A1157 NNP O
, P02324102A1157 , O
Cassiman P02324102A1157 NNP O
, P02324102A1157 , O
J. P02324102A1157 NNP O
, P02324102A1157 , O
Vanden P02324102A1157 NNP O
Berghe P02324102A1157 NNP O
, P02324102A1157 , O
H. P02324102A1157 NNP O
, P02324102A1157 , O
and P02324102A1157 CC O
David P02324102A1157 NNP O
, P02324102A1157 , O
C P02324102A1157 NNP O
. P02324102A1157 . O
. . O O

Is P09140474T0000 VBZ O
leishmaniasis P09140474T0000 JJ O
endemic P09140474T0000 JJ O
on P09140474T0000 IN O
the P09140474T0000 DT O
island P09140474T0000 NN O
of P09140474T0000 IN O
Minorca P09140474T0000 NNP O
( P09140474T0000 ( O
Spain P09140474T0000 NNP O
) P09140474T0000 ) O
? P09140474T0000 . O
A P09140474T0000 DT O
human P09140474T0000 JJ O
visceral P09140474T0000 JJ O
case P09140474T0000 NN O
after P09140474T0000 IN O
living P09140474T0000 VBG O
13 P09140474T0000 CD O
years P09140474T0000 NNS O
in P09140474T0000 IN O
Minorca P09140474T0000 NNP O
. P09140474T0000 . O
. . O O

The P11042204A0186 DT O
present P11042204A0186 JJ O
study P11042204A0186 NN O
shows P11042204A0186 VBZ O
that P11042204A0186 IN O
phosphatidylinositol P11042204A0186 JJ I-UN
3-kinase-dependent P11042204A0186 JJ O
p38 P11042204A0186 NN I-UN
kinase P11042204A0186 NN I-UN
activation P11042204A0186 NN O
regulates P11042204A0186 VBZ O
Akt P11042204A0186 NNP I-UN
phosphorylation P11042204A0186 NN O
and P11042204A0186 CC O
activity P11042204A0186 NN O
in P11042204A0186 IN O
human P11042204A0186 JJ O
neutrophils P11042204A0186 NNS O
. P11042204A0186 . O
. . O O

Full P08733881A0343 NNP O
thyroid P08733881A0343 NN O
function P08733881A0343 NN O
testing P08733881A0343 NN O
was P08733881A0343 VBD O
performed P08733881A0343 VBN O
on P08733881A0343 IN O
600 P08733881A0343 CD O
randomly P08733881A0343 RB O
selected P08733881A0343 VBN O
samples P08733881A0343 NNS O
with P08733881A0343 IN O
normal P08733881A0343 JJ O
TSH P08733881A0343 NNP I-UN
values P08733881A0343 NNS O
and P08733881A0343 CC O
also P08733881A0343 RB O
on P08733881A0343 IN O
subjects P08733881A0343 NNS O
with P08733881A0343 IN O
abnormal P08733881A0343 JJ O
TSH P08733881A0343 NNP I-UN
levels P08733881A0343 NNS O
. P08733881A0343 . O
. . O O

Both P11028944A1020 DT O
the P11028944A1020 DT O
Cmax P11028944A1020 NNP O
and P11028944A1020 CC O
AUC P11028944A1020 NNP O
values P11028944A1020 NNS O
were P11028944A1020 VBD O
almost P11028944A1020 RB O
doubled P11028944A1020 VBN O
with P11028944A1020 IN O
doubling P11028944A1020 VBG O
the P11028944A1020 DT O
dose P11028944A1020 NN O
. P11028944A1020 . O
. . O O

The P00163384A0000 DT O
carcass P00163384A0000 NN O
of P00163384A0000 IN O
a P00163384A0000 DT O
great P00163384A0000 JJ O
horned P00163384A0000 VBN O
owl P00163384A0000 NN O
( P00163384A0000 ( O
Bubo P00163384A0000 NNP O
virginianus P00163384A0000 NN O
) P00163384A0000 ) O
, P00163384A0000 , O
which P00163384A0000 WDT O
had P00163384A0000 VBD O
been P00163384A0000 VBN O
found P00163384A0000 VBN O
moribund P00163384A0000 RBR O
in P00163384A0000 IN O
southern P00163384A0000 JJ O
Ontario P00163384A0000 NNP O
, P00163384A0000 , O
was P00163384A0000 VBD O
presented P00163384A0000 VBN O
for P00163384A0000 IN O
necropsy P00163384A0000 NN O
. P00163384A0000 . O
. . O O

S. P10555964A0778 NNP O
, P10555964A0778 , O
Kim P10555964A0778 NNP O
, P10555964A0778 , O
S P10555964A0778 NNP O
. P10555964A0778 . O
. . O O

Transcripts P08806491A0542 NNS O
for P08806491A0542 IN O
both P08806491A0542 DT O
ODV-E18 P08806491A0542 NNP I-UN
and P08806491A0542 CC O
ODV-EC27 P08806491A0542 NNP I-UN
initiate P08806491A0542 NN O
from P08806491A0542 IN O
conserved P08806491A0542 VBN O
TAAG P08806491A0542 NNP O
motifs P08806491A0542 NNS O
, P08806491A0542 , O
and P08806491A0542 CC O
transcripts P08806491A0542 NNS O
are P08806491A0542 VBP O
detected P08806491A0542 VBN O
from P08806491A0542 IN O
16 P08806491A0542 CD O
through P08806491A0542 IN O
72 P08806491A0542 CD O
hr P08806491A0542 NN O
p.i P08806491A0542 NN O
. P08806491A0542 . O
. . O O

We P07518561A0496 PRP O
recently P07518561A0496 RB O
found P07518561A0496 VBD O
that P07518561A0496 IN O
the P07518561A0496 DT O
p72syk P07518561A0496 NN I-UN
protein P07518561A0496 NN I-UN
tyrosine P07518561A0496 JJ I-UN
kinase P07518561A0496 NN I-UN
is P07518561A0496 VBZ O
physically P07518561A0496 RB O
associated P07518561A0496 VBN O
with P07518561A0496 IN O
the P07518561A0496 DT O
TCR P07518561A0496 NNP I-UN
/ P07518561A0496 NNP O
CD3 P07518561A0496 NNP I-UN
complex P07518561A0496 NN O
and P07518561A0496 CC O
is P07518561A0496 VBZ O
rapidly P07518561A0496 RB O
tyrosine P07518561A0496 JJ O
phosphorylated P07518561A0496 VBN O
and P07518561A0496 CC O
activated P07518561A0496 VBN O
by P07518561A0496 IN O
receptor P07518561A0496 NN O
triggering P07518561A0496 VBG O
also P07518561A0496 RB O
in P07518561A0496 IN O
T P07518561A0496 NNP O
cells P07518561A0496 NNS O
lacking P07518561A0496 VBG O
p56lck P07518561A0496 NN I-UN
. P07518561A0496 . O
. . O O

The P09843378A0187 DT O
dopamine P09843378A0187 NN I-UN
D4 P09843378A0187 NNP I-UN
receptor P09843378A0187 NN I-UN
as P09843378A0187 RB O
well P09843378A0187 RB O
as P09843378A0187 IN O
many P09843378A0187 JJ O
other P09843378A0187 JJ O
catecholaminergic P09843378A0187 JJ I-UN
receptors P09843378A0187 NNS I-UN
contain P09843378A0187 VBP O
several P09843378A0187 JJ O
putative P09843378A0187 JJ O
SH3 P09843378A0187 NNP I-UN
binding P09843378A0187 NN I-UN
domains P09843378A0187 NNS I-UN
. P09843378A0187 . O
. . O O

Their P02473942A1207 PRP$ O
hydropathic P02473942A1207 JJ O
plots P02473942A1207 NNS O
are P02473942A1207 VBP O
very P02473942A1207 RB O
similar P02473942A1207 JJ O
and P02473942A1207 CC O
both P02473942A1207 DT O
possess P02473942A1207 JJ O
three P02473942A1207 CD O
hydrophobic P02473942A1207 JJ O
segments P02473942A1207 NNS O
that P02473942A1207 WDT O
are P02473942A1207 VBP O
likely P02473942A1207 JJ O
alpha-helical P02473942A1207 JJ O
transmembrane P02473942A1207 NN O
segments P02473942A1207 NNS O
. P02473942A1207 . O
. . O O

The P10542260A0832 DT O
requirement P10542260A0832 NN O
for P10542260A0832 IN O
proteolytic P10542260A0832 JJ O
activity P10542260A0832 NN O
of P10542260A0832 IN O
both P10542260A0832 DT O
FVIIa P10542260A0832 NNP I-UN
and P10542260A0832 CC O
FXa P10542260A0832 NNP I-UN
suggests P10542260A0832 VBZ O
that P10542260A0832 IN O
protease-activated P10542260A0832 JJ O
receptors P10542260A0832 NNS O
may P10542260A0832 MD O
be P10542260A0832 VB O
involved P10542260A0832 VBN O
. P10542260A0832 . O
. . O O

In P10660604A0748 IN O
vivo P10660604A0748 NN O
, P10660604A0748 , O
CARbeta P10660604A0748 NNP I-UN
/ P10660604A0748 NNP O
RXRalpha P10660604A0748 NNP I-UN
activated P10660604A0748 VBD O
transcription P10660604A0748 NN O
from P10660604A0748 IN O
an P10660604A0748 DT O
HD-PPRE P10660604A0748 JJ O
luciferase P10660604A0748 NN I-UN
reporter P10660604A0748 NN I-UN
construct P10660604A0748 NN I-UN
. P10660604A0748 . O
. . O O

Despite P10234698A0728 IN O
the P10234698A0728 DT O
reported P10234698A0728 VBN O
detrimental P10234698A0728 JJ O
effects P10234698A0728 NNS O
on P10234698A0728 IN O
CNS P10234698A0728 NNP O
development P10234698A0728 NN O
, P10234698A0728 , O
a P10234698A0728 DT O
number P10234698A0728 NN O
of P10234698A0728 IN O
animal P10234698A0728 JJ O
studies P10234698A0728 NNS O
have P10234698A0728 VBP O
shown P10234698A0728 VBN O
that P10234698A0728 IN O
pretreatment P10234698A0728 NN O
with P10234698A0728 IN O
corticosteroids P10234698A0728 NNS O
nevertheless P10234698A0728 RB O
protect P10234698A0728 VBP O
the P10234698A0728 DT O
brain P10234698A0728 NN O
from P10234698A0728 IN O
hypoxia-ischemic P10234698A0728 JJ O
injury P10234698A0728 NN O
; P10234698A0728 : O
however P10234698A0728 RB O
, P10234698A0728 , O
clinically P10234698A0728 RB O
such P10234698A0728 JJ O
treatment P10234698A0728 NN O
is P10234698A0728 VBZ O
no P10234698A0728 RB O
longer P10234698A0728 RB O
favored P10234698A0728 VBN O
. P10234698A0728 . O
. . O O

EEA1 P07768953T0039 NNP I-UN
is P07768953T0039 VBZ O
a P07768953T0039 DT O
conserved P07768953T0039 JJ O
alpha-helical P07768953T0039 JJ O
peripheral P07768953T0039 JJ O
membrane P07768953T0039 NN O
protein P07768953T0039 NN O
flanked P07768953T0039 VBN O
by P07768953T0039 IN O
cysteine P07768953T0039 NN O
`` P07768953T0039 `` O
fingers P07768953T0039 NNS O
'' P07768953T0039 '' O
and P07768953T0039 CC O
contains P07768953T0039 VBZ O
a P07768953T0039 DT I-UN
calmodulin-binding P07768953T0039 JJ I-UN
IQ P07768953T0039 NNP I-UN
motif P07768953T0039 NN I-UN
. P07768953T0039 . O
. . O O

In P10675331A0600 IN O
contrast P10675331A0600 NN O
, P10675331A0600 , O
c-Src P10675331A0600 JJ I-UN
activated P10675331A0600 VBN O
by P10675331A0600 IN O
isoproterenol P10675331A0600 NN O
led P10675331A0600 VBN O
to P10675331A0600 TO O
tyrosine P10675331A0600 VB O
phosphorylation P10675331A0600 NN O
of P10675331A0600 IN O
Shc P10675331A0600 NNP I-UN
and P10675331A0600 CC O
subsequent P10675331A0600 JJ O
Erk P10675331A0600 NNP I-UN
activation P10675331A0600 NN O
, P10675331A0600 , O
but P10675331A0600 CC O
not P10675331A0600 RB O
tyrosine P10675331A0600 JJ O
phosphorylation P10675331A0600 NN O
of P10675331A0600 IN O
cortactin P10675331A0600 NN I-UN
or P10675331A0600 CC O
Stat3 P10675331A0600 NNP I-UN
. P10675331A0600 . O
. . O O

Genomic P08132541A0000 NNP O
DNA P08132541A0000 NNP O
clones P08132541A0000 NNS O
containing P08132541A0000 VBG O
the P08132541A0000 DT O
T-cell-specific P08132541A0000 JJ I-UN
human P08132541A0000 JJ I-UN
MAL P08132541A0000 NNP I-UN
gene P08132541A0000 NN I-UN
were P08132541A0000 VBD O
isolated P08132541A0000 VBN O
. P08132541A0000 . O
. . O O

Activation P11145887A1393 NN O
of P11145887A1393 IN O
transcription P11145887A1393 NN O
through P11145887A1393 IN O
the P11145887A1393 DT O
AP-1 P11145887A1393 NNP I-UN
site P11145887A1393 NN I-UN
in P11145887A1393 IN O
Jurkat P11145887A1393 NNP O
cells P11145887A1393 NNS O
by P11145887A1393 IN O
JunD P11145887A1393 NNP I-UN
and P11145887A1393 CC O
/ P11145887A1393 NNP O
or P11145887A1393 CC O
Fra-2 P11145887A1393 NNP I-UN
was P11145887A1393 VBD O
weak P11145887A1393 JJ O
. P11145887A1393 . O
c-Jun P11145887A1393 NN I-UN
, P11145887A1393 , O
JunB P11145887A1393 NNP I-UN
, P11145887A1393 , O
and P11145887A1393 CC O
c-Fos P11145887A1393 JJ I-UN
activation P11145887A1393 NN O
was P11145887A1393 VBD O
greater P11145887A1393 JJR O
, P11145887A1393 , O
although P11145887A1393 IN O
the P11145887A1393 DT O
level P11145887A1393 NN O
was P11145887A1393 VBD O
still P11145887A1393 RB O
less P11145887A1393 JJR O
than P11145887A1393 IN O
that P11145887A1393 DT O
with P11145887A1393 IN O
Tax P11145887A1393 NNP I-UN
. P11145887A1393 . O
. . O O

Spasmus P05101762T0000 JJ O
nutans P05101762T0000 NNS O
: P05101762T0000 : O
a P05101762T0000 DT O
syndrome P05101762T0000 NN O
of P05101762T0000 IN O
auto-arousal P05101762T0000 NN O
. P05101762T0000 . O
. . O O

Mutations P01911767T0000 NNS O
in P01911767T0000 IN O
the P01911767T0000 DT O
small P01911767T0000 JJ O
subunit P01911767T0000 NN O
of P01911767T0000 IN O
ribulosebisphosphate P01911767T0000 JJ I-UN
carboxylase P01911767T0000 NN I-UN
affect P01911767T0000 JJ O
subunit P01911767T0000 NN O
binding P01911767T0000 NN O
and P01911767T0000 CC O
catalysis P01911767T0000 NN O
. P01911767T0000 . O
. . O O

LysR P09524276A0939 NNP I-UN
proteins P09524276A0939 NNS I-UN
have P09524276A0939 VBP O
been P09524276A0939 VBN O
shown P09524276A0939 VBN O
to P09524276A0939 TO O
regulate P09524276A0939 VB O
urease P09524276A0939 NN I-UN
in P09524276A0939 IN I-UN
Klebsiella P09524276A0939 NNP I-UN
aerogenes P09524276A0939 NNS I-UN
( P09524276A0939 ( O
NAC P09524276A0939 NNP I-UN
) P09524276A0939 ) O
, P09524276A0939 , O
and P09524276A0939 CC O
catalase P09524276A0939 NN I-UN
in P09524276A0939 IN I-UN
Escherichia P09524276A0939 NNP I-UN
coli P09524276A0939 NN I-UN
( P09524276A0939 ( O
OxyR P09524276A0939 NNP I-UN
) P09524276A0939 ) O
, P09524276A0939 , O
which P09524276A0939 WDT O
offers P09524276A0939 VBZ O
the P09524276A0939 DT O
intracellular P09524276A0939 JJ O
bacterium P09524276A0939 NN O
protection P09524276A0939 NN O
from P09524276A0939 IN O
phagolysosome P09524276A0939 JJ O
damage P09524276A0939 NN O
. P09524276A0939 . O
. . O O

As P07569075A0585 IN O
for P07569075A0585 IN O
31 P07569075A0585 CD O
stage P07569075A0585 NN O
I-II P07569075A0585 JJ O
lung P07569075A0585 NN O
cancer P07569075A0585 NN O
patients P07569075A0585 NNS O
, P07569075A0585 , O
CR P07569075A0585 NNP O
has P07569075A0585 VBZ O
been P07569075A0585 VBN O
observed P07569075A0585 VBN O
in P07569075A0585 IN O
82.8 P07569075A0585 CD O
% P07569075A0585 NN O
of P07569075A0585 IN O
them P07569075A0585 PRP O
and P07569075A0585 CC O
PR P07569075A0585 NNP O
in P07569075A0585 IN O
13.8 P07569075A0585 CD O
% P07569075A0585 NN O
; P07569075A0585 : O
the P07569075A0585 DT O
response P07569075A0585 NN O
was P07569075A0585 VBD O
always P07569075A0585 RB O
assessed P07569075A0585 VBN O
with P07569075A0585 IN O
chest P07569075A0585 NN O
radiography P07569075A0585 NN O
, P07569075A0585 , O
CT P07569075A0585 NNP O
, P07569075A0585 , O
FBS P07569075A0585 NNP O
, P07569075A0585 , O
cytology P07569075A0585 NN O
and P07569075A0585 CC O
/ P07569075A0585 NN O
or P07569075A0585 CC O
histology P07569075A0585 NN O
. P07569075A0585 . O
. . O O

Molecular P07806507A0121 JJ O
dissection P07806507A0121 NN O
of P07806507A0121 IN O
the P07806507A0121 DT O
multimeric P07806507A0121 JJ O
CD3-TCR P07806507A0121 NNP O
complex P07806507A0121 NN O
revealed P07806507A0121 VBD O
that P07806507A0121 IN O
at P07806507A0121 IN O
least P07806507A0121 JJS O
two P07806507A0121 CD O
associated P07806507A0121 JJ O
polypeptides P07806507A0121 NNS O
, P07806507A0121 , O
CD3 P07806507A0121 NNP I-UN
zeta P07806507A0121 NN I-UN
and P07806507A0121 CC O
CD3 P07806507A0121 NNP I-UN
epsilon P07806507A0121 NN I-UN
, P07806507A0121 , O
autonomously P07806507A0121 RB O
couple P07806507A0121 JJ O
antigenic P07806507A0121 JJ O
recognition P07806507A0121 NN O
event P07806507A0121 NN O
to P07806507A0121 TO O
early P07806507A0121 JJ O
and P07806507A0121 CC O
late P07806507A0121 JJ O
events P07806507A0121 NNS O
of P07806507A0121 IN O
the P07806507A0121 DT O
intracytoplasmic P07806507A0121 JJ O
activation P07806507A0121 NN O
cascade P07806507A0121 NN O
. P07806507A0121 . O
. . O O

CDK4 P10344736A0796 NNP I-UN
kinase P10344736A0796 NN I-UN
activities P10344736A0796 NNS O
were P10344736A0796 VBD O
unaffected P10344736A0796 JJ O
, P10344736A0796 , O
as P10344736A0796 IN O
were P10344736A0796 VBD O
the P10344736A0796 DT O
levels P10344736A0796 NNS O
of P10344736A0796 IN O
the P10344736A0796 DT O
CDK P10344736A0796 NNP I-UN
inhibitor P10344736A0796 NN O
p21Cip1 P10344736A0796 NN I-UN
present P10344736A0796 NN O
in P10344736A0796 IN O
cyclin P10344736A0796 NN I-UN
E P10344736A0796 NNP I-UN
immunocomplexes P10344736A0796 NNS I-UN
. P10344736A0796 . O
. . O O

Fusion P01931966A0490 NN O
of P01931966A0490 IN O
ubiquitin P01931966A0490 NN I-UN
to P01931966A0490 TO O
pADPRP P01931966A0490 VB I-UN
increased P01931966A0490 VBN O
the P01931966A0490 DT O
yield P01931966A0490 NN O
of P01931966A0490 IN O
pADPRP P01931966A0490 NN I-UN
approximately P01931966A0490 RB O
10-fold P01931966A0490 JJ O
compared P01931966A0490 VBN O
to P01931966A0490 TO O
that P01931966A0490 DT O
of P01931966A0490 IN O
the P01931966A0490 DT O
unfused P01931966A0490 JJ O
enzyme P01931966A0490 NN O
. P01931966A0490 . O
. . O O

All P10865422A0138 DT O
were P10865422A0138 VBD O
tested P10865422A0138 VBN O
for P10865422A0138 IN O
serum P10865422A0138 NN O
ferritin P10865422A0138 NN I-UN
( P10865422A0138 ( O
SF P10865422A0138 NNP I-UN
) P10865422A0138 ) O
, P10865422A0138 , O
hemoglobin P10865422A0138 FW I-UN
( P10865422A0138 ( O
Hb P10865422A0138 NNP I-UN
) P10865422A0138 ) O
level P10865422A0138 NN O
and P10865422A0138 CC O
asked P10865422A0138 VBD O
for P10865422A0138 IN O
detailed P10865422A0138 JJ O
histories P10865422A0138 NNS O
of P10865422A0138 IN O
donations P10865422A0138 NNS O
and P10865422A0138 CC O
iron P10865422A0138 NN O
supplementation P10865422A0138 NN O
. P10865422A0138 . O
. . O O

Fission P08887647T0000 NNP I-UN
yeast P08887647T0000 NN I-UN
mal2+ P08887647T0000 NN I-UN
is P08887647T0000 VBZ O
required P08887647T0000 VBN O
for P08887647T0000 IN O
chromosome P08887647T0000 NN O
segregation P08887647T0000 NN O
. P08887647T0000 . O
. . O O

In P09360422A0135 IN O
a P09360422A0135 DT O
group P09360422A0135 NN O
of P09360422A0135 IN O
13 P09360422A0135 CD O
patients P09360422A0135 NNS O
with P09360422A0135 IN O
obliterative P09360422A0135 JJ O
arteriopathies P09360422A0135 NNS O
of P09360422A0135 IN O
the P09360422A0135 DT O
lower P09360422A0135 JJR O
limbs P09360422A0135 VBZ O
the P09360422A0135 DT O
plasma P09360422A0135 NN O
levels P09360422A0135 NNS O
of P09360422A0135 IN O
thrombomodulin P09360422A0135 NN I-UN
( P09360422A0135 ( O
TM P09360422A0135 NNP I-UN
) P09360422A0135 ) O
, P09360422A0135 , O
betathromboglobulin P09360422A0135 NN I-UN
( P09360422A0135 ( O
beta-TG P09360422A0135 JJ I-UN
) P09360422A0135 ) O
, P09360422A0135 , O
D-dimer P09360422A0135 NNP O
( P09360422A0135 ( O
DD P09360422A0135 NNP O
) P09360422A0135 ) O
and P09360422A0135 CC O
plasminogen P09360422A0135 JJ I-UN
activator-inhibitor P09360422A0135 NN I-UN
( P09360422A0135 ( O
pAI-1 P09360422A0135 JJ I-UN
) P09360422A0135 ) O
were P09360422A0135 VBD O
measured P09360422A0135 VBN O
, P09360422A0135 , O
and P09360422A0135 CC O
compared P09360422A0135 VBN O
to P09360422A0135 TO O
the P09360422A0135 DT O
values P09360422A0135 NNS O
obtained P09360422A0135 VBN O
from P09360422A0135 IN O
10 P09360422A0135 CD O
healthy P09360422A0135 JJ O
volunteers P09360422A0135 NNS O
. P09360422A0135 . O
. . O O

The P10884978A0633 DT O
duration P10884978A0633 NN O
of P10884978A0633 IN O
reactive P10884978A0633 JJ O
hyperemia P10884978A0633 NN O
decreased P10884978A0633 VBN O
with P10884978A0633 IN O
aging P10884978A0633 VBG O
, P10884978A0633 , O
but P10884978A0633 CC O
the P10884978A0633 DT O
difference P10884978A0633 NN O
between P10884978A0633 IN O
males P10884978A0633 NNS O
and P10884978A0633 CC O
females P10884978A0633 NNS O
was P10884978A0633 VBD O
not P10884978A0633 RB O
significant P10884978A0633 JJ O
at P10884978A0633 IN O
any P10884978A0633 DT O
age P10884978A0633 NN O
. P10884978A0633 . O
. . O O

Five P08533757A0204 CD O
families P08533757A0204 NNS O
of P08533757A0204 IN O
Ashkenazi P08533757A0204 NNP O
Jewish P08533757A0204 NNP O
descent P08533757A0204 NN O
carried P08533757A0204 VBD O
the P08533757A0204 DT O
185delAG P08533757A0204 CD O
mutation P08533757A0204 NN O
and P08533757A0204 CC O
shared P08533757A0204 VBD O
the P08533757A0204 DT O
same P08533757A0204 JJ O
haplotype P08533757A0204 NN O
at P08533757A0204 IN O
eight P08533757A0204 CD O
polymorphic P08533757A0204 JJ O
markers P08533757A0204 NNS O
spanning P08533757A0204 VBG O
approximately P08533757A0204 RB O
850 P08533757A0204 CD O
kb P08533757A0204 NNS O
at P08533757A0204 IN O
BRCA1 P08533757A0204 NNP I-UN
. P08533757A0204 . O
. . O O

Unlike P11255035A0331 IN O
other P11255035A0331 JJ O
progenitor P11255035A0331 NN O
cells P11255035A0331 NNS O
of P11255035A0331 IN O
the P11255035A0331 DT O
brain P11255035A0331 NN O
, P11255035A0331 , O
SVZa P11255035A0331 NNP O
progenitor P11255035A0331 NN O
cells P11255035A0331 NNS O
have P11255035A0331 VBP O
the P11255035A0331 DT O
capacity P11255035A0331 NN O
to P11255035A0331 TO O
divide P11255035A0331 VB O
even P11255035A0331 RB O
though P11255035A0331 IN O
they P11255035A0331 PRP O
express P11255035A0331 VBP O
a P11255035A0331 DT O
neuronal P11255035A0331 JJ O
phenotype P11255035A0331 NN O
. P11255035A0331 . O
. . O O

There P07505798A0000 EX O
are P07505798A0000 VBP O
two P07505798A0000 CD O
immunogenic P07505798A0000 JJ O
sites P07505798A0000 NNS O
on P07505798A0000 IN O
the P07505798A0000 DT O
type P07505798A0000 NN O
A P07505798A0000 NNP O
influenza P07505798A0000 NN O
A P07505798A0000 NNP O
/ P07505798A0000 NNP O
Japan P07505798A0000 NNP O
/ P07505798A0000 VBD O
57 P07505798A0000 CD O
( P07505798A0000 ( O
H2N2 P07505798A0000 NNP O
) P07505798A0000 ) O
hemagglutinin P07505798A0000 NN I-UN
( P07505798A0000 ( O
HA P07505798A0000 NNP I-UN
) P07505798A0000 ) O
that P07505798A0000 WDT O
can P07505798A0000 MD O
be P07505798A0000 VB O
recognized P07505798A0000 VBN O
by P07505798A0000 IN O
class P07505798A0000 NN I-UN
I P07505798A0000 PRP I-UN
major P07505798A0000 JJ I-UN
histocompatibility P07505798A0000 NN I-UN
complex P07505798A0000 NN I-UN
( P07505798A0000 ( O
MHC P07505798A0000 NNP I-UN
) P07505798A0000 ) O
, P07505798A0000 , O
H-2Kd-restricted P07505798A0000 JJ O
cytolytic P07505798A0000 JJ O
T P07505798A0000 NNP O
lymphocytes P07505798A0000 NNS O
( P07505798A0000 ( O
CTLs P07505798A0000 NNP O
) P07505798A0000 ) O
. P07505798A0000 . O
. . O O

In P08567847A1005 IN O
our P08567847A1005 PRP$ O
opinion P08567847A1005 NN O
, P08567847A1005 , O
the P08567847A1005 DT O
SM-CMA P08567847A1005 NNP O
system P08567847A1005 NN O
is P08567847A1005 VBZ O
, P08567847A1005 , O
despite P08567847A1005 IN O
some P08567847A1005 DT O
shortcomings P08567847A1005 NNS O
in P08567847A1005 IN O
its P08567847A1005 PRP$ O
user-interface P08567847A1005 NN O
, P08567847A1005 , O
a P08567847A1005 DT O
useful P08567847A1005 JJ O
and P08567847A1005 CC O
versatile P08567847A1005 JJ O
instrument P08567847A1005 NN O
for P08567847A1005 IN O
examination P08567847A1005 NN O
of P08567847A1005 IN O
human P08567847A1005 JJ O
semen P08567847A1005 NNS O
samples P08567847A1005 NNS O
, P08567847A1005 , O
with P08567847A1005 IN O
desirable P08567847A1005 JJ O
features P08567847A1005 NNS O
. P08567847A1005 . O
. . O O

These P06349364A1051 DT O
results P06349364A1051 NNS O
indicate P06349364A1051 VBP O
that P06349364A1051 IN O
both P06349364A1051 DT O
naturally P06349364A1051 RB O
acquired P06349364A1051 VBN O
and P06349364A1051 CC O
passive P06349364A1051 JJ O
( P06349364A1051 ( O
modified P06349364A1051 VBN O
immune P06349364A1051 NN I-UN
serum P06349364A1051 NN I-UN
globulin P06349364A1051 NN I-UN
) P06349364A1051 ) O
antibodies P06349364A1051 VBZ O
to P06349364A1051 TO O
type P06349364A1051 VB I-UN
III P06349364A1051 NNP I-UN
group P06349364A1051 NN I-UN
B P06349364A1051 NNP I-UN
Streptococcus P06349364A1051 NNP I-UN
antigen P06349364A1051 NN I-UN
are P06349364A1051 VBP O
partially P06349364A1051 RB O
protective P06349364A1051 JJ O
against P06349364A1051 IN O
intra-amniotic P06349364A1051 JJ O
infection P06349364A1051 NN O
. P06349364A1051 . O
. . O O

Phylogenetic P09767687T0000 JJ O
position P09767687T0000 NN O
of P09767687T0000 IN O
the P09767687T0000 DT O
Phacotaceae P09767687T0000 NNP O
within P09767687T0000 IN O
the P09767687T0000 DT O
Chlamydophyceaeas P09767687T0000 NNP O
revealed P09767687T0000 VBN O
by P09767687T0000 IN O
analysis P09767687T0000 NN O
of P09767687T0000 IN O
18S P09767687T0000 CD I-UN
rDNA P09767687T0000 NN I-UN
and P09767687T0000 CC O
rbcL P09767687T0000 NN I-UN
sequences P09767687T0000 NNS I-UN
. P09767687T0000 . O
. . O O

In P08463320A1219 IN O
situ P08463320A1219 JJ O
copper-phenanthroline P08463320A1219 JJ O
footprinting P08463320A1219 NN O
of P08463320A1219 IN O
individual P08463320A1219 JJ O
gel P08463320A1219 NN O
shift P08463320A1219 NN O
assembly P08463320A1219 RB O
intermediates P08463320A1219 VBZ O
shows P08463320A1219 NNS O
that P08463320A1219 IN O
on P08463320A1219 IN O
the P08463320A1219 DT O
302-nucleotide P08463320A1219 JJ O
G4oric P08463320A1219 NNP O
, P08463320A1219 , O
the P08463320A1219 DT O
first P08463320A1219 JJ O
two P08463320A1219 CD O
SSB P08463320A1219 NNP I-UN
tetramers P08463320A1219 NNS I-UN
assemble P08463320A1219 JJ O
at P08463320A1219 IN O
random P08463320A1219 NN O
, P08463320A1219 , O
but P08463320A1219 CC O
the P08463320A1219 DT O
addition P08463320A1219 NN O
of P08463320A1219 IN O
more P08463320A1219 JJR O
SSB P08463320A1219 JJ I-UN
tetramers P08463320A1219 NNS I-UN
results P08463320A1219 NNS O
in P08463320A1219 IN O
formation P08463320A1219 NN O
of P08463320A1219 IN O
a P08463320A1219 DT O
unique P08463320A1219 JJ O
structure P08463320A1219 NN O
. P08463320A1219 . O
. . O O

Mammalian P08013348A0143 JJ I-UN
ABPs P08013348A0143 NNP I-UN
and P08013348A0143 CC O
SHBGs P08013348A0143 NNP I-UN
bind P08013348A0143 VBP O
sex P08013348A0143 NN O
steroids P08013348A0143 NNS O
with P08013348A0143 IN O
high P08013348A0143 JJ O
affinity P08013348A0143 NN O
, P08013348A0143 , O
but P08013348A0143 CC O
some P08013348A0143 DT O
binding P08013348A0143 NN O
properties P08013348A0143 NNS O
differ P08013348A0143 VBP O
among P08013348A0143 IN O
species P08013348A0143 NNS O
. P08013348A0143 . O
. . O O

For P11031773A0174 IN O
this P11031773A0174 DT O
purpose P11031773A0174 NN O
, P11031773A0174 , O
the P11031773A0174 DT O
writhing P11031773A0174 VBG O
test P11031773A0174 NN O
, P11031773A0174 , O
capsaicin P11031773A0174 NN O
and P11031773A0174 CC O
formalin P11031773A0174 JJ O
induced-pain P11031773A0174 NN O
in P11031773A0174 IN O
mice P11031773A0174 NN O
were P11031773A0174 VBD O
used P11031773A0174 VBN O
. P11031773A0174 . O
. . O O

UAS1 P07760841A0221 NNP O
is P07760841A0221 VBZ O
the P07760841A0221 DT O
binding P07760841A0221 NN O
site P07760841A0221 NN O
for P07760841A0221 IN O
the P07760841A0221 DT O
transcriptional P07760841A0221 JJ O
regulator P07760841A0221 NN O
Adr1p P07760841A0221 NNP I-UN
. P07760841A0221 . O
. . O O

Replication P01327758A0000 NN O
of P01327758A0000 IN O
bovine P01327758A0000 JJ O
papillomavirus-1 P01327758A0000 JJ O
( P01327758A0000 ( O
BPV-1 P01327758A0000 NNP O
) P01327758A0000 ) O
DNA P01327758A0000 NNP O
requires P01327758A0000 VBZ O
two P01327758A0000 CD O
viral P01327758A0000 JJ O
gene P01327758A0000 NN O
products P01327758A0000 NNS O
, P01327758A0000 , O
the P01327758A0000 DT O
E1 P01327758A0000 NNP I-UN
protein P01327758A0000 NN I-UN
and P01327758A0000 CC O
the P01327758A0000 DT O
full-length P01327758A0000 JJ I-UN
E2 P01327758A0000 NNP I-UN
protein P01327758A0000 NN I-UN
. P01327758A0000 . O
. . O O

TBARS P11156484A0223 NN O
levels P11156484A0223 NNS O
, P11156484A0223 , O
oxygen-radical P11156484A0223 JJ O
absorbing P11156484A0223 NN O
capacity P11156484A0223 NN O
assay P11156484A0223 NN O
and P11156484A0223 CC O
AFR P11156484A0223 NNP O
release P11156484A0223 NN O
assessed P11156484A0223 VBN O
by P11156484A0223 IN O
electron P11156484A0223 NN O
paramagnetic P11156484A0223 JJ O
resonance P11156484A0223 NN O
( P11156484A0223 ( O
EPR P11156484A0223 NNP O
) P11156484A0223 ) O
were P11156484A0223 VBD O
used P11156484A0223 VBN O
to P11156484A0223 TO O
explore P11156484A0223 VB O
the P11156484A0223 DT O
existence P11156484A0223 NN O
of P11156484A0223 IN O
oxidative P11156484A0223 JJ O
stress P11156484A0223 NN O
in P11156484A0223 IN O
diabetes P11156484A0223 NNS O
. P11156484A0223 . O
. . O O

Gag P09261397A0509 NNP I-UN
protein P09261397A0509 NN O
sequence P09261397A0509 NN O
motifs P09261397A0509 NNS O
of P09261397A0509 IN O
the P09261397A0509 DT O
NC P09261397A0509 NNP I-UN
domain P09261397A0509 NN I-UN
of P09261397A0509 IN O
primate P09261397A0509 NN O
foamy P09261397A0509 NN O
viruses P09261397A0509 NNS O
assumed P09261397A0509 VBD O
to P09261397A0509 TO O
be P09261397A0509 VB O
involved P09261397A0509 VBN O
in P09261397A0509 IN O
genome P09261397A0509 JJ O
encapsidation P09261397A0509 NN O
are P09261397A0509 VBP O
not P09261397A0509 RB O
conserved P09261397A0509 VBN O
in P09261397A0509 IN O
FeFV P09261397A0509 NNP O
. P09261397A0509 . O
. . O O

The P10567589A1268 DT O
multiple P10567589A1268 JJ O
functions P10567589A1268 NNS O
of P10567589A1268 IN O
Pmt3p P10567589A1268 NNP I-UN
described P10567589A1268 VBD O
here P10567589A1268 RB O
suggest P10567589A1268 VBP O
that P10567589A1268 IN O
several P10567589A1268 JJ O
nuclear P10567589A1268 JJ O
proteins P10567589A1268 NNS O
are P10567589A1268 VBP O
regulated P10567589A1268 VBN O
by P10567589A1268 IN O
Pmt3p P10567589A1268 NNP I-UN
conjugation P10567589A1268 NN O
. P10567589A1268 . O
. . O O

The P03306340A0537 DT O
intrapancreatic P03306340A0537 JJ O
spread P03306340A0537 NN O
of P03306340A0537 IN O
the P03306340A0537 DT O
carcinoma P03306340A0537 NN O
correlated P03306340A0537 VBD O
with P03306340A0537 IN O
portal P03306340A0537 JJ O
invasion P03306340A0537 NN O
of P03306340A0537 IN O
carcinoma P03306340A0537 NN O
, P03306340A0537 , O
hardness P03306340A0537 NN O
of P03306340A0537 IN O
the P03306340A0537 DT O
body P03306340A0537 NN O
and P03306340A0537 CC O
tail P03306340A0537 NN O
, P03306340A0537 , O
obstruction P03306340A0537 NN O
of P03306340A0537 IN O
main P03306340A0537 JJ O
pancreatic P03306340A0537 JJ O
duct P03306340A0537 NN O
and P03306340A0537 CC O
irregular P03306340A0537 JJ O
pancreaticogram P03306340A0537 NN O
. P03306340A0537 . O
. . O O

Radiation P02541882A0251 NNP O
therapy P02541882A0251 NN O
was P02541882A0251 VBD O
effective P02541882A0251 JJ O
in P02541882A0251 IN O
controlling P02541882A0251 VBG O
symptomatic P02541882A0251 JJ O
metastasis P02541882A0251 NN O
in P02541882A0251 IN O
all P02541882A0251 DT O
three P02541882A0251 CD O
patients P02541882A0251 NNS O
. P02541882A0251 . O
. . O O

Selenium P07084198T0000 NN O
status P07084198T0000 NN O
of P07084198T0000 IN O
thoroughbreds P07084198T0000 NNS O
in P07084198T0000 IN O
the P07084198T0000 DT O
United P07084198T0000 NNP O
Kingdom P07084198T0000 NNP O
. P07084198T0000 . O
. . O O

The P09115265A1160 DT O
carboxyl-terminal P09115265A1160 JJ O
CCCC P09115265A1160 NNP O
module P09115265A1160 NN O
is P09115265A1160 VBZ O
structurally P09115265A1160 RB O
related P09115265A1160 VBN O
to P09115265A1160 TO O
the P09115265A1160 DT O
DNA-binding P09115265A1160 NNP O
domain P09115265A1160 NN O
of P09115265A1160 IN O
the P09115265A1160 DT O
erythroid P09115265A1160 JJ I-UN
transcription P09115265A1160 NN I-UN
factor P09115265A1160 NN I-UN
GATA-1 P09115265A1160 NNP I-UN
. P09115265A1160 . O
. . O O

Taken P11094066A1194 VBN O
together P11094066A1194 RB O
, P11094066A1194 , O
these P11094066A1194 DT O
observations P11094066A1194 NNS O
indicate P11094066A1194 VBP O
that P11094066A1194 IN O
inhibition P11094066A1194 NN O
of P11094066A1194 IN O
p27 P11094066A1194 NN I-UN
( P11094066A1194 ( O
KIP1 P11094066A1194 NNP I-UN
) P11094066A1194 ) O
transcription P11094066A1194 NN O
through P11094066A1194 IN O
PI3K-induced P11094066A1194 NNP O
FKHR-L1 P11094066A1194 NNP I-UN
phosphorylation P11094066A1194 NN O
provides P11094066A1194 VBZ O
a P11094066A1194 DT O
novel P11094066A1194 JJ O
mechanism P11094066A1194 NN O
of P11094066A1194 IN O
regulating P11094066A1194 VBG O
cytokine-mediated P11094066A1194 JJ O
survival P11094066A1194 NN O
and P11094066A1194 CC O
proliferation P11094066A1194 NN O
. P11094066A1194 . O
. . O O

Expression P07935375A1197 NN O
of P07935375A1197 IN O
a P07935375A1197 DT O
dominant-negative P07935375A1197 JJ I-UN
ras P07935375A1197 NN I-UN
gene P07935375A1197 NN I-UN
also P07935375A1197 RB O
blocks P07935375A1197 VBZ O
TIS10 P07935375A1197 NNP I-UN
/ P07935375A1197 NNP O
PGS2 P07935375A1197 NNP I-UN
induction P07935375A1197 NN O
by P07935375A1197 IN O
v-src P07935375A1197 NN I-UN
. P07935375A1197 . O
. . O O

P. P09442024A0236 NNP O
, P09442024A0236 , O
Peyron P09442024A0236 NNP O
, P09442024A0236 , O
J P09442024A0236 NNP O
. P09442024A0236 . O
. . O O

Analysis P09780336A0771 NN O
of P09780336A0771 IN O
Msy2 P09780336A0771 NNP I-UN
mRNA P09780336A0771 FW I-UN
expression P09780336A0771 NN O
in P09780336A0771 IN O
prepubertal P09780336A0771 JJ O
and P09780336A0771 CC O
adult P09780336A0771 NN O
mouse P09780336A0771 NN O
testes P09780336A0771 NNS O
, P09780336A0771 , O
and P09780336A0771 CC O
in P09780336A0771 IN O
isolated P09780336A0771 JJ O
populations P09780336A0771 NNS O
of P09780336A0771 IN O
germ P09780336A0771 NN O
cells P09780336A0771 NNS O
, P09780336A0771 , O
reveals P09780336A0771 NNS O
maximal P09780336A0771 JJ O
expression P09780336A0771 NN O
in P09780336A0771 IN O
postmeiotic P09780336A0771 JJ O
round P09780336A0771 NN O
spermatids P09780336A0771 NNS O
, P09780336A0771 , O
a P09780336A0771 DT O
cell P09780336A0771 NN O
type P09780336A0771 NN O
with P09780336A0771 IN O
abundant P09780336A0771 JJ O
amounts P09780336A0771 NNS O
of P09780336A0771 IN O
stored P09780336A0771 JJ O
messenger P09780336A0771 NN O
ribonucleoproteins P09780336A0771 NNS O
. P09780336A0771 . O
. . O O

The P07752886A0595 DT O
smallest P07752886A0595 JJS O
active P07752886A0595 JJ I-UN
FecR P07752886A0595 NNP I-UN
derivative P07752886A0595 NN I-UN
contained P07752886A0595 VBD O
59 P07752886A0595 CD O
amino P07752886A0595 NN O
acid P07752886A0595 NN O
residues P07752886A0595 NNS O
as P07752886A0595 IN O
compared P07752886A0595 VBN O
to P07752886A0595 TO O
the P07752886A0595 DT O
317 P07752886A0595 CD O
residues P07752886A0595 NNS O
of P07752886A0595 IN O
wild-type P07752886A0595 JJ I-UN
FecR P07752886A0595 NNP I-UN
. P07752886A0595 . O
. . O O

Effect P08222556T0000 NN O
of P08222556T0000 IN O
aging P08222556T0000 VBG O
on P08222556T0000 IN O
respiratory P08222556T0000 NN O
skeletal P08222556T0000 JJ O
muscles P08222556T0000 NNS O
. P08222556T0000 . O
. . O O

Isolation P06130348T0000 NN O
of P06130348T0000 IN O
Aeromonas P06130348T0000 NNP O
from P06130348T0000 IN O
faeces P06130348T0000 NNS O
. P06130348T0000 . O
. . O O

Further P10318918A0824 RB O
, P10318918A0824 , O
mutational P10318918A0824 JJ O
analysis P10318918A0824 NN O
of P10318918A0824 IN O
NS5A P10318918A0824 NNP I-UN
assigned P10318918A0824 VBD O
the P10318918A0824 DT O
SH3-binding P10318918A0824 JJ I-UN
region P10318918A0824 NN I-UN
to P10318918A0824 TO O
a P10318918A0824 DT O
proline-rich P10318918A0824 JJ O
motif P10318918A0824 NN O
that P10318918A0824 WDT O
is P10318918A0824 VBZ O
highly P10318918A0824 RB O
conserved P10318918A0824 VBN O
among P10318918A0824 IN O
HCV P10318918A0824 NNP O
genotypes P10318918A0824 NNS O
. P10318918A0824 . O
. . O O

CONCLUSIONS P11054011A1685 NN O
: P11054011A1685 : O
The P11054011A1685 DT O
surgical P11054011A1685 JJ O
or P11054011A1685 CC O
multimodality P11054011A1685 NN O
treatment P11054011A1685 NN O
of P11054011A1685 IN O
MSGT P11054011A1685 NNP O
has P11054011A1685 VBZ O
provided P11054011A1685 VBN O
a P11054011A1685 DT O
good P11054011A1685 JJ O
locoregional P11054011A1685 NN O
control P11054011A1685 NN O
( P11054011A1685 ( O
78 P11054011A1685 CD O
% P11054011A1685 NN O
) P11054011A1685 ) O
and P11054011A1685 CC O
68 P11054011A1685 CD O
% P11054011A1685 NN O
10-year P11054011A1685 JJ O
survival P11054011A1685 NN O
in P11054011A1685 IN O
a P11054011A1685 DT O
series P11054011A1685 NN O
of P11054011A1685 IN O
patients P11054011A1685 NNS O
treated P11054011A1685 VBN O
at P11054011A1685 IN O
the P11054011A1685 DT O
oncology P11054011A1685 NN O
department P11054011A1685 NN O
of P11054011A1685 IN O
a P11054011A1685 DT O
general P11054011A1685 JJ O
hospital P11054011A1685 NN O
in P11054011A1685 IN O
Quito P11054011A1685 NNP O
, P11054011A1685 , O
Ecuador P11054011A1685 NNP O
. P11054011A1685 . O
. . O O

Immunofluorescence P08684522A0415 NNP O
microscopy P08684522A0415 NN O
revealed P08684522A0415 VBD O
extensive P08684522A0415 JJ O
deposition P08684522A0415 NN O
of P08684522A0415 IN O
such P08684522A0415 JJ O
extracellular P08684522A0415 JJ O
matrices P08684522A0415 NNS O
as P08684522A0415 IN O
type P08684522A0415 NN I-UN
IV P08684522A0415 NNP I-UN
collagen P08684522A0415 NN I-UN
and P08684522A0415 CC O
laminin P08684522A0415 NN I-UN
in P08684522A0415 IN O
the P08684522A0415 DT O
vascular P08684522A0415 JJ O
wall P08684522A0415 NN O
. P08684522A0415 . O
. . O O

Genetic P09450932A0142 JJ O
analysis P09450932A0142 NN O
has P09450932A0142 VBZ O
subsequently P09450932A0142 RB O
identified P09450932A0142 VBN O
subpathways P09450932A0142 NNS O
of P09450932A0142 IN O
the P09450932A0142 DT O
DNA P09450932A0142 NN O
structure P09450932A0142 NN O
checkpoints P09450932A0142 NNS O
, P09450932A0142 , O
including P09450932A0142 VBG O
the P09450932A0142 DT O
reversible P09450932A0142 JJ O
arrest P09450932A0142 NN O
of P09450932A0142 IN O
DNA P09450932A0142 NNP O
synthesis P09450932A0142 NN O
. P09450932A0142 . O
. . O O

High-resolution P01516427T0000 NN O
computed P01516427T0000 VBD O
tomography P01516427T0000 NN O
in P01516427T0000 IN O
the P01516427T0000 DT O
diagnosis P01516427T0000 NN O
of P01516427T0000 IN O
miliary P01516427T0000 JJ O
tuberculosis P01516427T0000 NN O
. P01516427T0000 . O
. . O O

From P03440780A0779 IN O
these P03440780A0779 DT O
results P03440780A0779 NNS O
, P03440780A0779 , O
it P03440780A0779 PRP O
is P03440780A0779 VBZ O
concluded P03440780A0779 VBN O
that P03440780A0779 IN O
EDLF P03440780A0779 NNP O
has P03440780A0779 VBZ O
clear P03440780A0779 JJ O
vasoconstrictor P03440780A0779 NN O
properties P03440780A0779 NNS O
which P03440780A0779 WDT O
are P03440780A0779 VBP O
not P03440780A0779 RB O
due P03440780A0779 JJ O
to P03440780A0779 TO O
adrenergic P03440780A0779 VB O
or P03440780A0779 CC O
calcium P03440780A0779 VB O
entry P03440780A0779 NN O
mechanisms P03440780A0779 NNS O
and P03440780A0779 CC O
that P03440780A0779 IN O
there P03440780A0779 EX O
are P03440780A0779 VBP O
differences P03440780A0779 NNS O
in P03440780A0779 IN O
the P03440780A0779 DT O
vasoconstrictor P03440780A0779 NN O
effects P03440780A0779 NNS O
of P03440780A0779 IN O
EDLFs P03440780A0779 NNP O
with P03440780A0779 IN O
respect P03440780A0779 NN O
to P03440780A0779 TO O
different P03440780A0779 JJ O
vascular P03440780A0779 JJ O
beds P03440780A0779 NNS O
. P03440780A0779 . O
. . O O

Gestational P01354506T0000 NNP O
trophoblastic P01354506T0000 JJ O
diseases P01354506T0000 NNS O
: P01354506T0000 : O
recent P01354506T0000 JJ O
advances P01354506T0000 NNS O
in P01354506T0000 IN O
the P01354506T0000 DT O
understanding P01354506T0000 NN O
of P01354506T0000 IN O
cytogenetics P01354506T0000 NNS O
, P01354506T0000 , O
histopathology P01354506T0000 NN O
, P01354506T0000 , O
and P01354506T0000 CC O
natural P01354506T0000 JJ O
history P01354506T0000 NN O
. P01354506T0000 . O
. . O O

Application P10764574A0718 NN O
of P10764574A0718 IN O
the P10764574A0718 DT O
method P10764574A0718 NN O
to P10764574A0718 TO O
a P10764574A0718 DT O
representative P10764574A0718 JJ O
set P10764574A0718 NN O
of P10764574A0718 IN O
50 P10764574A0718 CD O
known P10764574A0718 VBN O
genes P10764574A0718 NNS O
from P10764574A0718 IN O
Arabidopsis P10764574A0718 NNP O
thaliana P10764574A0718 NN O
showed P10764574A0718 VBD O
significant P10764574A0718 JJ O
improvement P10764574A0718 NN O
in P10764574A0718 IN O
prediction P10764574A0718 NN O
accuracy P10764574A0718 NN O
compared P10764574A0718 VBN O
to P10764574A0718 TO O
previous P10764574A0718 JJ O
spliced P10764574A0718 JJ O
alignment P10764574A0718 NN O
methods P10764574A0718 NNS O
. P10764574A0718 . O
. . O O

81 P02986279A0000 CD O
milk P02986279A0000 NN O
samples P02986279A0000 NNS O
collected P02986279A0000 VBN O
from P02986279A0000 IN O
35 P02986279A0000 CD O
donors P02986279A0000 NNS O
3 P02986279A0000 CD O
days P02986279A0000 NNS O
to P02986279A0000 TO O
7 P02986279A0000 CD O
months P02986279A0000 NNS O
after P02986279A0000 IN O
delivery P02986279A0000 NN O
were P02986279A0000 VBD O
examined P02986279A0000 VBN O
for P02986279A0000 IN O
the P02986279A0000 DT O
occurrence P02986279A0000 NN O
of P02986279A0000 IN O
cytomegalovirus P02986279A0000 NN O
( P02986279A0000 ( O
CMV P02986279A0000 NNP O
) P02986279A0000 ) O
. P02986279A0000 . O
. . O O

We P08255758A0000 PRP O
have P08255758A0000 VBP O
identified P08255758A0000 VBN O
in P08255758A0000 IN O
the P08255758A0000 DT O
5 P08255758A0000 CD O
' P08255758A0000 POS O
untranslated P08255758A0000 JJ O
region P08255758A0000 NN O
of P08255758A0000 IN O
the P08255758A0000 DT O
Drosophila P08255758A0000 NNP I-UN
copia P08255758A0000 NN I-UN
retrotransposon P08255758A0000 NN I-UN
, P08255758A0000 , O
3 P08255758A0000 CD O
' P08255758A0000 '' O
to P08255758A0000 TO O
the P08255758A0000 DT O
left P08255758A0000 NN O
LTR P08255758A0000 NNP O
, P08255758A0000 , O
a P08255758A0000 DT O
sequence P08255758A0000 NN O
for P08255758A0000 IN O
transcriptional P08255758A0000 JJ O
regulation P08255758A0000 NN O
by P08255758A0000 IN O
homeoproteins P08255758A0000 NNS O
. P08255758A0000 . O
. . O O

Serum P09549179A0774 NNP O
levels P09549179A0774 NNS O
of P09549179A0774 IN O
testosterone P09549179A0774 NN O
also P09549179A0774 RB O
showed P09549179A0774 VBD O
no P09549179A0774 DT O
significant P09549179A0774 JJ O
changes P09549179A0774 NNS O
by P09549179A0774 IN O
exposure P09549179A0774 NN O
to P09549179A0774 TO O
p P09549179A0774 VB O
, P09549179A0774 , O
p'-DDE P09549179A0774 JJ O
under P09549179A0774 IN O
the P09549179A0774 DT O
conditions P09549179A0774 NNS O
of P09549179A0774 IN O
this P09549179A0774 DT O
study P09549179A0774 NN O
. P09549179A0774 . O
. . O O

Taken P10498706A1219 VBN O
together P10498706A1219 RB O
, P10498706A1219 , O
our P10498706A1219 PRP$ O
data P10498706A1219 NNS O
suggest P10498706A1219 VBP O
that P10498706A1219 IN O
PecS P10498706A1219 NNP I-UN
attenuates P10498706A1219 VBZ O
pelD P10498706A1219 NNS I-UN
and P10498706A1219 CC O
pelE P10498706A1219 JJ I-UN
expression P10498706A1219 NN O
rather P10498706A1219 RB O
than P10498706A1219 IN O
acting P10498706A1219 VBG O
as P10498706A1219 IN O
a P10498706A1219 DT O
true P10498706A1219 JJ O
repressor P10498706A1219 NN O
like P10498706A1219 IN O
KdgR P10498706A1219 NNP I-UN
. P10498706A1219 . O
. . O O

A P02981840A0907 DT O
114-base P02981840A0907 JJ O
pair P02981840A0907 NN O
sequence P02981840A0907 NN O
of P02981840A0907 IN O
predominantly P02981840A0907 RB O
repeating P02981840A0907 VBG O
purine-pyrimidine P02981840A0907 JJ O
nucleotides P02981840A0907 NNS O
separates P02981840A0907 VBZ O
these P02981840A0907 DT O
two P02981840A0907 CD O
d P02981840A0907 NN O
( P02981840A0907 ( O
AC P02981840A0907 NNP O
) P02981840A0907 ) O
repeats P02981840A0907 NNS O
. P02981840A0907 . O
. . O O

Sequence P09139910A0350 NNP O
analysis P09139910A0350 NN O
of P09139910A0350 IN O
cloned P09139910A0350 VBN O
PCR P09139910A0350 NNP O
products P09139910A0350 NNS O
confirmed P09139910A0350 VBD O
the P09139910A0350 DT O
presence P09139910A0350 NN O
of P09139910A0350 IN O
two P09139910A0350 CD O
different P09139910A0350 JJ O
nifV-like P09139910A0350 JJ I-UN
DNA P09139910A0350 NN I-UN
fragments P09139910A0350 NNS I-UN
, P09139910A0350 , O
which P09139910A0350 WDT O
were P09139910A0350 VBD O
subsequently P09139910A0350 RB O
used P09139910A0350 VBN O
as P09139910A0350 IN O
nifV- P09139910A0350 JJ O
and P09139910A0350 CC O
leuA-specific P09139910A0350 JJ I-UN
probes P09139910A0350 NNS I-UN
, P09139910A0350 , O
respectively P09139910A0350 RB O
, P09139910A0350 , O
to P09139910A0350 TO O
clone P09139910A0350 VB O
XbaI P09139910A0350 NNP I-UN
fragments P09139910A0350 NNS I-UN
of P09139910A0350 IN O
2.1 P09139910A0350 CD O
kbp P09139910A0350 NNS O
( P09139910A0350 ( O
pOST4 P09139910A0350 NN O
) P09139910A0350 ) O
and P09139910A0350 CC O
2.6 P09139910A0350 CD O
kbp P09139910A0350 NN O
( P09139910A0350 ( O
pOST2 P09139910A0350 NN O
) P09139910A0350 ) O
. P09139910A0350 . O
. . O O

A P08647822T0000 DT O
direct P08647822T0000 JJ O
role P08647822T0000 NN O
for P08647822T0000 IN O
sterol P08647822T0000 NN I-UN
regulatory P08647822T0000 JJ I-UN
element P08647822T0000 NN I-UN
binding P08647822T0000 VBG I-UN
protein P08647822T0000 NN I-UN
in P08647822T0000 IN O
activation P08647822T0000 NN O
of P08647822T0000 IN O
3-hydroxy-3-methylglutaryl P08647822T0000 JJ I-UN
coenzyme P08647822T0000 NN I-UN
A P08647822T0000 NNP I-UN
reductase P08647822T0000 NN I-UN
gene P08647822T0000 NN I-UN
. P08647822T0000 . O
. . O O

Before P04040307A0145 IN O
birth P04040307A0145 NN O
, P04040307A0145 , O
there P04040307A0145 EX O
were P04040307A0145 VBD O
a P04040307A0145 DT O
few P04040307A0145 JJ O
perivascular P04040307A0145 JJ O
adrenergic P04040307A0145 JJ O
nerves P04040307A0145 NNS O
and P04040307A0145 CC O
correspondingly P04040307A0145 RB O
low P04040307A0145 JJ O
ovarian P04040307A0145 JJ O
NE P04040307A0145 NNP O
levels P04040307A0145 NNS O
. P04040307A0145 . O
. . O O

Genomic P08224907A0000 NNP O
Southern P08224907A0000 NNP O
blot P08224907A0000 NN O
analysis P08224907A0000 NN O
of P08224907A0000 IN O
rat P08224907A0000 NN I-UN
EFIA P08224907A0000 NNP I-UN
( P08224907A0000 ( O
gene P08224907A0000 NN O
encoding P08224907A0000 VBG O
enhancer P08224907A0000 JJ I-UN
factor P08224907A0000 NN I-UN
I P08224907A0000 PRP I-UN
subunit P08224907A0000 VBP I-UN
A P08224907A0000 DT I-UN
) P08224907A0000 ) O
reveals P08224907A0000 VBZ O
a P08224907A0000 DT O
complex P08224907A0000 JJ O
band P08224907A0000 NN O
pattern P08224907A0000 NN O
when P08224907A0000 WRB O
cDNA P08224907A0000 NN O
subfragment P08224907A0000 NN O
probes P08224907A0000 NNS O
are P08224907A0000 VBP O
used P08224907A0000 VBN O
. P08224907A0000 . O
. . O O

The P08884273A1413 DT O
TYAC P08884273A1413 NNP O
/ P08884273A1413 NNP O
P1 P08884273A1413 NNP O
resource P08884273A1413 NN O
, P08884273A1413 , O
derivative P08884273A1413 JJ O
STSs P08884273A1413 NNP O
, P08884273A1413 , O
and P08884273A1413 CC O
polymorphisms P08884273A1413 NNS O
constitute P08884273A1413 VBP O
an P08884273A1413 DT O
enabling P08884273A1413 VBG O
resource P08884273A1413 NN O
to P08884273A1413 TO O
further P08884273A1413 JJ O
studies P08884273A1413 NNS O
of P08884273A1413 IN O
telomere P08884273A1413 JJ O
structure P08884273A1413 NN O
and P08884273A1413 CC O
function P08884273A1413 NN O
and P08884273A1413 CC O
a P08884273A1413 DT O
means P08884273A1413 NN O
for P08884273A1413 IN O
physical P08884273A1413 JJ O
and P08884273A1413 CC O
genetic P08884273A1413 JJ O
map P08884273A1413 NN O
integration P08884273A1413 NN O
and P08884273A1413 CC O
closure P08884273A1413 NN O
. P08884273A1413 . O
. . O O

However P09411459A0729 RB O
, P09411459A0729 , O
in P09411459A0729 IN O
a P09411459A0729 DT O
new P09411459A0729 JJ O
experiment P09411459A0729 NN O
in P09411459A0729 IN O
which P09411459A0729 WDT O
the P09411459A0729 DT O
deletion P09411459A0729 NN O
task P09411459A0729 NN O
was P09411459A0729 VBD O
presented P09411459A0729 VBN O
as P09411459A0729 IN O
a P09411459A0729 DT O
puppet P09411459A0729 NN O
game P09411459A0729 NN O
, P09411459A0729 , O
and P09411459A0729 CC O
with P09411459A0729 IN O
pretraining P09411459A0729 NN O
and P09411459A0729 CC O
selection P09411459A0729 NN O
on P09411459A0729 IN O
vowel P09411459A0729 NN O
deletion P09411459A0729 NN O
, P09411459A0729 , O
a P09411459A0729 DT O
significantly P09411459A0729 RB O
higher P09411459A0729 JJR O
level P09411459A0729 NN O
of P09411459A0729 IN O
success P09411459A0729 NN O
was P09411459A0729 VBD O
achieved P09411459A0729 VBN O
by P09411459A0729 IN O
the P09411459A0729 DT O
children P09411459A0729 NNS O
working P09411459A0729 VBG O
with P09411459A0729 IN O
the P09411459A0729 DT O
CVCC P09411459A0729 NNP O
material P09411459A0729 NN O
. P09411459A0729 . O
. . O O

RXR-gamma P09716179A0974 JJ I-UN
expression P09716179A0974 NN O
produced P09716179A0974 VBD O
significant P09716179A0974 JJ O
reduction P09716179A0974 NN O
in P09716179A0974 IN O
levels P09716179A0974 NNS O
of P09716179A0974 IN O
RA-responsive P09716179A0974 JJ O
genes P09716179A0974 NNS O
including P09716179A0974 VBG O
the P09716179A0974 DT O
cyclin-dependent P09716179A0974 JJ I-UN
kinase P09716179A0974 NN I-UN
inhibitors P09716179A0974 NNS O
p21Cip1 P09716179A0974 VBP I-UN
/ P09716179A0974 JJ O
WAF1 P09716179A0974 NNP I-UN
and P09716179A0974 CC O
p27Kip1 P09716179A0974 NN I-UN
, P09716179A0974 , O
resulting P09716179A0974 VBG O
in P09716179A0974 IN O
increased P09716179A0974 VBN O
cdc2 P09716179A0974 NN I-UN
and P09716179A0974 CC O
cdk2 P09716179A0974 JJ I-UN
kinase P09716179A0974 NN I-UN
activity P09716179A0974 NN O
and P09716179A0974 CC O
RB P09716179A0974 NNP I-UN
phosphorylation P09716179A0974 NN O
. P09716179A0974 . O
. . O O

Within P03104248A0322 IN O
Stage P03104248A0322 NNP O
IA P03104248A0322 NNP O
, P03104248A0322 , O
141 P03104248A0322 CD O
patients P03104248A0322 NNS O
had P03104248A0322 VBD O
well P03104248A0322 RB O
differentiated P03104248A0322 VBN O
tumor P03104248A0322 NN O
( P03104248A0322 ( O
G1 P03104248A0322 NNP O
) P03104248A0322 ) O
, P03104248A0322 , O
20 P03104248A0322 CD O
had P03104248A0322 VBD O
moderately P03104248A0322 RB O
well P03104248A0322 RB O
differentiated P03104248A0322 JJ O
tumor P03104248A0322 NN O
( P03104248A0322 ( O
G2 P03104248A0322 NNP O
) P03104248A0322 ) O
, P03104248A0322 , O
and P03104248A0322 CC O
12 P03104248A0322 CD O
patients P03104248A0322 NNS O
had P03104248A0322 VBD O
poorly P03104248A0322 RB O
differentiated P03104248A0322 VBN O
( P03104248A0322 ( O
G3 P03104248A0322 NNP O
) P03104248A0322 ) O
. P03104248A0322 . O
. . O O

SPA P03380547A0169 NN O
from P03380547A0169 IN O
PAG P03380547A0169 NNP O
sites P03380547A0169 NNS O
was P03380547A0169 VBD O
associated P03380547A0169 VBN O
with P03380547A0169 IN O
aversion P03380547A0169 NN O
. P03380547A0169 . O
. . O O

We P07791764A0357 PRP O
report P07791764A0357 VBP O
here P07791764A0357 RB O
that P07791764A0357 IN O
in P07791764A0357 IN O
cultured P07791764A0357 JJ O
Jurkat P07791764A0357 NNP O
T P07791764A0357 NNP O
cells P07791764A0357 NNS O
, P07791764A0357 , O
Cbl P07791764A0357 NNP I-UN
is P07791764A0357 VBZ O
coprecipitated P07791764A0357 VBN O
with P07791764A0357 IN O
antibody P07791764A0357 NN O
against P07791764A0357 IN O
the P07791764A0357 DT O
adapter P07791764A0357 NN I-UN
protein P07791764A0357 NN I-UN
Grb2 P07791764A0357 NNP I-UN
. P07791764A0357 . O
. . O O

Amikacin P03717936A0252 NNP O
was P03717936A0252 VBD O
the P03717936A0252 DT O
most P03717936A0252 RBS O
stable P03717936A0252 JJ O
and P03717936A0252 CC O
tobramycin P03717936A0252 NN O
was P03717936A0252 VBD O
the P03717936A0252 DT O
least P03717936A0252 JJS O
stable P03717936A0252 JJ O
aminoglycoside P03717936A0252 NN O
under P03717936A0252 IN O
the P03717936A0252 DT O
conditions P03717936A0252 NNS O
tested P03717936A0252 VBD O
. P03717936A0252 . O
. . O O

We P09043768A0139 PRP O
have P09043768A0139 VBP O
studied P09043768A0139 VBN O
the P09043768A0139 DT O
biokinetics P09043768A0139 NNS O
of P09043768A0139 IN O
BLM P09043768A0139 NNP O
labeled P09043768A0139 VBD O
with P09043768A0139 IN O
indium-111 P09043768A0139 JJ O
( P09043768A0139 ( O
In-111 P09043768A0139 NNP O
) P09043768A0139 ) O
. P09043768A0139 . O
. . O O

Most P09185586A0000 JJS O
eukaryotic P09185586A0000 JJ O
mRNAs P09185586A0000 NN O
are P09185586A0000 VBP O
translated P09185586A0000 VBN O
by P09185586A0000 IN O
a P09185586A0000 DT O
`` P09185586A0000 `` O
scanning P09185586A0000 JJ O
ribosome P09185586A0000 NN O
'' P09185586A0000 '' O
mechanism P09185586A0000 NN O
. P09185586A0000 . O
. . O O

Epstein-Barr P08709224T0000 JJ I-UN
virus P08709224T0000 NN I-UN
nuclear P08709224T0000 JJ I-UN
protein P08709224T0000 NN I-UN
2 P08709224T0000 CD I-UN
( P08709224T0000 ( O
EBNA2 P08709224T0000 NNP I-UN
) P08709224T0000 ) O
binds P08709224T0000 VBZ O
to P08709224T0000 TO O
a P08709224T0000 DT O
component P08709224T0000 NN O
of P08709224T0000 IN O
the P08709224T0000 DT O
human P08709224T0000 JJ O
SNF-SWI P08709224T0000 NNP O
complex P08709224T0000 NN O
, P08709224T0000 , O
hSNF5 P08709224T0000 NN I-UN
/ P08709224T0000 NNP O
Ini1 P08709224T0000 NNP I-UN
. P08709224T0000 . O
. . O O

When P02983316A0310 WRB O
the P02983316A0310 DT O
coding P02983316A0310 NN O
segments P02983316A0310 NNS O
, P02983316A0310 , O
including P02983316A0310 VBG O
both P02983316A0310 DT O
framework P02983316A0310 NN O
and P02983316A0310 CC O
complementarity-determining P02983316A0310 JJ O
regions P02983316A0310 NNS O
, P02983316A0310 , O
of P02983316A0310 IN O
these P02983316A0310 DT O
genes P02983316A0310 NNS O
and P02983316A0310 CC O
the P02983316A0310 DT O
murine P02983316A0310 NN O
probe P02983316A0310 NN O
sequences P02983316A0310 NNS O
are P02983316A0310 VBP O
compared P02983316A0310 VBN O
by P02983316A0310 IN O
metric P02983316A0310 JJ O
analysis P02983316A0310 NN O
, P02983316A0310 , O
it P02983316A0310 PRP O
is P02983316A0310 VBZ O
apparent P02983316A0310 JJ O
that P02983316A0310 IN O
the P02983316A0310 DT O
caiman P02983316A0310 NN O
genes P02983316A0310 NNS O
are P02983316A0310 VBP O
only P02983316A0310 RB O
slightly P02983316A0310 RB O
more P02983316A0310 RBR O
related P02983316A0310 JJ O
to P02983316A0310 TO O
each P02983316A0310 DT O
other P02983316A0310 JJ O
than P02983316A0310 IN O
to P02983316A0310 TO O
the P02983316A0310 DT O
mammalian P02983316A0310 JJ O
sequence P02983316A0310 NN O
, P02983316A0310 , O
consistent P02983316A0310 JJ O
with P02983316A0310 IN O
significant P02983316A0310 JJ O
preservation P02983316A0310 NN O
of P02983316A0310 IN O
nucleotide P02983316A0310 JJ O
sequence P02983316A0310 NN O
over P02983316A0310 IN O
an P02983316A0310 DT O
extended P02983316A0310 JJ O
period P02983316A0310 NN O
of P02983316A0310 IN O
phylogenetic P02983316A0310 JJ O
time P02983316A0310 NN O
. P02983316A0310 . O
. . O O

The P07508082A0821 DT O
highest P07508082A0821 JJS O
decrease P07508082A0821 NN O
in P07508082A0821 IN O
mutagenic P07508082A0821 JJ O
activity P07508082A0821 NN O
was P07508082A0821 VBD O
observed P07508082A0821 VBN O
when P07508082A0821 WRB O
enzymatic P07508082A0821 JJ O
bleaching P07508082A0821 NN O
was P07508082A0821 VBD O
used P07508082A0821 VBN O
together P07508082A0821 RB O
with P07508082A0821 IN O
chlorine P07508082A0821 NN O
. P07508082A0821 . O
. . O O

Corticosteroid-mediated P11278286A1083 JJ O
transcriptional P11278286A1083 JJ O
inhibition P11278286A1083 NN O
was P11278286A1083 VBD O
greater P11278286A1083 JJR O
for P11278286A1083 IN O
MR P11278286A1083 NNP I-UN
/ P11278286A1083 NNP O
GR P11278286A1083 NNP I-UN
in P11278286A1083 IN O
combination P11278286A1083 NN O
than P11278286A1083 IN O
for P11278286A1083 IN O
MR P11278286A1083 NNP I-UN
or P11278286A1083 CC O
GR P11278286A1083 NNP I-UN
alone P11278286A1083 RB O
. P11278286A1083 . O
. . O O

On P05995140T0001 IN O
the P05995140T0001 DT O
amount P05995140T0001 NN O
and P05995140T0001 CC O
significance P05995140T0001 NN O
of P05995140T0001 IN O
the P05995140T0001 DT O
effective P05995140T0001 JJ O
glucose P05995140T0001 JJ O
level P05995140T0001 NN O
in P05995140T0001 IN O
tumors P05995140T0001 NNS O
. P05995140T0001 . O
. . O O

The P01482912A0617 DT O
CEM P01482912A0617 NNP O
receives P01482912A0617 VBZ O
registration P01482912A0617 NN O
updates P01482912A0617 NNS O
via P01482912A0617 IN O
an P01482912A0617 DT O
HL7 P01482912A0617 NNP O
message P01482912A0617 NN O
and P01482912A0617 CC O
evaluates P01482912A0617 VBZ O
data P01482912A0617 NNS O
dependencies P01482912A0617 NNS O
in P01482912A0617 IN O
rules P01482912A0617 NNS O
via P01482912A0617 IN O
an P01482912A0617 DT O
interface P01482912A0617 NN O
to P01482912A0617 TO O
the P01482912A0617 DT O
relational P01482912A0617 JJ O
database P01482912A0617 NN O
. P01482912A0617 . O
. . O O

Using P01418272A1072 VBG O
5 P01418272A1072 CD O
ng P01418272A1072 JJ O
/ P01418272A1072 NNP O
mL P01418272A1072 NN O
as P01418272A1072 IN O
the P01418272A1072 DT O
cutoff P01418272A1072 NN O
, P01418272A1072 , O
the P01418272A1072 DT O
sensitivity P01418272A1072 NN O
of P01418272A1072 IN O
CEA P01418272A1072 NNP I-UN
was P01418272A1072 VBD O
68 P01418272A1072 CD O
% P01418272A1072 NN O
. P01418272A1072 . O
. . O O

IX P05359130T0086 NNP O
. P05359130T0086 . O
. . O O

The P10841593A0780 DT O
model P10841593A0780 NN O
indicates P10841593A0780 VBZ O
that P10841593A0780 IN O
a P10841593A0780 DT O
0.076 P10841593A0780 CD O
% P10841593A0780 NN O
reduction P10841593A0780 NN O
in P10841593A0780 IN O
cigarette P10841593A0780 NN O
consumption P10841593A0780 NN O
is P10841593A0780 VBZ O
associated P10841593A0780 VBN O
with P10841593A0780 IN O
the P10841593A0780 DT O
availability P10841593A0780 NN O
of P10841593A0780 IN O
nicotine P10841593A0780 JJ O
patches P10841593A0780 NNS O
after P10841593A0780 IN O
1992 P10841593A0780 CD O
. P10841593A0780 . O
. . O O

A P09777600A0000 DT O
simple P09777600A0000 JJ O
analytical P09777600A0000 JJ O
method P09777600A0000 NN O
for P09777600A0000 IN O
l-menthol P09777600A0000 JJ O
by P09777600A0000 IN O
high-performance P09777600A0000 NN O
liquid P09777600A0000 NN O
chromatography P09777600A0000 NN O
with P09777600A0000 IN O
a P09777600A0000 DT O
polarized P09777600A0000 JJ O
photometric P09777600A0000 NN O
detector P09777600A0000 NN O
was P09777600A0000 VBD O
established P09777600A0000 VBN O
. P09777600A0000 . O
. . O O

Secretion P11287578A1311 NN O
of P11287578A1311 IN O
interleukin-8 P11287578A1311 NN I-UN
, P11287578A1311 , O
RANTES P11287578A1311 NNP I-UN
, P11287578A1311 , O
macrophage P11287578A1311 NN I-UN
inflammatory P11287578A1311 JJ I-UN
protein P11287578A1311 NN I-UN
1alpha P11287578A1311 CD I-UN
, P11287578A1311 , O
and P11287578A1311 CC O
10-kappaDa P11287578A1311 JJ I-UN
IFN-gamma-inducible P11287578A1311 JJ I-UN
protein P11287578A1311 NN I-UN
were P11287578A1311 VBD O
increased P11287578A1311 VBN O
in P11287578A1311 IN O
differentiating P11287578A1311 VBG O
keratinocytes P11287578A1311 NNS O
by P11287578A1311 IN O
E6 P11287578A1311 NNP I-UN
. P11287578A1311 . O
. . O O

( P08082440A0339a ( O
LH P08082440A0339a NNP I-UN
P P08082440A0339a NNP O
< P08082440A0339a NNP O
0.05 P08082440A0339a CD O
, P08082440A0339a , O
LH P08082440A0339a NNP I-UN
/ P08082440A0339a NNP O
FSH P08082440A0339a NNP I-UN
P P08082440A0339a NNP O
< P08082440A0339a NNP O
0.01 P08082440A0339a CD O
) P08082440A0339a ) O
. P08082440A0339a . O
. . O O

Nuclear P06027841T0000 JJ O
spin P06027841T0000 NN O
of P06027841T0000 IN O
249Bk P06027841T0000 CD O
from P06027841T0000 IN O
the P06027841T0000 DT O
hyperfine P06027841T0000 NN O
structure P06027841T0000 NN O
in P06027841T0000 IN O
its P06027841T0000 PRP$ O
emission P06027841T0000 NN O
spectrum P06027841T0000 NN O
. P06027841T0000 . O
. . O O

These P08063791A1370 DT O
results P08063791A1370 NNS O
demonstrate P08063791A1370 VBP O
that P08063791A1370 IN O
a P08063791A1370 DT O
diverse P08063791A1370 JJ O
set P08063791A1370 NN O
of P08063791A1370 IN O
carboxyl-terminal P08063791A1370 JJ O
sequence P08063791A1370 NN O
motifs P08063791A1370 NNS O
and P08063791A1370 CC O
posttranslational P08063791A1370 JJ O
modifications P08063791A1370 NNS O
lead P08063791A1370 VBP O
to P08063791A1370 TO O
functional P08063791A1370 JJ O
Ras P08063791A1370 NNP I-UN
proteins P08063791A1370 NNS I-UN
in P08063791A1370 IN O
yeast P08063791A1370 NN O
. P08063791A1370 . O
. . O O

Molecular P07844142A0640 JJ O
cloning P07844142A0640 NN O
and P07844142A0640 CC O
sequencing P07844142A0640 NN O
of P07844142A0640 IN O
a P07844142A0640 DT O
cDNA P07844142A0640 NN O
encoding P07844142A0640 VBG O
SR P07844142A0640 NNP I-UN
beta P07844142A0640 NN I-UN
revealed P07844142A0640 VBD O
that P07844142A0640 IN O
SR P07844142A0640 NNP I-UN
beta P07844142A0640 NN I-UN
is P07844142A0640 VBZ O
a P07844142A0640 DT O
transmembrane P07844142A0640 NN O
protein P07844142A0640 NN O
and P07844142A0640 CC O
, P07844142A0640 , O
like P07844142A0640 IN O
SR P07844142A0640 NNP I-UN
alpha P07844142A0640 NN I-UN
and P07844142A0640 CC O
SRP54 P07844142A0640 NNP I-UN
, P07844142A0640 , O
is P07844142A0640 VBZ O
a P07844142A0640 DT O
member P07844142A0640 NN O
of P07844142A0640 IN O
the P07844142A0640 DT O
GTPase P07844142A0640 NNP I-UN
superfamily P07844142A0640 RB I-UN
. P07844142A0640 . O
. . O O

Patients P00034935A0545 NNS O
with P00034935A0545 IN O
Parkinson P00034935A0545 NNP O
's P00034935A0545 POS O
disease P00034935A0545 NN O
showed P00034935A0545 VBD O
a P00034935A0545 DT O
relatively P00034935A0545 RB O
high P00034935A0545 JJ O
incidence P00034935A0545 NN O
to P00034935A0545 TO O
psychoses P00034935A0545 NNS O
during P00034935A0545 IN O
drug P00034935A0545 NN O
treatment P00034935A0545 NN O
( P00034935A0545 ( O
51.47 P00034935A0545 CD O
% P00034935A0545 NN O
) P00034935A0545 ) O
. P00034935A0545 . O
. . O O

Male-enhanced P02813404T0000 JJ I-UN
antigen P02813404T0000 NN I-UN
gene P02813404T0000 NN I-UN
is P02813404T0000 VBZ O
phylogenetically P02813404T0000 RB O
conserved P02813404T0000 VBN O
and P02813404T0000 CC O
expressed P02813404T0000 VBN O
at P02813404T0000 IN O
late P02813404T0000 JJ O
stages P02813404T0000 NNS O
of P02813404T0000 IN O
spermatogenesis P02813404T0000 NN O
. P02813404T0000 . O
. . O O

Vitiligo P04027182T0000 NNP O
in P04027182T0000 IN O
diabetes P04027182T0000 NNS O
mellitus P04027182T0000 NNS O
. P04027182T0000 . O
. . O O

Piroximone P07681513A0000 NN O
is P07681513A0000 VBZ O
a P07681513A0000 DT O
new P07681513A0000 JJ O
phosphodiesterase P07681513A0000 NN I-UN
III P07681513A0000 NNP I-UN
inhibitor P07681513A0000 NN O
that P07681513A0000 WDT O
combines P07681513A0000 VBZ O
inotropic P07681513A0000 NN O
and P07681513A0000 CC O
vasodilator P07681513A0000 NN O
properties P07681513A0000 NNS O
. P07681513A0000 . O
. . O O

Model P02689544A0456 NNP O
IV P02689544A0456 NNP O
: P02689544A0456 : O
primary P02689544A0456 JJ O
abutments P02689544A0456 NNS O
with P02689544A0456 IN O
the P02689544A0456 DT O
lateral P02689544A0456 JJ O
incisor P02689544A0456 NN O
and P02689544A0456 CC O
the P02689544A0456 DT O
second P02689544A0456 JJ O
molar P02689544A0456 NN O
as P02689544A0456 IN O
secondary P02689544A0456 JJ O
abutments P02689544A0456 NNS O
. P02689544A0456 . O
. . O O

Beg2 P08510647A1347 NNP I-UN
and P08510647A1347 CC O
Beg1 P08510647A1347 NNP I-UN
are P08510647A1347 VBP O
regulated P08510647A1347 VBN O
differently P08510647A1347 RB O
which P08510647A1347 WDT O
may P08510647A1347 MD O
indicate P08510647A1347 VB O
variation P08510647A1347 NN O
in P08510647A1347 IN O
storage P08510647A1347 NN O
or P08510647A1347 CC O
utilization P08510647A1347 NN O
properties P08510647A1347 NNS O
among P08510647A1347 IN O
the P08510647A1347 DT O
barley P08510647A1347 NN I-UN
globulins P08510647A1347 NNS I-UN
. P08510647A1347 . O
. . O O

Sequence P09168134A0858 NNP O
comparison P09168134A0858 NN O
of P09168134A0858 IN O
the P09168134A0858 DT O
0.38 P09168134A0858 CD O
kb P09168134A0858 NN O
promoter P09168134A0858 NN O
sequence P09168134A0858 NN O
with P09168134A0858 IN O
the P09168134A0858 DT O
promoters P09168134A0858 NNS O
of P09168134A0858 IN O
the P09168134A0858 DT O
Sm-E P09168134A0858 NNP I-UN
gene P09168134A0858 NN O
and P09168134A0858 CC O
U1 P09168134A0858 NNP I-UN
snRNA P09168134A0858 VBP I-UN
genes P09168134A0858 NNS I-UN
revealed P09168134A0858 VBD O
several P09168134A0858 JJ O
homologous P09168134A0858 JJ O
motifs P09168134A0858 NNS O
, P09168134A0858 , O
suggesting P09168134A0858 VBG O
that P09168134A0858 IN O
genes P09168134A0858 NNS O
encoding P09168134A0858 VBG O
the P09168134A0858 DT O
snRNP P09168134A0858 JJ O
components P09168134A0858 NNS O
may P09168134A0858 MD O
be P09168134A0858 VB O
coordinately P09168134A0858 RB O
regulated P09168134A0858 VBN O
. P09168134A0858 . O
. . O O

Ventral P02603374A0383 JJ O
rhinotomy P02603374A0383 NN O
is P02603374A0383 VBZ O
no P02603374A0383 DT O
more P02603374A0383 RBR O
difficult P02603374A0383 JJ O
than P02603374A0383 IN O
dorsal P02603374A0383 JJ O
rhinotomy P02603374A0383 NN O
, P02603374A0383 , O
has P02603374A0383 VBZ O
less P02603374A0383 JJR O
patient P02603374A0383 JJ O
morbidity P02603374A0383 NN O
and P02603374A0383 CC O
fewer P02603374A0383 JJR O
postoperative P02603374A0383 JJ O
complications P02603374A0383 NNS O
, P02603374A0383 , O
and P02603374A0383 CC O
is P02603374A0383 VBZ O
more P02603374A0383 RBR O
cosmetically P02603374A0383 RB O
acceptable P02603374A0383 JJ O
. P02603374A0383 . O
. . O O

The P07565113A0000 DT O
chloramphenicol-resistance P07565113A0000 NN I-UN
transposon P07565113A0000 NN I-UN
Tn4451 P07565113A0000 NNP I-UN
undergoes P07565113A0000 NNS O
precise P07565113A0000 RB O
conjugative P07565113A0000 JJ O
deletion P07565113A0000 NN O
from P07565113A0000 IN O
its P07565113A0000 PRP$ O
parent P07565113A0000 NN O
plasmid P07565113A0000 NN O
plP401 P07565113A0000 NN O
in P07565113A0000 IN O
Clostridium P07565113A0000 NNP O
perfringens P07565113A0000 NNS O
and P07565113A0000 CC O
precise P07565113A0000 VBP O
spontaneous P07565113A0000 JJ O
excision P07565113A0000 NN O
from P07565113A0000 IN O
multicopy P07565113A0000 NN O
plasmids P07565113A0000 NNS O
in P07565113A0000 IN O
Escherichia P07565113A0000 NNP O
coli P07565113A0000 NN O
. P07565113A0000 . O
. . O O

Acute P07624615A0267 NNP O
decrease P07624615A0267 NN O
in P07624615A0267 IN O
body P07624615A0267 NN O
temperature P07624615A0267 NN O
( P07624615A0267 ( O
TB P07624615A0267 NNP O
) P07624615A0267 ) O
lowered P07624615A0267 VBD O
PaCO2 P07624615A0267 NNP O
( P07624615A0267 ( O
32.5 P07624615A0267 CD O
to P07624615A0267 TO O
14.5 P07624615A0267 CD O
mmHg P07624615A0267 NN O
) P07624615A0267 ) O
and P07624615A0267 CC O
[ P07624615A0267 $ O
HCO3- P07624615A0267 NNP O
] P07624615A0267 NNP O
a P07624615A0267 DT O
( P07624615A0267 ( O
24.20 P07624615A0267 CD O
mEq P07624615A0267 NN O
/ P07624615A0267 NN O
L P07624615A0267 NNP O
to P07624615A0267 TO O
17.56 P07624615A0267 CD O
mEq P07624615A0267 NNS O
/ P07624615A0267 NNP O
L P07624615A0267 NNP O
) P07624615A0267 ) O
, P07624615A0267 , O
increased P07624615A0267 VBN O
pHa P07624615A0267 NN O
( P07624615A0267 ( O
7.481 P07624615A0267 CD O
to P07624615A0267 TO O
7.608 P07624615A0267 CD O
) P07624615A0267 ) O
and P07624615A0267 CC O
diminished P07624615A0267 VBD O
the P07624615A0267 DT O
[ P07624615A0267 JJ O
OH- P07624615A0267 NNP O
] P07624615A0267 NNP O
/ P07624615A0267 NNP O
[ P07624615A0267 NNP O
H+ P07624615A0267 NNP O
] P07624615A0267 NNP O
ratio P07624615A0267 NN O
, P07624615A0267 , O
but P07624615A0267 CC O
had P07624615A0267 VBD O
no P07624615A0267 DT O
significant P07624615A0267 JJ O
effect P07624615A0267 NN O
on P07624615A0267 IN O
[ P07624615A0267 NNP O
SID P07624615A0267 NNP O
] P07624615A0267 NNP O
or P07624615A0267 CC O
[ P07624615A0267 NNP O
Atot P07624615A0267 NNP O
] P07624615A0267 NNP O
, P07624615A0267 , O
although P07624615A0267 IN O
both P07624615A0267 DT O
total P07624615A0267 JJ O
phosphorus P07624615A0267 NN O
[ P07624615A0267 NNP O
PT P07624615A0267 NNP O
] P07624615A0267 NNP O
and P07624615A0267 CC O
inorganic P07624615A0267 JJ O
phosphate P07624615A0267 NN O
[ P07624615A0267 NNP O
Pi P07624615A0267 NNP O
] P07624615A0267 NNP O
increased P07624615A0267 VBD O
. P07624615A0267 . O
. . O O

To P08419333A0126 TO O
characterize P08419333A0126 VB O
the P08419333A0126 DT O
expression P08419333A0126 NN O
of P08419333A0126 IN O
this P08419333A0126 DT O
DNA P08419333A0126 NNP I-UN
repair P08419333A0126 NN I-UN
enzyme P08419333A0126 NN I-UN
, P08419333A0126 , O
we P08419333A0126 PRP O
have P08419333A0126 VBP O
isolated P08419333A0126 VBN O
the P08419333A0126 DT O
corresponding P08419333A0126 JJ O
genomic P08419333A0126 JJ O
clone P08419333A0126 NN O
. P08419333A0126 . O
. . O O

Radiosensitive P05145925T0000 JJ O
nature P05145925T0000 NN O
of P05145925T0000 IN O
paravascular P05145925T0000 JJ O
infiltrate-producing P05145925T0000 JJ O
potential P05145925T0000 NN O
of P05145925T0000 IN O
parental P05145925T0000 JJ O
spleen P05145925T0000 JJ O
cells P05145925T0000 NNS O
. P05145925T0000 . O
. . O O

Action P00635143T0001 NN O
of P00635143T0001 IN O
strontium-90 P00635143T0001 NN O
and P00635143T0001 CC O
metaphos P00635143T0001 NN O
on P00635143T0001 IN O
Cyprinus P00635143T0001 NNP O
carpio P00635143T0001 NN O
. P00635143T0001 . O
. . O O

Like P02902656A0481 IN O
scrotal P02902656A0481 JJ O
testes P02902656A0481 NNS O
, P02902656A0481 , O
undescended P02902656A0481 JJ O
testes P02902656A0481 NNS O
were P02902656A0481 VBD O
hypointense P02902656A0481 JJ O
to P02902656A0481 TO O
fat P02902656A0481 VB O
on P02902656A0481 IN O
sequences P02902656A0481 NNS O
with P02902656A0481 IN O
a P02902656A0481 DT O
short P02902656A0481 JJ O
repetition P02902656A0481 NN O
time P02902656A0481 NN O
( P02902656A0481 ( O
TR P02902656A0481 NNP O
) P02902656A0481 ) O
and P02902656A0481 CC O
echo P02902656A0481 JJ O
time P02902656A0481 NN O
( P02902656A0481 ( O
TE P02902656A0481 NNP O
) P02902656A0481 ) O
in P02902656A0481 IN O
all P02902656A0481 DT O
cases P02902656A0481 NNS O
, P02902656A0481 , O
and P02902656A0481 CC O
hyperintense P02902656A0481 NN O
or P02902656A0481 CC O
isointense P02902656A0481 NN O
to P02902656A0481 TO O
fat P02902656A0481 VB O
on P02902656A0481 IN O
long P02902656A0481 JJ O
TR P02902656A0481 NNP O
/ P02902656A0481 NNP O
TE P02902656A0481 NNP O
sequences P02902656A0481 NNS O
in P02902656A0481 IN O
all P02902656A0481 DT O
but P02902656A0481 CC O
two P02902656A0481 CD O
cases P02902656A0481 NNS O
. P02902656A0481 . O
. . O O

Gel P01986254A0452 NNP O
mobility P01986254A0452 NN O
shift P01986254A0452 NN O
assays P01986254A0452 VBZ O
using P01986254A0452 VBG O
a P01986254A0452 DT O
synthetic P01986254A0452 JJ O
E6 P01986254A0452 NNP I-UN
motif P01986254A0452 NN I-UN
detected P01986254A0452 VBD O
a P01986254A0452 DT O
B-cell-specific P01986254A0452 JJ O
complex P01986254A0452 NN O
in P01986254A0452 IN O
addition P01986254A0452 NN O
to P01986254A0452 TO O
a P01986254A0452 DT O
ubiquitous P01986254A0452 JJ O
band P01986254A0452 NN O
found P01986254A0452 VBD O
also P01986254A0452 RB O
in P01986254A0452 IN O
T P01986254A0452 NNP O
cells P01986254A0452 NNS O
and P01986254A0452 CC O
HeLa P01986254A0452 NNP O
cells P01986254A0452 NNS O
. P01986254A0452 . O
. . O O

Ventricular P06238540A0798 JJ O
volume P06238540A0798 NN O
stiffness P06238540A0798 NN O
vs. P06238540A0798 IN O
the P06238540A0798 DT O
mean P06238540A0798 NN O
wall P06238540A0798 NN O
stress P06238540A0798 NN O
relationship P06238540A0798 NN O
of P06238540A0798 IN O
LVH P06238540A0798 NNP O
shifted P06238540A0798 VBD O
upward P06238540A0798 RB O
, P06238540A0798 , O
whereas P06238540A0798 IN O
the P06238540A0798 DT O
normalized P06238540A0798 JJ O
wall P06238540A0798 NN O
muscle P06238540A0798 NN O
stiffness P06238540A0798 NN O
vs. P06238540A0798 IN O
the P06238540A0798 DT O
mean P06238540A0798 NN O
wall P06238540A0798 NN O
stress P06238540A0798 NN O
relationship P06238540A0798 NN O
of P06238540A0798 IN O
LVH P06238540A0798 NNP O
showed P06238540A0798 VBD O
a P06238540A0798 DT O
smaller P06238540A0798 JJR O
slope P06238540A0798 NN O
. P06238540A0798 . O
. . O O

The P03668736A0177 DT O
average P03668736A0177 JJ O
deviations P03668736A0177 NNS O
in P03668736A0177 IN O
the P03668736A0177 DT O
X-ray P03668736A0177 JJ O
counts P03668736A0177 NNS O
of P03668736A0177 IN O
the P03668736A0177 DT O
constant P03668736A0177 JJ O
elements P03668736A0177 NNS O
from P03668736A0177 IN O
the P03668736A0177 DT O
series P03668736A0177 NN O
means P03668736A0177 VBZ O
were P03668736A0177 VBD O
used P03668736A0177 VBN O
to P03668736A0177 TO O
correct P03668736A0177 VB O
the P03668736A0177 DT O
recorded P03668736A0177 JJ O
count P03668736A0177 NN O
of P03668736A0177 IN O
the P03668736A0177 DT O
variable P03668736A0177 JJ O
element P03668736A0177 NN O
in P03668736A0177 IN O
each P03668736A0177 DT O
block P03668736A0177 NN O
. P03668736A0177 . O
. . O O

We P08189503A0000 PRP O
have P08189503A0000 VBP O
used P08189503A0000 VBN O
a P08189503A0000 DT O
full-length P08189503A0000 JJ O
cDNA P08189503A0000 NN O
clone P08189503A0000 NN O
of P08189503A0000 IN O
a P08189503A0000 DT O
mouse P08189503A0000 NN O
hepatitis P08189503A0000 NN O
virus P08189503A0000 NN O
strain P08189503A0000 NN O
A59 P08189503A0000 NNP O
defective P08189503A0000 JJ O
interfering P08189503A0000 NN O
( P08189503A0000 ( O
DI P08189503A0000 NNP O
) P08189503A0000 ) O
RNA P08189503A0000 NNP O
, P08189503A0000 , O
pMIDI-C P08189503A0000 NN I-UN
, P08189503A0000 , O
and P08189503A0000 CC O
cassette P08189503A0000 NN O
mutagenesis P08189503A0000 NN O
to P08189503A0000 TO O
study P08189503A0000 VB O
the P08189503A0000 DT O
mechanism P08189503A0000 NN O
of P08189503A0000 IN O
coronavirus P08189503A0000 NN O
subgenomic P08189503A0000 JJ O
mRNA P08189503A0000 NN O
synthesis P08189503A0000 NN O
. P08189503A0000 . O
. . O O

The P09060623A0961 DT O
human P09060623A0961 JJ O
coreceptor P09060623A0961 NN O
was P09060623A0961 VBD O
as P09060623A0961 RB O
active P09060623A0961 JJ O
as P09060623A0961 IN O
the P09060623A0961 DT O
simian P09060623A0961 NN O
for P09060623A0961 IN O
SIV P09060623A0961 NNP O
entry P09060623A0961 NN O
. P09060623A0961 . O
. . O O

However P09651383A0967 RB O
, P09651383A0967 , O
mutations P09651383A0967 NNS O
in P09651383A0967 IN O
the P09651383A0967 DT O
HNF-4 P09651383A0967 NNP I-UN
binding P09651383A0967 NN I-UN
site P09651383A0967 NN I-UN
on P09651383A0967 IN O
element P09651383A0967 JJ I-UN
CIIB P09651383A0967 NNP I-UN
and P09651383A0967 CC O
inhibition P09651383A0967 NN O
of P09651383A0967 IN O
HNF-4 P09651383A0967 NNP I-UN
synthesis P09651383A0967 NN O
in P09651383A0967 IN O
HepG2 P09651383A0967 NNP O
cells P09651383A0967 NNS O
by P09651383A0967 IN O
antisense P09651383A0967 JJ O
HNF-4 P09651383A0967 NNP I-UN
constructs P09651383A0967 NNS I-UN
decreased P09651383A0967 VBD O
the P09651383A0967 DT O
apoCII P09651383A0967 JJ I-UN
promoter P09651383A0967 NN I-UN
activity P09651383A0967 NN O
to P09651383A0967 TO O
25-40 P09651383A0967 CD O
% P09651383A0967 NN O
of P09651383A0967 IN O
the P09651383A0967 DT O
control P09651383A0967 NN O
, P09651383A0967 , O
indicating P09651383A0967 VBG O
that P09651383A0967 IN O
HNF-4 P09651383A0967 NNP I-UN
is P09651383A0967 VBZ O
a P09651383A0967 DT O
positive P09651383A0967 JJ O
regulator P09651383A0967 NN O
of P09651383A0967 IN O
the P09651383A0967 DT O
apoCII P09651383A0967 JJ I-UN
gene P09651383A0967 NN I-UN
. P09651383A0967 . O
. . O O

No P02142240A0506 DT O
significant P02142240A0506 JJ O
differences P02142240A0506 NNS O
could P02142240A0506 MD O
be P02142240A0506 VB O
seen P02142240A0506 VBN O
in P02142240A0506 IN O
response P02142240A0506 NN O
rates P02142240A0506 NNS O
according P02142240A0506 VBG O
to P02142240A0506 TO O
the P02142240A0506 DT O
concentration P02142240A0506 NN O
of P02142240A0506 IN O
estrogen P02142240A0506 NN I-UN
receptors P02142240A0506 NNS I-UN
or P02142240A0506 CC O
presence P02142240A0506 NN O
of P02142240A0506 IN O
progesteron P02142240A0506 NN I-UN
receptors P02142240A0506 NNS I-UN
in P02142240A0506 IN O
this P02142240A0506 DT O
group P02142240A0506 NN O
of P02142240A0506 IN O
patients P02142240A0506 NNS O
. P02142240A0506 . O
. . O O

Isolation P08666404A0311 NN O
of P08666404A0311 IN O
a P08666404A0311 DT O
near P08666404A0311 JJ O
full-length P08666404A0311 JJ O
cDNA P08666404A0311 NN O
from P08666404A0311 IN O
a P08666404A0311 DT O
human P08666404A0311 JJ O
fetal P08666404A0311 NN O
brain P08666404A0311 NN O
cDNA P08666404A0311 NN O
library P08666404A0311 NN O
revealed P08666404A0311 VBD O
a P08666404A0311 DT O
protein P08666404A0311 JJ I-UN
serine-threonine P08666404A0311 JJ I-UN
phosphatase P08666404A0311 NN I-UN
with P08666404A0311 IN O
a P08666404A0311 DT O
tetratricopeptide P08666404A0311 NN O
motif P08666404A0311 NN O
, P08666404A0311 , O
almost P08666404A0311 RB O
identical P08666404A0311 JJ O
to P08666404A0311 TO O
human P08666404A0311 JJ I-UN
PPP5C P08666404A0311 NNP I-UN
( P08666404A0311 ( O
PP5 P08666404A0311 NNP I-UN
) P08666404A0311 ) O
and P08666404A0311 CC O
highly P08666404A0311 RB O
homologous P08666404A0311 JJ O
to P08666404A0311 TO O
rat P08666404A0311 VB I-UN
PPT P08666404A0311 NNP I-UN
. P08666404A0311 . O
. . O O

In P11920896A0298 IN O
this P11920896A0298 DT O
study P11920896A0298 NN O
we P11920896A0298 PRP O
wanted P11920896A0298 VBD O
to P11920896A0298 TO O
assess P11920896A0298 VB O
the P11920896A0298 DT O
DR P11920896A0298 NNP O
using P11920896A0298 VBG O
the P11920896A0298 DT O
'combined P11920896A0298 JJ O
test P11920896A0298 NN O
' P11920896A0298 '' O
in P11920896A0298 IN O
an P11920896A0298 DT O
unselected P11920896A0298 JJ O
population P11920896A0298 NN O
of P11920896A0298 IN O
self-referred P11920896A0298 JJ O
pregnant P11920896A0298 JJ O
women P11920896A0298 NNS O
at P11920896A0298 IN O
a P11920896A0298 DT O
false-positive P11920896A0298 JJ O
rate P11920896A0298 NN O
( P11920896A0298 ( O
FPR P11920896A0298 NNP O
) P11920896A0298 ) O
of P11920896A0298 IN O
about P11920896A0298 RB O
5 P11920896A0298 CD O
% P11920896A0298 NN O
. P11920896A0298 . O
. . O O

Alignment P10641688A0341 NN O
of P10641688A0341 IN O
the P10641688A0341 DT O
cervical P10641688A0341 JJ O
spine P10641688A0341 NN O
, P10641688A0341 , O
vertebral P10641688A0341 JJ O
abnormalities P10641688A0341 NNS O
, P10641688A0341 , O
and P10641688A0341 CC O
disc P10641688A0341 NN O
changes P10641688A0341 NNS O
also P10641688A0341 RB O
were P10641688A0341 VBD O
evaluated P10641688A0341 VBN O
. P10641688A0341 . O
. . O O

Nocodazole P01325221A0870 NNP O
arrest P01325221A0870 NN O
of P01325221A0870 IN O
DU249 P01325221A0870 NNP O
cells P01325221A0870 NNS O
was P01325221A0870 VBD O
exploited P01325221A0870 VBN O
for P01325221A0870 IN O
the P01325221A0870 DT O
detection P01325221A0870 NN O
of P01325221A0870 IN O
an P01325221A0870 DT O
M-phase-activated P01325221A0870 JJ O
MBP P01325221A0870 NNP I-UN
kinase P01325221A0870 NN I-UN
that P01325221A0870 WDT O
was P01325221A0870 VBD O
resolved P01325221A0870 VBN O
from P01325221A0870 IN O
p41 P01325221A0870 NN I-UN
MAP P01325221A0870 NNP I-UN
kinase P01325221A0870 NN I-UN
by P01325221A0870 IN O
phenyl-Superose P01325221A0870 JJ O
chromatography P01325221A0870 NN O
. P01325221A0870 . O
. . O O

We P10479382A1098 PRP O
discuss P10479382A1098 VBP O
these P10479382A1098 DT O
results P10479382A1098 NNS O
in P10479382A1098 IN O
terms P10479382A1098 NNS O
of P10479382A1098 IN O
the P10479382A1098 DT O
influence P10479382A1098 NN O
that P10479382A1098 IN O
time P10479382A1098 NN O
and P10479382A1098 CC O
nutritional P10479382A1098 JJ O
constraints P10479382A1098 NNS O
have P10479382A1098 VBP O
on P10479382A1098 IN O
odonate P10479382A1098 NN O
development P10479382A1098 NN O
patterns P10479382A1098 NNS O
and P10479382A1098 CC O
fitness P10479382A1098 NN O
. P10479382A1098 . O
. . O O

A P04394290T0000 DT O
study P04394290T0000 NN O
in P04394290T0000 IN O
vivo P04394290T0000 NN O
of P04394290T0000 IN O
adrenergic P04394290T0000 JJ I-UN
receptors P04394290T0000 NNS I-UN
in P04394290T0000 IN O
the P04394290T0000 DT O
rectum P04394290T0000 NN O
and P04394290T0000 CC O
in P04394290T0000 IN O
the P04394290T0000 DT O
internal P04394290T0000 JJ O
and P04394290T0000 CC O
sphincter P04394290T0000 NN O
of P04394290T0000 IN O
the P04394290T0000 DT O
cat P04394290T0000 NN O
. P04394290T0000 . O
. . O O

Cross-reaction P10702926T0089 NN O
between P10702926T0089 IN O
a P10702926T0089 DT O
monoclonal P10702926T0089 JJ O
antibody P10702926T0089 NN O
and P10702926T0089 CC O
two P10702926T0089 CD O
alpha P10702926T0089 NN I-UN
beta P10702926T0089 NN I-UN
T P10702926T0089 NNP I-UN
cell P10702926T0089 NN I-UN
receptors P10702926T0089 NNS I-UN
. P10702926T0089 . O
. . O O

The P09241232A0653 DT O
Ogg1 P09241232A0653 NNP I-UN
protein P09241232A0653 NN I-UN
efficiently P09241232A0653 RB O
cleaves P09241232A0653 VBZ O
a P09241232A0653 DT O
DNA P09241232A0653 NN O
duplex P09241232A0653 NN O
where P09241232A0653 WRB O
a P09241232A0653 DT O
preformed P09241232A0653 JJ O
AP P09241232A0653 NNP I-UN
site P09241232A0653 NN I-UN
is P09241232A0653 VBZ O
placed P09241232A0653 VBN O
opposite P09241232A0653 IN O
a P09241232A0653 DT O
cytosine P09241232A0653 NN O
( P09241232A0653 ( O
AP P09241232A0653 NNP O
/ P09241232A0653 NNP O
C P09241232A0653 NNP O
) P09241232A0653 ) O
. P09241232A0653 . O
. . O O

We P02247924A0078 PRP O
describe P02247924A0078 VBP O
a P02247924A0078 DT O
case P02247924A0078 NN O
of P02247924A0078 IN O
a P02247924A0078 DT O
perinephric P02247924A0078 JJ O
abscess P02247924A0078 NN O
treated P02247924A0078 VBN O
with P02247924A0078 IN O
amphotericin P02247924A0078 NN O
B P02247924A0078 NNP O
and P02247924A0078 CC O
nephrectomy P02247924A0078 NN O
. P02247924A0078 . O
. . O O

CONCLUSION P10423193A1309 NN O
: P10423193A1309 : O
These P10423193A1309 DT O
results P10423193A1309 NNS O
suggest P10423193A1309 VBP O
that P10423193A1309 IN O
vibration-induced P10423193A1309 JJ O
neural P10423193A1309 JJ O
involvement P10423193A1309 NN O
can P10423193A1309 MD O
be P10423193A1309 VB O
considered P10423193A1309 VBN O
neither P10423193A1309 DT O
pure P10423193A1309 JJ O
digital P10423193A1309 JJ O
neuropathy P10423193A1309 NN O
, P10423193A1309 , O
nor P10423193A1309 CC O
definite P10423193A1309 JJ O
CTS P10423193A1309 NNP O
, P10423193A1309 , O
as P10423193A1309 IN O
previously P10423193A1309 RB O
described P10423193A1309 VBN O
. P10423193A1309 . O
. . O O

The P02817724A0075 DT O
examination P02817724A0075 NN O
must P02817724A0075 MD O
include P02817724A0075 VB O
T1 P02817724A0075 NNP O
and P02817724A0075 CC O
T2 P02817724A0075 NNP O
sequences P02817724A0075 NNS O
and P02817724A0075 CC O
scans P02817724A0075 NNS O
in P02817724A0075 IN O
three P02817724A0075 CD O
planes P02817724A0075 NNS O
. P02817724A0075 . O
. . O O

We P08458849A0364 PRP O
now P08458849A0364 RB O
show P08458849A0364 VBP O
that P08458849A0364 IN O
regulation P08458849A0364 NN O
of P08458849A0364 IN O
flaN P08458849A0364 JJ I-UN
transcription P08458849A0364 NN O
in P08458849A0364 IN O
vivo P08458849A0364 JJ O
depends P08458849A0364 NNS O
on P08458849A0364 IN O
a P08458849A0364 DT O
sigma P08458849A0364 NN I-UN
54 P08458849A0364 CD I-UN
promoter P08458849A0364 NN I-UN
and P08458849A0364 CC O
two P08458849A0364 CD O
ftr P08458849A0364 JJ O
elements P08458849A0364 NNS O
located P08458849A0364 VBN O
downstream P08458849A0364 NN O
of P08458849A0364 IN O
the P08458849A0364 DT O
transcription P08458849A0364 NN O
start P08458849A0364 VB O
site P08458849A0364 NN O
at P08458849A0364 IN O
+86 P08458849A0364 NNP O
( P08458849A0364 ( O
ftr2 P08458849A0364 NN O
) P08458849A0364 ) O
and P08458849A0364 CC O
+120 P08458849A0364 NNP O
( P08458849A0364 ( O
ftr3 P08458849A0364 NN O
) P08458849A0364 ) O
. P08458849A0364 . O
. . O O

The P11054970A0282 DT O
plexiform P11054970A0282 NN O
neurofibroma P11054970A0282 NN O
and P11054970A0282 CC O
multiple P11054970A0282 JJ O
localized P11054970A0282 VBN O
neurofibromas P11054970A0282 NN O
are P11054970A0282 VBP O
characteristic P11054970A0282 JJ O
of P11054970A0282 IN O
NF1 P11054970A0282 NNP I-UN
. P11054970A0282 . O
. . O O

Truncation P01328884T0000 NN O
variants P01328884T0000 NNS O
of P01328884T0000 IN O
peptides P01328884T0000 NNS O
isolated P01328884T0000 VBN O
from P01328884T0000 IN O
MHC P01328884T0000 NNP I-UN
class P01328884T0000 NN I-UN
II P01328884T0000 NNP I-UN
molecules P01328884T0000 VBZ I-UN
suggest P01328884T0000 JJS O
sequence P01328884T0000 NN O
motifs P01328884T0000 NNS O
. P01328884T0000 . O
. . O O

Antibodies P09452421A1042 NNS O
raised P09452421A1042 VBN O
against P09452421A1042 IN O
GST P09452421A1042 NNP I-UN
mSH2-B P09452421A1042 JJ I-UN
identified P09452421A1042 VBD O
a P09452421A1042 DT O
cellular P09452421A1042 JJ O
protein P09452421A1042 NN O
of P09452421A1042 IN O
92 P09452421A1042 CD O
kDa P09452421A1042 NNS O
that P09452421A1042 WDT O
was P09452421A1042 VBD O
not P09452421A1042 RB O
found P09452421A1042 VBN O
to P09452421A1042 TO O
be P09452421A1042 VB O
phosphorylated P09452421A1042 VBN O
on P09452421A1042 IN O
Tyr P09452421A1042 NNP O
. P09452421A1042 . O
. . O O

Effects P04967824T0000 NNS O
of P04967824T0000 IN O
temperature P04967824T0000 NN O
and P04967824T0000 CC O
moulting P04967824T0000 VBG O
cycle P04967824T0000 NN O
on P04967824T0000 IN O
melanin P04967824T0000 NN O
synthesis P04967824T0000 NN O
in P04967824T0000 IN O
the P04967824T0000 DT O
newt P04967824T0000 NN O
, P04967824T0000 , O
Triturus P04967824T0000 NNP O
cristatus P04967824T0000 NN O
. P04967824T0000 . O
. . O O

A P03963860A0137 DT O
total P03963860A0137 NN O
of P03963860A0137 IN O
90 P03963860A0137 CD O
patients P03963860A0137 NNS O
were P03963860A0137 VBD O
randomly P03963860A0137 RB O
allocated P03963860A0137 VBN O
either P03963860A0137 RB O
to P03963860A0137 TO O
an P03963860A0137 DT O
MY-1 P03963860A0137 NNP O
treated P03963860A0137 VBD O
or P03963860A0137 CC O
an P03963860A0137 DT O
untreated P03963860A0137 JJ O
group P03963860A0137 NN O
. P03963860A0137 . O
. . O O

Administration P08823646A1012 NN O
of P08823646A1012 IN O
adrenaline P08823646A1012 NN O
resulted P08823646A1012 VBN O
in P08823646A1012 IN O
a P08823646A1012 DT O
large P08823646A1012 JJ O
overestimation P08823646A1012 NN O
of P08823646A1012 IN O
the P08823646A1012 DT O
SaO2 P08823646A1012 NNP O
in P08823646A1012 IN O
6 P08823646A1012 CD O
of P08823646A1012 IN O
the P08823646A1012 DT O
7 P08823646A1012 CD O
measurements P08823646A1012 NNS O
. P08823646A1012 . O
. . O O

Animal P02620085A0656 NNP O
experimental P02620085A0656 NN O
and P02620085A0656 CC O
clinical P02620085A0656 JJ O
applications P02620085A0656 NNS O
of P02620085A0656 IN O
plates P02620085A0656 NNS O
, P02620085A0656 , O
screws P02620085A0656 NNS O
and P02620085A0656 CC O
spinal P02620085A0656 JJ O
segmental P02620085A0656 JJ O
replacement P02620085A0656 NN O
implants P02620085A0656 NNS O
made P02620085A0656 VBN O
of P02620085A0656 IN O
this P02620085A0656 DT O
composite P02620085A0656 JJ O
material P02620085A0656 NN O
have P02620085A0656 VBP O
shown P02620085A0656 VBN O
good P02620085A0656 JJ O
results P02620085A0656 NNS O
so P02620085A0656 RB O
far P02620085A0656 RB O
. P02620085A0656 . O
. . O O

Such P07860646A1363 JJ O
an P07860646A1363 DT O
intervention P07860646A1363 NN O
may P07860646A1363 MD O
be P07860646A1363 VB O
of P07860646A1363 IN O
considerable P07860646A1363 JJ O
use P07860646A1363 NN O
for P07860646A1363 IN O
the P07860646A1363 DT O
treatment P07860646A1363 NN O
of P07860646A1363 IN O
angiogenesis-dependent P07860646A1363 JJ O
diseases P07860646A1363 NNS O
involving P07860646A1363 VBG O
FGF-2 P07860646A1363 NNP I-UN
. P07860646A1363 . O
. . O O

The P10864496A0401 DT O
equilibrium P10864496A0401 NN O
dissociation P10864496A0401 NN O
binding P10864496A0401 VBG O
constant P10864496A0401 JJ O
for P10864496A0401 IN O
the P10864496A0401 DT O
interaction P10864496A0401 NN O
of P10864496A0401 IN O
TnrA P10864496A0401 NNP I-UN
with P10864496A0401 IN O
the P10864496A0401 DT O
nrgAB P10864496A0401 JJ I-UN
promoter P10864496A0401 NN I-UN
fragment P10864496A0401 NN I-UN
was P10864496A0401 VBD O
7.7 P10864496A0401 CD O
nM P10864496A0401 JJ O
under P10864496A0401 IN O
the P10864496A0401 DT O
conditions P10864496A0401 NNS O
used P10864496A0401 VBN O
here P10864496A0401 RB O
. P10864496A0401 . O
. . O O

Recombinant P08244034T0000 NNP I-UN
Leishmania P08244034T0000 NNP I-UN
surface P08244034T0000 NN I-UN
glycoprotein P08244034T0000 NN I-UN
GP63 P08244034T0000 NNP I-UN
is P08244034T0000 VBZ O
secreted P08244034T0000 VBN O
in P08244034T0000 IN O
the P08244034T0000 DT O
baculovirus P08244034T0000 NN O
expression P08244034T0000 NN O
system P08244034T0000 NN O
as P08244034T0000 IN O
a P08244034T0000 DT O
latent P08244034T0000 JJ O
metalloproteinase P08244034T0000 NN I-UN
. P08244034T0000 . O
. . O O

Primary P03712153T0000 JJ O
invasive P03712153T0000 JJ O
Haemophilus P03712153T0000 NNP O
influenzae P03712153T0000 NN O
type P03712153T0000 NN O
b P03712153T0000 NN O
disease P03712153T0000 NN O
: P03712153T0000 : O
a P03712153T0000 DT O
population-based P03712153T0000 JJ O
assessment P03712153T0000 NN O
of P03712153T0000 IN O
risk P03712153T0000 NN O
factors P03712153T0000 NNS O
. P03712153T0000 . O
. . O O

A P00427715A0000 DT O
total P00427715A0000 NN O
of P00427715A0000 IN O
57 P00427715A0000 CD O
patients P00427715A0000 NNS O
with P00427715A0000 IN O
Hodgkin P00427715A0000 NNP O
's P00427715A0000 POS O
disease P00427715A0000 NN O
limited P00427715A0000 VBD O
to P00427715A0000 TO O
above P00427715A0000 IN O
the P00427715A0000 DT O
diaphragm P00427715A0000 NN O
( P00427715A0000 ( O
Stages P00427715A0000 NNP O
I P00427715A0000 PRP O
and P00427715A0000 CC O
II P00427715A0000 NNP O
, P00427715A0000 , O
A P00427715A0000 NNP O
and P00427715A0000 CC O
B P00427715A0000 NNP O
) P00427715A0000 ) O
were P00427715A0000 VBD O
treated P00427715A0000 VBN O
with P00427715A0000 IN O
radiation P00427715A0000 NN O
therapy P00427715A0000 NN O
alone P00427715A0000 RB O
at P00427715A0000 IN O
the P00427715A0000 DT O
University P00427715A0000 NNP O
of P00427715A0000 IN O
Florida P00427715A0000 NNP O
between P00427715A0000 IN O
1964 P00427715A0000 CD O
and P00427715A0000 CC O
1974 P00427715A0000 CD O
. P00427715A0000 . O
. . O O

Using P08881036A0351 VBG O
anchored P08881036A0351 JJ O
PCR P08881036A0351 NNP O
, P08881036A0351 , O
a P08881036A0351 DT O
VL P08881036A0351 NNP I-UN
element P08881036A0351 NN I-UN
rearranged P08881036A0351 VBD O
to P08881036A0351 TO O
CL2 P08881036A0351 NNP I-UN
was P08881036A0351 VBD O
isolated P08881036A0351 VBN O
. P08881036A0351 . O
. . O O

A P07639106A0678 DT O
model P07639106A0678 NN O
with P07639106A0678 IN O
age P07639106A0678 NN O
and P07639106A0678 CC O
weight P07639106A0678 NN O
described P07639106A0678 VBD O
the P07639106A0678 DT O
best P07639106A0678 JJS O
fit P07639106A0678 NN O
for P07639106A0678 IN O
TBBMD P07639106A0678 NNP O
, P07639106A0678 , O
whereas P07639106A0678 JJ O
age P07639106A0678 NN O
, P07639106A0678 , O
weight P07639106A0678 NN O
, P07639106A0678 , O
and P07639106A0678 CC O
height P07639106A0678 VBD O
described P07639106A0678 VBN O
the P07639106A0678 DT O
best P07639106A0678 JJS O
fit P07639106A0678 NN O
for P07639106A0678 IN O
total P07639106A0678 JJ O
body P07639106A0678 NN O
TBBMC P07639106A0678 NNP O
. P07639106A0678 . O
. . O O

The P10857215A0000 DT O
Menopause-Rating-Scale P10857215A0000 NNP O
( P10857215A0000 ( O
MRS P10857215A0000 NNP O
I P10857215A0000 PRP O
) P10857215A0000 ) O
was P10857215A0000 VBD O
used P10857215A0000 VBN O
in P10857215A0000 IN O
clinical P10857215A0000 JJ O
practice P10857215A0000 NN O
since P10857215A0000 IN O
1992 P10857215A0000 CD O
. P10857215A0000 . O
. . O O

As P11420612A0303 IN O
a P11420612A0303 DT O
complement P11420612A0303 NN O
to P11420612A0303 TO O
genome-wide P11420612A0303 JJ O
mapping P11420612A0303 NN O
and P11420612A0303 CC O
sequencing P11420612A0303 VBG O
efforts P11420612A0303 NNS O
, P11420612A0303 , O
it P11420612A0303 PRP O
is P11420612A0303 VBZ O
often P11420612A0303 RB O
important P11420612A0303 JJ O
to P11420612A0303 TO O
generate P11420612A0303 VB O
detailed P11420612A0303 JJ O
maps P11420612A0303 NNS O
and P11420612A0303 CC O
sequence P11420612A0303 NN O
data P11420612A0303 NNS O
for P11420612A0303 IN O
specific P11420612A0303 JJ O
regions P11420612A0303 NNS O
of P11420612A0303 IN O
interest P11420612A0303 NN O
. P11420612A0303 . O
. . O O

These P08370119A0642 DT O
contain P08370119A0642 VBP O
a P08370119A0642 DT O
single P08370119A0642 JJ O
1977-bp P08370119A0642 JJ O
exon P08370119A0642 NN O
that P08370119A0642 WDT O
encodes P08370119A0642 VBZ O
900 P08370119A0642 CD O
bp P08370119A0642 NN O
of P08370119A0642 IN O
the P08370119A0642 DT O
5 P08370119A0642 CD O
' P08370119A0642 POS O
and P08370119A0642 CC O
3 P08370119A0642 CD O
' P08370119A0642 '' O
untranslated P08370119A0642 JJ O
sequences P08370119A0642 NNS O
in P08370119A0642 IN O
addition P08370119A0642 NN O
to P08370119A0642 TO O
a P08370119A0642 DT O
1077-bp P08370119A0642 JJ O
open P08370119A0642 JJ O
reading P08370119A0642 NN O
frame P08370119A0642 NN O
identical P08370119A0642 JJ O
to P08370119A0642 TO O
that P08370119A0642 DT O
found P08370119A0642 VBN O
in P08370119A0642 IN O
vascular P08370119A0642 JJ I-UN
smooth P08370119A0642 JJ I-UN
muscle P08370119A0642 NN I-UN
cell P08370119A0642 NN I-UN
AT1a P08370119A0642 NNP I-UN
receptor P08370119A0642 NN I-UN
cDNAs P08370119A0642 NN I-UN
. P08370119A0642 . O
. . O O

We P02138707A0198 PRP O
have P02138707A0198 VBP O
previously P02138707A0198 RB O
identified P02138707A0198 VBN O
, P02138707A0198 , O
by P02138707A0198 IN O
screening P02138707A0198 VBG O
a P02138707A0198 DT O
lambda P02138707A0198 JJ O
gt11 P02138707A0198 NN O
expression P02138707A0198 NN O
library P02138707A0198 NN O
, P02138707A0198 , O
murine P02138707A0198 NN I-UN
protein P02138707A0198 NN I-UN
mXBP P02138707A0198 NN I-UN
, P02138707A0198 , O
which P02138707A0198 WDT O
binds P02138707A0198 VBZ O
to P02138707A0198 TO O
a P02138707A0198 DT O
sequence P02138707A0198 NN O
which P02138707A0198 WDT O
overlaps P02138707A0198 VBZ O
the P02138707A0198 DT O
3 P02138707A0198 CD O
' P02138707A0198 POS O
end P02138707A0198 NN O
of P02138707A0198 IN O
the P02138707A0198 DT O
murine P02138707A0198 NN I-UN
class P02138707A0198 NN I-UN
II P02138707A0198 NNP I-UN
major P02138707A0198 JJ I-UN
histocompatibility P02138707A0198 NN I-UN
complex P02138707A0198 VBP I-UN
A P02138707A0198 DT I-UN
alpha P02138707A0198 JJ I-UN
gene P02138707A0198 NN I-UN
X P02138707A0198 NNP I-UN
box P02138707A0198 NN I-UN
, P02138707A0198 , O
a P02138707A0198 DT O
conserved P02138707A0198 JJ O
transcription P02138707A0198 NN O
element P02138707A0198 NN O
found P02138707A0198 VBD O
upstream P02138707A0198 NN O
of P02138707A0198 IN O
all P02138707A0198 DT O
class P02138707A0198 NN O
II P02138707A0198 NNP O
genes P02138707A0198 NNS O
. P02138707A0198 . O
. . O O

Statistics P06911559T0000 NNS O
for P06911559T0000 IN O
nurse P06911559T0000 NN O
managers P06911559T0000 NNS O
-- P06911559T0000 : O
3 P06911559T0000 CD O
. P06911559T0000 . O
. . O O

In P01842867A0696 IN O
conclusion P01842867A0696 NN O
, P01842867A0696 , O
we P01842867A0696 PRP O
observed P01842867A0696 VBD O
a P01842867A0696 DT O
great P01842867A0696 JJ O
regeneration P01842867A0696 NN O
ability P01842867A0696 NN O
following P01842867A0696 VBG O
mechanical P01842867A0696 JJ O
injury P01842867A0696 NN O
in P01842867A0696 IN O
the P01842867A0696 DT O
nasal P01842867A0696 JJ O
mucosa P01842867A0696 NN O
. P01842867A0696 . O
. . O O

The P07680035A0221 DT O
roles P07680035A0221 NNS O
of P07680035A0221 IN O
phorbol P07680035A0221 NN O
esters P07680035A0221 NNS O
and P07680035A0221 CC O
cyclic P07680035A0221 JJ O
AMP P07680035A0221 NNP O
in P07680035A0221 IN O
mediating P07680035A0221 VBG O
the P07680035A0221 DT O
GnRH P07680035A0221 NNP I-UN
response P07680035A0221 NN O
were P07680035A0221 VBD O
also P07680035A0221 RB O
investigated P07680035A0221 VBN O
. P07680035A0221 . O
. . O O

Codon P09358069T0000 NNP O
optimization P09358069T0000 NN O
for P09358069T0000 IN O
high-level P09358069T0000 JJ O
expression P09358069T0000 NN O
of P09358069T0000 IN O
human P09358069T0000 JJ I-UN
erythropoietin P09358069T0000 NN I-UN
( P09358069T0000 ( O
EPO P09358069T0000 NNP I-UN
) P09358069T0000 ) O
in P09358069T0000 IN O
mammalian P09358069T0000 JJ O
cells P09358069T0000 NNS O
. P09358069T0000 . O
. . O O

After P02569411A0151 IN O
termination P02569411A0151 NN O
of P02569411A0151 IN O
medication P02569411A0151 NN O
the P02569411A0151 DT O
animals P02569411A0151 NNS O
were P02569411A0151 VBD O
kindled P02569411A0151 VBN O
electrically P02569411A0151 RB O
in P02569411A0151 IN O
the P02569411A0151 DT O
nucleus P02569411A0151 JJ O
amygdala P02569411A0151 NN O
. P02569411A0151 . O
. . O O

The P02139891A0532 DT O
major P02139891A0532 JJ O
promoter P02139891A0532 NN O
responds P02139891A0532 VBZ O
strongly P02139891A0532 RB O
to P02139891A0532 TO O
virus-encoded P02139891A0532 JJ O
trans P02139891A0532 NNS O
activators P02139891A0532 NNS O
EIA P02139891A0532 NNP I-UN
and P02139891A0532 CC O
EIV P02139891A0532 NNP I-UN
and P02139891A0532 CC O
contains P02139891A0532 VBZ O
four P02139891A0532 CD O
elements P02139891A0532 NNS O
: P02139891A0532 : O
a P02139891A0532 DT O
TAGA P02139891A0532 NNP O
motif P02139891A0532 NN O
analogous P02139891A0532 JJ O
to P02139891A0532 TO O
the P02139891A0532 DT O
TATA P02139891A0532 NNP O
box P02139891A0532 NN O
, P02139891A0532 , O
two P02139891A0532 CD O
EIIF P02139891A0532 NNP I-UN
sites P02139891A0532 NNS I-UN
present P02139891A0532 VBP O
in P02139891A0532 IN O
an P02139891A0532 DT O
inverted P02139891A0532 JJ O
orientation P02139891A0532 NN O
, P02139891A0532 , O
and P02139891A0532 CC O
an P02139891A0532 DT O
ATF P02139891A0532 NNP I-UN
/ P02139891A0532 NNP O
CREB P02139891A0532 NNP I-UN
site P02139891A0532 NN O
. P02139891A0532 . O
. . O O

Of P02666568A0000 IN O
110 P02666568A0000 CD O
previously P02666568A0000 RB O
untreated P02666568A0000 JJ O
patients P02666568A0000 NNS O
who P02666568A0000 WP O
had P02666568A0000 VBD O
entered P02666568A0000 VBN O
the P02666568A0000 DT O
study P02666568A0000 NN O
of P02666568A0000 IN O
protocol P02666568A0000 NN O
TCL821 P02666568A0000 NNP O
, P02666568A0000 , O
96 P02666568A0000 CD O
were P02666568A0000 VBD O
evaluable P02666568A0000 JJ O
. P02666568A0000 . O
. . O O

Using P02148291A0173 VBG O
appropriate P02148291A0173 JJ O
synthetic P02148291A0173 JJ O
HSE P02148291A0173 NNP O
oligonucleotides P02148291A0173 NNS O
, P02148291A0173 , O
three P02148291A0173 CD O
types P02148291A0173 NNS O
of P02148291A0173 IN O
clones P02148291A0173 NNS O
with P02148291A0173 IN O
potential P02148291A0173 JJ O
HSE P02148291A0173 NNP O
binding P02148291A0173 NN O
domains P02148291A0173 NNS O
were P02148291A0173 VBD O
isolated P02148291A0173 VBN O
from P02148291A0173 IN O
a P02148291A0173 DT O
tomato P02148291A0173 NN O
lambda P02148291A0173 NN O
gt11 P02148291A0173 NN O
expression P02148291A0173 NN O
library P02148291A0173 NN O
by P02148291A0173 IN O
DNA-ligand P02148291A0173 NNP O
screening P02148291A0173 NN O
. P02148291A0173 . O
. . O O

The P02148508A1478 DT O
results P02148508A1478 NNS O
supported P02148508A1478 VBD O
the P02148508A1478 DT O
therapeutic P02148508A1478 JJ O
principle P02148508A1478 NN O
of P02148508A1478 IN O
TCM P02148508A1478 NNP O
: P02148508A1478 : O
Treating P02148508A1478 NN O
patients P02148508A1478 NNS O
according P02148508A1478 VBG O
to P02148508A1478 TO O
their P02148508A1478 PRP$ O
pathophysiological P02148508A1478 JJ O
patterns P02148508A1478 NNS O
. P02148508A1478 . O
. . O O

Therefore P10082570A0440 RB O
, P10082570A0440 , O
we P10082570A0440 PRP O
have P10082570A0440 VBP O
named P10082570A0440 VBN O
this P10082570A0440 DT O
gene P10082570A0440 NN O
UBP43 P10082570A0440 NNP I-UN
. P10082570A0440 . O
. . O O

CM P09776360A0620 NNP O
reduced P09776360A0620 VBD O
the P09776360A0620 DT O
nuclear P09776360A0620 JJ O
binding P09776360A0620 NN O
activity P09776360A0620 NN O
of P09776360A0620 IN O
transcription P09776360A0620 NN I-UN
factor P09776360A0620 NN I-UN
AP-1 P09776360A0620 NNP I-UN
. P09776360A0620 . O
. . O O

By P03331933T0048 IN O
Felix P03331933T0048 NNP O
Lagrange P03331933T0048 NNP O
, P03331933T0048 , O
1918 P03331933T0048 CD O
. P03331933T0048 . O
. . O O

These P08574414A1037 DT O
primers P08574414A1037 NNS O
yielded P08574414A1037 VBD O
a P08574414A1037 DT O
PCR P08574414A1037 NNP O
product P08574414A1037 NN O
of P08574414A1037 IN O
a P08574414A1037 DT O
characteristic P08574414A1037 JJ O
length P08574414A1037 NN O
within P08574414A1037 IN O
most P08574414A1037 JJS O
Xanthomonas P08574414A1037 JJ O
species P08574414A1037 NNS O
and P08574414A1037 CC O
pathovars P08574414A1037 NNS O
tested P08574414A1037 VBN O
. P08574414A1037 . O
. . O O

The P07635140A0172 DT O
expression P07635140A0172 NN O
of P07635140A0172 IN O
the P07635140A0172 DT O
gene P07635140A0172 NN O
encoding P07635140A0172 VBG O
the P07635140A0172 DT O
enzyme P07635140A0172 NN O
( P07635140A0172 ( O
CYP19 P07635140A0172 NNP I-UN
) P07635140A0172 ) O
is P07635140A0172 VBZ O
regulated P07635140A0172 VBN O
, P07635140A0172 , O
in P07635140A0172 IN O
part P07635140A0172 NN O
, P07635140A0172 , O
by P07635140A0172 IN O
tissue-specific P07635140A0172 JJ O
promoters P07635140A0172 NNS O
through P07635140A0172 IN O
the P07635140A0172 DT O
use P07635140A0172 NN O
of P07635140A0172 IN O
alternative-splicing P07635140A0172 JJ O
mechanisms P07635140A0172 NNS O
. P07635140A0172 . O
. . O O

Epidemiological P08927841A0053 JJ O
data P08927841A0053 NNS O
are P08927841A0053 VBP O
quite P08927841A0053 JJ O
controversial P08927841A0053 JJ O
but P08927841A0053 CC O
sudden P08927841A0053 JJ O
death P08927841A0053 NN O
occurring P08927841A0053 VBG O
during P08927841A0053 IN O
sporting P08927841A0053 VBG O
activity P08927841A0053 NN O
is P08927841A0053 VBZ O
probably P08927841A0053 RB O
not P08927841A0053 RB O
a P08927841A0053 DT O
rare P08927841A0053 JJ O
occurrence P08927841A0053 NN O
. P08927841A0053 . O
. . O O

2. P07341346A0174 CD O
numerous P07341346A0174 JJ O
narrow P07341346A0174 JJ O
shunt P07341346A0174 NN O
vessels P07341346A0174 NNS O
departing P07341346A0174 VBG O
continuously P07341346A0174 RB O
from P07341346A0174 IN O
the P07341346A0174 DT O
primary P07341346A0174 JJ O
arteries P07341346A0174 NNS O
to P07341346A0174 TO O
feed P07341346A0174 VB O
a P07341346A0174 DT O
secondary P07341346A0174 JJ O
arterial P07341346A0174 NN O
system P07341346A0174 NN O
which P07341346A0174 WDT O
parallels P07341346A0174 VBZ O
the P07341346A0174 DT O
primary P07341346A0174 JJ O
one P07341346A0174 CD O
. P07341346A0174 . O
. . O O

In P10403690A0000 IN O
a P10403690A0000 DT O
prospective P10403690A0000 JJ O
randomized P10403690A0000 NN O
study P10403690A0000 NN O
, P10403690A0000 , O
287 P10403690A0000 CD O
patients P10403690A0000 NNS O
with P10403690A0000 IN O
advanced P10403690A0000 JJ O
non-small P10403690A0000 JJ O
cell P10403690A0000 NN O
lung P10403690A0000 NN O
cancer P10403690A0000 NN O
( P10403690A0000 ( O
NSCLC P10403690A0000 NNP O
) P10403690A0000 ) O
stage P10403690A0000 NN O
IIIb P10403690A0000 NNP O
or P10403690A0000 CC O
IV P10403690A0000 NNP O
with P10403690A0000 IN O
ECOG P10403690A0000 NNP O
performance P10403690A0000 NN O
status P10403690A0000 NN O
( P10403690A0000 ( O
PS P10403690A0000 NNP O
) P10403690A0000 ) O
0-1 P10403690A0000 NN O
or P10403690A0000 CC O
2 P10403690A0000 CD O
were P10403690A0000 VBD O
randomly P10403690A0000 RB O
assigned P10403690A0000 VBN O
to P10403690A0000 TO O
receive P10403690A0000 VB O
either P10403690A0000 RB O
best P10403690A0000 RBS O
supportive P10403690A0000 JJ O
care P10403690A0000 NN O
( P10403690A0000 ( O
BSC P10403690A0000 NNP O
) P10403690A0000 ) O
or P10403690A0000 CC O
supportive P10403690A0000 JJ O
care P10403690A0000 NN O
plus P10403690A0000 CC O
combination P10403690A0000 NN O
chemotherapy P10403690A0000 NN O
( P10403690A0000 ( O
IEP P10403690A0000 JJ O
regimen P10403690A0000 NNS O
: P10403690A0000 : O
ifosfamide P10403690A0000 RB O
3 P10403690A0000 CD O
gm P10403690A0000 NNS O
/ P10403690A0000 JJ O
m2 P10403690A0000 NNS O
IV P10403690A0000 NNP O
with P10403690A0000 IN O
mesna P10403690A0000 JJ O
uroprotection P10403690A0000 NN O
, P10403690A0000 , O
epirubicin P10403690A0000 VBZ O
60 P10403690A0000 CD O
mg P10403690A0000 NN O
/ P10403690A0000 NNP O
m2 P10403690A0000 NN O
IV P10403690A0000 NNP O
on P10403690A0000 IN O
day P10403690A0000 NN O
1 P10403690A0000 CD O
and P10403690A0000 CC O
cisplatin P10403690A0000 VB O
60 P10403690A0000 CD O
mg P10403690A0000 NN O
/ P10403690A0000 NNP O
m2 P10403690A0000 NN O
IV P10403690A0000 NNP O
on P10403690A0000 IN O
day P10403690A0000 NN O
2 P10403690A0000 CD O
; P10403690A0000 : O
or P10403690A0000 CC O
MVP P10403690A0000 NNP O
regimen P10403690A0000 NNS O
: P10403690A0000 : O
mitomycin-C P10403690A0000 JJ O
8 P10403690A0000 CD O
mg P10403690A0000 NN O
/ P10403690A0000 NNP O
m2 P10403690A0000 NN O
, P10403690A0000 , O
cisplatin P10403690A0000 NN O
100 P10403690A0000 CD O
mg P10403690A0000 NN O
/ P10403690A0000 NNP O
m2 P10403690A0000 NN O
IV P10403690A0000 NNP O
on P10403690A0000 IN O
day P10403690A0000 NN O
1 P10403690A0000 CD O
, P10403690A0000 , O
vinblastine P10403690A0000 NN O
4 P10403690A0000 CD O
mg P10403690A0000 NN O
/ P10403690A0000 NNP O
m2 P10403690A0000 NN O
IV P10403690A0000 NNP O
on P10403690A0000 IN O
days P10403690A0000 NNS O
1 P10403690A0000 CD O
and P10403690A0000 CC O
15 P10403690A0000 CD O
) P10403690A0000 ) O
. P10403690A0000 . O
. . O O

Thus P09724654A1120 RB O
, P09724654A1120 , O
in P09724654A1120 IN O
the P09724654A1120 DT O
presence P09724654A1120 NN O
of P09724654A1120 IN O
active P09724654A1120 JJ I-UN
S-CDKs P09724654A1120 NNP I-UN
and P09724654A1120 CC O
Dbf4 P09724654A1120 NNP I-UN
/ P09724654A1120 NNP O
Cdc7 P09724654A1120 NNP I-UN
, P09724654A1120 , O
Mcms P09724654A1120 NNP I-UN
may P09724654A1120 MD O
open P09724654A1120 VB O
origins P09724654A1120 NNS O
and P09724654A1120 CC O
thereby P09724654A1120 RB O
facilitate P09724654A1120 VB O
the P09724654A1120 DT O
loading P09724654A1120 NN O
of P09724654A1120 IN O
RPA P09724654A1120 NNP I-UN
. P09724654A1120 . O
. . O O

Evidence P02217307T0000 NN O
that P02217307T0000 IN O
therapeutic P02217307T0000 JJ O
alterations P02217307T0000 NNS O
of P02217307T0000 IN O
a P02217307T0000 DT O
circadian P02217307T0000 JJ O
rhythm P02217307T0000 NN O
for P02217307T0000 IN O
gastric P02217307T0000 JJ O
emptying P02217307T0000 VBG O
response P02217307T0000 NN O
may P02217307T0000 MD O
be P02217307T0000 VB O
possible P02217307T0000 JJ O
. P02217307T0000 . O
. . O O

Expression P08388496A1117 NN O
in P08388496A1117 IN O
established P08388496A1117 VBN O
LCLs P08388496A1117 NNP O
, P08388496A1117 , O
occurring P08388496A1117 VBG O
irrespective P08388496A1117 NN O
of P08388496A1117 IN O
virus P08388496A1117 NN O
producer P08388496A1117 NN O
status P08388496A1117 NN O
, P08388496A1117 , O
was P08388496A1117 VBD O
not P08388496A1117 RB O
a P08388496A1117 DT O
consequence P08388496A1117 NN O
of P08388496A1117 IN O
continued P08388496A1117 VBN O
in P08388496A1117 IN O
vitro P08388496A1117 JJ O
passage P08388496A1117 NN O
; P08388496A1117 : O
thus P08388496A1117 RB O
, P08388496A1117 , O
appropriately P08388496A1117 RB O
spliced P08388496A1117 VBD O
BamHI-A P08388496A1117 NNP I-UN
transcripts P08388496A1117 NNS I-UN
could P08388496A1117 MD O
be P08388496A1117 VB O
amplified P08388496A1117 VBN O
from P08388496A1117 IN O
normal P08388496A1117 JJ O
B P08388496A1117 NNP O
cells P08388496A1117 NNS O
within P08388496A1117 IN O
1 P08388496A1117 CD O
day P08388496A1117 NN O
of P08388496A1117 IN O
their P08388496A1117 PRP$ O
experimental P08388496A1117 JJ O
infection P08388496A1117 NN O
in P08388496A1117 IN O
vitro P08388496A1117 NN O
, P08388496A1117 , O
along P08388496A1117 IN O
with P08388496A1117 IN O
BamHI-C P08388496A1117 NNP I-UN
/ P08388496A1117 NNP I-UN
W P08388496A1117 NNP I-UN
promoter-initiated P08388496A1117 JJ O
but P08388496A1117 CC O
not P08388496A1117 RB O
BamHI-F P08388496A1117 NNP I-UN
promoter-initiated P08388496A1117 JJ I-UN
mRNAs P08388496A1117 NN I-UN
. P08388496A1117 . O
. . O O

Fortunately P01961213A0150 RB O
DDT- P01961213A0150 NNP O
, P01961213A0150 , O
HCH- P01961213A0150 NNP O
and P01961213A0150 CC O
HCB-levels P01961213A0150 NNP O
decreased P01961213A0150 VBD O
in P01961213A0150 IN O
breast P01961213A0150 NN O
milk P01961213A0150 NN O
during P01961213A0150 IN O
the P01961213A0150 DT O
last P01961213A0150 JJ O
years P01961213A0150 NNS O
. P01961213A0150 . O
. . O O

Ion P05807222T0052 NNP O
injection P05807222T0052 NN O
. P05807222T0052 . O
. . O O

We P02431314A0834 PRP O
conclude P02431314A0834 VBP O
that P02431314A0834 DT O
Hansel P02431314A0834 NNP O
's P02431314A0834 POS O
stain P02431314A0834 NN O
substantially P02431314A0834 RB O
improves P02431314A0834 VBZ O
the P02431314A0834 DT O
recognition P02431314A0834 NN O
of P02431314A0834 IN O
eosinophiluria P02431314A0834 NN O
as P02431314A0834 IN O
compared P02431314A0834 VBN O
with P02431314A0834 IN O
Wright P02431314A0834 NNP O
's P02431314A0834 POS O
stain P02431314A0834 NN O
. P02431314A0834 . O
. . O O

Letter P04600603T0001 NN O
: P04600603T0001 : O
Salmonella P04600603T0001 NN O
detection P04600603T0001 NN O
. P04600603T0001 . O
. . O O

This P01851876A0129 DT O
element P01851876A0129 NN O
was P01851876A0129 VBD O
used P01851876A0129 VBN O
to P01851876A0129 TO O
screen P01851876A0129 VB O
an P01851876A0129 DT O
EMBL3 P01851876A0129 NNP O
mouse P01851876A0129 NN O
genomic P01851876A0129 JJ O
library P01851876A0129 NN O
. P01851876A0129 . O
. . O O

Mutation P10871347A0477 NN O
analysis P10871347A0477 NN O
demonstrates P10871347A0477 VBZ O
that P10871347A0477 IN O
the P10871347A0477 DT O
motif P10871347A0477 NN O
TCCCCT P10871347A0477 NNP O
is P10871347A0477 VBZ O
critical P10871347A0477 JJ O
for P10871347A0477 IN O
PyRo1 P10871347A0477 NNP I-UN
interaction P10871347A0477 NN O
. P10871347A0477 . O
. . O O

The P08355063A0456 DT O
rCBF P08355063A0456 NN O
ratio P08355063A0456 NN O
was P08355063A0456 VBD O
mainly P08355063A0456 RB O
reduced P08355063A0456 VBN O
in P08355063A0456 IN O
frontal P08355063A0456 JJ O
lobes P08355063A0456 NN O
( P08355063A0456 ( O
65 P08355063A0456 CD O
% P08355063A0456 NN O
) P08355063A0456 ) O
. P08355063A0456 . O
. . O O

Autotransfusion P07304905A0336 NN O
was P07304905A0336 VBD O
performed P07304905A0336 VBN O
as P07304905A0336 IN O
follows P07304905A0336 VBZ O
: P07304905A0336 : O
Heparin-ACD-B- P07304905A0336 JJ O
Heparin-DPD- P07304905A0336 NNP O
Heparin-ACD-B P07304905A0336 NNP O
etc P07304905A0336 NN O
. P07304905A0336 . O
. . O O

The P10602507A0652 DT O
coordinate P10602507A0652 NN O
increase P10602507A0652 NN O
in P10602507A0652 IN O
cyclin P10602507A0652 JJ I-UN
D1 P10602507A0652 NNP I-UN
and P10602507A0652 CC O
p21 P10602507A0652 NN I-UN
had P10602507A0652 VBD O
the P10602507A0652 DT O
effect P10602507A0652 NN O
of P10602507A0652 IN O
decreasing P10602507A0652 VBG O
the P10602507A0652 DT O
specific P10602507A0652 NN O
but P10602507A0652 CC O
not P10602507A0652 RB O
absolute P10602507A0652 JJ O
activity P10602507A0652 NN O
of P10602507A0652 IN O
cyclin P10602507A0652 NN I-UN
D1 P10602507A0652 NNP I-UN
/ P10602507A0652 NNP O
cdk4 P10602507A0652 NN I-UN
. P10602507A0652 . O
p53 P10602507A0652 NN I-UN
was P10602507A0652 VBD O
not P10602507A0652 RB O
involved P10602507A0652 VBN O
since P10602507A0652 IN O
CSF-1 P10602507A0652 NNP I-UN
induction P10602507A0652 NN O
of P10602507A0652 IN O
p21 P10602507A0652 NN I-UN
was P10602507A0652 VBD O
unaffected P10602507A0652 VBN O
by P10602507A0652 IN O
dominant-negative P10602507A0652 JJ I-UN
p53 P10602507A0652 NN I-UN
expression P10602507A0652 NN O
. P10602507A0652 . O
. . O O

PKNbeta P10441506A0098 NNP I-UN
had P10441506A0098 VBD O
high P10441506A0098 JJ O
sequence P10441506A0098 NN O
homology P10441506A0098 NN O
with P10441506A0098 IN O
PKNalpha P10441506A0098 NNP I-UN
, P10441506A0098 , O
originally P10441506A0098 RB O
isolated P10441506A0098 VBN O
PKN P10441506A0098 NNP I-UN
, P10441506A0098 , O
especially P10441506A0098 RB O
in P10441506A0098 IN O
the P10441506A0098 DT O
repeats P10441506A0098 NNS O
of P10441506A0098 IN O
charged P10441506A0098 VBN O
amino P10441506A0098 NN O
acid-rich P10441506A0098 JJ O
region P10441506A0098 NN O
with P10441506A0098 IN O
leucine-zipper P10441506A0098 JJ O
like P10441506A0098 IN O
sequences P10441506A0098 NNS O
( P10441506A0098 ( O
CZ P10441506A0098 NNP O
region P10441506A0098 NN O
/ P10441506A0098 NNP O
HR1 P10441506A0098 NNP O
) P10441506A0098 ) O
, P10441506A0098 , O
in P10441506A0098 IN O
the P10441506A0098 DT O
carboxyl-terminal P10441506A0098 JJ O
catalytic P10441506A0098 JJ O
domain P10441506A0098 NN O
, P10441506A0098 , O
and P10441506A0098 CC O
in P10441506A0098 IN O
approximately P10441506A0098 RB O
130 P10441506A0098 CD O
amino P10441506A0098 JJ O
acid P10441506A0098 NN O
stretch P10441506A0098 NN O
( P10441506A0098 ( O
D P10441506A0098 NNP O
region P10441506A0098 NN O
/ P10441506A0098 NNP O
HR2 P10441506A0098 NNP O
) P10441506A0098 ) O
, P10441506A0098 , O
located P10441506A0098 VBN O
between P10441506A0098 IN O
CZ P10441506A0098 NNP O
region P10441506A0098 NN O
/ P10441506A0098 NNP O
HR1 P10441506A0098 NNP O
and P10441506A0098 CC O
the P10441506A0098 DT O
catalytic P10441506A0098 JJ O
domain P10441506A0098 NN O
. P10441506A0098 . O
. . O O

Relatively P01698761A1059 RB O
large P01698761A1059 JJ O
DNA P01698761A1059 NNP O
rearrangements P01698761A1059 NNS O
spanning P01698761A1059 VBG O
the P01698761A1059 DT O
region P01698761A1059 NN O
with P01698761A1059 IN O
tandem P01698761A1059 NN O
direct P01698761A1059 JJ O
repeats P01698761A1059 NNS O
encoding P01698761A1059 VBG O
the P01698761A1059 DT O
carboxy-terminal P01698761A1059 JJ O
histone P01698761A1059 NN I-UN
H1-like P01698761A1059 JJ I-UN
structure P01698761A1059 NN O
of P01698761A1059 IN O
AlgP P01698761A1059 NNP I-UN
were P01698761A1059 VBD O
detected P01698761A1059 VBN O
in P01698761A1059 IN O
several P01698761A1059 JJ O
strains P01698761A1059 NNS O
upon P01698761A1059 IN O
conversion P01698761A1059 NN O
from P01698761A1059 IN O
the P01698761A1059 DT O
mucoid P01698761A1059 NN O
to P01698761A1059 TO O
the P01698761A1059 DT O
nonmucoid P01698761A1059 JJ O
phenotype P01698761A1059 NN O
. P01698761A1059 . O
. . O O

Variables P08606267A0740 NNS O
evaluated P08606267A0740 VBN O
were P08606267A0740 VBD O
number P08606267A0740 NN O
of P08606267A0740 IN O
weekly P08606267A0740 JJ O
anginal P08606267A0740 JJ O
events P08606267A0740 NNS O
, P08606267A0740 , O
data P08606267A0740 NNS O
from P08606267A0740 IN O
ergometric P08606267A0740 JJ O
exercise P08606267A0740 NN O
testing P08606267A0740 VBG O
with P08606267A0740 IN O
simultaneous P08606267A0740 JJ O
electrocardiographic P08606267A0740 JJ O
registration P08606267A0740 NN O
, P08606267A0740 , O
semiquantitative P08606267A0740 JJ O
evaluation P08606267A0740 NN O
of P08606267A0740 IN O
Tc-99m P08606267A0740 NNP O
2-methoxy P08606267A0740 JJ O
isobutyl P08606267A0740 NN O
isonitrile P08606267A0740 NN O
( P08606267A0740 ( O
MIBI P08606267A0740 NNP O
) P08606267A0740 ) O
scans P08606267A0740 NNS O
and P08606267A0740 CC O
rheologic P08606267A0740 JJ O
variables P08606267A0740 NNS O
. P08606267A0740 . O
. . O O

In P10022858A0985 IN O
addition P10022858A0985 NN O
, P10022858A0985 , O
a P10022858A0985 DT O
potent P10022858A0985 NN O
splicing P10022858A0985 VBG O
enhancer P10022858A0985 JJ O
sequence P10022858A0985 NN O
isolated P10022858A0985 VBN O
in P10022858A0985 IN O
the P10022858A0985 DT O
selection P10022858A0985 NN O
specifically P10022858A0985 RB O
binds P10022858A0985 VBZ O
a P10022858A0985 DT O
20-kDa P10022858A0985 JJ I-UN
SR P10022858A0985 NNP I-UN
protein P10022858A0985 NN I-UN
. P10022858A0985 . O
. . O O

Here P11114718A0349 RB O
we P11114718A0349 PRP O
show P11114718A0349 VBP O
in P11114718A0349 IN O
mouse P11114718A0349 NN O
fibroblasts P11114718A0349 NNS O
stably P11114718A0349 RB O
transformed P11114718A0349 VBN O
by P11114718A0349 IN O
v-Src P11114718A0349 NN I-UN
that P11114718A0349 IN O
mRNA P11114718A0349 NN O
and P11114718A0349 CC O
protein P11114718A0349 NN O
levels P11114718A0349 NNS O
of P11114718A0349 IN O
p21 P11114718A0349 NN I-UN
( P11114718A0349 ( O
WAF1 P11114718A0349 NNP I-UN
/ P11114718A0349 NNP O
CIP1 P11114718A0349 NNP I-UN
) P11114718A0349 ) O
, P11114718A0349 , O
cyclin P11114718A0349 JJ I-UN
D1 P11114718A0349 NNP I-UN
, P11114718A0349 , O
and P11114718A0349 CC O
cyclin P11114718A0349 NN I-UN
E P11114718A0349 NNP I-UN
are P11114718A0349 VBP O
elevated P11114718A0349 VBN O
. P11114718A0349 . O
. . O O

Binding P08331728A0686 NNP O
of P08331728A0686 IN O
U2 P08331728A0686 NNP I-UN
small P08331728A0686 JJ I-UN
nuclear P08331728A0686 JJ I-UN
ribonucleoprotein P08331728A0686 NN I-UN
was P08331728A0686 VBD O
partially P08331728A0686 RB O
inhibited P08331728A0686 VBN O
. P08331728A0686 . O
. . O O

A P02167321T0000 DT O
DNA P02167321T0000 NNP O
motif P02167321T0000 NN O
related P02167321T0000 VBN O
to P02167321T0000 TO O
the P02167321T0000 DT O
cAMP-responsive P02167321T0000 JJ O
element P02167321T0000 NN O
and P02167321T0000 CC O
an P02167321T0000 DT O
exon-located P02167321T0000 JJ I-UN
activator P02167321T0000 NN I-UN
protein-2 P02167321T0000 NN I-UN
binding P02167321T0000 VBG I-UN
site P02167321T0000 NN I-UN
in P02167321T0000 IN O
the P02167321T0000 DT O
human P02167321T0000 JJ I-UN
tissue-type P02167321T0000 JJ I-UN
plasminogen P02167321T0000 NN I-UN
activator P02167321T0000 NN I-UN
gene P02167321T0000 NN I-UN
promoter P02167321T0000 NN I-UN
cooperate P02167321T0000 NN O
in P02167321T0000 IN O
basal P02167321T0000 JJ O
expression P02167321T0000 NN O
and P02167321T0000 CC O
convey P02167321T0000 JJ O
activation P02167321T0000 NN O
by P02167321T0000 IN O
phorbol P02167321T0000 NN O
ester P02167321T0000 NN O
and P02167321T0000 CC O
cAMP P02167321T0000 NN O
. P02167321T0000 . O
. . O O

A P07457931A0655 DT O
third P07457931A0655 JJ O
series P07457931A0655 NN O
of P07457931A0655 IN O
mice P07457931A0655 NNS O
were P07457931A0655 VBD O
given P07457931A0655 VBN O
a P07457931A0655 DT O
single P07457931A0655 JJ O
injection P07457931A0655 NN O
of P07457931A0655 IN O
5-OH-DA P07457931A0655 JJ O
, P07457931A0655 , O
sacrificed P07457931A0655 VBN O
, P07457931A0655 , O
and P07457931A0655 CC O
prepared P07457931A0655 VBD O
for P07457931A0655 IN O
ultrastructural P07457931A0655 JJ O
study P07457931A0655 NN O
. P07457931A0655 . O
. . O O

Control P09591221A0137 NNP O
subjects P09591221A0137 VBZ O
' P09591221A0137 POS O
evoked P09591221A0137 JJ O
potentials P09591221A0137 NNS O
( P09591221A0137 ( O
EPs P09591221A0137 NNP O
) P09591221A0137 ) O
were P09591221A0137 VBD O
characterized P09591221A0137 VBN O
by P09591221A0137 IN O
an P09591221A0137 DT O
initial P09591221A0137 JJ O
positivity P09591221A0137 NN O
in P09591221A0137 IN O
the P09591221A0137 DT O
90-140 P09591221A0137 JJ O
ms P09591221A0137 NN O
range P09591221A0137 NN O
( P09591221A0137 ( O
P1 P09591221A0137 NNP O
) P09591221A0137 ) O
at P09591221A0137 IN O
the P09591221A0137 DT O
temporo-occipital P09591221A0137 JJ O
site P09591221A0137 NN O
. P09591221A0137 . O
. . O O

The P04028871A0133 DT O
pharmacokinetics P04028871A0133 NNS O
of P04028871A0133 IN O
each P04028871A0133 DT O
tetracycline P04028871A0133 NN O
in P04028871A0133 IN O
serum P04028871A0133 NN O
and P04028871A0133 CC O
dermal P04028871A0133 NN O
, P04028871A0133 , O
suction P04028871A0133 NN O
blister P04028871A0133 NN O
fluid P04028871A0133 NN O
were P04028871A0133 VBD O
determined P04028871A0133 VBN O
after P04028871A0133 IN O
oral P04028871A0133 JJ O
doses P04028871A0133 NNS O
of P04028871A0133 IN O
300 P04028871A0133 CD O
mg P04028871A0133 JJ O
lymecycline P04028871A0133 NN O
or P04028871A0133 CC O
100 P04028871A0133 CD O
mg P04028871A0133 NNS O
doxycycline P04028871A0133 NN O
on P04028871A0133 IN O
the P04028871A0133 DT O
3rd P04028871A0133 CD O
day P04028871A0133 NN O
. P04028871A0133 . O
. . O O

Modeling P10809233A0606 VBG O
also P10809233A0606 RB O
revealed P10809233A0606 VBD O
a P10809233A0606 DT O
very P10809233A0606 RB O
hydrophobic P10809233A0606 JJ O
surface P10809233A0606 NN O
due P10809233A0606 JJ O
to P10809233A0606 TO O
the P10809233A0606 DT O
absence P10809233A0606 NN O
of P10809233A0606 IN O
H12 P10809233A0606 NNP O
, P10809233A0606 , O
exposing P10809233A0606 VBG O
residues P10809233A0606 NNS O
from P10809233A0606 IN O
H3 P10809233A0606 NNP O
, P10809233A0606 , O
loop P10809233A0606 VBZ O
3-4 P10809233A0606 JJ O
, P10809233A0606 , O
H4 P10809233A0606 NNP O
, P10809233A0606 , O
and P10809233A0606 CC O
H11 P10809233A0606 NNP O
. P10809233A0606 . O
. . O O

All P09386074A0694 DT O
pigs P09386074A0694 NNS O
had P09386074A0694 VBD O
significant P09386074A0694 JJ O
regional P09386074A0694 JJ O
LV P09386074A0694 NNP O
dysfunction P09386074A0694 NN O
and P09386074A0694 CC O
reduced P09386074A0694 JJ O
LV P09386074A0694 NNP O
ejection P09386074A0694 NN O
fraction P09386074A0694 NN O
( P09386074A0694 ( O
41+ P09386074A0694 CD O
/ P09386074A0694 RB O
-11 P09386074A0694 CD O
% P09386074A0694 NN O
) P09386074A0694 ) O
. P09386074A0694 . O
. . O O

Seventy-five P09721798A1734 JJ O
percent P09721798A1734 NN O
of P09721798A1734 IN O
children P09721798A1734 NNS O
who P09721798A1734 WP O
received P09721798A1734 VBD O
a P09721798A1734 DT O
second P09721798A1734 JJ O
transplant P09721798A1734 NN O
for P09721798A1734 IN O
HCV P09721798A1734 NNP O
hepatitis P09721798A1734 NN O
had P09721798A1734 VBD O
early P09721798A1734 JJ O
histologic P09721798A1734 JJ O
recurrence P09721798A1734 NN O
that P09721798A1734 WDT O
led P09721798A1734 VBD O
to P09721798A1734 TO O
liver P09721798A1734 VB O
failure P09721798A1734 NN O
and P09721798A1734 CC O
death P09721798A1734 NN O
. P09721798A1734 . O
. . O O

To P10913172A0442 TO O
determine P10913172A0442 VB O
whether P10913172A0442 IN O
the P10913172A0442 DT O
NTP-binding P10913172A0442 NNP O
motif P10913172A0442 NN O
is P10913172A0442 VBZ O
important P10913172A0442 JJ O
for P10913172A0442 IN O
Rad24 P10913172A0442 NNP I-UN
function P10913172A0442 NN O
, P10913172A0442 , O
we P10913172A0442 PRP O
mutated P10913172A0442 VBD O
the P10913172A0442 DT O
conserved P10913172A0442 JJ O
lysine P10913172A0442 NN O
( P10913172A0442 ( O
115 P10913172A0442 CD O
) P10913172A0442 ) O
residue P10913172A0442 NN O
in P10913172A0442 IN O
this P10913172A0442 DT O
motif P10913172A0442 NN O
. P10913172A0442 . O
. . O O

These P07675445A0463 DT O
clones P07675445A0463 NNS O
were P07675445A0463 VBD O
found P07675445A0463 VBN O
to P07675445A0463 TO O
share P07675445A0463 NN O
a P07675445A0463 DT O
common P07675445A0463 JJ O
domain P07675445A0463 NN O
encoded P07675445A0463 VBN O
by P07675445A0463 IN O
p P07675445A0463 NN O
( P07675445A0463 ( O
CA P07675445A0463 NNP O
) P07675445A0463 ) O
n P07675445A0463 NN O
repeats P07675445A0463 NNS O
; P07675445A0463 : O
a P07675445A0463 DT O
simple P07675445A0463 JJ O
sequence P07675445A0463 NN O
length P07675445A0463 NN O
polymorphism P07675445A0463 NN O
( P07675445A0463 ( O
SSLP P07675445A0463 NNP O
) P07675445A0463 ) O
. P07675445A0463 . O
. . O O

Analysis P08388510A0891 NN O
by P08388510A0891 IN O
cell P08388510A0891 NN O
surface P08388510A0891 NN O
immunofluorescence P08388510A0891 NN O
showed P08388510A0891 VBD O
that P08388510A0891 IN O
the P08388510A0891 DT O
UL28 P08388510A0891 NNP I-UN
gene P08388510A0891 NN I-UN
is P08388510A0891 VBZ O
not P08388510A0891 RB O
required P08388510A0891 VBN O
for P08388510A0891 IN O
expression P08388510A0891 NN O
of P08388510A0891 IN O
viral P08388510A0891 JJ O
glycoproteins P08388510A0891 NNS O
on P08388510A0891 IN O
the P08388510A0891 DT O
surface P08388510A0891 NN O
of P08388510A0891 IN O
infected P08388510A0891 JJ O
cells P08388510A0891 NNS O
. P08388510A0891 . O
. . O O

Subjects P02132636A0188 NNS O
were P02132636A0188 VBD O
16 P02132636A0188 CD O
male P02132636A0188 JJ O
chronic P02132636A0188 JJ O
schizophrenics P02132636A0188 NNS O
consisting P02132636A0188 VBG O
of P02132636A0188 IN O
8 P02132636A0188 CD O
DST P02132636A0188 NNP O
suppressors P02132636A0188 NNS O
and P02132636A0188 CC O
8 P02132636A0188 CD O
nonsuppressors P02132636A0188 NNS O
. P02132636A0188 . O
. . O O

Thus P09950213A1660 RB O
, P09950213A1660 , O
in P09950213A1660 IN O
normal P09950213A1660 JJ O
intestinal P09950213A1660 JJ O
epithelial P09950213A1660 JJ O
goblet P09950213A1660 NN O
cells P09950213A1660 NNS O
, P09950213A1660 , O
TbetaRI P09950213A1660 NNP I-UN
and P09950213A1660 CC O
TbetaRII P09950213A1660 NNP I-UN
can P09950213A1660 MD O
respond P09950213A1660 VB O
to P09950213A1660 TO O
autocrine P09950213A1660 VB O
but P09950213A1660 CC O
not P09950213A1660 RB O
exogenous P09950213A1660 JJ O
TGF-beta P09950213A1660 CD I-UN
without P09950213A1660 IN O
the P09950213A1660 DT O
participation P09950213A1660 NN O
of P09950213A1660 IN O
TbetaRIII P09950213A1660 NNP I-UN
. P09950213A1660 . O
. . O O

Methanesulfonyl P10192638T0000 NNP O
fluoride P10192638T0000 NN O
( P10192638T0000 ( O
MSF P10192638T0000 NNP O
) P10192638T0000 ) O
: P10192638T0000 : O
a P10192638T0000 DT O
double-blind P10192638T0000 NN O
, P10192638T0000 , O
placebo-controlled P10192638T0000 JJ O
study P10192638T0000 NN O
of P10192638T0000 IN O
safety P10192638T0000 NN O
and P10192638T0000 CC O
efficacy P10192638T0000 NN O
in P10192638T0000 IN O
the P10192638T0000 DT O
treatment P10192638T0000 NN O
of P10192638T0000 IN O
senile P10192638T0000 JJ O
dementia P10192638T0000 NN O
of P10192638T0000 IN O
the P10192638T0000 DT O
Alzheimer P10192638T0000 NNP O
type P10192638T0000 NN O
. P10192638T0000 . O
. . O O

The P08123787A0554 DT O
inferred P08123787A0554 JJ O
amino P08123787A0554 NN O
acid P08123787A0554 JJ O
sequence P08123787A0554 NN O
of P08123787A0554 IN O
the P08123787A0554 DT O
cyanobacterial P08123787A0554 JJ I-UN
HemB P08123787A0554 NNP I-UN
protein P08123787A0554 NN I-UN
indicates P08123787A0554 VBZ O
a P08123787A0554 DT O
significant P08123787A0554 JJ O
difference P08123787A0554 NN O
in P08123787A0554 IN O
the P08123787A0554 DT O
metal P08123787A0554 NN O
cofactor P08123787A0554 NN O
requirement P08123787A0554 NN O
from P08123787A0554 IN O
the P08123787A0554 DT O
higher-plant P08123787A0554 JJ O
enzymes P08123787A0554 NNS O
, P08123787A0554 , O
which P08123787A0554 WDT O
was P08123787A0554 VBD O
confirmed P08123787A0554 VBN O
by P08123787A0554 IN O
overexpression P08123787A0554 NN O
and P08123787A0554 CC O
biochemical P08123787A0554 JJ O
analysis P08123787A0554 NN O
. P08123787A0554 . O
. . O O

To P08959117A0708 TO O
elucidate P08959117A0708 VB O
whether P08959117A0708 IN O
potential P08959117A0708 JJ O
endocrine P08959117A0708 NN O
changes P08959117A0708 NNS O
resulted P08959117A0708 VBD O
from P08959117A0708 IN O
acute P08959117A0708 JJ O
hypoxaemia P08959117A0708 NN O
alone P08959117A0708 RB O
, P08959117A0708 , O
the P08959117A0708 DT O
underlying P08959117A0708 JJ O
disease P08959117A0708 NN O
, P08959117A0708 , O
or P08959117A0708 CC O
unspecific P08959117A0708 JJ O
influences P08959117A0708 NNS O
connected P08959117A0708 VBN O
with P08959117A0708 IN O
the P08959117A0708 DT O
ICU P08959117A0708 NNP O
setting P08959117A0708 NN O
, P08959117A0708 , O
all P08959117A0708 DT O
measurements P08959117A0708 NNS O
were P08959117A0708 VBD O
compared P08959117A0708 VBN O
to P08959117A0708 TO O
those P08959117A0708 DT O
of P08959117A0708 IN O
a P08959117A0708 DT O
completely P08959117A0708 RB O
healthy P08959117A0708 JJ O
reference P08959117A0708 NN O
group P08959117A0708 NN O
( P08959117A0708 ( O
REF P08959117A0708 NNP O
) P08959117A0708 ) O
with P08959117A0708 IN O
comparable P08959117A0708 JJ O
acute P08959117A0708 JJ O
experimental P08959117A0708 JJ O
hypoxaemia P08959117A0708 NN O
. P08959117A0708 . O
. . O O

A P02789062A1420 DT O
cDNA P02789062A1420 NN O
encoding P02789062A1420 VBG O
the P02789062A1420 DT O
NF-4FB P02789062A1420 JJ I-UN
enhancer P02789062A1420 NN I-UN
binding P02789062A1420 VBG I-UN
protein P02789062A1420 NN I-UN
has P02789062A1420 VBZ O
been P02789062A1420 VBN O
cloned P02789062A1420 VBN O
by P02789062A1420 IN O
screening P02789062A1420 VBG O
a P02789062A1420 DT O
lambda P02789062A1420 JJ O
gt11 P02789062A1420 NN O
cDNA P02789062A1420 NN O
library P02789062A1420 NN O
with P02789062A1420 IN O
a P02789062A1420 DT O
rabiolabelled P02789062A1420 JJ O
oligonucleotide P02789062A1420 NN O
corresponding P02789062A1420 VBG O
to P02789062A1420 TO O
the P02789062A1420 DT O
NF-4FB P02789062A1420 NNP I-UN
recognition P02789062A1420 NN I-UN
sequence P02789062A1420 NN I-UN
. P02789062A1420 . O
. . O O

Unlike P11095248A0423 IN O
the P11095248A0423 DT O
mammalian P11095248A0423 JJ O
proteins P11095248A0423 NNS O
, P11095248A0423 , O
XFGF3 P11095248A0423 NNP I-UN
is P11095248A0423 VBZ O
efficiently P11095248A0423 RB O
secreted P11095248A0423 VBN O
as P11095248A0423 IN O
a P11095248A0423 DT O
Mr P11095248A0423 NNP O
31,000 P11095248A0423 CD O
glycoprotein P11095248A0423 NN O
, P11095248A0423 , O
gp31 P11095248A0423 NN I-UN
, P11095248A0423 , O
which P11095248A0423 WDT O
undergoes P11095248A0423 VBZ O
proteolytic P11095248A0423 JJ O
cleavage P11095248A0423 NN O
to P11095248A0423 TO O
produce P11095248A0423 VB O
an P11095248A0423 DT O
NH2-terminally P11095248A0423 RB O
truncated P11095248A0423 JJ O
product P11095248A0423 NN O
, P11095248A0423 , O
gp27 P11095248A0423 NN I-UN
. P11095248A0423 . O
. . O O

Essentially P09618164A0709 RB O
, P09618164A0709 , O
2'- P09618164A0709 JJ O
O P09618164A0709 NNP O
-methyl P09618164A0709 NNP O
oligoribonucleotides P09618164A0709 NNS O
( P09618164A0709 ( O
2'OMeRNA P09618164A0709 CD O
) P09618164A0709 ) O
were P09618164A0709 VBD O
delivered P09618164A0709 VBN O
to P09618164A0709 TO O
the P09618164A0709 DT O
nuclei P09618164A0709 NN O
of P09618164A0709 IN O
primary P09618164A0709 JJ O
mdx P09618164A0709 NN O
myoblasts P09618164A0709 NNS O
in P09618164A0709 IN O
culture P09618164A0709 NN O
. P09618164A0709 . O
. . O O

In P03568311A0273 IN O
10 P03568311A0273 CD O
patients P03568311A0273 NNS O
with P03568311A0273 IN O
subacute P03568311A0273 JJ O
cardiac P03568311A0273 JJ O
tamponade P03568311A0273 NN O
, P03568311A0273 , O
pulmonary P03568311A0273 JJ O
wedge P03568311A0273 NN O
pressure P03568311A0273 NN O
( P03568311A0273 ( O
PWP P03568311A0273 NNP O
) P03568311A0273 ) O
, P03568311A0273 , O
RAP P03568311A0273 NNP O
, P03568311A0273 , O
and P03568311A0273 CC O
IPP P03568311A0273 NNP O
were P03568311A0273 VBD O
measured P03568311A0273 VBN O
along P03568311A0273 IN O
with P03568311A0273 IN O
indexes P03568311A0273 NNS O
of P03568311A0273 IN O
systolic P03568311A0273 JJ O
function P03568311A0273 NN O
. P03568311A0273 . O
. . O O

Both P06969638A0180 DT O
examinations P06969638A0180 NNS O
are P06969638A0180 VBP O
sensitive P06969638A0180 JJ O
indicators P06969638A0180 NNS O
of P06969638A0180 IN O
CNS P06969638A0180 NNP O
abnormalities P06969638A0180 NNS O
associated P06969638A0180 VBN O
with P06969638A0180 IN O
bacterial P06969638A0180 JJ O
meningeal P06969638A0180 NN O
infections P06969638A0180 NNS O
and P06969638A0180 CC O
are P06969638A0180 VBP O
important P06969638A0180 JJ O
determinants P06969638A0180 NNS O
of P06969638A0180 IN O
the P06969638A0180 DT O
therapy P06969638A0180 NN O
and P06969638A0180 CC O
ultimate P06969638A0180 JJ O
prognosis P06969638A0180 NN O
of P06969638A0180 IN O
such P06969638A0180 JJ O
complications P06969638A0180 NNS O
. P06969638A0180 . O
. . O O

Replicating P06272844A0000 VBG O
simian P06272844A0000 JJ O
virus P06272844A0000 NN O
40 P06272844A0000 CD O
( P06272844A0000 ( O
SV40 P06272844A0000 NNP O
) P06272844A0000 ) O
chromosomes P06272844A0000 NNS O
were P06272844A0000 VBD O
found P06272844A0000 VBN O
to P06272844A0000 TO O
be P06272844A0000 VB O
similar P06272844A0000 JJ O
to P06272844A0000 TO O
other P06272844A0000 JJ O
eukaryotic P06272844A0000 JJ O
chromosomes P06272844A0000 NNS O
in P06272844A0000 IN O
that P06272844A0000 DT O
the P06272844A0000 DT O
rate P06272844A0000 NN O
and P06272844A0000 CC O
extent P06272844A0000 NN O
of P06272844A0000 IN O
micrococcal P06272844A0000 JJ I-UN
nuclease P06272844A0000 NN I-UN
( P06272844A0000 ( O
MNase P06272844A0000 NNP I-UN
) P06272844A0000 ) O
digestion P06272844A0000 NN O
were P06272844A0000 VBD O
greater P06272844A0000 JJR O
with P06272844A0000 IN O
replicating P06272844A0000 VBG O
than P06272844A0000 IN O
with P06272844A0000 IN O
nonreplicating P06272844A0000 JJ O
mature P06272844A0000 NN O
SV40 P06272844A0000 NNP O
chromatin P06272844A0000 NN O
. P06272844A0000 . O
. . O O

These P06434572A0157 DT O
children P06434572A0157 NNS O
were P06434572A0157 VBD O
grouped P06434572A0157 VBN O
into P06434572A0157 IN O
four P06434572A0157 CD O
diagnostic P06434572A0157 JJ O
categories P06434572A0157 NNS O
: P06434572A0157 : O
1 P06434572A0157 CD O
) P06434572A0157 ) O
idiopathic P06434572A0157 JJ O
GH P06434572A0157 NNP I-UN
deficiency P06434572A0157 NN O
( P06434572A0157 ( O
n P06434572A0157 JJ O
= P06434572A0157 NNP O
10 P06434572A0157 CD O
) P06434572A0157 ) O
; P06434572A0157 : O
2 P06434572A0157 CD O
) P06434572A0157 ) O
organic P06434572A0157 JJ O
hypopituitarism P06434572A0157 NN O
( P06434572A0157 ( O
n P06434572A0157 JJ O
= P06434572A0157 NNP O
7 P06434572A0157 CD O
) P06434572A0157 ) O
; P06434572A0157 : O
3 P06434572A0157 CD O
) P06434572A0157 ) O
intrauterine P06434572A0157 NN O
growth P06434572A0157 NN O
retardation P06434572A0157 NN O
( P06434572A0157 ( O
n P06434572A0157 JJ O
= P06434572A0157 NNP O
5 P06434572A0157 CD O
) P06434572A0157 ) O
; P06434572A0157 : O
and P06434572A0157 CC O
4 P06434572A0157 CD O
) P06434572A0157 ) O
constitutional P06434572A0157 JJ O
delay P06434572A0157 NN O
of P06434572A0157 IN O
growth P06434572A0157 NN O
and P06434572A0157 CC O
/ P06434572A0157 NN O
or P06434572A0157 CC O
familial P06434572A0157 JJ O
short P06434572A0157 JJ O
stature P06434572A0157 NN O
( P06434572A0157 ( O
n P06434572A0157 JJ O
= P06434572A0157 NNP O
18 P06434572A0157 CD O
) P06434572A0157 ) O
, P06434572A0157 , O
by P06434572A0157 IN O
standard P06434572A0157 JJ O
clinical P06434572A0157 JJ O
criteria P06434572A0157 NNS O
and P06434572A0157 CC O
physiological P06434572A0157 JJ O
and P06434572A0157 CC O
pharmacological P06434572A0157 JJ O
tests P06434572A0157 NNS O
of P06434572A0157 IN O
GH P06434572A0157 NNP I-UN
reserve P06434572A0157 NN O
. P06434572A0157 . O
. . O O

Mapping P01333035T0000 VBG O
the P01333035T0000 DT O
cAMP P01333035T0000 NN I-UN
receptor P01333035T0000 NN I-UN
protein P01333035T0000 NN I-UN
contact P01333035T0000 NN I-UN
site P01333035T0000 NN I-UN
on P01333035T0000 IN O
the P01333035T0000 DT O
alpha P01333035T0000 JJ O
subunit P01333035T0000 NN O
of P01333035T0000 IN O
Escherichia P01333035T0000 NNP I-UN
coli P01333035T0000 NNS I-UN
RNA P01333035T0000 NNP I-UN
polymerase P01333035T0000 NN I-UN
. P01333035T0000 . O
. . O O

These P09154621A1475 DT O
results P09154621A1475 NNS O
suggest P09154621A1475 VBP O
that P09154621A1475 IN O
dietary P09154621A1475 JJ O
safflower P09154621A1475 JJR O
phospholipids P09154621A1475 NNS O
may P09154621A1475 MD O
be P09154621A1475 VB O
a P09154621A1475 DT O
valuable P09154621A1475 JJ O
ingredient P09154621A1475 NN O
to P09154621A1475 TO O
layers P09154621A1475 NNS O
for P09154621A1475 IN O
reducing P09154621A1475 VBG O
liver P09154621A1475 NN O
triglycerides P09154621A1475 NNS O
and P09154621A1475 CC O
serum P09154621A1475 VB O
cholesterol P09154621A1475 NN O
without P09154621A1475 IN O
any P09154621A1475 DT O
adverse P09154621A1475 JJ O
effects P09154621A1475 NNS O
. P09154621A1475 . O
. . O O

The P03615550A0000 DT O
effects P03615550A0000 NNS O
of P03615550A0000 IN O
several P03615550A0000 JJ O
opioid P03615550A0000 JJ O
agonists P03615550A0000 NNS O
and P03615550A0000 CC O
the P03615550A0000 DT O
opioid P03615550A0000 JJ O
antagonist P03615550A0000 NN O
naloxone P03615550A0000 NN O
were P03615550A0000 VBD O
examined P03615550A0000 VBN O
in P03615550A0000 IN O
rats P03615550A0000 NNS O
responding P03615550A0000 VBG O
under P03615550A0000 IN O
a P03615550A0000 DT O
fixed-consecutive-number P03615550A0000 JJ O
( P03615550A0000 ( O
FCN P03615550A0000 NNP O
) P03615550A0000 ) O
schedule P03615550A0000 NN O
. P03615550A0000 . O
. . O O

Two P08163498A0789 CD O
phosphopeptides P08163498A0789 NNS O
, P08163498A0789 , O
identified P08163498A0789 VBN O
as P08163498A0789 IN O
RS- P08163498A0789 NNP O
[ P08163498A0789 NNP O
32P P08163498A0789 CD O
] P08163498A0789 NNP O
SGASGLLTSEHHSR P08163498A0789 NNP O
and P08163498A0789 CC O
S- P08163498A0789 NNP O
[ P08163498A0789 NNP O
32P P08163498A0789 CD O
] P08163498A0789 NNP O
SGASGLLTSEHHSR P08163498A0789 NNP O
, P08163498A0789 , O
were P08163498A0789 VBD O
obtained P08163498A0789 VBN O
after P08163498A0789 IN O
stoichiometric P08163498A0789 JJ O
phosphorylation P08163498A0789 NN O
and P08163498A0789 CC O
trypsinization P08163498A0789 NN O
of P08163498A0789 IN O
the P08163498A0789 DT O
peptide P08163498A0789 NN O
. P08163498A0789 . O
. . O O

This P08294906A1315 DT O
distribution P08294906A1315 NN O
parallels P08294906A1315 VBZ O
that P08294906A1315 IN O
of P08294906A1315 IN O
the P08294906A1315 DT O
neurotransmitters P08294906A1315 NNS O
glutamate P08294906A1315 VBP O
and P08294906A1315 CC O
aspartate P08294906A1315 VBP O
; P08294906A1315 : O
however P08294906A1315 RB O
, P08294906A1315 , O
neither P08294906A1315 DT O
of P08294906A1315 IN O
these P08294906A1315 DT O
excitatory P08294906A1315 JJ O
amino P08294906A1315 NN O
acids P08294906A1315 NNS O
is P08294906A1315 VBZ O
a P08294906A1315 DT O
substrate P08294906A1315 NN O
for P08294906A1315 IN O
transport P08294906A1315 NN O
. P08294906A1315 . O
. . O O

The P06494297A0939 DT O
results P06494297A0939 NNS O
imply P06494297A0939 VBP O
that P06494297A0939 IN O
kindling P06494297A0939 VBG O
does P06494297A0939 VBZ O
not P06494297A0939 RB O
produce P06494297A0939 VB O
its P06494297A0939 PRP$ O
facilitating P06494297A0939 VBG O
effect P06494297A0939 NN O
on P06494297A0939 IN O
acquisition P06494297A0939 NN O
of P06494297A0939 IN O
HPC P06494297A0939 NNP O
SS P06494297A0939 NNP O
by P06494297A0939 IN O
removing P06494297A0939 VBG O
a P06494297A0939 DT O
disruptive P06494297A0939 JJ O
effect P06494297A0939 NN O
of P06494297A0939 IN O
the P06494297A0939 DT O
stimulation P06494297A0939 NN O
. P06494297A0939 . O
. . O O

Reliability P10903583T0000 NN O
of P10903583T0000 IN O
cervical P10903583T0000 JJ O
range P10903583T0000 NN O
of P10903583T0000 IN O
motion P10903583T0000 NN O
using P10903583T0000 VBG O
the P10903583T0000 DT O
OSI P10903583T0000 NNP O
CA P10903583T0000 NNP O
6000 P10903583T0000 CD O
spine P10903583T0000 NN O
motion P10903583T0000 NN O
analyser P10903583T0000 NN O
on P10903583T0000 IN O
asymptomatic P10903583T0000 JJ O
and P10903583T0000 CC O
symptomatic P10903583T0000 JJ O
subjects P10903583T0000 NNS O
. P10903583T0000 . O
. . O O

The P11764062A0000 DT O
Penn P11764062A0000 NNP O
State P11764062A0000 NNP O
Worry P11764062A0000 NNP O
Questionnaire P11764062A0000 NNP O
for P11764062A0000 IN O
Children P11764062A0000 NNP O
( P11764062A0000 ( O
PSWQ-C P11764062A0000 NNP O
) P11764062A0000 ) O
is P11764062A0000 VBZ O
a P11764062A0000 DT O
14-item P11764062A0000 JJ O
self-report P11764062A0000 NN O
questionnaire P11764062A0000 NN O
that P11764062A0000 WDT O
intends P11764062A0000 VBZ O
to P11764062A0000 TO O
measure P11764062A0000 VB O
the P11764062A0000 DT O
tendency P11764062A0000 NN O
of P11764062A0000 IN O
children P11764062A0000 NNS O
to P11764062A0000 TO O
engage P11764062A0000 VB O
in P11764062A0000 IN O
excessive P11764062A0000 JJ O
, P11764062A0000 , O
generalized P11764062A0000 VBN O
, P11764062A0000 , O
and P11764062A0000 CC O
uncontrollable P11764062A0000 JJ O
worry P11764062A0000 NN O
( P11764062A0000 ( O
Chorpita P11764062A0000 NNP O
et P11764062A0000 RB O
al. P11764062A0000 RB O
, P11764062A0000 , O
Behav P11764062A0000 NNP O
. P11764062A0000 . O
. . O O

Pregnant P00959656A0250 JJ O
women P00959656A0250 NNS O
at P00959656A0250 IN O
term P00959656A0250 NN O
had P00959656A0250 VBD O
the P00959656A0250 DT O
lowest P00959656A0250 JJS O
levels P00959656A0250 NNS O
of P00959656A0250 IN O
antithrombin P00959656A0250 NN I-UN
III P00959656A0250 NNP I-UN
. P00959656A0250 . O
. . O O

The P02691557A0273 DT O
incidence P02691557A0273 NN O
of P02691557A0273 IN O
fetal P02691557A0273 JJ O
breathing P02691557A0273 NN O
movements P02691557A0273 NNS O
( P02691557A0273 ( O
06.00-10.00 P02691557A0273 JJ O
h P02691557A0273 NN O
) P02691557A0273 ) O
decreased P02691557A0273 VBD O
with P02691557A0273 IN O
increasing P02691557A0273 VBG O
gestational P02691557A0273 JJ O
age P02691557A0273 NN O
while P02691557A0273 IN O
fetal P02691557A0273 JJ O
arterial P02691557A0273 JJ O
concentrations P02691557A0273 NNS O
of P02691557A0273 IN O
plasma P02691557A0273 JJ O
PGE P02691557A0273 NNP O
increased P02691557A0273 VBD O
significantly P02691557A0273 RB O
over P02691557A0273 IN O
the P02691557A0273 DT O
same P02691557A0273 JJ O
period P02691557A0273 NN O
of P02691557A0273 IN O
gestation P02691557A0273 NN O
. P02691557A0273 . O
. . O O

DESIGN P11428435A0446 NN O
: P11428435A0446 : O
A P11428435A0446 DT O
retrospective P11428435A0446 JJ O
chart P11428435A0446 NN O
review P11428435A0446 NN O
of P11428435A0446 IN O
9,322 P11428435A0446 CD O
patients P11428435A0446 NNS O
undergoing P11428435A0446 JJ O
surgical P11428435A0446 JJ O
procedures P11428435A0446 NNS O
in P11428435A0446 IN O
the P11428435A0446 DT O
period P11428435A0446 NN O
January P11428435A0446 NNP O
1993 P11428435A0446 CD O
to P11428435A0446 TO O
December P11428435A0446 NNP O
1998 P11428435A0446 CD O
. P11428435A0446 . O
. . O O

Unfolding P08226776A0990 VBG O
can P08226776A0990 MD O
be P08226776A0990 VB O
described P08226776A0990 VBN O
by P08226776A0990 IN O
a P08226776A0990 DT O
two-state P08226776A0990 JJ O
process P08226776A0990 NN O
since P08226776A0990 IN O
a P08226776A0990 DT O
ratio P08226776A0990 NN O
of P08226776A0990 IN O
delta P08226776A0990 NN O
Hcalorimetric P08226776A0990 NNP O
to P08226776A0990 TO O
delta P08226776A0990 VB O
Hva P08226776A0990 NNP O
n't P08226776A0990 RB O
Hoff P08226776A0990 NNP O
equals P08226776A0990 NNS O
0.96 P08226776A0990 CD O
. P08226776A0990 . O
. . O O

The P10448036A0748 DT O
interaction P10448036A0748 NN O
of P10448036A0748 IN O
zf4-6 P10448036A0748 NN I-UN
with P10448036A0748 IN O
full-length P10448036A0748 JJ I-UN
5 P10448036A0748 CD I-UN
S P10448036A0748 NNP I-UN
RNA P10448036A0748 NNP I-UN
was P10448036A0748 VBD O
far P10448036A0748 RB O
more P10448036A0748 RBR O
sensitive P10448036A0748 JJ O
to P10448036A0748 TO O
non-specific P10448036A0748 JJ O
competitor P10448036A0748 NN O
concentration P10448036A0748 NN O
than P10448036A0748 IN O
was P10448036A0748 VBD O
the P10448036A0748 DT O
zf4-7:5 P10448036A0748 JJ O
S P10448036A0748 NNP I-UN
RNA P10448036A0748 NNP I-UN
interaction P10448036A0748 NN O
, P10448036A0748 , O
suggesting P10448036A0748 VBG O
that P10448036A0748 IN O
finger P10448036A0748 NN O
seven P10448036A0748 CD O
contributes P10448036A0748 NNS O
to P10448036A0748 TO O
both P10448036A0748 DT O
affinity P10448036A0748 NN O
and P10448036A0748 CC O
specificity P10448036A0748 NN O
in P10448036A0748 IN O
this P10448036A0748 DT O
protein P10448036A0748 NN O
: P10448036A0748 : O
RNA P10448036A0748 JJ O
interaction P10448036A0748 NN O
. P10448036A0748 . O
. . O O

At P00932738A0116 IN O
a P00932738A0116 DT O
systolic P00932738A0116 JJ O
blood P00932738A0116 NN O
pressure P00932738A0116 NN O
( P00932738A0116 ( O
BP P00932738A0116 NNP O
) P00932738A0116 ) O
of P00932738A0116 IN O
60 P00932738A0116 CD O
mmHg P00932738A0116 NNS O
, P00932738A0116 , O
C02 P00932738A0116 NNP O
responsiveness P00932738A0116 NN O
was P00932738A0116 VBD O
abolished P00932738A0116 VBN O
, P00932738A0116 , O
but P00932738A0116 CC O
was P00932738A0116 VBD O
maintained P00932738A0116 VBN O
at P00932738A0116 IN O
higher P00932738A0116 JJR O
levels P00932738A0116 NNS O
of P00932738A0116 IN O
BP P00932738A0116 NNP O
. P00932738A0116 . O
. . O O

[ P08226794A0501 JJ I-UN
Ala85 P08226794A0501 NNP I-UN
] P08226794A0501 NNP I-UN
Dk P08226794A0501 NNP I-UN
( P08226794A0501 ( I-UN
69-85 P08226794A0501 JJ I-UN
) P08226794A0501 ) I-UN
retains P08226794A0501 VBZ O
full P08226794A0501 JJ O
biological P08226794A0501 JJ O
activity P08226794A0501 NN O
. P08226794A0501 . O
. . O O

An P08825639A0827 DT O
inverted P08825639A0827 JJ O
Alu P08825639A0827 NNP I-UN
repeat P08825639A0827 NN O
element P08825639A0827 NN O
, P08825639A0827 , O
flanked P08825639A0827 VBN O
by P08825639A0827 IN O
nonamer P08825639A0827 JJ O
direct P08825639A0827 JJ O
repeats P08825639A0827 NNS O
, P08825639A0827 , O
was P08825639A0827 VBD O
identified P08825639A0827 VBN O
within P08825639A0827 IN O
the P08825639A0827 DT O
region P08825639A0827 NN O
-913 P08825639A0827 NNP O
/ P08825639A0827 NNP O
-620 P08825639A0827 NNP O
, P08825639A0827 , O
relative P08825639A0827 JJ O
to P08825639A0827 TO O
the P08825639A0827 DT O
cap P08825639A0827 NN O
site P08825639A0827 NN O
. P08825639A0827 . O
. . O O

In P02126417A0408 IN O
the P02126417A0408 DT O
controls P02126417A0408 NNS O
, P02126417A0408 , O
it P02126417A0408 PRP O
was P02126417A0408 VBD O
found P02126417A0408 VBN O
that P02126417A0408 IN O
all P02126417A0408 DT O
right-handed P02126417A0408 JJ O
and P02126417A0408 CC O
10 P02126417A0408 CD O
out P02126417A0408 IN O
of P02126417A0408 IN O
14 P02126417A0408 CD O
left-handed P02126417A0408 JJ O
control P02126417A0408 NN O
subjects P02126417A0408 VBZ O
showed P02126417A0408 VBD O
a P02126417A0408 DT O
right P02126417A0408 JJ O
VHF P02126417A0408 NNP O
( P02126417A0408 ( O
i.e. P02126417A0408 FW O
, P02126417A0408 , O
left P02126417A0408 VBD O
hemisphere P02126417A0408 RB O
) P02126417A0408 ) O
advantage P02126417A0408 NN O
. P02126417A0408 . O
. . O O

Data P07743697A0703 NNS O
from P07743697A0703 IN O
the P07743697A0703 DT O
V-HeFT P07743697A0703 NNP O
II P07743697A0703 NNP O
show P07743697A0703 NN O
that P07743697A0703 WDT O
at P07743697A0703 IN O
2-year P07743697A0703 JJ O
follow-up P07743697A0703 NN O
, P07743697A0703 , O
a P07743697A0703 DT O
progressive P07743697A0703 JJ O
rise P07743697A0703 NN O
of P07743697A0703 IN O
plasma P07743697A0703 NN O
norepinephrine P07743697A0703 NN O
was P07743697A0703 VBD O
observed P07743697A0703 VBN O
in P07743697A0703 IN O
both P07743697A0703 DT O
treatment P07743697A0703 NN O
arms P07743697A0703 NNS O
, P07743697A0703 , O
suggesting P07743697A0703 VBG O
that P07743697A0703 IN O
disease P07743697A0703 NN O
progresses P07743697A0703 VBZ O
despite P07743697A0703 IN O
treatment P07743697A0703 NN O
with P07743697A0703 IN O
either P07743697A0703 DT O
an P07743697A0703 DT O
angiotensin-converting P07743697A0703 JJ I-UN
enzyme P07743697A0703 NN I-UN
inhibitor P07743697A0703 NN O
, P07743697A0703 , O
enalapril P07743697A0703 NN O
, P07743697A0703 , O
or P07743697A0703 CC O
vasodilator P07743697A0703 NN O
therapy P07743697A0703 NN O
with P07743697A0703 IN O
hydralazine P07743697A0703 JJ O
/ P07743697A0703 NNP O
isosorbide P07743697A0703 NN O
dinitrate P07743697A0703 NN O
. P07743697A0703 . O
. . O O

Refractory P06610347A0581 NNP O
periods P06610347A0581 NNS O
of P06610347A0581 IN O
the P06610347A0581 DT O
AV P06610347A0581 NNP O
junction P06610347A0581 NN O
were P06610347A0581 VBD O
altered P06610347A0581 VBN O
in P06610347A0581 IN O
a P06610347A0581 DT O
comparable P06610347A0581 JJ O
fashion P06610347A0581 NN O
to P06610347A0581 TO O
conduction P06610347A0581 NN O
through P06610347A0581 IN O
the P06610347A0581 DT O
AV P06610347A0581 NNP O
node P06610347A0581 NN O
. P06610347A0581 . O
. . O O

Acute P11743360A2491 NNP O
stress P11743360A2491 NN O
in P11743360A2491 IN O
7 P11743360A2491 CD O
rats P11743360A2491 NNS O
also P11743360A2491 RB O
increased P11743360A2491 VBD O
the P11743360A2491 DT O
mean P11743360A2491 JJ O
amount P11743360A2491 NN O
of P11743360A2491 IN O
IL-6 P11743360A2491 NNP I-UN
released P11743360A2491 VBN O
in P11743360A2491 IN O
the P11743360A2491 DT O
urine P11743360A2491 NN O
by P11743360A2491 IN O
31.5 P11743360A2491 CD O
% P11743360A2491 NN O
from P11743360A2491 IN O
775.9 P11743360A2491 CD O
+ P11743360A2491 NNS O
/ P11743360A2491 SYM O
- P11743360A2491 : O
69.2 P11743360A2491 CD O
to P11743360A2491 TO O
1,021.1 P11743360A2491 CD O
+ P11743360A2491 NNS O
/ P11743360A2491 SYM O
- P11743360A2491 : O
93.3 P11743360A2491 CD O
pg P11743360A2491 NN O
. P11743360A2491 . O
/ P11743360A2491 JJ O
ml P11743360A2491 NN O
. P11743360A2491 . O
. . O O

Thirty P09100202A0000 NNP O
Class P09100202A0000 NNP O
I P09100202A0000 PRP O
and P09100202A0000 CC O
Class P09100202A0000 NNP O
II P09100202A0000 NNP O
recessions P09100202A0000 NNS O
in P09100202A0000 IN O
30 P09100202A0000 CD O
patients P09100202A0000 NNS O
were P09100202A0000 VBD O
treated P09100202A0000 VBN O
with P09100202A0000 IN O
a P09100202A0000 DT O
modified P09100202A0000 JJ O
subepithelial P09100202A0000 JJ O
connective P09100202A0000 JJ O
tissue P09100202A0000 NN O
graft P09100202A0000 NN O
procedure P09100202A0000 NN O
. P09100202A0000 . O
. . O O

Molecule P10727511A0294 NNP O
( P10727511A0294 ( O
s P10727511A0294 PRP O
) P10727511A0294 ) O
secreted P10727511A0294 VBN O
by P10727511A0294 IN O
neuronal P10727511A0294 JJ O
cultures P10727511A0294 NNS O
contribute P10727511A0294 VBP O
to P10727511A0294 TO O
this P10727511A0294 DT O
induction P10727511A0294 NN O
of P10727511A0294 IN O
GLT-1 P10727511A0294 NNP I-UN
, P10727511A0294 , O
but P10727511A0294 CC O
little P10727511A0294 JJ O
is P10727511A0294 VBZ O
known P10727511A0294 VBN O
about P10727511A0294 IN O
the P10727511A0294 DT O
signaling P10727511A0294 NN O
pathways P10727511A0294 VBZ O
mediating P10727511A0294 VBG O
this P10727511A0294 DT O
regulation P10727511A0294 NN O
. P10727511A0294 . O
. . O O

CONCLUSION P07509472A1320 NN O
: P07509472A1320 : O
This P07509472A1320 DT O
study P07509472A1320 NN O
documents P07509472A1320 NNS O
that P07509472A1320 IN O
regression P07509472A1320 NN O
of P07509472A1320 IN O
choroidal P07509472A1320 JJ O
neovascularization P07509472A1320 NN O
that P07509472A1320 WDT O
occurred P07509472A1320 VBD O
with P07509472A1320 IN O
alpha P07509472A1320 NN I-UN
interferon P07509472A1320 NN I-UN
treatment P07509472A1320 NN O
was P07509472A1320 VBD O
minimal P07509472A1320 JJ O
. P07509472A1320 . O
. . O O

Computer-aided P01569015A0120 JJ O
`` P01569015A0120 `` O
FRAME P01569015A0120 NNP O
'' P01569015A0120 '' O
analysis P01569015A0120 NN O
revealed P01569015A0120 VBD O
four P01569015A0120 CD O
possible P01569015A0120 JJ O
open P01569015A0120 JJ O
reading P01569015A0120 NN O
frames P01569015A0120 NNS O
( P01569015A0120 ( O
ORFs P01569015A0120 NNP O
) P01569015A0120 ) O
, P01569015A0120 , O
three P01569015A0120 CD O
in P01569015A0120 IN O
one P01569015A0120 CD O
direction P01569015A0120 NN O
and P01569015A0120 CC O
one P01569015A0120 CD O
in P01569015A0120 IN O
the P01569015A0120 DT O
opposite P01569015A0120 JJ O
direction P01569015A0120 NN O
. P01569015A0120 . O
. . O O

Further P08981371A2049a RB O
, P08981371A2049a , O
the P08981371A2049a DT O
PIP2 P08981371A2049a NNP O
content P08981371A2049a NN O
of P08981371A2049a IN O
the P08981371A2049a DT O
85-90 P08981371A2049a JJ O
kDa P08981371A2049a NN O
protein P08981371A2049a NN O
appeared P08981371A2049a VBD O
to P08981371A2049a TO O
decrease P08981371A2049a VB O
with P08981371A2049a IN O
CSF-1 P08981371A2049a NNP I-UN
treatment P08981371A2049a NN O
. P08981371A2049a . O
. . O O

The P09528950A0716 DT O
genomic P09528950A0716 JJ O
fragments P09528950A0716 NNS O
were P09528950A0716 VBD O
fused P09528950A0716 VBN O
upstream P09528950A0716 NN O
of P09528950A0716 IN O
the P09528950A0716 DT O
luciferase P09528950A0716 NN I-UN
reporter P09528950A0716 NN I-UN
gene P09528950A0716 NN I-UN
. P09528950A0716 . O
. . O O

HTLV-1 P11589779T0000 JJ O
decreases P11589779T0000 NNS O
Th2 P11589779T0000 NNP O
type P11589779T0000 NN O
of P11589779T0000 IN O
immune P11589779T0000 JJ O
response P11589779T0000 NN O
in P11589779T0000 IN O
patients P11589779T0000 NNS O
with P11589779T0000 IN O
strongyloidiasis P11589779T0000 NN O
. P11589779T0000 . O
. . O O

HVH2 P07535768A1076 NNP I-UN
mRNA P07535768A1076 NN I-UN
showed P07535768A1076 VBD O
an P07535768A1076 DT O
expression P07535768A1076 NN O
pattern P07535768A1076 NN O
distinct P07535768A1076 NN O
from P07535768A1076 IN O
CL100 P07535768A1076 NNP I-UN
( P07535768A1076 ( O
human P07535768A1076 JJ I-UN
homologue P07535768A1076 NN I-UN
of P07535768A1076 IN I-UN
mouse P07535768A1076 NN I-UN
MKP1 P07535768A1076 NNP I-UN
) P07535768A1076 ) O
and P07535768A1076 CC O
PAC1 P07535768A1076 NNP I-UN
, P07535768A1076 , O
two P07535768A1076 CD O
previously P07535768A1076 RB O
identified P07535768A1076 VBN O
MAP P07535768A1076 NNP I-UN
kinase P07535768A1076 NN I-UN
phosphatases P07535768A1076 NNS I-UN
. P07535768A1076 . O
. . O O

Since P02283873A0308 IN O
one P02283873A0308 CD O
group P02283873A0308 NN O
of P02283873A0308 IN O
adolescents P02283873A0308 NNS O
more P02283873A0308 RBR O
difficult P02283873A0308 JJ O
to P02283873A0308 TO O
influence P02283873A0308 VB O
are P02283873A0308 VBP O
those P02283873A0308 DT O
whose P02283873A0308 WP$ O
parents P02283873A0308 NNS O
smoke P02283873A0308 VBD O
, P02283873A0308 , O
parental P02283873A0308 JJ O
involvement P02283873A0308 NN O
in P02283873A0308 IN O
smoking P02283873A0308 VBG O
prevention P02283873A0308 NN O
may P02283873A0308 MD O
be P02283873A0308 VB O
a P02283873A0308 DT O
powerful P02283873A0308 JJ O
enhancer P02283873A0308 NN O
. P02283873A0308 . O
. . O O

Children P09147832A0174 NNP O
's P09147832A0174 POS O
temperament P09147832A0174 NN O
and P09147832A0174 CC O
maternal P09147832A0174 JJ O
socialization P09147832A0174 NN O
at P09147832A0174 IN O
Time P09147832A0174 NNP O
1 P09147832A0174 CD O
( P09147832A0174 ( O
n P09147832A0174 JJ O
= P09147832A0174 NN O
103 P09147832A0174 CD O
, P09147832A0174 , O
aged P09147832A0174 VBN O
2-3 P09147832A0174 CD O
years P09147832A0174 NNS O
) P09147832A0174 ) O
were P09147832A0174 VBD O
considered P09147832A0174 VBN O
predictors P09147832A0174 NNS O
of P09147832A0174 IN O
future P09147832A0174 JJ O
conscience P09147832A0174 NN O
, P09147832A0174 , O
assessed P09147832A0174 VBD O
using P09147832A0174 VBG O
new P09147832A0174 JJ O
observational P09147832A0174 JJ O
and P09147832A0174 CC O
narrative P09147832A0174 JJ O
measures P09147832A0174 NNS O
. P09147832A0174 . O
. . O O

Guidelines P11397652A0381 NNS O
for P11397652A0381 IN O
performing P11397652A0381 VBG O
a P11397652A0381 DT O
routine P11397652A0381 JJ O
spiral P11397652A0381 NN O
assay P11397652A0381 NN O
are P11397652A0381 VBP O
presented P11397652A0381 VBN O
, P11397652A0381 , O
and P11397652A0381 CC O
alternative P11397652A0381 JJ O
test P11397652A0381 NN O
methods P11397652A0381 NNS O
intended P11397652A0381 VBN O
to P11397652A0381 TO O
overcome P11397652A0381 VB O
a P11397652A0381 DT O
variety P11397652A0381 NN O
of P11397652A0381 IN O
technical P11397652A0381 JJ O
difficulties P11397652A0381 NNS O
( P11397652A0381 ( O
such P11397652A0381 JJ O
as P11397652A0381 IN O
restricted P11397652A0381 JJ O
sample P11397652A0381 NN O
availability P11397652A0381 NN O
, P11397652A0381 , O
sample P11397652A0381 JJ O
viscosity P11397652A0381 NN O
or P11397652A0381 CC O
volatility P11397652A0381 NN O
, P11397652A0381 , O
etc P11397652A0381 FW O
. P11397652A0381 . O
) P11397652A0381 ) O
are P11397652A0381 VBP O
recommended P11397652A0381 VBN O
. P11397652A0381 . O
. . O O

Hypercalcemia P11407650A0661 NNP O
associated P11407650A0661 VBD O
with P11407650A0661 IN O
elevated P11407650A0661 JJ O
serum P11407650A0661 NN I-UN
PTH P11407650A0661 NNP I-UN
concentration P11407650A0661 NN O
indicating P11407650A0661 VBG O
primary P11407650A0661 JJ O
hyperparathyroidism P11407650A0661 NN O
was P11407650A0661 VBD O
found P11407650A0661 VBN O
in P11407650A0661 IN O
7 P11407650A0661 CD O
BC P11407650A0661 NNP O
patients P11407650A0661 NNS O
( P11407650A0661 ( O
7 P11407650A0661 CD O
% P11407650A0661 NN O
) P11407650A0661 ) O
and P11407650A0661 CC O
in P11407650A0661 IN O
none P11407650A0661 NN O
of P11407650A0661 IN O
healthy P11407650A0661 JJ O
women P11407650A0661 NNS O
or P11407650A0661 CC O
patients P11407650A0661 NNS O
with P11407650A0661 IN O
thyroid P11407650A0661 JJ O
cancer P11407650A0661 NN O
. P11407650A0661 . O
. . O O

Therapeutic P09504553T0000 JJ O
use P09504553T0000 NN O
of P09504553T0000 IN O
cannabis P09504553T0000 NN O
. P09504553T0000 . O
. . O O

The P02530470A0604 DT O
overall P02530470A0604 JJ O
prevalence P02530470A0604 NN O
of P02530470A0604 IN O
HBV P02530470A0604 NNP O
markers P02530470A0604 NNS O
was P02530470A0604 VBD O
higher P02530470A0604 JJR O
among P02530470A0604 IN O
staff P02530470A0604 NN O
members P02530470A0604 NNS O
than P02530470A0604 IN O
in P02530470A0604 IN O
the P02530470A0604 DT O
blood P02530470A0604 NN O
donors P02530470A0604 NNS O
of P02530470A0604 IN O
our P02530470A0604 PRP$ O
area P02530470A0604 NN O
. P02530470A0604 . O
. . O O

Genetic P01375224A0152 NNP O
and P01375224A0152 CC O
biochemical P01375224A0152 JJ O
evidence P01375224A0152 NN O
suggests P01375224A0152 VBZ O
that P01375224A0152 IN O
v-Crk P01375224A0152 NN I-UN
can P01375224A0152 MD O
induce P01375224A0152 VB O
transformation P01375224A0152 NN O
of P01375224A0152 IN O
chicken P01375224A0152 NN O
embryo P01375224A0152 NN O
fibroblasts P01375224A0152 NNS O
by P01375224A0152 IN O
influencing P01375224A0152 VBG O
the P01375224A0152 DT O
activity P01375224A0152 NN O
of P01375224A0152 IN O
cellular P01375224A0152 JJ O
proteins P01375224A0152 NNS O
involved P01375224A0152 VBN O
in P01375224A0152 IN O
growth P01375224A0152 NN O
regulation P01375224A0152 NN O
. P01375224A0152 . O
. . O O

We P07759529A0288 PRP O
used P07759529A0288 VBD O
two P07759529A0288 CD O
approaches P07759529A0288 NNS O
to P07759529A0288 TO O
ascertain P07759529A0288 VB O
whether P07759529A0288 IN O
CDP P07759529A0288 NNP I-UN
/ P07759529A0288 NNP O
cut P07759529A0288 VBD I-UN
serves P07759529A0288 NNS O
as P07759529A0288 IN O
a P07759529A0288 DT O
repressor P07759529A0288 NN O
of P07759529A0288 IN O
gp91-phox P07759529A0288 JJ O
gene P07759529A0288 NN O
expression P07759529A0288 NN O
. P07759529A0288 . O
. . O O

Characterization P11112700T0000 NN O
of P11112700T0000 IN O
the P11112700T0000 DT O
microtubule P11112700T0000 NN O
binding P11112700T0000 VBG O
domain P11112700T0000 NN O
of P11112700T0000 IN O
microtubule P11112700T0000 NN I-UN
actin P11112700T0000 IN I-UN
crosslinking P11112700T0000 VBG I-UN
factor P11112700T0000 NN I-UN
( P11112700T0000 ( O
MACF P11112700T0000 NNP I-UN
) P11112700T0000 ) O
: P11112700T0000 : O
identification P11112700T0000 NN O
of P11112700T0000 IN O
a P11112700T0000 DT O
novel P11112700T0000 JJ O
group P11112700T0000 NN O
of P11112700T0000 IN O
microtubule P11112700T0000 NN I-UN
associated P11112700T0000 VBN I-UN
proteins P11112700T0000 NNS I-UN
. P11112700T0000 . O
. . O O

These P08940132A1120 DT O
findings P08940132A1120 NNS O
suggest P08940132A1120 VBP O
that P08940132A1120 IN O
fodrin P08940132A1120 JJ I-UN
proteolysis P08940132A1120 NN O
in P08940132A1120 IN O
vivo P08940132A1120 NN O
may P08940132A1120 MD O
reflect P08940132A1120 VB O
the P08940132A1120 DT O
activity P08940132A1120 NN O
of P08940132A1120 IN O
multiple P08940132A1120 JJ O
ICE P08940132A1120 NNP I-UN
/ P08940132A1120 NNP O
Ced-3 P08940132A1120 NNP I-UN
proteases P08940132A1120 NNS O
whose P08940132A1120 WP$ O
partial P08940132A1120 JJ O
sensitivity P08940132A1120 NN O
to P08940132A1120 TO O
DEVD-CHO P08940132A1120 NNP O
reflects P08940132A1120 VBZ O
a P08940132A1120 DT O
limited P08940132A1120 JJ O
contribution P08940132A1120 NN O
from P08940132A1120 IN O
CPP32 P08940132A1120 NNP I-UN
, P08940132A1120 , O
or P08940132A1120 CC O
an P08940132A1120 DT O
ICE P08940132A1120 JJ I-UN
/ P08940132A1120 JJ O
Ced-3 P08940132A1120 JJ I-UN
protease P08940132A1120 NN O
less P08940132A1120 RBR O
sensitive P08940132A1120 JJ O
than P08940132A1120 IN O
CPP32 P08940132A1120 NNP I-UN
to P08940132A1120 TO O
DEVD-CHO P08940132A1120 NNP O
inhibition P08940132A1120 NN O
. P08940132A1120 . O
. . O O

To P09582267A0326 TO O
explore P09582267A0326 VB O
the P09582267A0326 DT O
function P09582267A0326 NN O
of P09582267A0326 IN O
human P09582267A0326 JJ O
SINA-homologous P09582267A0326 JJ I-UN
( P09582267A0326 ( I-UN
Siah P09582267A0326 NNP I-UN
) P09582267A0326 ) I-UN
proteins P09582267A0326 VBZ I-UN
, P09582267A0326 , O
expression P09582267A0326 NN O
plasmids P09582267A0326 NNS O
encoding P09582267A0326 VBG O
Siah-1A P09582267A0326 NNP I-UN
were P09582267A0326 VBD O
transiently P09582267A0326 RB O
transfected P09582267A0326 VBN O
into P09582267A0326 IN O
293 P09582267A0326 CD O
epithelial P09582267A0326 JJ O
cells P09582267A0326 NNS O
and P09582267A0326 CC O
GM701 P09582267A0326 NNP O
fibroblast P09582267A0326 NN O
cells P09582267A0326 NNS O
, P09582267A0326 , O
resulting P09582267A0326 VBG O
in P09582267A0326 IN O
growth P09582267A0326 NN O
arrest P09582267A0326 NN O
without P09582267A0326 IN O
induction P09582267A0326 NN O
of P09582267A0326 IN O
apoptosis P09582267A0326 NN O
. P09582267A0326 . O
. . O O

Once P02480959A0470 RB O
P-450scc P02480959A0470 NNP I-UN
mRNA P02480959A0470 NN I-UN
is P02480959A0470 VBZ O
induced P02480959A0470 VBN O
as P02480959A0470 IN O
a P02480959A0470 DT O
consequence P02480959A0470 NN O
of P02480959A0470 IN O
the P02480959A0470 DT O
LH P02480959A0470 NNP I-UN
/ P02480959A0470 NNP O
hCG P02480959A0470 NN I-UN
surge P02480959A0470 NN O
it P02480959A0470 PRP O
is P02480959A0470 VBZ O
constitutively P02480959A0470 RB O
maintained P02480959A0470 VBN O
by P02480959A0470 IN O
luteinized P02480959A0470 JJ O
cells P02480959A0470 NNS O
in P02480959A0470 IN O
vivo P02480959A0470 NN O
( P02480959A0470 ( O
0-4 P02480959A0470 JJ O
days P02480959A0470 NNS O
) P02480959A0470 ) O
and P02480959A0470 CC O
in P02480959A0470 IN O
vitro P02480959A0470 NN O
( P02480959A0470 ( O
0-9 P02480959A0470 JJ O
days P02480959A0470 NNS O
) P02480959A0470 ) O
in P02480959A0470 IN O
the P02480959A0470 DT O
absence P02480959A0470 NN O
of P02480959A0470 IN O
gonadotropins P02480959A0470 NNS I-UN
, P02480959A0470 , O
is P02480959A0470 VBZ O
susceptible P02480959A0470 JJ O
to P02480959A0470 TO O
modulation P02480959A0470 NN O
by P02480959A0470 IN O
prolactin P02480959A0470 NN I-UN
and P02480959A0470 CC O
is P02480959A0470 VBZ O
no P02480959A0470 DT O
longer P02480959A0470 RB O
regulated P02480959A0470 VBN O
by P02480959A0470 IN O
cAMP P02480959A0470 NN O
. P02480959A0470 . O
. . O O

The P02934778A0702 DT O
data P02934778A0702 NN O
indicates P02934778A0702 VBZ O
the P02934778A0702 DT O
presence P02934778A0702 NN O
of P02934778A0702 IN O
5-HT2 P02934778A0702 JJ I-UN
serotonergic P02934778A0702 JJ I-UN
receptors P02934778A0702 NNS I-UN
in P02934778A0702 IN O
the P02934778A0702 DT O
bronchial P02934778A0702 JJ O
artery P02934778A0702 NN O
of P02934778A0702 IN O
these P02934778A0702 DT O
species P02934778A0702 NNS O
. P02934778A0702 . O
. . O O

The P08230418A0812 DT O
action P08230418A0812 NN O
of P08230418A0812 IN O
nef P08230418A0812 NN I-UN
was P08230418A0812 VBD O
specific P08230418A0812 JJ O
to P08230418A0812 TO O
the P08230418A0812 DT O
LTR P08230418A0812 NNP O
, P08230418A0812 , O
as P08230418A0812 IN O
expression P08230418A0812 NN O
of P08230418A0812 IN O
nef P08230418A0812 NN I-UN
had P08230418A0812 VBD O
no P08230418A0812 DT O
effect P08230418A0812 NN O
on P08230418A0812 IN O
the P08230418A0812 DT O
activity P08230418A0812 NN O
of P08230418A0812 IN O
the P08230418A0812 DT O
simian P08230418A0812 JJ O
virus P08230418A0812 NN O
40 P08230418A0812 CD O
, P08230418A0812 , O
c-fms P08230418A0812 NN I-UN
, P08230418A0812 , O
urokinase P08230418A0812 JJ I-UN
plasminogen P08230418A0812 NN I-UN
activator P08230418A0812 NN I-UN
, P08230418A0812 , O
or P08230418A0812 CC O
type P08230418A0812 VB I-UN
5 P08230418A0812 CD I-UN
acid P08230418A0812 JJ I-UN
phosphatase P08230418A0812 NN I-UN
promoter P08230418A0812 NN I-UN
. P08230418A0812 . O
trans-activating P08230418A0812 JJ O
activity P08230418A0812 NN O
was P08230418A0812 VBD O
also P08230418A0812 RB O
manifested P08230418A0812 VBN O
by P08230418A0812 IN O
a P08230418A0812 DT O
frameshift P08230418A0812 NN O
mutant P08230418A0812 NN O
expressing P08230418A0812 VBG O
only P08230418A0812 RB O
the P08230418A0812 DT O
first P08230418A0812 JJ O
35 P08230418A0812 CD O
amino P08230418A0812 JJ O
acids P08230418A0812 NNS O
of P08230418A0812 IN O
the P08230418A0812 DT O
protein P08230418A0812 NN O
. P08230418A0812 . O
. . O O

CONCLUSION P08720407A1386 NN O
: P08720407A1386 : O
The P08720407A1386 DT O
results P08720407A1386 NNS O
demonstrate P08720407A1386 VBP O
that P08720407A1386 IN O
at P08720407A1386 IN O
the P08720407A1386 DT O
site P08720407A1386 NN O
of P08720407A1386 IN O
lumbar P08720407A1386 NN O
disc P08720407A1386 NN O
herniation P08720407A1386 NN O
, P08720407A1386 , O
inflammatory P08720407A1386 JJ O
cytokines P08720407A1386 NNS O
such P08720407A1386 JJ O
as P08720407A1386 IN O
interleukin-1 P08720407A1386 JJ I-UN
alpha P08720407A1386 NN I-UN
are P08720407A1386 VBP O
produced P08720407A1386 VBN O
, P08720407A1386 , O
which P08720407A1386 WDT O
increases P08720407A1386 VBZ O
prostaglandin P08720407A1386 NN O
E2 P08720407A1386 NNP O
production P08720407A1386 NN O
. P08720407A1386 . O
. . O O

The P01398074A1081 DT O
RNase P01398074A1081 NNP I-UN
MRP P01398074A1081 NNP I-UN
RNA P01398074A1081 NNP I-UN
gene P01398074A1081 NN I-UN
was P01398074A1081 VBD O
deleted P01398074A1081 VBN O
by P01398074A1081 IN O
insertional P01398074A1081 JJ O
replacement P01398074A1081 NN O
and P01398074A1081 CC O
found P01398074A1081 VBD O
to P01398074A1081 TO O
be P01398074A1081 VB O
essential P01398074A1081 JJ O
for P01398074A1081 IN O
cellular P01398074A1081 JJ O
viability P01398074A1081 NN O
, P01398074A1081 , O
indicating P01398074A1081 VBG O
a P01398074A1081 DT O
critical P01398074A1081 JJ O
nuclear P01398074A1081 JJ O
role P01398074A1081 NN O
for P01398074A1081 IN O
RNase P01398074A1081 NNP I-UN
MRP P01398074A1081 NNP I-UN
. P01398074A1081 . O
. . O O

The P09193671A0347 DT O
active P09193671A0347 JJ O
state P09193671A0347 NN O
is P09193671A0347 VBZ O
terminated P09193671A0347 VBN O
by P09193671A0347 IN O
hydrolysis P09193671A0347 NN O
of P09193671A0347 IN O
bound P09193671A0347 NN O
GTP P09193671A0347 NNP O
, P09193671A0347 , O
producing P09193671A0347 VBG O
inactive P09193671A0347 JJ O
ARF-GDP P09193671A0347 NNP I-UN
. P09193671A0347 . O
. . O O

The P03997467A0000 DT O
effect P03997467A0000 NN O
of P03997467A0000 IN O
the P03997467A0000 DT O
opiate P03997467A0000 JJ O
antagonist P03997467A0000 NN O
naloxone P03997467A0000 NN O
was P03997467A0000 VBD O
evaluated P03997467A0000 VBN O
in P03997467A0000 IN O
11 P03997467A0000 CD O
unselected P03997467A0000 JJ O
patients P03997467A0000 NNS O
with P03997467A0000 IN O
cerebral P03997467A0000 JJ O
ischemia P03997467A0000 NN O
. P03997467A0000 . O
. . O O

In P07715922A0188 IN O
this P07715922A0188 DT O
paper P07715922A0188 NN O
, P07715922A0188 , O
a P07715922A0188 DT O
comparison P07715922A0188 NN O
between P07715922A0188 IN O
the P07715922A0188 DT O
number P07715922A0188 NN O
and P07715922A0188 CC O
shape P07715922A0188 NN O
of P07715922A0188 IN O
corneal P07715922A0188 JJ O
endothelial P07715922A0188 JJ O
cells P07715922A0188 NNS O
has P07715922A0188 VBZ O
been P07715922A0188 VBN O
performed P07715922A0188 VBN O
in P07715922A0188 IN O
25 P07715922A0188 CD O
patients P07715922A0188 NNS O
before P07715922A0188 IN O
and P07715922A0188 CC O
6 P07715922A0188 CD O
months P07715922A0188 NNS O
after P07715922A0188 IN O
PRK P07715922A0188 NNP O
. P07715922A0188 . O
. . O O

All P08534848A0188b DT O
three P08534848A0188b CD O
NR P08534848A0188b NNP I-UN
isoforms P08534848A0188b NNS O
are P08534848A0188b VBP O
expressed P08534848A0188b VBN O
in P08534848A0188b IN O
cv P08534848A0188b NN O
. P08534848A0188b . O
. . O O

Acute P11198053T0000 JJ O
effects P11198053T0000 NNS O
of P11198053T0000 IN O
LI P11198053T0000 NNP O
160 P11198053T0000 CD O
( P11198053T0000 ( O
extract P11198053T0000 NN O
of P11198053T0000 IN O
Hypericum P11198053T0000 NNP O
perforatum P11198053T0000 NN O
, P11198053T0000 , O
St P11198053T0000 NNP O
John P11198053T0000 NNP O
's P11198053T0000 POS O
wort P11198053T0000 NN O
) P11198053T0000 ) O
and P11198053T0000 CC O
two P11198053T0000 CD O
of P11198053T0000 IN O
its P11198053T0000 PRP$ O
constituents P11198053T0000 NNS O
on P11198053T0000 IN O
neuroendocrine P11198053T0000 JJ O
responses P11198053T0000 NNS O
in P11198053T0000 IN O
the P11198053T0000 DT O
rat P11198053T0000 NN O
. P11198053T0000 . O
. . O O

Reaction P06516977T0000 NN O
of P06516977T0000 IN O
human P06516977T0000 JJ O
organism P06516977T0000 NN O
to P06516977T0000 TO O
exercise P06516977T0000 NN O
. P06516977T0000 . O
. . O O

The P01537334A0507 DT O
gene P01537334A0507 NN O
encoding P01537334A0507 VBG O
TRP-2 P01537334A0507 NNP I-UN
maps P01537334A0507 NNS O
to P01537334A0507 TO O
mouse P01537334A0507 VB O
chromosome P01537334A0507 NN O
14 P01537334A0507 CD O
, P01537334A0507 , O
in P01537334A0507 IN O
the P01537334A0507 DT O
region P01537334A0507 NN O
of P01537334A0507 IN O
the P01537334A0507 DT O
coat P01537334A0507 NN I-UN
colour P01537334A0507 NN I-UN
mutation P01537334A0507 NN I-UN
slaty P01537334A0507 NN I-UN
. P01537334A0507 . O
. . O O

Weak P07719527T0000 NNP O
allergenicity P07719527T0000 NN O
of P07719527T0000 IN O
recombinant P07719527T0000 JJ I-UN
hirudin P07719527T0000 NN I-UN
CGP P07719527T0000 NNP I-UN
39393 P07719527T0000 CD I-UN
( P07719527T0000 ( O
REVASC P07719527T0000 NNP O
) P07719527T0000 ) O
in P07719527T0000 IN O
immunocompetent P07719527T0000 NN O
volunteers P07719527T0000 NNS O
. P07719527T0000 . O
. . O O

No P01674817A0862 DT O
homology P01674817A0862 NN O
was P01674817A0862 VBD O
found P01674817A0862 VBN O
between P01674817A0862 IN O
RNA14 P01674817A0862 NNP I-UN
and P01674817A0862 CC O
RNA15 P01674817A0862 NNP I-UN
or P01674817A0862 CC O
between P01674817A0862 IN O
RNA14 P01674817A0862 NNP I-UN
and P01674817A0862 CC O
other P01674817A0862 JJ O
proteins P01674817A0862 NNS O
contained P01674817A0862 VBN O
in P01674817A0862 IN O
data P01674817A0862 NNS O
banks P01674817A0862 NNS O
. P01674817A0862 . O
. . O O

To P10364159A0813 TO O
address P10364159A0813 VB O
these P10364159A0813 DT O
questions P10364159A0813 NNS O
, P10364159A0813 , O
a P10364159A0813 DT O
recombinant P10364159A0813 JJ O
FRAP P10364159A0813 NNP I-UN
/ P10364159A0813 NNP O
mTOR P10364159A0813 NN I-UN
protein P10364159A0813 NN O
and P10364159A0813 CC O
a P10364159A0813 DT O
FRAP P10364159A0813 NNP I-UN
/ P10364159A0813 NNP O
mTOR P10364159A0813 NN I-UN
immunoprecipitate P10364159A0813 NN O
were P10364159A0813 VBD O
utilized P10364159A0813 VBN O
in P10364159A0813 IN O
in P10364159A0813 IN O
vitro P10364159A0813 JJ O
kinase P10364159A0813 NN O
assays P10364159A0813 NNS O
to P10364159A0813 TO O
phosphorylate P10364159A0813 VB O
4E-BP1 P10364159A0813 JJ I-UN
. P10364159A0813 . O
. . O O

Sequence P02340595A0124 NNP O
analysis P02340595A0124 NN O
of P02340595A0124 IN O
these P02340595A0124 DT O
genes P02340595A0124 NNS O
and P02340595A0124 CC O
their P02340595A0124 PRP$ O
surrounding P02340595A0124 NN O
sequences P02340595A0124 NNS O
are P02340595A0124 VBP O
presented P02340595A0124 VBN O
and P02340595A0124 CC O
compared P02340595A0124 VBN O
with P02340595A0124 IN O
other P02340595A0124 JJ O
known P02340595A0124 VBN O
tRNA P02340595A0124 JJ O
genes P02340595A0124 NNS O
from P02340595A0124 IN O
plant P02340595A0124 NN O
mitochondria P02340595A0124 NN O
. P02340595A0124 . O
. . O O

2 P11576776T0081 CD O
: P11576776T0081 : O
The P11576776T0081 DT O
dynamic P11576776T0081 JJ O
moduli P11576776T0081 NN O
of P11576776T0081 IN O
microcrystalline P11576776T0081 NN O
cellulose P11576776T0081 NN O
. P11576776T0081 . O
. . O O

Concentrations P11902781A0550 NNS O
of P11902781A0550 IN O
N P11902781A0550 NNP O
( P11902781A0550 ( O
O3- P11902781A0550 NNP O
) P11902781A0550 ) O
-N P11902781A0550 NN O
and P11902781A0550 CC O
N P11902781A0550 NNP O
( P11902781A0550 ( O
H3- P11902781A0550 NNP O
) P11902781A0550 ) O
-N P11902781A0550 NN O
at P11902781A0550 IN O
Deoprayag P11902781A0550 NNP O
varied P11902781A0550 VBD O
from P11902781A0550 IN O
0.30 P11902781A0550 CD O
to P11902781A0550 TO O
0.50 P11902781A0550 CD O
and P11902781A0550 CC O
0.02 P11902781A0550 CD O
to P11902781A0550 TO O
0.12 P11902781A0550 CD O
mg P11902781A0550 NNS O
/ P11902781A0550 JJ O
L P11902781A0550 NNP O
, P11902781A0550 , O
respectively P11902781A0550 RB O
, P11902781A0550 , O
depending P11902781A0550 VBG O
on P11902781A0550 IN O
season P11902781A0550 NN O
. P11902781A0550 . O
. . O O

Gel-mobility P09797189A0559 NNP O
shift P09797189A0559 NN O
analysis P09797189A0559 NN O
was P09797189A0559 VBD O
also P09797189A0559 RB O
performed P09797189A0559 VBN O
for P09797189A0559 IN O
the P09797189A0559 DT O
CCAAT P09797189A0559 NNP O
motif P09797189A0559 NN O
at P09797189A0559 IN O
-67 P09797189A0559 NNP O
. P09797189A0559 . O
. . O O

According P10326654A0351 VBG O
to P10326654A0351 TO O
pilot P10326654A0351 NN O
experiments P10326654A0351 NNS O
which P10326654A0351 WDT O
considered P10326654A0351 VBD O
various P10326654A0351 JJ O
durations P10326654A0351 NNS O
of P10326654A0351 IN O
global P10326654A0351 JJ O
no-flow P10326654A0351 JJ O
ischemia P10326654A0351 NN O
ranging P10326654A0351 VBG O
from P10326654A0351 IN O
10 P10326654A0351 CD O
to P10326654A0351 TO O
20 P10326654A0351 CD O
minutes P10326654A0351 NNS O
, P10326654A0351 , O
two P10326654A0351 CD O
durations P10326654A0351 NNS O
were P10326654A0351 VBD O
chosen P10326654A0351 VBN O
for P10326654A0351 IN O
the P10326654A0351 DT O
present P10326654A0351 JJ O
study P10326654A0351 NN O
: P10326654A0351 : O
20 P10326654A0351 CD O
minutes P10326654A0351 NNS O
( P10326654A0351 ( O
group P10326654A0351 NN O
20 P10326654A0351 CD O
) P10326654A0351 ) O
in P10326654A0351 IN O
which P10326654A0351 WDT O
ventricular P10326654A0351 JJ O
fibrillation P10326654A0351 NN O
( P10326654A0351 ( O
VF P10326654A0351 NNP O
) P10326654A0351 ) O
was P10326654A0351 VBD O
the P10326654A0351 DT O
predominant P10326654A0351 JJ O
form P10326654A0351 NN O
of P10326654A0351 IN O
arrhythmias P10326654A0351 NN O
, P10326654A0351 , O
and P10326654A0351 CC O
18 P10326654A0351 CD O
minutes P10326654A0351 NNS O
( P10326654A0351 ( O
group P10326654A0351 NN O
18 P10326654A0351 CD O
) P10326654A0351 ) O
in P10326654A0351 IN O
which P10326654A0351 WDT O
the P10326654A0351 DT O
prevalence P10326654A0351 NN O
of P10326654A0351 IN O
VF P10326654A0351 NNP O
was P10326654A0351 VBD O
markedly P10326654A0351 RB O
lower P10326654A0351 JJR O
despite P10326654A0351 IN O
the P10326654A0351 DT O
small P10326654A0351 JJ O
difference P10326654A0351 NN O
in P10326654A0351 IN O
the P10326654A0351 DT O
duration P10326654A0351 NN O
of P10326654A0351 IN O
ischemia P10326654A0351 NN O
. P10326654A0351 . O
. . O O

Heterogeneous P01963438T0000 NNP O
electron P01963438T0000 NN O
transfer P01963438T0000 NN O
of P01963438T0000 IN O
cytochrome P01963438T0000 JJ I-UN
c P01963438T0000 NNS I-UN
facilitated P01963438T0000 VBN O
by P01963438T0000 IN O
polypyrrole P01963438T0000 NN O
and P01963438T0000 CC O
methylene P01963438T0000 NN O
blue P01963438T0000 JJ O
polypyrrole P01963438T0000 NN O
film P01963438T0000 NN O
modified P01963438T0000 VBD O
electrodes P01963438T0000 NNS O
. P01963438T0000 . O
. . O O

The P11224226A0000 DT O
effects P11224226A0000 NNS O
of P11224226A0000 IN O
chlordiazepoxide P11224226A0000 NN O
( P11224226A0000 ( O
2.5-15.0mg P11224226A0000 JJ O
/ P11224226A0000 NNP O
kg P11224226A0000 NN O
) P11224226A0000 ) O
, P11224226A0000 , O
a P11224226A0000 DT O
full P11224226A0000 JJ O
benzodiazepine P11224226A0000 NN I-UN
receptor P11224226A0000 NN I-UN
agonist P11224226A0000 NN O
, P11224226A0000 , O
and P11224226A0000 CC O
bretazenil P11224226A0000 NN O
( P11224226A0000 ( O
5.0-30.0mg P11224226A0000 JJ O
/ P11224226A0000 NNP O
kg P11224226A0000 NN O
) P11224226A0000 ) O
, P11224226A0000 , O
a P11224226A0000 DT O
partial P11224226A0000 JJ O
benzodiazepine P11224226A0000 NN I-UN
receptor P11224226A0000 NN I-UN
agonist P11224226A0000 NN O
, P11224226A0000 , O
were P11224226A0000 VBD O
examined P11224226A0000 VBN O
in P11224226A0000 IN O
the P11224226A0000 DT O
murine P11224226A0000 NN O
elevated P11224226A0000 VBD O
plus-maze P11224226A0000 JJ O
paradigm P11224226A0000 NN O
. P11224226A0000 . O
. . O O

These P02351239A0693 DT O
findings P02351239A0693 NNS O
indicate P02351239A0693 VBP O
that P02351239A0693 IN O
hypergastrinemia P02351239A0693 NN O
induced P02351239A0693 VBN O
by P02351239A0693 IN O
surgical P02351239A0693 JJ O
removal P02351239A0693 NN O
of P02351239A0693 IN O
acid-producing P02351239A0693 JJ O
mucosa P02351239A0693 NN O
in P02351239A0693 IN O
the P02351239A0693 DT O
rat P02351239A0693 NN O
has P02351239A0693 VBZ O
the P02351239A0693 DT O
same P02351239A0693 JJ O
effects P02351239A0693 NNS O
on P02351239A0693 IN O
oxyntical P02351239A0693 JJ O
mucosal P02351239A0693 NN I-UN
HDC P02351239A0693 NNP I-UN
activity P02351239A0693 NN O
, P02351239A0693 , O
histamine P02351239A0693 NN O
concentration P02351239A0693 NN O
and P02351239A0693 CC O
ECL P02351239A0693 NNP O
cell P02351239A0693 VBP O
density P02351239A0693 NN O
as P02351239A0693 IN O
hypergastrinemia P02351239A0693 NN O
induced P02351239A0693 VBN O
by P02351239A0693 IN O
continuous P02351239A0693 JJ O
gastrin P02351239A0693 JJ I-UN
infusion P02351239A0693 NN O
or P02351239A0693 CC O
by P02351239A0693 IN O
long-term P02351239A0693 JJ O
treatment P02351239A0693 NN O
with P02351239A0693 IN O
effective P02351239A0693 JJ O
antisecretagogues P02351239A0693 NNS O
. P02351239A0693 . O
. . O O

Furthermore P10482620A1009 RB O
, P10482620A1009 , O
we P10482620A1009 PRP O
demonstrate P10482620A1009 VBP O
that P10482620A1009 DT O
transcription P10482620A1009 NN O
from P10482620A1009 IN O
the P10482620A1009 DT O
MMTV P10482620A1009 NNP I-UN
5 P10482620A1009 CD I-UN
' P10482620A1009 '' I-UN
LTR P10482620A1009 NNP I-UN
is P10482620A1009 VBZ O
highly P10482620A1009 RB O
active P10482620A1009 JJ O
in P10482620A1009 IN O
the P10482620A1009 DT O
absence P10482620A1009 NN O
of P10482620A1009 IN O
Stat5a P10482620A1009 NNP I-UN
, P10482620A1009 , O
a P10482620A1009 DT O
transcription P10482620A1009 NN O
factor P10482620A1009 NN O
that P10482620A1009 WDT O
had P10482620A1009 VBD O
been P10482620A1009 VBN O
shown P10482620A1009 VBN O
previously P10482620A1009 RB O
to P10482620A1009 TO O
be P10482620A1009 VB O
required P10482620A1009 VBN O
for P10482620A1009 IN O
transcription P10482620A1009 NN O
from P10482620A1009 IN O
the P10482620A1009 DT O
MMTV P10482620A1009 NNP I-UN
LTR P10482620A1009 NNP I-UN
. P10482620A1009 . O
. . O O

The P01735347A0482 DT O
primary P01735347A0482 JJ O
pancreatic P01735347A0482 JJ O
insult P01735347A0482 NN O
seemed P01735347A0482 VBD O
to P01735347A0482 TO O
be P01735347A0482 VB O
unaffected P01735347A0482 VBN O
by P01735347A0482 IN O
the P01735347A0482 DT O
treatment P01735347A0482 NN O
, P01735347A0482 , O
because P01735347A0482 IN O
neither P01735347A0482 CC O
the P01735347A0482 DT O
rise P01735347A0482 NN O
in P01735347A0482 IN O
plasma P01735347A0482 JJ I-UN
lipase P01735347A0482 NN I-UN
nor P01735347A0482 CC O
the P01735347A0482 DT O
development P01735347A0482 NN O
of P01735347A0482 IN O
ascites P01735347A0482 NNS O
or P01735347A0482 CC O
the P01735347A0482 DT O
extension P01735347A0482 NN O
of P01735347A0482 IN O
the P01735347A0482 DT O
pancreatic P01735347A0482 JJ O
necrosis P01735347A0482 NN O
were P01735347A0482 VBD O
diminished P01735347A0482 VBN O
. P01735347A0482 . O
. . O O

In P09503526A0614 IN O
patients P09503526A0614 NNS O
with P09503526A0614 IN O
myalgia P09503526A0614 NN O
, P09503526A0614 , O
Raynaud P09503526A0614 NNP O
's P09503526A0614 POS O
syndrome P09503526A0614 NN O
, P09503526A0614 , O
skin P09503526A0614 FW O
vasculitis P09503526A0614 NN O
and P09503526A0614 CC O
vascular P09503526A0614 JJ O
diseases P09503526A0614 NNS O
WFAg P09503526A0614 VBP I-UN
concentrations P09503526A0614 NNS O
were P09503526A0614 VBD O
higher P09503526A0614 JJR O
than P09503526A0614 IN O
in P09503526A0614 IN O
patients P09503526A0614 NNS O
without P09503526A0614 IN O
them P09503526A0614 PRP O
. P09503526A0614 . O
. . O O

After P01824944A0988 IN O
treatment P01824944A0988 NN O
with P01824944A0988 IN O
tunicamycin P01824944A0988 NN O
, P01824944A0988 , O
the P01824944A0988 DT O
transfectants P01824944A0988 NNS O
secreted P01824944A0988 VBD O
unglycosylated P01824944A0988 JJ O
18-kDa P01824944A0988 CD O
polypeptides P01824944A0988 NNS O
which P01824944A0988 WDT O
could P01824944A0988 MD O
also P01824944A0988 RB O
bind P01824944A0988 VB O
IgE P01824944A0988 NNP I-UN
. P01824944A0988 . O
. . O O

However P08496848A0692 RB O
, P08496848A0692 , O
essential P08496848A0692 JJ O
contrast P08496848A0692 NN O
differences P08496848A0692 NNS O
existing P08496848A0692 VBG O
between P08496848A0692 IN O
the P08496848A0692 DT O
FSE P08496848A0692 NNP O
sequences P08496848A0692 NNS O
and P08496848A0692 CC O
their P08496848A0692 PRP$ O
routine P08496848A0692 JJ O
asymmetric P08496848A0692 JJ O
dual P08496848A0692 JJ O
SE P08496848A0692 NNP O
counterpart P08496848A0692 NN O
can P08496848A0692 MD O
be P08496848A0692 VB O
identified P08496848A0692 VBN O
. P08496848A0692 . O
. . O O

The P10906317A0351 DT O
two P10906317A0351 CD O
main P10906317A0351 JJ O
experimental P10906317A0351 JJ O
variables P10906317A0351 NNS O
were P10906317A0351 VBD O
the P10906317A0351 DT O
attended P10906317A0351 JJ O
hemifield P10906317A0351 NN O
( P10906317A0351 ( O
left P10906317A0351 VBD O
or P10906317A0351 CC O
right P10906317A0351 JJ O
) P10906317A0351 ) O
and P10906317A0351 CC O
the P10906317A0351 DT O
proportion P10906317A0351 NN O
of P10906317A0351 IN O
trials P10906317A0351 NNS O
requiring P10906317A0351 VBG O
a P10906317A0351 DT O
shift P10906317A0351 NN O
within P10906317A0351 IN O
that P10906317A0351 DT O
hemifield P10906317A0351 NN O
( P10906317A0351 ( O
20 P10906317A0351 CD O
% P10906317A0351 NN O
or P10906317A0351 CC O
80 P10906317A0351 CD O
% P10906317A0351 NN O
) P10906317A0351 ) O
. P10906317A0351 . O
. . O O

In P07876192A0443 IN O
ICE P07876192A0443 NNP I-UN
gamma P07876192A0443 NN I-UN
, P07876192A0443 , O
most P07876192A0443 JJS O
of P07876192A0443 IN O
the P07876192A0443 DT O
propeptide P07876192A0443 NN O
( P07876192A0443 ( O
amino P07876192A0443 JJ O
acids P07876192A0443 NNS O
20-112 P07876192A0443 JJ O
) P07876192A0443 ) O
is P07876192A0443 VBZ O
deleted P07876192A0443 VBN O
, P07876192A0443 , O
which P07876192A0443 WDT O
suggests P07876192A0443 VBZ O
that P07876192A0443 IN O
it P07876192A0443 PRP O
may P07876192A0443 MD O
function P07876192A0443 VB O
as P07876192A0443 IN O
a P07876192A0443 DT O
catalyst P07876192A0443 NN O
for P07876192A0443 IN O
ICE P07876192A0443 NNP I-UN
autoprocessing P07876192A0443 VBG O
in P07876192A0443 IN O
vivo P07876192A0443 NN O
. P07876192A0443 . O
. . O O

In P01932650A0435 IN O
group P01932650A0435 NN O
III P01932650A0435 NNP O
, P01932650A0435 , O
patients P01932650A0435 NNS O
also P01932650A0435 RB O
received P01932650A0435 VBD O
their P01932650A0435 PRP$ O
own P01932650A0435 JJ O
mediastinal P01932650A0435 JJ O
drainage P01932650A0435 NN O
blood P01932650A0435 NN O
, P01932650A0435 , O
shed P01932650A0435 VBD O
for P01932650A0435 IN O
6 P01932650A0435 CD O
hours P01932650A0435 NNS O
after P01932650A0435 IN O
operation P01932650A0435 NN O
, P01932650A0435 , O
after P01932650A0435 IN O
concentration P01932650A0435 NN O
and P01932650A0435 CC O
washing P01932650A0435 NN O
in P01932650A0435 IN O
a P01932650A0435 DT O
MBRS P01932650A0435 NNP O
. P01932650A0435 . O
. . O O

Similar P06830033A0661 JJ O
observations P06830033A0661 NNS O
were P06830033A0661 VBD O
made P06830033A0661 VBN O
with P06830033A0661 IN O
unilateral P06830033A0661 JJ O
pneumothorax P06830033A0661 NN O
of P06830033A0661 IN O
15 P06830033A0661 CD O
cmH2O P06830033A0661 NN O
for P06830033A0661 IN O
30 P06830033A0661 CD O
min P06830033A0661 NN O
. P06830033A0661 . O
. . O O

Modern P01093845A0208 JJ O
studies P01093845A0208 NNS O
, P01093845A0208 , O
conducted P01093845A0208 VBN O
with P01093845A0208 IN O
Delta-9-THC P01093845A0208 NNP O
, P01093845A0208 , O
in P01093845A0208 IN O
healthy P01093845A0208 JJ O
voluntaries P01093845A0208 NNS O
, P01093845A0208 , O
again P01093845A0208 RB O
suggest P01093845A0208 VBP O
the P01093845A0208 DT O
comparison P01093845A0208 NN O
or P01093845A0208 CC O
even P01093845A0208 RB O
the P01093845A0208 DT O
identity P01093845A0208 NN O
of P01093845A0208 IN O
the P01093845A0208 DT O
modifications P01093845A0208 NNS O
caused P01093845A0208 VBN O
by P01093845A0208 IN O
cannabis P01093845A0208 NN O
with P01093845A0208 IN O
sleep P01093845A0208 NN O
and P01093845A0208 CC O
dream P01093845A0208 NN O
. P01093845A0208 . O
. . O O

Severe P10367646A0569 JJ O
hemolysis P10367646A0569 NN O
resulted P10367646A0569 VBD O
in P10367646A0569 IN O
statistically P10367646A0569 RB O
significant P10367646A0569 JJ O
changes P10367646A0569 NNS O
in P10367646A0569 IN O
the P10367646A0569 DT O
mean P10367646A0569 JJ O
values P10367646A0569 NNS O
of P10367646A0569 IN O
the P10367646A0569 DT O
above P10367646A0569 JJ O
analytes P10367646A0569 NNS O
in P10367646A0569 IN O
addition P10367646A0569 NN O
to P10367646A0569 TO O
the P10367646A0569 DT O
following P10367646A0569 JJ O
increases P10367646A0569 NNS O
: P10367646A0569 : O
alanine P10367646A0569 NN I-UN
aminotransferase P10367646A0569 NN I-UN
, P10367646A0569 , O
calcium P10367646A0569 NN O
, P10367646A0569 , O
and P10367646A0569 CC O
serum P10367646A0569 NN I-UN
globulins P10367646A0569 NNS I-UN
( P10367646A0569 ( O
P P10367646A0569 NNP O
< P10367646A0569 NNP O
0.001 P10367646A0569 CD O
) P10367646A0569 ) O
and P10367646A0569 CC O
albumin P10367646A0569 $ I-UN
and P10367646A0569 CC O
total P10367646A0569 JJ O
protein P10367646A0569 NN O
( P10367646A0569 ( O
P P10367646A0569 NNP O
< P10367646A0569 NNP O
0.01 P10367646A0569 CD O
) P10367646A0569 ) O
. P10367646A0569 . O
. . O O

The P03664038A0000 DT O
purpose P03664038A0000 NN O
of P03664038A0000 IN O
this P03664038A0000 DT O
study P03664038A0000 NN O
is P03664038A0000 VBZ O
twofold P03664038A0000 VBN O
: P03664038A0000 : O
( P03664038A0000 ( O
1 P03664038A0000 CD O
) P03664038A0000 ) O
to P03664038A0000 TO O
present P03664038A0000 VB O
a P03664038A0000 DT O
parallel P03664038A0000 JJ O
form P03664038A0000 NN O
of P03664038A0000 IN O
the P03664038A0000 DT O
Gudjonsson P03664038A0000 NNP O
Suggestibility P03664038A0000 NNP O
Scale P03664038A0000 NNP O
( P03664038A0000 ( O
GSS P03664038A0000 NNP O
, P03664038A0000 , O
Form P03664038A0000 NNP O
1 P03664038A0000 CD O
) P03664038A0000 ) O
; P03664038A0000 : O
( P03664038A0000 ( O
2 P03664038A0000 CD O
) P03664038A0000 ) O
to P03664038A0000 TO O
study P03664038A0000 VB O
test-retest P03664038A0000 JJ O
reliabilities P03664038A0000 NNS O
of P03664038A0000 IN O
interrogative P03664038A0000 JJ O
suggestibility P03664038A0000 NN O
. P03664038A0000 . O
. . O O

The P11031252A0646 DT O
LMW P11031252A0646 NNP I-UN
FGF-2 P11031252A0646 NNP I-UN
up-regulated P11031252A0646 JJ O
the P11031252A0646 DT O
PKC P11031252A0646 NNP I-UN
epsilon P11031252A0646 NN I-UN
levels P11031252A0646 NNS O
by P11031252A0646 IN O
1.6-fold P11031252A0646 JJ O
; P11031252A0646 : O
by P11031252A0646 IN O
contrast P11031252A0646 NN O
the P11031252A0646 DT O
HMW P11031252A0646 NNP I-UN
isoform P11031252A0646 NN I-UN
down-regulated P11031252A0646 VBD O
the P11031252A0646 DT O
level P11031252A0646 NN O
of P11031252A0646 IN O
this P11031252A0646 DT O
PKC P11031252A0646 NNP I-UN
isotype P11031252A0646 NN I-UN
by P11031252A0646 IN O
about P11031252A0646 IN O
3-fold P11031252A0646 JJ O
and P11031252A0646 CC O
increased P11031252A0646 VBD O
the P11031252A0646 DT O
amount P11031252A0646 NN O
of P11031252A0646 IN O
PKC P11031252A0646 NNP I-UN
delta P11031252A0646 NN I-UN
by P11031252A0646 IN O
1.7-fold P11031252A0646 JJ O
. P11031252A0646 . O
. . O O

Endotoxemia P08020702A0000 NN O
induced P08020702A0000 VBN O
by P08020702A0000 IN O
gram-negative P08020702A0000 JJ O
bacteria P08020702A0000 NNS O
leads P08020702A0000 VBZ O
to P08020702A0000 TO O
endotoxic P08020702A0000 VB O
shock P08020702A0000 NN O
pathogenetically P08020702A0000 RB O
stemming P08020702A0000 VBG O
from P08020702A0000 IN O
the P08020702A0000 DT O
integral P08020702A0000 JJ O
component P08020702A0000 NN O
of P08020702A0000 IN O
the P08020702A0000 DT O
bacterial P08020702A0000 JJ O
wall P08020702A0000 NN O
-- P08020702A0000 : O
lipid P08020702A0000 VBZ O
A P08020702A0000 DT O
. P08020702A0000 . O
. . O O

Transient P08208540A1114 JJ O
co-transfection P08208540A1114 NN O
assays P08208540A1114 NNS O
involving P08208540A1114 VBG O
NFKB2 P08208540A1114 NNP I-UN
expression P08208540A1114 NN O
vectors P08208540A1114 NNS O
and P08208540A1114 CC O
kappa P08208540A1114 VB I-UN
B-driven P08208540A1114 NNP O
reporter P08208540A1114 NN O
plasmids P08208540A1114 NNS O
indicate P08208540A1114 VBP O
that P08208540A1114 IN O
NFKB2 P08208540A1114 NNP I-UN
p85 P08208540A1114 NN I-UN
has P08208540A1114 VBZ O
lost P08208540A1114 VBN O
the P08208540A1114 DT O
transcriptional P08208540A1114 JJ O
repressor P08208540A1114 NN O
functions P08208540A1114 NNS O
typical P08208540A1114 JJ O
of P08208540A1114 IN O
normal P08208540A1114 JJ O
NFKB2 P08208540A1114 NNP I-UN
p52 P08208540A1114 NN I-UN
. P08208540A1114 . O
. . O O

To P03360667A0000 TO O
evaluate P03360667A0000 VB O
the P03360667A0000 DT O
effect P03360667A0000 NN O
of P03360667A0000 IN O
altitude P03360667A0000 NN O
on P03360667A0000 IN O
adolescent P03360667A0000 JJ O
growth P03360667A0000 NN O
and P03360667A0000 CC O
development P03360667A0000 NN O
, P03360667A0000 , O
three P03360667A0000 CD O
groups P03360667A0000 NNS O
of P03360667A0000 IN O
healthy P03360667A0000 JJ O
, P03360667A0000 , O
well-nourished P03360667A0000 JJ O
youth P03360667A0000 NN O
of P03360667A0000 IN O
similar P03360667A0000 JJ O
socioeconomic P03360667A0000 JJ O
status P03360667A0000 NN O
and P03360667A0000 CC O
ethnic P03360667A0000 JJ O
grouping P03360667A0000 NN O
who P03360667A0000 WP O
resided P03360667A0000 VBD O
at P03360667A0000 IN O
sea P03360667A0000 NN O
level P03360667A0000 NN O
( P03360667A0000 ( O
n P03360667A0000 JJ O
= P03360667A0000 NN O
1262 P03360667A0000 CD O
subjects P03360667A0000 NNS O
) P03360667A0000 ) O
, P03360667A0000 , O
mid-altitude P03360667A0000 JJ O
( P03360667A0000 ( O
n P03360667A0000 JJ O
= P03360667A0000 NN O
1743 P03360667A0000 CD O
subjects P03360667A0000 NNS O
) P03360667A0000 ) O
, P03360667A0000 , O
and P03360667A0000 CC O
high P03360667A0000 JJ O
altitude P03360667A0000 NN O
( P03360667A0000 ( O
n P03360667A0000 JJ O
= P03360667A0000 NN O
1137 P03360667A0000 CD O
subjects P03360667A0000 NNS O
) P03360667A0000 ) O
were P03360667A0000 VBD O
studied P03360667A0000 VBN O
. P03360667A0000 . O
. . O O

Using P07045156A0204 VBG O
an P07045156A0204 DT O
opsonophagocytic P07045156A0204 JJ O
bacterial P07045156A0204 JJ O
assay P07045156A0204 NN O
and P07045156A0204 CC O
a P07045156A0204 DT O
suckling P07045156A0204 JJ O
rat P07045156A0204 NN O
model P07045156A0204 NN O
of P07045156A0204 IN O
GBS P07045156A0204 NNP O
sepsis P07045156A0204 NN O
, P07045156A0204 , O
we P07045156A0204 PRP O
analyzed P07045156A0204 VBD O
a P07045156A0204 DT O
modified P07045156A0204 JJ O
human P07045156A0204 JJ I-UN
immunoglobulin P07045156A0204 NN I-UN
for P07045156A0204 IN O
opsonic P07045156A0204 JJ O
and P07045156A0204 CC O
protective P07045156A0204 JJ O
antibody P07045156A0204 NN O
. P07045156A0204 . O
. . O O

The P09227099A0106 DT O
following P09227099A0106 JJ O
technique P09227099A0106 NN O
describes P09227099A0106 VBZ O
a P09227099A0106 DT O
modification P09227099A0106 NN O
to P09227099A0106 TO O
a P09227099A0106 DT O
bar P09227099A0106 NN O
superstructure P09227099A0106 NN O
that P09227099A0106 WDT O
provided P09227099A0106 VBD O
the P09227099A0106 DT O
advantages P09227099A0106 NNS O
of P09227099A0106 IN O
convenience P09227099A0106 NN O
, P09227099A0106 , O
security P09227099A0106 NN O
, P09227099A0106 , O
and P09227099A0106 CC O
consistent P09227099A0106 JJ O
positioning P09227099A0106 VBG O
even P09227099A0106 RB O
though P09227099A0106 IN O
one P09227099A0106 CD O
implant P09227099A0106 NN O
was P09227099A0106 VBD O
lost P09227099A0106 VBN O
and P09227099A0106 CC O
the P09227099A0106 DT O
angulation P09227099A0106 NN O
of P09227099A0106 IN O
implants P09227099A0106 NNS O
limited P09227099A0106 JJ O
accuracy P09227099A0106 NN O
. P09227099A0106 . O
. . O O

Structural P10493575T0000 JJ O
changes P10493575T0000 NNS O
in P10493575T0000 IN O
the P10493575T0000 DT O
C-terminus P10493575T0000 NNP O
of P10493575T0000 IN O
Ca2+-bound P10493575T0000 NNP O
rat P10493575T0000 NN I-UN
S100B P10493575T0000 NNP I-UN
( P10493575T0000 ( O
beta P10493575T0000 VB I-UN
beta P10493575T0000 NN I-UN
) P10493575T0000 ) O
upon P10493575T0000 IN O
binding P10493575T0000 VBG O
to P10493575T0000 TO O
a P10493575T0000 DT O
peptide P10493575T0000 NN O
derived P10493575T0000 VBN O
from P10493575T0000 IN O
the P10493575T0000 DT O
C-terminal P10493575T0000 JJ O
regulatory P10493575T0000 JJ O
domain P10493575T0000 NN O
of P10493575T0000 IN O
p53 P10493575T0000 NN I-UN
. P10493575T0000 . O
. . O O

Identical P08139577T0000 JJ O
components P08139577T0000 NNS O
of P08139577T0000 IN O
yeast P08139577T0000 JJ O
transcription P08139577T0000 NN I-UN
factor P08139577T0000 NN I-UN
IIIB P08139577T0000 NNP I-UN
are P08139577T0000 VBP O
required P08139577T0000 VBN O
and P08139577T0000 CC O
sufficient P08139577T0000 JJ O
for P08139577T0000 IN O
transcription P08139577T0000 NN O
of P08139577T0000 IN O
TATA P08139577T0000 NNP O
box-containing P08139577T0000 NN O
and P08139577T0000 CC O
TATA-less P08139577T0000 NNP O
genes P08139577T0000 NNS O
. P08139577T0000 . O
. . O O

The P01010638A0161 DT O
feed P01010638A0161 NN O
consumed P01010638A0161 VBD O
which P01010638A0161 WDT O
was P01010638A0161 VBD O
lowered P01010638A0161 VBN O
by P01010638A0161 IN O
25 P01010638A0161 CD O
% P01010638A0161 NN O
initially P01010638A0161 RB O
, P01010638A0161 , O
did P01010638A0161 VBD O
not P01010638A0161 RB O
alter P01010638A0161 RB O
later P01010638A0161 RB O
. P01010638A0161 . O
. . O O

However P10225279A0450 RB O
, P10225279A0450 , O
we P10225279A0450 PRP O
identified P10225279A0450 VBD O
a P10225279A0450 DT O
gene P10225279A0450 NN O
between P10225279A0450 IN O
the P10225279A0450 DT O
MDV2 P10225279A0450 NNP I-UN
UL54 P10225279A0450 NNP I-UN
and P10225279A0450 CC O
UL55 P10225279A0450 NNP I-UN
genes P10225279A0450 NNS I-UN
with P10225279A0450 IN O
homology P10225279A0450 NN O
to P10225279A0450 TO O
the P10225279A0450 DT O
first P10225279A0450 JJ I-UN
ORF P10225279A0450 NNP I-UN
( P10225279A0450 ( I-UN
ORF-1 P10225279A0450 NNP I-UN
) P10225279A0450 ) I-UN
of P10225279A0450 IN I-UN
equine P10225279A0450 NN I-UN
herpesvirus P10225279A0450 NN I-UN
type P10225279A0450 NN I-UN
1 P10225279A0450 CD I-UN
and P10225279A0450 CC O
corresponding P10225279A0450 VBG O
gene P10225279A0450 NN O
identified P10225279A0450 VBN O
in P10225279A0450 IN O
pseudorabies P10225279A0450 NNS O
virus P10225279A0450 NN O
. P10225279A0450 . O
. . O O

To P09469833A0533 TO O
further P09469833A0533 RBR O
investigate P09469833A0533 VB O
the P09469833A0533 DT O
nature P09469833A0533 NN O
of P09469833A0533 IN O
the P09469833A0533 DT O
site P09469833A0533 NN O
specificity P09469833A0533 NN O
a P09469833A0533 DT O
set P09469833A0533 NN O
of P09469833A0533 IN O
deletion P09469833A0533 NN O
mutants P09469833A0533 NNS O
of P09469833A0533 IN O
the P09469833A0533 DT O
160 P09469833A0533 CD O
bp P09469833A0533 NN O
sequence P09469833A0533 NN O
were P09469833A0533 VBD O
analysed P09469833A0533 VBN O
. P09469833A0533 . O
. . O O

These P07249497A0688 DT O
women P07249497A0688 NNS O
should P07249497A0688 MD O
not P07249497A0688 RB O
be P07249497A0688 VB O
given P07249497A0688 VBN O
the P07249497A0688 DT O
current P07249497A0688 JJ O
estrogen P07249497A0688 NN O
PPI P07249497A0688 NNP O
, P07249497A0688 , O
which P07249497A0688 WDT O
was P07249497A0688 VBD O
designed P07249497A0688 VBN O
to P07249497A0688 TO O
warn P07249497A0688 VB O
women P07249497A0688 NNS O
of P07249497A0688 IN O
the P07249497A0688 DT O
risks P07249497A0688 NNS O
of P07249497A0688 IN O
long-term P07249497A0688 JJ O
estrogen P07249497A0688 NN O
use P07249497A0688 NN O
; P07249497A0688 : O
a P07249497A0688 DT O
PPI P07249497A0688 NNP O
should P07249497A0688 MD O
be P07249497A0688 VB O
written P07249497A0688 VBN O
specifically P07249497A0688 RB O
for P07249497A0688 IN O
patients P07249497A0688 NNS O
receiving P07249497A0688 VBG O
short P07249497A0688 JJ O
courses P07249497A0688 NNS O
. P07249497A0688 . O
. . O O

The P03597269A0409 DT O
other P03597269A0409 JJ O
model P03597269A0409 NN O
was P03597269A0409 VBD O
a P03597269A0409 DT O
continuous P03597269A0409 JJ O
exponential P03597269A0409 JJ O
plus P03597269A0409 CC O
constant P03597269A0409 JJ O
of P03597269A0409 IN O
the P03597269A0409 DT O
form P03597269A0409 NN O
La- P03597269A0409 NNP O
= P03597269A0409 VBZ O
a P03597269A0409 DT O
+ P03597269A0409 NN O
b P03597269A0409 NN O
[ P03597269A0409 NN O
exp P03597269A0409 NN O
( P03597269A0409 ( O
cVO2 P03597269A0409 NN O
) P03597269A0409 ) O
] P03597269A0409 NN O
. P03597269A0409 . O
. . O O

Most P09514159A0562 JJS O
pituitary P09514159A0562 JJ O
hormone-coding P09514159A0562 JJ O
gene P09514159A0562 NN O
promoters P09514159A0562 NNS O
are P09514159A0562 VBP O
activated P09514159A0562 VBN O
by P09514159A0562 IN O
Ptx1 P09514159A0562 NNP I-UN
. P09514159A0562 . O
. . O O

These P02060052A0954 DT O
data P02060052A0954 NNS O
suggest P02060052A0954 VBP O
that P02060052A0954 IN O
the P02060052A0954 DT O
levels P02060052A0954 NNS O
of P02060052A0954 IN O
oxygen P02060052A0954 NN O
free P02060052A0954 JJ O
radicals P02060052A0954 NNS O
were P02060052A0954 VBD O
increased P02060052A0954 VBN O
in P02060052A0954 IN O
hepatocytes P02060052A0954 NNS O
and P02060052A0954 CC O
mitochondria P02060052A0954 NNS O
. P02060052A0954 . O
. . O O

The P03443609A0000 DT O
role P03443609A0000 NN O
of P03443609A0000 IN O
supercritical P03443609A0000 JJ O
fluid P03443609A0000 NN O
chromatography P03443609A0000 NN O
( P03443609A0000 ( O
SFC P03443609A0000 NNP O
) P03443609A0000 ) O
as P03443609A0000 IN O
a P03443609A0000 DT O
viable P03443609A0000 JJ O
technique P03443609A0000 NN O
for P03443609A0000 IN O
analyzing P03443609A0000 VBG O
agricultural P03443609A0000 JJ O
products P03443609A0000 NNS O
has P03443609A0000 VBZ O
been P03443609A0000 VBN O
investigated P03443609A0000 VBN O
using P03443609A0000 VBG O
packed P03443609A0000 JJ O
and P03443609A0000 CC O
capillary P03443609A0000 JJ O
column P03443609A0000 NN O
methodology P03443609A0000 NN O
. P03443609A0000 . O
. . O O

Persistence P05949971T0000 NN O
of P05949971T0000 IN O
toxaphene P05949971T0000 NN O
in P05949971T0000 IN O
treated P05949971T0000 JJ O
lakes P05949971T0000 NNS O
. P05949971T0000 . O
. . O O

Also P08208618A1334 RB O
, P08208618A1334 , O
HR21ap P08208618A1334 NNP I-UN
as P08208618A1334 RB O
well P08208618A1334 RB O
as P08208618A1334 IN O
HR21Xap P08208618A1334 NNP I-UN
are P08208618A1334 VBP O
specific P08208618A1334 JJ O
in P08208618A1334 IN O
their P08208618A1334 PRP$ O
inhibition P08208618A1334 NN O
of P08208618A1334 IN O
Sp1 P08208618A1334 NNP I-UN
binding P08208618A1334 NN O
. P08208618A1334 . O
. . O O

The P08321741A0396 DT O
first P08321741A0396 JJ O
group P08321741A0396 NN O
of P08321741A0396 IN O
sequential P08321741A0396 JJ O
BMB P08321741A0396 NNP O
showed P08321741A0396 VBD O
a P08321741A0396 DT O
significant P08321741A0396 JJ O
progress P08321741A0396 NN O
to P08321741A0396 TO O
myelofibrosis P08321741A0396 VB O
in P08321741A0396 IN O
so-called P08321741A0396 JJ O
`` P08321741A0396 `` O
Chronic P08321741A0396 JJ O
Megakaryocytic-Granulocytic P08321741A0396 JJ O
Myelosis P08321741A0396 NN O
'' P08321741A0396 '' O
-- P08321741A0396 : O
CMGM- P08321741A0396 NNP O
, P08321741A0396 , O
which P08321741A0396 WDT O
corresponds P08321741A0396 VBZ O
to P08321741A0396 TO O
Agnogenic P08321741A0396 NNP O
Myeloid P08321741A0396 NNP O
Metaplasia-AMM-in P08321741A0396 NNP O
72.4 P08321741A0396 CD O
% P08321741A0396 NN O
( P08321741A0396 ( O
21 P08321741A0396 CD O
/ P08321741A0396 RB O
29 P08321741A0396 CD O
patients P08321741A0396 NNS O
) P08321741A0396 ) O
, P08321741A0396 , O
as P08321741A0396 RB O
well P08321741A0396 RB O
as P08321741A0396 IN O
in P08321741A0396 IN O
CML P08321741A0396 NNP O
with P08321741A0396 IN O
megakaryocytic P08321741A0396 JJ O
increase-CML.MI-in P08321741A0396 JJ O
39.2 P08321741A0396 CD O
% P08321741A0396 NN O
( P08321741A0396 ( O
20 P08321741A0396 CD O
/ P08321741A0396 RB O
51 P08321741A0396 CD O
) P08321741A0396 ) O
. P08321741A0396 . O
. . O O

Owing P01124944A0830 VBG O
to P01124944A0830 TO O
parental P01124944A0830 JJ O
attitude P01124944A0830 NN O
, P01124944A0830 , O
a P01124944A0830 DT O
low P01124944A0830 JJ O
protein P01124944A0830 NN O
diet P01124944A0830 NN O
( P01124944A0830 ( O
1-5 P01124944A0830 JJ O
g P01124944A0830 NN O
/ P01124944A0830 NNP O
kg P01124944A0830 NN O
) P01124944A0830 ) O
was P01124944A0830 VBD O
introduced P01124944A0830 VBN O
only P01124944A0830 RB O
late P01124944A0830 RB O
. P01124944A0830 . O
. . O O

We P08565330A1783 PRP O
propose P08565330A1783 VBP O
that P08565330A1783 IN O
epigenetic P08565330A1783 JJ O
features P08565330A1783 NNS O
of P08565330A1783 IN O
tissue-specific P08565330A1783 JJ O
control P08565330A1783 NN O
and P08565330A1783 CC O
of P08565330A1783 IN O
the P08565330A1783 DT O
control P08565330A1783 NN O
of P08565330A1783 IN O
allelic P08565330A1783 JJ O
expression P08565330A1783 NN O
are P08565330A1783 VBP O
intricately P08565330A1783 RB O
linked P08565330A1783 VBN O
. P08565330A1783 . O
. . O O

BACKGROUND P07918128A0000 NNS O
: P07918128A0000 : O
We P07918128A0000 PRP O
conducted P07918128A0000 VBD O
a P07918128A0000 DT O
phase P07918128A0000 NN O
I P07918128A0000 PRP O
study P07918128A0000 VBP O
with P07918128A0000 IN O
MDL P07918128A0000 NNP O
73,147EF P07918128A0000 CD O
, P07918128A0000 , O
a P07918128A0000 DT O
new P07918128A0000 JJ O
5 P07918128A0000 CD I-UN
hydroxytryptamine P07918128A0000 NN I-UN
3 P07918128A0000 CD I-UN
( P07918128A0000 ( I-UN
5-HT3 P07918128A0000 JJ I-UN
) P07918128A0000 ) I-UN
receptor P07918128A0000 NN I-UN
antagonist P07918128A0000 NN O
, P07918128A0000 , O
in P07918128A0000 IN O
25 P07918128A0000 CD O
patients P07918128A0000 NNS O
requiring P07918128A0000 VBG O
emetogenic P07918128A0000 JJ O
chemotherapy P07918128A0000 NN O
. P07918128A0000 . O
. . O O

NKX2.1 P10684967A0000 NNP I-UN
is P10684967A0000 VBZ O
a P10684967A0000 DT O
member P10684967A0000 NN O
of P10684967A0000 IN O
the P10684967A0000 DT O
NK2 P10684967A0000 NNP I-UN
family P10684967A0000 NN I-UN
of P10684967A0000 IN O
homeodomain-containing P10684967A0000 JJ I-UN
transcription P10684967A0000 NN I-UN
factors P10684967A0000 NNS I-UN
whose P10684967A0000 WP$ O
targeted P10684967A0000 JJ O
disruption P10684967A0000 NN O
in P10684967A0000 IN O
mouse P10684967A0000 NN O
results P10684967A0000 NNS O
in P10684967A0000 IN O
the P10684967A0000 DT O
absence P10684967A0000 NN O
of P10684967A0000 IN O
thyroid P10684967A0000 JJ O
tissue P10684967A0000 NN O
and P10684967A0000 CC O
a P10684967A0000 DT O
severely P10684967A0000 RB O
abnormal P10684967A0000 JJ O
lung P10684967A0000 NN O
phenotype P10684967A0000 NN O
. P10684967A0000 . O
. . O O

Modulation P09353343T0000 NN O
of P09353343T0000 IN O
AUUUA P09353343T0000 NNP O
response P09353343T0000 NN O
element P09353343T0000 NN O
binding P09353343T0000 NN O
by P09353343T0000 IN O
heterogeneous P09353343T0000 JJ I-UN
nuclear P09353343T0000 JJ I-UN
ribonucleoprotein P09353343T0000 NN I-UN
A1 P09353343T0000 NNP I-UN
in P09353343T0000 IN O
human P09353343T0000 JJ O
T P09353343T0000 NNP O
lymphocytes P09353343T0000 NNS O
. P09353343T0000 . O
. . O O

One P09851614A0109 CD O
of P09851614A0109 IN O
its P09851614A0109 PRP$ O
unique P09851614A0109 JJ O
features P09851614A0109 NNS O
appears P09851614A0109 VBZ O
to P09851614A0109 TO O
be P09851614A0109 VB O
the P09851614A0109 DT O
unusually P09851614A0109 RB O
short P09851614A0109 JJ O
5'-untranslated P09851614A0109 JJ O
regions P09851614A0109 NNS O
( P09851614A0109 ( O
UTR P09851614A0109 NNP O
) P09851614A0109 ) O
( P09851614A0109 ( O
1-6 P09851614A0109 JJ O
nucleotides P09851614A0109 NNS O
( P09851614A0109 ( O
nts P09851614A0109 NNS O
) P09851614A0109 ) O
) P09851614A0109 ) O
and P09851614A0109 CC O
the P09851614A0109 DT O
apparent P09851614A0109 JJ O
absence P09851614A0109 NN O
of P09851614A0109 IN O
5'-cap P09851614A0109 JJ O
structures P09851614A0109 NNS O
from P09851614A0109 IN O
its P09851614A0109 PRP$ O
mRNAs P09851614A0109 NN O
. P09851614A0109 . O
. . O O

[ P09643153T0000 JJ O
Treatment P09643153T0000 NNP O
of P09643153T0000 IN O
early P09643153T0000 JJ O
T1 P09643153T0000 NNP O
small P09643153T0000 JJ O
T2N P09643153T0000 NNP O
breast P09643153T0000 NN O
cancers P09643153T0000 NNS O
. P09643153T0000 . O
. . O O

Thus P01830114A1587 RB O
, P01830114A1587 , O
the P01830114A1587 DT O
positive P01830114A1587 JJ O
effect P01830114A1587 NN O
of P01830114A1587 IN O
NS1 P01830114A1587 NNP I-UN
on P01830114A1587 IN O
the P01830114A1587 DT O
steady-state P01830114A1587 JJ O
levels P01830114A1587 NNS O
of P01830114A1587 IN O
P4 P01830114A1587 NNP I-UN
transcripts P01830114A1587 NNS I-UN
depends P01830114A1587 VBZ O
on P01830114A1587 IN O
the P01830114A1587 DT O
amplification P01830114A1587 NN O
of P01830114A1587 IN O
gene P01830114A1587 NN O
copy P01830114A1587 NN O
number P01830114A1587 NN O
and P01830114A1587 CC O
the P01830114A1587 DT O
integrity P01830114A1587 NN O
of P01830114A1587 IN O
the P01830114A1587 DT O
terminal P01830114A1587 JJ O
repeats P01830114A1587 NNS O
. P01830114A1587 . O
. . O O

The P08172653A1589 DT O
variable P08172653A1589 JJ O
regions P08172653A1589 NNS O
of P08172653A1589 IN O
vertebrate P08172653A1589 NN O
striated P08172653A1589 VBN O
TnT P08172653A1589 NNP I-UN
isoforms P08172653A1589 NNS I-UN
reflect P08172653A1589 VBP O
the P08172653A1589 DT O
subsequent P08172653A1589 JJ O
addition P08172653A1589 NN O
and P08172653A1589 CC O
modification P08172653A1589 NN O
of P08172653A1589 IN O
genomic P08172653A1589 JJ O
sequences P08172653A1589 NNS O
to P08172653A1589 TO O
give P08172653A1589 VB O
rise P08172653A1589 NN O
to P08172653A1589 TO O
members P08172653A1589 NNS O
of P08172653A1589 IN O
the P08172653A1589 DT O
TnT P08172653A1589 NNP I-UN
multigene P08172653A1589 NNP I-UN
family P08172653A1589 NN I-UN
. P08172653A1589 . O
. . O O

Nucleotide P03379058A0188 RB O
sequencing P03379058A0188 VBG O
indicates P03379058A0188 VBZ O
that P03379058A0188 IN O
this P03379058A0188 DT O
E1 P03379058A0188 NNP I-UN
alpha P03379058A0188 NN I-UN
cDNA P03379058A0188 NN I-UN
clone P03379058A0188 NN O
is P03379058A0188 VBZ O
1821 P03379058A0188 CD O
base P03379058A0188 NN O
pairs P03379058A0188 NN O
( P03379058A0188 ( O
bp P03379058A0188 NN O
) P03379058A0188 ) O
in P03379058A0188 IN O
length P03379058A0188 NN O
with P03379058A0188 IN O
an P03379058A0188 DT O
open P03379058A0188 JJ O
reading P03379058A0188 NN O
frame P03379058A0188 NN O
of P03379058A0188 IN O
1365 P03379058A0188 CD O
bp P03379058A0188 NN O
and P03379058A0188 CC O
a P03379058A0188 DT O
3'-untranslated P03379058A0188 JJ O
region P03379058A0188 NN O
of P03379058A0188 IN O
356 P03379058A0188 CD O
bp P03379058A0188 NN O
. P03379058A0188 . O
. . O O

Nevertheless P09418882A0760 RB O
, P09418882A0760 , O
antibodies P09418882A0760 NNS O
directed P09418882A0760 VBD O
against P09418882A0760 IN O
an P09418882A0760 DT O
epitope-tagged P09418882A0760 JJ O
version P09418882A0760 NN O
of P09418882A0760 IN O
Prp42p P09418882A0760 NNP I-UN
specifically P09418882A0760 RB O
precipitate P09418882A0760 VBP O
U1 P09418882A0760 NNP I-UN
snRNA P09418882A0760 NN I-UN
from P09418882A0760 IN O
yeast P09418882A0760 JJ O
extracts P09418882A0760 NNS O
. P09418882A0760 . O
. . O O

40,000 P04049799A0466 CD O
) P04049799A0466 ) O
. P04049799A0466 . O
. . O O

Pressure P09716095T0000 NN O
ulcers P09716095T0000 NNS O
. P09716095T0000 . O
. . O O

Because P11742432A0798 IN O
results P11742432A0798 NNS O
of P11742432A0798 IN O
recent P11742432A0798 JJ O
randomized P11742432A0798 JJ O
trials P11742432A0798 NNS O
indicate P11742432A0798 VBP O
minimal P11742432A0798 JJ O
efficacy P11742432A0798 NN O
of P11742432A0798 IN O
continuing P11742432A0798 VBG O
MAC P11742432A0798 NNP O
prophylaxis P11742432A0798 NN O
in P11742432A0798 IN O
patients P11742432A0798 NNS O
who P11742432A0798 WP O
respond P11742432A0798 VBP O
to P11742432A0798 TO O
potent P11742432A0798 VB O
combination P11742432A0798 NN O
antiretroviral P11742432A0798 JJ O
therapy P11742432A0798 NN O
, P11742432A0798 , O
the P11742432A0798 DT O
observed P11742432A0798 JJ O
high P11742432A0798 JJ O
incidence P11742432A0798 NN O
of P11742432A0798 IN O
macrolide-resistant P11742432A0798 JJ O
bacterial P11742432A0798 JJ O
colonization P11742432A0798 NN O
of P11742432A0798 IN O
the P11742432A0798 DT O
respiratory P11742432A0798 NN O
tract P11742432A0798 NN O
in P11742432A0798 IN O
this P11742432A0798 DT O
trial P11742432A0798 NN O
supports P11742432A0798 VBZ O
the P11742432A0798 DT O
discontinuation P11742432A0798 NN O
of P11742432A0798 IN O
macrolide P11742432A0798 NN O
prophylaxis P11742432A0798 NN O
in P11742432A0798 IN O
all P11742432A0798 DT O
AIDS P11742432A0798 NNP O
patients P11742432A0798 NNS O
whose P11742432A0798 WP$ O
CD4 P11742432A0798 NNP I-UN
counts P11742432A0798 NNS O
have P11742432A0798 VBP O
risen P11742432A0798 VBN O
above P11742432A0798 IN O
100 P11742432A0798 CD O
cells P11742432A0798 NNS O
/ P11742432A0798 JJ O
microL P11742432A0798 NN O
. P11742432A0798 . O
. . O O

The P02776823A0000 DT O
clinical P02776823A0000 JJ O
tolerance P02776823A0000 NN O
and P02776823A0000 CC O
pharmacokinetics P02776823A0000 NNS O
of P02776823A0000 IN O
FCE P02776823A0000 NNP O
22101 P02776823A0000 CD O
( P02776823A0000 ( O
sodium P02776823A0000 NN O
( P02776823A0000 ( O
5R P02776823A0000 CD O
, P02776823A0000 , O
6S P02776823A0000 CD O
) P02776823A0000 ) O
-6- P02776823A0000 NN O
[ P02776823A0000 NNP O
( P02776823A0000 ( O
1R P02776823A0000 CD O
) P02776823A0000 ) O
-hydroxyethyl P02776823A0000 NN O
] P02776823A0000 NNP O
-2-carbamoyloxymethyl-2-penem-3-carboxylate P02776823A0000 NNP O
) P02776823A0000 ) O
, P02776823A0000 , O
a P02776823A0000 DT O
new P02776823A0000 JJ O
penem P02776823A0000 NN O
antibiotic P02776823A0000 JJ O
, P02776823A0000 , O
have P02776823A0000 VBP O
been P02776823A0000 VBN O
studied P02776823A0000 VBN O
after P02776823A0000 IN O
giving P02776823A0000 VBG O
a P02776823A0000 DT O
single P02776823A0000 JJ O
i.v P02776823A0000 NN O
. P02776823A0000 . O
dose P02776823A0000 NN O
of P02776823A0000 IN O
4 P02776823A0000 CD O
mg.kg-1 P02776823A0000 NN O
to P02776823A0000 TO O
ten P02776823A0000 VB O
healthy P02776823A0000 JJ O
male P02776823A0000 NN O
volunteers P02776823A0000 NNS O
. P02776823A0000 . O
. . O O

Here P03142875A0366 RB O
we P03142875A0366 PRP O
report P03142875A0366 VBP O
the P03142875A0366 DT O
complete P03142875A0366 JJ O
6-kilobase P03142875A0366 JJ O
cDNA P03142875A0366 NN O
sequence P03142875A0366 NN O
coding P03142875A0366 VBG O
for P03142875A0366 IN O
a P03142875A0366 DT O
chain P03142875A0366 NN O
of P03142875A0366 IN O
1775 P03142875A0366 CD O
amino P03142875A0366 NN O
acids P03142875A0366 NNS O
, P03142875A0366 , O
as P03142875A0366 RB O
well P03142875A0366 RB O
as P03142875A0366 IN O
the P03142875A0366 DT O
genomic P03142875A0366 JJ O
structure P03142875A0366 NN O
. P03142875A0366 . O
. . O O

The P02424743A0280 DT O
N1 P02424743A0280 NNP O
and P02424743A0280 CC O
P2 P02424743A0280 NNP O
were P02424743A0280 VBD O
comparable P02424743A0280 JJ O
in P02424743A0280 IN O
amplitude P02424743A0280 NN O
and P02424743A0280 CC O
both P02424743A0280 DT O
had P02424743A0280 VBD O
prolonged P02424743A0280 VBN O
refractory P02424743A0280 NN O
periods P02424743A0280 NNS O
. P02424743A0280 . O
. . O O

Elevated P11325944A0511 JJ O
expression P11325944A0511 NN O
of P11325944A0511 IN O
full-length P11325944A0511 JJ I-UN
UhpB P11325944A0511 NNP I-UN
or P11325944A0511 CC O
of P11325944A0511 IN O
a P11325944A0511 DT O
soluble P11325944A0511 JJ O
hybrid P11325944A0511 JJ O
protein P11325944A0511 NN O
, P11325944A0511 , O
GST-Bc P11325944A0511 NNP O
, P11325944A0511 , O
which P11325944A0511 WDT O
is P11325944A0511 VBZ O
glutathione P11325944A0511 JJ I-UN
S-transferase P11325944A0511 NNP I-UN
( P11325944A0511 ( O
GST P11325944A0511 NNP I-UN
) P11325944A0511 ) O
fused P11325944A0511 VBD O
to P11325944A0511 TO O
the P11325944A0511 DT O
cytoplasmic P11325944A0511 JJ O
C-terminal P11325944A0511 JJ O
portion P11325944A0511 NN O
of P11325944A0511 IN O
UhpB P11325944A0511 NNP I-UN
, P11325944A0511 , O
results P11325944A0511 NNS O
in P11325944A0511 IN O
complete P11325944A0511 JJ O
blockage P11325944A0511 NN O
of P11325944A0511 IN O
uhpT P11325944A0511 JJ I-UN
expression P11325944A0511 NN O
in P11325944A0511 IN O
a P11325944A0511 DT O
uhp P11325944A0511 NN I-UN
( P11325944A0511 ( I-UN
+ P11325944A0511 NNP I-UN
) P11325944A0511 ) I-UN
strain P11325944A0511 NN O
. P11325944A0511 . O
. . O O

The P11370174A0447 DT O
mean P11370174A0447 JJ O
serum P11370174A0447 NN O
creatinine P11370174A0447 NN O
level P11370174A0447 NN O
did P11370174A0447 VBD O
not P11370174A0447 RB O
change P11370174A0447 NN O
during P11370174A0447 IN O
the P11370174A0447 DT O
first P11370174A0447 JJ O
6 P11370174A0447 CD O
months P11370174A0447 NNS O
after P11370174A0447 IN O
withdrawal P11370174A0447 NN O
of P11370174A0447 IN O
MMF P11370174A0447 NNP O
. P11370174A0447 . O
. . O O

The P07455521A0414 DT O
ESEG P07455521A0414 NNP O
's P07455521A0414 POS O
are P07455521A0414 VBP O
a P07455521A0414 DT O
direct P07455521A0414 JJ O
result P07455521A0414 NN O
of P07455521A0414 IN O
the P07455521A0414 DT O
NEXT P07455521A0414 NNP O
study P07455521A0414 NN O
. P07455521A0414 . O
. . O O

This P01694009A0112 DT O
exon P01694009A0112 NN O
, P01694009A0112 , O
here P01694009A0112 RB O
named P01694009A0112 VBN O
exon P01694009A0112 RB O
0 P01694009A0112 CD O
, P01694009A0112 , O
contained P01694009A0112 VBD O
the P01694009A0112 DT O
entire P01694009A0112 JJ O
5 P01694009A0112 CD O
' P01694009A0112 POS O
untranslated P01694009A0112 JJ O
region P01694009A0112 NN O
and P01694009A0112 CC O
the P01694009A0112 DT O
N-terminal P01694009A0112 JJ O
signal P01694009A0112 JJ O
sequence P01694009A0112 NN O
of P01694009A0112 IN O
the P01694009A0112 DT O
polypeptide P01694009A0112 NN O
. P01694009A0112 . O
. . O O

The P08212897A0404 DT O
hydrophobicity P08212897A0404 NN O
profile P08212897A0404 NN O
of P08212897A0404 IN O
the P08212897A0404 DT O
methyltransferase P08212897A0404 NN O
reveals P08212897A0404 VBZ O
the P08212897A0404 DT O
presence P08212897A0404 NN O
of P08212897A0404 IN O
at P08212897A0404 IN O
least P08212897A0404 JJS O
five P08212897A0404 CD O
potential P08212897A0404 JJ O
transmembrane P08212897A0404 NN O
domains P08212897A0404 NNS O
. P08212897A0404 . O
. . O O

Furthermore P10699684A0661 RB O
, P10699684A0661 , O
Zelen P10699684A0661 NNP O
's P10699684A0661 POS O
method P10699684A0661 NN O
is P10699684A0661 VBZ O
used P10699684A0661 VBN O
to P10699684A0661 TO O
balance P10699684A0661 VB O
the P10699684A0661 DT O
number P10699684A0661 NN O
of P10699684A0661 IN O
patients P10699684A0661 NNS O
allocated P10699684A0661 VBN O
to P10699684A0661 TO O
the P10699684A0661 DT O
two P10699684A0661 CD O
groups P10699684A0661 NNS O
within P10699684A0661 IN O
each P10699684A0661 DT O
institution P10699684A0661 NN O
( P10699684A0661 ( O
M P10699684A0661 NNP O
. P10699684A0661 . O
. . O O

Results P08085609A0384 NNS O
indicate P08085609A0384 VBP O
that P08085609A0384 IN O
KNM-LU P08085609A0384 NNP O
335 P08085609A0384 CD O
differs P08085609A0384 NNS O
from P08085609A0384 IN O
both P08085609A0384 DT O
human P08085609A0384 JJ O
and P08085609A0384 CC O
chimpanzee P08085609A0384 JJ O
M1s P08085609A0384 NNP O
in P08085609A0384 IN O
relative P08085609A0384 JJ O
distances P08085609A0384 NNS O
( P08085609A0384 ( O
measured P08085609A0384 VBN O
in P08085609A0384 IN O
three P08085609A0384 CD O
dimensions P08085609A0384 NNS O
) P08085609A0384 ) O
between P08085609A0384 IN O
crown P08085609A0384 JJ O
fissure P08085609A0384 NN O
termini P08085609A0384 NN O
. P08085609A0384 . O
. . O O

They P10586107A0160 PRP O
are P10586107A0160 VBP O
subdivided P10586107A0160 VBN O
into P10586107A0160 IN O
two P10586107A0160 CD O
types P10586107A0160 NNS O
that P10586107A0160 IN O
activate P10586107A0160 VBP O
transduction P10586107A0160 NN O
pathways P10586107A0160 NNS O
via P10586107A0160 IN O
different P10586107A0160 JJ O
cell P10586107A0160 NN O
surface P10586107A0160 NN O
receptors P10586107A0160 NNS O
. P10586107A0160 . O
. . O O

Treatment P07493627A0882 NN O
of P07493627A0882 IN O
PCC4.aza1R P07493627A0882 NNP O
cells P07493627A0882 NNS O
with P07493627A0882 IN O
an P07493627A0882 DT O
RAR-selective P07493627A0882 JJ O
agonist P07493627A0882 NN O
also P07493627A0882 RB O
repressed P07493627A0882 VBD O
the P07493627A0882 DT O
expression P07493627A0882 NN O
of P07493627A0882 IN O
EC-1 P07493627A0882 NNP I-UN
mRNA P07493627A0882 NN I-UN
while P07493627A0882 IN O
treatment P07493627A0882 NN O
with P07493627A0882 IN O
an P07493627A0882 DT O
RXR-selective P07493627A0882 JJ O
agonist P07493627A0882 NN O
reduced P07493627A0882 VBD O
EC-1 P07493627A0882 NNP I-UN
expression P07493627A0882 NN O
slightly P07493627A0882 RB O
. P07493627A0882 . O
. . O O

In P07479004A0421 IN O
electrophoretic P07479004A0421 JJ O
mobility P07479004A0421 NN O
shift P07479004A0421 NN O
assays P07479004A0421 NNS O
, P07479004A0421 , O
the P07479004A0421 DT O
PERE P07479004A0421 NNP I-UN
formed P07479004A0421 VBD O
three P07479004A0421 CD O
major P07479004A0421 JJ O
complexes P07479004A0421 NNS O
( P07479004A0421 ( O
P1 P07479004A0421 NNP O
, P07479004A0421 , O
P2 P07479004A0421 NNP O
and P07479004A0421 CC O
P3 P07479004A0421 NNP O
) P07479004A0421 ) O
with P07479004A0421 IN O
proteins P07479004A0421 NNS O
in P07479004A0421 IN O
nuclear P07479004A0421 JJ O
extracts P07479004A0421 NNS O
from P07479004A0421 IN O
HeLa P07479004A0421 NNP O
or P07479004A0421 CC O
293 P07479004A0421 CD O
cells P07479004A0421 NNS O
. P07479004A0421 . O
. . O O

A. P11260662X0000 NN O
, P11260662X0000 , O
Slatkin P11260662X0000 NNP O
, P11260662X0000 , O
D P11260662X0000 NNP O
. P11260662X0000 . O
. . O O

TCR P10384129A0000 NNP I-UN
alpha P10384129A0000 NN I-UN
( P10384129A0000 ( O
TCRA P10384129A0000 NNP I-UN
) P10384129A0000 ) O
expression P10384129A0000 NN O
was P10384129A0000 VBD O
examined P10384129A0000 VBN O
in P10384129A0000 IN O
RNA P10384129A0000 NNP O
samples P10384129A0000 NNS O
from P10384129A0000 IN O
PBMC P10384129A0000 NNP O
and P10384129A0000 CC O
isolated P10384129A0000 JJ O
populations P10384129A0000 NNS O
of P10384129A0000 IN O
CD4+ P10384129A0000 NNP I-UN
, P10384129A0000 , O
CD8+ P10384129A0000 NNP I-UN
, P10384129A0000 , O
and P10384129A0000 CC O
DN P10384129A0000 NNP O
T P10384129A0000 NNP O
cells P10384129A0000 NNS O
from P10384129A0000 IN O
15 P10384129A0000 CD O
healthy P10384129A0000 JJ O
individuals P10384129A0000 NNS O
. P10384129A0000 . O
. . O O

To P07682842A0294 TO O
study P07682842A0294 VB O
the P07682842A0294 DT O
origin P07682842A0294 NN O
of P07682842A0294 IN O
different P07682842A0294 JJ O
fMLF-R P07682842A0294 JJ I-UN
transcripts P07682842A0294 NNS I-UN
, P07682842A0294 , O
the P07682842A0294 DT O
genetic P07682842A0294 JJ O
linkage P07682842A0294 NN O
of P07682842A0294 IN O
chemotactic P07682842A0294 JJ O
receptor P07682842A0294 NN O
genes P07682842A0294 NNS O
, P07682842A0294 , O
and P07682842A0294 CC O
the P07682842A0294 DT O
regulation P07682842A0294 NN O
of P07682842A0294 IN O
fMLF-R P07682842A0294 JJ I-UN
gene P07682842A0294 NN I-UN
expression P07682842A0294 NN O
, P07682842A0294 , O
we P07682842A0294 PRP O
determined P07682842A0294 VBD O
the P07682842A0294 DT O
copy P07682842A0294 NN O
number P07682842A0294 NN O
, P07682842A0294 , O
chromosomal P07682842A0294 JJ O
location P07682842A0294 NN O
, P07682842A0294 , O
structural P07682842A0294 JJ O
organization P07682842A0294 NN O
, P07682842A0294 , O
and P07682842A0294 CC O
5'-flanking P07682842A0294 JJ O
sequence P07682842A0294 NN O
of P07682842A0294 IN O
the P07682842A0294 DT O
human P07682842A0294 JJ I-UN
fMLF-R P07682842A0294 JJ I-UN
gene P07682842A0294 NN I-UN
. P07682842A0294 . O
. . O O

In P01718043A0384 IN O
patients P01718043A0384 NNS O
with P01718043A0384 IN O
osteomyelitis P01718043A0384 NN O
and P01718043A0384 CC O
joint P01718043A0384 JJ O
empyema P01718043A0384 NN O
( P01718043A0384 ( O
n P01718043A0384 JJ O
= P01718043A0384 NNP O
48 P01718043A0384 CD O
) P01718043A0384 ) O
PMN P01718043A0384 NNP I-UN
elastase P01718043A0384 NN I-UN
had P01718043A0384 VBD O
a P01718043A0384 DT O
sensitivity P01718043A0384 NN O
of P01718043A0384 IN O
77 P01718043A0384 CD O
% P01718043A0384 NN O
, P01718043A0384 , O
which P01718043A0384 WDT O
was P01718043A0384 VBD O
only P01718043A0384 RB O
exceeded P01718043A0384 VBN O
by P01718043A0384 IN O
that P01718043A0384 DT O
of P01718043A0384 IN O
the P01718043A0384 DT O
unspecific P01718043A0384 JJ O
erythrocyte P01718043A0384 JJ O
sedimentation P01718043A0384 NN O
rate P01718043A0384 NN O
( P01718043A0384 ( O
sensitivity P01718043A0384 JJ O
89 P01718043A0384 CD O
% P01718043A0384 NN O
) P01718043A0384 ) O
. P01718043A0384 . O
. . O O

Slowly P02325895T0000b RB O
adapting P02325895T0000b VBG O
type P02325895T0000b NN O
I P02325895T0000b PRP O
mechanoreceptor P02325895T0000b VBP O
discharge P02325895T0000b NN O
as P02325895T0000b IN O
a P02325895T0000b DT O
function P02325895T0000b NN O
of P02325895T0000b IN O
dynamic P02325895T0000b JJ O
force P02325895T0000b NN O
versus P02325895T0000b NN O
dynamic P02325895T0000b JJ O
displacement P02325895T0000b NN O
of P02325895T0000b IN O
glabrous P02325895T0000b JJ O
skin P02325895T0000b NN O
of P02325895T0000b IN O
raccoon P02325895T0000b NN O
and P02325895T0000b CC O
squirrel P02325895T0000b NN O
monkey P02325895T0000b JJ O
hand P02325895T0000b NN O
. P02325895T0000b . O
. . O O

Allergic P00592887T0000 NNP O
reaction P00592887T0000 NN O
to P00592887T0000 TO O
Patent P00592887T0000 NNP O
Blue P00592887T0000 NNP O
Violet P00592887T0000 NNP O
during P00592887T0000 IN O
lymphography P00592887T0000 NN O
. P00592887T0000 . O
. . O O

Successful P09550591A0454 JJ O
treatment P09550591A0454 NN O
with P09550591A0454 IN O
nasal P09550591A0454 JJ O
continuous P09550591A0454 JJ O
positive P09550591A0454 JJ O
airway P09550591A0454 NN O
pressure P09550591A0454 NN O
( P09550591A0454 ( O
8.3 P09550591A0454 CD O
+ P09550591A0454 NN O
/ P09550591A0454 NNP O
- P09550591A0454 : O
1.5 P09550591A0454 CD O
cmH2O P09550591A0454 NN O
) P09550591A0454 ) O
for P09550591A0454 IN O
3 P09550591A0454 CD O
days P09550591A0454 NNS O
caused P09550591A0454 VBD O
a P09550591A0454 DT O
significant P09550591A0454 JJ O
decrease P09550591A0454 NN O
in P09550591A0454 IN O
mean P09550591A0454 JJ O
blood P09550591A0454 NN O
pressure P09550591A0454 NN O
in P09550591A0454 IN O
OSAS P09550591A0454 NNP O
. P09550591A0454 . O
. . O O

It P09748669A0414 PRP O
may P09748669A0414 MD O
be P09748669A0414 VB O
time P09748669A0414 NN O
to P09748669A0414 TO O
reevaluate P09748669A0414 VB O
the P09748669A0414 DT O
dichotomy P09748669A0414 NN O
between P09748669A0414 IN O
AD P09748669A0414 NNP O
and P09748669A0414 CC O
VaD P09748669A0414 NNP O
. P09748669A0414 . O
. . O O

She P09365431A0314 PRP O
improved P09365431A0314 VBD O
with P09365431A0314 IN O
a P09365431A0314 DT O
combination P09365431A0314 NN O
of P09365431A0314 IN O
benzodiazepines P09365431A0314 NNS O
and P09365431A0314 CC O
the P09365431A0314 DT O
acetylcholinesterase P09365431A0314 NN I-UN
inhibitor P09365431A0314 NN O
physostigmine P09365431A0314 NN O
. P09365431A0314 . O
. . O O

Static P10694609A0309 JJ O
and P10694609A0309 CC O
dynamic P10694609A0309 JJ O
compliance P10694609A0309 NN O
was P10694609A0309 VBD O
measured P10694609A0309 VBN O
after P10694609A0309 IN O
induction P10694609A0309 NN O
of P10694609A0309 IN O
anesthesia P10694609A0309 NN O
, P10694609A0309 , O
before P10694609A0309 IN O
and P10694609A0309 CC O
immediately P10694609A0309 RB O
after P10694609A0309 IN O
filtration P10694609A0309 NN O
in P10694609A0309 IN O
the P10694609A0309 DT O
operating P10694609A0309 NN O
theater P10694609A0309 NN O
, P10694609A0309 , O
1 P10694609A0309 CD O
hour P10694609A0309 NN O
after P10694609A0309 IN O
return P10694609A0309 NN O
to P10694609A0309 TO O
the P10694609A0309 DT O
pediatric P10694609A0309 JJ O
intensive P10694609A0309 JJ O
care P10694609A0309 NN O
unit P10694609A0309 NN O
, P10694609A0309 , O
and P10694609A0309 CC O
24 P10694609A0309 CD O
hours P10694609A0309 NNS O
after P10694609A0309 IN O
the P10694609A0309 DT O
operation P10694609A0309 NN O
. P10694609A0309 . O
. . O O

When P08278929A0866 WRB O
Hy-Vac P08278929A0866 NNP O
SPF P08278929A0866 NNP O
type P08278929A0866 NN O
V P08278929A0866 NNP O
embryos P08278929A0866 NN O
were P08278929A0866 VBD O
exposed P08278929A0866 VBN O
to P08278929A0866 TO O
either P08278929A0866 DT O
0.20 P08278929A0866 CD O
ml P08278929A0866 VBD O
50 P08278929A0866 CD O
% P08278929A0866 NN O
ethanol P08278929A0866 NN O
in P08278929A0866 IN O
CRS P08278929A0866 NNP O
or P08278929A0866 CC O
to P08278929A0866 TO O
0.20 P08278929A0866 CD O
ml P08278929A0866 NNS O
CRS P08278929A0866 NNP O
( P08278929A0866 ( O
controls P08278929A0866 NNS O
) P08278929A0866 ) O
, P08278929A0866 , O
ethanol-treated P08278929A0866 JJ O
embryos P08278929A0866 NN O
showed P08278929A0866 VBD O
a P08278929A0866 DT O
VSD P08278929A0866 NNP O
incidence P08278929A0866 NN O
of P08278929A0866 IN O
34.1 P08278929A0866 CD O
% P08278929A0866 NN O
compared P08278929A0866 VBN O
with P08278929A0866 IN O
a P08278929A0866 DT O
3.6 P08278929A0866 CD O
% P08278929A0866 NN O
incidence P08278929A0866 NN O
in P08278929A0866 IN O
the P08278929A0866 DT O
controls P08278929A0866 NNS O
( P08278929A0866 ( O
P P08278929A0866 NNP O
= P08278929A0866 NNP O
0.0017 P08278929A0866 CD O
) P08278929A0866 ) O
. P08278929A0866 . O
. . O O

Identical P09681822A0520 JJ O
c-erbB3 P09681822A0520 NN I-UN
transcripts P09681822A0520 NNS I-UN
are P09681822A0520 VBP O
expressed P09681822A0520 VBN O
in P09681822A0520 IN O
normal P09681822A0520 JJ O
human P09681822A0520 JJ O
placental P09681822A0520 NN O
tissues P09681822A0520 NNS O
. P09681822A0520 . O
. . O O

Each P02231479A0585 DT O
parent P02231479A0585 NN O
interacted P02231479A0585 VBN O
with P02231479A0585 IN O
their P02231479A0585 PRP$ O
4- P02231479A0585 JJ O
or P02231479A0585 CC O
5-year-old P02231479A0585 JJ O
son P02231479A0585 NN O
or P02231479A0585 CC O
daughter P02231479A0585 NN O
in P02231479A0585 IN O
each P02231479A0585 DT O
of P02231479A0585 IN O
two P02231479A0585 CD O
conversations P02231479A0585 NNS O
-- P02231479A0585 : O
unstructured P02231479A0585 JJ O
( P02231479A0585 ( O
social P02231479A0585 JJ O
conversation P02231479A0585 NN O
) P02231479A0585 ) O
and P02231479A0585 CC O
structured P02231479A0585 VBN O
( P02231479A0585 ( O
task P02231479A0585 JJ O
activity P02231479A0585 NN O
) P02231479A0585 ) O
. P02231479A0585 . O
. . O O

These P00627129A0944 DT O
responses P00627129A0944 NNS O
were P00627129A0944 VBD O
compared P00627129A0944 VBN O
with P00627129A0944 IN O
others P00627129A0944 NNS O
in P00627129A0944 IN O
the P00627129A0944 DT O
same P00627129A0944 JJ O
subjects P00627129A0944 NNS O
under P00627129A0944 IN O
the P00627129A0944 DT O
same P00627129A0944 JJ O
conditions P00627129A0944 NNS O
and P00627129A0944 CC O
it P00627129A0944 PRP O
was P00627129A0944 VBD O
concluded P00627129A0944 VBN O
that P00627129A0944 IN O
the P00627129A0944 DT O
antihypertensive P00627129A0944 JJ O
effect P00627129A0944 NN O
of P00627129A0944 IN O
labetalol P00627129A0944 NN O
is P00627129A0944 VBZ O
explained P00627129A0944 VBN O
by P00627129A0944 IN O
concurrent P00627129A0944 NN O
blockade P00627129A0944 NN O
of P00627129A0944 IN O
alpha-and P00627129A0944 JJ I-UN
beta-adrenoceptors P00627129A0944 NNS I-UN
. P00627129A0944 . O
. . O O

Zn P01731933T0000b NNP O
( P01731933T0000b ( O
II P01731933T0000b NNP O
) P01731933T0000b ) O
coordination P01731933T0000b NN O
domain P01731933T0000b NN O
mutants P01731933T0000b NNS O
of P01731933T0000b IN O
T4 P01731933T0000b NNP I-UN
gene P01731933T0000b NN I-UN
32 P01731933T0000b CD I-UN
protein P01731933T0000b NN I-UN
. P01731933T0000b . O
. . O O

Multiparous P11227039A0953 JJ O
women P11227039A0953 NNS O
presented P11227039A0953 VBD O
higher P11227039A0953 JJR O
BMI P11227039A0953 NNP O
( P11227039A0953 ( O
P P11227039A0953 NNP O
= P11227039A0953 NNP O
0.01 P11227039A0953 CD O
) P11227039A0953 ) O
and P11227039A0953 CC O
PBF P11227039A0953 NNP O
( P11227039A0953 ( O
P P11227039A0953 NNP O
= P11227039A0953 NNP O
0.03 P11227039A0953 CD O
) P11227039A0953 ) O
compared P11227039A0953 VBN O
with P11227039A0953 IN O
primi- P11227039A0953 JJ O
and P11227039A0953 CC O
nulliparous P11227039A0953 JJ O
groups P11227039A0953 NNS O
. P11227039A0953 . O
. . O O

Several P03541263A0368 JJ O
new P03541263A0368 JJ O
techniques P03541263A0368 NNS O
are P03541263A0368 VBP O
available P03541263A0368 JJ O
for P03541263A0368 IN O
monitoring P03541263A0368 VBG O
control P03541263A0368 NN O
of P03541263A0368 IN O
diabetes P03541263A0368 NNS O
. P03541263A0368 . O
. . O O

Structural P08112601T0000 JJ O
organization P08112601T0000 NN O
of P08112601T0000 IN O
the P08112601T0000 DT O
gene P08112601T0000 NN O
encoding P08112601T0000 VBG O
the P08112601T0000 DT O
human P08112601T0000 JJ I-UN
lipocalin P08112601T0000 NN I-UN
tear P08112601T0000 IN I-UN
prealbumin P08112601T0000 NN I-UN
and P08112601T0000 CC O
synthesis P08112601T0000 NN O
of P08112601T0000 IN O
the P08112601T0000 DT O
recombinant P08112601T0000 JJ O
protein P08112601T0000 NN O
in P08112601T0000 IN O
Escherichia P08112601T0000 NNP O
coli P08112601T0000 NN O
. P08112601T0000 . O
. . O O

Cryopreservation P08495786A0085 NNP O
straws P08495786A0085 VBZ O
filled P08495786A0085 VBN O
with P08495786A0085 IN O
media P08495786A0085 NNS O
plus P08495786A0085 CC O
additive P08495786A0085 JJ O
are P08495786A0085 VBP O
emersed P08495786A0085 VBN O
below P08495786A0085 IN O
the P08495786A0085 DT O
surface P08495786A0085 NN O
of P08495786A0085 IN O
an P08495786A0085 DT O
unprocessed P08495786A0085 JJ O
donor P08495786A0085 NN O
ejaculate P08495786A0085 NN O
. P08495786A0085 . O
. . O O

Following P06426493A0331 VBG O
20 P06426493A0331 CD O
min P06426493A0331 NN O
of P06426493A0331 IN O
steady P06426493A0331 JJ O
state P06426493A0331 NN O
anaesthesia P06426493A0331 NN O
during P06426493A0331 IN O
which P06426493A0331 WDT O
measurements P06426493A0331 NNS O
of P06426493A0331 IN O
IOP P06426493A0331 NNP O
, P06426493A0331 , O
arterial P06426493A0331 JJ O
pressure P06426493A0331 NN O
, P06426493A0331 , O
heart P06426493A0331 NN O
rate P06426493A0331 NN O
, P06426493A0331 , O
FIO2 P06426493A0331 NNP O
, P06426493A0331 , O
FE'CO2 P06426493A0331 NNP O
and P06426493A0331 CC O
CVP P06426493A0331 NNP O
were P06426493A0331 VBD O
recorded P06426493A0331 VBN O
, P06426493A0331 , O
one P06426493A0331 CD O
group P06426493A0331 NN O
of P06426493A0331 IN O
patients P06426493A0331 NNS O
received P06426493A0331 VBD O
atracurium P06426493A0331 JJ O
0.45 P06426493A0331 CD O
mg P06426493A0331 JJ O
kg-1 P06426493A0331 NN O
and P06426493A0331 CC O
the P06426493A0331 DT O
other P06426493A0331 JJ O
pancuronium P06426493A0331 NN O
0.1 P06426493A0331 CD O
mg P06426493A0331 JJ O
kg-1 P06426493A0331 NN O
. P06426493A0331 . O
. . O O

Binding P07828600A0095 NNP O
of P07828600A0095 IN O
SSP P07828600A0095 NNP I-UN
to P07828600A0095 TO O
the P07828600A0095 DT O
stage P07828600A0095 NN I-UN
selector P07828600A0095 NN I-UN
element P07828600A0095 NN I-UN
( P07828600A0095 ( O
SSE P07828600A0095 NNP I-UN
) P07828600A0095 ) O
in P07828600A0095 IN O
the P07828600A0095 DT O
proximal P07828600A0095 JJ O
gamma-globin P07828600A0095 JJ I-UN
promoter P07828600A0095 NN I-UN
is P07828600A0095 VBZ O
integral P07828600A0095 JJ O
to P07828600A0095 TO O
the P07828600A0095 DT O
competitive P07828600A0095 JJ O
silencing P07828600A0095 NN O
of P07828600A0095 IN O
a P07828600A0095 DT O
linked P07828600A0095 VBN O
beta-promoter P07828600A0095 NN I-UN
in P07828600A0095 IN O
embryonic P07828600A0095 JJ O
/ P07828600A0095 NNP O
fetal P07828600A0095 JJ O
stage P07828600A0095 NN O
erythroleukemia P07828600A0095 NN O
( P07828600A0095 ( O
K562 P07828600A0095 NNP O
) P07828600A0095 ) O
cells P07828600A0095 NNS O
. P07828600A0095 . O
. . O O

Thus P10745563A0409 RB O
, P10745563A0409 , O
both P10745563A0409 DT O
the P10745563A0409 DT O
hyperplasia P10745563A0409 NN O
and P10745563A0409 CC O
thrombotic P10745563A0409 JJ O
complications P10745563A0409 NNS O
which P10745563A0409 WDT O
often P10745563A0409 RB O
follow P10745563A0409 VBP O
stenting P10745563A0409 VBG O
might P10745563A0409 MD O
be P10745563A0409 VB O
minimized P10745563A0409 VBN O
by P10745563A0409 IN O
employing P10745563A0409 VBG O
gold P10745563A0409 NN O
stents P10745563A0409 NNS O
, P10745563A0409 , O
which P10745563A0409 WDT O
have P10745563A0409 VBP O
a P10745563A0409 DT O
greater P10745563A0409 JJR O
capacity P10745563A0409 NN O
than P10745563A0409 IN O
steel P10745563A0409 NN O
in P10745563A0409 IN O
supporting P10745563A0409 VBG O
a P10745563A0409 DT O
functional P10745563A0409 JJ O
neo-endothelium P10745563A0409 NN O
. P10745563A0409 . O
. . O O

DR1 P01402647A0114 NNP I-UN
molecules P01402647A0114 NNS I-UN
purified P01402647A0114 VBD O
from P01402647A0114 IN O
human P01402647A0114 JJ O
lymphoblastoid P01402647A0114 NN O
cell P01402647A0114 NN O
lines P01402647A0114 NNS O
could P01402647A0114 MD O
specifically P01402647A0114 RB O
bind P01402647A0114 VB O
to P01402647A0114 TO O
these P01402647A0114 DT O
peptide P01402647A0114 JJ O
sequences P01402647A0114 NNS O
expressed P01402647A0114 VBN O
on P01402647A0114 IN O
the P01402647A0114 DT O
phage P01402647A0114 NN O
surface P01402647A0114 NN O
. P01402647A0114 . O
. . O O

Therefore P09081392A0174 RB O
more P09081392A0174 RBR O
active P09081392A0174 JJ O
and P09081392A0174 CC O
tolerable P09081392A0174 JJ O
salvage P09081392A0174 NN O
regimens P09081392A0174 NNS O
are P09081392A0174 VBP O
needed P09081392A0174 VBN O
. P09081392A0174 . O
. . O O

Using P07592676A0466 VBG O
varying P07592676A0466 VBG O
conditions P07592676A0466 NNS O
, P07592676A0466 , O
three P07592676A0466 CD O
distinct P07592676A0466 NN O
complexes P07592676A0466 NNS O
were P07592676A0466 VBD O
shown P07592676A0466 VBN O
to P07592676A0466 TO O
interact P07592676A0466 VB O
specifically P07592676A0466 RB O
with P07592676A0466 IN O
the P07592676A0466 DT O
NIP P07592676A0466 NNP I-UN
region P07592676A0466 NN I-UN
, P07592676A0466 , O
although P07592676A0466 IN O
only P07592676A0466 RB O
one P07592676A0466 CD O
correlates P07592676A0466 VBZ O
with P07592676A0466 IN O
repressor P07592676A0466 NN O
activity P07592676A0466 NN O
. P07592676A0466 . O
. . O O

The P11369410A0949 DT O
first P11369410A0949 JJ O
hypothesis P11369410A0949 NN O
was P11369410A0949 VBD O
supported P11369410A0949 VBN O
in P11369410A0949 IN O
the P11369410A0949 DT O
sense P11369410A0949 NN O
that P11369410A0949 WDT O
stimulus P11369410A0949 NN O
differences P11369410A0949 NNS O
might P11369410A0949 MD O
affect P11369410A0949 VB O
behaviour P11369410A0949 VB O
even P11369410A0949 RB O
without P11369410A0949 IN O
their P11369410A0949 PRP$ O
successful P11369410A0949 JJ O
attentive P11369410A0949 JJ O
processing P11369410A0949 NN O
in P11369410A0949 IN O
normal P11369410A0949 JJ O
participants P11369410A0949 NNS O
. P11369410A0949 . O
. . O O

The P09712915A0672 DT O
activity P09712915A0672 NN O
of P09712915A0672 IN O
the P09712915A0672 DT O
minimal P09712915A0672 JJ O
promoter P09712915A0672 NN O
was P09712915A0672 VBD O
found P09712915A0672 VBN O
to P09712915A0672 TO O
be P09712915A0672 VB O
controlled P09712915A0672 VBN O
by P09712915A0672 IN O
a P09712915A0672 DT O
combination P09712915A0672 NN O
of P09712915A0672 IN O
the P09712915A0672 DT O
activities P09712915A0672 NNS O
of P09712915A0672 IN O
the P09712915A0672 DT O
transcription P09712915A0672 NN O
factors P09712915A0672 NNS O
Sp1 P09712915A0672 NNP I-UN
, P09712915A0672 , O
Sp3 P09712915A0672 NNP I-UN
, P09712915A0672 , O
and P09712915A0672 CC O
NF-Y P09712915A0672 NNP I-UN
. P09712915A0672 . O
. . O O

To P11391793A0856 TO O
determine P11391793A0856 VB O
the P11391793A0856 DT O
genomic P11391793A0856 JJ O
complexity P11391793A0856 NN O
of P11391793A0856 IN O
the P11391793A0856 DT O
deleted P11391793A0856 JJ O
region P11391793A0856 NN O
shared P11391793A0856 VBN O
among P11391793A0856 IN O
tumors P11391793A0856 NNS O
, P11391793A0856 , O
we P11391793A0856 PRP O
assembled P11391793A0856 VBD O
a P11391793A0856 DT O
physical P11391793A0856 JJ O
map P11391793A0856 NN O
of P11391793A0856 IN O
the P11391793A0856 DT O
I P11391793A0856 PRP O
Mbp P11391793A0856 NNP O
SRO P11391793A0856 NNP O
consisting P11391793A0856 VBG O
predominantly P11391793A0856 RB O
of P11391793A0856 IN O
bacteriophage P11391793A0856 NN O
P1-derived P11391793A0856 JJ O
artificial P11391793A0856 JJ O
chromosome P11391793A0856 NN O
( P11391793A0856 ( O
PAC P11391793A0856 NNP O
) P11391793A0856 ) O
clones P11391793A0856 NNS O
. P11391793A0856 . O
. . O O

Overexpression P11103792A0755 NN O
of P11103792A0755 IN O
c-Myc P11103792A0755 NN I-UN
in P11103792A0755 IN O
serum-starved P11103792A0755 JJ O
human P11103792A0755 NN O
or P11103792A0755 CC O
mouse P11103792A0755 NN O
embryonic P11103792A0755 JJ O
cells P11103792A0755 NNS O
leads P11103792A0755 VBZ O
to P11103792A0755 TO O
apoptosis P11103792A0755 VB O
which P11103792A0755 WDT O
is P11103792A0755 VBZ O
significantly P11103792A0755 RB O
reduced P11103792A0755 VBN O
in P11103792A0755 IN O
the P11103792A0755 DT O
presence P11103792A0755 NN O
of P11103792A0755 IN O
growth P11103792A0755 NN O
factor-containing P11103792A0755 JJ O
serum P11103792A0755 NN O
. P11103792A0755 . O
c-Myc-induced P11103792A0755 JJ O
apoptosis P11103792A0755 NN O
appears P11103792A0755 VBZ O
to P11103792A0755 TO O
be P11103792A0755 VB O
deficient P11103792A0755 JJ O
in P11103792A0755 IN O
bax-null P11103792A0755 NN O
as P11103792A0755 IN O
compared P11103792A0755 VBN O
with P11103792A0755 IN O
bax-wild-type P11103792A0755 JJ O
mouse P11103792A0755 NN O
embryonic P11103792A0755 JJ O
fibroblasts P11103792A0755 NNS O
. P11103792A0755 . O
. . O O

In P10563836A1234 IN O
contrast P10563836A1234 NN O
, P10563836A1234 , O
AP-2 P10563836A1234 NNP I-UN
binding P10563836A1234 NN O
activity P10563836A1234 NN O
was P10563836A1234 VBD O
significantly P10563836A1234 RB O
greater P10563836A1234 JJR O
in P10563836A1234 IN O
T47D P10563836A1234 NNP O
cells P10563836A1234 NNS O
, P10563836A1234 , O
and P10563836A1234 CC O
Western P10563836A1234 JJ O
blots P10563836A1234 NNS O
confirmed P10563836A1234 VBD O
increased P10563836A1234 JJ O
AP-2 P10563836A1234 NNP I-UN
protein P10563836A1234 NN I-UN
levels P10563836A1234 NNS O
in P10563836A1234 IN O
these P10563836A1234 DT O
cells P10563836A1234 NNS O
. P10563836A1234 . O
. . O O

In P10872756A1325 IN O
NASCIS P10872756A1325 NNP O
III P10872756A1325 NNP O
, P10872756A1325 , O
a P10872756A1325 DT O
randomization P10872756A1325 NN O
imbalance P10872756A1325 NN O
occurred P10872756A1325 VBD O
that P10872756A1325 IN O
allocated P10872756A1325 VBD O
a P10872756A1325 DT O
disproportionate P10872756A1325 JJ O
number P10872756A1325 NN O
of P10872756A1325 IN O
patients P10872756A1325 NNS O
with P10872756A1325 IN O
no P10872756A1325 DT O
motor P10872756A1325 NN O
deficit P10872756A1325 NN O
( P10872756A1325 ( O
and P10872756A1325 CC O
therefore P10872756A1325 RB O
no P10872756A1325 DT O
chance P10872756A1325 NN O
for P10872756A1325 IN O
recovery P10872756A1325 NN O
) P10872756A1325 ) O
to P10872756A1325 TO O
the P10872756A1325 DT O
lower P10872756A1325 JJR O
dose P10872756A1325 JJ O
control P10872756A1325 NN O
group P10872756A1325 NN O
. P10872756A1325 . O
. . O O

Plasma P06851280A0144 NNP O
fibrinogen P06851280A0144 NN I-UN
was P06851280A0144 VBD O
measured P06851280A0144 VBN O
by P06851280A0144 IN O
the P06851280A0144 DT O
turbidimetric P06851280A0144 JJ O
method P06851280A0144 NN O
in P06851280A0144 IN O
timol P06851280A0144 JJ O
turbidimetric P06851280A0144 JJ O
units P06851280A0144 NNS O
. P06851280A0144 . O
. . O O

Microdetermination P04727344T0000 NN O
of P04727344T0000 IN O
adrenocortical P04727344T0000 JJ O
steroids P04727344T0000 NNS O
by P04727344T0000 IN O
double P04727344T0000 JJ O
isotope P04727344T0000 NN O
method P04727344T0000 NN O
. P04727344T0000 . O
. . O O

Evidence P09307312A0172 NN O
for P09307312A0172 IN O
such P09307312A0172 JJ O
peak P09307312A0172 JJ O
shifts P09307312A0172 NNS O
has P09307312A0172 VBZ O
been P09307312A0172 VBN O
found P09307312A0172 VBN O
in P09307312A0172 IN O
the P09307312A0172 DT O
responses P09307312A0172 NNS O
of P09307312A0172 IN O
auditory P09307312A0172 NN O
nerve P09307312A0172 NN O
fibers P09307312A0172 NNS O
, P09307312A0172 , O
cochlear P09307312A0172 JJ O
microphonics P09307312A0172 NNS O
, P09307312A0172 , O
and P09307312A0172 CC O
the P09307312A0172 DT O
responses P09307312A0172 NNS O
of P09307312A0172 IN O
outer P09307312A0172 JJ O
hair P09307312A0172 NN O
cells P09307312A0172 NNS O
and P09307312A0172 CC O
supporting P09307312A0172 VBG O
cells P09307312A0172 NNS O
in P09307312A0172 IN O
the P09307312A0172 DT O
cochlea P09307312A0172 NN O
, P09307312A0172 , O
as P09307312A0172 RB O
well P09307312A0172 RB O
as P09307312A0172 IN O
in P09307312A0172 IN O
basilar P09307312A0172 JJ O
membrane P09307312A0172 NN O
vibration P09307312A0172 NN O
measurements P09307312A0172 NNS O
, P09307312A0172 , O
and P09307312A0172 CC O
indirectly P09307312A0172 RB O
, P09307312A0172 , O
in P09307312A0172 IN O
psychophysical P09307312A0172 JJ O
data P09307312A0172 NNS O
. P09307312A0172 . O
. . O O

AgMNPV P01588315A0356 NNP O
and P01588315A0356 CC O
Orgyia P01588315A0356 NNP O
pseudotsugata P01588315A0356 NN O
MNPV P01588315A0356 NNP O
( P01588315A0356 ( O
OpMNPV P01588315A0356 NNP O
) P01588315A0356 ) O
are P01588315A0356 VBP O
similar P01588315A0356 JJ O
in P01588315A0356 IN O
terms P01588315A0356 NNS O
of P01588315A0356 IN O
promoter P01588315A0356 NN O
structure P01588315A0356 NN O
and P01588315A0356 CC O
polyhedrin P01588315A0356 JJ I-UN
primary P01588315A0356 JJ I-UN
sequence P01588315A0356 NN I-UN
, P01588315A0356 , O
and P01588315A0356 CC O
the P01588315A0356 DT O
polyhedrin P01588315A0356 JJ I-UN
gene P01588315A0356 NN I-UN
of P01588315A0356 IN O
both P01588315A0356 DT O
viruses P01588315A0356 NNS O
is P01588315A0356 VBZ O
transcribed P01588315A0356 VBN O
in P01588315A0356 IN O
the P01588315A0356 DT O
anti-clockwise P01588315A0356 JJ O
direction P01588315A0356 NN O
in P01588315A0356 IN O
relation P01588315A0356 NN O
to P01588315A0356 TO O
their P01588315A0356 PRP$ O
physical P01588315A0356 JJ O
maps P01588315A0356 NNS O
. P01588315A0356 . O
. . O O

An P04377003A0000 DT O
automated P04377003A0000 JJ O
method P04377003A0000 NN O
for P04377003A0000 IN O
the P04377003A0000 DT O
quantitative P04377003A0000 JJ O
analysis P04377003A0000 NN O
of P04377003A0000 IN O
the P04377003A0000 DT O
polyamines P04377003A0000 NNS O
putrescine P04377003A0000 NN O
, P04377003A0000 , O
spermidine P04377003A0000 NN O
and P04377003A0000 CC O
spermine P04377003A0000 NN O
in P04377003A0000 IN O
cerebrospinal P04377003A0000 JJ O
fluid P04377003A0000 NN O
( P04377003A0000 ( O
CSF P04377003A0000 NNP O
) P04377003A0000 ) O
was P04377003A0000 VBD O
used P04377003A0000 VBN O
to P04377003A0000 TO O
analyze P04377003A0000 VB O
CSF P04377003A0000 NNP O
samples P04377003A0000 NNS O
from P04377003A0000 IN O
37 P04377003A0000 CD O
patients P04377003A0000 NNS O
with P04377003A0000 IN O
central P04377003A0000 JJ O
nervous P04377003A0000 JJ O
system P04377003A0000 NN O
( P04377003A0000 ( O
CNS P04377003A0000 NNP O
) P04377003A0000 ) O
tumors P04377003A0000 NNS O
and P04377003A0000 CC O
from P04377003A0000 IN O
13 P04377003A0000 CD O
patients P04377003A0000 NNS O
without P04377003A0000 IN O
tumors P04377003A0000 NNS O
. P04377003A0000 . O
. . O O

Two-dimensional P07681147A1420 JJ O
phosphotryptic P07681147A1420 JJ O
analyses P07681147A1420 NNS O
indicate P07681147A1420 VBP O
that P07681147A1420 DT O
phosphorylation P07681147A1420 NN O
on P07681147A1420 IN O
Ser-12 P07681147A1420 NNP O
and P07681147A1420 CC O
Ser-48 P07681147A1420 NNP O
in P07681147A1420 IN O
unstimulated P07681147A1420 JJ O
cells P07681147A1420 NNS O
is P07681147A1420 VBZ O
associated P07681147A1420 VBN O
with P07681147A1420 IN O
the P07681147A1420 DT O
ability P07681147A1420 NN O
of P07681147A1420 IN O
overexpressed P07681147A1420 JJ O
pp60c-src P07681147A1420 NN I-UN
to P07681147A1420 TO O
potentiate P07681147A1420 VB O
beta-adrenergic P07681147A1420 JJ O
signalling P07681147A1420 NN O
. P07681147A1420 . O
. . O O

The P09858588A1046 DT O
slower-electrophoretic-mobility P09858588A1046 JJ O
form P09858588A1046 NN O
of P09858588A1046 IN O
p68 P09858588A1046 NN I-UN
was P09858588A1046 VBD O
absent P09858588A1046 JJ O
in P09858588A1046 IN O
human P09858588A1046 JJ O
cells P09858588A1046 NNS O
in P09858588A1046 IN O
G1 P09858588A1046 NNP O
/ P09858588A1046 NNP O
S P09858588A1046 NNP O
and P09858588A1046 CC O
appeared P09858588A1046 VBD O
as P09858588A1046 IN O
the P09858588A1046 DT O
cells P09858588A1046 NNS O
entered P09858588A1046 VBD O
G2 P09858588A1046 NNP O
/ P09858588A1046 NNP O
M P09858588A1046 NNP O
. P09858588A1046 . O
. . O O

Cerebral P10795098A0253 NNP O
vasculitis P10795098A0253 NN O
secondary P10795098A0253 JJ O
to P10795098A0253 TO O
Crohn P10795098A0253 NNP O
's P10795098A0253 POS O
disease P10795098A0253 NN O
seems P10795098A0253 VBZ O
to P10795098A0253 TO O
be P10795098A0253 VB O
a P10795098A0253 DT O
very P10795098A0253 RB O
rare P10795098A0253 JJ O
phenomenon P10795098A0253 NN O
. P10795098A0253 . O
. . O O

A P02355920A0681 DT O
consensus P02355920A0681 NN O
binding P02355920A0681 VBG O
site P02355920A0681 NN O
for P02355920A0681 IN O
the P02355920A0681 DT O
transcription P02355920A0681 NN O
factor P02355920A0681 NN O
SP1 P02355920A0681 NNP I-UN
was P02355920A0681 VBD O
identified P02355920A0681 VBN O
in P02355920A0681 IN O
intron P02355920A0681 NN O
As P02355920A0681 IN O
downstream P02355920A0681 NN O
of P02355920A0681 IN O
the P02355920A0681 DT O
proenkephalin P02355920A0681 JJ I-UN
germ P02355920A0681 NN I-UN
cell P02355920A0681 NN I-UN
cap P02355920A0681 NN I-UN
site P02355920A0681 NN I-UN
region P02355920A0681 NN I-UN
. P02355920A0681 . O
. . O O

Combined P03039387A0920 VBN O
immunochemotherapy P03039387A0920 NN O
with P03039387A0920 IN O
cyclophosphamide P03039387A0920 JJ O
plus P03039387A0920 CC O
BCG P03039387A0920 NNP O
gave P03039387A0920 VBD O
a P03039387A0920 DT O
better P03039387A0920 RBR O
enhancement P03039387A0920 NN O
of P03039387A0920 IN O
the P03039387A0920 DT O
antitumor P03039387A0920 JJ O
effect P03039387A0920 NN O
of P03039387A0920 IN O
the P03039387A0920 DT O
cytostatic P03039387A0920 JJ O
than P03039387A0920 IN O
that P03039387A0920 DT O
of P03039387A0920 IN O
the P03039387A0920 DT O
combination P03039387A0920 NN O
of P03039387A0920 IN O
methotrexate P03039387A0920 JJ O
plus P03039387A0920 CC O
BCG P03039387A0920 NNP O
and P03039387A0920 CC O
cyclophosphamide P03039387A0920 JJ O
plus P03039387A0920 CC O
levamisole P03039387A0920 JJ O
. P03039387A0920 . O
. . O O

In P01648142A1170 IN O
patients P01648142A1170 NNS O
with P01648142A1170 IN O
limited P01648142A1170 JJ O
disease P01648142A1170 NN O
, P01648142A1170 , O
the P01648142A1170 DT O
survival P01648142A1170 NN O
in P01648142A1170 IN O
the P01648142A1170 DT O
alternating P01648142A1170 NN O
arm P01648142A1170 NN O
was P01648142A1170 VBD O
significantly P01648142A1170 RB O
superior P01648142A1170 JJ O
to P01648142A1170 TO O
the P01648142A1170 DT O
survival P01648142A1170 NN O
in P01648142A1170 IN O
the P01648142A1170 DT O
CAV P01648142A1170 NNP O
arm P01648142A1170 NN O
( P01648142A1170 ( O
P P01648142A1170 NNP O
= P01648142A1170 NNP O
.014 P01648142A1170 NNP O
) P01648142A1170 ) O
or P01648142A1170 CC O
the P01648142A1170 DT O
survival P01648142A1170 NN O
in P01648142A1170 IN O
the P01648142A1170 DT O
PE P01648142A1170 NNP O
arm P01648142A1170 NN O
( P01648142A1170 ( O
P P01648142A1170 NNP O
= P01648142A1170 NNP O
.023 P01648142A1170 NNP O
) P01648142A1170 ) O
. P01648142A1170 . O
. . O O

Multiple P03567017A0000 NNP O
dosing P03567017A0000 VBG O
four P03567017A0000 CD O
times P03567017A0000 NNS O
daily P03567017A0000 RB O
for P03567017A0000 IN O
7 P03567017A0000 CD O
days P03567017A0000 NNS O
of P03567017A0000 IN O
indoprofen P03567017A0000 JJ O
200 P03567017A0000 CD O
mg P03567017A0000 NN O
, P03567017A0000 , O
a P03567017A0000 DT O
non-steroidal P03567017A0000 JJ O
anti-inflammatory P03567017A0000 JJ O
drug P03567017A0000 NN O
with P03567017A0000 IN O
a P03567017A0000 DT O
short P03567017A0000 JJ O
half-life P03567017A0000 NN O
( P03567017A0000 ( O
t1 P03567017A0000 JJ O
/ P03567017A0000 NNP O
2 P03567017A0000 CD O
) P03567017A0000 ) O
, P03567017A0000 , O
revealed P03567017A0000 VBD O
drug P03567017A0000 NN O
accumulation P03567017A0000 NN O
in P03567017A0000 IN O
eight P03567017A0000 CD O
elderly P03567017A0000 JJ O
subjects P03567017A0000 NNS O
. P03567017A0000 . O
. . O O

Quantitative P08816438A0316 JJ O
analysis P08816438A0316 NN O
of P08816438A0316 IN O
plasmid P08816438A0316 JJ O
loss P08816438A0316 NN O
rates P08816438A0316 NNS O
in P08816438A0316 IN O
cdc28-1N P08816438A0316 JJ I-UN
strains P08816438A0316 NNS O
carrying P08816438A0316 VBG O
plasmids P08816438A0316 NNS O
with P08816438A0316 IN O
multiple P08816438A0316 JJ O
replication P08816438A0316 NN O
origins P08816438A0316 NNS O
suggests P08816438A0316 VBZ O
that P08816438A0316 IN O
a P08816438A0316 DT O
defect P08816438A0316 NN O
in P08816438A0316 IN O
initiating P08816438A0316 VBG O
DNA P08816438A0316 NNP O
replication P08816438A0316 NN O
probably P08816438A0316 RB O
causes P08816438A0316 VBZ O
this P08816438A0316 DT O
plasmid P08816438A0316 JJ O
loss P08816438A0316 NN O
phenotype P08816438A0316 NN O
. P08816438A0316 . O
. . O O

To P09420219A0284 TO O
facilitate P09420219A0284 VB O
the P09420219A0284 DT O
investigation P09420219A0284 NN O
of P09420219A0284 IN O
parameters P09420219A0284 NNS O
that P09420219A0284 WDT O
govern P09420219A0284 VBP O
selective P09420219A0284 JJ O
export P09420219A0284 NN O
in P09420219A0284 IN O
adenovirus-infected P09420219A0284 JJ O
cells P09420219A0284 NNS O
, P09420219A0284 , O
we P09420219A0284 PRP O
constructed P09420219A0284 VBD O
a P09420219A0284 DT O
marked P09420219A0284 JJ O
human P09420219A0284 JJ O
beta-actin P09420219A0284 JJ I-UN
minigene P09420219A0284 NN I-UN
under P09420219A0284 IN O
the P09420219A0284 DT O
control P09420219A0284 NN O
of P09420219A0284 IN O
the P09420219A0284 DT O
glucocorticoid-inducible P09420219A0284 JJ I-UN
enhancer-promoter P09420219A0284 NN I-UN
of P09420219A0284 IN O
mouse P09420219A0284 NN O
mammary P09420219A0284 JJ O
tumor P09420219A0284 NN O
virus P09420219A0284 NN O
and P09420219A0284 CC O
introduced P09420219A0284 VBD O
it P09420219A0284 PRP O
into P09420219A0284 IN O
the P09420219A0284 DT O
left P09420219A0284 JJ O
end P09420219A0284 NN O
of P09420219A0284 IN O
the P09420219A0284 DT O
adenovirus P09420219A0284 NN O
type P09420219A0284 NN O
5 P09420219A0284 CD O
( P09420219A0284 ( O
Ad5 P09420219A0284 NNP O
) P09420219A0284 ) O
genome P09420219A0284 NN O
. P09420219A0284 . O
. . O O

Two P01097100A0217 CD O
patients P01097100A0217 NNS O
were P01097100A0217 VBD O
treated P01097100A0217 VBN O
with P01097100A0217 IN O
both P01097100A0217 DT O
regimens P01097100A0217 NNS O
. P01097100A0217 . O
. . O O

The P08955189A1198 DT O
0.22-kb P08955189A1198 JJ O
NheI P08955189A1198 NNP I-UN
/ P08955189A1198 NNP O
BglII P08955189A1198 NNP I-UN
promoter P08955189A1198 NN O
exhibited P08955189A1198 VBD O
PMA P08955189A1198 NNP O
inducibility P08955189A1198 NN O
in P08955189A1198 IN O
myeloid P08955189A1198 JJ O
cells P08955189A1198 NNS O
and P08955189A1198 CC O
contained P08955189A1198 VBD O
a P08955189A1198 DT O
PMA-responsive P08955189A1198 JJ O
element P08955189A1198 NN O
recognized P08955189A1198 VBN O
by P08955189A1198 IN O
Sp1 P08955189A1198 NNP I-UN
and P08955189A1198 CC O
EGR-1 P08955189A1198 NNP I-UN
transcription P08955189A1198 NN I-UN
factors P08955189A1198 NNS I-UN
. P08955189A1198 . O
. . O O

Plasma P01649539T0000 NNP O
vitamin P01649539T0000 NN O
E P01649539T0000 NNP O
, P01649539T0000 , O
total P01649539T0000 JJ O
lipids P01649539T0000 NNS O
and P01649539T0000 CC O
myeloperoxidase P01649539T0000 NN I-UN
levels P01649539T0000 NNS O
during P01649539T0000 IN O
spinal P01649539T0000 JJ O
surgery P01649539T0000 NN O
. P01649539T0000 . O
. . O O

Pharmacology P02913368A1037 NNP O
studies P02913368A1037 NNS O
with P02913368A1037 IN O
potassium P02913368A1037 NN O
chloride P02913368A1037 NN O
and P02913368A1037 CC O
acetylcholine P02913368A1037 NN O
suggest P02913368A1037 VBP O
that P02913368A1037 IN O
raveron P02913368A1037 NN O
acts P02913368A1037 NNS O
as P02913368A1037 IN O
a P02913368A1037 DT O
calcium P02913368A1037 NN O
antagonist P02913368A1037 NN O
by P02913368A1037 IN O
blocking P02913368A1037 VBG O
the P02913368A1037 DT O
influx P02913368A1037 NN O
of P02913368A1037 IN O
extracellular P02913368A1037 JJ O
calcium P02913368A1037 NN O
. P02913368A1037 . O
. . O O

E2F P09242506A1033 NNP I-UN
is P09242506A1033 VBZ O
a P09242506A1033 DT O
heterodimeric P09242506A1033 JJ O
complex P09242506A1033 JJ O
consisting P09242506A1033 NN O
of P09242506A1033 IN O
E2F P09242506A1033 NNP I-UN
family P09242506A1033 NN I-UN
members P09242506A1033 NNS I-UN
( P09242506A1033 ( I-UN
1-5 P09242506A1033 JJ I-UN
) P09242506A1033 ) I-UN
and P09242506A1033 CC O
DP P09242506A1033 NNP I-UN
proteins P09242506A1033 NNS I-UN
( P09242506A1033 ( I-UN
1-3 P09242506A1033 JJ I-UN
) P09242506A1033 ) I-UN
. P09242506A1033 . O
. . O O

No P11167019A1249 DT O
'TATA P11167019A1249 NNP O
' P11167019A1249 POS O
motif P11167019A1249 NN O
was P11167019A1249 VBD O
identified P11167019A1249 VBN O
near P11167019A1249 IN O
either P11167019A1249 CC O
the P11167019A1249 DT O
GABPalpha P11167019A1249 NNP I-UN
or P11167019A1249 CC O
ATPsynCF6 P11167019A1249 NNP I-UN
transcription P11167019A1249 JJ O
start P11167019A1249 NN O
sites P11167019A1249 NNS O
. P11167019A1249 . O
. . O O

Consistent P08414502A0244 JJ O
with P08414502A0244 IN O
the P08414502A0244 DT O
hypothesis P08414502A0244 NN O
that P08414502A0244 IN O
it P08414502A0244 PRP O
acts P08414502A0244 VBZ O
as P08414502A0244 IN O
transcriptional P08414502A0244 JJ O
regulator P08414502A0244 NN O
, P08414502A0244 , O
wild-type P08414502A0244 JJ I-UN
p53 P08414502A0244 NN I-UN
protein P08414502A0244 NN I-UN
binds P08414502A0244 VBZ O
DNA P08414502A0244 NNP O
and P08414502A0244 CC O
activates P08414502A0244 VBZ O
transcription P08414502A0244 NN O
of P08414502A0244 IN O
several P08414502A0244 JJ O
promoters P08414502A0244 NNS O
. P08414502A0244 . O
. . O O

These P02153243A0965 DT O
data P02153243A0965 NNS O
strongly P02153243A0965 RB O
implicate P02153243A0965 VBP O
the P02153243A0965 DT O
normal P02153243A0965 JJ O
product P02153243A0965 NN O
of P02153243A0965 IN O
the P02153243A0965 DT O
int-2 P02153243A0965 JJ I-UN
gene P02153243A0965 NN I-UN
, P02153243A0965 , O
which P02153243A0965 WDT O
is P02153243A0965 VBZ O
related P02153243A0965 VBN O
to P02153243A0965 TO O
the P02153243A0965 DT O
fibroblast P02153243A0965 NN I-UN
growth P02153243A0965 NN I-UN
factor P02153243A0965 NN I-UN
family P02153243A0965 NN I-UN
, P02153243A0965 , O
as P02153243A0965 IN O
a P02153243A0965 DT O
contributory P02153243A0965 NN O
factor P02153243A0965 NN O
in P02153243A0965 IN O
virally P02153243A0965 RB O
induced P02153243A0965 JJ O
mammary P02153243A0965 JJ O
tumors P02153243A0965 NNS O
. P02153243A0965 . O
. . O O

Experimental P00606849T0000 JJ O
ischemic P00606849T0000 JJ O
heart P00606849T0000 NN O
disease P00606849T0000 NN O
induced P00606849T0000 VBN O
by P00606849T0000 IN O
thromboxane P00606849T0000 NN O
A2 P00606849T0000 NNP O
in P00606849T0000 IN O
rabbits P00606849T0000 NNS O
. P00606849T0000 . O
. . O O

Both P10625683A0091 DT O
receptors P10625683A0091 NNS O
utilize P10625683A0091 VBP O
protein P10625683A0091 JJ I-UN
tyrosine P10625683A0091 NN I-UN
kinases P10625683A0091 NNS I-UN
( P10625683A0091 ( O
PTKs P10625683A0091 NNP I-UN
) P10625683A0091 ) O
for P10625683A0091 IN O
the P10625683A0091 DT O
phosphorylation P10625683A0091 NN O
of P10625683A0091 IN O
various P10625683A0091 JJ O
signaling P10625683A0091 VBG O
molecules P10625683A0091 NNS O
, P10625683A0091 , O
a P10625683A0091 DT O
process P10625683A0091 NN O
that P10625683A0091 WDT O
is P10625683A0091 VBZ O
critical P10625683A0091 JJ O
for P10625683A0091 IN O
the P10625683A0091 DT O
function P10625683A0091 NN O
of P10625683A0091 IN O
both P10625683A0091 DT O
receptors P10625683A0091 NNS O
. P10625683A0091 . O
. . O O

Our P09434979A0790 PRP$ O
results P09434979A0790 NNS O
showed P09434979A0790 VBD O
that P09434979A0790 IN O
compared P09434979A0790 VBN O
to P09434979A0790 TO O
the P09434979A0790 DT O
primary P09434979A0790 JJ O
photon P09434979A0790 NN O
fluence P09434979A0790 NN O
, P09434979A0790 , O
the P09434979A0790 DT O
extra-focal P09434979A0790 JJ O
photon P09434979A0790 NN O
fluence P09434979A0790 NN O
from P09434979A0790 IN O
the P09434979A0790 DT O
primary P09434979A0790 JJ O
collimator P09434979A0790 NN O
and P09434979A0790 CC O
the P09434979A0790 DT O
flattening P09434979A0790 NN O
filter P09434979A0790 NN O
was P09434979A0790 VBD O
11 P09434979A0790 CD O
% P09434979A0790 NN O
-16 P09434979A0790 CD O
% P09434979A0790 NN O
at P09434979A0790 IN O
the P09434979A0790 DT O
isocenter P09434979A0790 NN O
, P09434979A0790 , O
among P09434979A0790 IN O
which P09434979A0790 WDT O
70 P09434979A0790 CD O
% P09434979A0790 NN O
was P09434979A0790 VBD O
contributed P09434979A0790 VBN O
by P09434979A0790 IN O
the P09434979A0790 DT O
flattening P09434979A0790 NN O
filter P09434979A0790 NN O
. P09434979A0790 . O
. . O O

Upon P07743515A0223 IN O
analysis P07743515A0223 NN O
of P07743515A0223 IN O
the P07743515A0223 DT O
tissue P07743515A0223 NN O
distribution P07743515A0223 NN O
of P07743515A0223 IN O
AAMP P07743515A0223 NNP I-UN
, P07743515A0223 , O
it P07743515A0223 PRP O
was P07743515A0223 VBD O
found P07743515A0223 VBN O
to P07743515A0223 TO O
be P07743515A0223 VB O
expressed P07743515A0223 VBN O
strongly P07743515A0223 RB O
in P07743515A0223 IN O
endothelial P07743515A0223 JJ O
cells P07743515A0223 NNS O
, P07743515A0223 , O
cytotrophoblasts P07743515A0223 NNS O
, P07743515A0223 , O
and P07743515A0223 CC O
poorly P07743515A0223 RB O
differentiated P07743515A0223 VBN O
colon P07743515A0223 NN O
adenocarcinoma P07743515A0223 NN O
cells P07743515A0223 NNS O
found P07743515A0223 VBN O
in P07743515A0223 IN O
lymphatics P07743515A0223 NNS O
. P07743515A0223 . O
. . O O

Risk P06142279T0000 NN O
of P06142279T0000 IN O
HTLV P06142279T0000 NNP O
infection P06142279T0000 NN O
in P06142279T0000 IN O
patients P06142279T0000 NNS O
on P06142279T0000 IN O
haemodialysis P06142279T0000 NN O
. P06142279T0000 . O
. . O O

Against P11600365A0471 IN O
gram-positive P11600365A0471 JJ O
organisms P11600365A0471 NNS O
, P11600365A0471 , O
E-4767 P11600365A0471 NNP O
and P11600365A0471 CC O
E-5065 P11600365A0471 NNP O
were P11600365A0471 VBD O
, P11600365A0471 , O
in P11600365A0471 IN O
general P11600365A0471 JJ O
, P11600365A0471 , O
eight- P11600365A0471 JJ O
and P11600365A0471 CC O
fourfold P11600365A0471 VBD O
more P11600365A0471 RBR O
active P11600365A0471 JJ O
than P11600365A0471 IN O
tosufloxacin P11600365A0471 NN O
, P11600365A0471 , O
which P11600365A0471 WDT O
is P11600365A0471 VBZ O
the P11600365A0471 DT O
most P11600365A0471 RBS O
potent P11600365A0471 NN O
of P11600365A0471 IN O
the P11600365A0471 DT O
reference P11600365A0471 NN O
compounds P11600365A0471 NNS O
. P11600365A0471 . O
. . O O

Immunoprecipitation P10428862A0834 NN O
experiments P10428862A0834 NNS O
using P10428862A0834 VBG O
DokR-specific P10428862A0834 JJ I-UN
antibodies P10428862A0834 NNS I-UN
revealed P10428862A0834 VBD O
an P10428862A0834 DT O
interaction P10428862A0834 NN O
between P10428862A0834 IN O
endogenous P10428862A0834 JJ I-UN
DokR P10428862A0834 NNP I-UN
and P10428862A0834 CC O
a P10428862A0834 DT O
150-kDa P10428862A0834 JJ O
protein P10428862A0834 NN O
that P10428862A0834 WDT O
is P10428862A0834 VBZ O
tyrosine-phosphorylated P10428862A0834 JJ O
in P10428862A0834 IN O
EGF-stimulated P10428862A0834 JJ O
BaF P10428862A0834 NNP O
/ P10428862A0834 NNP O
3 P10428862A0834 CD O
cells P10428862A0834 NNS O
. P10428862A0834 . O
. . O O

An P08994968A0926 DT O
N-terminal P08994968A0926 JJ O
arm P08994968A0926 NN O
from P08994968A0926 IN O
each P08994968A0926 DT O
subunit P08994968A0926 NN O
wraps P08994968A0926 VBZ O
around P08994968A0926 IN O
the P08994968A0926 DT O
dinucleotide-binding P08994968A0926 JJ O
domain P08994968A0926 NN O
of P08994968A0926 IN O
an P08994968A0926 DT O
adjacent P08994968A0926 JJ O
subunit P08994968A0926 NN O
, P08994968A0926 , O
covering P08994968A0926 VBG O
the P08994968A0926 DT O
adenine P08994968A0926 JJ O
ring P08994968A0926 NN O
of P08994968A0926 IN O
NADP P08994968A0926 NNP O
. P08994968A0926 . O
. . O O

In P08499903A0883 IN O
17 P08499903A0883 CD O
patients P08499903A0883 NNS O
with P08499903A0883 IN O
deletions P08499903A0883 NNS O
, P08499903A0883 , O
the P08499903A0883 DT O
parental P08499903A0883 JJ O
origin P08499903A0883 NN O
of P08499903A0883 IN O
deletion P08499903A0883 NN O
was P08499903A0883 VBD O
determined P08499903A0883 VBN O
. P08499903A0883 . O
. . O O

The P09325322A1293 DT O
inhibition P09325322A1293 NN O
by P09325322A1293 IN O
cytosolic P09325322A1293 JJ O
Ca2+ P09325322A1293 NNP O
was P09325322A1293 VBD O
caused P09325322A1293 VBN O
by P09325322A1293 IN O
a P09325322A1293 DT O
decrease P09325322A1293 NN O
in P09325322A1293 IN O
cooperativity P09325322A1293 NN O
and P09325322A1293 CC O
by P09325322A1293 IN O
a P09325322A1293 DT O
shift P09325322A1293 NN O
in P09325322A1293 IN O
EC50 P09325322A1293 NNP O
toward P09325322A1293 IN O
higher P09325322A1293 JJR O
InsP3 P09325322A1293 NNP O
concentrations P09325322A1293 NNS O
. P09325322A1293 . O
. . O O

The P10843716A0406 DT O
tryptase P10843716A0406 NN I-UN
locus P10843716A0406 NN I-UN
also P10843716A0406 RB O
contains P10843716A0406 VBZ O
at P10843716A0406 IN O
least P10843716A0406 JJS O
four P10843716A0406 CD O
tryptase-like P10843716A0406 JJ I-UN
pseudogenes P10843716A0406 NNS I-UN
, P10843716A0406 , O
including P10843716A0406 VBG O
mastin P10843716A0406 NN I-UN
, P10843716A0406 , O
a P10843716A0406 DT O
gene P10843716A0406 NN O
expressed P10843716A0406 VBN O
in P10843716A0406 IN O
dogs P10843716A0406 NNS O
but P10843716A0406 CC O
not P10843716A0406 RB O
in P10843716A0406 IN O
humans P10843716A0406 NNS O
. P10843716A0406 . O
. . O O

In P09165039A1372 IN O
conclusion P09165039A1372 NN O
, P09165039A1372 , O
marmoset P09165039A1372 VB I-UN
monkey P09165039A1372 NN I-UN
LHR P09165039A1372 NNP I-UN
seems P09165039A1372 VBZ O
to P09165039A1372 TO O
lack P09165039A1372 VB O
the P09165039A1372 DT O
sequence P09165039A1372 NN O
corresponding P09165039A1372 VBG O
to P09165039A1372 TO O
exon P09165039A1372 VB O
10 P09165039A1372 CD O
of P09165039A1372 IN O
the P09165039A1372 DT O
LHR P09165039A1372 NNP I-UN
gene P09165039A1372 NN I-UN
in P09165039A1372 IN O
other P09165039A1372 JJ O
mammalian P09165039A1372 JJ O
species P09165039A1372 NNS O
. P09165039A1372 . O
. . O O

11-Aminoundecanoyl-SK-NH2 P09115247A2069 JJ O
and P09115247A2069 CC O
11-aminoundecanoyl-SH-NH2 P09115247A2069 JJ O
establish P09115247A2069 VB O
that P09115247A2069 IN O
a P09115247A2069 DT O
simple P09115247A2069 JJ O
alkyl P09115247A2069 NN O
backbone P09115247A2069 NN O
can P09115247A2069 MD O
maintain P09115247A2069 VB O
an P09115247A2069 DT O
appropriate P09115247A2069 JJ O
distance P09115247A2069 NN O
between P09115247A2069 IN O
three P09115247A2069 CD O
elements P09115247A2069 NNS O
critical P09115247A2069 JJ O
for P09115247A2069 IN O
recognition P09115247A2069 NN O
by P09115247A2069 IN O
the P09115247A2069 DT O
fungal P09115247A2069 JJ O
enzyme P09115247A2069 NN O
's P09115247A2069 POS O
peptide-binding P09115247A2069 JJ O
site P09115247A2069 NN O
: P09115247A2069 : O
a P09115247A2069 DT O
simple P09115247A2069 JJ O
omega-terminal P09115247A2069 JJ O
amino P09115247A2069 NN O
group P09115247A2069 NN O
, P09115247A2069 , O
a P09115247A2069 DT O
beta-hydroxyl P09115247A2069 NN O
, P09115247A2069 , O
and P09115247A2069 CC O
an P09115247A2069 DT O
epsilon-amino P09115247A2069 JJ O
group P09115247A2069 NN O
or P09115247A2069 CC O
an P09115247A2069 DT O
imidazole P09115247A2069 NN O
. P09115247A2069 . O
. . O O

Urological P07345217A0000 JJ O
complications P07345217A0000 NNS O
are P07345217A0000 VBP O
frequent P07345217A0000 JJ O
during P07345217A0000 IN O
and P07345217A0000 CC O
after P07345217A0000 IN O
the P07345217A0000 DT O
treatment P07345217A0000 NN O
of P07345217A0000 IN O
gynecological P07345217A0000 JJ O
malignancy P07345217A0000 NN O
. P07345217A0000 . O
. . O O

RESULTS P10218357A0486 NNP O
AND P10218357A0486 CC O
CONCLUSIONS P10218357A0486 NNP O
: P10218357A0486 : O
Brandt P10218357A0486 NNP O
's P10218357A0486 POS O
double P10218357A0486 JJ O
cuff-tubes P10218357A0486 NNS O
( P10218357A0486 ( O
G2 P10218357A0486 NNP O
) P10218357A0486 ) O
succeed P10218357A0486 VB O
in P10218357A0486 IN O
avoiding P10218357A0486 VBG O
uncontrolled P10218357A0486 JJ O
increase P10218357A0486 NN O
of P10218357A0486 IN O
cuff-pressure P10218357A0486 NN O
during P10218357A0486 IN O
anaesthesia P10218357A0486 NN O
with P10218357A0486 IN O
N2O P10218357A0486 NNP O
. P10218357A0486 . O
. . O O

The P07836471A0375 DT O
deduced P07836471A0375 JJ O
protein P07836471A0375 NN O
sequence P07836471A0375 NN O
was P07836471A0375 VBD O
88 P07836471A0375 CD O
% P07836471A0375 NN O
homologous P07836471A0375 JJ O
to P07836471A0375 TO O
that P07836471A0375 DT O
of P07836471A0375 IN O
hNUC P07836471A0375 NN I-UN
I P07836471A0375 PRP I-UN
, P07836471A0375 , O
isolated P07836471A0375 VBD O
from P07836471A0375 IN O
human P07836471A0375 JJ O
osteosarcoma P07836471A0375 NN O
cells P07836471A0375 NNS O
. P07836471A0375 . O
. . O O

Endothelial P01943184A1050 JJ O
cells P01943184A1050 NNS O
stored P01943184A1050 VBN O
with P01943184A1050 IN O
University P01943184A1050 NNP O
of P01943184A1050 IN O
Wisconsin P01943184A1050 NNP O
solution P01943184A1050 NN O
excluded P01943184A1050 VBD O
trypan P01943184A1050 NN O
blue P01943184A1050 NN O
better P01943184A1050 RBR O
( P01943184A1050 ( O
1.0 P01943184A1050 CD O
% P01943184A1050 NN O
+ P01943184A1050 NNP O
/ P01943184A1050 NNP O
- P01943184A1050 : O
0.5 P01943184A1050 CD O
% P01943184A1050 NN O
cells P01943184A1050 NNS O
stained P01943184A1050 VBN O
, P01943184A1050 , O
p P01943184A1050 VBZ O
less P01943184A1050 JJR O
than P01943184A1050 IN O
0.001 P01943184A1050 CD O
. P01943184A1050 . O
. . O O

Interferon-alpha P10323463T0000b NNP I-UN
may P10323463T0000b MD O
exacerbate P10323463T0000b VB O
cryoblobulinemia-related P10323463T0000b JJ O
ischemic P10323463T0000b JJ O
manifestations P10323463T0000b NNS O
: P10323463T0000b : O
an P10323463T0000b DT O
adverse P10323463T0000b JJ O
effect P10323463T0000b NN O
potentially P10323463T0000b RB O
related P10323463T0000b VBN O
to P10323463T0000b TO O
its P10323463T0000b PRP$ O
anti-angiogenic P10323463T0000b JJ O
activity P10323463T0000b NN O
. P10323463T0000b . O
. . O O

Molecular P09192769T0000 JJ O
cloning P09192769T0000 NN O
and P09192769T0000 CC O
characterization P09192769T0000 NN O
of P09192769T0000 IN O
a P09192769T0000 DT O
cDNA P09192769T0000 NN O
, P09192769T0000 , O
CHEMR1 P09192769T0000 NNP I-UN
, P09192769T0000 , O
encoding P09192769T0000 VBG O
a P09192769T0000 DT O
chemokine P09192769T0000 NN O
receptor P09192769T0000 NN O
with P09192769T0000 IN O
a P09192769T0000 DT O
homology P09192769T0000 NN O
to P09192769T0000 TO O
the P09192769T0000 DT O
human P09192769T0000 JJ I-UN
C-C P09192769T0000 NNP I-UN
chemokine P09192769T0000 NN I-UN
receptor P09192769T0000 NN I-UN
, P09192769T0000 , O
CCR-4 P09192769T0000 NNP I-UN
. P09192769T0000 . O
. . O O

Mutations P08626493A1468 NNS O
within P08626493A1468 IN O
conserved P08626493A1468 JJ O
region P08626493A1468 NN O
2 P08626493A1468 CD O
( P08626493A1468 ( O
CR2 P08626493A1468 NNP O
) P08626493A1468 ) O
of P08626493A1468 IN O
E1A P08626493A1468 NNP I-UN
that P08626493A1468 WDT O
inhibit P08626493A1468 VBZ O
the P08626493A1468 DT O
binding P08626493A1468 NN O
of P08626493A1468 IN O
E1A P08626493A1468 NNP I-UN
to P08626493A1468 TO O
the P08626493A1468 DT O
retinoblastoma P08626493A1468 NN I-UN
gene P08626493A1468 NN I-UN
product P08626493A1468 NN I-UN
( P08626493A1468 ( O
pRb P08626493A1468 NN I-UN
) P08626493A1468 ) O
further P08626493A1468 RB O
enhanced P08626493A1468 VBD O
the P08626493A1468 DT O
stimulation P08626493A1468 NN O
of P08626493A1468 IN O
transcription P08626493A1468 NN O
from P08626493A1468 IN O
the P08626493A1468 DT O
PEPCK P08626493A1468 NNP I-UN
promoter P08626493A1468 NN I-UN
by P08626493A1468 IN O
2 P08626493A1468 CD O
3-fold P08626493A1468 JJ O
compared P08626493A1468 VBN O
with P08626493A1468 IN O
wild P08626493A1468 JJ I-UN
type P08626493A1468 NN I-UN
E1A P08626493A1468 NNP I-UN
. P08626493A1468 . O
. . O O

A P11486476A0147 DT O
prospective P11486476A0147 JJ O
trial P11486476A0147 NN O
was P11486476A0147 VBD O
undertaken P11486476A0147 VBN O
to P11486476A0147 TO O
determine P11486476A0147 VB O
( P11486476A0147 ( O
1 P11486476A0147 CD O
) P11486476A0147 ) O
clinical P11486476A0147 JJ O
characteristics P11486476A0147 NNS O
of P11486476A0147 IN O
patients P11486476A0147 NNS O
with P11486476A0147 IN O
chest P11486476A0147 JJ O
pain P11486476A0147 NN O
; P11486476A0147 : O
( P11486476A0147 ( O
2 P11486476A0147 CD O
) P11486476A0147 ) O
value P11486476A0147 NN O
of P11486476A0147 IN O
cardiac P11486476A0147 JJ O
markers P11486476A0147 NNS O
troponin P11486476A0147 VBP I-UN
T P11486476A0147 NNP I-UN
, P11486476A0147 , O
myoglobin P11486476A0147 NN I-UN
and P11486476A0147 CC O
CK-MB P11486476A0147 JJ O
mass P11486476A0147 NN O
in P11486476A0147 IN O
differentiating P11486476A0147 VBG O
cardiac P11486476A0147 NN O
and P11486476A0147 CC O
noncardiac P11486476A0147 JJ O
chest P11486476A0147 NN O
pain P11486476A0147 NN O
; P11486476A0147 : O
( P11486476A0147 ( O
3 P11486476A0147 CD O
) P11486476A0147 ) O
the P11486476A0147 DT O
proportion P11486476A0147 NN O
of P11486476A0147 IN O
patients P11486476A0147 NNS O
with P11486476A0147 IN O
ACS P11486476A0147 NNP O
in P11486476A0147 IN O
whom P11486476A0147 WP O
these P11486476A0147 DT O
markers P11486476A0147 NNS O
provided P11486476A0147 VBD O
helpful P11486476A0147 JJ O
additional P11486476A0147 JJ O
information P11486476A0147 NN O
on P11486476A0147 IN O
admission P11486476A0147 NN O
and P11486476A0147 CC O
afterwards P11486476A0147 NNS O
. P11486476A0147 . O
. . O O

The P03352254A0203 DT O
same P03352254A0203 JJ O
rhythmic P03352254A0203 JJ O
structure P03352254A0203 NN O
enables P03352254A0203 VBZ O
a P03352254A0203 DT O
prediction P03352254A0203 NN O
to P03352254A0203 TO O
be P03352254A0203 VB O
made P03352254A0203 VBN O
concerning P03352254A0203 VBG O
when P03352254A0203 WRB O
vowels P03352254A0203 NNS O
of P03352254A0203 IN O
stressed P03352254A0203 JJ O
syllables P03352254A0203 NNS O
will P03352254A0203 MD O
be P03352254A0203 VB O
auditorily P03352254A0203 RB O
perceived P03352254A0203 VBN O
. P03352254A0203 . O
. . O O

On P05065548T0075 IN O
the P05065548T0075 DT O
constituents P05065548T0075 NNS O
of P05065548T0075 IN O
Dryopteris P05065548T0075 NNP O
polylepis P05065548T0075 NN O
. P05065548T0075 . O
. . O O

SUMMARY P08998115A0114 NNP O
BACKGROUND P08998115A0114 NNP O
DATA P08998115A0114 NNP O
: P08998115A0114 : O
Melanoma P08998115A0114 NNP O
care P08998115A0114 NN O
has P08998115A0114 VBZ O
not P08998115A0114 RB O
changed P08998115A0114 VBN O
significantly P08998115A0114 RB O
in P08998115A0114 IN O
the P08998115A0114 DT O
last P08998115A0114 JJ O
20 P08998115A0114 CD O
years P08998115A0114 NNS O
, P08998115A0114 , O
and P08998115A0114 CC O
the P08998115A0114 DT O
controversy P08998115A0114 NN O
of P08998115A0114 IN O
elective P08998115A0114 JJ O
lymph P08998115A0114 NN O
node P08998115A0114 NN O
dissections P08998115A0114 NNS O
in P08998115A0114 IN O
this P08998115A0114 DT O
disease P08998115A0114 NN O
continues P08998115A0114 VBZ O
to P08998115A0114 TO O
be P08998115A0114 VB O
discussed P08998115A0114 VBN O
. P08998115A0114 . O
. . O O

Levels P07592730A0204 NNS O
of P07592730A0204 IN O
TSG-14 P07592730A0204 NNP I-UN
protein P07592730A0204 NN I-UN
( P07592730A0204 ( O
also P07592730A0204 RB O
termed P07592730A0204 VBN O
PTX-3 P07592730A0204 NNP I-UN
) P07592730A0204 ) O
become P07592730A0204 NN O
elevated P07592730A0204 VBN O
in P07592730A0204 IN O
the P07592730A0204 DT O
serum P07592730A0204 NN O
of P07592730A0204 IN O
mice P07592730A0204 NNS O
and P07592730A0204 CC O
humans P07592730A0204 NNS O
after P07592730A0204 IN O
injection P07592730A0204 NN O
with P07592730A0204 IN O
bacterial P07592730A0204 JJ O
lipopolysaccharide P07592730A0204 NN O
, P07592730A0204 , O
but P07592730A0204 CC O
in P07592730A0204 IN O
contrast P07592730A0204 NN O
to P07592730A0204 TO O
conventional P07592730A0204 JJ O
acute P07592730A0204 JJ O
phase P07592730A0204 NN O
proteins P07592730A0204 NNS O
, P07592730A0204 , O
the P07592730A0204 DT O
bulk P07592730A0204 NN O
of P07592730A0204 IN O
TSG-14 P07592730A0204 JJ I-UN
synthesis P07592730A0204 NN O
in P07592730A0204 IN O
the P07592730A0204 DT O
intact P07592730A0204 JJ O
organism P07592730A0204 NN O
occurs P07592730A0204 VBZ O
outside P07592730A0204 IN O
the P07592730A0204 DT O
liver P07592730A0204 NN O
. P07592730A0204 . O
. . O O

Deletion P08432696A1117 NN O
of P08432696A1117 IN O
the P08432696A1117 DT O
apeA P08432696A1117 JJ I-UN
gene P08432696A1117 NN I-UN
, P08432696A1117 , O
either P08432696A1117 CC O
with P08432696A1117 IN O
or P08432696A1117 CC O
without P08432696A1117 IN O
deletion P08432696A1117 NN O
of P08432696A1117 IN O
other P08432696A1117 JJ O
proteinases P08432696A1117 NNS O
( P08432696A1117 ( O
protease P08432696A1117 NN I-UN
IV P08432696A1117 NNP I-UN
and P08432696A1117 CC O
aminopeptidase P08432696A1117 VB I-UN
N P08432696A1117 NNP I-UN
) P08432696A1117 ) O
, P08432696A1117 , O
did P08432696A1117 VBD O
not P08432696A1117 RB O
have P08432696A1117 VB O
any P08432696A1117 DT O
effect P08432696A1117 NN O
on P08432696A1117 IN O
cell P08432696A1117 NN O
growth P08432696A1117 NN O
in P08432696A1117 IN O
the P08432696A1117 DT O
various P08432696A1117 JJ O
media P08432696A1117 NNS O
tested P08432696A1117 VBN O
. P08432696A1117 . O
. . O O

DtxR P08106325A0000 NNP I-UN
is P08106325A0000 VBZ O
an P08106325A0000 DT O
iron-dependent P08106325A0000 JJ O
sequence-specific P08106325A0000 JJ O
DNA-binding P08106325A0000 NNP O
protein P08106325A0000 NN O
that P08106325A0000 WDT O
binds P08106325A0000 VBZ O
to P08106325A0000 TO O
the P08106325A0000 DT O
tox P08106325A0000 NN I-UN
operator P08106325A0000 NN I-UN
, P08106325A0000 , O
an P08106325A0000 DT O
inverted-repeat P08106325A0000 JJ O
nucleotide P08106325A0000 JJ O
sequence P08106325A0000 NN O
located P08106325A0000 VBN O
upstream P08106325A0000 RB O
from P08106325A0000 IN O
the P08106325A0000 DT O
diphtheria P08106325A0000 NN I-UN
toxin P08106325A0000 NN I-UN
gene P08106325A0000 NN I-UN
. P08106325A0000 . O
. . O O

Further P11046153A1052 RB O
, P11046153A1052 , O
Tax-mediated P11046153A1052 JJ O
apoptosis P11046153A1052 NN O
was P11046153A1052 VBD O
effectively P11046153A1052 RB O
prevented P11046153A1052 VBN O
by P11046153A1052 IN O
ectopic P11046153A1052 JJ O
expression P11046153A1052 NN O
of P11046153A1052 IN O
the P11046153A1052 DT O
p300 P11046153A1052 NN I-UN
coactivator P11046153A1052 NN I-UN
. P11046153A1052 . O
. . O O

This P08662928A1153 DT O
regulation P08662928A1153 NN O
could P08662928A1153 MD O
not P08662928A1153 RB O
be P08662928A1153 VB O
appreciably P08662928A1153 RB O
modified P08662928A1153 VBN O
by P08662928A1153 IN O
enhanced P08662928A1153 JJ O
expression P08662928A1153 NN O
of P08662928A1153 IN O
STAT P08662928A1153 NNP I-UN
proteins P08662928A1153 NNS I-UN
. P08662928A1153 . O
. . O O

We P07592946A0261 PRP O
report P07592946A0261 VBP O
here P07592946A0261 RB O
the P07592946A0261 DT O
cloning P07592946A0261 NN O
of P07592946A0261 IN O
the P07592946A0261 DT O
murine P07592946A0261 NN O
p44 P07592946A0261 NN I-UN
MAP P07592946A0261 NNP I-UN
kinase P07592946A0261 NN I-UN
( P07592946A0261 ( O
extracellular P07592946A0261 JJ I-UN
signal-regulated P07592946A0261 JJ I-UN
kinase P07592946A0261 NN I-UN
1 P07592946A0261 CD I-UN
) P07592946A0261 ) O
gene P07592946A0261 NN O
, P07592946A0261 , O
the P07592946A0261 DT O
determination P07592946A0261 NN O
of P07592946A0261 IN O
its P07592946A0261 PRP$ O
intron P07592946A0261 NN O
/ P07592946A0261 NN O
exon P07592946A0261 NN O
boundaries P07592946A0261 NNS O
, P07592946A0261 , O
and P07592946A0261 CC O
the P07592946A0261 DT O
characterization P07592946A0261 NN O
of P07592946A0261 IN O
its P07592946A0261 PRP$ O
promoter P07592946A0261 NN O
. P07592946A0261 . O
. . O O

Problems P05309471T0000 NNS O
in P05309471T0000 IN O
the P05309471T0000 DT O
determination P05309471T0000 NN O
of P05309471T0000 IN O
the P05309471T0000 DT O
antigenic P05309471T0000 JJ O
content P05309471T0000 NN O
of P05309471T0000 IN O
influenza P05309471T0000 JJ O
vaccines P05309471T0000 NNS O
. P05309471T0000 . O
. . O O

Lac P01563343A0548 NN I-UN
operators P01563343A0548 NNS O
were P01563343A0548 VBD O
introduced P01563343A0548 VBN O
into P01563343A0548 IN O
several P01563343A0548 JJ O
positions P01563343A0548 NNS O
within P01563343A0548 IN O
the P01563343A0548 DT O
CAB P01563343A0548 NNP I-UN
promoter P01563343A0548 NN I-UN
and P01563343A0548 CC O
operator-free P01563343A0548 JJ O
plasmid P01563343A0548 NN O
was P01563343A0548 VBD O
used P01563343A0548 VBN O
as P01563343A0548 IN O
control P01563343A0548 NN O
. P01563343A0548 . O
. . O O

In P07520098A0211 IN O
the P07520098A0211 DT O
B6-derived P07520098A0211 NNP O
Db P07520098A0211 NNP I-UN
mutant P07520098A0211 JJ I-UN
B6.CH-2bm13 P07520098A0211 NNP I-UN
( P07520098A0211 ( I-UN
bm13 P07520098A0211 NN I-UN
) P07520098A0211 ) I-UN
strain P07520098A0211 NN O
, P07520098A0211 , O
part P07520098A0211 NN O
of P07520098A0211 IN O
the P07520098A0211 DT O
class P07520098A0211 NN I-UN
I P07520098A0211 PRP I-UN
Db P07520098A0211 VBP I-UN
antigen-presenting P07520098A0211 JJ I-UN
groove P07520098A0211 NN I-UN
is P07520098A0211 VBZ O
shaped P07520098A0211 VBN O
by P07520098A0211 IN O
a P07520098A0211 DT O
class P07520098A0211 NN I-UN
I P07520098A0211 PRP I-UN
Kb-encoded P07520098A0211 VBD I-UN
sequence P07520098A0211 NN I-UN
. P07520098A0211 . O
. . O O

Second P09735368A0636 JJ O
, P09735368A0636 , O
the P09735368A0636 DT O
wild-type P09735368A0636 JJ I-UN
m8 P09735368A0636 NN I-UN
3 P09735368A0636 CD I-UN
' P09735368A0636 '' I-UN
UTR P09735368A0636 NNP I-UN
strongly P09735368A0636 RB O
reduces P09735368A0636 VBZ O
accumulation P09735368A0636 NN O
of P09735368A0636 IN O
heterologous P09735368A0636 JJ O
transcripts P09735368A0636 NNS O
in P09735368A0636 IN O
vivo P09735368A0636 NN O
, P09735368A0636 , O
an P09735368A0636 DT O
activity P09735368A0636 NN O
that P09735368A0636 WDT O
requires P09735368A0636 VBZ O
its P09735368A0636 PRP$ O
K P09735368A0636 NNP O
box P09735368A0636 NN O
sequences P09735368A0636 NNS O
. P09735368A0636 . O
. . O O

Mobilization P10951848A0230 NN O
with P10951848A0230 IN O
cyclophosphamide P10951848A0230 NN O
and P10951848A0230 CC O
granulocyte-colony P10951848A0230 JJ I-UN
stimulating P10951848A0230 NN I-UN
factor P10951848A0230 NN I-UN
was P10951848A0230 VBD O
effective P10951848A0230 JJ O
in P10951848A0230 IN O
terms P10951848A0230 NNS O
of P10951848A0230 IN O
CD34+ P10951848A0230 NNP I-UN
cell P10951848A0230 NN O
shift P10951848A0230 NN O
to P10951848A0230 TO O
peripheral P10951848A0230 JJ O
blood P10951848A0230 NN O
and P10951848A0230 CC O
the P10951848A0230 DT O
good P10951848A0230 JJ O
quality P10951848A0230 NN O
autograft P10951848A0230 NN O
reliably P10951848A0230 RB O
led P10951848A0230 VBD O
to P10951848A0230 TO O
haematopoetic P10951848A0230 JJ O
recovery P10951848A0230 NN O
after P10951848A0230 IN O
megachemotherapy P10951848A0230 NN O
. P10951848A0230 . O
. . O O

In P10563789A1951 IN O
addition P10563789A1951 NN O
, P10563789A1951 , O
media P10563789A1951 NNS O
containing P10563789A1951 VBG O
F P10563789A1951 NNP I-UN
beta P10563789A1951 NN I-UN
alpha P10563789A1951 NN I-UN
/ P10563789A1951 NNP O
CG P10563789A1951 NNP I-UN
beta P10563789A1951 NN I-UN
displayed P10563789A1951 VBD O
high-affinity P10563789A1951 NN O
binding P10563789A1951 NN O
to P10563789A1951 TO O
both P10563789A1951 DT O
CG P10563789A1951 NNP I-UN
and P10563789A1951 CC I-UN
FSH P10563789A1951 NNP I-UN
receptors P10563789A1951 NNS I-UN
. P10563789A1951 . O
. . O O

Skin P10575642T0000 NNP O
pH P10575642T0000 NN O
changes P10575642T0000 NNS O
associated P10575642T0000 VBN O
with P10575642T0000 IN O
iontophoresis P10575642T0000 NN O
. P10575642T0000 . O
. . O O

Thus P00917721A0484 RB O
analysis P00917721A0484 NN O
indicated P00917721A0484 VBD O
no P00917721A0484 DT O
reliable P00917721A0484 JJ O
evidence P00917721A0484 NN O
that P00917721A0484 IN O
conscious P00917721A0484 JJ O
presleep P00917721A0484 JJ O
suggestions P00917721A0484 NNS O
become P00917721A0484 VBP O
incorporated P00917721A0484 VBN O
into P00917721A0484 IN O
dream P00917721A0484 NN O
content P00917721A0484 NN O
. P00917721A0484 . O
. . O O

Androgens P04305850T0000 NNS O
and P04305850T0000 CC O
growth P04305850T0000 NN O
. P04305850T0000 . O
. . O O

Responsibility P09397723T0001 NN O
matters P09397723T0001 NNS O
-- P09397723T0001 : O
this P09397723T0001 DT O
is P09397723T0001 VBZ O
a P09397723T0001 DT O
scientific P09397723T0001 JJ O
council P09397723T0001 NN O
. P09397723T0001 . O
. . O O

Effects P00477794T0000 NNS O
of P00477794T0000 IN O
chronic P00477794T0000 JJ O
descending P00477794T0000 VBG O
tractotomy P00477794T0000 NN O
on P00477794T0000 IN O
the P00477794T0000 DT O
response P00477794T0000 NN O
patterns P00477794T0000 NNS O
of P00477794T0000 IN O
neurons P00477794T0000 NNS O
in P00477794T0000 IN O
the P00477794T0000 DT O
trigeminal P00477794T0000 JJ O
nuclei P00477794T0000 NN O
principalis P00477794T0000 NN O
and P00477794T0000 CC O
oralis P00477794T0000 NN O
. P00477794T0000 . O
. . O O

The P08752714A0000 DT O
occurrence P08752714A0000 NN O
of P08752714A0000 IN O
multiple P08752714A0000 JJ O
malignancy P08752714A0000 NN O
was P08752714A0000 VBD O
studied P08752714A0000 VBN O
in P08752714A0000 IN O
674 P08752714A0000 CD O
patients P08752714A0000 NNS O
with P08752714A0000 IN O
hematologic P08752714A0000 JJ O
malignancies P08752714A0000 NNS O
who P08752714A0000 WP O
were P08752714A0000 VBD O
admitted P08752714A0000 VBN O
to P08752714A0000 TO O
this P08752714A0000 DT O
department P08752714A0000 NN O
during P08752714A0000 IN O
the P08752714A0000 DT O
past P08752714A0000 JJ O
10 P08752714A0000 CD O
years P08752714A0000 NNS O
. P08752714A0000 . O
. . O O

Together P09269900A1035 RB O
, P09269900A1035 , O
these P09269900A1035 DT O
results P09269900A1035 NNS O
suggest P09269900A1035 VBP O
that P09269900A1035 IN O
EGF P09269900A1035 NNP I-UN
/ P09269900A1035 NNP O
Ras P09269900A1035 NNP I-UN
/ P09269900A1035 NNP O
Raf P09269900A1035 NNP I-UN
induces P09269900A1035 VBZ O
transcription P09269900A1035 NN O
via P09269900A1035 IN O
combined P09269900A1035 JJ O
activation P09269900A1035 NN O
of P09269900A1035 IN O
ATF3 P09269900A1035 NNP I-UN
/ P09269900A1035 NNP O
c-Jun P09269900A1035 NN I-UN
and P09269900A1035 CC O
a P09269900A1035 DT O
52-kDa P09269900A1035 JJ O
nuclear P09269900A1035 JJ O
factor P09269900A1035 NN O
, P09269900A1035 , O
whereas P09269900A1035 WP O
JunD P09269900A1035 NNP I-UN
acts P09269900A1035 VBZ O
as P09269900A1035 IN O
a P09269900A1035 DT O
repressor P09269900A1035 NN O
of P09269900A1035 IN O
this P09269900A1035 DT O
response P09269900A1035 NN O
. P09269900A1035 . O
. . O O

100 P02371517A0747 CD O
of P02371517A0747 IN O
the P02371517A0747 DT O
patients P02371517A0747 NNS O
who P02371517A0747 WP O
would P02371517A0747 MD O
have P02371517A0747 VB O
died P02371517A0747 VBN O
survive P02371517A0747 JJ O
. P02371517A0747 . O
. . O O

Furthermore P08095872A1672 RB O
, P08095872A1672 , O
this P08095872A1672 DT O
study P08095872A1672 NN O
demonstrates P08095872A1672 VBZ O
that P08095872A1672 IN O
reduced P08095872A1672 VBD O
inotropy P08095872A1672 NN O
with P08095872A1672 IN O
timolol P08095872A1672 NN O
helped P08095872A1672 VBD O
uniform P08095872A1672 VB O
local P08095872A1672 JJ O
contraction P08095872A1672 NN O
as P08095872A1672 IN O
estimated P08095872A1672 VBN O
by P08095872A1672 IN O
the P08095872A1672 DT O
increased P08095872A1672 VBN O
LONG P08095872A1672 NNP O
/ P08095872A1672 NNP O
CIRC P08095872A1672 NNP O
ratio P08095872A1672 NN O
, P08095872A1672 , O
a P08095872A1672 DT O
transition P08095872A1672 NN O
that P08095872A1672 WDT O
could P08095872A1672 MD O
improve P08095872A1672 VB O
contraction P08095872A1672 NN O
efficacy P08095872A1672 NN O
. P08095872A1672 . O
. . O O

Multiple P11372959A1447 JJ O
regression P11372959A1447 NN O
analysis P11372959A1447 NN O
performed P11372959A1447 VBD O
between P11372959A1447 IN O
these P11372959A1447 DT O
long-term P11372959A1447 JJ O
abiotic P11372959A1447 JJ O
factors P11372959A1447 NNS O
and P11372959A1447 CC O
nymphal P11372959A1447 JJ O
abundance P11372959A1447 NN O
in P11372959A1447 IN O
positive P11372959A1447 JJ O
sites P11372959A1447 NNS O
showed P11372959A1447 VBD O
high P11372959A1447 JJ O
relationship P11372959A1447 NN O
( P11372959A1447 ( O
R2 P11372959A1447 NNP O
coefficients P11372959A1447 NNS O
) P11372959A1447 ) O
for P11372959A1447 IN O
every P11372959A1447 DT O
habitat P11372959A1447 NN O
category P11372959A1447 NN O
and P11372959A1447 CC O
explained P11372959A1447 VBD O
> P11372959A1447 RB O
50 P11372959A1447 CD O
% P11372959A1447 NN O
of P11372959A1447 IN O
the P11372959A1447 DT O
variation P11372959A1447 NN O
in P11372959A1447 IN O
tick P11372959A1447 JJ O
abundance P11372959A1447 NN O
. P11372959A1447 . O
. . O O

The P07413806T0000 DT O
centromedial P07413806T0000 JJ O
amygdala P07413806T0000 NN O
and P07413806T0000 CC O
gastric P07413806T0000 JJ O
pathology P07413806T0000 NN O
in P07413806T0000 IN O
rats P07413806T0000 NNS O
. P07413806T0000 . O
. . O O

A P09177169A0935 DT O
similar P09177169A0935 JJ O
chimera P09177169A0935 NN O
was P09177169A0935 VBD O
assembled P09177169A0935 VBN O
from P09177169A0935 IN O
the P09177169A0935 DT O
two P09177169A0935 CD O
halves P09177169A0935 NNS O
of P09177169A0935 IN O
the P09177169A0935 DT O
molecule P09177169A0935 NN O
expressed P09177169A0935 VBD O
separately P09177169A0935 RB O
in P09177169A0935 IN O
different P09177169A0935 JJ O
bacteria P09177169A0935 NNS O
and P09177169A0935 CC O
refolded P09177169A0935 VBD O
together P09177169A0935 RB O
. P09177169A0935 . O
. . O O

These P10206698A2041 DT O
findings P10206698A2041 NNS O
demonstrate P10206698A2041 VBP O
that P10206698A2041 IN O
signature-tagged P10206698A2041 JJ O
mutagenesis P10206698A2041 NN O
is P10206698A2041 VBZ O
a P10206698A2041 DT O
viable P10206698A2041 JJ O
approach P10206698A2041 NN O
to P10206698A2041 TO O
identify P10206698A2041 VB O
bacterial P10206698A2041 JJ O
genes P10206698A2041 NNS O
associated P10206698A2041 VBN O
with P10206698A2041 IN O
the P10206698A2041 DT O
ability P10206698A2041 NN O
to P10206698A2041 TO O
infect P10206698A2041 VB O
the P10206698A2041 DT O
urinary P10206698A2041 JJ O
tract P10206698A2041 NN O
. P10206698A2041 . O
. . O O

In P02740196A0704 IN O
Experiment P02740196A0704 NNP O
2 P02740196A0704 CD O
, P02740196A0704 , O
we P02740196A0704 PRP O
again P02740196A0704 RB O
used P02740196A0704 VBD O
classification P02740196A0704 NN O
, P02740196A0704 , O
but P02740196A0704 CC O
the P02740196A0704 DT O
fixed P02740196A0704 JJ O
standard P02740196A0704 NN O
75 P02740196A0704 CD O
was P02740196A0704 VBD O
not P02740196A0704 RB O
at P02740196A0704 IN O
the P02740196A0704 DT O
center P02740196A0704 NN O
of P02740196A0704 IN O
the P02740196A0704 DT O
range P02740196A0704 NN O
of P02740196A0704 IN O
target P02740196A0704 NN O
numbers P02740196A0704 NNS O
( P02740196A0704 ( O
20 P02740196A0704 CD O
, P02740196A0704 , O
21 P02740196A0704 CD O
, P02740196A0704 , O
... P02740196A0704 : O
. . O O

A P02139473A1603 DT O
contiguous P02139473A1603 JJ O
and P02139473A1603 CC O
sequentially P02139473A1603 RB O
occupied P02139473A1603 JJ O
secondary P02139473A1603 JJ O
Fur-binding P02139473A1603 NNP I-UN
site P02139473A1603 NN I-UN
in P02139473A1603 IN O
entC P02139473A1603 NN I-UN
was P02139473A1603 VBD O
protected P02139473A1603 VBN O
at P02139473A1603 IN O
higher P02139473A1603 JJR O
Fur P02139473A1603 NNP I-UN
concentrations P02139473A1603 NNS O
, P02139473A1603 , O
extending P02139473A1603 VBG O
the P02139473A1603 DT O
protected P02139473A1603 JJ O
region P02139473A1603 NN O
to P02139473A1603 TO O
+49 P02139473A1603 VB O
, P02139473A1603 , O
and P02139473A1603 CC O
sequestering P02139473A1603 VBG O
the P02139473A1603 DT O
putative P02139473A1603 JJ O
Shine-Dalgarno P02139473A1603 JJ O
sequence P02139473A1603 NN O
. P02139473A1603 . O
. . O O

Osteocalcin P09368026A0000 NNP I-UN
( P09368026A0000 ( O
OC P09368026A0000 NNP I-UN
) P09368026A0000 ) O
is P09368026A0000 VBZ O
a P09368026A0000 DT O
matrix P09368026A0000 JJ I-UN
calcium-binding P09368026A0000 JJ I-UN
protein P09368026A0000 NN I-UN
expressed P09368026A0000 VBN O
in P09368026A0000 IN O
osteoblasts P09368026A0000 NNS O
and P09368026A0000 CC O
odontoblasts P09368026A0000 NNS O
undergoing P09368026A0000 VBG O
mineralization P09368026A0000 NN O
. P09368026A0000 . O
. . O O

The P08992115A0199 DT O
progression P08992115A0199 NN O
of P08992115A0199 IN O
acute P08992115A0199 JJ O
bronchitis P08992115A0199 NN O
is P08992115A0199 VBZ O
associated P08992115A0199 VBN O
with P08992115A0199 IN O
elevated P08992115A0199 JJ O
blood P08992115A0199 NN O
concentrations P08992115A0199 NNS O
of P08992115A0199 IN O
acute-phase P08992115A0199 JJ O
proteins P08992115A0199 NNS O
, P08992115A0199 , O
KKS P08992115A0199 NNP I-UN
activation P08992115A0199 NN O
in P08992115A0199 IN O
the P08992115A0199 DT O
blood P08992115A0199 NN O
and P08992115A0199 CC O
high P08992115A0199 JJ O
serotonin P08992115A0199 NN O
and P08992115A0199 CC O
lactic P08992115A0199 JJ O
acid P08992115A0199 NN O
content P08992115A0199 NN O
in P08992115A0199 IN O
the P08992115A0199 DT O
humor P08992115A0199 NN O
condensated P08992115A0199 VBD O
from P08992115A0199 IN O
the P08992115A0199 DT O
exhaled P08992115A0199 JJ O
air P08992115A0199 NN O
. P08992115A0199 . O
. . O O

OKT3 P07879204T0000 NNP I-UN
prophylaxis P07879204T0000 NN O
improves P07879204T0000 VBZ O
long-term P07879204T0000 JJ O
renal P07879204T0000 JJ O
graft P07879204T0000 NN O
survival P07879204T0000 NN O
in P07879204T0000 IN O
high-risk P07879204T0000 JJ O
patients P07879204T0000 NNS O
as P07879204T0000 IN O
compared P07879204T0000 VBN O
to P07879204T0000 TO O
cyclosporine P07879204T0000 VB O
: P07879204T0000 : O
combined P07879204T0000 VBN O
results P07879204T0000 NNS O
from P07879204T0000 IN O
the P07879204T0000 DT O
prospective P07879204T0000 JJ O
, P07879204T0000 , O
randomized P07879204T0000 JJ O
Belgian P07879204T0000 NN O
and P07879204T0000 CC O
US P07879204T0000 NNP O
studies P07879204T0000 NNS O
. P07879204T0000 . O
. . O O

Consistent P10380878A0542 JJ O
with P10380878A0542 IN O
this P10380878A0542 DT O
possibility P10380878A0542 NN O
, P10380878A0542 , O
a P10380878A0542 DT O
non-MBD P10380878A0542 JJ O
region P10380878A0542 NN O
of P10380878A0542 IN O
Bin1 P10380878A0542 NNP I-UN
was P10380878A0542 VBD O
sufficient P10380878A0542 JJ O
to P10380878A0542 TO O
recruit P10380878A0542 VB O
a P10380878A0542 DT O
repression P10380878A0542 NN O
function P10380878A0542 NN O
to P10380878A0542 TO O
DNA P10380878A0542 VB O
that P10380878A0542 DT O
was P10380878A0542 VBD O
unrelated P10380878A0542 JJ O
to P10380878A0542 TO O
histone P10380878A0542 VB I-UN
deacetylase P10380878A0542 NN I-UN
. P10380878A0542 . O
. . O O

Sixteen P00193088A0196 NNP O
other P00193088A0196 JJ O
normal P00193088A0196 JJ O
subjects P00193088A0196 NNS O
with P00193088A0196 IN O
2 P00193088A0196 CD O
g P00193088A0196 NN O
of P00193088A0196 IN O
Metyrapone P00193088A0196 NNP O
are P00193088A0196 VBP O
best P00193088A0196 JJS O
responses P00193088A0196 NNS O
. P00193088A0196 . O
. . O O

As P08939966A0816 IN O
the P08939966A0816 DT O
rate P08939966A0816 NN O
of P08939966A0816 IN O
protein P08939966A0816 NN O
synthesis P08939966A0816 NN O
decreases P08939966A0816 VBZ O
during P08939966A0816 IN O
late P08939966A0816 JJ O
embryogenesis P08939966A0816 NN O
, P08939966A0816 , O
levels P08939966A0816 NNS O
of P08939966A0816 IN O
SEC-1 P08939966A0816 NNP I-UN
and P08939966A0816 CC O
its P08939966A0816 PRP$ O
cognate P08939966A0816 NN O
mRNA P08939966A0816 NN O
decline P08939966A0816 NN O
precipitously P08939966A0816 RB O
. P08939966A0816 . O
. . O O

We P01485648A0000 PRP O
investigated P01485648A0000 VBD O
the P01485648A0000 DT O
diagnostic P01485648A0000 JJ O
value P01485648A0000 NN O
of P01485648A0000 IN O
a P01485648A0000 DT O
new P01485648A0000 JJ O
in P01485648A0000 IN O
vitro P01485648A0000 JJ O
test P01485648A0000 NN O
, P01485648A0000 , O
Pharmacia P01485648A0000 NNP O
CAP P01485648A0000 NNP O
System P01485648A0000 NNP O
( P01485648A0000 ( O
Pharmacia P01485648A0000 NNP O
Diagnostics P01485648A0000 NNP O
AB P01485648A0000 NNP O
, P01485648A0000 , O
Uppsala P01485648A0000 NNP O
, P01485648A0000 , O
Sweden P01485648A0000 NNP O
) P01485648A0000 ) O
, P01485648A0000 , O
for P01485648A0000 IN O
the P01485648A0000 DT O
quantitative P01485648A0000 JJ O
measurement P01485648A0000 NN O
of P01485648A0000 IN O
allergen-specific P01485648A0000 JJ I-UN
IgE P01485648A0000 NNP I-UN
antibodies P01485648A0000 NNS I-UN
by P01485648A0000 IN O
comparison P01485648A0000 NN O
with P01485648A0000 IN O
RAST P01485648A0000 NNP O
in P01485648A0000 IN O
2 P01485648A0000 CD O
groups P01485648A0000 NNS O
of P01485648A0000 IN O
patients P01485648A0000 NNS O
, P01485648A0000 , O
71 P01485648A0000 CD O
atopic P01485648A0000 NN O
and P01485648A0000 CC O
48 P01485648A0000 CD O
non-atopic P01485648A0000 NN O
. P01485648A0000 . O
. . O O

Outcome P08675608T0000 NN O
of P08675608T0000 IN O
severe P08675608T0000 JJ O
congenital P08675608T0000 JJ O
hypothyroidism P08675608T0000 NN O
. P08675608T0000 . O
. . O O

RESULTS P11049241A0659 NN O
: P11049241A0659 : O
In P11049241A0659 IN O
the P11049241A0659 DT O
pregnant P11049241A0659 JJ O
group P11049241A0659 NN O
, P11049241A0659 , O
serum P11049241A0659 NN O
PP14 P11049241A0659 NNP I-UN
concentrations P11049241A0659 NNS O
were P11049241A0659 VBD O
markedly P11049241A0659 RB O
increased P11049241A0659 VBN O
after P11049241A0659 IN O
ET P11049241A0659 NNP O
, P11049241A0659 , O
and P11049241A0659 CC O
a P11049241A0659 DT O
significant P11049241A0659 JJ O
difference P11049241A0659 NN O
between P11049241A0659 IN O
the P11049241A0659 DT O
pregnant P11049241A0659 JJ O
group P11049241A0659 NN O
and P11049241A0659 CC O
the P11049241A0659 DT O
nonpregnant P11049241A0659 JJ O
group P11049241A0659 NN O
was P11049241A0659 VBD O
observed P11049241A0659 VBN O
8 P11049241A0659 CD O
days P11049241A0659 NNS O
following P11049241A0659 VBG O
ET P11049241A0659 NNP O
( P11049241A0659 ( O
p P11049241A0659 JJ O
< P11049241A0659 NNP O
0.01 P11049241A0659 CD O
) P11049241A0659 ) O
. P11049241A0659 . O
. . O O

Raman P09983871T0000 NNP O
investigation P09983871T0000 NN O
of P09983871T0000 IN O
YBa2-xLaxCu3O7 P09983871T0000 JJ O
ceramics P09983871T0000 NNS O
. P09983871T0000 . O
. . O O

Regions P06755468A0180 NNS O
of P06755468A0180 IN O
the P06755468A0180 DT O
translated P06755468A0180 JJ O
open P06755468A0180 JJ O
reading P06755468A0180 VBG O
frames P06755468A0180 NNS O
of P06755468A0180 IN O
cobA P06755468A0180 NN I-UN
and P06755468A0180 CC O
the P06755468A0180 DT O
third P06755468A0180 JJ O
intron P06755468A0180 NN O
of P06755468A0180 IN O
the P06755468A0180 DT O
cob P06755468A0180 NN I-UN
gene P06755468A0180 NN I-UN
in P06755468A0180 IN I-UN
yeast P06755468A0180 NNP I-UN
show P06755468A0180 VBP O
high P06755468A0180 JJ O
amino P06755468A0180 NN O
acid P06755468A0180 NN O
homology P06755468A0180 NN O
. P06755468A0180 . O
. . O O

Preliminary P05525652T0064 JJ O
report P05525652T0064 NN O
. P05525652T0064 . O
. . O O

A P11843252A0907 DT O
global P11843252A0907 JJ O
response P11843252A0907 NN O
rate P11843252A0907 NN O
was P11843252A0907 VBD O
17 P11843252A0907 CD O
% P11843252A0907 NN O
( P11843252A0907 ( O
95 P11843252A0907 CD O
% P11843252A0907 NN O
confidence P11843252A0907 NN O
interval P11843252A0907 NN O
( P11843252A0907 ( O
95 P11843252A0907 CD O
% P11843252A0907 NN O
CI P11843252A0907 NNP O
) P11843252A0907 ) O
: P11843252A0907 : O
2 P11843252A0907 CD O
% P11843252A0907 NN O
-32 P11843252A0907 NNP O
% P11843252A0907 NN O
) P11843252A0907 ) O
and P11843252A0907 CC O
the P11843252A0907 DT O
median P11843252A0907 JJ O
overall P11843252A0907 JJ O
survival P11843252A0907 NN O
was P11843252A0907 VBD O
12 P11843252A0907 CD O
months P11843252A0907 NNS O
. P11843252A0907 . O
. . O O

Also P09186056A0514 RB O
, P09186056A0514 , O
transient P09186056A0514 JJ O
overexpression P09186056A0514 NN O
of P09186056A0514 IN O
this P09186056A0514 DT O
protein P09186056A0514 NN O
in P09186056A0514 IN O
C2C12 P09186056A0514 NNP O
cells P09186056A0514 NNS O
reduced P09186056A0514 VBD O
the P09186056A0514 DT O
transcription P09186056A0514 NN O
of P09186056A0514 IN O
a P09186056A0514 DT O
CAT-reporter P09186056A0514 NNP O
regulated P09186056A0514 VBN O
by P09186056A0514 IN O
an P09186056A0514 DT O
E12 P09186056A0514 NNP I-UN
/ P09186056A0514 NNP O
MyoD P09186056A0514 NNP I-UN
driven P09186056A0514 JJ O
enhancer P09186056A0514 NN O
. P09186056A0514 . O
. . O O

The P07655184A0852 DT O
transport P07655184A0852 NN O
of P07655184A0852 IN O
a P07655184A0852 DT O
genetically P07655184A0852 RB O
engineered P07655184A0852 VBN O
chimeric P07655184A0852 JJ O
transmembrane P07655184A0852 NN O
protein P07655184A0852 NN O
connected P07655184A0852 VBD O
to P07655184A0852 TO O
this P07655184A0852 DT O
ER P07655184A0852 NNP O
leader P07655184A0852 NN O
sequence P07655184A0852 NN O
was P07655184A0852 VBD O
as P07655184A0852 RB O
efficient P07655184A0852 JJ O
as P07655184A0852 IN O
that P07655184A0852 DT O
of P07655184A0852 IN O
the P07655184A0852 DT O
original P07655184A0852 JJ O
protein P07655184A0852 NN O
from P07655184A0852 IN O
which P07655184A0852 WDT O
the P07655184A0852 DT O
ER P07655184A0852 NNP O
sequence P07655184A0852 NN O
has P07655184A0852 VBZ O
been P07655184A0852 VBN O
derived P07655184A0852 VBN O
. P07655184A0852 . O
. . O O

In P11235777A0878 IN O
Klinefelter P11235777A0878 NNP O
's P11235777A0878 POS O
syndrome P11235777A0878 NN O
( P11235777A0878 ( O
47XXY P11235777A0878 CD O
) P11235777A0878 ) O
, P11235777A0878 , O
serum P11235777A0878 VBP O
testosterone P11235777A0878 NN O
levels P11235777A0878 NNS O
are P11235777A0878 VBP O
at P11235777A0878 IN O
the P11235777A0878 DT O
lower P11235777A0878 JJR O
end P11235777A0878 NN O
of P11235777A0878 IN O
the P11235777A0878 DT O
normal P11235777A0878 JJ O
range P11235777A0878 NN O
and P11235777A0878 CC O
dihydrotestosterone P11235777A0878 NN O
levels P11235777A0878 NNS O
are P11235777A0878 VBP O
low P11235777A0878 JJ O
. P11235777A0878 . O
. . O O

Upon P10640734A0190 IN O
tyrosine P10640734A0190 JJ O
phosphorylation P10640734A0190 NN O
at P10640734A0190 IN O
the P10640734A0190 DT O
ITIMs P10640734A0190 NNP O
, P10640734A0190 , O
these P10640734A0190 DT O
molecules P10640734A0190 NNS O
recruit P10640734A0190 VBP O
SH2 P10640734A0190 NNP I-UN
domain-containing P10640734A0190 JJ O
phosphatases P10640734A0190 NNS O
such P10640734A0190 JJ O
as P10640734A0190 IN O
SH2-containing P10640734A0190 JJ O
tyrosine P10640734A0190 NN I-UN
phosphatase-1 P10640734A0190 NN I-UN
and P10640734A0190 CC O
negatively P10640734A0190 RB O
regulate P10640734A0190 VB O
cell P10640734A0190 NN O
activity P10640734A0190 NN O
. P10640734A0190 . O
. . O O

The P09552469A0225 DT O
interaction P09552469A0225 NN O
between P09552469A0225 IN O
piroxicam P09552469A0225 NN O
and P09552469A0225 CC O
poloxamer P09552469A0225 NN O
was P09552469A0225 VBD O
studied P09552469A0225 VBN O
by P09552469A0225 IN O
x-ray P09552469A0225 JJ O
diffractometry P09552469A0225 NN O
( P09552469A0225 ( O
XRD P09552469A0225 NNP O
) P09552469A0225 ) O
, P09552469A0225 , O
infrared P09552469A0225 VBN O
( P09552469A0225 ( O
IR P09552469A0225 NNP O
) P09552469A0225 ) O
spectroscopy P09552469A0225 NN O
and P09552469A0225 CC O
differential P09552469A0225 JJ O
thermal P09552469A0225 JJ O
analysis P09552469A0225 NN O
( P09552469A0225 ( O
DTA P09552469A0225 NNP O
) P09552469A0225 ) O
with P09552469A0225 IN O
a P09552469A0225 DT O
solid P09552469A0225 JJ O
dispersion P09552469A0225 NN O
, P09552469A0225 , O
coprecipitate P09552469A0225 NN O
, P09552469A0225 , O
or P09552469A0225 CC O
physical P09552469A0225 JJ O
mixture P09552469A0225 NN O
. P09552469A0225 . O
. . O O

In P00879329A0176 IN O
the P00879329A0176 DT O
control P00879329A0176 NN O
preparation P00879329A0176 NN O
before P00879329A0176 IN O
weight P00879329A0176 NN O
was P00879329A0176 VBD O
allowed P00879329A0176 VBN O
to P00879329A0176 TO O
increase P00879329A0176 VB O
, P00879329A0176 , O
isogravimetric P00879329A0176 JJ O
capillary P00879329A0176 JJ O
pressure P00879329A0176 NN O
( P00879329A0176 ( O
Pci P00879329A0176 NNP O
) P00879329A0176 ) O
averaged P00879329A0176 VBD O
8 P00879329A0176 CD O
mmHg P00879329A0176 NNS O
lower P00879329A0176 JJR O
than P00879329A0176 IN O
colloid P00879329A0176 JJ O
osmotic P00879329A0176 JJ O
pressure P00879329A0176 NN O
of P00879329A0176 IN O
the P00879329A0176 DT O
plasma P00879329A0176 NN O
( P00879329A0176 ( O
IIp P00879329A0176 NNP O
) P00879329A0176 ) O
. P00879329A0176 . O
. . O O

Delayed P00644314T0000 NNP O
hypersensitivity P00644314T0000 NN O
in P00644314T0000 IN O
man P00644314T0000 NN O
: P00644314T0000 : O
effects P00644314T0000 NNS O
of P00644314T0000 IN O
systemic P00644314T0000 JJ O
anticoagulation P00644314T0000 NN O
. P00644314T0000 . O
. . O O

The P07659746A1464 DT O
CVA16.4 P07659746A1464 NNP I-UN
proteolipid P07659746A1464 JJ I-UN
transcript P07659746A1464 NN I-UN
is P07659746A1464 VBZ O
the P07659746A1464 DT O
most P07659746A1464 RBS O
prevalent P07659746A1464 NN O
of P07659746A1464 IN O
the P07659746A1464 DT O
two P07659746A1464 CD O
proteolipid P07659746A1464 JJ O
messages P07659746A1464 NNS O
in P07659746A1464 IN O
expanding P07659746A1464 VBG O
ovules P07659746A1464 NNS O
harvested P07659746A1464 VBD O
10 P07659746A1464 CD O
d P07659746A1464 JJ O
post-anthesis P07659746A1464 NN O
. P07659746A1464 . O
. . O O

In P10198061A0339 IN O
the P10198061A0339 DT O
cell-free P10198061A0339 JJ O
import P10198061A0339 NN O
assay P10198061A0339 NN O
, P10198061A0339 , O
beta-catenin P10198061A0339 JJ I-UN
rapidly P10198061A0339 RB O
migrates P10198061A0339 VBZ O
into P10198061A0339 IN O
the P10198061A0339 DT O
nucleus P10198061A0339 NN O
without P10198061A0339 IN O
the P10198061A0339 DT O
exogenous P10198061A0339 JJ O
addition P10198061A0339 NN O
of P10198061A0339 IN O
cytosol P10198061A0339 NN O
, P10198061A0339 , O
Ran P10198061A0339 NNP I-UN
, P10198061A0339 , O
or P10198061A0339 CC O
ATP P10198061A0339 NNP O
/ P10198061A0339 NNP O
GTP P10198061A0339 NNP O
. P10198061A0339 . O
. . O O

A P02883871A1075 DT O
drug P02883871A1075 NN O
with P02883871A1075 IN O
ISA P02883871A1075 NNP O
`` P02883871A1075 `` O
down P02883871A1075 RB O
regulates P02883871A1075 NNS O
'' P02883871A1075 '' O
beta P02883871A1075 NN I-UN
receptors P02883871A1075 NNS I-UN
; P02883871A1075 : O
thus P02883871A1075 RB O
, P02883871A1075 , O
when P02883871A1075 WRB O
the P02883871A1075 DT O
drug P02883871A1075 NN O
is P02883871A1075 VBZ O
withdrawn P02883871A1075 VBN O
there P02883871A1075 EX O
is P02883871A1075 VBZ O
no P02883871A1075 DT O
post-beta-blocking P02883871A1075 JJ O
drug P02883871A1075 NN O
hypersensitivity P02883871A1075 NN O
in P02883871A1075 IN O
contrast P02883871A1075 NN O
to P02883871A1075 TO O
agents P02883871A1075 NNS O
without P02883871A1075 IN O
ISA P02883871A1075 NNP O
. P02883871A1075 . O
. . O O

The P09781874A1061 DT O
cwg2-1 P09781874A1061 JJ I-UN
mutation P09781874A1061 NN I-UN
was P09781874A1061 VBD O
identified P09781874A1061 VBN O
as P09781874A1061 IN O
a P09781874A1061 DT O
guanine P09781874A1061 NN O
to P09781874A1061 TO O
adenine P09781874A1061 VB O
substitution P09781874A1061 NN O
at P09781874A1061 IN O
nucleotide P09781874A1061 JJ O
604 P09781874A1061 CD O
of P09781874A1061 IN O
the P09781874A1061 DT O
coding P09781874A1061 VBG O
region P09781874A1061 NN O
, P09781874A1061 , O
originating P09781874A1061 VBG O
the P09781874A1061 DT O
change P09781874A1061 NN O
A202T P09781874A1061 NNP O
in P09781874A1061 IN O
the P09781874A1061 DT O
cwg2p P09781874A1061 NN I-UN
. P09781874A1061 . O
. . O O

Expression P11168588T0000 NN O
of P11168588T0000 IN O
herpes P11168588T0000 NNS I-UN
simplex P11168588T0000 JJ I-UN
virus P11168588T0000 NN I-UN
type P11168588T0000 NN I-UN
2 P11168588T0000 CD I-UN
US3 P11168588T0000 NNP I-UN
affects P11168588T0000 VBZ O
the P11168588T0000 DT O
Cdc42 P11168588T0000 NNP I-UN
/ P11168588T0000 NNP O
Rac P11168588T0000 NNP I-UN
pathway P11168588T0000 NN O
and P11168588T0000 CC O
attenuates P11168588T0000 VBZ O
c-Jun P11168588T0000 JJ I-UN
N-terminal P11168588T0000 JJ I-UN
kinase P11168588T0000 NN I-UN
activation P11168588T0000 NN O
. P11168588T0000 . O
. . O O

Retroviral P10775267A0363 JJ O
transduction P10775267A0363 NN O
of P10775267A0363 IN O
T P10775267A0363 NNP I-UN
/ P10775267A0363 NNP I-UN
T P10775267A0363 NNP I-UN
( P10775267A0363 ( I-UN
L P10775267A0363 NNP I-UN
) P10775267A0363 ) I-UN
causes P10775267A0363 VBZ O
a P10775267A0363 DT O
rapidly P10775267A0363 RB O
fatal P10775267A0363 JJ O
myeloproliferative P10775267A0363 JJ O
disease P10775267A0363 NN O
in P10775267A0363 IN O
a P10775267A0363 DT O
murine P10775267A0363 NN O
bone P10775267A0363 NN O
marrow P10775267A0363 NN O
transplant P10775267A0363 NN O
( P10775267A0363 ( O
BMT P10775267A0363 NNP O
) P10775267A0363 ) O
model P10775267A0363 NN O
, P10775267A0363 , O
whereas P10775267A0363 JJ O
T P10775267A0363 NNP I-UN
/ P10775267A0363 NNP I-UN
T P10775267A0363 NNP I-UN
( P10775267A0363 ( I-UN
F P10775267A0363 NNP I-UN
) P10775267A0363 ) I-UN
causes P10775267A0363 VBZ O
a P10775267A0363 DT O
long-latency P10775267A0363 NN O
, P10775267A0363 , O
pre-B-cell P10775267A0363 JJ O
lymphoblastic P10775267A0363 JJ O
lymphoma P10775267A0363 NN O
. P10775267A0363 . O
. . O O

A P11094073A0000 DT O
recently P11094073A0000 RB O
reported P11094073A0000 VBN O
new P11094073A0000 JJ O
member P11094073A0000 NN O
of P11094073A0000 IN O
the P11094073A0000 DT O
Vav P11094073A0000 NNP I-UN
family P11094073A0000 NN I-UN
proteins P11094073A0000 NNS I-UN
, P11094073A0000 , O
Vav3 P11094073A0000 NNP I-UN
has P11094073A0000 VBZ O
been P11094073A0000 VBN O
identified P11094073A0000 VBN O
as P11094073A0000 IN O
a P11094073A0000 DT O
Ros P11094073A0000 NNP I-UN
receptor P11094073A0000 NN I-UN
protein P11094073A0000 NN I-UN
tyrosine P11094073A0000 JJ I-UN
kinase P11094073A0000 NN I-UN
( P11094073A0000 ( O
RPTK P11094073A0000 NNP I-UN
) P11094073A0000 ) O
interacting P11094073A0000 VBG O
protein P11094073A0000 NN O
by P11094073A0000 IN O
yeast P11094073A0000 JJ O
two-hybrid P11094073A0000 JJ O
screening P11094073A0000 NN O
. P11094073A0000 . O
. . O O

These P01398073A0986 DT O
results P01398073A0986 NNS O
lead P01398073A0986 VBP O
us P01398073A0986 PRP O
to P01398073A0986 TO O
hypothesize P01398073A0986 VB O
that P01398073A0986 IN O
a P01398073A0986 DT O
single P01398073A0986 JJ O
multisubunit P01398073A0986 NN I-UN
TFIID P01398073A0986 NNP I-UN
protein P01398073A0986 NN I-UN
supports P01398073A0986 VBZ O
transcriptional P01398073A0986 JJ O
stimulation P01398073A0986 NN O
by P01398073A0986 IN O
diverse P01398073A0986 JJ O
activation P01398073A0986 NN O
domains P01398073A0986 NNS O
and P01398073A0986 CC O
from P01398073A0986 IN O
a P01398073A0986 DT O
TATA-less P01398073A0986 JJ O
promoter P01398073A0986 NN O
. P01398073A0986 . O
. . O O

Quantitative P01923628T0001 JJ O
analysis P01923628T0001 NN O
of P01923628T0001 IN O
DNA P01923628T0001 NNP O
using P01923628T0001 VBG O
flow P01923628T0001 JJ O
cytometry P01923628T0001 NN O
and P01923628T0001 CC O
immunocytochemical P01923628T0001 JJ O
findings P01923628T0001 NNS O
in P01923628T0001 IN O
16 P01923628T0001 CD O
cases P01923628T0001 NNS O
of P01923628T0001 IN O
cardiac P01923628T0001 JJ O
myxomas P01923628T0001 NN O
. P01923628T0001 . O
. . O O

However P08976253A0637 RB O
, P08976253A0637 , O
we P08976253A0637 PRP O
did P08976253A0637 VBD O
not P08976253A0637 RB O
observe P08976253A0637 VB O
a P08976253A0637 DT O
correlation P08976253A0637 NN O
between P08976253A0637 IN O
serum P08976253A0637 NN O
and P08976253A0637 CC O
seminal P08976253A0637 JJ I-UN
plasma P08976253A0637 NN I-UN
PSA P08976253A0637 NNP I-UN
levels P08976253A0637 NNS O
. P08976253A0637 . O
. . O O

Studies P04152725T0001 NNS O
on P04152725T0001 IN O
alcoholic P04152725T0001 JJ O
liver P04152725T0001 JJ O
injury P04152725T0001 NN O
. P04152725T0001 . O
. . O O

The P01278251A0000 DT O
authors P01278251A0000 NNS O
report P01278251A0000 VBP O
the P01278251A0000 DT O
results P01278251A0000 NNS O
of P01278251A0000 IN O
a P01278251A0000 DT O
series P01278251A0000 NN O
of P01278251A0000 IN O
toxicological P01278251A0000 JJ O
tests P01278251A0000 NNS O
conducted P01278251A0000 VBN O
on P01278251A0000 IN O
plastic P01278251A0000 NN O
materials P01278251A0000 NNS O
( P01278251A0000 ( O
polyethylene P01278251A0000 NN O
) P01278251A0000 ) O
activated P01278251A0000 VBD O
with P01278251A0000 IN O
tetraphenylbutadiene P01278251A0000 NN O
( P01278251A0000 ( O
TPB P01278251A0000 NNP O
) P01278251A0000 ) O
an P01278251A0000 DT O
additive P01278251A0000 JJ O
recently P01278251A0000 RB O
proposed P01278251A0000 VBN O
as P01278251A0000 IN O
a P01278251A0000 DT O
sensitizer P01278251A0000 NN O
capable P01278251A0000 JJ O
of P01278251A0000 IN O
photodegrading P01278251A0000 VBG O
plastic P01278251A0000 JJ O
materials P01278251A0000 NNS O
. P01278251A0000 . O
. . O O

In P03602261A0238 IN O
the P03602261A0238 DT O
normal P03602261A0238 JJ O
, P03602261A0238 , O
basal P03602261A0238 NN O
( P03602261A0238 ( O
unstimulated P03602261A0238 JJ O
) P03602261A0238 ) O
condition P03602261A0238 NN O
there P03602261A0238 EX O
were P03602261A0238 VBD O
no P03602261A0238 DT O
significant P03602261A0238 JJ O
correlations P03602261A0238 NNS O
( P03602261A0238 ( O
p P03602261A0238 NN O
greater P03602261A0238 JJR O
than P03602261A0238 IN O
0.05 P03602261A0238 CD O
) P03602261A0238 ) O
between P03602261A0238 IN O
the P03602261A0238 DT O
systolic P03602261A0238 JJ O
blood P03602261A0238 NN O
pressure P03602261A0238 NN O
and P03602261A0238 CC O
dopamine P03602261A0238 NN O
( P03602261A0238 ( O
r P03602261A0238 JJ O
= P03602261A0238 NNP O
0.09 P03602261A0238 CD O
) P03602261A0238 ) O
, P03602261A0238 , O
norepinephrine P03602261A0238 JJ O
( P03602261A0238 ( O
r P03602261A0238 VB O
= P03602261A0238 RB O
0.26 P03602261A0238 CD O
) P03602261A0238 ) O
, P03602261A0238 , O
or P03602261A0238 CC O
epinephrine P03602261A0238 NN O
( P03602261A0238 ( O
r P03602261A0238 JJ O
= P03602261A0238 NNP O
0.27 P03602261A0238 CD O
) P03602261A0238 ) O
, P03602261A0238 , O
nor P03602261A0238 CC O
were P03602261A0238 VBD O
there P03602261A0238 EX O
significant P03602261A0238 JJ O
correlations P03602261A0238 NNS O
between P03602261A0238 IN O
melatonin P03602261A0238 NN O
and P03602261A0238 CC O
dopamine P03602261A0238 NN O
( P03602261A0238 ( O
r P03602261A0238 JJ O
= P03602261A0238 NNP O
-0.01 P03602261A0238 NNP O
) P03602261A0238 ) O
, P03602261A0238 , O
norepinephrine P03602261A0238 JJ O
( P03602261A0238 ( O
r P03602261A0238 JJ O
= P03602261A0238 NNP O
-0.26 P03602261A0238 NNP O
) P03602261A0238 ) O
, P03602261A0238 , O
or P03602261A0238 CC O
growth P03602261A0238 NN I-UN
hormone P03602261A0238 NN I-UN
( P03602261A0238 ( O
r P03602261A0238 JJ O
= P03602261A0238 NNP O
0.17 P03602261A0238 CD O
) P03602261A0238 ) O
. P03602261A0238 . O
. . O O

The P09582953A1670 DT O
data P09582953A1670 NN O
suggest P09582953A1670 NN O
that P09582953A1670 IN O
plasminogen P09582953A1670 NN I-UN
, P09582953A1670 , O
alpha P09582953A1670 RB I-UN
2AP P09582953A1670 CD I-UN
, P09582953A1670 , O
and P09582953A1670 CC O
C1-INH P09582953A1670 NNP I-UN
, P09582953A1670 , O
should P09582953A1670 MD O
be P09582953A1670 VB O
considered P09582953A1670 VBN O
equine P09582953A1670 JJ O
acute-phase P09582953A1670 JJ O
proteins P09582953A1670 NNS O
. P09582953A1670 . O
. . O O

The P00918556A0000 DT O
prevalence P00918556A0000 NN O
of P00918556A0000 IN O
hepatitis P00918556A0000 NN I-UN
B P00918556A0000 NNP I-UN
surface P00918556A0000 NN I-UN
antigen P00918556A0000 NN I-UN
( P00918556A0000 ( O
HBsAg P00918556A0000 NNP I-UN
) P00918556A0000 ) O
and P00918556A0000 CC O
anti-HBs P00918556A0000 NN I-UN
was P00918556A0000 VBD O
determined P00918556A0000 VBN O
by P00918556A0000 IN O
a P00918556A0000 DT O
sensitive P00918556A0000 JJ O
double-antibody P00918556A0000 JJ O
radio-immunoassay P00918556A0000 NN O
technique P00918556A0000 NN O
in P00918556A0000 IN O
a P00918556A0000 DT O
series P00918556A0000 NN O
of P00918556A0000 IN O
patients P00918556A0000 NNS O
with P00918556A0000 IN O
chronic P00918556A0000 JJ O
liver P00918556A0000 NN O
diseases P00918556A0000 NNS O
. P00918556A0000 . O
. . O O

MKK3 P09162092A0675 NNP I-UN
autophosphorylation P09162092A0675 NN O
and P09162092A0675 CC O
activation P09162092A0675 NN O
of P09162092A0675 IN O
p38 P09162092A0675 NN I-UN
was P09162092A0675 VBD O
also P09162092A0675 RB O
observed P09162092A0675 VBN O
following P09162092A0675 VBG O
coexpression P09162092A0675 NN O
of P09162092A0675 IN O
MKK3 P09162092A0675 NNP I-UN
with P09162092A0675 IN O
MEKK3 P09162092A0675 NNP I-UN
, P09162092A0675 , O
but P09162092A0675 CC O
not P09162092A0675 RB O
with P09162092A0675 IN O
MEKK2 P09162092A0675 NNP I-UN
. P09162092A0675 . O
. . O O

Mapping P09271496T0000 VBG O
features P09271496T0000 NNS O
of P09271496T0000 IN O
HIV-1 P09271496T0000 NNP I-UN
integrase P09271496T0000 NN I-UN
near P09271496T0000 IN O
selected P09271496T0000 VBN O
sites P09271496T0000 NNS O
on P09271496T0000 IN O
viral P09271496T0000 JJ O
and P09271496T0000 CC O
target P09271496T0000 NN O
DNA P09271496T0000 NNP O
molecules P09271496T0000 NNS O
in P09271496T0000 IN O
an P09271496T0000 DT O
active P09271496T0000 JJ O
enzyme-DNA P09271496T0000 NN O
complex P09271496T0000 NN O
by P09271496T0000 IN O
photo-cross-linking P09271496T0000 NN O
. P09271496T0000 . O
. . O O

For P01287197A0761 IN O
the P01287197A0761 DT O
first P01287197A0761 JJ O
group P01287197A0761 NN O
, P01287197A0761 , O
the P01287197A0761 DT O
maximal P01287197A0761 JJ O
decrease P01287197A0761 NN O
in P01287197A0761 IN O
plasma P01287197A0761 JJ O
potassium P01287197A0761 NN O
elicited P01287197A0761 VBN O
by P01287197A0761 IN O
salbutamol P01287197A0761 NN O
was P01287197A0761 VBD O
0.80 P01287197A0761 CD O
+ P01287197A0761 JJ O
/ P01287197A0761 NNP O
- P01287197A0761 : O
0.19 P01287197A0761 CD O
, P01287197A0761 , O
0.48 P01287197A0761 CD O
+ P01287197A0761 NN O
/ P01287197A0761 NNP O
- P01287197A0761 : O
0.22 P01287197A0761 CD O
, P01287197A0761 , O
and P01287197A0761 CC O
0.78 P01287197A0761 CD O
+ P01287197A0761 NN O
/ P01287197A0761 NNP O
- P01287197A0761 : O
0.46 P01287197A0761 CD O
mmol P01287197A0761 NN O
/ P01287197A0761 NNP O
l P01287197A0761 NN O
, P01287197A0761 , O
and P01287197A0761 CC O
for P01287197A0761 IN O
the P01287197A0761 DT O
second P01287197A0761 JJ O
group P01287197A0761 NN O
, P01287197A0761 , O
maximal P01287197A0761 JJ O
decrement P01287197A0761 NN O
was P01287197A0761 VBD O
1.31 P01287197A0761 CD O
+ P01287197A0761 JJ O
/ P01287197A0761 NNP O
- P01287197A0761 : O
0.37 P01287197A0761 CD O
, P01287197A0761 , O
0.70 P01287197A0761 CD O
+ P01287197A0761 NN O
/ P01287197A0761 NNP O
- P01287197A0761 : O
0.24 P01287197A0761 CD O
, P01287197A0761 , O
and P01287197A0761 CC O
0.84 P01287197A0761 CD O
+ P01287197A0761 NN O
/ P01287197A0761 NNP O
- P01287197A0761 : O
0.17 P01287197A0761 CD O
mmol P01287197A0761 NN O
/ P01287197A0761 NNP O
l P01287197A0761 NN O
for P01287197A0761 IN O
the P01287197A0761 DT O
iv P01287197A0761 NN O
, P01287197A0761 , O
po P01287197A0761 NN O
, P01287197A0761 , O
and P01287197A0761 CC O
it P01287197A0761 PRP O
routes P01287197A0761 VBZ O
, P01287197A0761 , O
respectively P01287197A0761 RB O
. P01287197A0761 . O
. . O O

Our P08228997A0866 PRP$ O
results P08228997A0866 NNS O
indicate P08228997A0866 VBP O
that P08228997A0866 IN O
periseizure P08228997A0866 NN O
lipid P08228997A0866 JJ O
accumulation P08228997A0866 NN O
is P08228997A0866 VBZ O
related P08228997A0866 VBN O
to P08228997A0866 TO O
cortical P08228997A0866 JJ O
oxygenation P08228997A0866 NN O
. P08228997A0866 . O
. . O O

Molecular P09891009T0000 JJ O
cloning P09891009T0000 NN O
of P09891009T0000 IN O
mouse P09891009T0000 NN I-UN
glycolate P09891009T0000 NN I-UN
oxidase P09891009T0000 NN I-UN
. P09891009T0000 . O
. . O O

This P09849421A0332 DT O
survey P09849421A0332 NN O
included P09849421A0332 VBD O
3000 P09849421A0332 CD O
randomly P09849421A0332 RB O
selected P09849421A0332 VBN O
Norwegians P09849421A0332 NNPS O
above P09849421A0332 IN O
18 P09849421A0332 CD O
years P09849421A0332 NNS O
of P09849421A0332 IN O
age P09849421A0332 NN O
who P09849421A0332 WP O
received P09849421A0332 VBD O
the P09849421A0332 DT O
European P09849421A0332 JJ O
Organization P09849421A0332 NNP O
for P09849421A0332 IN O
Research P09849421A0332 NNP O
and P09849421A0332 CC O
Treatment P09849421A0332 NNP O
of P09849421A0332 IN O
Cancer P09849421A0332 NNP O
Core P09849421A0332 NNP O
Quality P09849421A0332 NNP O
of P09849421A0332 IN O
Life P09849421A0332 NNP O
Questionnaire P09849421A0332 NNP O
( P09849421A0332 ( O
EORTC P09849421A0332 NNP O
QLQ-C30 P09849421A0332 NNP O
( P09849421A0332 ( O
+3 P09849421A0332 NNP O
) P09849421A0332 ) O
by P09849421A0332 IN O
mail P09849421A0332 NN O
. P09849421A0332 . O
. . O O

The P09220177A0564 DT O
CPK-MB P09220177A0564 NNP I-UN
isoenzyme P09220177A0564 NN O
showed P09220177A0564 VBD O
no P09220177A0564 DT O
percentage P09220177A0564 NN O
increase P09220177A0564 NN O
of P09220177A0564 IN O
total P09220177A0564 JJ O
CPK P09220177A0564 NNP I-UN
higher P09220177A0564 JJR O
than P09220177A0564 IN O
5 P09220177A0564 CD O
% P09220177A0564 NN O
, P09220177A0564 , O
measured P09220177A0564 VBN O
at P09220177A0564 IN O
6 P09220177A0564 CD O
, P09220177A0564 , O
12 P09220177A0564 CD O
, P09220177A0564 , O
and P09220177A0564 CC O
24 P09220177A0564 CD O
h P09220177A0564 NN O
after P09220177A0564 IN O
the P09220177A0564 DT O
shock P09220177A0564 NN O
, P09220177A0564 , O
independent P09220177A0564 JJ O
of P09220177A0564 IN O
the P09220177A0564 DT O
number P09220177A0564 NN O
of P09220177A0564 IN O
attempts P09220177A0564 NNS O
of P09220177A0564 IN O
cardioversion P09220177A0564 NN O
. P09220177A0564 . O
. . O O

2 P08081293A0078 CD O
. P08081293A0078 . O
. . O O

The P07554541A0587 DT O
optimal P07554541A0587 JJ O
care P07554541A0587 NN O
of P07554541A0587 IN O
CHF P07554541A0587 NNP O
patient P07554541A0587 NN O
includes P07554541A0587 VBZ O
the P07554541A0587 DT O
recognition P07554541A0587 NN O
and P07554541A0587 CC O
management P07554541A0587 NN O
of P07554541A0587 IN O
these P07554541A0587 DT O
electrolyte P07554541A0587 JJ O
disturbances P07554541A0587 NNS O
. P07554541A0587 . O
. . O O

Polypyrimidine P10202006A1266 NNP O
and P10202006A1266 CC O
ssDNA P10202006A1266 NN O
binding P10202006A1266 NN O
by P10202006A1266 IN O
the P10202006A1266 DT O
isolated P10202006A1266 JJ O
VH P10202006A1266 NNP I-UN
domain P10202006A1266 NN I-UN
of P10202006A1266 IN O
immunization-induced P10202006A1266 JJ O
anti-Z-DNA P10202006A1266 JJ O
Ab P10202006A1266 NNP O
resembles P10202006A1266 VBZ O
the P10202006A1266 DT O
activity P10202006A1266 NN O
of P10202006A1266 IN O
natural P10202006A1266 JJ O
autoantibodies P10202006A1266 NNS O
and P10202006A1266 CC O
suggests P10202006A1266 VBZ O
that P10202006A1266 IN O
VH-dependent P10202006A1266 NNP O
binding P10202006A1266 NN O
to P10202006A1266 TO O
a P10202006A1266 DT O
ligand P10202006A1266 NN O
mimicked P10202006A1266 VBN O
by P10202006A1266 IN O
polypyrimidines P10202006A1266 NNS O
may P10202006A1266 MD O
play P10202006A1266 VB O
a P10202006A1266 DT O
role P10202006A1266 NN O
in P10202006A1266 IN O
B P10202006A1266 NNP O
cell P10202006A1266 NN O
selection P10202006A1266 NN O
before P10202006A1266 IN O
immunization P10202006A1266 NN O
with P10202006A1266 IN O
Z-DNA P10202006A1266 NNP O
. P10202006A1266 . O
. . O O

The P03709627A0247 DT O
subjects P03709627A0247 NNS O
received P03709627A0247 VBD O
a P03709627A0247 DT O
single P03709627A0247 JJ O
500 P03709627A0247 CD O
mg P03709627A0247 NN O
dose P03709627A0247 NN O
of P03709627A0247 IN O
acetaminophen P03709627A0247 JJ O
i.v P03709627A0247 NN O
. P03709627A0247 . O
and P03709627A0247 CC O
concentrations P03709627A0247 NNS O
in P03709627A0247 IN O
plasma P03709627A0247 NN O
were P03709627A0247 VBD O
measured P03709627A0247 VBN O
for P03709627A0247 IN O
360 P03709627A0247 CD O
minutes P03709627A0247 NNS O
and P03709627A0247 CC O
in P03709627A0247 IN O
urine P03709627A0247 NN O
for P03709627A0247 IN O
24 P03709627A0247 CD O
h P03709627A0247 NN O
in P03709627A0247 IN O
order P03709627A0247 NN O
to P03709627A0247 TO O
estimate P03709627A0247 VB O
the P03709627A0247 DT O
production P03709627A0247 NN O
of P03709627A0247 IN O
metabolites P03709627A0247 NNS O
. P03709627A0247 . O
. . O O

In P09824001A1665 IN O
contrast P09824001A1665 NN O
to P09824001A1665 TO O
hemodynamic P09824001A1665 VB O
and P09824001A1665 CC O
histopathological P09824001A1665 JJ O
predictors P09824001A1665 NNS O
of P09824001A1665 IN O
survival P09824001A1665 NN O
, P09824001A1665 , O
vWF P09824001A1665 NN I-UN
: P09824001A1665 : O
Ag P09824001A1665 NN O
does P09824001A1665 VBZ O
not P09824001A1665 RB O
require P09824001A1665 VB O
invasive P09824001A1665 JJ O
techniques P09824001A1665 NNS O
to P09824001A1665 TO O
be P09824001A1665 VB O
determined P09824001A1665 VBN O
. P09824001A1665 . O
. . O O

Mean P03465957A1008 JJ O
fluorosis P03465957A1008 NN O
scores P03465957A1008 NNS O
, P03465957A1008 , O
however P03465957A1008 RB O
, P03465957A1008 , O
were P03465957A1008 VBD O
similar P03465957A1008 JJ O
. P03465957A1008 . O
. . O O

Several P10571047A1009 JJ O
7SL P10571047A1009 CD I-UN
RNA-encoding P10571047A1009 JJ I-UN
sequences P10571047A1009 NNS I-UN
and P10571047A1009 CC O
various P10571047A1009 JJ O
intergenic P10571047A1009 JJ O
spacers P10571047A1009 NNS O
were P10571047A1009 VBD O
amplified P10571047A1009 VBN O
from P10571047A1009 IN O
the P10571047A1009 DT O
individual P10571047A1009 JJ O
HindIII P10571047A1009 NNP I-UN
fragments P10571047A1009 NNS I-UN
of P10571047A1009 IN O
about P10571047A1009 IN O
1.3 P10571047A1009 CD O
and P10571047A1009 CC O
2.8 P10571047A1009 CD O
kb P10571047A1009 NN O
. P10571047A1009 . O
. . O O

Study P08750702A0183 NN O
groups P08750702A0183 NNS O
were P08750702A0183 VBD O
control P08750702A0183 NN O
, P08750702A0183 , O
and P08750702A0183 CC O
those P08750702A0183 DT O
treated P08750702A0183 VBN O
with P08750702A0183 IN O
the P08750702A0183 DT O
alpha1-adrenoceptor-subtype P08750702A0183 JJ I-UN
blockers P08750702A0183 NNS O
WB4101 P08750702A0183 NNP O
( P08750702A0183 ( O
0.5 P08750702A0183 CD O
mg P08750702A0183 NN O
/ P08750702A0183 NNP O
kg P08750702A0183 NN O
i.v P08750702A0183 NN O
. P08750702A0183 . O
) P08750702A0183 ) O
or P08750702A0183 CC O
chloroethylclonidine P08750702A0183 NN O
( P08750702A0183 ( O
1.9 P08750702A0183 CD O
mg P08750702A0183 NN O
/ P08750702A0183 NNP O
kg P08750702A0183 NN O
i.v P08750702A0183 NN O
. P08750702A0183 . O
) P08750702A0183 ) O
. P08750702A0183 . O
. . O O

Molecular P07490079T0000 JJ O
cloning P07490079T0000 NN O
of P07490079T0000 IN O
the P07490079T0000 DT O
human P07490079T0000 JJ O
homolog P07490079T0000 NN O
of P07490079T0000 IN O
a P07490079T0000 DT O
striatum-enriched P07490079T0000 JJ I-UN
phosphatase P07490079T0000 NN I-UN
( P07490079T0000 ( I-UN
STEP P07490079T0000 NNP I-UN
) P07490079T0000 ) I-UN
gene P07490079T0000 NN I-UN
and P07490079T0000 CC O
chromosomal P07490079T0000 JJ O
mapping P07490079T0000 NN O
of P07490079T0000 IN O
the P07490079T0000 DT O
human P07490079T0000 JJ O
and P07490079T0000 CC O
murine P07490079T0000 JJ O
loci P07490079T0000 NN O
. P07490079T0000 . O
. . O O

Whereas P06953957A0503 NNP O
creatine P06953957A0503 JJ I-UN
kinase P06953957A0503 NN I-UN
activity P06953957A0503 NN O
declined P06953957A0503 VBD O
exponentially P06953957A0503 RB O
from P06953957A0503 IN O
a P06953957A0503 DT O
single P06953957A0503 JJ O
peak P06953957A0503 NN O
, P06953957A0503 , O
myoglobin P06953957A0503 NN I-UN
appeared P06953957A0503 VBD O
in P06953957A0503 IN O
multiple P06953957A0503 JJ O
episodes P06953957A0503 NNS O
inadequately P06953957A0503 RB O
represented P06953957A0503 VBN O
by P06953957A0503 IN O
a P06953957A0503 DT O
single P06953957A0503 JJ O
peak P06953957A0503 NN O
value P06953957A0503 NN O
and P06953957A0503 CC O
having P06953957A0503 VBG O
no P06953957A0503 DT O
clear P06953957A0503 JJ O
clinical P06953957A0503 JJ O
correlation P06953957A0503 NN O
. P06953957A0503 . O
. . O O

Toxicity P01740682A0703 NN O
was P01740682A0703 VBD O
mild P01740682A0703 JJ O
, P01740682A0703 , O
mainly P01740682A0703 RB O
consisting P01740682A0703 VBG O
of P01740682A0703 IN O
emesis P01740682A0703 NN O
( P01740682A0703 ( O
81 P01740682A0703 CD O
% P01740682A0703 NN O
of P01740682A0703 IN O
the P01740682A0703 DT O
patients P01740682A0703 NNS O
; P01740682A0703 : O
66 P01740682A0703 CD O
% P01740682A0703 NN O
of P01740682A0703 IN O
the P01740682A0703 DT O
courses P01740682A0703 NNS O
) P01740682A0703 ) O
, P01740682A0703 , O
leukopenia P01740682A0703 NN O
of P01740682A0703 IN O
World P01740682A0703 NNP O
Health P01740682A0703 NNP O
Organization P01740682A0703 NNP O
( P01740682A0703 ( O
WHO P01740682A0703 NNP O
) P01740682A0703 ) O
grade P01740682A0703 VBD O
1 P01740682A0703 CD O
to P01740682A0703 TO O
2 P01740682A0703 CD O
( P01740682A0703 ( O
47 P01740682A0703 CD O
% P01740682A0703 NN O
of P01740682A0703 IN O
the P01740682A0703 DT O
patients P01740682A0703 NNS O
; P01740682A0703 : O
18 P01740682A0703 CD O
% P01740682A0703 NN O
of P01740682A0703 IN O
the P01740682A0703 DT O
courses P01740682A0703 NNS O
) P01740682A0703 ) O
, P01740682A0703 , O
and P01740682A0703 CC O
thrombocytopenia P01740682A0703 NN O
( P01740682A0703 ( O
12 P01740682A0703 CD O
% P01740682A0703 NN O
of P01740682A0703 IN O
the P01740682A0703 DT O
patients P01740682A0703 NNS O
; P01740682A0703 : O
3 P01740682A0703 CD O
% P01740682A0703 NN O
of P01740682A0703 IN O
the P01740682A0703 DT O
courses P01740682A0703 NNS O
) P01740682A0703 ) O
. P01740682A0703 . O
. . O O

VEGF P11059786A0682 NNP I-UN
promoter P11059786A0682 NN I-UN
activity P11059786A0682 NN O
in P11059786A0682 IN O
transient P11059786A0682 JJ O
transfections P11059786A0682 NNS O
was P11059786A0682 VBD O
decreased P11059786A0682 VBN O
by P11059786A0682 IN O
either P11059786A0682 DT O
pharmacological P11059786A0682 JJ O
or P11059786A0682 CC O
genetic P11059786A0682 JJ O
inhibition P11059786A0682 NN O
of P11059786A0682 IN O
EGFR P11059786A0682 NNP I-UN
, P11059786A0682 , O
Ras P11059786A0682 NNP I-UN
, P11059786A0682 , O
or P11059786A0682 CC O
phosphatidylinositol P11059786A0682 VB I-UN
3'-kinase P11059786A0682 JJ I-UN
[ P11059786A0682 NNP I-UN
PI P11059786A0682 NNP I-UN
( P11059786A0682 ( I-UN
3 P11059786A0682 CD I-UN
) P11059786A0682 ) I-UN
kinase P11059786A0682 NN I-UN
] P11059786A0682 NN I-UN
. P11059786A0682 . O
. . O O

The P08673026T0000 DT O
factor P08673026T0000 NN O
structure P08673026T0000 NN O
of P08673026T0000 IN O
`` P08673026T0000 `` O
schizotypal P08673026T0000 JJ O
' P08673026T0000 '' O
traits P08673026T0000 NNS O
: P08673026T0000 : O
a P08673026T0000 DT O
large P08673026T0000 JJ O
replication P08673026T0000 NN O
study P08673026T0000 NN O
. P08673026T0000 . O
. . O O

SIM1 P09020169A0552 NNP I-UN
and P09020169A0552 CC O
SIM2 P09020169A0552 NNP I-UN
do P09020169A0552 VBP O
not P09020169A0552 RB O
form P09020169A0552 VB O
homodimers P09020169A0552 NNS O
, P09020169A0552 , O
and P09020169A0552 CC O
they P09020169A0552 PRP O
do P09020169A0552 VBP O
not P09020169A0552 RB O
interact P09020169A0552 VB O
with P09020169A0552 IN O
AHR P09020169A0552 NNP I-UN
. P09020169A0552 . O
. . O O

Homozygous P02195715A0143 JJ O
individuals P02195715A0143 NNS O
usually P02195715A0143 RB O
develop P02195715A0143 VBP O
purpura P02195715A0143 JJ O
fulminans P02195715A0143 NNS O
as P02195715A0143 IN O
newborns P02195715A0143 NNS O
; P02195715A0143 : O
heterozygous P02195715A0143 JJ O
protein P02195715A0143 IN I-UN
C-deficient P02195715A0143 JJ O
individuals P02195715A0143 NNS O
are P02195715A0143 VBP O
at P02195715A0143 IN O
increased P02195715A0143 VBN O
risk P02195715A0143 NN O
for P02195715A0143 IN O
venous P02195715A0143 JJ O
thrombosis P02195715A0143 NN O
and P02195715A0143 CC O
pulmonary P02195715A0143 JJ O
embolism P02195715A0143 NN O
. P02195715A0143 . O
. . O O

2 P00640584A0250 CD O
) P00640584A0250 ) O
The P00640584A0250 DT O
time-sharing P00640584A0250 JJ O
principle P00640584A0250 NN O
was P00640584A0250 VBD O
applied P00640584A0250 VBN O
to P00640584A0250 TO O
gain P00640584A0250 VB O
high P00640584A0250 JJ O
stability P00640584A0250 NN O
. P00640584A0250 . O
. . O O

The P04050771A0474 DT O
Cox P04050771A0474 NNP O
proportional P04050771A0474 JJ O
hazards P04050771A0474 NNS O
model P04050771A0474 NN O
was P04050771A0474 VBD O
applied P04050771A0474 VBN O
to P04050771A0474 TO O
the P04050771A0474 DT O
data P04050771A0474 NNS O
in P04050771A0474 IN O
order P04050771A0474 NN O
to P04050771A0474 TO O
determine P04050771A0474 VB O
the P04050771A0474 DT O
prognostic P04050771A0474 JJ O
factors P04050771A0474 NNS O
for P04050771A0474 IN O
long-term P04050771A0474 JJ O
survival P04050771A0474 NN O
. P04050771A0474 . O
. . O O

AIDS-related P09392979T0000 JJ O
disseminated P09392979T0000 JJ O
histoplasmosis P09392979T0000 NN O
in P09392979T0000 IN O
San P09392979T0000 NNP O
Francisco P09392979T0000 NNP O
, P09392979T0000 , O
California P09392979T0000 NNP O
. P09392979T0000 . O
. . O O

Of P11275986A0091 IN O
its P11275986A0091 PRP$ O
gene P11275986A0091 NN O
products P11275986A0091 NNS O
, P11275986A0091 , O
E6 P11275986A0091 NNP I-UN
binds P11275986A0091 VBZ O
to P11275986A0091 TO O
and P11275986A0091 CC O
inactivates P11275986A0091 NNS O
p53 P11275986A0091 VBP I-UN
tumor P11275986A0091 NN I-UN
suppressor P11275986A0091 NN I-UN
protein P11275986A0091 NN I-UN
by P11275986A0091 IN O
ubiquitin P11275986A0091 JJ I-UN
/ P11275986A0091 JJ O
proteasome-dependent P11275986A0091 JJ O
degradation P11275986A0091 NN O
. P11275986A0091 . O
. . O O

National P04062128T0028 NNP O
Institutes P04062128T0028 NNP O
of P04062128T0028 IN O
Health P04062128T0028 NNP O
Consensus P04062128T0028 NNP O
Development P04062128T0028 NNP O
Conference P04062128T0028 NNP O
Statement P04062128T0028 NNP O
. P04062128T0028 . O
. . O O

The P07963782A0000 DT O
physical P07963782A0000 JJ O
and P07963782A0000 CC O
chemical P07963782A0000 JJ O
stability P07963782A0000 NN O
of P07963782A0000 IN O
a P07963782A0000 DT O
combination P07963782A0000 NN O
of P07963782A0000 IN O
drugs P07963782A0000 NNS O
commonly P07963782A0000 RB O
administered P07963782A0000 VBD O
into P07963782A0000 IN O
the P07963782A0000 DT O
epidural P07963782A0000 JJ O
or P07963782A0000 CC O
intrathecal P07963782A0000 JJ O
space P07963782A0000 NN O
for P07963782A0000 IN O
the P07963782A0000 DT O
treatment P07963782A0000 NN O
of P07963782A0000 IN O
chronic P07963782A0000 JJ O
pain P07963782A0000 NN O
was P07963782A0000 VBD O
investigated P07963782A0000 VBN O
. P07963782A0000 . O
. . O O

1,3-bis P04563045T0000 JJ O
( P04563045T0000 ( O
2-chloroethyl P04563045T0000 JJ O
) P04563045T0000 ) O
-1-nitrosourea P04563045T0000 NN O
( P04563045T0000 ( O
bcnu P04563045T0000 NN O
) P04563045T0000 ) O
and P04563045T0000 CC O
other P04563045T0000 JJ O
nitrosoureas P04563045T0000 NNS O
in P04563045T0000 IN O
cancer P04563045T0000 NN O
treatment P04563045T0000 NN O
: P04563045T0000 : O
a P04563045T0000 DT O
review P04563045T0000 NN O
. P04563045T0000 . O
. . O O

This P03418727A0992 DT O
rapid P03418727A0992 JJ O
and P03418727A0992 CC O
extensive P03418727A0992 JJ O
penetration P03418727A0992 NN O
of P03418727A0992 IN O
intrathecally P03418727A0992 RB O
administered P03418727A0992 VBN O
chemotherapy P03418727A0992 NN O
may P03418727A0992 MD O
offer P03418727A0992 VB O
insight P03418727A0992 NN O
into P03418727A0992 IN O
the P03418727A0992 DT O
myelopathy P03418727A0992 JJ O
observed P03418727A0992 VBN O
with P03418727A0992 IN O
these P03418727A0992 DT O
treatments P03418727A0992 NNS O
. P03418727A0992 . O
. . O O

However P11559789A0314 RB O
, P11559789A0314 , O
during P11559789A0314 IN O
our P11559789A0314 PRP$ O
work P11559789A0314 NN O
with P11559789A0314 IN O
a P11559789A0314 DT O
replication-deficient P11559789A0314 JJ O
virus P11559789A0314 NN O
expressing P11559789A0314 VBG O
the P11559789A0314 DT O
ASF P11559789A0314 NNP I-UN
/ P11559789A0314 NNP O
SF2 P11559789A0314 NNP I-UN
splicing P11559789A0314 VBG O
factor P11559789A0314 NN O
from P11559789A0314 IN O
a P11559789A0314 DT O
progesterone P11559789A0314 NN O
antagonist-inducible P11559789A0314 JJ O
gene P11559789A0314 NN O
cassette P11559789A0314 NN O
, P11559789A0314 , O
we P11559789A0314 PRP O
discovered P11559789A0314 VBD O
that P11559789A0314 IN O
ASF P11559789A0314 NNP I-UN
/ P11559789A0314 NNP O
SF2 P11559789A0314 NNP I-UN
was P11559789A0314 VBD O
expressed P11559789A0314 VBN O
at P11559789A0314 IN O
a P11559789A0314 DT O
significant P11559789A0314 JJ O
level P11559789A0314 NN O
in P11559789A0314 IN O
the P11559789A0314 DT O
293 P11559789A0314 CD O
producer P11559789A0314 NN O
cell P11559789A0314 NN O
line P11559789A0314 NN O
, P11559789A0314 , O
even P11559789A0314 RB O
in P11559789A0314 IN O
the P11559789A0314 DT O
absence P11559789A0314 NN O
of P11559789A0314 IN O
inducer P11559789A0314 NN O
. P11559789A0314 . O
. . O O

There P11533340A1285 EX O
was P11533340A1285 VBD O
no P11533340A1285 DT O
significant P11533340A1285 JJ O
difference P11533340A1285 NN O
in P11533340A1285 IN O
developmental P11533340A1285 JJ O
scores P11533340A1285 NNS O
at P11533340A1285 IN O
9 P11533340A1285 CD O
or P11533340A1285 CC O
18 P11533340A1285 CD O
months P11533340A1285 NNS O
, P11533340A1285 , O
although P11533340A1285 IN O
PDF P11533340A1285 NNP O
infants P11533340A1285 NNS O
had P11533340A1285 VBD O
a P11533340A1285 DT O
2.8 P11533340A1285 CD O
( P11533340A1285 ( O
-1.3-6.8 P11533340A1285 NN O
) P11533340A1285 ) O
point P11533340A1285 NN O
advantage P11533340A1285 NN O
in P11533340A1285 IN O
Bayley P11533340A1285 NNP O
motor P11533340A1285 NN O
score P11533340A1285 NN O
scales P11533340A1285 NNS O
. P11533340A1285 . O
. . O O

Indeed P11395469A1373 RB O
, P11395469A1373 , O
mutation P11395469A1373 NN O
of P11395469A1373 IN O
two P11395469A1373 CD O
of P11395469A1373 IN O
these P11395469A1373 DT O
motifs P11395469A1373 NNS O
, P11395469A1373 , O
known P11395469A1373 VBN O
to P11395469A1373 TO O
be P11395469A1373 VB O
important P11395469A1373 JJ O
to P11395469A1373 TO O
regulation P11395469A1373 NN O
of P11395469A1373 IN O
sid1 P11395469A1373 NN I-UN
, P11395469A1373 , O
altered P11395469A1373 VBD O
the P11395469A1373 DT O
differential P11395469A1373 JJ O
regulation P11395469A1373 NN O
of P11395469A1373 IN O
sid2 P11395469A1373 NN I-UN
by P11395469A1373 IN O
iron P11395469A1373 NN O
. P11395469A1373 . O
. . O O

Many P01806314A0322 JJ O
cells P01806314A0322 NNS O
were P01806314A0322 VBD O
negative P01806314A0322 JJ O
for P01806314A0322 IN O
endothelial-cell P01806314A0322 JJ O
markers P01806314A0322 NNS O
, P01806314A0322 , O
and P01806314A0322 CC O
they P01806314A0322 PRP O
reacted P01806314A0322 VBD O
with P01806314A0322 IN O
a P01806314A0322 DT O
monoclonal P01806314A0322 JJ O
antibody P01806314A0322 NN O
against P01806314A0322 IN O
muscle P01806314A0322 NN O
actin P01806314A0322 NN I-UN
. P01806314A0322 . O
. . O O

Also P00956554A0414 RB O
, P00956554A0414 , O
samples P00956554A0414 NNS O
of P00956554A0414 IN O
serum P00956554A0414 NN O
were P00956554A0414 VBD O
absorbed P00956554A0414 VBN O
with P00956554A0414 IN O
the P00956554A0414 DT O
various P00956554A0414 JJ O
solid-phase P00956554A0414 JJ O
allergens P00956554A0414 NNS O
and P00956554A0414 CC O
the P00956554A0414 DT O
reactivity P00956554A0414 NN O
of P00956554A0414 IN O
the P00956554A0414 DT O
remaining P00956554A0414 VBG O
IgE P00956554A0414 NNP I-UN
antibodies P00956554A0414 NNS I-UN
was P00956554A0414 VBD O
determined P00956554A0414 VBN O
. P00956554A0414 . O
. . O O

It P02154602A0092 PRP O
is P02154602A0092 VBZ O
the P02154602A0092 DT O
human P02154602A0092 JJ O
homolog P02154602A0092 NN O
of P02154602A0092 IN O
the P02154602A0092 DT O
mouse P02154602A0092 NN I-UN
Mx P02154602A0092 NNP I-UN
protein P02154602A0092 NN I-UN
involved P02154602A0092 VBN O
in P02154602A0092 IN O
resistance P02154602A0092 NN O
to P02154602A0092 TO O
influenza P02154602A0092 VB O
virus P02154602A0092 NN O
. P02154602A0092 . O
. . O O

Ozagrel P10399136A0389 NNP O
, P10399136A0389 , O
ifenprodil P10399136A0389 NN O
, P10399136A0389 , O
cinnarizine P10399136A0389 NN O
and P10399136A0389 CC O
dilazep P10399136A0389 NN O
were P10399136A0389 VBD O
more P10399136A0389 RBR O
effective P10399136A0389 JJ O
than P10399136A0389 IN O
pentoxifylline P10399136A0389 NN O
in P10399136A0389 IN O
increasing P10399136A0389 VBG O
rCBF P10399136A0389 NN O
at P10399136A0389 IN O
the P10399136A0389 DT O
HPC P10399136A0389 NNP O
. P10399136A0389 . O
. . O O

272 P10471383A0229 CD O
, P10471383A0229 , O
1904 P10471383A0229 CD O
] P10471383A0229 NN O
. P10471383A0229 . O
. . O O

This P01640778A0485 DT O
accurate P01640778A0485 NN O
and P01640778A0485 CC O
rapid P01640778A0485 JJ O
method P01640778A0485 NN O
makes P01640778A0485 VBZ O
the P01640778A0485 DT O
MLPA P01640778A0485 NNP O
test P01640778A0485 NN O
logistically P01640778A0485 RB O
feasible P01640778A0485 JJ O
for P01640778A0485 IN O
large-scale P01640778A0485 JJ O
screening P01640778A0485 NN O
. P01640778A0485 . O
. . O O

Mutational P01347944A0964 JJ O
studies P01347944A0964 NNS O
revealed P01347944A0964 VBD O
that P01347944A0964 IN O
it P01347944A0964 PRP O
was P01347944A0964 VBD O
the P01347944A0964 DT O
homeodomain P01347944A0964 NN I-UN
binding P01347944A0964 VBG I-UN
site P01347944A0964 NN I-UN
II P01347944A0964 NNP I-UN
sequence P01347944A0964 NN I-UN
that P01347944A0964 WDT O
was P01347944A0964 VBD O
required P01347944A0964 VBN O
for P01347944A0964 IN O
this P01347944A0964 DT O
regulation P01347944A0964 NN O
. P01347944A0964 . O
. . O O

The P08769568A0949 DT O
structure P08769568A0949 NN O
of P08769568A0949 IN O
these P08769568A0949 DT O
genes P08769568A0949 NNS O
suggests P08769568A0949 VBZ O
a P08769568A0949 DT O
common P08769568A0949 JJ O
ancestor P08769568A0949 NN O
for P08769568A0949 IN O
all P08769568A0949 DT O
viperid P08769568A0949 JJ I-UN
PLA2 P08769568A0949 NNP I-UN
genes P08769568A0949 NNS I-UN
. P08769568A0949 . O
. . O O

We P10958698A0280 PRP O
have P10958698A0280 VBP O
carried P10958698A0280 VBN O
out P10958698A0280 RP O
a P10958698A0280 DT O
comprehensive P10958698A0280 JJ O
and P10958698A0280 CC O
systematic P10958698A0280 JJ O
mutagenesis P10958698A0280 NN O
of P10958698A0280 IN O
the P10958698A0280 DT O
Cse4p P10958698A0280 NNP I-UN
N P10958698A0280 NNP I-UN
terminus P10958698A0280 NN I-UN
to P10958698A0280 TO O
analyze P10958698A0280 VB O
its P10958698A0280 PRP$ O
function P10958698A0280 NN O
. P10958698A0280 . O
. . O O

Eleven P08160905A0217 JJ O
patients P08160905A0217 NNS O
tested P08160905A0217 VBD O
positive P08160905A0217 JJ O
for P08160905A0217 IN O
the P08160905A0217 DT O
hepatitis P08160905A0217 NN I-UN
B P08160905A0217 NNP I-UN
surface P08160905A0217 NN I-UN
antigen P08160905A0217 NN I-UN
( P08160905A0217 ( O
HBsAg P08160905A0217 NNP I-UN
) P08160905A0217 ) O
. P08160905A0217 . O
. . O O

DPA P02895566A0187 NNP O
attenuated P02895566A0187 VBD O
the P02895566A0187 DT O
increase P02895566A0187 NN O
of P02895566A0187 IN O
the P02895566A0187 DT O
intensity P02895566A0187 NN O
of P02895566A0187 IN O
the P02895566A0187 DT O
ischemic P02895566A0187 JJ O
and P02895566A0187 CC O
pressure P02895566A0187 NN O
pain P02895566A0187 NN O
components P02895566A0187 NNS O
with P02895566A0187 IN O
increasing P02895566A0187 VBG O
ischemia P02895566A0187 NN O
duration P02895566A0187 NN O
, P02895566A0187 , O
but P02895566A0187 CC O
only P02895566A0187 RB O
the P02895566A0187 DT O
effect P02895566A0187 NN O
on P02895566A0187 IN O
the P02895566A0187 DT O
pressure P02895566A0187 NN O
pain P02895566A0187 NN O
component P02895566A0187 NN O
was P02895566A0187 VBD O
significant P02895566A0187 JJ O
. P02895566A0187 . O
. . O O

These P07657705A1181 DT O
results P07657705A1181 NNS O
indicate P07657705A1181 VBP O
that P07657705A1181 IN O
K-glypican P07657705A1181 NNP I-UN
is P07657705A1181 VBZ O
a P07657705A1181 DT O
novel P07657705A1181 JJ O
GPI-anchored P07657705A1181 JJ I-UN
HSPG P07657705A1181 NNP I-UN
involved P07657705A1181 VBN O
in P07657705A1181 IN O
embryonic P07657705A1181 JJ O
development P07657705A1181 NN O
. P07657705A1181 . O
. . O O

The P07898589T0000 DT O
`` P07898589T0000 `` O
tobacco P07898589T0000 JJ O
issue P07898589T0000 NN O
'' P07898589T0000 '' O
. P07898589T0000 . O
. . O O

Six P11543662A0562 CD O
of P11543662A0562 IN O
the P11543662A0562 DT O
gstC P11543662A0562 NN I-UN
' P11543662A0562 POS I-UN
mutants P11543662A0562 NNS I-UN
, P11543662A0562 , O
primarily P11543662A0562 RB O
in P11543662A0562 IN O
the P11543662A0562 DT O
C-terminal P11543662A0562 JJ O
half P11543662A0562 NN O
of P11543662A0562 IN O
C P11543662A0562 NNP I-UN
' P11543662A0562 POS I-UN
, P11543662A0562 , O
exhibited P11543662A0562 VBD O
a P11543662A0562 DT O
defect P11543662A0562 NN O
in P11543662A0562 IN O
the P11543662A0562 DT O
ability P11543662A0562 NN O
to P11543662A0562 TO O
bind P11543662A0562 VB O
L P11543662A0562 NNP I-UN
protein P11543662A0562 NN I-UN
. P11543662A0562 . O
. . O O

Characterization P10855793A1418 NN O
of P10855793A1418 IN O
polymorphic P10855793A1418 JJ O
TNRs P10855793A1418 NNP O
in P10855793A1418 IN O
novel P10855793A1418 NN O
and P10855793A1418 CC O
even P10855793A1418 RB O
known P10855793A1418 VBN O
genes P10855793A1418 NNS O
expressed P10855793A1418 VBN O
in P10855793A1418 IN O
human P10855793A1418 JJ O
spinal P10855793A1418 JJ O
cord P10855793A1418 NN O
is P10855793A1418 VBZ O
likely P10855793A1418 JJ O
to P10855793A1418 TO O
help P10855793A1418 VB O
in P10855793A1418 IN O
the P10855793A1418 DT O
identification P10855793A1418 NN O
of P10855793A1418 IN O
new P10855793A1418 JJ O
candidates P10855793A1418 NNS O
for P10855793A1418 IN O
genes P10855793A1418 NNS O
involved P10855793A1418 VBN O
in P10855793A1418 IN O
neurodegenerative P10855793A1418 JJ O
disorders P10855793A1418 NNS O
. P10855793A1418 . O
. . O O

These P10077533A0976 DT O
data P10077533A0976 NNS O
provide P10077533A0976 VBP O
the P10077533A0976 DT O
molecular P10077533A0976 JJ O
tools P10077533A0976 NNS O
for P10077533A0976 IN O
the P10077533A0976 DT O
final P10077533A0976 JJ O
identification P10077533A0976 NN O
of P10077533A0976 IN O
the P10077533A0976 DT O
MKS P10077533A0976 NNP I-UN
and P10077533A0976 CC O
the P10077533A0976 DT O
MUL P10077533A0976 NNP I-UN
genes P10077533A0976 NNS I-UN
. P10077533A0976 . O
. . O O

These P10187864A1372 DT O
results P10187864A1372 NNS O
suggest P10187864A1372 VBP O
KCC3 P10187864A1372 NNP I-UN
is P10187864A1372 VBZ O
a P10187864A1372 DT O
new P10187864A1372 JJ O
member P10187864A1372 NN O
of P10187864A1372 IN O
the P10187864A1372 DT O
KCC P10187864A1372 NNP I-UN
family P10187864A1372 NN I-UN
that P10187864A1372 WDT O
is P10187864A1372 VBZ O
under P10187864A1372 IN O
distinct P10187864A1372 JJ O
regulation P10187864A1372 NN O
from P10187864A1372 IN O
KCC1 P10187864A1372 NNP I-UN
. P10187864A1372 . O
. . O O

( P07929238A0734 ( O
1992 P07929238A0734 CD O
) P07929238A0734 ) O
Genomics P07929238A0734 NNPS O
12 P07929238A0734 CD O
, P07929238A0734 , O
58-62 P07929238A0734 JJ O
) P07929238A0734 ) O
. P07929238A0734 . O
. . O O

Immunochemical P04973523T0000 JJ O
studies P04973523T0000 NNS O
with P04973523T0000 IN O
filarial P04973523T0000 JJ O
antigens P04973523T0000 NNS O
. P04973523T0000 . O
. . O O

Both P08421295A0365 DT O
fusion P08421295A0365 NN O
proteins P08421295A0365 VBZ O
form P08421295A0365 RBR O
stable P08421295A0365 JJ O
specific P08421295A0365 JJ O
complexes P08421295A0365 NNS O
with P08421295A0365 IN O
a P08421295A0365 DT O
short P08421295A0365 JJ O
DNA P08421295A0365 NN O
duplex P08421295A0365 JJ O
harboring P08421295A0365 VBG O
the P08421295A0365 DT O
CTGT P08421295A0365 NNP O
( P08421295A0365 ( O
at P08421295A0365 IN O
) P08421295A0365 ) O
4ACAG P08421295A0365 CD O
consensus P08421295A0365 NN O
sequence P08421295A0365 NN O
of P08421295A0365 IN O
the P08421295A0365 DT O
LexA P08421295A0365 NNP I-UN
repressor P08421295A0365 NN I-UN
. P08421295A0365 . O
. . O O

Role P00929418T0001 NNP O
of P00929418T0001 IN O
the P00929418T0001 DT O
infectious-disease P00929418T0001 JJ O
specialist P00929418T0001 NN O
of P00929418T0001 IN O
a P00929418T0001 DT O
polyclinic P00929418T0001 NN O
in P00929418T0001 IN O
reducing P00929418T0001 VBG O
the P00929418T0001 DT O
incidence P00929418T0001 NN O
of P00929418T0001 IN O
communicable P00929418T0001 JJ O
diseases P00929418T0001 NNS O
. P00929418T0001 . O
. . O O

Schistosoma P11842728X0001 NNP O
mansoni P11842728X0001 PRP O
schistosomiasis P11842728X0001 VBD O
] P11842728X0001 JJ O
Schistosomosis P11842728X0001 NNP O
are P11842728X0001 VBP O
parasitic P11842728X0001 JJ O
diseases P11842728X0001 NNS O
caused P11842728X0001 VBN O
by P11842728X0001 IN O
blood P11842728X0001 NN O
flukes P11842728X0001 NNS O
of P11842728X0001 IN O
the P11842728X0001 DT O
Schistosoma P11842728X0001 NNP O
genus P11842728X0001 NN O
. P11842728X0001 . O
. . O O

AP P01284032A0213 NNP O
was P01284032A0213 VBD O
induced P01284032A0213 VBN O
by P01284032A0213 IN O
intraductal P01284032A0213 JJ O
infusion P01284032A0213 NN O
of P01284032A0213 IN O
two P01284032A0213 CD O
different P01284032A0213 JJ O
concentrations P01284032A0213 NNS O
of P01284032A0213 IN O
glycodeoxycholic P01284032A0213 JJ O
acid P01284032A0213 NN O
( P01284032A0213 ( O
GDOC P01284032A0213 NNP O
17 P01284032A0213 CD O
mmol P01284032A0213 NN O
and P01284032A0213 CC O
34 P01284032A0213 CD O
mmol P01284032A0213 NN O
) P01284032A0213 ) O
. P01284032A0213 . O
. . O O

Factors P01523111A0769 NNS O
associated P01523111A0769 VBN O
with P01523111A0769 IN O
afterdrop P01523111A0769 NN O
included P01523111A0769 VBD O
age P01523111A0769 NN O
, P01523111A0769 , O
end-of-surgery P01523111A0769 JJ O
temperature P01523111A0769 NN O
( P01523111A0769 ( O
both P01523111A0769 DT O
positively P01523111A0769 RB O
) P01523111A0769 ) O
and P01523111A0769 CC O
body P01523111A0769 NN O
mass P01523111A0769 NN O
( P01523111A0769 ( O
negatively P01523111A0769 RB O
) P01523111A0769 ) O
. P01523111A0769 . O
. . O O

These P03499608A1054 DT O
data P03499608A1054 NNS O
should P03499608A1054 MD O
be P03499608A1054 VB O
useful P03499608A1054 JJ O
in P03499608A1054 IN O
developing P03499608A1054 VBG O
reagents P03499608A1054 NNS O
for P03499608A1054 IN O
heterozygote P03499608A1054 NN O
detection P03499608A1054 NN O
and P03499608A1054 CC O
prenatal P03499608A1054 JJ O
diagnosis P03499608A1054 NN O
of P03499608A1054 IN O
11 P03499608A1054 CD I-UN
beta-hydroxylase P03499608A1054 JJ I-UN
deficiency P03499608A1054 NN O
, P03499608A1054 , O
the P03499608A1054 DT O
second P03499608A1054 JJ O
most P03499608A1054 RBS O
frequent P03499608A1054 JJ O
cause P03499608A1054 NN O
of P03499608A1054 IN O
congenital P03499608A1054 JJ O
adrenal P03499608A1054 JJ O
hyperplasia P03499608A1054 NN O
. P03499608A1054 . O
. . O O

Primer P07768836A1126 NNP O
extension P07768836A1126 NN O
experiments P07768836A1126 NNS O
revealed P07768836A1126 VBD O
a P07768836A1126 DT O
strong P07768836A1126 JJ O
transcription P07768836A1126 NN O
initiation P07768836A1126 NN O
site P07768836A1126 NN O
102 P07768836A1126 CD O
bp P07768836A1126 JJ O
upstream P07768836A1126 NN O
of P07768836A1126 IN O
the P07768836A1126 DT O
translational P07768836A1126 JJ O
start P07768836A1126 NN O
site P07768836A1126 NN O
. P07768836A1126 . O
. . O O

The P11404016A1922 DT O
co-existence P11404016A1922 NN O
of P11404016A1922 IN O
TE P11404016A1922 NNP I-UN
domains P11404016A1922 NNS I-UN
within P11404016A1922 IN O
modular P11404016A1922 JJ O
PKSs P11404016A1922 NNP I-UN
along P11404016A1922 IN O
with P11404016A1922 IN O
physically P11404016A1922 RB O
separated P11404016A1922 VBN O
, P11404016A1922 , O
monofunctional P11404016A1922 JJ O
TEs P11404016A1922 NNP I-UN
( P11404016A1922 ( O
TE P11404016A1922 NNP I-UN
IIs P11404016A1922 NNP I-UN
) P11404016A1922 ) O
has P11404016A1922 VBZ O
been P11404016A1922 VBN O
reported P11404016A1922 VBN O
for P11404016A1922 IN O
a P11404016A1922 DT O
number P11404016A1922 NN O
of P11404016A1922 IN O
modular P11404016A1922 JJ O
polyketide P11404016A1922 NN O
and P11404016A1922 CC O
non-ribosomal P11404016A1922 JJ I-UN
peptide P11404016A1922 NN I-UN
synthases P11404016A1922 NNS I-UN
( P11404016A1922 ( O
NRPS P11404016A1922 NNP I-UN
) P11404016A1922 ) O
. P11404016A1922 . O
. . O O

In P08386637A1220 IN O
contrast P08386637A1220 NN O
to P08386637A1220 TO O
the P08386637A1220 DT O
situation P08386637A1220 NN O
in P08386637A1220 IN O
mammalian P08386637A1220 JJ O
cells P08386637A1220 NNS O
, P08386637A1220 , O
prolonged P08386637A1220 JJ O
exposure P08386637A1220 NN O
of P08386637A1220 IN O
the P08386637A1220 DT O
agonist P08386637A1220 NN O
( P08386637A1220 ( O
24 P08386637A1220 CD O
h P08386637A1220 NN O
) P08386637A1220 ) O
does P08386637A1220 VBZ O
not P08386637A1220 RB O
result P08386637A1220 VB O
in P08386637A1220 IN O
down P08386637A1220 JJ O
regulation P08386637A1220 NN O
of P08386637A1220 IN O
the P08386637A1220 DT O
remaining P08386637A1220 VBG O
70 P08386637A1220 CD O
% P08386637A1220 NN O
of P08386637A1220 IN O
the P08386637A1220 DT O
receptors P08386637A1220 NNS O
. P08386637A1220 . O
. . O O

MOP5 P09079689A0472 NNP I-UN
contained P09079689A0472 VBD O
the P09079689A0472 DT O
characteristic P09079689A0472 JJ O
PAS P09079689A0472 NNP I-UN
domain P09079689A0472 NN O
and P09079689A0472 CC O
a P09079689A0472 DT O
variable P09079689A0472 JJ O
C P09079689A0472 NNP O
terminus P09079689A0472 NN O
; P09079689A0472 : O
it P09079689A0472 PRP O
is P09079689A0472 VBZ O
possible P09079689A0472 JJ O
that P09079689A0472 IN O
the P09079689A0472 DT O
cDNA P09079689A0472 NN O
contains P09079689A0472 VBZ O
a P09079689A0472 DT O
bHLH P09079689A0472 NN O
domain P09079689A0472 NN O
, P09079689A0472 , O
but P09079689A0472 CC O
the P09079689A0472 DT O
entire P09079689A0472 JJ O
open P09079689A0472 JJ O
reading P09079689A0472 NN O
frame P09079689A0472 NN O
has P09079689A0472 VBZ O
yet P09079689A0472 RB O
to P09079689A0472 TO O
be P09079689A0472 VB O
completed P09079689A0472 VBN O
. P09079689A0472 . O
. . O O

Beta P10490955T0000 $ I-UN
1 P10490955T0000 CD I-UN
integrin- P10490955T0000 JJ O
and P10490955T0000 CC O
proteoglycan-mediated P10490955T0000 JJ O
stimulation P10490955T0000 NN O
of P10490955T0000 IN O
T P10490955T0000 NNP O
lymphoma P10490955T0000 NN O
cell P10490955T0000 NN O
adhesion P10490955T0000 NN O
and P10490955T0000 CC O
mitogen-activated P10490955T0000 JJ I-UN
protein P10490955T0000 NN I-UN
kinase P10490955T0000 NN I-UN
signaling P10490955T0000 VBG O
by P10490955T0000 IN O
thrombospondin-1 P10490955T0000 JJ I-UN
and P10490955T0000 CC O
thrombospondin-1 P10490955T0000 JJ I-UN
peptides P10490955T0000 NNS I-UN
. P10490955T0000 . O
. . O O

In P07916577A0190 IN O
order P07916577A0190 NN O
to P07916577A0190 TO O
define P07916577A0190 VB O
potential P07916577A0190 JJ O
candidate P07916577A0190 NN O
genes P07916577A0190 NNS O
for P07916577A0190 IN O
inherited P07916577A0190 JJ O
disorders P07916577A0190 NNS O
characterized P07916577A0190 VBN O
by P07916577A0190 IN O
aberrant P07916577A0190 JJ O
gene P07916577A0190 NN O
expression P07916577A0190 NN O
, P07916577A0190 , O
we P07916577A0190 PRP O
utilized P07916577A0190 VBD O
Kruppel-related P07916577A0190 NNP I-UN
sequences P07916577A0190 NNS I-UN
to P07916577A0190 TO O
isolate P07916577A0190 VB O
zinc P07916577A0190 JJ O
finger-containing P07916577A0190 JJ O
cDNAs P07916577A0190 NN O
. P07916577A0190 . O
. . O O

Viruses P10935880A1049 NNS O
were P10935880A1049 VBD O
isolated P10935880A1049 VBN O
from P10935880A1049 IN O
9 P10935880A1049 CD O
lungs P10935880A1049 NNS O
: P10935880A1049 : O
7 P10935880A1049 CD O
with P10935880A1049 IN O
PI-3V P10935880A1049 NNP O
, P10935880A1049 , O
1 P10935880A1049 CD O
with P10935880A1049 IN O
NCP P10935880A1049 NNP O
BVDV P10935880A1049 NNP O
type P10935880A1049 NN O
1 P10935880A1049 CD O
, P10935880A1049 , O
and P10935880A1049 CC O
1 P10935880A1049 CD O
with P10935880A1049 IN O
both P10935880A1049 DT O
BVHV-1 P10935880A1049 NNP O
and P10935880A1049 CC O
BVDV P10935880A1049 NNP O
. P10935880A1049 . O
. . O O

A P00465681A0000 DT O
rise P00465681A0000 NN O
of P00465681A0000 IN O
hemoglobin P00465681A0000 JJ I-UN
concentration P00465681A0000 NN O
accompanied P00465681A0000 VBN O
by P00465681A0000 IN O
an P00465681A0000 DT O
increase P00465681A0000 NN O
of P00465681A0000 IN O
the P00465681A0000 DT O
total P00465681A0000 JJ O
iron P00465681A0000 NN O
in P00465681A0000 IN O
the P00465681A0000 DT O
blood P00465681A0000 NN O
serum P00465681A0000 NN O
of P00465681A0000 IN O
white P00465681A0000 JJ O
mice P00465681A0000 NN O
was P00465681A0000 VBD O
found P00465681A0000 VBN O
under P00465681A0000 IN O
oxygen P00465681A0000 NN O
pressure P00465681A0000 NN O
of P00465681A0000 IN O
4 P00465681A0000 CD O
atm P00465681A0000 NN O
for P00465681A0000 IN O
an P00465681A0000 DT O
hour P00465681A0000 NN O
( P00465681A0000 ( O
preconvulsive P00465681A0000 JJ O
state P00465681A0000 NN O
) P00465681A0000 ) O
and P00465681A0000 CC O
6 P00465681A0000 CD O
atm P00465681A0000 NN O
( P00465681A0000 ( O
convulsive P00465681A0000 JJ O
state P00465681A0000 NN O
) P00465681A0000 ) O
. P00465681A0000 . O
. . O O

The P09427544A0000 DT O
pel P09427544A0000 JJ I-UN
gene P09427544A0000 NN I-UN
from P09427544A0000 IN O
an P09427544A0000 DT O
Amycolata P09427544A0000 NNP O
sp P09427544A0000 NN O
. P09427544A0000 . O
encoding P09427544A0000 VBG O
a P09427544A0000 DT O
pectate P09427544A0000 NN I-UN
lyase P09427544A0000 NN I-UN
( P09427544A0000 ( O
EC P09427544A0000 NNP I-UN
4.2.2.2 P09427544A0000 CD I-UN
) P09427544A0000 ) O
was P09427544A0000 VBD O
isolated P09427544A0000 VBN O
by P09427544A0000 IN O
activity P09427544A0000 NN O
screening P09427544A0000 VBG O
a P09427544A0000 DT O
genomic P09427544A0000 JJ O
DNA P09427544A0000 NNP O
library P09427544A0000 NN O
in P09427544A0000 IN O
Streptomyces P09427544A0000 NNS O
lividans P09427544A0000 NNS O
TK24 P09427544A0000 NNP O
. P09427544A0000 . O
. . O O

Late P00061478T0000 JJ O
complications P00061478T0000 NNS O
of P00061478T0000 IN O
catheterisation P00061478T0000 NN O
for P00061478T0000 IN O
intravenous P00061478T0000 JJ O
nutrition P00061478T0000 NN O
. P00061478T0000 . O
. . O O

The P06237518A0117 DT O
customary P06237518A0117 JJ O
coupling P06237518A0117 NN O
reagent P06237518A0117 NN O
sulfanilic P06237518A0117 JJ O
acid P06237518A0117 NN O
has P06237518A0117 VBZ O
been P06237518A0117 VBN O
replaced P06237518A0117 VBN O
by P06237518A0117 IN O
1,3-dimethylbarbituric P06237518A0117 JJ O
acid P06237518A0117 NN O
; P06237518A0117 : O
CNCl P06237518A0117 NNP O
is P06237518A0117 VBZ O
produced P06237518A0117 VBN O
in P06237518A0117 IN O
the P06237518A0117 DT O
flow P06237518A0117 NN O
through P06237518A0117 IN O
system P06237518A0117 NN O
directly P06237518A0117 RB O
from P06237518A0117 IN O
KCN P06237518A0117 NNP O
and P06237518A0117 CC O
chloramine P06237518A0117 JJ O
T P06237518A0117 NNP O
. P06237518A0117 . O
. . O O

Signaling P08910292T0000 VBG O
from P08910292T0000 IN O
the P08910292T0000 DT O
small P08910292T0000 JJ I-UN
GTP-binding P08910292T0000 JJ I-UN
proteins P08910292T0000 NNS I-UN
Rac1 P08910292T0000 NNP I-UN
and P08910292T0000 CC O
Cdc42 P08910292T0000 NNP I-UN
to P08910292T0000 TO O
the P08910292T0000 DT O
c-Jun P08910292T0000 JJ I-UN
N-terminal P08910292T0000 JJ I-UN
kinase P08910292T0000 NN I-UN
/ P08910292T0000 NNP O
stress-activated P08910292T0000 JJ I-UN
protein P08910292T0000 NN I-UN
kinase P08910292T0000 VB I-UN
pathway P08910292T0000 NN O
. P08910292T0000 . O
. . O O

Serum P03862898A0563 NNP I-UN
IgM P03862898A0563 NNP I-UN
and P03862898A0563 CC O
IgE P03862898A0563 NNP I-UN
concentrations P03862898A0563 NNS O
, P03862898A0563 , O
allergen-specific P03862898A0563 JJ I-UN
IgE P03862898A0563 NNP I-UN
scores P03862898A0563 NNS O
, P03862898A0563 , O
and P03862898A0563 CC O
the P03862898A0563 DT O
tumor P03862898A0563 NN O
E2R P03862898A0563 NNP I-UN
status P03862898A0563 NN O
were P03862898A0563 VBD O
combined P03862898A0563 VBN O
to P03862898A0563 TO O
construct P03862898A0563 VB O
a P03862898A0563 DT O
three-level P03862898A0563 JJ O
risk P03862898A0563 NN O
classification P03862898A0563 NN O
that P03862898A0563 WDT O
was P03862898A0563 VBD O
more P03862898A0563 RBR O
prognostic P03862898A0563 JJ O
than P03862898A0563 IN O
any P03862898A0563 DT O
of P03862898A0563 IN O
the P03862898A0563 DT O
individual P03862898A0563 JJ O
components P03862898A0563 NNS O
. P03862898A0563 . O
. . O O

The P10438593A0000 DT O
human P10438593A0000 JJ I-UN
immunodeficiency P10438593A0000 NN I-UN
virus P10438593A0000 NN I-UN
type-1 P10438593A0000 NN I-UN
( P10438593A0000 ( I-UN
HIV-1 P10438593A0000 NNP I-UN
) P10438593A0000 ) I-UN
Tat P10438593A0000 NNP I-UN
protein P10438593A0000 NN I-UN
regulates P10438593A0000 VBZ O
transcription P10438593A0000 NN O
by P10438593A0000 IN O
stimulating P10438593A0000 VBG O
RNA P10438593A0000 NNP I-UN
polymerase P10438593A0000 NN I-UN
processivity P10438593A0000 NN O
. P10438593A0000 . O
. . O O

Reaction P10699354A0557 NN O
time P10699354A0557 NN O
( P10699354A0557 ( O
RT P10699354A0557 NNP O
) P10699354A0557 ) O
and P10699354A0557 CC O
P300 P10699354A0557 NNP O
were P10699354A0557 VBD O
collected P10699354A0557 VBN O
simultaneously P10699354A0557 RB O
. P10699354A0557 . O
. . O O

Its P01674242A0358 PRP$ O
clearance P01674242A0358 NN O
has P01674242A0358 VBZ O
been P01674242A0358 VBN O
found P01674242A0358 VBN O
to P01674242A0358 TO O
be P01674242A0358 VB O
decreased P01674242A0358 VBN O
( P01674242A0358 ( O
typically P01674242A0358 RB O
by P01674242A0358 IN O
around P01674242A0358 IN O
25 P01674242A0358 CD O
% P01674242A0358 NN O
, P01674242A0358 , O
but P01674242A0358 CC O
often P01674242A0358 RB O
by P01674242A0358 IN O
far P01674242A0358 RB O
more P01674242A0358 JJR O
) P01674242A0358 ) O
by P01674242A0358 IN O
erythromycin P01674242A0358 NN O
, P01674242A0358 , O
troleandomycin P01674242A0358 NN O
( P01674242A0358 ( O
triacetyloleandomycin P01674242A0358 NN O
) P01674242A0358 ) O
, P01674242A0358 , O
roxithromycin P01674242A0358 NN O
, P01674242A0358 , O
enoxacin P01674242A0358 NN O
, P01674242A0358 , O
ciprofloxacin P01674242A0358 NN O
, P01674242A0358 , O
pefloxacin P01674242A0358 NN O
, P01674242A0358 , O
norfloxacin P01674242A0358 RB O
, P01674242A0358 , O
ofloxacin P01674242A0358 PRP O
, P01674242A0358 , O
fluoroquinolone P01674242A0358 RB O
T-3262 P01674242A0358 NNP O
, P01674242A0358 , O
pipemidic P01674242A0358 JJ O
acid P01674242A0358 NN O
, P01674242A0358 , O
cimetidine P01674242A0358 NN O
, P01674242A0358 , O
etintidine P01674242A0358 NN O
, P01674242A0358 , O
propranolol P01674242A0358 NN O
, P01674242A0358 , O
verapamil P01674242A0358 NN O
, P01674242A0358 , O
diltiazem P01674242A0358 NN O
, P01674242A0358 , O
nifedipine P01674242A0358 NN O
, P01674242A0358 , O
furosemide P01674242A0358 NN O
( P01674242A0358 ( O
frusemide P01674242A0358 NN O
) P01674242A0358 ) O
, P01674242A0358 , O
at P01674242A0358 IN O
least P01674242A0358 JJS O
some P01674242A0358 DT O
anovulent P01674242A0358 JJ O
agents P01674242A0358 NNS O
, P01674242A0358 , O
viloxazine P01674242A0358 NN O
, P01674242A0358 , O
allopurinol P01674242A0358 NN O
, P01674242A0358 , O
ticlopidine P01674242A0358 NN O
, P01674242A0358 , O
idrocilamide P01674242A0358 NN O
, P01674242A0358 , O
thiabendazole P01674242A0358 NN O
, P01674242A0358 , O
disulfiram P01674242A0358 NN O
, P01674242A0358 , O
influenza- P01674242A0358 JJ O
and P01674242A0358 CC O
BCG-vaccination P01674242A0358 NNP O
, P01674242A0358 , O
interferon P01674242A0358 NN I-UN
, P01674242A0358 , O
and P01674242A0358 CC O
caffeine P01674242A0358 NN O
( P01674242A0358 ( O
half-life P01674242A0358 JJ O
increase P01674242A0358 NN O
) P01674242A0358 ) O
. P01674242A0358 . O
. . O O

TDEYA P07874060A0810 NN O
at P07874060A0810 IN O
doses P07874060A0810 NNS O
of P07874060A0810 IN O
200 P07874060A0810 CD O
to P07874060A0810 TO O
500 P07874060A0810 CD O
mg P07874060A0810 NNS O
/ P07874060A0810 JJ O
kg P07874060A0810 VBP O
significantly P07874060A0810 RB O
suppressed P07874060A0810 VBN O
xanthine P07874060A0810 JJ I-UN
oxidase P07874060A0810 NN I-UN
( P07874060A0810 ( O
XO P07874060A0810 NNP I-UN
) P07874060A0810 ) O
activity P07874060A0810 NN O
in P07874060A0810 IN O
the P07874060A0810 DT O
stomach P07874060A0810 NN O
tissue P07874060A0810 NN O
following P07874060A0810 VBG O
its P07874060A0810 PRP$ O
oral P07874060A0810 JJ O
administration P07874060A0810 NN O
. P07874060A0810 . O
. . O O

The P11438838A0788 DT O
other P11438838A0788 JJ O
inhibitor P11438838A0788 NN O
was P11438838A0788 VBD O
a P11438838A0788 DT O
single P11438838A0788 JJ O
TAR P11438838A0788 NNP I-UN
decoy P11438838A0788 NN O
, P11438838A0788 , O
driven P11438838A0788 VBN O
by P11438838A0788 IN O
the P11438838A0788 DT O
U6 P11438838A0788 NNP I-UN
small P11438838A0788 JJ I-UN
nuclear P11438838A0788 JJ I-UN
RNA P11438838A0788 NNP I-UN
promoter P11438838A0788 NN I-UN
( P11438838A0788 ( O
U6-P P11438838A0788 NNP I-UN
) P11438838A0788 ) O
. P11438838A0788 . O
. . O O

The P11134033A0000 DT O
murine P11134033A0000 JJ I-UN
int-6 P11134033A0000 JJ I-UN
locus P11134033A0000 NN I-UN
, P11134033A0000 , O
identified P11134033A0000 VBN O
as P11134033A0000 IN O
a P11134033A0000 DT O
frequent P11134033A0000 JJ O
integration P11134033A0000 NN O
site P11134033A0000 NN O
of P11134033A0000 IN O
mouse P11134033A0000 NN O
mammary P11134033A0000 JJ O
tumor P11134033A0000 NN O
viruses P11134033A0000 NNS O
, P11134033A0000 , O
encodes P11134033A0000 VBZ O
the P11134033A0000 DT O
48-kDa P11134033A0000 JJ I-UN
eIF3e P11134033A0000 NN I-UN
subunit P11134033A0000 NN I-UN
of P11134033A0000 IN I-UN
translation P11134033A0000 NN I-UN
initiation P11134033A0000 NN I-UN
factor P11134033A0000 NN I-UN
eIF3 P11134033A0000 NN I-UN
. P11134033A0000 . O
. . O O

This P02757033A0905 DT O
would P02757033A0905 MD O
have P02757033A0905 VB O
had P02757033A0905 VBD O
the P02757033A0905 DT O
effect P02757033A0905 NN O
of P02757033A0905 IN O
positioning P02757033A0905 VBG O
the P02757033A0905 DT O
genes P02757033A0905 NNS O
currently P02757033A0905 RB O
on P02757033A0905 IN O
the P02757033A0905 DT O
long P02757033A0905 JJ O
arm P02757033A0905 NN O
adjacent P02757033A0905 NN O
to P02757033A0905 TO O
the P02757033A0905 DT O
centromeric P02757033A0905 JJ O
heterochromatin P02757033A0905 NN O
, P02757033A0905 , O
perhaps P02757033A0905 RB O
resulting P02757033A0905 VBG O
in P02757033A0905 IN O
a P02757033A0905 DT O
`` P02757033A0905 `` O
position P02757033A0905 NN O
effect P02757033A0905 NN O
'' P02757033A0905 '' O
on P02757033A0905 IN O
transcription P02757033A0905 NN O
of P02757033A0905 IN O
these P02757033A0905 DT O
genes P02757033A0905 NNS O
. P02757033A0905 . O
. . O O

A P10954913A0152 DT O
2.3-kb P10954913A0152 JJ O
full-length P10954913A0152 JJ O
cDNA P10954913A0152 NN O
clone P10954913A0152 NN O
of P10954913A0152 IN O
an P10954913A0152 DT O
Atlantic P10954913A0152 NNP I-UN
halibut P10954913A0152 NN I-UN
Mx P10954913A0152 NNP I-UN
gene P10954913A0152 NN I-UN
was P10954913A0152 VBD O
isolated P10954913A0152 VBN O
from P10954913A0152 IN O
a P10954913A0152 DT O
liver P10954913A0152 NN O
cDNA P10954913A0152 NN O
library P10954913A0152 NN O
. P10954913A0152 . O
. . O O

XXI P06070204T0025 NN O
. P06070204T0025 . O
. . O O

METHOD P09676419A0158 NN O
: P09676419A0158 : O
50 P09676419A0158 CD O
consecutive P09676419A0158 JJ O
children P09676419A0158 NNS O
aged P09676419A0158 VBN O
from P09676419A0158 IN O
6 P09676419A0158 CD O
months P09676419A0158 NNS O
to P09676419A0158 TO O
17 P09676419A0158 CD O
years P09676419A0158 NNS O
were P09676419A0158 VBD O
included P09676419A0158 VBN O
into P09676419A0158 IN O
the P09676419A0158 DT O
study P09676419A0158 NN O
which P09676419A0158 WDT O
comprised P09676419A0158 VBD O
questionnaires P09676419A0158 NNS O
of P09676419A0158 IN O
patient P09676419A0158 NN O
and P09676419A0158 CC O
family P09676419A0158 NN O
histories P09676419A0158 NNS O
, P09676419A0158 , O
serological P09676419A0158 JJ O
screening P09676419A0158 NN O
tests P09676419A0158 NNS O
for P09676419A0158 IN O
common P09676419A0158 JJ O
inhalational P09676419A0158 JJ O
allergens P09676419A0158 NNS O
( P09676419A0158 ( O
CAP P09676419A0158 NNP O
SX1 P09676419A0158 NNP O
) P09676419A0158 ) O
, P09676419A0158 , O
and P09676419A0158 CC O
determination P09676419A0158 NN O
of P09676419A0158 IN O
total P09676419A0158 JJ O
serum P09676419A0158 NN I-UN
immunoglobulin P09676419A0158 NN I-UN
E P09676419A0158 NNP I-UN
( P09676419A0158 ( O
IgE P09676419A0158 NNP I-UN
) P09676419A0158 ) O
and P09676419A0158 CC O
of P09676419A0158 IN O
latex-specific P09676419A0158 JJ O
serum P09676419A0158 NN I-UN
IgE P09676419A0158 NNP I-UN
by P09676419A0158 IN O
solid-phase P09676419A0158 JJ O
immunoassays P09676419A0158 NNS O
. P09676419A0158 . O
. . O O

In P09121430A1075 IN O
contrast P09121430A1075 NN O
, P09121430A1075 , O
Y239 P09121430A1075 NNP I-UN
/ P09121430A1075 VBZ I-UN
240F P09121430A1075 CD I-UN
Shc P09121430A1075 NNP I-UN
, P09121430A1075 , O
but P09121430A1075 CC O
not P09121430A1075 RB O
Y317F P09121430A1075 NNP I-UN
Shc P09121430A1075 NNP I-UN
, P09121430A1075 , O
reduced P09121430A1075 VBD O
the P09121430A1075 DT O
EGF-induced P09121430A1075 JJ O
c-myc P09121430A1075 JJ I-UN
message P09121430A1075 NN O
. P09121430A1075 . O
. . O O

To P10359664A0579 TO O
identify P10359664A0579 VB O
these P10359664A0579 DT O
sites P10359664A0579 NNS O
, P10359664A0579 , O
Cdk2-phosphorylated P10359664A0579 JJ O
MARCKS P10359664A0579 NNP I-UN
was P10359664A0579 VBD O
digested P10359664A0579 VBN O
with P10359664A0579 IN O
lysyl P10359664A0579 JJ I-UN
endoprotease P10359664A0579 NN I-UN
and P10359664A0579 CC O
analysed P10359664A0579 VBN O
by P10359664A0579 IN O
electrospray P10359664A0579 NN O
MS P10359664A0579 NNP O
. P10359664A0579 . O
. . O O

The P07568026A0622 DT O
Stat5b P07568026A0622 NNP I-UN
mRNA P07568026A0622 NN I-UN
has P07568026A0622 VBZ O
a P07568026A0622 DT O
size P07568026A0622 NN O
of P07568026A0622 IN O
5.6 P07568026A0622 CD O
kb P07568026A0622 NNS O
and P07568026A0622 CC O
encodes P07568026A0622 VBZ O
a P07568026A0622 DT O
protein P07568026A0622 NN O
of P07568026A0622 IN O
786 P07568026A0622 CD O
amino P07568026A0622 JJ O
acids P07568026A0622 NNS O
. P07568026A0622 . O
. . O O

A P01474990A0000 DT O
genomic P01474990A0000 JJ O
clone P01474990A0000 NN O
, P01474990A0000 , O
pTt21 P01474990A0000 NN O
, P01474990A0000 , O
containing P01474990A0000 VBG O
DNA P01474990A0000 NNP O
apparently P01474990A0000 RB O
transcribed P01474990A0000 VBD O
specifically P01474990A0000 RB O
in P01474990A0000 IN O
Trypanosoma P01474990A0000 NNP O
cruzi P01474990A0000 NN O
trypomastigotes P01474990A0000 NNS O
, P01474990A0000 , O
was P01474990A0000 VBD O
obtained P01474990A0000 VBN O
by P01474990A0000 IN O
differentially P01474990A0000 RB O
screening P01474990A0000 VBG O
a P01474990A0000 DT O
genomic P01474990A0000 JJ O
library P01474990A0000 NN O
with P01474990A0000 IN O
trypomastigote P01474990A0000 NN O
and P01474990A0000 CC O
epimastigote P01474990A0000 NN O
cDNA P01474990A0000 NN O
. P01474990A0000 . O
. . O O

CONCLUSION P09278758A1636 NN O
: P09278758A1636 : O
Patients P09278758A1636 NNS O
wit P09278758A1636 VBP O
clinically P09278758A1636 RB O
palpable P09278758A1636 JJ O
neck P09278758A1636 NN O
disease P09278758A1636 NN O
( P09278758A1636 ( O
N1-3 P09278758A1636 NNP O
) P09278758A1636 ) O
, P09278758A1636 , O
histological P09278758A1636 JJ O
evidence P09278758A1636 NN O
of P09278758A1636 IN O
metastatic P09278758A1636 JJ O
nodal P09278758A1636 JJ O
disease P09278758A1636 NN O
, P09278758A1636 , O
extracapsular P09278758A1636 JJ O
spread P09278758A1636 NN O
, P09278758A1636 , O
and P09278758A1636 CC O
three P09278758A1636 CD O
or P09278758A1636 CC O
more P09278758A1636 JJR O
positive P09278758A1636 JJ O
lymph P09278758A1636 NN O
nodes P09278758A1636 NNS O
are P09278758A1636 VBP O
at P09278758A1636 IN O
greater P09278758A1636 JJR O
risk P09278758A1636 NN O
of P09278758A1636 IN O
developing P09278758A1636 VBG O
failure P09278758A1636 NN O
at P09278758A1636 IN O
distant P09278758A1636 JJ O
sites P09278758A1636 NNS O
. P09278758A1636 . O
. . O O

These P11311464A0362 DT O
disorders P11311464A0362 NNS O
include P11311464A0362 VBP O
low-back P11311464A0362 JJ O
pain P11311464A0362 NN O
, P11311464A0362 , O
saddle P11311464A0362 JJ O
anesthesia P11311464A0362 NN O
, P11311464A0362 , O
bilateral P11311464A0362 JJ O
sciatica P11311464A0362 NN O
, P11311464A0362 , O
then P11311464A0362 RB O
motor P11311464A0362 NN O
weakness P11311464A0362 NN O
of P11311464A0362 IN O
the P11311464A0362 DT O
lower P11311464A0362 JJR O
extremities P11311464A0362 NNS O
or P11311464A0362 CC O
chronic P11311464A0362 JJ O
paraplegia P11311464A0362 NN O
and P11311464A0362 CC O
, P11311464A0362 , O
bladder P11311464A0362 JJR O
dysfunction P11311464A0362 NN O
. P11311464A0362 . O
. . O O

The P09878256A0000 DT O
peroxisome P09878256A0000 JJ O
biogenesis P09878256A0000 NN O
disorders P09878256A0000 NNS O
( P09878256A0000 ( O
PBDs P09878256A0000 NNP O
) P09878256A0000 ) O
are P09878256A0000 VBP O
a P09878256A0000 DT O
set P09878256A0000 NN O
of P09878256A0000 IN O
lethal P09878256A0000 JJ O
genetic P09878256A0000 JJ O
diseases P09878256A0000 NNS O
characterized P09878256A0000 VBN O
by P09878256A0000 IN O
peroxisomal P09878256A0000 JJ O
metabolic P09878256A0000 JJ O
deficiencies P09878256A0000 NNS O
, P09878256A0000 , O
multisystem P09878256A0000 NN O
abnormalities P09878256A0000 NNS O
, P09878256A0000 , O
mental P09878256A0000 JJ O
retardation P09878256A0000 NN O
, P09878256A0000 , O
and P09878256A0000 CC O
premature P09878256A0000 JJ O
death P09878256A0000 NN O
. P09878256A0000 . O
. . O O

SUMMARY P08610328A0228 NNP O
OF P08610328A0228 NNP O
REVIEW P08610328A0228 NNP O
: P08610328A0228 : O
We P08610328A0228 PRP O
discuss P08610328A0228 VBP O
the P08610328A0228 DT O
criteria P08610328A0228 NNS O
that P08610328A0228 WDT O
make P08610328A0228 VBP O
such P08610328A0228 JJ O
studies P08610328A0228 NNS O
comparable P08610328A0228 JJ O
, P08610328A0228 , O
drawing P08610328A0228 VBG O
on P08610328A0228 IN O
the P08610328A0228 DT O
experiences P08610328A0228 NNS O
of P08610328A0228 IN O
recent P08610328A0228 JJ O
studies P08610328A0228 NNS O
performed P08610328A0228 VBN O
around P08610328A0228 IN O
the P08610328A0228 DT O
world P08610328A0228 NN O
. P08610328A0228 . O
. . O O

SBF P08566747A0756 NNP I-UN
binds P08566747A0756 VBZ O
to P08566747A0756 TO O
the P08566747A0756 DT O
promoter P08566747A0756 NN O
prior P08566747A0756 RB O
to P08566747A0756 TO O
the P08566747A0756 DT O
activation P08566747A0756 NN O
of P08566747A0756 IN O
transcription P08566747A0756 NN O
in P08566747A0756 IN O
late P08566747A0756 JJ O
G1 P08566747A0756 NNP O
, P08566747A0756 , O
suggesting P08566747A0756 VBG O
that P08566747A0756 IN O
Cln P08566747A0756 NNP I-UN
/ P08566747A0756 NNP O
Cdc28 P08566747A0756 NNP I-UN
kinase P08566747A0756 NN O
regulates P08566747A0756 VBZ O
the P08566747A0756 DT O
ability P08566747A0756 NN O
of P08566747A0756 IN O
previously P08566747A0756 RB O
bound P08566747A0756 VBN O
SBF P08566747A0756 NNP I-UN
to P08566747A0756 TO O
activate P08566747A0756 VB O
transcription P08566747A0756 NN O
. P08566747A0756 . O
. . O O

Clone P09749533A0764 NN O
39 P09749533A0764 CD O
was P09749533A0764 VBD O
a P09749533A0764 DT O
homolog P09749533A0764 NN O
of P09749533A0764 IN O
CONSTANS P09749533A0764 NNP I-UN
, P09749533A0764 , O
which P09749533A0764 WDT O
is P09749533A0764 VBZ O
a P09749533A0764 DT O
gene P09749533A0764 NN O
involved P09749533A0764 VBN O
in P09749533A0764 IN O
controlling P09749533A0764 VBG O
the P09749533A0764 DT O
flowering P09749533A0764 NN O
time P09749533A0764 NN O
in P09749533A0764 IN O
Arabidopsis P09749533A0764 NNP O
. P09749533A0764 . O
. . O O

Evaluation P00630713T0000 NN O
of P00630713T0000 IN O
the P00630713T0000 DT O
Du P00630713T0000 NNP O
Pont P00630713T0000 NNP O
aca P00630713T0000 VBZ O
ammonia P00630713T0000 JJ O
procedure P00630713T0000 NN O
. P00630713T0000 . O
. . O O

Consistent P08552095A0686 JJ O
with P08552095A0686 IN O
a P08552095A0686 DT O
possible P08552095A0686 JJ O
role P08552095A0686 NN O
in P08552095A0686 IN O
transcription P08552095A0686 NN O
, P08552095A0686 , O
Paf1p P08552095A0686 NNP I-UN
is P08552095A0686 VBZ O
localized P08552095A0686 VBN O
to P08552095A0686 TO O
the P08552095A0686 DT O
nucleus P08552095A0686 NN O
. P08552095A0686 . O
. . O O

We P09441664A0377 PRP O
have P09441664A0377 VBP O
previously P09441664A0377 RB O
identified P09441664A0377 VBN O
a P09441664A0377 DT O
liver-enriched P09441664A0377 JJ O
transcription P09441664A0377 NN O
factor P09441664A0377 NN O
, P09441664A0377 , O
HNF-6 P09441664A0377 NNP I-UN
, P09441664A0377 , O
which P09441664A0377 WDT O
is P09441664A0377 VBZ O
required P09441664A0377 VBN O
for P09441664A0377 IN O
HNF-3 P09441664A0377 NNP I-UN
beta P09441664A0377 NN I-UN
promoter P09441664A0377 NN I-UN
activity P09441664A0377 NN O
and P09441664A0377 CC O
also P09441664A0377 RB O
recognizes P09441664A0377 VBZ O
the P09441664A0377 DT O
regulatory P09441664A0377 JJ O
region P09441664A0377 NN O
of P09441664A0377 IN O
numerous P09441664A0377 JJ O
hepatocyte-specific P09441664A0377 JJ O
genes P09441664A0377 NNS O
. P09441664A0377 . O
. . O O

These P09365201A2018 DT O
studies P09365201A2018 NNS O
serve P09365201A2018 VBP O
as P09365201A2018 IN O
the P09365201A2018 DT O
basis P09365201A2018 NN O
for P09365201A2018 IN O
the P09365201A2018 DT O
further P09365201A2018 JJ O
characterization P09365201A2018 NN O
of P09365201A2018 IN O
the P09365201A2018 DT O
regulatory P09365201A2018 JJ O
mechanism P09365201A2018 NN O
of P09365201A2018 IN O
aromatase P09365201A2018 JJ I-UN
expression P09365201A2018 NN O
in P09365201A2018 IN O
human P09365201A2018 JJ O
breast P09365201A2018 NN O
cancer P09365201A2018 NN O
and P09365201A2018 CC O
ASCs P09365201A2018 NNP O
. P09365201A2018 . O
. . O O

The P09925372A1063 DT O
3.3-fold P09925372A1063 JJ O
higher P09925372A1063 JJR O
expression P09925372A1063 NN O
in P09925372A1063 IN O
the P09925372A1063 DT O
fetal P09925372A1063 JJ O
heart P09925372A1063 NN O
than P09925372A1063 IN O
in P09925372A1063 IN O
the P09925372A1063 DT O
adult P09925372A1063 NN O
heart P09925372A1063 NN O
suggests P09925372A1063 VBZ O
that P09925372A1063 IN O
HFHZ P09925372A1063 NNP I-UN
mRNA P09925372A1063 NN I-UN
is P09925372A1063 VBZ O
downregulated P09925372A1063 VBN O
in P09925372A1063 IN O
the P09925372A1063 DT O
process P09925372A1063 NN O
of P09925372A1063 IN O
development P09925372A1063 NN O
. P09925372A1063 . O
. . O O

Plethysmographic P01071715A0903 NNP O
technique P01071715A0903 NN O
and P01071715A0903 CC O
indirect P01071715A0903 JJ O
blood P01071715A0903 NN O
pressure P01071715A0903 NN O
recordings P01071715A0903 NNS O
were P01071715A0903 VBD O
used P01071715A0903 VBN O
. P01071715A0903 . O
. . O O

The P09832518A0615 DT O
repression P09832518A0615 NN O
domain P09832518A0615 NN O
, P09832518A0615 , O
and P09832518A0615 CC O
indeed P09832518A0615 RB O
the P09832518A0615 DT O
entire P09832518A0615 JJ O
Cdc68 P09832518A0615 NNP I-UN
protein P09832518A0615 NN I-UN
, P09832518A0615 , O
is P09832518A0615 VBZ O
highly P09832518A0615 RB O
conserved P09832518A0615 VBN O
, P09832518A0615 , O
as P09832518A0615 IN O
shown P09832518A0615 VBN O
by P09832518A0615 IN O
the P09832518A0615 DT O
sequence P09832518A0615 NN O
of P09832518A0615 IN O
the P09832518A0615 DT O
Cdc68 P09832518A0615 NNP I-UN
functional P09832518A0615 JJ I-UN
homolog P09832518A0615 NN I-UN
from P09832518A0615 IN O
the P09832518A0615 DT O
yeast P09832518A0615 NN O
Kluyveromyces P09832518A0615 NNP O
lactis P09832518A0615 NN O
and P09832518A0615 CC O
by P09832518A0615 IN O
database P09832518A0615 NN O
searches P09832518A0615 NNS O
. P09832518A0615 . O
. . O O

Modification P02236060A1671 NN O
by P02236060A1671 IN O
this P02236060A1671 DT O
latter P02236060A1671 JJ O
compound P02236060A1671 NN O
was P02236060A1671 VBD O
so P02236060A1671 RB O
extensive P02236060A1671 JJ O
that P02236060A1671 IN O
the P02236060A1671 DT O
amount P02236060A1671 NN O
of P02236060A1671 IN O
membrane-associated P02236060A1671 JJ O
N-myristoylated P02236060A1671 JJ O
protein P02236060A1671 NN O
was P02236060A1671 VBD O
decreased P02236060A1671 VBN O
. P02236060A1671 . O
. . O O

NH2-terminal P11095248A1523 JJ O
trimming P11095248A1523 NN O
of P11095248A1523 IN O
Xenopus P11095248A1523 NNP O
and P11095248A1523 CC O
mammalian P11095248A1523 JJ I-UN
FGF3s P11095248A1523 NNP I-UN
may P11095248A1523 MD O
therefore P11095248A1523 RB O
be P11095248A1523 VB O
a P11095248A1523 DT O
prerequisite P11095248A1523 NN O
of P11095248A1523 IN O
optimal P11095248A1523 JJ O
biological P11095248A1523 JJ O
activity P11095248A1523 NN O
. P11095248A1523 . O
. . O O

Women P08194970A0000 NNP O
's P08194970A0000 POS O
opportunities P08194970A0000 NNS O
for P08194970A0000 IN O
paid P08194970A0000 VBN O
work P08194970A0000 NN O
outside P08194970A0000 IN O
the P08194970A0000 DT O
home P08194970A0000 NN O
are P08194970A0000 VBP O
constrained P08194970A0000 VBN O
by P08194970A0000 IN O
their P08194970A0000 PRP$ O
role P08194970A0000 NN O
as P08194970A0000 IN O
primary P08194970A0000 JJ O
carer P08194970A0000 NN O
within P08194970A0000 IN O
the P08194970A0000 DT O
family P08194970A0000 NN O
, P08194970A0000 , O
writes P08194970A0000 VBZ O
Trudy P08194970A0000 NNP O
Wynne P08194970A0000 NNP O
. P08194970A0000 . O
. . O O

Insulin-stimulated P07835273A0000 JJ O
glucose P07835273A0000 JJ O
transport P07835273A0000 NN O
in P07835273A0000 IN O
adipocytes P07835273A0000 NNS O
is P07835273A0000 VBZ O
mediated P07835273A0000 VBN O
by P07835273A0000 IN O
the P07835273A0000 DT O
insulin P07835273A0000 NN I-UN
receptor P07835273A0000 NN I-UN
. P07835273A0000 . O
. . O O

We P09927570A0507 PRP O
now P09927570A0507 RB O
show P09927570A0507 VBP O
that P09927570A0507 IN O
RNU2 P09927570A0507 NNP I-UN
fragility P09927570A0507 NN O
can P09927570A0507 MD O
be P09927570A0507 VB O
induced P09927570A0507 VBN O
by P09927570A0507 IN O
transfection P09927570A0507 NN O
with P09927570A0507 IN O
an P09927570A0507 DT O
expression P09927570A0507 NN O
vector P09927570A0507 NN O
encoding P09927570A0507 VBG O
Ad12 P09927570A0507 NNP I-UN
E1B P09927570A0507 NNP I-UN
55 P09927570A0507 CD O
kDa P09927570A0507 NN O
alone P09927570A0507 RB O
but P09927570A0507 CC O
not P09927570A0507 RB O
by P09927570A0507 IN O
an P09927570A0507 DT O
E1 P09927570A0507 NNP I-UN
vector P09927570A0507 NN O
encoding P09927570A0507 VBG O
all P09927570A0507 DT O
E1 P09927570A0507 NNP I-UN
products P09927570A0507 NNS I-UN
( P09927570A0507 ( O
3 P09927570A0507 CD O
E1A P09927570A0507 NNP I-UN
proteins P09927570A0507 NNS I-UN
, P09927570A0507 , O
as P09927570A0507 RB O
well P09927570A0507 RB O
as P09927570A0507 IN O
the P09927570A0507 DT O
E1B P09927570A0507 NNP I-UN
19 P09927570A0507 CD O
kDa P09927570A0507 NN O
and P09927570A0507 CC O
55 P09927570A0507 CD O
kDa P09927570A0507 NN O
proteins P09927570A0507 NNS O
) P09927570A0507 ) O
. P09927570A0507 . O
. . O O

It P09556566A0174 PRP O
bound P09556566A0174 VBD O
to P09556566A0174 TO O
vitamin P09556566A0174 VB I-UN
D P09556566A0174 NNP I-UN
receptor P09556566A0174 NN I-UN
( P09556566A0174 ( O
VDR P09556566A0174 NNP I-UN
) P09556566A0174 ) O
but P09556566A0174 CC O
not P09556566A0174 RB O
retinoic P09556566A0174 JJ I-UN
acid P09556566A0174 NN I-UN
Xalpha P09556566A0174 NNP I-UN
receptor P09556566A0174 NN I-UN
( P09556566A0174 ( O
RXRalpha P09556566A0174 NNP I-UN
) P09556566A0174 ) O
in P09556566A0174 IN O
the P09556566A0174 DT O
human P09556566A0174 JJ O
T P09556566A0174 NNP O
cell P09556566A0174 NN O
line P09556566A0174 NN O
MT2 P09556566A0174 NNP O
cells P09556566A0174 NNS O
. P09556566A0174 . O
. . O O

In P08618433A1720 IN O
contrast P08618433A1720 NN O
to P08618433A1720 TO O
the P08618433A1720 DT O
selective P08618433A1720 JJ O
expression P08618433A1720 NN O
of P08618433A1720 IN O
the P08618433A1720 DT O
receptor P08618433A1720 NN O
, P08618433A1720 , O
FL P08618433A1720 NNP I-UN
expression P08618433A1720 NN O
was P08618433A1720 VBD O
detected P08618433A1720 VBN O
in P08618433A1720 IN O
90-100 P08618433A1720 CD O
% P08618433A1720 NN O
of P08618433A1720 IN O
the P08618433A1720 DT O
various P08618433A1720 JJ O
cell P08618433A1720 NN O
types P08618433A1720 NNS O
of P08618433A1720 IN O
leukemia P08618433A1720 NN O
cell P08618433A1720 NN O
lines P08618433A1720 NNS O
from P08618433A1720 IN O
all P08618433A1720 DT O
hematopoietic P08618433A1720 JJ O
cell P08618433A1720 NN O
lineages P08618433A1720 NNS O
. P08618433A1720 . O
. . O O

Selective P06245672T0000 JJ O
macrophage P06245672T0000 NN O
inhibition P06245672T0000 NN O
abolishes P06245672T0000 VBZ O
warfarin-induced P06245672T0000 JJ O
reduction P06245672T0000 NN O
of P06245672T0000 IN O
metastasis P06245672T0000 NN O
. P06245672T0000 . O
. . O O

SPECT P03027779A0000 NNP O
examination P03027779A0000 NN O
of P03027779A0000 IN O
the P03027779A0000 DT O
TMJ P03027779A0000 NNP O
using P03027779A0000 VBG O
99m P03027779A0000 CD O
Tc-MDP P03027779A0000 NN O
was P03027779A0000 VBD O
performed P03027779A0000 VBN O
in P03027779A0000 IN O
43 P03027779A0000 CD O
patients P03027779A0000 NNS O
with P03027779A0000 IN O
arthrographically P03027779A0000 RB O
proven P03027779A0000 VBN O
anterior P03027779A0000 JJ O
dislocation P03027779A0000 NN O
of P03027779A0000 IN O
the P03027779A0000 DT O
disc P03027779A0000 NN O
and P03027779A0000 CC O
in P03027779A0000 IN O
30 P03027779A0000 CD O
normals P03027779A0000 NNS O
. P03027779A0000 . O
. . O O

As P11120441A1193 IN O
hypothesized P11120441A1193 VBN O
, P11120441A1193 , O
believers P11120441A1193 NNS O
showed P11120441A1193 VBD O
relatively P11120441A1193 RB O
higher P11120441A1193 JJR O
right P11120441A1193 JJ O
hemispheric P11120441A1193 JJ O
activation P11120441A1193 NN O
and P11120441A1193 CC O
reduced P11120441A1193 JJ O
hemispheric P11120441A1193 JJ O
asymmetry P11120441A1193 NN O
of P11120441A1193 IN O
functional P11120441A1193 JJ O
complexity P11120441A1193 NN O
. P11120441A1193 . O
. . O O

Extensive P08065327A0000 JJ O
DNA P08065327A0000 NNP O
rearrangement P08065327A0000 NN O
occurs P08065327A0000 VBZ O
during P08065327A0000 IN O
the P08065327A0000 DT O
development P08065327A0000 NN O
of P08065327A0000 IN O
the P08065327A0000 DT O
somatic P08065327A0000 JJ O
macronucleus P08065327A0000 NN O
from P08065327A0000 IN O
the P08065327A0000 DT O
germ P08065327A0000 JJ O
line P08065327A0000 NN O
micronucleus P08065327A0000 NN O
in P08065327A0000 IN O
ciliated P08065327A0000 JJ O
protozoans P08065327A0000 NNS O
. P08065327A0000 . O
. . O O

We P01372900A1017 PRP O
also P01372900A1017 RB O
report P01372900A1017 VBP O
here P01372900A1017 RB O
the P01372900A1017 DT O
complete P01372900A1017 JJ O
structural P01372900A1017 JJ O
organization P01372900A1017 NN O
of P01372900A1017 IN O
the P01372900A1017 DT O
goat P01372900A1017 NN I-UN
alpha P01372900A1017 VBZ I-UN
s1-casein P01372900A1017 JJ I-UN
transcription P01372900A1017 NN I-UN
unit P01372900A1017 NN I-UN
, P01372900A1017 , O
deduced P01372900A1017 VBN O
from P01372900A1017 IN O
polymerase P01372900A1017 NN O
chain P01372900A1017 NN O
reaction P01372900A1017 NN O
experiments P01372900A1017 NNS O
. P01372900A1017 . O
. . O O

Characterization P01281771T0000 NN O
of P01281771T0000 IN O
the P01281771T0000 DT O
human P01281771T0000 JJ I-UN
gene P01281771T0000 NN I-UN
encoding P01281771T0000 VBG I-UN
cytokeratin P01281771T0000 JJ I-UN
17 P01281771T0000 CD I-UN
and P01281771T0000 CC O
its P01281771T0000 PRP$ O
expression P01281771T0000 NN O
pattern P01281771T0000 NN O
. P01281771T0000 . O
. . O O

AIM P11819326A0000 NN O
: P11819326A0000 : O
To P11819326A0000 TO O
understand P11819326A0000 VB O
the P11819326A0000 DT O
role P11819326A0000 NN O
of P11819326A0000 IN O
nutritional P11819326A0000 JJ O
status P11819326A0000 NN O
in P11819326A0000 IN O
cirrhotic P11819326A0000 JJ O
patients P11819326A0000 NNS O
without P11819326A0000 IN O
clinical P11819326A0000 JJ O
porto-systemic P11819326A0000 JJ O
encephalopathy P11819326A0000 NN O
( P11819326A0000 ( O
PSE P11819326A0000 NNP O
) P11819326A0000 ) O
.METHODS P11819326A0000 NN O
: P11819326A0000 : O
Fifty-one P11819326A0000 JJ O
non-alcoholic P11819326A0000 JJ O
patients P11819326A0000 NNS O
with P11819326A0000 IN O
cirrhosis P11819326A0000 NN O
without P11819326A0000 IN O
PSE P11819326A0000 NNP O
were P11819326A0000 VBD O
studied P11819326A0000 VBN O
prospectively P11819326A0000 RB O
and P11819326A0000 CC O
compared P11819326A0000 VBN O
with P11819326A0000 IN O
20 P11819326A0000 CD O
healthy P11819326A0000 JJ O
volunteers P11819326A0000 NNS O
. P11819326A0000 . O
. . O O

An P09348931T0000 DT O
end P09348931T0000 NN O
to P09348931T0000 TO O
the P09348931T0000 DT O
lottery P09348931T0000 NN O
. P09348931T0000 . O
. . O O

A P09149825A0151 DT O
promising P09149825A0151 JJ O
new P09149825A0151 JJ O
cement P09149825A0151 NN O
, P09149825A0151 , O
4-META P09149825A0151 JJ O
/ P09149825A0151 JJ O
MMA-TBB P09149825A0151 NNP O
opaque P09149825A0151 NN O
resin P09149825A0151 NN O
, P09149825A0151 , O
has P09149825A0151 VBZ O
shown P09149825A0151 VBN O
remarkable P09149825A0151 JJ O
adhesive P09149825A0151 JJ O
properties P09149825A0151 NNS O
as P09149825A0151 IN O
a P09149825A0151 DT O
bone P09149825A0151 NN O
cement P09149825A0151 NN O
in P09149825A0151 IN O
vivo P09149825A0151 NN O
. P09149825A0151 . O
. . O O

In P07565672A0798 IN O
cells P07565672A0798 NNS O
limited P07565672A0798 VBN O
for P07565672A0798 IN O
His P07565672A0798 PRP$ O
, P07565672A0798 , O
increased P07565672A0798 JJ O
expression P07565672A0798 NN O
of P07565672A0798 IN O
arg-2 P07565672A0798 JJ I-UN
and P07565672A0798 CC O
cpc-1 P07565672A0798 JJ I-UN
, P07565672A0798 , O
and P07565672A0798 CC O
decreased P07565672A0798 JJ O
expression P07565672A0798 NN O
of P07565672A0798 IN O
cox-5 P07565672A0798 NN I-UN
, P07565672A0798 , O
also P07565672A0798 RB O
had P07565672A0798 VBD O
translational P07565672A0798 JJ O
and P07565672A0798 CC O
transcriptional P07565672A0798 JJ O
components P07565672A0798 NNS O
. P07565672A0798 . O
. . O O

These P11602353A0770 DT O
included P11602353A0770 VBD O
HNF-3 P11602353A0770 NNP I-UN
beta P11602353A0770 NN I-UN
, P11602353A0770 , O
HFH-1 P11602353A0770 NNP I-UN
, P11602353A0770 , O
HFH-2 P11602353A0770 NNP I-UN
, P11602353A0770 , O
HFH-3 P11602353A0770 NNP I-UN
, P11602353A0770 , O
C P11602353A0770 NNP I-UN
/ P11602353A0770 NNP I-UN
EBP P11602353A0770 NNP I-UN
, P11602353A0770 , O
and P11602353A0770 CC O
C P11602353A0770 NNP I-UN
/ P11602353A0770 NNP I-UN
EBP P11602353A0770 NNP I-UN
beta P11602353A0770 NN I-UN
, P11602353A0770 , O
all P11602353A0770 DT O
of P11602353A0770 IN O
which P11602353A0770 WDT O
are P11602353A0770 VBP O
consistent P11602353A0770 JJ O
with P11602353A0770 IN O
the P11602353A0770 DT O
tissue-specific P11602353A0770 JJ O
expression P11602353A0770 NN O
profiles P11602353A0770 NNS O
of P11602353A0770 IN O
the P11602353A0770 DT O
gene P11602353A0770 NN O
. P11602353A0770 . O
. . O O

These P10940553A0912 DT O
regions P10940553A0912 NNS O
may P10940553A0912 MD O
be P10940553A0912 VB O
differentially P10940553A0912 RB O
involved P10940553A0912 VBN O
in P10940553A0912 IN O
tissue-specificity P10940553A0912 NN O
, P10940553A0912 , O
and P10940553A0912 CC O
/ P10940553A0912 NNP O
or P10940553A0912 CC O
circadian P10940553A0912 JJ O
regulation P10940553A0912 NN O
, P10940553A0912 , O
of P10940553A0912 IN O
the P10940553A0912 DT O
human P10940553A0912 JJ I-UN
hPer1 P10940553A0912 NN I-UN
gene P10940553A0912 NN I-UN
transcription P10940553A0912 NN O
. P10940553A0912 . O
. . O O

These P08382300A0341 DT O
cell P08382300A0341 NN O
lines P08382300A0341 NNS O
, P08382300A0341 , O
selected P08382300A0341 VBN O
for P08382300A0341 IN O
the P08382300A0341 DT O
ability P08382300A0341 NN O
to P08382300A0341 TO O
support P08382300A0341 VB O
the P08382300A0341 DT O
replication P08382300A0341 NN O
of P08382300A0341 IN O
a P08382300A0341 DT O
temperature-sensitive P08382300A0341 JJ O
VP5 P08382300A0341 NNP I-UN
mutant P08382300A0341 NN I-UN
, P08382300A0341 , O
were P08382300A0341 VBD O
used P08382300A0341 VBN O
to P08382300A0341 TO O
isolate P08382300A0341 VB O
VP5 P08382300A0341 NNP I-UN
and P08382300A0341 CC O
VP23 P08382300A0341 NNP I-UN
null P08382300A0341 JJ O
mutants P08382300A0341 NNS O
. P08382300A0341 . O
. . O O

The P01067493A0119 DT O
contraceptive P01067493A0119 JJ O
pattern P01067493A0119 NN O
of P01067493A0119 IN O
157 P01067493A0119 CD O
women P01067493A0119 NNS O
was P01067493A0119 VBD O
analysed P01067493A0119 VBN O
and P01067493A0119 CC O
13.8 P01067493A0119 CD O
percent P01067493A0119 NN O
were P01067493A0119 VBD O
using P01067493A0119 VBG O
inefficient P01067493A0119 JJ O
methods P01067493A0119 NNS O
. P01067493A0119 . O
. . O O

We P06181216A0070 PRP O
have P06181216A0070 VBP O
followed P06181216A0070 VBN O
37 P06181216A0070 CD O
phenytoin-treated P06181216A0070 JJ O
patients P06181216A0070 NNS O
with P06181216A0070 IN O
reduced P06181216A0070 JJ O
serum P06181216A0070 NN I-UN
IgA P06181216A0070 NNP I-UN
concentrations P06181216A0070 NNS O
for P06181216A0070 IN O
2-7 P06181216A0070 JJ O
years P06181216A0070 NNS O
. P06181216A0070 . O
. . O O

Biol P08419318A1695 NNP O
. P08419318A1695 . O
. . O O

From P11535014A1157 IN O
the P11535014A1157 DT O
above P11535014A1157 JJ O
results P11535014A1157 NNS O
, P11535014A1157 , O
we P11535014A1157 PRP O
might P11535014A1157 MD O
infer P11535014A1157 VB O
that P11535014A1157 IN O
the P11535014A1157 DT O
seizure P11535014A1157 NN O
type P11535014A1157 NN O
of P11535014A1157 IN O
TLE P11535014A1157 NNP O
and P11535014A1157 CC O
a P11535014A1157 DT O
high P11535014A1157 JJ O
frequency P11535014A1157 NN O
of P11535014A1157 IN O
seizure P11535014A1157 NN O
are P11535014A1157 VBP O
two P11535014A1157 CD O
major P11535014A1157 JJ O
independent P11535014A1157 JJ O
precipitate P11535014A1157 NN O
factors P11535014A1157 NNS O
for P11535014A1157 IN O
abnormal P11535014A1157 JJ O
latencies P11535014A1157 NNS O
of P11535014A1157 IN O
P300 P11535014A1157 NNP O
in P11535014A1157 IN O
the P11535014A1157 DT O
epileptic P11535014A1157 JJ O
patients P11535014A1157 NNS O
. P11535014A1157 . O
. . O O

Studies P11003805A0443 NNS O
suggest P11003805A0443 VBP O
that P11003805A0443 IN O
the P11003805A0443 DT O
DGOR P11003805A0443 NNP O
without P11003805A0443 IN O
acid P11003805A0443 JJ O
reflux P11003805A0443 NN O
may P11003805A0443 MD O
result P11003805A0443 VB O
in P11003805A0443 IN O
symptoms P11003805A0443 NNS O
but P11003805A0443 CC O
unless P11003805A0443 IN O
acid P11003805A0443 JJ O
reflux P11003805A0443 NN O
is P11003805A0443 VBZ O
present P11003805A0443 JJ O
simultaneously P11003805A0443 RB O
, P11003805A0443 , O
it P11003805A0443 PRP O
does P11003805A0443 VBZ O
not P11003805A0443 RB O
cause P11003805A0443 VB O
oesophagitis P11003805A0443 NN O
. P11003805A0443 . O
. . O O

Over-expression P09826778A0943 NN O
of P09826778A0943 IN O
the P09826778A0943 DT O
cofactor P09826778A0943 NN O
p300 P09826778A0943 NN I-UN
, P09826778A0943 , O
which P09826778A0943 WDT O
functions P09826778A0943 VBZ O
as P09826778A0943 IN O
a P09826778A0943 DT O
coactivator P09826778A0943 NN O
of P09826778A0943 IN O
myoD-mediated P09826778A0943 JJ O
transcription P09826778A0943 NN O
, P09826778A0943 , O
alleviated P09826778A0943 VBN O
repression P09826778A0943 NN O
by P09826778A0943 IN O
COUP-TF P09826778A0943 NNP I-UN
II P09826778A0943 NNP I-UN
. P09826778A0943 . O
. . O O

Determination P02317554T0000 NN O
of P02317554T0000 IN O
three-dimensional P02317554T0000 JJ O
imaging P02317554T0000 VBG O
properties P02317554T0000 NNS O
of P02317554T0000 IN O
a P02317554T0000 DT O
light P02317554T0000 JJ O
microscope P02317554T0000 NN O
system P02317554T0000 NN O
. P02317554T0000 . O
. . O O

Management P11572467T0000 NN O
of P11572467T0000 IN O
postvitrectomy P11572467T0000 NN O
diabetic P11572467T0000 JJ O
vitreous P11572467T0000 JJ O
hemorrhage P11572467T0000 NN O
with P11572467T0000 IN O
tissue P11572467T0000 NN I-UN
plasminogen P11572467T0000 NN I-UN
activator P11572467T0000 NN I-UN
( P11572467T0000 ( O
t-PA P11572467T0000 JJ I-UN
) P11572467T0000 ) O
and P11572467T0000 CC O
volume P11572467T0000 NN O
homeostatic P11572467T0000 JJ O
fluid-fluid P11572467T0000 JJ O
exchanger P11572467T0000 NN O
. P11572467T0000 . O
. . O O

The P10723727A0713 DT O
newly P10723727A0713 RB O
defined P10723727A0713 VBN O
region P10723727A0713 NN O
contains P10723727A0713 VBZ O
an P10723727A0713 DT O
intron P10723727A0713 NN O
that P10723727A0713 WDT O
may P10723727A0713 MD O
be P10723727A0713 VB O
alternatively P10723727A0713 RB O
spliced P10723727A0713 VBN O
and P10723727A0713 CC O
seven P10723727A0713 CD O
polyadenylation P10723727A0713 NN O
signal P10723727A0713 JJ O
sequences P10723727A0713 NNS O
. P10723727A0713 . O
. . O O

Detailed P08668201A1059 JJ O
mutagenesis P08668201A1059 NN O
of P08668201A1059 IN O
the P08668201A1059 DT O
element P08668201A1059 NN O
's P08668201A1059 POS O
rare-codon P08668201A1059 JJ O
/ P08668201A1059 JJ O
AU-rich P08668201A1059 JJ O
sequence P08668201A1059 NN O
boundary P08668201A1059 NN O
revealed P08668201A1059 VBD O
that P08668201A1059 IN O
the P08668201A1059 DT O
destabilizing P08668201A1059 JJ O
activity P08668201A1059 NN O
of P08668201A1059 IN O
the P08668201A1059 DT O
MATalpha1 P08668201A1059 NNP I-UN
IE P08668201A1059 NNP I-UN
is P08668201A1059 VBZ O
observed P08668201A1059 VBN O
when P08668201A1059 WRB O
the P08668201A1059 DT O
terminal P08668201A1059 JJ O
codon P08668201A1059 NN O
of P08668201A1059 IN O
the P08668201A1059 DT O
element P08668201A1059 NN O
's P08668201A1059 POS O
rare-codon P08668201A1059 JJ O
interval P08668201A1059 NN O
is P08668201A1059 VBZ O
translated P08668201A1059 VBN O
. P08668201A1059 . O
. . O O

The P03473379A0183 DT O
diagnosis P03473379A0183 NN O
of P03473379A0183 IN O
amyloidosis P03473379A0183 NN O
was P03473379A0183 VBD O
determined P03473379A0183 VBN O
from P03473379A0183 IN O
a P03473379A0183 DT O
labial P03473379A0183 JJ O
salivary P03473379A0183 JJ O
gland P03473379A0183 NN O
biopsy P03473379A0183 NN O
. P03473379A0183 . O
. . O O

We P01768648A0853 PRP O
exploit P01768648A0853 VBP O
the P01768648A0853 DT O
properties P01768648A0853 NNS O
of P01768648A0853 IN O
LexA P01768648A0853 NNP I-UN
fusion P01768648A0853 NN I-UN
proteins P01768648A0853 NNS I-UN
to P01768648A0853 TO O
study P01768648A0853 VB O
the P01768648A0853 DT O
dimerization P01768648A0853 NN O
and P01768648A0853 CC O
DNA-contacting P01768648A0853 NNP O
domains P01768648A0853 NNS O
of P01768648A0853 IN O
cRel P01768648A0853 NN I-UN
. P01768648A0853 . O
. . O O

In P09531559A1153 IN O
vitro P09531559A1153 JJ O
affinity P09531559A1153 NN O
analyses P09531559A1153 NNS O
demonstrated P09531559A1153 VBD O
that P09531559A1153 IN O
recombinant P09531559A1153 JJ O
130-kD P09531559A1153 JJ O
protein P09531559A1153 NN O
directly P09531559A1153 RB O
interacts P09531559A1153 VBZ O
with P09531559A1153 IN O
ZO-1 P09531559A1153 NNP I-UN
and P09531559A1153 CC O
the P09531559A1153 DT O
cytoplasmic P09531559A1153 JJ O
domain P09531559A1153 NN O
of P09531559A1153 IN O
occludin P09531559A1153 NN I-UN
, P09531559A1153 , O
but P09531559A1153 CC O
not P09531559A1153 RB O
with P09531559A1153 IN O
ZO-2 P09531559A1153 NNP I-UN
. P09531559A1153 . O
. . O O

METHODS P09673037A0358 NN O
: P09673037A0358 : O
Fibrotic P09673037A0358 JJ O
changes P09673037A0358 NNS O
involving P09673037A0358 VBG O
bone P09673037A0358 NN O
marrow P09673037A0358 NN O
were P09673037A0358 VBD O
evaluated P09673037A0358 VBN O
histologically P09673037A0358 RB O
semiquantitatively P09673037A0358 RB O
using P09673037A0358 VBG O
reticulin P09673037A0358 JJ I-UN
fiber P09673037A0358 JJ O
impregnation P09673037A0358 NN O
( P09673037A0358 ( O
method P09673037A0358 NN O
of P09673037A0358 IN O
Gomori P09673037A0358 NNP O
) P09673037A0358 ) O
. P09673037A0358 . O
. . O O

Small P08932385T0000 JJ O
Maf P08932385T0000 NNP I-UN
proteins P08932385T0000 NNS I-UN
interact P08932385T0000 NN O
with P08932385T0000 IN O
the P08932385T0000 DT O
human P08932385T0000 JJ O
transcription P08932385T0000 NN O
factor P08932385T0000 NN O
TCF11 P08932385T0000 NNP I-UN
/ P08932385T0000 NNP O
Nrf1 P08932385T0000 NNP I-UN
/ P08932385T0000 NNP O
LCR-F1 P08932385T0000 NNP I-UN
. P08932385T0000 . O
. . O O

Mycotoxins P05340801T0000 NNS O
in P05340801T0000 IN O
feeds P05340801T0000 NNS O
and P05340801T0000 CC O
foods P05340801T0000 NNS O
. P05340801T0000 . O
. . O O

Pathology P04445874T0001 NN O
of P04445874T0001 IN O
neuritis P04445874T0001 NN O
caudae P04445874T0001 NN O
equinae P04445874T0001 NN O
in P04445874T0001 IN O
the P04445874T0001 DT O
horse P04445874T0001 NN O
. P04445874T0001 . O
. . O O

We P02162467A0311 PRP O
show P02162467A0311 VBP O
that P02162467A0311 IN O
cytR P02162467A0311 JJ I-UN
expression P02162467A0311 NN O
is P02162467A0311 VBZ O
negatively P02162467A0311 RB O
controlled P02162467A0311 VBN O
by P02162467A0311 IN O
the P02162467A0311 DT O
CytR P02162467A0311 NNP I-UN
protein P02162467A0311 NN I-UN
and P02162467A0311 CC O
positively P02162467A0311 RB O
affected P02162467A0311 VBN O
by P02162467A0311 IN O
the P02162467A0311 DT O
cAMP P02162467A0311 NN I-UN
/ P02162467A0311 JJ I-UN
CAP P02162467A0311 NNP I-UN
complex P02162467A0311 NN I-UN
. P02162467A0311 . O
. . O O

Several P10026275A0549 JJ O
secondary P10026275A0549 JJ O
structure P10026275A0549 NN O
elements P10026275A0549 NNS O
were P10026275A0549 VBD O
identified P10026275A0549 VBN O
. P10026275A0549 . O
. . O O

Saccharomyces P11356835A0000 NNS O
cerevisiae P11356835A0000 VBP O
activates P11356835A0000 VBZ O
a P11356835A0000 DT O
regulatory P11356835A0000 JJ O
network P11356835A0000 NN O
called P11356835A0000 VBN O
`` P11356835A0000 `` O
general P11356835A0000 JJ O
control P11356835A0000 NN O
'' P11356835A0000 '' O
that P11356835A0000 WDT O
provides P11356835A0000 VBZ O
the P11356835A0000 DT O
cell P11356835A0000 NN O
with P11356835A0000 IN O
sufficient P11356835A0000 JJ O
amounts P11356835A0000 NNS O
of P11356835A0000 IN O
protein P11356835A0000 NN O
precursors P11356835A0000 NNS O
during P11356835A0000 IN O
amino P11356835A0000 JJ O
acid P11356835A0000 JJ O
starvation P11356835A0000 NN O
. P11356835A0000 . O
. . O O

While P03799790A0146 IN O
the P03799790A0146 DT O
examiner P03799790A0146 NN O
observed P03799790A0146 VBD O
the P03799790A0146 DT O
interior P03799790A0146 NN O
of P03799790A0146 IN O
the P03799790A0146 DT O
eye P03799790A0146 NN O
with P03799790A0146 IN O
indirect P03799790A0146 JJ O
ophthalmoscopy P03799790A0146 NN O
, P03799790A0146 , O
the P03799790A0146 DT O
point P03799790A0146 NN O
source P03799790A0146 NN O
of P03799790A0146 IN O
light P03799790A0146 NN O
from P03799790A0146 IN O
the P03799790A0146 DT O
fiberoptic P03799790A0146 JJ O
light P03799790A0146 NN O
pipe P03799790A0146 NN O
was P03799790A0146 VBD O
moved P03799790A0146 VBN O
along P03799790A0146 IN O
the P03799790A0146 DT O
margins P03799790A0146 NNS O
of P03799790A0146 IN O
the P03799790A0146 DT O
episcleral P03799790A0146 JJ O
plaque P03799790A0146 NN O
. P03799790A0146 . O
. . O O

The P09765277A0000 DT O
murine P09765277A0000 NN I-UN
facilitative P09765277A0000 JJ I-UN
glucose P09765277A0000 NN I-UN
transporter P09765277A0000 NN I-UN
isoform P09765277A0000 NN I-UN
3 P09765277A0000 CD I-UN
( P09765277A0000 ( O
Glut P09765277A0000 NNP I-UN
3 P09765277A0000 CD I-UN
) P09765277A0000 ) O
is P09765277A0000 VBZ O
developmentally P09765277A0000 RB O
regulated P09765277A0000 VBN O
and P09765277A0000 CC O
is P09765277A0000 VBZ O
predominantly P09765277A0000 RB O
expressed P09765277A0000 VBN O
in P09765277A0000 IN O
neurons P09765277A0000 NNS O
and P09765277A0000 CC O
trophoblasts P09765277A0000 NNS O
. P09765277A0000 . O
. . O O

Clinical P09661676T0000 JJ O
implication P09661676T0000 NN O
of P09661676T0000 IN O
protein P09661676T0000 NN O
levels P09661676T0000 NNS O
of P09661676T0000 IN O
IL-5 P09661676T0000 NNP I-UN
in P09661676T0000 IN O
induced P09661676T0000 JJ O
sputum P09661676T0000 NN O
in P09661676T0000 IN O
asthmatic P09661676T0000 JJ O
patients P09661676T0000 NNS O
. P09661676T0000 . O
. . O O

The P10958456A0529 DT O
2 P10958456A0529 CD O
cDNAs P10958456A0529 NN O
differed P10958456A0529 VBN O
in P10958456A0529 IN O
the P10958456A0529 DT O
length P10958456A0529 NN O
of P10958456A0529 IN O
their P10958456A0529 PRP$ O
respective P10958456A0529 JJ O
3 P10958456A0529 CD O
' P10958456A0529 POS O
untranslated P10958456A0529 JJ O
regions P10958456A0529 NNS O
, P10958456A0529 , O
of P10958456A0529 IN O
577 P10958456A0529 CD O
bp P10958456A0529 NN O
in P10958456A0529 IN O
Cp.F6 P10958456A0529 NNP I-UN
and P10958456A0529 CC O
72 P10958456A0529 CD O
bp P10958456A0529 NN O
in P10958456A0529 IN O
Cp.F10 P10958456A0529 NNP I-UN
, P10958456A0529 , O
in P10958456A0529 IN O
both P10958456A0529 DT O
of P10958456A0529 IN O
which P10958456A0529 WDT O
a P10958456A0529 DT O
putative P10958456A0529 JJ O
polyadenylation P10958456A0529 NN O
signal P10958456A0529 NN O
was P10958456A0529 VBD O
identified P10958456A0529 VBN O
. P10958456A0529 . O
. . O O

In P03592297A0679 IN O
subjects P03592297A0679 NNS O
( P03592297A0679 ( O
n P03592297A0679 JJ O
= P03592297A0679 NNP O
5 P03592297A0679 CD O
) P03592297A0679 ) O
with P03592297A0679 IN O
quadriplegia P03592297A0679 NN O
and P03592297A0679 CC O
reduced P03592297A0679 JJ O
sympathetic P03592297A0679 JJ O
tone P03592297A0679 NN O
secondary P03592297A0679 JJ O
to P03592297A0679 TO O
cervical P03592297A0679 JJ O
cord P03592297A0679 NN O
trauma P03592297A0679 NN O
, P03592297A0679 , O
TcpO2 P03592297A0679 NNP O
at P03592297A0679 IN O
42 P03592297A0679 CD O
degrees P03592297A0679 NNS O
C P03592297A0679 NNP O
and P03592297A0679 CC O
vasodilation P03592297A0679 NN O
index P03592297A0679 NN O
were P03592297A0679 VBD O
increased P03592297A0679 VBN O
( P03592297A0679 ( O
45.0 P03592297A0679 CD O
mmHg P03592297A0679 NN O
and P03592297A0679 CC O
0.61 P03592297A0679 CD O
) P03592297A0679 ) O
; P03592297A0679 : O
TcpO2 P03592297A0679 NNP O
at P03592297A0679 IN O
45 P03592297A0679 CD O
degrees P03592297A0679 NNS O
C P03592297A0679 NNPS O
did P03592297A0679 VBD O
not P03592297A0679 RB O
change P03592297A0679 NN O
. P03592297A0679 . O
. . O O

Ischemic P03413681A0659 NNP O
heart P03413681A0659 NN O
disease P03413681A0659 NN O
, P03413681A0659 , O
age P03413681A0659 NN O
of P03413681A0659 IN O
more P03413681A0659 JJR O
than P03413681A0659 IN O
75 P03413681A0659 CD O
years P03413681A0659 NNS O
, P03413681A0659 , O
and P03413681A0659 CC O
the P03413681A0659 DT O
fact P03413681A0659 NN O
that P03413681A0659 IN O
the P03413681A0659 DT O
patient P03413681A0659 NN O
was P03413681A0659 VBD O
a P03413681A0659 DT O
woman P03413681A0659 NN O
were P03413681A0659 VBD O
independent P03413681A0659 JJ O
predictors P03413681A0659 NNS O
of P03413681A0659 IN O
poor P03413681A0659 JJ O
cardiac P03413681A0659 JJ O
function P03413681A0659 NN O
. P03413681A0659 . O
. . O O

As P10992299A0745 IN O
in P10992299A0745 IN O
the P10992299A0745 DT O
other P10992299A0745 JJ O
three P10992299A0745 CD O
members P10992299A0745 NNS O
whose P10992299A0745 WP$ O
gene P10992299A0745 NN O
expression P10992299A0745 NN O
is P10992299A0745 VBZ O
altered P10992299A0745 VBN O
during P10992299A0745 IN O
tumorigenesis P10992299A0745 NN O
, P10992299A0745 , O
PI12 P10992299A0745 NNP I-UN
expression P10992299A0745 NN O
was P10992299A0745 VBD O
found P10992299A0745 VBN O
to P10992299A0745 TO O
be P10992299A0745 VB O
down-regulated P10992299A0745 JJ O
in P10992299A0745 IN O
tumor P10992299A0745 NN O
brain P10992299A0745 NN O
tissues P10992299A0745 NNS O
and P10992299A0745 CC O
in P10992299A0745 IN O
two P10992299A0745 CD O
brain P10992299A0745 NN O
cancer P10992299A0745 NN O
cell P10992299A0745 NN O
lines P10992299A0745 NNS O
: P10992299A0745 : O
U-87 P10992299A0745 JJ O
MG P10992299A0745 NNP O
and P10992299A0745 CC O
H4 P10992299A0745 NNP O
. P10992299A0745 . O
. . O O

The P08264579A1209 DT O
cloning P08264579A1209 NN O
of P08264579A1209 IN O
PTR2 P08264579A1209 NNP I-UN
represents P08264579A1209 VBZ O
the P08264579A1209 DT O
first P08264579A1209 JJ O
example P08264579A1209 NN O
of P08264579A1209 IN O
the P08264579A1209 DT O
molecular P08264579A1209 JJ O
genetic P08264579A1209 JJ O
characterization P08264579A1209 NN O
of P08264579A1209 IN O
a P08264579A1209 DT O
eucaryotic P08264579A1209 JJ O
peptide P08264579A1209 NN O
transport P08264579A1209 NN O
gene P08264579A1209 NN O
. P08264579A1209 . O
. . O O

Attitudes P02348408A0126 NNS O
were P02348408A0126 VBD O
found P02348408A0126 VBN O
to P02348408A0126 TO O
be P02348408A0126 VB O
multidimensional P02348408A0126 JJ O
, P02348408A0126 , O
with P02348408A0126 IN O
similar P02348408A0126 JJ O
dimensions P02348408A0126 NNS O
being P02348408A0126 VBG O
identified P02348408A0126 VBN O
in P02348408A0126 IN O
both P02348408A0126 DT O
samples P02348408A0126 NNS O
. P02348408A0126 . O
. . O O

Normocapnic P02712450A0989 NNP O
( P02712450A0989 ( O
PACO2 P02712450A0989 NNP O
= P02712450A0989 VBZ O
40 P02712450A0989 CD O
mm P02712450A0989 NN O
Hg P02712450A0989 NNP O
) P02712450A0989 ) O
ventilatory P02712450A0989 NN O
drive P02712450A0989 NN O
increased P02712450A0989 VBN O
significantly P02712450A0989 RB O
( P02712450A0989 ( O
p P02712450A0989 NN O
less P02712450A0989 JJR O
than P02712450A0989 IN O
0.05 P02712450A0989 CD O
) P02712450A0989 ) O
in P02712450A0989 IN O
six P02712450A0989 CD O
subjects P02712450A0989 NNS O
( P02712450A0989 ( O
Type P02712450A0989 NNP O
1 P02712450A0989 CD O
response P02712450A0989 NN O
) P02712450A0989 ) O
and P02712450A0989 CC O
decreased P02712450A0989 VBN O
substantially P02712450A0989 RB O
in P02712450A0989 IN O
the P02712450A0989 DT O
others P02712450A0989 NNS O
( P02712450A0989 ( O
Type P02712450A0989 VB O
2 P02712450A0989 CD O
response P02712450A0989 NN O
) P02712450A0989 ) O
; P02712450A0989 : O
with P02712450A0989 IN O
hypercapnia P02712450A0989 NN O
, P02712450A0989 , O
the P02712450A0989 DT O
changes P02712450A0989 NNS O
in P02712450A0989 IN O
drive P02712450A0989 NN O
were P02712450A0989 VBD O
attenuated P02712450A0989 VBN O
in P02712450A0989 IN O
both P02712450A0989 DT O
groups P02712450A0989 NNS O
. P02712450A0989 . O
. . O O

In P07978406A0998 IN O
the P07978406A0998 DT O
ISO P07978406A0998 NNP O
group P07978406A0998 NN O
, P07978406A0998 , O
at P07978406A0998 IN O
pre-DEX P07978406A0998 JJ O
, P07978406A0998 , O
CBF P07978406A0998 NNP O
increased P07978406A0998 VBD O
from P07978406A0998 IN O
86 P07978406A0998 CD O
+ P07978406A0998 NNS O
/ P07978406A0998 SYM O
- P07978406A0998 : O
8 P07978406A0998 CD O
to P07978406A0998 TO O
166 P07978406A0998 CD O
+ P07978406A0998 NNS O
/ P07978406A0998 SYM O
- P07978406A0998 : O
19 P07978406A0998 CD O
mL.min-1.100 P07978406A0998 JJ O
g-1 P07978406A0998 NN O
in P07978406A0998 IN O
response P07978406A0998 NN O
to P07978406A0998 TO O
hypercapnia P07978406A0998 VB O
( P07978406A0998 ( O
PCO2 P07978406A0998 NNP O
approximately P07978406A0998 RB O
90 P07978406A0998 CD O
mmHg P07978406A0998 NN O
) P07978406A0998 ) O
. P07978406A0998 . O
( P07978406A0998 ( O
ABSTRACT P07978406A0998 NNP O
TRUNCATED P07978406A0998 NNP O
AT P07978406A0998 NNP O
250 P07978406A0998 CD O
WORDS P07978406A0998 NNP O
) P07978406A0998 ) O
. P07978406A0998 . O
. . O O

Presidential P02242222T0000 NNP O
address P02242222T0000 NN O
1990 P02242222T0000 CD O
-- P02242222T0000 : O
coming P02242222T0000 VBG O
in P02242222T0000 IN O
from P02242222T0000 IN O
the P02242222T0000 DT O
cold P02242222T0000 NN O
. P02242222T0000 . O
. . O O

It P00503336A0285 PRP O
has P00503336A0285 VBZ O
come P00503336A0285 VBN O
out P00503336A0285 RP O
that P00503336A0285 IN O
CAEC P00503336A0285 NNP O
is P00503336A0285 VBZ O
between P00503336A0285 IN O
CC P00503336A0285 NNP O
and P00503336A0285 CC O
CIEC P00503336A0285 NNP O
and P00503336A0285 CC O
that P00503336A0285 IN O
attacks P00503336A0285 NNS O
of P00503336A0285 IN O
biliary P00503336A0285 JJ O
fever P00503336A0285 NN O
and P00503336A0285 CC O
high P00503336A0285 JJ O
levels P00503336A0285 NNS O
of P00503336A0285 IN O
alkaline P00503336A0285 JJ I-UN
phosphatase P00503336A0285 NN I-UN
and P00503336A0285 CC O
transaminases P00503336A0285 NNS O
in P00503336A0285 IN O
the P00503336A0285 DT O
serum P00503336A0285 NN O
are P00503336A0285 VBP O
the P00503336A0285 DT O
helpful P00503336A0285 JJ O
findings P00503336A0285 NNS O
for P00503336A0285 IN O
preoperative P00503336A0285 JJ O
diagnosis P00503336A0285 NN O
. P00503336A0285 . O
. . O O

Postdocs P11796977T0000 NNP O
face P11796977T0000 NN O
hardship P11796977T0000 NN O
across P11796977T0000 IN O
mainland P11796977T0000 NNP O
Europe P11796977T0000 NNP O
. P11796977T0000 . O
. . O O

The P10220275A0694 DT O
binding P10220275A0694 NN O
of P10220275A0694 IN O
PH P10220275A0694 NNP I-UN
domains P10220275A0694 NNS I-UN
to P10220275A0694 TO O
Gbetagamma P10220275A0694 NNP I-UN
was P10220275A0694 VBD O
inhibited P10220275A0694 VBN O
by P10220275A0694 IN O
preincubation P10220275A0694 NN O
of P10220275A0694 IN O
Gbetagamma P10220275A0694 NNP I-UN
with P10220275A0694 IN O
the P10220275A0694 DT O
GDP-bound P10220275A0694 NNP O
but P10220275A0694 CC O
not P10220275A0694 RB O
the P10220275A0694 DT O
GTP-bound P10220275A0694 JJ O
form P10220275A0694 NN O
of P10220275A0694 IN O
Gialpha P10220275A0694 NNP I-UN
. P10220275A0694 . O
. . O O

Nucleotide P01993181T0000 NNP O
sequence P01993181T0000 NN O
analysis P01993181T0000 NN O
of P01993181T0000 IN O
the P01993181T0000 DT O
Pseudomonas P01993181T0000 NNP I-UN
putida P01993181T0000 NN I-UN
PpG7 P01993181T0000 NNP I-UN
salicylate P01993181T0000 NN I-UN
hydroxylase P01993181T0000 NN I-UN
gene P01993181T0000 NN I-UN
( P01993181T0000 ( O
nahG P01993181T0000 JJ I-UN
) P01993181T0000 ) O
and P01993181T0000 CC O
its P01993181T0000 PRP$ O
3'-flanking P01993181T0000 JJ O
region P01993181T0000 NN O
. P01993181T0000 . O
. . O O

Phase P11709561T0000 NNP O
II P11709561T0000 NNP O
trial P11709561T0000 NN O
of P11709561T0000 IN O
the P11709561T0000 DT O
anti-G P11709561T0000 JJ I-UN
( P11709561T0000 ( I-UN
D2 P11709561T0000 NNP I-UN
) P11709561T0000 ) I-UN
monoclonal P11709561T0000 VBD I-UN
antibody P11709561T0000 NN I-UN
3F8 P11709561T0000 CD I-UN
and P11709561T0000 CC O
granulocyte-macrophage P11709561T0000 JJ I-UN
colony-stimulating P11709561T0000 JJ I-UN
factor P11709561T0000 NN I-UN
for P11709561T0000 IN O
neuroblastoma P11709561T0000 NN O
. P11709561T0000 . O
. . O O

The P01764899A0399 DT O
model P01764899A0399 NN O
is P01764899A0399 VBZ O
able P01764899A0399 JJ O
to P01764899A0399 TO O
anticipate P01764899A0399 VB O
why P01764899A0399 WRB O
the P01764899A0399 DT O
effect P01764899A0399 NN O
of P01764899A0399 IN O
water P01764899A0399 NN O
fluoridation P01764899A0399 NN O
on P01764899A0399 IN O
caries P01764899A0399 NNS O
prevalence P01764899A0399 NN O
is P01764899A0399 VBZ O
most P01764899A0399 RBS O
pronounced P01764899A0399 JJ O
when P01764899A0399 WRB O
caries P01764899A0399 NNS O
is P01764899A0399 VBZ O
diagnosed P01764899A0399 VBN O
at P01764899A0399 IN O
cavity P01764899A0399 NN O
level P01764899A0399 NN O
. P01764899A0399 . O
. . O O

The P01420363A0818 DT O
TIMP P01420363A0818 NNP I-UN
( P01420363A0818 ( O
-59 P01420363A0818 NNP O
/ P01420363A0818 NNP O
-53 P01420363A0818 NNP O
) P01420363A0818 ) O
AP1 P01420363A0818 NNP I-UN
site P01420363A0818 NN O
is P01420363A0818 VBZ O
a P01420363A0818 DT O
promiscuous P01420363A0818 JJ O
motif P01420363A0818 NN O
that P01420363A0818 WDT O
binds P01420363A0818 VBZ O
c-Fos P01420363A0818 JJ I-UN
/ P01420363A0818 JJ O
c-Jun P01420363A0818 JJ I-UN
AP1 P01420363A0818 NNP I-UN
translated P01420363A0818 VBN O
in P01420363A0818 IN O
vitro P01420363A0818 NN O
and P01420363A0818 CC O
is P01420363A0818 VBZ O
an P01420363A0818 DT O
effective P01420363A0818 JJ O
competitor P01420363A0818 NN O
for P01420363A0818 IN O
binding P01420363A0818 NN O
of P01420363A0818 IN O
nuclear P01420363A0818 JJ I-UN
AP1 P01420363A0818 NNP I-UN
factors P01420363A0818 NNS I-UN
to P01420363A0818 TO O
the P01420363A0818 DT O
consensus P01420363A0818 NN O
TRE P01420363A0818 NNP O
, P01420363A0818 , O
but P01420363A0818 CC O
in P01420363A0818 IN O
addition P01420363A0818 NN O
it P01420363A0818 PRP O
binds P01420363A0818 VBZ O
factors P01420363A0818 NNS O
that P01420363A0818 WDT O
do P01420363A0818 VBP O
not P01420363A0818 RB O
associate P01420363A0818 VB O
with P01420363A0818 IN O
the P01420363A0818 DT O
consensus P01420363A0818 NN O
TRE P01420363A0818 NNP O
. P01420363A0818 . O
. . O O

The P06868345A0000 DT O
presence P06868345A0000 NN O
of P06868345A0000 IN O
visna-maedi P06868345A0000 NN O
in P06868345A0000 IN O
Italy P06868345A0000 NNP O
is P06868345A0000 VBZ O
reported P06868345A0000 VBN O
for P06868345A0000 IN O
the P06868345A0000 DT O
first P06868345A0000 JJ O
time P06868345A0000 NN O
. P06868345A0000 . O
. . O O

In P02565807A1198 IN O
contrast P02565807A1198 NN O
, P02565807A1198 , O
the P02565807A1198 DT O
neu P02565807A1198 JJ I-UN
proto-oncogene P02565807A1198 NN I-UN
did P02565807A1198 VBD O
not P02565807A1198 RB O
show P02565807A1198 VB O
kinase P02565807A1198 JJ O
activity P02565807A1198 NN O
or P02565807A1198 CC O
transforming P02565807A1198 NN O
properties P02565807A1198 NNS O
when P02565807A1198 WRB O
expressed P02565807A1198 VBN O
at P02565807A1198 IN O
similar P02565807A1198 JJ O
levels P02565807A1198 NNS O
in P02565807A1198 IN O
NIH P02565807A1198 NNP O
3T3 P02565807A1198 CD O
cells P02565807A1198 NNS O
. P02565807A1198 . O
( P02565807A1198 ( O
ABSTRACT P02565807A1198 NNP O
TRUNCATED P02565807A1198 NNP O
AT P02565807A1198 NNP O
250 P02565807A1198 CD O
WORDS P02565807A1198 NNP O
) P02565807A1198 ) O
. P02565807A1198 . O
. . O O

SEA P01583819A0377 NNP O
was P01583819A0377 VBD O
recorded P01583819A0377 VBN O
with P01583819A0377 IN O
bidirectional P01583819A0377 JJ O
filters P01583819A0377 NNS O
at P01583819A0377 IN O
25-250 P01583819A0377 JJ O
HZ P01583819A0377 NNP O
and P01583819A0377 CC O
40-250 P01583819A0377 JJ O
Hz P01583819A0377 NNP O
using P01583819A0377 VBG O
Simson P01583819A0377 NNP O
method P01583819A0377 NN O
. P01583819A0377 . O
. . O O

Three P01191964A0000 CD O
groups P01191964A0000 NNS O
of P01191964A0000 IN O
patients P01191964A0000 NNS O
who P01191964A0000 WP O
had P01191964A0000 VBD O
undergone P01191964A0000 JJ O
subtotal P01191964A0000 JJ O
thyroidectomy P01191964A0000 NN O
for P01191964A0000 IN O
Graves P01191964A0000 NNP O
's P01191964A0000 POS O
disease P01191964A0000 NN O
, P01191964A0000 , O
toxic P01191964A0000 JJ O
multinodular P01191964A0000 NN O
goitre P01191964A0000 NN O
, P01191964A0000 , O
or P01191964A0000 CC O
euthyroid P01191964A0000 VB O
multinodular P01191964A0000 JJ O
goitre P01191964A0000 NN O
12 P01191964A0000 CD O
to P01191964A0000 TO O
15 P01191964A0000 CD O
years P01191964A0000 NNS O
before P01191964A0000 RB O
and P01191964A0000 CC O
in P01191964A0000 IN O
whom P01191964A0000 WP O
a P01191964A0000 DT O
normal P01191964A0000 JJ O
serum P01191964A0000 NN O
thyroxine P01191964A0000 NN O
( P01191964A0000 ( O
T-4 P01191964A0000 NNP O
) P01191964A0000 ) O
level P01191964A0000 NN O
was P01191964A0000 VBD O
found P01191964A0000 VBN O
were P01191964A0000 VBD O
each P01191964A0000 DT O
divided P01191964A0000 VBN O
into P01191964A0000 IN O
two P01191964A0000 CD O
subgroups P01191964A0000 NNS O
on P01191964A0000 IN O
the P01191964A0000 DT O
basis P01191964A0000 NN O
of P01191964A0000 IN O
a P01191964A0000 DT O
normal P01191964A0000 JJ O
or P01191964A0000 CC O
a P01191964A0000 DT O
raised P01191964A0000 VBN O
serum P01191964A0000 NN O
thyrotrophin P01191964A0000 JJ I-UN
concentration P01191964A0000 NN O
. P01191964A0000 . O
. . O O

Remarkably P09012405A0785 RB O
, P09012405A0785 , O
both P09012405A0785 DT O
TTD-A P09012405A0785 NNP O
and P09012405A0785 CC O
XP-D P09012405A0785 JJ O
defects P09012405A0785 NNS O
are P09012405A0785 VBP O
associated P09012405A0785 VBN O
with P09012405A0785 IN O
subunits P09012405A0785 NNS O
of P09012405A0785 IN O
TFIIH P09012405A0785 NNP I-UN
, P09012405A0785 , O
a P09012405A0785 DT O
basal P09012405A0785 NN O
transcription P09012405A0785 NN O
factor P09012405A0785 NN O
with P09012405A0785 IN O
a P09012405A0785 DT O
second P09012405A0785 JJ O
function P09012405A0785 NN O
in P09012405A0785 IN O
DNA P09012405A0785 NNP O
repair P09012405A0785 NN O
. P09012405A0785 . O
. . O O

Liver P07512258A0441 NNP O
transplantation P07512258A0441 NN O
in P07512258A0441 IN O
one P07512258A0441 CD O
patient P07512258A0441 NN O
resolved P07512258A0441 VBD O
metabolic P07512258A0441 JJ O
complications P07512258A0441 NNS O
but P07512258A0441 CC O
did P07512258A0441 VBD O
not P07512258A0441 RB O
improve P07512258A0441 VB O
PMN P07512258A0441 NNP O
count P07512258A0441 NN O
or P07512258A0441 CC O
the P07512258A0441 DT O
infectious P07512258A0441 JJ O
status P07512258A0441 NN O
, P07512258A0441 , O
while P07512258A0441 IN O
neutropenia P07512258A0441 NN O
was P07512258A0441 VBD O
corrected P07512258A0441 VBN O
by P07512258A0441 IN O
G-CSF P07512258A0441 NNP I-UN
. P07512258A0441 . O
. . O O

This P01334493A0289 DT O
soluble P01334493A0289 JJ O
form P01334493A0289 NN O
of P01334493A0289 IN O
the P01334493A0289 DT O
HGFr P01334493A0289 NNP I-UN
( P01334493A0289 ( O
sHGFr P01334493A0289 NN I-UN
) P01334493A0289 ) O
bound P01334493A0289 NN O
HGF P01334493A0289 NNP I-UN
with P01334493A0289 IN O
an P01334493A0289 DT O
affinity P01334493A0289 NN O
similar P01334493A0289 JJ O
to P01334493A0289 TO O
that P01334493A0289 DT O
of P01334493A0289 IN O
the P01334493A0289 DT O
authentic P01334493A0289 JJ O
, P01334493A0289 , O
membrane-associated P01334493A0289 JJ O
receptor P01334493A0289 NN O
. P01334493A0289 . O
. . O O

During P07579023A0214 IN O
the P07579023A0214 DT O
dose-finding P07579023A0214 JJ O
, P07579023A0214 , O
two P07579023A0214 CD O
patients P07579023A0214 NNS O
were P07579023A0214 VBD O
temporarily P07579023A0214 RB O
withdrawn P07579023A0214 VBN O
from P07579023A0214 IN O
medication P07579023A0214 NN O
and P07579023A0214 CC O
one P07579023A0214 CD O
patient P07579023A0214 NN O
was P07579023A0214 VBD O
excluded P07579023A0214 VBN O
because P07579023A0214 IN O
of P07579023A0214 IN O
elevated P07579023A0214 JJ O
levels P07579023A0214 NNS O
of P07579023A0214 IN O
liver P07579023A0214 NN O
enzymes P07579023A0214 NNS O
. P07579023A0214 . O
. . O O

Fibrinogen P07293327T0001 NNP I-UN
determination P07293327T0001 NN O
using P07293327T0001 VBG O
the P07293327T0001 DT O
KZM-1 P07293327T0001 NNP O
meter P07293327T0001 NN O
. P07293327T0001 . O
. . O O

When P00025557A0100 WRB O
the P00025557A0100 DT O
CO2 P00025557A0100 NNP O
content P00025557A0100 NN O
reached P00025557A0100 VBD O
9 P00025557A0100 CD O
Vol P00025557A0100 NNP O
% P00025557A0100 NN O
the P00025557A0100 DT O
animals P00025557A0100 NNS O
became P00025557A0100 VBD O
apathic P00025557A0100 JJ O
and P00025557A0100 CC O
lost P00025557A0100 VBN O
body P00025557A0100 NN O
weight P00025557A0100 NN O
. P00025557A0100 . O
. . O O

Sequence P02642466T0000 NNP O
analysis P02642466T0000 NN O
of P02642466T0000 IN O
the P02642466T0000 DT O
47-kilodalton P02642466T0000 JJ I-UN
major P02642466T0000 JJ I-UN
integral P02642466T0000 JJ I-UN
membrane P02642466T0000 NN I-UN
immunogen P02642466T0000 NN I-UN
of P02642466T0000 IN I-UN
Treponema P02642466T0000 NNP I-UN
pallidum P02642466T0000 NN I-UN
. P02642466T0000 . O
. . O O

They P07844555A0406 PRP O
also P07844555A0406 RB O
reported P07844555A0406 VBD O
that P07844555A0406 IN O
E P07844555A0406 NNP I-UN
mu P07844555A0406 VBD I-UN
pim-1 P07844555A0406 JJ I-UN
transgenic P07844555A0406 JJ O
mice P07844555A0406 NN O
show P07844555A0406 NN O
greatly P07844555A0406 RB O
accelerated P07844555A0406 VBD O
lymphoma P07844555A0406 NN O
development P07844555A0406 NN O
when P07844555A0406 WRB O
infected P07844555A0406 VBN O
with P07844555A0406 IN O
wild-type P07844555A0406 JJ O
M-MuLV P07844555A0406 NNP O
at P07844555A0406 IN O
birth P07844555A0406 NN O
. P07844555A0406 . O
. . O O

Effects P02907533T0000 NNS O
of P02907533T0000 IN O
a P02907533T0000 DT O
perfluorochemical P02907533T0000 JJ O
blood P02907533T0000 NN O
substitute P02907533T0000 NN O
on P02907533T0000 IN O
diazepam P02907533T0000 NN O
binding P02907533T0000 NN O
by P02907533T0000 IN O
human P02907533T0000 JJ I-UN
albumin P02907533T0000 NN I-UN
. P02907533T0000 . O
. . O O

The P10469656T0000 DT O
nucleosomal P10469656T0000 JJ O
response P10469656T0000 NN O
associated P10469656T0000 VBN O
with P10469656T0000 IN O
immediate-early P10469656T0000 JJ I-UN
gene P10469656T0000 NN I-UN
induction P10469656T0000 NN O
is P10469656T0000 VBZ O
mediated P10469656T0000 VBN O
via P10469656T0000 IN O
alternative P10469656T0000 JJ O
MAP P10469656T0000 NNP I-UN
kinase P10469656T0000 NN I-UN
cascades P10469656T0000 NNS I-UN
: P10469656T0000 : O
MSK1 P10469656T0000 NNP I-UN
as P10469656T0000 IN O
a P10469656T0000 DT O
potential P10469656T0000 JJ O
histone P10469656T0000 NN I-UN
H3 P10469656T0000 NNP I-UN
/ P10469656T0000 NNP O
HMG-14 P10469656T0000 NNP I-UN
kinase P10469656T0000 NN O
. P10469656T0000 . O
. . O O

Most P10724519A1185 JJS O
likely P10724519A1185 JJ O
they P10724519A1185 PRP O
might P10724519A1185 MD O
represent P10724519A1185 VB O
regulatory P10724519A1185 JJ O
RNAs P10724519A1185 NNP O
or P10724519A1185 CC O
transcribed P10724519A1185 VBN O
transposable P10724519A1185 JJ O
elements P10724519A1185 NNS O
. P10724519A1185 . O
. . O O

The P00136175A1137 DT O
maintenance P00136175A1137 NN O
of P00136175A1137 IN O
increased P00136175A1137 VBN O
myocardial P00136175A1137 JJ O
capillary P00136175A1137 JJ O
density P00136175A1137 NN O
required P00136175A1137 VBN O
a P00136175A1137 DT O
similar P00136175A1137 JJ O
amount P00136175A1137 NN O
of P00136175A1137 IN O
exercise P00136175A1137 NN O
, P00136175A1137 , O
and P00136175A1137 CC O
at P00136175A1137 IN O
least P00136175A1137 JJS O
1 P00136175A1137 CD O
h P00136175A1137 NN O
of P00136175A1137 IN O
exercise P00136175A1137 NN O
once P00136175A1137 RB O
a P00136175A1137 DT O
week P00136175A1137 NN O
was P00136175A1137 VBD O
necessary P00136175A1137 JJ O
to P00136175A1137 TO O
maintain P00136175A1137 VB O
the P00136175A1137 DT O
enlargement P00136175A1137 NN O
of P00136175A1137 IN O
ECA.20 P00136175A1137 NNP O
. P00136175A1137 . O
. . O O

Electrophoretic P07969136A0273 JJ O
mobility P07969136A0273 NN O
shift P07969136A0273 NN O
assays P07969136A0273 NNS O
with P07969136A0273 IN O
each P07969136A0273 DT O
of P07969136A0273 IN O
these P07969136A0273 DT O
sequences P07969136A0273 NNS O
demonstrated P07969136A0273 VBD O
complexes P07969136A0273 NNS O
with P07969136A0273 IN O
mobilities P07969136A0273 NNS O
identical P07969136A0273 JJ O
to P07969136A0273 TO O
those P07969136A0273 DT O
of P07969136A0273 IN O
the P07969136A0273 DT O
NF-kappa P07969136A0273 NNP I-UN
B P07969136A0273 NNP I-UN
site P07969136A0273 NN I-UN
from P07969136A0273 IN O
the P07969136A0273 DT O
kappa P07969136A0273 JJ I-UN
light-chain P07969136A0273 JJ I-UN
gene P07969136A0273 NN I-UN
. P07969136A0273 . O
. . O O

Unitary-group P09904139T0000 JJ O
approach P09904139T0000 NN O
to P09904139T0000 TO O
spin-dependent P09904139T0000 JJ O
operators P09904139T0000 NNS O
. P09904139T0000 . O
. . O O

No P08237112A0553 DT O
homology P08237112A0553 NN O
was P08237112A0553 VBD O
found P08237112A0553 VBN O
between P08237112A0553 IN O
the P08237112A0553 DT O
36K P08237112A0553 CD O
protein P08237112A0553 NN O
and P08237112A0553 CC O
known P08237112A0553 JJ O
structures P08237112A0553 NNS O
of P08237112A0553 IN O
proteins P08237112A0553 NNS O
. P08237112A0553 . O
. . O O

No P10051030A1080 DT O
difference P10051030A1080 NN O
in P10051030A1080 IN O
percentage P10051030A1080 NN O
of P10051030A1080 IN O
males P10051030A1080 NNS O
in P10051030A1080 IN O
semen P10051030A1080 JJ O
production P10051030A1080 NN O
was P10051030A1080 VBD O
noted P10051030A1080 VBN O
between P10051030A1080 IN O
strains P10051030A1080 NNS O
, P10051030A1080 , O
CP P10051030A1080 NNP O
levels P10051030A1080 NNS O
, P10051030A1080 , O
or P10051030A1080 CC O
feeding P10051030A1080 VBG O
regimens P10051030A1080 NNS O
. P10051030A1080 . O
. . O O

Distinguishing P08408194T0000 VBG O
roles P08408194T0000 NNS O
of P08408194T0000 IN O
the P08408194T0000 DT O
membrane-cytoskeleton P08408194T0000 NN O
and P08408194T0000 CC O
cadherin P08408194T0000 NN I-UN
mediated P08408194T0000 VBD O
cell-cell P08408194T0000 JJ O
adhesion P08408194T0000 NN O
in P08408194T0000 IN O
generating P08408194T0000 VBG O
different P08408194T0000 JJ O
Na+ P08408194T0000 NNP I-UN
, P08408194T0000 , I-UN
K P08408194T0000 NNP I-UN
( P08408194T0000 ( I-UN
+ P08408194T0000 NNP I-UN
) P08408194T0000 ) I-UN
-ATPase P08408194T0000 NN I-UN
distributions P08408194T0000 NNS O
in P08408194T0000 IN O
polarized P08408194T0000 JJ O
epithelia P08408194T0000 NN O
. P08408194T0000 . O
. . O O

As P11148042A1258 IN O
well P11148042A1258 RB O
, P11148042A1258 , O
mixtures P11148042A1258 NNS O
of P11148042A1258 IN O
( P11148042A1258 ( O
LA P11148042A1258 NNP O
) P11148042A1258 ) O
( P11148042A1258 ( O
12 P11148042A1258 CD O
) P11148042A1258 ) O
with P11148042A1258 IN O
the P11148042A1258 DT O
longer P11148042A1258 JJR O
chain P11148042A1258 NN O
PEs P11148042A1258 NNP O
exhibit P11148042A1258 NN O
unusual P11148042A1258 JJ O
biomodal P11148042A1258 NN O
enthalpy P11148042A1258 NN O
variations P11148042A1258 NNS O
, P11148042A1258 , O
suggesting P11148042A1258 VBG O
peptide P11148042A1258 JJ O
immiscibility P11148042A1258 NN O
in P11148042A1258 IN O
thicker P11148042A1258 NN O
gel P11148042A1258 NN O
state P11148042A1258 NN O
bilayers P11148042A1258 NNS O
. P11148042A1258 . O
. . O O

Synaptic P10748194T0000 JJ O
targeting P10748194T0000 NN O
of P10748194T0000 IN O
the P10748194T0000 DT O
postsynaptic P10748194T0000 JJ I-UN
density P10748194T0000 NN I-UN
protein P10748194T0000 IN I-UN
PSD-95 P10748194T0000 NNP I-UN
mediated P10748194T0000 VBN O
by P10748194T0000 IN O
a P10748194T0000 DT O
tyrosine-based P10748194T0000 JJ O
trafficking P10748194T0000 NN O
signal P10748194T0000 NN O
. P10748194T0000 . O
. . O O

The P06579147A0060 DT O
salient P06579147A0060 JJ O
clinical P06579147A0060 JJ O
features P06579147A0060 NNS O
, P06579147A0060 , O
the P06579147A0060 DT O
problems P06579147A0060 NNS O
of P06579147A0060 IN O
management P06579147A0060 NN O
and P06579147A0060 CC O
the P06579147A0060 DT O
modern P06579147A0060 JJ O
approaches P06579147A0060 NNS O
to P06579147A0060 TO O
the P06579147A0060 DT O
reconstruction P06579147A0060 NN O
of P06579147A0060 IN O
facial P06579147A0060 JJ O
deformities P06579147A0060 NNS O
seen P06579147A0060 VBN O
in P06579147A0060 IN O
this P06579147A0060 DT O
disease P06579147A0060 NN O
are P06579147A0060 VBP O
described P06579147A0060 VBN O
. P06579147A0060 . O
. . O O

Chagas P01844982A0324 NNP O
' P01844982A0324 POS O
disease P01844982A0324 NN O
, P01844982A0324 , O
visceral P01844982A0324 JJ O
leishmaniasis P01844982A0324 NN O
, P01844982A0324 , O
anti-nuclear P01844982A0324 JJ I-UN
factor P01844982A0324 NN I-UN
, P01844982A0324 , O
schistosomiasis P01844982A0324 NN O
, P01844982A0324 , O
rheumatoid P01844982A0324 JJ I-UN
factor P01844982A0324 NN I-UN
and P01844982A0324 CC O
normal P01844982A0324 JJ O
controls P01844982A0324 NNS O
. P01844982A0324 . O
. . O O

However P01782669A0496 RB O
, P01782669A0496 , O
it P01782669A0496 PRP O
was P01782669A0496 VBD O
synthesized P01782669A0496 VBN O
at P01782669A0496 IN O
both P01782669A0496 DT O
temperatures P01782669A0496 NNS O
after P01782669A0496 IN O
addition P01782669A0496 NN O
of P01782669A0496 IN O
A23187 P01782669A0496 NNP O
. P01782669A0496 . O
. . O O

A P11354975A0850 DT O
new P11354975A0850 JJ O
species P11354975A0850 NNS O
of P11354975A0850 IN O
Euspondylus P11354975A0850 NNP O
is P11354975A0850 VBZ O
described P11354975A0850 VBN O
based P11354975A0850 VBN O
on P11354975A0850 IN O
a P11354975A0850 DT O
female P11354975A0850 NN O
( P11354975A0850 ( O
taken P11354975A0850 VBN O
within P11354975A0850 IN O
a P11354975A0850 DT O
bromeliad P11354975A0850 NN O
) P11354975A0850 ) O
from P11354975A0850 IN O
Cerro P11354975A0850 NNP O
El P11354975A0850 NNP O
Humo P11354975A0850 NNP O
, P11354975A0850 , O
Sucre P11354975A0850 NNP O
, P11354975A0850 , O
northeastern P11354975A0850 JJ O
Venezuela P11354975A0850 NNP O
. P11354975A0850 . O
. . O O

The P08413209A0159 DT O
amino-terminal P08413209A0159 JJ O
third P08413209A0159 NN O
of P08413209A0159 IN O
the P08413209A0159 DT O
protein P08413209A0159 NN O
contains P08413209A0159 VBZ O
a P08413209A0159 DT O
high-mobility-group P08413209A0159 JJ I-UN
motif P08413209A0159 NN I-UN
characteristic P08413209A0159 NN O
of P08413209A0159 IN O
DNA-binding P08413209A0159 NNP O
proteins P08413209A0159 NNS O
. P08413209A0159 . O
. . O O

Mutations P09710591A0981 NNS O
within P09710591A0981 IN O
the P09710591A0981 DT O
C P09710591A0981 NNP O
terminus P09710591A0981 NN O
of P09710591A0981 IN O
c-fos P09710591A0981 NN I-UN
at P09710591A0981 IN O
serine P09710591A0981 NN O
residues P09710591A0981 NNS O
that P09710591A0981 WDT O
are P09710591A0981 VBP O
phosphorylation P09710591A0981 JJ O
targets P09710591A0981 NNS O
for P09710591A0981 IN O
growth P09710591A0981 NN O
factors P09710591A0981 NNS O
and P09710591A0981 CC O
MAP P09710591A0981 NNP I-UN
kinase P09710591A0981 NNP I-UN
completely P09710591A0981 RB O
abrogate P09710591A0981 JJ O
transactivation P09710591A0981 NN O
and P09710591A0981 CC O
block P09710591A0981 NN O
potentiation P09710591A0981 NN O
by P09710591A0981 IN O
MAP P09710591A0981 NNP I-UN
kinase P09710591A0981 NN I-UN
. P09710591A0981 . O
. . O O

The P09233809A0381 DT O
two P09233809A0381 CD O
mouse P09233809A0381 NN O
lines P09233809A0381 NNS O
carrying P09233809A0381 VBG O
the P09233809A0381 DT O
unfragmented P09233809A0381 JJ O
Hnf3g-lacZ P09233809A0381 NNP O
YAC P09233809A0381 NNP O
showed P09233809A0381 VBD O
tissue-specific P09233809A0381 JJ O
, P09233809A0381 , O
copy P09233809A0381 JJ O
number-dependent P09233809A0381 JJ O
and P09233809A0381 CC O
position-independent P09233809A0381 JJ O
expression P09233809A0381 NN O
, P09233809A0381 , O
proving P09233809A0381 VBG O
that P09233809A0381 IN O
170 P09233809A0381 CD O
kb P09233809A0381 NN O
of P09233809A0381 IN O
the P09233809A0381 DT O
Hnf3g P09233809A0381 NNP I-UN
locus P09233809A0381 NN O
contain P09233809A0381 VBP O
all P09233809A0381 DT O
elements P09233809A0381 NNS O
important P09233809A0381 JJ O
in P09233809A0381 IN O
the P09233809A0381 DT O
regulation P09233809A0381 NN O
of P09233809A0381 IN O
Hnf3g P09233809A0381 NNP I-UN
. P09233809A0381 . O
. . O O

The P10196127A1059 DT O
catalytic P10196127A1059 JJ O
site P10196127A1059 NN O
has P10196127A1059 VBZ O
an P10196127A1059 DT O
S1 P10196127A1059 NNP O
pocket P10196127A1059 NN O
lined P10196127A1059 VBD O
with P10196127A1059 IN O
conserved P10196127A1059 JJ O
hydrophobic P10196127A1059 NN O
residues P10196127A1059 NNS O
to P10196127A1059 TO O
accommodate P10196127A1059 VB O
the P10196127A1059 DT O
pyroglutamyl P10196127A1059 NN O
residue P10196127A1059 NN O
. P10196127A1059 . O
. . O O

Transcription P08861963T0000 NNP O
factor P08861963T0000 NN O
recognition P08861963T0000 NN O
surface P08861963T0000 NN O
on P08861963T0000 IN O
the P08861963T0000 DT O
RNA P08861963T0000 NNP I-UN
polymerase P08861963T0000 NN I-UN
alpha P08861963T0000 NN I-UN
subunit P08861963T0000 NN I-UN
is P08861963T0000 VBZ O
involved P08861963T0000 VBN O
in P08861963T0000 IN O
contact P08861963T0000 NN O
with P08861963T0000 IN O
the P08861963T0000 DT O
DNA P08861963T0000 NNP O
enhancer P08861963T0000 NN O
element P08861963T0000 NN O
. P08861963T0000 . O
. . O O

It P02113174A0064 PRP O
encodes P02113174A0064 VBZ O
a P02113174A0064 DT O
protein P02113174A0064 NN O
with P02113174A0064 IN O
three P02113174A0064 CD O
zinc P02113174A0064 NN O
fingers P02113174A0064 NNS O
similar P02113174A0064 JJ O
to P02113174A0064 TO O
those P02113174A0064 DT O
of P02113174A0064 IN O
the P02113174A0064 DT O
transcription P02113174A0064 NN I-UN
factor P02113174A0064 NN I-UN
Sp1 P02113174A0064 NNP I-UN
. P02113174A0064 . O
. . O O

The P08387507A1015 DT O
regulation P08387507A1015 NN O
of P08387507A1015 IN O
Myf-5 P08387507A1015 NNP I-UN
and P08387507A1015 CC O
MyoD P08387507A1015 NNP I-UN
function P08387507A1015 NN O
by P08387507A1015 IN O
a P08387507A1015 DT O
cAMP-dependent P08387507A1015 JJ O
pathway P08387507A1015 NN O
may P08387507A1015 MD O
partly P08387507A1015 RB O
explain P08387507A1015 VB O
how P08387507A1015 WRB O
external P08387507A1015 JJ O
signals P08387507A1015 NNS O
generated P08387507A1015 VBN O
by P08387507A1015 IN O
serum P08387507A1015 NN O
and P08387507A1015 CC O
certain P08387507A1015 JJ O
peptide P08387507A1015 JJ O
growth P08387507A1015 NN O
factors P08387507A1015 NNS O
can P08387507A1015 MD O
be P08387507A1015 VB O
transduced P08387507A1015 VBN O
to P08387507A1015 TO O
the P08387507A1015 DT O
nucleus P08387507A1015 NN O
and P08387507A1015 CC O
inhibit P08387507A1015 VB O
dominant-acting P08387507A1015 JJ O
factors P08387507A1015 NNS O
that P08387507A1015 WDT O
are P08387507A1015 VBP O
responsible P08387507A1015 JJ O
for P08387507A1015 IN O
myoblast P08387507A1015 JJ O
differentiation P08387507A1015 NN O
. P08387507A1015 . O
. . O O

Surprisingly P07983744A0920 RB O
, P07983744A0920 , O
nuclear P07983744A0920 JJ O
forms P07983744A0920 NNS O
of P07983744A0920 IN O
IE110 P07983744A0920 NNP I-UN
were P07983744A0920 VBD O
found P07983744A0920 VBN O
to P07983744A0920 TO O
move P07983744A0920 VB O
a P07983744A0920 DT O
cytoplasmic P07983744A0920 JJ O
form P07983744A0920 NN O
of P07983744A0920 IN O
IE175 P07983744A0920 NNP I-UN
into P07983744A0920 IN O
nuclear P07983744A0920 JJ O
punctate P07983744A0920 NN O
structures P07983744A0920 NNS O
, P07983744A0920 , O
and P07983744A0920 CC O
a P07983744A0920 DT O
cytoplasmic P07983744A0920 JJ O
form P07983744A0920 NN O
of P07983744A0920 IN O
IE110 P07983744A0920 NNP I-UN
was P07983744A0920 VBD O
able P07983744A0920 JJ O
to P07983744A0920 TO O
retain P07983744A0920 VB O
nuclear P07983744A0920 JJ O
forms P07983744A0920 NNS O
of P07983744A0920 IN O
IE175 P07983744A0920 NNP I-UN
in P07983744A0920 IN O
cytoplasmic P07983744A0920 JJ O
punctate P07983744A0920 NN O
structures P07983744A0920 NNS O
. P07983744A0920 . O
. . O O

The P08547205A1060 DT O
results P08547205A1060 NNS O
indicate P08547205A1060 VBP O
that P08547205A1060 IN O
the P08547205A1060 DT O
bradycardic P08547205A1060 JJ O
agents P08547205A1060 NNS O
alinidine P08547205A1060 JJ O
and P08547205A1060 CC O
zatebradine P08547205A1060 NN O
do P08547205A1060 VBP O
not P08547205A1060 RB O
exert P08547205A1060 VB O
antiarrhythmic P08547205A1060 JJ O
efficacy P08547205A1060 NN O
against P08547205A1060 IN O
SVT P08547205A1060 NNP O
induced P08547205A1060 VBD O
during P08547205A1060 IN O
subacute P08547205A1060 JJ O
myocardial P08547205A1060 JJ O
infarction P08547205A1060 NN O
in P08547205A1060 IN O
conscious P08547205A1060 JJ O
dogs P08547205A1060 NNS O
. P08547205A1060 . O
. . O O

A P09676349A0000 DT O
`` P09676349A0000 `` O
Level P09676349A0000 NN O
A P09676349A0000 DT O
'' P09676349A0000 '' O
in P09676349A0000 IN O
vitro P09676349A0000 JJ O
/ P09676349A0000 NN O
in P09676349A0000 IN O
vivo P09676349A0000 JJ O
correlation P09676349A0000 NN O
was P09676349A0000 VBD O
established P09676349A0000 VBN O
for P09676349A0000 IN O
a P09676349A0000 DT O
sustained P09676349A0000 JJ O
release P09676349A0000 NN O
theophylline P09676349A0000 NN O
( P09676349A0000 ( O
CAS P09676349A0000 NNP O
58-55-9 P09676349A0000 NNP O
) P09676349A0000 ) O
preparation P09676349A0000 NN O
( P09676349A0000 ( O
Bronchoretard P09676349A0000 NNP O
) P09676349A0000 ) O
under P09676349A0000 IN O
investigation P09676349A0000 NN O
. P09676349A0000 . O
. . O O

In P08973630A0923 IN O
some P08973630A0923 DT O
cases P08973630A0923 NNS O
, P08973630A0923 , O
factor-induced P08973630A0923 JJ O
Rac P08973630A0923 NNP I-UN
activation P08973630A0923 NN O
results P08973630A0923 NNS O
in P08973630A0923 IN O
Rho P08973630A0923 NNP I-UN
activation P08973630A0923 NN O
, P08973630A0923 , O
and P08973630A0923 CC O
factor-induced P08973630A0923 JJ O
Cdc42 P08973630A0923 NNP I-UN
activation P08973630A0923 NN O
leads P08973630A0923 VBZ O
to P08973630A0923 TO O
Rac P08973630A0923 NNP I-UN
activation P08973630A0923 NN O
, P08973630A0923 , O
as P08973630A0923 IN O
determined P08973630A0923 VBN O
by P08973630A0923 IN O
specific P08973630A0923 JJ O
morphological P08973630A0923 JJ O
changes P08973630A0923 NNS O
. P08973630A0923 . O
. . O O

We P10548622A0906 PRP O
recommend P10548622A0906 VBP O
that P10548622A0906 DT O
paracervical P10548622A0906 JJ O
block P10548622A0906 NN O
with P10548622A0906 IN O
lignocaine P10548622A0906 NN O
should P10548622A0906 MD O
be P10548622A0906 VB O
used P10548622A0906 VBN O
in P10548622A0906 IN O
conjunction P10548622A0906 NN O
with P10548622A0906 IN O
i.v P10548622A0906 NN O
. P10548622A0906 . O
sedation P10548622A0906 NN O
/ P10548622A0906 NNP O
analgesia P10548622A0906 NN O
during P10548622A0906 IN O
egg P10548622A0906 NN O
collection P10548622A0906 NN O
performed P10548622A0906 VBD O
through P10548622A0906 IN O
the P10548622A0906 DT O
transvaginal P10548622A0906 JJ O
route P10548622A0906 NN O
under P10548622A0906 IN O
ultrasound P10548622A0906 JJ O
guidance P10548622A0906 NN O
( P10548622A0906 ( O
TUGOR P10548622A0906 NNP O
) P10548622A0906 ) O
to P10548622A0906 TO O
reduce P10548622A0906 VB O
the P10548622A0906 DT O
pain P10548622A0906 NN O
of P10548622A0906 IN O
the P10548622A0906 DT O
procedure P10548622A0906 NN O
. P10548622A0906 . O
. . O O

Experiences P04115870T0000 NNS O
with P04115870T0000 IN O
the P04115870T0000 DT O
clinical P04115870T0000 JJ O
and P04115870T0000 CC O
experimental P04115870T0000 JJ O
use P04115870T0000 NN O
of P04115870T0000 IN O
Urat-I P04115870T0000 NNP O
lithotriptor P04115870T0000 NN O
. P04115870T0000 . O
. . O O

Here P11118438A0411 RB O
, P11118438A0411 , O
we P11118438A0411 PRP O
describe P11118438A0411 VBP O
the P11118438A0411 DT O
isolation P11118438A0411 NN O
of P11118438A0411 IN O
MdPin1 P11118438A0411 NNP I-UN
, P11118438A0411 , O
a P11118438A0411 DT O
Pin1 P11118438A0411 NNP I-UN
homologue P11118438A0411 NN O
from P11118438A0411 IN O
the P11118438A0411 DT O
plant P11118438A0411 NN O
species P11118438A0411 NNS O
apple P11118438A0411 NN O
( P11118438A0411 ( O
Malus P11118438A0411 NNP O
domestica P11118438A0411 NN O
) P11118438A0411 ) O
and P11118438A0411 CC O
show P11118438A0411 VBP O
that P11118438A0411 IN O
it P11118438A0411 PRP O
has P11118438A0411 VBZ O
the P11118438A0411 DT O
same P11118438A0411 JJ O
phosphorylation-specific P11118438A0411 JJ O
substrate P11118438A0411 NN O
specificity P11118438A0411 NN O
and P11118438A0411 CC O
can P11118438A0411 MD O
be P11118438A0411 VB O
inhibited P11118438A0411 VBN O
by P11118438A0411 IN O
juglone P11118438A0411 NN O
in P11118438A0411 IN O
vitro P11118438A0411 NN O
, P11118438A0411 , O
as P11118438A0411 IN O
is P11118438A0411 VBZ O
the P11118438A0411 DT O
case P11118438A0411 NN O
for P11118438A0411 IN O
Pin1 P11118438A0411 NNP I-UN
. P11118438A0411 . O
. . O O

For P11525102A0970 IN O
the P11525102A0970 DT O
sample P11525102A0970 NN O
of P11525102A0970 IN O
systematic P11525102A0970 JJ O
reviews P11525102A0970 NNS O
drawn P11525102A0970 VBN O
from P11525102A0970 IN O
ACP P11525102A0970 NNP O
Journal P11525102A0970 NNP O
Club P11525102A0970 NNP O
( P11525102A0970 ( O
n P11525102A0970 JJ O
= P11525102A0970 NNP O
103 P11525102A0970 CD O
) P11525102A0970 ) O
, P11525102A0970 , O
the P11525102A0970 DT O
PubMed P11525102A0970 NNP O
strategy P11525102A0970 NN O
achieved P11525102A0970 VBD O
a P11525102A0970 DT O
sensitivity P11525102A0970 NN O
of P11525102A0970 IN O
97 P11525102A0970 CD O
% P11525102A0970 NN O
( P11525102A0970 ( O
CI P11525102A0970 NNP O
, P11525102A0970 , O
91 P11525102A0970 CD O
% P11525102A0970 NN O
to P11525102A0970 TO O
99 P11525102A0970 CD O
% P11525102A0970 NN O
) P11525102A0970 ) O
. P11525102A0970 . O
. . O O

The P11014821T0000 DT O
LAMMER P11014821T0000 NNP I-UN
protein P11014821T0000 NN O
kinase P11014821T0000 NN O
encoded P11014821T0000 VBN O
by P11014821T0000 IN O
the P11014821T0000 DT O
Doa P11014821T0000 NNP I-UN
locus P11014821T0000 NN I-UN
of P11014821T0000 IN O
Drosophila P11014821T0000 NNP O
is P11014821T0000 VBZ O
required P11014821T0000 VBN O
in P11014821T0000 IN O
both P11014821T0000 DT O
somatic P11014821T0000 JJ O
and P11014821T0000 CC O
germline P11014821T0000 JJ O
cells P11014821T0000 NNS O
and P11014821T0000 CC O
is P11014821T0000 VBZ O
expressed P11014821T0000 VBN O
as P11014821T0000 IN O
both P11014821T0000 DT O
nuclear P11014821T0000 JJ O
and P11014821T0000 CC O
cytoplasmic P11014821T0000 JJ O
isoforms P11014821T0000 NNS O
throughout P11014821T0000 IN O
development P11014821T0000 NN O
. P11014821T0000 . O
. . O O

This P00429893A0000 DT O
multiple-electrode P00429893A0000 JJ O
array P00429893A0000 NN O
for P00429893A0000 IN O
round P00429893A0000 NN O
window P00429893A0000 NN O
cochlear P00429893A0000 JJ O
implantation P00429893A0000 NN O
is P00429893A0000 VBZ O
a P00429893A0000 DT O
robust P00429893A0000 JJ O
, P00429893A0000 , O
reliable P00429893A0000 JJ O
system P00429893A0000 NN O
for P00429893A0000 IN O
inserting P00429893A0000 VBG O
20 P00429893A0000 CD O
mm P00429893A0000 NN O
along P00429893A0000 IN O
the P00429893A0000 DT O
scala P00429893A0000 NN O
tympani P00429893A0000 NN O
with P00429893A0000 IN O
a P00429893A0000 DT O
minimum P00429893A0000 NN O
of P00429893A0000 IN O
trauma P00429893A0000 NN O
and P00429893A0000 CC O
can P00429893A0000 MD O
provide P00429893A0000 VB O
for P00429893A0000 IN O
bipolar P00429893A0000 JJ O
stimulation P00429893A0000 NN O
. P00429893A0000 . O
. . O O

The P01310178A0876 DT O
JS78 P01310178A0876 NNP O
mutation P01310178A0876 NN O
changes P01310178A0876 NNS O
Gln243 P01310178A0876 NNP O
in P01310178A0876 IN O
gp0.7 P01310178A0876 NN O
to P01310178A0876 TO O
an P01310178A0876 DT O
amber P01310178A0876 NN O
codon P01310178A0876 NN O
, P01310178A0876 , O
which P01310178A0876 WDT O
explains P01310178A0876 VBZ O
the P01310178A0876 DT O
production P01310178A0876 NN O
of P01310178A0876 IN O
the P01310178A0876 DT O
truncated P01310178A0876 JJ O
, P01310178A0876 , O
30-kDa P01310178A0876 JJ I-UN
gp0.7-related P01310178A0876 JJ I-UN
polypeptide P01310178A0876 NN I-UN
, P01310178A0876 , O
and P01310178A0876 CC O
implicates P01310178A0876 VBZ O
the P01310178A0876 DT O
11-kDa P01310178A0876 JJ O
C-terminal P01310178A0876 JJ O
domain P01310178A0876 NN O
in P01310178A0876 IN O
host P01310178A0876 NN O
transcription P01310178A0876 NN O
shut-off P01310178A0876 NN O
. P01310178A0876 . O
. . O O

Thus P11520436A0705 RB O
, P11520436A0705 , O
BALB P11520436A0705 NNP O
/ P11520436A0705 NNP O
c P11520436A0705 JJ O
mice P11520436A0705 NN O
appear P11520436A0705 VBP O
to P11520436A0705 TO O
be P11520436A0705 VB O
the P11520436A0705 DT O
most P11520436A0705 RBS O
appropriate P11520436A0705 JJ O
strain P11520436A0705 NN O
of P11520436A0705 IN O
mice P11520436A0705 NNS O
to P11520436A0705 TO O
perform P11520436A0705 VB O
studies P11520436A0705 NNS O
on P11520436A0705 IN O
the P11520436A0705 DT O
possible P11520436A0705 JJ O
connection P11520436A0705 NN O
between P11520436A0705 IN O
infection P11520436A0705 NN O
with P11520436A0705 IN O
T. P11520436A0705 NNP O
canis P11520436A0705 NN O
and P11520436A0705 CC O
allergic P11520436A0705 JJ O
asthma P11520436A0705 NN O
. P11520436A0705 . O
. . O O

False P00066874T0000 NNP O
positive P00066874T0000 JJ O
amniotic P00066874T0000 JJ I-UN
fluid P00066874T0000 NN I-UN
alpha P00066874T0000 NN I-UN
fetoprotein P00066874T0000 NN I-UN
levels P00066874T0000 NNS O
resulting P00066874T0000 VBG O
from P00066874T0000 IN O
contamination P00066874T0000 NN O
with P00066874T0000 IN O
fetal P00066874T0000 JJ O
blood P00066874T0000 NN O
: P00066874T0000 : O
results P00066874T0000 NNS O
of P00066874T0000 IN O
an P00066874T0000 DT O
experiment P00066874T0000 NN O
. P00066874T0000 . O
. . O O

E1A P09512550T0000 NNP I-UN
represses P09512550T0000 VBZ O
apolipoprotein P09512550T0000 RB I-UN
AI P09512550T0000 NNP I-UN
enhancer P09512550T0000 NN I-UN
activity P09512550T0000 NN O
in P09512550T0000 IN O
liver P09512550T0000 NN O
cells P09512550T0000 NNS O
through P09512550T0000 IN O
a P09512550T0000 DT O
pRb- P09512550T0000 JJ O
and P09512550T0000 CC O
CBP-independent P09512550T0000 JJ O
pathway P09512550T0000 NN O
. P09512550T0000 . O
. . O O

These P02201905A1004 DT O
latter P02201905A1004 JJ O
results P02201905A1004 NNS O
showed P02201905A1004 VBD O
that P02201905A1004 IN O
the P02201905A1004 DT O
ABFI P02201905A1004 NNP I-UN
protein P02201905A1004 NN I-UN
, P02201905A1004 , O
like P02201905A1004 IN O
the P02201905A1004 DT O
RAP1 P02201905A1004 NNP I-UN
protein P02201905A1004 NN I-UN
, P02201905A1004 , O
bound P02201905A1004 JJ O
sequences P02201905A1004 NNS O
required P02201905A1004 VBN O
for P02201905A1004 IN O
positive P02201905A1004 JJ O
as P02201905A1004 RB O
well P02201905A1004 RB O
as P02201905A1004 IN O
negative P02201905A1004 JJ O
regulation P02201905A1004 NN O
of P02201905A1004 IN O
gene P02201905A1004 NN O
expression P02201905A1004 NN O
. P02201905A1004 . O
. . O O

Staphylococcal P07567300T0000 JJ I-UN
enterotoxin P07567300T0000 NN I-UN
A P07567300T0000 DT I-UN
involvement P07567300T0000 NN O
in P07567300T0000 IN O
the P07567300T0000 DT O
illness P07567300T0000 NN O
of P07567300T0000 IN O
a P07567300T0000 DT O
20-month-old P07567300T0000 JJ O
burn P07567300T0000 NN O
patient P07567300T0000 NN O
. P07567300T0000 . O
. . O O

The P08825636T0000 DT O
complete P08825636T0000 JJ O
exon-intron P08825636T0000 JJ O
structure P08825636T0000 NN O
of P08825636T0000 IN O
the P08825636T0000 DT O
156-kb P08825636T0000 JJ I-UN
human P08825636T0000 JJ I-UN
gene P08825636T0000 NN I-UN
NFKB1 P08825636T0000 NNP I-UN
, P08825636T0000 , O
which P08825636T0000 WDT O
encodes P08825636T0000 VBZ O
the P08825636T0000 DT O
p105 P08825636T0000 NN I-UN
and P08825636T0000 CC O
p50 P08825636T0000 JJ I-UN
proteins P08825636T0000 NNS I-UN
of P08825636T0000 IN O
transcription P08825636T0000 NN O
factors P08825636T0000 NNS O
NF-kappa P08825636T0000 NNP I-UN
B P08825636T0000 NNP I-UN
and P08825636T0000 CC O
I P08825636T0000 PRP I-UN
kappa P08825636T0000 VBP I-UN
B-gamma P08825636T0000 JJ I-UN
: P08825636T0000 : O
implications P08825636T0000 NNS O
for P08825636T0000 IN O
NF-kappa P08825636T0000 NNP I-UN
B-mediated P08825636T0000 NNP O
signal P08825636T0000 JJ O
transduction P08825636T0000 NN O
. P08825636T0000 . O
. . O O

Increased P00659962T0000 VBN O
urinary P00659962T0000 JJ O
riboflavin P00659962T0000 NN O
excretion P00659962T0000 NN O
resulting P00659962T0000 VBG O
from P00659962T0000 IN O
boric P00659962T0000 JJ O
acid P00659962T0000 NN O
ingestion P00659962T0000 NN O
. P00659962T0000 . O
. . O O

Positron P09327881T0000 NNP O
emission P09327881T0000 NN O
tomography P09327881T0000 NN O
radioligands P09327881T0000 VBZ O
for P09327881T0000 IN O
dopamine P09327881T0000 NN I-UN
transporters P09327881T0000 NNS I-UN
and P09327881T0000 CC O
studies P09327881T0000 NNS O
in P09327881T0000 IN O
human P09327881T0000 JJ O
and P09327881T0000 CC O
nonhuman P09327881T0000 JJ O
primates P09327881T0000 NNS O
. P09327881T0000 . O
. . O O

It P09147420A0623 PRP O
has P09147420A0623 VBZ O
repeatedly P09147420A0623 RB O
been P09147420A0623 VBN O
shown P09147420A0623 VBN O
that P09147420A0623 IN O
HCMV P09147420A0623 NNP O
IE1 P09147420A0623 NNP I-UN
/ P09147420A0623 NNP O
IE2 P09147420A0623 NNP I-UN
can P09147420A0623 MD O
independently P09147420A0623 RB O
transactivate P09147420A0623 VB O
HIV-1 P09147420A0623 NNP I-UN
LTR P09147420A0623 NNP I-UN
. P09147420A0623 . O
. . O O

Erythrocyte P07897696A0000 NNP I-UN
delta-aminolevulinic P07897696A0000 JJ I-UN
acid P07897696A0000 NN I-UN
dehydratase P07897696A0000 NN I-UN
( P07897696A0000 ( O
ALAD P07897696A0000 NNP I-UN
) P07897696A0000 ) O
activity P07897696A0000 NN O
, P07897696A0000 , O
erythrocyte P07897696A0000 NN O
zinc P07897696A0000 NN O
protoporphyrin P07897696A0000 NN O
( P07897696A0000 ( O
ZPP P07897696A0000 NNP O
) P07897696A0000 ) O
/ P07897696A0000 VBP O
heme P07897696A0000 JJ O
ratio P07897696A0000 NN O
, P07897696A0000 , O
and P07897696A0000 CC O
urinary P07897696A0000 JJ O
coproporphyrin P07897696A0000 NN O
( P07897696A0000 ( O
UC P07897696A0000 NNP O
) P07897696A0000 ) O
concentration P07897696A0000 NN O
have P07897696A0000 VBP O
been P07897696A0000 VBN O
employed P07897696A0000 VBN O
as P07897696A0000 IN O
biological P07897696A0000 JJ O
indicators P07897696A0000 NNS O
of P07897696A0000 IN O
moderate-to P07897696A0000 JJ O
high-level P07897696A0000 JJ O
lead P07897696A0000 NN O
exposure P07897696A0000 NN O
, P07897696A0000 , O
corresponding P07897696A0000 VBG O
to P07897696A0000 TO O
blood P07897696A0000 NN O
levels P07897696A0000 NNS O
in P07897696A0000 IN O
excess P07897696A0000 NN O
of P07897696A0000 IN O
50 P07897696A0000 CD O
micrograms P07897696A0000 NNS O
/ P07897696A0000 JJ O
dl P07897696A0000 NN O
, P07897696A0000 , O
in P07897696A0000 IN O
human P07897696A0000 JJ O
subjects P07897696A0000 NNS O
. P07897696A0000 . O
. . O O

One P03746107A0192 CD O
hundred P03746107A0192 CD O
and P03746107A0192 CC O
four P03746107A0192 CD O
( P03746107A0192 ( O
14 P03746107A0192 CD O
per P03746107A0192 IN O
cent P03746107A0192 NN O
) P03746107A0192 ) O
second P03746107A0192 JJ O
primary P03746107A0192 JJ O
tumours P03746107A0192 NNS O
were P03746107A0192 VBD O
reported P03746107A0192 VBN O
. P03746107A0192 . O
. . O O

Reverse P02107548A0727 JJ O
transcription-PCR P02107548A0727 NN O
was P02107548A0727 VBD O
then P02107548A0727 RB O
used P02107548A0727 VBN O
to P02107548A0727 TO O
clone P02107548A0727 VB O
from P02107548A0727 IN O
human P02107548A0727 JJ O
poly P02107548A0727 NN O
( P02107548A0727 ( O
A P02107548A0727 DT O
) P02107548A0727 ) O
+ P02107548A0727 NN O
RNA P02107548A0727 NNP O
the P02107548A0727 DT O
cDNA P02107548A0727 NN O
corresponding P02107548A0727 VBG O
to P02107548A0727 TO O
the P02107548A0727 DT O
expressed P02107548A0727 VBN O
homolog P02107548A0727 NN O
of P02107548A0727 IN O
psi P02107548A0727 NN I-UN
ARF P02107548A0727 NNP I-UN
4 P02107548A0727 CD I-UN
, P02107548A0727 , O
referred P02107548A0727 VBD O
to P02107548A0727 TO O
as P02107548A0727 IN O
human P02107548A0727 JJ I-UN
ARF P02107548A0727 NNP I-UN
4 P02107548A0727 CD I-UN
. P02107548A0727 . O
. . O O

Bone P00381783T0000 NNP O
marrow P00381783T0000 VBD O
transplantation-1979 P00381783T0000 NN O
. P00381783T0000 . O
. . O O

However P11254504A0766 RB O
, P11254504A0766 , O
the P11254504A0766 DT O
promoter P11254504A0766 NN O
region P11254504A0766 NN O
contains P11254504A0766 VBZ O
several P11254504A0766 JJ O
potential P11254504A0766 JJ O
cis-regulatory P11254504A0766 JJ O
elements P11254504A0766 NNS O
such P11254504A0766 JJ O
as P11254504A0766 IN O
Sp1 P11254504A0766 NNP I-UN
, P11254504A0766 , O
early P11254504A0766 JJ I-UN
growth P11254504A0766 NN I-UN
response-1 P11254504A0766 NN I-UN
, P11254504A0766 , O
activator P11254504A0766 NN I-UN
protein-2 P11254504A0766 NN I-UN
, P11254504A0766 , O
MyoD P11254504A0766 NNP I-UN
, P11254504A0766 , O
p300 P11254504A0766 NN I-UN
, P11254504A0766 , O
nuclear P11254504A0766 JJ I-UN
factor-kappaB P11254504A0766 NN I-UN
, P11254504A0766 , O
myeloid P11254504A0766 JJ I-UN
zinc P11254504A0766 NN I-UN
finger P11254504A0766 NN I-UN
protein-1 P11254504A0766 JJ I-UN
, P11254504A0766 , O
caudal-related P11254504A0766 JJ I-UN
homeobox P11254504A0766 NN I-UN
( P11254504A0766 ( I-UN
Cdx P11254504A0766 NNP I-UN
) P11254504A0766 ) I-UN
gene P11254504A0766 NN I-UN
A P11254504A0766 NNP I-UN
, P11254504A0766 , O
and P11254504A0766 CC O
Cdx P11254504A0766 NNP I-UN
protein-2 P11254504A0766 NN I-UN
binding P11254504A0766 NN I-UN
sites P11254504A0766 NNS I-UN
. P11254504A0766 . O
. . O O

No P08011017A0169 DT O
drop P08011017A0169 NN O
in P08011017A0169 IN O
oxygen P08011017A0169 NN O
saturation P08011017A0169 NN O
( P08011017A0169 ( O
SaO2 P08011017A0169 NNP O
) P08011017A0169 ) O
or P08011017A0169 CC O
visual P08011017A0169 JJ O
evidence P08011017A0169 NN O
of P08011017A0169 IN O
transient P08011017A0169 JJ O
electroencephalographic P08011017A0169 JJ O
( P08011017A0169 ( O
EEG P08011017A0169 NNP O
) P08011017A0169 ) O
arousals P08011017A0169 NNS O
can P08011017A0169 MD O
be P08011017A0169 VB O
found P08011017A0169 VBN O
at P08011017A0169 IN O
repeat P08011017A0169 NN O
polysomnography P08011017A0169 NN O
. P08011017A0169 . O
. . O O

We P10944466A0451 PRP O
have P10944466A0451 VBP O
determined P10944466A0451 VBN O
the P10944466A0451 DT O
structure P10944466A0451 NN O
of P10944466A0451 IN O
the P10944466A0451 DT O
WNT-2B P10944466A0451 NNP I-UN
gene P10944466A0451 NN I-UN
. P10944466A0451 . O
. . O O

To P09049198A0289 TO O
gain P09049198A0289 VB O
insight P09049198A0289 NN O
into P09049198A0289 IN O
the P09049198A0289 DT O
possible P09049198A0289 JJ O
involvement P09049198A0289 NN O
of P09049198A0289 IN O
p21 P09049198A0289 NN I-UN
in P09049198A0289 IN O
liver P09049198A0289 NN O
cell P09049198A0289 NN O
growth P09049198A0289 NN O
, P09049198A0289 , O
the P09049198A0289 DT O
expression P09049198A0289 NN O
and P09049198A0289 CC O
regulation P09049198A0289 NN O
of P09049198A0289 IN O
the P09049198A0289 DT O
p21 P09049198A0289 NN I-UN
gene P09049198A0289 NN I-UN
was P09049198A0289 VBD O
evaluated P09049198A0289 VBN O
in P09049198A0289 IN O
rodent P09049198A0289 JJ O
models P09049198A0289 NNS O
of P09049198A0289 IN O
liver P09049198A0289 JJ O
regeneration P09049198A0289 NN O
and P09049198A0289 CC O
specimens P09049198A0289 NNS O
of P09049198A0289 IN O
human P09049198A0289 JJ O
liver P09049198A0289 NN O
diseases P09049198A0289 NNS O
. P09049198A0289 . O
. . O O

Plasmids P06314276T0000 NNS O
for P06314276T0000 IN O
the P06314276T0000 DT O
cloning P06314276T0000 NN O
and P06314276T0000 CC O
expression P06314276T0000 NN O
of P06314276T0000 IN O
full-length P06314276T0000 JJ O
double-stranded P06314276T0000 JJ O
cDNAs P06314276T0000 NN O
under P06314276T0000 IN O
control P06314276T0000 NN O
of P06314276T0000 IN O
the P06314276T0000 DT O
SV40 P06314276T0000 NNP I-UN
early P06314276T0000 JJ I-UN
or P06314276T0000 CC O
late P06314276T0000 JJ I-UN
gene P06314276T0000 NN I-UN
promoter P06314276T0000 NN O
. P06314276T0000 . O
. . O O

The P07872788A1717 DT O
high P07872788A1717 JJ O
degree P07872788A1717 NN O
of P07872788A1717 IN O
sequence P07872788A1717 NN O
identity P07872788A1717 NN O
( P07872788A1717 ( O
96 P07872788A1717 CD O
% P07872788A1717 NN O
) P07872788A1717 ) O
between P07872788A1717 IN O
hydrolase P07872788A1717 NN I-UN
B P07872788A1717 NNP I-UN
and P07872788A1717 CC I-UN
C P07872788A1717 NNP I-UN
, P07872788A1717 , O
particularly P07872788A1717 RB O
in P07872788A1717 IN O
the P07872788A1717 DT O
3 P07872788A1717 CD O
' P07872788A1717 POS O
untranslated P07872788A1717 JJ O
region P07872788A1717 NN O
, P07872788A1717 , O
suggests P07872788A1717 VBZ O
that P07872788A1717 IN O
the P07872788A1717 DT O
genes P07872788A1717 NNS O
encoding P07872788A1717 VBG O
these P07872788A1717 DT O
two P07872788A1717 CD O
carboxylesterases P07872788A1717 NNS I-UN
evolved P07872788A1717 VBN O
by P07872788A1717 IN O
duplication P07872788A1717 NN O
and P07872788A1717 CC O
divergence P07872788A1717 NN O
of P07872788A1717 IN O
a P07872788A1717 DT O
common P07872788A1717 JJ O
ancestral P07872788A1717 JJ O
gene P07872788A1717 NN O
. P07872788A1717 . O
. . O O

Although P03513989A1149 IN O
not P03513989A1149 RB O
common P03513989A1149 JJ O
, P03513989A1149 , O
the P03513989A1149 DT O
disorder P03513989A1149 NN O
is P03513989A1149 VBZ O
the P03513989A1149 DT O
most P03513989A1149 RBS O
frequently P03513989A1149 RB O
diagnosed P03513989A1149 VBN O
disturbance P03513989A1149 NN O
of P03513989A1149 IN O
porphyrin P03513989A1149 JJ O
metabolism P03513989A1149 NN O
in P03513989A1149 IN O
many P03513989A1149 JJ O
countries P03513989A1149 NNS O
, P03513989A1149 , O
and P03513989A1149 CC O
further P03513989A1149 RB O
insight P03513989A1149 RB O
into P03513989A1149 IN O
its P03513989A1149 PRP$ O
unusual P03513989A1149 JJ O
pathogenesis P03513989A1149 NN O
may P03513989A1149 MD O
clarify P03513989A1149 VB O
the P03513989A1149 DT O
hepatotoxic P03513989A1149 JJ O
effects P03513989A1149 NNS O
of P03513989A1149 IN O
the P03513989A1149 DT O
4 P03513989A1149 CD O
etiologic P03513989A1149 JJ O
agents P03513989A1149 NNS O
. P03513989A1149 . O
. . O O

Two P03033283A0837 CD O
separate P03033283A0837 JJ O
NF1-binding P03033283A0837 JJ I-UN
loci P03033283A0837 NN I-UN
were P03033283A0837 VBD O
also P03033283A0837 RB O
found P03033283A0837 VBN O
in P03033283A0837 IN O
the P03033283A0837 DT O
equivalent P03033283A0837 JJ O
IE68 P03033283A0837 NNP I-UN
gene P03033283A0837 NN I-UN
of P03033283A0837 IN O
HCMV P03033283A0837 NNP O
( P03033283A0837 ( O
Towne P03033283A0837 NNP O
) P03033283A0837 ) O
DNA P03033283A0837 NN O
, P03033283A0837 , O
but P03033283A0837 CC O
in P03033283A0837 IN O
this P03033283A0837 DT O
case P03033283A0837 NN O
the P03033283A0837 DT O
DNA P03033283A0837 NNP O
sequence P03033283A0837 NN O
and P03033283A0837 CC O
competition P03033283A0837 NN O
filter P03033283A0837 NN O
binding P03033283A0837 VBG O
experiments P03033283A0837 NNS O
indicated P03033283A0837 VBD O
a P03033283A0837 DT O
maximum P03033283A0837 NN O
of P03033283A0837 IN O
only P03033283A0837 RB O
four P03033283A0837 CD O
to P03033283A0837 TO O
five P03033283A0837 CD O
consensus P03033283A0837 NN O
binding P03033283A0837 NN O
sites P03033283A0837 VBZ O
encompassing P03033283A0837 VBG O
the P03033283A0837 DT O
promoter-enhancer P03033283A0837 JJ O
region P03033283A0837 NN O
. P03033283A0837 . O
. . O O

As P06597709A0596 IN O
pleural P06597709A0596 JJ O
thickening P06597709A0596 NN O
is P06597709A0596 VBZ O
seen P06597709A0596 VBN O
commonly P06597709A0596 RB O
in P06597709A0596 IN O
asbestosis P06597709A0596 NN O
and P06597709A0596 CC O
may P06597709A0596 MD O
influence P06597709A0596 VB O
lung P06597709A0596 NN O
volumes P06597709A0596 NNS O
and P06597709A0596 CC O
the P06597709A0596 DT O
ratio P06597709A0596 NN O
of P06597709A0596 IN O
transfer P06597709A0596 NN I-UN
factor P06597709A0596 NN I-UN
to P06597709A0596 TO O
effective P06597709A0596 JJ O
alveolar P06597709A0596 JJ O
volume P06597709A0596 NN O
, P06597709A0596 , O
the P06597709A0596 DT O
results P06597709A0596 NNS O
of P06597709A0596 IN O
these P06597709A0596 DT O
measurements P06597709A0596 NNS O
were P06597709A0596 VBD O
compared P06597709A0596 VBN O
only P06597709A0596 RB O
in P06597709A0596 IN O
the P06597709A0596 DT O
cases P06597709A0596 NNS O
showing P06597709A0596 VBG O
absent P06597709A0596 NN O
or P06597709A0596 CC O
minimal P06597709A0596 JJ O
pleural P06597709A0596 JJ O
thickening P06597709A0596 NN O
. P06597709A0596 . O
. . O O

All P11125411A0857 DT O
9 P11125411A0857 CD O
untreated P11125411A0857 JJ O
patients P11125411A0857 NNS O
underwent P11125411A0857 JJ O
laparoscopy P11125411A0857 NN O
, P11125411A0857 , O
which P11125411A0857 WDT O
identified P11125411A0857 VBD O
3 P11125411A0857 CD O
intra-abdominal P11125411A0857 JJ O
, P11125411A0857 , O
3 P11125411A0857 CD O
vanished P11125411A0857 VBD O
and P11125411A0857 CC O
2 P11125411A0857 CD O
peeping P11125411A0857 NN O
testes P11125411A0857 NNS O
, P11125411A0857 , O
and P11125411A0857 CC O
1 P11125411A0857 CD O
atrophic P11125411A0857 JJ O
testis P11125411A0857 NN O
in P11125411A0857 IN O
the P11125411A0857 DT O
inguinal P11125411A0857 JJ O
canal P11125411A0857 NN O
. P11125411A0857 . O
. . O O

STP1 P01588961A0000 NNP I-UN
is P01588961A0000 VBZ O
an P01588961A0000 DT O
unessential P01588961A0000 JJ O
yeast P01588961A0000 NN O
gene P01588961A0000 NN O
involved P01588961A0000 VBN O
in P01588961A0000 IN O
the P01588961A0000 DT O
removal P01588961A0000 NN O
of P01588961A0000 IN O
intervening P01588961A0000 VBG O
sequences P01588961A0000 NNS O
from P01588961A0000 IN O
some P01588961A0000 DT O
, P01588961A0000 , O
but P01588961A0000 CC O
not P01588961A0000 RB O
all P01588961A0000 DT O
, P01588961A0000 , O
families P01588961A0000 NNS O
of P01588961A0000 IN O
intervening P01588961A0000 VBG O
sequence-containing P01588961A0000 JJ O
pre-tRNAs P01588961A0000 NN O
. P01588961A0000 . O
. . O O

These P08440688A1509 DT O
studies P08440688A1509 NNS O
demonstrate P08440688A1509 VBP O
that P08440688A1509 IN O
both P08440688A1509 DT O
G P08440688A1509 NNP I-UN
alpha P08440688A1509 NN I-UN
i P08440688A1509 NN I-UN
genes P08440688A1509 NNS I-UN
are P08440688A1509 VBP O
dynamically P08440688A1509 RB O
regulated P08440688A1509 VBN O
in P08440688A1509 IN O
LLC-PK1 P08440688A1509 NNP O
cells P08440688A1509 NNS O
by P08440688A1509 IN O
both P08440688A1509 DT O
growth P08440688A1509 NN O
, P08440688A1509 , O
differentiation P08440688A1509 NN O
, P08440688A1509 , O
and P08440688A1509 CC O
hormone P08440688A1509 NN O
signals P08440688A1509 NNS O
. P08440688A1509 . O
. . O O

This P07575416A1970 DT O
work P07575416A1970 NN O
, P07575416A1970 , O
therefore P07575416A1970 RB O
, P07575416A1970 , O
also P07575416A1970 RB O
emphasizes P07575416A1970 VBZ O
the P07575416A1970 DT O
importance P07575416A1970 NN O
of P07575416A1970 IN O
careful P07575416A1970 JJ O
choice P07575416A1970 NN O
of P07575416A1970 IN O
oligonucleotide P07575416A1970 NN O
and P07575416A1970 CC O
cDNA P07575416A1970 NN O
probes P07575416A1970 NNS O
to P07575416A1970 TO O
study P07575416A1970 VB O
PKC P07575416A1970 NNP I-UN
zeta P07575416A1970 NNP I-UN
mRNA P07575416A1970 NN I-UN
. P07575416A1970 . O
. . O O

Ectopic P11195338A0494 NNP O
expression P11195338A0494 NN O
of P11195338A0494 IN O
the P11195338A0494 DT O
dominant P11195338A0494 JJ I-UN
mutant P11195338A0494 JJ I-UN
Lg3 P11195338A0494 NNP I-UN
allele P11195338A0494 NN I-UN
is P11195338A0494 VBZ O
believed P11195338A0494 VBN O
to P11195338A0494 TO O
cause P11195338A0494 VB O
the P11195338A0494 DT O
phenotype P11195338A0494 NN O
. P11195338A0494 . O
. . O O

Risk P01138215T0001 NN O
of P01138215T0001 IN O
infection P01138215T0001 NN O
in P01138215T0001 IN O
the P01138215T0001 DT O
treatment P01138215T0001 NN O
of P01138215T0001 IN O
fractures P01138215T0001 NNS O
. P01138215T0001 . O
. . O O

We P08649427A0689 PRP O
report P08649427A0689 VBP O
here P08649427A0689 RB O
the P08649427A0689 DT O
identification P08649427A0689 NN O
of P08649427A0689 IN O
a P08649427A0689 DT O
cDNA P08649427A0689 NN O
that P08649427A0689 WDT O
encodes P08649427A0689 VBZ O
a P08649427A0689 DT O
new P08649427A0689 JJ O
member P08649427A0689 NN O
of P08649427A0689 IN O
the P08649427A0689 DT O
GTPase-activating P08649427A0689 NNP I-UN
protein P08649427A0689 NN I-UN
( P08649427A0689 ( O
GAP P08649427A0689 NNP I-UN
) P08649427A0689 ) O
family P08649427A0689 NN O
of P08649427A0689 IN O
GTPase P08649427A0689 NNP I-UN
regulators P08649427A0689 NNS O
. P08649427A0689 . O
. . O O

The P09132061A0828 DT O
atp P09132061A0828 NN I-UN
1 P09132061A0828 CD I-UN
and P09132061A0828 CC O
atp P09132061A0828 $ I-UN
2 P09132061A0828 CD I-UN
types P09132061A0828 NNS O
of P09132061A0828 IN O
cDNA P09132061A0828 NN O
sequences P09132061A0828 NNS O
were P09132061A0828 VBD O
the P09132061A0828 DT O
most P09132061A0828 RBS O
redundant P09132061A0828 JJ O
among P09132061A0828 IN O
the P09132061A0828 DT O
28 P09132061A0828 CD O
different P09132061A0828 JJ O
isoperoxidases P09132061A0828 NNS I-UN
identified P09132061A0828 VBN O
among P09132061A0828 IN O
about P09132061A0828 RB O
200 P09132061A0828 CD O
peroxidase P09132061A0828 NN I-UN
encoding P09132061A0828 VBG I-UN
ESTs P09132061A0828 NNP I-UN
. P09132061A0828 . O
. . O O

In P10210952A0261 IN O
retrospect P10210952A0261 NN O
, P10210952A0261 , O
the P10210952A0261 DT O
diagnoses P10210952A0261 NNS O
were P10210952A0261 VBD O
reconsidered P10210952A0261 VBN O
applying P10210952A0261 VBG O
strict P10210952A0261 JJ O
criteria P10210952A0261 NNS O
. P10210952A0261 . O
. . O O

Their P08837746A0951 PRP$ O
use P08837746A0951 NN O
established P08837746A0951 VBD O
that P08837746A0951 IN O
the P08837746A0951 DT O
BrAAP P08837746A0951 NNP O
activity P08837746A0951 NN O
catalyzed P08837746A0951 VBD O
both P08837746A0951 DT O
a P08837746A0951 DT O
postproline P08837746A0951 NN O
and P08837746A0951 CC O
a P08837746A0951 DT O
postglutamate P08837746A0951 JJ O
cleavage P08837746A0951 NN O
and P08837746A0951 CC O
therefore P08837746A0951 NN O
has P08837746A0951 VBZ O
a P08837746A0951 DT O
broader P08837746A0951 JJR O
specificity P08837746A0951 NN O
than P08837746A0951 IN O
previously P08837746A0951 RB O
recognized P08837746A0951 VBN O
. P08837746A0951 . O
. . O O

None P02590391A0442 NN O
of P02590391A0442 IN O
the P02590391A0442 DT O
measured P02590391A0442 JJ O
parameters P02590391A0442 NNS O
( P02590391A0442 ( O
heart P02590391A0442 NN O
contents P02590391A0442 NNS O
of P02590391A0442 IN O
neutral P02590391A0442 JJ O
lipids P02590391A0442 NNS O
, P02590391A0442 , O
total P02590391A0442 JJ O
phospholipids P02590391A0442 NNS O
, P02590391A0442 , O
phosphatidylcholine P02590391A0442 NN O
, P02590391A0442 , O
phosphatidylethanolamine P02590391A0442 NN O
, P02590391A0442 , O
diphosphatidylglycerol P02590391A0442 NN O
, P02590391A0442 , O
sphingomyelin P02590391A0442 NN O
and P02590391A0442 CC O
fatty P02590391A0442 JJ O
acid P02590391A0442 JJ O
composition P02590391A0442 NN O
of P02590391A0442 IN O
each P02590391A0442 DT O
phospholipid P02590391A0442 JJ O
class P02590391A0442 NN O
) P02590391A0442 ) O
appeared P02590391A0442 VBD O
to P02590391A0442 TO O
be P02590391A0442 VB O
related P02590391A0442 VBN O
with P02590391A0442 IN O
the P02590391A0442 DT O
grading P02590391A0442 NN O
of P02590391A0442 IN O
the P02590391A0442 DT O
lesions P02590391A0442 NNS O
. P02590391A0442 . O
. . O O

Institution P01562659A0676 NN O
of P01562659A0676 IN O
both P01562659A0676 DT O
intravenous P01562659A0676 JJ O
and P01562659A0676 CC O
intracisternal P01562659A0676 JJ O
administration P01562659A0676 NN O
of P01562659A0676 IN O
amphotericin P01562659A0676 NN O
B P01562659A0676 NNP O
and P01562659A0676 CC O
possibly P01562659A0676 RB O
concomitant P01562659A0676 VB O
intravenous P01562659A0676 JJ O
administration P01562659A0676 NN O
of P01562659A0676 IN O
dexamethasone P01562659A0676 NN O
may P01562659A0676 MD O
be P01562659A0676 VB O
warranted P01562659A0676 VBN O
in P01562659A0676 IN O
situations P01562659A0676 NNS O
in P01562659A0676 IN O
which P01562659A0676 WDT O
the P01562659A0676 DT O
association P01562659A0676 NN O
of P01562659A0676 IN O
C. P01562659A0676 NNP O
immitis P01562659A0676 NN O
with P01562659A0676 IN O
CNS P01562659A0676 NNP O
vasculitis P01562659A0676 NN O
or P01562659A0676 CC O
encephalitis P01562659A0676 NN O
appears P01562659A0676 VBZ O
likely P01562659A0676 JJ O
before P01562659A0676 IN O
serologic P01562659A0676 JJ O
or P01562659A0676 CC O
cultural P01562659A0676 JJ O
confirmation P01562659A0676 NN O
of P01562659A0676 IN O
C. P01562659A0676 NNP O
immitis P01562659A0676 NN O
infection P01562659A0676 NN O
involving P01562659A0676 VBG O
the P01562659A0676 DT O
CNS P01562659A0676 NNP O
is P01562659A0676 VBZ O
available P01562659A0676 JJ O
. P01562659A0676 . O
. . O O

We P08706731A1303 PRP O
identify P08706731A1303 VBP O
considerable P08706731A1303 JJ O
spatio-temporal P08706731A1303 JJ O
similarities P08706731A1303 NNS O
between P08706731A1303 IN O
reported P08706731A1303 VBN O
expression P08706731A1303 NN O
patterns P08706731A1303 NNS O
of P08706731A1303 IN O
Ypr10 P08706731A1303 NNP I-UN
genes P08706731A1303 NNS I-UN
and P08706731A1303 CC O
ribonuclease P08706731A1303 NN O
genes P08706731A1303 NNS O
, P08706731A1303 , O
which P08706731A1303 WDT O
, P08706731A1303 , O
together P08706731A1303 RB O
with P08706731A1303 IN O
the P08706731A1303 DT O
significant P08706731A1303 JJ O
sequence P08706731A1303 NN O
similarity P08706731A1303 NN O
to P08706731A1303 TO O
the P08706731A1303 DT O
ginseng P08706731A1303 NN I-UN
ribonuclease P08706731A1303 NN I-UN
, P08706731A1303 , O
support P08706731A1303 VB O
the P08706731A1303 DT O
hypothesis P08706731A1303 NN O
of P08706731A1303 IN O
a P08706731A1303 DT O
ribonuclease P08706731A1303 NN O
function P08706731A1303 NN O
for P08706731A1303 IN O
PR-10 P08706731A1303 NNP I-UN
proteins P08706731A1303 NNS I-UN
and P08706731A1303 CC O
allow P08706731A1303 VB O
the P08706731A1303 DT O
prediction P08706731A1303 NN O
of P08706731A1303 IN O
possible P08706731A1303 JJ O
biological P08706731A1303 JJ O
roles P08706731A1303 NNS O
. P08706731A1303 . O
. . O O

An P10630471T0000 DT O
ASIC-chip P10630471T0000 NN O
for P10630471T0000 IN O
stereoscopic P10630471T0000 NN O
depth P10630471T0000 NN O
analysis P10630471T0000 NN O
in P10630471T0000 IN O
video-real-time P10630471T0000 NN O
based P10630471T0000 VBN O
on P10630471T0000 IN O
visual P10630471T0000 JJ O
cortical P10630471T0000 JJ O
cell P10630471T0000 NN O
behavior P10630471T0000 NN O
. P10630471T0000 . O
. . O O

A P08849834A0000 DT O
system P08849834A0000 NN O
is P08849834A0000 VBZ O
described P08849834A0000 VBN O
in P08849834A0000 IN O
which P08849834A0000 WDT O
the P08849834A0000 DT O
volume P08849834A0000 NN O
flow P08849834A0000 NN O
rate P08849834A0000 NN O
of P08849834A0000 IN O
blood P08849834A0000 NN O
in P08849834A0000 IN O
a P08849834A0000 DT O
vessel P08849834A0000 NN O
is P08849834A0000 VBZ O
determined P08849834A0000 VBN O
using P08849834A0000 VBG O
transverse P08849834A0000 JJ O
colour P08849834A0000 NN O
Doppler P08849834A0000 NNP O
ultrasound P08849834A0000 IN O
imaging P08849834A0000 VBG O
. P08849834A0000 . O
. . O O

The P02825139A0661 DT O
major P02825139A0661 JJ O
inserted P02825139A0661 VBN O
DNA P02825139A0661 NNP O
has P02825139A0661 VBZ O
no P02825139A0661 DT O
significant P02825139A0661 JJ O
homology P02825139A0661 NN O
to P02825139A0661 TO O
published P02825139A0661 VBN O
human P02825139A0661 JJ O
nucleic P02825139A0661 JJ O
acid P02825139A0661 NN O
sequences P02825139A0661 NNS O
. P02825139A0661 . O
. . O O

CONCLUSION P11727073A0842 NN O
: P11727073A0842 : O
The P11727073A0842 DT O
training P11727073A0842 NN O
of P11727073A0842 IN O
novices P11727073A0842 NNS O
using P11727073A0842 VBG O
MIST-VR P11727073A0842 JJ O
yields P11727073A0842 NNS O
quantifiable P11727073A0842 JJ O
changes P11727073A0842 NNS O
in P11727073A0842 IN O
skill P11727073A0842 NN O
that P11727073A0842 WDT O
are P11727073A0842 VBP O
transferable P11727073A0842 JJ O
to P11727073A0842 TO O
a P11727073A0842 DT O
simple P11727073A0842 JJ O
real P11727073A0842 JJ O
task P11727073A0842 NN O
and P11727073A0842 CC O
are P11727073A0842 VBP O
similar P11727073A0842 JJ O
to P11727073A0842 TO O
the P11727073A0842 DT O
results P11727073A0842 NNS O
achieved P11727073A0842 VBD O
with P11727073A0842 IN O
conventional P11727073A0842 JJ O
training P11727073A0842 NN O
. P11727073A0842 . O
. . O O

Acetoin-dependent P09045805A0945 JJ O
expression P09045805A0945 NN O
of P09045805A0945 IN O
the P09045805A0945 DT O
acoABCD P09045805A0945 NN I-UN
operon P09045805A0945 NN I-UN
could P09045805A0945 MD O
be P09045805A0945 VB O
restored P09045805A0945 VBN O
in P09045805A0945 IN O
the P09045805A0945 DT O
E. P09045805A0945 NNP I-UN
coli P09045805A0945 NNS I-UN
acoK P09045805A0945 JJ I-UN
mutants P09045805A0945 NNS I-UN
by P09045805A0945 IN O
supplying P09045805A0945 VBG O
a P09045805A0945 DT O
plasmid P09045805A0945 NN O
carrying P09045805A0945 VBG O
an P09045805A0945 DT O
intact P09045805A0945 JJ O
acoK P09045805A0945 NN I-UN
, P09045805A0945 , O
suggesting P09045805A0945 VBG O
a P09045805A0945 DT O
transactivating P09045805A0945 VBG O
function P09045805A0945 NN O
of P09045805A0945 IN O
the P09045805A0945 DT O
gene P09045805A0945 NN O
product P09045805A0945 NN O
. P09045805A0945 . O
. . O O

This P07859301A0325 DT O
region P07859301A0325 NN O
constitutes P07859301A0325 VBZ O
the P07859301A0325 DT O
DNA-binding P07859301A0325 JJ O
domain P07859301A0325 NN O
with P07859301A0325 IN O
basic-helix-loop-helix P07859301A0325 JJ O
and P07859301A0325 CC O
leucine-zipper P07859301A0325 JJ O
motifs P07859301A0325 NNS O
, P07859301A0325 , O
features P07859301A0325 NNS O
common P07859301A0325 JJ O
to P07859301A0325 TO O
the P07859301A0325 DT O
myc-related P07859301A0325 JJ I-UN
transcription P07859301A0325 NN I-UN
factor P07859301A0325 NN I-UN
family P07859301A0325 NN I-UN
. P07859301A0325 . O
. . O O

Selenium P06816123A0526 NN O
, P06816123A0526 , O
as P06816123A0526 IN O
a P06816123A0526 DT O
constituent P06816123A0526 NN O
of P06816123A0526 IN O
glutathione P06816123A0526 NN I-UN
peroxidase P06816123A0526 NN I-UN
, P06816123A0526 , O
plays P06816123A0526 VBZ O
a P06816123A0526 DT O
role P06816123A0526 NN O
in P06816123A0526 IN O
the P06816123A0526 DT O
antioxidant P06816123A0526 JJ O
defense P06816123A0526 NN O
systems P06816123A0526 NNS O
of P06816123A0526 IN O
the P06816123A0526 DT O
body P06816123A0526 NN O
, P06816123A0526 , O
but P06816123A0526 CC O
other P06816123A0526 JJ O
metabolic P06816123A0526 JJ O
roles P06816123A0526 NNS O
for P06816123A0526 IN O
selenium P06816123A0526 NN O
may P06816123A0526 MD O
yet P06816123A0526 RB O
be P06816123A0526 VB O
discovered P06816123A0526 VBN O
. P06816123A0526 . O
. . O O

Subsequently P10932527A0947 RB O
, P10932527A0947 , O
HD P10932527A0947 NNP O
inhibited P10932527A0947 VBD O
healing P10932527A0947 NN O
because P10932527A0947 IN O
it P10932527A0947 PRP O
significantly P10932527A0947 RB O
delayed P10932527A0947 VBD O
epithelialization P10932527A0947 NN O
and P10932527A0947 CC O
caused P10932527A0947 VBD O
protracted P10932527A0947 VBN O
inflammation P10932527A0947 NN O
. P10932527A0947 . O
. . O O

CT P01808049A0262 NNP O
abnormalities P01808049A0262 NNS O
noted P01808049A0262 VBD O
in P01808049A0262 IN O
term P01808049A0262 NN O
babies P01808049A0262 NNS O
included P01808049A0262 VBN O
hemorrhage P01808049A0262 NN O
( P01808049A0262 ( O
subarachnoid P01808049A0262 JJ O
5.8 P01808049A0262 CD O
% P01808049A0262 NN O
, P01808049A0262 , O
intracerebral P01808049A0262 JJ O
11.6 P01808049A0262 CD O
% P01808049A0262 NN O
) P01808049A0262 ) O
, P01808049A0262 , O
hypodensity P01808049A0262 NN O
( P01808049A0262 ( O
mild P01808049A0262 JJ O
23.2 P01808049A0262 CD O
% P01808049A0262 NN O
, P01808049A0262 , O
moderate P01808049A0262 JJ O
11.6 P01808049A0262 CD O
% P01808049A0262 NN O
severe P01808049A0262 JJ O
5.8 P01808049A0262 CD O
% P01808049A0262 NN O
) P01808049A0262 ) O
; P01808049A0262 : O
hypodensity P01808049A0262 NN O
with P01808049A0262 IN O
hemorrhage P01808049A0262 NN O
5.8 P01808049A0262 CD O
% P01808049A0262 NN O
and P01808049A0262 CC O
cerebral P01808049A0262 JJ O
atrophy P01808049A0262 NN O
5.8 P01808049A0262 CD O
% P01808049A0262 NN O
. P01808049A0262 . O
. . O O

Colorimetric P06764669T0001 JJ O
determination P06764669T0001 NN O
of P06764669T0001 IN O
urinary P06764669T0001 JJ O
iron P06764669T0001 NN O
, P06764669T0001 , O
chelated P06764669T0001 VBN O
with P06764669T0001 IN O
deferoxamine P06764669T0001 NN O
B P06764669T0001 NNP O
, P06764669T0001 , O
using P06764669T0001 VBG O
a P06764669T0001 DT O
single P06764669T0001 JJ O
reagent P06764669T0001 NN O
. P06764669T0001 . O
. . O O

When P09550919A0365 WRB O
data P09550919A0365 NNS O
were P09550919A0365 VBD O
expressed P09550919A0365 VBN O
in P09550919A0365 IN O
a P09550919A0365 DT O
cumulative P09550919A0365 JJ O
manner P09550919A0365 NN O
, P09550919A0365 , O
the P09550919A0365 DT O
response P09550919A0365 NN O
to P09550919A0365 TO O
intravenous P09550919A0365 JJ O
adenosine P09550919A0365 JJ O
3 P09550919A0365 CD O
mg P09550919A0365 NN O
, P09550919A0365 , O
6 P09550919A0365 CD O
mg P09550919A0365 NN O
, P09550919A0365 , O
9 P09550919A0365 CD O
mg P09550919A0365 NN O
and P09550919A0365 CC O
12 P09550919A0365 CD O
mg P09550919A0365 NN O
in P09550919A0365 IN O
the P09550919A0365 DT O
24 P09550919A0365 CD O
episodes P09550919A0365 NNS O
of P09550919A0365 IN O
PSVT P09550919A0365 NNP O
were P09550919A0365 VBD O
5 P09550919A0365 CD O
episodes P09550919A0365 NNS O
( P09550919A0365 ( O
21 P09550919A0365 CD O
% P09550919A0365 NN O
) P09550919A0365 ) O
, P09550919A0365 , O
16 P09550919A0365 CD O
episodes P09550919A0365 NNS O
( P09550919A0365 ( O
67 P09550919A0365 CD O
% P09550919A0365 NN O
) P09550919A0365 ) O
, P09550919A0365 , O
20 P09550919A0365 CD O
episodes P09550919A0365 NNS O
( P09550919A0365 ( O
83 P09550919A0365 CD O
% P09550919A0365 NN O
) P09550919A0365 ) O
and P09550919A0365 CC O
20 P09550919A0365 CD O
episodes P09550919A0365 NNS O
( P09550919A0365 ( O
83 P09550919A0365 CD O
% P09550919A0365 NN O
) P09550919A0365 ) O
respectively P09550919A0365 RB O
. P09550919A0365 . O
. . O O

Intriguingly P09755199A0559 RB O
, P09755199A0559 , O
three P09755199A0559 CD O
hypomorphic P09755199A0559 JJ O
Scm P09755199A0559 NNP I-UN
mutations P09755199A0559 NNS O
, P09755199A0559 , O
which P09755199A0559 WDT O
map P09755199A0559 VBP O
within P09755199A0559 IN O
an P09755199A0559 DT O
mbt P09755199A0559 NN I-UN
repeat P09755199A0559 NN I-UN
, P09755199A0559 , O
interact P09755199A0559 NN O
with P09755199A0559 IN O
PcG P09755199A0559 NNP I-UN
mutations P09755199A0559 NNS I-UN
more P09755199A0559 RBR O
strongly P09755199A0559 RB O
than P09755199A0559 IN O
do P09755199A0559 VB O
Scm P09755199A0559 NNP I-UN
null P09755199A0559 VB O
alleles P09755199A0559 NNS O
. P09755199A0559 . O
. . O O

Immunohistochemical P10487040A0453 JJ O
staining P10487040A0453 VBG O
with P10487040A0453 IN O
MIB-1 P10487040A0453 NNP I-UN
and P10487040A0453 CC O
p53 P10487040A0453 NN I-UN
antibodies P10487040A0453 NNS I-UN
showed P10487040A0453 VBD O
low P10487040A0453 JJ O
( P10487040A0453 ( O
< P10487040A0453 JJ O
1 P10487040A0453 CD O
% P10487040A0453 NN O
) P10487040A0453 ) O
and P10487040A0453 CC O
negative P10487040A0453 JJ O
reaction P10487040A0453 NN O
. P10487040A0453 . O
. . O O

High-pressure P10043466T0000 JJ O
effects P10043466T0000 NNS O
on P10043466T0000 IN O
ultrafast-relaxation P10043466T0000 JJ O
kinetics P10043466T0000 NNS O
of P10043466T0000 IN O
excitons P10043466T0000 NNS O
in P10043466T0000 IN O
polydiacetylene P10043466T0000 NN O
4BCMU P10043466T0000 CD O
. P10043466T0000 . O
. . O O

The P07824657A1456 DT O
enhanced P07824657A1456 JJ O
cysteine P07824657A1456 NN O
formation P07824657A1456 NN O
in P07824657A1456 IN O
a P07824657A1456 DT O
pCSK4F P07824657A1456 NN O
plant P07824657A1456 NN O
responding P07824657A1456 VBG O
to P07824657A1456 TO O
sulfite P07824657A1456 VB O
was P07824657A1456 VBD O
also P07824657A1456 RB O
observed P07824657A1456 VBN O
in P07824657A1456 IN O
leaf P07824657A1456 JJ O
discs P07824657A1456 NN O
. P07824657A1456 . O
. . O O

Evidence P02983331T0000 NN O
for P02983331T0000 IN O
a P02983331T0000 DT O
role P02983331T0000 NN O
of P02983331T0000 IN O
endogenous P02983331T0000 JJ I-UN
corticotropin-releasing P02983331T0000 JJ I-UN
factor P02983331T0000 NN I-UN
in P02983331T0000 IN O
cold P02983331T0000 NN O
, P02983331T0000 , O
ether P02983331T0000 RB O
, P02983331T0000 , O
immobilization P02983331T0000 NN O
, P02983331T0000 , O
and P02983331T0000 CC O
traumatic P02983331T0000 JJ O
stress P02983331T0000 NN O
. P02983331T0000 . O
. . O O

These P03257146A1037 DT O
results P03257146A1037 NNS O
indicate P03257146A1037 VBP O
that P03257146A1037 IN O
CSFHU P03257146A1037 NNP I-UN
can P03257146A1037 MD O
increase P03257146A1037 VB O
neutrophil P03257146A1037 JJ O
counts P03257146A1037 NNS O
by P03257146A1037 IN O
increasing P03257146A1037 VBG O
the P03257146A1037 DT O
number P03257146A1037 NN O
and P03257146A1037 CC O
maturity P03257146A1037 NN O
of P03257146A1037 IN O
the P03257146A1037 DT O
marrow P03257146A1037 NN O
neutrophil P03257146A1037 JJ O
precursors P03257146A1037 NNS O
in P03257146A1037 IN O
some P03257146A1037 DT O
types P03257146A1037 NNS O
of P03257146A1037 IN O
childhood P03257146A1037 NN O
chronic P03257146A1037 JJ O
neutropenia P03257146A1037 NN O
. P03257146A1037 . O
. . O O

Thus P02378945A0487 RB O
adaptation P02378945A0487 NN O
to P02378945A0487 TO O
continuous P02378945A0487 JJ O
mild P02378945A0487 JJ O
stress P02378945A0487 NN O
has P02378945A0487 VBZ O
a P02378945A0487 DT O
potent P02378945A0487 JJ O
antiarrhythmic P02378945A0487 JJ O
effect P02378945A0487 NN O
which P02378945A0487 WDT O
occurs P02378945A0487 VBZ O
due P02378945A0487 JJ O
to P02378945A0487 TO O
the P02378945A0487 DT O
increased P02378945A0487 VBN O
vagal P02378945A0487 NN O
tone P02378945A0487 NN O
. P02378945A0487 . O
. . O O

The P02463050A0514 DT O
corticosterone P02463050A0514 NN O
synthesis P02463050A0514 NN O
inhibitor P02463050A0514 NN O
metyrapone P02463050A0514 NN O
( P02463050A0514 ( O
75 P02463050A0514 CD O
mg P02463050A0514 NN O
/ P02463050A0514 NNP O
kg P02463050A0514 NN O
i.p P02463050A0514 NN O
. P02463050A0514 . O
) P02463050A0514 ) O
was P02463050A0514 VBD O
given P02463050A0514 VBN O
to P02463050A0514 TO O
attenuate P02463050A0514 VB O
the P02463050A0514 DT O
rise P02463050A0514 NN O
of P02463050A0514 IN O
corticosterone P02463050A0514 NN O
to P02463050A0514 TO O
a P02463050A0514 DT O
level P02463050A0514 JJ O
typical P02463050A0514 NN O
of P02463050A0514 IN O
stressed P02463050A0514 JJ O
males P02463050A0514 NNS O
. P02463050A0514 . O
. . O O

In P02368931A0587 IN O
addition P02368931A0587 NN O
serum P02368931A0587 NN I-UN
IgE P02368931A0587 NNP I-UN
concentrations P02368931A0587 NNS O
were P02368931A0587 VBD O
not P02368931A0587 RB O
statistically P02368931A0587 RB O
different P02368931A0587 JJ O
. P02368931A0587 . O
. . O O

We P07933095A0000 PRP O
previously P07933095A0000 RB O
showed P07933095A0000 VBD O
that P07933095A0000 IN O
v-Rel P07933095A0000 NN I-UN
, P07933095A0000 , O
the P07933095A0000 DT O
oncoprotein P07933095A0000 NN O
of P07933095A0000 IN O
the P07933095A0000 DT O
avian P07933095A0000 JJ O
retrovirus P07933095A0000 NN O
Rev-T P07933095A0000 NNP O
, P07933095A0000 , O
can P07933095A0000 MD O
increase P07933095A0000 VB O
expression P07933095A0000 NN O
from P07933095A0000 IN O
promoters P07933095A0000 NNS O
containing P07933095A0000 VBG O
binding P07933095A0000 NN O
sites P07933095A0000 NNS O
for P07933095A0000 IN O
the P07933095A0000 DT O
cellular P07933095A0000 JJ O
transcription P07933095A0000 NN O
factor P07933095A0000 NN O
Sp1 P07933095A0000 NNP I-UN
in P07933095A0000 IN O
chicken P07933095A0000 NN O
embryo P07933095A0000 NN O
fibroblasts P07933095A0000 NNS O
( P07933095A0000 ( O
S P07933095A0000 NNP O
. P07933095A0000 . O
. . O O

A P10413662A0193 DT O
recombinant P10413662A0193 JJ O
derivative P10413662A0193 JJ O
harboring P10413662A0193 VBG O
the P10413662A0193 DT O
pMJ101 P10413662A0193 NN O
replication P10413662A0193 NN O
region P10413662A0193 NN O
proved P10413662A0193 VBD O
to P10413662A0193 TO O
be P10413662A0193 VB O
compatible P10413662A0193 JJ O
with P10413662A0193 IN O
pJM1 P10413662A0193 NN O
, P10413662A0193 , O
a P10413662A0193 DT O
plasmid P10413662A0193 NN O
containing P10413662A0193 VBG O
the P10413662A0193 DT O
iron P10413662A0193 NN O
acquisition P10413662A0193 NN O
system P10413662A0193 NN O
required P10413662A0193 VBN O
for P10413662A0193 IN O
the P10413662A0193 DT O
virulence P10413662A0193 NN O
of P10413662A0193 IN O
V. P10413662A0193 NNP O
anguillarum P10413662A0193 NN O
775 P10413662A0193 CD O
, P10413662A0193 , O
another P10413662A0193 DT O
important P10413662A0193 JJ O
pathogen P10413662A0193 NN O
that P10413662A0193 WDT O
causes P10413662A0193 VBZ O
vibriosis P10413662A0193 NN O
. P10413662A0193 . O
. . O O

The P08325720A0840 DT O
O2 P08325720A0840 NNP O
deficit P08325720A0840 NN O
was P08325720A0840 VBD O
not P08325720A0840 RB O
related P08325720A0840 VBN O
to P08325720A0840 TO O
blood P08325720A0840 VB O
lactate P08325720A0840 NN O
during P08325720A0840 IN O
submaximal P08325720A0840 JJ O
exercise P08325720A0840 NN O
, P08325720A0840 , O
muscle P08325720A0840 NN O
enzyme P08325720A0840 NN O
activity P08325720A0840 NN O
( P08325720A0840 ( O
citrate P08325720A0840 JJ I-UN
synthase P08325720A0840 NN I-UN
, P08325720A0840 , O
3-hydroxyacyl-CoA-dehydrogenase P08325720A0840 JJ I-UN
, P08325720A0840 , O
lactate P08325720A0840 JJ I-UN
dehydrogenase P08325720A0840 NN I-UN
) P08325720A0840 ) O
, P08325720A0840 , O
number P08325720A0840 NN O
of P08325720A0840 IN O
muscle P08325720A0840 NN O
capillaries P08325720A0840 NNS O
, P08325720A0840 , O
% P08325720A0840 NN O
ST P08325720A0840 NNP O
fibres P08325720A0840 VBZ O
or P08325720A0840 CC O
muscle P08325720A0840 NN O
buffer P08325720A0840 VBP O
capacity P08325720A0840 NN O
. P08325720A0840 . O
. . O O

Cross-talking P09466931T0000 NN O
among P09466931T0000 IN O
Drosophila P09466931T0000 NNP O
nuclear P09466931T0000 JJ O
receptors P09466931T0000 NNS O
at P09466931T0000 IN O
the P09466931T0000 DT O
promiscuous P09466931T0000 JJ O
response P09466931T0000 NN O
element P09466931T0000 NN O
of P09466931T0000 IN O
the P09466931T0000 DT O
ng-1 P09466931T0000 JJ I-UN
and P09466931T0000 CC O
ng-2 P09466931T0000 JJ I-UN
intermolt P09466931T0000 NN I-UN
genes P09466931T0000 NNS I-UN
. P09466931T0000 . O
. . O O

Moreover P07891708A1192 RB O
, P07891708A1192 , O
the P07891708A1192 DT O
hypoxia-induced P07891708A1192 JJ O
expression P07891708A1192 NN O
of P07891708A1192 IN O
the P07891708A1192 DT O
endogenous P07891708A1192 JJ O
Epo P07891708A1192 NNP I-UN
gene P07891708A1192 NN I-UN
was P07891708A1192 VBD O
significantly P07891708A1192 RB O
inhibited P07891708A1192 VBN O
in P07891708A1192 IN O
Hep3B P07891708A1192 NNP O
cells P07891708A1192 NNS O
stably P07891708A1192 RB O
transfected P07891708A1192 VBD O
with P07891708A1192 IN O
HNF-4 P07891708A1192 NNP I-UN
delta P07891708A1192 NN I-UN
C P07891708A1192 NNP I-UN
. P07891708A1192 . O
. . O O

The P07534306A0444 DT O
overexpressed P07534306A0444 JJ O
His6-tagged P07534306A0444 NNP I-UN
GrsA P07534306A0444 NNP I-UN
derivatives P07534306A0444 NNS I-UN
were P07534306A0444 VBD O
affinity-purified P07534306A0444 JJ O
, P07534306A0444 , O
and P07534306A0444 CC O
the P07534306A0444 DT O
catalytic P07534306A0444 JJ O
properties P07534306A0444 NNS O
of P07534306A0444 IN O
the P07534306A0444 DT O
deletion P07534306A0444 NN O
mutants P07534306A0444 NNS O
were P07534306A0444 VBD O
examined P07534306A0444 VBN O
by P07534306A0444 IN O
biochemical P07534306A0444 JJ O
studies P07534306A0444 NNS O
including P07534306A0444 VBG O
ATP-dependent P07534306A0444 JJ O
amino P07534306A0444 NN O
acid P07534306A0444 NN O
activation P07534306A0444 NN O
, P07534306A0444 , O
carboxyl P07534306A0444 VBP O
thioester P07534306A0444 NN O
formation P07534306A0444 NN O
, P07534306A0444 , O
and P07534306A0444 CC O
the P07534306A0444 DT O
ability P07534306A0444 NN O
to P07534306A0444 TO O
racemize P07534306A0444 VB O
the P07534306A0444 DT O
covalently P07534306A0444 RB O
bound P07534306A0444 VBN O
phenylalanine P07534306A0444 NN O
from P07534306A0444 IN O
L- P07534306A0444 NNP O
to P07534306A0444 TO O
the P07534306A0444 DT O
D-isomer P07534306A0444 NNP O
. P07534306A0444 . O
. . O O

Lung P09205677A0577 NNP O
and P09205677A0577 CC O
multi-system P09205677A0577 JJ O
damage P09205677A0577 NN O
were P09205677A0577 VBD O
early P09205677A0577 JJ O
indicators P09205677A0577 NNS O
of P09205677A0577 IN O
poor P09205677A0577 JJ O
outcome P09205677A0577 NN O
in P09205677A0577 IN O
severe P09205677A0577 JJ O
non-fatal P09205677A0577 JJ O
disease P09205677A0577 NN O
. P09205677A0577 . O
. . O O

Univariate P07937656A0182 NNP O
statistical P07937656A0182 JJ O
analysis P07937656A0182 NN O
based P07937656A0182 VBN O
on P07937656A0182 IN O
Kaplan-Meier-estimates P07937656A0182 NNS O
and P07937656A0182 CC O
Log-Rank-Test P07937656A0182 NNP O
showed P07937656A0182 VBD O
the P07937656A0182 DT O
following P07937656A0182 VBG O
prognostically P07937656A0182 RB O
beneficial P07937656A0182 JJ O
factors P07937656A0182 NNS O
: P07937656A0182 : O
Limited P07937656A0182 JJ O
disease P07937656A0182 NN O
stage P07937656A0182 NN O
( P07937656A0182 ( O
p P07937656A0182 JJ O
= P07937656A0182 NNP O
0.009 P07937656A0182 CD O
) P07937656A0182 ) O
, P07937656A0182 , O
NSE P07937656A0182 NNP I-UN
serum P07937656A0182 VBD O
level P07937656A0182 NN O
less P07937656A0182 JJR O
than P07937656A0182 IN O
25 P07937656A0182 CD O
micrograms P07937656A0182 NNS O
/ P07937656A0182 JJ O
l P07937656A0182 NN O
( P07937656A0182 ( O
p P07937656A0182 JJ O
= P07937656A0182 NNP O
0.016 P07937656A0182 CD O
) P07937656A0182 ) O
, P07937656A0182 , O
serum P07937656A0182 JJ O
alkaline P07937656A0182 JJ I-UN
phosphatase P07937656A0182 NN I-UN
less P07937656A0182 JJR O
than P07937656A0182 IN O
200 P07937656A0182 CD O
U P07937656A0182 NNP O
/ P07937656A0182 NNP O
l P07937656A0182 NN O
( P07937656A0182 ( O
p P07937656A0182 JJ O
= P07937656A0182 NNP O
0.035 P07937656A0182 CD O
) P07937656A0182 ) O
, P07937656A0182 , O
normal P07937656A0182 JJ O
serum P07937656A0182 NN O
albumin P07937656A0182 NN I-UN
( P07937656A0182 ( O
p P07937656A0182 JJ O
= P07937656A0182 NNP O
0.003 P07937656A0182 CD O
) P07937656A0182 ) O
and P07937656A0182 CC O
activity P07937656A0182 NN O
index P07937656A0182 NN O
of P07937656A0182 IN O
minimum P07937656A0182 NN O
of P07937656A0182 IN O
70 P07937656A0182 CD O
( P07937656A0182 ( O
p P07937656A0182 NN O
< P07937656A0182 RB O
0.001 P07937656A0182 CD O
) P07937656A0182 ) O
. P07937656A0182 . O
. . O O

Total P06886031A0898 JJ O
PGE P06886031A0898 NNP O
levels P06886031A0898 NNS O
in P06886031A0898 IN O
synovial P06886031A0898 JJ O
fluid P06886031A0898 NN O
remained P06886031A0898 VBD O
significantly P06886031A0898 RB O
depressed P06886031A0898 VBN O
in P06886031A0898 IN O
the P06886031A0898 DT O
patient P06886031A0898 NN O
group P06886031A0898 NN O
for P06886031A0898 IN O
24 P06886031A0898 CD O
hours P06886031A0898 NNS O
after P06886031A0898 IN O
the P06886031A0898 DT O
400-mg P06886031A0898 JJ O
test P06886031A0898 NN O
dose P06886031A0898 NN O
of P06886031A0898 IN O
tolmetin P06886031A0898 NN O
on P06886031A0898 IN O
day P06886031A0898 NN O
8 P06886031A0898 CD O
. P06886031A0898 . O
. . O O

Moreover P08406004A0691 RB O
, P08406004A0691 , O
in P08406004A0691 IN O
transient P08406004A0691 JJ O
transfection P08406004A0691 NN O
assays P08406004A0691 NNS O
, P08406004A0691 , O
PU.1 P08406004A0691 NNP I-UN
alone P08406004A0691 RB O
activated P08406004A0691 VBD O
reporter P08406004A0691 JJ O
constructs P08406004A0691 NNS O
containing P08406004A0691 VBG O
the P08406004A0691 DT O
JB P08406004A0691 NNP O
cis-element P08406004A0691 NN O
, P08406004A0691 , O
and P08406004A0691 CC O
the P08406004A0691 DT O
activation P08406004A0691 NN O
was P08406004A0691 VBD O
shown P08406004A0691 VBN O
to P08406004A0691 TO O
be P08406004A0691 VB O
dependent P08406004A0691 JJ O
on P08406004A0691 IN O
a P08406004A0691 DT O
glutamine-rich P08406004A0691 JJ O
sequence P08406004A0691 NN O
in P08406004A0691 IN O
the P08406004A0691 DT O
amino-terminal P08406004A0691 JJ O
portion P08406004A0691 NN O
of P08406004A0691 IN O
PU.1 P08406004A0691 NNP I-UN
. P08406004A0691 . O
. . O O

By P01409643A0618 IN O
using P01409643A0618 VBG O
lambda P01409643A0618 JJ O
gt11 P01409643A0618 JJ O
expression P01409643A0618 NN O
cloning P01409643A0618 VBG O
with P01409643A0618 IN O
oligonucleotides P01409643A0618 NNS O
corresponding P01409643A0618 VBG O
to P01409643A0618 TO O
the P01409643A0618 DT O
human P01409643A0618 JJ O
immunodeficiency P01409643A0618 NN O
virus P01409643A0618 NN O
1 P01409643A0618 CD O
TATA P01409643A0618 NNP O
element P01409643A0618 NN O
, P01409643A0618 , O
we P01409643A0618 PRP O
report P01409643A0618 VBP O
the P01409643A0618 DT O
identification P01409643A0618 NN O
of P01409643A0618 IN O
a P01409643A0618 DT O
cellular P01409643A0618 JJ O
protein P01409643A0618 NN O
with P01409643A0618 IN O
a P01409643A0618 DT O
calculated P01409643A0618 JJ O
molecular P01409643A0618 JJ O
mass P01409643A0618 NN O
of P01409643A0618 IN O
123 P01409643A0618 CD O
kDa P01409643A0618 NNS O
that P01409643A0618 IN O
we P01409643A0618 PRP O
designate P01409643A0618 VBP O
TATA P01409643A0618 NNP I-UN
element P01409643A0618 NN I-UN
modulatory P01409643A0618 NN I-UN
factor P01409643A0618 NN I-UN
( P01409643A0618 ( O
TMF P01409643A0618 NNP I-UN
) P01409643A0618 ) O
. P01409643A0618 . O
. . O O

CONCLUSIONS P09508119A0498 NN O
: P09508119A0498 : O
The P09508119A0498 DT O
special P09508119A0498 JJ O
clinical P09508119A0498 JJ O
presentation P09508119A0498 NN O
of P09508119A0498 IN O
our P09508119A0498 PRP$ O
case P09508119A0498 NN O
of P09508119A0498 IN O
possible P09508119A0498 JJ O
Gardner P09508119A0498 NNP O
's P09508119A0498 POS O
syndrome P09508119A0498 NN O
is P09508119A0498 VBZ O
discussed P09508119A0498 VBN O
. P09508119A0498 . O
. . O O

Recently P09649438A0182 RB O
, P09649438A0182 , O
a P09649438A0182 DT O
human P09649438A0182 JJ I-UN
transcription P09649438A0182 NN I-UN
elongation P09649438A0182 NN I-UN
factor P09649438A0182 NN I-UN
P-TEFb P09649438A0182 NNP I-UN
, P09649438A0182 , O
consisting P09649438A0182 VBG O
of P09649438A0182 IN O
CDK9 P09649438A0182 NNP I-UN
kinase P09649438A0182 NN I-UN
, P09649438A0182 , O
cyclin P09649438A0182 NN I-UN
T P09649438A0182 NNP I-UN
and P09649438A0182 CC O
other P09649438A0182 JJ O
associated P09649438A0182 JJ O
factors P09649438A0182 NNS O
, P09649438A0182 , O
has P09649438A0182 VBZ O
been P09649438A0182 VBN O
shown P09649438A0182 VBN O
to P09649438A0182 TO O
interact P09649438A0182 VB O
with P09649438A0182 IN O
Tat P09649438A0182 NNP I-UN
to P09649438A0182 TO O
restore P09649438A0182 VB O
Tat P09649438A0182 NNP I-UN
activation P09649438A0182 NN O
in P09649438A0182 IN O
HeLa P09649438A0182 NNP O
nuclear P09649438A0182 JJ O
extract P09649438A0182 NN O
depleted P09649438A0182 VBN O
of P09649438A0182 IN O
P-TEFb P09649438A0182 NNP I-UN
. P09649438A0182 . O
. . O O

Both P10606515A0389 DT O
domains P10606515A0389 NNS O
were P10606515A0389 VBD O
required P10606515A0389 VBN O
for P10606515A0389 IN O
specific P10606515A0389 JJ O
DNA P10606515A0389 NNP O
binding P10606515A0389 NN O
to P10606515A0389 TO O
the P10606515A0389 DT O
beta-retinoic P10606515A0389 JJ I-UN
acid P10606515A0389 NN I-UN
receptor P10606515A0389 NN I-UN
element P10606515A0389 NN I-UN
, P10606515A0389 , O
producing P10606515A0389 VBG O
a P10606515A0389 DT O
DNase P10606515A0389 NNP I-UN
I P10606515A0389 PRP I-UN
footprint P10606515A0389 VBP O
covering P10606515A0389 VBG O
predominantly P10606515A0389 RB O
one P10606515A0389 CD O
strand P10606515A0389 NN O
. P10606515A0389 . O
. . O O

Here P09837920A0222 RB O
we P09837920A0222 PRP O
have P09837920A0222 VBP O
investigated P09837920A0222 VBN O
the P09837920A0222 DT O
structural P09837920A0222 JJ O
requirements P09837920A0222 NNS O
and P09837920A0222 CC O
consequences P09837920A0222 NNS O
of P09837920A0222 IN O
regulatory P09837920A0222 JJ O
phosphorylation P09837920A0222 NN O
for P09837920A0222 IN O
the P09837920A0222 DT O
interaction P09837920A0222 NN O
between P09837920A0222 IN O
c-Jun P09837920A0222 NN I-UN
and P09837920A0222 CC O
JNK P09837920A0222 NNP I-UN
in P09837920A0222 IN O
vivo P09837920A0222 NN O
. P09837920A0222 . O
. . O O

Although P04071063A0863 IN O
no P04071063A0863 DT O
differences P04071063A0863 NNS O
were P04071063A0863 VBD O
noted P04071063A0863 VBN O
in P04071063A0863 IN O
the P04071063A0863 DT O
decrease P04071063A0863 NN O
in P04071063A0863 IN O
platelet P04071063A0863 NN O
counts P04071063A0863 NNS O
between P04071063A0863 IN O
the P04071063A0863 DT O
two P04071063A0863 CD O
groups P04071063A0863 NNS O
, P04071063A0863 , O
fibrinogen P04071063A0863 NN I-UN
levels P04071063A0863 NNS O
and P04071063A0863 CC O
alpha P04071063A0863 VB I-UN
2-antiplasmin P04071063A0863 JJ I-UN
levels P04071063A0863 NNS O
declined P04071063A0863 VBD O
less P04071063A0863 RBR O
drastically P04071063A0863 RB O
in P04071063A0863 IN O
the P04071063A0863 DT O
antithrombin-treated P04071063A0863 JJ O
group P04071063A0863 NN O
. P04071063A0863 . O
. . O O

Intraperitoneal P08902548A0144 NNP O
administration P08902548A0144 NN O
of P08902548A0144 IN O
L-5-hydroxytryptophan P08902548A0144 NNP O
( P08902548A0144 ( O
L-5-HTP P08902548A0144 NNP O
) P08902548A0144 ) O
at P08902548A0144 IN O
doses P08902548A0144 NNS O
of P08902548A0144 IN O
25 P08902548A0144 CD O
to P08902548A0144 TO O
100 P08902548A0144 CD O
mg P08902548A0144 NNS O
/ P08902548A0144 JJ O
kg P08902548A0144 VBP O
dramatically P08902548A0144 RB O
increase P08902548A0144 JJ O
defecation P08902548A0144 NN O
in P08902548A0144 IN O
mice P08902548A0144 NN O
. P08902548A0144 . O
. . O O

We P07547510A0261 PRP O
have P07547510A0261 VBP O
demonstrated P07547510A0261 VBN O
previously P07547510A0261 RB O
that P07547510A0261 IN O
two P07547510A0261 CD O
binding P07547510A0261 VBG O
sites P07547510A0261 NNS O
in P07547510A0261 IN O
the P07547510A0261 DT O
-184 P07547510A0261 JJ I-UN
HNF-3 P07547510A0261 NNP I-UN
beta P07547510A0261 NN I-UN
promoter P07547510A0261 NN I-UN
are P07547510A0261 VBP O
recognized P07547510A0261 VBN O
by P07547510A0261 IN O
widely P07547510A0261 RB O
distributed P07547510A0261 VBN O
factors P07547510A0261 NNS O
and P07547510A0261 CC O
that P07547510A0261 IN O
there P07547510A0261 EX O
is P07547510A0261 VBZ O
also P07547510A0261 RB O
a P07547510A0261 DT O
critical P07547510A0261 JJ O
autoregulatory P07547510A0261 NN O
site P07547510A0261 NN O
, P07547510A0261 , O
we P07547510A0261 PRP O
identified P07547510A0261 VBD O
a P07547510A0261 DT O
binding P07547510A0261 NN O
site P07547510A0261 NN O
for P07547510A0261 IN O
a P07547510A0261 DT O
cell-specific P07547510A0261 JJ O
factor P07547510A0261 NN O
, P07547510A0261 , O
LF-H3 P07547510A0261 NNP I-UN
beta P07547510A0261 NN I-UN
, P07547510A0261 , O
that P07547510A0261 WDT O
may P07547510A0261 MD O
function P07547510A0261 VB O
in P07547510A0261 IN O
restricting P07547510A0261 VBG O
HNF-3 P07547510A0261 NNP I-UN
beta P07547510A0261 NN I-UN
gene P07547510A0261 NN I-UN
expression P07547510A0261 NN O
to P07547510A0261 TO O
hepatocytes P07547510A0261 NNS O
. P07547510A0261 . O
. . O O

3.04+ P11134822A0629 CD O
/ P11134822A0629 JJ O
-1.2 P11134822A0629 NN O
, P11134822A0629 , O
P P11134822A0629 NNP O
< P11134822A0629 NNP O
0.0001 P11134822A0629 CD O
) P11134822A0629 ) O
, P11134822A0629 , O
large P11134822A0629 JJ O
accelerations P11134822A0629 NNS O
/ P11134822A0629 VBP O
30 P11134822A0629 CD O
min P11134822A0629 NN O
( P11134822A0629 ( O
1.46+ P11134822A0629 CD O
/ P11134822A0629 NNP O
-1.96 P11134822A0629 NNP O
vs P11134822A0629 NN O
. P11134822A0629 . O
. . O O

Mutagenesis P11278583A0873 NN O
of P11278583A0873 IN O
SNT1 P11278583A0873 NNP I-UN
( P11278583A0873 ( O
IRS P11278583A0873 NNP I-UN
) P11278583A0873 ) O
CX P11278583A0873 NNP I-UN
identified P11278583A0873 VBD O
three P11278583A0873 CD O
classes P11278583A0873 NNS O
of P11278583A0873 IN O
effector P11278583A0873 NN O
motifs P11278583A0873 NNS O
within P11278583A0873 IN O
SNT P11278583A0873 NNP I-UN
critical P11278583A0873 JJ O
for P11278583A0873 IN O
both P11278583A0873 DT O
sustained P11278583A0873 VBN O
ERK P11278583A0873 NNP I-UN
activation P11278583A0873 NN O
and P11278583A0873 CC O
neuronal P11278583A0873 JJ O
differentiation P11278583A0873 NN O
: P11278583A0873 : O
1 P11278583A0873 CD O
) P11278583A0873 ) O
four P11278583A0873 CD O
phosphotyrosine P11278583A0873 NN O
motifs P11278583A0873 NNS O
that P11278583A0873 WDT O
mediate P11278583A0873 VBP O
recruitment P11278583A0873 NN O
of P11278583A0873 IN O
Grb2 P11278583A0873 NNP I-UN
, P11278583A0873 , O
2 P11278583A0873 CD O
) P11278583A0873 ) O
two P11278583A0873 CD O
phosphotyrosine P11278583A0873 NN O
motifs P11278583A0873 NNS O
that P11278583A0873 WDT O
mediate P11278583A0873 VBP O
recruitment P11278583A0873 NN O
of P11278583A0873 IN O
Shp2 P11278583A0873 NNP I-UN
, P11278583A0873 , O
and P11278583A0873 CC O
3 P11278583A0873 CD O
) P11278583A0873 ) O
a P11278583A0873 DT O
C-terminal P11278583A0873 JJ O
motif P11278583A0873 NN O
that P11278583A0873 IN O
functions P11278583A0873 NNS O
by P11278583A0873 IN O
helping P11278583A0873 VBG O
to P11278583A0873 TO O
recruit P11278583A0873 VB O
Sos P11278583A0873 NNP I-UN
. P11278583A0873 . O
. . O O

Using P08704124A0420 VBG O
one P08704124A0420 CD O
of P08704124A0420 IN O
the P08704124A0420 DT O
six P08704124A0420 CD O
fragments P08704124A0420 NNS O
( P08704124A0420 ( O
CPK3-8 P08704124A0420 NNP I-UN
) P08704124A0420 ) O
, P08704124A0420 , O
we P08704124A0420 PRP O
isolated P08704124A0420 VBD O
a P08704124A0420 DT O
2022 P08704124A0420 CD I-UN
bp P08704124A0420 NN I-UN
cDNA P08704124A0420 NN I-UN
( P08704124A0420 ( I-UN
VrCDPK-1 P08704124A0420 NNP I-UN
) P08704124A0420 ) I-UN
from P08704124A0420 IN O
a P08704124A0420 DT O
Vigna P08704124A0420 NNP O
radiata P08704124A0420 NN O
lambda P08704124A0420 NN O
gt11 P08704124A0420 NN O
library P08704124A0420 NN O
. P08704124A0420 . O
. . O O

RESULTS P11849796A0452 NN O
: P11849796A0452 : O
The P11849796A0452 DT O
target P11849796A0452 NN O
dose P11849796A0452 NN O
was P11849796A0452 VBD O
comparable P11849796A0452 JJ O
in P11849796A0452 IN O
the P11849796A0452 DT O
3D-CRT P11849796A0452 JJ O
and P11849796A0452 CC O
IMRT P11849796A0452 NNP O
plans P11849796A0452 NNS O
, P11849796A0452 , O
although P11849796A0452 IN O
improvements P11849796A0452 NNS O
were P11849796A0452 VBD O
seen P11849796A0452 VBN O
when P11849796A0452 WRB O
seven P11849796A0452 CD O
and P11849796A0452 CC O
nine P11849796A0452 CD O
IMRT P11849796A0452 NNP O
fields P11849796A0452 NNS O
were P11849796A0452 VBD O
used P11849796A0452 VBN O
. P11849796A0452 . O
. . O O

Furthermore P08937981A0840 RB O
, P08937981A0840 , O
co-expression P08937981A0840 NN O
of P08937981A0840 IN O
both P08937981A0840 DT O
p46 P08937981A0840 NNS I-UN
and P08937981A0840 CC O
p54 P08937981A0840 VB I-UN
subunits P08937981A0840 NNS I-UN
markedly P08937981A0840 RB O
altered P08937981A0840 VBD O
the P08937981A0840 DT O
subcellular P08937981A0840 JJ O
distribution P08937981A0840 NN O
of P08937981A0840 IN O
p46 P08937981A0840 NN I-UN
; P08937981A0840 : O
co-expressed P08937981A0840 JJ O
p46 P08937981A0840 NN I-UN
was P08937981A0840 VBD O
transported P08937981A0840 VBN O
into P08937981A0840 IN O
the P08937981A0840 DT O
nucleus P08937981A0840 NN O
as P08937981A0840 RB O
efficiently P08937981A0840 RB O
as P08937981A0840 IN O
p54 P08937981A0840 NN I-UN
. P08937981A0840 . O
. . O O

5- P05671267T0000 JJ O
( P05671267T0000 ( O
Dimethylaminopropyl P05671267T0000 NNP O
) P05671267T0000 ) O
-19,11-dihydro-5H-benzo P05671267T0000 VBD O
[ P05671267T0000 $ O
2,3 P05671267T0000 CD O
] P05671267T0000 NNP O
pyrido P05671267T0000 NN O
[ P05671267T0000 NNP O
6,7-b P05671267T0000 JJ O
] P05671267T0000 NNP O
azepine P05671267T0000 NN O
. P05671267T0000 . O
. . O O

The P07958446A0000 DT O
hepatocyte P07958446A0000 JJ I-UN
nuclear P07958446A0000 JJ I-UN
factor-3 P07958446A0000 JJ I-UN
( P07958446A0000 ( O
HNF-3 P07958446A0000 NNP I-UN
) P07958446A0000 ) O
/ P07958446A0000 FW O
forkhead P07958446A0000 NN I-UN
( P07958446A0000 ( O
fkh P07958446A0000 NN I-UN
) P07958446A0000 ) O
proteins P07958446A0000 VBZ O
consist P07958446A0000 NN O
of P07958446A0000 IN O
an P07958446A0000 DT O
extensive P07958446A0000 JJ O
family P07958446A0000 NN O
of P07958446A0000 IN O
tissue-specific P07958446A0000 JJ O
and P07958446A0000 CC O
developmental P07958446A0000 JJ O
gene P07958446A0000 NN O
regulators P07958446A0000 NNS O
which P07958446A0000 WDT O
share P07958446A0000 NN O
homology P07958446A0000 NN O
within P07958446A0000 IN O
the P07958446A0000 DT O
winged P07958446A0000 JJ O
helix P07958446A0000 NN O
DNA P07958446A0000 NNP O
binding P07958446A0000 NN O
motif P07958446A0000 NN O
. P07958446A0000 . O
. . O O

Improved P08783180A0000 VBN O
methods P08783180A0000 NNS O
have P08783180A0000 VBP O
been P08783180A0000 VBN O
developed P08783180A0000 VBN O
for P08783180A0000 IN O
maintaining P08783180A0000 VBG O
and P08783180A0000 CC O
breeding P08783180A0000 VBG O
the P08783180A0000 DT O
neotropical P08783180A0000 JJ O
short-tailed P08783180A0000 JJ O
fruit P08783180A0000 NN O
bat P08783180A0000 NN O
, P08783180A0000 , O
Carollia P08783180A0000 NNP O
perspicillata P08783180A0000 NN O
, P08783180A0000 , O
in P08783180A0000 IN O
an P08783180A0000 DT O
easily-reproduced P08783180A0000 JJ O
, P08783180A0000 , O
laboratory P08783180A0000 JJ O
setting P08783180A0000 NN O
. P08783180A0000 . O
. . O O

The P02746099A0000 DT O
mobility P02746099A0000 NN O
of P02746099A0000 IN O
the P02746099A0000 DT O
upper P02746099A0000 JJ O
and P02746099A0000 CC O
lower P02746099A0000 JJR O
premolars P02746099A0000 NNS O
under P02746099A0000 IN O
load P02746099A0000 NN O
was P02746099A0000 VBD O
investigated P02746099A0000 VBN O
in P02746099A0000 IN O
relation P02746099A0000 NN O
to P02746099A0000 TO O
the P02746099A0000 DT O
interproximal P02746099A0000 JJ O
contact P02746099A0000 NN O
and P02746099A0000 CC O
occlusal P02746099A0000 JJ O
facets P02746099A0000 NNS O
. P02746099A0000 . O
. . O O

Comments P01392277A0000 NNS O
are P01392277A0000 VBP O
given P01392277A0000 VBN O
on P01392277A0000 IN O
the P01392277A0000 DT O
present P01392277A0000 JJ O
status P01392277A0000 NN O
of P01392277A0000 IN O
regulations P01392277A0000 NNS O
concerning P01392277A0000 VBG O
water P01392277A0000 NN O
in P01392277A0000 IN O
swimming P01392277A0000 NN O
pools P01392277A0000 NNS O
and P01392277A0000 CC O
baths P01392277A0000 NNS O
-- P01392277A0000 : O
1991 P01392277A0000 CD O
-- P01392277A0000 : O
( P01392277A0000 ( O
in P01392277A0000 IN O
connection P01392277A0000 NN O
with P01392277A0000 IN O
the P01392277A0000 DT O
KOK P01392277A0000 NNP O
regulations P01392277A0000 NNS O
-- P01392277A0000 : O
1972 P01392277A0000 CD O
-- P01392277A0000 : O
and P01392277A0000 CC O
the P01392277A0000 DT O
Federal P01392277A0000 JJ O
German P01392277A0000 NNP O
standard P01392277A0000 NN O
[ P01392277A0000 NNP O
DIN P01392277A0000 NNP O
] P01392277A0000 NNP O
No P01392277A0000 NNP O
. P01392277A0000 . O
. . O O

Measurement P09171969A1165 NN O
of P09171969A1165 IN O
the P09171969A1165 DT O
time P09171969A1165 NN O
constant P09171969A1165 NN O
of P09171969A1165 IN O
VO2 P09171969A1165 NNP O
and P09171969A1165 CC O
oxygen P09171969A1165 NN O
pulse P09171969A1165 NN O
during P09171969A1165 IN O
constant P09171969A1165 JJ O
work P09171969A1165 NN O
rate P09171969A1165 NN O
exercise P09171969A1165 NN O
are P09171969A1165 VBP O
useful P09171969A1165 JJ O
for P09171969A1165 IN O
the P09171969A1165 DT O
objective P09171969A1165 JJ O
evaluation P09171969A1165 NN O
of P09171969A1165 IN O
the P09171969A1165 DT O
training P09171969A1165 NN O
effect P09171969A1165 NN O
of P09171969A1165 IN O
patients P09171969A1165 NNS O
with P09171969A1165 IN O
COPD P09171969A1165 NNP O
. P09171969A1165 . O
. . O O

Suppressive P09665361T0000 JJ O
therapy P09665361T0000 NN O
for P09665361T0000 IN O
thyroid P09665361T0000 JJ O
nodules P09665361T0000 NNS O
. P09665361T0000 . O
. . O O

Repair P10430580A0000 NN O
of P10430580A0000 IN O
double-strand P10430580A0000 NN O
breaks P10430580A0000 NNS O
( P10430580A0000 ( O
DSBs P10430580A0000 NNP O
) P10430580A0000 ) O
in P10430580A0000 IN O
chromosomal P10430580A0000 JJ O
DNA P10430580A0000 NN O
by P10430580A0000 IN O
nonhomologous P10430580A0000 JJ O
end-joining P10430580A0000 NN O
( P10430580A0000 ( O
NHEJ P10430580A0000 NNP O
) P10430580A0000 ) O
is P10430580A0000 VBZ O
not P10430580A0000 RB O
well P10430580A0000 RB O
characterized P10430580A0000 VBN O
in P10430580A0000 IN O
the P10430580A0000 DT O
yeast P10430580A0000 NN O
Saccharomyces P10430580A0000 NNP O
cerevisiae P10430580A0000 NN O
. P10430580A0000 . O
. . O O

The P08762472A0000 DT O
effect P08762472A0000 NN O
of P08762472A0000 IN O
ligustrazine P08762472A0000 NN O
hydrochloride P08762472A0000 NN O
( P08762472A0000 ( O
LTH P08762472A0000 NNP O
) P08762472A0000 ) O
on P08762472A0000 IN O
depressing P08762472A0000 VBG O
pulmonary P08762472A0000 JJ O
artery P08762472A0000 NN O
hypertension P08762472A0000 NN O
has P08762472A0000 VBZ O
been P08762472A0000 VBN O
proved P08762472A0000 VBN O
in P08762472A0000 IN O
recent P08762472A0000 JJ O
studies P08762472A0000 NNS O
. P08762472A0000 . O
. . O O

However P08044802A0462 RB O
, P08044802A0462 , O
Southern P08044802A0462 NNP O
blot P08044802A0462 NN O
and P08044802A0462 CC O
karyotype P08044802A0462 NN O
analyses P08044802A0462 NNS O
did P08044802A0462 VBD O
not P08044802A0462 RB O
reveal P08044802A0462 VB O
any P08044802A0462 DT O
significant P08044802A0462 JJ O
changes P08044802A0462 NNS O
in P08044802A0462 IN O
copy P08044802A0462 NN O
number P08044802A0462 NN O
or P08044802A0462 CC O
gross P08044802A0462 JJ O
rearrangements P08044802A0462 NNS O
of P08044802A0462 IN O
the P08044802A0462 DT O
p53 P08044802A0462 NN I-UN
gene P08044802A0462 NN I-UN
in P08044802A0462 IN O
any P08044802A0462 DT O
of P08044802A0462 IN O
the P08044802A0462 DT O
p53- P08044802A0462 NN I-UN
cell P08044802A0462 NN O
lines P08044802A0462 NNS O
. P08044802A0462 . O
. . O O

We P07816619A0000 PRP O
characterized P07816619A0000 VBD O
three P07816619A0000 CD O
Arabidopsis P07816619A0000 NNP O
thaliana P07816619A0000 NN O
cDNA P07816619A0000 NN O
clones P07816619A0000 NNS O
that P07816619A0000 WDT O
could P07816619A0000 MD O
rescue P07816619A0000 VB O
the P07816619A0000 DT O
sterile P07816619A0000 JJ O
phenotype P07816619A0000 NN O
of P07816619A0000 IN O
the P07816619A0000 DT O
Schizosaccharomyces P07816619A0000 NNP I-UN
pombe P07816619A0000 NN I-UN
pde1 P07816619A0000 NN I-UN
mutant P07816619A0000 NN I-UN
, P07816619A0000 , O
which P07816619A0000 WDT O
is P07816619A0000 VBZ O
defective P07816619A0000 JJ O
in P07816619A0000 IN O
cAMP P07816619A0000 JJ I-UN
phosphodiesterase P07816619A0000 NN I-UN
. P07816619A0000 . O
. . O O

A P07913080A0564 DT O
decanucleotide P07913080A0564 JJ O
promoter P07913080A0564 NN O
sequence P07913080A0564 NN O
homologous P07913080A0564 JJ O
to P07913080A0564 TO O
those P07913080A0564 DT O
found P07913080A0564 VBN O
in P07913080A0564 IN O
humans P07913080A0564 NNS O
and P07913080A0564 CC O
mice P07913080A0564 NN O
was P07913080A0564 VBD O
located P07913080A0564 VBN O
in P07913080A0564 IN O
the P07913080A0564 DT O
5 P07913080A0564 CD O
' P07913080A0564 POS O
untranslated P07913080A0564 JJ O
region P07913080A0564 NN O
of P07913080A0564 IN O
one P07913080A0564 CD O
horse P07913080A0564 NN O
gene P07913080A0564 NN O
. P07913080A0564 . O
. . O O

BACKGROUND P11251951A0000 NN O
: P11251951A0000 : O
Dermoscopy P11251951A0000 NNP O
is P11251951A0000 VBZ O
a P11251951A0000 DT O
noninvasive P11251951A0000 JJ O
technique P11251951A0000 NN O
that P11251951A0000 WDT O
increases P11251951A0000 VBZ O
the P11251951A0000 DT O
diagnostic P11251951A0000 JJ O
accuracy P11251951A0000 NN O
of P11251951A0000 IN O
pigmented P11251951A0000 JJ O
skin P11251951A0000 NN O
lesions P11251951A0000 NNS O
, P11251951A0000 , O
particularly P11251951A0000 RB O
improving P11251951A0000 VBG O
the P11251951A0000 DT O
diagnosis P11251951A0000 NN O
of P11251951A0000 IN O
patients P11251951A0000 NNS O
with P11251951A0000 IN O
cutaneous P11251951A0000 JJ O
melanoma P11251951A0000 NN O
in P11251951A0000 IN O
situ P11251951A0000 NN O
( P11251951A0000 ( O
CMIS P11251951A0000 NNP O
) P11251951A0000 ) O
and P11251951A0000 CC O
early P11251951A0000 JJ O
invasive P11251951A0000 JJ O
melanoma P11251951A0000 NN O
. P11251951A0000 . O
. . O O

Analysis P01314457T0000 NN O
of P01314457T0000 IN O
nucleotide P01314457T0000 JJ O
sequence P01314457T0000 NN O
of P01314457T0000 IN O
the P01314457T0000 DT O
rightmost P01314457T0000 NN O
43 P01314457T0000 CD O
kbp P01314457T0000 NN O
of P01314457T0000 IN O
herpesvirus P01314457T0000 NN O
saimiri P01314457T0000 NN O
( P01314457T0000 ( O
HVS P01314457T0000 NNP O
) P01314457T0000 ) O
L-DNA P01314457T0000 NN O
: P01314457T0000 : O
general P01314457T0000 JJ O
conservation P01314457T0000 NN O
of P01314457T0000 IN O
genetic P01314457T0000 JJ O
organization P01314457T0000 NN O
between P01314457T0000 IN O
HVS P01314457T0000 NNP O
and P01314457T0000 CC O
Epstein-Barr P01314457T0000 NNP O
virus P01314457T0000 NN O
. P01314457T0000 . O
. . O O

This P11424992A0712 DT O
is P11424992A0712 VBZ O
necessary P11424992A0712 JJ O
if P11424992A0712 IN O
psychiatric P11424992A0712 JJ O
diagnoses P11424992A0712 NNS O
are P11424992A0712 VBP O
ultimately P11424992A0712 RB O
going P11424992A0712 VBG O
to P11424992A0712 TO O
be P11424992A0712 VB O
refined P11424992A0712 VBN O
and P11424992A0712 CC O
validated P11424992A0712 VBN O
against P11424992A0712 IN O
biological P11424992A0712 JJ O
criteria P11424992A0712 NNS O
. P11424992A0712 . O
. . O O

Chronic P01403391T0000 NNP O
hepatitis P01403391T0000 NN O
B P01403391T0000 NNP O
in P01403391T0000 IN O
adopted P01403391T0000 JJ O
Romanian P01403391T0000 JJ O
children P01403391T0000 NNS O
. P01403391T0000 . O
. . O O

The P07748493A1045 DT O
characterized P07748493A1045 JJ O
Aplysia P07748493A1045 NNP I-UN
Afurin2 P07748493A1045 NNP I-UN
is P07748493A1045 VBZ O
a P07748493A1045 DT O
candidate P07748493A1045 JJ O
PC P07748493A1045 NN I-UN
that P07748493A1045 WDT O
may P07748493A1045 MD O
play P07748493A1045 VB O
an P07748493A1045 DT O
important P07748493A1045 JJ O
role P07748493A1045 NN O
in P07748493A1045 IN O
the P07748493A1045 DT O
processing P07748493A1045 NN O
of P07748493A1045 IN O
egg-laying P07748493A1045 JJ I-UN
hormone P07748493A1045 NN I-UN
( P07748493A1045 ( O
ELH P07748493A1045 NNP I-UN
) P07748493A1045 ) O
-related P07748493A1045 VBD O
precursors P07748493A1045 NNS O
in P07748493A1045 IN O
the P07748493A1045 DT O
secretory P07748493A1045 JJ O
cells P07748493A1045 NNS O
of P07748493A1045 IN O
the P07748493A1045 DT O
atrial P07748493A1045 JJ O
gland P07748493A1045 NN O
. P07748493A1045 . O
. . O O

Krox-24 P02113174A0957 NNP I-UN
is P02113174A0957 VBZ O
therefore P02113174A0957 RB O
a P02113174A0957 DT O
sequence-specific P02113174A0957 JJ O
transcriptional P02113174A0957 JJ O
activator P02113174A0957 NN O
. P02113174A0957 . O
. . O O

Transcriptional P09573187T0000 JJ O
repression P09573187T0000 NN O
mediated P09573187T0000 VBN O
by P09573187T0000 IN O
LysR-type P09573187T0000 NNP I-UN
regulator P09573187T0000 NN I-UN
CatR P09573187T0000 NNP I-UN
bound P09573187T0000 NN O
at P09573187T0000 IN O
multiple P09573187T0000 JJ O
binding P09573187T0000 VBG O
sites P09573187T0000 NNS O
. P09573187T0000 . O
. . O O

Prostacyclin P03061301A0624 NNP O
formation P03061301A0624 NN O
, P03061301A0624 , O
reflected P03061301A0624 VBN O
by P03061301A0624 IN O
the P03061301A0624 DT O
excretion P03061301A0624 NN O
rate P03061301A0624 NN O
of P03061301A0624 IN O
its P03061301A0624 PRP$ O
stable P03061301A0624 JJ O
metabolite P03061301A0624 JJ O
6-keto-prostaglandin P03061301A0624 JJ O
F1 P03061301A0624 NNP O
alpha P03061301A0624 NN O
, P03061301A0624 , O
was P03061301A0624 VBD O
measured P03061301A0624 VBN O
by P03061301A0624 IN O
means P03061301A0624 NNS O
of P03061301A0624 IN O
radioimmunoassay P03061301A0624 NN O
in P03061301A0624 IN O
4-hour P03061301A0624 JJ O
urine P03061301A0624 JJ O
specimens P03061301A0624 NNS O
obtained P03061301A0624 VBN O
during P03061301A0624 IN O
a P03061301A0624 DT O
smoking-free P03061301A0624 JJ O
period P03061301A0624 NN O
and P03061301A0624 CC O
after P03061301A0624 IN O
participants P03061301A0624 NNS O
had P03061301A0624 VBD O
inhaled P03061301A0624 VBN O
smoke P03061301A0624 NN O
from P03061301A0624 IN O
four P03061301A0624 CD O
high-nicotine P03061301A0624 NN O
cigarettes P03061301A0624 NNS O
. P03061301A0624 . O
. . O O

The P08803845A0665 DT O
presence P08803845A0665 NN O
of P08803845A0665 IN O
unidentified P08803845A0665 JJ O
macroscopic P08803845A0665 NN O
or P08803845A0665 CC O
microscopic P08803845A0665 NN O
clusters P08803845A0665 NNS O
of P08803845A0665 IN O
neoplastic P08803845A0665 JJ O
cells P08803845A0665 NNS O
, P08803845A0665 , O
lying P08803845A0665 VBG O
around P08803845A0665 RB O
, P08803845A0665 , O
more P08803845A0665 JJR O
or P08803845A0665 CC O
less P08803845A0665 RBR O
close P08803845A0665 JJ O
to P08803845A0665 TO O
, P08803845A0665 , O
the P08803845A0665 DT O
line P08803845A0665 NN O
of P08803845A0665 IN O
insertion P08803845A0665 NN O
of P08803845A0665 IN O
lesion P08803845A0665 NN O
, P08803845A0665 , O
could P08803845A0665 MD O
render P08803845A0665 VB O
any P08803845A0665 DT O
attempt P08803845A0665 NN O
to P08803845A0665 TO O
gain P08803845A0665 VB O
a P08803845A0665 DT O
`` P08803845A0665 `` O
radical P08803845A0665 JJ O
'' P08803845A0665 '' O
excision P08803845A0665 NN O
useless P08803845A0665 NN O
. P08803845A0665 . O
. . O O

Amisulpride P10350027A0942 RB O
400 P10350027A0942 CD O
mg P10350027A0942 NNS O
had P10350027A0942 VBD O
several P10350027A0942 JJ O
adverse P10350027A0942 JJ O
effects P10350027A0942 NNS O
on P10350027A0942 IN O
psychomotor P10350027A0942 NN O
and P10350027A0942 CC O
, P10350027A0942 , O
although P10350027A0942 IN O
less P10350027A0942 JJR O
severe P10350027A0942 JJ O
, P10350027A0942 , O
on P10350027A0942 IN O
cognitive P10350027A0942 JJ O
performance P10350027A0942 NN O
on P10350027A0942 IN O
the P10350027A0942 DT O
fifth P10350027A0942 JJ O
day P10350027A0942 NN O
only P10350027A0942 RB O
. P10350027A0942 . O
. . O O

Overproduction P01563635T0000 NN O
, P01563635T0000 , O
purification P01563635T0000 NN O
and P01563635T0000 CC O
characterization P01563635T0000 NN O
of P01563635T0000 IN O
M.HinfI P01563635T0000 NNP I-UN
methyltransferase P01563635T0000 NN I-UN
and P01563635T0000 CC O
its P01563635T0000 PRP$ O
deletion P01563635T0000 NN O
mutant P01563635T0000 NN O
. P01563635T0000 . O
. . O O

In P09642214A0244 IN O
this P09642214A0244 DT O
report P09642214A0244 NN O
we P09642214A0244 PRP O
studied P09642214A0244 VBD O
the P09642214A0244 DT O
role P09642214A0244 NN O
of P09642214A0244 IN O
protein-tyrosine P09642214A0244 JJ I-UN
phosphatase P09642214A0244 NN I-UN
SHP-2 P09642214A0244 NNP I-UN
in P09642214A0244 IN O
ErbB-mediated P09642214A0244 NNP O
activation P09642214A0244 NN O
of P09642214A0244 IN O
mitogen-activated P09642214A0244 JJ I-UN
protein P09642214A0244 NN I-UN
kinase P09642214A0244 NN I-UN
( P09642214A0244 ( O
MAPK P09642214A0244 NNP I-UN
) P09642214A0244 ) O
by P09642214A0244 IN O
overexpressing P09642214A0244 VBG O
SHP-2 P09642214A0244 JJ I-UN
mutants P09642214A0244 NNS I-UN
in P09642214A0244 IN O
COS-7 P09642214A0244 NNP O
cells P09642214A0244 NNS O
. P09642214A0244 . O
. . O O

Similarly P08262054A0565 RB O
, P08262054A0565 , O
the P08262054A0565 DT O
N-terminal P08262054A0565 JJ O
cytoplasmic P08262054A0565 JJ O
domain P08262054A0565 NN O
of P08262054A0565 IN O
the P08262054A0565 DT O
latent P08262054A0565 JJ I-UN
membrane P08262054A0565 NN I-UN
protein P08262054A0565 NN I-UN
2A P08262054A0565 CD I-UN
( P08262054A0565 ( O
LMP2A P08262054A0565 NNP I-UN
) P08262054A0565 ) O
of P08262054A0565 IN O
the P08262054A0565 DT O
Epstein-Barr P08262054A0565 NNP O
virus P08262054A0565 NN O
( P08262054A0565 ( O
EBV P08262054A0565 NNP O
) P08262054A0565 ) O
contains P08262054A0565 VBZ O
a P08262054A0565 DT O
single P08262054A0565 JJ O
copy P08262054A0565 NN O
of P08262054A0565 IN O
the P08262054A0565 DT O
Tyr-X-X-Leu P08262054A0565 NNP O
/ P08262054A0565 NNP O
Ile-containing P08262054A0565 NNP O
motif P08262054A0565 NN O
which P08262054A0565 WDT O
could P08262054A0565 MD O
play P08262054A0565 VB O
a P08262054A0565 DT O
critical P08262054A0565 JJ O
role P08262054A0565 NN O
in P08262054A0565 IN O
B P08262054A0565 NNP O
cell P08262054A0565 NN O
transformation P08262054A0565 NN O
. P08262054A0565 . O
. . O O

The P02320999A0606 DT O
procedure P02320999A0606 NN O
has P02320999A0606 VBZ O
been P02320999A0606 VBN O
applied P02320999A0606 VBN O
to P02320999A0606 TO O
three P02320999A0606 CD O
materials P02320999A0606 NNS O
: P02320999A0606 : O
particle P02320999A0606 NN O
board P02320999A0606 NN O
with P02320999A0606 IN O
carpet P02320999A0606 NN O
; P02320999A0606 : O
gypsum P02320999A0606 CC O
board P02320999A0606 NN O
with P02320999A0606 IN O
wallpaper P02320999A0606 NN O
; P02320999A0606 : O
and P02320999A0606 CC O
plywood P02320999A0606 NN O
with P02320999A0606 IN O
polyurethane P02320999A0606 NN O
lacquer P02320999A0606 NN O
, P02320999A0606 , O
for P02320999A0606 IN O
which P02320999A0606 WDT O
the P02320999A0606 DT O
steady-state P02320999A0606 JJ O
emission P02320999A0606 NN O
factors P02320999A0606 NNS O
( P02320999A0606 ( O
mg P02320999A0606 JJ O
m-2 P02320999A0606 JJ O
h-1 P02320999A0606 NN O
) P02320999A0606 ) O
of P02320999A0606 IN O
several P02320999A0606 JJ O
compounds P02320999A0606 NNS O
are P02320999A0606 VBP O
given P02320999A0606 VBN O
. P02320999A0606 . O
. . O O

The P11279324A0710 DT O
size P11279324A0710 NN O
of P11279324A0710 IN O
the P11279324A0710 DT O
infarct P11279324A0710 NN O
was P11279324A0710 VBD O
determined P11279324A0710 VBN O
using P11279324A0710 VBG O
the P11279324A0710 DT O
creatine P11279324A0710 NN I-UN
kinase P11279324A0710 NN I-UN
integral P11279324A0710 JJ O
method P11279324A0710 NN O
. P11279324A0710 . O
. . O O

S1 P02542612A0530 NNP I-UN
nuclease P02542612A0530 JJ I-UN
analysis P02542612A0530 NN O
of P02542612A0530 IN O
RNA P02542612A0530 NNP O
from P02542612A0530 IN O
chemically P02542612A0530 RB O
induced P02542612A0530 VBN O
B95-8 P02542612A0530 NNP O
cells P02542612A0530 NNS O
and P02542612A0530 CC O
from P02542612A0530 IN O
Vero P02542612A0530 NNP O
cells P02542612A0530 NNS O
cotransfected P02542612A0530 VBN O
with P02542612A0530 IN O
NotI P02542612A0530 NNP I-UN
repeat P02542612A0530 NN I-UN
promoter-CAT P02542612A0530 NN O
and P02542612A0530 CC O
Z P02542612A0530 NNP I-UN
showed P02542612A0530 VBD O
that P02542612A0530 IN O
Z P02542612A0530 NNP I-UN
transactivation P02542612A0530 NN O
increased P02542612A0530 VBD O
the P02542612A0530 DT O
level P02542612A0530 NN O
of P02542612A0530 IN O
correctly P02542612A0530 RB O
initiated P02542612A0530 VBN O
, P02542612A0530 , O
stable P02542612A0530 JJ O
RNA P02542612A0530 NNP O
transcripts P02542612A0530 NNS O
. P02542612A0530 . O
. . O O

The P10644753A0725 DT O
three P10644753A0725 CD O
isoforms P10644753A0725 NNS O
purified P10644753A0725 VBN O
with P10644753A0725 IN O
anti-FLAG P10644753A0725 JJ I-UN
antibody P10644753A0725 NN I-UN
affinity P10644753A0725 NN O
column P10644753A0725 NN O
transferred P10644753A0725 VBD O
sulfate P10644753A0725 NN O
to P10644753A0725 TO O
heparan P10644753A0725 VB O
sulfate P10644753A0725 NN O
and P10644753A0725 CC O
heparin P10644753A0725 NN O
but P10644753A0725 CC O
not P10644753A0725 RB O
to P10644753A0725 TO O
other P10644753A0725 JJ O
glycosaminoglycans P10644753A0725 NNS O
. P10644753A0725 . O
. . O O

As P11400644A0435 IN O
a P11400644A0435 DT O
reflection P11400644A0435 NN O
of P11400644A0435 IN O
uncertainties P11400644A0435 NNS O
in P11400644A0435 IN O
the P11400644A0435 DT O
estimates P11400644A0435 NNS O
for P11400644A0435 IN O
individual P11400644A0435 JJ O
sources P11400644A0435 NNS O
, P11400644A0435 , O
the P11400644A0435 DT O
90th P11400644A0435 CD O
percentiles P11400644A0435 NNS O
of P11400644A0435 IN O
PCDD P11400644A0435 NNP O
/ P11400644A0435 NNP O
F P11400644A0435 NNP O
releases P11400644A0435 VBZ O
for P11400644A0435 IN O
1999 P11400644A0435 CD O
ranged P11400644A0435 VBD O
up P11400644A0435 RB O
to P11400644A0435 TO O
4.1 P11400644A0435 CD O
g P11400644A0435 NNS O
I-TEQ P11400644A0435 NNP O
/ P11400644A0435 NNP O
y P11400644A0435 NN O
. P11400644A0435 . O
. . O O

Transfection P09153319A1332 NN O
experiments P09153319A1332 NNS O
using P09153319A1332 VBG O
preformed P09153319A1332 VBD O
triplexes P09153319A1332 NNS O
with P09153319A1332 IN O
a P09153319A1332 DT O
reporter P09153319A1332 NN O
plasmid P09153319A1332 NN O
containing P09153319A1332 VBG O
the P09153319A1332 DT O
collagen P09153319A1332 NN I-UN
promoter P09153319A1332 NN I-UN
sequence P09153319A1332 NN I-UN
showed P09153319A1332 VBD O
significant P09153319A1332 JJ O
inhibition P09153319A1332 NN O
of P09153319A1332 IN O
transcription P09153319A1332 NN O
when P09153319A1332 WRB O
compared P09153319A1332 VBN O
with P09153319A1332 IN O
a P09153319A1332 DT O
control P09153319A1332 NN O
phosphorothioate P09153319A1332 NN O
ODN P09153319A1332 NNP O
. P09153319A1332 . O
. . O O

PATIENTS P10802909A0478 NNS O
OR P10802909A0478 CC O
OTHER P10802909A0478 JJ O
PARTICIPANTS P10802909A0478 NNS O
: P10802909A0478 : O
Twenty P10802909A0478 NNP O
children P10802909A0478 NNS O
met P10802909A0478 VBD O
the P10802909A0478 DT O
criteria P10802909A0478 NNS O
for P10802909A0478 IN O
being P10802909A0478 VBG O
learning P10802909A0478 VBG O
disabled P10802909A0478 VBN O
. P10802909A0478 . O
. . O O

Our P09122176A0970 PRP$ O
results P09122176A0970 NNS O
indicate P09122176A0970 VBP O
that P09122176A0970 IN O
RA-mediated P09122176A0970 JJ O
repression P09122176A0970 NN O
of P09122176A0970 IN O
the P09122176A0970 DT O
hMGP P09122176A0970 NN I-UN
gene P09122176A0970 NN I-UN
is P09122176A0970 VBZ O
due P09122176A0970 JJ O
to P09122176A0970 TO O
binding P09122176A0970 VBG O
of P09122176A0970 IN O
liganded P09122176A0970 JJ O
RAR P09122176A0970 NNP I-UN
/ P09122176A0970 NNP O
RXR P09122176A0970 NNP I-UN
to P09122176A0970 TO O
a P09122176A0970 DT O
novel P09122176A0970 JJ O
negative P09122176A0970 JJ O
RA P09122176A0970 NNP O
response P09122176A0970 NN O
element P09122176A0970 NN O
. P09122176A0970 . O
. . O O

The P02188096A0955 DT O
contribution P02188096A0955 NN O
that P02188096A0955 WDT O
alternative P02188096A0955 JJ O
splicing P02188096A0955 VBG O
events P02188096A0955 NNS O
in P02188096A0955 IN O
c-myb P02188096A0955 JJ I-UN
expression P02188096A0955 NN O
may P02188096A0955 MD O
make P02188096A0955 VB O
on P02188096A0955 IN O
c-myb P02188096A0955 JJ I-UN
function P02188096A0955 NN O
remains P02188096A0955 VBZ O
to P02188096A0955 TO O
be P02188096A0955 VB O
elucidated P02188096A0955 VBN O
. P02188096A0955 . O
. . O O

During P03110119A0267 IN O
BH P03110119A0267 NNP O
the P03110119A0267 DT O
ventilator P03110119A0267 NN O
was P03110119A0267 VBD O
disconnected P03110119A0267 VBN O
and P03110119A0267 CC O
a P03110119A0267 DT O
bias P03110119A0267 NN O
flow P03110119A0267 NN O
of P03110119A0267 IN O
50 P03110119A0267 CD O
% P03110119A0267 NN O
O2 P03110119A0267 NNP O
at P03110119A0267 IN O
4-5 P03110119A0267 JJ O
l P03110119A0267 NN O
/ P03110119A0267 NNP O
min P03110119A0267 NN O
was P03110119A0267 VBD O
delivered P03110119A0267 VBN O
through P03110119A0267 IN O
the P03110119A0267 DT O
side P03110119A0267 NN O
ports P03110119A0267 NNS O
of P03110119A0267 IN O
a P03110119A0267 DT O
small P03110119A0267 JJ O
catheter P03110119A0267 NN O
whose P03110119A0267 WP$ O
tip P03110119A0267 NN O
was P03110119A0267 VBD O
positioned P03110119A0267 VBN O
1 P03110119A0267 CD O
cm P03110119A0267 JJ O
cephalad P03110119A0267 NN O
of P03110119A0267 IN O
the P03110119A0267 DT O
carina P03110119A0267 NN O
. P03110119A0267 . O
. . O O

Recovery P03228785A1047 NN O
was P03228785A1047 VBD O
characterized P03228785A1047 VBN O
by P03228785A1047 IN O
rapid P03228785A1047 JJ O
improvement P03228785A1047 NN O
such P03228785A1047 JJ O
that P03228785A1047 IN O
all P03228785A1047 DT O
measured P03228785A1047 VBD O
parameters P03228785A1047 NNS O
normalized P03228785A1047 VBN O
by P03228785A1047 IN O
1 P03228785A1047 CD O
week P03228785A1047 NN O
, P03228785A1047 , O
except P03228785A1047 IN O
for P03228785A1047 IN O
cross-sectional P03228785A1047 JJ O
cardiac P03228785A1047 JJ O
area P03228785A1047 NN O
which P03228785A1047 WDT O
remained P03228785A1047 VBD O
dilated P03228785A1047 VBD O
up P03228785A1047 RB O
to P03228785A1047 TO O
4 P03228785A1047 CD O
weeks P03228785A1047 NNS O
( P03228785A1047 ( O
14 P03228785A1047 CD O
+ P03228785A1047 NN O
/ P03228785A1047 NNP O
- P03228785A1047 : O
3 P03228785A1047 CD O
cm2 P03228785A1047 NN O
, P03228785A1047 , O
p P03228785A1047 NN O
less P03228785A1047 JJR O
than P03228785A1047 IN O
0.05 P03228785A1047 CD O
versus P03228785A1047 NNS O
control P03228785A1047 NN O
) P03228785A1047 ) O
. P03228785A1047 . O
( P03228785A1047 ( O
ABSTRACT P03228785A1047 NNP O
TRUNCATED P03228785A1047 NNP O
AT P03228785A1047 NNP O
250 P03228785A1047 CD O
WORDS P03228785A1047 NNP O
) P03228785A1047 ) O
. P03228785A1047 . O
. . O O

In P09701821A1108 IN O
contrast P09701821A1108 NN O
, P09701821A1108 , O
transcription P09701821A1108 NN O
initiating P09701821A1108 VBG O
from P09701821A1108 IN O
opuE P09701821A1108 JJ I-UN
P-1 P09701821A1108 NNP I-UN
( P09701821A1108 ( O
sigma P09701821A1108 VB I-UN
A P09701821A1108 NNP I-UN
) P09701821A1108 ) O
rose P09701821A1108 VBD O
in P09701821A1108 IN O
proportion P09701821A1108 NN O
to P09701821A1108 TO O
the P09701821A1108 DT O
external P09701821A1108 JJ O
osmolarity P09701821A1108 NN O
and P09701821A1108 CC O
was P09701821A1108 VBD O
maintained P09701821A1108 VBN O
at P09701821A1108 IN O
high P09701821A1108 JJ O
levels P09701821A1108 NNS O
. P09701821A1108 . O
. . O O

The P01480183A0000 DT O
5'-flanking P01480183A0000 JJ O
region P01480183A0000 NN O
of P01480183A0000 IN O
the P01480183A0000 DT O
human P01480183A0000 JJ I-UN
lactoferrin P01480183A0000 NN I-UN
gene P01480183A0000 NN I-UN
was P01480183A0000 VBD O
isolated P01480183A0000 VBN O
from P01480183A0000 IN O
a P01480183A0000 DT O
human P01480183A0000 JJ O
placental P01480183A0000 JJ O
genomic P01480183A0000 JJ O
library P01480183A0000 NN O
. P01480183A0000 . O
. . O O

An P11356716A0372 DT O
18-kb P11356716A0372 JJ O
genomic P11356716A0372 JJ O
clone P11356716A0372 NN O
including P11356716A0372 VBG O
sequences P11356716A0372 NNS O
encoding P11356716A0372 VBG O
for P11356716A0372 IN O
the P11356716A0372 DT O
two P11356716A0372 CD O
GHS-R P11356716A0372 JJ I-UN
variants P11356716A0372 NNS I-UN
was P11356716A0372 VBD O
isolated P11356716A0372 VBN O
. P11356716A0372 . O
. . O O

Liver P02274509A0623 NNP O
dysfunction P02274509A0623 NN O
in P02274509A0623 IN O
the P02274509A0623 DT O
presence P02274509A0623 NN O
of P02274509A0623 IN O
different P02274509A0623 JJ O
adverse P02274509A0623 JJ O
reactions P02274509A0623 NNS O
presented P02274509A0623 VBN O
with P02274509A0623 IN O
a P02274509A0623 DT O
higher P02274509A0623 JJR O
activity P02274509A0623 NN O
in P02274509A0623 IN O
the P02274509A0623 DT O
blood P02274509A0623 NN O
serum P02274509A0623 NN O
of P02274509A0623 IN O
indicator P02274509A0623 NN O
liver P02274509A0623 NN O
enzymes P02274509A0623 NNS O
and P02274509A0623 CC O
its P02274509A0623 PRP$ O
impaired P02274509A0623 JJ O
protein-forming P02274509A0623 JJ O
function P02274509A0623 NN O
. P02274509A0623 . O
. . O O

The P08977401A0227 DT O
RI P08977401A0227 NNP I-UN
alpha P08977401A0227 NN I-UN
gene P08977401A0227 NN I-UN
is P08977401A0227 VBZ O
composed P08977401A0227 VBN O
of P08977401A0227 IN O
nine P08977401A0227 CD O
coding P08977401A0227 VBG O
exons P08977401A0227 NNS O
of P08977401A0227 IN O
varying P08977401A0227 VBG O
lengths P08977401A0227 NNS O
, P08977401A0227 , O
separated P08977401A0227 VBN O
by P08977401A0227 IN O
introns P08977401A0227 NNS O
, P08977401A0227 , O
giving P08977401A0227 VBG O
the P08977401A0227 DT O
gene P08977401A0227 NN O
a P08977401A0227 DT O
total P08977401A0227 JJ O
length P08977401A0227 NN O
of P08977401A0227 IN O
at P08977401A0227 IN O
least P08977401A0227 JJS O
21 P08977401A0227 CD O
kb P08977401A0227 NN O
. P08977401A0227 . O
our P08977401A0227 PRP$ O
recent P08977401A0227 JJ O
cloning P08977401A0227 NN O
of P08977401A0227 IN O
a P08977401A0227 DT O
processed P08977401A0227 JJ O
RI P08977401A0227 NNP I-UN
alpha P08977401A0227 NN I-UN
pseudogene P08977401A0227 NN I-UN
with P08977401A0227 IN O
a P08977401A0227 DT O
5'-noncoding P08977401A0227 JJ O
region P08977401A0227 NN O
different P08977401A0227 JJ O
from P08977401A0227 IN O
the P08977401A0227 DT O
previously P08977401A0227 RB O
reported P08977401A0227 VBN O
RI P08977401A0227 NNP I-UN
alpha P08977401A0227 JJ I-UN
complementary P08977401A0227 JJ I-UN
RNA P08977401A0227 NNP I-UN
indicated P08977401A0227 VBD O
that P08977401A0227 IN O
the P08977401A0227 DT O
RI P08977401A0227 NNP I-UN
alpha P08977401A0227 JJ I-UN
gene P08977401A0227 NN I-UN
may P08977401A0227 MD O
have P08977401A0227 VB O
multiple P08977401A0227 JJ O
leader P08977401A0227 NN O
exons P08977401A0227 NNS O
giving P08977401A0227 VBG O
rise P08977401A0227 NN O
to P08977401A0227 TO O
alternately P08977401A0227 RB O
spliced P08977401A0227 JJ O
messenger P08977401A0227 NN O
RNAs P08977401A0227 NNP O
( P08977401A0227 ( O
mRNAs P08977401A0227 NN O
) P08977401A0227 ) O
. P08977401A0227 . O
. . O O

Position-independent P09512559T0000 JJ O
expression P09512559T0000 NN O
of P09512559T0000 IN O
a P09512559T0000 DT O
human P09512559T0000 JJ O
nerve P09512559T0000 NN I-UN
growth P09512559T0000 NN I-UN
factor-luciferase P09512559T0000 JJ O
reporter P09512559T0000 NN O
gene P09512559T0000 NN O
cloned P09512559T0000 VBN O
on P09512559T0000 IN O
a P09512559T0000 DT O
yeast P09512559T0000 JJ O
artificial P09512559T0000 JJ O
chromosome P09512559T0000 NN O
vector P09512559T0000 NN O
. P09512559T0000 . O
. . O O

In P01400401A0065 IN O
humans P01400401A0065 NNS O
, P01400401A0065 , O
four P01400401A0065 CD O
AMP P01400401A0065 NNP I-UN
deaminase P01400401A0065 NN I-UN
variants P01400401A0065 NNS I-UN
, P01400401A0065 , O
termed P01400401A0065 VBN O
M P01400401A0065 NNP I-UN
( P01400401A0065 ( O
muscle P01400401A0065 NN O
) P01400401A0065 ) O
, P01400401A0065 , O
L P01400401A0065 NNP I-UN
( P01400401A0065 ( O
liver P01400401A0065 NN O
) P01400401A0065 ) O
, P01400401A0065 , O
E1 P01400401A0065 NNP I-UN
, P01400401A0065 , O
and P01400401A0065 CC O
E2 P01400401A0065 NNP I-UN
( P01400401A0065 ( O
erythrocyte P01400401A0065 NN O
) P01400401A0065 ) O
can P01400401A0065 MD O
be P01400401A0065 VB O
distinguished P01400401A0065 VBN O
by P01400401A0065 IN O
a P01400401A0065 DT O
variety P01400401A0065 NN O
of P01400401A0065 IN O
biochemical P01400401A0065 JJ O
and P01400401A0065 CC O
immunological P01400401A0065 JJ O
criteria P01400401A0065 NNS O
. P01400401A0065 . O
. . O O

Taken P09650299A1334 VBN O
together P09650299A1334 RB O
, P09650299A1334 , O
these P09650299A1334 DT O
data P09650299A1334 NNS O
indicate P09650299A1334 VBP O
that P09650299A1334 IN O
the P09650299A1334 DT O
VirD2 P09650299A1334 NNP I-UN
omega P09650299A1334 NN I-UN
domain P09650299A1334 NN I-UN
is P09650299A1334 VBZ O
important P09650299A1334 JJ O
for P09650299A1334 IN O
efficient P09650299A1334 JJ O
T-DNA P09650299A1334 JJ O
integration P09650299A1334 NN O
. P09650299A1334 . O
. . O O

Total P01248124A0281 JJ O
cholesterol P01248124A0281 NN O
was P01248124A0281 VBD O
measured P01248124A0281 VBN O
in P01248124A0281 IN O
amniotic P01248124A0281 JJ O
fluids P01248124A0281 NNS O
collected P01248124A0281 VBN O
at P01248124A0281 IN O
different P01248124A0281 JJ O
stages P01248124A0281 NNS O
of P01248124A0281 IN O
gestation P01248124A0281 NN O
. P01248124A0281 . O
. . O O

In P01627828A0475 IN O
agreement P01627828A0475 NN O
with P01627828A0475 IN O
this P01627828A0475 DT O
southern P01627828A0475 JJ O
blotting P01627828A0475 NN O
of P01627828A0475 IN O
mouse P01627828A0475 NN O
DNA P01627828A0475 NN O
with P01627828A0475 IN O
SmN P01627828A0475 NNP I-UN
probes P01627828A0475 NNS O
reveals P01627828A0475 NNS O
bands P01627828A0475 NNS O
, P01627828A0475 , O
additional P01627828A0475 JJ O
to P01627828A0475 TO O
those P01627828A0475 DT O
derived P01627828A0475 VBN O
from P01627828A0475 IN O
the P01627828A0475 DT O
pseudogene P01627828A0475 NN O
, P01627828A0475 , O
which P01627828A0475 WDT O
are P01627828A0475 VBP O
characteristic P01627828A0475 JJ O
of P01627828A0475 IN O
an P01627828A0475 DT O
intron-containing P01627828A0475 JJ O
SmN P01627828A0475 NNP I-UN
gene P01627828A0475 NN I-UN
. P01627828A0475 . O
. . O O

Articles P07966873A0693 NNS O
addressing P07966873A0693 VBG O
valvular P07966873A0693 JJ O
heart P07966873A0693 NN O
disease P07966873A0693 NN O
or P07966873A0693 CC O
heart P07966873A0693 NN O
failure P07966873A0693 NN O
secondary P07966873A0693 JJ O
to P07966873A0693 TO O
acute P07966873A0693 VB O
myocardial P07966873A0693 JJ O
infarction P07966873A0693 NN O
or P07966873A0693 CC O
Chagas P07966873A0693 NNP O
' P07966873A0693 POS O
disease P07966873A0693 NN O
were P07966873A0693 VBD O
excluded P07966873A0693 VBN O
. P07966873A0693 . O
. . O O

All P09920539A0272 DT O
stimulations P09920539A0272 NNS O
were P09920539A0272 VBD O
down-regulated P09920539A0272 JJ O
with P09920539A0272 IN O
GnRH-a P09920539A0272 NNP I-UN
commenced P09920539A0272 VBD O
on P09920539A0272 IN O
day P09920539A0272 NN O
21 P09920539A0272 CD O
in P09920539A0272 IN O
a P09920539A0272 DT O
long P09920539A0272 JJ O
protocol P09920539A0272 NN O
before P09920539A0272 IN O
gonadotropin P09920539A0272 JJ I-UN
stimulation P09920539A0272 NN O
. P09920539A0272 . O
. . O O

The P02283378A0385 DT O
former P02283378A0385 JJ O
procedure P02283378A0385 NN O
is P02283378A0385 VBZ O
economical P02283378A0385 JJ O
but P02283378A0385 CC O
complicated P02283378A0385 VBD O
, P02283378A0385 , O
whereas P02283378A0385 IN O
the P02283378A0385 DT O
latter P02283378A0385 NN O
is P02283378A0385 VBZ O
simple P02283378A0385 JJ O
and P02283378A0385 CC O
labour-saving P02283378A0385 JJ O
, P02283378A0385 , O
but P02283378A0385 CC O
a P02283378A0385 DT O
special P02283378A0385 JJ O
ultrafiltration P02283378A0385 NN O
tube P02283378A0385 NN O
is P02283378A0385 VBZ O
required P02283378A0385 VBN O
. P02283378A0385 . O
. . O O

To P11404019A0532 TO O
gain P11404019A0532 VB O
an P11404019A0532 DT O
understanding P11404019A0532 NN O
of P11404019A0532 IN O
the P11404019A0532 DT O
mGSTM2 P11404019A0532 NN I-UN
regulation P11404019A0532 NN O
, P11404019A0532 , O
we P11404019A0532 PRP O
have P11404019A0532 VBP O
also P11404019A0532 RB O
cloned P11404019A0532 VBN O
and P11404019A0532 CC O
analyzed P11404019A0532 VBN O
its P11404019A0532 PRP$ O
promoter P11404019A0532 NN O
region P11404019A0532 NN O
. P11404019A0532 . O
. . O O

The P07984261A0536 DT O
ICBF P07984261A0536 NNP O
in P07984261A0536 IN O
the P07984261A0536 DT O
ischaemic P07984261A0536 JJ O
cortex P07984261A0536 NN O
revealed P07984261A0536 VBD O
a P07984261A0536 DT O
graded P07984261A0536 JJ O
reduction P07984261A0536 NN O
from P07984261A0536 IN O
the P07984261A0536 DT O
ischaemic P07984261A0536 JJ O
centre P07984261A0536 NN O
to P07984261A0536 TO O
the P07984261A0536 DT O
surrounding P07984261A0536 VBG O
tissues P07984261A0536 NNS O
. P07984261A0536 . O
. . O O

XII P08360112T0036 NN O
. P08360112T0036 . O
. . O O

The P10470220A1011 DT O
arrangement P10470220A1011 NN O
of P10470220A1011 IN O
these P10470220A1011 DT O
cutoff-levels P10470220A1011 NNS O
leads P10470220A1011 VBZ O
to P10470220A1011 TO O
a P10470220A1011 DT O
sensitivity P10470220A1011 NN O
of P10470220A1011 IN O
85 P10470220A1011 CD O
% P10470220A1011 NN O
at P10470220A1011 IN O
a P10470220A1011 DT O
specificity P10470220A1011 NN O
of P10470220A1011 IN O
55 P10470220A1011 CD O
% P10470220A1011 NN O
for P10470220A1011 IN O
Protein P10470220A1011 NNP I-UN
S100 P10470220A1011 NNP I-UN
when P10470220A1011 WRB O
measured P10470220A1011 VBN O
by P10470220A1011 IN O
RIA P10470220A1011 NNP O
, P10470220A1011 , O
and P10470220A1011 CC O
to P10470220A1011 TO O
a P10470220A1011 DT O
sensitivity P10470220A1011 NN O
of P10470220A1011 IN O
77 P10470220A1011 CD O
% P10470220A1011 NN O
at P10470220A1011 IN O
a P10470220A1011 DT O
specificity P10470220A1011 NN O
of P10470220A1011 IN O
61 P10470220A1011 CD O
% P10470220A1011 NN O
when P10470220A1011 WRB O
measured P10470220A1011 VBN O
by P10470220A1011 IN O
LIA P10470220A1011 NNP O
. P10470220A1011 . O
. . O O

Lymphocyte P01083784T0000 NNP O
subpopulations P01083784T0000 NNS O
, P01083784T0000 , O
serum P01083784T0000 NN I-UN
IgE P01083784T0000 NNP I-UN
and P01083784T0000 CC O
total P01083784T0000 JJ O
eosinophil P01083784T0000 NN O
counts P01083784T0000 NNS O
in P01083784T0000 IN O
patients P01083784T0000 NNS O
with P01083784T0000 IN O
bronchial P01083784T0000 JJ O
asthma P01083784T0000 NN O
. P01083784T0000 . O
. . O O

Interestingly P09649426A0636 RB O
, P09649426A0636 , O
PKA P09649426A0636 NNP I-UN
activity P09649426A0636 NN O
is P09649426A0636 VBZ O
dispensable P09649426A0636 JJ O
in P09649426A0636 IN O
a P09649426A0636 DT O
strain P09649426A0636 NN O
lacking P09649426A0636 VBG O
Msn2p P09649426A0636 NNP I-UN
and P09649426A0636 CC O
Msn4p P09649426A0636 NNP I-UN
activity P09649426A0636 NN O
. P09649426A0636 . O
. . O O

Endurance P03684517A0462 NN O
training P03684517A0462 NN O
resulted P03684517A0462 VBD O
in P03684517A0462 IN O
an P03684517A0462 DT O
increase P03684517A0462 NN O
of P03684517A0462 IN O
stiffness P03684517A0462 NN O
associated P03684517A0462 VBN O
with P03684517A0462 IN O
a P03684517A0462 DT O
decrease P03684517A0462 NN O
of P03684517A0462 IN O
type P03684517A0462 NN O
II P03684517A0462 NNP O
fibers P03684517A0462 NNS O
. P03684517A0462 . O
. . O O

The P02423533A1790 DT O
cDNAs P02423533A1790 JJ O
cross-hybridize P02423533A1790 NN O
with P02423533A1790 IN O
genomic P02423533A1790 JJ O
sequences P02423533A1790 NNS O
in P02423533A1790 IN O
rat P02423533A1790 NN O
, P02423533A1790 , O
human P02423533A1790 JJ O
, P02423533A1790 , O
and P02423533A1790 CC O
chicken P02423533A1790 NN O
DNA P02423533A1790 NN O
, P02423533A1790 , O
but P02423533A1790 CC O
not P02423533A1790 RB O
with P02423533A1790 IN O
DNA P02423533A1790 NN O
from P02423533A1790 IN O
frog P02423533A1790 NN O
, P02423533A1790 , O
Drosophila P02423533A1790 NNP O
, P02423533A1790 , O
or P02423533A1790 CC O
sea P02423533A1790 NN O
urchin P02423533A1790 JJ O
. P02423533A1790 . O
. . O O

Purified P09086268A0611 NNP I-UN
P7 P09086268A0611 NNP I-UN
could P09086268A0611 MD O
be P09086268A0611 VB O
assembled P09086268A0611 VBN O
onto P09086268A0611 IN O
particles P09086268A0611 NNS O
lacking P09086268A0611 VBG O
P7 P09086268A0611 NNP I-UN
and P09086268A0611 CC O
particles P09086268A0611 NNS O
lacking P09086268A0611 VBG O
both P09086268A0611 DT O
P2 P09086268A0611 NNP I-UN
( P09086268A0611 ( O
RNA P09086268A0611 NNP I-UN
polymerase P09086268A0611 NN I-UN
) P09086268A0611 ) O
and P09086268A0611 CC O
P7 P09086268A0611 NNP I-UN
. P09086268A0611 . O
. . O O

Specifically P09576915A0269 RB O
, P09576915A0269 , O
recombination P09576915A0269 NN O
at P09576915A0269 IN O
HMR P09576915A0269 NNP I-UN
was P09576915A0269 VBD O
used P09576915A0269 VBN O
to P09576915A0269 TO O
produce P09576915A0269 VB O
rings P09576915A0269 NNS O
that P09576915A0269 WDT O
lacked P09576915A0269 VBD O
the P09576915A0269 DT O
E P09576915A0269 NNP O
and P09576915A0269 CC O
I P09576915A0269 PRP O
silencers P09576915A0269 NNS O
. P09576915A0269 . O
. . O O

This P08430095A0161 DT O
report P08430095A0161 NN O
describes P08430095A0161 VBZ O
the P08430095A0161 DT O
identification P08430095A0161 NN O
of P08430095A0161 IN O
a P08430095A0161 DT O
gene P08430095A0161 NN O
of P08430095A0161 IN O
related P08430095A0161 JJ O
function P08430095A0161 NN O
, P08430095A0161 , O
SMD1 P08430095A0161 NNP I-UN
, P08430095A0161 , O
located P08430095A0161 VBN O
immediately P08430095A0161 RB O
3 P08430095A0161 CD O
' P08430095A0161 '' O
to P08430095A0161 TO O
PRP38 P08430095A0161 NNP I-UN
. P08430095A0161 . O
. . O O

CONCLUSION P09806516A1689 NN O
: P09806516A1689 : O
Local P09806516A1689 JJ O
control P09806516A1689 NN O
was P09806516A1689 VBD O
highest P09806516A1689 JJS O
with P09806516A1689 IN O
Preop P09806516A1689 NNP O
in P09806516A1689 IN O
patients P09806516A1689 NNS O
presenting P09806516A1689 VBG O
primarily P09806516A1689 RB O
with P09806516A1689 IN O
gross P09806516A1689 JJ O
disease P09806516A1689 NN O
, P09806516A1689 , O
and P09806516A1689 CC O
with P09806516A1689 IN O
Postop P09806516A1689 NNP O
in P09806516A1689 IN O
patients P09806516A1689 NNS O
presenting P09806516A1689 VBG O
primarily P09806516A1689 RB O
following P09806516A1689 VBG O
gross P09806516A1689 JJ O
total P09806516A1689 JJ O
excision P09806516A1689 NN O
. P09806516A1689 . O
. . O O

One P02850472A0112 CD O
of P02850472A0112 IN O
these P02850472A0112 DT O
, P02850472A0112 , O
the P02850472A0112 DT O
origin P02850472A0112 NN O
core P02850472A0112 NN O
, P02850472A0112 , O
is P02850472A0112 VBZ O
required P02850472A0112 VBN O
only P02850472A0112 RB O
for P02850472A0112 IN O
DNA P02850472A0112 NNP O
replication P02850472A0112 NN O
. P02850472A0112 . O
. . O O

These P02233680A1115 DT O
results P02233680A1115 NNS O
indicate P02233680A1115 VBP O
that P02233680A1115 IN O
the P02233680A1115 DT O
cis-regulatory P02233680A1115 JJ O
elements P02233680A1115 NNS O
required P02233680A1115 VBN O
for P02233680A1115 IN O
developmental P02233680A1115 JJ O
control P02233680A1115 NN O
of P02233680A1115 IN O
the P02233680A1115 DT O
HaG3-A P02233680A1115 NNP I-UN
helianthinin P02233680A1115 NN I-UN
gene P02233680A1115 NN I-UN
are P02233680A1115 VBP O
located P02233680A1115 VBN O
in P02233680A1115 IN O
a P02233680A1115 DT O
2.4 P02233680A1115 CD O
kb P02233680A1115 NN O
upstream P02233680A1115 JJ O
region P02233680A1115 NN O
of P02233680A1115 IN O
this P02233680A1115 DT O
gene P02233680A1115 NN O
. P02233680A1115 . O
. . O O

Twenty-one P06743061A0239 CD O
percent P06743061A0239 NN O
of P06743061A0239 IN O
these P06743061A0239 DT O
patients P06743061A0239 NNS O
had P06743061A0239 VBD O
neurologic P06743061A0239 JJ O
disease P06743061A0239 NN O
that P06743061A0239 WDT O
appeared P06743061A0239 VBD O
to P06743061A0239 TO O
be P06743061A0239 VB O
responsible P06743061A0239 JJ O
for P06743061A0239 IN O
the P06743061A0239 DT O
tinnitus P06743061A0239 NN O
. P06743061A0239 . O
. . O O

The P09151828A0919 DT O
altered P09151828A0919 JJ O
amino P09151828A0919 NN O
acid P09151828A0919 NN O
residues P09151828A0919 NNS O
of P09151828A0919 IN O
the P09151828A0919 DT O
seven P09151828A0919 CD O
mutant P09151828A0919 JJ I-UN
9ORF1 P09151828A0919 CD I-UN
polypeptides P09151828A0919 NNS I-UN
clustered P09151828A0919 VBD O
within P09151828A0919 IN O
three P09151828A0919 CD O
separate P09151828A0919 JJ O
regions P09151828A0919 NNS O
referred P09151828A0919 VBN O
to P09151828A0919 TO O
as P09151828A0919 IN O
region P09151828A0919 NN O
I P09151828A0919 PRP O
( P09151828A0919 ( O
residues P09151828A0919 VB O
34 P09151828A0919 CD O
to P09151828A0919 TO O
41 P09151828A0919 CD O
) P09151828A0919 ) O
, P09151828A0919 , O
region P09151828A0919 NN O
II P09151828A0919 NNP O
( P09151828A0919 ( O
residues P09151828A0919 VBZ O
89 P09151828A0919 CD O
to P09151828A0919 TO O
91 P09151828A0919 CD O
) P09151828A0919 ) O
, P09151828A0919 , O
and P09151828A0919 CC O
C-terminal P09151828A0919 JJ O
region P09151828A0919 NN O
III P09151828A0919 NNP O
( P09151828A0919 ( O
residues P09151828A0919 VBZ O
122 P09151828A0919 CD O
to P09151828A0919 TO O
125 P09151828A0919 CD O
) P09151828A0919 ) O
. P09151828A0919 . O
. . O O

Mutation P10488087A0340 NN O
of P10488087A0340 IN O
TTF-1-binding P10488087A0340 NNP I-UN
sites P10488087A0340 NNS I-UN
( P10488087A0340 ( I-UN
TBE P10488087A0340 NNP I-UN
) P10488087A0340 ) I-UN
1 P10488087A0340 CD I-UN
, P10488087A0340 , I-UN
3 P10488087A0340 CD I-UN
, P10488087A0340 , I-UN
and P10488087A0340 CC I-UN
4 P10488087A0340 CD I-UN
in P10488087A0340 IN O
combination P10488087A0340 NN O
markedly P10488087A0340 RB O
decreased P10488087A0340 VBD O
transcriptional P10488087A0340 JJ O
activity P10488087A0340 NN O
of P10488087A0340 IN O
SP-A P10488087A0340 NNP I-UN
promoter-chloramphenicol P10488087A0340 JJ O
acetyltransferase P10488087A0340 NN I-UN
constructs P10488087A0340 NNS O
containing P10488087A0340 VBG O
SP-A P10488087A0340 JJ I-UN
gene P10488087A0340 NN I-UN
sequences P10488087A0340 NNS O
from P10488087A0340 IN O
-256 P10488087A0340 NN O
to P10488087A0340 TO O
+45 P10488087A0340 VB O
. P10488087A0340 . O
. . O O

As P03561622A0659 IN O
a P03561622A0659 DT O
last P03561622A0659 JJ O
resort P03561622A0659 NN O
, P03561622A0659 , O
it P03561622A0659 PRP O
may P03561622A0659 MD O
be P03561622A0659 VB O
possible P03561622A0659 JJ O
to P03561622A0659 TO O
maintain P03561622A0659 VB O
a P03561622A0659 DT O
patient P03561622A0659 NN O
on P03561622A0659 IN O
dialysis P03561622A0659 NN O
in P03561622A0659 IN O
reasonable P03561622A0659 JJ O
health P03561622A0659 NN O
with P03561622A0659 IN O
a P03561622A0659 DT O
DiaTAP P03561622A0659 NNP O
button P03561622A0659 NN O
graft P03561622A0659 NN O
complex P03561622A0659 NN O
infected P03561622A0659 VBN O
with P03561622A0659 IN O
Staphylococcus P03561622A0659 NNP O
epidermidis P03561622A0659 NN O
and P03561622A0659 CC O
intermittent P03561622A0659 JJ O
positive P03561622A0659 JJ O
blood P03561622A0659 NN O
cultures P03561622A0659 NNS O
using P03561622A0659 VBG O
long P03561622A0659 JJ O
term P03561622A0659 NN O
vancomycin P03561622A0659 NN O
therapy P03561622A0659 NN O
. P03561622A0659 . O
. . O O

The P07937106A0100 DT O
v-ets P07937106A0100 JJ I-UN
oncogene P07937106A0100 NN I-UN
of P07937106A0100 IN O
the P07937106A0100 DT O
avian P07937106A0100 JJ O
retrovirus P07937106A0100 NN O
E26 P07937106A0100 NNP O
differs P07937106A0100 NNS O
from P07937106A0100 IN O
its P07937106A0100 PRP$ O
cellular P07937106A0100 JJ O
progenitor P07937106A0100 NN O
p68c-ets-1 P07937106A0100 JJ I-UN
by P07937106A0100 IN O
two P07937106A0100 CD O
amino P07937106A0100 NN O
acid P07937106A0100 NN O
substitutions P07937106A0100 NNS O
( P07937106A0100 ( O
alanine P07937106A0100 JJ O
285 P07937106A0100 CD O
and P07937106A0100 CC O
isoleucine P07937106A0100 VB O
445 P07937106A0100 CD O
in P07937106A0100 IN O
c-ets-1 P07937106A0100 JJ I-UN
both P07937106A0100 DT O
substituted P07937106A0100 VBN O
by P07937106A0100 IN O
valine P07937106A0100 NN O
in P07937106A0100 IN O
v-ets P07937106A0100 NNS I-UN
, P07937106A0100 , O
mutations P07937106A0100 NNS O
A P07937106A0100 NNP O
and P07937106A0100 CC O
B P07937106A0100 NNP O
respectively P07937106A0100 RB O
) P07937106A0100 ) O
and P07937106A0100 CC O
its P07937106A0100 PRP$ O
carboxy-terminal P07937106A0100 JJ O
end P07937106A0100 NN O
( P07937106A0100 ( O
mutation P07937106A0100 NN O
C P07937106A0100 NNP O
) P07937106A0100 ) O
. P07937106A0100 . O
. . O O

Commonly P10224513A0240 RB O
used P10224513A0240 VBN O
stressors P10224513A0240 NNS O
are P10224513A0240 VBP O
mental P10224513A0240 JJ O
arithmetics P10224513A0240 NNS O
, P10224513A0240 , O
speech P10224513A0240 NN O
tasks P10224513A0240 NNS O
, P10224513A0240 , O
the P10224513A0240 DT O
Stroop P10224513A0240 NNP O
test P10224513A0240 NN O
, P10224513A0240 , O
videogame P10224513A0240 NN O
playing P10224513A0240 NN O
, P10224513A0240 , O
films P10224513A0240 NNS O
or P10224513A0240 CC O
videotapes P10224513A0240 NNS O
and P10224513A0240 CC O
interviews P10224513A0240 NNS O
. P10224513A0240 . O
. . O O

These P07741255A0194 DT O
six P07741255A0194 CD O
districts P07741255A0194 NNS O
have P07741255A0194 VBP O
an P07741255A0194 DT O
area P07741255A0194 NN O
of P07741255A0194 IN O
34,000 P07741255A0194 CD O
km2 P07741255A0194 NNS O
and P07741255A0194 CC O
hold P07741255A0194 VB O
a P07741255A0194 DT O
population P07741255A0194 NN O
of P07741255A0194 IN O
30 P07741255A0194 CD O
million P07741255A0194 CD O
. P07741255A0194 . O
. . O O

PowerBLAST P09445488A1169 NNP O
analysis P09445488A1169 NN O
identified P09445488A1169 VBD O
six P09445488A1169 CD O
clusters P09445488A1169 NNS O
of P09445488A1169 IN O
expressed P09445488A1169 JJ O
sequence P09445488A1169 NN O
tags P09445488A1169 NNS O
( P09445488A1169 ( O
ESTs P09445488A1169 NNP O
) P09445488A1169 ) O
, P09445488A1169 , O
two P09445488A1169 CD O
known P09445488A1169 VBN O
genes P09445488A1169 NNS O
( P09445488A1169 ( O
BIR P09445488A1169 NNP I-UN
, P09445488A1169 , O
SUR1 P09445488A1169 NNP I-UN
) P09445488A1169 ) O
mapped P09445488A1169 VBD O
previously P09445488A1169 RB O
to P09445488A1169 TO O
this P09445488A1169 DT O
region P09445488A1169 NN O
, P09445488A1169 , O
and P09445488A1169 CC O
a P09445488A1169 DT O
previously P09445488A1169 RB O
characterized P09445488A1169 VBN O
but P09445488A1169 CC O
unmapped P09445488A1169 JJ O
gene P09445488A1169 NN I-UN
NEFA P09445488A1169 NNP I-UN
( P09445488A1169 ( O
DNA P09445488A1169 NNP I-UN
binding P09445488A1169 VBG I-UN
/ P09445488A1169 JJ I-UN
EF P09445488A1169 NNP I-UN
hand P09445488A1169 NN I-UN
/ P09445488A1169 NNP I-UN
acidic P09445488A1169 IN I-UN
amino-acid-rich P09445488A1169 JJ I-UN
) P09445488A1169 ) O
. P09445488A1169 . O
. . O O

This P07829519A1251 DT O
utilization P07829519A1251 NN O
of P07829519A1251 IN O
an P07829519A1251 DT O
intronic P07829519A1251 JJ O
polyadenylation P07829519A1251 NN O
site P07829519A1251 NN O
without P07829519A1251 IN O
alternative P07829519A1251 JJ O
exon P07829519A1251 NN O
usage P07829519A1251 NN O
is P07829519A1251 VBZ O
comparable P07829519A1251 JJ O
to P07829519A1251 TO O
the P07829519A1251 DT O
mechanism P07829519A1251 NN O
whereby P07829519A1251 WRB O
both P07829519A1251 DT O
secreted P07829519A1251 VBN O
and P07829519A1251 CC O
membrane-bound P07829519A1251 JJ O
forms P07829519A1251 NNS O
of P07829519A1251 IN O
the P07829519A1251 DT O
immunoglobulin P07829519A1251 NN I-UN
mu P07829519A1251 NN I-UN
heavy P07829519A1251 NN I-UN
chain P07829519A1251 NN I-UN
are P07829519A1251 VBP O
made P07829519A1251 VBN O
from P07829519A1251 IN O
a P07829519A1251 DT O
single P07829519A1251 JJ O
genetic P07829519A1251 JJ O
locus P07829519A1251 NN O
. P07829519A1251 . O
. . O O

A P02157764A1115 DT O
rabbit P02157764A1115 NN O
antiserum P02157764A1115 NN O
was P02157764A1115 VBD O
raised P02157764A1115 VBN O
against P02157764A1115 IN O
a P02157764A1115 DT O
synthetic P02157764A1115 JJ O
peptide P02157764A1115 NN O
corresponding P02157764A1115 VBG O
to P02157764A1115 TO O
a P02157764A1115 DT O
hydrophilic P02157764A1115 JJ O
portion P02157764A1115 NN O
of P02157764A1115 IN O
the P02157764A1115 DT O
translated P02157764A1115 JJ O
murine P02157764A1115 NN O
cDNA P02157764A1115 NN O
sequence P02157764A1115 NN O
. P02157764A1115 . O
. . O O

Thus P11071651A1308 RB O
, P11071651A1308 , O
blocks P11071651A1308 NNS O
in P11071651A1308 IN O
the P11071651A1308 DT O
RARalpha-specific P11071651A1308 JJ O
pathway P11071651A1308 NN O
of P11071651A1308 IN O
retinoid-induced P11071651A1308 JJ O
differentiation P11071651A1308 NN O
may P11071651A1308 MD O
be P11071651A1308 VB O
bypassed P11071651A1308 VBN O
during P11071651A1308 IN O
retinoid P11071651A1308 JJ O
induction P11071651A1308 NN O
of P11071651A1308 IN O
FR-beta P11071651A1308 NNP I-UN
expression P11071651A1308 NN O
. P11071651A1308 . O
. . O O

It P09343433A0000 PRP O
has P09343433A0000 VBZ O
been P09343433A0000 VBN O
previously P09343433A0000 RB O
shown P09343433A0000 VBN O
that P09343433A0000 IN O
genes P09343433A0000 NNS O
transcribed P09343433A0000 VBN O
by P09343433A0000 IN O
RNA P09343433A0000 NNP I-UN
polymerase P09343433A0000 NN I-UN
II P09343433A0000 NNP I-UN
( P09343433A0000 ( O
RNAP P09343433A0000 NNP I-UN
II P09343433A0000 NNP I-UN
) P09343433A0000 ) O
are P09343433A0000 VBP O
subject P09343433A0000 JJ O
to P09343433A0000 TO O
position P09343433A0000 NN O
effect P09343433A0000 NN O
variegation P09343433A0000 NN O
when P09343433A0000 WRB O
located P09343433A0000 VBN O
near P09343433A0000 IN O
yeast P09343433A0000 NN O
telomeres P09343433A0000 NNS O
. P09343433A0000 . O
. . O O

We P09159111A0437 PRP O
have P09159111A0437 VBP O
tested P09159111A0437 VBN O
this P09159111A0437 DT O
proposal P09159111A0437 NN O
by P09159111A0437 IN O
carrying P09159111A0437 VBG O
out P09159111A0437 RP O
circular P09159111A0437 JJ O
dichroism P09159111A0437 NN O
( P09159111A0437 ( O
CD P09159111A0437 NN O
) P09159111A0437 ) O
and P09159111A0437 CC O
NMR P09159111A0437 NNP O
experiments P09159111A0437 NNS O
on P09159111A0437 IN O
the P09159111A0437 DT O
Skn P09159111A0437 NNP I-UN
domain P09159111A0437 NN I-UN
and P09159111A0437 CC O
five P09159111A0437 CD O
truncated P09159111A0437 JJ O
proteins P09159111A0437 NNS O
. P09159111A0437 . O
. . O O

Sak P10607900T0000 NNP I-UN
kinase P10607900T0000 VBD I-UN
gene P10607900T0000 NN O
structure P10607900T0000 NN O
and P10607900T0000 CC O
transcriptional P10607900T0000 JJ O
regulation P10607900T0000 NN O
. P10607900T0000 . O
. . O O

Weaned P03612316A0102 VBN O
rats P03612316A0102 NNS O
were P03612316A0102 VBD O
fed P03612316A0102 VBN O
a P03612316A0102 DT O
normal P03612316A0102 JJ O
diet P03612316A0102 NN O
or P03612316A0102 CC O
a P03612316A0102 DT O
low-protein P03612316A0102 JJ O
, P03612316A0102 , O
low-energy P03612316A0102 JJ O
diet P03612316A0102 NN O
, P03612316A0102 , O
and P03612316A0102 CC O
injected P03612316A0102 VBD O
with P03612316A0102 IN O
saline P03612316A0102 NN O
or P03612316A0102 CC O
thyroxine P03612316A0102 NN O
( P03612316A0102 ( O
5 P03612316A0102 CD O
micrograms P03612316A0102 NNS O
/ P03612316A0102 VBP O
100 P03612316A0102 CD O
g P03612316A0102 JJ O
BW P03612316A0102 NNP O
) P03612316A0102 ) O
for P03612316A0102 IN O
22 P03612316A0102 CD O
days P03612316A0102 NNS O
. P03612316A0102 . O
. . O O

The P10037378A0176 DT O
dorsal P10037378A0176 JJ O
nerves P10037378A0176 NNS O
of P10037378A0176 IN O
the P10037378A0176 DT O
penis P10037378A0176 NN O
were P10037378A0176 VBD O
anesthetized P10037378A0176 VBN O
bilaterally P10037378A0176 RB O
with P10037378A0176 IN O
lidocaine P10037378A0176 NN O
. P10037378A0176 . O
. . O O

The P06602600A0582 DT O
Sarns P06602600A0582 NNP O
51F P06602600A0582 CD O
cavoatrial P06602600A0582 JJ O
cannula P06602600A0582 NN O
decompressed P06602600A0582 VBD O
the P06602600A0582 DT O
venous P06602600A0582 JJ O
system P06602600A0582 NN O
as P06602600A0582 RB O
efficiently P06602600A0582 RB O
as P06602600A0582 IN O
the P06602600A0582 DT O
double P06602600A0582 JJ O
caval P06602600A0582 NN O
cannulas P06602600A0582 NNS O
. P06602600A0582 . O
. . O O

On P08971721A1314 IN O
the P08971721A1314 DT O
basis P08971721A1314 NN O
of P08971721A1314 IN O
serological P08971721A1314 JJ O
studies P08971721A1314 NNS O
, P08971721A1314 , O
the P08971721A1314 DT O
highly P08971721A1314 RB O
conserved P08971721A1314 VBN O
A P08971721A1314 NNP O
domain P08971721A1314 NN O
of P08971721A1314 IN O
HspA P08971721A1314 NNP I-UN
was P08971721A1314 VBD O
found P08971721A1314 VBN O
to P08971721A1314 TO O
be P08971721A1314 VB O
the P08971721A1314 DT O
immunodominant P08971721A1314 JJ O
domain P08971721A1314 NN O
. P08971721A1314 . O
. . O O

The P01339468A0272 DT O
ORF1 P01339468A0272 NNP O
protein P01339468A0272 NN O
was P01339468A0272 VBD O
found P01339468A0272 VBN O
to P01339468A0272 TO O
be P01339468A0272 VB O
highly P01339468A0272 RB O
homologous P01339468A0272 JJ O
to P01339468A0272 TO O
the P01339468A0272 DT O
putative P01339468A0272 JJ O
potexvirus P01339468A0272 NN I-UN
RNA P01339468A0272 NNP I-UN
replicases P01339468A0272 VBZ I-UN
; P01339468A0272 : O
ORF2 P01339468A0272 NNP O
, P01339468A0272 , O
-3 P01339468A0272 NNP O
, P01339468A0272 , O
-5 P01339468A0272 NNP O
and P01339468A0272 CC O
-6 P01339468A0272 NNP O
proteins P01339468A0272 NNS O
also P01339468A0272 RB O
have P01339468A0272 VBP O
analogues P01339468A0272 NNS O
among P01339468A0272 IN O
the P01339468A0272 DT O
potex- P01339468A0272 NN O
and P01339468A0272 CC O
/ P01339468A0272 NN O
or P01339468A0272 CC O
carlavirus-encoded P01339468A0272 JJ O
proteins P01339468A0272 NNS O
. P01339468A0272 . O
. . O O

A P09618475A0747 DT O
large P09618475A0747 JJ O
deletion P09618475A0747 NN O
in P09618475A0747 IN O
the P09618475A0747 DT O
CTD-binding P09618475A0747 NNP I-UN
motif P09618475A0747 NN I-UN
blocks P09618475A0747 NNS O
down-regulation P09618475A0747 NN O
but P09618475A0747 CC O
does P09618475A0747 VBZ O
not P09618475A0747 RB O
affect P09618475A0747 VB O
the P09618475A0747 DT O
essential P09618475A0747 JJ O
function P09618475A0747 NN O
of P09618475A0747 IN O
Nrd1 P09618475A0747 NNP I-UN
. P09618475A0747 . O
. . O O

Supraventricular P04041346T0000 JJ O
arrhythmias P04041346T0000 NN O
-- P04041346T0000 : O
digoxin P04041346T0000 NN O
and P04041346T0000 CC O
quinidine P04041346T0000 NN O
revisited P04041346T0000 VBN O
. P04041346T0000 . O
. . O O

However P03732252A0556 RB O
, P03732252A0556 , O
further P03732252A0556 JJ O
analyses P03732252A0556 NNS O
of P03732252A0556 IN O
the P03732252A0556 DT O
data P03732252A0556 NNS O
indicate P03732252A0556 VBP O
that P03732252A0556 IN O
increasing P03732252A0556 VBG O
VO2 P03732252A0556 NNP O
AT P03732252A0556 NNP O
( P03732252A0556 ( O
r P03732252A0556 NN O
= P03732252A0556 NNP O
-0.63 P03732252A0556 NNP O
, P03732252A0556 , O
P P03732252A0556 NNP O
less P03732252A0556 JJR O
than P03732252A0556 IN O
0.05 P03732252A0556 CD O
) P03732252A0556 ) O
rather P03732252A0556 RB O
than P03732252A0556 IN O
VO2max P03732252A0556 NNP O
( P03732252A0556 ( O
r P03732252A0556 NN O
= P03732252A0556 NNP O
-0.15 P03732252A0556 NNP O
) P03732252A0556 ) O
could P03732252A0556 MD O
result P03732252A0556 VB O
in P03732252A0556 IN O
improving P03732252A0556 VBG O
the P03732252A0556 DT O
10,000 P03732252A0556 CD O
m P03732252A0556 NN O
race P03732252A0556 NN O
performance P03732252A0556 NN O
to P03732252A0556 TO O
a P03732252A0556 DT O
larger P03732252A0556 JJR O
extent P03732252A0556 NN O
, P03732252A0556 , O
and P03732252A0556 CC O
that P03732252A0556 IN O
the P03732252A0556 DT O
absolute P03732252A0556 JJ O
amount P03732252A0556 NN O
of P03732252A0556 IN O
change P03732252A0556 NN O
( P03732252A0556 ( O
delta P03732252A0556 NN O
) P03732252A0556 ) O
in P03732252A0556 IN O
the P03732252A0556 DT O
10,000 P03732252A0556 CD O
m P03732252A0556 NNS O
run P03732252A0556 JJ O
time P03732252A0556 NN O
is P03732252A0556 VBZ O
best P03732252A0556 RB O
accounted P03732252A0556 VBN O
for P03732252A0556 IN O
by P03732252A0556 IN O
a P03732252A0556 DT O
combination P03732252A0556 NN O
of P03732252A0556 IN O
delta P03732252A0556 JJ O
VO2 P03732252A0556 NNP O
AT P03732252A0556 NNP O
and P03732252A0556 CC O
delta P03732252A0556 $ O
5,000 P03732252A0556 CD O
m P03732252A0556 NN O
run P03732252A0556 NN O
time P03732252A0556 NN O
. P03732252A0556 . O
. . O O

Finger P08464056A0000 NNP I-UN
associated P08464056A0000 VBD I-UN
box-zinc P08464056A0000 JJ I-UN
finger P08464056A0000 NN I-UN
proteins P08464056A0000 NNS I-UN
( P08464056A0000 ( O
FAX-ZFPs P08464056A0000 NNP I-UN
) P08464056A0000 ) O
constitute P08464056A0000 VBP O
a P08464056A0000 DT O
subfamily P08464056A0000 NN O
of P08464056A0000 IN O
the P08464056A0000 DT O
many P08464056A0000 JJ O
C2H2 P08464056A0000 NNP I-UN
type P08464056A0000 NN I-UN
ZFPs P08464056A0000 NNP I-UN
in P08464056A0000 IN O
Xenopus P08464056A0000 NNP O
laevis P08464056A0000 NN O
. P08464056A0000 . O
. . O O

We P10698974A0951 PRP O
have P10698974A0951 VBP O
mapped P10698974A0951 VBN O
the P10698974A0951 DT O
human P10698974A0951 JJ I-UN
STAG3 P10698974A0951 NNP I-UN
gene P10698974A0951 NN I-UN
to P10698974A0951 TO O
the P10698974A0951 DT O
7q22 P10698974A0951 CD O
region P10698974A0951 NN O
of P10698974A0951 IN O
chromosome P10698974A0951 NN O
7 P10698974A0951 CD O
; P10698974A0951 : O
six P10698974A0951 CD O
human P10698974A0951 JJ I-UN
STAG3-related P10698974A0951 JJ I-UN
genes P10698974A0951 NNS I-UN
have P10698974A0951 VBP O
also P10698974A0951 RB O
been P10698974A0951 VBN O
mapped P10698974A0951 VBN O
: P10698974A0951 : O
two P10698974A0951 CD O
at P10698974A0951 IN O
7q22 P10698974A0951 CD O
near P10698974A0951 IN O
the P10698974A0951 DT O
functional P10698974A0951 JJ O
gene P10698974A0951 NN O
, P10698974A0951 , O
one P10698974A0951 CD O
at P10698974A0951 IN O
7q11.22 P10698974A0951 CD O
, P10698974A0951 , O
and P10698974A0951 CC O
three P10698974A0951 CD O
at P10698974A0951 IN O
7q11.23 P10698974A0951 CD O
, P10698974A0951 , O
two P10698974A0951 CD O
of P10698974A0951 IN O
them P10698974A0951 PRP O
flanking P10698974A0951 VBG O
the P10698974A0951 DT O
breakpoints P10698974A0951 NNS O
commonly P10698974A0951 RB O
associated P10698974A0951 VBN O
with P10698974A0951 IN O
the P10698974A0951 DT O
Williams-Beuren P10698974A0951 JJ I-UN
syndrome P10698974A0951 NN I-UN
( P10698974A0951 ( I-UN
WBS P10698974A0951 NNP I-UN
) P10698974A0951 ) I-UN
deletion P10698974A0951 NN I-UN
. P10698974A0951 . O
. . O O

Cyclin P09111314A0970 NNP I-UN
D1 P09111314A0970 NNP I-UN
could P09111314A0970 MD O
not P09111314A0970 RB O
be P09111314A0970 VB O
displaced P09111314A0970 VBN O
from P09111314A0970 IN O
cdk4 P09111314A0970 NN I-UN
in P09111314A0970 IN O
the P09111314A0970 DT O
resistant P09111314A0970 JJ O
184A1L5R P09111314A0970 CD O
cell P09111314A0970 NN O
lysates P09111314A0970 NNS O
. P09111314A0970 . O
. . O O

Oxfendazole P02934889A0558 NNP O
, P02934889A0558 , O
which P02934889A0558 WDT O
was P02934889A0558 VBD O
active P02934889A0558 JJ O
for P02934889A0558 IN O
the P02934889A0558 DT O
shortest P02934889A0558 JJ O
time P02934889A0558 NN O
( P02934889A0558 ( O
about P02934889A0558 IN O
65 P02934889A0558 CD O
days P02934889A0558 NNS O
) P02934889A0558 ) O
from P02934889A0558 IN O
the P02934889A0558 DT O
start P02934889A0558 NN O
of P02934889A0558 IN O
grazing P02934889A0558 NN O
( P02934889A0558 ( O
May P02934889A0558 NNP O
1 P02934889A0558 CD O
) P02934889A0558 ) O
, P02934889A0558 , O
produced P02934889A0558 VBD O
a P02934889A0558 DT O
78.1 P02934889A0558 CD O
per P02934889A0558 IN O
cent P02934889A0558 NN O
reduction P02934889A0558 NN O
in P02934889A0558 IN O
Ostertagia P02934889A0558 NNP O
species P02934889A0558 NNS O
and P02934889A0558 CC O
an P02934889A0558 DT O
84.4 P02934889A0558 CD O
per P02934889A0558 IN O
cent P02934889A0558 NN O
reduction P02934889A0558 NN O
in P02934889A0558 IN O
D P02934889A0558 NNP O
viviparus P02934889A0558 NN O
. P02934889A0558 . O
. . O O

Four P01498607A0000 CD O
short P01498607A0000 JJ O
nucleotide P01498607A0000 NN O
sequences P01498607A0000 NNS O
( P01498607A0000 ( O
boxes P01498607A0000 NNS O
I P01498607A0000 PRP O
to P01498607A0000 TO O
IV P01498607A0000 NNP O
) P01498607A0000 ) O
contribute P01498607A0000 NN O
to P01498607A0000 TO O
the P01498607A0000 DT O
light P01498607A0000 JJ O
responsiveness P01498607A0000 NN O
of P01498607A0000 IN O
the P01498607A0000 DT O
parsley P01498607A0000 NN I-UN
chalcone P01498607A0000 NN I-UN
synthase P01498607A0000 NN I-UN
promoter P01498607A0000 NN I-UN
. P01498607A0000 . O
. . O O

Removal P07852361A0868 NN O
of P07852361A0868 IN O
PDMP P07852361A0868 NNP O
from P07852361A0868 IN O
the P07852361A0868 DT O
cell P07852361A0868 NN O
medium P07852361A0868 NN O
resulted P07852361A0868 VBD O
in P07852361A0868 IN O
reversal P07852361A0868 NN O
of P07852361A0868 IN O
the P07852361A0868 DT O
cell P07852361A0868 NN O
cycle P07852361A0868 NN O
changes P07852361A0868 NNS O
, P07852361A0868 , O
with P07852361A0868 IN O
cells P07852361A0868 NNS O
re-entering P07852361A0868 VBG O
the P07852361A0868 DT O
S P07852361A0868 NNP O
phase P07852361A0868 NN O
. P07852361A0868 . O
. . O O

Mutational P08208247T0030 JJ O
analysis P08208247T0030 NN O
of P08208247T0030 IN O
chromosomal P08208247T0030 JJ O
segment P08208247T0030 NN O
64AB P08208247T0030 CD O
, P08208247T0030 , O
a P08208247T0030 DT O
region P08208247T0030 NN O
containing P08208247T0030 VBG O
the P08208247T0030 DT O
glutamic P08208247T0030 JJ I-UN
acid P08208247T0030 NN I-UN
decarboxylase P08208247T0030 NN I-UN
gene P08208247T0030 NN I-UN
. P08208247T0030 . O
. . O O

Eleven P06373855A0000 RB O
biopsy P06373855A0000 NN O
specimens P06373855A0000 NNS O
( P06373855A0000 ( O
five P06373855A0000 CD O
papules P06373855A0000 NNS O
and P06373855A0000 CC O
six P06373855A0000 CD O
dusky P06373855A0000 NN O
or P06373855A0000 CC O
crusted P06373855A0000 VBN O
lesions P06373855A0000 NNS O
) P06373855A0000 ) O
from P06373855A0000 IN O
four P06373855A0000 CD O
patients P06373855A0000 NNS O
with P06373855A0000 IN O
pityriasis P06373855A0000 NN O
lichenoides P06373855A0000 NNS O
et P06373855A0000 VBP O
varioliformis P06373855A0000 JJ O
acuta P06373855A0000 NN O
( P06373855A0000 ( O
PLEVA P06373855A0000 NNP O
) P06373855A0000 ) O
were P06373855A0000 VBD O
studied P06373855A0000 VBN O
by P06373855A0000 IN O
direct P06373855A0000 JJ O
immunofluorescence P06373855A0000 NN O
and P06373855A0000 CC O
immunoperoxidase P06373855A0000 NN I-UN
technics P06373855A0000 NNS O
. P06373855A0000 . O
. . O O

1 P07126413A0000 CD O
A P07126413A0000 NNP O
colonic P07126413A0000 JJ O
delivery P07126413A0000 NN O
system P07126413A0000 NN O
is P07126413A0000 VBZ O
described P07126413A0000 VBN O
to P07126413A0000 TO O
deliver P07126413A0000 VB O
orally P07126413A0000 RB O
ingested P07126413A0000 VBN O
drugs P07126413A0000 NNS O
to P07126413A0000 TO O
the P07126413A0000 DT O
colon P07126413A0000 NN O
and P07126413A0000 CC O
release P07126413A0000 VB O
them P07126413A0000 PRP O
at P07126413A0000 IN O
that P07126413A0000 DT O
site P07126413A0000 NN O
by P07126413A0000 IN O
coating P07126413A0000 VBG O
with P07126413A0000 IN O
an P07126413A0000 DT O
acrylic P07126413A0000 NN O
based P07126413A0000 VBN O
resin P07126413A0000 NN O
( P07126413A0000 ( O
Eudragit P07126413A0000 NNP O
S P07126413A0000 NNP O
) P07126413A0000 ) O
. P07126413A0000 . O
. . O O

When P03749226A0506 WRB O
phencyclidine P03749226A0506 NN O
was P03749226A0506 VBD O
administered P03749226A0506 VBN O
alone P03749226A0506 RB O
, P03749226A0506 , O
overall P03749226A0506 JJ O
response P03749226A0506 NN O
rate P03749226A0506 NN O
decreased P03749226A0506 VBN O
and P03749226A0506 CC O
percent P03749226A0506 JJ O
errors P03749226A0506 NNS O
increased P03749226A0506 VBD O
with P03749226A0506 IN O
increasing P03749226A0506 VBG O
doses P03749226A0506 NNS O
. P03749226A0506 . O
. . O O

Consequently P09596536A0219 RB O
, P09596536A0219 , O
it P09596536A0219 PRP O
is P09596536A0219 VBZ O
not P09596536A0219 RB O
known P09596536A0219 VBN O
how P09596536A0219 WRB O
knee P09596536A0219 JJ O
loading P09596536A0219 NN O
changes P09596536A0219 NNS O
following P09596536A0219 VBG O
ACL P09596536A0219 NNP O
transection P09596536A0219 NN O
, P09596536A0219 , O
and P09596536A0219 CC O
how P09596536A0219 WRB O
it P09596536A0219 PRP O
contributes P09596536A0219 VBZ O
to P09596536A0219 TO O
cartilage P09596536A0219 VB O
degeneration P09596536A0219 NN O
. P09596536A0219 . O
. . O O

Both P07016141A0238 DT O
resting P07016141A0238 VBG O
blood P07016141A0238 NN O
flow P07016141A0238 NN O
( P07016141A0238 ( O
RBF P07016141A0238 NNP O
) P07016141A0238 ) O
and P07016141A0238 CC O
maximal P07016141A0238 JJ O
blood P07016141A0238 NN O
flow P07016141A0238 NN O
( P07016141A0238 ( O
NBF P07016141A0238 NNP O
) P07016141A0238 ) O
were P07016141A0238 VBD O
studied P07016141A0238 VBN O
by P07016141A0238 IN O
Xenon P07016141A0238 NNP O
133 P07016141A0238 CD O
clearance P07016141A0238 NN O
. P07016141A0238 . O
. . O O

The P08375651T0000 DT O
Drosophila P08375651T0000 NNP O
clathrin P08375651T0000 NN I-UN
heavy P08375651T0000 NN I-UN
chain P08375651T0000 NN I-UN
gene P08375651T0000 NN O
: P08375651T0000 : O
clathrin P08375651T0000 JJ I-UN
function P08375651T0000 NN O
is P08375651T0000 VBZ O
essential P08375651T0000 JJ O
in P08375651T0000 IN O
a P08375651T0000 DT O
multicellular P08375651T0000 JJ O
organism P08375651T0000 NN O
. P08375651T0000 . O
. . O O

Increased P07608649A1429 VBN O
blood P07608649A1429 NN O
pressure P07608649A1429 NN O
during P07608649A1429 IN O
CyA P07608649A1429 NNP O
treatment P07608649A1429 NN O
was P07608649A1429 VBD O
independent P07608649A1429 JJ O
of P07608649A1429 IN O
circulating P07608649A1429 VBG O
ET-1 P07608649A1429 JJ I-UN
levels P07608649A1429 NNS O
. P07608649A1429 . O
. . O O

Two P02442837A0060 CD O
of P02442837A0060 IN O
the P02442837A0060 DT O
three P02442837A0060 CD O
groups P02442837A0060 NNS O
were P02442837A0060 VBD O
administered P02442837A0060 VBN O
dauricine P02442837A0060 NN O
, P02442837A0060 , O
as P02442837A0060 IN O
a P02442837A0060 DT O
new P02442837A0060 JJ O
calcium P02442837A0060 NN O
channel P02442837A0060 NN O
blocker P02442837A0060 NN O
, P02442837A0060 , O
and P02442837A0060 CC O
verapamil P02442837A0060 RB O
, P02442837A0060 , O
as P02442837A0060 IN O
a P02442837A0060 DT O
generally P02442837A0060 RB O
recognized P02442837A0060 VBN O
calcium P02442837A0060 NN O
channel P02442837A0060 NN O
blocker P02442837A0060 NN O
, P02442837A0060 , O
respectively P02442837A0060 RB O
, P02442837A0060 , O
from P02442837A0060 IN O
15 P02442837A0060 CD O
minutes P02442837A0060 NNS O
pre-bypass P02442837A0060 JJ O
to P02442837A0060 TO O
the P02442837A0060 DT O
end P02442837A0060 NN O
of P02442837A0060 IN O
the P02442837A0060 DT O
bypass P02442837A0060 NN O
procedure P02442837A0060 NN O
( P02442837A0060 ( O
a P02442837A0060 DT O
period P02442837A0060 NN O
of P02442837A0060 IN O
95 P02442837A0060 CD O
minutes P02442837A0060 NNS O
) P02442837A0060 ) O
. P02442837A0060 . O
. . O O

Posttranslational P09566871T0000 NNP O
regulation P09566871T0000 NN O
of P09566871T0000 IN O
Ty1 P09566871T0000 NNP I-UN
retrotransposition P09566871T0000 NN O
by P09566871T0000 IN O
mitogen-activated P09566871T0000 JJ I-UN
protein P09566871T0000 NN I-UN
kinase P09566871T0000 NN I-UN
Fus3 P09566871T0000 NNP I-UN
. P09566871T0000 . O
. . O O

Taken P09731513A1090 VBN O
together P09731513A1090 RB O
, P09731513A1090 , O
these P09731513A1090 DT O
results P09731513A1090 NNS O
suggest P09731513A1090 VBP O
that P09731513A1090 IN O
the P09731513A1090 DT O
cooperation P09731513A1090 NN O
of P09731513A1090 IN O
transcription P09731513A1090 NN I-UN
factors P09731513A1090 NNS I-UN
NF-kappaB P09731513A1090 NNP I-UN
and P09731513A1090 CC O
AP-1 P09731513A1090 NNP I-UN
is P09731513A1090 VBZ O
essential P09731513A1090 JJ O
for P09731513A1090 IN O
transactivation P09731513A1090 NN O
of P09731513A1090 IN O
IL-8 P09731513A1090 NNP I-UN
gene P09731513A1090 NN I-UN
by P09731513A1090 IN O
HTLV-I P09731513A1090 NNP I-UN
Tax P09731513A1090 NNP I-UN
. P09731513A1090 . O
. . O O

None P08664347A0923 NN O
of P08664347A0923 IN O
the P08664347A0923 DT O
five P08664347A0923 CD O
proprotein P08664347A0923 NN O
processing P08664347A0923 NN O
proteases P08664347A0923 NNS O
tested P08664347A0923 VBN O
were P08664347A0923 VBD O
capable P08664347A0923 JJ O
of P08664347A0923 IN O
cleaving P08664347A0923 VBG O
human P08664347A0923 JJ I-UN
pro-LPH P08664347A0923 NN I-UN
, P08664347A0923 , O
strongly P08664347A0923 RB O
suggesting P08664347A0923 VBG O
that P08664347A0923 IN O
they P08664347A0923 PRP O
are P08664347A0923 VBP O
not P08664347A0923 RB O
involved P08664347A0923 VBN O
in P08664347A0923 IN O
the P08664347A0923 DT O
maturation P08664347A0923 NN O
of P08664347A0923 IN O
this P08664347A0923 DT O
enzyme P08664347A0923 NN O
. P08664347A0923 . O
. . O O

Germ-free P04068663A0452 JJ O
rabbits P04068663A0452 NNS O
given P04068663A0452 VBN O
mouse P04068663A0452 VBP O
CRF-flora P04068663A0452 JJ O
showed P04068663A0452 VBD O
values P04068663A0452 NNS O
quite P04068663A0452 RB O
different P04068663A0452 JJ O
from P04068663A0452 IN O
control P04068663A0452 NN O
animals P04068663A0452 NNS O
for P04068663A0452 IN O
most P04068663A0452 JJS O
parameters P04068663A0452 NNS O
, P04068663A0452 , O
indicating P04068663A0452 VBG O
unsuitability P04068663A0452 NN O
of P04068663A0452 IN O
mouse P04068663A0452 NN O
CRF P04068663A0452 NNP O
flora P04068663A0452 NN O
to P04068663A0452 TO O
'normalize P04068663A0452 VB O
' P04068663A0452 '' O
rabbits P04068663A0452 NNS O
. P04068663A0452 . O
. . O O

During P03035658A0355 IN O
pentobarbital P03035658A0355 JJ O
anesthesia P03035658A0355 NN O
, P03035658A0355 , O
the P03035658A0355 DT O
basal P03035658A0355 NN O
VO2 P03035658A0355 NNP O
was P03035658A0355 VBD O
5.26 P03035658A0355 CD O
ml P03035658A0355 NN O
/ P03035658A0355 NNP O
kg P03035658A0355 NNP O
/ P03035658A0355 NNP O
min P03035658A0355 NN O
and P03035658A0355 CC O
was P03035658A0355 VBD O
increased P03035658A0355 VBN O
by P03035658A0355 IN O
epinephrine P03035658A0355 NN O
in P03035658A0355 IN O
a P03035658A0355 DT O
dose P03035658A0355 JJ O
dependent P03035658A0355 JJ O
manner P03035658A0355 NN O
at P03035658A0355 IN O
plasma P03035658A0355 JJ O
concentrations P03035658A0355 NNS O
between P03035658A0355 IN O
3.9 P03035658A0355 CD O
ng P03035658A0355 JJ O
/ P03035658A0355 NN O
ml P03035658A0355 NN O
( P03035658A0355 ( O
VO2 P03035658A0355 NNP O
= P03035658A0355 VBZ O
5.68 P03035658A0355 CD O
ml P03035658A0355 NN O
/ P03035658A0355 NNP O
kg P03035658A0355 NNP O
/ P03035658A0355 NNP O
min P03035658A0355 NN O
) P03035658A0355 ) O
and P03035658A0355 CC O
36.5 P03035658A0355 CD O
ng P03035658A0355 JJ O
/ P03035658A0355 NN O
ml P03035658A0355 NN O
( P03035658A0355 ( O
VO2 P03035658A0355 NNP O
= P03035658A0355 VBZ O
6.47 P03035658A0355 CD O
ml P03035658A0355 NN O
/ P03035658A0355 NNP O
kg P03035658A0355 NNP O
/ P03035658A0355 NNP O
min P03035658A0355 NN O
) P03035658A0355 ) O
. P03035658A0355 . O
. . O O

To P10439040A0658 TO O
determine P10439040A0658 VB O
what P10439040A0658 WP O
role P10439040A0658 NN O
eIF4E P10439040A0658 NN I-UN
might P10439040A0658 MD O
play P10439040A0658 VB O
in P10439040A0658 IN O
c-myc P10439040A0658 JJ I-UN
expression P10439040A0658 NN O
, P10439040A0658 , O
the P10439040A0658 DT O
c-myc P10439040A0658 JJ I-UN
5 P10439040A0658 CD I-UN
' P10439040A0658 POS I-UN
untranslated P10439040A0658 JJ I-UN
region P10439040A0658 NN I-UN
( P10439040A0658 ( I-UN
UTR P10439040A0658 NNP I-UN
) P10439040A0658 ) I-UN
was P10439040A0658 VBD O
fused P10439040A0658 VBN O
in-frame P10439040A0658 NN O
to P10439040A0658 TO O
CAT P10439040A0658 NNP I-UN
reporters P10439040A0658 NNS I-UN
, P10439040A0658 , O
and P10439040A0658 CC O
several P10439040A0658 JJ O
more P10439040A0658 RBR O
derivative P10439040A0658 JJ O
constructs P10439040A0658 NNS O
were P10439040A0658 VBD O
made P10439040A0658 VBN O
. P10439040A0658 . O
. . O O

8 P10908822A0519 CD O
% P10908822A0519 NN O
( P10908822A0519 ( O
95 P10908822A0519 CD O
% P10908822A0519 NN O
CI P10908822A0519 NNP O
, P10908822A0519 , O
21.3-44.3 P10908822A0519 CD O
% P10908822A0519 NN O
) P10908822A0519 ) O
. P10908822A0519 . O
. . O O

To P08395681A0388 TO O
study P08395681A0388 VB O
the P08395681A0388 DT O
functional P08395681A0388 JJ O
differences P08395681A0388 NNS O
between P08395681A0388 IN O
cutaneous P08395681A0388 JJ O
HPV5 P08395681A0388 NNP O
and P08395681A0388 CC O
HPV8 P08395681A0388 NNP O
E7s P08395681A0388 NNP I-UN
and P08395681A0388 CC O
genital P08395681A0388 JJ I-UN
HPV16 P08395681A0388 NNP I-UN
E7 P08395681A0388 NNP I-UN
, P08395681A0388 , O
we P08395681A0388 PRP O
cloned P08395681A0388 VBD O
each P08395681A0388 DT O
of P08395681A0388 IN O
the P08395681A0388 DT O
E7 P08395681A0388 NNP I-UN
open P08395681A0388 JJ O
reading P08395681A0388 NN O
frames P08395681A0388 NNS O
and P08395681A0388 CC O
tested P08395681A0388 VBD O
their P08395681A0388 PRP$ O
immortalizing P08395681A0388 NN O
and P08395681A0388 CC O
transforming P08395681A0388 NN O
activities P08395681A0388 NNS O
, P08395681A0388 , O
the P08395681A0388 DT O
binding P08395681A0388 VBG O
ability P08395681A0388 NN O
of P08395681A0388 IN O
their P08395681A0388 PRP$ O
products P08395681A0388 NNS O
with P08395681A0388 IN O
retinoblastoma P08395681A0388 NN I-UN
protein P08395681A0388 NN I-UN
( P08395681A0388 ( O
RB P08395681A0388 NNP I-UN
) P08395681A0388 ) O
and P08395681A0388 CC O
their P08395681A0388 PRP$ O
complementation P08395681A0388 NN O
activity P08395681A0388 NN O
of P08395681A0388 IN O
a P08395681A0388 DT O
RB-nonbinding P08395681A0388 JJ I-UN
adenovirus P08395681A0388 NN I-UN
E1A P08395681A0388 NNP I-UN
mutant P08395681A0388 NN I-UN
. P08395681A0388 . O
. . O O

Mining P05819249T0000 VBG O
the P05819249T0000 DT O
diagnostic P05819249T0000 JJ O
iron P05819249T0000 NN O
ore P05819249T0000 NN O
. P05819249T0000 . O
. . O O

As P09223229A0565 IN O
with P09223229A0565 IN O
the P09223229A0565 DT O
murine P09223229A0565 NN I-UN
and P09223229A0565 CC I-UN
human P09223229A0565 JJ I-UN
mb-1 P09223229A0565 JJ I-UN
genes P09223229A0565 NNS I-UN
, P09223229A0565 , O
the P09223229A0565 DT O
5 P09223229A0565 CD O
' P09223229A0565 POS O
region P09223229A0565 NN O
of P09223229A0565 IN O
the P09223229A0565 DT O
bovine P09223229A0565 JJ I-UN
mb-1 P09223229A0565 JJ I-UN
gene P09223229A0565 NN I-UN
lacked P09223229A0565 VBD O
a P09223229A0565 DT O
TATA P09223229A0565 NNP O
box P09223229A0565 NN O
. P09223229A0565 . O
. . O O

Responses P11179400T0000 NNS O
of P11179400T0000 IN O
single-unit P11179400T0000 JJ O
carotid P11179400T0000 NN O
body P11179400T0000 NN O
chemoreceptors P11179400T0000 NNS O
in P11179400T0000 IN O
adult P11179400T0000 NN O
rats P11179400T0000 NNS O
. P11179400T0000 . O
. . O O

Electron P07306839T0001 NNP O
microscopic P07306839T0001 NN O
picture P07306839T0001 NN O
of P07306839T0001 IN O
the P07306839T0001 DT O
cerebral P07306839T0001 JJ O
cortex P07306839T0001 NN O
in P07306839T0001 IN O
rats P07306839T0001 NNS O
cooled P07306839T0001 VBD O
to P07306839T0001 TO O
22 P07306839T0001 CD O
degrees P07306839T0001 NNS O
C P07306839T0001 NNP O
. P07306839T0001 . O
. . O O

Ha-RasV12 P08808707A0631 NNP I-UN
and P08808707A0631 CC O
activated P08808707A0631 VBD O
proteins P08808707A0631 NNS O
in P08808707A0631 IN O
both P08808707A0631 DT O
the P08808707A0631 DT O
extra-cellular P08808707A0631 JJ I-UN
regulated P08808707A0631 JJ I-UN
kinase P08808707A0631 NN I-UN
( P08808707A0631 ( O
ERK P08808707A0631 NNP I-UN
) P08808707A0631 ) O
and P08808707A0631 CC O
the P08808707A0631 DT O
stress-activated P08808707A0631 JJ I-UN
protein P08808707A0631 NN I-UN
kinase P08808707A0631 NN I-UN
( P08808707A0631 ( O
SAPK P08808707A0631 NNP I-UN
) P08808707A0631 ) O
or P08808707A0631 CC O
Jun P08808707A0631 NNP I-UN
N-terminal P08808707A0631 JJ I-UN
kinase P08808707A0631 NN I-UN
( P08808707A0631 ( O
JNK P08808707A0631 NNP I-UN
) P08808707A0631 ) O
cascades P08808707A0631 VBZ O
independently P08808707A0631 RB O
stimulated P08808707A0631 VBN O
PEA3-mediated P08808707A0631 JJ O
gene P08808707A0631 NN O
expression P08808707A0631 NN O
. P08808707A0631 . O
. . O O

We P09545638A0330a PRP O
recently P09545638A0330a RB O
characterized P09545638A0330a VBD O
a P09545638A0330a DT O
single P09545638A0330a JJ O
yeast P09545638A0330a NN I-UN
hnRNP P09545638A0330a NN I-UN
methyltransferase P09545638A0330a NN I-UN
( P09545638A0330a ( O
HMT1 P09545638A0330a NNP I-UN
) P09545638A0330a ) O
. P09545638A0330a . O
. . O O

The P08657150A1049 DT O
role P08657150A1049 NN O
of P08657150A1049 IN O
negative P08657150A1049 JJ O
regulators P08657150A1049 NNS O
such P08657150A1049 JJ O
as P08657150A1049 IN O
NCE3 P08657150A1049 NNP I-UN
, P08657150A1049 , O
as P08657150A1049 RB O
well P08657150A1049 RB O
as P08657150A1049 IN O
the P08657150A1049 DT O
previously P08657150A1049 RB O
described P08657150A1049 VBN O
SIN5 P08657150A1049 NNP I-UN
gene P08657150A1049 NN I-UN
, P08657150A1049 , O
in P08657150A1049 IN O
determining P08657150A1049 VBG O
the P08657150A1049 DT O
promoter P08657150A1049 NN O
specificity P08657150A1049 NN O
of P08657150A1049 IN O
homologous P08657150A1049 JJ O
activators P08657150A1049 NNS O
is P08657150A1049 VBZ O
discussed P08657150A1049 VBN O
. P08657150A1049 . O
. . O O

Northern P08893822A0560 NNP O
analysis P08893822A0560 NN O
of P08893822A0560 IN O
the P08893822A0560 DT O
3.1-kb P08893822A0560 JJ I-UN
PWP2H P08893822A0560 NNP I-UN
cDNA P08893822A0560 NN I-UN
revealed P08893822A0560 VBD O
that P08893822A0560 IN O
a P08893822A0560 DT O
3.3-kb P08893822A0560 JJ O
major P08893822A0560 JJ O
transcript P08893822A0560 NN O
is P08893822A0560 VBZ O
ubiquitously P08893822A0560 RB O
expressed P08893822A0560 VBN O
in P08893822A0560 IN O
human P08893822A0560 JJ O
adult P08893822A0560 NN O
tissues P08893822A0560 NNS O
. P08893822A0560 . O
. . O O

Specifically P02600306A0140 RB O
, P02600306A0140 , O
they P02600306A0140 PRP O
were P02600306A0140 VBD O
performed P02600306A0140 VBN O
to P02600306A0140 TO O
determine P02600306A0140 VB O
whether P02600306A0140 IN O
detection P02600306A0140 NN O
of P02600306A0140 IN O
envelope P02600306A0140 NN O
phase P02600306A0140 NN O
disparity P02600306A0140 NN O
was P02600306A0140 VBD O
consistent P02600306A0140 JJ O
with P02600306A0140 IN O
processing P02600306A0140 NN O
within P02600306A0140 IN O
a P02600306A0140 DT O
single P02600306A0140 JJ O
channel P02600306A0140 NN O
in P02600306A0140 IN O
which P02600306A0140 WDT O
the P02600306A0140 DT O
AM P02600306A0140 NNP O
tones P02600306A0140 NNS O
were P02600306A0140 VBD O
simply P02600306A0140 RB O
added P02600306A0140 VBN O
. P02600306A0140 . O
. . O O

In P03149774A0173 IN O
the P03149774A0173 DT O
IA P03149774A0173 NNP O
task P03149774A0173 NN O
, P03149774A0173 , O
post-training P03149774A0173 JJ O
intraperitoneal P03149774A0173 JJ O
injections P03149774A0173 NNS O
of P03149774A0173 IN O
picrotoxin P03149774A0173 NN O
and P03149774A0173 CC O
bicuculline P03149774A0173 NN O
induced P03149774A0173 VBD O
a P03149774A0173 DT O
dose-dependent P03149774A0173 JJ O
enhancement P03149774A0173 NN O
of P03149774A0173 IN O
retention P03149774A0173 NN O
measured P03149774A0173 VBD O
24 P03149774A0173 CD O
h P03149774A0173 NN O
after P03149774A0173 IN O
the P03149774A0173 DT O
training P03149774A0173 NN O
, P03149774A0173 , O
while P03149774A0173 IN O
retention P03149774A0173 NN O
was P03149774A0173 VBD O
not P03149774A0173 RB O
affected P03149774A0173 VBN O
by P03149774A0173 IN O
bicuculline P03149774A0173 NN O
methiodide P03149774A0173 NN O
( P03149774A0173 ( O
a P03149774A0173 DT O
GABA P03149774A0173 NNP I-UN
receptor P03149774A0173 NN I-UN
antagonist P03149774A0173 NN O
that P03149774A0173 WDT O
does P03149774A0173 VBZ O
not P03149774A0173 RB O
readily P03149774A0173 RB O
cross P03149774A0173 VB O
the P03149774A0173 DT O
blood-brain P03149774A0173 JJ O
barrier P03149774A0173 NN O
) P03149774A0173 ) O
. P03149774A0173 . O
. . O O

METHODS P10679649A0311 NN O
: P10679649A0311 : O
TBN P10679649A0311 NN O
measurements P10679649A0311 NNS O
were P10679649A0311 VBD O
performed P10679649A0311 VBN O
in P10679649A0311 IN O
31 P10679649A0311 CD O
female P10679649A0311 JJ O
outpatients P10679649A0311 NNS O
with P10679649A0311 IN O
breast P10679649A0311 NN O
carcinoma P10679649A0311 NN O
who P10679649A0311 WP O
were P10679649A0311 VBD O
undergoing P10679649A0311 VBG O
standard P10679649A0311 JJ O
cyclophosphamide P10679649A0311 NN O
, P10679649A0311 , O
methotrexate P10679649A0311 NN O
, P10679649A0311 , O
and P10679649A0311 CC O
5-fluorouracil P10679649A0311 JJ O
( P10679649A0311 ( O
CMF P10679649A0311 NNP O
) P10679649A0311 ) O
-based P10679649A0311 VBD O
chemotherapy P10679649A0311 NN O
( P10679649A0311 ( O
median P10679649A0311 JJ O
age P10679649A0311 NN O
, P10679649A0311 , O
48 P10679649A0311 CD O
years P10679649A0311 NNS O
; P10679649A0311 : O
range P10679649A0311 NN O
, P10679649A0311 , O
26- P10679649A0311 JJ O
77 P10679649A0311 CD O
years P10679649A0311 NNS O
) P10679649A0311 ) O
. P10679649A0311 . O
. . O O

Histological P03066208A0310 JJ O
examination P03066208A0310 NN O
revealed P03066208A0310 VBD O
a P03066208A0310 DT O
small P03066208A0310 JJ O
simple P03066208A0310 JJ O
renal P03066208A0310 JJ O
cyst P03066208A0310 NN O
associated P03066208A0310 VBN O
with P03066208A0310 IN O
renal P03066208A0310 JJ O
cell P03066208A0310 NN O
carcinoma P03066208A0310 NN O
. P03066208A0310 . O
. . O O

Differential P06191243T0000 JJ O
drawing P06191243T0000 VBG O
size P06191243T0000 NN O
associated P06191243T0000 VBN O
with P06191243T0000 IN O
unilateral P06191243T0000 JJ O
brain P06191243T0000 NN O
damage P06191243T0000 NN O
. P06191243T0000 . O
. . O O

Since P00885562A0281 IN O
GAGs P00885562A0281 NNP O
are P00885562A0281 VBP O
the P00885562A0281 DT O
components P00885562A0281 NNS O
of P00885562A0281 IN O
cartilage P00885562A0281 NN O
matrix P00885562A0281 NN O
, P00885562A0281 , O
the P00885562A0281 DT O
depletion P00885562A0281 NN O
of P00885562A0281 IN O
which P00885562A0281 WDT O
is P00885562A0281 VBZ O
associated P00885562A0281 VBN O
with P00885562A0281 IN O
osteoarthrosis P00885562A0281 NN O
, P00885562A0281 , O
a P00885562A0281 DT O
method P00885562A0281 NN O
for P00885562A0281 IN O
measuring P00885562A0281 VBG O
sulphated P00885562A0281 VBN O
GAG P00885562A0281 NNP O
synthesis P00885562A0281 NN O
in P00885562A0281 IN O
culture P00885562A0281 NN O
has P00885562A0281 VBZ O
been P00885562A0281 VBN O
investigated P00885562A0281 VBN O
. P00885562A0281 . O
. . O O

The P06208477A0000 DT O
construction P06208477A0000 NN O
of P06208477A0000 IN O
a P06208477A0000 DT O
small P06208477A0000 JJ O
library P06208477A0000 NN O
of P06208477A0000 IN O
mouse P06208477A0000 NN O
repetitive P06208477A0000 JJ O
DNA P06208477A0000 NNP O
has P06208477A0000 VBZ O
been P06208477A0000 VBN O
previously P06208477A0000 RB O
reported P06208477A0000 VBN O
( P06208477A0000 ( O
Pietras P06208477A0000 NNP O
et P06208477A0000 RB O
al. P06208477A0000 RB O
, P06208477A0000 , O
Nucleic P06208477A0000 NNP O
Acids P06208477A0000 NNP O
Res P06208477A0000 NNP O
. P06208477A0000 . O
. . O O

We P01918070A0281 PRP O
examined P01918070A0281 VBD O
the P01918070A0281 DT O
binding P01918070A0281 NN O
of P01918070A0281 IN O
purified P01918070A0281 JJ O
T3 P01918070A0281 NNP I-UN
receptor P01918070A0281 NN I-UN
alpha P01918070A0281 NN I-UN
( P01918070A0281 ( O
T3R P01918070A0281 NNP I-UN
alpha P01918070A0281 RB I-UN
) P01918070A0281 ) O
, P01918070A0281 , O
overexpressed P01918070A0281 VBN O
in P01918070A0281 IN O
Escherichia P01918070A0281 NNP O
coli P01918070A0281 NN O
, P01918070A0281 , O
to P01918070A0281 TO O
wild-type P01918070A0281 NN O
and P01918070A0281 CC O
up P01918070A0281 RB O
and P01918070A0281 CC O
down P01918070A0281 IN O
mutations P01918070A0281 NNS O
of P01918070A0281 IN O
the P01918070A0281 DT O
rGH P01918070A0281 NN I-UN
T3RE P01918070A0281 NNP I-UN
to P01918070A0281 TO O
evaluate P01918070A0281 VB O
whether P01918070A0281 IN O
transcriptional P01918070A0281 JJ O
potency P01918070A0281 NN O
correlates P01918070A0281 VBZ O
with P01918070A0281 IN O
changes P01918070A0281 NNS O
in P01918070A0281 IN O
T3R P01918070A0281 NNP I-UN
binding P01918070A0281 NN O
. P01918070A0281 . O
. . O O

The P09236441A0639 DT O
remaining P09236441A0639 VBG O
80 P09236441A0639 CD O
patients P09236441A0639 NNS O
underwent P09236441A0639 JJ O
recordings P09236441A0639 NNS O
of P09236441A0639 IN O
ECG P09236441A0639 NNP O
, P09236441A0639 , O
beat-to-beat P09236441A0639 JJ O
arterial P09236441A0639 JJ O
oxygen P09236441A0639 NN O
saturation P09236441A0639 NN O
( P09236441A0639 ( O
SaO2 P09236441A0639 NNP O
) P09236441A0639 ) O
, P09236441A0639 , O
and P09236441A0639 CC O
respiration P09236441A0639 NN O
during P09236441A0639 IN O
both P09236441A0639 DT O
spontaneous P09236441A0639 JJ O
and P09236441A0639 CC O
controlled P09236441A0639 VBD O
breathing P09236441A0639 NN O
. P09236441A0639 . O
. . O O

Rats P02236276T0000 NNS O
with P02236276T0000 IN O
one P02236276T0000 CD O
olfactory P02236276T0000 NN O
bulb P02236276T0000 NN O
removed P02236276T0000 VBD O
and P02236276T0000 CC O
the P02236276T0000 DT O
contralateral P02236276T0000 JJ O
naris P02236276T0000 NNS O
closed P02236276T0000 VBD O
can P02236276T0000 MD O
detect P02236276T0000 VB O
odors P02236276T0000 NNS O
. P02236276T0000 . O
. . O O

By P07739566A1076 IN O
creating P07739566A1076 VBG O
Pax-6-BSAP P07739566A1076 NNP O
fusion P07739566A1076 NN O
proteins P07739566A1076 NNS O
, P07739566A1076 , O
we P07739566A1076 PRP O
were P07739566A1076 VBD O
able P07739566A1076 JJ O
to P07739566A1076 TO O
identify P07739566A1076 VB O
a P07739566A1076 DT O
short P07739566A1076 JJ O
amino P07739566A1076 NN O
acid P07739566A1076 JJ O
stretch P07739566A1076 NN O
in P07739566A1076 IN O
the P07739566A1076 DT O
N-terminal P07739566A1076 JJ O
part P07739566A1076 NN O
of P07739566A1076 IN O
the P07739566A1076 DT O
paired P07739566A1076 VBN I-UN
domain P07739566A1076 NN O
which P07739566A1076 WDT O
is P07739566A1076 VBZ O
responsible P07739566A1076 JJ O
for P07739566A1076 IN O
these P07739566A1076 DT O
differences P07739566A1076 NNS O
in P07739566A1076 IN O
DNA-binding P07739566A1076 NNP O
specificity P07739566A1076 NN O
. P07739566A1076 . O
. . O O

The P09294453A0949 DT O
ORF3 P09294453A0949 NNP O
mutant P09294453A0949 NN O
produced P09294453A0949 VBD O
reduced P09294453A0949 JJ O
levels P09294453A0949 NNS O
of P09294453A0949 IN O
tabtoxin P09294453A0949 NN I-UN
, P09294453A0949 , O
indicating P09294453A0949 VBG O
that P09294453A0949 IN O
ORF3 P09294453A0949 NNP O
may P09294453A0949 MD O
have P09294453A0949 VB O
a P09294453A0949 DT O
role P09294453A0949 NN O
in P09294453A0949 IN O
T P09294453A0949 NNP I-UN
beta P09294453A0949 NN I-UN
L P09294453A0949 NNP I-UN
biosynthesis P09294453A0949 NN O
. P09294453A0949 . O
. . O O

Clinical P08105994T0000 JJ O
aspects P08105994T0000 NNS O
of P08105994T0000 IN O
early P08105994T0000 JJ O
increase P08105994T0000 NN O
in P08105994T0000 IN O
serum P08105994T0000 JJ O
gamma-glutamyl P08105994T0000 JJ I-UN
transferase P08105994T0000 NN I-UN
in P08105994T0000 IN O
cerebral P08105994T0000 JJ O
infarction P08105994T0000 NN O
. P08105994T0000 . O
. . O O

The P08703005A0645 DT O
cis-acting P08703005A0645 JJ O
elements P08703005A0645 NNS O
that P08703005A0645 WDT O
control P08703005A0645 VBP O
promoter P08703005A0645 NN O
activity P08703005A0645 NN O
include P08703005A0645 VBP O
binding P08703005A0645 VBG O
sites P08703005A0645 NNS O
for P08703005A0645 IN O
transcription P08703005A0645 NN O
factors P08703005A0645 NNS O
Sp1 P08703005A0645 NNP I-UN
and P08703005A0645 CC O
alphaCbf P08703005A0645 RB I-UN
, P08703005A0645 , O
a P08703005A0645 DT O
60-kDa P08703005A0645 JJ I-UN
CCAAT P08703005A0645 NNP I-UN
box-binding P08703005A0645 NN I-UN
protein P08703005A0645 NN I-UN
. P08703005A0645 . O
. . O O

In P09344650A0967 IN O
the P09344650A0967 DT O
predicted P09344650A0967 JJ O
transmembrane P09344650A0967 NN O
domain P09344650A0967 NN O
, P09344650A0967 , O
Casr-rs2 P09344650A0967 NNP I-UN
and P09344650A0967 CC O
Casr-rs3 P09344650A0967 NNP I-UN
are P09344650A0967 VBP O
95 P09344650A0967 CD O
% P09344650A0967 NN O
identical P09344650A0967 JJ O
to P09344650A0967 TO O
Casr-rs1 P09344650A0967 NNP I-UN
. P09344650A0967 . O
. . O O

In P10318806A0476 IN O
the P10318806A0476 DT O
present P10318806A0476 JJ O
study P10318806A0476 NN O
, P10318806A0476 , O
we P10318806A0476 PRP O
have P10318806A0476 VBP O
investigated P10318806A0476 VBN O
the P10318806A0476 DT O
functional P10318806A0476 JJ O
role P10318806A0476 NN O
of P10318806A0476 IN O
the P10318806A0476 DT O
other P10318806A0476 JJ O
MAP P10318806A0476 NNP I-UN
kinases P10318806A0476 NNS I-UN
in P10318806A0476 IN O
PDGF-mediated P10318806A0476 NNP O
cellular P10318806A0476 JJ O
responses P10318806A0476 NNS O
. P10318806A0476 . O
. . O O

Superoxide P07841663A0685 JJ I-UN
dismutase P07841663A0685 NN I-UN
( P07841663A0685 ( O
SOD P07841663A0685 NNP I-UN
) P07841663A0685 ) O
activity P07841663A0685 NN O
decreased P07841663A0685 VBN O
significantly P07841663A0685 RB O
in P07841663A0685 IN O
sperm P07841663A0685 NN O
subjected P07841663A0685 VBN O
to P07841663A0685 TO O
direct P07841663A0685 VB O
electric P07841663A0685 JJ O
current P07841663A0685 JJ O
in P07841663A0685 IN O
comparison P07841663A0685 NN O
to P07841663A0685 TO O
the P07841663A0685 DT O
control P07841663A0685 NN O
or P07841663A0685 CC O
the P07841663A0685 DT O
sample P07841663A0685 NN O
incubated P07841663A0685 VBN O
with P07841663A0685 IN O
electrolyzed P07841663A0685 JJ O
medium P07841663A0685 NN O
. P07841663A0685 . O
. . O O

CONCLUSIONS P08258025A1131 NN O
: P08258025A1131 : O
In P08258025A1131 IN O
our P08258025A1131 PRP$ O
patients P08258025A1131 NNS O
and P08258025A1131 CC O
within P08258025A1131 IN O
the P08258025A1131 DT O
range P08258025A1131 NN O
of P08258025A1131 IN O
treatment P08258025A1131 NN O
variables P08258025A1131 NNS O
studied P08258025A1131 VBN O
, P08258025A1131 , O
age P08258025A1131 NN O
, P08258025A1131 , O
Karnofsky P08258025A1131 NNP O
index P08258025A1131 NN O
, P08258025A1131 , O
and P08258025A1131 CC O
graft-versus-host P08258025A1131 JJ O
disease P08258025A1131 NN O
are P08258025A1131 VBP O
the P08258025A1131 DT O
most P08258025A1131 RBS O
important P08258025A1131 JJ O
factors P08258025A1131 NNS O
related P08258025A1131 VBN O
with P08258025A1131 IN O
early P08258025A1131 JJ O
mortality P08258025A1131 NN O
. P08258025A1131 . O
. . O O

These P11283354A0548 DT O
data P11283354A0548 NNS O
define P11283354A0548 VBP O
a P11283354A0548 DT O
conserved P11283354A0548 JJ O
pathway P11283354A0548 NN O
wherein P11283354A0548 IN O
sequential P11283354A0548 JJ O
histone P11283354A0548 NN I-UN
modifications P11283354A0548 NNS O
establish P11283354A0548 VB O
a P11283354A0548 DT O
`` P11283354A0548 `` O
histone P11283354A0548 NN I-UN
code P11283354A0548 NN O
'' P11283354A0548 '' O
essential P11283354A0548 NN O
for P11283354A0548 IN O
the P11283354A0548 DT O
epigenetic P11283354A0548 JJ O
inheritance P11283354A0548 NN O
of P11283354A0548 IN O
heterochromatin P11283354A0548 NN O
assembly P11283354A0548 NN O
. P11283354A0548 . O
. . O O

In P02118525A0737 IN O
addition P02118525A0737 NN O
, P02118525A0737 , O
the P02118525A0737 DT O
-119 P02118525A0737 NN O
to P02118525A0737 TO O
-81 P02118525A0737 VB O
fragment P02118525A0737 NN O
of P02118525A0737 IN O
the P02118525A0737 DT O
CCK P02118525A0737 NNP I-UN
promoter P02118525A0737 NN I-UN
contains P02118525A0737 VBZ O
a P02118525A0737 DT O
transcriptional P02118525A0737 JJ O
enhancer P02118525A0737 NN O
that P02118525A0737 WDT O
potentiates P02118525A0737 VBZ O
the P02118525A0737 DT O
transcription P02118525A0737 NN O
from P02118525A0737 IN O
the P02118525A0737 DT O
herpes P02118525A0737 NNS O
simplex P02118525A0737 JJ O
virus P02118525A0737 NN O
thymidine P02118525A0737 NN I-UN
kinase P02118525A0737 NN I-UN
promoter P02118525A0737 NN I-UN
in P02118525A0737 IN O
a P02118525A0737 DT O
position- P02118525A0737 JJ O
and P02118525A0737 CC O
orientation-independent P02118525A0737 JJ O
manner P02118525A0737 NN O
. P02118525A0737 . O
. . O O

Enhancement P06362602T0001 NN O
of P06362602T0001 IN O
the P06362602T0001 DT O
immune P06362602T0001 JJ O
response P06362602T0001 NN O
by P06362602T0001 IN O
aspecific P06362602T0001 JJ O
action P06362602T0001 NN O
of P06362602T0001 IN O
vaccine P06362602T0001 NN O
additives P06362602T0001 NNS O
in P06362602T0001 IN O
the P06362602T0001 DT O
aerogenic P06362602T0001 JJ O
immunization P06362602T0001 NN O
of P06362602T0001 IN O
swine P06362602T0001 NN O
against P06362602T0001 IN O
swine P06362602T0001 JJ O
plague P06362602T0001 NN O
. P06362602T0001 . O
. . O O

A P08226777A0936 DT O
Dictyostelium P08226777A0936 NNP O
transformant P08226777A0936 NN O
overexpressing P08226777A0936 VBG O
DdPTPa P08226777A0936 NNP I-UN
does P08226777A0936 VBZ O
not P08226777A0936 RB O
develop P08226777A0936 VB O
normally P08226777A0936 RB O
. P08226777A0936 . O
. . O O

Results P02396415T0001 NNS O
of P02396415T0001 IN O
the P02396415T0001 DT O
long-term P02396415T0001 JJ O
observation P02396415T0001 NN O
and P02396415T0001 CC O
treatment P02396415T0001 NN O
of P02396415T0001 IN O
patients P02396415T0001 NNS O
with P02396415T0001 IN O
arterial P02396415T0001 JJ O
hypertension P02396415T0001 NN O
. P02396415T0001 . O
. . O O

A P01639724A0452 DT O
control P01639724A0452 NN O
group P01639724A0452 NN O
of P01639724A0452 IN O
nine P01639724A0452 CD O
women P01639724A0452 NNS O
( P01639724A0452 ( O
age P01639724A0452 NN O
23-40 P01639724A0452 CD O
years P01639724A0452 NNS O
) P01639724A0452 ) O
on P01639724A0452 IN O
oral P01639724A0452 JJ O
contraceptives P01639724A0452 NNS O
( P01639724A0452 ( O
Nordette-28 P01639724A0452 NNP O
) P01639724A0452 ) O
was P01639724A0452 VBD O
also P01639724A0452 RB O
studied P01639724A0452 VBN O
four P01639724A0452 CD O
times P01639724A0452 NNS O
during P01639724A0452 IN O
a P01639724A0452 DT O
pill P01639724A0452 NN O
cycle P01639724A0452 NN O
. P01639724A0452 . O
. . O O

Resting P06370553A0444 VBG O
plasma P06370553A0444 NN O
norepinephrine P06370553A0444 NN O
( P06370553A0444 ( O
NE P06370553A0444 NNP O
) P06370553A0444 ) O
and P06370553A0444 CC O
epinephrine P06370553A0444 NN O
( P06370553A0444 ( O
E P06370553A0444 NNP O
) P06370553A0444 ) O
levels P06370553A0444 NNS O
were P06370553A0444 VBD O
lower P06370553A0444 JJR O
during P06370553A0444 IN O
active P06370553A0444 JJ O
therapy P06370553A0444 NN O
than P06370553A0444 IN O
2 P06370553A0444 CD O
wk P06370553A0444 NN O
after P06370553A0444 IN O
withdrawal P06370553A0444 NN O
( P06370553A0444 ( O
guanfacine P06370553A0444 JJ O
and P06370553A0444 CC O
control P06370553A0444 NN O
: P06370553A0444 : O
plasma P06370553A0444 NN O
NE P06370553A0444 NNP O
, P06370553A0444 , O
0.27 P06370553A0444 CD O
+ P06370553A0444 NN O
/ P06370553A0444 NNP O
- P06370553A0444 : O
0.03 P06370553A0444 CD O
/ P06370553A0444 $ O
0.64 P06370553A0444 CD O
+ P06370553A0444 NNP O
/ P06370553A0444 NNP O
- P06370553A0444 : O
0.13 P06370553A0444 CD O
ng P06370553A0444 JJ O
/ P06370553A0444 NNP O
ml P06370553A0444 NN O
; P06370553A0444 : O
plasma P06370553A0444 CC O
E P06370553A0444 NNP O
, P06370553A0444 , O
0.09 P06370553A0444 CD O
+ P06370553A0444 NN O
/ P06370553A0444 NNP O
- P06370553A0444 : O
0.02 P06370553A0444 CD O
/ P06370553A0444 $ O
0.17 P06370553A0444 CD O
+ P06370553A0444 NNP O
/ P06370553A0444 NNP O
- P06370553A0444 : O
0.05 P06370553A0444 CD O
ng P06370553A0444 JJ O
/ P06370553A0444 NNP O
ml P06370553A0444 NN O
) P06370553A0444 ) O
. P06370553A0444 . O
. . O O

Flow P11027833A0362 JJ O
cytomery P11027833A0362 NN O
was P11027833A0362 VBD O
used P11027833A0362 VBN O
for P11027833A0362 IN O
cell P11027833A0362 NN O
cycle P11027833A0362 NN O
analysis P11027833A0362 NN O
. P11027833A0362 . O
. . O O

The P02674141A1202 DT O
seventh P02674141A1202 JJ O
cysteine P02674141A1202 NN O
residue P02674141A1202 NN O
of P02674141A1202 IN O
CTSE P02674141A1202 NNP I-UN
is P02674141A1202 VBZ O
located P02674141A1202 VBN O
within P02674141A1202 IN O
the P02674141A1202 DT O
activation P02674141A1202 NN O
peptide P02674141A1202 IN O
region P02674141A1202 NN O
of P02674141A1202 IN O
the P02674141A1202 DT O
proenzyme P02674141A1202 NN O
. P02674141A1202 . O
. . O O

A P11862350T0000 DT O
comparative P11862350T0000 JJ O
study P11862350T0000 NN O
of P11862350T0000 IN O
the P11862350T0000 DT O
effects P11862350T0000 NNS O
of P11862350T0000 IN O
carbamazepine P11862350T0000 NN O
and P11862350T0000 CC O
the P11862350T0000 DT O
NMDA P11862350T0000 NNP I-UN
receptor P11862350T0000 NN I-UN
antagonist P11862350T0000 NN O
remacemide P11862350T0000 NN O
on P11862350T0000 IN O
road P11862350T0000 NN O
tracking P11862350T0000 NN O
and P11862350T0000 CC O
car-following P11862350T0000 JJ O
performance P11862350T0000 NN O
in P11862350T0000 IN O
actual P11862350T0000 JJ O
traffic P11862350T0000 NN O
. P11862350T0000 . O
. . O O

The P00890028A0507 DT O
length P00890028A0507 NN O
scales P00890028A0507 NNS O
of P00890028A0507 IN O
the P00890028A0507 DT O
turbulence P00890028A0507 NN O
were P00890028A0507 VBD O
also P00890028A0507 RB O
estimated P00890028A0507 VBN O
: P00890028A0507 : O
at P00890028A0507 IN O
a P00890028A0507 DT O
Reynolds P00890028A0507 NNP O
number P00890028A0507 NN O
near P00890028A0507 IN O
4,000 P00890028A0507 CD O
the P00890028A0507 DT O
macroscale P00890028A0507 NN O
is P00890028A0507 VBZ O
about P00890028A0507 IN O
1.25 P00890028A0507 CD O
mm P00890028A0507 NNS O
, P00890028A0507 , O
the P00890028A0507 DT O
Taylor P00890028A0507 NNP O
microscale P00890028A0507 NN O
is P00890028A0507 VBZ O
about P00890028A0507 IN O
0.85 P00890028A0507 CD O
mm P00890028A0507 NNS O
, P00890028A0507 , O
and P00890028A0507 CC O
the P00890028A0507 DT O
Kolmogoroff P00890028A0507 NNP O
scale P00890028A0507 NN O
is P00890028A0507 VBZ O
near P00890028A0507 IN O
0.075 P00890028A0507 CD O
mm P00890028A0507 NNS O
. P00890028A0507 . O
. . O O

Sulfuric P04679807T0000 JJ O
acid P04679807T0000 NN O
concentration P04679807T0000 NN O
in P04679807T0000 IN O
the P04679807T0000 DT O
catalyzed P04679807T0000 JJ O
breathalyzer P04679807T0000 NN O
ampules P04679807T0000 NNS O
. P04679807T0000 . O
. . O O

Comparison P08828152A1238 NNP O
of P08828152A1238 IN O
the P08828152A1238 DT O
amino P08828152A1238 NN O
acid P08828152A1238 JJ O
sequences P08828152A1238 NNS O
of P08828152A1238 IN O
the P08828152A1238 DT O
RPO1 P08828152A1238 NNP I-UN
polypeptides P08828152A1238 NNS I-UN
of P08828152A1238 IN I-UN
IIV6 P08828152A1238 NNP I-UN
, P08828152A1238 , I-UN
LCDV P08828152A1238 NNP I-UN
, P08828152A1238 , I-UN
and P08828152A1238 CC I-UN
MCV-1 P08828152A1238 NNP I-UN
with P08828152A1238 IN O
the P08828152A1238 DT O
corresponding P08828152A1238 JJ O
prokaryotic P08828152A1238 JJ O
, P08828152A1238 , O
eukaryotic P08828152A1238 JJ O
, P08828152A1238 , O
and P08828152A1238 CC O
viral P08828152A1238 JJ O
proteins P08828152A1238 NNS O
revealed P08828152A1238 VBD O
differences P08828152A1238 NNS O
in P08828152A1238 IN O
amino P08828152A1238 NN O
acid P08828152A1238 NN O
similarity P08828152A1238 NN O
and P08828152A1238 CC O
phylogenetic P08828152A1238 JJ O
relationships P08828152A1238 NNS O
. P08828152A1238 . O
. . O O

A P02182240A0355 DT O
total P02182240A0355 NN O
of P02182240A0355 IN O
112 P02182240A0355 CD O
patients P02182240A0355 NNS O
received P02182240A0355 JJ O
anistreplase P02182240A0355 NN O
and P02182240A0355 CC O
119 P02182240A0355 CD O
received P02182240A0355 VBD O
heparin P02182240A0355 NN O
within P02182240A0355 IN O
a P02182240A0355 DT O
mean P02182240A0355 JJ O
period P02182240A0355 NN O
of P02182240A0355 IN O
188 P02182240A0355 CD O
+ P02182240A0355 NNS O
/ P02182240A0355 SYM O
- P02182240A0355 : O
62 P02182240A0355 CD O
min P02182240A0355 NN O
following P02182240A0355 VBG O
the P02182240A0355 DT O
onset P02182240A0355 NN O
of P02182240A0355 IN O
symptoms P02182240A0355 NNS O
. P02182240A0355 . O
. . O O

Clone P02547611A0318 NN O
4c P02547611A0318 CD O
( P02547611A0318 ( O
2681 P02547611A0318 CD O
bp P02547611A0318 NN O
) P02547611A0318 ) O
had P02547611A0318 VBD O
a P02547611A0318 DT O
coding P02547611A0318 JJ O
region P02547611A0318 NN O
identical P02547611A0318 JJ O
to P02547611A0318 TO O
that P02547611A0318 DT O
of P02547611A0318 IN O
clone P02547611A0318 NN O
22c P02547611A0318 CD O
but P02547611A0318 CC O
it P02547611A0318 PRP O
included P02547611A0318 VBD O
a P02547611A0318 DT O
putative P02547611A0318 JJ O
intron P02547611A0318 NN O
of P02547611A0318 IN O
959 P02547611A0318 CD O
bp P02547611A0318 NN O
. P02547611A0318 . O
. . O O

Furthermore P02052544A0641 RB O
, P02052544A0641 , O
the P02052544A0641 DT O
DNA P02052544A0641 NNP I-UN
polymerase P02052544A0641 NN I-UN
II P02052544A0641 NNP I-UN
complex P02052544A0641 NN I-UN
was P02052544A0641 VBD O
difficult P02052544A0641 JJ O
to P02052544A0641 TO O
obtain P02052544A0641 VB O
from P02052544A0641 IN O
dpb2-1 P02052544A0641 JJ I-UN
mutant P02052544A0641 NN O
cells P02052544A0641 NNS O
, P02052544A0641 , O
suggesting P02052544A0641 VBG O
that P02052544A0641 IN O
a P02052544A0641 DT O
stable P02052544A0641 JJ O
DNA P02052544A0641 NNP I-UN
polymerase P02052544A0641 NN I-UN
II P02052544A0641 NNP I-UN
complex P02052544A0641 NN I-UN
requires P02052544A0641 VBZ O
DPB2 P02052544A0641 NNP I-UN
and P02052544A0641 CC O
is P02052544A0641 VBZ O
essential P02052544A0641 JJ O
for P02052544A0641 IN O
chromosomal P02052544A0641 JJ O
replication P02052544A0641 NN O
. P02052544A0641 . O
. . O O

The P08234166A0425 DT O
bioavailability P08234166A0425 NN O
of P08234166A0425 IN O
etodolac P08234166A0425 NN O
from P08234166A0425 IN O
capsules P08234166A0425 NNS O
exposed P08234166A0425 VBN O
to P08234166A0425 TO O
stressed P08234166A0425 JJ O
conditions P08234166A0425 NNS O
was P08234166A0425 VBD O
compared P08234166A0425 VBN O
in P08234166A0425 IN O
both P08234166A0425 DT O
dogs P08234166A0425 NNS O
and P08234166A0425 CC O
humans P08234166A0425 NNS O
to P08234166A0425 TO O
capsules P08234166A0425 NNS O
stored P08234166A0425 VBN O
at P08234166A0425 IN O
RT P08234166A0425 NNP O
conditions P08234166A0425 NNS O
. P08234166A0425 . O
. . O O

Endothelial P02070227T0000 NNP O
cell P02070227T0000 NN O
seeding P02070227T0000 NN O
. P02070227T0000 . O
. . O O

The P03366864A0099 DT O
skin P03366864A0099 NN O
site P03366864A0099 NN O
, P03366864A0099 , O
6-cm-distal P03366864A0099 JJ O
and P03366864A0099 CC O
-proximal P03366864A0099 JJ O
subcutaneous P03366864A0099 JJ O
segments P03366864A0099 NNS O
of P03366864A0099 IN O
the P03366864A0099 DT O
catheter P03366864A0099 NN O
, P03366864A0099 , O
exudates P03366864A0099 VBZ O
, P03366864A0099 , O
and P03366864A0099 CC O
blood P03366864A0099 NN O
were P03366864A0099 VBD O
cultured P03366864A0099 VBN O
. P03366864A0099 . O
. . O O

Moreover P11763176A0918 RB O
, P11763176A0918 , O
a P11763176A0918 DT O
severe P11763176A0918 JJ O
decrease P11763176A0918 NN O
of P11763176A0918 IN O
antithrombin P11763176A0918 JJ I-UN
activity P11763176A0918 NN O
became P11763176A0918 VBD O
evident P11763176A0918 JJ O
during P11763176A0918 IN O
both P11763176A0918 DT O
experiments P11763176A0918 NNS O
( P11763176A0918 ( O
eg P11763176A0918 NN O
, P11763176A0918 , O
in P11763176A0918 IN O
experiment P11763176A0918 JJ O
2 P11763176A0918 CD O
from P11763176A0918 IN O
95.6 P11763176A0918 CD O
+ P11763176A0918 NNS O
/ P11763176A0918 SYM O
- P11763176A0918 : O
4.8 P11763176A0918 CD O
to P11763176A0918 TO O
59.2 P11763176A0918 CD O
+ P11763176A0918 NNS O
/ P11763176A0918 SYM O
- P11763176A0918 : O
6.6 P11763176A0918 CD O
% P11763176A0918 NN O
) P11763176A0918 ) O
. P11763176A0918 . O
. . O O

The P09264466A0947 DT O
Cut9 P09264466A0947 NNP I-UN
subunit P09264466A0947 NN I-UN
is P09264466A0947 VBZ O
likely P09264466A0947 JJ O
to P09264466A0947 TO O
be P09264466A0947 VB O
a P09264466A0947 DT O
target P09264466A0947 NN O
for P09264466A0947 IN O
regulating P09264466A0947 VBG O
APC P09264466A0947 NNP I-UN
/ P09264466A0947 NNP I-UN
cyclosome P09264466A0947 NN I-UN
function P09264466A0947 NN O
through P09264466A0947 IN O
protein-protein P09264466A0947 JJ O
interactions P09264466A0947 NNS O
and P09264466A0947 CC O
phosphorylation P09264466A0947 NN O
. P09264466A0947 . O
. . O O

Additional P09133122A0656 JJ O
information P09133122A0656 NN O
including P09133122A0656 VBG O
echocardiographic P09133122A0656 JJ O
sequences P09133122A0656 NNS O
, P09133122A0656 , O
perioperative P09133122A0656 JJ O
video P09133122A0656 NN O
sequences P09133122A0656 NNS O
, P09133122A0656 , O
x-ray P09133122A0656 JJ O
analysis P09133122A0656 NN O
, P09133122A0656 , O
angiograms P09133122A0656 NNS O
, P09133122A0656 , O
etc P09133122A0656 FW O
. P09133122A0656 . O
is P09133122A0656 VBZ O
represented P09133122A0656 VBN O
in P09133122A0656 IN O
the P09133122A0656 DT O
program P09133122A0656 NN O
. P09133122A0656 . O
. . O O

The P01628806A1347 DT O
observed P01628806A1347 JJ O
sequence P01628806A1347 NN O
variation P01628806A1347 NN O
disrupts P01628806A1347 VBZ O
the P01628806A1347 DT O
first P01628806A1347 JJ O
ORF P01628806A1347 NNP O
in P01628806A1347 IN O
many P01628806A1347 JJ O
Y P01628806A1347 NNP I-UN
's P01628806A1347 POS O
while P01628806A1347 IN O
most P01628806A1347 JJS O
of P01628806A1347 IN O
the P01628806A1347 DT O
second P01628806A1347 JJ O
ORF P01628806A1347 NNP O
including P01628806A1347 VBG O
the P01628806A1347 DT O
putative P01628806A1347 JJ O
helicase P01628806A1347 NN I-UN
region P01628806A1347 NN I-UN
is P01628806A1347 VBZ O
unaffected P01628806A1347 VBN O
. P01628806A1347 . O
. . O O

PURPOSE P09787323A0000 NN O
: P09787323A0000 : O
The P09787323A0000 DT O
role P09787323A0000 NN O
interleukin-6 P09787323A0000 JJ I-UN
( P09787323A0000 ( O
IL-6 P09787323A0000 NNP I-UN
) P09787323A0000 ) O
in P09787323A0000 IN O
the P09787323A0000 DT O
treatment P09787323A0000 NN O
of P09787323A0000 IN O
congenital P09787323A0000 JJ O
thrombocytopenias P09787323A0000 NN O
is P09787323A0000 VBZ O
unknown P09787323A0000 JJ O
. P09787323A0000 . O
. . O O

In P11328699A0000 IN O
the P11328699A0000 DT O
free-swimming P11328699A0000 JJ O
rotatory P11328699A0000 NN O
test P11328699A0000 NN O
mice P11328699A0000 NN O
spend P11328699A0000 VBP O
most P11328699A0000 JJS O
of P11328699A0000 IN O
the P11328699A0000 DT O
time P11328699A0000 NN O
swimming P11328699A0000 VBG O
close P11328699A0000 RB O
to P11328699A0000 TO O
the P11328699A0000 DT O
wall P11328699A0000 NN O
of P11328699A0000 IN O
the P11328699A0000 DT O
container P11328699A0000 NN O
attempting P11328699A0000 VBG O
to P11328699A0000 TO O
escape P11328699A0000 VB O
from P11328699A0000 IN O
an P11328699A0000 DT O
aversive P11328699A0000 JJ O
test P11328699A0000 NN O
situation P11328699A0000 NN O
. P11328699A0000 . O
. . O O

Behavior P05425195T0001 NNP O
of P05425195T0001 IN O
aspartate P05425195T0001 JJ I-UN
aminotransferase P05425195T0001 NN I-UN
( P05425195T0001 ( O
EC P05425195T0001 NNP I-UN
2.6.1.1 P05425195T0001 CD I-UN
) P05425195T0001 ) O
and P05425195T0001 CC O
alanine P05425195T0001 JJ I-UN
aminotransferase P05425195T0001 NN I-UN
( P05425195T0001 ( O
EC P05425195T0001 NNP I-UN
2.6.1.2 P05425195T0001 CD I-UN
) P05425195T0001 ) O
in P05425195T0001 IN O
rat P05425195T0001 NN O
serum P05425195T0001 NN O
during P05425195T0001 IN O
the P05425195T0001 DT O
course P05425195T0001 NN O
of P05425195T0001 IN O
acute P05425195T0001 JJ O
radiation P05425195T0001 NN O
syndrome P05425195T0001 NN O
following P05425195T0001 VBG O
whole P05425195T0001 JJ O
body P05425195T0001 NN O
X-irradiation P05425195T0001 NN O
. P05425195T0001 . O
. . O O

On P11707977A0750 IN O
the P11707977A0750 DT O
other P11707977A0750 JJ O
hand P11707977A0750 NN O
, P11707977A0750 , O
hepatic P11707977A0750 JJ O
arterial P11707977A0750 JJ O
infusion P11707977A0750 NN O
therapy P11707977A0750 NN O
prolongs P11707977A0750 VBZ O
the P11707977A0750 DT O
survival P11707977A0750 NN O
of P11707977A0750 IN O
H3 P11707977A0750 NNP O
patients P11707977A0750 NNS O
only P11707977A0750 RB O
. P11707977A0750 . O
. . O O

However P01846491A0459 RB O
, P01846491A0459 , O
the P01846491A0459 DT O
relative P01846491A0459 JJ O
positions P01846491A0459 NNS O
of P01846491A0459 IN O
the P01846491A0459 DT O
VV P01846491A0459 NNP O
genes P01846491A0459 NNS O
( P01846491A0459 ( O
genus P01846491A0459 JJ O
Orthopoxvirus P01846491A0459 NNP O
) P01846491A0459 ) O
are P01846491A0459 VBP O
different P01846491A0459 JJ O
than P01846491A0459 IN O
those P01846491A0459 DT O
of P01846491A0459 IN O
the P01846491A0459 DT O
corresponding P01846491A0459 JJ O
ORFs P01846491A0459 NNP O
in P01846491A0459 IN O
SFV P01846491A0459 NNP O
( P01846491A0459 ( O
genus P01846491A0459 FW O
Leporipoxvirus P01846491A0459 NNP O
) P01846491A0459 ) O
, P01846491A0459 , O
indicating P01846491A0459 VBG O
complex P01846491A0459 JJ O
rearrangements P01846491A0459 NNS O
of P01846491A0459 IN O
DNA P01846491A0459 NN O
in P01846491A0459 IN O
the P01846491A0459 DT O
genome P01846491A0459 NN O
of P01846491A0459 IN O
one P01846491A0459 CD O
or P01846491A0459 CC O
both P01846491A0459 DT O
of P01846491A0459 IN O
these P01846491A0459 DT O
viruses P01846491A0459 NNS O
subsequent P01846491A0459 VBP O
to P01846491A0459 TO O
their P01846491A0459 PRP$ O
divergence P01846491A0459 NN O
from P01846491A0459 IN O
a P01846491A0459 DT O
common P01846491A0459 JJ O
ancestor P01846491A0459 NN O
. P01846491A0459 . O
. . O O

Sequence P08349632A0679 NNP O
comparison P08349632A0679 NN O
indicates P08349632A0679 VBZ O
that P08349632A0679 IN O
exons P08349632A0679 NNS O
5 P08349632A0679 CD O
' P08349632A0679 '' O
/ P08349632A0679 JJ O
L P08349632A0679 NNP O
and P08349632A0679 CC O
L P08349632A0679 NNP O
/ P08349632A0679 NNP O
N P08349632A0679 NNP O
in P08349632A0679 IN O
PSG12 P08349632A0679 NNP I-UN
and P08349632A0679 CC O
PSG12 P08349632A0679 NNP I-UN
psi P08349632A0679 NNS I-UN
are P08349632A0679 VBP O
99 P08349632A0679 CD O
% P08349632A0679 NN O
identical P08349632A0679 JJ O
, P08349632A0679 , O
except P08349632A0679 IN O
that P08349632A0679 IN O
the P08349632A0679 DT O
L P08349632A0679 NNP O
/ P08349632A0679 NNP O
N P08349632A0679 NNP O
exon P08349632A0679 NN O
in P08349632A0679 IN O
the P08349632A0679 DT O
PSG12 P08349632A0679 NNP I-UN
psi P08349632A0679 NN I-UN
gene P08349632A0679 NN I-UN
contains P08349632A0679 VBZ O
a P08349632A0679 DT O
stop P08349632A0679 JJ O
codon P08349632A0679 NN O
. P08349632A0679 . O
. . O O

In P06173860A0000 IN O
most P06173860A0000 JJS O
cases P06173860A0000 NNS O
of P06173860A0000 IN O
acute P06173860A0000 JJ O
transmural P06173860A0000 JJ O
infarction P06173860A0000 NN O
, P06173860A0000 , O
the P06173860A0000 DT O
reciprocal P06173860A0000 JJ O
ST P06173860A0000 NNP O
segment P06173860A0000 NN O
depressions P06173860A0000 NNS O
observed P06173860A0000 VBD O
in P06173860A0000 IN O
contralateral P06173860A0000 JJ O
leads P06173860A0000 NNS O
are P06173860A0000 VBP O
less P06173860A0000 RBR O
marked P06173860A0000 JJ O
than P06173860A0000 IN O
the P06173860A0000 DT O
primary P06173860A0000 JJ O
ST P06173860A0000 NNP O
segment P06173860A0000 NN O
elevations P06173860A0000 NNS O
. P06173860A0000 . O
. . O O

To P08213747A0000 TO O
determine P08213747A0000 VB O
whether P08213747A0000 IN O
the P08213747A0000 DT O
excess P08213747A0000 JJ O
prevalence P08213747A0000 NN O
of P08213747A0000 IN O
human P08213747A0000 JJ O
immunodeficiency P08213747A0000 NN O
virus P08213747A0000 NN O
type P08213747A0000 NN O
1 P08213747A0000 CD O
( P08213747A0000 ( O
HIV-1 P08213747A0000 NNP O
) P08213747A0000 ) O
infection P08213747A0000 NN O
in P08213747A0000 IN O
US P08213747A0000 NNP O
black P08213747A0000 JJ O
and P08213747A0000 CC O
Hispanic P08213747A0000 JJ O
homosexual P08213747A0000 JJ O
men P08213747A0000 NNS O
relative P08213747A0000 VBP O
to P08213747A0000 TO O
white P08213747A0000 JJ O
men P08213747A0000 NNS O
can P08213747A0000 MD O
be P08213747A0000 VB O
explained P08213747A0000 VBN O
by P08213747A0000 IN O
differences P08213747A0000 NNS O
in P08213747A0000 IN O
sociodemographic P08213747A0000 JJ O
factors P08213747A0000 NNS O
, P08213747A0000 , O
history P08213747A0000 NN O
of P08213747A0000 IN O
sexually P08213747A0000 RB O
transmitted P08213747A0000 VBN O
diseases P08213747A0000 NNS O
, P08213747A0000 , O
or P08213747A0000 CC O
sexual P08213747A0000 JJ O
and P08213747A0000 CC O
drug-use P08213747A0000 JJ O
behaviors P08213747A0000 NNS O
, P08213747A0000 , O
the P08213747A0000 DT O
authors P08213747A0000 NNS O
conducted P08213747A0000 VBD O
a P08213747A0000 DT O
cross-sectional P08213747A0000 JJ O
analysis P08213747A0000 NN O
of P08213747A0000 IN O
baseline P08213747A0000 JJ O
HIV-1 P08213747A0000 NNP O
seroprevalence P08213747A0000 NN O
and P08213747A0000 CC O
HIV-1 P08213747A0000 NNP O
risk P08213747A0000 NN O
factors P08213747A0000 NNS O
among P08213747A0000 IN O
4,475 P08213747A0000 CD O
non-Hispanic P08213747A0000 JJ O
white P08213747A0000 JJ O
, P08213747A0000 , O
234 P08213747A0000 CD O
Hispanic P08213747A0000 NNP O
white P08213747A0000 JJ O
, P08213747A0000 , O
and P08213747A0000 CC O
194 P08213747A0000 CD O
black P08213747A0000 JJ O
homosexual P08213747A0000 JJ O
men P08213747A0000 NNS O
from P08213747A0000 IN O
four P08213747A0000 CD O
centers P08213747A0000 NNS O
in P08213747A0000 IN O
the P08213747A0000 DT O
United P08213747A0000 NNP O
States P08213747A0000 NNPS O
( P08213747A0000 ( O
Baltimore P08213747A0000 NNP O
/ P08213747A0000 NNP O
Washington P08213747A0000 NNP O
, P08213747A0000 , O
DC P08213747A0000 NNP O
, P08213747A0000 , O
Pittsburgh P08213747A0000 NNP O
, P08213747A0000 , O
Chicago P08213747A0000 NNP O
, P08213747A0000 , O
and P08213747A0000 CC O
Los P08213747A0000 NNP O
Angeles P08213747A0000 NNP O
) P08213747A0000 ) O
. P08213747A0000 . O
. . O O

This P09203586A1197 DT O
indicates P09203586A1197 VBZ O
that P09203586A1197 IN O
recruitment P09203586A1197 NN O
of P09203586A1197 IN O
large P09203586A1197 JJ I-UN
T P09203586A1197 NNP I-UN
antigen P09203586A1197 NN I-UN
to P09203586A1197 TO O
the P09203586A1197 DT O
rRNA P09203586A1197 NN O
promoter P09203586A1197 NN O
by P09203586A1197 IN O
SL1 P09203586A1197 NNP I-UN
constitutes P09203586A1197 VBZ O
a P09203586A1197 DT O
crucial P09203586A1197 JJ O
step P09203586A1197 NN O
in P09203586A1197 IN O
the P09203586A1197 DT O
activation P09203586A1197 NN O
process P09203586A1197 NN O
. P09203586A1197 . O
. . O O

Interferon P01441818T0001 NNP I-UN
type P01441818T0001 NN I-UN
I P01441818T0001 PRP I-UN
in P01441818T0001 IN O
protective P01441818T0001 JJ O
body P01441818T0001 NN O
reactions P01441818T0001 NNS O
in P01441818T0001 IN O
an P01441818T0001 DT O
experimental P01441818T0001 JJ O
Klebsiella P01441818T0001 NNP O
infection P01441818T0001 NN O
. P01441818T0001 . O
. . O O

Stringent P01548756A1102 JJ O
hybridization P01548756A1102 NN O
of P01548756A1102 IN O
EHS-1 P01548756A1102 NNP I-UN
back P01548756A1102 NN O
to P01548756A1102 TO O
primate P01548756A1102 VB O
genomic P01548756A1102 JJ O
DNA P01548756A1102 NNP O
indicates P01548756A1102 VBZ O
two P01548756A1102 CD O
distinct P01548756A1102 JJ O
EHS-1 P01548756A1102 JJ I-UN
loci P01548756A1102 NN I-UN
in P01548756A1102 IN O
normal P01548756A1102 JJ O
human P01548756A1102 JJ O
DNA P01548756A1102 NNP O
, P01548756A1102 , O
an P01548756A1102 DT O
identical P01548756A1102 JJ O
band P01548756A1102 NN O
pattern P01548756A1102 NN O
in P01548756A1102 IN O
chimpanzee P01548756A1102 NN O
DNA P01548756A1102 NNP O
, P01548756A1102 , O
and P01548756A1102 CC O
a P01548756A1102 DT O
single P01548756A1102 JJ O
locus P01548756A1102 NN O
in P01548756A1102 IN O
rhesus P01548756A1102 NN O
monkey P01548756A1102 NN O
DNA P01548756A1102 NNP O
. P01548756A1102 . O
. . O O

Protein P09436795A0350 NNP I-UN
C P09436795A0350 NNP I-UN
deficiency P09436795A0350 NN O
or P09436795A0350 CC O
protein P09436795A0350 NN I-UN
S P09436795A0350 NNP I-UN
deficiency P09436795A0350 NN O
was P09436795A0350 VBD O
the P09436795A0350 DT O
only P09436795A0350 JJ O
identified P09436795A0350 JJ O
risk P09436795A0350 NN O
factor P09436795A0350 NN O
for P09436795A0350 IN O
5.4 P09436795A0350 CD O
% P09436795A0350 NN O
( P09436795A0350 ( O
2 P09436795A0350 CD O
patients P09436795A0350 NNS O
) P09436795A0350 ) O
and P09436795A0350 CC O
13.5 P09436795A0350 CD O
% P09436795A0350 NN O
( P09436795A0350 ( O
5 P09436795A0350 CD O
patients P09436795A0350 NNS O
) P09436795A0350 ) O
, P09436795A0350 , O
respectively P09436795A0350 RB O
, P09436795A0350 , O
of P09436795A0350 IN O
these P09436795A0350 DT O
37 P09436795A0350 CD O
children P09436795A0350 NNS O
. P09436795A0350 . O
. . O O

Effects P05497793T0000 NNS O
of P05497793T0000 IN O
chronic P05497793T0000 JJ O
metaraminol P05497793T0000 NN O
treatment P05497793T0000 NN O
on P05497793T0000 IN O
the P05497793T0000 DT O
sympathetic P05497793T0000 JJ O
activity P05497793T0000 NN O
of P05497793T0000 IN O
intact P05497793T0000 JJ O
and P05497793T0000 CC O
adrenal P05497793T0000 JJ O
demedullated P05497793T0000 JJ O
rats P05497793T0000 NNS O
kept P05497793T0000 VBD O
in P05497793T0000 IN O
warm P05497793T0000 JJ O
or P05497793T0000 CC O
cold P05497793T0000 JJ O
environments P05497793T0000 NNS O
. P05497793T0000 . O
. . O O

Moreover P09620873A1710 RB O
, P09620873A1710 , O
the P09620873A1710 DT O
observation P09620873A1710 NN O
of P09620873A1710 IN O
enhanced P09620873A1710 JJ O
luteal P09620873A1710 JJ I-UN
HSP-27 P09620873A1710 JJ I-UN
phosphorylation P09620873A1710 NN O
in P09620873A1710 IN O
vivo P09620873A1710 NN O
, P09620873A1710 , O
in P09620873A1710 IN O
late P09620873A1710 JJ O
pregnancy P09620873A1710 NN O
, P09620873A1710 , O
when P09620873A1710 WRB O
PKC-delta P09620873A1710 NNP I-UN
is P09620873A1710 VBZ O
abundant P09620873A1710 JJ O
and P09620873A1710 CC O
active P09620873A1710 JJ O
, P09620873A1710 , O
suggests P09620873A1710 VBZ O
that P09620873A1710 IN O
select P09620873A1710 NN O
PKC P09620873A1710 NNP I-UN
family P09620873A1710 NN I-UN
members P09620873A1710 NNS I-UN
contribute P09620873A1710 VBP O
to P09620873A1710 TO O
sHSP P09620873A1710 VB I-UN
phosphorylation P09620873A1710 NN O
events P09620873A1710 NNS O
in P09620873A1710 IN O
vivo P09620873A1710 NN O
. P09620873A1710 . O
. . O O

However P08474464A0348 RB O
, P08474464A0348 , O
despite P08474464A0348 IN O
its P08474464A0348 PRP$ O
relationship P08474464A0348 NN O
to P08474464A0348 TO O
the P08474464A0348 DT O
TR P08474464A0348 NNP I-UN
, P08474464A0348 , O
Rev-Erb P08474464A0348 NNP O
bound P08474464A0348 VBD O
poorly P08474464A0348 RB O
to P08474464A0348 TO O
TR P08474464A0348 NNP I-UN
binding P08474464A0348 VBG I-UN
sites P08474464A0348 NNS I-UN
. P08474464A0348 . O
. . O O

The P09485308A1165 DT O
FMN P09485308A1165 NNP O
moiety P09485308A1165 NN O
but P09485308A1165 CC O
not P09485308A1165 RB O
the P09485308A1165 DT O
[ P09485308A1165 JJ O
3Fe-4S P09485308A1165 JJ O
] P09485308A1165 NNP O
cluster P09485308A1165 NN O
of P09485308A1165 IN O
the P09485308A1165 DT O
subunit P09485308A1165 NN O
appears P09485308A1165 VBZ O
to P09485308A1165 TO O
participate P09485308A1165 VB O
in P09485308A1165 IN O
this P09485308A1165 DT O
reaction P09485308A1165 NN O
. P09485308A1165 . O
. . O O

Alternatively P07862141A0317 RB O
, P07862141A0317 , O
loss-of-function P07862141A0317 JJ O
alleles P07862141A0317 NNS O
of P07862141A0317 IN O
genes P07862141A0317 NNS O
that P07862141A0317 WDT O
inhibit P07862141A0317 VBP O
cAPK P07862141A0317 JJ I-UN
lead P07862141A0317 NN O
to P07862141A0317 TO O
the P07862141A0317 DT O
inability P07862141A0317 NN O
to P07862141A0317 TO O
undergo P07862141A0317 VB O
sexual P07862141A0317 JJ O
differentiation P07862141A0317 NN O
. P07862141A0317 . O
. . O O

In P11223255A1034 IN O
addition P11223255A1034 NN O
, P11223255A1034 , O
the P11223255A1034 DT O
consensus P11223255A1034 NN O
amino P11223255A1034 NN O
acid P11223255A1034 VBP O
motif P11223255A1034 NN O
for P11223255A1034 IN O
serine P11223255A1034 JJ I-UN
threonine P11223255A1034 NN I-UN
receptor P11223255A1034 NN I-UN
kinases P11223255A1034 NNS I-UN
was P11223255A1034 VBD O
also P11223255A1034 RB O
present P11223255A1034 JJ O
. P11223255A1034 . O
. . O O

At P09618150A0127 IN O
physiological P09618150A0127 JJ O
doses P09618150A0127 NNS O
, P09618150A0127 , O
either P09618150A0127 DT O
insulin-like P09618150A0127 JJ I-UN
growth P09618150A0127 NN I-UN
factor P09618150A0127 NN I-UN
I P09618150A0127 PRP I-UN
( P09618150A0127 ( O
IGF-I P09618150A0127 NNP I-UN
) P09618150A0127 ) O
or P09618150A0127 CC O
insulin P09618150A0127 NN I-UN
turned P09618150A0127 VBD O
out P09618150A0127 RP O
to P09618150A0127 TO O
be P09618150A0127 VB O
as P09618150A0127 RB O
potent P09618150A0127 JJ O
as P09618150A0127 IN O
dibutyryl P09618150A0127 NN O
cAMP P09618150A0127 NN O
( P09618150A0127 ( O
dbcAMP P09618150A0127 NN O
) P09618150A0127 ) O
in P09618150A0127 IN O
increasing P09618150A0127 VBG O
UCP1 P09618150A0127 NNP I-UN
gene P09618150A0127 NN I-UN
transcription P09618150A0127 NN O
rate P09618150A0127 NN O
( P09618150A0127 ( O
1 P09618150A0127 CD O
h P09618150A0127 NN O
) P09618150A0127 ) O
and P09618150A0127 CC O
also P09618150A0127 RB O
UCP1 P09618150A0127 NNP I-UN
mRNA P09618150A0127 NN I-UN
accumulation P09618150A0127 NN O
( P09618150A0127 ( O
3 P09618150A0127 CD O
h P09618150A0127 NN O
) P09618150A0127 ) O
, P09618150A0127 , O
their P09618150A0127 PRP$ O
maximal P09618150A0127 JJ O
effect P09618150A0127 NN O
( P09618150A0127 ( O
15-fold P09618150A0127 JJ O
increase P09618150A0127 NN O
) P09618150A0127 ) O
reached P09618150A0127 VBD O
upon P09618150A0127 IN O
treatment P09618150A0127 NN O
for P09618150A0127 IN O
24 P09618150A0127 CD O
h P09618150A0127 NN O
. P09618150A0127 . O
. . O O

Experimental P11387950X0001 JJ O
study P11387950X0001 NN O
of P11387950X0001 IN O
ta P11387950X0001 NN O
chengchi P11387950X0001 NN O
tang P11387950X0001 NN O
decoction P11387950X0001 NN O
for P11387950X0001 IN O
relieving P11387950X0001 VBG O
lung P11387950X0001 JJ O
injury P11387950X0001 NN O
during P11387950X0001 IN O
acute P11387950X0001 JJ O
necrotizing P11387950X0001 VBG O
pancreatitis P11387950X0001 NN O
] P11387950X0001 VBD O
The P11387950X0001 DT O
objectives P11387950X0001 NNS O
of P11387950X0001 IN O
the P11387950X0001 DT O
study P11387950X0001 NN O
were P11387950X0001 VBD O
to P11387950X0001 TO O
investigate P11387950X0001 VB O
the P11387950X0001 DT O
changes P11387950X0001 NNS O
of P11387950X0001 IN O
leukocyte P11387950X0001 NN O
adhesiveness P11387950X0001 NN O
and P11387950X0001 CC O
tumor P11387950X0001 NN I-UN
necrosis P11387950X0001 NN I-UN
factor P11387950X0001 NN I-UN
( P11387950X0001 ( O
TNF P11387950X0001 NNP I-UN
) P11387950X0001 ) O
in P11387950X0001 IN O
the P11387950X0001 DT O
early P11387950X0001 JJ O
stage P11387950X0001 NN O
of P11387950X0001 IN O
acute P11387950X0001 JJ O
necrotizing P11387950X0001 VBG O
pancreatitis P11387950X0001 NN O
( P11387950X0001 ( O
ANP P11387950X0001 NNP O
) P11387950X0001 ) O
, P11387950X0001 , O
to P11387950X0001 TO O
go P11387950X0001 VB O
further P11387950X0001 RB O
into P11387950X0001 IN O
the P11387950X0001 DT O
relation P11387950X0001 NN O
of P11387950X0001 IN O
those P11387950X0001 DT O
changes P11387950X0001 NNS O
to P11387950X0001 TO O
lung P11387950X0001 VB O
injury P11387950X0001 NN O
of P11387950X0001 IN O
ANP P11387950X0001 NNP O
, P11387950X0001 , O
and P11387950X0001 CC O
to P11387950X0001 TO O
evaluate P11387950X0001 VB O
the P11387950X0001 DT O
prohibitive P11387950X0001 JJ O
effect P11387950X0001 NN O
of P11387950X0001 IN O
ta P11387950X0001 NN O
chengchi P11387950X0001 NN O
tang P11387950X0001 NN O
Decoction P11387950X0001 NNP O
on P11387950X0001 IN O
leukocyte P11387950X0001 JJ O
adhesion P11387950X0001 NN O
and P11387950X0001 CC O
TNF P11387950X0001 NNP I-UN
secretion P11387950X0001 NN O
. P11387950X0001 . O
. . O O

The P09544991A0750 DT O
dominant P09544991A0750 JJ O
negative P09544991A0750 JJ O
mutant P09544991A0750 NN O
of P09544991A0750 IN O
SHP-2 P09544991A0750 NNP I-UN
was P09544991A0750 VBD O
found P09544991A0750 VBN O
to P09544991A0750 TO O
inhibit P09544991A0750 VB O
the P09544991A0750 DT O
induction P09544991A0750 NN O
of P09544991A0750 IN O
tyrosine P09544991A0750 JJ O
phosphorylation P09544991A0750 NN O
and P09544991A0750 CC O
DNA-binding P09544991A0750 JJ O
activity P09544991A0750 NN O
of P09544991A0750 IN O
m-Stat5a P09544991A0750 NN I-UN
, P09544991A0750 , O
m-Stat5b P09544991A0750 NN I-UN
, P09544991A0750 , O
and P09544991A0750 CC O
the P09544991A0750 DT O
carboxyl-terminal P09544991A0750 JJ O
deletion P09544991A0750 NN O
variant P09544991A0750 JJ O
m-Stat5adelta749 P09544991A0750 NN I-UN
, P09544991A0750 , O
as P09544991A0750 RB O
well P09544991A0750 RB O
as P09544991A0750 IN O
the P09544991A0750 DT O
transactivation P09544991A0750 NN O
potential P09544991A0750 NN O
of P09544991A0750 IN O
m-Stat5a P09544991A0750 JJ I-UN
and P09544991A0750 CC O
m-Stat5b P09544991A0750 JJ I-UN
. P09544991A0750 . O
. . O O

The P11207216A0719 DT O
regulation P11207216A0719 NN O
of P11207216A0719 IN O
PGHS-2 P11207216A0719 NNP I-UN
mRNA P11207216A0719 NN I-UN
and P11207216A0719 CC O
protein P11207216A0719 NN O
was P11207216A0719 VBD O
studied P11207216A0719 VBN O
in P11207216A0719 IN O
primary P11207216A0719 JJ O
cultures P11207216A0719 NNS O
of P11207216A0719 IN O
bovine P11207216A0719 JJ O
uterine P11207216A0719 JJ O
stromal P11207216A0719 JJ O
cells P11207216A0719 NNS O
stimulated P11207216A0719 VBN O
with P11207216A0719 IN O
phorbol P11207216A0719 JJ O
12-myristate P11207216A0719 JJ O
13-acetate P11207216A0719 JJ O
( P11207216A0719 ( O
PMA P11207216A0719 NNP O
; P11207216A0719 : O
100 P11207216A0719 CD O
nM P11207216A0719 NN O
) P11207216A0719 ) O
. P11207216A0719 . O
. . O O

Taken P10964995A2152 VBN O
together P10964995A2152 RB O
, P10964995A2152 , O
they P10964995A2152 PRP O
uphold P10964995A2152 VBP O
the P10964995A2152 DT O
emerging P10964995A2152 VBG O
concern P10964995A2152 NN O
that P10964995A2152 IN O
women P10964995A2152 NNS O
with P10964995A2152 IN O
ER P10964995A2152 NNP I-UN
( P10964995A2152 ( I-UN
+ P10964995A2152 NNP I-UN
) P10964995A2152 ) I-UN
cancers P10964995A2152 NNS O
may P10964995A2152 MD O
not P10964995A2152 RB O
benefit P10964995A2152 VB O
significantly P10964995A2152 RB O
from P10964995A2152 IN O
endocrine P10964995A2152 JJ O
treatment P10964995A2152 NN O
if P10964995A2152 IN O
the P10964995A2152 DT O
tumors P10964995A2152 NNS O
also P10964995A2152 RB O
overexpress P10964995A2152 RB O
HER-2 P10964995A2152 NNP I-UN
. P10964995A2152 . O
. . O O

The P03543936A0000 DT O
rho P03543936A0000 NN I-UN
genes P03543936A0000 NNS I-UN
comprise P03543936A0000 VBP O
an P03543936A0000 DT O
evolutionarily P03543936A0000 RB O
conserved P03543936A0000 VBN O
family P03543936A0000 NN O
with P03543936A0000 IN O
significant P03543936A0000 JJ O
homology P03543936A0000 NN O
to P03543936A0000 TO O
the P03543936A0000 DT O
ras P03543936A0000 NNS I-UN
oncogene P03543936A0000 VBP I-UN
family P03543936A0000 NN I-UN
. P03543936A0000 . O
. . O O

On P00528144T0000 IN O
the P00528144T0000 DT O
role P00528144T0000 NN O
of P00528144T0000 IN O
transferrin P00528144T0000 NN I-UN
in P00528144T0000 IN O
the P00528144T0000 DT O
uptake P00528144T0000 NN O
of P00528144T0000 IN O
gallium P00528144T0000 NN O
by P00528144T0000 IN O
tumor P00528144T0000 NN O
cells P00528144T0000 NNS O
. P00528144T0000 . O
. . O O

DNA P03053713A0752 NN O
sequencing P03053713A0752 NN O
of P03053713A0752 IN O
the P03053713A0752 DT O
DPM1 P03053713A0752 NNP I-UN
gene P03053713A0752 NN I-UN
revealed P03053713A0752 VBD O
an P03053713A0752 DT O
open P03053713A0752 JJ O
reading P03053713A0752 NN O
frame P03053713A0752 NN O
of P03053713A0752 IN O
801 P03053713A0752 CD O
bases P03053713A0752 NNS O
. P03053713A0752 . O
. . O O

E1A P07951410A1332 NNP I-UN
autoactivation P07951410A1332 NN O
mediated P07951410A1332 VBN O
by P07951410A1332 IN O
these P07951410A1332 DT O
sites P07951410A1332 NNS O
was P07951410A1332 VBD O
about P07951410A1332 IN O
twofold P07951410A1332 JJ O
compared P07951410A1332 VBN O
with P07951410A1332 IN O
a P07951410A1332 DT O
ninefold P07951410A1332 JJ O
activation P07951410A1332 NN O
described P07951410A1332 VBD O
for P07951410A1332 IN O
the P07951410A1332 DT O
complete P07951410A1332 JJ O
E1A P07951410A1332 NNP I-UN
promoter P07951410A1332 NN I-UN
. P07951410A1332 . O
. . O O

The P10805729A0987 DT O
stoichiometry P10805729A0987 NN O
of P10805729A0987 IN O
the P10805729A0987 DT O
complexes P10805729A0987 NNS O
formed P10805729A0987 VBN O
with P10805729A0987 IN O
the P10805729A0987 DT O
dodeca-satellite P10805729A0987 JJ O
C P10805729A0987 NNP O
strand P10805729A0987 NN O
suggests P10805729A0987 VBZ O
that P10805729A0987 IN O
, P10805729A0987 , O
in P10805729A0987 IN O
DDP1 P10805729A0987 NNP I-UN
, P10805729A0987 , O
the P10805729A0987 DT O
15 P10805729A0987 CD O
consecutive P10805729A0987 JJ O
KH P10805729A0987 NNP O
domains P10805729A0987 NNS O
are P10805729A0987 VBP O
organized P10805729A0987 VBN O
such P10805729A0987 JJ O
that P10805729A0987 IN O
they P10805729A0987 PRP O
define P10805729A0987 VBP O
two P10805729A0987 CD O
nucleic P10805729A0987 JJ O
acid P10805729A0987 NNS O
binding P10805729A0987 VBG O
surfaces P10805729A0987 NNS O
. P10805729A0987 . O
. . O O

This P01848871A0392 DT O
study P01848871A0392 NN O
tested P01848871A0392 VBD O
the P01848871A0392 DT O
hypothesis P01848871A0392 NN O
that P01848871A0392 WDT O
sodium P01848871A0392 JJ O
channel P01848871A0392 NNS O
blocking P01848871A0392 VBG O
drugs P01848871A0392 NNS O
selectively P01848871A0392 RB O
prolong P01848871A0392 IN O
the P01848871A0392 DT O
late P01848871A0392 JJ O
potential P01848871A0392 NN O
, P01848871A0392 , O
or P01848871A0392 CC O
terminal P01848871A0392 JJ O
low P01848871A0392 JJ O
amplitude P01848871A0392 JJ O
signal P01848871A0392 NN O
, P01848871A0392 , O
portion P01848871A0392 NN O
of P01848871A0392 IN O
the P01848871A0392 DT O
signal-averaged P01848871A0392 JJ O
QRS P01848871A0392 NNP O
complex P01848871A0392 NN O
and P01848871A0392 CC O
that P01848871A0392 DT O
prolongation P01848871A0392 NN O
of P01848871A0392 IN O
the P01848871A0392 DT O
late P01848871A0392 JJ O
potential P01848871A0392 NN O
would P01848871A0392 MD O
correlate P01848871A0392 VB O
with P01848871A0392 IN O
slowing P01848871A0392 NN O
of P01848871A0392 IN O
ventricular P01848871A0392 JJ O
tachycardia P01848871A0392 NN O
. P01848871A0392 . O
. . O O

The P08004442A0265 DT O
effects P08004442A0265 NNS O
of P08004442A0265 IN O
social P08004442A0265 JJ O
isolation P08004442A0265 NN O
on P08004442A0265 IN O
morphine-induced P08004442A0265 JJ O
locomotor P08004442A0265 NN O
activity P08004442A0265 NN O
were P08004442A0265 VBD O
compared P08004442A0265 VBN O
in P08004442A0265 IN O
: P08004442A0265 : O
( P08004442A0265 ( O
i P08004442A0265 NN O
) P08004442A0265 ) O
animals P08004442A0265 NNS O
with P08004442A0265 IN O
an P08004442A0265 DT O
intact P08004442A0265 JJ O
hypothalamo-pituitary-adrenal P08004442A0265 JJ O
( P08004442A0265 ( O
HPA P08004442A0265 NNP O
) P08004442A0265 ) O
axis P08004442A0265 NN O
; P08004442A0265 : O
( P08004442A0265 ( O
ii P08004442A0265 NN O
) P08004442A0265 ) O
animals P08004442A0265 NNS O
in P08004442A0265 IN O
which P08004442A0265 WDT O
stress-induced P08004442A0265 JJ O
corticosterone P08004442A0265 NN O
secretion P08004442A0265 NN O
was P08004442A0265 VBD O
blocked P08004442A0265 VBN O
by P08004442A0265 IN O
adrenalectomy P08004442A0265 NN O
. P08004442A0265 . O
. . O O

Activated P10484818A0292 VBN O
areas P10484818A0292 NNS O
have P10484818A0292 VBP O
been P10484818A0292 VBN O
identified P10484818A0292 VBN O
by P10484818A0292 IN O
means P10484818A0292 NNS O
of P10484818A0292 IN O
cross-correlation P10484818A0292 NN O
analysis P10484818A0292 NN O
. P10484818A0292 . O
. . O O

In P11373277A0812 IN O
summary P11373277A0812 JJ O
, P11373277A0812 , O
we P11373277A0812 PRP O
conclude P11373277A0812 VBP O
that P11373277A0812 IN O
the P11373277A0812 DT O
adenoviral P11373277A0812 JJ O
oncoprotein P11373277A0812 NN O
E1A P11373277A0812 NNP I-UN
activates P11373277A0812 VBZ O
transcription P11373277A0812 NN O
from P11373277A0812 IN O
the P11373277A0812 DT O
endogenous P11373277A0812 JJ O
AP-2alpha P11373277A0812 NNP I-UN
gene P11373277A0812 NN I-UN
, P11373277A0812 , O
an P11373277A0812 DT O
effect P11373277A0812 NN O
that P11373277A0812 WDT O
involves P11373277A0812 VBZ O
transcriptional P11373277A0812 JJ O
derepression P11373277A0812 NN O
of P11373277A0812 IN O
the P11373277A0812 DT O
AP-2alpha P11373277A0812 NNP I-UN
promoter P11373277A0812 NN I-UN
by P11373277A0812 IN O
interaction P11373277A0812 NN O
of P11373277A0812 IN O
E1A P11373277A0812 NNP I-UN
with P11373277A0812 IN O
the P11373277A0812 DT O
AP-2rep P11373277A0812 NNP I-UN
corepressor P11373277A0812 NN O
CtBP1 P11373277A0812 NNP I-UN
. P11373277A0812 . O
. . O O

The P10771709A0291 DT O
physicians P10771709A0291 NNS O
in P10771709A0291 IN O
charge P10771709A0291 NN O
of P10771709A0291 IN O
all P10771709A0291 DT O
patients P10771709A0291 NNS O
with P10771709A0291 IN O
evidence P10771709A0291 NN O
of P10771709A0291 IN O
acute P10771709A0291 JJ O
Q P10771709A0291 NNP O
fever P10771709A0291 NN O
( P10771709A0291 ( O
seroconversion P10771709A0291 NN O
and P10771709A0291 CC O
/ P10771709A0291 NN O
or P10771709A0291 CC O
presence P10771709A0291 NN O
of P10771709A0291 IN O
IgM P10771709A0291 NNP I-UN
) P10771709A0291 ) O
or P10771709A0291 CC O
chronic P10771709A0291 JJ O
Q P10771709A0291 NNP O
fever P10771709A0291 NN O
( P10771709A0291 ( O
prolonged P10771709A0291 JJ O
disease P10771709A0291 NN O
and P10771709A0291 CC O
/ P10771709A0291 NN O
or P10771709A0291 CC O
IgG P10771709A0291 NNP I-UN
antibody P10771709A0291 NN I-UN
titer P10771709A0291 NN O
to P10771709A0291 TO O
phase P10771709A0291 VB O
I P10771709A0291 PRP O
of P10771709A0291 IN O
Coxiella P10771709A0291 NNP O
burnetii P10771709A0291 NN O
> P10771709A0291 NN O
or P10771709A0291 CC O
= P10771709A0291 VB O
800 P10771709A0291 CD O
) P10771709A0291 ) O
were P10771709A0291 VBD O
asked P10771709A0291 VBN O
to P10771709A0291 TO O
complete P10771709A0291 VB O
a P10771709A0291 DT O
questionnaire P10771709A0291 NN O
, P10771709A0291 , O
which P10771709A0291 WDT O
was P10771709A0291 VBD O
computerized P10771709A0291 VBN O
. P10771709A0291 . O
. . O O

Null P10471696A0734 NNP O
alleles P10471696A0734 NNS O
of P10471696A0734 IN O
SAS4 P10471696A0734 NNP I-UN
and P10471696A0734 CC O
SAS5 P10471696A0734 NNP I-UN
bypassed P10471696A0734 VBD O
the P10471696A0734 DT O
role P10471696A0734 NN O
of P10471696A0734 IN O
the P10471696A0734 DT O
Abf1p P10471696A0734 NNP I-UN
binding P10471696A0734 VBG I-UN
site P10471696A0734 NN I-UN
of P10471696A0734 IN O
the P10471696A0734 DT O
HMR-E P10471696A0734 NNP I-UN
silencer P10471696A0734 NN I-UN
but P10471696A0734 CC O
not P10471696A0734 RB O
the P10471696A0734 DT O
role P10471696A0734 NN O
of P10471696A0734 IN O
the P10471696A0734 DT O
ACS P10471696A0734 NNP I-UN
or P10471696A0734 CC O
Rap1p P10471696A0734 NNP I-UN
binding P10471696A0734 VBG I-UN
site P10471696A0734 NN I-UN
. P10471696A0734 . O
. . O O

Ang P11108151A0560 NNP I-UN
II-induced P11108151A0560 NNP O
fibronectin P11108151A0560 NN I-UN
mRNA P11108151A0560 NN O
was P11108151A0560 VBD O
not P11108151A0560 RB O
affected P11108151A0560 VBN O
by P11108151A0560 IN O
PKC P11108151A0560 NNP I-UN
inhibitors P11108151A0560 NNS O
or P11108151A0560 CC O
PKC P11108151A0560 NNP I-UN
depletion P11108151A0560 NN O
, P11108151A0560 , O
whereas P11108151A0560 WP O
specific P11108151A0560 JJ O
inhibition P11108151A0560 NN O
of P11108151A0560 IN O
EGF-R P11108151A0560 NNP I-UN
function P11108151A0560 NN O
by P11108151A0560 IN O
a P11108151A0560 DT O
dominant P11108151A0560 JJ I-UN
negative P11108151A0560 JJ I-UN
EGF-R P11108151A0560 NNP I-UN
mutant P11108151A0560 NN I-UN
and P11108151A0560 CC O
tyrphostin P11108151A0560 NN O
AG1478 P11108151A0560 NNP O
abolished P11108151A0560 VBD O
induction P11108151A0560 NN O
of P11108151A0560 IN O
fibronectin P11108151A0560 NN I-UN
mRNA P11108151A0560 NN I-UN
. P11108151A0560 . O
. . O O

The P03125422A0202 DT O
results P03125422A0202 NNS O
of P03125422A0202 IN O
these P03125422A0202 DT O
experiments P03125422A0202 NNS O
indicate P03125422A0202 VBP O
that P03125422A0202 IN O
at P03125422A0202 IN O
least P03125422A0202 JJS O
two P03125422A0202 CD O
upstream P03125422A0202 JJ O
activator P03125422A0202 NN O
sequences P03125422A0202 NNS O
( P03125422A0202 ( O
UAS P03125422A0202 NNP O
) P03125422A0202 ) O
mediate P03125422A0202 VBP O
maximum P03125422A0202 JJ O
induction P03125422A0202 NN O
by P03125422A0202 IN O
galactose P03125422A0202 NN O
. P03125422A0202 . O
. . O O

These P02595451A1136 DT O
data P02595451A1136 NNS O
locate P02595451A1136 VBP O
the P02595451A1136 DT O
aniridia P02595451A1136 NN I-UN
gene P02595451A1136 NN I-UN
( P02595451A1136 ( O
AN2 P02595451A1136 NNP I-UN
) P02595451A1136 ) O
and P02595451A1136 CC O
a P02595451A1136 DT O
recurrent P02595451A1136 JJ O
T-cell P02595451A1136 NNP I-UN
leukemia P02595451A1136 NN I-UN
breakpoint P02595451A1136 NN I-UN
( P02595451A1136 ( O
TCL2 P02595451A1136 NNP I-UN
) P02595451A1136 ) O
in P02595451A1136 IN O
the P02595451A1136 DT O
marker P02595451A1136 NN O
sequence P02595451A1136 NN O
, P02595451A1136 , O
on P02595451A1136 IN O
opposite P02595451A1136 JJ O
sides P02595451A1136 NNS O
of P02595451A1136 IN O
MIC1 P02595451A1136 NNP I-UN
. P02595451A1136 . O
. . O O

Use P02306539T0000 NNP O
of P02306539T0000 IN O
Selenastrum P02306539T0000 NNP O
capricornutum P02306539T0000 NN O
and P02306539T0000 CC O
Microfeast P02306539T0000 NNP O
as P02306539T0000 IN O
food P02306539T0000 NN O
for P02306539T0000 IN O
Daphnia P02306539T0000 NNP O
pulex P02306539T0000 NN O
. P02306539T0000 . O
. . O O

III P00825571T0031 NNP O
. P00825571T0031 . O
. . O O

Aggravating P08708984T0000 VBG O
process P08708984T0000 NN O
induced P08708984T0000 VBN O
by P08708984T0000 IN O
indomethacin P08708984T0000 NN O
on P08708984T0000 IN O
chronic P08708984T0000 JJ O
gastric P08708984T0000 JJ O
lesion P08708984T0000 NN O
in P08708984T0000 IN O
rat P08708984T0000 NN O
. P08708984T0000 . O
. . O O

A P03733563A0716 DT O
significant P03733563A0716 JJ O
herd P03733563A0716 NN O
X P03733563A0716 NNP O
period P03733563A0716 NN O
interaction P03733563A0716 NN O
existed P03733563A0716 VBD O
for P03733563A0716 IN O
liver P03733563A0716 NN O
TG P03733563A0716 NNP O
and P03733563A0716 CC O
serum P03733563A0716 NN O
dextran P03733563A0716 NN O
precipitable P03733563A0716 JJ O
cholesterol P03733563A0716 NN O
concentrations P03733563A0716 NNS O
. P03733563A0716 . O
. . O O

A P06277159T0033 DT O
hypothesis P06277159T0033 NN O
. P06277159T0033 . O
. . O O

Additionally P10333481A1102 RB O
, P10333481A1102 , O
deletion P10333481A1102 NN O
analysis P10333481A1102 NN O
of P10333481A1102 IN O
the P10333481A1102 DT O
UCP2 P10333481A1102 NNP I-UN
promoter-PLAP P10333481A1102 JJ O
constructs P10333481A1102 NNS O
indicated P10333481A1102 VBD O
that P10333481A1102 IN O
the P10333481A1102 DT O
minimal P10333481A1102 JJ O
region P10333481A1102 NN O
exhibiting P10333481A1102 VBG O
the P10333481A1102 DT O
promoter P10333481A1102 NN O
activity P10333481A1102 NN O
was P10333481A1102 VBD O
located P10333481A1102 VBN O
between P10333481A1102 IN O
nt P10333481A1102 JJ O
-33 P10333481A1102 NNP O
and P10333481A1102 CC O
+100 P10333481A1102 NNP O
, P10333481A1102 , O
and P10333481A1102 CC O
that P10333481A1102 IN O
a P10333481A1102 DT O
strong P10333481A1102 JJ O
enhancer P10333481A1102 NN O
was P10333481A1102 VBD O
present P10333481A1102 JJ O
within P10333481A1102 IN O
601 P10333481A1102 CD O
bp P10333481A1102 NN O
of P10333481A1102 IN O
the P10333481A1102 DT O
5'-promoter P10333481A1102 JJ O
region P10333481A1102 NN O
. P10333481A1102 . O
. . O O

The P02693593A0866 DT O
encoded P02693593A0866 JJ O
protein P02693593A0866 NN O
has P02693593A0866 VBZ O
a P02693593A0866 DT O
leader P02693593A0866 NN O
sequence P02693593A0866 NN O
of P02693593A0866 IN O
27 P02693593A0866 CD O
amino P02693593A0866 JJ O
acids P02693593A0866 NNS O
. P02693593A0866 . O
. . O O

Multistep P03001705T0000 NNP O
transformation P03001705T0000 NN O
by P03001705T0000 IN O
defined P03001705T0000 JJ O
fragments P03001705T0000 NNS O
of P03001705T0000 IN O
herpes P03001705T0000 NNS O
simplex P03001705T0000 JJ O
virus P03001705T0000 NN O
type P03001705T0000 NN O
2 P03001705T0000 CD O
DNA P03001705T0000 NN O
: P03001705T0000 : O
oncogenic P03001705T0000 JJ O
region P03001705T0000 NN O
and P03001705T0000 CC O
its P03001705T0000 PRP$ O
gene P03001705T0000 NN O
product P03001705T0000 NN O
. P03001705T0000 . O
. . O O

In P10453006A0478 IN O
addition P10453006A0478 NN O
to P10453006A0478 TO O
homologues P10453006A0478 NNS O
of P10453006A0478 IN O
the P10453006A0478 DT O
human P10453006A0478 JJ I-UN
genes P10453006A0478 NNS I-UN
PSMB5 P10453006A0478 NNP I-UN
through P10453006A0478 IN O
PSMB9 P10453006A0478 NNP I-UN
, P10453006A0478 , O
two P10453006A0478 CD O
new P10453006A0478 JJ O
genes P10453006A0478 NNS O
, P10453006A0478 , O
PSMB11 P10453006A0478 NNP I-UN
and P10453006A0478 CC O
PSMB12 P10453006A0478 NNP I-UN
, P10453006A0478 , O
have P10453006A0478 VBP O
been P10453006A0478 VBN O
found P10453006A0478 VBN O
for P10453006A0478 IN O
which P10453006A0478 WDT O
there P10453006A0478 EX O
are P10453006A0478 VBP O
no P10453006A0478 DT O
known P10453006A0478 JJ O
corresponding P10453006A0478 VBG O
genes P10453006A0478 NNS O
in P10453006A0478 IN O
humans P10453006A0478 NNS O
. P10453006A0478 . O
. . O O

Cotransfection P09765394A1590 NN O
of P09765394A1590 IN O
the P09765394A1590 DT O
helicase-primase P09765394A1590 JJ O
proteins P09765394A1590 NNS O
, P09765394A1590 , O
one P09765394A1590 CD O
of P09765394A1590 IN O
which P09765394A1590 WDT O
was P09765394A1590 VBD O
fused P09765394A1590 VBN O
to P09765394A1590 TO O
a P09765394A1590 DT O
heterologous P09765394A1590 JJ O
activation P09765394A1590 NN O
domain P09765394A1590 NN O
, P09765394A1590 , O
led P09765394A1590 VBN O
to P09765394A1590 TO O
Zta-dependent P09765394A1590 JJ O
superactivation P09765394A1590 NN O
of P09765394A1590 IN O
CAT P09765394A1590 NNP I-UN
expression P09765394A1590 NN O
. P09765394A1590 . O
. . O O

Thus P03591464A0840a RB O
, P03591464A0840a , O
a P03591464A0840a DT O
negative P03591464A0840a JJ O
test P03591464A0840a NN O
is P03591464A0840a VBZ O
compatible P03591464A0840a JJ O
with P03591464A0840a IN O
low P03591464A0840a JJ O
disease P03591464A0840a NN O
activity P03591464A0840a NN O
and P03591464A0840a CC O
/ P03591464A0840a NN O
or P03591464A0840a CC O
efficacy P03591464A0840a NN O
of P03591464A0840a IN O
calcium P03591464A0840a JJ O
antagonist P03591464A0840a NN O
treatment P03591464A0840a NN O
. P03591464A0840a . O
. . O O

Chronic P09102113A0739 NNP O
renal P09102113A0739 JJ O
failure P09102113A0739 NN O
patients P09102113A0739 NNS O
essentially P09102113A0739 RB O
die P09102113A0739 VBP O
from P09102113A0739 IN O
cardiovascular P09102113A0739 JJ O
causes P09102113A0739 NNS O
, P09102113A0739 , O
and P09102113A0739 CC O
the P09102113A0739 DT O
frequency P09102113A0739 NN O
of P09102113A0739 IN O
malignant P09102113A0739 JJ O
disease P09102113A0739 NN O
responsible P09102113A0739 JJ O
for P09102113A0739 IN O
death P09102113A0739 NN O
is P09102113A0739 VBZ O
estimated P09102113A0739 VBN O
to P09102113A0739 TO O
be P09102113A0739 VB O
10 P09102113A0739 CD O
% P09102113A0739 NN O
. P09102113A0739 . O
. . O O

The P08423831A0523 DT O
use P08423831A0523 NN O
of P08423831A0523 IN O
this P08423831A0523 DT O
model P08423831A0523 NN O
for P08423831A0523 IN O
investigating P08423831A0523 VBG O
pathophysiologically P08423831A0523 RB O
significant P08423831A0523 JJ O
issues P08423831A0523 NNS O
in P08423831A0523 IN O
denervating P08423831A0523 VBG O
diseases P08423831A0523 NNS O
is P08423831A0523 VBZ O
illustrated P08423831A0523 VBN O
with P08423831A0523 IN O
five P08423831A0523 CD O
different P08423831A0523 JJ O
sets P08423831A0523 NNS O
of P08423831A0523 IN O
parameters P08423831A0523 NNS O
. P08423831A0523 . O
. . O O

Role P10846069T0000 NNP O
of P10846069T0000 IN O
NH P10846069T0000 NNP O
( P10846069T0000 ( O
2 P10846069T0000 CD O
) P10846069T0000 ) O
- P10846069T0000 : O
and P10846069T0000 CC O
COOH-terminal P10846069T0000 JJ O
domains P10846069T0000 NNS O
of P10846069T0000 IN O
the P10846069T0000 DT O
P P10846069T0000 NNP I-UN
protein P10846069T0000 NN I-UN
of P10846069T0000 IN O
human P10846069T0000 JJ O
parainfluenza P10846069T0000 NN O
virus P10846069T0000 NN O
type P10846069T0000 NN O
3 P10846069T0000 CD O
in P10846069T0000 IN O
transcription P10846069T0000 NN O
and P10846069T0000 CC O
replication P10846069T0000 NN O
. P10846069T0000 . O
. . O O

After P08680706A0889 IN O
6 P08680706A0889 CD O
h P08680706A0889 NN O
of P08680706A0889 IN O
reperfusion P08680706A0889 NN O
, P08680706A0889 , O
PO2 P08680706A0889 NNP O
/ P08680706A0889 NNP O
FlO2 P08680706A0889 NNP O
ratio P08680706A0889 NN O
was P08680706A0889 VBD O
significantly P08680706A0889 RB O
better P08680706A0889 JJR O
after P08680706A0889 IN O
Combined P08680706A0889 VBN O
Therapy P08680706A0889 NNP O
( P08680706A0889 ( O
372 P08680706A0889 CD O
+ P08680706A0889 NN O
/ P08680706A0889 NNP O
- P08680706A0889 : O
52 P08680706A0889 CD O
mm P08680706A0889 NN O
Hg P08680706A0889 NNP O
) P08680706A0889 ) O
than P08680706A0889 IN O
in P08680706A0889 IN O
the P08680706A0889 DT O
Recipient P08680706A0889 NNP O
Instilled P08680706A0889 NNP O
( P08680706A0889 ( O
117 P08680706A0889 CD O
+ P08680706A0889 NN O
/ P08680706A0889 NNP O
- P08680706A0889 : O
47 P08680706A0889 CD O
mm P08680706A0889 NN O
Hg P08680706A0889 NNP O
) P08680706A0889 ) O
and P08680706A0889 CC O
Control P08680706A0889 NNP O
groups P08680706A0889 NNS O
( P08680706A0889 ( O
87 P08680706A0889 CD O
+ P08680706A0889 NN O
/ P08680706A0889 NNP O
- P08680706A0889 : O
26 P08680706A0889 CD O
mm P08680706A0889 NN O
Hg P08680706A0889 NNP O
) P08680706A0889 ) O
, P08680706A0889 , O
with P08680706A0889 IN O
intermediate P08680706A0889 JJ O
values P08680706A0889 NNS O
in P08680706A0889 IN O
Donor P08680706A0889 NNP O
Aerosol P08680706A0889 NNP O
dogs P08680706A0889 NNS O
( P08680706A0889 ( O
232 P08680706A0889 CD O
+ P08680706A0889 NN O
/ P08680706A0889 NNP O
- P08680706A0889 : O
64 P08680706A0889 CD O
mm P08680706A0889 NN O
Hg P08680706A0889 NNP O
) P08680706A0889 ) O
. P08680706A0889 . O
. . O O

A P09651367T0000 DT O
role P09651367T0000 NN O
for P09651367T0000 IN O
RalGDS P09651367T0000 NNP I-UN
and P09651367T0000 CC O
a P09651367T0000 DT O
novel P09651367T0000 JJ O
Ras P09651367T0000 NNP I-UN
effector P09651367T0000 NN O
in P09651367T0000 IN O
the P09651367T0000 DT O
Ras-mediated P09651367T0000 JJ O
inhibition P09651367T0000 NN O
of P09651367T0000 IN O
skeletal P09651367T0000 JJ O
myogenesis P09651367T0000 NN O
. P09651367T0000 . O
. . O O

In P02199311A0620 IN O
vitro P02199311A0620 JJ O
transcription P02199311A0620 NN O
extracts P02199311A0620 NNS O
from P02199311A0620 IN O
ret1-1 P02199311A0620 JJ I-UN
cells P02199311A0620 NNS O
terminate P02199311A0620 NN O
less P02199311A0620 RBR O
efficiently P02199311A0620 RB O
at P02199311A0620 IN O
weak P02199311A0620 JJ O
transcription P02199311A0620 NN O
termination P02199311A0620 NN O
signals P02199311A0620 NNS O
than P02199311A0620 IN O
those P02199311A0620 DT O
from P02199311A0620 IN O
RET1 P02199311A0620 NNP I-UN
cells P02199311A0620 NNS O
, P02199311A0620 , O
using P02199311A0620 VBG O
a P02199311A0620 DT O
variety P02199311A0620 NN O
of P02199311A0620 IN O
tRNA P02199311A0620 JJ O
templates P02199311A0620 NNS O
. P02199311A0620 . O
. . O O

The P10857215A0806 DT O
MRS P10857215A0806 NNP O
II P10857215A0806 NNP O
meets P10857215A0806 VBZ O
a P10857215A0806 DT O
high P10857215A0806 JJ O
methodological P10857215A0806 JJ O
standard P10857215A0806 NN O
as P10857215A0806 IN O
an P10857215A0806 DT O
instrument P10857215A0806 NN O
standardized P10857215A0806 VBN O
in P10857215A0806 IN O
the P10857215A0806 DT O
population P10857215A0806 NN O
. P10857215A0806 . O
. . O O

Their P04295031T0062 PRP$ O
effect P04295031T0062 NN O
on P04295031T0062 IN O
the P04295031T0062 DT O
guinea P04295031T0062 NN O
pig P04295031T0062 NN O
vas P04295031T0062 NN O
deferens P04295031T0062 NNS O
. P04295031T0062 . O
. . O O

All P08164302A0547 DT O
of P08164302A0547 IN O
the P08164302A0547 DT O
basal P08164302A0547 NN O
TPN P08164302A0547 NNP O
solutions P08164302A0547 NNS O
were P08164302A0547 VBD O
isonitrogenous P08164302A0547 JJ O
and P08164302A0547 CC O
identical P08164302A0547 JJ O
in P08164302A0547 IN O
nutrient P08164302A0547 JJ O
composition P08164302A0547 NN O
, P08164302A0547 , O
except P08164302A0547 IN O
for P08164302A0547 IN O
the P08164302A0547 DT O
difference P08164302A0547 NN O
in P08164302A0547 IN O
energy P08164302A0547 NN O
level P08164302A0547 NN O
, P08164302A0547 , O
which P08164302A0547 WDT O
was P08164302A0547 VBD O
adjusted P08164302A0547 VBN O
with P08164302A0547 IN O
glucose P08164302A0547 NN O
. P08164302A0547 . O
. . O O

Group P02940334A0141 NNP O
A P02940334A0141 NNP O
was P02940334A0141 VBD O
treated P02940334A0141 VBN O
with P02940334A0141 IN O
three P02940334A0141 CD O
or P02940334A0141 CC O
four P02940334A0141 CD O
doses P02940334A0141 NNS O
of P02940334A0141 IN O
hepatitis P02940334A0141 NN I-UN
B P02940334A0141 NNP I-UN
immune P02940334A0141 NN I-UN
globulin P02940334A0141 NN I-UN
( P02940334A0141 ( O
HBIG P02940334A0141 NNP I-UN
) P02940334A0141 ) O
in P02940334A0141 IN O
one P02940334A0141 CD O
of P02940334A0141 IN O
three P02940334A0141 CD O
different P02940334A0141 JJ O
schedules P02940334A0141 NNS O
. P02940334A0141 . O
. . O O

Out P06674977A1181 IN O
of P06674977A1181 IN O
these P06674977A1181 DT O
families P06674977A1181 NNS O
74,3 P06674977A1181 CD O
% P06674977A1181 NN O
planned P06674977A1181 VBN O
next P06674977A1181 JJ O
pregnancy P06674977A1181 NN O
( P06674977A1181 ( O
table P06674977A1181 JJ O
IX P06674977A1181 NNP O
) P06674977A1181 ) O
, P06674977A1181 , O
57,6 P06674977A1181 CD O
% P06674977A1181 NN O
wanted P06674977A1181 VBD O
to P06674977A1181 TO O
have P06674977A1181 VB O
prenatal P06674977A1181 JJ O
diagnosis P06674977A1181 NN O
( P06674977A1181 ( O
table P06674977A1181 JJ O
VI P06674977A1181 NNP O
) P06674977A1181 ) O
. P06674977A1181 . O
. . O O

Unusual P06184276T0001 JJ O
course P06184276T0001 NN O
of P06184276T0001 IN O
plasmocytosis P06184276T0001 NN O
. P06184276T0001 . O
. . O O

Thus P11274179A0610 RB O
, P11274179A0610 , O
our P11274179A0610 PRP$ O
studies P11274179A0610 NNS O
define P11274179A0610 VBP O
Rac P11274179A0610 NNP I-UN
/ P11274179A0610 NNP O
Cdc42 P11274179A0610 NNP I-UN
/ P11274179A0610 NNP O
Pak P11274179A0610 NNP I-UN
as P11274179A0610 IN O
a P11274179A0610 DT O
module P11274179A0610 NN O
upstream P11274179A0610 NN O
of P11274179A0610 IN O
Raf-1 P11274179A0610 NNP I-UN
during P11274179A0610 IN O
its P11274179A0610 PRP$ O
activation P11274179A0610 NN O
by P11274179A0610 IN O
microtubule P11274179A0610 NN O
disruption P11274179A0610 NN O
. P11274179A0610 . O
. . O O

The P09294422A1223 DT O
two P09294422A1223 CD O
cysteine P09294422A1223 NN O
residues P09294422A1223 NNS O
located P09294422A1223 VBN O
in P09294422A1223 IN O
this P09294422A1223 DT O
additional P09294422A1223 JJ O
region P09294422A1223 NN O
may P09294422A1223 MD O
be P09294422A1223 VB O
involved P09294422A1223 VBN O
in P09294422A1223 IN O
the P09294422A1223 DT O
formation P09294422A1223 NN O
of P09294422A1223 IN O
a P09294422A1223 DT O
disulfide P09294422A1223 NN O
bridge P09294422A1223 NN O
associated P09294422A1223 VBN O
with P09294422A1223 IN O
the P09294422A1223 DT O
activation P09294422A1223 NN O
process P09294422A1223 NN O
of P09294422A1223 IN O
the P09294422A1223 DT O
catalytic P09294422A1223 JJ O
activity P09294422A1223 NN O
. P09294422A1223 . O
. . O O

The P09753769A0362 DT O
primers P09753769A0362 NNS O
were P09753769A0362 VBD O
degenerate P09753769A0362 JJ O
sets P09753769A0362 NNS O
of P09753769A0362 IN O
oligonucleotides P09753769A0362 NNS O
derived P09753769A0362 VBN O
from P09753769A0362 IN O
known P09753769A0362 VBN O
amino P09753769A0362 NN O
acid P09753769A0362 NN O
sequences P09753769A0362 NNS O
of P09753769A0362 IN O
the P09753769A0362 DT O
PBAN P09753769A0362 NNP I-UN
precursor P09753769A0362 NN I-UN
. P09753769A0362 . O
. . O O

The P08288240A0304 DT O
sequence P08288240A0304 NN O
similarity P08288240A0304 NN O
has P08288240A0304 VBZ O
suggested P08288240A0304 VBN O
that P08288240A0304 IN O
SCG10 P08288240A0304 NNP I-UN
and P08288240A0304 CC O
stathmin P08288240A0304 NNS I-UN
have P08288240A0304 VBP O
been P08288240A0304 VBN O
derived P08288240A0304 VBN O
from P08288240A0304 IN O
structurally P08288240A0304 RB O
and P08288240A0304 CC O
evolutionarily P08288240A0304 RB O
related P08288240A0304 VBN O
genes P08288240A0304 NNS O
. P08288240A0304 . O
. . O O

No P11825801A1212 DT O
increased P11825801A1212 VBD O
tumor-related P11825801A1212 JJ O
mortality P11825801A1212 NN O
was P11825801A1212 VBD O
observed P11825801A1212 VBN O
after P11825801A1212 IN O
a P11825801A1212 DT O
mean P11825801A1212 JJ O
follow-up P11825801A1212 NN O
of P11825801A1212 IN O
44 P11825801A1212 CD O
months P11825801A1212 NNS O
. P11825801A1212 . O
. . O O

Additionally P10723723A0781 RB O
, P10723723A0781 , O
the P10723723A0781 DT O
mouse P10723723A0781 NN O
promoter P10723723A0781 NN O
contains P10723723A0781 VBZ O
22 P10723723A0781 CD O
copies P10723723A0781 NNS O
of P10723723A0781 IN O
a P10723723A0781 DT O
CT P10723723A0781 NNP O
dinucleotide P10723723A0781 NN O
repeat P10723723A0781 NN O
sequence P10723723A0781 NN O
located P10723723A0781 VBD O
approximately P10723723A0781 RB O
155 P10723723A0781 CD O
bp P10723723A0781 VBD O
5 P10723723A0781 CD O
' P10723723A0781 '' O
to P10723723A0781 TO O
exon P10723723A0781 VB O
1 P10723723A0781 CD O
. P10723723A0781 . O
. . O O

Seventy-two P03207975A0709 JJ O
hours P03207975A0709 NNS O
after P03207975A0709 IN O
administration P03207975A0709 NN O
of P03207975A0709 IN O
vitamin P03207975A0709 JJ O
K1 P03207975A0709 NNP O
, P03207975A0709 , O
plasma P03207975A0709 JJ O
concentrations P03207975A0709 NNS O
of P03207975A0709 IN O
the P03207975A0709 DT O
vitamin P03207975A0709 NN O
were P03207975A0709 VBD O
not P03207975A0709 RB O
different P03207975A0709 JJ O
from P03207975A0709 IN O
normal P03207975A0709 JJ O
. P03207975A0709 . O
. . O O

Our P10760132A1169 PRP$ O
data P10760132A1169 NNS O
suggest P10760132A1169 VBP O
that P10760132A1169 IN O
, P10760132A1169 , O
at P10760132A1169 IN O
least P10760132A1169 JJS O
at P10760132A1169 IN O
high P10760132A1169 JJ O
temperature P10760132A1169 NN O
, P10760132A1169 , O
a P10760132A1169 DT O
critical P10760132A1169 JJ O
minimal P10760132A1169 JJ O
level P10760132A1169 NN O
of P10760132A1169 IN O
Ypt P10760132A1169 NNP I-UN
protein P10760132A1169 NN I-UN
prenylation P10760132A1169 NN O
is P10760132A1169 VBZ O
required P10760132A1169 VBN O
for P10760132A1169 IN O
maintaining P10760132A1169 VBG O
vesicle P10760132A1169 NN O
polarization P10760132A1169 NN O
. P10760132A1169 . O
. . O O

Causes P02852894T0000 NNS O
of P02852894T0000 IN O
death P02852894T0000 NN O
found P02852894T0000 VBN O
in P02852894T0000 IN O
an P02852894T0000 DT O
epidemiological P02852894T0000 JJ O
study P02852894T0000 NN O
of P02852894T0000 IN O
native P02852894T0000 JJ O
chickens P02852894T0000 NNS O
in P02852894T0000 IN O
Thai P02852894T0000 NNP O
villages P02852894T0000 NNS O
. P02852894T0000 . O
. . O O

Administration P07130335A1081 NN O
of P07130335A1081 IN O
the P07130335A1081 DT O
dopamine P07130335A1081 JJ O
agonist P07130335A1081 NN O
bromocriptine P07130335A1081 NN O
( P07130335A1081 ( O
2.5 P07130335A1081 CD O
mg P07130335A1081 NN O
three P07130335A1081 CD O
times P07130335A1081 NNS O
a P07130335A1081 DT O
day P07130335A1081 NN O
for P07130335A1081 IN O
4 P07130335A1081 CD O
days P07130335A1081 NNS O
) P07130335A1081 ) O
suppressed P07130335A1081 VBD O
( P07130335A1081 ( O
P P07130335A1081 NNP O
less P07130335A1081 JJR O
than P07130335A1081 IN O
0.01 P07130335A1081 CD O
) P07130335A1081 ) O
mean P07130335A1081 VB O
24-h P07130335A1081 JJ O
plasma P07130335A1081 JJ O
18-OHB P07130335A1081 JJ O
levels P07130335A1081 NNS O
from P07130335A1081 IN O
21.9 P07130335A1081 CD O
+ P07130335A1081 NNS O
/ P07130335A1081 SYM O
- P07130335A1081 : O
2.0 P07130335A1081 CD O
to P07130335A1081 TO O
14.8 P07130335A1081 CD O
+ P07130335A1081 NNS O
/ P07130335A1081 SYM O
- P07130335A1081 : O
1.4 P07130335A1081 CD O
ng P07130335A1081 JJ O
/ P07130335A1081 NNP O
dl P07130335A1081 NN O
. P07130335A1081 . O
. . O O

The P10329566A0610 DT O
3 P10329566A0610 CD O
' P10329566A0610 POS O
terminus P10329566A0610 NN O
of P10329566A0610 IN O
the P10329566A0610 DT O
genome P10329566A0610 NN O
can P10329566A0610 MD O
be P10329566A0610 VB O
folded P10329566A0610 VBN O
into P10329566A0610 IN O
a P10329566A0610 DT O
tRNA-like P10329566A0610 JJ O
secondary P10329566A0610 JJ O
structure P10329566A0610 NN O
that P10329566A0610 WDT O
has P10329566A0610 VBZ O
a P10329566A0610 DT O
valine P10329566A0610 JJ O
anticodon P10329566A0610 NN O
; P10329566A0610 : O
the P10329566A0610 DT O
tRNA-like P10329566A0610 JJ O
structure P10329566A0610 NN O
lacks P10329566A0610 VBZ O
a P10329566A0610 DT O
pseudoknot P10329566A0610 NN O
in P10329566A0610 IN O
the P10329566A0610 DT O
aminoacyl P10329566A0610 JJ O
stem P10329566A0610 NN O
, P10329566A0610 , O
a P10329566A0610 DT O
feature P10329566A0610 NN O
common P10329566A0610 JJ O
to P10329566A0610 TO O
both P10329566A0610 DT O
genera P10329566A0610 NN O
of P10329566A0610 IN O
tetraviruses P10329566A0610 NNS O
. P10329566A0610 . O
. . O O

Sp1 P09488441A0615 NNP I-UN
can P09488441A0615 MD O
activate P09488441A0615 VB O
transcription P09488441A0615 NN O
through P09488441A0615 IN O
immunoglobulin P09488441A0615 JJ I-UN
kappa-chain P09488441A0615 JJ I-UN
enhancer P09488441A0615 NN I-UN
or P09488441A0615 CC O
P-selectin P09488441A0615 JJ I-UN
promoter P09488441A0615 NN I-UN
NF-kappaB P09488441A0615 NNP I-UN
sites P09488441A0615 NNS I-UN
. P09488441A0615 . O
p50 P09488441A0615 NN I-UN
homodimers P09488441A0615 NNS I-UN
replace P09488441A0615 VB O
Sp1 P09488441A0615 NNP I-UN
from P09488441A0615 IN O
the P09488441A0615 DT O
P-selectin P09488441A0615 NNP I-UN
promoter P09488441A0615 NN I-UN
by P09488441A0615 IN O
binding P09488441A0615 VBG O
site P09488441A0615 NN O
competition P09488441A0615 NN O
and P09488441A0615 CC O
thereby P09488441A0615 NN O
either P09488441A0615 CC O
inhibit P09488441A0615 NN O
basal P09488441A0615 JJ O
Sp1-driven P09488441A0615 JJ O
expression P09488441A0615 NN O
or P09488441A0615 CC O
, P09488441A0615 , O
in P09488441A0615 IN O
concert P09488441A0615 NN O
with P09488441A0615 IN O
Bcl-3 P09488441A0615 NNP I-UN
, P09488441A0615 , O
stimulate P09488441A0615 JJ O
expression P09488441A0615 NN O
. P09488441A0615 . O
. . O O

It P00481612A1121 PRP O
is P00481612A1121 VBZ O
concluded P00481612A1121 VBN O
that P00481612A1121 IN O
opiate P00481612A1121 JJ I-UN
receptors P00481612A1121 NNS I-UN
bordering P00481612A1121 VBG O
the P00481612A1121 DT O
fourth P00481612A1121 JJ O
cerebral P00481612A1121 JJ O
ventricle P00481612A1121 NN O
mediate P00481612A1121 VBP O
the P00481612A1121 DT O
cardiovascular P00481612A1121 NN O
and P00481612A1121 CC O
hypnotic P00481612A1121 JJ O
action P00481612A1121 NN O
of P00481612A1121 IN O
fentanyl P00481612A1121 NN O
. P00481612A1121 . O
. . O O

Proceedings P04544430T0001 NNS O
: P04544430T0001 : O
Reversible P04544430T0001 JJ O
complete P04544430T0001 JJ O
heart P04544430T0001 NN O
block P04544430T0001 NN O
following P04544430T0001 VBG O
surgery P04544430T0001 NN O
of P04544430T0001 IN O
congenital P04544430T0001 JJ O
heart P04544430T0001 NN O
defects P04544430T0001 NNS O
. P04544430T0001 . O
. . O O

Clones P08552643A0261 NNS O
that P08552643A0261 WDT O
expressed P08552643A0261 VBD O
DBD P08552643A0261 NNP O
exhibited P08552643A0261 VBD O
a P08552643A0261 DT O
dominant P08552643A0261 JJ O
negative P08552643A0261 JJ O
phenotype P08552643A0261 NN O
and P08552643A0261 CC O
did P08552643A0261 VBD O
not P08552643A0261 RB O
elicit P08552643A0261 VB O
antiviral P08552643A0261 JJ O
activity P08552643A0261 NN O
against P08552643A0261 IN O
vesicular P08552643A0261 JJ O
stomatitis P08552643A0261 NN O
virus P08552643A0261 NN O
( P08552643A0261 ( O
VSV P08552643A0261 NNP O
) P08552643A0261 ) O
infection P08552643A0261 NN O
upon P08552643A0261 IN O
IFN P08552643A0261 NNP I-UN
treatment P08552643A0261 NN O
. P08552643A0261 . O
. . O O

Here P08810278A0682 RB O
we P08810278A0682 PRP O
demonstrate P08810278A0682 VBP O
that P08810278A0682 IN O
another P08810278A0682 DT O
cellular P08810278A0682 JJ O
protein P08810278A0682 NN O
linked P08810278A0682 VBD O
to P08810278A0682 TO O
BCR P08810278A0682 NNP I-UN
/ P08810278A0682 NNP O
ABL P08810278A0682 NNP I-UN
through P08810278A0682 IN O
the P08810278A0682 DT O
CRKL-SH2 P08810278A0682 NNP O
domain P08810278A0682 NN O
is P08810278A0682 VBZ O
p130 P08810278A0682 JJ I-UN
( P08810278A0682 ( O
CAS P08810278A0682 NNP I-UN
) P08810278A0682 ) O
. P08810278A0682 . O
p130 P08810278A0682 NN I-UN
( P08810278A0682 ( O
CAS P08810278A0682 NNP I-UN
) P08810278A0682 ) O
was P08810278A0682 VBD O
found P08810278A0682 VBN O
to P08810278A0682 TO O
be P08810278A0682 VB O
tyrosine P08810278A0682 JJ O
phosphorylated P08810278A0682 VBN O
and P08810278A0682 CC O
associated P08810278A0682 VBN O
with P08810278A0682 IN O
CRKL P08810278A0682 NNP I-UN
in P08810278A0682 IN O
BCR P08810278A0682 NNP I-UN
/ P08810278A0682 NNP O
ABL P08810278A0682 NNP I-UN
expressing P08810278A0682 VBG O
cell P08810278A0682 NN O
lines P08810278A0682 NNS O
and P08810278A0682 CC O
in P08810278A0682 IN O
samples P08810278A0682 NNS O
obtained P08810278A0682 VBN O
from P08810278A0682 IN O
CML P08810278A0682 NNP O
and P08810278A0682 CC O
ALL P08810278A0682 NNP O
patients P08810278A0682 NNS O
, P08810278A0682 , O
but P08810278A0682 CC O
not P08810278A0682 RB O
in P08810278A0682 IN O
samples P08810278A0682 NNS O
from P08810278A0682 IN O
controls P08810278A0682 NNS O
. P08810278A0682 . O
. . O O

The P09083563A0971 DT O
prominent P09083563A0971 JJ O
lesions P09083563A0971 NNS O
were P09083563A0971 VBD O
confined P09083563A0971 VBN O
to P09083563A0971 TO O
the P09083563A0971 DT O
cerebral P09083563A0971 JJ O
surface P09083563A0971 NN O
layer P09083563A0971 NN O
and P09083563A0971 CC O
leptomeningeal P09083563A0971 JJ O
tissue P09083563A0971 NN O
including P09083563A0971 VBG O
the P09083563A0971 DT O
arachnoid P09083563A0971 NN O
vessels P09083563A0971 NNS O
, P09083563A0971 , O
which P09083563A0971 WDT O
were P09083563A0971 VBD O
all P09083563A0971 DT O
bathed P09083563A0971 VBN O
in P09083563A0971 IN O
the P09083563A0971 DT O
cerebrospinal P09083563A0971 JJ O
fluid P09083563A0971 NN O
, P09083563A0971 , O
suggesting P09083563A0971 VBG O
that P09083563A0971 IN O
some P09083563A0971 DT O
necrotizing P09083563A0971 NN O
toxins P09083563A0971 NNS O
had P09083563A0971 VBD O
been P09083563A0971 VBN O
secreted P09083563A0971 VBN O
into P09083563A0971 IN O
the P09083563A0971 DT O
fluid P09083563A0971 NN O
by P09083563A0971 IN O
the P09083563A0971 DT O
B. P09083563A0971 NNP O
cereus P09083563A0971 NN O
. P09083563A0971 . O
. . O O

Native P00150066A0100 JJ O
human P00150066A0100 JJ I-UN
fibrinogen P00150066A0100 NN I-UN
was P00150066A0100 VBD O
brought P00150066A0100 VBN O
to P00150066A0100 TO O
coagulation P00150066A0100 NN O
by P00150066A0100 IN O
adding P00150066A0100 VBG O
thrombin P00150066A0100 NN I-UN
. P00150066A0100 . O
. . O O

In P11207609A0994 IN O
contrast P11207609A0994 NN O
, P11207609A0994 , O
the P11207609A0994 DT O
failure P11207609A0994 NN O
of P11207609A0994 IN O
the P11207609A0994 DT O
QKTT P11207609A0994 NNP O
motif P11207609A0994 NN O
and P11207609A0994 CC O
TGN46 P11207609A0994 NNP O
cytoplasmic P11207609A0994 JJ O
tail P11207609A0994 NN O
to P11207609A0994 TO O
induce P11207609A0994 VB O
steady-state P11207609A0994 JJ O
ER P11207609A0994 NNP O
localization P11207609A0994 NN O
of P11207609A0994 IN O
vesicular P11207609A0994 JJ I-UN
stomatitis P11207609A0994 NN I-UN
virus P11207609A0994 NN I-UN
glycoprotein P11207609A0994 NN I-UN
( P11207609A0994 ( O
VSVG P11207609A0994 NNP I-UN
) P11207609A0994 ) O
chimeras P11207609A0994 NN O
in P11207609A0994 IN O
HeLa P11207609A0994 NNP O
and P11207609A0994 CC O
NRK P11207609A0994 NNP O
cells P11207609A0994 NNS O
indicates P11207609A0994 VBZ O
that P11207609A0994 IN O
significant P11207609A0994 JJ O
differences P11207609A0994 NNS O
in P11207609A0994 IN O
early P11207609A0994 JJ O
secretory P11207609A0994 NN O
trafficking P11207609A0994 NN O
also P11207609A0994 RB O
exist P11207609A0994 VBP O
. P11207609A0994 . O
. . O O

Using P09400613A1209 VBG O
GST-PKR P09400613A1209 NNP O
fusion P09400613A1209 NN O
chromatography P09400613A1209 NN O
, P09400613A1209 , O
direct P09400613A1209 JJ O
physical P09400613A1209 JJ O
interaction P09400613A1209 NN O
between P09400613A1209 IN O
the P09400613A1209 DT O
mouse P09400613A1209 NN O
and P09400613A1209 CC O
human P09400613A1209 JJ I-UN
PKR P09400613A1209 NNP I-UN
homologs P09400613A1209 NN I-UN
was P09400613A1209 VBD O
established P09400613A1209 VBN O
. P09400613A1209 . O
. . O O

Cattaneo P03013841A0207 NNP O
, P03013841A0207 , O
and P03013841A0207 CC O
J P03013841A0207 NNP O
. P03013841A0207 . O
. . O O

The P08112611A0404 DT O
sequence P08112611A0404 NN O
has P08112611A0404 VBZ O
a P08112611A0404 DT O
1092-bp P08112611A0404 JJ O
open P08112611A0404 JJ O
reading P08112611A0404 NN O
frame P08112611A0404 NN O
encoding P08112611A0404 VBG O
a P08112611A0404 DT O
protein P08112611A0404 NN O
of P08112611A0404 IN O
364 P08112611A0404 CD O
amino P08112611A0404 JJ O
acids P08112611A0404 NNS O
. P08112611A0404 . O
. . O O

188 P06330478A0304 CD O
patients P06330478A0304 NNS O
received P06330478A0304 VBD O
cimetidine P06330478A0304 JJ O
400 P06330478A0304 CD O
mg P06330478A0304 NN O
q.i.d P06330478A0304 NN O
. P06330478A0304 . O
intravenously P06330478A0304 RB O
and P06330478A0304 CC O
1,000 P06330478A0304 CD O
mg P06330478A0304 NNS O
daily P06330478A0304 RB O
orally P06330478A0304 RB O
in P06330478A0304 IN O
divided P06330478A0304 JJ O
doses P06330478A0304 NNS O
. P06330478A0304 . O
. . O O

CONCLUSIONS P09866068A1058 NN O
: P09866068A1058 : O
Pretreatment P09866068A1058 NN O
with P09866068A1058 IN O
OCs P09866068A1058 NNP O
prior P09866068A1058 RB O
to P09866068A1058 TO O
pituitary P09866068A1058 JJ O
suppression P09866068A1058 NN O
in P09866068A1058 IN O
the P09866068A1058 DT O
early P09866068A1058 JJ O
follicular P09866068A1058 JJ O
phase P09866068A1058 NN O
decreases P09866068A1058 VBZ O
ovarian P09866068A1058 JJ O
cyst P09866068A1058 NN O
formation P09866068A1058 NN O
, P09866068A1058 , O
without P09866068A1058 IN O
an P09866068A1058 DT O
apparent P09866068A1058 JJ O
effect P09866068A1058 NN O
on P09866068A1058 IN O
subsequent P09866068A1058 JJ O
follicular P09866068A1058 JJ O
recruitment P09866068A1058 NN O
or P09866068A1058 CC O
pregnancy P09866068A1058 NN O
rates P09866068A1058 NNS O
. P09866068A1058 . O
. . O O

After P09778006A0718 IN O
measuring P09778006A0718 VBG O
baseline P09778006A0718 NN O
Vmca P09778006A0718 NNP O
at P09778006A0718 IN O
a P09778006A0718 DT O
partial P09778006A0718 JJ O
pressure P09778006A0718 NN O
of P09778006A0718 IN O
carbon P09778006A0718 NN O
dioxide P09778006A0718 NN O
in P09778006A0718 IN O
arterial P09778006A0718 JJ O
blood P09778006A0718 NN O
( P09778006A0718 ( O
PaCO2 P09778006A0718 NNP O
) P09778006A0718 ) O
of P09778006A0718 IN O
37.7 P09778006A0718 CD O
+ P09778006A0718 NNS O
/ P09778006A0718 SYM O
- P09778006A0718 : O
4.5 P09778006A0718 CD O
mmHg P09778006A0718 NN O
( P09778006A0718 ( O
mean P09778006A0718 JJ O
+ P09778006A0718 NNP O
/ P09778006A0718 NNP O
- P09778006A0718 : O
SD P09778006A0718 NN O
) P09778006A0718 ) O
, P09778006A0718 , O
measurements P09778006A0718 NNS O
were P09778006A0718 VBD O
repeated P09778006A0718 VBN O
at P09778006A0718 IN O
a P09778006A0718 DT O
PaCO P09778006A0718 NNP O
of P09778006A0718 IN O
44.2 P09778006A0718 CD O
+ P09778006A0718 NNS O
/ P09778006A0718 SYM O
- P09778006A0718 : O
3.8 P09778006A0718 CD O
mmHg P09778006A0718 NN O
, P09778006A0718 , O
and P09778006A0718 CC O
the P09778006A0718 DT O
carbon P09778006A0718 NN O
dioxide P09778006A0718 NN O
reactivity P09778006A0718 NN O
( P09778006A0718 ( O
absolute P09778006A0718 JJ O
value P09778006A0718 NN O
: P09778006A0718 : O
cm P09778006A0718 NN O
x P09778006A0718 NN O
s P09778006A0718 NN O
( P09778006A0718 ( O
-1 P09778006A0718 NNP O
) P09778006A0718 ) O
x P09778006A0718 VBP O
mmHg P09778006A0718 NN O
( P09778006A0718 ( O
-1 P09778006A0718 NNP O
) P09778006A0718 ) O
; P09778006A0718 : O
relative P09778006A0718 JJ O
value P09778006A0718 NN O
: P09778006A0718 : O
percentage P09778006A0718 NN O
of P09778006A0718 IN O
baseline P09778006A0718 NN O
Vmca P09778006A0718 NNP O
/ P09778006A0718 NNP O
mmHg P09778006A0718 NN O
) P09778006A0718 ) O
was P09778006A0718 VBD O
calculated P09778006A0718 VBN O
. P09778006A0718 . O
. . O O

SCFFWD1 P10228155A1293 NNP I-UN
may P10228155A1293 MD O
be P10228155A1293 VB O
critical P10228155A1293 JJ O
for P10228155A1293 IN O
tumor P10228155A1293 NN O
development P10228155A1293 NN O
and P10228155A1293 CC O
suppression P10228155A1293 NN O
through P10228155A1293 IN O
regulation P10228155A1293 NN O
of P10228155A1293 IN O
beta-catenin P10228155A1293 JJ I-UN
protein P10228155A1293 NN I-UN
stability P10228155A1293 NN O
. P10228155A1293 . O
. . O O

In P02720966A0455 IN O
cerebrospinal P02720966A0455 JJ O
fluid P02720966A0455 NN O
, P02720966A0455 , O
an P02720966A0455 DT O
ADA P02720966A0455 NNP I-UN
catalytic P02720966A0455 JJ O
concentration P02720966A0455 NN O
above P02720966A0455 IN O
0.15 P02720966A0455 CD O
mu P02720966A0455 NNS O
kat P02720966A0455 JJ O
/ P02720966A0455 NNP O
L P02720966A0455 NNP O
strongly P02720966A0455 RB O
suggests P02720966A0455 VBZ O
tuberculous P02720966A0455 JJ O
meningitis P02720966A0455 NN O
in P02720966A0455 IN O
patients P02720966A0455 NNS O
older P02720966A0455 JJR O
than P02720966A0455 IN O
7 P02720966A0455 CD O
years P02720966A0455 NNS O
( P02720966A0455 ( O
sensitivity P02720966A0455 NN O
1.00 P02720966A0455 CD O
, P02720966A0455 , O
specificity P02720966A0455 NN O
0.99 P02720966A0455 CD O
and P02720966A0455 CC O
efficiency P02720966A0455 $ O
0.99 P02720966A0455 CD O
) P02720966A0455 ) O
. P02720966A0455 . O
. . O O

Replacement P08387743A0624 NN O
of P08387743A0624 IN O
the P08387743A0624 DT O
wild-type P08387743A0624 JJ O
5'-regulatory P08387743A0624 JJ O
region P08387743A0624 NN O
with P08387743A0624 IN O
either P08387743A0624 DT O
of P08387743A0624 IN O
the P08387743A0624 DT O
mutants P08387743A0624 NNS O
' P08387743A0624 POS O
cis-acting P08387743A0624 JJ O
regulatory P08387743A0624 JJ O
element P08387743A0624 NN O
resulted P08387743A0624 VBD O
in P08387743A0624 IN O
the P08387743A0624 DT O
anaerobic P08387743A0624 JJ O
expression P08387743A0624 NN O
of P08387743A0624 IN O
active P08387743A0624 JJ I-UN
Mn-superoxide P08387743A0624 JJ I-UN
dismutase P08387743A0624 NN I-UN
. P08387743A0624 . O
. . O O

Telomeres P01975428A0151 NNS O
prevent P01975428A0151 VBP O
end-to-end P01975428A0151 JJ O
fusions P01975428A0151 NNS O
and P01975428A0151 CC O
exonucleolytic P01975428A0151 JJ O
degradation P01975428A0151 NN O
, P01975428A0151 , O
enable P01975428A0151 VB O
the P01975428A0151 DT O
end P01975428A0151 NN O
of P01975428A0151 IN O
the P01975428A0151 DT O
linear P01975428A0151 JJ O
DNA P01975428A0151 NNP O
molecule P01975428A0151 NN O
to P01975428A0151 TO O
replicate P01975428A0151 VB O
, P01975428A0151 , O
and P01975428A0151 CC O
function P01975428A0151 NN O
in P01975428A0151 IN O
cell P01975428A0151 NN O
division P01975428A0151 NN O
. P01975428A0151 . O
. . O O

The P08393143A1281 DT O
Sp1 P08393143A1281 NNP I-UN
region P08393143A1281 NN I-UN
, P08393143A1281 , O
however P08393143A1281 RB O
, P08393143A1281 , O
is P08393143A1281 VBZ O
converted P08393143A1281 VBN O
to P08393143A1281 TO O
a P08393143A1281 DT O
functionally P08393143A1281 RB O
strong P08393143A1281 JJ O
TRE P08393143A1281 NNP O
by P08393143A1281 IN O
the P08393143A1281 DT O
viral P08393143A1281 JJ I-UN
tat P08393143A1281 NN I-UN
factor P08393143A1281 NN I-UN
. P08393143A1281 . O
. . O O

A P00618078A0367 DT O
decrease P00618078A0367 NN O
of P00618078A0367 IN O
the P00618078A0367 DT O
lysozyme P00618078A0367 NN I-UN
activity P00618078A0367 NN O
coincided P00618078A0367 VBN O
with P00618078A0367 IN O
the P00618078A0367 DT O
clinical P00618078A0367 JJ O
improvement P00618078A0367 NN O
of P00618078A0367 IN O
the P00618078A0367 DT O
bacterial P00618078A0367 JJ O
meningitis P00618078A0367 NN O
. P00618078A0367 . O
. . O O

KRN2391 P07979827A0722 NNP O
and P07979827A0722 CC O
cromakalim P07979827A0722 NN O
produced P07979827A0722 VBD O
a P07979827A0722 DT O
dose-dependent P07979827A0722 JJ O
increase P07979827A0722 NN O
in P07979827A0722 IN O
aortic P07979827A0722 JJ O
and P07979827A0722 CC O
coronary P07979827A0722 JJ O
blood P07979827A0722 NN O
flow P07979827A0722 NN O
. P07979827A0722 . O
. . O O

This P09238850A2042 DT O
night-day P09238850A2042 JJ O
oscillation P09238850A2042 NN O
is P09238850A2042 VBZ O
driven P09238850A2042 VBN O
by P09238850A2042 IN O
the P09238850A2042 DT O
endogenous P09238850A2042 JJ O
clock P09238850A2042 NN O
( P09238850A2042 ( O
located P09238850A2042 VBN O
in P09238850A2042 IN O
the P09238850A2042 DT O
suprachiasmatic P09238850A2042 JJ O
nucleus P09238850A2042 NN O
, P09238850A2042 , O
SCN P09238850A2042 NNP O
) P09238850A2042 ) O
. P09238850A2042 . O
. . O O

For P07149047A0260 IN O
various P07149047A0260 JJ O
dog P07149047A0260 NN O
vessels P07149047A0260 NNS O
in P07149047A0260 IN O
vivo P07149047A0260 NN O
, P07149047A0260 , O
Q P07149047A0260 NNP O
/ P07149047A0260 NNP O
Dk P07149047A0260 NNP O
ranged P07149047A0260 VBD O
from P07149047A0260 IN O
0.15 P07149047A0260 CD O
to P07149047A0260 TO O
47 P07149047A0260 CD O
X P07149047A0260 NNS O
10 P07149047A0260 CD O
( P07149047A0260 ( O
5 P07149047A0260 CD O
) P07149047A0260 ) O
Torr P07149047A0260 NNP O
/ P07149047A0260 NNP O
cm2 P07149047A0260 NN O
. P07149047A0260 . O
. . O O

Further P03008405A0532 RB O
outbreaks P03008405A0532 NNS O
of P03008405A0532 IN O
ocular P03008405A0532 JJ O
disease P03008405A0532 NN O
in P03008405A0532 IN O
farmed P03008405A0532 JJ O
red P03008405A0532 JJ O
deer P03008405A0532 NN O
calves P03008405A0532 NNS O
caused P03008405A0532 VBN O
by P03008405A0532 IN O
HVC-1 P03008405A0532 NNP O
were P03008405A0532 VBD O
investigated P03008405A0532 VBN O
. P03008405A0532 . O
. . O O

Comparison P11642687T0000 NNP O
of P11642687T0000 IN O
German P11642687T0000 JJ O
language P11642687T0000 NN O
versions P11642687T0000 NNS O
of P11642687T0000 IN O
the P11642687T0000 DT O
QWB-SA P11642687T0000 NNP O
and P11642687T0000 CC O
SF-36 P11642687T0000 NNP O
evaluating P11642687T0000 VBG O
outcomes P11642687T0000 NNS O
for P11642687T0000 IN O
patients P11642687T0000 NNS O
with P11642687T0000 IN O
prostate P11642687T0000 JJ O
disease P11642687T0000 NN O
. P11642687T0000 . O
. . O O

MotA P09918715A0304 NNP I-UN
also P09918715A0304 RB O
binds P09918715A0304 VBZ O
a P09918715A0304 DT O
DNA P09918715A0304 NN O
sequence P09918715A0304 NN O
( P09918715A0304 ( O
a P09918715A0304 DT O
MotA P09918715A0304 NNP I-UN
box P09918715A0304 NN I-UN
) P09918715A0304 ) O
, P09918715A0304 , O
centered P09918715A0304 VBN O
at P09918715A0304 IN O
position P09918715A0304 NN O
-30 P09918715A0304 NN O
. P09918715A0304 . O
. . O O

Overexpression P10187798A1098 NN O
of P10187798A1098 IN O
either P10187798A1098 DT O
DAP-1 P10187798A1098 NNP I-UN
or P10187798A1098 CC O
sentrin P10187798A1098 JJ I-UN
causes P10187798A1098 NNS O
apoptosis P10187798A1098 NN O
of P10187798A1098 IN O
TNF-sensitive P10187798A1098 JJ O
L929 P10187798A1098 NNP O
fibroblast P10187798A1098 NN O
cell P10187798A1098 NN O
line P10187798A1098 NN O
, P10187798A1098 , O
as P10187798A1098 RB O
well P10187798A1098 RB O
as P10187798A1098 IN O
TNF-resistant P10187798A1098 JJ O
osteosarcoma P10187798A1098 NN O
cell P10187798A1098 NN O
line P10187798A1098 NN O
, P10187798A1098 , O
U2OS P10187798A1098 NNP O
. P10187798A1098 . O
. . O O

Members P09525891T0000 NNS O
of P09525891T0000 IN O
the P09525891T0000 DT O
meis1 P09525891T0000 NN I-UN
and P09525891T0000 CC O
pbx P09525891T0000 NN I-UN
homeodomain P09525891T0000 NN I-UN
protein P09525891T0000 JJ I-UN
families P09525891T0000 NNS I-UN
cooperatively P09525891T0000 RB O
bind P09525891T0000 IN O
a P09525891T0000 DT O
cAMP-responsive P09525891T0000 JJ O
sequence P09525891T0000 NN O
( P09525891T0000 ( O
CRS1 P09525891T0000 NNP O
) P09525891T0000 ) O
from P09525891T0000 IN O
bovine P09525891T0000 NN I-UN
CYP17 P09525891T0000 NNP I-UN
. P09525891T0000 . O
. . O O

After P09631366A0951 IN O
the P09631366A0951 DT O
first P09631366A0951 JJ O
cycle P09631366A0951 NN O
, P09631366A0951 , O
18 P09631366A0951 CD O
cases P09631366A0951 NNS O
were P09631366A0951 VBD O
treated P09631366A0951 VBN O
at P09631366A0951 IN O
dose P09631366A0951 JJ O
level P09631366A0951 NN O
1 P09631366A0951 CD O
, P09631366A0951 , O
after P09631366A0951 IN O
a P09631366A0951 DT O
second P09631366A0951 JJ O
cycle P09631366A0951 NN O
, P09631366A0951 , O
13 P09631366A0951 CD O
cases P09631366A0951 NNS O
were P09631366A0951 VBD O
treated P09631366A0951 VBN O
at P09631366A0951 IN O
dose P09631366A0951 JJ O
level P09631366A0951 NN O
2 P09631366A0951 CD O
. P09631366A0951 . O
. . O O

Molecular P01545806T0000 JJ O
and P01545806T0000 CC O
genetic P01545806T0000 JJ O
analysis P01545806T0000 NN O
of P01545806T0000 IN O
the P01545806T0000 DT O
yeast P01545806T0000 JJS I-UN
early P01545806T0000 JJ I-UN
meiotic P01545806T0000 JJ I-UN
recombination P01545806T0000 NN I-UN
genes P01545806T0000 NNS I-UN
REC102 P01545806T0000 NNP I-UN
and P01545806T0000 CC O
REC107 P01545806T0000 NNP I-UN
/ P01545806T0000 NNP O
MER2 P01545806T0000 NNP I-UN
. P01545806T0000 . O
. . O O

Coexpression P09400613A0594 NN O
of P09400613A0594 IN O
mouse P09400613A0594 NN O
PKR P09400613A0594 NNP I-UN
( P09400613A0594 ( I-UN
1-515 P09400613A0594 JJ I-UN
) P09400613A0594 ) I-UN
WT P09400613A0594 NNP I-UN
as P09400613A0594 IN O
a P09400613A0594 DT O
Gal4 P09400613A0594 NNP I-UN
DNA-binding P09400613A0594 NNP O
domain P09400613A0594 NN O
fusion P09400613A0594 NN O
with P09400613A0594 IN O
either P09400613A0594 DT O
the P09400613A0594 DT O
catalytic-deficient P09400613A0594 JJ O
human P09400613A0594 JJ O
PKR P09400613A0594 NNP I-UN
( P09400613A0594 ( I-UN
1-551 P09400613A0594 JJ I-UN
) P09400613A0594 ) I-UN
K296R P09400613A0594 NNP O
mutant P09400613A0594 NN O
, P09400613A0594 , O
the P09400613A0594 DT O
RNA-binding-deficient P09400613A0594 JJ O
human P09400613A0594 JJ O
PKR P09400613A0594 NNP I-UN
( P09400613A0594 ( I-UN
1-551 P09400613A0594 JJ I-UN
) P09400613A0594 ) I-UN
K64E P09400613A0594 NNP I-UN
/ P09400613A0594 NNP I-UN
K296R P09400613A0594 NNP I-UN
double P09400613A0594 JJ O
mutant P09400613A0594 NN O
, P09400613A0594 , O
or P09400613A0594 CC O
wild-type P09400613A0594 JJ O
mouse P09400613A0594 NN O
PKR P09400613A0594 NNP I-UN
( P09400613A0594 ( I-UN
1-515 P09400613A0594 JJ I-UN
) P09400613A0594 ) I-UN
WT P09400613A0594 NNP I-UN
as P09400613A0594 IN O
full-length P09400613A0594 JJ O
PKR-Gal4 P09400613A0594 NNP O
activation P09400613A0594 NN O
domain P09400613A0594 NN O
fusions P09400613A0594 NNS O
resulted P09400613A0594 VBD O
in P09400613A0594 IN O
activation P09400613A0594 NN O
of P09400613A0594 IN O
the P09400613A0594 DT O
HIS3 P09400613A0594 NNP I-UN
and P09400613A0594 CC O
lacZ P09400613A0594 JJ I-UN
reporters P09400613A0594 NNS O
. P09400613A0594 . O
. . O O

Pathological P04645078T0001 JJ O
processes P04645078T0001 NNS O
in P04645078T0001 IN O
the P04645078T0001 DT O
cervix P04645078T0001 NN O
uteri P04645078T0001 NN O
. P04645078T0001 . O
. . O O

The P07472582A0993 DT O
identification P07472582A0993 NN O
of P07472582A0993 IN O
viable P07472582A0993 JJ O
myocardium P07472582A0993 NN O
with P07472582A0993 IN O
both P07472582A0993 DT O
99mTc-tetrofosmin P07472582A0993 CD O
and P07472582A0993 CC O
201Tl P07472582A0993 CD O
can P07472582A0993 MD O
be P07472582A0993 VB O
greatly P07472582A0993 RB O
enhanced P07472582A0993 VBN O
to P07472582A0993 TO O
a P07472582A0993 DT O
similar P07472582A0993 JJ O
degree P07472582A0993 NN O
if P07472582A0993 IN O
the P07472582A0993 DT O
severity P07472582A0993 NN O
of P07472582A0993 IN O
reduction P07472582A0993 NN O
in P07472582A0993 IN O
activity P07472582A0993 NN O
within P07472582A0993 IN O
nonreversible P07472582A0993 JJ O
defects P07472582A0993 NNS O
is P07472582A0993 VBZ O
considered P07472582A0993 VBN O
. P07472582A0993 . O
. . O O

IFN P08306959A0278 NNP I-UN
alpha P08306959A0278 NN I-UN
and P08306959A0278 CC O
IFN P08306959A0278 NNP I-UN
gamma P08306959A0278 NN I-UN
inducibility P08306959A0278 NN O
is P08306959A0278 VBZ O
mediated P08306959A0278 VBN O
by P08306959A0278 IN O
a P08306959A0278 DT O
single P08306959A0278 JJ O
element P08306959A0278 NN O
: P08306959A0278 : O
a P08306959A0278 DT O
high P08306959A0278 JJ O
affinity P08306959A0278 NN O
, P08306959A0278 , O
nearly P08306959A0278 RB O
palindromic P08306959A0278 JJ O
version P08306959A0278 NN O
of P08306959A0278 IN O
the P08306959A0278 DT O
IFN P08306959A0278 NNP I-UN
gamma P08306959A0278 NN I-UN
activation P08306959A0278 NN I-UN
site P08306959A0278 NN I-UN
( P08306959A0278 ( O
GAS P08306959A0278 NNP I-UN
) P08306959A0278 ) O
. P08306959A0278 . O
. . O O

2 P02213128A0209 CD O
. P02213128A0209 . O
. . O O

We P08649425A0373 PRP O
found P08649425A0373 VBD O
that P08649425A0373 IN O
120 P08649425A0373 CD O
bp P08649425A0373 NN O
of P08649425A0373 IN O
the P08649425A0373 DT O
enhancer P08649425A0373 NN O
's P08649425A0373 POS O
transcriptional P08649425A0373 JJ O
core P08649425A0373 NN O
becomes P08649425A0373 VBZ O
DNase P08649425A0373 NNP I-UN
I P08649425A0373 PRP I-UN
hypersensitive P08649425A0373 VBP O
early P08649425A0373 JJ O
in P08649425A0373 IN O
B-cell P08649425A0373 NNP O
development P08649425A0373 NN O
. P08649425A0373 . O
. . O O

The P10355536A0172 DT O
median P10355536A0172 JJ O
age P10355536A0172 NN O
was P10355536A0172 VBD O
33 P10355536A0172 CD O
years P10355536A0172 NNS O
( P10355536A0172 ( O
range P10355536A0172 VB O
17-56 P10355536A0172 CD O
years P10355536A0172 NNS O
) P10355536A0172 ) O
. P10355536A0172 . O
. . O O

Forskolin P11259503A0212 NNP O
treatment P11259503A0212 NN O
( P11259503A0212 ( O
10 P11259503A0212 CD O
microM P11259503A0212 NN O
) P11259503A0212 ) O
of P11259503A0212 IN O
the P11259503A0212 DT O
transfected P11259503A0212 JJ O
cells P11259503A0212 NNS O
for P11259503A0212 IN O
3 P11259503A0212 CD O
-- P11259503A0212 : O
6 P11259503A0212 CD O
h P11259503A0212 NN O
maximally P11259503A0212 RB O
induced P11259503A0212 JJ O
luciferase P11259503A0212 NN I-UN
threefold P11259503A0212 NN O
. P11259503A0212 . O
. . O O

Among P01531632A0000 IN O
the P01531632A0000 DT O
few P01531632A0000 JJ O
proteins P01531632A0000 NNS O
of P01531632A0000 IN O
the P01531632A0000 DT O
eukaryotic P01531632A0000 JJ O
nucleolus P01531632A0000 NN O
that P01531632A0000 WDT O
have P01531632A0000 VBP O
been P01531632A0000 VBN O
characterized P01531632A0000 VBN O
, P01531632A0000 , O
four P01531632A0000 CD O
proteins P01531632A0000 NNS O
, P01531632A0000 , O
nucleolin P01531632A0000 RB I-UN
, P01531632A0000 , O
fibrillarin P01531632A0000 NN I-UN
, P01531632A0000 , O
SSB1 P01531632A0000 NNP I-UN
and P01531632A0000 CC O
NSR1 P01531632A0000 NNP I-UN
, P01531632A0000 , O
possess P01531632A0000 NN O
a P01531632A0000 DT O
common P01531632A0000 JJ O
structural P01531632A0000 JJ O
motif P01531632A0000 NN O
, P01531632A0000 , O
the P01531632A0000 DT O
GAR P01531632A0000 NNP O
domain P01531632A0000 NN O
, P01531632A0000 , O
which P01531632A0000 WDT O
is P01531632A0000 VBZ O
rich P01531632A0000 JJ O
in P01531632A0000 IN O
glycine P01531632A0000 NN O
and P01531632A0000 CC O
arginine P01531632A0000 NN O
residues P01531632A0000 NNS O
. P01531632A0000 . O
. . O O

Statistical P03395009A1750 JJ O
analysis P03395009A1750 NN O
of P03395009A1750 IN O
the P03395009A1750 DT O
degrees P03395009A1750 NNS O
of P03395009A1750 IN O
secondary P03395009A1750 JJ O
spinal P03395009A1750 JJ O
cord P03395009A1750 NN O
compression P03395009A1750 NN O
was P03395009A1750 VBD O
performed P03395009A1750 VBN O
in P03395009A1750 IN O
group-1 P03395009A1750 JJ O
dogs P03395009A1750 NNS O
by P03395009A1750 IN O
measuring P03395009A1750 VBG O
and P03395009A1750 CC O
comparing P03395009A1750 VBG O
ratios P03395009A1750 NNS O
of P03395009A1750 IN O
the P03395009A1750 DT O
vertical P03395009A1750 JJ O
to P03395009A1750 TO O
the P03395009A1750 DT O
horizontal P03395009A1750 JJ O
diameters P03395009A1750 NNS O
of P03395009A1750 IN O
the P03395009A1750 DT O
transverse P03395009A1750 JJ O
spinal P03395009A1750 JJ O
cord P03395009A1750 NN O
sections P03395009A1750 NNS O
from P03395009A1750 IN O
locations P03395009A1750 NNS O
within P03395009A1750 IN O
( P03395009A1750 ( O
T12 P03395009A1750 NNP O
to P03395009A1750 TO O
L1 P03395009A1750 NNP O
) P03395009A1750 ) O
and P03395009A1750 CC O
out P03395009A1750 IN O
of P03395009A1750 IN O
( P03395009A1750 ( O
T11 P03395009A1750 NNP O
, P03395009A1750 , O
T11-12 P03395009A1750 NNP O
, P03395009A1750 , O
L1-2 P03395009A1750 NNP O
, P03395009A1750 , O
and P03395009A1750 CC O
L2 P03395009A1750 NNP O
) P03395009A1750 ) O
the P03395009A1750 DT O
region P03395009A1750 NN O
of P03395009A1750 IN O
surgical P03395009A1750 JJ O
intervention P03395009A1750 NN O
. P03395009A1750 . O
. . O O

The P09280747A0195 DT O
combination P09280747A0195 NN O
of P09280747A0195 IN O
hydralazine P09280747A0195 JJ O
hydrochloride P09280747A0195 NN O
and P09280747A0195 CC O
isosorbide P09280747A0195 NN O
dinitrate P09280747A0195 NN O
also P09280747A0195 RB O
improves P09280747A0195 VBZ O
survival P09280747A0195 JJ O
, P09280747A0195 , O
but P09280747A0195 CC O
direct P09280747A0195 JJ O
comparison P09280747A0195 NN O
of P09280747A0195 IN O
both P09280747A0195 DT O
regimens P09280747A0195 NNS O
provided P09280747A0195 VBD O
evidence P09280747A0195 NN O
for P09280747A0195 IN O
a P09280747A0195 DT O
less P09280747A0195 RBR O
favourable P09280747A0195 JJ O
effect P09280747A0195 NN O
than P09280747A0195 IN O
that P09280747A0195 DT O
of P09280747A0195 IN O
the P09280747A0195 DT O
ACE P09280747A0195 NNP I-UN
inhibitors P09280747A0195 NNS O
. P09280747A0195 . O
. . O O

The P09599897A0000 DT O
clinical P09599897A0000 JJ O
and P09599897A0000 CC O
laboratory P09599897A0000 JJ O
features P09599897A0000 NNS O
of P09599897A0000 IN O
72 P09599897A0000 CD O
children P09599897A0000 NNS O
with P09599897A0000 IN O
Henoch-Schonlein P09599897A0000 NNP O
purpura P09599897A0000 NN O
( P09599897A0000 ( O
HSP P09599897A0000 NNP O
) P09599897A0000 ) O
were P09599897A0000 VBD O
examined P09599897A0000 VBN O
to P09599897A0000 TO O
determine P09599897A0000 VB O
if P09599897A0000 IN O
there P09599897A0000 EX O
were P09599897A0000 VBD O
associations P09599897A0000 NNS O
between P09599897A0000 IN O
the P09599897A0000 DT O
laboratory P09599897A0000 NN O
indices P09599897A0000 NNS O
-- P09599897A0000 : O
including P09599897A0000 VBG O
white P09599897A0000 JJ O
blood P09599897A0000 NN O
cell P09599897A0000 NN O
( P09599897A0000 ( O
WBC P09599897A0000 NNP O
) P09599897A0000 ) O
counts P09599897A0000 VBZ O
, P09599897A0000 , O
serum P09599897A0000 JJ I-UN
C-reactive P09599897A0000 JJ I-UN
protein P09599897A0000 NN I-UN
( P09599897A0000 ( O
CRP P09599897A0000 NNP I-UN
) P09599897A0000 ) O
levels P09599897A0000 NNS O
, P09599897A0000 , O
platelet P09599897A0000 NN O
( P09599897A0000 ( O
PLT P09599897A0000 NNP O
) P09599897A0000 ) O
counts P09599897A0000 VBZ O
-- P09599897A0000 : O
and P09599897A0000 CC O
the P09599897A0000 DT O
clinical P09599897A0000 JJ O
manifestations P09599897A0000 NNS O
of P09599897A0000 IN O
acute P09599897A0000 JJ O
HSP P09599897A0000 NNP O
. P09599897A0000 . O
. . O O

Ligand P09794795A0183 NNP O
binding P09794795A0183 VBG O
to P09794795A0183 TO O
the P09794795A0183 DT O
receptor P09794795A0183 NN O
complex P09794795A0183 JJ O
leads P09794795A0183 VBZ O
to P09794795A0183 TO O
tyrosine P09794795A0183 VB O
phosphorylation P09794795A0183 NN O
and P09794795A0183 CC O
activation P09794795A0183 NN O
of P09794795A0183 IN O
Janus P09794795A0183 NNP I-UN
kinases P09794795A0183 NNS I-UN
( P09794795A0183 ( O
Jak P09794795A0183 NNP I-UN
) P09794795A0183 ) O
, P09794795A0183 , O
phosphorylation P09794795A0183 NN O
of P09794795A0183 IN O
the P09794795A0183 DT O
signal P09794795A0183 JJ I-UN
transducing P09794795A0183 NN I-UN
subunit P09794795A0183 NN I-UN
gp130 P09794795A0183 NN I-UN
, P09794795A0183 , O
followed P09794795A0183 VBN O
by P09794795A0183 IN O
recruitment P09794795A0183 NN O
and P09794795A0183 CC O
phosphorylation P09794795A0183 NN O
of P09794795A0183 IN O
the P09794795A0183 DT O
signal P09794795A0183 JJ I-UN
transducer P09794795A0183 NN I-UN
and P09794795A0183 CC I-UN
activator P09794795A0183 NN I-UN
of P09794795A0183 IN I-UN
transcription P09794795A0183 NN I-UN
factors P09794795A0183 NNS I-UN
STAT3 P09794795A0183 NNP I-UN
and P09794795A0183 CC O
STAT1 P09794795A0183 NNP I-UN
and P09794795A0183 CC O
the P09794795A0183 DT O
src P09794795A0183 NN I-UN
homology P09794795A0183 NN I-UN
domain P09794795A0183 NN I-UN
( P09794795A0183 ( O
SH2 P09794795A0183 NNP I-UN
) P09794795A0183 ) O
-containing P09794795A0183 VBG O
protein P09794795A0183 JJ I-UN
tyrosine P09794795A0183 JJ I-UN
phosphatase P09794795A0183 NN I-UN
( P09794795A0183 ( O
SHP2 P09794795A0183 NNP I-UN
) P09794795A0183 ) O
. P09794795A0183 . O
. . O O

Using P11415633A1253 VBG O
the P11415633A1253 DT O
postural P11415633A1253 JJ O
and P11415633A1253 CC O
force P11415633A1253 NN O
data P11415633A1253 NNS O
as P11415633A1253 IN O
input P11415633A1253 NN O
to P11415633A1253 TO O
a P11415633A1253 DT O
3-D P11415633A1253 JJ O
biomechanical P11415633A1253 JJ O
model P11415633A1253 NN O
, P11415633A1253 , O
the P11415633A1253 DT O
lumbosacral P11415633A1253 JJ O
spinal P11415633A1253 JJ O
compression P11415633A1253 NN O
was P11415633A1253 VBD O
calculated P11415633A1253 VBN O
. P11415633A1253 . O
. . O O

We P08040468A0303 PRP O
speculate P08040468A0303 VBP O
that P08040468A0303 IN O
mast P08040468A0303 NN O
cell P08040468A0303 NN O
degranulation P08040468A0303 NN O
may P08040468A0303 MD O
be P08040468A0303 VB O
involved P08040468A0303 VBN O
in P08040468A0303 IN O
the P08040468A0303 DT O
pathogenesis P08040468A0303 NN O
of P08040468A0303 IN O
necrobiosis P08040468A0303 NN O
by P08040468A0303 IN O
altering P08040468A0303 VBG O
fibroblast P08040468A0303 JJ O
enzyme P08040468A0303 JJ O
activity P08040468A0303 NN O
and P08040468A0303 CC O
/ P08040468A0303 NN O
or P08040468A0303 CC O
producing P08040468A0303 VBG O
prolonged P08040468A0303 JJ O
inflammatory P08040468A0303 JJ O
reactions P08040468A0303 NNS O
. P08040468A0303 . O
. . O O

Interestingly P09402029A1632 RB O
, P09402029A1632 , O
the P09402029A1632 DT O
avirulent P09402029A1632 NN O
strain P09402029A1632 NN O
H37Ra P09402029A1632 NNP O
showed P09402029A1632 VBD O
weak P09402029A1632 JJ O
hybridization P09402029A1632 NN O
with P09402029A1632 IN O
these P09402029A1632 DT O
two P09402029A1632 CD O
probes P09402029A1632 NNS O
, P09402029A1632 , O
suggesting P09402029A1632 VBG O
that P09402029A1632 IN O
these P09402029A1632 DT O
genes P09402029A1632 NNS O
might P09402029A1632 MD O
have P09402029A1632 VB O
been P09402029A1632 VBN O
deleted P09402029A1632 VBN O
in P09402029A1632 IN O
the P09402029A1632 DT O
avirulent P09402029A1632 NN O
strain P09402029A1632 NN O
or P09402029A1632 CC O
are P09402029A1632 VBP O
present P09402029A1632 JJ O
in P09402029A1632 IN O
limited P09402029A1632 JJ O
copy P09402029A1632 NN O
numbers P09402029A1632 NNS O
as P09402029A1632 IN O
opposed P09402029A1632 VBN O
to P09402029A1632 TO O
those P09402029A1632 DT O
in P09402029A1632 IN O
the P09402029A1632 DT O
virulent P09402029A1632 NN O
strain P09402029A1632 NN O
H37Rv P09402029A1632 NNP O
. P09402029A1632 . O
. . O O

The P10090943A1426 DT O
mean P10090943A1426 JJ O
value P10090943A1426 NN O
of P10090943A1426 IN O
the P10090943A1426 DT O
CD79b P10090943A1426 NNP I-UN
to P10090943A1426 TO O
the P10090943A1426 DT O
CD79b P10090943A1426 NNP I-UN
internally P10090943A1426 RB O
deleted P10090943A1426 VBD O
ratio P10090943A1426 NN O
was P10090943A1426 VBD O
0.64 P10090943A1426 CD O
+ P10090943A1426 JJ O
/ P10090943A1426 NNP O
- P10090943A1426 : O
0.20 P10090943A1426 CD O
SD P10090943A1426 NNP O
in P10090943A1426 IN O
normal P10090943A1426 JJ O
donors P10090943A1426 NNS O
and P10090943A1426 CC O
0.44 P10090943A1426 CD O
+ P10090943A1426 NN O
/ P10090943A1426 NNP O
- P10090943A1426 : O
0.27 P10090943A1426 CD O
SD P10090943A1426 NNP O
in P10090943A1426 IN O
B-CLL P10090943A1426 NNP O
( P10090943A1426 ( O
P P10090943A1426 NNP O
=.01 P10090943A1426 NNP O
) P10090943A1426 ) O
. P10090943A1426 . O
. . O O

We P09096958A0000 PRP O
have P09096958A0000 VBP O
characterized P09096958A0000 VBN O
a P09096958A0000 DT O
panel P09096958A0000 NN O
of P09096958A0000 IN O
6 P09096958A0000 CD O
monoclonal P09096958A0000 JJ O
antibodies P09096958A0000 NNS O
raised P09096958A0000 VBN O
against P09096958A0000 IN O
human P09096958A0000 JJ I-UN
platelet P09096958A0000 NN I-UN
talin P09096958A0000 NN I-UN
by P09096958A0000 IN O
Western P09096958A0000 JJ O
blotting P09096958A0000 NN O
, P09096958A0000 , O
immune P09096958A0000 JJ O
precipitation P09096958A0000 NN O
, P09096958A0000 , O
and P09096958A0000 CC O
immunofluorescence P09096958A0000 NN O
, P09096958A0000 , O
and P09096958A0000 CC O
shown P09096958A0000 VBN O
that P09096958A0000 IN O
antibodies P09096958A0000 NNS I-UN
TA205 P09096958A0000 NNP I-UN
and P09096958A0000 CC O
TD77 P09096958A0000 NNP I-UN
disrupt P09096958A0000 VBP O
actin P09096958A0000 JJ I-UN
stress P09096958A0000 NN O
fibers P09096958A0000 NNS O
and P09096958A0000 CC O
focal P09096958A0000 JJ O
adhesions P09096958A0000 NNS O
, P09096958A0000 , O
and P09096958A0000 CC O
inhibit P09096958A0000 NN O
cell P09096958A0000 NN O
motility P09096958A0000 NN O
when P09096958A0000 WRB O
microinjected P09096958A0000 VBN O
into P09096958A0000 IN O
human P09096958A0000 JJ O
fibroblasts P09096958A0000 NNS O
. P09096958A0000 . O
. . O O

Transfer P01660925T0000 NN O
RNA P01660925T0000 NNP O
genes P01660925T0000 NNS O
from P01660925T0000 IN O
Dictyostelium P01660925T0000 NNP O
discoideum P01660925T0000 NN O
are P01660925T0000 VBP O
frequently P01660925T0000 RB O
associated P01660925T0000 VBN O
with P01660925T0000 IN O
repetitive P01660925T0000 JJ O
elements P01660925T0000 NNS O
and P01660925T0000 CC O
contain P01660925T0000 VB O
consensus P01660925T0000 NN O
boxes P01660925T0000 NNS O
in P01660925T0000 IN O
their P01660925T0000 PRP$ O
5 P01660925T0000 CD O
' P01660925T0000 POS O
and P01660925T0000 CC O
3'-flanking P01660925T0000 JJ O
regions P01660925T0000 NNS O
. P01660925T0000 . O
. . O O

OBJECTIVE P10451209A0000 NN O
: P10451209A0000 : O
To P10451209A0000 TO O
determine P10451209A0000 VB O
whether P10451209A0000 IN O
administration P10451209A0000 NN O
of P10451209A0000 IN O
misoprostol P10451209A0000 JJ O
prevents P10451209A0000 NNS O
gastric P10451209A0000 JJ O
hemorrhage P10451209A0000 NN O
in P10451209A0000 IN O
healthy P10451209A0000 JJ O
dogs P10451209A0000 NNS O
treated P10451209A0000 VBN O
with P10451209A0000 IN O
high P10451209A0000 JJ O
doses P10451209A0000 NNS O
of P10451209A0000 IN O
methylprednisolone P10451209A0000 NN O
sodium P10451209A0000 NN O
succinate P10451209A0000 NN O
( P10451209A0000 ( O
MPSS P10451209A0000 NNP O
) P10451209A0000 ) O
. P10451209A0000 . O
. . O O

Most P08367487A1014 JJS O
importantly P08367487A1014 RB O
, P08367487A1014 , O
the P08367487A1014 DT O
addition P08367487A1014 NN O
of P08367487A1014 IN O
purified P08367487A1014 JJ O
17S P08367487A1014 CD I-UN
U2 P08367487A1014 NNP I-UN
snRNPs P08367487A1014 NN I-UN
, P08367487A1014 , O
but P08367487A1014 CC O
not P08367487A1014 RB O
of P08367487A1014 IN O
12S P08367487A1014 CD I-UN
U2 P08367487A1014 NNP I-UN
snRNPs P08367487A1014 NN I-UN
, P08367487A1014 , O
to P08367487A1014 TO O
HeLa P08367487A1014 NNP O
splicing P08367487A1014 VBG O
extracts P08367487A1014 NNS O
in P08367487A1014 IN O
which P08367487A1014 WDT O
the P08367487A1014 DT O
endogeneous P08367487A1014 JJ I-UN
U2 P08367487A1014 NNP I-UN
snRNPs P08367487A1014 NN I-UN
have P08367487A1014 VBP O
been P08367487A1014 VBN O
functionally P08367487A1014 RB O
neutralized P08367487A1014 VBN O
with P08367487A1014 IN O
anti-PRP9 P08367487A1014 JJ I-UN
antibodies P08367487A1014 NNS I-UN
fully P08367487A1014 RB O
restores P08367487A1014 VBZ O
the P08367487A1014 DT O
mRNA-splicing P08367487A1014 JJ O
activity P08367487A1014 NN O
of P08367487A1014 IN O
the P08367487A1014 DT O
extracts P08367487A1014 NNS O
. P08367487A1014 . O
. . O O

Mechanism P07507187T0000 NN O
of P07507187T0000 IN O
enhancement P07507187T0000 NN O
of P07507187T0000 IN O
DNA P07507187T0000 NNP O
expression P07507187T0000 NN O
consequent P07507187T0000 NN O
to P07507187T0000 TO O
cointernalization P07507187T0000 NN O
of P07507187T0000 IN O
a P07507187T0000 DT O
replication-deficient P07507187T0000 JJ O
adenovirus P07507187T0000 NN O
and P07507187T0000 CC O
unmodified P07507187T0000 JJ O
plasmid P07507187T0000 NN O
DNA P07507187T0000 NNP O
. P07507187T0000 . O
. . O O

After P10967531A1025 IN O
declamping P10967531A1025 VBG O
of P10967531A1025 IN O
the P10967531A1025 DT O
aorta P10967531A1025 NN O
, P10967531A1025 , O
there P10967531A1025 EX O
were P10967531A1025 VBD O
also P10967531A1025 RB O
severe P10967531A1025 JJ O
edema P10967531A1025 NN O
, P10967531A1025 , O
local P10967531A1025 JJ O
fibre P10967531A1025 NN O
necrosis P10967531A1025 NN O
, P10967531A1025 , O
and P10967531A1025 CC O
adhesion P10967531A1025 NN O
of P10967531A1025 IN O
leucocytes P10967531A1025 NNS O
, P10967531A1025 , O
whereas P10967531A1025 NNS O
muscle P10967531A1025 VBP O
fibre P10967531A1025 JJ O
areas P10967531A1025 NNS O
became P10967531A1025 VBD O
3,935.18 P10967531A1025 CD O
micro P10967531A1025 NN O
531 P10967531A1025 CD O
microm P10967531A1025 NN O
( P10967531A1025 ( O
2 P10967531A1025 CD O
) P10967531A1025 ) O
for P10967531A1025 IN O
type P10967531A1025 NN O
I P10967531A1025 PRP O
and P10967531A1025 CC O
5,804 P10967531A1025 CD O
+ P10967531A1025 NN O
/ P10967531A1025 NNP O
- P10967531A1025 : O
1,075 P10967531A1025 CD O
microm P10967531A1025 NN O
( P10967531A1025 ( O
2 P10967531A1025 CD O
) P10967531A1025 ) O
for P10967531A1025 IN O
type P10967531A1025 NN O
II P10967531A1025 NNP O
. P10967531A1025 . O
. . O O

The P10359673A0000 DT O
yeast P10359673A0000 NN I-UN
LPD1 P10359673A0000 NNP I-UN
gene P10359673A0000 NN I-UN
encoding P10359673A0000 VBG O
lipoamide P10359673A0000 JJ I-UN
dehydrogenase P10359673A0000 NN I-UN
is P10359673A0000 VBZ O
subject P10359673A0000 JJ O
to P10359673A0000 TO O
the P10359673A0000 DT O
general P10359673A0000 JJ O
control P10359673A0000 NN O
of P10359673A0000 IN O
amino P10359673A0000 NN O
acid P10359673A0000 JJ O
biosynthesis P10359673A0000 NN O
mediated P10359673A0000 VBN O
by P10359673A0000 IN O
the P10359673A0000 DT O
GCN4 P10359673A0000 NNP I-UN
transcription P10359673A0000 NN I-UN
factor P10359673A0000 NN I-UN
. P10359673A0000 . O
. . O O

High-affinity P10026784A0929 NNP O
site-specific P10026784A0929 JJ O
DNA P10026784A0929 NNP O
binding P10026784A0929 NN O
by P10026784A0929 IN O
POU P10026784A0929 NNP I-UN
domain P10026784A0929 NN I-UN
transcription P10026784A0929 NN I-UN
factors P10026784A0929 NNS I-UN
requires P10026784A0929 VBZ O
both P10026784A0929 DT O
the P10026784A0929 DT O
POU-specific P10026784A0929 NNP I-UN
and P10026784A0929 CC O
the P10026784A0929 DT O
POU-homeodomain P10026784A0929 NNP I-UN
. P10026784A0929 . O
. . O O

Based P11092850A1023 VBN O
on P11092850A1023 IN O
16S P11092850A1023 CD I-UN
rRNA P11092850A1023 JJ I-UN
gene P11092850A1023 NN I-UN
sequence P11092850A1023 NN I-UN
analysis P11092850A1023 NN O
, P11092850A1023 , O
the P11092850A1023 DT O
11 P11092850A1023 CD O
species P11092850A1023 NNS O
having P11092850A1023 VBG O
two P11092850A1023 CD O
tuf P11092850A1023 JJ I-UN
genes P11092850A1023 NNS I-UN
all P11092850A1023 DT O
have P11092850A1023 VBP O
a P11092850A1023 DT O
common P11092850A1023 JJ O
ancestor P11092850A1023 NN O
, P11092850A1023 , O
while P11092850A1023 IN O
the P11092850A1023 DT O
six P11092850A1023 CD O
species P11092850A1023 NNS O
having P11092850A1023 VBG O
only P11092850A1023 RB O
one P11092850A1023 CD O
copy P11092850A1023 NN O
diverged P11092850A1023 VBN O
from P11092850A1023 IN O
the P11092850A1023 DT O
enterococcal P11092850A1023 JJ O
lineage P11092850A1023 NN O
before P11092850A1023 IN O
that P11092850A1023 DT O
common P11092850A1023 JJ O
ancestor P11092850A1023 NN O
. P11092850A1023 . O
. . O O

Endothelium P06468632A0135 NN O
of P06468632A0135 IN O
the P06468632A0135 DT O
central P06468632A0135 JJ O
ear P06468632A0135 JJ O
artery P06468632A0135 NN O
of P06468632A0135 IN O
an P06468632A0135 DT O
anesthetized P06468632A0135 JJ O
rabbit P06468632A0135 NN O
is P06468632A0135 VBZ O
damaged P06468632A0135 VBN O
by P06468632A0135 IN O
placing P06468632A0135 VBG O
artery P06468632A0135 JJ O
forceps P06468632A0135 NNS O
on P06468632A0135 IN O
the P06468632A0135 DT O
ear P06468632A0135 NN O
directly P06468632A0135 RB O
over P06468632A0135 IN O
the P06468632A0135 DT O
vessel P06468632A0135 NN O
. P06468632A0135 . O
. . O O

However P07957559A1557 RB O
, P07957559A1557 , O
rapamycin P07957559A1557 RB O
inhibited P07957559A1557 JJ O
proliferation P07957559A1557 NN O
of P07957559A1557 IN O
Ba P07957559A1557 NNP O
/ P07957559A1557 NNP O
F3-EpoRgp55 P07957559A1557 NNP O
but P07957559A1557 CC O
not P07957559A1557 RB O
of P07957559A1557 IN O
MEL P07957559A1557 NNP O
cells P07957559A1557 NNS O
despite P07957559A1557 IN O
inhibition P07957559A1557 NN O
of P07957559A1557 IN O
p70 P07957559A1557 NN I-UN
S6 P07957559A1557 NNP I-UN
kinase P07957559A1557 NN I-UN
activity P07957559A1557 NN O
in P07957559A1557 IN O
both P07957559A1557 DT O
cells P07957559A1557 NNS O
. P07957559A1557 . O
. . O O

Either P04032268A0358 CC O
a P04032268A0358 DT O
UV P04032268A0358 NNP O
detector P04032268A0358 NN O
set P04032268A0358 NN O
at P04032268A0358 IN O
268 P04032268A0358 CD O
nm P04032268A0358 NN O
or P04032268A0358 CC O
an P04032268A0358 DT O
electrochemical P04032268A0358 JJ O
( P04032268A0358 ( O
EC P04032268A0358 NNP O
) P04032268A0358 ) O
detector P04032268A0358 NN O
set P04032268A0358 VBN O
at P04032268A0358 IN O
a P04032268A0358 DT O
potential P04032268A0358 NN O
of P04032268A0358 IN O
+0.9 P04032268A0358 JJ O
V P04032268A0358 NNP O
( P04032268A0358 ( O
versus P04032268A0358 NN O
Ag P04032268A0358 NNP O
/ P04032268A0358 NNP O
AgCl P04032268A0358 NNP O
/ P04032268A0358 VBD O
3 P04032268A0358 CD O
M P04032268A0358 NNP O
NaCl P04032268A0358 NNP O
) P04032268A0358 ) O
was P04032268A0358 VBD O
used P04032268A0358 VBN O
to P04032268A0358 TO O
monitor P04032268A0358 VB O
the P04032268A0358 DT O
drug P04032268A0358 NN O
. P04032268A0358 . O
. . O O

Here P01331501A0397 RB O
we P01331501A0397 PRP O
show P01331501A0397 VBP O
that P01331501A0397 IN O
short P01331501A0397 JJ O
synthetic P01331501A0397 JJ O
peptides P01331501A0397 NNS O
containing P01331501A0397 VBG O
the P01331501A0397 DT O
pRB-binding P01331501A0397 JJ I-UN
sequences P01331501A0397 NNS I-UN
of P01331501A0397 IN O
E1A P01331501A0397 NNP I-UN
are P01331501A0397 VBP O
sufficient P01331501A0397 JJ O
for P01331501A0397 IN O
interaction P01331501A0397 NN O
with P01331501A0397 IN O
p107 P01331501A0397 NN I-UN
, P01331501A0397 , O
cyclin P01331501A0397 NN I-UN
A P01331501A0397 NNP I-UN
, P01331501A0397 , O
and P01331501A0397 CC O
p130 P01331501A0397 NN I-UN
. P01331501A0397 . O
. . O O

DNA P07777518A0483 NN O
sequencing P07777518A0483 NN O
and P07777518A0483 CC O
Southern P07777518A0483 NNP O
blot P07777518A0483 NN O
analyses P07777518A0483 NNS O
established P07777518A0483 VBD O
that P07777518A0483 IN O
the P07777518A0483 DT O
cDNA P07777518A0483 NN O
clones P07777518A0483 NNS O
are P07777518A0483 VBP O
derived P07777518A0483 VBN O
from P07777518A0483 IN O
two P07777518A0483 CD O
different P07777518A0483 JJ O
genes P07777518A0483 NNS O
. P07777518A0483 . O
. . O O

Only P10964833A1696 RB O
two P10964833A1696 CD O
of P10964833A1696 IN O
27 P10964833A1696 CD O
participants P10964833A1696 NNS O
( P10964833A1696 ( O
7.4 P10964833A1696 CD O
% P10964833A1696 NN O
) P10964833A1696 ) O
with P10964833A1696 IN O
definite P10964833A1696 JJ O
POAG P10964833A1696 NNP O
had P10964833A1696 VBD O
been P10964833A1696 VBN O
previously P10964833A1696 RB O
diagnosed P10964833A1696 VBN O
and P10964833A1696 CC O
treated P10964833A1696 VBN O
, P10964833A1696 , O
and P10964833A1696 CC O
66.7 P10964833A1696 CD O
% P10964833A1696 NN O
of P10964833A1696 IN O
the P10964833A1696 DT O
previously P10964833A1696 RB O
undiagnosed P10964833A1696 VBN O
had P10964833A1696 VBD O
IOP P10964833A1696 NNP O
less P10964833A1696 JJR O
than P10964833A1696 IN O
22 P10964833A1696 CD O
mmHg P10964833A1696 NN O
. P10964833A1696 . O
. . O O

Vitrectomy P00614915T0001 NNP O
in P00614915T0001 IN O
ocular P00614915T0001 JJ O
traumatology P00614915T0001 NN O
. P00614915T0001 . O
. . O O

Furthermore P08195216A1022 RB O
, P08195216A1022 , O
unlike P08195216A1022 IN O
the P08195216A1022 DT O
case P08195216A1022 NN O
for P08195216A1022 IN O
HIS3 P08195216A1022 NNP I-UN
where P08195216A1022 WRB O
only P08195216A1022 RB O
a P08195216A1022 DT O
limited P08195216A1022 JJ O
subset P08195216A1022 NN O
of P08195216A1022 IN O
TATA-like P08195216A1022 JJ O
sequences P08195216A1022 NNS O
can P08195216A1022 MD O
activate P08195216A1022 VB O
transcription P08195216A1022 NN O
in P08195216A1022 IN O
conjunction P08195216A1022 NN O
with P08195216A1022 IN O
GCN4p P08195216A1022 NNP I-UN
, P08195216A1022 , O
many P08195216A1022 JJ O
divergent P08195216A1022 JJ O
TATA-like P08195216A1022 JJ O
sequences P08195216A1022 NNS O
allowed P08195216A1022 VBN O
GCN4p P08195216A1022 NNP I-UN
activation P08195216A1022 NN O
of P08195216A1022 IN O
TRP3 P08195216A1022 NNP I-UN
. P08195216A1022 . O
. . O O

Substitutions P11207288A0897 NNS O
in P11207288A0897 IN O
the P11207288A0897 DT O
YFV P11207288A0897 NNP I-UN
Ag-binding P11207288A0897 JJ I-UN
region P11207288A0897 NN I-UN
( P11207288A0897 ( O
ABR P11207288A0897 NNP I-UN
) P11207288A0897 ) O
occur P11207288A0897 VBP O
at P11207288A0897 IN O
four P11207288A0897 CD O
of P11207288A0897 IN O
the P11207288A0897 DT O
eight P11207288A0897 CD O
highly P11207288A0897 RB O
conserved P11207288A0897 VBN O
residues P11207288A0897 NNS O
that P11207288A0897 WDT O
are P11207288A0897 VBP O
essential P11207288A0897 JJ O
for P11207288A0897 IN O
binding P11207288A0897 VBG O
of P11207288A0897 IN O
peptide-Ag P11207288A0897 NN O
in P11207288A0897 IN O
the P11207288A0897 DT O
class P11207288A0897 NN O
Ia P11207288A0897 NNP O
molecules P11207288A0897 NNS O
. P11207288A0897 . O
. . O O

We P11409425A0000 PRP O
used P11409425A0000 VBD O
stored P11409425A0000 VBN O
plasma P11409425A0000 JJ O
samples P11409425A0000 NNS O
from P11409425A0000 IN O
409 P11409425A0000 CD O
patients P11409425A0000 NNS O
in P11409425A0000 IN O
the P11409425A0000 DT O
National P11409425A0000 NNP O
Institute P11409425A0000 NNP O
of P11409425A0000 IN O
Neurological P11409425A0000 NNP O
Diseases P11409425A0000 NNP O
and P11409425A0000 CC O
Stroke P11409425A0000 NNP O
( P11409425A0000 ( O
NINDS P11409425A0000 NNP O
) P11409425A0000 ) O
tissue P11409425A0000 NN I-UN
plasminogen P11409425A0000 NN I-UN
activator P11409425A0000 NN I-UN
( P11409425A0000 ( O
t-PA P11409425A0000 JJ I-UN
) P11409425A0000 ) O
Stroke P11409425A0000 NNP O
Trial P11409425A0000 NNP O
to P11409425A0000 TO O
examine P11409425A0000 VB O
the P11409425A0000 DT O
relationship P11409425A0000 NN O
between P11409425A0000 IN O
an P11409425A0000 DT O
apolipoprotein P11409425A0000 NN I-UN
( P11409425A0000 ( I-UN
Apo P11409425A0000 NNP I-UN
) P11409425A0000 ) I-UN
E2 P11409425A0000 NNP I-UN
or P11409425A0000 CC O
an P11409425A0000 DT O
Apo P11409425A0000 NNP I-UN
E4 P11409425A0000 NNP I-UN
phenotype P11409425A0000 NN O
and P11409425A0000 CC O
a P11409425A0000 DT O
favorable P11409425A0000 JJ O
outcome P11409425A0000 NN O
3 P11409425A0000 CD O
months P11409425A0000 NNS O
after P11409425A0000 IN O
stroke P11409425A0000 NN O
, P11409425A0000 , O
the P11409425A0000 DT O
risk P11409425A0000 NN O
of P11409425A0000 IN O
intracerebral P11409425A0000 JJ O
hemorrhage P11409425A0000 NN O
, P11409425A0000 , O
and P11409425A0000 CC O
the P11409425A0000 DT O
response P11409425A0000 NN O
to P11409425A0000 TO O
intravenous P11409425A0000 JJ O
t-PA P11409425A0000 JJ I-UN
therapy P11409425A0000 NN O
. P11409425A0000 . O
. . O O

The P09434185A0902 DT O
organization P09434185A0902 NN O
of P09434185A0902 IN O
SPP1 P09434185A0902 NNP I-UN
genes P09434185A0902 NNS I-UN
involved P09434185A0902 VBN O
in P09434185A0902 IN O
the P09434185A0902 DT O
replication P09434185A0902 NN O
, P09434185A0902 , O
DNA P09434185A0902 NNP O
packaging P09434185A0902 NN O
and P09434185A0902 CC O
phage P09434185A0902 NN O
assembly P09434185A0902 RB O
proteins P09434185A0902 VBZ O
resembles P09434185A0902 VBZ O
the P09434185A0902 DT O
organization P09434185A0902 NN O
of P09434185A0902 IN O
genes P09434185A0902 NNS O
of P09434185A0902 IN O
equivalent P09434185A0902 JJ O
regions P09434185A0902 NNS O
of P09434185A0902 IN O
different P09434185A0902 JJ O
E. P09434185A0902 NNP O
coli P09434185A0902 NNS O
double-stranded P09434185A0902 JJ O
DNA P09434185A0902 NNP O
phages P09434185A0902 NNS O
. P09434185A0902 . O
. . O O

The P09820163A0565 DT O
mapping P09820163A0565 NN O
was P09820163A0565 VBD O
completed P09820163A0565 VBN O
with P09820163A0565 IN O
Southern P09820163A0565 NNP O
blotting P09820163A0565 NN O
and P09820163A0565 CC O
restriction P09820163A0565 NN O
analysis P09820163A0565 NN O
. P09820163A0565 . O
. . O O

However P09986796A1761 RB O
, P09986796A1761 , O
deletions P09986796A1761 NNS O
of P09986796A1761 IN O
the P09986796A1761 DT O
C P09986796A1761 NNP O
terminal P09986796A1761 JJ O
11 P09986796A1761 CD O
or P09986796A1761 CC O
14 P09986796A1761 CD O
amino P09986796A1761 JJ O
acids P09986796A1761 NNS O
had P09986796A1761 VBD O
more P09986796A1761 RBR O
substantial P09986796A1761 JJ O
effects P09986796A1761 NNS O
. P09986796A1761 . O
. . O O

METHODS P11496617A0301 NN O
: P11496617A0301 : O
93 P11496617A0301 CD O
female P11496617A0301 NN O
and P11496617A0301 CC O
43 P11496617A0301 CD O
male P11496617A0301 NN O
patients P11496617A0301 NNS O
undergoing P11496617A0301 VBG O
thyroid P11496617A0301 JJ O
surgery P11496617A0301 NN O
were P11496617A0301 VBD O
stratified P11496617A0301 VBN O
according P11496617A0301 VBG O
to P11496617A0301 TO O
gender P11496617A0301 NN O
and P11496617A0301 CC O
then P11496617A0301 RB O
randomised P11496617A0301 VBD O
to P11496617A0301 TO O
receive P11496617A0301 VB O
double-blind P11496617A0301 JJ O
one P11496617A0301 CD O
of P11496617A0301 IN O
four P11496617A0301 CD O
antiemetic P11496617A0301 JJ O
regimes P11496617A0301 NNS O
: P11496617A0301 : O
50 P11496617A0301 CD O
mg P11496617A0301 NN O
dolasetron P11496617A0301 NN O
given P11496617A0301 VBN O
orally P11496617A0301 RB O
45 P11496617A0301 CD O
minutes P11496617A0301 NNS O
prior P11496617A0301 RB O
to P11496617A0301 TO O
induction P11496617A0301 NN O
of P11496617A0301 IN O
anaesthesia P11496617A0301 NN O
( P11496617A0301 ( O
group P11496617A0301 NN O
I P11496617A0301 PRP O
) P11496617A0301 ) O
, P11496617A0301 , O
12.5 P11496617A0301 CD O
mg P11496617A0301 NN O
dolasetron P11496617A0301 NN O
given P11496617A0301 VBN O
intravenously P11496617A0301 RB O
during P11496617A0301 IN O
induction P11496617A0301 NN O
of P11496617A0301 IN O
anaesthesia P11496617A0301 NN O
( P11496617A0301 ( O
group P11496617A0301 NN O
II P11496617A0301 NNP O
) P11496617A0301 ) O
, P11496617A0301 , O
1.25 P11496617A0301 CD O
mg P11496617A0301 NN O
DHB P11496617A0301 NNP I-UN
given P11496617A0301 VBN O
intravenously P11496617A0301 RB O
during P11496617A0301 IN O
induction P11496617A0301 NN O
of P11496617A0301 IN O
anaesthesia P11496617A0301 NN O
( P11496617A0301 ( O
group P11496617A0301 NN O
III P11496617A0301 NNP O
) P11496617A0301 ) O
or P11496617A0301 CC O
placebo P11496617A0301 NN O
( P11496617A0301 ( O
group P11496617A0301 NN O
IV P11496617A0301 NNP O
) P11496617A0301 ) O
. P11496617A0301 . O
. . O O

Regional P01811243A0000 JJ O
cerebral P01811243A0000 JJ O
blood P01811243A0000 NN O
flow P01811243A0000 NN O
( P01811243A0000 ( O
rCBF P01811243A0000 NN O
) P01811243A0000 ) O
measurements P01811243A0000 NNS O
and P01811243A0000 CC O
psychiatric P01811243A0000 JJ O
ratings P01811243A0000 NNS O
were P01811243A0000 VBD O
performed P01811243A0000 VBN O
on P01811243A0000 IN O
seven P01811243A0000 CD O
schizophrenic P01811243A0000 JJ O
patients P01811243A0000 NNS O
( P01811243A0000 ( O
mean P01811243A0000 JJ O
age P01811243A0000 NN O
= P01811243A0000 VBD O
41.4 P01811243A0000 CD O
years P01811243A0000 NNS O
) P01811243A0000 ) O
who P01811243A0000 WP O
had P01811243A0000 VBD O
been P01811243A0000 VBN O
examined P01811243A0000 VBN O
18 P01811243A0000 CD O
years P01811243A0000 NNS O
previously P01811243A0000 RB O
in P01811243A0000 IN O
a P01811243A0000 DT O
study P01811243A0000 NN O
that P01811243A0000 WDT O
used P01811243A0000 VBD O
similar P01811243A0000 JJ O
psychiatric P01811243A0000 JJ O
ratings P01811243A0000 NNS O
and P01811243A0000 CC O
a P01811243A0000 DT O
comparable P01811243A0000 JJ O
rCBF P01811243A0000 NN O
technique P01811243A0000 NN O
. P01811243A0000 . O
. . O O

The P10611228A1388 DT O
DAP5 P10611228A1388 NNP I-UN
/ P10611228A1388 NNP O
p86 P10611228A1388 VBZ I-UN
apoptotic P10611228A1388 JJ O
form P10611228A1388 NN O
was P10611228A1388 VBD O
more P10611228A1388 RBR O
potent P10611228A1388 JJ O
than P10611228A1388 IN O
DAP5 P10611228A1388 NNP I-UN
/ P10611228A1388 NNP O
p97 P10611228A1388 NN I-UN
in P10611228A1388 IN O
these P10611228A1388 DT O
functional P10611228A1388 JJ O
assays P10611228A1388 NNS O
. P10611228A1388 . O
. . O O

Most P03486405A0341 JJS O
of P03486405A0341 IN O
the P03486405A0341 DT O
prepeptide P03486405A0341 JJ O
portion P03486405A0341 NN O
of P03486405A0341 IN O
the P03486405A0341 DT O
precursor P03486405A0341 NN O
polypeptide P03486405A0341 NN O
is P03486405A0341 VBZ O
encoded P03486405A0341 VBN O
by P03486405A0341 IN O
the P03486405A0341 DT O
next P03486405A0341 JJ O
three P03486405A0341 CD O
exons P03486405A0341 NNS O
, P03486405A0341 , O
and P03486405A0341 CC O
the P03486405A0341 DT O
mature P03486405A0341 JJ O
form P03486405A0341 NN O
of P03486405A0341 IN O
IL-1 P03486405A0341 NNP I-UN
alpha P03486405A0341 NN I-UN
is P03486405A0341 VBZ O
encoded P03486405A0341 VBN O
by P03486405A0341 IN O
the P03486405A0341 DT O
remaining P03486405A0341 VBG O
three P03486405A0341 CD O
exons P03486405A0341 NNS O
. P03486405A0341 . O
. . O O

Hyperthyroidism P03645733T0001 NN O
. P03645733T0001 . O
. . O O

One P11489597A0561 CD O
maternal P11489597A0561 JJ O
death P11489597A0561 NN O
, P11489597A0561 , O
reduced P11489597A0561 VBD O
body P11489597A0561 NN O
weight P11489597A0561 NN O
, P11489597A0561 , O
and P11489597A0561 CC O
reduced P11489597A0561 VBD O
weight P11489597A0561 JJ O
gain P11489597A0561 NN O
were P11489597A0561 VBD O
noted P11489597A0561 VBN O
at P11489597A0561 IN O
the P11489597A0561 DT O
high P11489597A0561 JJ O
dose P11489597A0561 NN O
; P11489597A0561 : O
confirmed P11489597A0561 JJ O
pregnancy P11489597A0561 NN O
rates P11489597A0561 NNS O
were P11489597A0561 VBD O
84 P11489597A0561 CD O
to P11489597A0561 TO O
100 P11489597A0561 CD O
% P11489597A0561 NN O
for P11489597A0561 IN O
each P11489597A0561 DT O
group P11489597A0561 NN O
. P11489597A0561 . O
. . O O

The P00989973A0000 DT O
response P00989973A0000 NN O
of P00989973A0000 IN O
the P00989973A0000 DT O
plasma P00989973A0000 NN I-UN
fibrinogen P00989973A0000 NN I-UN
level P00989973A0000 NN O
to P00989973A0000 TO O
the P00989973A0000 DT O
subucutaneous P00989973A0000 JJ O
injection P00989973A0000 NN O
of P00989973A0000 IN O
turpentine P00989973A0000 NN O
and P00989973A0000 CC O
to P00989973A0000 TO O
the P00989973A0000 DT O
intravenous P00989973A0000 JJ O
injection P00989973A0000 NN O
of P00989973A0000 IN O
endotoxin P00989973A0000 NN O
was P00989973A0000 VBD O
measured P00989973A0000 VBN O
in P00989973A0000 IN O
normal P00989973A0000 JJ O
rabbits P00989973A0000 NNS O
and P00989973A0000 CC O
in P00989973A0000 IN O
rabbits P00989973A0000 NNS O
made P00989973A0000 VBN O
granulocytopenic P00989973A0000 JJ O
and P00989973A0000 CC O
thrombocytopenic P00989973A0000 JJ O
with P00989973A0000 IN O
busulfan P00989973A0000 NN O
. P00989973A0000 . O
. . O O

The P03104245A0402 DT O
8 P03104245A0402 CD O
patients P03104245A0402 NNS O
receiving P03104245A0402 VBG O
Ir192 P03104245A0402 NNP O
implant P03104245A0402 NN O
in P03104245A0402 IN O
addition P03104245A0402 NN O
to P03104245A0402 TO O
external P03104245A0402 VB O
radiation P03104245A0402 NN O
showed P03104245A0402 VBD O
improved P03104245A0402 VBN O
( P03104245A0402 ( O
p P03104245A0402 JJ O
= P03104245A0402 NNP O
0.06 P03104245A0402 CD O
) P03104245A0402 ) O
survival P03104245A0402 NN O
compared P03104245A0402 VBN O
to P03104245A0402 TO O
the P03104245A0402 DT O
9 P03104245A0402 CD O
receiving P03104245A0402 VBG O
external P03104245A0402 JJ O
only P03104245A0402 RB O
: P03104245A0402 : O
median P03104245A0402 JJ O
15 P03104245A0402 CD O
months P03104245A0402 NNS O
( P03104245A0402 ( O
range P03104245A0402 VB O
1.5-34 P03104245A0402 JJ O
+ P03104245A0402 NNP O
months P03104245A0402 NNS O
) P03104245A0402 ) O
versus P03104245A0402 VBP O
7 P03104245A0402 CD O
months P03104245A0402 NNS O
( P03104245A0402 ( O
range P03104245A0402 VB O
2.5-21 P03104245A0402 JJ O
months P03104245A0402 NNS O
) P03104245A0402 ) O
. P03104245A0402 . O
. . O O

Therefore P11179668A0869 RB O
, P11179668A0869 , O
we P11179668A0869 PRP O
suggested P11179668A0869 VBD O
that P11179668A0869 IN O
both P11179668A0869 DT O
proteins P11179668A0869 NNS O
might P11179668A0869 MD O
belong P11179668A0869 VB O
to P11179668A0869 TO O
the P11179668A0869 DT O
PLTP P11179668A0869 NNP I-UN
family P11179668A0869 NN I-UN
. P11179668A0869 . O
. . O O

Recovery P01872856A0277 NN O
of P01872856A0277 IN O
radiolabelled P01872856A0277 JJ O
BA P01872856A0277 NNP O
through P01872856A0277 IN O
urine P01872856A0277 NN O
( P01872856A0277 ( O
28 P01872856A0277 CD O
% P01872856A0277 NN O
) P01872856A0277 ) O
and P01872856A0277 CC O
faeces P01872856A0277 NNS O
( P01872856A0277 ( O
22 P01872856A0277 CD O
% P01872856A0277 NN O
) P01872856A0277 ) O
up P01872856A0277 RB O
to P01872856A0277 TO O
96 P01872856A0277 CD O
hrs P01872856A0277 NNS O
averaged P01872856A0277 VBD O
50 P01872856A0277 CD O
% P01872856A0277 NN O
, P01872856A0277 , O
whereas P01872856A0277 JJ O
residual P01872856A0277 JJ O
radioactivity P01872856A0277 NN O
in P01872856A0277 IN O
liver P01872856A0277 NN O
and P01872856A0277 CC O
testis P01872856A0277 NN O
experienced P01872856A0277 VBD O
a P01872856A0277 DT O
recovery P01872856A0277 NN O
of P01872856A0277 IN O
29 P01872856A0277 CD O
% P01872856A0277 NN O
in P01872856A0277 IN O
scorbutic P01872856A0277 JJ O
animals P01872856A0277 NNS O
. P01872856A0277 . O
. . O O

Furthermore P10216052A1682 RB O
, P10216052A1682 , O
the P10216052A1682 DT O
validity P10216052A1682 NN O
of P10216052A1682 IN O
this P10216052A1682 DT O
new P10216052A1682 JJ O
subset P10216052A1682 NN O
of P10216052A1682 IN O
questions P10216052A1682 NNS O
was P10216052A1682 VBD O
shown P10216052A1682 VBN O
to P10216052A1682 TO O
be P10216052A1682 VB O
significant P10216052A1682 JJ O
( P10216052A1682 ( O
r=0.037 P10216052A1682 NN O
, P10216052A1682 , O
p P10216052A1682 NN O
< P10216052A1682 NNP O
0.05 P10216052A1682 CD O
) P10216052A1682 ) O
for P10216052A1682 IN O
the P10216052A1682 DT O
correlation P10216052A1682 NN O
between P10216052A1682 IN O
a P10216052A1682 DT O
measure P10216052A1682 NN O
of P10216052A1682 IN O
the P10216052A1682 DT O
severity P10216052A1682 NN O
of P10216052A1682 IN O
binocular P10216052A1682 JJ O
visual P10216052A1682 JJ O
field P10216052A1682 NN O
loss P10216052A1682 NN O
and P10216052A1682 CC O
the P10216052A1682 DT O
mean P10216052A1682 JJ O
score P10216052A1682 NN O
of P10216052A1682 IN O
the P10216052A1682 DT O
variables P10216052A1682 NNS O
used P10216052A1682 VBN O
in P10216052A1682 IN O
the P10216052A1682 DT O
glaucoma P10216052A1682 NN O
specific P10216052A1682 JJ O
subgroup P10216052A1682 NN O
of P10216052A1682 IN O
questions P10216052A1682 NNS O
. P10216052A1682 . O
. . O O

A P10406122T0000 DT O
13-bp P10406122T0000 JJ O
cis-regulatory P10406122T0000 JJ O
element P10406122T0000 NN O
in P10406122T0000 IN O
the P10406122T0000 DT O
LTR P10406122T0000 NNP O
promoter P10406122T0000 NN O
of P10406122T0000 IN O
the P10406122T0000 DT O
tobacco P10406122T0000 NN I-UN
retrotransposon P10406122T0000 NN I-UN
Tto1 P10406122T0000 NNP I-UN
is P10406122T0000 VBZ O
involved P10406122T0000 VBN O
in P10406122T0000 IN O
responsiveness P10406122T0000 NN O
to P10406122T0000 TO O
tissue P10406122T0000 VB O
culture P10406122T0000 NN O
, P10406122T0000 , O
wounding P10406122T0000 NN O
, P10406122T0000 , O
methyl P10406122T0000 JJ O
jasmonate P10406122T0000 NN O
and P10406122T0000 CC O
fungal P10406122T0000 JJ O
elicitors P10406122T0000 NNS O
. P10406122T0000 . O
. . O O

Structure P10034615T0000 NNP O
determination P10034615T0000 NN O
of P10034615T0000 IN O
an P10034615T0000 DT O
adsorbate-induced P10034615T0000 JJ O
multilayer P10034615T0000 NN O
reconstruction P10034615T0000 NN O
: P10034615T0000 : O
( P10034615T0000 ( O
1 P10034615T0000 CD O
x P10034615T0000 RB O
2 P10034615T0000 CD O
) P10034615T0000 ) O
-H P10034615T0000 NN O
/ P10034615T0000 JJ O
Ni P10034615T0000 NNP O
( P10034615T0000 ( O
110 P10034615T0000 CD O
) P10034615T0000 ) O
. P10034615T0000 . O
. . O O

Dose P01968156T0000 NNP O
standardisation P01968156T0000 NN O
of P01968156T0000 IN O
botulinum P01968156T0000 NN I-UN
toxin P01968156T0000 NN I-UN
. P01968156T0000 . O
. . O O

Functional P02497340A0989 NNP O
rearranged P02497340A0989 VBD O
antibody P02497340A0989 NN O
genes P02497340A0989 NNS O
were P02497340A0989 VBD O
detected P02497340A0989 VBN O
with P02497340A0989 IN O
JH P02497340A0989 NNP I-UN
and P02497340A0989 CC O
VH P02497340A0989 NNP I-UN
heavy P02497340A0989 VBP I-UN
chain P02497340A0989 NN I-UN
probes P02497340A0989 NNS O
and P02497340A0989 CC O
with P02497340A0989 IN O
Jk P02497340A0989 NNP I-UN
and P02497340A0989 CC O
Vk P02497340A0989 NNP I-UN
light P02497340A0989 VBD I-UN
chain P02497340A0989 NN I-UN
probes P02497340A0989 NNS O
. P02497340A0989 . O
. . O O

Plasma P00431832T0001 NNP O
ion P00431832T0001 NN O
changes P00431832T0001 NNS O
in P00431832T0001 IN O
venous P00431832T0001 JJ O
blood P00431832T0001 NN O
incubated P00431832T0001 VBN O
with P00431832T0001 IN O
beta P00431832T0001 NN I-UN
receptor P00431832T0001 NN I-UN
blockers P00431832T0001 NNS O
and P00431832T0001 CC O
subjected P00431832T0001 VBN O
to P00431832T0001 TO O
tonometry P00431832T0001 VB O
in P00431832T0001 IN O
vitro P00431832T0001 NN O
. P00431832T0001 . O
. . O O

Serum P00748978T0000 NNP I-UN
relaxin P00748978T0000 NN I-UN
levels P00748978T0000 NNS O
in P00748978T0000 IN O
prostaglandin P00748978T0000 NN O
E2 P00748978T0000 NNP O
induced P00748978T0000 VBD O
abortions P00748978T0000 NNS O
. P00748978T0000 . O
. . O O

Thus P08178490A0879 RB O
, P08178490A0879 , O
we P08178490A0879 PRP O
have P08178490A0879 VBP O
separated P08178490A0879 VBN O
the P08178490A0879 DT O
signal P08178490A0879 JJ O
function P08178490A0879 NN O
from P08178490A0879 IN O
the P08178490A0879 DT O
anchor P08178490A0879 NN O
function P08178490A0879 NN O
of P08178490A0879 IN O
the P08178490A0879 DT O
6.7K P08178490A0879 CD O
SA P08178490A0879 NNP O
domain P08178490A0879 NN O
. P08178490A0879 . O
. . O O

Detailed P07916326A0000 VBN O
molecular P07916326A0000 JJ O
organization P07916326A0000 NN O
of P07916326A0000 IN O
the P07916326A0000 DT O
coding P07916326A0000 NN O
and P07916326A0000 CC O
upstream P07916326A0000 JJ O
regulatory P07916326A0000 JJ O
regions P07916326A0000 NNS O
of P07916326A0000 IN O
the P07916326A0000 DT O
murine P07916326A0000 JJ O
homeodomain-containing P07916326A0000 JJ I-UN
gene P07916326A0000 NN I-UN
, P07916326A0000 , O
Msx-1 P07916326A0000 NNP I-UN
, P07916326A0000 , O
is P07916326A0000 VBZ O
reported P07916326A0000 VBN O
. P07916326A0000 . O
. . O O

Transcriptional P03025606T0000 NNP O
control P03025606T0000 NN O
signals P03025606T0000 NNS O
of P03025606T0000 IN O
a P03025606T0000 DT O
herpes P03025606T0000 NNS I-UN
simplex P03025606T0000 JJ I-UN
virus P03025606T0000 NN I-UN
type P03025606T0000 VBD I-UN
1 P03025606T0000 CD I-UN
late P03025606T0000 JJ I-UN
( P03025606T0000 ( I-UN
gamma P03025606T0000 JJ I-UN
2 P03025606T0000 CD I-UN
) P03025606T0000 ) I-UN
gene P03025606T0000 NN I-UN
lie P03025606T0000 NN O
within P03025606T0000 IN O
bases P03025606T0000 NNS O
-34 P03025606T0000 VBP O
to P03025606T0000 TO O
+124 P03025606T0000 VB O
relative P03025606T0000 JJ O
to P03025606T0000 TO O
the P03025606T0000 DT O
5 P03025606T0000 CD O
' P03025606T0000 POS O
terminus P03025606T0000 NN O
of P03025606T0000 IN O
the P03025606T0000 DT O
mRNA P03025606T0000 NN O
. P03025606T0000 . O
. . O O

Mutations P08599945T0000 NNS O
in P08599945T0000 IN O
the P08599945T0000 DT O
alpha-amanitin P08599945T0000 JJ I-UN
conserved P08599945T0000 JJ O
domain P08599945T0000 NN O
of P08599945T0000 IN O
the P08599945T0000 DT O
largest P08599945T0000 JJS O
subunit P08599945T0000 NN O
of P08599945T0000 IN O
yeast P08599945T0000 NN I-UN
RNA P08599945T0000 NNP I-UN
polymerase P08599945T0000 NN I-UN
III P08599945T0000 NNP I-UN
affect P08599945T0000 NN O
pausing P08599945T0000 NN O
, P08599945T0000 , O
RNA P08599945T0000 NNP O
cleavage P08599945T0000 NN O
and P08599945T0000 CC O
transcriptional P08599945T0000 JJ O
transitions P08599945T0000 NNS O
. P08599945T0000 . O
. . O O

This P07476971A0381 DT O
is P07476971A0381 VBZ O
particularly P07476971A0381 RB O
intriguing P07476971A0381 JJ O
because P07476971A0381 IN O
SKUT-1B-20 P07476971A0381 NNP O
cells P07476971A0381 NNS O
lack P07476971A0381 VBP O
the P07476971A0381 DT O
transcription P07476971A0381 NN O
factor P07476971A0381 NN O
Pit-1 P07476971A0381 NNP I-UN
. P07476971A0381 . O
. . O O

As P10090943A1976 IN O
normal P10090943A1976 JJ O
B P10090943A1976 NNP O
cells P10090943A1976 NNS O
also P10090943A1976 RB O
present P10090943A1976 VBP O
this P10090943A1976 DT O
variant P10090943A1976 NN O
, P10090943A1976 , O
the P10090943A1976 DT O
mechanism P10090943A1976 NN O
of P10090943A1976 IN O
CD79b P10090943A1976 NNP I-UN
posttranscriptional P10090943A1976 JJ O
regulation P10090943A1976 NN O
might P10090943A1976 MD O
reflect P10090943A1976 VB O
the P10090943A1976 DT O
activation P10090943A1976 NN O
stage P10090943A1976 NN O
of P10090943A1976 IN O
the P10090943A1976 DT O
normal P10090943A1976 JJ O
B P10090943A1976 NNP O
cell P10090943A1976 NN O
from P10090943A1976 IN O
which P10090943A1976 WDT O
B-CLL P10090943A1976 NNP O
derives P10090943A1976 NNS O
. P10090943A1976 . O
. . O O

Clinical P03114829T0000 JJ O
and P03114829T0000 CC O
biological P03114829T0000 JJ O
correlates P03114829T0000 NNS O
of P03114829T0000 IN O
panic P03114829T0000 JJ O
states P03114829T0000 NNS O
. P03114829T0000 . O
. . O O

In P09138076A1099 IN O
gel P09138076A1099 JJ O
mobility P09138076A1099 NN O
shift P09138076A1099 NN O
assays P09138076A1099 NNS O
, P09138076A1099 , O
factors P09138076A1099 NNS O
present P09138076A1099 VBP O
in P09138076A1099 IN O
nuclear P09138076A1099 JJ O
extracts P09138076A1099 NNS O
derived P09138076A1099 VBN O
from P09138076A1099 IN O
differentiated P09138076A1099 VBN O
osteoblast P09138076A1099 NN O
bound P09138076A1099 NN O
to P09138076A1099 TO O
oligonucleotide P09138076A1099 VB O
probes P09138076A1099 NNS O
containing P09138076A1099 VBG O
the P09138076A1099 DT O
E-box P09138076A1099 JJ O
1 P09138076A1099 CD O
and P09138076A1099 CC O
E-box P09138076A1099 JJ O
2 P09138076A1099 CD O
elements P09138076A1099 NNS O
. P09138076A1099 . O
. . O O

However P09722043A2070 RB O
, P09722043A2070 , O
both P09722043A2070 DT O
TPN P09722043A2070 NNP O
groups P09722043A2070 NNS O
showed P09722043A2070 VBD O
a P09722043A2070 DT O
marked P09722043A2070 JJ O
increase P09722043A2070 NN O
in P09722043A2070 IN O
activities P09722043A2070 NNS O
of P09722043A2070 IN O
liver P09722043A2070 NN O
lysosomal P09722043A2070 JJ I-UN
enzymes P09722043A2070 NNS I-UN
. P09722043A2070 . O
. . O O

Nuclease P11142380A0389 NNP O
probing P11142380A0389 VBG O
and P11142380A0389 CC O
structure-directed P11142380A0389 JJ O
mutagenesis P11142380A0389 NN O
revealed P11142380A0389 VBD O
that P11142380A0389 IN O
the P11142380A0389 DT O
105-nt P11142380A0389 JJ O
TE P11142380A0389 NNP O
( P11142380A0389 ( O
TE105 P11142380A0389 NNP O
) P11142380A0389 ) O
forms P11142380A0389 VBZ O
a P11142380A0389 DT O
cruciform P11142380A0389 NN O
secondary P11142380A0389 JJ O
structure P11142380A0389 NN O
containing P11142380A0389 VBG O
four P11142380A0389 CD O
helices P11142380A0389 NNS O
connected P11142380A0389 VBN O
by P11142380A0389 IN O
single-stranded P11142380A0389 JJ O
regions P11142380A0389 NNS O
. P11142380A0389 . O
. . O O

The P08914388A1645 DT O
assessment P08914388A1645 NN O
using P08914388A1645 VBG O
7 P08914388A1645 CD O
H P08914388A1645 NNP O
9 P08914388A1645 CD O
liquid P08914388A1645 NN O
medium P08914388A1645 NN O
by P08914388A1645 IN O
the P08914388A1645 DT O
former P08914388A1645 JJ O
author P08914388A1645 NN O
demonstrated P08914388A1645 VBD O
the P08914388A1645 DT O
potent P08914388A1645 JJ O
activities P08914388A1645 NNS O
of P08914388A1645 IN O
both P08914388A1645 DT O
CS-940* P08914388A1645 NNP O
and P08914388A1645 CC O
sparfloxacin P08914388A1645 NN O
( P08914388A1645 ( O
SPFX P08914388A1645 NNP O
) P08914388A1645 ) O
, P08914388A1645 , O
followed P08914388A1645 VBN O
by P08914388A1645 IN O
AM-1155* P08914388A1645 NNP O
, P08914388A1645 , O
ciprofloxacin P08914388A1645 NN O
( P08914388A1645 ( O
CPFX P08914388A1645 NNP O
) P08914388A1645 ) O
, P08914388A1645 , O
levofloxacin P08914388A1645 FW O
( P08914388A1645 ( O
LVFX P08914388A1645 NNP O
) P08914388A1645 ) O
, P08914388A1645 , O
OPC-17116* P08914388A1645 NNP O
, P08914388A1645 , O
NM-394* P08914388A1645 NNP O
in P08914388A1645 IN O
sequence P08914388A1645 NN O
. P08914388A1645 . O
. . O O

The P08980522A0280 DT O
cDNA P08980522A0280 NN O
of P08980522A0280 IN O
cpm7 P08980522A0280 NN I-UN
encodes P08980522A0280 VBZ O
a P08980522A0280 DT O
closely P08980522A0280 RB O
related P08980522A0280 JJ O
protein P08980522A0280 NN O
of P08980522A0280 IN O
36.8 P08980522A0280 CD O
kDa P08980522A0280 NNS O
. P08980522A0280 . O
. . O O

To P07623807A0162 TO O
dissect P07623807A0162 VB O
these P07623807A0162 DT O
mechanisms P07623807A0162 NNS O
, P07623807A0162 , O
wild-type P07623807A0162 JJ O
and P07623807A0162 CC O
mutant P07623807A0162 JJ I-UN
Raf-1 P07623807A0162 JJ I-UN
proteins P07623807A0162 NNS I-UN
were P07623807A0162 VBD O
studied P07623807A0162 VBN O
in P07623807A0162 IN O
an P07623807A0162 DT O
in P07623807A0162 IN O
vitro P07623807A0162 NN O
system P07623807A0162 NN O
with P07623807A0162 IN O
purified P07623807A0162 JJ O
plasma P07623807A0162 NN O
membranes P07623807A0162 NNS O
from P07623807A0162 IN O
v-Ras- P07623807A0162 JJ O
and P07623807A0162 CC O
v-Src-transformed P07623807A0162 JJ O
cells P07623807A0162 NNS O
( P07623807A0162 ( O
transformed P07623807A0162 VBN O
membranes P07623807A0162 NNS O
) P07623807A0162 ) O
. P07623807A0162 . O
. . O O

Laryngographic P03828209T0000 JJ O
changes P03828209T0000 NNS O
following P03828209T0000 VBG O
endotracheal P03828209T0000 JJ O
intubation P03828209T0000 NN O
in P03828209T0000 IN O
adults P03828209T0000 NNS O
. P03828209T0000 . O
. . O O

However P09083345A0851 RB O
, P09083345A0851 , O
the P09083345A0851 DT O
range P09083345A0851 NN O
of P09083345A0851 IN O
values P09083345A0851 NNS O
observed P09083345A0851 VBN O
is P09083345A0851 VBZ O
suggestive P09083345A0851 JJ O
of P09083345A0851 IN O
the P09083345A0851 DT O
need P09083345A0851 NN O
to P09083345A0851 TO O
investigate P09083345A0851 VB O
districts P09083345A0851 NNS O
with P09083345A0851 IN O
contrasting P09083345A0851 VBG O
values P09083345A0851 NNS O
of P09083345A0851 IN O
SYPLR P09083345A0851 NNP O
with P09083345A0851 IN O
respect P09083345A0851 NN O
to P09083345A0851 TO O
the P09083345A0851 DT O
inter-relationships P09083345A0851 NNS O
between P09083345A0851 IN O
sociodemographic P09083345A0851 JJ O
characteristics P09083345A0851 NNS O
, P09083345A0851 , O
duration P09083345A0851 NN O
of P09083345A0851 IN O
symptoms P09083345A0851 NNS O
, P09083345A0851 , O
clinical P09083345A0851 JJ O
presentation P09083345A0851 NN O
and P09083345A0851 CC O
treatment P09083345A0851 NN O
efficacy P09083345A0851 NN O
. P09083345A0851 . O
. . O O

This P09060444A0557 DT O
promoter P09060444A0557 NN O
segment P09060444A0557 NN O
could P09060444A0557 MD O
drive P09060444A0557 VB O
expression P09060444A0557 NN O
of P09060444A0557 IN O
a P09060444A0557 DT O
luciferase P09060444A0557 NN I-UN
reporter P09060444A0557 NN I-UN
gene P09060444A0557 NN I-UN
, P09060444A0557 , O
could P09060444A0557 MD O
confer P09060444A0557 VB O
correct P09060444A0557 JJ O
transcriptional P09060444A0557 JJ O
initiation P09060444A0557 NN O
to P09060444A0557 TO O
the P09060444A0557 DT O
reporter P09060444A0557 NN O
and P09060444A0557 CC O
could P09060444A0557 MD O
confer P09060444A0557 VB O
the P09060444A0557 DT O
EGF-responsiveness P09060444A0557 NNP O
previously P09060444A0557 RB O
observed P09060444A0557 VBD O
in P09060444A0557 IN O
the P09060444A0557 DT O
native P09060444A0557 JJ O
gene P09060444A0557 NN O
. P09060444A0557 . O
. . O O

Studies P05719031T0000 NNS O
on P05719031T0000 IN O
the P05719031T0000 DT O
method P05719031T0000 NN O
of P05719031T0000 IN O
size P05719031T0000 NN O
reduction P05719031T0000 NN O
of P05719031T0000 IN O
medicinal P05719031T0000 JJ O
compounds P05719031T0000 NNS O
. P05719031T0000 . O
. . O O

A P01810108A0000 DT O
two P01810108A0000 CD O
phase P01810108A0000 NN O
slug P01810108A0000 NN O
flow P01810108A0000 NN O
tubular P01810108A0000 NN O
heat P01810108A0000 NN O
exchanger P01810108A0000 NN O
was P01810108A0000 VBD O
used P01810108A0000 VBN O
for P01810108A0000 IN O
the P01810108A0000 DT O
thermal P01810108A0000 JJ O
inactivation P01810108A0000 NN O
of P01810108A0000 IN O
Listeria P01810108A0000 NNP O
monocytogenes P01810108A0000 NNS O
in P01810108A0000 IN O
natural P01810108A0000 JJ O
infected P01810108A0000 JJ O
milk P01810108A0000 NN O
from P01810108A0000 IN O
seven P01810108A0000 CD O
cows P01810108A0000 NNS O
. P01810108A0000 . O
. . O O

A P02781567A0544 DT O
soap P02781567A0544 NN O
and P02781567A0544 CC O
water P02781567A0544 NN O
( P02781567A0544 ( O
1:1 P02781567A0544 CD O
, P02781567A0544 , O
v P02781567A0544 FW O
/ P02781567A0544 NNP O
v P02781567A0544 NN O
) P02781567A0544 ) O
solution P02781567A0544 NN O
effectively P02781567A0544 RB O
decontaminated P02781567A0544 VBD O
powdered P02781567A0544 JJ O
stratum P02781567A0544 NN O
corneum P02781567A0544 NN O
. P02781567A0544 . O
. . O O

Besides P09756687A0981 IN O
the P09756687A0981 DT O
characterization P09756687A0981 NN O
and P09756687A0981 CC O
discussion P09756687A0981 NN O
of P09756687A0981 IN O
the P09756687A0981 DT O
experimental P09756687A0981 JJ O
setup P09756687A0981 NN O
used P09756687A0981 VBN O
, P09756687A0981 , O
the P09756687A0981 DT O
rate P09756687A0981 NN O
constants P09756687A0981 NNS O
obtained P09756687A0981 VBN O
are P09756687A0981 VBP O
discussed P09756687A0981 VBN O
and P09756687A0981 CC O
compared P09756687A0981 VBN O
with P09756687A0981 IN O
estimated P09756687A0981 VBN O
values P09756687A0981 NNS O
. P09756687A0981 . O
. . O O

Furthermore P08805824A1155 RB O
, P08805824A1155 , O
the P08805824A1155 DT O
use P08805824A1155 NN O
of P08805824A1155 IN O
zero-loss P08805824A1155 NN O
filtering P08805824A1155 NN O
in P08805824A1155 IN O
combination P08805824A1155 NN O
with P08805824A1155 IN O
exit P08805824A1155 NN O
wavefront P08805824A1155 NN O
reconstruction P08805824A1155 NN O
is P08805824A1155 VBZ O
considerably P08805824A1155 RB O
more P08805824A1155 RBR O
effective P08805824A1155 JJ O
at P08805824A1155 IN O
removing P08805824A1155 VBG O
the P08805824A1155 DT O
effects P08805824A1155 NNS O
of P08805824A1155 IN O
multiple P08805824A1155 JJ O
elastic P08805824A1155 JJ O
and P08805824A1155 CC O
inelastic P08805824A1155 JJ O
scattering P08805824A1155 NN O
and P08805824A1155 CC O
microscope P08805824A1155 NN O
objective P08805824A1155 VBP O
lens P08805824A1155 NNS O
aberrations P08805824A1155 NNS O
than P08805824A1155 IN O
either P08805824A1155 DT O
technique P08805824A1155 NN O
by P08805824A1155 IN O
itself P08805824A1155 PRP O
. P08805824A1155 . O
. . O O

A P09572965A1235 DT O
third P09572965A1235 JJ O
ORF P09572965A1235 NNP O
, P09572965A1235 , O
ORF5 P09572965A1235 NNP O
, P09572965A1235 , O
shows P09572965A1235 VBZ O
homology P09572965A1235 NN O
with P09572965A1235 IN O
gene P09572965A1235 NN I-UN
agrB P09572965A1235 NN I-UN
from P09572965A1235 IN O
Staphylococcus P09572965A1235 NNP O
aureus P09572965A1235 NN O
, P09572965A1235 , O
which P09572965A1235 WDT O
is P09572965A1235 VBZ O
involved P09572965A1235 VBN O
in P09572965A1235 IN O
the P09572965A1235 DT O
mechanism P09572965A1235 NN O
of P09572965A1235 IN O
regulation P09572965A1235 NN O
of P09572965A1235 IN O
the P09572965A1235 DT O
virulence P09572965A1235 NN O
phenotype P09572965A1235 NN O
in P09572965A1235 IN O
this P09572965A1235 DT O
species P09572965A1235 NNS O
. P09572965A1235 . O
. . O O

The P01647656A0000 DT O
relation P01647656A0000 NN O
between P01647656A0000 IN O
myocardial P01647656A0000 JJ I-UN
beta-adrenergic P01647656A0000 JJ I-UN
receptor P01647656A0000 NN I-UN
and P01647656A0000 CC O
left P01647656A0000 VBD O
ventricular P01647656A0000 NN O
( P01647656A0000 ( O
LV P01647656A0000 NNP O
) P01647656A0000 ) O
function P01647656A0000 NN O
was P01647656A0000 VBD O
studied P01647656A0000 VBN O
in P01647656A0000 IN O
10 P01647656A0000 CD O
patients P01647656A0000 NNS O
, P01647656A0000 , O
aged P01647656A0000 VBD O
41 P01647656A0000 CD O
to P01647656A0000 TO O
61 P01647656A0000 CD O
years P01647656A0000 NNS O
( P01647656A0000 ( O
average P01647656A0000 JJ O
51 P01647656A0000 CD O
) P01647656A0000 ) O
, P01647656A0000 , O
with P01647656A0000 IN O
LV P01647656A0000 NNP O
volume P01647656A0000 NN O
overload P01647656A0000 NN O
mainly P01647656A0000 RB O
due P01647656A0000 JJ O
to P01647656A0000 TO O
chronic P01647656A0000 JJ O
mitral P01647656A0000 JJ O
regurgitation P01647656A0000 NN O
. P01647656A0000 . O
. . O O

Antisense P09073074T0000 NNP O
transcription P09073074T0000 NN O
of P09073074T0000 IN O
a P09073074T0000 DT O
murine P09073074T0000 JJ I-UN
FGFR-3 P09073074T0000 JJ I-UN
psuedogene P09073074T0000 NN I-UN
during P09073074T0000 IN O
fetal P09073074T0000 JJ O
developement P09073074T0000 NN O
. P09073074T0000 . O
. . O O

The P01675424A0991 DT O
most P01675424A0991 RBS O
striking P01675424A0991 JJ O
difference P01675424A0991 NN O
in P01675424A0991 IN O
the P01675424A0991 DT O
birch P01675424A0991 NN I-UN
NAD P01675424A0991 NNP I-UN
( P01675424A0991 ( I-UN
P P01675424A0991 NNP I-UN
) P01675424A0991 ) I-UN
H-NR P01675424A0991 NNP I-UN
sequence P01675424A0991 NN I-UN
in P01675424A0991 IN O
comparison P01675424A0991 NN O
to P01675424A0991 TO O
NADH-NR P01675424A0991 NNP I-UN
sequences P01675424A0991 NNS I-UN
was P01675424A0991 VBD O
found P01675424A0991 VBN O
at P01675424A0991 IN O
the P01675424A0991 DT O
putative P01675424A0991 JJ O
pyridine P01675424A0991 NN O
nucleotide P01675424A0991 IN O
binding P01675424A0991 VBG O
site P01675424A0991 NN O
. P01675424A0991 . O
. . O O

RESULTS P09846033A0488 NN O
: P09846033A0488 : O
Significant P09846033A0488 JJ O
changes P09846033A0488 NNS O
from P09846033A0488 IN O
pretreatment P09846033A0488 NN O
to P09846033A0488 TO O
posttreatment P09846033A0488 VB O
were P09846033A0488 VBD O
observed P09846033A0488 VBN O
( P09846033A0488 ( O
p P09846033A0488 JJ O
< P09846033A0488 NNP O
0.001 P09846033A0488 CD O
) P09846033A0488 ) O
. P09846033A0488 . O
. . O O

These P10556063A0092 DT O
kinases P10556063A0092 NNS O
belong P10556063A0092 VBP O
to P10556063A0092 TO O
a P10556063A0092 DT O
new P10556063A0092 JJ O
subfamily P10556063A0092 RB O
related P10556063A0092 VBN O
to P10556063A0092 TO O
the P10556063A0092 DT O
Trk P10556063A0092 NNP I-UN
subfamily P10556063A0092 RB I-UN
. P10556063A0092 . O
. . O O

The P10652800A0984 DT O
insulin P10652800A0984 NN I-UN
therapy P10652800A0984 NN O
regimen P10652800A0984 NNS O
did P10652800A0984 VBD O
not P10652800A0984 RB O
affect P10652800A0984 VB O
the P10652800A0984 DT O
evolution P10652800A0984 NN O
of P10652800A0984 IN O
the P10652800A0984 DT O
patients P10652800A0984 NNS O
and P10652800A0984 CC O
no P10652800A0984 DT O
significant P10652800A0984 JJ O
relationship P10652800A0984 NN O
existed P10652800A0984 VBD O
between P10652800A0984 IN O
the P10652800A0984 DT O
age P10652800A0984 NN O
at P10652800A0984 IN O
diagnosis P10652800A0984 NN O
, P10652800A0984 , O
duration P10652800A0984 NN O
of P10652800A0984 IN O
diabetes P10652800A0984 NNS O
, P10652800A0984 , O
daily P10652800A0984 JJ O
insulin P10652800A0984 NN I-UN
dosage P10652800A0984 NN O
or P10652800A0984 CC O
metabolic P10652800A0984 JJ O
control P10652800A0984 NN O
and P10652800A0984 CC O
height P10652800A0984 NN O
or P10652800A0984 CC O
BMI P10652800A0984 NNP O
. P10652800A0984 . O
. . O O

Surprisingly P09334264A0540 RB O
, P09334264A0540 , O
calf P09334264A0540 NN I-UN
thymus P09334264A0540 NN I-UN
CstF P09334264A0540 NNP I-UN
contained P09334264A0540 VBD O
an P09334264A0540 DT O
additional P09334264A0540 JJ O
, P09334264A0540 , O
novel P09334264A0540 JJ O
form P09334264A0540 NN O
of P09334264A0540 IN O
the P09334264A0540 DT O
64-kDa P09334264A0540 JJ O
subunit P09334264A0540 NN O
with P09334264A0540 IN O
a P09334264A0540 DT O
molecular P09334264A0540 JJ O
mass P09334264A0540 NN O
of P09334264A0540 IN O
70 P09334264A0540 CD O
kDa P09334264A0540 NNS O
. P09334264A0540 . O
. . O O

Activation P10873158A0000 NN O
of P10873158A0000 IN O
nuclear P10873158A0000 JJ I-UN
factor P10873158A0000 NN I-UN
( P10873158A0000 ( I-UN
NF P10873158A0000 NNP I-UN
) P10873158A0000 ) I-UN
-kappaB P10873158A0000 NN I-UN
and P10873158A0000 CC O
subsequent P10873158A0000 JJ O
proinflammatory P10873158A0000 NN O
gene P10873158A0000 NN O
expression P10873158A0000 NN O
in P10873158A0000 IN O
human P10873158A0000 JJ O
airway P10873158A0000 NN O
epithelial P10873158A0000 JJ O
cells P10873158A0000 NNS O
can P10873158A0000 MD O
be P10873158A0000 VB O
evoked P10873158A0000 VBN O
by P10873158A0000 IN O
oxidative P10873158A0000 JJ O
stress P10873158A0000 NN O
. P10873158A0000 . O
. . O O

There P02053289A0701 EX O
were P02053289A0701 VBD O
45 P02053289A0701 CD O
to P02053289A0701 TO O
56 P02053289A0701 CD O
nt P02053289A0701 NNS O
differences P02053289A0701 NNS O
between P02053289A0701 IN O
the P02053289A0701 DT O
virulent P02053289A0701 NN O
and P02053289A0701 CC O
avirulent P02053289A0701 NN O
groups P02053289A0701 NNS O
while P02053289A0701 IN O
there P02053289A0701 EX O
were P02053289A0701 VBD O
6 P02053289A0701 CD O
to P02053289A0701 TO O
14 P02053289A0701 CD O
nt P02053289A0701 NNS O
differences P02053289A0701 NNS O
among P02053289A0701 IN O
four P02053289A0701 CD O
avirulent P02053289A0701 NN O
strains P02053289A0701 NNS O
. P02053289A0701 . O
. . O O

Recombination P01658356T0000 NN O
between P01658356T0000 IN O
feline P01658356T0000 JJ O
leukemia P01658356T0000 NN O
virus P01658356T0000 NN O
subgroup P01658356T0000 NN O
B P01658356T0000 NNP O
or P01658356T0000 CC O
C P01658356T0000 NNP O
and P01658356T0000 CC O
endogenous P01658356T0000 JJ O
env P01658356T0000 NN I-UN
elements P01658356T0000 NNS O
alters P01658356T0000 VBZ O
the P01658356T0000 DT O
in P01658356T0000 IN O
vitro P01658356T0000 JJ O
biological P01658356T0000 JJ O
activities P01658356T0000 NNS O
of P01658356T0000 IN O
the P01658356T0000 DT O
viruses P01658356T0000 NNS O
. P01658356T0000 . O
. . O O

Significantly P10773455A1268 RB O
, P10773455A1268 , O
two P10773455A1268 CD O
proximal P10773455A1268 JJ O
GATA-1-binding P10773455A1268 VBG I-UN
sites P10773455A1268 NNS I-UN
( P10773455A1268 ( O
-118 P10773455A1268 JJ O
/ P10773455A1268 NNP O
-113 P10773455A1268 NNP O
and P10773455A1268 CC O
-98 P10773455A1268 NNP O
/ P10773455A1268 NNP O
-93 P10773455A1268 NNP O
) P10773455A1268 ) O
and P10773455A1268 CC O
a P10773455A1268 DT O
region P10773455A1268 NN O
located P10773455A1268 VBN O
within P10773455A1268 IN O
-518 P10773455A1268 NN O
to P10773455A1268 TO O
-315bp P10773455A1268 VB O
of P10773455A1268 IN O
the P10773455A1268 DT O
mouse P10773455A1268 NN I-UN
ALAS2 P10773455A1268 NNP I-UN
promoter P10773455A1268 NN I-UN
were P10773455A1268 VBD O
essential P10773455A1268 JJ O
for P10773455A1268 IN O
transcriptional P10773455A1268 JJ O
activation P10773455A1268 NN O
during P10773455A1268 IN O
chemically P10773455A1268 RB O
induced P10773455A1268 JJ O
differentiation P10773455A1268 NN O
of P10773455A1268 IN O
MEL P10773455A1268 NNP O
cells P10773455A1268 NNS O
, P10773455A1268 , O
implying P10773455A1268 VBG O
their P10773455A1268 PRP$ O
importance P10773455A1268 NN O
in P10773455A1268 IN O
conferring P10773455A1268 VBG O
erythroid P10773455A1268 JJ O
specificity P10773455A1268 NN O
to P10773455A1268 TO O
the P10773455A1268 DT O
ALAS2 P10773455A1268 NNP I-UN
transcriptional P10773455A1268 JJ O
activation P10773455A1268 NN O
. P10773455A1268 . O
. . O O

Notably P07957243A1316 RB O
, P07957243A1316 , O
these P07957243A1316 DT O
residues P07957243A1316 NNS O
are P07957243A1316 VBP O
located P07957243A1316 VBN O
in P07957243A1316 IN O
different P07957243A1316 JJ O
domains P07957243A1316 NNS O
. P07957243A1316 . O
. . O O

NF-kappaB P11063742A0000 NNP I-UN
is P11063742A0000 VBZ O
a P11063742A0000 DT O
redox-sensitive P11063742A0000 JJ O
transcription P11063742A0000 NN O
factor P11063742A0000 NN O
known P11063742A0000 VBN O
to P11063742A0000 TO O
be P11063742A0000 VB O
activated P11063742A0000 VBN O
by P11063742A0000 IN O
oxidative P11063742A0000 JJ O
stress P11063742A0000 NN O
as P11063742A0000 RB O
well P11063742A0000 RB O
as P11063742A0000 IN O
chemical P11063742A0000 NN O
and P11063742A0000 CC O
biological P11063742A0000 JJ O
reductants P11063742A0000 NNS O
. P11063742A0000 . O
. . O O

Except P10496388A1956a IN O
for P10496388A1956a IN O
nonperfusion P10496388A1956a NN O
of P10496388A1956a IN O
neurosensory P10496388A1956a JJ O
retinal P10496388A1956a JJ O
vessels P10496388A1956a NNS O
at P10496388A1956a IN O
a P10496388A1956a DT O
light P10496388A1956a JJ O
dose P10496388A1956a NN O
of P10496388A1956a IN O
150 P10496388A1956a CD O
J P10496388A1956a NNP O
/ P10496388A1956a NNP O
cm2 P10496388A1956a NN O
, P10496388A1956a , O
no P10496388A1956a DT O
other P10496388A1956a JJ O
adverse P10496388A1956a JJ O
events P10496388A1956a NNS O
were P10496388A1956a VBD O
of P10496388A1956a IN O
concern P10496388A1956a NN O
. P10496388A1956a . O
. . O O

The P09182281A0197 DT O
most P09182281A0197 RBS O
important P09182281A0197 JJ O
one P09182281A0197 NN O
among P09182281A0197 IN O
them P09182281A0197 PRP O
is P09182281A0197 VBZ O
Cyclosporin P09182281A0197 NNP O
A P09182281A0197 NNP O
, P09182281A0197 , O
which P09182281A0197 WDT O
is P09182281A0197 VBZ O
a P09182281A0197 DT O
selective P09182281A0197 JJ O
immunosuppressive P09182281A0197 JJ O
drug P09182281A0197 NN O
. P09182281A0197 . O
. . O O

In P07173729A0000 IN O
vitro P07173729A0000 JJ O
penetration P07173729A0000 NN O
tests P07173729A0000 NNS O
of P07173729A0000 IN O
human P07173729A0000 JJ O
sperm P07173729A0000 NN O
into P07173729A0000 IN O
cervical P07173729A0000 JJ O
mucus P07173729A0000 NN O
were P07173729A0000 VBD O
introduced P07173729A0000 VBN O
in P07173729A0000 IN O
order P07173729A0000 NN O
to P07173729A0000 TO O
study P07173729A0000 VB O
the P07173729A0000 DT O
interaction P07173729A0000 NN O
between P07173729A0000 IN O
sperm P07173729A0000 NN O
and P07173729A0000 CC O
cervical P07173729A0000 JJ O
mucus P07173729A0000 NN O
. P07173729A0000 . O
. . O O

Both P01692837A0390 DT O
genes P01692837A0390 NNS O
comprise P01692837A0390 VBP O
three P01692837A0390 CD O
exons P01692837A0390 NNS O
, P01692837A0390 , O
two P01692837A0390 CD O
introns P01692837A0390 NNS O
and P01692837A0390 CC O
an P01692837A0390 DT O
unusually P01692837A0390 RB O
long P01692837A0390 JJ O
3'-untranslated P01692837A0390 JJ O
region P01692837A0390 NN O
( P01692837A0390 ( O
3.2 P01692837A0390 CD O
kilobase P01692837A0390 NN O
pairs P01692837A0390 NN O
) P01692837A0390 ) O
, P01692837A0390 , O
specificying P01692837A0390 VBG O
a P01692837A0390 DT O
mRNA P01692837A0390 NN O
of P01692837A0390 IN O
approximately P01692837A0390 RB O
4.1 P01692837A0390 CD O
kilobases P01692837A0390 NNS O
. P01692837A0390 . O
. . O O

Lacrimal P07184598T0001 JJ O
secretion P07184598T0001 NN O
in P07184598T0001 IN O
hyperthyroidism P07184598T0001 NN O
. P07184598T0001 . O
. . O O

The P11288930A0000 DT O
reproductive P11288930A0000 JJ O
effects P11288930A0000 NNS O
of P11288930A0000 IN O
the P11288930A0000 DT O
administration P11288930A0000 NN O
of P11288930A0000 IN O
4-chloro-2-methylphenoxyacetic P11288930A0000 JJ O
acid P11288930A0000 NN O
( P11288930A0000 ( O
MCPA P11288930A0000 NNP O
) P11288930A0000 ) O
to P11288930A0000 TO O
rats P11288930A0000 NNS O
were P11288930A0000 VBD O
evaluated P11288930A0000 VBN O
through P11288930A0000 IN O
two P11288930A0000 CD O
generations P11288930A0000 NNS O
, P11288930A0000 , O
from P11288930A0000 IN O
prior P11288930A0000 JJ O
to P11288930A0000 TO O
mating P11288930A0000 NN O
, P11288930A0000 , O
throughout P11288930A0000 IN O
mating P11288930A0000 NN O
, P11288930A0000 , O
to P11288930A0000 TO O
gestation P11288930A0000 NN O
and P11288930A0000 CC O
lactation P11288930A0000 NN O
. P11288930A0000 . O
. . O O

Plasma P09737453A0557 NNP O
was P09737453A0557 VBD O
tested P09737453A0557 VBN O
before P09737453A0557 IN O
and P09737453A0557 CC O
after P09737453A0557 IN O
( P09737453A0557 ( O
14 P09737453A0557 CD O
+ P09737453A0557 NN O
/ P09737453A0557 NNP O
- P09737453A0557 : O
7.5 P09737453A0557 CD O
[ P09737453A0557 JJ O
SD P09737453A0557 NNP O
] P09737453A0557 NNP O
days P09737453A0557 NNS O
) P09737453A0557 ) O
surgery P09737453A0557 NN O
for P09737453A0557 IN O
IgG P09737453A0557 NNP I-UN
antibodies P09737453A0557 NNS I-UN
to P09737453A0557 TO O
the P09737453A0557 DT O
complex P09737453A0557 NN O
of P09737453A0557 IN O
heparin P09737453A0557 NN I-UN
/ P09737453A0557 NNP I-UN
platelet P09737453A0557 NN I-UN
factor P09737453A0557 NN I-UN
4 P09737453A0557 CD I-UN
, P09737453A0557 , O
using P09737453A0557 VBG O
a P09737453A0557 DT O
standardized P09737453A0557 JJ O
, P09737453A0557 , O
validated P09737453A0557 VBD O
enzyme-linked P09737453A0557 JJ O
immunosorbent P09737453A0557 NN O
assay P09737453A0557 NN O
( P09737453A0557 ( O
ELISA P09737453A0557 NNP O
) P09737453A0557 ) O
. P09737453A0557 . O
. . O O

The P00843232A0100 DT O
background P00843232A0100 NN O
processes P00843232A0100 VBZ O
depending P00843232A0100 VBG O
on P00843232A0100 IN O
the P00843232A0100 DT O
etiological P00843232A0100 JJ O
factor P00843232A0100 NN O
and P00843232A0100 CC O
the P00843232A0100 DT O
character P00843232A0100 NN O
of P00843232A0100 IN O
lesion P00843232A0100 NN O
of P00843232A0100 IN O
the P00843232A0100 DT O
epithelium P00843232A0100 NN O
are P00843232A0100 VBP O
divided P00843232A0100 VBN O
into P00843232A0100 IN O
dyshormonal P00843232A0100 JJ O
, P00843232A0100 , O
inflammatory P00843232A0100 JJ O
, P00843232A0100 , O
and P00843232A0100 CC O
posttraumatic P00843232A0100 JJ O
. P00843232A0100 . O
. . O O

Similarly P09171235A0851 RB O
, P09171235A0851 , O
overexpression P09171235A0851 NN O
of P09171235A0851 IN O
increasing P09171235A0851 VBG O
concentration P09171235A0851 NN O
of P09171235A0851 IN O
COUP-TFI P09171235A0851 NNP I-UN
, P09171235A0851 , O
but P09171235A0851 CC O
not P09171235A0851 RB O
COUP-TFI P09171235A0851 NNP I-UN
delta35 P09171235A0851 NN I-UN
, P09171235A0851 , O
can P09171235A0851 MD O
squelch P09171235A0851 VB O
the P09171235A0851 DT O
silencing P09171235A0851 NN O
activity P09171235A0851 NN O
of P09171235A0851 IN O
the P09171235A0851 DT O
unliganded P09171235A0851 JJ O
TRbeta P09171235A0851 NNP I-UN
. P09171235A0851 . O
. . O O

Furthermore P08798893A0611 RB O
, P08798893A0611 , O
freezing P08798893A0611 VBG O
in P08798893A0611 IN O
the P08798893A0611 DT O
presence P08798893A0611 NN O
of P08798893A0611 IN O
bovine P08798893A0611 NN I-UN
lactalbumin P08798893A0611 NN I-UN
resulted P08798893A0611 VBD O
in P08798893A0611 IN O
a P08798893A0611 DT O
good P08798893A0611 JJ O
maintenance P08798893A0611 NN O
of P08798893A0611 IN O
the P08798893A0611 DT O
cellular P08798893A0611 JJ O
viability P08798893A0611 NN O
and P08798893A0611 CC O
of P08798893A0611 IN O
the P08798893A0611 DT O
CCCD P08798893A0611 NNP O
heterogeneity P08798893A0611 NN O
in P08798893A0611 IN O
respect P08798893A0611 NN O
to P08798893A0611 TO O
fresh P08798893A0611 JJ O
cells P08798893A0611 NNS O
. P08798893A0611 . O
. . O O

Non-complement-dependent P06785113A0337 JJ O
sperm-immobilizing P06785113A0337 JJ O
activity P06785113A0337 NN O
was P06785113A0337 VBD O
also P06785113A0337 RB O
detected P06785113A0337 VBN O
in P06785113A0337 IN O
the P06785113A0337 DT O
cervical P06785113A0337 JJ O
mucus P06785113A0337 NN O
of P06785113A0337 IN O
several P06785113A0337 JJ O
patients P06785113A0337 NNS O
. P06785113A0337 . O
. . O O

Abnormal P00832096T0000 JJ O
calcium P00832096T0000 NN O
metabolism P00832096T0000 NN O
in P00832096T0000 IN O
normocalcaemic P00832096T0000 JJ O
sarcoidosis P00832096T0000 NN O
. P00832096T0000 . O
. . O O

Per P02361812A1110 NNP O
kg P02361812A1110 NN O
FFM P02361812A1110 NNP O
SMR P02361812A1110 NNP O
was P02361812A1110 VBD O
almost P02361812A1110 RB O
restored P02361812A1110 VBN O
to P02361812A1110 TO O
baseline P02361812A1110 VB O
values P02361812A1110 NNS O
for P02361812A1110 IN O
the P02361812A1110 DT O
EX P02361812A1110 NNP O
group P02361812A1110 NN O
, P02361812A1110 , O
whereas P02361812A1110 IN O
the P02361812A1110 DT O
non-exercising P02361812A1110 JJ O
subjects P02361812A1110 NNS O
still P02361812A1110 RB O
showed P02361812A1110 VBD O
depressed P02361812A1110 JJ O
values P02361812A1110 NNS O
( P02361812A1110 ( O
EX P02361812A1110 NNP O
3.7 P02361812A1110 CD O
per P02361812A1110 IN O
cent P02361812A1110 NN O
and P02361812A1110 CC O
D P02361812A1110 NNP O
+ P02361812A1110 NNP O
DE P02361812A1110 NNP O
15.8 P02361812A1110 CD O
per P02361812A1110 IN O
cent P02361812A1110 NN O
lower P02361812A1110 JJR O
than P02361812A1110 IN O
before P02361812A1110 RB O
treatment P02361812A1110 NN O
; P02361812A1110 : O
P P02361812A1110 NNP O
less P02361812A1110 JJR O
than P02361812A1110 IN O
0.05 P02361812A1110 CD O
) P02361812A1110 ) O
. P02361812A1110 . O
. . O O

These P01791363A0208 DT O
results P01791363A0208 NNS O
were P01791363A0208 VBD O
superior P01791363A0208 JJ O
to P01791363A0208 TO O
those P01791363A0208 DT O
in P01791363A0208 IN O
24 P01791363A0208 CD O
patients P01791363A0208 NNS O
with P01791363A0208 IN O
conventional P01791363A0208 JJ O
end-to-end P01791363A0208 JJ O
sutures P01791363A0208 NNS O
on P01791363A0208 IN O
clinical P01791363A0208 JJ O
testing P01791363A0208 NN O
. P01791363A0208 . O
. . O O

Homology P01714452A0559 NN O
with P01714452A0559 IN O
the P01714452A0559 DT O
human P01714452A0559 JJ O
protein P01714452A0559 NN O
is P01714452A0559 VBZ O
only P01714452A0559 RB O
34 P01714452A0559 CD O
% P01714452A0559 NN O
in P01714452A0559 IN O
the P01714452A0559 DT O
tandem P01714452A0559 NN O
repeat P01714452A0559 NN O
domain P01714452A0559 NN O
, P01714452A0559 , O
mainly P01714452A0559 RB O
showing P01714452A0559 VBG O
conservation P01714452A0559 NN O
of P01714452A0559 IN O
serines P01714452A0559 NNS O
and P01714452A0559 CC O
threonines P01714452A0559 NNS O
, P01714452A0559 , O
presumed P01714452A0559 VBN O
sites P01714452A0559 NNS O
of P01714452A0559 IN O
O-linked P01714452A0559 JJ O
carbohydrate P01714452A0559 NN O
attachment P01714452A0559 NN O
. P01714452A0559 . O
. . O O

Poor P02859434T0000 NNP O
response P02859434T0000 NN O
when P02859434T0000 WRB O
laboratory P02859434T0000 NN O
recommended P02859434T0000 VBD O
range P02859434T0000 NN O
for P02859434T0000 IN O
serum P02859434T0000 NN O
lithium P02859434T0000 NN O
is P02859434T0000 VBZ O
changed P02859434T0000 VBN O
. P02859434T0000 . O
. . O O

Adding P11152081A0413 VBG O
10 P11152081A0413 CD O
mmol P11152081A0413 JJ O
SDS P11152081A0413 NNP O
/ P11152081A0413 NNP O
l P11152081A0413 NN O
led P11152081A0413 VBD O
to P11152081A0413 TO O
transient P11152081A0413 VB O
inhibition P11152081A0413 NN O
of P11152081A0413 IN O
acidification P11152081A0413 NN O
, P11152081A0413 , O
metal P11152081A0413 JJ O
solubilization P11152081A0413 NN O
and P11152081A0413 CC O
sulfur P11152081A0413 JJ O
oxidation P11152081A0413 NN O
. P11152081A0413 . O
. . O O

After P07517544A0515 IN O
7 P07517544A0515 CD O
days P07517544A0515 NNS O
, P07517544A0515 , O
a P07517544A0515 DT O
spontaneous P07517544A0515 JJ O
regression P07517544A0515 NN O
of P07517544A0515 IN O
the P07517544A0515 DT O
morphologic P07517544A0515 JJ O
alterations P07517544A0515 NNS O
caused P07517544A0515 VBN O
by P07517544A0515 IN O
caerulein-induced P07517544A0515 JJ O
acute P07517544A0515 NN O
pancreatitis P07517544A0515 NN O
occurs P07517544A0515 VBZ O
; P07517544A0515 : O
however P07517544A0515 RB O
, P07517544A0515 , O
recovery P07517544A0515 NN O
of P07517544A0515 IN O
the P07517544A0515 DT O
secretory P07517544A0515 JJ O
function P07517544A0515 NN O
of P07517544A0515 IN O
the P07517544A0515 DT O
pancreas P07517544A0515 NN O
was P07517544A0515 VBD O
only P07517544A0515 RB O
reached P07517544A0515 VBN O
after P07517544A0515 IN O
this P07517544A0515 DT O
period P07517544A0515 NN O
of P07517544A0515 IN O
time P07517544A0515 NN O
when P07517544A0515 WRB O
L-364,718 P07517544A0515 NNP O
was P07517544A0515 VBD O
administered P07517544A0515 VBN O
therapeutically P07517544A0515 RB O
( P07517544A0515 ( O
0.1 P07517544A0515 CD O
mg P07517544A0515 NN O
/ P07517544A0515 NNP O
kg P07517544A0515 NN O
/ P07517544A0515 NNP O
day P07517544A0515 NN O
) P07517544A0515 ) O
. P07517544A0515 . O
. . O O

A P06252883A0100 DT O
haemolytic P06252883A0100 JJ O
enterotoxigenic P06252883A0100 JJ O
strain P06252883A0100 NN O
of P06252883A0100 IN O
E. P06252883A0100 NNP O
coli P06252883A0100 NNS O
( P06252883A0100 ( O
O149 P06252883A0100 NNP O
: P06252883A0100 : O
K88 P06252883A0100 NN O
: P06252883A0100 : O
H10 P06252883A0100 NNP O
) P06252883A0100 ) O
was P06252883A0100 VBD O
regularly P06252883A0100 RB O
recovered P06252883A0100 VBN O
from P06252883A0100 IN O
piglets P06252883A0100 NNS O
with P06252883A0100 IN O
PWD P06252883A0100 NNP O
while P06252883A0100 IN O
rotavirus P06252883A0100 NN O
was P06252883A0100 VBD O
demonstrated P06252883A0100 VBN O
on P06252883A0100 IN O
a P06252883A0100 DT O
number P06252883A0100 NN O
of P06252883A0100 IN O
occasions P06252883A0100 NNS O
. P06252883A0100 . O
. . O O

Elimination P00627039T0000 NN O
of P00627039T0000 IN O
bagassosis P00627039T0000 NN O
in P00627039T0000 IN O
Louisiana P00627039T0000 NNP O
paper P00627039T0000 NN O
manufacturing P00627039T0000 NN O
plant P00627039T0000 NN O
workers P00627039T0000 NNS O
. P00627039T0000 . O
. . O O

In P09028998A0143 IN O
order P09028998A0143 NN O
to P09028998A0143 TO O
provide P09028998A0143 VB O
adequate P09028998A0143 JJ O
local P09028998A0143 JJ O
control P09028998A0143 NN O
without P09028998A0143 IN O
compromising P09028998A0143 VBG O
cosmetic P09028998A0143 JJ O
outcome P09028998A0143 NN O
, P09028998A0143 , O
the P09028998A0143 DT O
amount P09028998A0143 NN O
of P09028998A0143 IN O
breast P09028998A0143 NN O
tissue P09028998A0143 NN O
that P09028998A0143 WDT O
must P09028998A0143 MD O
be P09028998A0143 VB O
excised P09028998A0143 VBN O
in P09028998A0143 IN O
BCT P09028998A0143 NNP O
needs P09028998A0143 NNS O
to P09028998A0143 TO O
be P09028998A0143 VB O
individualized P09028998A0143 VBN O
. P09028998A0143 . O
. . O O

Nevertheless P10347220A1477 RB O
, P10347220A1477 , O
we P10347220A1477 PRP O
demonstrate P10347220A1477 VBP O
that P10347220A1477 IN O
the P10347220A1477 DT O
entire P10347220A1477 JJ O
three-component P10347220A1477 JJ O
yeast P10347220A1477 NN O
capping P10347220A1477 NN O
apparatus P10347220A1477 NN O
, P10347220A1477 , O
consisting P10347220A1477 VBG O
of P10347220A1477 IN O
RNA P10347220A1477 NNP I-UN
5'-triphosphatase P10347220A1477 NNP I-UN
( P10347220A1477 ( O
Cet1p P10347220A1477 NNP I-UN
) P10347220A1477 ) O
, P10347220A1477 , O
RNA P10347220A1477 NNP I-UN
guanylyltransferase P10347220A1477 NN I-UN
( P10347220A1477 ( O
Ceg1p P10347220A1477 NNP I-UN
) P10347220A1477 ) O
, P10347220A1477 , O
and P10347220A1477 CC O
Abd1p P10347220A1477 NNP I-UN
could P10347220A1477 MD O
be P10347220A1477 VB O
replaced P10347220A1477 VBN O
in P10347220A1477 IN O
vivo P10347220A1477 NN O
by P10347220A1477 IN O
the P10347220A1477 DT O
two-component P10347220A1477 JJ O
mammalian P10347220A1477 JJ O
apparatus P10347220A1477 NN O
consisting P10347220A1477 NN O
of P10347220A1477 IN O
a P10347220A1477 DT O
bifunctional P10347220A1477 JJ O
triphosphatase-guanylyltransferase P10347220A1477 NN I-UN
Mce1p P10347220A1477 NNP I-UN
and P10347220A1477 CC O
the P10347220A1477 DT O
methyltransferase P10347220A1477 NN I-UN
Hcm1 P10347220A1477 NNP I-UN
( P10347220A1477 ( I-UN
121-476 P10347220A1477 JJ I-UN
) P10347220A1477 ) I-UN
p P10347220A1477 NN I-UN
. P10347220A1477 . O
. . O O

CONCLUSIONS P09545146A0884 NN O
: P09545146A0884 : O
These P09545146A0884 DT O
routinely P09545146A0884 RB O
collected P09545146A0884 VBN O
data P09545146A0884 NN O
provided P09545146A0884 VBD O
quantitative P09545146A0884 JJ O
estimates P09545146A0884 NNS O
of P09545146A0884 IN O
changes P09545146A0884 NNS O
in P09545146A0884 IN O
CBZ P09545146A0884 NNP O
Cl P09545146A0884 NNP O
/ P09545146A0884 NNP O
F P09545146A0884 NNP O
due P09545146A0884 JJ O
to P09545146A0884 TO O
comedication P09545146A0884 NN O
and P09545146A0884 CC O
an P09545146A0884 DT O
age-related P09545146A0884 JJ O
decrease P09545146A0884 NN O
in P09545146A0884 IN O
Cl P09545146A0884 NNP O
/ P09545146A0884 NNP O
F P09545146A0884 NNP O
The P09545146A0884 DT O
derived P09545146A0884 JJ O
regression P09545146A0884 NN O
equations P09545146A0884 NNS O
reasonably P09545146A0884 RB O
predicted P09545146A0884 VBD O
concentrations P09545146A0884 NNS O
in P09545146A0884 IN O
a P09545146A0884 DT O
separate P09545146A0884 JJ O
validation P09545146A0884 NN O
set P09545146A0884 VBN O
. P09545146A0884 . O
. . O O

A P01630454A0635 DT O
38-bp P01630454A0635 JJ O
poly P01630454A0635 NN O
( P01630454A0635 ( O
dA-dT P01630454A0635 JJ O
) P01630454A0635 ) O
region P01630454A0635 NN O
was P01630454A0635 VBD O
found P01630454A0635 VBN O
to P01630454A0635 TO O
be P01630454A0635 VB O
a P01630454A0635 DT O
positive P01630454A0635 JJ O
regulator P01630454A0635 NN O
of P01630454A0635 IN O
Act1 P01630454A0635 NNP I-UN
promoter P01630454A0635 NN I-UN
activity P01630454A0635 NN O
. P01630454A0635 . O
. . O O

The P07640309A0000 DT O
C-terminal P07640309A0000 JJ O
peptide P07640309A0000 NN O
sequences P07640309A0000 NNS O
of P07640309A0000 IN O
the P07640309A0000 DT O
human P07640309A0000 JJ I-UN
lymphocyte-specific P07640309A0000 JJ I-UN
high P07640309A0000 JJ I-UN
mobility P07640309A0000 NN I-UN
group P07640309A0000 NN I-UN
( P07640309A0000 ( I-UN
HMG P07640309A0000 NNP I-UN
) P07640309A0000 ) I-UN
-box P07640309A0000 VBZ I-UN
transcription P07640309A0000 JJ I-UN
factor P07640309A0000 NN I-UN
TCF-1 P07640309A0000 NNP I-UN
are P07640309A0000 VBP O
determined P07640309A0000 VBN O
by P07640309A0000 IN O
alternative P07640309A0000 JJ O
splice P07640309A0000 NN O
mechanisms P07640309A0000 NNS O
affecting P07640309A0000 VBG O
the P07640309A0000 DT O
exons P07640309A0000 NNS O
VIII P07640309A0000 NNP O
to P07640309A0000 TO O
X P07640309A0000 VB O
. P07640309A0000 . O
. . O O

Analysis P10721704X0000 NN O
of P10721704X0000 IN O
the P10721704X0000 DT O
5 P10721704X0000 CD O
' P10721704X0000 POS O
end P10721704X0000 NN O
of P10721704X0000 IN O
the P10721704X0000 DT O
mouse P10721704X0000 NN I-UN
Elavl1 P10721704X0000 NNP I-UN
( P10721704X0000 ( O
mHuA P10721704X0000 NN I-UN
) P10721704X0000 ) O
gene P10721704X0000 NN O
reveals P10721704X0000 VBZ O
a P10721704X0000 DT O
transcriptional P10721704X0000 JJ O
regulatory P10721704X0000 JJ O
element P10721704X0000 NN O
and P10721704X0000 CC O
evidence P10721704X0000 NN O
for P10721704X0000 IN O
conserved P10721704X0000 JJ O
genomic P10721704X0000 JJ O
organization P10721704X0000 NN O
. P10721704X0000 . O
mHuA P10721704X0000 NN I-UN
( P10721704X0000 ( O
Elavl1 P10721704X0000 NNP I-UN
) P10721704X0000 ) O
belongs P10721704X0000 VBZ O
to P10721704X0000 TO O
a P10721704X0000 DT O
highly P10721704X0000 RB O
conserved P10721704X0000 VBN O
family P10721704X0000 NN O
of P10721704X0000 IN O
genes P10721704X0000 NNS O
encoding P10721704X0000 VBG O
RNA-binding P10721704X0000 JJ O
proteins P10721704X0000 NNS O
and P10721704X0000 CC O
has P10721704X0000 VBZ O
been P10721704X0000 VBN O
linked P10721704X0000 VBN O
to P10721704X0000 TO O
cell P10721704X0000 VB O
growth P10721704X0000 NN O
and P10721704X0000 CC O
proliferation P10721704X0000 NN O
through P10721704X0000 IN O
its P10721704X0000 PRP$ O
regulation P10721704X0000 NN O
of P10721704X0000 IN O
mRNA P10721704X0000 JJ O
stability P10721704X0000 NN O
. P10721704X0000 . O
. . O O

However P09920930A0959 RB O
, P09920930A0959 , O
C3 P09920930A0959 NNP I-UN
toxin P09920930A0959 NN I-UN
alone P09920930A0959 RB O
or P09920930A0959 CC O
in P09920930A0959 IN O
combination P09920930A0959 NN O
with P09920930A0959 IN O
growth P09920930A0959 NN O
factors P09920930A0959 NNS O
did P09920930A0959 VBD O
not P09920930A0959 RB O
stimulate P09920930A0959 VB O
AP-1 P09920930A0959 NNP I-UN
: P09920930A0959 : O
Luc P09920930A0959 NNP I-UN
activity P09920930A0959 NN O
and P09920930A0959 CC O
actually P09920930A0959 RB O
antagonized P09920930A0959 VBD O
the P09920930A0959 DT O
synergistic P09920930A0959 JJ O
activation P09920930A0959 NN O
of P09920930A0959 IN O
AP-1 P09920930A0959 NNP I-UN
: P09920930A0959 : O
Luc P09920930A0959 NNP I-UN
observed P09920930A0959 VBD O
in P09920930A0959 IN O
response P09920930A0959 NN O
to P09920930A0959 TO O
co-stimulation P09920930A0959 NN O
with P09920930A0959 IN O
growth P09920930A0959 NN O
factors P09920930A0959 NNS O
and P09920930A0959 CC O
Ro-31-8220 P09920930A0959 NNP O
. P09920930A0959 . O
. . O O

Doctor P03982288T0000 NNP O
Berglund P03982288T0000 NNP O
warns P03982288T0000 VBZ O
members P03982288T0000 NNS O
of P03982288T0000 IN O
union P03982288T0000 NN O
pitfalls P03982288T0000 NNS O
. P03982288T0000 . O
. . O O

Contraction P03697798T0001 NN O
of P03697798T0001 IN O
the P03697798T0001 DT O
tracheal P03697798T0001 JJ O
muscle P03697798T0001 NN O
and P03697798T0001 CC O
the P03697798T0001 DT O
activity P03697798T0001 NN O
of P03697798T0001 IN O
stretch P03697798T0001 NN O
receptors P03697798T0001 NNS O
in P03697798T0001 IN O
the P03697798T0001 DT O
trachea P03697798T0001 NN O
. P03697798T0001 . O
. . O O

The P11054539A0114 DT O
gene P11054539A0114 NN O
is P11054539A0114 VBZ O
separated P11054539A0114 VBN O
into P11054539A0114 IN O
four P11054539A0114 CD O
exons P11054539A0114 NNS O
by P11054539A0114 IN O
three P11054539A0114 CD O
short P11054539A0114 JJ O
introns P11054539A0114 NNS O
, P11054539A0114 , O
and P11054539A0114 CC O
the P11054539A0114 DT O
open P11054539A0114 JJ O
reading P11054539A0114 NN O
frame P11054539A0114 NN O
consists P11054539A0114 VBZ O
of P11054539A0114 IN O
6660 P11054539A0114 CD O
base P11054539A0114 NN O
pairs P11054539A0114 NN O
( P11054539A0114 ( O
bp P11054539A0114 NN O
) P11054539A0114 ) O
capable P11054539A0114 NN O
of P11054539A0114 IN O
encoding P11054539A0114 VBG O
a P11054539A0114 DT O
polypeptide P11054539A0114 NN O
of P11054539A0114 IN O
2220 P11054539A0114 CD O
amino P11054539A0114 NN O
acid P11054539A0114 NN O
residues P11054539A0114 NNS O
. P11054539A0114 . O
. . O O

In P08659545A0000 IN O
an P08659545A0000 DT O
effort P08659545A0000 NN O
to P08659545A0000 TO O
contribute P08659545A0000 VB O
to P08659545A0000 TO O
the P08659545A0000 DT O
transcript P08659545A0000 NN O
map P08659545A0000 NN O
of P08659545A0000 IN O
human P08659545A0000 JJ O
chromosome P08659545A0000 NN O
21 P08659545A0000 CD O
and P08659545A0000 CC O
the P08659545A0000 DT O
understanding P08659545A0000 NN O
of P08659545A0000 IN O
the P08659545A0000 DT O
pathophysiology P08659545A0000 NN O
of P08659545A0000 IN O
trisomy P08659545A0000 NN O
21 P08659545A0000 CD O
, P08659545A0000 , O
we P08659545A0000 PRP O
have P08659545A0000 VBP O
used P08659545A0000 VBN O
exon P08659545A0000 RB O
trapping P08659545A0000 VBG O
to P08659545A0000 TO O
identify P08659545A0000 VB O
fragments P08659545A0000 NNS O
of P08659545A0000 IN O
chromosome P08659545A0000 NN O
21 P08659545A0000 CD O
genes P08659545A0000 NNS O
. P08659545A0000 . O
. . O O

However P07574064A1416 RB O
, P07574064A1416 , O
2 P07574064A1416 CD O
minimum P07574064A1416 JJ O
alveolar P07574064A1416 JJ O
concentration P07574064A1416 NN O
anesthesia P07574064A1416 NN O
did P07574064A1416 VBD O
significantly P07574064A1416 RB O
decrease P07574064A1416 VB O
the P07574064A1416 DT O
calculated P07574064A1416 JJ O
VE P07574064A1416 NNP O
at P07574064A1416 IN O
a P07574064A1416 DT O
PCO2 P07574064A1416 NNP O
of P07574064A1416 IN O
60 P07574064A1416 CD O
mmHg P07574064A1416 NNS O
( P07574064A1416 ( O
from P07574064A1416 IN O
7.4 P07574064A1416 CD O
+ P07574064A1416 NNS O
/ P07574064A1416 SYM O
- P07574064A1416 : O
1.2 P07574064A1416 CD O
to P07574064A1416 TO O
4.0 P07574064A1416 CD O
+ P07574064A1416 NNS O
/ P07574064A1416 SYM O
- P07574064A1416 : O
0.6 P07574064A1416 CD O
l.min-1 P07574064A1416 NN O
) P07574064A1416 ) O
, P07574064A1416 , O
indicating P07574064A1416 VBG O
a P07574064A1416 DT O
rightward P07574064A1416 NN O
shift P07574064A1416 NN O
in P07574064A1416 IN O
the P07574064A1416 DT O
response P07574064A1416 NN O
relationship P07574064A1416 NN O
. P07574064A1416 . O
. . O O

In P09311796A0218 IN O
our P09311796A0218 PRP$ O
previous P09311796A0218 JJ O
studies P09311796A0218 NNS O
, P09311796A0218 , O
transcriptional P09311796A0218 JJ O
activation P09311796A0218 NN O
was P09311796A0218 VBD O
shown P09311796A0218 VBN O
to P09311796A0218 TO O
correlate P09311796A0218 VB O
with P09311796A0218 IN O
IEP86 P09311796A0218 NNP I-UN
binding P09311796A0218 VBG O
to P09311796A0218 TO O
both P09311796A0218 DT O
the P09311796A0218 DT O
TATA-box P09311796A0218 NNP I-UN
binding P09311796A0218 NN I-UN
protein P09311796A0218 NN I-UN
( P09311796A0218 ( O
TBP P09311796A0218 NNP I-UN
) P09311796A0218 ) O
and P09311796A0218 CC O
the P09311796A0218 DT O
transcription P09311796A0218 NN O
factor P09311796A0218 NN O
bound P09311796A0218 IN O
upstream P09311796A0218 NN O
. P09311796A0218 . O
. . O O

Electron P10652093A0139 NNP O
microscopic P10652093A0139 NN O
and P10652093A0139 CC O
enzymatic P10652093A0139 JJ O
analyses P10652093A0139 NNS O
revealed P10652093A0139 VBD O
that P10652093A0139 IN O
the P10652093A0139 DT O
A118 P10652093A0139 NNP O
genome P10652093A0139 NN O
is P10652093A0139 VBZ O
a P10652093A0139 DT O
linear P10652093A0139 JJ O
, P10652093A0139 , O
circularly P10652093A0139 RB O
permuted P10652093A0139 VBN O
, P10652093A0139 , O
terminally P10652093A0139 RB O
redundant P10652093A0139 JJ O
collection P10652093A0139 NN O
of P10652093A0139 IN O
double-stranded P10652093A0139 JJ O
DNA P10652093A0139 NNP O
molecules P10652093A0139 NNS O
. P10652093A0139 . O
. . O O

The P07829097A0000 DT O
region P07829097A0000 NN O
between P07829097A0000 IN O
DXS52 P07829097A0000 NNP I-UN
and P07829097A0000 CC O
Factor P07829097A0000 NNP I-UN
VIII P07829097A0000 NNP I-UN
gene P07829097A0000 NN I-UN
in P07829097A0000 IN O
the P07829097A0000 DT O
human P07829097A0000 JJ O
Xq28 P07829097A0000 NNP O
chromosomal P07829097A0000 NN O
band P07829097A0000 NN O
contains P07829097A0000 VBZ O
a P07829097A0000 DT O
G+C-rich P07829097A0000 JJ O
isochore P07829097A0000 NN O
to P07829097A0000 TO O
which P07829097A0000 WDT O
many P07829097A0000 JJ O
genes P07829097A0000 NNS O
have P07829097A0000 VBP O
been P07829097A0000 VBN O
mapped P07829097A0000 VBN O
. P07829097A0000 . O
. . O O

Predictors P10236651T0000 NNS O
of P10236651T0000 IN O
success P10236651T0000 NN O
in P10236651T0000 IN O
pharmacy P10236651T0000 JJ O
school P10236651T0000 NN O
: P10236651T0000 : O
PCAT P10236651T0000 NNP O
vs. P10236651T0000 IN O
other P10236651T0000 JJ O
admission P10236651T0000 NN O
criteria P10236651T0000 NNS O
. P10236651T0000 . O
. . O O

Deletion P08370119A1521 NN O
of P08370119A1521 IN O
a P08370119A1521 DT O
53-bp P08370119A1521 JJ O
early P08370119A1521 JJ O
promoter P08370119A1521 NN O
region P08370119A1521 NN O
containing P08370119A1521 VBG O
the P08370119A1521 DT O
transcription P08370119A1521 NN O
start P08370119A1521 NN O
site P08370119A1521 NN O
and P08370119A1521 CC O
a P08370119A1521 DT O
putative P08370119A1521 JJ O
TATA P08370119A1521 NNP O
box P08370119A1521 NN O
completely P08370119A1521 RB O
abolishes P08370119A1521 VBZ O
the P08370119A1521 DT O
ability P08370119A1521 NN O
of P08370119A1521 IN O
upstream P08370119A1521 JJ O
elements P08370119A1521 NNS O
to P08370119A1521 TO O
drive P08370119A1521 VB O
transcription P08370119A1521 NN O
of P08370119A1521 IN O
the P08370119A1521 DT O
luciferase P08370119A1521 NN I-UN
cDNA P08370119A1521 NN I-UN
. P08370119A1521 . O
. . O O

Substitution P01420177A1065 NN O
of P01420177A1065 IN O
either P01420177A1065 DT O
Val33 P01420177A1065 NNP O
( P01420177A1065 ( O
by P01420177A1065 IN O
Gly P01420177A1065 NNP O
) P01420177A1065 ) O
or P01420177A1065 CC O
Gly28 P01420177A1065 NNP O
( P01420177A1065 ( O
by P01420177A1065 IN O
Ser P01420177A1065 NNP O
) P01420177A1065 ) O
, P01420177A1065 , O
two P01420177A1065 CD O
of P01420177A1065 IN O
the P01420177A1065 DT O
most P01420177A1065 RBS O
conserved P01420177A1065 JJ O
residues P01420177A1065 NNS O
in P01420177A1065 IN O
all P01420177A1065 DT O
protein P01420177A1065 NN O
kinases P01420177A1065 NNS O
, P01420177A1065 , O
resulted P01420177A1065 VBD O
in P01420177A1065 IN O
enzyme P01420177A1065 NN O
with P01420177A1065 IN O
marginally P01420177A1065 RB O
detectable P01420177A1065 JJ O
activity P01420177A1065 NN O
. P01420177A1065 . O
. . O O

Transcription P09391173A0811 NNP O
start P09391173A0811 VBP O
sites P09391173A0811 NNS O
of P09391173A0811 IN O
the P09391173A0811 DT O
plastid P09391173A0811 JJ O
ACCase P09391173A0811 NNP I-UN
genes P09391173A0811 NNS I-UN
were P09391173A0811 VBD O
estimated P09391173A0811 VBN O
from P09391173A0811 IN O
the P09391173A0811 DT O
longest P09391173A0811 JJS O
cDNA P09391173A0811 NN O
clones P09391173A0811 NNS O
obtained P09391173A0811 VBN O
by P09391173A0811 IN O
5'-RACE P09391173A0811 JJ O
( P09391173A0811 ( O
rapid P09391173A0811 JJ O
amplification P09391173A0811 NN O
of P09391173A0811 IN O
cDNA P09391173A0811 NN O
ends P09391173A0811 NNS O
) P09391173A0811 ) O
. P09391173A0811 . O
. . O O

A P08000427A0000 DT O
cDNA P08000427A0000 NN O
clone P08000427A0000 NN O
pCZ1 P08000427A0000 NN O
, P08000427A0000 , O
with P08000427A0000 IN O
a P08000427A0000 DT O
1.1 P08000427A0000 CD O
kb P08000427A0000 NN O
insert P08000427A0000 NN O
, P08000427A0000 , O
was P08000427A0000 VBD O
isolated P08000427A0000 VBN O
from P08000427A0000 IN O
a P08000427A0000 DT O
NaCl-adapted P08000427A0000 JJ O
tobacco P08000427A0000 NN O
cell P08000427A0000 NN O
cDNA P08000427A0000 NN O
library P08000427A0000 NN O
that P08000427A0000 WDT O
encodes P08000427A0000 VBZ O
an P08000427A0000 DT O
apparently P08000427A0000 RB O
full-length P08000427A0000 JJ O
29 P08000427A0000 CD O
kDa P08000427A0000 NN O
protein P08000427A0000 NN O
( P08000427A0000 ( O
251 P08000427A0000 CD O
amino P08000427A0000 NN O
acids P08000427A0000 NNS O
) P08000427A0000 ) O
with P08000427A0000 IN O
a P08000427A0000 DT O
calculated P08000427A0000 JJ O
pI P08000427A0000 NN O
of P08000427A0000 IN O
5.7 P08000427A0000 CD O
. P08000427A0000 . O
. . O O

T-cell P01330077A0000 NNP I-UN
receptor P01330077A0000 NN I-UN
beta P01330077A0000 NN I-UN
( P01330077A0000 ( O
TCR P01330077A0000 NNP I-UN
beta P01330077A0000 NN I-UN
) P01330077A0000 ) O
gene P01330077A0000 NN O
rearrangements P01330077A0000 NNS O
occur P01330077A0000 VBP O
in P01330077A0000 IN O
a P01330077A0000 DT O
third P01330077A0000 JJ O
of P01330077A0000 IN O
early P01330077A0000 JJ O
B-cell P01330077A0000 NNP O
acute P01330077A0000 NN O
lymphoblastic P01330077A0000 JJ O
leukemias P01330077A0000 NN O
( P01330077A0000 ( O
ALLs P01330077A0000 NNP O
) P01330077A0000 ) O
. P01330077A0000 . O
. . O O

First P10688646A0535 RB O
, P10688646A0535 , O
human P10688646A0535 JJ O
erythroid P10688646A0535 NN O
K562 P10688646A0535 NNP O
cells P10688646A0535 NNS O
stably P10688646A0535 RB O
integrated P10688646A0535 VBN O
with P10688646A0535 IN O
various P10688646A0535 JJ O
HS-40 P10688646A0535 JJ I-UN
mutants P10688646A0535 NNS I-UN
cis P10688646A0535 NN O
linked P10688646A0535 VBN O
to P10688646A0535 TO O
a P10688646A0535 DT O
human P10688646A0535 JJ I-UN
alpha-globin P10688646A0535 JJ I-UN
promoter-growth P10688646A0535 NN O
hormone P10688646A0535 NN I-UN
hybrid P10688646A0535 JJ O
gene P10688646A0535 NN O
were P10688646A0535 VBD O
analyzed P10688646A0535 VBN O
by P10688646A0535 IN O
genomic P10688646A0535 JJ O
footprinting P10688646A0535 NN O
and P10688646A0535 CC O
expression P10688646A0535 NN O
analysis P10688646A0535 NN O
. P10688646A0535 . O
. . O O

Ectopic P00199012T0000 NNP O
ACTH P00199012T0000 NNP I-UN
syndrome P00199012T0000 NN O
and P00199012T0000 CC O
medullary P00199012T0000 JJ O
thyroid P00199012T0000 NN O
carcinoma P00199012T0000 NN O
. P00199012T0000 . O
. . O O

Mutation P08386280T0000 NN O
of P08386280T0000 IN O
the P08386280T0000 DT O
C P08386280T0000 NNP I-UN
/ P08386280T0000 NNP I-UN
EBP P08386280T0000 NNP I-UN
binding P08386280T0000 VBG I-UN
sites P08386280T0000 NNS I-UN
in P08386280T0000 IN O
the P08386280T0000 DT O
Rous P08386280T0000 NNP I-UN
sarcoma P08386280T0000 NN I-UN
virus P08386280T0000 NN I-UN
long P08386280T0000 JJ I-UN
terminal P08386280T0000 JJ I-UN
repeat P08386280T0000 NN I-UN
and P08386280T0000 CC O
gag P08386280T0000 NN I-UN
enhancers P08386280T0000 NNS I-UN
. P08386280T0000 . O
. . O O

By P07564004A0292 IN O
150 P07564004A0292 CD O
minutes P07564004A0292 NNS O
after P07564004A0292 IN O
Cr2O3 P07564004A0292 NNP O
inhalation P07564004A0292 NN O
, P07564004A0292 , O
FEV1.0 P07564004A0292 NNP O
had P07564004A0292 VBD O
decreased P07564004A0292 VBN O
by P07564004A0292 IN O
32 P07564004A0292 CD O
% P07564004A0292 NN O
. P07564004A0292 . O
. . O O

The P02392032A0657 DT O
results P02392032A0657 NNS O
corroborate P02392032A0657 VBP O
the P02392032A0657 DT O
idea P02392032A0657 NN O
that P02392032A0657 IN O
the P02392032A0657 DT O
structure P02392032A0657 NN O
of P02392032A0657 IN O
relaxation P02392032A0657 NN O
curves P02392032A0657 NNS O
contains P02392032A0657 VBZ O
information P02392032A0657 NN O
on P02392032A0657 IN O
the P02392032A0657 DT O
distance P02392032A0657 NN O
scale P02392032A0657 NN O
and P02392032A0657 CC O
on P02392032A0657 IN O
the P02392032A0657 DT O
architecture P02392032A0657 NN O
of P02392032A0657 IN O
the P02392032A0657 DT O
pore P02392032A0657 NN O
space P02392032A0657 NN O
, P02392032A0657 , O
even P02392032A0657 RB O
if P02392032A0657 IN O
it P02392032A0657 PRP O
is P02392032A0657 VBZ O
difficult P02392032A0657 JJ O
to P02392032A0657 TO O
extract P02392032A0657 VB O
it P02392032A0657 PRP O
without P02392032A0657 IN O
ambiguities P02392032A0657 NNS O
. P02392032A0657 . O
. . O O

The P00550399A0615 DT O
six P00550399A0615 CD O
commonest P00550399A0615 JJS O
causes P00550399A0615 NNS O
of P00550399A0615 IN O
death P00550399A0615 NN O
varied P00550399A0615 VBN O
in P00550399A0615 IN O
the P00550399A0615 DT O
three P00550399A0615 CD O
ethnic P00550399A0615 JJ O
groups P00550399A0615 NNS O
. P00550399A0615 . O
. . O O

The P03770143A1209 DT O
possibility P03770143A1209 NN O
of P03770143A1209 IN O
a P03770143A1209 DT O
hereditary P03770143A1209 JJ O
disorder P03770143A1209 NN O
leading P03770143A1209 VBG O
to P03770143A1209 TO O
a P03770143A1209 DT O
minor P03770143A1209 JJ O
defect P03770143A1209 NN O
in P03770143A1209 IN O
elastic P03770143A1209 JJ O
fibre P03770143A1209 NN O
structure P03770143A1209 NN O
which P03770143A1209 WDT O
could P03770143A1209 MD O
be P03770143A1209 VB O
responsible P03770143A1209 JJ O
for P03770143A1209 IN O
the P03770143A1209 DT O
spontaneous P03770143A1209 JJ O
lesions P03770143A1209 NNS O
is P03770143A1209 VBZ O
discussed P03770143A1209 VBN O
. P03770143A1209 . O
. . O O

The P01956285A0000 DT O
sequence P01956285A0000 NN O
was P01956285A0000 VBD O
determined P01956285A0000 VBN O
of P01956285A0000 IN O
6493 P01956285A0000 CD O
nucleotides P01956285A0000 NNS O
encompassing P01956285A0000 VBG O
the P01956285A0000 DT O
bet P01956285A0000 NN I-UN
genes P01956285A0000 NNS I-UN
of P01956285A0000 IN I-UN
Escherichia P01956285A0000 NNP I-UN
coli P01956285A0000 NN I-UN
which P01956285A0000 WDT O
encode P01956285A0000 VBZ O
the P01956285A0000 DT O
osmoregulatory P01956285A0000 JJ O
choline-glycine P01956285A0000 JJ O
betaine P01956285A0000 NN O
pathway P01956285A0000 NN O
. P01956285A0000 . O
. . O O

Substantial P08668210A0000 JJ O
evidence P08668210A0000 NN O
supports P08668210A0000 VBZ O
a P08668210A0000 DT O
critical P08668210A0000 JJ O
role P08668210A0000 NN O
for P08668210A0000 IN O
the P08668210A0000 DT O
activation P08668210A0000 NN O
of P08668210A0000 IN O
the P08668210A0000 DT O
Raf-1 P08668210A0000 NNP I-UN
/ P08668210A0000 NNP O
MEK P08668210A0000 NNP I-UN
/ P08668210A0000 NNP O
mitogen-activated P08668210A0000 JJ I-UN
protein P08668210A0000 NN I-UN
kinase P08668210A0000 VB I-UN
pathway P08668210A0000 NN O
in P08668210A0000 IN O
oncogenic P08668210A0000 JJ O
Ras-mediated P08668210A0000 JJ O
transformation P08668210A0000 NN O
. P08668210A0000 . O
. . O O

The P08277632A0997 DT O
survival P08277632A0997 NN O
rate P08277632A0997 NN O
at P08277632A0997 IN O
forty P08277632A0997 JJ O
months P08277632A0997 NNS O
in P08277632A0997 IN O
15 P08277632A0997 CD O
patients P08277632A0997 NNS O
with P08277632A0997 IN O
N2 P08277632A0997 NNP O
disease P08277632A0997 NN O
who P08277632A0997 WP O
underwent P08277632A0997 JJ O
R2b P08277632A0997 NNP O
operation P08277632A0997 NN O
was P08277632A0997 VBD O
51 P08277632A0997 CD O
% P08277632A0997 NN O
. P08277632A0997 . O
. . O O

LHbeta P10551788A0229 NNP I-UN
is P10551788A0229 VBZ O
expressed P10551788A0229 VBN O
in P10551788A0229 IN O
pituitary P10551788A0229 JJ O
gonadotrope P10551788A0229 NN O
cells P10551788A0229 NNS O
and P10551788A0229 CC O
CGbeta P10551788A0229 NNP I-UN
is P10551788A0229 VBZ O
expressed P10551788A0229 VBN O
in P10551788A0229 IN O
placental P10551788A0229 JJ O
trophoblast P10551788A0229 NN O
cells P10551788A0229 NNS O
. P10551788A0229 . O
. . O O

Performance P09118196A0281 NN O
on P09118196A0281 IN O
two P09118196A0281 CD O
verbal P09118196A0281 JJ O
measures-the P09118196A0281 JJ O
National P09118196A0281 NNP O
Adult P09118196A0281 NNP O
Reading P09118196A0281 NNP O
Test-Revised P09118196A0281 JJ O
( P09118196A0281 ( O
NART-R P09118196A0281 NNP O
) P09118196A0281 ) O
and P09118196A0281 CC O
the P09118196A0281 DT O
Vocabulary P09118196A0281 NNP O
subtest P09118196A0281 NN O
from P09118196A0281 IN O
the P09118196A0281 DT O
Wechsler P09118196A0281 NNP O
Adult P09118196A0281 NNP O
Intelligence P09118196A0281 NNP O
Scale-Revised P09118196A0281 JJ O
( P09118196A0281 ( O
WAIS-R P09118196A0281 NNP O
) P09118196A0281 ) O
-showed P09118196A0281 VBD O
strong P09118196A0281 JJ O
correlations P09118196A0281 NNS O
with P09118196A0281 IN O
level P09118196A0281 NN O
of P09118196A0281 IN O
education P09118196A0281 NN O
. P09118196A0281 . O
. . O O

Differential P10644414T0000 JJ O
expression P10644414T0000 NN O
and P10644414T0000 CC O
regulation P10644414T0000 NN O
by P10644414T0000 IN O
20-hydroxyecdysone P10644414T0000 CD O
of P10644414T0000 IN O
mosquito P10644414T0000 NN O
ultraspiracle P10644414T0000 NN O
isoforms P10644414T0000 NNS O
. P10644414T0000 . O
. . O O

Susceptibilities P01324639T0000 NNS O
of P01324639T0000 IN O
540 P01324639T0000 CD O
anaerobic P01324639T0000 JJ O
gram-negative P01324639T0000 JJ O
bacilli P01324639T0000 NN O
to P01324639T0000 TO O
amoxicillin P01324639T0000 VB O
, P01324639T0000 , O
amoxicillin-BRL P01324639T0000 JJ O
42715 P01324639T0000 CD O
, P01324639T0000 , O
amoxicillin-clavulanate P01324639T0000 NN O
, P01324639T0000 , O
temafloxacin P01324639T0000 NN O
, P01324639T0000 , O
and P01324639T0000 CC O
clindamycin P01324639T0000 NN O
. P01324639T0000 . O
. . O O

Competition P11504545A0393 NNP O
electrophoretic P11504545A0393 JJ O
mobility P11504545A0393 NN O
shift P11504545A0393 NN O
and P11504545A0393 CC O
immunoshift P11504545A0393 NN O
assays P11504545A0393 NNS O
confirmed P11504545A0393 VBD O
that P11504545A0393 IN O
NF1 P11504545A0393 NNP I-UN
factors P11504545A0393 NNS I-UN
present P11504545A0393 VBP O
in P11504545A0393 IN O
nuclear P11504545A0393 JJ O
extracts P11504545A0393 NNS O
of P11504545A0393 IN O
HeLa P11504545A0393 NNP O
and P11504545A0393 CC O
CV-1 P11504545A0393 NNP O
cells P11504545A0393 NNS O
bind P11504545A0393 NN O
to P11504545A0393 TO O
the P11504545A0393 DT O
BKV-MLP P11504545A0393 NNP I-UN
. P11504545A0393 . O
. . O O

As P10681562A0263 IN O
no P10681562A0263 DT O
complete P10681562A0263 JJ O
PPARgamma P10681562A0263 NNP I-UN
antagonists P10681562A0263 NNS O
have P10681562A0263 VBP O
been P10681562A0263 VBN O
described P10681562A0263 VBN O
hitherto P10681562A0263 JJ O
, P10681562A0263 , O
we P10681562A0263 PRP O
have P10681562A0263 VBP O
constructed P10681562A0263 VBN O
a P10681562A0263 DT O
dominant-negative P10681562A0263 JJ O
mutant P10681562A0263 NN O
receptor P10681562A0263 NN O
to P10681562A0263 TO O
inhibit P10681562A0263 VB O
wild-type P10681562A0263 JJ O
PPARgamma P10681562A0263 NNP I-UN
action P10681562A0263 NN O
. P10681562A0263 . O
. . O O

Given P10793991A0569 VBN O
its P10793991A0569 PRP$ O
relative P10793991A0569 JJ O
longevity P10793991A0569 NN O
on P10793991A0569 IN O
the P10793991A0569 DT O
Web P10793991A0569 NNP O
, P10793991A0569 , O
TIE P10793991A0569 NNP O
researchers P10793991A0569 NNS O
have P10793991A0569 VBP O
been P10793991A0569 VBN O
in P10793991A0569 IN O
a P10793991A0569 DT O
unique P10793991A0569 JJ O
position P10793991A0569 NN O
to P10793991A0569 TO O
observe P10793991A0569 VB O
trends P10793991A0569 NNS O
in P10793991A0569 IN O
telemedicine P10793991A0569 NN O
. P10793991A0569 . O
. . O O

Insertion P03023682A0271 NN O
of P03023682A0271 IN O
4 P03023682A0271 CD O
bp P03023682A0271 NN O
reduced P03023682A0271 VBD O
SV40 P03023682A0271 NNP I-UN
early P03023682A0271 JJ I-UN
promoter-dependent P03023682A0271 NN O
chloramphenicol P03023682A0271 NN I-UN
acetyltransferase P03023682A0271 NN I-UN
( P03023682A0271 ( O
CAT P03023682A0271 NNP I-UN
) P03023682A0271 ) O
expression P03023682A0271 NN O
by P03023682A0271 IN O
six- P03023682A0271 JJ O
to P03023682A0271 TO O
eightfold P03023682A0271 VB O
. P03023682A0271 . O
. . O O

A P01909960A0134 DT O
single P01909960A0134 JJ O
i.p P01909960A0134 NN O
. P01909960A0134 . O
injection P01909960A0134 NN O
of P01909960A0134 IN O
d P01909960A0134 NN O
, P01909960A0134 , O
l-baclofen P01909960A0134 JJ O
10 P01909960A0134 CD O
mg P01909960A0134 NN O
/ P01909960A0134 NN O
kg P01909960A0134 VB O
both P01909960A0134 DT O
reduced P01909960A0134 VBN O
noradrenaline P01909960A0134 NN O
( P01909960A0134 ( O
NA P01909960A0134 NNP O
) P01909960A0134 ) O
biosynthesis P01909960A0134 NN O
in P01909960A0134 IN O
vivo P01909960A0134 NN O
( P01909960A0134 ( O
31 P01909960A0134 CD O
% P01909960A0134 NN O
) P01909960A0134 ) O
and P01909960A0134 CC O
the P01909960A0134 DT O
endogenous P01909960A0134 JJ O
concentration P01909960A0134 NN O
of P01909960A0134 IN O
normetanephrine P01909960A0134 NN O
( P01909960A0134 ( O
NMN P01909960A0134 NNP O
) P01909960A0134 ) O
( P01909960A0134 ( O
32 P01909960A0134 CD O
% P01909960A0134 NN O
) P01909960A0134 ) O
and P01909960A0134 CC O
increased P01909960A0134 VBD O
NA P01909960A0134 NNP O
levels P01909960A0134 NNS O
( P01909960A0134 ( O
28 P01909960A0134 CD O
% P01909960A0134 NN O
) P01909960A0134 ) O
. P01909960A0134 . O
. . O O

A P10396343T0000 DT O
multi-centre P10396343T0000 JJ O
evaluation P10396343T0000 NN O
of P10396343T0000 IN O
the P10396343T0000 DT O
card P10396343T0000 NN O
indirect P10396343T0000 JJ O
agglutination P10396343T0000 NN O
test P10396343T0000 NN O
for P10396343T0000 IN O
trypanosomiasis P10396343T0000 NN O
( P10396343T0000 ( O
TrypTect P10396343T0000 NNP O
CIATT P10396343T0000 NNP O
) P10396343T0000 ) O
. P10396343T0000 . O
. . O O

One P03039177A0503 CD O
group P03039177A0503 NN O
of P03039177A0503 IN O
six P03039177A0503 CD O
cDNA P03039177A0503 NN O
clones P03039177A0503 NNS O
was P03039177A0503 VBD O
derived P03039177A0503 VBN O
from P03039177A0503 IN O
a P03039177A0503 DT O
2.9-kilobase P03039177A0503 JJ O
early P03039177A0503 JJ O
transcript P03039177A0503 NN O
encoded P03039177A0503 VBN O
by P03039177A0503 IN O
the P03039177A0503 DT O
IR2 P03039177A0503 NNP O
repeat P03039177A0503 NN O
element P03039177A0503 NN O
and P03039177A0503 CC O
showed P03039177A0503 VBD O
restriction P03039177A0503 NN O
site P03039177A0503 NN O
polymorphism P03039177A0503 NN O
for P03039177A0503 IN O
the P03039177A0503 DT O
enzyme P03039177A0503 NN I-UN
SmaI P03039177A0503 NNP I-UN
. P03039177A0503 . O
. . O O

Activation P07513703T0000 NN O
of P07513703T0000 IN O
the P07513703T0000 DT O
SH2-containing P07513703T0000 NNP I-UN
protein P07513703T0000 NN I-UN
tyrosine P07513703T0000 NN I-UN
phosphatase P07513703T0000 NN I-UN
, P07513703T0000 , O
SH-PTP2 P07513703T0000 NNP I-UN
, P07513703T0000 , O
by P07513703T0000 IN O
phosphotyrosine-containing P07513703T0000 JJ O
peptides P07513703T0000 NNS O
derived P07513703T0000 VBN O
from P07513703T0000 IN O
insulin P07513703T0000 NN I-UN
receptor P07513703T0000 NN I-UN
substrate-1 P07513703T0000 NN I-UN
. P07513703T0000 . O
. . O O

OBJECTIVE P07783822A0000 NN O
: P07783822A0000 : O
To P07783822A0000 TO O
investigate P07783822A0000 VB O
the P07783822A0000 DT O
incidence P07783822A0000 NN O
and P07783822A0000 CC O
presentation P07783822A0000 NN O
of P07783822A0000 IN O
acute P07783822A0000 JJ O
pernicious P07783822A0000 JJ O
or P07783822A0000 CC O
fulminating P07783822A0000 VBG O
beriberi P07783822A0000 NN O
in P07783822A0000 IN O
a P07783822A0000 DT O
general P07783822A0000 JJ O
district P07783822A0000 NN O
hospital P07783822A0000 NN O
. P07783822A0000 . O
. . O O

A P10760950A1133 DT O
distinct P10760950A1133 JJ O
staining P10760950A1133 NN O
pattern P10760950A1133 NN O
for P10760950A1133 IN O
the P10760950A1133 DT O
N-utrophin P10760950A1133 NNP I-UN
was P10760950A1133 VBD O
not P10760950A1133 RB O
detectable P10760950A1133 JJ O
, P10760950A1133 , O
although P10760950A1133 IN O
it P10760950A1133 PRP O
was P10760950A1133 VBD O
expected P10760950A1133 VBN O
to P10760950A1133 TO O
localise P10760950A1133 VB O
at P10760950A1133 IN O
the P10760950A1133 DT O
actin P10760950A1133 NN I-UN
stress P10760950A1133 NN O
fibers P10760950A1133 NNS O
. P10760950A1133 . O
. . O O

Effect P04839176T0001 NN O
of P04839176T0001 IN O
a P04839176T0001 DT O
high-intensity P04839176T0001 JJ O
SHF P04839176T0001 NNP O
field P04839176T0001 NN O
on P04839176T0001 IN O
the P04839176T0001 DT O
blood P04839176T0001 NN O
coagulation P04839176T0001 NN O
system P04839176T0001 NN O
. P04839176T0001 . O
. . O O

Plasma P10201468A0297 NNP O
glucose P10201468A0297 NN O
, P10201468A0297 , O
immunoreactive P10201468A0297 JJ I-UN
insulin P10201468A0297 NN I-UN
( P10201468A0297 ( O
IRI P10201468A0297 NNP I-UN
) P10201468A0297 ) O
, P10201468A0297 , O
C-peptide P10201468A0297 NNP I-UN
, P10201468A0297 , O
glucagon P10201468A0297 NN I-UN
, P10201468A0297 , O
and P10201468A0297 CC O
GLP-1 P10201468A0297 NNP I-UN
levels P10201468A0297 NNS O
at P10201468A0297 IN O
each P10201468A0297 DT O
time P10201468A0297 NN O
point P10201468A0297 NN O
during P10201468A0297 IN O
OGTT P10201468A0297 NNP O
were P10201468A0297 VBD O
measured P10201468A0297 VBN O
. P10201468A0297 . O
. . O O

Dosimetric P03340774A0328 NNP O
estimates P03340774A0328 NNS O
for P03340774A0328 IN O
these P03340774A0328 DT O
organs P03340774A0328 NNS O
were P03340774A0328 VBD O
2.3 P03340774A0328 CD O
+ P03340774A0328 NNP O
/ P03340774A0328 NNP O
- P03340774A0328 : O
1.1 P03340774A0328 CD O
and P03340774A0328 CC O
2.3 P03340774A0328 CD O
+ P03340774A0328 NN O
/ P03340774A0328 NNP O
- P03340774A0328 : O
1.4 P03340774A0328 CD O
rad P03340774A0328 NN O
( P03340774A0328 ( O
.02 P03340774A0328 JJ O
+ P03340774A0328 NNP O
/ P03340774A0328 NNP O
- P03340774A0328 : O
.01 P03340774A0328 NN O
Gy P03340774A0328 NNP O
) P03340774A0328 ) O
, P03340774A0328 , O
respectively P03340774A0328 RB O
, P03340774A0328 , O
with P03340774A0328 IN O
a P03340774A0328 DT O
whole-body P03340774A0328 JJ O
estimate P03340774A0328 NN O
of P03340774A0328 IN O
0.28 P03340774A0328 CD O
rad P03340774A0328 NN O
( P03340774A0328 ( O
.003 P03340774A0328 NNP O
Gy P03340774A0328 NNP O
) P03340774A0328 ) O
. P03340774A0328 . O
. . O O

These P11502758A0869 DT O
findings P11502758A0869 NNS O
suggest P11502758A0869 VBP O
a P11502758A0869 DT O
novel P11502758A0869 JJ O
ankyrin-independent P11502758A0869 JJ O
role P11502758A0869 NN O
for P11502758A0869 IN O
LAD-1 P11502758A0869 NNP I-UN
related P11502758A0869 JJ O
to P11502758A0869 TO O
FGFR P11502758A0869 NNP I-UN
signaling P11502758A0869 NN O
. P11502758A0869 . O
. . O O

Selected P04460692T0000 VBN O
topics P04460692T0000 NNS O
in P04460692T0000 IN O
laboratory P04460692T0000 NN O
animal P04460692T0000 JJ O
medicine P04460692T0000 NN O
. P04460692T0000 . O
. . O O

The P08848013A1469 DT O
nonconsensus P08848013A1469 NN O
TATA P08848013A1469 NNP O
box P08848013A1469 NN O
in P08848013A1469 IN O
promoter P08848013A1469 NN O
B P08848013A1469 NNP O
plays P08848013A1469 VBZ O
a P08848013A1469 DT O
more P08848013A1469 RBR O
important P08848013A1469 JJ O
role P08848013A1469 NN O
in P08848013A1469 IN O
promoter P08848013A1469 NN O
activity P08848013A1469 NN O
than P08848013A1469 IN O
the P08848013A1469 DT O
TATA P08848013A1469 NNP O
box P08848013A1469 NN O
in P08848013A1469 IN O
promoter P08848013A1469 NN O
A P08848013A1469 NNP O
. P08848013A1469 . O
. . O O

However P10706475A0644 RB O
, P10706475A0644 , O
when P10706475A0644 WRB O
, P10706475A0644 , O
where P10706475A0644 WRB O
and P10706475A0644 CC O
how P10706475A0644 WRB O
the P10706475A0644 DT O
DSPP P10706475A0644 NNP I-UN
is P10706475A0644 VBZ O
cleaved P10706475A0644 VBN O
into P10706475A0644 IN O
DSP P10706475A0644 NNP I-UN
and P10706475A0644 CC O
DPP P10706475A0644 NNP I-UN
is P10706475A0644 VBZ O
not P10706475A0644 RB O
clear P10706475A0644 JJ O
. P10706475A0644 . O
. . O O

Recurrence P03075154T0000 NN O
of P03075154T0000 IN O
oxalate P03075154T0000 JJ O
deposition P03075154T0000 NN O
in P03075154T0000 IN O
a P03075154T0000 DT O
renal P03075154T0000 JJ O
transplant P03075154T0000 NN O
during P03075154T0000 IN O
ciclosporin P03075154T0000 NN O
A P03075154T0000 NNP O
therapy P03075154T0000 NN O
. P03075154T0000 . O
. . O O

These P01883992A0922 DT O
results P01883992A0922 NNS O
suggest P01883992A0922 VBP O
that P01883992A0922 IN O
beta-1 P01883992A0922 NN I-UN
may P01883992A0922 MD O
act P01883992A0922 VB O
as P01883992A0922 IN O
a P01883992A0922 DT O
tissue-specific P01883992A0922 JJ O
, P01883992A0922 , O
trans-acting P01883992A0922 JJ O
regulator P01883992A0922 NN O
of P01883992A0922 IN O
the P01883992A0922 DT O
expression P01883992A0922 NN O
of P01883992A0922 IN O
the P01883992A0922 DT O
beta-zein P01883992A0922 JJ I-UN
gene P01883992A0922 NN I-UN
in P01883992A0922 IN O
developing P01883992A0922 VBG O
maize P01883992A0922 JJ O
endosperm P01883992A0922 NN O
. P01883992A0922 . O
. . O O

T. P09774403A0107 NNP O
, P09774403A0107 , O
Mahasneh P09774403A0107 NNP O
, P09774403A0107 , O
A. P09774403A0107 NNP O
, P09774403A0107 , O
and P09774403A0107 CC O
Cote P09774403A0107 NNP O
, P09774403A0107 , O
G P09774403A0107 NNP O
. P09774403A0107 . O
. . O O

In P02294048A0881 IN O
particular P02294048A0881 JJ O
, P02294048A0881 , O
71 P02294048A0881 CD O
and P02294048A0881 CC O
69 P02294048A0881 CD O
% P02294048A0881 NN O
amino P02294048A0881 NN O
acid P02294048A0881 JJ O
sequence P02294048A0881 NN O
similarities P02294048A0881 NNS O
were P02294048A0881 VBD O
identified P02294048A0881 VBN O
with P02294048A0881 IN O
hsp70 P02294048A0881 NN I-UN
of P02294048A0881 IN I-UN
Escherichia P02294048A0881 NNP I-UN
coli P02294048A0881 NNS I-UN
and P02294048A0881 CC I-UN
Bacillus P02294048A0881 NNP I-UN
megaterium P02294048A0881 NN I-UN
, P02294048A0881 , O
respectively P02294048A0881 RB O
. P02294048A0881 . O
. . O O

The P09862481A0000 DT O
Mig1 P09862481A0000 NNP I-UN
repressor P09862481A0000 NN I-UN
is P09862481A0000 VBZ O
a P09862481A0000 DT O
zinc P09862481A0000 NN I-UN
finger P09862481A0000 NN I-UN
protein P09862481A0000 VBP I-UN
that P09862481A0000 IN O
mediates P09862481A0000 NNS O
glucose P09862481A0000 JJ O
repression P09862481A0000 NN O
in P09862481A0000 IN O
yeast P09862481A0000 NN O
. P09862481A0000 . O
. . O O

We P08909546A0810 PRP O
have P08909546A0810 VBP O
found P08909546A0810 VBN O
that P08909546A0810 IN O
PEA2 P08909546A0810 NNP I-UN
is P08909546A0810 VBZ O
also P08909546A0810 RB O
required P08909546A0810 VBN O
for P08909546A0810 IN O
the P08909546A0810 DT O
bipolar P08909546A0810 JJ O
budding P08909546A0810 NN O
pattern P08909546A0810 NN O
and P08909546A0810 CC O
that P08909546A0810 IN O
it P08909546A0810 PRP O
encodes P08909546A0810 VBZ O
a P08909546A0810 DT O
novel P08909546A0810 JJ O
protein P08909546A0810 NN O
with P08909546A0810 IN O
a P08909546A0810 DT O
predicted P08909546A0810 JJ O
coiled-coil P08909546A0810 NN O
domain P08909546A0810 NN O
. P08909546A0810 . O
. . O O

Two P08843411A0801 CD O
classes P08843411A0801 NNS O
of P08843411A0801 IN O
inactive P08843411A0801 JJ O
receptors P08843411A0801 NNS O
were P08843411A0801 VBD O
identified P08843411A0801 VBN O
: P08843411A0801 : O
one P08843411A0801 CD O
in P08843411A0801 IN O
which P08843411A0801 WDT O
both P08843411A0801 DT O
transcriptional P08843411A0801 JJ O
activation P08843411A0801 NN O
and P08843411A0801 CC O
dimerization P08843411A0801 NN O
were P08843411A0801 VBD O
compromised P08843411A0801 VBN O
and P08843411A0801 CC O
a P08843411A0801 DT O
second P08843411A0801 NN O
in P08843411A0801 IN O
which P08843411A0801 WDT O
only P08843411A0801 RB O
transcriptional P08843411A0801 JJ O
activation P08843411A0801 NN O
was P08843411A0801 VBD O
abolished P08843411A0801 VBN O
. P08843411A0801 . O
. . O O

The P11454703A0000 DT O
telomerase P11454703A0000 JJ I-UN
RNA-protein P11454703A0000 NNP I-UN
complex P11454703A0000 NN I-UN
responsible P11454703A0000 JJ O
for P11454703A0000 IN O
maintenance P11454703A0000 NN O
of P11454703A0000 IN O
telomeric P11454703A0000 JJ O
DNA P11454703A0000 NN O
at P11454703A0000 IN O
chromosome P11454703A0000 NN O
ends P11454703A0000 NNS O
, P11454703A0000 , O
is P11454703A0000 VBZ O
usually P11454703A0000 RB O
inactive P11454703A0000 JJ O
in P11454703A0000 IN O
most P11454703A0000 JJS O
primary P11454703A0000 JJ O
somatic P11454703A0000 JJ O
human P11454703A0000 NN O
cells P11454703A0000 NNS O
, P11454703A0000 , O
but P11454703A0000 CC O
is P11454703A0000 VBZ O
specifically P11454703A0000 RB O
activated P11454703A0000 VBN O
with P11454703A0000 IN O
in P11454703A0000 IN O
vitro P11454703A0000 JJ O
immortalization P11454703A0000 NN O
and P11454703A0000 CC O
during P11454703A0000 IN O
tumorigenesis P11454703A0000 NN O
. P11454703A0000 . O
. . O O

Our P06441624A0263 PRP$ O
results P06441624A0263 NNS O
indicate P06441624A0263 VBP O
that P06441624A0263 IN O
serum P06441624A0263 NN I-UN
BGP P06441624A0263 NNP I-UN
is P06441624A0263 VBZ O
a P06441624A0263 DT O
valuable P06441624A0263 JJ O
measurement P06441624A0263 NN O
of P06441624A0263 IN O
bone P06441624A0263 NN O
metabolism P06441624A0263 NN O
. P06441624A0263 . O
. . O O

However P11433014A0683 RB O
, P11433014A0683 , O
when P11433014A0683 WRB O
directed P11433014A0683 VBN O
to P11433014A0683 TO O
the P11433014A0683 DT O
nucleosome P11433014A0683 NN O
by P11433014A0683 IN O
fusion P11433014A0683 NN O
to P11433014A0683 TO O
core P11433014A0683 VB I-UN
histone P11433014A0683 NN I-UN
H2A P11433014A0683 NNP I-UN
or P11433014A0683 CC O
H2B P11433014A0683 NNP I-UN
, P11433014A0683 , O
the P11433014A0683 DT O
non-histone P11433014A0683 JJ O
tail P11433014A0683 NN O
forms P11433014A0683 NNS O
an P11433014A0683 DT O
MCB P11433014A0683 NNP O
that P11433014A0683 WDT O
appears P11433014A0683 VBZ O
identical P11433014A0683 JJ O
to P11433014A0683 TO O
that P11433014A0683 DT O
of P11433014A0683 IN O
the P11433014A0683 DT O
endogenous P11433014A0683 JJ O
protein P11433014A0683 NN O
. P11433014A0683 . O
. . O O

Diagnostic P01687050T0000 JJ O
value P01687050T0000 NN O
of P01687050T0000 IN O
cerebrospinal P01687050T0000 JJ I-UN
fluid P01687050T0000 NN I-UN
immunoglobulin P01687050T0000 NN I-UN
G P01687050T0000 NNP I-UN
( P01687050T0000 ( O
IgG P01687050T0000 NNP I-UN
) P01687050T0000 ) O
in P01687050T0000 IN O
pediatric P01687050T0000 JJ O
neurological P01687050T0000 JJ O
diseases P01687050T0000 NNS O
. P01687050T0000 . O
. . O O

The P03577670A0236 DT O
diagnosis P03577670A0236 NN O
of P03577670A0236 IN O
metachromatic P03577670A0236 JJ O
leukodystrophy P03577670A0236 NN O
( P03577670A0236 ( O
MLD P03577670A0236 NNP O
) P03577670A0236 ) O
was P03577670A0236 VBD O
confirmed P03577670A0236 VBN O
by P03577670A0236 IN O
the P03577670A0236 DT O
finding P03577670A0236 NN O
of P03577670A0236 IN O
low P03577670A0236 JJ O
arylsulfatase P03577670A0236 NN I-UN
A P03577670A0236 NNP I-UN
( P03577670A0236 ( O
ASA P03577670A0236 NNP I-UN
) P03577670A0236 ) O
levels P03577670A0236 NNS O
in P03577670A0236 IN O
cultured P03577670A0236 JJ O
fibroblasts P03577670A0236 NNS O
in P03577670A0236 IN O
both P03577670A0236 DT O
sisters P03577670A0236 NNS O
. P03577670A0236 . O
. . O O

Comparison P09884232A0286 NNP O
of P09884232A0286 IN O
the P09884232A0286 DT O
sequences P09884232A0286 NNS O
of P09884232A0286 IN O
attP P09884232A0286 NN I-UN
, P09884232A0286 , O
attB P09884232A0286 NN I-UN
and P09884232A0286 CC O
bacteria-prophage P09884232A0286 NN O
junctions P09884232A0286 NNS O
attL P09884232A0286 NN I-UN
and P09884232A0286 CC O
attR P09884232A0286 NN I-UN
showed P09884232A0286 VBD O
a P09884232A0286 DT O
26 P09884232A0286 CD O
bp P09884232A0286 JJ O
common P09884232A0286 JJ O
core P09884232A0286 NN O
sequence P09884232A0286 NN O
, P09884232A0286 , O
where P09884232A0286 WRB O
recombination P09884232A0286 NN O
takes P09884232A0286 VBZ O
place P09884232A0286 NN O
, P09884232A0286 , O
near P09884232A0286 IN O
the P09884232A0286 DT O
5 P09884232A0286 CD O
' P09884232A0286 POS O
end P09884232A0286 NN O
of P09884232A0286 IN O
the P09884232A0286 DT O
integrase P09884232A0286 NN I-UN
gene P09884232A0286 NN I-UN
. P09884232A0286 . O
. . O O

Within P08094464A2014 IN O
the P08094464A2014 DT O
span P08094464A2014 NN O
of P08094464A2014 IN O
attenuator P08094464A2014 NN O
region P08094464A2014 NN O
encoding P08094464A2014 VBG O
the P08094464A2014 DT O
three P08094464A2014 CD O
stem-loop P08094464A2014 JJ O
structures P08094464A2014 NNS O
of P08094464A2014 IN O
mRNA P08094464A2014 NN O
secondary P08094464A2014 JJ O
configuration P08094464A2014 NN O
, P08094464A2014 , O
hot P08094464A2014 JJ O
spots P08094464A2014 NNS O
of P08094464A2014 IN O
base-residue P08094464A2014 JJ O
divergence P08094464A2014 NN O
were P08094464A2014 VBD O
localized P08094464A2014 VBN O
to P08094464A2014 TO O
looped-out P08094464A2014 JJ O
regions P08094464A2014 NNS O
. P08094464A2014 . O
. . O O

A P07124743A1223 DT O
limited P07124743A1223 JJ O
study P07124743A1223 NN O
in P07124743A1223 IN O
a P07124743A1223 DT O
glassware P07124743A1223 NN O
factory P07124743A1223 NN O
( P07124743A1223 ( O
As2O3 P07124743A1223 NNP O
exposure P07124743A1223 NN O
) P07124743A1223 ) O
involving P07124743A1223 VBG O
the P07124743A1223 DT O
measurement P07124743A1223 NN O
of P07124743A1223 IN O
total P07124743A1223 JJ O
airborne P07124743A1223 JJ O
arsenic P07124743A1223 NN O
, P07124743A1223 , O
the P07124743A1223 DT O
determination P07124743A1223 NN O
of P07124743A1223 IN O
urinary P07124743A1223 JJ O
arsenic P07124743A1223 NN O
, P07124743A1223 , O
and P07124743A1223 CC O
the P07124743A1223 DT O
evaluation P07124743A1223 NN O
of P07124743A1223 IN O
hand P07124743A1223 NN O
and P07124743A1223 CC O
mouth P07124743A1223 NN O
contamination P07124743A1223 NN O
by P07124743A1223 IN O
arsenic P07124743A1223 JJ O
before P07124743A1223 IN O
and P07124743A1223 CC O
after P07124743A1223 IN O
the P07124743A1223 DT O
workshift P07124743A1223 NN O
suggests P07124743A1223 VBZ O
that P07124743A1223 IN O
the P07124743A1223 DT O
high P07124743A1223 JJ O
urinary P07124743A1223 JJ O
arsenic P07124743A1223 NN O
levels P07124743A1223 NNS O
( P07124743A1223 ( O
300 P07124743A1223 CD O
microgram P07124743A1223 NN O
/ P07124743A1223 NN O
g P07124743A1223 FW O
creatinine P07124743A1223 NN O
) P07124743A1223 ) O
are P07124743A1223 VBP O
likely P07124743A1223 JJ O
to P07124743A1223 TO O
be P07124743A1223 VB O
more P07124743A1223 RBR O
related P07124743A1223 JJ O
to P07124743A1223 TO O
an P07124743A1223 DT O
increased P07124743A1223 VBN O
oral P07124743A1223 JJ O
intake P07124743A1223 NN O
from P07124743A1223 IN O
contaminated P07124743A1223 VBN O
hands P07124743A1223 NNS O
than P07124743A1223 IN O
to P07124743A1223 TO O
an P07124743A1223 DT O
increased P07124743A1223 VBN O
absorption P07124743A1223 NN O
from P07124743A1223 IN O
the P07124743A1223 DT O
lungs P07124743A1223 NNS O
. P07124743A1223 . O
. . O O

Paper P10841601T0000 NNP O
alert P10841601T0000 NN O
. P10841601T0000 . O
. . O O

Transient P10464310A0218 NNP O
tyrosine P10464310A0218 JJ O
phosphorylation P10464310A0218 NN O
of P10464310A0218 IN O
Crk P10464310A0218 NNP I-UN
in P10464310A0218 IN O
fibroblast P10464310A0218 JJ I-UN
growth P10464310A0218 NN I-UN
factor-2-stimulated P10464310A0218 JJ O
endothelial P10464310A0218 JJ O
cells P10464310A0218 NNS O
was P10464310A0218 VBD O
dependent P10464310A0218 JJ O
on P10464310A0218 IN O
the P10464310A0218 DT O
juxtamembrane P10464310A0218 NN O
tyrosine P10464310A0218 NN O
residue P10464310A0218 JJ O
463 P10464310A0218 CD O
in P10464310A0218 IN O
FGFR-1 P10464310A0218 NNP I-UN
, P10464310A0218 , O
and P10464310A0218 CC O
a P10464310A0218 DT O
Crk P10464310A0218 NNP I-UN
SH2 P10464310A0218 NNP I-UN
domain P10464310A0218 NN I-UN
precipitated P10464310A0218 VBD O
FGFR-1 P10464310A0218 NNP I-UN
via P10464310A0218 IN O
phosphorylated P10464310A0218 VBN O
Tyr-463 P10464310A0218 NNP O
, P10464310A0218 , O
indicating P10464310A0218 VBG O
direct P10464310A0218 JJ O
complex P10464310A0218 JJ O
formation P10464310A0218 NN O
between P10464310A0218 IN O
Crk P10464310A0218 NNP I-UN
and P10464310A0218 CC O
FGFR-1 P10464310A0218 NNP I-UN
. P10464310A0218 . O
. . O O

Cross P07237817T0000 NNP O
reactivity P07237817T0000 NN O
in P07237817T0000 IN O
theophylline P07237817T0000 NN O
RIA P07237817T0000 NNP O
kit P07237817T0000 NN O
decreased P07237817T0000 VBD O
. P07237817T0000 . O
. . O O

There P11072155A0764 EX O
was P11072155A0764 VBD O
a P11072155A0764 DT O
weak P11072155A0764 JJ O
significant P11072155A0764 JJ O
correlation P11072155A0764 NN O
between P11072155A0764 IN O
TGF P11072155A0764 NNP I-UN
beta P11072155A0764 VBD I-UN
1 P11072155A0764 CD I-UN
levels P11072155A0764 NNS O
and P11072155A0764 CC O
normal P11072155A0764 JJ O
cell P11072155A0764 NN O
radiosensitivity P11072155A0764 NN O
( P11072155A0764 ( O
lymphocyte P11072155A0764 JJ O
SF2 P11072155A0764 NNP O
) P11072155A0764 ) O
. P11072155A0764 . O
. . O O

There P08006773A0836 EX O
was P08006773A0836 VBD O
no P08006773A0836 DT O
difference P08006773A0836 NN O
in P08006773A0836 IN O
plasma P08006773A0836 JJ O
concentrations P08006773A0836 NNS O
of P08006773A0836 IN O
PGI2 P08006773A0836 NNP O
( P08006773A0836 ( O
figure P08006773A0836 NN O
4 P08006773A0836 CD O
) P08006773A0836 ) O
and P08006773A0836 CC O
TxA2 P08006773A0836 NNP O
in P08006773A0836 IN O
patients P08006773A0836 NNS O
with P08006773A0836 IN O
normal P08006773A0836 JJ O
blood P08006773A0836 NN O
pressure P08006773A0836 NN O
, P08006773A0836 , O
mild P08006773A0836 JJ O
preeclampsia P08006773A0836 NN O
and P08006773A0836 CC O
hypotension P08006773A0836 NN O
, P08006773A0836 , O
whereas P08006773A0836 NNS O
in P08006773A0836 IN O
severe P08006773A0836 JJ O
preeclampsia P08006773A0836 NN O
, P08006773A0836 , O
the P08006773A0836 DT O
plasma P08006773A0836 JJ O
concentration P08006773A0836 NN O
of P08006773A0836 IN O
PGI2 P08006773A0836 NNP O
was P08006773A0836 VBD O
significantly P08006773A0836 RB O
lower P08006773A0836 JJR O
( P08006773A0836 ( O
p P08006773A0836 JJ O
< P08006773A0836 NNP O
0.001 P08006773A0836 CD O
) P08006773A0836 ) O
and P08006773A0836 CC O
of P08006773A0836 IN O
TxA2 P08006773A0836 NNP O
significantly P08006773A0836 RB O
higher P08006773A0836 JJR O
( P08006773A0836 ( O
p P08006773A0836 JJ O
< P08006773A0836 NNP O
0.001 P08006773A0836 CD O
) P08006773A0836 ) O
. P08006773A0836 . O
. . O O

Expression P10406843A1265 NN O
of P10406843A1265 IN O
GlcNAc-TI P10406843A1265 NNP I-UN
mRNA P10406843A1265 NN I-UN
in P10406843A1265 IN O
tobacco P10406843A1265 NN O
leaves P10406843A1265 NNS O
was P10406843A1265 VBD O
detected P10406843A1265 VBN O
using P10406843A1265 VBG O
RT-PCR P10406843A1265 NNP O
. P10406843A1265 . O
. . O O

Atopic P07721074A0766 NNP O
dermatitis P07721074A0766 NN O
is P07721074A0766 VBZ O
an P07721074A0766 DT O
`` P07721074A0766 `` O
itch P07721074A0766 NN O
which P07721074A0766 WDT O
rashes P07721074A0766 NNS O
and P07721074A0766 CC O
not P07721074A0766 RB O
a P07721074A0766 DT O
rash P07721074A0766 NN O
which P07721074A0766 WDT O
itches P07721074A0766 NNS O
'' P07721074A0766 '' O
and P07721074A0766 CC O
therefore P07721074A0766 RB O
, P07721074A0766 , O
any P07721074A0766 DT O
patient P07721074A0766 JJ O
treatment P07721074A0766 NN O
program P07721074A0766 NN O
should P07721074A0766 MD O
address P07721074A0766 VB O
the P07721074A0766 DT O
multiplicity P07721074A0766 NN O
of P07721074A0766 IN O
potential P07721074A0766 JJ O
trigger P07721074A0766 NN O
factors P07721074A0766 NNS O
that P07721074A0766 WDT O
provoke P07721074A0766 VBD O
this P07721074A0766 DT O
itching P07721074A0766 NN O
. P07721074A0766 . O
. . O O

The P00494659A0391 DT O
major P00494659A0391 JJ O
urinary P00494659A0391 JJ O
metabolites P00494659A0391 NNS O
were P00494659A0391 VBD O
3- P00494659A0391 JJ O
( P00494659A0391 ( O
3-carboxyphenyl P00494659A0391 JJ O
) P00494659A0391 ) O
-5-hydroxymethyl-2-oxazolidinone P00494659A0391 NN O
and P00494659A0391 CC O
a P00494659A0391 DT O
glucuronide P00494659A0391 NN O
of P00494659A0391 IN O
toloxatone P00494659A0391 NN O
. P00494659A0391 . O
. . O O

The P06324121A0256 DT O
12,000 P06324121A0256 CD I-UN
MW P06324121A0256 NNP I-UN
( P06324121A0256 ( I-UN
12K P06324121A0256 CD I-UN
) P06324121A0256 ) I-UN
IE P06324121A0256 NNP I-UN
polypeptide P06324121A0256 NN I-UN
encoded P06324121A0256 VBN O
by P06324121A0256 IN O
IEmRNA-5 P06324121A0256 NNP I-UN
is P06324121A0256 VBZ O
translated P06324121A0256 VBN O
from P06324121A0256 IN O
an P06324121A0256 DT O
88 P06324121A0256 CD O
codon P06324121A0256 NN O
open P06324121A0256 JJ O
reading P06324121A0256 NN O
frame P06324121A0256 NN O
, P06324121A0256 , O
leaving P06324121A0256 VBG O
a P06324121A0256 DT O
1200 P06324121A0256 CD O
base P06324121A0256 NN O
3 P06324121A0256 CD O
' P06324121A0256 POS O
non-translated P06324121A0256 JJ O
region P06324121A0256 NN O
. P06324121A0256 . O
. . O O

METHODS P11773921A0397 NNS O
: P11773921A0397 : O
P-selectin P11773921A0397 JJ I-UN
expression P11773921A0397 NN O
of P11773921A0397 IN O
nonstimulated P11773921A0397 JJ O
and P11773921A0397 CC O
ADP-stimulated P11773921A0397 JJ O
platelets P11773921A0397 NNS O
was P11773921A0397 VBD O
flow P11773921A0397 JJ O
cytometrically P11773921A0397 RB O
measured P11773921A0397 VBN O
before P11773921A0397 IN O
the P11773921A0397 DT O
clopidogrel P11773921A0397 NN O
loading P11773921A0397 VBG O
dose P11773921A0397 JJ O
and P11773921A0397 CC O
on P11773921A0397 IN O
3 P11773921A0397 CD O
consecutive P11773921A0397 JJ O
days P11773921A0397 NNS O
in P11773921A0397 IN O
52 P11773921A0397 CD O
patients P11773921A0397 NNS O
with P11773921A0397 IN O
coronary P11773921A0397 JJ O
artery P11773921A0397 NN O
disease P11773921A0397 NN O
: P11773921A0397 : O
21 P11773921A0397 CD O
patients P11773921A0397 NNS O
in P11773921A0397 IN O
group P11773921A0397 NN O
1 P11773921A0397 CD O
received P11773921A0397 VBD O
300 P11773921A0397 CD O
mg P11773921A0397 NN O
of P11773921A0397 IN O
clopidogrel P11773921A0397 NN O
after P11773921A0397 IN O
stent P11773921A0397 JJ O
implantation P11773921A0397 NN O
and P11773921A0397 CC O
11 P11773921A0397 CD O
patients P11773921A0397 NNS O
in P11773921A0397 IN O
group P11773921A0397 NN O
2 P11773921A0397 CD O
received P11773921A0397 VBD O
the P11773921A0397 DT O
higher P11773921A0397 JJR O
450-mg P11773921A0397 JJ O
clopidogrel P11773921A0397 NN O
loading P11773921A0397 VBG O
dose P11773921A0397 NN O
followed P11773921A0397 VBN O
by P11773921A0397 IN O
a P11773921A0397 DT O
daily P11773921A0397 JJ O
dose P11773921A0397 NN O
of P11773921A0397 IN O
75 P11773921A0397 CD O
mg P11773921A0397 NN O
of P11773921A0397 IN O
clopidogrel P11773921A0397 NN O
for P11773921A0397 IN O
both P11773921A0397 DT O
groups P11773921A0397 NNS O
. P11773921A0397 . O
. . O O

Here P11883682A0162 RB O
is P11883682A0162 VBZ O
presented P11883682A0162 VBN O
the P11883682A0162 DT O
monitoring P11883682A0162 NN O
of P11883682A0162 IN O
the P11883682A0162 DT O
accidental P11883682A0162 JJ O
spill P11883682A0162 NN O
on P11883682A0162 IN O
vertical P11883682A0162 JJ O
distribution P11883682A0162 NN O
of P11883682A0162 IN O
heavy P11883682A0162 JJ O
metals P11883682A0162 NNS O
in P11883682A0162 IN O
the P11883682A0162 DT O
estuarine P11883682A0162 NN O
sediments P11883682A0162 NNS O
. P11883682A0162 . O
. . O O

N-Substituted P03771703A0000 JJ O
trimethylsilylcarbamates P03771703A0000 NNS O
were P03771703A0000 VBD O
tested P03771703A0000 VBN O
as P03771703A0000 IN O
derivatizing P03771703A0000 VBG O
reagents P03771703A0000 NNS O
for P03771703A0000 IN O
gas P03771703A0000 NN O
chromatographic P03771703A0000 JJ O
analysis P03771703A0000 NN O
. P03771703A0000 . O
. . O O

When P11561626A0197 WRB O
mixed P11561626A0197 JJ O
with P11561626A0197 IN O
aqueous P11561626A0197 JJ O
solutions P11561626A0197 NNS O
of P11561626A0197 IN O
TMT-55 P11561626A0197 NNP O
, P11561626A0197 , O
aqueous P11561626A0197 JJ O
solutions P11561626A0197 NNS O
of P11561626A0197 IN O
either P11561626A0197 DT O
reagent-grade P11561626A0197 JJ O
zinc P11561626A0197 NN O
, P11561626A0197 , O
cadmium P11561626A0197 NN O
, P11561626A0197 , O
or P11561626A0197 CC O
lead P11561626A0197 JJ O
salts P11561626A0197 NNS O
precipitate P11561626A0197 VBP O
crystalline P11561626A0197 JJ O
`` P11561626A0197 `` O
Zn-TMT P11561626A0197 JJ O
'' P11561626A0197 '' O
, P11561626A0197 , O
amorphous P11561626A0197 JJ O
or P11561626A0197 CC O
crystalline P11561626A0197 JJ O
`` P11561626A0197 `` O
Cd-TMT P11561626A0197 JJ O
'' P11561626A0197 '' O
or P11561626A0197 CC O
amorphous P11561626A0197 JJ O
`` P11561626A0197 `` O
Pb-TMT P11561626A0197 JJ O
'' P11561626A0197 '' O
( P11561626A0197 ( O
M3 P11561626A0197 NNP O
[ P11561626A0197 NNP O
S3C3N3 P11561626A0197 NNP O
] P11561626A0197 NNP O
2.nH2O P11561626A0197 CD O
, P11561626A0197 , O
where P11561626A0197 WRB O
M=Cd2+ P11561626A0197 NNP O
, P11561626A0197 , O
Pb2+ P11561626A0197 NNP O
, P11561626A0197 , O
and P11561626A0197 CC O
Zn2+ P11561626A0197 NNP O
and P11561626A0197 CC O
n P11561626A0197 JJ O
> P11561626A0197 NN O
or P11561626A0197 CC O
= P11561626A0197 VB O
0 P11561626A0197 CD O
) P11561626A0197 ) O
that P11561626A0197 WDT O
may P11561626A0197 MD O
eventually P11561626A0197 RB O
crystallize P11561626A0197 VB O
if P11561626A0197 IN O
stored P11561626A0197 VBN O
in P11561626A0197 IN O
air P11561626A0197 NN O
. P11561626A0197 . O
. . O O

These P09416467A0959 DT O
results P09416467A0959 NNS O
suggest P09416467A0959 VBP O
that P09416467A0959 IN O
, P09416467A0959 , O
in P09416467A0959 IN O
this P09416467A0959 DT O
experimental P09416467A0959 JJ O
model P09416467A0959 NN O
, P09416467A0959 , O
ACE P09416467A0959 NNP I-UN
inhibitors P09416467A0959 NNS O
limit P09416467A0959 VBP O
the P09416467A0959 DT O
arrhythmias P09416467A0959 NN O
following P09416467A0959 VBG O
ischemia-reperfusion P09416467A0959 NN O
and P09416467A0959 CC O
free P09416467A0959 JJ O
radical P09416467A0959 JJ O
scavenging P09416467A0959 VBG O
action P09416467A0959 NN O
of P09416467A0959 IN O
these P09416467A0959 DT O
drugs P09416467A0959 NNS O
does P09416467A0959 VBZ O
not P09416467A0959 RB O
have P09416467A0959 VB O
a P09416467A0959 DT O
major P09416467A0959 JJ O
contributory P09416467A0959 NN O
role P09416467A0959 NN O
in P09416467A0959 IN O
their P09416467A0959 PRP$ O
protective P09416467A0959 JJ O
effect P09416467A0959 NN O
. P09416467A0959 . O
. . O O

During P00676416A0320 IN O
the P00676416A0320 DT O
following P00676416A0320 VBG O
9 P00676416A0320 CD O
1 P00676416A0320 CD O
/ P00676416A0320 JJ O
2 P00676416A0320 CD O
years P00676416A0320 NNS O
three P00676416A0320 CD O
sequential P00676416A0320 JJ O
liver P00676416A0320 NN O
biopsies P00676416A0320 NNS O
were P00676416A0320 VBD O
performed P00676416A0320 VBN O
. P00676416A0320 . O
. . O O

The P10692433A0000 DT O
transcription P10692433A0000 NN O
factor P10692433A0000 NN O
E2F P10692433A0000 NNP I-UN
plays P10692433A0000 VBZ O
an P10692433A0000 DT O
important P10692433A0000 JJ O
role P10692433A0000 NN O
in P10692433A0000 IN O
G P10692433A0000 NNP O
( P10692433A0000 ( O
1 P10692433A0000 CD O
) P10692433A0000 ) O
to P10692433A0000 TO O
S P10692433A0000 NNP O
phase P10692433A0000 NN O
transition P10692433A0000 NN O
in P10692433A0000 IN O
the P10692433A0000 DT O
higher P10692433A0000 JJR O
eukaryotic P10692433A0000 JJ O
cell P10692433A0000 NN O
cycle P10692433A0000 NN O
. P10692433A0000 . O
. . O O

Modern P06467241A0000 JJ O
cancer P06467241A0000 NN O
therapy P06467241A0000 NN O
has P06467241A0000 VBZ O
included P06467241A0000 VBN O
surgery P06467241A0000 NN O
, P06467241A0000 , O
radiotherapy P06467241A0000 NN O
, P06467241A0000 , O
chemotherapy P06467241A0000 NN O
, P06467241A0000 , O
and P06467241A0000 CC O
most P06467241A0000 JJS O
recently P06467241A0000 RB O
, P06467241A0000 , O
immunotherapy P06467241A0000 NN O
and P06467241A0000 CC O
hyperthermia P06467241A0000 NN O
. P06467241A0000 . O
. . O O

It P09880327A0322 PRP O
is P09880327A0322 VBZ O
related P09880327A0322 VBN O
to P09880327A0322 TO O
a P09880327A0322 DT O
variety P09880327A0322 NN O
of P09880327A0322 IN O
mammalian P09880327A0322 JJ O
Golgi-associated P09880327A0322 JJ O
proteins P09880327A0322 NNS O
and P09880327A0322 CC O
to P09880327A0322 TO O
the P09880327A0322 DT O
yeast P09880327A0322 NN O
Uso1p P09880327A0322 NNP I-UN
, P09880327A0322 , O
an P09880327A0322 DT O
essential P09880327A0322 JJ O
protein P09880327A0322 NN O
involved P09880327A0322 VBN O
in P09880327A0322 IN O
docking P09880327A0322 NN O
of P09880327A0322 IN O
endoplasmic P09880327A0322 JJ O
reticulum-derived P09880327A0322 JJ O
vesicles P09880327A0322 NNS O
to P09880327A0322 TO O
the P09880327A0322 DT O
cis-Golgi P09880327A0322 NN O
. P09880327A0322 . O
. . O O

Tumor P11177538A0655 NNP O
cell P11177538A0655 NN O
lines P11177538A0655 NNS O
transduced P11177538A0655 VBD O
at P11177538A0655 IN O
an P11177538A0655 DT O
MOI P11177538A0655 NNP O
of P11177538A0655 IN O
8 P11177538A0655 CD O
for P11177538A0655 IN O
3 P11177538A0655 CD O
days P11177538A0655 NNS O
led P11177538A0655 VBN O
to P11177538A0655 TO O
> P11177538A0655 VB O
90 P11177538A0655 CD O
% P11177538A0655 NN O
gene P11177538A0655 NN O
transfer P11177538A0655 NN O
efficiency P11177538A0655 NN O
. P11177538A0655 . O
. . O O

According P02630543A0210 VBG O
to P02630543A0210 TO O
their P02630543A0210 PRP$ O
staining P02630543A0210 NN O
affinity P02630543A0210 NN O
for P02630543A0210 IN O
anti-T P02630543A0210 JJ I-UN
antibodies P02630543A0210 NNS I-UN
, P02630543A0210 , O
the P02630543A0210 DT O
glandular P02630543A0210 JJ O
tissue P02630543A0210 NN O
cells P02630543A0210 NNS O
were P02630543A0210 VBD O
classified P02630543A0210 VBN O
as P02630543A0210 IN O
T- P02630543A0210 NNP O
, P02630543A0210 , O
T+ P02630543A0210 NNP O
, P02630543A0210 , O
T++ P02630543A0210 NNP O
, P02630543A0210 , O
and P02630543A0210 CC O
T P02630543A0210 NNP I-UN
and P02630543A0210 CC O
the P02630543A0210 DT O
annual P02630543A0210 JJ O
changes P02630543A0210 NNS O
in P02630543A0210 IN O
the P02630543A0210 DT O
numbers P02630543A0210 NNS O
of P02630543A0210 IN O
these P02630543A0210 DT O
cell P02630543A0210 NN O
populations P02630543A0210 NNS O
, P02630543A0210 , O
as P02630543A0210 RB O
well P02630543A0210 RB O
as P02630543A0210 IN O
in P02630543A0210 IN O
the P02630543A0210 DT O
volume P02630543A0210 NN O
occupied P02630543A0210 VBN O
by P02630543A0210 IN O
the P02630543A0210 DT O
glandular P02630543A0210 JJ O
tissue P02630543A0210 NN O
, P02630543A0210 , O
were P02630543A0210 VBD O
calculated P02630543A0210 VBN O
. P02630543A0210 . O
. . O O

Particles P04387103T0000 NNS O
resembling P04387103T0000 VBG O
microbodies P04387103T0000 NNS O
in P04387103T0000 IN O
normal P04387103T0000 JJ O
and P04387103T0000 CC O
neoplastic P04387103T0000 JJ O
perianal P04387103T0000 JJ O
glands P04387103T0000 NNS O
of P04387103T0000 IN O
dogs P04387103T0000 NNS O
. P04387103T0000 . O
. . O O

This P09745797A0943 DT O
suggests P09745797A0943 VBZ O
that P09745797A0943 IN O
while P09745797A0943 IN O
underpredictions P09745797A0943 NNS O
of P09745797A0943 IN O
pain P09745797A0943 NN O
do P09745797A0943 VBP O
not P09745797A0943 RB O
hurt P09745797A0943 VB O
more P09745797A0943 RBR O
, P09745797A0943 , O
disruption P09745797A0943 NN O
on P09745797A0943 IN O
primary P09745797A0943 JJ O
tasks P09745797A0943 NNS O
and P09745797A0943 CC O
physiological P09745797A0943 JJ O
impact P09745797A0943 NN O
are P09745797A0943 VBP O
higher P09745797A0943 JJR O
. P09745797A0943 . O
. . O O

Morphine-dependent P06798609A0000 JJ O
and P06798609A0000 CC O
control P06798609A0000 NN O
rats P06798609A0000 NNS O
in P06798609A0000 IN O
an P06798609A0000 DT O
oral P06798609A0000 JJ O
free-choice P06798609A0000 NN O
protocol P06798609A0000 NN O
were P06798609A0000 VBD O
treated P06798609A0000 VBN O
with P06798609A0000 IN O
gamma-vinyl P06798609A0000 JJ O
GABA P06798609A0000 NNP O
( P06798609A0000 ( O
GVG P06798609A0000 NNP O
) P06798609A0000 ) O
, P06798609A0000 , O
60 P06798609A0000 CD O
, P06798609A0000 , O
120 P06798609A0000 CD O
and P06798609A0000 CC O
240 P06798609A0000 CD O
mg P06798609A0000 NN O
/ P06798609A0000 NNP O
kg P06798609A0000 NN O
IP P06798609A0000 NNP O
, P06798609A0000 , O
for P06798609A0000 IN O
3 P06798609A0000 CD O
days P06798609A0000 NNS O
over P06798609A0000 IN O
three P06798609A0000 CD O
successive P06798609A0000 JJ O
periods P06798609A0000 NNS O
. P06798609A0000 . O
. . O O

The P09421507A0000 DT O
SR P09421507A0000 NNP I-UN
protein P09421507A0000 NN I-UN
family P09421507A0000 NN I-UN
is P09421507A0000 VBZ O
involved P09421507A0000 VBN O
in P09421507A0000 IN O
constitutive P09421507A0000 JJ O
and P09421507A0000 CC O
regulated P09421507A0000 VBD O
pre-mRNA P09421507A0000 JJ O
splicing P09421507A0000 NN O
and P09421507A0000 CC O
has P09421507A0000 VBZ O
been P09421507A0000 VBN O
found P09421507A0000 VBN O
to P09421507A0000 TO O
be P09421507A0000 VB O
evolutionarily P09421507A0000 RB O
conserved P09421507A0000 VBN O
in P09421507A0000 IN O
metazoan P09421507A0000 NN O
organisms P09421507A0000 NNS O
. P09421507A0000 . O
. . O O

DNA-dependent P08816792A0000 JJ I-UN
protein P08816792A0000 NN I-UN
kinase P08816792A0000 NN I-UN
( P08816792A0000 ( O
DNA-PK P08816792A0000 NNP I-UN
) P08816792A0000 ) O
consists P08816792A0000 VBZ O
of P08816792A0000 IN O
a P08816792A0000 DT O
heterodimeric P08816792A0000 JJ O
protein P08816792A0000 NN O
( P08816792A0000 ( O
Ku P08816792A0000 NNP I-UN
) P08816792A0000 ) O
and P08816792A0000 CC O
a P08816792A0000 DT O
large P08816792A0000 JJ O
catalytic P08816792A0000 JJ O
subunit P08816792A0000 NN O
( P08816792A0000 ( O
DNA-PKcs P08816792A0000 NNP I-UN
) P08816792A0000 ) O
. P08816792A0000 . O
. . O O

High-level P10092132A0285 JJ O
gains P10092132A0285 NNS O
( P10092132A0285 ( O
HLGs P10092132A0285 NNP O
) P10092132A0285 ) O
indicative P10092132A0285 NN O
of P10092132A0285 IN O
gene P10092132A0285 NN O
amplifications P10092132A0285 NNS O
were P10092132A0285 VBD O
identified P10092132A0285 VBN O
at P10092132A0285 IN O
11q13 P10092132A0285 CD O
in P10092132A0285 IN O
two P10092132A0285 CD O
cases P10092132A0285 NNS O
, P10092132A0285 , O
and P10092132A0285 CC O
in P10092132A0285 IN O
one P10092132A0285 CD O
case P10092132A0285 NN O
each P10092132A0285 DT O
at P10092132A0285 IN O
2q33-34 P10092132A0285 JJ O
, P10092132A0285 , O
3q25-29 P10092132A0285 JJ O
, P10092132A0285 , O
5p15.1-15.2 P10092132A0285 JJ O
, P10092132A0285 , O
7q21-22 P10092132A0285 JJ O
, P10092132A0285 , O
11p11.2 P10092132A0285 CD O
, P10092132A0285 , O
12p11.2-12 P10092132A0285 CD O
, P10092132A0285 , O
and P10092132A0285 CC O
13q34 P10092132A0285 CD O
. P10092132A0285 . O
. . O O

The P03001084A0406 DT O
sequence P03001084A0406 NN O
was P03001084A0406 VBD O
determined P03001084A0406 VBN O
for P03001084A0406 IN O
a P03001084A0406 DT O
4024-base P03001084A0406 JJ O
pair P03001084A0406 NN O
( P03001084A0406 ( O
bp P03001084A0406 NN O
) P03001084A0406 ) O
segment P03001084A0406 NN O
that P03001084A0406 WDT O
extends P03001084A0406 VBZ O
from P03001084A0406 IN O
149 P03001084A0406 CD O
bp P03001084A0406 NN O
5 P03001084A0406 CD O
' P03001084A0406 '' O
to P03001084A0406 TO O
the P03001084A0406 DT O
cap P03001084A0406 NN O
site P03001084A0406 NN O
of P03001084A0406 IN O
alpha P03001084A0406 JJ I-UN
1 P03001084A0406 CD I-UN
to P03001084A0406 TO O
207 P03001084A0406 CD O
bp P03001084A0406 NN O
3 P03001084A0406 CD O
' P03001084A0406 '' O
to P03001084A0406 TO O
psi P03001084A0406 VB I-UN
alpha P03001084A0406 NN I-UN
. P03001084A0406 . O
. . O O

Consistent P09447973A0168 JJ O
with P09447973A0168 IN O
previous P09447973A0168 JJ O
reports P09447973A0168 NNS O
, P09447973A0168 , O
addition P09447973A0168 NN O
of P09447973A0168 IN O
a P09447973A0168 DT O
myristoylation P09447973A0168 NN O
signal P09447973A0168 NN O
to P09447973A0168 TO O
mSos1 P09447973A0168 VB I-UN
( P09447973A0168 ( O
MyrSos1 P09447973A0168 NNP I-UN
) P09447973A0168 ) O
rendered P09447973A0168 VBD O
it P09447973A0168 PRP O
transforming P09447973A0168 VBG O
for P09447973A0168 IN O
NIH P09447973A0168 NNP O
3T3 P09447973A0168 CD O
cells P09447973A0168 NNS O
and P09447973A0168 CC O
deletion P09447973A0168 NN O
of P09447973A0168 IN O
the P09447973A0168 DT O
mSos P09447973A0168 NN I-UN
C P09447973A0168 NNP I-UN
terminus P09447973A0168 NN I-UN
( P09447973A0168 ( O
MyrSos1-deltaC P09447973A0168 NNP I-UN
) P09447973A0168 ) O
did P09447973A0168 VBD O
not P09447973A0168 RB O
interfere P09447973A0168 VB O
with P09447973A0168 IN O
this P09447973A0168 DT O
activity P09447973A0168 NN O
. P09447973A0168 . O
. . O O

Transcriptional P09712644T0000 JJ O
regulation P09712644T0000 NN O
of P09712644T0000 IN O
the P09712644T0000 DT O
GluR2 P09712644T0000 NNP I-UN
gene P09712644T0000 NN I-UN
: P09712644T0000 : O
neural-specific P09712644T0000 JJ O
expression P09712644T0000 NN O
, P09712644T0000 , O
multiple P09712644T0000 JJ O
promoters P09712644T0000 NNS O
, P09712644T0000 , O
and P09712644T0000 CC O
regulatory P09712644T0000 JJ O
elements P09712644T0000 NNS O
. P09712644T0000 . O
. . O O

The P10961585A0273 DT O
manifestations P10961585A0273 NNS O
often P10961585A0273 RB O
include P10961585A0273 VBP O
a P10961585A0273 DT O
moderate P10961585A0273 JJ O
thrombocytopenia P10961585A0273 NN O
and P10961585A0273 CC O
, P10961585A0273 , O
less P10961585A0273 JJR O
commonly P10961585A0273 RB O
, P10961585A0273 , O
hemolysis P10961585A0273 NN O
. P10961585A0273 . O
. . O O

The P08914522A0118 DT O
STE20 P08914522A0118 NNP I-UN
gene P08914522A0118 NN I-UN
, P08914522A0118 , O
encoding P08914522A0118 VBG O
a P08914522A0118 DT O
protein P08914522A0118 JJ O
kinase P08914522A0118 NN O
required P08914522A0118 VBN O
for P08914522A0118 IN O
pheromone P08914522A0118 JJ O
signal P08914522A0118 JJ O
transduction P08914522A0118 NN O
, P08914522A0118 , O
has P08914522A0118 VBZ O
recently P08914522A0118 RB O
been P08914522A0118 VBN O
identified P08914522A0118 VBN O
in P08914522A0118 IN O
a P08914522A0118 DT O
genetic P08914522A0118 JJ O
screen P08914522A0118 NN O
for P08914522A0118 IN O
high-gene-dosage P08914522A0118 JJ O
suppressors P08914522A0118 NNS O
of P08914522A0118 IN O
a P08914522A0118 DT O
partly P08914522A0118 RB O
defective P08914522A0118 JJ O
G P08914522A0118 NNP I-UN
beta P08914522A0118 NN I-UN
mutation P08914522A0118 NN O
. P08914522A0118 . O
. . O O

Mutations P06750608A1442 NNS O
in P06750608A1442 IN O
seven P06750608A1442 CD O
other P06750608A1442 JJ O
lts P06750608A1442 NNS I-UN
genes P06750608A1442 NNS I-UN
do P06750608A1442 VBP O
not P06750608A1442 RB O
result P06750608A1442 VB O
in P06750608A1442 IN O
the P06750608A1442 DT O
mak- P06750608A1442 JJ I-UN
phenotype P06750608A1442 NN I-UN
. P06750608A1442 . O
. . O O

This P09143328A1002 DT O
finding P09143328A1002 NN O
is P09143328A1002 VBZ O
the P09143328A1002 DT O
first P09143328A1002 JJ O
example P09143328A1002 NN O
of P09143328A1002 IN O
utilization P09143328A1002 NN O
of P09143328A1002 IN O
noncomplementary P09143328A1002 JJ O
dinucleotide P09143328A1002 NN O
primer P09143328A1002 NN O
by P09143328A1002 IN O
an P09143328A1002 DT O
RNA P09143328A1002 NNP I-UN
polymerase P09143328A1002 NN I-UN
. P09143328A1002 . O
. . O O

On P03745833A0258 IN O
transition P03745833A0258 NN O
from P03745833A0258 IN O
high P03745833A0258 JJ O
to P03745833A0258 TO O
low P03745833A0258 JJ O
voltage P03745833A0258 NN O
there P03745833A0258 EX O
was P03745833A0258 VBD O
a P03745833A0258 DT O
significant P03745833A0258 JJ O
fall P03745833A0258 NN O
in P03745833A0258 IN O
arterial P03745833A0258 JJ O
pressure P03745833A0258 NN O
( P03745833A0258 ( O
7 P03745833A0258 CD O
% P03745833A0258 NN O
) P03745833A0258 ) O
and P03745833A0258 CC O
an P03745833A0258 DT O
increase P03745833A0258 NN O
in P03745833A0258 IN O
flow P03745833A0258 JJ O
( P03745833A0258 ( O
19-38 P03745833A0258 JJ O
% P03745833A0258 NN O
) P03745833A0258 ) O
to P03745833A0258 TO O
areas P03745833A0258 NNS O
of P03745833A0258 IN O
the P03745833A0258 DT O
brain P03745833A0258 NN O
corresponding P03745833A0258 NN O
to P03745833A0258 TO O
the P03745833A0258 DT O
arborization P03745833A0258 NN O
of P03745833A0258 IN O
the P03745833A0258 DT O
reticular P03745833A0258 JJ O
formation P03745833A0258 NN O
, P03745833A0258 , O
i.e P03745833A0258 NN O
. P03745833A0258 . O
excluding P03745833A0258 VBG O
the P03745833A0258 DT O
cerebrum P03745833A0258 NN O
and P03745833A0258 CC O
cerebellum P03745833A0258 NN O
. P03745833A0258 . O
. . O O

Molecular P02733690T0000 JJ O
cloning P02733690T0000 NN O
and P02733690T0000 CC O
characterisation P02733690T0000 NN O
of P02733690T0000 IN O
the P02733690T0000 DT O
two P02733690T0000 CD O
homologous P02733690T0000 JJ O
genes P02733690T0000 NNS O
coding P02733690T0000 VBG O
for P02733690T0000 IN O
nitrate P02733690T0000 JJ I-UN
reductase P02733690T0000 NN I-UN
in P02733690T0000 IN I-UN
tobacco P02733690T0000 NN I-UN
. P02733690T0000 . O
. . O O

With P09199348A0156 IN O
a P09199348A0156 DT O
view P09199348A0156 NN O
to P09199348A0156 TO O
identifying P09199348A0156 VBG O
other P09199348A0156 JJ O
important P09199348A0156 JJ O
U14 P09199348A0156 NNP I-UN
interactions P09199348A0156 NNS O
, P09199348A0156 , O
a P09199348A0156 DT O
stem-loop P09199348A0156 JJ O
domain P09199348A0156 NN O
required P09199348A0156 VBN O
for P09199348A0156 IN O
activity P09199348A0156 NN O
of P09199348A0156 IN O
Saccharomyces P09199348A0156 NNP I-UN
cerevisiae P09199348A0156 NN I-UN
U14 P09199348A0156 NNP I-UN
RNAs P09199348A0156 NNP I-UN
( P09199348A0156 ( O
the P09199348A0156 DT O
Y P09199348A0156 NNP O
domain P09199348A0156 NN O
) P09199348A0156 ) O
was P09199348A0156 VBD O
first P09199348A0156 RB O
subjected P09199348A0156 VBN O
to P09199348A0156 TO O
detailed P09199348A0156 VB O
mutational P09199348A0156 JJ O
analysis P09199348A0156 NN O
. P09199348A0156 . O
. . O O

In P10085120A0000 IN O
this P10085120A0000 DT O
study P10085120A0000 NN O
, P10085120A0000 , O
we P10085120A0000 PRP O
elucidate P10085120A0000 VBP O
signaling P10085120A0000 VBG O
pathways P10085120A0000 NNS O
induced P10085120A0000 VBN O
by P10085120A0000 IN O
photodynamic P10085120A0000 JJ O
therapy P10085120A0000 NN O
( P10085120A0000 ( O
PDT P10085120A0000 NNP O
) P10085120A0000 ) O
with P10085120A0000 IN O
hypericin P10085120A0000 NN O
. P10085120A0000 . O
. . O O

Our P02115116A1137 PRP$ O
results P02115116A1137 NNS O
suggest P02115116A1137 VBP O
that P02115116A1137 IN O
a P02115116A1137 DT O
sequence P02115116A1137 NN O
match P02115116A1137 NN O
between P02115116A1137 IN O
enhancers P02115116A1137 NNS O
and P02115116A1137 CC O
certain P02115116A1137 JJ O
promoter P02115116A1137 NN O
elements P02115116A1137 NNS O
is P02115116A1137 VBZ O
critical P02115116A1137 JJ O
. P02115116A1137 . O
. . O O

Scanning P10748164A1284 VBG O
mutations P10748164A1284 NNS O
throughout P10748164A1284 IN O
the P10748164A1284 DT O
AC P10748164A1284 NNP O
element P10748164A1284 NN O
interfered P10748164A1284 VBD O
with P10748164A1284 IN O
induction P10748164A1284 NN O
but P10748164A1284 CC O
allowed P10748164A1284 VBD O
us P10748164A1284 PRP O
to P10748164A1284 TO O
define P10748164A1284 VB O
five P10748164A1284 CD O
overlapping P10748164A1284 VBG O
sites P10748164A1284 NNS O
for P10748164A1284 IN O
regulatory P10748164A1284 JJ O
factors P10748164A1284 NNS O
in P10748164A1284 IN O
AC P10748164A1284 NNP O
and P10748164A1284 CC O
to P10748164A1284 TO O
design P10748164A1284 VB O
probes P10748164A1284 JJ O
binding P10748164A1284 NN O
just P10748164A1284 RB O
one P10748164A1284 CD O
or P10748164A1284 CC O
two P10748164A1284 CD O
factors P10748164A1284 NNS O
. P10748164A1284 . O
. . O O

The P10597232A0000 DT O
RET P10597232A0000 NNP I-UN
/ P10597232A0000 NNP O
PTC3 P10597232A0000 NNP I-UN
rearrangement P10597232A0000 NN O
is P10597232A0000 VBZ O
formed P10597232A0000 VBN O
by P10597232A0000 IN O
fusion P10597232A0000 NN O
of P10597232A0000 IN O
the P10597232A0000 DT O
ELE1 P10597232A0000 NNP I-UN
and P10597232A0000 CC O
RET P10597232A0000 NNP I-UN
genes P10597232A0000 NNS I-UN
, P10597232A0000 , O
and P10597232A0000 CC O
is P10597232A0000 VBZ O
highly P10597232A0000 RB O
prevalent P10597232A0000 JJ O
in P10597232A0000 IN O
radiation-induced P10597232A0000 JJ O
post-Chernobyl P10597232A0000 JJ O
papillary P10597232A0000 JJ O
thyroid P10597232A0000 NN O
carcinomas P10597232A0000 NN O
. P10597232A0000 . O
. . O O

More P08652081A1953 RBR O
specific P08652081A1953 JJ O
adverse P08652081A1953 JJ O
events P08652081A1953 NNS O
, P08652081A1953 , O
also P08652081A1953 RB O
frequently P08652081A1953 RB O
considered P08652081A1953 VBN O
as P08652081A1953 IN O
dose-limiting P08652081A1953 JJ O
toxicities P08652081A1953 NNS O
, P08652081A1953 , O
include P08652081A1953 VBP O
hypotension P08652081A1953 NN O
with P08652081A1953 IN O
IL-1 P08652081A1953 NNP I-UN
, P08652081A1953 , O
severe P08652081A1953 JJ O
headache P08652081A1953 NN O
or P08652081A1953 CC O
skin P08652081A1953 VB O
rash P08652081A1953 NN O
with P08652081A1953 IN O
IL-3 P08652081A1953 NNP I-UN
, P08652081A1953 , O
and P08652081A1953 CC O
nasal P08652081A1953 JJ O
congestion P08652081A1953 NN O
and P08652081A1953 CC O
gastroduodenal P08652081A1953 JJ O
lesions P08652081A1953 NNS O
with P08652081A1953 IN O
IL-4 P08652081A1953 NNP I-UN
. P08652081A1953 . O
. . O O

Anterior P08343961A0000 NNP O
body P08343961A0000 NN O
pattern P08343961A0000 NN O
in P08343961A0000 IN O
Drosophila P08343961A0000 NNP O
is P08343961A0000 VBZ O
specified P08343961A0000 VBN O
by P08343961A0000 IN O
the P08343961A0000 DT O
graded P08343961A0000 JJ O
distribution P08343961A0000 NN O
of P08343961A0000 IN O
the P08343961A0000 DT O
bicoid P08343961A0000 NN I-UN
protein P08343961A0000 NN I-UN
( P08343961A0000 ( O
bcd P08343961A0000 NN I-UN
) P08343961A0000 ) O
, P08343961A0000 , O
which P08343961A0000 WDT O
activates P08343961A0000 VBZ O
subordinate P08343961A0000 JJ O
genes P08343961A0000 NNS O
in P08343961A0000 IN O
distinct P08343961A0000 JJ O
anterior P08343961A0000 JJ O
domains P08343961A0000 NNS O
. P08343961A0000 . O
. . O O

Both P08604338A0198 DT O
EWS-FLI-1 P08604338A0198 NNP O
and P08604338A0198 CC O
FLI-1 P08604338A0198 NNP I-UN
proteins P08604338A0198 VBZ I-UN
function P08604338A0198 NN O
as P08604338A0198 IN O
transcription P08604338A0198 NN O
factors P08604338A0198 NNS O
that P08604338A0198 WDT O
bind P08604338A0198 VBP O
specifically P08604338A0198 RB O
to P08604338A0198 TO O
ets P08604338A0198 NNS I-UN
sequences P08604338A0198 NNS O
( P08604338A0198 ( O
the P08604338A0198 DT O
ets P08604338A0198 NNS I-UN
boxes P08604338A0198 NNS O
) P08604338A0198 ) O
present P08604338A0198 VBP O
in P08604338A0198 IN O
promoter P08604338A0198 NN O
elements P08604338A0198 NNS O
. P08604338A0198 . O
. . O O

The P02689439A0000 DT O
cytosolic P02689439A0000 JJ O
glutathione P02689439A0000 NN I-UN
S-transferases P02689439A0000 NNP I-UN
( P02689439A0000 ( O
GSTs P02689439A0000 NNP I-UN
, P02689439A0000 , O
EC P02689439A0000 NNP I-UN
2.5.1.18 P02689439A0000 CD I-UN
) P02689439A0000 ) O
are P02689439A0000 VBP O
a P02689439A0000 DT O
superfamily P02689439A0000 NN O
of P02689439A0000 IN O
dimeric P02689439A0000 NN O
isoenzymes P02689439A0000 NNS O
which P02689439A0000 WDT O
catalyze P02689439A0000 VBP O
the P02689439A0000 DT O
conjugation P02689439A0000 NN O
of P02689439A0000 IN O
electrophilic P02689439A0000 JJ O
substrates P02689439A0000 NNS O
with P02689439A0000 IN O
glutathione P02689439A0000 NN O
. P02689439A0000 . O
. . O O

Horvath P07532278A0833 NNP O
, P07532278A0833 , O
I P07532278A0833 PRP O
. P07532278A0833 . O
. . O O

The P09538220A0000 DT O
mitochondrial P09538220A0000 JJ I-UN
regulatory P09538220A0000 JJ I-UN
region P09538220A0000 NN I-UN
( P09538220A0000 ( O
mrr P09538220A0000 NN I-UN
) P09538220A0000 ) O
located P09538220A0000 VBD O
between P09538220A0000 IN O
the P09538220A0000 DT O
tRNAPhe P09538220A0000 NN I-UN
and P09538220A0000 CC O
tRNAPro P09538220A0000 JJ I-UN
genes P09538220A0000 NNS I-UN
of P09538220A0000 IN O
mitochondrial P09538220A0000 JJ O
DNA P09538220A0000 NNP O
( P09538220A0000 ( O
mtDNA P09538220A0000 NN O
) P09538220A0000 ) O
is P09538220A0000 VBZ O
essential P09538220A0000 JJ O
for P09538220A0000 IN O
regulation P09538220A0000 NN O
of P09538220A0000 IN O
replication P09538220A0000 NN O
and P09538220A0000 CC O
transcription P09538220A0000 NN O
of P09538220A0000 IN O
the P09538220A0000 DT O
mitochondrial P09538220A0000 JJ O
genome P09538220A0000 NN O
. P09538220A0000 . O
. . O O

CONTEXT P09929088A0000 NN O
: P09929088A0000 : O
ThinPrep P09929088A0000 NNP O
, P09929088A0000 , O
AutoPap P09929088A0000 NNP O
, P09929088A0000 , O
and P09929088A0000 CC O
Papnet P09929088A0000 NNP O
are P09929088A0000 VBP O
3 P09929088A0000 CD O
new P09929088A0000 JJ O
technologies P09929088A0000 NNS O
that P09929088A0000 WDT O
increase P09929088A0000 VBP O
the P09929088A0000 DT O
sensitivity P09929088A0000 NN O
and P09929088A0000 CC O
cost P09929088A0000 NN O
of P09929088A0000 IN O
cervical P09929088A0000 JJ O
cancer P09929088A0000 NN O
screening P09929088A0000 NN O
. P09929088A0000 . O
. . O O

At P09409774A0214 IN O
the P09409774A0214 DT O
genomic P09409774A0214 JJ O
level P09409774A0214 NN O
, P09409774A0214 , O
the P09409774A0214 DT O
sequences P09409774A0214 NNS O
of P09409774A0214 IN O
two P09409774A0214 CD O
members P09409774A0214 NNS O
of P09409774A0214 IN O
this P09409774A0214 DT O
family P09409774A0214 NN O
are P09409774A0214 VBP O
known P09409774A0214 VBN O
in P09409774A0214 IN O
the P09409774A0214 DT O
rat P09409774A0214 NN O
Rattus P09409774A0214 NNP O
norvegicus P09409774A0214 NN O
: P09409774A0214 : O
the P09409774A0214 DT O
VCSA1 P09409774A0214 NNP I-UN
gene P09409774A0214 NN I-UN
, P09409774A0214 , O
encoding P09409774A0214 VBG O
the P09409774A0214 DT O
prohormone-like P09409774A0214 JJ I-UN
polypeptide P09409774A0214 NN I-UN
SMR1 P09409774A0214 NNP I-UN
, P09409774A0214 , O
and P09409774A0214 CC O
the P09409774A0214 DT O
VCSB1 P09409774A0214 NNP I-UN
gene P09409774A0214 NN I-UN
, P09409774A0214 , O
encoding P09409774A0214 VBG O
a P09409774A0214 DT O
salivary P09409774A0214 JJ O
Pro-rich P09409774A0214 JJ O
polypeptide P09409774A0214 NN O
. P09409774A0214 . O
. . O O

Circulatory P00931089T0001 JJ O
arrest P00931089T0001 NN O
in P00931089T0001 IN O
the P00931089T0001 DT O
operating P00931089T0001 NN O
room P00931089T0001 NN O
. P00931089T0001 . O
. . O O

However P09226345A0436 RB O
, P09226345A0436 , O
mean P09226345A0436 JJ O
food P09226345A0436 NN O
intake P09226345A0436 NN O
in P09226345A0436 IN O
the P09226345A0436 DT O
40 P09226345A0436 CD O
% P09226345A0436 NN O
group P09226345A0436 NN O
was P09226345A0436 VBD O
half P09226345A0436 PDT O
that P09226345A0436 IN O
of P09226345A0436 IN O
the P09226345A0436 DT O
ACT P09226345A0436 NNP O
group P09226345A0436 NN O
( P09226345A0436 ( O
p P09226345A0436 JJ O
< P09226345A0436 NNP O
0.001 P09226345A0436 CD O
) P09226345A0436 ) O
and P09226345A0436 CC O
significantly P09226345A0436 RB O
less P09226345A0436 JJR O
( P09226345A0436 ( O
p P09226345A0436 JJ O
< P09226345A0436 NNP O
0.01 P09226345A0436 CD O
) P09226345A0436 ) O
than P09226345A0436 IN O
the P09226345A0436 DT O
SEP P09226345A0436 NNP O
group P09226345A0436 NN O
, P09226345A0436 , O
which P09226345A0436 WDT O
consumed P09226345A0436 VBD O
amounts P09226345A0436 NNS O
equivalent P09226345A0436 JJ O
to P09226345A0436 TO O
65 P09226345A0436 CD O
% P09226345A0436 NN O
of P09226345A0436 IN O
daily P09226345A0436 JJ O
requirement P09226345A0436 NN O
. P09226345A0436 . O
. . O O

Tumour P02572777T0000 CD I-UN
necrosis P02572777T0000 NN I-UN
factor P02572777T0000 NN I-UN
and P02572777T0000 CC O
adult P02572777T0000 NN O
respiratory P02572777T0000 NN O
distress P02572777T0000 JJ O
syndrome P02572777T0000 NN O
. P02572777T0000 . O
. . O O

Effects P01734570T0000 NNS O
of P01734570T0000 IN O
thromboxane P01734570T0000 NN I-UN
synthetase P01734570T0000 NN I-UN
inhibition P01734570T0000 NN O
on P01734570T0000 IN O
postburn P01734570T0000 NN O
mesenteric P01734570T0000 JJ O
vascular P01734570T0000 JJ O
resistance P01734570T0000 NN O
and P01734570T0000 CC O
the P01734570T0000 DT O
rate P01734570T0000 NN O
of P01734570T0000 IN O
bacterial P01734570T0000 JJ O
translocation P01734570T0000 NN O
in P01734570T0000 IN O
a P01734570T0000 DT O
chronic P01734570T0000 JJ O
porcine P01734570T0000 NN O
model P01734570T0000 NN O
. P01734570T0000 . O
. . O O

We P02894689A0000 PRP O
have P02894689A0000 VBP O
been P02894689A0000 VBN O
able P02894689A0000 JJ O
to P02894689A0000 TO O
map P02894689A0000 VB O
specific P02894689A0000 JJ O
DNA P02894689A0000 NNP O
fragments P02894689A0000 NNS O
at P02894689A0000 IN O
the P02894689A0000 DT O
bases P02894689A0000 NNS O
of P02894689A0000 IN O
chromatin P02894689A0000 NN O
loops P02894689A0000 NNS O
with P02894689A0000 IN O
the P02894689A0000 DT O
help P02894689A0000 NN O
of P02894689A0000 IN O
a P02894689A0000 DT O
novel P02894689A0000 JJ O
extraction P02894689A0000 NN O
procedure P02894689A0000 NN O
by P02894689A0000 IN O
using P02894689A0000 VBG O
lithium-3',5'-diiodosalicylate P02894689A0000 NN O
. P02894689A0000 . O
. . O O

Elevation P07771745A0442 NN O
of P07771745A0442 IN O
the P07771745A0442 DT O
tissues P07771745A0442 NNS O
of P07771745A0442 IN O
the P07771745A0442 DT O
face P07771745A0442 NN O
is P07771745A0442 VBZ O
essentially P07771745A0442 RB O
vertical P07771745A0442 JJ O
and P07771745A0442 CC O
acts P07771745A0442 VBZ O
on P07771745A0442 IN O
the P07771745A0442 DT O
forehead P07771745A0442 NN O
, P07771745A0442 , O
temporal P07771745A0442 JJ O
region P07771745A0442 NN O
, P07771745A0442 , O
gaze P07771745A0442 NN O
and P07771745A0442 CC O
cheekbones P07771745A0442 NNS O
. P07771745A0442 . O
. . O O

A P03166458A1356 DT O
protein P03166458A1356 NN O
footprint P03166458A1356 NN O
also P03166458A1356 RB O
was P03166458A1356 VBD O
identified P03166458A1356 VBN O
for P03166458A1356 IN O
a P03166458A1356 DT O
GC P03166458A1356 NNP O
box P03166458A1356 NN O
element P03166458A1356 NN O
at P03166458A1356 IN O
nucleotides P03166458A1356 NNS O
-59 P03166458A1356 VBP O
to P03166458A1356 TO O
-45 P03166458A1356 VB O
. P03166458A1356 . O
. . O O

Comparison P08760889A0531 NNP O
of P08760889A0531 IN O
the P08760889A0531 DT O
deduced P08760889A0531 JJ O
amino P08760889A0531 NN O
acid P08760889A0531 NN O
sequences P08760889A0531 NNS O
with P08760889A0531 IN O
protein P08760889A0531 JJ O
sequences P08760889A0531 NNS O
of P08760889A0531 IN O
T. P08760889A0531 NNP O
pyriformis P08760889A0531 NN O
H2As P08760889A0531 NNP I-UN
showed P08760889A0531 VBD O
only P08760889A0531 RB O
two P08760889A0531 CD O
and P08760889A0531 CC O
three P08760889A0531 CD O
differences P08760889A0531 NNS O
respectively P08760889A0531 RB O
, P08760889A0531 , O
in P08760889A0531 IN O
a P08760889A0531 DT O
total P08760889A0531 NN O
of P08760889A0531 IN O
137 P08760889A0531 CD O
amino P08760889A0531 JJ O
acids P08760889A0531 NNS O
for P08760889A0531 IN O
H2A1 P08760889A0531 NNP I-UN
, P08760889A0531 , O
and P08760889A0531 CC O
132 P08760889A0531 CD O
amino P08760889A0531 NN O
acids P08760889A0531 NNS O
for P08760889A0531 IN O
H2A2 P08760889A0531 NNP I-UN
, P08760889A0531 , O
indicating P08760889A0531 VBG O
the P08760889A0531 DT O
two P08760889A0531 CD O
genes P08760889A0531 NNS O
arose P08760889A0531 VBD O
before P08760889A0531 IN O
the P08760889A0531 DT O
divergence P08760889A0531 NN O
of P08760889A0531 IN O
these P08760889A0531 DT O
two P08760889A0531 CD O
species P08760889A0531 NNS O
. P08760889A0531 . O
. . O O

Mean P00985279A0493 NNP O
corpuscular P00985279A0493 JJ I-UN
hemoglobin P00985279A0493 NN I-UN
concentrations P00985279A0493 NNS O
remained P00985279A0493 VBD O
normal P00985279A0493 JJ O
for P00985279A0493 IN O
48 P00985279A0493 CD O
h P00985279A0493 NN O
and P00985279A0493 CC O
then P00985279A0493 RB O
decreased P00985279A0493 VBN O
in P00985279A0493 IN O
both P00985279A0493 DT O
groups P00985279A0493 NNS O
, P00985279A0493 , O
the P00985279A0493 DT O
CO2 P00985279A0493 NNP O
group P00985279A0493 NN O
showing P00985279A0493 VBG O
the P00985279A0493 DT O
larger P00985279A0493 JJR O
decrease P00985279A0493 NN O
. P00985279A0493 . O
. . O O

Intensive P10540553A0980 JJ O
synthesis P10540553A0980 NN O
of P10540553A0980 IN O
PNA P10540553A0980 NNP I-UN
in P10540553A0980 IN O
the P10540553A0980 DT O
cells P10540553A0980 NNS O
of P10540553A0980 IN O
microvascular P10540553A0980 JJ O
wall P10540553A0980 NN O
evidenced P10540553A0980 VBD O
of P10540553A0980 IN O
their P10540553A0980 PRP$ O
high P10540553A0980 JJ O
functional P10540553A0980 JJ O
activity P10540553A0980 NN O
, P10540553A0980 , O
and P10540553A0980 CC O
the P10540553A0980 DT O
synthesis P10540553A0980 NN O
of P10540553A0980 IN O
DNA P10540553A0980 NN O
in P10540553A0980 IN O
them P10540553A0980 PRP O
showed P10540553A0980 VBD O
their P10540553A0980 PRP$ O
ability P10540553A0980 NN O
for P10540553A0980 IN O
proliferation P10540553A0980 NN O
, P10540553A0980 , O
i.g. P10540553A0980 NN O
-- P10540553A0980 : O
for P10540553A0980 IN O
growth P10540553A0980 NN O
. P10540553A0980 . O
. . O O

The P10026146A0680 DT O
inhibition P10026146A0680 NN O
by P10026146A0680 IN O
the P10026146A0680 DT O
RIalpha P10026146A0680 NNP I-UN
subunit P10026146A0680 NN I-UN
is P10026146A0680 VBZ O
reversed P10026146A0680 VBN O
by P10026146A0680 IN O
addition P10026146A0680 NN O
of P10026146A0680 IN O
nanomolar P10026146A0680 JJ O
concentrations P10026146A0680 NNS O
of P10026146A0680 IN O
cAMP P10026146A0680 NN O
( P10026146A0680 ( O
Ka P10026146A0680 NNP O
= P10026146A0680 VBZ O
40 P10026146A0680 CD O
nM P10026146A0680 NN O
) P10026146A0680 ) O
, P10026146A0680 , O
thus P10026146A0680 RB O
demonstrating P10026146A0680 VBG O
that P10026146A0680 IN O
PrKX P10026146A0680 NNP I-UN
is P10026146A0680 VBZ O
a P10026146A0680 DT O
novel P10026146A0680 NN O
, P10026146A0680 , O
type P10026146A0680 NN I-UN
I P10026146A0680 PRP I-UN
cAMP-dependent P10026146A0680 JJ I-UN
protein P10026146A0680 NN I-UN
kinase P10026146A0680 NN I-UN
that P10026146A0680 WDT O
is P10026146A0680 VBZ O
activated P10026146A0680 VBN O
at P10026146A0680 IN O
lower P10026146A0680 JJR O
cAMP P10026146A0680 NN O
concentrations P10026146A0680 NNS O
than P10026146A0680 IN O
the P10026146A0680 DT O
holoenzyme P10026146A0680 NN O
with P10026146A0680 IN O
the P10026146A0680 DT O
Calpha P10026146A0680 NNP I-UN
subunit P10026146A0680 NN I-UN
of P10026146A0680 IN O
cAMP-dependent P10026146A0680 JJ I-UN
protein P10026146A0680 NN I-UN
kinase P10026146A0680 NN I-UN
. P10026146A0680 . O
. . O O

Transient P10640683A0670 JJ O
transfection P10640683A0670 NN O
assays P10640683A0670 NNS O
using P10640683A0670 VBG O
P19 P10640683A0670 NNP O
cells P10640683A0670 NNS O
revealed P10640683A0670 VBD O
that P10640683A0670 IN O
expression P10640683A0670 NN O
of P10640683A0670 IN O
NDRF P10640683A0670 NNP I-UN
/ P10640683A0670 NNP O
NeuroD2 P10640683A0670 NNP I-UN
increased P10640683A0670 VBD O
the P10640683A0670 DT O
transactivation P10640683A0670 NN O
of P10640683A0670 IN O
the P10640683A0670 DT O
rat P10640683A0670 NN I-UN
insulin P10640683A0670 NN I-UN
promoter P10640683A0670 NN I-UN
element P10640683A0670 NN I-UN
3 P10640683A0670 CD I-UN
( P10640683A0670 ( O
RIPE3 P10640683A0670 NNP I-UN
) P10640683A0670 ) O
enhancer P10640683A0670 VBZ O
up P10640683A0670 RP O
to P10640683A0670 TO O
approximately P10640683A0670 RB O
12-fold P10640683A0670 JJ O
and P10640683A0670 CC O
that P10640683A0670 IN O
co-expression P10640683A0670 NN O
of P10640683A0670 IN O
catalytically P10640683A0670 RB O
active P10640683A0670 JJ O
form P10640683A0670 NN O
of P10640683A0670 IN O
PKN P10640683A0670 NNP I-UN
, P10640683A0670 , O
but P10640683A0670 CC O
not P10640683A0670 RB O
kinase-deficient P10640683A0670 JJ O
derivative P10640683A0670 NN O
, P10640683A0670 , O
resulted P10640683A0670 VBD O
in P10640683A0670 IN O
a P10640683A0670 DT O
further P10640683A0670 JJ O
threefold P10640683A0670 JJ O
increase P10640683A0670 NN O
of P10640683A0670 IN O
NDRF P10640683A0670 NNP I-UN
/ P10640683A0670 NNP O
NeuroD2-mediated P10640683A0670 JJ O
transcription P10640683A0670 NN O
. P10640683A0670 . O
. . O O

Therefore P09539721A0599 RB O
, P09539721A0599 , O
we P09539721A0599 PRP O
conclude P09539721A0599 VBP O
that P09539721A0599 IN O
DnaA P09539721A0599 NNP I-UN
may P09539721A0599 MD O
contact P09539721A0599 VB O
the P09539721A0599 DT O
beta P09539721A0599 NN O
subunit P09539721A0599 NN O
of P09539721A0599 IN O
RNA P09539721A0599 NNP I-UN
polymerase P09539721A0599 NN I-UN
during P09539721A0599 IN O
activation P09539721A0599 NN O
of P09539721A0599 IN O
the P09539721A0599 DT O
pR P09539721A0599 NN I-UN
promoter P09539721A0599 NN I-UN
. P09539721A0599 . O
. . O O

The P11427329A1077 DT O
validity P11427329A1077 NN O
of P11427329A1077 IN O
the P11427329A1077 DT O
FPS-R P11427329A1077 NNP O
was P11427329A1077 VBD O
further P11427329A1077 RBR O
supported P11427329A1077 VBN O
by P11427329A1077 IN O
strong P11427329A1077 JJ O
positive P11427329A1077 JJ O
correlations P11427329A1077 NNS O
with P11427329A1077 IN O
the P11427329A1077 DT O
VAS P11427329A1077 NNP O
( P11427329A1077 ( O
r=0.92 P11427329A1077 NN O
, P11427329A1077 , O
N=45 P11427329A1077 NNP O
) P11427329A1077 ) O
and P11427329A1077 CC O
the P11427329A1077 DT O
CAS P11427329A1077 NNP O
( P11427329A1077 ( O
r=0.84 P11427329A1077 NN O
, P11427329A1077 , O
N=45 P11427329A1077 NNP O
) P11427329A1077 ) O
in P11427329A1077 IN O
this P11427329A1077 DT O
clinical P11427329A1077 JJ O
sample P11427329A1077 NN O
. P11427329A1077 . O
. . O O

Transitory P06428116T0000 NNP O
subclinical P06428116T0000 JJ O
and P06428116T0000 CC O
permanent P06428116T0000 JJ O
hypothyroidism P06428116T0000 NN O
in P06428116T0000 IN O
the P06428116T0000 DT O
course P06428116T0000 NN O
of P06428116T0000 IN O
subacute P06428116T0000 JJ O
thyroiditis P06428116T0000 NN O
( P06428116T0000 ( O
de P06428116T0000 FW O
Quervain P06428116T0000 NNP O
) P06428116T0000 ) O
. P06428116T0000 . O
. . O O

A P07659515T0000 DT O
new P07659515T0000 JJ O
non-LTR P07659515T0000 JJ O
retrotransposon P07659515T0000 NN O
provides P07659515T0000 VBZ O
evidence P07659515T0000 NN O
for P07659515T0000 IN O
multiple P07659515T0000 JJ O
distinct P07659515T0000 JJ O
site-specific P07659515T0000 JJ O
elements P07659515T0000 NNS O
in P07659515T0000 IN O
Crithidia P07659515T0000 NNP O
fasciculata P07659515T0000 NN O
miniexon P07659515T0000 NN O
arrays P07659515T0000 NNS O
. P07659515T0000 . O
. . O O

Young P11108616A0000 NNP O
fish P11108616A0000 NN O
( P11108616A0000 ( O
Oreochromis P11108616A0000 NNP O
mossambicus P11108616A0000 NN O
) P11108616A0000 ) O
were P11108616A0000 VBD O
exposed P11108616A0000 VBN O
to P11108616A0000 TO O
microgravity P11108616A0000 NN O
( P11108616A0000 ( O
micro P11108616A0000 JJ O
g P11108616A0000 NN O
) P11108616A0000 ) O
for P11108616A0000 IN O
9 P11108616A0000 CD O
to P11108616A0000 TO O
10 P11108616A0000 CD O
days P11108616A0000 NNS O
during P11108616A0000 IN O
space P11108616A0000 NN O
missions P11108616A0000 NNS O
STS-55 P11108616A0000 NNP O
and P11108616A0000 CC O
STS-84 P11108616A0000 NNP O
, P11108616A0000 , O
or P11108616A0000 CC O
to P11108616A0000 TO O
hypergravity P11108616A0000 NN O
( P11108616A0000 ( O
hg P11108616A0000 NN O
) P11108616A0000 ) O
for P11108616A0000 IN O
9 P11108616A0000 CD O
days P11108616A0000 NNS O
. P11108616A0000 . O
. . O O

Dementia P11872570T0000 NN O
is P11872570T0000 VBZ O
being P11872570T0000 VBG O
avoided P11872570T0000 VBN O
in P11872570T0000 IN O
NHS P11872570T0000 NNP O
and P11872570T0000 CC O
social P11872570T0000 JJ O
care P11872570T0000 NN O
. P11872570T0000 . O
. . O O

Furthermore P08709831A0599 RB O
, P08709831A0599 , O
the P08709831A0599 DT O
potency P08709831A0599 NN O
of P08709831A0599 IN O
Dacarbacine P08709831A0599 NNP O
in P08709831A0599 IN O
the P08709831A0599 DT O
treatment P08709831A0599 NN O
of P08709831A0599 IN O
carcinoid P08709831A0599 NN O
tumors P08709831A0599 NNS O
seems P08709831A0599 VBZ O
to P08709831A0599 TO O
be P08709831A0599 VB O
underestimated P08709831A0599 VBN O
up P08709831A0599 RP O
to P08709831A0599 TO O
now P08709831A0599 RB O
. P08709831A0599 . O
. . O O

Twenty-five P11243980A0510 JJ O
patients P11243980A0510 NNS O
also P11243980A0510 RB O
received P11243980A0510 VBD O
PET P11243980A0510 NNP O
examinations P11243980A0510 NNS O
during P11243980A0510 IN O
the P11243980A0510 DT O
staging P11243980A0510 NN O
procedures P11243980A0510 NNS O
. P11243980A0510 . O
. . O O

Induction P01986241A0117 NN O
requires P01986241A0117 VBZ O
the P01986241A0117 DT O
ACE1 P01986241A0117 NNP I-UN
gene P01986241A0117 NN I-UN
product P01986241A0117 NN I-UN
, P01986241A0117 , O
which P01986241A0117 WDT O
binds P01986241A0117 VBZ O
to P01986241A0117 TO O
specific P01986241A0117 VB O
sites P01986241A0117 NNS O
in P01986241A0117 IN O
the P01986241A0117 DT O
promoter P01986241A0117 NN O
region P01986241A0117 NN O
of P01986241A0117 IN O
the P01986241A0117 DT O
CUP1 P01986241A0117 NNP I-UN
gene P01986241A0117 NN I-UN
. P01986241A0117 . O
. . O O

None P09583201A0759 NN O
of P09583201A0759 IN O
the P09583201A0759 DT O
patients P09583201A0759 NNS O
was P09583201A0759 VBD O
obese P09583201A0759 JJ O
. P09583201A0759 . O
. . O O

Genomic P09649537A0000 NNP O
and P09649537A0000 CC O
cDNA P09649537A0000 NN O
clones P09649537A0000 NNS O
homologous P09649537A0000 JJ O
to P09649537A0000 TO O
the P09649537A0000 DT O
yeast P09649537A0000 NN O
GCN2 P09649537A0000 NNP I-UN
eIF-2alpha P09649537A0000 JJ I-UN
kinase P09649537A0000 NN O
( P09649537A0000 ( O
yGCN2 P09649537A0000 NN O
) P09649537A0000 ) O
were P09649537A0000 VBD O
isolated P09649537A0000 VBN O
from P09649537A0000 IN O
Drosophila P09649537A0000 NNP O
melanogaster P09649537A0000 NN O
. P09649537A0000 . O
. . O O

RNA P09645576A0148 NNP O
of P09645576A0148 IN O
GBV-C P09645576A0148 NNP O
was P09645576A0148 VBD O
detected P09645576A0148 VBN O
in P09645576A0148 IN O
14 P09645576A0148 CD O
( P09645576A0148 ( O
18 P09645576A0148 CD O
% P09645576A0148 NN O
) P09645576A0148 ) O
patients P09645576A0148 NNS O
before P09645576A0148 IN O
BMT P09645576A0148 NNP O
. P09645576A0148 . O
. . O O

Moreover P10208865A1246 RB O
, P10208865A1246 , O
when P10208865A1246 WRB O
added P10208865A1246 VBN O
to P10208865A1246 TO O
the P10208865A1246 DT O
osteoclast P10208865A1246 NN O
cultures P10208865A1246 NNS O
, P10208865A1246 , O
mrIhh-N P10208865A1246 JJ I-UN
markedly P10208865A1246 RB O
stimulated P10208865A1246 VBD O
the P10208865A1246 DT O
formation P10208865A1246 NN O
of P10208865A1246 IN O
resorption P10208865A1246 NN O
pits P10208865A1246 NNS O
on P10208865A1246 IN O
dentine P10208865A1246 NN O
slices P10208865A1246 NNS O
. P10208865A1246 . O
. . O O

Recombinant P09089653A0615 JJ O
plasmids P09089653A0615 NNS O
containing P09089653A0615 VBG O
the P09089653A0615 DT O
entire P09089653A0615 JJ O
322 P09089653A0615 CD O
nt P09089653A0615 RB O
5 P09089653A0615 CD O
' P09089653A0615 '' O
UTR P09089653A0615 NNP O
of P09089653A0615 IN O
exon P09089653A0615 $ O
1 P09089653A0615 CD O
and P09089653A0615 CC O
a P09089653A0615 DT O
1630 P09089653A0615 CD O
nt P09089653A0615 JJ O
segment P09089653A0615 NN O
of P09089653A0615 IN O
5 P09089653A0615 CD O
' P09089653A0615 POS O
flanking P09089653A0615 VBG O
sequence P09089653A0615 NN O
stimulated P09089653A0615 VBD O
luciferase P09089653A0615 JJ I-UN
activity P09089653A0615 NN O
nearly P09089653A0615 RB O
70 P09089653A0615 CD O
times P09089653A0615 NNS O
higher P09089653A0615 JJR O
than P09089653A0615 IN O
a P09089653A0615 DT O
promoterless P09089653A0615 NN O
control P09089653A0615 NN O
plasmid P09089653A0615 NN O
. P09089653A0615 . O
. . O O

One P07434456A0286 CD O
hundred P07434456A0286 CD O
twenty P07434456A0286 JJ O
units P07434456A0286 NNS O
of P07434456A0286 IN O
deglycerolized P07434456A0286 JJ O
red P07434456A0286 JJ O
blood P07434456A0286 NN O
cells P07434456A0286 NNS O
, P07434456A0286 , O
some P07434456A0286 DT O
with P07434456A0286 IN O
glycerol P07434456A0286 NN O
added P07434456A0286 VBD O
so P07434456A0286 RB O
as P07434456A0286 IN O
to P07434456A0286 TO O
exceed P07434456A0286 VB O
an P07434456A0286 DT O
acceptable P07434456A0286 JJ O
1 P07434456A0286 CD O
% P07434456A0286 NN O
glycerol P07434456A0286 NN O
content P07434456A0286 NN O
, P07434456A0286 , O
had P07434456A0286 VBD O
measurements P07434456A0286 NNS O
made P07434456A0286 VBN O
of P07434456A0286 IN O
the P07434456A0286 DT O
post-wash P07434456A0286 JJ O
supernatant P07434456A0286 NN O
fluid P07434456A0286 NN O
by P07434456A0286 IN O
refractive P07434456A0286 JJ O
index P07434456A0286 NN O
and P07434456A0286 CC O
osmometry P07434456A0286 NN O
. P07434456A0286 . O
. . O O

The P03615550A1094 DT O
rate-decreasing P03615550A1094 JJ O
effects P03615550A1094 NNS O
of P03615550A1094 IN O
morphine P03615550A1094 NN O
and P03615550A1094 CC O
U50488 P03615550A1094 NNP O
were P03615550A1094 VBD O
reversed P03615550A1094 VBN O
completely P03615550A1094 RB O
by P03615550A1094 IN O
a P03615550A1094 DT O
0.01 P03615550A1094 CD O
and P03615550A1094 CC O
1.0 P03615550A1094 CD O
mg P03615550A1094 NN O
/ P03615550A1094 NNP O
kg P03615550A1094 NNP O
dose P03615550A1094 NN O
of P03615550A1094 IN O
naloxone P03615550A1094 NN O
, P03615550A1094 , O
respectively P03615550A1094 RB O
. P03615550A1094 . O
. . O O

1 P01348684A0000 CD O
. P01348684A0000 . O
. . O O

To P02969316A0002 TO O
assess P02969316A0002 VB O
the P02969316A0002 DT O
ability P02969316A0002 NN O
of P02969316A0002 IN O
the P02969316A0002 DT O
atria P02969316A0002 NN O
to P02969316A0002 TO O
maintain P02969316A0002 VB O
elevated P02969316A0002 JJ O
plasma P02969316A0002 JJ O
concentrations P02969316A0002 NNS O
of P02969316A0002 IN O
atrial P02969316A0002 JJ I-UN
natriuretic P02969316A0002 JJ I-UN
peptide P02969316A0002 NN I-UN
( P02969316A0002 ( O
ANP P02969316A0002 NNP I-UN
) P02969316A0002 ) O
, P02969316A0002 , O
the P02969316A0002 DT O
temporal P02969316A0002 JJ O
changes P02969316A0002 NNS O
in P02969316A0002 IN O
plasma P02969316A0002 NN I-UN
ANP P02969316A0002 NNP I-UN
concentrations P02969316A0002 NNS O
were P02969316A0002 VBD O
studied P02969316A0002 VBN O
in P02969316A0002 IN O
seven P02969316A0002 CD O
chloralose-anaesthetized P02969316A0002 JJ O
dogs P02969316A0002 NNS O
during P02969316A0002 IN O
4 P02969316A0002 CD O
h P02969316A0002 NN O
of P02969316A0002 IN O
sustained P02969316A0002 JJ O
rapid P02969316A0002 JJ O
cardiac P02969316A0002 JJ O
pacing P02969316A0002 NN O
. P02969316A0002 . O
. . O O

These P07648338A0815 DT O
results P07648338A0815 NNS O
suggest P07648338A0815 VBP O
that P07648338A0815 IN O
different P07648338A0815 JJ O
models P07648338A0815 NNS O
of P07648338A0815 IN O
intestinal P07648338A0815 JJ O
ischemia P07648338A0815 NN O
have P07648338A0815 VBP O
different P07648338A0815 JJ O
cytokine P07648338A0815 NN O
profiles P07648338A0815 NNS O
and P07648338A0815 CC O
that P07648338A0815 IN O
the P07648338A0815 DT O
early P07648338A0815 JJ O
TNF P07648338A0815 NNP I-UN
response P07648338A0815 NN O
associated P07648338A0815 VBN O
with P07648338A0815 IN O
SMA P07648338A0815 NNP O
occlusion P07648338A0815 NN O
model P07648338A0815 NN O
is P07648338A0815 VBZ O
primarily P07648338A0815 RB O
due P07648338A0815 JJ O
to P07648338A0815 TO O
the P07648338A0815 DT O
laparotomy P07648338A0815 NN O
. P07648338A0815 . O
. . O O

The P11469701A0377 DT O
novel P11469701A0377 JJ O
approach P11469701A0377 NN O
to P11469701A0377 TO O
insulin P11469701A0377 VB I-UN
administration P11469701A0377 NN O
known P11469701A0377 VBN O
as P11469701A0377 IN O
chronic P11469701A0377 JJ O
intermittent P11469701A0377 NN O
intravenous P11469701A0377 JJ O
insulin P11469701A0377 NN I-UN
therapy P11469701A0377 NN O
( P11469701A0377 ( O
CIIIT P11469701A0377 NNP O
) P11469701A0377 ) O
delivers P11469701A0377 NNS O
insulin P11469701A0377 VBP I-UN
in P11469701A0377 IN O
a P11469701A0377 DT O
pulsatile P11469701A0377 JJ O
fashion P11469701A0377 NN O
and P11469701A0377 CC O
achieves P11469701A0377 VBZ O
physiological P11469701A0377 JJ O
insulin P11469701A0377 NN I-UN
concentration P11469701A0377 NN O
in P11469701A0377 IN O
the P11469701A0377 DT O
portal P11469701A0377 JJ O
vein P11469701A0377 NN O
. P11469701A0377 . O
. . O O

Each P07824726A0454 DT O
type P07824726A0454 NN O
was P07824726A0454 VBD O
divided P07824726A0454 VBN O
into P07824726A0454 IN O
two P07824726A0454 CD O
subgroups P07824726A0454 NNS O
on P07824726A0454 IN O
the P07824726A0454 DT O
basis P07824726A0454 NN O
of P07824726A0454 IN O
whether P07824726A0454 IN O
the P07824726A0454 DT O
body P07824726A0454 NN O
and P07824726A0454 CC O
tail P07824726A0454 NN O
of P07824726A0454 IN O
the P07824726A0454 DT O
pancreas P07824726A0454 NN O
showed P07824726A0454 VBD O
intense P07824726A0454 JJ O
fatty P07824726A0454 JJ O
replacement P07824726A0454 NN O
( P07824726A0454 ( O
type P07824726A0454 VB O
a P07824726A0454 DT O
= P07824726A0454 JJ O
negative P07824726A0454 JJ O
for P07824726A0454 IN O
intense P07824726A0454 JJ O
fatty P07824726A0454 JJ O
replacement P07824726A0454 NN O
, P07824726A0454 , O
type P07824726A0454 NN O
b P07824726A0454 NN O
= P07824726A0454 NNP O
positive P07824726A0454 JJ O
for P07824726A0454 IN O
intense P07824726A0454 JJ O
fatty P07824726A0454 JJ O
replacement P07824726A0454 NN O
) P07824726A0454 ) O
. P07824726A0454 . O
. . O O

These P09060676A1634 DT O
changes P09060676A1634 NNS O
in P09060676A1634 IN O
virus P09060676A1634 NN O
entry P09060676A1634 NN O
features P09060676A1634 NNS O
may P09060676A1634 MD O
result P09060676A1634 VB O
in P09060676A1634 IN O
coronaviruses P09060676A1634 NNS O
with P09060676A1634 IN O
novel P09060676A1634 JJ O
pathogenic P09060676A1634 JJ O
properties P09060676A1634 NNS O
. P09060676A1634 . O
. . O O

Interferon-alpha-induced P01529530T0000 JJ O
gene P01529530T0000 NN O
expression P01529530T0000 NN O
: P01529530T0000 : O
evidence P01529530T0000 NN O
for P01529530T0000 IN O
a P01529530T0000 DT O
selective P01529530T0000 JJ O
effect P01529530T0000 NN O
of P01529530T0000 IN O
ouabain P01529530T0000 NN O
on P01529530T0000 IN O
activation P01529530T0000 NN O
of P01529530T0000 IN O
the P01529530T0000 DT O
ISGF3 P01529530T0000 NNP I-UN
transcription P01529530T0000 NN I-UN
complex P01529530T0000 NN I-UN
. P01529530T0000 . O
. . O O

The P01995951A0000 DT O
long P01995951A0000 JJ O
terminal P01995951A0000 JJ O
repeat P01995951A0000 NN O
( P01995951A0000 ( O
LTR P01995951A0000 NNP O
) P01995951A0000 ) O
of P01995951A0000 IN O
the P01995951A0000 DT O
human P01995951A0000 JJ O
immunodeficiency P01995951A0000 NN O
virus P01995951A0000 NN O
( P01995951A0000 ( O
HIV P01995951A0000 NNP O
) P01995951A0000 ) O
contains P01995951A0000 VBZ O
three P01995951A0000 CD O
binding P01995951A0000 NN O
sites P01995951A0000 NNS O
for P01995951A0000 IN O
the P01995951A0000 DT O
transcriptional P01995951A0000 JJ O
factor P01995951A0000 NN O
Sp1 P01995951A0000 NNP I-UN
. P01995951A0000 . O
. . O O

However P11587514A0758 RB O
, P11587514A0758 , O
the P11587514A0758 DT O
abi1-1 P11587514A0758 JJ I-UN
gene P11587514A0758 NN I-UN
product P11587514A0758 NN I-UN
has P11587514A0758 VBZ O
no P11587514A0758 DT O
effect P11587514A0758 NN O
on P11587514A0758 IN O
the P11587514A0758 DT O
ABA P11587514A0758 NNP O
suppression P11587514A0758 NN O
of P11587514A0758 IN O
a P11587514A0758 DT O
GA-responsive P11587514A0758 JJ O
alpha-amylase P11587514A0758 JJ I-UN
gene P11587514A0758 NN I-UN
. P11587514A0758 . O
. . O O

Movement P06419251T0000 NNP O
programming P06419251T0000 VBG O
depends P06419251T0000 NNS O
on P06419251T0000 IN O
understanding P06419251T0000 NN O
of P06419251T0000 IN O
behavioral P06419251T0000 JJ O
requirements P06419251T0000 NNS O
. P06419251T0000 . O
. . O O

Foxp1 P11358962A0344 NNP I-UN
and P11358962A0344 CC O
Foxp2 P11358962A0344 NNP I-UN
are P11358962A0344 VBP O
expressed P11358962A0344 VBN O
at P11358962A0344 IN O
high P11358962A0344 JJ O
levels P11358962A0344 NNS O
in P11358962A0344 IN O
the P11358962A0344 DT O
lung P11358962A0344 NN O
as P11358962A0344 RB O
early P11358962A0344 RB O
as P11358962A0344 IN O
E12.5 P11358962A0344 NNP O
of P11358962A0344 IN O
mouse P11358962A0344 NN O
development P11358962A0344 NN O
with P11358962A0344 IN O
Foxp2 P11358962A0344 NNP I-UN
expression P11358962A0344 NN O
restricted P11358962A0344 VBD O
to P11358962A0344 TO O
the P11358962A0344 DT O
airway P11358962A0344 NN O
epithelium P11358962A0344 NN O
. P11358962A0344 . O
. . O O

Role P02417023T0001 NNP O
of P02417023T0001 IN O
superoxide P02417023T0001 JJ I-UN
dismutase P02417023T0001 NN I-UN
in P02417023T0001 IN O
cellular P02417023T0001 JJ O
oxidative P02417023T0001 JJ O
processes P02417023T0001 NNS O
and P02417023T0001 CC O
method P02417023T0001 NN O
of P02417023T0001 IN O
its P02417023T0001 PRP$ O
determination P02417023T0001 NN O
in P02417023T0001 IN O
biological P02417023T0001 JJ O
materials P02417023T0001 NNS O
. P02417023T0001 . O
. . O O

Mutational P09172641A0181 JJ O
studies P09172641A0181 NNS O
provide P09172641A0181 VBP O
evidence P09172641A0181 NN O
to P09172641A0181 TO O
this P09172641A0181 DT O
end P09172641A0181 NN O
and P09172641A0181 CC O
indicate P09172641A0181 NN O
that P09172641A0181 IN O
the P09172641A0181 DT O
side P09172641A0181 NN O
chains P09172641A0181 NNS O
of P09172641A0181 IN O
subdomain P09172641A0181 NN O
4.2 P09172641A0181 CD O
make P09172641A0181 NN O
specific P09172641A0181 JJ O
contacts P09172641A0181 NNS O
with P09172641A0181 IN O
the P09172641A0181 DT O
nucleotides P09172641A0181 NNS O
at P09172641A0181 IN O
-35 P09172641A0181 NNP O
. P09172641A0181 . O
. . O O

OBJECTIVE P08684742A0000 NN O
: P08684742A0000 : O
To P08684742A0000 TO O
compare P08684742A0000 VB O
pregnancy P08684742A0000 NN O
complications P08684742A0000 NNS O
in P08684742A0000 IN O
women P08684742A0000 NNS O
having P08684742A0000 VBG O
genetic P08684742A0000 JJ O
amniocentesis P08684742A0000 NN O
at P08684742A0000 IN O
11-14 P08684742A0000 JJ O
weeks P08684742A0000 NNS O
versus P08684742A0000 IN O
those P08684742A0000 DT O
undergoing P08684742A0000 JJ O
amniocentesis P08684742A0000 NN O
at P08684742A0000 IN O
16-19 P08684742A0000 JJ O
weeks P08684742A0000 NNS O
' P08684742A0000 POS O
gestation P08684742A0000 NN O
. P08684742A0000 . O
. . O O

In P07878040A0505 IN O
the P07878040A0505 DT O
first P07878040A0505 JJ O
, P07878040A0505 , O
homologous P07878040A0505 JJ O
sequences P07878040A0505 NNS O
were P07878040A0505 VBD O
deleted P07878040A0505 VBN O
from P07878040A0505 IN O
a P07878040A0505 DT O
mouse P07878040A0505 NN O
enhancer P07878040A0505 NN O
, P07878040A0505 , O
resulting P07878040A0505 VBG O
in P07878040A0505 IN O
a P07878040A0505 DT O
tissue-specific P07878040A0505 JJ O
loss P07878040A0505 NN O
of P07878040A0505 IN O
activity P07878040A0505 NN O
when P07878040A0505 WRB O
assayed P07878040A0505 VBN O
in P07878040A0505 IN O
transgenic P07878040A0505 JJ O
mice P07878040A0505 NN O
. P07878040A0505 . O
. . O O

The P10882462T0000 DT O
science P10882462T0000 NN O
of P10882462T0000 IN O
tissue P10882462T0000 NN O
engineering P10882462T0000 NN O
. P10882462T0000 . O
. . O O

Bacteriostatic P00807356T0001 NNP O
and P00807356T0001 CC O
bacteriacidal P00807356T0001 JJ O
activity P00807356T0001 NN O
of P00807356T0001 IN O
hydroxy-9 P00807356T0001 JJ O
ellipticine P00807356T0001 NN O
in P00807356T0001 IN O
vitro P00807356T0001 NN O
. P00807356T0001 . O
. . O O

Mutations P01532796A0107 NNS O
in P01532796A0107 IN O
either P01532796A0107 DT O
gene P01532796A0107 NN O
block P01532796A0107 NN O
some P01532796A0107 DT O
crucial P01532796A0107 JJ O
late P01532796A0107 JJ O
step P01532796A0107 NN O
in P01532796A0107 IN O
assembly P01532796A0107 NN O
of P01532796A0107 IN O
F1 P01532796A0107 NNP I-UN
, P01532796A0107 , O
causing P01532796A0107 VBG O
the P01532796A0107 DT O
alpha P01532796A0107 NN O
and P01532796A0107 CC O
beta P01532796A0107 NN O
subunits P01532796A0107 NNS O
to P01532796A0107 TO O
accumulate P01532796A0107 VB O
in P01532796A0107 IN O
mitochondria P01532796A0107 NN O
as P01532796A0107 IN O
inactive P01532796A0107 JJ O
aggregates P01532796A0107 NNS O
( P01532796A0107 ( O
Ackerman P01532796A0107 NNP O
, P01532796A0107 , O
S P01532796A0107 NNP O
. P01532796A0107 . O
. . O O

Deletion P08196607A0280 NNP O
analysis P08196607A0280 NN O
of P08196607A0280 IN O
the P08196607A0280 DT O
ICL1 P08196607A0280 NNP I-UN
promoter P08196607A0280 NN I-UN
led P08196607A0280 VBD O
to P08196607A0280 TO O
the P08196607A0280 DT O
identification P08196607A0280 NN O
of P08196607A0280 IN O
an P08196607A0280 DT O
upstream P08196607A0280 JJ O
activating P08196607A0280 NN O
sequence P08196607A0280 NN O
element P08196607A0280 NN O
, P08196607A0280 , O
UASICL1 P08196607A0280 NNP O
( P08196607A0280 ( O
5 P08196607A0280 CD O
' P08196607A0280 '' O
CATTCATCCG P08196607A0280 NNP O
3 P08196607A0280 CD O
' P08196607A0280 '' O
) P08196607A0280 ) O
, P08196607A0280 , O
necessary P08196607A0280 JJ O
and P08196607A0280 CC O
sufficient P08196607A0280 JJ O
for P08196607A0280 IN O
conferring P08196607A0280 VBG O
carbon P08196607A0280 NN O
source-dependent P08196607A0280 JJ O
regulation P08196607A0280 NN O
on P08196607A0280 IN O
a P08196607A0280 DT O
heterologous P08196607A0280 JJ O
reporter P08196607A0280 NN O
gene P08196607A0280 NN O
. P08196607A0280 . O
. . O O

Pathol P10206959A0368 NNP O
. P10206959A0368 . O
. . O O

Sequence P09765411A0991 NN O
comparisons P09765411A0991 NNS O
strongly P09765411A0991 RB O
suggest P09765411A0991 VBP O
that P09765411A0991 IN O
the P09765411A0991 DT O
S27a P09765411A0991 NNP I-UN
and P09765411A0991 CC O
the P09765411A0991 DT O
ubiquitin P09765411A0991 JJ I-UN
coding P09765411A0991 NN O
sequences P09765411A0991 NNS O
found P09765411A0991 VBN O
in P09765411A0991 IN O
the P09765411A0991 DT O
genome P09765411A0991 NN O
of P09765411A0991 IN O
CP P09765411A0991 NNP O
Rit P09765411A0991 NNP O
were P09765411A0991 VBD O
both P09765411A0991 DT O
derived P09765411A0991 VBN O
from P09765411A0991 IN O
a P09765411A0991 DT O
bovine P09765411A0991 NN O
mRNA P09765411A0991 NN O
encoding P09765411A0991 VBG O
a P09765411A0991 DT O
hybrid P09765411A0991 JJ O
protein P09765411A0991 NN O
with P09765411A0991 IN O
the P09765411A0991 DT O
structure P09765411A0991 NN O
NH2-ubiquitin-S27a-COOH P09765411A0991 NNP O
. P09765411A0991 . O
. . O O

Structure P08086453T0000 NN O
, P08086453T0000 , O
promoter P08086453T0000 NN O
analysis P08086453T0000 NN O
and P08086453T0000 CC O
chromosomal P08086453T0000 JJ O
assignment P08086453T0000 NN O
of P08086453T0000 IN O
the P08086453T0000 DT O
human P08086453T0000 JJ I-UN
APEX P08086453T0000 NNP I-UN
gene P08086453T0000 NN I-UN
. P08086453T0000 . O
. . O O

MATERIAL P07776711A0295 NNP O
AND P07776711A0295 CC O
METHODS P07776711A0295 NNP O
: P07776711A0295 : O
Of P07776711A0295 IN O
the P07776711A0295 DT O
17 P07776711A0295 CD O
men P07776711A0295 NNS O
and P07776711A0295 CC O
17 P07776711A0295 CD O
women P07776711A0295 NNS O
, P07776711A0295 , O
who P07776711A0295 WP O
were P07776711A0295 VBD O
21 P07776711A0295 CD O
to P07776711A0295 TO O
80 P07776711A0295 CD O
years P07776711A0295 NNS O
of P07776711A0295 IN O
age P07776711A0295 NN O
, P07776711A0295 , O
27 P07776711A0295 CD O
had P07776711A0295 VBD O
hereditary P07776711A0295 JJ O
motor P07776711A0295 NN O
and P07776711A0295 CC O
sensory P07776711A0295 JJ O
neuropathy P07776711A0295 JJ O
type P07776711A0295 NN O
I P07776711A0295 PRP O
and P07776711A0295 CC O
7 P07776711A0295 CD O
had P07776711A0295 VBD O
acquired P07776711A0295 VBN O
demyelinating P07776711A0295 VBG O
polyneuropathy P07776711A0295 NN O
. P07776711A0295 . O
. . O O

Here P08676858A0309 RB O
, P08676858A0309 , O
the P08676858A0309 DT O
cloning P08676858A0309 NN O
and P08676858A0309 CC O
characterization P08676858A0309 NN O
of P08676858A0309 IN O
S-RNase P08676858A0309 NNP I-UN
genes P08676858A0309 NNS I-UN
from P08676858A0309 IN O
two P08676858A0309 CD O
species P08676858A0309 NNS O
of P08676858A0309 IN O
Rosaceae P08676858A0309 NNP O
, P08676858A0309 , O
apple P08676858A0309 NN O
( P08676858A0309 ( O
Malus P08676858A0309 NNP O
x P08676858A0309 NNP O
domestica P08676858A0309 NN O
) P08676858A0309 ) O
and P08676858A0309 CC O
Japanese P08676858A0309 JJ O
pear P08676858A0309 NN O
( P08676858A0309 ( O
Pyrus P08676858A0309 NNP O
serotina P08676858A0309 NN O
) P08676858A0309 ) O
is P08676858A0309 VBZ O
described P08676858A0309 VBN O
and P08676858A0309 CC O
these P08676858A0309 DT O
sequences P08676858A0309 NNS O
are P08676858A0309 VBP O
compared P08676858A0309 VBN O
with P08676858A0309 IN O
those P08676858A0309 DT O
of P08676858A0309 IN O
other P08676858A0309 JJ O
T2-type P08676858A0309 JJ I-UN
RNases P08676858A0309 NNS I-UN
. P08676858A0309 . O
. . O O

The P02532210A0000 DT O
adenovirus P02532210A0000 NN I-UN
E1A P02532210A0000 NNP I-UN
gene P02532210A0000 NN I-UN
encodes P02532210A0000 VBZ O
a P02532210A0000 DT O
protein P02532210A0000 NN O
that P02532210A0000 WDT O
transcriptionally P02532210A0000 RB O
activates P02532210A0000 VBZ O
viral P02532210A0000 JJ I-UN
early P02532210A0000 JJ I-UN
genes P02532210A0000 NNS I-UN
. P02532210A0000 . O
. . O O

We P07425838A0182 PRP O
report P07425838A0182 VBP O
a P07425838A0182 DT O
case P07425838A0182 NN O
of P07425838A0182 IN O
pheochromocytoma P07425838A0182 NN O
manifesting P07425838A0182 VBG O
during P07425838A0182 IN O
the P07425838A0182 DT O
third P07425838A0182 JJ O
trimester P07425838A0182 NN O
of P07425838A0182 IN O
pregnancy P07425838A0182 NN O
. P07425838A0182 . O
. . O O

Structure P09407090T0000 NN O
and P09407090T0000 CC O
localization P09407090T0000 NN O
of P09407090T0000 IN O
the P09407090T0000 DT O
human P09407090T0000 JJ O
gene P09407090T0000 NN O
encoding P09407090T0000 VBG O
SR-BI P09407090T0000 JJ I-UN
/ P09407090T0000 JJ O
CLA-1 P09407090T0000 NNP I-UN
. P09407090T0000 . O
. . O O

Dermatology P10670358A0143 NNP O
is P10670358A0143 VBZ O
no P10670358A0143 DT O
exception P10670358A0143 NN O
. P10670358A0143 . O
. . O O

For P10513756A0584 IN O
EPV P10513756A0584 NNP O
3 P10513756A0584 CD O
, P10513756A0584 , O
10 P10513756A0584 CD O
, P10513756A0584 , O
or P10513756A0584 CC O
40 P10513756A0584 CD O
, P10513756A0584 , O
the P10513756A0584 DT O
bias P10513756A0584 NN O
exceeded P10513756A0584 VBD O
25 P10513756A0584 CD O
% P10513756A0584 NN O
for P10513756A0584 IN O
7 P10513756A0584 CD O
, P10513756A0584 , O
3 P10513756A0584 CD O
, P10513756A0584 , O
and P10513756A0584 CC O
1 P10513756A0584 CD O
in P10513756A0584 IN O
the P10513756A0584 DT O
8-predictor P10513756A0584 JJ O
model P10513756A0584 NN O
respectively P10513756A0584 RB O
, P10513756A0584 , O
when P10513756A0584 WRB O
a P10513756A0584 DT O
conventional P10513756A0584 JJ O
selection P10513756A0584 NN O
criterion P10513756A0584 NN O
was P10513756A0584 VBD O
used P10513756A0584 VBN O
( P10513756A0584 ( O
alpha P10513756A0584 JJ O
= P10513756A0584 NNP O
0.05 P10513756A0584 CD O
) P10513756A0584 ) O
. P10513756A0584 . O
. . O O

Urinary P06749072A0116 JJ O
urate P06749072A0116 JJ O
excretion P06749072A0116 NN O
, P06749072A0116 , O
urate P06749072A0116 JJ O
clearance P06749072A0116 NN O
, P06749072A0116 , O
and P06749072A0116 CC O
fractional P06749072A0116 JJ O
excretion P06749072A0116 NN O
of P06749072A0116 IN O
urate P06749072A0116 JJ O
all P06749072A0116 DT O
increased P06749072A0116 VBN O
significantly P06749072A0116 RB O
during P06749072A0116 IN O
water P06749072A0116 NN O
immersion P06749072A0116 NN O
, P06749072A0116 , O
and P06749072A0116 CC O
decreased P06749072A0116 VBN O
in P06749072A0116 IN O
the P06749072A0116 DT O
hour P06749072A0116 NN O
following P06749072A0116 VBG O
water P06749072A0116 NN O
immersion P06749072A0116 NN O
. P06749072A0116 . O
. . O O

The P00747722A0486 DT O
data P00747722A0486 NN O
indicate P00747722A0486 NN O
a P00747722A0486 DT O
three-phase P00747722A0486 JJ O
reaction P00747722A0486 NN O
after P00747722A0486 IN O
B1 P00747722A0486 NNP O
injection P00747722A0486 NN O
: P00747722A0486 : O
Phase P00747722A0486 NN O
1 P00747722A0486 CD O
-- P00747722A0486 : O
shortly P00747722A0486 RB O
after P00747722A0486 IN O
injection P00747722A0486 NN O
there P00747722A0486 EX O
is P00747722A0486 VBZ O
a P00747722A0486 DT O
drop P00747722A0486 NN O
of P00747722A0486 IN O
all P00747722A0486 DT O
parameters P00747722A0486 NNS O
lasting P00747722A0486 VBG O
for P00747722A0486 IN O
30 P00747722A0486 CD O
sec P00747722A0486 NN O
. P00747722A0486 . O
. . O O

Psychological P03377891A0652 JJ O
disturbance P03377891A0652 NN O
was P03377891A0652 VBD O
greater P03377891A0652 JJR O
in P03377891A0652 IN O
the P03377891A0652 DT O
high P03377891A0652 JJ O
life P03377891A0652 NN O
stress P03377891A0652 NN O
group P03377891A0652 NN O
as P03377891A0652 IN O
indicated P03377891A0652 VBN O
by P03377891A0652 IN O
significant P03377891A0652 JJ O
elevations P03377891A0652 NNS O
on P03377891A0652 IN O
the P03377891A0652 DT O
global P03377891A0652 JJ O
severity P03377891A0652 NN O
index P03377891A0652 NN O
of P03377891A0652 IN O
the P03377891A0652 DT O
Symptom P03377891A0652 NNP O
Checklist-90 P03377891A0652 NNP O
and P03377891A0652 CC O
elevations P03377891A0652 NNS O
on P03377891A0652 IN O
somatization P03377891A0652 NN O
, P03377891A0652 , O
obsessive P03377891A0652 JJ O
compulsive P03377891A0652 NN O
, P03377891A0652 , O
interpersonal P03377891A0652 JJ O
sensitivity P03377891A0652 NN O
, P03377891A0652 , O
depression P03377891A0652 NN O
, P03377891A0652 , O
anxiety P03377891A0652 NN O
and P03377891A0652 CC O
psychoticism P03377891A0652 NN O
subscales P03377891A0652 NNS O
. P03377891A0652 . O
. . O O

Neither P09598205A0430 CC O
the P09598205A0430 DT O
reaction P09598205A0430 NN O
of P09598205A0430 IN O
monosaccharides P09598205A0430 NNS O
nor P09598205A0430 CC O
the P09598205A0430 DT O
disaccharides P09598205A0430 NNS O
with P09598205A0430 IN O
beta-alanine P09598205A0430 NN O
resulted P09598205A0430 VBN O
in P09598205A0430 IN O
the P09598205A0430 DT O
formation P09598205A0430 NN O
of P09598205A0430 IN O
maltol P09598205A0430 NN O
. P09598205A0430 . O
. . O O

We P11521191A0000 PRP O
have P11521191A0000 VBP O
previously P11521191A0000 RB O
shown P11521191A0000 VBN O
that P11521191A0000 IN O
the P11521191A0000 DT O
adenoviral P11521191A0000 JJ I-UN
12S P11521191A0000 CD I-UN
E1A P11521191A0000 NNP I-UN
protein P11521191A0000 NN I-UN
modulates P11521191A0000 VBZ O
the P11521191A0000 DT O
phosphorylation P11521191A0000 NN O
status P11521191A0000 NN O
of P11521191A0000 IN O
p130 P11521191A0000 NN I-UN
and P11521191A0000 CC O
p107 P11521191A0000 NN I-UN
without P11521191A0000 IN O
apparent P11521191A0000 JJ O
changes P11521191A0000 NNS O
in P11521191A0000 IN O
the P11521191A0000 DT O
cell P11521191A0000 NN O
cycle P11521191A0000 NN O
dependent P11521191A0000 JJ O
phosphorylation P11521191A0000 NN O
of P11521191A0000 IN O
the P11521191A0000 DT O
retinoblastoma P11521191A0000 NN I-UN
protein P11521191A0000 NN I-UN
. P11521191A0000 . O
. . O O

A P06258699T0000 DT O
double-blind P06258699T0000 JJ O
trial P06258699T0000 NN O
of P06258699T0000 IN O
half-strength P06258699T0000 JJ O
Polybactrin P06258699T0000 NNP O
Soluble P06258699T0000 NNP O
GU P06258699T0000 NNP O
bladder P06258699T0000 NN O
irrigation P06258699T0000 NN O
in P06258699T0000 IN O
cystoscopy P06258699T0000 NN O
. P06258699T0000 . O
. . O O

Efferent P00985110T0001 JJ O
projections P00985110T0001 NNS O
of P00985110T0001 IN O
the P00985110T0001 DT O
ventral P00985110T0001 JJ O
portion P00985110T0001 NN O
of P00985110T0001 IN O
the P00985110T0001 DT O
putamen P00985110T0001 NNS O
to P00985110T0001 TO O
the P00985110T0001 DT O
frontal P00985110T0001 NN O
, P00985110T0001 , O
parietal P00985110T0001 JJ O
and P00985110T0001 CC O
temporal P00985110T0001 JJ O
regions P00985110T0001 NNS O
of P00985110T0001 IN O
the P00985110T0001 DT O
cat P00985110T0001 JJ O
cerebral P00985110T0001 JJ O
cortex P00985110T0001 NN O
. P00985110T0001 . O
. . O O

( P09126487A1399 ( O
1994 P09126487A1399 CD O
, P09126487A1399 , O
Hum P09126487A1399 NNP O
. P09126487A1399 . O
. . O O

In P07927838A0000 IN O
eight P07927838A0000 CD O
groups P07927838A0000 NNS O
of P07927838A0000 IN O
subjects P07927838A0000 NNS O
operating P07927838A0000 VBG O
various P07927838A0000 JJ O
hand-held P07927838A0000 JJ O
vibrating P07927838A0000 NN O
tools P07927838A0000 NNS O
and P07927838A0000 CC O
aged P07927838A0000 VBN O
from P07927838A0000 IN O
30 P07927838A0000 CD O
to P07927838A0000 TO O
59 P07927838A0000 CD O
years P07927838A0000 NNS O
, P07927838A0000 , O
the P07927838A0000 DT O
prevalence P07927838A0000 NN O
rates P07927838A0000 NNS O
of P07927838A0000 IN O
vibration-induced P07927838A0000 JJ O
white P07927838A0000 JJ O
finger P07927838A0000 NN O
( P07927838A0000 ( O
VWF P07927838A0000 NNP O
) P07927838A0000 ) O
and P07927838A0000 CC O
numbness P07927838A0000 JJ O
, P07927838A0000 , O
pain P07927838A0000 NN O
, P07927838A0000 , O
or P07927838A0000 CC O
stiffness P07927838A0000 NN O
in P07927838A0000 IN O
the P07927838A0000 DT O
upper P07927838A0000 JJ O
and P07927838A0000 CC O
lower P07927838A0000 JJR O
extremities P07927838A0000 NNS O
were P07927838A0000 VBD O
investigated P07927838A0000 VBN O
. P07927838A0000 . O
. . O O

We P01901443A0297 PRP O
report P01901443A0297 VBP O
two P01901443A0297 CD O
patients P01901443A0297 NNS O
receiving P01901443A0297 VBG O
maintenance P01901443A0297 NN O
valproate P01901443A0297 NN O
, P01901443A0297 , O
one P01901443A0297 CD O
with P01901443A0297 IN O
resolving P01901443A0297 VBG O
acute P01901443A0297 JJ O
hepatitis P01901443A0297 NN O
C P01901443A0297 NNP O
and P01901443A0297 CC O
the P01901443A0297 DT O
other P01901443A0297 JJ O
with P01901443A0297 IN O
chronic P01901443A0297 JJ O
persistent P01901443A0297 NN O
hepatitis P01901443A0297 NN O
C P01901443A0297 NNP O
, P01901443A0297 , O
with P01901443A0297 IN O
incidental P01901443A0297 JJ O
microvesicular P01901443A0297 JJ O
steatosis P01901443A0297 NN O
demonstrated P01901443A0297 VBD O
on P01901443A0297 IN O
oil-red P01901443A0297 JJ O
O P01901443A0297 NNP O
stains P01901443A0297 NNS O
. P01901443A0297 . O
. . O O

However P08876167A0322 RB O
, P08876167A0322 , O
an P08876167A0322 DT O
intrinsic P08876167A0322 JJ O
DNA-binding P08876167A0322 JJ O
subunit P08876167A0322 NN O
for P08876167A0322 IN O
HiNF-D P08876167A0322 NNP I-UN
was P08876167A0322 VBD O
not P08876167A0322 RB O
identified P08876167A0322 VBN O
. P08876167A0322 . O
. . O O

Glucose P04656185T0000 JJ O
disappearance P04656185T0000 NN O
rate P04656185T0000 NN O
and P04656185T0000 CC O
changes P04656185T0000 NNS O
in P04656185T0000 IN O
plasma P04656185T0000 NN O
nutrients P04656185T0000 NNS O
after P04656185T0000 IN O
intravenouly P04656185T0000 RB O
injected P04656185T0000 JJ O
glucose P04656185T0000 NN O
in P04656185T0000 IN O
normoglycaemic P04656185T0000 JJ O
and P04656185T0000 CC O
hypoglycaemic P04656185T0000 JJ O
underweight P04656185T0000 JJ O
newborns P04656185T0000 NNS O
. P04656185T0000 . O
. . O O

RESULTS P08512728A0991 NN O
: P08512728A0991 : O
Statistically P08512728A0991 RB O
significant P08512728A0991 JJ O
differences P08512728A0991 NNS O
were P08512728A0991 VBD O
obtained P08512728A0991 VBN O
between P08512728A0991 IN O
group P08512728A0991 NN O
I P08512728A0991 PRP O
and P08512728A0991 CC O
II P08512728A0991 NNP O
concerning P08512728A0991 VBG O
the P08512728A0991 DT O
number P08512728A0991 NN O
of P08512728A0991 IN O
patients P08512728A0991 NNS O
in P08512728A0991 IN O
whom P08512728A0991 WP O
induced P08512728A0991 JJ O
atrial P08512728A0991 JJ O
fibrillation P08512728A0991 NN O
with P08512728A0991 IN O
conduction P08512728A0991 NN O
by P08512728A0991 IN O
the P08512728A0991 DT O
accessory P08512728A0991 JJ O
pathway P08512728A0991 NN O
and P08512728A0991 CC O
RR P08512728A0991 NNP O
< P08512728A0991 NNP O
or P08512728A0991 CC O
= P08512728A0991 $ O
250 P08512728A0991 CD O
msec P08512728A0991 NN O
was P08512728A0991 VBD O
found P08512728A0991 VBN O
( P08512728A0991 ( O
0 P08512728A0991 CD O
vs P08512728A0991 NN O
6 P08512728A0991 CD O
, P08512728A0991 , O
p P08512728A0991 NN O
= P08512728A0991 NNP O
0.0045 P08512728A0991 CD O
) P08512728A0991 ) O
. P08512728A0991 . O
. . O O

When P08106512A0522 WRB O
the P08106512A0522 DT O
promoter P08106512A0522 NN O
region P08106512A0522 NN O
was P08106512A0522 VBD O
linked P08106512A0522 VBN O
with P08106512A0522 IN O
a P08106512A0522 DT O
heterologous P08106512A0522 JJ O
reporter P08106512A0522 NN O
gene P08106512A0522 NN O
, P08106512A0522 , O
we P08106512A0522 PRP O
found P08106512A0522 VBD O
that P08106512A0522 IN O
the P08106512A0522 DT O
promoter P08106512A0522 NN O
region P08106512A0522 NN O
is P08106512A0522 VBZ O
inducible P08106512A0522 JJ O
by P08106512A0522 IN O
both P08106512A0522 DT O
interferons P08106512A0522 NNS I-UN
( P08106512A0522 ( O
interferon-alpha P08106512A0522 JJ I-UN
and P08106512A0522 CC I-UN
-gamma P08106512A0522 NN I-UN
) P08106512A0522 ) O
and P08106512A0522 CC O
interferon P08106512A0522 $ I-UN
regulatory P08106512A0522 JJ I-UN
factor P08106512A0522 NN I-UN
1 P08106512A0522 CD I-UN
. P08106512A0522 . O
. . O O

The P11266227A0295 DT O
flux P11266227A0295 JJ O
rates P11266227A0295 NNS O
of P11266227A0295 IN O
p-toluidine P11266227A0295 NN O
decreased P11266227A0295 VBN O
as P11266227A0295 IN O
the P11266227A0295 DT O
pH P11266227A0295 NN O
value P11266227A0295 NN O
in P11266227A0295 IN O
the P11266227A0295 DT O
donor P11266227A0295 JJ O
solution P11266227A0295 NN O
increased P11266227A0295 VBD O
. P11266227A0295 . O
. . O O

In P02957125A0601 IN O
nine P02957125A0601 CD O
patients P02957125A0601 NNS O
with P02957125A0601 IN O
renal P02957125A0601 JJ O
failure P02957125A0601 NN O
routine P02957125A0601 JJ O
haemodialysis P02957125A0601 NN O
was P02957125A0601 VBD O
accompanied P02957125A0601 VBN O
by P02957125A0601 IN O
a P02957125A0601 DT O
30 P02957125A0601 CD O
per P02957125A0601 IN O
cent P02957125A0601 NN O
reduction P02957125A0601 NN O
in P02957125A0601 IN O
plasma P02957125A0601 NN O
ANP P02957125A0601 NNP I-UN
concentration P02957125A0601 NN O
. P02957125A0601 . O
. . O O

In P09420275A1111 IN O
addition P09420275A1111 NN O
, P09420275A1111 , O
the P09420275A1111 DT O
affinities P09420275A1111 NNS O
of P09420275A1111 IN O
CBF2 P09420275A1111 NNP I-UN
for P09420275A1111 IN O
binding P09420275A1111 VBG O
to P09420275A1111 TO O
the P09420275A1111 DT O
LMP-1 P09420275A1111 NNP I-UN
, P09420275A1111 , O
LMP-2 P09420275A1111 NNP I-UN
, P09420275A1111 , O
and P09420275A1111 CC O
CD23 P09420275A1111 NNP I-UN
promoters P09420275A1111 NNS I-UN
were P09420275A1111 VBD O
also P09420275A1111 RB O
measured P09420275A1111 VBN O
. P09420275A1111 . O
. . O O

To P08917696A0485 TO O
analyze P08917696A0485 VB O
the P08917696A0485 DT O
mechanism P08917696A0485 NN O
of P08917696A0485 IN O
fos P08917696A0485 JJ I-UN
/ P08917696A0485 NNP O
jun P08917696A0485 NN I-UN
activation P08917696A0485 NN O
by P08917696A0485 IN O
TCDD P08917696A0485 NNP O
we P08917696A0485 PRP O
have P08917696A0485 VBP O
used P08917696A0485 VBN O
electrophoretic P08917696A0485 JJ O
mobility P08917696A0485 NN O
shift P08917696A0485 NN O
and P08917696A0485 CC O
transient P08917696A0485 JJ O
expression P08917696A0485 NN O
assays P08917696A0485 NNS O
of P08917696A0485 IN O
reporter P08917696A0485 NN O
gene P08917696A0485 NN O
constructs P08917696A0485 NNS O
containing P08917696A0485 VBG O
response P08917696A0485 NN O
elements P08917696A0485 NNS O
for P08917696A0485 IN O
12-O-tetradecanoyl-phorbol-13-acetate P08917696A0485 JJ O
( P08917696A0485 ( O
TRE P08917696A0485 NNP O
) P08917696A0485 ) O
, P08917696A0485 , O
serum P08917696A0485 FW O
( P08917696A0485 ( O
SRE P08917696A0485 NNP O
) P08917696A0485 ) O
, P08917696A0485 , O
cAMP P08917696A0485 NN O
( P08917696A0485 ( O
CRE P08917696A0485 NNP O
) P08917696A0485 ) O
, P08917696A0485 , O
and P08917696A0485 CC O
aromatic P08917696A0485 JJ O
hydrocarbons P08917696A0485 NNS O
( P08917696A0485 ( O
AhRE P08917696A0485 NNP O
) P08917696A0485 ) O
from P08917696A0485 IN O
the P08917696A0485 DT O
fos P08917696A0485 NN I-UN
and P08917696A0485 CC O
jun P08917696A0485 NN I-UN
genes P08917696A0485 NNS I-UN
fused P08917696A0485 VBD O
to P08917696A0485 TO O
the P08917696A0485 DT O
firefly P08917696A0485 NN I-UN
luciferase P08917696A0485 NN I-UN
gene P08917696A0485 NN I-UN
under P08917696A0485 IN O
the P08917696A0485 DT O
control P08917696A0485 NN O
of P08917696A0485 IN O
the P08917696A0485 DT O
SV40 P08917696A0485 NNP I-UN
minimal P08917696A0485 JJ I-UN
promoter P08917696A0485 NN I-UN
. P08917696A0485 . O
. . O O

Studies P05959588T0000 NNS O
on P05959588T0000 IN O
Coxsackie P05959588T0000 NNP O
B P05959588T0000 NNP O
Type P05959588T0000 NNP O
5 P05959588T0000 CD O
virus P05959588T0000 NN O
infections P05959588T0000 NNS O
. P05959588T0000 . O
. . O O

Simple P02283378T0000 JJ O
method P02283378T0000 NN O
for P02283378T0000 IN O
determination P02283378T0000 NN O
of P02283378T0000 IN O
the P02283378T0000 DT O
cephalosporin P02283378T0000 JJ O
DQ-2556 P02283378T0000 NNP O
in P02283378T0000 IN O
biological P02283378T0000 JJ O
fluids P02283378T0000 NNS O
by P02283378T0000 IN O
high-performance P02283378T0000 NN O
liquid P02283378T0000 NN O
chromatography P02283378T0000 NN O
. P02283378T0000 . O
. . O O

Despite P10102627A0217 IN O
this P10102627A0217 DT O
DNA P10102627A0217 NNP O
binding P10102627A0217 NN O
activity P10102627A0217 NN O
, P10102627A0217 , O
AP-1 P10102627A0217 NNP I-UN
reporter P10102627A0217 NN I-UN
activity P10102627A0217 NN O
was P10102627A0217 VBD O
suppressed P10102627A0217 VBN O
in P10102627A0217 IN O
these P10102627A0217 DT O
cells P10102627A0217 NNS O
. P10102627A0217 . O
. . O O

Petko P02123293A0227 NNP O
, P02123293A0227 , O
and P02123293A0227 CC O
S P02123293A0227 NNP O
. P02123293A0227 . O
. . O O

Phosphorylation P09873060A0901 NN O
analyses P09873060A0901 NNS O
indicated P09873060A0901 VBD O
that P09873060A0901 IN O
inhibition P09873060A0901 NN O
of P09873060A0901 IN O
ERK-1 P09873060A0901 NNP I-UN
/ P09873060A0901 NNP I-UN
2 P09873060A0901 CD I-UN
decreased P09873060A0901 VBD O
okadaic P09873060A0901 JJ O
acid-elevated P09873060A0901 JJ O
phosphorylation P09873060A0901 NN O
of P09873060A0901 IN O
JunD P09873060A0901 NNP I-UN
and P09873060A0901 CC O
FosB P09873060A0901 NNP I-UN
. P09873060A0901 . O
. . O O

Variability P00129659T0000 NN O
within P00129659T0000 IN O
Down P00129659T0000 NNP O
's P00129659T0000 POS O
syndrome P00129659T0000 NN O
( P00129659T0000 ( O
trisomy-21 P00129659T0000 JJ O
) P00129659T0000 ) O
: P00129659T0000 : O
empirically P00129659T0000 RB O
observed P00129659T0000 VBD O
sex P00129659T0000 NN O
differences P00129659T0000 NNS O
in P00129659T0000 IN O
IQs P00129659T0000 NNP O
. P00129659T0000 . O
. . O O

Stroop P08223823T0000 JJ O
interference P08223823T0000 NN O
: P08223823T0000 : O
aging P08223823T0000 JJ O
effects P08223823T0000 NNS O
assessed P08223823T0000 VBN O
with P08223823T0000 IN O
the P08223823T0000 DT O
Stroop P08223823T0000 NNP O
Color-Word P08223823T0000 NNP O
Test P08223823T0000 NNP O
. P08223823T0000 . O
. . O O

There P08703959A0659 EX O
was P08703959A0659 VBD O
a P08703959A0659 DT O
general P08703959A0659 JJ O
broadening P08703959A0659 NN O
of P08703959A0659 IN O
proton P08703959A0659 NN O
resonances P08703959A0659 NNS O
for P08703959A0659 IN O
a P08703959A0659 DT O
three-nucleotide P08703959A0659 JJ O
segment P08703959A0659 NN O
centered P08703959A0659 VBD O
about P08703959A0659 IN O
the P08703959A0659 DT O
lesion P08703959A0659 NN O
site P08703959A0659 NN O
which P08703959A0659 WDT O
resulted P08703959A0659 VBD O
in P08703959A0659 IN O
a P08703959A0659 DT O
tentative P08703959A0659 JJ O
assignment P08703959A0659 NN O
for P08703959A0659 IN O
the P08703959A0659 DT O
sugar P08703959A0659 NN O
protons P08703959A0659 NNS O
of P08703959A0659 IN O
the P08703959A0659 DT O
C7 P08703959A0659 NNP O
residue P08703959A0659 NN O
in P08703959A0659 IN O
the P08703959A0659 DT O
spectrum P08703959A0659 NN O
of P08703959A0659 IN O
the P08703959A0659 DT O
adduct P08703959A0659 NN O
duplex P08703959A0659 NN O
. P08703959A0659 . O
. . O O

No P08622030A0667 DT O
significant P08622030A0667 JJ O
differences P08622030A0667 NNS O
existed P08622030A0667 VBD O
between P08622030A0667 IN O
the P08622030A0667 DT O
two P08622030A0667 CD O
age P08622030A0667 NN O
groups P08622030A0667 NNS O
in P08622030A0667 IN O
baseline P08622030A0667 NN O
characteristics P08622030A0667 NNS O
, P08622030A0667 , O
including P08622030A0667 VBG O
treatment P08622030A0667 NN O
protocol P08622030A0667 NN O
, P08622030A0667 , O
performance P08622030A0667 NN O
status P08622030A0667 NN O
, P08622030A0667 , O
and P08622030A0667 CC O
serum P08622030A0667 JJ I-UN
lactate P08622030A0667 NN I-UN
dehydrogenase P08622030A0667 NN I-UN
( P08622030A0667 ( O
LDH P08622030A0667 NNP I-UN
) P08622030A0667 ) O
level P08622030A0667 NN O
. P08622030A0667 . O
. . O O

When P11572467A0658 WRB O
the P11572467A0658 DT O
blood P11572467A0658 NN O
clot P11572467A0658 NN O
is P11572467A0658 VBZ O
formed P11572467A0658 VBN O
in P11572467A0658 IN O
the P11572467A0658 DT O
vitreous P11572467A0658 JJ O
cavity P11572467A0658 NN O
, P11572467A0658 , O
intravitreal P11572467A0658 JJ O
injection P11572467A0658 NN O
of P11572467A0658 IN O
t-PA P11572467A0658 NN I-UN
can P11572467A0658 MD O
convert P11572467A0658 VB O
plasminogen P11572467A0658 NN I-UN
to P11572467A0658 TO O
plasmin P11572467A0658 VB I-UN
and P11572467A0658 CC O
remove P11572467A0658 VB O
the P11572467A0658 DT O
clot P11572467A0658 NN O
. P11572467A0658 . O
. . O O

The P02745444A0391 DT O
transcription P02745444A0391 NN O
initiation P02745444A0391 NN O
site P02745444A0391 NN O
was P02745444A0391 VBD O
determined P02745444A0391 VBN O
by P02745444A0391 IN O
S1 P02745444A0391 NNP I-UN
nuclease P02745444A0391 NN I-UN
mapping P02745444A0391 NN O
. P02745444A0391 . O
. . O O

The P08322117A1019 DT O
two P08322117A1019 CD O
methods P08322117A1019 NNS O
identify P08322117A1019 VBP O
the P08322117A1019 DT O
same P08322117A1019 JJ O
patients P08322117A1019 NNS O
only P08322117A1019 RB O
if P08322117A1019 IN O
micturitional P08322117A1019 JJ O
pressures P08322117A1019 NNS O
are P08322117A1019 VBP O
normal P08322117A1019 JJ O
( P08322117A1019 ( O
40 P08322117A1019 CD O
to P08322117A1019 TO O
60 P08322117A1019 CD O
cmH2O P08322117A1019 NN O
) P08322117A1019 ) O
to P08322117A1019 TO O
high P08322117A1019 JJ O
( P08322117A1019 ( O
over P08322117A1019 IN O
60 P08322117A1019 CD O
cmH2O P08322117A1019 NN O
) P08322117A1019 ) O
and P08322117A1019 CC O
the P08322117A1019 DT O
Sussett P08322117A1019 NNP O
formula P08322117A1019 NN O
is P08322117A1019 VBZ O
used P08322117A1019 VBN O
with P08322117A1019 IN O
a P08322117A1019 DT O
higher P08322117A1019 JJR O
( P08322117A1019 ( O
95th P08322117A1019 CD O
centile P08322117A1019 NN O
) P08322117A1019 ) O
cutoff P08322117A1019 NN O
. P08322117A1019 . O
. . O O

Several P08794869A0274 JJ O
lines P08794869A0274 NNS O
of P08794869A0274 IN O
evidence P08794869A0274 NN O
presented P08794869A0274 VBN O
here P08794869A0274 RB O
suggest P08794869A0274 VBP O
that P08794869A0274 IN O
PKC-zeta P08794869A0274 NNP I-UN
plays P08794869A0274 VBZ O
a P08794869A0274 DT O
role P08794869A0274 NN O
in P08794869A0274 IN O
alpha P08794869A0274 JJ I-UN
2 P08794869A0274 CD I-UN
integrin P08794869A0274 JJ I-UN
gene P08794869A0274 NN I-UN
expression P08794869A0274 NN O
. P08794869A0274 . O
. . O O

This P08913186A0431 DT O
report P08913186A0431 NN O
provides P08913186A0431 VBZ O
further P08913186A0431 JJ O
evidence P08913186A0431 NN O
for P08913186A0431 IN O
the P08913186A0431 DT O
riMLF P08913186A0431 NN O
in P08913186A0431 IN O
the P08913186A0431 DT O
control P08913186A0431 NN O
of P08913186A0431 IN O
downgaze P08913186A0431 NN O
, P08913186A0431 , O
and P08913186A0431 CC O
a P08913186A0431 DT O
synkinesis P08913186A0431 NN O
is P08913186A0431 VBZ O
postulated P08913186A0431 VBN O
for P08913186A0431 IN O
the P08913186A0431 DT O
development P08913186A0431 NN O
of P08913186A0431 IN O
the P08913186A0431 DT O
convergence P08913186A0431 NN O
retraction P08913186A0431 NN O
nystagmus P08913186A0431 NN O
. P08913186A0431 . O
. . O O

Visual P07405701T0000 NNP O
averaged P07405701T0000 VBD O
evoked P07405701T0000 JJ O
responses P07405701T0000 NNS O
and P07405701T0000 CC O
platelet P07405701T0000 NN I-UN
monoamine P07405701T0000 NN I-UN
oxidase P07405701T0000 NN I-UN
in P07405701T0000 IN O
patients P07405701T0000 NNS O
suffering P07405701T0000 VBG O
from P07405701T0000 IN O
alcoholism P07405701T0000 NN O
. P07405701T0000 . O
. . O O

A P02044785A0000 DT O
single P02044785A0000 JJ O
case P02044785A0000 NN O
of P02044785A0000 IN O
an P02044785A0000 DT O
adenocarcinoma P02044785A0000 NN O
, P02044785A0000 , O
arising P02044785A0000 VBG O
in P02044785A0000 IN O
a P02044785A0000 DT O
retroperitoneal P02044785A0000 NN O
enterogenous P02044785A0000 JJ O
cyst P02044785A0000 NN O
and P02044785A0000 CC O
which P02044785A0000 WDT O
presented P02044785A0000 VBD O
as P02044785A0000 IN O
a P02044785A0000 DT O
left P02044785A0000 JJ O
renal P02044785A0000 JJ O
cyst P02044785A0000 NN O
, P02044785A0000 , O
is P02044785A0000 VBZ O
reported P02044785A0000 VBN O
. P02044785A0000 . O
. . O O

We P09837913A0419 PRP O
have P09837913A0419 VBP O
identified P09837913A0419 VBN O
two P09837913A0419 CD O
overlapping P09837913A0419 VBG O
expressed P09837913A0419 VBN O
sequence P09837913A0419 NN O
tag P09837913A0419 NN O
clones P09837913A0419 NNS O
, P09837913A0419 , O
which P09837913A0419 WDT O
contain P09837913A0419 VBP O
the P09837913A0419 DT O
missing P09837913A0419 VBG O
4.4-kb P09837913A0419 JJ O
3'-UTR P09837913A0419 CD O
of P09837913A0419 IN O
the P09837913A0419 DT O
human P09837913A0419 JJ I-UN
D2 P09837913A0419 NNP I-UN
( P09837913A0419 ( O
hD2 P09837913A0419 NN I-UN
) P09837913A0419 ) O
cDNA P09837913A0419 NN O
. P09837913A0419 . O
. . O O

The P04239041T0045 DT O
effect P04239041T0045 NN O
of P04239041T0045 IN O
anticonvulsants P04239041T0045 NNS O
on P04239041T0045 IN O
sodium-potassium-activated P04239041T0045 JJ I-UN
ATPase P04239041T0045 NNP I-UN
, P04239041T0045 , O
sodium P04239041T0045 NN O
, P04239041T0045 , O
and P04239041T0045 CC O
potassim P04239041T0045 NN O
in P04239041T0045 IN O
cortex P04239041T0045 NN O
. P04239041T0045 . O
. . O O

Transcription P09643546A0436 NN O
initiation P09643546A0436 NN O
occurred P09643546A0436 VBD O
predominantly P09643546A0436 RB O
at P09643546A0436 IN O
the P09643546A0436 DT O
putative P09643546A0436 JJ O
sigmaA-dependent P09643546A0436 JJ I-UN
promoter P09643546A0436 NN I-UN
in P09643546A0436 IN O
exponentially P09643546A0436 RB O
growing P09643546A0436 VBG O
cells P09643546A0436 NNS O
and P09643546A0436 CC O
was P09643546A0436 VBD O
induced P09643546A0436 VBN O
under P09643546A0436 IN O
stress P09643546A0436 NN O
conditions P09643546A0436 NNS O
. P09643546A0436 . O
. . O O

Ten-year P05012220T0000 JJ O
experience P05012220T0000 NN O
with P05012220T0000 IN O
one-stage P05012220T0000 JJ O
proctocolectomy P05012220T0000 NN O
and P05012220T0000 CC O
anal P05012220T0000 JJ O
ileostomy P05012220T0000 NN O
. P05012220T0000 . O
. . O O

Translation P03023067A0779 NN O
of P03023067A0779 IN O
specific P03023067A0779 JJ O
cellular P03023067A0779 JJ O
genes P03023067A0779 NNS O
from P03023067A0779 IN O
the P03023067A0779 DT O
chimeric P03023067A0779 JJ O
viral-cellular P03023067A0779 JJ O
transcripts P03023067A0779 NNS O
seems P03023067A0779 VBZ O
to P03023067A0779 TO O
be P03023067A0779 VB O
unlikely P03023067A0779 JJ O
. P03023067A0779 . O
. . O O

Administration P08943928A1137 NN O
of P08943928A1137 IN O
a P08943928A1137 DT O
second P08943928A1137 JJ O
dose P08943928A1137 NN O
of P08943928A1137 IN O
vaccine P08943928A1137 NN O
during P08943928A1137 IN O
the P08943928A1137 DT O
outbreak P08943928A1137 NN O
was P08943928A1137 VBD O
not P08943928A1137 RB O
protective P08943928A1137 JJ O
. P08943928A1137 . O
. . O O

The P07744954A0418 DT O
protein P07744954A0418 NN O
is P07744954A0418 VBZ O
composed P07744954A0418 VBN O
of P07744954A0418 IN O
a P07744954A0418 DT O
central P07744954A0418 JJ O
alpha-helical P07744954A0418 JJ O
portion P07744954A0418 NN O
with P07744954A0418 IN O
globular P07744954A0418 JJ O
domains P07744954A0418 NNS O
at P07744954A0418 IN O
both P07744954A0418 DT O
NH2 P07744954A0418 NNP O
and P07744954A0418 CC O
COOH P07744954A0418 NNP O
termini P07744954A0418 NN O
, P07744954A0418 , O
and P07744954A0418 CC O
the P07744954A0418 DT O
epitope P07744954A0418 NN O
to P07744954A0418 TO O
the P07744954A0418 DT O
monoclonal P07744954A0418 JJ O
antibody P07744954A0418 NN O
resides P07744954A0418 NNS O
in P07744954A0418 IN O
the P07744954A0418 DT O
central P07744954A0418 JJ O
alpha-helical P07744954A0418 JJ O
stalk P07744954A0418 NN O
. P07744954A0418 . O
. . O O

The P09199286A0086 DT O
coding P09199286A0086 VBG O
region P09199286A0086 NN O
of P09199286A0086 IN O
mkh1 P09199286A0086 NN I-UN
is P09199286A0086 VBZ O
contained P09199286A0086 VBN O
within P09199286A0086 IN O
a P09199286A0086 DT O
single P09199286A0086 JJ O
exon P09199286A0086 NN O
encoding P09199286A0086 VBG O
a P09199286A0086 DT O
1,116-amino-acid P09199286A0086 JJ O
protein P09199286A0086 NN O
. P09199286A0086 . O
. . O O

In P10811079A1277 IN O
the P10811079A1277 DT O
SPP2 P10811079A1277 NNP O
screening P10811079A1277 VBG O
test P10811079A1277 NN O
, P10811079A1277 , O
a P10811079A1277 DT O
few P10811079A1277 JJ O
plates P10811079A1277 NNS O
were P10811079A1277 VBD O
not P10811079A1277 RB O
seen P10811079A1277 VBN O
in P10811079A1277 IN O
both P10811079A1277 DT O
groups P10811079A1277 NNS O
. P10811079A1277 . O
. . O O

Nursing P00587791T0054 NN O
of P00587791T0054 IN O
patients P00587791T0054 NNS O
with P00587791T0054 IN O
gynecological P00587791T0054 JJ O
diseases P00587791T0054 NNS O
. P00587791T0054 . O
. . O O

In P07948129A0297 IN O
these P07948129A0297 DT O
vectors P07948129A0297 NNS O
the P07948129A0297 DT O
chimeric P07948129A0297 NN I-UN
long P07948129A0297 JJ I-UN
terminal P07948129A0297 JJ I-UN
repeat P07948129A0297 NN I-UN
( P07948129A0297 ( O
chLTR P07948129A0297 NN I-UN
) P07948129A0297 ) O
drives P07948129A0297 VBZ O
the P07948129A0297 DT O
expression P07948129A0297 NN O
of P07948129A0297 IN O
the P07948129A0297 DT O
chloramphenicol P07948129A0297 NN I-UN
acetyl P07948129A0297 NN I-UN
transferase P07948129A0297 NN I-UN
( P07948129A0297 ( O
CAT P07948129A0297 NNP I-UN
) P07948129A0297 ) O
reporter P07948129A0297 NN O
gene P07948129A0297 NN O
that P07948129A0297 WDT O
is P07948129A0297 VBZ O
followed P07948129A0297 VBN O
by P07948129A0297 IN O
an P07948129A0297 DT O
internal P07948129A0297 JJ O
SV40 P07948129A0297 NNP I-UN
virus P07948129A0297 NN I-UN
early P07948129A0297 JJ I-UN
region P07948129A0297 NN I-UN
promoter P07948129A0297 NN I-UN
linked P07948129A0297 VBN O
to P07948129A0297 TO O
the P07948129A0297 DT O
neomycin P07948129A0297 JJ I-UN
phosphotransferase P07948129A0297 NN I-UN
II P07948129A0297 NNP I-UN
( P07948129A0297 ( O
NEO P07948129A0297 NNP I-UN
) P07948129A0297 ) O
gene P07948129A0297 NN O
. P07948129A0297 . O
. . O O

Four P01459921A0000 CD O
ruminally P01459921A0000 RB O
and P01459921A0000 CC O
duodenally P01459921A0000 RB O
cannulated P01459921A0000 VBN O
Hampshire P01459921A0000 NNP O
wethers P01459921A0000 NNS O
were P01459921A0000 VBD O
used P01459921A0000 VBN O
in P01459921A0000 IN O
a P01459921A0000 DT O
4 P01459921A0000 CD O
x P01459921A0000 NN O
4 P01459921A0000 CD O
Latin P01459921A0000 NNP O
square P01459921A0000 JJ O
experiment P01459921A0000 NN O
to P01459921A0000 TO O
determine P01459921A0000 VB O
whether P01459921A0000 IN O
linoleoyl P01459921A0000 JJ O
methionine P01459921A0000 NN O
and P01459921A0000 CC O
calcium P01459921A0000 NN O
linoleate P01459921A0000 NN O
would P01459921A0000 MD O
increase P01459921A0000 VB O
duodenal P01459921A0000 JJ O
flow P01459921A0000 NN O
of P01459921A0000 IN O
unsaturated P01459921A0000 JJ O
fatty P01459921A0000 JJ O
acids P01459921A0000 NNS O
( P01459921A0000 ( O
C18:2 P01459921A0000 NNP O
+ P01459921A0000 NNP O
cis P01459921A0000 NN O
C18:1 P01459921A0000 NNP O
) P01459921A0000 ) O
. P01459921A0000 . O
. . O O

A P10497199A0559 DT O
genetic P10497199A0559 JJ O
screen P10497199A0559 NN O
in P10497199A0559 IN O
yeast P10497199A0559 NN O
has P10497199A0559 VBZ O
allowed P10497199A0559 VBN O
us P10497199A0559 PRP O
to P10497199A0559 TO O
identify P10497199A0559 VB O
a P10497199A0559 DT O
novel P10497199A0559 JJ O
transcriptional P10497199A0559 JJ O
factor P10497199A0559 NN O
binding P10497199A0559 VBG O
to P10497199A0559 TO O
the P10497199A0559 DT O
GlRE P10497199A0559 NNP O
, P10497199A0559 , O
i.e P10497199A0559 NN O
. P10497199A0559 . O
the P10497199A0559 DT O
chicken P10497199A0559 NN I-UN
ovalbumin P10497199A0559 JJ I-UN
upstream P10497199A0559 JJ I-UN
promoter-transcription P10497199A0559 NN I-UN
factor P10497199A0559 NN I-UN
II P10497199A0559 NNP I-UN
( P10497199A0559 ( O
COUP-TFII P10497199A0559 NNP I-UN
) P10497199A0559 ) O
. P10497199A0559 . O
. . O O

A P02069738A0000 DT O
method P02069738A0000 NN O
for P02069738A0000 IN O
establishing P02069738A0000 VBG O
stimulus P02069738A0000 JJ O
control P02069738A0000 NN O
of P02069738A0000 IN O
ethanol P02069738A0000 NN O
responding P02069738A0000 NN O
was P02069738A0000 VBD O
developed P02069738A0000 VBN O
. P02069738A0000 . O
. . O O

The P03722016A0797 DT O
FFA P03722016A0797 NNP O
levels P03722016A0797 NNS O
were P03722016A0797 VBD O
not P03722016A0797 RB O
affected P03722016A0797 VBN O
( P03722016A0797 ( O
P P03722016A0797 NNP O
greater P03722016A0797 JJR O
than P03722016A0797 IN O
.1 P03722016A0797 NN O
) P03722016A0797 ) O
by P03722016A0797 IN O
meal P03722016A0797 NN O
interval P03722016A0797 NN O
. P03722016A0797 . O
. . O O

BACKGROUND P10391277A0000 NN O
: P10391277A0000 : O
The P10391277A0000 DT O
MAZE-III P10391277A0000 NNP O
is P10391277A0000 VBZ O
the P10391277A0000 DT O
surgical P10391277A0000 JJ O
treatment P10391277A0000 NN O
of P10391277A0000 IN O
choice P10391277A0000 NN O
for P10391277A0000 IN O
medically P10391277A0000 RB O
refractory P10391277A0000 JJ O
atrial P10391277A0000 JJ O
fibrillation P10391277A0000 NN O
. P10391277A0000 . O
. . O O

The P07565723A0200 DT O
kinase P07565723A0200 NN O
is P07565723A0200 VBZ O
essential P07565723A0200 JJ O
in P07565723A0200 IN O
vivo P07565723A0200 NN O
for P07565723A0200 IN O
normal P07565723A0200 JJ O
phosphorylation P07565723A0200 NN O
of P07565723A0200 IN O
the P07565723A0200 DT O
CTD P07565723A0200 NNP O
and P07565723A0200 CC O
for P07565723A0200 IN O
normal P07565723A0200 JJ O
growth P07565723A0200 NN O
and P07565723A0200 CC O
differentiation P07565723A0200 NN O
. P07565723A0200 . O
. . O O

The P00870859A0121 DT O
data P00870859A0121 NNS O
normally P00870859A0121 RB O
available P00870859A0121 JJ O
are P00870859A0121 VBP O
insufficient P00870859A0121 JJ O
and P00870859A0121 CC O
take P00870859A0121 VB O
no P00870859A0121 DT O
account P00870859A0121 NN O
of P00870859A0121 IN O
the P00870859A0121 DT O
direction P00870859A0121 NN O
of P00870859A0121 IN O
recirculation P00870859A0121 NN O
, P00870859A0121 , O
which P00870859A0121 WDT O
may P00870859A0121 MD O
be P00870859A0121 VB O
a P00870859A0121 DT O
determining P00870859A0121 JJ O
factor P00870859A0121 NN O
. P00870859A0121 . O
. . O O

The P10824485A0393 DT O
patients P10824485A0393 NNS O
who P10824485A0393 WP O
presented P10824485A0393 VBD O
with P10824485A0393 IN O
mucocutaneous P10824485A0393 JJ O
disease P10824485A0393 NN O
also P10824485A0393 RB O
had P10824485A0393 VBD O
low P10824485A0393 JJ O
CD4+ P10824485A0393 NNP I-UN
T P10824485A0393 NNP O
lymphocyte P10824485A0393 NN O
counts P10824485A0393 NNS O
, P10824485A0393 , O
and P10824485A0393 CC O
most P10824485A0393 JJS O
of P10824485A0393 IN O
them P10824485A0393 PRP O
had P10824485A0393 VBD O
AIDS P10824485A0393 NNP O
defining P10824485A0393 NN O
illnesses P10824485A0393 NNS O
. P10824485A0393 . O
. . O O

The P02347102A0000 DT O
pseudolymphoma P02347102A0000 NN O
syndrome P02347102A0000 NN O
is P02347102A0000 VBZ O
a P02347102A0000 DT O
reversible P02347102A0000 JJ O
reactive P02347102A0000 JJ O
condition P02347102A0000 NN O
consisting P02347102A0000 VBG O
of P02347102A0000 IN O
fever P02347102A0000 NN O
, P02347102A0000 , O
lymphadenopathy P02347102A0000 JJ O
and P02347102A0000 CC O
generalized P02347102A0000 JJ O
rash P02347102A0000 NN O
. P02347102A0000 . O
. . O O

Neither P06098719A0369 DT O
side P06098719A0369 NN O
effect P06098719A0369 NN O
nor P06098719A0369 CC O
abnormal P06098719A0369 JJ O
laboratory P06098719A0369 NN O
findings P06098719A0369 NNS O
due P06098719A0369 JJ O
to P06098719A0369 TO O
this P06098719A0369 DT O
drug P06098719A0369 NN O
were P06098719A0369 VBD O
observed P06098719A0369 VBN O
. P06098719A0369 . O
. . O O

Escalation P11038042A0948 NN O
to P11038042A0948 TO O
180 P11038042A0948 CD O
mg P11038042A0948 NNS O
/ P11038042A0948 JJ O
m2 P11038042A0948 NN O
was P11038042A0948 VBD O
to P11038042A0948 TO O
be P11038042A0948 VB O
carried P11038042A0948 VBN O
out P11038042A0948 IN O
if P11038042A0948 IN O
white P11038042A0948 JJ O
blood P11038042A0948 NN O
cell P11038042A0948 NN O
nadir P11038042A0948 RB O
count P11038042A0948 NN O
was P11038042A0948 VBD O
> P11038042A0948 JJ O
2.0 P11038042A0948 CD O
x P11038042A0948 JJ O
10 P11038042A0948 CD O
( P11038042A0948 ( O
9 P11038042A0948 CD O
) P11038042A0948 ) O
/ P11038042A0948 NN O
l P11038042A0948 NN O
and P11038042A0948 CC O
platelet P11038042A0948 NN O
nadir P11038042A0948 NN O
count P11038042A0948 NN O
was P11038042A0948 VBD O
> P11038042A0948 JJ O
75 P11038042A0948 CD O
x P11038042A0948 JJ O
10 P11038042A0948 CD O
( P11038042A0948 ( O
9 P11038042A0948 CD O
) P11038042A0948 ) O
/ P11038042A0948 NN O
l P11038042A0948 NN O
. P11038042A0948 . O
. . O O

Effects P11082587X0000 NNS O
of P11082587X0000 IN O
spatial P11082587X0000 JJ O
and P11082587X0000 CC O
temporal P11082587X0000 JJ O
smoothing P11082587X0000 NN O
on P11082587X0000 IN O
stimulated P11082587X0000 JJ O
brillouin P11082587X0000 NN O
scattering P11082587X0000 NN O
in P11082587X0000 IN O
the P11082587X0000 DT O
independent-hot-spot P11082587X0000 JJ O
model P11082587X0000 NN O
limit P11082587X0000 VBD O
The P11082587X0000 DT O
influence P11082587X0000 NN O
of P11082587X0000 IN O
laser P11082587X0000 NN O
beam P11082587X0000 NN O
smoothing P11082587X0000 VBG O
on P11082587X0000 IN O
stimulated P11082587X0000 VBN O
Brillouin P11082587X0000 NNP O
backscattering P11082587X0000 NN O
( P11082587X0000 ( O
SBBS P11082587X0000 NNP O
) P11082587X0000 ) O
is P11082587X0000 VBZ O
studied P11082587X0000 VBN O
analytically P11082587X0000 RB O
in P11082587X0000 IN O
the P11082587X0000 DT O
limit P11082587X0000 NN O
of P11082587X0000 IN O
the P11082587X0000 DT O
independent P11082587X0000 JJ O
hot P11082587X0000 JJ O
spot P11082587X0000 NN O
model P11082587X0000 NN O
. P11082587X0000 . O
. . O O

We P09474648A0298 PRP O
analyzed P09474648A0298 VBD O
the P09474648A0298 DT O
P-SAECG P09474648A0298 NNP O
in P09474648A0298 IN O
the P09474648A0298 DT O
time P09474648A0298 NN O
and P09474648A0298 CC O
frequency P09474648A0298 NN O
domain P09474648A0298 NN O
in P09474648A0298 IN O
23 P09474648A0298 CD O
patients P09474648A0298 NNS O
with P09474648A0298 IN O
Paf P09474648A0298 NNP O
and P09474648A0298 CC O
19 P09474648A0298 CD O
controls P09474648A0298 NNS O
. P09474648A0298 . O
. . O O

Vascular P08901658A0498 JJ O
responses P08901658A0498 NNS O
to P08901658A0498 TO O
reactive P08901658A0498 VB O
hyperemia P08901658A0498 NN O
( P08901658A0498 ( O
with P08901658A0498 IN O
flow P08901658A0498 NN O
increase P08901658A0498 NN O
leading P08901658A0498 VBG O
to P08901658A0498 TO O
endothelium-dependent P08901658A0498 JJ O
dilation P08901658A0498 NN O
) P08901658A0498 ) O
and P08901658A0498 CC O
to P08901658A0498 TO O
sublingual P08901658A0498 VB O
glyceryl P08901658A0498 NN O
trinitrate P08901658A0498 NN O
( P08901658A0498 ( O
GTN P08901658A0498 NNP O
; P08901658A0498 : O
endothelium-independent P08901658A0498 JJ O
dilation P08901658A0498 NN O
) P08901658A0498 ) O
were P08901658A0498 VBD O
recorded P08901658A0498 VBN O
. P08901658A0498 . O
. . O O

Doxorubicin P03995513T0000 NNP O
, P03995513T0000 , O
dacarbazine P03995513T0000 NN O
, P03995513T0000 , O
vincristine P03995513T0000 NN O
, P03995513T0000 , O
and P03995513T0000 CC O
cyclophosphamide P03995513T0000 NN O
in P03995513T0000 IN O
the P03995513T0000 DT O
treatment P03995513T0000 NN O
of P03995513T0000 IN O
advanced P03995513T0000 JJ O
gastrointestinal P03995513T0000 JJ O
leiomyosarcoma P03995513T0000 NN O
. P03995513T0000 . O
. . O O

The P07742550A0407 DT O
cases P07742550A0407 NNS O
included P07742550A0407 VBD O
35 P07742550A0407 CD O
de P07742550A0407 IN O
novo P07742550A0407 FW O
diffuse P07742550A0407 NN O
aggressive P07742550A0407 JJ O
lymphomas P07742550A0407 NN O
( P07742550A0407 ( O
DAL P07742550A0407 NNP O
; P07742550A0407 : O
19 P07742550A0407 CD O
large-cell P07742550A0407 NN O
, P07742550A0407 , O
4 P07742550A0407 CD O
mixed-cell P07742550A0407 NN O
, P07742550A0407 , O
and P07742550A0407 CC O
12 P07742550A0407 CD O
large-cell P07742550A0407 JJ O
immunoblastic P07742550A0407 NN O
) P07742550A0407 ) O
, P07742550A0407 , O
52 P07742550A0407 CD O
transformed P07742550A0407 VBD O
aggressive P07742550A0407 JJ O
lymphomas P07742550A0407 NN O
derived P07742550A0407 VBN O
from P07742550A0407 IN O
follicular P07742550A0407 JJ O
lymphomas P07742550A0407 NN O
( P07742550A0407 ( O
TFL P07742550A0407 NNP O
) P07742550A0407 ) O
, P07742550A0407 , O
42 P07742550A0407 CD O
indolent P07742550A0407 NN O
follicular P07742550A0407 JJ O
lymphomas P07742550A0407 NN O
( P07742550A0407 ( O
FL P07742550A0407 NNP O
) P07742550A0407 ) O
, P07742550A0407 , O
14 P07742550A0407 CD O
mantle P07742550A0407 NN O
cell P07742550A0407 NN O
lymphomas P07742550A0407 NN O
( P07742550A0407 ( O
MCL P07742550A0407 NNP O
) P07742550A0407 ) O
, P07742550A0407 , O
and P07742550A0407 CC O
27 P07742550A0407 CD O
small P07742550A0407 JJ O
noncleaved P07742550A0407 VBN O
cell P07742550A0407 NN O
lymphomas P07742550A0407 NN O
( P07742550A0407 ( O
SNCL P07742550A0407 NNP O
) P07742550A0407 ) O
. P07742550A0407 . O
. . O O

Taken P03417104A0536 VBN O
together P03417104A0536 RB O
, P03417104A0536 , O
the P03417104A0536 DT O
results P03417104A0536 NNS O
suggest P03417104A0536 VBP O
that P03417104A0536 IN O
chlorphentermine P03417104A0536 NN O
may P03417104A0536 MD O
be P03417104A0536 VB O
capable P03417104A0536 JJ O
of P03417104A0536 IN O
producing P03417104A0536 VBG O
dual P03417104A0536 JJ O
stimulus P03417104A0536 NN O
effects P03417104A0536 NNS O
in P03417104A0536 IN O
animals P03417104A0536 NNS O
. P03417104A0536 . O
. . O O

It P08321227A0854 PRP O
could P08321227A0854 MD O
be P08321227A0854 VB O
detected P08321227A0854 VBN O
exclusively P08321227A0854 RB O
in P08321227A0854 IN O
the P08321227A0854 DT O
culture P08321227A0854 NN O
medium P08321227A0854 NN O
of P08321227A0854 IN O
cDNA-transfected P08321227A0854 JJ O
COS P08321227A0854 NNP O
cells P08321227A0854 NNS O
. P08321227A0854 . O
. . O O

Determination P07249660T0000 NN O
of P07249660T0000 IN O
aortic P07249660T0000 JJ O
distensibility P07249660T0000 NN O
and P07249660T0000 CC O
its P07249660T0000 PRP$ O
variations P07249660T0000 NNS O
in P07249660T0000 IN O
arterial P07249660T0000 JJ O
hypertension P07249660T0000 NN O
. P07249660T0000 . O
. . O O

Steroidogenic P08395654T0000 NNP I-UN
factor P08395654T0000 NN I-UN
1 P08395654T0000 CD I-UN
, P08395654T0000 , O
an P08395654T0000 DT O
orphan P08395654T0000 JJ I-UN
nuclear P08395654T0000 JJ I-UN
receptor P08395654T0000 NN I-UN
, P08395654T0000 , O
regulates P08395654T0000 VBZ O
the P08395654T0000 DT O
expression P08395654T0000 NN O
of P08395654T0000 IN O
the P08395654T0000 DT O
rat P08395654T0000 NN I-UN
aromatase P08395654T0000 NN I-UN
gene P08395654T0000 NN I-UN
in P08395654T0000 IN O
gonadal P08395654T0000 JJ O
tissues P08395654T0000 NNS O
. P08395654T0000 . O
. . O O

Within P09294139A0729 IN O
a P09294139A0729 DT O
135-bp P09294139A0729 JJ O
core P09294139A0729 NN O
homology P09294139A0729 NN O
region P09294139A0729 NN O
, P09294139A0729 , O
the P09294139A0729 DT O
human P09294139A0729 JJ I-UN
HS12 P09294139A0729 NNP I-UN
enhancers P09294139A0729 NNS I-UN
are P09294139A0729 VBP O
approximately P09294139A0729 RB O
90 P09294139A0729 CD O
% P09294139A0729 NN O
identical P09294139A0729 JJ O
to P09294139A0729 TO O
the P09294139A0729 DT O
murine P09294139A0729 NN O
homolog P09294139A0729 NN O
and P09294139A0729 CC O
include P09294139A0729 VBP O
several P09294139A0729 JJ O
motifs P09294139A0729 NNS O
previously P09294139A0729 RB O
demonstrated P09294139A0729 VBD O
to P09294139A0729 TO O
be P09294139A0729 VB O
important P09294139A0729 JJ O
for P09294139A0729 IN O
function P09294139A0729 NN O
of P09294139A0729 IN O
the P09294139A0729 DT O
murine P09294139A0729 JJ O
enhancer P09294139A0729 NN O
; P09294139A0729 : O
additional P09294139A0729 JJ O
segments P09294139A0729 NNS O
of P09294139A0729 IN O
high P09294139A0729 JJ O
sequence P09294139A0729 NN O
conservation P09294139A0729 NN O
suggest P09294139A0729 VBP O
the P09294139A0729 DT O
possibility P09294139A0729 NN O
of P09294139A0729 IN O
previously P09294139A0729 RB O
unrecognized P09294139A0729 JJ O
functional P09294139A0729 JJ O
motifs P09294139A0729 NNS O
. P09294139A0729 . O
. . O O

The P02308496A0000 DT O
paper P02308496A0000 NN O
is P02308496A0000 VBZ O
concerned P02308496A0000 VBN O
with P02308496A0000 IN O
the P02308496A0000 DT O
data P02308496A0000 NNS O
on P02308496A0000 IN O
change P02308496A0000 NN O
in P02308496A0000 IN O
the P02308496A0000 DT O
blood P02308496A0000 NN O
level P02308496A0000 NN O
of P02308496A0000 IN O
ACTH P02308496A0000 NNP I-UN
, P02308496A0000 , O
STH P02308496A0000 NNP I-UN
, P02308496A0000 , O
TSH P02308496A0000 NNP I-UN
, P02308496A0000 , O
cortisol P02308496A0000 NN O
, P02308496A0000 , O
T3 P02308496A0000 NNP O
, P02308496A0000 , O
insulin P02308496A0000 NN I-UN
, P02308496A0000 , O
C-peptide P02308496A0000 NNP I-UN
during P02308496A0000 IN O
a P02308496A0000 DT O
25-minute P02308496A0000 JJ O
session P02308496A0000 NN O
of P02308496A0000 IN O
respiration P02308496A0000 NN O
using P02308496A0000 VBG O
a P02308496A0000 DT O
gaseous P02308496A0000 JJ O
hypoxic P02308496A0000 NN O
mixture P02308496A0000 NN O
with P02308496A0000 IN O
10 P02308496A0000 CD O
% P02308496A0000 NN O
oxygen P02308496A0000 NN O
( P02308496A0000 ( O
GHM-10 P02308496A0000 NNP O
) P02308496A0000 ) O
. P02308496A0000 . O
. . O O

Measurements P10921197A0179 NNS O
were P10921197A0179 VBD O
compared P10921197A0179 VBN O
with P10921197A0179 IN O
two P10921197A0179 CD O
computerised P10921197A0179 JJ O
treatment P10921197A0179 NN O
planning P10921197A0179 VBG O
systems P10921197A0179 NNS O
-- P10921197A0179 : O
Theraplan P10921197A0179 NNP O
VO5B P10921197A0179 NNP O
and P10921197A0179 CC O
ADAC P10921197A0179 NNP O
Pinnacle3 P10921197A0179 NNP O
V4.0b P10921197A0179 NNP O
. P10921197A0179 . O
. . O O

The P03139750A0000 DT O
genetic P03139750A0000 JJ O
basis P03139750A0000 NN O
for P03139750A0000 IN O
the P03139750A0000 DT O
expression P03139750A0000 NN O
of P03139750A0000 IN O
a P03139750A0000 DT O
latent P03139750A0000 JJ O
VH P03139750A0000 NNP I-UN
allotype P03139750A0000 NN I-UN
in P03139750A0000 IN O
the P03139750A0000 DT O
rabbit P03139750A0000 NN O
was P03139750A0000 VBD O
investigated P03139750A0000 VBN O
. P03139750A0000 . O
. . O O

IgE P07665948A0591 NN I-UN
levels P07665948A0591 NNS O
showed P07665948A0591 VBD O
higher P07665948A0591 JJR O
values P07665948A0591 NNS O
compared P07665948A0591 VBN O
to P07665948A0591 TO O
normal P07665948A0591 JJ O
individuals P07665948A0591 NNS O
and P07665948A0591 CC O
IgE P07665948A0591 NNP I-UN
levels P07665948A0591 NNS O
were P07665948A0591 VBD O
higher P07665948A0591 JJR O
in P07665948A0591 IN O
children P07665948A0591 NNS O
groups P07665948A0591 NNS O
than P07665948A0591 IN O
in P07665948A0591 IN O
adults P07665948A0591 JJ O
regardless P07665948A0591 NN O
of P07665948A0591 IN O
the P07665948A0591 DT O
intensity P07665948A0591 NN O
of P07665948A0591 IN O
infection P07665948A0591 NN O
. P07665948A0591 . O
. . O O

One P09418057A0684 CD O
R-EST P09418057A0684 NN O
and P09418057A0684 CC O
one P09418057A0684 CD O
Pto-like P09418057A0684 JJ I-UN
sequence P09418057A0684 NN I-UN
each P09418057A0684 DT O
mapped P09418057A0684 VBD O
to P09418057A0684 TO O
two P09418057A0684 CD O
locations P09418057A0684 NNS O
. P09418057A0684 . O
. . O O

Thus P09712898A0911 RB O
, P09712898A0911 , O
TRAF2 P09712898A0911 NNP I-UN
initiates P09712898A0911 VBZ O
SAPK P09712898A0911 NNP I-UN
and P09712898A0911 CC O
p38 P09712898A0911 JJ I-UN
activation P09712898A0911 NN O
by P09712898A0911 IN O
binding P09712898A0911 VBG O
two P09712898A0911 CD O
proximal P09712898A0911 JJ O
protein P09712898A0911 NN O
kinases P09712898A0911 NNS O
: P09712898A0911 : O
GCK P09712898A0911 NNP I-UN
and P09712898A0911 CC O
RIP P09712898A0911 NNP I-UN
. P09712898A0911 . O
. . O O

e P01696715T0074 NN O
. P01696715T0074 . O
. . O O

Catalytic P11062068T0000 JJ O
activation P11062068T0000 NN O
of P11062068T0000 IN O
mitogen-activated P11062068T0000 JJ I-UN
protein P11062068T0000 NN I-UN
( P11062068T0000 ( I-UN
MAP P11062068T0000 NNP I-UN
) P11062068T0000 ) I-UN
kinase P11062068T0000 VBD I-UN
phosphatase-1 P11062068T0000 JJ I-UN
by P11062068T0000 IN O
binding P11062068T0000 VBG O
to P11062068T0000 TO O
p38 P11062068T0000 VB I-UN
MAP P11062068T0000 NNP I-UN
kinase P11062068T0000 NN I-UN
: P11062068T0000 : O
critical P11062068T0000 JJ O
role P11062068T0000 NN O
of P11062068T0000 IN O
the P11062068T0000 DT O
p38 P11062068T0000 JJ I-UN
C-terminal P11062068T0000 JJ I-UN
domain P11062068T0000 NN I-UN
in P11062068T0000 IN O
its P11062068T0000 PRP$ O
negative P11062068T0000 JJ O
regulation P11062068T0000 NN O
. P11062068T0000 . O
. . O O

Recombination P09990057T0000 NN O
and P09990057T0000 CC O
transcription P09990057T0000 NN O
of P09990057T0000 IN O
the P09990057T0000 DT O
endogenous P09990057T0000 JJ I-UN
Ig P09990057T0000 NNP I-UN
heavy P09990057T0000 NN I-UN
chain P09990057T0000 NN I-UN
locus P09990057T0000 NN I-UN
is P09990057T0000 VBZ O
effected P09990057T0000 VBN O
by P09990057T0000 IN O
the P09990057T0000 DT O
Ig P09990057T0000 NNP I-UN
heavy P09990057T0000 NN I-UN
chain P09990057T0000 NN I-UN
intronic P09990057T0000 JJ I-UN
enhancer P09990057T0000 NN I-UN
core P09990057T0000 NN I-UN
region P09990057T0000 NN I-UN
in P09990057T0000 IN O
the P09990057T0000 DT O
absence P09990057T0000 NN O
of P09990057T0000 IN O
the P09990057T0000 DT O
matrix P09990057T0000 NN O
attachment P09990057T0000 NN O
regions P09990057T0000 NNS O
. P09990057T0000 . O
. . O O

Resistance P09414074A0827 NN O
training P09414074A0827 NN O
shifts P09414074A0827 VBD O
the P09414074A0827 DT O
power P09414074A0827 NN O
curve P09414074A0827 NN O
in P09414074A0827 IN O
a P09414074A0827 DT O
positive P09414074A0827 JJ O
direction P09414074A0827 NN O
when P09414074A0827 WRB O
the P09414074A0827 DT O
measurements P09414074A0827 NNS O
are P09414074A0827 VBP O
determined P09414074A0827 VBN O
with P09414074A0827 IN O
absolute P09414074A0827 JJ O
loads P09414074A0827 NNS O
, P09414074A0827 , O
but P09414074A0827 CC O
the P09414074A0827 DT O
increased P09414074A0827 JJ O
power P09414074A0827 NN O
may P09414074A0827 MD O
not P09414074A0827 RB O
be P09414074A0827 VB O
transferred P09414074A0827 VBN O
to P09414074A0827 TO O
an P09414074A0827 DT O
absolute P09414074A0827 JJ O
performance P09414074A0827 NN O
task P09414074A0827 NN O
like P09414074A0827 IN O
the P09414074A0827 DT O
SSP P09414074A0827 NNP O
. P09414074A0827 . O
. . O O

The P07964624A0491 DT O
P131 P07964624A0491 NNP O
ORF P07964624A0491 NNP O
is P07964624A0491 VBZ O
followed P07964624A0491 VBN O
in-frame P07964624A0491 JJ O
by P07964624A0491 IN O
a P07964624A0491 DT O
second P07964624A0491 JJ O
ORF P07964624A0491 NNP O
which P07964624A0491 WDT O
is P07964624A0491 VBZ O
probably P07964624A0491 RB O
expressed P07964624A0491 VBN O
by P07964624A0491 IN O
partial P07964624A0491 JJ O
readthrough P07964624A0491 NN O
of P07964624A0491 IN O
the P07964624A0491 DT O
UGA P07964624A0491 NNP O
termination P07964624A0491 NN O
codon P07964624A0491 NN O
of P07964624A0491 IN O
the P07964624A0491 DT O
P131 P07964624A0491 NNP O
ORF P07964624A0491 NNP O
to P07964624A0491 TO O
produce P07964624A0491 VB O
a P07964624A0491 DT O
polypeptide P07964624A0491 NN O
of P07964624A0491 IN O
M P07964624A0491 NNP O
( P07964624A0491 ( O
r P07964624A0491 NN O
) P07964624A0491 ) O
191044 P07964624A0491 CD O
( P07964624A0491 ( O
P191 P07964624A0491 NNP O
) P07964624A0491 ) O
. P07964624A0491 . O
. . O O

Finally P01717718A1255 RB O
, P01717718A1255 , O
some P01717718A1255 DT O
point P01717718A1255 NN O
mutations P01717718A1255 NNS O
in P01717718A1255 IN O
the P01717718A1255 DT O
Gag-Pol P01717718A1255 NNP O
PR P01717718A1255 NNP I-UN
domain P01717718A1255 NN O
inhibited P01717718A1255 JJ O
activation P01717718A1255 NN O
of P01717718A1255 IN O
RT P01717718A1255 NNP I-UN
in P01717718A1255 IN O
trans P01717718A1255 NNS O
by P01717718A1255 IN O
a P01717718A1255 DT O
wild-type P01717718A1255 JJ O
PR P01717718A1255 NNP I-UN
, P01717718A1255 , O
suggesting P01717718A1255 VBG O
that P01717718A1255 IN O
the P01717718A1255 DT O
correct P01717718A1255 JJ O
conformation P01717718A1255 NN O
of P01717718A1255 IN O
the P01717718A1255 DT O
PR P01717718A1255 NNP I-UN
domain P01717718A1255 NN O
in P01717718A1255 IN O
Gag-Pol P01717718A1255 NNP O
is P01717718A1255 VBZ O
prerequisite P01717718A1255 JJ O
for P01717718A1255 IN O
activation P01717718A1255 NN O
of P01717718A1255 IN O
RT P01717718A1255 NNP I-UN
. P01717718A1255 . O
. . O O

Apart P08626529A0799 RB O
from P08626529A0799 IN O
two P08626529A0799 CD O
proline-rich P08626529A0799 JJ O
regions P08626529A0799 NNS O
( P08626529A0799 ( O
amino P08626529A0799 JJ O
acids P08626529A0799 NNS O
1-117 P08626529A0799 JJ O
and P08626529A0799 CC O
239-270 P08626529A0799 JJ O
) P08626529A0799 ) O
, P08626529A0799 , O
p230 P08626529A0799 JJ I-UN
contains P08626529A0799 VBZ O
a P08626529A0799 DT O
very P08626529A0799 RB O
high P08626529A0799 JJ O
frequency P08626529A0799 NN O
of P08626529A0799 IN O
heptad P08626529A0799 NN O
repeats P08626529A0799 NNS O
, P08626529A0799 , O
characteristic P08626529A0799 JJ O
of P08626529A0799 IN O
alpha-helices P08626529A0799 NNS O
that P08626529A0799 WDT O
form P08626529A0799 VBP O
dimeric P08626529A0799 JJ O
coiled-coil P08626529A0799 NN O
structures P08626529A0799 NNS O
. P08626529A0799 . O
p230 P08626529A0799 NN I-UN
also P08626529A0799 RB O
includes P08626529A0799 VBZ O
the P08626529A0799 DT O
sequence P08626529A0799 NN O
ESLALEELEL P08626529A0799 NNP O
( P08626529A0799 ( O
amino P08626529A0799 JJ O
acids P08626529A0799 NNS O
538-546 P08626529A0799 JJ O
) P08626529A0799 ) O
, P08626529A0799 , O
a P08626529A0799 DT O
motif P08626529A0799 NN O
found P08626529A0799 VBN O
in P08626529A0799 IN O
the P08626529A0799 DT O
granin P08626529A0799 JJ I-UN
family P08626529A0799 NN I-UN
of P08626529A0799 IN O
acidic P08626529A0799 JJ O
proteins P08626529A0799 NNS O
present P08626529A0799 JJ O
in P08626529A0799 IN O
secretory P08626529A0799 JJ O
granules P08626529A0799 NNS O
of P08626529A0799 IN O
neuroendocrine P08626529A0799 JJ O
cells P08626529A0799 NNS O
. P08626529A0799 . O
. . O O

The P06327638A0155 DT O
gene P06327638A0155 NN I-UN
cat-86 P06327638A0155 NN I-UN
, P06327638A0155 , O
specifying P06327638A0155 VBG O
chloramphenicol-inducible P06327638A0155 JJ I-UN
chloramphenicol P06327638A0155 NN I-UN
acetyltransferase P06327638A0155 NN I-UN
, P06327638A0155 , O
is P06327638A0155 VBZ O
located P06327638A0155 VBN O
on P06327638A0155 IN O
the P06327638A0155 DT O
1.1-kilobase P06327638A0155 JJ O
cloned P06327638A0155 JJ O
DNA P06327638A0155 NN O
. P06327638A0155 . O
. . O O

Manifest P04760826T0000 JJS O
anxiety P04760826T0000 NN O
of P04760826T0000 IN O
Vietnam P04760826T0000 NNP O
returnees P04760826T0000 NNS O
and P04760826T0000 CC O
undergraduates P04760826T0000 NNS O
. P04760826T0000 . O
. . O O

To P10601290A0742 TO O
understand P10601290A0742 VB O
the P10601290A0742 DT O
basis P10601290A0742 NN O
for P10601290A0742 IN O
the P10601290A0742 DT O
increased P10601290A0742 VBN O
cell P10601290A0742 NN O
surface P10601290A0742 NN O
stability P10601290A0742 NN O
compared P10601290A0742 VBN O
with P10601290A0742 IN O
wild-type P10601290A0742 JJ O
peptide P10601290A0742 NN O
and P10601290A0742 CC O
to P10601290A0742 TO O
understand P10601290A0742 VB O
the P10601290A0742 DT O
differences P10601290A0742 NNS O
in P10601290A0742 IN O
T P10601290A0742 NNP O
cell P10601290A0742 NN O
recognition P10601290A0742 NN O
between P10601290A0742 IN O
I1Y P10601290A0742 NNP I-UN
and P10601290A0742 CC O
I1F P10601290A0742 NNP I-UN
, P10601290A0742 , O
we P10601290A0742 PRP O
determined P10601290A0742 VBD O
the P10601290A0742 DT O
x-ray P10601290A0742 JJ O
crystal P10601290A0742 JJ O
structures P10601290A0742 NNS O
of P10601290A0742 IN O
the P10601290A0742 DT O
two P10601290A0742 CD O
class P10601290A0742 NN I-UN
I P10601290A0742 PRP I-UN
MHC-peptide P10601290A0742 NNP I-UN
complexes P10601290A0742 NNS I-UN
. P10601290A0742 . O
. . O O

The P10826861A0000 DT O
monoclonal P10826861A0000 JJ O
immunoglobulin P10826861A0000 NN I-UN
products P10826861A0000 NNS O
of P10826861A0000 IN O
plasma P10826861A0000 NN O
cell P10826861A0000 NN O
neoplasm P10826861A0000 NNS O
can P10826861A0000 MD O
give P10826861A0000 VB O
rise P10826861A0000 NN O
to P10826861A0000 TO O
a P10826861A0000 DT O
variety P10826861A0000 NN O
of P10826861A0000 IN O
manifestations P10826861A0000 NNS O
including P10826861A0000 VBG O
hyperviscosity P10826861A0000 NN O
, P10826861A0000 , O
amyloidosis P10826861A0000 NN O
, P10826861A0000 , O
cryoglobulinemia P10826861A0000 NN O
, P10826861A0000 , O
neuropathy P10826861A0000 JJ O
, P10826861A0000 , O
and P10826861A0000 CC O
renal P10826861A0000 JJ O
failure P10826861A0000 NN O
. P10826861A0000 . O
. . O O

Signaling P08144631A0000 VBG O
by P08144631A0000 IN O
tyrosine P08144631A0000 JJ I-UN
kinases P08144631A0000 NNS I-UN
involves P08144631A0000 VBZ O
direct P08144631A0000 JJ O
associations P08144631A0000 NNS O
between P08144631A0000 IN O
proteins P08144631A0000 NNS O
with P08144631A0000 IN O
Src P08144631A0000 NNP I-UN
homology P08144631A0000 NN I-UN
2 P08144631A0000 CD I-UN
( P08144631A0000 ( O
SH2 P08144631A0000 NNP I-UN
) P08144631A0000 ) O
domains P08144631A0000 NNS O
and P08144631A0000 CC O
sites P08144631A0000 NNS O
of P08144631A0000 IN O
tyrosine P08144631A0000 JJ O
phosphorylation P08144631A0000 NN O
. P08144631A0000 . O
. . O O

The P09210478A0000 DT O
ubiquitously P09210478A0000 RB O
expressed P09210478A0000 VBN O
hypoxia-inducible P09210478A0000 JJ I-UN
factor-1 P09210478A0000 NN I-UN
( P09210478A0000 ( O
HIF-1 P09210478A0000 NNP I-UN
) P09210478A0000 ) O
is P09210478A0000 VBZ O
involved P09210478A0000 VBN O
in P09210478A0000 IN O
expression P09210478A0000 NN O
of P09210478A0000 IN O
a P09210478A0000 DT O
large P09210478A0000 JJ O
number P09210478A0000 NN O
of P09210478A0000 IN O
oxygen-regulated P09210478A0000 JJ O
genes P09210478A0000 NNS O
. P09210478A0000 . O
. . O O

Although P09435789A0961a IN O
RAD17 P09435789A0961a NNP I-UN
, P09435789A0961a , O
RAD24 P09435789A0961a NNP I-UN
and P09435789A0961a CC O
MEC3 P09435789A0961a NNP I-UN
are P09435789A0961a VBP O
not P09435789A0961a RB O
required P09435789A0961a VBN O
for P09435789A0961a IN O
cell P09435789A0961a NN O
cycle P09435789A0961a NN O
arrest P09435789A0961a NN O
when P09435789A0961a WRB O
S P09435789A0961a NNP O
phase P09435789A0961a NN O
is P09435789A0961a VBZ O
inhibited P09435789A0961a VBN O
by P09435789A0961a IN O
hydroxyurea P09435789A0961a NN O
( P09435789A0961a ( O
HU P09435789A0961a NNP O
) P09435789A0961a ) O
, P09435789A0961a , O
they P09435789A0961a PRP O
do P09435789A0961a VBP O
contribute P09435789A0961a VB O
to P09435789A0961a TO O
the P09435789A0961a DT O
viability P09435789A0961a NN O
of P09435789A0961a IN O
yeast P09435789A0961a NN O
cells P09435789A0961a NNS O
grown P09435789A0961a VBN O
in P09435789A0961a IN O
the P09435789A0961a DT O
presence P09435789A0961a NN O
of P09435789A0961a IN O
HU P09435789A0961a NNP O
, P09435789A0961a , O
possibly P09435789A0961a RB O
because P09435789A0961a IN O
they P09435789A0961a PRP O
are P09435789A0961a VBP O
required P09435789A0961a VBN O
for P09435789A0961a IN O
the P09435789A0961a DT O
repair P09435789A0961a NN O
of P09435789A0961a IN O
HU-induced P09435789A0961a NNP O
DNA P09435789A0961a NNP O
damage P09435789A0961a NN O
. P09435789A0961a . O
. . O O

Furthermore P07961957A1565 RB O
, P07961957A1565 , O
our P07961957A1565 PRP$ O
data P07961957A1565 NNS O
also P07961957A1565 RB O
show P07961957A1565 VBP O
that P07961957A1565 IN O
, P07961957A1565 , O
in P07961957A1565 IN O
addition P07961957A1565 NN O
to P07961957A1565 TO O
TEF-1 P07961957A1565 NNP I-UN
, P07961957A1565 , O
another P07961957A1565 DT O
HF-1a-related P07961957A1565 JJ I-UN
factor P07961957A1565 NN I-UN
may P07961957A1565 MD O
be P07961957A1565 VB O
recognized P07961957A1565 VBN O
by P07961957A1565 IN O
the P07961957A1565 DT O
alpha-MHC P07961957A1565 JJ I-UN
gene P07961957A1565 NN I-UN
EM P07961957A1565 NNP O
element P07961957A1565 NN O
. P07961957A1565 . O
. . O O

Epstein-Barr P10559303A0000 JJ I-UN
virus P10559303A0000 NN I-UN
( P10559303A0000 ( I-UN
EBV P10559303A0000 NNP I-UN
) P10559303A0000 ) I-UN
latent P10559303A0000 NN I-UN
membrane P10559303A0000 NN I-UN
protein P10559303A0000 NN I-UN
1 P10559303A0000 CD I-UN
( P10559303A0000 ( O
LMP1 P10559303A0000 NNP I-UN
) P10559303A0000 ) O
is P10559303A0000 VBZ O
essential P10559303A0000 JJ O
for P10559303A0000 IN O
EBV-mediated P10559303A0000 JJ O
transformation P10559303A0000 NN O
of P10559303A0000 IN O
primary P10559303A0000 JJ O
B P10559303A0000 NNP O
lymphocytes P10559303A0000 NNS O
. P10559303A0000 . O
. . O O

Osteosarcoma P05253274T0001 NNP O
caused P05253274T0001 VBN O
by P05253274T0001 IN O
3,4-benzopyrene P05253274T0001 JJ O
. P05253274T0001 . O
. . O O

The P07720710A0861 DT O
Oct P07720710A0861 NNP I-UN
and P07720710A0861 CC O
HMG2 P07720710A0861 NNP I-UN
proteins P07720710A0861 NNS I-UN
also P07720710A0861 RB O
interact P07720710A0861 VBP O
in P07720710A0861 IN O
vivo P07720710A0861 NN O
. P07720710A0861 . O
. . O O

An P11297419A0894 DT O
F222W P11297419A0894 NN I-UN
: P11297419A0894 : I-UN
W21F P11297419A0894 JJ I-UN
rGST P11297419A0894 NN I-UN
A1-1 P11297419A0894 NNP I-UN
double P11297419A0894 JJ I-UN
mutant P11297419A0894 NN I-UN
provides P11297419A0894 VBZ O
a P11297419A0894 DT O
direct P11297419A0894 JJ O
fluorescence P11297419A0894 NN O
probe P11297419A0894 NN O
of P11297419A0894 IN O
changes P11297419A0894 NNS O
in P11297419A0894 IN O
the P11297419A0894 DT O
environment P11297419A0894 NN O
of P11297419A0894 IN O
the P11297419A0894 DT O
C-terminal P11297419A0894 JJ O
residue P11297419A0894 NN O
. P11297419A0894 . O
. . O O

Fgd3 P10721717A0676 NNP I-UN
and P10721717A0676 CC O
FGD1 P10721717A0676 NNP I-UN
share P10721717A0676 NN O
a P10721717A0676 DT O
high P10721717A0676 JJ O
degree P10721717A0676 NN O
of P10721717A0676 IN O
sequence P10721717A0676 NN O
identity P10721717A0676 NN O
that P10721717A0676 WDT O
spans P10721717A0676 VBZ O
> P10721717A0676 JJ O
560 P10721717A0676 CD O
contiguous P10721717A0676 JJ O
amino P10721717A0676 NN O
acid P10721717A0676 NN O
residues P10721717A0676 NNS O
. P10721717A0676 . O
. . O O

Copyright P11528253X1211 JJ O
2001 P11528253X1211 CD O
S P11528253X1211 NNP O
. P11528253X1211 . O
. . O O

These P07474124A1360 DT O
results P07474124A1360 NNS O
demonstrate P07474124A1360 VBP O
that P07474124A1360 IN O
although P07474124A1360 IN O
PI2 P07474124A1360 NNP O
and P07474124A1360 CC O
PI3 P07474124A1360 NNP O
viruses P07474124A1360 NNS O
belong P07474124A1360 RB O
to P07474124A1360 TO O
the P07474124A1360 DT O
same P07474124A1360 JJ O
parainfluenza P07474124A1360 NN O
virus P07474124A1360 NN O
genus P07474124A1360 NN O
, P07474124A1360 , O
these P07474124A1360 DT O
viruses P07474124A1360 NNS O
show P07474124A1360 VBP O
marked P07474124A1360 JJ O
differences P07474124A1360 NNS O
with P07474124A1360 IN O
respect P07474124A1360 NN O
to P07474124A1360 TO O
functional P07474124A1360 JJ O
requirements P07474124A1360 NNS O
for P07474124A1360 IN O
the P07474124A1360 DT O
cytoplasmic P07474124A1360 JJ O
tail P07474124A1360 NN O
of P07474124A1360 IN O
the P07474124A1360 DT O
F P07474124A1360 NNP I-UN
glycoprotein P07474124A1360 NN I-UN
. P07474124A1360 . O
. . O O

Sequence P10393251T0000 NN O
of P10393251T0000 IN O
10q24 P10393251T0000 CD I-UN
locus P10393251T0000 NN I-UN
surrounding P10393251T0000 VBG O
the P10393251T0000 DT O
HOX11 P10393251T0000 NNP I-UN
oncogene P10393251T0000 NN I-UN
reveals P10393251T0000 VBZ O
a P10393251T0000 DT O
new P10393251T0000 JJ O
gene P10393251T0000 NN O
HUG1 P10393251T0000 NNP I-UN
expressed P10393251T0000 VBD O
in P10393251T0000 IN O
a P10393251T0000 DT O
T-ALL P10393251T0000 NNP O
cell P10393251T0000 NN O
line P10393251T0000 NN O
. P10393251T0000 . O
. . O O

Transfection P11318608A1155 NN O
of P11318608A1155 IN O
EGFP-tagged P11318608A1155 NNP O
DENTT P11318608A1155 NNP I-UN
NLS P11318608A1155 NNP O
deletion P11318608A1155 NN O
constructs P11318608A1155 NNS O
lacking P11318608A1155 VBG O
the P11318608A1155 DT O
bipartite P11318608A1155 JJ O
NLS-1 P11318608A1155 NNP I-UN
were P11318608A1155 VBD O
excluded P11318608A1155 VBN O
from P11318608A1155 IN O
the P11318608A1155 DT O
nucleolus P11318608A1155 NN O
. P11318608A1155 . O
. . O O

The P09843412A0130 DT O
highly P09843412A0130 RB O
amyloidogenic P09843412A0130 JJ O
42-residue P09843412A0130 JJ O
form P09843412A0130 NN O
of P09843412A0130 IN O
Abeta P09843412A0130 NNP I-UN
( P09843412A0130 ( O
Abeta42 P09843412A0130 NNP I-UN
) P09843412A0130 ) O
is P09843412A0130 VBZ O
the P09843412A0130 DT O
first P09843412A0130 JJ O
species P09843412A0130 NNS O
to P09843412A0130 TO O
be P09843412A0130 VB O
deposited P09843412A0130 VBN O
in P09843412A0130 IN O
both P09843412A0130 DT O
sporadic P09843412A0130 JJ O
and P09843412A0130 CC O
familial P09843412A0130 JJ O
AD P09843412A0130 NNP O
. P09843412A0130 . O
. . O O

Production P01634400A1101 NN O
costs P01634400A1101 NNS O
included P01634400A1101 VBD O
feed P01634400A1101 NN O
, P01634400A1101 , O
non-feed P01634400A1101 JJ O
operating P01634400A1101 NN O
, P01634400A1101 , O
fixed P01634400A1101 VBN O
, P01634400A1101 , O
and P01634400A1101 CC O
replacement P01634400A1101 NN O
stock P01634400A1101 NN O
costs P01634400A1101 NNS O
. P01634400A1101 . O
. . O O

The P03545955A0751 DT O
glucose P03545955A0751 JJ O
areas P03545955A0751 NNS O
following P03545955A0751 VBG O
the P03545955A0751 DT O
ingestion P03545955A0751 NN O
of P03545955A0751 IN O
the P03545955A0751 DT O
foods P03545955A0751 NNS O
were P03545955A0751 VBD O
: P03545955A0751 : O
Study P03545955A0751 NN O
1 P03545955A0751 CD O
: P03545955A0751 : O
glucose P03545955A0751 JJ O
11.7 P03545955A0751 CD O
, P03545955A0751 , O
orange P03545955A0751 NN O
juice P03545955A0751 NN O
7.3 P03545955A0751 CD O
, P03545955A0751 , O
sucrose P03545955A0751 VBD O
5.2 P03545955A0751 CD O
, P03545955A0751 , O
glucose P03545955A0751 JJ O
+ P03545955A0751 NNP O
fructose P03545955A0751 VBD O
6.3 P03545955A0751 CD O
, P03545955A0751 , O
and P03545955A0751 CC O
fructose P03545955A0751 RB O
0.7 P03545955A0751 CD O
mmol P03545955A0751 NNS O
X P03545955A0751 NNP O
h P03545955A0751 NN O
/ P03545955A0751 NNP O
l P03545955A0751 NN O
; P03545955A0751 : O
Study P03545955A0751 NNP O
2 P03545955A0751 CD O
: P03545955A0751 : O
glucose P03545955A0751 JJ O
14.6 P03545955A0751 CD O
, P03545955A0751 , O
orange P03545955A0751 NN O
juice P03545955A0751 NN O
7.3 P03545955A0751 CD O
, P03545955A0751 , O
apples P03545955A0751 NNS O
5.5 P03545955A0751 CD O
, P03545955A0751 , O
and P03545955A0751 CC O
apple P03545955A0751 NN O
juice P03545955A0751 NN O
4.7 P03545955A0751 CD O
mmol P03545955A0751 NN O
X P03545955A0751 NNP O
h P03545955A0751 NN O
/ P03545955A0751 NNP O
l P03545955A0751 NN O
; P03545955A0751 : O
Study P03545955A0751 NNP O
3 P03545955A0751 CD O
: P03545955A0751 : O
glucose P03545955A0751 JJ O
12.6 P03545955A0751 CD O
, P03545955A0751 , O
ice P03545955A0751 NN O
cream P03545955A0751 NN O
8.1 P03545955A0751 CD O
, P03545955A0751 , O
milk P03545955A0751 NN O
3.7 P03545955A0751 CD O
, P03545955A0751 , O
and P03545955A0751 CC O
lactose P03545955A0751 RB O
4.1 P03545955A0751 CD O
mmol P03545955A0751 NNS O
X P03545955A0751 NNP O
h P03545955A0751 NN O
/ P03545955A0751 NNP O
l P03545955A0751 NN O
. P03545955A0751 . O
. . O O

These P09121774A0611 DT O
activities P09121774A0611 NNS O
are P09121774A0611 VBP O
all P09121774A0611 DT O
required P09121774A0611 VBN O
for P09121774A0611 IN O
stimulation P09121774A0611 NN O
of P09121774A0611 IN O
cell P09121774A0611 NN O
growth P09121774A0611 NN O
by P09121774A0611 IN O
middle-T P09121774A0611 NN I-UN
and P09121774A0611 CC O
activate P09121774A0611 JJ O
members P09121774A0611 NNS O
of P09121774A0611 IN O
the P09121774A0611 DT O
MAP P09121774A0611 NNP I-UN
kinase P09121774A0611 NNP I-UN
family P09121774A0611 NN I-UN
. P09121774A0611 . O
. . O O

Homodimers P01373374A0735 NNS O
of P01373374A0735 IN O
the P01373374A0735 DT O
three P01373374A0735 CD O
proteins P01373374A0735 NNS O
specifically P01373374A0735 RB O
recognize P01373374A0735 VBP O
the P01373374A0735 DT O
G-box P01373374A0735 NNP O
motif P01373374A0735 NN O
, P01373374A0735 , O
with P01373374A0735 IN O
GBF1 P01373374A0735 NNP I-UN
and P01373374A0735 CC O
GBF3 P01373374A0735 NNP I-UN
binding P01373374A0735 VBG O
symmetrically P01373374A0735 RB O
to P01373374A0735 TO O
this P01373374A0735 DT O
palindromic P01373374A0735 JJ O
sequence P01373374A0735 NN O
. P01373374A0735 . O
. . O O

Paracrine P08918918T0000 NNP O
activation P08918918T0000 NN O
of P08918918T0000 IN O
the P08918918T0000 DT O
HIV-1 P08918918T0000 NNP I-UN
LTR P08918918T0000 NNP I-UN
promoter P08918918T0000 NN I-UN
by P08918918T0000 IN O
the P08918918T0000 DT O
viral P08918918T0000 JJ I-UN
Tat P08918918T0000 NNP I-UN
protein P08918918T0000 NN I-UN
is P08918918T0000 VBZ O
mechanistically P08918918T0000 RB O
similar P08918918T0000 JJ O
to P08918918T0000 TO O
trans-activation P08918918T0000 NN O
within P08918918T0000 IN O
a P08918918T0000 DT O
cell P08918918T0000 NN O
. P08918918T0000 . O
. . O O

Ultrastructural P02287860T0001 JJ O
and P02287860T0001 CC O
morphometric P02287860T0001 JJ O
study P02287860T0001 NN O
of P02287860T0001 IN O
the P02287860T0001 DT O
myeloid P02287860T0001 NN O
parenchyma P02287860T0001 NN O
cells P02287860T0001 NNS O
of P02287860T0001 IN O
mice P02287860T0001 NN O
prior P02287860T0001 RB O
and P02287860T0001 CC O
after P02287860T0001 IN O
X-ray P02287860T0001 JJ O
exposure P02287860T0001 NN O
. P02287860T0001 . O
. . O O

DNase P11094072A0842 NNP I-UN
I P11094072A0842 PRP I-UN
genomic P11094072A0842 VBP O
footprinting P11094072A0842 VBG O
revealed P11094072A0842 VBD O
that P11094072A0842 IN O
the P11094072A0842 DT O
c-Myb P11094072A0842 JJ I-UN
site P11094072A0842 NN I-UN
is P11094072A0842 VBZ O
occupied P11094072A0842 VBN O
in P11094072A0842 IN O
a P11094072A0842 DT O
tissue-specific P11094072A0842 JJ O
fashion P11094072A0842 NN O
in P11094072A0842 IN O
vivo P11094072A0842 NN O
. P11094072A0842 . O
. . O O

A P09111048X0000 DT O
novel P09111048X0000 NN O
, P09111048X0000 , O
testis-specific P09111048X0000 JJ I-UN
mRNA P09111048X0000 NN I-UN
transcript P09111048X0000 NN I-UN
encoding P09111048X0000 VBG O
an P09111048X0000 DT O
NH2-terminal P09111048X0000 JJ I-UN
truncated P09111048X0000 JJ I-UN
nitric-oxide P09111048X0000 JJ I-UN
synthase P09111048X0000 NN I-UN
. P09111048X0000 . O
mRNA P09111048X0000 JJ O
diversity P09111048X0000 NN O
represents P09111048X0000 VBZ O
a P09111048X0000 DT O
major P09111048X0000 JJ O
theme P09111048X0000 NN O
of P09111048X0000 IN O
neuronal P09111048X0000 JJ I-UN
nitric-oxide P09111048X0000 JJ I-UN
synthase P09111048X0000 NN I-UN
( P09111048X0000 ( O
nNOS P09111048X0000 JJ I-UN
) P09111048X0000 ) O
gene P09111048X0000 NN O
expression P09111048X0000 NN O
in P09111048X0000 IN O
somatic P09111048X0000 JJ O
cells P09111048X0000 NNS O
/ P09111048X0000 JJ O
tissues P09111048X0000 NNS O
. P09111048X0000 . O
. . O O

One P07969132A0268 CD O
class P07969132A0268 NN O
of P07969132A0268 IN O
plasmids P07969132A0268 NNS O
contained P07969132A0268 VBN O
tRNA P07969132A0268 NN I-UN
( P07969132A0268 ( I-UN
His P07969132A0268 PRP$ I-UN
) P07969132A0268 ) I-UN
genes P07969132A0268 NNS I-UN
and P07969132A0268 CC O
conferred P07969132A0268 VBD O
efficient P07969132A0268 JJ O
suppression P07969132A0268 NN O
only P07969132A0268 RB O
when P07969132A0268 WRB O
cells P07969132A0268 NNS O
were P07969132A0268 VBD O
starved P07969132A0268 VBN O
for P07969132A0268 IN O
histidine P07969132A0268 NN O
; P07969132A0268 : O
these P07969132A0268 DT O
plasmids P07969132A0268 NNS O
suppressed P07969132A0268 VBD O
a P07969132A0268 DT O
gcn2 P07969132A0268 JJ I-UN
deletion P07969132A0268 NN O
much P07969132A0268 RB O
less P07969132A0268 RBR O
efficiently P07969132A0268 RB O
than P07969132A0268 IN O
they P07969132A0268 PRP O
suppressed P07969132A0268 VBD O
gcn2-507 P07969132A0268 NN I-UN
. P07969132A0268 . O
. . O O

SKP1-SnRK P11387208T0000 JJ O
protein P11387208T0000 NN O
kinase P11387208T0000 NN O
interactions P11387208T0000 NNS O
mediate P11387208T0000 VBP O
proteasomal P11387208T0000 JJ O
binding P11387208T0000 NN O
of P11387208T0000 IN O
a P11387208T0000 DT O
plant P11387208T0000 NN O
SCF P11387208T0000 NNP I-UN
ubiquitin P11387208T0000 JJ I-UN
ligase P11387208T0000 NN I-UN
. P11387208T0000 . O
. . O O

Fulminant P03940818T0000 NNP O
hepatitis P03940818T0000 VBD O
A P03940818T0000 NNP O
in P03940818T0000 IN O
chronic P03940818T0000 JJ O
HBV P03940818T0000 NNP O
carrier P03940818T0000 NN O
. P03940818T0000 . O
. . O O

Pentazocine P08269439X0000 JJ O
analgesia P08269439X0000 NN O
: P08269439X0000 : O
is P08269439X0000 VBZ O
there P08269439X0000 EX O
a P08269439X0000 DT O
niche P08269439X0000 NN O
for P08269439X0000 IN O
Talwin P08269439X0000 NNP O
Nx P08269439X0000 NNP O
? P08269439X0000 . O
Pentazocine P08269439X0000 NN O
can P08269439X0000 MD O
be P08269439X0000 VB O
a P08269439X0000 DT O
useful P08269439X0000 JJ O
analgesic P08269439X0000 JJ O
agent P08269439X0000 NN O
for P08269439X0000 IN O
the P08269439X0000 DT O
management P08269439X0000 NN O
of P08269439X0000 IN O
acute P08269439X0000 JJ O
dental P08269439X0000 JJ O
pain P08269439X0000 NN O
. P08269439X0000 . O
. . O O

It P11111051A0051 PRP O
was P11111051A0051 VBD O
subsequently P11111051A0051 RB O
shown P11111051A0051 VBN O
that P11111051A0051 IN O
Tip60 P11111051A0051 NNP I-UN
had P11111051A0051 VBD O
histone P11111051A0051 VBN I-UN
acetyltransferase P11111051A0051 NN I-UN
( P11111051A0051 ( O
HAT P11111051A0051 NNP I-UN
) P11111051A0051 ) O
activity P11111051A0051 NN O
. P11111051A0051 . O
. . O O

A P07221179A0156 DT O
dose-dependent P07221179A0156 JJ O
fall P07221179A0156 NN O
in P07221179A0156 IN O
GABA P07221179A0156 NNP O
content P07221179A0156 NN O
was P07221179A0156 VBD O
observed P07221179A0156 VBN O
; P07221179A0156 : O
GABA P07221179A0156 NNP O
decrease P07221179A0156 NN O
was P07221179A0156 VBD O
evident P07221179A0156 JJ O
15 P07221179A0156 CD O
min P07221179A0156 NN O
after P07221179A0156 IN O
the P07221179A0156 DT O
administration P07221179A0156 NN O
, P07221179A0156 , O
reached P07221179A0156 VBD O
its P07221179A0156 PRP$ O
nadir P07221179A0156 NN O
at P07221179A0156 IN O
60 P07221179A0156 CD O
min P07221179A0156 NN O
and P07221179A0156 CC O
disappeared P07221179A0156 VBD O
at P07221179A0156 IN O
120 P07221179A0156 CD O
minutes P07221179A0156 NNS O
. P07221179A0156 . O
. . O O

The P02038326A0538 DT O
gcd2-503 P02038326A0538 JJ I-UN
mutation P02038326A0538 NN O
also P02038326A0538 RB O
results P02038326A0538 NNS O
in P02038326A0538 IN O
polysome P02038326A0538 JJ O
runoff P02038326A0538 NN O
, P02038326A0538 , O
accumulation P02038326A0538 NN O
of P02038326A0538 IN O
inactive P02038326A0538 JJ O
80S P02038326A0538 CD I-UN
ribosomal P02038326A0538 JJ I-UN
couples P02038326A0538 NNS I-UN
, P02038326A0538 , O
and P02038326A0538 CC O
accumulation P02038326A0538 NN O
of P02038326A0538 IN O
at P02038326A0538 IN O
least P02038326A0538 JJS O
one P02038326A0538 CD O
of P02038326A0538 IN O
the P02038326A0538 DT O
subunits P02038326A0538 NNS O
of P02038326A0538 IN O
the P02038326A0538 DT O
general P02038326A0538 JJ I-UN
translation P02038326A0538 NN I-UN
initiation P02038326A0538 NN I-UN
factor P02038326A0538 NN I-UN
2 P02038326A0538 CD I-UN
( P02038326A0538 ( O
eIF-2 P02038326A0538 JJ I-UN
alpha P02038326A0538 NN I-UN
) P02038326A0538 ) O
in P02038326A0538 IN O
43S-48S P02038326A0538 JJ O
particles P02038326A0538 NNS O
following P02038326A0538 VBG O
a P02038326A0538 DT O
shift P02038326A0538 NN O
to P02038326A0538 TO O
the P02038326A0538 DT O
restrictive P02038326A0538 JJ O
temperature P02038326A0538 NN O
. P02038326A0538 . O
. . O O

The P03061383A0000 DT O
in P03061383A0000 IN O
vitro P03061383A0000 JJ O
activity P03061383A0000 NN O
of P03061383A0000 IN O
mecillinam P03061383A0000 NN O
and P03061383A0000 CC O
amoxicillin P03061383A0000 NN O
/ P03061383A0000 NNP O
clavulanic P03061383A0000 JJ O
acid P03061383A0000 NN O
against P03061383A0000 IN O
Escherichia P03061383A0000 NNP O
coli P03061383A0000 VBP O
strains P03061383A0000 NNS O
producing P03061383A0000 VBG O
beta-lactamases P03061383A0000 NNS I-UN
of P03061383A0000 IN O
the P03061383A0000 DT O
TEM-1 P03061383A0000 NNP I-UN
, P03061383A0000 , O
Oxa-1 P03061383A0000 NNP I-UN
and P03061383A0000 CC O
chromosomal P03061383A0000 JJ O
type P03061383A0000 NN O
were P03061383A0000 VBD O
studied P03061383A0000 VBN O
using P03061383A0000 VBG O
the P03061383A0000 DT O
broth P03061383A0000 NN O
and P03061383A0000 CC O
agar P03061383A0000 JJ O
dilution P03061383A0000 NN O
technique P03061383A0000 NN O
. P03061383A0000 . O
. . O O

E2 P10392903A0889 NNP I-UN
point P10392903A0889 NN O
mutants P10392903A0889 NNS O
unable P10392903A0889 JJ O
to P10392903A0889 TO O
inhibit P10392903A0889 VB O
cell P10392903A0889 JJ O
growth P10392903A0889 NN O
did P10392903A0889 VBD O
not P10392903A0889 RB O
repress P10392903A0889 VB O
cdc25A P10392903A0889 NN I-UN
and P10392903A0889 CC O
cdc25B P10392903A0889 NN I-UN
expression P10392903A0889 NN O
, P10392903A0889 , O
nor P10392903A0889 CC O
did P10392903A0889 VBD O
the P10392903A0889 DT O
cell P10392903A0889 NN O
cycle P10392903A0889 NN O
inhibitors P10392903A0889 NNS O
hydroxyurea P10392903A0889 VBP O
and P10392903A0889 CC O
mimosine P10392903A0889 VBP O
. P10392903A0889 . O
. . O O

These P11005808A1082 DT O
results P11005808A1082 NNS O
demonstrate P11005808A1082 VBP O
Ras- P11005808A1082 JJ O
and P11005808A1082 CC O
Raf-independent P11005808A1082 JJ O
ERK P11005808A1082 NNP I-UN
MAPK P11005808A1082 NNP O
activation P11005808A1082 NN O
maintains P11005808A1082 NNS O
cell P11005808A1082 VBP O
viability P11005808A1082 NN O
following P11005808A1082 VBG O
heat P11005808A1082 NN O
shock P11005808A1082 NN O
. P11005808A1082 . O
. . O O

Treating P02344529T0000 VBG O
renal P02344529T0000 JJ O
anaemia P02344529T0000 NN O
with P02344529T0000 IN O
recombinant P02344529T0000 JJ O
human P02344529T0000 JJ O
erythropoietin P02344529T0000 NN I-UN
. P02344529T0000 . O
. . O O

Recombinant P09199970A1101 NNP I-UN
soluble P09199970A1101 JJ I-UN
pMCP P09199970A1101 NN I-UN
that P09199970A1101 WDT O
lacked P09199970A1101 VBD O
transmembrane P09199970A1101 NN O
and P09199970A1101 CC O
cytoplasmic P09199970A1101 JJ O
domains P09199970A1101 NNS O
had P09199970A1101 VBD O
factor P09199970A1101 NN I-UN
I P09199970A1101 PRP I-UN
cofactor P09199970A1101 VBP I-UN
activity P09199970A1101 NN O
in P09199970A1101 IN O
C3b P09199970A1101 NNP I-UN
cleavage P09199970A1101 NN O
, P09199970A1101 , O
indicating P09199970A1101 VBG O
that P09199970A1101 IN O
it P09199970A1101 PRP O
is P09199970A1101 VBZ O
functionally P09199970A1101 RB O
, P09199970A1101 , O
as P09199970A1101 RB O
well P09199970A1101 RB O
as P09199970A1101 IN O
structurally P09199970A1101 RB O
homologous P09199970A1101 JJ O
to P09199970A1101 TO O
MCP P09199970A1101 NNP I-UN
. P09199970A1101 . O
. . O O

Consistent P09287352A0930 JJ O
with P09287352A0930 IN O
effects P09287352A0930 NNS O
on P09287352A0930 IN O
STAT P09287352A0930 NNP I-UN
activation P09287352A0930 NN O
, P09287352A0930 , O
altered P09287352A0930 VBD O
SHP-1 P09287352A0930 NNP I-UN
expression P09287352A0930 NN O
also P09287352A0930 RB O
affected P09287352A0930 VBD O
EGF-induced P09287352A0930 JJ O
activation P09287352A0930 NN O
of P09287352A0930 IN O
the P09287352A0930 DT O
mitogen-activated P09287352A0930 JJ I-UN
protein P09287352A0930 NN I-UN
kinase P09287352A0930 VB I-UN
pathway P09287352A0930 RB O
; P09287352A0930 : O
expression P09287352A0930 NN O
of P09287352A0930 IN O
SHP-1- P09287352A0930 NNP I-UN
( P09287352A0930 ( I-UN
Cys P09287352A0930 NNP I-UN
-- P09287352A0930 : I-UN
> P09287352A0930 NNP I-UN
Ser P09287352A0930 NNP I-UN
) P09287352A0930 ) I-UN
inhibited P09287352A0930 VBD O
activity P09287352A0930 NN O
of P09287352A0930 IN O
MEK P09287352A0930 NNP I-UN
by P09287352A0930 IN O
approximately P09287352A0930 RB O
25 P09287352A0930 CD O
% P09287352A0930 NN O
, P09287352A0930 , O
whereas P09287352A0930 JJ O
expression P09287352A0930 NN O
of P09287352A0930 IN O
SHP-1 P09287352A0930 NNP I-UN
resulted P09287352A0930 VBD O
in P09287352A0930 IN O
a P09287352A0930 DT O
approximately P09287352A0930 RB O
25 P09287352A0930 CD O
% P09287352A0930 NN O
increase P09287352A0930 NN O
. P09287352A0930 . O
. . O O

The P09467044A0973 DT O
ipsilateral P09467044A0973 JJ O
breast P09467044A0973 NN O
tumor P09467044A0973 NN O
relapse P09467044A0973 NN O
rate P09467044A0973 NN O
was P09467044A0973 VBD O
similar P09467044A0973 JJ O
between P09467044A0973 IN O
the P09467044A0973 DT O
PALP P09467044A0973 NNP O
and P09467044A0973 CC O
MGDET P09467044A0973 NNP O
groups P09467044A0973 NNS O
. P09467044A0973 . O
. . O O

One P07593266A1174 CD O
of P07593266A1174 IN O
these P07593266A1174 DT O
is P07593266A1174 VBZ O
surrounded P07593266A1174 VBN O
by P07593266A1174 IN O
an P07593266A1174 DT O
adenine-uridine P07593266A1174 JJ O
rich P07593266A1174 JJ O
region P07593266A1174 NN O
that P07593266A1174 WDT O
can P07593266A1174 MD O
form P07593266A1174 VB O
an P07593266A1174 DT O
11-base P07593266A1174 JJ O
pair P07593266A1174 NN O
stem P07593266A1174 NN O
structure P07593266A1174 NN O
. P07593266A1174 . O
. . O O

In P08304342A0605 IN O
the P08304342A0605 DT O
present P08304342A0605 JJ O
report P08304342A0605 NN O
, P08304342A0605 , O
66 P08304342A0605 CD O
hemochromatosis P08304342A0605 NN O
families P08304342A0605 NNS O
yielding P08304342A0605 VBG O
151 P08304342A0605 CD O
hemochromatosis P08304342A0605 NN O
chromosomes P08304342A0605 NNS O
and P08304342A0605 CC O
182 P08304342A0605 CD O
normal P08304342A0605 JJ O
chromosomes P08304342A0605 NNS O
were P08304342A0605 VBD O
RFLP-typed P08304342A0605 JJ O
with P08304342A0605 IN O
a P08304342A0605 DT O
battery P08304342A0605 NN O
of P08304342A0605 IN O
probes P08304342A0605 NNS O
, P08304342A0605 , O
including P08304342A0605 VBG O
two P08304342A0605 CD O
newly P08304342A0605 RB O
derived P08304342A0605 VBN O
polymorphic P08304342A0605 JJ O
markers P08304342A0605 NNS O
from P08304342A0605 IN O
the P08304342A0605 DT O
6.7 P08304342A0605 CD O
and P08304342A0605 CC O
HLA-F P08304342A0605 NNP I-UN
loci P08304342A0605 NN I-UN
located P08304342A0605 VBD O
150 P08304342A0605 CD O
and P08304342A0605 CC O
250 P08304342A0605 CD O
kb P08304342A0605 NNS O
telomeric P08304342A0605 JJ O
to P08304342A0605 TO O
HLA-A P08304342A0605 NNP I-UN
, P08304342A0605 , O
respectively P08304342A0605 RB O
. P08304342A0605 . O
. . O O

Cardiac P11486476A1512 JJ O
markers P11486476A1512 NNS O
troponin P11486476A1512 VBP I-UN
T P11486476A1512 NNP I-UN
, P11486476A1512 , O
CK-MB P11486476A1512 NNP O
mass P11486476A1512 NN O
and P11486476A1512 CC O
myoglobin P11486476A1512 NN I-UN
were P11486476A1512 VBD O
helpful P11486476A1512 JJ O
in P11486476A1512 IN O
the P11486476A1512 DT O
differential P11486476A1512 JJ O
diagnosis P11486476A1512 NN O
of P11486476A1512 IN O
chest P11486476A1512 NN O
pain P11486476A1512 NN O
, P11486476A1512 , O
even P11486476A1512 RB O
when P11486476A1512 WRB O
the P11486476A1512 DT O
ECG P11486476A1512 NNP O
was P11486476A1512 VBD O
unremarkable P11486476A1512 JJ O
or P11486476A1512 CC O
nonspecific P11486476A1512 JJ O
. P11486476A1512 . O
. . O O

This P11160307A0394 DT O
molecule P11160307A0394 NN O
, P11160307A0394 , O
wH22xeGFP P11160307A0394 NN I-UN
, P11160307A0394 , O
consists P11160307A0394 VBZ O
of P11160307A0394 IN O
the P11160307A0394 DT O
entire P11160307A0394 JJ I-UN
humanized P11160307A0394 VBN I-UN
anti-FcgammaRI P11160307A0394 NN I-UN
mAb P11160307A0394 NN I-UN
H22 P11160307A0394 NNP I-UN
with P11160307A0394 IN O
eGFP P11160307A0394 NNP I-UN
genetically P11160307A0394 RB O
fused P11160307A0394 VBD O
to P11160307A0394 TO O
the P11160307A0394 DT O
C-terminal P11160307A0394 JJ O
end P11160307A0394 NN O
of P11160307A0394 IN O
each P11160307A0394 DT O
CH3 P11160307A0394 NNP I-UN
domain P11160307A0394 NN I-UN
. P11160307A0394 . O
wH22xeGFP P11160307A0394 NN I-UN
binds P11160307A0394 NNS O
within P11160307A0394 IN O
the P11160307A0394 DT O
ligand-binding P11160307A0394 JJ O
region P11160307A0394 NN O
by P11160307A0394 IN O
its P11160307A0394 PRP$ O
Fc P11160307A0394 NNP I-UN
end P11160307A0394 NN O
, P11160307A0394 , O
as P11160307A0394 RB O
well P11160307A0394 RB O
as P11160307A0394 IN O
outside P11160307A0394 IN O
the P11160307A0394 DT O
ligand-binding P11160307A0394 JJ O
region P11160307A0394 NN O
by P11160307A0394 IN O
its P11160307A0394 PRP$ O
Fab P11160307A0394 NNP I-UN
ends P11160307A0394 VBZ O
, P11160307A0394 , O
thereby P11160307A0394 RB O
cross-linking P11160307A0394 JJ O
FcgammaRI P11160307A0394 NNP I-UN
. P11160307A0394 . O
. . O O

The P08164684A1266 DT O
ligand P08164684A1266 NN O
for P08164684A1266 IN O
RXR P08164684A1266 NNP I-UN
, P08164684A1266 , O
9-cis P08164684A1266 JJ O
retinoic P08164684A1266 NN O
acid P08164684A1266 NN O
, P08164684A1266 , O
has P08164684A1266 VBZ O
the P08164684A1266 DT O
opposite P08164684A1266 JJ O
effect P08164684A1266 NN O
of P08164684A1266 IN O
destabilizing P08164684A1266 VBG O
the P08164684A1266 DT O
heterodimeric-DNA P08164684A1266 NN O
complex P08164684A1266 NN O
. P08164684A1266 . O
. . O O

Transgenic P08555446A0000 NNP O
tobacco P08555446A0000 NN O
plants P08555446A0000 NNS O
( P08555446A0000 ( O
ppa-1 P08555446A0000 NN I-UN
) P08555446A0000 ) O
constitutively P08555446A0000 RB O
expressing P08555446A0000 VBG O
Escherichia P08555446A0000 NNP I-UN
coli P08555446A0000 NN I-UN
pyrophosphatase P08555446A0000 NN I-UN
behind P08555446A0000 IN O
the P08555446A0000 DT O
35S P08555446A0000 CD I-UN
CaMV P08555446A0000 NNP I-UN
promoter P08555446A0000 NN I-UN
accumulate P08555446A0000 VBP O
high P08555446A0000 JJ O
levels P08555446A0000 NNS O
of P08555446A0000 IN O
soluble P08555446A0000 JJ O
sugars P08555446A0000 NNS O
in P08555446A0000 IN O
their P08555446A0000 PRP$ O
leaves P08555446A0000 NNS O
[ P08555446A0000 VBP O
27 P08555446A0000 CD O
] P08555446A0000 NN O
. P08555446A0000 . O
. . O O

Here P07637718A0218 RB O
we P07637718A0218 PRP O
show P07637718A0218 VBP O
that P07637718A0218 IN O
messenger P07637718A0218 JJR O
RNAs P07637718A0218 NNP O
encoding P07637718A0218 VBG O
trans-sialidases P07637718A0218 NNS O
containing P07637718A0218 VBG O
the P07637718A0218 DT O
repeats P07637718A0218 NNS O
are P07637718A0218 VBP O
not P07637718A0218 RB O
present P07637718A0218 JJ O
in P07637718A0218 IN O
epimastigotes P07637718A0218 NNS O
but P07637718A0218 CC O
are P07637718A0218 VBP O
abundant P07637718A0218 JJ O
in P07637718A0218 IN O
trypomastigotes P07637718A0218 NNS O
. P07637718A0218 . O
. . O O

Wnt-1 P10915780A1063 JJ I-UN
overexpression P10915780A1063 NN O
in P10915780A1063 IN O
mammary P10915780A1063 JJ O
epithelial P10915780A1063 JJ O
cells P10915780A1063 NNS O
induced P10915780A1063 VBN O
cyclin P10915780A1063 JJ I-UN
D1 P10915780A1063 NNP I-UN
mRNA P10915780A1063 NN I-UN
and P10915780A1063 CC O
targeted P10915780A1063 JJ O
overexpression P10915780A1063 NN O
of P10915780A1063 IN O
Wnt-1 P10915780A1063 NNP I-UN
in P10915780A1063 IN O
the P10915780A1063 DT O
mammary P10915780A1063 JJ O
gland P10915780A1063 NN O
of P10915780A1063 IN O
transgenic P10915780A1063 JJ O
mice P10915780A1063 NN O
increased P10915780A1063 VBD O
both P10915780A1063 DT O
ILK P10915780A1063 NNP I-UN
activity P10915780A1063 NN O
and P10915780A1063 CC O
cyclin P10915780A1063 NN I-UN
D1 P10915780A1063 NNP I-UN
levels P10915780A1063 NNS O
. P10915780A1063 . O
. . O O

The P08057833A0573 DT O
two P08057833A0573 CD O
ParA P08057833A0573 NNP I-UN
proteins P08057833A0573 NNS I-UN
that P08057833A0573 WDT O
are P08057833A0573 VBP O
produced P08057833A0573 VBN O
as P08057833A0573 IN O
a P08057833A0573 DT O
result P08057833A0573 NN O
of P08057833A0573 IN O
independent P08057833A0573 JJ O
translation P08057833A0573 NN O
initiation P08057833A0573 NN O
at P08057833A0573 IN O
two P08057833A0573 CD O
different P08057833A0573 JJ O
start P08057833A0573 NN O
codons P08057833A0573 NNS O
within P08057833A0573 IN O
the P08057833A0573 DT O
same P08057833A0573 JJ O
open P08057833A0573 JJ O
reading P08057833A0573 NN O
frame P08057833A0573 NN O
were P08057833A0573 VBD O
overexpressed P08057833A0573 VBN O
in P08057833A0573 IN O
Escherichia P08057833A0573 NNP O
coli P08057833A0573 NN O
and P08057833A0573 CC O
partially P08057833A0573 RB O
purified P08057833A0573 VBN O
. P08057833A0573 . O
. . O O

The P01662807A1182 DT O
factor P01662807A1182 NN O
which P01662807A1182 WDT O
binds P01662807A1182 VBZ O
to P01662807A1182 TO O
the P01662807A1182 DT O
TR P01662807A1182 NNP I-UN
promoter P01662807A1182 NN I-UN
co-sedimented P01662807A1182 JJ O
with P01662807A1182 IN O
SV40 P01662807A1182 NNP O
chromosomes P01662807A1182 NNS O
extracted P01662807A1182 VBD O
late P01662807A1182 JJ O
in P01662807A1182 IN O
infection P01662807A1182 NN O
. P01662807A1182 . O
. . O O

Both P09371731A0627 DT O
inserts P09371731A0627 NNS O
are P09371731A0627 VBP O
larger P09371731A0627 JJR O
than P09371731A0627 IN O
their P09371731A0627 PRP$ O
homologues P09371731A0627 NNS O
in P09371731A0627 IN O
eIF-2alpha P09371731A0627 JJ I-UN
kinases P09371731A0627 NNS I-UN
. P09371731A0627 . O
. . O O

In P01811948A0289 IN O
the P01811948A0289 DT O
present P01811948A0289 JJ O
study P01811948A0289 NN O
, P01811948A0289 , O
we P01811948A0289 PRP O
identified P01811948A0289 VBD O
a P01811948A0289 DT O
strong P01811948A0289 JJ O
positive P01811948A0289 JJ O
cis-regulatory P01811948A0289 JJ O
element P01811948A0289 NN O
at P01811948A0289 IN O
-70 P01811948A0289 NNP O
bp P01811948A0289 NN O
to P01811948A0289 TO O
-75 P01811948A0289 VB O
bp P01811948A0289 NN O
in P01811948A0289 IN O
the P01811948A0289 DT O
LpS1 P01811948A0289 NNP I-UN
beta P01811948A0289 NN I-UN
promoter P01811948A0289 NN I-UN
with P01811948A0289 IN O
the P01811948A0289 DT O
sequence P01811948A0289 NN O
( P01811948A0289 ( O
G P01811948A0289 NNP O
) P01811948A0289 ) O
6 P01811948A0289 CD O
and P01811948A0289 CC O
a P01811948A0289 DT O
similar P01811948A0289 JJ O
, P01811948A0289 , O
more P01811948A0289 RBR O
distal P01811948A0289 JJ O
cis-element P01811948A0289 NN O
at P01811948A0289 IN O
-721 P01811948A0289 NNP O
bp P01811948A0289 NN O
to P01811948A0289 TO O
-726 P01811948A0289 VB O
bp P01811948A0289 NN O
. P01811948A0289 . O
. . O O

Approximately P09847397A0935 RB O
50 P09847397A0935 CD O
% P09847397A0935 NN O
of P09847397A0935 IN O
the P09847397A0935 DT O
residues P09847397A0935 NNS O
are P09847397A0935 VBP O
conserved P09847397A0935 VBN O
among P09847397A0935 IN O
all P09847397A0935 DT O
three P09847397A0935 CD O
sequences P09847397A0935 NNS O
, P09847397A0935 , O
yet P09847397A0935 RB O
all P09847397A0935 DT O
three P09847397A0935 CD O
viruses P09847397A0935 NNS O
have P09847397A0935 VBP O
retained P09847397A0935 VBN O
response P09847397A0935 NN O
elements P09847397A0935 NNS O
for P09847397A0935 IN O
glucocorticoids P09847397A0935 NNS O
, P09847397A0935 , O
two P09847397A0935 CD O
positionally P09847397A0935 RB O
conserved P09847397A0935 VBN O
CCAAT P09847397A0935 NNP O
boxes P09847397A0935 NNS O
, P09847397A0935 , O
and P09847397A0935 CC O
positionally P09847397A0935 RB O
conserved P09847397A0935 VBN O
TATA P09847397A0935 NNP O
boxes P09847397A0935 NNS O
. P09847397A0935 . O
. . O O

Similarly P07579695A0336 RB O
, P07579695A0336 , O
we P07579695A0336 PRP O
observed P07579695A0336 VBD O
synthetic P07579695A0336 JJ O
phenotypes P07579695A0336 NNS O
between P07579695A0336 IN O
mutations P07579695A0336 NNS O
in P07579695A0336 IN O
MIF2 P07579695A0336 NNP I-UN
and P07579695A0336 CC O
trans-acting P07579695A0336 JJ O
mutations P07579695A0336 NNS O
in P07579695A0336 IN O
three P07579695A0336 CD O
known P07579695A0336 VBN O
yeast P07579695A0336 RB O
centromere P07579695A0336 JJ O
protein P07579695A0336 JJ O
genes-CEP1 P07579695A0336 JJ O
/ P07579695A0336 NN O
CBF1 P07579695A0336 NNP I-UN
/ P07579695A0336 NNP O
CPF1 P07579695A0336 NNP I-UN
, P07579695A0336 , O
NDC10 P07579695A0336 NNP I-UN
/ P07579695A0336 NNP O
CBF2 P07579695A0336 NNP I-UN
, P07579695A0336 , O
and P07579695A0336 CC O
CEP3 P07579695A0336 NNP I-UN
/ P07579695A0336 NNP O
CBF3B P07579695A0336 NNP I-UN
. P07579695A0336 . O
. . O O

The P09000589A0000 DT O
resurgence P09000589A0000 NN O
of P09000589A0000 IN O
drug-resistant P09000589A0000 JJ O
malaria P09000589A0000 NNS O
makes P09000589A0000 VBZ O
urgent P09000589A0000 JJ O
the P09000589A0000 DT O
evaluation P09000589A0000 NN O
of P09000589A0000 IN O
new P09000589A0000 JJ O
antimalarial P09000589A0000 JJ O
agents P09000589A0000 NNS O
. P09000589A0000 . O
. . O O

Alginate P08051019A0365 NNP O
biosynthesis P08051019A0365 NN O
is P08051019A0365 VBZ O
controlled P08051019A0365 VBN O
by P08051019A0365 IN O
a P08051019A0365 DT O
complex P08051019A0365 JJ O
regulatory P08051019A0365 JJ O
mechanism P08051019A0365 NN O
. P08051019A0365 . O
. . O O

The P08622893A0000 DT O
large P08622893A0000 JJ O
subfamily P08622893A0000 NN O
of P08622893A0000 IN O
receptor P08622893A0000 NN I-UN
tyrosine P08622893A0000 NN I-UN
kinases P08622893A0000 NNS I-UN
( P08622893A0000 ( O
RTKs P08622893A0000 NNP I-UN
) P08622893A0000 ) O
for P08622893A0000 IN O
which P08622893A0000 WDT O
EPH P08622893A0000 NNP I-UN
is P08622893A0000 VBZ O
the P08622893A0000 DT O
prototype P08622893A0000 NN O
have P08622893A0000 VBP O
likely P08622893A0000 JJ O
roles P08622893A0000 NNS O
in P08622893A0000 IN O
intercellular P08622893A0000 JJ O
communication P08622893A0000 NN O
during P08622893A0000 IN O
normal P08622893A0000 JJ O
mammalian P08622893A0000 JJ O
development P08622893A0000 NN O
, P08622893A0000 , O
but P08622893A0000 CC O
the P08622893A0000 DT O
biochemical P08622893A0000 JJ O
signalling P08622893A0000 NN O
pathways P08622893A0000 NNS O
utilised P08622893A0000 VBN O
by P08622893A0000 IN O
this P08622893A0000 DT O
family P08622893A0000 NN O
are P08622893A0000 VBP O
poorly P08622893A0000 RB O
characterised P08622893A0000 VBN O
. P08622893A0000 . O
. . O O

An P08521717A0126 DT O
immunoperoxidase P08521717A0126 NN I-UN
reaction P08521717A0126 NN O
, P08521717A0126 , O
PAP P08521717A0126 NNP I-UN
method P08521717A0126 NN O
, P08521717A0126 , O
with P08521717A0126 IN O
the P08521717A0126 DT O
antiserum P08521717A0126 NN O
of P08521717A0126 IN O
Factor P08521717A0126 NNP I-UN
VIII P08521717A0126 NNP I-UN
as P08521717A0126 IN O
the P08521717A0126 DT O
primary P08521717A0126 JJ O
antibody P08521717A0126 NN O
, P08521717A0126 , O
was P08521717A0126 VBD O
carried P08521717A0126 VBN O
out P08521717A0126 RP O
in P08521717A0126 IN O
the P08521717A0126 DT O
endometrial P08521717A0126 JJ O
biopsies P08521717A0126 NNS O
to P08521717A0126 TO O
detect P08521717A0126 VB O
the P08521717A0126 DT O
Factor P08521717A0126 NNP I-UN
VIII P08521717A0126 NNP I-UN
activity P08521717A0126 NN O
in P08521717A0126 IN O
the P08521717A0126 DT O
endometrial P08521717A0126 JJ O
endothelium P08521717A0126 NN O
before P08521717A0126 IN O
and P08521717A0126 CC O
after P08521717A0126 IN O
insertion P08521717A0126 NN O
of P08521717A0126 IN O
LNG-IUD-20 P08521717A0126 NNP O
. P08521717A0126 . O
. . O O

In P10226029A0905 IN O
epithelial P10226029A0905 JJ O
cells P10226029A0905 NNS O
, P10226029A0905 , O
the P10226029A0905 DT O
PH P10226029A0905 NNP I-UN
domain P10226029A0905 NN I-UN
of P10226029A0905 IN O
Akt P10226029A0905 NNP I-UN
/ P10226029A0905 NNP O
PKB P10226029A0905 NNP I-UN
localised P10226029A0905 VBD O
to P10226029A0905 TO O
sites P10226029A0905 NNS O
of P10226029A0905 IN O
cell-cell P10226029A0905 NN O
and P10226029A0905 CC O
cell-matrix P10226029A0905 JJ O
contact P10226029A0905 NN O
, P10226029A0905 , O
distinct P10226029A0905 NN O
from P10226029A0905 IN O
focal P10226029A0905 JJ O
contacts P10226029A0905 NNS O
, P10226029A0905 , O
even P10226029A0905 RB O
in P10226029A0905 IN O
the P10226029A0905 DT O
absence P10226029A0905 NN O
of P10226029A0905 IN O
serum P10226029A0905 NN O
. P10226029A0905 . O
. . O O

Furthermore P08666241A0930 RB O
, P08666241A0930 , O
we P08666241A0930 PRP O
have P08666241A0930 VBP O
identified P08666241A0930 VBN O
a P08666241A0930 DT O
43-bp P08666241A0930 JJ O
region P08666241A0930 NN O
of P08666241A0930 IN O
the P08666241A0930 DT O
24p3 P08666241A0930 CD I-UN
promoter P08666241A0930 NN I-UN
required P08666241A0930 VBN O
for P08666241A0930 IN O
the P08666241A0930 DT O
Dex P08666241A0930 NNP O
responsiveness P08666241A0930 NN O
. P08666241A0930 . O
. . O O

Electrophoretic P09278450A1338 JJ O
mobility P09278450A1338 NN O
shift P09278450A1338 NN O
assays P09278450A1338 NNS O
and P09278450A1338 CC O
competition P09278450A1338 NN O
experiments P09278450A1338 NNS O
showed P09278450A1338 VBD O
that P09278450A1338 IN O
site P09278450A1338 NN O
A P09278450A1338 DT O
is P09278450A1338 VBZ O
recognized P09278450A1338 VBN O
by P09278450A1338 IN O
an P09278450A1338 DT O
NF1 P09278450A1338 NNP I-UN
protein P09278450A1338 NN I-UN
. P09278450A1338 . O
. . O O

Analysis P07530549A0956 NN O
of P07530549A0956 IN O
the P07530549A0956 DT O
sequences P07530549A0956 NNS O
with P07530549A0956 IN O
the P07530549A0956 DT O
BLAST P07530549A0956 NNP O
and P07530549A0956 CC O
GRAIL P07530549A0956 NNP O
programs P07530549A0956 NNS O
provided P07530549A0956 VBD O
additional P07530549A0956 JJ O
independent P07530549A0956 JJ O
evidence P07530549A0956 NN O
that P07530549A0956 IN O
15 P07530549A0956 CD O
of P07530549A0956 IN O
these P07530549A0956 DT O
17 P07530549A0956 CD O
clones P07530549A0956 NNS O
contain P07530549A0956 VBP O
coding P07530549A0956 VBG O
sequences P07530549A0956 NNS O
and P07530549A0956 CC O
that P07530549A0956 DT O
nine P07530549A0956 CD O
other P07530549A0956 JJ O
clones P07530549A0956 NNS O
are P07530549A0956 VBP O
likely P07530549A0956 JJ O
to P07530549A0956 TO O
contain P07530549A0956 VB O
sequences P07530549A0956 NNS O
coding P07530549A0956 VBG O
for P07530549A0956 IN O
portions P07530549A0956 NNS O
of P07530549A0956 IN O
new P07530549A0956 JJ O
genes P07530549A0956 NNS O
. P07530549A0956 . O
. . O O

Mutations P11007961A0930 NNS O
in P11007961A0930 IN O
genes P11007961A0930 NNS O
encoding P11007961A0930 VBG O
PR65 P11007961A0930 NNP I-UN
/ P11007961A0930 VBZ I-UN
A P11007961A0930 NNP I-UN
subunits P11007961A0930 NNS I-UN
have P11007961A0930 VBP O
been P11007961A0930 VBN O
identified P11007961A0930 VBN O
in P11007961A0930 IN O
several P11007961A0930 JJ O
different P11007961A0930 JJ O
human P11007961A0930 JJ O
cancers P11007961A0930 NNS O
and P11007961A0930 CC O
the P11007961A0930 DT O
PP2A P11007961A0930 NNP I-UN
inhibitor P11007961A0930 NN O
, P11007961A0930 , O
termed P11007961A0930 VBD O
fostriecin P11007961A0930 NN O
, P11007961A0930 , O
is P11007961A0930 VBZ O
being P11007961A0930 VBG O
tested P11007961A0930 VBN O
as P11007961A0930 IN O
an P11007961A0930 DT O
anticancer P11007961A0930 JJ O
drug P11007961A0930 NN O
. P11007961A0930 . O
. . O O

Component P04070725A0442 NNP O
P100 P04070725A0442 NNP O
was P04070725A0442 VBD O
associated P04070725A0442 VBN O
with P04070725A0442 IN O
a P04070725A0442 DT O
frontal P04070725A0442 JJ O
negativity P04070725A0442 NN O
of P04070725A0442 IN O
similar P04070725A0442 JJ O
latency P04070725A0442 NN O
favoring P04070725A0442 VBG O
the P04070725A0442 DT O
hypothesis P04070725A0442 NN O
of P04070725A0442 IN O
a P04070725A0442 DT O
dipolar P04070725A0442 JJ O
occipital P04070725A0442 JJ O
generator P04070725A0442 NN O
. P04070725A0442 . O
. . O O

Roles P09596738T0000 NNS O
of P09596738T0000 IN O
the P09596738T0000 DT O
Candida P09596738T0000 NNP I-UN
albicans P09596738T0000 VBZ I-UN
mitogen-activated P09596738T0000 JJ I-UN
protein P09596738T0000 NN I-UN
kinase P09596738T0000 NN I-UN
homolog P09596738T0000 NN I-UN
, P09596738T0000 , O
Cek1p P09596738T0000 NNP I-UN
, P09596738T0000 , O
in P09596738T0000 IN O
hyphal P09596738T0000 NN O
development P09596738T0000 NN O
and P09596738T0000 CC O
systemic P09596738T0000 JJ O
candidiasis P09596738T0000 NN O
. P09596738T0000 . O
. . O O

Further P02115115A1053 RB O
, P02115115A1053 , O
they P02115115A1053 PRP O
are P02115115A1053 VBP O
consistent P02115115A1053 JJ O
with P02115115A1053 IN O
the P02115115A1053 DT O
suggestion P02115115A1053 NN O
that P02115115A1053 WDT O
sites P02115115A1053 VBZ O
homologous P02115115A1053 JJ O
to P02115115A1053 TO O
the P02115115A1053 DT O
CAR1 P02115115A1053 NNP I-UN
URS P02115115A1053 NNP I-UN
may P02115115A1053 MD O
be P02115115A1053 VB O
situated P02115115A1053 VBN O
in P02115115A1053 IN O
the P02115115A1053 DT O
5'-flanking P02115115A1053 JJ O
regions P02115115A1053 NNS O
of P02115115A1053 IN O
multiple P02115115A1053 JJ O
unrelated P02115115A1053 JJ O
yeast P02115115A1053 NN O
genes P02115115A1053 NNS O
. P02115115A1053 . O
. . O O

Having P09108038A1128 VBG O
an P09108038A1128 DT O
LRR P09108038A1128 NNP I-UN
domain P09108038A1128 NN I-UN
and P09108038A1128 CC O
an P09108038A1128 DT O
SH3-binding P09108038A1128 JJ I-UN
domain P09108038A1128 NN I-UN
, P09108038A1128 , O
Acan125 P09108038A1128 NNP I-UN
and P09108038A1128 CC O
the P09108038A1128 DT O
C. P09108038A1128 NNP O
elegans P09108038A1128 VBZ O
homologue P09108038A1128 JJ O
define P09108038A1128 NN O
a P09108038A1128 DT O
novel P09108038A1128 JJ O
family P09108038A1128 NN O
of P09108038A1128 IN O
bifunctional P09108038A1128 JJ O
binding P09108038A1128 NN O
proteins P09108038A1128 NNS O
. P09108038A1128 . O
. . O O

To P07624119A0528 TO O
compare P07624119A0528 VB O
the P07624119A0528 DT O
PAX3 P07624119A0528 NNP I-UN
and P07624119A0528 CC O
putative P07624119A0528 JJ O
PAX3-FKHR P07624119A0528 NNP O
transactivation P07624119A0528 NN O
domains P07624119A0528 NNS O
, P07624119A0528 , O
we P07624119A0528 PRP O
fused P07624119A0528 VBD O
C-terminal P07624119A0528 JJ O
test P07624119A0528 NN O
fragments P07624119A0528 NNS O
to P07624119A0528 TO O
the P07624119A0528 DT O
heterologous P07624119A0528 JJ O
GAL4 P07624119A0528 NNP I-UN
DNA-binding P07624119A0528 NNP I-UN
domain P07624119A0528 NN I-UN
and P07624119A0528 CC O
tested P07624119A0528 JJ O
activation P07624119A0528 NN O
of P07624119A0528 IN O
a P07624119A0528 DT O
reporter P07624119A0528 NN O
gene P07624119A0528 NN O
co-transfected P07624119A0528 JJ O
into P07624119A0528 IN O
four P07624119A0528 CD O
cell P07624119A0528 NN O
types P07624119A0528 NNS O
. P07624119A0528 . O
. . O O

( P09442017A0435 ( O
1997 P09442017A0435 CD O
) P09442017A0435 ) O
Science P09442017A0435 NN O
275 P09442017A0435 CD O
, P09442017A0435 , O
1927-1930 P09442017A0435 JJ O
) P09442017A0435 ) O
. P09442017A0435 . O
. . O O

The P10896859A0000 DT O
effect P10896859A0000 NN O
of P10896859A0000 IN O
water P10896859A0000 NN O
deprivation P10896859A0000 NN O
for P10896859A0000 IN O
19 P10896859A0000 CD O
h P10896859A0000 NN O
on P10896859A0000 IN O
renal P10896859A0000 JJ O
Na P10896859A0000 NNP O
excretion P10896859A0000 NN O
of P10896859A0000 IN O
conscious P10896859A0000 JJ O
adrenalectomized P10896859A0000 VBN O
( P10896859A0000 ( O
ADX P10896859A0000 NNP O
) P10896859A0000 ) O
sheep P10896859A0000 VBP O
maintained P10896859A0000 VBN O
on P10896859A0000 IN O
a P10896859A0000 DT O
constant P10896859A0000 JJ O
intravenous P10896859A0000 JJ O
infusion P10896859A0000 NN O
of P10896859A0000 IN O
aldosterone P10896859A0000 NN O
and P10896859A0000 CC O
cortisol P10896859A0000 NN O
( P10896859A0000 ( O
ADX-constant P10896859A0000 JJ O
steroid P10896859A0000 NN O
sheep P10896859A0000 NN O
) P10896859A0000 ) O
was P10896859A0000 VBD O
investigated P10896859A0000 VBN O
. P10896859A0000 . O
. . O O

In P09822825A0141 IN O
this P09822825A0141 DT O
paper P09822825A0141 NN O
, P09822825A0141 , O
we P09822825A0141 PRP O
show P09822825A0141 VBP O
that P09822825A0141 IN O
, P09822825A0141 , O
like P09822825A0141 IN O
BAP2 P09822825A0141 NNP I-UN
, P09822825A0141 , O
the P09822825A0141 DT O
expression P09822825A0141 NN O
of P09822825A0141 IN O
the P09822825A0141 DT O
BAP3 P09822825A0141 NNP I-UN
gene P09822825A0141 NN I-UN
in P09822825A0141 IN O
S. P09822825A0141 NNP O
cerevisiae P09822825A0141 NN O
is P09822825A0141 VBZ O
induced P09822825A0141 VBN O
by P09822825A0141 IN O
the P09822825A0141 DT O
addition P09822825A0141 NN O
of P09822825A0141 IN O
branched-chain P09822825A0141 NN O
amino P09822825A0141 NN O
acids P09822825A0141 NNS O
to P09822825A0141 TO O
the P09822825A0141 DT O
medium P09822825A0141 NN O
. P09822825A0141 . O
. . O O

Furthermore P08702826A0870 RB O
, P08702826A0870 , O
upstream P08702826A0870 JJ O
insertion P08702826A0870 NN O
of P08702826A0870 IN O
the P08702826A0870 DT O
GSTP1 P08702826A0870 NNP I-UN
silencer P08702826A0870 NN I-UN
element P08702826A0870 NN I-UN
failed P08702826A0870 VBD O
to P08702826A0870 TO O
inhibit P08702826A0870 VB O
activity P08702826A0870 NN O
of P08702826A0870 IN O
a P08702826A0870 DT O
heterologous P08702826A0870 JJ O
promoter P08702826A0870 NN O
in P08702826A0870 IN O
MCF7 P08702826A0870 NNP O
cells P08702826A0870 NNS O
. P08702826A0870 . O
. . O O

We P02339447A0162 PRP O
have P02339447A0162 VBP O
synthesized P02339447A0162 VBN O
[ P02339447A0162 JJ O
7,7-2H2 P02339447A0162 JJ O
] P02339447A0162 NN O
-19-OHA P02339447A0162 NN O
with P02339447A0162 IN O
high P02339447A0162 JJ O
deuterium P02339447A0162 NN O
content P02339447A0162 NN O
and P02339447A0162 CC O
, P02339447A0162 , O
together P02339447A0162 RB O
with P02339447A0162 IN O
[ P02339447A0162 JJ O
7,7-2H2 P02339447A0162 JJ O
] P02339447A0162 NN O
A P02339447A0162 NNP O
and P02339447A0162 CC O
[ P02339447A0162 NNP O
9,11-2H2 P02339447A0162 CD O
] P02339447A0162 NNP O
estrone P02339447A0162 NN O
( P02339447A0162 ( O
E1 P02339447A0162 NNP O
) P02339447A0162 ) O
, P02339447A0162 , O
have P02339447A0162 VBP O
developed P02339447A0162 VBN O
a P02339447A0162 DT O
quantitative P02339447A0162 JJ O
assay P02339447A0162 NN O
of P02339447A0162 IN O
serum P02339447A0162 JJ O
level P02339447A0162 NN O
19-OHA P02339447A0162 JJ O
, P02339447A0162 , O
A P02339447A0162 NNP O
, P02339447A0162 , O
and P02339447A0162 CC O
E1 P02339447A0162 NNP O
using P02339447A0162 VBG O
the P02339447A0162 DT O
gas P02339447A0162 NN O
chromatography P02339447A0162 NN O
/ P02339447A0162 JJ O
mass P02339447A0162 NN O
spectrometry-mass P02339447A0162 NN O
fragmentography P02339447A0162 NN O
method P02339447A0162 NN O
to P02339447A0162 TO O
monitor P02339447A0162 VB O
individual P02339447A0162 JJ O
subjects P02339447A0162 NNS O
throughout P02339447A0162 IN O
pregnancy P02339447A0162 NN O
. P02339447A0162 . O
. . O O

Endocytosis P07565740T0000 NN O
and P07565740T0000 CC O
vacuolar P07565740T0000 JJ O
degradation P07565740T0000 NN O
of P07565740T0000 IN O
the P07565740T0000 DT O
plasma P07565740T0000 JJ O
membrane-localized P07565740T0000 JJ O
Pdr5 P07565740T0000 NNP I-UN
ATP-binding P07565740T0000 NNP I-UN
cassette P07565740T0000 NN I-UN
multidrug P07565740T0000 NN I-UN
transporter P07565740T0000 NN I-UN
in P07565740T0000 IN O
Saccharomyces P07565740T0000 NNP O
cerevisiae P07565740T0000 NN O
. P07565740T0000 . O
. . O O

Therefore P10880702A0966 RB O
, P10880702A0966 , O
the P10880702A0966 DT O
results P10880702A0966 NNS O
indicate P10880702A0966 VBP O
that P10880702A0966 IN O
repeated P10880702A0966 VBD O
exposure P10880702A0966 NN O
to P10880702A0966 TO O
amphetamine P10880702A0966 VB O
or P10880702A0966 CC O
apomorphine P10880702A0966 VB O
overcomes P10880702A0966 VBZ O
the P10880702A0966 DT O
context-dependent P10880702A0966 JJ O
component P10880702A0966 NN O
of P10880702A0966 IN O
sensitization P10880702A0966 NN O
of P10880702A0966 IN O
amphetamine- P10880702A0966 JJ O
or P10880702A0966 CC O
apomorphine-induced P10880702A0966 JJ O
stereotyped P10880702A0966 JJ O
behavior P10880702A0966 NN O
. P10880702A0966 . O
. . O O

Characterization P10195425T0000 NN O
of P10195425T0000 IN O
the P10195425T0000 DT O
transcription P10195425T0000 NN I-UN
factor P10195425T0000 NN I-UN
MTF-1 P10195425T0000 NNP I-UN
from P10195425T0000 IN O
the P10195425T0000 DT O
Japanese P10195425T0000 JJ O
pufferfish P10195425T0000 NN O
( P10195425T0000 ( O
Fugu P10195425T0000 NNP O
rubripes P10195425T0000 VBZ O
) P10195425T0000 ) O
reveals P10195425T0000 NNS O
evolutionary P10195425T0000 JJ O
conservation P10195425T0000 NN O
of P10195425T0000 IN O
heavy P10195425T0000 JJ O
metal P10195425T0000 NN O
stress P10195425T0000 NN O
response P10195425T0000 NN O
. P10195425T0000 . O
. . O O

These P01467828A0542 DT O
results P01467828A0542 NNS O
indicate P01467828A0542 VBP O
a P01467828A0542 DT O
possible P01467828A0542 JJ O
involvement P01467828A0542 NN O
of P01467828A0542 IN O
endogenous P01467828A0542 JJ O
opioid P01467828A0542 JJ O
peptides P01467828A0542 NNS O
in P01467828A0542 IN O
the P01467828A0542 DT O
cardiac P01467828A0542 JJ O
effects P01467828A0542 NNS O
due P01467828A0542 JJ O
to P01467828A0542 TO O
myocardial P01467828A0542 JJ O
ischaemia P01467828A0542 NN O
and P01467828A0542 CC O
reperfusion P01467828A0542 NN O
, P01467828A0542 , O
mediated P01467828A0542 VBN O
by P01467828A0542 IN O
opiate P01467828A0542 NN I-UN
receptors P01467828A0542 NNS I-UN
through P01467828A0542 IN O
opiate P01467828A0542 JJ O
antagonism P01467828A0542 NN O
. P01467828A0542 . O
. . O O

The P07846163A0422 DT O
mRNAs P07846163A0422 NN O
of P07846163A0422 IN O
the P07846163A0422 DT O
GRF P07846163A0422 NNP I-UN
genes P07846163A0422 NNS I-UN
are P07846163A0422 VBP O
encoded P07846163A0422 VBN O
by P07846163A0422 IN O
six P07846163A0422 CD O
exons P07846163A0422 NNS O
interrupted P07846163A0422 VBN O
by P07846163A0422 IN O
five P07846163A0422 CD O
introns P07846163A0422 NNS O
. P07846163A0422 . O
. . O O

The P09322738A0510 DT O
histidine-tagged P09322738A0510 JJ O
gene P09322738A0510 NN O
, P09322738A0510 , O
rpoCHIS P09322738A0510 NN I-UN
, P09322738A0510 , O
was P09322738A0510 VBD O
used P09322738A0510 VBN O
to P09322738A0510 TO O
replace P09322738A0510 VB O
the P09322738A0510 DT O
wild-type P09322738A0510 JJ O
allele P09322738A0510 NN O
in P09322738A0510 IN O
the P09322738A0510 DT O
chromosome P09322738A0510 NN O
of P09322738A0510 IN O
S. P09322738A0510 NNP O
coelicolor P09322738A0510 NN O
and P09322738A0510 CC O
S. P09322738A0510 NNP O
lividans P09322738A0510 NNS O
. P09322738A0510 . O
. . O O

Previously P01516829A0113 RB O
, P01516829A0113 , O
we P01516829A0113 PRP O
showed P01516829A0113 VBD O
that P01516829A0113 IN O
SNF2 P01516829A0113 NNP I-UN
, P01516829A0113 , O
SNF5 P01516829A0113 NNP I-UN
, P01516829A0113 , O
and P01516829A0113 CC O
SNF6 P01516829A0113 NNP I-UN
function P01516829A0113 NN O
interdependently P01516829A0113 RB O
in P01516829A0113 IN O
transcriptional P01516829A0113 JJ O
activation P01516829A0113 NN O
, P01516829A0113 , O
possibly P01516829A0113 RB O
forming P01516829A0113 VBG O
a P01516829A0113 DT O
heteromeric P01516829A0113 JJ O
complex P01516829A0113 NN O
. P01516829A0113 . O
. . O O

Recombinant P08264617A0000 JJ O
expression P08264617A0000 NN O
of P08264617A0000 IN O
a P08264617A0000 DT O
chimeric P08264617A0000 JJ O
EGFR P08264617A0000 NNP I-UN
/ P08264617A0000 NNP O
ErbB-3 P08264617A0000 NNP I-UN
receptor P08264617A0000 NN I-UN
in P08264617A0000 IN O
NIH P08264617A0000 NNP O
3T3 P08264617A0000 CD O
fibroblasts P08264617A0000 NNS O
allowed P08264617A0000 VBD O
us P08264617A0000 PRP O
to P08264617A0000 TO O
investigate P08264617A0000 VB O
cytoplasmic P08264617A0000 JJ O
events P08264617A0000 NNS O
associated P08264617A0000 VBN O
with P08264617A0000 IN O
ErbB-3 P08264617A0000 NNP I-UN
signal P08264617A0000 JJ O
transduction P08264617A0000 NN O
upon P08264617A0000 IN O
ligand P08264617A0000 NN O
activation P08264617A0000 NN O
. P08264617A0000 . O
. . O O

Interestingly P10688660A0992 RB O
, P10688660A0992 , O
addition P10688660A0992 NN O
of P10688660A0992 IN O
purified P10688660A0992 JJ O
CBP P10688660A0992 NNP I-UN
to P10688660A0992 TO O
the P10688660A0992 DT O
nuclear P10688660A0992 JJ O
extracts P10688660A0992 NNS O
of P10688660A0992 IN O
T47D P10688660A0992 NNP O
cells P10688660A0992 NNS O
markedly P10688660A0992 RB O
stimulated P10688660A0992 VBD O
progesterone- P10688660A0992 JJ O
and P10688660A0992 CC O
PR-dependent P10688660A0992 JJ O
transcription P10688660A0992 NN O
from P10688660A0992 IN O
a P10688660A0992 DT O
nucleosome-free P10688660A0992 JJ O
, P10688660A0992 , O
progesterone P10688660A0992 JJ O
response P10688660A0992 NN O
element P10688660A0992 NN O
( P10688660A0992 ( O
PRE P10688660A0992 NNP O
) P10688660A0992 ) O
-linked P10688660A0992 VBD O
reporter P10688660A0992 NN O
DNA P10688660A0992 NNP O
template P10688660A0992 NN O
. P10688660A0992 . O
. . O O

The P06225279A0498 DT O
abluminal P06225279A0498 JJ O
surface P06225279A0498 NN O
is P06225279A0498 VBZ O
often P06225279A0498 RB O
almost P06225279A0498 RB O
entirely P06225279A0498 RB O
encircled P06225279A0498 VBN O
by P06225279A0498 IN O
a P06225279A0498 DT O
thick P06225279A0498 JJ O
layer P06225279A0498 NN O
of P06225279A0498 IN O
fibrillary P06225279A0498 JJ O
connective P06225279A0498 JJ O
tissue P06225279A0498 NN O
. P06225279A0498 . O
. . O O

Analysis P07413144T0018 NN O
of P07413144T0018 IN O
an P07413144T0018 DT O
autopsy P07413144T0018 JJ O
population P07413144T0018 NN O
. P07413144T0018 . O
. . O O

Consistent P09182527A0443 JJ O
with P09182527A0443 IN O
its P09182527A0443 PRP$ O
role P09182527A0443 NN O
in P09182527A0443 IN O
p53 P09182527A0443 NN I-UN
ubiquitination P09182527A0443 NN O
, P09182527A0443 , O
mE6-AP P09182527A0443 NN I-UN
was P09182527A0443 VBD O
found P09182527A0443 VBN O
both P09182527A0443 DT O
in P09182527A0443 IN O
the P09182527A0443 DT O
nucleus P09182527A0443 NN O
and P09182527A0443 CC O
cytosol P09182527A0443 NN O
, P09182527A0443 , O
while P09182527A0443 IN O
Nedd-4 P09182527A0443 NNP I-UN
was P09182527A0443 VBD O
found P09182527A0443 VBN O
only P09182527A0443 RB O
in P09182527A0443 IN O
the P09182527A0443 DT O
cytosol P09182527A0443 NN O
. P09182527A0443 . O
. . O O

The P02868446A0184 DT O
C-terminal P02868446A0184 JJ O
domains P02868446A0184 NNS O
( P02868446A0184 ( O
CTDs P02868446A0184 NNP O
) P02868446A0184 ) O
of P02868446A0184 IN O
the P02868446A0184 DT O
RPase P02868446A0184 NNP I-UN
beta P02868446A0184 NN I-UN
subunit P02868446A0184 NN I-UN
and P02868446A0184 CC O
DNA P02868446A0184 NNP I-UN
primase P02868446A0184 NN I-UN
( P02868446A0184 ( O
dnaG P02868446A0184 JJ I-UN
protein P02868446A0184 NN I-UN
) P02868446A0184 ) O
were P02868446A0184 VBD O
not P02868446A0184 RB O
only P02868446A0184 RB O
strongly P02868446A0184 RB O
homologous P02868446A0184 JJ O
to P02868446A0184 TO O
each P02868446A0184 DT O
other P02868446A0184 JJ O
but P02868446A0184 CC O
also P02868446A0184 RB O
considerably P02868446A0184 RB O
homologous P02868446A0184 JJ O
to P02868446A0184 TO O
the P02868446A0184 DT O
RPase P02868446A0184 NNP I-UN
alpha P02868446A0184 NN I-UN
, P02868446A0184 , O
suggesting P02868446A0184 VBG O
that P02868446A0184 IN O
an P02868446A0184 DT O
alpha P02868446A0184 JJ O
subunit-like P02868446A0184 JJ O
enzyme P02868446A0184 NN O
must P02868446A0184 MD O
have P02868446A0184 VB O
been P02868446A0184 VBN O
commonly P02868446A0184 RB O
ancestral P02868446A0184 JJ O
to P02868446A0184 TO O
core P02868446A0184 VB I-UN
enzyme P02868446A0184 JJ I-UN
subunits P02868446A0184 NNS I-UN
and P02868446A0184 CC O
primase P02868446A0184 NN I-UN
. P02868446A0184 . O
. . O O

A P10748054T0048 DT O
pathway P10748054T0048 NN O
for P10748054T0048 IN O
regulation P10748054T0048 NN O
of P10748054T0048 IN O
B P10748054T0048 NNP I-UN
lymphocyte P10748054T0048 NN I-UN
antigen P10748054T0048 NN I-UN
receptor-induced P10748054T0048 JJ O
calcium P10748054T0048 NN O
flux P10748054T0048 NN O
. P10748054T0048 . O
. . O O

Protein P01572549A0000 NNP I-UN
tyrosine P01572549A0000 NN I-UN
kinases P01572549A0000 NNS I-UN
( P01572549A0000 ( O
PTKs P01572549A0000 NNP I-UN
) P01572549A0000 ) O
are P01572549A0000 VBP O
implicated P01572549A0000 VBN O
in P01572549A0000 IN O
the P01572549A0000 DT O
control P01572549A0000 NN O
of P01572549A0000 IN O
cell P01572549A0000 NN O
growth P01572549A0000 NN O
by P01572549A0000 IN O
virtue P01572549A0000 NN O
of P01572549A0000 IN O
their P01572549A0000 PRP$ O
frequent P01572549A0000 JJ O
appearance P01572549A0000 NN O
as P01572549A0000 IN O
products P01572549A0000 NNS O
of P01572549A0000 IN O
retroviral P01572549A0000 JJ O
oncogenes P01572549A0000 NNS O
, P01572549A0000 , O
as P01572549A0000 IN O
intracellular P01572549A0000 JJ O
signal P01572549A0000 NN O
transducers P01572549A0000 NNS O
, P01572549A0000 , O
and P01572549A0000 CC O
as P01572549A0000 IN O
growth P01572549A0000 NN I-UN
factor P01572549A0000 NN I-UN
receptors P01572549A0000 NNS I-UN
or P01572549A0000 CC O
components P01572549A0000 NNS O
thereof P01572549A0000 NN O
. P01572549A0000 . O
. . O O

Indoor P08777374A1471 JJ O
concentrations P08777374A1471 NNS O
were P08777374A1471 VBD O
only P08777374A1471 RB O
weakly P08777374A1471 RB O
correlated P08777374A1471 VBN O
with P08777374A1471 IN O
outdoor P08777374A1471 JJ O
concentrations P08777374A1471 NNS O
, P08777374A1471 , O
however P08777374A1471 RB O
, P08777374A1471 , O
and P08777374A1471 CC O
personal P08777374A1471 JJ O
exposures P08777374A1471 NNS O
were P08777374A1471 VBD O
even P08777374A1471 RB O
more P08777374A1471 JJR O
poorly P08777374A1471 RB O
correlated P08777374A1471 VBN O
with P08777374A1471 IN O
outdoor P08777374A1471 JJ O
concentrations P08777374A1471 NNS O
. P08777374A1471 . O
. . O O

Biol P11279217A0273 NNP O
. P11279217A0273 . O
. . O O

Since P01647813A0512 IN O
each P01647813A0512 DT O
transcript P01647813A0512 NN O
appears P01647813A0512 VBZ O
to P01647813A0512 TO O
encode P01647813A0512 VB O
the P01647813A0512 DT O
same P01647813A0512 JJ O
protein P01647813A0512 NN O
, P01647813A0512 , O
this P01647813A0512 DT O
complexity P01647813A0512 NN O
may P01647813A0512 MD O
reflect P01647813A0512 VB O
the P01647813A0512 DT O
need P01647813A0512 NN O
for P01647813A0512 IN O
lineage-specific P01647813A0512 JJ O
or P01647813A0512 CC O
differentiation-dependent P01647813A0512 JJ O
control P01647813A0512 NN O
of P01647813A0512 IN O
expression P01647813A0512 NN O
. P01647813A0512 . O
. . O O

Addition P03423732A0341 NN O
of P03423732A0341 IN O
sucralfate P03423732A0341 NN O
or P03423732A0341 CC O
De-Nol P03423732A0341 NNP O
resulted P03423732A0341 VBD O
in P03423732A0341 IN O
increments P03423732A0341 NNS O
of P03423732A0341 IN O
gastric P03423732A0341 JJ O
HCO3 P03423732A0341 NNP O
secretion P03423732A0341 NN O
, P03423732A0341 , O
reaching P03423732A0341 VBG O
about P03423732A0341 IN O
45 P03423732A0341 CD O
% P03423732A0341 NN O
and P03423732A0341 CC O
59 P03423732A0341 CD O
% P03423732A0341 NN O
, P03423732A0341 , O
respectively P03423732A0341 RB O
, P03423732A0341 , O
of P03423732A0341 IN O
the P03423732A0341 DT O
maximal P03423732A0341 JJ O
HCO3 P03423732A0341 NNP O
response P03423732A0341 NN O
to P03423732A0341 TO O
16,16-dimethyl P03423732A0341 JJ O
PGE2 P03423732A0341 NNP O
( P03423732A0341 ( O
dmPGE2 P03423732A0341 NN O
) P03423732A0341 ) O
. P03423732A0341 . O
. . O O

Recombinant P10049359A1073 JJ O
unr P10049359A1073 JJ I-UN
acts P10049359A1073 NNS O
synergistically P10049359A1073 RB O
with P10049359A1073 IN O
recombinant P10049359A1073 JJ O
PTB P10049359A1073 NNP I-UN
to P10049359A1073 TO O
stimulate P10049359A1073 VB O
translation P10049359A1073 NN O
dependent P10049359A1073 NN O
on P10049359A1073 IN O
the P10049359A1073 DT O
rhinovirus P10049359A1073 NN O
IRES P10049359A1073 NNP O
. P10049359A1073 . O
. . O O

Synthesis P10488129T0058 NN O
of P10488129T0058 IN O
antisense P10488129T0058 NN O
RNA P10488129T0058 NNP O
and P10488129T0058 CC O
S P10488129T0058 NNP O
phase-dependent P10488129T0058 JJ O
binding P10488129T0058 NN O
of P10488129T0058 IN O
E2F P10488129T0058 NNP I-UN
complexes P10488129T0058 NNS I-UN
in P10488129T0058 IN O
intron P10488129T0058 NN O
1 P10488129T0058 CD O
. P10488129T0058 . O
. . O O

It P09649069A0490 PRP O
can P09649069A0490 MD O
also P09649069A0490 RB O
be P09649069A0490 VB O
used P09649069A0490 VBN O
to P09649069A0490 TO O
examine P09649069A0490 VB O
various P09649069A0490 JJ O
laryngeal P09649069A0490 JJ O
parameters P09649069A0490 NNS O
obtained P09649069A0490 VBN O
from P09649069A0490 IN O
videotaped P09649069A0490 JJ O
endoscopic P09649069A0490 NN O
and P09649069A0490 CC O
stroboscopic P09649069A0490 NN O
examinations P09649069A0490 NNS O
. P09649069A0490 . O
. . O O

Five P06259220A0000 CD O
experiments P06259220A0000 NNS O
examined P06259220A0000 VBD O
the P06259220A0000 DT O
influence P06259220A0000 NN O
of P06259220A0000 IN O
opiate P06259220A0000 NN O
antagonists P06259220A0000 NNS O
on P06259220A0000 IN O
both P06259220A0000 DT O
the P06259220A0000 DT O
short-term P06259220A0000 JJ O
analgesic P06259220A0000 JJ O
reaction P06259220A0000 NN O
resulting P06259220A0000 VBG O
30 P06259220A0000 CD O
min P06259220A0000 NN O
after P06259220A0000 IN O
exposure P06259220A0000 NN O
to P06259220A0000 TO O
inescapable P06259220A0000 VB O
shock P06259220A0000 NN O
and P06259220A0000 CC O
the P06259220A0000 DT O
long-term P06259220A0000 JJ O
analgesic P06259220A0000 JJ O
reaction P06259220A0000 NN O
resulting P06259220A0000 VBG O
after P06259220A0000 IN O
reexposure P06259220A0000 NN O
to P06259220A0000 TO O
shock P06259220A0000 VB O
24 P06259220A0000 CD O
hr P06259220A0000 NN O
after P06259220A0000 IN O
inescapable P06259220A0000 JJ O
shock P06259220A0000 NN O
exposure P06259220A0000 NN O
. P06259220A0000 . O
. . O O

Growth P01748630A0125 NNP O
factor P01748630A0125 NN O
stimulation P01748630A0125 NN O
of P01748630A0125 IN O
cells P01748630A0125 NNS O
causes P01748630A0125 VBZ O
the P01748630A0125 DT O
phosphorylation P01748630A0125 NN O
of P01748630A0125 IN O
the P01748630A0125 DT O
c-Myc P01748630A0125 JJ I-UN
transcriptional P01748630A0125 JJ I-UN
activation P01748630A0125 NN I-UN
domain P01748630A0125 NN I-UN
at P01748630A0125 IN O
Ser62 P01748630A0125 NNP O
within P01748630A0125 IN O
a P01748630A0125 DT O
proline-rich P01748630A0125 JJ O
region P01748630A0125 NN O
that P01748630A0125 WDT O
is P01748630A0125 VBZ O
highly P01748630A0125 RB O
conserved P01748630A0125 VBN O
among P01748630A0125 IN O
members P01748630A0125 NNS O
of P01748630A0125 IN O
the P01748630A0125 DT O
Myc P01748630A0125 NNP I-UN
family P01748630A0125 NN I-UN
( P01748630A0125 ( O
Alvarez P01748630A0125 NNP O
, P01748630A0125 , O
E. P01748630A0125 NNP O
, P01748630A0125 , O
Northwood P01748630A0125 NNP O
, P01748630A0125 , O
I.C. P01748630A0125 NNP O
, P01748630A0125 , O
Gonzalez P01748630A0125 NNP O
, P01748630A0125 , O
F P01748630A0125 NNP O
. P01748630A0125 . O
. . O O

Flap P09529216A0644 NNP O
survival P09529216A0644 NN O
depends P09529216A0644 VBZ O
on P09529216A0644 IN O
the P09529216A0644 DT O
development P09529216A0644 NN O
of P09529216A0644 IN O
a P09529216A0644 DT O
small P09529216A0644 JJ O
number P09529216A0644 NN O
of P09529216A0644 IN O
vascular P09529216A0644 JJ O
connections P09529216A0644 NNS O
between P09529216A0644 IN O
vessels P09529216A0644 NNS O
arising P09529216A0644 VBG O
from P09529216A0644 IN O
the P09529216A0644 DT O
pedicle P09529216A0644 NN O
and P09529216A0644 CC O
preexisting P09529216A0644 VBG O
dermal P09529216A0644 JJ O
vessels P09529216A0644 NNS O
. P09529216A0644 . O
. . O O

Selection P08887652A0341 NN O
was P08887652A0341 VBD O
based P08887652A0341 VBN O
on P08887652A0341 IN O
expression P08887652A0341 NN O
of P08887652A0341 IN O
an P08887652A0341 DT O
integrated P08887652A0341 VBN O
DNA P08887652A0341 NNP O
fragment P08887652A0341 NN O
containing P08887652A0341 VBG O
the P08887652A0341 DT O
con-10 P08887652A0341 JJ I-UN
promoter-regulatory P08887652A0341 JJ I-UN
region P08887652A0341 NN I-UN
followed P08887652A0341 VBN O
by P08887652A0341 IN O
the P08887652A0341 DT O
initial P08887652A0341 JJ O
segment P08887652A0341 NN O
of P08887652A0341 IN O
the P08887652A0341 DT O
con-10 P08887652A0341 JJ I-UN
open P08887652A0341 JJ I-UN
reading P08887652A0341 NN I-UN
frame P08887652A0341 NN I-UN
fused P08887652A0341 VBN O
in P08887652A0341 IN O
frame P08887652A0341 NN O
with P08887652A0341 IN O
the P08887652A0341 DT O
bacterial P08887652A0341 JJ I-UN
hygromycin P08887652A0341 NN I-UN
B P08887652A0341 NNP I-UN
phosphotransferase P08887652A0341 NN I-UN
structural P08887652A0341 JJ I-UN
gene P08887652A0341 NN I-UN
( P08887652A0341 ( O
con10'-'hph P08887652A0341 JJ I-UN
) P08887652A0341 ) O
. P08887652A0341 . O
. . O O

Sci P03182802A0278 NNP O
. P03182802A0278 . O
. . O O

Likewise P02408248A0414 RB O
, P02408248A0414 , O
whether P02408248A0414 IN O
or P02408248A0414 CC O
not P02408248A0414 RB O
the P02408248A0414 DT O
hypotensive P02408248A0414 JJ O
action P02408248A0414 NN O
of P02408248A0414 IN O
converting P02408248A0414 VBG O
enzyme P02408248A0414 JJ O
inhibitors P02408248A0414 NNS O
is P02408248A0414 VBZ O
age-related P02408248A0414 JJ O
is P02408248A0414 VBZ O
as P02408248A0414 IN O
yet P02408248A0414 RB O
unknown P02408248A0414 JJ O
. P02408248A0414 . O
. . O O

The P06214605A0123 DT O
number P06214605A0123 NN O
of P06214605A0123 IN O
elements P06214605A0123 NNS O
and P06214605A0123 CC O
their P06214605A0123 PRP$ O
sizes P06214605A0123 NNS O
relative P06214605A0123 VBP O
to P06214605A0123 TO O
the P06214605A0123 DT O
configuration P06214605A0123 NN O
were P06214605A0123 VBD O
varied P06214605A0123 VBN O
in P06214605A0123 IN O
a P06214605A0123 DT O
series P06214605A0123 NN O
of P06214605A0123 IN O
five P06214605A0123 CD O
experiments P06214605A0123 NNS O
. P06214605A0123 . O
. . O O

Reperfusion P02875224A1059 NN O
with P02875224A1059 IN O
normal P02875224A1059 JJ O
blood P02875224A1059 NN O
in P02875224A1059 IN O
the P02875224A1059 DT O
beating P02875224A1059 NN O
, P02875224A1059 , O
working P02875224A1059 VBG O
hearts P02875224A1059 NNS O
caused P02875224A1059 VBD O
extensive P02875224A1059 JJ O
structural P02875224A1059 JJ O
damage P02875224A1059 NN O
, P02875224A1059 , O
reduced P02875224A1059 VBD O
reflow P02875224A1059 NN O
, P02875224A1059 , O
and P02875224A1059 CC O
failed P02875224A1059 VBD O
to P02875224A1059 TO O
restore P02875224A1059 VB O
contractility P02875224A1059 NN O
in P02875224A1059 IN O
any P02875224A1059 DT O
instance P02875224A1059 NN O
( P02875224A1059 ( O
-27 P02875224A1059 CD O
% P02875224A1059 NN O
systolic P02875224A1059 JJ O
shortening P02875224A1059 NN O
, P02875224A1059 , O
p P02875224A1059 NN O
less P02875224A1059 JJR O
than P02875224A1059 IN O
0.05 P02875224A1059 CD O
) P02875224A1059 ) O
. P02875224A1059 . O
. . O O

The P11806132A0253 DT O
TB P11806132A0253 NNP O
incidence P11806132A0253 NN O
in P11806132A0253 IN O
the P11806132A0253 DT O
`` P11806132A0253 `` O
AIRIN P11806132A0253 NNP O
'' P11806132A0253 '' O
area P11806132A0253 NN O
, P11806132A0253 , O
where P11806132A0253 WRB O
about P11806132A0253 RB O
20 P11806132A0253 CD O
% P11806132A0253 NN O
TB P11806132A0253 NN O
patients P11806132A0253 NNS O
are P11806132A0253 VBP O
homeless P11806132A0253 JJ O
, P11806132A0253 , O
shows P11806132A0253 VBZ O
highest P11806132A0253 JJS O
rate P11806132A0253 NN O
of P11806132A0253 IN O
above P11806132A0253 IN O
1,000 P11806132A0253 CD O
/ P11806132A0253 JJ O
100,000 P11806132A0253 CD O
. P11806132A0253 . O
. . O O

These P08556707A1390 DT O
data P08556707A1390 NNS O
indicate P08556707A1390 VBP O
that P08556707A1390 IN O
although P08556707A1390 IN O
218leu P08556707A1390 CD O
retains P08556707A1390 NNS O
normal P08556707A1390 JJ O
transactivation P08556707A1390 NN O
activity P08556707A1390 NN O
on P08556707A1390 IN O
a P08556707A1390 DT O
p53 P08556707A1390 NN I-UN
promoter P08556707A1390 NN I-UN
in P08556707A1390 IN O
yeast P08556707A1390 NN O
at P08556707A1390 IN O
physiological P08556707A1390 JJ O
temperatures P08556707A1390 NNS O
, P08556707A1390 , O
it P08556707A1390 PRP O
is P08556707A1390 VBZ O
not P08556707A1390 RB O
capable P08556707A1390 JJ O
of P08556707A1390 IN O
normal P08556707A1390 JJ O
p53 P08556707A1390 NN I-UN
function P08556707A1390 NN O
in P08556707A1390 IN O
the P08556707A1390 DT O
presence P08556707A1390 NN O
of P08556707A1390 IN O
a P08556707A1390 DT O
248trp P08556707A1390 CD I-UN
allele P08556707A1390 NN I-UN
in P08556707A1390 IN O
SNU-C5 P08556707A1390 NNP O
cells P08556707A1390 NNS O
. P08556707A1390 . O
. . O O

This P07670504A0834 DT O
shows P07670504A0834 VBZ O
that P07670504A0834 IN O
the P07670504A0834 DT O
characteristically P07670504A0834 RB O
diffuse P07670504A0834 VBP O
banding P07670504A0834 VBG O
pattern P07670504A0834 NN O
of P07670504A0834 IN O
plant P07670504A0834 NN O
nuclear P07670504A0834 JJ O
proteins P07670504A0834 VBZ O
interacting P07670504A0834 VBG O
with P07670504A0834 IN O
the P07670504A0834 DT O
G-box P07670504A0834 NNP O
is P07670504A0834 VBZ O
also P07670504A0834 RB O
observed P07670504A0834 VBN O
in P07670504A0834 IN O
a P07670504A0834 DT O
binding P07670504A0834 NN O
assay P07670504A0834 NN O
using P07670504A0834 VBG O
only P07670504A0834 RB O
one P07670504A0834 CD O
recombinant P07670504A0834 NN I-UN
GBF P07670504A0834 NNP I-UN
. P07670504A0834 . O
. . O O

One P11126806A0206 CD O
of P11126806A0206 IN O
the P11126806A0206 DT O
sequelae P11126806A0206 NN O
of P11126806A0206 IN O
the P11126806A0206 DT O
antiphospholipid-antibodies P11126806A0206 NNS O
is P11126806A0206 VBZ O
an P11126806A0206 DT O
impaired P11126806A0206 JJ O
uteroplacental P11126806A0206 JJ O
circulation P11126806A0206 NN O
. P11126806A0206 . O
. . O O

TATA P08223592A0424 NNP O
and P08223592A0424 CC O
CCAAT P08223592A0424 NNP O
boxes P08223592A0424 NNS O
are P08223592A0424 VBP O
located P08223592A0424 VBN O
34-bp P08223592A0424 JJ O
and P08223592A0424 CC O
68-bp P08223592A0424 JJ O
, P08223592A0424 , O
respectively P08223592A0424 RB O
, P08223592A0424 , O
upstream P08223592A0424 NN O
of P08223592A0424 IN O
the P08223592A0424 DT O
transcription P08223592A0424 NN O
start P08223592A0424 NN O
site P08223592A0424 NN O
, P08223592A0424 , O
the P08223592A0424 DT O
5'-untranslated P08223592A0424 JJ O
leader P08223592A0424 NN O
is P08223592A0424 VBZ O
78 P08223592A0424 CD O
nucleotides P08223592A0424 NNS O
long P08223592A0424 RB O
, P08223592A0424 , O
and P08223592A0424 CC O
the P08223592A0424 DT O
intronless P08223592A0424 NN O
gene P08223592A0424 NN O
has P08223592A0424 VBZ O
at P08223592A0424 IN O
least P08223592A0424 JJS O
two P08223592A0424 CD O
different P08223592A0424 JJ O
polyadenylation P08223592A0424 NN O
sites P08223592A0424 NNS O
. P08223592A0424 . O
. . O O

With P02157141A0923 IN O
only P02157141A0923 RB O
purified P02157141A0923 JJ O
T P02157141A0923 NNP I-UN
antigen P02157141A0923 NN I-UN
in P02157141A0923 IN O
the P02157141A0923 DT O
presence P02157141A0923 NN O
of P02157141A0923 IN O
topoisomerase P02157141A0923 NN I-UN
I P02157141A0923 PRP I-UN
to P02157141A0923 TO O
unwind P02157141A0923 VB O
purified P02157141A0923 JJ O
DNA P02157141A0923 NNP O
, P02157141A0923 , O
ori-auxiliary P02157141A0923 JJ O
sequences P02157141A0923 NNS O
strongly P02157141A0923 RB O
facilitated P02157141A0923 VBD O
T-antigen-dependent P02157141A0923 JJ O
DNA P02157141A0923 NNP O
conformational P02157141A0923 NN O
changes P02157141A0923 NNS O
consistent P02157141A0923 VBP O
with P02157141A0923 IN O
melting P02157141A0923 VBG O
the P02157141A0923 DT O
first P02157141A0923 JJ O
50 P02157141A0923 CD O
base P02157141A0923 NN O
pairs P02157141A0923 NN O
. P02157141A0923 . O
. . O O

We P07860208A0000 PRP O
have P07860208A0000 VBP O
measured P07860208A0000 VBN O
the P07860208A0000 DT O
release P07860208A0000 NN O
of P07860208A0000 IN O
interleukin-1 P07860208A0000 JJ I-UN
beta P07860208A0000 NN I-UN
( P07860208A0000 ( O
IL-1 P07860208A0000 NNP I-UN
) P07860208A0000 ) O
and P07860208A0000 CC O
tumour P07860208A0000 JJ I-UN
necrosis P07860208A0000 NN I-UN
factor-alpha P07860208A0000 NN I-UN
( P07860208A0000 ( O
TNF P07860208A0000 NNP I-UN
) P07860208A0000 ) O
by P07860208A0000 IN O
unstimulated P07860208A0000 JJ O
monocytes P07860208A0000 NNS O
and P07860208A0000 CC O
monocytes P07860208A0000 NNS O
stimulated P07860208A0000 VBN O
with P07860208A0000 IN O
lipopolysaccharide P07860208A0000 NN O
( P07860208A0000 ( O
LPS P07860208A0000 NNP O
) P07860208A0000 ) O
isolated P07860208A0000 VBD O
from P07860208A0000 IN O
the P07860208A0000 DT O
peripheral P07860208A0000 JJ O
blood P07860208A0000 NN O
of P07860208A0000 IN O
two P07860208A0000 CD O
patients P07860208A0000 NNS O
with P07860208A0000 IN O
acute P07860208A0000 JJ O
poststreptococcal P07860208A0000 JJ O
glomerulonephritis P07860208A0000 NN O
( P07860208A0000 ( O
AGN P07860208A0000 NNP O
) P07860208A0000 ) O
and P07860208A0000 CC O
16 P07860208A0000 CD O
healthy P07860208A0000 JJ O
controls P07860208A0000 NNS O
. P07860208A0000 . O
. . O O

The P10369757A0000 DT O
major P10369757A0000 JJ O
transcription P10369757A0000 NN O
factors P10369757A0000 NNS O
controlling P10369757A0000 VBG O
arginine P10369757A0000 JJ O
metabolism P10369757A0000 NN O
in P10369757A0000 IN O
Escherichia P10369757A0000 NNP O
coli P10369757A0000 NN O
and P10369757A0000 CC O
Bacillus P10369757A0000 NNP O
subtilis P10369757A0000 NNS O
, P10369757A0000 , O
ArgR P10369757A0000 NNP I-UN
and P10369757A0000 CC O
AhrC P10369757A0000 NNP I-UN
, P10369757A0000 , O
respectively P10369757A0000 RB O
, P10369757A0000 , O
are P10369757A0000 VBP O
homologous P10369757A0000 JJ O
multimeric P10369757A0000 JJ O
proteins P10369757A0000 NNS O
that P10369757A0000 WDT O
form P10369757A0000 VBP O
l P10369757A0000 JJ O
-arginine-dependent P10369757A0000 JJ O
DNA-binding P10369757A0000 NN O
complexes P10369757A0000 NNS O
capable P10369757A0000 JJ O
of P10369757A0000 IN O
repressing P10369757A0000 VBG O
transcription P10369757A0000 NN O
of P10369757A0000 IN O
the P10369757A0000 DT O
biosynthetic P10369757A0000 JJ O
genes P10369757A0000 NNS O
( P10369757A0000 ( O
both P10369757A0000 DT O
) P10369757A0000 ) O
, P10369757A0000 , O
activating P10369757A0000 VBG O
transcription P10369757A0000 NN O
of P10369757A0000 IN O
catabolic P10369757A0000 JJ O
genes P10369757A0000 NNS O
( P10369757A0000 ( O
AhrC P10369757A0000 NNP I-UN
only P10369757A0000 RB O
) P10369757A0000 ) O
or P10369757A0000 CC O
facilitating P10369757A0000 VBG O
plasmid P10369757A0000 JJ O
dimer P10369757A0000 JJ O
resolution P10369757A0000 NN O
( P10369757A0000 ( O
both P10369757A0000 DT O
) P10369757A0000 ) O
. P10369757A0000 . O
. . O O

State-approved P04552263T0000 JJ O
schools P04552263T0000 NNS O
of P04552263T0000 IN O
nursing P04552263T0000 NN O
-- P04552263T0000 : O
R.N. P04552263T0000 NNP O
, P04552263T0000 , O
1972 P04552263T0000 CD O
. P04552263T0000 . O
. . O O

The P09833610A0626 DT O
exodomain P09833610A0626 NN O
alone P09833610A0626 RB O
has P09833610A0626 VBZ O
the P09833610A0626 DT O
high P09833610A0626 JJ O
affinity P09833610A0626 NN O
hormone P09833610A0626 NN O
binding P09833610A0626 VBG O
site P09833610A0626 NN O
but P09833610A0626 CC O
is P09833610A0626 VBZ O
not P09833610A0626 RB O
capable P09833610A0626 JJ O
of P09833610A0626 IN O
generating P09833610A0626 VBG O
hormonal P09833610A0626 JJ O
signal P09833610A0626 NN O
. P09833610A0626 . O
. . O O

51.9 P09458021A1373 CD O
% P09458021A1373 NN O
( P09458021A1373 ( O
P=0.0006 P09458021A1373 NNP O
) P09458021A1373 ) O
in P09458021A1373 IN O
the P09458021A1373 DT O
MMF P09458021A1373 NNP O
versus P09458021A1373 IN O
the P09458021A1373 DT O
AZA P09458021A1373 NNP O
groups P09458021A1373 NNS O
, P09458021A1373 , O
respectively P09458021A1373 RB O
. P09458021A1373 . O
. . O O

The P08973185T0061 DT O
effect P08973185T0061 NN O
of P08973185T0061 IN O
six P08973185T0061 CD O
arginine P08973185T0061 JJ O
mutations P08973185T0061 NNS O
of P08973185T0061 IN O
oxidative P08973185T0061 JJ O
phosphorylation P08973185T0061 NN O
and P08973185T0061 CC O
AAC P08973185T0061 NNP I-UN
expression P08973185T0061 NN O
. P08973185T0061 . O
. . O O

In P02889495A0000 IN O
a P02889495A0000 DT O
randomised P02889495A0000 JJ O
double-blind P02889495A0000 NN O
study P02889495A0000 NN O
, P02889495A0000 , O
46 P02889495A0000 CD O
first P02889495A0000 JJ O
episode P02889495A0000 NN O
schizophrenics P02889495A0000 NNS O
were P02889495A0000 VBD O
given P02889495A0000 VBN O
pimozide P02889495A0000 RB O
or P02889495A0000 CC O
flupenthixol P02889495A0000 NN O
for P02889495A0000 IN O
up P02889495A0000 IN O
to P02889495A0000 TO O
5 P02889495A0000 CD O
weeks P02889495A0000 NNS O
; P02889495A0000 : O
the P02889495A0000 DT O
mean P02889495A0000 JJ O
daily P02889495A0000 JJ O
dose P02889495A0000 NN O
at P02889495A0000 IN O
the P02889495A0000 DT O
end P02889495A0000 NN O
was P02889495A0000 VBD O
18.8 P02889495A0000 CD O
mg P02889495A0000 JJ O
pimozide P02889495A0000 NN O
and P02889495A0000 CC O
20 P02889495A0000 CD O
mg P02889495A0000 NN O
flupenthixol P02889495A0000 NN O
. P02889495A0000 . O
. . O O

Notice P08234308T0000 NNP O
of P08234308T0000 IN O
retraction P08234308T0000 NN O
. P08234308T0000 . O
. . O O

The P10601280A0674 DT O
first P10601280A0674 JJ O
one P10601280A0674 NN O
is P10601280A0674 VBZ O
a P10601280A0674 DT O
TPA-responsive P10601280A0674 JJ O
element P10601280A0674 NN O
that P10601280A0674 WDT O
controls P10601280A0674 VBZ O
the P10601280A0674 DT O
base-line P10601280A0674 JJ O
ST3 P10601280A0674 NNP I-UN
promoter P10601280A0674 NN I-UN
activity P10601280A0674 NN O
but P10601280A0674 CC O
is P10601280A0674 VBZ O
not P10601280A0674 RB O
required P10601280A0674 VBN O
for P10601280A0674 IN O
its P10601280A0674 PRP$ O
activation P10601280A0674 NN O
. P10601280A0674 . O
. . O O

The P01967130A0645 DT O
1489-base P01967130A0645 JJ O
pair P01967130A0645 NN O
EFIA P01967130A0645 NNP I-UN
cDNA P01967130A0645 NN O
encodes P01967130A0645 VBZ O
a P01967130A0645 DT O
322-amino P01967130A0645 JJ O
acid P01967130A0645 NN O
protein P01967130A0645 NN O
which P01967130A0645 WDT O
is P01967130A0645 VBZ O
nearly P01967130A0645 RB O
identical P01967130A0645 JJ O
to P01967130A0645 TO O
two P01967130A0645 CD O
previously P01967130A0645 RB O
described P01967130A0645 VBN O
human P01967130A0645 JJ O
DNA P01967130A0645 NNP O
binding P01967130A0645 NN O
proteins P01967130A0645 NNS O
. P01967130A0645 . O
. . O O

We P09376782A0328 PRP O
have P09376782A0328 VBP O
reviewed P09376782A0328 VBN O
the P09376782A0328 DT O
experience P09376782A0328 NN O
of P09376782A0328 IN O
a P09376782A0328 DT O
major P09376782A0328 JJ O
MMT P09376782A0328 NNP O
general P09376782A0328 JJ O
practice P09376782A0328 NN O
with P09376782A0328 IN O
hepatitis P09376782A0328 NN O
C P09376782A0328 NNP O
virus P09376782A0328 NN O
( P09376782A0328 ( O
HCV P09376782A0328 NNP O
) P09376782A0328 ) O
infection P09376782A0328 NN O
from P09376782A0328 IN O
1991 P09376782A0328 CD O
to P09376782A0328 TO O
1995 P09376782A0328 CD O
. P09376782A0328 . O
. . O O

205 P01438224A0749 CD O
, P01438224A0749 , O
285-290 P01438224A0749 JJ O
] P01438224A0749 NN O
and P01438224A0749 CC O
was P01438224A0749 VBD O
subsequently P01438224A0749 RB O
cloned P01438224A0749 VBN O
and P01438224A0749 CC O
sequenced P01438224A0749 VBN O
[ P01438224A0749 NNP O
J P01438224A0749 NNP O
. P01438224A0749 . O
. . O O

However P02496109A0754 RB O
, P02496109A0754 , O
experiments P02496109A0754 NNS O
with P02496109A0754 IN O
S1 P02496109A0754 NNP I-UN
mapping P02496109A0754 NN O
of P02496109A0754 IN O
in P02496109A0754 IN O
vivo P02496109A0754 NN O
transcripts P02496109A0754 NNS O
, P02496109A0754 , O
gene P02496109A0754 NN O
disruptions P02496109A0754 NNS O
in P02496109A0754 IN O
the P02496109A0754 DT O
alpha P02496109A0754 JJ O
region P02496109A0754 NN O
, P02496109A0754 , O
and P02496109A0754 CC O
a P02496109A0754 DT O
single-copy P02496109A0754 JJ O
transcriptional P02496109A0754 JJ O
fusion P02496109A0754 NN O
vector P02496109A0754 NN O
all P02496109A0754 DT O
suggested P02496109A0754 VBD O
that P02496109A0754 IN O
these P02496109A0754 DT O
possible P02496109A0754 JJ O
promoters P02496109A0754 NNS O
were P02496109A0754 VBD O
largely P02496109A0754 RB O
inactive P02496109A0754 JJ O
during P02496109A0754 IN O
logarithmic P02496109A0754 JJ O
growth P02496109A0754 NN O
, P02496109A0754 , O
that P02496109A0754 IN O
the P02496109A0754 DT O
major P02496109A0754 JJ O
promoter P02496109A0754 NN O
for P02496109A0754 IN O
the P02496109A0754 DT O
alpha P02496109A0754 NN O
operon P02496109A0754 NN O
lay P02496109A0754 VBD O
upstream P02496109A0754 RB O
from P02496109A0754 IN O
the P02496109A0754 DT O
region P02496109A0754 NN O
cloned P02496109A0754 VBN O
, P02496109A0754 , O
and P02496109A0754 CC O
that P02496109A0754 IN O
the P02496109A0754 DT O
genes P02496109A0754 NNS O
in P02496109A0754 IN O
the P02496109A0754 DT O
IF1 P02496109A0754 NNP I-UN
to P02496109A0754 TO O
L17 P02496109A0754 NNP I-UN
interval P02496109A0754 NN O
were P02496109A0754 VBD O
cotranscribed P02496109A0754 VBN O
. P02496109A0754 . O
. . O O

A P02848842A0643 DT O
family P02848842A0643 NN O
of P02848842A0643 IN O
RNA P02848842A0643 NNP O
molecules P02848842A0643 NNS O
in P02848842A0643 IN O
the P02848842A0643 DT O
2.0-2.2-kilobase P02848842A0643 JJ O
range P02848842A0643 NN O
identified P02848842A0643 VBN O
with P02848842A0643 IN O
a P02848842A0643 DT O
probe P02848842A0643 NN O
from P02848842A0643 IN O
this P02848842A0643 DT O
gene P02848842A0643 NN O
was P02848842A0643 VBD O
overexpressed P02848842A0643 VBN O
in P02848842A0643 IN O
the P02848842A0643 DT O
resistant P02848842A0643 JJ O
cells P02848842A0643 NNS O
. P02848842A0643 . O
. . O O

Pulmonary P11536063A0178 JJ O
embolectomy P11536063A0178 NN O
and P11536063A0178 CC O
lung P11536063A0178 NN O
transplantation P11536063A0178 NN O
are P11536063A0178 VBP O
the P11536063A0178 DT O
main P11536063A0178 JJ O
indications P11536063A0178 NNS O
for P11536063A0178 IN O
the P11536063A0178 DT O
use P11536063A0178 NN O
of P11536063A0178 IN O
heart-lung-machine P11536063A0178 NN O
. P11536063A0178 . O
. . O O

1 P08409593A0357 CD O
) P08409593A0357 ) O
CFDN P08409593A0357 NNP O
, P08409593A0357 , O
AMPC P08409593A0357 NNP O
and P08409593A0357 CC O
MNZ P08409593A0357 NNP O
showed P08409593A0357 VBD O
a P08409593A0357 DT O
potent P08409593A0357 JJ O
antimicrobial P08409593A0357 JJ O
activity P08409593A0357 NN O
against P08409593A0357 IN O
H. P08409593A0357 NNP O
pylori P08409593A0357 NN O
, P08409593A0357 , O
and P08409593A0357 CC O
especially P08409593A0357 RB O
, P08409593A0357 , O
AMPC P08409593A0357 NNP O
showed P08409593A0357 VBD O
a P08409593A0357 DT O
marked P08409593A0357 JJ O
bactericidal P08409593A0357 NN O
activity P08409593A0357 NN O
in P08409593A0357 IN O
a P08409593A0357 DT O
short P08409593A0357 JJ O
time P08409593A0357 NN O
. P08409593A0357 . O
. . O O

Deletion P02198259A0685 NN O
from P02198259A0685 IN O
either P02198259A0685 CC O
the P02198259A0685 DT O
N- P02198259A0685 JJ O
or P02198259A0685 CC O
C-terminal P02198259A0685 JJ O
ends P02198259A0685 NNS O
of P02198259A0685 IN O
repA P02198259A0685 NN I-UN
( P02198259A0685 ( O
28 P02198259A0685 CD O
and P02198259A0685 CC O
69 P02198259A0685 CD O
codons P02198259A0685 NNS O
, P02198259A0685 , O
respectively P02198259A0685 RB O
, P02198259A0685 , O
out P02198259A0685 IN O
of P02198259A0685 IN O
the P02198259A0685 DT O
286-codon P02198259A0685 JJ O
open P02198259A0685 JJ O
reading P02198259A0685 NN O
frame P02198259A0685 NN O
) P02198259A0685 ) O
affected P02198259A0685 VBD O
the P02198259A0685 DT O
initiator P02198259A0685 NN O
but P02198259A0685 CC O
not P02198259A0685 RB O
the P02198259A0685 DT O
inhibitory P02198259A0685 NN O
activity P02198259A0685 NN O
. P02198259A0685 . O
. . O O

The P01357528A0084 DT O
subunit P01357528A0084 NN O
protein P01357528A0084 NN O
of P01357528A0084 IN O
curli P01357528A0084 NN I-UN
was P01357528A0084 VBD O
highly P01357528A0084 RB O
homologous P01357528A0084 JJ O
at P01357528A0084 IN O
its P01357528A0084 PRP$ O
amino P01357528A0084 NN O
terminus P01357528A0084 NN O
to P01357528A0084 TO O
SEF-17 P01357528A0084 NNP I-UN
, P01357528A0084 , O
the P01357528A0084 DT O
subunit P01357528A0084 NN O
protein P01357528A0084 NN O
of P01357528A0084 IN O
thin P01357528A0084 JJ O
, P01357528A0084 , O
aggregative P01357528A0084 JJ O
fimbriae P01357528A0084 NN O
of P01357528A0084 IN O
Salmonella P01357528A0084 NNP O
enteritidis P01357528A0084 FW O
27655 P01357528A0084 CD O
strain P01357528A0084 NN O
3b P01357528A0084 CD O
, P01357528A0084 , O
suggesting P01357528A0084 VBG O
that P01357528A0084 IN O
these P01357528A0084 DT O
fibres P01357528A0084 NNS O
form P01357528A0084 VBP O
a P01357528A0084 DT O
novel P01357528A0084 JJ O
class P01357528A0084 NN O
of P01357528A0084 IN O
surface P01357528A0084 NN O
organelles P01357528A0084 NNS O
on P01357528A0084 IN O
enterobacteria P01357528A0084 NN O
. P01357528A0084 . O
. . O O

Antibodies P10788476A0891 NNS O
raised P10788476A0891 VBN O
against P10788476A0891 IN O
a P10788476A0891 DT O
C-terminal P10788476A0891 JJ O
portion P10788476A0891 NN O
of P10788476A0891 IN O
Sec31A P10788476A0891 NNP I-UN
co-precipitate P10788476A0891 JJ O
Sec13 P10788476A0891 NNP I-UN
and P10788476A0891 CC O
inhibit P10788476A0891 VB O
ER-Golgi P10788476A0891 JJ O
transport P10788476A0891 NN O
of P10788476A0891 IN O
temperature-arrested P10788476A0891 JJ O
vesicular P10788476A0891 JJ O
stomatitis P10788476A0891 NN I-UN
G P10788476A0891 NNP I-UN
protein P10788476A0891 NN I-UN
in P10788476A0891 IN O
a P10788476A0891 DT O
semi-intact P10788476A0891 JJ O
cell P10788476A0891 NN O
assay P10788476A0891 NN O
. P10788476A0891 . O
. . O O

Human P09368760A0665 NNP I-UN
PDK1 P09368760A0665 NNP I-UN
is P09368760A0665 VBZ O
homologous P09368760A0665 JJ O
to P09368760A0665 TO O
the P09368760A0665 DT O
Drosophila P09368760A0665 NNP I-UN
protein P09368760A0665 NN I-UN
kinase P09368760A0665 NN I-UN
DSTPK61 P09368760A0665 NNP I-UN
, P09368760A0665 , O
which P09368760A0665 WDT O
has P09368760A0665 VBZ O
been P09368760A0665 VBN O
implicated P09368760A0665 VBN O
in P09368760A0665 IN O
the P09368760A0665 DT O
regulation P09368760A0665 NN O
of P09368760A0665 IN O
sex P09368760A0665 NN O
differentiation P09368760A0665 NN O
, P09368760A0665 , O
oogenesis P09368760A0665 NN O
and P09368760A0665 CC O
spermatogenesis P09368760A0665 NN O
. P09368760A0665 . O
. . O O

In P09577365A0747 IN O
angiodysplasia P09577365A0747 NN O
, P09577365A0747 , O
ectatic P09577365A0747 JJ O
vessels P09577365A0747 NNS O
in P09577365A0747 IN O
the P09577365A0747 DT O
mucosa P09577365A0747 NN O
appeared P09577365A0747 VBD O
to P09577365A0747 TO O
contain P09577365A0747 VB O
less P09577365A0747 JJR O
collagen P09577365A0747 NN I-UN
type P09577365A0747 NN I-UN
IV P09577365A0747 NNP I-UN
than P09577365A0747 IN O
similarly P09577365A0747 RB O
sized P09577365A0747 VBN O
vessels P09577365A0747 NNS O
in P09577365A0747 IN O
the P09577365A0747 DT O
submucosa P09577365A0747 NN O
, P09577365A0747 , O
and P09577365A0747 CC O
perforating P09577365A0747 VBG O
vessels P09577365A0747 NNS O
appeared P09577365A0747 VBD O
in P09577365A0747 IN O
many P09577365A0747 JJ O
cases P09577365A0747 NNS O
to P09577365A0747 TO O
lose P09577365A0747 VB O
staining P09577365A0747 NN O
at P09577365A0747 IN O
the P09577365A0747 DT O
level P09577365A0747 NN O
of P09577365A0747 IN O
the P09577365A0747 DT O
muscularis P09577365A0747 NN O
mucosae P09577365A0747 NN O
. P09577365A0747 . O
. . O O

In P09115242A0934 IN O
particular P09115242A0934 JJ O
, P09115242A0934 , O
Western P09115242A0934 JJ O
, P09115242A0934 , O
supershift P09115242A0934 NN O
, P09115242A0934 , O
and P09115242A0934 CC O
promoter P09115242A0934 NN O
deletion P09115242A0934 NN O
analyses P09115242A0934 NNS O
suggested P09115242A0934 VBD O
a P09115242A0934 DT O
role P09115242A0934 NN O
for P09115242A0934 IN O
CCAAT P09115242A0934 NNP I-UN
/ P09115242A0934 NNP I-UN
enhancer-binding P09115242A0934 JJ I-UN
protein-beta P09115242A0934 NN I-UN
( P09115242A0934 ( O
C P09115242A0934 NNP I-UN
/ P09115242A0934 NNP I-UN
EBP-beta P09115242A0934 NNP I-UN
) P09115242A0934 ) O
binding P09115242A0934 VBG O
site P09115242A0934 NN O
between P09115242A0934 IN O
-2010 P09115242A0934 NNP O
and P09115242A0934 CC O
-1954 P09115242A0934 NNP O
in P09115242A0934 IN O
regulating P09115242A0934 VBG O
transcription P09115242A0934 NN O
of P09115242A0934 IN O
collagenase-1 P09115242A0934 NN I-UN
in P09115242A0934 IN O
monocytic P09115242A0934 JJ O
cells P09115242A0934 NNS O
. P09115242A0934 . O
. . O O

This P10725017A0673 DT O
paper P10725017A0673 NN O
reviews P10725017A0673 VBZ O
the P10725017A0673 DT O
middleware-based P10725017A0673 JJ O
approach P10725017A0673 NN O
adopted P10725017A0673 VBN O
by P10725017A0673 IN O
CEN P10725017A0673 NNP O
ENV P10725017A0673 NNP O
12967-1 P10725017A0673 CD O
and P10725017A0673 CC O
the P10725017A0673 DT O
specialisation P10725017A0673 NN O
necessary P10725017A0673 JJ O
for P10725017A0673 IN O
the P10725017A0673 DT O
healthcare P10725017A0673 NN O
record P10725017A0673 NN O
based P10725017A0673 VBN O
on P10725017A0673 IN O
CEN P10725017A0673 NNP O
ENV P10725017A0673 NNP O
12265 P10725017A0673 CD O
'Electronic P10725017A0673 NNP O
Healthcare P10725017A0673 NNP O
Record P10725017A0673 NNP O
Architecture P10725017A0673 NNP O
' P10725017A0673 POS O
. P10725017A0673 . O
. . O O

Sequence P11223246A0359 NN O
analysis P11223246A0359 NN O
indicates P11223246A0359 VBZ O
that P11223246A0359 IN O
RBP21 P11223246A0359 NNP I-UN
shares P11223246A0359 NNS O
homology P11223246A0359 NN O
with P11223246A0359 IN O
other P11223246A0359 JJ O
retinoblastoma-binding P11223246A0359 JJ I-UN
proteins P11223246A0359 NNS I-UN
in P11223246A0359 IN O
the P11223246A0359 DT O
pRb-binding P11223246A0359 JJ I-UN
motif P11223246A0359 NN I-UN
LxCxE P11223246A0359 NNP O
at P11223246A0359 IN O
the P11223246A0359 DT O
C-terminal P11223246A0359 JJ O
region P11223246A0359 NN O
. P11223246A0359 . O
. . O O

Stable P03283881A0216 JJ O
patients P03283881A0216 NNS O
have P03283881A0216 VBP O
mucous P03283881A0216 JJ O
hypersecretion P03283881A0216 NN O
and P03283881A0216 CC O
little P03283881A0216 JJ O
evidence P03283881A0216 NN O
of P03283881A0216 IN O
acute P03283881A0216 JJ O
inflammation P03283881A0216 NN O
. P03283881A0216 . O
. . O O

Senior P02315151T0020 JJ O
systems P02315151T0020 NNS O
-- P02315151T0020 : O
45 P02315151T0020 CD O
; P02315151T0020 : O
Mental P02315151T0020 NNP O
health P02315151T0020 NN O
and P02315151T0020 CC O
illness P02315151T0020 NN O
in P02315151T0020 IN O
old P02315151T0020 JJ O
age P02315151T0020 NN O
-- P02315151T0020 : O
3 P02315151T0020 CD O
. P02315151T0020 . O
. . O O

We P02115572A1323 PRP O
also P02115572A1323 RB O
discovered P02115572A1323 VBD O
a P02115572A1323 DT O
V P02115572A1323 NNP I-UN
lambda P02115572A1323 NN I-UN
pseudogene P02115572A1323 NN I-UN
, P02115572A1323 , O
called P02115572A1323 VBN O
psi P02115572A1323 NN I-UN
V P02115572A1323 NNP I-UN
lambda P02115572A1323 VBZ I-UN
1 P02115572A1323 CD I-UN
, P02115572A1323 , O
3 P02115572A1323 CD O
kb P02115572A1323 NN O
upstream P02115572A1323 NN O
of P02115572A1323 IN O
the P02115572A1323 DT O
U266 P02115572A1323 NNP I-UN
lambda P02115572A1323 NN I-UN
gene P02115572A1323 NN I-UN
. P02115572A1323 . O
. . O O

As P10375640A0153 IN O
is P10375640A0153 VBZ O
deduced P10375640A0153 VBN O
from P10375640A0153 IN O
the P10375640A0153 DT O
nucleotide P10375640A0153 JJ O
sequence P10375640A0153 NN O
of P10375640A0153 IN O
the P10375640A0153 DT O
cDNA P10375640A0153 NN O
, P10375640A0153 , O
CBS-1 P10375640A0153 NNP I-UN
contains P10375640A0153 VBZ O
an P10375640A0153 DT O
open P10375640A0153 JJ O
reading P10375640A0153 NN O
frame P10375640A0153 NN O
consisting P10375640A0153 VBG O
of P10375640A0153 IN O
182 P10375640A0153 CD O
amino P10375640A0153 NN O
acids P10375640A0153 NNS O
, P10375640A0153 , O
with P10375640A0153 IN O
a P10375640A0153 DT O
molecular P10375640A0153 JJ O
weight P10375640A0153 NN O
of P10375640A0153 IN O
19.5kDa P10375640A0153 CD O
. P10375640A0153 . O
. . O O

Acute P09667795A0000 NNP O
pancreatitis P09667795A0000 NN O
is P09667795A0000 VBZ O
a P09667795A0000 DT O
rather P09667795A0000 RB O
common P09667795A0000 JJ O
abdominal P09667795A0000 JJ O
disorder P09667795A0000 NN O
. P09667795A0000 . O
. . O O

Determination P02176021T0000 NN O
of P02176021T0000 IN O
diquat P02176021T0000 NN O
in P02176021T0000 IN O
biological P02176021T0000 JJ O
materials P02176021T0000 NNS O
by P02176021T0000 IN O
electron P02176021T0000 NN O
spin P02176021T0000 NN O
resonance P02176021T0000 NN O
spectroscopy P02176021T0000 NN O
. P02176021T0000 . O
. . O O

Elimination P09614065A0966 NN O
of P09614065A0966 IN O
the P09614065A0966 DT O
inducible P09614065A0966 JJ O
response P09614065A0966 NN O
requires P09614065A0966 VBZ O
simultaneous P09614065A0966 JJ O
mutation P09614065A0966 NN O
of P09614065A0966 IN O
both P09614065A0966 DT O
sequences P09614065A0966 NNS O
, P09614065A0966 , O
however P09614065A0966 RB O
, P09614065A0966 , O
in P09614065A0966 IN O
the P09614065A0966 DT O
presence P09614065A0966 NN O
of P09614065A0966 IN O
an P09614065A0966 DT O
intact P09614065A0966 JJ O
EpRE P09614065A0966 NNP O
the P09614065A0966 DT O
upstream P09614065A0966 JJ O
AP-1 P09614065A0966 NNP I-UN
site P09614065A0966 NN I-UN
is P09614065A0966 VBZ O
irrelevant P09614065A0966 JJ O
to P09614065A0966 TO O
induction P09614065A0966 NN O
. P09614065A0966 . O
. . O O

Additional P08289339A0527 JJ O
exonuclease P08289339A0527 NN I-UN
III P08289339A0527 NNP I-UN
protection P08289339A0527 NN O
was P08289339A0527 VBD O
observed P08289339A0527 VBN O
beyond P08289339A0527 IN O
the P08289339A0527 DT O
core P08289339A0527 NN O
region P08289339A0527 NN O
on P08289339A0527 IN O
both P08289339A0527 CC O
the P08289339A0527 DT O
5 P08289339A0527 CD O
' P08289339A0527 POS O
and P08289339A0527 CC O
3 P08289339A0527 CD O
' P08289339A0527 '' O
sides P08289339A0527 NNS O
, P08289339A0527 , O
suggesting P08289339A0527 VBG O
that P08289339A0527 IN O
E1 P08289339A0527 NNP I-UN
interacted P08289339A0527 VBD O
with P08289339A0527 IN O
more P08289339A0527 RBR O
distal P08289339A0527 JJ O
sequences P08289339A0527 NNS O
as P08289339A0527 RB O
well P08289339A0527 RB O
. P08289339A0527 . O
. . O O

The P03115087A0515 DT O
mean P03115087A0515 JJ O
weight P03115087A0515 NN O
and P03115087A0515 CC O
height P03115087A0515 JJ O
velocities P03115087A0515 NNS O
were P03115087A0515 VBD O
148 P03115087A0515 CD O
% P03115087A0515 NN O
and P03115087A0515 CC O
122 P03115087A0515 CD O
% P03115087A0515 NN O
of P03115087A0515 IN O
the P03115087A0515 DT O
standard P03115087A0515 NN O
, P03115087A0515 , O
respectively P03115087A0515 RB O
. P03115087A0515 . O
. . O O

The P04055593A0523 DT O
fast P04055593A0523 JJ O
real-time P04055593A0523 JJ O
digital P04055593A0523 JJ O
processing P04055593A0523 NN O
of P04055593A0523 IN O
the P04055593A0523 DT O
N2 P04055593A0523 NNP O
and P04055593A0523 CC O
flow P04055593A0523 JJ O
signals P04055593A0523 NNS O
incorporated P04055593A0523 VBN O
filtering P04055593A0523 NN O
, P04055593A0523 , O
delay P04055593A0523 NN O
compensation P04055593A0523 NN O
, P04055593A0523 , O
and P04055593A0523 CC O
corrections P04055593A0523 NNS O
for P04055593A0523 IN O
the P04055593A0523 DT O
effects P04055593A0523 NNS O
of P04055593A0523 IN O
changes P04055593A0523 NNS O
in P04055593A0523 IN O
gas P04055593A0523 NN O
composition P04055593A0523 NN O
and P04055593A0523 CC O
temperature P04055593A0523 NN O
. P04055593A0523 . O
. . O O

We P10359014A1077 PRP O
also P10359014A1077 RB O
localized P10359014A1077 VBD O
the P10359014A1077 DT O
Fra-2 P10359014A1077 NNP I-UN
phosphorylation P10359014A1077 NN I-UN
sites P10359014A1077 NNS I-UN
by P10359014A1077 IN O
MAPK P10359014A1077 NNP I-UN
to P10359014A1077 TO O
three P10359014A1077 CD O
threonine P10359014A1077 NN O
and P10359014A1077 CC O
three P10359014A1077 CD O
serine P10359014A1077 NN O
residues P10359014A1077 NNS O
in P10359014A1077 IN O
the P10359014A1077 DT O
COOH-terminal P10359014A1077 JJ O
region P10359014A1077 NN O
by P10359014A1077 IN O
means P10359014A1077 NNS O
of P10359014A1077 IN O
site-directed P10359014A1077 JJ O
mutagenesis P10359014A1077 NN O
and P10359014A1077 CC O
showed P10359014A1077 VBD O
that P10359014A1077 IN O
the P10359014A1077 DT O
threonine P10359014A1077 NN O
residues P10359014A1077 NNS O
were P10359014A1077 VBD O
more P10359014A1077 RBR O
susceptible P10359014A1077 JJ O
to P10359014A1077 TO O
MAPK P10359014A1077 NNP I-UN
. P10359014A1077 . O
. . O O

Using P11513579A0372 VBG O
the P11513579A0372 DT O
two-hybrid P11513579A0372 JJ O
system P11513579A0372 NN O
, P11513579A0372 , O
we P11513579A0372 PRP O
show P11513579A0372 VBP O
that P11513579A0372 IN O
nonprenylated P11513579A0372 JJ O
Rac1 P11513579A0372 NNP I-UN
interacts P11513579A0372 VBZ O
very P11513579A0372 RB O
weakly P11513579A0372 JJ O
with P11513579A0372 IN O
Rho-GDI P11513579A0372 NNP I-UN
, P11513579A0372 , O
pointing P11513579A0372 VBG O
to P11513579A0372 TO O
the P11513579A0372 DT O
predominant P11513579A0372 JJ O
role P11513579A0372 NN O
of P11513579A0372 IN O
protein-isoprene P11513579A0372 JJ O
interaction P11513579A0372 NN O
in P11513579A0372 IN O
complex P11513579A0372 JJ O
formation P11513579A0372 NN O
. P11513579A0372 . O
. . O O

Experimental P00646023T0058 JJ O
studies P00646023T0058 NNS O
on P00646023T0058 IN O
virus P00646023T0058 NN O
excretion P00646023T0058 NN O
and P00646023T0058 CC O
non-arthropod P00646023T0058 JJ O
transmission P00646023T0058 NN O
. P00646023T0058 . O
. . O O

These P03663789A0568 DT O
results P03663789A0568 NNS O
suggest P03663789A0568 VBP O
that P03663789A0568 IN O
less P03663789A0568 JJR O
antidopaminergic P03663789A0568 JJ O
activity P03663789A0568 NN O
of P03663789A0568 IN O
RHAL P03663789A0568 NNP O
in P03663789A0568 IN O
this P03663789A0568 DT O
neuroleptic P03663789A0568 JJ O
test P03663789A0568 NN O
might P03663789A0568 MD O
be P03663789A0568 VB O
explained P03663789A0568 VBN O
by P03663789A0568 IN O
the P03663789A0568 DT O
lesser P03663789A0568 JJR O
conversion P03663789A0568 NN O
of P03663789A0568 IN O
RHAL P03663789A0568 NNP O
to P03663789A0568 TO O
HAL P03663789A0568 NNP O
. P03663789A0568 . O
. . O O

Promoter P02394707A0789 NN O
elements P02394707A0789 NNS O
include P02394707A0789 VBP O
an P02394707A0789 DT O
atypical P02394707A0789 JJ O
TATA P02394707A0789 NNP O
box P02394707A0789 NN O
( P02394707A0789 ( O
GTTA P02394707A0789 NNP O
) P02394707A0789 ) O
, P02394707A0789 , O
one P02394707A0789 CD O
CCAAT P02394707A0789 NNP O
box P02394707A0789 NN O
much P02394707A0789 RB O
further P02394707A0789 RBR O
from P02394707A0789 IN O
the P02394707A0789 DT O
initiation P02394707A0789 NN O
site P02394707A0789 NN O
, P02394707A0789 , O
three P02394707A0789 CD O
reverse P02394707A0789 NN O
compliments P02394707A0789 NNS O
of P02394707A0789 IN O
CCAAT P02394707A0789 NNP O
( P02394707A0789 ( O
ATTGG P02394707A0789 NNP O
) P02394707A0789 ) O
, P02394707A0789 , O
and P02394707A0789 CC O
two P02394707A0789 CD O
pyrimidine-rich P02394707A0789 JJ O
nucleotide P02394707A0789 JJ O
stretches P02394707A0789 NNS O
. P02394707A0789 . O
. . O O

In P11356853A0429 IN O
Ka13 P11356853A0429 NNP O
cells P11356853A0429 NNS O
, P11356853A0429 , O
CoCl P11356853A0429 NNP O
( P11356853A0429 ( O
2 P11356853A0429 CD O
) P11356853A0429 ) O
stimulated P11356853A0429 VBN O
expression P11356853A0429 NN O
of P11356853A0429 IN O
a P11356853A0429 DT O
luciferase P11356853A0429 NN I-UN
reporter P11356853A0429 NN I-UN
gene P11356853A0429 NN I-UN
under P11356853A0429 IN O
the P11356853A0429 DT O
control P11356853A0429 NN O
of P11356853A0429 IN O
a P11356853A0429 DT O
15-kilobase P11356853A0429 JJ I-UN
pair P11356853A0429 NN I-UN
mouse P11356853A0429 IN I-UN
ho-1 P11356853A0429 JJ I-UN
promoter P11356853A0429 NN I-UN
( P11356853A0429 ( O
pHO15luc P11356853A0429 NN I-UN
) P11356853A0429 ) O
. P11356853A0429 . O
. . O O

Dosage P09656414A0220 NN O
in P09656414A0220 IN O
both P09656414A0220 DT O
cases P09656414A0220 NNS O
was P09656414A0220 VBD O
0.2 P09656414A0220 CD O
g P09656414A0220 JJ O
/ P09656414A0220 NNP O
m2 P09656414A0220 NN O
. P09656414A0220 . O
. . O O

Cutis P01631229T0000 NNP O
aplasia P01631229T0000 NN O
. P01631229T0000 . O
. . O O

A P02747653A0910 DT O
larval P02747653A0910 JJ I-UN
albumin-like P02747653A0910 JJ I-UN
protein P02747653A0910 NN I-UN
was P02747653A0910 VBD O
not P02747653A0910 RB O
detectable P02747653A0910 JJ O
by P02747653A0910 IN O
silver P02747653A0910 NN O
staining P02747653A0910 NN O
in P02747653A0910 IN O
serum P02747653A0910 NN O
of P02747653A0910 IN O
tadpoles P02747653A0910 NNS O
before P02747653A0910 IN O
the P02747653A0910 DT O
beginning P02747653A0910 NN O
of P02747653A0910 IN O
metamorphosis P02747653A0910 NN O
at P02747653A0910 IN O
stage P02747653A0910 NN O
48 P02747653A0910 CD O
. P02747653A0910 . O
. . O O

Assessment P01101272T0000 NN O
of P01101272T0000 IN O
the P01101272T0000 DT O
carcinogenicity P01101272T0000 NN O
of P01101272T0000 IN O
non-nutritive P01101272T0000 JJ O
sweetners P01101272T0000 NNS O
II P01101272T0000 NNP O
: P01101272T0000 : O
Cyclamates P01101272T0000 NNS O
and P01101272T0000 CC O
cyclohexylamine P01101272T0000 NN O
. P01101272T0000 . O
. . O O

XYL1 P07557424A0124 NN I-UN
was P07557424A0124 VBD O
isolated P07557424A0124 VBN O
as P07557424A0124 IN O
a P07557424A0124 DT O
highly P07557424A0124 RB O
expressed P07557424A0124 VBN O
fusion P07557424A0124 NN O
clone P07557424A0124 NN O
from P07557424A0124 IN O
a P07557424A0124 DT O
'lacZ P07557424A0124 JJ I-UN
translational P07557424A0124 JJ O
fusion P07557424A0124 NN O
library P07557424A0124 NN O
. P07557424A0124 . O
. . O O

The P05799686T0001 DT O
possibility P05799686T0001 NN O
of P05799686T0001 IN O
selective P05799686T0001 JJ O
chemotherapy P05799686T0001 NN O
of P05799686T0001 IN O
progressive P05799686T0001 JJ O
recurring P05799686T0001 VBG O
ovarian P05799686T0001 JJ O
carcinoma P05799686T0001 NN O
with P05799686T0001 IN O
the P05799686T0001 DT O
aid P05799686T0001 NN O
of P05799686T0001 IN O
cytodiagnosis P05799686T0001 NN O
and P05799686T0001 CC O
incorporation P05799686T0001 NN O
of P05799686T0001 IN O
tagged P05799686T0001 JJ O
idoxuridine P05799686T0001 NN O
. P05799686T0001 . O
. . O O

A P10103002A0705 DT O
single P10103002A0705 JJ O
N-glycosylation P10103002A0705 NNP O
site P10103002A0705 NN O
present P10103002A0705 NN O
in P10103002A0705 IN O
chicken P10103002A0705 NN I-UN
gp42 P10103002A0705 NN I-UN
is P10103002A0705 VBZ O
conserved P10103002A0705 VBN O
among P10103002A0705 IN O
all P10103002A0705 DT O
five P10103002A0705 CD O
of P10103002A0705 IN O
these P10103002A0705 DT O
proteins P10103002A0705 NNS O
: P10103002A0705 : O
carbohydrate P10103002A0705 NN O
analysis P10103002A0705 NN O
of P10103002A0705 IN O
gp42 P10103002A0705 NN I-UN
revealed P10103002A0705 VBD O
the P10103002A0705 DT O
presence P10103002A0705 NN O
of P10103002A0705 IN O
a P10103002A0705 DT O
complex P10103002A0705 JJ O
type P10103002A0705 NN O
glycan P10103002A0705 NN O
chain P10103002A0705 NN O
at P10103002A0705 IN O
this P10103002A0705 DT O
site P10103002A0705 NN O
. P10103002A0705 . O
. . O O

DESIGN P09583592A0263 NNP O
AND P09583592A0263 CC O
METHODS P09583592A0263 NNP O
: P09583592A0263 : O
Case P09583592A0263 NN O
study P09583592A0263 NN O
. P09583592A0263 . O
. . O O

The P01171935A0313 DT O
appearance P01171935A0313 NN O
of P01171935A0313 IN O
dyskinetic P01171935A0313 JJ O
movement P01171935A0313 NN O
disorders P01171935A0313 NNS O
in P01171935A0313 IN O
humans P01171935A0313 NNS O
following P01171935A0313 VBG O
the P01171935A0313 DT O
chronic P01171935A0313 JJ O
use P01171935A0313 NN O
of P01171935A0313 IN O
levodopa P01171935A0313 NN O
or P01171935A0313 CC O
amphetamine P01171935A0313 NN O
may P01171935A0313 MD O
be P01171935A0313 VB O
a P01171935A0313 DT O
manifestation P01171935A0313 NN O
of P01171935A0313 IN O
similarly P01171935A0313 RB O
increased P01171935A0313 VBN O
dopamine P01171935A0313 NN I-UN
receptor P01171935A0313 NN I-UN
site P01171935A0313 NN I-UN
sensitivity P01171935A0313 NN O
within P01171935A0313 IN O
the P01171935A0313 DT O
striatum P01171935A0313 NN O
. P01171935A0313 . O
. . O O

In P11121043A0074 IN O
Xenopus P11121043A0074 NNP O
, P11121043A0074 , O
BMPs P11121043A0074 NNP I-UN
act P11121043A0074 NN O
as P11121043A0074 IN O
epidermal P11121043A0074 JJ O
inducers P11121043A0074 NNS O
and P11121043A0074 CC O
also P11121043A0074 RB O
as P11121043A0074 IN O
negative P11121043A0074 JJ O
regulators P11121043A0074 NNS O
of P11121043A0074 IN O
neurogenesis P11121043A0074 NN O
. P11121043A0074 . O
. . O O

This P06654047A0694 DT O
phenomenon P06654047A0694 NN O
may P06654047A0694 MD O
be P06654047A0694 VB O
regarded P06654047A0694 VBN O
as P06654047A0694 IN O
a P06654047A0694 DT O
variant P06654047A0694 NN O
of P06654047A0694 IN O
selective P06654047A0694 JJ O
individual P06654047A0694 JJ O
cell P06654047A0694 NN O
death P06654047A0694 NN O
, P06654047A0694 , O
currently P06654047A0694 RB O
referred P06654047A0694 VBN O
to P06654047A0694 TO O
as P06654047A0694 IN O
apoptosis P06654047A0694 NN O
, P06654047A0694 , O
which P06654047A0694 WDT O
has P06654047A0694 VBZ O
not P06654047A0694 RB O
been P06654047A0694 VBN O
previously P06654047A0694 RB O
reported P06654047A0694 VBN O
in P06654047A0694 IN O
a P06654047A0694 DT O
case P06654047A0694 NN O
of P06654047A0694 IN O
embryonal P06654047A0694 JJ O
rhabdomyosarcoma P06654047A0694 NN O
. P06654047A0694 . O
. . O O

Similar P10074921A1169 JJ O
results P10074921A1169 NNS O
were P10074921A1169 VBD O
also P10074921A1169 RB O
obtained P10074921A1169 VBN O
with P10074921A1169 IN O
a P10074921A1169 DT O
HepG2 P10074921A1169 NNP O
hepatoblastoma P10074921A1169 NN O
cell P10074921A1169 NN O
line P10074921A1169 NN O
carrying P10074921A1169 VBG O
wt P10074921A1169 JJ I-UN
p53 P10074921A1169 NN I-UN
. P10074921A1169 . O
. . O O

CONCLUSION P09611016A0652 NN O
: P09611016A0652 : O
In P09611016A0652 IN O
women P09611016A0652 NNS O
who P09611016A0652 WP O
want P09611016A0652 VBP O
or P09611016A0652 CC O
require P09611016A0652 VBP O
conservative P09611016A0652 JJ O
management P09611016A0652 NN O
of P09611016A0652 IN O
grade P09611016A0652 NN O
4 P09611016A0652 CD O
prolapse P09611016A0652 NN O
and P09611016A0652 CC O
are P09611016A0652 VBP O
unable P09611016A0652 JJ O
to P09611016A0652 TO O
retain P09611016A0652 VB O
a P09611016A0652 DT O
single P09611016A0652 JJ O
pessary P09611016A0652 NN O
, P09611016A0652 , O
the P09611016A0652 DT O
placement P09611016A0652 NN O
of P09611016A0652 IN O
two P09611016A0652 CD O
pessaries P09611016A0652 NNS O
often P09611016A0652 RB O
will P09611016A0652 MD O
be P09611016A0652 VB O
successful P09611016A0652 JJ O
. P09611016A0652 . O
. . O O

Of P03227288A0542 IN O
the P03227288A0542 DT O
43 P03227288A0542 CD O
infants P03227288A0542 NNS O
with P03227288A0542 IN O
a P03227288A0542 DT O
( P03227288A0542 ( O
probable P03227288A0542 JJ O
) P03227288A0542 ) O
loss P03227288A0542 NN O
18 P03227288A0542 CD O
were P03227288A0542 VBD O
examined P03227288A0542 VBN O
again P03227288A0542 RB O
at P03227288A0542 IN O
3 P03227288A0542 CD O
months P03227288A0542 NNS O
corrected P03227288A0542 VBN O
age P03227288A0542 NN O
. P03227288A0542 . O
. . O O

No P07739520A1250 DT O
homologs P07739520A1250 NN O
of P07739520A1250 IN O
other P07739520A1250 JJ O
members P07739520A1250 NNS O
of P07739520A1250 IN O
the P07739520A1250 DT O
Surfeit P07739520A1250 NNP I-UN
gene P07739520A1250 NN I-UN
cluster P07739520A1250 NN I-UN
were P07739520A1250 VBD O
detected P07739520A1250 VBN O
in P07739520A1250 IN O
close P07739520A1250 JJ O
proximity P07739520A1250 NN O
to P07739520A1250 TO O
the P07739520A1250 DT O
D. P07739520A1250 NNP O
melanogaster P07739520A1250 NN O
Surf-3 P07739520A1250 NNP I-UN
/ P07739520A1250 NNP O
rpL7a P07739520A1250 NN I-UN
gene P07739520A1250 NN O
. P07739520A1250 . O
. . O O

HNF-3 P01324404A1208 JJ I-UN
beta P01324404A1208 NN I-UN
amino-terminal P01324404A1208 JJ I-UN
sequences P01324404A1208 NNS I-UN
defined P01324404A1208 VBN O
by P01324404A1208 IN O
conserved P01324404A1208 JJ O
region P01324404A1208 NN O
IV P01324404A1208 NNP O
also P01324404A1208 RB O
contributed P01324404A1208 VBD O
to P01324404A1208 TO O
transactivation P01324404A1208 NN O
, P01324404A1208 , O
but P01324404A1208 CC O
region P01324404A1208 NN O
IV P01324404A1208 NNP O
activity P01324404A1208 NN O
required P01324404A1208 VBD O
the P01324404A1208 DT O
participation P01324404A1208 NN O
of P01324404A1208 IN O
the P01324404A1208 DT O
region P01324404A1208 NN O
II-III P01324404A1208 NNP O
domain P01324404A1208 NN O
. P01324404A1208 . O
. . O O

MDBP P08413274A0452 NN I-UN
from P08413274A0452 IN O
HeLa P08413274A0452 NNP O
and P08413274A0452 CC O
Raji P08413274A0452 NNP O
cells P08413274A0452 NNS O
formed P08413274A0452 VBD O
DNA-protein P08413274A0452 NNP O
complexes P08413274A0452 NNS O
with P08413274A0452 IN O
X-box P08413274A0452 NNP O
oligonucleotides P08413274A0452 NNS O
that P08413274A0452 WDT O
coelectrophoresed P08413274A0452 VBD O
with P08413274A0452 IN O
those P08413274A0452 DT O
containing P08413274A0452 VBG O
standard P08413274A0452 JJ O
MDBP P08413274A0452 NNP I-UN
sites P08413274A0452 NNS I-UN
. P08413274A0452 . O
. . O O

Using P07823953A0777 VBG O
a P07823953A0777 DT O
battery P07823953A0777 NN O
of P07823953A0777 IN O
I P07823953A0777 PRP I-UN
kappa P07823953A0777 VBP I-UN
B P07823953A0777 NNP I-UN
alpha P07823953A0777 NN I-UN
mutants P07823953A0777 NNS I-UN
, P07823953A0777 , O
we P07823953A0777 PRP O
show P07823953A0777 VBP O
that P07823953A0777 IN O
( P07823953A0777 ( O
i P07823953A0777 NN O
) P07823953A0777 ) O
a P07823953A0777 DT O
dimer P07823953A0777 NN O
binds P07823953A0777 VBZ O
a P07823953A0777 DT O
single P07823953A0777 JJ O
I P07823953A0777 PRP I-UN
kappa P07823953A0777 VBP I-UN
B P07823953A0777 NNP I-UN
alpha P07823953A0777 NN I-UN
molecule P07823953A0777 NN I-UN
, P07823953A0777 , O
( P07823953A0777 ( O
ii P07823953A0777 NN O
) P07823953A0777 ) O
the P07823953A0777 DT O
acidic P07823953A0777 JJ O
C-terminal P07823953A0777 JJ O
region P07823953A0777 NN O
of P07823953A0777 IN O
I P07823953A0777 PRP I-UN
kappa P07823953A0777 VBP I-UN
B P07823953A0777 NNP I-UN
alpha P07823953A0777 NN I-UN
is P07823953A0777 VBZ O
not P07823953A0777 RB O
required P07823953A0777 VBN O
for P07823953A0777 IN O
protein-protein P07823953A0777 JJ O
binding P07823953A0777 NN O
and P07823953A0777 CC O
does P07823953A0777 VBZ O
not P07823953A0777 RB O
mask P07823953A0777 VB O
the P07823953A0777 DT O
nuclear P07823953A0777 JJ O
localization P07823953A0777 NN O
signal P07823953A0777 NN O
of P07823953A0777 IN O
the P07823953A0777 DT O
dimer P07823953A0777 NN O
, P07823953A0777 , O
( P07823953A0777 ( O
iii P07823953A0777 NN O
) P07823953A0777 ) O
the P07823953A0777 DT O
same P07823953A0777 JJ O
C-terminal P07823953A0777 JJ O
region P07823953A0777 NN O
is P07823953A0777 VBZ O
required P07823953A0777 VBN O
for P07823953A0777 IN O
inhibition P07823953A0777 NN O
of P07823953A0777 IN O
DNA P07823953A0777 NNP O
binding P07823953A0777 NN O
, P07823953A0777 , O
and P07823953A0777 CC O
( P07823953A0777 ( O
iv P07823953A0777 NN O
) P07823953A0777 ) O
this P07823953A0777 DT O
inhibition P07823953A0777 NN O
may P07823953A0777 MD O
be P07823953A0777 VB O
accomplished P07823953A0777 VBN O
by P07823953A0777 IN O
direct P07823953A0777 JJ O
interaction P07823953A0777 NN O
between P07823953A0777 IN O
the P07823953A0777 DT O
PEST-like P07823953A0777 NNP O
region P07823953A0777 NN O
and P07823953A0777 CC O
the P07823953A0777 DT O
DNA-binding P07823953A0777 JJ O
region P07823953A0777 NN O
of P07823953A0777 IN O
one P07823953A0777 CD O
of P07823953A0777 IN O
the P07823953A0777 DT O
subunits P07823953A0777 NNS O
of P07823953A0777 IN O
the P07823953A0777 DT O
dimer P07823953A0777 NN O
. P07823953A0777 . O
. . O O

Influence P11787322X0001 NN O
of P11787322X0001 IN O
different P11787322X0001 JJ O
methods P11787322X0001 NNS O
of P11787322X0001 IN O
chemical P11787322X0001 JJ O
disinfection P11787322X0001 NN O
on P11787322X0001 IN O
the P11787322X0001 DT O
physical P11787322X0001 JJ O
properties P11787322X0001 NNS O
of P11787322X0001 IN O
type P11787322X0001 NN O
IV P11787322X0001 NNP O
and P11787322X0001 CC O
V P11787322X0001 NNP O
gypsum P11787322X0001 NN O
dies P11787322X0001 VBZ O
] P11787322X0001 NNP O
Several P11787322X0001 NNP O
instruments P11787322X0001 NNS O
and P11787322X0001 CC O
materials P11787322X0001 NNS O
frequently P11787322X0001 RB O
used P11787322X0001 VBN O
in P11787322X0001 IN O
prosthodontics P11787322X0001 NNS O
-- P11787322X0001 : O
such P11787322X0001 JJ O
as P11787322X0001 IN O
stone P11787322X0001 NN O
casts P11787322X0001 NNS O
, P11787322X0001 , O
dental P11787322X0001 JJ O
impressions P11787322X0001 NNS O
, P11787322X0001 , O
interocclusal P11787322X0001 NN O
records P11787322X0001 NNS O
-- P11787322X0001 : O
are P11787322X0001 VBP O
classified P11787322X0001 VBN O
, P11787322X0001 , O
by P11787322X0001 IN O
the P11787322X0001 DT O
dental P11787322X0001 JJ O
literature P11787322X0001 NN O
, P11787322X0001 , O
as P11787322X0001 IN O
vehicles P11787322X0001 NNS O
of P11787322X0001 IN O
transmission P11787322X0001 NN O
of P11787322X0001 IN O
infectious P11787322X0001 JJ O
diseases P11787322X0001 NNS O
to P11787322X0001 TO O
those P11787322X0001 DT O
who P11787322X0001 WP O
handle P11787322X0001 VBP O
them P11787322X0001 PRP O
. P11787322X0001 . O
. . O O

Five P03019505A0390 CD O
patients P03019505A0390 NNS O
developed P03019505A0390 VBD O
metastatic P03019505A0390 JJ O
spread P03019505A0390 NN O
, P03019505A0390 , O
and P03019505A0390 CC O
all P03019505A0390 DT O
of P03019505A0390 IN O
them P03019505A0390 PRP O
died P03019505A0390 VBD O
of P03019505A0390 IN O
tumor P03019505A0390 NN O
. P03019505A0390 . O
. . O O

In P07642538A0744 IN O
contrast P07642538A0744 NN O
, P07642538A0744 , O
both P07642538A0744 DT O
C-Lys P07642538A0744 NNP O
and P07642538A0744 CC O
C-Thr P07642538A0744 NNP O
retained P07642538A0744 VBD O
high P07642538A0744 JJ O
levels P07642538A0744 NNS O
of P07642538A0744 IN O
kinase P07642538A0744 NN O
activity P07642538A0744 NN O
and P07642538A0744 CC O
were P07642538A0744 VBD O
capable P07642538A0744 JJ O
of P07642538A0744 IN O
responding P07642538A0744 VBG O
to P07642538A0744 TO O
stimulation P07642538A0744 NN O
. P07642538A0744 . O
. . O O

Demonstration P01237206A0199 NN O
of P01237206A0199 IN O
the P01237206A0199 DT O
agent P01237206A0199 NN O
was P01237206A0199 VBD O
performed P01237206A0199 VBN O
from P01237206A0199 IN O
the P01237206A0199 DT O
6th P01237206A0199 CD O
to P01237206A0199 TO O
the P01237206A0199 DT O
11th P01237206A0199 CD O
day P01237206A0199 NN O
p.i P01237206A0199 NN O
. P01237206A0199 . O
by P01237206A0199 IN O
direct P01237206A0199 JJ O
microscopic P01237206A0199 NN O
methods P01237206A0199 NNS O
( P01237206A0199 ( O
Stamp P01237206A0199 NNP O
and P01237206A0199 CC O
auramine P01237206A0199 JJ O
staining P01237206A0199 NN O
, P01237206A0199 , O
fluorescent P01237206A0199 JJ O
antibody P01237206A0199 NN O
technique P01237206A0199 NN O
) P01237206A0199 ) O
; P01237206A0199 : O
the P01237206A0199 DT O
Coxiella P01237206A0199 NNP O
content P01237206A0199 NN O
was P01237206A0199 VBD O
determined P01237206A0199 VBN O
by P01237206A0199 IN O
titration P01237206A0199 NN O
in P01237206A0199 IN O
embryonated P01237206A0199 JJ O
hen P01237206A0199 NN O
's P01237206A0199 POS O
eggs P01237206A0199 NNS O
. P01237206A0199 . O
. . O O

Because P09322872A0745 IN O
the P09322872A0745 DT O
deletion P09322872A0745 NN O
included P09322872A0745 VBD O
the P09322872A0745 DT O
TK P09322872A0745 NNP I-UN
gene P09322872A0745 NN I-UN
, P09322872A0745 , O
selection P09322872A0745 NN O
with P09322872A0745 IN O
gancyclovir P09322872A0745 NN O
against P09322872A0745 IN O
cells P09322872A0745 NNS O
not P09322872A0745 RB O
having P09322872A0745 VBG O
undergone P09322872A0745 JJ O
recombination P09322872A0745 NN O
was P09322872A0745 VBD O
possible P09322872A0745 JJ O
. P09322872A0745 . O
. . O O

These P01433502A1163 DT O
results P01433502A1163 NNS O
suggest P01433502A1163 VBP O
that P01433502A1163 IN O
decreased P01433502A1163 JJ O
class P01433502A1163 NN O
I P01433502A1163 PRP O
enhancer P01433502A1163 VBP O
activity P01433502A1163 NN O
in P01433502A1163 IN O
Ad12-transformed P01433502A1163 NNP O
cells P01433502A1163 NNS O
may P01433502A1163 MD O
, P01433502A1163 , O
at P01433502A1163 IN O
least P01433502A1163 JJS O
in P01433502A1163 IN O
part P01433502A1163 NN O
, P01433502A1163 , O
be P01433502A1163 VB O
due P01433502A1163 JJ O
to P01433502A1163 TO O
the P01433502A1163 DT O
higher P01433502A1163 JJR O
levels P01433502A1163 NNS O
of P01433502A1163 IN O
an P01433502A1163 DT O
enhancer-specific P01433502A1163 JJ O
factor P01433502A1163 NN O
, P01433502A1163 , O
possibly P01433502A1163 RB O
acting P01433502A1163 VBG O
as P01433502A1163 IN O
a P01433502A1163 DT O
repressor P01433502A1163 NN O
. P01433502A1163 . O
. . O O

The P02958233A0123 DT O
clinical P02958233A0123 JJ O
picture P02958233A0123 NN O
and P02958233A0123 CC O
laboratory P02958233A0123 NN O
parameters P02958233A0123 NNS O
were P02958233A0123 VBD O
consistent P02958233A0123 JJ O
with P02958233A0123 IN O
a P02958233A0123 DT O
serum P02958233A0123 NN O
sickness P02958233A0123 NN O
reaction P02958233A0123 NN O
. P02958233A0123 . O
. . O O

Capsular P00390932T0001 JJ O
antigens P00390932T0001 NNS O
of P00390932T0001 IN O
Staphylococcus P00390932T0001 NNP O
aureus P00390932T0001 NN O
. P00390932T0001 . O
. . O O

Health P05553261T0000 NNP O
: P05553261T0000 : O
an P05553261T0000 DT O
integrative P05553261T0000 JJ O
reticulum P05553261T0000 NN O
. P05553261T0000 . O
. . O O

Since P07687541A0992 IN O
RCC1p P07687541A0992 NNP I-UN
acts P07687541A0992 VBZ O
as P07687541A0992 IN O
GNRP P07687541A0992 NNP I-UN
for P07687541A0992 IN O
Ran P07687541A0992 NNP I-UN
, P07687541A0992 , O
a P07687541A0992 DT O
small P07687541A0992 JJ I-UN
nuclear P07687541A0992 JJ I-UN
GTPase P07687541A0992 NNP I-UN
of P07687541A0992 IN O
the P07687541A0992 DT O
ras P07687541A0992 NNS I-UN
superfamily P07687541A0992 RB I-UN
, P07687541A0992 , O
we P07687541A0992 PRP O
have P07687541A0992 VBP O
identified P07687541A0992 VBN O
two P07687541A0992 CD O
homologs P07687541A0992 NNS O
of P07687541A0992 IN O
Ran P07687541A0992 NNP I-UN
in P07687541A0992 IN O
S.cerevisiae P07687541A0992 NNP O
( P07687541A0992 ( O
CNR1 P07687541A0992 NNP I-UN
and P07687541A0992 CC O
CNR2 P07687541A0992 NNP I-UN
) P07687541A0992 ) O
. P07687541A0992 . O
. . O O

In P09564860A2139 IN O
contrast P09564860A2139 NN O
, P09564860A2139 , O
receptor P09564860A2139 NN I-UN
/ P09564860A2139 NNP I-UN
G P09564860A2139 NNP I-UN
protein P09564860A2139 NN I-UN
coupling P09564860A2139 VBG O
appeared P09564860A2139 VBD O
unaffected P09564860A2139 JJ O
by P09564860A2139 IN O
expression P09564860A2139 NN O
of P09564860A2139 IN O
loop P09564860A2139 $ O
3i P09564860A2139 CD O
domains P09564860A2139 NNS O
derived P09564860A2139 VBN O
from P09564860A2139 IN O
two P09564860A2139 CD O
receptors P09564860A2139 NNS O
coupled P09564860A2139 VBD O
to P09564860A2139 TO O
G P09564860A2139 NNP I-UN
( P09564860A2139 ( I-UN
i P09564860A2139 JJ I-UN
/ P09564860A2139 VBP I-UN
o P09564860A2139 NN I-UN
) P09564860A2139 ) I-UN
proteins P09564860A2139 VBZ I-UN
( P09564860A2139 ( O
M2Ach-muscarinic P09564860A2139 JJ I-UN
and P09564860A2139 CC I-UN
alpha2A-adrenergic P09564860A2139 JJ I-UN
receptors P09564860A2139 NNS I-UN
) P09564860A2139 ) O
. P09564860A2139 . O
. . O O

Ischemic P02195715T0000 NNP O
stroke P02195715T0000 VBD O
due P02195715T0000 JJ O
to P02195715T0000 TO O
protein P02195715T0000 VB I-UN
C P02195715T0000 NNP I-UN
deficiency P02195715T0000 NN O
. P02195715T0000 . O
. . O O

A P09524122A0336 DT O
constitutive P09524122A0336 JJ O
allele P09524122A0336 NN O
of P09524122A0336 IN O
GPA2 P09524122A0336 NNP I-UN
could P09524122A0336 MD O
stimulate P09524122A0336 VB O
growth P09524122A0336 NN O
of P09524122A0336 IN O
a P09524122A0336 DT O
strain P09524122A0336 NN O
lacking P09524122A0336 VBG O
both P09524122A0336 DT O
RAS P09524122A0336 NNP I-UN
genes P09524122A0336 NNS I-UN
. P09524122A0336 . O
. . O O

At P07438346A0381 IN O
pH P07438346A0381 JJ O
6.9 P07438346A0381 CD O
, P07438346A0381 , O
the P07438346A0381 DT O
same P07438346A0381 JJ O
lidocaine P07438346A0381 NN O
concentrations P07438346A0381 NNS O
significantly P07438346A0381 RB O
reduced P07438346A0381 VBD O
resting P07438346A0381 VBG O
potential P07438346A0381 JJ O
( P07438346A0381 ( O
3-10 P07438346A0381 JJ O
% P07438346A0381 NN O
) P07438346A0381 ) O
, P07438346A0381 , O
action P07438346A0381 NN O
potential P07438346A0381 JJ O
amplitude P07438346A0381 NN O
( P07438346A0381 ( O
3-8 P07438346A0381 CD O
% P07438346A0381 NN O
) P07438346A0381 ) O
and P07438346A0381 CC O
Vmax P07438346A0381 NNP O
( P07438346A0381 ( O
14-22 P07438346A0381 CD O
% P07438346A0381 NN O
) P07438346A0381 ) O
. P07438346A0381 . O
. . O O

Prostaglandins P02756731T0001 NNS O
and P02756731T0001 CC O
gallstones P02756731T0001 NNS O
. P02756731T0001 . O
. . O O

Consistent P08631797A0982 JJ O
with P08631797A0982 IN O
ErbB-2 P08631797A0982 NNP I-UN
being P08631797A0982 VBG O
a P08631797A0982 DT O
shared P08631797A0982 VBN O
receptor P08631797A0982 NN O
subunit P08631797A0982 NN O
, P08631797A0982 , O
its P08631797A0982 PRP$ O
tyrosine P08631797A0982 JJ O
phosphorylation P08631797A0982 NN O
was P08631797A0982 VBD O
increased P08631797A0982 VBN O
by P08631797A0982 IN O
both P08631797A0982 DT O
heterologous P08631797A0982 JJ O
ligands P08631797A0982 NNS O
and P08631797A0982 CC O
it P08631797A0982 PRP O
mediated P08631797A0982 VBD O
a P08631797A0982 DT O
trans-inhibitory P08631797A0982 JJ O
effect P08631797A0982 NN O
of P08631797A0982 IN O
NDF P08631797A0982 NNP I-UN
on P08631797A0982 IN O
EGF P08631797A0982 NNP I-UN
binding P08631797A0982 NN O
. P08631797A0982 . O
. . O O

Gel P09724772A0840 NNP O
retardation P09724772A0840 NN O
assays P09724772A0840 NNS O
detected P09724772A0840 VBD O
ZiaR-dependent P09724772A0840 JJ O
complexes P09724772A0840 NNS O
forming P09724772A0840 VBG O
with P09724772A0840 IN O
the P09724772A0840 DT O
zia P09724772A0840 NN I-UN
operator-promoter P09724772A0840 NN I-UN
and P09724772A0840 CC O
ZiaR-DNA P09724772A0840 JJ O
binding P09724772A0840 NN O
was P09724772A0840 VBD O
enhanced P09724772A0840 VBN O
by P09724772A0840 IN O
treatment P09724772A0840 NN O
with P09724772A0840 IN O
a P09724772A0840 DT O
metal-chelator P09724772A0840 NN O
in P09724772A0840 IN O
vitro P09724772A0840 NN O
. P09724772A0840 . O
. . O O

Three P10854699A0424 CD O
FGF-AS P10854699A0424 JJ I-UN
cDNAs P10854699A0424 NNS I-UN
were P10854699A0424 VBD O
isolated P10854699A0424 VBN O
; P10854699A0424 : O
the P10854699A0424 DT O
full-length P10854699A0424 JJ I-UN
FGF-AS P10854699A0424 NNP I-UN
mRNA P10854699A0424 NN I-UN
and P10854699A0424 CC O
two P10854699A0424 CD O
alternative P10854699A0424 JJ O
splice P10854699A0424 NN O
variants P10854699A0424 NNS O
lacking P10854699A0424 VBG O
exon P10854699A0424 JJ O
2 P10854699A0424 CD O
or P10854699A0424 CC O
exons P10854699A0424 NNS O
2 P10854699A0424 CD O
and P10854699A0424 CC O
3 P10854699A0424 CD O
of P10854699A0424 IN O
the P10854699A0424 DT O
FGF-AS P10854699A0424 NNP I-UN
sequence P10854699A0424 NN I-UN
. P10854699A0424 . O
. . O O

The P08575609A0526 DT O
C P08575609A0526 NNP O
/ P08575609A0526 NNP O
D P08575609A0526 NNP O
ratio P08575609A0526 NN O
was P08575609A0526 VBD O
equal P08575609A0526 JJ O
to P08575609A0526 TO O
or P08575609A0526 CC O
over P08575609A0526 IN O
0.6 P08575609A0526 CD O
in P08575609A0526 IN O
9 P08575609A0526 CD O
cases P08575609A0526 NNS O
( P08575609A0526 ( O
16 P08575609A0526 CD O
eyes P08575609A0526 NNS O
) P08575609A0526 ) O
, P08575609A0526 , O
and P08575609A0526 CC O
the P08575609A0526 DT O
values P08575609A0526 NNS O
were P08575609A0526 VBD O
inconsistent P08575609A0526 JJ O
between P08575609A0526 IN O
both P08575609A0526 DT O
eyes P08575609A0526 NNS O
in P08575609A0526 IN O
55 P08575609A0526 CD O
% P08575609A0526 NN O
of P08575609A0526 IN O
the P08575609A0526 DT O
patients P08575609A0526 NNS O
. P08575609A0526 . O
. . O O

A P09599724A0193 DT O
stratified P09599724A0193 JJ O
random P09599724A0193 JJ O
sample P09599724A0193 NN O
of P09599724A0193 IN O
20 P09599724A0193 CD O
active P09599724A0193 JJ O
employees P09599724A0193 NNS O
from P09599724A0193 IN O
a P09599724A0193 DT O
cohort P09599724A0193 NN O
of P09599724A0193 IN O
phenoxy P09599724A0193 JJ O
herbicide P09599724A0193 NN O
workers P09599724A0193 NNS O
was P09599724A0193 VBD O
selected P09599724A0193 VBN O
in P09599724A0193 IN O
1995 P09599724A0193 CD O
for P09599724A0193 IN O
determining P09599724A0193 VBG O
PCDD P09599724A0193 NNP O
and P09599724A0193 CC O
PCDF P09599724A0193 NNP O
congeners P09599724A0193 NNS O
in P09599724A0193 IN O
blood P09599724A0193 NN O
lipids P09599724A0193 NNS O
to P09599724A0193 TO O
assess P09599724A0193 VB O
the P09599724A0193 DT O
extent P09599724A0193 NN O
of P09599724A0193 IN O
past P09599724A0193 JJ O
PCDD P09599724A0193 NNP O
and P09599724A0193 CC O
PCDF P09599724A0193 NNP O
exposure P09599724A0193 NN O
in P09599724A0193 IN O
this P09599724A0193 DT O
cohort P09599724A0193 NN O
and P09599724A0193 CC O
whether P09599724A0193 IN O
that P09599724A0193 DT O
exposure P09599724A0193 NN O
might P09599724A0193 MD O
explain P09599724A0193 VB O
site-specific P09599724A0193 JJ O
cancer P09599724A0193 NN O
findings P09599724A0193 NNS O
in P09599724A0193 IN O
the P09599724A0193 DT O
total P09599724A0193 JJ O
cohort P09599724A0193 NN O
. P09599724A0193 . O
. . O O

Forty-one P09024039A0247 CD O
ASA P09024039A0247 NNP O
physical P09024039A0247 JJ O
status P09024039A0247 NN O
I P09024039A0247 PRP O
or P09024039A0247 CC O
II P09024039A0247 NNP O
adult P09024039A0247 NN O
patients P09024039A0247 NNS O
undergoing P09024039A0247 VBG O
a P09024039A0247 DT O
variety P09024039A0247 NN O
of P09024039A0247 IN O
1-1.5 P09024039A0247 JJ O
h P09024039A0247 JJ O
surgical P09024039A0247 JJ O
procedures P09024039A0247 NNS O
were P09024039A0247 VBD O
randomly P09024039A0247 RB O
allocated P09024039A0247 VBN O
to P09024039A0247 TO O
receive P09024039A0247 VB O
CCA P09024039A0247 NNP O
with P09024039A0247 IN O
desflurane P09024039A0247 NN O
or P09024039A0247 CC O
isoflurane P09024039A0247 NN O
with P09024039A0247 IN O
ventilation P09024039A0247 NN O
being P09024039A0247 VBG O
either P09024039A0247 CC O
spontaneous P09024039A0247 JJ O
or P09024039A0247 CC O
controlled P09024039A0247 VBN O
. P09024039A0247 . O
. . O O

In P07644503A0729 IN O
contrast P07644503A0729 NN O
, P07644503A0729 , O
over-expression P07644503A0729 NN O
of P07644503A0729 IN O
RAR P07644503A0729 NNP I-UN
beta P07644503A0729 NN I-UN
only P07644503A0729 RB O
poorly P07644503A0729 RB O
restored P07644503A0729 VBN O
differentiation P07644503A0729 NN O
, P07644503A0729 , O
although P07644503A0729 IN O
it P07644503A0729 PRP O
could P07644503A0729 MD O
replace P07644503A0729 VB O
RAR P07644503A0729 NNP I-UN
gamma P07644503A0729 NN I-UN
for P07644503A0729 IN O
the P07644503A0729 DT O
activation P07644503A0729 NN O
of P07644503A0729 IN O
target P07644503A0729 NN O
genes P07644503A0729 NNS O
. P07644503A0729 . O
. . O O

The P09343432A0209 DT O
Scm P09343432A0209 NNP I-UN
and P09343432A0209 CC O
ph P09343432A0209 NN I-UN
proteins P09343432A0209 NNS O
share P09343432A0209 NN O
a P09343432A0209 DT O
homology P09343432A0209 NN O
domain P09343432A0209 NN O
with P09343432A0209 IN O
38 P09343432A0209 CD O
% P09343432A0209 NN O
identity P09343432A0209 NN O
over P09343432A0209 IN O
a P09343432A0209 DT O
length P09343432A0209 NN O
of P09343432A0209 IN O
65 P09343432A0209 CD O
amino P09343432A0209 NN O
acids P09343432A0209 NNS O
, P09343432A0209 , O
termed P09343432A0209 VBD O
the P09343432A0209 DT O
SPM P09343432A0209 NNP O
domain P09343432A0209 NN O
, P09343432A0209 , O
that P09343432A0209 WDT O
is P09343432A0209 VBZ O
located P09343432A0209 VBN O
at P09343432A0209 IN O
their P09343432A0209 PRP$ O
respective P09343432A0209 JJ O
C P09343432A0209 NNP O
termini P09343432A0209 NN O
. P09343432A0209 . O
. . O O

Characterization P07800505T0000 NN O
of P07800505T0000 IN O
the P07800505T0000 DT O
promoter P07800505T0000 NN O
for P07800505T0000 IN O
the P07800505T0000 DT O
human P07800505T0000 JJ I-UN
85 P07800505T0000 CD I-UN
kDa P07800505T0000 NN I-UN
cytosolic P07800505T0000 JJ I-UN
phospholipase P07800505T0000 NN I-UN
A2 P07800505T0000 NNP I-UN
gene P07800505T0000 NN I-UN
. P07800505T0000 . O
. . O O

OND P08639310A0548 $ O
8 P08639310A0548 CD O
mg P08639310A0548 NN O
tid P08639310A0548 JJ O
days P08639310A0548 NNS O
2-3 P08639310A0548 CD O
, P08639310A0548 , O
and P08639310A0548 CC O
8 P08639310A0548 CD O
mg P08639310A0548 NN O
tid P08639310A0548 NN O
prn P08639310A0548 JJ O
days P08639310A0548 NNS O
4-5 P08639310A0548 CD O
and P08639310A0548 CC O
prednisolone P08639310A0548 VB O
75-100 P08639310A0548 JJ O
mg P08639310A0548 NNS O
qds P08639310A0548 JJ O
days P08639310A0548 NNS O
2-5 P08639310A0548 CD O
and P08639310A0548 CC O
2 P08639310A0548 CD O
) P08639310A0548 ) O
MCP P08639310A0548 NNP O
30 P08639310A0548 CD O
mg P08639310A0548 NN O
/ P08639310A0548 NNP O
metylprednisolone P08639310A0548 NN O
80 P08639310A0548 CD O
mg P08639310A0548 NN O
i.v P08639310A0548 NN O
. P08639310A0548 . O
before P08639310A0548 IN O
CT P08639310A0548 NNP O
and P08639310A0548 CC O
MCP P08639310A0548 NNP O
20 P08639310A0548 CD O
mg P08639310A0548 NN O
p.r P08639310A0548 NN O
. P08639310A0548 . O
after P08639310A0548 IN O
4 P08639310A0548 CD O
and P08639310A0548 CC O
8 P08639310A0548 CD O
h P08639310A0548 NN O
respectively P08639310A0548 RB O
. P08639310A0548 . O
. . O O

The P09510398A1138 DT O
risk P09510398A1138 NN O
factors P09510398A1138 NNS O
for P09510398A1138 IN O
hematuria P09510398A1138 NN O
in P09510398A1138 IN O
patients P09510398A1138 NNS O
with P09510398A1138 IN O
renal P09510398A1138 JJ O
hypouricemia P09510398A1138 NN O
are P09510398A1138 VBP O
the P09510398A1138 DT O
elevation P09510398A1138 NN O
of P09510398A1138 IN O
urinary P09510398A1138 JJ O
urate P09510398A1138 JJ O
concentration P09510398A1138 NN O
and P09510398A1138 CC O
the P09510398A1138 DT O
subtypes P09510398A1138 NNS O
of P09510398A1138 IN O
Post P09510398A1138 NNP O
and P09510398A1138 CC O
Secretion P09510398A1138 NNP O
. P09510398A1138 . O
. . O O

Only P08621420A1166 RB O
one P08621420A1166 CD O
of P08621420A1166 IN O
these P08621420A1166 DT O
bands P08621420A1166 NNS O
was P08621420A1166 VBD O
supershifted P08621420A1166 VBN O
by P08621420A1166 IN O
antibody P08621420A1166 NN O
to P08621420A1166 TO O
p50 P08621420A1166 VB I-UN
, P08621420A1166 , O
whereas P08621420A1166 JJ O
antibodies P08621420A1166 NNS O
to P08621420A1166 TO O
p65 P08621420A1166 VB I-UN
or P08621420A1166 CC O
other P08621420A1166 JJ O
NF-kappaB P08621420A1166 JJ I-UN
proteins P08621420A1166 NNS I-UN
had P08621420A1166 VBD O
no P08621420A1166 DT O
effect P08621420A1166 NN O
. P08621420A1166 . O
. . O O

There P07508250A0537 EX O
was P07508250A0537 VBD O
also P07508250A0537 RB O
a P07508250A0537 DT O
highly P07508250A0537 RB O
significant P07508250A0537 JJ O
correlation P07508250A0537 NN O
between P07508250A0537 IN O
total P07508250A0537 JJ O
selenium P07508250A0537 NN O
intake P07508250A0537 NN O
and P07508250A0537 CC O
liver P07508250A0537 NN O
selenium P07508250A0537 NN O
concentration P07508250A0537 NN O
( P07508250A0537 ( O
r P07508250A0537 JJ O
= P07508250A0537 NN O
0.99 P07508250A0537 CD O
, P07508250A0537 , O
p P07508250A0537 NN O
< P07508250A0537 NNP O
0.01 P07508250A0537 CD O
) P07508250A0537 ) O
after P07508250A0537 IN O
1 P07508250A0537 CD O
mo P07508250A0537 NN O
of P07508250A0537 IN O
treatment P07508250A0537 NN O
, P07508250A0537 , O
but P07508250A0537 CC O
this P07508250A0537 DT O
time P07508250A0537 NN O
liver P07508250A0537 VBZ O
selenium P07508250A0537 NN O
did P07508250A0537 VBD O
not P07508250A0537 RB O
change P07508250A0537 VB O
with P07508250A0537 IN O
time P07508250A0537 NN O
, P07508250A0537 , O
and P07508250A0537 CC O
the P07508250A0537 DT O
correlation P07508250A0537 NN O
remained P07508250A0537 VBD O
highly P07508250A0537 RB O
significant P07508250A0537 JJ O
throughout P07508250A0537 IN O
the P07508250A0537 DT O
investigation P07508250A0537 NN O
. P07508250A0537 . O
. . O O

From P09515924A0104 IN O
250 P09515924A0104 CD O
g P09515924A0104 NN O
of P09515924A0104 IN O
cells P09515924A0104 NNS O
, P09515924A0104 , O
we P09515924A0104 PRP O
isolated P09515924A0104 VBD O
1 P09515924A0104 CD O
mg P09515924A0104 NN O
of P09515924A0104 IN O
PDH P09515924A0104 NNP I-UN
complex P09515924A0104 NN I-UN
with P09515924A0104 IN O
a P09515924A0104 DT O
specific P09515924A0104 JJ O
activity P09515924A0104 NN O
of P09515924A0104 IN O
12.6 P09515924A0104 CD O
U P09515924A0104 NNP O
/ P09515924A0104 NNP O
mg P09515924A0104 NN O
of P09515924A0104 IN O
protein P09515924A0104 NN O
. P09515924A0104 . O
. . O O

Analysis P07601121A0153 NN O
of P07601121A0153 IN O
this P07601121A0153 DT O
sequence P07601121A0153 NN O
combined P07601121A0153 VBN O
with P07601121A0153 IN O
that P07601121A0153 DT O
previously P07601121A0153 RB O
reported P07601121A0153 VBN O
for P07601121A0153 IN O
the P07601121A0153 DT O
5'-flanking P07601121A0153 JJ O
region P07601121A0153 NN O
directly P07601121A0153 RB O
proximal P07601121A0153 VBZ O
to P07601121A0153 TO O
the P07601121A0153 DT O
start P07601121A0153 NN O
of P07601121A0153 IN O
transcription P07601121A0153 NN O
revealed P07601121A0153 VBD O
several P07601121A0153 JJ O
putative P07601121A0153 JJ O
regulatory P07601121A0153 JJ O
sequences P07601121A0153 NNS O
. P07601121A0153 . O
. . O O

The P02332798A0725 DT O
afferents P02332798A0725 NNS O
' P02332798A0725 POS O
phase P02332798A0725 NN O
of P02332798A0725 IN O
response P02332798A0725 NN O
was P02332798A0725 VBD O
unmodified P02332798A0725 VBN O
by P02332798A0725 IN O
electrical P02332798A0725 JJ O
EVS P02332798A0725 NNP O
stimulation P02332798A0725 NN O
. P02332798A0725 . O
. . O O

Cholesteryl P11689217T0000 NNP I-UN
ester P11689217T0000 NN I-UN
transfer P11689217T0000 NN I-UN
protein P11689217T0000 NN I-UN
and P11689217T0000 CC O
atherosclerosis P11689217T0000 NN O
in P11689217T0000 IN O
Japanese P11689217T0000 JJ O
subjects P11689217T0000 NNS O
: P11689217T0000 : O
a P11689217T0000 DT O
study P11689217T0000 NN O
based P11689217T0000 VBN O
on P11689217T0000 IN O
coronary P11689217T0000 JJ O
angiography P11689217T0000 NN O
. P11689217T0000 . O
. . O O

The P02154599T0000 DT O
zta P02154599T0000 NN I-UN
transactivator P02154599T0000 NN I-UN
involved P02154599T0000 VBN O
in P02154599T0000 IN O
induction P02154599T0000 NN O
of P02154599T0000 IN O
lytic P02154599T0000 JJ O
cycle P02154599T0000 NN O
gene P02154599T0000 NN O
expression P02154599T0000 NN O
in P02154599T0000 IN O
Epstein-Barr P02154599T0000 NNP O
virus-infected P02154599T0000 JJ O
lymphocytes P02154599T0000 NNS O
binds P02154599T0000 NNS O
to P02154599T0000 TO O
both P02154599T0000 DT O
AP-1 P02154599T0000 NNP I-UN
and P02154599T0000 CC O
ZRE P02154599T0000 NNP I-UN
sites P02154599T0000 NNS I-UN
in P02154599T0000 IN O
target P02154599T0000 NN O
promoter P02154599T0000 NN O
and P02154599T0000 CC O
enhancer P02154599T0000 NN O
regions P02154599T0000 NNS O
. P02154599T0000 . O
. . O O

The P09396722A0185 DT O
gene P09396722A0185 NN O
( P09396722A0185 ( O
ApxII P09396722A0185 NNP I-UN
) P09396722A0185 ) O
encoding P09396722A0185 VBG O
both P09396722A0185 DT O
chloroplastic P09396722A0185 JJ I-UN
ascorbate P09396722A0185 NN I-UN
peroxidase P09396722A0185 NN I-UN
isoenzymes P09396722A0185 NNS I-UN
was P09396722A0185 VBD O
isolated P09396722A0185 VBN O
and P09396722A0185 CC O
the P09396722A0185 DT O
organization P09396722A0185 NN O
of P09396722A0185 IN O
the P09396722A0185 DT O
gene P09396722A0185 NN O
was P09396722A0185 VBD O
determined P09396722A0185 VBN O
. P09396722A0185 . O
. . O O

Molecular P09079915T0000 JJ O
characterization P09079915T0000 NN O
of P09079915T0000 IN O
a P09079915T0000 DT O
large P09079915T0000 JJ O
Borrelia P09079915T0000 NNP O
burgdorferi P09079915T0000 NN O
motility P09079915T0000 NN O
operon P09079915T0000 NN O
which P09079915T0000 WDT O
is P09079915T0000 VBZ O
initiated P09079915T0000 VBN O
by P09079915T0000 IN O
a P09079915T0000 DT O
consensus P09079915T0000 NN O
sigma70 P09079915T0000 NN I-UN
promoter P09079915T0000 NN I-UN
. P09079915T0000 . O
. . O O

C.D2-Chr P09482902A0423 JJ O
4 P09482902A0423 CD O
congenic P09482902A0423 JJ O
strains P09482902A0423 NNS O
harboring P09482902A0423 VBG O
DBA P09482902A0423 NNP O
/ P09482902A0423 $ O
2 P09482902A0423 CD O
alleles P09482902A0423 NNS O
associated P09482902A0423 VBN O
with P09482902A0423 IN O
the P09482902A0423 DT O
Pctr1 P09482902A0423 NNP I-UN
locus P09482902A0423 NN I-UN
contained P09482902A0423 VBD O
DBA P09482902A0423 NNP O
/ P09482902A0423 NNP O
2 P09482902A0423 CD O
`` P09482902A0423 `` O
resistant P09482902A0423 JJ O
'' P09482902A0423 '' O
alleles P09482902A0423 NNS O
of P09482902A0423 IN O
the P09482902A0423 DT O
CDK4 P09482902A0423 NNP I-UN
/ P09482902A0423 NNP O
CDK6 P09482902A0423 NNP I-UN
inhibitors P09482902A0423 NNS O
p16 P09482902A0423 VBP I-UN
and P09482902A0423 CC O
p15 P09482902A0423 VBP I-UN
. P09482902A0423 . O
. . O O

None P02537441A0231 NN O
were P02537441A0231 VBD O
restricted P02537441A0231 VBN O
from P02537441A0231 IN O
clinical P02537441A0231 JJ O
duties P02537441A0231 NNS O
, P02537441A0231 , O
were P02537441A0231 VBD O
given P02537441A0231 VBN O
varicella-zoster P02537441A0231 JJ I-UN
immune P02537441A0231 JJ I-UN
globulin P02537441A0231 NN I-UN
, P02537441A0231 , O
or P02537441A0231 CC O
developed P02537441A0231 VBD O
disease P02537441A0231 NN O
. P02537441A0231 . O
. . O O

A P06321505A0401 DT O
promoter P06321505A0401 NN O
sequence P06321505A0401 NN O
( P06321505A0401 ( O
Goldberg-Hogness P06321505A0401 NNP O
or P06321505A0401 CC O
TATA P06321505A0401 NNP O
box P06321505A0401 NN O
) P06321505A0401 ) O
is P06321505A0401 VBZ O
situated P06321505A0401 VBN O
28 P06321505A0401 CD O
base P06321505A0401 NN O
pairs P06321505A0401 NNS O
upstream P06321505A0401 RB O
from P06321505A0401 IN O
the P06321505A0401 DT O
point P06321505A0401 NN O
of P06321505A0401 IN O
initiation P06321505A0401 NN O
of P06321505A0401 IN O
transcription P06321505A0401 NN O
which P06321505A0401 WDT O
was P06321505A0401 VBD O
found P06321505A0401 VBN O
by P06321505A0401 IN O
S1 P06321505A0401 NNP I-UN
nuclease P06321505A0401 NN I-UN
mapping P06321505A0401 NN O
and P06321505A0401 CC O
by P06321505A0401 IN O
oligonucleotide-primed P06321505A0401 JJ O
reverse P06321505A0401 JJ O
transcription P06321505A0401 NN O
of P06321505A0401 IN O
rat P06321505A0401 NN I-UN
PTH P06321505A0401 NNP I-UN
mRNA P06321505A0401 NN I-UN
. P06321505A0401 . O
. . O O

In P08749394A0874 IN O
vitro P08749394A0874 JJ O
interaction P08749394A0874 NN O
studies P08749394A0874 NNS O
, P08749394A0874 , O
using P08749394A0874 VBG O
proteins P08749394A0874 NNS O
fused P08749394A0874 VBN O
to P08749394A0874 TO O
glutathione-S-transferase P08749394A0874 NN I-UN
, P08749394A0874 , O
showed P08749394A0874 VBD O
that P08749394A0874 IN O
RBP-J P08749394A0874 NNP I-UN
kappa P08749394A0874 NN I-UN
and P08749394A0874 CC O
Su P08749394A0874 NNP I-UN
( P08749394A0874 ( I-UN
H P08749394A0874 NNP I-UN
) P08749394A0874 ) I-UN
bind P08749394A0874 VBP O
directly P08749394A0874 RB O
to P08749394A0874 TO O
the P08749394A0874 DT O
RAM23 P08749394A0874 NNP I-UN
regions P08749394A0874 NNS I-UN
of P08749394A0874 IN O
mouse P08749394A0874 NN I-UN
Notch1 P08749394A0874 NNP I-UN
and P08749394A0874 CC O
Drosophila P08749394A0874 NNP I-UN
Notch P08749394A0874 NNP I-UN
, P08749394A0874 , O
respectively P08749394A0874 RB O
. P08749394A0874 . O
. . O O

The P10801860A0000 DT O
Siglecs P10801860A0000 NNP I-UN
are P10801860A0000 VBP O
a P10801860A0000 DT O
subfamily P10801860A0000 NN O
of P10801860A0000 IN O
I-type P10801860A0000 JJ I-UN
lectins P10801860A0000 NNS I-UN
( P10801860A0000 ( O
immunoglobulin P10801860A0000 JJ I-UN
superfamily P10801860A0000 RB I-UN
proteins P10801860A0000 VBZ I-UN
that P10801860A0000 IN O
bind P10801860A0000 NN O
sugars P10801860A0000 NNS O
) P10801860A0000 ) O
that P10801860A0000 WDT O
specifically P10801860A0000 RB O
recognize P10801860A0000 VBP O
sialic P10801860A0000 JJ O
acids P10801860A0000 NNS O
. P10801860A0000 . O
. . O O

The P07678051A1303 DT O
PDGFR P07678051A1303 NNP I-UN
mutants P07678051A1303 NNS I-UN
that P07678051A1303 WDT O
failed P07678051A1303 VBD O
to P07678051A1303 TO O
associate P07678051A1303 VB O
with P07678051A1303 IN O
PLC P07678051A1303 NNP I-UN
gamma P07678051A1303 NNS I-UN
were P07678051A1303 VBD O
not P07678051A1303 RB O
able P07678051A1303 JJ O
to P07678051A1303 TO O
mediate P07678051A1303 VB O
the P07678051A1303 DT O
PDGF-dependent P07678051A1303 JJ O
production P07678051A1303 NN O
of P07678051A1303 IN O
inositol P07678051A1303 NN O
phosphates P07678051A1303 NNS O
. P07678051A1303 . O
. . O O

The P02110148A0423 DT O
cloned P02110148A0423 JJ O
HindIII P02110148A0423 NNP I-UN
fragment P02110148A0423 NN I-UN
, P02110148A0423 , O
which P02110148A0423 WDT O
was P02110148A0423 VBD O
shown P02110148A0423 VBN O
by P02110148A0423 IN O
DNA P02110148A0423 NNP O
sequence P02110148A0423 NN O
analysis P02110148A0423 NN O
to P02110148A0423 TO O
encode P02110148A0423 VB O
the P02110148A0423 DT O
N-terminal P02110148A0423 JJ O
half P02110148A0423 NN O
of P02110148A0423 IN O
the P02110148A0423 DT O
B. P02110148A0423 NNP I-UN
subtilis P02110148A0423 NNS I-UN
IF2 P02110148A0423 NNP I-UN
protein P02110148A0423 NN I-UN
and P02110148A0423 CC O
0.2 P02110148A0423 CD O
kb P02110148A0423 NN O
of P02110148A0423 IN O
upstream P02110148A0423 JJ O
flanking P02110148A0423 NN O
sequence P02110148A0423 NN O
, P02110148A0423 , O
was P02110148A0423 VBD O
utilized P02110148A0423 VBN O
as P02110148A0423 IN O
a P02110148A0423 DT O
homologous P02110148A0423 JJ O
probe P02110148A0423 NN O
to P02110148A0423 TO O
clone P02110148A0423 VB O
an P02110148A0423 DT O
overlapping P02110148A0423 VBG O
2.76-kb P02110148A0423 JJ I-UN
ClaI P02110148A0423 NNP I-UN
chromosomal P02110148A0423 NN I-UN
fragment P02110148A0423 NN I-UN
containing P02110148A0423 VBG O
the P02110148A0423 DT O
entire P02110148A0423 JJ I-UN
IF2 P02110148A0423 NNP I-UN
structural P02110148A0423 JJ I-UN
gene P02110148A0423 NN I-UN
. P02110148A0423 . O
. . O O

Using P07720709A0755 VBG O
Ki-ras-transformed P07720709A0755 NNP O
3T3 P07720709A0755 CD O
cells P07720709A0755 NNS O
as P07720709A0755 IN O
a P07720709A0755 DT O
model P07720709A0755 NN O
system P07720709A0755 NN O
, P07720709A0755 , O
we P07720709A0755 PRP O
show P07720709A0755 VBP O
that P07720709A0755 IN O
both P07720709A0755 DT O
RA P07720709A0755 NNP O
and P07720709A0755 CC O
the P07720709A0755 DT O
'dissociating P07720709A0755 VBG O
' P07720709A0755 POS O
retinoids P07720709A0755 NNS O
inhibit P07720709A0755 VBP O
anchorage-independent P07720709A0755 JJ O
cell P07720709A0755 NN O
proliferation P07720709A0755 NN O
, P07720709A0755 , O
suggesting P07720709A0755 VBG O
that P07720709A0755 IN O
retinoid-induced P07720709A0755 JJ O
growth P07720709A0755 NN O
inhibition P07720709A0755 NN O
may P07720709A0755 MD O
be P07720709A0755 VB O
related P07720709A0755 VBN O
to P07720709A0755 TO O
AP1 P07720709A0755 NNP I-UN
transrepression P07720709A0755 NN O
. P07720709A0755 . O
. . O O

Results P10396793A0815 NNS O
for P10396793A0815 IN O
men P10396793A0815 NNS O
who P10396793A0815 WP O
drank P10396793A0815 VBD O
up P10396793A0815 RB O
to P10396793A0815 TO O
two P10396793A0815 CD O
drinks P10396793A0815 NNS O
per P10396793A0815 IN O
day P10396793A0815 NN O
suggest P10396793A0815 VBP O
that P10396793A0815 IN O
if P10396793A0815 IN O
the P10396793A0815 DT O
dependence P10396793A0815 NN O
criteria P10396793A0815 NNS O
were P10396793A0815 VBD O
invalid P10396793A0815 JJ O
, P10396793A0815 , O
reductions P10396793A0815 NNS O
in P10396793A0815 IN O
the P10396793A0815 DT O
prevalence P10396793A0815 NN O
of P10396793A0815 IN O
specific P10396793A0815 JJ O
indicators P10396793A0815 NNS O
of P10396793A0815 IN O
alcohol P10396793A0815 NN O
dependence P10396793A0815 NN O
would P10396793A0815 MD O
range P10396793A0815 VB O
from P10396793A0815 IN O
0.3 P10396793A0815 CD O
% P10396793A0815 NN O
to P10396793A0815 TO O
5.2 P10396793A0815 CD O
% P10396793A0815 NN O
. P10396793A0815 . O
. . O O

Selective P00038408T0000 JJ O
stimulation P00038408T0000 NN O
of P00038408T0000 IN O
central P00038408T0000 JJ O
alpha-autoreceptors P00038408T0000 NNS I-UN
following P00038408T0000 VBG O
treatment P00038408T0000 NN O
with P00038408T0000 IN O
alpha-methyldopa P00038408T0000 JJ O
and P00038408T0000 CC O
FLA P00038408T0000 NNP O
136 P00038408T0000 CD O
. P00038408T0000 . O
. . O O

When P07612557A0635 WRB O
excluding P07612557A0635 VBG O
children P07612557A0635 NNS O
with P07612557A0635 IN O
ocular P07612557A0635 JJ O
and P07612557A0635 CC O
cerebral P07612557A0635 JJ O
pathology P07612557A0635 NN O
, P07612557A0635 , O
32 P07612557A0635 CD O
matched P07612557A0635 VBD O
pairs P07612557A0635 NNS O
of P07612557A0635 IN O
premature P07612557A0635 NN O
and P07612557A0635 CC O
control P07612557A0635 NN O
children P07612557A0635 NNS O
remained P07612557A0635 VBD O
. P07612557A0635 . O
. . O O

In P02735364A1330 IN O
the P02735364A1330 DT O
final P02735364A1330 JJ O
model P02735364A1330 NN O
, P02735364A1330 , O
grade P02735364A1330 NN O
( P02735364A1330 ( O
p P02735364A1330 JJ O
= P02735364A1330 NNP O
0.0002 P02735364A1330 CD O
) P02735364A1330 ) O
, P02735364A1330 , O
peritoneal P02735364A1330 JJ O
cytologic P02735364A1330 JJ O
results P02735364A1330 NNS O
( P02735364A1330 ( O
p P02735364A1330 JJ O
= P02735364A1330 NNP O
0.0002 P02735364A1330 CD O
) P02735364A1330 ) O
, P02735364A1330 , O
progesterone P02735364A1330 JJ I-UN
receptor P02735364A1330 NN I-UN
status P02735364A1330 NN O
( P02735364A1330 ( O
p P02735364A1330 JJ O
= P02735364A1330 NNP O
0.004 P02735364A1330 CD O
) P02735364A1330 ) O
, P02735364A1330 , O
and P02735364A1330 CC O
age P02735364A1330 NN O
as P02735364A1330 IN O
a P02735364A1330 DT O
continuous P02735364A1330 JJ O
variable P02735364A1330 NN O
( P02735364A1330 ( O
p P02735364A1330 JJ O
= P02735364A1330 NNP O
0.008 P02735364A1330 CD O
) P02735364A1330 ) O
were P02735364A1330 VBD O
most P02735364A1330 RBS O
closely P02735364A1330 RB O
associated P02735364A1330 VBN O
with P02735364A1330 IN O
disease-free P02735364A1330 JJ O
survival P02735364A1330 NN O
. P02735364A1330 . O
. . O O

Scanning P00927633T0001 VBG O
electron P00927633T0001 NN O
microscopic P00927633T0001 NN O
investigations P00927633T0001 NNS O
on P00927633T0001 IN O
the P00927633T0001 DT O
formation P00927633T0001 NN O
of P00927633T0001 IN O
Reissner P00927633T0001 NNP O
's P00927633T0001 POS O
fiber P00927633T0001 NN O
in P00927633T0001 IN O
Rattus P00927633T0001 NNP O
rattus P00927633T0001 NN O
. P00927633T0001 . O
. . O O

CSF P07112320A0086 NNP O
adenosine P07112320A0086 JJ I-UN
deaminase P07112320A0086 NN I-UN
activity P07112320A0086 NN O
( P07112320A0086 ( O
ADA P07112320A0086 NNP O
) P07112320A0086 ) O
was P07112320A0086 VBD O
measured P07112320A0086 VBN O
at P07112320A0086 IN O
the P07112320A0086 DT O
same P07112320A0086 JJ O
time P07112320A0086 NN O
. P07112320A0086 . O
. . O O

Survival P02677429A0366 JJ O
rates P02677429A0366 NNS O
for P02677429A0366 IN O
the P02677429A0366 DT O
original P02677429A0366 JJ O
treatment P02677429A0366 NN O
group P02677429A0366 NN O
were P02677429A0366 VBD O
84.5 P02677429A0366 CD O
% P02677429A0366 NN O
and P02677429A0366 CC O
57.6 P02677429A0366 CD O
% P02677429A0366 NN O
at P02677429A0366 IN O
12 P02677429A0366 CD O
and P02677429A0366 CC O
21 P02677429A0366 CD O
months P02677429A0366 NNS O
, P02677429A0366 , O
respectively P02677429A0366 RB O
; P02677429A0366 : O
for P02677429A0366 IN O
the P02677429A0366 DT O
delayed P02677429A0366 JJ O
treatment P02677429A0366 NN O
group P02677429A0366 NN O
, P02677429A0366 , O
78.8 P02677429A0366 CD O
% P02677429A0366 NN O
and P02677429A0366 CC O
64.6 P02677429A0366 CD O
% P02677429A0366 NN O
at P02677429A0366 IN O
12 P02677429A0366 CD O
and P02677429A0366 CC O
21 P02677429A0366 CD O
months P02677429A0366 NNS O
, P02677429A0366 , O
respectively P02677429A0366 RB O
, P02677429A0366 , O
and P02677429A0366 CC O
78.8 P02677429A0366 CD O
% P02677429A0366 NN O
and P02677429A0366 CC O
47.5 P02677429A0366 CD O
% P02677429A0366 NN O
at P02677429A0366 IN O
12 P02677429A0366 CD O
and P02677429A0366 CC O
21 P02677429A0366 CD O
months P02677429A0366 NNS O
, P02677429A0366 , O
respectively P02677429A0366 RB O
, P02677429A0366 , O
for P02677429A0366 IN O
77 P02677429A0366 CD O
subjects P02677429A0366 NNS O
with P02677429A0366 IN O
AIDS P02677429A0366 NNP O
and P02677429A0366 CC O
93.0 P02677429A0366 CD O
% P02677429A0366 NN O
and P02677429A0366 CC O
71.8 P02677429A0366 CD O
% P02677429A0366 NN O
, P02677429A0366 , O
respectively P02677429A0366 RB O
, P02677429A0366 , O
for P02677429A0366 IN O
50 P02677429A0366 CD O
subjects P02677429A0366 NNS O
with P02677429A0366 IN O
AIDS-related P02677429A0366 NNP O
complex P02677429A0366 NN O
in P02677429A0366 IN O
the P02677429A0366 DT O
original P02677429A0366 JJ O
treatment P02677429A0366 NN O
group P02677429A0366 NN O
. P02677429A0366 . O
. . O O

The P01549118A0000 DT O
Caenorhabditis P01549118A0000 NNP I-UN
elegans P01549118A0000 VBZ I-UN
vitellogenin P01549118A0000 JJ I-UN
genes P01549118A0000 NNS I-UN
are P01549118A0000 VBP O
subject P01549118A0000 JJ O
to P01549118A0000 TO O
sex- P01549118A0000 JJ O
, P01549118A0000 , O
stage- P01549118A0000 JJ O
, P01549118A0000 , O
and P01549118A0000 CC O
tissue-specific P01549118A0000 JJ O
regulation P01549118A0000 NN O
: P01549118A0000 : O
they P01549118A0000 PRP O
are P01549118A0000 VBP O
expressed P01549118A0000 VBN O
solely P01549118A0000 RB O
in P01549118A0000 IN O
the P01549118A0000 DT O
adult P01549118A0000 NN O
hermaphrodite P01549118A0000 JJ O
intestine P01549118A0000 NN O
. P01549118A0000 . O
. . O O

Rare P02560415T0012 NNP O
neurogenic P02560415T0012 JJ O
tumor P02560415T0012 NN O
with P02560415T0012 IN O
metastasis P02560415T0012 NN O
to P02560415T0012 TO O
mouth P02560415T0012 VB O
, P02560415T0012 , O
jaw P02560415T0012 NN O
and P02560415T0012 CC O
face P02560415T0012 NN O
regions P02560415T0012 NNS O
. P02560415T0012 . O
. . O O

We P09150566A0316 PRP O
also P09150566A0316 RB O
review P09150566A0316 VBP O
the P09150566A0316 DT O
role P09150566A0316 NN O
of P09150566A0316 IN O
grains P09150566A0316 NNS O
in P09150566A0316 IN O
the P09150566A0316 DT O
formation P09150566A0316 NN O
of P09150566A0316 IN O
complex P09150566A0316 JJ O
molecules P09150566A0316 NNS O
in P09150566A0316 IN O
interstellar P09150566A0316 JJ O
molecular P09150566A0316 JJ O
clouds P09150566A0316 NN O
. P09150566A0316 . O
. . O O

Acta P07980468A0298 NNP O
572 P07980468A0298 CD O
, P07980468A0298 , O
113-120 P07980468A0298 JJ O
] P07980468A0298 NN O
. P07980468A0298 . O
. . O O

Analyses P07954475A0714 NNS O
of P07954475A0714 IN O
additional P07954475A0714 JJ O
tumors P07954475A0714 NNS O
induced P07954475A0714 VBD O
in P07954475A0714 IN O
mice P07954475A0714 NN O
from P07954475A0714 IN O
two P07954475A0714 CD O
reciprocal P07954475A0714 JJ O
crosses P07954475A0714 NNS O
, P07954475A0714 , O
A P07954475A0714 NNP O
/ P07954475A0714 NNP O
J P07954475A0714 NNP O
x P07954475A0714 NNP O
C3H P07954475A0714 NNP O
/ P07954475A0714 NNP O
HeJ P07954475A0714 NNP O
F1 P07954475A0714 NNP O
( P07954475A0714 ( O
hereafter P07954475A0714 NN O
called P07954475A0714 VBN O
AC3F1 P07954475A0714 NNP O
) P07954475A0714 ) O
and P07954475A0714 CC O
C3H P07954475A0714 NNP O
/ P07954475A0714 NNP O
HeJ P07954475A0714 NNP O
x P07954475A0714 VBZ O
A P07954475A0714 NNP O
/ P07954475A0714 NNP O
J P07954475A0714 NNP O
F1 P07954475A0714 NNP O
( P07954475A0714 ( O
hereafter P07954475A0714 NN O
called P07954475A0714 VBN O
C3AF1 P07954475A0714 NNP O
) P07954475A0714 ) O
, P07954475A0714 , O
provided P07954475A0714 VBD O
evidence P07954475A0714 NN O
for P07954475A0714 IN O
the P07954475A0714 DT O
inactivation P07954475A0714 NN O
of P07954475A0714 IN O
one P07954475A0714 CD O
allele P07954475A0714 NN O
of P07954475A0714 IN O
the P07954475A0714 DT O
putative P07954475A0714 JJ O
chromosome P07954475A0714 NN O
4 P07954475A0714 CD O
tumor P07954475A0714 NN O
suppressor P07954475A0714 NN O
gene P07954475A0714 NN O
by P07954475A0714 IN O
parental P07954475A0714 JJ O
imprinting P07954475A0714 NN O
. P07954475A0714 . O
. . O O

The P11098217A0674 DT O
Aie1 P11098217A0674 NNP I-UN
locus P11098217A0674 NN I-UN
was P11098217A0674 VBD O
mapped P11098217A0674 VBN O
to P11098217A0674 TO O
mouse P11098217A0674 VB O
chromosome P11098217A0674 JJ O
7A2-A3 P11098217A0674 JJ O
by P11098217A0674 IN O
fluorescent P11098217A0674 NN O
in P11098217A0674 IN O
situ P11098217A0674 JJ O
hybridization P11098217A0674 NN O
. P11098217A0674 . O
. . O O

Of P00056837A0000 IN O
600 P00056837A0000 CD O
mediastinoscopies P00056837A0000 NNS O
carried P00056837A0000 VBD O
out P00056837A0000 IN O
from P00056837A0000 IN O
1966 P00056837A0000 CD O
to P00056837A0000 TO O
1973 P00056837A0000 CD O
, P00056837A0000 , O
479 P00056837A0000 CD O
were P00056837A0000 VBD O
performed P00056837A0000 VBN O
to P00056837A0000 TO O
assess P00056837A0000 VB O
the P00056837A0000 DT O
operability P00056837A0000 NN O
of P00056837A0000 IN O
a P00056837A0000 DT O
pulmonary P00056837A0000 JJ O
carcinoma P00056837A0000 NN O
. P00056837A0000 . O
. . O O

The P07553942A0810 DT O
pea P07553942A0810 NN I-UN
rps10 P07553942A0810 NN I-UN
intron P07553942A0810 NN I-UN
is P07553942A0810 VBZ O
homologous P07553942A0810 JJ O
to P07553942A0810 TO O
introns P07553942A0810 NNS O
in P07553942A0810 IN O
rrn26 P07553942A0810 NN I-UN
and P07553942A0810 CC O
cox3 P07553942A0810 NN I-UN
in P07553942A0810 IN O
the P07553942A0810 DT O
Marchantia P07553942A0810 NNP O
mitochondrial P07553942A0810 JJ O
genome P07553942A0810 NN O
, P07553942A0810 , O
while P07553942A0810 IN O
the P07553942A0810 DT O
Marchantia P07553942A0810 NNP I-UN
rps10 P07553942A0810 NN I-UN
gene P07553942A0810 NN I-UN
lacks P07553942A0810 VBZ O
an P07553942A0810 DT O
intron P07553942A0810 NN O
. P07553942A0810 . O
. . O O

Structural P10677214A2842 JJ O
changes P10677214A2842 NNS O
in P10677214A2842 IN O
the P10677214A2842 DT O
kinetically P10677214A2842 RB O
more P10677214A2842 RBR O
damaged P10677214A2842 JJ O
E44D P10677214A2842 NNP O
mutant P10677214A2842 NN O
detected P10677214A2842 VBN O
in P10677214A2842 IN O
( P10677214A2842 ( O
1 P10677214A2842 CD O
) P10677214A2842 ) O
H- P10677214A2842 NNP O
( P10677214A2842 ( O
15 P10677214A2842 CD O
) P10677214A2842 ) O
N P10677214A2842 NNP O
HSQC P10677214A2842 NNP O
spectra P10677214A2842 NN O
were P10677214A2842 VBD O
largely P10677214A2842 RB O
limited P10677214A2842 VBN O
to P10677214A2842 TO O
the P10677214A2842 DT O
loop P10677214A2842 JJ O
I-helix P10677214A2842 NNP O
I P10677214A2842 PRP O
motif P10677214A2842 VBP O
, P10677214A2842 , O
suggesting P10677214A2842 VBG O
that P10677214A2842 IN O
Glu-44 P10677214A2842 NNP O
stabilizes P10677214A2842 VBZ O
the P10677214A2842 DT O
active P10677214A2842 JJ O
site P10677214A2842 NN O
region P10677214A2842 NN O
. P10677214A2842 . O
. . O O

These P06683876A0244 DT O
cells P06683876A0244 NNS O
averaged P06683876A0244 VBD O
17 P06683876A0244 CD O
microns P06683876A0244 NNS O
in P06683876A0244 IN O
diameter P06683876A0244 NN O
and P06683876A0244 CC O
reproduced P06683876A0244 VBN O
by P06683876A0244 IN O
fission P06683876A0244 NN O
, P06683876A0244 , O
forming P06683876A0244 VBG O
clusters P06683876A0244 NNS O
of P06683876A0244 IN O
two P06683876A0244 CD O
or P06683876A0244 CC O
four P06683876A0244 CD O
daughter P06683876A0244 NN O
cells P06683876A0244 NNS O
. P06683876A0244 . O
. . O O

The P07903099A0918 DT O
presence P07903099A0918 NN O
of P07903099A0918 IN O
an P07903099A0918 DT O
unusual P07903099A0918 JJ O
transcript P07903099A0918 NN O
possessing P07903099A0918 VBG O
IVS2C P07903099A0918 NNP I-UN
beta P07903099A0918 NN I-UN
1 P07903099A0918 CD I-UN
at P07903099A0918 IN O
the P07903099A0918 DT O
5 P07903099A0918 CD O
' P07903099A0918 POS O
terminus P07903099A0918 NN O
suggests P07903099A0918 VBZ O
that P07903099A0918 IN O
cleavage P07903099A0918 NN O
of P07903099A0918 IN O
its P07903099A0918 PRP$ O
splice P07903099A0918 NN O
acceptor P07903099A0918 NN O
is P07903099A0918 VBZ O
inefficient P07903099A0918 JJ O
or P07903099A0918 CC O
negatively P07903099A0918 RB O
regulated P07903099A0918 VBN O
. P07903099A0918 . O
. . O O

Among P01792580A0198 IN O
blood P01792580A0198 NN O
donors P01792580A0198 NNS O
in P01792580A0198 IN O
the P01792580A0198 DT O
Republic P01792580A0198 NNP O
of P01792580A0198 IN O
Serbia P01792580A0198 NNP O
, P01792580A0198 , O
regardless P01792580A0198 RB O
the P01792580A0198 DT O
number P01792580A0198 NN O
of P01792580A0198 IN O
blood P01792580A0198 NN O
donations P01792580A0198 NNS O
, P01792580A0198 , O
the P01792580A0198 DT O
percentage P01792580A0198 NN O
of P01792580A0198 IN O
female P01792580A0198 JJ O
donors P01792580A0198 NNS O
is P01792580A0198 VBZ O
significantly P01792580A0198 RB O
lower P01792580A0198 JJR O
compared P01792580A0198 VBN O
to P01792580A0198 TO O
the P01792580A0198 DT O
percentage P01792580A0198 NN O
of P01792580A0198 IN O
male P01792580A0198 NN O
blood P01792580A0198 NN O
donors P01792580A0198 NNS O
. P01792580A0198 . O
. . O O

In P03873141A0304 IN O
19 P03873141A0304 CD O
patients P03873141A0304 NNS O
vagotomy P03873141A0304 MD O
not P03873141A0304 RB O
only P03873141A0304 RB O
curbed P03873141A0304 VBD O
the P03873141A0304 DT O
bleeding P03873141A0304 NN O
but P03873141A0304 CC O
provided P03873141A0304 VBD O
definitive P03873141A0304 JJ O
therapy P03873141A0304 NN O
( P03873141A0304 ( O
Visick P03873141A0304 NNP O
I-II P03873141A0304 NNP O
) P03873141A0304 ) O
; P03873141A0304 : O
4 P03873141A0304 CD O
patients P03873141A0304 NNS O
died P03873141A0304 VBD O
( P03873141A0304 ( O
mortality P03873141A0304 NN O
rate P03873141A0304 NN O
16 P03873141A0304 CD O
% P03873141A0304 NN O
) P03873141A0304 ) O
. P03873141A0304 . O
. . O O

Src P11012680A0676 NNP I-UN
activation P11012680A0676 NN O
induced P11012680A0676 VBN O
by P11012680A0676 IN O
FGF1 P11012680A0676 NNP I-UN
was P11012680A0676 VBD O
blocked P11012680A0676 VBN O
by P11012680A0676 IN O
the P11012680A0676 DT O
SH2 P11012680A0676 NNP I-UN
domain P11012680A0676 NN I-UN
of P11012680A0676 IN O
Src P11012680A0676 NNP I-UN
and P11012680A0676 CC O
PP2 P11012680A0676 NNP I-UN
, P11012680A0676 , O
a P11012680A0676 DT O
specific P11012680A0676 JJ O
inhibitor P11012680A0676 NN O
of P11012680A0676 IN O
Src P11012680A0676 NNP I-UN
. P11012680A0676 . O
. . O O

Over-expression P09799362A1463 NN O
of P09799362A1463 IN O
Azf1p P09799362A1463 NNP I-UN
in P09799362A1463 IN O
the P09799362A1463 DT O
yeast P09799362A1463 NN O
cell P09799362A1463 NN O
does P09799362A1463 VBZ O
not P09799362A1463 RB O
influence P09799362A1463 VB O
the P09799362A1463 DT O
expression P09799362A1463 NN O
level P09799362A1463 NN O
of P09799362A1463 IN O
the P09799362A1463 DT O
mitochondrial P09799362A1463 JJ I-UN
transcription P09799362A1463 NN I-UN
factor P09799362A1463 NN I-UN
Mtf1p P09799362A1463 NNP I-UN
, P09799362A1463 , O
indicating P09799362A1463 VBG O
that P09799362A1463 IN O
the P09799362A1463 DT O
influence P09799362A1463 NN O
of P09799362A1463 IN O
Azf1p P09799362A1463 NNP I-UN
on P09799362A1463 IN O
the P09799362A1463 DT O
suppression P09799362A1463 NN O
of P09799362A1463 IN O
the P09799362A1463 DT O
special P09799362A1463 JJ O
mitochondrial P09799362A1463 JJ I-UN
RNA P09799362A1463 NNP I-UN
polymerase P09799362A1463 NN I-UN
mutant P09799362A1463 NN I-UN
is P09799362A1463 VBZ O
an P09799362A1463 DT O
indirect P09799362A1463 JJ O
one P09799362A1463 CD O
. P09799362A1463 . O
. . O O

A P10570996A1213 DT O
phylogenetic P10570996A1213 JJ O
analysis P10570996A1213 NN O
with P10570996A1213 IN O
the P10570996A1213 DT O
TK P10570996A1213 NNP I-UN
domains P10570996A1213 NNS I-UN
from P10570996A1213 IN O
these P10570996A1213 DT O
sequences P10570996A1213 NNS O
and P10570996A1213 CC O
a P10570996A1213 DT O
fourth P10570996A1213 JJ O
, P10570996A1213 , O
from P10570996A1213 IN O
a P10570996A1213 DT O
novel P10570996A1213 JJ O
scavenger P10570996A1213 NN I-UN
RTK P10570996A1213 NNP I-UN
( P10570996A1213 ( O
all P10570996A1213 DT O
domains P10570996A1213 NNS O
comprise P10570996A1213 VBP O
the P10570996A1213 DT O
signature P10570996A1213 NN O
for P10570996A1213 IN O
the P10570996A1213 DT O
TK P10570996A1213 NNP I-UN
class P10570996A1213 NN I-UN
II P10570996A1213 NNP I-UN
receptors P10570996A1213 NNS I-UN
) P10570996A1213 ) O
, P10570996A1213 , O
showed P10570996A1213 VBD O
that P10570996A1213 IN O
they P10570996A1213 PRP O
are P10570996A1213 VBP O
distantly P10570996A1213 RB O
related P10570996A1213 VBN O
to P10570996A1213 TO O
the P10570996A1213 DT O
insulin P10570996A1213 NN I-UN
and P10570996A1213 CC O
insulin-like P10570996A1213 JJ I-UN
receptors P10570996A1213 NNS I-UN
. P10570996A1213 . O
. . O O

INTERVENTIONS P10965830A0305 NN O
: P10965830A0305 : O
Subcutaneous P10965830A0305 JJ O
tissue P10965830A0305 NN O
PO2 P10965830A0305 NNP O
and P10965830A0305 CC O
PCO2 P10965830A0305 NNP O
tensions P10965830A0305 NNS O
were P10965830A0305 VBD O
measured P10965830A0305 VBN O
directly P10965830A0305 RB O
in P10965830A0305 IN O
patients P10965830A0305 NNS O
with P10965830A0305 IN O
necrotising P10965830A0305 JJ O
fasciitis P10965830A0305 NN O
and P10965830A0305 CC O
in P10965830A0305 IN O
healthy P10965830A0305 JJ O
volunteers P10965830A0305 NNS O
during P10965830A0305 IN O
normobaric P10965830A0305 JJ O
and P10965830A0305 CC O
hyperbaric P10965830A0305 JJ O
conditions P10965830A0305 NNS O
. P10965830A0305 . O
. . O O

All P08383526A0591 DT O
four P08383526A0591 CD O
of P08383526A0591 IN O
the P08383526A0591 DT O
genes P08383526A0591 NNS O
have P08383526A0591 VBP O
a P08383526A0591 DT O
similar P08383526A0591 JJ O
structure P08383526A0591 NN O
, P08383526A0591 , O
with P08383526A0591 IN O
the P08383526A0591 DT O
receptor P08383526A0591 NN O
protein P08383526A0591 NN O
encoded P08383526A0591 VBD O
in P08383526A0591 IN O
a P08383526A0591 DT O
single P08383526A0591 JJ O
exon P08383526A0591 NN O
. P08383526A0591 . O
. . O O

Bites P10748672A0130 NNS O
by P10748672A0130 IN O
two P10748672A0130 CD O
species P10748672A0130 NNS O
of P10748672A0130 IN O
adders P10748672A0130 NNS O
( P10748672A0130 ( O
Vipera P10748672A0130 NNP O
aspis P10748672A0130 NN O
and P10748672A0130 CC O
Vipera P10748672A0130 NNP O
berus P10748672A0130 NN O
) P10748672A0130 ) O
can P10748672A0130 MD O
lead P10748672A0130 VB O
to P10748672A0130 TO O
extensive P10748672A0130 JJ O
swelling P10748672A0130 VBG O
with P10748672A0130 IN O
multiorgan P10748672A0130 JJ O
failure P10748672A0130 NN O
. P10748672A0130 . O
. . O O

In P03013477A0000 IN O
order P03013477A0000 NN O
to P03013477A0000 TO O
study P03013477A0000 VB O
the P03013477A0000 DT O
influence P03013477A0000 NN O
of P03013477A0000 IN O
iron P03013477A0000 NN O
overload P03013477A0000 NN O
on P03013477A0000 IN O
the P03013477A0000 DT O
polymorphonuclear P03013477A0000 JJ O
leucocyte P03013477A0000 NN O
( P03013477A0000 ( O
PMN P03013477A0000 NNP O
) P03013477A0000 ) O
metabolism P03013477A0000 NN O
of P03013477A0000 IN O
patients P03013477A0000 NNS O
on P03013477A0000 IN O
chronic P03013477A0000 JJ O
hemodialysis P03013477A0000 NN O
, P03013477A0000 , O
generation P03013477A0000 NN O
of P03013477A0000 IN O
superoxide P03013477A0000 JJ O
anion P03013477A0000 NN O
( P03013477A0000 ( O
O2- P03013477A0000 NNP O
) P03013477A0000 ) O
by P03013477A0000 IN O
PMN P03013477A0000 NNP O
in P03013477A0000 IN O
whole P03013477A0000 JJ O
blood P03013477A0000 NN O
was P03013477A0000 VBD O
compared P03013477A0000 VBN O
in P03013477A0000 IN O
two P03013477A0000 CD O
groups P03013477A0000 NNS O
of P03013477A0000 IN O
hemodialyzed P03013477A0000 JJ O
patients P03013477A0000 NNS O
: P03013477A0000 : O
group P03013477A0000 NN O
A P03013477A0000 NNP O
consisted P03013477A0000 VBD O
of P03013477A0000 IN O
twenty-one P03013477A0000 JJ O
individuals P03013477A0000 NNS O
with P03013477A0000 IN O
serum P03013477A0000 NN O
ferritin P03013477A0000 NN I-UN
levels P03013477A0000 NNS O
above P03013477A0000 IN O
1000 P03013477A0000 CD O
ng P03013477A0000 JJ O
/ P03013477A0000 NNP O
ml P03013477A0000 NN O
and P03013477A0000 CC O
group P03013477A0000 NN O
B P03013477A0000 NNP O
of P03013477A0000 IN O
nineteen P03013477A0000 JJ O
individuals P03013477A0000 NNS O
with P03013477A0000 IN O
serum P03013477A0000 NN O
ferritin P03013477A0000 NN I-UN
levels P03013477A0000 NNS O
below P03013477A0000 IN O
1000 P03013477A0000 CD O
ng P03013477A0000 JJ O
/ P03013477A0000 NNP O
ml P03013477A0000 NN O
. P03013477A0000 . O
. . O O

These P01649318A1222 DT O
experiments P01649318A1222 NNS O
delineate P01649318A1222 VBP O
a P01649318A1222 DT O
186-bp P01649318A1222 JJ O
, P01649318A1222 , O
EBNA-2-responsive P01649318A1222 JJ O
cell P01649318A1222 NN O
DNA P01649318A1222 NNP O
fragment P01649318A1222 NN O
and P01649318A1222 CC O
provide P01649318A1222 VB O
firm P01649318A1222 JJ O
evidence P01649318A1222 NN O
that P01649318A1222 IN O
EBNA-2 P01649318A1222 NNP I-UN
transactivates P01649318A1222 VBZ O
transcription P01649318A1222 NN O
of P01649318A1222 IN O
cell P01649318A1222 NN O
genes P01649318A1222 NNS O
. P01649318A1222 . O
. . O O

Consequently P01395755A1023 RB O
, P01395755A1023 , O
significant P01395755A1023 JJ O
differences P01395755A1023 NNS O
between P01395755A1023 IN O
the P01395755A1023 DT O
measured P01395755A1023 VBN O
and P01395755A1023 CC O
calculated P01395755A1023 VBN O
methods P01395755A1023 NNS O
were P01395755A1023 VBD O
noted P01395755A1023 VBN O
in P01395755A1023 IN O
oxygen P01395755A1023 NN O
uptake P01395755A1023 NN O
( P01395755A1023 ( O
213 P01395755A1023 CD O
+ P01395755A1023 NN O
/ P01395755A1023 NNP O
- P01395755A1023 : O
41 P01395755A1023 CD O
ml P01395755A1023 NN O
/ P01395755A1023 NNP O
min P01395755A1023 NN O
vs P01395755A1023 NN O
193 P01395755A1023 CD O
+ P01395755A1023 NN O
/ P01395755A1023 NNP O
- P01395755A1023 : O
25 P01395755A1023 CD O
ml P01395755A1023 NN O
/ P01395755A1023 NNP O
min P01395755A1023 NN O
, P01395755A1023 , O
p P01395755A1023 NN O
< P01395755A1023 NNP O
0.001 P01395755A1023 CD O
) P01395755A1023 ) O
, P01395755A1023 , O
oxygen P01395755A1023 JJ O
delivery P01395755A1023 NN O
( P01395755A1023 ( O
780 P01395755A1023 CD O
+ P01395755A1023 NN O
/ P01395755A1023 NNP O
- P01395755A1023 : O
297 P01395755A1023 CD O
ml P01395755A1023 NN O
/ P01395755A1023 NNP O
min P01395755A1023 NN O
vs P01395755A1023 NN O
716 P01395755A1023 CD O
+ P01395755A1023 NN O
/ P01395755A1023 NNP O
- P01395755A1023 : O
296 P01395755A1023 CD O
ml P01395755A1023 NN O
/ P01395755A1023 NNP O
min P01395755A1023 NN O
, P01395755A1023 , O
p P01395755A1023 NN O
< P01395755A1023 NNP O
0.001 P01395755A1023 CD O
) P01395755A1023 ) O
, P01395755A1023 , O
and P01395755A1023 CC O
cardiac P01395755A1023 JJ O
output P01395755A1023 NN O
( P01395755A1023 ( O
5.8 P01395755A1023 CD O
+ P01395755A1023 NN O
/ P01395755A1023 NNP O
- P01395755A1023 : O
2.2 P01395755A1023 CD O
L P01395755A1023 NNP O
/ P01395755A1023 NNP O
min P01395755A1023 NNP O
vs P01395755A1023 VBD O
5.3 P01395755A1023 CD O
+ P01395755A1023 NNP O
/ P01395755A1023 NNP O
- P01395755A1023 : O
1.8 P01395755A1023 CD O
L P01395755A1023 NNP O
/ P01395755A1023 NNP O
min P01395755A1023 NN O
, P01395755A1023 , O
p P01395755A1023 NN O
< P01395755A1023 NNP O
0.001 P01395755A1023 CD O
) P01395755A1023 ) O
. P01395755A1023 . O
. . O O

Thus P09368057A1083 RB O
, P09368057A1083 , O
unlike P09368057A1083 IN O
other P09368057A1083 JJ O
proteins P09368057A1083 NNS O
reported P09368057A1083 VBN O
to P09368057A1083 TO O
inhibit P09368057A1083 VB O
SRF P09368057A1083 NNP I-UN
activity P09368057A1083 NN O
, P09368057A1083 , O
the P09368057A1083 DT O
repressor P09368057A1083 NN O
activity P09368057A1083 NN O
associated P09368057A1083 VBN O
with P09368057A1083 IN O
the P09368057A1083 DT O
GC-rich P09368057A1083 JJ O
element P09368057A1083 NN O
does P09368057A1083 VBZ O
not P09368057A1083 RB O
appear P09368057A1083 VB O
to P09368057A1083 TO O
function P09368057A1083 VB O
through P09368057A1083 IN O
direct P09368057A1083 JJ O
inhibition P09368057A1083 NN O
of P09368057A1083 IN O
SRF P09368057A1083 NNP I-UN
binding P09368057A1083 NN O
. P09368057A1083 . O
. . O O

It P08531373A0470 PRP O
is P08531373A0470 VBZ O
considered P08531373A0470 VBN O
that P08531373A0470 IN O
the P08531373A0470 DT O
recurrent P08531373A0470 NN O
annular P08531373A0470 JJ O
erythema P08531373A0470 NN O
is P08531373A0470 VBZ O
a P08531373A0470 DT O
specific P08531373A0470 JJ O
skin P08531373A0470 JJ O
manifestation P08531373A0470 NN O
of P08531373A0470 IN O
SjS P08531373A0470 NNP O
with P08531373A0470 IN O
anti P08531373A0470 JJ I-UN
SS-A P08531373A0470 JJ I-UN
/ P08531373A0470 JJ O
SS-B P08531373A0470 JJ I-UN
antibodies P08531373A0470 NNS I-UN
. P08531373A0470 . O
. . O O

No P09444316A0388 DT O
apparent P09444316A0388 JJ O
clinical P09444316A0388 JJ O
signs P09444316A0388 NNS O
indicative P09444316A0388 NN O
of P09444316A0388 IN O
systemic P09444316A0388 JJ O
toxicity P09444316A0388 NN O
were P09444316A0388 VBD O
observed P09444316A0388 VBN O
in P09444316A0388 IN O
the P09444316A0388 DT O
F0 P09444316A0388 NNP O
and P09444316A0388 CC O
F1 P09444316A0388 NNP O
animals P09444316A0388 NNS O
of P09444316A0388 IN O
either P09444316A0388 DT O
sex P09444316A0388 NN O
. P09444316A0388 . O
. . O O

We P08892859A0563 PRP O
report P08892859A0563 VBP O
an P08892859A0563 DT O
example P08892859A0563 NN O
of P08892859A0563 IN O
an P08892859A0563 DT O
MDV-transformed P08892859A0563 JJ O
T-lymphoblastoid P08892859A0563 NNP O
cell P08892859A0563 NN O
line P08892859A0563 NN O
( P08892859A0563 ( O
T9 P08892859A0563 NNP O
) P08892859A0563 ) O
expressing P08892859A0563 VBG O
high P08892859A0563 JJ O
levels P08892859A0563 NNS O
of P08892859A0563 IN O
a P08892859A0563 DT O
truncated P08892859A0563 JJ I-UN
C-MYB P08892859A0563 JJ I-UN
protein P08892859A0563 NN I-UN
as P08892859A0563 IN O
a P08892859A0563 DT O
result P08892859A0563 NN O
of P08892859A0563 IN O
RAV P08892859A0563 NNP O
integration P08892859A0563 NN O
within P08892859A0563 IN O
one P08892859A0563 CD O
c-myb P08892859A0563 JJ I-UN
allele P08892859A0563 NN I-UN
. P08892859A0563 . O
. . O O

In P08901635A0000 IN O
spite P08901635A0000 NN O
of P08901635A0000 IN O
much P08901635A0000 JJ O
effort P08901635A0000 NN O
, P08901635A0000 , O
no P08901635A0000 DT O
one P08901635A0000 NN O
has P08901635A0000 VBZ O
succeeded P08901635A0000 VBN O
in P08901635A0000 IN O
isolating P08901635A0000 VBG O
and P08901635A0000 CC O
characterizing P08901635A0000 VBG O
the P08901635A0000 DT O
enzyme P08901635A0000 NN O
( P08901635A0000 ( O
s P08901635A0000 PRP O
) P08901635A0000 ) O
responsible P08901635A0000 JJ O
for P08901635A0000 IN O
synthesis P08901635A0000 NN O
of P08901635A0000 IN O
cellulose P08901635A0000 NN O
, P08901635A0000 , O
the P08901635A0000 DT O
major P08901635A0000 JJ O
cell P08901635A0000 NN O
wall P08901635A0000 NN O
polymer P08901635A0000 NN O
of P08901635A0000 IN O
plants P08901635A0000 NNS O
. P08901635A0000 . O
. . O O

The P09079638A0883 DT O
3ASubE P09079638A0883 CD O
cells P09079638A0883 NNS O
expressing P09079638A0883 VBG O
CXCR2 P09079638A0883 NNP I-UN
with P09079638A0883 IN O
mutation P09079638A0883 NN O
of P09079638A0883 IN O
Ser-346 P09079638A0883 NNP O
, P09079638A0883 , O
-347 P09079638A0883 NNP O
, P09079638A0883 , O
and P09079638A0883 CC O
-348 P09079638A0883 VBZ O
to P09079638A0883 TO O
alanine P09079638A0883 VB O
, P09079638A0883 , O
or P09079638A0883 CC O
with P09079638A0883 IN O
mutation P09079638A0883 NN O
of P09079638A0883 IN O
only P09079638A0883 RB O
one P09079638A0883 CD O
serine P09079638A0883 NN O
in P09079638A0883 IN O
this P09079638A0883 DT O
domain P09079638A0883 NN O
, P09079638A0883 , O
continue P09079638A0883 VBP O
to P09079638A0883 TO O
be P09079638A0883 VB O
phosphorylated P09079638A0883 VBN O
in P09079638A0883 IN O
response P09079638A0883 NN O
to P09079638A0883 TO O
ligand P09079638A0883 VB O
and P09079638A0883 CC O
are P09079638A0883 VBP O
60-70 P09079638A0883 JJ O
% P09079638A0883 NN O
desensitized P09079638A0883 VBN O
following P09079638A0883 VBG O
the P09079638A0883 DT O
initial P09079638A0883 JJ O
ligand P09079638A0883 NN O
challenge P09079638A0883 NN O
. P09079638A0883 . O
. . O O

In P02876820A0841 IN O
metabolic P02876820A0841 JJ O
acidosis P02876820A0841 NN O
there P02876820A0841 EX O
was P02876820A0841 VBD O
a P02876820A0841 DT O
marked P02876820A0841 JJ O
stimulation P02876820A0841 NN O
when P02876820A0841 WRB O
clamped P02876820A0841 NN O
at P02876820A0841 IN O
-10 P02876820A0841 NNP O
to P02876820A0841 TO O
-100 P02876820A0841 VB O
mV P02876820A0841 NN O
. P02876820A0841 . O
. . O O

Molecular P00210220X0000 JJ O
neurochemistry P00210220X0000 NN O
of P00210220X0000 IN O
addictive P00210220X0000 JJ O
drugs P00210220X0000 NNS O
. P00210220X0000 . O
. . O O

CONCLUSION P09641167A1359 NN O
: P09641167A1359 : O
TNF P09641167A1359 NNP I-UN
alpha P09641167A1359 NN I-UN
, P09641167A1359 , O
TGF P09641167A1359 NNP I-UN
beta P09641167A1359 NN I-UN
, P09641167A1359 , O
PDGF P09641167A1359 NNP I-UN
and P09641167A1359 CC O
IL-1beta P09641167A1359 NNP I-UN
increased P09641167A1359 VBD O
LDLr P09641167A1359 NNP I-UN
gene P09641167A1359 NN I-UN
expression P09641167A1359 NN O
by P09641167A1359 IN O
increasing P09641167A1359 VBG O
sterol-independent P09641167A1359 JJ O
and P09641167A1359 CC O
mitogenesis-independent P09641167A1359 JJ O
gene P09641167A1359 NN O
transcription P09641167A1359 NN O
. P09641167A1359 . O
. . O O

The P10556028A0292 DT O
cop P10556028A0292 NN I-UN
region P10556028A0292 NN I-UN
also P10556028A0292 RB O
harbors P10556028A0292 VBZ O
a P10556028A0292 DT O
region P10556028A0292 NN O
of P10556028A0292 IN O
plasmid P10556028A0292 JJ O
incompatibility P10556028A0292 NN O
, P10556028A0292 , O
inc P10556028A0292 NN I-UN
, P10556028A0292 , O
encompassing P10556028A0292 VBG O
a P10556028A0292 DT O
stem-loop P10556028A0292 JJ O
structure P10556028A0292 NN O
, P10556028A0292 , O
the P10556028A0292 DT O
repA P10556028A0292 NN I-UN
promoter P10556028A0292 NN I-UN
, P10556028A0292 , O
Prep P10556028A0292 NNP I-UN
, P10556028A0292 , O
as P10556028A0292 RB O
well P10556028A0292 RB O
as P10556028A0292 IN O
two P10556028A0292 CD O
distinct P10556028A0292 JJ O
RepA P10556028A0292 NNP I-UN
binding P10556028A0292 NN I-UN
sites P10556028A0292 NNS I-UN
, P10556028A0292 , O
BD-1 P10556028A0292 NNP O
and P10556028A0292 CC O
BD-2 P10556028A0292 NNP O
. P10556028A0292 . O
. . O O

Cyclin P07559524A0741 NNP I-UN
D1 P07559524A0741 NNP I-UN
promoter P07559524A0741 NN I-UN
activity P07559524A0741 NN O
was P07559524A0741 VBD O
stimulated P07559524A0741 VBN O
by P07559524A0741 IN O
overexpression P07559524A0741 NN O
of P07559524A0741 IN O
mitogen-activated P07559524A0741 JJ I-UN
protein P07559524A0741 NN I-UN
kinase P07559524A0741 NN I-UN
( P07559524A0741 ( O
p41MAPK P07559524A0741 NN I-UN
) P07559524A0741 ) O
or P07559524A0741 CC O
c-Ets-2 P07559524A0741 JJ I-UN
through P07559524A0741 IN O
the P07559524A0741 DT O
proximal P07559524A0741 JJ O
22 P07559524A0741 CD O
base P07559524A0741 NN O
pairs P07559524A0741 NN O
. P07559524A0741 . O
. . O O

PATIENTS P07696450A0271 NNS O
AND P07696450A0271 CC O
METHODS P07696450A0271 NNP O
: P07696450A0271 : O
We P07696450A0271 PRP O
report P07696450A0271 VBP O
our P07696450A0271 PRP$ O
experience P07696450A0271 NN O
with P07696450A0271 IN O
seven P07696450A0271 CD O
children P07696450A0271 NNS O
with P07696450A0271 IN O
active P07696450A0271 JJ O
small P07696450A0271 JJ O
bowel P07696450A0271 NN O
Crohn P07696450A0271 NNP O
's P07696450A0271 POS O
disease P07696450A0271 NN O
given P07696450A0271 VBN O
a P07696450A0271 DT O
casein-based P07696450A0271 JJ O
, P07696450A0271 , O
polymeric P07696450A0271 JJ O
feed P07696450A0271 NN O
rich P07696450A0271 JJ O
in P07696450A0271 IN O
TGF-beta P07696450A0271 JJ I-UN
2 P07696450A0271 CD I-UN
( P07696450A0271 ( O
Specific P07696450A0271 NNP O
Polymeric P07696450A0271 NNP O
Diet P07696450A0271 NNP O
; P07696450A0271 : O
Nestle-Clintec P07696450A0271 JJ O
; P07696450A0271 : O
Vevey P07696450A0271 NNP O
, P07696450A0271 , O
Switzerland P07696450A0271 NNP O
) P07696450A0271 ) O
as P07696450A0271 IN O
complete P07696450A0271 JJ O
nutrition P07696450A0271 NN O
for P07696450A0271 IN O
8 P07696450A0271 CD O
weeks P07696450A0271 NNS O
. P07696450A0271 . O
. . O O

All P01657249A1019 DT O
anti-I P01657249A1019 JJ I-UN
and P01657249A1019 CC O
anti-i P01657249A1019 JJ I-UN
CA P01657249A1019 NNP I-UN
were P01657249A1019 VBD O
shown P01657249A1019 VBN O
to P01657249A1019 TO O
express P01657249A1019 VB O
VH4 P01657249A1019 NNP I-UN
heavy P01657249A1019 JJ I-UN
chains P01657249A1019 NNS I-UN
, P01657249A1019 , O
and P01657249A1019 CC O
14 P01657249A1019 CD O
of P01657249A1019 IN O
17 P01657249A1019 CD O
CA P01657249A1019 NNP I-UN
expressed P01657249A1019 VBD O
a P01657249A1019 DT O
previously P01657249A1019 RB O
described P01657249A1019 VBN O
VH4 P01657249A1019 NNP I-UN
second P01657249A1019 JJ O
hypervariable P01657249A1019 JJ O
region P01657249A1019 NN O
determinant P01657249A1019 NN O
, P01657249A1019 , O
termed P01657249A1019 VBD O
VH4-HV2a P01657249A1019 NNP I-UN
. P01657249A1019 . O
. . O O

This P02165181A0299 DT O
cohort P02165181A0299 NN O
of P02165181A0299 IN O
patients P02165181A0299 NNS O
was P02165181A0299 VBD O
selected P02165181A0299 VBN O
on P02165181A0299 IN O
the P02165181A0299 DT O
basis P02165181A0299 NN O
of P02165181A0299 IN O
clinical P02165181A0299 JJ O
stage P02165181A0299 NN O
. P02165181A0299 . O
. . O O

Two P10640701T0000 CD O
Pax2 P10640701T0000 NNP I-UN
/ P10640701T0000 VBD I-UN
5 P10640701T0000 CD I-UN
/ P10640701T0000 JJ I-UN
8-binding P10640701T0000 JJ I-UN
sites P10640701T0000 NNS I-UN
in P10640701T0000 IN O
Engrailed2 P10640701T0000 NNP I-UN
are P10640701T0000 VBP O
required P10640701T0000 VBN O
for P10640701T0000 IN O
proper P10640701T0000 JJ O
initiation P10640701T0000 NN O
of P10640701T0000 IN O
endogenous P10640701T0000 JJ O
mid-hindbrain P10640701T0000 JJ O
expression P10640701T0000 NN O
. P10640701T0000 . O
. . O O

The P03329716A0187 DT O
activity P03329716A0187 NN O
of P03329716A0187 IN O
the P03329716A0187 DT O
EGF P03329716A0187 NNP I-UN
receptor P03329716A0187 NN I-UN
promoter P03329716A0187 NN I-UN
can P03329716A0187 MD O
be P03329716A0187 VB O
modulated P03329716A0187 VBN O
by P03329716A0187 IN O
E1A P03329716A0187 NNP I-UN
protein P03329716A0187 NN I-UN
and P03329716A0187 CC O
receptor P03329716A0187 NN O
RNA P03329716A0187 NNP O
levels P03329716A0187 NNS O
increased P03329716A0187 VBN O
by P03329716A0187 IN O
stimulation P03329716A0187 NN O
with P03329716A0187 IN O
phorbol P03329716A0187 NN O
ester P03329716A0187 NN O
or P03329716A0187 CC O
fetal P03329716A0187 JJ O
calf P03329716A0187 NN O
serum P03329716A0187 NN O
. P03329716A0187 . O
. . O O

One P09666103A0496 CD O
missense P09666103A0496 NN O
allele P09666103A0496 NN O
( P09666103A0496 ( O
P236S P09666103A0496 NNP O
) P09666103A0496 ) O
with P09666103A0496 IN O
complete P09666103A0496 JJ O
loss P09666103A0496 NN O
of P09666103A0496 IN O
function P09666103A0496 NN O
at P09666103A0496 IN O
30 P09666103A0496 CD O
degreesC P09666103A0496 NNS O
and P09666103A0496 CC O
four P09666103A0496 CD O
missense P09666103A0496 NN O
alleles P09666103A0496 NNS O
( P09666103A0496 ( O
L173F P09666103A0496 NNP O
, P09666103A0496 , O
E225K P09666103A0496 NNP O
, P09666103A0496 , O
S269L P09666103A0496 NNP O
and P09666103A0496 CC O
E274K P09666103A0496 NNP O
) P09666103A0496 ) O
that P09666103A0496 WDT O
conferred P09666103A0496 VBD O
a P09666103A0496 DT O
temperature P09666103A0496 NN O
sensitive P09666103A0496 JJ O
phenotype P09666103A0496 NN O
were P09666103A0496 VBD O
identified P09666103A0496 VBN O
. P09666103A0496 . O
. . O O

These P09050867A0542 DT O
elements P09050867A0542 NNS O
comprise P09050867A0542 VBP O
a P09050867A0542 DT O
binding P09050867A0542 NN O
site P09050867A0542 NN O
for P09050867A0542 IN O
Krox P09050867A0542 NNP I-UN
proteins P09050867A0542 NNS I-UN
, P09050867A0542 , O
one P09050867A0542 CD O
for P09050867A0542 IN O
nuclear P09050867A0542 JJ I-UN
factor P09050867A0542 NN I-UN
1 P09050867A0542 CD I-UN
, P09050867A0542 , O
an P09050867A0542 DT O
octamer P09050867A0542 NN O
motif P09050867A0542 NN O
that P09050867A0542 WDT O
binds P09050867A0542 VBZ O
POU-homeodomain P09050867A0542 JJ I-UN
proteins P09050867A0542 NNS I-UN
, P09050867A0542 , O
and P09050867A0542 CC O
a P09050867A0542 DT O
novel P09050867A0542 JJ O
TN P09050867A0542 NNP I-UN
control P09050867A0542 NN I-UN
element P09050867A0542 NN I-UN
. P09050867A0542 . O
. . O O

Here P10322629A0198 RB O
we P10322629A0198 PRP O
report P10322629A0198 VBP O
the P10322629A0198 DT O
cloning P10322629A0198 NN O
and P10322629A0198 CC O
characterization P10322629A0198 NN O
of P10322629A0198 IN O
Xenopus P10322629A0198 NNP I-UN
Pax-5 P10322629A0198 NNP I-UN
and P10322629A0198 CC O
Pax-8 P10322629A0198 NNP I-UN
, P10322629A0198 , O
two P10322629A0198 CD O
orthologues P10322629A0198 NNS O
of P10322629A0198 IN O
the P10322629A0198 DT O
Pax-2 P10322629A0198 NNP I-UN
/ P10322629A0198 NNP I-UN
5 P10322629A0198 CD I-UN
/ P10322629A0198 NNP I-UN
8 P10322629A0198 CD I-UN
gene P10322629A0198 NN I-UN
family P10322629A0198 NN I-UN
. P10322629A0198 . O
. . O O

These P02989637A0671 DT O
data P02989637A0671 NNS O
suggest P02989637A0671 VBP O
that P02989637A0671 IN O
dopaminergic P02989637A0671 JJ O
regulation P02989637A0671 NN O
of P02989637A0671 IN O
adrenal P02989637A0671 JJ O
zona P02989637A0671 NN O
glomerulosa P02989637A0671 NN O
corticosteroid P02989637A0671 NN O
and P02989637A0671 CC O
renal P02989637A0671 JJ I-UN
renin P02989637A0671 NN I-UN
secretion P02989637A0671 NN O
is P02989637A0671 VBZ O
absent P02989637A0671 JJ O
in P02989637A0671 IN O
patients P02989637A0671 NNS O
with P02989637A0671 IN O
high P02989637A0671 JJ O
spinal P02989637A0671 JJ O
cord P02989637A0671 NN O
transections P02989637A0671 NNS O
, P02989637A0671 , O
suggesting P02989637A0671 VBG O
that P02989637A0671 IN O
intact P02989637A0671 JJ O
neural P02989637A0671 JJ O
pathways P02989637A0671 NNS O
from P02989637A0671 IN O
the P02989637A0671 DT O
central P02989637A0671 JJ O
nervous P02989637A0671 JJ O
system P02989637A0671 NN O
are P02989637A0671 VBP O
necessary P02989637A0671 JJ O
for P02989637A0671 IN O
metoclopramide P02989637A0671 JJ O
stimulation P02989637A0671 NN O
of P02989637A0671 IN O
aldosterone P02989637A0671 NN O
and P02989637A0671 CC O
renin P02989637A0671 NN I-UN
secretion P02989637A0671 NN O
in P02989637A0671 IN O
men P02989637A0671 NNS O
. P02989637A0671 . O
. . O O

It P09638650A0169 PRP O
contains P09638650A0169 VBZ O
a P09638650A0169 DT O
5'-noncoding P09638650A0169 JJ O
region P09638650A0169 NN O
( P09638650A0169 ( O
NCR P09638650A0169 NNP O
) P09638650A0169 ) O
of P09638650A0169 IN O
73 P09638650A0169 CD O
nucleotides P09638650A0169 NNS O
, P09638650A0169 , O
five P09638650A0169 CD O
open P09638650A0169 JJ O
reading P09638650A0169 NN O
frames P09638650A0169 NNS O
( P09638650A0169 ( O
ORFs P09638650A0169 $ O
1 P09638650A0169 CD O
to P09638650A0169 TO O
5 P09638650A0169 CD O
) P09638650A0169 ) O
which P09638650A0169 WDT O
encode P09638650A0169 VBP O
proteins P09638650A0169 NNS O
with P09638650A0169 IN O
M P09638650A0169 NNP O
( P09638650A0169 ( O
r P09638650A0169 NN O
) P09638650A0169 ) O
160 P09638650A0169 CD I-UN
kDa P09638650A0169 JJ I-UN
RNA-dependent P09638650A0169 JJ I-UN
RNA P09638650A0169 NNP I-UN
polymerase P09638650A0169 NN I-UN
( P09638650A0169 ( I-UN
ORF1 P09638650A0169 NNP I-UN
) P09638650A0169 ) I-UN
, P09638650A0169 , O
26 P09638650A0169 CD I-UN
kDa P09638650A0169 NN I-UN
movement P09638650A0169 NN I-UN
protein P09638650A0169 NN I-UN
1 P09638650A0169 CD I-UN
( P09638650A0169 ( I-UN
ORF2 P09638650A0169 NNP I-UN
) P09638650A0169 ) I-UN
, P09638650A0169 , O
13 P09638650A0169 CD I-UN
kDa P09638650A0169 NN I-UN
movement P09638650A0169 NN I-UN
protein P09638650A0169 NN I-UN
2 P09638650A0169 CD I-UN
( P09638650A0169 ( I-UN
ORF3 P09638650A0169 NNP I-UN
) P09638650A0169 ) I-UN
, P09638650A0169 , O
10 P09638650A0169 CD I-UN
kDa P09638650A0169 NN I-UN
movement P09638650A0169 NN I-UN
protein P09638650A0169 NN I-UN
3 P09638650A0169 CD I-UN
( P09638650A0169 ( I-UN
ORF4 P09638650A0169 NNP I-UN
) P09638650A0169 ) I-UN
, P09638650A0169 , O
24 P09638650A0169 CD I-UN
kDa P09638650A0169 NN I-UN
coat P09638650A0169 NN I-UN
protein P09638650A0169 NN I-UN
( P09638650A0169 ( I-UN
OFR5 P09638650A0169 NNP I-UN
) P09638650A0169 ) I-UN
, P09638650A0169 , O
and P09638650A0169 CC O
a P09638650A0169 DT O
3 P09638650A0169 CD O
' P09638650A0169 POS O
NCR P09638650A0169 NNP O
of P09638650A0169 IN O
76 P09638650A0169 CD O
nucleotides P09638650A0169 NNS O
. P09638650A0169 . O
. . O O

The P11522431A0673 DT O
prevalence P11522431A0673 NN O
of P11522431A0673 IN O
tobacco P11522431A0673 NN O
dependence P11522431A0673 NN O
diagnosed P11522431A0673 VBD O
according P11522431A0673 VBG O
to P11522431A0673 TO O
the P11522431A0673 DT O
ICD-10 P11522431A0673 NNP O
criteria P11522431A0673 NN O
was P11522431A0673 VBD O
higher P11522431A0673 JJR O
in P11522431A0673 IN O
alcohol-dependent P11522431A0673 JJ O
individuals P11522431A0673 NNS O
( P11522431A0673 ( O
58.1 P11522431A0673 CD O
% P11522431A0673 NN O
) P11522431A0673 ) O
than P11522431A0673 IN O
in P11522431A0673 IN O
nondrinkers P11522431A0673 NNS O
or P11522431A0673 CC O
social P11522431A0673 JJ O
drinkers P11522431A0673 NNS O
( P11522431A0673 ( O
12.8 P11522431A0673 CD O
% P11522431A0673 NN O
) P11522431A0673 ) O
. P11522431A0673 . O
. . O O

This P09605934A0801 DT O
E P09605934A0801 NNP O
box P09605934A0801 NN O
sequence P09605934A0801 NN O
( P09605934A0801 ( O
CACGTG P09605934A0801 NNP O
) P09605934A0801 ) O
is P09605934A0801 VBZ O
identical P09605934A0801 JJ O
to P09605934A0801 TO O
the P09605934A0801 DT O
binding P09605934A0801 NN O
element P09605934A0801 NN O
for P09605934A0801 IN O
USF P09605934A0801 NNP I-UN
( P09605934A0801 ( O
upstream P09605934A0801 JJ I-UN
stimulatory P09605934A0801 NN I-UN
factor P09605934A0801 NN I-UN
) P09605934A0801 ) O
, P09605934A0801 , O
a P09605934A0801 DT O
member P09605934A0801 NN O
of P09605934A0801 IN O
the P09605934A0801 DT O
helix-loop-helix P09605934A0801 JJ I-UN
family P09605934A0801 NN I-UN
of P09605934A0801 IN I-UN
transcription P09605934A0801 NN I-UN
factors P09605934A0801 NNS I-UN
. P09605934A0801 . O
. . O O

Doppler P02657883T0001 NNP O
echo P02657883T0001 NN O
in P02657883T0001 IN O
evaluating P02657883T0001 VBG O
arteriovenous P02657883T0001 JJ O
fistulae P02657883T0001 NN O
for P02657883T0001 IN O
dialysis P02657883T0001 NN O
. P02657883T0001 . O
. . O O

This P11283010A0701 DT O
activation P11283010A0701 NN O
was P11283010A0701 VBD O
then P11283010A0701 RB O
blocked P11283010A0701 VBN O
by P11283010A0701 IN O
CGS P11283010A0701 NNP O
12066A P11283010A0701 CD O
. P11283010A0701 . O
. . O O

Comparisons P01448917A0775 NNS O
with P01448917A0775 IN O
the P01448917A0775 DT O
available P01448917A0775 JJ O
amino P01448917A0775 NN O
acid P01448917A0775 NN O
residue P01448917A0775 NN O
( P01448917A0775 ( O
aa P01448917A0775 NN O
) P01448917A0775 ) O
sequence P01448917A0775 NN O
information P01448917A0775 NN O
from P01448917A0775 IN O
the P01448917A0775 DT O
complete P01448917A0775 JJ O
CPMV P01448917A0775 NNP I-UN
RNA P01448917A0775 NNP I-UN
1 P01448917A0775 CD I-UN
sequence P01448917A0775 NN I-UN
and P01448917A0775 CC O
the P01448917A0775 DT O
partial P01448917A0775 JJ O
sequence P01448917A0775 NN O
of P01448917A0775 IN O
red P01448917A0775 JJ I-UN
clover P01448917A0775 NN I-UN
mottle P01448917A0775 RB I-UN
virus P01448917A0775 JJ I-UN
RNA P01448917A0775 NNP I-UN
1 P01448917A0775 CD I-UN
suggest P01448917A0775 NN O
that P01448917A0775 IN O
CPSMV P01448917A0775 NNP I-UN
RNA P01448917A0775 NNP I-UN
1 P01448917A0775 CD I-UN
specifies P01448917A0775 VBZ O
the P01448917A0775 DT O
expected P01448917A0775 JJ O
set P01448917A0775 NN O
of P01448917A0775 IN O
five P01448917A0775 CD O
mature P01448917A0775 JJ O
proteins P01448917A0775 NNS O
: P01448917A0775 : O
32K P01448917A0775 CD I-UN
proteinase P01448917A0775 NN I-UN
cofactor P01448917A0775 NN I-UN
, P01448917A0775 , O
58K P01448917A0775 CD I-UN
presumed P01448917A0775 JJ I-UN
helicase P01448917A0775 NN I-UN
, P01448917A0775 , O
VPg P01448917A0775 NNP I-UN
5'-linked P01448917A0775 JJ I-UN
protein P01448917A0775 NN I-UN
of P01448917A0775 IN O
the P01448917A0775 DT O
genomic P01448917A0775 JJ O
RNAs P01448917A0775 NNP O
, P01448917A0775 , O
24K P01448917A0775 CD I-UN
proteinase P01448917A0775 NN I-UN
, P01448917A0775 , O
and P01448917A0775 CC O
87K P01448917A0775 CD I-UN
presumed P01448917A0775 JJ I-UN
polymerase P01448917A0775 NN I-UN
, P01448917A0775 , O
separated P01448917A0775 VBN O
by P01448917A0775 IN O
four P01448917A0775 CD O
cleavage P01448917A0775 NN O
sites P01448917A0775 NNS O
. P01448917A0775 . O
. . O O

Isolation P00416758T0001 NN O
of P00416758T0001 IN O
T. P00416758T0001 NNP O
gambiense P00416758T0001 NN O
strains P00416758T0001 NNS O
in P00416758T0001 IN O
Zaire P00416758T0001 NNP O
and P00416758T0001 CC O
their P00416758T0001 PRP$ O
adaptation P00416758T0001 NN O
to P00416758T0001 TO O
laboratory P00416758T0001 NN O
animals P00416758T0001 NNS O
. P00416758T0001 . O
. . O O

The P00386251A0899 DT O
IDF P00386251A0899 NNP O
standard P00386251A0899 NN O
method P00386251A0899 NN O
for P00386251A0899 IN O
the P00386251A0899 DT O
detection P00386251A0899 NN O
of P00386251A0899 IN O
penicillin P00386251A0899 NN O
in P00386251A0899 IN O
milk P00386251A0899 NN O
is P00386251A0899 VBZ O
not P00386251A0899 RB O
suitable P00386251A0899 JJ O
for P00386251A0899 IN O
the P00386251A0899 DT O
detection P00386251A0899 NN O
of P00386251A0899 IN O
sulphonamide P00386251A0899 NN O
residues P00386251A0899 NNS O
in P00386251A0899 IN O
milk P00386251A0899 NN O
. P00386251A0899 . O
. . O O

A P08794348A1067 DT O
transgenic P08794348A1067 JJ O
complementation P08794348A1067 NN O
assay P08794348A1067 NN O
was P08794348A1067 VBD O
used P08794348A1067 VBN O
to P08794348A1067 TO O
test P08794348A1067 VB O
whether P08794348A1067 IN O
NIa P08794348A1067 NNP I-UN
supplied P08794348A1067 VBD O
in P08794348A1067 IN O
trans P08794348A1067 NNS O
could P08794348A1067 MD O
rescue P08794348A1067 VB O
amplification-defective P08794348A1067 JJ O
viral P08794348A1067 JJ O
genomes P08794348A1067 NNS O
encoding P08794348A1067 VBG O
altered P08794348A1067 VBD O
NIa P08794348A1067 NNP I-UN
proteins P08794348A1067 NNS I-UN
. P08794348A1067 . O
. . O O

GLUT5 P01695905A0480 NNP I-UN
mRNA P01695905A0480 NN I-UN
is P01695905A0480 VBZ O
expressed P01695905A0480 VBN O
at P01695905A0480 IN O
highest P01695905A0480 JJS O
levels P01695905A0480 NNS O
in P01695905A0480 IN O
small P01695905A0480 JJ O
intestine P01695905A0480 NN O
and P01695905A0480 CC O
at P01695905A0480 IN O
much P01695905A0480 JJ O
lower P01695905A0480 JJR O
levels P01695905A0480 NNS O
in P01695905A0480 IN O
kidney P01695905A0480 NN O
, P01695905A0480 , O
skeletal P01695905A0480 JJ O
muscle P01695905A0480 NN O
, P01695905A0480 , O
and P01695905A0480 CC O
adipose P01695905A0480 JJ O
tissue P01695905A0480 NN O
. P01695905A0480 . O
. . O O

During P07953785A0648 IN O
heat P07953785A0648 NN O
exposure P07953785A0648 NN O
, P07953785A0648 , O
chicks P07953785A0648 NNS O
that P07953785A0648 WDT O
had P07953785A0648 VBD O
been P07953785A0648 VBN O
subjected P07953785A0648 VBN O
to P07953785A0648 TO O
early P07953785A0648 RB O
60 P07953785A0648 CD O
% P07953785A0648 NN O
restriction P07953785A0648 NN O
with P07953785A0648 IN O
non-metyrapone-treated P07953785A0648 JJ O
food P07953785A0648 NN O
had P07953785A0648 VBD O
lower P07953785A0648 JJR O
H P07953785A0648 NNP O
/ P07953785A0648 NNP O
L P07953785A0648 NNP O
ratios P07953785A0648 NNS O
and P07953785A0648 CC O
improved P07953785A0648 VBD O
resistance P07953785A0648 NN O
to P07953785A0648 TO O
marble P07953785A0648 VB O
spleen P07953785A0648 JJ O
disease P07953785A0648 NN O
infection P07953785A0648 NN O
. P07953785A0648 . O
. . O O

Pharmacokinetics P01721261T0000 NNS O
of P01721261T0000 IN O
FK P01721261T0000 NNP O
506 P01721261T0000 CD O
in P01721261T0000 IN O
transplant P01721261T0000 JJ O
patients P01721261T0000 NNS O
. P01721261T0000 . O
. . O O

The P11915436A0491 DT O
observed P11915436A0491 JJ O
incidence P11915436A0491 NN O
rates P11915436A0491 NNS O
were P11915436A0491 VBD O
compared P11915436A0491 VBN O
to P11915436A0491 TO O
expected P11915436A0491 VBN O
rates P11915436A0491 NNS O
in P11915436A0491 IN O
the P11915436A0491 DT O
general P11915436A0491 JJ O
population P11915436A0491 NN O
. P11915436A0491 . O
. . O O

The P09469415A1337 DT O
observation P09469415A1337 NN O
that P09469415A1337 IN O
beta P09469415A1337 VBZ I-UN
2m P09469415A1337 CD I-UN
with P09469415A1337 IN O
covalently P09469415A1337 RB O
attached P09469415A1337 VBN O
peptide P09469415A1337 NN O
can P09469415A1337 MD O
effectively P09469415A1337 RB O
create P09469415A1337 VB O
CTL P09469415A1337 NNP O
target P09469415A1337 NN O
structures P09469415A1337 NNS O
in P09469415A1337 IN O
vitro P09469415A1337 NN O
offers P09469415A1337 NNS O
new P09469415A1337 JJ O
possibilities P09469415A1337 NNS O
for P09469415A1337 IN O
the P09469415A1337 DT O
in P09469415A1337 IN O
vivo P09469415A1337 JJ O
induction P09469415A1337 NN O
of P09469415A1337 IN O
epitope-specific P09469415A1337 JJ O
CTL P09469415A1337 NNP O
responses P09469415A1337 NNS O
by P09469415A1337 IN O
either P09469415A1337 DT O
DNA P09469415A1337 NNP O
immunization P09469415A1337 NN O
or P09469415A1337 CC O
injection P09469415A1337 NN O
of P09469415A1337 IN O
the P09469415A1337 DT O
purified P09469415A1337 JJ O
epitope-linked P09469415A1337 JJ O
beta P09469415A1337 NN I-UN
2m P09469415A1337 CD I-UN
. P09469415A1337 . O
. . O O

The P08422975A1205 DT O
obvious P08422975A1205 JJ O
functional P08422975A1205 JJ O
necessity P08422975A1205 NN O
for P08422975A1205 IN O
editing P08422975A1205 VBG O
in P08422975A1205 IN O
kinetoplastid P08422975A1205 NN O
mitochondria P08422975A1205 NN O
is P08422975A1205 VBZ O
the P08422975A1205 DT O
formation P08422975A1205 NN O
of P08422975A1205 IN O
translatable P08422975A1205 JJ O
mRNAs P08422975A1205 NN O
. P08422975A1205 . O
. . O O

In P08196624A0593 IN O
Mv1Lu P08196624A0593 NNP O
lung P08196624A0593 NN O
epithelial P08196624A0593 JJ O
cells P08196624A0593 NNS O
, P08196624A0593 , O
ActR-IB P08196624A0593 NNP I-UN
and P08196624A0593 CC O
T P08196624A0593 NNP I-UN
beta P08196624A0593 VBD I-UN
R-I P08196624A0593 NNP I-UN
signal P08196624A0593 NN O
a P08196624A0593 DT O
common P08196624A0593 JJ O
set P08196624A0593 NN O
of P08196624A0593 IN O
growth-inhibitory P08196624A0593 JJ O
and P08196624A0593 CC O
transcriptional P08196624A0593 JJ O
responses P08196624A0593 NNS O
in P08196624A0593 IN O
association P08196624A0593 NN O
with P08196624A0593 IN O
their P08196624A0593 PRP$ O
corresponding P08196624A0593 JJ O
ligands P08196624A0593 NNS O
and P08196624A0593 CC O
type P08196624A0593 NN I-UN
II P08196624A0593 NNP I-UN
receptors P08196624A0593 NNS I-UN
. P08196624A0593 . O
. . O O

Another P07592721A0827 DT O
common P07592721A0827 JJ O
mutation P07592721A0827 NN O
involved P07592721A0827 VBN O
amino P07592721A0827 JJ O
acids P07592721A0827 NNS O
that P07592721A0827 WDT O
are P07592721A0827 VBP O
thought P07592721A0827 VBN O
to P07592721A0827 TO O
make P07592721A0827 VB O
specific P07592721A0827 JJ O
contacts P07592721A0827 NNS O
with P07592721A0827 IN O
DNA P07592721A0827 NNP O
. P07592721A0827 . O
. . O O

The P07909936A0672 DT O
present P07909936A0672 JJ O
treatment P07909936A0672 NN O
strategy P07909936A0672 NN O
in P07909936A0672 IN O
progressive P07909936A0672 JJ O
disorders P07909936A0672 NNS O
is P07909936A0672 VBZ O
mainly P07909936A0672 RB O
based P07909936A0672 VBN O
on P07909936A0672 IN O
the P07909936A0672 DT O
complementary P07909936A0672 JJ O
effect P07909936A0672 NN O
of P07909936A0672 IN O
intensive P07909936A0672 JJ O
radiochemotherapy P07909936A0672 NN O
, P07909936A0672 , O
autologous P07909936A0672 JJ O
stem-cell P07909936A0672 JJ O
transplantation P07909936A0672 NN O
and P07909936A0672 CC O
the P07909936A0672 DT O
rational P07909936A0672 JJ O
use P07909936A0672 NN O
of P07909936A0672 IN O
cytokines P07909936A0672 NNS O
, P07909936A0672 , O
mostly P07909936A0672 RB O
colony-stimulating P07909936A0672 JJ I-UN
factors P07909936A0672 NNS I-UN
. P07909936A0672 . O
. . O O

Restriction P02551886A0332 NNP O
maps P02551886A0332 NNS O
of P02551886A0332 IN O
the P02551886A0332 DT O
cloned P02551886A0332 JJ O
plasmids P02551886A0332 NNS O
revealed P02551886A0332 VBD O
that P02551886A0332 IN O
their P02551886A0332 PRP$ O
chromosomal P02551886A0332 JJ O
inserts P02551886A0332 NNS O
consisted P02551886A0332 VBD O
of P02551886A0332 IN O
overlapping P02551886A0332 VBG O
fragments P02551886A0332 NNS O
. P02551886A0332 . O
. . O O

The P00304310A0000 DT O
end-stage P00304310A0000 NN O
or P00304310A0000 CC O
involutional P00304310A0000 JJ O
phase P00304310A0000 NN O
of P00304310A0000 IN O
proliferative P00304310A0000 JJ O
diabetic P00304310A0000 JJ O
retinopathy P00304310A0000 NN O
may P00304310A0000 MD O
result P00304310A0000 VB O
in P00304310A0000 IN O
stabilization P00304310A0000 NN O
of P00304310A0000 IN O
vision P00304310A0000 NN O
for P00304310A0000 IN O
long P00304310A0000 JJ O
periods P00304310A0000 NNS O
of P00304310A0000 IN O
time P00304310A0000 NN O
. P00304310A0000 . O
. . O O

Interestingly P11161816A0851 RB O
, P11161816A0851 , O
the P11161816A0851 DT O
similarities P11161816A0851 NNS O
with P11161816A0851 IN O
the P11161816A0851 DT O
endophilin P11161816A0851 NN I-UN
proteins P11161816A0851 VBZ I-UN
cover P11161816A0851 VB O
the P11161816A0851 DT O
entire P11161816A0851 JJ O
sequence P11161816A0851 NN O
of P11161816A0851 IN O
the P11161816A0851 DT O
SH3GLB P11161816A0851 NNP I-UN
family P11161816A0851 NN I-UN
, P11161816A0851 , O
suggesting P11161816A0851 VBG O
a P11161816A0851 DT O
common P11161816A0851 JJ O
fold P11161816A0851 NN O
and P11161816A0851 CC O
presumably P11161816A0851 RB O
a P11161816A0851 DT O
common P11161816A0851 JJ O
mode P11161816A0851 NN O
of P11161816A0851 IN O
action P11161816A0851 NN O
. P11161816A0851 . O
. . O O

On P00304806A0760 IN O
the P00304806A0760 DT O
basis P00304806A0760 NN O
of P00304806A0760 IN O
serum P00304806A0760 NN I-UN
alpha1AT P00304806A0760 NN I-UN
quantitation P00304806A0760 NN O
, P00304806A0760 , O
newborn P00304806A0760 JJ O
infants P00304806A0760 NNS O
may P00304806A0760 MD O
be P00304806A0760 VB O
separated P00304806A0760 VBN O
into P00304806A0760 IN O
two P00304806A0760 CD O
groups P00304806A0760 NNS O
, P00304806A0760 , O
characterized P00304806A0760 VBN O
respectively P00304806A0760 RB O
by P00304806A0760 IN O
concentrations P00304806A0760 NNS O
above P00304806A0760 IN O
or P00304806A0760 CC O
below P00304806A0760 IN O
150 P00304806A0760 CD O
mg P00304806A0760 NN O
% P00304806A0760 NN O
. P00304806A0760 . O
. . O O

We P09463174A0670 PRP O
present P09463174A0670 VBP O
the P09463174A0670 DT O
preliminary P09463174A0670 JJ O
results P09463174A0670 NNS O
obtained P09463174A0670 VBD O
on P09463174A0670 IN O
36 P09463174A0670 CD O
patients P09463174A0670 NNS O
which P09463174A0670 WDT O
were P09463174A0670 VBD O
followed P09463174A0670 VBN O
for P09463174A0670 IN O
a P09463174A0670 DT O
mean P09463174A0670 JJ O
period P09463174A0670 NN O
of P09463174A0670 IN O
12 P09463174A0670 CD O
months P09463174A0670 NNS O
. P09463174A0670 . O
. . O O

Fragments P02154686A0185 NNS O
containing P02154686A0185 VBG O
the P02154686A0185 DT O
21-base-pair P02154686A0185 JJ O
repeat P02154686A0185 NN O
region P02154686A0185 NN O
, P02154686A0185 , O
the P02154686A0185 DT O
enhancer P02154686A0185 NN I-UN
of P02154686A0185 IN I-UN
simian P02154686A0185 JJ I-UN
virus P02154686A0185 NN I-UN
40 P02154686A0185 CD I-UN
or P02154686A0185 CC O
both P02154686A0185 DT O
strongly P02154686A0185 RB O
stimulated P02154686A0185 VBN O
beta-galactosidase P02154686A0185 JJ I-UN
synthesis P02154686A0185 NN O
, P02154686A0185 , O
and P02154686A0185 CC O
three P02154686A0185 CD O
fragments P02154686A0185 NNS O
from P02154686A0185 IN O
the P02154686A0185 DT O
polyomavirus P02154686A0185 NN I-UN
enhancer P02154686A0185 NN I-UN
region P02154686A0185 NN I-UN
stimulated P02154686A0185 VBD O
moderate P02154686A0185 JJ O
levels P02154686A0185 NNS O
. P02154686A0185 . O
. . O O

Future P09233487A1386 JJ O
analysis P09233487A1386 NN O
of P09233487A1386 IN O
long-term P09233487A1386 JJ O
outcome P09233487A1386 JJ O
measures P09233487A1386 NNS O
of P09233487A1386 IN O
performance P09233487A1386 NN O
with P09233487A1386 IN O
the P09233487A1386 DT O
implant P09233487A1386 NN O
will P09233487A1386 MD O
confirm P09233487A1386 VB O
or P09233487A1386 CC O
dispute P09233487A1386 VB O
the P09233487A1386 DT O
benefit P09233487A1386 NN O
of P09233487A1386 IN O
ear P09233487A1386 JJ O
selection P09233487A1386 NN O
using P09233487A1386 VBG O
the P09233487A1386 DT O
Prom-EABR P09233487A1386 NNP O
. P09233487A1386 . O
. . O O

We P10568455A0000 PRP O
determined P10568455A0000 VBD O
whether P10568455A0000 IN O
a P10568455A0000 DT O
single P10568455A0000 JJ O
injection P10568455A0000 NN O
of P10568455A0000 IN O
slow-release P10568455A0000 JJ O
estradiol-17beta P10568455A0000 NN O
( P10568455A0000 ( O
SRE2 P10568455A0000 NNP O
) P10568455A0000 ) O
would P10568455A0000 MD O
induce P10568455A0000 VB O
pseudopregnancy P10568455A0000 NN O
in P10568455A0000 IN O
gilts P10568455A0000 NNS O
and P10568455A0000 CC O
whether P10568455A0000 IN O
PGF2alpha P10568455A0000 NNP O
would P10568455A0000 MD O
regress P10568455A0000 VB O
the P10568455A0000 DT O
corpora P10568455A0000 NN O
lutea P10568455A0000 NN O
( P10568455A0000 ( O
CL P10568455A0000 NNP O
) P10568455A0000 ) O
of P10568455A0000 IN O
pseudopregnancy P10568455A0000 NN O
. P10568455A0000 . O
. . O O

These P01398071A0526 DT O
temperature- P01398071A0526 JJ O
and P01398071A0526 CC O
cold-sensitive P01398071A0526 JJ O
strains P01398071A0526 NNS O
were P01398071A0526 VBD O
used P01398071A0526 VBN O
to P01398071A0526 TO O
prepare P01398071A0526 VB O
extracts P01398071A0526 NNS O
deficient P01398071A0526 JJ O
in P01398071A0526 IN O
BRF1 P01398071A0526 NNP I-UN
activity P01398071A0526 NN O
and P01398071A0526 CC O
were P01398071A0526 VBD O
tested P01398071A0526 VBN O
for P01398071A0526 IN O
transcriptional P01398071A0526 JJ O
activity P01398071A0526 NN O
by P01398071A0526 IN O
RNA P01398071A0526 NNP I-UN
polymerases P01398071A0526 NNS I-UN
I P01398071A0526 PRP I-UN
, P01398071A0526 , I-UN
II P01398071A0526 NNP I-UN
, P01398071A0526 , I-UN
and P01398071A0526 CC I-UN
III P01398071A0526 NNP I-UN
in P01398071A0526 IN O
vitro P01398071A0526 NN O
. P01398071A0526 . O
. . O O

Which P03403826T0000 WDT O
cineangiographically P03403826T0000 RB O
assessed P03403826T0000 VBD O
anatomic P03403826T0000 JJ O
variable P03403826T0000 JJ O
correlates P03403826T0000 NNS O
best P03403826T0000 RB O
with P03403826T0000 IN O
functional P03403826T0000 JJ O
measurements P03403826T0000 NNS O
of P03403826T0000 IN O
stenosis P03403826T0000 NN O
severity P03403826T0000 NN O
? P03403826T0000 . O
A P03403826T0000 DT O
comparison P03403826T0000 NN O
of P03403826T0000 IN O
quantitative P03403826T0000 JJ O
analysis P03403826T0000 NN O
of P03403826T0000 IN O
the P03403826T0000 DT O
coronary P03403826T0000 JJ O
cineangiogram P03403826T0000 NN O
with P03403826T0000 IN O
measured P03403826T0000 JJ O
coronary P03403826T0000 JJ O
flow P03403826T0000 NN O
reserve P03403826T0000 NN O
and P03403826T0000 CC O
exercise P03403826T0000 NN O
/ P03403826T0000 JJ O
redistribution P03403826T0000 NN O
thallium-201 P03403826T0000 JJ O
scintigraphy P03403826T0000 NN O
. P03403826T0000 . O
. . O O

The P10567524T0000 DT O
elm1 P10567524T0000 JJ I-UN
kinase P10567524T0000 NN I-UN
functions P10567524T0000 NNS O
in P10567524T0000 IN O
a P10567524T0000 DT O
mitotic P10567524T0000 JJ O
signaling P10567524T0000 NN O
network P10567524T0000 NN O
in P10567524T0000 IN O
budding P10567524T0000 VBG O
yeast P10567524T0000 NN O
. P10567524T0000 . O
. . O O

Inhibition P11389085A1032 NN O
of P11389085A1032 IN O
constitutive P11389085A1032 JJ O
NF-kappaB P11389085A1032 JJ I-UN
activity P11389085A1032 NN O
results P11389085A1032 NNS O
in P11389085A1032 IN O
cell P11389085A1032 JJ O
death P11389085A1032 NN O
of P11389085A1032 IN O
TT P11389085A1032 NNP O
cells P11389085A1032 NNS O
and P11389085A1032 CC O
blocks P11389085A1032 NNS O
focus P11389085A1032 VBP O
formation P11389085A1032 NN O
induced P11389085A1032 VBN O
by P11389085A1032 IN O
oncogenic P11389085A1032 JJ O
forms P11389085A1032 NNS O
of P11389085A1032 IN O
RET P11389085A1032 NNP I-UN
in P11389085A1032 IN O
NIH P11389085A1032 NNP O
3T3 P11389085A1032 CD O
cells P11389085A1032 NNS O
. P11389085A1032 . O
. . O O

We P02348728A1153 PRP O
conclude P02348728A1153 VBP O
that P02348728A1153 IN O
DNA P02348728A1153 NNP O
ploidy P02348728A1153 NN O
is P02348728A1153 VBZ O
a P02348728A1153 DT O
major P02348728A1153 JJ O
objective P02348728A1153 JJ O
prognostic P02348728A1153 JJ O
factor P02348728A1153 NN O
and P02348728A1153 CC O
therapeutic P02348728A1153 JJ O
determinant P02348728A1153 NN O
for P02348728A1153 IN O
endometrial P02348728A1153 JJ O
carcinoma P02348728A1153 NN O
. P02348728A1153 . O
. . O O

We P11234223A1451 PRP O
can P11234223A1451 MD O
classify P11234223A1451 VB O
antibiotics P11234223A1451 NNS O
into P11234223A1451 IN O
two P11234223A1451 CD O
groups P11234223A1451 NNS O
based P11234223A1451 VBN O
on P11234223A1451 IN O
initial P11234223A1451 JJ O
bactericidal P11234223A1451 JJ O
activity P11234223A1451 NN O
against P11234223A1451 IN O
P. P11234223A1451 NNP O
aeruginosa P11234223A1451 NN O
; P11234223A1451 : O
one P11234223A1451 CD O
class P11234223A1451 NN O
is P11234223A1451 VBZ O
antibiotics P11234223A1451 NNS O
having P11234223A1451 VBG O
rapid P11234223A1451 JJ O
initial P11234223A1451 JJ O
killing P11234223A1451 VBG O
such P11234223A1451 JJ O
as P11234223A1451 IN O
AMK P11234223A1451 NNP O
, P11234223A1451 , O
IPM P11234223A1451 NNP O
and P11234223A1451 CC O
PAPM P11234223A1451 NNP O
, P11234223A1451 , O
the P11234223A1451 DT O
other P11234223A1451 JJ O
is P11234223A1451 VBZ O
CAZ P11234223A1451 NNP O
, P11234223A1451 , O
MEPM P11234223A1451 NNP O
showing P11234223A1451 VBG O
slow P11234223A1451 JJ O
initial P11234223A1451 JJ O
killing P11234223A1451 NN O
. P11234223A1451 . O
. . O O

No P09168083A0987 DT O
patient P09168083A0987 NN O
in P09168083A0987 IN O
group P09168083A0987 NN O
2 P09168083A0987 CD O
developed P09168083A0987 VBD O
HAT P09168083A0987 NNP O
( P09168083A0987 ( O
P P09168083A0987 NNP O
= P09168083A0987 VBZ O
0.006 P09168083A0987 CD O
versus P09168083A0987 NN O
group P09168083A0987 NN O
1 P09168083A0987 CD O
) P09168083A0987 ) O
. P09168083A0987 . O
. . O O

In P01435698A0000 IN O
order P01435698A0000 NN O
to P01435698A0000 TO O
investigate P01435698A0000 VB O
the P01435698A0000 DT O
blood P01435698A0000 NN O
compatibility P01435698A0000 NN O
of P01435698A0000 IN O
autogenous P01435698A0000 JJ O
vein P01435698A0000 NN O
graft P01435698A0000 NN O
( P01435698A0000 ( O
AVG P01435698A0000 NNP O
) P01435698A0000 ) O
, P01435698A0000 , O
changes P01435698A0000 NNS O
in P01435698A0000 IN O
prostacyclin P01435698A0000 NN O
( P01435698A0000 ( O
PGI2 P01435698A0000 NNP O
) P01435698A0000 ) O
production P01435698A0000 NN O
following P01435698A0000 VBG O
harvesting P01435698A0000 NN O
and P01435698A0000 CC O
arterial P01435698A0000 JJ O
implantation P01435698A0000 NN O
were P01435698A0000 VBD O
studied P01435698A0000 VBN O
experimentally P01435698A0000 RB O
. P01435698A0000 . O
. . O O

Diagnosis P04069756T0025 NN O
: P04069756T0025 : O
progressive P04069756T0025 JJ O
multifocal P04069756T0025 JJ O
leukoencephalopathy P04069756T0025 NN O
. P04069756T0025 . O
. . O O

Radioimmunoassay P06244732T0000 NNP O
of P06244732T0000 IN O
serum P06244732T0000 JJ O
creatine P06244732T0000 NN I-UN
kinase P06244732T0000 NN I-UN
B P06244732T0000 NNP I-UN
isoenzyme P06244732T0000 NN I-UN
in P06244732T0000 IN O
the P06244732T0000 DT O
diagnosis P06244732T0000 NN O
of P06244732T0000 IN O
acute P06244732T0000 JJ O
myocardial P06244732T0000 JJ O
infarction P06244732T0000 NN O
. P06244732T0000 . O
. . O O

Cytogenetic P07681539A0000 JJ O
studies P07681539A0000 NNS O
were P07681539A0000 VBD O
performed P07681539A0000 VBN O
in P07681539A0000 IN O
lymphocytes P07681539A0000 NNS O
from P07681539A0000 IN O
hospital P07681539A0000 JJ O
workers P07681539A0000 NNS O
exposed P07681539A0000 VBD O
to P07681539A0000 TO O
low P07681539A0000 JJ O
doses P07681539A0000 NNS O
of P07681539A0000 IN O
radiation P07681539A0000 NN O
( P07681539A0000 ( O
1.6-42.71 P07681539A0000 JJ O
mSv P07681539A0000 NN O
) P07681539A0000 ) O
. P07681539A0000 . O
. . O O

In P09538258A0200 IN O
this P09538258A0200 DT O
report P09538258A0200 NN O
, P09538258A0200 , O
we P09538258A0200 PRP O
investigate P09538258A0200 VBP O
the P09538258A0200 DT O
mechanism P09538258A0200 NN O
underlying P09538258A0200 VBG O
Ras P09538258A0200 NNP I-UN
activation P09538258A0200 NN O
upon P09538258A0200 IN O
stimulation P09538258A0200 NN O
of P09538258A0200 IN O
these P09538258A0200 DT O
two P09538258A0200 CD O
types P09538258A0200 NNS O
of P09538258A0200 IN O
receptors P09538258A0200 NNS O
in P09538258A0200 IN O
hematopoietic P09538258A0200 JJ O
cells P09538258A0200 NNS O
. P09538258A0200 . O
. . O O

During P02604420A0234 IN O
challenge P02604420A0234 NN O
, P02604420A0234 , O
rebiopsy P02604420A0234 NN O
was P02604420A0234 VBD O
done P02604420A0234 VBN O
when P02604420A0234 WRB O
reticulin P02604420A0234 NN I-UN
antibodies P02604420A0234 NNS I-UN
turned P02604420A0234 VBD O
positive P02604420A0234 JJ O
( P02604420A0234 ( O
mean P02604420A0234 JJ O
0.6 P02604420A0234 CD O
years P02604420A0234 NNS O
, P02604420A0234 , O
range P02604420A0234 VB O
0.2-2.0 P02604420A0234 JJ O
) P02604420A0234 ) O
or P02604420A0234 CC O
at P02604420A0234 IN O
the P02604420A0234 DT O
end P02604420A0234 NN O
of P02604420A0234 IN O
the P02604420A0234 DT O
two P02604420A0234 CD O
year P02604420A0234 NN O
study P02604420A0234 NN O
. P02604420A0234 . O
. . O O

Roizman P07966602A0130 NNP O
, P07966602A0130 , O
J P07966602A0130 NNP O
. P07966602A0130 . O
. . O O

The P10425094A1006 DT O
in P10425094A1006 IN O
vitro P10425094A1006 JJ O
relaxivity P10425094A1006 NN O
of P10425094A1006 IN O
the P10425094A1006 DT O
complex P10425094A1006 NN O
is P10425094A1006 VBZ O
16.24 P10425094A1006 CD O
s P10425094A1006 NN O
( P10425094A1006 ( O
-1 P10425094A1006 NNP O
) P10425094A1006 ) O
mM P10425094A1006 NN O
( P10425094A1006 ( O
-1 P10425094A1006 NNP O
) P10425094A1006 ) O
. P10425094A1006 . O
. . O O

Later P08954725A1175 RB O
in P08954725A1175 IN O
development P08954725A1175 NN O
, P08954725A1175 , O
Tbx6 P08954725A1175 NNP I-UN
expression P08954725A1175 NN O
is P08954725A1175 VBZ O
restricted P08954725A1175 VBN O
to P08954725A1175 TO O
presomitic P08954725A1175 JJ O
, P08954725A1175 , O
paraxial P08954725A1175 JJ O
mesoderm P08954725A1175 NN O
and P08954725A1175 CC O
to P08954725A1175 TO O
the P08954725A1175 DT O
tail P08954725A1175 NN O
bud P08954725A1175 NN O
, P08954725A1175 , O
which P08954725A1175 WDT O
replaces P08954725A1175 VBZ O
the P08954725A1175 DT O
streak P08954725A1175 NN O
as P08954725A1175 IN O
the P08954725A1175 DT O
source P08954725A1175 NN O
of P08954725A1175 IN O
mesoderm P08954725A1175 NN O
. P08954725A1175 . O
. . O O

To P10734312A0503 TO O
understand P10734312A0503 VB O
whether P10734312A0503 IN O
Shc P10734312A0503 NNP I-UN
localization P10734312A0503 NN O
in P10734312A0503 IN O
membrane P10734312A0503 NN O
rafts P10734312A0503 NNS O
is P10734312A0503 VBZ O
sufficient P10734312A0503 JJ O
to P10734312A0503 TO O
regulate P10734312A0503 VB O
Shc P10734312A0503 NNP I-UN
function P10734312A0503 NN O
, P10734312A0503 , O
we P10734312A0503 PRP O
constructed P10734312A0503 VBD O
a P10734312A0503 DT O
Shc P10734312A0503 NNP I-UN
chimera P10734312A0503 NN I-UN
containing P10734312A0503 VBG O
the P10734312A0503 DT O
Ras P10734312A0503 NNP I-UN
membrane P10734312A0503 NN I-UN
localization P10734312A0503 NN I-UN
motif P10734312A0503 NN I-UN
at P10734312A0503 IN O
the P10734312A0503 DT O
C-terminus P10734312A0503 NNP O
. P10734312A0503 . O
. . O O

Further P04562038T0001 JJ O
investigation P04562038T0001 NN O
on P04562038T0001 IN O
the P04562038T0001 DT O
chemotactic P04562038T0001 JJ O
influence P04562038T0001 NN O
of P04562038T0001 IN O
thymic P04562038T0001 JJ I-UN
hormone P04562038T0001 NN I-UN
on P04562038T0001 IN O
lymphocytes P04562038T0001 NNS O
. P04562038T0001 . O
. . O O

Female P06684624A0298 NNP O
but P06684624A0298 CC O
not P06684624A0298 RB O
male P06684624A0298 JJ O
mortalities P06684624A0298 NNS O
were P06684624A0298 VBD O
significantly P06684624A0298 RB O
higher P06684624A0298 JJR O
for P06684624A0298 IN O
cake-fed P06684624A0298 JJ O
rats P06684624A0298 NNS O
than P06684624A0298 IN O
for P06684624A0298 IN O
those P06684624A0298 DT O
fed P06684624A0298 VBN O
diet P06684624A0298 JJ O
41B P06684624A0298 CD O
. P06684624A0298 . O
. . O O

Identification P08631817T0000 NN O
of P08631817T0000 IN O
a P08631817T0000 DT O
consensus P08631817T0000 NN O
cyclin-dependent P08631817T0000 JJ I-UN
kinase P08631817T0000 NN I-UN
phosphorylation P08631817T0000 NN I-UN
site P08631817T0000 NN I-UN
unique P08631817T0000 NN O
to P08631817T0000 TO O
the P08631817T0000 DT O
nuclear P08631817T0000 JJ O
form P08631817T0000 NN O
of P08631817T0000 IN O
human P08631817T0000 JJ I-UN
deoxyuridine P08631817T0000 NN I-UN
triphosphate P08631817T0000 NN I-UN
nucleotidohydrolase P08631817T0000 NN I-UN
. P08631817T0000 . O
. . O O

Two P10940892A0573 CD O
distinct P10940892A0573 JJ O
recessive P10940892A0573 JJ O
susceptibility P10940892A0573 NN O
loci P10940892A0573 NN O
for P10940892A0573 IN O
vasculitis P10940892A0573 NN O
were P10940892A0573 VBD O
mapped P10940892A0573 VBN O
on P10940892A0573 IN O
chromosome P10940892A0573 NN O
( P10940892A0573 ( O
Chr P10940892A0573 NNP O
) P10940892A0573 ) O
4 P10940892A0573 CD O
at P10940892A0573 IN O
D4Mit89 P10940892A0573 NNP I-UN
and P10940892A0573 CC O
D4Mit147 P10940892A0573 NNP I-UN
in P10940892A0573 IN O
both P10940892A0573 DT O
progenies P10940892A0573 NNS O
. P10940892A0573 . O
. . O O

Histamine-2 P01674177T0001 JJ O
blockade P01674177T0001 NN O
in P01674177T0001 IN O
psoriasis P01674177T0001 NN O
. P01674177T0001 . O
. . O O

The P06138313A0948 DT O
distribution P06138313A0948 NN O
phase P06138313A0948 NN O
is P06138313A0948 VBZ O
followed P06138313A0948 VBN O
by P06138313A0948 IN O
an P06138313A0948 DT O
elimination P06138313A0948 NN O
phase P06138313A0948 NN O
with P06138313A0948 IN O
a P06138313A0948 DT O
much P06138313A0948 RB O
longer P06138313A0948 JJR O
half-life P06138313A0948 NN O
( P06138313A0948 ( O
mean P06138313A0948 JJ O
value P06138313A0948 NN O
375 P06138313A0948 CD O
min P06138313A0948 NN O
) P06138313A0948 ) O
and P06138313A0948 CC O
a P06138313A0948 DT O
volume P06138313A0948 NN O
of P06138313A0948 IN O
distribution P06138313A0948 NN O
of P06138313A0948 IN O
approximately P06138313A0948 RB O
200-400 P06138313A0948 JJ O
l P06138313A0948 NN O
. P06138313A0948 . O
. . O O

Six P02999267A0606 NNP O
( P02999267A0606 ( O
four P02999267A0606 CD O
FAP P02999267A0606 NNP O
; P02999267A0606 : O
two P02999267A0606 CD O
primary P02999267A0606 JJ O
amyloidosis P02999267A0606 NN O
) P02999267A0606 ) O
also P02999267A0606 RB O
had P02999267A0606 VBD O
diffusely P02999267A0606 RB O
positive P02999267A0606 JJ O
myocardial P02999267A0606 JJ O
uptakes P02999267A0606 NNS O
, P02999267A0606 , O
but P02999267A0606 CC O
the P02999267A0606 DT O
intensity P02999267A0606 NN O
was P02999267A0606 VBD O
less P02999267A0606 JJR O
than P02999267A0606 IN O
that P02999267A0606 DT O
of P02999267A0606 IN O
the P02999267A0606 DT O
sternum P02999267A0606 NN O
. P02999267A0606 . O
. . O O

This P03175942A0706 DT O
effect P03175942A0706 NN O
and P03175942A0706 CC O
the P03175942A0706 DT O
fact P03175942A0706 NN O
that P03175942A0706 IN O
all P03175942A0706 DT O
three P03175942A0706 CD O
doses P03175942A0706 NNS O
were P03175942A0706 VBD O
toxic P03175942A0706 JJ O
to P03175942A0706 TO O
the P03175942A0706 DT O
dams P03175942A0706 NNS O
dictated P03175942A0706 VBD O
that P03175942A0706 IN O
a P03175942A0706 DT O
second P03175942A0706 JJ O
experiment P03175942A0706 NN O
be P03175942A0706 VB O
carried P03175942A0706 VBN O
out P03175942A0706 RP O
at P03175942A0706 IN O
lower P03175942A0706 JJR O
doses P03175942A0706 NNS O
. P03175942A0706 . O
. . O O

Two P05574818T0000 CD O
Lab P05574818T0000 NNP O
8 P05574818T0000 CD O
computer P05574818T0000 NN O
programmes P05574818T0000 NNS O
for P05574818T0000 IN O
use P05574818T0000 NN O
in P05574818T0000 IN O
the P05574818T0000 DT O
study P05574818T0000 NN O
of P05574818T0000 IN O
the P05574818T0000 DT O
isometric P05574818T0000 JJ O
and P05574818T0000 CC O
isotonic P05574818T0000 JJ O
contractile P05574818T0000 NN O
characteristics P05574818T0000 NNS O
of P05574818T0000 IN O
skeletal P05574818T0000 JJ O
muscle P05574818T0000 NN O
. P05574818T0000 . O
. . O O

The P01948783A0000 DT O
antihypertensive P01948783A0000 JJ O
effect P01948783A0000 NN O
of P01948783A0000 IN O
Estulic P01948783A0000 NNP O
has P01948783A0000 VBZ O
been P01948783A0000 VBN O
examined P01948783A0000 VBN O
over P01948783A0000 IN O
a P01948783A0000 DT O
12-month P01948783A0000 JJ O
period P01948783A0000 NN O
in P01948783A0000 IN O
101 P01948783A0000 CD O
hypertensive P01948783A0000 JJ O
patients P01948783A0000 NNS O
. P01948783A0000 . O
. . O O

Colorimetric P02423773T0001 NNP O
method P02423773T0001 NN O
of P02423773T0001 IN O
determining P02423773T0001 VBG O
glycerin P02423773T0001 NN O
in P02423773T0001 IN O
the P02423773T0001 DT O
blood P02423773T0001 NN O
. P02423773T0001 . O
. . O O

The P11003669A0000 DT O
product P11003669A0000 NN O
of P11003669A0000 IN O
rat P11003669A0000 JJ I-UN
gene P11003669A0000 NN I-UN
33 P11003669A0000 CD I-UN
was P11003669A0000 VBD O
identified P11003669A0000 VBN O
as P11003669A0000 IN O
an P11003669A0000 DT O
ErbB-2-interacting P11003669A0000 JJ I-UN
protein P11003669A0000 NN I-UN
in P11003669A0000 IN O
a P11003669A0000 DT O
two-hybrid P11003669A0000 JJ O
screen P11003669A0000 NN O
employing P11003669A0000 VBG O
the P11003669A0000 DT O
ErbB-2 P11003669A0000 NNP I-UN
juxtamembrane P11003669A0000 NN I-UN
and P11003669A0000 CC I-UN
kinase P11003669A0000 NN I-UN
domains P11003669A0000 NNS I-UN
as P11003669A0000 IN O
bait P11003669A0000 NN O
. P11003669A0000 . O
. . O O

Complete P09931391A0944 JJ O
recovery P09931391A0944 NN O
of P09931391A0944 IN O
liver P09931391A0944 NN O
function P09931391A0944 NN O
after P09931391A0944 IN O
this P09931391A0944 DT O
surgery P09931391A0944 NN O
tended P09931391A0944 VBD O
to P09931391A0944 TO O
be P09931391A0944 VB O
slow P09931391A0944 JJ O
. P09931391A0944 . O
. . O O

We P02068085A1273 PRP O
also P02068085A1273 RB O
present P02068085A1273 VBD O
evidence P02068085A1273 NN O
for P02068085A1273 IN O
a P02068085A1273 DT O
negative P02068085A1273 JJ O
regulatory P02068085A1273 JJ O
element P02068085A1273 NN O
in P02068085A1273 IN O
the P02068085A1273 DT O
5 P02068085A1273 CD O
' P02068085A1273 POS O
flanking P02068085A1273 JJ O
region P02068085A1273 NN O
of P02068085A1273 IN O
the P02068085A1273 DT O
Mlu P02068085A1273 NNP I-UN
I P02068085A1273 PRP I-UN
upstream P02068085A1273 VBP I-UN
activation P02068085A1273 NN I-UN
sequence P02068085A1273 NN I-UN
. P02068085A1273 . O
. . O O

This P07575438A1409 DT O
action P07575438A1409 NN O
is P07575438A1409 VBZ O
dependent P07575438A1409 JJ O
on P07575438A1409 IN O
helix-loop-helix P07575438A1409 JJ I-UN
factors P07575438A1409 NNS I-UN
bound P07575438A1409 IN O
to P07575438A1409 TO O
the P07575438A1409 DT O
E1 P07575438A1409 NNP I-UN
element P07575438A1409 NN O
. P07575438A1409 . O
. . O O

A P02717133T0001 DT O
method P02717133T0001 NN O
for P02717133T0001 IN O
determining P02717133T0001 VBG O
optimal P02717133T0001 JJ O
development P02717133T0001 NN O
conditions P02717133T0001 NNS O
by P02717133T0001 IN O
summary P02717133T0001 JJ O
oxygen P02717133T0001 NN O
consumption P02717133T0001 NN O
. P02717133T0001 . O
. . O O

However P02868848A0167 RB O
, P02868848A0167 , O
vancomycin P02868848A0167 NN O
and P02868848A0167 CC O
fosfomycin P02868848A0167 NN O
, P02868848A0167 , O
which P02868848A0167 WDT O
revealed P02868848A0167 VBD O
suboptimal P02868848A0167 NN O
in P02868848A0167 IN O
vitro P02868848A0167 JJ O
bactericidal P02868848A0167 NN O
activity P02868848A0167 NN O
, P02868848A0167 , O
proved P02868848A0167 VBD O
as P02868848A0167 RB O
efficacious P02868848A0167 JJ O
as P02868848A0167 IN O
penicillin P02868848A0167 NN O
G P02868848A0167 NNP O
and P02868848A0167 CC O
imipenem P02868848A0167 NN O
in P02868848A0167 IN O
an P02868848A0167 DT O
experimental P02868848A0167 JJ O
mode P02868848A0167 NN O
of P02868848A0167 IN O
murine P02868848A0167 NN O
gas P02868848A0167 NN O
gangrene P02868848A0167 NN O
. P02868848A0167 . O
. . O O

The P10349084T0000 DT O
influence P10349084T0000 NN O
of P10349084T0000 IN O
Epstein-Barr P10349084T0000 NNP O
virus P10349084T0000 NN O
seropositivity P10349084T0000 NN O
on P10349084T0000 IN O
the P10349084T0000 DT O
efficacy P10349084T0000 NN O
of P10349084T0000 IN O
intravenous P10349084T0000 JJ O
immune P10349084T0000 JJ I-UN
globulin P10349084T0000 NN I-UN
in P10349084T0000 IN O
children P10349084T0000 NNS O
with P10349084T0000 IN O
immune P10349084T0000 JJ O
thrombocytopenic P10349084T0000 JJ O
purpura P10349084T0000 NN O
. P10349084T0000 . O
. . O O

Adrenergic P07663963A1588 NNP O
system P07663963A1588 NN O
activation P07663963A1588 NN O
, P07663963A1588 , O
indicated P07663963A1588 VBN O
by P07663963A1588 IN O
metanephrine P07663963A1588 NN O
/ P07663963A1588 NNP O
epinephrine P07663963A1588 NN O
ratio P07663963A1588 NN O
, P07663963A1588 , O
increased P07663963A1588 VBN O
with P07663963A1588 IN O
time P07663963A1588 NN O
in P07663963A1588 IN O
losing P07663963A1588 VBG O
males P07663963A1588 NNS O
, P07663963A1588 , O
except P07663963A1588 IN O
that P07663963A1588 DT O
after P07663963A1588 IN O
one P07663963A1588 CD O
month P07663963A1588 NN O
of P07663963A1588 IN O
cohabitation P07663963A1588 NN O
, P07663963A1588 , O
turnover P07663963A1588 NN O
returned P07663963A1588 VBD O
to P07663963A1588 TO O
levels P07663963A1588 NNS O
that P07663963A1588 WDT O
equaled P07663963A1588 VBD O
those P07663963A1588 DT O
of P07663963A1588 IN O
control P07663963A1588 NN O
animals P07663963A1588 NNS O
. P07663963A1588 . O
. . O O

We P10954564A1262 PRP O
have P10954564A1262 VBP O
also P10954564A1262 RB O
identified P10954564A1262 VBN O
a P10954564A1262 DT O
functional P10954564A1262 JJ O
domain P10954564A1262 NN O
in P10954564A1262 IN O
the P10954564A1262 DT O
ORF P10954564A1262 NNP O
50 P10954564A1262 CD O
protein P10954564A1262 NN O
, P10954564A1262 , O
an P10954564A1262 DT O
immediate-early P10954564A1262 JJ I-UN
gene P10954564A1262 NN I-UN
product P10954564A1262 NN I-UN
that P10954564A1262 WDT O
is P10954564A1262 VBZ O
mainly P10954564A1262 RB O
encoded P10954564A1262 VBN O
by P10954564A1262 IN O
ORF P10954564A1262 NNP O
50 P10954564A1262 CD O
. P10954564A1262 . O
. . O O

Yusuf P04941419T0000 NNP O
Dawood P04941419T0000 NNP O
Docrat P04941419T0000 NNP O
L.R.C.P P04941419T0000 NNP O
. P04941419T0000 . O
. . O O

MCh P02262439A0508 NNP O
infusion P02262439A0508 NN O
caused P02262439A0508 VBD O
a P02262439A0508 DT O
concentration-dependent P02262439A0508 JJ O
increase P02262439A0508 NN O
in P02262439A0508 IN O
airway P02262439A0508 JJ O
resistance P02262439A0508 NN O
at P02262439A0508 IN O
constant P02262439A0508 JJ O
QBA P02262439A0508 NNP O
. P02262439A0508 . O
. . O O

Inhibition P09792439T0000 NN O
of P09792439T0000 IN O
the P09792439T0000 DT O
apolipoprotein P09792439T0000 NN I-UN
B P09792439T0000 NNP I-UN
mRNA P09792439T0000 NN I-UN
editing P09792439T0000 VBG O
enzyme-complex P09792439T0000 JJ O
by P09792439T0000 IN O
hnRNP P09792439T0000 NN I-UN
C1 P09792439T0000 NNP I-UN
protein P09792439T0000 NN I-UN
and P09792439T0000 CC O
40S P09792439T0000 CD I-UN
hnRNP P09792439T0000 NN I-UN
complexes P09792439T0000 NNS I-UN
. P09792439T0000 . O
. . O O

Thus P09393706A1171 RB O
, P09393706A1171 , O
Fis P09393706A1171 NNP I-UN
acts P09393706A1171 VBZ O
as P09393706A1171 IN O
an P09393706A1171 DT O
accessory P09393706A1171 JJ O
transcriptional P09393706A1171 JJ O
activator P09393706A1171 NN O
at P09393706A1171 IN O
the P09393706A1171 DT O
mar P09393706A1171 NN I-UN
promoter P09393706A1171 NN I-UN
. P09393706A1171 . O
. . O O

Addition P09658403A1207 NN O
of P09658403A1207 IN O
Rap P09658403A1207 NNP O
or P09658403A1207 CC O
KN62 P09658403A1207 NNP O
after P09658403A1207 IN O
exposure P09658403A1207 NN O
of P09658403A1207 IN O
cells P09658403A1207 NNS O
to P09658403A1207 TO O
progesterone P09658403A1207 VB O
agonist P09658403A1207 NN O
Org P09658403A1207 NNP O
2058 P09658403A1207 CD O
had P09658403A1207 VBD O
no P09658403A1207 DT O
effect P09658403A1207 NN O
on P09658403A1207 IN O
induction P09658403A1207 NN O
of P09658403A1207 IN O
CAT P09658403A1207 NNP I-UN
activity P09658403A1207 NN O
. P09658403A1207 . O
. . O O

E. P01718983A1640 NNP O
, P01718983A1640 , O
Hession P01718983A1640 NNP O
, P01718983A1640 , O
C. P01718983A1640 NNP O
, P01718983A1640 , O
Goff P01718983A1640 NNP O
, P01718983A1640 , O
D. P01718983A1640 NNP O
, P01718983A1640 , O
Griffiths P01718983A1640 NNP O
, P01718983A1640 , O
B. P01718983A1640 NNP O
, P01718983A1640 , O
Tizard P01718983A1640 NNP O
, P01718983A1640 , O
R. P01718983A1640 NNP O
, P01718983A1640 , O
Newman P01718983A1640 NNP O
, P01718983A1640 , O
B. P01718983A1640 NNP O
, P01718983A1640 , O
Chi-Rosso P01718983A1640 NNP O
, P01718983A1640 , O
G. P01718983A1640 NNP O
, P01718983A1640 , O
and P01718983A1640 CC O
Lobb P01718983A1640 NNP O
, P01718983A1640 , O
R. P01718983A1640 NNP O
, P01718983A1640 , O
( P01718983A1640 ( O
1990 P01718983A1640 CD O
) P01718983A1640 ) O
Cell P01718983A1640 NNP O
63 P01718983A1640 CD O
, P01718983A1640 , O
1349-1356 P01718983A1640 JJ O
) P01718983A1640 ) O
. P01718983A1640 . O
. . O O

The P11235817A0000 DT O
histamine P11235817A0000 NN I-UN
H1 P11235817A0000 NNP I-UN
receptor P11235817A0000 NN I-UN
antagonists P11235817A0000 NNS O
( P11235817A0000 ( O
antihistamines P11235817A0000 NNS O
) P11235817A0000 ) O
are P11235817A0000 VBP O
an P11235817A0000 DT O
important P11235817A0000 JJ O
class P11235817A0000 NN O
of P11235817A0000 IN O
medications P11235817A0000 NNS O
used P11235817A0000 VBN O
for P11235817A0000 IN O
the P11235817A0000 DT O
relief P11235817A0000 NN O
of P11235817A0000 IN O
common P11235817A0000 JJ O
symptoms P11235817A0000 NNS O
associated P11235817A0000 VBN O
with P11235817A0000 IN O
hyperhistaminic P11235817A0000 JJ O
conditions P11235817A0000 NNS O
occurring P11235817A0000 VBG O
in P11235817A0000 IN O
children P11235817A0000 NNS O
and P11235817A0000 CC O
adults P11235817A0000 NNS O
. P11235817A0000 . O
. . O O

Electrochemical P03998071T0000 JJ O
detection P03998071T0000 NN O
of P03998071T0000 IN O
depressed P03998071T0000 JJ O
circulating P03998071T0000 NN O
levels P03998071T0000 NNS O
of P03998071T0000 IN O
vitamin P03998071T0000 NN O
K1 P03998071T0000 NNP O
in P03998071T0000 IN O
osteoporosis P03998071T0000 NN O
. P03998071T0000 . O
. . O O

The P11723928A0294 DT O
process P11723928A0294 NN O
has P11723928A0294 VBZ O
been P11723928A0294 VBN O
applied P11723928A0294 VBN O
to P11723928A0294 TO O
the P11723928A0294 DT O
river P11723928A0294 NN O
reclamation P11723928A0294 NN O
in P11723928A0294 IN O
Yangpu P11723928A0294 NNP O
District P11723928A0294 NNP O
of P11723928A0294 IN O
Shanghai P11723928A0294 NNP O
City P11723928A0294 NNP O
, P11723928A0294 , O
China P11723928A0294 NNP O
. P11723928A0294 . O
. . O O

The P00089778A0000 DT O
concentration P00089778A0000 NN O
of P00089778A0000 IN O
alpha P00089778A0000 JJ I-UN
2-macroglobulin P00089778A0000 JJ I-UN
, P00089778A0000 , O
alpha P00089778A0000 JJ I-UN
1-antitrypsin P00089778A0000 CD I-UN
, P00089778A0000 , O
plasminogen P00089778A0000 NN I-UN
, P00089778A0000 , O
C3-complement P00089778A0000 NNP I-UN
, P00089778A0000 , O
fibrinogen P00089778A0000 NN I-UN
degradation P00089778A0000 NN I-UN
products P00089778A0000 NNS I-UN
( P00089778A0000 ( O
FDP P00089778A0000 NNP I-UN
) P00089778A0000 ) O
and P00089778A0000 CC O
fibrinolytic P00089778A0000 JJ O
activity P00089778A0000 NN O
, P00089778A0000 , O
were P00089778A0000 VBD O
studied P00089778A0000 VBN O
in P00089778A0000 IN O
the P00089778A0000 DT O
aqueous P00089778A0000 JJ O
humour P00089778A0000 NN O
and P00089778A0000 CC O
serum P00089778A0000 NN O
from P00089778A0000 IN O
nine P00089778A0000 CD O
patients P00089778A0000 NNS O
with P00089778A0000 IN O
Fuchs P00089778A0000 NNP O
' P00089778A0000 POS O
endothelial P00089778A0000 JJ O
dystrophy P00089778A0000 NN O
, P00089778A0000 , O
17 P00089778A0000 CD O
patients P00089778A0000 NNS O
with P00089778A0000 IN O
uncomplicated P00089778A0000 JJ O
senile P00089778A0000 NN O
cataract P00089778A0000 NN O
and P00089778A0000 CC O
in P00089778A0000 IN O
the P00089778A0000 DT O
secondary P00089778A0000 JJ O
aqueous P00089778A0000 JJ O
from P00089778A0000 IN O
six P00089778A0000 CD O
cataract P00089778A0000 JJ O
patients P00089778A0000 NNS O
. P00089778A0000 . O
. . O O

60 P07917540A0000 CD O
patients P07917540A0000 NNS O
were P07917540A0000 VBD O
entered P07917540A0000 VBN O
into P07917540A0000 IN O
a P07917540A0000 DT O
randomised P07917540A0000 JJ O
study P07917540A0000 NN O
comparing P07917540A0000 VBG O
vindesine P07917540A0000 NN O
( P07917540A0000 ( O
3 P07917540A0000 CD O
mg P07917540A0000 NN O
/ P07917540A0000 NNP O
m2 P07917540A0000 NN O
/ P07917540A0000 NNP O
week P07917540A0000 NN O
) P07917540A0000 ) O
plus P07917540A0000 CC O
interferon-alpha P07917540A0000 JJ I-UN
2b P07917540A0000 CD I-UN
( P07917540A0000 ( O
6 P07917540A0000 CD O
U P07917540A0000 NNP O
/ P07917540A0000 NNP O
m2 P07917540A0000 VBD O
3 P07917540A0000 CD O
times P07917540A0000 NNS O
per P07917540A0000 IN O
week P07917540A0000 NN O
) P07917540A0000 ) O
to P07917540A0000 TO O
vindesine P07917540A0000 VB O
alone P07917540A0000 RB O
or P07917540A0000 CC O
to P07917540A0000 TO O
interferon P07917540A0000 VB I-UN
alone P07917540A0000 RB O
for P07917540A0000 IN O
the P07917540A0000 DT O
treatment P07917540A0000 NN O
of P07917540A0000 IN O
metastatic P07917540A0000 JJ O
malignant P07917540A0000 JJ O
melanoma P07917540A0000 NN O
. P07917540A0000 . O
. . O O

However P02550118A0610 RB O
, P02550118A0610 , O
bilateral P02550118A0610 JJ O
diffuse P02550118A0610 NN O
pulmonary P02550118A0610 JJ O
infiltrations P02550118A0610 NNS O
developed P02550118A0610 VBD O
21 P02550118A0610 CD O
days P02550118A0610 NNS O
later P02550118A0610 RB O
. P02550118A0610 . O
. . O O

When P10205176A0704 WRB O
tethered P10205176A0704 VBN O
to P10205176A0704 TO O
a P10205176A0704 DT O
heterologous P10205176A0704 JJ O
DNA-binding P10205176A0704 NNP O
domain P10205176A0704 NN O
, P10205176A0704 , O
PSU1 P10205176A0704 NNP I-UN
can P10205176A0704 MD O
activate P10205176A0704 VB O
transcription P10205176A0704 NN O
on P10205176A0704 IN O
its P10205176A0704 PRP$ O
own P10205176A0704 JJ O
. P10205176A0704 . O
. . O O

Tolterodine P10860131A0847 NN O
users P10860131A0847 NNS O
were P10860131A0847 VBD O
7.5 P10860131A0847 CD O
times P10860131A0847 NNS O
more P10860131A0847 RBR O
likely P10860131A0847 JJ O
to P10860131A0847 TO O
have P10860131A0847 VB O
received P10860131A0847 VBN O
another P10860131A0847 DT O
spasmolytic P10860131A0847 JJ O
drug P10860131A0847 NN O
( P10860131A0847 ( O
RR P10860131A0847 NNP O
7.5 P10860131A0847 CD O
, P10860131A0847 , O
95 P10860131A0847 CD O
% P10860131A0847 NN O
CI P10860131A0847 NNP O
4.8 P10860131A0847 CD O
to P10860131A0847 TO O
11.9 P10860131A0847 CD O
) P10860131A0847 ) O
. P10860131A0847 . O
. . O O

Frequent P08187088A0530 JJ O
loss P08187088A0530 NN O
of P08187088A0530 IN O
heterozygosity P08187088A0530 NN O
( P08187088A0530 ( O
LOH P08187088A0530 NNP O
) P08187088A0530 ) O
of P08187088A0530 IN O
> P08187088A0530 $ O
30 P08187088A0530 CD O
% P08187088A0530 NN O
of P08187088A0530 IN O
the P08187088A0530 DT O
informative P08187088A0530 JJ O
cases P08187088A0530 NNS O
was P08187088A0530 VBD O
observed P08187088A0530 VBN O
on P08187088A0530 IN O
chromosomes P08187088A0530 NNS O
3p P08187088A0530 CD O
( P08187088A0530 ( O
41.1 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
5q P08187088A0530 CD O
( P08187088A0530 ( O
52.6 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
6p P08187088A0530 CD O
( P08187088A0530 ( O
30.4 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
8p P08187088A0530 CD O
( P08187088A0530 ( O
33.3 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
9p P08187088A0530 CD O
( P08187088A0530 ( O
35.7 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
9q P08187088A0530 CD O
( P08187088A0530 ( O
30.8 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
11p P08187088A0530 CD O
( P08187088A0530 ( O
32.4 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
13q P08187088A0530 CD O
( P08187088A0530 ( O
52.7 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
17p P08187088A0530 CD O
( P08187088A0530 ( O
55.2 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
17q P08187088A0530 CD O
( P08187088A0530 ( O
33.3 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
18q P08187088A0530 CD O
( P08187088A0530 ( O
45.7 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
, P08187088A0530 , O
and P08187088A0530 CC O
19q P08187088A0530 CD O
( P08187088A0530 ( O
30.4 P08187088A0530 CD O
% P08187088A0530 NN O
) P08187088A0530 ) O
. P08187088A0530 . O
. . O O

Calcitriol P09513759A0716 NNP O
therapy P09513759A0716 NN O
was P09513759A0716 VBD O
associated P09513759A0716 VBN O
with P09513759A0716 IN O
a P09513759A0716 DT O
decrease P09513759A0716 NN O
in P09513759A0716 IN O
serum P09513759A0716 JJ O
iPTH P09513759A0716 NN I-UN
levels P09513759A0716 NNS O
( P09513759A0716 ( O
701 P09513759A0716 CD O
+ P09513759A0716 NN O
/ P09513759A0716 NNP O
- P09513759A0716 : O
103.9 P09513759A0716 CD O
vs P09513759A0716 NN O
. P09513759A0716 . O
. . O O

By P10739671A0136 IN O
electrophoresis P10739671A0136 NN O
mobility P10739671A0136 NN O
shift P10739671A0136 NN O
assays P10739671A0136 VBZ O
using P10739671A0136 VBG O
probes P10739671A0136 NNS O
corresponding P10739671A0136 VBG O
to P10739671A0136 TO O
different P10739671A0136 JJ O
segments P10739671A0136 NNS O
of P10739671A0136 IN O
the P10739671A0136 DT O
putative P10739671A0136 JJ O
human P10739671A0136 JJ I-UN
c-myb P10739671A0136 NN I-UN
intron P10739671A0136 NN I-UN
1 P10739671A0136 CD I-UN
transcription P10739671A0136 NN I-UN
pause P10739671A0136 NN I-UN
region P10739671A0136 NN I-UN
and P10739671A0136 CC O
nuclear P10739671A0136 JJ O
extracts P10739671A0136 NNS O
from P10739671A0136 IN O
myeloid P10739671A0136 JJ O
leukemia P10739671A0136 NN O
HL P10739671A0136 NNP O
60 P10739671A0136 CD O
and P10739671A0136 CC O
fibroblast P10739671A0136 VBD O
WI P10739671A0136 NNP O
38 P10739671A0136 CD O
cells P10739671A0136 NNS O
, P10739671A0136 , O
we P10739671A0136 PRP O
detected P10739671A0136 VBD O
a P10739671A0136 DT O
HL-60-specific P10739671A0136 JJ O
DNA-protein P10739671A0136 NNP O
complex P10739671A0136 NN O
with P10739671A0136 IN O
a P10739671A0136 DT O
123-bp P10739671A0136 JJ O
fragment P10739671A0136 NN O
containing P10739671A0136 VBG O
binding P10739671A0136 VBG O
sites P10739671A0136 NNS O
for P10739671A0136 IN O
the P10739671A0136 DT O
interferon P10739671A0136 NN I-UN
regulatory P10739671A0136 JJ I-UN
factors P10739671A0136 NNS I-UN
( P10739671A0136 ( O
IRFs P10739671A0136 NNP I-UN
) P10739671A0136 ) O
nuclear P10739671A0136 JJ O
proteins P10739671A0136 NNS O
. P10739671A0136 . O
. . O O

The P02995999A0000 DT O
sequence P02995999A0000 NN O
analysis P02995999A0000 NN O
of P02995999A0000 IN O
both P02995999A0000 DT O
products P02995999A0000 NNS O
of P02995999A0000 IN O
individual P02995999A0000 JJ O
phi P02995999A0000 NN O
80 P02995999A0000 CD O
site-specific P02995999A0000 JJ O
recombination P02995999A0000 NN O
events P02995999A0000 NNS O
in P02995999A0000 IN O
vivo P02995999A0000 NN O
shows P02995999A0000 NNS O
that P02995999A0000 IN O
recombination P02995999A0000 NN O
with P02995999A0000 IN O
a P02995999A0000 DT O
secondary P02995999A0000 JJ O
attachment P02995999A0000 NN O
( P02995999A0000 ( O
att P02995999A0000 NN O
) P02995999A0000 ) O
site P02995999A0000 NN O
generates P02995999A0000 VBZ O
several P02995999A0000 JJ O
different P02995999A0000 JJ O
novel P02995999A0000 JJ O
joints P02995999A0000 NNS O
at P02995999A0000 IN O
the P02995999A0000 DT O
mismatched P02995999A0000 JJ O
position P02995999A0000 NN O
: P02995999A0000 : O
one P02995999A0000 CD O
recombination P02995999A0000 NN O
event P02995999A0000 NN O
resulted P02995999A0000 VBD O
in P02995999A0000 IN O
a P02995999A0000 DT O
single P02995999A0000 JJ O
base-pair P02995999A0000 NN O
deletion P02995999A0000 NN O
and P02995999A0000 CC O
two P02995999A0000 CD O
other P02995999A0000 JJ O
recombination P02995999A0000 NN O
events P02995999A0000 NNS O
resulted P02995999A0000 VBD O
in P02995999A0000 IN O
two P02995999A0000 CD O
different P02995999A0000 JJ O
single P02995999A0000 JJ O
base-pair P02995999A0000 NN O
substitutions P02995999A0000 NNS O
. P02995999A0000 . O
. . O O

The P10501969A1329 DT O
results P10501969A1329 NNS O
suggest P10501969A1329 VBP O
that P10501969A1329 IN O
GATA-5 P10501969A1329 NNP I-UN
may P10501969A1329 MD O
have P10501969A1329 VB O
specific P10501969A1329 JJ O
downstream P10501969A1329 NN O
targets P10501969A1329 NNS O
and P10501969A1329 CC O
that P10501969A1329 DT O
GATA-4 P10501969A1329 NNP I-UN
, P10501969A1329 , I-UN
-5 P10501969A1329 NNP I-UN
, P10501969A1329 , I-UN
and P10501969A1329 CC I-UN
-6 P10501969A1329 NN I-UN
can P10501969A1329 MD O
only P10501969A1329 RB O
partially P10501969A1329 RB O
substitute P10501969A1329 JJ O
for P10501969A1329 IN O
each P10501969A1329 DT O
other P10501969A1329 JJ O
in P10501969A1329 IN O
cardiogenesis P10501969A1329 NN O
. P10501969A1329 . O
. . O O

Analysis P07902583A0545 NN O
of P07902583A0545 IN O
disassociation P07902583A0545 NN O
rates P07902583A0545 NNS O
indicates P07902583A0545 VBZ O
that P07902583A0545 IN O
the P07902583A0545 DT O
Grf10-Swi5-DNA P07902583A0545 NNP O
complex P07902583A0545 NN O
has P07902583A0545 VBZ O
a P07902583A0545 DT O
longer P07902583A0545 RBR O
half-life P07902583A0545 JJ O
than P07902583A0545 IN O
protein-DNA P07902583A0545 NN O
complexes P07902583A0545 NNS O
that P07902583A0545 WDT O
contain P07902583A0545 VBP O
only P07902583A0545 RB O
Swi5 P07902583A0545 NNP I-UN
or P07902583A0545 CC O
Grf10 P07902583A0545 NNP I-UN
. P07902583A0545 . O
. . O O

In P10235265A0197 IN O
one P10235265A0197 CD O
mechanism P10235265A0197 NN O
, P10235265A0197 , O
a P10235265A0197 DT O
specialized P10235265A0197 JJ O
ubiquitin-dependent P10235265A0197 JJ O
proteolytic P10235265A0197 JJ O
system P10235265A0197 NN O
( P10235265A0197 ( O
called P10235265A0197 VBN O
the P10235265A0197 DT O
APC-dependent P10235265A0197 JJ O
proteolysis P10235265A0197 NN O
machinery P10235265A0197 NN O
) P10235265A0197 ) O
degrades P10235265A0197 VBZ O
the P10235265A0197 DT O
mitotic P10235265A0197 JJ O
( P10235265A0197 ( O
Clb P10235265A0197 NNP I-UN
) P10235265A0197 ) O
cyclin P10235265A0197 NN I-UN
subunit P10235265A0197 NN I-UN
. P10235265A0197 . O
. . O O

Recent P09037064A0183 JJ O
application P09037064A0183 NN O
of P09037064A0183 IN O
recombinant P09037064A0183 JJ O
canarypox P09037064A0183 NN O
ALVAC P09037064A0183 NNP O
/ P09037064A0183 NNP O
HIV-1 P09037064A0183 NNP O
vectors P09037064A0183 NNS O
as P09037064A0183 IN O
vaccine P09037064A0183 NN O
immunogens P09037064A0183 NNS O
in P09037064A0183 IN O
HIV-1 P09037064A0183 NNP O
, P09037064A0183 , O
-noninfected P09037064A0183 VBD O
volunteers P09037064A0183 NNS O
has P09037064A0183 VBZ O
produced P09037064A0183 VBN O
CTL P09037064A0183 NNP O
responses P09037064A0183 NNS O
in P09037064A0183 IN O
a P09037064A0183 DT O
significant P09037064A0183 JJ O
number P09037064A0183 NN O
of P09037064A0183 IN O
vaccinees P09037064A0183 NNS O
. P09037064A0183 . O
. . O O

Another P09565606A0520 DT O
stem-loop P09565606A0520 NN O
called P09565606A0520 VBN O
structure P09565606A0520 NN O
III P09565606A0520 NNP O
near P09565606A0520 IN O
the P09565606A0520 DT O
3'-end P09565606A0520 CD O
of P09565606A0520 IN O
repY P09565606A0520 NN I-UN
sequesters P09565606A0520 NNS O
both P09565606A0520 DT O
the P09565606A0520 DT O
5'-rCGCC-3 P09565606A0520 JJ O
' P09565606A0520 POS O
sequence P09565606A0520 NN O
and P09565606A0520 CC O
the P09565606A0520 DT O
repZ P09565606A0520 JJ I-UN
ribosome-binding P09565606A0520 JJ I-UN
site P09565606A0520 NN I-UN
. P09565606A0520 . O
. . O O

Only P02709819A0495 RB O
one P02709819A0495 CD O
ADR P02709819A0495 NNP O
was P02709819A0495 VBD O
related P02709819A0495 VBN O
definitely P02709819A0495 RB O
to P02709819A0495 TO O
ciprofloxacin P02709819A0495 VB O
therapy P02709819A0495 NN O
. P02709819A0495 . O
. . O O

The P02154885A0153 DT O
sites P02154885A0153 NNS O
targeted P02154885A0153 VBD O
for P02154885A0153 IN O
mutagenesis P02154885A0153 NN O
, P02154885A0153 , O
residues P02154885A0153 VBZ O
60 P02154885A0153 CD O
, P02154885A0153 , O
61 P02154885A0153 CD O
, P02154885A0153 , O
and P02154885A0153 CC O
66 P02154885A0153 CD O
, P02154885A0153 , O
are P02154885A0153 VBP O
located P02154885A0153 VBN O
within P02154885A0153 IN O
a P02154885A0153 DT O
putative P02154885A0153 JJ O
helical P02154885A0153 JJ O
loop P02154885A0153 NN O
structure P02154885A0153 NN O
which P02154885A0153 WDT O
may P02154885A0153 MD O
be P02154885A0153 VB O
involved P02154885A0153 VBN O
in P02154885A0153 IN O
substrate P02154885A0153 JJ O
recognition P02154885A0153 NN O
by P02154885A0153 IN O
the P02154885A0153 DT O
enzyme P02154885A0153 NN O
. P02154885A0153 . O
. . O O

Of P07689501A0420 IN O
these P07689501A0420 DT O
carriers P07689501A0420 NNS O
149 P07689501A0420 CD O
were P07689501A0420 VBD O
diagnosed P07689501A0420 VBN O
to P07689501A0420 TO O
be P07689501A0420 VB O
asymptomatic P07689501A0420 JJ O
clinically P07689501A0420 RB O
, P07689501A0420 , O
biochemically P07689501A0420 RB O
and P07689501A0420 CC O
echographically P07689501A0420 RB O
. P07689501A0420 . O
. . O O

Analysis P03079276T0029 NN O
in P03079276T0029 IN O
3 P03079276T0029 CD O
groups P03079276T0029 NNS O
of P03079276T0029 IN O
patients P03079276T0029 NNS O
suffering P03079276T0029 VBG O
from P03079276T0029 IN O
simple P03079276T0029 JJ O
acute P03079276T0029 NN O
and P03079276T0029 CC O
pernicious P03079276T0029 JJ O
malarial P03079276T0029 JJ O
flare-ups P03079276T0029 NNS O
. P03079276T0029 . O
. . O O

As P11418130A0499 IN O
expected P11418130A0499 VBN O
, P11418130A0499 , O
homologous P11418130A0499 JJ I-UN
loxP P11418130A0499 NN I-UN
sequences P11418130A0499 NNS I-UN
efficiently P11418130A0499 RB O
underwent P11418130A0499 JJ O
Cre-mediated P11418130A0499 JJ O
recombination P11418130A0499 NN O
. P11418130A0499 . O
. . O O

In P09655916A0415 IN O
the P09655916A0415 DT O
DNA P09655916A0415 NNP O
recognition P09655916A0415 NN O
helix P09655916A0415 NN O
of P09655916A0415 IN O
finger P09655916A0415 NN O
II P09655916A0415 NNP O
, P09655916A0415 , O
the P09655916A0415 DT O
conserved P09655916A0415 JJ O
Arg P09655916A0415 NNP O
at P09655916A0415 IN O
position P09655916A0415 NN O
62 P09655916A0415 CD O
( P09655916A0415 ( O
N-terminal P09655916A0415 JJ O
side P09655916A0415 NN O
of P09655916A0415 IN O
the P09655916A0415 DT O
first P09655916A0415 JJ O
zinc-coordinating P09655916A0415 JJ O
histidine P09655916A0415 NN O
) P09655916A0415 ) O
was P09655916A0415 VBD O
changed P09655916A0415 VBN O
to P09655916A0415 TO O
a P09655916A0415 DT O
Leu P09655916A0415 NNP O
or P09655916A0415 CC O
Gln P09655916A0415 NNP O
. P09655916A0415 . O
. . O O

Both P07544357A0808 DT O
PPC-1 P07544357A0808 NNP O
and P07544357A0808 CC O
ALVA-31 P07544357A0808 NNP O
cells P07544357A0808 NNS O
display P07544357A0808 VBP O
tumorigenesis P07544357A0808 NN O
and P07544357A0808 CC O
invasiveness P07544357A0808 NN O
in P07544357A0808 IN O
nude P07544357A0808 JJ O
mice P07544357A0808 NN O
, P07544357A0808 , O
whereas P07544357A0808 JJ O
LNCap P07544357A0808 NNP O
cells P07544357A0808 NNS O
exhibit P07544357A0808 VBP O
a P07544357A0808 DT O
less P07544357A0808 RBR O
malignant P07544357A0808 JJ O
phenotype P07544357A0808 NN O
, P07544357A0808 , O
suggesting P07544357A0808 VBG O
a P07544357A0808 DT O
correlation P07544357A0808 NN O
between P07544357A0808 IN O
CD44 P07544357A0808 NNP I-UN
variant P07544357A0808 NN I-UN
( P07544357A0808 ( O
CD44v P07544357A0808 NNP I-UN
) P07544357A0808 ) O
expression P07544357A0808 NN O
and P07544357A0808 CC O
aggressive P07544357A0808 JJ O
prostate P07544357A0808 NN O
tumor P07544357A0808 NN O
behavior P07544357A0808 NN O
. P07544357A0808 . O
. . O O

Letter P00952734T0000 NN O
: P00952734T0000 : O
Is P00952734T0000 VBZ O
actinic P00952734T0000 JJ O
( P00952734T0000 ( O
solar P00952734T0000 JJ O
) P00952734T0000 ) O
damage P00952734T0000 NN O
the P00952734T0000 DT O
provoking P00952734T0000 NN O
cause P00952734T0000 NN O
of P00952734T0000 IN O
'post-inflammatory P00952734T0000 JJ O
elastolysis P00952734T0000 NN O
and P00952734T0000 CC O
cutis P00952734T0000 NN O
laxa P00952734T0000 NN O
( P00952734T0000 ( O
PECL P00952734T0000 NNP O
) P00952734T0000 ) O
' P00952734T0000 POS O
? P00952734T0000 . O
. P00952734T0000 . O
. . O O

Susceptibility P11191365A0682 NN O
to P11191365A0682 TO O
ischemia-induced P11191365A0682 JJ O
arrhythmias P11191365A0682 NN O
was P11191365A0682 VBD O
lower P11191365A0682 JJR O
in P11191365A0682 IN O
1-week P11191365A0682 JJ O
diabetics P11191365A0682 NNS O
: P11191365A0682 : O
only P11191365A0682 RB O
42 P11191365A0682 CD O
% P11191365A0682 NN O
of P11191365A0682 IN O
diabetic P11191365A0682 JJ O
hearts P11191365A0682 NNS O
exhibited P11191365A0682 VBD O
ventricular P11191365A0682 JJ O
tachycardia P11191365A0682 NN O
( P11191365A0682 ( O
VT P11191365A0682 NNP O
) P11191365A0682 ) O
and P11191365A0682 CC O
16 P11191365A0682 CD O
% P11191365A0682 NN O
had P11191365A0682 VBD O
short P11191365A0682 JJ O
episodes P11191365A0682 NNS O
of P11191365A0682 IN O
ventricular P11191365A0682 JJ O
fibrillation P11191365A0682 NN O
( P11191365A0682 ( O
VF P11191365A0682 NNP O
) P11191365A0682 ) O
as P11191365A0682 IN O
compared P11191365A0682 VBN O
to P11191365A0682 TO O
VT P11191365A0682 VB O
100 P11191365A0682 CD O
% P11191365A0682 NN O
and P11191365A0682 CC O
VF P11191365A0682 NNP O
70 P11191365A0682 CD O
% P11191365A0682 NN O
( P11191365A0682 ( O
including P11191365A0682 VBG O
sustained P11191365A0682 VBN O
VF P11191365A0682 NNP O
36 P11191365A0682 CD O
% P11191365A0682 NN O
) P11191365A0682 ) O
in P11191365A0682 IN O
the P11191365A0682 DT O
non-diabetics P11191365A0682 NNS O
( P11191365A0682 ( O
P P11191365A0682 NNP O
< P11191365A0682 NNP O
0.05 P11191365A0682 CD O
) P11191365A0682 ) O
. P11191365A0682 . O
. . O O

In P06546392A0542 IN O
this P06546392A0542 DT O
respect P06546392A0542 NN O
C P06546392A0542 NNP I-UN
reactive P06546392A0542 JJ I-UN
protein P06546392A0542 NN I-UN
concentrations P06546392A0542 NNS O
are P06546392A0542 VBP O
superior P06546392A0542 JJ O
to P06546392A0542 TO O
white P06546392A0542 JJ O
cell P06546392A0542 NN O
count P06546392A0542 NN O
, P06546392A0542 , O
erythrocyte P06546392A0542 JJ O
sedimentation P06546392A0542 NN O
rate P06546392A0542 NN O
, P06546392A0542 , O
and P06546392A0542 CC O
temperature P06546392A0542 NN O
and P06546392A0542 CC O
the P06546392A0542 DT O
concentrations P06546392A0542 NNS O
of P06546392A0542 IN O
antiproteases P06546392A0542 NNS O
. P06546392A0542 . O
. . O O

Auditory P01769919A0393 NNP O
threshold P01769919A0393 JJ O
shifts P01769919A0393 NNS O
, P01769919A0393 , O
as P01769919A0393 IN O
measured P01769919A0393 VBN O
by P01769919A0393 IN O
the P01769919A0393 DT O
auditory P01769919A0393 NN O
evoked P01769919A0393 VBD O
brainstem P01769919A0393 NN O
response P01769919A0393 NN O
, P01769919A0393 , O
were P01769919A0393 VBD O
measured P01769919A0393 VBN O
at P01769919A0393 IN O
2,4,8,12,16 P01769919A0393 CD O
, P01769919A0393 , O
20 P01769919A0393 CD O
and P01769919A0393 CC O
24 P01769919A0393 CD O
kHz P01769919A0393 NN O
. P01769919A0393 . O
. . O O

Choice P04753073T0000 NNP O
of P04753073T0000 IN O
vessel P04753073T0000 NN O
. P04753073T0000 . O
. . O O

The P06689413A0174 DT O
apparatus P06689413A0174 NN O
consists P06689413A0174 VBZ O
of P06689413A0174 IN O
an P06689413A0174 DT O
Am-241 P06689413A0174 JJ O
exciting P06689413A0174 NN O
source P06689413A0174 NN O
( P06689413A0174 ( O
300 P06689413A0174 CD O
mCi P06689413A0174 NN O
) P06689413A0174 ) O
and P06689413A0174 CC O
pure P06689413A0174 JJ O
Ge P06689413A0174 NNP O
detector P06689413A0174 NN O
( P06689413A0174 ( O
50 P06689413A0174 CD O
mm2 P06689413A0174 NN O
X P06689413A0174 NNP O
5 P06689413A0174 CD O
mm P06689413A0174 NN O
) P06689413A0174 ) O
for P06689413A0174 IN O
measuring P06689413A0174 VBG O
K P06689413A0174 NNP O
alpha P06689413A0174 JJ O
fluorescent P06689413A0174 JJ O
x-rays P06689413A0174 NNS O
( P06689413A0174 ( O
28.3 P06689413A0174 CD O
and P06689413A0174 CC O
28.6 P06689413A0174 CD O
KeV P06689413A0174 NNP O
) P06689413A0174 ) O
emitted P06689413A0174 VBD O
from P06689413A0174 IN O
exited P06689413A0174 VBN O
iodine P06689413A0174 NN O
. P06689413A0174 . O
. . O O

Several P09971790A0856 JJ O
mutations P09971790A0856 NNS O
disrupted P09971790A0856 VBD O
the P09971790A0856 DT O
endonuclease P09971790A0856 NN O
and P09971790A0856 CC O
helicase P09971790A0856 NN I-UN
activities P09971790A0856 NNS O
; P09971790A0856 : O
however P09971790A0856 RB O
, P09971790A0856 , O
only P09971790A0856 RB O
one P09971790A0856 CD O
amino-terminal-charge P09971790A0856 NN I-UN
cluster P09971790A0856 NN I-UN
mutant P09971790A0856 NN I-UN
protein P09971790A0856 NN I-UN
( P09971790A0856 ( O
D40A-D42A-D44A P09971790A0856 NNP O
) P09971790A0856 ) O
completely P09971790A0856 RB O
lost P09971790A0856 VBN O
AAV P09971790A0856 NNP O
hairpin P09971790A0856 NN O
DNA P09971790A0856 NNP O
binding P09971790A0856 NN O
activity P09971790A0856 NN O
. P09971790A0856 . O
. . O O

After P02323517A0557 IN O
4 P02323517A0557 CD O
h P02323517A0557 NN O
, P02323517A0557 , O
lesions P02323517A0557 NNS O
in P02323517A0557 IN O
the P02323517A0557 DT O
secretory P02323517A0557 JJ O
part P02323517A0557 NN O
of P02323517A0557 IN O
the P02323517A0557 DT O
stomach P02323517A0557 NN O
were P02323517A0557 VBD O
scored P02323517A0557 VBN O
and P02323517A0557 CC O
mucosal P02323517A0557 JJ O
prostaglandin P02323517A0557 NN O
E2 P02323517A0557 NNP O
synthesis P02323517A0557 NN O
was P02323517A0557 VBD O
determined P02323517A0557 VBN O
by P02323517A0557 IN O
the P02323517A0557 DT O
ex P02323517A0557 NN O
vivo P02323517A0557 NN O
prostaglandin P02323517A0557 JJ O
generation P02323517A0557 NN O
technique P02323517A0557 NN O
. P02323517A0557 . O
. . O O

This P10336495A0547 DT O
repression P10336495A0547 NN O
was P10336495A0547 VBD O
reversed P10336495A0547 JJ O
agonists P10336495A0547 NNS O
of P10336495A0547 IN O
either P10336495A0547 DT O
receptor P10336495A0547 NN O
demonstrating P10336495A0547 VBG O
a P10336495A0547 DT O
functional P10336495A0547 JJ O
interaction P10336495A0547 NN O
between P10336495A0547 IN O
NCoR P10336495A0547 NNP I-UN
and P10336495A0547 CC O
PPARalpha.RXRalpha P10336495A0547 NNP O
heterodimeric P10336495A0547 NN O
complexes P10336495A0547 NNS O
in P10336495A0547 IN O
mammalian P10336495A0547 JJ O
cells P10336495A0547 NNS O
. P10336495A0547 . O
. . O O

Purified P08522511A1250 NNP O
PLB P08522511A1250 NNP I-UN
showed P08522511A1250 VBD O
optimal P08522511A1250 JJ O
lyase P08522511A1250 NN I-UN
activity P08522511A1250 NN O
at P08522511A1250 IN O
pH P08522511A1250 NN O
10.0 P08522511A1250 CD O
. P08522511A1250 . O
. . O O

To P02019572A0000 TO O
identify P02019572A0000 VB O
the P02019572A0000 DT O
DNA P02019572A0000 NN O
sequences P02019572A0000 VBZ O
that P02019572A0000 IN O
cis-regulate P02019572A0000 NN O
the P02019572A0000 DT O
expression P02019572A0000 NN O
of P02019572A0000 IN O
the P02019572A0000 DT O
rat P02019572A0000 NN I-UN
liver P02019572A0000 NN I-UN
pyruvate P02019572A0000 NN I-UN
kinase P02019572A0000 NN I-UN
( P02019572A0000 ( O
L-PK P02019572A0000 NNP I-UN
) P02019572A0000 ) O
genes P02019572A0000 NNS O
, P02019572A0000 , O
a P02019572A0000 DT O
series P02019572A0000 NN O
of P02019572A0000 IN O
constructs P02019572A0000 NNS O
in P02019572A0000 IN O
which P02019572A0000 WDT O
the P02019572A0000 DT O
chloramphenicol P02019572A0000 NN I-UN
acetyltransferase P02019572A0000 NN I-UN
reporter P02019572A0000 NN I-UN
genes P02019572A0000 NNS I-UN
is P02019572A0000 VBZ O
driven P02019572A0000 VBN O
by P02019572A0000 IN O
various P02019572A0000 JJ O
deleted P02019572A0000 JJ O
fragments P02019572A0000 NNS O
of P02019572A0000 IN O
the P02019572A0000 DT O
3200 P02019572A0000 CD O
base P02019572A0000 NN O
pairs P02019572A0000 NN O
( P02019572A0000 ( O
bp P02019572A0000 NN O
) P02019572A0000 ) O
upstream P02019572A0000 NN O
of P02019572A0000 IN O
the P02019572A0000 DT O
L-PK P02019572A0000 NNP I-UN
gene P02019572A0000 NN I-UN
cap P02019572A0000 NN I-UN
site P02019572A0000 NN I-UN
have P02019572A0000 VBP O
been P02019572A0000 VBN O
assayed P02019572A0000 VBN O
for P02019572A0000 IN O
transient P02019572A0000 NN O
expression P02019572A0000 NN O
after P02019572A0000 IN O
introduction P02019572A0000 NN O
into P02019572A0000 IN O
hepatoma P02019572A0000 NN O
HepG2 P02019572A0000 NNP O
cells P02019572A0000 NNS O
, P02019572A0000 , O
rat P02019572A0000 NN O
hepatocytes P02019572A0000 NNS O
in P02019572A0000 IN O
primary P02019572A0000 JJ O
culture P02019572A0000 NN O
, P02019572A0000 , O
fibroblast P02019572A0000 JJ O
LTK- P02019572A0000 NNP O
cells P02019572A0000 NNS O
, P02019572A0000 , O
myogenic P02019572A0000 JJ O
C2C12 P02019572A0000 NNP O
cells P02019572A0000 NNS O
, P02019572A0000 , O
and P02019572A0000 CC O
CHO P02019572A0000 NNP O
cells P02019572A0000 NNS O
. P02019572A0000 . O
. . O O

An P08844448A0000 DT O
open-label P08844448A0000 JJ O
, P08844448A0000 , O
placebo-controlled P08844448A0000 JJ O
, P08844448A0000 , O
randomized P08844448A0000 VBN O
, P08844448A0000 , O
two-way P08844448A0000 JJ O
crossover P08844448A0000 NN O
study P08844448A0000 NN O
was P08844448A0000 VBD O
performed P08844448A0000 VBN O
in P08844448A0000 IN O
12 P08844448A0000 CD O
healthy P08844448A0000 JJ O
volunteers P08844448A0000 NNS O
( P08844448A0000 ( O
between P08844448A0000 IN O
20 P08844448A0000 CD O
and P08844448A0000 CC O
44 P08844448A0000 CD O
years P08844448A0000 NNS O
of P08844448A0000 IN O
age P08844448A0000 NN O
) P08844448A0000 ) O
to P08844448A0000 TO O
assess P08844448A0000 VB O
the P08844448A0000 DT O
effect P08844448A0000 NN O
of P08844448A0000 IN O
orlistat P08844448A0000 NN O
, P08844448A0000 , O
a P08844448A0000 DT O
gastrointestinal P08844448A0000 JJ I-UN
lipase P08844448A0000 NN I-UN
inhibitor P08844448A0000 NN O
that P08844448A0000 WDT O
reduces P08844448A0000 VBZ O
dietary P08844448A0000 JJ O
fat P08844448A0000 JJ O
absorption P08844448A0000 NN O
and P08844448A0000 CC O
is P08844448A0000 VBZ O
being P08844448A0000 VBG O
developed P08844448A0000 VBN O
for P08844448A0000 IN O
weight P08844448A0000 NN O
control P08844448A0000 NN O
in P08844448A0000 IN O
obesity P08844448A0000 NN O
, P08844448A0000 , O
on P08844448A0000 IN O
the P08844448A0000 DT O
absorption P08844448A0000 NN O
of P08844448A0000 IN O
vitamins P08844448A0000 NNS O
A P08844448A0000 NNP O
and P08844448A0000 CC O
E P08844448A0000 NNP O
. P08844448A0000 . O
. . O O

Caries P01496348A0000 NNS O
and P01496348A0000 CC O
parodontitis P01496348A0000 NN O
have P01496348A0000 VBP O
been P01496348A0000 VBN O
one P01496348A0000 CD O
of P01496348A0000 IN O
the P01496348A0000 DT O
most P01496348A0000 RBS O
spread P01496348A0000 JJ O
diseases P01496348A0000 NNS O
of P01496348A0000 IN O
mankind P01496348A0000 NN O
. P01496348A0000 . O
. . O O

The P10347144A0516 DT O
recombinant P10347144A0516 NN O
purified P10347144A0516 VBD O
protein P10347144A0516 NN O
expressed P10347144A0516 VBN O
in P10347144A0516 IN O
the P10347144A0516 DT O
baculovirus P10347144A0516 NN O
system P10347144A0516 NN O
had P10347144A0516 VBD O
an P10347144A0516 DT O
approximate P10347144A0516 JJ O
molecular P10347144A0516 JJ O
size P10347144A0516 NN O
20 P10347144A0516 CD O
kDa P10347144A0516 NN O
with P10347144A0516 IN O
amino-terminal P10347144A0516 JJ O
sequence P10347144A0516 NN O
of P10347144A0516 IN O
AVQGP P10347144A0516 NNP O
. P10347144A0516 . O
. . O O

These P11564871A1184 DT O
results P11564871A1184 NNS O
indicate P11564871A1184 VBP O
the P11564871A1184 DT O
presence P11564871A1184 NN O
of P11564871A1184 IN O
TATA-unified P11564871A1184 NNP O
transcription P11564871A1184 NN O
systems P11564871A1184 NNS O
in P11564871A1184 IN O
contemporary P11564871A1184 JJ O
eukaryotes P11564871A1184 NNS O
and P11564871A1184 CC O
provide P11564871A1184 VB O
insight P11564871A1184 NN O
into P11564871A1184 IN O
the P11564871A1184 DT O
residual P11564871A1184 JJ O
need P11564871A1184 NN O
for P11564871A1184 IN O
TBP P11564871A1184 NNP I-UN
by P11564871A1184 IN O
all P11564871A1184 DT O
three P11564871A1184 CD O
Pols P11564871A1184 NNP I-UN
in P11564871A1184 IN O
other P11564871A1184 JJ O
eukaryotes P11564871A1184 NNS O
despite P11564871A1184 IN O
a P11564871A1184 DT O
lack P11564871A1184 NN O
of P11564871A1184 IN O
TATA P11564871A1184 NNP O
elements P11564871A1184 NNS O
in P11564871A1184 IN O
their P11564871A1184 PRP$ O
promoters P11564871A1184 NNS O
. P11564871A1184 . O
. . O O

In P09918096A0520 IN O
the P09918096A0520 DT O
second P09918096A0520 JJ O
case P09918096A0520 NN O
, P09918096A0520 , O
an P09918096A0520 DT O
epidermal P09918096A0520 JJ O
cyst P09918096A0520 NN O
was P09918096A0520 VBD O
diagnosed P09918096A0520 VBN O
. P09918096A0520 . O
. . O O

The P09636358A0000 DT O
virus-associated P09636358A0000 JJ O
VAI P09636358A0000 NNP I-UN
RNA P09636358A0000 NNP O
of P09636358A0000 IN O
adenovirus P09636358A0000 NN O
is P09636358A0000 VBZ O
a P09636358A0000 DT O
small P09636358A0000 JJ O
highly P09636358A0000 RB O
structured P09636358A0000 JJ O
RNA P09636358A0000 NNP O
that P09636358A0000 WDT O
is P09636358A0000 VBZ O
required P09636358A0000 VBN O
for P09636358A0000 IN O
the P09636358A0000 DT O
efficient P09636358A0000 JJ O
translation P09636358A0000 NN O
of P09636358A0000 IN O
cellular P09636358A0000 JJ O
and P09636358A0000 CC O
viral P09636358A0000 JJ O
mRNAs P09636358A0000 NN O
at P09636358A0000 IN O
late P09636358A0000 JJ O
times P09636358A0000 NNS O
after P09636358A0000 IN O
infection P09636358A0000 NN O
. P09636358A0000 . O
. . O O

Endoscopic P09753241A0524 NNP O
examinations P09753241A0524 NNS O
, P09753241A0524 , O
peripheral P09753241A0524 JJ O
white P09753241A0524 JJ O
blood P09753241A0524 NN O
cell P09753241A0524 NN O
( P09753241A0524 ( O
WBC P09753241A0524 NNP O
) P09753241A0524 ) O
counts P09753241A0524 VBZ O
, P09753241A0524 , O
and P09753241A0524 CC O
assays P09753241A0524 NNS O
of P09753241A0524 IN O
myeloperoxidase P09753241A0524 NN I-UN
activity P09753241A0524 NN O
( P09753241A0524 ( O
MPO P09753241A0524 NNP I-UN
) P09753241A0524 ) O
in P09753241A0524 IN O
homogenates P09753241A0524 NNS O
of P09753241A0524 IN O
colon P09753241A0524 NN O
mucosa P09753241A0524 NN O
were P09753241A0524 VBD O
performed P09753241A0524 VBN O
after P09753241A0524 IN O
one P09753241A0524 CD O
week P09753241A0524 NN O
( P09753241A0524 ( O
4 P09753241A0524 CD O
% P09753241A0524 NN O
DSS P09753241A0524 NNP O
model P09753241A0524 NN O
) P09753241A0524 ) O
and P09753241A0524 CC O
eight P09753241A0524 CD O
weeks P09753241A0524 NNS O
( P09753241A0524 ( O
1 P09753241A0524 CD O
% P09753241A0524 NN O
DSS P09753241A0524 NNP O
model P09753241A0524 NN O
) P09753241A0524 ) O
. P09753241A0524 . O
. . O O

Our P11230145A0732 PRP$ O
results P11230145A0732 NNS O
suggest P11230145A0732 VBP O
that P11230145A0732 IN O
the P11230145A0732 DT O
central P11230145A0732 JJ O
role P11230145A0732 NN O
of P11230145A0732 IN O
the P11230145A0732 DT O
Notch-CBF1 P11230145A0732 NNP O
/ P11230145A0732 NNP O
RBP-Jkappa P11230145A0732 NNP I-UN
signaling P11230145A0732 VBG O
pathway P11230145A0732 NN O
in P11230145A0732 IN O
cell P11230145A0732 NN O
fate P11230145A0732 NN O
decisions P11230145A0732 NNS O
renders P11230145A0732 NNS O
it P11230145A0732 PRP O
susceptible P11230145A0732 JJ O
to P11230145A0732 TO O
pathways P11230145A0732 NNS O
of P11230145A0732 IN O
viral P11230145A0732 JJ O
replication P11230145A0732 NN O
and P11230145A0732 CC O
oncogenic P11230145A0732 JJ O
conversion P11230145A0732 NN O
. P11230145A0732 . O
. . O O

The P11085600A0123 DT O
authors P11085600A0123 NNS O
proposed P11085600A0123 VBD O
that P11085600A0123 IN O
the P11085600A0123 DT O
highly P11085600A0123 RB O
convergent P11085600A0123 JJ O
inputs P11085600A0123 NNS O
to P11085600A0123 TO O
the P11085600A0123 DT O
entorhinal P11085600A0123 JJ O
cortex P11085600A0123 NN O
indicate P11085600A0123 VBP O
this P11085600A0123 DT O
region P11085600A0123 NN O
may P11085600A0123 MD O
be P11085600A0123 VB O
particularly P11085600A0123 RB O
important P11085600A0123 JJ O
for P11085600A0123 IN O
selecting P11085600A0123 VBG O
or P11085600A0123 CC O
compressing P11085600A0123 VBG O
information P11085600A0123 NN O
. P11085600A0123 . O
. . O O

Cloning P08648726A0713 NN O
of P08648726A0713 IN O
individual P08648726A0713 JJ O
ZI P08648726A0713 NNP O
domains P08648726A0713 VBZ O
upstream P08648726A0713 NN O
of P08648726A0713 IN O
a P08648726A0713 DT O
minimal P08648726A0713 JJ O
promoter P08648726A0713 NN O
demonstrated P08648726A0713 VBD O
that P08648726A0713 IN O
the P08648726A0713 DT O
ZIA P08648726A0713 NNP O
, P08648726A0713 , O
ZIC P08648726A0713 NNP O
, P08648726A0713 , O
and P08648726A0713 CC O
ZID P08648726A0713 NNP O
domains P08648726A0713 NNS O
, P08648726A0713 , O
but P08648726A0713 CC O
not P08648726A0713 RB O
the P08648726A0713 DT O
ZIB P08648726A0713 NNP O
domain P08648726A0713 NN O
, P08648726A0713 , O
are P08648726A0713 VBP O
TPA P08648726A0713 NNP O
responsive P08648726A0713 NN O
. P08648726A0713 . O
. . O O

A P07937147A0205 DT O
genetic P07937147A0205 JJ O
system P07937147A0205 NN O
was P07937147A0205 VBD O
devised P07937147A0205 VBN O
to P07937147A0205 TO O
select P07937147A0205 VB O
for P07937147A0205 IN O
pi P07937147A0205 NN I-UN
protein P07937147A0205 NN I-UN
mutants P07937147A0205 NNS I-UN
which P07937147A0205 WDT O
discriminate P07937147A0205 VBP O
between P07937147A0205 IN O
IR P07937147A0205 NNP O
and P07937147A0205 CC O
DR P07937147A0205 NNP O
( P07937147A0205 ( O
York P07937147A0205 NNP O
et P07937147A0205 RB O
al. P07937147A0205 RB O
, P07937147A0205 , O
Gene P07937147A0205 NNP O
( P07937147A0205 ( O
Amst P07937147A0205 NNP O
. P07937147A0205 . O
) P07937147A0205 ) O
116 P07937147A0205 CD O
, P07937147A0205 , O
7-12 P07937147A0205 CD O
, P07937147A0205 , O
1992 P07937147A0205 CD O
; P07937147A0205 : O
York P07937147A0205 NNP O
and P07937147A0205 CC O
Filutowicz P07937147A0205 NNP O
, P07937147A0205 , O
J P07937147A0205 NNP O
. P07937147A0205 . O
. . O O

The P08864219A0178 DT O
minimum P08864219A0178 JJ O
inhibitory P08864219A0178 JJ O
concentrations P08864219A0178 NNS O
( P08864219A0178 ( O
MICs P08864219A0178 NNP O
) P08864219A0178 ) O
of P08864219A0178 IN O
ketoconazole P08864219A0178 NN O
, P08864219A0178 , O
miconazole P08864219A0178 NN O
, P08864219A0178 , O
itraconazole P08864219A0178 NN O
, P08864219A0178 , O
fluconazole P08864219A0178 NN O
, P08864219A0178 , O
and P08864219A0178 CC O
amphotericin P08864219A0178 NN O
B P08864219A0178 NNP O
were P08864219A0178 VBD O
significantly P08864219A0178 RB O
influenced P08864219A0178 VBN O
by P08864219A0178 IN O
the P08864219A0178 DT O
inoculum P08864219A0178 NN O
size P08864219A0178 NN O
, P08864219A0178 , O
regardless P08864219A0178 RB O
of P08864219A0178 IN O
the P08864219A0178 DT O
techniques P08864219A0178 NNS O
used P08864219A0178 VBN O
. P08864219A0178 . O
. . O O

BACKGROUND P11888867A0000 NNS O
: P11888867A0000 : O
We P11888867A0000 PRP O
hypothesized P11888867A0000 VBD O
that P11888867A0000 IN O
the P11888867A0000 DT O
postoperative P11888867A0000 JJ O
serum P11888867A0000 NN O
level P11888867A0000 NN O
of P11888867A0000 IN O
TA90-IC P11888867A0000 NNP I-UN
, P11888867A0000 , O
an P11888867A0000 DT O
immune P11888867A0000 JJ O
complex P11888867A0000 NN O
of P11888867A0000 IN O
a P11888867A0000 DT O
90-kDa P11888867A0000 JJ O
tumor-associated P11888867A0000 JJ O
antigen P11888867A0000 NN O
and P11888867A0000 CC O
its P11888867A0000 PRP$ O
antibody P11888867A0000 NN O
, P11888867A0000 , O
might P11888867A0000 MD O
have P11888867A0000 VB O
a P11888867A0000 DT O
significant P11888867A0000 JJ O
correlation P11888867A0000 NN O
with P11888867A0000 IN O
recurrence P11888867A0000 NN O
and P11888867A0000 CC O
survival P11888867A0000 NN O
in P11888867A0000 IN O
patients P11888867A0000 NNS O
with P11888867A0000 IN O
thick P11888867A0000 JJ O
primary P11888867A0000 JJ O
melanomas P11888867A0000 NN O
. P11888867A0000 . O
. . O O

We P09668098A0868 PRP O
isolated P09668098A0868 VBD O
the P09668098A0868 DT O
human P09668098A0868 JJ I-UN
FGF-BP P09668098A0868 NNP I-UN
promoter P09668098A0868 NN I-UN
and P09668098A0868 CC O
determined P09668098A0868 VBN O
by P09668098A0868 IN O
deletion P09668098A0868 NN O
analysis P09668098A0868 NN O
that P09668098A0868 WDT O
TPA P09668098A0868 NNP O
regulatory P09668098A0868 JJ O
elements P09668098A0868 NNS O
were P09668098A0868 VBD O
all P09668098A0868 DT O
contained P09668098A0868 VBN O
in P09668098A0868 IN O
the P09668098A0868 DT O
first P09668098A0868 JJ O
118 P09668098A0868 CD O
base P09668098A0868 NN O
pairs P09668098A0868 NNS O
upstream P09668098A0868 NN O
of P09668098A0868 IN O
the P09668098A0868 DT O
transcription P09668098A0868 NN O
start P09668098A0868 NN O
site P09668098A0868 NN O
. P09668098A0868 . O
. . O O

Structure P01339373T0000 NN O
and P01339373T0000 CC O
expression P01339373T0000 NN O
of P01339373T0000 IN O
a P01339373T0000 DT O
gene P01339373T0000 NN O
from P01339373T0000 IN O
Arabidopsis P01339373T0000 NNP O
thaliana P01339373T0000 NN O
encoding P01339373T0000 VBG O
a P01339373T0000 DT O
protein P01339373T0000 NN O
related P01339373T0000 VBN O
to P01339373T0000 TO O
SNF1 P01339373T0000 NNP I-UN
protein P01339373T0000 NN O
kinase P01339373T0000 NN O
. P01339373T0000 . O
. . O O

Altogether P08163546A1230 RB O
, P08163546A1230 , O
these P08163546A1230 DT O
data P08163546A1230 NNS O
suggest P08163546A1230 VBP O
that P08163546A1230 IN O
Ypt51p P08163546A1230 NNP I-UN
, P08163546A1230 , O
Ypt52p P08163546A1230 NNP I-UN
, P08163546A1230 , O
and P08163546A1230 CC O
Ypt53p P08163546A1230 NNP I-UN
are P08163546A1230 VBP O
required P08163546A1230 VBN O
for P08163546A1230 IN O
transport P08163546A1230 NN O
in P08163546A1230 IN O
the P08163546A1230 DT O
endocytic P08163546A1230 JJ O
pathway P08163546A1230 NN O
and P08163546A1230 CC O
for P08163546A1230 IN O
correct P08163546A1230 JJ O
sorting P08163546A1230 NN O
of P08163546A1230 IN O
vacuolar P08163546A1230 JJ I-UN
hydrolases P08163546A1230 NNS I-UN
suggesting P08163546A1230 VBG O
a P08163546A1230 DT O
possible P08163546A1230 JJ O
intersection P08163546A1230 NN O
of P08163546A1230 IN O
the P08163546A1230 DT O
endocytic P08163546A1230 JJ O
with P08163546A1230 IN O
the P08163546A1230 DT O
vacuolar P08163546A1230 JJ O
sorting P08163546A1230 VBG O
pathway P08163546A1230 NN O
. P08163546A1230 . O
. . O O

Calcitonin P10024383T0000 NNP I-UN
simultaneously P10024383T0000 RB O
regulates P10024383T0000 VBZ O
both P10024383T0000 DT O
periosteal P10024383T0000 JJ O
hyperostosis P10024383T0000 NN O
and P10024383T0000 CC O
trabecular P10024383T0000 JJ O
osteopenia P10024383T0000 NN O
in P10024383T0000 IN O
the P10024383T0000 DT O
spinal P10024383T0000 JJ O
hyperostotic P10024383T0000 JJ O
mouse P10024383T0000 NN O
( P10024383T0000 ( O
twy P10024383T0000 JJ I-UN
/ P10024383T0000 NNP O
twy P10024383T0000 NN I-UN
) P10024383T0000 ) O
in P10024383T0000 IN O
vivo P10024383T0000 NN O
. P10024383T0000 . O
. . O O

Induction P02850967T0000 NN O
of P02850967T0000 IN O
proto-oncogene P02850967T0000 JJ I-UN
fos P02850967T0000 NN I-UN
transcription P02850967T0000 NN O
through P02850967T0000 IN O
the P02850967T0000 DT O
adenylate P02850967T0000 JJ I-UN
cyclase P02850967T0000 NN I-UN
pathway P02850967T0000 NN O
: P02850967T0000 : O
characterization P02850967T0000 NN O
of P02850967T0000 IN O
a P02850967T0000 DT O
cAMP-responsive P02850967T0000 JJ O
element P02850967T0000 NN O
. P02850967T0000 . O
. . O O

Cerebral125 P08166402A0631 NNP I-UN
albumin P08166402A0631 NN I-UN
was P08166402A0631 VBD O
increased P08166402A0631 VBN O
to P08166402A0631 TO O
similar P08166402A0631 JJ O
proportions P08166402A0631 NNS O
in P08166402A0631 IN O
those P08166402A0631 DT O
groups P08166402A0631 NNS O
submitted P08166402A0631 VBD O
to P08166402A0631 TO O
hyperosmolality P08166402A0631 NN O
. P08166402A0631 . O
. . O O

Since P07888156A0169 IN O
1990 P07888156A0169 CD O
the P07888156A0169 DT O
University P07888156A0169 NNP O
Hospital P07888156A0169 NNP O
of P07888156A0169 IN O
Tromso P07888156A0169 NNP O
has P07888156A0169 VBZ O
provided P07888156A0169 VBN O
local P07888156A0169 JJ O
hospitals P07888156A0169 NNS O
in P07888156A0169 IN O
northern P07888156A0169 JJ O
Norway P07888156A0169 NNP O
with P07888156A0169 IN O
a P07888156A0169 DT O
remote P07888156A0169 JJ O
frozen P07888156A0169 JJ O
section P07888156A0169 NN O
service P07888156A0169 NN O
and P07888156A0169 CC O
with P07888156A0169 IN O
access P07888156A0169 NN O
to P07888156A0169 TO O
video P07888156A0169 VB O
conferences P07888156A0169 NNS O
for P07888156A0169 IN O
the P07888156A0169 DT O
review P07888156A0169 NN O
of P07888156A0169 IN O
microscopic P07888156A0169 JJ O
findings P07888156A0169 NNS O
and P07888156A0169 CC O
for P07888156A0169 IN O
the P07888156A0169 DT O
discussion P07888156A0169 NN O
of P07888156A0169 IN O
major P07888156A0169 JJ O
diagnostic P07888156A0169 JJ O
issues P07888156A0169 NNS O
. P07888156A0169 . O
. . O O

Concurrently P11023853A0188 RB O
, P11023853A0188 , O
we P11023853A0188 PRP O
monitored P11023853A0188 VBD O
weather P11023853A0188 CC O
conditions P11023853A0188 NNS O
and P11023853A0188 CC O
used P11023853A0188 VBD O
time-activity P11023853A0188 NN O
budget P11023853A0188 NN O
data P11023853A0188 NNS O
of P11023853A0188 IN O
free-living P11023853A0188 JJ O
birds P11023853A0188 NNS O
and P11023853A0188 CC O
laboratory P11023853A0188 NN O
data P11023853A0188 NNS O
on P11023853A0188 IN O
resting P11023853A0188 VBG O
metabolic P11023853A0188 JJ O
rate P11023853A0188 NN O
to P11023853A0188 TO O
construct P11023853A0188 VB O
time-activity P11023853A0188 JJ O
laboratory P11023853A0188 NN O
( P11023853A0188 ( O
TAL P11023853A0188 NNP O
) P11023853A0188 ) O
estimates P11023853A0188 NNS O
of P11023853A0188 IN O
daily P11023853A0188 JJ O
energy P11023853A0188 NN O
expenditure P11023853A0188 NN O
( P11023853A0188 ( O
DEE P11023853A0188 NNP O
) P11023853A0188 ) O
and P11023853A0188 CC O
to P11023853A0188 TO O
partition P11023853A0188 VB O
the P11023853A0188 DT O
verdins P11023853A0188 NNS O
' P11023853A0188 POS O
energy P11023853A0188 NN O
budget P11023853A0188 NN O
into P11023853A0188 IN O
thermoregulatory P11023853A0188 NN O
, P11023853A0188 , O
activity P11023853A0188 NN O
and P11023853A0188 CC O
basal P11023853A0188 NN O
components P11023853A0188 NNS O
. P11023853A0188 . O
. . O O

We P11851941A0372 PRP O
therefore P11851941A0372 RB O
applied P11851941A0372 VBD O
a P11851941A0372 DT O
radiolabelled P11851941A0372 JJ O
serumalbumin P11851941A0372 NN I-UN
method P11851941A0372 NN O
to P11851941A0372 TO O
determine P11851941A0372 VB O
blood P11851941A0372 NN O
volume P11851941A0372 NN O
after P11851941A0372 IN O
haemodilution P11851941A0372 NN O
with P11851941A0372 IN O
crosslinked P11851941A0372 JJ O
or P11851941A0372 CC O
conjugated P11851941A0372 JJ O
haemoglobin P11851941A0372 NN I-UN
, P11851941A0372 , O
in P11851941A0372 IN O
comparison P11851941A0372 NN O
with P11851941A0372 IN O
a P11851941A0372 DT O
reference P11851941A0372 NN O
solution P11851941A0372 NN O
of P11851941A0372 IN O
hydroxyethyl P11851941A0372 NN O
starch P11851941A0372 NN O
( P11851941A0372 ( O
HES P11851941A0372 NNP O
) P11851941A0372 ) O
. P11851941A0372 . O
. . O O

A P11238947A0636 DT O
single P11238947A0636 JJ O
base P11238947A0636 NN O
change P11238947A0636 NN O
( P11238947A0636 ( O
A8G P11238947A0636 NNP O
) P11238947A0636 ) O
in P11238947A0636 IN O
either P11238947A0636 DT O
sequence P11238947A0636 NN O
reduces P11238947A0636 NNS O
hnRNP P11238947A0636 VBP I-UN
A2 P11238947A0636 NNP I-UN
binding P11238947A0636 NN O
and P11238947A0636 CC O
, P11238947A0636 , O
in P11238947A0636 IN O
the P11238947A0636 DT O
case P11238947A0636 NN O
of P11238947A0636 IN O
A2RE-2 P11238947A0636 NNP I-UN
, P11238947A0636 , O
inhibits P11238947A0636 VBZ O
RNA P11238947A0636 NNP O
transport P11238947A0636 NN O
. P11238947A0636 . O
. . O O

The P09011591A0309 DT O
total P09011591A0309 JJ O
number P09011591A0309 NN O
of P09011591A0309 IN O
specimens P09011591A0309 NNS O
was P09011591A0309 VBD O
131 P09011591A0309 CD O
with P09011591A0309 IN O
78 P09011591A0309 CD O
nonsmokers P09011591A0309 NNS O
and P09011591A0309 CC O
53 P09011591A0309 CD O
smokers P09011591A0309 NNS O
. P09011591A0309 . O
. . O O

A P09017443A0734 DT O
false P09017443A0734 JJ O
positive P09017443A0734 JJ O
marker P09017443A0734 NN O
screen P09017443A0734 NN O
was P09017443A0734 VBD O
associated P09017443A0734 VBN O
with P09017443A0734 IN O
the P09017443A0734 DT O
occurrence P09017443A0734 NN O
of P09017443A0734 IN O
hand-foot P09017443A0734 JJ O
syndrome P09017443A0734 NN O
even P09017443A0734 RB O
when P09017443A0734 WRB O
the P09017443A0734 DT O
effect P09017443A0734 NN O
of P09017443A0734 IN O
regimen P09017443A0734 NNS O
was P09017443A0734 VBD O
accounted P09017443A0734 VBN O
for P09017443A0734 IN O
by P09017443A0734 IN O
stratification P09017443A0734 NN O
( P09017443A0734 ( O
p P09017443A0734 JJ O
= P09017443A0734 NNP O
.01 P09017443A0734 NNP O
) P09017443A0734 ) O
. P09017443A0734 . O
. . O O

Horseradish P02209811T0000 JJ I-UN
peroxidase P02209811T0000 NN I-UN
as P02209811T0000 IN O
a P02209811T0000 DT O
permeability P02209811T0000 NN O
marker P02209811T0000 NN O
in P02209811T0000 IN O
injured P02209811T0000 JJ O
rat P02209811T0000 NN O
caudal P02209811T0000 NN O
and P02209811T0000 CC O
iliac P02209811T0000 JJ O
arteries P02209811T0000 NNS O
. P02209811T0000 . O
. . O O

The P00221725A0523 DT O
decline P00221725A0523 NN O
in P00221725A0523 IN O
the P00221725A0523 DT O
activity P00221725A0523 NN O
of P00221725A0523 IN O
cytochrome P00221725A0523 JJ I-UN
oxidase P00221725A0523 NN I-UN
, P00221725A0523 , O
peroxidase P00221725A0523 NN I-UN
and P00221725A0523 CC O
in P00221725A0523 IN O
the P00221725A0523 DT O
lipid P00221725A0523 JJ O
content P00221725A0523 NN O
of P00221725A0523 IN O
peripheral P00221725A0523 JJ O
neutrophils P00221725A0523 NNS O
was P00221725A0523 VBD O
followed P00221725A0523 VBN O
by P00221725A0523 IN O
a P00221725A0523 DT O
decrease P00221725A0523 NN O
in P00221725A0523 IN O
the P00221725A0523 DT O
phagocytic P00221725A0523 JJ O
activity P00221725A0523 NN O
. P00221725A0523 . O
. . O O

Taken P10585417A1412 VBN O
together P10585417A1412 RB O
, P10585417A1412 , O
differences P10585417A1412 NNS O
in P10585417A1412 IN O
signaling P10585417A1412 VBG O
and P10585417A1412 CC O
tissue P10585417A1412 NN O
expression P10585417A1412 NN O
suggest P10585417A1412 VBP O
that P10585417A1412 IN O
the P10585417A1412 DT O
human P10585417A1412 JJ I-UN
intermediate P10585417A1412 NN I-UN
PRLr P10585417A1412 NNP I-UN
differs P10585417A1412 NNS O
from P10585417A1412 IN O
the P10585417A1412 DT O
long P10585417A1412 JJ I-UN
PRLr P10585417A1412 NNP I-UN
in P10585417A1412 IN O
physiological P10585417A1412 JJ O
function P10585417A1412 NN O
. P10585417A1412 . O
. . O O

FK506 P08946668A0077 NNP O
is P08946668A0077 VBZ O
10- P08946668A0077 JJ O
to P08946668A0077 TO O
100-fold P08946668A0077 CD O
more P08946668A0077 JJR O
potent P08946668A0077 NN O
than P08946668A0077 IN O
cyclosporin P08946668A0077 VBZ O
A P08946668A0077 NNP O
in P08946668A0077 IN O
preventing P08946668A0077 VBG O
organ P08946668A0077 JJ O
rejection P08946668A0077 NN O
and P08946668A0077 CC O
in P08946668A0077 IN O
toxicity P08946668A0077 NN O
. P08946668A0077 . O
. . O O

These P10518956A0137 DT O
thyroid P10518956A0137 VB O
hormone P10518956A0137 NN O
changes P10518956A0137 NNS O
may P10518956A0137 MD O
be P10518956A0137 VB O
mediated P10518956A0137 VBN O
in P10518956A0137 IN O
part P10518956A0137 NN O
by P10518956A0137 IN O
cytokines P10518956A0137 NNS O
or P10518956A0137 CC O
other P10518956A0137 JJ O
inflammatory P10518956A0137 JJ O
mediators P10518956A0137 NNS O
, P10518956A0137 , O
acting P10518956A0137 VBG O
at P10518956A0137 IN O
the P10518956A0137 DT O
level P10518956A0137 NN O
of P10518956A0137 IN O
the P10518956A0137 DT O
hypothalamus P10518956A0137 NN O
and P10518956A0137 CC O
pituitary P10518956A0137 JJ O
gland P10518956A0137 NN O
, P10518956A0137 , O
the P10518956A0137 DT O
thyroid P10518956A0137 NN O
gland P10518956A0137 NN O
, P10518956A0137 , O
and P10518956A0137 CC O
the P10518956A0137 DT O
hepatic P10518956A0137 JJ I-UN
deiodinase P10518956A0137 NN I-UN
system P10518956A0137 NN O
. P10518956A0137 . O
. . O O

The P09886850A0145 DT O
transcriptional P09886850A0145 JJ O
activity P09886850A0145 NN O
of P09886850A0145 IN O
PPARgamma P09886850A0145 NNP I-UN
is P09886850A0145 VBZ O
positively P09886850A0145 RB O
modulated P09886850A0145 VBN O
by P09886850A0145 IN O
ligand P09886850A0145 NN O
binding P09886850A0145 NN O
and P09886850A0145 CC O
negatively P09886850A0145 RB O
regulated P09886850A0145 VBN O
by P09886850A0145 IN O
phosphorylation P09886850A0145 NN O
mediated P09886850A0145 VBN O
by P09886850A0145 IN O
the P09886850A0145 DT O
MEK P09886850A0145 NNP I-UN
/ P09886850A0145 NNP O
ERK P09886850A0145 NNP I-UN
signaling P09886850A0145 VBG O
pathway P09886850A0145 RB O
. P09886850A0145 . O
. . O O

The P09846927A0227 DT O
tip P09846927A0227 NN O
of P09846927A0227 IN O
the P09846927A0227 DT O
button P09846927A0227 NN O
caused P09846927A0227 VBD O
a P09846927A0227 DT O
perforation P09846927A0227 NN O
of P09846927A0227 IN O
the P09846927A0227 DT O
posterior P09846927A0227 JJ O
stomach P09846927A0227 NN O
wall P09846927A0227 NN O
, P09846927A0227 , O
leading P09846927A0227 VBG O
to P09846927A0227 TO O
death P09846927A0227 NN O
. P09846927A0227 . O
. . O O

An P11182746A0872 DT O
additional P11182746A0872 JJ O
9 P11182746A0872 CD O
patients P11182746A0872 NNS O
achieved P11182746A0872 VBN O
normal P11182746A0872 JJ O
levels P11182746A0872 NNS O
with P11182746A0872 IN O
adjunctive P11182746A0872 JJ O
drug P11182746A0872 NN O
therapy P11182746A0872 NN O
. P11182746A0872 . O
. . O O

This P02138992A0911 DT O
multimodality P02138992A0911 NN O
treatment P02138992A0911 NN O
for P02138992A0911 IN O
locally P02138992A0911 RB O
advanced P02138992A0911 JJ O
gynecologic P02138992A0911 NN O
tumors P02138992A0911 NNS O
appears P02138992A0911 VBZ O
feasible P02138992A0911 JJ O
with P02138992A0911 IN O
modification P02138992A0911 NN O
, P02138992A0911 , O
and P02138992A0911 CC O
continued P02138992A0911 VBD O
work P02138992A0911 NN O
exploring P02138992A0911 VBG O
this P02138992A0911 DT O
approach P02138992A0911 NN O
is P02138992A0911 VBZ O
encouraged P02138992A0911 VBN O
. P02138992A0911 . O
. . O O

Handling P09785114A1026 VBG O
on P09785114A1026 IN O
PND P09785114A1026 NNP O
9 P09785114A1026 CD O
did P09785114A1026 VBD O
not P09785114A1026 RB O
result P09785114A1026 VB O
in P09785114A1026 IN O
elevated P09785114A1026 JJ O
CORT P09785114A1026 NNP O
levels P09785114A1026 NNS O
in P09785114A1026 IN O
any P09785114A1026 DT O
of P09785114A1026 IN O
the P09785114A1026 DT O
groups P09785114A1026 NNS O
. P09785114A1026 . O
. . O O

This P07828811A0556 DT O
failure P07828811A0556 NN O
to P07828811A0556 TO O
execute P07828811A0556 VB O
regulated P07828811A0556 JJ O
G1 P07828811A0556 NNP O
/ P07828811A0556 NNP O
S P07828811A0556 NNP O
arrest P07828811A0556 NN O
is P07828811A0556 VBZ O
correlated P07828811A0556 VBN O
with P07828811A0556 IN O
enhanced P07828811A0556 JJ O
thermosensitivity P07828811A0556 NN O
of P07828811A0556 IN O
colony-forming P07828811A0556 JJ O
ability P07828811A0556 NN O
. P07828811A0556 . O
. . O O

Selective P08666238T0000 JJ O
translation P08666238T0000 NN O
initiation P08666238T0000 NN O
by P08666238T0000 IN O
ribosome P08666238T0000 JJ O
jumping P08666238T0000 NN O
in P08666238T0000 IN O
adenovirus-infected P08666238T0000 JJ O
and P08666238T0000 CC O
heat-shocked P08666238T0000 JJ O
cells P08666238T0000 NNS O
. P08666238T0000 . O
. . O O

Bilateral P07263745T0000 NNP O
Charnley P07263745T0000 NNP O
arthroplasty P07263745T0000 NN O
as P07263745T0000 IN O
a P07263745T0000 DT O
single P07263745T0000 JJ O
procedure P07263745T0000 NN O
. P07263745T0000 . O
. . O O

Addition P07530502A0974 NN O
of P07530502A0974 IN O
soluble P07530502A0974 JJ O
recombinant P07530502A0974 JJ I-UN
human P07530502A0974 JJ I-UN
SLF P07530502A0974 NNP I-UN
to P07530502A0974 TO O
SI4-h220 P07530502A0974 NNP O
cultures P07530502A0974 NNS O
enhanced P07530502A0974 VBD O
reduction P07530502A0974 NN O
of P07530502A0974 IN O
cell-surface P07530502A0974 JJ O
c-kit P07530502A0974 JJ I-UN
expression P07530502A0974 NN O
and P07530502A0974 CC O
its P07530502A0974 PRP$ O
protein P07530502A0974 NN O
degradation P07530502A0974 NN O
. P07530502A0974 . O
. . O O

Although P09428799A0897 IN O
the P09428799A0897 DT O
gene P09428799A0897 NN O
is P09428799A0897 VBZ O
substantially P09428799A0897 RB O
smaller P09428799A0897 JJR O
than P09428799A0897 IN O
the P09428799A0897 DT O
human P09428799A0897 JJ O
genes P09428799A0897 NNS O
for P09428799A0897 IN O
other P09428799A0897 JJ O
mitochondrial P09428799A0897 JJ O
enzymes P09428799A0897 NNS O
, P09428799A0897 , O
its P09428799A0897 PRP$ O
intron P09428799A0897 NN O
/ P09428799A0897 NN O
exon P09428799A0897 JJ O
organization P09428799A0897 NN O
is P09428799A0897 VBZ O
very P09428799A0897 RB O
similar P09428799A0897 JJ O
, P09428799A0897 , O
especially P09428799A0897 RB O
to P09428799A0897 TO O
that P09428799A0897 DT O
of P09428799A0897 IN O
P450scc P09428799A0897 NNP I-UN
. P09428799A0897 . O
. . O O

Consistent P07636187A0585 JJ O
with P07636187A0585 IN O
the P07636187A0585 DT O
protein P07636187A0585 NN O
expression P07636187A0585 NN O
data P07636187A0585 NNS O
, P07636187A0585 , O
V P07636187A0585 NNP I-UN
beta P07636187A0585 VBZ I-UN
8.3 P07636187A0585 CD I-UN
gene P07636187A0585 NN I-UN
transcripts P07636187A0585 NNS I-UN
were P07636187A0585 VBD O
found P07636187A0585 VBN O
only P07636187A0585 RB O
in P07636187A0585 IN O
the P07636187A0585 DT O
transgenic P07636187A0585 JJ O
lines P07636187A0585 NNS O
with P07636187A0585 IN O
the P07636187A0585 DT O
wild-type P07636187A0585 JJ O
promoter P07636187A0585 NN O
. P07636187A0585 . O
. . O O

Viral P06310159A0000 NNP O
RNA P06310159A0000 NNP O
, P06310159A0000 , O
molecularly P06310159A0000 RB O
cloned P06310159A0000 VBN O
proviral P06310159A0000 JJ O
DNA P06310159A0000 NNP O
, P06310159A0000 , O
and P06310159A0000 CC O
virus-specific P06310159A0000 JJ O
protein P06310159A0000 NN O
of P06310159A0000 IN O
avian P06310159A0000 JJ O
retrovirus P06310159A0000 NN O
MH2 P06310159A0000 NNP O
were P06310159A0000 VBD O
analyzed P06310159A0000 VBN O
. P06310159A0000 . O
. . O O

It P09335298A0529 PRP O
has P09335298A0529 VBZ O
been P09335298A0529 VBN O
proposed P09335298A0529 VBN O
that P09335298A0529 IN O
the P09335298A0529 DT O
parCBA P09335298A0529 NN I-UN
operon P09335298A0529 NN I-UN
encodes P09335298A0529 VBZ O
a P09335298A0529 DT O
plasmid P09335298A0529 NN O
partitioning P09335298A0529 NN O
system P09335298A0529 NN O
( P09335298A0529 ( O
M P09335298A0529 NNP O
. P09335298A0529 . O
. . O O

We P11137367A0297 PRP O
used P11137367A0297 VBD O
the P11137367A0297 DT O
Toshiba P11137367A0297 NNP O
IIDR P11137367A0297 NNP O
system P11137367A0297 NN O
, P11137367A0297 , O
which P11137367A0297 WDT O
is P11137367A0297 VBZ O
composed P11137367A0297 VBN O
of P11137367A0297 IN O
an P11137367A0297 DT O
X-ray P11137367A0297 JJ O
TV P11137367A0297 NN O
system P11137367A0297 NN O
and P11137367A0297 CC O
a P11137367A0297 DT O
digital P11137367A0297 JJ O
image P11137367A0297 NN O
managing P11137367A0297 VBG O
circuit P11137367A0297 NN O
. P11137367A0297 . O
. . O O

Working P05049711T0000 VBG O
session P05049711T0000 NN O
report P05049711T0000 NN O
: P05049711T0000 : O
in P05049711T0000 IN O
vivo-in P05049711T0000 JJ O
vitro P05049711T0000 NN O
screening P05049711T0000 NN O
. P05049711T0000 . O
. . O O

The P09765261A0000 DT O
human P09765261A0000 JJ O
T P09765261A0000 NNP O
cell P09765261A0000 NN O
lymphotropic P09765261A0000 NN O
retrovirus P09765261A0000 NN O
type P09765261A0000 NN O
I P09765261A0000 PRP O
( P09765261A0000 ( O
HTLV-I P09765261A0000 NNP O
) P09765261A0000 ) O
trans-activator P09765261A0000 NN O
, P09765261A0000 , O
Tax P09765261A0000 NNP I-UN
, P09765261A0000 , O
interacts P09765261A0000 VBZ O
specifically P09765261A0000 RB O
with P09765261A0000 IN O
the P09765261A0000 DT O
basic-domain P09765261A0000 JJ I-UN
/ P09765261A0000 JJ I-UN
leucine-zipper P09765261A0000 NN I-UN
( P09765261A0000 ( I-UN
bZip P09765261A0000 NN I-UN
) P09765261A0000 ) I-UN
protein P09765261A0000 NN I-UN
, P09765261A0000 , O
cAMP P09765261A0000 JJ I-UN
response P09765261A0000 NN I-UN
element P09765261A0000 NN I-UN
binding P09765261A0000 VBG I-UN
protein P09765261A0000 NN I-UN
( P09765261A0000 ( O
CREB P09765261A0000 NNP I-UN
) P09765261A0000 ) O
, P09765261A0000 , O
bound P09765261A0000 UH O
to P09765261A0000 TO O
the P09765261A0000 DT O
viral P09765261A0000 JJ I-UN
Tax-responsive P09765261A0000 JJ I-UN
element P09765261A0000 NN I-UN
consisting P09765261A0000 NN O
of P09765261A0000 IN O
three P09765261A0000 CD O
imperfect P09765261A0000 JJ O
21-base P09765261A0000 JJ O
pair P09765261A0000 NN O
repeats P09765261A0000 NNS O
, P09765261A0000 , O
each P09765261A0000 DT O
with P09765261A0000 IN O
a P09765261A0000 DT O
cAMP P09765261A0000 NN O
response P09765261A0000 NN O
element P09765261A0000 NN O
core P09765261A0000 NN O
flanked P09765261A0000 VBN O
by P09765261A0000 IN O
G P09765261A0000 NNP O
/ P09765261A0000 NNP O
C-rich P09765261A0000 NNP O
sequences P09765261A0000 NNS O
. P09765261A0000 . O
. . O O

Minor P03296254A0556 JJ O
differences P03296254A0556 NNS O
were P03296254A0556 VBD O
noted P03296254A0556 VBN O
with P03296254A0556 IN O
latamoxef P03296254A0556 JJ O
producing P03296254A0556 VBG O
mild P03296254A0556 JJ O
persistant P03296254A0556 JJ O
elevation P03296254A0556 NN O
of P03296254A0556 IN O
prothrombin P03296254A0556 JJ I-UN
time P03296254A0556 NN O
( P03296254A0556 ( O
0.7 P03296254A0556 CD O
second P03296254A0556 NN O
) P03296254A0556 ) O
associated P03296254A0556 VBN O
with P03296254A0556 IN O
depression P03296254A0556 NN O
of P03296254A0556 IN O
factor P03296254A0556 NN I-UN
II P03296254A0556 NNP I-UN
and P03296254A0556 CC O
factor P03296254A0556 NN I-UN
VII P03296254A0556 NNP I-UN
. P03296254A0556 . O
. . O O

This P10576177A0308 DT O
distinction P10576177A0308 NN O
was P10576177A0308 VBD O
based P10576177A0308 VBN O
upon P10576177A0308 IN O
whether P10576177A0308 IN O
the P10576177A0308 DT O
diagnosis P10576177A0308 NN O
provided P10576177A0308 VBD O
a P10576177A0308 DT O
straightforward P10576177A0308 JJ O
range P10576177A0308 NN O
of P10576177A0308 IN O
prognoses P10576177A0308 NNS O
or P10576177A0308 CC O
an P10576177A0308 DT O
ambiguous P10576177A0308 JJ O
clinical P10576177A0308 JJ O
implication P10576177A0308 NN O
. P10576177A0308 . O
. . O O

That P02541251A1327 DT O
of P02541251A1327 IN O
the P02541251A1327 DT O
T2 P02541251A1327 NNP I-UN
gene P02541251A1327 NN I-UN
contains P02541251A1327 VBZ O
numerous P02541251A1327 JJ O
potential P02541251A1327 JJ O
sites P02541251A1327 NNS O
for P02541251A1327 IN O
binding P02541251A1327 VBG O
the P02541251A1327 DT O
mammalian P02541251A1327 JJ I-UN
transcription P02541251A1327 NN I-UN
factor P02541251A1327 NN I-UN
SP1 P02541251A1327 NNP I-UN
, P02541251A1327 , O
but P02541251A1327 CC O
no P02541251A1327 DT O
TATA P02541251A1327 NNP O
or P02541251A1327 CC O
CCAAT P02541251A1327 NNP O
sequences P02541251A1327 NNS O
are P02541251A1327 VBP O
evident P02541251A1327 JJ O
near P02541251A1327 IN O
to P02541251A1327 TO O
its P02541251A1327 PRP$ O
5 P02541251A1327 CD O
' P02541251A1327 '' O
end P02541251A1327 NN O
, P02541251A1327 , O
although P02541251A1327 IN O
these P02541251A1327 DT O
latter P02541251A1327 JJ O
features P02541251A1327 NNS O
are P02541251A1327 VBP O
associated P02541251A1327 VBN O
with P02541251A1327 IN O
the P02541251A1327 DT O
human P02541251A1327 JJ I-UN
T1 P02541251A1327 NNP I-UN
gene P02541251A1327 NN I-UN
. P02541251A1327 . O
. . O O

KAR1 P08070654A0000 NNP I-UN
encodes P08070654A0000 VBZ O
an P08070654A0000 DT O
essential P08070654A0000 JJ O
component P08070654A0000 NN O
of P08070654A0000 IN O
the P08070654A0000 DT O
yeast P08070654A0000 NN O
spindle P08070654A0000 JJ O
pole P08070654A0000 NN O
body P08070654A0000 NN O
( P08070654A0000 ( O
SPB P08070654A0000 NNP O
) P08070654A0000 ) O
that P08070654A0000 WDT O
is P08070654A0000 VBZ O
required P08070654A0000 VBN O
for P08070654A0000 IN O
karyogamy P08070654A0000 NN O
and P08070654A0000 CC O
SPB P08070654A0000 NNP O
duplication P08070654A0000 NN O
. P08070654A0000 . O
. . O O

Time P11875695A0718 NN O
to P11875695A0718 TO O
progression P11875695A0718 NN O
was P11875695A0718 VBD O
6 P11875695A0718 CD O
months P11875695A0718 NNS O
( P11875695A0718 ( O
5-7 P11875695A0718 JJ O
months P11875695A0718 NNS O
) P11875695A0718 ) O
with P11875695A0718 IN O
a P11875695A0718 DT O
median P11875695A0718 JJ O
survival P11875695A0718 NN O
from P11875695A0718 IN O
registration P11875695A0718 NN O
of P11875695A0718 IN O
9.6 P11875695A0718 CD O
months P11875695A0718 NNS O
( P11875695A0718 ( O
95 P11875695A0718 CD O
% P11875695A0718 NN O
CI P11875695A0718 NNP O
8-12 P11875695A0718 CD O
months P11875695A0718 NNS O
) P11875695A0718 ) O
. P11875695A0718 . O
. . O O

Gimpl P11451447A0205 NNP O
, P11451447A0205 , O
F P11451447A0205 NNP O
. P11451447A0205 . O
. . O O

RESULTS P10864989A0484 NN O
: P10864989A0484 : O
The P10864989A0484 DT O
introduction P10864989A0484 NN O
of P10864989A0484 IN O
the P10864989A0484 DT O
PAIP P10864989A0484 NNP O
resulted P10864989A0484 VBD O
in P10864989A0484 IN O
a P10864989A0484 DT O
significant P10864989A0484 JJ O
( P10864989A0484 ( O
p P10864989A0484 JJ O
< P10864989A0484 NNP O
0.001 P10864989A0484 CD O
) P10864989A0484 ) O
reduction P10864989A0484 NN O
in P10864989A0484 IN O
contaminating P10864989A0484 VBG O
WBCs P10864989A0484 NNP O
( P10864989A0484 ( O
median P10864989A0484 JJ O
, P10864989A0484 , O
30,000 P10864989A0484 CD O
) P10864989A0484 ) O
from P10864989A0484 IN O
the P10864989A0484 DT O
numbers P10864989A0484 NNS O
seen P10864989A0484 VBN O
with P10864989A0484 IN O
FIP P10864989A0484 NNP O
( P10864989A0484 ( O
median P10864989A0484 JJ O
, P10864989A0484 , O
2,300,000 P10864989A0484 CD O
) P10864989A0484 ) O
while P10864989A0484 IN O
maintaining P10864989A0484 VBG O
the P10864989A0484 DT O
separation P10864989A0484 NN O
efficacy P10864989A0484 NN O
( P10864989A0484 ( O
47 P10864989A0484 CD O
% P10864989A0484 NN O
) P10864989A0484 ) O
and P10864989A0484 CC O
separation P10864989A0484 NN O
time P10864989A0484 NN O
. P10864989A0484 . O
. . O O

Ectopic P08994832A0782 NNP O
expression P08994832A0782 NN O
of P08994832A0782 IN O
Apo-3 P08994832A0782 NNP I-UN
in P08994832A0782 IN O
HEK293 P08994832A0782 NNP O
or P08994832A0782 CC O
HeLa P08994832A0782 NNP O
cells P08994832A0782 NNS O
induced P08994832A0782 VBD O
marked P08994832A0782 JJ O
apoptosis P08994832A0782 NN O
. P08994832A0782 . O
. . O O

The P02774808A0194 DT O
values P02774808A0194 NNS O
were P02774808A0194 VBD O
consistently P02774808A0194 RB O
lower P02774808A0194 JJR O
( P02774808A0194 ( O
P P02774808A0194 NNP O
less P02774808A0194 JJR O
than P02774808A0194 IN O
0.01 P02774808A0194 CD O
) P02774808A0194 ) O
during P02774808A0194 IN O
summer P02774808A0194 NN O
( P02774808A0194 ( O
3.79 P02774808A0194 CD O
+ P02774808A0194 NN O
/ P02774808A0194 NNP O
- P02774808A0194 : O
0.13 P02774808A0194 CD O
micrograms P02774808A0194 NNS O
/ P02774808A0194 VBP O
100 P02774808A0194 CD O
ml P02774808A0194 NN O
) P02774808A0194 ) O
, P02774808A0194 , O
as P02774808A0194 IN O
compared P02774808A0194 VBN O
to P02774808A0194 TO O
winter P02774808A0194 VB O
( P02774808A0194 ( O
5.06 P02774808A0194 CD O
+ P02774808A0194 NN O
/ P02774808A0194 NNP O
- P02774808A0194 : O
0.27 P02774808A0194 CD O
) P02774808A0194 ) O
. P02774808A0194 . O
. . O O

However P09303437A0875 RB O
, P09303437A0875 , O
although P09303437A0875 IN O
deletion P09303437A0875 NN O
of P09303437A0875 IN O
Fp1 P09303437A0875 NNP I-UN
in P09303437A0875 IN O
the P09303437A0875 DT O
hCRBP1 P09303437A0875 NN I-UN
gene P09303437A0875 NN I-UN
yielded P09303437A0875 VBN O
increased P09303437A0875 JJ O
CAT P09303437A0875 NNP I-UN
activity P09303437A0875 NN O
, P09303437A0875 , O
pointing P09303437A0875 VBG O
toward P09303437A0875 IN O
a P09303437A0875 DT O
negative P09303437A0875 JJ O
regulatory P09303437A0875 JJ O
function P09303437A0875 NN O
exerted P09303437A0875 VBN O
by P09303437A0875 IN O
this P09303437A0875 DT O
element P09303437A0875 NN O
, P09303437A0875 , O
its P09303437A0875 PRP$ O
insertion P09303437A0875 NN O
upstream P09303437A0875 NN O
of P09303437A0875 IN O
the P09303437A0875 DT O
p12 P09303437A0875 NN I-UN
basal P09303437A0875 NN I-UN
promoter P09303437A0875 NN I-UN
results P09303437A0875 NNS O
in P09303437A0875 IN O
an P09303437A0875 DT O
impressive P09303437A0875 JJ O
positive P09303437A0875 JJ O
stimulation P09303437A0875 NN O
of P09303437A0875 IN O
CAT P09303437A0875 NNP I-UN
gene P09303437A0875 NN I-UN
expression P09303437A0875 NN O
. P09303437A0875 . O
. . O O

TNF-alpha P09393771A1659 JJ I-UN
exposure P09393771A1659 NN O
markedly P09393771A1659 RB O
increased P09393771A1659 VBD O
activity P09393771A1659 NN O
of P09393771A1659 IN O
several P09393771A1659 JJ O
RNA-binding P09393771A1659 JJ O
proteins P09393771A1659 NNS O
, P09393771A1659 , O
especially P09393771A1659 RB O
a P09393771A1659 DT O
novel P09393771A1659 JJ O
Mr P09393771A1659 NNP O
50,000-55,000 P09393771A1659 CD O
RNA-binding P09393771A1659 NNP O
protein P09393771A1659 NN O
. P09393771A1659 . O
. . O O

Fregnac P09602124A0127 NNP O
, P09602124A0127 , O
M P09602124A0127 NNP O
. P09602124A0127 . O
. . O O

The P10762254A0954 DT O
MMA P10762254A0954 NNP I-UN
, P10762254A0954 , I-UN
DMA P10762254A0954 NNP I-UN
, P10762254A0954 , I-UN
and P10762254A0954 CC I-UN
TMA P10762254A0954 NNP I-UN
methyltransferases P10762254A0954 NNS I-UN
are P10762254A0954 VBP O
not P10762254A0954 RB O
homologs P10762254A0954 NNS O
; P10762254A0954 : O
however P10762254A0954 RB O
, P10762254A0954 , O
like P10762254A0954 IN O
the P10762254A0954 DT O
MMA P10762254A0954 NNP I-UN
methyltransferase P10762254A0954 NN I-UN
gene P10762254A0954 NN I-UN
, P10762254A0954 , O
the P10762254A0954 DT O
genes P10762254A0954 NNS O
encoding P10762254A0954 VBG O
the P10762254A0954 DT O
DMA P10762254A0954 NNP I-UN
and P10762254A0954 CC I-UN
TMA P10762254A0954 NNP I-UN
methyltransferases P10762254A0954 VBZ I-UN
each P10762254A0954 DT O
contain P10762254A0954 NN O
a P10762254A0954 DT O
single P10762254A0954 JJ O
in-frame P10762254A0954 JJ O
amber P10762254A0954 NN O
codon P10762254A0954 NN O
. P10762254A0954 . O
. . O O

These P09792682A0713 DT O
results P09792682A0713 NNS O
indicate P09792682A0713 VBP O
that P09792682A0713 IN O
the P09792682A0713 DT O
total P09792682A0713 JJ O
number P09792682A0713 NN O
of P09792682A0713 IN O
subunit P09792682A0713 JJ O
c P09792682A0713 NN O
in P09792682A0713 IN O
F0 P09792682A0713 NNP I-UN
should P09792682A0713 MD O
be P09792682A0713 VB O
a P09792682A0713 DT O
multiple P09792682A0713 NN O
of P09792682A0713 IN O
2 P09792682A0713 CD O
and P09792682A0713 CC O
3 P09792682A0713 CD O
. P09792682A0713 . O
. . O O

Thus P07969135A0913 RB O
, P07969135A0913 , O
the P07969135A0913 DT O
presence P07969135A0913 NN O
of P07969135A0913 IN O
the P07969135A0913 DT O
Cln2 P07969135A0913 NNP I-UN
PEST P07969135A0913 NNP I-UN
domain P07969135A0913 NN I-UN
was P07969135A0913 VBD O
sufficient P07969135A0913 JJ O
to P07969135A0913 TO O
destabilize P07969135A0913 VB O
a P07969135A0913 DT O
heterologous P07969135A0913 JJ O
protein P07969135A0913 NN O
. P07969135A0913 . O
. . O O

Auditory P10402022A0432 NN O
clicks P10402022A0432 NNS O
were P10402022A0432 VBD O
given P10402022A0432 VBN O
at P10402022A0432 IN O
a P10402022A0432 DT O
rate P10402022A0432 NN O
of P10402022A0432 IN O
20 P10402022A0432 CD O
s P10402022A0432 NN O
( P10402022A0432 ( O
-1 P10402022A0432 NNP O
) P10402022A0432 ) O
. P10402022A0432 . O
. . O O

One P07951235A0277 CD O
gene P07951235A0277 NN O
appears P07951235A0277 VBZ O
ubiquitously P07951235A0277 RB O
expressed P07951235A0277 VBN O
while P07951235A0277 IN O
the P07951235A0277 DT O
other P07951235A0277 JJ O
is P07951235A0277 VBZ O
prominently P07951235A0277 RB O
expressed P07951235A0277 VBN O
in P07951235A0277 IN O
muscle P07951235A0277 NN O
. P07951235A0277 . O
. . O O

With P10564484A0859 IN O
constructs P10564484A0859 NNS O
containing P10564484A0859 VBG O
the P10564484A0859 DT O
binding P10564484A0859 VBG O
site P10564484A0859 NN O
of P10564484A0859 IN O
one P10564484A0859 CD O
gene P10564484A0859 NN O
fused P10564484A0859 VBD O
to P10564484A0859 TO O
the P10564484A0859 DT O
promoter P10564484A0859 NN O
of P10564484A0859 IN O
the P10564484A0859 DT O
other P10564484A0859 JJ O
, P10564484A0859 , O
we P10564484A0859 PRP O
demonstrated P10564484A0859 VBD O
that P10564484A0859 IN O
the P10564484A0859 DT O
positional P10564484A0859 JJ O
requirements P10564484A0859 NNS O
are P10564484A0859 VBP O
a P10564484A0859 DT O
function P10564484A0859 NN O
of P10564484A0859 IN O
the P10564484A0859 DT O
specific P10564484A0859 JJ O
binding P10564484A0859 NN O
site P10564484A0859 NN O
, P10564484A0859 , O
not P10564484A0859 RB O
the P10564484A0859 DT O
promoter P10564484A0859 NN O
. P10564484A0859 . O
. . O O

Early P01982190T0001 JJ O
cirrhosis P01982190T0001 NN O
, P01982190T0001 , O
an P01982190T0001 DT O
early P01982190T0001 JJ O
modality P01982190T0001 NN O
of P01982190T0001 IN O
the P01982190T0001 DT O
evolution P01982190T0001 NN O
of P01982190T0001 IN O
acute P01982190T0001 JJ O
hepatitis P01982190T0001 NN O
. P01982190T0001 . O
. . O O

Isolation P08639742T0000 NN O
by P08639742T0000 IN O
PCR P08639742T0000 NNP O
of P08639742T0000 IN O
a P08639742T0000 DT O
cDNA P08639742T0000 NN O
clone P08639742T0000 NN O
from P08639742T0000 IN O
pea P08639742T0000 JJ O
petals P08639742T0000 NNS O
with P08639742T0000 IN O
similarity P08639742T0000 NN O
to P08639742T0000 TO O
petunia P08639742T0000 VB O
and P08639742T0000 CC O
wheat P08639742T0000 VB I-UN
zinc P08639742T0000 NN I-UN
finger P08639742T0000 NN I-UN
proteins P08639742T0000 NNS I-UN
. P08639742T0000 . O
. . O O

Collectively P10455183A0930 RB O
, P10455183A0930 , O
these P10455183A0930 DT O
results P10455183A0930 NNS O
show P10455183A0930 VBP O
that P10455183A0930 IN O
the P10455183A0930 DT O
differential P10455183A0930 JJ O
utilization P10455183A0930 NN O
of P10455183A0930 IN O
Staf P10455183A0930 NNP I-UN
zinc P10455183A0930 NNP I-UN
finger P10455183A0930 NN I-UN
1 P10455183A0930 CD I-UN
represents P10455183A0930 VBZ O
a P10455183A0930 DT O
new P10455183A0930 JJ O
, P10455183A0930 , O
critical P10455183A0930 JJ O
determinant P10455183A0930 NN O
of P10455183A0930 IN O
the P10455183A0930 DT O
transcriptional P10455183A0930 JJ O
activation P10455183A0930 NN O
mechanism P10455183A0930 NN O
for P10455183A0930 IN O
the P10455183A0930 DT O
Xenopus P10455183A0930 NNP I-UN
tRNA P10455183A0930 NN I-UN
( P10455183A0930 ( O
Sec P10455183A0930 NNP I-UN
) P10455183A0930 ) O
and P10455183A0930 CC O
human P10455183A0930 JJ I-UN
U6 P10455183A0930 NNP I-UN
snRNA P10455183A0930 NN I-UN
genes P10455183A0930 NNS I-UN
. P10455183A0930 . O
. . O O

Previous P01845829A0158 JJ O
analysis P01845829A0158 NN O
of P01845829A0158 IN O
the P01845829A0158 DT O
98-bp P01845829A0158 JJ O
sequence P01845829A0158 NN O
has P01845829A0158 VBZ O
delineated P01845829A0158 VBN O
several P01845829A0158 JJ O
protein-binding P01845829A0158 JJ O
domains P01845829A0158 NNS O
that P01845829A0158 WDT O
are P01845829A0158 VBP O
recognized P01845829A0158 VBN O
by P01845829A0158 IN O
nuclear P01845829A0158 JJ O
factors P01845829A0158 NNS O
present P01845829A0158 VBP O
in P01845829A0158 IN O
human P01845829A0158 JJ O
brain P01845829A0158 NN O
cells P01845829A0158 NNS O
. P01845829A0158 . O
. . O O

The P08682155A0902 DT O
euglobulin P08682155A0902 NN I-UN
clot P08682155A0902 NN O
lysis P08682155A0902 NN O
time P08682155A0902 NN O
was P08682155A0902 VBD O
slightly P08682155A0902 RB O
longer P08682155A0902 RBR O
in P08682155A0902 IN O
the P08682155A0902 DT O
smokers P08682155A0902 NNS O
than P08682155A0902 IN O
in P08682155A0902 IN O
the P08682155A0902 DT O
non-smokers P08682155A0902 NNS O
in P08682155A0902 IN O
all P08682155A0902 DT O
three P08682155A0902 CD O
experimental P08682155A0902 JJ O
situations P08682155A0902 NNS O
, P08682155A0902 , O
but P08682155A0902 CC O
the P08682155A0902 DT O
differences P08682155A0902 NNS O
were P08682155A0902 VBD O
not P08682155A0902 RB O
significant P08682155A0902 JJ O
. P08682155A0902 . O
. . O O

OBJECTIVE P11035867A0000 NN O
: P11035867A0000 : O
To P11035867A0000 TO O
evaluate P11035867A0000 VB O
the P11035867A0000 DT O
overall P11035867A0000 JJ O
performance P11035867A0000 NN O
of P11035867A0000 IN O
a P11035867A0000 DT O
new P11035867A0000 JJ O
oscillometric P11035867A0000 JJ O
wrist P11035867A0000 NN O
blood P11035867A0000 NN O
pressure P11035867A0000 NN O
monitor P11035867A0000 NN O
( P11035867A0000 ( O
Braun P11035867A0000 NNP O
PrecisionSensor P11035867A0000 NNP O
, P11035867A0000 , O
Braun P11035867A0000 NNP O
GmbH P11035867A0000 NNP O
, P11035867A0000 , O
Kronberg P11035867A0000 NNP O
, P11035867A0000 , O
Germany P11035867A0000 NNP O
) P11035867A0000 ) O
as P11035867A0000 IN O
defined P11035867A0000 VBN O
by P11035867A0000 IN O
the P11035867A0000 DT O
ANSI P11035867A0000 NNP O
/ P11035867A0000 NNP O
AAMI P11035867A0000 NNP O
SP10-1992 P11035867A0000 NNP O
guidelines P11035867A0000 NNS O
, P11035867A0000 , O
and P11035867A0000 CC O
to P11035867A0000 TO O
analyze P11035867A0000 VB O
the P11035867A0000 DT O
data P11035867A0000 NN O
for P11035867A0000 IN O
the P11035867A0000 DT O
optimized P11035867A0000 JJ O
selection P11035867A0000 NN O
of P11035867A0000 IN O
the P11035867A0000 DT O
algorithm P11035867A0000 NN O
that P11035867A0000 WDT O
derives P11035867A0000 VBZ O
the P11035867A0000 DT O
blood P11035867A0000 NN O
pressure P11035867A0000 NN O
values P11035867A0000 NNS O
from P11035867A0000 IN O
the P11035867A0000 DT O
oscillometric P11035867A0000 JJ O
blood P11035867A0000 NN O
pressure P11035867A0000 NN O
curves P11035867A0000 NNS O
. P11035867A0000 . O
. . O O

Insulin-like P10488088T0000 JJ I-UN
growth P10488088T0000 NN I-UN
factor-I P10488088T0000 JJ I-UN
induces P10488088T0000 NNS O
bcl-2 P10488088T0000 JJ I-UN
promoter P10488088T0000 NN I-UN
through P10488088T0000 IN O
the P10488088T0000 DT O
transcription P10488088T0000 NN O
factor P10488088T0000 NN O
cAMP-response P10488088T0000 JJ I-UN
element-binding P10488088T0000 JJ I-UN
protein P10488088T0000 NN I-UN
. P10488088T0000 . O
. . O O

These P10864641A1400 DT O
results P10864641A1400 NNS O
demonstrate P10864641A1400 VBP O
that P10864641A1400 IN O
N-glycans P10864641A1400 NNP O
flanking P10864641A1400 VBG O
the P10864641A1400 DT O
receptor-binding P10864641A1400 JJ O
site P10864641A1400 NN O
of P10864641A1400 IN O
the P10864641A1400 DT O
HA P10864641A1400 NNP I-UN
molecule P10864641A1400 NN I-UN
are P10864641A1400 VBP O
potent P10864641A1400 JJ O
regulators P10864641A1400 NNS O
of P10864641A1400 IN O
influenza P10864641A1400 NN O
virus P10864641A1400 NN O
growth P10864641A1400 NN O
, P10864641A1400 , O
with P10864641A1400 IN O
the P10864641A1400 DT O
glycan P10864641A1400 NN O
at P10864641A1400 IN O
Asn149 P10864641A1400 NNP O
being P10864641A1400 VBG O
dominant P10864641A1400 JJ O
and P10864641A1400 CC O
that P10864641A1400 DT O
at P10864641A1400 IN O
Asn123 P10864641A1400 NNP O
being P10864641A1400 VBG O
less P10864641A1400 RBR O
effective P10864641A1400 JJ O
. P10864641A1400 . O
. . O O

Age P02017414A0307 NNP O
at P02017414A0307 IN O
POI P02017414A0307 NNP O
and P02017414A0307 CC O
asymptote P02017414A0307 VB O
were P02017414A0307 VBD O
achieved P02017414A0307 VBN O
later P02017414A0307 RB O
for P02017414A0307 IN O
Line P02017414A0307 NNP O
RBC2 P02017414A0307 NNP O
than P02017414A0307 IN O
for P02017414A0307 IN O
Line P02017414A0307 NNP O
F P02017414A0307 NNP O
. P02017414A0307 . O
. . O O

Value P00716366T0001 NNP O
of P00716366T0001 IN O
determination P00716366T0001 NN O
of P00716366T0001 IN O
alkaline P00716366T0001 JJ I-UN
phosphatase P00716366T0001 NN I-UN
isoenzymes P00716366T0001 NNS I-UN
for P00716366T0001 IN O
differential P00716366T0001 JJ O
diagnosis P00716366T0001 NN O
of P00716366T0001 IN O
obstructive P00716366T0001 JJ O
jaundice P00716366T0001 NN O
and P00716366T0001 CC O
biliary P00716366T0001 JJ O
liver P00716366T0001 NN O
cirrhosis P00716366T0001 NN O
. P00716366T0001 . O
. . O O

The P09705258A0837 DT O
IE13.1 P09705258A0837 NNP O
cell P09705258A0837 NN O
line P09705258A0837 NN O
was P09705258A0837 VBD O
able P09705258A0837 JJ O
to P09705258A0837 TO O
complement P09705258A0837 VB O
a P09705258A0837 DT O
recombinant P09705258A0837 JJ O
virus P09705258A0837 NN O
in P09705258A0837 IN O
which P09705258A0837 WDT O
both P09705258A0837 DT O
copies P09705258A0837 NNS O
of P09705258A0837 IN O
the P09705258A0837 DT O
IE P09705258A0837 NNP I-UN
gene P09705258A0837 NN I-UN
were P09705258A0837 VBD O
replaced P09705258A0837 VBN O
by P09705258A0837 IN O
insertion P09705258A0837 NN O
of P09705258A0837 IN O
the P09705258A0837 DT O
Escherichia P09705258A0837 NNP I-UN
coli P09705258A0837 NN I-UN
lacZ P09705258A0837 NN I-UN
gene P09705258A0837 NN I-UN
. P09705258A0837 . O
. . O O

Genomic P07672822T0000 NNP O
structure P07672822T0000 NN O
and P07672822T0000 CC O
chromosomal P07672822T0000 JJ O
location P07672822T0000 NN O
of P07672822T0000 IN O
the P07672822T0000 DT O
mouse P07672822T0000 NN I-UN
pre-T-cell P07672822T0000 NN I-UN
receptor P07672822T0000 NN I-UN
alpha P07672822T0000 JJ I-UN
gene P07672822T0000 NN I-UN
. P07672822T0000 . O
. . O O

To P09180687A0096 TO O
determine P09180687A0096 VB O
which P09180687A0096 WDT O
region P09180687A0096 NN O
of P09180687A0096 IN O
SulA P09180687A0096 NNP I-UN
is P09180687A0096 VBZ O
essential P09180687A0096 JJ O
for P09180687A0096 IN O
the P09180687A0096 DT O
inhibition P09180687A0096 NN O
of P09180687A0096 IN O
cell P09180687A0096 NN O
division P09180687A0096 NN O
, P09180687A0096 , O
we P09180687A0096 PRP O
constructed P09180687A0096 VBD O
a P09180687A0096 DT O
series P09180687A0096 NN O
of P09180687A0096 IN O
N-terminal P09180687A0096 JJ O
and P09180687A0096 CC O
C-terminal P09180687A0096 JJ O
deletions P09180687A0096 NNS O
of P09180687A0096 IN O
SulA P09180687A0096 NNP I-UN
and P09180687A0096 CC O
a P09180687A0096 DT O
series P09180687A0096 NN O
of P09180687A0096 IN O
alanine P09180687A0096 JJ O
substitution P09180687A0096 NN O
mutants P09180687A0096 NNS O
. P09180687A0096 . O
. . O O

Scotchbond P02700977A0444 NN O
2 P02700977A0444 CD O
showed P02700977A0444 VBD O
the P02700977A0444 DT O
least P02700977A0444 JJS O
dye P02700977A0444 JJ O
penetration P02700977A0444 NN O
but P02700977A0444 CC O
not P02700977A0444 RB O
statistically P02700977A0444 RB O
less P02700977A0444 JJR O
than P02700977A0444 IN O
the P02700977A0444 DT O
XR P02700977A0444 NNP O
bond P02700977A0444 NN O
/ P02700977A0444 NNP O
Silus P02700977A0444 NNP O
Plus P02700977A0444 NNP O
combination P02700977A0444 NN O
. P02700977A0444 . O
. . O O

Mutations P08098842A0660 NNS O
in P08098842A0660 IN O
a P08098842A0660 DT O
region P08098842A0660 NN O
located P08098842A0660 VBN O
15 P08098842A0660 CD O
to P08098842A0660 TO O
30 P08098842A0660 CD O
bp P08098842A0660 NNS O
downstream P08098842A0660 NN O
from P08098842A0660 IN O
the P08098842A0660 DT O
major P08098842A0660 JJ O
transcription P08098842A0660 NN O
start P08098842A0660 NN O
site P08098842A0660 NN O
that P08098842A0660 WDT O
shows P08098842A0660 VBZ O
good P08098842A0660 JJ O
homology P08098842A0660 NN O
to P08098842A0660 TO O
a P08098842A0660 DT O
sequence P08098842A0660 NN O
in P08098842A0660 IN O
the P08098842A0660 DT O
first P08098842A0660 JJ O
exon P08098842A0660 NN O
of P08098842A0660 IN O
c-fos P08098842A0660 NN I-UN
implicated P08098842A0660 VBN O
as P08098842A0660 IN O
a P08098842A0660 DT O
negative P08098842A0660 JJ O
regulatory P08098842A0660 JJ O
element P08098842A0660 NN O
resulted P08098842A0660 VBD O
in P08098842A0660 IN O
a P08098842A0660 DT O
significant P08098842A0660 JJ O
increase P08098842A0660 NN O
in P08098842A0660 IN O
basal P08098842A0660 JJ O
gene P08098842A0660 NN O
expression P08098842A0660 NN O
but P08098842A0660 CC O
did P08098842A0660 VBD O
not P08098842A0660 RB O
affect P08098842A0660 VB O
regulation P08098842A0660 NN O
. P08098842A0660 . O
. . O O

Zatebradine P08739209A0700 NNP O
weakly P08739209A0700 NN O
depressed P08739209A0700 VBD O
the P08739209A0700 DT O
ectopic P08739209A0700 JJ O
ventricular P08739209A0700 JJ O
rate P08739209A0700 NN O
but P08739209A0700 CC O
not P08739209A0700 RB O
the P08739209A0700 DT O
arrhythmic P08739209A0700 JJ O
ratio P08739209A0700 NN O
of P08739209A0700 IN O
the P08739209A0700 DT O
ventricular P08739209A0700 JJ O
arrhythmias P08739209A0700 NN O
induced P08739209A0700 VBN O
by P08739209A0700 IN O
two-stage P08739209A0700 JJ O
coronary P08739209A0700 JJ O
ligation P08739209A0700 NN O
24 P08739209A0700 CD O
h P08739209A0700 NN O
after P08739209A0700 IN O
the P08739209A0700 DT O
ligation P08739209A0700 NN O
in P08739209A0700 IN O
conscious P08739209A0700 JJ O
dogs P08739209A0700 NNS O
. P08739209A0700 . O
. . O O

Our P07865787A1086 PRP$ O
results P07865787A1086 NNS O
suggested P07865787A1086 VBD O
that P07865787A1086 IN O
the P07865787A1086 DT O
hexamer P07865787A1086 NN O
and P07865787A1086 CC O
the P07865787A1086 DT O
octamer P07865787A1086 JJR O
motifs P07865787A1086 NNS O
may P07865787A1086 MD O
play P07865787A1086 VB O
important P07865787A1086 JJ O
role P07865787A1086 NN O
( P07865787A1086 ( O
s P07865787A1086 PRP O
) P07865787A1086 ) O
in P07865787A1086 IN O
regulation P07865787A1086 NN O
of P07865787A1086 IN O
replication-dependent P07865787A1086 NN O
but P07865787A1086 CC O
not P07865787A1086 RB O
of P07865787A1086 IN O
replication-independent P07865787A1086 JJ O
expression P07865787A1086 NN O
of P07865787A1086 IN O
the P07865787A1086 DT O
wheat P07865787A1086 NN I-UN
histone P07865787A1086 NN I-UN
H3 P07865787A1086 NNP I-UN
gene P07865787A1086 NN I-UN
. P07865787A1086 . O
. . O O

VP5 P02552143A0748 NNP I-UN
, P02552143A0748 , O
which P02552143A0748 WDT O
encodes P02552143A0748 VBZ O
the P02552143A0748 DT O
major P02552143A0748 JJ I-UN
capsid P02552143A0748 NN I-UN
protein P02552143A0748 NN I-UN
, P02552143A0748 , O
each P02552143A0748 DT O
fused P02552143A0748 VBN O
to P02552143A0748 TO O
the P02552143A0748 DT O
chloramphenicol P02552143A0748 NN I-UN
acetyltransferase P02552143A0748 NN I-UN
gene P02552143A0748 NN I-UN
. P02552143A0748 . O
. . O O

Comparison P10592791T0001 NNP O
of P10592791T0001 IN O
immunoassay P10592791T0001 NN O
kits P10592791T0001 NNS O
for P10592791T0001 IN O
detection P10592791T0001 NN O
of P10592791T0001 IN O
staphylococcal P10592791T0001 JJ I-UN
enterotoxins P10592791T0001 NNS I-UN
produced P10592791T0001 VBN O
by P10592791T0001 IN O
Staphylococcus P10592791T0001 NNP O
aureus P10592791T0001 NN O
. P10592791T0001 . O
. . O O

Liquid P09606924T0000 NNP O
chromatographic P09606924T0000 JJ O
method P09606924T0000 NN O
for P09606924T0000 IN O
analysis P09606924T0000 NN O
of P09606924T0000 IN O
all-rac-alpha-tocopheryl P09606924T0000 JJ O
acetate P09606924T0000 NN O
and P09606924T0000 CC O
retinyl P09606924T0000 NN O
palmitate P09606924T0000 NN O
in P09606924T0000 IN O
milk-based P09606924T0000 JJ O
infant P09606924T0000 NN O
formula P09606924T0000 NN O
using P09606924T0000 VBG O
matrix P09606924T0000 JJ O
solid-phase P09606924T0000 JJ O
dispersion P09606924T0000 NN O
. P09606924T0000 . O
. . O O

BACKGROUND P08053697A0000 NNP O
AND P08053697A0000 CC O
DESIGN P08053697A0000 NNP O
: P08053697A0000 : O
Fifty-nine P08053697A0000 JJ O
melanocytic P08053697A0000 JJ O
nevi P08053697A0000 NN O
with P08053697A0000 IN O
eccentric P08053697A0000 JJ O
foci P08053697A0000 NN O
of P08053697A0000 IN O
hyperpigmentation P08053697A0000 NN O
( P08053697A0000 ( O
`` P08053697A0000 `` O
small P08053697A0000 JJ O
dark P08053697A0000 JJ O
dots P08053697A0000 NNS O
'' P08053697A0000 '' O
) P08053697A0000 ) O
that P08053697A0000 WDT O
measured P08053697A0000 VBD O
primarily P08053697A0000 RB O
1 P08053697A0000 CD O
to P08053697A0000 TO O
2 P08053697A0000 CD O
mm P08053697A0000 NNS O
in P08053697A0000 IN O
diameter P08053697A0000 NN O
were P08053697A0000 VBD O
prospectively P08053697A0000 RB O
examined P08053697A0000 VBN O
to P08053697A0000 TO O
determine P08053697A0000 VB O
the P08053697A0000 DT O
histologic P08053697A0000 JJ O
correlates P08053697A0000 NNS O
of P08053697A0000 IN O
the P08053697A0000 DT O
dark P08053697A0000 JJ O
dots P08053697A0000 NNS O
. P08053697A0000 . O
. . O O

Transcriptional P11559547T0000 JJ O
regulation P11559547T0000 NN O
of P11559547T0000 IN O
the P11559547T0000 DT O
estrogen-inducible P11559547T0000 JJ O
pS2 P11559547T0000 NN I-UN
breast P11559547T0000 NN I-UN
cancer P11559547T0000 NN I-UN
marker P11559547T0000 NN I-UN
gene P11559547T0000 NN I-UN
by P11559547T0000 IN O
the P11559547T0000 DT O
ERR P11559547T0000 NNP I-UN
family P11559547T0000 NN I-UN
of P11559547T0000 IN O
orphan P11559547T0000 JJ I-UN
nuclear P11559547T0000 JJ I-UN
receptors P11559547T0000 NNS I-UN
. P11559547T0000 . O
. . O O

Gene P07865786A0457 NNP O
expression P07865786A0457 NN O
occurs P07865786A0457 VBZ O
in P07865786A0457 IN O
a P07865786A0457 DT O
circadian P07865786A0457 JJ O
rhythm P07865786A0457 NN O
and P07865786A0457 CC O
induced P07865786A0457 VBN O
by P07865786A0457 IN O
light P07865786A0457 NN O
in P07865786A0457 IN O
leaves P07865786A0457 NNS O
of P07865786A0457 IN O
dark-adapted P07865786A0457 JJ O
plants P07865786A0457 NNS O
. P07865786A0457 . O
. . O O

Among P02906027A1156 IN O
unusual P02906027A1156 JJ O
features P02906027A1156 NNS O
, P02906027A1156 , O
we P02906027A1156 PRP O
report P02906027A1156 VBP O
numerous P02906027A1156 JJ O
large P02906027A1156 JJ O
G P02906027A1156 NNP O
+ P02906027A1156 NNP O
C-rich P02906027A1156 NNP O
conserved P02906027A1156 VBD O
sequences P02906027A1156 NNS O
located P02906027A1156 VBN O
in P02906027A1156 IN O
the P02906027A1156 DT O
first P02906027A1156 JJ O
intron P02906027A1156 NN O
. P02906027A1156 . O
. . O O

Previously P02476664A0563 RB O
, P02476664A0563 , O
we P02476664A0563 PRP O
reported P02476664A0563 VBD O
the P02476664A0563 DT O
sequence P02476664A0563 NN O
of P02476664A0563 IN O
the P02476664A0563 DT O
gene P02476664A0563 NN I-UN
encoding P02476664A0563 VBG I-UN
human P02476664A0563 JJ I-UN
K14 P02476664A0563 NNP I-UN
( P02476664A0563 ( O
D P02476664A0563 NNP O
. P02476664A0563 . O
. . O O

Linkage P08824881A0133 NN O
studies P08824881A0133 NNS O
have P08824881A0133 VBP O
shown P08824881A0133 VBN O
locus P08824881A0133 JJ O
heterogeneity P08824881A0133 NN O
with P08824881A0133 IN O
one P08824881A0133 CD O
TSC P08824881A0133 NNP I-UN
gene P08824881A0133 NN I-UN
mapped P08824881A0133 VBD O
to P08824881A0133 TO O
chromosome P08824881A0133 VB O
9q34 P08824881A0133 CD O
and P08824881A0133 CC O
a P08824881A0133 DT O
second P08824881A0133 JJ O
to P08824881A0133 TO O
16p13.3 P08824881A0133 CD O
. P08824881A0133 . O
. . O O

SAM-TR-68-54 P05303700T0066 NNP O
. P05303700T0066 . O
. . O O

Regulated P08397123T0000 VBN O
activity P08397123T0000 NN O
of P08397123T0000 IN O
the P08397123T0000 DT O
distal P08397123T0000 JJ O
promoter-like P08397123T0000 JJ O
element P08397123T0000 NN O
of P08397123T0000 IN O
the P08397123T0000 DT O
human P08397123T0000 JJ I-UN
corticotropin-releasing P08397123T0000 NN I-UN
hormone P08397123T0000 NN I-UN
gene P08397123T0000 NN I-UN
and P08397123T0000 CC O
secondary P08397123T0000 JJ O
structural P08397123T0000 JJ O
features P08397123T0000 NNS O
of P08397123T0000 IN O
its P08397123T0000 PRP$ O
corresponding P08397123T0000 NN O
transcripts P08397123T0000 NNS O
. P08397123T0000 . O
. . O O

Relationship P04863895T0000 NN O
between P04863895T0000 IN O
gross P04863895T0000 JJ O
lesions P04863895T0000 NNS O
and P04863895T0000 CC O
Escherichia P04863895T0000 NNP O
coli P04863895T0000 VBP O
serotypes P04863895T0000 NNS O
in P04863895T0000 IN O
chronic P04863895T0000 JJ O
respiratory P04863895T0000 NN O
disease P04863895T0000 NN O
( P04863895T0000 ( O
CRD P04863895T0000 NNP O
) P04863895T0000 ) O
of P04863895T0000 IN O
poultry P04863895T0000 NN O
. P04863895T0000 . O
. . O O

CONCLUSIONS P10496303A1968 NN O
: P10496303A1968 : O
These P10496303A1968 DT O
results P10496303A1968 NNS O
show P10496303A1968 VBP O
that P10496303A1968 DT O
once P10496303A1968 RB O
daily P10496303A1968 JJ O
oral P10496303A1968 JJ O
valganciclovir P10496303A1968 NN O
can P10496303A1968 MD O
produce P10496303A1968 VB O
exposures P10496303A1968 NNS O
of P10496303A1968 IN O
ganciclovir P10496303A1968 NN O
( P10496303A1968 ( O
AUC24 P10496303A1968 NNP O
) P10496303A1968 ) O
exceeding P10496303A1968 VBG O
those P10496303A1968 DT O
attained P10496303A1968 VBN O
using P10496303A1968 VBG O
intravenous P10496303A1968 JJ O
ganciclovir P10496303A1968 NNS O
10 P10496303A1968 CD O
mg P10496303A1968 NNS O
/ P10496303A1968 JJ O
kg P10496303A1968 NN O
. P10496303A1968 . O
. . O O

Two P07487811A0000 CD O
experiments P07487811A0000 NNS O
investigating P07487811A0000 VBG O
the P07487811A0000 DT O
effects P07487811A0000 NNS O
of P07487811A0000 IN O
short-term P07487811A0000 JJ O
spaceflight P07487811A0000 NN O
on P07487811A0000 IN O
cancellous P07487811A0000 JJ O
bone P07487811A0000 NN O
turnover P07487811A0000 NN O
were P07487811A0000 VBD O
carried P07487811A0000 VBN O
out P07487811A0000 IN O
: P07487811A0000 : O
Physiological P07487811A0000 JJ O
Systems P07487811A0000 NNP O
Experiment-1 P07487811A0000 NNP O
( P07487811A0000 ( O
PSE-1 P07487811A0000 NNP O
) P07487811A0000 ) O
( P07487811A0000 ( O
a P07487811A0000 DT O
4-d P07487811A0000 JJ O
orbital P07487811A0000 JJ O
spaceflight P07487811A0000 NN O
) P07487811A0000 ) O
and P07487811A0000 CC O
PSE-2 P07487811A0000 NNP O
( P07487811A0000 ( O
a P07487811A0000 DT O
10-d P07487811A0000 JJ O
flight P07487811A0000 NN O
) P07487811A0000 ) O
. P07487811A0000 . O
. . O O

Urine P01964989A0145 NN O
specimens P01964989A0145 VBZ O
containing P01964989A0145 VBG O
either P01964989A0145 CC O
phencyclidine P01964989A0145 NN O
( P01964989A0145 ( O
PCP P01964989A0145 NNP O
) P01964989A0145 ) O
or P01964989A0145 CC O
11-nor-delta P01964989A0145 JJ O
9-tetrahydrocannabinol-9-carboxylic P01964989A0145 JJ O
acid P01964989A0145 NN O
( P01964989A0145 ( O
9-THC-COOH P01964989A0145 CD O
) P01964989A0145 ) O
were P01964989A0145 VBD O
adulterated P01964989A0145 VBN O
with P01964989A0145 IN O
sodium P01964989A0145 NN O
chloride P01964989A0145 NN O
, P01964989A0145 , O
bleach P01964989A0145 NN O
, P01964989A0145 , O
vinegar P01964989A0145 NN O
, P01964989A0145 , O
potassium P01964989A0145 NN O
hydroxide P01964989A0145 NN O
, P01964989A0145 , O
liquid P01964989A0145 JJ O
soap P01964989A0145 NN O
, P01964989A0145 , O
2-propanol P01964989A0145 JJ O
, P01964989A0145 , O
and P01964989A0145 CC O
ammonia P01964989A0145 NN O
. P01964989A0145 . O
. . O O

CONCLUSIONS P08002857A1070 NN O
: P08002857A1070 : O
These P08002857A1070 DT O
findings P08002857A1070 NNS O
indicate P08002857A1070 VBP O
a P08002857A1070 DT O
physical P08002857A1070 JJ O
barrier P08002857A1070 NN O
of P08002857A1070 IN O
oesophageal P08002857A1070 NN O
surfactant P08002857A1070 NN O
which P08002857A1070 WDT O
could P08002857A1070 MD O
offer P08002857A1070 VB O
some P08002857A1070 DT O
degree P08002857A1070 NN O
of P08002857A1070 IN O
protection P08002857A1070 NN O
against P08002857A1070 IN O
gastro-oesophageal P08002857A1070 JJ O
reflux P08002857A1070 NN O
but P08002857A1070 CC O
one P08002857A1070 CD O
which P08002857A1070 WDT O
is P08002857A1070 VBZ O
particularly P08002857A1070 RB O
prone P08002857A1070 JJ O
to P08002857A1070 TO O
attack P08002857A1070 VB O
by P08002857A1070 IN O
bile P08002857A1070 NN O
. P08002857A1070 . O
. . O O

No P02190134A0572 DT O
therapy P02190134A0572 NN O
exists P02190134A0572 VBZ O
for P02190134A0572 IN O
halting P02190134A0572 VBG O
the P02190134A0572 DT O
progression P02190134A0572 NN O
of P02190134A0572 IN O
the P02190134A0572 DT O
disease P02190134A0572 NN O
with P02190134A0572 IN O
the P02190134A0572 DT O
possible P02190134A0572 JJ O
exception P02190134A0572 NN O
of P02190134A0572 IN O
laser P02190134A0572 NN O
photocoagulation P02190134A0572 NN O
treatment P02190134A0572 NN O
used P02190134A0572 VBN O
to P02190134A0572 TO O
ablate P02190134A0572 VB O
subretinal P02190134A0572 JJ O
neovascular P02190134A0572 JJ O
membranes P02190134A0572 NNS O
in P02190134A0572 IN O
an P02190134A0572 DT O
attempt P02190134A0572 NN O
to P02190134A0572 TO O
avoid P02190134A0572 VB O
complications P02190134A0572 NNS O
of P02190134A0572 IN O
subretinal P02190134A0572 JJ O
hemorrhages P02190134A0572 NNS O
. P02190134A0572 . O
. . O O

The P04615525T0001 DT O
effect P04615525T0001 NN O
of P04615525T0001 IN O
antilymphocyte P04615525T0001 NN O
sera P04615525T0001 NN O
on P04615525T0001 IN O
formation P04615525T0001 NN O
of P04615525T0001 IN O
transplantation P04615525T0001 NN O
and P04615525T0001 CC O
anti-infection P04615525T0001 NN O
immunity P04615525T0001 NN O
in P04615525T0001 IN O
mice P04615525T0001 NN O
. P04615525T0001 . O
. . O O

These P09170159A0721 DT O
mutations P09170159A0721 NNS O
create P09170159A0721 VBP O
stop P09170159A0721 JJ O
codons P09170159A0721 NNS O
in P09170159A0721 IN O
exon P09170159A0721 JJ O
7 P09170159A0721 CD O
and P09170159A0721 CC O
8 P09170159A0721 CD O
, P09170159A0721 , O
respectively P09170159A0721 RB O
, P09170159A0721 , O
and P09170159A0721 CC O
probably P09170159A0721 RB O
result P09170159A0721 NN O
in P09170159A0721 IN O
truncated P09170159A0721 JJ O
proteins P09170159A0721 NNS O
lacking P09170159A0721 VBG O
HLH-Zip P09170159A0721 NNP O
or P09170159A0721 CC O
Zip P09170159A0721 NNP O
structure P09170159A0721 NN O
. P09170159A0721 . O
. . O O

In P08595012A0817 IN O
nondiabetics P08595012A0817 NNS O
the P08595012A0817 DT O
response P08595012A0817 NN O
of P08595012A0817 IN O
tcPO2 P08595012A0817 NN O
but P08595012A0817 CC O
not P08595012A0817 RB O
of P08595012A0817 IN O
LDF P08595012A0817 NNP O
was P08595012A0817 VBD O
influenced P08595012A0817 VBN O
by P08595012A0817 IN O
the P08595012A0817 DT O
values P08595012A0817 NNS O
at P08595012A0817 IN O
rest P08595012A0817 NN O
. P08595012A0817 . O
. . O O

Hantaan P02861238T0000 NNP O
virus P02861238T0000 NN O
. P02861238T0000 . O
. . O O

However P07576179A0781 RB O
, P07576179A0781 , O
a P07576179A0781 DT O
strongly P07576179A0781 RB O
increased P07576179A0781 JJ O
frequency P07576179A0781 NN O
of P07576179A0781 IN O
CpG P07576179A0781 NNP O
dinucleotides P07576179A0781 NNS O
was P07576179A0781 VBD O
found P07576179A0781 VBN O
. P07576179A0781 . O
. . O O

The P08412665A0000 DT O
scr P08412665A0000 NN I-UN
regulon P08412665A0000 NN I-UN
of P08412665A0000 IN O
pUR400 P08412665A0000 NN O
and P08412665A0000 CC O
the P08412665A0000 DT O
chromosomally P08412665A0000 RB I-UN
encoded P08412665A0000 VBN I-UN
scr P08412665A0000 NN I-UN
regulon P08412665A0000 NN I-UN
of P08412665A0000 IN I-UN
Klebsiella P08412665A0000 NNP I-UN
pneumoniae P08412665A0000 NN I-UN
KAY2026 P08412665A0000 NNP I-UN
are P08412665A0000 VBP O
both P08412665A0000 DT O
negatively P08412665A0000 RB O
controlled P08412665A0000 VBN O
by P08412665A0000 IN O
a P08412665A0000 DT O
specific P08412665A0000 JJ O
repressor P08412665A0000 NN O
( P08412665A0000 ( O
ScrR P08412665A0000 NNP I-UN
) P08412665A0000 ) O
. P08412665A0000 . O
. . O O

These P00509703A0581 DT O
differences P00509703A0581 NNS O
are P00509703A0581 VBP O
smaller P00509703A0581 JJR O
than P00509703A0581 IN O
those P00509703A0581 DT O
described P00509703A0581 VBN O
in P00509703A0581 IN O
standard P00509703A0581 JJ O
textbooks P00509703A0581 NNS O
. P00509703A0581 . O
. . O O

We P09328833A0588 PRP O
cloned P09328833A0588 VBD O
a P09328833A0588 DT O
complete P09328833A0588 JJ O
cDNA P09328833A0588 NN O
( P09328833A0588 ( O
2.9 P09328833A0588 CD O
kb P09328833A0588 NN O
) P09328833A0588 ) O
for P09328833A0588 IN O
HET P09328833A0588 NNP I-UN
from P09328833A0588 IN O
an P09328833A0588 DT O
MCF-7 P09328833A0588 JJ O
cDNA P09328833A0588 NN O
library P09328833A0588 NN O
. P09328833A0588 . O
. . O O

Pentane P00686836A0000 NNP O
and P00686836A0000 CC O
ethane P00686836A0000 NN O
, P00686836A0000 , O
which P00686836A0000 WDT O
arise P00686836A0000 VBP O
during P00686836A0000 IN O
lipid P00686836A0000 JJ O
peroxidation P00686836A0000 NN O
in P00686836A0000 IN O
vivo P00686836A0000 NN O
, P00686836A0000 , O
were P00686836A0000 VBD O
measured P00686836A0000 VBN O
by P00686836A0000 IN O
gas P00686836A0000 NN O
chromatography P00686836A0000 NN O
in P00686836A0000 IN O
breath P00686836A0000 NN O
samples P00686836A0000 NNS O
of P00686836A0000 IN O
rats P00686836A0000 NNS O
fed P00686836A0000 VBP O
for P00686836A0000 IN O
8 P00686836A0000 CD O
weeks P00686836A0000 NNS O
a P00686836A0000 DT O
vitamin P00686836A0000 JJ O
E-deficient P00686836A0000 JJ O
diet P00686836A0000 NN O
to P00686836A0000 TO O
which P00686836A0000 WDT O
had P00686836A0000 VBD O
been P00686836A0000 VBN O
added P00686836A0000 VBN O
0 P00686836A0000 CD O
, P00686836A0000 , O
11 P00686836A0000 CD O
, P00686836A0000 , O
or P00686836A0000 CC O
40 P00686836A0000 CD O
IU P00686836A0000 NNP O
vitamin P00686836A0000 NN O
E P00686836A0000 NNP O
acetate P00686836A0000 NN O
per P00686836A0000 IN O
kg P00686836A0000 NN O
. P00686836A0000 . O
. . O O

The P11266615A0258 DT O
protein P11266615A0258 NN O
is P11266615A0258 VBZ O
composed P11266615A0258 VBN O
of P11266615A0258 IN O
two P11266615A0258 CD O
major P11266615A0258 JJ O
domains P11266615A0258 NNS O
separated P11266615A0258 VBN O
by P11266615A0258 IN O
a P11266615A0258 DT O
hydrophobic P11266615A0258 JJ O
linker P11266615A0258 NN O
region P11266615A0258 NN O
of P11266615A0258 IN O
20 P11266615A0258 CD O
amino P11266615A0258 NN O
acid P11266615A0258 NN O
residues P11266615A0258 NNS O
. P11266615A0258 . O
. . O O

Applications P01938178T0000 NNS O
of P01938178T0000 IN O
three-dimensional P01938178T0000 JJ O
analysis P01938178T0000 NN O
to P01938178T0000 TO O
the P01938178T0000 DT O
auditory P01938178T0000 NN O
P300 P01938178T0000 NNP O
. P01938178T0000 . O
. . O O

Blood P11200568A0830 NN O
from P11200568A0830 IN O
dams P11200568A0830 NN O
was P11200568A0830 VBD O
collected P11200568A0830 VBN O
prior P11200568A0830 RB O
to P11200568A0830 TO O
inoculation P11200568A0830 NN O
and P11200568A0830 CC O
at P11200568A0830 IN O
time P11200568A0830 NN O
of P11200568A0830 IN O
necropsy P11200568A0830 NN O
for P11200568A0830 IN O
measurement P11200568A0830 NN O
of P11200568A0830 IN O
IgM P11200568A0830 NNP I-UN
and P11200568A0830 CC O
IgG P11200568A0830 NNP I-UN
antibodies P11200568A0830 NNS I-UN
to P11200568A0830 TO O
M. P11200568A0830 NNP O
pulmonis P11200568A0830 NN O
. P11200568A0830 . O
. . O O

Cells P09528768A0000 NNS O
respond P09528768A0000 NN O
to P09528768A0000 TO O
the P09528768A0000 DT O
accumulation P09528768A0000 NN O
of P09528768A0000 IN O
unfolded P09528768A0000 JJ O
proteins P09528768A0000 NNS O
in P09528768A0000 IN O
the P09528768A0000 DT O
endoplasmic P09528768A0000 JJ O
reticulum P09528768A0000 NN O
( P09528768A0000 ( O
ER P09528768A0000 NNP O
) P09528768A0000 ) O
by P09528768A0000 IN O
increasing P09528768A0000 VBG O
the P09528768A0000 DT O
transcription P09528768A0000 NN O
of P09528768A0000 IN O
the P09528768A0000 DT O
genes P09528768A0000 NNS O
encoding P09528768A0000 VBG O
ER-resident P09528768A0000 JJ I-UN
chaperone P09528768A0000 NN I-UN
proteins P09528768A0000 NNS I-UN
. P09528768A0000 . O
. . O O

Diminished P05437405T0000 VBN O
forearm P05437405T0000 NN O
arteriolar P05437405T0000 NN O
dilator P05437405T0000 NN O
capacity P05437405T0000 NN O
produced P05437405T0000 VBN O
by P05437405T0000 IN O
mineralocorticoid-induced P05437405T0000 JJ O
salt P05437405T0000 NN O
retention P05437405T0000 NN O
in P05437405T0000 IN O
man P05437405T0000 NN O
. P05437405T0000 . O
. . O O

Hematocrit P09635149A1148 NNP O
and P09635149A1148 CC O
PaO2 P09635149A1148 NNP O
did P09635149A1148 VBD O
not P09635149A1148 RB O
change P09635149A1148 NN O
. P09635149A1148 . O
. . O O

Heparin P08051102A0532 NNP O
had P08051102A0532 VBD O
no P08051102A0532 DT O
effect P08051102A0532 NN O
on P08051102A0532 IN O
rAC-st P08051102A0532 JJ I-UN
myosin P08051102A0532 NN I-UN
light P08051102A0532 NN I-UN
chain P08051102A0532 NN I-UN
phosphatase P08051102A0532 NN I-UN
activity P08051102A0532 NN O
, P08051102A0532 , O
while P08051102A0532 IN O
the P08051102A0532 DT O
B P08051102A0532 NNP O
subunit-containing P08051102A0532 NN O
forms P08051102A0532 NNS O
were P08051102A0532 VBD O
stimulated P08051102A0532 VBN O
2-3-fold P08051102A0532 JJ O
. P08051102A0532 . O
. . O O

For P07951410A0647 IN O
HeLa P07951410A0647 NNP O
, P07951410A0647 , O
293 P07951410A0647 CD O
, P07951410A0647 , O
U937 P07951410A0647 NNP O
, P07951410A0647 , O
and P07951410A0647 CC O
A549 P07951410A0647 NNP O
cells P07951410A0647 NNS O
, P07951410A0647 , O
participation P07951410A0647 NN O
of P07951410A0647 IN O
E2F-1 P07951410A0647 NNP I-UN
, P07951410A0647 , O
DP-1 P07951410A0647 NNP I-UN
, P07951410A0647 , O
cyclin P07951410A0647 VBZ I-UN
A P07951410A0647 NNP I-UN
, P07951410A0647 , O
and P07951410A0647 CC O
RB P07951410A0647 NNP I-UN
was P07951410A0647 VBD O
involved P07951410A0647 VBN O
in P07951410A0647 IN O
formation P07951410A0647 NN O
of P07951410A0647 IN O
some P07951410A0647 DT O
complexes P07951410A0647 NNS O
only P07951410A0647 RB O
, P07951410A0647 , O
assuming P07951410A0647 VBG O
participation P07951410A0647 NN O
of P07951410A0647 IN O
factors P07951410A0647 NNS O
different P07951410A0647 JJ O
from P07951410A0647 IN O
E2F-1 P07951410A0647 NNP I-UN
or P07951410A0647 CC O
DP-1 P07951410A0647 NNP I-UN
in P07951410A0647 IN O
others P07951410A0647 NNS O
. P07951410A0647 . O
. . O O

These P08248253A1785 DT O
combined P08248253A1785 VBN O
observations P08248253A1785 NNS O
define P08248253A1785 VBP O
a P08248253A1785 DT O
promoter P08248253A1785 NN O
and P08248253A1785 CC O
an P08248253A1785 DT O
enhancer P08248253A1785 NN O
for P08248253A1785 IN O
the P08248253A1785 DT O
chicken P08248253A1785 JJ I-UN
L-CAM P08248253A1785 JJ I-UN
gene P08248253A1785 NN I-UN
. P08248253A1785 . O
. . O O

Solution P09562558T0000 NN O
structure P09562558T0000 NN O
of P09562558T0000 IN O
the P09562558T0000 DT O
IRF-2 P09562558T0000 NNP I-UN
DNA-binding P09562558T0000 NNP I-UN
domain P09562558T0000 NN I-UN
: P09562558T0000 : O
a P09562558T0000 DT O
novel P09562558T0000 JJ O
subgroup P09562558T0000 NN O
of P09562558T0000 IN O
the P09562558T0000 DT O
winged P09562558T0000 JJ I-UN
helix-turn-helix P09562558T0000 JJ I-UN
family P09562558T0000 NN I-UN
. P09562558T0000 . O
. . O O

Levels P09454735A1782 NNS O
of P09454735A1782 IN O
the P09454735A1782 DT O
MEK P09454735A1782 NNP I-UN
inhibitor P09454735A1782 NN O
PD98059 P09454735A1782 NNP O
that P09454735A1782 IN O
block P09454735A1782 NN O
EGF-induced P09454735A1782 NNP O
mitogenesis P09454735A1782 NN O
and P09454735A1782 CC O
MAP P09454735A1782 NNP I-UN
kinase P09454735A1782 NNP I-UN
phosphorylation P09454735A1782 NN O
also P09454735A1782 RB O
abrogate P09454735A1782 JJ O
EGF-induced P09454735A1782 NNP O
focal P09454735A1782 JJ O
adhesion P09454735A1782 NN O
disassembly P09454735A1782 RB O
and P09454735A1782 CC O
cell P09454735A1782 NN O
motility P09454735A1782 NN O
. P09454735A1782 . O
. . O O

Previously P10628750A0298 RB O
, P10628750A0298 , O
we P10628750A0298 PRP O
showed P10628750A0298 VBD O
that P10628750A0298 IN O
the P10628750A0298 DT O
APRE P10628750A0298 NNP O
is P10628750A0298 VBZ O
a P10628750A0298 DT O
cytokine P10628750A0298 JJ O
[ P10628750A0298 JJ O
tumor P10628750A0298 NN I-UN
necrosis P10628750A0298 NN I-UN
factor-alpha P10628750A0298 NN I-UN
( P10628750A0298 ( O
TNFalpha P10628750A0298 NNP I-UN
) P10628750A0298 ) O
] P10628750A0298 SYM O
- P10628750A0298 : O
inducible P10628750A0298 JJ O
enhancer P10628750A0298 NN O
by P10628750A0298 IN O
binding P10628750A0298 VBG O
the P10628750A0298 DT O
heterodimeric P10628750A0298 JJ I-UN
nuclear P10628750A0298 JJ I-UN
factor-kappaB P10628750A0298 JJ I-UN
( P10628750A0298 ( O
NF-kappaB P10628750A0298 NNP I-UN
) P10628750A0298 ) O
complex P10628750A0298 VBP O
Rel P10628750A0298 NNP I-UN
A P10628750A0298 NNP I-UN
x P10628750A0298 NNP O
NF-kappaB1 P10628750A0298 NNP I-UN
. P10628750A0298 . O
. . O O

First P01779433A0694 RB O
, P01779433A0694 , O
the P01779433A0694 DT O
finding P01779433A0694 NN O
of P01779433A0694 IN O
a P01779433A0694 DT O
monomeric P01779433A0694 JJ O
Alu P01779433A0694 NNP I-UN
family P01779433A0694 NN O
repeat P01779433A0694 NN O
at P01779433A0694 IN O
the P01779433A0694 DT O
junction P01779433A0694 NN O
between P01779433A0694 IN O
nonhomology P01779433A0694 NN O
block P01779433A0694 NN O
I P01779433A0694 PRP O
and P01779433A0694 CC O
homology P01779433A0694 NN O
block P01779433A0694 NN O
Y P01779433A0694 NNP O
of P01779433A0694 IN O
the P01779433A0694 DT O
alpha P01779433A0694 JJ I-UN
2 P01779433A0694 CD I-UN
gene-containing P01779433A0694 JJ I-UN
unit P01779433A0694 NN I-UN
in P01779433A0694 IN I-UN
rhesus P01779433A0694 NN I-UN
macaque P01779433A0694 NN I-UN
suggests P01779433A0694 VBZ O
that P01779433A0694 IN O
the P01779433A0694 DT O
dimeric P01779433A0694 JJ O
Alu P01779433A0694 NNP I-UN
family P01779433A0694 NN O
repeat P01779433A0694 NN O
, P01779433A0694 , O
Alu P01779433A0694 NNP I-UN
3 P01779433A0694 CD I-UN
, P01779433A0694 , O
at P01779433A0694 IN O
the P01779433A0694 DT O
orthologous P01779433A0694 JJ O
position P01779433A0694 NN O
in P01779433A0694 IN O
human P01779433A0694 NN O
was P01779433A0694 VBD O
generated P01779433A0694 VBN O
by P01779433A0694 IN O
insertion P01779433A0694 NN O
of P01779433A0694 IN O
a P01779433A0694 DT O
monomeric P01779433A0694 JJ O
Alu P01779433A0694 NNP I-UN
family P01779433A0694 NN O
repeat P01779433A0694 NN O
into P01779433A0694 IN O
the P01779433A0694 DT O
3 P01779433A0694 CD O
' P01779433A0694 POS O
end P01779433A0694 NN O
of P01779433A0694 IN O
another P01779433A0694 DT O
preexisting P01779433A0694 VBG O
Alu P01779433A0694 NNP I-UN
family P01779433A0694 NN O
repeat P01779433A0694 NN O
. P01779433A0694 . O
. . O O

ArgR P09286981A0147 NNP I-UN
was P09286981A0147 VBD O
shown P09286981A0147 VBN O
to P09286981A0147 TO O
be P09286981A0147 VB O
a P09286981A0147 DT O
dimer P09286981A0147 NN O
of P09286981A0147 IN O
two P09286981A0147 CD O
equal P09286981A0147 JJ O
subunits P09286981A0147 NNS O
, P09286981A0147 , O
each P09286981A0147 DT O
with P09286981A0147 IN O
a P09286981A0147 DT O
molecular P09286981A0147 JJ O
mass P09286981A0147 NN O
of P09286981A0147 IN O
37,000 P09286981A0147 CD O
Da P09286981A0147 NNP O
. P09286981A0147 . O
. . O O

In P03381039A0364 IN O
contrast P03381039A0364 NN O
, P03381039A0364 , O
the P03381039A0364 DT O
MAN P03381039A0364 NNP O
showed P03381039A0364 VBD O
a P03381039A0364 DT O
unimodal P03381039A0364 JJ O
, P03381039A0364 , O
skewed P03381039A0364 JJ O
distribution P03381039A0364 NN O
, P03381039A0364 , O
with P03381039A0364 IN O
a P03381039A0364 DT O
range P03381039A0364 NN O
from P03381039A0364 IN O
approximately P03381039A0364 RB O
1 P03381039A0364 CD O
to P03381039A0364 TO O
14 P03381039A0364 CD O
micron P03381039A0364 NN O
and P03381039A0364 CC O
a P03381039A0364 DT O
maximum P03381039A0364 JJ O
at P03381039A0364 IN O
3-4 P03381039A0364 JJ O
micron P03381039A0364 NN O
. P03381039A0364 . O
. . O O

Cloning P11241672T0000 VBG O
and P11241672T0000 CC O
characterization P11241672T0000 NN O
of P11241672T0000 IN O
the P11241672T0000 DT O
murine P11241672T0000 NN I-UN
beta P11241672T0000 NN I-UN
( P11241672T0000 ( I-UN
3 P11241672T0000 CD I-UN
) P11241672T0000 ) I-UN
integrin P11241672T0000 NN I-UN
gene P11241672T0000 NN I-UN
promoter P11241672T0000 NN O
: P11241672T0000 : O
identification P11241672T0000 NN O
of P11241672T0000 IN O
an P11241672T0000 DT O
interleukin-4 P11241672T0000 JJ I-UN
responsive P11241672T0000 JJ I-UN
element P11241672T0000 NN I-UN
and P11241672T0000 CC O
regulation P11241672T0000 NN O
by P11241672T0000 IN O
STAT-6 P11241672T0000 NNP I-UN
. P11241672T0000 . O
. . O O

Using P06668316A0178 VBG O
a P06668316A0178 DT O
MOS-Hypersil P06668316A0178 JJ O
reversed-phase P06668316A0178 JJ O
column P06668316A0178 NN O
with P06668316A0178 IN O
a P06668316A0178 DT O
phosphate P06668316A0178 NN O
buffer P06668316A0178 NN O
-- P06668316A0178 : O
acetonitrile P06668316A0178 IN O
mobile P06668316A0178 JJ O
phase P06668316A0178 NN O
, P06668316A0178 , O
baseline P06668316A0178 JJ O
separation P06668316A0178 NN O
of P06668316A0178 IN O
antipyrine P06668316A0178 NN O
, P06668316A0178 , O
its P06668316A0178 PRP$ O
metabolites P06668316A0178 NNS O
3-hydroxymethylantipyrine P06668316A0178 JJ O
, P06668316A0178 , O
norantipyrine P06668316A0178 JJ O
and P06668316A0178 CC O
4-hydroxyantipyrine P06668316A0178 JJ O
, P06668316A0178 , O
and P06668316A0178 CC O
the P06668316A0178 DT O
internal P06668316A0178 JJ O
standard P06668316A0178 NN O
, P06668316A0178 , O
phenacetin P06668316A0178 NN O
, P06668316A0178 , O
was P06668316A0178 VBD O
achieved P06668316A0178 VBN O
within P06668316A0178 IN O
6 P06668316A0178 CD O
min P06668316A0178 NNS O
. P06668316A0178 . O
. . O O

Fluorescence P09551972A1033 NN O
in P09551972A1033 IN O
situ P09551972A1033 JJ O
hybridization P09551972A1033 NN O
of P09551972A1033 IN O
metaphase P09551972A1033 NN O
spreads P09551972A1033 NNS O
of P09551972A1033 IN O
chromosome P09551972A1033 NN O
8 P09551972A1033 CD O
, P09551972A1033 , O
containing P09551972A1033 VBG O
hybrid P09551972A1033 JJ O
cell P09551972A1033 NN O
line P09551972A1033 NN O
706-B6 P09551972A1033 JJ O
clone P09551972A1033 NN O
17 P09551972A1033 CD O
( P09551972A1033 ( O
CL-17 P09551972A1033 NNP O
) P09551972A1033 ) O
with P09551972A1033 IN O
cosmid P09551972A1033 NN O
c101F1 P09551972A1033 NN O
, P09551972A1033 , O
placed P09551972A1033 VBD O
the P09551972A1033 DT O
9804 P09551972A1033 CD I-UN
gene P09551972A1033 NN I-UN
close P09551972A1033 RB O
to P09551972A1033 TO O
the P09551972A1033 DT O
telomere P09551972A1033 NN O
at P09551972A1033 IN O
8q24.3 P09551972A1033 CD O
. P09551972A1033 . O
. . O O

The P09677330A0584 DT O
PDE4A-subfamily-specific P09677330A0584 JJ I-UN
linker P09677330A0584 NN I-UN
region P09677330A0584 NN I-UN
LR1 P09677330A0584 NNP O
, P09677330A0584 , O
which P09677330A0584 WDT O
joins P09677330A0584 VBZ O
UCR1 P09677330A0584 NNP O
and P09677330A0584 CC O
UCR2 P09677330A0584 NNP O
, P09677330A0584 , O
is P09677330A0584 VBZ O
encoded P09677330A0584 VBN O
by P09677330A0584 IN O
two P09677330A0584 CD O
exons P09677330A0584 NNS O
, P09677330A0584 , O
whereas P09677330A0584 NNS O
LR2 P09677330A0584 NNP O
, P09677330A0584 , O
which P09677330A0584 WDT O
joins P09677330A0584 VBZ O
UCR2 P09677330A0584 NNP O
to P09677330A0584 TO O
the P09677330A0584 DT O
catalytic P09677330A0584 JJ O
unit P09677330A0584 NN O
, P09677330A0584 , O
is P09677330A0584 VBZ O
encoded P09677330A0584 VBN O
by P09677330A0584 IN O
a P09677330A0584 DT O
single P09677330A0584 JJ O
exon P09677330A0584 NN O
. P09677330A0584 . O
. . O O

Mechanism P09811730T0000 NN O
of P09811730T0000 IN O
interferon P09811730T0000 JJ I-UN
action P09811730T0000 NN O
: P09811730T0000 : O
identification P09811730T0000 NN O
of P09811730T0000 IN O
essential P09811730T0000 JJ O
positions P09811730T0000 NNS O
within P09811730T0000 IN O
the P09811730T0000 DT O
novel P09811730T0000 JJ O
15-base-pair P09811730T0000 JJ I-UN
KCS P09811730T0000 NNP I-UN
element P09811730T0000 NN I-UN
required P09811730T0000 VBN O
for P09811730T0000 IN O
transcriptional P09811730T0000 JJ O
activation P09811730T0000 NN O
of P09811730T0000 IN O
the P09811730T0000 DT O
RNA-dependent P09811730T0000 JJ I-UN
protein P09811730T0000 NN I-UN
kinase P09811730T0000 NN I-UN
pkr P09811730T0000 JJ I-UN
gene P09811730T0000 NN I-UN
. P09811730T0000 . O
. . O O

The P09872832A1262 DT O
BAL P09872832A1262 NNP O
concentrations P09872832A1262 NNS O
of P09872832A1262 IN O
the P09872832A1262 DT O
nine P09872832A1262 CD O
cytokines P09872832A1262 NNS O
evaluated P09872832A1262 VBN O
for P09872832A1262 IN O
the P09872832A1262 DT O
more P09872832A1262 JJR O
and P09872832A1262 CC O
less P09872832A1262 RBR O
affected P09872832A1262 JJ O
lungs P09872832A1262 NNS O
were P09872832A1262 VBD O
compared P09872832A1262 VBN O
: P09872832A1262 : O
interleukin-6 P09872832A1262 JJ I-UN
( P09872832A1262 ( O
IL-6 P09872832A1262 NNP I-UN
) P09872832A1262 ) O
, P09872832A1262 , O
IL-8 P09872832A1262 NNP I-UN
, P09872832A1262 , O
IL-12 P09872832A1262 NNP I-UN
, P09872832A1262 , O
tumor P09872832A1262 NN I-UN
necrosis P09872832A1262 NN I-UN
factor-alpha P09872832A1262 JJ I-UN
( P09872832A1262 ( O
TNF-alpha P09872832A1262 NNP I-UN
) P09872832A1262 ) O
, P09872832A1262 , O
and P09872832A1262 CC O
interferon P09872832A1262 VB I-UN
gamma P09872832A1262 NN I-UN
( P09872832A1262 ( O
IFN-gamma P09872832A1262 NNP I-UN
) P09872832A1262 ) O
showed P09872832A1262 VBD O
significant P09872832A1262 JJ O
differences P09872832A1262 NNS O
( P09872832A1262 ( O
p P09872832A1262 VB O
ranged P09872832A1262 VBN O
between P09872832A1262 IN O
0 P09872832A1262 CD O
. P09872832A1262 . O
. . O O

Evidence P03774111T0000 NN O
that P03774111T0000 IN O
opiate P03774111T0000 JJ O
addiction P03774111T0000 NN O
is P03774111T0000 VBZ O
in P03774111T0000 IN O
part P03774111T0000 NN O
an P03774111T0000 DT O
immune P03774111T0000 JJ O
response P03774111T0000 NN O
. P03774111T0000 . O
. . O O

Two P09609720A0357 CD O
protease-resistant P09609720A0357 JJ O
fragments P09609720A0357 NNS O
spanning P09609720A0357 VBG O
the P09609720A0357 DT O
N- P09609720A0357 JJ O
and P09609720A0357 CC O
C-terminal P09609720A0357 JJ O
halves P09609720A0357 NNS O
of P09609720A0357 IN O
the P09609720A0357 DT O
nuclease P09609720A0357 NN O
were P09609720A0357 VBD O
identified P09609720A0357 VBN O
using P09609720A0357 VBG O
different P09609720A0357 JJ O
proteases P09609720A0357 NNS O
which P09609720A0357 WDT O
cleave P09609720A0357 VBP O
the P09609720A0357 DT O
protein P09609720A0357 NN O
in P09609720A0357 IN O
the P09609720A0357 DT O
same P09609720A0357 JJ O
region P09609720A0357 NN O
. P09609720A0357 . O
. . O O

Fast P03758250A0000 RB O
goal-directed P03758250A0000 JJ O
voluntary P03758250A0000 JJ O
movements P03758250A0000 NNS O
of P03758250A0000 IN O
the P03758250A0000 DT O
human P03758250A0000 JJ O
upper P03758250A0000 JJ O
extremity P03758250A0000 NN O
are P03758250A0000 VBP O
known P03758250A0000 VBN O
to P03758250A0000 TO O
be P03758250A0000 VB O
associated P03758250A0000 VBN O
with P03758250A0000 IN O
three P03758250A0000 CD O
distinct P03758250A0000 JJ O
bursts P03758250A0000 NNS O
of P03758250A0000 IN O
EMG P03758250A0000 NNP O
activity P03758250A0000 NN O
in P03758250A0000 IN O
antagonistic P03758250A0000 JJ O
muscles P03758250A0000 NNS O
. P03758250A0000 . O
. . O O

Plastic P04871589T0001 JJ O
solution P04871589T0001 NN O
of P04871589T0001 IN O
elbow P04871589T0001 JJ O
joint P04871589T0001 JJ O
ankylosis P04871589T0001 NN O
with P04871589T0001 IN O
a P04871589T0001 DT O
decorticated P04871589T0001 JJ O
cylindrical P04871589T0001 JJ O
flap P04871589T0001 NN O
. P04871589T0001 . O
. . O O

U24 P08721999A0727 NNP I-UN
has P08721999A0727 VBZ O
two P08721999A0727 CD O
separate P08721999A0727 JJ O
12 P08721999A0727 CD O
nt P08721999A0727 RB O
long P08721999A0727 JJ O
complementarities P08721999A0727 NNS O
to P08721999A0727 TO O
a P08721999A0727 DT O
highly P08721999A0727 RB O
conserved P08721999A0727 VBN O
tract P08721999A0727 NN O
of P08721999A0727 IN O
28S P08721999A0727 CD I-UN
rRNA P08721999A0727 NN I-UN
. P08721999A0727 . O
. . O O

We P08849778A0226 PRP O
have P08849778A0226 VBP O
performed P08849778A0226 VBN O
toeprinting P08849778A0226 JJ O
analyses P08849778A0226 NNS O
on P08849778A0226 IN O
repA P08849778A0226 NN I-UN
mRNA P08849778A0226 NN I-UN
of P08849778A0226 IN O
plasmid P08849778A0226 NN O
R1 P08849778A0226 NNP O
, P08849778A0226 , O
both P08849778A0226 DT O
free P08849778A0226 JJ O
and P08849778A0226 CC O
in P08849778A0226 IN O
duplex P08849778A0226 NN O
with P08849778A0226 IN O
the P08849778A0226 DT O
antisense P08849778A0226 NN O
RNA P08849778A0226 NNP O
, P08849778A0226 , O
CopA P08849778A0226 NNP I-UN
. P08849778A0226 . O
. . O O

The P03563604A1075 DT O
spleen P03563604A1075 JJ O
rate P03563604A1075 NN O
of P03563604A1075 IN O
about P03563604A1075 IN O
600 P03563604A1075 CD O
villagers P03563604A1075 NNS O
of P03563604A1075 IN O
RK P03563604A1075 NNP O
I P03563604A1075 PRP O
examined P03563604A1075 VBD O
was P03563604A1075 VBD O
54.3 P03563604A1075 CD O
% P03563604A1075 NN O
and P03563604A1075 CC O
the P03563604A1075 DT O
parasite P03563604A1075 JJ O
rate P03563604A1075 NN O
13.2 P03563604A1075 CD O
% P03563604A1075 NN O
before P03563604A1075 IN O
the P03563604A1075 DT O
drug P03563604A1075 NN O
intervention P03563604A1075 NN O
. P03563604A1075 . O
. . O O

The P02253663A0687 DT O
circadian P02253663A0687 JJ O
rhythm P02253663A0687 NN O
, P02253663A0687 , O
however P02253663A0687 RB O
, P02253663A0687 , O
was P02253663A0687 VBD O
not P02253663A0687 RB O
affected P02253663A0687 VBN O
and P02253663A0687 CC O
the P02253663A0687 DT O
difference P02253663A0687 NN O
between P02253663A0687 IN O
minimum P02253663A0687 NN O
( P02253663A0687 ( O
12.00 P02253663A0687 CD O
h P02253663A0687 NN O
) P02253663A0687 ) O
and P02253663A0687 CC O
maximum P02253663A0687 JJ O
( P02253663A0687 ( O
18.50 P02253663A0687 CD O
h P02253663A0687 NN O
) P02253663A0687 ) O
serum P02253663A0687 NN O
concentrations P02253663A0687 NNS O
was P02253663A0687 VBD O
31.3 P02253663A0687 CD O
% P02253663A0687 NN O
. P02253663A0687 . O
. . O O

Cytohesin-1 P09050849A0000 NNP I-UN
, P09050849A0000 , O
a P09050849A0000 DT O
protein P09050849A0000 NN O
abundant P09050849A0000 NN O
in P09050849A0000 IN O
cells P09050849A0000 NNS O
of P09050849A0000 IN O
the P09050849A0000 DT O
immune P09050849A0000 NN O
system P09050849A0000 NN O
, P09050849A0000 , O
has P09050849A0000 VBZ O
been P09050849A0000 VBN O
proposed P09050849A0000 VBN O
to P09050849A0000 TO O
be P09050849A0000 VB O
a P09050849A0000 DT O
human P09050849A0000 JJ O
homolog P09050849A0000 NN O
of P09050849A0000 IN O
the P09050849A0000 DT O
Saccharomyces P09050849A0000 NNP I-UN
cerevisiae P09050849A0000 NN I-UN
Sec7 P09050849A0000 NNP I-UN
gene P09050849A0000 NN I-UN
product P09050849A0000 NN I-UN
, P09050849A0000 , O
which P09050849A0000 WDT O
is P09050849A0000 VBZ O
crucial P09050849A0000 JJ O
in P09050849A0000 IN O
protein P09050849A0000 JJ O
transport P09050849A0000 NN O
. P09050849A0000 . O
. . O O

Modification P07154928T0001 NN O
of P07154928T0001 IN O
enteral P07154928T0001 JJ O
resorption P07154928T0001 NN O
by P07154928T0001 IN O
cytostatic P07154928T0001 JJ O
therapy P07154928T0001 NN O
. P07154928T0001 . O
. . O O

Complexes P09020172A0964 NNS O
of P09020172A0964 IN O
qTBP42 P09020172A0964 NN I-UN
with P09020172A0964 IN O
each P09020172A0964 DT O
complementary P09020172A0964 JJ O
strand P09020172A0964 NN O
of P09020172A0964 IN O
telomeric P09020172A0964 JJ O
DNA P09020172A0964 NNP O
and P09020172A0964 CC O
with P09020172A0964 IN O
quadruplex P09020172A0964 JJ O
forms P09020172A0964 NNS O
of P09020172A0964 IN O
the P09020172A0964 DT O
guanine-rich P09020172A0964 JJ O
strand P09020172A0964 NN O
had P09020172A0964 VBD O
3.7-14.6 P09020172A0964 JJ O
nM P09020172A0964 JJ O
dissociation P09020172A0964 NN O
constants P09020172A0964 NNS O
, P09020172A0964 , O
Kd P09020172A0964 NNP O
, P09020172A0964 , O
whereas P09020172A0964 IN O
complexes P09020172A0964 NNS O
with P09020172A0964 IN O
double-stranded P09020172A0964 JJ O
telomeric P09020172A0964 JJ O
DNA P09020172A0964 NN O
had P09020172A0964 VBD O
up P09020172A0964 RP O
to P09020172A0964 TO O
100-fold P09020172A0964 JJ O
higher P09020172A0964 JJR O
Kd P09020172A0964 NNP O
values P09020172A0964 NNS O
. P09020172A0964 . O
. . O O

Since P09827878A0091 IN O
glutathione P09827878A0091 NN I-UN
peroxidase P09827878A0091 NN I-UN
( P09827878A0091 ( O
GPX P09827878A0091 NNP I-UN
) P09827878A0091 ) O
and P09827878A0091 CC O
superoxide P09827878A0091 JJ I-UN
dismutase P09827878A0091 NN I-UN
( P09827878A0091 ( O
SOD P09827878A0091 NNP I-UN
) P09827878A0091 ) O
play P09827878A0091 VBP O
a P09827878A0091 DT O
significant P09827878A0091 JJ O
role P09827878A0091 NN O
in P09827878A0091 IN O
erythrocyte P09827878A0091 JJ O
antioxidative P09827878A0091 JJ O
defence P09827878A0091 NN O
, P09827878A0091 , O
it P09827878A0091 PRP O
is P09827878A0091 VBZ O
very P09827878A0091 RB O
important P09827878A0091 JJ O
to P09827878A0091 TO O
determine P09827878A0091 VB O
their P09827878A0091 PRP$ O
activity P09827878A0091 NN O
in P09827878A0091 IN O
occupationally P09827878A0091 RB O
exposed P09827878A0091 JJ O
workers P09827878A0091 NNS O
. P09827878A0091 . O
. . O O

The P01313909A0526 DT O
phenotypes P01313909A0526 NNS O
of P01313909A0526 IN O
the P01313909A0526 DT O
ICP0 P01313909A0526 NNP I-UN
nonsense P01313909A0526 NN O
mutants P01313909A0526 NNS O
were P01313909A0526 VBD O
intermediate P01313909A0526 JJ O
between P01313909A0526 IN O
those P01313909A0526 DT O
of P01313909A0526 IN O
the P01313909A0526 DT O
wild-type P01313909A0526 JJ O
virus P01313909A0526 NN O
and P01313909A0526 CC O
7134 P01313909A0526 CD O
in P01313909A0526 IN O
that P01313909A0526 DT O
the P01313909A0526 DT O
more P01313909A0526 JJR O
ICP0-coding P01313909A0526 JJ I-UN
sequence P01313909A0526 NN I-UN
expressed P01313909A0526 VBN O
by P01313909A0526 IN O
a P01313909A0526 DT O
given P01313909A0526 VBN O
nonsense P01313909A0526 NN O
mutant P01313909A0526 NN O
, P01313909A0526 , O
the P01313909A0526 DT O
more P01313909A0526 JJR O
wild P01313909A0526 JJ O
type-like P01313909A0526 NN O
was P01313909A0526 VBD O
its P01313909A0526 PRP$ O
phenotype P01313909A0526 NN O
. P01313909A0526 . O
. . O O

The P08576131A0685 DT O
preferential P08576131A0685 JJ O
heterodimerization P08576131A0685 NN O
of P08576131A0685 IN O
USF P08576131A0685 NNP I-UN
subunits P08576131A0685 NNS I-UN
was P08576131A0685 VBD O
reproduced P08576131A0685 VBN O
ex P08576131A0685 JJ O
vivo P08576131A0685 NNS O
, P08576131A0685 , O
while P08576131A0685 IN O
the P08576131A0685 DT O
in P08576131A0685 IN O
vitro P08576131A0685 NNP O
association P08576131A0685 NN O
of P08576131A0685 IN O
cotranslated P08576131A0685 JJ O
subunits P08576131A0685 NNS O
, P08576131A0685 , O
or P08576131A0685 CC O
recombinant P08576131A0685 JJ I-UN
USF P08576131A0685 NNP I-UN
proteins P08576131A0685 NNS I-UN
, P08576131A0685 , O
appeared P08576131A0685 VBD O
to P08576131A0685 TO O
be P08576131A0685 VB O
random P08576131A0685 JJ O
. P08576131A0685 . O
. . O O

The P08597596A0135 DT O
gene P08597596A0135 NN O
encodes P08597596A0135 VBZ O
an P08597596A0135 DT O
ATP-binding P08597596A0135 JJ I-UN
cassette P08597596A0135 NN I-UN
, P08597596A0135 , O
ABC P08597596A0135 NNP I-UN
transporter P08597596A0135 NN I-UN
. P08597596A0135 . O
. . O O

Distribution P01470741T0062 NN O
and P01470741T0062 CC O
changing P01470741T0062 VBG O
morphological P01470741T0062 JJ O
course P01470741T0062 NN O
. P01470741T0062 . O
. . O O

Intravenous P11325685A1624 JJ O
L-carnitine P11325685A1624 JJ O
treatment P11325685A1624 NN O
increased P11325685A1624 VBD O
plasma P11325685A1624 JJ O
carnitine P11325685A1624 NN O
concentrations P11325685A1624 NNS O
, P11325685A1624 , O
improved P11325685A1624 VBN O
patient-assessed P11325685A1624 JJ O
fatigue P11325685A1624 NN O
, P11325685A1624 , O
and P11325685A1624 CC O
may P11325685A1624 MD O
prevent P11325685A1624 VB O
the P11325685A1624 DT O
decline P11325685A1624 NN O
in P11325685A1624 IN O
peak P11325685A1624 JJ O
exercise P11325685A1624 NN O
capacity P11325685A1624 NN O
in P11325685A1624 IN O
hemodialysis P11325685A1624 NN O
patients P11325685A1624 NNS O
. P11325685A1624 . O
. . O O

Postnatal P04086657T0000 JJ O
volumetric P04086657T0000 JJ O
development P04086657T0000 NN O
of P04086657T0000 IN O
the P04086657T0000 DT O
prefrontal P04086657T0000 JJ O
cortex P04086657T0000 NN O
in P04086657T0000 IN O
the P04086657T0000 DT O
rat P04086657T0000 NN O
. P04086657T0000 . O
. . O O

The P08439564A0883 DT O
amino P08439564A0883 NN O
acid P08439564A0883 JJ O
sequence P08439564A0883 NN O
alignment P08439564A0883 NN O
of P08439564A0883 IN O
TC P08439564A0883 NNP I-UN
II P08439564A0883 NNP I-UN
with P08439564A0883 IN O
that P08439564A0883 DT O
of P08439564A0883 IN O
other P08439564A0883 JJ O
Cbl P08439564A0883 NNP I-UN
binding P08439564A0883 NN I-UN
proteins P08439564A0883 NNS I-UN
( P08439564A0883 ( O
rat P08439564A0883 VB I-UN
intrinsic P08439564A0883 JJ I-UN
factor P08439564A0883 NN I-UN
, P08439564A0883 , O
human P08439564A0883 JJ I-UN
transcobalamin P08439564A0883 NN I-UN
I P08439564A0883 PRP I-UN
and P08439564A0883 CC O
porcine P08439564A0883 VB I-UN
haptocorrin P08439564A0883 NN I-UN
) P08439564A0883 ) O
revealed P08439564A0883 VBD O
only P08439564A0883 RB O
33 P08439564A0883 CD O
% P08439564A0883 NN O
overall P08439564A0883 JJ O
homology P08439564A0883 NN O
. P08439564A0883 . O
. . O O

CXC P08550564T0000 NNP O
chemokines P08550564T0000 NNS O
bind P08550564T0000 NN O
to P08550564T0000 TO O
unique P08550564T0000 JJ O
sets P08550564T0000 NNS O
of P08550564T0000 IN O
selectivity P08550564T0000 NN O
determinants P08550564T0000 NNS O
that P08550564T0000 WDT O
can P08550564T0000 MD O
function P08550564T0000 VB O
independently P08550564T0000 RB O
and P08550564T0000 CC O
are P08550564T0000 VBP O
broadly P08550564T0000 RB O
distributed P08550564T0000 VBN O
on P08550564T0000 IN O
multiple P08550564T0000 JJ O
domains P08550564T0000 NNS O
of P08550564T0000 IN O
human P08550564T0000 JJ O
interleukin-8 P08550564T0000 JJ I-UN
receptor P08550564T0000 NN I-UN
B P08550564T0000 NNP I-UN
. P08550564T0000 . O
. . O O

In P07109788A0333 IN O
concept P07109788A0333 NN O
II P07109788A0333 NNP O
62 P07109788A0333 CD O
patients P07109788A0333 NNS O
were P07109788A0333 VBD O
treated P07109788A0333 VBN O
with P07109788A0333 IN O
selective P07109788A0333 JJ O
vagotomy P07109788A0333 NN O
and P07109788A0333 CC O
pyloroplasty P07109788A0333 NN O
. P07109788A0333 . O
. . O O

Possible P03249792A0241 JJ O
factors P03249792A0241 NNS O
for P03249792A0241 IN O
the P03249792A0241 DT O
development P03249792A0241 NN O
of P03249792A0241 IN O
psychotic P03249792A0241 JJ O
symptomatology P03249792A0241 NN O
during P03249792A0241 IN O
group P03249792A0241 NN O
activities P03249792A0241 NNS O
and P03249792A0241 CC O
the P03249792A0241 DT O
role P03249792A0241 NN O
of P03249792A0241 IN O
group P03249792A0241 NN O
dynamics P03249792A0241 NNS O
acting P03249792A0241 VBG O
as P03249792A0241 IN O
stress P03249792A0241 JJ O
factors P03249792A0241 NNS O
precipitating P03249792A0241 VBG O
functional P03249792A0241 JJ O
psychoses P03249792A0241 NNS O
, P03249792A0241 , O
especially P03249792A0241 RB O
bipolar P03249792A0241 JJ O
manifestations P03249792A0241 NNS O
, P03249792A0241 , O
are P03249792A0241 VBP O
discussed P03249792A0241 VBN O
. P03249792A0241 . O
. . O O

Endocytosis P07876194T0000 NN O
and P07876194T0000 CC O
lysosomal P07876194T0000 JJ O
targeting P07876194T0000 NN O
of P07876194T0000 IN O
epidermal P07876194T0000 JJ I-UN
growth P07876194T0000 NN I-UN
factor P07876194T0000 NN I-UN
receptors P07876194T0000 NNS I-UN
are P07876194T0000 VBP O
mediated P07876194T0000 VBN O
by P07876194T0000 IN O
distinct P07876194T0000 JJ O
sequences P07876194T0000 NNS O
independent P07876194T0000 JJ O
of P07876194T0000 IN O
the P07876194T0000 DT O
tyrosine P07876194T0000 JJ I-UN
kinase P07876194T0000 NN I-UN
domain P07876194T0000 NN I-UN
. P07876194T0000 . O
. . O O

The P09009208A0337 DT O
primer P09009208A0337 NN O
is P09009208A0337 VBZ O
generated P09009208A0337 VBN O
by P09009208A0337 IN O
a P09009208A0337 DT O
cleavage P09009208A0337 NN O
that P09009208A0337 WDT O
occurs P09009208A0337 VBZ O
between P09009208A0337 IN O
bases P09009208A0337 NNS O
11 P09009208A0337 CD O
and P09009208A0337 CC O
12 P09009208A0337 CD O
of P09009208A0337 IN O
the P09009208A0337 DT O
Tf1 P09009208A0337 NNP I-UN
mRNA P09009208A0337 NN I-UN
. P09009208A0337 . O
. . O O

CTF1alpha P09139694A0789 NNP I-UN
, P09139694A0789 , O
expressed P09139694A0789 VBD O
in P09139694A0789 IN O
Escherichia P09139694A0789 NNP O
coli P09139694A0789 NN O
, P09139694A0789 , O
showed P09139694A0789 VBD O
specific P09139694A0789 JJ O
binding P09139694A0789 VBG O
to P09139694A0789 TO O
the P09139694A0789 DT O
palindrome P09139694A0789 NN O
2 P09139694A0789 CD O
DNA P09139694A0789 NNP O
fragment P09139694A0789 NN O
but P09139694A0789 CC O
not P09139694A0789 RB O
to P09139694A0789 TO O
palindrome P09139694A0789 VB O
1 P09139694A0789 CD O
or P09139694A0789 CC O
mutant P09139694A0789 JJ O
palindrome P09139694A0789 JJ O
2 P09139694A0789 CD O
DNA P09139694A0789 NN O
fragments P09139694A0789 NNS O
, P09139694A0789 , O
suggesting P09139694A0789 VBG O
specific P09139694A0789 JJ O
binding P09139694A0789 NN O
of P09139694A0789 IN O
CTF1alpha P09139694A0789 NNP I-UN
to P09139694A0789 TO O
palindrome P09139694A0789 VB O
2 P09139694A0789 CD O
. P09139694A0789 . O
. . O O

TG-day P07944461A0321 JJ O
and P07944461A0321 CC O
TG-night P07944461A0321 NNP O
were P07944461A0321 VBD O
19.4 P07944461A0321 CD O
+ P07944461A0321 NNP O
/ P07944461A0321 NNP O
- P07944461A0321 : O
6.1 P07944461A0321 CD O
% P07944461A0321 NN O
, P07944461A0321 , O
26.6 P07944461A0321 CD O
+ P07944461A0321 NN O
/ P07944461A0321 NNP O
- P07944461A0321 : O
5.3 P07944461A0321 CD O
% P07944461A0321 NN O
, P07944461A0321 , O
( P07944461A0321 ( O
750 P07944461A0321 CD O
mm3 P07944461A0321 NN O
< P07944461A0321 NNP O
T P07944461A0321 NNP O
. P07944461A0321 . O
. . O O

Specimen P11295760A1374 NNP O
mass P11295760A1374 NN O
reduction P11295760A1374 NN O
increased P11295760A1374 VBD O
with P11295760A1374 IN O
irradiance P11295760A1374 NN O
from P11295760A1374 IN O
19 P11295760A1374 CD O
to P11295760A1374 TO O
72 P11295760A1374 CD O
% P11295760A1374 NN O
of P11295760A1374 IN O
the P11295760A1374 DT O
initial P11295760A1374 JJ O
mass P11295760A1374 NN O
for P11295760A1374 IN O
9 P11295760A1374 CD O
-- P11295760A1374 : O
31 P11295760A1374 CD O
W P11295760A1374 NNP O
/ P11295760A1374 NNP O
cm P11295760A1374 NN O
( P11295760A1374 ( O
2 P11295760A1374 CD O
) P11295760A1374 ) O
, P11295760A1374 , O
respectively P11295760A1374 RB O
. P11295760A1374 . O
. . O O

Lack P09323612A0374 NN O
of P09323612A0374 IN O
controlled P09323612A0374 JJ O
prospective P09323612A0374 JJ O
studies P09323612A0374 NNS O
of P09323612A0374 IN O
sleep P09323612A0374 JJ O
electroencephalograms P09323612A0374 NNS O
( P09323612A0374 ( O
EEG P09323612A0374 NNP O
) P09323612A0374 ) O
, P09323612A0374 , O
and P09323612A0374 CC O
the P09323612A0374 DT O
use P09323612A0374 NN O
of P09323612A0374 IN O
medication P09323612A0374 NN O
, P09323612A0374 , O
in P09323612A0374 IN O
children P09323612A0374 NNS O
with P09323612A0374 IN O
developmental P09323612A0374 JJ O
dysphasia P09323612A0374 NN O
, P09323612A0374 , O
may P09323612A0374 MD O
deny P09323612A0374 VB O
appropriate P09323612A0374 JJ O
treatment P09323612A0374 NN O
strategies P09323612A0374 NNS O
to P09323612A0374 TO O
children P09323612A0374 NNS O
with P09323612A0374 IN O
severe P09323612A0374 JJ O
developmental P09323612A0374 JJ O
speech P09323612A0374 NN O
and P09323612A0374 CC O
language P09323612A0374 NN O
disorders P09323612A0374 NNS O
. P09323612A0374 . O
. . O O

The P03965012A0163 DT O
results P03965012A0163 NNS O
from P03965012A0163 IN O
the P03965012A0163 DT O
first P03965012A0163 JJ O
five P03965012A0163 CD O
years P03965012A0163 NNS O
of P03965012A0163 IN O
follow P03965012A0163 VBP O
up P03965012A0163 RP O
in P03965012A0163 IN O
1972 P03965012A0163 CD O
showed P03965012A0163 VBD O
a P03965012A0163 DT O
4.7-fold P03965012A0163 JJ O
excess P03965012A0163 JJ O
mortality P03965012A0163 NN O
for P03965012A0163 IN O
ischaemic P03965012A0163 JJ O
and P03965012A0163 CC O
other P03965012A0163 JJ O
heart P03965012A0163 NN O
diseases P03965012A0163 NNS O
( P03965012A0163 ( O
ICD P03965012A0163 NNP O
A83-A84 P03965012A0163 NNP O
) P03965012A0163 ) O
compared P03965012A0163 VBN O
with P03965012A0163 IN O
a P03965012A0163 DT O
comparable P03965012A0163 JJ O
reference P03965012A0163 NN O
cohort P03965012A0163 NN O
of P03965012A0163 IN O
paper P03965012A0163 NN O
mill P03965012A0163 NN O
workers P03965012A0163 NNS O
. P03965012A0163 . O
. . O O

Unusual P11281268A0000 JJ O
two-domain P11281268A0000 JJ I-UN
arginine P11281268A0000 NN I-UN
kinases P11281268A0000 NNS I-UN
( P11281268A0000 ( O
AKs P11281268A0000 NNP I-UN
) P11281268A0000 ) O
arose P11281268A0000 VBD O
independently P11281268A0000 RB O
at P11281268A0000 IN O
least P11281268A0000 JJS O
two P11281268A0000 CD O
times P11281268A0000 NNS O
during P11281268A0000 IN O
molecular P11281268A0000 JJ O
evolution P11281268A0000 NN O
of P11281268A0000 IN O
phosphagen P11281268A0000 NN I-UN
kinases P11281268A0000 NNS I-UN
: P11281268A0000 : O
AKs P11281268A0000 NN I-UN
from P11281268A0000 IN O
the P11281268A0000 DT O
primitive P11281268A0000 JJ O
sea P11281268A0000 NN O
anemone P11281268A0000 NN O
Anthopleurura P11281268A0000 NNP O
japonicus P11281268A0000 NN O
and P11281268A0000 CC O
from P11281268A0000 IN O
the P11281268A0000 DT O
clam P11281268A0000 NN O
Pseudocardium P11281268A0000 NNP O
sachalinensis P11281268A0000 NN O
. P11281268A0000 . O
. . O O

Transfection P10727433A0560 NN O
with P10727433A0560 IN O
a P10727433A0560 DT O
CSF-1R P10727433A0560 JJ I-UN
expression P10727433A0560 NN O
plasmid P10727433A0560 NN O
permitted P10727433A0560 VBD O
CSF-1-dependent P10727433A0560 JJ O
activation P10727433A0560 NN O
of P10727433A0560 IN O
the P10727433A0560 DT O
signalling P10727433A0560 VBG O
pathway P10727433A0560 NN O
targeting P10727433A0560 VBG O
an P10727433A0560 DT O
Ets P10727433A0560 NNP I-UN
/ P10727433A0560 NNP O
AP1 P10727433A0560 NNP I-UN
( P10727433A0560 ( O
activator P10727433A0560 NN I-UN
protein P10727433A0560 RB I-UN
1 P10727433A0560 CD I-UN
) P10727433A0560 ) O
element P10727433A0560 NN O
in P10727433A0560 IN O
the P10727433A0560 DT O
uPA P10727433A0560 JJ I-UN
promoter P10727433A0560 NN I-UN
that P10727433A0560 WDT O
has P10727433A0560 VBZ O
been P10727433A0560 VBN O
shown P10727433A0560 VBN O
previously P10727433A0560 RB O
to P10727433A0560 TO O
be P10727433A0560 VB O
a P10727433A0560 DT O
target P10727433A0560 NN O
of P10727433A0560 IN O
oncogenic P10727433A0560 JJ I-UN
ras P10727433A0560 NNS I-UN
and P10727433A0560 CC O
protein P10727433A0560 JJ O
kinase P10727433A0560 NN O
C P10727433A0560 NNP O
pathways P10727433A0560 NNS O
. P10727433A0560 . O
. . O O

RUSH-1 P08923460A0565 JJ I-UN
beta P08923460A0565 NN I-UN
is P08923460A0565 VBZ O
a P08923460A0565 DT O
95-kDa P08923460A0565 JJ O
truncated P08923460A0565 JJ O
version P08923460A0565 NN O
of P08923460A0565 IN O
RUSH-1 P08923460A0565 NNP I-UN
alpha P08923460A0565 NN I-UN
that P08923460A0565 WDT O
results P08923460A0565 NNS O
from P08923460A0565 IN O
alternative P08923460A0565 JJ O
splicing P08923460A0565 NN O
of P08923460A0565 IN O
a P08923460A0565 DT O
57-bp P08923460A0565 JJ O
exon P08923460A0565 NN O
as P08923460A0565 IN O
confirmed P08923460A0565 VBN O
by P08923460A0565 IN O
genomic P08923460A0565 JJ O
cloning P08923460A0565 NN O
. P08923460A0565 . O
. . O O

The P02357537A0451 DT O
effects P02357537A0451 NNS O
on P02357537A0451 IN O
reflex P02357537A0451 JJ O
latencies P02357537A0451 NNS O
but P02357537A0451 CC O
not P02357537A0451 RB O
on P02357537A0451 IN O
paCO2 P02357537A0451 NN O
or P02357537A0451 CC O
pHa P02357537A0451 NN O
were P02357537A0451 VBD O
blocked P02357537A0451 VBN O
by P02357537A0451 IN O
naloxone P02357537A0451 NN O
( P02357537A0451 ( O
2 P02357537A0451 CD O
mg P02357537A0451 NN O
/ P02357537A0451 NNP O
kg P02357537A0451 NN O
) P02357537A0451 ) O
, P02357537A0451 , O
and P02357537A0451 CC O
were P02357537A0451 VBD O
not P02357537A0451 RB O
present P02357537A0451 JJ O
in P02357537A0451 IN O
morphine-tolerant P02357537A0451 JJ O
animals P02357537A0451 NNS O
. P02357537A0451 . O
. . O O

Primer P07665187A0824 NNP O
extension P07665187A0824 NN O
and P07665187A0824 CC O
S1 P07665187A0824 NNP I-UN
nuclease P07665187A0824 NN I-UN
mapping P07665187A0824 NN O
experiments P07665187A0824 NNS O
were P07665187A0824 VBD O
used P07665187A0824 VBN O
to P07665187A0824 TO O
locate P07665187A0824 VB O
the P07665187A0824 DT O
transcription P07665187A0824 NN O
initiation P07665187A0824 NN O
site P07665187A0824 NN O
of P07665187A0824 IN O
Nramp1 P07665187A0824 NNP I-UN
and P07665187A0824 CC O
revealed P07665187A0824 VBD O
the P07665187A0824 DT O
presence P07665187A0824 NN O
of P07665187A0824 IN O
one P07665187A0824 CD O
major P07665187A0824 JJ O
and P07665187A0824 CC O
several P07665187A0824 JJ O
minor P07665187A0824 JJ O
initiation P07665187A0824 NN O
sites P07665187A0824 NNS O
. P07665187A0824 . O
. . O O

Dorsal P03592297A0138 NNP O
foot P03592297A0138 NN O
TcpO2 P03592297A0138 NNP O
was P03592297A0138 VBD O
measured P03592297A0138 VBN O
by P03592297A0138 IN O
using P03592297A0138 VBG O
oxygen-sensing P03592297A0138 JJ O
electrodes P03592297A0138 NNS O
with P03592297A0138 IN O
surface P03592297A0138 NN O
temperatures P03592297A0138 NNS O
of P03592297A0138 IN O
42 P03592297A0138 CD O
degrees P03592297A0138 NNS O
C P03592297A0138 NNP O
and P03592297A0138 CC O
45 P03592297A0138 CD O
degrees P03592297A0138 NNS O
C P03592297A0138 NNP O
; P03592297A0138 : O
in P03592297A0138 IN O
theory P03592297A0138 NN O
, P03592297A0138 , O
changes P03592297A0138 NNS O
in P03592297A0138 IN O
sympathetic P03592297A0138 JJ O
activity P03592297A0138 NN O
should P03592297A0138 MD O
affect P03592297A0138 VB O
vasomotor P03592297A0138 NN O
tone P03592297A0138 NN O
and P03592297A0138 CC O
TcpO2 P03592297A0138 NNP O
in P03592297A0138 IN O
skin P03592297A0138 NNP O
beneath P03592297A0138 NN O
an P03592297A0138 DT O
electrode P03592297A0138 NN O
at P03592297A0138 IN O
42 P03592297A0138 CD O
degrees P03592297A0138 NNS O
C P03592297A0138 NNP O
( P03592297A0138 ( O
submaximal P03592297A0138 JJ O
vasodilation P03592297A0138 NN O
) P03592297A0138 ) O
, P03592297A0138 , O
but P03592297A0138 CC O
not P03592297A0138 RB O
at P03592297A0138 IN O
45 P03592297A0138 CD O
degrees P03592297A0138 NNS O
C P03592297A0138 NNP O
( P03592297A0138 ( O
maximal P03592297A0138 JJ O
vasodilation P03592297A0138 NN O
) P03592297A0138 ) O
. P03592297A0138 . O
. . O O

There P03332022A1094 EX O
is P03332022A1094 VBZ O
a P03332022A1094 DT O
cysteine P03332022A1094 NN O
clustering P03332022A1094 VBG O
region P03332022A1094 NN O
in P03332022A1094 IN O
an P03332022A1094 DT O
N-terminal P03332022A1094 JJ O
region P03332022A1094 NN O
of P03332022A1094 IN O
the P03332022A1094 DT O
c-raf P03332022A1094 NN I-UN
( P03332022A1094 ( I-UN
-1 P03332022A1094 JJ I-UN
) P03332022A1094 ) I-UN
product P03332022A1094 NN I-UN
deduced P03332022A1094 VBN O
from P03332022A1094 IN O
the P03332022A1094 DT O
nucleotide P03332022A1094 JJ O
sequence P03332022A1094 NN O
, P03332022A1094 , O
and P03332022A1094 CC O
this P03332022A1094 DT O
cysteine P03332022A1094 NN O
clustering P03332022A1094 VBG O
region P03332022A1094 NN O
was P03332022A1094 VBD O
found P03332022A1094 VBN O
to P03332022A1094 TO O
be P03332022A1094 VB O
highly P03332022A1094 RB O
homologous P03332022A1094 JJ O
to P03332022A1094 TO O
that P03332022A1094 DT O
present P03332022A1094 JJ O
in P03332022A1094 IN O
an P03332022A1094 DT O
N-terminal P03332022A1094 JJ O
region P03332022A1094 NN O
of P03332022A1094 IN O
protein P03332022A1094 NN I-UN
kinase P03332022A1094 NN I-UN
C P03332022A1094 NNP I-UN
, P03332022A1094 , O
although P03332022A1094 IN O
, P03332022A1094 , O
in P03332022A1094 IN O
the P03332022A1094 DT O
latter P03332022A1094 JJ O
cysteine P03332022A1094 NN O
clusters P03332022A1094 NNS O
are P03332022A1094 VBP O
present P03332022A1094 JJ O
in P03332022A1094 IN O
duplicate P03332022A1094 NN O
. P03332022A1094 . O
. . O O

The P08882492A0000 DT O
mammalian P08882492A0000 JJ I-UN
homeodomain P08882492A0000 NN I-UN
proteins P08882492A0000 NNS I-UN
encoded P08882492A0000 VBN O
by P08882492A0000 IN O
Hox P08882492A0000 NNP I-UN
genes P08882492A0000 NNS I-UN
play P08882492A0000 VBP O
an P08882492A0000 DT O
important P08882492A0000 JJ O
role P08882492A0000 NN O
in P08882492A0000 IN O
embryonic P08882492A0000 JJ O
development P08882492A0000 NN O
by P08882492A0000 IN O
providing P08882492A0000 VBG O
positional P08882492A0000 JJ O
queues P08882492A0000 NNS O
which P08882492A0000 WDT O
define P08882492A0000 VBP O
developmental P08882492A0000 JJ O
identities P08882492A0000 NNS O
along P08882492A0000 IN O
the P08882492A0000 DT O
anteroposterior P08882492A0000 JJ O
axis P08882492A0000 NN O
of P08882492A0000 IN O
developing P08882492A0000 VBG O
organisms P08882492A0000 NNS O
. P08882492A0000 . O
. . O O

Biological P00921032T0000 JJ O
evaluation P00921032T0000 NN O
of P00921032T0000 IN O
mibolerone P00921032T0000 NN O
in P00921032T0000 IN O
the P00921032T0000 DT O
female P00921032T0000 JJ O
Beagle P00921032T0000 NNP O
. P00921032T0000 . O
. . O O

These P09813635A0678 DT O
striations P09813635A0678 NNS O
were P09813635A0678 VBD O
caused P09813635A0678 VBN O
by P09813635A0678 IN O
contact P09813635A0678 NN O
between P09813635A0678 IN O
the P09813635A0678 DT O
sharp P09813635A0678 JJ O
edge P09813635A0678 NN O
of P09813635A0678 IN O
the P09813635A0678 DT O
upper P09813635A0678 JJ O
canine P09813635A0678 NN O
and P09813635A0678 CC O
the P09813635A0678 DT O
P3 P09813635A0678 NNP O
during P09813635A0678 IN O
honing P09813635A0678 VBG O
( P09813635A0678 ( O
canine P09813635A0678 JJ O
/ P09813635A0678 NNP O
premolar P09813635A0678 NN O
complex P09813635A0678 NN O
) P09813635A0678 ) O
. P09813635A0678 . O
. . O O

[ P11723500X0000 JJ O
Clinical P11723500X0000 NNP O
and P11723500X0000 CC O
epidemiological P11723500X0000 JJ O
characteristics P11723500X0000 NNS O
of P11723500X0000 IN O
squamous P11723500X0000 JJ O
cell P11723500X0000 NN O
carcinoma P11723500X0000 NN O
of P11723500X0000 IN O
the P11723500X0000 DT O
oral P11723500X0000 JJ O
cavity P11723500X0000 NN O
in P11723500X0000 IN O
women P11723500X0000 NNS O
] P11723500X0000 JJ O
BACKGROUND P11723500X0000 NNP O
: P11723500X0000 : O
Squamous P11723500X0000 JJ O
cell P11723500X0000 NN O
carcinoma P11723500X0000 NN O
( P11723500X0000 ( O
SCC P11723500X0000 NNP O
) P11723500X0000 ) O
of P11723500X0000 IN O
the P11723500X0000 DT O
oral P11723500X0000 JJ O
cavity P11723500X0000 NN O
occurs P11723500X0000 VBZ O
mainly P11723500X0000 RB O
in P11723500X0000 IN O
the P11723500X0000 DT O
male P11723500X0000 JJ O
population P11723500X0000 NN O
. P11723500X0000 . O
. . O O

This P10492169A0939 DT O
cluster P10492169A0939 NN O
consisted P10492169A0939 VBD O
of P10492169A0939 IN O
four P10492169A0939 CD O
apparently P10492169A0939 RB O
unrelated P10492169A0939 JJ O
ESTs P10492169A0939 NNP O
and P10492169A0939 CC O
two P10492169A0939 CD O
genes P10492169A0939 NNS O
, P10492169A0939 , O
pregnancy-associated P10492169A0939 JJ I-UN
plasma P10492169A0939 NN I-UN
protein-A P10492169A0939 NN I-UN
( P10492169A0939 ( O
PAPP-A P10492169A0939 NNP I-UN
) P10492169A0939 ) O
and P10492169A0939 CC O
a P10492169A0939 DT O
novel P10492169A0939 JJ O
gene P10492169A0939 NN O
( P10492169A0939 ( O
tentatively P10492169A0939 RB O
named P10492169A0939 VBN O
EST-YD1 P10492169A0939 NNP I-UN
) P10492169A0939 ) O
. P10492169A0939 . O
. . O O

The P06279309A0000 DT O
genome P06279309A0000 NN O
of P06279309A0000 IN O
avian P06279309A0000 JJ O
erythroblastosis P06279309A0000 NN O
virus P06279309A0000 NN O
contains P06279309A0000 VBZ O
two P06279309A0000 CD O
independently P06279309A0000 RB O
expressed P06279309A0000 VBN O
genetic P06279309A0000 JJ O
loci P06279309A0000 NN O
( P06279309A0000 ( O
v-erbA P06279309A0000 JJ I-UN
and P06279309A0000 CC O
v-erbB P06279309A0000 JJ I-UN
) P06279309A0000 ) O
whose P06279309A0000 WP$ O
activities P06279309A0000 NNS O
are P06279309A0000 VBP O
probably P06279309A0000 RB O
responsible P06279309A0000 JJ O
for P06279309A0000 IN O
oncogenesis P06279309A0000 NN O
by P06279309A0000 IN O
the P06279309A0000 DT O
virus P06279309A0000 NN O
. P06279309A0000 . O
. . O O

The P03610674T0000 DT O
effect P03610674T0000 NN O
of P03610674T0000 IN O
dietary P03610674T0000 JJ O
zinc P03610674T0000 NN O
deficiency P03610674T0000 NN O
on P03610674T0000 IN O
the P03610674T0000 DT O
mossy P03610674T0000 JJ O
fiber P03610674T0000 NN O
zinc P03610674T0000 NN O
content P03610674T0000 NN O
of P03610674T0000 IN O
the P03610674T0000 DT O
rat P03610674T0000 NN O
hippocampus P03610674T0000 NN O
. P03610674T0000 . O
. . O O

Proceedings P04791420T0000 NNS O
: P04791420T0000 : O
Barrels P04791420T0000 NNS O
and P04791420T0000 CC O
somatotopy P04791420T0000 NN O
in P04791420T0000 IN O
S P04791420T0000 NNP O
I P04791420T0000 PRP O
neocortex P04791420T0000 VBP O
of P04791420T0000 IN O
the P04791420T0000 DT O
brush-tailed P04791420T0000 JJ O
possum P04791420T0000 NN O
. P04791420T0000 . O
. . O O

Previous P08869825A0000 JJ O
studies P08869825A0000 NNS O
demonstrated P08869825A0000 VBD O
that P08869825A0000 IN O
the P08869825A0000 DT O
flavin-containing P08869825A0000 JJ I-UN
monooxygenases P08869825A0000 NNS I-UN
( P08869825A0000 ( O
FMO P08869825A0000 NNP I-UN
) P08869825A0000 ) O
are P08869825A0000 VBP O
expressed P08869825A0000 VBN O
in P08869825A0000 IN O
a P08869825A0000 DT O
tissue-specific P08869825A0000 JJ O
manner P08869825A0000 NN O
. P08869825A0000 . O
. . O O

Grossly P02550682A0411 RB O
, P02550682A0411 , O
the P02550682A0411 DT O
incidence P02550682A0411 NN O
of P02550682A0411 IN O
a P02550682A0411 DT O
type P02550682A0411 NN O
IIc P02550682A0411 NNP O
carcinoma P02550682A0411 NN O
was P02550682A0411 VBD O
46.5 P02550682A0411 CD O
% P02550682A0411 NN O
and P02550682A0411 CC O
that P02550682A0411 IN O
of P02550682A0411 IN O
a P02550682A0411 DT O
IIc P02550682A0411 NNP O
+ P02550682A0411 NNP O
III P02550682A0411 NNP O
type P02550682A0411 NN O
was P02550682A0411 VBD O
20.5 P02550682A0411 CD O
% P02550682A0411 NN O
, P02550682A0411 , O
respectively P02550682A0411 RB O
. P02550682A0411 . O
. . O O

These P07841663A0845 DT O
studies P07841663A0845 NNS O
indicate P07841663A0845 VBP O
that P07841663A0845 IN O
in P07841663A0845 IN O
vitro P07841663A0845 NN O
and P07841663A0845 CC O
in P07841663A0845 IN O
vivo P07841663A0845 JJ O
electrical P07841663A0845 JJ O
stimulation P07841663A0845 NN O
generate P07841663A0845 NN O
reactive P07841663A0845 JJ O
oxygen P07841663A0845 NN O
species P07841663A0845 NNS O
and P07841663A0845 CC O
affect P07841663A0845 JJ O
SOD P07841663A0845 NNP I-UN
activity P07841663A0845 NN O
, P07841663A0845 , O
which P07841663A0845 WDT O
in P07841663A0845 IN O
part P07841663A0845 NN O
are P07841663A0845 VBP O
responsible P07841663A0845 JJ O
for P07841663A0845 IN O
decreased P07841663A0845 JJ O
sperm P07841663A0845 JJ O
motion P07841663A0845 NN O
and P07841663A0845 CC O
viability P07841663A0845 NN O
. P07841663A0845 . O
. . O O

In P10331646A0595 IN O
contrast P10331646A0595 NN O
, P10331646A0595 , O
the P10331646A0595 DT O
deduced P10331646A0595 JJ O
amino P10331646A0595 NN O
acid P10331646A0595 JJ O
sequence P10331646A0595 NN O
of P10331646A0595 IN O
a P10331646A0595 DT O
second P10331646A0595 JJ O
family P10331646A0595 NN O
( P10331646A0595 ( O
ART5 P10331646A0595 NNP I-UN
) P10331646A0595 ) O
of P10331646A0595 IN O
transferases P10331646A0595 NNS O
, P10331646A0595 , O
cloned P10331646A0595 VBN O
from P10331646A0595 IN O
murine P10331646A0595 JJ O
lymphoma P10331646A0595 NN O
cells P10331646A0595 NNS O
and P10331646A0595 CC O
expressed P10331646A0595 VBN O
in P10331646A0595 IN O
high P10331646A0595 JJ O
abundance P10331646A0595 NN O
in P10331646A0595 IN O
testis P10331646A0595 NN O
, P10331646A0595 , O
displays P10331646A0595 VBZ O
a P10331646A0595 DT O
hydrophobic P10331646A0595 JJ O
amino P10331646A0595 NN O
terminus P10331646A0595 NN O
, P10331646A0595 , O
consistent P10331646A0595 JJ O
with P10331646A0595 IN O
a P10331646A0595 DT O
signal P10331646A0595 JJ O
sequence P10331646A0595 NN O
, P10331646A0595 , O
but P10331646A0595 CC O
lacks P10331646A0595 VBZ O
a P10331646A0595 DT O
hydrophobic P10331646A0595 JJ O
signal P10331646A0595 JJ O
sequence P10331646A0595 NN O
at P10331646A0595 IN O
its P10331646A0595 PRP$ O
carboxyl P10331646A0595 NN O
terminus P10331646A0595 NN O
, P10331646A0595 , O
suggesting P10331646A0595 VBG O
that P10331646A0595 IN O
the P10331646A0595 DT O
protein P10331646A0595 NN O
is P10331646A0595 VBZ O
destined P10331646A0595 VBN O
for P10331646A0595 IN O
export P10331646A0595 NN O
. P10331646A0595 . O
. . O O

The P09738010A0305 DT O
FAS P09738010A0305 NNP I-UN
promoter P09738010A0305 NN I-UN
was P09738010A0305 VBD O
up-regulated P09738010A0305 JJ O
by P09738010A0305 IN O
insulin P09738010A0305 NN I-UN
through P09738010A0305 IN O
the P09738010A0305 DT O
proximal P09738010A0305 JJ O
insulin P09738010A0305 NN I-UN
response P09738010A0305 NN I-UN
sequence P09738010A0305 NN I-UN
containing P09738010A0305 VBG O
an P09738010A0305 DT O
E-box P09738010A0305 JJ O
motif P09738010A0305 NN O
at P09738010A0305 IN O
the P09738010A0305 DT O
-65-base P09738010A0305 NNP O
pair P09738010A0305 NN O
position P09738010A0305 NN O
. P09738010A0305 . O
. . O O

B P09670943T0000 NNP I-UN
cell P09670943T0000 NN I-UN
antigen P09670943T0000 NN I-UN
receptor P09670943T0000 NN I-UN
( P09670943T0000 ( O
BCR P09670943T0000 NNP I-UN
) P09670943T0000 ) O
-mediated P09670943T0000 VBD O
formation P09670943T0000 NN O
of P09670943T0000 IN O
a P09670943T0000 DT O
SHP-2-pp120 P09670943T0000 NNP O
complex P09670943T0000 NN O
and P09670943T0000 CC O
its P09670943T0000 PRP$ O
inhibition P09670943T0000 NN O
by P09670943T0000 IN O
Fc P09670943T0000 NNP I-UN
gamma P09670943T0000 VBD I-UN
RIIB1-BCR P09670943T0000 NNP O
coligation P09670943T0000 NN O
. P09670943T0000 . O
. . O O

Chick P02223773A0000 NNP I-UN
brain P02223773A0000 NN I-UN
actin P02223773A0000 NN I-UN
depolymerizing P02223773A0000 VBG I-UN
factor P02223773A0000 NN I-UN
( P02223773A0000 ( O
ADF P02223773A0000 NNP I-UN
) P02223773A0000 ) O
is P02223773A0000 VBZ O
a P02223773A0000 DT O
19-kDa P02223773A0000 JJ O
protein P02223773A0000 NN O
that P02223773A0000 IN O
severs P02223773A0000 NNS O
actin P02223773A0000 VBP I-UN
filaments P02223773A0000 NNS I-UN
and P02223773A0000 CC O
binds P02223773A0000 NNS O
actin P02223773A0000 JJ I-UN
monomers P02223773A0000 NNS I-UN
. P02223773A0000 . O
. . O O

Compared P10624787A0432 VBN O
to P10624787A0432 TO O
those P10624787A0432 DT O
with P10624787A0432 IN O
normal P10624787A0432 JJ O
renal P10624787A0432 JJ O
functions P10624787A0432 NNS O
, P10624787A0432 , O
these P10624787A0432 DT O
patients P10624787A0432 NNS O
were P10624787A0432 VBD O
older P10624787A0432 JJR O
( P10624787A0432 ( O
P P10624787A0432 NNP O
< P10624787A0432 NNP O
or P10624787A0432 CC O
= P10624787A0432 VB O
0.01 P10624787A0432 CD O
) P10624787A0432 ) O
, P10624787A0432 , O
had P10624787A0432 VBD O
significantly P10624787A0432 RB O
elevated P10624787A0432 VBN O
blood P10624787A0432 NN O
pressures P10624787A0432 NNS O
( P10624787A0432 ( O
P P10624787A0432 NNP O
< P10624787A0432 VBZ O
0.01 P10624787A0432 CD O
or P10624787A0432 CC O
P P10624787A0432 NNP O
= P10624787A0432 NNP O
0.0001 P10624787A0432 CD O
) P10624787A0432 ) O
, P10624787A0432 , O
and P10624787A0432 CC O
in P10624787A0432 IN O
the P10624787A0432 DT O
case P10624787A0432 NN O
of P10624787A0432 IN O
Type P10624787A0432 NNP O
1 P10624787A0432 CD O
DM P10624787A0432 NNP O
, P10624787A0432 , O
with P10624787A0432 IN O
a P10624787A0432 DT O
higher P10624787A0432 JJR O
body P10624787A0432 NN O
mass P10624787A0432 NN O
index P10624787A0432 NN O
( P10624787A0432 ( O
P P10624787A0432 NNP O
= P10624787A0432 NNP O
0.0001 P10624787A0432 CD O
) P10624787A0432 ) O
and P10624787A0432 CC O
waist-hip P10624787A0432 JJ O
ratio P10624787A0432 NN O
( P10624787A0432 ( O
P P10624787A0432 NNP O
< P10624787A0432 NNP O
0.01 P10624787A0432 CD O
) P10624787A0432 ) O
. P10624787A0432 . O
. . O O

We P08350398A1616 PRP O
suggest P08350398A1616 VBP O
that P08350398A1616 IN O
the P08350398A1616 DT O
ER P08350398A1616 NNP O
lumenal P08350398A1616 JJ O
variable P08350398A1616 JJ O
domain P08350398A1616 NN O
of P08350398A1616 IN O
gp19K P08350398A1616 NN I-UN
has P08350398A1616 VBZ O
a P08350398A1616 DT O
specific P08350398A1616 JJ O
tertiary P08350398A1616 JJ O
structure P08350398A1616 NN O
that P08350398A1616 WDT O
is P08350398A1616 VBZ O
important P08350398A1616 JJ O
for P08350398A1616 IN O
binding P08350398A1616 VBG O
to P08350398A1616 TO O
the P08350398A1616 DT O
polymorphic P08350398A1616 JJ O
alpha P08350398A1616 NN O
1 P08350398A1616 CD O
and P08350398A1616 CC O
alpha P08350398A1616 $ O
2 P08350398A1616 CD O
domains P08350398A1616 NNS O
of P08350398A1616 IN O
class P08350398A1616 NN I-UN
I P08350398A1616 PRP I-UN
heavy P08350398A1616 VBP I-UN
( P08350398A1616 ( I-UN
alpha P08350398A1616 JJ I-UN
) P08350398A1616 ) I-UN
chains P08350398A1616 NNS I-UN
. P08350398A1616 . O
. . O O

Regionalization P08130942A0051 NN O
of P08130942A0051 IN O
drug P08130942A0051 NN O
delivery P08130942A0051 NN O
is P08130942A0051 VBZ O
a P08130942A0051 DT O
potential P08130942A0051 JJ O
method P08130942A0051 NN O
to P08130942A0051 TO O
avoid P08130942A0051 VB O
this P08130942A0051 DT O
problem P08130942A0051 NN O
. P08130942A0051 . O
. . O O

Fourth P08995659A0563 NN O
, P08995659A0563 , O
the P08995659A0563 DT O
3'-region P08995659A0563 JJ O
splice P08995659A0563 NN O
junctions P08995659A0563 NNS O
of P08995659A0563 IN O
the P08995659A0563 DT O
MSRs P08995659A0563 NNP I-UN
during P08995659A0563 IN O
latent P08995659A0563 NN O
and P08995659A0563 CC O
productive P08995659A0563 JJ O
infection P08995659A0563 NN O
were P08995659A0563 VBD O
determined P08995659A0563 VBN O
by P08995659A0563 IN O
sequencing P08995659A0563 VBG O
RNA-PCR P08995659A0563 JJ O
products P08995659A0563 NNS O
generated P08995659A0563 VBN O
with P08995659A0563 IN O
primers P08995659A0563 NNS O
that P08995659A0563 WDT O
flank P08995659A0563 VBD O
the P08995659A0563 DT O
3 P08995659A0563 CD O
' P08995659A0563 POS O
splice P08995659A0563 JJ O
region P08995659A0563 NN O
. P08995659A0563 . O
. . O O

Laboratory P01452703A0782 NN O
studies P01452703A0782 NNS O
showed P01452703A0782 VBD O
that P01452703A0782 IN O
the P01452703A0782 DT O
direct P01452703A0782 JJ O
fluorescent-antibody P01452703A0782 NN O
kits P01452703A0782 NNS O
were P01452703A0782 VBD O
the P01452703A0782 DT O
least P01452703A0782 JJS O
sensitive P01452703A0782 JJ O
in P01452703A0782 IN O
this P01452703A0782 DT O
case P01452703A0782 NN O
and P01452703A0782 CC O
did P01452703A0782 VBD O
not P01452703A0782 RB O
detect P01452703A0782 VB O
fewer P01452703A0782 JJR O
than P01452703A0782 IN O
10 P01452703A0782 CD O
( P01452703A0782 ( O
4 P01452703A0782 CD O
) P01452703A0782 ) O
elementary P01452703A0782 JJ O
bodies P01452703A0782 NNS O
per P01452703A0782 IN O
ml P01452703A0782 NN O
, P01452703A0782 , O
while P01452703A0782 IN O
most P01452703A0782 JJS O
ELISA P01452703A0782 NNP O
kits P01452703A0782 NNS O
detected P01452703A0782 VBD O
between P01452703A0782 IN O
130 P01452703A0782 CD O
and P01452703A0782 CC O
600 P01452703A0782 CD O
elementary P01452703A0782 JJ O
bodies P01452703A0782 NNS O
per P01452703A0782 IN O
ml P01452703A0782 NN O
. P01452703A0782 . O
. . O O

As P09160881A0491 IN O
opposed P09160881A0491 VBN O
to P09160881A0491 TO O
in P09160881A0491 IN O
vitro P09160881A0491 JJ O
co-precipitation P09160881A0491 NN O
studies P09160881A0491 NNS O
, P09160881A0491 , O
the P09160881A0491 DT O
yeast P09160881A0491 JJ O
two-hybrid P09160881A0491 JJ O
screen P09160881A0491 NN O
reveals P09160881A0491 NNS O
in P09160881A0491 IN O
vivo P09160881A0491 JJ O
protein-protein P09160881A0491 JJ O
interactions P09160881A0491 NNS O
. P09160881A0491 . O
. . O O

Here P09268638A0332 RB O
, P09268638A0332 , O
we P09268638A0332 PRP O
describe P09268638A0332 VBP O
directional P09268638A0332 JJ O
chromosome P09268638A0332 NN O
walking P09268638A0332 VBG O
studies P09268638A0332 NNS O
starting P09268638A0332 VBG O
from P09268638A0332 IN O
D8S260 P09268638A0332 NNP I-UN
as P09268638A0332 RB O
well P09268638A0332 RB O
as P09268638A0332 IN O
D8S285 P09268638A0332 NNP I-UN
. P09268638A0332 . O
. . O O

Is P04113011T0000 VBZ O
desensitization P04113011T0000 NN O
' P04113011T0000 '' O
for P04113011T0000 IN O
ragweed P04113011T0000 NN O
hay P04113011T0000 NN O
fever P04113011T0000 NN O
immunologically P04113011T0000 RB O
specific P04113011T0000 JJ O
? P04113011T0000 . O
. P04113011T0000 . O
. . O O

Depth-controlled P10032581T0000 JJ O
grazing-incidence P10032581T0000 NN O
diffraction P10032581T0000 NN O
of P10032581T0000 IN O
synchrotron P10032581T0000 NN O
x P10032581T0000 NN O
radiation P10032581T0000 NN O
. P10032581T0000 . O
. . O O

Thus P11423991A1393 RB O
, P11423991A1393 , O
the P11423991A1393 DT O
screen P11423991A1393 NN O
for P11423991A1393 IN O
toxic P11423991A1393 JJ O
p53 P11423991A1393 NN I-UN
mutants P11423991A1393 NNS I-UN
in P11423991A1393 IN O
yeast P11423991A1393 NN O
can P11423991A1393 MD O
identify P11423991A1393 VB O
novel P11423991A1393 JJ O
p53 P11423991A1393 NN I-UN
variants P11423991A1393 NNS O
that P11423991A1393 WDT O
may P11423991A1393 MD O
be P11423991A1393 VB O
useful P11423991A1393 JJ O
in P11423991A1393 IN O
dissecting P11423991A1393 VBG O
p53 P11423991A1393 NN I-UN
regulated P11423991A1393 VBD O
cellular P11423991A1393 JJ O
responses P11423991A1393 NNS O
and P11423991A1393 CC O
in P11423991A1393 IN O
developing P11423991A1393 VBG O
p53-based P11423991A1393 JJ O
cancer P11423991A1393 NN O
therapies P11423991A1393 NNS O
. P11423991A1393 . O
. . O O

The P06721188A0200 DT O
statistical P06721188A0200 JJ O
analysis P06721188A0200 NN O
consist P06721188A0200 NN O
of P06721188A0200 IN O
the P06721188A0200 DT O
F P06721188A0200 NNP O
test P06721188A0200 NN O
followed P06721188A0200 VBN O
by P06721188A0200 IN O
Snedecor P06721188A0200 NNP O
's P06721188A0200 POS O
contrast P06721188A0200 NN O
test P06721188A0200 NN O
. P06721188A0200 . O
. . O O

While P09083291A1378 IN O
TGF-beta1 P09083291A1378 NNP I-UN
does P09083291A1378 VBZ O
not P09083291A1378 RB O
alter P09083291A1378 VB O
the P09083291A1378 DT O
mitogen-induced P09083291A1378 JJ O
expression P09083291A1378 NN O
and P09083291A1378 CC O
abundance P09083291A1378 NN O
of P09083291A1378 IN O
G1 P09083291A1378 NNP O
phase P09083291A1378 NN O
cyclin P09083291A1378 NN I-UN
D1 P09083291A1378 NNP I-UN
and P09083291A1378 CC O
cdks P09083291A1378 VB I-UN
4 P09083291A1378 CD I-UN
and P09083291A1378 CC I-UN
2 P09083291A1378 CD I-UN
in P09083291A1378 IN O
MCs P09083291A1378 NNP O
, P09083291A1378 , O
it P09083291A1378 PRP O
inhibits P09083291A1378 VBZ O
cyclin P09083291A1378 JJ I-UN
E-cdk P09083291A1378 JJ O
2 P09083291A1378 CD I-UN
activity P09083291A1378 NN O
, P09083291A1378 , O
thus P09083291A1378 RB O
preventing P09083291A1378 VBG O
mitogen-elicited P09083291A1378 JJ O
phosphorylation P09083291A1378 NN O
and P09083291A1378 CC O
inactivation P09083291A1378 NN O
of P09083291A1378 IN O
pRb P09083291A1378 NN I-UN
in P09083291A1378 IN O
G1 P09083291A1378 NNP O
phase P09083291A1378 NN O
and P09083291A1378 CC O
transition P09083291A1378 NN O
to P09083291A1378 TO O
S P09083291A1378 NNP O
phase P09083291A1378 NN O
. P09083291A1378 . O
. . O O

Antithrombin P10209759T0000 NNP I-UN
III P10209759T0000 NNP I-UN
prevents P10209759T0000 VBZ O
60 P10209759T0000 CD O
min P10209759T0000 NN O
warm P10209759T0000 JJ O
intestinal P10209759T0000 JJ O
ischemia P10209759T0000 NN O
reperfusion P10209759T0000 NN O
injury P10209759T0000 NN O
in P10209759T0000 IN O
rats P10209759T0000 NNS O
. P10209759T0000 . O
. . O O

Cyclin P10713176A0422 NNP I-UN
A P10713176A0422 DT I-UN
expression P10713176A0422 NN O
is P10713176A0422 VBZ O
repressed P10713176A0422 VBN O
in P10713176A0422 IN O
quiescent P10713176A0422 NN O
cells P10713176A0422 NNS O
by P10713176A0422 IN O
E2F P10713176A0422 NNP I-UN
acting P10713176A0422 VBG O
in P10713176A0422 IN O
conjunction P10713176A0422 NN O
with P10713176A0422 IN O
its P10713176A0422 PRP$ O
pocket P10713176A0422 NN O
protein P10713176A0422 NN O
partners P10713176A0422 NNS O
Rb P10713176A0422 NNP I-UN
, P10713176A0422 , O
p107 P10713176A0422 NN I-UN
, P10713176A0422 , O
and P10713176A0422 CC O
p130 P10713176A0422 NN I-UN
; P10713176A0422 : O
however P10713176A0422 RB O
, P10713176A0422 , O
v-Jun P10713176A0422 JJ I-UN
overrides P10713176A0422 IN O
this P10713176A0422 DT O
control P10713176A0422 NN O
, P10713176A0422 , O
causing P10713176A0422 VBG O
phosphorylated P10713176A0422 VBN O
Rb P10713176A0422 NNP I-UN
and P10713176A0422 CC O
proliferation-specific P10713176A0422 JJ O
E2F-p107 P10713176A0422 NNP O
complexes P10713176A0422 NNS O
to P10713176A0422 TO O
persist P10713176A0422 VB O
after P10713176A0422 IN O
mitogen P10713176A0422 NN O
withdrawal P10713176A0422 NN O
. P10713176A0422 . O
. . O O

A P08778265A0422 DT O
neuropsychological P08778265A0422 JJ O
test P08778265A0422 NN O
battery P08778265A0422 NN O
was P08778265A0422 VBD O
used P08778265A0422 VBN O
that P08778265A0422 IN O
contained P08778265A0422 VBD O
the P08778265A0422 DT O
Wisconsin P08778265A0422 NNP O
card P08778265A0422 NN O
sorting P08778265A0422 VBG O
test P08778265A0422 NN O
, P08778265A0422 , O
Street P08778265A0422 NNP O
completion P08778265A0422 NN O
test P08778265A0422 NN O
, P08778265A0422 , O
Stroop P08778265A0422 NNP O
test P08778265A0422 NN O
, P08778265A0422 , O
a P08778265A0422 DT O
dichotic P08778265A0422 JJ O
memory P08778265A0422 NN O
listening P08778265A0422 VBG O
test P08778265A0422 NN O
, P08778265A0422 , O
and P08778265A0422 CC O
a P08778265A0422 DT O
facial P08778265A0422 JJ O
recognition P08778265A0422 NN O
test P08778265A0422 NN O
. P08778265A0422 . O
. . O O

Approximately P01690812A0000 RB O
50 P01690812A0000 CD O
% P01690812A0000 NN O
of P01690812A0000 IN O
the P01690812A0000 DT O
ribosomal P01690812A0000 JJ O
DNA P01690812A0000 NNP O
( P01690812A0000 ( O
rDNA P01690812A0000 NN O
) P01690812A0000 ) O
units P01690812A0000 NNS O
of P01690812A0000 IN O
Drosophila P01690812A0000 NNP O
melanogaster P01690812A0000 NN O
are P01690812A0000 VBP O
inactivated P01690812A0000 VBN O
by P01690812A0000 IN O
two P01690812A0000 CD O
different P01690812A0000 JJ O
28 P01690812A0000 CD I-UN
S P01690812A0000 NNP I-UN
RNA P01690812A0000 NNP I-UN
ribosomal P01690812A0000 JJ I-UN
gene P01690812A0000 NN I-UN
insertions P01690812A0000 NNS O
( P01690812A0000 ( O
type P01690812A0000 NN O
I P01690812A0000 PRP O
and P01690812A0000 CC O
type P01690812A0000 VB O
II P01690812A0000 NNP O
) P01690812A0000 ) O
. P01690812A0000 . O
. . O O

Inhibition P07706299A0563 NNP O
assays P07706299A0563 NNS O
performed P07706299A0563 VBD O
with P07706299A0563 IN O
over P07706299A0563 IN O
30 P07706299A0563 CD O
different P07706299A0563 JJ O
natural P07706299A0563 JJ O
and P07706299A0563 CC O
synthetic P07706299A0563 JJ O
sialylated P07706299A0563 VBN O
and P07706299A0563 CC O
/ P07706299A0563 CD O
or P07706299A0563 CC O
sulfated P07706299A0563 VBN O
compounds P07706299A0563 NNS O
are P07706299A0563 VBP O
utilized P07706299A0563 JJ O
to P07706299A0563 TO O
define P07706299A0563 VB O
in P07706299A0563 IN O
greater P07706299A0563 JJR O
detail P07706299A0563 NN O
specific P07706299A0563 JJ O
structural P07706299A0563 JJ O
features P07706299A0563 NNS O
involved P07706299A0563 VBN O
in P07706299A0563 IN O
oligosaccharide-protein P07706299A0563 JJ O
binding P07706299A0563 NN O
. P07706299A0563 . O
. . O O

Thus P02482511A0860 RB O
, P02482511A0860 , O
phosphodiesterase P02482511A0860 NN O
inhibitors P02482511A0860 NNS O
that P02482511A0860 WDT O
produce P02482511A0860 VBP O
an P02482511A0860 DT O
opiate P02482511A0860 JJ O
quasi-withdrawal P02482511A0860 JJ O
syndrome P02482511A0860 NN O
potentiate P02482511A0860 NN O
interoceptive P02482511A0860 JJ O
stimuli P02482511A0860 NNS O
and P02482511A0860 CC O
weight P02482511A0860 JJ O
loss P02482511A0860 NN O
associated P02482511A0860 VBN O
with P02482511A0860 IN O
the P02482511A0860 DT O
withdrawal P02482511A0860 NN O
syndrome P02482511A0860 NN O
precipitated P02482511A0860 VBN O
by P02482511A0860 IN O
naltrexone P02482511A0860 NN O
in P02482511A0860 IN O
morphine-dependent P02482511A0860 JJ O
rats P02482511A0860 NNS O
. P02482511A0860 . O
. . O O

Treatment P07935577A0305 NN O
with P07935577A0305 IN O
amphotericin P07935577A0305 NN O
B P07935577A0305 NNP O
and P07935577A0305 CC O
flucytosine P07935577A0305 NN O
led P07935577A0305 VBN O
to P07935577A0305 TO O
improvement P07935577A0305 NN O
of P07935577A0305 IN O
the P07935577A0305 DT O
symptoms P07935577A0305 NNS O
but P07935577A0305 CC O
did P07935577A0305 VBD O
not P07935577A0305 RB O
eradicate P07935577A0305 VB O
the P07935577A0305 DT O
micro-organisms P07935577A0305 NN O
from P07935577A0305 IN O
the P07935577A0305 DT O
cerebrospinal P07935577A0305 JJ O
fluid P07935577A0305 NN O
( P07935577A0305 ( O
CSF P07935577A0305 NNP O
) P07935577A0305 ) O
. P07935577A0305 . O
. . O O

In P11353770A0085 IN O
regards P11353770A0085 NNS O
to P11353770A0085 TO O
the P11353770A0085 DT O
latter P11353770A0085 JJ O
activity P11353770A0085 NN O
, P11353770A0085 , O
it P11353770A0085 PRP O
has P11353770A0085 VBZ O
been P11353770A0085 VBN O
shown P11353770A0085 VBN O
that P11353770A0085 IN O
S3 P11353770A0085 NNP I-UN
contains P11353770A0085 VBZ O
vigorous P11353770A0085 JJ O
N-glycosylase P11353770A0085 NNP I-UN
activity P11353770A0085 NN O
for P11353770A0085 IN O
the P11353770A0085 DT O
removal P11353770A0085 NN O
of P11353770A0085 IN O
8-oxoguanine P11353770A0085 JJ O
residues P11353770A0085 NNS O
in P11353770A0085 IN O
DNA P11353770A0085 NN O
that P11353770A0085 WDT O
leaves P11353770A0085 VBZ O
baseless P11353770A0085 JJ O
sites P11353770A0085 NNS O
in P11353770A0085 IN O
their P11353770A0085 PRP$ O
places P11353770A0085 NNS O
. P11353770A0085 . O
. . O O

These P08816452A0936 DT O
findings P08816452A0936 NNS O
and P08816452A0936 CC O
the P08816452A0936 DT O
differential P08816452A0936 JJ O
tissue P08816452A0936 NN O
distribution P08816452A0936 NN O
of P08816452A0936 IN O
p54 P08816452A0936 NN I-UN
suggest P08816452A0936 VBP O
that P08816452A0936 IN O
this P08816452A0936 DT O
novel P08816452A0936 JJ O
SR P08816452A0936 NNP I-UN
protein P08816452A0936 NN I-UN
may P08816452A0936 MD O
participate P08816452A0936 VB O
in P08816452A0936 IN O
regulation P08816452A0936 NN O
of P08816452A0936 IN O
alternative P08816452A0936 JJ O
splicing P08816452A0936 NN O
in P08816452A0936 IN O
a P08816452A0936 DT O
tissue- P08816452A0936 JJ O
and P08816452A0936 CC O
substrate-dependent P08816452A0936 JJ O
manner P08816452A0936 NN O
. P08816452A0936 . O
. . O O

Phosphorylation P10744974T0000 NN O
and P10744974T0000 CC O
spindle P10744974T0000 JJ O
pole P10744974T0000 NN O
body P10744974T0000 NN O
localization P10744974T0000 NN O
of P10744974T0000 IN O
the P10744974T0000 DT O
Cdc15p P10744974T0000 NNP I-UN
mitotic P10744974T0000 JJ I-UN
regulatory P10744974T0000 JJ I-UN
protein P10744974T0000 NN I-UN
kinase P10744974T0000 NN I-UN
in P10744974T0000 IN I-UN
budding P10744974T0000 VBG I-UN
yeast P10744974T0000 NN I-UN
. P10744974T0000 . O
. . O O

The P11231287A0158 DT O
sensitivity P11231287A0158 NN O
of P11231287A0158 IN O
human P11231287A0158 JJ O
neuroblastoma P11231287A0158 JJ O
cells P11231287A0158 NNS O
SK-N-SH P11231287A0158 JJ O
to P11231287A0158 TO O
undergo P11231287A0158 VB O
apoptosis P11231287A0158 NN O
induced P11231287A0158 VBN O
by P11231287A0158 IN O
thapsigargin P11231287A0158 NN O
was P11231287A0158 VBD O
examined P11231287A0158 VBN O
. P11231287A0158 . O
. . O O

Two P01577819A0709 CD O
variant P01577819A0709 JJ O
PRP-precursor P01577819A0709 NNP I-UN
alleles P01577819A0709 NNS I-UN
occur P01577819A0709 VBP O
which P01577819A0709 WDT O
slightly P01577819A0709 RB O
differ P01577819A0709 VBP O
in P01577819A0709 IN O
the P01577819A0709 DT O
number P01577819A0709 NN O
of P01577819A0709 IN O
repeats P01577819A0709 NNS O
in P01577819A0709 IN O
domain P01577819A0709 NN O
C P01577819A0709 NNP O
. P01577819A0709 . O
. . O O

Although P07550216A0195 IN O
within P07550216A0195 IN O
normal P07550216A0195 JJ O
limits P07550216A0195 NNS O
, P07550216A0195 , O
latency P07550216A0195 NN O
was P07550216A0195 VBD O
high P07550216A0195 JJ O
. P07550216A0195 . O
. . O O

A P10503540A0602 DT O
total P10503540A0602 NN O
of P10503540A0602 IN O
174 P10503540A0602 CD O
primer P10503540A0602 JJ O
pairs P10503540A0602 NNS O
gave P10503540A0602 VBD O
interpretable P10503540A0602 JJ O
banding P10503540A0602 NN O
patterns P10503540A0602 NNS O
, P10503540A0602 , O
137 P10503540A0602 CD O
( P10503540A0602 ( O
79 P10503540A0602 CD O
% P10503540A0602 NN O
) P10503540A0602 ) O
of P10503540A0602 IN O
which P10503540A0602 WDT O
revealed P10503540A0602 VBD O
at P10503540A0602 IN O
least P10503540A0602 JJS O
two P10503540A0602 CD O
alleles P10503540A0602 NNS O
on P10503540A0602 IN O
native P10503540A0602 JJ O
polyacrylamide P10503540A0602 NN O
gels P10503540A0602 NNS O
. P10503540A0602 . O
. . O O

Mutation P09743233A0526 NN O
of P09743233A0526 IN O
either P09743233A0526 CC O
the P09743233A0526 DT O
AP-1 P09743233A0526 NNP I-UN
or P09743233A0526 CC O
the P09743233A0526 DT O
ets P09743233A0526 NNS I-UN
component P09743233A0526 NN O
of P09743233A0526 IN O
this P09743233A0526 DT O
site P09743233A0526 NN O
also P09743233A0526 RB O
prevented P09743233A0526 VBD O
promoter P09743233A0526 NN O
activity P09743233A0526 NN O
in P09743233A0526 IN O
SMCs P09743233A0526 NNP O
. P09743233A0526 . O
. . O O

Truncated P01460054A0478 VBN I-UN
ICSBP P01460054A0478 NNP I-UN
lacking P01460054A0478 VBG O
the P01460054A0478 DT O
first P01460054A0478 JJ O
33 P01460054A0478 CD O
amino-terminal P01460054A0478 JJ O
amino P01460054A0478 NN O
acids P01460054A0478 NNS O
fails P01460054A0478 VBZ O
to P01460054A0478 TO O
bind P01460054A0478 VB O
to P01460054A0478 TO O
the P01460054A0478 DT O
ICS P01460054A0478 NNP I-UN
, P01460054A0478 , O
indicating P01460054A0478 VBG O
that P01460054A0478 IN O
at P01460054A0478 IN O
least P01460054A0478 JJS O
part P01460054A0478 NN O
of P01460054A0478 IN O
the P01460054A0478 DT O
DNA P01460054A0478 NNP O
binding P01460054A0478 NN O
domain P01460054A0478 NN O
is P01460054A0478 VBZ O
located P01460054A0478 VBN O
within P01460054A0478 IN O
the P01460054A0478 DT O
well P01460054A0478 NN O
conserved P01460054A0478 VBD O
amino P01460054A0478 JJ O
terminus P01460054A0478 NN O
. P01460054A0478 . O
. . O O

The P08415643A0555 DT O
E1 P08415643A0555 NNP I-UN
gene P08415643A0555 NN I-UN
is P08415643A0555 VBZ O
located P08415643A0555 VBN O
within P08415643A0555 IN O
the P08415643A0555 DT O
first P08415643A0555 JJ O
intron P08415643A0555 NN O
of P08415643A0555 IN O
the P08415643A0555 DT O
gene P08415643A0555 NN O
for P08415643A0555 IN O
RCC1 P08415643A0555 NNP I-UN
, P08415643A0555 , O
a P08415643A0555 DT O
protein P08415643A0555 NN O
that P08415643A0555 WDT O
regulates P08415643A0555 VBZ O
onset P08415643A0555 IN O
of P08415643A0555 IN O
mitosis P08415643A0555 NN O
. P08415643A0555 . O
. . O O

Constructs P07864652A0753 NNS O
designed P07864652A0753 VBN O
and P07864652A0753 CC O
expressed P07864652A0753 VBN O
were P07864652A0753 VBD O
E2L1 P07864652A0753 NNP I-UN
( P07864652A0753 ( I-UN
1-98 P07864652A0753 JJ I-UN
) P07864652A0753 ) I-UN
, P07864652A0753 , O
E2L1.H1 P07864652A0753 NNP I-UN
( P07864652A0753 ( I-UN
1-128 P07864652A0753 JJ I-UN
) P07864652A0753 ) I-UN
, P07864652A0753 , O
E2L2 P07864652A0753 NNP I-UN
( P07864652A0753 ( I-UN
120-233 P07864652A0753 JJ I-UN
) P07864652A0753 ) I-UN
, P07864652A0753 , O
E2H1.L2 P07864652A0753 NNP I-UN
( P07864652A0753 ( I-UN
98-233 P07864652A0753 CD I-UN
) P07864652A0753 ) I-UN
, P07864652A0753 , O
and P07864652A0753 CC O
E2L1.H1.L2 P07864652A0753 NNP I-UN
( P07864652A0753 ( I-UN
1-233 P07864652A0753 JJ I-UN
) P07864652A0753 ) I-UN
, P07864652A0753 , O
where P07864652A0753 WRB O
numbers P07864652A0753 NNS O
in P07864652A0753 IN O
parentheses P07864652A0753 NNS O
give P07864652A0753 VBP O
the P07864652A0753 DT O
amino P07864652A0753 NN O
acid P07864652A0753 NN O
sequence P07864652A0753 NN O
for P07864652A0753 IN O
the P07864652A0753 DT O
portions P07864652A0753 NNS O
of P07864652A0753 IN O
the P07864652A0753 DT O
E2 P07864652A0753 NNP I-UN
component P07864652A0753 NN O
incorporated P07864652A0753 VBN O
into P07864652A0753 IN O
a P07864652A0753 DT O
construct P07864652A0753 NN O
. P07864652A0753 . O
. . O O

CONCLUSIONS P11910344A1119 NN O
: P11910344A1119 : O
This P11910344A1119 DT O
retrospective P11910344A1119 NN O
uncontrolled P11910344A1119 VBD O
study P11910344A1119 NN O
shows P11910344A1119 NNS O
that P11910344A1119 IN O
in P11910344A1119 IN O
patients P11910344A1119 NNS O
with P11910344A1119 IN O
type P11910344A1119 JJ O
1 P11910344A1119 CD O
HRS P11910344A1119 NNP O
, P11910344A1119 , O
terlipressin-induced P11910344A1119 JJ O
improved P11910344A1119 VBN O
renal P11910344A1119 JJ O
function P11910344A1119 NN O
is P11910344A1119 VBZ O
associated P11910344A1119 VBN O
with P11910344A1119 IN O
an P11910344A1119 DT O
increase P11910344A1119 NN O
in P11910344A1119 IN O
survival P11910344A1119 NN O
. P11910344A1119 . O
. . O O

From P01391001A0583 IN O
all P01391001A0583 DT O
clinically P01391001A0583 RB O
important P01391001A0583 JJ O
yeasts P01391001A0583 NNS O
species P01391001A0583 NNS O
, P01391001A0583 , O
a P01391001A0583 DT O
total P01391001A0583 NN O
of P01391001A0583 IN O
96 P01391001A0583 CD O
% P01391001A0583 NN O
were P01391001A0583 VBD O
identified P01391001A0583 VBN O
by P01391001A0583 IN O
ATB P01391001A0583 NNP O
method P01391001A0583 NN O
according P01391001A0583 VBG O
to P01391001A0583 TO O
conventional P01391001A0583 JJ O
methods P01391001A0583 NNS O
. P01391001A0583 . O
. . O O

An P03826871A0000 DT O
ion P03826871A0000 NN O
chromatographic P03826871A0000 JJ O
method P03826871A0000 NN O
was P03826871A0000 VBD O
used P03826871A0000 VBN O
to P03826871A0000 TO O
determine P03826871A0000 VB O
Br P03826871A0000 NNP O
ion P03826871A0000 NN O
in P03826871A0000 IN O
the P03826871A0000 DT O
urine P03826871A0000 NN O
of P03826871A0000 IN O
Greyhounds P03826871A0000 NNP O
. P03826871A0000 . O
. . O O

This P03097509A0654 DT O
gave P03097509A0654 VBD O
rise P03097509A0654 NN O
to P03097509A0654 TO O
RNA P03097509A0654 NNP O
molecules P03097509A0654 NNS O
with P03097509A0654 IN O
3'-untranslated P03097509A0654 JJ O
regions P03097509A0654 NNS O
of P03097509A0654 IN O
roughly P03097509A0654 RB O
375 P03097509A0654 CD O
, P03097509A0654 , O
655 P03097509A0654 CD O
, P03097509A0654 , O
and P03097509A0654 CC O
945 P03097509A0654 CD O
base P03097509A0654 NN O
pairs P03097509A0654 NN O
. P03097509A0654 . O
. . O O

PrpB P09006051A1162 NNP I-UN
showed P09006051A1162 VBD O
homology P09006051A1162 NN O
to P09006051A1162 TO O
carboxyphosphonoenolpyruvate P09006051A1162 VB I-UN
phosphonomutase P09006051A1162 NN I-UN
of P09006051A1162 IN I-UN
Streptomyces P09006051A1162 NNP I-UN
hygroscopicus P09006051A1162 NN I-UN
and P09006051A1162 CC O
to P09006051A1162 TO O
its P09006051A1162 PRP$ O
homolog P09006051A1162 NN O
in P09006051A1162 IN O
the P09006051A1162 DT O
carnation P09006051A1162 NN O
Dianthus P09006051A1162 NNP O
caryophyllus P09006051A1162 NN O
; P09006051A1162 : O
PrpC P09006051A1162 NNP I-UN
was P09006051A1162 VBD O
homologous P09006051A1162 JJ O
to P09006051A1162 TO O
both P09006051A1162 DT O
archaeal P09006051A1162 NN I-UN
and P09006051A1162 CC I-UN
bacterial P09006051A1162 JJ I-UN
citrate P09006051A1162 NN I-UN
synthases P09006051A1162 NNS I-UN
; P09006051A1162 : O
PrpD P09006051A1162 NNP I-UN
showed P09006051A1162 VBD O
homology P09006051A1162 NN O
to P09006051A1162 TO O
yeast P09006051A1162 VB O
and P09006051A1162 CC O
Bacillus P09006051A1162 NNP O
subtilis P09006051A1162 VBP O
proteins P09006051A1162 NNS O
of P09006051A1162 IN O
unknown P09006051A1162 JJ O
function P09006051A1162 NN O
; P09006051A1162 : O
PrpE P09006051A1162 NNP I-UN
showed P09006051A1162 VBD O
homology P09006051A1162 NN O
to P09006051A1162 TO O
acetyl P09006051A1162 VB I-UN
coenzyme P09006051A1162 VB I-UN
A P09006051A1162 DT I-UN
synthetases P09006051A1162 NNS I-UN
. P09006051A1162 . O
. . O O

Here P10758489A0206 RB O
we P10758489A0206 PRP O
report P10758489A0206 VBP O
on P10758489A0206 IN O
the P10758489A0206 DT O
isolation P10758489A0206 NN O
of P10758489A0206 IN O
ICK2 P10758489A0206 NNP I-UN
, P10758489A0206 , O
and P10758489A0206 CC O
show P10758489A0206 VBP O
that P10758489A0206 IN O
it P10758489A0206 PRP O
interacts P10758489A0206 VBZ O
with P10758489A0206 IN O
Cdc2aAt P10758489A0206 NNP I-UN
, P10758489A0206 , O
but P10758489A0206 CC O
not P10758489A0206 RB O
with P10758489A0206 IN O
a P10758489A0206 DT O
second P10758489A0206 JJ O
CDK P10758489A0206 NNP I-UN
from P10758489A0206 IN I-UN
Arabidopsis P10758489A0206 NNP I-UN
, P10758489A0206 , O
Cdc2bAt P10758489A0206 NNP I-UN
. P10758489A0206 . O
. . O O

Lethal P00439618T0001 NNP O
Tachmalcor P00439618T0001 NNP O
( P00439618T0001 ( O
4- P00439618T0001 JJ O
( P00439618T0001 ( O
3'-diethylamino-2'-hydroxypropyl P00439618T0001 JJ O
) P00439618T0001 ) O
-ajmaline P00439618T0001 NN O
) P00439618T0001 ) O
poisoning P00439618T0001 NN O
in P00439618T0001 IN O
childhood P00439618T0001 NN O
. P00439618T0001 . O
. . O O

Valuing P10710985T0000 VBG O
families P10710985T0000 NNS O
: P10710985T0000 : O
social P10710985T0000 JJ O
work P10710985T0000 NN O
practice P10710985T0000 NN O
with P10710985T0000 IN O
families P10710985T0000 NNS O
from P10710985T0000 IN O
a P10710985T0000 DT O
strengths P10710985T0000 JJ O
perspective P10710985T0000 NN O
. P10710985T0000 . O
. . O O

MutY P10350454A0000 NNP I-UN
is P10350454A0000 VBZ O
an P10350454A0000 DT O
adenine-DNA P10350454A0000 JJ I-UN
glycosylase P10350454A0000 NN I-UN
with P10350454A0000 IN O
specificity P10350454A0000 NN O
for P10350454A0000 IN O
mismatches P10350454A0000 NNS O
involving P10350454A0000 VBG O
8-oxoguanine P10350454A0000 JJ O
( P10350454A0000 ( O
oG.A P10350454A0000 JJ O
) P10350454A0000 ) O
or P10350454A0000 CC O
guanine P10350454A0000 NN O
( P10350454A0000 ( O
G.A P10350454A0000 NNP O
) P10350454A0000 ) O
. P10350454A0000 . O
. . O O

By P08403804A0754 IN O
stepwise P08403804A0754 NN O
linear P08403804A0754 JJ O
multiple P08403804A0754 JJ O
regression P08403804A0754 NN O
analysis P08403804A0754 NN O
, P08403804A0754 , O
ionized P08403804A0754 JJ O
magnesium P08403804A0754 NN O
was P08403804A0754 VBD O
significantly P08403804A0754 RB O
related P08403804A0754 VBN O
to P08403804A0754 TO O
cyclosporin P08403804A0754 VB O
trough P08403804A0754 JJ O
level P08403804A0754 NN O
and P08403804A0754 CC O
total P08403804A0754 JJ O
cholesterol P08403804A0754 NN O
but P08403804A0754 CC O
not P08403804A0754 RB O
to P08403804A0754 TO O
serum P08403804A0754 VB O
creatinine P08403804A0754 NN O
, P08403804A0754 , O
time P08403804A0754 NN O
after P08403804A0754 IN O
transplant P08403804A0754 NN O
or P08403804A0754 CC O
the P08403804A0754 DT O
dose P08403804A0754 NN O
of P08403804A0754 IN O
cyclosporin P08403804A0754 NN O
. P08403804A0754 . O
. . O O

A P10381257A0000 DT O
recently P10381257A0000 RB O
described P10381257A0000 VBN O
protein P10381257A0000 NN O
, P10381257A0000 , O
metaxin P10381257A0000 NN I-UN
1 P10381257A0000 CD I-UN
, P10381257A0000 , O
serves P10381257A0000 VBZ O
as P10381257A0000 IN O
a P10381257A0000 DT O
component P10381257A0000 NN O
of P10381257A0000 IN O
a P10381257A0000 DT O
preprotein P10381257A0000 JJ O
import P10381257A0000 NN O
complex P10381257A0000 NN O
in P10381257A0000 IN O
the P10381257A0000 DT O
outer P10381257A0000 NN O
membrane P10381257A0000 NN O
of P10381257A0000 IN O
the P10381257A0000 DT O
mammalian P10381257A0000 JJ O
mitochondrion P10381257A0000 NN O
. P10381257A0000 . O
. . O O

Porcelain P01389362T0000 NN O
to P01389362T0000 TO O
dentin P01389362T0000 VB O
bond P01389362T0000 NN O
strength P01389362T0000 NN O
with P01389362T0000 IN O
a P01389362T0000 DT O
dentin P01389362T0000 NN O
adhesive P01389362T0000 NN O
. P01389362T0000 . O
. . O O

A P02165589A0888 DT O
portion P02165589A0888 NN O
of P02165589A0888 IN O
Region P02165589A0888 NNP O
II P02165589A0888 NNP O
also P02165589A0888 RB O
resembles P02165589A0888 VBZ O
part P02165589A0888 NN O
of P02165589A0888 IN O
the P02165589A0888 DT O
human P02165589A0888 JJ O
c-jun P02165589A0888 JJ I-UN
oncoprotein P02165589A0888 NN O
's P02165589A0888 POS O
leucine P02165589A0888 JJ O
zipper P02165589A0888 NN O
, P02165589A0888 , O
which P02165589A0888 WDT O
in P02165589A0888 IN O
turn P02165589A0888 NN O
, P02165589A0888 , O
has P02165589A0888 VBZ O
been P02165589A0888 VBN O
demonstrated P02165589A0888 VBN O
to P02165589A0888 TO O
be P02165589A0888 VB O
the P02165589A0888 DT O
heterodimerization P02165589A0888 NN O
site P02165589A0888 NN O
between P02165589A0888 IN O
the P02165589A0888 DT O
jun P02165589A0888 NN I-UN
and P02165589A0888 CC O
fos P02165589A0888 NN I-UN
oncoproteins P02165589A0888 NNS I-UN
. P02165589A0888 . O
. . O O

Three P10364314A0919 CD O
subgenomes P10364314A0919 NNS O
also P10364314A0919 RB O
comprised P10364314A0919 VBD O
15 P10364314A0919 CD O
to P10364314A0919 TO O
75 P10364314A0919 CD O
nucleotides P10364314A0919 NNS O
derived P10364314A0919 VBN O
from P10364314A0919 IN O
the P10364314A0919 DT O
5 P10364314A0919 CD O
' P10364314A0919 POS O
part P10364314A0919 NN O
of P10364314A0919 IN O
the P10364314A0919 DT O
NS2 P10364314A0919 NNP I-UN
gene P10364314A0919 NN I-UN
. P10364314A0919 . O
. . O O

The P02156828A0164 DT O
deduced P02156828A0164 JJ O
amino P02156828A0164 NN O
acid P02156828A0164 JJ O
sequence P02156828A0164 NN O
of P02156828A0164 IN O
destrin P02156828A0164 NN I-UN
is P02156828A0164 VBZ O
165 P02156828A0164 CD O
residues P02156828A0164 NNS O
long P02156828A0164 JJ O
and P02156828A0164 CC O
is P02156828A0164 VBZ O
very P02156828A0164 RB O
similar P02156828A0164 JJ O
( P02156828A0164 ( O
71 P02156828A0164 CD O
% P02156828A0164 NN O
identical P02156828A0164 JJ O
) P02156828A0164 ) O
to P02156828A0164 TO O
that P02156828A0164 DT O
of P02156828A0164 IN O
cofilin P02156828A0164 NN I-UN
, P02156828A0164 , O
a P02156828A0164 DT O
widely P02156828A0164 RB O
distributed P02156828A0164 VBN O
, P02156828A0164 , O
pH-sensitive P02156828A0164 JJ O
actin-modulating P02156828A0164 JJ O
protein P02156828A0164 NN O
. P02156828A0164 . O
. . O O

Dissipation P08371650T0000 NN O
of P08371650T0000 IN O
claudication P08371650T0000 NN O
pain P08371650T0000 NN O
after P08371650T0000 IN O
walking P08371650T0000 NN O
: P08371650T0000 : O
implications P08371650T0000 NNS O
for P08371650T0000 IN O
endurance P08371650T0000 NN O
training P08371650T0000 NN O
. P08371650T0000 . O
. . O O

Circulating P07784942T0001 VBG O
thrombomodulin P07784942T0001 NN I-UN
: P07784942T0001 : O
current P07784942T0001 JJ O
knowledge P07784942T0001 NN O
and P07784942T0001 CC O
future P07784942T0001 JJ O
prospects P07784942T0001 NNS O
. P07784942T0001 . O
. . O O

Yeast P02115121A0000 NN O
mutants P02115121A0000 NNS O
assigned P02115121A0000 VBN O
to P02115121A0000 TO O
the P02115121A0000 DT O
pet P02115121A0000 JJ I-UN
complementation P02115121A0000 NN O
group P02115121A0000 NN O
G104 P02115121A0000 NNP O
were P02115121A0000 VBD O
found P02115121A0000 VBN O
to P02115121A0000 TO O
lack P02115121A0000 VB O
alpha-ketoglutarate P02115121A0000 JJ I-UN
dehydrogenase P02115121A0000 NN I-UN
activity P02115121A0000 NN O
as P02115121A0000 IN O
a P02115121A0000 DT O
result P02115121A0000 NN O
of P02115121A0000 IN O
mutations P02115121A0000 NNS O
in P02115121A0000 IN O
the P02115121A0000 DT O
dihydrolipoyl P02115121A0000 NN I-UN
transsuccinylase P02115121A0000 NN I-UN
( P02115121A0000 ( O
KE2 P02115121A0000 NNP I-UN
) P02115121A0000 ) O
component P02115121A0000 NN O
of P02115121A0000 IN O
the P02115121A0000 DT O
complex P02115121A0000 NN O
. P02115121A0000 . O
. . O O

The P06494766A0241 DT O
persistent P06494766A0241 JJ O
fetal P06494766A0241 JJ O
dispersion P06494766A0241 NN O
of P06494766A0241 IN O
nodal P06494766A0241 JJ O
and P06494766A0241 CC O
Hiss P06494766A0241 NNP O
bundle P06494766A0241 NN O
fragments P06494766A0241 NNS O
within P06494766A0241 IN O
the P06494766A0241 DT O
ventricular P06494766A0241 JJ O
septum P06494766A0241 NN O
is P06494766A0241 VBZ O
proposed P06494766A0241 VBN O
as P06494766A0241 IN O
a P06494766A0241 DT O
possible P06494766A0241 JJ O
explanation P06494766A0241 NN O
. P06494766A0241 . O
. . O O

Transition P11218739A0811 NN O
between P11218739A0811 IN O
P- P11218739A0811 NNP O
and P11218739A0811 CC O
H-BPPV P11218739A0811 NNP O
was P11218739A0811 VBD O
found P11218739A0811 VBN O
in P11218739A0811 IN O
6 P11218739A0811 CD O
cases P11218739A0811 NNS O
. P11218739A0811 . O
. . O O

The P01898164A0839 DT O
currently P01898164A0839 RB O
proposed P01898164A0839 VBN O
extended P01898164A0839 VBN O
arch P01898164A0839 NN O
repair P01898164A0839 NN O
should P01898164A0839 MD O
be P01898164A0839 VB O
reserved P01898164A0839 VBN O
for P01898164A0839 IN O
the P01898164A0839 DT O
small P01898164A0839 JJ O
group P01898164A0839 NN O
of P01898164A0839 IN O
infants P01898164A0839 NNS O
with P01898164A0839 IN O
transverse P01898164A0839 JJ O
aortic P01898164A0839 JJ O
arch P01898164A0839 NN O
to P01898164A0839 TO O
ascending P01898164A0839 VBG O
aorta P01898164A0839 JJ O
diameter P01898164A0839 NN O
ratios P01898164A0839 NNS O
( P01898164A0839 ( O
arch P01898164A0839 JJ O
indices P01898164A0839 NNS O
) P01898164A0839 ) O
of P01898164A0839 IN O
less P01898164A0839 JJR O
than P01898164A0839 IN O
0.25 P01898164A0839 CD O
. P01898164A0839 . O
. . O O

Re-examination P07184774T0000 NN O
of P07184774T0000 IN O
the P07184774T0000 DT O
ED01 P07184774T0000 NNP O
study P07184774T0000 NN O
. P07184774T0000 . O
. . O O

EBER1 P09242551A0653 NNP I-UN
mRNA P09242551A0653 NN I-UN
, P09242551A0653 , O
a P09242551A0653 DT O
consistent P09242551A0653 JJ O
marker P09242551A0653 NN O
of P09242551A0653 IN O
viral P09242551A0653 JJ O
latency P09242551A0653 NN O
, P09242551A0653 , O
was P09242551A0653 VBD O
positive P09242551A0653 JJ O
in P09242551A0653 IN O
all P09242551A0653 DT O
PEL P09242551A0653 NNP O
cases P09242551A0653 NNS O
, P09242551A0653 , O
although P09242551A0653 IN O
at P09242551A0653 IN O
lower P09242551A0653 JJR O
levels P09242551A0653 NNS O
than P09242551A0653 IN O
in P09242551A0653 IN O
the P09242551A0653 DT O
non-PEL P09242551A0653 JJ O
controls P09242551A0653 NNS O
due P09242551A0653 JJ O
to P09242551A0653 TO O
EBER1 P09242551A0653 NNP I-UN
expression P09242551A0653 NN O
by P09242551A0653 IN O
only P09242551A0653 RB O
a P09242551A0653 DT O
variable P09242551A0653 JJ O
subset P09242551A0653 NN O
of P09242551A0653 IN O
lymphoma P09242551A0653 NN O
cells P09242551A0653 NNS O
. P09242551A0653 . O
. . O O

Western P09390183A1027 JJ O
blot P09390183A1027 NN O
analysis P09390183A1027 NN O
of P09390183A1027 IN O
various P09390183A1027 JJ O
bovine P09390183A1027 NN O
tissues P09390183A1027 NNS O
with P09390183A1027 IN O
human P09390183A1027 JJ O
NMT P09390183A1027 NNP I-UN
peptide P09390183A1027 NN I-UN
antibody P09390183A1027 NN I-UN
indicated P09390183A1027 VBD O
a P09390183A1027 DT O
common P09390183A1027 JJ O
prominent P09390183A1027 JJ O
immunoreactive P09390183A1027 JJ O
band P09390183A1027 NN O
with P09390183A1027 IN O
an P09390183A1027 DT O
apparent P09390183A1027 JJ O
molecular P09390183A1027 JJ O
mass P09390183A1027 NN O
of P09390183A1027 IN O
48.5-50 P09390183A1027 JJ O
kDa P09390183A1027 NN O
in P09390183A1027 IN O
all P09390183A1027 DT O
tissues P09390183A1027 NNS O
. P09390183A1027 . O
. . O O

Mutational P07565775T0000 JJ O
analysis P07565775T0000 NN O
of P07565775T0000 IN O
mRNA P07565775T0000 NN I-UN
capping P07565775T0000 VBG I-UN
enzyme P07565775T0000 JJ I-UN
identifies P07565775T0000 NNS O
amino P07565775T0000 VBP O
acids P07565775T0000 NNS O
involved P07565775T0000 VBN O
in P07565775T0000 IN O
GTP P07565775T0000 NNP O
binding P07565775T0000 NN O
, P07565775T0000 , O
enzyme-guanylate P07565775T0000 JJ O
formation P07565775T0000 NN O
, P07565775T0000 , O
and P07565775T0000 CC O
GMP P07565775T0000 NNP O
transfer P07565775T0000 NN O
to P07565775T0000 TO O
RNA P07565775T0000 NNP O
. P07565775T0000 . O
. . O O

Following P08453950A0498 VBG O
seizure P08453950A0498 NN O
induction P08453950A0498 NN O
, P08453950A0498 , O
MABP P08453950A0498 NNP O
increased P08453950A0498 VBD O
to P08453950A0498 TO O
105 P08453950A0498 CD O
mm P08453950A0498 NNS O
Hg P08453950A0498 NNP O
and P08453950A0498 CC O
brain P08453950A0498 NN O
pHi P08453950A0498 NN O
fell P08453950A0498 VBD O
to P08453950A0498 TO O
6.79 P08453950A0498 CD O
+ P08453950A0498 NNS O
/ P08453950A0498 SYM O
- P08453950A0498 : O
0.03 P08453950A0498 CD O
within P08453950A0498 IN O
15 P08453950A0498 CD O
min P08453950A0498 NNS O
and P08453950A0498 CC O
remained P08453950A0498 VBD O
at P08453950A0498 IN O
this P08453950A0498 DT O
level P08453950A0498 NN O
for P08453950A0498 IN O
1 P08453950A0498 CD O
h P08453950A0498 NN O
( P08453950A0498 ( O
P P08453950A0498 NNP O
< P08453950A0498 NNP O
0.001 P08453950A0498 CD O
) P08453950A0498 ) O
. P08453950A0498 . O
. . O O

Factor P10553551A0000 NNP I-UN
XI P10553551A0000 NNP I-UN
deficiency P10553551A0000 NN O
is P10553551A0000 VBZ O
a P10553551A0000 DT O
rare P10553551A0000 JJ O
hereditary P10553551A0000 JJ O
bleeding P10553551A0000 NN O
disorder P10553551A0000 NN O
affecting P10553551A0000 VBG O
the P10553551A0000 DT O
intrinsic P10553551A0000 JJ O
pathway P10553551A0000 NN O
. P10553551A0000 . O
. . O O

Analysis P01871971A0836 NN O
of P01871971A0836 IN O
viral P01871971A0836 JJ O
mutants P01871971A0836 NNS O
in P01871971A0836 IN O
vivo P01871971A0836 NN O
demonstrated P01871971A0836 VBD O
that P01871971A0836 IN O
the P01871971A0836 DT O
NFIII P01871971A0836 NNP I-UN
/ P01871971A0836 NNP O
OCT-1 P01871971A0836 NNP I-UN
binding P01871971A0836 NN O
site P01871971A0836 NN O
and P01871971A0836 CC O
a P01871971A0836 DT O
conserved P01871971A0836 JJ O
ATF P01871971A0836 NNP I-UN
motif P01871971A0836 NN I-UN
were P01871971A0836 VBD O
important P01871971A0836 JJ O
for P01871971A0836 IN O
efficient P01871971A0836 JJ O
viral P01871971A0836 JJ O
growth P01871971A0836 NN O
. P01871971A0836 . O
. . O O

Molecular P08892757T0000 JJ O
cloning P08892757T0000 NN O
of P08892757T0000 IN O
Elk-3 P08892757T0000 NNP I-UN
, P08892757T0000 , O
a P08892757T0000 DT O
new P08892757T0000 JJ O
member P08892757T0000 NN O
of P08892757T0000 IN O
the P08892757T0000 DT O
Ets P08892757T0000 NNP I-UN
family P08892757T0000 NN I-UN
expressed P08892757T0000 VBD O
during P08892757T0000 IN O
mouse P08892757T0000 NN O
embryogenesis P08892757T0000 NN O
and P08892757T0000 CC O
analysis P08892757T0000 NN O
of P08892757T0000 IN O
its P08892757T0000 PRP$ O
transcriptional P08892757T0000 JJ O
repression P08892757T0000 NN O
activity P08892757T0000 NN O
. P08892757T0000 . O
. . O O

The P09150728A0596 DT O
mRNA P09150728A0596 NN O
from P09150728A0596 IN O
this P09150728A0596 DT O
gene P09150728A0596 NN O
, P09150728A0596 , O
termed P09150728A0596 VBD O
HES1 P09150728A0596 NNP I-UN
, P09150728A0596 , O
is P09150728A0596 VBZ O
ubiquitously P09150728A0596 RB O
expressed P09150728A0596 VBN O
, P09150728A0596 , O
but P09150728A0596 CC O
strongly P09150728A0596 RB O
so P09150728A0596 RB O
in P09150728A0596 IN O
heart P09150728A0596 NN O
and P09150728A0596 CC O
skeletal P09150728A0596 JJ O
muscle P09150728A0596 NN O
. P09150728A0596 . O
. . O O

Transvenous P07075438T0000 JJ O
serial P07075438T0000 JJ O
xeroradiography P07075438T0000 NN O
. P07075438T0000 . O
. . O O

The P06527872T0000 DT O
segmental P06527872T0000 NN O
and P06527872T0000 CC O
regional P06527872T0000 JJ O
projections P06527872T0000 NNS O
of P06527872T0000 IN O
the P06527872T0000 DT O
sciatic P06527872T0000 JJ O
, P06527872T0000 , O
tibial P06527872T0000 JJ O
and P06527872T0000 CC O
common P06527872T0000 JJ O
peroneal P06527872T0000 NN O
nerves P06527872T0000 NNS O
to P06527872T0000 TO O
the P06527872T0000 DT O
substantia P06527872T0000 NN O
gelatinosa P06527872T0000 NN O
of P06527872T0000 IN O
the P06527872T0000 DT O
spinal P06527872T0000 JJ O
cord P06527872T0000 NN O
in P06527872T0000 IN O
rats P06527872T0000 NNS O
-- P06527872T0000 : O
an P06527872T0000 DT O
experimental P06527872T0000 JJ O
study P06527872T0000 NN O
by P06527872T0000 IN O
means P06527872T0000 NNS O
of P06527872T0000 IN O
an P06527872T0000 DT O
acid P06527872T0000 JJ I-UN
phosphatase P06527872T0000 NN I-UN
( P06527872T0000 ( O
ACP P06527872T0000 NNP I-UN
) P06527872T0000 ) O
method P06527872T0000 NN O
. P06527872T0000 . O
. . O O

Benefits P07606548T0000 NNS O
of P07606548T0000 IN O
obtaining P07606548T0000 VBG O
board P07606548T0000 NN O
certification P07606548T0000 NN O
in P07606548T0000 IN O
pharmacotherapy P07606548T0000 NN O
. P07606548T0000 . O
. . O O

One P07822329A0773 CD O
complex P07822329A0773 JJ O
appears P07822329A0773 VBZ O
to P07822329A0773 TO O
be P07822329A0773 VB O
ubiquitous P07822329A0773 JJ O
but P07822329A0773 CC O
enriched P07822329A0773 VBD O
in P07822329A0773 IN O
lymphoid P07822329A0773 JJ O
cells P07822329A0773 NNS O
and P07822329A0773 CC O
represents P07822329A0773 VBZ O
the P07822329A0773 DT O
binding P07822329A0773 NN O
of P07822329A0773 IN O
a P07822329A0773 DT O
potentially P07822329A0773 RB O
novel P07822329A0773 JJ O
factor P07822329A0773 NN O
with P07822329A0773 IN O
an P07822329A0773 DT O
apparent P07822329A0773 JJ O
molecular P07822329A0773 JJ O
mass P07822329A0773 NN O
of P07822329A0773 IN O
approximately P07822329A0773 RB O
50 P07822329A0773 CD O
kDa P07822329A0773 NNS O
. P07822329A0773 . O
. . O O

The P02023097A0000 DT O
human P02023097A0000 JJ I-UN
immunodeficiency P02023097A0000 NN I-UN
virus P02023097A0000 NN I-UN
type P02023097A0000 NN I-UN
1 P02023097A0000 CD I-UN
( P02023097A0000 ( I-UN
HIV-1 P02023097A0000 NNP I-UN
) P02023097A0000 ) I-UN
Rev P02023097A0000 NNP I-UN
protein P02023097A0000 NN I-UN
is P02023097A0000 VBZ O
a P02023097A0000 DT O
positive P02023097A0000 JJ O
posttranscriptional P02023097A0000 JJ O
regulator P02023097A0000 NN O
of P02023097A0000 IN O
viral P02023097A0000 JJ O
structural P02023097A0000 JJ O
gene P02023097A0000 NN O
expression P02023097A0000 NN O
and P02023097A0000 CC O
essential P02023097A0000 JJ O
for P02023097A0000 IN O
virus P02023097A0000 JJ O
replication P02023097A0000 NN O
. P02023097A0000 . O
. . O O

The P01684791A0000 DT O
cis-acting P01684791A0000 JJ O
element P01684791A0000 NN O
mediating P01684791A0000 VBG O
glucocorticoid P01684791A0000 JJ O
inducibility P01684791A0000 NN O
of P01684791A0000 IN O
the P01684791A0000 DT O
chicken P01684791A0000 NN I-UN
glutamine P01684791A0000 NN I-UN
synthetase P01684791A0000 NN I-UN
gene P01684791A0000 NN I-UN
has P01684791A0000 VBZ O
been P01684791A0000 VBN O
identified P01684791A0000 VBN O
. P01684791A0000 . O
. . O O

Grade P10343189A0911 $ O
3 P10343189A0911 CD O
mucositis P10343189A0911 NN O
was P10343189A0911 VBD O
reported P10343189A0911 VBN O
in P10343189A0911 IN O
1 P10343189A0911 CD O
patient P10343189A0911 NN O
. P10343189A0911 . O
. . O O

However P10360454A0916 RB O
, P10360454A0916 , O
the P10360454A0916 DT O
serum P10360454A0916 JJ I-UN
TNF-a P10360454A0916 NNP I-UN
concentration P10360454A0916 NN O
decreased P10360454A0916 VBD O
significantly P10360454A0916 RB O
in P10360454A0916 IN O
patients P10360454A0916 NNS O
receiving P10360454A0916 VBG O
pentoxifylline P10360454A0916 NN O
( P10360454A0916 ( O
basal P10360454A0916 JJ O
623+ P10360454A0916 CD O
/ P10360454A0916 JJ O
-366 P10360454A0916 NNP O
pg P10360454A0916 NN O
/ P10360454A0916 NNP O
ml P10360454A0916 NN O
; P10360454A0916 : O
6th P10360454A0916 CD O
month P10360454A0916 NN O
562+ P10360454A0916 CD O
/ P10360454A0916 NN O
-358 P10360454A0916 NNP O
pg P10360454A0916 NN O
/ P10360454A0916 NNP O
ml P10360454A0916 NN O
, P10360454A0916 , O
p P10360454A0916 NN O
< P10360454A0916 NNP O
0.01 P10360454A0916 CD O
) P10360454A0916 ) O
, P10360454A0916 , O
but P10360454A0916 CC O
not P10360454A0916 RB O
in P10360454A0916 IN O
the P10360454A0916 DT O
control P10360454A0916 NN O
group P10360454A0916 NN O
. P10360454A0916 . O
. . O O

Factor P08902988A0258 NNP O
V P08902988A0258 NNP O
Leiden P08902988A0258 NNP O
is P08902988A0258 VBZ O
a P08902988A0258 DT O
genetic P08902988A0258 JJ O
disorder P08902988A0258 NN O
associated P08902988A0258 VBN O
with P08902988A0258 IN O
an P08902988A0258 DT O
increased P08902988A0258 VBN O
risk P08902988A0258 NN O
of P08902988A0258 IN O
venous P08902988A0258 JJ O
thrombosis P08902988A0258 NN O
. P08902988A0258 . O
. . O O

Transcription P01904437A0000 NN O
of P01904437A0000 IN O
the P01904437A0000 DT O
metH P01904437A0000 NN I-UN
gene P01904437A0000 NN I-UN
in P01904437A0000 IN I-UN
Salmonella P01904437A0000 NNP I-UN
typhimurium P01904437A0000 NN I-UN
and P01904437A0000 CC I-UN
Escherichia P01904437A0000 NNP I-UN
coli P01904437A0000 NN I-UN
is P01904437A0000 VBZ O
positively P01904437A0000 RB O
regulated P01904437A0000 VBN O
by P01904437A0000 IN O
the P01904437A0000 DT O
metR P01904437A0000 JJ I-UN
gene P01904437A0000 NN I-UN
product P01904437A0000 NN I-UN
, P01904437A0000 , O
a P01904437A0000 DT O
DNA P01904437A0000 NN O
binding P01904437A0000 VBG O
protein P01904437A0000 NN O
. P01904437A0000 . O
. . O O

Because P06838388A0896 IN O
of P06838388A0896 IN O
a P06838388A0896 DT O
rapid P06838388A0896 JJ O
development P06838388A0896 NN O
of P06838388A0896 IN O
the P06838388A0896 DT O
connective P06838388A0896 JJ O
tissue P06838388A0896 NN O
scars P06838388A0896 NNS O
, P06838388A0896 , O
however P06838388A0896 RB O
, P06838388A0896 , O
at P06838388A0896 IN O
the P06838388A0896 DT O
place P06838388A0896 NN O
of P06838388A0896 IN O
the P06838388A0896 DT O
destroyed P06838388A0896 JJ O
glandular P06838388A0896 NN O
parenchyma P06838388A0896 NN O
areas P06838388A0896 NNS O
, P06838388A0896 , O
there P06838388A0896 EX O
is P06838388A0896 VBZ O
no P06838388A0896 DT O
normalization P06838388A0896 NN O
of P06838388A0896 IN O
the P06838388A0896 DT O
organ P06838388A0896 NN O
's P06838388A0896 POS O
structure P06838388A0896 NN O
and P06838388A0896 CC O
function P06838388A0896 NN O
by P06838388A0896 IN O
the P06838388A0896 DT O
42d P06838388A0896 CD O
day P06838388A0896 NN O
. P06838388A0896 . O
. . O O

Microcirculatory P10446833T0000 NNP O
oxygenation P10446833T0000 NN O
and P10446833T0000 CC O
shunting P10446833T0000 NN O
in P10446833T0000 IN O
sepsis P10446833T0000 NN O
and P10446833T0000 CC O
shock P10446833T0000 NN O
. P10446833T0000 . O
. . O O

The P02634490A0186 DT O
differential P02634490A0186 JJ O
diagnosis P02634490A0186 NN O
of P02634490A0186 IN O
both P02634490A0186 DT O
affections P02634490A0186 NNS O
is P02634490A0186 VBZ O
based P02634490A0186 VBN O
on P02634490A0186 IN O
the P02634490A0186 DT O
clinical P02634490A0186 JJ O
course P02634490A0186 NN O
, P02634490A0186 , O
sialography P02634490A0186 NN O
and P02634490A0186 CC O
CT P02634490A0186 NNP O
examination P02634490A0186 NN O
which P02634490A0186 WDT O
along P02634490A0186 RB O
with P02634490A0186 IN O
modern P02634490A0186 JJ O
ATB P02634490A0186 NNP O
treatment P02634490A0186 NN O
significantly P02634490A0186 RB O
modify P02634490A0186 VB O
hitherto P02634490A0186 NN O
used P02634490A0186 VBN O
surgical P02634490A0186 JJ O
therapy P02634490A0186 NN O
. P02634490A0186 . O
. . O O

Diltiazem P07610735A1471 NNP O
caused P07610735A1471 VBD O
significant P07610735A1471 JJ O
decrease P07610735A1471 NN O
in P07610735A1471 IN O
the P07610735A1471 DT O
ventricular P07610735A1471 JJ O
response P07610735A1471 NN O
without P07610735A1471 IN O
conversion P07610735A1471 NN O
to P07610735A1471 TO O
sinus P07610735A1471 VB O
rhythm P07610735A1471 NN O
. P07610735A1471 . O
. . O O

The P11534900A0000 DT O
binary P11534900A0000 JJ O
and P11534900A0000 CC O
tertiary P11534900A0000 JJ O
combinations P11534900A0000 NNS O
of P11534900A0000 IN O
plant-derived P11534900A0000 JJ O
molluscicides P11534900A0000 NNS O
Azadirachta P11534900A0000 NNP O
indica P11534900A0000 NN O
and P11534900A0000 CC O
Cedrus P11534900A0000 NNP O
deodara P11534900A0000 VB O
oil P11534900A0000 NN O
with P11534900A0000 IN O
synergists P11534900A0000 NNS O
MGK-264 P11534900A0000 NNP O
, P11534900A0000 , O
piperonyl P11534900A0000 NN O
butoxide P11534900A0000 NN O
( P11534900A0000 ( O
PB P11534900A0000 NNP O
) P11534900A0000 ) O
and P11534900A0000 CC O
fruit P11534900A0000 JJ O
powder P11534900A0000 NN O
of P11534900A0000 IN O
Embelia P11534900A0000 NNP O
ribes P11534900A0000 NNS O
were P11534900A0000 VBD O
used P11534900A0000 VBN O
against P11534900A0000 IN O
the P11534900A0000 DT O
Lymnaea P11534900A0000 NNP O
acuminata P11534900A0000 NN O
. P11534900A0000 . O
. . O O

Reduction P01245162A0262 NN O
in P01245162A0262 IN O
dosage P01245162A0262 NN O
restored P01245162A0262 VBN O
normal P01245162A0262 JJ O
taste P01245162A0262 NN O
sense P01245162A0262 NN O
in P01245162A0262 IN O
all P01245162A0262 DT O
three P01245162A0262 CD O
, P01245162A0262 , O
but P01245162A0262 CC O
in P01245162A0262 IN O
two P01245162A0262 CD O
the P01245162A0262 DT O
drug P01245162A0262 NN O
had P01245162A0262 VBD O
to P01245162A0262 TO O
be P01245162A0262 VB O
discontinued P01245162A0262 VBN O
because P01245162A0262 IN O
of P01245162A0262 IN O
persisting P01245162A0262 VBG O
high P01245162A0262 JJ O
transaminase P01245162A0262 NN O
levels P01245162A0262 NNS O
. P01245162A0262 . O
. . O O

The P08317092A0304 DT O
C-terminal P08317092A0304 JJ O
region P08317092A0304 NN O
of P08317092A0304 IN O
the P08317092A0304 DT O
150-kDa P08317092A0304 JJ O
protein P08317092A0304 NN O
contains P08317092A0304 VBZ O
an P08317092A0304 DT O
NTP-binding P08317092A0304 JJ O
helicase P08317092A0304 NN I-UN
motif P08317092A0304 NN I-UN
and P08317092A0304 CC O
the P08317092A0304 DT O
readthrough P08317092A0304 JJ O
region P08317092A0304 NN O
, P08317092A0304 , O
an P08317092A0304 DT O
RNA P08317092A0304 NNP I-UN
polymerase P08317092A0304 NN I-UN
motif P08317092A0304 NN I-UN
, P08317092A0304 , O
indicating P08317092A0304 VBG O
that P08317092A0304 IN O
these P08317092A0304 DT O
two P08317092A0304 CD O
overlapping P08317092A0304 VBG O
proteins P08317092A0304 NNS O
may P08317092A0304 MD O
form P08317092A0304 VB O
an P08317092A0304 DT O
RNA P08317092A0304 NNP O
replication P08317092A0304 NN O
complex P08317092A0304 NN O
similar P08317092A0304 JJ O
to P08317092A0304 TO O
those P08317092A0304 DT O
of P08317092A0304 IN O
tobamo- P08317092A0304 JJ O
and P08317092A0304 CC O
tobraviruses P08317092A0304 NNS O
. P08317092A0304 . O
. . O O

Lauciello P06373409A1163 NNP O
describes P06373409A1163 VBZ O
a P06373409A1163 DT O
technique P06373409A1163 NN O
for P06373409A1163 IN O
the P06373409A1163 DT O
placement P06373409A1163 NN O
of P06373409A1163 IN O
functionally P06373409A1163 RB O
generated P06373409A1163 VBN O
amalgam P06373409A1163 JJ O
stops P06373409A1163 NNS O
as P06373409A1163 IN O
restorations P06373409A1163 NNS O
within P06373409A1163 IN O
mandibular P06373409A1163 JJ O
acrylic P06373409A1163 JJ O
teeth P06373409A1163 NNS O
. P06373409A1163 . O
. . O O

CONCLUSIONS P10910439A1196 NN O
: P10910439A1196 : O
In P10910439A1196 IN O
essential P10910439A1196 JJ O
hypertension P10910439A1196 NN O
an P10910439A1196 DT O
acute P10910439A1196 JJ O
protein P10910439A1196 NN O
load P10910439A1196 NN O
induces P10910439A1196 VBZ O
a P10910439A1196 DT O
decrease P10910439A1196 NN O
in P10910439A1196 IN O
GFR P10910439A1196 NNP O
that P10910439A1196 WDT O
may P10910439A1196 MD O
normalize P10910439A1196 VB O
under P10910439A1196 IN O
antihypertensive P10910439A1196 JJ O
treatment P10910439A1196 NN O
. P10910439A1196 . O
. . O O

Clipping P08249319A0578 VBG O
resulted P08249319A0578 VBN O
in P08249319A0578 IN O
a P08249319A0578 DT O
serious P08249319A0578 JJ O
mislocalization P08249319A0578 NN O
of P08249319A0578 IN O
the P08249319A0578 DT O
position P08249319A0578 NN O
of P08249319A0578 IN O
the P08249319A0578 DT O
peak P08249319A0578 NN O
of P08249319A0578 IN O
the P08249319A0578 DT O
epicortical P08249319A0578 JJ O
potential P08249319A0578 JJ O
field P08249319A0578 NN O
. P08249319A0578 . O
. . O O

This P09733647A1960 DT O
sequence P09733647A1960 NN O
, P09733647A1960 , O
Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe P09733647A1960 NNP O
, P09733647A1960 , O
forms P09733647A1960 VBZ O
part P09733647A1960 NN O
of P09733647A1960 IN O
the P09733647A1960 DT O
B-loop P09733647A1960 NNP O
and P09733647A1960 CC O
is P09733647A1960 VBZ O
conserved P09733647A1960 VBN O
in P09733647A1960 IN O
a P09733647A1960 DT O
wide P09733647A1960 JJ O
variety P09733647A1960 NN O
of P09733647A1960 IN O
organisms P09733647A1960 NNS O
that P09733647A1960 WDT O
include P09733647A1960 VBP O
bacteria P09733647A1960 NNS O
, P09733647A1960 , O
algae P09733647A1960 NN O
and P09733647A1960 CC O
archeabacteria P09733647A1960 NN O
. P09733647A1960 . O
. . O O

According P02523800A1178 VBG O
to P02523800A1178 TO O
the P02523800A1178 DT O
published P02523800A1178 VBN O
sequence P02523800A1178 NN O
of P02523800A1178 IN O
the P02523800A1178 DT O
CHS1 P02523800A1178 NNP I-UN
gene P02523800A1178 NN I-UN
, P02523800A1178 , O
this P02523800A1178 DT O
fragment P02523800A1178 NN O
contains P02523800A1178 VBZ O
four P02523800A1178 CD O
repeats P02523800A1178 NN O
of P02523800A1178 IN O
a P02523800A1178 DT O
TGAAACA P02523800A1178 NNP O
consensus P02523800A1178 NN O
sequence P02523800A1178 NN O
previously P02523800A1178 RB O
identified P02523800A1178 VBN O
in P02523800A1178 IN O
the P02523800A1178 DT O
alpha-factor-inducible P02523800A1178 JJ O
BAR1 P02523800A1178 NNP I-UN
promoter P02523800A1178 NN I-UN
[ P02523800A1178 NNP O
Kronstad P02523800A1178 NNP O
, P02523800A1178 , O
J P02523800A1178 NNP O
. P02523800A1178 . O
. . O O

CONCLUSIONS P11789206A1182 NN O
: P11789206A1182 : O
The P11789206A1182 DT O
mechanism P11789206A1182 NN O
of P11789206A1182 IN O
MIRI P11789206A1182 NNP O
is P11789206A1182 VBZ O
Qi P11789206A1182 NNP O
deficiency P11789206A1182 NN O
and P11789206A1182 CC O
blood P11789206A1182 NN O
stasis P11789206A1182 NN O
in P11789206A1182 IN O
TCM P11789206A1182 NNP O
, P11789206A1182 , O
its P11789206A1182 PRP$ O
treating P11789206A1182 VBG O
principles P11789206A1182 NNS O
should P11789206A1182 MD O
be P11789206A1182 VB O
promoting P11789206A1182 VBG O
Qi P11789206A1182 NNP O
and P11789206A1182 CC O
removing P11789206A1182 VBG O
the P11789206A1182 DT O
blood P11789206A1182 NN O
stasis P11789206A1182 NN O
. P11789206A1182 . O
. . O O

12-O-Tetradecanoylphorbol P01765095A0680 JJ O
13-acetate P01765095A0680 NN O
was P01765095A0680 VBD O
found P01765095A0680 VBN O
to P01765095A0680 TO O
inhibit P01765095A0680 VB O
rapidly P01765095A0680 RB O
and P01765095A0680 CC O
potently P01765095A0680 RB O
the P01765095A0680 DT O
expression P01765095A0680 NN O
of P01765095A0680 IN O
mRNAs P01765095A0680 NN O
coding P01765095A0680 VBG O
for P01765095A0680 IN O
the P01765095A0680 DT O
myogenic P01765095A0680 JJ O
regulators P01765095A0680 NNS O
CMD1 P01765095A0680 NNP I-UN
and P01765095A0680 CC O
myogenin P01765095A0680 NN I-UN
. P01765095A0680 . O
. . O O

Lengthy P01909621A0119 NNP O
and P01909621A0119 CC O
repeated P01909621A0119 VBN O
hemodialyses P01909621A0119 NNS O
were P01909621A0119 VBD O
required P01909621A0119 VBN O
to P01909621A0119 TO O
lower P01909621A0119 VB O
lithemia P01909621A0119 NN O
to P01909621A0119 TO O
nontoxic P01909621A0119 JJ O
ranges P01909621A0119 NNS O
. P01909621A0119 . O
. . O O

The P10888570A0678 DT O
total P10888570A0678 JJ O
alkaloids P10888570A0678 NNS O
contained P10888570A0678 VBN O
in P10888570A0678 IN O
the P10888570A0678 DT O
peel P10888570A0678 NN O
of P10888570A0678 IN O
Atzimba P10888570A0678 NNP O
, P10888570A0678 , O
Lopez P10888570A0678 NNP O
, P10888570A0678 , O
Marciana P10888570A0678 NNP O
, P10888570A0678 , O
Montsama P10888570A0678 NNP O
, P10888570A0678 , O
Murca P10888570A0678 NNP O
, P10888570A0678 , O
and P10888570A0678 CC O
Puebla P10888570A0678 NNP O
was P10888570A0678 VBD O
lower P10888570A0678 JJR O
than P10888570A0678 IN O
the P10888570A0678 DT O
limits P10888570A0678 NNS O
recommended P10888570A0678 VBD O
for P10888570A0678 IN O
food P10888570A0678 NN O
safety P10888570A0678 NN O
. P10888570A0678 . O
. . O O

Yap1p P09857197A0289 NN I-UN
is P09857197A0289 VBZ O
constitutively P09857197A0289 RB O
nuclear P09857197A0289 JJ O
in P09857197A0289 IN O
a P09857197A0289 DT O
crm1 P09857197A0289 NN I-UN
mutant P09857197A0289 NN I-UN
, P09857197A0289 , O
and P09857197A0289 CC O
Crm1p P09857197A0289 NNP I-UN
binds P09857197A0289 VBZ O
to P09857197A0289 TO O
a P09857197A0289 DT O
nuclear P09857197A0289 JJ O
export P09857197A0289 NN O
sequence P09857197A0289 NN O
( P09857197A0289 ( O
NES P09857197A0289 NNP O
) P09857197A0289 ) O
-like P09857197A0289 VBP O
sequence P09857197A0289 NN O
in P09857197A0289 IN O
Yap1p P09857197A0289 NNP I-UN
in P09857197A0289 IN O
the P09857197A0289 DT O
presence P09857197A0289 NN O
of P09857197A0289 IN O
RanGTP P09857197A0289 NNP I-UN
. P09857197A0289 . O
. . O O

M-Ras P10446149A0809 NNP I-UN
interacted P10446149A0809 VBD O
poorly P10446149A0809 RB O
in P10446149A0809 IN O
a P10446149A0809 DT O
yeast P10446149A0809 JJ O
two-hybrid P10446149A0809 JJ O
assay P10446149A0809 NN O
with P10446149A0809 IN O
multiple P10446149A0809 JJ O
Ras P10446149A0809 NNP I-UN
effectors P10446149A0809 NNS O
, P10446149A0809 , O
including P10446149A0809 VBG O
c-Raf-1 P10446149A0809 JJ I-UN
, P10446149A0809 , O
A-Raf P10446149A0809 NNP I-UN
, P10446149A0809 , O
B-Raf P10446149A0809 NNP I-UN
, P10446149A0809 , O
phosphoinositol-3 P10446149A0809 JJ I-UN
kinase P10446149A0809 NN I-UN
delta P10446149A0809 NN I-UN
, P10446149A0809 , O
RalGDS P10446149A0809 NNP I-UN
, P10446149A0809 , O
and P10446149A0809 CC O
Rin1 P10446149A0809 NNP I-UN
. P10446149A0809 . O
. . O O

However P08120019A1500 RB O
, P08120019A1500 , O
three P08120019A1500 CD O
Hm1 P08120019A1500 NNP I-UN
mutants P08120019A1500 NNS I-UN
that P08120019A1500 WDT O
were P08120019A1500 VBD O
moderately P08120019A1500 RB O
deficient P08120019A1500 JJ O
in P08120019A1500 IN O
stimulating P08120019A1500 VBG O
PI P08120019A1500 NNP O
turnover P08120019A1500 RB O
displayed P08120019A1500 VBD O
normal P08120019A1500 JJ O
sequestration P08120019A1500 NN O
, P08120019A1500 , O
suggesting P08120019A1500 VBG O
distinct P08120019A1500 JJ O
mechanisms P08120019A1500 NNS O
. P08120019A1500 . O
. . O O

Framingham P03818866A0116 NNP O
Type P03818866A0116 NNP O
A P03818866A0116 NNP O
behavior P03818866A0116 NN O
was P03818866A0116 VBD O
positively P03818866A0116 RB O
associated P03818866A0116 VBN O
with P03818866A0116 IN O
diastolic P03818866A0116 JJ O
blood P03818866A0116 NN O
pressure P03818866A0116 NN O
( P03818866A0116 ( O
r P03818866A0116 JJ O
= P03818866A0116 NN O
0.17 P03818866A0116 CD O
, P03818866A0116 , O
p P03818866A0116 NN O
less P03818866A0116 JJR O
than P03818866A0116 IN O
0.05 P03818866A0116 CD O
) P03818866A0116 ) O
among P03818866A0116 IN O
the P03818866A0116 DT O
women P03818866A0116 NNS O
. P03818866A0116 . O
. . O O

The P09423968A0039 DT O
mechanism P09423968A0039 NN O
underlying P09423968A0039 VBG O
such P09423968A0039 JJ O
analgesia P09423968A0039 NN O
has P09423968A0039 VBZ O
been P09423968A0039 VBN O
suggested P09423968A0039 VBN O
to P09423968A0039 TO O
involve P09423968A0039 VB O
the P09423968A0039 DT O
interaction P09423968A0039 NN O
between P09423968A0039 IN O
the P09423968A0039 DT O
two P09423968A0039 CD O
separate P09423968A0039 JJ O
but P09423968A0039 CC O
interconnected P09423968A0039 JJ O
motivational P09423968A0039 JJ O
systems P09423968A0039 NNS O
`` P09423968A0039 `` O
defense P09423968A0039 NN O
'' P09423968A0039 '' O
and P09423968A0039 CC O
`` P09423968A0039 `` O
pain P09423968A0039 NN O
. P09423968A0039 . O
'' P09423968A0039 '' O
To P09423968A0039 TO O
determine P09423968A0039 VB O
the P09423968A0039 DT O
developmental P09423968A0039 JJ O
course P09423968A0039 NN O
of P09423968A0039 IN O
defense P09423968A0039 NN O
and P09423968A0039 CC O
nociception P09423968A0039 NN O
, P09423968A0039 , O
these P09423968A0039 DT O
processes P09423968A0039 NNS O
were P09423968A0039 VBD O
analyzed P09423968A0039 VBN O
during P09423968A0039 IN O
early P09423968A0039 JJ O
ontogeny P09423968A0039 NN O
in P09423968A0039 IN O
rats P09423968A0039 NNS O
. P09423968A0039 . O
. . O O

Among P11117263A0570 IN O
eight P11117263A0570 CD O
graminaceous P11117263A0570 JJ O
species P11117263A0570 NNS O
tested P11117263A0570 VBN O
, P11117263A0570 , O
Ids3 P11117263A0570 NNP I-UN
expression P11117263A0570 NN O
was P11117263A0570 VBD O
observed P11117263A0570 VBN O
only P11117263A0570 RB O
in P11117263A0570 IN O
Fe-deficient P11117263A0570 NNP O
roots P11117263A0570 NNS O
of P11117263A0570 IN O
H. P11117263A0570 NNP O
vulgare P11117263A0570 NN O
and P11117263A0570 CC O
Secale P11117263A0570 NNP O
cereale P11117263A0570 NN O
. P11117263A0570 . O
which P11117263A0570 WDT O
not P11117263A0570 RB O
only P11117263A0570 RB O
secrete P11117263A0570 JJ O
2'-deoxymugineic P11117263A0570 JJ O
acid P11117263A0570 NN O
( P11117263A0570 ( O
DMA P11117263A0570 NNP O
) P11117263A0570 ) O
, P11117263A0570 , O
but P11117263A0570 CC O
also P11117263A0570 RB O
mugineic P11117263A0570 JJ O
acid P11117263A0570 NN O
( P11117263A0570 ( O
MA P11117263A0570 NNP O
) P11117263A0570 ) O
and P11117263A0570 CC O
3-epihydroxymugineic P11117263A0570 JJ O
acid P11117263A0570 NN O
( P11117263A0570 ( O
epiHMA P11117263A0570 JJ O
, P11117263A0570 , O
H. P11117263A0570 NNP O
vulgare P11117263A0570 NN O
) P11117263A0570 ) O
, P11117263A0570 , O
and P11117263A0570 CC O
3-hydroxymugineic P11117263A0570 JJ O
acid P11117263A0570 NN O
( P11117263A0570 ( O
HMA P11117263A0570 NNP O
, P11117263A0570 , O
S. P11117263A0570 NNP O
cereale P11117263A0570 NN O
) P11117263A0570 ) O
. P11117263A0570 . O
. . O O

Solitary P07704689T0000 JJ O
thyroid P07704689T0000 NN O
nodule P07704689T0000 NN O
. P07704689T0000 . O
. . O O

A P07534286A0842 DT O
chicken P07534286A0842 NN I-UN
paxillin P07534286A0842 NN I-UN
cDNA P07534286A0842 NN I-UN
was P07534286A0842 VBD O
also P07534286A0842 RB O
cloned P07534286A0842 VBN O
and P07534286A0842 CC O
is P07534286A0842 VBZ O
predicted P07534286A0842 VBN O
to P07534286A0842 TO O
encode P07534286A0842 VB O
a P07534286A0842 DT O
protein P07534286A0842 NN O
approximately P07534286A0842 RB O
90 P07534286A0842 CD O
% P07534286A0842 NN O
identical P07534286A0842 JJ O
to P07534286A0842 TO O
human P07534286A0842 JJ I-UN
paxil-lin P07534286A0842 NN I-UN
. P07534286A0842 . O
. . O O

Developmental P10355910A0369 JJ O
follow-up P10355910A0369 NN O
at P10355910A0369 IN O
age P10355910A0369 NN O
2 P10355910A0369 CD O
years P10355910A0369 NNS O
was P10355910A0369 VBD O
performed P10355910A0369 VBN O
. P10355910A0369 . O
. . O O

In P02142955A0248 IN O
Experiments P02142955A0248 NNS O
1 P02142955A0248 CD O
and P02142955A0248 CC O
2 P02142955A0248 CD O
, P02142955A0248 , O
infants P02142955A0248 NNS O
, P02142955A0248 , O
like P02142955A0248 IN O
adults P02142955A0248 NNS O
, P02142955A0248 , O
initially P02142955A0248 RB O
categorized P02142955A0248 VBN O
novel P02142955A0248 JJ O
objects P02142955A0248 NNS O
on P02142955A0248 IN O
the P02142955A0248 DT O
basis P02142955A0248 NN O
of P02142955A0248 IN O
physical P02142955A0248 JJ O
appearance P02142955A0248 NN O
, P02142955A0248 , O
but P02142955A0248 CC O
only P02142955A0248 RB O
if P02142955A0248 IN O
trained P02142955A0248 VBN O
with P02142955A0248 IN O
multiple P02142955A0248 JJ O
exemplars P02142955A0248 NNS O
, P02142955A0248 , O
after P02142955A0248 IN O
delays P02142955A0248 NNS O
of P02142955A0248 IN O
1 P02142955A0248 CD O
and P02142955A0248 CC O
7 P02142955A0248 CD O
days P02142955A0248 NNS O
. P02142955A0248 . O
. . O O

In P11301189A1396 IN O
contrast P11301189A1396 NN O
, P11301189A1396 , O
the P11301189A1396 DT O
ubiquitous P11301189A1396 JJ O
expression P11301189A1396 NN O
of P11301189A1396 IN O
p19 P11301189A1396 NN I-UN
( P11301189A1396 ( O
INK4d P11301189A1396 NNP I-UN
) P11301189A1396 ) O
has P11301189A1396 VBZ O
not P11301189A1396 RB O
been P11301189A1396 VBN O
previously P11301189A1396 RB O
described P11301189A1396 VBN O
in P11301189A1396 IN O
human P11301189A1396 JJ O
or P11301189A1396 CC O
murine P11301189A1396 JJ O
B-lineage P11301189A1396 JJ O
cells P11301189A1396 NNS O
. P11301189A1396 . O
. . O O

We P08511994A0000 PRP O
have P08511994A0000 VBP O
found P08511994A0000 VBN O
out P08511994A0000 RP O
that P08511994A0000 IN O
one-year-old P08511994A0000 JJ O
carps P08511994A0000 NNS O
are P08511994A0000 VBP O
extremely P08511994A0000 RB O
sensitive P08511994A0000 JJ O
to P08511994A0000 TO O
ichthiomycin P08511994A0000 VB O
in P08511994A0000 IN O
concentrations P08511994A0000 NNS O
between P08511994A0000 IN O
25-125 P08511994A0000 JJ O
micrograms P08511994A0000 NNS O
/ P08511994A0000 VBP O
dm3 P08511994A0000 NN O
. P08511994A0000 . O
. . O O

The P11041308A0156 DT O
subjects P11041308A0156 NNS O
were P11041308A0156 VBD O
diagnosed P11041308A0156 VBN O
on P11041308A0156 IN O
the P11041308A0156 DT O
basis P11041308A0156 NN O
of P11041308A0156 IN O
DSM-IV P11041308A0156 NNP O
pathological P11041308A0156 JJ O
gambling P11041308A0156 NN O
criteria P11041308A0156 NNS O
and P11041308A0156 CC O
completed P11041308A0156 VBD O
the P11041308A0156 DT O
Turkish P11041308A0156 JJ O
Version P11041308A0156 NNP O
of P11041308A0156 IN O
South P11041308A0156 NNP O
Oaks P11041308A0156 NNPS O
Gambling P11041308A0156 VBG O
Screen P11041308A0156 NNP O
( P11041308A0156 ( O
SOGS P11041308A0156 NNP O
) P11041308A0156 ) O
. P11041308A0156 . O
. . O O

The P07607669A1112 DT O
5'flanking P07607669A1112 CD O
region P07607669A1112 NN O
is P07607669A1112 VBZ O
highly P07607669A1112 RB O
GC P07607669A1112 NNP O
rich P07607669A1112 JJ O
, P07607669A1112 , O
with P07607669A1112 IN O
multiple P07607669A1112 JJ O
CpG P07607669A1112 NNP O
doublets P07607669A1112 NNS O
, P07607669A1112 , O
and P07607669A1112 CC O
contains P07607669A1112 VBZ O
multiple P07607669A1112 JJ O
binding P07607669A1112 NN O
sites P07607669A1112 NNS O
for P07607669A1112 IN O
Sp1 P07607669A1112 NNP I-UN
. P07607669A1112 . O
. . O O

Transformed P02895472A0178 VBN O
bacterial P02895472A0178 JJ O
colonies P02895472A0178 NNS O
were P02895472A0178 VBD O
screened P02895472A0178 VBN O
for P02895472A0178 IN O
recombinant P02895472A0178 JJ O
plasmids P02895472A0178 NNS O
containing P02895472A0178 VBG O
cDNA P02895472A0178 NN O
coding P02895472A0178 VBG O
for P02895472A0178 IN O
BiP P02895472A0178 NNP I-UN
by P02895472A0178 IN O
hybrid-selected P02895472A0178 JJ O
mRNA P02895472A0178 NN O
translation P02895472A0178 NN O
. P02895472A0178 . O
. . O O

Low-selenium P11519466A0196 JJ O
diet P11519466A0196 NN O
has P11519466A0196 VBZ O
a P11519466A0196 DT O
human P11519466A0196 JJ O
unfavourable P11519466A0196 JJ O
impact P11519466A0196 NN O
. P11519466A0196 . O
. . O O

Of P10693314A0521 IN O
the P10693314A0521 DT O
153 P10693314A0521 CD O
patients P10693314A0521 NNS O
studied P10693314A0521 VBN O
, P10693314A0521 , O
CK-MB P10693314A0521 JJ I-UN
results P10693314A0521 NNS O
were P10693314A0521 VBD O
positive P10693314A0521 JJ O
in P10693314A0521 IN O
91 P10693314A0521 CD O
( P10693314A0521 ( O
59 P10693314A0521 CD O
% P10693314A0521 NN O
) P10693314A0521 ) O
patients P10693314A0521 NNS O
; P10693314A0521 : O
ECG P10693314A0521 NNP O
revealed P10693314A0521 VBD O
AMI P10693314A0521 NNP O
in P10693314A0521 IN O
72 P10693314A0521 CD O
( P10693314A0521 ( O
47 P10693314A0521 CD O
% P10693314A0521 NN O
) P10693314A0521 ) O
patients P10693314A0521 NNS O
. P10693314A0521 . O
. . O O

Furthermore P09882499A0231 RB O
, P09882499A0231 , O
using P09882499A0231 VBG O
transgenic P09882499A0231 JJ O
mouse P09882499A0231 NN O
technology P09882499A0231 NN O
we P09882499A0231 PRP O
localized P09882499A0231 VBD O
independent P09882499A0231 JJ O
cis-regulatory P09882499A0231 JJ O
elements P09882499A0231 NNS O
controlling P09882499A0231 VBG O
the P09882499A0231 DT O
tissue-specific P09882499A0231 JJ O
expression P09882499A0231 NN O
of P09882499A0231 IN O
Pax6 P09882499A0231 NNP I-UN
. P09882499A0231 . O
. . O O

Our P07910716A0359 PRP$ O
study P07910716A0359 NN O
cohorts P07910716A0359 NNS O
consisted P07910716A0359 VBD O
of P07910716A0359 IN O
15 P07910716A0359 CD O
patients P07910716A0359 NNS O
who P07910716A0359 WP O
received P07910716A0359 VBD O
SC P07910716A0359 NNP O
rIL-2 P07910716A0359 NN I-UN
at P07910716A0359 IN O
doses P07910716A0359 NNS O
of P07910716A0359 IN O
4.8-14.4 P07910716A0359 JJ O
million P07910716A0359 CD O
IU P07910716A0359 NNP O
/ P07910716A0359 NNP O
m2 P07910716A0359 NN O
/ P07910716A0359 NNP O
day P07910716A0359 NN O
on P07910716A0359 IN O
5 P07910716A0359 CD O
days P07910716A0359 NNS O
per P07910716A0359 IN O
week P07910716A0359 NN O
for P07910716A0359 IN O
a P07910716A0359 DT O
total P07910716A0359 NN O
of P07910716A0359 IN O
8 P07910716A0359 CD O
weeks P07910716A0359 NNS O
, P07910716A0359 , O
20 P07910716A0359 CD O
patients P07910716A0359 NNS O
who P07910716A0359 WP O
received P07910716A0359 VBD O
rIFN-alpha P07910716A0359 JJ I-UN
2b P07910716A0359 CD I-UN
at P07910716A0359 IN O
3.0-6.0 P07910716A0359 CD O
million P07910716A0359 CD O
U P07910716A0359 NNP O
/ P07910716A0359 NNP O
m2 P07910716A0359 NN O
/ P07910716A0359 NNP O
day P07910716A0359 NN O
thrice P07910716A0359 JJ O
weekly P07910716A0359 RB O
for P07910716A0359 IN O
a P07910716A0359 DT O
total P07910716A0359 NN O
of P07910716A0359 IN O
6 P07910716A0359 CD O
weeks P07910716A0359 NNS O
, P07910716A0359 , O
and P07910716A0359 CC O
72 P07910716A0359 CD O
patients P07910716A0359 NNS O
who P07910716A0359 WP O
were P07910716A0359 VBD O
given P07910716A0359 VBN O
SC P07910716A0359 NNP O
rIFN-alpha P07910716A0359 JJ I-UN
2b P07910716A0359 CD I-UN
at P07910716A0359 IN O
6.0 P07910716A0359 CD O
million P07910716A0359 CD O
U P07910716A0359 NNP O
/ P07910716A0359 NNP O
m2 P07910716A0359 NN O
/ P07910716A0359 NNP O
day P07910716A0359 NN O
thrice P07910716A0359 JJ O
weekly P07910716A0359 JJ O
plus P07910716A0359 CC O
SC P07910716A0359 JJ O
rIL-2 P07910716A0359 NN I-UN
at P07910716A0359 IN O
14.4-18.0 P07910716A0359 CD O
million P07910716A0359 CD O
IU P07910716A0359 NNP O
/ P07910716A0359 NNP O
m2 P07910716A0359 NN O
/ P07910716A0359 NNP O
day P07910716A0359 NN O
on P07910716A0359 IN O
days P07910716A0359 NNS O
1 P07910716A0359 CD O
and P07910716A0359 CC O
2 P07910716A0359 CD O
, P07910716A0359 , O
followed P07910716A0359 VBN O
by P07910716A0359 IN O
4.8 P07910716A0359 CD O
million P07910716A0359 CD O
IU P07910716A0359 NNP O
/ P07910716A0359 NNP O
m2 P07910716A0359 NN O
/ P07910716A0359 NNP O
day P07910716A0359 NN O
, P07910716A0359 , O
5 P07910716A0359 CD O
days P07910716A0359 NNS O
per P07910716A0359 IN O
week P07910716A0359 NN O
for P07910716A0359 IN O
6 P07910716A0359 CD O
consecutive P07910716A0359 JJ O
weeks P07910716A0359 NNS O
. P07910716A0359 . O
. . O O

Both P09931252A1055 DT O
mutations P09931252A1055 NNS O
confer P09931252A1055 VBP O
amino P09931252A1055 JJ O
acid P09931252A1055 JJ O
substitutions P09931252A1055 NNS O
in P09931252A1055 IN O
the P09931252A1055 DT O
viral P09931252A1055 JJ I-UN
coat P09931252A1055 NN I-UN
protein P09931252A1055 NN I-UN
but P09931252A1055 CC O
differ P09931252A1055 VBP O
in P09931252A1055 IN O
their P09931252A1055 PRP$ O
relative P09931252A1055 JJ O
abilities P09931252A1055 NNS O
to P09931252A1055 TO O
utilize P09931252A1055 VB O
the P09931252A1055 DT O
foreign P09931252A1055 JJ O
scaffolding P09931252A1055 NN I-UN
protein P09931252A1055 NN I-UN
. P09931252A1055 . O
. . O O

Furthermore P09891065A1493 RB O
, P09891065A1493 , O
rhoA-mediated P09891065A1493 JJ O
SRE P09891065A1493 NNP O
activation P09891065A1493 NN O
was P09891065A1493 VBD O
blocked P09891065A1493 VBN O
by P09891065A1493 IN O
dominant P09891065A1493 JJ O
negative P09891065A1493 JJ O
mutants P09891065A1493 NNS O
of P09891065A1493 IN O
PKC-alpha P09891065A1493 NNP I-UN
or P09891065A1493 CC O
PKC-epsilon P09891065A1493 NNP I-UN
. P09891065A1493 . O
. . O O

Mean P11443999A0573 NNP O
Hg P11443999A0573 NNP O
concentrations P11443999A0573 NNS O
in P11443999A0573 IN O
the P11443999A0573 DT O
livers P11443999A0573 NNS O
of P11443999A0573 IN O
mice P11443999A0573 NN O
at P11443999A0573 IN O
some P11443999A0573 DT O
sites P11443999A0573 NNS O
in P11443999A0573 IN O
Isle P11443999A0573 NNP O
Royale P11443999A0573 NNP O
are P11443999A0573 VBP O
not P11443999A0573 RB O
significantly P11443999A0573 RB O
lower P11443999A0573 JJR O
( P11443999A0573 ( O
P P11443999A0573 NNP O
= P11443999A0573 NNP O
0.62 P11443999A0573 CD O
) P11443999A0573 ) O
than P11443999A0573 IN O
Hg P11443999A0573 NNP O
concentrations P11443999A0573 NNS O
considered P11443999A0573 VBN O
by P11443999A0573 IN O
some P11443999A0573 DT O
government P11443999A0573 NN O
agencies P11443999A0573 NNS O
to P11443999A0573 TO O
be P11443999A0573 VB O
unhealthy P11443999A0573 JJ O
for P11443999A0573 IN O
human P11443999A0573 JJ O
consumption P11443999A0573 NN O
. P11443999A0573 . O
. . O O

Two P10627834A0178 CD O
US P10627834A0178 PRP O
commercial P10627834A0178 JJ O
cultivars P10627834A0178 NNS O
( P10627834A0178 ( O
Tehama P10627834A0178 NNP O
and P10627834A0178 CC O
Vina P10627834A0178 NNP O
) P10627834A0178 ) O
, P10627834A0178 , O
three P10627834A0178 CD O
European P10627834A0178 JJ O
commercial P10627834A0178 JJ O
cultivars P10627834A0178 NNS O
( P10627834A0178 ( O
Esterhazy P10627834A0178 NNP O
, P10627834A0178 , O
139 P10627834A0178 CD O
, P10627834A0178 , O
G120 P10627834A0178 NNP O
) P10627834A0178 ) O
and P10627834A0178 CC O
five P10627834A0178 CD O
New P10627834A0178 NNP O
Zealand P10627834A0178 NNP O
selections P10627834A0178 NNS O
( P10627834A0178 ( O
Rex P10627834A0178 NNP O
, P10627834A0178 , O
Dublin P10627834A0178 NNP O
's P10627834A0178 POS O
Glory P10627834A0178 NNP O
, P10627834A0178 , O
Meyric P10627834A0178 NNP O
, P10627834A0178 , O
McKinster P10627834A0178 NNP O
, P10627834A0178 , O
Stanley P10627834A0178 NNP O
) P10627834A0178 ) O
were P10627834A0178 VBD O
evaluated P10627834A0178 VBN O
. P10627834A0178 . O
. . O O

This P09144958A0047 DT O
protein P09144958A0047 NN O
can P09144958A0047 MD O
bind P09144958A0047 VB O
to P09144958A0047 TO O
a P09144958A0047 DT O
region P09144958A0047 NN O
of P09144958A0047 IN O
the P09144958A0047 DT O
promoter P09144958A0047 NN O
of P09144958A0047 IN O
an P09144958A0047 DT O
Arabidopsis P09144958A0047 NNP I-UN
light-harvesting P09144958A0047 NN I-UN
chlorophyll P09144958A0047 NN I-UN
a P09144958A0047 DT I-UN
/ P09144958A0047 NN I-UN
b P09144958A0047 NN I-UN
protein P09144958A0047 NN I-UN
gene P09144958A0047 NN I-UN
, P09144958A0047 , O
Lhcb1*3 P09144958A0047 NNP I-UN
, P09144958A0047 , O
which P09144958A0047 WDT O
is P09144958A0047 VBZ O
necessary P09144958A0047 JJ O
for P09144958A0047 IN O
its P09144958A0047 PRP$ O
regulation P09144958A0047 NN O
by P09144958A0047 IN O
phytochrome P09144958A0047 NN I-UN
. P09144958A0047 . O
. . O O

Combination P04788701T0001 NN O
of P04788701T0001 IN O
3 P04788701T0001 CD O
multiple P04788701T0001 JJ O
primary P04788701T0001 JJ O
malignant P04788701T0001 NN O
and P04788701T0001 CC O
benign P04788701T0001 JJ O
tumors P04788701T0001 NNS O
of P04788701T0001 IN O
the P04788701T0001 DT O
breasts P04788701T0001 NNS O
and P04788701T0001 CC O
uterus P04788701T0001 NN O
. P04788701T0001 . O
. . O O

Previous P09769209A0100 JJ O
genetic P09769209A0100 JJ O
studies P09769209A0100 NNS O
led P09769209A0100 VBN O
to P09769209A0100 TO O
the P09769209A0100 DT O
conclusion P09769209A0100 NN O
that P09769209A0100 WDT O
nitrate P09769209A0100 NN O
and P09769209A0100 CC O
nitrite P09769209A0100 JJ O
induction P09769209A0100 NN O
of P09769209A0100 IN O
nasF P09769209A0100 JJ I-UN
operon P09769209A0100 NN I-UN
expression P09769209A0100 NN O
is P09769209A0100 VBZ O
determined P09769209A0100 VBN O
by P09769209A0100 IN O
a P09769209A0100 DT O
transcriptional P09769209A0100 JJ O
antitermination P09769209A0100 NN O
mechanism P09769209A0100 NN O
. P09769209A0100 . O
. . O O

Altogether P08798762A1279 RB O
, P08798762A1279 , O
our P08798762A1279 PRP$ O
results P08798762A1279 NNS O
indicate P08798762A1279 VBP O
that P08798762A1279 IN O
the P08798762A1279 DT O
transcriptional P08798762A1279 JJ O
activity P08798762A1279 NN O
of P08798762A1279 IN O
Cut P08798762A1279 NNP I-UN
proteins P08798762A1279 NNS I-UN
is P08798762A1279 VBZ O
modulated P08798762A1279 VBN O
by P08798762A1279 IN O
PKC P08798762A1279 NNP I-UN
. P08798762A1279 . O
. . O O

The P01545792A0000 DT O
cardiac P01545792A0000 JJ I-UN
myosin P01545792A0000 NN I-UN
light P01545792A0000 VBD I-UN
chain-2 P01545792A0000 NN I-UN
( P01545792A0000 ( O
MLC-2 P01545792A0000 NNP I-UN
) P01545792A0000 ) O
gene P01545792A0000 NN O
promoter P01545792A0000 NN O
contains P01545792A0000 VBZ O
several P01545792A0000 JJ O
positive P01545792A0000 JJ O
and P01545792A0000 CC O
negative P01545792A0000 JJ O
cis-acting P01545792A0000 NN O
sequences P01545792A0000 NNS O
that P01545792A0000 WDT O
are P01545792A0000 VBP O
involved P01545792A0000 VBN O
in P01545792A0000 IN O
the P01545792A0000 DT O
regulation P01545792A0000 NN O
of P01545792A0000 IN O
its P01545792A0000 PRP$ O
expression P01545792A0000 NN O
. P01545792A0000 . O
. . O O

The P11802580A0000 DT O
General P11802580A0000 NNP O
Practice P11802580A0000 NNP O
Research P11802580A0000 NNP O
Database P11802580A0000 NNP O
( P11802580A0000 ( O
GPRD P11802580A0000 NNP O
) P11802580A0000 ) O
is P11802580A0000 VBZ O
the P11802580A0000 DT O
world P11802580A0000 NN O
's P11802580A0000 POS O
largest P11802580A0000 JJS O
computerized P11802580A0000 JJ O
database P11802580A0000 NN O
of P11802580A0000 IN O
anonymized P11802580A0000 JJ O
longitudinal P11802580A0000 JJ O
patient P11802580A0000 NN O
records P11802580A0000 NNS O
from P11802580A0000 IN O
general P11802580A0000 JJ O
practice P11802580A0000 NN O
and P11802580A0000 CC O
is P11802580A0000 VBZ O
a P11802580A0000 DT O
unique P11802580A0000 JJ O
public P11802580A0000 JJ O
health P11802580A0000 NN O
research P11802580A0000 NN O
tool P11802580A0000 NN O
. P11802580A0000 . O
. . O O

Low-grade P09823561T0001 JJ O
gastric P09823561T0001 JJ O
MALT P09823561T0001 NNP O
lymphoma P09823561T0001 NN O
and P09823561T0001 CC O
helicobacter P09823561T0001 NN O
heilmannii P09823561T0001 NN O
( P09823561T0001 ( O
Gastrospirillum P09823561T0001 NNP O
hominis P09823561T0001 NN O
. P09823561T0001 . O
. . O O

C. P10819327T0000 NNP O
elegans P10819327T0000 VBZ O
KLP-11 P10819327T0000 NNP I-UN
/ P10819327T0000 NNP O
OSM-3 P10819327T0000 NNP I-UN
/ P10819327T0000 NNP O
KAP-1 P10819327T0000 NNP I-UN
: P10819327T0000 : O
orthologs P10819327T0000 NNS O
of P10819327T0000 IN O
the P10819327T0000 DT O
sea P10819327T0000 NN I-UN
urchin P10819327T0000 JJ I-UN
kinesin-II P10819327T0000 NN I-UN
, P10819327T0000 , O
and P10819327T0000 CC O
mouse P10819327T0000 RB O
KIF3A P10819327T0000 NNP I-UN
/ P10819327T0000 NNP O
KIFB P10819327T0000 NNP I-UN
/ P10819327T0000 NNP O
KAP3 P10819327T0000 NNP I-UN
kinesin P10819327T0000 NN I-UN
complexes P10819327T0000 NNS O
. P10819327T0000 . O
. . O O

As P01754381A0000 IN O
an P01754381A0000 DT O
initial P01754381A0000 JJ O
step P01754381A0000 NN O
towards P01754381A0000 IN O
the P01754381A0000 DT O
characterization P01754381A0000 NN O
of P01754381A0000 IN O
replicative P01754381A0000 JJ O
DNA P01754381A0000 NNP I-UN
polymerases P01754381A0000 NNS I-UN
of P01754381A0000 IN I-UN
trypanosomes P01754381A0000 NNS I-UN
, P01754381A0000 , O
we P01754381A0000 PRP O
have P01754381A0000 VBP O
cloned P01754381A0000 VBN O
, P01754381A0000 , O
sequenced P01754381A0000 VBN O
and P01754381A0000 CC O
examined P01754381A0000 VBN O
the P01754381A0000 DT O
expression P01754381A0000 NN O
of P01754381A0000 IN O
the P01754381A0000 DT O
Trypanosoma P01754381A0000 NNP O
( P01754381A0000 ( O
Trypanozoon P01754381A0000 NNP O
) P01754381A0000 ) O
brucei P01754381A0000 NN O
brucei P01754381A0000 NN O
gene P01754381A0000 NN O
that P01754381A0000 WDT O
encodes P01754381A0000 VBZ O
the P01754381A0000 DT O
DNA P01754381A0000 NNP I-UN
polymerase P01754381A0000 NN I-UN
alpha P01754381A0000 RB I-UN
catalytic P01754381A0000 JJ I-UN
core P01754381A0000 NN I-UN
( P01754381A0000 ( O
pol P01754381A0000 JJ I-UN
alpha P01754381A0000 NN I-UN
) P01754381A0000 ) O
. P01754381A0000 . O
. . O O

Together P08530418A1182 RB O
, P08530418A1182 , O
our P08530418A1182 PRP$ O
data P08530418A1182 NNS O
suggest P08530418A1182 VBP O
that P08530418A1182 IN O
the P08530418A1182 DT O
TR2 P08530418A1182 NNP I-UN
orphan P08530418A1182 MD I-UN
receptor P08530418A1182 VB I-UN
may P08530418A1182 MD O
be P08530418A1182 VB O
a P08530418A1182 DT O
master P08530418A1182 NN O
regulator P08530418A1182 NN O
in P08530418A1182 IN O
modulating P08530418A1182 VBG O
the P08530418A1182 DT O
activation P08530418A1182 NN O
of P08530418A1182 IN O
two P08530418A1182 CD O
key P08530418A1182 JJ O
HREs P08530418A1182 NNP O
, P08530418A1182 , O
RARE P08530418A1182 NNP O
beta P08530418A1182 NN O
and P08530418A1182 CC O
CRBPIIp P08530418A1182 NNP O
, P08530418A1182 , O
involved P08530418A1182 VBN O
in P08530418A1182 IN O
the P08530418A1182 DT O
retinoic P08530418A1182 NN O
acid P08530418A1182 JJ O
signal P08530418A1182 JJ O
transduction P08530418A1182 NN O
pathway P08530418A1182 NN O
. P08530418A1182 . O
. . O O

Lars P02327159T0001 NNP O
has P02327159T0001 VBZ O
AIDS P02327159T0001 NNP O
-- P02327159T0001 : O
a P02327159T0001 DT O
more P02327159T0001 RBR O
dignified P02327159T0001 JJ O
life P02327159T0001 NN O
with P02327159T0001 IN O
care P02327159T0001 NN O
at P02327159T0001 IN O
home P02327159T0001 NN O
. P02327159T0001 . O
. . O O

METHODS P11838058A0084 NN O
: P11838058A0084 : O
9 P11838058A0084 CD O
cases P11838058A0084 NNS O
of P11838058A0084 IN O
conventional P11838058A0084 JJ O
intermittent P11838058A0084 JJ O
tissue P11838058A0084 NN O
expansion P11838058A0084 NN O
( P11838058A0084 ( O
CITE P11838058A0084 NNP O
) P11838058A0084 ) O
and P11838058A0084 CC O
9 P11838058A0084 CD O
cases P11838058A0084 NNS O
of P11838058A0084 IN O
continuous P11838058A0084 JJ O
pressure-controlled P11838058A0084 JJ O
tissue P11838058A0084 NN O
expansion P11838058A0084 NN O
( P11838058A0084 ( O
CPTE P11838058A0084 NNP O
) P11838058A0084 ) O
were P11838058A0084 VBD O
chosen P11838058A0084 VBN O
for P11838058A0084 IN O
the P11838058A0084 DT O
study P11838058A0084 NN O
. P11838058A0084 . O
. . O O

Results P10571474A0571 NNS O
confirmed P10571474A0571 VBD O
that P10571474A0571 IN O
stress P10571474A0571 NN O
produced P10571474A0571 VBD O
CA3 P10571474A0571 NNP O
dendritic P10571474A0571 JJ O
atrophy P10571474A0571 NN O
and P10571474A0571 CC O
tianeptine P10571474A0571 NN O
prevented P10571474A0571 VBD O
it P10571474A0571 PRP O
. P10571474A0571 . O
. . O O

With P07890485A0827 IN O
steady P07890485A0827 JJ O
illumination P07890485A0827 NN O
, P07890485A0827 , O
outer P07890485A0827 JJ O
retinal P07890485A0827 NN O
( P07890485A0827 ( O
photoreceptor P07890485A0827 NN O
) P07890485A0827 ) O
QO2 P07890485A0827 NNP O
decreased P07890485A0827 VBD O
to P07890485A0827 TO O
1.4 P07890485A0827 CD O
+ P07890485A0827 NNS O
/ P07890485A0827 SYM O
- P07890485A0827 : O
0.9 P07890485A0827 CD O
ml P07890485A0827 NN O
O2 P07890485A0827 NNP O
/ P07890485A0827 NNP O
( P07890485A0827 ( O
100 P07890485A0827 CD O
g.min P07890485A0827 NN O
) P07890485A0827 ) O
, P07890485A0827 , O
but P07890485A0827 CC O
inner P07890485A0827 JJ O
retinal P07890485A0827 JJ O
QO2 P07890485A0827 NNP O
remained P07890485A0827 VBD O
unchanged P07890485A0827 JJ O
at P07890485A0827 IN O
3.7 P07890485A0827 CD O
+ P07890485A0827 NN O
/ P07890485A0827 NNP O
- P07890485A0827 : O
1.5 P07890485A0827 CD O
ml P07890485A0827 NN O
O2 P07890485A0827 NNP O
/ P07890485A0827 NNP O
( P07890485A0827 ( O
100 P07890485A0827 CD O
g.min P07890485A0827 NN O
) P07890485A0827 ) O
( P07890485A0827 ( O
5 P07890485A0827 CD O
cats P07890485A0827 NNS O
) P07890485A0827 ) O
. P07890485A0827 . O
. . O O

Immunological P11359827T0000 JJ O
and P11359827T0000 CC O
biochemical P11359827T0000 JJ O
characterization P11359827T0000 NN O
of P11359827T0000 IN O
streptococcal P11359827T0000 JJ I-UN
pyrogenic P11359827T0000 NN I-UN
exotoxins P11359827T0000 NNS I-UN
I P11359827T0000 PRP I-UN
and P11359827T0000 CC I-UN
J P11359827T0000 NNP I-UN
( P11359827T0000 ( O
SPE-I P11359827T0000 NNP I-UN
and P11359827T0000 CC O
SPE-J P11359827T0000 NNP I-UN
) P11359827T0000 ) O
from P11359827T0000 IN O
Streptococcus P11359827T0000 NNP O
pyogenes P11359827T0000 NNS O
. P11359827T0000 . O
. . O O

Cyclophilins P09819421A0000 NNS I-UN
are P09819421A0000 VBP O
cis-trans-peptidyl-prolyl P09819421A0000 JJ I-UN
isomerases P09819421A0000 NNS I-UN
that P09819421A0000 WDT O
bind P09819421A0000 VBP O
to P09819421A0000 TO O
and P09819421A0000 CC O
are P09819421A0000 VBP O
inhibited P09819421A0000 VBN O
by P09819421A0000 IN O
the P09819421A0000 DT O
immunosuppressant P09819421A0000 JJ O
cyclosporin P09819421A0000 NN O
A P09819421A0000 NNP O
( P09819421A0000 ( O
CsA P09819421A0000 NNP O
) P09819421A0000 ) O
. P09819421A0000 . O
. . O O

However P09315678A0278 RB O
, P09315678A0278 , O
Cbf5p P09315678A0278 NNP I-UN
was P09315678A0278 VBD O
found P09315678A0278 VBN O
to P09315678A0278 TO O
be P09315678A0278 VB O
nucleolar P09315678A0278 JJ O
and P09315678A0278 CC O
is P09315678A0278 VBZ O
highly P09315678A0278 RB O
homologous P09315678A0278 JJ O
to P09315678A0278 TO O
the P09315678A0278 DT O
rat P09315678A0278 NN I-UN
nucleolar P09315678A0278 JJ I-UN
protein P09315678A0278 NN I-UN
NAP57 P09315678A0278 NNP I-UN
, P09315678A0278 , O
which P09315678A0278 WDT O
coimmunoprecipitates P09315678A0278 VBZ O
with P09315678A0278 IN O
Nopp140 P09315678A0278 NNP I-UN
and P09315678A0278 CC O
which P09315678A0278 WDT O
is P09315678A0278 VBZ O
postulated P09315678A0278 VBN O
to P09315678A0278 TO O
be P09315678A0278 VB O
involved P09315678A0278 VBN O
in P09315678A0278 IN O
nucleolar-cytoplasmic P09315678A0278 JJ O
shuttling P09315678A0278 NN O
( P09315678A0278 ( O
U P09315678A0278 NNP O
. P09315678A0278 . O
. . O O

The P09364211A0319 DT O
cell P09364211A0319 NN O
cycle-regulated P09364211A0319 JJ O
transcription P09364211A0319 NN O
factor P09364211A0319 NN O
E2F P09364211A0319 NNP I-UN
is P09364211A0319 VBZ O
also P09364211A0319 RB O
known P09364211A0319 VBN O
to P09364211A0319 TO O
bend P09364211A0319 VB O
DNA P09364211A0319 NNP O
upon P09364211A0319 IN O
binding P09364211A0319 NN O
. P09364211A0319 . O
. . O O

Here P11353774A0255 RB O
we P11353774A0255 PRP O
report P11353774A0255 VBP O
the P11353774A0255 DT O
isolation P11353774A0255 NN O
and P11353774A0255 CC O
characterization P11353774A0255 NN O
of P11353774A0255 IN O
the P11353774A0255 DT O
forkhead P11353774A0255 JJ I-UN
homologue P11353774A0255 NN I-UN
in P11353774A0255 IN I-UN
rhabdomyosarcoma P11353774A0255 NN I-UN
( P11353774A0255 ( O
FKHR P11353774A0255 NNP I-UN
) P11353774A0255 ) O
, P11353774A0255 , O
a P11353774A0255 DT O
recently P11353774A0255 RB O
described P11353774A0255 VBN O
member P11353774A0255 NN O
of P11353774A0255 IN O
the P11353774A0255 DT O
hepatocyte P11353774A0255 NN I-UN
nuclear P11353774A0255 JJ I-UN
factor P11353774A0255 NN I-UN
3 P11353774A0255 CD I-UN
/ P11353774A0255 JJ O
forkhead P11353774A0255 JJ I-UN
homeotic P11353774A0255 JJ I-UN
gene P11353774A0255 NN I-UN
family P11353774A0255 NN I-UN
, P11353774A0255 , O
as P11353774A0255 IN O
a P11353774A0255 DT O
nuclear P11353774A0255 JJ I-UN
hormone P11353774A0255 NN I-UN
receptor P11353774A0255 NN I-UN
( P11353774A0255 ( O
NR P11353774A0255 NNP I-UN
) P11353774A0255 ) O
intermediary P11353774A0255 JJ O
protein P11353774A0255 NN O
. P11353774A0255 . O
. . O O

Concerted P08300611T0000 JJ O
action P08300611T0000 NN O
of P08300611T0000 IN O
three P08300611T0000 CD O
distinct P08300611T0000 JJ O
domains P08300611T0000 NNS O
in P08300611T0000 IN O
the P08300611T0000 DT O
DNA P08300611T0000 NNP O
cleaving-joining P08300611T0000 JJ O
reaction P08300611T0000 NN O
catalyzed P08300611T0000 VBN O
by P08300611T0000 IN O
relaxase P08300611T0000 NN I-UN
( P08300611T0000 ( O
TraI P08300611T0000 NNP I-UN
) P08300611T0000 ) O
of P08300611T0000 IN O
conjugative P08300611T0000 JJ O
plasmid P08300611T0000 NN O
RP4 P08300611T0000 NNP O
. P08300611T0000 . O
. . O O

The P11244568A0506 DT O
Gap69C P11244568A0506 NNP I-UN
is P11244568A0506 VBZ O
a P11244568A0506 DT O
single-copy P11244568A0506 JJ O
gene P11244568A0506 NN O
producing P11244568A0506 VBG O
a P11244568A0506 DT O
major P11244568A0506 JJ O
2.1-kb P11244568A0506 JJ O
mRNA P11244568A0506 NN O
throughout P11244568A0506 IN O
development P11244568A0506 NN O
, P11244568A0506 , O
but P11244568A0506 CC O
its P11244568A0506 PRP$ O
amount P11244568A0506 NN O
is P11244568A0506 VBZ O
decreased P11244568A0506 VBN O
in P11244568A0506 IN O
larvae P11244568A0506 NN O
. P11244568A0506 . O
. . O O

No P00150066A0554 DT O
post-operative P00150066A0554 JJ O
haemorrhages P00150066A0554 NNS O
from P00150066A0554 IN O
the P00150066A0554 DT O
prostheses P00150066A0554 NNS O
were P00150066A0554 VBD O
observed P00150066A0554 VBN O
. P00150066A0554 . O
. . O O

2 P11462004A1500 CD O
were P11462004A1500 VBD O
nonviable P11462004A1500 JJ O
, P11462004A1500 , O
and P11462004A1500 CC O
the P11462004A1500 DT O
mutant P11462004A1500 JJ I-UN
Vp1s P11462004A1500 NNP I-UN
unexpectedly P11462004A1500 RB O
failed P11462004A1500 VBD O
to P11462004A1500 TO O
localize P11462004A1500 VB O
to P11462004A1500 TO O
the P11462004A1500 DT O
nucleus P11462004A1500 JJ O
though P11462004A1500 IN O
Vp2 P11462004A1500 NNP I-UN
and P11462004A1500 CC O
Vp3 P11462004A1500 NNP I-UN
did P11462004A1500 VBD O
, P11462004A1500 , O
suggesting P11462004A1500 VBG O
that P11462004A1500 IN O
the P11462004A1500 DT O
mutated P11462004A1500 JJ I-UN
NLS1 P11462004A1500 NNP I-UN
acted P11462004A1500 VBD O
as P11462004A1500 IN O
a P11462004A1500 DT O
dominant P11462004A1500 JJ O
signal P11462004A1500 NN O
for P11462004A1500 IN O
the P11462004A1500 DT O
cytoplasmic P11462004A1500 JJ O
localization P11462004A1500 NN O
of P11462004A1500 IN O
Vp1 P11462004A1500 NNP I-UN
. P11462004A1500 . O
. . O O

The P09747873T0000 DT O
SH2-containing P09747873T0000 JJ O
adapter P09747873T0000 NN O
protein P09747873T0000 NN O
GRB10 P09747873T0000 NNP I-UN
interacts P09747873T0000 VBZ O
with P09747873T0000 IN O
BCR-ABL P09747873T0000 NNP O
. P09747873T0000 . O
. . O O

We P10891399A1185 PRP O
concluded P10891399A1185 VBD O
that P10891399A1185 IN O
activation P10891399A1185 NN O
of P10891399A1185 IN O
c-fosER P10891399A1185 NN I-UN
mediated P10891399A1185 VBN O
transcriptional P10891399A1185 JJ O
inhibition P10891399A1185 NN O
of P10891399A1185 IN O
p21 P10891399A1185 NN I-UN
( P10891399A1185 ( O
Cip1 P10891399A1185 NNP I-UN
/ P10891399A1185 NNP O
WAF1 P10891399A1185 NNP I-UN
) P10891399A1185 ) O
through P10891399A1185 IN O
a P10891399A1185 DT O
previously P10891399A1185 RB O
uncharacterized P10891399A1185 JJ O
AP-1 P10891399A1185 NNP I-UN
site P10891399A1185 NN I-UN
, P10891399A1185 , O
revealing P10891399A1185 VBG O
an P10891399A1185 DT O
important P10891399A1185 JJ O
role P10891399A1185 NN O
for P10891399A1185 IN O
c-fos P10891399A1185 NN I-UN
in P10891399A1185 IN O
negative P10891399A1185 JJ O
control P10891399A1185 NN O
of P10891399A1185 IN O
cell P10891399A1185 NN O
cycle P10891399A1185 NN O
regulatory P10891399A1185 JJ O
genes P10891399A1185 NNS O
. P10891399A1185 . O
. . O O

The P02253274A0000 DT O
Mauriceville P02253274A0000 NNP O
and P02253274A0000 CC O
Varkud P02253274A0000 NNP O
mitochondrial P02253274A0000 JJ O
plasmids P02253274A0000 NNS O
are P02253274A0000 VBP O
closely P02253274A0000 RB O
related P02253274A0000 JJ O
, P02253274A0000 , O
closed-circular P02253274A0000 JJ O
DNAs P02253274A0000 NNP O
( P02253274A0000 ( O
3.6 P02253274A0000 CD O
and P02253274A0000 CC O
3.7 P02253274A0000 CD O
kb P02253274A0000 NN O
, P02253274A0000 , O
respectively P02253274A0000 RB O
) P02253274A0000 ) O
that P02253274A0000 WDT O
have P02253274A0000 VBP O
characteristics P02253274A0000 NNS O
of P02253274A0000 IN O
mtDNA P02253274A0000 NN O
introns P02253274A0000 NNS O
and P02253274A0000 CC O
retroid P02253274A0000 JJ O
elements P02253274A0000 NNS O
. P02253274A0000 . O
. . O O

Three P08394862A0565 CD O
group P08394862A0565 NN O
1 P08394862A0565 CD O
patients P08394862A0565 NNS O
developed P08394862A0565 VBD O
CMV P08394862A0565 NNP O
disease P08394862A0565 NN O
; P08394862A0565 : O
1 P08394862A0565 CD O
group P08394862A0565 NN O
2 P08394862A0565 CD O
patient P08394862A0565 NN O
developed P08394862A0565 VBD O
CMV P08394862A0565 NNP O
hepatitis P08394862A0565 NN O
. P08394862A0565 . O
. . O O

Recombinant P07963540A0795 JJ I-UN
I-kappa P07963540A0795 NNP I-UN
B P07963540A0795 NNP I-UN
alpha P07963540A0795 NN I-UN
inhibited P07963540A0795 VBD O
kappa P07963540A0795 NN I-UN
B P07963540A0795 NNP I-UN
motif P07963540A0795 NN I-UN
binding P07963540A0795 NN O
by P07963540A0795 IN O
nuclear P07963540A0795 JJ I-UN
factor-kappa P07963540A0795 JJ I-UN
B1 P07963540A0795 NNP I-UN
, P07963540A0795 , O
RelA P07963540A0795 NNP I-UN
, P07963540A0795 , O
and P07963540A0795 CC O
c-Rel P07963540A0795 NN I-UN
as P07963540A0795 IN O
indicated P07963540A0795 VBN O
by P07963540A0795 IN O
studies P07963540A0795 NNS O
using P07963540A0795 VBG O
UV P07963540A0795 NNP O
radiation-induced P07963540A0795 JJ O
covalent P07963540A0795 NN O
cross-linking P07963540A0795 NN O
to P07963540A0795 TO O
a P07963540A0795 DT O
bromodeoxyuridine-substituted P07963540A0795 JJ O
kappa P07963540A0795 NN I-UN
B P07963540A0795 NNP I-UN
oligonucleotide P07963540A0795 NN I-UN
. P07963540A0795 . O
. . O O

Nine P11309077A0953 JJ O
strains P11309077A0953 NNS O
were P11309077A0953 VBD O
subtyped P11309077A0953 VBN O
as P11309077A0953 IN O
Camp P11309077A0953 NNP O
. P11309077A0953 . O
jejuni P11309077A0953 NN O
subsp P11309077A0953 NN O
. P11309077A0953 . O
jejuni P11309077A0953 NN O
biotype P11309077A0953 NN O
II P11309077A0953 NNP O
and P11309077A0953 CC O
the P11309077A0953 DT O
remaining P11309077A0953 VBG O
ones P11309077A0953 NNS O
as P11309077A0953 IN O
biotype P11309077A0953 NN O
I P11309077A0953 PRP O
. P11309077A0953 . O
. . O O

The P08276865A1188 DT O
kinase P08276865A1188 NN O
inhibitor P08276865A1188 NN O
staurosporine P08276865A1188 NN O
( P08276865A1188 ( O
1 P08276865A1188 CD O
microM P08276865A1188 NN O
) P08276865A1188 ) O
blocks P08276865A1188 VBZ O
LPA-induced P08276865A1188 JJ O
, P08276865A1188 , O
but P08276865A1188 CC O
not P08276865A1188 RB O
epidermal P08276865A1188 JJ O
growth P08276865A1188 NN O
factor-induced P08276865A1188 JJ O
, P08276865A1188 , O
activation P08276865A1188 NN O
of P08276865A1188 IN O
p21ras P08276865A1188 NNS I-UN
and P08276865A1188 CC O
MAP P08276865A1188 NNP I-UN
kinase P08276865A1188 NNP I-UN
, P08276865A1188 , O
consistent P08276865A1188 NN O
with P08276865A1188 IN O
an P08276865A1188 DT O
intermediate P08276865A1188 JJ O
protein P08276865A1188 NN O
kinase P08276865A1188 NN O
linking P08276865A1188 VBG O
the P08276865A1188 DT O
LPA P08276865A1188 NNP I-UN
receptor P08276865A1188 NN I-UN
to P08276865A1188 TO O
p21ras P08276865A1188 VB I-UN
activation P08276865A1188 NN O
. P08276865A1188 . O
. . O O

Similar P10549354A2371 JJ O
mechanisms P10549354A2371 NNS O
leading P10549354A2371 VBG O
to P10549354A2371 TO O
deregulation P10549354A2371 NN O
of P10549354A2371 IN O
Tcf P10549354A2371 NNP I-UN
target P10549354A2371 NN I-UN
gene P10549354A2371 NN I-UN
activity P10549354A2371 NN O
are P10549354A2371 VBP O
likely P10549354A2371 JJ O
to P10549354A2371 TO O
be P10549354A2371 VB O
involved P10549354A2371 VBN O
in P10549354A2371 IN O
melanoma P10549354A2371 NN O
and P10549354A2371 CC O
other P10549354A2371 JJ O
forms P10549354A2371 NNS O
of P10549354A2371 IN O
cancer P10549354A2371 NN O
. P10549354A2371 . O
. . O O

A P09427627A0930 DT O
cytosolic P09427627A0930 JJ O
variant P09427627A0930 NN O
of P09427627A0930 IN O
the P09427627A0930 DT O
protein P09427627A0930 NN O
underwent P09427627A0930 JJ O
efficient P09427627A0930 JJ O
transphosphorylation P09427627A0930 NN O
, P09427627A0930 , O
yet P09427627A0930 RB O
failed P09427627A0930 VBN O
to P09427627A0930 TO O
activate P09427627A0930 VB O
appreciably P09427627A0930 RB O
either P09427627A0930 DT O
p70 P09427627A0930 NN I-UN
( P09427627A0930 ( O
S6k P09427627A0930 NNP I-UN
) P09427627A0930 ) O
or P09427627A0930 CC O
MAP P09427627A0930 NNP I-UN
kinase P09427627A0930 NN I-UN
following P09427627A0930 VBG O
treatment P09427627A0930 NN O
with P09427627A0930 IN O
FK1012 P09427627A0930 NNP O
. P09427627A0930 . O
. . O O

The P10333526A0459 DT O
hTERT P10333526A0459 NN I-UN
gene P10333526A0459 NN I-UN
encompasses P10333526A0459 VBZ O
more P10333526A0459 JJR O
than P10333526A0459 IN O
37kb P10333526A0459 CD O
and P10333526A0459 CC O
consists P10333526A0459 NNS O
of P10333526A0459 IN O
16 P10333526A0459 CD O
exons P10333526A0459 NNS O
. P10333526A0459 . O
. . O O

In P11055513A0564 IN O
general P11055513A0564 JJ O
lookback P11055513A0564 NN O
, P11055513A0564 , O
all P11055513A0564 DT O
patients P11055513A0564 NNS O
who P11055513A0564 WP O
received P11055513A0564 VBD O
blood P11055513A0564 NN O
before P11055513A0564 IN O
being P11055513A0564 VBG O
tested P11055513A0564 VBN O
for P11055513A0564 IN O
hepatitis P11055513A0564 NN O
C P11055513A0564 NNP O
are P11055513A0564 VBP O
advised P11055513A0564 VBN O
to P11055513A0564 TO O
undergo P11055513A0564 VB O
testing P11055513A0564 NN O
. P11055513A0564 . O
. . O O

Furthermore P09261155A0833 RB O
, P09261155A0833 , O
the P09261155A0833 DT O
PH P09261155A0833 NNP I-UN
and P09261155A0833 CC O
PTB P09261155A0833 NNP O
domains P09261155A0833 NNS O
are P09261155A0833 VBP O
highly P09261155A0833 RB O
homologous P09261155A0833 JJ O
( P09261155A0833 ( O
at P09261155A0833 IN O
least P09261155A0833 JJS O
40 P09261155A0833 CD O
% P09261155A0833 NN O
identical P09261155A0833 JJ O
) P09261155A0833 ) O
to P09261155A0833 TO O
those P09261155A0833 DT O
found P09261155A0833 VBN O
in P09261155A0833 IN O
insulin P09261155A0833 NN I-UN
receptor P09261155A0833 NN I-UN
substrates P09261155A0833 VBZ I-UN
1 P09261155A0833 CD I-UN
, P09261155A0833 , I-UN
2 P09261155A0833 CD I-UN
, P09261155A0833 , I-UN
and P09261155A0833 CC I-UN
3 P09261155A0833 CD I-UN
( P09261155A0833 ( O
IRS-1 P09261155A0833 NNP I-UN
, P09261155A0833 , O
IRS-2 P09261155A0833 NNP I-UN
, P09261155A0833 , O
and P09261155A0833 CC O
IRS-3 P09261155A0833 NNP I-UN
) P09261155A0833 ) O
. P09261155A0833 . O
. . O O

The P10603349A1667 DT O
signalling P10603349A1667 NN O
molecules P10603349A1667 NNS O
Wnt1 P10603349A1667 NNP I-UN
and P10603349A1667 CC O
Sonic P10603349A1667 NNP I-UN
hedgehog P10603349A1667 NN I-UN
, P10603349A1667 , O
implicated P10603349A1667 VBN O
in P10603349A1667 IN O
the P10603349A1667 DT O
activation P10603349A1667 NN O
of P10603349A1667 IN O
Myf5 P10603349A1667 NNP I-UN
in P10603349A1667 IN O
myogenic P10603349A1667 JJ O
progenitor P10603349A1667 NN O
cells P10603349A1667 NNS O
in P10603349A1667 IN O
the P10603349A1667 DT O
somite P10603349A1667 NN O
, P10603349A1667 , O
are P10603349A1667 VBP O
also P10603349A1667 RB O
produced P10603349A1667 VBN O
in P10603349A1667 IN O
the P10603349A1667 DT O
viscinity P10603349A1667 NN O
of P10603349A1667 IN O
the P10603349A1667 DT O
Myf5 P10603349A1667 NNP I-UN
expression P10603349A1667 NN I-UN
domain P10603349A1667 NN I-UN
in P10603349A1667 IN O
the P10603349A1667 DT O
mesencephalon P10603349A1667 NN O
. P10603349A1667 . O
. . O O

The P03040403A0155 DT O
PSS P03040403A0155 NNP I-UN
gene P03040403A0155 NN I-UN
was P03040403A0155 VBD O
subcloned P03040403A0155 VBN O
into P03040403A0155 IN O
a P03040403A0155 DT O
1.1-kb P03040403A0155 JJ O
fragment P03040403A0155 NN O
of P03040403A0155 IN O
the P03040403A0155 DT O
yeast P03040403A0155 NN O
DNA P03040403A0155 NN O
on P03040403A0155 IN O
the P03040403A0155 DT O
YEp13 P03040403A0155 NNP O
vector P03040403A0155 NN O
. P03040403A0155 . O
. . O O

Here P10722969A0510 RB O
we P10722969A0510 PRP O
review P10722969A0510 VBP O
progress P10722969A0510 NN O
to P10722969A0510 TO O
date P10722969A0510 NN O
in P10722969A0510 IN O
this P10722969A0510 DT O
area P10722969A0510 NN O
. P10722969A0510 . O
. . O O

The P01690728A1166 DT O
presence P01690728A1166 NN O
of P01690728A1166 IN O
the P01690728A1166 DT O
corresponding P01690728A1166 JJ O
mature P01690728A1166 NN O
mRNA P01690728A1166 NN O
transcripts P01690728A1166 NNS O
( P01690728A1166 ( O
3.2-3.5 P01690728A1166 JJ O
kilobase P01690728A1166 NN O
pairs P01690728A1166 NNS O
( P01690728A1166 ( O
kb P01690728A1166 VB O
] P01690728A1166 NN O
in P01690728A1166 IN O
human P01690728A1166 JJ O
fibroblasts P01690728A1166 NNS O
was P01690728A1166 VBD O
shown P01690728A1166 VBN O
by P01690728A1166 IN O
Northern P01690728A1166 NNP O
blot P01690728A1166 NN O
hybridization P01690728A1166 NN O
, P01690728A1166 , O
S1 P01690728A1166 NNP I-UN
nuclease P01690728A1166 NN I-UN
protection P01690728A1166 NN O
assay P01690728A1166 NN O
, P01690728A1166 , O
and P01690728A1166 CC O
the P01690728A1166 DT O
polymerase P01690728A1166 NN O
chain P01690728A1166 NN O
reaction P01690728A1166 NN O
. P01690728A1166 . O
. . O O

40 P00425547A0000 CD O
patients P00425547A0000 NNS O
with P00425547A0000 IN O
chronic P00425547A0000 JJ O
osteomyelitis P00425547A0000 NN O
were P00425547A0000 VBD O
treated P00425547A0000 VBN O
per P00425547A0000 IN O
os P00425547A0000 NN O
with P00425547A0000 IN O
the P00425547A0000 DT O
bactericidal P00425547A0000 JJ O
beta-lactam-antibiotic P00425547A0000 JJ O
cephalexin P00425547A0000 NN O
during P00425547A0000 IN O
3 P00425547A0000 CD O
to P00425547A0000 TO O
60 P00425547A0000 CD O
weeks P00425547A0000 NNS O
. P00425547A0000 . O
. . O O

Two P09277629A0268 CD O
experiments P09277629A0268 NNS O
( P09277629A0268 ( O
N P09277629A0268 NNP O
= P09277629A0268 RB O
20 P09277629A0268 CD O
each P09277629A0268 DT O
) P09277629A0268 ) O
were P09277629A0268 VBD O
carried P09277629A0268 VBN O
out P09277629A0268 IN O
to P09277629A0268 TO O
explore P09277629A0268 VB O
the P09277629A0268 DT O
nature P09277629A0268 NN O
of P09277629A0268 IN O
ERP P09277629A0268 NNP O
negativities P09277629A0268 NNS O
in P09277629A0268 IN O
a P09277629A0268 DT O
visuospatial P09277629A0268 JJ O
memory P09277629A0268 NN O
task P09277629A0268 NN O
and P09277629A0268 CC O
in P09277629A0268 IN O
an P09277629A0268 DT O
auditory P09277629A0268 JJ O
spatial P09277629A0268 JJ O
memory P09277629A0268 NN O
task P09277629A0268 NN O
, P09277629A0268 , O
respectively P09277629A0268 RB O
. P09277629A0268 . O
. . O O

Perilunar P01999999T0001 NNP O
luxation P01999999T0001 NN O
-- P01999999T0001 : O
an P01999999T0001 DT O
unusual P01999999T0001 JJ O
injury P01999999T0001 NN O
demanding P01999999T0001 VBG O
immediate P01999999T0001 JJ O
and P01999999T0001 CC O
correct P01999999T0001 JJ O
treatment P01999999T0001 NN O
. P01999999T0001 . O
. . O O

The P08192140A0209 DT O
participants P08192140A0209 NNS O
were P08192140A0209 VBD O
homosexual P08192140A0209 JJ O
men P08192140A0209 NNS O
in P08192140A0209 IN O
hepatitis P08192140A0209 NN O
B P08192140A0209 NNP O
vaccine P08192140A0209 NN O
trials P08192140A0209 NNS O
in P08192140A0209 IN O
Amsterdam P08192140A0209 NNP O
( P08192140A0209 ( O
n P08192140A0209 JJ O
= P08192140A0209 NNP O
74 P08192140A0209 CD O
) P08192140A0209 ) O
, P08192140A0209 , O
New P08192140A0209 NNP O
York P08192140A0209 NNP O
City P08192140A0209 NNP O
( P08192140A0209 ( O
n P08192140A0209 JJ O
= P08192140A0209 NNP O
120 P08192140A0209 CD O
) P08192140A0209 ) O
, P08192140A0209 , O
and P08192140A0209 CC O
San P08192140A0209 NNP O
Francisco P08192140A0209 NNP O
( P08192140A0209 ( O
n P08192140A0209 JJ O
= P08192140A0209 NNP O
168 P08192140A0209 CD O
) P08192140A0209 ) O
. P08192140A0209 . O
. . O O

After P03355122A0238 IN O
the P03355122A0238 DT O
meal P03355122A0238 NN O
containing P03355122A0238 VBG O
potato P03355122A0238 NN O
, P03355122A0238 , O
plasma P03355122A0238 VBP O
glucose P03355122A0238 JJ O
levels P03355122A0238 NNS O
rose P03355122A0238 VBD O
sharply P03355122A0238 RB O
, P03355122A0238 , O
peaked P03355122A0238 VBD O
at P03355122A0238 IN O
30-45 P03355122A0238 JJ O
min P03355122A0238 NN O
and P03355122A0238 CC O
fell P03355122A0238 VBD O
below P03355122A0238 IN O
initial P03355122A0238 JJ O
levels P03355122A0238 NNS O
2 P03355122A0238 CD O
to P03355122A0238 TO O
3 P03355122A0238 CD O
h P03355122A0238 NN O
later P03355122A0238 RB O
. P03355122A0238 . O
. . O O

Investigation P10826946A1198 NN O
of P10826946A1198 IN O
the P10826946A1198 DT O
structural P10826946A1198 JJ O
basis P10826946A1198 NN O
of P10826946A1198 IN O
the P10826946A1198 DT O
interaction P10826946A1198 NN O
between P10826946A1198 IN O
human P10826946A1198 JJ I-UN
Igs P10826946A1198 NNP I-UN
and P10826946A1198 CC O
gp120 P10826946A1198 NN I-UN
shows P10826946A1198 NNS O
that P10826946A1198 IN O
the P10826946A1198 DT O
viral P10826946A1198 JJ I-UN
gp120 P10826946A1198 NN I-UN
SAg P10826946A1198 NNP I-UN
can P10826946A1198 MD O
interact P10826946A1198 VB O
only P10826946A1198 RB O
with P10826946A1198 IN O
a P10826946A1198 DT O
subset P10826946A1198 NN O
of P10826946A1198 IN O
human P10826946A1198 JJ I-UN
V P10826946A1198 NNP I-UN
( P10826946A1198 ( I-UN
H P10826946A1198 NNP I-UN
) P10826946A1198 ) I-UN
3+ P10826946A1198 CD I-UN
Igs P10826946A1198 NNP I-UN
. P10826946A1198 . O
. . O O

The P11297514A0218 DT O
recessive P11297514A0218 JJ O
hos1 P11297514A0218 NN I-UN
mutation P11297514A0218 NN O
causes P11297514A0218 VBZ O
enhanced P11297514A0218 JJ O
induction P11297514A0218 NN O
of P11297514A0218 IN O
the P11297514A0218 DT O
CBF P11297514A0218 NNP I-UN
transcription P11297514A0218 NN I-UN
factors P11297514A0218 NNS I-UN
by P11297514A0218 IN O
low P11297514A0218 JJ O
temperature P11297514A0218 NN O
as P11297514A0218 RB O
well P11297514A0218 RB O
as P11297514A0218 IN O
of P11297514A0218 IN O
their P11297514A0218 PRP$ O
downstream P11297514A0218 NN O
cold-responsive P11297514A0218 JJ O
genes P11297514A0218 NNS O
. P11297514A0218 . O
. . O O

Effects P09984526T0000 NNS O
of P09984526T0000 IN O
point P09984526T0000 NN O
defects P09984526T0000 NNS O
on P09984526T0000 IN O
lattice P09984526T0000 NN O
parameters P09984526T0000 NNS O
of P09984526T0000 IN O
semiconductors P09984526T0000 NNS O
. P09984526T0000 . O
. . O O

Hybridization P02457922A0991 NN O
of P02457922A0991 IN O
a P02457922A0991 DT O
probe P02457922A0991 NN O
from P02457922A0991 IN O
this P02457922A0991 DT O
region P02457922A0991 NN O
to P02457922A0991 TO O
electrophoretic P02457922A0991 JJ O
blots P02457922A0991 NNS O
of P02457922A0991 IN O
RNAs P02457922A0991 NNP O
from P02457922A0991 IN O
different P02457922A0991 JJ O
human P02457922A0991 JJ O
tissues P02457922A0991 NNS O
showed P02457922A0991 VBD O
a P02457922A0991 DT O
predominant P02457922A0991 JJ O
2.8-kilobase P02457922A0991 JJ O
( P02457922A0991 ( O
kb P02457922A0991 NN O
) P02457922A0991 ) O
message P02457922A0991 NN O
accompanied P02457922A0991 VBN O
by P02457922A0991 IN O
weaker P02457922A0991 JJR O
bands P02457922A0991 NNS O
4.1 P02457922A0991 CD O
and P02457922A0991 CC O
2.1 P02457922A0991 CD O
kb P02457922A0991 NN O
in P02457922A0991 IN O
size P02457922A0991 NN O
. P02457922A0991 . O
. . O O

We P06319040A1627 PRP O
conclude P06319040A1627 VBP O
that P06319040A1627 IN O
, P06319040A1627 , O
with P06319040A1627 IN O
autonomic P06319040A1627 JJ O
nervous P06319040A1627 JJ O
system P06319040A1627 NN O
activity P06319040A1627 NN O
intact P06319040A1627 JJ O
, P06319040A1627 , O
carotid P06319040A1627 JJ O
chemoreceptor P06319040A1627 NN O
reflex P06319040A1627 JJ O
activation P06319040A1627 NN O
can P06319040A1627 MD O
elicit P06319040A1627 VB O
an P06319040A1627 DT O
absolute P06319040A1627 JJ O
reflexly P06319040A1627 NN O
mediated P06319040A1627 VBN O
reduction P06319040A1627 NN O
in P06319040A1627 IN O
coronary P06319040A1627 JJ O
blood P06319040A1627 NN O
flow P06319040A1627 NN O
in P06319040A1627 IN O
the P06319040A1627 DT O
normal P06319040A1627 JJ O
, P06319040A1627 , O
conscious P06319040A1627 JJ O
dog P06319040A1627 NN O
, P06319040A1627 , O
despite P06319040A1627 IN O
an P06319040A1627 DT O
increase P06319040A1627 NN O
in P06319040A1627 IN O
arterial P06319040A1627 JJ O
pressure P06319040A1627 NN O
. P06319040A1627 . O
. . O O

Newcastle P00725336T0000 NNP O
disease P00725336T0000 NN O
virus P00725336T0000 NN O
surveillance P00725336T0000 NN O
in P00725336T0000 IN O
Hong P00725336T0000 NNP O
Kong P00725336T0000 NNP O
on P00725336T0000 IN O
local P00725336T0000 JJ O
and P00725336T0000 CC O
imported P00725336T0000 JJ O
poultry P00725336T0000 NN O
. P00725336T0000 . O
. . O O

In P01804671A1001 IN O
line P01804671A1001 NN O
with P01804671A1001 IN O
the P01804671A1001 DT O
small P01804671A1001 JJ O
values P01804671A1001 NNS O
for P01804671A1001 IN O
QS P01804671A1001 NNP O
/ P01804671A1001 NNP O
QC P01804671A1001 NNP O
, P01804671A1001 , O
our P01804671A1001 PRP$ O
results P01804671A1001 NNS O
further P01804671A1001 RBR O
indicate P01804671A1001 VBP O
that P01804671A1001 IN O
even P01804671A1001 RB O
large P01804671A1001 JJ O
, P01804671A1001 , O
well-perfused P01804671A1001 JJ O
, P01804671A1001 , O
occluded P01804671A1001 VBD O
air P01804671A1001 NN O
spaces P01804671A1001 NNS O
in P01804671A1001 IN O
the P01804671A1001 DT O
lung P01804671A1001 NN O
will P01804671A1001 MD O
hardly P01804671A1001 RB O
affect P01804671A1001 VB O
the P01804671A1001 DT O
recovered P01804671A1001 JJ O
ventilation P01804671A1001 NN O
/ P01804671A1001 NNP O
perfusion P01804671A1001 NN O
distribution P01804671A1001 NN O
obtained P01804671A1001 VBN O
from P01804671A1001 IN O
inert P01804671A1001 JJ O
gas P01804671A1001 NN O
data P01804671A1001 NNS O
when P01804671A1001 WRB O
CDCSF6 P01804671A1001 NNP O
exceeds P01804671A1001 VBZ O
0.1 P01804671A1001 CD O
ml.min-1.mmHg-1 P01804671A1001 NN O
. P01804671A1001 . O
. . O O

Regulatory P10229682A1151 NNP O
motifs P10229682A1151 NNS O
for P10229682A1151 IN O
gene P10229682A1151 NN O
expression P10229682A1151 NN O
such P10229682A1151 JJ O
as P10229682A1151 IN O
nuclear-factor-kappaB-binding-site-like P10229682A1151 JJ I-UN
sequence P10229682A1151 NN I-UN
( P10229682A1151 ( O
kappaB P10229682A1151 VB I-UN
site P10229682A1151 NN I-UN
) P10229682A1151 ) O
and P10229682A1151 CC O
nuclear-factor-interleukin-6-binding-site-like P10229682A1151 JJ I-UN
sequence P10229682A1151 NN I-UN
( P10229682A1151 ( O
NF-IL-6 P10229682A1151 NNP I-UN
site P10229682A1151 NN I-UN
) P10229682A1151 ) O
were P10229682A1151 VBD O
found P10229682A1151 VBN O
in P10229682A1151 IN O
the P10229682A1151 DT O
5'-upstream P10229682A1151 JJ O
regulatory P10229682A1151 JJ O
region P10229682A1151 NN O
. P10229682A1151 . O
. . O O

In P00868301A0043 IN O
diethyl P00868301A0043 NN O
ether P00868301A0043 CC O
solution P00868301A0043 NN O
the P00868301A0043 DT O
main P00868301A0043 JJ O
peak P00868301A0043 NN O
is P00868301A0043 VBZ O
that P00868301A0043 IN O
of P00868301A0043 IN O
2-benzylidenamio-1-phenylpropane P00868301A0043 NNP O
, P00868301A0043 , O
which P00868301A0043 WDT O
has P00868301A0043 VBZ O
a P00868301A0043 DT O
retention P00868301A0043 NN O
time P00868301A0043 NN O
of P00868301A0043 IN O
23,2 P00868301A0043 CD O
minutes P00868301A0043 NNS O
under P00868301A0043 IN O
the P00868301A0043 DT O
condition P00868301A0043 NN O
delineated P00868301A0043 VBD O
. P00868301A0043 . O
. . O O

Factor P06797063A0000 NNP I-UN
VIII P06797063A0000 NNP I-UN
procoagulant P06797063A0000 NN O
activity P06797063A0000 NN O
, P06797063A0000 , O
antigen P06797063A0000 NN O
concentration P06797063A0000 NN O
and P06797063A0000 CC O
von P06797063A0000 JJ I-UN
Willebrand P06797063A0000 NNP I-UN
activity P06797063A0000 NN O
as P06797063A0000 IN O
ristocetin P06797063A0000 NN I-UN
cofactor P06797063A0000 NN I-UN
were P06797063A0000 VBD O
determined P06797063A0000 VBN O
several P06797063A0000 JJ O
times P06797063A0000 NNS O
in P06797063A0000 IN O
10 P06797063A0000 CD O
patients P06797063A0000 NNS O
with P06797063A0000 IN O
DIC P06797063A0000 NNP O
. P06797063A0000 . O
. . O O

Zarix P11569949A2087 NNP O
expected P11569949A2087 VBD O
patient P11569949A2087 JJ O
enrollment P11569949A2087 NN O
in P11569949A2087 IN O
Canadian P11569949A2087 JJ O
clinical P11569949A2087 JJ O
sites P11569949A2087 NNS O
to P11569949A2087 TO O
begin P11569949A2087 VB O
in P11569949A2087 IN O
Spring P11569949A2087 NN O
2001 P11569949A2087 CD O
[ P11569949A2087 NN O
397955 P11569949A2087 CD O
] P11569949A2087 NN O
, P11569949A2087 , O
[ P11569949A2087 VBZ O
405928 P11569949A2087 CD O
] P11569949A2087 NN O
. P11569949A2087 . O
. . O O

Nor P10822117A1386 CC O
is P10822117A1386 VBZ O
such P10822117A1386 JJ O
adjustment P10822117A1386 NN O
possible P10822117A1386 JJ O
unless P10822117A1386 IN O
one P10822117A1386 CD O
posits P10822117A1386 VBZ O
a P10822117A1386 DT O
model P10822117A1386 NN O
that P10822117A1386 WDT O
relates P10822117A1386 VBZ O
the P10822117A1386 DT O
missing P10822117A1386 VBG O
observations P10822117A1386 NNS O
to P10822117A1386 TO O
other P10822117A1386 JJ O
observed P10822117A1386 JJ O
information P10822117A1386 NN O
for P10822117A1386 IN O
each P10822117A1386 DT O
subject-models P10822117A1386 NNS O
that P10822117A1386 WDT O
are P10822117A1386 VBP O
inherently P10822117A1386 RB O
untestable P10822117A1386 JJ O
. P10822117A1386 . O
. . O O

In P00313766A0666 IN O
patients P00313766A0666 NNS O
who P00313766A0666 WP O
were P00313766A0666 VBD O
not P00313766A0666 RB O
vented P00313766A0666 VBN O
, P00313766A0666 , O
there P00313766A0666 EX O
was P00313766A0666 VBD O
overall P00313766A0666 JJ O
significant P00313766A0666 JJ O
depression P00313766A0666 NN O
of P00313766A0666 IN O
function P00313766A0666 NN O
( P00313766A0666 ( O
67 P00313766A0666 CD O
+ P00313766A0666 NN O
/ P00313766A0666 NNP O
- P00313766A0666 : O
5 P00313766A0666 CD O
% P00313766A0666 NN O
of P00313766A0666 IN O
control P00313766A0666 NN O
; P00313766A0666 : O
range P00313766A0666 NN O
, P00313766A0666 , O
91 P00313766A0666 CD O
-- P00313766A0666 : O
45 P00313766A0666 CD O
% P00313766A0666 NN O
, P00313766A0666 , O
p P00313766A0666 NN O
less P00313766A0666 JJR O
than P00313766A0666 IN O
0.01 P00313766A0666 CD O
) P00313766A0666 ) O
. P00313766A0666 . O
. . O O

Riboflavin P00173860A0475 NNP O
did P00173860A0475 VBD O
not P00173860A0475 RB O
affect P00173860A0475 VB O
the P00173860A0475 DT O
percentage P00173860A0475 NN O
of P00173860A0475 IN O
aflatoxin-treated P00173860A0475 JJ O
animals P00173860A0475 NNS O
with P00173860A0475 IN O
abnormal P00173860A0475 JJ O
urinary P00173860A0475 JJ O
excretion P00173860A0475 NN O
patterns P00173860A0475 NNS O
, P00173860A0475 , O
but P00173860A0475 CC O
did P00173860A0475 VBD O
increase P00173860A0475 VB O
the P00173860A0475 DT O
magnitude P00173860A0475 NN O
of P00173860A0475 IN O
the P00173860A0475 DT O
disturbances P00173860A0475 NNS O
in P00173860A0475 IN O
elimination P00173860A0475 NN O
of P00173860A0475 IN O
kynurenic P00173860A0475 JJ O
and P00173860A0475 CC O
xanthurenic P00173860A0475 JJ O
acids P00173860A0475 NNS O
. P00173860A0475 . O
. . O O

Reversal P03126531T0000 NN O
of P03126531T0000 IN O
the P03126531T0000 DT O
increase P03126531T0000 NN O
in P03126531T0000 IN O
apomorphine-induced P03126531T0000 JJ O
stereotypy P03126531T0000 NN O
and P03126531T0000 CC O
aggression P03126531T0000 NN O
in P03126531T0000 IN O
REM P03126531T0000 NNP O
sleep P03126531T0000 VBP O
deprived P03126531T0000 VBN O
rats P03126531T0000 NNS O
by P03126531T0000 IN O
dopamine P03126531T0000 JJ O
agonist P03126531T0000 NN O
pretreatments P03126531T0000 NNS O
. P03126531T0000 . O
. . O O

Pilot P06720371T0000 NNP O
study P06720371T0000 NN O
of P06720371T0000 IN O
blood P06720371T0000 NN O
coagulation P06720371T0000 NN O
in P06720371T0000 IN O
gout P06720371T0000 NN O
patients P06720371T0000 NNS O
. P06720371T0000 . O
. . O O

Cdk2 P08647086A0622 NNP I-UN
formed P08647086A0622 VBD O
a P08647086A0622 DT O
complex P08647086A0622 JJ O
with P08647086A0622 IN O
cyclin P08647086A0622 NN I-UN
D1 P08647086A0622 NNP I-UN
in P08647086A0622 IN O
this P08647086A0622 DT O
system P08647086A0622 NN O
. P08647086A0622 . O
. . O O

C P08997490A1127 NNP I-UN
/ P08997490A1127 NNP I-UN
EBP P08997490A1127 NNP I-UN
beta P08997490A1127 NN I-UN
V P08997490A1127 NNP I-UN
> P08997490A1127 VBZ O
A P08997490A1127 NNP O
selectively P08997490A1127 RB O
binds P08997490A1127 VBZ O
only P08997490A1127 RB O
the P08997490A1127 DT O
subset P08997490A1127 NN O
of P08997490A1127 IN O
C P08997490A1127 NNP I-UN
/ P08997490A1127 NNP I-UN
EBP P08997490A1127 NNP I-UN
sites P08997490A1127 VBZ I-UN
that P08997490A1127 WDT O
are P08997490A1127 VBP O
also P08997490A1127 RB O
DBP P08997490A1127 NNP I-UN
sites P08997490A1127 NNS I-UN
, P08997490A1127 , O
both P08997490A1127 CC O
as P08997490A1127 IN O
oligonucleotides P08997490A1127 NNS O
and P08997490A1127 CC O
within P08997490A1127 IN O
the P08997490A1127 DT O
natural P08997490A1127 JJ O
contexts P08997490A1127 NN O
of P08997490A1127 IN O
the P08997490A1127 DT O
albumin P08997490A1127 NN I-UN
and P08997490A1127 CC O
cholesterol P08997490A1127 NN I-UN
hydroxylase P08997490A1127 NN I-UN
promoters P08997490A1127 NNS I-UN
. P08997490A1127 . O
. . O O

In P08833153A0628 IN O
addition P08833153A0628 NN O
, P08833153A0628 , O
a P08833153A0628 DT O
comparison P08833153A0628 NN O
of P08833153A0628 IN O
the P08833153A0628 DT O
hCHLR P08833153A0628 NN I-UN
gene P08833153A0628 NN I-UN
sequences P08833153A0628 NNS I-UN
with P08833153A0628 IN O
available P08833153A0628 JJ O
databases P08833153A0628 NNS O
indicates P08833153A0628 VBZ O
that P08833153A0628 IN O
a P08833153A0628 DT O
large P08833153A0628 JJ O
portion P08833153A0628 NN O
of P08833153A0628 IN O
these P08833153A0628 DT O
genes P08833153A0628 NNS O
, P08833153A0628 , O
including P08833153A0628 VBG O
exons P08833153A0628 NNS O
encoding P08833153A0628 VBG O
two P08833153A0628 CD O
functional P08833153A0628 JJ O
domains P08833153A0628 NNS O
of P08833153A0628 IN O
the P08833153A0628 DT O
carboxyl-terminal P08833153A0628 JJ O
region P08833153A0628 NN O
of P08833153A0628 IN O
these P08833153A0628 DT O
proteins P08833153A0628 NNS O
, P08833153A0628 , O
has P08833153A0628 VBZ O
been P08833153A0628 VBN O
duplicated P08833153A0628 VBN O
as P08833153A0628 IN O
part P08833153A0628 NN O
of P08833153A0628 IN O
a P08833153A0628 DT O
larger P08833153A0628 JJR O
human P08833153A0628 JJ O
telomeric P08833153A0628 JJ O
repeat P08833153A0628 NN O
sequence P08833153A0628 NN O
found P08833153A0628 VBD O
on P08833153A0628 IN O
many P08833153A0628 JJ O
human P08833153A0628 JJ O
chromosomes P08833153A0628 NNS O
. P08833153A0628 . O
. . O O

Effects P06772612A0000 NNS O
of P06772612A0000 IN O
dopamine P06772612A0000 NN O
and P06772612A0000 CC O
of P06772612A0000 IN O
a P06772612A0000 DT O
dopaminergic P06772612A0000 JJ O
blocker P06772612A0000 NN O
, P06772612A0000 , O
haloperidol P06772612A0000 NN O
, P06772612A0000 , O
on P06772612A0000 IN O
the P06772612A0000 DT O
responses P06772612A0000 NNS O
of P06772612A0000 IN O
carotid P06772612A0000 NN O
body P06772612A0000 NN O
chemoreceptors P06772612A0000 NNS O
to P06772612A0000 TO O
hypoxia P06772612A0000 VB O
and P06772612A0000 CC O
hypercapnia P06772612A0000 VB O
were P06772612A0000 VBD O
investigated P06772612A0000 VBN O
in P06772612A0000 IN O
16 P06772612A0000 CD O
anesthetized P06772612A0000 JJ O
cats P06772612A0000 NNS O
. P06772612A0000 . O
. . O O

Determination P06833422T0000 NN O
of P06833422T0000 IN O
20 P06833422T0000 CD O
alpha-hydroxy-9 P06833422T0000 JJ O
beta,10 P06833422T0000 NN O
alpha-pregna-4,6-dien-3-one P06833422T0000 NN O
in P06833422T0000 IN O
plasma P06833422T0000 NN O
by P06833422T0000 IN O
selected P06833422T0000 VBN O
ion P06833422T0000 NN O
monitoring P06833422T0000 NN O
. P06833422T0000 . O
. . O O

Conjugated P07740490T0000 VBN O
estrogens P07740490T0000 NNS O
shorten P07740490T0000 VB O
bleeding P07740490T0000 JJ O
time P07740490T0000 NN O
in P07740490T0000 IN O
uraemia P07740490T0000 NN O
: P07740490T0000 : O
a P07740490T0000 DT O
possible P07740490T0000 JJ O
role P07740490T0000 NN O
of P07740490T0000 IN O
serotonin P07740490T0000 NN O
? P07740490T0000 . O
. P07740490T0000 . O
. . O O

Cyclosporine P03632739T0000 NNP O
treatment P03632739T0000 NN O
for P03632739T0000 IN O
intractable P03632739T0000 JJ O
polymyositis P03632739T0000 NN O
. P03632739T0000 . O
. . O O

Because P11145566A0000 IN O
the P11145566A0000 DT O
high-density P11145566A0000 NN I-UN
lipoprotein P11145566A0000 NN I-UN
receptor P11145566A0000 NN I-UN
( P11145566A0000 ( O
HDL-R P11145566A0000 NNP I-UN
) P11145566A0000 ) O
is P11145566A0000 VBZ O
a P11145566A0000 DT O
key P11145566A0000 JJ O
element P11145566A0000 NN O
in P11145566A0000 IN O
cholesterol P11145566A0000 NN O
homeostasis P11145566A0000 NN O
and P11145566A0000 CC O
a P11145566A0000 DT O
potential P11145566A0000 JJ O
therapeutic P11145566A0000 JJ O
target P11145566A0000 NN O
for P11145566A0000 IN O
hypercholesterolemic P11145566A0000 JJ O
drugs P11145566A0000 NNS O
, P11145566A0000 , O
an P11145566A0000 DT O
understanding P11145566A0000 NN O
of P11145566A0000 IN O
HDL-R P11145566A0000 NNP I-UN
regulation P11145566A0000 NN O
is P11145566A0000 VBZ O
essential P11145566A0000 JJ O
. P11145566A0000 . O
. . O O

Resistance P00479222A0682 NN O
to P00479222A0682 TO O
the P00479222A0682 DT O
simulated P00479222A0682 VBN O
physiologic P00479222A0682 NN O
environment P00479222A0682 NN O
was P00479222A0682 VBD O
tested P00479222A0682 VBN O
by P00479222A0682 IN O
measured P00479222A0682 JJ O
retention P00479222A0682 NN O
of P00479222A0682 IN O
mechanical P00479222A0682 JJ O
properties P00479222A0682 NNS O
after P00479222A0682 IN O
immersion P00479222A0682 NN O
times P00479222A0682 NNS O
in P00479222A0682 IN O
pseudo-extracellular P00479222A0682 JJ O
fluid P00479222A0682 NN O
( P00479222A0682 ( O
PECF P00479222A0682 NNP O
) P00479222A0682 ) O
at P00479222A0682 IN O
37 P00479222A0682 CD O
degrees P00479222A0682 NNS O
C P00479222A0682 NNP O
for P00479222A0682 IN O
as P00479222A0682 RB O
long P00479222A0682 RB O
as P00479222A0682 IN O
three P00479222A0682 CD O
years P00479222A0682 NNS O
. P00479222A0682 . O
. . O O

An P03582149T0001 DT O
epidemiological P03582149T0001 JJ O
survey P03582149T0001 NN O
of P03582149T0001 IN O
rheumatic P03582149T0001 JJ O
valve P03582149T0001 NN O
disease P03582149T0001 NN O
and P03582149T0001 CC O
rheumatic P03582149T0001 JJ O
fever P03582149T0001 NN O
in P03582149T0001 IN O
primary P03582149T0001 JJ O
and P03582149T0001 CC O
secondary P03582149T0001 JJ O
school P03582149T0001 NN O
students P03582149T0001 NNS O
in P03582149T0001 IN O
Jiangxi P03582149T0001 NNP O
Province P03582149T0001 NNP O
. P03582149T0001 . O
. . O O

Calmodulin-binding P09047344A0000 JJ I-UN
peptide P09047344A0000 NN I-UN
( P09047344A0000 ( O
CBP P09047344A0000 NNP I-UN
) P09047344A0000 ) O
, P09047344A0000 , O
a P09047344A0000 DT O
peptide P09047344A0000 NN O
of P09047344A0000 IN O
26 P09047344A0000 CD O
amino P09047344A0000 JJ O
acids P09047344A0000 NNS O
derived P09047344A0000 VBN O
from P09047344A0000 IN O
muscle P09047344A0000 NN I-UN
myosin P09047344A0000 NN I-UN
light P09047344A0000 NN I-UN
chain P09047344A0000 NN I-UN
kinase P09047344A0000 NN I-UN
( P09047344A0000 ( O
MLCK P09047344A0000 NNP I-UN
) P09047344A0000 ) O
, P09047344A0000 , O
binds P09047344A0000 VBZ O
to P09047344A0000 TO O
calmodulin P09047344A0000 VB I-UN
with P09047344A0000 IN O
nanomolar P09047344A0000 JJ O
affinity P09047344A0000 NN O
. P09047344A0000 . O
. . O O

RESULTS P11573891A0525 NN O
: P11573891A0525 : O
Sixty P11573891A0525 NNP O
per P11573891A0525 IN O
cent P11573891A0525 NN O
of P11573891A0525 IN O
African P11573891A0525 JJ O
Americans P11573891A0525 NNPS O
exposed P11573891A0525 VBN O
in P11573891A0525 IN O
26 P11573891A0525 CD O
community P11573891A0525 NN O
outbreaks P11573891A0525 NNS O
were P11573891A0525 VBD O
TST P11573891A0525 NNP O
positive P11573891A0525 JJ O
compared P11573891A0525 VBN O
to P11573891A0525 TO O
only P11573891A0525 RB O
40 P11573891A0525 CD O
% P11573891A0525 NN O
of P11573891A0525 IN O
whites P11573891A0525 NNS O
following P11573891A0525 VBG O
comparable P11573891A0525 JJ O
exposures P11573891A0525 NNS O
. P11573891A0525 . O
. . O O

The P10579331A1225 DT O
results P10579331A1225 NNS O
of P10579331A1225 IN O
these P10579331A1225 DT O
studies P10579331A1225 NNS O
demonstrate P10579331A1225 VBP O
that P10579331A1225 IN O
the P10579331A1225 DT O
rat P10579331A1225 NN O
HDL P10579331A1225 NNP O
receptor P10579331A1225 NN O
SR-BI P10579331A1225 NNP I-UN
promoter P10579331A1225 NN O
contains P10579331A1225 VBZ O
two P10579331A1225 CD O
sterol P10579331A1225 NN O
response P10579331A1225 NN O
elements P10579331A1225 NNS O
( P10579331A1225 ( O
pSRE P10579331A1225 NN O
and P10579331A1225 CC O
dSRE P10579331A1225 NN O
) P10579331A1225 ) O
through P10579331A1225 IN O
which P10579331A1225 WDT O
SREBP-1a P10579331A1225 NNP I-UN
can P10579331A1225 MD O
bind P10579331A1225 VB O
and P10579331A1225 CC O
activate P10579331A1225 VB O
transcription P10579331A1225 NN O
of P10579331A1225 IN O
this P10579331A1225 DT O
gene P10579331A1225 NN O
. P10579331A1225 . O
. . O O

TBPf P01389573A1071 NNP O
is P01389573A1071 VBZ O
defined P01389573A1071 VBN O
as P01389573A1071 IN O
a P01389573A1071 DT O
quotient P01389573A1071 NN O
of P01389573A1071 IN O
the P01389573A1071 DT O
difference P01389573A1071 NN O
of P01389573A1071 IN O
the P01389573A1071 DT O
first P01389573A1071 JJ O
and P01389573A1071 CC O
the P01389573A1071 DT O
second P01389573A1071 JJ O
measurement P01389573A1071 NN O
: P01389573A1071 : O
TBPf P01389573A1071 NNP O
= P01389573A1071 NNP O
( P01389573A1071 ( O
P1 P01389573A1071 NNP O
- P01389573A1071 : O
P2 P01389573A1071 NN O
) P01389573A1071 ) O
/ P01389573A1071 NN O
( P01389573A1071 ( O
A1 P01389573A1071 NNP O
- P01389573A1071 : O
A2 P01389573A1071 NN O
) P01389573A1071 ) O
. P01389573A1071 . O
. . O O

This P01358592A0752 DT O
negative P01358592A0752 JJ O
regulatory P01358592A0752 JJ O
pathway P01358592A0752 NN O
may P01358592A0752 MD O
be P01358592A0752 VB O
important P01358592A0752 JJ O
for P01358592A0752 IN O
determining P01358592A0752 VBG O
cell P01358592A0752 NN O
fate P01358592A0752 NN O
or P01358592A0752 CC O
maintaining P01358592A0752 VBG O
an P01358592A0752 DT O
inducible P01358592A0752 JJ O
state P01358592A0752 NN O
in P01358592A0752 IN O
the P01358592A0752 DT O
ventroposterior P01358592A0752 JJ O
region P01358592A0752 NN O
of P01358592A0752 IN O
the P01358592A0752 DT O
embryo P01358592A0752 NN O
. P01358592A0752 . O
. . O O

Ras P07565669T0000 NNP I-UN
p21Val P07565669T0000 NN I-UN
inhibits P07565669T0000 NNS O
myogenesis P07565669T0000 NN O
without P07565669T0000 IN O
altering P07565669T0000 VBG O
the P07565669T0000 DT O
DNA P07565669T0000 NN O
binding P07565669T0000 NN O
or P07565669T0000 CC O
transcriptional P07565669T0000 JJ O
activities P07565669T0000 NNS O
of P07565669T0000 IN O
the P07565669T0000 DT O
myogenic P07565669T0000 JJ I-UN
basic P07565669T0000 JJ I-UN
helix-loop-helix P07565669T0000 JJ I-UN
factors P07565669T0000 NNS I-UN
. P07565669T0000 . O
. . O O

After P06653755A0192 IN O
clofelin P06653755A0192 JJ O
administration P06653755A0192 NN O
the P06653755A0192 DT O
autoregulation P06653755A0192 NN O
borders P06653755A0192 NNS O
shifted P06653755A0192 VBD O
to P06653755A0192 TO O
the P06653755A0192 DT O
right P06653755A0192 JJ O
i. P06653755A0192 NN O
e. P06653755A0192 NN O
towards P06653755A0192 IN O
higher P06653755A0192 JJR O
AP P06653755A0192 NNP O
levels P06653755A0192 NNS O
. P06653755A0192 . O
. . O O

Peripheral P09505135A0182 JJ O
visual P09505135A0182 JJ O
stimuli P09505135A0182 NN O
and P09505135A0182 CC O
monoaural P09505135A0182 JJ O
auditory P09505135A0182 NN O
stimuli P09505135A0182 NNS O
were P09505135A0182 VBD O
used P09505135A0182 VBN O
as P09505135A0182 IN O
targets P09505135A0182 NNS O
. P09505135A0182 . O
. . O O

The P02028125A0101 DT O
prevalence P02028125A0101 NN O
of P02028125A0101 IN O
opportunistic P02028125A0101 JJ O
infection P02028125A0101 NN O
among P02028125A0101 IN O
surviving P02028125A0101 VBG O
AIDS P02028125A0101 NNP O
patients P02028125A0101 NNS O
and P02028125A0101 CC O
the P02028125A0101 DT O
probability P02028125A0101 NN O
of P02028125A0101 IN O
being P02028125A0101 VBG O
in P02028125A0101 IN O
tumour P02028125A0101 JJ O
response P02028125A0101 NN O
following P02028125A0101 VBG O
cancer P02028125A0101 NN O
therapy P02028125A0101 NN O
conditional P02028125A0101 NN O
on P02028125A0101 IN O
being P02028125A0101 VBG O
alive P02028125A0101 JJ O
are P02028125A0101 VBP O
two P02028125A0101 CD O
examples P02028125A0101 NNS O
of P02028125A0101 IN O
such P02028125A0101 JJ O
functions P02028125A0101 NNS O
. P02028125A0101 . O
. . O O

The P06324089A0453 DT O
primary P06324089A0453 JJ O
structure P06324089A0453 NN O
of P06324089A0453 IN O
the P06324089A0453 DT O
GAL7 P06324089A0453 NNP I-UN
5 P06324089A0453 CD I-UN
' P06324089A0453 '' I-UN
flanking P06324089A0453 VBG I-UN
region P06324089A0453 NN I-UN
has P06324089A0453 VBZ O
many P06324089A0453 JJ O
features P06324089A0453 NNS O
common P06324089A0453 JJ O
to P06324089A0453 TO O
those P06324089A0453 DT O
of P06324089A0453 IN O
multicellular P06324089A0453 JJ O
eukaryotic P06324089A0453 JJ O
genes P06324089A0453 NNS O
. P06324089A0453 . O
. . O O

We P07646439A0535 PRP O
purified P07646439A0535 VBD O
both P07646439A0535 DT O
proteins P07646439A0535 NNS O
from P07646439A0535 IN O
human P07646439A0535 JJ O
platelet P07646439A0535 NN O
membranes P07646439A0535 NNS O
using P07646439A0535 VBG O
DEAE-Sepharose P07646439A0535 NNP O
chromatography P07646439A0535 NN O
followed P07646439A0535 VBN O
by P07646439A0535 IN O
mAb P07646439A0535 NN I-UN
F11 P07646439A0535 NNP I-UN
affinity P07646439A0535 NN O
chromatography P07646439A0535 NN O
. P07646439A0535 . O
. . O O

After P07021505A0510 IN O
acclimation P07021505A0510 NN O
, P07021505A0510 , O
resting P07021505A0510 VBG O
supine P07021505A0510 NN O
and P07021505A0510 CC O
sitting P07021505A0510 VBG O
DPB P07021505A0510 NNP O
decreased P07021505A0510 VBD O
( P07021505A0510 ( O
P P07021505A0510 NNP O
less P07021505A0510 JJR O
than P07021505A0510 IN O
0.05 P07021505A0510 CD O
) P07021505A0510 ) O
by P07021505A0510 IN O
6 P07021505A0510 CD O
and P07021505A0510 CC O
9 P07021505A0510 CD O
mmHg P07021505A0510 NN O
, P07021505A0510 , O
respectively P07021505A0510 RB O
. P07021505A0510 . O
. . O O

We P09374541A0277 PRP O
found P09374541A0277 VBD O
14 P09374541A0277 CD O
protein P09374541A0277 NN O
binding P09374541A0277 VBG O
sites P09374541A0277 NNS O
that P09374541A0277 WDT O
were P09374541A0277 VBD O
occupied P09374541A0277 VBN O
in P09374541A0277 IN O
vivo P09374541A0277 NN O
. P09374541A0277 . O
. . O O

Thus P01379150A0996 RB O
, P01379150A0996 , O
cibenzoline P01379150A0996 NN O
is P01379150A0996 VBZ O
an P01379150A0996 DT O
effective P01379150A0996 JJ O
antiarrhythmic P01379150A0996 JJ O
agent P01379150A0996 NN O
with P01379150A0996 IN O
a P01379150A0996 DT O
favourable P01379150A0996 JJ O
pharmacokinetic P01379150A0996 JJ O
profile P01379150A0996 NN O
that P01379150A0996 WDT O
may P01379150A0996 MD O
be P01379150A0996 VB O
considered P01379150A0996 VBN O
with P01379150A0996 IN O
other P01379150A0996 JJ O
class P01379150A0996 NN O
I P01379150A0996 PRP O
drugs P01379150A0996 NNS O
in P01379150A0996 IN O
patients P01379150A0996 NNS O
requiring P01379150A0996 VBG O
therapy P01379150A0996 NN O
for P01379150A0996 IN O
high P01379150A0996 JJ O
risk P01379150A0996 NN O
arrhythmias P01379150A0996 NNS O
. P01379150A0996 . O
. . O O

Sweet P06354594A0114 NNP O
oranges P06354594A0114 NNS O
, P06354594A0114 , O
mandarin P06354594A0114 NN O
, P06354594A0114 , O
grapefruit P06354594A0114 NN O
, P06354594A0114 , O
lemon P06354594A0114 NN O
, P06354594A0114 , O
and P06354594A0114 CC O
lime P06354594A0114 NN O
are P06354594A0114 VBP O
generally P06354594A0114 RB O
used P06354594A0114 VBN O
for P06354594A0114 IN O
processing P06354594A0114 NN O
. P06354594A0114 . O
. . O O

Study P05982700T0000 NN O
on P05982700T0000 IN O
the P05982700T0000 DT O
evagination P05982700T0000 NN O
of P05982700T0000 IN O
Cysticercus P05982700T0000 NNP O
pisiformis P05982700T0000 NN O
. P05982700T0000 . O
. . O O

MSMS P07311881T0000 NNP O
Council P07311881T0000 NNP O
hears P07311881T0000 VBZ O
new P07311881T0000 JJ O
public P07311881T0000 JJ O
health P07311881T0000 NN O
director P07311881T0000 NN O
. P07311881T0000 . O
. . O O

At P06212776A0000 IN O
Cabras P06212776A0000 NNP O
( P06212776A0000 ( O
Oristano P06212776A0000 NNP O
) P06212776A0000 ) O
, P06212776A0000 , O
a P06212776A0000 DT O
town P06212776A0000 NN O
characterized P06212776A0000 VBN O
by P06212776A0000 IN O
a P06212776A0000 DT O
high P06212776A0000 JJ O
incidence P06212776A0000 NN O
of P06212776A0000 IN O
thalassaemia P06212776A0000 NN O
and P06212776A0000 CC O
G6PD P06212776A0000 NNP I-UN
deficiency P06212776A0000 NN O
less P06212776A0000 JJR O
than P06212776A0000 IN O
half P06212776A0000 PDT O
the P06212776A0000 DT O
people P06212776A0000 NNS O
between P06212776A0000 IN O
18 P06212776A0000 CD O
and P06212776A0000 CC O
35 P06212776A0000 CD O
have P06212776A0000 VBP O
a P06212776A0000 DT O
fair P06212776A0000 JJ O
knowledge P06212776A0000 NN O
of P06212776A0000 IN O
genetic P06212776A0000 JJ O
diseases P06212776A0000 NNS O
and P06212776A0000 CC O
of P06212776A0000 IN O
their P06212776A0000 PRP$ O
prevention P06212776A0000 NN O
. P06212776A0000 . O
. . O O

Peter P07960796A0154 NNP O
Elfer P07960796A0154 NNP O
explores P07960796A0154 VBZ O
the P07960796A0154 DT O
implications P07960796A0154 NNS O
of P07960796A0154 IN O
the P07960796A0154 DT O
ruling P07960796A0154 NN O
. P07960796A0154 . O
. . O O

Asthmatic P06818113A0384 JJ O
patients P06818113A0384 NNS O
showed P06818113A0384 VBD O
greater P06818113A0384 JJR O
responses P06818113A0384 NNS O
of P06818113A0384 IN O
both P06818113A0384 DT O
parameters P06818113A0384 NNS O
to P06818113A0384 TO O
adrenaline P06818113A0384 VB O
than P06818113A0384 IN O
controls P06818113A0384 NNS O
indicating P06818113A0384 VBG O
that P06818113A0384 IN O
long-term P06818113A0384 JJ O
corticosteroid P06818113A0384 NN O
treatment P06818113A0384 NN O
enhances P06818113A0384 VBZ O
the P06818113A0384 DT O
acute P06818113A0384 JJ O
responses P06818113A0384 NNS O
of P06818113A0384 IN O
plasminogen P06818113A0384 NN I-UN
activator P06818113A0384 NN I-UN
and P06818113A0384 CC O
clotting P06818113A0384 VBG I-UN
factor P06818113A0384 NN I-UN
VIII P06818113A0384 NNP I-UN
to P06818113A0384 TO O
adrenaline P06818113A0384 VB O
infusion P06818113A0384 NN O
. P06818113A0384 . O
. . O O

In P10601344A1653 IN O
addition P10601344A1653 NN O
, P10601344A1653 , O
using P10601344A1653 VBG O
biochemical P10601344A1653 JJ O
activity P10601344A1653 NN O
assays P10601344A1653 NNS O
for P10601344A1653 IN O
Rho-like P10601344A1653 JJ O
GTPases P10601344A1653 NNS I-UN
, P10601344A1653 , O
we P10601344A1653 PRP O
show P10601344A1653 VBP O
that P10601344A1653 IN O
the P10601344A1653 DT O
expression P10601344A1653 NN O
of P10601344A1653 IN O
beta1A P10601344A1653 NN I-UN
, P10601344A1653 , O
beta1D P10601344A1653 NN I-UN
, P10601344A1653 , O
or P10601344A1653 CC O
IL2R-beta1A P10601344A1653 NNP O
in P10601344A1653 IN O
GE11 P10601344A1653 NNP O
or P10601344A1653 CC O
GD25 P10601344A1653 NNP O
cells P10601344A1653 NNS O
triggers P10601344A1653 VBZ O
activation P10601344A1653 NN O
of P10601344A1653 IN O
both P10601344A1653 DT O
RhoA P10601344A1653 NNP I-UN
and P10601344A1653 CC O
Rac1 P10601344A1653 NNP I-UN
, P10601344A1653 , O
but P10601344A1653 CC O
not P10601344A1653 RB O
of P10601344A1653 IN O
Cdc42 P10601344A1653 NNP I-UN
. P10601344A1653 . O
. . O O

Therapeutic P02194972T0000 JJ O
effects P02194972T0000 NNS O
of P02194972T0000 IN O
cefpirome P02194972T0000 NN O
( P02194972T0000 ( O
HR P02194972T0000 NNP O
810 P02194972T0000 CD O
) P02194972T0000 ) O
on P02194972T0000 IN O
experimental P02194972T0000 JJ O
mixed P02194972T0000 JJ O
infections P02194972T0000 NNS O
with P02194972T0000 IN O
Enterococcus P02194972T0000 NNP O
faecalis P02194972T0000 NNS O
and P02194972T0000 CC O
Escherichia P02194972T0000 NNP O
coli P02194972T0000 VBP O
in P02194972T0000 IN O
mice P02194972T0000 NN O
. P02194972T0000 . O
. . O O

GRP78 P08576245A0000 NNP I-UN
, P08576245A0000 , O
a P08576245A0000 DT O
molecular P08576245A0000 JJ O
chaperone P08576245A0000 NN O
expressed P08576245A0000 VBN O
in P08576245A0000 IN O
the P08576245A0000 DT O
endoplasmic P08576245A0000 JJ O
reticulum P08576245A0000 NN O
, P08576245A0000 , O
is P08576245A0000 VBZ O
a P08576245A0000 DT O
`` P08576245A0000 `` O
glucose-regulated P08576245A0000 JJ O
protein P08576245A0000 NN O
'' P08576245A0000 '' O
induced P08576245A0000 VBN O
by P08576245A0000 IN O
stress P08576245A0000 NN O
responses P08576245A0000 NNS O
that P08576245A0000 WDT O
deplete P08576245A0000 VBP O
glucose P08576245A0000 VB O
or P08576245A0000 CC O
intracisternal P08576245A0000 JJ O
calcium P08576245A0000 NN O
or P08576245A0000 CC O
otherwise P08576245A0000 RB O
disrupt P08576245A0000 JJ O
glycoprotein P08576245A0000 NN O
trafficking P08576245A0000 NN O
. P08576245A0000 . O
. . O O

Subsequent P08496185A0484 JJ O
cloning P08496185A0484 NN O
and P08496185A0484 CC O
nucleotide P08496185A0484 JJ O
sequence P08496185A0484 NN O
analysis P08496185A0484 NN O
of P08496185A0484 IN O
the P08496185A0484 DT O
S. P08496185A0484 NNP I-UN
pombe P08496185A0484 NN I-UN
adenylate P08496185A0484 NN I-UN
kinase P08496185A0484 NN I-UN
gene P08496185A0484 NN I-UN
, P08496185A0484 , O
adk1 P08496185A0484 RB I-UN
, P08496185A0484 , O
revealed P08496185A0484 VBD O
a P08496185A0484 DT O
coding P08496185A0484 JJ O
region P08496185A0484 NN O
of P08496185A0484 IN O
660 P08496185A0484 CD O
nucleotides P08496185A0484 NNS O
. P08496185A0484 . O
. . O O

PACAP P11350957A0457 NNP I-UN
mRNA P11350957A0457 NN I-UN
was P11350957A0457 VBD O
widely P11350957A0457 RB O
expressed P11350957A0457 VBN O
in P11350957A0457 IN O
most P11350957A0457 JJS O
human P11350957A0457 JJ O
tissues P11350957A0457 NNS O
; P11350957A0457 : O
in P11350957A0457 IN O
transfected P11350957A0457 JJ O
cells P11350957A0457 NNS O
, P11350957A0457 , O
PACAP P11350957A0457 NNP I-UN
was P11350957A0457 VBD O
diffusely P11350957A0457 RB O
expressed P11350957A0457 VBN O
in P11350957A0457 IN O
the P11350957A0457 DT O
cytoplasm P11350957A0457 NN O
. P11350957A0457 . O
. . O O

Alignment P11595170A0582 NN O
of P11595170A0582 IN O
different P11595170A0582 JJ O
cDNAs P11595170A0582 NN O
of P11595170A0582 IN O
the P11595170A0582 DT O
NR5A2 P11595170A0582 NNP I-UN
( P11595170A0582 ( O
hB1F P11595170A0582 NN I-UN
) P11595170A0582 ) O
gene P11595170A0582 NN O
with P11595170A0582 IN O
the P11595170A0582 DT O
genomic P11595170A0582 JJ O
sequence P11595170A0582 NN O
facilitated P11595170A0582 VBD O
the P11595170A0582 DT O
delineation P11595170A0582 NN O
of P11595170A0582 IN O
its P11595170A0582 PRP$ O
structural P11595170A0582 JJ O
organization P11595170A0582 NN O
, P11595170A0582 , O
which P11595170A0582 WDT O
spans P11595170A0582 VBZ O
over P11595170A0582 IN O
150 P11595170A0582 CD O
kb P11595170A0582 NNS O
and P11595170A0582 CC O
consists P11595170A0582 NNS O
of P11595170A0582 IN O
eight P11595170A0582 CD O
exons P11595170A0582 NNS O
interrupted P11595170A0582 VBN O
by P11595170A0582 IN O
seven P11595170A0582 CD O
introns P11595170A0582 NNS O
. P11595170A0582 . O
. . O O

The P03258069A0000 DT O
purposes P03258069A0000 NNS O
of P03258069A0000 IN O
this P03258069A0000 DT O
study P03258069A0000 NN O
were P03258069A0000 VBD O
1 P03258069A0000 CD O
) P03258069A0000 ) O
to P03258069A0000 TO O
examine P03258069A0000 VB O
the P03258069A0000 DT O
effect P03258069A0000 NN O
of P03258069A0000 IN O
high P03258069A0000 JJ O
intensity P03258069A0000 NN O
, P03258069A0000 , O
low P03258069A0000 JJ O
frequency P03258069A0000 NN O
transcutaneous P03258069A0000 JJ O
electrical P03258069A0000 JJ O
nerve P03258069A0000 NN O
stimulation P03258069A0000 NN O
at P03258069A0000 IN O
auricular P03258069A0000 JJ O
acupuncture P03258069A0000 NN O
points P03258069A0000 NNS O
on P03258069A0000 IN O
experimental P03258069A0000 JJ O
pain P03258069A0000 NN O
threshold P03258069A0000 NN O
measured P03258069A0000 VBN O
at P03258069A0000 IN O
the P03258069A0000 DT O
wrist P03258069A0000 NN O
and P03258069A0000 CC O
2 P03258069A0000 CD O
) P03258069A0000 ) O
to P03258069A0000 TO O
determine P03258069A0000 VB O
the P03258069A0000 DT O
changes P03258069A0000 NNS O
in P03258069A0000 IN O
effect P03258069A0000 NN O
over P03258069A0000 IN O
time P03258069A0000 NN O
. P03258069A0000 . O
. . O O

In P10938556A0248 IN O
addition P10938556A0248 NN O
, P10938556A0248 , O
the P10938556A0248 DT O
ketamine-treated P10938556A0248 JJ O
rats P10938556A0248 NNS O
had P10938556A0248 VBD O
more P10938556A0248 JJR O
neurons P10938556A0248 NNS O
and P10938556A0248 CC O
glial P10938556A0248 JJ O
cells P10938556A0248 NNS O
surrounding P10938556A0248 VBG O
the P10938556A0248 DT O
ventricles P10938556A0248 NNS O
. P10938556A0248 . O
. . O O

CSR P11369700A0074 NNP O
is P11369700A0074 VBZ O
directed P11369700A0074 VBN O
to P11369700A0074 TO O
specific P11369700A0074 JJ O
heavy P11369700A0074 JJ O
chain P11369700A0074 NN O
isotypes P11369700A0074 NNS O
by P11369700A0074 IN O
cytokines P11369700A0074 NNS O
and P11369700A0074 CC O
B P11369700A0074 NNP O
cell P11369700A0074 NN O
activators P11369700A0074 NNS O
that P11369700A0074 WDT O
induce P11369700A0074 VBP O
transcription P11369700A0074 NN O
from P11369700A0074 IN O
the P11369700A0074 DT O
unrearranged P11369700A0074 JJ O
, P11369700A0074 , O
or P11369700A0074 CC O
germline P11369700A0074 NN O
( P11369700A0074 ( O
GL P11369700A0074 NNP O
) P11369700A0074 ) O
, P11369700A0074 , O
C P11369700A0074 NNP I-UN
( P11369700A0074 ( I-UN
H P11369700A0074 NNP I-UN
) P11369700A0074 ) I-UN
region P11369700A0074 NN I-UN
genes P11369700A0074 NNS I-UN
. P11369700A0074 . O
. . O O

Sevelamer P11210401A0000 NNP O
hydrochloride P11210401A0000 NN O
( P11210401A0000 ( O
Renagel P11210401A0000 NNP O
) P11210401A0000 ) O
is P11210401A0000 VBZ O
a P11210401A0000 DT O
nonabsorbed P11210401A0000 JJ O
phosphate-binding P11210401A0000 JJ O
polymer P11210401A0000 NN O
marketed P11210401A0000 VBN O
for P11210401A0000 IN O
the P11210401A0000 DT O
treatment P11210401A0000 NN O
of P11210401A0000 IN O
hyperphosphatemia P11210401A0000 NN O
in P11210401A0000 IN O
adult P11210401A0000 NN O
patients P11210401A0000 NNS O
receiving P11210401A0000 VBG O
hemodialysis P11210401A0000 NN O
. P11210401A0000 . O
. . O O

Three P10022905A0446 CD O
mog-1 P10022905A0446 JJ I-UN
alleles P10022905A0446 NNS I-UN
possess P10022905A0446 JJ O
premature P10022905A0446 JJ O
stop P10022905A0446 JJ O
codons P10022905A0446 NNS O
and P10022905A0446 CC O
are P10022905A0446 VBP O
likely P10022905A0446 JJ O
to P10022905A0446 TO O
be P10022905A0446 VB O
null P10022905A0446 JJ O
alleles P10022905A0446 NNS O
, P10022905A0446 , O
and P10022905A0446 CC O
one P10022905A0446 CD O
is P10022905A0446 VBZ O
a P10022905A0446 DT O
missense P10022905A0446 JJ O
mutation P10022905A0446 NN O
and P10022905A0446 CC O
is P10022905A0446 VBZ O
likely P10022905A0446 JJ O
to P10022905A0446 TO O
retain P10022905A0446 VB O
residual P10022905A0446 JJ O
activity P10022905A0446 NN O
. P10022905A0446 . O
mog-1 P10022905A0446 JJ I-UN
mRNA P10022905A0446 NN I-UN
is P10022905A0446 VBZ O
expressed P10022905A0446 VBN O
in P10022905A0446 IN O
both P10022905A0446 DT O
germ P10022905A0446 JJ O
line P10022905A0446 NN O
and P10022905A0446 CC O
somatic P10022905A0446 JJ O
tissues P10022905A0446 NNS O
and P10022905A0446 CC O
appears P10022905A0446 VBZ O
to P10022905A0446 TO O
be P10022905A0446 VB O
ubiquitous P10022905A0446 JJ O
. P10022905A0446 . O
. . O O

The P00594466T0001 DT O
induction P00594466T0001 NN O
of P00594466T0001 IN O
seizures P00594466T0001 NNS O
in P00594466T0001 IN O
`` P00594466T0001 `` O
Papio P00594466T0001 NNP O
papio P00594466T0001 NN O
'' P00594466T0001 '' O
following P00594466T0001 VBG O
allylglycine P00594466T0001 VB O
alone P00594466T0001 RB O
or P00594466T0001 CC O
in P00594466T0001 IN O
combination P00594466T0001 NN O
with P00594466T0001 IN O
intermittent P00594466T0001 JJ O
photic P00594466T0001 JJ O
stimulation P00594466T0001 NN O
. P00594466T0001 . O
. . O O

PURPOSE P10416558A0000 NN O
: P10416558A0000 : O
The P10416558A0000 DT O
purposes P10416558A0000 NNS O
of P10416558A0000 IN O
the P10416558A0000 DT O
present P10416558A0000 JJ O
study P10416558A0000 NN O
were P10416558A0000 VBD O
to P10416558A0000 TO O
assess P10416558A0000 VB O
the P10416558A0000 DT O
effects P10416558A0000 NNS O
of P10416558A0000 IN O
a P10416558A0000 DT O
12-wk P10416558A0000 JJ O
laboratory P10416558A0000 NN O
based P10416558A0000 VBN O
aerobic P10416558A0000 JJ O
exercise P10416558A0000 NN O
program P10416558A0000 NN O
on P10416558A0000 IN O
cardiopulmonary P10416558A0000 JJ O
function P10416558A0000 NN O
, P10416558A0000 , O
CD4 P10416558A0000 NNP I-UN
cell P10416558A0000 NN O
count P10416558A0000 NN O
, P10416558A0000 , O
and P10416558A0000 CC O
physician-assessed P10416558A0000 JJ O
health P10416558A0000 NN O
status P10416558A0000 NN O
among P10416558A0000 IN O
symptomatic P10416558A0000 JJ O
pre-AIDS P10416558A0000 JJ O
HIV-infected P10416558A0000 JJ O
individuals P10416558A0000 NNS O
( P10416558A0000 ( O
N P10416558A0000 NNP O
= P10416558A0000 NNP O
28 P10416558A0000 CD O
) P10416558A0000 ) O
and P10416558A0000 CC O
to P10416558A0000 TO O
assess P10416558A0000 VB O
the P10416558A0000 DT O
degree P10416558A0000 NN O
to P10416558A0000 TO O
which P10416558A0000 WDT O
ill P10416558A0000 VB O
health P10416558A0000 NN O
was P10416558A0000 VBD O
associated P10416558A0000 VBN O
with P10416558A0000 IN O
exercise P10416558A0000 NN O
relapse P10416558A0000 NN O
. P10416558A0000 . O
. . O O

The P07765118A0967 DT O
maximum P07765118A0967 JJ O
induction P07765118A0967 NN O
of P07765118A0967 IN O
ACC-oxidase P07765118A0967 NNP I-UN
transcripts P07765118A0967 NNS I-UN
occurred P07765118A0967 VBD O
at P07765118A0967 IN O
about P07765118A0967 IN O
6 P07765118A0967 CD O
h P07765118A0967 NN O
after P07765118A0967 IN O
excision P07765118A0967 NN O
, P07765118A0967 , O
while P07765118A0967 IN O
the P07765118A0967 DT O
maximum P07765118A0967 JJ O
enzyme P07765118A0967 NN O
activity P07765118A0967 NN O
was P07765118A0967 VBD O
observed P07765118A0967 VBN O
at P07765118A0967 IN O
24 P07765118A0967 CD O
h P07765118A0967 NN O
. P07765118A0967 . O
. . O O

Following P10895417A0669 VBG O
EPI-C0401 P10895417A0669 NNP O
, P10895417A0669 , O
but P10895417A0669 CC O
not P10895417A0669 RB O
saline P10895417A0669 VB O
or P10895417A0669 CC O
DepoFoam P10895417A0669 NNP O
vehicle P10895417A0669 NN O
, P10895417A0669 , O
there P10895417A0669 EX O
were P10895417A0669 VBD O
transient P10895417A0669 NN O
( P10895417A0669 ( O
< P10895417A0669 JJ O
72 P10895417A0669 CD O
hr P10895417A0669 NN O
) P10895417A0669 ) O
decreases P10895417A0669 VBZ O
in P10895417A0669 IN O
food P10895417A0669 NN O
consumption P10895417A0669 NN O
, P10895417A0669 , O
arousal P10895417A0669 NN O
, P10895417A0669 , O
hindlimb P10895417A0669 JJ O
muscle P10895417A0669 NN O
tone P10895417A0669 NN O
, P10895417A0669 , O
and P10895417A0669 CC O
body P10895417A0669 NN O
temperature P10895417A0669 NN O
. P10895417A0669 . O
. . O O

The P07673128A0989 DT O
third P07673128A0989 JJ O
domain P07673128A0989 NN O
had P07673128A0989 VBD O
the P07673128A0989 DT O
motif P07673128A0989 NN O
of P07673128A0989 IN O
a P07673128A0989 DT O
cAMP P07673128A0989 NN O
response P07673128A0989 NN O
element P07673128A0989 NN O
( P07673128A0989 ( O
CRE P07673128A0989 NNP O
) P07673128A0989 ) O
. P07673128A0989 . O
. . O O

Thus P08035833A1556 RB O
, P08035833A1556 , O
YMIP P08035833A1556 NNP I-UN
is P08035833A1556 VBZ O
a P08035833A1556 DT O
functional P08035833A1556 JJ O
homolog P08035833A1556 NN O
of P08035833A1556 IN O
RMIP P08035833A1556 NNP I-UN
and P08035833A1556 CC O
represents P08035833A1556 VBZ O
a P08035833A1556 DT O
new P08035833A1556 JJ O
component P08035833A1556 NN O
of P08035833A1556 IN O
the P08035833A1556 DT O
yeast P08035833A1556 NN O
mitochondrial P08035833A1556 JJ O
import P08035833A1556 NN O
machinery P08035833A1556 NN O
. P08035833A1556 . O
. . O O

Surprisingly P07983716A1082 RB O
, P07983716A1082 , O
Northern P07983716A1082 NNP O
( P07983716A1082 ( O
RNA P07983716A1082 NNP O
) P07983716A1082 ) O
blot P07983716A1082 NN O
analysis P07983716A1082 NN O
and P07983716A1082 CC O
reverse P07983716A1082 VB I-UN
transcriptase-PCRs P07983716A1082 NN O
performed P07983716A1082 VBN O
after P07983716A1082 IN O
transfection P07983716A1082 NN O
of P07983716A1082 IN O
COS-7 P07983716A1082 NNP O
or P07983716A1082 CC O
HeLa P07983716A1082 NNP O
cells P07983716A1082 NNS O
with P07983716A1082 IN O
these P07983716A1082 DT O
viral P07983716A1082 JJ O
RNAs P07983716A1082 NNP O
revealed P07983716A1082 VBD O
that P07983716A1082 IN O
Y88S P07983716A1082 NNP I-UN
and P07983716A1082 CC O
Y88L P07983716A1082 NNP I-UN
RNAs P07983716A1082 NNP I-UN
replicated P07983716A1082 VBD O
at P07983716A1082 IN O
only P07983716A1082 RB O
very P07983716A1082 RB O
low P07983716A1082 JJ O
levels P07983716A1082 NNS O
. P07983716A1082 . O
. . O O

Dermoid P05718386T0001 NNP O
cyst P05718386T0001 NN O
in P05718386T0001 IN O
a P05718386T0001 DT O
free P05718386T0001 JJ O
skin P05718386T0001 NN O
flap P05718386T0001 NN O
as P05718386T0001 IN O
the P05718386T0001 DT O
complication P05718386T0001 NN O
after P05718386T0001 IN O
treatment P05718386T0001 NN O
of P05718386T0001 IN O
recurring P05718386T0001 VBG O
hernia P05718386T0001 NN O
. P05718386T0001 . O
. . O O

This P03781000A0101 DT O
lack P03781000A0101 NN O
of P03781000A0101 IN O
correlation P03781000A0101 NN O
may P03781000A0101 MD O
be P03781000A0101 VB O
due P03781000A0101 JJ O
to P03781000A0101 TO O
variations P03781000A0101 NNS O
in P03781000A0101 IN O
the P03781000A0101 DT O
metabolic P03781000A0101 JJ O
activity P03781000A0101 NN O
of P03781000A0101 IN O
the P03781000A0101 DT O
endometriotic P03781000A0101 JJ O
implants P03781000A0101 NNS O
present P03781000A0101 JJ O
at P03781000A0101 IN O
different P03781000A0101 JJ O
stages P03781000A0101 NNS O
of P03781000A0101 IN O
the P03781000A0101 DT O
disease P03781000A0101 NN O
. P03781000A0101 . O
. . O O

Survival P07892076A0578 NN O
after P07892076A0578 IN O
development P07892076A0578 NN O
of P07892076A0578 IN O
symptomatic P07892076A0578 JJ O
infection P07892076A0578 NN O
( P07892076A0578 ( O
P-2 P07892076A0578 NNP O
) P07892076A0578 ) O
did P07892076A0578 VBD O
not P07892076A0578 RB O
differ P07892076A0578 VB O
by P07892076A0578 IN O
transmission P07892076A0578 NN O
mode P07892076A0578 NN O
. P07892076A0578 . O
. . O O

In P07870305A1015 IN O
nucleus P07870305A1015 JJ O
ventralis P07870305A1015 JJ O
anterior P07870305A1015 JJ O
thalami-nucleus P07870305A1015 JJ O
ventralis P07870305A1015 NN O
lateralis P07870305A1015 NN O
thalami P07870305A1015 NN O
neurons P07870305A1015 NNS O
with P07870305A1015 IN O
an P07870305A1015 DT O
inhibitory P07870305A1015 NN O
input P07870305A1015 NN O
from P07870305A1015 IN O
nucleus P07870305A1015 JJ O
entopeduncularis P07870305A1015 NN O
, P07870305A1015 , O
a P07870305A1015 DT O
shortening P07870305A1015 NN O
of P07870305A1015 IN O
inhibition P07870305A1015 NN O
from P07870305A1015 IN O
17.5 P07870305A1015 CD O
+ P07870305A1015 NNS O
/ P07870305A1015 SYM O
- P07870305A1015 : O
3.6 P07870305A1015 CD O
to P07870305A1015 TO O
9.1 P07870305A1015 CD O
+ P07870305A1015 NNS O
/ P07870305A1015 SYM O
- P07870305A1015 : O
1.8 P07870305A1015 CD O
ms P07870305A1015 NN O
( P07870305A1015 ( O
P P07870305A1015 NNP O
< P07870305A1015 NNP O
0.05 P07870305A1015 CD O
) P07870305A1015 ) O
under P07870305A1015 IN O
the P07870305A1015 DT O
haloperidol P07870305A1015 NN O
influence P07870305A1015 NN O
was P07870305A1015 VBD O
evident P07870305A1015 JJ O
. P07870305A1015 . O
. . O O

Finally P01360180A1568 RB O
, P01360180A1568 , O
we P01360180A1568 PRP O
determined P01360180A1568 VBD O
that P01360180A1568 IN O
the P01360180A1568 DT O
P68 P01360180A1568 NNP I-UN
amino P01360180A1568 NN O
terminus P01360180A1568 NN O
was P01360180A1568 VBD O
both P01360180A1568 DT O
necessary P01360180A1568 JJ O
and P01360180A1568 CC O
sufficient P01360180A1568 JJ O
for P01360180A1568 IN O
binding P01360180A1568 VBG O
dsRNA P01360180A1568 NN O
as P01360180A1568 IN O
we P01360180A1568 PRP O
were P01360180A1568 VBD O
able P01360180A1568 JJ O
to P01360180A1568 TO O
transfer P01360180A1568 VB O
dsRNA-binding P01360180A1568 JJ O
properties P01360180A1568 NNS O
to P01360180A1568 TO O
a P01360180A1568 DT O
reporter P01360180A1568 NN O
gene P01360180A1568 NN O
product P01360180A1568 NN O
previously P01360180A1568 RB O
unable P01360180A1568 JJ O
to P01360180A1568 TO O
bind P01360180A1568 VB O
RNA P01360180A1568 NNP O
. P01360180A1568 . O
. . O O

Angionephroscintigraphy P06658586T0001 NN O
in P06658586T0001 IN O
the P06658586T0001 DT O
diagnosis P06658586T0001 NN O
of P06658586T0001 IN O
diseases P06658586T0001 NNS O
of P06658586T0001 IN O
the P06658586T0001 DT O
kidney P06658586T0001 NN O
. P06658586T0001 . O
. . O O

The P03811852A0109 DT O
risk P03811852A0109 NN O
for P03811852A0109 IN O
these P03811852A0109 DT O
complications P03811852A0109 NNS O
is P03811852A0109 VBZ O
increased P03811852A0109 VBN O
by P03811852A0109 IN O
the P03811852A0109 DT O
following P03811852A0109 JJ O
factors P03811852A0109 NNS O
: P03811852A0109 : O
multiple P03811852A0109 JJ O
gestation P03811852A0109 NN O
, P03811852A0109 , O
the P03811852A0109 DT O
combination P03811852A0109 NN O
of P03811852A0109 IN O
magnesium P03811852A0109 NN O
sulfate P03811852A0109 NN O
and P03811852A0109 CC O
beta-adrenergic P03811852A0109 JJ O
agonist P03811852A0109 NN O
, P03811852A0109 , O
and P03811852A0109 CC O
the P03811852A0109 DT O
use P03811852A0109 NN O
of P03811852A0109 IN O
adrenocortico-steroids P03811852A0109 NNS O
to P03811852A0109 TO O
hasten P03811852A0109 VB O
fetal P03811852A0109 JJ O
pulmonary P03811852A0109 JJ O
maturity P03811852A0109 NN O
. P03811852A0109 . O
. . O O

Multivariate P09778068A1129 NNP O
Cox P09778068A1129 NNP O
survival P09778068A1129 NN O
analysis P09778068A1129 NN O
identified P09778068A1129 VBN O
baseline P09778068A1129 NN O
EF P09778068A1129 NNP O
< P09778068A1129 NNP O
or P09778068A1129 CC O
= P09778068A1129 VB O
30 P09778068A1129 CD O
% P09778068A1129 NN O
, P09778068A1129 , O
presence P09778068A1129 NN O
of P09778068A1129 IN O
significant P09778068A1129 JJ O
mitral P09778068A1129 JJ O
regurgitation P09778068A1129 NN O
( P09778068A1129 ( O
> P09778068A1129 JJ O
2+ P09778068A1129 CD O
) P09778068A1129 ) O
before P09778068A1129 IN O
ablation P09778068A1129 NN O
, P09778068A1129 , O
and P09778068A1129 CC O
failure P09778068A1129 NN O
to P09778068A1129 TO O
exhibit P09778068A1129 VB O
improved P09778068A1129 JJ O
cardiac P09778068A1129 JJ O
performance P09778068A1129 NN O
by P09778068A1129 IN O
1 P09778068A1129 CD O
month P09778068A1129 NN O
after P09778068A1129 IN O
ablation P09778068A1129 NN O
as P09778068A1129 IN O
the P09778068A1129 DT O
only P09778068A1129 JJ O
independent P09778068A1129 JJ O
predictors P09778068A1129 NNS O
of P09778068A1129 IN O
death P09778068A1129 NN O
. P09778068A1129 . O
. . O O

We P01652372A0153 PRP O
have P01652372A0153 VBP O
identified P01652372A0153 VBN O
SWI5 P01652372A0153 NNP I-UN
's P01652372A0153 POS O
nuclear P01652372A0153 JJ O
localization P01652372A0153 NN O
signal P01652372A0153 NN O
( P01652372A0153 ( O
NLS P01652372A0153 NNP O
) P01652372A0153 ) O
and P01652372A0153 CC O
show P01652372A0153 VBP O
that P01652372A0153 IN O
it P01652372A0153 PRP O
can P01652372A0153 MD O
confer P01652372A0153 VB O
cell P01652372A0153 JJ O
cycle-dependent P01652372A0153 JJ O
nuclear P01652372A0153 JJ O
entry P01652372A0153 NN O
to P01652372A0153 TO O
a P01652372A0153 DT O
heterologous P01652372A0153 JJ O
protein P01652372A0153 NN O
. P01652372A0153 . O
. . O O

During P10702253A0357 IN O
the P10702253A0357 DT O
cloning P10702253A0357 NN O
by P10702253A0357 IN O
reverse P10702253A0357 JJ I-UN
transcriptase-polymerase P10702253A0357 NN O
chain P10702253A0357 NN O
reaction P10702253A0357 NN O
of P10702253A0357 IN O
the P10702253A0357 DT O
human P10702253A0357 JJ I-UN
HIF-1alpha P10702253A0357 NNP I-UN
subunit P10702253A0357 NN I-UN
, P10702253A0357 , O
we P10702253A0357 PRP O
isolated P10702253A0357 VBD O
two P10702253A0357 CD O
cDNA P10702253A0357 NN O
clones P10702253A0357 NNS O
which P10702253A0357 WDT O
corresponded P10702253A0357 VBD O
to P10702253A0357 TO O
alternative P10702253A0357 VB O
splicing P10702253A0357 NN O
of P10702253A0357 IN O
the P10702253A0357 DT O
HIF-1alpha P10702253A0357 NNP I-UN
gene P10702253A0357 NN I-UN
. P10702253A0357 . O
. . O O

Effects P03626129T0001 NNS O
of P03626129T0001 IN O
a P03626129T0001 DT O
low-energy P03626129T0001 JJ O
laser P03626129T0001 NN O
beam P03626129T0001 NN O
on P03626129T0001 IN O
the P03626129T0001 DT O
cells P03626129T0001 NNS O
of P03626129T0001 IN O
the P03626129T0001 DT O
newt P03626129T0001 JJ O
embryo P03626129T0001 NN O
. P03626129T0001 . O
. . O O

AMDA P10787804T0000 NNP O
white P10787804T0000 JJ O
paper P10787804T0000 NN O
identifies P10787804T0000 NNS O
ways P10787804T0000 NNS O
to P10787804T0000 TO O
improve P10787804T0000 VB O
pharmaceutical P10787804T0000 JJ O
care P10787804T0000 NN O
in P10787804T0000 IN O
SNFs P10787804T0000 NNP O
. P10787804T0000 . O
. . O O

The P07935395A0094 DT O
protein P07935395A0094 NN O
encoded P07935395A0094 VBD O
is P07935395A0094 VBZ O
114 P07935395A0094 CD O
kDa P07935395A0094 NN O
and P07935395A0094 CC O
contains P07935395A0094 NNS O
eight P07935395A0094 CD O
zinc P07935395A0094 NN O
finger P07935395A0094 NN O
motifs P07935395A0094 NNS O
, P07935395A0094 , O
seven P07935395A0094 CD O
of P07935395A0094 IN O
which P07935395A0094 WDT O
are P07935395A0094 VBP O
present P07935395A0094 JJ O
in P07935395A0094 IN O
two P07935395A0094 CD O
clusters P07935395A0094 NNS O
at P07935395A0094 IN O
opposite P07935395A0094 JJ O
ends P07935395A0094 NNS O
of P07935395A0094 IN O
the P07935395A0094 DT O
molecule P07935395A0094 NN O
. P07935395A0094 . O
. . O O

They P10791251A0110 PRP O
are P10791251A0110 VBP O
present P10791251A0110 JJ O
in P10791251A0110 IN O
many P10791251A0110 JJ O
kinds P10791251A0110 NNS O
of P10791251A0110 IN O
living P10791251A0110 NN O
things P10791251A0110 NNS O
, P10791251A0110 , O
but P10791251A0110 CC O
their P10791251A0110 PRP$ O
functions P10791251A0110 NNS O
, P10791251A0110 , O
especially P10791251A0110 RB O
those P10791251A0110 DT O
in P10791251A0110 IN O
humans P10791251A0110 NNS O
, P10791251A0110 , O
are P10791251A0110 VBP O
unclear P10791251A0110 JJ O
. P10791251A0110 . O
. . O O

The P00024600A0522 DT O
variable P00024600A0522 JJ O
HMG P00024600A0522 NNP I-UN
dosage P00024600A0522 NN O
regimen P00024600A0522 NN O
was P00024600A0522 VBD O
found P00024600A0522 VBN O
to P00024600A0522 TO O
offer P00024600A0522 VB O
no P00024600A0522 DT O
advantages P00024600A0522 NNS O
when P00024600A0522 WRB O
compared P00024600A0522 VBN O
with P00024600A0522 IN O
our P00024600A0522 PRP$ O
standard P00024600A0522 JJ O
daily P00024600A0522 JJ O
dosage P00024600A0522 NN O
regimen P00024600A0522 NNS O
. P00024600A0522 . O
. . O O

Among P09925372A0458 IN O
these P09925372A0458 DT O
360 P09925372A0458 CD O
ZFPs P09925372A0458 NNP I-UN
, P09925372A0458 , O
a P09925372A0458 DT O
novel P09925372A0458 JJ O
ZFP P09925372A0458 NNP I-UN
cDNA P09925372A0458 NN I-UN
named P09925372A0458 VBN O
HFHZ P09925372A0458 NNP I-UN
( P09925372A0458 ( O
human P09925372A0458 JJ I-UN
fetal P09925372A0458 JJ I-UN
heart P09925372A0458 NN I-UN
ZFP P09925372A0458 NNP I-UN
) P09925372A0458 ) O
with P09925372A0458 IN O
sequence P09925372A0458 NN O
homology P09925372A0458 NN O
to P09925372A0458 TO O
a P09925372A0458 DT O
Kruppel-associated P09925372A0458 JJ I-UN
box P09925372A0458 NN I-UN
( P09925372A0458 ( O
KRAB P09925372A0458 NNP I-UN
) P09925372A0458 ) O
was P09925372A0458 VBD O
identified P09925372A0458 VBN O
. P09925372A0458 . O
. . O O

Blocked P09652737A1244 VBN O
shift P09652737A1244 NN O
/ P09652737A1244 NNP O
supershift P09652737A1244 NN O
analysis P09652737A1244 NN O
indicates P09652737A1244 VBZ O
that P09652737A1244 IN O
Fos P09652737A1244 NNP I-UN
family P09652737A1244 NN I-UN
member P09652737A1244 NN O
proteins P09652737A1244 VBZ O
especially P09652737A1244 RB O
Fra-1 P09652737A1244 JJ I-UN
and P09652737A1244 CC O
Fra-2 P09652737A1244 NNS I-UN
are P09652737A1244 VBP O
related P09652737A1244 VBN O
to P09652737A1244 TO O
progression P09652737A1244 NN O
and P09652737A1244 CC O
no P09652737A1244 DT O
changes P09652737A1244 NNS O
found P09652737A1244 VBN O
in P09652737A1244 IN O
the P09652737A1244 DT O
Jun P09652737A1244 NNP I-UN
family P09652737A1244 NN I-UN
member P09652737A1244 NN O
proteins P09652737A1244 NNS O
although P09652737A1244 IN O
they P09652737A1244 PRP O
are P09652737A1244 VBP O
present P09652737A1244 JJ O
in P09652737A1244 IN O
the P09652737A1244 DT O
AP-1 P09652737A1244 NNP I-UN
/ P09652737A1244 NNP I-UN
DNA P09652737A1244 NNP I-UN
binding P09652737A1244 VBG I-UN
complex P09652737A1244 JJ I-UN
. P09652737A1244 . O
. . O O

Greater P04066194A0163 NNP O
attenuation P04066194A0163 NN O
of P04066194A0163 IN O
the P04066194A0163 DT O
N1-P2 P04066194A0163 NNP O
and P04066194A0163 CC O
baseline-P2 P04066194A0163 JJ O
amplitude P04066194A0163 NN O
of P04066194A0163 IN O
the P04066194A0163 DT O
probe P04066194A0163 NN O
EPs P04066194A0163 NNP O
was P04066194A0163 VBD O
observed P04066194A0163 VBN O
when P04066194A0163 WRB O
the P04066194A0163 DT O
probe P04066194A0163 NN O
stimulus P04066194A0163 NN O
was P04066194A0163 VBD O
presented P04066194A0163 VBN O
to P04066194A0163 TO O
the P04066194A0163 DT O
right P04066194A0163 JJ O
ear P04066194A0163 NN O
and P04066194A0163 CC O
the P04066194A0163 DT O
verbal P04066194A0163 JJ O
material P04066194A0163 NN O
presented P04066194A0163 VBN O
to P04066194A0163 TO O
the P04066194A0163 DT O
left P04066194A0163 NN O
ear P04066194A0163 NN O
than P04066194A0163 IN O
when P04066194A0163 WRB O
the P04066194A0163 DT O
opposite P04066194A0163 JJ O
stimulation P04066194A0163 NN O
arrangement P04066194A0163 NN O
was P04066194A0163 VBD O
used P04066194A0163 VBN O
. P04066194A0163 . O
. . O O

Interestingly P10094314A0935 RB O
, P10094314A0935 , O
the P10094314A0935 DT O
RNA P10094314A0935 NNP O
sequences P10094314A0935 NNS O
selected P10094314A0935 VBN O
by P10094314A0935 IN O
the P10094314A0935 DT O
mutated P10094314A0935 VBN O
zinc P10094314A0935 NN I-UN
knuckle P10094314A0935 NN I-UN
9G8 P10094314A0935 CD I-UN
variant P10094314A0935 NN I-UN
are P10094314A0935 VBP O
efficiently P10094314A0935 RB O
recognized P10094314A0935 VBN O
by P10094314A0935 IN O
SRp20 P10094314A0935 NNP I-UN
, P10094314A0935 , O
in P10094314A0935 IN O
agreement P10094314A0935 NN O
with P10094314A0935 IN O
the P10094314A0935 DT O
fact P10094314A0935 NN O
that P10094314A0935 IN O
the P10094314A0935 DT O
RBD P10094314A0935 NNP O
of P10094314A0935 IN O
9G8 P10094314A0935 CD I-UN
and P10094314A0935 CC O
SRp20 P10094314A0935 NNP I-UN
are P10094314A0935 VBP O
similar P10094314A0935 JJ O
. P10094314A0935 . O
. . O O

Use P00339289T0049 NNP O
of P00339289T0049 IN O
radioactive P00339289T0049 JJ O
isotopes P00339289T0049 NNS O
in P00339289T0049 IN O
the P00339289T0049 DT O
chemistry P00339289T0049 NN O
of P00339289T0049 IN O
proteins P00339289T0049 NNS O
. P00339289T0049 . O
. . O O

By P01406703A1435 IN O
screening P01406703A1435 VBG O
a P01406703A1435 DT O
Y1 P01406703A1435 NNP O
cell P01406703A1435 NN O
cDNA P01406703A1435 NN O
library P01406703A1435 NN O
with P01406703A1435 IN O
the P01406703A1435 DT O
DNA-binding P01406703A1435 JJ O
region P01406703A1435 NN O
of P01406703A1435 IN O
the P01406703A1435 DT O
H-2RIIBP P01406703A1435 NNP I-UN
nuclear P01406703A1435 JJ I-UN
hormone P01406703A1435 NN I-UN
receptor P01406703A1435 NN I-UN
cDNA P01406703A1435 NN I-UN
, P01406703A1435 , O
we P01406703A1435 PRP O
isolated P01406703A1435 VBD O
a P01406703A1435 DT O
cDNA P01406703A1435 NN O
that P01406703A1435 WDT O
is P01406703A1435 VBZ O
selectively P01406703A1435 RB O
expressed P01406703A1435 VBN O
in P01406703A1435 IN O
steroidogenic P01406703A1435 JJ O
cells P01406703A1435 NNS O
. P01406703A1435 . O
. . O O

DNA P02777797A0720 NN O
blot P02777797A0720 NN O
hybridization P02777797A0720 NN O
suggests P02777797A0720 VBZ O
that P02777797A0720 IN O
the P02777797A0720 DT O
rat P02777797A0720 NN O
genome P02777797A0720 NN O
may P02777797A0720 MD O
contain P02777797A0720 VB O
more P02777797A0720 JJR O
than P02777797A0720 IN O
one P02777797A0720 CD O
gene P02777797A0720 NN O
encoding P02777797A0720 VBG O
PtdIns P02777797A0720 NNP I-UN
transfer P02777797A0720 NN I-UN
protein P02777797A0720 NN I-UN
. P02777797A0720 . O
. . O O

Concomitant P02646007T0000 NNP O
chronic P02646007T0000 JJ O
lymphocytic P02646007T0000 JJ O
leukemia P02646007T0000 NN O
, P02646007T0000 , O
acute P02646007T0000 JJ O
myeloid P02646007T0000 NN O
leukemia P02646007T0000 NN O
, P02646007T0000 , O
and P02646007T0000 CC O
thrombosis P02646007T0000 NN O
with P02646007T0000 IN O
protein P02646007T0000 JJ I-UN
C P02646007T0000 NNP I-UN
deficiency P02646007T0000 NN O
. P02646007T0000 . O
. . O O

Primer P02708353A1080 NNP O
extension P02708353A1080 NN O
experiments P02708353A1080 NNS O
indicated P02708353A1080 VBD O
that P02708353A1080 IN O
the P02708353A1080 DT O
transcription P02708353A1080 NN O
initiation P02708353A1080 NN O
site P02708353A1080 NN O
mapped P02708353A1080 VBD O
to P02708353A1080 TO O
a P02708353A1080 DT O
position P02708353A1080 NN O
on P02708353A1080 IN O
gene P02708353A1080 NN I-UN
IV P02708353A1080 NNP I-UN
that P02708353A1080 WDT O
was P02708353A1080 VBD O
analogous P02708353A1080 JJ O
to P02708353A1080 TO O
that P02708353A1080 DT O
reported P02708353A1080 VBN O
for P02708353A1080 IN O
the P02708353A1080 DT O
structurally P02708353A1080 RB O
similar P02708353A1080 JJ O
P-450e P02708353A1080 NNP I-UN
gene P02708353A1080 NN I-UN
. P02708353A1080 . O
. . O O

We P01448107A0361 PRP O
describe P01448107A0361 VBP O
here P01448107A0361 RB O
17 P01448107A0361 CD O
dominant P01448107A0361 JJ I-UN
GCN2 P01448107A0361 NNP I-UN
mutations P01448107A0361 NNS I-UN
that P01448107A0361 WDT O
lead P01448107A0361 VBP O
to P01448107A0361 TO O
derepression P01448107A0361 NN O
of P01448107A0361 IN O
GCN4 P01448107A0361 NNP I-UN
expression P01448107A0361 NN O
in P01448107A0361 IN O
the P01448107A0361 DT O
absence P01448107A0361 NN O
of P01448107A0361 IN O
amino P01448107A0361 NN O
acid P01448107A0361 JJ O
starvation P01448107A0361 NN O
. P01448107A0361 . O
. . O O

None P09082335A0730 NN O
of P09082335A0730 IN O
these P09082335A0730 DT O
organic P09082335A0730 JJ O
manifestations P09082335A0730 NNS O
was P09082335A0730 VBD O
discovered P09082335A0730 VBN O
by P09082335A0730 IN O
scintigraphic P09082335A0730 JJ O
means P09082335A0730 NNS O
. P09082335A0730 . O
. . O O

The P10747879A0607 DT O
evolution P10747879A0607 NN O
of P10747879A0607 IN O
the P10747879A0607 DT O
CCR5 P10747879A0607 NNP I-UN
cis-regulatory P10747879A0607 JJ I-UN
region P10747879A0607 NN I-UN
versus P10747879A0607 IN O
the P10747879A0607 DT O
open P10747879A0607 JJ O
reading P10747879A0607 NN O
frame P10747879A0607 NN O
as P10747879A0607 RB O
well P10747879A0607 RB O
as P10747879A0607 IN O
among P10747879A0607 IN O
different P10747879A0607 JJ O
domains P10747879A0607 NNS O
of P10747879A0607 IN O
the P10747879A0607 DT O
open P10747879A0607 JJ O
reading P10747879A0607 NN O
frame P10747879A0607 NN O
differed P10747879A0607 VBD O
from P10747879A0607 IN O
one P10747879A0607 CD O
another P10747879A0607 DT O
. P10747879A0607 . O
. . O O

There P10599013A0505 EX O
were P10599013A0505 VBD O
15 P10599013A0505 CD O
deaths P10599013A0505 NNS O
, P10599013A0505 , O
seven P10599013A0505 CD O
of P10599013A0505 IN O
which P10599013A0505 WDT O
were P10599013A0505 VBD O
felt P10599013A0505 VBN O
to P10599013A0505 TO O
be P10599013A0505 VB O
avoidable P10599013A0505 JJ O
. P10599013A0505 . O
. . O O

We P02454976A0944 PRP O
discuss P02454976A0944 VBP O
the P02454976A0944 DT O
results P02454976A0944 NNS O
in P02454976A0944 IN O
relation P02454976A0944 NN O
to P02454976A0944 TO O
previous P02454976A0944 JJ O
systems P02454976A0944 NNS O
for P02454976A0944 IN O
parcellating P02454976A0944 VBG O
the P02454976A0944 DT O
posterior P02454976A0944 JJ O
ectosylvian P02454976A0944 JJ O
gyrus P02454976A0944 NN O
of P02454976A0944 IN O
the P02454976A0944 DT O
cat P02454976A0944 NN O
and P02454976A0944 CC O
consider P02454976A0944 VB O
the P02454976A0944 DT O
possibility P02454976A0944 NN O
that P02454976A0944 IN O
divisions P02454976A0944 NNS O
of P02454976A0944 IN O
the P02454976A0944 DT O
feline P02454976A0944 NN O
posterior P02454976A0944 JJ O
ectosylvian P02454976A0944 JJ O
gyrus P02454976A0944 NN O
correspond P02454976A0944 NN O
directly P02454976A0944 RB O
to P02454976A0944 TO O
areas P02454976A0944 NNS O
making P02454976A0944 VBG O
up P02454976A0944 RP O
the P02454976A0944 DT O
superior P02454976A0944 JJ O
temporal P02454976A0944 JJ O
gyrus P02454976A0944 NN O
in P02454976A0944 IN O
primates P02454976A0944 NNS O
. P02454976A0944 . O
. . O O

To P02045524A0000 TO O
facilitate P02045524A0000 VB O
the P02045524A0000 DT O
availability P02045524A0000 NN O
of P02045524A0000 IN O
important P02045524A0000 JJ O
new P02045524A0000 JJ O
therapeutic P02045524A0000 JJ O
agents P02045524A0000 NNS O
, P02045524A0000 , O
the P02045524A0000 DT O
Food P02045524A0000 NNP O
and P02045524A0000 CC O
Drug P02045524A0000 NNP O
Administration P02045524A0000 NNP O
( P02045524A0000 ( O
FDA P02045524A0000 NNP O
) P02045524A0000 ) O
in P02045524A0000 IN O
the P02045524A0000 DT O
mid-1970s P02045524A0000 NNS O
began P02045524A0000 VBD O
assigning P02045524A0000 VBG O
therapeutic P02045524A0000 JJ O
ratings P02045524A0000 NNS O
to P02045524A0000 TO O
investigational P02045524A0000 VB O
new P02045524A0000 JJ O
drugs P02045524A0000 NNS O
and P02045524A0000 CC O
holding P02045524A0000 VBG O
end-of-phase P02045524A0000 JJ O
II P02045524A0000 NNP O
conferences P02045524A0000 NNS O
with P02045524A0000 IN O
drug P02045524A0000 NN O
sponsors P02045524A0000 NNS O
. P02045524A0000 . O
. . O O

The P08251506A0503 DT O
247-kDa P08251506A0503 JJ O
complex P08251506A0503 JJ O
appears P08251506A0503 VBZ O
to P08251506A0503 TO O
contain P08251506A0503 VB O
two P08251506A0503 CD O
distinct P08251506A0503 JJ O
protein-DNA P08251506A0503 JJ O
complexes P08251506A0503 NNS O
of P08251506A0503 IN O
approximately P08251506A0503 RB O
232 P08251506A0503 CD O
and P08251506A0503 CC O
256 P08251506A0503 CD O
kDa P08251506A0503 NN O
and P08251506A0503 CC O
represents P08251506A0503 VBZ O
two P08251506A0503 CD O
proteins P08251506A0503 NNS O
covalently P08251506A0503 RB O
cross-linked P08251506A0503 VBD O
to P08251506A0503 TO O
a P08251506A0503 DT O
single P08251506A0503 JJ O
DRE P08251506A0503 NNP O
oligonucleotide P08251506A0503 NN O
, P08251506A0503 , O
while P08251506A0503 IN O
the P08251506A0503 DT O
97 P08251506A0503 CD O
, P08251506A0503 , O
105 P08251506A0503 CD O
, P08251506A0503 , O
and P08251506A0503 CC O
115-kDa P08251506A0503 JJ O
complexes P08251506A0503 NNS O
represent P08251506A0503 VBP O
single P08251506A0503 JJ O
protein-DRE P08251506A0503 JJ O
cross-links P08251506A0503 NNS O
. P08251506A0503 . O
. . O O

The P07226440T0000 DT O
hemodynamics P07226440T0000 NNS O
of P07226440T0000 IN O
isoproterenol-induced P07226440T0000 JJ O
cardiac P07226440T0000 JJ O
failure P07226440T0000 NN O
in P07226440T0000 IN O
the P07226440T0000 DT O
rat P07226440T0000 NN O
. P07226440T0000 . O
. . O O

BACKGROUND P08917270A0229 NN O
: P08917270A0229 : O
The P08917270A0229 DT O
Bazett-corrected P08917270A0229 JJ O
QT P08917270A0229 NNP O
( P08917270A0229 ( O
QTc P08917270A0229 NNP O
) P08917270A0229 ) O
interval P08917270A0229 NN O
during P08917270A0229 IN O
exercise P08917270A0229 NN O
has P08917270A0229 VBZ O
been P08917270A0229 VBN O
used P08917270A0229 VBN O
as P08917270A0229 IN O
a P08917270A0229 DT O
marker P08917270A0229 NN O
for P08917270A0229 IN O
ischemic P08917270A0229 JJ O
disease P08917270A0229 NN O
, P08917270A0229 , O
arrhythmogenic P08917270A0229 JJ O
substrate P08917270A0229 NN O
and P08917270A0229 CC O
the P08917270A0229 DT O
long P08917270A0229 JJ O
QT P08917270A0229 NNP O
syndrome P08917270A0229 NN O
. P08917270A0229 . O
. . O O

Effect P06163433T0000 NN O
of P06163433T0000 IN O
2- P06163433T0000 JJ O
( P06163433T0000 ( O
p-chlorophenyl P06163433T0000 JJ O
) P06163433T0000 ) O
cyclopropylamine P06163433T0000 NN O
on P06163433T0000 IN O
5-hydroxyindole P06163433T0000 JJ O
concentration P06163433T0000 NN O
and P06163433T0000 CC O
monoamine P06163433T0000 JJ I-UN
oxidase P06163433T0000 NN I-UN
activity P06163433T0000 NN O
in P06163433T0000 IN O
rat P06163433T0000 NN O
brain P06163433T0000 NN O
. P06163433T0000 . O
. . O O

Dietetics P00756511T0036 NNS O
of P00756511T0036 IN O
childhood- P00756511T0036 NN O
and P00756511T0036 CC O
juvenile P00756511T0036 NN O
diabetes P00756511T0036 NNS O
. P00756511T0036 . O
. . O O

Sequence P10095061A0592 NN O
analysis P10095061A0592 NN O
revealed P10095061A0592 VBD O
that P10095061A0592 IN O
the P10095061A0592 DT O
MEMA P10095061A0592 NNP I-UN
protein P10095061A0592 NN I-UN
is P10095061A0592 VBZ O
identical P10095061A0592 JJ O
with P10095061A0592 IN O
a P10095061A0592 DT O
160 P10095061A0592 CD I-UN
kDa P10095061A0592 NN I-UN
nuclear P10095061A0592 JJ I-UN
'domain P10095061A0592 CD I-UN
rich P10095061A0592 JJ I-UN
in P10095061A0592 IN I-UN
serines P10095061A0592 NNS I-UN
' P10095061A0592 POS I-UN
( P10095061A0592 ( I-UN
DRS P10095061A0592 NNP I-UN
) P10095061A0592 ) I-UN
protein P10095061A0592 VBP I-UN
occurring P10095061A0592 VBG O
free P10095061A0592 JJ O
in P10095061A0592 IN O
the P10095061A0592 DT O
nucleoplasm P10095061A0592 NN O
and P10095061A0592 CC O
in P10095061A0592 IN O
U2-ribonucleoprotein P10095061A0592 NNP I-UN
structures P10095061A0592 NNS I-UN
. P10095061A0592 . O
. . O O

The P00759049A0185 DT O
micromethod P00759049A0185 NN O
uses P00759049A0185 VBZ O
microcuvettes P00759049A0185 NNS O
and P00759049A0185 CC O
substitutes P00759049A0185 NNS O
ferrozine P00759049A0185 VBP O
for P00759049A0185 IN O
the P00759049A0185 DT O
bathophenanthroline P00759049A0185 NN O
chromogen P00759049A0185 NN O
of P00759049A0185 IN O
the P00759049A0185 DT O
ICSH P00759049A0185 NNP O
. P00759049A0185 . O
. . O O

Acute P03984683A0000 JJ O
appearance P03984683A0000 NN O
of P03984683A0000 IN O
hemiparesis P03984683A0000 NN O
or P03984683A0000 CC O
hemiplegia P03984683A0000 NN O
with P03984683A0000 IN O
initial P03984683A0000 JJ O
marked P03984683A0000 JJ O
spasticity P03984683A0000 NN O
was P03984683A0000 VBD O
observed P03984683A0000 VBN O
in P03984683A0000 IN O
8 P03984683A0000 CD O
stroke P03984683A0000 NN O
patients P03984683A0000 NNS O
. P03984683A0000 . O
. . O O

Mutations P08474439A0877 NNS O
at P08474439A0877 IN O
three P08474439A0877 CD O
sites P08474439A0877 NNS O
have P08474439A0877 VBP O
larger P08474439A0877 JJR O
effects P08474439A0877 NNS O
in P08474439A0877 IN O
muscle P08474439A0877 NN O
than P08474439A0877 IN O
nonmuscle P08474439A0877 NN O
cells P08474439A0877 NNS O
; P08474439A0877 : O
an P08474439A0877 DT O
A P08474439A0877 NNP O
/ P08474439A0877 NN O
T-rich P08474439A0877 NNP O
site P08474439A0877 NN O
mutation P08474439A0877 NN O
has P08474439A0877 VBZ O
a P08474439A0877 DT O
pronounced P08474439A0877 JJ O
effect P08474439A0877 NN O
in P08474439A0877 IN O
both P08474439A0877 DT O
striated P08474439A0877 JJ O
muscle P08474439A0877 NN O
types P08474439A0877 NNS O
, P08474439A0877 , O
mutations P08474439A0877 NNS O
at P08474439A0877 IN O
the P08474439A0877 DT O
MEF1 P08474439A0877 NNP I-UN
( P08474439A0877 ( I-UN
Right P08474439A0877 NNP I-UN
E-box P08474439A0877 NNP I-UN
) P08474439A0877 ) I-UN
site P08474439A0877 NN I-UN
are P08474439A0877 VBP O
relatively P08474439A0877 RB O
specific P08474439A0877 JJ O
to P08474439A0877 TO O
expression P08474439A0877 NN O
in P08474439A0877 IN O
skeletal P08474439A0877 JJ O
muscle P08474439A0877 NN O
, P08474439A0877 , O
and P08474439A0877 CC O
mutations P08474439A0877 NNS O
at P08474439A0877 IN O
the P08474439A0877 DT O
CArG P08474439A0877 NNP O
site P08474439A0877 NN O
are P08474439A0877 VBP O
relatively P08474439A0877 RB O
specific P08474439A0877 JJ O
to P08474439A0877 TO O
expression P08474439A0877 NN O
in P08474439A0877 IN O
cardiac P08474439A0877 JJ O
muscle P08474439A0877 NN O
. P08474439A0877 . O
. . O O

Disruption P01597462A0457 NN O
demonstrates P01597462A0457 VBZ O
that P01597462A0457 IN O
CDC14 P01597462A0457 NNP I-UN
is P01597462A0457 VBZ O
an P01597462A0457 DT O
essential P01597462A0457 JJ O
gene P01597462A0457 NN O
. P01597462A0457 . O
. . O O

Online P11392306T0000 JJ O
teaching P11392306T0000 NN O
: P11392306T0000 : O
design P11392306T0000 NN O
and P11392306T0000 CC O
techniques P11392306T0000 NNS O
. P11392306T0000 . O
. . O O

Relationship P08001136T0000 NN O
of P08001136T0000 IN O
CDK-activating P08001136T0000 NNP I-UN
kinase P08001136T0000 NN I-UN
and P08001136T0000 CC O
RNA P08001136T0000 NNP I-UN
polymerase P08001136T0000 NN I-UN
II P08001136T0000 NNP I-UN
CTD P08001136T0000 NNP O
kinase P08001136T0000 NNP O
TFIIH P08001136T0000 NNP I-UN
/ P08001136T0000 NNP O
TFIIK P08001136T0000 NNP I-UN
. P08001136T0000 . O
. . O O

The P09205965A1249 DT O
results P09205965A1249 NNS O
suggest P09205965A1249 VBP O
that P09205965A1249 IN O
the P09205965A1249 DT O
bulbospinal P09205965A1249 JJ O
micturition P09205965A1249 NN O
reflex P09205965A1249 NN O
evoked P09205965A1249 VBN O
by P09205965A1249 IN O
bladder P09205965A1249 NN O
filling P09205965A1249 NN O
and P09205965A1249 CC O
L-dopa P09205965A1249 NNP O
involves P09205965A1249 VBZ O
a P09205965A1249 DT O
descending P09205965A1249 NN O
pathway P09205965A1249 NN O
where P09205965A1249 WRB O
transmission P09205965A1249 NN O
is P09205965A1249 VBZ O
partly P09205965A1249 RB O
mediated P09205965A1249 VBN O
by P09205965A1249 IN O
spinal P09205965A1249 JJ I-UN
alpha P09205965A1249 JJ I-UN
1-adrenoceptors P09205965A1249 NNS I-UN
. P09205965A1249 . O
. . O O

The P11368363A1103 DT O
human P11368363A1103 JJ O
protein P11368363A1103 NN O
sequence P11368363A1103 NN O
exhibits P11368363A1103 VBZ O
a P11368363A1103 DT O
putative P11368363A1103 JJ O
DNA-binding P11368363A1103 NNP O
domain P11368363A1103 NN O
similar P11368363A1103 JJ O
to P11368363A1103 TO O
that P11368363A1103 DT O
seen P11368363A1103 VBN O
in P11368363A1103 IN O
rat P11368363A1103 NN I-UN
HBP1 P11368363A1103 NNP I-UN
and P11368363A1103 CC O
shows P11368363A1103 VBZ O
homology P11368363A1103 NN O
with P11368363A1103 IN O
the P11368363A1103 DT O
activation P11368363A1103 NN O
and P11368363A1103 CC O
repressor P11368363A1103 NN O
domains P11368363A1103 NNS O
previously P11368363A1103 RB O
demonstrated P11368363A1103 VBN O
in P11368363A1103 IN O
the P11368363A1103 DT O
rat P11368363A1103 NN O
protein P11368363A1103 NN O
. P11368363A1103 . O
. . O O

Motivational P08822399A0518 JJ O
factors P08822399A0518 NNS O
focusing P08822399A0518 VBG O
on P08822399A0518 IN O
attitudes P08822399A0518 NNS O
, P08822399A0518 , O
perceived P08822399A0518 VBD O
susceptibility P08822399A0518 NN O
to P08822399A0518 TO O
pregnancy P08822399A0518 NN O
, P08822399A0518 , O
and P08822399A0518 CC O
normative P08822399A0518 JJ O
factors P08822399A0518 NNS O
were P08822399A0518 VBD O
also P08822399A0518 RB O
relevant P08822399A0518 JJ O
. P08822399A0518 . O
. . O O

Homologous P08709251A0000 JJ O
recombination P08709251A0000 NN O
between P08709251A0000 IN O
the P08709251A0000 DT O
Autographa P08709251A0000 NNP O
californica P08709251A0000 NN O
nuclear P08709251A0000 JJ O
polyhedrosis P08709251A0000 NN O
virus P08709251A0000 NN O
( P08709251A0000 ( O
AcNPV P08709251A0000 NNP O
) P08709251A0000 ) O
genome P08709251A0000 NN O
and P08709251A0000 CC O
a P08709251A0000 DT O
0.6-kbp-long P08709251A0000 JJ O
DNA P08709251A0000 NNP O
fragment P08709251A0000 NN O
derived P08709251A0000 VBD O
from P08709251A0000 IN O
the P08709251A0000 DT O
putative P08709251A0000 JJ O
DNA P08709251A0000 NNP I-UN
helicase P08709251A0000 NN I-UN
gene P08709251A0000 NN I-UN
of P08709251A0000 IN I-UN
Bombyx P08709251A0000 NNP I-UN
mori P08709251A0000 FW I-UN
nuclear P08709251A0000 JJ I-UN
polyhedrosis P08709251A0000 NN I-UN
virus P08709251A0000 NN I-UN
generates P08709251A0000 VBZ O
eh2-AcNPV P08709251A0000 JJ O
, P08709251A0000 , O
an P08709251A0000 DT O
expanded-host-range P08709251A0000 JJ O
AcNPV P08709251A0000 NNP O
mutant P08709251A0000 NN O
( P08709251A0000 ( O
S P08709251A0000 NNP O
. P08709251A0000 . O
. . O O

Energy P11150439A0701 NNP O
expenditure P11150439A0701 NN O
was P11150439A0701 VBD O
obtained P11150439A0701 VBN O
using P11150439A0701 VBG O
a P11150439A0701 DT O
primed P11150439A0701 VBN O
, P11150439A0701 , O
3-hour P11150439A0701 JJ O
infusion P11150439A0701 NN O
of P11150439A0701 IN O
NaH P11150439A0701 NNP O
( P11150439A0701 ( O
13 P11150439A0701 CD O
) P11150439A0701 ) O
CO P11150439A0701 NNP O
( P11150439A0701 ( O
3 P11150439A0701 CD O
' P11150439A0701 '' O
) P11150439A0701 ) O
, P11150439A0701 , O
breath P11150439A0701 NN O
( P11150439A0701 ( O
13 P11150439A0701 CD O
) P11150439A0701 ) O
CO P11150439A0701 NNP O
( P11150439A0701 ( O
2 P11150439A0701 CD O
) P11150439A0701 ) O
enrichment P11150439A0701 NN O
determination P11150439A0701 NN O
by P11150439A0701 IN O
isotope P11150439A0701 NN O
ratio P11150439A0701 NN O
mass P11150439A0701 NN O
spectroscopy P11150439A0701 NN O
, P11150439A0701 , O
and P11150439A0701 CC O
the P11150439A0701 DT O
application P11150439A0701 NN O
of P11150439A0701 IN O
a P11150439A0701 DT O
standard P11150439A0701 JJ O
regression P11150439A0701 NN O
equation P11150439A0701 NN O
. P11150439A0701 . O
. . O O

The P10383966A0000 DT O
penicillin P10383966A0000 NN I-UN
binding P10383966A0000 NN I-UN
proteins P10383966A0000 NNS I-UN
( P10383966A0000 ( O
PBPs P10383966A0000 NNP I-UN
) P10383966A0000 ) O
synthesize P10383966A0000 NN O
and P10383966A0000 CC O
remodel P10383966A0000 NN O
peptidoglycan P10383966A0000 NN O
, P10383966A0000 , O
the P10383966A0000 DT O
structural P10383966A0000 JJ O
component P10383966A0000 NN O
of P10383966A0000 IN O
the P10383966A0000 DT O
bacterial P10383966A0000 JJ O
cell P10383966A0000 NN O
wall P10383966A0000 NN O
. P10383966A0000 . O
. . O O

Studies P05734847T0000 NNS O
carried P05734847T0000 VBD O
out P05734847T0000 RP O
with P05734847T0000 IN O
the P05734847T0000 DT O
Glossina P05734847T0000 NNP O
morsitans P05734847T0000 NNS O
colony P05734847T0000 NN O
of P05734847T0000 IN O
Lisbon P05734847T0000 NNP O
. P05734847T0000 . O
. . O O

Midge P05379901T0000 NNP O
control P05379901T0000 NN O
in P05379901T0000 IN O
flood P05379901T0000 NN O
channels P05379901T0000 NNS O
. P05379901T0000 . O
. . O O

Twenty P10915728A0216 NNP O
eligible P10915728A0216 JJ O
patients P10915728A0216 NNS O
with P10915728A0216 IN O
cirrhosis P10915728A0216 NN O
were P10915728A0216 VBD O
randomized P10915728A0216 VBN O
into P10915728A0216 IN O
two P10915728A0216 CD O
groups P10915728A0216 NNS O
: P10915728A0216 : O
10 P10915728A0216 CD O
patients P10915728A0216 NNS O
treated P10915728A0216 VBN O
with P10915728A0216 IN O
6 P10915728A0216 CD O
million P10915728A0216 CD O
units P10915728A0216 NNS O
of P10915728A0216 IN O
natural P10915728A0216 JJ O
IFN-beta P10915728A0216 NNP I-UN
twice P10915728A0216 NN O
a P10915728A0216 DT O
week P10915728A0216 NN O
for P10915728A0216 IN O
36 P10915728A0216 CD O
months P10915728A0216 NNS O
and P10915728A0216 CC O
10 P10915728A0216 CD O
patients P10915728A0216 NNS O
without P10915728A0216 IN O
IFN P10915728A0216 NNP I-UN
therapy P10915728A0216 NN O
. P10915728A0216 . O
. . O O

A P00741476A0000 DT O
36 P00741476A0000 CD O
year-old P00741476A0000 JJ O
woman P00741476A0000 NN O
was P00741476A0000 VBD O
given P00741476A0000 VBN O
Ergotamine P00741476A0000 NNP O
Tartrate P00741476A0000 NNP O
4.5 P00741476A0000 CD O
mg P00741476A0000 NN O
p.d P00741476A0000 NN O
. P00741476A0000 . O
during P00741476A0000 IN O
seven P00741476A0000 CD O
days P00741476A0000 NNS O
, P00741476A0000 , O
after P00741476A0000 IN O
an P00741476A0000 DT O
abortion P00741476A0000 NN O
( P00741476A0000 ( O
a P00741476A0000 DT O
still P00741476A0000 RB O
birth P00741476A0000 NN O
) P00741476A0000 ) O
. P00741476A0000 . O
. . O O

Furthermore P08839498A0507 RB O
, P08839498A0507 , O
although P08839498A0507 IN O
the P08839498A0507 DT O
regional P08839498A0507 JJ O
distribution P08839498A0507 NN O
of P08839498A0507 IN O
lean P08839498A0507 JJ O
tissue P08839498A0507 NN O
mass P08839498A0507 NN O
in P08839498A0507 IN O
the P08839498A0507 DT O
trunk P08839498A0507 NN O
and P08839498A0507 CC O
legs P08839498A0507 NNS O
remained P08839498A0507 VBD O
fairly P08839498A0507 RB O
constant P08839498A0507 JJ O
at P08839498A0507 IN O
different P08839498A0507 JJ O
pubertal P08839498A0507 JJ O
stages P08839498A0507 NNS O
, P08839498A0507 , O
the P08839498A0507 DT O
regional P08839498A0507 JJ O
distribution P08839498A0507 NN O
of P08839498A0507 IN O
fat P08839498A0507 NN O
was P08839498A0507 VBD O
altered P08839498A0507 VBN O
significantly P08839498A0507 RB O
, P08839498A0507 , O
becoming P08839498A0507 VBG O
more P08839498A0507 RBR O
central P08839498A0507 JJ O
and P08839498A0507 CC O
less P08839498A0507 RBR O
peripheral P08839498A0507 JJ O
. P08839498A0507 . O
. . O O

In P11787720A1313 IN O
sterilized P11787720A1313 VBN O
milk P11787720A1313 NN O
there P11787720A1313 EX O
was P11787720A1313 VBD O
a P11787720A1313 DT O
slight P11787720A1313 JJ O
decrease P11787720A1313 NN O
of P11787720A1313 IN O
linoleic P11787720A1313 JJ O
acid P11787720A1313 NN O
( P11787720A1313 ( O
C18:2n6 P11787720A1313 NNP O
; P11787720A1313 : O
-0.7 P11787720A1313 CD O
% P11787720A1313 NN O
vs. P11787720A1313 FW O
fresh P11787720A1313 JJ O
; P11787720A1313 : O
P P11787720A1313 NNP O
= P11787720A1313 NNP O
0.006 P11787720A1313 CD O
) P11787720A1313 ) O
and P11787720A1313 CC O
arachidonic P11787720A1313 JJ O
acid P11787720A1313 NN O
( P11787720A1313 ( O
C20:4n6 P11787720A1313 NNP O
; P11787720A1313 : O
-2.5 P11787720A1313 CD O
% P11787720A1313 NN O
; P11787720A1313 : O
P P11787720A1313 NNP O
= P11787720A1313 NNP O
0.045 P11787720A1313 CD O
) P11787720A1313 ) O
. P11787720A1313 . O
. . O O

Interaction P08761480A0331 NN O
was P08761480A0331 VBD O
apparently P08761480A0331 RB O
determined P08761480A0331 VBN O
by P08761480A0331 IN O
the P08761480A0331 DT O
N-terminal P08761480A0331 JJ O
splice P08761480A0331 JJ O
region P08761480A0331 NN O
of P08761480A0331 IN O
RPDE-6 P08761480A0331 NNP I-UN
, P08761480A0331 , O
as P08761480A0331 IN O
the P08761480A0331 DT O
PDE4A P08761480A0331 NNP I-UN
splice P08761480A0331 NN O
variant P08761480A0331 NN O
RPDE-39 P08761480A0331 NNP I-UN
, P08761480A0331 , O
which P08761480A0331 WDT O
differs P08761480A0331 VBZ O
from P08761480A0331 IN O
RPDE-6 P08761480A0331 NNP I-UN
at P08761480A0331 IN O
the P08761480A0331 DT O
extreme P08761480A0331 JJ O
N-terminus P08761480A0331 NNP O
, P08761480A0331 , O
failed P08761480A0331 VBD O
to P08761480A0331 TO O
associate P08761480A0331 VB O
with P08761480A0331 IN O
v-Src-SH3 P08761480A0331 JJ O
; P08761480A0331 : O
met26RD1 P08761480A0331 NN I-UN
( P08761480A0331 ( O
where P08761480A0331 WRB O
RD1 P08761480A0331 NNP I-UN
is P08761480A0331 VBZ O
rat P08761480A0331 JJ I-UN
'dunc-like P08761480A0331 JJ I-UN
' P08761480A0331 POS I-UN
PDE P08761480A0331 NNP I-UN
) P08761480A0331 ) O
, P08761480A0331 , O
which P08761480A0331 WDT O
has P08761480A0331 VBZ O
the P08761480A0331 DT O
N-terminal P08761480A0331 JJ O
splice P08761480A0331 NN O
region P08761480A0331 NN O
deleted P08761480A0331 VBN O
, P08761480A0331 , O
failed P08761480A0331 VBD O
to P08761480A0331 TO O
associate P08761480A0331 VB O
with P08761480A0331 IN O
v-Src-SH3 P08761480A0331 JJ O
, P08761480A0331 , O
and P08761480A0331 CC O
the P08761480A0331 DT O
association P08761480A0331 NN O
of P08761480A0331 IN O
RPDE-6 P08761480A0331 NNP I-UN
and P08761480A0331 CC O
v-Src-SH3 P08761480A0331 NN O
was P08761480A0331 VBD O
blocked P08761480A0331 VBN O
by P08761480A0331 IN O
a P08761480A0331 DT O
fusion P08761480A0331 NN O
protein P08761480A0331 NN O
formed P08761480A0331 VBD O
from P08761480A0331 IN O
the P08761480A0331 DT O
N-terminal P08761480A0331 JJ O
splice P08761480A0331 NN O
region P08761480A0331 NN O
. P08761480A0331 . O
. . O O

Replacement P08445729A0657 NN O
of P08445729A0657 IN O
the P08445729A0657 DT O
spacer P08445729A0657 NN O
sequence P08445729A0657 NN O
between P08445729A0657 IN O
the P08445729A0657 DT O
two P08445729A0657 CD O
ARMs P08445729A0657 NNP O
with P08445729A0657 IN O
a P08445729A0657 DT O
shorter P08445729A0657 JJR O
stretch P08445729A0657 NN O
of P08445729A0657 IN O
sequence P08445729A0657 NN O
also P08445729A0657 RB O
reduced P08445729A0657 VBD O
RNA P08445729A0657 NNP O
binding P08445729A0657 NN O
in P08445729A0657 IN O
vitro P08445729A0657 NN O
. P08445729A0657 . O
. . O O

NiCl P11133741A0617 NNP O
( P11133741A0617 ( O
2 P11133741A0617 CD O
) P11133741A0617 ) O
-induced P11133741A0617 VBD O
MCP-1 P11133741A0617 JJ I-UN
synthesis P11133741A0617 NN O
required P11133741A0617 VBN O
activation P11133741A0617 NN O
of P11133741A0617 IN O
NF-kappaB P11133741A0617 NNP I-UN
since P11133741A0617 IN O
mutation P11133741A0617 NN O
of P11133741A0617 IN O
NF-kappaB-binding P11133741A0617 NNP I-UN
sites P11133741A0617 NNS I-UN
in P11133741A0617 IN O
the P11133741A0617 DT O
promoter P11133741A0617 NN O
resulted P11133741A0617 VBD O
in P11133741A0617 IN O
complete P11133741A0617 JJ O
loss P11133741A0617 NN O
of P11133741A0617 IN O
inducible P11133741A0617 JJ O
promoter P11133741A0617 NN O
activity P11133741A0617 NN O
. P11133741A0617 . O
. . O O

Differential P10501656A1415 JJ O
expression P10501656A1415 NN O
was P10501656A1415 VBD O
confirmed P10501656A1415 VBN O
by P10501656A1415 IN O
Northern P10501656A1415 NNP O
blot P10501656A1415 NN O
analysis P10501656A1415 NN O
employing P10501656A1415 VBG O
multiple P10501656A1415 JJ O
normal P10501656A1415 JJ O
and P10501656A1415 CC O
tumor P10501656A1415 NN O
cell P10501656A1415 NN O
lines P10501656A1415 NNS O
. P10501656A1415 . O
. . O O

Therefore P08950352A0525 RB O
, P08950352A0525 , O
both P08950352A0525 PDT O
the P08950352A0525 DT O
Chilean P08950352A0525 NNP O
and P08950352A0525 CC O
the P08950352A0525 DT O
Japanese P08950352A0525 JJ O
samples P08950352A0525 NNS O
collected P08950352A0525 VBN O
in P08950352A0525 IN O
high-risk P08950352A0525 JJ O
areas P08950352A0525 NNS O
showed P08950352A0525 VBD O
higher P08950352A0525 JJR O
mutagenic P08950352A0525 NN O
rates P08950352A0525 NNS O
than P08950352A0525 IN O
the P08950352A0525 DT O
Japanese P08950352A0525 JJ O
ones P08950352A0525 NNS O
in P08950352A0525 IN O
a P08950352A0525 DT O
low-risk P08950352A0525 JJ O
area P08950352A0525 NN O
, P08950352A0525 , O
with P08950352A0525 IN O
a P08950352A0525 DT O
statistical P08950352A0525 JJ O
significance P08950352A0525 NN O
( P08950352A0525 ( O
p P08950352A0525 JJ O
< P08950352A0525 NNP O
0.001 P08950352A0525 CD O
) P08950352A0525 ) O
, P08950352A0525 , O
chi-square P08950352A0525 JJ O
test P08950352A0525 NN O
) P08950352A0525 ) O
. P08950352A0525 . O
. . O O

Specialized P09557708A1426 NNP O
actin P09557708A1426 NN I-UN
tails P09557708A1426 NNS O
that P09557708A1426 WDT O
propel P09557708A1426 VBP O
IEV P09557708A1426 NNP O
particles P09557708A1426 NNS O
to P09557708A1426 TO O
the P09557708A1426 DT O
periphery P09557708A1426 NN O
and P09557708A1426 CC O
virus-tipped P09557708A1426 JJ O
microvilli P09557708A1426 NN O
( P09557708A1426 ( O
both P09557708A1426 DT O
common P09557708A1426 JJ O
in P09557708A1426 IN O
wild-type-infected P09557708A1426 JJ O
cells P09557708A1426 NNS O
) P09557708A1426 ) O
were P09557708A1426 VBD O
absent P09557708A1426 JJ O
in P09557708A1426 IN O
cells P09557708A1426 NNS O
infected P09557708A1426 VBN O
with P09557708A1426 IN O
vA33delta P09557708A1426 NN O
. P09557708A1426 . O
. . O O

The P11121397A0587 DT O
present P11121397A0587 JJ O
findings P11121397A0587 NNS O
revealed P11121397A0587 VBD O
that P11121397A0587 IN O
the P11121397A0587 DT O
rib-2 P11121397A0587 JJ I-UN
protein P11121397A0587 NN I-UN
was P11121397A0587 VBD O
a P11121397A0587 DT O
unique P11121397A0587 JJ O
alpha1,4-N-acetylglucosaminyltransferase P11121397A0587 NN I-UN
involved P11121397A0587 VBN O
in P11121397A0587 IN O
the P11121397A0587 DT O
biosynthetic P11121397A0587 JJ O
initiation P11121397A0587 NN O
and P11121397A0587 CC O
elongation P11121397A0587 NN O
of P11121397A0587 IN O
heparan P11121397A0587 NN O
sulfate P11121397A0587 NN O
. P11121397A0587 . O
. . O O

Mapping P10049775T0000 NN O
of P10049775T0000 IN O
the P10049775T0000 DT O
human P10049775T0000 JJ I-UN
Voltage-Dependent P10049775T0000 JJ I-UN
Anion P10049775T0000 NNP I-UN
Channel P10049775T0000 NNP I-UN
isoforms P10049775T0000 VBZ I-UN
1 P10049775T0000 CD I-UN
and P10049775T0000 CC I-UN
2 P10049775T0000 CD I-UN
reconsidered P10049775T0000 VBN O
. P10049775T0000 . O
. . O O

The P07474772A0274 DT O
Laser P07474772A0274 NNP O
Scanning P07474772A0274 NNP O
Ophthalmoscope P07474772A0274 NNP O
enables P07474772A0274 VBZ O
a P07474772A0274 DT O
fundus-based P07474772A0274 JJ O
examination P07474772A0274 NN O
and P07474772A0274 CC O
therefore P07474772A0274 RB O
allows P07474772A0274 NNS O
exact P07474772A0274 VBP O
comparison P07474772A0274 NN O
between P07474772A0274 IN O
morphologic P07474772A0274 JJ O
appearance P07474772A0274 NN O
and P07474772A0274 CC O
corresponding P07474772A0274 JJ O
function P07474772A0274 NN O
. P07474772A0274 . O
. . O O

Chemical P10406954A0715 NNP O
stability P10406954A0715 NN O
tests P10406954A0715 NNS O
and P10406954A0715 CC O
site-specific P10406954A0715 JJ O
mutagenesis P10406954A0715 NN O
identified P10406954A0715 VBN O
amino P10406954A0715 JJ O
acids P10406954A0715 NNS O
H219 P10406954A0715 NNP O
and P10406954A0715 CC O
D63 P10406954A0715 NNP O
of P10406954A0715 IN O
RegS P10406954A0715 NNP I-UN
and P10406954A0715 CC O
RegR P10406954A0715 NNP I-UN
, P10406954A0715 , O
respectively P10406954A0715 RB O
, P10406954A0715 , O
as P10406954A0715 IN O
the P10406954A0715 DT O
phosphorylated P10406954A0715 JJ O
residues P10406954A0715 NNS O
. P10406954A0715 . O
. . O O

Demyelinating P10586626A0607 VBG O
diseases P10586626A0607 NNS O
involving P10586626A0607 VBG O
the P10586626A0607 DT O
grey P10586626A0607 JJ O
matter P10586626A0607 NN O
were P10586626A0607 VBD O
very P10586626A0607 RB O
rare P10586626A0607 JJ O
, P10586626A0607 , O
but P10586626A0607 CC O
we P10586626A0607 PRP O
must P10586626A0607 MD O
consider P10586626A0607 VB O
the P10586626A0607 DT O
presence P10586626A0607 NN O
of P10586626A0607 IN O
symmetrical P10586626A0607 JJ O
thalamic P10586626A0607 JJ O
involvement P10586626A0607 NN O
in P10586626A0607 IN O
patients P10586626A0607 NNS O
with P10586626A0607 IN O
ADEM P10586626A0607 NNP O
. P10586626A0607 . O
. . O O

The P08969495A0256 DT O
sequencing P08969495A0256 NN O
of P08969495A0256 IN O
the P08969495A0256 DT O
conditional P08969495A0256 JJ O
lethal P08969495A0256 JJ O
mutation P08969495A0256 NN O
ts-A13 P08969495A0256 NN O
, P08969495A0256 , O
localized P08969495A0256 VBN O
in P08969495A0256 IN O
the P08969495A0256 DT O
nrdE P08969495A0256 JJ I-UN
cistron P08969495A0256 NN I-UN
, P08969495A0256 , O
and P08969495A0256 CC O
the P08969495A0256 DT O
lethality P08969495A0256 NN O
of P08969495A0256 IN O
insertional P08969495A0256 JJ O
mutations P08969495A0256 NNS O
targeted P08969495A0256 VBN O
in P08969495A0256 IN O
the P08969495A0256 DT O
internal P08969495A0256 JJ O
region P08969495A0256 NN O
of P08969495A0256 IN O
nrdE P08969495A0256 NN I-UN
and P08969495A0256 CC O
nrdF P08969495A0256 NN I-UN
, P08969495A0256 , O
demonstrated P08969495A0256 VBD O
the P08969495A0256 DT O
essential P08969495A0256 JJ O
role P08969495A0256 NN O
of P08969495A0256 IN O
this P08969495A0256 DT O
locus P08969495A0256 NN O
. P08969495A0256 . O
. . O O

The P11302072A0508 DT O
results P11302072A0508 NNS O
show P11302072A0508 VBP O
that P11302072A0508 IN O
cognitive P11302072A0508 JJ O
stimulation P11302072A0508 NN O
enhanced P11302072A0508 VBD O
performance P11302072A0508 NN O
on P11302072A0508 IN O
the P11302072A0508 DT O
Boston P11302072A0508 NNP O
Naming P11302072A0508 NNP O
Test P11302072A0508 NNP O
and P11302072A0508 CC O
a P11302072A0508 DT O
Word P11302072A0508 NNP O
List P11302072A0508 NNP O
Recognition P11302072A0508 NNP O
Task P11302072A0508 NNP O
; P11302072A0508 : O
physical P11302072A0508 JJ O
intervention P11302072A0508 NN O
, P11302072A0508 , O
however P11302072A0508 RB O
, P11302072A0508 , O
did P11302072A0508 VBD O
not P11302072A0508 RB O
reach P11302072A0508 VB O
statistical P11302072A0508 JJ O
significance P11302072A0508 NN O
. P11302072A0508 . O
. . O O

A P07147622T0000 DT O
suspected P07147622T0000 JJ O
new P07147622T0000 JJ O
storage P07147622T0000 NN O
disease P07147622T0000 NN O
in P07147622T0000 IN O
cattle P07147622T0000 NNS O
. P07147622T0000 . O
. . O O

These P11319098A0164 DT O
genes P11319098A0164 NNS O
encode P11319098A0164 VBP O
a P11319098A0164 DT O
tryptophanyl P11319098A0164 NN I-UN
tRNA P11319098A0164 NN I-UN
, P11319098A0164 , O
the P11319098A0164 DT O
protein P11319098A0164 NN I-UN
translocase P11319098A0164 NN I-UN
component P11319098A0164 NN O
SecE P11319098A0164 NNP I-UN
, P11319098A0164 , O
the P11319098A0164 DT O
antiterminator P11319098A0164 NN I-UN
protein P11319098A0164 NN I-UN
NusG P11319098A0164 NNP I-UN
, P11319098A0164 , O
and P11319098A0164 CC O
the P11319098A0164 DT O
ribosomal P11319098A0164 JJ O
proteins P11319098A0164 NNS O
L11 P11319098A0164 NNP I-UN
and P11319098A0164 CC O
L1 P11319098A0164 NNP I-UN
in P11319098A0164 IN O
addition P11319098A0164 NN O
to P11319098A0164 TO O
PkwR P11319098A0164 NNP I-UN
, P11319098A0164 , O
a P11319098A0164 DT O
putative P11319098A0164 JJ O
regulatory P11319098A0164 JJ O
protein P11319098A0164 NN O
of P11319098A0164 IN O
the P11319098A0164 DT O
LacI-GalR P11319098A0164 NNP O
family P11319098A0164 NN O
. P11319098A0164 . O
. . O O

We P10229668A0190 PRP O
show P10229668A0190 VBP O
that P10229668A0190 IN O
other P10229668A0190 JJ O
cdc33 P10229668A0190 NN I-UN
mutants P10229668A0190 NNS I-UN
also P10229668A0190 RB O
arrest P10229668A0190 VBP O
in P10229668A0190 IN O
G1 P10229668A0190 NNP O
. P10229668A0190 . O
. . O O

IL-1beta P10464291A0597 NNP I-UN
( P10464291A0597 ( O
10 P10464291A0597 CD O
ng P10464291A0597 RB O
/ P10464291A0597 NNP O
ml P10464291A0597 NN O
) P10464291A0597 ) O
drastically P10464291A0597 RB O
increased P10464291A0597 VBD O
both P10464291A0597 DT O
PDGFalphaR P10464291A0597 NNP I-UN
and P10464291A0597 CC O
CCAAT P10464291A0597 NNP I-UN
/ P10464291A0597 NNP I-UN
enhancer-binding P10464291A0597 JJ I-UN
protein P10464291A0597 NN I-UN
delta P10464291A0597 NN I-UN
( P10464291A0597 ( O
C P10464291A0597 NNP I-UN
/ P10464291A0597 NNP I-UN
EBPdelta P10464291A0597 NNP I-UN
) P10464291A0597 ) O
mRNA P10464291A0597 NN O
levels P10464291A0597 NNS O
in P10464291A0597 IN O
a P10464291A0597 DT O
time P10464291A0597 NN O
dependent P10464291A0597 JJ O
manner P10464291A0597 NN O
. P10464291A0597 . O
. . O O

PATIENTS P07931490A0237 NNS O
AND P07931490A0237 CC O
METHODS P07931490A0237 NNP O
: P07931490A0237 : O
One P07931490A0237 CD O
hundred P07931490A0237 VBD O
eighty-four P07931490A0237 JJ O
chemotherapy-naive P07931490A0237 JJ O
patients P07931490A0237 NNS O
receiving P07931490A0237 VBG O
high-dose P07931490A0237 JJ O
cisplatin P07931490A0237 NN O
( P07931490A0237 ( O
81 P07931490A0237 CD O
to P07931490A0237 TO O
120 P07931490A0237 CD O
mg P07931490A0237 NNS O
/ P07931490A0237 NNP O
m2 P07931490A0237 NN O
) P07931490A0237 ) O
were P07931490A0237 VBD O
randomized P07931490A0237 VBN O
to P07931490A0237 TO O
receive P07931490A0237 VB O
one P07931490A0237 CD O
of P07931490A0237 IN O
four P07931490A0237 CD O
granisetron P07931490A0237 NN O
doses P07931490A0237 NNS O
( P07931490A0237 ( O
5 P07931490A0237 CD O
, P07931490A0237 , O
10 P07931490A0237 CD O
, P07931490A0237 , O
20 P07931490A0237 CD O
, P07931490A0237 , O
or P07931490A0237 CC O
40 P07931490A0237 CD O
micrograms P07931490A0237 NNS O
/ P07931490A0237 NNP O
kg P07931490A0237 NN O
) P07931490A0237 ) O
administered P07931490A0237 VBD O
before P07931490A0237 IN O
chemotherapy P07931490A0237 NN O
. P07931490A0237 . O
. . O O

Qualitatively P02744123A0237 RB O
, P02744123A0237 , O
the P02744123A0237 DT O
results P02744123A0237 NNS O
are P02744123A0237 VBP O
similar P02744123A0237 JJ O
for P02744123A0237 IN O
the P02744123A0237 DT O
two P02744123A0237 CD O
species P02744123A0237 NNS O
: P02744123A0237 : O
Both P02744123A0237 DT O
rhesus P02744123A0237 VBP O
monkey P02744123A0237 NN O
and P02744123A0237 CC O
man P02744123A0237 NN O
have P02744123A0237 VBP O
photopic P02744123A0237 VBN O
and P02744123A0237 CC O
scotopic P02744123A0237 JJ O
branches P02744123A0237 NNS O
, P02744123A0237 , O
which P02744123A0237 WDT O
cross P02744123A0237 VBP O
at P02744123A0237 IN O
approximately P02744123A0237 RB O
the P02744123A0237 DT O
same P02744123A0237 JJ O
time P02744123A0237 NN O
in P02744123A0237 IN O
the P02744123A0237 DT O
dark P02744123A0237 NN O
and P02744123A0237 CC O
at P02744123A0237 IN O
approximately P02744123A0237 RB O
the P02744123A0237 DT O
same P02744123A0237 JJ O
background P02744123A0237 NN O
luminance P02744123A0237 NN O
. P02744123A0237 . O
. . O O

Analysis P04789916T0001 NN O
of P04789916T0001 IN O
clearance P04789916T0001 NN O
curve P04789916T0001 NN O
of P04789916T0001 IN O
rose P04789916T0001 VBD O
bengal-I-131 P04789916T0001 NN O
. P04789916T0001 . O
. . O O

The P11853943A0122 DT O
long-term P11853943A0122 JJ O
prediction P11853943A0122 NN O
is P11853943A0122 VBZ O
based P11853943A0122 VBN O
on P11853943A0122 IN O
an P11853943A0122 DT O
algorithm P11853943A0122 NN O
for P11853943A0122 IN O
R-R P11853943A0122 NNP O
interval P11853943A0122 JJ O
estimation P11853943A0122 NN O
. P11853943A0122 . O
. . O O

Serum P10496161A0503 NNP O
antibodies P10496161A0503 NNS O
were P10496161A0503 VBD O
detected P10496161A0503 VBN O
in P10496161A0503 IN O
at P10496161A0503 IN O
least P10496161A0503 JJS O
95 P10496161A0503 CD O
% P10496161A0503 NN O
of P10496161A0503 IN O
the P10496161A0503 DT O
infected P10496161A0503 JJ O
guinea P10496161A0503 NN O
pigs P10496161A0503 NNS O
between P10496161A0503 IN O
4-30 P10496161A0503 JJ O
WPI P10496161A0503 NNP O
and P10496161A0503 CC O
rats P10496161A0503 NNS O
between P10496161A0503 IN O
3-16 P10496161A0503 JJ O
WPI P10496161A0503 NNP O
. P10496161A0503 . O
. . O O

Hematopoietic P07737944A0000 JJ I-UN
growth P07737944A0000 NN I-UN
factors P07737944A0000 NNS I-UN
have P07737944A0000 VBP O
already P07737944A0000 RB O
had P07737944A0000 VBN O
an P07737944A0000 DT O
enormous P07737944A0000 JJ O
impact P07737944A0000 NN O
on P07737944A0000 IN O
transfusion P07737944A0000 NN O
practice P07737944A0000 NN O
by P07737944A0000 IN O
eliminating P07737944A0000 VBG O
or P07737944A0000 CC O
reducing P07737944A0000 VBG O
the P07737944A0000 DT O
need P07737944A0000 NN O
for P07737944A0000 IN O
red P07737944A0000 JJ O
blood P07737944A0000 NN O
cell P07737944A0000 NN O
transfusions P07737944A0000 NNS O
in P07737944A0000 IN O
a P07737944A0000 DT O
variety P07737944A0000 NN O
of P07737944A0000 IN O
anemic P07737944A0000 JJ O
states P07737944A0000 NNS O
characterized P07737944A0000 VBN O
by P07737944A0000 IN O
an P07737944A0000 DT O
absolute P07737944A0000 NN O
or P07737944A0000 CC O
relative P07737944A0000 JJ O
decrease P07737944A0000 NN O
in P07737944A0000 IN O
erythropoietin P07737944A0000 NN I-UN
. P07737944A0000 . O
. . O O

Comparison P02400070T0000 NNP O
of P02400070T0000 IN O
propofol P02400070T0000 NN O
and P02400070T0000 CC O
thiopentone P02400070T0000 NN O
as P02400070T0000 IN O
anaesthetic P02400070T0000 JJ O
agents P02400070T0000 NNS O
for P02400070T0000 IN O
electroconvulsive P02400070T0000 JJ O
therapy P02400070T0000 NN O
. P02400070T0000 . O
. . O O

The P10209031A0832 DT O
Fyn P10209031A0832 NNP I-UN
NH2 P10209031A0832 NNP I-UN
terminus P10209031A0832 NN I-UN
was P10209031A0832 VBD O
necessary P10209031A0832 JJ O
but P10209031A0832 CC O
not P10209031A0832 RB O
sufficient P10209031A0832 JJ O
for P10209031A0832 IN O
interaction P10209031A0832 NN O
with P10209031A0832 IN O
zeta P10209031A0832 NN O
and P10209031A0832 CC O
both P10209031A0832 DT O
Fyn P10209031A0832 NNP I-UN
kinase P10209031A0832 NN I-UN
and P10209031A0832 CC O
SH2 P10209031A0832 NNP I-UN
domains P10209031A0832 NNS I-UN
were P10209031A0832 VBD O
required P10209031A0832 VBN O
, P10209031A0832 , O
directing P10209031A0832 VBG O
phosphorylation P10209031A0832 NN O
of P10209031A0832 IN O
zeta P10209031A0832 NN I-UN
ITAM P10209031A0832 NNP I-UN
tyrosines P10209031A0832 NNS O
and P10209031A0832 CC O
binding P10209031A0832 VBG O
to P10209031A0832 TO O
zeta P10209031A0832 VB I-UN
ITAM P10209031A0832 NNP I-UN
phosphotyrosines P10209031A0832 NNS O
. P10209031A0832 . O
. . O O

We P11223256A1212 PRP O
have P11223256A1212 VBP O
also P11223256A1212 RB O
isolated P11223256A1212 VBN O
and P11223256A1212 CC O
analyzed P11223256A1212 VBD O
the P11223256A1212 DT O
5 P11223256A1212 CD O
' P11223256A1212 POS O
flanking P11223256A1212 JJ O
region P11223256A1212 NN O
of P11223256A1212 IN O
the P11223256A1212 DT O
pea P11223256A1212 NN O
33RNP P11223256A1212 CD I-UN
gene P11223256A1212 NN I-UN
. P11223256A1212 . O
. . O O

In P10592791A0370 IN O
conclusion P10592791A0370 NN O
: P10592791A0370 : O
( P10592791A0370 ( O
i P10592791A0370 NN O
) P10592791A0370 ) O
TECRA P10592791A0370 NNP O
kit P10592791A0370 NN O
is P10592791A0370 VBZ O
suggested P10592791A0370 VBN O
to P10592791A0370 TO O
be P10592791A0370 VB O
used P10592791A0370 VBN O
for P10592791A0370 IN O
screening P10592791A0370 VBG O
SE P10592791A0370 NNP O
producing P10592791A0370 VBG O
strains P10592791A0370 NNS O
; P10592791A0370 : O
( P10592791A0370 ( O
ii P10592791A0370 NN O
) P10592791A0370 ) O
SET-RPLA P10592791A0370 NNP O
and P10592791A0370 CC O
RIDASCREEN P10592791A0370 NNP O
kits P10592791A0370 NNS O
are P10592791A0370 VBP O
suitable P10592791A0370 JJ O
for P10592791A0370 IN O
epidemiological P10592791A0370 JJ O
investigation P10592791A0370 NN O
of P10592791A0370 IN O
SE P10592791A0370 NNP O
types P10592791A0370 NNS O
, P10592791A0370 , O
but P10592791A0370 CC O
the P10592791A0370 DT O
lack P10592791A0370 NN O
of P10592791A0370 IN O
ability P10592791A0370 NN O
for P10592791A0370 IN O
detecting P10592791A0370 VBG O
SEE P10592791A0370 NNP O
, P10592791A0370 , O
long P10592791A0370 JJ O
time P10592791A0370 NN O
required P10592791A0370 VBN O
for P10592791A0370 IN O
testing P10592791A0370 VBG O
with P10592791A0370 IN O
SET-RPLA P10592791A0370 NNP O
kit P10592791A0370 NN O
and P10592791A0370 CC O
high P10592791A0370 JJ O
background P10592791A0370 NN O
when P10592791A0370 WRB O
using P10592791A0370 VBG O
RIDASCREEN P10592791A0370 NNP O
kit P10592791A0370 NN O
must P10592791A0370 MD O
be P10592791A0370 VB O
overcome P10592791A0370 VBN O
; P10592791A0370 : O
and P10592791A0370 CC O
( P10592791A0370 ( O
iii P10592791A0370 NN O
) P10592791A0370 ) O
because P10592791A0370 IN O
of P10592791A0370 IN O
the P10592791A0370 DT O
complicated P10592791A0370 JJ O
test P10592791A0370 NN O
procedures P10592791A0370 NNS O
and P10592791A0370 CC O
the P10592791A0370 DT O
lack P10592791A0370 NN O
of P10592791A0370 IN O
ability P10592791A0370 NN O
for P10592791A0370 IN O
detecting P10592791A0370 VBG O
SEE P10592791A0370 NNP O
, P10592791A0370 , O
the P10592791A0370 DT O
practicality P10592791A0370 NN O
of P10592791A0370 IN O
SET-EIA P10592791A0370 NNP O
kit P10592791A0370 NN O
in P10592791A0370 IN O
screening P10592791A0370 VBG O
and P10592791A0370 CC O
epidemiological P10592791A0370 JJ O
research P10592791A0370 NN O
purposes P10592791A0370 NNS O
is P10592791A0370 VBZ O
low P10592791A0370 JJ O
. P10592791A0370 . O
. . O O

ISIS P07908187T0000 NNP O
5 P07908187T0000 CD O
possibilities P07908187T0000 NNS O
. P07908187T0000 . O
. . O O

The P09650186A1043 DT O
low P09650186A1043 JJ O
number P09650186A1043 NN O
of P09650186A1043 IN O
false P09650186A1043 JJ O
positives P09650186A1043 NNS O
indicates P09650186A1043 VBZ O
that P09650186A1043 IN O
our P09650186A1043 PRP$ O
scheme P09650186A1043 NN O
would P09650186A1043 MD O
not P09650186A1043 RB O
confuse P09650186A1043 VB O
the P09650186A1043 DT O
radiologist P09650186A1043 NN O
by P09650186A1043 IN O
suggesting P09650186A1043 VBG O
normal P09650186A1043 JJ O
regions P09650186A1043 NNS O
as P09650186A1043 IN O
suspicious P09650186A1043 JJ O
. P09650186A1043 . O
. . O O

100 P02502960A0762 CD O
and P02502960A0762 CC O
14 P02502960A0762 CD O
p P02502960A0762 NN O
. P02502960A0762 . O
. . O O

Many P11562278A0169 JJ O
of P11562278A0169 IN O
the P11562278A0169 DT O
important P11562278A0169 JJ O
genes P11562278A0169 NNS O
associated P11562278A0169 VBN O
with P11562278A0169 IN O
G1 P11562278A0169 NNP O
regulation P11562278A0169 NN O
have P11562278A0169 VBP O
been P11562278A0169 VBN O
shown P11562278A0169 VBN O
to P11562278A0169 TO O
play P11562278A0169 VB O
a P11562278A0169 DT O
key P11562278A0169 JJ O
role P11562278A0169 NN O
in P11562278A0169 IN O
proliferation P11562278A0169 NN O
, P11562278A0169 , O
differentiation P11562278A0169 NN O
and P11562278A0169 CC O
oncogenic P11562278A0169 JJ O
transformation P11562278A0169 NN O
and P11562278A0169 CC O
programmed P11562278A0169 VBD O
cell P11562278A0169 NN O
death P11562278A0169 NN O
( P11562278A0169 ( O
apoptosis P11562278A0169 NN O
) P11562278A0169 ) O
. P11562278A0169 . O
. . O O

SCID P09398855A0438 NNP O
V P09398855A0438 NNP I-UN
( P09398855A0438 ( O
D P09398855A0438 NNP I-UN
) P09398855A0438 ) O
J P09398855A0438 NNP I-UN
recombination P09398855A0438 NN O
can P09398855A0438 MD O
be P09398855A0438 VB O
partly P09398855A0438 RB O
rescued P09398855A0438 VBN O
in P09398855A0438 IN O
T-lymphocytes P09398855A0438 NNP O
by P09398855A0438 IN O
either P09398855A0438 DT O
DNA-damaging P09398855A0438 JJ O
agents P09398855A0438 NNS O
( P09398855A0438 ( O
gamma-irradiation P09398855A0438 NN O
and P09398855A0438 CC O
bieomycin P09398855A0438 NN O
) P09398855A0438 ) O
or P09398855A0438 CC O
a P09398855A0438 DT O
null P09398855A0438 JJ O
mutation P09398855A0438 NN O
of P09398855A0438 IN O
the P09398855A0438 DT O
p53 P09398855A0438 NN I-UN
gene P09398855A0438 NN I-UN
, P09398855A0438 , O
possibly P09398855A0438 RB O
because P09398855A0438 IN O
of P09398855A0438 IN O
transiently P09398855A0438 RB O
elevated P09398855A0438 VBN O
DNA P09398855A0438 NNP O
repair P09398855A0438 NN O
activity P09398855A0438 NN O
in P09398855A0438 IN O
response P09398855A0438 NN O
to P09398855A0438 TO O
DNA P09398855A0438 NNP O
damage P09398855A0438 NN O
or P09398855A0438 CC O
to P09398855A0438 TO O
delayed P09398855A0438 VB O
apoptosis P09398855A0438 NN O
in P09398855A0438 IN O
the P09398855A0438 DT O
absence P09398855A0438 NN O
of P09398855A0438 IN O
p53 P09398855A0438 NN I-UN
. P09398855A0438 . O
. . O O

Vbeta P10850719A0680 NN I-UN
segments P10850719A0680 NNS O
are P10850719A0680 VBP O
appended P10850719A0680 VBN O
to P10850719A0680 TO O
DJbeta P10850719A0680 NNP I-UN
rearrangements P10850719A0680 NNS O
, P10850719A0680 , O
with P10850719A0680 IN O
little P10850719A0680 JJ O
or P10850719A0680 CC O
no P10850719A0680 DT O
direct P10850719A0680 JJ O
Vbeta P10850719A0680 NNP I-UN
to P10850719A0680 TO O
Jbeta P10850719A0680 NNP I-UN
joining P10850719A0680 NN O
, P10850719A0680 , O
despite P10850719A0680 IN O
12 P10850719A0680 CD O
/ P10850719A0680 JJ O
23 P10850719A0680 CD O
compatibility P10850719A0680 NN O
of P10850719A0680 IN O
Vbeta P10850719A0680 NNP I-UN
23-RSSs P10850719A0680 JJ I-UN
and P10850719A0680 CC O
Jbeta12-RSSs P10850719A0680 NNP I-UN
. P10850719A0680 . O
. . O O

Our P11046517A0619 PRP$ O
results P11046517A0619 NNS O
, P11046517A0619 , O
however P11046517A0619 RB O
, P11046517A0619 , O
were P11046517A0619 VBD O
obtained P11046517A0619 VBN O
for P11046517A0619 IN O
Z P11046517A0619 NNP O
itself P11046517A0619 PRP O
and P11046517A0619 CC O
not P11046517A0619 RB O
for P11046517A0619 IN O
[ P11046517A0619 NNP O
Z P11046517A0619 NNP O
] P11046517A0619 NNP O
. P11046517A0619 . O
. . O O

A P07840643A1006 DT O
comparison P07840643A1006 NN O
of P07840643A1006 IN O
the P07840643A1006 DT O
Flavobacterium P07840643A1006 NNP O
glycosylasparaginase P07840643A1006 NN I-UN
with P07840643A1006 IN O
a P07840643A1006 DT O
mammalian P07840643A1006 JJ O
glycosylasparaginase P07840643A1006 NN I-UN
revealed P07840643A1006 VBD O
30 P07840643A1006 CD O
% P07840643A1006 NN O
structural P07840643A1006 JJ O
identity P07840643A1006 NN O
and P07840643A1006 CC O
60 P07840643A1006 CD O
% P07840643A1006 NN O
overall P07840643A1006 JJ O
similarity P07840643A1006 NN O
between P07840643A1006 IN O
the P07840643A1006 DT O
prokaryotic P07840643A1006 JJ O
and P07840643A1006 CC O
eukaryotic P07840643A1006 JJ O
forms P07840643A1006 NNS O
of P07840643A1006 IN O
the P07840643A1006 DT O
enzyme P07840643A1006 NN O
. P07840643A1006 . O
. . O O

I P08005412A0608 PRP O
hypothesize P08005412A0608 VBP O
that P08005412A0608 IN O
white P08005412A0608 JJ I-UN
gene P08005412A0608 NN I-UN
expression P08005412A0608 NN O
from P08005412A0608 IN O
P P08005412A0608 NNP I-UN
[ P08005412A0608 NNP I-UN
en P08005412A0608 FW I-UN
] P08005412A0608 NN I-UN
is P08005412A0608 VBZ O
repressed P08005412A0608 VBN O
by P08005412A0608 IN O
the P08005412A0608 DT O
formation P08005412A0608 NN O
of P08005412A0608 IN O
a P08005412A0608 DT O
protein P08005412A0608 NN O
complex P08005412A0608 NN O
which P08005412A0608 WDT O
is P08005412A0608 VBZ O
initiated P08005412A0608 VBN O
at P08005412A0608 IN O
the P08005412A0608 DT O
engrailed P08005412A0608 JJ I-UN
PS P08005412A0608 NNP I-UN
sites P08005412A0608 NNS I-UN
and P08005412A0608 CC O
also P08005412A0608 RB O
requires P08005412A0608 VBZ O
interactions P08005412A0608 NNS O
with P08005412A0608 IN O
flanking P08005412A0608 VBG O
genomic P08005412A0608 JJ O
DNA P08005412A0608 NN O
. P08005412A0608 . O
. . O O

Site-directed P10087993A1352 JJ O
mutagenesis P10087993A1352 NN O
of P10087993A1352 IN O
binding P10087993A1352 VBG O
sites P10087993A1352 NNS O
for P10087993A1352 IN O
the P10087993A1352 DT O
repressor P10087993A1352 NN I-UN
proteins P10087993A1352 VBZ I-UN
BP1 P10087993A1352 NNP I-UN
and P10087993A1352 CC O
BP2 P10087993A1352 NNP I-UN
in P10087993A1352 IN O
the P10087993A1352 DT O
upstream P10087993A1352 JJ O
portion P10087993A1352 NN O
of P10087993A1352 IN O
the P10087993A1352 DT O
beta P10087993A1352 NN I-UN
globin P10087993A1352 NN I-UN
gene P10087993A1352 NN I-UN
flanking P10087993A1352 VBG I-UN
region P10087993A1352 NN I-UN
led P10087993A1352 VBD O
to P10087993A1352 TO O
a P10087993A1352 DT O
4-6 P10087993A1352 JJ O
fold P10087993A1352 JJ O
increase P10087993A1352 NN O
in P10087993A1352 IN O
promoter P10087993A1352 NN O
activity P10087993A1352 NN O
. P10087993A1352 . O
. . O O

This P01781923A0744 DT O
differential P01781923A0744 JJ O
sensitivity P01781923A0744 NN O
to P01781923A0744 TO O
DB P01781923A0744 NNP O
, P01781923A0744 , O
as P01781923A0744 IN O
measured P01781923A0744 VBN O
by P01781923A0744 IN O
a P01781923A0744 DT O
lower P01781923A0744 JJR O
concentration P01781923A0744 NN O
of P01781923A0744 IN O
DB P01781923A0744 NNP O
which P01781923A0744 WDT O
caused P01781923A0744 VBD O
loss P01781923A0744 NN O
of P01781923A0744 IN O
righting P01781923A0744 VBG O
in P01781923A0744 IN O
LS P01781923A0744 NNP O
, P01781923A0744 , O
was P01781923A0744 VBD O
accompanied P01781923A0744 VBN O
by P01781923A0744 IN O
an P01781923A0744 DT O
equal P01781923A0744 JJ O
rate P01781923A0744 NN O
of P01781923A0744 IN O
water-soluble P01781923A0744 JJ O
barbiturate P01781923A0744 NN O
brain P01781923A0744 NN O
distribution P01781923A0744 NN O
and P01781923A0744 CC O
elimination P01781923A0744 NN O
in P01781923A0744 IN O
the P01781923A0744 DT O
two P01781923A0744 CD O
lines P01781923A0744 NNS O
. P01781923A0744 . O
. . O O

The P10786671A0182 DT O
rate-limiting P10786671A0182 JJ O
step P10786671A0182 NN O
for P10786671A0182 IN O
telomerase P10786671A0182 NN I-UN
activity P10786671A0182 NN O
seems P10786671A0182 VBZ O
to P10786671A0182 TO O
be P10786671A0182 VB O
the P10786671A0182 DT O
expression P10786671A0182 NN O
of P10786671A0182 IN O
the P10786671A0182 DT O
catalytic P10786671A0182 JJ O
subunit P10786671A0182 NN O
of P10786671A0182 IN O
the P10786671A0182 DT O
enzyme P10786671A0182 NN O
, P10786671A0182 , O
encoded P10786671A0182 VBN O
by P10786671A0182 IN O
the P10786671A0182 DT O
human P10786671A0182 JJ I-UN
telomerase P10786671A0182 NN I-UN
reverse P10786671A0182 NN I-UN
transcriptase P10786671A0182 NN I-UN
( P10786671A0182 ( O
hTERT P10786671A0182 NN I-UN
) P10786671A0182 ) O
gene P10786671A0182 NN O
. P10786671A0182 . O
. . O O

Regulatory P10562456T0000 JJ O
regions P10562456T0000 NNS O
in P10562456T0000 IN O
the P10562456T0000 DT O
promoter P10562456T0000 NN O
and P10562456T0000 CC O
third P10562456T0000 JJ O
intron P10562456T0000 NN O
of P10562456T0000 IN O
the P10562456T0000 DT O
growth P10562456T0000 NN I-UN
hormone P10562456T0000 NN I-UN
gene P10562456T0000 NN I-UN
in P10562456T0000 IN I-UN
rainbow P10562456T0000 NN I-UN
trout P10562456T0000 NN I-UN
, P10562456T0000 , O
Oncorhynchus P10562456T0000 NNP O
mykiss P10562456T0000 NN O
walbaum P10562456T0000 NN O
. P10562456T0000 . O
. . O O

Previous P11114294A0075 JJ O
studies P11114294A0075 NNS O
have P11114294A0075 VBP O
shown P11114294A0075 VBN O
that P11114294A0075 IN O
the P11114294A0075 DT O
pro-inflammatory P11114294A0075 JJ O
cytokines P11114294A0075 NNS O
tumor P11114294A0075 NN I-UN
necrosis P11114294A0075 NN I-UN
factor P11114294A0075 NN I-UN
alpha P11114294A0075 NN I-UN
and P11114294A0075 CC O
interferon P11114294A0075 NN I-UN
gamma P11114294A0075 NN I-UN
reduce P11114294A0075 VB O
the P11114294A0075 DT O
expression P11114294A0075 NN O
of P11114294A0075 IN O
the P11114294A0075 DT O
cystic P11114294A0075 JJ I-UN
fibrosis P11114294A0075 NN I-UN
transmembrane P11114294A0075 NN I-UN
conductance P11114294A0075 NN I-UN
regulator P11114294A0075 NN I-UN
( P11114294A0075 ( O
CFTR P11114294A0075 NNP I-UN
) P11114294A0075 ) O
gene P11114294A0075 NN O
( P11114294A0075 ( O
CFTR P11114294A0075 NNP I-UN
) P11114294A0075 ) O
in P11114294A0075 IN O
HT-29 P11114294A0075 NNP O
and P11114294A0075 CC O
T84 P11114294A0075 NNP O
cells P11114294A0075 NNS O
by P11114294A0075 IN O
acting P11114294A0075 VBG O
post-transcriptionally P11114294A0075 RB O
. P11114294A0075 . O
. . O O

In P10330146A0730 IN O
the P10330146A0730 DT O
case P10330146A0730 NN O
of P10330146A0730 IN O
the P10330146A0730 DT O
unspliceable P10330146A0730 JJ O
intron P10330146A0730 NN O
, P10330146A0730 , O
repression P10330146A0730 NN O
of P10330146A0730 IN O
luciferase P10330146A0730 NN I-UN
expression P10330146A0730 NN O
likely P10330146A0730 RB O
involved P10330146A0730 JJ O
two P10330146A0730 CD O
AUF1-binding P10330146A0730 JJ I-UN
sequences P10330146A0730 NNS I-UN
, P10330146A0730 , O
since P10330146A0730 IN O
luciferase P10330146A0730 NN I-UN
expression P10330146A0730 NN O
was P10330146A0730 VBD O
increased P10330146A0730 VBN O
by P10330146A0730 IN O
deletion P10330146A0730 NN O
of P10330146A0730 IN O
these P10330146A0730 DT O
sites P10330146A0730 NNS O
. P10330146A0730 . O
. . O O

Of P02674671A0601 IN O
the P02674671A0601 DT O
single-stranded P02674671A0601 JJ O
DNA P02674671A0601 NN O
transformants P02674671A0601 NNS O
, P02674671A0601 , O
65 P02674671A0601 CD O
% P02674671A0601 NN O
resulted P02674671A0601 VBD O
from P02674671A0601 IN O
replacement P02674671A0601 NN O
of P02674671A0601 IN O
the P02674671A0601 DT O
resident P02674671A0601 NN O
met2 P02674671A0601 NN I-UN
mutation P02674671A0601 NN I-UN
by P02674671A0601 IN O
the P02674671A0601 DT O
exogenous P02674671A0601 JJ O
wild-type P02674671A0601 JJ O
allele P02674671A0601 NN O
. P02674671A0601 . O
. . O O

However P01190120A0832 RB O
, P01190120A0832 , O
a P01190120A0832 DT O
10 P01190120A0832 CD O
-- P01190120A0832 : O
15 P01190120A0832 CD O
% P01190120A0832 NN O
lengthening P01190120A0832 NN O
of P01190120A0832 IN O
the P01190120A0832 DT O
partial P01190120A0832 JJ O
thromboplastin P01190120A0832 NN I-UN
time P01190120A0832 NN O
is P01190120A0832 VBZ O
evident P01190120A0832 JJ O
after P01190120A0832 IN O
24 P01190120A0832 CD O
hours P01190120A0832 NNS O
of P01190120A0832 IN O
storage P01190120A0832 NN O
. P01190120A0832 . O
. . O O

Students P05595036T0001 NNS O
, P05595036T0001 , O
parents P05595036T0001 NNS O
, P05595036T0001 , O
teachers P05595036T0001 NNS O
and P05595036T0001 CC O
hearing P05595036T0001 VBG O
disorders P05595036T0001 NNS O
. P05595036T0001 . O
. . O O

The P01147436T0000 DT O
American P01147436T0000 JJ O
Burkitt P01147436T0000 NNP O
Lymphoma P01147436T0000 NNP O
Registry P01147436T0000 NNP O
: P01147436T0000 : O
a P01147436T0000 DT O
progress P01147436T0000 NN O
report P01147436T0000 NN O
. P01147436T0000 . O
. . O O

Both P09218436A0443 DT O
promoters P09218436A0443 NNS O
lack P09218436A0443 VBP O
a P09218436A0443 DT O
TATA P09218436A0443 NNP O
box P09218436A0443 NN O
, P09218436A0443 , O
and P09218436A0443 CC O
Pint P09218436A0443 NNP I-UN
belongs P09218436A0443 NNS O
to P09218436A0443 TO O
the P09218436A0443 DT O
MED-1 P09218436A0443 NNP I-UN
class P09218436A0443 NN O
of P09218436A0443 IN O
promoters P09218436A0443 NNS O
, P09218436A0443 , O
which P09218436A0443 WDT O
initiate P09218436A0443 VBP O
transcription P09218436A0443 NN O
at P09218436A0443 IN O
multiple P09218436A0443 JJ O
sites P09218436A0443 NNS O
. P09218436A0443 . O
. . O O

We P09891046A0554 PRP O
isolated P09891046A0554 VBD O
a P09891046A0554 DT O
ribosomal P09891046A0554 JJ I-UN
protein P09891046A0554 NN I-UN
L18 P09891046A0554 NNP I-UN
by P09891046A0554 IN O
interaction P09891046A0554 NN O
with P09891046A0554 IN O
PKR P09891046A0554 NNP I-UN
. P09891046A0554 . O
. . O O

Refugees P08525186A0288 NNS O
living P08525186A0288 VBG O
in P08525186A0288 IN O
Lund P08525186A0288 NNP O
and P08525186A0288 CC O
repatriated P08525186A0288 VBN O
to P08525186A0288 TO O
Chile P08525186A0288 NNP O
considered P08525186A0288 VBN O
their P08525186A0288 PRP$ O
health P08525186A0288 NN O
as P08525186A0288 IN O
bad P08525186A0288 JJ O
in P08525186A0288 IN O
a P08525186A0288 DT O
higher P08525186A0288 JJR O
proportion P08525186A0288 NN O
than P08525186A0288 IN O
their P08525186A0288 PRP$ O
Swedish P08525186A0288 JJ O
counterparts P08525186A0288 NNS O
, P08525186A0288 , O
with P08525186A0288 IN O
an P08525186A0288 DT O
odds P08525186A0288 NNS O
ratio P08525186A0288 NN O
of P08525186A0288 IN O
3.48 P08525186A0288 CD O
( P08525186A0288 ( O
2.03-5.66 P08525186A0288 JJ O
) P08525186A0288 ) O
and P08525186A0288 CC O
4.78 P08525186A0288 CD O
( P08525186A0288 ( O
2.1-10.25 P08525186A0288 JJ O
) P08525186A0288 ) O
respectively P08525186A0288 RB O
. P08525186A0288 . O
. . O O

K P02511207A0282 NNP O
. P02511207A0282 . O
. . O O

Estrogen P10779508T0000 NNP I-UN
receptor-related P10779508T0000 JJ I-UN
receptor P10779508T0000 NN I-UN
alpha P10779508T0000 VBD I-UN
1 P10779508T0000 CD I-UN
interacts P10779508T0000 NNS O
with P10779508T0000 IN O
coactivator P10779508T0000 NN O
and P10779508T0000 CC O
constitutively P10779508T0000 RB O
activates P10779508T0000 VBZ O
the P10779508T0000 DT O
estrogen P10779508T0000 NN O
response P10779508T0000 NN O
elements P10779508T0000 NNS O
of P10779508T0000 IN O
the P10779508T0000 DT O
human P10779508T0000 JJ I-UN
lactoferrin P10779508T0000 NN I-UN
gene P10779508T0000 NN I-UN
. P10779508T0000 . O
. . O O

To P08189533A0203 TO O
study P08189533A0203 VB O
the P08189533A0203 DT O
structure-function P08189533A0203 NN O
of P08189533A0203 IN O
the P08189533A0203 DT O
gene P08189533A0203 NN I-UN
5 P08189533A0203 CD I-UN
product P08189533A0203 NN I-UN
, P08189533A0203 , O
wild-type P08189533A0203 JJ O
and P08189533A0203 CC O
mutant P08189533A0203 JJ O
forms P08189533A0203 NNS O
of P08189533A0203 IN O
NS53 P08189533A0203 NNP I-UN
were P08189533A0203 VBD O
produced P08189533A0203 VBN O
by P08189533A0203 IN O
using P08189533A0203 VBG O
a P08189533A0203 DT O
recombinant P08189533A0203 JJ O
baculovirus P08189533A0203 NN O
expression P08189533A0203 NN O
system P08189533A0203 NN O
and P08189533A0203 CC O
a P08189533A0203 DT O
recombinant P08189533A0203 JJ O
vaccinia P08189533A0203 NN O
virus P08189533A0203 NN O
/ P08189533A0203 NNP O
T7 P08189533A0203 NNP O
( P08189533A0203 ( O
vTF7-3 P08189533A0203 NN O
) P08189533A0203 ) O
expression P08189533A0203 NN O
system P08189533A0203 NN O
. P08189533A0203 . O
. . O O

The P07762431A0356 DT O
protein P07762431A0356 NN O
expressed P07762431A0356 VBD O
from P07762431A0356 IN O
the P07762431A0356 DT O
cloned P07762431A0356 VBN O
cDNA P07762431A0356 NN O
is P07762431A0356 VBZ O
secreted P07762431A0356 VBN O
into P07762431A0356 IN O
the P07762431A0356 DT O
culture P07762431A0356 NN O
medium P07762431A0356 NN O
and P07762431A0356 CC O
yields P07762431A0356 NNS O
of P07762431A0356 IN O
up P07762431A0356 IN O
to P07762431A0356 TO O
40 P07762431A0356 CD O
mg P07762431A0356 NNS O
per P07762431A0356 IN O
litre P07762431A0356 NN O
have P07762431A0356 VBP O
been P07762431A0356 VBN O
obtained P07762431A0356 VBN O
. P07762431A0356 . O
. . O O

There P03772471A1054 EX O
were P03772471A1054 VBD O
18 P03772471A1054 CD O
patients P03772471A1054 NNS O
with P03772471A1054 IN O
Group P03772471A1054 NNP O
II P03772471A1054 NNP O
( P03772471A1054 ( O
a P03772471A1054 DT O
) P03772471A1054 ) O
tumors P03772471A1054 NNS O
; P03772471A1054 : O
although P03772471A1054 IN O
tumor P03772471A1054 NN O
biopsy P03772471A1054 NN O
was P03772471A1054 VBD O
attempted P03772471A1054 VBN O
on P03772471A1054 IN O
eight P03772471A1054 CD O
of P03772471A1054 IN O
these P03772471A1054 DT O
, P03772471A1054 , O
pathological P03772471A1054 JJ O
diagnosis P03772471A1054 NN O
at P03772471A1054 IN O
the P03772471A1054 DT O
time P03772471A1054 NN O
of P03772471A1054 IN O
surgery P03772471A1054 NN O
was P03772471A1054 VBD O
made P03772471A1054 VBN O
in P03772471A1054 IN O
only P03772471A1054 RB O
one P03772471A1054 CD O
case P03772471A1054 NN O
. P03772471A1054 . O
. . O O

Among P10837126A1004 IN O
genes P10837126A1004 NNS O
induced P10837126A1004 VBN O
by P10837126A1004 IN O
added P10837126A1004 JJ O
pMesogenin1 P10837126A1004 NN I-UN
is P10837126A1004 VBZ O
Xwnt-8 P10837126A1004 JJ I-UN
, P10837126A1004 , O
a P10837126A1004 DT O
signaling P10837126A1004 VBG O
factor P10837126A1004 NN O
that P10837126A1004 WDT O
induces P10837126A1004 VBZ O
a P10837126A1004 DT O
similar P10837126A1004 JJ O
repertoire P10837126A1004 NN O
of P10837126A1004 IN O
marker P10837126A1004 NN O
genes P10837126A1004 NNS O
and P10837126A1004 CC O
a P10837126A1004 DT O
similar P10837126A1004 JJ O
cellular P10837126A1004 JJ O
phenotype P10837126A1004 NN O
. P10837126A1004 . O
. . O O

We P07590268A0350 PRP O
have P07590268A0350 VBP O
isolated P07590268A0350 VBN O
a P07590268A0350 DT O
Drosophila P07590268A0350 NNP O
melanogaster P07590268A0350 NN O
( P07590268A0350 ( O
Dm P07590268A0350 NNP O
) P07590268A0350 ) O
cDNA P07590268A0350 NN O
encoding P07590268A0350 VBG O
a P07590268A0350 DT O
polypeptide P07590268A0350 NN O
that P07590268A0350 WDT O
has P07590268A0350 VBZ O
extensive P07590268A0350 JJ O
sequence P07590268A0350 NN O
similarity P07590268A0350 NN O
to P07590268A0350 TO O
the P07590268A0350 DT O
mammalian P07590268A0350 JJ I-UN
MAPKAPK-2 P07590268A0350 NNP I-UN
. P07590268A0350 . O
. . O O

Pure P09143465A0838 NNP O
T1 P09143465A0838 NNP O
and P09143465A0838 CC O
dual-T1 P09143465A0838 JJ O
images P09143465A0838 NNS O
were P09143465A0838 VBD O
visually P09143465A0838 RB O
evaluated P09143465A0838 VBN O
for P09143465A0838 IN O
image P09143465A0838 NN O
quality P09143465A0838 NN O
( P09143465A0838 ( O
IQ P09143465A0838 NNP O
) P09143465A0838 ) O
on P09143465A0838 IN O
a P09143465A0838 DT O
five-point P09143465A0838 JJ O
scale P09143465A0838 NN O
( P09143465A0838 ( O
0 P09143465A0838 CD O
= P09143465A0838 RB O
unacceptable P09143465A0838 JJ O
to P09143465A0838 TO O
4 P09143465A0838 CD O
= P09143465A0838 NNP O
excellent P09143465A0838 NN O
) P09143465A0838 ) O
. P09143465A0838 . O
. . O O

Large P08070004A0782 JJ O
interpatient P08070004A0782 JJ O
variation P08070004A0782 NN O
in P08070004A0782 IN O
peak P08070004A0782 NN O
PCZ P08070004A0782 NNP O
plasma P08070004A0782 NN O
levels P08070004A0782 NNS O
( P08070004A0782 ( O
91-3215 P08070004A0782 CD O
ng P08070004A0782 NN O
/ P08070004A0782 NNP O
ml P08070004A0782 NN O
) P08070004A0782 ) O
was P08070004A0782 VBD O
seen P08070004A0782 VBN O
, P08070004A0782 , O
with P08070004A0782 IN O
the P08070004A0782 DT O
plasma P08070004A0782 JJ O
half-life P08070004A0782 NN O
( P08070004A0782 ( O
t1 P08070004A0782 JJ O
/ P08070004A0782 $ O
2 P08070004A0782 CD O
alpha P08070004A0782 NN O
) P08070004A0782 ) O
being P08070004A0782 VBG O
approximately P08070004A0782 RB O
57 P08070004A0782 CD O
min P08070004A0782 NNS O
in P08070004A0782 IN O
patients P08070004A0782 NNS O
given P08070004A0782 VBN O
135-180 P08070004A0782 JJ O
mg P08070004A0782 NN O
/ P08070004A0782 NNP O
m2 P08070004A0782 NN O
PCZ P08070004A0782 NNP O
. P08070004A0782 . O
. . O O

A P11428283A0228 DT O
5-month-old P11428283A0228 JJ O
infant P11428283A0228 NN O
with P11428283A0228 IN O
persistent P11428283A0228 JJ O
congenital P11428283A0228 JJ O
stridor P11428283A0228 NN O
and P11428283A0228 CC O
acute P11428283A0228 JJ O
respiratory P11428283A0228 NN O
distress P11428283A0228 NN O
is P11428283A0228 VBZ O
presented P11428283A0228 VBN O
. P11428283A0228 . O
. . O O

Recessive P02511069A0532 JJ O
lethal P02511069A0532 JJ O
mutations P02511069A0532 NNS O
were P02511069A0532 VBD O
isolated P02511069A0532 VBN O
based P02511069A0532 VBN O
upon P02511069A0532 IN O
failure P02511069A0532 NN O
to P02511069A0532 TO O
complement P02511069A0532 VB O
the P02511069A0532 DT O
recessive P02511069A0532 JJ O
lethality P02511069A0532 NN O
of P02511069A0532 IN O
Df P02511069A0532 NNP O
( P02511069A0532 ( O
3L P02511069A0532 CD O
) P02511069A0532 ) O
RR2 P02511069A0532 NNP O
, P02511069A0532 , O
a P02511069A0532 DT O
deletion P02511069A0532 NN O
of P02511069A0532 IN O
the P02511069A0532 DT O
DRE P02511069A0532 NNP O
region P02511069A0532 NN O
that P02511069A0532 WDT O
removes P02511069A0532 VBZ O
16-18 P02511069A0532 JJ O
polytene P02511069A0532 NN O
chromosome P02511069A0532 NN O
bands P02511069A0532 NNS O
. P02511069A0532 . O
. . O O

The P10535715A0268 DT O
RMR P10535715A0268 NNP O
was P10535715A0268 VBD O
measured P10535715A0268 VBN O
twice P10535715A0268 RB O
in P10535715A0268 IN O
each P10535715A0268 DT O
phase P10535715A0268 NN O
and P10535715A0268 CC O
found P10535715A0268 VBD O
to P10535715A0268 TO O
be P10535715A0268 VB O
similar P10535715A0268 JJ O
( P10535715A0268 ( O
F P10535715A0268 NNP O
( P10535715A0268 ( O
1,18 P10535715A0268 CD O
) P10535715A0268 ) O
= P10535715A0268 FW O
0.863 P10535715A0268 CD O
) P10535715A0268 ) O
across P10535715A0268 IN O
the P10535715A0268 DT O
follicular P10535715A0268 NN O
( P10535715A0268 ( O
5018 P10535715A0268 CD O
kJ P10535715A0268 NN O
/ P10535715A0268 VBD O
24 P10535715A0268 CD O
h P10535715A0268 NN O
) P10535715A0268 ) O
and P10535715A0268 CC O
the P10535715A0268 DT O
luteal P10535715A0268 NN O
( P10535715A0268 ( O
5098 P10535715A0268 CD O
kJ P10535715A0268 NN O
/ P10535715A0268 VBD O
24 P10535715A0268 CD O
h P10535715A0268 NN O
) P10535715A0268 ) O
phases P10535715A0268 VBZ O
. P10535715A0268 . O
. . O O

An P08702936A0168 DT O
expression P08702936A0168 NN O
library P08702936A0168 NN O
was P08702936A0168 VBD O
constructed P08702936A0168 VBN O
by P08702936A0168 IN O
inserting P08702936A0168 VBG O
5 P08702936A0168 CD O
' P08702936A0168 POS O
portion-enriched P08702936A0168 JJ O
cDNAs P08702936A0168 NN O
from P08702936A0168 IN O
phytohemagglutinin-stimulated P08702936A0168 JJ O
peripheral P08702936A0168 JJ O
blood P08702936A0168 NN O
mononuclear P08702936A0168 NN O
cells P08702936A0168 NNS O
into P08702936A0168 IN O
upstream P08702936A0168 NN O
of P08702936A0168 IN O
signal P08702936A0168 JJ I-UN
sequence-deleted P08702936A0168 JJ I-UN
CD4 P08702936A0168 NNP I-UN
cDNA P08702936A0168 NN I-UN
in P08702936A0168 IN O
an P08702936A0168 DT O
Epstein-Barr P08702936A0168 JJ O
virus P08702936A0168 NN O
shuttle P08702936A0168 NN O
vector P08702936A0168 NN O
. P08702936A0168 . O
. . O O

Furthermore P09736715A0729 RB O
, P09736715A0729 , O
phosphatidylinositol P09736715A0729 NN O
( P09736715A0729 ( O
3,4,5 P09736715A0729 CD O
) P09736715A0729 ) O
trisphosphate P09736715A0729 NN O
specifically P09736715A0729 RB O
stimulates P09736715A0729 VBZ O
the P09736715A0729 DT O
activity P09736715A0729 NN O
of P09736715A0729 IN O
ILK P09736715A0729 NNP I-UN
in P09736715A0729 IN O
vitro P09736715A0729 NN O
, P09736715A0729 , O
and P09736715A0729 CC O
in P09736715A0729 IN O
addition P09736715A0729 NN O
, P09736715A0729 , O
membrane P09736715A0729 NN O
targetted P09736715A0729 VBD O
constitutively P09736715A0729 RB O
active P09736715A0729 JJ O
Pi P09736715A0729 NNP I-UN
( P09736715A0729 ( I-UN
3 P09736715A0729 CD I-UN
) P09736715A0729 ) I-UN
K P09736715A0729 NNP I-UN
activates P09736715A0729 VBZ O
ILK P09736715A0729 NNP I-UN
in P09736715A0729 IN O
vivo P09736715A0729 NN O
. P09736715A0729 . O
. . O O

In P10598101A0000 IN O
addition P10598101A0000 NN O
to P10598101A0000 TO O
the P10598101A0000 DT O
bZIP P10598101A0000 NN I-UN
protein P10598101A0000 NN I-UN
Opaque2 P10598101A0000 NNP I-UN
( P10598101A0000 ( O
O2 P10598101A0000 NNP I-UN
) P10598101A0000 ) O
, P10598101A0000 , O
there P10598101A0000 EX O
are P10598101A0000 VBP O
other P10598101A0000 JJ O
maize P10598101A0000 JJ O
endosperm P10598101A0000 JJ O
nuclear P10598101A0000 JJ O
proteins P10598101A0000 NNS O
that P10598101A0000 WDT O
recognize P10598101A0000 VBP O
the P10598101A0000 DT O
O2 P10598101A0000 NNP I-UN
box P10598101A0000 NN I-UN
in P10598101A0000 IN O
22 P10598101A0000 CD O
kDa P10598101A0000 NNS O
zein P10598101A0000 CD I-UN
gene P10598101A0000 NN O
promoters P10598101A0000 NNS O
. P10598101A0000 . O
. . O O

Positive P11408099A0518 JJ O
and P11408099A0518 CC O
significant P11408099A0518 JJ O
correlations P11408099A0518 NNS O
were P11408099A0518 VBD O
found P11408099A0518 VBN O
between P11408099A0518 IN O
the P11408099A0518 DT O
weeks P11408099A0518 NNS O
of P11408099A0518 IN O
pregnancy P11408099A0518 NN O
and P11408099A0518 CC O
Se P11408099A0518 NNP O
levels P11408099A0518 NNS O
in P11408099A0518 IN O
kidney P11408099A0518 NN O
( P11408099A0518 ( O
r=0.433 P11408099A0518 NN O
, P11408099A0518 , O
P=0.023 P11408099A0518 NNP O
) P11408099A0518 ) O
and P11408099A0518 CC O
heart P11408099A0518 NN O
( P11408099A0518 ( O
r=0.313 P11408099A0518 NN O
, P11408099A0518 , O
P=0.030 P11408099A0518 NNP O
) P11408099A0518 ) O
. P11408099A0518 . O
. . O O

Its P07509053A0139 PRP$ O
role P07509053A0139 NN O
in P07509053A0139 IN O
these P07509053A0139 DT O
processes P07509053A0139 NNS O
suggests P07509053A0139 VBZ O
that P07509053A0139 IN O
the P07509053A0139 DT O
function P07509053A0139 NN O
of P07509053A0139 IN O
c-Myb P07509053A0139 NN I-UN
may P07509053A0139 MD O
be P07509053A0139 VB O
important P07509053A0139 JJ O
early P07509053A0139 JJ O
in P07509053A0139 IN O
the P07509053A0139 DT O
establishment P07509053A0139 NN O
of P07509053A0139 IN O
the P07509053A0139 DT O
hematopoietic P07509053A0139 JJ O
lineage P07509053A0139 NN O
. P07509053A0139 . O
. . O O

Pituitary P08625900T0000 JJ O
adenylate P08625900T0000 NN I-UN
cyclase-activating P08625900T0000 JJ I-UN
polypeptide P08625900T0000 NN I-UN
regulates P08625900T0000 VBZ O
prolactin P08625900T0000 JJ I-UN
promoter P08625900T0000 NN I-UN
activity P08625900T0000 NN O
via P08625900T0000 IN O
a P08625900T0000 DT O
protein P08625900T0000 JJ I-UN
kinase P08625900T0000 NN I-UN
A-mediated P08625900T0000 NNP O
pathway P08625900T0000 NN O
that P08625900T0000 WDT O
is P08625900T0000 VBZ O
independent P08625900T0000 JJ O
of P08625900T0000 IN O
the P08625900T0000 DT O
transcriptional P08625900T0000 JJ O
pathway P08625900T0000 NN O
employed P08625900T0000 VBN O
by P08625900T0000 IN O
thyrotropin-releasing P08625900T0000 JJ I-UN
hormone P08625900T0000 NN I-UN
. P08625900T0000 . O
. . O O

It P06823837A0562 PRP O
then P06823837A0562 RB O
merged P06823837A0562 VBD O
with P06823837A0562 IN O
right P06823837A0562 JJ O
ventricular P06823837A0562 JJ O
wavefronts P06823837A0562 NNS O
ending P06823837A0562 VBG O
along P06823837A0562 IN O
the P06823837A0562 DT O
right P06823837A0562 JJ O
ventricular P06823837A0562 NN O
anterior P06823837A0562 RB O
atrioventricular P06823837A0562 JJ O
groove P06823837A0562 NN O
and P06823837A0562 CC O
outflow P06823837A0562 JJ O
tract P06823837A0562 NN O
. P06823837A0562 . O
. . O O

The P02783181A0000 DT O
cytoprotective P02783181A0000 NN O
and P02783181A0000 CC O
antiulcer P02783181A0000 NN O
activities P02783181A0000 NNS O
of P02783181A0000 IN O
the P02783181A0000 DT O
antacid P02783181A0000 NN O
magaldrate P02783181A0000 NN O
( P02783181A0000 ( O
ES P02783181A0000 NNP O
Riopan P02783181A0000 NNP O
) P02783181A0000 ) O
as P02783181A0000 RB O
well P02783181A0000 RB O
as P02783181A0000 IN O
its P02783181A0000 PRP$ O
effects P02783181A0000 NNS O
on P02783181A0000 IN O
gastric P02783181A0000 JJ O
mucosal P02783181A0000 NN O
blood P02783181A0000 NN O
flow P02783181A0000 NN O
and P02783181A0000 CC O
mucus P02783181A0000 NN O
secretions P02783181A0000 NNS O
, P02783181A0000 , O
were P02783181A0000 VBD O
determined P02783181A0000 VBN O
in P02783181A0000 IN O
the P02783181A0000 DT O
rat P02783181A0000 NN O
. P02783181A0000 . O
. . O O

As P10767560A0105 IN O
an P10767560A0105 DT O
extension P10767560A0105 NN O
of P10767560A0105 IN O
our P10767560A0105 PRP$ O
structural P10767560A0105 JJ O
characterization P10767560A0105 NN O
of P10767560A0105 IN O
the P10767560A0105 DT O
exon-intron P10767560A0105 JJ O
organization P10767560A0105 NN O
of P10767560A0105 IN O
the P10767560A0105 DT O
mouse P10767560A0105 NN I-UN
Pkr P10767560A0105 NNP I-UN
gene P10767560A0105 NN I-UN
, P10767560A0105 , O
we P10767560A0105 PRP O
now P10767560A0105 RB O
have P10767560A0105 VBP O
isolated P10767560A0105 VBN O
and P10767560A0105 CC O
characterized P10767560A0105 VBN O
the P10767560A0105 DT O
mouse P10767560A0105 NN I-UN
Pkr P10767560A0105 NNP I-UN
promoter P10767560A0105 NN I-UN
region P10767560A0105 NN I-UN
required P10767560A0105 VBN O
for P10767560A0105 IN O
IFN-inducible P10767560A0105 JJ O
transcription P10767560A0105 NN O
. P10767560A0105 . O
. . O O

State P00987649T0001 NN O
of P00987649T0001 IN O
the P00987649T0001 DT O
body P00987649T0001 NN O
in P00987649T0001 IN O
disorders P00987649T0001 NNS O
of P00987649T0001 IN O
diurnal P00987649T0001 JJ O
physiological P00987649T0001 JJ O
rhythms P00987649T0001 NN O
and P00987649T0001 CC O
long-term P00987649T0001 JJ O
hypokinesia P00987649T0001 NN O
. P00987649T0001 . O
. . O O

Commercially P02402678A0463 RB O
available P02402678A0463 JJ O
formulations P02402678A0463 NNS O
of P02402678A0463 IN O
2.5 P02402678A0463 CD O
% P02402678A0463 NN O
and P02402678A0463 CC O
5 P02402678A0463 CD O
% P02402678A0463 NN O
lambdacyhalothrin P02402678A0463 NN O
can P02402678A0463 MD O
be P02402678A0463 VB O
diluted P02402678A0463 VBN O
either P02402678A0463 DT O
with P02402678A0463 IN O
water P02402678A0463 NN O
for P02402678A0463 IN O
ULV P02402678A0463 NNP O
cold P02402678A0463 JJ O
aerosol P02402678A0463 NN O
space-spraying P02402678A0463 NN O
or P02402678A0463 CC O
with P02402678A0463 IN O
diesel P02402678A0463 JJ O
/ P02402678A0463 NNP O
kerosene P02402678A0463 NN O
for P02402678A0463 IN O
thermal P02402678A0463 JJ O
fogging P02402678A0463 NN O
at P02402678A0463 IN O
recommended P02402678A0463 JJ O
application P02402678A0463 NN O
rates P02402678A0463 NNS O
of P02402678A0463 IN O
0.5-1 P02402678A0463 JJ O
g P02402678A0463 NN O
ai P02402678A0463 NN O
/ P02402678A0463 NNP O
ha P02402678A0463 NN O
for P02402678A0463 IN O
mosquito P02402678A0463 NN O
control P02402678A0463 NN O
and P02402678A0463 CC O
2 P02402678A0463 CD O
g P02402678A0463 NN O
ai P02402678A0463 NN O
/ P02402678A0463 NNP O
ha P02402678A0463 NN O
for P02402678A0463 IN O
housefly P02402678A0463 NN O
control P02402678A0463 NN O
. P02402678A0463 . O
. . O O

Element P10650958A1315 NN O
B P10650958A1315 NNP O
( P10650958A1315 ( O
-249 P10650958A1315 NNP O
/ P10650958A1315 NNP O
-229 P10650958A1315 NNP O
) P10650958A1315 ) O
shows P10650958A1315 VBZ O
more P10650958A1315 JJR O
than P10650958A1315 IN O
80 P10650958A1315 CD O
% P10650958A1315 NN O
homology P10650958A1315 NN O
to P10650958A1315 TO O
a P10650958A1315 DT O
consensus P10650958A1315 NN I-UN
c-myb P10650958A1315 JJ I-UN
element P10650958A1315 NN I-UN
, P10650958A1315 , O
but P10650958A1315 CC O
formed P10650958A1315 VBD O
two P10650958A1315 CD O
specific P10650958A1315 JJ O
complexes P10650958A1315 NNS O
that P10650958A1315 WDT O
differed P10650958A1315 VBD O
from P10650958A1315 IN O
that P10650958A1315 DT O
of P10650958A1315 IN O
c-myb P10650958A1315 NN I-UN
in P10650958A1315 IN O
the P10650958A1315 DT O
electrophoretic P10650958A1315 JJ O
mobility P10650958A1315 NN O
shift P10650958A1315 NN O
assay P10650958A1315 NN O
. P10650958A1315 . O
. . O O

Interspecific P09988767A1496 NNP O
mouse P09988767A1496 RBS O
back-cross P09988767A1496 JJ O
analysis P09988767A1496 NN O
identified P09988767A1496 VBD O
the P09988767A1496 DT O
loci P09988767A1496 NN O
for P09988767A1496 IN O
mouse P09988767A1496 NN I-UN
3Ost P09988767A1496 CD I-UN
genes P09988767A1496 NNS I-UN
and P09988767A1496 CC O
syntenic P09988767A1496 JJ O
assignments P09988767A1496 NNS O
of P09988767A1496 IN O
corresponding P09988767A1496 VBG O
human P09988767A1496 JJ O
isologs P09988767A1496 NNS O
were P09988767A1496 VBD O
confirmed P09988767A1496 VBN O
by P09988767A1496 IN O
the P09988767A1496 DT O
identification P09988767A1496 NN O
of P09988767A1496 IN O
mapped P09988767A1496 JJ O
sequence-tagged P09988767A1496 JJ O
site P09988767A1496 NN O
markers P09988767A1496 NNS O
. P09988767A1496 . O
. . O O

In P08887674A0920 IN O
both P08887674A0920 DT O
settings P08887674A0920 NNS O
, P08887674A0920 , O
it P08887674A0920 PRP O
can P08887674A0920 MD O
be P08887674A0920 VB O
phosphorylated P08887674A0920 VBN O
by P08887674A0920 IN O
cyclin P08887674A0920 JJ I-UN
D-dependent P08887674A0920 JJ I-UN
kinases P08887674A0920 NNS I-UN
, P08887674A0920 , O
suggesting P08887674A0920 VBG O
that P08887674A0920 IN O
its P08887674A0920 PRP$ O
transcriptional P08887674A0920 JJ O
activity P08887674A0920 NN O
may P08887674A0920 MD O
normally P08887674A0920 RB O
be P08887674A0920 VB O
regulated P08887674A0920 VBN O
through P08887674A0920 IN O
such P08887674A0920 JJ O
mechanisms P08887674A0920 NNS O
. P08887674A0920 . O
. . O O

There P04085589A0264b EX O
was P04085589A0264b VBD O
no P04085589A0264b DT O
correlation P04085589A0264b NN O
between P04085589A0264b IN O
secretor P04085589A0264b NN O
status P04085589A0264b NN O
and P04085589A0264b CC O
clinical P04085589A0264b JJ O
status P04085589A0264b NN O
, P04085589A0264b , O
spirometry P04085589A0264b NN O
measurements P04085589A0264b NNS O
, P04085589A0264b , O
salivary P04085589A0264b JJ O
and P04085589A0264b CC O
serum P04085589A0264b JJ I-UN
lysozyme P04085589A0264b NN I-UN
levels P04085589A0264b NNS O
or P04085589A0264b CC O
rates P04085589A0264b NNS O
of P04085589A0264b IN O
respiratory P04085589A0264b JJ O
tract P04085589A0264b JJ O
colonization P04085589A0264b NN O
with P04085589A0264b IN O
P. P04085589A0264b NNP O
aeruginosa P04085589A0264b NN O
and P04085589A0264b CC O
S. P04085589A0264b NNP O
aureus P04085589A0264b NN O
. P04085589A0264b . O
. . O O

The P09892422A1096 DT O
perifascicular P09892422A1096 JJ O
connective P09892422A1096 JJ O
tissue P09892422A1096 NN O
sheath P09892422A1096 NN O
is P09892422A1096 VBZ O
important P09892422A1096 JJ O
in P09892422A1096 IN O
organising P09892422A1096 VBG O
the P09892422A1096 DT O
contraction P09892422A1096 NN O
of P09892422A1096 IN O
the P09892422A1096 DT O
myocardium P09892422A1096 NN O
by P09892422A1096 IN O
preventing P09892422A1096 VBG O
lateral P09892422A1096 JJ O
spread P09892422A1096 NN O
of P09892422A1096 IN O
conduction P09892422A1096 NN O
and P09892422A1096 CC O
by P09892422A1096 IN O
permitting P09892422A1096 VBG O
transmission P09892422A1096 NN O
of P09892422A1096 IN O
the P09892422A1096 DT O
impulse P09892422A1096 JJ O
only P09892422A1096 RB O
at P09892422A1096 IN O
the P09892422A1096 DT O
termination P09892422A1096 NN O
of P09892422A1096 IN O
the P09892422A1096 DT O
purkinje P09892422A1096 NN O
fibre P09892422A1096 NN O
. P09892422A1096 . O
. . O O

Atherosclerosis P01178637T0001 NN O
. P01178637T0001 . O
. . O O

Equine P01928923A0000 NNP O
amnion P01928923A0000 NN O
and P01928923A0000 CC O
live P01928923A0000 JJ O
yeast P01928923A0000 NN O
cell P01928923A0000 NN O
derivative P01928923A0000 JJ O
were P01928923A0000 VBD O
evaluated P01928923A0000 VBN O
as P01928923A0000 IN O
a P01928923A0000 DT O
biological P01928923A0000 JJ O
dressing P01928923A0000 NN O
and P01928923A0000 CC O
as P01928923A0000 IN O
a P01928923A0000 DT O
topical P01928923A0000 JJ O
wound P01928923A0000 NN O
medicament P01928923A0000 NN O
respectively P01928923A0000 RB O
, P01928923A0000 , O
in P01928923A0000 IN O
the P01928923A0000 DT O
treatment P01928923A0000 NN O
of P01928923A0000 IN O
granulating P01928923A0000 VBG O
wounds P01928923A0000 NNS O
of P01928923A0000 IN O
the P01928923A0000 DT O
distal P01928923A0000 JJ O
portion P01928923A0000 NN O
of P01928923A0000 IN O
the P01928923A0000 DT O
limbs P01928923A0000 NNS O
of P01928923A0000 IN O
horses P01928923A0000 NNS O
. P01928923A0000 . O
. . O O

Absence P04371279T0000 NN O
of P04371279T0000 IN O
action P04371279T0000 NN O
potentials P04371279T0000 NNS O
in P04371279T0000 IN O
frog P04371279T0000 JJ O
slow P04371279T0000 JJ O
muscle P04371279T0000 NN O
fibres P04371279T0000 NNS O
paralysed P04371279T0000 VBN O
by P04371279T0000 IN O
botulinum P04371279T0000 NN I-UN
toxin P04371279T0000 NN I-UN
. P04371279T0000 . O
. . O O

Based P07622521A0418 VBN O
on P07622521A0418 IN O
previous P07622521A0418 JJ O
mapping P07622521A0418 NN O
of P07622521A0418 IN O
the P07622521A0418 DT O
G P07622521A0418 NNP I-UN
beta P07622521A0418 NN I-UN
gamma P07622521A0418 NN I-UN
binding P07622521A0418 VBG I-UN
region P07622521A0418 NN I-UN
of P07622521A0418 IN O
beta P07622521A0418 NN I-UN
ARK P07622521A0418 NNP I-UN
, P07622521A0418 , O
and P07622521A0418 CC O
conserved P07622521A0418 VBD O
residues P07622521A0418 NNS O
within P07622521A0418 IN O
the P07622521A0418 DT O
PH P07622521A0418 NNP I-UN
domain P07622521A0418 NN I-UN
, P07622521A0418 , O
we P07622521A0418 PRP O
have P07622521A0418 VBP O
constructed P07622521A0418 VBN O
a P07622521A0418 DT O
series P07622521A0418 NN O
of P07622521A0418 IN O
mutants P07622521A0418 NNS O
in P07622521A0418 IN O
the P07622521A0418 DT O
carboxyl P07622521A0418 JJ O
terminus P07622521A0418 NN O
of P07622521A0418 IN O
beta P07622521A0418 NN I-UN
ARK P07622521A0418 NNP I-UN
in P07622521A0418 IN O
order P07622521A0418 NN O
to P07622521A0418 TO O
determine P07622521A0418 VB O
important P07622521A0418 JJ O
residues P07622521A0418 NNS O
involved P07622521A0418 VBN O
in P07622521A0418 IN O
G P07622521A0418 NNP I-UN
beta P07622521A0418 NN I-UN
gamma P07622521A0418 NN I-UN
and P07622521A0418 CC O
PIP2 P07622521A0418 NNP O
binding P07622521A0418 NN O
. P07622521A0418 . O
. . O O

The P09341158A0167 DT O
medium P09341158A0167 NN O
chains P09341158A0167 NNS O
of P09341158A0167 IN O
these P09341158A0167 DT O
complexes P09341158A0167 NNS O
, P09341158A0167 , O
mu1 P09341158A0167 NN I-UN
and P09341158A0167 CC O
mu2 P09341158A0167 NN I-UN
, P09341158A0167 , O
have P09341158A0167 VBP O
been P09341158A0167 VBN O
implicated P09341158A0167 VBN O
in P09341158A0167 IN O
two P09341158A0167 CD O
types P09341158A0167 NNS O
of P09341158A0167 IN O
interaction P09341158A0167 NN O
: P09341158A0167 : O
assembly P09341158A0167 NN O
with P09341158A0167 IN O
the P09341158A0167 DT O
beta1 P09341158A0167 NN I-UN
and P09341158A0167 CC I-UN
beta2 P09341158A0167 NN I-UN
chains P09341158A0167 NNS I-UN
of P09341158A0167 IN O
the P09341158A0167 DT O
corresponding P09341158A0167 NN O
complexes P09341158A0167 NNS O
and P09341158A0167 CC O
recognition P09341158A0167 NN O
of P09341158A0167 IN O
tyrosine-based P09341158A0167 JJ O
sorting P09341158A0167 NN O
signals P09341158A0167 NNS O
. P09341158A0167 . O
. . O O

The P09036529A0343 DT O
workup P09036529A0343 NN O
included P09036529A0343 VBD O
skin P09036529A0343 JJ O
tests P09036529A0343 NNS O
( P09036529A0343 ( O
up P09036529A0343 IN O
to P09036529A0343 TO O
1 P09036529A0343 CD O
microgram P09036529A0343 NNS O
/ P09036529A0343 JJ O
ml P09036529A0343 NN O
, P09036529A0343 , O
Pharmacia P09036529A0343 NNP O
) P09036529A0343 ) O
, P09036529A0343 , O
measurement P09036529A0343 NN O
of P09036529A0343 IN O
specific P09036529A0343 JJ O
serum P09036529A0343 NN O
IgE P09036529A0343 NNP I-UN
with P09036529A0343 IN O
RAST-CAP P09036529A0343 NNP O
( P09036529A0343 ( O
Pharmacia P09036529A0343 NNP O
) P09036529A0343 ) O
, P09036529A0343 , O
and P09036529A0343 CC O
CAST P09036529A0343 NNP O
with P09036529A0343 IN O
three P09036529A0343 CD O
concentrations P09036529A0343 NNS O
of P09036529A0343 IN O
bee P09036529A0343 NN O
( P09036529A0343 ( O
Apis P09036529A0343 NNP O
mellifera P09036529A0343 NN O
) P09036529A0343 ) O
and P09036529A0343 CC O
wasp P09036529A0343 $ O
( P09036529A0343 ( O
Vespula P09036529A0343 NNP O
spec P09036529A0343 RB O
. P09036529A0343 . O
) P09036529A0343 ) O
venom P09036529A0343 NN O
( P09036529A0343 ( O
Aquagen P09036529A0343 NNP O
ALK P09036529A0343 NNP O
) P09036529A0343 ) O
. P09036529A0343 . O
. . O O

RESULTS P10976413A0514 NN O
: P10976413A0514 : O
Neither P10976413A0514 CC O
basal P10976413A0514 JJ O
FSH P10976413A0514 NNP I-UN
level P10976413A0514 NN O
nor P10976413A0514 CC O
stimulated P10976413A0514 JJ O
FSH P10976413A0514 NNP I-UN
level P10976413A0514 NN O
alone P10976413A0514 RB O
were P10976413A0514 VBD O
statistically P10976413A0514 RB O
significant P10976413A0514 JJ O
predictors P10976413A0514 NNS O
of P10976413A0514 IN O
IVF P10976413A0514 NNP O
success P10976413A0514 NN O
; P10976413A0514 : O
however P10976413A0514 RB O
, P10976413A0514 , O
no P10976413A0514 DT O
patient P10976413A0514 NN O
with P10976413A0514 IN O
a P10976413A0514 DT O
day P10976413A0514 NN O
3 P10976413A0514 CD O
FSH P10976413A0514 NNP I-UN
level P10976413A0514 NN O
> P10976413A0514 VBD O
11.1 P10976413A0514 CD O
mIU P10976413A0514 NN O
/ P10976413A0514 NNP O
ml P10976413A0514 NN O
or P10976413A0514 CC O
a P10976413A0514 DT O
stimulated P10976413A0514 JJ O
day P10976413A0514 NN O
10 P10976413A0514 CD O
FSH P10976413A0514 NNP I-UN
level P10976413A0514 NN O
> P10976413A0514 VBD O
13.5 P10976413A0514 CD O
mIU P10976413A0514 NN O
/ P10976413A0514 NNP O
ml P10976413A0514 NN O
conceived P10976413A0514 VBD O
and P10976413A0514 CC O
carried P10976413A0514 VBD O
a P10976413A0514 DT O
pregnancy P10976413A0514 NN O
. P10976413A0514 . O
. . O O

Comparative P05322747T0034 NNP O
study P05322747T0034 NN O
on P05322747T0034 IN O
acute P05322747T0034 JJ O
oral P05322747T0034 JJ O
overload P05322747T0034 NN O
using P05322747T0034 VBG O
tolbutamide P05322747T0034 NN O
and P05322747T0034 CC O
tolazamide P05322747T0034 NN O
in P05322747T0034 IN O
normal P05322747T0034 JJ O
and P05322747T0034 CC O
diabetic P05322747T0034 JJ O
subjects P05322747T0034 NNS O
. P05322747T0034 . O
. . O O

Polymerization P08621664A1430 NN O
of P08621664A1430 IN O
neurofilament P08621664A1430 JJ I-UN
L P08621664A1430 NNP I-UN
protein P08621664A1430 NN I-UN
in P08621664A1430 IN O
vitro P08621664A1430 NN O
was P08621664A1430 VBD O
inhibited P08621664A1430 VBN O
by P08621664A1430 IN O
phosphorylation P08621664A1430 NN O
of P08621664A1430 IN O
neurofilament P08621664A1430 JJ I-UN
L P08621664A1430 NNP I-UN
protein P08621664A1430 NN I-UN
by P08621664A1430 IN O
PKN P08621664A1430 NNP I-UN
. P08621664A1430 . O
. . O O

Serum P00984209A0614 NNP O
gastrin P00984209A0614 NN I-UN
levels P00984209A0614 NNS O
did P00984209A0614 VBD O
not P00984209A0614 RB O
change P00984209A0614 VB O
in P00984209A0614 IN O
either P00984209A0614 DT O
group P00984209A0614 NN O
; P00984209A0614 : O
however P00984209A0614 RB O
, P00984209A0614 , O
background P00984209A0614 IN O
serum P00984209A0614 JJ O
gastrin P00984209A0614 JJ I-UN
concentrations P00984209A0614 NNS O
were P00984209A0614 VBD O
significantly P00984209A0614 RB O
greater P00984209A0614 JJR O
for P00984209A0614 IN O
V P00984209A0614 NNP O
& P00984209A0614 CC O
P P00984209A0614 NNP O
patients P00984209A0614 NNS O
than P00984209A0614 IN O
V P00984209A0614 NNP O
& P00984209A0614 CC O
A P00984209A0614 NNP O
patients P00984209A0614 NNS O
throughout P00984209A0614 IN O
the P00984209A0614 DT O
study P00984209A0614 NN O
. P00984209A0614 . O
. . O O

It P01389585A0825 PRP O
was P01389585A0825 VBD O
concluded P01389585A0825 VBN O
that P01389585A0825 IN O
Scotchbond P01389585A0825 NNP O
2 P01389585A0825 CD O
and P01389585A0825 CC O
Prisma P01389585A0825 NNP O
Universal P01389585A0825 NNP O
Bond P01389585A0825 NNP O
2 P01389585A0825 CD O
are P01389585A0825 VBP O
effective P01389585A0825 JJ O
and P01389585A0825 CC O
are P01389585A0825 VBP O
the P01389585A0825 DT O
dentine P01389585A0825 JJ O
bonding P01389585A0825 NN O
agents P01389585A0825 NNS O
of P01389585A0825 IN O
choice P01389585A0825 NN O
. P01389585A0825 . O
. . O O

A P08649393A0000 DT O
chromosome P08649393A0000 NN I-UN
transmission P08649393A0000 NN I-UN
fidelity P08649393A0000 NN I-UN
( P08649393A0000 ( O
ctf P08649393A0000 NN I-UN
) P08649393A0000 ) O
mutant P08649393A0000 NN O
, P08649393A0000 , O
s138 P08649393A0000 NN O
, P08649393A0000 , O
of P08649393A0000 IN O
Saccharomyces P08649393A0000 NNP O
cerevisiae P08649393A0000 NN O
was P08649393A0000 VBD O
identified P08649393A0000 VBN O
by P08649393A0000 IN O
its P08649393A0000 PRP$ O
centromere P08649393A0000 NN O
( P08649393A0000 ( O
CEN P08649393A0000 NNP O
) P08649393A0000 ) O
transcriptional P08649393A0000 JJ O
readthrough P08649393A0000 NN O
phenotype P08649393A0000 NN O
, P08649393A0000 , O
suggesting P08649393A0000 VBG O
perturbed P08649393A0000 VBN O
kinetochore P08649393A0000 JJ O
integrity P08649393A0000 NN O
in P08649393A0000 IN O
vivo P08649393A0000 NN O
. P08649393A0000 . O
. . O O

However P06524761A0596 RB O
, P06524761A0596 , O
there P06524761A0596 EX O
was P06524761A0596 VBD O
a P06524761A0596 DT O
difference P06524761A0596 NN O
in P06524761A0596 IN O
the P06524761A0596 DT O
quality P06524761A0596 NN O
of P06524761A0596 IN O
immunity P06524761A0596 NN O
: P06524761A0596 : O
fever P06524761A0596 NN O
and P06524761A0596 CC O
body P06524761A0596 NN O
weight P06524761A0596 JJ O
loss P06524761A0596 NN O
were P06524761A0596 VBD O
seen P06524761A0596 VBN O
in P06524761A0596 IN O
hamsters P06524761A0596 NNS O
vaccinated P06524761A0596 VBN O
with P06524761A0596 IN O
the P06524761A0596 DT O
killed-toxoplasma P06524761A0596 JJ O
vaccine P06524761A0596 NN O
after P06524761A0596 IN O
they P06524761A0596 PRP O
were P06524761A0596 VBD O
challenge P06524761A0596 NNS O
exposed P06524761A0596 VBN O
with P06524761A0596 IN O
T-1 P06524761A0596 NNP O
strain P06524761A0596 NN O
, P06524761A0596 , O
whereas P06524761A0596 IN O
these P06524761A0596 DT O
changes P06524761A0596 NNS O
were P06524761A0596 VBD O
rarely P06524761A0596 RB O
seen P06524761A0596 VBN O
in P06524761A0596 IN O
hamsters P06524761A0596 NNS O
given P06524761A0596 VBN O
the P06524761A0596 DT O
live-toxoplasma P06524761A0596 JJ O
vaccine P06524761A0596 NN O
and P06524761A0596 CC O
then P06524761A0596 RB O
challenge P06524761A0596 VB O
exposed P06524761A0596 VBN O
with P06524761A0596 IN O
RH P06524761A0596 NNP O
strain P06524761A0596 NN O
. P06524761A0596 . O
. . O O

Multiple P08649373T0000 JJ O
single-stranded P08649373T0000 JJ O
cis P08649373T0000 NN O
elements P08649373T0000 NNS O
are P08649373T0000 VBP O
associated P08649373T0000 VBN O
with P08649373T0000 IN O
activated P08649373T0000 JJ O
chromatin P08649373T0000 NN O
of P08649373T0000 IN O
the P08649373T0000 DT O
human P08649373T0000 JJ I-UN
c-myc P08649373T0000 JJ I-UN
gene P08649373T0000 NN I-UN
in P08649373T0000 IN O
vivo P08649373T0000 NN O
. P08649373T0000 . O
. . O O

Both P08621661A1035 DT O
P5CDh P08621661A1035 NNP I-UN
cDNA P08621661A1035 NN I-UN
clones P08621661A1035 NNS O
detect P08621661A1035 VBP O
a P08621661A1035 DT O
single P08621661A1035 JJ O
3.2-kb P08621661A1035 JJ O
transcript P08621661A1035 NN O
on P08621661A1035 IN O
Northern P08621661A1035 NNP O
blots P08621661A1035 NNS O
of P08621661A1035 IN O
multiple P08621661A1035 JJ O
human P08621661A1035 JJ O
tissues P08621661A1035 NNS O
, P08621661A1035 , O
indicating P08621661A1035 VBG O
the P08621661A1035 DT O
long P08621661A1035 JJ O
cDNA P08621661A1035 NN O
containing P08621661A1035 VBG O
the P08621661A1035 DT O
3'-untranslated P08621661A1035 JJ O
intron P08621661A1035 NN O
represents P08621661A1035 VBZ O
the P08621661A1035 DT O
predominant P08621661A1035 JJ O
transcript P08621661A1035 NN O
. P08621661A1035 . O
. . O O

The P08055939A0707 DT O
location P08055939A0707 NN O
and P08055939A0707 CC O
approximate P08055939A0707 JJ O
length P08055939A0707 NN O
of P08055939A0707 IN O
the P08055939A0707 DT O
intron P08055939A0707 NN O
are P08055939A0707 VBP O
conserved P08055939A0707 VBN O
in P08055939A0707 IN O
both P08055939A0707 DT O
the P08055939A0707 DT O
tomato P08055939A0707 NN O
and P08055939A0707 CC O
Arabidopsis P08055939A0707 NNP O
genes P08055939A0707 NNS O
, P08055939A0707 , O
with P08055939A0707 IN O
the P08055939A0707 DT O
intron P08055939A0707 NN O
separating P08055939A0707 VBG O
the P08055939A0707 DT O
'nose P08055939A0707 NNP O
' P08055939A0707 POS O
region P08055939A0707 NN O
( P08055939A0707 ( O
encoded P08055939A0707 VBN O
by P08055939A0707 IN O
exon P08055939A0707 $ O
1 P08055939A0707 CD O
) P08055939A0707 ) O
from P08055939A0707 IN O
the P08055939A0707 DT O
central P08055939A0707 JJ O
globular P08055939A0707 NN O
domain P08055939A0707 NN O
( P08055939A0707 ( O
exon P08055939A0707 JJ O
2 P08055939A0707 CD O
) P08055939A0707 ) O
. P08055939A0707 . O
. . O O

We P08614403A0557 PRP O
observed P08614403A0557 VBD O
abundant P08614403A0557 JJ O
levels P08614403A0557 NNS O
of P08614403A0557 IN O
Rev-erbA P08614403A0557 NNP O
alpha P08614403A0557 NN I-UN
mRNA P08614403A0557 NN O
in P08614403A0557 IN O
dividing P08614403A0557 VBG O
C2C12 P08614403A0557 NNP O
myoblasts P08614403A0557 NNS O
, P08614403A0557 , O
which P08614403A0557 WDT O
were P08614403A0557 VBD O
suppressed P08614403A0557 VBN O
when P08614403A0557 WRB O
the P08614403A0557 DT O
cells P08614403A0557 NNS O
differentiated P08614403A0557 VBN O
into P08614403A0557 IN O
postmitotic P08614403A0557 JJ O
multinucleated P08614403A0557 VBN O
myotubes P08614403A0557 NNS O
. P08614403A0557 . O
. . O O

These P10752475A1376 DT O
studies P10752475A1376 NNS O
identify P10752475A1376 VBP O
several P10752475A1376 JJ O
of P10752475A1376 IN O
the P10752475A1376 DT O
signal-transduction P10752475A1376 JJ O
events P10752475A1376 NNS O
involved P10752475A1376 VBN O
in P10752475A1376 IN O
the P10752475A1376 DT O
apoptosis P10752475A1376 NN O
of P10752475A1376 IN O
malignant P10752475A1376 JJ O
B P10752475A1376 NNP O
cells P10752475A1376 NNS O
that P10752475A1376 WDT O
transpire P10752475A1376 VBP O
following P10752475A1376 VBG O
ligation P10752475A1376 NN O
of P10752475A1376 IN O
CD20 P10752475A1376 NNP I-UN
by P10752475A1376 IN O
anti-CD20 P10752475A1376 JJ I-UN
antibodies P10752475A1376 NNS I-UN
in P10752475A1376 IN O
the P10752475A1376 DT O
presence P10752475A1376 NN O
of P10752475A1376 IN O
Fc-receptor-expressing P10752475A1376 NNP O
cells P10752475A1376 NNS O
or P10752475A1376 CC O
secondary P10752475A1376 JJ O
goat P10752475A1376 NN O
anti- P10752475A1376 NN I-UN
( P10752475A1376 ( I-UN
mouse P10752475A1376 IN I-UN
Ig P10752475A1376 NNP I-UN
) P10752475A1376 ) I-UN
antibodies P10752475A1376 NNS I-UN
and P10752475A1376 CC O
which P10752475A1376 WDT O
may P10752475A1376 MD O
contribute P10752475A1376 VB O
to P10752475A1376 TO O
the P10752475A1376 DT O
tumor P10752475A1376 NN O
regressions P10752475A1376 NNS O
observed P10752475A1376 VBD O
in P10752475A1376 IN O
mouse P10752475A1376 NN O
models P10752475A1376 NNS O
and P10752475A1376 CC O
clinical P10752475A1376 JJ O
trials P10752475A1376 NNS O
. P10752475A1376 . O
. . O O

All P03024343A0372 DT O
tumors P03024343A0372 NNS O
proved P03024343A0372 VBD O
histologically P03024343A0372 RB O
to P03024343A0372 TO O
be P03024343A0372 VB O
neuroendocrine P03024343A0372 JJ O
in P03024343A0372 IN O
origin P03024343A0372 NN O
. P03024343A0372 . O
. . O O

Dopamine P02349998A0297 NNP O
SERS P02349998A0297 NNP O
spectra P02349998A0297 VBP O
from P02349998A0297 IN O
these P02349998A0297 DT O
electrodes P02349998A0297 NNS O
are P02349998A0297 VBP O
similar P02349998A0297 JJ O
to P02349998A0297 TO O
those P02349998A0297 DT O
obtained P02349998A0297 VBN O
at P02349998A0297 IN O
uncoated P02349998A0297 JJ O
electrodes P02349998A0297 NNS O
. P02349998A0297 . O
. . O O

While P10342536A0954 IN O
determination P10342536A0954 NN O
of P10342536A0954 IN O
the P10342536A0954 DT O
protein P10342536A0954 NN O
content P10342536A0954 NN O
of P10342536A0954 IN O
the P10342536A0954 DT O
formulae P10342536A0954 NN O
gave P10342536A0954 VBD O
no P10342536A0954 DT O
valid P10342536A0954 JJ O
information P10342536A0954 NN O
, P10342536A0954 , O
RAST P10342536A0954 NNP O
/ P10342536A0954 NNP O
EAST P10342536A0954 NNP O
inhibition P10342536A0954 NN O
was P10342536A0954 VBD O
highest P10342536A0954 JJS O
for P10342536A0954 IN O
cow P10342536A0954 NN O
's P10342536A0954 POS O
milk P10342536A0954 NN O
, P10342536A0954 , O
followed P10342536A0954 VBN O
by P10342536A0954 IN O
the P10342536A0954 DT O
partially P10342536A0954 RB O
hydrolysed P10342536A0954 VBN O
whey P10342536A0954 NN O
formula P10342536A0954 NN O
, P10342536A0954 , O
partially P10342536A0954 RB O
hydrolysed P10342536A0954 VBD O
whey P10342536A0954 JJ O
/ P10342536A0954 NNP O
casein P10342536A0954 NN I-UN
formula P10342536A0954 NN O
, P10342536A0954 , O
soy P10342536A0954 NN I-UN
/ P10342536A0954 NNP I-UN
pork P10342536A0954 NN I-UN
collagen P10342536A0954 NN I-UN
formula P10342536A0954 NN O
, P10342536A0954 , O
and P10342536A0954 CC O
the P10342536A0954 DT O
amino P10342536A0954 NN O
acid P10342536A0954 JJ O
formula P10342536A0954 NN O
. P10342536A0954 . O
. . O O

Beta-endorphin P02557217A0000 NNP I-UN
, P02557217A0000 , O
ACTH P02557217A0000 NNP I-UN
and P02557217A0000 CC O
cortisol P02557217A0000 JJ O
secretion P02557217A0000 NN O
were P02557217A0000 VBD O
measured P02557217A0000 VBN O
in P02557217A0000 IN O
twelve P02557217A0000 NN O
healthy P02557217A0000 JJ O
adult P02557217A0000 NN O
males P02557217A0000 NNS O
after P02557217A0000 IN O
nasal P02557217A0000 JJ O
spray P02557217A0000 JJ O
administration P02557217A0000 NN O
200 P02557217A0000 CD O
IU P02557217A0000 NNP O
salmon P02557217A0000 NN I-UN
calcitonin P02557217A0000 NN I-UN
. P02557217A0000 . O
. . O O

The P08847138A0609 DT O
detection P08847138A0609 NN O
ratio P08847138A0609 NN O
peaked P08847138A0609 VBD O
at P08847138A0609 IN O
ages P08847138A0609 NNS O
30 P08847138A0609 CD O
to P08847138A0609 TO O
34 P08847138A0609 CD O
and P08847138A0609 CC O
decreased P08847138A0609 VBD O
heavily P08847138A0609 RB O
during P08847138A0609 IN O
the P08847138A0609 DT O
next P08847138A0609 JJ O
15 P08847138A0609 CD O
years P08847138A0609 NNS O
of P08847138A0609 IN O
age P08847138A0609 NN O
. P08847138A0609 . O
. . O O

Stress-inducible P10212278A0387 JJ I-UN
protein P10212278A0387 NN I-UN
kinases P10212278A0387 VBZ I-UN
capable P10212278A0387 JJ O
of P10212278A0387 IN O
activating P10212278A0387 VBG O
c-jun P10212278A0387 JJ I-UN
expression P10212278A0387 NN O
include P10212278A0387 VBP O
stress-activated P10212278A0387 JJ I-UN
protein P10212278A0387 JJ I-UN
kinase P10212278A0387 NN I-UN
/ P10212278A0387 JJ O
c-Jun P10212278A0387 JJ I-UN
N-terminal P10212278A0387 JJ I-UN
protein P10212278A0387 NN I-UN
kinase P10212278A0387 NN I-UN
( P10212278A0387 ( O
SAPK P10212278A0387 NNP I-UN
/ P10212278A0387 NNP O
JNK P10212278A0387 NNP I-UN
) P10212278A0387 ) O
and P10212278A0387 CC O
p38 P10212278A0387 JJ I-UN
members P10212278A0387 NNS O
of P10212278A0387 IN O
the P10212278A0387 DT O
mitogen-activated P10212278A0387 JJ I-UN
protein P10212278A0387 NN I-UN
kinase P10212278A0387 NN I-UN
( P10212278A0387 ( O
MAPK P10212278A0387 NNP I-UN
) P10212278A0387 ) O
superfamily P10212278A0387 RB O
of P10212278A0387 IN O
signaling P10212278A0387 VBG O
molecules P10212278A0387 NNS O
. P10212278A0387 . O
. . O O

Examination P11328853A0644 NN O
of P11328853A0644 IN O
various P11328853A0644 JJ O
promoter P11328853A0644 NN O
deletion P11328853A0644 NN O
mutants P11328853A0644 NNS O
indicated P11328853A0644 VBD O
that P11328853A0644 IN O
SF-1 P11328853A0644 JJ I-UN
acts P11328853A0644 NNS O
through P11328853A0644 IN O
the P11328853A0644 DT O
proximal P11328853A0644 JJ O
promoter P11328853A0644 NN O
region P11328853A0644 NN O
and P11328853A0644 CC O
upstream P11328853A0644 JJ O
promoter P11328853A0644 NN O
sequences P11328853A0644 NNS O
. P11328853A0644 . O
. . O O

Trials P05732641T0001 NNS O
of P05732641T0001 IN O
sevine P05732641T0001 JJ O
activity P05732641T0001 NN O
against P05732641T0001 IN O
mosquito P05732641T0001 NN O
larvae P05732641T0001 NN O
. P05732641T0001 . O
. . O O

Mothers P08278423A0147 NNS O
with P08278423A0147 IN O
severe P08278423A0147 JJ O
anatomical P08278423A0147 JJ O
abnormalities P08278423A0147 NNS O
, P08278423A0147 , O
who P08278423A0147 WP O
are P08278423A0147 VBP O
HIV P08278423A0147 NNP O
positive P08278423A0147 JJ O
, P08278423A0147 , O
have P08278423A0147 VBP O
active P08278423A0147 JJ O
TB P08278423A0147 NNP O
or P08278423A0147 CC O
whose P08278423A0147 WP$ O
children P08278423A0147 NNS O
have P08278423A0147 VBP O
inherited P08278423A0147 VBN O
mono- P08278423A0147 NN O
or P08278423A0147 CC O
disaccharide P08278423A0147 NN O
intolerances P08278423A0147 NNS O
should P08278423A0147 MD O
not P08278423A0147 RB O
breastfeed P08278423A0147 VB O
. P08278423A0147 . O
. . O O

To P11268887A1174 TO O
avoid P11268887A1174 VB O
misinterpretations P11268887A1174 NNS O
, P11268887A1174 , O
special P11268887A1174 JJ O
reference P11268887A1174 NN O
values P11268887A1174 NNS O
should P11268887A1174 MD O
be P11268887A1174 VB O
applied P11268887A1174 VBN O
for P11268887A1174 IN O
preadolescents P11268887A1174 NNS O
, P11268887A1174 , O
at P11268887A1174 IN O
least P11268887A1174 JJS O
with P11268887A1174 IN O
regard P11268887A1174 NN O
to P11268887A1174 TO O
FVC P11268887A1174 NNP O
and P11268887A1174 CC O
FEV1 P11268887A1174 NNP O
. P11268887A1174 . O
. . O O

Examination P08470895A1617 NN O
of P08470895A1617 IN O
the P08470895A1617 DT O
immediate P08470895A1617 JJ O
sequence P08470895A1617 NN O
5 P08470895A1617 CD O
' P08470895A1617 '' O
to P08470895A1617 TO O
the P08470895A1617 DT O
mRNA P08470895A1617 JJ O
start P08470895A1617 NN O
site P08470895A1617 NN O
reveals P08470895A1617 VBZ O
no P08470895A1617 DT O
TATA P08470895A1617 NNP O
box P08470895A1617 NN O
and P08470895A1617 CC O
multiple P08470895A1617 JJ O
known P08470895A1617 VBN O
enhancer P08470895A1617 NN O
sequences P08470895A1617 NNS O
. P08470895A1617 . O
. . O O

In P06882578A0464 IN O
the P06882578A0464 DT O
ultramarathon P06882578A0464 JJ O
runner P06882578A0464 NN O
the P06882578A0464 DT O
testosterone P06882578A0464 NN O
levels P06882578A0464 NNS O
sharply P06882578A0464 RB O
rose P06882578A0464 VBD O
at P06882578A0464 IN O
the P06882578A0464 DT O
beginning P06882578A0464 NN O
of P06882578A0464 IN O
the P06882578A0464 DT O
training P06882578A0464 NN O
session P06882578A0464 NN O
( P06882578A0464 ( O
from P06882578A0464 IN O
the P06882578A0464 DT O
7,20 P06882578A0464 CD O
ng P06882578A0464 JJ O
/ P06882578A0464 NNP O
ml P06882578A0464 NN O
to P06882578A0464 TO O
11,50 P06882578A0464 CD O
ng P06882578A0464 NNS O
/ P06882578A0464 JJ O
ml P06882578A0464 NN O
after P06882578A0464 IN O
20 P06882578A0464 CD O
' P06882578A0464 '' O
training P06882578A0464 NN O
) P06882578A0464 ) O
, P06882578A0464 , O
and P06882578A0464 CC O
subsequently P06882578A0464 RB O
decrease P06882578A0464 NN O
after P06882578A0464 IN O
3 P06882578A0464 CD O
hours P06882578A0464 NNS O
( P06882578A0464 ( O
9,20 P06882578A0464 CD O
ng P06882578A0464 RB O
/ P06882578A0464 NNP O
ml P06882578A0464 NN O
) P06882578A0464 ) O
and P06882578A0464 CC O
at P06882578A0464 IN O
the P06882578A0464 DT O
end P06882578A0464 NN O
of P06882578A0464 IN O
the P06882578A0464 DT O
6 P06882578A0464 CD O
hours P06882578A0464 NNS O
training P06882578A0464 VBG O
( P06882578A0464 ( O
4,60 P06882578A0464 CD O
ng P06882578A0464 RB O
/ P06882578A0464 NNP O
ml P06882578A0464 NN O
) P06882578A0464 ) O
. P06882578A0464 . O
. . O O

Oseltamivir P10536125A0093 NNP O
( P10536125A0093 ( O
GS4104 P10536125A0093 NNP O
) P10536125A0093 ) O
, P10536125A0093 , O
which P10536125A0093 WDT O
can P10536125A0093 MD O
be P10536125A0093 VB O
administered P10536125A0093 VBN O
orally P10536125A0093 RB O
, P10536125A0093 , O
is P10536125A0093 VBZ O
the P10536125A0093 DT O
prodrug P10536125A0093 NN O
of P10536125A0093 IN O
GS4071 P10536125A0093 NNP O
, P10536125A0093 , O
a P10536125A0093 DT O
potent P10536125A0093 NN O
and P10536125A0093 CC O
selective P10536125A0093 JJ O
inhibitor P10536125A0093 NN O
of P10536125A0093 IN O
influenzavirus P10536125A0093 NN I-UN
neuraminidases P10536125A0093 NNS I-UN
. P10536125A0093 . O
. . O O

We P02538450A0000 PRP O
have P02538450A0000 VBP O
isolated P02538450A0000 VBN O
cDNA P02538450A0000 NN O
clones P02538450A0000 NNS O
from P02538450A0000 IN O
rat P02538450A0000 NN O
brain P02538450A0000 NN O
and P02538450A0000 CC O
human P02538450A0000 JJ O
liver P02538450A0000 NN O
encoding P02538450A0000 VBG O
a P02538450A0000 DT O
putative P02538450A0000 JJ O
isoform P02538450A0000 NN O
of P02538450A0000 IN O
the P02538450A0000 DT O
Na P02538450A0000 NNP I-UN
, P02538450A0000 , I-UN
K-ATPase P02538450A0000 NNP I-UN
beta P02538450A0000 NN I-UN
subunit P02538450A0000 NN I-UN
. P02538450A0000 . O
. . O O

METHOD P10784367A0133 NN O
: P10784367A0133 : O
The P10784367A0133 DT O
sample P10784367A0133 NN O
of P10784367A0133 IN O
subjects P10784367A0133 NNS O
was P10784367A0133 VBD O
drawn P10784367A0133 VBN O
from P10784367A0133 IN O
the P10784367A0133 DT O
Suffolk P10784367A0133 NNP O
County P10784367A0133 NNP O
Mental P10784367A0133 NNP O
Health P10784367A0133 NNP O
Project P10784367A0133 NNP O
, P10784367A0133 , O
a P10784367A0133 DT O
longitudinal P10784367A0133 JJ O
epidemiologic P10784367A0133 NN O
study P10784367A0133 NN O
of P10784367A0133 IN O
first-hospitalized P10784367A0133 JJ O
subjects P10784367A0133 NNS O
with P10784367A0133 IN O
psychotic P10784367A0133 JJ O
disorders P10784367A0133 NNS O
; P10784367A0133 : O
the P10784367A0133 DT O
present P10784367A0133 JJ O
study P10784367A0133 NN O
focused P10784367A0133 VBD O
on P10784367A0133 IN O
patients P10784367A0133 NNS O
with P10784367A0133 IN O
schizophrenic P10784367A0133 JJ O
disorders P10784367A0133 NNS O
. P10784367A0133 . O
. . O O

Nephrectomy P05692759T0001 NNP O
applied P05692759T0001 VBD O
to P05692759T0001 TO O
cattle P05692759T0001 VB O
. P05692759T0001 . O
. . O O

In P08702845A0000 IN O
order P08702845A0000 NN O
to P08702845A0000 TO O
delineate P08702845A0000 VB O
structural P08702845A0000 JJ O
motifs P08702845A0000 NNS O
regulating P08702845A0000 VBG O
substrate P08702845A0000 JJ O
affinity P08702845A0000 NN O
and P08702845A0000 CC O
recognition P08702845A0000 NN O
for P08702845A0000 IN O
the P08702845A0000 DT O
human P08702845A0000 JJ I-UN
dopamine P08702845A0000 NN I-UN
transporter P08702845A0000 NN I-UN
( P08702845A0000 ( O
DAT P08702845A0000 NNP I-UN
) P08702845A0000 ) O
, P08702845A0000 , O
we P08702845A0000 PRP O
assessed P08702845A0000 VBD O
[ P08702845A0000 $ O
3H P08702845A0000 CD O
] P08702845A0000 NNP O
dopamine P08702845A0000 NN O
uptake P08702845A0000 NN O
kinetics P08702845A0000 NNS O
and P08702845A0000 CC O
[ P08702845A0000 $ O
3H P08702845A0000 CD O
] P08702845A0000 NNP O
CFT P08702845A0000 NNP O
binding P08702845A0000 VBG O
characteristics P08702845A0000 NNS O
of P08702845A0000 IN O
COS-7 P08702845A0000 NNP O
cells P08702845A0000 NNS O
transiently P08702845A0000 RB O
expressing P08702845A0000 VBG O
mutant P08702845A0000 JJ I-UN
DATs P08702845A0000 NNP I-UN
in P08702845A0000 IN O
which P08702845A0000 WDT O
the P08702845A0000 DT O
COOH P08702845A0000 NNP O
terminus P08702845A0000 NN O
was P08702845A0000 VBD O
truncated P08702845A0000 VBN O
or P08702845A0000 CC O
substituted P08702845A0000 VBN O
. P08702845A0000 . O
. . O O

Its P10529198A0068 PRP$ O
C-terminal P10529198A0068 JJ O
catalytic P10529198A0068 JJ O
domain P10529198A0068 NN O
was P10529198A0068 VBD O
found P10529198A0068 VBN O
to P10529198A0068 TO O
be P10529198A0068 VB O
highly P10529198A0068 RB O
conserved P10529198A0068 VBN O
in P10529198A0068 IN O
the P10529198A0068 DT O
homologues P10529198A0068 NNS O
p140 P10529198A0068 VBP I-UN
( P10529198A0068 ( O
ras-GRF P10529198A0068 NN O
) P10529198A0068 ) O
and P10529198A0068 CC O
Sos P10529198A0068 NNP I-UN
. P10529198A0068 . O
. . O O

A P01702426A1006 DT O
new P01702426A1006 JJ O
set P01702426A1006 NN O
of P01702426A1006 IN O
cDNA P01702426A1006 NN O
clones P01702426A1006 NNS O
spanning P01702426A1006 VBG O
approximately P01702426A1006 RB O
3.2 P01702426A1006 CD O
kb P01702426A1006 NN O
was P01702426A1006 VBD O
isolated P01702426A1006 VBN O
from P01702426A1006 IN O
a P01702426A1006 DT O
lambda-ZAP P01702426A1006 JJ O
goose P01702426A1006 NN O
liver P01702426A1006 NN O
cDNA P01702426A1006 NN O
library P01702426A1006 NN O
using P01702426A1006 VBG O
the P01702426A1006 DT O
5'-most P01702426A1006 JJ O
exon-containing P01702426A1006 JJ O
fragment P01702426A1006 NN O
of P01702426A1006 IN O
the P01702426A1006 DT O
5'-most P01702426A1006 JJ O
genomic P01702426A1006 JJ O
DNA P01702426A1006 NNP O
clone P01702426A1006 NN O
. P01702426A1006 . O
. . O O

Osteoadherin P09642227A0000 NNP I-UN
is P09642227A0000 VBZ O
a P09642227A0000 DT O
recently P09642227A0000 RB O
described P09642227A0000 VBN O
bone P09642227A0000 NN O
proteoglycan P09642227A0000 JJ O
containing P09642227A0000 VBG O
keratan P09642227A0000 JJ O
sulfate P09642227A0000 NN O
. P09642227A0000 . O
. . O O

The P09372937T0000 DT O
yeast P09372937T0000 JJ O
silent P09372937T0000 JJ I-UN
information P09372937T0000 NN I-UN
regulator P09372937T0000 NN I-UN
Sir4p P09372937T0000 NNP I-UN
anchors P09372937T0000 NNS O
and P09372937T0000 CC O
partitions P09372937T0000 NNS O
plasmids P09372937T0000 NNS O
. P09372937T0000 . O
. . O O

The P06959130A0996 DT O
arginyl P06959130A0996 JJ O
peptide P06959130A0996 NN O
bonds P06959130A0996 NNS O
that P06959130A0996 WDT O
are P06959130A0996 VBP O
cleaved P06959130A0996 VBN O
in P06959130A0996 IN O
the P06959130A0996 DT O
conversion P06959130A0996 NN O
of P06959130A0996 IN O
human P06959130A0996 JJ I-UN
factor P06959130A0996 NN I-UN
IX P06959130A0996 NNP I-UN
to P06959130A0996 TO O
factor P06959130A0996 VB I-UN
IXa P06959130A0996 NNP I-UN
by P06959130A0996 IN O
factor P06959130A0996 NN I-UN
XIa P06959130A0996 NNP I-UN
were P06959130A0996 VBD O
identified P06959130A0996 VBN O
as P06959130A0996 IN O
Arg145-Ala146 P06959130A0996 NNP O
and P06959130A0996 CC O
Arg180-Val181 P06959130A0996 NNP O
. P06959130A0996 . O
. . O O

DDP1 P10393197A0543 NNP I-UN
also P10393197A0543 RB O
localizes P10393197A0543 VBZ O
to P10393197A0543 TO O
heterochromatin P10393197A0543 VB O
in P10393197A0543 IN O
interphase P10393197A0543 JJ O
nuclei P10393197A0543 NN O
of P10393197A0543 IN O
larval P10393197A0543 JJ O
neuroblasts P10393197A0543 NNS O
. P10393197A0543 . O
. . O O

The P11084334A0590 DT O
swa2-1 P11084334A0590 JJ I-UN
allele P11084334A0590 NN I-UN
recovered P11084334A0590 VBN O
from P11084334A0590 IN O
the P11084334A0590 DT O
original P11084334A0590 JJ O
screen P11084334A0590 NN O
carries P11084334A0590 VBZ O
a P11084334A0590 DT O
point P11084334A0590 NN O
mutation P11084334A0590 NN O
in P11084334A0590 IN O
its P11084334A0590 PRP$ O
tetratricopeptide P11084334A0590 NN O
repeat P11084334A0590 NN O
( P11084334A0590 ( O
TPR P11084334A0590 NNP O
) P11084334A0590 ) O
domain P11084334A0590 NN O
, P11084334A0590 , O
a P11084334A0590 DT O
motif P11084334A0590 NN O
not P11084334A0590 RB O
found P11084334A0590 VBN O
in P11084334A0590 IN O
auxilin P11084334A0590 NN I-UN
but P11084334A0590 CC O
known P11084334A0590 VBN O
in P11084334A0590 IN O
other P11084334A0590 JJ O
proteins P11084334A0590 NNS O
to P11084334A0590 TO O
mediate P11084334A0590 VB O
interaction P11084334A0590 NN O
with P11084334A0590 IN O
heat-shock P11084334A0590 JJ I-UN
proteins P11084334A0590 NNS I-UN
. P11084334A0590 . O
. . O O

In P00598012A0174 IN O
girls P00598012A0174 NNS O
prolactin P00598012A0174 NN I-UN
levels P00598012A0174 NNS O
rise P00598012A0174 VBP O
at P00598012A0174 IN O
stage P00598012A0174 NN O
2 P00598012A0174 CD O
, P00598012A0174 , O
and P00598012A0174 CC O
are P00598012A0174 VBP O
higher P00598012A0174 JJR O
after P00598012A0174 IN O
menarche P00598012A0174 NN O
; P00598012A0174 : O
in P00598012A0174 IN O
boys P00598012A0174 NNS O
there P00598012A0174 EX O
is P00598012A0174 VBZ O
no P00598012A0174 DT O
change P00598012A0174 NN O
in P00598012A0174 IN O
prolactin P00598012A0174 NN I-UN
levels P00598012A0174 NNS O
. P00598012A0174 . O
. . O O

Effect P00231555T0001 NN O
of P00231555T0001 IN O
corticosteroid-containing P00231555T0001 JJ O
antirheumatic P00231555T0001 JJ O
combination P00231555T0001 NN O
drugs P00231555T0001 NNS O
on P00231555T0001 IN O
endogenous P00231555T0001 JJ O
ACTH P00231555T0001 NNP I-UN
and P00231555T0001 CC O
cortisol P00231555T0001 JJ O
production P00231555T0001 NN O
. P00231555T0001 . O
. . O O

The P04084607A0663 DT O
imino P04084607A0663 NN O
proton P04084607A0663 NN O
of P04084607A0663 IN O
T3 P04084607A0663 NNP O
in P04084607A0663 IN O
the P04084607A0663 DT O
O6meG.T P04084607A0663 NNP O
12-mer P04084607A0663 JJ O
and P04084607A0663 CC O
G3 P04084607A0663 NNP O
in P04084607A0663 IN O
the P04084607A0663 DT O
O6meG.N P04084607A0663 NNP O
12-mer P04084607A0663 JJ O
helix P04084607A0663 NN O
, P04084607A0663 , O
which P04084607A0663 WDT O
are P04084607A0663 VBP O
associated P04084607A0663 VBN O
with P04084607A0663 IN O
the P04084607A0663 DT O
modification P04084607A0663 NN O
site P04084607A0663 NN O
, P04084607A0663 , O
resonate P04084607A0663 NN O
at P04084607A0663 IN O
unusually P04084607A0663 RB O
high P04084607A0663 JJ O
field P04084607A0663 NN O
( P04084607A0663 ( O
8.5 P04084607A0663 CD O
to P04084607A0663 TO O
9.0 P04084607A0663 CD O
ppm P04084607A0663 NN O
) P04084607A0663 ) O
compared P04084607A0663 VBN O
to P04084607A0663 TO O
imino P04084607A0663 VB O
protons P04084607A0663 NNS O
in P04084607A0663 IN O
Watson-Crick P04084607A0663 NNP O
base P04084607A0663 NN O
pairs P04084607A0663 NN O
( P04084607A0663 ( O
12.5 P04084607A0663 CD O
to P04084607A0663 TO O
14.5 P04084607A0663 CD O
ppm P04084607A0663 NN O
) P04084607A0663 ) O
. P04084607A0663 . O
. . O O

Deleting P09671464A0316 VBG O
SNF1 P09671464A0316 NNP I-UN
repressed P09671464A0316 VBD O
meiosis P09671464A0316 NN O
at P09671464A0316 IN O
the P09671464A0316 DT O
same P09671464A0316 JJ O
three P09671464A0316 CD O
steps P09671464A0316 NNS O
that P09671464A0316 WDT O
were P09671464A0316 VBD O
inhibited P09671464A0316 VBN O
by P09671464A0316 IN O
glucose P09671464A0316 NN O
, P09671464A0316 , O
suggesting P09671464A0316 VBG O
that P09671464A0316 IN O
glucose P09671464A0316 NN O
blocks P09671464A0316 NNS O
meiosis P09671464A0316 NN O
by P09671464A0316 IN O
inhibiting P09671464A0316 VBG O
Snf1 P09671464A0316 NNP I-UN
. P09671464A0316 . O
. . O O

Remarkably P11113179A1020 RB O
, P11113179A1020 , O
a P11113179A1020 DT O
construct P11113179A1020 NN O
corresponding P11113179A1020 VBG O
to P11113179A1020 TO O
residues P11113179A1020 VB O
631 P11113179A1020 CD O
to P11113179A1020 TO O
970 P11113179A1020 CD O
, P11113179A1020 , O
which P11113179A1020 WDT O
contains P11113179A1020 VBZ O
only P11113179A1020 RB O
the P11113179A1020 DT O
LXXLL P11113179A1020 NNP O
motifs P11113179A1020 NNS O
and P11113179A1020 CC O
the P11113179A1020 DT O
AD1 P11113179A1020 NNP O
region P11113179A1020 NN O
of P11113179A1020 IN O
SRC1 P11113179A1020 NNP I-UN
, P11113179A1020 , O
retained P11113179A1020 VBD O
strong P11113179A1020 JJ O
coactivator P11113179A1020 NN O
activity P11113179A1020 NN O
in P11113179A1020 IN O
our P11113179A1020 PRP$ O
assays P11113179A1020 NNS O
. P11113179A1020 . O
. . O O

We P01748292A0000 PRP O
have P01748292A0000 VBP O
isolated P01748292A0000 VBN O
cDNAs P01748292A0000 NN O
for P01748292A0000 IN O
a P01748292A0000 DT O
gene P01748292A0000 NN O
coding P01748292A0000 VBG O
for P01748292A0000 IN O
a P01748292A0000 DT O
G P01748292A0000 NNP I-UN
protein P01748292A0000 NN I-UN
alpha P01748292A0000 VBD I-UN
subunit P01748292A0000 NN I-UN
from P01748292A0000 IN I-UN
tomato P01748292A0000 NN I-UN
( P01748292A0000 ( O
Lycopersicon P01748292A0000 NNP O
esculentum P01748292A0000 NN O
, P01748292A0000 , O
cv P01748292A0000 NN O
. P01748292A0000 . O
. . O O

Band-shift P09694725A0500 JJ O
assays P09694725A0500 NNS O
were P09694725A0500 VBD O
performed P09694725A0500 VBN O
using P09694725A0500 VBG O
the P09694725A0500 DT O
LPS-and P09694725A0500 NNP I-UN
IL-1-responsive P09694725A0500 JJ I-UN
element P09694725A0500 NN I-UN
( P09694725A0500 ( O
LILRE P09694725A0500 NNP I-UN
) P09694725A0500 ) O
oligonucleotide P09694725A0500 RB O
, P09694725A0500 , O
a P09694725A0500 DT O
gamma P09694725A0500 NN I-UN
interferon P09694725A0500 NN I-UN
activation P09694725A0500 NN I-UN
site-like P09694725A0500 JJ I-UN
site P09694725A0500 NN I-UN
that P09694725A0500 WDT O
is P09694725A0500 VBZ O
present P09694725A0500 JJ O
in P09694725A0500 IN O
the P09694725A0500 DT O
human P09694725A0500 JJ I-UN
IL-1beta P09694725A0500 NNP I-UN
promoter P09694725A0500 NN I-UN
. P09694725A0500 . O
. . O O

Catch-up P06482179A0497 JJ O
growth P06482179A0497 NN O
was P06482179A0497 VBD O
observed P06482179A0497 VBN O
only P06482179A0497 RB O
for P06482179A0497 IN O
a P06482179A0497 DT O
12-month P06482179A0497 JJ O
period P06482179A0497 NN O
in P06482179A0497 IN O
4 P06482179A0497 CD O
children P06482179A0497 NNS O
with P06482179A0497 IN O
a P06482179A0497 DT O
bone P06482179A0497 NN O
age P06482179A0497 NN O
of P06482179A0497 IN O
7 P06482179A0497 CD O
to P06482179A0497 TO O
8 P06482179A0497 CD O
years P06482179A0497 NNS O
. P06482179A0497 . O
. . O O

Patients P02229282A0454 NNS O
with P02229282A0454 IN O
detectable P02229282A0454 JJ O
serum P02229282A0454 NN O
TNF P02229282A0454 NNP I-UN
levels P02229282A0454 NNS O
had P02229282A0454 VBD O
significantly P02229282A0454 RB O
lower P02229282A0454 JJR O
serum P02229282A0454 NN O
T3 P02229282A0454 NNP O
concentrations P02229282A0454 NNS O
compared P02229282A0454 VBN O
to P02229282A0454 TO O
those P02229282A0454 DT O
with P02229282A0454 IN O
undetectable P02229282A0454 JJ O
levels P02229282A0454 NNS O
[ P02229282A0454 VBP O
1.072 P02229282A0454 CD O
+ P02229282A0454 NNP O
/ P02229282A0454 NNP O
- P02229282A0454 : O
0.588 P02229282A0454 CD O
vs P02229282A0454 NN O
. P02229282A0454 . O
. . O O

The P00837262A0000 DT O
responsiveness P00837262A0000 NN O
of P00837262A0000 IN O
visual P00837262A0000 JJ O
cortex P00837262A0000 NN O
( P00837262A0000 ( O
VC P00837262A0000 NNP O
) P00837262A0000 ) O
and P00837262A0000 CC O
superior P00837262A0000 JJ O
colliculus P00837262A0000 NN O
( P00837262A0000 ( O
SC P00837262A0000 NNP O
) P00837262A0000 ) O
was P00837262A0000 VBD O
simultaneously P00837262A0000 RB O
compared P00837262A0000 VBN O
following P00837262A0000 VBG O
conditioning P00837262A0000 VBG O
`` P00837262A0000 `` O
ON P00837262A0000 NNP O
'' P00837262A0000 '' O
or P00837262A0000 CC O
`` P00837262A0000 `` O
OFF P00837262A0000 IN O
'' P00837262A0000 '' O
stimulation P00837262A0000 NN O
, P00837262A0000 , O
in P00837262A0000 IN O
the P00837262A0000 DT O
rabbit P00837262A0000 NN O
. P00837262A0000 . O
. . O O

They P01653918A0286 PRP O
were P01653918A0286 VBD O
almost P01653918A0286 RB O
regularly P01653918A0286 RB O
excited P01653918A0286 VBN O
by P01653918A0286 IN O
pressure P01653918A0286 NN O
to P01653918A0286 TO O
the P01653918A0286 DT O
ipsilateral P01653918A0286 JJ O
cornea P01653918A0286 NN O
or P01653918A0286 CC O
to P01653918A0286 TO O
both P01653918A0286 DT O
corneas P01653918A0286 NNS O
at P01653918A0286 IN O
a P01653918A0286 DT O
strength P01653918A0286 NN O
well P01653918A0286 RB O
above P01653918A0286 IN O
the P01653918A0286 DT O
human P01653918A0286 JJ O
corneal P01653918A0286 NN O
pain P01653918A0286 NN O
threshold P01653918A0286 NN O
. P01653918A0286 . O
. . O O

In P10693246A0252 IN O
two-field P10693246A0252 JJ O
nodal P10693246A0252 JJ O
dissection P10693246A0252 NN O
, P10693246A0252 , O
two P10693246A0252 CD O
components P10693246A0252 NNS O
are P10693246A0252 VBP O
included P10693246A0252 VBN O
with P10693246A0252 IN O
( P10693246A0252 ( O
modern P10693246A0252 JJ O
two-field P10693246A0252 NN O
) P10693246A0252 ) O
or P10693246A0252 CC O
without P10693246A0252 IN O
( P10693246A0252 ( O
traditional P10693246A0252 JJ O
two-field P10693246A0252 NN O
) P10693246A0252 ) O
nodal P10693246A0252 FW O
dissection P10693246A0252 NN O
around P10693246A0252 IN O
both P10693246A0252 DT O
recurrent P10693246A0252 JJ O
laryngeal P10693246A0252 NN O
nerve P10693246A0252 NN O
chains P10693246A0252 NNS O
in P10693246A0252 IN O
the P10693246A0252 DT O
upper P10693246A0252 JJ O
mediastinum P10693246A0252 NN O
. P10693246A0252 . O
. . O O

Although P08561893A0100 IN O
a P08561893A0100 DT O
great P08561893A0100 JJ O
deal P08561893A0100 NN O
is P08561893A0100 VBZ O
understood P08561893A0100 VBN O
about P08561893A0100 IN O
how P08561893A0100 WRB O
bHLH P08561893A0100 JJ I-UN
factors P08561893A0100 NNS I-UN
activate P08561893A0100 VBP O
gene P08561893A0100 NN O
transcription P08561893A0100 NN O
via P08561893A0100 IN O
E-box P08561893A0100 NNP O
DNA P08561893A0100 NNP O
consensus P08561893A0100 NN O
sequences P08561893A0100 NNS O
, P08561893A0100 , O
studies P08561893A0100 NNS O
of P08561893A0100 IN O
bHLH P08561893A0100 JJ I-UN
factor P08561893A0100 NN I-UN
function P08561893A0100 NN O
in P08561893A0100 IN O
higher P08561893A0100 JJR O
eukaryotes P08561893A0100 NNS O
often P08561893A0100 RB O
have P08561893A0100 VBP O
been P08561893A0100 VBN O
hindered P08561893A0100 VBN O
by P08561893A0100 IN O
the P08561893A0100 DT O
presence P08561893A0100 NN O
of P08561893A0100 IN O
multiple P08561893A0100 JJ O
family P08561893A0100 NN O
members P08561893A0100 NNS O
. P08561893A0100 . O
. . O O

Chlamydia P01885752A0198 NNP O
trachomatis P01885752A0198 NN O
and P01885752A0198 CC O
Chlamydia P01885752A0198 NNP O
psittaci P01885752A0198 NN O
were P01885752A0198 VBD O
not P01885752A0198 RB O
affected P01885752A0198 VBN O
by P01885752A0198 IN O
methanol P01885752A0198 JJ O
fixation P01885752A0198 NN O
. P01885752A0198 . O
. . O O

Measurements P06767648A0734 NNS O
of P06767648A0734 IN O
perfusion P06767648A0734 NN O
also P06767648A0734 RB O
showed P06767648A0734 VBD O
significantly P06767648A0734 RB O
higher P06767648A0734 JJR O
values P06767648A0734 NNS O
under P06767648A0734 IN O
active P06767648A0734 JJ O
therapy P06767648A0734 NN O
. P06767648A0734 . O
. . O O

NERVTRACK P02721169A0171 NNP O
contains P02721169A0171 VBZ O
4000 P02721169A0171 CD O
anatomical P02721169A0171 JJ O
data P02721169A0171 NNS O
items P02721169A0171 NNS O
arranged P02721169A0171 VBN O
in P02721169A0171 IN O
a P02721169A0171 DT O
tree-like P02721169A0171 JJ O
manner P02721169A0171 NN O
reflecting P02721169A0171 VBG O
structural P02721169A0171 JJ O
and P02721169A0171 CC O
functional P02721169A0171 JJ O
relationships P02721169A0171 NNS O
. P02721169A0171 . O
. . O O

Genoa P09935377T0108 NNP O
, P09935377T0108 , O
Italy P09935377T0108 NNP O
, P09935377T0108 , O
24-28 P09935377T0108 JJ O
August P09935377T0108 NNP O
1997 P09935377T0108 CD O
. P09935377T0108 . O
. . O O

LA-3848-MS P04970918T0069 NNP O
. P04970918T0069 . O
. . O O

We P11007949A1607 PRP O
have P11007949A1607 VBP O
demonstrated P11007949A1607 VBN O
that P11007949A1607 IN O
the P11007949A1607 DT O
activity P11007949A1607 NN O
of P11007949A1607 IN O
ILK P11007949A1607 NNP I-UN
is P11007949A1607 VBZ O
constitutively P11007949A1607 RB O
elevated P11007949A1607 VBN O
in P11007949A1607 IN O
PTEN P11007949A1607 NNP I-UN
mutant P11007949A1607 JJ I-UN
cells P11007949A1607 NNS O
. P11007949A1607 . O
. . O O

Eight P11597936A0570 CD O
CAD P11597936A0570 NNP O
patients P11597936A0570 NNS O
who P11597936A0570 WP O
were P11597936A0570 VBD O
matched P11597936A0570 VBN O
to P11597936A0570 TO O
the P11597936A0570 DT O
treated P11597936A0570 JJ O
patients P11597936A0570 NNS O
for P11597936A0570 IN O
age P11597936A0570 NN O
( P11597936A0570 ( O
+ P11597936A0570 JJ O
/ P11597936A0570 NNP O
-3 P11597936A0570 NNP O
years P11597936A0570 NNS O
) P11597936A0570 ) O
, P11597936A0570 , O
baseline P11597936A0570 JJ O
low P11597936A0570 JJ I-UN
density P11597936A0570 NN I-UN
lipoprotein P11597936A0570 NN I-UN
( P11597936A0570 ( O
+ P11597936A0570 JJ O
/ P11597936A0570 NNP O
-5 P11597936A0570 NNP O
mg P11597936A0570 NN O
/ P11597936A0570 NNP O
dL P11597936A0570 NN O
) P11597936A0570 ) O
, P11597936A0570 , O
and P11597936A0570 CC O
triglycerides P11597936A0570 NNS O
( P11597936A0570 ( O
+ P11597936A0570 JJ O
/ P11597936A0570 NNP O
-50 P11597936A0570 NNP O
mg P11597936A0570 NN O
/ P11597936A0570 NNP O
dL P11597936A0570 NN O
) P11597936A0570 ) O
but P11597936A0570 CC O
who P11597936A0570 WP O
had P11597936A0570 VBD O
never P11597936A0570 RB O
been P11597936A0570 VBN O
treated P11597936A0570 VBN O
with P11597936A0570 IN O
lipid-lowering P11597936A0570 JJ O
drugs P11597936A0570 NNS O
were P11597936A0570 VBD O
selected P11597936A0570 VBN O
as P11597936A0570 IN O
controls P11597936A0570 NNS O
. P11597936A0570 . O
. . O O

When P08413223A0847 WRB O
multiple P08413223A0847 JJ O
copies P08413223A0847 NNS O
of P08413223A0847 IN O
the P08413223A0847 DT O
IL-1 P08413223A0847 NNP I-UN
beta P08413223A0847 NN I-UN
NF-kappa P08413223A0847 NNP I-UN
B P08413223A0847 NNP I-UN
site P08413223A0847 NN I-UN
were P08413223A0847 VBD O
linked P08413223A0847 VBN O
to P08413223A0847 TO O
an P08413223A0847 DT O
enhancerless P08413223A0847 NN O
simian P08413223A0847 JJ I-UN
virus P08413223A0847 NN I-UN
40 P08413223A0847 CD I-UN
promoter P08413223A0847 NN I-UN
, P08413223A0847 , O
this P08413223A0847 DT O
element P08413223A0847 NN O
was P08413223A0847 VBD O
able P08413223A0847 JJ O
to P08413223A0847 TO O
mediate P08413223A0847 VB O
phorbol P08413223A0847 JJ O
ester- P08413223A0847 JJ O
or P08413223A0847 CC O
lipopolysaccharide-inducible P08413223A0847 JJ O
gene P08413223A0847 NN O
expression P08413223A0847 NN O
. P08413223A0847 . O
. . O O

Baseline P11194101A0532 NNP O
BMD P11194101A0532 NNP O
values P11194101A0532 NNS O
were P11194101A0532 VBD O
significantly P11194101A0532 RB O
lower P11194101A0532 JJR O
in P11194101A0532 IN O
the P11194101A0532 DT O
oligo-amenorrheic P11194101A0532 JJ O
group P11194101A0532 NN O
than P11194101A0532 IN O
in P11194101A0532 IN O
the P11194101A0532 DT O
two P11194101A0532 CD O
others P11194101A0532 NNS O
at P11194101A0532 IN O
the P11194101A0532 DT O
level P11194101A0532 NN O
of P11194101A0532 IN O
lumbar P11194101A0532 NN O
spine P11194101A0532 NN O
( P11194101A0532 ( O
anteroposterior P11194101A0532 JJ O
view P11194101A0532 NN O
: P11194101A0532 : O
0.941+ P11194101A0532 CD O
/ P11194101A0532 NN O
-0.039 P11194101A0532 NN O
in P11194101A0532 IN O
oligo-amenorrheic P11194101A0532 JJ O
vs P11194101A0532 NN O
1.077+ P11194101A0532 CD O
/ P11194101A0532 JJ O
-0.029 P11194101A0532 NN O
or P11194101A0532 CC O
1.051 P11194101A0532 CD O
+ P11194101A0532 JJ O
/ P11194101A0532 NNP O
-0.017 P11194101A0532 NNP O
g P11194101A0532 NN O
x P11194101A0532 NNP O
cm P11194101A0532 NN O
( P11194101A0532 ( O
-2 P11194101A0532 NNP O
) P11194101A0532 ) O
, P11194101A0532 , O
P P11194101A0532 NNP O
< P11194101A0532 NNP O
0.005 P11194101A0532 CD O
, P11194101A0532 , O
in P11194101A0532 IN O
the P11194101A0532 DT O
eumenorrheic P11194101A0532 NN O
and P11194101A0532 CC O
contraceptive P11194101A0532 JJ O
user P11194101A0532 NN O
groups P11194101A0532 NNS O
, P11194101A0532 , O
respectively P11194101A0532 RB O
) P11194101A0532 ) O
but P11194101A0532 CC O
not P11194101A0532 RB O
in P11194101A0532 IN O
weight-bearing P11194101A0532 JJ O
bone P11194101A0532 NN O
such P11194101A0532 JJ O
as P11194101A0532 IN O
proximal P11194101A0532 JJ O
and P11194101A0532 CC O
midshaft P11194101A0532 JJ O
femur P11194101A0532 NN O
. P11194101A0532 . O
. . O O

All P10653733A0596 DT O
four P10653733A0596 CD O
domains P10653733A0596 NNS O
were P10653733A0596 VBD O
linked P10653733A0596 VBN O
via P10653733A0596 IN O
proline-threonine-rich P10653733A0596 JJ O
peptides P10653733A0596 NNS O
. P10653733A0596 . O
. . O O

Among P09290571A0420 IN O
38 P09290571A0420 CD O
patients P09290571A0420 NNS O
with P09290571A0420 IN O
inducible P09290571A0420 JJ O
reentrant P09290571A0420 JJ O
VTs P09290571A0420 NNP O
who P09290571A0420 WP O
underwent P09290571A0420 VBD O
electrophysiologic P09290571A0420 JJ O
study P09290571A0420 NN O
( P09290571A0420 ( O
EPS P09290571A0420 NNP O
) P09290571A0420 ) O
, P09290571A0420 , O
10 P09290571A0420 CD O
VTs P09290571A0420 NNP O
of P09290571A0420 IN O
six P09290571A0420 CD O
patients P09290571A0420 NNS O
were P09290571A0420 VBD O
selected P09290571A0420 VBN O
. P09290571A0420 . O
. . O O

In P01348590A0000 IN O
a P01348590A0000 DT O
retrospective P01348590A0000 JJ O
analysis P01348590A0000 NN O
of P01348590A0000 IN O
data P01348590A0000 NNS O
from P01348590A0000 IN O
35 P01348590A0000 CD O
cases P01348590A0000 NNS O
with P01348590A0000 IN O
malignant P01348590A0000 JJ O
lymphoma P01348590A0000 NN O
from P01348590A0000 IN O
a P01348590A0000 DT O
cohort P01348590A0000 NN O
of P01348590A0000 IN O
2017 P01348590A0000 CD O
HIV-infected P01348590A0000 JJ O
patients P01348590A0000 NNS O
, P01348590A0000 , O
the P01348590A0000 DT O
stage P01348590A0000 NN O
of P01348590A0000 IN O
HIV-disease P01348590A0000 NNP O
, P01348590A0000 , O
the P01348590A0000 DT O
CD4 P01348590A0000 NNP I-UN
counts P01348590A0000 VBZ O
at P01348590A0000 IN O
the P01348590A0000 DT O
time P01348590A0000 NN O
of P01348590A0000 IN O
diagnosis P01348590A0000 NN O
, P01348590A0000 , O
and P01348590A0000 CC O
the P01348590A0000 DT O
use P01348590A0000 NN O
of P01348590A0000 IN O
antineoplastic P01348590A0000 JJ O
agents P01348590A0000 NNS O
or P01348590A0000 CC O
radiotherapy P01348590A0000 NN O
were P01348590A0000 VBD O
correlated P01348590A0000 VBN O
with P01348590A0000 IN O
outcome P01348590A0000 NN O
. P01348590A0000 . O
. . O O

Story P05938720T0000 NN O
of P05938720T0000 IN O
a P05938720T0000 DT O
hospital P05938720T0000 NN O
that P05938720T0000 WDT O
filmed P05938720T0000 VBD O
its P05938720T0000 PRP$ O
employee P05938720T0000 NN O
orientation P05938720T0000 NN O
program P05938720T0000 NN O
. P05938720T0000 . O
. . O O

The P08878019A0357 DT O
intranodal P08878019A0357 JJ O
mesothelial P08878019A0357 JJ O
cells P08878019A0357 NNS O
occupied P08878019A0357 VBD O
the P08878019A0357 DT O
sinusoids P08878019A0357 NNS O
of P08878019A0357 IN O
the P08878019A0357 DT O
lymph P08878019A0357 NN O
nodes P08878019A0357 NNS O
and P08878019A0357 CC O
were P08878019A0357 VBD O
initially P08878019A0357 RB O
suspected P08878019A0357 VBN O
of P08878019A0357 IN O
being P08878019A0357 VBG O
metastatic P08878019A0357 JJ O
from P08878019A0357 IN O
the P08878019A0357 DT O
ovarian P08878019A0357 JJ O
tumor P08878019A0357 NN O
in P08878019A0357 IN O
each P08878019A0357 DT O
case P08878019A0357 NN O
. P08878019A0357 . O
. . O O

Besides P06579152A1061 IN O
, P06579152A1061 , O
it P06579152A1061 PRP O
was P06579152A1061 VBD O
considered P06579152A1061 VBN O
that P06579152A1061 IN O
the P06579152A1061 DT O
NPF P06579152A1061 NNP O
was P06579152A1061 VBD O
a P06579152A1061 DT O
useful P06579152A1061 JJ O
tool P06579152A1061 NN O
for P06579152A1061 IN O
activation P06579152A1061 NN O
of P06579152A1061 IN O
velopharyngeal P06579152A1061 NN O
activity P06579152A1061 NN O
by P06579152A1061 IN O
way P06579152A1061 NN O
of P06579152A1061 IN O
visual P06579152A1061 JJ O
feed-back P06579152A1061 NN O
control P06579152A1061 NN O
. P06579152A1061 . O
. . O O

These P09360953A1057 DT O
residues P09360953A1057 NNS O
, P09360953A1057 , O
Ile244 P09360953A1057 NNP O
at P09360953A1057 IN O
the P09360953A1057 DT O
extracellular P09360953A1057 JJ O
end P09360953A1057 NN O
of P09360953A1057 IN O
transmembrane P09360953A1057 NN O
helix P09360953A1057 NN O
3 P09360953A1057 CD O
, P09360953A1057 , O
and P09360953A1057 CC O
Tyr318 P09360953A1057 NNP O
at P09360953A1057 IN O
the P09360953A1057 DT O
COOH-terminal P09360953A1057 JJ O
portion P09360953A1057 NN O
of P09360953A1057 IN O
extracellular P09360953A1057 JJ O
loop P09360953A1057 NN O
2 P09360953A1057 CD O
, P09360953A1057 , O
are P09360953A1057 VBP O
replaced P09360953A1057 VBN O
by P09360953A1057 IN O
Leu P09360953A1057 NNP O
and P09360953A1057 CC O
Ile P09360953A1057 NNP O
in P09360953A1057 IN O
the P09360953A1057 DT O
PTH-1 P09360953A1057 NNP I-UN
receptor P09360953A1057 NN I-UN
, P09360953A1057 , O
respectively P09360953A1057 RB O
. P09360953A1057 . O
. . O O

Next P10880486A0790 JJ O
, P10880486A0790 , O
we P10880486A0790 PRP O
show P10880486A0790 VBP O
that P10880486A0790 IN O
two P10880486A0790 CD O
EMS-induced P10880486A0790 JJ O
mutations P10880486A0790 NNS O
, P10880486A0790 , O
previously P10880486A0790 RB O
shown P10880486A0790 VBN O
to P10880486A0790 TO O
interact P10880486A0790 VB O
genetically P10880486A0790 RB O
with P10880486A0790 IN O
zipper P10880486A0790 NN O
( P10880486A0790 ( O
Ebr P10880486A0790 NNP I-UN
) P10880486A0790 ) O
, P10880486A0790 , O
disrupt P10880486A0790 VBZ O
the P10880486A0790 DT O
RhoA P10880486A0790 NNP I-UN
locus P10880486A0790 NN I-UN
. P10880486A0790 . O
. . O O

We P07547500A0066 PRP O
showed P07547500A0066 VBD O
previously P07547500A0066 RB O
that P07547500A0066 IN O
a P07547500A0066 DT O
fusion P07547500A0066 NN O
protein P07547500A0066 NN O
( P07547500A0066 ( O
GAL4-p40 P07547500A0066 NNP O
) P07547500A0066 ) O
containing P07547500A0066 VBG O
the P07547500A0066 DT O
DNA-binding P07547500A0066 NNP O
domain P07547500A0066 NN O
of P07547500A0066 IN O
GAL4 P07547500A0066 NNP I-UN
and P07547500A0066 CC O
sequences P07547500A0066 NNS O
of P07547500A0066 IN O
chicken P07547500A0066 NN I-UN
l P07547500A0066 NN I-UN
kappa P07547500A0066 VBD I-UN
B-alpha P07547500A0066 NNP I-UN
( P07547500A0066 ( O
p40 P07547500A0066 NN I-UN
) P07547500A0066 ) O
inhibits P07547500A0066 VBZ O
growth P07547500A0066 NN O
in P07547500A0066 IN O
the P07547500A0066 DT O
yeast P07547500A0066 NN O
Saccharomyces P07547500A0066 NNP O
cerevisiae P07547500A0066 NN O
. P07547500A0066 . O
. . O O

This P08479742A0985 DT O
may P08479742A0985 MD O
account P08479742A0985 VB O
, P08479742A0985 , O
at P08479742A0985 IN O
least P08479742A0985 JJS O
in P08479742A0985 IN O
part P08479742A0985 NN O
, P08479742A0985 , O
for P08479742A0985 IN O
the P08479742A0985 DT O
ability P08479742A0985 NN O
of P08479742A0985 IN O
excess P08479742A0985 JJ O
wt P08479742A0985 NN I-UN
p53 P08479742A0985 NN I-UN
to P08479742A0985 TO O
inhibit P08479742A0985 VB O
cell P08479742A0985 NN O
proliferation P08479742A0985 NN O
and P08479742A0985 CC O
to P08479742A0985 TO O
interfere P08479742A0985 VB O
with P08479742A0985 IN O
neoplastic P08479742A0985 JJ O
processes P08479742A0985 NNS O
. P08479742A0985 . O
. . O O

Antibodies P07508441A0487 NNS O
affinity-purified P07508441A0487 JJ O
using P07508441A0487 VBG O
the P07508441A0487 DT O
bacterially P07508441A0487 RB O
expressed P07508441A0487 VBN O
recombinant P07508441A0487 JJ O
protein P07508441A0487 NN O
recognized P07508441A0487 VBD O
the P07508441A0487 DT O
56K P07508441A0487 CD I-UN
autoantigen P07508441A0487 NN I-UN
in P07508441A0487 IN O
a P07508441A0487 DT O
HeLa P07508441A0487 NNP O
cell P07508441A0487 NN O
extract P07508441A0487 NN O
. P07508441A0487 . O
cDNA P07508441A0487 NN O
sequencing P07508441A0487 VBG O
revealed P07508441A0487 VBD O
that P07508441A0487 IN O
the P07508441A0487 DT O
56K P07508441A0487 CD I-UN
cDNA P07508441A0487 NN I-UN
shares P07508441A0487 NNS O
a P07508441A0487 DT O
high P07508441A0487 JJ O
degree P07508441A0487 NN O
of P07508441A0487 IN O
homology P07508441A0487 NN O
in P07508441A0487 IN O
both P07508441A0487 DT O
nucleotide P07508441A0487 JJ O
( P07508441A0487 ( O
87 P07508441A0487 CD O
% P07508441A0487 NN O
) P07508441A0487 ) O
and P07508441A0487 CC O
amino P07508441A0487 JJ O
acid P07508441A0487 NN O
sequence P07508441A0487 NN O
( P07508441A0487 ( O
92.5 P07508441A0487 CD O
% P07508441A0487 NN O
) P07508441A0487 ) O
with P07508441A0487 IN O
bovine P07508441A0487 NN I-UN
annexin P07508441A0487 NN I-UN
XI P07508441A0487 NNP I-UN
, P07508441A0487 , O
indicating P07508441A0487 VBG O
that P07508441A0487 IN O
the P07508441A0487 DT O
56K P07508441A0487 CD I-UN
cDNA P07508441A0487 NN I-UN
encodes P07508441A0487 VBZ O
the P07508441A0487 DT O
human P07508441A0487 JJ I-UN
homologue P07508441A0487 NN I-UN
of P07508441A0487 IN I-UN
annexin P07508441A0487 NN I-UN
XI P07508441A0487 NNP I-UN
, P07508441A0487 , O
a P07508441A0487 DT O
member P07508441A0487 NN O
of P07508441A0487 IN O
the P07508441A0487 DT O
Ca P07508441A0487 NNP I-UN
( P07508441A0487 ( I-UN
2+ P07508441A0487 CD I-UN
) P07508441A0487 ) I-UN
-dependent P07508441A0487 NN I-UN
phospholipid P07508441A0487 JJ I-UN
binding P07508441A0487 VBG I-UN
protein P07508441A0487 JJ I-UN
family P07508441A0487 NN I-UN
. P07508441A0487 . O
. . O O

In P07862129A1391 IN O
acute-phase P07862129A1391 JJ O
livers P07862129A1391 NNS O
, P07862129A1391 , O
we P07862129A1391 PRP O
observed P07862129A1391 VBD O
a P07862129A1391 DT O
dramatic P07862129A1391 JJ O
reduction P07862129A1391 NN O
in P07862129A1391 IN O
HNF-3 P07862129A1391 NNP I-UN
alpha P07862129A1391 NN I-UN
expression P07862129A1391 NN O
which P07862129A1391 WDT O
correlates P07862129A1391 VBZ O
with P07862129A1391 IN O
a P07862129A1391 DT O
decrease P07862129A1391 NN O
in P07862129A1391 IN O
the P07862129A1391 DT O
expression P07862129A1391 NN O
of P07862129A1391 IN O
its P07862129A1391 PRP$ O
target P07862129A1391 NN O
gene P07862129A1391 NN O
, P07862129A1391 , O
the P07862129A1391 DT O
TTR P07862129A1391 NNP I-UN
gene P07862129A1391 NN I-UN
. P07862129A1391 . O
. . O O

L. P08112341A1128 NNP O
, P08112341A1128 , O
Greer P08112341A1128 NNP O
, P08112341A1128 , O
J P08112341A1128 NNP O
. P08112341A1128 . O
& P08112341A1128 CC O
Carter P08112341A1128 NNP O
, P08112341A1128 , O
G P08112341A1128 NNP O
. P08112341A1128 . O
. . O O

Tumor P10838531A0675 NN O
stages P10838531A0675 NNS O
were P10838531A0675 VBD O
IIB P10838531A0675 NNP O
( P10838531A0675 ( O
T3 P10838531A0675 NNP O
N0 P10838531A0675 NNP O
) P10838531A0675 ) O
in P10838531A0675 IN O
52 P10838531A0675 CD O
% P10838531A0675 NN O
, P10838531A0675 , O
IIIA P10838531A0675 NNP O
in P10838531A0675 IN O
15 P10838531A0675 CD O
% P10838531A0675 NN O
, P10838531A0675 , O
and P10838531A0675 CC O
IIIB P10838531A0675 NNP O
in P10838531A0675 IN O
27 P10838531A0675 CD O
% P10838531A0675 NN O
of P10838531A0675 IN O
patients P10838531A0675 NNS O
. P10838531A0675 . O
. . O O

The P07600111A0000 DT O
prevalence P07600111A0000 NN O
and P07600111A0000 CC O
incidence P07600111A0000 NN O
of P07600111A0000 IN O
human P07600111A0000 JJ O
immunodeficiency P07600111A0000 NN O
virus P07600111A0000 NN O
types P07600111A0000 VBZ O
1 P07600111A0000 CD O
and P07600111A0000 CC O
2 P07600111A0000 CD O
( P07600111A0000 ( O
HIV-1 P07600111A0000 NNP O
, P07600111A0000 , O
HIV-2 P07600111A0000 NNP O
) P07600111A0000 ) O
, P07600111A0000 , O
human P07600111A0000 JJ O
T-lymphotropic P07600111A0000 NNP O
virus P07600111A0000 NN O
types P07600111A0000 NNS O
I P07600111A0000 PRP O
and P07600111A0000 CC O
II P07600111A0000 NNP O
( P07600111A0000 ( O
HTLV-I P07600111A0000 NNP O
/ P07600111A0000 NNP O
II P07600111A0000 NNP O
) P07600111A0000 ) O
, P07600111A0000 , O
and P07600111A0000 CC O
syphilitic P07600111A0000 JJ O
infections P07600111A0000 NNS O
and P07600111A0000 CC O
the P07600111A0000 DT O
association P07600111A0000 NN O
between P07600111A0000 IN O
these P07600111A0000 DT O
infections P07600111A0000 NNS O
were P07600111A0000 VBD O
determined P07600111A0000 VBN O
in P07600111A0000 IN O
a P07600111A0000 DT O
cohort P07600111A0000 NN O
of P07600111A0000 IN O
police P07600111A0000 NN O
officers P07600111A0000 NNS O
in P07600111A0000 IN O
Guinea-Bissau P07600111A0000 NNP O
. P07600111A0000 . O
. . O O

These P07856102A1616 DT O
data P07856102A1616 NNS O
indicate P07856102A1616 VBP O
that P07856102A1616 IN O
phosphorylation P07856102A1616 NN O
of P07856102A1616 IN O
M P07856102A1616 NNP I-UN
protein P07856102A1616 NN I-UN
at P07856102A1616 IN O
the P07856102A1616 DT O
major P07856102A1616 JJ O
in P07856102A1616 IN O
vivo P07856102A1616 NN O
sites P07856102A1616 NNS O
is P07856102A1616 VBZ O
not P07856102A1616 RB O
essential P07856102A1616 JJ O
for P07856102A1616 IN O
virus P07856102A1616 NN O
assembly P07856102A1616 NN O
. P07856102A1616 . O
. . O O

The P01309244A0798 DT O
target P01309244A0798 NN O
contained P01309244A0798 VBD O
between P01309244A0798 IN O
positions P01309244A0798 NNS O
-403 P01309244A0798 NNP O
and P01309244A0798 CC O
-125 P01309244A0798 NNP O
acts P01309244A0798 VBZ O
independently P01309244A0798 RB O
of P01309244A0798 IN O
orientation P01309244A0798 NN O
, P01309244A0798 , O
in P01309244A0798 IN O
different P01309244A0798 JJ O
cell P01309244A0798 NN O
types P01309244A0798 NNS O
and P01309244A0798 CC O
species P01309244A0798 NNS O
, P01309244A0798 , O
and P01309244A0798 CC O
in P01309244A0798 IN O
the P01309244A0798 DT O
context P01309244A0798 NN O
of P01309244A0798 IN O
a P01309244A0798 DT O
heterologous P01309244A0798 JJ O
promoter P01309244A0798 NN O
. P01309244A0798 . O
. . O O

The P08078416A0581 DT O
bactericidal P08078416A0581 JJ O
effect P08078416A0581 NN O
of P08078416A0581 IN O
disinfectants P08078416A0581 NNS O
against P08078416A0581 IN O
biofilm P08078416A0581 NN O
cells P08078416A0581 NNS O
was P08078416A0581 VBD O
found P08078416A0581 VBN O
to P08078416A0581 TO O
be P08078416A0581 VB O
considerably P08078416A0581 RB O
enhanced P08078416A0581 VBN O
by P08078416A0581 IN O
increasing P08078416A0581 VBG O
the P08078416A0581 DT O
concentrations P08078416A0581 NNS O
of P08078416A0581 IN O
the P08078416A0581 DT O
disinfectants P08078416A0581 NNS O
. P08078416A0581 . O
. . O O

When P10812294X0000 WRB O
the P10812294X0000 DT O
entire P10812294X0000 JJ O
diet P10812294X0000 NN O
consisted P10812294X0000 VBD O
of P10812294X0000 IN O
SBF P10812294X0000 NNP O
, P10812294X0000 , O
voluntary P10812294X0000 JJ O
feed P10812294X0000 NN O
intake P10812294X0000 NN O
was P10812294X0000 VBD O
reduced P10812294X0000 VBN O
, P10812294X0000 , O
indicating P10812294X0000 VBG O
that P10812294X0000 IN O
SBF P10812294X0000 NNP O
should P10812294X0000 MD O
not P10812294X0000 RB O
be P10812294X0000 VB O
fed P10812294X0000 VBN O
to P10812294X0000 TO O
ponies P10812294X0000 NNS O
as P10812294X0000 IN O
the P10812294X0000 DT O
sole P10812294X0000 JJ O
dietary P10812294X0000 JJ O
ingredient P10812294X0000 NN O
. P10812294X0000 . O
. . O O

Neither P08836740A1025 DT O
CES1 P08836740A1025 NNP I-UN
nor P08836740A1025 CC O
CES4 P08836740A1025 NNP I-UN
is P08836740A1025 VBZ O
essential P08836740A1025 JJ O
for P08836740A1025 IN O
cell P08836740A1025 NN O
growth P08836740A1025 NN O
, P08836740A1025 , O
and P08836740A1025 CC O
a P08836740A1025 DT O
double P08836740A1025 JJ O
deletion P08836740A1025 NN O
mutant P08836740A1025 NN O
is P08836740A1025 VBZ O
viable P08836740A1025 JJ O
. P08836740A1025 . O
. . O O

In P09218599A0184 IN O
this P09218599A0184 DT O
study P09218599A0184 NN O
, P09218599A0184 , O
we P09218599A0184 PRP O
sought P09218599A0184 VBD O
to P09218599A0184 TO O
identify P09218599A0184 VB O
mechanisms P09218599A0184 NNS O
that P09218599A0184 WDT O
could P09218599A0184 MD O
account P09218599A0184 VB O
for P09218599A0184 IN O
the P09218599A0184 DT O
antimitogenic P09218599A0184 JJ O
effects P09218599A0184 NNS O
of P09218599A0184 IN O
IL-4 P09218599A0184 NNP I-UN
. P09218599A0184 . O
. . O O

In P09368026A0435 IN O
this P09368026A0435 DT O
study P09368026A0435 NN O
, P09368026A0435 , O
we P09368026A0435 PRP O
examine P09368026A0435 VBP O
the P09368026A0435 DT O
effects P09368026A0435 NNS O
of P09368026A0435 IN O
Msx2 P09368026A0435 NNP I-UN
expression P09368026A0435 NN O
on P09368026A0435 IN O
OC P09368026A0435 NNP I-UN
promoter P09368026A0435 NN I-UN
activation P09368026A0435 NN O
( P09368026A0435 ( O
luciferase P09368026A0435 JJ I-UN
reporter P09368026A0435 NN I-UN
) P09368026A0435 ) O
by P09368026A0435 IN O
FGF2 P09368026A0435 NNP I-UN
/ P09368026A0435 NNP O
FSK P09368026A0435 NNP I-UN
and P09368026A0435 CC O
calcitriol P09368026A0435 NN O
in P09368026A0435 IN O
MC3T3-E1 P09368026A0435 NNP O
osteoblasts P09368026A0435 NNS O
. P09368026A0435 . O
. . O O

Cytogenetic P10972990A0966 JJ O
analysis P10972990A0966 NN O
of P10972990A0966 IN O
LOH P10972990A0966 NNP O
mutants P10972990A0966 NNS O
by P10972990A0966 IN O
chromosome P10972990A0966 NN O
painting P10972990A0966 NN O
indicated P10972990A0966 VBD O
a P10972990A0966 DT O
mosaic P10972990A0966 NN O
of P10972990A0966 IN O
chromosomal P10972990A0966 JJ O
aberrations P10972990A0966 NNS O
involving P10972990A0966 VBG O
chromosome P10972990A0966 NN O
17 P10972990A0966 CD O
, P10972990A0966 , O
in P10972990A0966 IN O
which P10972990A0966 WDT O
partial P10972990A0966 JJ O
chromosome P10972990A0966 NN O
deletions P10972990A0966 NNS O
, P10972990A0966 , O
amplifications P10972990A0966 NNS O
, P10972990A0966 , O
and P10972990A0966 CC O
multiple P10972990A0966 JJ O
translocations P10972990A0966 NNS O
appeared P10972990A0966 VBD O
heterogeneously P10972990A0966 RB O
in P10972990A0966 IN O
a P10972990A0966 DT O
single P10972990A0966 JJ O
mutant P10972990A0966 NN O
. P10972990A0966 . O
. . O O

Novel P03840480T0000 NNP O
multigene P03840480T0000 NN O
families P03840480T0000 NNS O
encoding P03840480T0000 VBG O
highly P03840480T0000 RB O
repetitive P03840480T0000 JJ O
peptide P03840480T0000 NN O
sequences P03840480T0000 NNS O
. P03840480T0000 . O
. . O O

A P09446600A0260 DT O
fusion P09446600A0260 NN O
protein P09446600A0260 NN O
composed P09446600A0260 VBD O
of P09446600A0260 IN O
beta-galactosidase P09446600A0260 NN I-UN
and P09446600A0260 CC O
full-length P09446600A0260 JJ I-UN
Ahr P09446600A0260 NNP I-UN
translocates P09446600A0260 NNS O
from P09446600A0260 IN O
the P09446600A0260 DT O
cytoplasm P09446600A0260 NN O
to P09446600A0260 TO O
the P09446600A0260 DT O
nucleus P09446600A0260 NN O
in P09446600A0260 IN O
a P09446600A0260 DT O
ligand-dependent P09446600A0260 JJ O
manner P09446600A0260 NN O
. P09446600A0260 . O
. . O O

These P11693461A1649 DT O
utilisation P11693461A1649 NN O
data P11693461A1649 NNS O
imply P11693461A1649 VBP O
annual P11693461A1649 JJ O
drug P11693461A1649 NN O
costs P11693461A1649 NNS O
in P11693461A1649 IN O
the P11693461A1649 DT O
range P11693461A1649 NN O
of P11693461A1649 IN O
$ P11693461A1649 $ O
US P11693461A1649 PRP O
480,000 P11693461A1649 CD O
to P11693461A1649 TO O
$ P11693461A1649 $ O
US P11693461A1649 PRP O
3,600,000 P11693461A1649 CD O
for P11693461A1649 IN O
TNF P11693461A1649 NNP I-UN
antagonists P11693461A1649 NNS O
for P11693461A1649 IN O
RA P11693461A1649 NNP O
per P11693461A1649 IN O
1 P11693461A1649 CD O
million P11693461A1649 CD O
population P11693461A1649 NN O
. P11693461A1649 . O
. . O O

Erratum P09976626T0000 NN O
: P09976626T0000 : O
Absence P09976626T0000 NN O
of P09976626T0000 IN O
precursor P09976626T0000 NN O
effects P09976626T0000 NNS O
above P09976626T0000 IN O
the P09976626T0000 DT O
martensitic P09976626T0000 JJ O
transformation P09976626T0000 NN O
in P09976626T0000 IN O
a P09976626T0000 DT O
virgin P09976626T0000 JJ O
crystal P09976626T0000 NN O
of P09976626T0000 IN O
Li P09976626T0000 NNP O
metal P09976626T0000 NN O
. P09976626T0000 . O
. . O O

PCR P09524222A1113 NNP O
analysis P09524222A1113 NN O
indicates P09524222A1113 VBZ O
that P09524222A1113 IN O
this P09524222A1113 DT O
new P09524222A1113 JJ O
beta-adducin P09524222A1113 JJ I-UN
isoform P09524222A1113 NN I-UN
is P09524222A1113 VBZ O
expressed P09524222A1113 VBN O
in P09524222A1113 IN O
fetal P09524222A1113 JJ O
brain P09524222A1113 NN O
and P09524222A1113 CC O
liver P09524222A1113 NN O
, P09524222A1113 , O
bone P09524222A1113 NN O
marrow P09524222A1113 NN O
, P09524222A1113 , O
and P09524222A1113 CC O
NT-2 P09524222A1113 NNP O
( P09524222A1113 ( O
neuroepithelial P09524222A1113 JJ O
) P09524222A1113 ) O
cells P09524222A1113 NNS O
, P09524222A1113 , O
but P09524222A1113 CC O
is P09524222A1113 VBZ O
not P09524222A1113 RB O
detected P09524222A1113 VBN O
in P09524222A1113 IN O
several P09524222A1113 JJ O
other P09524222A1113 JJ O
tissues P09524222A1113 NNS O
. P09524222A1113 . O
. . O O

We P10068674A0644 PRP O
also P10068674A0644 RB O
identified P10068674A0644 VBD O
an P10068674A0644 DT O
alternative P10068674A0644 JJ O
spliced P10068674A0644 JJ O
form P10068674A0644 NN O
of P10068674A0644 IN O
Lyp P10068674A0644 NNP I-UN
RNA P10068674A0644 NNP I-UN
, P10068674A0644 , O
Lyp2 P10068674A0644 NNP I-UN
. P10068674A0644 . O
. . O O

The P11311153T0000 DT O
relationship P11311153T0000 NN O
of P11311153T0000 IN O
the P11311153T0000 DT O
factor P11311153T0000 NN I-UN
V P11311153T0000 NNP I-UN
Leiden P11311153T0000 NNP I-UN
mutation P11311153T0000 NN I-UN
or P11311153T0000 CC O
the P11311153T0000 DT O
deletion-deletion P11311153T0000 JJ O
polymorphism P11311153T0000 NN O
of P11311153T0000 IN O
the P11311153T0000 DT O
angiotensin P11311153T0000 NN I-UN
converting P11311153T0000 VBG I-UN
enzyme P11311153T0000 NN I-UN
to P11311153T0000 TO O
postoperative P11311153T0000 VB O
thromboembolic P11311153T0000 JJ O
events P11311153T0000 NNS O
following P11311153T0000 VBG O
total P11311153T0000 JJ O
joint P11311153T0000 JJ O
arthroplasty P11311153T0000 NN O
. P11311153T0000 . O
. . O O

Acute P08049885T0000 JJ O
pancreatitis P08049885T0000 NN O
: P08049885T0000 : O
a P08049885T0000 DT O
multisystem P08049885T0000 NN O
disease P08049885T0000 NN O
. P08049885T0000 . O
. . O O

Incidence P02220102A0271 NN O
correlated P02220102A0271 VBN O
with P02220102A0271 IN O
the P02220102A0271 DT O
grade P02220102A0271 NN O
of P02220102A0271 IN O
oral P02220102A0271 JJ O
hygiene P02220102A0271 NN O
und P02220102A0271 IN O
periodontal P02220102A0271 JJ O
disease P02220102A0271 NN O
. P02220102A0271 . O
. . O O

Weak P08438584A0524 JJ O
promoter P08438584A0524 NN O
activity P08438584A0524 NN O
was P08438584A0524 VBD O
observed P08438584A0524 VBN O
for P08438584A0524 IN O
the P08438584A0524 DT O
promoter P08438584A0524 NN O
of P08438584A0524 IN O
the P08438584A0524 DT O
C1 P08438584A0524 NNP I-UN
and P08438584A0524 CC O
C2 P08438584A0524 NNP I-UN
ORFs P08438584A0524 NNP O
( P08438584A0524 ( O
C1-C2 P08438584A0524 NNP O
gene P08438584A0524 NN O
) P08438584A0524 ) O
and P08438584A0524 CC O
for P08438584A0524 IN O
the P08438584A0524 DT O
promoter P08438584A0524 NN O
of P08438584A0524 IN O
the P08438584A0524 DT O
V1 P08438584A0524 NNP I-UN
ORF P08438584A0524 NNP I-UN
. P08438584A0524 . O
. . O O

Stable P11297545A0948 JJ O
transfection P11297545A0948 NN O
of P11297545A0948 IN O
human P11297545A0948 JJ I-UN
CHOP P11297545A0948 NNP I-UN
cDNA P11297545A0948 NN I-UN
into P11297545A0948 IN O
mammary P11297545A0948 JJ O
carcinoma P11297545A0948 NN O
cells P11297545A0948 NNS O
demonstrated P11297545A0948 VBD O
that P11297545A0948 IN O
CHOP P11297545A0948 NNP I-UN
functioned P11297545A0948 VBD O
not P11297545A0948 RB O
as P11297545A0948 IN O
a P11297545A0948 DT O
mediator P11297545A0948 NN O
of P11297545A0948 IN O
hGH-stimulated P11297545A0948 JJ O
mitogenesis P11297545A0948 NN O
but P11297545A0948 CC O
rather P11297545A0948 RB O
enhanced P11297545A0948 VBD O
the P11297545A0948 DT O
protection P11297545A0948 NN O
from P11297545A0948 IN O
apoptosis P11297545A0948 NN O
afforded P11297545A0948 VBN O
by P11297545A0948 IN O
hGH P11297545A0948 NN I-UN
in P11297545A0948 IN O
a P11297545A0948 DT O
p38 P11297545A0948 JJ I-UN
MAPK-dependent P11297545A0948 JJ O
manner P11297545A0948 NN O
. P11297545A0948 . O
. . O O

The P07377954A0117 DT O
following P07377954A0117 JJ O
aspects P07377954A0117 NNS O
were P07377954A0117 VBD O
assessed P07377954A0117 VBN O
: P07377954A0117 : O
( P07377954A0117 ( O
1 P07377954A0117 CD O
) P07377954A0117 ) O
The P07377954A0117 DT O
effect P07377954A0117 NN O
on P07377954A0117 IN O
the P07377954A0117 DT O
cardiovascular P07377954A0117 JJ O
system P07377954A0117 NN O
in P07377954A0117 IN O
terms P07377954A0117 NNS O
of P07377954A0117 IN O
brachial P07377954A0117 JJ O
arterial P07377954A0117 JJ O
pressure P07377954A0117 NN O
, P07377954A0117 , O
pulse P07377954A0117 JJ O
rate P07377954A0117 NN O
, P07377954A0117 , O
and P07377954A0117 CC O
oxygen P07377954A0117 NN O
consumption P07377954A0117 NN O
( P07377954A0117 ( O
VO2 P07377954A0117 NNP O
) P07377954A0117 ) O
during P07377954A0117 IN O
exercise P07377954A0117 NN O
in P07377954A0117 IN O
5 P07377954A0117 CD O
health P07377954A0117 NN O
volunteers P07377954A0117 NNS O
; P07377954A0117 : O
( P07377954A0117 ( O
2 P07377954A0117 CD O
) P07377954A0117 ) O
emg P07377954A0117 NN O
activity P07377954A0117 NN O
of P07377954A0117 IN O
the P07377954A0117 DT O
tibialis P07377954A0117 NN O
anterior P07377954A0117 NN O
and P07377954A0117 CC O
gastrocnemius P07377954A0117 NN O
muscles P07377954A0117 NNS O
during P07377954A0117 IN O
exercise P07377954A0117 NN O
in P07377954A0117 IN O
the P07377954A0117 DT O
same P07377954A0117 JJ O
5 P07377954A0117 CD O
volunteers P07377954A0117 NNS O
; P07377954A0117 : O
and P07377954A0117 CC O
( P07377954A0117 ( O
3 P07377954A0117 CD O
) P07377954A0117 ) O
postexercise P07377954A0117 NN O
ankle P07377954A0117 JJ O
pressure P07377954A0117 NN O
changes P07377954A0117 NNS O
in P07377954A0117 IN O
10 P07377954A0117 CD O
subjects P07377954A0117 NNS O
with P07377954A0117 IN O
angiographically P07377954A0117 RB O
proven P07377954A0117 JJ O
occlusive P07377954A0117 JJ O
arterial P07377954A0117 JJ O
diseases P07377954A0117 NNS O
of P07377954A0117 IN O
the P07377954A0117 DT O
lower P07377954A0117 JJR O
extremities P07377954A0117 NNS O
. P07377954A0117 . O
. . O O

Collectively P10683244A1860 RB O
, P10683244A1860 , O
these P10683244A1860 DT O
experiments P10683244A1860 NNS O
demonstrate P10683244A1860 VBP O
that P10683244A1860 IN O
CFTR P10683244A1860 NNP I-UN
's P10683244A1860 POS I-UN
NBF1+R P10683244A1860 NNP I-UN
region P10683244A1860 NN I-UN
and P10683244A1860 CC O
its P10683244A1860 PRP$ O
NBF2 P10683244A1860 NNP I-UN
domain P10683244A1860 NN I-UN
, P10683244A1860 , O
after P10683244A1860 IN O
folding P10683244A1860 VBG O
separately P10683244A1860 RB O
as P10683244A1860 IN O
distinct P10683244A1860 JJ O
units P10683244A1860 NNS O
, P10683244A1860 , O
have P10683244A1860 VBP O
a P10683244A1860 DT O
strong P10683244A1860 JJ O
propensity P10683244A1860 NN O
to P10683244A1860 TO O
interact P10683244A1860 VB O
and P10683244A1860 CC O
that P10683244A1860 IN O
this P10683244A1860 DT O
interaction P10683244A1860 NN O
is P10683244A1860 VBZ O
stable P10683244A1860 JJ O
in P10683244A1860 IN O
the P10683244A1860 DT O
absence P10683244A1860 NN O
of P10683244A1860 IN O
added P10683244A1860 JJ O
nucleotides P10683244A1860 NNS O
or P10683244A1860 CC O
exogenously P10683244A1860 RB O
induced P10683244A1860 JJ O
phosphorylation P10683244A1860 NN O
. P10683244A1860 . O
. . O O

The P10100605A0392 DT O
induced P10100605A0392 JJ O
respiratory P10100605A0392 NN O
burst P10100605A0392 NN O
was P10100605A0392 VBD O
investigated P10100605A0392 VBN O
by P10100605A0392 IN O
the P10100605A0392 DT O
intracellular P10100605A0392 JJ O
oxidative P10100605A0392 JJ O
transformation P10100605A0392 NN O
of P10100605A0392 IN O
dihydrorhodamine P10100605A0392 NN O
123 P10100605A0392 CD O
to P10100605A0392 TO O
the P10100605A0392 DT O
fluorescent P10100605A0392 NN O
dye P10100605A0392 NN O
rhodamine P10100605A0392 NN O
123 P10100605A0392 CD O
via P10100605A0392 IN O
flow P10100605A0392 JJ O
cytometry P10100605A0392 NN O
. P10100605A0392 . O
. . O O

The P09801333A0174 DT O
full-length P09801333A0174 JJ O
N P09801333A0174 NNP I-UN
gene P09801333A0174 NN I-UN
, P09801333A0174 , O
encoded P09801333A0174 VBN O
by P09801333A0174 IN O
open P09801333A0174 JJ O
reading P09801333A0174 NN O
frame P09801333A0174 NN O
7 P09801333A0174 CD O
, P09801333A0174 , O
was P09801333A0174 VBD O
cloned P09801333A0174 VBN O
from P09801333A0174 IN O
the P09801333A0174 DT O
Canadian P09801333A0174 NNP O
PRRS P09801333A0174 NNP O
virus P09801333A0174 NN O
, P09801333A0174 , O
PA-8 P09801333A0174 NNP O
. P09801333A0174 . O
. . O O

Whereas P09741391A0581 NNP O
, P09741391A0581 , O
in P09741391A0581 IN O
the P09741391A0581 DT O
single-chambered P09741391A0581 JJ O
body P09741391A0581 NN O
box P09741391A0581 NN O
, P09741391A0581 , O
PenH P09741391A0581 NNP O
units P09741391A0581 NNS O
( P09741391A0581 ( O
Enhanced P09741391A0581 NNP O
Pause P09741391A0581 NNP O
) P09741391A0581 ) O
reflect P09741391A0581 VBP O
`` P09741391A0581 `` O
effort P09741391A0581 NN O
of P09741391A0581 IN O
breathing P09741391A0581 VBG O
. P09741391A0581 . O
'' P09741391A0581 '' O
This P09741391A0581 DT O
is P09741391A0581 VBZ O
measured P09741391A0581 VBN O
as P09741391A0581 IN O
the P09741391A0581 DT O
pause P09741391A0581 NN O
between P09741391A0581 IN O
inspiration P09741391A0581 NN O
and P09741391A0581 CC O
expiration P09741391A0581 NN O
. P09741391A0581 . O
. . O O

This P08044800A0550 DT O
DNA P08044800A0550 NN O
containing P08044800A0550 VBG O
promoter P08044800A0550 NN O
activity P08044800A0550 NN O
has P08044800A0550 VBZ O
been P08044800A0550 VBN O
sequenced P08044800A0550 VBN O
in P08044800A0550 IN O
its P08044800A0550 PRP$ O
entirety P08044800A0550 NN O
and P08044800A0550 CC O
found P08044800A0550 VBD O
to P08044800A0550 TO O
contain P08044800A0550 VB O
multiple P08044800A0550 JJ O
putative P08044800A0550 JJ O
regulatory P08044800A0550 JJ O
sites P08044800A0550 NNS O
. P08044800A0550 . O
. . O O

The P02557217A0398 DT O
data P02557217A0398 NN O
indicate P02557217A0398 NN O
that P02557217A0398 IN O
calcitonin P02557217A0398 NN I-UN
induced P02557217A0398 VBD O
a P02557217A0398 DT O
beta-endorphin P02557217A0398 JJ I-UN
increase P02557217A0398 NN O
independent P02557217A0398 JJ O
of P02557217A0398 IN O
enhanced P02557217A0398 JJ O
corticotrophin-cortisol P02557217A0398 JJ O
release P02557217A0398 NN O
. P02557217A0398 . O
. . O O

Synthetic P02543734A0414 JJ O
oligonucleotides P02543734A0414 NNS O
representing P02543734A0414 VBG O
the P02543734A0414 DT O
19 P02543734A0414 CD O
bp P02543734A0414 NN O
repeat P02543734A0414 NN O
unit P02543734A0414 NN O
strongly P02543734A0414 RB O
reduced P02543734A0414 VBD O
the P02543734A0414 DT O
activity P02543734A0414 NN O
of P02543734A0414 IN O
the P02543734A0414 DT O
IE1 P02543734A0414 NNP I-UN
/ P02543734A0414 NNP I-UN
2 P02543734A0414 CD I-UN
enhancer P02543734A0414 NN I-UN
/ P02543734A0414 NN I-UN
promoter P02543734A0414 NN I-UN
in P02543734A0414 IN O
cotransfection P02543734A0414 NN O
assays P02543734A0414 NNS O
after P02543734A0414 IN O
transient P02543734A0414 JJ O
expression P02543734A0414 NN O
. P02543734A0414 . O
. . O O

EMSA P08626667A1372 NNP O
competition P08626667A1372 NN O
experiments P08626667A1372 NNS O
showed P08626667A1372 VBD O
that P08626667A1372 IN O
mutations P08626667A1372 NNS O
within P08626667A1372 IN O
the P08626667A1372 DT O
direct P08626667A1372 JJ O
repeats P08626667A1372 NNS O
failed P08626667A1372 VBD O
to P08626667A1372 TO O
compete P08626667A1372 VB O
for P08626667A1372 IN O
binding P08626667A1372 NN O
of P08626667A1372 IN O
the P08626667A1372 DT O
nuclear P08626667A1372 JJ O
proteins P08626667A1372 NNS O
to P08626667A1372 TO O
labeled P08626667A1372 VB O
wild P08626667A1372 JJ O
type P08626667A1372 NN O
oligonucleotide P08626667A1372 NN O
. P08626667A1372 . O
. . O O

Many P03251210A0981 JJ O
children P03251210A0981 NNS O
with P03251210A0981 IN O
BGC P03251210A0981 NNP O
are P03251210A0981 VBP O
delayed P03251210A0981 VBN O
in P03251210A0981 IN O
their P03251210A0981 PRP$ O
development P03251210A0981 NN O
, P03251210A0981 , O
but P03251210A0981 CC O
calcifications P03251210A0981 NNS O
are P03251210A0981 VBP O
not P03251210A0981 RB O
directly P03251210A0981 RB O
related P03251210A0981 VBN O
to P03251210A0981 TO O
specific P03251210A0981 JJ O
forms P03251210A0981 NNS O
of P03251210A0981 IN O
neurologic P03251210A0981 JJ O
dysfunction P03251210A0981 NN O
. P03251210A0981 . O
. . O O

Anamnestic P07297978A0570 JJ O
data P07297978A0570 NNS O
were P07297978A0570 VBD O
obtained P07297978A0570 VBN O
from P07297978A0570 IN O
case P07297978A0570 NN O
history P07297978A0570 NN O
, P07297978A0570 , O
smoking P07297978A0570 VBG O
habits P07297978A0570 NNS O
were P07297978A0570 VBD O
not P07297978A0570 RB O
known P07297978A0570 VBN O
in P07297978A0570 IN O
collective P07297978A0570 NN O
A P07297978A0570 NN O
and P07297978A0570 CC O
C P07297978A0570 NNP O
. P07297978A0570 . O
. . O O

Experiments P02261254A0168 NNS O
showed P02261254A0168 VBD O
that P02261254A0168 IN O
temporary P02261254A0168 JJ O
arrest P02261254A0168 NN O
of P02261254A0168 IN O
pulmonary P02261254A0168 JJ O
circulation P02261254A0168 NN O
under P02261254A0168 IN O
conditions P02261254A0168 NNS O
of P02261254A0168 IN O
extracorporeal P02261254A0168 JJ O
circulation P02261254A0168 NN O
is P02261254A0168 VBZ O
attended P02261254A0168 VBN O
by P02261254A0168 IN O
the P02261254A0168 DT O
development P02261254A0168 NN O
of P02261254A0168 IN O
ischemia P02261254A0168 NN O
of P02261254A0168 IN O
the P02261254A0168 DT O
respiratory P02261254A0168 NN O
pulmonary P02261254A0168 JJ O
tissue P02261254A0168 NN O
. P02261254A0168 . O
. . O O

At P07406527A0212 IN O
the P07406527A0212 DT O
end P07406527A0212 NN O
of P07406527A0212 IN O
the P07406527A0212 DT O
experiment P07406527A0212 NN O
the P07406527A0212 DT O
urinary P07406527A0212 JJ O
porphyrin P07406527A0212 NN O
excretion P07406527A0212 NN O
and P07406527A0212 CC O
the P07406527A0212 DT O
porphyrin P07406527A0212 NN O
content P07406527A0212 NN O
in P07406527A0212 IN O
lijver P07406527A0212 NN O
and P07406527A0212 CC O
skin P07406527A0212 NN O
were P07406527A0212 VBD O
diminished P07406527A0212 VBN O
in P07406527A0212 IN O
HCB-CQ-treated P07406527A0212 JJ O
animals P07406527A0212 NNS O
by P07406527A0212 IN O
about P07406527A0212 IN O
50 P07406527A0212 CD O
% P07406527A0212 NN O
compared P07406527A0212 VBN O
to P07406527A0212 TO O
the P07406527A0212 DT O
HCB P07406527A0212 NNP O
controls P07406527A0212 NNS O
. P07406527A0212 . O
. . O O

Northern P03038891A0935 NNP O
analyses P03038891A0935 NNS O
of P03038891A0935 IN O
RNAs P03038891A0935 NNP O
from P03038891A0935 IN O
mouse P03038891A0935 NN O
tissues P03038891A0935 NNS O
and P03038891A0935 CC O
cell P03038891A0935 NN O
lines P03038891A0935 NNS O
indicated P03038891A0935 VBD O
that P03038891A0935 IN O
p11 P03038891A0935 NN I-UN
mRNA P03038891A0935 NN I-UN
levels P03038891A0935 NNS O
vary P03038891A0935 VBP O
widely P03038891A0935 RB O
. P03038891A0935 . O
. . O O

The P01656235A0946 DT O
single P01656235A0946 JJ O
most P01656235A0946 RBS O
important P01656235A0946 JJ O
element P01656235A0946 NN O
, P01656235A0946 , O
by P01656235A0946 IN O
linker-scanning P01656235A0946 JJ O
analysis P01656235A0946 NN O
, P01656235A0946 , O
is P01656235A0946 VBZ O
a P01656235A0946 DT O
10-bp P01656235A0946 JJ O
region P01656235A0946 NN O
that P01656235A0946 WDT O
contains P01656235A0946 VBZ O
a P01656235A0946 DT O
CCAAT P01656235A0946 NNP O
motif P01656235A0946 NN O
. P01656235A0946 . O
. . O O

These P03417668A1233 DT O
findings P03417668A1233 NNS O
indicate P03417668A1233 VBP O
that P03417668A1233 IN O
autophosphorylation P03417668A1233 NN O
of P03417668A1233 IN O
Thr286 P03417668A1233 NNP O
( P03417668A1233 ( O
alpha P03417668A1233 JJ O
subunit P03417668A1233 NN O
) P03417668A1233 ) O
and P03417668A1233 CC O
Thr287 P03417668A1233 NNP O
( P03417668A1233 ( O
beta P03417668A1233 VB O
subunit P03417668A1233 NN O
) P03417668A1233 ) O
is P03417668A1233 VBZ O
responsible P03417668A1233 JJ O
for P03417668A1233 IN O
transition P03417668A1233 NN O
of P03417668A1233 IN O
CaM-kinase P03417668A1233 NNP I-UN
II P03417668A1233 NNP I-UN
to P03417668A1233 TO O
the P03417668A1233 DT O
Ca2+-independent P03417668A1233 JJ O
form P03417668A1233 NN O
. P03417668A1233 . O
. . O O

Initiation P07666538A0000 NN O
of P07666538A0000 IN O
translation P07666538A0000 NN O
of P07666538A0000 IN O
the P07666538A0000 DT O
human P07666538A0000 JJ O
hepatitis P07666538A0000 NN O
C P07666538A0000 NNP O
virus P07666538A0000 NN O
( P07666538A0000 ( O
HCV P07666538A0000 NNP O
) P07666538A0000 ) O
RNA P07666538A0000 NNP O
genome P07666538A0000 NN O
occurs P07666538A0000 NNS O
by P07666538A0000 IN O
internal P07666538A0000 JJ O
ribosome P07666538A0000 NN O
entry P07666538A0000 NN O
into P07666538A0000 IN O
the P07666538A0000 DT O
5 P07666538A0000 CD O
' P07666538A0000 POS O
noncoding P07666538A0000 JJ O
region P07666538A0000 NN O
( P07666538A0000 ( O
5'NCR P07666538A0000 CD O
) P07666538A0000 ) O
in P07666538A0000 IN O
a P07666538A0000 DT O
cap-independent P07666538A0000 JJ O
manner P07666538A0000 NN O
. P07666538A0000 . O
. . O O

Initially P09652742A0455 RB O
, P09652742A0455 , O
we P09652742A0455 PRP O
observed P09652742A0455 VBD O
that P09652742A0455 IN O
unmutated P09652742A0455 JJ O
p53 P09652742A0455 NN I-UN
is P09652742A0455 VBZ O
strongly P09652742A0455 RB O
expressed P09652742A0455 VBN O
in P09652742A0455 IN O
premalignant P09652742A0455 JJ O
mammary P09652742A0455 JJ O
glands P09652742A0455 NNS O
and P09652742A0455 CC O
in P09652742A0455 IN O
mammary P09652742A0455 JJ O
tumors P09652742A0455 NNS O
derived P09652742A0455 VBN O
from P09652742A0455 IN O
the P09652742A0455 DT O
MMTV-c-myc P09652742A0455 NNP O
strain P09652742A0455 NN O
. P09652742A0455 . O
. . O O

These P11416132A1351 DT O
studies P11416132A1351 NNS O
demonstrate P11416132A1351 VBP O
that P11416132A1351 IN O
site-specific P11416132A1351 JJ O
recognition P11416132A1351 NN O
of P11416132A1351 IN O
the P11416132A1351 DT O
bxd P11416132A1351 NN I-UN
PRE P11416132A1351 NNP I-UN
by P11416132A1351 IN O
d P11416132A1351 NN O
( P11416132A1351 ( O
GA P11416132A1351 NNP O
) P11416132A1351 ) O
( P11416132A1351 ( O
n P11416132A1351 JJ O
) P11416132A1351 ) O
repeat P11416132A1351 NN O
binding P11416132A1351 VBG O
activities P11416132A1351 NNS O
mediates P11416132A1351 VBZ O
PcG-dependent P11416132A1351 JJ O
silencing P11416132A1351 NN O
. P11416132A1351 . O
. . O O

The P11539522A0612 DT O
NAUSICAA P11539522A0612 NNP O
system P11539522A0612 NN O
gives P11539522A0612 VBZ O
a P11539522A0612 DT O
good P11539522A0612 JJ O
knowledge P11539522A0612 NN O
of P11539522A0612 IN O
LET P11539522A0612 NNP O
spectra P11539522A0612 NNP O
for P11539522A0612 IN O
the P11539522A0612 DT O
first P11539522A0612 JJ O
time P11539522A0612 NN O
in P11539522A0612 IN O
space P11539522A0612 NN O
dosimetry P11539522A0612 NN O
. P11539522A0612 . O
. . O O

Group P09543227A0815 NNP O
A P09543227A0815 NNP O
( P09543227A0815 ( O
68.7+ P09543227A0815 CD O
/ P09543227A0815 NNP O
-2.7 P09543227A0815 NNP O
years P09543227A0815 NNS O
) P09543227A0815 ) O
consisted P09543227A0815 VBD O
of P09543227A0815 IN O
patients P09543227A0815 NNS O
with P09543227A0815 IN O
0 P09543227A0815 CD O
or P09543227A0815 CC O
1 P09543227A0815 CD O
risk P09543227A0815 NN O
factors P09543227A0815 NNS O
; P09543227A0815 : O
B P09543227A0815 NNP O
( P09543227A0815 ( O
68.3+ P09543227A0815 CD O
/ P09543227A0815 NNP O
-4.2 P09543227A0815 NNP O
years P09543227A0815 NNS O
) P09543227A0815 ) O
those P09543227A0815 DT O
with P09543227A0815 IN O
2 P09543227A0815 CD O
risk P09543227A0815 NN O
factors P09543227A0815 NNS O
; P09543227A0815 : O
and P09543227A0815 CC O
C P09543227A0815 NNP O
( P09543227A0815 ( O
69.2+ P09543227A0815 CD O
/ P09543227A0815 NNP O
-3.6 P09543227A0815 NNP O
years P09543227A0815 NNS O
) P09543227A0815 ) O
those P09543227A0815 DT O
with P09543227A0815 IN O
3 P09543227A0815 CD O
or P09543227A0815 CC O
more P09543227A0815 JJR O
risk P09543227A0815 NN O
factors P09543227A0815 NNS O
. P09543227A0815 . O
. . O O

Transient P09057648A0422 JJ O
cotransfection P09057648A0422 NN O
of P09057648A0422 IN O
tat P09057648A0422 NN I-UN
cDNA P09057648A0422 NN I-UN
in P09057648A0422 IN O
sense P09057648A0422 NN O
orientation P09057648A0422 NN O
( P09057648A0422 ( O
tat P09057648A0422 JJ I-UN
/ P09057648A0422 NNP I-UN
S P09057648A0422 NNP I-UN
) P09057648A0422 ) O
, P09057648A0422 , O
together P09057648A0422 RB O
with P09057648A0422 IN O
a P09057648A0422 DT O
plasmid P09057648A0422 NN O
containing P09057648A0422 VBG O
the P09057648A0422 DT O
c-fos P09057648A0422 JJ I-UN
promoter P09057648A0422 NN I-UN
( P09057648A0422 ( O
FC3 P09057648A0422 NNP I-UN
, P09057648A0422 , O
from P09057648A0422 IN O
-711 P09057648A0422 NN O
to P09057648A0422 TO O
+42 P09057648A0422 VB O
) P09057648A0422 ) O
in P09057648A0422 IN O
front P09057648A0422 NN O
of P09057648A0422 IN O
the P09057648A0422 DT O
bacterial P09057648A0422 JJ I-UN
chloramphenicol P09057648A0422 NN I-UN
acetyltransferase P09057648A0422 NN I-UN
( P09057648A0422 ( O
CAT P09057648A0422 NNP I-UN
) P09057648A0422 ) O
gene P09057648A0422 NN O
significantly P09057648A0422 RB O
enhanced P09057648A0422 VBD O
CAT P09057648A0422 NNP I-UN
activity P09057648A0422 NN O
in P09057648A0422 IN O
Jurkat P09057648A0422 NNP O
cells P09057648A0422 NNS O
activated P09057648A0422 VBN O
by P09057648A0422 IN O
the P09057648A0422 DT O
addition P09057648A0422 NN O
of P09057648A0422 IN O
15 P09057648A0422 CD O
% P09057648A0422 NN O
fetal P09057648A0422 JJ O
calf P09057648A0422 NN O
serum P09057648A0422 NN O
( P09057648A0422 ( O
FCS P09057648A0422 NNP O
) P09057648A0422 ) O
or P09057648A0422 CC O
5 P09057648A0422 CD O
micrograms P09057648A0422 NNS O
/ P09057648A0422 VBP O
mL P09057648A0422 JJ O
phytohemagglutinin P09057648A0422 NN I-UN
plus P09057648A0422 CC O
10 P09057648A0422 CD O
( P09057648A0422 ( O
-7 P09057648A0422 NN O
) P09057648A0422 ) O
mol P09057648A0422 NN O
/ P09057648A0422 NNP O
L P09057648A0422 NNP O
phorbol P09057648A0422 NN O
myristate P09057648A0422 NN O
acetate P09057648A0422 NN O
( P09057648A0422 ( O
PMA P09057648A0422 NNP O
) P09057648A0422 ) O
and P09057648A0422 CC O
U937 P09057648A0422 NNP O
cells P09057648A0422 NNS O
activated P09057648A0422 VBN O
by P09057648A0422 IN O
15 P09057648A0422 CD O
% P09057648A0422 NN O
FCS P09057648A0422 NNP O
or P09057648A0422 CC O
10 P09057648A0422 CD O
( P09057648A0422 ( O
-7 P09057648A0422 NN O
) P09057648A0422 ) O
mol P09057648A0422 NN O
/ P09057648A0422 NNP O
L P09057648A0422 NNP O
PMA P09057648A0422 NNP O
. P09057648A0422 . O
. . O O

We P03769224A0000 PRP O
analyzed P03769224A0000 VBD O
data P03769224A0000 NNS O
from P03769224A0000 IN O
56 P03769224A0000 CD O
patients P03769224A0000 NNS O
with P03769224A0000 IN O
Systemic P03769224A0000 NNP O
Lupus P03769224A0000 NNP O
Erythematosus P03769224A0000 NNP O
( P03769224A0000 ( O
SLE P03769224A0000 NNP O
) P03769224A0000 ) O
in P03769224A0000 IN O
whom P03769224A0000 WP O
renal P03769224A0000 JJ O
biopsies P03769224A0000 NNS O
were P03769224A0000 VBD O
done P03769224A0000 VBN O
systematically P03769224A0000 RB O
. P03769224A0000 . O
. . O O

Members P09079650A0136 NNS O
of P09079650A0136 IN O
the P09079650A0136 DT O
MAPK P09079650A0136 NNP I-UN
family P09079650A0136 NN I-UN
include P09079650A0136 VBP O
the P09079650A0136 DT O
extracellular P09079650A0136 JJ I-UN
response P09079650A0136 NN I-UN
kinases P09079650A0136 NNS I-UN
( P09079650A0136 ( O
ERKs P09079650A0136 NNP I-UN
or P09079650A0136 CC O
p42 P09079650A0136 VB I-UN
/ P09079650A0136 JJ I-UN
44 P09079650A0136 CD I-UN
( P09079650A0136 ( O
MAPK P09079650A0136 NNP I-UN
) P09079650A0136 ) O
) P09079650A0136 ) O
, P09079650A0136 , O
the P09079650A0136 DT O
c-Jun P09079650A0136 JJ I-UN
amino-terminal P09079650A0136 JJ I-UN
kinases P09079650A0136 NNS I-UN
( P09079650A0136 ( O
JNKs P09079650A0136 NNP I-UN
) P09079650A0136 ) O
, P09079650A0136 , O
and P09079650A0136 CC O
the P09079650A0136 DT O
p38 P09079650A0136 NN I-UN
/ P09079650A0136 NNP O
Hog P09079650A0136 NNP I-UN
1 P09079650A0136 CD I-UN
protein P09079650A0136 NN O
kinases P09079650A0136 NNS O
. P09079650A0136 . O
. . O O

When P02062933A0738 WRB O
given P02062933A0738 VBN O
the P02062933A0738 DT O
choice P02062933A0738 NN O
between P02062933A0738 IN O
an P02062933A0738 DT O
estrous P02062933A0738 JJ O
female P02062933A0738 NN O
and P02062933A0738 CC O
a P02062933A0738 DT O
sexually P02062933A0738 RB O
active P02062933A0738 JJ O
male P02062933A0738 NN O
in P02062933A0738 IN O
the P02062933A0738 DT O
AOF P02062933A0738 NNP O
, P02062933A0738 , O
flutamide P02062933A0738 NN O
females P02062933A0738 NNS O
, P02062933A0738 , O
as P02062933A0738 RB O
well P02062933A0738 RB O
as P02062933A0738 IN O
controls P02062933A0738 NNS O
, P02062933A0738 , O
preferred P02062933A0738 VBD O
the P02062933A0738 DT O
male P02062933A0738 NN O
partner P02062933A0738 NN O
. P02062933A0738 . O
. . O O

Quantum-statistical P09999256T0000 JJ O
theory P09999256T0000 NN O
of P09999256T0000 IN O
high-field P09999256T0000 JJ O
transport P09999256T0000 NN O
phenomena P09999256T0000 NN O
. P09999256T0000 . O
. . O O

However P08676495A0129 RB O
, P08676495A0129 , O
one P08676495A0129 CD O
3 P08676495A0129 CD O
' P08676495A0129 POS O
splice P08676495A0129 NN O
site P08676495A0129 NN O
, P08676495A0129 , O
located P08676495A0129 VBN O
at P08676495A0129 IN O
nucleotide P08676495A0129 RB O
( P08676495A0129 ( O
nt P08676495A0129 NN O
) P08676495A0129 ) O
3225 P08676495A0129 CD O
, P08676495A0129 , O
is P08676495A0129 VBZ O
used P08676495A0129 VBN O
for P08676495A0129 IN O
the P08676495A0129 DT O
processing P08676495A0129 NN O
of P08676495A0129 IN O
most P08676495A0129 JJS O
BPV-1 P08676495A0129 JJ O
pre-mRNAs P08676495A0129 NN O
in P08676495A0129 IN O
BPV-1-transformed P08676495A0129 NNP O
C127 P08676495A0129 NNP O
cells P08676495A0129 NNS O
and P08676495A0129 CC O
at P08676495A0129 IN O
early P08676495A0129 RB O
to P08676495A0129 TO O
intermediate P08676495A0129 VB O
times P08676495A0129 NNS O
in P08676495A0129 IN O
productively P08676495A0129 RB O
infected P08676495A0129 JJ O
warts P08676495A0129 NNS O
. P08676495A0129 . O
. . O O

The P10903843A0447 DT O
chromosomal P10903843A0447 JJ O
localization P10903843A0447 NN O
on P10903843A0447 IN O
distal P10903843A0447 JJ O
chromosome P10903843A0447 NN O
7 P10903843A0447 CD O
places P10903843A0447 NNS O
it P10903843A0447 PRP O
in P10903843A0447 IN O
a P10903843A0447 DT O
cluster P10903843A0447 NN O
of P10903843A0447 IN O
imprinted P10903843A0447 JJ O
genes P10903843A0447 NNS O
, P10903843A0447 , O
flanked P10903843A0447 VBN O
by P10903843A0447 IN O
the P10903843A0447 DT O
previously P10903843A0447 RB O
described P10903843A0447 VBN O
Tapa1 P10903843A0447 NNP I-UN
and P10903843A0447 CC O
Kcnq1 P10903843A0447 NNP I-UN
genes P10903843A0447 NNS I-UN
. P10903843A0447 . O
. . O O

PET P09345495A0000 NNP O
activation P09345495A0000 NN O
studies P09345495A0000 NNS O
are P09345495A0000 VBP O
performed P09345495A0000 VBN O
widely P09345495A0000 RB O
to P09345495A0000 TO O
study P09345495A0000 VB O
human P09345495A0000 JJ O
brain P09345495A0000 NN O
function P09345495A0000 NN O
. P09345495A0000 . O
. . O O

In P03887769A0584 IN O
the P03887769A0584 DT O
region P03887769A0584 NN O
Walgau P03887769A0584 NNP O
with P03887769A0584 IN O
mixed P03887769A0584 JJ O
industrial-rural P03887769A0584 JJ O
population P03887769A0584 NN O
an P03887769A0584 DT O
iodine P03887769A0584 JJ O
deficiency P03887769A0584 NN O
I P03887769A0584 PRP O
was P03887769A0584 VBD O
found P03887769A0584 VBN O
in P03887769A0584 IN O
81 P03887769A0584 CD O
% P03887769A0584 NN O
and P03887769A0584 CC O
an P03887769A0584 DT O
iodine P03887769A0584 JJ O
deficiency P03887769A0584 NN O
II P03887769A0584 NNP O
in P03887769A0584 IN O
45 P03887769A0584 CD O
% P03887769A0584 NN O
. P03887769A0584 . O
. . O O

Aneurysmal P08169709T0000 NNP O
bone P08169709T0000 NN O
cyst P08169709T0000 NN O
of P08169709T0000 IN O
the P08169709T0000 DT O
jaws P08169709T0000 NN O
: P08169709T0000 : O
analysis P08169709T0000 NN O
of P08169709T0000 IN O
11 P08169709T0000 CD O
cases P08169709T0000 NNS O
. P08169709T0000 . O
. . O O

Rat P08929563T0000 NNP I-UN
liver P08929563T0000 NN I-UN
catalase P08929563T0000 NN I-UN
is P08929563T0000 VBZ O
sorted P08929563T0000 VBN O
to P08929563T0000 TO O
peroxisomes P08929563T0000 NNS O
by P08929563T0000 IN O
its P08929563T0000 PRP$ O
C-terminal P08929563T0000 JJ O
tripeptide P08929563T0000 JJ O
Ala-Asn-Leu P08929563T0000 NNP O
, P08929563T0000 , O
not P08929563T0000 RB O
by P08929563T0000 IN O
the P08929563T0000 DT O
internal P08929563T0000 JJ O
Ser-Lys-Leu P08929563T0000 NNP O
motif P08929563T0000 NN O
. P08929563T0000 . O
. . O O

Because P01617776A0343 IN O
the P01617776A0343 DT O
adrenergic P01617776A0343 NN O
nervous P01617776A0343 JJ O
system P01617776A0343 NN O
influences P01617776A0343 NNS O
cardiac P01617776A0343 JJ O
arrhythmias P01617776A0343 NN O
and P01617776A0343 CC O
myocardial P01617776A0343 JJ O
infarction P01617776A0343 NN O
can P01617776A0343 MD O
directly P01617776A0343 RB O
affect P01617776A0343 VB O
sympathetic P01617776A0343 JJ O
innervation P01617776A0343 NN O
in P01617776A0343 IN O
the P01617776A0343 DT O
heart P01617776A0343 NN O
, P01617776A0343 , O
we P01617776A0343 PRP O
investigated P01617776A0343 VBD O
the P01617776A0343 DT O
role P01617776A0343 NN O
of P01617776A0343 IN O
the P01617776A0343 DT O
sympathetic P01617776A0343 JJ O
nervous P01617776A0343 JJ O
system P01617776A0343 NN O
on P01617776A0343 IN O
reentry P01617776A0343 NN O
in P01617776A0343 IN O
the P01617776A0343 DT O
canine P01617776A0343 JJ O
heart P01617776A0343 NN O
4 P01617776A0343 CD O
days P01617776A0343 NNS O
after P01617776A0343 IN O
infarction P01617776A0343 NN O
. P01617776A0343 . O
. . O O

CO2 P05488121T0000 NNP O
assimilation P05488121T0000 NN O
by P05488121T0000 IN O
chloroplasts P05488121T0000 NNS O
illuminated P05488121T0000 VBN O
on P05488121T0000 IN O
filter P05488121T0000 JJ O
paper P05488121T0000 NN O
. P05488121T0000 . O
. . O O

In P08625987A1086 IN O
sorted P08625987A1086 VBN O
bone P08625987A1086 NN O
marrow P08625987A1086 NN O
cells P08625987A1086 NNS O
expression P08625987A1086 NN O
of P08625987A1086 IN O
both P08625987A1086 DT O
VpreB P08625987A1086 NNP I-UN
genes P08625987A1086 NNS I-UN
was P08625987A1086 VBD O
detected P08625987A1086 VBN O
in P08625987A1086 IN O
pro-B P08625987A1086 JJ O
/ P08625987A1086 JJ O
pre-BI P08625987A1086 NN O
and P08625987A1086 CC O
large P08625987A1086 JJ O
pre-BII P08625987A1086 JJ O
cells P08625987A1086 NNS O
, P08625987A1086 , O
while P08625987A1086 IN O
the P08625987A1086 DT O
RNA P08625987A1086 NNP O
steady P08625987A1086 JJ O
state P08625987A1086 NN O
levels P08625987A1086 NNS O
were P08625987A1086 VBD O
at P08625987A1086 IN O
least P08625987A1086 JJS O
100-fold P08625987A1086 JJ O
lower P08625987A1086 JJR O
in P08625987A1086 IN O
small P08625987A1086 JJ O
pre-BII P08625987A1086 NN O
and P08625987A1086 CC O
immature P08625987A1086 NN O
/ P08625987A1086 NNP O
mature P08625987A1086 NN O
B P08625987A1086 NNP O
cells P08625987A1086 NNS O
. P08625987A1086 . O
. . O O

Deaths P00851286A0375 NNP O
stopped P00851286A0375 VBD O
11 P00851286A0375 CD O
hours P00851286A0375 NNS O
after P00851286A0375 IN O
copper P00851286A0375 NN O
concentrations P00851286A0375 NNS O
decreased P00851286A0375 VBD O
below P00851286A0375 IN O
0.2 P00851286A0375 CD O
ppm P00851286A0375 NN O
and P00851286A0375 CC O
signs P00851286A0375 NNS O
of P00851286A0375 IN O
distress P00851286A0375 NN O
stopped P00851286A0375 VBN O
in P00851286A0375 IN O
surviving P00851286A0375 VBG O
pinfish P00851286A0375 JJ O
by P00851286A0375 IN O
approximately P00851286A0375 RB O
6 P00851286A0375 CD O
hours P00851286A0375 NNS O
after P00851286A0375 IN O
the P00851286A0375 DT O
last P00851286A0375 JJ O
death P00851286A0375 NN O
. P00851286A0375 . O
. . O O

The P00626014T0001 DT O
malignity P00626014T0001 NN O
of P00626014T0001 IN O
nevoid P00626014T0001 JJ O
lentigo P00626014T0001 NN O
. P00626014T0001 . O
. . O O

OBJECTIVE P11793614A0000 NN O
: P11793614A0000 : O
To P11793614A0000 TO O
demonstrate P11793614A0000 VB O
a P11793614A0000 DT O
lack P11793614A0000 NN O
of P11793614A0000 IN O
effect P11793614A0000 NN O
of P11793614A0000 IN O
steady-state P11793614A0000 JJ O
concentrations P11793614A0000 NNS O
of P11793614A0000 IN O
cilomilast P11793614A0000 NN O
, P11793614A0000 , O
a P11793614A0000 DT O
new P11793614A0000 JJ O
oral P11793614A0000 JJ O
phosphodiesterase P11793614A0000 NN I-UN
4 P11793614A0000 CD I-UN
inhibitor P11793614A0000 NN O
for P11793614A0000 IN O
the P11793614A0000 DT O
treatment P11793614A0000 NN O
of P11793614A0000 IN O
chronic P11793614A0000 JJ O
obstructive P11793614A0000 JJ O
pulmonary P11793614A0000 JJ O
disease P11793614A0000 NN O
, P11793614A0000 , O
on P11793614A0000 IN O
warfarin-induced P11793614A0000 JJ O
anticoagulation P11793614A0000 NN O
. P11793614A0000 . O
. . O O

Furthermore P09771967A1052 RB O
, P09771967A1052 , O
LB1 P09771967A1052 NNP I-UN
gene P09771967A1052 NN I-UN
mapped P09771967A1052 VBD O
to P09771967A1052 TO O
chromosome P09771967A1052 VB O
13q14 P09771967A1052 CD O
, P09771967A1052 , O
a P09771967A1052 DT O
region P09771967A1052 NN O
that P09771967A1052 WDT O
has P09771967A1052 VBZ O
been P09771967A1052 VBN O
involved P09771967A1052 VBN O
as P09771967A1052 IN O
a P09771967A1052 DT O
chromosomal P09771967A1052 JJ O
breakpoint P09771967A1052 NN O
in P09771967A1052 IN O
DLBL P09771967A1052 NNP O
. P09771967A1052 . O
. . O O

The P08496184A0772 DT O
active P08496184A0772 JJ O
open P08496184A0772 JJ O
reading P08496184A0772 NN O
frame P08496184A0772 NN O
in P08496184A0772 IN O
the P08496184A0772 DT O
clone P08496184A0772 NN O
maps P08496184A0772 NN O
at P08496184A0772 IN O
27 P08496184A0772 CD O
min P08496184A0772 NN O
on P08496184A0772 IN O
the P08496184A0772 DT O
E. P08496184A0772 NNP O
coli P08496184A0772 NNS O
chromosome P08496184A0772 NN O
and P08496184A0772 CC O
is P08496184A0772 VBZ O
identical P08496184A0772 JJ O
in P08496184A0772 IN O
sequence P08496184A0772 NN O
to P08496184A0772 TO O
a P08496184A0772 DT O
wild P08496184A0772 JJ O
type P08496184A0772 JJ O
counterpart P08496184A0772 NN O
. P08496184A0772 . O
. . O O

The P01612085A0624 DT O
serum P01612085A0624 NN O
erythropoietin P01612085A0624 NN I-UN
( P01612085A0624 ( O
EPO P01612085A0624 NNP I-UN
) P01612085A0624 ) O
concentrations P01612085A0624 NNS O
of P01612085A0624 IN O
15 P01612085A0624 CD O
male P01612085A0624 NN O
triathletes P01612085A0624 NNS O
( P01612085A0624 ( O
26.3 P01612085A0624 CD O
U.ml-1 P01612085A0624 NN O
) P01612085A0624 ) O
were P01612085A0624 VBD O
significantly P01612085A0624 RB O
lower P01612085A0624 JJR O
than P01612085A0624 IN O
those P01612085A0624 DT O
of P01612085A0624 IN O
45 P01612085A0624 CD O
male P01612085A0624 JJ O
distance P01612085A0624 NN O
runners P01612085A0624 NNS O
( P01612085A0624 ( O
31.6 P01612085A0624 CD O
U.ml-1 P01612085A0624 NN O
; P01612085A0624 : O
P P01612085A0624 NNP O
less P01612085A0624 JJR O
than P01612085A0624 IN O
0.05 P01612085A0624 CD O
) P01612085A0624 ) O
. P01612085A0624 . O
. . O O

Comparative P08108343A0000 JJ O
analysis P08108343A0000 NN O
with P08108343A0000 IN O
an P08108343A0000 DT O
antiandrogen P08108343A0000 NN O
niftolid P08108343A0000 JJ O
and P08108343A0000 CC O
synthetic P08108343A0000 JJ I-UN
GnRH P08108343A0000 NNP I-UN
was P08108343A0000 VBD O
carried P08108343A0000 VBN O
out P08108343A0000 RP O
in P08108343A0000 IN O
22 P08108343A0000 CD O
normal P08108343A0000 JJ O
subjects P08108343A0000 NNS O
, P08108343A0000 , O
14 P08108343A0000 CD O
patients P08108343A0000 NNS O
with P08108343A0000 IN O
primary P08108343A0000 JJ O
and P08108343A0000 CC O
20 P08108343A0000 CD O
ones P08108343A0000 NNS O
with P08108343A0000 IN O
secondary P08108343A0000 JJ O
hypogonadism P08108343A0000 NN O
, P08108343A0000 , O
and P08108343A0000 CC O
in P08108343A0000 IN O
5 P08108343A0000 CD O
patients P08108343A0000 NNS O
with P08108343A0000 IN O
clinical P08108343A0000 JJ O
signs P08108343A0000 NNS O
of P08108343A0000 IN O
gonadal P08108343A0000 JJ O
insufficiency P08108343A0000 NN O
and P08108343A0000 CC O
obscure P08108343A0000 JJ O
diagnosis P08108343A0000 NN O
in P08108343A0000 IN O
order P08108343A0000 NN O
to P08108343A0000 TO O
elucidate P08108343A0000 VB O
the P08108343A0000 DT O
pituitary P08108343A0000 JJ I-UN
gonadotropin P08108343A0000 NN I-UN
reserves P08108343A0000 NNS O
. P08108343A0000 . O
. . O O

TB P10934640A1114 NNP O
bone P10934640A1114 NN O
area P10934640A1114 NN O
( P10934640A1114 ( O
p P10934640A1114 JJ O
< P10934640A1114 NNP O
0.001 P10934640A1114 CD O
) P10934640A1114 ) O
, P10934640A1114 , O
height P10934640A1114 NN O
( P10934640A1114 ( O
p P10934640A1114 JJ O
< P10934640A1114 NNP O
0.01 P10934640A1114 CD O
) P10934640A1114 ) O
, P10934640A1114 , O
years P10934640A1114 NNS O
in P10934640A1114 IN O
present P10934640A1114 JJ O
colony P10934640A1114 NN O
( P10934640A1114 ( O
p P10934640A1114 JJ O
= P10934640A1114 NNP O
0.03 P10934640A1114 CD O
) P10934640A1114 ) O
, P10934640A1114 , O
and P10934640A1114 CC O
menses P10934640A1114 NNS O
( P10934640A1114 ( O
p P10934640A1114 JJ O
< P10934640A1114 NNP O
0.01 P10934640A1114 CD O
) P10934640A1114 ) O
predicted P10934640A1114 VBD O
TB P10934640A1114 NNP O
BMC P10934640A1114 NNP O
. P10934640A1114 . O
. . O O

Identification P08552670T0000 NN O
, P08552670T0000 , O
purification P08552670T0000 NN O
, P08552670T0000 , O
and P08552670T0000 CC O
molecular P08552670T0000 JJ O
cloning P08552670T0000 NN O
of P08552670T0000 IN O
autonomously P08552670T0000 RB I-UN
replicating P08552670T0000 VBG I-UN
sequence-binding P08552670T0000 JJ I-UN
protein P08552670T0000 NN I-UN
1 P08552670T0000 CD I-UN
from P08552670T0000 IN I-UN
fission P08552670T0000 NN I-UN
yeast P08552670T0000 NN I-UN
Schizosaccharomyces P08552670T0000 NNP I-UN
pombe P08552670T0000 NN I-UN
. P08552670T0000 . O
. . O O

In P03292082A0486 IN O
contrast P03292082A0486 NN O
, P03292082A0486 , O
we P03292082A0486 PRP O
observed P03292082A0486 VBD O
high P03292082A0486 JJ O
concentrations P03292082A0486 NNS O
in P03292082A0486 IN O
29 P03292082A0486 CD O
of P03292082A0486 IN O
75 P03292082A0486 CD O
patients P03292082A0486 NNS O
with P03292082A0486 IN O
tumors P03292082A0486 NNS O
of P03292082A0486 IN O
the P03292082A0486 DT O
central P03292082A0486 JJ O
nervous P03292082A0486 JJ O
system P03292082A0486 NN O
, P03292082A0486 , O
especially P03292082A0486 RB O
in P03292082A0486 IN O
meningioma P03292082A0486 NN O
( P03292082A0486 ( O
6 P03292082A0486 CD O
/ P03292082A0486 RB O
9 P03292082A0486 CD O
) P03292082A0486 ) O
, P03292082A0486 , O
glioblastoma P03292082A0486 NN O
( P03292082A0486 ( O
9 P03292082A0486 CD O
/ P03292082A0486 RB O
23 P03292082A0486 CD O
) P03292082A0486 ) O
, P03292082A0486 , O
and P03292082A0486 CC O
neurinoma P03292082A0486 NN O
( P03292082A0486 ( O
5 P03292082A0486 CD O
/ P03292082A0486 RB O
5 P03292082A0486 CD O
) P03292082A0486 ) O
. P03292082A0486 . O
. . O O

Thromboxane P07640422A0649 NNP O
B2 P07640422A0649 NNP O
increased P07640422A0649 VBD O
( P07640422A0649 ( O
97 P07640422A0649 CD O
+ P07640422A0649 NN O
/ P07640422A0649 NNP O
- P07640422A0649 : O
105 P07640422A0649 CD O
versus P07640422A0649 NN O
40 P07640422A0649 CD O
+ P07640422A0649 NN O
/ P07640422A0649 NNP O
- P07640422A0649 : O
26 P07640422A0649 CD O
pg P07640422A0649 NN O
/ P07640422A0649 NNP O
ml P07640422A0649 NN O
) P07640422A0649 ) O
and P07640422A0649 CC O
was P07640422A0649 VBD O
significantly P07640422A0649 RB O
higher P07640422A0649 JJR O
during P07640422A0649 IN O
heparin P07640422A0649 JJ O
free P07640422A0649 JJ O
hemodialysis P07640422A0649 NN O
than P07640422A0649 IN O
during P07640422A0649 IN O
hemodialysis P07640422A0649 NN O
with P07640422A0649 IN O
heparin P07640422A0649 NN O
( P07640422A0649 ( O
p P07640422A0649 JJ O
= P07640422A0649 NN O
0.01 P07640422A0649 CD O
, P07640422A0649 , O
Wilcoxon P07640422A0649 NNP O
matched P07640422A0649 VBD O
pairs P07640422A0649 NNS O
signed P07640422A0649 VBD O
rank P07640422A0649 JJ O
test P07640422A0649 NN O
) P07640422A0649 ) O
. P07640422A0649 . O
. . O O

The P08300625A1352 DT O
COOH-terminal P08300625A1352 JJ O
46 P08300625A1352 CD O
codons P08300625A1352 NNS O
of P08300625A1352 IN O
slyD P08300625A1352 NN I-UN
encode P08300625A1352 NN O
a P08300625A1352 DT O
remarkable P08300625A1352 JJ O
histidine-rich P08300625A1352 JJ O
peptide P08300625A1352 NN O
sequence P08300625A1352 NN O
which P08300625A1352 WDT O
is P08300625A1352 VBZ O
at P08300625A1352 IN O
least P08300625A1352 JJS O
partly P08300625A1352 RB O
dispensable P08300625A1352 JJ O
for P08300625A1352 IN O
slyD P08300625A1352 JJ I-UN
function P08300625A1352 NN O
in P08300625A1352 IN O
E-mediated P08300625A1352 JJ O
lysis P08300625A1352 NN O
. P08300625A1352 . O
. . O O

Deletion P07729427A0942 NN O
analysis P07729427A0942 NN O
indicates P07729427A0942 VBZ O
that P07729427A0942 IN O
TBP P07729427A0942 NNP I-UN
and P07729427A0942 CC O
hTAFII18 P07729427A0942 NN I-UN
bind P07729427A0942 NN O
to P07729427A0942 TO O
distinct P07729427A0942 VB O
domains P07729427A0942 NNS O
of P07729427A0942 IN O
hTAFII28 P07729427A0942 NN I-UN
. P07729427A0942 . O
hTAFII18 P07729427A0942 NN I-UN
also P07729427A0942 RB O
interacts P07729427A0942 VBZ O
with P07729427A0942 IN O
TBP P07729427A0942 NNP I-UN
, P07729427A0942 , O
but P07729427A0942 CC O
it P07729427A0942 PRP O
interacts P07729427A0942 VBZ O
more P07729427A0942 RBR O
strongly P07729427A0942 RB O
with P07729427A0942 IN O
hTAFII28 P07729427A0942 NN I-UN
and P07729427A0942 CC O
hTAFII30 P07729427A0942 NN I-UN
. P07729427A0942 . O
. . O O

Glutathione P04518624T0000 NNP I-UN
peroxidase P04518624T0000 NN I-UN
in P04518624T0000 IN O
human P04518624T0000 JJ O
red P04518624T0000 JJ O
cells P04518624T0000 NNS O
in P04518624T0000 IN O
health P04518624T0000 NN O
and P04518624T0000 CC O
disease P04518624T0000 NN O
. P04518624T0000 . O
. . O O

The P07530128A0578 DT O
median P07530128A0578 JJ O
post-treatment P07530128A0578 NN O
, P07530128A0578 , O
pre-operative P07530128A0578 JJ O
serum P07530128A0578 NN I-UN
PSA P07530128A0578 NNP I-UN
was P07530128A0578 VBD O
0.4 P07530128A0578 CD O
ng P07530128A0578 JJ O
/ P07530128A0578 NNP O
ml P07530128A0578 NN O
. P07530128A0578 . O
. . O O

PMEK1 P07888623A0721 NNP I-UN
displays P07888623A0721 VBZ O
96 P07888623A0721 CD O
and P07888623A0721 CC O
80 P07888623A0721 CD O
% P07888623A0721 NN O
identity P07888623A0721 NN O
respectively P07888623A0721 RB O
with P07888623A0721 IN O
the P07888623A0721 DT O
tobacco P07888623A0721 NN I-UN
NTF3 P07888623A0721 NNP I-UN
and P07888623A0721 CC O
Arabidopsis P07888623A0721 NNP I-UN
ATMPK1 P07888623A0721 NNP I-UN
kinases P07888623A0721 NNS I-UN
, P07888623A0721 , O
and P07888623A0721 CC O
only P07888623A0721 RB O
50 P07888623A0721 CD O
% P07888623A0721 NN O
to P07888623A0721 TO O
the P07888623A0721 DT O
more P07888623A0721 RBR O
distantly P07888623A0721 RB O
related P07888623A0721 VBN O
plant P07888623A0721 NN O
MAP P07888623A0721 NNP O
kinase P07888623A0721 NNP O
MsERK1 P07888623A0721 NNP I-UN
from P07888623A0721 IN O
alfalfa P07888623A0721 NN O
. P07888623A0721 . O
. . O O

This P08084339A0907 DT O
alternatively P08084339A0907 RB O
spliced P08084339A0907 JJ O
transcript P08084339A0907 NN O
contained P08084339A0907 VBD O
an P08084339A0907 DT O
open P08084339A0907 JJ O
reading P08084339A0907 NN O
frame P08084339A0907 NN O
extending P08084339A0907 VBG O
from P08084339A0907 IN O
the P08084339A0907 DT O
upstream P08084339A0907 JJ O
J P08084339A0907 NNP O
alpha P08084339A0907 POS O
11-2 P08084339A0907 JJ O
region P08084339A0907 NN O
to P08084339A0907 TO O
82 P08084339A0907 CD O
nucleotides P08084339A0907 NNS O
downstream P08084339A0907 NN O
of P08084339A0907 IN O
the P08084339A0907 DT O
beginning P08084339A0907 NN O
of P08084339A0907 IN O
the P08084339A0907 DT O
TCR P08084339A0907 NNP I-UN
C P08084339A0907 NNP I-UN
alpha P08084339A0907 JJ I-UN
region P08084339A0907 NN I-UN
, P08084339A0907 , O
and P08084339A0907 CC O
potentially P08084339A0907 RB O
encoded P08084339A0907 VBD O
a P08084339A0907 DT O
36 P08084339A0907 CD O
amino P08084339A0907 NN O
acid P08084339A0907 NN O
polypeptide P08084339A0907 NN O
. P08084339A0907 . O
. . O O

Arnt3 P09704006A0224 NNP I-UN
mRNA P09704006A0224 NN I-UN
was P09704006A0224 VBD O
expressed P09704006A0224 VBN O
in P09704006A0224 IN O
brain P09704006A0224 NN O
, P09704006A0224 , O
skeletal P09704006A0224 JJ O
muscle P09704006A0224 NN O
, P09704006A0224 , O
13.5-day P09704006A0224 JJ O
embryos P09704006A0224 NN O
, P09704006A0224 , O
and P09704006A0224 CC O
P19 P09704006A0224 NNP O
cells P09704006A0224 NNS O
treated P09704006A0224 VBD O
with P09704006A0224 IN O
retinoic P09704006A0224 JJ O
acid P09704006A0224 NN O
. P09704006A0224 . O
. . O O

Eighty P02631887A0000 JJ O
patients P02631887A0000 NNS O
presenting P02631887A0000 VBG O
to P02631887A0000 TO O
HGGM P02631887A0000 NNP O
with P02631887A0000 IN O
non-Hodgkin P02631887A0000 JJ O
's P02631887A0000 POS O
lymphomas P02631887A0000 NN O
between P02631887A0000 IN O
1962 P02631887A0000 CD O
and P02631887A0000 CC O
1986 P02631887A0000 CD O
, P02631887A0000 , O
were P02631887A0000 VBD O
reviewed P02631887A0000 VBN O
. P02631887A0000 . O
. . O O

Subsequent P09025122A0374 JJ O
experiments P09025122A0374 NNS O
showed P09025122A0374 VBD O
that P09025122A0374 IN O
motoric P09025122A0374 JJ O
tasks P09025122A0374 NNS O
rather P09025122A0374 RB O
than P09025122A0374 IN O
cognitive P09025122A0374 JJ O
aspects P09025122A0374 NNS O
of P09025122A0374 IN O
the P09025122A0374 DT O
COWA P09025122A0374 NNP O
task P09025122A0374 NN O
were P09025122A0374 VBD O
critical P09025122A0374 JJ O
in P09025122A0374 IN O
potentiating P09025122A0374 VBG O
finger-tapping P09025122A0374 JJ O
performance P09025122A0374 NN O
. P09025122A0374 . O
. . O O

UK P03352727T0000 NNP O
's P03352727T0000 POS O
biotechnology P03352727T0000 NN O
lacking P03352727T0000 NN O
specialists P03352727T0000 NNS O
. P03352727T0000 . O
. . O O

In P10786742A0670 IN O
the P10786742A0670 DT O
control P10786742A0670 NN O
group P10786742A0670 NN O
, P10786742A0670 , O
platelet P10786742A0670 NN O
markers P10786742A0670 NNS O
increased P10786742A0670 VBD O
1 P10786742A0670 CD O
h P10786742A0670 NN O
after P10786742A0670 IN O
surgery P10786742A0670 NN O
. P10786742A0670 . O
. . O O

Amino P02016053A0752 NNP O
acid P02016053A0752 JJ O
sequence P02016053A0752 NN O
comparisons P02016053A0752 NNS O
of P02016053A0752 IN O
the P02016053A0752 DT O
E74A P02016053A0752 NNP I-UN
protein P02016053A0752 NN I-UN
reveal P02016053A0752 VBD O
a P02016053A0752 DT O
highly P02016053A0752 RB O
conserved P02016053A0752 VBN O
C-terminal P02016053A0752 JJ O
region P02016053A0752 NN O
that P02016053A0752 WDT O
is P02016053A0752 VBZ O
rich P02016053A0752 JJ O
in P02016053A0752 IN O
basic P02016053A0752 JJ O
amino P02016053A0752 NN O
acid P02016053A0752 NN O
residues P02016053A0752 NNS O
and P02016053A0752 CC O
which P02016053A0752 WDT O
has P02016053A0752 VBZ O
been P02016053A0752 VBN O
proposed P02016053A0752 VBN O
to P02016053A0752 TO O
possess P02016053A0752 VB O
sequence-specific P02016053A0752 JJ O
DNA P02016053A0752 NNP O
binding P02016053A0752 NN O
activity P02016053A0752 NN O
. P02016053A0752 . O
. . O O

They P11371160A0193 PRP O
correspond P11371160A0193 VBP O
to P11371160A0193 TO O
nucleotides P11371160A0193 VB O
equivalent P11371160A0193 JJ O
to P11371160A0193 TO O
base-pair P11371160A0193 JJ O
C1-G72 P11371160A0193 NNP O
and P11371160A0193 CC O
discriminator P11371160A0193 NN O
base P11371160A0193 NN O
A73 P11371160A0193 NNP O
in P11371160A0193 IN O
the P11371160A0193 DT O
amino P11371160A0193 NN O
acid-acceptor P11371160A0193 JJ O
branch P11371160A0193 NN O
of P11371160A0193 IN O
the P11371160A0193 DT O
molecule P11371160A0193 NN O
. P11371160A0193 . O
. . O O

Foreigners P11441163T0000 NNS O
return P11441163T0000 VBP O
. P11441163T0000 . O
. . O O

Five-year P08803710A0701 JJ O
survivals P08803710A0701 NNS O
amounted P08803710A0701 VBD O
to P08803710A0701 TO O
100 P08803710A0701 CD O
% P08803710A0701 NN O
, P08803710A0701 , O
86.2 P08803710A0701 CD O
% P08803710A0701 NN O
, P08803710A0701 , O
59.4 P08803710A0701 CD O
% P08803710A0701 NN O
, P08803710A0701 , O
29.8 P08803710A0701 CD O
% P08803710A0701 NN O
, P08803710A0701 , O
and P08803710A0701 CC O
20 P08803710A0701 CD O
% P08803710A0701 NN O
for P08803710A0701 IN O
stages P08803710A0701 NNS O
I P08803710A0701 PRP O
, P08803710A0701 , O
II P08803710A0701 NNP O
, P08803710A0701 , O
III P08803710A0701 NNP O
, P08803710A0701 , O
IVA P08803710A0701 NNP O
and P08803710A0701 CC O
IVB P08803710A0701 NNP O
respectively P08803710A0701 RB O
. P08803710A0701 . O
. . O O

Clinical P04081425T0016 JJ O
aspects P04081425T0016 NNS O
and P04081425T0016 CC O
therapy P04081425T0016 NN O
. P04081425T0016 . O
. . O O

CONCLUSIONS P09990507A0763 NN O
: P09990507A0763 : O
Fission P09990507A0763 NN I-UN
yeast P09990507A0763 NN I-UN
SCF P09990507A0763 NNP I-UN
is P09990507A0763 VBZ O
composed P09990507A0763 VBN O
of P09990507A0763 IN O
Pop1 P09990507A0763 NNP I-UN
and P09990507A0763 CC O
Pop2 P09990507A0763 NNP I-UN
, P09990507A0763 , O
two P09990507A0763 CD O
structurally P09990507A0763 RB O
related P09990507A0763 VBN O
but P09990507A0763 CC O
functionally P09990507A0763 RB O
independent P09990507A0763 JJ O
F-box P09990507A0763 JJ I-UN
/ P09990507A0763 JJ I-UN
WD-repeat P09990507A0763 JJ I-UN
proteins P09990507A0763 NNS I-UN
. P09990507A0763 . O
. . O O

Inhibition P09388200A0639 NN O
appears P09388200A0639 VBZ O
to P09388200A0639 TO O
result P09388200A0639 VB O
from P09388200A0639 IN O
titration P09388200A0639 NN O
of P09388200A0639 IN O
general P09388200A0639 JJ O
transcription P09388200A0639 NN O
factors P09388200A0639 NNS O
because P09388200A0639 IN O
MDM2 P09388200A0639 NNP I-UN
overexpression P09388200A0639 NN O
inhibits P09388200A0639 VBZ O
c-fos P09388200A0639 NN I-UN
as P09388200A0639 RB O
well P09388200A0639 RB O
as P09388200A0639 IN O
other P09388200A0639 JJ O
promoters P09388200A0639 NNS O
in P09388200A0639 IN O
vivo P09388200A0639 NN O
and P09388200A0639 CC O
basal P09388200A0639 NN O
transcription P09388200A0639 NN O
in P09388200A0639 IN O
vitro P09388200A0639 NN O
. P09388200A0639 . O
. . O O

Sensitivities P05567721T0000 NNS O
of P05567721T0000 IN O
thromboplastins P05567721T0000 NNS I-UN
to P05567721T0000 TO O
factor P05567721T0000 VB I-UN
VII P05567721T0000 NNP I-UN
deficiency P05567721T0000 NN O
. P05567721T0000 . O
. . O O

Mutants P08756597A0854 NNS O
lacking P08756597A0854 VBG O
the P08756597A0854 DT O
3 P08756597A0854 CD O
' P08756597A0854 POS O
stem-loop P08756597A0854 NN O
exhibited P08756597A0854 VBD O
a P08756597A0854 DT O
75 P08756597A0854 CD O
% P08756597A0854 NN O
reduction P08756597A0854 NN O
in P08756597A0854 IN O
the P08756597A0854 DT O
level P08756597A0854 NN O
of P08756597A0854 IN O
psaB P08756597A0854 JJ I-UN
mRNA P08756597A0854 NN O
. P08756597A0854 . O
. . O O

In P09703213A0280 IN O
experiments P09703213A0280 NNS O
with P09703213A0280 IN O
the P09703213A0280 DT O
D1 P09703213A0280 NNP O
antagonist P09703213A0280 NN O
SCH P09703213A0280 NNP O
23390 P09703213A0280 CD O
, P09703213A0280 , O
buprenorphine-induced P09703213A0280 JJ O
depression P09703213A0280 NN O
was P09703213A0280 VBD O
consistently P09703213A0280 RB O
blocked P09703213A0280 VBN O
, P09703213A0280 , O
but P09703213A0280 CC O
facilitation P09703213A0280 NN O
was P09703213A0280 VBD O
unaffected P09703213A0280 VBN O
. P09703213A0280 . O
. . O O

The P08044794A0000 DT O
tumor P08044794A0000 NN O
suppressor P08044794A0000 NN O
and P08044794A0000 CC O
transcriptional P08044794A0000 JJ O
factor P08044794A0000 NN O
p53 P08044794A0000 NN I-UN
is P08044794A0000 VBZ O
a P08044794A0000 DT O
phosphorylated P08044794A0000 JJ O
protein P08044794A0000 NN O
. P08044794A0000 . O
. . O O

Lithium P02752303A0000 NNP O
delays P02752303A0000 VBZ O
the P02752303A0000 DT O
circadian P02752303A0000 JJ O
rhythm P02752303A0000 NN O
of P02752303A0000 IN O
wheel-running P02752303A0000 NN O
in P02752303A0000 IN O
Syrian P02752303A0000 JJ O
hamsters P02752303A0000 NNS O
at P02752303A0000 IN O
plasma P02752303A0000 JJ O
concentrations P02752303A0000 NNS O
( P02752303A0000 ( O
0.59-0.74 P02752303A0000 JJ O
mM P02752303A0000 NN O
) P02752303A0000 ) O
that P02752303A0000 WDT O
also P02752303A0000 RB O
cause P02752303A0000 VBP O
toxic P02752303A0000 JJ O
weight P02752303A0000 JJ O
loss P02752303A0000 NN O
. P02752303A0000 . O
. . O O

His P07751848A0222 PRP$ O
carnitine P07751848A0222 NN I-UN
palmitoyltransferase P07751848A0222 NN I-UN
( P07751848A0222 ( I-UN
CPT P07751848A0222 NNP I-UN
) P07751848A0222 ) I-UN
I P07751848A0222 PRP I-UN
and P07751848A0222 CC I-UN
II P07751848A0222 NNP I-UN
activities P07751848A0222 NNS O
were P07751848A0222 VBD O
0.06 P07751848A0222 CD O
and P07751848A0222 CC O
0.12 P07751848A0222 CD O
nmol P07751848A0222 JJ O
/ P07751848A0222 NNP O
min P07751848A0222 NN O
/ P07751848A0222 NNP O
mg P07751848A0222 NN O
protein P07751848A0222 NN O
, P07751848A0222 , O
as P07751848A0222 IN O
compared P07751848A0222 VBN O
with P07751848A0222 IN O
a P07751848A0222 DT O
mean P07751848A0222 JJ O
value P07751848A0222 NN O
of P07751848A0222 IN O
0.22 P07751848A0222 CD O
+ P07751848A0222 NNS O
/ P07751848A0222 SYM O
- P07751848A0222 : O
0.14 P07751848A0222 CD O
and P07751848A0222 CC O
0.27 P07751848A0222 CD O
+ P07751848A0222 NN O
/ P07751848A0222 NNP O
- P07751848A0222 : O
0.07 P07751848A0222 CD O
nmol P07751848A0222 JJ O
/ P07751848A0222 NNP O
min P07751848A0222 NN O
/ P07751848A0222 NNP O
mg P07751848A0222 NN O
protein P07751848A0222 NN O
, P07751848A0222 , O
respectively P07751848A0222 RB O
, P07751848A0222 , O
in P07751848A0222 IN O
control P07751848A0222 NN O
subjects P07751848A0222 NNS O
. P07751848A0222 . O
. . O O

Topical P02895754A0000 JJ O
1 P02895754A0000 CD O
percent P02895754A0000 NN O
isoproterenol P02895754A0000 NN O
in P02895754A0000 IN O
the P02895754A0000 DT O
presence P02895754A0000 NN O
of P02895754A0000 IN O
the P02895754A0000 DT O
phosphodiesterase P02895754A0000 NN O
inhibitor P02895754A0000 NN O
theophylline P02895754A0000 NN O
was P02895754A0000 VBD O
tested P02895754A0000 VBN O
for P02895754A0000 IN O
its P02895754A0000 PRP$ O
ability P02895754A0000 NN O
to P02895754A0000 TO O
stimulate P02895754A0000 VB O
the P02895754A0000 DT O
rate P02895754A0000 NN O
of P02895754A0000 IN O
aqueous P02895754A0000 JJ O
humor P02895754A0000 NN O
flow P02895754A0000 NN O
through P02895754A0000 IN O
the P02895754A0000 DT O
anterior P02895754A0000 JJ O
chamber P02895754A0000 NN O
of P02895754A0000 IN O
the P02895754A0000 DT O
normal P02895754A0000 JJ O
and P02895754A0000 CC O
the P02895754A0000 DT O
partially P02895754A0000 RB O
adrenergically P02895754A0000 RB O
denervated P02895754A0000 VBN O
human P02895754A0000 JJ O
eye P02895754A0000 NN O
( P02895754A0000 ( O
Horner P02895754A0000 NNP O
's P02895754A0000 POS O
syndrome P02895754A0000 NN O
) P02895754A0000 ) O
. P02895754A0000 . O
. . O O

The P08020965A0465 DT O
sequenced P08020965A0465 JJ O
genomic P08020965A0465 JJ O
region P08020965A0465 NN O
thus P08020965A0465 RB O
accounts P08020965A0465 NNS O
for P08020965A0465 IN O
essentially P08020965A0465 RB O
all P08020965A0465 DT O
of P08020965A0465 IN O
the P08020965A0465 DT O
longest P08020965A0465 JJS O
known P08020965A0465 VBN O
transcript P08020965A0465 NN O
( P08020965A0465 ( O
4.5 P08020965A0465 CD O
kb P08020965A0465 NN O
) P08020965A0465 ) O
, P08020965A0465 , O
although P08020965A0465 IN O
the P08020965A0465 DT O
precise P08020965A0465 JJ O
ends P08020965A0465 NNS O
of P08020965A0465 IN O
this P08020965A0465 DT O
transcript P08020965A0465 NN O
have P08020965A0465 VBP O
not P08020965A0465 RB O
been P08020965A0465 VBN O
defined P08020965A0465 VBN O
. P08020965A0465 . O
. . O O

PNT P08435755A1078 NNP O
, P08435755A1078 , O
ADD P08435755A1078 NNP O
and P08435755A1078 CC O
BSS P08435755A1078 NNP O
in P08435755A1078 IN O
the P08435755A1078 DT O
initial P08435755A1078 JJ O
stage P08435755A1078 NN O
of P08435755A1078 IN O
kindling P08435755A1078 NN O
, P08435755A1078 , O
kindling P08435755A1078 VBG O
rate P08435755A1078 NN O
for P08435755A1078 IN O
the P08435755A1078 DT O
stage-3 P08435755A1078 JJ O
and P08435755A1078 CC O
-5 P08435755A1078 JJ O
seizures P08435755A1078 NNS O
, P08435755A1078 , O
seizure P08435755A1078 NN O
parameters P08435755A1078 NNS O
at P08435755A1078 IN O
the P08435755A1078 DT O
first P08435755A1078 JJ O
stage-3 P08435755A1078 NN O
and P08435755A1078 CC O
-5 P08435755A1078 NN O
were P08435755A1078 VBD O
recorded P08435755A1078 VBN O
and P08435755A1078 CC O
compared P08435755A1078 VBN O
to P08435755A1078 TO O
the P08435755A1078 DT O
values P08435755A1078 NNS O
of P08435755A1078 IN O
saline-treated P08435755A1078 JJ O
, P08435755A1078 , O
control P08435755A1078 NN O
group P08435755A1078 NN O
. P08435755A1078 . O
. . O O

Online P10271171A0458 NNP O
LATCH P10271171A0458 NNP O
demonstrates P10271171A0458 VBZ O
a P10271171A0458 DT O
shift P10271171A0458 NN O
in P10271171A0458 IN O
identification P10271171A0458 NN O
of P10271171A0458 IN O
the P10271171A0458 DT O
library P10271171A0458 NN O
as P10271171A0458 IN O
an P10271171A0458 DT O
isolated P10271171A0458 JJ O
unit P10271171A0458 NN O
to P10271171A0458 TO O
an P10271171A0458 DT O
interactive P10271171A0458 JJ O
resource P10271171A0458 NN O
center P10271171A0458 NN O
. P10271171A0458 . O
. . O O

I P06309969T0055 PRP O
. P06309969T0055 . O
. . O O

Regulation P10792583A0000 NN O
of P10792583A0000 IN O
pituitary P10792583A0000 JJ O
vasopressin P10792583A0000 NN I-UN
V1b P10792583A0000 NNP I-UN
receptors P10792583A0000 NNS I-UN
plays P10792583A0000 VBZ O
a P10792583A0000 DT O
critical P10792583A0000 JJ O
role P10792583A0000 NN O
in P10792583A0000 IN O
regulating P10792583A0000 VBG O
pituitary P10792583A0000 JJ I-UN
adrenocorticotropic P10792583A0000 NN I-UN
hormone P10792583A0000 NN I-UN
( P10792583A0000 ( O
ACTH P10792583A0000 NNP I-UN
) P10792583A0000 ) O
secretion P10792583A0000 NN O
during P10792583A0000 IN O
adaptation P10792583A0000 NN O
to P10792583A0000 TO O
stress P10792583A0000 VB O
. P10792583A0000 . O
. . O O

This P00484177A0242 DT O
expression P00484177A0242 NN O
assumes P00484177A0242 VBZ O
: P00484177A0242 : O
( P00484177A0242 ( O
1 P00484177A0242 CD O
) P00484177A0242 ) O
a P00484177A0242 DT O
laminar P00484177A0242 NN O
flow P00484177A0242 JJ O
regimen P00484177A0242 NNS O
during P00484177A0242 IN O
expiration P00484177A0242 NN O
, P00484177A0242 , O
and P00484177A0242 CC O
( P00484177A0242 ( O
2 P00484177A0242 CD O
) P00484177A0242 ) O
a P00484177A0242 DT O
constant P00484177A0242 JJ O
CT P00484177A0242 NNP O
value P00484177A0242 NN O
over P00484177A0242 IN O
the P00484177A0242 DT O
range P00484177A0242 NN O
of P00484177A0242 IN O
VT P00484177A0242 NNP O
. P00484177A0242 . O
. . O O

Thus P10430890A1059 RB O
, P10430890A1059 , O
elongin P10430890A1059 JJ I-UN
C P10430890A1059 NNP I-UN
is P10430890A1059 VBZ O
found P10430890A1059 VBN O
to P10430890A1059 TO O
oligomerize P10430890A1059 VB O
in P10430890A1059 IN O
solution P10430890A1059 NN O
and P10430890A1059 CC O
to P10430890A1059 TO O
undergo P10430890A1059 VB O
significant P10430890A1059 JJ O
structural P10430890A1059 JJ O
rearrangements P10430890A1059 NNS O
upon P10430890A1059 IN O
binding P10430890A1059 VBG O
of P10430890A1059 IN O
two P10430890A1059 CD O
different P10430890A1059 JJ O
partner P10430890A1059 NN O
proteins P10430890A1059 NNS O
. P10430890A1059 . O
. . O O

We P11859400A0229 PRP O
compared P11859400A0229 VBN O
the P11859400A0229 DT O
efficacy P11859400A0229 NN O
and P11859400A0229 CC O
costs P11859400A0229 NNS O
of P11859400A0229 IN O
valacyclovir P11859400A0229 NN O
in P11859400A0229 IN O
preventing P11859400A0229 VBG O
HSV P11859400A0229 NNP O
reactivation P11859400A0229 NN O
among P11859400A0229 IN O
HSV P11859400A0229 NNP O
seropositive P11859400A0229 VBP O
autologous P11859400A0229 JJ O
progenitor P11859400A0229 NN O
cell P11859400A0229 NN O
transplantation P11859400A0229 NN O
( P11859400A0229 ( O
APCT P11859400A0229 NNP O
) P11859400A0229 ) O
patients P11859400A0229 NNS O
with P11859400A0229 IN O
historical P11859400A0229 JJ O
controls P11859400A0229 NNS O
in P11859400A0229 IN O
whom P11859400A0229 WP O
intravenous P11859400A0229 JJ O
acyclovir P11859400A0229 NN O
or P11859400A0229 CC O
no P11859400A0229 DT O
HSV P11859400A0229 NNP O
prophylaxis P11859400A0229 NN O
were P11859400A0229 VBD O
used P11859400A0229 VBN O
. P11859400A0229 . O
. . O O

The P07501700A0000 DT O
effects P07501700A0000 NNS O
of P07501700A0000 IN O
a P07501700A0000 DT O
1- P07501700A0000 JJ O
or P07501700A0000 CC O
24-hour P07501700A0000 JJ O
pretreatment P07501700A0000 JJ O
regimen P07501700A0000 NNS O
with P07501700A0000 IN O
monophosphoryl P07501700A0000 NN O
lipid P07501700A0000 VBP O
A P07501700A0000 NNP O
( P07501700A0000 ( O
MLA P07501700A0000 NNP O
, P07501700A0000 , O
35 P07501700A0000 CD O
micrograms P07501700A0000 NNS O
/ P07501700A0000 VBP O
kg P07501700A0000 JJ O
i.v P07501700A0000 NN O
. P07501700A0000 . O
) P07501700A0000 ) O
on P07501700A0000 IN O
myocardial P07501700A0000 JJ O
stunning P07501700A0000 NN O
produced P07501700A0000 VBN O
by P07501700A0000 IN O
repetitive P07501700A0000 JJ O
coronary P07501700A0000 JJ O
occlusions P07501700A0000 NNS O
were P07501700A0000 VBD O
studied P07501700A0000 VBN O
in P07501700A0000 IN O
barbital-anesthetized P07501700A0000 JJ O
dogs P07501700A0000 NNS O
. P07501700A0000 . O
. . O O

The P07791768A0930 DT O
effect P07791768A0930 NN O
of P07791768A0930 IN O
these P07791768A0930 DT O
cell P07791768A0930 NN O
cycle P07791768A0930 NN O
regulators P07791768A0930 NNS O
is P07791768A0930 VBZ O
not P07791768A0930 RB O
specific P07791768A0930 JJ O
to P07791768A0930 TO O
the P07791768A0930 DT O
rap1s P07791768A0930 NN I-UN
or P07791768A0930 CC O
hmr P07791768A0930 NN I-UN
delta P07791768A0930 NN I-UN
A P07791768A0930 DT I-UN
mutation P07791768A0930 NN I-UN
, P07791768A0930 , O
since P07791768A0930 IN O
swi6 P07791768A0930 NN I-UN
, P07791768A0930 , O
swi4 P07791768A0930 NN I-UN
, P07791768A0930 , O
and P07791768A0930 CC O
clb5 P07791768A0930 NN I-UN
mutations P07791768A0930 NNS I-UN
also P07791768A0930 RB O
suppress P07791768A0930 VBP O
mutations P07791768A0930 NNS O
in P07791768A0930 IN O
SIR1 P07791768A0930 NNP I-UN
, P07791768A0930 , O
another P07791768A0930 DT O
gene P07791768A0930 NN O
implicated P07791768A0930 VBN O
in P07791768A0930 IN O
the P07791768A0930 DT O
establishment P07791768A0930 NN O
of P07791768A0930 IN O
silencing P07791768A0930 NN O
. P07791768A0930 . O
. . O O

The P02280777T0000 DT O
uteroglobin P02280777T0000 JJ I-UN
promoter P02280777T0000 NN I-UN
contains P02280777T0000 VBZ O
a P02280777T0000 DT O
noncanonical P02280777T0000 JJ O
estrogen P02280777T0000 NN O
responsive P02280777T0000 JJ O
element P02280777T0000 NN O
. P02280777T0000 . O
. . O O

Lead P09869528T0000 JJ O
fixation P09869528T0000 NN O
in P09869528T0000 IN O
dogs P09869528T0000 NNS O
achieved P09869528T0000 VBN O
with P09869528T0000 IN O
RF P09869528T0000 NNP O
energy P09869528T0000 NN O
. P09869528T0000 . O
. . O O

Since P02342477A1292 IN O
the P02342477A1292 DT O
UfAP P02342477A1292 NNP I-UN
and P02342477A1292 CC O
UTMP P02342477A1292 NNP I-UN
share P02342477A1292 NN O
many P02342477A1292 JJ O
biosynthetic P02342477A1292 JJ O
and P02342477A1292 CC O
structural P02342477A1292 JJ O
features P02342477A1292 NNS O
that P02342477A1292 WDT O
include P02342477A1292 VBP O
site P02342477A1292 NN O
of P02342477A1292 IN O
biosynthesis P02342477A1292 NN O
in P02342477A1292 IN O
the P02342477A1292 DT O
endometrium P02342477A1292 NN O
, P02342477A1292 , O
P4-responsiveness P02342477A1292 NNP O
, P02342477A1292 , O
the P02342477A1292 DT O
presence P02342477A1292 NN O
of P02342477A1292 IN O
the P02342477A1292 DT O
mannose P02342477A1292 JJ O
6-phosphate P02342477A1292 JJ O
lysosomal P02342477A1292 JJ O
recognition P02342477A1292 NN O
marker P02342477A1292 NN O
, P02342477A1292 , O
and P02342477A1292 CC O
considerable P02342477A1292 JJ O
sequence P02342477A1292 NN O
similarity P02342477A1292 NN O
, P02342477A1292 , O
the P02342477A1292 DT O
UfAP P02342477A1292 NNP I-UN
and P02342477A1292 CC O
the P02342477A1292 DT O
UTMP P02342477A1292 NNP I-UN
may P02342477A1292 MD O
have P02342477A1292 VB O
homologous P02342477A1292 JJ O
function P02342477A1292 NN O
which P02342477A1292 WDT O
for P02342477A1292 IN O
both P02342477A1292 DT O
still P02342477A1292 RB O
remains P02342477A1292 VBZ O
obscure P02342477A1292 JJ O
. P02342477A1292 . O
. . O O

Genomic P10940562T0000 NNP O
and P10940562T0000 CC O
functional P10940562T0000 JJ O
characterization P10940562T0000 NN O
of P10940562T0000 IN O
the P10940562T0000 DT O
oas P10940562T0000 JJ I-UN
gene P10940562T0000 NN I-UN
family P10940562T0000 NN I-UN
encoding P10940562T0000 VBG O
O-acetylserine P10940562T0000 NNP I-UN
( P10940562T0000 ( I-UN
thiol P10940562T0000 NN I-UN
) P10940562T0000 ) I-UN
lyases P10940562T0000 VBZ I-UN
, P10940562T0000 , O
enzymes P10940562T0000 VBZ O
catalyzing P10940562T0000 VBG O
the P10940562T0000 DT O
final P10940562T0000 JJ O
step P10940562T0000 NN O
in P10940562T0000 IN O
cysteine P10940562T0000 JJ O
biosynthesis P10940562T0000 NN O
in P10940562T0000 IN O
Arabidopsis P10940562T0000 NNP O
thaliana P10940562T0000 NN O
. P10940562T0000 . O
. . O O

The P01618256A0521 DT O
mean P01618256A0521 JJ O
minimum P01618256A0521 JJ O
steady-state P01618256A0521 JJ O
concentration P01618256A0521 NN O
after P01618256A0521 IN O
the P01618256A0521 DT O
oral P01618256A0521 JJ O
regimen P01618256A0521 NNS O
( P01618256A0521 ( O
23 P01618256A0521 CD O
micrograms.l-1 P01618256A0521 NN O
) P01618256A0521 ) O
was P01618256A0521 VBD O
78 P01618256A0521 CD O
% P01618256A0521 NN O
of P01618256A0521 IN O
that P01618256A0521 DT O
after P01618256A0521 IN O
the P01618256A0521 DT O
intramuscular P01618256A0521 JJ O
regime P01618256A0521 NN O
( P01618256A0521 ( O
29 P01618256A0521 CD O
micrograms.l-1 P01618256A0521 NN O
) P01618256A0521 ) O
. P01618256A0521 . O
. . O O

How P00254537T0000 WRB O
do P00254537T0000 VB O
graduates P00254537T0000 NNS O
of P00254537T0000 IN O
different P00254537T0000 JJ O
types P00254537T0000 NNS O
of P00254537T0000 IN O
programs P00254537T0000 NNS O
perform P00254537T0000 VBP O
on P00254537T0000 IN O
state P00254537T0000 NN O
boards P00254537T0000 NNS O
? P00254537T0000 . O
. P00254537T0000 . O
. . O O

Twenty P07365183A0000 CD O
patients P07365183A0000 NNS O
aged P07365183A0000 VBD O
45 P07365183A0000 CD O
or P07365183A0000 CC O
older P07365183A0000 JJR O
with P07365183A0000 IN O
the P07365183A0000 DT O
diagnosis P07365183A0000 NN O
of P07365183A0000 IN O
endogenous P07365183A0000 JJ O
depression P07365183A0000 NN O
were P07365183A0000 VBD O
evaluated P07365183A0000 VBN O
in P07365183A0000 IN O
terms P07365183A0000 NNS O
of P07365183A0000 IN O
safety P07365183A0000 NN O
and P07365183A0000 CC O
efficacy P07365183A0000 NN O
in P07365183A0000 IN O
their P07365183A0000 PRP$ O
response P07365183A0000 NN O
to P07365183A0000 TO O
multiple P07365183A0000 VB O
monitored P07365183A0000 JJ O
electroconvulsive P07365183A0000 JJ O
therapy P07365183A0000 NN O
( P07365183A0000 ( O
MMECT P07365183A0000 NNP O
) P07365183A0000 ) O
versus P07365183A0000 NN O
single P07365183A0000 JJ O
electroconvulsive P07365183A0000 JJ O
therapy P07365183A0000 NN O
( P07365183A0000 ( O
SECT P07365183A0000 NNP O
) P07365183A0000 ) O
. P07365183A0000 . O
. . O O

The P08902847A1946 DT O
evidence P08902847A1946 NN O
in P08902847A1946 IN O
support P08902847A1946 NN O
of P08902847A1946 IN O
this P08902847A1946 DT O
was P08902847A1946 VBD O
derived P08902847A1946 VBN O
from P08902847A1946 IN O
the P08902847A1946 DT O
fact P08902847A1946 NN O
that P08902847A1946 IN O
the P08902847A1946 DT O
affinity P08902847A1946 NN O
or P08902847A1946 CC O
interaction P08902847A1946 NN O
between P08902847A1946 IN O
the P08902847A1946 DT O
two P08902847A1946 CD O
subunits P08902847A1946 NNS O
was P08902847A1946 VBD O
impaired P08902847A1946 VBN O
as P08902847A1946 IN O
indicated P08902847A1946 VBN O
by P08902847A1946 IN O
the P08902847A1946 DT O
first P08902847A1946 JJ O
order P08902847A1946 NN O
rate P08902847A1946 NN O
constant P08902847A1946 NN O
of P08902847A1946 IN O
hCG P08902847A1946 NN I-UN
alpha P08902847A1946 NN I-UN
1 P08902847A1946 CD I-UN
beta P08902847A1946 NN I-UN
( P08902847A1946 ( O
km P08902847A1946 VB O
= P08902847A1946 RB O
4.1 P08902847A1946 CD O
x P08902847A1946 JJ O
10 P08902847A1946 CD O
( P08902847A1946 ( O
-2 P08902847A1946 NN O
) P08902847A1946 ) O
min-1 P08902847A1946 NN O
) P08902847A1946 ) O
at P08902847A1946 IN O
pH P08902847A1946 $ O
3.0 P08902847A1946 CD O
at P08902847A1946 IN O
23 P08902847A1946 CD O
degrees P08902847A1946 NNS O
C P08902847A1946 NNP O
which P08902847A1946 WDT O
is P08902847A1946 VBZ O
one P08902847A1946 CD O
order P08902847A1946 NN O
of P08902847A1946 IN O
magnitude P08902847A1946 NN O
greater P08902847A1946 JJR O
relative P08902847A1946 JJ O
to P08902847A1946 TO O
rehCG P08902847A1946 VB I-UN
( P08902847A1946 ( O
kw P08902847A1946 VB O
= P08902847A1946 RB O
4.6 P08902847A1946 CD O
x P08902847A1946 JJ O
10 P08902847A1946 CD O
( P08902847A1946 ( O
-3 P08902847A1946 NN O
) P08902847A1946 ) O
min-1 P08902847A1946 NN O
) P08902847A1946 ) O
. P08902847A1946 . O
. . O O

Preface P00084275T0063 NN O
. P00084275T0063 . O
. . O O

After P02975680A0000 IN O
one P02975680A0000 CD O
accommodation P02975680A0000 NN O
night P02975680A0000 NN O
, P02975680A0000 , O
sleep P02975680A0000 JJ O
EEG P02975680A0000 NNP O
recordings P02975680A0000 NNS O
were P02975680A0000 VBD O
performed P02975680A0000 VBN O
during P02975680A0000 IN O
three P02975680A0000 CD O
consecutive P02975680A0000 JJ O
nights P02975680A0000 NNS O
in P02975680A0000 IN O
ten P02975680A0000 JJ O
drug-free P02975680A0000 JJ O
inpatients P02975680A0000 NNS O
presenting P02975680A0000 VBG O
generalized P02975680A0000 JJ O
anxiety P02975680A0000 NN O
disorder P02975680A0000 NN O
( P02975680A0000 ( O
GAD P02975680A0000 NNP O
) P02975680A0000 ) O
with P02975680A0000 IN O
significant P02975680A0000 JJ O
depression P02975680A0000 NN O
, P02975680A0000 , O
compared P02975680A0000 VBN O
with P02975680A0000 IN O
a P02975680A0000 DT O
age- P02975680A0000 JJ O
and P02975680A0000 CC O
sex-matched P02975680A0000 JJ O
group P02975680A0000 NN O
of P02975680A0000 IN O
patients P02975680A0000 NNS O
with P02975680A0000 IN O
GAD P02975680A0000 NNP O
and P02975680A0000 CC O
a P02975680A0000 DT O
group P02975680A0000 NN O
of P02975680A0000 IN O
primary P02975680A0000 JJ O
major P02975680A0000 JJ O
depressive P02975680A0000 JJ O
disorder P02975680A0000 NN O
( P02975680A0000 ( O
MDD P02975680A0000 NNP O
) P02975680A0000 ) O
patients P02975680A0000 NNS O
. P02975680A0000 . O
. . O O

Genetic P09590294A0453 JJ O
studies P09590294A0453 NNS O
in P09590294A0453 IN O
Drosophila P09590294A0453 NNP O
have P09590294A0453 VBP O
led P09590294A0453 VBN O
to P09590294A0453 TO O
the P09590294A0453 DT O
identification P09590294A0453 NN O
of P09590294A0453 IN O
several P09590294A0453 JJ O
components P09590294A0453 NNS O
of P09590294A0453 IN O
the P09590294A0453 DT O
Notch P09590294A0453 NNP I-UN
pathway P09590294A0453 NN O
. P09590294A0453 . O
. . O O

An P10665798A0598 DT O
increase P10665798A0598 NN O
in P10665798A0598 IN O
the P10665798A0598 DT O
level P10665798A0598 NN O
of P10665798A0598 IN O
serum P10665798A0598 NN O
enzymes P10665798A0598 NNS O
, P10665798A0598 , O
such P10665798A0598 JJ O
as P10665798A0598 IN O
aspartate P10665798A0598 JJ I-UN
transaminase P10665798A0598 NN I-UN
, P10665798A0598 , O
alkaline P10665798A0598 JJ I-UN
phosphatase P10665798A0598 NN I-UN
, P10665798A0598 , O
creatine P10665798A0598 JJ I-UN
phosphokinase P10665798A0598 NN I-UN
, P10665798A0598 , O
lactate P10665798A0598 JJ I-UN
dehydrogenase P10665798A0598 NN I-UN
after P10665798A0598 IN O
D. P10665798A0598 NNP O
russelli P10665798A0598 VBD O
venom P10665798A0598 JJ O
injection P10665798A0598 NN O
in P10665798A0598 IN O
albino P10665798A0598 NN O
rats P10665798A0598 NNS O
is P10665798A0598 VBZ O
indicative P10665798A0598 JJ O
of P10665798A0598 IN O
cell P10665798A0598 NN O
or P10665798A0598 CC O
tissue P10665798A0598 NN O
damage P10665798A0598 NN O
. P10665798A0598 . O
. . O O

We P02543679A1291 PRP O
also P02543679A1291 RB O
provide P02543679A1291 VBP O
evidence P02543679A1291 NN O
that P02543679A1291 IN O
neither P02543679A1291 CC O
the P02543679A1291 DT O
lambda P02543679A1291 JJ I-UN
O P02543679A1291 NNP I-UN
and P02543679A1291 CC O
P P02543679A1291 NNP I-UN
initiators P02543679A1291 NNS I-UN
nor P02543679A1291 CC O
the P02543679A1291 DT O
E. P02543679A1291 NNP I-UN
coli P02543679A1291 NNS I-UN
DnaJ P02543679A1291 NNP I-UN
and P02543679A1291 CC O
DnaK P02543679A1291 NNP I-UN
heat P02543679A1291 NN O
shock P02543679A1291 NN O
proteins P02543679A1291 NNS O
play P02543679A1291 VBP O
a P02543679A1291 DT O
direct P02543679A1291 JJ O
role P02543679A1291 NN O
in P02543679A1291 IN O
the P02543679A1291 DT O
propagation P02543679A1291 NN O
of P02543679A1291 IN O
lambda P02543679A1291 JJ O
replication P02543679A1291 NN O
forks P02543679A1291 NNS O
in P02543679A1291 IN O
vitro P02543679A1291 NN O
. P02543679A1291 . O
. . O O

The P01840608A0823 DT O
N-terminus P01840608A0823 NNP O
of P01840608A0823 IN O
another P01840608A0823 DT O
open P01840608A0823 JJ O
reading P01840608A0823 NN O
frame P01840608A0823 NN O
was P01840608A0823 VBD O
found P01840608A0823 VBN O
3 P01840608A0823 CD O
' P01840608A0823 '' O
from P01840608A0823 IN O
nifA P01840608A0823 NNS I-UN
and P01840608A0823 CC O
tentatively P01840608A0823 RB O
identified P01840608A0823 VBN O
as P01840608A0823 IN O
nifB P01840608A0823 NN I-UN
by P01840608A0823 IN O
amino P01840608A0823 NN O
acid P01840608A0823 JJ O
sequence P01840608A0823 NN O
comparison P01840608A0823 NN O
. P01840608A0823 . O
. . O O

3 P02049617A0504 CD O
. P02049617A0504 . O
. . O O

Cheung P08550461A0284 NNP O
and P08550461A0284 CC O
S P08550461A0284 NNP O
. P08550461A0284 . O
. . O O

9 P02137458A1129 CD O
, P02137458A1129 , O
1498-1506 P02137458A1129 JJ O
) P02137458A1129 ) O
. P02137458A1129 . O
. . O O

Although P08794339A1162 IN O
the P08794339A1162 DT O
binding P08794339A1162 NN O
of P08794339A1162 IN O
IE2 P08794339A1162 NNP I-UN
86 P08794339A1162 CD I-UN
to P08794339A1162 TO O
nonphosphorylated P08794339A1162 VBN O
full-length P08794339A1162 JJ I-UN
CREB P08794339A1162 NNP I-UN
or P08794339A1162 CC O
deltaCREB P08794339A1162 NN I-UN
is P08794339A1162 VBZ O
minimal P08794339A1162 JJ O
, P08794339A1162 , O
IE2 P08794339A1162 NNP I-UN
86 P08794339A1162 CD I-UN
does P08794339A1162 VBZ O
form P08794339A1162 VB O
complexes P08794339A1162 NNS O
with P08794339A1162 IN O
p300 P08794339A1162 NN I-UN
and P08794339A1162 CC O
the P08794339A1162 DT O
CREB-binding P08794339A1162 NNP I-UN
protein P08794339A1162 NN I-UN
( P08794339A1162 ( O
CBP P08794339A1162 NNP I-UN
) P08794339A1162 ) O
, P08794339A1162 , O
which P08794339A1162 WDT O
in P08794339A1162 IN O
turn P08794339A1162 NN O
bind P08794339A1162 NN O
to P08794339A1162 TO O
CREB P08794339A1162 NNP I-UN
and P08794339A1162 CC O
can P08794339A1162 MD O
serve P08794339A1162 VB O
as P08794339A1162 IN O
adaptor P08794339A1162 NN O
proteins P08794339A1162 NNS O
for P08794339A1162 IN O
CREB P08794339A1162 NNP I-UN
function P08794339A1162 NN O
. P08794339A1162 . O
. . O O

METHODS P07569770A0298 NNS O
: P07569770A0298 : O
All P07569770A0298 PDT O
these P07569770A0298 DT O
30 P07569770A0298 CD O
non-responders P07569770A0298 NNS O
received P07569770A0298 VBD O
an P07569770A0298 DT O
extra P07569770A0298 JJ O
dose P07569770A0298 NN O
of P07569770A0298 IN O
the P07569770A0298 DT O
same P07569770A0298 JJ O
vaccine P07569770A0298 NN O
2 P07569770A0298 CD O
months P07569770A0298 NNS O
after P07569770A0298 IN O
primary P07569770A0298 JJ O
immunization P07569770A0298 NN O
and P07569770A0298 CC O
a P07569770A0298 DT O
booster P07569770A0298 NN O
dose P07569770A0298 NN O
with P07569770A0298 IN O
a P07569770A0298 DT O
yeast-derived P07569770A0298 JJ O
vaccine P07569770A0298 NN O
6 P07569770A0298 CD O
years P07569770A0298 NNS O
later P07569770A0298 RB O
. P07569770A0298 . O
. . O O

Computerized P07891638T0000 JJ O
detection P07891638T0000 NN O
of P07891638T0000 IN O
abnormal P07891638T0000 JJ O
asymmetry P07891638T0000 NN O
in P07891638T0000 IN O
digital P07891638T0000 JJ O
chest P07891638T0000 NN O
radiographs P07891638T0000 NN O
. P07891638T0000 . O
. . O O

Because P04034220A0205 IN O
of P04034220A0205 IN O
its P04034220A0205 PRP$ O
wide P04034220A0205 JJ O
spectrum P04034220A0205 NN O
of P04034220A0205 IN O
activity P04034220A0205 NN O
particularly P04034220A0205 RB O
against P04034220A0205 IN O
ampicillin P04034220A0205 NN O
resistant P04034220A0205 JJ O
strains P04034220A0205 NNS O
of P04034220A0205 IN O
H. P04034220A0205 NNP O
influenzae P04034220A0205 NN O
and P04034220A0205 CC O
because P04034220A0205 IN O
of P04034220A0205 IN O
its P04034220A0205 PRP$ O
good P04034220A0205 JJ O
tolerance P04034220A0205 NN O
Cefaclor P04034220A0205 NNP O
is P04034220A0205 VBZ O
very P04034220A0205 RB O
useful P04034220A0205 JJ O
in P04034220A0205 IN O
treatment P04034220A0205 NN O
of P04034220A0205 IN O
respiratory P04034220A0205 NN O
tract P04034220A0205 NN O
infections P04034220A0205 NNS O
in P04034220A0205 IN O
children P04034220A0205 NNS O
. P04034220A0205 . O
. . O O

A P11614398T0000 DT O
peculiar P11614398T0000 JJ O
people P11614398T0000 NNS O
: P11614398T0000 : O
`` P11614398T0000 `` O
the P11614398T0000 DT O
physiological P11614398T0000 JJ O
aspects P11614398T0000 NNS O
of P11614398T0000 IN O
Mormonism P11614398T0000 NNP O
1850-1975 P11614398T0000 JJ O
. P11614398T0000 . O
`` P11614398T0000 `` O
. P11614398T0000 . O
. . O O

We P08491383A1291 PRP O
conclude P08491383A1291 VBP O
that P08491383A1291 IN O
the P08491383A1291 DT O
alpha-subunit P08491383A1291 NN O
of P08491383A1291 IN O
the P08491383A1291 DT O
telomere-binding P08491383A1291 JJ I-UN
protein P08491383A1291 NN I-UN
, P08491383A1291 , O
like P08491383A1291 IN O
many P08491383A1291 JJ O
transcription P08491383A1291 NN O
factors P08491383A1291 NNS O
, P08491383A1291 , O
has P08491383A1291 VBZ O
separable P08491383A1291 JJ O
DNA-binding P08491383A1291 JJ O
and P08491383A1291 CC O
protein-protein P08491383A1291 JJ O
interaction P08491383A1291 NN O
domains P08491383A1291 NNS O
. P08491383A1291 . O
. . O O

One P11902068T0000 CD O
CKD P11902068T0000 NNP O
patient P11902068T0000 NN O
's P11902068T0000 POS O
journey P11902068T0000 NN O
. P11902068T0000 . O
. . O O

Fluorimetric P11227484T0000 NNP O
determination P11227484T0000 NN O
of P11227484T0000 IN O
methylmercury P11227484T0000 NN O
as P11227484T0000 IN O
an P11227484T0000 DT O
ion-association P11227484T0000 NN O
complex P11227484T0000 NN O
with P11227484T0000 IN O
rhodamine P11227484T0000 NN O
B P11227484T0000 NNP O
in P11227484T0000 IN O
the P11227484T0000 DT O
presence P11227484T0000 NN O
of P11227484T0000 IN O
iodide P11227484T0000 NN O
. P11227484T0000 . O
. . O O

Courses P07960608A0228 NNS O
were P07960608A0228 VBD O
repeated P07960608A0228 VBN O
every P07960608A0228 DT O
four P07960608A0228 CD O
weeks P07960608A0228 NNS O
. P07960608A0228 . O
. . O O

A P09575217A0971 DT O
site-directed P09575217A0971 JJ O
R618K P09575217A0971 NNP O
mutation P09575217A0971 NN O
in P09575217A0971 IN O
the P09575217A0971 DT O
Stat5 P09575217A0971 NNP I-UN
SH2 P09575217A0971 NNP I-UN
domain P09575217A0971 NN I-UN
abolished P09575217A0971 VBD O
the P09575217A0971 DT O
phosphorylation P09575217A0971 NN O
by P09575217A0971 IN O
Jak2 P09575217A0971 NNP I-UN
, P09575217A0971 , O
while P09575217A0971 IN O
deletion P09575217A0971 NN O
of P09575217A0971 IN O
the P09575217A0971 DT O
C P09575217A0971 NNP O
terminus P09575217A0971 NN O
led P09575217A0971 VBD O
to P09575217A0971 TO O
Stat5 P09575217A0971 NNP I-UN
hyperphosphorylation P09575217A0971 NN O
. P09575217A0971 . O
. . O O

Exposure P06466804A0686 NN O
of P06466804A0686 IN O
endothelium P06466804A0686 NN O
to P06466804A0686 TO O
pulsatile P06466804A0686 VB O
shear P06466804A0686 JJ O
stresses P06466804A0686 NNS O
that P06466804A0686 WDT O
followed P06466804A0686 VBD O
a P06466804A0686 DT O
tape P06466804A0686 NN O
recording P06466804A0686 NN O
of P06466804A0686 IN O
physiological P06466804A0686 JJ O
flow P06466804A0686 NN O
waveforms P06466804A0686 NNS O
( P06466804A0686 ( O
electromagnetic P06466804A0686 JJ O
flowmeter P06466804A0686 NN O
) P06466804A0686 ) O
did P06466804A0686 VBD O
not P06466804A0686 RB O
cause P06466804A0686 VB O
gross P06466804A0686 JJ O
injury P06466804A0686 NN O
or P06466804A0686 CC O
denudation P06466804A0686 NN O
even P06466804A0686 RB O
when P06466804A0686 WRB O
peak P06466804A0686 JJ O
shear P06466804A0686 NN O
exceeded P06466804A0686 VBD O
1500 P06466804A0686 CD O
dyne P06466804A0686 NN O
/ P06466804A0686 NNP O
cm2 P06466804A0686 NN O
. P06466804A0686 . O
. . O O

Candidate P09094671A1192 NNP O
tumor P09094671A1192 NN O
suppressor P09094671A1192 NN O
genes P09094671A1192 NNS O
, P09094671A1192 , O
Mts1 P09094671A1192 NNP I-UN
( P09094671A1192 ( O
p16INK4a P09094671A1192 NN I-UN
) P09094671A1192 ) O
and P09094671A1192 CC O
Mts2 P09094671A1192 NNP I-UN
( P09094671A1192 ( O
p15INK4b P09094671A1192 NN I-UN
) P09094671A1192 ) O
, P09094671A1192 , O
have P09094671A1192 VBP O
been P09094671A1192 VBN O
mapped P09094671A1192 VBN O
to P09094671A1192 TO O
this P09094671A1192 DT O
region P09094671A1192 NN O
, P09094671A1192 , O
but P09094671A1192 CC O
by P09094671A1192 IN O
Southern P09094671A1192 NNP O
blot P09094671A1192 NN O
analysis P09094671A1192 NN O
, P09094671A1192 , O
no P09094671A1192 DT O
homozygous P09094671A1192 JJ O
deletions P09094671A1192 NNS O
were P09094671A1192 VBD O
detected P09094671A1192 VBN O
in P09094671A1192 IN O
either P09094671A1192 DT O
gene P09094671A1192 NN O
. P09094671A1192 . O
. . O O

In P06883385A0509 IN O
patients P06883385A0509 NNS O
with P06883385A0509 IN O
complete P06883385A0509 JJ O
or P06883385A0509 CC O
partial P06883385A0509 JJ O
remission P06883385A0509 NN O
of P06883385A0509 IN O
the P06883385A0509 DT O
tumor P06883385A0509 NN O
, P06883385A0509 , O
the P06883385A0509 DT O
neopterine P06883385A0509 JJ O
excretion P06883385A0509 NN O
dropped P06883385A0509 VBD O
to P06883385A0509 TO O
normal P06883385A0509 JJ O
values P06883385A0509 NNS O
. P06883385A0509 . O
. . O O

Carbohydrates P09890778T0000 NNS O
and P09890778T0000 CC O
glycoconjugates P09890778T0000 NNS O
biophysical P09890778T0000 JJ O
methods P09890778T0000 NNS O
. P09890778T0000 . O
. . O O

Composites P04511139T0001 NNS O
as P04511139T0001 IN O
restoration P04511139T0001 NN O
materials P04511139T0001 NNS O
. P04511139T0001 . O
. . O O

Conditions P04369884T0000 NNS O
influencing P04369884T0000 VBG O
inhibitors P04369884T0000 NNS O
of P04369884T0000 IN O
the P04369884T0000 DT O
colony-stimulating P04369884T0000 JJ I-UN
factor P04369884T0000 NN I-UN
( P04369884T0000 ( O
CSF P04369884T0000 NNP I-UN
) P04369884T0000 ) O
. P04369884T0000 . O
. . O O

Five P09186430A0341 CD O
of P09186430A0341 IN O
these P09186430A0341 DT O
have P09186430A0341 VBP O
ocular P09186430A0341 NN O
or P09186430A0341 CC O
oculocutaneous P09186430A0341 JJ O
albinism P09186430A0341 NN O
. P09186430A0341 . O
. . O O

The P03023970A0922 DT O
96-bp P03023970A0922 JJ O
insert P03023970A0922 NN O
contained P03023970A0922 VBD O
a P03023970A0922 DT O
termination P03023970A0922 NN O
signal P03023970A0922 NN O
which P03023970A0922 WDT O
caused P03023970A0922 VBD O
the P03023970A0922 DT O
premature P03023970A0922 JJ O
termination P03023970A0922 NN O
of P03023970A0922 IN O
the P03023970A0922 DT O
protein P03023970A0922 NN O
, P03023970A0922 , O
leading P03023970A0922 VBG O
to P03023970A0922 TO O
the P03023970A0922 DT O
generation P03023970A0922 NN O
of P03023970A0922 IN O
a P03023970A0922 DT O
p53 P03023970A0922 NN I-UN
product P03023970A0922 NN I-UN
9 P03023970A0922 CD O
amino P03023970A0922 JJ O
acids P03023970A0922 NNS O
shorter P03023970A0922 JJR O
than P03023970A0922 IN O
usual P03023970A0922 JJ O
. P03023970A0922 . O
. . O O

Hyperthyroidism P02897651A0000 NN O
is P02897651A0000 VBZ O
one P02897651A0000 CD O
of P02897651A0000 IN O
the P02897651A0000 DT O
numerous P02897651A0000 JJ O
causes P02897651A0000 NNS O
of P02897651A0000 IN O
infertility P02897651A0000 NN O
and P02897651A0000 CC O
recurrent P02897651A0000 JJ O
abortion P02897651A0000 NN O
. P02897651A0000 . O
. . O O

Human P05890351T0001 NNP O
antitetanus P05890351T0001 VBZ O
serum P05890351T0001 NN O
: P05890351T0001 : O
an P05890351T0001 DT O
unused P05890351T0001 JJ O
wealth P05890351T0001 NN O
. P05890351T0001 . O
. . O O

During P11371343A0125 IN O
most P11371343A0125 JJS O
of P11371343A0125 IN O
the P11371343A0125 DT O
cell P11371343A0125 NN O
cycle P11371343A0125 NN O
, P11371343A0125 , O
separase P11371343A0125 NN I-UN
is P11371343A0125 VBZ O
kept P11371343A0125 VBN O
inactive P11371343A0125 JJ O
by P11371343A0125 IN O
binding P11371343A0125 VBG O
to P11371343A0125 TO O
an P11371343A0125 DT O
inhibitory P11371343A0125 NN O
protein P11371343A0125 NN O
called P11371343A0125 VBD O
securin P11371343A0125 NN I-UN
. P11371343A0125 . O
. . O O

The P09988850A0000 DT O
Scales P09988850A0000 NNP O
of P09988850A0000 IN O
Cognitive P09988850A0000 NNP O
Impairment P09988850A0000 NNP O
Rated P09988850A0000 VBN O
From P09988850A0000 IN O
Institutional P09988850A0000 NNP O
Records P09988850A0000 NNP O
( P09988850A0000 ( O
SCIRFIR P09988850A0000 NNP O
) P09988850A0000 ) O
, P09988850A0000 , O
a P09988850A0000 DT O
battery P09988850A0000 NN O
based P09988850A0000 VBN O
on P09988850A0000 IN O
commonly P09988850A0000 RB O
used P09988850A0000 VBN O
dementia P09988850A0000 NN O
rating P09988850A0000 NN O
instruments P09988850A0000 NNS O
, P09988850A0000 , O
was P09988850A0000 VBD O
tested P09988850A0000 VBN O
on P09988850A0000 IN O
the P09988850A0000 DT O
records P09988850A0000 NNS O
of P09988850A0000 IN O
26 P09988850A0000 CD O
chronically P09988850A0000 RB O
institutionalized P09988850A0000 VBN O
, P09988850A0000 , O
elderly P09988850A0000 JJ O
schizophrenia P09988850A0000 NN O
patients P09988850A0000 NNS O
, P09988850A0000 , O
for P09988850A0000 IN O
the P09988850A0000 DT O
purpose P09988850A0000 NN O
of P09988850A0000 IN O
retrospectively P09988850A0000 RB O
evaluating P09988850A0000 VBG O
the P09988850A0000 DT O
long-term P09988850A0000 JJ O
course P09988850A0000 NN O
of P09988850A0000 IN O
cognitive P09988850A0000 JJ O
change P09988850A0000 NN O
in P09988850A0000 IN O
schizophrenia P09988850A0000 NN O
and P09988850A0000 CC O
relating P09988850A0000 VBG O
it P09988850A0000 PRP O
to P09988850A0000 TO O
available P09988850A0000 JJ O
autopsy P09988850A0000 JJ O
materials P09988850A0000 NNS O
. P09988850A0000 . O
. . O O

Anoxia P02826717A0179 NNP O
was P02826717A0179 VBD O
introduced P02826717A0179 VBN O
by P02826717A0179 IN O
perfusing P02826717A0179 VBG O
the P02826717A0179 DT O
gill P02826717A0179 NN O
with P02826717A0179 IN O
water P02826717A0179 NN O
deprived P02826717A0179 VBN O
of P02826717A0179 IN O
oxygen P02826717A0179 NN O
or P02826717A0179 CC O
by P02826717A0179 IN O
halting P02826717A0179 VBG O
the P02826717A0179 DT O
water P02826717A0179 NN O
flow P02826717A0179 NN O
to P02826717A0179 TO O
the P02826717A0179 DT O
gill P02826717A0179 NN O
. P02826717A0179 . O
. . O O

Mutation P11356853A0554 NN O
analyses P11356853A0554 NNS O
identified P11356853A0554 VBD O
the P11356853A0554 DT O
cobalt-responsive P11356853A0554 JJ O
sequences P11356853A0554 NNS O
as P11356853A0554 IN O
the P11356853A0554 DT O
stress-response P11356853A0554 JJ O
elements P11356853A0554 NNS O
( P11356853A0554 ( O
StREs P11356853A0554 NNP O
) P11356853A0554 ) O
. P11356853A0554 . O
. . O O

By P10400593A1084 IN O
contrast P10400593A1084 NN O
, P10400593A1084 , O
PvirE P10400593A1084 NNP I-UN
or P10400593A1084 CC O
Plac P10400593A1084 NNP I-UN
promoter P10400593A1084 NN I-UN
constructs P10400593A1084 NNS I-UN
yielded P10400593A1084 VBD O
functional P10400593A1084 JJ O
VirE2 P10400593A1084 NNP I-UN
only P10400593A1084 RB O
if P10400593A1084 IN O
virE1 P10400593A1084 NN I-UN
was P10400593A1084 VBD O
coexpressed P10400593A1084 VBN O
with P10400593A1084 IN O
virE2 P10400593A1084 NN I-UN
. P10400593A1084 . O
. . O O

The P11313961A1323 DT O
mice P11313961A1323 NN O
are P11313961A1323 VBP O
phenotypically P11313961A1323 RB O
normal P11313961A1323 JJ O
and P11313961A1323 CC O
do P11313961A1323 VBP O
not P11313961A1323 RB O
develop P11313961A1323 VB O
spontaneous P11313961A1323 JJ O
tumors P11313961A1323 NNS O
at P11313961A1323 IN O
an P11313961A1323 DT O
early P11313961A1323 JJ O
age P11313961A1323 NN O
, P11313961A1323 , O
in P11313961A1323 IN O
contrast P11313961A1323 NN O
to P11313961A1323 TO O
knock-out P11313961A1323 NN O
( P11313961A1323 ( O
p53 P11313961A1323 NN I-UN
( P11313961A1323 ( I-UN
- P11313961A1323 : I-UN
/ P11313961A1323 SYM I-UN
- P11313961A1323 : I-UN
) P11313961A1323 ) I-UN
) P11313961A1323 ) O
strains P11313961A1323 VBZ O
with P11313961A1323 IN O
a P11313961A1323 DT O
defective P11313961A1323 JJ O
p53 P11313961A1323 NN I-UN
gene P11313961A1323 NN I-UN
. P11313961A1323 . O
. . O O

Schwab P10091619A0104 NNP O
and P10091619A0104 CC O
England P10091619A0104 NNP O
ADL P10091619A0104 NNP O
scores P10091619A0104 VBZ O
in P10091619A0104 IN O
the P10091619A0104 DT O
`` P10091619A0104 `` O
off P10091619A0104 RP O
'' P10091619A0104 '' O
state P10091619A0104 NN O
were P10091619A0104 VBD O
improved P10091619A0104 VBN O
by P10091619A0104 IN O
18 P10091619A0104 CD O
% P10091619A0104 NN O
and P10091619A0104 CC O
in P10091619A0104 IN O
the P10091619A0104 DT O
`` P10091619A0104 `` O
on P10091619A0104 IN O
'' P10091619A0104 '' O
state P10091619A0104 NN O
the P10091619A0104 DT O
scores P10091619A0104 NNS O
declined P10091619A0104 VBD O
by P10091619A0104 IN O
2 P10091619A0104 CD O
% P10091619A0104 NN O
. P10091619A0104 . O
. . O O

Expression P08509419A0785 NN O
of P08509419A0785 IN O
this P08509419A0785 DT O
protein P08509419A0785 NN O
in P08509419A0785 IN O
E. P08509419A0785 NNP O
coli P08509419A0785 NNS O
demonstrated P08509419A0785 VBD O
that P08509419A0785 IN O
tyrosine P08509419A0785 NN O
was P08509419A0785 VBD O
incorporated P08509419A0785 VBN O
during P08509419A0785 IN O
suppression P08509419A0785 NN O
and P08509419A0785 CC O
that P08509419A0785 IN O
yeast P08509419A0785 JJ I-UN
cytoplasmic P08509419A0785 JJ I-UN
TyrRS P08509419A0785 NNP I-UN
activity P08509419A0785 NN O
was P08509419A0785 VBD O
produced P08509419A0785 VBN O
. P08509419A0785 . O
. . O O

Thus P08868473A1287 RB O
, P08868473A1287 , O
although P08868473A1287 IN O
p28 P08868473A1287 NN I-UN
may P08868473A1287 MD O
play P08868473A1287 VB O
only P08868473A1287 RB O
a P08868473A1287 DT O
limited P08868473A1287 JJ O
role P08868473A1287 NN O
during P08868473A1287 IN O
the P08868473A1287 DT O
early P08868473A1287 JJ O
embryonic P08868473A1287 NN O
cleavages P08868473A1287 NNS O
, P08868473A1287 , O
it P08868473A1287 PRP O
may P08868473A1287 MD O
function P08868473A1287 VB O
later P08868473A1287 RB O
in P08868473A1287 IN O
development P08868473A1287 NN O
to P08868473A1287 TO O
establish P08868473A1287 VB O
a P08868473A1287 DT O
somatic P08868473A1287 JJ O
type P08868473A1287 NN O
of P08868473A1287 IN O
cell P08868473A1287 NN O
cycle P08868473A1287 NN O
. P08868473A1287 . O
. . O O

However P09871353A0174 RB O
, P09871353A0174 , O
there P09871353A0174 EX O
has P09871353A0174 VBZ O
not P09871353A0174 RB O
been P09871353A0174 VBN O
any P09871353A0174 DT O
evidence P09871353A0174 NN O
of P09871353A0174 IN O
A. P09871353A0174 NNP O
salmonicida P09871353A0174 JJ O
infections P09871353A0174 NNS O
, P09871353A0174 , O
specifically P09871353A0174 RB O
furunculosis P09871353A0174 NN O
, P09871353A0174 , O
associated P09871353A0174 VBN O
with P09871353A0174 IN O
the P09871353A0174 DT O
fish P09871353A0174 NN O
in P09871353A0174 IN O
this P09871353A0174 DT O
loch P09871353A0174 NN O
. P09871353A0174 . O
. . O O

In P02648396A0565 IN O
Rat-1a P02648396A0565 NNP O
cells P02648396A0565 NNS O
the P02648396A0565 DT O
expression P02648396A0565 NN O
of P02648396A0565 IN O
human P02648396A0565 JJ I-UN
c-jun P02648396A0565 JJ I-UN
mRNA P02648396A0565 NN I-UN
was P02648396A0565 VBD O
associated P02648396A0565 VBN O
with P02648396A0565 IN O
the P02648396A0565 DT O
ability P02648396A0565 NN O
to P02648396A0565 TO O
clone P02648396A0565 VB O
in P02648396A0565 IN O
soft P02648396A0565 JJ O
agarose P02648396A0565 NN O
and P02648396A0565 CC O
form P02648396A0565 NN O
tumors P02648396A0565 NNS O
in P02648396A0565 IN O
nude P02648396A0565 JJ O
mice P02648396A0565 NN O
. P02648396A0565 . O
. . O O

Direct P11251697T0000 JJ O
superoxide P11251697T0000 NN O
scavenging P11251697T0000 VBG O
activity P11251697T0000 NN O
of P11251697T0000 IN O
nonsteroidal P11251697T0000 JJ O
anti-inflammatory P11251697T0000 JJ O
drugs P11251697T0000 NNS O
: P11251697T0000 : O
determination P11251697T0000 NN O
by P11251697T0000 IN O
electron P11251697T0000 NN O
spin P11251697T0000 NN O
resonance P11251697T0000 NN O
using P11251697T0000 VBG O
the P11251697T0000 DT O
spin P11251697T0000 NN O
trap P11251697T0000 NN O
method P11251697T0000 NN O
. P11251697T0000 . O
. . O O

These P02272095A0832 DT O
results P02272095A0832 NNS O
may P02272095A0832 MD O
suggest P02272095A0832 VB O
involvement P02272095A0832 NN O
of P02272095A0832 IN O
peripheral P02272095A0832 JJ O
enkephalins P02272095A0832 NNS O
in P02272095A0832 IN O
pain P02272095A0832 NN O
modulation P02272095A0832 NN O
in P02272095A0832 IN O
patients P02272095A0832 NNS O
with P02272095A0832 IN O
episodic P02272095A0832 JJ O
cluster P02272095A0832 NN O
headache P02272095A0832 NN O
. P02272095A0832 . O
. . O O

Effect P02339005T0000 NN O
of P02339005T0000 IN O
hyperglycemia P02339005T0000 NN O
on P02339005T0000 IN O
pain P02339005T0000 NN O
threshold P02339005T0000 NN O
in P02339005T0000 IN O
alloxan-diabetic P02339005T0000 JJ O
rats P02339005T0000 NNS O
. P02339005T0000 . O
. . O O

The P07934666A0158 DT O
transverse P07934666A0158 JJ O
magnetization P07934666A0158 NN O
decays P07934666A0158 NNS O
mentioned P07934666A0158 VBN O
above P07934666A0158 RB O
exhibited P07934666A0158 VBN O
two P07934666A0158 CD O
components P07934666A0158 NNS O
, P07934666A0158 , O
a P07934666A0158 DT O
T2 P07934666A0158 NNP O
fast P07934666A0158 NN O
( P07934666A0158 ( O
T2f P07934666A0158 NNP O
) P07934666A0158 ) O
and P07934666A0158 CC O
a P07934666A0158 DT O
T2 P07934666A0158 NNP O
slow P07934666A0158 NN O
( P07934666A0158 ( O
T2s P07934666A0158 NNP O
) P07934666A0158 ) O
component P07934666A0158 NN O
. P07934666A0158 . O
. . O O

The P05500957T0001 DT O
association P05500957T0001 NN O
of P05500957T0001 IN O
clopamide P05500957T0001 NN O
and P05500957T0001 CC O
hydergine P05500957T0001 NN O
( P05500957T0001 ( O
Brinedine P05500957T0001 NNP O
) P05500957T0001 ) O
in P05500957T0001 IN O
the P05500957T0001 DT O
treatment P05500957T0001 NN O
of P05500957T0001 IN O
the P05500957T0001 DT O
vasculo-renal P05500957T0001 JJ O
syndromes P05500957T0001 NNS O
of P05500957T0001 IN O
pregnancy P05500957T0001 NN O
. P05500957T0001 . O
. . O O

Hoeben P08754827A0231 NNP O
, P08754827A0231 , O
F.J P08754827A0231 NNP O
. P08754827A0231 . O
. . O O

The P08075421A0621b DT O
partial P08075421A0621b JJ O
ORF P08075421A0621b NNP O
was P08075421A0621b VBD O
found P08075421A0621b VBN O
to P08075421A0621b TO O
be P08075421A0621b VB O
identical P08075421A0621b JJ O
to P08075421A0621b TO O
the P08075421A0621b DT O
C P08075421A0621b NNP O
terminus P08075421A0621b NN O
of P08075421A0621b IN O
HrpJ2 P08075421A0621b NNP I-UN
. P08075421A0621b . O
. . O O

Improvement P01050400T0000 NN O
of P01050400T0000 IN O
nursing P01050400T0000 VBG O
instruction P01050400T0000 NN O
to P01050400T0000 TO O
be P01050400T0000 VB O
given P01050400T0000 VBN O
at P01050400T0000 IN O
the P01050400T0000 DT O
time P01050400T0000 NN O
of P01050400T0000 IN O
discharge P01050400T0000 NN O
from P01050400T0000 IN O
the P01050400T0000 DT O
ward P01050400T0000 NN O
for P01050400T0000 IN O
premature P01050400T0000 JJ O
infants P01050400T0000 NNS O
. P01050400T0000 . O
. . O O

Rarely P02443924A0083 RB O
, P02443924A0083 , O
patients P02443924A0083 NNS O
with P02443924A0083 IN O
locally P02443924A0083 RB O
advanced P02443924A0083 VBN O
, P02443924A0083 , O
uncontrollable P02443924A0083 JJ O
, P02443924A0083 , O
non-metastatic P02443924A0083 JJ O
prostatic P02443924A0083 JJ O
cancer P02443924A0083 NN O
enjoy P02443924A0083 NN O
prolonged P02443924A0083 VBD O
survival P02443924A0083 NN O
. P02443924A0083 . O
. . O O

A P08655497A0000 DT O
novel P08655497A0000 JJ O
gene P08655497A0000 NN O
designated P08655497A0000 VBN O
cmr P08655497A0000 NN I-UN
, P08655497A0000 , O
which P08655497A0000 WDT O
mapped P08655497A0000 VBD O
to P08655497A0000 TO O
18.8 P08655497A0000 CD O
min P08655497A0000 NN O
of P08655497A0000 IN O
the P08655497A0000 DT O
Escherichia P08655497A0000 NNP O
coli P08655497A0000 VBD O
K-12 P08655497A0000 NNP O
genome P08655497A0000 NN O
, P08655497A0000 , O
was P08655497A0000 VBD O
shown P08655497A0000 VBN O
to P08655497A0000 TO O
mediate P08655497A0000 VB O
resistance P08655497A0000 NN O
to P08655497A0000 TO O
chloramphenicol P08655497A0000 VB O
when P08655497A0000 WRB O
it P08655497A0000 PRP O
was P08655497A0000 VBD O
expressed P08655497A0000 VBN O
from P08655497A0000 IN O
a P08655497A0000 DT O
multicopy P08655497A0000 NN O
vector P08655497A0000 NN O
. P08655497A0000 . O
. . O O

The P08218056A0000 DT O
ultrastructure P08218056A0000 NN O
of P08218056A0000 IN O
retinal P08218056A0000 JJ O
vessels P08218056A0000 NNS O
was P08218056A0000 VBD O
examined P08218056A0000 VBN O
in P08218056A0000 IN O
three P08218056A0000 CD O
eyes P08218056A0000 NNS O
from P08218056A0000 IN O
diabetic P08218056A0000 JJ O
patients P08218056A0000 NNS O
and P08218056A0000 CC O
two P08218056A0000 CD O
eyes P08218056A0000 NNS O
from P08218056A0000 IN O
control P08218056A0000 NN O
subjects P08218056A0000 NNS O
. P08218056A0000 . O
. . O O

Symptomatic P03147912A0422 JJ O
hyperventilators P03147912A0422 NNS O
had P03147912A0422 VBD O
a P03147912A0422 DT O
larger P03147912A0422 JJR O
number P03147912A0422 NN O
of P03147912A0422 IN O
sighs P03147912A0422 NNS O
and P03147912A0422 CC O
abnormally P03147912A0422 RB O
wide P03147912A0422 JJ O
fluctuations P03147912A0422 NNS O
in P03147912A0422 IN O
baseline P03147912A0422 NN O
for P03147912A0422 IN O
inspiratory P03147912A0422 JJ O
time P03147912A0422 NN O
, P03147912A0422 , O
expiratory P03147912A0422 JJ O
time P03147912A0422 NN O
, P03147912A0422 , O
and P03147912A0422 CC O
PETCO2 P03147912A0422 NNP O
. P03147912A0422 . O
. . O O

Heparin P11876937A0261 NNP O
( P11876937A0261 ( O
100 P11876937A0261 CD O
U P11876937A0261 NNP O
. P11876937A0261 . O
kg P11876937A0261 NN O
( P11876937A0261 ( O
-1 P11876937A0261 NNP O
) P11876937A0261 ) O
. P11876937A0261 . O
day P11876937A0261 NN O
( P11876937A0261 ( O
-1 P11876937A0261 NNP O
) P11876937A0261 ) O
) P11876937A0261 ) O
was P11876937A0261 VBD O
injected P11876937A0261 VBN O
subcutaneously P11876937A0261 RB O
to P11876937A0261 TO O
the P11876937A0261 DT O
rats P11876937A0261 NNS O
in P11876937A0261 IN O
H P11876937A0261 NNP O
group P11876937A0261 NN O
while P11876937A0261 IN O
normal P11876937A0261 JJ O
saline P11876937A0261 NN O
to P11876937A0261 TO O
those P11876937A0261 DT O
in P11876937A0261 IN O
N P11876937A0261 NNP O
group P11876937A0261 NN O
once P11876937A0261 RB O
a P11876937A0261 DT O
day P11876937A0261 NN O
. P11876937A0261 . O
. . O O

During P06615403A0718 IN O
a P06615403A0718 DT O
single P06615403A0718 JJ O
LAD P06615403A0718 NNP O
occlusion P06615403A0718 NN O
lasting P06615403A0718 VBG O
35 P06615403A0718 CD O
minutes P06615403A0718 NNS O
( P06615403A0718 ( O
series P06615403A0718 NN O
I P06615403A0718 PRP O
, P06615403A0718 , O
n P06615403A0718 RB O
= P06615403A0718 VBZ O
10 P06615403A0718 CD O
) P06615403A0718 ) O
9 P06615403A0718 CD O
microns P06615403A0718 NNS O
TMs P06615403A0718 NNP O
were P06615403A0718 VBD O
infused P06615403A0718 VBN O
immediately P06615403A0718 RB O
and P06615403A0718 CC O
30 P06615403A0718 CD O
minutes P06615403A0718 NNS O
after P06615403A0718 IN O
ligation P06615403A0718 NN O
, P06615403A0718 , O
15 P06615403A0718 CD O
microns P06615403A0718 NNS O
TMs P06615403A0718 NNP O
being P06615403A0718 VBG O
infused P06615403A0718 VBN O
after P06615403A0718 IN O
15-20 P06615403A0718 JJ O
minutes P06615403A0718 NNS O
. P06615403A0718 . O
. . O O

The P01832152A0000 DT O
incompatibility P01832152A0000 NN O
group P01832152A0000 NN O
W P01832152A0000 NNP O
plasmid P01832152A0000 VBZ O
pSa P01832152A0000 JJ O
suppresses P01832152A0000 NNS O
Agrobacterium P01832152A0000 VBP O
tumefaciens P01832152A0000 NNS O
oncogenicity P01832152A0000 NN O
( P01832152A0000 ( O
J P01832152A0000 NNP O
. P01832152A0000 . O
. . O O

GCD10 P07542616A0486 NNP I-UN
binds P07542616A0486 VBZ O
RNA P07542616A0486 NNP O
in P07542616A0486 IN O
vitro P07542616A0486 NN O
and P07542616A0486 CC O
we P07542616A0486 PRP O
present P07542616A0486 VBP O
strong P07542616A0486 JJ O
biochemical P07542616A0486 JJ O
evidence P07542616A0486 NN O
that P07542616A0486 IN O
it P07542616A0486 PRP O
is P07542616A0486 VBZ O
identical P07542616A0486 JJ O
to P07542616A0486 TO O
the P07542616A0486 DT O
RNA-binding P07542616A0486 NNP O
subunit P07542616A0486 NN O
of P07542616A0486 IN O
yeast P07542616A0486 JJ I-UN
initiation P07542616A0486 NN I-UN
factor-3 P07542616A0486 NN I-UN
( P07542616A0486 ( O
eIF-3 P07542616A0486 JJ I-UN
) P07542616A0486 ) O
. P07542616A0486 . O
eIF-3 P07542616A0486 NN I-UN
is P07542616A0486 VBZ O
a P07542616A0486 DT O
multisubunit P07542616A0486 NN O
complex P07542616A0486 NN O
that P07542616A0486 WDT O
stimulates P07542616A0486 VBZ O
translation P07542616A0486 NN O
initiation P07542616A0486 NN O
in P07542616A0486 IN O
vitro P07542616A0486 NN O
at P07542616A0486 IN O
several P07542616A0486 JJ O
different P07542616A0486 JJ O
steps P07542616A0486 NNS O
. P07542616A0486 . O
. . O O

The P01633435A0743 DT O
DRF-2 P01633435A0743 JJ I-UN
nuclear P01633435A0743 JJ I-UN
protein P01633435A0743 NN I-UN
has P01633435A0743 VBZ O
characteristics P01633435A0743 NNS O
similar P01633435A0743 JJ O
to P01633435A0743 TO O
those P01633435A0743 DT O
of P01633435A0743 IN O
the P01633435A0743 DT O
muscle-specific P01633435A0743 JJ O
regulatory P01633435A0743 JJ O
factor P01633435A0743 NN O
, P01633435A0743 , O
MEF-2 P01633435A0743 NNP I-UN
( P01633435A0743 ( O
Buskin P01633435A0743 NNP O
and P01633435A0743 CC O
Hauschka P01633435A0743 NNP O
1989 P01633435A0743 CD O
; P01633435A0743 : O
Gossett P01633435A0743 NNP O
et P01633435A0743 FW O
al. P01633435A0743 NN O
, P01633435A0743 , O
1989 P01633435A0743 CD O
) P01633435A0743 ) O
. P01633435A0743 . O
. . O O

RT-PCR P09515032A1230 JJ O
indicated P09515032A1230 VBD O
that P09515032A1230 IN O
p21 P09515032A1230 NN I-UN
mRNA P09515032A1230 NN I-UN
was P09515032A1230 VBD O
induced P09515032A1230 VBN O
1.4- P09515032A1230 JJ O
, P09515032A1230 , O
2.0- P09515032A1230 JJ O
, P09515032A1230 , O
and P09515032A1230 CC O
3.1-fold P09515032A1230 JJ O
in P09515032A1230 IN O
the P09515032A1230 DT O
2-day P09515032A1230 JJ O
neonatal P09515032A1230 JJ O
, P09515032A1230 , O
7-day P09515032A1230 JJ O
neonatal P09515032A1230 NN O
, P09515032A1230 , O
and P09515032A1230 CC O
adult P09515032A1230 NN O
stages P09515032A1230 NNS O
, P09515032A1230 , O
respectively P09515032A1230 RB O
, P09515032A1230 , O
compared P09515032A1230 VBN O
to P09515032A1230 TO O
the P09515032A1230 DT O
17-day P09515032A1230 JJ O
fetal P09515032A1230 JJ O
stage P09515032A1230 NN O
. P09515032A1230 . O
. . O O

With P11303638A0559 IN O
NEU P11303638A0559 NNP I-UN
overexpression P11303638A0559 NN O
, P11303638A0559 , O
nodal P11303638A0559 JJ O
control P11303638A0559 NN O
decreased P11303638A0559 VBD O
from P11303638A0559 IN O
72 P11303638A0559 CD O
% P11303638A0559 NN O
to P11303638A0559 TO O
34 P11303638A0559 CD O
% P11303638A0559 NN O
( P11303638A0559 ( O
p P11303638A0559 JJ O
= P11303638A0559 NNP O
.008 P11303638A0559 NNP O
) P11303638A0559 ) O
. P11303638A0559 . O
. . O O

In P09882489A0451 IN O
this P09882489A0451 DT O
study P09882489A0451 NN O
, P09882489A0451 , O
evidence P09882489A0451 NN O
is P09882489A0451 VBZ O
presented P09882489A0451 VBN O
that P09882489A0451 IN O
temporally P09882489A0451 RB O
and P09882489A0451 CC O
spatially P09882489A0451 RB O
specific P09882489A0451 JJ O
mef2 P09882489A0451 NN I-UN
expression P09882489A0451 NN O
is P09882489A0451 VBZ O
controlled P09882489A0451 VBN O
by P09882489A0451 IN O
a P09882489A0451 DT O
complex P09882489A0451 JJ O
array P09882489A0451 NN O
of P09882489A0451 IN O
cis-acting P09882489A0451 JJ O
regulatory P09882489A0451 JJ O
modules P09882489A0451 NNS O
that P09882489A0451 WDT O
are P09882489A0451 VBP O
responsive P09882489A0451 JJ O
to P09882489A0451 TO O
different P09882489A0451 JJ O
genetic P09882489A0451 JJ O
signals P09882489A0451 NNS O
. P09882489A0451 . O
. . O O

Positive P05627251T0000 JJ O
shifts P05627251T0000 NNS O
of P05627251T0000 IN O
basal P05627251T0000 NN O
skin P05627251T0000 JJ O
potentials P05627251T0000 NNS O
during P05627251T0000 IN O
human P05627251T0000 JJ O
sleep P05627251T0000 NN O
. P05627251T0000 . O
. . O O

Overall P06316623A0188 JJ O
prevalences P06316623A0188 NNS O
of P06316623A0188 IN O
antibody P06316623A0188 NN O
were P06316623A0188 VBD O
70 P06316623A0188 CD O
per P06316623A0188 IN O
cent P06316623A0188 NN O
in P06316623A0188 IN O
cattle P06316623A0188 NNS O
, P06316623A0188 , O
67 P06316623A0188 CD O
per P06316623A0188 IN O
cent P06316623A0188 NN O
in P06316623A0188 IN O
sheep P06316623A0188 NN O
and P06316623A0188 CC O
76 P06316623A0188 CD O
per P06316623A0188 IN O
cent P06316623A0188 NN O
in P06316623A0188 IN O
goats P06316623A0188 NNS O
as P06316623A0188 IN O
assessed P06316623A0188 VBN O
by P06316623A0188 IN O
an P06316623A0188 DT O
immunodiffusion P06316623A0188 NN O
test P06316623A0188 NN O
. P06316623A0188 . O
. . O O

Indeed P09582308A1165 RB O
, P09582308A1165 , O
it P09582308A1165 PRP O
is P09582308A1165 VBZ O
shown P09582308A1165 VBN O
that P09582308A1165 IN O
it P09582308A1165 PRP O
mediates P09582308A1165 VBZ O
the P09582308A1165 DT O
formation P09582308A1165 NN O
of P09582308A1165 IN O
disulfide-linked P09582308A1165 JJ O
homodimers P09582308A1165 NNS O
and P09582308A1165 CC O
that P09582308A1165 IN O
the P09582308A1165 DT O
formation P09582308A1165 NN O
of P09582308A1165 IN O
homo- P09582308A1165 NN O
and P09582308A1165 CC O
heterodimers P09582308A1165 NNS O
are P09582308A1165 VBP O
mutually P09582308A1165 RB O
excluded P09582308A1165 VBN O
. P09582308A1165 . O
. . O O

These P09297698A0933 DT O
transcripts P09297698A0933 NNS O
contain P09297698A0933 VBP O
the P09297698A0933 DT O
5 P09297698A0933 CD O
' P09297698A0933 POS O
ends P09297698A0933 NNS O
of P09297698A0933 IN O
mature P09297698A0933 NN O
UbCRBP P09297698A0933 NNP I-UN
mRNAs P09297698A0933 NN I-UN
; P09297698A0933 : O
extend P09297698A0933 CC O
through P09297698A0933 IN O
UbCRBP P09297698A0933 NNP I-UN
, P09297698A0933 , O
across P09297698A0933 IN O
the P09297698A0933 DT O
intergenic P09297698A0933 JJ O
region P09297698A0933 NN O
, P09297698A0933 , O
and P09297698A0933 CC O
a P09297698A0933 DT O
significant P09297698A0933 JJ O
distance P09297698A0933 NN O
3 P09297698A0933 CD O
' P09297698A0933 '' O
into P09297698A0933 IN O
the P09297698A0933 DT O
enolase P09297698A0933 JJ I-UN
gene P09297698A0933 NN I-UN
. P09297698A0933 . O
. . O O

( P02852805A0216 ( O
total P02852805A0216 JJ O
soluble P02852805A0216 JJ O
solids P02852805A0216 NNS O
) P02852805A0216 ) O
and P02852805A0216 CC O
organoleptic P02852805A0216 JJ O
characteristics P02852805A0216 NNS O
under P02852805A0216 IN O
the P02852805A0216 DT O
influence P02852805A0216 NN O
of P02852805A0216 IN O
different P02852805A0216 JJ O
treatments P02852805A0216 NNS O
. P02852805A0216 . O
. . O O

Additionally P01907941A0275 RB O
, P01907941A0275 , O
I P01907941A0275 PRP I-UN
kappa P01907941A0275 VBP I-UN
B P01907941A0275 NNP I-UN
beta P01907941A0275 NN I-UN
, P01907941A0275 , O
but P01907941A0275 CC O
not P01907941A0275 RB O
I P01907941A0275 PRP I-UN
kappa P01907941A0275 VBP I-UN
B P01907941A0275 NNP I-UN
alpha P01907941A0275 NN I-UN
, P01907941A0275 , O
also P01907941A0275 RB O
prevented P01907941A0275 VBD O
the P01907941A0275 DT O
binding P01907941A0275 NN O
of P01907941A0275 IN O
Rel P01907941A0275 NNP I-UN
to P01907941A0275 TO O
the P01907941A0275 DT O
kappa P01907941A0275 NN I-UN
B P01907941A0275 NNP I-UN
site P01907941A0275 NN I-UN
. P01907941A0275 . O
. . O O

Nodular P02590097A0093 JJ O
involvement P02590097A0093 NN O
of P02590097A0093 IN O
the P02590097A0093 DT O
left P02590097A0093 NN O
lung P02590097A0093 NN O
and P02590097A0093 CC O
infiltration P02590097A0093 NN O
of P02590097A0093 IN O
the P02590097A0093 DT O
mucosa P02590097A0093 NN O
of P02590097A0093 IN O
the P02590097A0093 DT O
left P02590097A0093 NN O
lower P02590097A0093 JJR O
lobe P02590097A0093 NN O
bronchus P02590097A0093 NN O
followed P02590097A0093 VBD O
very P02590097A0093 RB O
gradually P02590097A0093 RB O
and P02590097A0093 CC O
a P02590097A0093 DT O
monoclonal P02590097A0093 JJ O
gammopathy P02590097A0093 NN O
( P02590097A0093 ( O
IgA P02590097A0093 NNP I-UN
-- P02590097A0093 : I-UN
Type P02590097A0093 NNP I-UN
Kappa P02590097A0093 NNP I-UN
) P02590097A0093 ) O
was P02590097A0093 VBD O
demonstrated P02590097A0093 VBN O
. P02590097A0093 . O
. . O O

Responses P11543154T0000 NNS O
of P11543154T0000 IN O
TLD P11543154T0000 NNP O
Mg2SiO4 P11543154T0000 NNP O
: P11543154T0000 : O
Tb P11543154T0000 NN O
and P11543154T0000 CC O
radiophotoluminescent P11543154T0000 NN O
glass P11543154T0000 NN O
to P11543154T0000 TO O
heavy P11543154T0000 VB O
charged P11543154T0000 VBN O
particles P11543154T0000 NNS O
and P11543154T0000 CC O
space P11543154T0000 NN O
radiation P11543154T0000 NN O
. P11543154T0000 . O
. . O O

These P09304123A0079 DT O
discoloration P09304123A0079 NN O
's P09304123A0079 POS O
can P09304123A0079 MD O
be P09304123A0079 VB O
treated P09304123A0079 VBN O
in P09304123A0079 IN O
several P09304123A0079 JJ O
ways P09304123A0079 NNS O
but P09304123A0079 CC O
up P09304123A0079 RB O
to P09304123A0079 TO O
lately P09304123A0079 RB O
tooth P09304123A0079 VB O
structure P09304123A0079 NN O
had P09304123A0079 VBD O
to P09304123A0079 TO O
be P09304123A0079 VB O
removed P09304123A0079 VBN O
in P09304123A0079 IN O
an P09304123A0079 DT O
irreversible P09304123A0079 JJ O
manner P09304123A0079 NN O
in P09304123A0079 IN O
order P09304123A0079 NN O
to P09304123A0079 TO O
provide P09304123A0079 VB O
sufficient P09304123A0079 JJ O
bulk P09304123A0079 NN O
for P09304123A0079 IN O
the P09304123A0079 DT O
new P09304123A0079 JJ O
restorative P09304123A0079 JJ O
material P09304123A0079 NN O
. P09304123A0079 . O
. . O O

The P08781119A0723 DT O
5 P08781119A0723 CD O
' P08781119A0723 POS O
flanking P08781119A0723 JJ O
region P08781119A0723 NN O
of P08781119A0723 IN O
the P08781119A0723 DT O
mouse P08781119A0723 NN I-UN
Met-ase-1 P08781119A0723 NNP I-UN
gene P08781119A0723 NN I-UN
also P08781119A0723 RB O
shares P08781119A0723 NNS O
considerable P08781119A0723 JJ O
regions P08781119A0723 NNS O
of P08781119A0723 IN O
identity P08781119A0723 NN O
with P08781119A0723 IN O
the P08781119A0723 DT O
5 P08781119A0723 CD O
' P08781119A0723 POS O
flanking P08781119A0723 JJ O
region P08781119A0723 NN O
of P08781119A0723 IN O
the P08781119A0723 DT O
rat P08781119A0723 NN I-UN
Met-ase-1 P08781119A0723 NNP I-UN
gene P08781119A0723 NN I-UN
. P08781119A0723 . O
. . O O

The P02469451A0239 DT O
investigation P02469451A0239 NN O
was P02469451A0239 VBD O
thereafter P02469451A0239 RB O
continued P02469451A0239 VBN O
in P02469451A0239 IN O
an P02469451A0239 DT O
open P02469451A0239 JJ O
fashion P02469451A0239 NN O
by P02469451A0239 IN O
administering P02469451A0239 VBG O
a P02469451A0239 DT O
single P02469451A0239 JJ O
10 P02469451A0239 CD O
mg P02469451A0239 NN O
dose P02469451A0239 NN O
of P02469451A0239 IN O
the P02469451A0239 DT O
MAO-B P02469451A0239 NNP I-UN
inhibitor P02469451A0239 NN O
deprenyl P02469451A0239 NN O
to P02469451A0239 TO O
the P02469451A0239 DT O
same P02469451A0239 JJ O
subjects P02469451A0239 NNS O
. P02469451A0239 . O
. . O O

HL-A P04139081T0001 JJ I-UN
antibodies P04139081T0001 NNS I-UN
in P04139081T0001 IN O
polytransfused P04139081T0001 JJ O
patients P04139081T0001 NNS O
. P04139081T0001 . O
. . O O

Domains P09121435A1183 NNS O
I P09121435A1183 PRP O
and P09121435A1183 CC O
II P09121435A1183 NNP O
of P09121435A1183 IN O
B P09121435A1183 NNP I-UN
'' P09121435A1183 '' O
are P09121435A1183 VBP O
buried P09121435A1183 VBN O
upon P09121435A1183 IN O
assembly P09121435A1183 NN O
of P09121435A1183 IN O
the P09121435A1183 DT O
TFIIIB-DNA P09121435A1183 NNP I-UN
complex P09121435A1183 NN I-UN
, P09121435A1183 , O
as P09121435A1183 IN O
determined P09121435A1183 VBN O
by P09121435A1183 IN O
protein P09121435A1183 NN O
footprinting P09121435A1183 NN O
. P09121435A1183 . O
. . O O

Characterization P07563090A0624 NN O
of P07563090A0624 IN O
the P07563090A0624 DT O
3 P07563090A0624 CD O
' P07563090A0624 POS O
ends P07563090A0624 NNS O
of P07563090A0624 IN O
the P07563090A0624 DT O
plus-strand P07563090A0624 NN O
DNA P07563090A0624 NN O
fragments P07563090A0624 NNS O
reveals P07563090A0624 NNS O
( P07563090A0624 ( O
1 P07563090A0624 CD O
) P07563090A0624 ) O
that P07563090A0624 IN O
the P07563090A0624 DT O
upstream P07563090A0624 JJ O
fragment P07563090A0624 NN O
is P07563090A0624 VBZ O
elongated P07563090A0624 VBN O
beyond P07563090A0624 IN O
PPT2 P07563090A0624 NNP I-UN
creating P07563090A0624 VBG O
a P07563090A0624 DT O
plus-strand P07563090A0624 NN O
overlap P07563090A0624 NN O
and P07563090A0624 CC O
( P07563090A0624 ( O
2 P07563090A0624 CD O
) P07563090A0624 ) O
that P07563090A0624 IN O
the P07563090A0624 DT O
majority P07563090A0624 NN O
of P07563090A0624 IN O
plus-strand P07563090A0624 JJ O
strong-stop P07563090A0624 JJ O
DNA P07563090A0624 NN O
fragments P07563090A0624 NNS O
bear P07563090A0624 VBP O
a P07563090A0624 DT O
copy P07563090A0624 NN O
of P07563090A0624 IN O
the P07563090A0624 DT O
minus-strand P07563090A0624 JJ O
primer P07563090A0624 NN O
binding P07563090A0624 VBG O
site P07563090A0624 NN O
in P07563090A0624 IN O
agreement P07563090A0624 NN O
with P07563090A0624 IN O
the P07563090A0624 DT O
accepted P07563090A0624 JJ O
model P07563090A0624 NN O
of P07563090A0624 IN O
retroviral P07563090A0624 JJ O
genomic P07563090A0624 JJ O
RNA P07563090A0624 NNP O
reverse P07563090A0624 NN O
transcription P07563090A0624 NN O
. P07563090A0624 . O
. . O O

Its P01664192A1577 PRP$ O
neuromuscular P01664192A1577 JJ O
effects P01664192A1577 NNS O
are P01664192A1577 VBP O
similar P01664192A1577 JJ O
to P01664192A1577 TO O
a P01664192A1577 DT O
single P01664192A1577 JJ O
ED90 P01664192A1577 NNP O
dose P01664192A1577 NN O
of P01664192A1577 IN O
vecuronium P01664192A1577 NN O
. P01664192A1577 . O
. . O O

Time P03296019T0000 NNP O
delay P03296019T0000 NN O
effects P03296019T0000 NNS O
on P03296019T0000 IN O
the P03296019T0000 DT O
tensile P03296019T0000 JJ O
bond P03296019T0000 NN O
strength P03296019T0000 NN O
developed P03296019T0000 VBN O
by P03296019T0000 IN O
the P03296019T0000 DT O
Silicoater P03296019T0000 NNP O
. P03296019T0000 . O
. . O O

Through P08103379A0577 IN O
a P08103379A0577 DT O
stretch P08103379A0577 NN O
of P08103379A0577 IN O
56 P08103379A0577 CD O
amino P08103379A0577 NN O
acids P08103379A0577 NNS O
, P08103379A0577 , O
constituting P08103379A0577 VBG O
the P08103379A0577 DT O
MADS P08103379A0577 NNP I-UN
domain P08103379A0577 NN I-UN
, P08103379A0577 , O
the P08103379A0577 DT O
two P08103379A0577 CD O
proteins P08103379A0577 NNS O
are P08103379A0577 VBP O
identical P08103379A0577 JJ O
except P08103379A0577 IN O
for P08103379A0577 IN O
two P08103379A0577 CD O
conservative P08103379A0577 JJ O
amino P08103379A0577 NN O
acid P08103379A0577 JJ O
substitutions P08103379A0577 NNS O
. P08103379A0577 . O
. . O O

The P02451872A0391 DT O
recovery P02451872A0391 NN O
of P02451872A0391 IN O
labelled P02451872A0391 JJ O
methoxydextrane P02451872A0391 NN O
is P02451872A0391 VBZ O
98 P02451872A0391 CD O
+ P02451872A0391 NN O
/ P02451872A0391 NNP O
- P02451872A0391 : O
7 P02451872A0391 CD O
% P02451872A0391 NN O
. P02451872A0391 . O
. . O O

Clicking P11816458A0319 VBG O
on P11816458A0319 IN O
`` P11816458A0319 `` O
Examples P11816458A0319 NNS O
and P11816458A0319 CC O
Explanations P11816458A0319 NNS O
of P11816458A0319 IN O
APA P11816458A0319 NNP O
Form P11816458A0319 NNP O
'' P11816458A0319 '' O
provides P11816458A0319 VBZ O
a P11816458A0319 DT O
help P11816458A0319 NN O
system P11816458A0319 NN O
with P11816458A0319 IN O
examples P11816458A0319 NNS O
of P11816458A0319 IN O
the P11816458A0319 DT O
various P11816458A0319 JJ O
sections P11816458A0319 NNS O
of P11816458A0319 IN O
a P11816458A0319 DT O
review P11816458A0319 NN O
article P11816458A0319 NN O
, P11816458A0319 , O
journal P11816458A0319 JJ O
article P11816458A0319 NN O
that P11816458A0319 WDT O
has P11816458A0319 VBZ O
one P11816458A0319 CD O
experiment P11816458A0319 NN O
, P11816458A0319 , O
or P11816458A0319 CC O
journal P11816458A0319 JJ O
article P11816458A0319 NN O
that P11816458A0319 WDT O
has P11816458A0319 VBZ O
two P11816458A0319 CD O
or P11816458A0319 CC O
more P11816458A0319 JJR O
experiments P11816458A0319 NNS O
. P11816458A0319 . O
. . O O

In P11911552A0776 IN O
patients P11911552A0776 NNS O
who P11911552A0776 WP O
respond P11911552A0776 VBP O
to P11911552A0776 TO O
quetiapine P11911552A0776 VB O
, P11911552A0776 , O
therapy P11911552A0776 NN O
should P11911552A0776 MD O
be P11911552A0776 VB O
continued P11911552A0776 VBN O
at P11911552A0776 IN O
the P11911552A0776 DT O
optimal P11911552A0776 JJ O
dose P11911552A0776 NN O
that P11911552A0776 WDT O
maintains P11911552A0776 VBZ O
remission P11911552A0776 NN O
, P11911552A0776 , O
within P11911552A0776 IN O
the P11911552A0776 DT O
range P11911552A0776 NN O
of P11911552A0776 IN O
150 P11911552A0776 CD O
to P11911552A0776 TO O
750 P11911552A0776 CD O
mg P11911552A0776 NNS O
/ P11911552A0776 JJ O
d P11911552A0776 NN O
. P11911552A0776 . O
. . O O

D P01178153A0056 NNP O
. P01178153A0056 . O
. . O O

After P06685536A0502 IN O
1.5 P06685536A0502 CD O
years P06685536A0502 NNS O
of P06685536A0502 IN O
such P06685536A0502 JJ O
photoperiodic P06685536A0502 JJ O
control P06685536A0502 NN O
, P06685536A0502 , O
all P06685536A0502 DT O
ewes P06685536A0502 NNS O
were P06685536A0502 VBD O
blinded P06685536A0502 VBN O
by P06685536A0502 IN O
bilateral P06685536A0502 JJ O
orbital P06685536A0502 JJ O
enucleation P06685536A0502 NN O
. P06685536A0502 . O
. . O O

Results P03763836T0001 NNS O
of P03763836T0001 IN O
electron P03763836T0001 JJ O
therapy P03763836T0001 NN O
of P03763836T0001 IN O
tumors P03763836T0001 NNS O
in P03763836T0001 IN O
different P03763836T0001 JJ O
sites P03763836T0001 NNS O
. P03763836T0001 . O
. . O O

Gonadal P00354315T0000 NNP O
dysfunction P00354315T0000 NN O
in P00354315T0000 IN O
patients P00354315T0000 NNS O
with P00354315T0000 IN O
ataxia P00354315T0000 JJ O
telangiectasia P00354315T0000 NN O
. P00354315T0000 . O
. . O O

Unlike P01427034A0440 IN O
the P01427034A0440 DT O
introns P01427034A0440 NNS O
of P01427034A0440 IN O
other P01427034A0440 JJ O
duplicated P01427034A0440 VBN O
ribosomal P01427034A0440 JJ I-UN
protein P01427034A0440 NN I-UN
genes P01427034A0440 NNS I-UN
which P01427034A0440 WDT O
are P01427034A0440 VBP O
highly P01427034A0440 RB O
diverged P01427034A0440 VBN O
, P01427034A0440 , O
the P01427034A0440 DT O
duplicated P01427034A0440 JJ O
S13 P01427034A0440 NNP I-UN
genes P01427034A0440 NNS I-UN
have P01427034A0440 VBP O
two P01427034A0440 CD O
nearly P01427034A0440 RB O
identical P01427034A0440 JJ O
DNA P01427034A0440 NNP O
sequences P01427034A0440 NNS O
of P01427034A0440 IN O
25 P01427034A0440 CD O
and P01427034A0440 CC O
31 P01427034A0440 CD O
bp P01427034A0440 NN O
in P01427034A0440 IN O
length P01427034A0440 NN O
within P01427034A0440 IN O
their P01427034A0440 PRP$ O
introns P01427034A0440 NNS O
. P01427034A0440 . O
. . O O

The P01851527T0000 DT O
promoter P01851527T0000 NN O
activity P01851527T0000 NN O
of P01851527T0000 IN O
the P01851527T0000 DT O
gene P01851527T0000 NN I-UN
encoding P01851527T0000 VBG I-UN
Alzheimer P01851527T0000 NNP I-UN
beta-amyloid P01851527T0000 NN I-UN
precursor P01851527T0000 NN I-UN
protein P01851527T0000 NN I-UN
( P01851527T0000 ( O
APP P01851527T0000 NNP I-UN
) P01851527T0000 ) O
is P01851527T0000 VBZ O
regulated P01851527T0000 VBN O
by P01851527T0000 IN O
two P01851527T0000 CD O
blocks P01851527T0000 NNS O
of P01851527T0000 IN O
upstream P01851527T0000 JJ O
sequences P01851527T0000 NNS O
. P01851527T0000 . O
. . O O

The P03403313A0298 DT O
actuarial P03403313A0298 JJ O
local P03403313A0298 JJ O
control P03403313A0298 NN O
rates P03403313A0298 NNS O
at P03403313A0298 IN O
10 P03403313A0298 CD O
years P03403313A0298 NNS O
for P03403313A0298 IN O
the P03403313A0298 DT O
three P03403313A0298 CD O
treatment P03403313A0298 NN O
groups P03403313A0298 NNS O
were P03403313A0298 VBD O
as P03403313A0298 IN O
follows P03403313A0298 VBZ O
: P03403313A0298 : O
subtotal P03403313A0298 JJ O
excision P03403313A0298 NN O
alone P03403313A0298 RB O
, P03403313A0298 , O
18 P03403313A0298 CD O
% P03403313A0298 NN O
; P03403313A0298 : O
subtotal P03403313A0298 JJ O
excision P03403313A0298 NN O
plus P03403313A0298 CC O
postoperative P03403313A0298 JJ O
radiation P03403313A0298 NN O
therapy P03403313A0298 NN O
, P03403313A0298 , O
82 P03403313A0298 CD O
% P03403313A0298 NN O
; P03403313A0298 : O
and P03403313A0298 CC O
total P03403313A0298 JJ O
excision P03403313A0298 NN O
alone P03403313A0298 RB O
, P03403313A0298 , O
77 P03403313A0298 CD O
% P03403313A0298 NN O
. P03403313A0298 . O
. . O O

Intraventricular P07957632A0000 JJ O
injection P07957632A0000 NN O
of P07957632A0000 IN O
( P07957632A0000 ( O
2S,1'R,2'R,3'R P07957632A0000 CD O
) P07957632A0000 ) O
-2- P07957632A0000 NN O
( P07957632A0000 ( O
2,3-dicarboxycyclopropyl P07957632A0000 JJ O
) P07957632A0000 ) O
glycine P07957632A0000 NN O
( P07957632A0000 ( O
DCG-IV P07957632A0000 NNP O
) P07957632A0000 ) O
, P07957632A0000 , O
a P07957632A0000 DT O
potent P07957632A0000 JJ O
agonist P07957632A0000 NN O
for P07957632A0000 IN O
metabotropic P07957632A0000 NN O
glutamate P07957632A0000 NN I-UN
receptors P07957632A0000 NNS I-UN
, P07957632A0000 , O
to P07957632A0000 TO O
rats P07957632A0000 VB O
retarded P07957632A0000 JJ O
dose-dependently P07957632A0000 RB O
the P07957632A0000 DT O
recovery P07957632A0000 NN O
from P07957632A0000 IN O
halothane P07957632A0000 NN O
anesthesia P07957632A0000 NN O
at P07957632A0000 IN O
a P07957632A0000 DT O
dose P07957632A0000 JJ O
range P07957632A0000 NN O
from P07957632A0000 IN O
30 P07957632A0000 CD O
to P07957632A0000 TO O
300 P07957632A0000 CD O
pmol P07957632A0000 NNS O
/ P07957632A0000 JJ O
rat P07957632A0000 NN O
. P07957632A0000 . O
. . O O

These P08947028A0992 DT O
results P08947028A0992 NNS O
suggest P08947028A0992 VBP O
that P08947028A0992 IN O
Rho1p P08947028A0992 NNP I-UN
regulates P08947028A0992 VBZ O
cytoskeletal P08947028A0992 JJ O
reorganization P08947028A0992 NN O
at P08947028A0992 IN O
least P08947028A0992 JJS O
through P08947028A0992 IN O
Bni1p P08947028A0992 NNP I-UN
and P08947028A0992 CC O
Pkc1p P08947028A0992 NNP I-UN
. P08947028A0992 . O
. . O O

Retreatment P07540607A0709 NN O
of P07540607A0709 IN O
these P07540607A0709 DT O
2 P07540607A0709 CD O
dogs P07540607A0709 NNS O
resulted P07540607A0709 VBD O
in P07540607A0709 IN O
a P07540607A0709 DT O
similar P07540607A0709 JJ O
, P07540607A0709 , O
but P07540607A0709 CC O
blunted P07540607A0709 VBD O
, P07540607A0709 , O
response P07540607A0709 NN O
to P07540607A0709 TO O
human P07540607A0709 JJ I-UN
immunoglobulin P07540607A0709 NN I-UN
. P07540607A0709 . O
. . O O

High P00331128A0000 JJ O
levels P00331128A0000 NNS O
of P00331128A0000 IN O
serum P00331128A0000 NN O
calcitonin P00331128A0000 NN I-UN
were P00331128A0000 VBD O
found P00331128A0000 VBN O
in P00331128A0000 IN O
patients P00331128A0000 NNS O
with P00331128A0000 IN O
chronic P00331128A0000 JJ O
renal P00331128A0000 JJ O
failure P00331128A0000 NN O
. P00331128A0000 . O
. . O O

During P10853778A0316 IN O
surgery P10853778A0316 NN O
bone P10853778A0316 NN O
cysts P10853778A0316 NNS O
were P10853778A0316 VBD O
excised P10853778A0316 VBN O
and P10853778A0316 CC O
filled P10853778A0316 VBN O
by P10853778A0316 IN O
bone P10853778A0316 NN O
grafts P10853778A0316 NNS O
. P10853778A0316 . O
. . O O

The P04084896A0569 DT O
recommendation P04084896A0569 NN O
is P04084896A0569 VBZ O
made P04084896A0569 VBN O
that P04084896A0569 IN O
specific P04084896A0569 JJ O
sub-groups P04084896A0569 NNS O
of P04084896A0569 IN O
attempters P04084896A0569 NNS O
need P04084896A0569 VBP O
to P04084896A0569 TO O
be P04084896A0569 VB O
identified P04084896A0569 VBN O
and P04084896A0569 CC O
may P04084896A0569 MD O
warrant P04084896A0569 VB O
specialized P04084896A0569 JJ O
intervention P04084896A0569 NN O
strategies P04084896A0569 NNS O
. P04084896A0569 . O
. . O O

Legionella P03559287T0000 NNP O
, P03559287T0000 , O
microbial P03559287T0000 JJ O
ecology P03559287T0000 NN O
, P03559287T0000 , O
and P03559287T0000 CC O
inconspicuous P03559287T0000 JJ O
consumption P03559287T0000 NN O
. P03559287T0000 . O
. . O O

Eukaryotic P10938102T0000 JJ I-UN
translation P10938102T0000 NN I-UN
initiation P10938102T0000 NN I-UN
factor P10938102T0000 NN I-UN
4GI P10938102T0000 CD I-UN
is P10938102T0000 VBZ O
a P10938102T0000 DT O
cellular P10938102T0000 JJ O
target P10938102T0000 NN O
for P10938102T0000 IN O
NS1 P10938102T0000 NNP I-UN
protein P10938102T0000 NN I-UN
, P10938102T0000 , O
a P10938102T0000 DT O
translational P10938102T0000 JJ O
activator P10938102T0000 NN O
of P10938102T0000 IN O
influenza P10938102T0000 JJ O
virus P10938102T0000 NN O
. P10938102T0000 . O
. . O O

Comparable P01464606A0344 JJ O
amounts P01464606A0344 NNS O
of P01464606A0344 IN O
alpha P01464606A0344 NN I-UN
5 P01464606A0344 CD I-UN
beta P01464606A0344 NN I-UN
1 P01464606A0344 CD I-UN
integrin P01464606A0344 NN I-UN
were P01464606A0344 VBD O
isolated P01464606A0344 VBN O
from P01464606A0344 IN O
these P01464606A0344 DT O
cells P01464606A0344 NNS O
by P01464606A0344 IN O
chromatography P01464606A0344 NN O
of P01464606A0344 IN O
detergent P01464606A0344 NN O
extracts P01464606A0344 NNS O
on P01464606A0344 IN O
a P01464606A0344 DT O
fibronectin P01464606A0344 JJ I-UN
cell-binding P01464606A0344 JJ O
fragment P01464606A0344 NN O
affinity P01464606A0344 NN O
column P01464606A0344 NN O
and P01464606A0344 CC O
elution P01464606A0344 NN O
with P01464606A0344 IN O
EDTA P01464606A0344 NNP O
. P01464606A0344 . O
. . O O

4 P10670681A0952 CD O
. P10670681A0952 . O
. . O O

The P10078876A0000 DT O
origins P10078876A0000 NNS O
of P10078876A0000 IN O
reflected P10078876A0000 JJ O
light P10078876A0000 JJ O
changes P10078876A0000 NNS O
associated P10078876A0000 VBN O
with P10078876A0000 IN O
neuronal P10078876A0000 JJ O
activity P10078876A0000 NN O
( P10078876A0000 ( O
optical P10078876A0000 JJ O
signals P10078876A0000 NNS O
) P10078876A0000 ) O
were P10078876A0000 VBD O
investigated P10078876A0000 VBN O
in P10078876A0000 IN O
rat P10078876A0000 NN O
somatosensory P10078876A0000 NN O
cortex P10078876A0000 NN O
with P10078876A0000 IN O
optical P10078876A0000 JJ O
imaging P10078876A0000 NN O
, P10078876A0000 , O
microspectrophotometry P10078876A0000 NN O
, P10078876A0000 , O
and P10078876A0000 CC O
laser-Doppler P10078876A0000 JJ O
flowmetry P10078876A0000 NN O
, P10078876A0000 , O
and P10078876A0000 CC O
dynamic P10078876A0000 JJ O
changes P10078876A0000 NNS O
in P10078876A0000 IN O
local P10078876A0000 JJ O
hemoglobin P10078876A0000 NN I-UN
concentration P10078876A0000 NN O
and P10078876A0000 CC O
oxygenation P10078876A0000 NN O
were P10078876A0000 VBD O
focused P10078876A0000 VBN O
on P10078876A0000 IN O
. P10078876A0000 . O
. . O O

Control P01555556A0565 NNP O
Tmuscle P01555556A0565 NNP O
was P01555556A0565 VBD O
35.8 P01555556A0565 CD O
+ P01555556A0565 JJ O
/ P01555556A0565 NNP O
- P01555556A0565 : O
0.7 P01555556A0565 CD O
degrees P01555556A0565 NNS O
C P01555556A0565 NNP O
, P01555556A0565 , O
with P01555556A0565 IN O
control P01555556A0565 NN O
Wi P01555556A0565 NNP O
, P01555556A0565 , O
max P01555556A0565 VBD O
being P01555556A0565 VBG O
51.6 P01555556A0565 CD O
( P01555556A0565 ( O
SD P01555556A0565 NNP O
8.7 P01555556A0565 CD O
) P01555556A0565 ) O
W.kg-1 P01555556A0565 NN O
. P01555556A0565 . O
. . O O

It P10232872A0081 PRP O
is P10232872A0081 VBZ O
clear P10232872A0081 JJ O
that P10232872A0081 IN O
subclinical P10232872A0081 JJ O
and P10232872A0081 CC O
silent P10232872A0081 JJ O
CD P10232872A0081 NN O
exist P10232872A0081 VBP O
in P10232872A0081 IN O
a P10232872A0081 DT O
large P10232872A0081 JJ O
subgroup P10232872A0081 NN O
of P10232872A0081 IN O
the P10232872A0081 DT O
celiac P10232872A0081 JJ O
population P10232872A0081 NN O
. P10232872A0081 . O
. . O O

Correlating P08910550A0501 VBG O
with P08910550A0501 IN O
the P08910550A0501 DT O
previous P08910550A0501 JJ O
observation P08910550A0501 NN O
that P08910550A0501 IN O
CBF P08910550A0501 NNP I-UN
binding P08910550A0501 VBG O
to P08910550A0501 TO O
the P08910550A0501 DT O
78C1 P08910550A0501 CD O
site P08910550A0501 NN O
is P08910550A0501 VBZ O
enhanced P08910550A0501 VBN O
by P08910550A0501 IN O
EGTA P08910550A0501 NNP O
and P08910550A0501 CC O
EDTA P08910550A0501 NNP O
, P08910550A0501 , O
these P08910550A0501 DT O
divalent P08910550A0501 JJ O
cation P08910550A0501 NN O
chelators P08910550A0501 NNS O
specifically P08910550A0501 RB O
stimulate P08910550A0501 VBP O
78C1-directed P08910550A0501 JJ O
transcription P08910550A0501 NN O
. P08910550A0501 . O
. . O O

The P00819176T0001 DT O
effect P00819176T0001 NN O
of P00819176T0001 IN O
hydrostatic P00819176T0001 JJ O
pressure P00819176T0001 NN O
on P00819176T0001 IN O
the P00819176T0001 DT O
swimming P00819176T0001 NN O
activity P00819176T0001 NN O
of P00819176T0001 IN O
three P00819176T0001 CD O
hyponeustonic P00819176T0001 JJ O
crustacea P00819176T0001 NN O
, P00819176T0001 , O
Anomalocera P00819176T0001 NNP O
patersoni P00819176T0001 NN O
, P00819176T0001 , O
Pontella P00819176T0001 NNP O
mediterranea P00819176T0001 NN O
, P00819176T0001 , O
Labidocera P00819176T0001 NNP O
wollastoni P00819176T0001 NN O
. P00819176T0001 . O
. . O O

The P09837714A1068 DT O
results P09837714A1068 NNS O
raise P09837714A1068 VBP O
the P09837714A1068 DT O
possibility P09837714A1068 NN O
that P09837714A1068 IN O
pH P09837714A1068 NN O
induced P09837714A1068 VBD O
post-translational P09837714A1068 JJ O
modifications P09837714A1068 NNS O
of P09837714A1068 IN O
DdRPA P09837714A1068 NNP I-UN
are P09837714A1068 VBP O
involved P09837714A1068 VBN O
in P09837714A1068 IN O
events P09837714A1068 NNS O
that P09837714A1068 WDT O
halt P09837714A1068 VBP O
cell P09837714A1068 VB O
proliferation P09837714A1068 NN O
and P09837714A1068 CC O
induce P09837714A1068 VB O
differentiation P09837714A1068 NN O
in P09837714A1068 IN O
Dictyostelium P09837714A1068 NNP O
. P09837714A1068 . O
. . O O

Temperature P10008261T0000 NN O
dependence P10008261T0000 NN O
of P10008261T0000 IN O
the P10008261T0000 DT O
sublattice P10008261T0000 NN O
spontaneous P10008261T0000 JJ O
magnetization P10008261T0000 NN O
of P10008261T0000 IN O
YBa2Cu3O6 P10008261T0000 NNP O
. P10008261T0000 . O
. . O O

Cytokine-induced P10477620A0580 JJ O
NF-kappa P10477620A0580 NNP I-UN
B P10477620A0580 NNP I-UN
DNA P10477620A0580 NNP O
binding P10477620A0580 NN O
activity P10477620A0580 NN O
, P10477620A0580 , O
RelA P10477620A0580 NNP I-UN
nuclear P10477620A0580 JJ O
translocation P10477620A0580 NN O
, P10477620A0580 , O
I P10477620A0580 PRP I-UN
kappa P10477620A0580 VBP I-UN
B P10477620A0580 NNP I-UN
alpha P10477620A0580 NN I-UN
degradation P10477620A0580 NN O
, P10477620A0580 , O
I P10477620A0580 PRP I-UN
kappa P10477620A0580 VBP I-UN
B P10477620A0580 NNP I-UN
serine P10477620A0580 NN O
32 P10477620A0580 CD O
phosphorylation P10477620A0580 NN O
, P10477620A0580 , O
and P10477620A0580 CC O
I P10477620A0580 PRP I-UN
kappa P10477620A0580 VBP I-UN
B P10477620A0580 JJ I-UN
kinase P10477620A0580 NN I-UN
( P10477620A0580 ( O
IKK P10477620A0580 NNP I-UN
) P10477620A0580 ) O
activity P10477620A0580 NN O
were P10477620A0580 VBD O
blocked P10477620A0580 VBN O
by P10477620A0580 IN O
curcumin P10477620A0580 NN O
treatment P10477620A0580 NN O
. P10477620A0580 . O
. . O O

This P08396913A1379 DT O
negative P08396913A1379 JJ O
element P08396913A1379 NN O
may P08396913A1379 MD O
, P08396913A1379 , O
at P08396913A1379 IN O
least P08396913A1379 JJS O
in P08396913A1379 IN O
part P08396913A1379 NN O
, P08396913A1379 , O
be P08396913A1379 VB O
responsible P08396913A1379 JJ O
for P08396913A1379 IN O
the P08396913A1379 DT O
cell P08396913A1379 NN O
type-specific P08396913A1379 JJ O
expression P08396913A1379 NN O
of P08396913A1379 IN O
the P08396913A1379 DT O
DGK P08396913A1379 NNP I-UN
gene P08396913A1379 NN I-UN
. P08396913A1379 . O
. . O O

All P06155967A1132 DT O
radiologists P06155967A1132 NNS O
using P06155967A1132 VBG O
the P06155967A1132 DT O
machine P06155967A1132 NN O
found P06155967A1132 VBD O
that P06155967A1132 IN O
the P06155967A1132 DT O
reporting P06155967A1132 NN O
terminal P06155967A1132 NN O
was P06155967A1132 VBD O
simple P06155967A1132 JJ O
to P06155967A1132 TO O
operate P06155967A1132 VB O
, P06155967A1132 , O
but P06155967A1132 CC O
found P06155967A1132 VBD O
that P06155967A1132 IN O
reporting P06155967A1132 VBG O
abnormalities P06155967A1132 NNS O
caused P06155967A1132 VBD O
an P06155967A1132 DT O
increased P06155967A1132 JJ O
effort P06155967A1132 NN O
and P06155967A1132 CC O
took P06155967A1132 VBD O
a P06155967A1132 DT O
longer P06155967A1132 JJR O
time P06155967A1132 NN O
. P06155967A1132 . O
. . O O

Significance P01420223T0000 NN O
of P01420223T0000 IN O
the P01420223T0000 DT O
biopsy P01420223T0000 NN O
site P01420223T0000 NN O
of P01420223T0000 IN O
the P01420223T0000 DT O
latissimus P01420223T0000 NN O
dorsi P01420223T0000 NN O
muscle P01420223T0000 NN O
for P01420223T0000 IN O
fiber P01420223T0000 NN O
typing P01420223T0000 NN O
. P01420223T0000 . O
. . O O

PCR-derived P02362803A0608 JJ O
fragments P02362803A0608 NNS O
were P02362803A0608 VBD O
used P02362803A0608 VBN O
as P02362803A0608 IN O
probes P02362803A0608 NNS O
for P02362803A0608 IN O
the P02362803A0608 DT O
isolation P02362803A0608 NN O
of P02362803A0608 IN O
the P02362803A0608 DT O
U3 P02362803A0608 NNP I-UN
snRNA P02362803A0608 NN I-UN
genes P02362803A0608 NNS I-UN
from P02362803A0608 IN O
a P02362803A0608 DT O
genomic P02362803A0608 JJ O
library P02362803A0608 NN O
of P02362803A0608 IN O
Arabidopsis P02362803A0608 NNP O
. P02362803A0608 . O
. . O O

Traditional P11775180A0379 JJ O
surgical P11775180A0379 JJ O
exploration P11775180A0379 NN O
was P11775180A0379 VBD O
followed P11775180A0379 VBN O
by P11775180A0379 IN O
survey P11775180A0379 NN O
with P11775180A0379 IN O
a P11775180A0379 DT O
gamma-detecting P11775180A0379 JJ O
probe P11775180A0379 NN O
. P11775180A0379 . O
. . O O

This P11522658A0870 DT O
plus P11522658A0870 VBZ O
the P11522658A0870 DT O
reduced P11522658A0870 JJ O
phosphorylation P11522658A0870 NN O
of P11522658A0870 IN O
p27 P11522658A0870 NN I-UN
by P11522658A0870 IN O
MAPK P11522658A0870 NNP I-UN
enhanced P11522658A0870 VBD O
the P11522658A0870 DT O
stability P11522658A0870 NN O
of P11522658A0870 IN O
p27 P11522658A0870 NN I-UN
that P11522658A0870 WDT O
associated P11522658A0870 VBD O
with P11522658A0870 IN O
nuclear P11522658A0870 JJ I-UN
Cdk2 P11522658A0870 NNP I-UN
at P11522658A0870 IN O
high P11522658A0870 JJ O
stoichiometry P11522658A0870 NN O
and P11522658A0870 CC O
inhibited P11522658A0870 VBD O
its P11522658A0870 PRP$ O
kinase P11522658A0870 NN O
activity P11522658A0870 NN O
. P11522658A0870 . O
. . O O

Mechanism P04624863T0001 NN O
of P04624863T0001 IN O
immunogenesis P04624863T0001 NN O
in P04624863T0001 IN O
vaccination P04624863T0001 NN O
with P04624863T0001 IN O
streptomycin-dependent P04624863T0001 JJ O
mutants P04624863T0001 NNS O
of P04624863T0001 IN O
salmonellae P04624863T0001 NN O
and P04624863T0001 CC O
shigellae P04624863T0001 NN O
. P04624863T0001 . O
. . O O

Cardiac P11555516A0639 NNP O
output P11555516A0639 NN O
at P11555516A0639 IN O
anaerobic P11555516A0639 JJ O
threshold P11555516A0639 NN O
( P11555516A0639 ( O
COAT P11555516A0639 NNP O
) P11555516A0639 ) O
< P11555516A0639 VBD O
or P11555516A0639 CC O
= P11555516A0639 $ O
7.3 P11555516A0639 CD O
L P11555516A0639 NNP O
/ P11555516A0639 NNP O
min P11555516A0639 NN O
was P11555516A0639 VBD O
the P11555516A0639 DT O
best P11555516A0639 JJS O
cutoff P11555516A0639 NN O
value P11555516A0639 NN O
for P11555516A0639 IN O
identifying P11555516A0639 VBG O
multivessel P11555516A0639 NN O
coronary P11555516A0639 JJ O
artery P11555516A0639 NN O
disease P11555516A0639 NN O
( P11555516A0639 ( O
relative P11555516A0639 JJ O
risk P11555516A0639 NN O
, P11555516A0639 , O
3.1 P11555516A0639 CD O
) P11555516A0639 ) O
. P11555516A0639 . O
. . O O

We P08576131A0151 PRP O
report P08576131A0151 VBP O
the P08576131A0151 DT O
molecular P08576131A0151 JJ O
cloning P08576131A0151 NN O
and P08576131A0151 CC O
functional P08576131A0151 JJ O
characterization P08576131A0151 NN O
of P08576131A0151 IN O
USF2 P08576131A0151 NNP I-UN
isoforms P08576131A0151 NNS I-UN
, P08576131A0151 , O
corresponding P08576131A0151 VBG O
to P08576131A0151 TO O
a P08576131A0151 DT O
44-kDa P08576131A0151 JJ O
subunit P08576131A0151 NN O
, P08576131A0151 , O
USF2a P08576131A0151 NNP I-UN
, P08576131A0151 , O
and P08576131A0151 CC O
a P08576131A0151 DT O
new P08576131A0151 JJ O
38-kDa P08576131A0151 JJ O
subunit P08576131A0151 NN O
, P08576131A0151 , O
USF2b P08576131A0151 NNP I-UN
, P08576131A0151 , O
generated P08576131A0151 VBN O
by P08576131A0151 IN O
differential P08576131A0151 JJ O
splicing P08576131A0151 NN O
. P08576131A0151 . O
. . O O

Salzburg P03687148T0187 NNP O
, P03687148T0187 , O
9-12 P03687148T0187 CD O
September P03687148T0187 NNP O
1987 P03687148T0187 CD O
. P03687148T0187 . O
. . O O

The P09388271A1243 DT O
mobility P09388271A1243 NN O
shift P09388271A1243 NN O
of P09388271A1243 IN O
both P09388271A1243 DT O
of P09388271A1243 IN O
these P09388271A1243 DT O
proteins P09388271A1243 NNS O
is P09388271A1243 VBZ O
abolished P09388271A1243 VBN O
by P09388271A1243 IN O
treatment P09388271A1243 NN O
with P09388271A1243 IN O
inhibitors P09388271A1243 NNS O
of P09388271A1243 IN O
PKC P09388271A1243 NNP I-UN
or P09388271A1243 CC O
mitogen-activated P09388271A1243 JJ I-UN
protein P09388271A1243 NN I-UN
kinase P09388271A1243 NN I-UN
/ P09388271A1243 NNP O
extracellular P09388271A1243 JJ I-UN
signal-related P09388271A1243 JJ I-UN
kinase P09388271A1243 NN I-UN
kinase P09388271A1243 NN I-UN
. P09388271A1243 . O
. . O O

The P07654712A0774 DT O
yeast P07654712A0774 NN O
enzyme P07654712A0774 NN O
was P07654712A0774 VBD O
6-fold P07654712A0774 JJ O
slower P07654712A0774 JJR O
than P07654712A0774 IN O
the P07654712A0774 DT O
mammalian P07654712A0774 JJ O
enzymes P07654712A0774 NNS O
, P07654712A0774 , O
which P07654712A0774 WDT O
made P07654712A0774 VBD O
it P07654712A0774 PRP O
amenable P07654712A0774 JJ O
to P07654712A0774 TO O
pre-steady-state P07654712A0774 JJ O
stopped-flow P07654712A0774 JJ O
spectroscopic P07654712A0774 NN O
kinetic P07654712A0774 JJ O
analysis P07654712A0774 NN O
at P07654712A0774 IN O
30 P07654712A0774 CD O
degrees P07654712A0774 NNS O
C P07654712A0774 NNP O
and P07654712A0774 CC O
pH P07654712A0774 $ O
6.0 P07654712A0774 CD O
. P07654712A0774 . O
. . O O

A P01568960A1129 DT O
possible P01568960A1129 JJ O
mechanism P01568960A1129 NN O
is P01568960A1129 VBZ O
that P01568960A1129 IN O
elevated P01568960A1129 JJ O
alveolar P01568960A1129 JJ O
pressure P01568960A1129 NN O
and P01568960A1129 CC O
decreased P01568960A1129 JJ O
cardiac P01568960A1129 NN O
output P01568960A1129 NN O
eliminate P01568960A1129 VB O
blood P01568960A1129 NN O
flow P01568960A1129 NN O
from P01568960A1129 IN O
corner P01568960A1129 NN O
vessels P01568960A1129 NNS O
in P01568960A1129 IN O
nondependent P01568960A1129 JJ O
high P01568960A1129 JJ O
VA P01568960A1129 NNP O
/ P01568960A1129 NNP O
Q P01568960A1129 NNP O
regions P01568960A1129 NNS O
. P01568960A1129 . O
. . O O

METHODS P07557091A0314 NN O
: P07557091A0314 : O
rHb1.1 P07557091A0314 NN I-UN
or P07557091A0314 CC O
human P07557091A0314 JJ I-UN
serum P07557091A0314 NN I-UN
albumin P07557091A0314 NN I-UN
was P07557091A0314 VBD O
administered P07557091A0314 VBN O
intravenously P07557091A0314 RB O
to P07557091A0314 TO O
fasting P07557091A0314 VBG O
male P07557091A0314 JJ O
volunteers P07557091A0314 NNS O
. P07557091A0314 . O
. . O O

Heart P02776742A0000 NNP O
rate P02776742A0000 NN O
( P02776742A0000 ( O
HR P02776742A0000 NNP O
) P02776742A0000 ) O
, P02776742A0000 , O
rectal P02776742A0000 JJ O
temperature P02776742A0000 NN O
( P02776742A0000 ( O
Tre P02776742A0000 NNP O
) P02776742A0000 ) O
, P02776742A0000 , O
blood P02776742A0000 NN O
pressure P02776742A0000 NN O
, P02776742A0000 , O
temperature P02776742A0000 NN O
and P02776742A0000 CC O
relative P02776742A0000 JJ O
humidity P02776742A0000 NN O
changes P02776742A0000 NNS O
inside P02776742A0000 IN O
clothing P02776742A0000 NN O
were P02776742A0000 VBD O
measured P02776742A0000 VBN O
on P02776742A0000 IN O
18 P02776742A0000 CD O
professional P02776742A0000 JJ O
firemen P02776742A0000 NNS O
( P02776742A0000 ( O
mean P02776742A0000 JJ O
age P02776742A0000 NN O
29.4 P02776742A0000 CD O
+ P02776742A0000 NN O
/ P02776742A0000 NNP O
- P02776742A0000 : O
7.4 P02776742A0000 CD O
yr P02776742A0000 NN O
, P02776742A0000 , O
VO2 P02776742A0000 NNP O
max P02776742A0000 VBD O
41.4 P02776742A0000 CD O
+ P02776742A0000 JJ O
8.8 P02776742A0000 CD O
ml P02776742A0000 JJ O
kg-1 P02776742A0000 JJ O
min-1 P02776742A0000 NN O
) P02776742A0000 ) O
wearing P02776742A0000 VBG O
fire P02776742A0000 NN O
fighter P02776742A0000 NN O
's P02776742A0000 POS O
uniforms P02776742A0000 NNS O
( P02776742A0000 ( O
SU P02776742A0000 NNP O
) P02776742A0000 ) O
or P02776742A0000 CC O
aluminized P02776742A0000 VBN O
, P02776742A0000 , O
fire P02776742A0000 NN O
resistant P02776742A0000 NN O
, P02776742A0000 , O
impermeable P02776742A0000 JJ O
clothing P02776742A0000 NN O
with P02776742A0000 IN O
self P02776742A0000 NN O
contained P02776742A0000 VBN O
breathing P02776742A0000 VBG O
apparatus P02776742A0000 NN O
( P02776742A0000 ( O
FE P02776742A0000 NNP O
) P02776742A0000 ) O
. P02776742A0000 . O
. . O O

The P01812102A0101 DT O
present P01812102A0101 JJ O
study P01812102A0101 NN O
reports P01812102A0101 NNS O
visual P01812102A0101 JJ O
evoked P01812102A0101 VBD O
potential P01812102A0101 JJ O
responses P01812102A0101 NNS O
to P01812102A0101 TO O
pattern P01812102A0101 VB O
reversal P01812102A0101 NN O
( P01812102A0101 ( O
VEP-P P01812102A0101 NNP O
) P01812102A0101 ) O
in P01812102A0101 IN O
ten P01812102A0101 JJ O
third P01812102A0101 JJ O
trimester P01812102A0101 NN O
pregnant P01812102A0101 JJ O
women P01812102A0101 NNS O
and P01812102A0101 CC O
changes P01812102A0101 NNS O
in P01812102A0101 IN O
latency P01812102A0101 NN O
of P01812102A0101 IN O
NPN P01812102A0101 NNP O
complex P01812102A0101 NN O
when P01812102A0101 WRB O
compared P01812102A0101 VBN O
with P01812102A0101 IN O
these P01812102A0101 DT O
responses P01812102A0101 NNS O
in P01812102A0101 IN O
the P01812102A0101 DT O
non P01812102A0101 NN O
pregnant P01812102A0101 JJ O
state P01812102A0101 NN O
. P01812102A0101 . O
. . O O

The P07857163A0551 DT O
activity P07857163A0551 NN O
of P07857163A0551 IN O
6-fluoroquinolones P07857163A0551 NNS O
and P07857163A0551 CC O
their P07857163A0551 PRP$ O
nonfluorinated P07857163A0551 JJ O
derivatives P07857163A0551 NNS O
is P07857163A0551 VBZ O
compared P07857163A0551 VBN O
in P07857163A0551 IN O
general P07857163A0551 JJ O
. P07857163A0551 . O
. . O O

A P07190627T0000 DT O
further P07190627T0000 JJ O
study P07190627T0000 NN O
on P07190627T0000 IN O
plasminogen P07190627T0000 NN I-UN
activator P07190627T0000 NN I-UN
release P07190627T0000 NN O
by P07190627T0000 IN O
vasoactive P07190627T0000 JJ O
agents P07190627T0000 NNS O
in P07190627T0000 IN O
the P07190627T0000 DT O
isolated P07190627T0000 JJ O
perfused P07190627T0000 JJ O
dog P07190627T0000 NN O
leg P07190627T0000 NN O
. P07190627T0000 . O
. . O O

Both P08661114A0564 DT O
of P08661114A0564 IN O
these P08661114A0564 DT O
domains P08661114A0564 NNS O
have P08661114A0564 VBP O
striking P08661114A0564 VBG O
sequence P08661114A0564 NN O
homology P08661114A0564 NN O
with P08661114A0564 IN O
human P08661114A0564 JJ O
SIM P08661114A0564 NNP I-UN
and P08661114A0564 CC O
Drosophila P08661114A0564 NNP O
SIM P08661114A0564 NNP I-UN
proteins P08661114A0564 VBZ O
. P08661114A0564 . O
. . O O

S. P09430730A0374 NNP O
, P09430730A0374 , O
and P09430730A0374 CC O
Walter P09430730A0374 NNP O
, P09430730A0374 , O
P P09430730A0374 NNP O
. P09430730A0374 . O
. . O O

Phenazone P10753553T0000 NN O
potentiates P10753553T0000 VBZ O
the P10753553T0000 DT O
local P10753553T0000 JJ O
anaesthetic P10753553T0000 JJ O
effect P10753553T0000 NN O
of P10753553T0000 IN O
lidocaine P10753553T0000 NN O
in P10753553T0000 IN O
mice P10753553T0000 NN O
. P10753553T0000 . O
. . O O

Cell P11369759A0605 NNP O
. P11369759A0605 . O
. . O O

Our P11407448A0815 PRP$ O
results P11407448A0815 NNS O
are P11407448A0815 VBP O
reassuring P11407448A0815 VBG O
and P11407448A0815 CC O
we P11407448A0815 PRP O
therefore P11407448A0815 VBP O
advise P11407448A0815 RP O
that P11407448A0815 DT O
in P11407448A0815 IN O
patients P11407448A0815 NNS O
undergoing P11407448A0815 JJ O
free P11407448A0815 JJ O
jejunum P11407448A0815 NN O
flap P11407448A0815 JJ O
reconstruction P11407448A0815 NN O
of P11407448A0815 IN O
the P11407448A0815 DT O
hypopharyngo-esophageal P11407448A0815 JJ O
tract P11407448A0815 NN O
voice P11407448A0815 NN O
restoration P11407448A0815 NN O
should P11407448A0815 MD O
be P11407448A0815 VB O
attempted P11407448A0815 VBN O
by P11407448A0815 IN O
placing P11407448A0815 VBG O
a P11407448A0815 DT O
voice P11407448A0815 NN O
prosthesis P11407448A0815 NN O
through P11407448A0815 IN O
a P11407448A0815 DT O
secondary P11407448A0815 JJ O
tracheo-esophageal P11407448A0815 JJ O
puncture P11407448A0815 NN O
and P11407448A0815 CC O
providing P11407448A0815 VBG O
intensive P11407448A0815 JJ O
speech P11407448A0815 NN O
training P11407448A0815 NN O
. P11407448A0815 . O
. . O O

Comparison P11741554T0000 NNP O
of P11741554T0000 IN O
remnant-like P11741554T0000 JJ O
lipoprotein P11741554T0000 NN O
particles P11741554T0000 NNS O
in P11741554T0000 IN O
postmenopausal P11741554T0000 JJ O
women P11741554T0000 NNS O
with P11741554T0000 IN O
and P11741554T0000 CC O
without P11741554T0000 IN O
coronary P11741554T0000 JJ O
artery P11741554T0000 NN O
disease P11741554T0000 NN O
and P11741554T0000 CC O
in P11741554T0000 IN O
men P11741554T0000 NNS O
with P11741554T0000 IN O
coronary P11741554T0000 JJ O
artery P11741554T0000 NN O
disease P11741554T0000 NN O
. P11741554T0000 . O
. . O O

In P02795923A0000 IN O
order P02795923A0000 NN O
to P02795923A0000 TO O
identify P02795923A0000 VB O
and P02795923A0000 CC O
classify P02795923A0000 VB O
the P02795923A0000 DT O
basic P02795923A0000 JJ O
CT P02795923A0000 NNP O
appearances P02795923A0000 NNS O
of P02795923A0000 IN O
interstitial P02795923A0000 JJ O
pneumonia P02795923A0000 NN O
, P02795923A0000 , O
radiologic P02795923A0000 JJ O
-pathologic P02795923A0000 NNP O
correlative P02795923A0000 NN O
study P02795923A0000 NN O
was P02795923A0000 VBD O
performed P02795923A0000 VBN O
using P02795923A0000 VBG O
inflated P02795923A0000 JJ O
and P02795923A0000 CC O
fixed P02795923A0000 JJ O
lungs P02795923A0000 NNS O
from P02795923A0000 IN O
autopsy P02795923A0000 NN O
and P02795923A0000 CC O
surgery P02795923A0000 NN O
. P02795923A0000 . O
. . O O

In P08428722A1123 IN O
the P08428722A1123 DT O
multivariate P08428722A1123 NN O
analysis P08428722A1123 NN O
, P08428722A1123 , O
six P08428722A1123 CD O
variables P08428722A1123 NNS O
were P08428722A1123 VBD O
independently P08428722A1123 RB O
correlated P08428722A1123 VBN O
with P08428722A1123 IN O
survival P08428722A1123 NN O
: P08428722A1123 : O
blood P08428722A1123 NN O
urea P08428722A1123 JJ O
nitrogen P08428722A1123 NN O
level P08428722A1123 NN O
, P08428722A1123 , O
serum P08428722A1123 JJ I-UN
aspartate P08428722A1123 NN I-UN
aminotransferase P08428722A1123 NN I-UN
level P08428722A1123 NN O
, P08428722A1123 , O
community-acquired P08428722A1123 JJ O
vs. P08428722A1123 FW O
hospital-acquired P08428722A1123 JJ O
peritonitis P08428722A1123 NN O
, P08428722A1123 , O
age P08428722A1123 NN O
, P08428722A1123 , O
Child-Pugh P08428722A1123 NNP O
score P08428722A1123 NN O
and P08428722A1123 CC O
ileus P08428722A1123 NN O
. P08428722A1123 . O
. . O O

Both P07892353A0667 DT O
factors P07892353A0667 NNS O
demonstrated P07892353A0667 VBD O
significant P07892353A0667 JJ O
correlations P07892353A0667 NNS O
with P07892353A0667 IN O
rCBF P07892353A0667 NN O
in P07892353A0667 IN O
the P07892353A0667 DT O
medial P07892353A0667 JJ O
prefrontal P07892353A0667 NN O
cortex P07892353A0667 NN O
and P07892353A0667 CC O
frontal P07892353A0667 JJ O
polar P07892353A0667 JJ O
cortex P07892353A0667 NN O
while P07892353A0667 IN O
for P07892353A0667 IN O
each P07892353A0667 DT O
factor P07892353A0667 NN O
there P07892353A0667 EX O
were P07892353A0667 VBD O
also P07892353A0667 RB O
unique P07892353A0667 JJ O
patterns P07892353A0667 NNS O
of P07892353A0667 IN O
correlations P07892353A0667 NNS O
with P07892353A0667 IN O
posterior P07892353A0667 JJ O
brain P07892353A0667 NN O
regions P07892353A0667 NNS O
. P07892353A0667 . O
. . O O

Immunohistochemical P02174105A1232 JJ O
analysis P02174105A1232 NN O
of P02174105A1232 IN O
several P02174105A1232 JJ O
rat P02174105A1232 NNS O
organs P02174105A1232 NNS O
also P02174105A1232 RB O
showed P02174105A1232 VBD O
staining P02174105A1232 VBG O
in P02174105A1232 IN O
epithelial P02174105A1232 JJ O
cells P02174105A1232 NNS O
. P02174105A1232 . O
. . O O

Calibration P05451324T0000 NN O
and P05451324T0000 CC O
a P05451324T0000 DT O
correction P05451324T0000 NN O
of P05451324T0000 IN O
blood P05451324T0000 NN O
O2 P05451324T0000 NNP O
content P05451324T0000 NN O
measured P05451324T0000 VBN O
by P05451324T0000 IN O
Po2 P05451324T0000 NNP O
and P05451324T0000 CC O
CO P05451324T0000 NNP O
saturation P05451324T0000 NN O
. P05451324T0000 . O
. . O O

An P08643382A0752 DT O
apparent P08643382A0752 JJ O
N-terminal P08643382A0752 JJ O
transit P08643382A0752 NN O
peptide P08643382A0752 NN O
in P08643382A0752 IN O
the P08643382A0752 DT O
coding P08643382A0752 NN O
region P08643382A0752 NN O
and P08643382A0752 CC O
a P08643382A0752 DT O
3 P08643382A0752 CD O
' P08643382A0752 POS O
poly P08643382A0752 NN O
( P08643382A0752 ( O
A P08643382A0752 DT O
) P08643382A0752 ) O
tail P08643382A0752 NN O
exist P08643382A0752 NN O
in P08643382A0752 IN O
the P08643382A0752 DT O
cDNA P08643382A0752 NN O
clone P08643382A0752 NN O
indicated P08643382A0752 VBD O
that P08643382A0752 IN O
this P08643382A0752 DT O
chloroplast P08643382A0752 NN O
protein P08643382A0752 NN O
as P08643382A0752 IN O
nuclear P08643382A0752 JJ O
encoded P08643382A0752 VBD O
. P08643382A0752 . O
. . O O

Serial P11178696A0301 JJ O
US P11178696A0301 NNP O
images P11178696A0301 NNS O
were P11178696A0301 VBD O
obtained P11178696A0301 VBN O
before P11178696A0301 IN O
and P11178696A0301 CC O
20 P11178696A0301 CD O
, P11178696A0301 , O
30 P11178696A0301 CD O
, P11178696A0301 , O
40 P11178696A0301 CD O
, P11178696A0301 , O
50 P11178696A0301 CD O
, P11178696A0301 , O
60 P11178696A0301 CD O
, P11178696A0301 , O
90 P11178696A0301 CD O
, P11178696A0301 , O
120 P11178696A0301 CD O
, P11178696A0301 , O
150 P11178696A0301 CD O
, P11178696A0301 , O
180 P11178696A0301 CD O
, P11178696A0301 , O
240 P11178696A0301 CD O
, P11178696A0301 , O
and P11178696A0301 CC O
300 P11178696A0301 CD O
s P11178696A0301 NN O
after P11178696A0301 IN O
intravenous P11178696A0301 JJ O
injection P11178696A0301 NN O
of P11178696A0301 IN O
2 P11178696A0301 CD O
g P11178696A0301 NN O
of P11178696A0301 IN O
contrast P11178696A0301 NN O
agent P11178696A0301 NN O
using P11178696A0301 VBG O
conventional P11178696A0301 JJ O
and P11178696A0301 CC O
harmonic P11178696A0301 JJ O
PD P11178696A0301 NNP O
US P11178696A0301 NNP O
. P11178696A0301 . O
. . O O

Marinol P09046384A0403 NNP O
/ P09046384A0403 NNP O
marijuana P09046384A0403 NNP O
usage P09046384A0403 NN O
was P09046384A0403 VBD O
associated P09046384A0403 VBN O
with P09046384A0403 IN O
depressed P09046384A0403 JJ O
CD4+ P09046384A0403 NNP I-UN
counts P09046384A0403 NNS O
and P09046384A0403 CC O
elevated P09046384A0403 JJ O
amylase P09046384A0403 NN I-UN
levels P09046384A0403 NNS O
within P09046384A0403 IN O
the P09046384A0403 DT O
DDI P09046384A0403 NNP O
subgroup P09046384A0403 NN O
. P09046384A0403 . O
. . O O

Complementary P08973527A0000 NNP O
DNAs P08973527A0000 NNP O
encompassing P08973527A0000 VBG O
the P08973527A0000 DT O
coat P08973527A0000 NN I-UN
protein P08973527A0000 NN I-UN
coding P08973527A0000 NN O
and P08973527A0000 CC O
adjacent P08973527A0000 JJ O
regions P08973527A0000 NNS O
of P08973527A0000 IN O
Agropyron P08973527A0000 NNP O
mosaic P08973527A0000 FW O
virus P08973527A0000 NN O
( P08973527A0000 ( O
AgMV P08973527A0000 NNP O
) P08973527A0000 ) O
and P08973527A0000 CC O
Hordeum P08973527A0000 NNP O
mosaic P08973527A0000 VBP O
virus P08973527A0000 NN O
( P08973527A0000 ( O
HoMV P08973527A0000 NNP O
) P08973527A0000 ) O
were P08973527A0000 VBD O
cloned P08973527A0000 VBN O
and P08973527A0000 CC O
sequenced P08973527A0000 VBN O
. P08973527A0000 . O
. . O O

A P08270257A0551 DT O
sequence P08270257A0551 NN O
homology P08270257A0551 NN O
analysis P08270257A0551 NN O
between P08270257A0551 IN O
human P08270257A0551 JJ I-UN
nm23-H1 P08270257A0551 JJ I-UN
and P08270257A0551 CC O
the P08270257A0551 DT O
homolog P08270257A0551 NN O
gene P08270257A0551 NN O
of P08270257A0551 IN O
the P08270257A0551 DT O
rat P08270257A0551 NN O
( P08270257A0551 ( O
NDP-K P08270257A0551 NNP I-UN
beta P08270257A0551 NN I-UN
) P08270257A0551 ) O
shows P08270257A0551 VBZ O
that P08270257A0551 IN O
exon-intron P08270257A0551 JJ O
boundaries P08270257A0551 NNS O
are P08270257A0551 VBP O
well P08270257A0551 RB O
conserved P08270257A0551 VBN O
between P08270257A0551 IN O
these P08270257A0551 DT O
two P08270257A0551 CD O
species P08270257A0551 NNS O
. P08270257A0551 . O
. . O O

Two P09393966A0190 CD O
closely P09393966A0190 RB O
related P09393966A0190 JJ O
IgH P09393966A0190 NNP I-UN
constant P09393966A0190 JJ O
region P09393966A0190 NN O
genes P09393966A0190 NNS O
, P09393966A0190 , O
CHA P09393966A0190 NNP I-UN
and P09393966A0190 CC O
CHB P09393966A0190 NNP I-UN
, P09393966A0190 , O
have P09393966A0190 VBP O
been P09393966A0190 VBN O
sequenced P09393966A0190 VBN O
completely P09393966A0190 RB O
. P09393966A0190 . O
. . O O

The P11562870A0892 DT O
probability P11562870A0892 NN O
of P11562870A0892 IN O
treatment P11562870A0892 NN O
with P11562870A0892 IN O
lamotrigine P11562870A0892 JJ O
being P11562870A0892 VBG O
maintained P11562870A0892 VBN O
for P11562870A0892 IN O
six P11562870A0892 CD O
months P11562870A0892 NNS O
was P11562870A0892 VBD O
86 P11562870A0892 CD O
% P11562870A0892 NN O
, P11562870A0892 , O
for P11562870A0892 IN O
twelve P11562870A0892 JJ O
months P11562870A0892 NNS O
61 P11562870A0892 CD O
% P11562870A0892 NN O
and P11562870A0892 CC O
for P11562870A0892 IN O
three P11562870A0892 CD O
years P11562870A0892 NNS O
31 P11562870A0892 CD O
% P11562870A0892 NN O
. P11562870A0892 . O
. . O O

A P01464329T0000 DT O
coiled-coil P01464329T0000 NN I-UN
related P01464329T0000 JJ I-UN
protein P01464329T0000 NN I-UN
specific P01464329T0000 NN O
for P01464329T0000 IN O
synapsed P01464329T0000 JJ O
regions P01464329T0000 NNS O
of P01464329T0000 IN O
meiotic P01464329T0000 JJ O
prophase P01464329T0000 NN O
chromosomes P01464329T0000 NNS O
. P01464329T0000 . O
. . O O

For P06805504A0629 IN O
steers P06805504A0629 NNS O
the P06805504A0629 DT O
urinary P06805504A0629 JJ O
N P06805504A0629 NNP O
values P06805504A0629 NNS O
were P06805504A0629 VBD O
403 P06805504A0629 CD O
and P06805504A0629 CC O
295 P06805504A0629 CD O
mg P06805504A0629 NN O
/ P06805504A0629 NNP O
kg P06805504A0629 NN O
W0.75 P06805504A0629 NNP O
at P06805504A0629 IN O
200 P06805504A0629 CD O
and P06805504A0629 CC O
350 P06805504A0629 CD O
kg P06805504A0629 NNS O
live P06805504A0629 JJ O
weight P06805504A0629 NN O
respectively P06805504A0629 RB O
and P06805504A0629 CC O
total P06805504A0629 JJ O
N P06805504A0629 NNP O
excretion P06805504A0629 NN O
including P06805504A0629 VBG O
faecal P06805504A0629 JJ O
N P06805504A0629 NNP O
was P06805504A0629 VBD O
408 P06805504A0629 CD O
and P06805504A0629 CC O
320 P06805504A0629 CD O
mg P06805504A0629 NN O
/ P06805504A0629 NNP O
kg P06805504A0629 NN O
W0.75 P06805504A0629 NNP O
. P06805504A0629 . O
. . O O

These P02542194A1496 DT O
results P02542194A1496 NNS O
indicate P02542194A1496 VBP O
that P02542194A1496 IN O
patients P02542194A1496 NNS O
who P02542194A1496 WP O
undergo P02542194A1496 VBP O
postoperative P02542194A1496 JJ O
irradiation P02542194A1496 NN O
for P02542194A1496 IN O
low P02542194A1496 JJ O
grade P02542194A1496 JJ O
spinal P02542194A1496 NN O
astrocytomas P02542194A1496 NN O
and P02542194A1496 CC O
localized P02542194A1496 VBD O
spinal P02542194A1496 JJ O
ependymomas P02542194A1496 NN O
achieve P02542194A1496 VBP O
excellent P02542194A1496 JJ O
survival P02542194A1496 NN O
. P02542194A1496 . O
. . O O

These P07563076A0766 DT O
intron P07563076A0766 NN O
chimeras P07563076A0766 NN O
show P07563076A0766 NN O
that P07563076A0766 IN O
peripheral P07563076A0766 JJ O
sequences P07563076A0766 NNS O
and P07563076A0766 CC O
the P07563076A0766 DT O
elements P07563076A0766 NNS O
that P07563076A0766 WDT O
define P07563076A0766 VBP O
the P07563076A0766 DT O
splice P07563076A0766 NN O
sites P07563076A0766 NNS O
are P07563076A0766 VBP O
adequate P07563076A0766 JJ O
for P07563076A0766 IN O
self-splicing P07563076A0766 JJ O
activity P07563076A0766 NN O
but P07563076A0766 CC O
that P07563076A0766 IN O
the P07563076A0766 DT O
central P07563076A0766 JJ O
portions P07563076A0766 NNS O
containing P07563076A0766 VBG O
the P07563076A0766 DT O
catalytic P07563076A0766 JJ O
cores P07563076A0766 NNS O
of P07563076A0766 IN O
ai4 P07563076A0766 NN I-UN
and P07563076A0766 CC O
bi4 P07563076A0766 NN I-UN
are P07563076A0766 VBP O
deficient P07563076A0766 JJ O
; P07563076A0766 : O
these P07563076A0766 DT O
cores P07563076A0766 NNS O
are P07563076A0766 VBP O
the P07563076A0766 DT O
likely P07563076A0766 JJ O
targets P07563076A0766 NNS O
of P07563076A0766 IN O
the P07563076A0766 DT O
splicing P07563076A0766 NN O
proteins P07563076A0766 NNS O
. P07563076A0766 . O
. . O O

With P10873388A0623 IN O
the P10873388A0623 DT O
human P10873388A0623 JJ I-UN
Rhotekin P10873388A0623 NNP I-UN
cDNA P10873388A0623 NN I-UN
as P10873388A0623 IN O
a P10873388A0623 DT O
probe P10873388A0623 NN O
, P10873388A0623 , O
Northern P10873388A0623 NNP O
hybridization P10873388A0623 NN O
revealed P10873388A0623 VBD O
that P10873388A0623 IN O
a P10873388A0623 DT O
4.0-kb P10873388A0623 JJ O
transcript P10873388A0623 NN O
was P10873388A0623 VBD O
expressed P10873388A0623 VBN O
at P10873388A0623 IN O
a P10873388A0623 DT O
high P10873388A0623 JJ O
level P10873388A0623 NN O
in P10873388A0623 IN O
prostate P10873388A0623 NN O
and P10873388A0623 CC O
at P10873388A0623 IN O
a P10873388A0623 DT O
middle P10873388A0623 JJ O
level P10873388A0623 NN O
in P10873388A0623 IN O
13 P10873388A0623 CD O
of P10873388A0623 IN O
16 P10873388A0623 CD O
tissues P10873388A0623 NNS O
examined P10873388A0623 VBN O
, P10873388A0623 , O
but P10873388A0623 CC O
it P10873388A0623 PRP O
can P10873388A0623 MD O
not P10873388A0623 RB O
be P10873388A0623 VB O
detected P10873388A0623 VBN O
in P10873388A0623 IN O
liver P10873388A0623 NN O
and P10873388A0623 CC O
lung P10873388A0623 NN O
tissues P10873388A0623 NNS O
. P10873388A0623 . O
. . O O

The P06719057A0181 DT O
importance P06719057A0181 NN O
of P06719057A0181 IN O
selective P06719057A0181 JJ O
renal P06719057A0181 JJ O
vein P06719057A0181 NN O
phlebography P06719057A0181 NN O
in P06719057A0181 IN O
the P06719057A0181 DT O
evaluation P06719057A0181 NN O
of P06719057A0181 IN O
unexplained P06719057A0181 JJ O
hematuria P06719057A0181 NNS O
and P06719057A0181 CC O
filing P06719057A0181 VBG O
defects P06719057A0181 NNS O
in P06719057A0181 IN O
the P06719057A0181 DT O
excretory P06719057A0181 NN O
urogram P06719057A0181 NN O
is P06719057A0181 VBZ O
illustrated P06719057A0181 VBN O
. P06719057A0181 . O
. . O O

The P09004504A0000 DT O
primary P09004504A0000 JJ O
structure P09004504A0000 NN O
of P09004504A0000 IN O
a P09004504A0000 DT O
2671 P09004504A0000 CD O
bp P09004504A0000 NN O
DNA P09004504A0000 NNP O
fragment P09004504A0000 NN O
between P09004504A0000 IN O
the P09004504A0000 DT O
pla P09004504A0000 NN I-UN
gene P09004504A0000 NN I-UN
( P09004504A0000 ( O
encoding P09004504A0000 VBG O
plasminogen P09004504A0000 NN I-UN
activator P09004504A0000 NN I-UN
) P09004504A0000 ) O
and P09004504A0000 CC O
the P09004504A0000 DT O
origin P09004504A0000 NN O
of P09004504A0000 IN O
replication P09004504A0000 NN O
of P09004504A0000 IN O
the P09004504A0000 DT O
wild-type P09004504A0000 JJ O
Yersinia P09004504A0000 NNP O
pestis P09004504A0000 NN O
plasmid P09004504A0000 NN O
pYP358 P09004504A0000 NN O
was P09004504A0000 VBD O
determined P09004504A0000 VBN O
. P09004504A0000 . O
. . O O

A P10679781A1183 DT O
385 P10679781A1183 CD O
bp P10679781A1183 NN O
Glucocorticoid P10679781A1183 NNP O
Response P10679781A1183 NNP O
Unit P10679781A1183 NNP O
( P10679781A1183 ( O
GRU P10679781A1183 NNP O
) P10679781A1183 ) O
was P10679781A1183 VBD O
identified P10679781A1183 VBN O
whose P10679781A1183 WP$ O
glucocorticoid P10679781A1183 JJ O
induction P10679781A1183 NN O
was P10679781A1183 VBD O
enhanced P10679781A1183 VBN O
by P10679781A1183 IN O
dibutyryl-cAMP P10679781A1183 NN O
and P10679781A1183 CC O
reduced P10679781A1183 VBN O
by P10679781A1183 IN O
phorbol P10679781A1183 NN O
esters P10679781A1183 NNS O
. P10679781A1183 . O
. . O O

In P07581364A0500 IN O
two P07581364A0500 CD O
further P07581364A0500 JJ O
cases P07581364A0500 NNS O
( P07581364A0500 ( O
one P07581364A0500 CD O
type P07581364A0500 NN O
I P07581364A0500 PRP O
and P07581364A0500 CC O
one P07581364A0500 CD O
type P07581364A0500 NN O
III P07581364A0500 NNP O
SMA P07581364A0500 NNP O
) P07581364A0500 ) O
, P07581364A0500 , O
de P07581364A0500 FW O
novo P07581364A0500 FW O
deletions P07581364A0500 NNS O
of P07581364A0500 IN O
only P07581364A0500 RB O
one P07581364A0500 CD O
copy P07581364A0500 NN O
of P07581364A0500 IN O
Ag1-CA P07581364A0500 NNP I-UN
and P07581364A0500 CC O
C212 P07581364A0500 NNP I-UN
were P07581364A0500 VBD O
found P07581364A0500 VBN O
. P07581364A0500 . O
. . O O

Convulsive P09587549T0001 JJ O
seizure P09587549T0001 NN O
during P09587549T0001 IN O
a P09587549T0001 DT O
treatment P09587549T0001 NN O
with P09587549T0001 IN O
interferon P09587549T0001 NN I-UN
alpha P09587549T0001 NN I-UN
for P09587549T0001 IN O
chronic P09587549T0001 JJ O
viral P09587549T0001 JJ O
hepatitis P09587549T0001 NN O
C P09587549T0001 NNP O
. P09587549T0001 . O
. . O O

The P03922116A0197 DT O
distribution P03922116A0197 NN O
of P03922116A0197 IN O
patients P03922116A0197 NNS O
was P03922116A0197 VBD O
as P03922116A0197 IN O
follows P03922116A0197 VBZ O
: P03922116A0197 : O
group P03922116A0197 NN O
1 P03922116A0197 CD O
-- P03922116A0197 : O
complex P03922116A0197 JJ O
gamma-therapy P03922116A0197 NN O
( P03922116A0197 ( O
55 P03922116A0197 CD O
cases P03922116A0197 NNS O
) P03922116A0197 ) O
, P03922116A0197 , O
group P03922116A0197 NN O
2 P03922116A0197 CD O
-- P03922116A0197 : O
complex P03922116A0197 JJ O
gamma-therapy P03922116A0197 JJ O
plus P03922116A0197 CC O
iliac P03922116A0197 JJ O
lymphadenectomy P03922116A0197 NN O
( P03922116A0197 ( O
50 P03922116A0197 CD O
cases P03922116A0197 NNS O
) P03922116A0197 ) O
and P03922116A0197 CC O
group P03922116A0197 NN O
3 P03922116A0197 CD O
-- P03922116A0197 : O
complex P03922116A0197 JJ O
radiation P03922116A0197 NN O
treatment P03922116A0197 NN O
with P03922116A0197 IN O
megavolt P03922116A0197 NN O
bremsstrahlung P03922116A0197 NN O
beam P03922116A0197 NN O
from P03922116A0197 IN O
the P03922116A0197 DT O
luc P03922116A0197 NN O
type P03922116A0197 NN O
installation P03922116A0197 NN O
and P03922116A0197 CC O
iliac P03922116A0197 JJ O
lymphadenectomy P03922116A0197 NN O
( P03922116A0197 ( O
50 P03922116A0197 CD O
cases P03922116A0197 NNS O
) P03922116A0197 ) O
. P03922116A0197 . O
. . O O

These P08617802A0993 DT O
results P08617802A0993 NNS O
demonstrate P08617802A0993 VBP O
that P08617802A0993 IN O
sequences P08617802A0993 NNS O
in P08617802A0993 IN O
the P08617802A0993 DT O
SH2 P08617802A0993 NNP I-UN
/ P08617802A0993 NNP O
SH3 P08617802A0993 NNP I-UN
/ P08617802A0993 NNP O
SH2 P08617802A0993 NNP I-UN
region P08617802A0993 NN O
of P08617802A0993 IN O
p120 P08617802A0993 NN I-UN
GAP P08617802A0993 NNP I-UN
are P08617802A0993 VBP O
required P08617802A0993 VBN O
for P08617802A0993 IN O
full P08617802A0993 JJ O
catalytic P08617802A0993 JJ O
activity P08617802A0993 NN O
toward P08617802A0993 IN O
Ras P08617802A0993 NNP I-UN
. P08617802A0993 . O
. . O O

Thus P09396427A1488 RB O
, P09396427A1488 , O
the P09396427A1488 DT O
absence P09396427A1488 NN O
of P09396427A1488 IN O
residual P09396427A1488 JJ O
infarct-zone P09396427A1488 JJ O
viability P09396427A1488 NN O
discriminates P09396427A1488 VBZ O
patients P09396427A1488 NNS O
who P09396427A1488 WP O
develop P09396427A1488 VBP O
progressive P09396427A1488 JJ O
left P09396427A1488 VBD O
ventricular P09396427A1488 JJ O
dilation P09396427A1488 NN O
after P09396427A1488 IN O
reperfused P09396427A1488 VBN O
AMI P09396427A1488 NNP O
from P09396427A1488 IN O
those P09396427A1488 DT O
who P09396427A1488 WP O
maintain P09396427A1488 VBP O
normal P09396427A1488 JJ O
left P09396427A1488 VBD O
ventricular P09396427A1488 JJ O
geometry P09396427A1488 NN O
. P09396427A1488 . O
. . O O

In P10359663A1280 IN O
co-transfection P10359663A1280 NN O
studies P10359663A1280 NNS O
, P10359663A1280 , O
the P10359663A1280 DT O
expression P10359663A1280 NN O
of P10359663A1280 IN O
c-Jun P10359663A1280 JJ I-UN
plus P10359663A1280 CC O
c-Fos P10359663A1280 JJ I-UN
enhanced P10359663A1280 VBD O
the P10359663A1280 DT O
transactivation P10359663A1280 NN O
of P10359663A1280 IN O
oIFNtau-CAT P10359663A1280 JJ O
but P10359663A1280 CC O
the P10359663A1280 DT O
expression P10359663A1280 NN O
of P10359663A1280 IN O
GATA-1 P10359663A1280 NNP I-UN
, P10359663A1280 , O
GATA-2 P10359663A1280 NNP I-UN
or P10359663A1280 CC O
GATA-3 P10359663A1280 NNP I-UN
did P10359663A1280 VBD O
not P10359663A1280 RB O
. P10359663A1280 . O
. . O O

The P08662789A0673 DT O
corresponding P08662789A0673 JJ O
gene P08662789A0673 NN O
was P08662789A0673 VBD O
identified P08662789A0673 VBN O
in P08662789A0673 IN O
the P08662789A0673 DT O
GenBankTM P08662789A0673 NNP O
data P08662789A0673 NNS O
base P08662789A0673 NN O
by P08662789A0673 IN O
sequence P08662789A0673 NN O
alignment P08662789A0673 NN O
and P08662789A0673 CC O
termed P08662789A0673 VBD O
RPS30A P08662789A0673 NNP I-UN
. P08662789A0673 . O
. . O O

RESULTS P09798068A0290 NNS O
: P09798068A0290 : O
We P09798068A0290 PRP O
identified P09798068A0290 VBD O
a P09798068A0290 DT O
full-length P09798068A0290 JJ O
cDNA P09798068A0290 NN O
with P09798068A0290 IN O
an P09798068A0290 DT O
open P09798068A0290 JJ O
reading P09798068A0290 NN O
frame P09798068A0290 NN O
of P09798068A0290 IN O
2883 P09798068A0290 CD O
bp P09798068A0290 NN O
corresponding P09798068A0290 VBG O
to P09798068A0290 TO O
a P09798068A0290 DT O
predicted P09798068A0290 JJ O
protein P09798068A0290 NN O
of P09798068A0290 IN O
961 P09798068A0290 CD O
amino P09798068A0290 NN O
acids P09798068A0290 NNS O
that P09798068A0290 WDT O
shares P09798068A0290 NNS O
greater P09798068A0290 JJR O
than P09798068A0290 IN O
95 P09798068A0290 CD O
% P09798068A0290 NN O
homology P09798068A0290 NN O
with P09798068A0290 IN O
the P09798068A0290 DT O
rat P09798068A0290 NN I-UN
gamma-aminobutyric P09798068A0290 JJ I-UN
acid P09798068A0290 NN I-UN
B P09798068A0290 NNP I-UN
( P09798068A0290 ( I-UN
GABAB P09798068A0290 NNP I-UN
) P09798068A0290 ) I-UN
receptor P09798068A0290 NN I-UN
. P09798068A0290 . O
. . O O

Computer P09176837A0211 NNP O
software P09176837A0211 NN O
assisted P09176837A0211 VBD O
ordering P09176837A0211 VBG O
( P09176837A0211 ( O
CSAO P09176837A0211 NNP O
) P09176837A0211 ) O
was P09176837A0211 VBD O
developed P09176837A0211 VBN O
to P09176837A0211 TO O
integrate P09176837A0211 VB O
PN P09176837A0211 NNP O
Ca P09176837A0211 NNP O
: P09176837A0211 : O
P P09176837A0211 NNP O
solubility P09176837A0211 NN O
with P09176837A0211 IN O
clinical P09176837A0211 JJ O
data P09176837A0211 NNS O
to P09176837A0211 TO O
improve P09176837A0211 VB O
parenteral P09176837A0211 JJ O
Ca P09176837A0211 NNP O
and P09176837A0211 CC O
P P09176837A0211 NNP O
administration P09176837A0211 NN O
. P09176837A0211 . O
. . O O

Comparison P09653648A0445 NNP O
of P09653648A0445 IN O
cDNA P09653648A0445 NN O
and P09653648A0445 CC O
genomic P09653648A0445 JJ O
sequences P09653648A0445 NNS O
shows P09653648A0445 VBZ O
that P09653648A0445 IN O
the P09653648A0445 DT O
ZNF189 P09653648A0445 NNP I-UN
gene P09653648A0445 NN I-UN
spans P09653648A0445 NNS O
approximately P09653648A0445 RB O
11 P09653648A0445 CD O
kb P09653648A0445 NNS O
and P09653648A0445 CC O
is P09653648A0445 VBZ O
organized P09653648A0445 VBN O
into P09653648A0445 IN O
at P09653648A0445 IN O
least P09653648A0445 JJS O
four P09653648A0445 CD O
exons P09653648A0445 NNS O
, P09653648A0445 , O
the P09653648A0445 DT O
large P09653648A0445 JJ O
3'-end P09653648A0445 JJ O
exon P09653648A0445 NN O
coding P09653648A0445 VBG O
for P09653648A0445 IN O
the P09653648A0445 DT O
complete P09653648A0445 JJ O
zinc P09653648A0445 NN O
finger P09653648A0445 NN O
domain P09653648A0445 NN O
and P09653648A0445 CC O
the P09653648A0445 DT O
3 P09653648A0445 CD O
' P09653648A0445 POS O
untranslated P09653648A0445 JJ O
region P09653648A0445 NN O
. P09653648A0445 . O
. . O O

Schizosaccharomyces P09843577A0000 NNS O
pombe P09843577A0000 VBP O
cells P09843577A0000 NNS O
respond P09843577A0000 NN O
to P09843577A0000 TO O
nutrient P09843577A0000 JJ O
deprivation P09843577A0000 NN O
by P09843577A0000 IN O
altering P09843577A0000 VBG O
G2 P09843577A0000 NNP O
/ P09843577A0000 NNP O
M P09843577A0000 NNP O
cell P09843577A0000 NN O
size P09843577A0000 NN O
control P09843577A0000 NN O
. P09843577A0000 . O
. . O O

The P02270587A0000 DT O
endodontal P02270587A0000 JJ O
treatment P02270587A0000 NN O
need P02270587A0000 NN O
has P02270587A0000 VBZ O
been P02270587A0000 VBN O
forming P02270587A0000 VBG O
a P02270587A0000 DT O
clinical P02270587A0000 JJ O
order P02270587A0000 NN O
of P02270587A0000 IN O
magnitude P02270587A0000 NN O
. P02270587A0000 . O
. . O O

In P08916960A1331 IN O
all P08916960A1331 DT O
eight P08916960A1331 CD O
cases P08916960A1331 NNS O
, P08916960A1331 , O
neither P08916960A1331 CC O
FL P08916960A1331 NNP O
nor P08916960A1331 CC O
DLL P08916960A1331 NNP O
cells P08916960A1331 NNS O
showed P08916960A1331 VBD O
alterations P08916960A1331 NNS O
of P08916960A1331 IN O
bcl-2 P08916960A1331 JJ I-UN
gene P08916960A1331 NN I-UN
sequences P08916960A1331 NNS I-UN
in P08916960A1331 IN O
the P08916960A1331 DT O
breakpoint P08916960A1331 NN O
region P08916960A1331 NN O
, P08916960A1331 , O
suggesting P08916960A1331 VBG O
high P08916960A1331 JJ O
conservation P08916960A1331 NN O
of P08916960A1331 IN O
the P08916960A1331 DT O
bcl-2 P08916960A1331 JJ I-UN
gene P08916960A1331 NN I-UN
during P08916960A1331 IN O
both P08916960A1331 DT O
t P08916960A1331 NNP O
( P08916960A1331 ( O
14 P08916960A1331 CD O
; P08916960A1331 : O
18 P08916960A1331 CD O
) P08916960A1331 ) O
translocation P08916960A1331 NN O
and P08916960A1331 CC O
morphologic P08916960A1331 JJ O
transformation P08916960A1331 NN O
of P08916960A1331 IN O
the P08916960A1331 DT O
FL P08916960A1331 NNP O
cells P08916960A1331 NNS O
. P08916960A1331 . O
. . O O

We P02418701A0000 PRP O
evaluated P02418701A0000 VBD O
the P02418701A0000 DT O
likelihood P02418701A0000 NN O
of P02418701A0000 IN O
tissues P02418701A0000 NNS O
to P02418701A0000 TO O
be P02418701A0000 VB O
positive P02418701A0000 JJ O
for P02418701A0000 IN O
carcinoembryonic P02418701A0000 JJ I-UN
antigen P02418701A0000 NN I-UN
and P02418701A0000 CC O
the P02418701A0000 DT O
intensity P02418701A0000 NN O
of P02418701A0000 IN O
carcinoembryonic P02418701A0000 JJ I-UN
antigen P02418701A0000 NN I-UN
staining P02418701A0000 VBG O
in P02418701A0000 IN O
specimens P02418701A0000 NNS O
of P02418701A0000 IN O
villous P02418701A0000 JJ O
adenomas P02418701A0000 NN O
, P02418701A0000 , O
mixed P02418701A0000 JJ O
polypoid P02418701A0000 VBP O
villous P02418701A0000 JJ O
adenomas P02418701A0000 NN O
, P02418701A0000 , O
polypoid P02418701A0000 JJ O
adenomas P02418701A0000 NN O
, P02418701A0000 , O
and P02418701A0000 CC O
diverticulitis P02418701A0000 NN O
using P02418701A0000 VBG O
the P02418701A0000 DT O
peroxidase-antiperoxidase P02418701A0000 NN O
technique P02418701A0000 NN O
. P02418701A0000 . O
. . O O

Delayed P00565136T0000 NNP O
mortality P00565136T0000 NN O
of P00565136T0000 IN O
mice P00565136T0000 NN O
following P00565136T0000 VBG O
inhalation P00565136T0000 NN O
of P00565136T0000 IN O
acute P00565136T0000 JJ O
doses P00565136T0000 NNS O
of P00565136T0000 IN O
CH2O P00565136T0000 NNP O
, P00565136T0000 , O
SO2Cl2 P00565136T0000 NNP O
, P00565136T0000 , O
and P00565136T0000 CC O
Br2 P00565136T0000 NNP O
. P00565136T0000 . O
. . O O

The P08816498A0000 DT O
serine P08816498A0000 NN I-UN
/ P08816498A0000 NNP I-UN
threonine P08816498A0000 NN I-UN
kinase P08816498A0000 NN I-UN
Raf-1 P08816498A0000 NNP I-UN
functions P08816498A0000 NNS O
downstream P08816498A0000 NN O
of P08816498A0000 IN O
Rats P08816498A0000 NNP I-UN
in P08816498A0000 IN O
a P08816498A0000 DT O
signal P08816498A0000 JJ O
transduction P08816498A0000 NN O
cascade P08816498A0000 NN O
which P08816498A0000 WDT O
transmits P08816498A0000 VBZ O
mitogenic P08816498A0000 JJ O
stimuli P08816498A0000 NNS O
from P08816498A0000 IN O
the P08816498A0000 DT O
plasma P08816498A0000 NN O
membrane P08816498A0000 NN O
to P08816498A0000 TO O
the P08816498A0000 DT O
nucleus P08816498A0000 NN O
. P08816498A0000 . O
. . O O

Furthermore P02123467A0811 RB O
, P02123467A0811 , O
expression P02123467A0811 NN O
of P02123467A0811 IN O
the P02123467A0811 DT O
promoter P02123467A0811 NN O
in P02123467A0811 IN O
embryonic P02123467A0811 JJ O
Drosophila P02123467A0811 NNP O
melanogaster P02123467A0811 NN O
cells P02123467A0811 NNS O
that P02123467A0811 WDT O
lack P02123467A0811 VBP O
MyoD1 P02123467A0811 NNP I-UN
and P02123467A0811 CC O
Sp1 P02123467A0811 NNP I-UN
is P02123467A0811 VBZ O
strictly P02123467A0811 RB O
dependent P02123467A0811 JJ O
on P02123467A0811 IN O
all P02123467A0811 DT O
three P02123467A0811 CD O
sites P02123467A0811 NNS O
remaining P02123467A0811 VBG O
intact P02123467A0811 JJ O
and P02123467A0811 CC O
on P02123467A0811 IN O
the P02123467A0811 DT O
presence P02123467A0811 NN O
of P02123467A0811 IN O
exogenously P02123467A0811 RB O
supplied P02123467A0811 VBN O
Sp1 P02123467A0811 NNP I-UN
and P02123467A0811 CC O
MyoD1 P02123467A0811 NNP I-UN
. P02123467A0811 . O
. . O O

Plasma P11201250A0849 NNP O
DHE P11201250A0849 NNP O
concentration P11201250A0849 NN O
rose P11201250A0849 VBD O
promptly P11201250A0849 RB O
above P11201250A0849 IN O
5 P11201250A0849 CD O
ng P11201250A0849 JJ O
/ P11201250A0849 NNP O
ml P11201250A0849 NN O
after P11201250A0849 IN O
the P11201250A0849 DT O
application P11201250A0849 NN O
of P11201250A0849 IN O
the P11201250A0849 DT O
PSA P11201250A0849 NNP O
tape P11201250A0849 NN O
onto P11201250A0849 IN O
the P11201250A0849 DT O
damaged P11201250A0849 VBN O
skin P11201250A0849 NN O
in P11201250A0849 IN O
hairless P11201250A0849 JJ O
rat P11201250A0849 NN O
. P11201250A0849 . O
. . O O

On P09798100A0705 IN O
Day P09798100A0705 NNP O
8 P09798100A0705 CD O
, P09798100A0705 , O
the P09798100A0705 DT O
CIDR-B P09798100A0705 NNP O
was P09798100A0705 VBD O
removed P09798100A0705 VBN O
and P09798100A0705 CC O
500 P09798100A0705 CD O
micrograms P09798100A0705 NNS O
cloprostenol P09798100A0705 RB O
injected P09798100A0705 VBN O
, P09798100A0705 , O
IM P09798100A0705 NNP O
. P09798100A0705 . O
. . O O

After P07192722A0682 IN O
successful P07192722A0682 JJ O
subtotal P07192722A0682 JJ O
parathyroidectomy P07192722A0682 NN O
, P07192722A0682 , O
evident P07192722A0682 JJ O
by P07192722A0682 IN O
the P07192722A0682 DT O
decrease P07192722A0682 NN O
of P07192722A0682 IN O
serum P07192722A0682 NN O
iPTH P07192722A0682 NN I-UN
levels P07192722A0682 NNS O
, P07192722A0682 , O
both P07192722A0682 CC O
the P07192722A0682 DT O
CL P07192722A0682 NNP O
of P07192722A0682 IN O
group P07192722A0682 NN O
2 P07192722A0682 CD O
PMNs P07192722A0682 NNP O
and P07192722A0682 CC O
the P07192722A0682 DT O
ability P07192722A0682 NN O
of P07192722A0682 IN O
group P07192722A0682 NN O
2 P07192722A0682 CD O
sera P07192722A0682 NN O
to P07192722A0682 TO O
induce P07192722A0682 VB O
augmented P07192722A0682 JJ O
CL P07192722A0682 NNP O
in P07192722A0682 IN O
normal P07192722A0682 JJ O
PMNs P07192722A0682 NNP O
decreased P07192722A0682 VBD O
( P07192722A0682 ( O
p P07192722A0682 JJ O
< P07192722A0682 NNP O
0.025 P07192722A0682 CD O
) P07192722A0682 ) O
. P07192722A0682 . O
. . O O

1- P02779752A0776 JJ O
( P02779752A0776 ( O
m-Chlorophenyl P02779752A0776 JJ O
) P02779752A0776 ) O
piperazine P02779752A0776 NN O
( P02779752A0776 ( O
mCPP P02779752A0776 JJ O
, P02779752A0776 , O
0.1-3.0 P02779752A0776 JJ O
mg P02779752A0776 NN O
/ P02779752A0776 NNP O
kg P02779752A0776 NN O
) P02779752A0776 ) O
and P02779752A0776 CC O
1- P02779752A0776 JJ O
( P02779752A0776 ( O
m-trifluoromethylphenyl P02779752A0776 JJ O
) P02779752A0776 ) O
piperazine P02779752A0776 NN O
( P02779752A0776 ( O
TFMPP P02779752A0776 NNP O
, P02779752A0776 , O
0.1-3.0 P02779752A0776 JJ O
mg P02779752A0776 NN O
/ P02779752A0776 NNP O
kg P02779752A0776 NN O
) P02779752A0776 ) O
, P02779752A0776 , O
both P02779752A0776 DT O
thought P02779752A0776 VBN O
to P02779752A0776 TO O
act P02779752A0776 VB O
primarily P02779752A0776 RB O
at P02779752A0776 IN O
5-HT1 P02779752A0776 JJ I-UN
sites P02779752A0776 NNS I-UN
, P02779752A0776 , O
also P02779752A0776 RB O
decreased P02779752A0776 VBD O
responding P02779752A0776 VBG O
and P02779752A0776 CC O
this P02779752A0776 DT O
effect P02779752A0776 NN O
was P02779752A0776 VBD O
blocked P02779752A0776 VBN O
by P02779752A0776 IN O
methysergide P02779752A0776 NN O
and P02779752A0776 CC O
by P02779752A0776 IN O
1-NP P02779752A0776 JJ O
, P02779752A0776 , O
but P02779752A0776 CC O
not P02779752A0776 RB O
by P02779752A0776 IN O
ketanserin P02779752A0776 NN O
. P02779752A0776 . O
. . O O

The P08280925A0261 DT O
secondary P08280925A0261 JJ O
, P08280925A0261 , O
but P08280925A0261 CC O
not P08280925A0261 RB O
the P08280925A0261 DT O
primary P08280925A0261 JJ O
, P08280925A0261 , O
antibody P08280925A0261 JJ O
responses P08280925A0261 NNS O
of P08280925A0261 IN O
male P08280925A0261 JJ O
C57Bl P08280925A0261 NNP O
/ P08280925A0261 NNP O
6 P08280925A0261 CD O
mice P08280925A0261 NN O
were P08280925A0261 VBD O
higher P08280925A0261 JJR O
among P08280925A0261 IN O
mice P08280925A0261 NNS O
housed P08280925A0261 VBD O
alone P08280925A0261 RB O
compared P08280925A0261 VBN O
to P08280925A0261 TO O
mice P08280925A0261 NNS O
housed P08280925A0261 VBN O
in P08280925A0261 IN O
groups P08280925A0261 NNS O
; P08280925A0261 : O
differences P08280925A0261 NNS O
were P08280925A0261 VBD O
observed P08280925A0261 VBN O
for P08280925A0261 IN O
both P08280925A0261 DT O
IgM P08280925A0261 NNP I-UN
and P08280925A0261 CC O
IgG P08280925A0261 NNP I-UN
anti-KLH P08280925A0261 JJ I-UN
antibodies P08280925A0261 NNS I-UN
. P08280925A0261 . O
. . O O

RESULTS P11126353A0582 NN O
: P11126353A0582 : O
Prevalence P11126353A0582 NN O
of P11126353A0582 IN O
obesity P11126353A0582 NN O
( P11126353A0582 ( O
BMI P11126353A0582 NNP O
SDS P11126353A0582 NNP O
> P11126353A0582 NNP O
2.0 P11126353A0582 CD O
) P11126353A0582 ) O
was P11126353A0582 VBD O
< P11126353A0582 JJ O
2 P11126353A0582 CD O
% P11126353A0582 NN O
at P11126353A0582 IN O
diagnosis P11126353A0582 NN O
, P11126353A0582 , O
but P11126353A0582 CC O
increased P11126353A0582 VBD O
to P11126353A0582 TO O
16 P11126353A0582 CD O
% P11126353A0582 NN O
at P11126353A0582 IN O
3y P11126353A0582 CD O
. P11126353A0582 . O
. . O O

The P08115744A0846 DT O
GafChromic P08115744A0846 NNP O
method P08115744A0846 NN O
has P08115744A0846 VBZ O
proven P08115744A0846 VBN O
to P08115744A0846 TO O
be P08115744A0846 VB O
an P08115744A0846 DT O
accurate P08115744A0846 NN O
and P08115744A0846 CC O
rapid P08115744A0846 JJ O
method P08115744A0846 NN O
of P08115744A0846 IN O
analysis P08115744A0846 NN O
and P08115744A0846 CC O
could P08115744A0846 MD O
be P08115744A0846 VB O
easily P08115744A0846 RB O
incorporated P08115744A0846 VBN O
into P08115744A0846 IN O
a P08115744A0846 DT O
quality P08115744A0846 JJ O
assurance P08115744A0846 NN O
program P08115744A0846 NN O
. P08115744A0846 . O
. . O O

On P02223652A0939 IN O
an P02223652A0939 DT O
antithrombin P02223652A0939 JJ I-UN
unit P02223652A0939 NN O
basis P02223652A0939 NN O
, P02223652A0939 , O
CY P02223652A0939 NNP O
216 P02223652A0939 CD O
and P02223652A0939 CC O
CY P02223652A0939 NNP O
222 P02223652A0939 CD O
were P02223652A0939 VBD O
equivalent P02223652A0939 JJ O
and P02223652A0939 CC O
more P02223652A0939 RBR O
potent P02223652A0939 JJ O
than P02223652A0939 IN O
UH P02223652A0939 NNP O
. P02223652A0939 . O
. . O O

Neural-specific P01584812T0000 JJ O
expression P01584812T0000 NN O
, P01584812T0000 , O
genomic P01584812T0000 JJ O
structure P01584812T0000 NN O
, P01584812T0000 , O
and P01584812T0000 CC O
chromosomal P01584812T0000 JJ O
localization P01584812T0000 NN O
of P01584812T0000 IN O
the P01584812T0000 DT O
gene P01584812T0000 NN O
encoding P01584812T0000 VBG O
the P01584812T0000 DT O
zinc-finger P01584812T0000 JJ I-UN
transcription P01584812T0000 NN I-UN
factor P01584812T0000 NN I-UN
NGFI-C P01584812T0000 NNP I-UN
. P01584812T0000 . O
. . O O

The P02237431A0833 DT O
Ets-1 P02237431A0833 NNP I-UN
binding P02237431A0833 NN I-UN
site P02237431A0833 NN I-UN
was P02237431A0833 VBD O
localized P02237431A0833 VBN O
to P02237431A0833 TO O
a P02237431A0833 DT O
17-base P02237431A0833 JJ O
pair P02237431A0833 NN O
( P02237431A0833 ( O
bp P02237431A0833 NN O
) P02237431A0833 ) O
region P02237431A0833 NN O
from P02237431A0833 IN O
the P02237431A0833 DT O
3 P02237431A0833 CD O
' P02237431A0833 POS O
end P02237431A0833 NN O
of P02237431A0833 IN O
T P02237431A0833 NNP I-UN
alpha P02237431A0833 VBD I-UN
2 P02237431A0833 CD I-UN
. P02237431A0833 . O
. . O O

We P09510189A0192 PRP O
have P09510189A0192 VBP O
elucidated P09510189A0192 VBN O
the P09510189A0192 DT O
exon-intron P09510189A0192 JJ O
organization P09510189A0192 NN O
of P09510189A0192 IN O
the P09510189A0192 DT O
entire P09510189A0192 JJ O
human P09510189A0192 JJ O
CD58 P09510189A0192 NNP I-UN
gene P09510189A0192 NN I-UN
, P09510189A0192 , O
including P09510189A0192 VBG O
approximately P09510189A0192 RB O
2.5 P09510189A0192 CD O
kilobases P09510189A0192 NNS O
( P09510189A0192 ( O
kb P09510189A0192 NN O
) P09510189A0192 ) O
of P09510189A0192 IN O
5'-flanking P09510189A0192 JJ O
DNA P09510189A0192 NNP O
. P09510189A0192 . O
. . O O

This P10523663A0404 DT O
motif P10523663A0404 NN O
, P10523663A0404 , O
first P10523663A0404 RB O
described P10523663A0404 VBN O
for P10523663A0404 IN O
the P10523663A0404 DT O
Drosophila P10523663A0404 NNP I-UN
homeobox P10523663A0404 NN I-UN
activator P10523663A0404 NN I-UN
DEAF-1 P10523663A0404 NNP I-UN
, P10523663A0404 , O
identifies P10523663A0404 VBZ O
an P10523663A0404 DT O
emerging P10523663A0404 VBG O
group P10523663A0404 NN O
of P10523663A0404 IN O
metazoan P10523663A0404 NN O
transcriptional P10523663A0404 JJ O
modulators P10523663A0404 NNS O
. P10523663A0404 . O
. . O O

Moreover P07990136A1124 RB O
, P07990136A1124 , O
the P07990136A1124 DT O
ability P07990136A1124 NN O
to P07990136A1124 TO O
selectivity P07990136A1124 NN O
arrest P07990136A1124 NN O
elongation P07990136A1124 NN O
by P07990136A1124 IN O
polIII P07990136A1124 NN I-UN
at P07990136A1124 IN O
defined P07990136A1124 JJ O
positions P07990136A1124 NNS O
within P07990136A1124 IN O
the P07990136A1124 DT O
tRNA P07990136A1124 JJ O
gene P07990136A1124 NN O
transcription P07990136A1124 NN O
unit P07990136A1124 NN O
has P07990136A1124 VBZ O
permitted P07990136A1124 VBN O
the P07990136A1124 DT O
identification P07990136A1124 NN O
of P07990136A1124 IN O
discrete P07990136A1124 JJ O
functional P07990136A1124 JJ O
properties P07990136A1124 NNS O
of P07990136A1124 IN O
paused P07990136A1124 JJ O
mammalian P07990136A1124 JJ I-UN
polIII P07990136A1124 NN I-UN
ternary P07990136A1124 JJ I-UN
complexes P07990136A1124 NNS I-UN
. P07990136A1124 . O
. . O O

MAIN P09006555A0738 NNP O
OUTCOME P09006555A0738 NNP O
MEASURES P09006555A0738 NNP O
: P09006555A0738 : O
Systemic P09006555A0738 NNP O
and P09006555A0738 CC O
pulmonary P09006555A0738 JJ O
hemodynamics P09006555A0738 NNS O
, P09006555A0738 , O
arterial P09006555A0738 JJ O
blood P09006555A0738 NN O
gas P09006555A0738 NN O
determination P09006555A0738 NN O
, P09006555A0738 , O
bronchoalveolar P09006555A0738 JJ O
lavage P09006555A0738 NN O
protein P09006555A0738 NN O
and P09006555A0738 CC O
neutrophil P09006555A0738 JJ O
content P09006555A0738 NN O
, P09006555A0738 , O
neutrophil P09006555A0738 JJ O
oxidant P09006555A0738 JJ O
burst P09006555A0738 NN O
, P09006555A0738 , O
lung P09006555A0738 NN I-UN
myeloperoxidase P09006555A0738 NN I-UN
content P09006555A0738 NN O
, P09006555A0738 , O
and P09006555A0738 CC O
scanning P09006555A0738 VBG O
electron P09006555A0738 NN O
micrographic P09006555A0738 JJ O
studies P09006555A0738 NNS O
. P09006555A0738 . O
. . O O

The P04843031T0000 DT O
levels P04843031T0000 NNS O
of P04843031T0000 IN O
galactosyltransferase P04843031T0000 NN I-UN
activity P04843031T0000 NN O
in P04843031T0000 IN O
sera P04843031T0000 NN O
from P04843031T0000 IN O
normal P04843031T0000 JJ O
children P04843031T0000 NNS O
and P04843031T0000 CC O
patients P04843031T0000 NNS O
with P04843031T0000 IN O
cystic P04843031T0000 JJ O
fibrosis P04843031T0000 NN O
. P04843031T0000 . O
. . O O

The P01737789A0800 DT O
upstream P01737789A0800 JJ O
delta-alpha P01737789A0800 NN O
breakpoint P01737789A0800 NN O
is P01737789A0800 VBZ O
flanked P01737789A0800 VBN O
by P01737789A0800 IN O
the P01737789A0800 DT O
direct P01737789A0800 JJ O
repeats P01737789A0800 NN O
of P01737789A0800 IN O
the P01737789A0800 DT O
acceptor P01737789A0800 NN O
splice P01737789A0800 NN O
site P01737789A0800 NN O
, P01737789A0800 , O
whereas P01737789A0800 IN O
the P01737789A0800 DT O
down-stream P01737789A0800 JJ O
alpha-delta P01737789A0800 JJ O
breakpoint P01737789A0800 NN O
is P01737789A0800 VBZ O
located P01737789A0800 VBN O
in P01737789A0800 IN O
the P01737789A0800 DT O
adjacent P01737789A0800 JJ O
intron P01737789A0800 NN O
. P01737789A0800 . O
. . O O

Contagious P11193704A0000 JJ O
bovine P11193704A0000 NN O
pleuropneumonia P11193704A0000 NN O
is P11193704A0000 VBZ O
a P11193704A0000 DT O
major P11193704A0000 JJ O
threat P11193704A0000 NN O
for P11193704A0000 IN O
cattle P11193704A0000 NNS O
in P11193704A0000 IN O
Africa P11193704A0000 NNP O
. P11193704A0000 . O
. . O O

During P02930623A0404 IN O
flexion P02930623A0404 NN O
whiplash P02930623A0404 NN O
, P02930623A0404 , O
the P02930623A0404 DT O
torque P02930623A0404 NN O
at P02930623A0404 IN O
the P02930623A0404 DT O
occipital P02930623A0404 JJ O
condyle P02930623A0404 NN O
reverses P02930623A0404 VBZ O
its P02930623A0404 PRP$ O
direction P02930623A0404 NN O
at P02930623A0404 IN O
about P02930623A0404 RB O
25 P02930623A0404 CD O
ms P02930623A0404 NNS O
after P02930623A0404 IN O
impact P02930623A0404 NN O
. P02930623A0404 . O
. . O O

However P07651835A0652 RB O
, P07651835A0652 , O
the P07651835A0652 DT O
relative P07651835A0652 JJ O
binding P07651835A0652 NN O
affinity P07651835A0652 NN O
for P07651835A0652 IN O
the P07651835A0652 DT O
motifs P07651835A0652 NN O
is P07651835A0652 VBZ O
different P07651835A0652 JJ O
. P07651835A0652 . O
. . O O

Female P00669800A0579 JJ O
mice P00669800A0579 NN O
were P00669800A0579 VBD O
significantly P00669800A0579 RB O
more P00669800A0579 RBR O
resistant P00669800A0579 JJ O
to P00669800A0579 TO O
infection P00669800A0579 NN O
than P00669800A0579 IN O
males P00669800A0579 NNS O
. P00669800A0579 . O
. . O O

R-wave P03253219T0000 JJ O
voltage P03253219T0000 NN O
in P03253219T0000 IN O
the P03253219T0000 DT O
right P03253219T0000 JJ O
precordial P03253219T0000 JJ O
leads P03253219T0000 NNS O
in P03253219T0000 IN O
anthracycline P03253219T0000 NN O
cardiomyopathy P03253219T0000 NN O
: P03253219T0000 : O
a P03253219T0000 DT O
clinical P03253219T0000 JJ O
study P03253219T0000 NN O
. P03253219T0000 . O
. . O O

Furthermore P09343210A1112 RB O
, P09343210A1112 , O
deletion P09343210A1112 NN O
and P09343210A1112 CC O
mutation P09343210A1112 NN O
analyses P09343210A1112 NNS O
of P09343210A1112 IN O
the P09343210A1112 DT O
VCAM-1 P09343210A1112 NNP I-UN
promoter P09343210A1112 NN I-UN
performed P09343210A1112 VBD O
with P09343210A1112 IN O
chloramphenicol P09343210A1112 JJ I-UN
acetyltransferase P09343210A1112 NN I-UN
constructs P09343210A1112 NNS I-UN
revealed P09343210A1112 VBD O
that P09343210A1112 IN O
Tax P09343210A1112 NNP I-UN
was P09343210A1112 VBD O
trans P09343210A1112 NNS O
activating P09343210A1112 VBG O
the P09343210A1112 DT O
VCAM-1 P09343210A1112 JJ I-UN
promoter P09343210A1112 NN I-UN
via P09343210A1112 IN O
two P09343210A1112 CD O
NF-kappaB P09343210A1112 JJ I-UN
sites P09343210A1112 NNS I-UN
present P09343210A1112 JJ O
at P09343210A1112 IN O
bp P09343210A1112 NN O
-72 P09343210A1112 NN O
and P09343210A1112 CC O
-57 P09343210A1112 NN O
in P09343210A1112 IN O
the P09343210A1112 DT O
VCAM-1 P09343210A1112 NNP I-UN
gene P09343210A1112 NN I-UN
promoter P09343210A1112 NN I-UN
, P09343210A1112 , O
with P09343210A1112 IN O
both P09343210A1112 DT O
of P09343210A1112 IN O
them P09343210A1112 PRP O
being P09343210A1112 VBG O
required P09343210A1112 VBN O
for P09343210A1112 IN O
the P09343210A1112 DT O
Tax-induced P09343210A1112 NNP O
expression P09343210A1112 NN O
of P09343210A1112 IN O
this P09343210A1112 DT O
adhesion P09343210A1112 NN O
molecule P09343210A1112 NN O
. P09343210A1112 . O
. . O O

The P09858572A0000 DT O
yeast P09858572A0000 NN O
retrotransposon P09858572A0000 NN I-UN
Ty5 P09858572A0000 NNP I-UN
preferentially P09858572A0000 RB O
integrates P09858572A0000 VBZ O
into P09858572A0000 IN O
regions P09858572A0000 NNS O
of P09858572A0000 IN O
silent P09858572A0000 JJ O
chromatin P09858572A0000 NN O
. P09858572A0000 . O
. . O O

The P02522297A0000 DT O
effect P02522297A0000 NN O
of P02522297A0000 IN O
the P02522297A0000 DT O
thromboxane P02522297A0000 NN I-UN
A2 P02522297A0000 NNP I-UN
( P02522297A0000 ( I-UN
TXA2 P02522297A0000 NNP I-UN
) P02522297A0000 ) I-UN
/ P02522297A0000 VBP I-UN
prostaglandin P02522297A0000 JJ I-UN
endoperoxide P02522297A0000 JJ I-UN
receptor P02522297A0000 NN I-UN
antagonist P02522297A0000 NN O
, P02522297A0000 , O
SQ P02522297A0000 NNP O
29,548 P02522297A0000 CD O
on P02522297A0000 IN O
pacing-induced P02522297A0000 JJ O
ischemia P02522297A0000 NN O
was P02522297A0000 VBD O
determined P02522297A0000 VBN O
in P02522297A0000 IN O
anesthetized P02522297A0000 JJ O
open-chest P02522297A0000 JJ O
dogs P02522297A0000 NNS O
. P02522297A0000 . O
. . O O

The P02148799A0000 DT O
nmr P02148799A0000 JJ I-UN
gene P02148799A0000 NN I-UN
is P02148799A0000 VBZ O
the P02148799A0000 DT O
major P02148799A0000 JJ O
negative P02148799A0000 JJ O
regulatory P02148799A0000 JJ O
gene P02148799A0000 NN O
in P02148799A0000 IN O
the P02148799A0000 DT O
nitrogen P02148799A0000 NN O
control P02148799A0000 NN O
circuit P02148799A0000 NN O
of P02148799A0000 IN O
Neurospora P02148799A0000 NNP O
crassa P02148799A0000 NN O
, P02148799A0000 , O
which P02148799A0000 WDT O
, P02148799A0000 , O
together P02148799A0000 RB O
with P02148799A0000 IN O
positive P02148799A0000 JJ O
regulatory P02148799A0000 JJ O
genes P02148799A0000 NNS O
, P02148799A0000 , O
governs P02148799A0000 VBZ O
the P02148799A0000 DT O
expression P02148799A0000 NN O
of P02148799A0000 IN O
multiple P02148799A0000 JJ O
unlinked P02148799A0000 JJ O
structural P02148799A0000 JJ O
genes P02148799A0000 NNS O
of P02148799A0000 IN O
the P02148799A0000 DT O
circuit P02148799A0000 NN O
. P02148799A0000 . O
. . O O

The P07667097A0267 DT O
association P07667097A0267 NN O
of P07667097A0267 IN O
p255 P07667097A0267 NN I-UN
with P07667097A0267 IN O
splicing P07667097A0267 VBG O
complexes P07667097A0267 NNS O
is P07667097A0267 VBZ O
suggested P07667097A0267 VBN O
by P07667097A0267 IN O
the P07667097A0267 DT O
finding P07667097A0267 NN O
that P07667097A0267 WDT O
mAb P07667097A0267 VBZ I-UN
CC3 P07667097A0267 NNP I-UN
can P07667097A0267 MD O
inhibit P07667097A0267 VB O
in P07667097A0267 IN O
vitro P07667097A0267 JJ O
splicing P07667097A0267 NN O
and P07667097A0267 CC O
immunoprecipitate P07667097A0267 VB O
pre-messenger P07667097A0267 NN O
RNA P07667097A0267 NNP O
and P07667097A0267 CC O
splicing P07667097A0267 VBG O
products P07667097A0267 NNS O
. P07667097A0267 . O
. . O O

A P02144558A1022 DT O
needs P02144558A1022 JJ O
assessment P02144558A1022 NN O
of P02144558A1022 IN O
these P02144558A1022 DT O
families P02144558A1022 NNS O
was P02144558A1022 VBD O
also P02144558A1022 RB O
done P02144558A1022 VBN O
. P02144558A1022 . O
. . O O

3 P01256410T0001 CD O
activities P01256410T0001 NNS O
of P01256410T0001 IN O
the P01256410T0001 DT O
factor P01256410T0001 NN I-UN
II P01256410T0001 NNP I-UN
molecule P01256410T0001 NN O
in P01256410T0001 IN O
the P01256410T0001 DT O
newborn P01256410T0001 JJ O
infant P01256410T0001 NN O
at P01256410T0001 IN O
term P01256410T0001 NN O
. P01256410T0001 . O
. . O O

Identification P03035218T0000 NN O
of P03035218T0000 IN O
p40x-responsive P03035218T0000 JJ O
regulatory P03035218T0000 JJ O
sequences P03035218T0000 NNS O
within P03035218T0000 IN O
the P03035218T0000 DT O
human P03035218T0000 JJ O
T-cell P03035218T0000 NNP O
leukemia P03035218T0000 NN O
virus P03035218T0000 NN O
type P03035218T0000 NN O
I P03035218T0000 PRP O
long P03035218T0000 JJ O
terminal P03035218T0000 JJ O
repeat P03035218T0000 NN O
. P03035218T0000 . O
. . O O

Side P06361318A1127 JJ O
effect P06361318A1127 NN O
including P06361318A1127 VBG O
subjective P06361318A1127 JJ O
and P06361318A1127 CC O
objective P06361318A1127 JJ O
symptoms P06361318A1127 NNS O
were P06361318A1127 VBD O
strictly P06361318A1127 RB O
evaluated P06361318A1127 VBN O
in P06361318A1127 IN O
163 P06361318A1127 CD O
cases P06361318A1127 NNS O
( P06361318A1127 ( O
KS-R1 P06361318A1127 NNP O
group P06361318A1127 NN O
in P06361318A1127 IN O
83 P06361318A1127 CD O
cases P06361318A1127 NNS O
, P06361318A1127 , O
oral P06361318A1127 JJ O
group P06361318A1127 NN O
in P06361318A1127 IN O
80 P06361318A1127 CD O
cases P06361318A1127 NNS O
) P06361318A1127 ) O
, P06361318A1127 , O
but P06361318A1127 CC O
the P06361318A1127 DT O
incidence P06361318A1127 NN O
rate P06361318A1127 NN O
which P06361318A1127 WDT O
was P06361318A1127 VBD O
22.9 P06361318A1127 CD O
% P06361318A1127 NN O
for P06361318A1127 IN O
the P06361318A1127 DT O
KS-R1 P06361318A1127 NNP O
group P06361318A1127 NN O
and P06361318A1127 CC O
23.8 P06361318A1127 CD O
% P06361318A1127 NN O
for P06361318A1127 IN O
the P06361318A1127 DT O
oral P06361318A1127 JJ O
group P06361318A1127 NN O
showed P06361318A1127 VBD O
no P06361318A1127 DT O
significant P06361318A1127 JJ O
difference P06361318A1127 NN O
. P06361318A1127 . O
. . O O

In P08918885A1087 IN O
contrast P08918885A1087 NN O
, P08918885A1087 , O
dig1 P08918885A1087 VBP I-UN
dig2 P08918885A1087 JJ I-UN
cells P08918885A1087 NNS O
constitutively P08918885A1087 RB O
invade P08918885A1087 VBP O
agar P08918885A1087 JJ O
medium P08918885A1087 NN O
, P08918885A1087 , O
whereas P08918885A1087 IN O
a P08918885A1087 DT O
dig1 P08918885A1087 NN I-UN
dig2 P08918885A1087 NN I-UN
ste12 P08918885A1087 NN I-UN
triple P08918885A1087 JJ O
mutant P08918885A1087 NN O
does P08918885A1087 VBZ O
not P08918885A1087 RB O
, P08918885A1087 , O
indicating P08918885A1087 VBG O
that P08918885A1087 IN O
Dig1 P08918885A1087 NNP I-UN
and P08918885A1087 CC O
Dig2 P08918885A1087 NNP I-UN
share P08918885A1087 NN O
a P08918885A1087 DT O
role P08918885A1087 NN O
in P08918885A1087 IN O
negatively P08918885A1087 RB O
regulating P08918885A1087 VBG O
the P08918885A1087 DT O
invasive P08918885A1087 JJ O
growth P08918885A1087 NN O
pathway P08918885A1087 NN O
. P08918885A1087 . O
. . O O

However P08617311A0979 RB O
, P08617311A0979 , O
while P08617311A0979 IN O
the P08617311A0979 DT O
sequence P08617311A0979 NN O
similarity P08617311A0979 NN O
between P08617311A0979 IN O
the P08617311A0979 DT O
membrane P08617311A0979 NN O
exons P08617311A0979 NNS O
of P08617311A0979 IN O
avian P08617311A0979 JJ I-UN
mIgY P08617311A0979 NN I-UN
and P08617311A0979 CC O
mammalian P08617311A0979 JJ I-UN
mIgG P08617311A0979 NN I-UN
and P08617311A0979 CC I-UN
IgE P08617311A0979 NNP I-UN
is P08617311A0979 VBZ O
striking P08617311A0979 VBG O
, P08617311A0979 , O
the P08617311A0979 DT O
overall P08617311A0979 JJ O
similarity P08617311A0979 NN O
with P08617311A0979 IN O
Xenopus P08617311A0979 NNP I-UN
mIgY P08617311A0979 NN I-UN
is P08617311A0979 VBZ O
very P08617311A0979 RB O
low P08617311A0979 JJ O
. P08617311A0979 . O
. . O O

No P06591992A0569 DT O
anisotropism P06591992A0569 NN O
was P06591992A0569 VBD O
recorded P06591992A0569 VBN O
in P06591992A0569 IN O
a P06591992A0569 DT O
tetrahydrofuran P06591992A0569 JJ O
solution P06591992A0569 NN O
. P06591992A0569 . O
. . O O

We P10627532A0739 PRP O
demonstrate P10627532A0739 VBP O
that P10627532A0739 IN O
both P10627532A0739 DT O
R P10627532A0739 NNP I-UN
and P10627532A0739 CC O
Z P10627532A0739 NNP I-UN
activate P10627532A0739 VBP O
the P10627532A0739 DT O
cellular P10627532A0739 JJ O
stress P10627532A0739 NN O
mitogen-activated P10627532A0739 JJ I-UN
protein P10627532A0739 NN I-UN
( P10627532A0739 ( I-UN
MAP P10627532A0739 NNP I-UN
) P10627532A0739 ) I-UN
kinases P10627532A0739 VBZ I-UN
, P10627532A0739 , O
p38 P10627532A0739 NN I-UN
and P10627532A0739 CC O
JNK P10627532A0739 NNP I-UN
, P10627532A0739 , O
resulting P10627532A0739 VBG O
in P10627532A0739 IN O
phosphorylation P10627532A0739 NN O
( P10627532A0739 ( O
and P10627532A0739 CC O
activation P10627532A0739 NN O
) P10627532A0739 ) O
of P10627532A0739 IN O
the P10627532A0739 DT O
cellular P10627532A0739 JJ I-UN
transcription P10627532A0739 NN I-UN
factor P10627532A0739 NN I-UN
ATF2 P10627532A0739 NNP I-UN
. P10627532A0739 . O
. . O O

Protein P09363759A0000 NNP O
phosphatases P09363759A0000 VBZ O
play P09363759A0000 VB O
a P09363759A0000 DT O
critical P09363759A0000 JJ O
role P09363759A0000 NN O
in P09363759A0000 IN O
the P09363759A0000 DT O
regulation P09363759A0000 NN O
of P09363759A0000 IN O
the P09363759A0000 DT O
eukaryotic P09363759A0000 JJ O
cell P09363759A0000 NN O
cycle P09363759A0000 NN O
and P09363759A0000 CC O
signal P09363759A0000 JJ O
transduction P09363759A0000 NN O
. P09363759A0000 . O
. . O O

In P09489670A1157 IN O
C. P09489670A1157 NNP O
albicans P09489670A1157 NNS O
, P09489670A1157 , O
HST6 P09489670A1157 NNP I-UN
is P09489670A1157 VBZ O
expressed P09489670A1157 VBN O
constitutively P09489670A1157 RB O
at P09489670A1157 IN O
high P09489670A1157 JJ O
levels P09489670A1157 NNS O
in P09489670A1157 IN O
the P09489670A1157 DT O
different P09489670A1157 JJ O
cell P09489670A1157 NN O
types P09489670A1157 NNS O
analysed P09489670A1157 VBN O
( P09489670A1157 ( O
yeast P09489670A1157 UH O
, P09489670A1157 , O
hyphae P09489670A1157 JJ O
, P09489670A1157 , O
white P09489670A1157 JJ O
and P09489670A1157 CC O
opaque P09489670A1157 NN O
) P09489670A1157 ) O
, P09489670A1157 , O
demonstrating P09489670A1157 VBG O
that P09489670A1157 IN O
HST6 P09489670A1157 NNP I-UN
transcription P09489670A1157 NN O
is P09489670A1157 VBZ O
not P09489670A1157 RB O
repressed P09489670A1157 VBN O
in P09489670A1157 IN O
this P09489670A1157 DT O
diploid P09489670A1157 NN O
yeast P09489670A1157 NN O
, P09489670A1157 , O
unlike P09489670A1157 IN O
in P09489670A1157 IN O
diploid P09489670A1157 NN O
S. P09489670A1157 NNP O
cerevisiae P09489670A1157 NN O
, P09489670A1157 , O
and P09489670A1157 CC O
suggesting P09489670A1157 VBG O
a P09489670A1157 DT O
basic P09489670A1157 JJ O
biological P09489670A1157 JJ O
function P09489670A1157 NN O
for P09489670A1157 IN O
the P09489670A1157 DT O
Hst6p P09489670A1157 NNP I-UN
transporter P09489670A1157 NN O
in P09489670A1157 IN O
C. P09489670A1157 NNP O
albicans P09489670A1157 NNS O
. P09489670A1157 . O
. . O O

Biol P09278441A0163 NNP O
. P09278441A0163 . O
. . O O

ERV1 P07954891T0000 NNP I-UN
is P07954891T0000 VBZ O
involved P07954891T0000 VBN O
in P07954891T0000 IN O
the P07954891T0000 DT O
cell-division P07954891T0000 NN O
cycle P07954891T0000 NN O
and P07954891T0000 CC O
the P07954891T0000 DT O
maintenance P07954891T0000 NN O
of P07954891T0000 IN O
mitochondrial P07954891T0000 JJ O
genomes P07954891T0000 NNS O
in P07954891T0000 IN O
Saccharomyces P07954891T0000 NNP O
cerevisiae P07954891T0000 NN O
. P07954891T0000 . O
. . O O

The P07487363A0447 DT O
serum P07487363A0447 NN O
levels P07487363A0447 NNS O
of P07487363A0447 IN O
IgE P07487363A0447 NNP I-UN
, P07487363A0447 , O
and P07487363A0447 CC O
asIgE P07487363A0447 NN I-UN
and P07487363A0447 CC O
IgG-4 P07487363A0447 NNP I-UN
against P07487363A0447 IN O
14 P07487363A0447 CD O
common P07487363A0447 JJ O
food P07487363A0447 NN O
allergens P07487363A0447 NNS O
were P07487363A0447 VBD O
determined P07487363A0447 VBN O
. P07487363A0447 . O
. . O O

Effects P04418687T0000 NNS O
of P04418687T0000 IN O
estrogen P04418687T0000 NN O
and P04418687T0000 CC O
glucocorticoids P04418687T0000 NNS O
on P04418687T0000 IN O
the P04418687T0000 DT O
adrenal P04418687T0000 JJ O
development P04418687T0000 NN O
of P04418687T0000 IN O
the P04418687T0000 DT O
fetus P04418687T0000 NN O
. P04418687T0000 . O
. . O O

In P10455183A0530 IN O
contrast P10455183A0530 NN O
, P10455183A0530 , O
the P10455183A0530 DT O
xtRNA P10455183A0530 NNP I-UN
( P10455183A0530 ( O
Sec P10455183A0530 NNP I-UN
) P10455183A0530 ) O
gene P10455183A0530 NN O
needs P10455183A0530 VBZ O
the P10455183A0530 DT O
binding P10455183A0530 NN O
of P10455183A0530 IN O
the P10455183A0530 DT O
seven P10455183A0530 CD O
Staf P10455183A0530 NNP I-UN
zinc P10455183A0530 NN I-UN
fingers P10455183A0530 NNS I-UN
, P10455183A0530 , O
but P10455183A0530 CC O
not P10455183A0530 RB O
Oct-1 P10455183A0530 NNP I-UN
, P10455183A0530 , O
for P10455183A0530 IN O
optimal P10455183A0530 JJ O
transcriptional P10455183A0530 JJ O
capacity P10455183A0530 NN O
. P10455183A0530 . O
. . O O

Renin P05362866T0000 NNP I-UN
secretion P05362866T0000 NN O
in P05362866T0000 IN O
essential P05362866T0000 JJ O
and P05362866T0000 CC O
accelerated P05362866T0000 JJ O
hypertension P05362866T0000 NN O
. P05362866T0000 . O
. . O O

These P01547775A1024 DT O
data P01547775A1024 NNS O
support P01547775A1024 NN O
a P01547775A1024 DT O
possible P01547775A1024 JJ O
biological P01547775A1024 JJ O
significance P01547775A1024 NN O
of P01547775A1024 IN O
the P01547775A1024 DT O
frameshift P01547775A1024 NN O
to P01547775A1024 TO O
occur P01547775A1024 VB O
at P01547775A1024 IN O
this P01547775A1024 DT O
position P01547775A1024 NN O
of P01547775A1024 IN O
the P01547775A1024 DT O
large P01547775A1024 JJ O
overlap P01547775A1024 NN O
by P01547775A1024 IN O
including P01547775A1024 VBG O
the P01547775A1024 DT O
putative P01547775A1024 JJ O
RNA P01547775A1024 NNP O
template-binding P01547775A1024 JJ O
site P01547775A1024 NN O
of P01547775A1024 IN O
the P01547775A1024 DT O
PLRV P01547775A1024 NNP I-UN
replicase P01547775A1024 NN I-UN
in P01547775A1024 IN O
the P01547775A1024 DT O
ORF2a P01547775A1024 NNP I-UN
/ P01547775A1024 NNP I-UN
ORF2b P01547775A1024 NNP I-UN
transframe P01547775A1024 NN I-UN
protein P01547775A1024 NN I-UN
. P01547775A1024 . O
. . O O

Sequence P09326246A0567 NNP O
analysis P09326246A0567 NN O
of P09326246A0567 IN O
this P09326246A0567 DT O
region P09326246A0567 NN O
revealed P09326246A0567 VBD O
three P09326246A0567 CD O
eight-bp P09326246A0567 JJ O
repetitive P09326246A0567 JJ O
elements P09326246A0567 NNS O
, P09326246A0567 , O
the P09326246A0567 DT O
deletion P09326246A0567 NN O
of P09326246A0567 IN O
which P09326246A0567 WDT O
restored P09326246A0567 VBD O
wild-type P09326246A0567 JJ O
levels P09326246A0567 NNS O
of P09326246A0567 IN O
luciferase P09326246A0567 NN I-UN
activity P09326246A0567 NN O
to P09326246A0567 TO O
the P09326246A0567 DT O
-916-bp P09326246A0567 NNP O
reporter P09326246A0567 NN O
plasmid P09326246A0567 NN O
. P09326246A0567 . O
. . O O

Moreover P09463380A1050 RB O
, P09463380A1050 , O
xTAK1KN P09463380A1050 NNP I-UN
could P09463380A1050 MD O
block P09463380A1050 VB O
the P09463380A1050 DT O
expression P09463380A1050 NN O
of P09463380A1050 IN O
ventral P09463380A1050 JJ O
mesoderm P09463380A1050 NN O
marker P09463380A1050 NN O
genes P09463380A1050 NNS O
induced P09463380A1050 VBN O
by P09463380A1050 IN O
Smad1 P09463380A1050 NNP I-UN
or P09463380A1050 CC I-UN
5 P09463380A1050 CD I-UN
. P09463380A1050 . O
. . O O

Although P01396432A0388 IN O
a P01396432A0388 DT O
wide P01396432A0388 JJ O
range P01396432A0388 NN O
of P01396432A0388 IN O
cognitive P01396432A0388 JJ O
functions P01396432A0388 NNS O
had P01396432A0388 VBD O
been P01396432A0388 VBN O
tested P01396432A0388 VBN O
, P01396432A0388 , O
all P01396432A0388 DT O
but P01396432A0388 CC O
one P01396432A0388 CD O
seizure P01396432A0388 NN O
occurred P01396432A0388 VBD O
during P01396432A0388 IN O
assessment P01396432A0388 NN O
of P01396432A0388 IN O
memory P01396432A0388 NN O
performance P01396432A0388 NN O
. P01396432A0388 . O
. . O O

Hydrallazine P06394347A1024 NNP O
also P06394347A1024 RB O
caused P06394347A1024 VBD O
a P06394347A1024 DT O
slight P06394347A1024 JJ O
increase P06394347A1024 NN O
in P06394347A1024 IN O
plasma P06394347A1024 JJ I-UN
renin P06394347A1024 NN I-UN
activity P06394347A1024 NN O
and P06394347A1024 CC O
urinary P06394347A1024 JJ O
excretion P06394347A1024 NN O
of P06394347A1024 IN O
noradrenaline P06394347A1024 NN O
. P06394347A1024 . O
. . O O

The P07473742A0187 DT O
protein P07473742A0187 NN I-UN
ELT-1 P07473742A0187 NNP I-UN
, P07473742A0187 , O
encoded P07473742A0187 VBN O
by P07473742A0187 IN O
a P07473742A0187 DT O
single-copy P07473742A0187 JJ O
gene P07473742A0187 NN O
homologous P07473742A0187 JJ O
to P07473742A0187 TO O
the P07473742A0187 DT O
GATA P07473742A0187 NNP I-UN
family P07473742A0187 NN I-UN
of P07473742A0187 IN I-UN
vertebrate P07473742A0187 JJ I-UN
transcription P07473742A0187 NN I-UN
factors P07473742A0187 NNS I-UN
, P07473742A0187 , O
is P07473742A0187 VBZ O
potentially P07473742A0187 RB O
capable P07473742A0187 JJ O
of P07473742A0187 IN O
interacting P07473742A0187 VBG O
with P07473742A0187 IN O
this P07473742A0187 DT O
element P07473742A0187 NN O
. P07473742A0187 . O
. . O O

Genomic P09756895A0322 NNP O
locus P09756895A0322 NN O
of P09756895A0322 IN O
chCTCF P09756895A0322 NN I-UN
contains P09756895A0322 VBZ O
a P09756895A0322 DT O
GC-rich P09756895A0322 JJ O
untranslated P09756895A0322 JJ O
exon P09756895A0322 NN O
separated P09756895A0322 VBN O
from P09756895A0322 IN O
seven P09756895A0322 CD O
coding P09756895A0322 VBG O
exons P09756895A0322 NNS O
by P09756895A0322 IN O
a P09756895A0322 DT O
long P09756895A0322 JJ O
intron P09756895A0322 NN O
. P09756895A0322 . O
. . O O

METHODS P10520800A0307 NNS O
: P10520800A0307 : O
We P10520800A0307 PRP O
studied P10520800A0307 VBD O
20 P10520800A0307 CD O
symptomatic P10520800A0307 JJ O
patients P10520800A0307 NNS O
with P10520800A0307 IN O
HOCM P10520800A0307 NNP O
( P10520800A0307 ( O
12 P10520800A0307 CD O
men P10520800A0307 NNS O
) P10520800A0307 ) O
, P10520800A0307 , O
mean P10520800A0307 JJ O
age P10520800A0307 NN O
52 P10520800A0307 CD O
+ P10520800A0307 NN O
/ P10520800A0307 NNP O
- P10520800A0307 : O
17 P10520800A0307 CD O
years P10520800A0307 NNS O
, P10520800A0307 , O
before P10520800A0307 IN O
and P10520800A0307 CC O
after P10520800A0307 IN O
septal P10520800A0307 JJ O
reduction P10520800A0307 NN O
using P10520800A0307 VBG O
echocardiography P10520800A0307 NN O
and P10520800A0307 CC O
electrocardiogram P10520800A0307 NN O
( P10520800A0307 ( O
ECG P10520800A0307 NNP O
) P10520800A0307 ) O
. P10520800A0307 . O
. . O O

Sci P02144290A1444 NNP O
. P02144290A1444 . O
. . O O

Ultrastructural P03449358T0001 JJ O
study P03449358T0001 NN O
of P03449358T0001 IN O
polyarteritis P03449358T0001 NN O
. P03449358T0001 . O
. . O O

The P11899489A0119 DT O
effects P11899489A0119 NNS O
of P11899489A0119 IN O
pharmacological P11899489A0119 JJ O
treatment P11899489A0119 NN O
and P11899489A0119 CC O
professional P11899489A0119 JJ O
care P11899489A0119 NN O
and P11899489A0119 CC O
support P11899489A0119 NN O
may P11899489A0119 MD O
improve P11899489A0119 VB O
when P11899489A0119 WRB O
dementia P11899489A0119 NN O
is P11899489A0119 VBZ O
detected P11899489A0119 VBN O
in P11899489A0119 IN O
an P11899489A0119 DT O
early P11899489A0119 JJ O
stage P11899489A0119 NN O
. P11899489A0119 . O
. . O O

Structural P09015757T0000 JJ O
analysis P09015757T0000 NN O
and P09015757T0000 CC O
characterization P09015757T0000 NN O
of P09015757T0000 IN O
tissue P09015757T0000 NN O
and P09015757T0000 CC O
hormonal P09015757T0000 JJ O
responsive P09015757T0000 JJ O
expression P09015757T0000 NN O
of P09015757T0000 IN O
the P09015757T0000 DT O
avian P09015757T0000 JJ I-UN
bone P09015757T0000 NN I-UN
sialoprotein P09015757T0000 NN I-UN
( P09015757T0000 ( O
BSP P09015757T0000 NNP I-UN
) P09015757T0000 ) O
gene P09015757T0000 NN O
. P09015757T0000 . O
. . O O

Induction P09351242A0719 NN O
of P09351242A0719 IN O
AtP5CS1 P09351242A0719 NNP I-UN
mRNA P09351242A0719 FW I-UN
accumulation P09351242A0719 NN O
in P09351242A0719 IN O
salt-treated P09351242A0719 JJ O
seedlings P09351242A0719 NNS O
involves P09351242A0719 VBZ O
an P09351242A0719 DT O
immediate P09351242A0719 JJ O
early P09351242A0719 JJ O
transcriptional P09351242A0719 JJ O
response P09351242A0719 NN O
regulated P09351242A0719 VBN O
by P09351242A0719 IN O
ABA P09351242A0719 NNP O
signalling P09351242A0719 VBG O
that P09351242A0719 DT O
is P09351242A0719 VBZ O
not P09351242A0719 RB O
inhibited P09351242A0719 VBN O
by P09351242A0719 IN O
cycloheximide P09351242A0719 NN O
, P09351242A0719 , O
but P09351242A0719 CC O
abolished P09351242A0719 VBN O
by P09351242A0719 IN O
the P09351242A0719 DT O
deficiency P09351242A0719 NN O
of P09351242A0719 IN O
ABA P09351242A0719 NNP O
biosynthesis P09351242A0719 NN O
in P09351242A0719 IN O
the P09351242A0719 DT O
aba1 P09351242A0719 JJ I-UN
Arabidopsis P09351242A0719 NNP I-UN
mutant P09351242A0719 NN I-UN
. P09351242A0719 . O
. . O O

Transformation P11085267A0562 NN O
of P11085267A0562 IN O
the P11085267A0562 DT O
sconC3 P11085267A0562 NN I-UN
mutant P11085267A0562 NN I-UN
with P11085267A0562 IN O
sconB+ P11085267A0562 JJ I-UN
restores P11085267A0562 NNS O
the P11085267A0562 DT O
wild-type P11085267A0562 JJ O
phenotype P11085267A0562 NN O
. P11085267A0562 . O
. . O O

We P03981640A0168 PRP O
have P03981640A0168 VBP O
now P03981640A0168 RB O
located P03981640A0168 VBN O
the P03981640A0168 DT O
5 P03981640A0168 CD O
' P03981640A0168 POS O
ends P03981640A0168 NNS O
of P03981640A0168 IN O
the P03981640A0168 DT O
two P03981640A0168 CD O
remaining P03981640A0168 VBG O
late P03981640A0168 JJ O
mRNAs P03981640A0168 NN O
. P03981640A0168 . O
. . O O

E P00996364X0000 NN O
50 P00996364X0000 CD O
, P00996364X0000 , O
843 P00996364X0000 CD O
( P00996364X0000 ( O
1994 P00996364X0000 CD O
) P00996364X0000 ) O
] P00996364X0000 NN O
. P00996364X0000 . O
. . O O

The P02597549A0964 DT O
two P02597549A0964 CD O
most P02597549A0964 RBS O
recent P02597549A0964 JJ O
patients P02597549A0964 NNS O
( P02597549A0964 ( O
35 P02597549A0964 CD O
and P02597549A0964 CC O
132 P02597549A0964 CD O
days P02597549A0964 NNS O
) P02597549A0964 ) O
received P02597549A0964 VBD O
only P02597549A0964 RB O
oral P02597549A0964 JJ O
dipyridamole P02597549A0964 NN O
( P02597549A0964 ( O
75 P02597549A0964 CD O
mg P02597549A0964 NN O
X P02597549A0964 NNP O
3 P02597549A0964 CD O
/ P02597549A0964 NNP O
day P02597549A0964 NN O
) P02597549A0964 ) O
and P02597549A0964 CC O
aspirin P02597549A0964 NN O
( P02597549A0964 ( O
80 P02597549A0964 CD O
mg P02597549A0964 NNS O
/ P02597549A0964 JJ O
day P02597549A0964 NN O
) P02597549A0964 ) O
after P02597549A0964 IN O
the P02597549A0964 DT O
early P02597549A0964 JJ O
recovery P02597549A0964 NN O
period P02597549A0964 NN O
( P02597549A0964 ( O
four-six P02597549A0964 JJ O
days P02597549A0964 NNS O
) P02597549A0964 ) O
, P02597549A0964 , O
resulting P02597549A0964 VBG O
in P02597549A0964 IN O
normal P02597549A0964 JJ O
prothrombin P02597549A0964 NN I-UN
and P02597549A0964 CC O
partial P02597549A0964 JJ O
thromboplastin P02597549A0964 NN I-UN
times P02597549A0964 NNS O
. P02597549A0964 . O
. . O O

These P11222639A1273 DT O
results P11222639A1273 NNS O
suggested P11222639A1273 VBD O
a P11222639A1273 DT O
critical P11222639A1273 JJ O
role P11222639A1273 NN O
for P11222639A1273 IN O
tyrosine P11222639A1273 NN O
residue P11222639A1273 JJ O
1229 P11222639A1273 CD O
in P11222639A1273 IN O
the P11222639A1273 DT O
regulation P11222639A1273 NN O
of P11222639A1273 IN O
L1 P11222639A1273 NNP I-UN
endocytosis P11222639A1273 NN O
. P11222639A1273 . O
. . O O

The P06298720A0893 DT O
strong P06298720A0893 JJ O
conservation P06298720A0893 NN O
of P06298720A0893 IN O
the P06298720A0893 DT O
inverted P06298720A0893 JJ O
terminal P06298720A0893 JJ O
repeat P06298720A0893 NN O
sequence P06298720A0893 NN O
may P06298720A0893 MD O
reflect P06298720A0893 VB O
a P06298720A0893 DT O
common P06298720A0893 JJ O
integration P06298720A0893 NN O
mechanism P06298720A0893 NN O
for P06298720A0893 IN O
VL30 P06298720A0893 NNP I-UN
elements P06298720A0893 NNS I-UN
and P06298720A0893 CC O
MuLV P06298720A0893 NNP O
proviruses P06298720A0893 NNS O
. P06298720A0893 . O
. . O O

The P08569443A0123 DT O
purpose P08569443A0123 NN O
of P08569443A0123 IN O
the P08569443A0123 DT O
study P08569443A0123 NN O
reported P08569443A0123 VBD O
here P08569443A0123 RB O
was P08569443A0123 VBD O
to P08569443A0123 TO O
investigate P08569443A0123 VB O
whether P08569443A0123 IN O
differences P08569443A0123 NNS O
in P08569443A0123 IN O
T1 P08569443A0123 NNP O
and P08569443A0123 CC O
T2 P08569443A0123 NNP O
between P08569443A0123 IN O
tumors P08569443A0123 NNS O
are P08569443A0123 VBP O
mainly P08569443A0123 RB O
a P08569443A0123 DT O
consequence P08569443A0123 NN O
of P08569443A0123 IN O
differences P08569443A0123 NNS O
in P08569443A0123 IN O
the P08569443A0123 DT O
fractional P08569443A0123 JJ O
volume P08569443A0123 NN O
of P08569443A0123 IN O
the P08569443A0123 DT O
extracellular P08569443A0123 JJ O
compartment P08569443A0123 NN O
. P08569443A0123 . O
. . O O

3 P09639565A0225 LS O
) P09639565A0225 ) O
and P09639565A0225 CC O
one P09639565A0225 CD O
distal P09639565A0225 NN O
( P09639565A0225 ( O
-11.8 P09639565A0225 JJ O
/ P09639565A0225 NNP O
-10.9 P09639565A0225 NNP O
) P09639565A0225 ) O
, P09639565A0225 , O
presented P09639565A0225 VBD O
an P09639565A0225 DT O
enhancer P09639565A0225 NN O
activity P09639565A0225 NN O
in P09639565A0225 IN O
pituitary P09639565A0225 JJ O
cells P09639565A0225 NNS O
when P09639565A0225 WRB O
placed P09639565A0225 VBN O
upstream P09639565A0225 NN O
of P09639565A0225 IN O
the P09639565A0225 DT O
SV40 P09639565A0225 NNP I-UN
promoter P09639565A0225 NN I-UN
. P09639565A0225 . O
. . O O

Differential P09371596T0000 NNP O
regulation P09371596T0000 NN O
of P09371596T0000 IN O
the P09371596T0000 DT O
pre-C P09371596T0000 NN I-UN
and P09371596T0000 CC O
pregenomic P09371596T0000 JJ O
promoters P09371596T0000 NNS O
of P09371596T0000 IN O
human P09371596T0000 JJ O
hepatitis P09371596T0000 NN O
B P09371596T0000 NNP O
virus P09371596T0000 NN O
by P09371596T0000 IN O
members P09371596T0000 NNS O
of P09371596T0000 IN O
the P09371596T0000 DT O
nuclear P09371596T0000 JJ I-UN
receptor P09371596T0000 NN I-UN
superfamily P09371596T0000 RB I-UN
. P09371596T0000 . O
. . O O

These P08083998A1723b DT O
results P08083998A1723b NNS O
suggest P08083998A1723b VBP O
that P08083998A1723b IN O
leader-mRNA P08083998A1723b JJ O
fusion P08083998A1723b NN O
in P08083998A1723b IN O
coronavirus P08083998A1723b JJ O
transcription P08083998A1723b NN O
does P08083998A1723b VBZ O
not P08083998A1723b RB O
require P08083998A1723b VB O
direct P08083998A1723b JJ O
RNA-RNA P08083998A1723b JJ O
interaction P08083998A1723b NN O
between P08083998A1723b IN O
complementary P08083998A1723b JJ O
sequences P08083998A1723b NNS O
. P08083998A1723b . O
. . O O

Isolation P08298129T0000 NN O
and P08298129T0000 CC O
characterization P08298129T0000 NN O
of P08298129T0000 IN O
a P08298129T0000 DT O
TATA-less P08298129T0000 JJ O
promoter P08298129T0000 NN O
for P08298129T0000 IN O
the P08298129T0000 DT O
human P08298129T0000 JJ I-UN
beta P08298129T0000 NN I-UN
3 P08298129T0000 CD I-UN
integrin P08298129T0000 JJ I-UN
gene P08298129T0000 NN I-UN
. P08298129T0000 . O
. . O O

ORFA P11114924A0808 NNP O
and P11114924A0808 CC O
ccdA P11114924A0808 NN I-UN
were P11114924A0808 VBD O
constitutively P11114924A0808 RB O
cotranscribed P11114924A0808 VBN O
as P11114924A0808 IN O
determined P11114924A0808 VBN O
by P11114924A0808 IN O
primer P11114924A0808 JJ O
extension P11114924A0808 NN O
analysis P11114924A0808 NN O
. P11114924A0808 . O
. . O O

Structural P09498553T0000 JJ O
and P09498553T0000 CC O
evolutionary P09498553T0000 JJ O
studies P09498553T0000 NNS O
on P09498553T0000 IN O
sterol P09498553T0000 NN I-UN
14-demethylase P09498553T0000 JJ I-UN
P450 P09498553T0000 NNP I-UN
( P09498553T0000 ( O
CYP51 P09498553T0000 NNP I-UN
) P09498553T0000 ) O
, P09498553T0000 , O
the P09498553T0000 DT O
most P09498553T0000 RBS O
conserved P09498553T0000 JJ O
P450 P09498553T0000 NNP I-UN
monooxygenase P09498553T0000 NN I-UN
: P09498553T0000 : O
I P09498553T0000 PRP O
. P09498553T0000 . O
. . O O

To P01930470A0337 TO O
lower P01930470A0337 VB O
the P01930470A0337 DT O
current P01930470A0337 JJ O
high P01930470A0337 JJ O
incidence P01930470A0337 NN O
of P01930470A0337 IN O
NANB-induced P01930470A0337 NNP O
PTH P01930470A0337 NNP O
, P01930470A0337 , O
in P01930470A0337 IN O
1986 P01930470A0337 CD O
, P01930470A0337 , O
the P01930470A0337 DT O
American P01930470A0337 NNP O
Association P01930470A0337 NNP O
of P01930470A0337 IN O
Blood P01930470A0337 NNP O
Banks P01930470A0337 NNP O
( P01930470A0337 ( O
AABB P01930470A0337 NNP O
) P01930470A0337 ) O
recommended P01930470A0337 VBD O
testing P01930470A0337 VBG O
for P01930470A0337 IN O
these P01930470A0337 DT O
PTH-associated P01930470A0337 JJ O
`` P01930470A0337 `` O
surrogate P01930470A0337 NN O
'' P01930470A0337 '' O
markers P01930470A0337 NNS O
on P01930470A0337 IN O
all P01930470A0337 DT O
donated P01930470A0337 VBN O
units P01930470A0337 NNS O
of P01930470A0337 IN O
blood P01930470A0337 NN O
. P01930470A0337 . O
. . O O

Fufang P01910505A0000 NNP O
wuzi P01910505A0000 NN O
yanzong P01910505A0000 RB O
pills P01910505A0000 NNS O
have P01910505A0000 VBP O
strong P01910505A0000 JJ O
leukogenic P01910505A0000 JJ O
effect P01910505A0000 NN O
on P01910505A0000 IN O
cyclophosphamide P01910505A0000 NN O
induced P01910505A0000 VBN O
leukopenia P01910505A0000 NN O
in P01910505A0000 IN O
mice P01910505A0000 NN O
. P01910505A0000 . O
. . O O

CONCLUSIONS P11552724A0527 NN O
: P11552724A0527 : O
ChromaFlo-enhanced P11552724A0527 JJ O
IVUS P11552724A0527 NNP O
demonstrates P11552724A0527 VBZ O
colorized P11552724A0527 VBN O
blood P11552724A0527 NN O
flow P11552724A0527 NN O
inside P11552724A0527 IN O
the P11552724A0527 DT O
vessel P11552724A0527 JJ O
lumen P11552724A0527 NNS O
, P11552724A0527 , O
which P11552724A0527 WDT O
is P11552724A0527 VBZ O
helpful P11552724A0527 JJ O
in P11552724A0527 IN O
distinguishing P11552724A0527 VBG O
echolucent P11552724A0527 JJ O
disease P11552724A0527 NN O
from P11552724A0527 IN O
luminal P11552724A0527 JJ O
blood P11552724A0527 NN O
flow P11552724A0527 NN O
and P11552724A0527 CC O
can P11552724A0527 MD O
also P11552724A0527 RB O
be P11552724A0527 VB O
used P11552724A0527 VBN O
to P11552724A0527 TO O
perform P11552724A0527 VB O
peripheral P11552724A0527 JJ O
interventions P11552724A0527 NNS O
in P11552724A0527 IN O
patients P11552724A0527 NNS O
with P11552724A0527 IN O
renal P11552724A0527 JJ O
failure P11552724A0527 NN O
or P11552724A0527 CC O
allergy P11552724A0527 NN O
, P11552724A0527 , O
avoiding P11552724A0527 VBG O
the P11552724A0527 DT O
use P11552724A0527 NN O
of P11552724A0527 IN O
contrast P11552724A0527 NN O
media P11552724A0527 NNS O
. P11552724A0527 . O
. . O O

Caution P01190251A0335 NN O
should P01190251A0335 MD O
be P01190251A0335 VB O
exercised P01190251A0335 VBN O
in P01190251A0335 IN O
the P01190251A0335 DT O
use P01190251A0335 NN O
of P01190251A0335 IN O
these P01190251A0335 DT O
dyes P01190251A0335 NNS O
for P01190251A0335 IN O
lymphograms P01190251A0335 NNS O
. P01190251A0335 . O
. . O O

Comparison P07914507A1029 NNP O
of P07914507A1029 IN O
cDNA P07914507A1029 NN O
sequences P07914507A1029 NNS O
revealed P07914507A1029 VBD O
that P07914507A1029 IN O
the P07914507A1029 DT O
two P07914507A1029 CD O
mRNA P07914507A1029 NN O
species P07914507A1029 NNS O
arise P07914507A1029 VBP O
as P07914507A1029 IN O
a P07914507A1029 DT O
result P07914507A1029 NN O
of P07914507A1029 IN O
alternate P07914507A1029 NN O
use P07914507A1029 NN O
of P07914507A1029 IN O
poly P07914507A1029 NN O
( P07914507A1029 ( O
A P07914507A1029 DT O
) P07914507A1029 ) O
-addition P07914507A1029 NN O
sites P07914507A1029 NNS O
. P07914507A1029 . O
. . O O

The P09712859A1110 DT O
binding P09712859A1110 NN O
of P09712859A1110 IN O
NF-ATp P09712859A1110 NNP I-UN
, P09712859A1110 , O
although P09712859A1110 IN O
not P09712859A1110 RB O
NF-AT4 P09712859A1110 NNP I-UN
, P09712859A1110 , O
to P09712859A1110 TO O
this P09712859A1110 DT O
enhancer P09712859A1110 NN O
also P09712859A1110 RB O
occurs P09712859A1110 VBZ O
along P09712859A1110 IN O
with P09712859A1110 IN O
HTLV-I-mediated P09712859A1110 JJ O
infection P09712859A1110 NN O
of P09712859A1110 IN O
human P09712859A1110 JJ O
peripheral P09712859A1110 JJ O
blood P09712859A1110 NN O
T-cells P09712859A1110 NNP O
. P09712859A1110 . O
. . O O

Treatment P08711631A0989 NN O
is P08711631A0989 VBZ O
instituted P08711631A0989 VBN O
with P08711631A0989 IN O
prednisone P08711631A0989 NN O
and P08711631A0989 CC O
cyclophosphamide P08711631A0989 NN O
. P08711631A0989 . O
. . O O

It P07942076A0497 PRP O
was P07942076A0497 VBD O
shown P07942076A0497 VBN O
that P07942076A0497 IN O
estradiol P07942076A0497 JJ O
concentrations P07942076A0497 NNS O
obtained P07942076A0497 VBN O
after P07942076A0497 IN O
estradiol P07942076A0497 JJ O
valerate P07942076A0497 NN O
and P07942076A0497 CC O
micronized P07942076A0497 VBN O
estradiol P07942076A0497 JJ O
ingestion P07942076A0497 NN O
were P07942076A0497 VBD O
dependent P07942076A0497 JJ O
on P07942076A0497 IN O
the P07942076A0497 DT O
patient P07942076A0497 NN O
's P07942076A0497 POS O
age P07942076A0497 NN O
as P07942076A0497 RB O
well P07942076A0497 RB O
as P07942076A0497 IN O
on P07942076A0497 IN O
the P07942076A0497 DT O
constitutional P07942076A0497 JJ O
type P07942076A0497 NN O
. P07942076A0497 . O
. . O O

BACKGROUND P09518383A0000 NNP O
AND P09518383A0000 CC O
OBJECTIVES P09518383A0000 NNP O
: P09518383A0000 : O
The P09518383A0000 DT O
sexually P09518383A0000 RB O
transmitted P09518383A0000 VBN O
diseases P09518383A0000 NNS O
( P09518383A0000 ( O
STD P09518383A0000 NNP O
) P09518383A0000 ) O
control P09518383A0000 NN O
program P09518383A0000 NN O
for P09518383A0000 IN O
female P09518383A0000 JJ O
sex P09518383A0000 NN O
workers P09518383A0000 NNS O
( P09518383A0000 ( O
FSW P09518383A0000 NNP O
) P09518383A0000 ) O
in P09518383A0000 IN O
Lima P09518383A0000 NNP O
, P09518383A0000 , O
Peru P09518383A0000 NNP O
, P09518383A0000 , O
provided P09518383A0000 VBD O
periodic P09518383A0000 JJ O
serological P09518383A0000 JJ O
tests P09518383A0000 NNS O
for P09518383A0000 IN O
syphilis P09518383A0000 NN O
and P09518383A0000 CC O
cervical P09518383A0000 JJ O
smears P09518383A0000 NNS O
for P09518383A0000 IN O
gonococci P09518383A0000 NN O
, P09518383A0000 , O
but P09518383A0000 CC O
not P09518383A0000 RB O
medication P09518383A0000 NN O
for P09518383A0000 IN O
STD P09518383A0000 NNP O
or P09518383A0000 CC O
condoms P09518383A0000 NNS O
. P09518383A0000 . O
. . O O

( P07821790A1084 ( O
iv P07821790A1084 NN O
) P07821790A1084 ) O
Although P07821790A1084 IN O
UCRBP P07821790A1084 NNP I-UN
has P07821790A1084 VBZ O
been P07821790A1084 VBN O
previously P07821790A1084 RB O
shown P07821790A1084 VBN O
to P07821790A1084 TO O
act P07821790A1084 VB O
as P07821790A1084 IN O
a P07821790A1084 DT O
transcriptional P07821790A1084 JJ O
repressor P07821790A1084 NN O
, P07821790A1084 , O
we P07821790A1084 PRP O
show P07821790A1084 VBP O
here P07821790A1084 RB O
that P07821790A1084 IN O
UCRBP P07821790A1084 NNP I-UN
can P07821790A1084 MD O
also P07821790A1084 RB O
act P07821790A1084 VB O
as P07821790A1084 IN O
a P07821790A1084 DT O
positive P07821790A1084 JJ O
transactivator P07821790A1084 NN O
of P07821790A1084 IN O
a P07821790A1084 DT O
reporter P07821790A1084 NN O
driven P07821790A1084 VBN O
by P07821790A1084 IN O
UCR P07821790A1084 NNP O
elements P07821790A1084 NNS O
when P07821790A1084 WRB O
used P07821790A1084 VBN O
in P07821790A1084 IN O
co-transfection P07821790A1084 NN O
assays P07821790A1084 NNS O
. P07821790A1084 . O
. . O O

Mus81p P10905349A0329 NNP I-UN
also P10905349A0329 RB O
shares P10905349A0329 NNS O
homology P10905349A0329 VBP O
with P10905349A0329 IN O
motifs P10905349A0329 NNS O
found P10905349A0329 VBN O
in P10905349A0329 IN O
the P10905349A0329 DT O
XPF P10905349A0329 NNP I-UN
endonuclease P10905349A0329 NN I-UN
superfamily P10905349A0329 RB I-UN
. P10905349A0329 . O
. . O O

Problems P01553407T0000 NNS O
remain P01553407T0000 VBP O
to P01553407T0000 TO O
be P01553407T0000 VB O
resolved P01553407T0000 VBN O
in P01553407T0000 IN O
the P01553407T0000 DT O
area P01553407T0000 NN O
of P01553407T0000 IN O
quantitative P01553407T0000 JJ O
risk P01553407T0000 NN O
assessment P01553407T0000 NN O
. P01553407T0000 . O
. . O O

The P08647086A0720 DT O
Cdk2-cyclin-D1 P08647086A0720 NNP O
complex P08647086A0720 NN O
did P08647086A0720 VBD O
not P08647086A0720 RB O
phosphorylate P08647086A0720 VB O
any P08647086A0720 DT O
tested P08647086A0720 JJ O
substrates P08647086A0720 NNS O
, P08647086A0720 , O
such P08647086A0720 JJ O
as P08647086A0720 IN O
H1 P08647086A0720 NNP I-UN
histone P08647086A0720 NN I-UN
, P08647086A0720 , O
pRB P08647086A0720 NN I-UN
, P08647086A0720 , O
SV40 P08647086A0720 NNP I-UN
large P08647086A0720 JJ I-UN
T P08647086A0720 NNP I-UN
antigen P08647086A0720 NN I-UN
, P08647086A0720 , O
p53 P08647086A0720 NN I-UN
, P08647086A0720 , O
E2F-1 P08647086A0720 NNP I-UN
or P08647086A0720 CC O
a P08647086A0720 DT O
preparation P08647086A0720 NN O
of P08647086A0720 IN O
nuclear P08647086A0720 JJ O
proteins P08647086A0720 NNS O
from P08647086A0720 IN O
HeLa P08647086A0720 NNP O
cells P08647086A0720 NNS O
; P08647086A0720 : O
in P08647086A0720 IN O
contrast P08647086A0720 NN O
, P08647086A0720 , O
Cdk2-cyclin-E P08647086A0720 NNP O
and P08647086A0720 CC O
Cdk2-cyclin-A P08647086A0720 NNP O
phosphorylated P08647086A0720 VBD O
these P08647086A0720 DT O
proteins P08647086A0720 NNS O
. P08647086A0720 . O
. . O O

A P10498616A0157 DT O
G22V P10498616A0157 NNP I-UN
mutant P10498616A0157 NN I-UN
of P10498616A0157 IN O
M-Ras P10498616A0157 NNP I-UN
was P10498616A0157 VBD O
constitutively P10498616A0157 RB O
active P10498616A0157 JJ O
and P10498616A0157 CC O
its P10498616A0157 PRP$ O
expression P10498616A0157 NN O
in P10498616A0157 IN O
an P10498616A0157 DT O
interleukin-3 P10498616A0157 JJ I-UN
( P10498616A0157 ( O
IL-3 P10498616A0157 NNP I-UN
) P10498616A0157 ) O
-dependent P10498616A0157 VBD O
mast P10498616A0157 NN O
cell P10498616A0157 NN O
/ P10498616A0157 NNP O
megakaryocyte P10498616A0157 NN O
cell P10498616A0157 NN O
line P10498616A0157 NN O
resulted P10498616A0157 VBD O
in P10498616A0157 IN O
increased P10498616A0157 JJ O
survival P10498616A0157 NN O
in P10498616A0157 IN O
the P10498616A0157 DT O
absence P10498616A0157 NN O
of P10498616A0157 IN O
IL-3 P10498616A0157 NNP I-UN
, P10498616A0157 , O
increased P10498616A0157 VBD O
growth P10498616A0157 NN O
in P10498616A0157 IN O
IL-4 P10498616A0157 NNP I-UN
, P10498616A0157 , O
and P10498616A0157 CC O
, P10498616A0157 , O
at P10498616A0157 IN O
high P10498616A0157 JJ O
expression P10498616A0157 NN O
levels P10498616A0157 NNS O
, P10498616A0157 , O
in P10498616A0157 IN O
factor-independent P10498616A0157 JJ O
growth P10498616A0157 NN O
. P10498616A0157 . O
. . O O

In P10625438A1429 IN O
all P10625438A1429 DT O
tissues P10625438A1429 NNS O
examined P10625438A1429 VBN O
only P10625438A1429 RB O
transcripts P10625438A1429 NNS O
positive P10625438A1429 JJ O
for P10625438A1429 IN O
insert P10625438A1429 JJ O
3 P10625438A1429 CD O
, P10625438A1429 , O
an P10625438A1429 DT O
18 P10625438A1429 CD O
bp P10625438A1429 NN O
insertion P10625438A1429 NN O
in P10625438A1429 IN O
repeat P10625438A1429 NN O
21 P10625438A1429 CD O
, P10625438A1429 , O
were P10625438A1429 VBD O
amplified P10625438A1429 VBN O
, P10625438A1429 , O
even P10625438A1429 RB O
under P10625438A1429 IN O
conditions P10625438A1429 NNS O
in P10625438A1429 IN O
which P10625438A1429 WDT O
a P10625438A1429 DT O
30 P10625438A1429 CD O
% P10625438A1429 NN O
level P10625438A1429 NN O
of P10625438A1429 IN O
insert P10625438A1429 JJ O
3 P10625438A1429 CD O
negative P10625438A1429 JJ O
transcript P10625438A1429 NN O
could P10625438A1429 MD O
be P10625438A1429 VB O
easily P10625438A1429 RB O
detected P10625438A1429 VBN O
in P10625438A1429 IN O
artificially P10625438A1429 RB O
prepared P10625438A1429 JJ O
control P10625438A1429 NN O
samples P10625438A1429 NNS O
. P10625438A1429 . O
. . O O

Hydrocortisone P06479362A0680 NN O
seems P06479362A0680 VBZ O
to P06479362A0680 TO O
be P06479362A0680 VB O
unable P06479362A0680 JJ O
to P06479362A0680 TO O
hinder P06479362A0680 VB O
the P06479362A0680 DT O
postdenervation P06479362A0680 NN O
changes P06479362A0680 NNS O
in P06479362A0680 IN O
the P06479362A0680 DT O
muscle P06479362A0680 NN O
membrane P06479362A0680 NN O
whereas P06479362A0680 RB O
high P06479362A0680 JJ O
doses P06479362A0680 NNS O
of P06479362A0680 IN O
the P06479362A0680 DT O
hormone P06479362A0680 NN O
are P06479362A0680 VBP O
able P06479362A0680 JJ O
to P06479362A0680 TO O
induce P06479362A0680 VB O
changes P06479362A0680 NNS O
in P06479362A0680 IN O
the P06479362A0680 DT O
muscle P06479362A0680 NN O
membrane P06479362A0680 NN O
. P06479362A0680 . O
. . O O

On P04039307A0613 IN O
d P04039307A0613 NN O
112 P04039307A0613 CD O
, P04039307A0613 , O
progesterone P04039307A0613 NN O
was P04039307A0613 VBD O
higher P04039307A0613 JJR O
( P04039307A0613 ( O
P P04039307A0613 NNP O
less P04039307A0613 JJR O
than P04039307A0613 IN O
.05 P04039307A0613 NN O
) P04039307A0613 ) O
in P04039307A0613 IN O
hysterectomized P04039307A0613 JJ O
heifers P04039307A0613 NNS O
than P04039307A0613 IN O
in P04039307A0613 IN O
other P04039307A0613 JJ O
treatment P04039307A0613 NN O
groups P04039307A0613 NNS O
. P04039307A0613 . O
. . O O

Data P06224974A0833 NNS O
are P06224974A0833 VBP O
presented P06224974A0833 VBN O
hinting P06224974A0833 VBG O
that P06224974A0833 IN O
the P06224974A0833 DT O
15 P06224974A0833 CD O
beta-hydroxy- P06224974A0833 NN O
, P06224974A0833 , O
metabolite P06224974A0833 NN O
of P06224974A0833 IN O
CPA P06224974A0833 NNP O
may P06224974A0833 MD O
actually P06224974A0833 RB O
be P06224974A0833 VB O
the P06224974A0833 DT O
biologically P06224974A0833 RB O
active P06224974A0833 JJ O
agent P06224974A0833 NN O
. P06224974A0833 . O
. . O O

We P08425221A0000 PRP O
describe P08425221A0000 VBP O
a P08425221A0000 DT O
novel P08425221A0000 JJ O
cytoplasmic P08425221A0000 JJ I-UN
tyrosine P08425221A0000 NN I-UN
kinase P08425221A0000 NN I-UN
, P08425221A0000 , O
termed P08425221A0000 VBN O
BPK P08425221A0000 NNP I-UN
( P08425221A0000 ( O
B P08425221A0000 NNP I-UN
cell P08425221A0000 NN I-UN
progenitor P08425221A0000 NN I-UN
kinase P08425221A0000 NN I-UN
) P08425221A0000 ) O
, P08425221A0000 , O
which P08425221A0000 WDT O
is P08425221A0000 VBZ O
expressed P08425221A0000 VBN O
in P08425221A0000 IN O
all P08425221A0000 DT O
stages P08425221A0000 NNS O
of P08425221A0000 IN O
the P08425221A0000 DT O
B P08425221A0000 NNP O
lineage P08425221A0000 NN O
and P08425221A0000 CC O
in P08425221A0000 IN O
myeloid P08425221A0000 JJ O
cells P08425221A0000 NNS O
. P08425221A0000 . O
. . O O

Current P07278578T0001 JJ O
status P07278578T0001 NN O
of P07278578T0001 IN O
chemotherapy P07278578T0001 NN O
for P07278578T0001 IN O
Hodgkin P07278578T0001 NNP O
's P07278578T0001 POS O
disease P07278578T0001 NN O
. P07278578T0001 . O
. . O O

This P10765095A0308 DT O
study P10765095A0308 NN O
was P10765095A0308 VBD O
carried P10765095A0308 VBN O
out P10765095A0308 IN O
to P10765095A0308 TO O
analyze P10765095A0308 VB O
PRL P10765095A0308 NNP I-UN
secretion P10765095A0308 NN O
in P10765095A0308 IN O
metastatic P10765095A0308 JJ O
prostate P10765095A0308 NN O
cancer P10765095A0308 NN O
patients P10765095A0308 NNS O
both P10765095A0308 DT O
at P10765095A0308 IN O
basal P10765095A0308 NN O
conditions P10765095A0308 NNS O
and P10765095A0308 CC O
in P10765095A0308 IN O
response P10765095A0308 NN O
to P10765095A0308 TO O
L-Dopa P10765095A0308 NNP O
and P10765095A0308 CC O
metoclopramide P10765095A0308 NN O
, P10765095A0308 , O
which P10765095A0308 WDT O
represents P10765095A0308 VBZ O
the P10765095A0308 DT O
most P10765095A0308 RBS O
classical P10765095A0308 JJ O
inhibitory P10765095A0308 NN O
and P10765095A0308 CC O
stimulatory P10765095A0308 NN O
tests P10765095A0308 NNS O
for P10765095A0308 IN O
PRL P10765095A0308 NNP I-UN
secretion P10765095A0308 NN O
, P10765095A0308 , O
respectively P10765095A0308 RB O
. P10765095A0308 . O
. . O O

To P09157100A0583 TO O
determine P09157100A0583 VB O
if P09157100A0583 IN O
signing P09157100A0583 NN O
, P09157100A0583 , O
when P09157100A0583 WRB O
established P09157100A0583 VBN O
, P09157100A0583 , O
would P09157100A0583 MD O
compete P09157100A0583 VB O
with P09157100A0583 IN O
SIB P09157100A0583 NNP O
when P09157100A0583 WRB O
both P09157100A0583 DT O
were P09157100A0583 VBD O
reinforced P09157100A0583 VBN O
, P09157100A0583 , O
extinction P09157100A0583 NN O
was P09157100A0583 VBD O
then P09157100A0583 RB O
withdrawn P09157100A0583 NN O
. P09157100A0583 . O
. . O O

Cotransfection P08615012A0627 NN O
with P08615012A0627 IN O
the P08615012A0627 DT O
ie1 P08615012A0627 JJ I-UN
gene P08615012A0627 NN I-UN
resulted P08615012A0627 VBD O
in P08615012A0627 IN O
a P08615012A0627 DT O
dramatic P08615012A0627 JJ O
increase P08615012A0627 NN O
in P08615012A0627 IN O
the P08615012A0627 DT O
amount P08615012A0627 NN O
of P08615012A0627 IN O
the P08615012A0627 DT O
two P08615012A0627 CD O
enzymes P08615012A0627 NNS O
expressed P08615012A0627 VBN O
in P08615012A0627 IN O
the P08615012A0627 DT O
transfected P08615012A0627 JJ O
cells P08615012A0627 NNS O
. P08615012A0627 . O
. . O O

Autoionization P09903722T0000 NN O
rates P09903722T0000 NNS O
and P09903722T0000 CC O
energy P09903722T0000 NN O
levels P09903722T0000 NNS O
of P09903722T0000 IN O
triplet P09903722T0000 NN O
nf P09903722T0000 NN O
, P09903722T0000 , O
v=1 P09903722T0000 FW O
Rydberg P09903722T0000 NNP O
states P09903722T0000 NNS O
of P09903722T0000 IN O
H2 P09903722T0000 NNP O
. P09903722T0000 . O
. . O O

First P09382498A0618 RB O
, P09382498A0618 , O
two P09382498A0618 CD O
MCTs P09382498A0618 NNP O
using P09382498A0618 VBG O
a P09382498A0618 DT O
long P09382498A0618 JJ O
electrode P09382498A0618 NN O
, P09382498A0618 , O
3 P09382498A0618 CD O
cm P09382498A0618 NN O
in P09382498A0618 IN O
size P09382498A0618 NN O
, P09382498A0618 , O
were P09382498A0618 VBD O
performed P09382498A0618 VBN O
in P09382498A0618 IN O
the P09382498A0618 DT O
central P09382498A0618 JJ O
area P09382498A0618 NN O
of P09382498A0618 IN O
the P09382498A0618 DT O
tumor P09382498A0618 NN O
, P09382498A0618 , O
and P09382498A0618 CC O
eight P09382498A0618 CD O
MCTs P09382498A0618 NNP O
by P09382498A0618 IN O
a P09382498A0618 DT O
short P09382498A0618 JJ O
electrode P09382498A0618 NN O
, P09382498A0618 , O
2 P09382498A0618 CD O
cm P09382498A0618 NN O
in P09382498A0618 IN O
size P09382498A0618 NN O
, P09382498A0618 , O
were P09382498A0618 VBD O
done P09382498A0618 VBN O
in P09382498A0618 IN O
the P09382498A0618 DT O
peripheral P09382498A0618 JJ O
and P09382498A0618 CC O
surrounding P09382498A0618 VBG O
area P09382498A0618 NN O
of P09382498A0618 IN O
the P09382498A0618 DT O
tumor P09382498A0618 NN O
. P09382498A0618 . O
. . O O

The P09508775A0293 DT O
cAMP-dependent P09508775A0293 JJ O
mitogenic P09508775A0293 JJ O
pathway P09508775A0293 NN O
is P09508775A0293 VBZ O
unique P09508775A0293 JJ O
as P09508775A0293 IN O
it P09508775A0293 PRP O
is P09508775A0293 VBZ O
independent P09508775A0293 JJ O
of P09508775A0293 IN O
mitogen-activated P09508775A0293 JJ I-UN
protein P09508775A0293 NN I-UN
kinase P09508775A0293 NN I-UN
activation P09508775A0293 NN O
and P09508775A0293 CC O
differs P09508775A0293 NNS O
from P09508775A0293 IN O
growth P09508775A0293 NN O
factor-dependent P09508775A0293 JJ O
pathways P09508775A0293 NNS O
at P09508775A0293 IN O
the P09508775A0293 DT O
level P09508775A0293 NN O
of P09508775A0293 IN O
the P09508775A0293 DT O
expression P09508775A0293 NN O
of P09508775A0293 IN O
several P09508775A0293 JJ O
protooncogenes P09508775A0293 NNS O
/ P09508775A0293 JJ O
transcription P09508775A0293 NN O
factors P09508775A0293 NNS O
. P09508775A0293 . O
. . O O

The P01556068A0000 DT O
Klebsiella P01556068A0000 NNP I-UN
aerogenes P01556068A0000 NNS I-UN
gene P01556068A0000 NN I-UN
maoA P01556068A0000 NN I-UN
, P01556068A0000 , O
which P01556068A0000 WDT O
is P01556068A0000 VBZ O
involved P01556068A0000 VBN O
in P01556068A0000 IN O
the P01556068A0000 DT O
synthesis P01556068A0000 NN O
of P01556068A0000 IN O
monoamine P01556068A0000 NN I-UN
oxidase P01556068A0000 NN I-UN
, P01556068A0000 , O
was P01556068A0000 VBD O
induced P01556068A0000 VBN O
by P01556068A0000 IN O
tyramine P01556068A0000 NN O
and P01556068A0000 CC O
the P01556068A0000 DT O
related P01556068A0000 JJ O
compounds P01556068A0000 NNS O
, P01556068A0000 , O
subjected P01556068A0000 VBN O
to P01556068A0000 TO O
catabolite P01556068A0000 VB O
and P01556068A0000 CC O
ammonium P01556068A0000 VB O
ion P01556068A0000 NN O
repression P01556068A0000 NN O
, P01556068A0000 , O
and P01556068A0000 CC O
cloned P01556068A0000 VBD O
. P01556068A0000 . O
. . O O

Three P09173733A0404 CD O
different P09173733A0404 JJ O
techniques P09173733A0404 NNS O
of P09173733A0404 IN O
EA P09173733A0404 NNP O
analysis P09173733A0404 NN O
were P09173733A0404 VBD O
used P09173733A0404 VBN O
in P09173733A0404 IN O
the P09173733A0404 DT O
study P09173733A0404 NN O
: P09173733A0404 : O
1 P09173733A0404 CD O
) P09173733A0404 ) O
fast P09173733A0404 RB O
Fourier P09173733A0404 NNP O
transformation P09173733A0404 NN O
( P09173733A0404 ( O
FFT P09173733A0404 NNP O
) P09173733A0404 ) O
of P09173733A0404 IN O
EA P09173733A0404 NNP O
in P09173733A0404 IN O
a P09173733A0404 DT O
broad P09173733A0404 JJ O
band P09173733A0404 NN O
, P09173733A0404 , O
2 P09173733A0404 CD O
) P09173733A0404 ) O
developed P09173733A0404 VBN O
by P09173733A0404 IN O
us P09173733A0404 PRP O
alternative P09173733A0404 JJ O
method P09173733A0404 NN O
of P09173733A0404 IN O
non-harmonic P09173733A0404 JJ O
expansion P09173733A0404 NN O
of P09173733A0404 IN O
the P09173733A0404 DT O
EEG P09173733A0404 NNP O
curves P09173733A0404 VBZ O
taking P09173733A0404 VBG O
into P09173733A0404 IN O
account P09173733A0404 PDT O
their P09173733A0404 PRP$ O
shape P09173733A0404 NN O
, P09173733A0404 , O
3 P09173733A0404 CD O
) P09173733A0404 ) O
factor P09173733A0404 NN O
analysis P09173733A0404 NN O
of P09173733A0404 IN O
the P09173733A0404 DT O
EA P09173733A0404 NNP O
spectral P09173733A0404 JJ O
densities P09173733A0404 NNS O
. P09173733A0404 . O
. . O O

Conversely P07642544A0868 RB O
, P07642544A0868 , O
treatment P07642544A0868 NN O
of P07642544A0868 IN O
human P07642544A0868 JJ I-UN
protein-tyrosine P07642544A0868 JJ I-UN
phosphatase P07642544A0868 NN I-UN
alpha-overexpressing P07642544A0868 JJ O
cells P07642544A0868 NNS O
with P07642544A0868 IN O
phenylarsine P07642544A0868 JJ O
oxide P07642544A0868 NN O
led P07642544A0868 VBD O
to P07642544A0868 TO O
a P07642544A0868 DT O
loss P07642544A0868 NN O
of P07642544A0868 IN O
the P07642544A0868 DT O
constitutive P07642544A0868 JJ O
NF-kappa P07642544A0868 NNP I-UN
B P07642544A0868 NNP I-UN
activity P07642544A0868 NN O
. P07642544A0868 . O
. . O O

Other P11552058A0833 JJ O
therapies P11552058A0833 NNS O
are P11552058A0833 VBP O
also P11552058A0833 RB O
available P11552058A0833 JJ O
, P11552058A0833 , O
including P11552058A0833 VBG O
hypertonic P11552058A0833 JJ O
saline P11552058A0833 NN O
solution P11552058A0833 NN O
, P11552058A0833 , O
THAM P11552058A0833 NNP O
( P11552058A0833 ( O
Tris-hydroxy-methyl-aminomethane P11552058A0833 NNP O
) P11552058A0833 ) O
buffer P11552058A0833 NN O
, P11552058A0833 , O
and P11552058A0833 CC O
high-dose P11552058A0833 JJ O
barbiturates P11552058A0833 NNS O
. P11552058A0833 . O
. . O O

Interventions P11380837A1505 NNS O
aimed P11380837A1505 VBN O
at P11380837A1505 IN O
these P11380837A1505 DT O
specific P11380837A1505 JJ O
mediators P11380837A1505 NNS O
and P11380837A1505 CC O
processes P11380837A1505 NNS O
may P11380837A1505 MD O
be P11380837A1505 VB O
successful P11380837A1505 JJ O
in P11380837A1505 IN O
reducing P11380837A1505 VBG O
the P11380837A1505 DT O
very P11380837A1505 RB O
significant P11380837A1505 JJ O
human P11380837A1505 NN O
and P11380837A1505 CC O
economic P11380837A1505 JJ O
costs P11380837A1505 NNS O
of P11380837A1505 IN O
vascular P11380837A1505 JJ O
access P11380837A1505 NN O
dysfunction P11380837A1505 NN O
. P11380837A1505 . O
. . O O

Taste P02264601A0000 NNP O
reactivity P02264601A0000 NN O
tests P02264601A0000 NNS O
were P02264601A0000 VBD O
used P02264601A0000 VBN O
to P02264601A0000 TO O
examine P02264601A0000 VB O
the P02264601A0000 DT O
orofacial P02264601A0000 JJ O
responses P02264601A0000 NNS O
of P02264601A0000 IN O
alcohol P02264601A0000 NN O
preferring P02264601A0000 NN O
( P02264601A0000 ( O
P P02264601A0000 NNP O
) P02264601A0000 ) O
rats P02264601A0000 NNS O
and P02264601A0000 CC O
alcohol P02264601A0000 NN O
nonpreferring P02264601A0000 NN O
( P02264601A0000 ( O
NP P02264601A0000 NNP O
) P02264601A0000 ) O
rats P02264601A0000 VBZ O
to P02264601A0000 TO O
the P02264601A0000 DT O
taste P02264601A0000 NN O
of P02264601A0000 IN O
alcohol P02264601A0000 NN O
. P02264601A0000 . O
. . O O

Differences P02024625A0202 NNS O
in P02024625A0202 IN O
the P02024625A0202 DT O
clinical P02024625A0202 JJ O
presentation P02024625A0202 NN O
and P02024625A0202 CC O
the P02024625A0202 DT O
gross P02024625A0202 JJ O
appearance P02024625A0202 NN O
of P02024625A0202 IN O
the P02024625A0202 DT O
two P02024625A0202 CD O
cases P02024625A0202 NNS O
are P02024625A0202 VBP O
described P02024625A0202 VBN O
, P02024625A0202 , O
and P02024625A0202 CC O
similarities P02024625A0202 NNS O
in P02024625A0202 IN O
the P02024625A0202 DT O
microscopic P02024625A0202 NN O
features P02024625A0202 NNS O
are P02024625A0202 VBP O
discussed P02024625A0202 VBN O
. P02024625A0202 . O
. . O O

By P08975713A0454 IN O
screening P08975713A0454 VBG O
a P08975713A0454 DT O
cDNA P08975713A0454 NN O
library P08975713A0454 NN O
with P08975713A0454 IN O
a P08975713A0454 DT O
probe P08975713A0454 NN O
derived P08975713A0454 VBN O
from P08975713A0454 IN O
sequences P08975713A0454 NNS O
downstream P08975713A0454 NN O
of P08975713A0454 IN O
the P08975713A0454 DT O
p53p2 P08975713A0454 JJ I-UN
start P08975713A0454 NN O
site P08975713A0454 NN O
, P08975713A0454 , O
we P08975713A0454 PRP O
have P08975713A0454 VBP O
cloned P08975713A0454 VBN O
and P08975713A0454 CC O
characterized P08975713A0454 VBN O
a P08975713A0454 DT O
cDNA P08975713A0454 NN O
that P08975713A0454 WDT O
represents P08975713A0454 VBZ O
a P08975713A0454 DT O
mRNA P08975713A0454 NN O
that P08975713A0454 WDT O
appears P08975713A0454 VBZ O
to P08975713A0454 TO O
have P08975713A0454 VB O
been P08975713A0454 VBN O
initiated P08975713A0454 VBN O
from P08975713A0454 IN O
the P08975713A0454 DT O
p53p2 P08975713A0454 NN I-UN
promoter P08975713A0454 NN I-UN
. P08975713A0454 . O
. . O O

The P08302589A1132 DT O
HGF-induced P08302589A1132 NNP O
cell P08302589A1132 NN O
motility P08302589A1132 NN O
was P08302589A1132 VBD O
mimicked P08302589A1132 VBN O
by P08302589A1132 IN O
12-0-tetradecanoyl-phorbol-13-acetate P08302589A1132 JJ O
, P08302589A1132 , O
a P08302589A1132 DT O
protein P08302589A1132 JJ I-UN
kinase P08302589A1132 NN I-UN
C-activating P08302589A1132 NNP O
phorbol P08302589A1132 NN O
ester P08302589A1132 NN O
, P08302589A1132 , O
but P08302589A1132 CC O
not P08302589A1132 RB O
by P08302589A1132 IN O
Ca2+ P08302589A1132 NNP O
ionophore P08302589A1132 NN O
. P08302589A1132 . O
. . O O

The P11480555A0928 DT O
production P11480555A0928 NN O
of P11480555A0928 IN O
ceramide P11480555A0928 NN O
is P11480555A0928 VBZ O
emerging P11480555A0928 VBG O
as P11480555A0928 IN O
a P11480555A0928 DT O
fixture P11480555A0928 NN O
of P11480555A0928 IN O
programmed P11480555A0928 JJ O
cell P11480555A0928 NN O
death P11480555A0928 NN O
. P11480555A0928 . O
. . O O

A P09565576T0000 DT O
catalytic P09565576T0000 JJ O
domain P09565576T0000 NN O
of P09565576T0000 IN O
eukaryotic P09565576T0000 JJ I-UN
DNA P09565576T0000 NNP I-UN
topoisomerase P09565576T0000 NN I-UN
I P09565576T0000 PRP I-UN
. P09565576T0000 . O
. . O O

Transfection P10657238A0541 NN O
experiments P10657238A0541 NNS O
demonstrated P10657238A0541 VBD O
that P10657238A0541 IN O
the P10657238A0541 DT O
5'-flanking P10657238A0541 JJ O
region P10657238A0541 NN O
( P10657238A0541 ( O
-1894 P10657238A0541 UH O
to P10657238A0541 TO O
+37 P10657238A0541 VB O
) P10657238A0541 ) O
of P10657238A0541 IN O
the P10657238A0541 DT O
mStaf P10657238A0541 JJ I-UN
gene P10657238A0541 NN I-UN
drives P10657238A0541 NNS O
transcription P10657238A0541 NN O
in P10657238A0541 IN O
mouse P10657238A0541 NN O
NMuMG P10657238A0541 NNP O
cells P10657238A0541 NNS O
and P10657238A0541 CC O
that P10657238A0541 IN O
a P10657238A0541 DT O
construct P10657238A0541 NN O
containing P10657238A0541 VBG O
a P10657238A0541 DT O
fragment P10657238A0541 NN O
from P10657238A0541 IN O
-387 P10657238A0541 NN O
to P10657238A0541 TO O
+37 P10657238A0541 VB O
showed P10657238A0541 PDT O
the P10657238A0541 DT O
highest P10657238A0541 JJS O
transcriptional P10657238A0541 JJ O
activity P10657238A0541 NN O
. P10657238A0541 . O
. . O O

Effect P04428800T0001 NN O
of P04428800T0001 IN O
noise P04428800T0001 NN O
on P04428800T0001 IN O
CO-induced P04428800T0001 NNP O
increases P04428800T0001 NNS O
of P04428800T0001 IN O
LAP P04428800T0001 NNP I-UN
and P04428800T0001 CC O
GPT P04428800T0001 NNP I-UN
activity P04428800T0001 NN O
in P04428800T0001 IN O
the P04428800T0001 DT O
plasma P04428800T0001 NN O
of P04428800T0001 IN O
rats P04428800T0001 NNS O
. P04428800T0001 . O
. . O O

S6 P02236064A1178 NNP I-UN
kinase P02236064A1178 NN I-UN
activation P02236064A1178 NN O
requires P02236064A1178 VBZ O
displacement P02236064A1178 NN O
of P02236064A1178 IN O
this P02236064A1178 DT O
inhibitory P02236064A1178 NN O
segment P02236064A1178 NN O
, P02236064A1178 , O
which P02236064A1178 WDT O
is P02236064A1178 VBZ O
proposed P02236064A1178 VBN O
to P02236064A1178 TO O
occur P02236064A1178 VB O
consequent P02236064A1178 NN O
to P02236064A1178 TO O
its P02236064A1178 PRP$ O
multiple P02236064A1178 JJ O
phosphorylation P02236064A1178 NN O
. P02236064A1178 . O
. . O O

The P09057840A0946 DT O
recombinant P09057840A0946 JJ O
protein P09057840A0946 NN O
was P09057840A0946 VBD O
purified P09057840A0946 VBN O
to P09057840A0946 TO O
homogeneity P09057840A0946 NN O
by P09057840A0946 IN O
( P09057840A0946 ( O
NH4 P09057840A0946 NNP O
) P09057840A0946 ) O
2SO4-precipitation P09057840A0946 NN O
and P09057840A0946 CC O
affinity P09057840A0946 NN O
chromatography P09057840A0946 NN O
on P09057840A0946 IN O
5 P09057840A0946 CD O
' P09057840A0946 POS O
AMP-Sepharose P09057840A0946 JJ O
. P09057840A0946 . O
. . O O

However P08726024A0532 RB O
, P08726024A0532 , O
as P08726024A0532 IN O
determined P08726024A0532 VBN O
by P08726024A0532 IN O
PCR P08726024A0532 NNP O
with P08726024A0532 IN O
primers P08726024A0532 NNS O
specific P08726024A0532 VBP O
for P08726024A0532 IN O
the P08726024A0532 DT O
26-kDa P08726024A0532 JJ O
product P08726024A0532 NN O
, P08726024A0532 , O
the P08726024A0532 DT O
majority P08726024A0532 NN O
of P08726024A0532 IN O
cats P08726024A0532 NNS O
at P08726024A0532 IN O
2 P08726024A0532 CD O
and P08726024A0532 CC O
4 P08726024A0532 CD O
weeks P08726024A0532 NNS O
p.t P08726024A0532 NN O
. P08726024A0532 . O
had P08726024A0532 VBD O
gastric P08726024A0532 JJ O
fluid P08726024A0532 NN O
samples P08726024A0532 NNS O
which P08726024A0532 WDT O
were P08726024A0532 VBD O
positive P08726024A0532 JJ O
for P08726024A0532 IN O
H. P08726024A0532 NNP O
pylori P08726024A0532 NN O
and P08726024A0532 CC O
three P08726024A0532 CD O
of P08726024A0532 IN O
three P08726024A0532 CD O
cats P08726024A0532 NNS O
at P08726024A0532 IN O
2 P08726024A0532 CD O
weeks P08726024A0532 NNS O
p.t P08726024A0532 NN O
. P08726024A0532 . O
had P08726024A0532 VBD O
dental P08726024A0532 NN O
plaque P08726024A0532 NN O
which P08726024A0532 WDT O
was P08726024A0532 VBD O
positive P08726024A0532 JJ O
for P08726024A0532 IN O
H. P08726024A0532 NNP O
pylori P08726024A0532 NN O
. P08726024A0532 . O
. . O O

An P06588501T0059 DT O
experimental P06588501T0059 JJ O
long-term P06588501T0059 JJ O
study P06588501T0059 NN O
. P06588501T0059 . O
. . O O

Isolation P04828587T0000 NN O
of P04828587T0000 IN O
tha P04828587T0000 NN O
avian P04828587T0000 JJ O
reticuloendothelial P04828587T0000 JJ O
virus P04828587T0000 NN O
( P04828587T0000 ( O
strain P04828587T0000 JJ O
T P04828587T0000 NNP O
) P04828587T0000 ) O
. P04828587T0000 . O
. . O O

Breitbart P08455629A0335 NNP O
, P08455629A0335 , O
L P08455629A0335 NNP O
. P08455629A0335 . O
. . O O

The P03436529A1066 DT O
structure P03436529A1066 NN O
of P03436529A1066 IN O
the P03436529A1066 DT O
enhancer P03436529A1066 NN O
was P03436529A1066 VBD O
also P03436529A1066 RB O
probed P03436529A1066 VBN O
by P03436529A1066 IN O
inserting P03436529A1066 VBG O
a P03436529A1066 DT O
pair P03436529A1066 NN O
of P03436529A1066 IN O
complementary P03436529A1066 JJ O
synthetic P03436529A1066 JJ O
oligodeoxynucleotides P03436529A1066 NNS O
which P03436529A1066 WDT O
represented P03436529A1066 VBD O
the P03436529A1066 DT O
region P03436529A1066 NN O
between P03436529A1066 IN O
nt P03436529A1066 JJ O
positions P03436529A1066 NNS O
-235 P03436529A1066 VBP O
and P03436529A1066 CC O
-215 P03436529A1066 VBP O
into P03436529A1066 IN O
a P03436529A1066 DT O
truncated P03436529A1066 JJ O
template P03436529A1066 NN O
which P03436529A1066 WDT O
lacked P03436529A1066 VBD O
the P03436529A1066 DT O
enhancer P03436529A1066 NN O
. P03436529A1066 . O
. . O O

The P09123787A0486 DT O
electromyographically P09123787A0486 RB O
recorded P09123787A0486 JJ O
responses P09123787A0486 NNS O
consisted P09123787A0486 VBD O
of P09123787A0486 IN O
an P09123787A0486 DT O
early P09123787A0486 JJ O
R1 P09123787A0486 NNP O
response P09123787A0486 NN O
in P09123787A0486 IN O
the P09123787A0486 DT O
orbicularis P09123787A0486 JJ O
oculi P09123787A0486 JJ O
muscle P09123787A0486 NN O
ipsilateral P09123787A0486 JJ O
to P09123787A0486 TO O
the P09123787A0486 DT O
side P09123787A0486 NN O
of P09123787A0486 IN O
stimulation P09123787A0486 NN O
, P09123787A0486 , O
a P09123787A0486 DT O
bilateral P09123787A0486 JJ O
late P09123787A0486 JJ O
response P09123787A0486 NN O
( P09123787A0486 ( O
ipsilateral P09123787A0486 JJ O
R2 P09123787A0486 NNP O
and P09123787A0486 CC O
contralateral P09123787A0486 JJ O
Rc P09123787A0486 NNP O
) P09123787A0486 ) O
and P09123787A0486 CC O
a P09123787A0486 DT O
third P09123787A0486 JJ O
, P09123787A0486 , O
R3 P09123787A0486 NNP O
response P09123787A0486 NN O
, P09123787A0486 , O
in P09123787A0486 IN O
the P09123787A0486 DT O
ipsilateral P09123787A0486 JJ O
orbicularis P09123787A0486 NN O
oculi P09123787A0486 JJ O
muscle P09123787A0486 NN O
. P09123787A0486 . O
. . O O

One P09632709A0464 CD O
cDNA P09632709A0464 NN O
clone P09632709A0464 NN O
designated P09632709A0464 VBN O
NCoA-62 P09632709A0464 NNP O
, P09632709A0464 , O
encoded P09632709A0464 VBD O
a P09632709A0464 DT O
62 P09632709A0464 CD O
, P09632709A0464 , O
000-Da P09632709A0464 JJ O
protein P09632709A0464 NN O
that P09632709A0464 WDT O
is P09632709A0464 VBZ O
highly P09632709A0464 RB O
related P09632709A0464 VBN O
to P09632709A0464 TO O
BX42 P09632709A0464 NNP I-UN
, P09632709A0464 , O
a P09632709A0464 DT O
Drosophila P09632709A0464 NNP O
melanogaster P09632709A0464 NN O
nuclear P09632709A0464 JJ O
protein P09632709A0464 NN O
involved P09632709A0464 VBN O
in P09632709A0464 IN O
ecdysone-stimulated P09632709A0464 JJ O
gene P09632709A0464 NN O
expression P09632709A0464 NN O
. P09632709A0464 . O
. . O O

Each P08643633A1187 DT O
immunoprecipitate P08643633A1187 NN O
contained P08643633A1187 VBD O
a P08643633A1187 DT O
complex P08643633A1187 NN O
of P08643633A1187 IN O
N1 P08643633A1187 NNP I-UN
( P08643633A1187 ( I-UN
deltaEC P08643633A1187 NN I-UN
) P08643633A1187 ) I-UN
and P08643633A1187 CC O
CBF1 P08643633A1187 NNP I-UN
. P08643633A1187 . O
. . O O

Hodgkin P04512496T0000 NNP O
's P04512496T0000 POS O
disease P04512496T0000 NN O
. P04512496T0000 . O
. . O O

Nucleotide P01431809T0000 NNP O
sequence P01431809T0000 NN O
and P01431809T0000 CC O
transcriptional P01431809T0000 JJ O
analysis P01431809T0000 NN O
of P01431809T0000 IN O
the P01431809T0000 DT O
polyhedrin P01431809T0000 JJ I-UN
gene P01431809T0000 NN I-UN
of P01431809T0000 IN O
Spodoptera P01431809T0000 NNP O
exigua P01431809T0000 FW O
nuclear P01431809T0000 JJ O
polyhedrosis P01431809T0000 NN O
virus P01431809T0000 NN O
. P01431809T0000 . O
. . O O

Encapsidation P07853488T0000 NN O
of P07853488T0000 IN O
poliovirus P07853488T0000 NN O
replicons P07853488T0000 NNS O
encoding P07853488T0000 VBG O
the P07853488T0000 DT O
complete P07853488T0000 JJ O
human P07853488T0000 JJ I-UN
immunodeficiency P07853488T0000 NN I-UN
virus P07853488T0000 NN I-UN
type P07853488T0000 NN I-UN
1 P07853488T0000 CD I-UN
gag P07853488T0000 NN I-UN
gene P07853488T0000 NN I-UN
by P07853488T0000 IN O
using P07853488T0000 VBG O
a P07853488T0000 DT O
complementation P07853488T0000 NN O
system P07853488T0000 NN O
which P07853488T0000 WDT O
provides P07853488T0000 VBZ O
the P07853488T0000 DT O
P1 P07853488T0000 NNP I-UN
capsid P07853488T0000 NN I-UN
protein P07853488T0000 NN I-UN
in P07853488T0000 IN O
trans P07853488T0000 NNS O
. P07853488T0000 . O
. . O O

CONCLUSION P08058948A0810 NN O
: P08058948A0810 : O
Sonographic P08058948A0810 JJ O
angiography P08058948A0810 NN O
has P08058948A0810 VBZ O
a P08058948A0810 DT O
possible P08058948A0810 JJ O
role P08058948A0810 NN O
in P08058948A0810 IN O
the P08058948A0810 DT O
detection P08058948A0810 NN O
of P08058948A0810 IN O
small P08058948A0810 JJ O
nodules P08058948A0810 NNS O
in P08058948A0810 IN O
patients P08058948A0810 NNS O
with P08058948A0810 IN O
CRF P08058948A0810 NNP O
. P08058948A0810 . O
. . O O

In P01569344A0404 IN O
both P01569344A0404 DT O
cities P01569344A0404 NNS O
, P01569344A0404 , O
HTLV-I P01569344A0404 NNP O
/ P01569344A0404 NNP O
II P01569344A0404 NNP O
prevalence P01569344A0404 NN O
increased P01569344A0404 VBD O
significantly P01569344A0404 RB O
with P01569344A0404 IN O
age P01569344A0404 NN O
, P01569344A0404 , O
and P01569344A0404 CC O
the P01569344A0404 DT O
New P01569344A0404 NNP O
Orleans P01569344A0404 NNP O
age- P01569344A0404 JJ O
and P01569344A0404 CC O
sex-adjusted P01569344A0404 JJ O
HTLV-I P01569344A0404 NNP O
/ P01569344A0404 NNP O
II P01569344A0404 NNP O
prevalence P01569344A0404 NN O
was P01569344A0404 VBD O
significantly P01569344A0404 RB O
higher P01569344A0404 JJR O
than P01569344A0404 IN O
that P01569344A0404 DT O
of P01569344A0404 IN O
Baltimore P01569344A0404 NNP O
( P01569344A0404 ( O
P P01569344A0404 NNP O
less P01569344A0404 JJR O
than P01569344A0404 IN O
.001 P01569344A0404 NN O
) P01569344A0404 ) O
. P01569344A0404 . O
. . O O

Early P10730292T0000 JJ O
treatment P10730292T0000 NN O
mechanics P10730292T0000 NNS O
of P10730292T0000 IN O
the P10730292T0000 DT O
Class P10730292T0000 NNP O
II P10730292T0000 NNP O
division P10730292T0000 NN O
2 P10730292T0000 CD O
malocclusion P10730292T0000 NN O
. P10730292T0000 . O
. . O O

Proximal P08832146A0959 NNP O
CBD P08832146A0959 NNP O
was P08832146A0959 VBD O
inversely P08832146A0959 RB O
correlated P08832146A0959 VBN O
with P08832146A0959 IN O
bone P08832146A0959 NN I-UN
alkaline P08832146A0959 NN I-UN
phosphatase P08832146A0959 NN I-UN
( P08832146A0959 ( O
r P08832146A0959 JJ O
= P08832146A0959 NNP O
-0.71 P08832146A0959 NNP O
, P08832146A0959 , O
p P08832146A0959 NN O
< P08832146A0959 NNP O
0.01 P08832146A0959 CD O
) P08832146A0959 ) O
and P08832146A0959 CC O
intact P08832146A0959 JJ O
PTH P08832146A0959 NNP I-UN
( P08832146A0959 ( O
r P08832146A0959 NN O
= P08832146A0959 NNP O
-0.59 P08832146A0959 NNP O
, P08832146A0959 , O
p P08832146A0959 NN O
< P08832146A0959 NNP O
0.05 P08832146A0959 CD O
) P08832146A0959 ) O
. P08832146A0959 . O
. . O O

On P02694731A0241 IN O
the P02694731A0241 DT O
other P02694731A0241 JJ O
hand P02694731A0241 NN O
, P02694731A0241 , O
knowledge P02694731A0241 NN O
of P02694731A0241 IN O
the P02694731A0241 DT O
epidemiology P02694731A0241 NN O
of P02694731A0241 IN O
Parkinson P02694731A0241 NNP O
's P02694731A0241 POS O
disease P02694731A0241 NN O
is P02694731A0241 VBZ O
necessary P02694731A0241 JJ O
in P02694731A0241 IN O
creating P02694731A0241 VBG O
etiological P02694731A0241 JJ O
hypotheses P02694731A0241 NNS O
, P02694731A0241 , O
since P02694731A0241 IN O
only P02694731A0241 RB O
hypotheses P02694731A0241 VBZ O
consistent P02694731A0241 JJ O
with P02694731A0241 IN O
the P02694731A0241 DT O
epidemiological P02694731A0241 JJ O
profile P02694731A0241 NN O
deserve P02694731A0241 NN O
careful P02694731A0241 JJ O
testing P02694731A0241 NN O
. P02694731A0241 . O
. . O O

The P03420266A0000 DT O
interaction P03420266A0000 NN O
of P03420266A0000 IN O
radiation P03420266A0000 NN O
and P03420266A0000 CC O
hyperthermia P03420266A0000 NN O
was P03420266A0000 VBD O
systematically P03420266A0000 RB O
studied P03420266A0000 VBN O
in P03420266A0000 IN O
the P03420266A0000 DT O
Dunning P03420266A0000 NNP O
R3327G P03420266A0000 NNP O
prostatic P03420266A0000 JJ O
adenocarcinoma P03420266A0000 NN O
, P03420266A0000 , O
the P03420266A0000 DT O
preeminent P03420266A0000 NN O
animal P03420266A0000 NN O
model P03420266A0000 NN O
for P03420266A0000 IN O
human P03420266A0000 JJ O
prostatic P03420266A0000 JJ O
cancer P03420266A0000 NN O
. P03420266A0000 . O
. . O O

The P08106313A1492 DT O
results P08106313A1492 NNS O
indicate P08106313A1492 VBP O
that P08106313A1492 IN O
hrpRS P08106313A1492 NN I-UN
and P08106313A1492 CC O
hrpL P08106313A1492 NN I-UN
are P08106313A1492 VBP O
part P08106313A1492 NN O
of P08106313A1492 IN O
a P08106313A1492 DT O
regulatory P08106313A1492 JJ O
cascade P08106313A1492 NN O
in P08106313A1492 IN O
which P08106313A1492 WDT O
HrpR P08106313A1492 NNP I-UN
and P08106313A1492 CC O
HrpS P08106313A1492 NNP I-UN
activate P08106313A1492 VBP O
expression P08106313A1492 NN O
of P08106313A1492 IN O
hrpL P08106313A1492 NN I-UN
and P08106313A1492 CC O
HrpL P08106313A1492 NNP I-UN
, P08106313A1492 , O
a P08106313A1492 DT O
putative P08106313A1492 JJ O
sigma P08106313A1492 NN I-UN
factor P08106313A1492 NN I-UN
, P08106313A1492 , O
induces P08106313A1492 VBZ O
expression P08106313A1492 NN O
of P08106313A1492 IN O
HrpL-responsive P08106313A1492 JJ I-UN
genes P08106313A1492 NNS I-UN
. P08106313A1492 . O
. . O O

A P08649386A1032 DT O
new P08649386A1032 JJ O
UASH P08649386A1032 NNP O
consensus P08649386A1032 NN O
sequence P08649386A1032 NN O
derived P08649386A1032 VBN O
from P08649386A1032 IN O
this P08649386A1032 DT O
mutational P08649386A1032 JJ O
analysis P08649386A1032 NN O
closely P08649386A1032 RB O
matches P08649386A1032 VBZ O
a P08649386A1032 DT O
consensus P08649386A1032 NN O
Abf1 P08649386A1032 NNP I-UN
binding P08649386A1032 NN I-UN
site P08649386A1032 NN I-UN
. P08649386A1032 . O
. . O O

In P08970979A1246 IN O
contrast P08970979A1246 NN O
, P08970979A1246 , O
extracts P08970979A1246 NNS O
of P08970979A1246 IN O
the P08970979A1246 DT O
mutant P08970979A1246 JJ O
virions P08970979A1246 NNS O
catalyze P08970979A1246 VBP O
the P08970979A1246 DT O
wild-type P08970979A1246 JJ O
level P08970979A1246 NN O
of P08970979A1246 IN O
transcription P08970979A1246 NN O
from P08970979A1246 IN O
an P08970979A1246 DT O
exogenous P08970979A1246 JJ O
template P08970979A1246 NN O
containing P08970979A1246 VBG O
an P08970979A1246 DT O
early P08970979A1246 JJ O
promoter P08970979A1246 NN O
. P08970979A1246 . O
. . O O

PO2 P01886368A0000 NN O
measurements P01886368A0000 NNS O
using P01886368A0000 VBG O
a P01886368A0000 DT O
double P01886368A0000 JJ O
barrelled P01886368A0000 JJ O
recess P01886368A0000 NN O
type P01886368A0000 NN O
microelectrodes P01886368A0000 NNS O
were P01886368A0000 VBD O
measured P01886368A0000 VBN O
in P01886368A0000 IN O
the P01886368A0000 DT O
optic P01886368A0000 JJ O
nerve P01886368A0000 NN O
head P01886368A0000 NN O
of P01886368A0000 IN O
miniature P01886368A0000 NN O
pigs P01886368A0000 NNS O
in P01886368A0000 IN O
normoxia P01886368A0000 NN O
and P01886368A0000 CC O
hyperoxia P01886368A0000 NN O
. P01886368A0000 . O
. . O O

This P11070078A1153 DT O
dynamic P11070078A1153 JJ O
response P11070078A1153 NN O
strongly P11070078A1153 RB O
suggests P11070078A1153 VBZ O
that P11070078A1153 IN O
the P11070078A1153 DT O
p53 P11070078A1153 NN I-UN
and P11070078A1153 CC O
Rb P11070078A1153 NNP I-UN
tumor P11070078A1153 NN O
suppressor P11070078A1153 NN O
pathways P11070078A1153 NNS O
are P11070078A1153 VBP O
intact P11070078A1153 JJ O
in P11070078A1153 IN O
HeLa P11070078A1153 NNP O
cells P11070078A1153 NNS O
and P11070078A1153 CC O
that P11070078A1153 DT O
repression P11070078A1153 NN O
of P11070078A1153 IN O
HPV P11070078A1153 NNP I-UN
E6 P11070078A1153 NNP I-UN
and P11070078A1153 CC O
E7 P11070078A1153 NNP I-UN
mobilizes P11070078A1153 VBZ O
these P11070078A1153 DT O
pathways P11070078A1153 NNS O
in P11070078A1153 IN O
an P11070078A1153 DT O
orderly P11070078A1153 JJ O
fashion P11070078A1153 NN O
to P11070078A1153 TO O
deliver P11070078A1153 VB O
growth P11070078A1153 NN O
inhibitory P11070078A1153 NN O
signals P11070078A1153 NNS O
to P11070078A1153 TO O
the P11070078A1153 DT O
cells P11070078A1153 NNS O
. P11070078A1153 . O
. . O O

We P09774450A0000 PRP O
have P09774450A0000 VBP O
recently P09774450A0000 RB O
identified P09774450A0000 VBN O
a P09774450A0000 DT O
mouse P09774450A0000 NN O
enzyme P09774450A0000 NN O
termed P09774450A0000 VBD O
gamma-glutamyl P09774450A0000 JJ I-UN
leukotrienase P09774450A0000 NN I-UN
( P09774450A0000 ( O
GGL P09774450A0000 NNP I-UN
) P09774450A0000 ) O
that P09774450A0000 WDT O
converts P09774450A0000 VBZ O
leukotriene P09774450A0000 NN O
C4 P09774450A0000 NNP O
( P09774450A0000 ( O
LTC4 P09774450A0000 NNP O
) P09774450A0000 ) O
to P09774450A0000 TO O
leukotriene P09774450A0000 VB O
D4 P09774450A0000 NNP O
( P09774450A0000 ( O
LTD4 P09774450A0000 NNP O
) P09774450A0000 ) O
. P09774450A0000 . O
. . O O

Of P03384033A0155 IN O
the P03384033A0155 DT O
53 P03384033A0155 CD O
units P03384033A0155 NNS O
tested P03384033A0155 VBN O
during P03384033A0155 IN O
sinusoidal P03384033A0155 JJ O
motion P03384033A0155 NN O
at P03384033A0155 IN O
0.05 P03384033A0155 CD O
Hz P03384033A0155 NNP O
( P03384033A0155 ( O
9.1 P03384033A0155 CD O
cm P03384033A0155 NN O
/ P03384033A0155 NNP O
s P03384033A0155 NN O
) P03384033A0155 ) O
, P03384033A0155 , O
1 P03384033A0155 CD O
( P03384033A0155 ( O
1.9 P03384033A0155 CD O
% P03384033A0155 NN O
) P03384033A0155 ) O
was P03384033A0155 VBD O
responsive P03384033A0155 JJ O
to P03384033A0155 TO O
the P03384033A0155 DT O
otolith P03384033A0155 NN O
input P03384033A0155 NN O
only P03384033A0155 RB O
, P03384033A0155 , O
13 P03384033A0155 CD O
( P03384033A0155 ( O
24.5 P03384033A0155 CD O
% P03384033A0155 NN O
) P03384033A0155 ) O
were P03384033A0155 VBD O
influenced P03384033A0155 VBN O
by P03384033A0155 IN O
the P03384033A0155 DT O
visual P03384033A0155 JJ O
input P03384033A0155 NN O
only P03384033A0155 RB O
and P03384033A0155 CC O
23 P03384033A0155 CD O
( P03384033A0155 ( O
43.4 P03384033A0155 CD O
% P03384033A0155 NN O
) P03384033A0155 ) O
responded P03384033A0155 VBD O
to P03384033A0155 TO O
both P03384033A0155 DT O
modalities P03384033A0155 NNS O
. P03384033A0155 . O
. . O O

Three P07898275A0254 CD O
classes P07898275A0254 NNS O
of P07898275A0254 IN O
test P07898275A0254 NN O
objects P07898275A0254 NNS O
were P07898275A0254 VBD O
considered P07898275A0254 VBN O
: P07898275A0254 : O
( P07898275A0254 ( O
1 P07898275A0254 CD O
) P07898275A0254 ) O
a P07898275A0254 DT O
multicompartment P07898275A0254 JJ O
test P07898275A0254 NN O
object P07898275A0254 NN O
for P07898275A0254 IN O
31P P07898275A0254 CD O
MRS P07898275A0254 NNP O
measurements P07898275A0254 NNS O
performed P07898275A0254 VBN O
with P07898275A0254 IN O
slice-selective P07898275A0254 JJ O
sequences P07898275A0254 NNS O
; P07898275A0254 : O
( P07898275A0254 ( O
2 P07898275A0254 CD O
) P07898275A0254 ) O
a P07898275A0254 DT O
two-compartment P07898275A0254 JJ O
test P07898275A0254 NN O
object P07898275A0254 NN O
for P07898275A0254 IN O
volume-selection P07898275A0254 NN O
1H P07898275A0254 CD O
MRS P07898275A0254 NNP O
; P07898275A0254 : O
and P07898275A0254 CC O
( P07898275A0254 ( O
3 P07898275A0254 CD O
) P07898275A0254 ) O
two-compartment P07898275A0254 JJ O
test P07898275A0254 NN O
objects P07898275A0254 NNS O
for P07898275A0254 IN O
assessing P07898275A0254 VBG O
the P07898275A0254 DT O
performance P07898275A0254 NN O
of P07898275A0254 IN O
experimental P07898275A0254 JJ O
systems P07898275A0254 NNS O
using P07898275A0254 VBG O
ISIS P07898275A0254 NNP O
as P07898275A0254 IN O
volume P07898275A0254 NN O
localization P07898275A0254 NN O
sequence P07898275A0254 NN O
in P07898275A0254 IN O
31P P07898275A0254 CD O
MRS P07898275A0254 NNP O
. P07898275A0254 . O
. . O O

Recently P10502402A0129 RB O
, P10502402A0129 , O
cell-surface P10502402A0129 NN O
TRAIL P10502402A0129 NNP I-UN
has P10502402A0129 VBZ O
been P10502402A0129 VBN O
shown P10502402A0129 VBN O
to P10502402A0129 TO O
be P10502402A0129 VB O
expressed P10502402A0129 VBN O
by P10502402A0129 IN O
activated P10502402A0129 JJ O
human P10502402A0129 JJ O
and P10502402A0129 CC O
mouse P10502402A0129 NN O
T P10502402A0129 NNP O
lymphocytes P10502402A0129 VBZ O
, P10502402A0129 , O
raising P10502402A0129 VBG O
the P10502402A0129 DT O
possibility P10502402A0129 NN O
that P10502402A0129 IN O
TRAIL P10502402A0129 NNP I-UN
might P10502402A0129 MD O
be P10502402A0129 VB O
involved P10502402A0129 VBN O
in P10502402A0129 IN O
T P10502402A0129 NNP O
cell-mediated P10502402A0129 JJ O
cytotoxicity P10502402A0129 NN O
and P10502402A0129 CC O
/ P10502402A0129 NN O
or P10502402A0129 CC O
immune P10502402A0129 JJ O
regulation P10502402A0129 NN O
. P10502402A0129 . O
. . O O

This P07798271A0330 DT O
last P07798271A0330 JJ O
region P07798271A0330 NN O
contains P07798271A0330 NNS O
two P07798271A0330 CD O
sites P07798271A0330 NNS O
that P07798271A0330 IN O
bind P07798271A0330 VBP O
Ets-related P07798271A0330 JJ I-UN
proteins P07798271A0330 NNS I-UN
present P07798271A0330 JJ O
in P07798271A0330 IN O
liver P07798271A0330 JJ O
nuclear P07798271A0330 JJ O
extracts P07798271A0330 NNS O
as P07798271A0330 RB O
well P07798271A0330 RB O
as P07798271A0330 IN O
recombinant P07798271A0330 JJ I-UN
purified P07798271A0330 VBD I-UN
Ets-1 P07798271A0330 JJ I-UN
protein P07798271A0330 NN I-UN
. P07798271A0330 . O
. . O O

The P07588240A0000 DT O
Caenorhabditis P07588240A0000 NNP I-UN
elegans P07588240A0000 VBZ I-UN
death P07588240A0000 NN I-UN
susceptibility P07588240A0000 NN I-UN
gene P07588240A0000 NN I-UN
, P07588240A0000 , O
ced-3 P07588240A0000 NN I-UN
, P07588240A0000 , O
has P07588240A0000 VBZ O
a P07588240A0000 DT O
number P07588240A0000 NN O
of P07588240A0000 IN O
homologs P07588240A0000 NNS O
in P07588240A0000 IN O
vertebrate P07588240A0000 NN O
species P07588240A0000 NNS O
, P07588240A0000 , O
including P07588240A0000 VBG O
interleukin-1 P07588240A0000 JJ I-UN
beta P07588240A0000 NN I-UN
( P07588240A0000 ( I-UN
IL-1 P07588240A0000 NNP I-UN
beta P07588240A0000 NN I-UN
) P07588240A0000 ) I-UN
-converting P07588240A0000 VBG I-UN
enzyme P07588240A0000 NN I-UN
( P07588240A0000 ( O
ICE P07588240A0000 NNP I-UN
) P07588240A0000 ) O
, P07588240A0000 , O
Ich-1long P07588240A0000 NNP I-UN
, P07588240A0000 , O
and P07588240A0000 CC O
CPP32 P07588240A0000 NNP I-UN
. P07588240A0000 . O
. . O O

Our P10802669A1434 PRP$ O
data P10802669A1434 NNS O
provide P10802669A1434 VB O
a P10802669A1434 DT O
biochemical P10802669A1434 JJ O
explanation P10802669A1434 NN O
for P10802669A1434 IN O
the P10802669A1434 DT O
similarity P10802669A1434 NN O
in P10802669A1434 IN O
phenotype P10802669A1434 NN O
between P10802669A1434 IN O
A-T P10802669A1434 NNP O
and P10802669A1434 CC O
NBS P10802669A1434 NNP O
. P10802669A1434 . O
. . O O

The P09584180A0701 DT O
same P09584180A0701 JJ O
IL-4-inducible P09584180A0701 JJ O
reporter P09584180A0701 NN O
gene P09584180A0701 NN O
is P09584180A0701 VBZ O
also P09584180A0701 RB O
synergistically P09584180A0701 RB O
activated P09584180A0701 VBN O
by P09584180A0701 IN O
the P09584180A0701 DT O
endogenous P09584180A0701 JJ I-UN
Stat6 P09584180A0701 NNP I-UN
and P09584180A0701 CC O
NF-kappaB P09584180A0701 NNP I-UN
proteins P09584180A0701 NNS I-UN
in P09584180A0701 IN O
IL-4-stimulated P09584180A0701 NNP O
I.29mu P09584180A0701 NNP O
B P09584180A0701 NNP O
lymphoma P09584180A0701 NN O
cells P09584180A0701 NNS O
. P09584180A0701 . O
. . O O

Maximum P08505075A0236 JJ O
number P08505075A0236 NN O
of P08505075A0236 IN O
strains P08505075A0236 NNS O
( P08505075A0236 ( O
39.1 P08505075A0236 CD O
% P08505075A0236 NN O
) P08505075A0236 ) O
were P08505075A0236 VBD O
resistant P08505075A0236 JJ O
in P08505075A0236 IN O
S. P08505075A0236 NNP O
bareilly P08505075A0236 RB O
serotype P08505075A0236 VBD O
, P08505075A0236 , O
followed P08505075A0236 VBN O
by P08505075A0236 IN O
S. P08505075A0236 NNP O
typhimurium P08505075A0236 NN O
( P08505075A0236 ( O
21.7 P08505075A0236 CD O
% P08505075A0236 NN O
) P08505075A0236 ) O
and P08505075A0236 CC O
least P08505075A0236 JJS O
in P08505075A0236 IN O
S. P08505075A0236 NNP O
typhi P08505075A0236 NN O
( P08505075A0236 ( O
17.4 P08505075A0236 CD O
% P08505075A0236 NN O
) P08505075A0236 ) O
. P08505075A0236 . O
. . O O

Of P07264787A0351 IN O
the P07264787A0351 DT O
117 P07264787A0351 CD O
patients P07264787A0351 NNS O
( P07264787A0351 ( O
out P07264787A0351 IN O
of P07264787A0351 IN O
the P07264787A0351 DT O
136 P07264787A0351 CD O
) P07264787A0351 ) O
with P07264787A0351 IN O
serologic P07264787A0351 JJ O
evidence P07264787A0351 NN O
of P07264787A0351 IN O
chronic P07264787A0351 JJ O
thyroiditis P07264787A0351 NN O
who P07264787A0351 WP O
could P07264787A0351 MD O
be P07264787A0351 VB O
studied P07264787A0351 VBN O
, P07264787A0351 , O
eight P07264787A0351 CD O
( P07264787A0351 ( O
7 P07264787A0351 CD O
% P07264787A0351 NN O
) P07264787A0351 ) O
had P07264787A0351 VBD O
hyperthyroidism P07264787A0351 NN O
and P07264787A0351 CC O
45 P07264787A0351 CD O
( P07264787A0351 ( O
38 P07264787A0351 CD O
% P07264787A0351 NN O
) P07264787A0351 ) O
were P07264787A0351 VBD O
hypothyroid P07264787A0351 JJ O
. P07264787A0351 . O
. . O O

Furthermore P08040336A0435 RB O
, P08040336A0435 , O
an P08040336A0435 DT O
upstream P08040336A0435 JJ O
element P08040336A0435 NN O
, P08040336A0435 , O
collagen P08040336A0435 NN I-UN
element P08040336A0435 NN I-UN
I P08040336A0435 PRP I-UN
( P08040336A0435 ( I-UN
-370 P08040336A0435 JJ I-UN
/ P08040336A0435 NNP I-UN
-344 P08040336A0435 NNP I-UN
) P08040336A0435 ) I-UN
, P08040336A0435 , O
which P08040336A0435 WDT O
shares P08040336A0435 NNS O
homology P08040336A0435 NN O
with P08040336A0435 IN O
the P08040336A0435 DT O
LAP P08040336A0435 NNP I-UN
binding P08040336A0435 VBG O
cis-element P08040336A0435 NN O
of P08040336A0435 IN O
the P08040336A0435 DT O
albumin P08040336A0435 NN I-UN
promoter P08040336A0435 NN I-UN
( P08040336A0435 ( O
9 P08040336A0435 CD O
of P08040336A0435 IN O
13 P08040336A0435 CD O
bp P08040336A0435 NN O
) P08040336A0435 ) O
is P08040336A0435 VBZ O
described P08040336A0435 VBN O
. P08040336A0435 . O
. . O O

The P11599840A0813 DT O
moduli P11599840A0813 NN O
of P11599840A0813 IN O
elasticity P11599840A0813 NN O
of P11599840A0813 IN O
the P11599840A0813 DT O
gray P11599840A0813 JJ O
and P11599840A0813 CC O
white P11599840A0813 JJ O
matter P11599840A0813 NN O
were P11599840A0813 VBD O
3.4+ P11599840A0813 CD O
/ P11599840A0813 JJ O
-1.4 P11599840A0813 NN O
kPa P11599840A0813 NN O
( P11599840A0813 ( O
mean P11599840A0813 JJ O
+ P11599840A0813 NNP O
/ P11599840A0813 NNP O
- P11599840A0813 : O
standard P11599840A0813 JJ O
deviation P11599840A0813 NN O
) P11599840A0813 ) O
and P11599840A0813 CC O
3.4+ P11599840A0813 CD O
/ P11599840A0813 NN O
-0.9 P11599840A0813 NNP O
kPa P11599840A0813 NN O
in P11599840A0813 IN O
the P11599840A0813 DT O
axial P11599840A0813 JJ O
section P11599840A0813 NN O
, P11599840A0813 , O
3+ P11599840A0813 CD O
/ P11599840A0813 NN O
-0.3 P11599840A0813 NNP O
kPa P11599840A0813 NN O
and P11599840A0813 CC O
3.5+ P11599840A0813 CD O
/ P11599840A0813 NN O
-0.5 P11599840A0813 NNP O
kPa P11599840A0813 NN O
in P11599840A0813 IN O
the P11599840A0813 DT O
frontal P11599840A0813 JJ O
section P11599840A0813 NN O
, P11599840A0813 , O
and P11599840A0813 CC O
3.5+ P11599840A0813 CD O
/ P11599840A0813 NN O
-0.9 P11599840A0813 NNP O
kPa P11599840A0813 NN O
and P11599840A0813 CC O
2.8+ P11599840A0813 CD O
/ P11599840A0813 NN O
-0.4 P11599840A0813 NNP O
kPa P11599840A0813 NN O
in P11599840A0813 IN O
the P11599840A0813 DT O
sagittal P11599840A0813 JJ O
section P11599840A0813 NN O
, P11599840A0813 , O
respectively P11599840A0813 RB O
. P11599840A0813 . O
. . O O

The P07782113A0726 DT O
roxithromycin P07782113A0726 NN O
doses P07782113A0726 VBZ O
that P07782113A0726 WDT O
were P07782113A0726 VBD O
chosen P07782113A0726 VBN O
for P07782113A0726 IN O
these P07782113A0726 DT O
studies P07782113A0726 NNS O
were P07782113A0726 VBD O
less P07782113A0726 JJR O
than P07782113A0726 IN O
achievable P07782113A0726 JJ O
blood P07782113A0726 NN O
levels P07782113A0726 NNS O
. P07782113A0726 . O
. . O O

We P09671579A1168 PRP O
propose P09671579A1168 VBP O
that P09671579A1168 IN O
noi P09671579A1168 JJ I-UN
/ P09671579A1168 NNP O
pax2.1 P09671579A1168 NN I-UN
participates P09671579A1168 NNS O
in P09671579A1168 IN O
sequential P09671579A1168 JJ O
signaling P09671579A1168 NN O
processes P09671579A1168 VBZ O
as P09671579A1168 IN O
a P09671579A1168 DT O
key P09671579A1168 JJ O
integrator P09671579A1168 NN O
of P09671579A1168 IN O
midbrain-hindbrain P09671579A1168 JJ O
boundary P09671579A1168 JJ O
development P09671579A1168 NN O
. P09671579A1168 . O
. . O O

We P02631743A0275 PRP O
investigated P02631743A0275 VBD O
the P02631743A0275 DT O
incidence P02631743A0275 NN O
of P02631743A0275 IN O
congenital P02631743A0275 JJ O
color P02631743A0275 NN O
deficiency P02631743A0275 NN O
among P02631743A0275 IN O
Koreans P02631743A0275 NNS O
by P02631743A0275 IN O
the P02631743A0275 DT O
use P02631743A0275 NN O
of P02631743A0275 IN O
H-R-R P02631743A0275 NNP O
pseudoisochromatic P02631743A0275 JJ O
plates P02631743A0275 NNS O
. P02631743A0275 . O
. . O O

As P07579328A1345 IN O
with P07579328A1345 IN O
the P07579328A1345 DT O
heterologous P07579328A1345 JJ O
DNA P07579328A1345 NNP O
binding P07579328A1345 NN O
domain P07579328A1345 NN O
, P07579328A1345 , O
MZF-1 P07579328A1345 NNP I-UN
represses P07579328A1345 VBZ O
reporter P07579328A1345 NN O
gene P07579328A1345 NN O
expression P07579328A1345 NN O
in P07579328A1345 IN O
nonhematopoietic P07579328A1345 JJ O
cell P07579328A1345 NN O
lines P07579328A1345 NNS O
and P07579328A1345 CC O
activates P07579328A1345 VBZ O
expression P07579328A1345 NN O
in P07579328A1345 IN O
hematopoietic P07579328A1345 JJ O
cell P07579328A1345 NN O
lines P07579328A1345 NNS O
. P07579328A1345 . O
. . O O

Diagnosis P02703121T0000 NN O
of P02703121T0000 IN O
primary P02703121T0000 JJ O
sclerosing P02703121T0000 VBG O
cholangitis P02703121T0000 NN O
in P02703121T0000 IN O
a P02703121T0000 DT O
blood P02703121T0000 NN O
donor P02703121T0000 NN O
with P02703121T0000 IN O
elevated P02703121T0000 JJ O
serum P02703121T0000 NN I-UN
alanine P02703121T0000 NN I-UN
aminotransferase P02703121T0000 NN I-UN
. P02703121T0000 . O
. . O O

This P08790288A0068 DT O
is P08790288A0068 VBZ O
concluded P08790288A0068 VBN O
from P08790288A0068 IN O
the P08790288A0068 DT O
isolation P08790288A0068 NN O
of P08790288A0068 IN O
cDNAs P08790288A0068 NN O
from P08790288A0068 IN O
spinach P08790288A0068 NN O
( P08790288A0068 ( O
Spinacia P08790288A0068 NNP O
oleracea P08790288A0068 NN O
) P08790288A0068 ) O
and P08790288A0068 CC O
barley P08790288A0068 NN O
( P08790288A0068 ( O
Hordeum P08790288A0068 NNP O
vulgare P08790288A0068 NN O
cv P08790288A0068 NN O
. P08790288A0068 . O
. . O O

In P07623814A1040 IN O
CV-1 P07623814A1040 NNP O
cells P07623814A1040 NNS O
, P07623814A1040 , O
cotransfection P07623814A1040 NN O
of P07623814A1040 IN O
the P07623814A1040 DT O
retinoid P07623814A1040 NN I-UN
and P07623814A1040 CC I-UN
estrogen P07623814A1040 NN I-UN
receptors P07623814A1040 NNS I-UN
led P07623814A1040 VBD O
to P07623814A1040 TO O
mutual P07623814A1040 JJ O
inhibition P07623814A1040 NN O
of P07623814A1040 IN O
the P07623814A1040 DT O
other P07623814A1040 JJ O
's P07623814A1040 POS O
activity P07623814A1040 NN O
, P07623814A1040 , O
while P07623814A1040 IN O
an P07623814A1040 DT O
RA-dependent P07623814A1040 JJ O
inhibition P07623814A1040 NN O
of P07623814A1040 IN O
ER P07623814A1040 NNP I-UN
activity P07623814A1040 NN O
was P07623814A1040 VBD O
observed P07623814A1040 VBN O
in P07623814A1040 IN O
breast P07623814A1040 NN O
cancer P07623814A1040 NN O
cells P07623814A1040 NNS O
. P07623814A1040 . O
. . O O

Descriptions P11357063A0138 NNS O
of P11357063A0138 IN O
this P11357063A0138 DT O
locus P11357063A0138 NN O
would P11357063A0138 MD O
allow P11357063A0138 VB O
comparison P11357063A0138 NN O
with P11357063A0138 IN O
functionally P11357063A0138 RB O
relevant P11357063A0138 JJ O
molecular P11357063A0138 JJ O
genetic P11357063A0138 JJ O
features P11357063A0138 NNS O
of P11357063A0138 IN O
other P11357063A0138 JJ O
species P11357063A0138 NNS O
' P11357063A0138 POS O
homologous P11357063A0138 JJ O
loci P11357063A0138 NNS O
including P11357063A0138 VBG O
the P11357063A0138 DT O
single-copy P11357063A0138 JJ O
equid P11357063A0138 NN O
LH P11357063A0138 NNP I-UN
/ P11357063A0138 NNP O
CGbeta P11357063A0138 NNP I-UN
gene P11357063A0138 NN O
and P11357063A0138 CC O
the P11357063A0138 DT O
primate P11357063A0138 JJ O
LHbeta-CGbeta P11357063A0138 NNP O
gene P11357063A0138 NN O
cluster P11357063A0138 NN O
locus P11357063A0138 NN O
. P11357063A0138 . O
. . O O

When P10517672A1417 WRB O
the P10517672A1417 DT O
73-bp P10517672A1417 JJ O
fragment P10517672A1417 NN O
was P10517672A1417 VBD O
fused P10517672A1417 VBN O
to P10517672A1417 TO O
an P10517672A1417 DT O
alpha1-globin P10517672A1417 JJ I-UN
promoter-CAT P10517672A1417 JJ O
construct P10517672A1417 NN O
and P10517672A1417 CC O
cotransfected P10517672A1417 VBN O
with P10517672A1417 IN O
CCAAT P10517672A1417 NNP I-UN
transcription P10517672A1417 NN I-UN
factor P10517672A1417 NN I-UN
1 P10517672A1417 CD I-UN
( P10517672A1417 ( O
CTF1 P10517672A1417 NNP I-UN
) P10517672A1417 ) O
/ P10517672A1417 FW O
NF1 P10517672A1417 NNP I-UN
into P10517672A1417 IN O
Drosophila P10517672A1417 NNP O
Schneider P10517672A1417 NNP O
SL2 P10517672A1417 NNP O
insect P10517672A1417 NN O
cells P10517672A1417 NNS O
( P10517672A1417 ( O
which P10517672A1417 WDT O
lack P10517672A1417 VBP O
NF1-like P10517672A1417 JJ I-UN
proteins P10517672A1417 NNS I-UN
) P10517672A1417 ) O
trans-activation P10517672A1417 NN O
of P10517672A1417 IN O
CAT P10517672A1417 NNP I-UN
activity P10517672A1417 NN O
was P10517672A1417 VBD O
observed P10517672A1417 VBN O
. P10517672A1417 . O
. . O O

Serum P09218459A0000 NNP I-UN
response P09218459A0000 NN I-UN
factor P09218459A0000 NN I-UN
( P09218459A0000 ( O
SRF P09218459A0000 NNP I-UN
) P09218459A0000 ) O
, P09218459A0000 , O
a P09218459A0000 DT O
member P09218459A0000 NN O
of P09218459A0000 IN O
an P09218459A0000 DT O
ancient P09218459A0000 JJ O
family P09218459A0000 NN O
of P09218459A0000 IN O
DNA-binding P09218459A0000 NNP O
proteins P09218459A0000 NNS O
, P09218459A0000 , O
is P09218459A0000 VBZ O
generally P09218459A0000 RB O
assumed P09218459A0000 VBN O
to P09218459A0000 TO O
be P09218459A0000 VB O
a P09218459A0000 DT O
ubiquitous P09218459A0000 JJ O
transcription P09218459A0000 NN O
factor P09218459A0000 NN O
involved P09218459A0000 VBN O
in P09218459A0000 IN O
regulating P09218459A0000 VBG O
growth P09218459A0000 NN O
factor-responsive P09218459A0000 JJ O
genes P09218459A0000 NNS O
. P09218459A0000 . O
. . O O

Here P08065324A0458 RB O
we P08065324A0458 PRP O
show P08065324A0458 VBP O
that P08065324A0458 IN O
for P08065324A0458 IN O
expression P08065324A0458 NN O
of P08065324A0458 IN O
snRNA P08065324A0458 JJ O
genes P08065324A0458 NNS O
in P08065324A0458 IN O
maize P08065324A0458 NN O
, P08065324A0458 , O
a P08065324A0458 DT O
monocotyledonous P08065324A0458 JJ O
plant P08065324A0458 NN O
, P08065324A0458 , O
the P08065324A0458 DT O
USE P08065324A0458 NNP O
and P08065324A0458 CC O
TATA P08065324A0458 NNP O
elements P08065324A0458 NNS O
are P08065324A0458 VBP O
essential P08065324A0458 JJ O
, P08065324A0458 , O
but P08065324A0458 CC O
not P08065324A0458 RB O
sufficient P08065324A0458 JJ O
, P08065324A0458 , O
for P08065324A0458 IN O
transcription P08065324A0458 NN O
. P08065324A0458 . O
. . O O

TMBr-1 P02320008A0651 NNP I-UN
is P02320008A0651 VBZ O
identical P02320008A0651 JJ O
to P02320008A0651 TO O
striated P02320008A0651 JJ I-UN
muscle P02320008A0651 NN I-UN
alpha-tropomyosin P02320008A0651 NN I-UN
from P02320008A0651 IN O
amino P02320008A0651 JJ O
acids P02320008A0651 NNS O
1 P02320008A0651 CD O
through P02320008A0651 IN O
258 P02320008A0651 CD O
but P02320008A0651 CC O
contains P02320008A0651 VBZ O
a P02320008A0651 DT O
novel P02320008A0651 JJ O
COOH-terminal P02320008A0651 JJ O
region P02320008A0651 NN O
from P02320008A0651 IN O
amino P02320008A0651 JJ O
acids P02320008A0651 NNS O
259 P02320008A0651 CD O
through P02320008A0651 IN O
281 P02320008A0651 CD O
. P02320008A0651 . O
. . O O

The P08374753A0335 DT O
transverse P08374753A0335 JJ O
relaxation P08374753A0335 NN O
time P08374753A0335 NN O
( P08374753A0335 ( O
T2 P08374753A0335 NNP O
) P08374753A0335 ) O
and P08374753A0335 CC O
apparent P08374753A0335 JJ O
diffusion P08374753A0335 NN O
coefficient P08374753A0335 NN O
of P08374753A0335 IN O
water P08374753A0335 NN O
were P08374753A0335 VBD O
determined P08374753A0335 VBN O
. P08374753A0335 . O
. . O O

Together P09362473A1540 RB O
, P09362473A1540 , O
our P09362473A1540 PRP$ O
results P09362473A1540 NNS O
show P09362473A1540 VBP O
that P09362473A1540 IN O
tinman P09362473A1540 NN I-UN
is P09362473A1540 VBZ O
controlled P09362473A1540 VBN O
by P09362473A1540 IN O
an P09362473A1540 DT O
array P09362473A1540 NN O
of P09362473A1540 IN O
discrete P09362473A1540 JJ O
enhancer P09362473A1540 NN O
elements P09362473A1540 NNS O
that P09362473A1540 WDT O
are P09362473A1540 VBP O
activated P09362473A1540 VBN O
successively P09362473A1540 RB O
by P09362473A1540 IN O
differential P09362473A1540 JJ O
genetic P09362473A1540 JJ O
inputs P09362473A1540 NNS O
, P09362473A1540 , O
as P09362473A1540 RB O
well P09362473A1540 RB O
as P09362473A1540 IN O
by P09362473A1540 IN O
closely P09362473A1540 RB O
linked P09362473A1540 VBN O
activator P09362473A1540 NN O
and P09362473A1540 CC O
repressor P09362473A1540 NN O
binding P09362473A1540 NN O
sites P09362473A1540 NNS O
within P09362473A1540 IN O
an P09362473A1540 DT O
early-acting P09362473A1540 JJ O
enhancer P09362473A1540 NN O
, P09362473A1540 , O
which P09362473A1540 WDT O
restrict P09362473A1540 VBP O
twist P09362473A1540 NN I-UN
activity P09362473A1540 NN O
to P09362473A1540 TO O
specific P09362473A1540 JJ O
areas P09362473A1540 NNS O
within P09362473A1540 IN O
the P09362473A1540 DT O
twist P09362473A1540 JJ I-UN
expression P09362473A1540 NN I-UN
domain P09362473A1540 NN I-UN
. P09362473A1540 . O
. . O O

In P08649428A1227 IN O
this P08649428A1227 DT O
study P08649428A1227 NN O
, P08649428A1227 , O
we P08649428A1227 PRP O
further P08649428A1227 RB O
investigated P08649428A1227 VBD O
the P08649428A1227 DT O
regulation P08649428A1227 NN O
of P08649428A1227 IN O
the P08649428A1227 DT O
synthesis P08649428A1227 NN O
of P08649428A1227 IN O
the P08649428A1227 DT O
c-mos P08649428A1227 JJ I-UN
oncogene P08649428A1227 NN I-UN
product P08649428A1227 NN I-UN
, P08649428A1227 , O
which P08649428A1227 WDT O
is P08649428A1227 VBZ O
necessary P08649428A1227 JJ O
for P08649428A1227 IN O
the P08649428A1227 DT O
activation P08649428A1227 NN O
of P08649428A1227 IN O
Cdc2 P08649428A1227 NNP I-UN
. P08649428A1227 . O
. . O O

Isolation P02504603T0000 NN O
of P02504603T0000 IN O
Weeksella P02504603T0000 NNP O
virosa P02504603T0000 NN O
( P02504603T0000 ( O
formerly P02504603T0000 RB O
CDC P02504603T0000 NNP O
group P02504603T0000 NN O
IIf P02504603T0000 NNP O
) P02504603T0000 ) O
from P02504603T0000 IN O
a P02504603T0000 DT O
vaginal P02504603T0000 JJ O
sample P02504603T0000 NN O
. P02504603T0000 . O
. . O O

METHODS P11291552A0156 NN O
: P11291552A0156 : O
126 P11291552A0156 CD O
patients P11291552A0156 NNS O
with P11291552A0156 IN O
histologically P11291552A0156 RB O
confirmed P11291552A0156 VBN O
MFH P11291552A0156 NNP O
were P11291552A0156 VBD O
analyzed P11291552A0156 VBN O
. P11291552A0156 . O
. . O O

Among P10733569A0364 IN O
mammalian P10733569A0364 JJ I-UN
HSFs P10733569A0364 NNP I-UN
, P10733569A0364 , O
HSF1 P10733569A0364 NNP I-UN
has P10733569A0364 VBZ O
been P10733569A0364 VBN O
shown P10733569A0364 VBN O
to P10733569A0364 TO O
be P10733569A0364 VB O
important P10733569A0364 JJ O
for P10733569A0364 IN O
regulation P10733569A0364 NN O
of P10733569A0364 IN O
the P10733569A0364 DT O
heat-induced P10733569A0364 JJ O
stress P10733569A0364 NN O
gene P10733569A0364 NN O
expression P10733569A0364 NN O
, P10733569A0364 , O
whereas P10733569A0364 IN O
the P10733569A0364 DT O
function P10733569A0364 NN O
of P10733569A0364 IN O
HSF2 P10733569A0364 NNP I-UN
in P10733569A0364 IN O
stress P10733569A0364 NN O
response P10733569A0364 NN O
is P10733569A0364 VBZ O
unclear P10733569A0364 JJ O
. P10733569A0364 . O
. . O O

Elledge P08391534A0828 NNP O
, P08391534A0828 , O
P P08391534A0828 NNP O
. P08391534A0828 . O
. . O O

The P09136015A0529 DT O
sequencing P09136015A0529 NN O
of P09136015A0529 IN O
Stellate P09136015A0529 NNP I-UN
copies P09136015A0529 NNS O
located P09136015A0529 VBN O
along P09136015A0529 IN O
the P09136015A0529 DT O
discontinuous P09136015A0529 JJ O
cluster P09136015A0529 NN O
revealed P09136015A0529 VBD O
a P09136015A0529 DT O
complex P09136015A0529 JJ O
pattern P09136015A0529 NN O
of P09136015A0529 IN O
diversification P09136015A0529 NN O
. P09136015A0529 . O
. . O O

The P08633855A1064 DT O
lacS P08633855A1064 JJ I-UN
gene P08633855A1064 NN I-UN
was P08633855A1064 VBD O
cloned P08633855A1064 VBN O
in P08633855A1064 IN O
an P08633855A1064 DT O
E. P08633855A1064 NNP O
coli-Streptococcus P08633855A1064 JJ O
shuttle P08633855A1064 NN O
vector P08633855A1064 NN O
and P08633855A1064 CC O
was P08633855A1064 VBD O
expressed P08633855A1064 VBN O
both P08633855A1064 DT O
in P08633855A1064 IN O
a P08633855A1064 DT O
lacS P08633855A1064 JJ I-UN
deletion P08633855A1064 NN O
derivative P08633855A1064 NN O
of P08633855A1064 IN O
S. P08633855A1064 NNP O
thermophilus P08633855A1064 NN O
and P08633855A1064 CC O
in P08633855A1064 IN O
a P08633855A1064 DT O
pNZ63-cured P08633855A1064 JJ O
strain P08633855A1064 NN O
, P08633855A1064 , O
L. P08633855A1064 NNP O
lactis P08633855A1064 NN O
NZ6091 P08633855A1064 NNP O
. P08633855A1064 . O
. . O O

The P09278441A1160 DT O
pattern P09278441A1160 NN O
and P09278441A1160 CC O
timing P09278441A1160 NN O
of P09278441A1160 IN O
CARP P09278441A1160 NNP I-UN
mRNA P09278441A1160 NNP I-UN
expression P09278441A1160 NN O
, P09278441A1160 , O
including P09278441A1160 VBG O
transient P09278441A1160 JJ O
expression P09278441A1160 NN O
in P09278441A1160 IN O
the P09278441A1160 DT O
tongue P09278441A1160 NN O
at P09278441A1160 IN O
14.5 P09278441A1160 CD O
days P09278441A1160 NNS O
p.c. P09278441A1160 RB O
, P09278441A1160 , O
coincides P09278441A1160 NNS O
with P09278441A1160 IN O
that P09278441A1160 DT O
of P09278441A1160 IN O
Nkx2.5 P09278441A1160 NNP I-UN
/ P09278441A1160 NNP O
Csx P09278441A1160 NNP I-UN
( P09278441A1160 ( O
a P09278441A1160 DT O
putative P09278441A1160 JJ O
homolog P09278441A1160 NN O
of P09278441A1160 IN O
tinman P09278441A1160 NN I-UN
, P09278441A1160 , O
the P09278441A1160 DT O
Drosophila P09278441A1160 NNP O
melanogaster P09278441A1160 NN O
gene P09278441A1160 NN O
responsible P09278441A1160 JJ O
for P09278441A1160 IN O
cardiac P09278441A1160 JJ O
development P09278441A1160 NN O
) P09278441A1160 ) O
. P09278441A1160 . O
. . O O

The P10543730A0000 DT O
yeast P10543730A0000 JJ O
C-type P10543730A0000 JJ I-UN
cyclin P10543730A0000 NN I-UN
Ume3p P10543730A0000 NNP I-UN
/ P10543730A0000 NNP O
Srb11p P10543730A0000 NNP I-UN
and P10543730A0000 CC O
its P10543730A0000 PRP$ O
cyclin-dependent P10543730A0000 JJ I-UN
kinase P10543730A0000 NN I-UN
( P10543730A0000 ( O
Cdk P10543730A0000 NNP I-UN
) P10543730A0000 ) O
Ume5p P10543730A0000 NNP I-UN
are P10543730A0000 VBP O
required P10543730A0000 VBN O
for P10543730A0000 IN O
the P10543730A0000 DT O
full P10543730A0000 JJ O
repression P10543730A0000 NN O
of P10543730A0000 IN O
genes P10543730A0000 NNS O
involved P10543730A0000 VBN O
in P10543730A0000 IN O
the P10543730A0000 DT O
stress P10543730A0000 NN O
response P10543730A0000 NN O
or P10543730A0000 CC O
meiosis P10543730A0000 NN O
. P10543730A0000 . O
. . O O

Promoter P02102823A0492 NN O
activities P02102823A0492 NNS O
were P02102823A0492 VBD O
estimated P02102823A0492 VBN O
using P02102823A0492 VBG O
beta-glucuronidase P02102823A0492 NN I-UN
and P02102823A0492 CC O
neomycin P02102823A0492 JJ I-UN
phosphotransferase P02102823A0492 NN I-UN
II P02102823A0492 NNP I-UN
reporter P02102823A0492 NN I-UN
gene P02102823A0492 NN I-UN
systems P02102823A0492 NNS I-UN
. P02102823A0492 . O
. . O O

Of P09537651A0366 IN O
these P09537651A0366 DT O
sites P09537651A0366 NNS O
, P09537651A0366 , O
PEA3 P09537651A0366 NNP I-UN
and P09537651A0366 CC O
STAT P09537651A0366 NNP I-UN
contributed P09537651A0366 VBD O
specifically P09537651A0366 RB O
to P09537651A0366 TO O
induction P09537651A0366 NN O
by P09537651A0366 IN O
v-src P09537651A0366 NN I-UN
, P09537651A0366 , O
whereas P09537651A0366 IN O
the P09537651A0366 DT O
remaining P09537651A0366 VBG O
elements P09537651A0366 NNS O
were P09537651A0366 VBD O
also P09537651A0366 RB O
involved P09537651A0366 VBN O
in P09537651A0366 IN O
induction P09537651A0366 NN O
by P09537651A0366 IN O
the P09537651A0366 DT O
phorbol P09537651A0366 NN O
ester P09537651A0366 NN O
phorbol P09537651A0366 NN O
myristate P09537651A0366 NN O
acetate P09537651A0366 NN O
( P09537651A0366 ( O
PMA P09537651A0366 NNP O
) P09537651A0366 ) O
. P09537651A0366 . O
. . O O

This P01906111A1295 DT O
study P01906111A1295 NN O
indicates P01906111A1295 VBZ O
that P01906111A1295 IN O
this P01906111A1295 DT O
dose-intense P01906111A1295 JJ O
regimen P01906111A1295 NNS O
can P01906111A1295 MD O
be P01906111A1295 VB O
safely P01906111A1295 RB O
administered P01906111A1295 VBN O
, P01906111A1295 , O
even P01906111A1295 RB O
with P01906111A1295 IN O
the P01906111A1295 DT O
use P01906111A1295 NN O
of P01906111A1295 IN O
purged P01906111A1295 JJ O
marrow P01906111A1295 NN O
, P01906111A1295 , O
with P01906111A1295 IN O
an P01906111A1295 DT O
acceptable P01906111A1295 JJ O
toxicity P01906111A1295 NN O
profile P01906111A1295 NN O
. P01906111A1295 . O
. . O O

Chlamydial P01275335A0158 JJ O
agents P01275335A0158 NNS O
were P01275335A0158 VBD O
isolated P01275335A0158 VBN O
from P01275335A0158 IN O
the P01275335A0158 DT O
semen P01275335A0158 NNS O
near P01275335A0158 IN O
the P01275335A0158 DT O
end P01275335A0158 NN O
of P01275335A0158 IN O
the P01275335A0158 DT O
chlamydemic P01275335A0158 JJ O
phase P01275335A0158 NN O
. P01275335A0158 . O
. . O O

Twenty-one P09249710A0331 CD O
ELISA-positive P09249710A0331 JJ O
sera P09249710A0331 NN O
were P09249710A0331 VBD O
tested P09249710A0331 VBN O
and P09249710A0331 CC O
confirmed P09249710A0331 VBN O
positive P09249710A0331 JJ O
by P09249710A0331 IN O
plaque P09249710A0331 JJ O
reduction P09249710A0331 NN O
neutralization P09249710A0331 NN O
testing P09249710A0331 NN O
. P09249710A0331 . O
. . O O

Oligonucleotide P02975753A1333 IN O
mutagenesis P02975753A1333 NN O
of P02975753A1333 IN O
these P02975753A1333 DT O
binding P02975753A1333 VBG O
domains P02975753A1333 NNS O
indicated P02975753A1333 VBD O
their P02975753A1333 PRP$ O
importance P02975753A1333 NN O
in P02975753A1333 IN O
the P02975753A1333 DT O
transcriptional P02975753A1333 JJ O
regulation P02975753A1333 NN O
of P02975753A1333 IN O
the P02975753A1333 DT O
E3 P02975753A1333 NNP I-UN
promoter P02975753A1333 NN I-UN
in P02975753A1333 IN O
yeast P02975753A1333 NN O
cells P02975753A1333 NNS O
. P02975753A1333 . O
. . O O

Alternatively P10704499A0682 RB O
, P10704499A0682 , O
PC12-E2 P10704499A0682 NNP O
cells P10704499A0682 NNS O
were P10704499A0682 VBD O
submitted P10704499A0682 VBN O
to P10704499A0682 TO O
treatment P10704499A0682 NN O
with P10704499A0682 IN O
antibodies P10704499A0682 NNS O
to P10704499A0682 TO O
the P10704499A0682 DT O
fibroblast P10704499A0682 NN I-UN
growth P10704499A0682 NN I-UN
factor P10704499A0682 NN I-UN
( P10704499A0682 ( I-UN
FGF P10704499A0682 NNP I-UN
) P10704499A0682 ) I-UN
receptor P10704499A0682 NN I-UN
, P10704499A0682 , O
inhibitors P10704499A0682 NNS O
of P10704499A0682 IN O
the P10704499A0682 DT O
nonreceptor P10704499A0682 NN I-UN
tyrosine P10704499A0682 NN I-UN
kinase P10704499A0682 NN I-UN
p59 P10704499A0682 NN I-UN
( P10704499A0682 ( O
fyn P10704499A0682 NN I-UN
) P10704499A0682 ) O
, P10704499A0682 , O
PLC P10704499A0682 NNP I-UN
, P10704499A0682 , O
PKC P10704499A0682 NNP I-UN
and P10704499A0682 CC O
MEK P10704499A0682 NNP I-UN
and P10704499A0682 CC O
an P10704499A0682 DT O
activator P10704499A0682 NN O
of P10704499A0682 IN O
PKC P10704499A0682 NNP I-UN
, P10704499A0682 , O
phorbol-12-myristate-13-acetate P10704499A0682 NN O
( P10704499A0682 ( O
PMA P10704499A0682 NNP O
) P10704499A0682 ) O
. P10704499A0682 . O
. . O O

Changes P00413854A0958 NNS O
in P00413854A0958 IN O
tissue P00413854A0958 NN O
PCO2 P00413854A0958 NNP O
were P00413854A0958 VBD O
less P00413854A0958 RBR O
dramatic P00413854A0958 JJ O
and P00413854A0958 CC O
did P00413854A0958 VBD O
not P00413854A0958 RB O
vary P00413854A0958 JJ O
significantly P00413854A0958 RB O
from P00413854A0958 IN O
those P00413854A0958 DT O
recorded P00413854A0958 VBN O
in P00413854A0958 IN O
venous P00413854A0958 JJ O
blood P00413854A0958 NN O
. P00413854A0958 . O
. . O O

Can P06120429T0000 MD O
thyroglobulin P06120429T0000 VB I-UN
assay P06120429T0000 VB O
really P06120429T0000 RB O
supplant P06120429T0000 JJ O
radioiodine P06120429T0000 NN O
scans P06120429T0000 NNS O
in P06120429T0000 IN O
patients P06120429T0000 NNS O
with P06120429T0000 IN O
differentiated P06120429T0000 JJ O
thyroid P06120429T0000 NN O
cancer P06120429T0000 NN O
? P06120429T0000 . O
. P06120429T0000 . O
. . O O

This P08389365A1344 DT O
observation P08389365A1344 NN O
suggests P08389365A1344 VBZ O
that P08389365A1344 IN O
the P08389365A1344 DT O
methyl-directed P08389365A1344 JJ O
repair P08389365A1344 NN O
system P08389365A1344 NN O
utilizes P08389365A1344 VBZ O
the P08389365A1344 DT O
proximal P08389365A1344 JJ O
d P08389365A1344 NN O
( P08389365A1344 ( O
GATC P08389365A1344 NNP O
) P08389365A1344 ) O
sequence P08389365A1344 NN O
to P08389365A1344 TO O
direct P08389365A1344 JJ O
correction P08389365A1344 NN O
. P08389365A1344 . O
. . O O

Update P10804379T0001 VB O
on P10804379T0001 IN O
maternal-fetal P10804379T0001 JJ O
infections P10804379T0001 NNS O
by P10804379T0001 IN O
hepatitis P10804379T0001 NN O
C P10804379T0001 NNP O
, P10804379T0001 , O
HIV P10804379T0001 NNP O
and P10804379T0001 CC O
cytomegalovirus P10804379T0001 NN O
. P10804379T0001 . O
. . O O

Single P06760394T0001 NNP O
tooth P06760394T0001 CC O
replacement P06760394T0001 NN O
with P06760394T0001 IN O
the P06760394T0001 DT O
aid P06760394T0001 NN O
of P06760394T0001 IN O
the P06760394T0001 DT O
ITI P06760394T0001 NNP O
( P06760394T0001 ( O
International P06760394T0001 NNP O
Team P06760394T0001 NNP O
fur P06760394T0001 RB O
Implantologie P06760394T0001 NNP O
) P06760394T0001 ) O
type P06760394T0001 NN O
F P06760394T0001 NNP O
hollow-cylinder P06760394T0001 NN O
implant P06760394T0001 NN O
. P06760394T0001 . O
. . O O

Tissue P01284828T0001 NNP I-UN
plasminogen P01284828T0001 NN I-UN
activator P01284828T0001 NN I-UN
, P01284828T0001 , O
its P01284828T0001 PRP$ O
inhibitor P01284828T0001 NN O
and P01284828T0001 CC O
other P01284828T0001 JJ O
parameters P01284828T0001 NNS O
of P01284828T0001 IN O
fibrinolysis P01284828T0001 NN O
in P01284828T0001 IN O
blood P01284828T0001 NN O
of P01284828T0001 IN O
patients P01284828T0001 NNS O
operated P01284828T0001 VBN O
for P01284828T0001 IN O
mild P01284828T0001 JJ O
hypertrophy P01284828T0001 NN O
of P01284828T0001 IN O
the P01284828T0001 DT O
prostate P01284828T0001 NN O
. P01284828T0001 . O
. . O O

Using P09790771A1032 VBG O
an P09790771A1032 DT O
interspecific P09790771A1032 JJ O
backcross P09790771A1032 NN O
panel P09790771A1032 NN O
, P09790771A1032 , O
we P09790771A1032 PRP O
localized P09790771A1032 VBD O
both P09790771A1032 DT O
Gng3 P09790771A1032 NNP I-UN
and P09790771A1032 CC O
Gng3lg P09790771A1032 NNP I-UN
to P09790771A1032 TO O
the P09790771A1032 DT O
same P09790771A1032 JJ O
locus P09790771A1032 NN O
on P09790771A1032 IN O
chromosome P09790771A1032 NN O
19 P09790771A1032 CD O
. P09790771A1032 . O
. . O O

Binding P11279108T0000 NNP O
of P11279108T0000 IN O
serum P11279108T0000 NN I-UN
response P11279108T0000 NN I-UN
factor P11279108T0000 NN I-UN
to P11279108T0000 TO O
CArG P11279108T0000 NNP O
box P11279108T0000 NN O
sequences P11279108T0000 NNS O
is P11279108T0000 VBZ O
necessary P11279108T0000 JJ O
but P11279108T0000 CC O
not P11279108T0000 RB O
sufficient P11279108T0000 JJ O
to P11279108T0000 TO O
restrict P11279108T0000 VB O
gene P11279108T0000 NN O
expression P11279108T0000 NN O
to P11279108T0000 TO O
arterial P11279108T0000 JJ O
smooth P11279108T0000 JJ O
muscle P11279108T0000 NN O
cells P11279108T0000 NNS O
. P11279108T0000 . O
. . O O

In P08443340A0522 IN O
order P08443340A0522 NN O
to P08443340A0522 TO O
investigate P08443340A0522 VB O
how P08443340A0522 WRB O
these P08443340A0522 DT O
expression P08443340A0522 NN O
patterns P08443340A0522 NNS O
are P08443340A0522 VBP O
established P08443340A0522 VBN O
, P08443340A0522 , O
we P08443340A0522 PRP O
fused P08443340A0522 VBD O
promoter P08443340A0522 NN O
regions P08443340A0522 NNS O
of P08443340A0522 IN O
an P08443340A0522 DT O
acidic P08443340A0522 JJ O
and P08443340A0522 CC O
a P08443340A0522 DT O
basic P08443340A0522 JJ O
glucanase P08443340A0522 NN I-UN
gene P08443340A0522 NN I-UN
to P08443340A0522 TO O
the P08443340A0522 DT O
beta-glucuronidase P08443340A0522 NN I-UN
( P08443340A0522 ( O
GUS P08443340A0522 NNP I-UN
) P08443340A0522 ) O
reporter P08443340A0522 NN O
gene P08443340A0522 NN O
and P08443340A0522 CC O
examined P08443340A0522 JJ O
expression P08443340A0522 NN O
of P08443340A0522 IN O
these P08443340A0522 DT O
constructs P08443340A0522 NNS O
in P08443340A0522 IN O
transgenic P08443340A0522 JJ O
tobacco P08443340A0522 NN O
plants P08443340A0522 NNS O
. P08443340A0522 . O
. . O O

CYP2C19 P11552922A0361 NNP I-UN
genotype P11552922A0361 NN I-UN
was P11552922A0361 VBD O
determined P11552922A0361 VBN O
by P11552922A0361 IN O
the P11552922A0361 DT O
polymerase P11552922A0361 NN O
chain P11552922A0361 NN O
reaction-restriction P11552922A0361 NN O
fragment P11552922A0361 NN O
length P11552922A0361 NN O
polymorphism P11552922A0361 NN O
method P11552922A0361 NN O
. P11552922A0361 . O
. . O O

Antibodies P07790377A0561 NNS O
to P07790377A0561 TO O
the P07790377A0561 DT O
human P07790377A0561 JJ I-UN
PTS1R P07790377A0561 NNP I-UN
recognize P07790377A0561 NN O
this P07790377A0561 DT O
protein P07790377A0561 NN O
in P07790377A0561 IN O
human P07790377A0561 JJ O
, P07790377A0561 , O
monkey P07790377A0561 NN O
, P07790377A0561 , O
rat P07790377A0561 NN O
, P07790377A0561 , O
and P07790377A0561 CC O
hamster P07790377A0561 NN O
cells P07790377A0561 NNS O
. P07790377A0561 . O
. . O O

BCL-2 P09002648A0202 NNP I-UN
, P09002648A0202 , O
an P09002648A0202 DT O
inhibitor P09002648A0202 NN O
of P09002648A0202 IN O
apoptosis P09002648A0202 NN O
in P09002648A0202 IN O
a P09002648A0202 DT O
wide P09002648A0202 JJ O
variety P09002648A0202 NN O
of P09002648A0202 IN O
cell P09002648A0202 NN O
types P09002648A0202 NNS O
, P09002648A0202 , O
has P09002648A0202 VBZ O
been P09002648A0202 VBN O
reported P09002648A0202 VBN O
to P09002648A0202 TO O
prevent P09002648A0202 VB O
oxidative P09002648A0202 JJ O
stress-induced P09002648A0202 JJ O
cell P09002648A0202 NN O
death P09002648A0202 NN O
. P09002648A0202 . O
. . O O

No P06209403A0562 DT O
direct P06209403A0562 JJ O
repeats P06209403A0562 NNS O
flank P06209403A0562 VBD O
the P06209403A0562 DT O
pseudogene P06209403A0562 NN O
in P06209403A0562 IN O
the P06209403A0562 DT O
U2 P06209403A0562 NNP I-UN
/ P06209403A0562 NNP I-UN
4 P06209403A0562 CD I-UN
locus P06209403A0562 NN I-UN
. P06209403A0562 . O
. . O O

Changes P07539314T0000 NNS O
induced P07539314T0000 VBN O
in P07539314T0000 IN O
the P07539314T0000 DT O
gills P07539314T0000 NNS O
of P07539314T0000 IN O
milkfish P07539314T0000 NN O
( P07539314T0000 ( O
Chanos P07539314T0000 NNP O
chanos P07539314T0000 VBP O
Forsskal P07539314T0000 NNP O
) P07539314T0000 ) O
fingerlings P07539314T0000 NNS O
after P07539314T0000 IN O
acute P07539314T0000 JJ O
exposure P07539314T0000 NN O
to P07539314T0000 TO O
nifurpirinol P07539314T0000 VB O
( P07539314T0000 ( O
Furanace P07539314T0000 NNP O
; P07539314T0000 : O
P-7138 P07539314T0000 NNP O
) P07539314T0000 ) O
. P07539314T0000 . O
. . O O

It P06446048A0356 PRP O
is P06446048A0356 VBZ O
concluded P06446048A0356 VBN O
that P06446048A0356 IN O
axillo-axillary P06446048A0356 JJ O
by-pass P06446048A0356 NN O
is P06446048A0356 VBZ O
a P06446048A0356 DT O
simple P06446048A0356 JJ O
solution P06446048A0356 NN O
for P06446048A0356 IN O
a P06446048A0356 DT O
complex P06446048A0356 JJ O
haemodynamic P06446048A0356 NN O
, P06446048A0356 , O
clinical P06446048A0356 JJ O
and P06446048A0356 CC O
therapeutic P06446048A0356 JJ O
problem P06446048A0356 NN O
. P06446048A0356 . O
. . O O

With P03913522A0000 IN O
aging P03913522A0000 VBG O
, P03913522A0000 , O
many P03913522A0000 JJ O
aspects P03913522A0000 NNS O
of P03913522A0000 IN O
immune P03913522A0000 JJ O
function P03913522A0000 NN O
change P03913522A0000 NN O
. P03913522A0000 . O
. . O O

Although P07559355A0066 IN O
eight P07559355A0066 CD O
contiguous P07559355A0066 JJ O
genes P07559355A0066 NNS O
necessary P07559355A0066 JJ O
for P07559355A0066 IN O
urease P07559355A0066 JJ I-UN
activity P07559355A0066 NN O
have P07559355A0066 VBP O
been P07559355A0066 VBN O
cloned P07559355A0066 VBN O
and P07559355A0066 CC O
sequenced P07559355A0066 VBN O
, P07559355A0066 , O
the P07559355A0066 DT O
transcriptional P07559355A0066 JJ O
organization P07559355A0066 NN O
and P07559355A0066 CC O
regulation P07559355A0066 NN O
of P07559355A0066 IN O
specific P07559355A0066 JJ O
genes P07559355A0066 NNS O
within P07559355A0066 IN O
the P07559355A0066 DT O
Proteus P07559355A0066 NNP I-UN
gene P07559355A0066 NN I-UN
cluster P07559355A0066 NN I-UN
has P07559355A0066 VBZ O
not P07559355A0066 RB O
been P07559355A0066 VBN O
investigated P07559355A0066 VBN O
in P07559355A0066 IN O
detail P07559355A0066 NN O
. P07559355A0066 . O
. . O O

Isolation P08103935T0000 NN O
and P08103935T0000 CC O
characterization P08103935T0000 NN O
of P08103935T0000 IN O
SRF P08103935T0000 NNP I-UN
accessory P08103935T0000 NN I-UN
proteins P08103935T0000 NNS I-UN
. P08103935T0000 . O
. . O O

Effect P00715180T0074 NN O
of P00715180T0074 IN O
time P00715180T0074 NN O
and P00715180T0074 CC O
dose P00715180T0074 VB O
on P00715180T0074 IN O
alterations P00715180T0074 NNS O
following P00715180T0074 VBG O
inhalation P00715180T0074 NN O
of P00715180T0074 IN O
plutonium-239 P00715180T0074 JJ O
dioxide P00715180T0074 NN O
aerosol P00715180T0074 NN O
in P00715180T0074 IN O
rat P00715180T0074 NN O
. P00715180T0074 . O
. . O O

This P08890537A0355 DT O
technique P08890537A0355 NN O
was P08890537A0355 VBD O
employed P08890537A0355 VBN O
in P08890537A0355 IN O
12 P08890537A0355 CD O
patients P08890537A0355 NNS O
with P08890537A0355 IN O
a P08890537A0355 DT O
unicameral P08890537A0355 JJ O
bone P08890537A0355 NN O
cyst P08890537A0355 NN O
. P08890537A0355 . O
. . O O

We P09393875A0873 PRP O
speculate P09393875A0873 VBP O
that P09393875A0873 IN O
the P09393875A0873 DT O
human P09393875A0873 JJ O
papillomavirus P09393875A0873 NN O
late P09393875A0873 JJ O
mRNAs P09393875A0873 NN O
, P09393875A0873 , O
produced P09393875A0873 VBN O
from P09393875A0873 IN O
several P09393875A0873 JJ O
hundred P09393875A0873 CD O
copies P09393875A0873 NNS O
of P09393875A0873 IN O
the P09393875A0873 DT O
virus P09393875A0873 NN O
genome P09393875A0873 JJ O
present P09393875A0873 NN O
in P09393875A0873 IN O
infected P09393875A0873 JJ O
cells P09393875A0873 NNS O
, P09393875A0873 , O
compete P09393875A0873 NN O
with P09393875A0873 IN O
the P09393875A0873 DT O
c-fos P09393875A0873 JJ I-UN
mRNAs P09393875A0873 NN I-UN
for P09393875A0873 IN O
destabilizing P09393875A0873 VBG O
cellular P09393875A0873 JJ O
factors P09393875A0873 NNS O
and P09393875A0873 CC O
that P09393875A0873 IN O
this P09393875A0873 DT O
may P09393875A0873 MD O
lead P09393875A0873 VB O
to P09393875A0873 TO O
elevated P09393875A0873 JJ O
Fos P09393875A0873 NNP I-UN
protein P09393875A0873 NN I-UN
levels P09393875A0873 NNS O
in P09393875A0873 IN O
human P09393875A0873 JJ O
papillomavirus P09393875A0873 NN O
infected P09393875A0873 VBD O
cells P09393875A0873 NNS O
. P09393875A0873 . O
. . O O

Comprehensive P02225687A0546 NNP O
care P02225687A0546 NN O
of P02225687A0546 IN O
the P02225687A0546 DT O
patient P02225687A0546 NN O
exposed P02225687A0546 VBD O
to P02225687A0546 TO O
a P02225687A0546 DT O
human P02225687A0546 JJ O
teratogen P02225687A0546 NN O
may P02225687A0546 MD O
also P02225687A0546 RB O
include P02225687A0546 VB O
discussion P02225687A0546 NN O
of P02225687A0546 IN O
prenatal P02225687A0546 JJ O
diagnostic P02225687A0546 JJ O
procedures P02225687A0546 NNS O
and P02225687A0546 CC O
other P02225687A0546 JJ O
pregnancy P02225687A0546 NN O
management P02225687A0546 NN O
options P02225687A0546 NNS O
. P02225687A0546 . O
. . O O

The P09042755T0000 DT O
alternative P09042755T0000 JJ O
sigma P09042755T0000 NN I-UN
factor P09042755T0000 NN I-UN
sigmaB P09042755T0000 NN I-UN
in P09042755T0000 IN I-UN
Staphylococcus P09042755T0000 NNP I-UN
aureus P09042755T0000 NN I-UN
: P09042755T0000 : O
regulation P09042755T0000 NN O
of P09042755T0000 IN O
the P09042755T0000 DT O
sigB P09042755T0000 NN I-UN
operon P09042755T0000 NN I-UN
in P09042755T0000 IN O
response P09042755T0000 NN O
to P09042755T0000 TO O
growth P09042755T0000 NN O
phase P09042755T0000 NN O
and P09042755T0000 CC O
heat P09042755T0000 NN O
shock P09042755T0000 NN O
. P09042755T0000 . O
. . O O

We P02158927A0000 PRP O
have P02158927A0000 VBP O
determined P02158927A0000 VBN O
the P02158927A0000 DT O
nucleotide P02158927A0000 NN O
( P02158927A0000 ( O
nt P02158927A0000 JJ O
) P02158927A0000 ) O
sequence P02158927A0000 NN O
of P02158927A0000 IN O
the P02158927A0000 DT O
7.5-kb P02158927A0000 JJ I-UN
COR P02158927A0000 NNP I-UN
segment P02158927A0000 NN I-UN
that P02158927A0000 WDT O
encompasses P02158927A0000 VBZ O
a P02158927A0000 DT O
cluster P02158927A0000 NN O
of P02158927A0000 IN O
six P02158927A0000 CD O
genes P02158927A0000 NNS O
( P02158927A0000 ( O
CYC1 P02158927A0000 NNP I-UN
, P02158927A0000 , O
UTR1 P02158927A0000 NNP I-UN
, P02158927A0000 , O
UTR3 P02158927A0000 NNP I-UN
, P02158927A0000 , O
OSM1 P02158927A0000 NNP I-UN
, P02158927A0000 , O
tRNA P02158927A0000 NN I-UN
( P02158927A0000 ( I-UN
Gly P02158927A0000 NNP I-UN
) P02158927A0000 ) I-UN
and P02158927A0000 CC O
RAD7 P02158927A0000 NNP I-UN
) P02158927A0000 ) O
located P02158927A0000 VBN O
on P02158927A0000 IN O
chromosome P02158927A0000 NN O
X P02158927A0000 NN O
of P02158927A0000 IN O
the P02158927A0000 DT O
yeast P02158927A0000 NN O
Saccharomyces P02158927A0000 NNP O
cerevisiae P02158927A0000 NN O
. P02158927A0000 . O
. . O O

Biochemical P11428897A0318 JJ O
experiments P11428897A0318 NNS O
have P11428897A0318 VBP O
shown P11428897A0318 VBN O
that P11428897A0318 IN O
CopG P11428897A0318 NNP I-UN
co-operatively P11428897A0318 RB O
associates P11428897A0318 VBZ O
to P11428897A0318 TO O
its P11428897A0318 PRP$ O
target P11428897A0318 NN O
DNA P11428897A0318 NN O
at P11428897A0318 IN O
low P11428897A0318 JJ O
protein P11428897A0318 NN O
: P11428897A0318 : O
DNA P11428897A0318 NN O
ratios P11428897A0318 NNS O
, P11428897A0318 , O
completely P11428897A0318 RB O
protecting P11428897A0318 VBG O
four P11428897A0318 CD O
helical P11428897A0318 JJ O
turns P11428897A0318 NNS O
on P11428897A0318 IN O
the P11428897A0318 DT O
same P11428897A0318 JJ O
face P11428897A0318 NN O
of P11428897A0318 IN O
the P11428897A0318 DT O
double P11428897A0318 JJ O
helix P11428897A0318 NN O
in P11428897A0318 IN O
both P11428897A0318 DT O
directions P11428897A0318 NNS O
from P11428897A0318 IN O
the P11428897A0318 DT O
inverted P11428897A0318 JJ O
repeat P11428897A0318 NN O
that P11428897A0318 WDT O
constitutes P11428897A0318 VBZ O
the P11428897A0318 DT O
CopG P11428897A0318 NNP I-UN
primary P11428897A0318 JJ O
target P11428897A0318 NN O
. P11428897A0318 . O
. . O O

The P07628438T0000 DT O
Drosophila P07628438T0000 NNP I-UN
insulin P07628438T0000 NN I-UN
receptor P07628438T0000 NN I-UN
homolog P07628438T0000 NN I-UN
: P07628438T0000 : O
a P07628438T0000 DT O
gene P07628438T0000 NN O
essential P07628438T0000 JJ O
for P07628438T0000 IN O
embryonic P07628438T0000 JJ O
development P07628438T0000 NN O
encodes P07628438T0000 NNS O
two P07628438T0000 CD O
receptor P07628438T0000 NN O
isoforms P07628438T0000 NNS O
with P07628438T0000 IN O
different P07628438T0000 JJ O
signaling P07628438T0000 VBG O
potential P07628438T0000 NN O
. P07628438T0000 . O
. . O O

Model P09961682T0000 NN O
of P09961682T0000 IN O
spatiotemporal P09961682T0000 JJ O
dynamics P09961682T0000 NNS O
of P09961682T0000 IN O
stick-slip P09961682T0000 JJ O
motion P09961682T0000 NN O
. P09961682T0000 . O
. . O O

Guiding P02200150A1381 VBG O
patients P02200150A1381 NNS O
in P02200150A1381 IN O
the P02200150A1381 DT O
decision P02200150A1381 NN O
should P02200150A1381 MD O
involve P02200150A1381 VB O
a P02200150A1381 DT O
multidisciplinary P02200150A1381 JJ O
team P02200150A1381 NN O
composed P02200150A1381 VBD O
of P02200150A1381 IN O
a P02200150A1381 DT O
surgical P02200150A1381 JJ O
oncologist P02200150A1381 NN O
, P02200150A1381 , O
geneticist P02200150A1381 NN O
, P02200150A1381 , O
pathologist P02200150A1381 NN O
, P02200150A1381 , O
psychotherapist P02200150A1381 NN O
and P02200150A1381 CC O
plastic P02200150A1381 NN O
surgeon P02200150A1381 NN O
. P02200150A1381 . O
. . O O

Using P11044097A0422 VBG O
purified P11044097A0422 VBN O
recombinant P11044097A0422 JJ I-UN
HMG P11044097A0422 NNP I-UN
I P11044097A0422 PRP I-UN
, P11044097A0422 , O
we P11044097A0422 PRP O
have P11044097A0422 VBP O
identified P11044097A0422 VBN O
several P11044097A0422 JJ O
high-affinity P11044097A0422 NN O
binding P11044097A0422 NN O
sites P11044097A0422 NNS O
which P11044097A0422 WDT O
overlap P11044097A0422 VBP O
important P11044097A0422 JJ O
transcription P11044097A0422 NN O
factor P11044097A0422 NN O
binding P11044097A0422 VBG O
sites P11044097A0422 NNS O
. P11044097A0422 . O
. . O O

Our P01396592A1113 PRP$ O
experiments P01396592A1113 NNS O
suggest P01396592A1113 VBP O
that P01396592A1113 IN O
the P01396592A1113 DT O
SCL P01396592A1113 NNP I-UN
gene P01396592A1113 NN I-UN
can P01396592A1113 MD O
be P01396592A1113 VB O
a P01396592A1113 DT O
target P01396592A1113 NN O
for P01396592A1113 IN O
the P01396592A1113 DT O
erythroid P01396592A1113 JJ I-UN
transcription P01396592A1113 NN I-UN
factor P01396592A1113 NN I-UN
GATA-1 P01396592A1113 NNP I-UN
and P01396592A1113 CC O
that P01396592A1113 IN O
the P01396592A1113 DT O
SCL P01396592A1113 NNP I-UN
gene P01396592A1113 NN I-UN
product P01396592A1113 NN I-UN
serves P01396592A1113 VBZ O
as P01396592A1113 IN O
a P01396592A1113 DT O
positive P01396592A1113 JJ O
regulator P01396592A1113 NN O
of P01396592A1113 IN O
erythroid P01396592A1113 JJ O
differentiation P01396592A1113 NN O
. P01396592A1113 . O
. . O O

This P08083220A0988 DT O
mode P08083220A0988 NN O
of P08083220A0988 IN O
ternary P08083220A0988 JJ O
complex P08083220A0988 JJ O
formation P08083220A0988 NN O
is P08083220A0988 VBZ O
in P08083220A0988 IN O
contrast P08083220A0988 NN O
to P08083220A0988 TO O
the P08083220A0988 DT O
one P08083220A0988 CD O
seen P08083220A0988 VBN O
in P08083220A0988 IN O
the P08083220A0988 DT O
promoter P08083220A0988 NN O
of P08083220A0988 IN O
the P08083220A0988 DT O
c-fos P08083220A0988 JJ I-UN
protooncogene P08083220A0988 NN I-UN
, P08083220A0988 , O
where P08083220A0988 WRB O
formation P08083220A0988 NN O
of P08083220A0988 IN O
the P08083220A0988 DT O
ternary P08083220A0988 JJ O
complex P08083220A0988 NN O
is P08083220A0988 VBZ O
dependent P08083220A0988 JJ O
on P08083220A0988 IN O
the P08083220A0988 DT O
prior P08083220A0988 JJ O
assembly P08083220A0988 NN O
of P08083220A0988 IN O
the P08083220A0988 DT O
serum P08083220A0988 JJ I-UN
response P08083220A0988 NN I-UN
factor-DNA P08083220A0988 JJ I-UN
binary P08083220A0988 JJ I-UN
complex P08083220A0988 NN I-UN
. P08083220A0988 . O
. . O O

The P08530369A0099 DT O
site P08530369A0099 NN O
of P08530369A0099 IN O
autophosphorylation P08530369A0099 NN O
is P08530369A0099 VBZ O
Tyr397 P08530369A0099 NNP O
which P08530369A0099 WDT O
corresponds P08530369A0099 VBZ O
to P08530369A0099 TO O
the P08530369A0099 DT O
consensus P08530369A0099 NN O
autophosphorylation P08530369A0099 NN O
site P08530369A0099 NN O
of P08530369A0099 IN O
other P08530369A0099 JJ O
Src P08530369A0099 NNP I-UN
family P08530369A0099 NN I-UN
tyrosine P08530369A0099 NN I-UN
kinases P08530369A0099 NNS I-UN
. P08530369A0099 . O
. . O O

Homozygous P02206858A0000 JJ O
protein P02206858A0000 NN I-UN
C P02206858A0000 NNP I-UN
( P02206858A0000 ( O
PC P02206858A0000 NN I-UN
) P02206858A0000 ) O
deficiency P02206858A0000 NN O
is P02206858A0000 VBZ O
reported P02206858A0000 VBN O
in P02206858A0000 IN O
two P02206858A0000 CD O
siblings P02206858A0000 NNS O
( P02206858A0000 ( O
girl P02206858A0000 NN O
and P02206858A0000 CC O
boy P02206858A0000 NN O
) P02206858A0000 ) O
who P02206858A0000 WP O
received P02206858A0000 VBD O
their P02206858A0000 PRP$ O
proper P02206858A0000 JJ O
diagnoses P02206858A0000 NNS O
at P02206858A0000 IN O
the P02206858A0000 DT O
ages P02206858A0000 NNS O
of P02206858A0000 IN O
7 P02206858A0000 CD O
4 P02206858A0000 CD O
/ P02206858A0000 NN O
12 P02206858A0000 CD O
and P02206858A0000 CC O
1 P02206858A0000 CD O
3 P02206858A0000 CD O
/ P02206858A0000 JJ O
12 P02206858A0000 CD O
years P02206858A0000 NNS O
respectively P02206858A0000 RB O
. P02206858A0000 . O
. . O O

Serological P00779272T0001 JJ O
studies P00779272T0001 NNS O
of P00779272T0001 IN O
antibodies P00779272T0001 NNS O
to P00779272T0001 TO O
Epstein-Barr P00779272T0001 NNP O
virus P00779272T0001 NN O
in P00779272T0001 IN O
infectious P00779272T0001 JJ O
mononucleosis P00779272T0001 NN O
. P00779272T0001 . O
. . O O

Local P11524815A0753 JJ O
control P11524815A0753 NN O
rates P11524815A0753 NNS O
were P11524815A0753 VBD O
91 P11524815A0753 CD O
% P11524815A0753 NN O
for P11524815A0753 IN O
metastatic P11524815A0753 JJ O
lung P11524815A0753 NN O
cancer P11524815A0753 NN O
, P11524815A0753 , O
89 P11524815A0753 CD O
% P11524815A0753 NN O
for P11524815A0753 IN O
primary P11524815A0753 JJ O
lung P11524815A0753 NN O
cancer P11524815A0753 NN O
and P11524815A0753 CC O
85 P11524815A0753 CD O
% P11524815A0753 NN O
for P11524815A0753 IN O
T1 P11524815A0753 NNP O
, P11524815A0753 , O
2N0M0 P11524815A0753 CD O
cases P11524815A0753 NNS O
. P11524815A0753 . O
. . O O

Although P10727428A0000 IN O
MAP P10727428A0000 NNP I-UN
( P10727428A0000 ( I-UN
mitogen-activated P10727428A0000 JJ I-UN
protein P10727428A0000 NN I-UN
) P10727428A0000 ) I-UN
kinases P10727428A0000 NNS I-UN
are P10727428A0000 VBP O
implicated P10727428A0000 VBN O
in P10727428A0000 IN O
cell P10727428A0000 NN O
proliferation P10727428A0000 NN O
and P10727428A0000 CC O
differentiation P10727428A0000 NN O
in P10727428A0000 IN O
many P10727428A0000 JJ O
cell P10727428A0000 NN O
types P10727428A0000 NNS O
, P10727428A0000 , O
the P10727428A0000 DT O
role P10727428A0000 NN O
of P10727428A0000 IN O
MAP P10727428A0000 NNP I-UN
kinases P10727428A0000 NNS I-UN
in P10727428A0000 IN O
cardiac P10727428A0000 JJ O
hypertrophy P10727428A0000 NN O
remains P10727428A0000 VBZ O
unclear P10727428A0000 JJ O
. P10727428A0000 . O
. . O O

The P01833637A0531 DT O
abundance P01833637A0531 NN O
of P01833637A0531 IN O
transcripts P01833637A0531 NNS O
from P01833637A0531 IN O
several P01833637A0531 JJ O
unrelated P01833637A0531 JJ O
genes P01833637A0531 NNS O
is P01833637A0531 VBZ O
decreased P01833637A0531 VBN O
in P01833637A0531 IN O
cdc68-1 P01833637A0531 JJ I-UN
mutant P01833637A0531 NN I-UN
cells P01833637A0531 NNS O
after P01833637A0531 IN O
transfer P01833637A0531 NN O
to P01833637A0531 TO O
the P01833637A0531 DT O
restrictive P01833637A0531 JJ O
temperature P01833637A0531 NN O
, P01833637A0531 , O
while P01833637A0531 IN O
at P01833637A0531 IN O
least P01833637A0531 JJS O
one P01833637A0531 CD O
transcript P01833637A0531 NN O
, P01833637A0531 , O
from P01833637A0531 IN O
the P01833637A0531 DT O
HSP82 P01833637A0531 NNP I-UN
gene P01833637A0531 NN I-UN
, P01833637A0531 , O
persists P01833637A0531 NNS O
in P01833637A0531 IN O
an P01833637A0531 DT O
aberrant P01833637A0531 JJ O
fashion P01833637A0531 NN O
. P01833637A0531 . O
. . O O

If P01904154A0164 IN O
this P01904154A0164 DT O
is P01904154A0164 VBZ O
the P01904154A0164 DT O
case P01904154A0164 NN O
, P01904154A0164 , O
identification P01904154A0164 NN O
and P01904154A0164 CC O
characterization P01904154A0164 NN O
of P01904154A0164 IN O
transcripts P01904154A0164 NNS O
from P01904154A0164 IN O
the P01904154A0164 DT O
Ig P01904154A0164 NNP I-UN
loci P01904154A0164 NN I-UN
should P01904154A0164 MD O
permit P01904154A0164 VB O
a P01904154A0164 DT O
better P01904154A0164 JJR O
understanding P01904154A0164 NN O
of P01904154A0164 IN O
the P01904154A0164 DT O
gene P01904154A0164 NN O
rearrangement P01904154A0164 JJ O
process P01904154A0164 NN O
. P01904154A0164 . O
. . O O

Analysis P02075876T0001 NN O
of P02075876T0001 IN O
electrically P02075876T0001 RB O
evoked P02075876T0001 VBN O
response P02075876T0001 NN O
( P02075876T0001 ( O
EER P02075876T0001 NNP O
) P02075876T0001 ) O
in P02075876T0001 IN O
relation P02075876T0001 NN O
to P02075876T0001 TO O
the P02075876T0001 DT O
central P02075876T0001 JJ O
visual P02075876T0001 JJ O
pathway P02075876T0001 NN O
of P02075876T0001 IN O
the P02075876T0001 DT O
cat P02075876T0001 NN O
( P02075876T0001 ( O
1 P02075876T0001 CD O
) P02075876T0001 ) O
. P02075876T0001 . O
. . O O

A P11334124A0903 DT O
log-linear P11334124A0903 JJ O
dose-response P11334124A0903 NN O
was P11334124A0903 VBD O
obtained P11334124A0903 VBN O
for P11334124A0903 IN O
the P11334124A0903 DT O
average P11334124A0903 JJ O
increase P11334124A0903 NN O
in P11334124A0903 IN O
FEV1 P11334124A0903 NNP O
up P11334124A0903 RB O
to P11334124A0903 TO O
6 P11334124A0903 CD O
h P11334124A0903 NN O
( P11334124A0903 ( O
AUC0-6 P11334124A0903 NNP O
h P11334124A0903 NN O
) P11334124A0903 ) O
and P11334124A0903 CC O
peak P11334124A0903 JJ O
FEV1 P11334124A0903 NNP O
across P11334124A0903 IN O
the P11334124A0903 DT O
dose P11334124A0903 NN O
range P11334124A0903 NN O
administered P11334124A0903 VBN O
by P11334124A0903 IN O
Respimat P11334124A0903 NNP O
. P11334124A0903 . O
. . O O

The P09586832A0229 DT O
lines P09586832A0229 NNS O
also P09586832A0229 RB O
differed P09586832A0229 VBN O
in P09586832A0229 IN O
postsynaptic P09586832A0229 JJ O
, P09586832A0229 , O
but P09586832A0229 CC O
not P09586832A0229 RB O
presynaptic P09586832A0229 JJ O
, P09586832A0229 , O
5-HT1A P09586832A0229 JJ I-UN
receptors P09586832A0229 NNS I-UN
. P09586832A0229 . O
. . O O

Physical P07851758A0330 JJ O
analysis P07851758A0330 NN O
maps P07851758A0330 NNS O
SAL6 P07851758A0330 NNP I-UN
to P07851758A0330 TO O
chromosome P07851758A0330 VB O
XVI P07851758A0330 NNP O
between P07851758A0330 IN O
TPK2 P07851758A0330 NNP I-UN
and P07851758A0330 CC O
spt14 P07851758A0330 NN I-UN
. P07851758A0330 . O
. . O O

The P10398682A0365 DT O
crystal P10398682A0365 JJ O
structure P10398682A0365 NN O
of P10398682A0365 IN O
the P10398682A0365 DT O
VP16 P10398682A0365 NNP I-UN
core P10398682A0365 NN I-UN
has P10398682A0365 VBZ O
been P10398682A0365 VBN O
determined P10398682A0365 VBN O
at P10398682A0365 IN O
2.1 P10398682A0365 CD O
A P10398682A0365 DT O
resolution P10398682A0365 NN O
. P10398682A0365 . O
. . O O

Strikingly P09199292A0536 RB O
, P09199292A0536 , O
stoichiometric P09199292A0536 JJ O
association P09199292A0536 NN O
of P09199292A0536 IN O
p107 P09199292A0536 NN I-UN
or P09199292A0536 CC O
p130 P09199292A0536 NN I-UN
with P09199292A0536 IN O
either P09199292A0536 DT O
cyclin P09199292A0536 JJ I-UN
E-cdk2 P09199292A0536 NNP O
or P09199292A0536 CC O
cyclin P09199292A0536 VB I-UN
A-cdk2 P09199292A0536 NNP O
negated P09199292A0536 VBD O
the P09199292A0536 DT O
activities P09199292A0536 NNS O
of P09199292A0536 IN O
these P09199292A0536 DT O
kinases P09199292A0536 NNS O
. P09199292A0536 . O
. . O O

The P08812012T0000 DT O
effects P08812012T0000 NNS O
of P08812012T0000 IN O
procedural P08812012T0000 JJ O
variations P08812012T0000 NNS O
on P08812012T0000 IN O
lateralized P08812012T0000 JJ O
Stroop P08812012T0000 NNP O
effects P08812012T0000 NNS O
. P08812012T0000 . O
. . O O

Structure P08145646T0000 NN O
and P08145646T0000 CC O
expression P08145646T0000 NN O
of P08145646T0000 IN O
the P08145646T0000 DT O
alternative P08145646T0000 JJ O
sigma P08145646T0000 NN I-UN
factor P08145646T0000 NN I-UN
, P08145646T0000 , O
RpoN P08145646T0000 NNP I-UN
, P08145646T0000 , O
in P08145646T0000 IN O
Rhodobacter P08145646T0000 NNP O
capsulatus P08145646T0000 NN O
; P08145646T0000 : O
physiological P08145646T0000 JJ O
relevance P08145646T0000 NN O
of P08145646T0000 IN O
an P08145646T0000 DT O
autoactivated P08145646T0000 JJ O
nifU2-rpoN P08145646T0000 JJ O
superoperon P08145646T0000 NN O
. P08145646T0000 . O
. . O O

Antidromic P05412687T0000 NNP O
invasion P05412687T0000 NN O
of P05412687T0000 IN O
impulses P05412687T0000 NNS O
and P05412687T0000 CC O
recurrent P05412687T0000 JJ O
collateral P05412687T0000 NN O
inhibition P05412687T0000 NN O
in P05412687T0000 IN O
pyramidal P05412687T0000 JJ O
tract P05412687T0000 NN O
neurones P05412687T0000 NNS O
. P05412687T0000 . O
. . O O

Some P07477245A0625 DT O
strains P07477245A0625 NNS O
of P07477245A0625 IN O
A. P07477245A0625 NN O
parasiticus P07477245A0625 NN O
produced P07477245A0625 VBD O
all P07477245A0625 DT O
four P07477245A0625 CD O
aflatoxins P07477245A0625 NNS O
B1 P07477245A0625 NNP O
B2 P07477245A0625 NNP O
G1 P07477245A0625 NNP O
G2 P07477245A0625 NNP O
, P07477245A0625 , O
while P07477245A0625 IN O
the P07477245A0625 DT O
other P07477245A0625 JJ O
ones P07477245A0625 NNS O
produced P07477245A0625 VBN O
AF P07477245A0625 NNP O
B1 P07477245A0625 NNP O
+ P07477245A0625 NNP O
G1 P07477245A0625 NNP O
only P07477245A0625 RB O
, P07477245A0625 , O
with P07477245A0625 IN O
concentrations P07477245A0625 NNS O
of P07477245A0625 IN O
aflatoxins P07477245A0625 NNS O
from P07477245A0625 IN O
0.1 P07477245A0625 CD O
to P07477245A0625 TO O
450 P07477245A0625 CD O
mg P07477245A0625 NNS O
/ P07477245A0625 JJ O
kg P07477245A0625 NN O
. P07477245A0625 . O
. . O O

The P03678372A0170 DT O
number P03678372A0170 NN O
of P03678372A0170 IN O
fecal P03678372A0170 JJ O
pellets P03678372A0170 NNS O
ingested P03678372A0170 VBN O
peaked P03678372A0170 VBD O
at P03678372A0170 IN O
5 P03678372A0170 CD O
to P03678372A0170 TO O
6 P03678372A0170 CD O
weeks P03678372A0170 NNS O
old P03678372A0170 JJ O
( P03678372A0170 ( O
13 P03678372A0170 CD O
pellets P03678372A0170 NNS O
/ P03678372A0170 JJ O
day P03678372A0170 NN O
) P03678372A0170 ) O
and P03678372A0170 CC O
gradually P03678372A0170 RB O
decreased P03678372A0170 VBN O
, P03678372A0170 , O
thereafter P03678372A0170 RB O
( P03678372A0170 ( O
2.1 P03678372A0170 CD O
pellets P03678372A0170 NNS O
at P03678372A0170 IN O
78 P03678372A0170 CD O
weeks P03678372A0170 NNS O
old P03678372A0170 JJ O
, P03678372A0170 , O
1.5 P03678372A0170 CD O
pellets P03678372A0170 NNS O
at P03678372A0170 IN O
104 P03678372A0170 CD O
weeks P03678372A0170 NNS O
old P03678372A0170 JJ O
) P03678372A0170 ) O
. P03678372A0170 . O
. . O O

D3S1261 P10385915A1341 NNP I-UN
is P10385915A1341 VBZ O
physically P10385915A1341 RB O
located P10385915A1341 VBN O
at P10385915A1341 IN O
or P10385915A1341 CC O
near P10385915A1341 IN O
the P10385915A1341 DT O
MITF P10385915A1341 NNP I-UN
locus P10385915A1341 NN I-UN
, P10385915A1341 , O
while P10385915A1341 IN O
D3S2465 P10385915A1341 NNP I-UN
and P10385915A1341 CC O
D3S1766 P10385915A1341 NNP I-UN
are P10385915A1341 VBP O
flanking P10385915A1341 VBG O
the P10385915A1341 DT O
locus P10385915A1341 NN O
at P10385915A1341 IN O
about P10385915A1341 IN O
17.5 P10385915A1341 CD O
cM P10385915A1341 NNS O
genetic P10385915A1341 JJ O
distance P10385915A1341 NN O
each P10385915A1341 DT O
side P10385915A1341 NN O
. P10385915A1341 . O
. . O O

The P11793172A0545 DT O
weight-bearing P11793172A0545 JJ O
surface P11793172A0545 NN O
of P11793172A0545 IN O
the P11793172A0545 DT O
PE P11793172A0545 NNP O
head P11793172A0545 NN O
became P11793172A0545 VBD O
smoother P11793172A0545 RB O
with P11793172A0545 IN O
time P11793172A0545 NN O
after P11793172A0545 IN O
THA P11793172A0545 NNP O
, P11793172A0545 , O
and P11793172A0545 CC O
the P11793172A0545 DT O
friction P11793172A0545 NN O
coefficient P11793172A0545 NN O
did P11793172A0545 VBD O
not P11793172A0545 RB O
differ P11793172A0545 VB O
significantly P11793172A0545 RB O
from P11793172A0545 IN O
that P11793172A0545 IN O
of P11793172A0545 IN O
an P11793172A0545 DT O
unused P11793172A0545 JJ O
PE P11793172A0545 NNP O
head P11793172A0545 NN O
. P11793172A0545 . O
. . O O

No P10679922A1110 DT O
somatic P10679922A1110 JJ O
mutations P10679922A1110 NNS O
were P10679922A1110 VBD O
found P10679922A1110 VBN O
in P10679922A1110 IN O
any P10679922A1110 DT O
of P10679922A1110 IN O
the P10679922A1110 DT O
samples P10679922A1110 NNS O
, P10679922A1110 , O
suggesting P10679922A1110 VBG O
that P10679922A1110 IN O
ING1 P10679922A1110 NNP I-UN
is P10679922A1110 VBZ O
not P10679922A1110 RB O
a P10679922A1110 DT O
tumor P10679922A1110 NN O
suppressor P10679922A1110 NN O
gene P10679922A1110 NN O
target P10679922A1110 NN O
in P10679922A1110 IN O
head P10679922A1110 NN O
and P10679922A1110 CC O
neck P10679922A1110 NN O
cancer P10679922A1110 NN O
. P10679922A1110 . O
. . O O

DESIGN P08189174A0148 NNP O
-- P08189174A0148 : O
A P08189174A0148 DT O
randomised P08189174A0148 JJ O
study P08189174A0148 NN O
was P08189174A0148 VBD O
conducted P08189174A0148 VBN O
in P08189174A0148 IN O
all P08189174A0148 DT O
women P08189174A0148 NNS O
aged P08189174A0148 VBN O
50-70 P08189174A0148 JJ O
years P08189174A0148 NNS O
who P08189174A0148 WP O
were P08189174A0148 VBD O
eligible P08189174A0148 JJ O
for P08189174A0148 IN O
breast P08189174A0148 NN O
cancer P08189174A0148 NN O
screening P08189174A0148 NN O
and P08189174A0148 CC O
living P08189174A0148 NN O
in P08189174A0148 IN O
the P08189174A0148 DT O
city P08189174A0148 NN O
of P08189174A0148 IN O
Utrecht P08189174A0148 NNP O
. P08189174A0148 . O
. . O O

The P10810083A1283 DT O
serine-threonine P10810083A1283 JJ I-UN
kinase P10810083A1283 NN I-UN
gene P10810083A1283 NN I-UN
is P10810083A1283 VBZ O
likely P10810083A1283 JJ O
functional P10810083A1283 JJ O
, P10810083A1283 , O
whereas P10810083A1283 IN O
the P10810083A1283 DT O
zinc P10810083A1283 NN O
finger P10810083A1283 NN O
motif P10810083A1283 NN O
is P10810083A1283 VBZ O
likely P10810083A1283 JJ O
nonfunctional P10810083A1283 JJ O
. P10810083A1283 . O
. . O O

DNA P07928954A0545 NN O
sequence P07928954A0545 NN O
analysis P07928954A0545 NN O
showed P07928954A0545 VBD O
that P07928954A0545 IN O
the P07928954A0545 DT O
gene P07928954A0545 NN O
was P07928954A0545 VBD O
525 P07928954A0545 CD O
bp P07928954A0545 NN O
long P07928954A0545 RB O
and P07928954A0545 CC O
encoded P07928954A0545 VBD O
a P07928954A0545 DT O
175-amino-acid P07928954A0545 JJ O
protein P07928954A0545 NN O
with P07928954A0545 IN O
a P07928954A0545 DT O
molecular P07928954A0545 JJ O
weight P07928954A0545 NN O
of P07928954A0545 IN O
19,094 P07928954A0545 CD O
containing P07928954A0545 VBG O
a P07928954A0545 DT O
21-residue P07928954A0545 JJ O
typical P07928954A0545 JJ O
lipoprotein P07928954A0545 NN O
signal P07928954A0545 JJ O
peptide P07928954A0545 NN O
and P07928954A0545 CC O
consensus P07928954A0545 NN O
prolipoprotein P07928954A0545 NN O
processing P07928954A0545 VBG O
site P07928954A0545 NN O
. P07928954A0545 . O
. . O O

Acad P09371612A1964 NNP O
. P09371612A1964 . O
. . O O

We P11863811A0259 PRP O
find P11863811A0259 VBP O
that P11863811A0259 IN O
the P11863811A0259 DT O
measured P11863811A0259 VBN O
Nusselt P11863811A0259 NNP O
number P11863811A0259 NN O
decreased P11863811A0259 VBD O
about P11863811A0259 RB O
20 P11863811A0259 CD O
% P11863811A0259 NN O
over P11863811A0259 IN O
the P11863811A0259 DT O
range P11863811A0259 NN O
of P11863811A0259 IN O
Pr P11863811A0259 NNP O
spanned P11863811A0259 VBD O
in P11863811A0259 IN O
the P11863811A0259 DT O
experiment P11863811A0259 NN O
. P11863811A0259 . O
. . O O

Piroxicam P03977603A0326 NNP O
produced P03977603A0326 VBD O
a P03977603A0326 DT O
lower P03977603A0326 JJR O
incidence P03977603A0326 NN O
of P03977603A0326 IN O
gastric P03977603A0326 JJ O
ulcers P03977603A0326 NNS O
than P03977603A0326 IN O
equivalent P03977603A0326 JJ O
doses P03977603A0326 NNS O
of P03977603A0326 IN O
indomethacin P03977603A0326 NN O
. P03977603A0326 . O
. . O O

Dual P01009841T0001 JJ O
innervation P01009841T0001 NN O
of P01009841T0001 IN O
fast P01009841T0001 JJ O
fibers P01009841T0001 NNS O
in P01009841T0001 IN O
trunk P01009841T0001 NN O
muscles P01009841T0001 NNS O
of P01009841T0001 IN O
lamprey P01009841T0001 JJ O
larvae P01009841T0001 NN O
. P01009841T0001 . O
. . O O

The P03123310A0000 DT O
Drosophila P03123310A0000 NNP I-UN
melanogaster P03123310A0000 NN I-UN
Gart P03123310A0000 NNP I-UN
gene P03123310A0000 NN I-UN
encodes P03123310A0000 NNS O
three P03123310A0000 CD O
enzymatic P03123310A0000 JJ O
activities P03123310A0000 NNS O
in P03123310A0000 IN O
the P03123310A0000 DT O
pathway P03123310A0000 NN O
for P03123310A0000 IN O
purine P03123310A0000 NN O
de P03123310A0000 FW O
novo P03123310A0000 FW O
synthesis P03123310A0000 NN O
. P03123310A0000 . O
. . O O

They P10361038A0281 PRP O
also P10361038A0281 RB O
occur P10361038A0281 VBP O
in P10361038A0281 IN O
similar P10361038A0281 JJ O
locations P10361038A0281 NNS O
in P10361038A0281 IN O
the P10361038A0281 DT O
promoters P10361038A0281 NNS O
of P10361038A0281 IN O
several P10361038A0281 JJ O
other P10361038A0281 JJ O
ribosomal P10361038A0281 JJ I-UN
protein P10361038A0281 NN I-UN
genes P10361038A0281 NNS I-UN
. P10361038A0281 . O
. . O O

These P01447189A1546 DT O
data P01447189A1546 NNS O
indicate P01447189A1546 VBP O
that P01447189A1546 IN O
RNK-Met-1 P01447189A1546 NNP I-UN
is P01447189A1546 VBZ O
a P01447189A1546 DT O
serine P01447189A1546 JJ I-UN
protease P01447189A1546 NN I-UN
with P01447189A1546 IN O
unique P01447189A1546 JJ O
activity P01447189A1546 NN O
that P01447189A1546 WDT O
is P01447189A1546 VBZ O
expressed P01447189A1546 VBN O
in P01447189A1546 IN O
the P01447189A1546 DT O
granules P01447189A1546 NNS O
of P01447189A1546 IN O
large P01447189A1546 JJ O
granular P01447189A1546 JJ O
lymphocytes P01447189A1546 NNS O
. P01447189A1546 . O
. . O O

IFN-gamma P09933428A0351 NNP I-UN
was P09933428A0351 VBD O
elevated P09933428A0351 VBN O
during P09933428A0351 IN O
active P09933428A0351 JJ O
TB P09933428A0351 NNP O
when P09933428A0351 WRB O
compared P09933428A0351 VBN O
with P09933428A0351 IN O
healthy P09933428A0351 JJ O
controls P09933428A0351 NNS O
, P09933428A0351 , O
declining P09933428A0351 VBG O
during P09933428A0351 IN O
and P09933428A0351 CC O
after P09933428A0351 IN O
treatment P09933428A0351 NN O
. P09933428A0351 . O
. . O O

Overexpression P09199167A0942 NN O
of P09199167A0942 IN O
Sed5p P09199167A0942 NNP I-UN
allowed P09199167A0942 VBD O
growth P09199167A0942 NN O
in P09199167A0942 IN O
the P09199167A0942 DT O
absence P09199167A0942 NN O
of P09199167A0942 IN O
Vti1p P09199167A0942 NNP I-UN
. P09199167A0942 . O
. . O O

In P03331525T0001 IN O
vitro P03331525T0001 NN O
study P03331525T0001 NN O
of P03331525T0001 IN O
dentin P03331525T0001 JJ O
adhesion P03331525T0001 NN O
to P03331525T0001 TO O
adhesives P03331525T0001 NNS O
made P03331525T0001 VBN O
from P03331525T0001 IN O
urethane P03331525T0001 JJ O
molecules P03331525T0001 NNS O
with P03331525T0001 IN O
free P03331525T0001 JJ O
groups P03331525T0001 NNS O
of P03331525T0001 IN O
isocyanate P03331525T0001 NN O
. P03331525T0001 . O
. . O O

Ultraviolet P04164669T0000 NNP O
light-induced P04164669T0000 JJ O
kinin P04164669T0000 NN I-UN
formation P04164669T0000 NN O
in P04164669T0000 IN O
human P04164669T0000 JJ O
skin P04164669T0000 NN O
. P04164669T0000 . O
. . O O

The P07739544A0364 DT O
predicted P07739544A0364 VBN O
amino P07739544A0364 NN O
acid P07739544A0364 JJ O
sequence P07739544A0364 NN O
of P07739544A0364 IN O
the P07739544A0364 DT O
SGC1 P07739544A0364 NNP I-UN
gene P07739544A0364 NN I-UN
product P07739544A0364 NN I-UN
includes P07739544A0364 VBZ O
a P07739544A0364 DT O
region P07739544A0364 NN O
with P07739544A0364 IN O
substantial P07739544A0364 JJ O
similarity P07739544A0364 NN O
to P07739544A0364 TO O
the P07739544A0364 DT O
basic-helix-loop-helix P07739544A0364 JJ O
domain P07739544A0364 NN O
of P07739544A0364 IN O
the P07739544A0364 DT O
Myc P07739544A0364 NNP I-UN
family P07739544A0364 NN I-UN
of P07739544A0364 IN O
DNA-binding P07739544A0364 NNP O
proteins P07739544A0364 NNS O
. P07739544A0364 . O
. . O O

Seventeen P07096587A0267 NN O
of P07096587A0267 IN O
the P07096587A0267 DT O
35 P07096587A0267 CD O
patients P07096587A0267 NNS O
were P07096587A0267 VBD O
randomly P07096587A0267 RB O
chosen P07096587A0267 VBN O
to P07096587A0267 TO O
receive P07096587A0267 VB O
a P07096587A0267 DT O
training P07096587A0267 NN O
program P07096587A0267 NN O
( P07096587A0267 ( O
lasting P07096587A0267 VBG O
approximately P07096587A0267 RB O
1 P07096587A0267 CD O
month P07096587A0267 NN O
) P07096587A0267 ) O
designed P07096587A0267 VBD O
to P07096587A0267 TO O
establish P07096587A0267 VB O
a P07096587A0267 DT O
systematic P07096587A0267 JJ O
strategy P07096587A0267 NN O
of P07096587A0267 IN O
organizing P07096587A0267 VBG O
complex P07096587A0267 JJ O
visual P07096587A0267 JJ O
material P07096587A0267 NN O
. P07096587A0267 . O
. . O O

An P07706291T0000 DT O
E P07706291T0000 NNP O
box P07706291T0000 NN O
element P07706291T0000 NN O
is P07706291T0000 VBZ O
required P07706291T0000 VBN O
for P07706291T0000 IN O
the P07706291T0000 DT O
expression P07706291T0000 NN O
of P07706291T0000 IN O
the P07706291T0000 DT O
ad4bp P07706291T0000 JJ I-UN
gene P07706291T0000 NN I-UN
, P07706291T0000 , O
a P07706291T0000 DT O
mammalian P07706291T0000 JJ I-UN
homologue P07706291T0000 NN I-UN
of P07706291T0000 IN I-UN
ftz-f1 P07706291T0000 JJ I-UN
gene P07706291T0000 NN I-UN
, P07706291T0000 , O
which P07706291T0000 WDT O
is P07706291T0000 VBZ O
essential P07706291T0000 JJ O
for P07706291T0000 IN O
adrenal P07706291T0000 JJ O
and P07706291T0000 CC O
gonadal P07706291T0000 JJ O
development P07706291T0000 NN O
. P07706291T0000 . O
. . O O

The P03143485A0366 DT O
Euglena P03143485A0366 NNP I-UN
ribosomal P03143485A0366 NN I-UN
protein P03143485A0366 NN I-UN
gene P03143485A0366 NN I-UN
cluster P03143485A0366 NN I-UN
resembles P03143485A0366 VBZ O
the P03143485A0366 DT O
S-10 P03143485A0366 NNP I-UN
ribosomal P03143485A0366 JJ I-UN
protein P03143485A0366 NN I-UN
operon P03143485A0366 NN I-UN
of P03143485A0366 IN I-UN
Escherichia P03143485A0366 NNP I-UN
coli P03143485A0366 NNS I-UN
in P03143485A0366 IN O
gene P03143485A0366 NN O
organization P03143485A0366 NN O
and P03143485A0366 CC O
follows P03143485A0366 VBZ O
the P03143485A0366 DT O
exact P03143485A0366 JJ O
linear P03143485A0366 JJ O
order P03143485A0366 NN O
of P03143485A0366 IN O
the P03143485A0366 DT O
analogous P03143485A0366 JJ O
genes P03143485A0366 NNS O
in P03143485A0366 IN O
the P03143485A0366 DT O
tobacco P03143485A0366 NN O
and P03143485A0366 CC O
liverwort P03143485A0366 NN O
chloroplast P03143485A0366 NN O
genomes P03143485A0366 NNS O
. P03143485A0366 . O
. . O O

We P08057762A0878 PRP O
have P08057762A0878 VBP O
found P08057762A0878 VBN O
a P08057762A0878 DT O
satisfactory P08057762A0878 JJ O
reproducibility P08057762A0878 NN O
in P08057762A0878 IN O
vitro P08057762A0878 NN O
( P08057762A0878 ( O
T1 P08057762A0878 NNP O
: P08057762A0878 : O
1.9 P08057762A0878 CD O
% P08057762A0878 NN O
; P08057762A0878 : O
T2 P08057762A0878 NNP O
: P08057762A0878 : O
6.2 P08057762A0878 CD O
% P08057762A0878 NN O
) P08057762A0878 ) O
, P08057762A0878 , O
while P08057762A0878 IN O
the P08057762A0878 DT O
reproducibility P08057762A0878 NN O
was P08057762A0878 VBD O
less P08057762A0878 RBR O
satisfactory P08057762A0878 JJ O
in P08057762A0878 IN O
vivo P08057762A0878 NN O
( P08057762A0878 ( O
T1 P08057762A0878 NNP O
: P08057762A0878 : O
16.4 P08057762A0878 CD O
% P08057762A0878 NN O
; P08057762A0878 : O
T2 P08057762A0878 NNP O
: P08057762A0878 : O
13.4 P08057762A0878 CD O
% P08057762A0878 NN O
) P08057762A0878 ) O
. P08057762A0878 . O
. . O O

To P02162049A0291 TO O
address P02162049A0291 VB O
this P02162049A0291 DT O
issue P02162049A0291 NN O
, P02162049A0291 , O
the P02162049A0291 DT O
gene P02162049A0291 NN O
for P02162049A0291 IN O
factor P02162049A0291 NN I-UN
Y P02162049A0291 NNP I-UN
has P02162049A0291 VBZ O
been P02162049A0291 VBN O
cloned P02162049A0291 VBN O
molecularly P02162049A0291 RB O
and P02162049A0291 CC O
its P02162049A0291 PRP$ O
DNA P02162049A0291 NN O
sequence P02162049A0291 NN O
has P02162049A0291 VBZ O
been P02162049A0291 VBN O
determined P02162049A0291 VBN O
. P02162049A0291 . O
. . O O

Two P09573202A0900 CD O
of P09573202A0900 IN O
these P09573202A0900 DT O
resulted P09573202A0900 VBN O
in P09573202A0900 IN O
increased P09573202A0900 JJ O
levels P09573202A0900 NNS O
of P09573202A0900 IN O
the P09573202A0900 DT O
alpha P09573202A0900 NN O
subunit P09573202A0900 NN O
, P09573202A0900 , O
and P09573202A0900 CC O
one P09573202A0900 CD O
caused P09573202A0900 VBD O
a P09573202A0900 DT O
substitution P09573202A0900 NN O
of P09573202A0900 IN O
glycine P09573202A0900 NN O
for P09573202A0900 IN O
the P09573202A0900 DT O
aspartic P09573202A0900 JJ O
acid P09573202A0900 NN O
residue P09573202A0900 NN O
at P09573202A0900 IN O
position P09573202A0900 NN O
171 P09573202A0900 CD O
, P09573202A0900 , O
in P09573202A0900 IN O
the P09573202A0900 DT O
N-terminal P09573202A0900 JJ O
domain P09573202A0900 NN O
. P09573202A0900 . O
. . O O

Functional P07488247T0000 JJ O
analysis P07488247T0000 NN O
of P07488247T0000 IN O
aryl P07488247T0000 JJ I-UN
hydrocarbon P07488247T0000 NN I-UN
receptor P07488247T0000 NN I-UN
nuclear P07488247T0000 JJ I-UN
translocator P07488247T0000 NN I-UN
interactions P07488247T0000 NNS O
with P07488247T0000 IN O
aryl P07488247T0000 JJ I-UN
hydrocarbon P07488247T0000 NN I-UN
receptor P07488247T0000 NN I-UN
in P07488247T0000 IN O
the P07488247T0000 DT O
yeast P07488247T0000 NN O
two-hybrid P07488247T0000 JJ O
system P07488247T0000 NN O
. P07488247T0000 . O
. . O O

Somatostatin P02566613T0000 NNP I-UN
gene P02566613T0000 NN I-UN
expression P02566613T0000 NN O
in P02566613T0000 IN O
pancreatic P02566613T0000 JJ O
islet P02566613T0000 NN O
cells P02566613T0000 NNS O
is P02566613T0000 VBZ O
directed P02566613T0000 VBN O
by P02566613T0000 IN O
cell-specific P02566613T0000 JJ O
DNA P02566613T0000 NNP O
control P02566613T0000 NN O
elements P02566613T0000 NNS O
and P02566613T0000 CC O
DNA-binding P02566613T0000 JJ O
proteins P02566613T0000 NNS O
. P02566613T0000 . O
. . O O

Pigs P01808186A0984 NNS O
were P01808186A0984 VBD O
switched P01808186A0984 VBN O
from P01808186A0984 IN O
the P01808186A0984 DT O
growing P01808186A0984 VBG O
to P01808186A0984 TO O
the P01808186A0984 DT O
finishing P01808186A0984 NN O
diet P01808186A0984 NN O
at P01808186A0984 IN O
57 P01808186A0984 CD O
and P01808186A0984 CC O
61 P01808186A0984 CD O
kg P01808186A0984 NN O
in P01808186A0984 IN O
Exp P01808186A0984 NNP O
. P01808186A0984 . O
. . O O

Altogether P09440616A0422 RB O
46 P09440616A0422 CD O
phase P09440616A0422 NN O
III P09440616A0422 NNP O
activities P09440616A0422 NNS O
were P09440616A0422 VBD O
recorded P09440616A0422 VBN O
. P09440616A0422 . O
. . O O

Data P03406054A0351 NNS O
on P03406054A0351 IN O
the P03406054A0351 DT O
line P03406054A0351 NN O
spread P03406054A0351 NN O
function P03406054A0351 NN O
( P03406054A0351 ( O
LSF P03406054A0351 NNP O
) P03406054A0351 ) O
were P03406054A0351 VBD O
obtained P03406054A0351 VBN O
from P03406054A0351 IN O
the P03406054A0351 DT O
image P03406054A0351 NN O
of P03406054A0351 IN O
a P03406054A0351 DT O
0.2 P03406054A0351 CD O
mm P03406054A0351 NN O
wide P03406054A0351 JJ O
slit P03406054A0351 NN O
between P03406054A0351 IN O
tungsten P03406054A0351 NN O
blocks P03406054A0351 NNS O
that P03406054A0351 WDT O
were P03406054A0351 VBD O
positioned P03406054A0351 VBN O
at P03406054A0351 IN O
the P03406054A0351 DT O
isocentre P03406054A0351 NN O
in P03406054A0351 IN O
front P03406054A0351 NN O
of P03406054A0351 IN O
a P03406054A0351 DT O
polystyrene P03406054A0351 NN O
phantom P03406054A0351 NN O
. P03406054A0351 . O
. . O O

Here P11336698A0075 RB O
, P11336698A0075 , O
we P11336698A0075 PRP O
identify P11336698A0075 VBP O
Rsc3 P11336698A0075 NNP I-UN
and P11336698A0075 CC O
Rsc30 P11336698A0075 NNP I-UN
as P11336698A0075 IN O
novel P11336698A0075 JJ O
components P11336698A0075 NNS O
of P11336698A0075 IN O
the P11336698A0075 DT O
essential P11336698A0075 JJ O
yeast P11336698A0075 NN I-UN
remodeler P11336698A0075 NN I-UN
RSC P11336698A0075 NNP I-UN
complex P11336698A0075 NN I-UN
. P11336698A0075 . O
. . O O

Thus P10666238A1322 RB O
, P10666238A1322 , O
the P10666238A1322 DT O
induction P10666238A1322 NN O
of P10666238A1322 IN O
E2F P10666238A1322 NNP I-UN
binding P10666238A1322 VBG O
to P10666238A1322 TO O
the P10666238A1322 DT O
E2F-1 P10666238A1322 NNP I-UN
promoter P10666238A1322 NN I-UN
by P10666238A1322 IN O
the P10666238A1322 DT O
E4-6 P10666238A1322 NNP I-UN
/ P10666238A1322 NNP I-UN
7 P10666238A1322 CD I-UN
protein P10666238A1322 NN I-UN
observed P10666238A1322 VBD O
in P10666238A1322 IN O
vitro P10666238A1322 NN O
correlates P10666238A1322 NNS O
with P10666238A1322 IN O
transactivation P10666238A1322 NN O
of P10666238A1322 IN O
E2F-1 P10666238A1322 NNP I-UN
promoter P10666238A1322 NN I-UN
activity P10666238A1322 NN O
in P10666238A1322 IN O
vivo P10666238A1322 NN O
. P10666238A1322 . O
. . O O

Use P11572377T0000 NNP O
of P11572377T0000 IN O
a P11572377T0000 DT O
dual-pulse P11572377T0000 JJ O
lithotripter P11572377T0000 NN O
to P11572377T0000 TO O
generate P11572377T0000 VB O
a P11572377T0000 DT O
localized P11572377T0000 JJ O
and P11572377T0000 CC O
intensified P11572377T0000 JJ O
cavitation P11572377T0000 NN O
field P11572377T0000 NN O
. P11572377T0000 . O
. . O O

A P03887085A0000 DT O
high P03887085A0000 JJ O
efficacy P03887085A0000 NN O
of P03887085A0000 IN O
the P03887085A0000 DT O
combined P03887085A0000 VBN O
use P03887085A0000 NN O
of P03887085A0000 IN O
nontoxic P03887085A0000 JJ O
doses P03887085A0000 NNS O
of P03887085A0000 IN O
two P03887085A0000 CD O
pharmaceuticals P03887085A0000 NNS O
: P03887085A0000 : O
cystamine P03887085A0000 NN O
( P03887085A0000 ( O
50 P03887085A0000 CD O
mg P03887085A0000 NN O
/ P03887085A0000 NNP O
kg P03887085A0000 NN O
) P03887085A0000 ) O
and P03887085A0000 CC O
mexamine P03887085A0000 NN O
( P03887085A0000 ( O
25 P03887085A0000 CD O
mg P03887085A0000 NN O
/ P03887085A0000 NNP O
kg P03887085A0000 NN O
) P03887085A0000 ) O
under P03887085A0000 IN O
the P03887085A0000 DT O
conditions P03887085A0000 NNS O
of P03887085A0000 IN O
short-term P03887085A0000 JJ O
exogenous P03887085A0000 JJ O
hypoxia P03887085A0000 NN O
( P03887085A0000 ( O
7.5 P03887085A0000 CD O
% P03887085A0000 NN O
O2 P03887085A0000 NNP O
) P03887085A0000 ) O
was P03887085A0000 VBD O
found P03887085A0000 VBN O
in P03887085A0000 IN O
( P03887085A0000 ( O
CBA P03887085A0000 NNP O
X P03887085A0000 NNP O
C57Bl P03887085A0000 NNP O
) P03887085A0000 ) O
F1 P03887085A0000 NNP O
mice P03887085A0000 NN O
. P03887085A0000 . O
. . O O

A P07711667A0766 DT O
multivariate P07711667A0766 JJ O
analysis P07711667A0766 NN O
of P07711667A0766 IN O
risk P07711667A0766 NN O
factors P07711667A0766 NNS O
for P07711667A0766 IN O
relapse P07711667A0766 NN O
examined P07711667A0766 VBN O
age P07711667A0766 NN O
, P07711667A0766 , O
WBC P07711667A0766 NNP O
at P07711667A0766 IN O
diagnosis P07711667A0766 NN O
, P07711667A0766 , O
blast P07711667A0766 NN O
count P07711667A0766 NN O
at P07711667A0766 IN O
diagnosis P07711667A0766 NN O
, P07711667A0766 , O
percentage P07711667A0766 NN O
of P07711667A0766 IN O
marrow P07711667A0766 NN O
blasts P07711667A0766 NNS O
, P07711667A0766 , O
FAB P07711667A0766 NNP I-UN
subtype P07711667A0766 NN O
, P07711667A0766 , O
the P07711667A0766 DT O
number P07711667A0766 NN O
of P07711667A0766 IN O
remission P07711667A0766 NN O
induction P07711667A0766 NN O
courses P07711667A0766 NNS O
to P07711667A0766 TO O
achieve P07711667A0766 VB O
a P07711667A0766 DT O
remission P07711667A0766 NN O
, P07711667A0766 , O
maintenance P07711667A0766 NN O
therapy P07711667A0766 NN O
, P07711667A0766 , O
consolidation P07711667A0766 NN O
therapy P07711667A0766 NN O
, P07711667A0766 , O
marrow P07711667A0766 NN O
cell P07711667A0766 NN O
dose P07711667A0766 NN O
, P07711667A0766 , O
donor-recipient P07711667A0766 JJ O
sex P07711667A0766 NN O
, P07711667A0766 , O
GVHD P07711667A0766 NNP O
prophylaxis P07711667A0766 VBZ O
regimen P07711667A0766 NNS O
and P07711667A0766 CC O
isolation P07711667A0766 NN O
and P07711667A0766 CC O
decontamination P07711667A0766 NN O
in P07711667A0766 IN O
laminar P07711667A0766 JJ O
airflow P07711667A0766 NN O
rooms P07711667A0766 NNS O
. P07711667A0766 . O
. . O O

The P07693967A0905 DT O
presence P07693967A0905 NN O
of P07693967A0905 IN O
the P07693967A0905 DT O
RV P07693967A0905 NNP O
5 P07693967A0905 CD O
' P07693967A0905 '' O
( P07693967A0905 ( O
+ P07693967A0905 FW O
) P07693967A0905 ) O
SL P07693967A0905 NNP O
sequence P07693967A0905 NN O
had P07693967A0905 VBD O
the P07693967A0905 DT O
primary P07693967A0905 JJ O
enhancing P07693967A0905 VBG O
effect P07693967A0905 NN O
on P07693967A0905 IN O
translation P07693967A0905 NN O
. P07693967A0905 . O
. . O O

The P03057259A0514 DT O
relationship P03057259A0514 NN O
between P03057259A0514 IN O
primary P03057259A0514 JJ O
malignant P03057259A0514 JJ O
lymphoma P03057259A0514 NN O
of P03057259A0514 IN O
the P03057259A0514 DT O
thyroid P03057259A0514 NN O
and P03057259A0514 CC O
chronic P03057259A0514 JJ O
thyroiditis P03057259A0514 NN O
is P03057259A0514 VBZ O
discussed P03057259A0514 VBN O
. P03057259A0514 . O
. . O O

Studies P05999607T0001 NNS O
of P05999607T0001 IN O
lipogenesis P05999607T0001 NN O
by P05999607T0001 IN O
labelled P05999607T0001 JJ O
precursors P05999607T0001 NNS O
in P05999607T0001 IN O
the P05999607T0001 DT O
pregnant P05999607T0001 JJ O
rat P05999607T0001 NN O
. P05999607T0001 . O
. . O O

The P08276732A0799 DT O
rate P08276732A0799 NN O
of P08276732A0799 IN O
decrement P08276732A0799 NN O
in P08276732A0799 IN O
DPOAE P08276732A0799 NNP O
amplitude P08276732A0799 NN O
over P08276732A0799 IN O
a P08276732A0799 DT O
prescribed P08276732A0799 JJ O
time P08276732A0799 NN O
period P08276732A0799 NN O
was P08276732A0799 VBD O
utilized P08276732A0799 VBN O
as P08276732A0799 IN O
a P08276732A0799 DT O
measure P08276732A0799 NN O
of P08276732A0799 IN O
susceptibility P08276732A0799 NN O
to P08276732A0799 TO O
the P08276732A0799 DT O
acoustic P08276732A0799 JJ O
trauma P08276732A0799 NN O
. P08276732A0799 . O
. . O O

The P06675047A0000 DT O
authors P06675047A0000 NNS O
have P06675047A0000 VBP O
tested P06675047A0000 VBN O
the P06675047A0000 DT O
interference P06675047A0000 NN O
of P06675047A0000 IN O
the P06675047A0000 DT O
hemoglobin P06675047A0000 NN I-UN
by P06675047A0000 IN O
two P06675047A0000 CD O
routine P06675047A0000 JJ O
methods P06675047A0000 NNS O
( P06675047A0000 ( O
Berthelot P06675047A0000 NNP O
classic P06675047A0000 JJ O
and P06675047A0000 CC O
Berthelot P06675047A0000 NNP O
modified P06675047A0000 VBD O
) P06675047A0000 ) O
for P06675047A0000 IN O
the P06675047A0000 DT O
determination P06675047A0000 NN O
of P06675047A0000 IN O
plasmatic P06675047A0000 JJ O
urea P06675047A0000 NN O
. P06675047A0000 . O
. . O O

Both P02143961A0400 DT O
antidepressants P02143961A0400 NNS O
elevated P02143961A0400 VBD O
the P02143961A0400 DT O
pain P02143961A0400 NN O
threshold P02143961A0400 NN O
acutely P02143961A0400 RB O
, P02143961A0400 , O
while P02143961A0400 IN O
pretreatment P02143961A0400 NN O
with P02143961A0400 IN O
pCPA P02143961A0400 NN O
largely P02143961A0400 RB O
blocked P02143961A0400 VBD O
the P02143961A0400 DT O
analgesia P02143961A0400 NN O
. P02143961A0400 . O
. . O O

Azithromycin P09517646A0149 NNP O
is P09517646A0149 VBZ O
a P09517646A0149 DT O
new P09517646A0149 JJ O
generation P09517646A0149 NN O
macrolide P09517646A0149 RBR O
antibiotic P09517646A0149 JJ O
with P09517646A0149 IN O
unusual P09517646A0149 JJ O
and P09517646A0149 CC O
favorable P09517646A0149 JJ O
pharmacokinetics P09517646A0149 NNS O
, P09517646A0149 , O
and P09517646A0149 CC O
seems P09517646A0149 VBZ O
to P09517646A0149 TO O
be P09517646A0149 VB O
a P09517646A0149 DT O
very P09517646A0149 RB O
promising P09517646A0149 JJ O
agent P09517646A0149 NN O
for P09517646A0149 IN O
innovative P09517646A0149 JJ O
anti-H. P09517646A0149 JJ O
pylori P09517646A0149 NN O
regimens P09517646A0149 NNS O
. P09517646A0149 . O
. . O O

These P07511818A0485 DT O
human P07511818A0485 JJ O
IFN-beta-transformed P07511818A0485 NNP O
cell P07511818A0485 NN O
populations P07511818A0485 NNS O
have P07511818A0485 VBP O
acquired P07511818A0485 VBN O
a P07511818A0485 DT O
low P07511818A0485 JJ O
, P07511818A0485 , O
constitutive P07511818A0485 JJ O
production P07511818A0485 NN O
of P07511818A0485 IN O
human P07511818A0485 JJ I-UN
IFN P07511818A0485 NNP I-UN
, P07511818A0485 , O
while P07511818A0485 IN O
replicating P07511818A0485 VBG O
at P07511818A0485 IN O
a P07511818A0485 DT O
rate P07511818A0485 NN O
similar P07511818A0485 JJ O
to P07511818A0485 TO O
that P07511818A0485 DT O
of P07511818A0485 IN O
untransformed P07511818A0485 JJ O
cells P07511818A0485 NNS O
and P07511818A0485 CC O
of P07511818A0485 IN O
cells P07511818A0485 NNS O
transformed P07511818A0485 VBN O
with P07511818A0485 IN O
the P07511818A0485 DT O
control P07511818A0485 NN O
vector P07511818A0485 NN O
carrying P07511818A0485 VBG O
a P07511818A0485 DT O
human P07511818A0485 JJ I-UN
IFN-beta P07511818A0485 JJ I-UN
sequence P07511818A0485 NN I-UN
encoding P07511818A0485 VBG O
an P07511818A0485 DT O
inactive P07511818A0485 JJ O
, P07511818A0485 , O
mutated P07511818A0485 VBD O
protein P07511818A0485 NN O
. P07511818A0485 . O
. . O O

The P01504178T0000 DT O
next P01504178T0000 JJ O
twenty P01504178T0000 NN O
years P01504178T0000 NNS O
of P01504178T0000 IN O
prevention P01504178T0000 NN O
in P01504178T0000 IN O
Indian P01504178T0000 JJ O
country P01504178T0000 NN O
: P01504178T0000 : O
visionary P01504178T0000 JJ O
, P01504178T0000 , O
complex P01504178T0000 JJ O
, P01504178T0000 , O
and P01504178T0000 CC O
practical P01504178T0000 JJ O
. P01504178T0000 . O
. . O O

The P07819225A1094 DT O
introduction P07819225A1094 NN O
of P07819225A1094 IN O
an P07819225A1094 DT O
acidic P07819225A1094 JJ O
residue P07819225A1094 NN O
at P07819225A1094 IN O
the P07819225A1094 DT O
second P07819225A1094 JJ O
site P07819225A1094 NN O
was P07819225A1094 VBD O
essential P07819225A1094 JJ O
for P07819225A1094 IN O
suppression P07819225A1094 NN O
of P07819225A1094 IN O
the P07819225A1094 DT O
Asn-285 P07819225A1094 NNP O
mutation P07819225A1094 NN O
because P07819225A1094 IN O
Lys-220 P07819225A1094 NNP O
and P07819225A1094 CC O
Gln-220 P07819225A1094 NNP O
second-site P07819225A1094 JJ O
mutants P07819225A1094 NNS O
of P07819225A1094 IN O
the P07819225A1094 DT O
Asn-285 P07819225A1094 NNP O
mutant P07819225A1094 NN O
showed P07819225A1094 VBD O
very P07819225A1094 RB O
low P07819225A1094 JJ O
tetracycline P07819225A1094 NN O
resistance P07819225A1094 NN O
. P07819225A1094 . O
( P07819225A1094 ( O
ABSTRACT P07819225A1094 NNP O
TRUNCATED P07819225A1094 NNP O
AT P07819225A1094 NNP O
250 P07819225A1094 CD O
WORDS P07819225A1094 NNP O
) P07819225A1094 ) O
. P07819225A1094 . O
. . O O

All P06716977A0136 DT O
samples P06716977A0136 NNS O
exhibited P06716977A0136 VBD O
a P06716977A0136 DT O
decline P06716977A0136 NN O
in P06716977A0136 IN O
ethanol P06716977A0136 JJ O
concentration P06716977A0136 NN O
, P06716977A0136 , O
with P06716977A0136 IN O
most P06716977A0136 JJS O
losses P06716977A0136 NNS O
falling P06716977A0136 VBG O
within P06716977A0136 IN O
the P06716977A0136 DT O
expected P06716977A0136 JJ O
20 P06716977A0136 CD O
to P06716977A0136 TO O
40 P06716977A0136 CD O
mg P06716977A0136 NN O
% P06716977A0136 NN O
range P06716977A0136 NN O
. P06716977A0136 . O
. . O O

As P08886845A1274 IN O
extensively P08886845A1274 RB O
examined P08886845A1274 VBN O
with P08886845A1274 IN O
the P08886845A1274 DT O
myogenin P08886845A1274 NN I-UN
promoter P08886845A1274 NN I-UN
, P08886845A1274 , O
presence P08886845A1274 NN O
of P08886845A1274 IN O
one P08886845A1274 CD O
or P08886845A1274 CC O
multiple P08886845A1274 JJ O
copies P08886845A1274 NNS O
of P08886845A1274 IN O
Me P08886845A1274 NNP I-UN
in P08886845A1274 IN O
the P08886845A1274 DT O
vectors P08886845A1274 NNS O
elevated P08886845A1274 VBD O
the P08886845A1274 DT O
expression P08886845A1274 NN O
activity P08886845A1274 NN O
in P08886845A1274 IN O
myotubes P08886845A1274 NNS O
by P08886845A1274 IN O
4.5- P08886845A1274 JJ O
to P08886845A1274 TO O
19-fold P08886845A1274 JJ O
over P08886845A1274 IN O
those P08886845A1274 DT O
without P08886845A1274 IN O
Me P08886845A1274 NNP I-UN
, P08886845A1274 , O
but P08886845A1274 CC O
not P08886845A1274 RB O
significantly P08886845A1274 RB O
in P08886845A1274 IN O
myoblasts P08886845A1274 NNS O
. P08886845A1274 . O
. . O O

The P10369965A0000 DT O
Aa-Pri2 P10369965A0000 NNP I-UN
gene P10369965A0000 NN I-UN
, P10369965A0000 , O
specifically P10369965A0000 RB O
expressed P10369965A0000 VBN O
during P10369965A0000 IN O
basidiocarp P10369965A0000 JJ O
differentiation P10369965A0000 NN O
of P10369965A0000 IN O
the P10369965A0000 DT O
mushroom P10369965A0000 NN O
Agrocybe P10369965A0000 NNP O
aegerita P10369965A0000 NN O
, P10369965A0000 , O
was P10369965A0000 VBD O
cloned P10369965A0000 VBN O
. P10369965A0000 . O
. . O O

A P02910496A0583 DT O
decamer P02910496A0583 NN O
sequence P02910496A0583 NN O
, P02910496A0583 , O
5'-CGA-CCCCUCC-3 P02910496A0583 JJ O
' P02910496A0583 '' O
, P02910496A0583 , O
complementary P02910496A0583 JJ O
to P02910496A0583 TO O
a P02910496A0583 DT O
conserved P02910496A0583 VBN O
sequence P02910496A0583 NN O
adjacent P02910496A0583 NN O
to P02910496A0583 TO O
the P02910496A0583 DT O
enzymatic P02910496A0583 JJ O
cleavage P02910496A0583 NN O
site P02910496A0583 NN O
on P02910496A0583 IN O
the P02910496A0583 DT O
mitochondrial P02910496A0583 JJ O
RNA P02910496A0583 NNP O
substrate P02910496A0583 NN O
, P02910496A0583 , O
is P02910496A0583 VBZ O
present P02910496A0583 JJ O
in P02910496A0583 IN O
the P02910496A0583 DT O
RNAase P02910496A0583 NNP I-UN
MRP P02910496A0583 NNP I-UN
RNA P02910496A0583 NNP I-UN
. P02910496A0583 . O
. . O O

Rev-erbAalpha P09611234A0098 JJ O
/ P09611234A0098 NNP I-UN
beta P09611234A0098 NN I-UN
) P09611234A0098 ) O
, P09611234A0098 , O
Mxi-1 P09611234A0098 NNP I-UN
and P09611234A0098 CC O
Mad P09611234A0098 NNP I-UN
bHLH-zip P09611234A0098 JJ O
proteins P09611234A0098 NNS O
and P09611234A0098 CC O
the P09611234A0098 DT O
oncoproteins P09611234A0098 NNS O
PLZF P09611234A0098 NNP I-UN
and P09611234A0098 CC O
LAZ3 P09611234A0098 NNP I-UN
/ P09611234A0098 NNP O
BCL6 P09611234A0098 NNP I-UN
is P09611234A0098 VBZ O
mediated P09611234A0098 VBN O
by P09611234A0098 IN O
the P09611234A0098 DT O
corepressors P09611234A0098 NNS O
N-CoR P09611234A0098 NNP I-UN
and P09611234A0098 CC O
SMRT P09611234A0098 NNP I-UN
. P09611234A0098 . O
. . O O

In P07675449A0848 IN O
one P07675449A0848 CD O
glioblastoma P07675449A0848 NN O
cell P07675449A0848 NN O
line P07675449A0848 NN O
, P07675449A0848 , O
a P07675449A0848 DT O
Shc-associated P07675449A0848 JJ O
p190 P07675449A0848 NN I-UN
was P07675449A0848 VBD O
identified P07675449A0848 VBN O
as P07675449A0848 IN O
the P07675449A0848 DT O
activated P07675449A0848 JJ O
PDGFR P07675449A0848 NNP I-UN
. P07675449A0848 . O
. . O O

Histological P10617126A1005 JJ O
analysis P10617126A1005 NN O
showed P10617126A1005 VBD O
that P10617126A1005 IN O
the P10617126A1005 DT O
neuronal P10617126A1005 JJ O
loss P10617126A1005 NN O
in P10617126A1005 IN O
the P10617126A1005 DT O
DHED-treated P10617126A1005 NNP O
group P10617126A1005 NN O
was P10617126A1005 VBD O
notably P10617126A1005 RB O
reduced P10617126A1005 VBN O
in P10617126A1005 IN O
the P10617126A1005 DT O
hippocampal P10617126A1005 JJ O
area P10617126A1005 NN O
( P10617126A1005 ( O
CA1 P10617126A1005 NNP O
) P10617126A1005 ) O
of P10617126A1005 IN O
ischemic P10617126A1005 JJ O
rats P10617126A1005 NNS O
and P10617126A1005 CC O
in P10617126A1005 IN O
the P10617126A1005 DT O
dentate P10617126A1005 NN O
gyrus P10617126A1005 NN O
and P10617126A1005 CC O
hippocampal P10617126A1005 JJ O
area P10617126A1005 NN O
( P10617126A1005 ( O
CA1 P10617126A1005 NNP O
and P10617126A1005 CC O
CA3 P10617126A1005 NNP O
) P10617126A1005 ) O
of P10617126A1005 IN O
EC-lesioned P10617126A1005 JJ O
rats P10617126A1005 NNS O
compared P10617126A1005 VBN O
with P10617126A1005 IN O
the P10617126A1005 DT O
nontreated P10617126A1005 JJ O
group P10617126A1005 NN O
. P10617126A1005 . O
. . O O

Low P06671385A0856 NNP O
NA P06671385A0856 NNP O
and P06671385A0856 CC O
A P06671385A0856 NNP O
may P06671385A0856 MD O
participate P06671385A0856 VB O
in P06671385A0856 IN O
lowering P06671385A0856 VBG O
the P06671385A0856 DT O
plasma P06671385A0856 JJ I-UN
renin P06671385A0856 NN I-UN
activity P06671385A0856 NN O
which P06671385A0856 WDT O
in P06671385A0856 IN O
PA P06671385A0856 NNP O
in P06671385A0856 IN O
suppressed P06671385A0856 VBN O
, P06671385A0856 , O
sometimes P06671385A0856 RB O
disproportionately P06671385A0856 RB O
to P06671385A0856 TO O
the P06671385A0856 DT O
actual P06671385A0856 JJ O
body P06671385A0856 NN O
sodium P06671385A0856 NN O
content P06671385A0856 NN O
. P06671385A0856 . O
. . O O

Influence P03036415T0000 NN O
of P03036415T0000 IN O
cyclo-oxygenase P03036415T0000 NN I-UN
inhibition P03036415T0000 NN O
and P03036415T0000 CC O
of P03036415T0000 IN O
leukotriene P03036415T0000 JJ I-UN
receptor P03036415T0000 NN I-UN
blockade P03036415T0000 NN O
on P03036415T0000 IN O
pulmonary P03036415T0000 JJ O
vascular P03036415T0000 JJ O
pressure P03036415T0000 NN O
/ P03036415T0000 NNP O
cardiac P03036415T0000 NN O
index P03036415T0000 NN O
relationships P03036415T0000 NNS O
in P03036415T0000 IN O
hyperoxic P03036415T0000 NN O
and P03036415T0000 CC O
in P03036415T0000 IN O
hypoxic P03036415T0000 JJ O
dogs P03036415T0000 NNS O
. P03036415T0000 . O
. . O O

Only P02034669A0293 RB O
the P02034669A0293 DT O
3.0-kb P02034669A0293 JJ O
transcript P02034669A0293 NN O
was P02034669A0293 VBD O
detected P02034669A0293 VBN O
in P02034669A0293 IN O
adult P02034669A0293 NN O
tissues P02034669A0293 NNS O
, P02034669A0293 , O
where P02034669A0293 WRB O
its P02034669A0293 PRP$ O
expression P02034669A0293 NN O
was P02034669A0293 VBD O
restricted P02034669A0293 VBN O
almost P02034669A0293 RB O
exclusively P02034669A0293 RB O
to P02034669A0293 TO O
the P02034669A0293 DT O
central P02034669A0293 JJ O
nervous P02034669A0293 JJ O
system P02034669A0293 NN O
. P02034669A0293 . O
. . O O

However P08912807A0411 RB O
, P08912807A0411 , O
the P08912807A0411 DT O
truncated P08912807A0411 JJ O
deer P08912807A0411 NN I-UN
receptor P08912807A0411 NN I-UN
lacks P08912807A0411 VBZ O
the P08912807A0411 DT O
most P08912807A0411 RBS O
C-terminal P08912807A0411 JJ O
tyrosine P08912807A0411 NN O
residue P08912807A0411 NN O
in P08912807A0411 IN O
the P08912807A0411 DT O
intracellular P08912807A0411 NN O
domain P08912807A0411 NN O
which P08912807A0411 WDT O
is P08912807A0411 VBZ O
believed P08912807A0411 VBN O
to P08912807A0411 TO O
be P08912807A0411 VB O
essential P08912807A0411 JJ O
for P08912807A0411 IN O
activation P08912807A0411 NN O
of P08912807A0411 IN O
the P08912807A0411 DT O
beta-casein P08912807A0411 JJ I-UN
promoter P08912807A0411 NN I-UN
. P08912807A0411 . O
. . O O

In P03045117A0936 IN O
general P03045117A0936 JJ O
, P03045117A0936 , O
the P03045117A0936 DT O
values P03045117A0936 NNS O
obtained P03045117A0936 VBN O
by P03045117A0936 IN O
the P03045117A0936 DT O
two P03045117A0936 CD O
methods P03045117A0936 NNS O
were P03045117A0936 VBD O
in P03045117A0936 IN O
agreement P03045117A0936 NN O
for P03045117A0936 IN O
each P03045117A0936 DT O
species P03045117A0936 NNS O
of P03045117A0936 IN O
epidermal P03045117A0936 JJ I-UN
growth P03045117A0936 NN I-UN
factor P03045117A0936 NN I-UN
and P03045117A0936 CC O
followed P03045117A0936 VBD O
the P03045117A0936 DT O
order P03045117A0936 NN O
: P03045117A0936 : O
wild P03045117A0936 JJ O
type P03045117A0936 NN O
greater P03045117A0936 JJR O
than P03045117A0936 IN O
Glu24 P03045117A0936 NNP O
-- P03045117A0936 : O
-- P03045117A0936 : O
Gly P03045117A0936 NNP O
greater P03045117A0936 JJR O
than P03045117A0936 IN O
Asp27 P03045117A0936 NNP O
-- P03045117A0936 : O
-- P03045117A0936 : O
Gly P03045117A0936 NNP O
much P03045117A0936 RB O
greater P03045117A0936 JJR O
than P03045117A0936 IN O
Pro7 P03045117A0936 NNP O
-- P03045117A0936 : O
-- P03045117A0936 : O
Thr P03045117A0936 VBP O
greater P03045117A0936 JJR O
than P03045117A0936 IN O
Tyr29 P03045117A0936 NNP O
-- P03045117A0936 : O
-- P03045117A0936 : O
Gly P03045117A0936 NNP O
greater P03045117A0936 JJR O
than P03045117A0936 IN O
Leu47 P03045117A0936 NNP O
-- P03045117A0936 : O
-- P03045117A0936 : O
His P03045117A0936 PRP$ O
. P03045117A0936 . O
. . O O

Rigid P10709705T0000 JJ O
point P10709705T0000 NN O
feature P10709705T0000 NN O
registration P10709705T0000 NN O
using P10709705T0000 VBG O
mutual P10709705T0000 JJ O
information P10709705T0000 NN O
. P10709705T0000 . O
. . O O

Angiography P03964855A0254 NNP O
was P03964855A0254 VBD O
performed P03964855A0254 VBN O
following P03964855A0254 VBG O
the P03964855A0254 DT O
rCBF P03964855A0254 NN O
study P03964855A0254 NN O
and P03964855A0254 CC O
the P03964855A0254 DT O
degree P03964855A0254 NN O
of P03964855A0254 IN O
vasospasm P03964855A0254 NN O
was P03964855A0254 VBD O
measured P03964855A0254 VBN O
on P03964855A0254 IN O
the P03964855A0254 DT O
angiograms P03964855A0254 NNS O
. P03964855A0254 . O
. . O O

Among P03016301A0605 IN O
the P03016301A0605 DT O
v-myc P03016301A0605 JJ I-UN
codons P03016301A0605 NNS O
, P03016301A0605 , O
the P03016301A0605 DT O
first P03016301A0605 JJ O
5 P03016301A0605 CD O
are P03016301A0605 VBP O
derived P03016301A0605 VBN O
from P03016301A0605 IN O
the P03016301A0605 DT O
noncoding P03016301A0605 VBG O
5 P03016301A0605 CD O
' P03016301A0605 '' O
terminus P03016301A0605 NN O
of P03016301A0605 IN O
the P03016301A0605 DT O
second P03016301A0605 JJ O
c-myc P03016301A0605 JJ I-UN
exon P03016301A0605 NN O
, P03016301A0605 , O
and P03016301A0605 CC O
412 P03016301A0605 CD O
codons P03016301A0605 NNS O
correspond P03016301A0605 NN O
to P03016301A0605 TO O
the P03016301A0605 DT O
c-myc P03016301A0605 JJ I-UN
coding P03016301A0605 NN O
region P03016301A0605 NN O
. P03016301A0605 . O
. . O O

Isolation P08973917T0000 NN O
and P08973917T0000 CC O
genomic P08973917T0000 JJ O
structure P08973917T0000 NN O
of P08973917T0000 IN O
a P08973917T0000 DT O
human P08973917T0000 JJ O
homolog P08973917T0000 NN O
of P08973917T0000 IN O
the P08973917T0000 DT O
yeast P08973917T0000 NN I-UN
periodic P08973917T0000 JJ I-UN
tryptophan P08973917T0000 NN I-UN
protein P08973917T0000 NN I-UN
2 P08973917T0000 CD I-UN
( P08973917T0000 ( O
PWP2 P08973917T0000 NNP I-UN
) P08973917T0000 ) O
gene P08973917T0000 NN O
mapping P08973917T0000 VBG O
to P08973917T0000 TO O
21q22.3 P08973917T0000 CD O
. P08973917T0000 . O
. . O O

In P07655505A0527 IN O
both P07655505A0527 DT O
shoots P07655505A0527 NNS O
and P07655505A0527 CC O
roots P07655505A0527 NNS O
, P07655505A0527 , O
GT-2 P07655505A0527 NNP I-UN
protein P07655505A0527 NN I-UN
is P07655505A0527 VBZ O
undetectable P07655505A0527 JJ O
in P07655505A0527 IN O
meristematic P07655505A0527 JJ O
tissue P07655505A0527 NN O
but P07655505A0527 CC O
becomes P07655505A0527 NNS O
expressed P07655505A0527 VBN O
at P07655505A0527 IN O
later P07655505A0527 JJ O
stages P07655505A0527 NNS O
of P07655505A0527 IN O
cellular P07655505A0527 JJ O
development P07655505A0527 NN O
, P07655505A0527 , O
consistent P07655505A0527 NN O
with P07655505A0527 IN O
a P07655505A0527 DT O
role P07655505A0527 NN O
in P07655505A0527 IN O
contributing P07655505A0527 VBG O
to P07655505A0527 TO O
the P07655505A0527 DT O
pattern P07655505A0527 NN O
of P07655505A0527 IN O
phytochrome P07655505A0527 NN I-UN
A P07655505A0527 NNP I-UN
gene P07655505A0527 NN I-UN
expression P07655505A0527 NN O
. P07655505A0527 . O
. . O O

Statistical P11454239A0478 JJ O
Analysis P11454239A0478 NNP O
included P11454239A0478 VBD O
ANOVA P11454239A0478 NNP O
, P11454239A0478 , O
the P11454239A0478 DT O
Pearson P11454239A0478 NNP O
Product P11454239A0478 NNP O
Moment P11454239A0478 NNP O
Correlation P11454239A0478 NNP O
Coefficient P11454239A0478 NNP O
, P11454239A0478 , O
Principal P11454239A0478 NNP O
Components P11454239A0478 NNP O
Analysis P11454239A0478 NNP O
and P11454239A0478 CC O
Discriminant P11454239A0478 NNP O
Function P11454239A0478 NNP O
Analysis P11454239A0478 NNP O
and P11454239A0478 CC O
the P11454239A0478 DT O
calculation P11454239A0478 NN O
of P11454239A0478 IN O
Cronbach P11454239A0478 NNP O
's P11454239A0478 POS O
alpha P11454239A0478 NN O
( P11454239A0478 ( O
alpha P11454239A0478 NN O
) P11454239A0478 ) O
RESULTS P11454239A0478 NN O
: P11454239A0478 : O
Both P11454239A0478 DT O
Sensitivity P11454239A0478 NNP O
and P11454239A0478 CC O
specificity P11454239A0478 NN O
exceed P11454239A0478 VBP O
90.00 P11454239A0478 CD O
at P11454239A0478 IN O
23 P11454239A0478 CD O
/ P11454239A0478 JJ O
24 P11454239A0478 CD O
, P11454239A0478 , O
Chronbach P11454239A0478 NNP O
's P11454239A0478 POS O
alpha P11454239A0478 NN O
for P11454239A0478 IN O
the P11454239A0478 DT O
total P11454239A0478 JJ O
scale P11454239A0478 NN O
was P11454239A0478 VBD O
equal P11454239A0478 JJ O
to P11454239A0478 TO O
0.95 P11454239A0478 CD O
. P11454239A0478 . O
. . O O

The P09371626A1345 DT O
results P09371626A1345 NNS O
of P09371626A1345 IN O
replicase P09371626A1345 NN I-UN
assays P09371626A1345 NNS O
performed P09371626A1345 VBN O
with P09371626A1345 IN O
mutant P09371626A1345 JJ I-UN
VP2 P09371626A1345 NNP I-UN
containing P09371626A1345 VBG O
a P09371626A1345 DT O
deletion P09371626A1345 NN O
in P09371626A1345 IN O
its P09371626A1345 PRP$ O
RNA-binding P09371626A1345 JJ O
domain P09371626A1345 NN O
suggests P09371626A1345 VBZ O
that P09371626A1345 IN O
the P09371626A1345 DT O
essential P09371626A1345 JJ O
role P09371626A1345 NN O
for P09371626A1345 IN O
VP2 P09371626A1345 NNP I-UN
in P09371626A1345 IN O
replication P09371626A1345 NN O
is P09371626A1345 VBZ O
linked P09371626A1345 VBN O
to P09371626A1345 TO O
the P09371626A1345 DT O
protein P09371626A1345 NN O
's P09371626A1345 POS O
ability P09371626A1345 NN O
to P09371626A1345 TO O
bind P09371626A1345 VB O
the P09371626A1345 DT O
mRNA P09371626A1345 NN O
template P09371626A1345 NN O
for P09371626A1345 IN O
minus-strand P09371626A1345 JJ O
synthesis P09371626A1345 NN O
. P09371626A1345 . O
. . O O

A P02902615A0000 DT O
new P02902615A0000 JJ O
physiopathological P02902615A0000 JJ O
treatment P02902615A0000 NN O
of P02902615A0000 IN O
HBV-related P02902615A0000 NNP O
polyarteritis P02902615A0000 NN O
inspired P02902615A0000 VBN O
by P02902615A0000 IN O
advances P02902615A0000 NNS O
in P02902615A0000 IN O
the P02902615A0000 DT O
treatment P02902615A0000 NN O
of P02902615A0000 IN O
chronic P02902615A0000 JJ O
active P02902615A0000 JJ O
hepatitis P02902615A0000 NN O
B P02902615A0000 NNP O
was P02902615A0000 VBD O
tested P02902615A0000 VBN O
in P02902615A0000 IN O
7 P02902615A0000 CD O
patients P02902615A0000 NNS O
. P02902615A0000 . O
. . O O

Gel P09415711A1348 NNP O
mobility P09415711A1348 NN O
shift P09415711A1348 NN O
and P09415711A1348 CC O
super-shift P09415711A1348 JJ O
assays P09415711A1348 NNS O
using P09415711A1348 VBG O
liver P09415711A1348 JJ O
nuclear P09415711A1348 JJ O
extracts P09415711A1348 NNS O
from P09415711A1348 IN O
either P09415711A1348 DT O
rat P09415711A1348 NN O
liver P09415711A1348 NN O
or P09415711A1348 CC O
DDT1MF-2 P09415711A1348 NNP O
cells P09415711A1348 NNS O
demonstrated P09415711A1348 VBD O
that P09415711A1348 IN O
the P09415711A1348 DT O
CRE P09415711A1348 NNP O
in P09415711A1348 IN O
the P09415711A1348 DT O
alpha P09415711A1348 JJ I-UN
1B-AR P09415711A1348 JJ I-UN
gene P09415711A1348 NN I-UN
bound P09415711A1348 IN O
CRE P09415711A1348 NNP I-UN
binding P09415711A1348 VBG I-UN
protein P09415711A1348 NN I-UN
. P09415711A1348 . O
. . O O

The P09643548A0000 DT O
genes P09643548A0000 NNS O
encoding P09643548A0000 VBG O
( P09643548A0000 ( I-UN
2Fe-2S P09643548A0000 JJ I-UN
) P09643548A0000 ) I-UN
plant-like P09643548A0000 NN I-UN
ferredoxins P09643548A0000 NNS I-UN
were P09643548A0000 VBD O
studied P09643548A0000 VBN O
in P09643548A0000 IN O
the P09643548A0000 DT O
widely P09643548A0000 RB O
used P09643548A0000 JJ O
cyanobacterium P09643548A0000 NN O
Synechocystis P09643548A0000 NNP O
PCC6803 P09643548A0000 NNP O
. P09643548A0000 . O
. . O O

R P07559430A0909 NN O
. P07559430A0909 . O
. . O O

These P11376134A1506 DT O
corrections P11376134A1506 NNS O
do P11376134A1506 VBP O
not P11376134A1506 RB O
involve P11376134A1506 VB O
sequences P11376134A1506 NNS O
predicted P11376134A1506 VBN O
to P11376134A1506 TO O
function P11376134A1506 VB O
as P11376134A1506 IN O
transcription P11376134A1506 NN O
factor P11376134A1506 NN O
binding P11376134A1506 VBG O
sites P11376134A1506 NNS O
. P11376134A1506 . O
. . O O

The P01549346A0000 DT O
c-Ets-1 P01549346A0000 JJ I-UN
oncoprotein P01549346A0000 NN I-UN
is P01549346A0000 VBZ O
a P01549346A0000 DT O
transcription P01549346A0000 NN O
activator P01549346A0000 NN O
that P01549346A0000 WDT O
specifically P01549346A0000 RB O
binds P01549346A0000 VBZ O
to P01549346A0000 TO O
DNA P01549346A0000 NNP O
. P01549346A0000 . O
. . O O

Inhibition P11350812A0829 NN O
of P11350812A0829 IN O
the P11350812A0829 DT O
Raf-1 P11350812A0829 NNP I-UN
target P11350812A0829 NN I-UN
ERK P11350812A0829 NNP I-UN
kinase P11350812A0829 NN I-UN
( P11350812A0829 ( O
MEK P11350812A0829 NNP I-UN
) P11350812A0829 ) O
either P11350812A0829 RB O
attenuated P11350812A0829 VBD O
or P11350812A0829 CC O
abolished P11350812A0829 VBD O
Rp-cAMPS- P11350812A0829 NNP O
and P11350812A0829 CC O
PKI-induced P11350812A0829 NNP O
ERK P11350812A0829 NNP I-UN
activation P11350812A0829 NN O
, P11350812A0829 , O
caldesmon P11350812A0829 JJ I-UN
phosphorylation P11350812A0829 NN O
, P11350812A0829 , O
and P11350812A0829 CC O
stress P11350812A0829 JJ O
fiber P11350812A0829 NN O
formation P11350812A0829 NN O
. P11350812A0829 . O
. . O O

On P08616743T0000 IN O
the P08616743T0000 DT O
trail P08616743T0000 NN O
of P08616743T0000 IN O
Dr P08616743T0000 NNP O
. P08616743T0000 . O
. . O O

Only P11803325A0868 RB O
one P11803325A0868 CD O
DC P11803325A0868 NNP O
cardioversion P11803325A0868 NN O
was P11803325A0868 VBD O
required P11803325A0868 VBN O
in P11803325A0868 IN O
the P11803325A0868 DT O
HBS P11803325A0868 NNP O
group P11803325A0868 NN O
, P11803325A0868 , O
whereas P11803325A0868 IN O
2 P11803325A0868 CD O
DC P11803325A0868 NNP O
in P11803325A0868 IN O
the P11803325A0868 DT O
CBC P11803325A0868 NNP O
group P11803325A0868 NN O
and P11803325A0868 CC O
total P11803325A0868 JJ O
7 P11803325A0868 CD O
DC P11803325A0868 NNP O
in P11803325A0868 IN O
the P11803325A0868 DT O
GIK P11803325A0868 NNP O
group P11803325A0868 NN O
. P11803325A0868 . O
. . O O

Routine P09621372A0369 JJ O
blood P09621372A0369 NN O
examination P09621372A0369 NN O
showed P09621372A0369 VBD O
leukocytosis P09621372A0369 NN O
, P09621372A0369 , O
thrombocytopenia P09621372A0369 NN O
, P09621372A0369 , O
positive P09621372A0369 JJ O
CRP P09621372A0369 NNP I-UN
, P09621372A0369 , O
and P09621372A0369 CC O
elevated P09621372A0369 VBD O
myocardial P09621372A0369 JJ O
enzymes P09621372A0369 NNS O
. P09621372A0369 . O
. . O O

PATIENTS P09396402A0264 NNS O
AND P09396402A0264 CC O
METHODS P09396402A0264 NNP O
: P09396402A0264 : O
Semen P09396402A0264 NNS O
analyses P09396402A0264 NNS O
were P09396402A0264 VBD O
performed P09396402A0264 VBN O
on P09396402A0264 IN O
58 P09396402A0264 CD O
patients P09396402A0264 NNS O
with P09396402A0264 IN O
stages P09396402A0264 NNS O
I-III P09396402A0264 NNP O
HD P09396402A0264 NNP O
before P09396402A0264 IN O
, P09396402A0264 , O
during P09396402A0264 IN O
, P09396402A0264 , O
and P09396402A0264 CC O
after P09396402A0264 IN O
chemotherapy P09396402A0264 NN O
and P09396402A0264 CC O
after P09396402A0264 IN O
the P09396402A0264 DT O
sperm P09396402A0264 JJ O
count P09396402A0264 NN O
recovered P09396402A0264 VBD O
from P09396402A0264 IN O
the P09396402A0264 DT O
effects P09396402A0264 NNS O
of P09396402A0264 IN O
abdominal P09396402A0264 JJ O
radiotherapy P09396402A0264 NN O
that P09396402A0264 WDT O
was P09396402A0264 VBD O
given P09396402A0264 VBN O
after P09396402A0264 IN O
chemotherapy P09396402A0264 NN O
. P09396402A0264 . O
. . O O

Twenty-two P06084279A0218 NN O
of P06084279A0218 IN O
the P06084279A0218 DT O
24 P06084279A0218 CD O
patients P06084279A0218 NNS O
had P06084279A0218 VBD O
a P06084279A0218 DT O
rise P06084279A0218 NN O
in P06084279A0218 IN O
the P06084279A0218 DT O
total P06084279A0218 JJ O
serum P06084279A0218 JJ O
amylase P06084279A0218 NN I-UN
following P06084279A0218 VBG O
ERCP P06084279A0218 NNP O
. P06084279A0218 . O
. . O O

These P09564860A2315 DT O
data P09564860A2315 NNS O
indicate P09564860A2315 VBP O
that P09564860A2315 IN O
the P09564860A2315 DT O
third P09564860A2315 JJ O
intracellular P09564860A2315 JJ O
loop P09564860A2315 NN O
of P09564860A2315 IN O
the P09564860A2315 DT O
rat P09564860A2315 NN I-UN
GnRH-R P09564860A2315 NNP I-UN
is P09564860A2315 VBZ O
involved P09564860A2315 VBN O
in P09564860A2315 IN O
receptor P09564860A2315 NN I-UN
G P09564860A2315 NNP I-UN
( P09564860A2315 ( I-UN
q P09564860A2315 JJ I-UN
/ P09564860A2315 NNP I-UN
11 P09564860A2315 CD I-UN
) P09564860A2315 ) I-UN
protein P09564860A2315 NN I-UN
coupling P09564860A2315 VBG O
and P09564860A2315 CC O
/ P09564860A2315 NNP O
or P09564860A2315 CC O
selectivity P09564860A2315 NN O
, P09564860A2315 , O
and P09564860A2315 CC O
in P09564860A2315 IN O
the P09564860A2315 DT O
GGH P09564860A2315 NNP O
( P09564860A2315 ( O
3 P09564860A2315 CD O
) P09564860A2315 ) O
1 P09564860A2315 CD O
' P09564860A2315 '' O
cell P09564860A2315 NN O
line P09564860A2315 NN O
, P09564860A2315 , O
this P09564860A2315 DT O
loop P09564860A2315 NN O
is P09564860A2315 VBZ O
also P09564860A2315 RB O
involved P09564860A2315 VBN O
in P09564860A2315 IN O
signal P09564860A2315 JJ O
transduction P09564860A2315 NN O
mediated P09564860A2315 VBD O
through P09564860A2315 IN O
the P09564860A2315 DT O
Gs P09564860A2315 NNP I-UN
protein P09564860A2315 NN O
pathway P09564860A2315 NN O
. P09564860A2315 . O
. . O O

In P07651398A0257 IN O
flies P07651398A0257 NNS O
, P07651398A0257 , O
the P07651398A0257 DT O
dShc P07651398A0257 NN I-UN
protein P07651398A0257 NN I-UN
physically P07651398A0257 RB O
associates P07651398A0257 VBZ O
with P07651398A0257 IN O
the P07651398A0257 DT O
activated P07651398A0257 JJ O
Drosophila P07651398A0257 NNP I-UN
epidermal P07651398A0257 JJ I-UN
growth P07651398A0257 NN I-UN
factor P07651398A0257 NN I-UN
receptor P07651398A0257 NN I-UN
homolog P07651398A0257 NN I-UN
( P07651398A0257 ( O
DER P07651398A0257 NNP I-UN
) P07651398A0257 ) O
and P07651398A0257 CC O
is P07651398A0257 VBZ O
inducibly P07651398A0257 RB O
phosphorylated P07651398A0257 VBN O
on P07651398A0257 IN O
tyrosine P07651398A0257 NN O
by P07651398A0257 IN O
DER P07651398A0257 NNP I-UN
. P07651398A0257 . O
. . O O

In P02941237A0160 IN O
the P02941237A0160 DT O
former P02941237A0160 JJ O
instance P02941237A0160 NN O
, P02941237A0160 , O
in P02941237A0160 IN O
addition P02941237A0160 NN O
to P02941237A0160 TO O
serum P02941237A0160 VB O
calcium P02941237A0160 NN O
and P02941237A0160 CC O
phosphorous P02941237A0160 JJ O
ion P02941237A0160 NN O
concentrations P02941237A0160 NNS O
, P02941237A0160 , O
tissue P02941237A0160 NN O
pH P02941237A0160 NN O
, P02941237A0160 , O
blood P02941237A0160 NN O
supply P02941237A0160 NN O
, P02941237A0160 , O
hormones P02941237A0160 NNS O
, P02941237A0160 , O
i.e. P02941237A0160 FW O
, P02941237A0160 , O
vitamin P02941237A0160 FW O
D P02941237A0160 NNP O
, P02941237A0160 , O
vitamin P02941237A0160 VBZ O
A P02941237A0160 NNP O
, P02941237A0160 , O
and P02941237A0160 CC O
various P02941237A0160 JJ O
enzymes P02941237A0160 NNS O
( P02941237A0160 ( O
e.g. P02941237A0160 NN O
, P02941237A0160 , O
alkaline P02941237A0160 JJ I-UN
phosphatase P02941237A0160 NN I-UN
and P02941237A0160 CC O
pyrophosphatase P02941237A0160 NN I-UN
) P02941237A0160 ) O
may P02941237A0160 MD O
all P02941237A0160 DT O
play P02941237A0160 VB O
significant P02941237A0160 JJ O
, P02941237A0160 , O
ancillary P02941237A0160 JJ O
, P02941237A0160 , O
time-dependent P02941237A0160 JJ O
, P02941237A0160 , O
but P02941237A0160 CC O
as P02941237A0160 IN O
yet P02941237A0160 RB O
undetermined P02941237A0160 JJ O
roles P02941237A0160 NNS O
. P02941237A0160 . O
. . O O

A P06300662T0000 DT O
cDNA P06300662T0000 NN O
cloning P06300662T0000 VBG O
vector P06300662T0000 NN O
that P06300662T0000 IN O
permits P06300662T0000 VBZ O
expression P06300662T0000 NN O
of P06300662T0000 IN O
cDNA P06300662T0000 NN O
inserts P06300662T0000 NNS O
in P06300662T0000 IN O
mammalian P06300662T0000 JJ O
cells P06300662T0000 NNS O
. P06300662T0000 . O
. . O O

Further P09130700A0676 JJ O
support P09130700A0676 NN O
for P09130700A0676 IN O
a P09130700A0676 DT O
direct P09130700A0676 JJ O
interaction P09130700A0676 NN O
of P09130700A0676 IN O
Tub4p P09130700A0676 NNP I-UN
, P09130700A0676 , O
Spc98p P09130700A0676 NNP I-UN
and P09130700A0676 CC O
Spc97p P09130700A0676 NNP I-UN
comes P09130700A0676 VBZ O
from P09130700A0676 IN O
the P09130700A0676 DT O
toxicity P09130700A0676 NN O
of P09130700A0676 IN O
strong P09130700A0676 JJ O
SPC97 P09130700A0676 NNP I-UN
overexpression P09130700A0676 NN O
which P09130700A0676 WDT O
is P09130700A0676 VBZ O
suppressed P09130700A0676 VBN O
by P09130700A0676 IN O
co-overexpression P09130700A0676 NN O
of P09130700A0676 IN O
TUB4 P09130700A0676 NNP I-UN
or P09130700A0676 CC O
SPC98 P09130700A0676 NNP I-UN
. P09130700A0676 . O
. . O O

Increasing P06652293A0353 VBG O
the P06652293A0353 DT O
cut-off P06652293A0353 NN O
point P06652293A0353 NN O
to P06652293A0353 TO O
3 P06652293A0353 CD O
positive P06652293A0353 JJ O
responses P06652293A0353 NNS O
decreased P06652293A0353 VBD O
the P06652293A0353 DT O
sensitivity P06652293A0353 NN O
to P06652293A0353 TO O
81 P06652293A0353 CD O
% P06652293A0353 NN O
and P06652293A0353 CC O
increased P06652293A0353 VBD O
the P06652293A0353 DT O
specificity P06652293A0353 NN O
to P06652293A0353 TO O
94 P06652293A0353 CD O
% P06652293A0353 NN O
. P06652293A0353 . O
. . O O

Pneumoscrotum P08333643A0000 NNP O
is P08333643A0000 VBZ O
a P08333643A0000 DT O
rare P08333643A0000 JJ O
condition P08333643A0000 NN O
that P08333643A0000 WDT O
receives P08333643A0000 VBZ O
little P08333643A0000 JJ O
discussion P08333643A0000 NN O
in P08333643A0000 IN O
standard P08333643A0000 JJ O
texts P08333643A0000 NN O
of P08333643A0000 IN O
urology P08333643A0000 NN O
. P08333643A0000 . O
. . O O

Hexsyn P03504971A0000 NNP O
is P03504971A0000 VBZ O
the P03504971A0000 DT O
Goodyear P03504971A0000 NNP O
Tire P03504971A0000 NNP O
and P03504971A0000 CC O
Rubber P03504971A0000 NNP O
Company P03504971A0000 NNP O
tradename P03504971A0000 NN O
for P03504971A0000 IN O
a P03504971A0000 DT O
polyolefin P03504971A0000 JJ O
rubber P03504971A0000 NN O
synthesized P03504971A0000 VBN O
from P03504971A0000 IN O
1-hexene P03504971A0000 JJ O
with P03504971A0000 IN O
3-5 P03504971A0000 JJ O
% P03504971A0000 NN O
methylhexadiene P03504971A0000 NN O
as P03504971A0000 IN O
the P03504971A0000 DT O
source P03504971A0000 NN O
of P03504971A0000 IN O
residual P03504971A0000 JJ O
double P03504971A0000 JJ O
bonds P03504971A0000 NNS O
for P03504971A0000 IN O
vulcanization P03504971A0000 NN O
. P03504971A0000 . O
. . O O

Electrical P03970191A0275 JJ O
activity P03970191A0275 NN O
was P03970191A0275 VBD O
evaluated P03970191A0275 VBN O
by P03970191A0275 IN O
monitoring P03970191A0275 VBG O
the P03970191A0275 DT O
general P03970191A0275 JJ O
electrocorticogram P03970191A0275 NN O
( P03970191A0275 ( O
ECoG P03970191A0275 NNP O
) P03970191A0275 ) O
as P03970191A0275 RB O
well P03970191A0275 RB O
as P03970191A0275 IN O
local P03970191A0275 JJ O
DC P03970191A0275 NNP O
steady P03970191A0275 JJ O
potential P03970191A0275 NN O
( P03970191A0275 ( O
two P03970191A0275 CD O
sites P03970191A0275 NNS O
) P03970191A0275 ) O
. P03970191A0275 . O
. . O O

Substitution P09566918A1115 NN O
of P09566918A1115 IN O
the P09566918A1115 DT O
Ser-Thr P09566918A1115 NNP O
sites P09566918A1115 NNS O
with P09566918A1115 IN O
the P09566918A1115 DT O
phosphomimetic P09566918A1115 JJ O
Asp P09566918A1115 NNP O
generated P09566918A1115 VBD O
a P09566918A1115 DT O
constitutively P09566918A1115 RB O
active P09566918A1115 JJ O
form P09566918A1115 NN O
of P09566918A1115 IN O
IRF-3 P09566918A1115 NNP I-UN
that P09566918A1115 WDT O
functioned P09566918A1115 VBD O
as P09566918A1115 IN O
a P09566918A1115 DT O
very P09566918A1115 RB O
strong P09566918A1115 JJ O
activator P09566918A1115 NN O
of P09566918A1115 IN O
promoters P09566918A1115 NNS O
containing P09566918A1115 VBG O
PRDI-PRDIII P09566918A1115 NNP O
or P09566918A1115 CC O
ISRE P09566918A1115 NNP I-UN
regulatory P09566918A1115 JJ I-UN
elements P09566918A1115 NNS I-UN
. P09566918A1115 . O
. . O O

The P06685643A0179 DT O
concentrations P06685643A0179 NNS O
of P06685643A0179 IN O
C4 P06685643A0179 NNP I-UN
and P06685643A0179 CC O
C1-INH P06685643A0179 NNP I-UN
increased P06685643A0179 VBD O
with P06685643A0179 IN O
advancing P06685643A0179 VBG O
stage P06685643A0179 NN O
of P06685643A0179 IN O
disease P06685643A0179 NN O
and P06685643A0179 CC O
were P06685643A0179 VBD O
above P06685643A0179 IN O
normal P06685643A0179 JJ O
mean P06685643A0179 JJ O
values P06685643A0179 NNS O
in P06685643A0179 IN O
all P06685643A0179 DT O
stages P06685643A0179 NNS O
. P06685643A0179 . O
. . O O

Forty P02520622A0200 NN O
patients P02520622A0200 NNS O
, P02520622A0200 , O
divided P02520622A0200 VBD O
according P02520622A0200 VBG O
to P02520622A0200 TO O
their P02520622A0200 PRP$ O
initial P02520622A0200 JJ O
total P02520622A0200 JJ O
gastrointestinal P02520622A0200 JJ O
transit P02520622A0200 NN O
times P02520622A0200 NNS O
and P02520622A0200 CC O
presenting P02520622A0200 VBG O
symptoms P02520622A0200 NNS O
, P02520622A0200 , O
were P02520622A0200 VBD O
treated P02520622A0200 VBN O
with P02520622A0200 IN O
cimetropium P02520622A0200 NN O
bromide P02520622A0200 NN O
50 P02520622A0200 CD O
mg P02520622A0200 NN O
t.d.s P02520622A0200 NN O
. P02520622A0200 . O
or P02520622A0200 CC O
placebo P02520622A0200 NN O
for P02520622A0200 IN O
1 P02520622A0200 CD O
month P02520622A0200 NN O
according P02520622A0200 VBG O
to P02520622A0200 TO O
a P02520622A0200 DT O
double-blind P02520622A0200 NN O
, P02520622A0200 , O
parallel P02520622A0200 JJ O
group P02520622A0200 NN O
design P02520622A0200 NN O
. P02520622A0200 . O
. . O O

Mouse P11116084A0000 NNP I-UN
Impact P11116084A0000 NNP I-UN
is P11116084A0000 VBZ O
a P11116084A0000 DT O
paternally P11116084A0000 RB O
expressed P11116084A0000 VBN O
gene P11116084A0000 NN O
encoding P11116084A0000 VBG O
an P11116084A0000 DT O
evolutionarily P11116084A0000 RB O
conserved P11116084A0000 VBN O
protein P11116084A0000 NN O
of P11116084A0000 IN O
unknown P11116084A0000 JJ O
function P11116084A0000 NN O
. P11116084A0000 . O
. . O O

The P06815368A0203 DT O
osmotic P06815368A0203 JJ O
diuretic P06815368A0203 JJ O
mannitol P06815368A0203 NN O
was P06815368A0203 VBD O
administered P06815368A0203 VBN O
to P06815368A0203 TO O
21 P06815368A0203 CD O
patients P06815368A0203 NNS O
. P06815368A0203 . O
. . O O

Analysis P07744846A1006 NN O
of P07744846A1006 IN O
Bcl-2 P07744846A1006 NNP I-UN
/ P07744846A1006 NNP O
Bcl-2 P07744846A1006 NNP I-UN
homodimerization P07744846A1006 NN O
using P07744846A1006 VBG O
both P07744846A1006 DT O
in P07744846A1006 IN O
vitro P07744846A1006 NN O
binding P07744846A1006 NN O
assays P07744846A1006 NNS O
as P07744846A1006 RB O
well P07744846A1006 RB O
as P07744846A1006 IN O
a P07744846A1006 DT O
yeast P07744846A1006 JJ O
two-hybrid P07744846A1006 JJ O
method P07744846A1006 NN O
provided P07744846A1006 VBD O
evidence P07744846A1006 NN O
in P07744846A1006 IN O
support P07744846A1006 NN O
of P07744846A1006 IN O
a P07744846A1006 DT O
head-to-tail P07744846A1006 JJ O
model P07744846A1006 NN O
for P07744846A1006 IN O
Bcl-2 P07744846A1006 NNP I-UN
/ P07744846A1006 NNP O
Bcl-2 P07744846A1006 NNP I-UN
homodimerization P07744846A1006 NN O
and P07744846A1006 CC O
revealed P07744846A1006 VBD O
that P07744846A1006 IN O
sequences P07744846A1006 NNS O
within P07744846A1006 IN O
the P07744846A1006 DT O
NH2-terminal P07744846A1006 JJ O
A P07744846A1006 NNP O
domain P07744846A1006 NN O
interact P07744846A1006 NN O
with P07744846A1006 IN O
a P07744846A1006 DT O
structure P07744846A1006 NN O
that P07744846A1006 WDT O
requires P07744846A1006 VBZ O
the P07744846A1006 DT O
presence P07744846A1006 NN O
of P07744846A1006 IN O
both P07744846A1006 CC O
the P07744846A1006 DT O
carboxyl P07744846A1006 NN O
B P07744846A1006 NNP O
and P07744846A1006 CC O
C P07744846A1006 NNP O
domains P07744846A1006 NNS O
in P07744846A1006 IN O
combination P07744846A1006 NN O
. P07744846A1006 . O
. . O O

These P10358138A0672 DT O
results P10358138A0672 NNS O
suggest P10358138A0672 VBP O
that P10358138A0672 IN O
the P10358138A0672 DT O
phenotype P10358138A0672 NN O
of P10358138A0672 IN O
XLP P10358138A0672 NNP O
may P10358138A0672 MD O
result P10358138A0672 VB O
from P10358138A0672 IN O
perturbed P10358138A0672 NN O
signaling P10358138A0672 VBG O
not P10358138A0672 RB O
only P10358138A0672 RB O
through P10358138A0672 IN O
SLAM P10358138A0672 NNP I-UN
, P10358138A0672 , O
but P10358138A0672 CC O
also P10358138A0672 RB O
other P10358138A0672 JJ O
cell P10358138A0672 NN O
surface P10358138A0672 NN O
molecules P10358138A0672 VBZ O
that P10358138A0672 IN O
utilize P10358138A0672 JJ O
SAP P10358138A0672 NNP I-UN
as P10358138A0672 IN O
a P10358138A0672 DT O
signaling P10358138A0672 VBG O
adaptor P10358138A0672 NN O
protein P10358138A0672 NN O
. P10358138A0672 . O
. . O O

A P02116071A0000 DT O
long P02116071A0000 JJ O
follow-up P02116071A0000 NN O
study P02116071A0000 NN O
revealed P02116071A0000 VBD O
that P02116071A0000 IN O
convalescent P02116071A0000 NN O
stage P02116071A0000 NN O
children P02116071A0000 NNS O
still P02116071A0000 RB O
have P02116071A0000 VBP O
the P02116071A0000 DT O
potency P02116071A0000 NN O
to P02116071A0000 TO O
have P02116071A0000 VB O
an P02116071A0000 DT O
immediate P02116071A0000 JJ O
type P02116071A0000 NN O
hypersensitivity P02116071A0000 NN O
reaction P02116071A0000 NN O
on P02116071A0000 IN O
exposure P02116071A0000 NN O
to P02116071A0000 TO O
mite P02116071A0000 VB O
antigen P02116071A0000 NN O
, P02116071A0000 , O
with P02116071A0000 IN O
a P02116071A0000 DT O
high P02116071A0000 JJ O
titer P02116071A0000 NN O
of P02116071A0000 IN O
mite P02116071A0000 NN I-UN
specific P02116071A0000 JJ I-UN
IgE P02116071A0000 NNP I-UN
in P02116071A0000 IN O
their P02116071A0000 PRP$ O
sera P02116071A0000 NN O
, P02116071A0000 , O
but P02116071A0000 CC O
they P02116071A0000 PRP O
are P02116071A0000 VBP O
free P02116071A0000 JJ O
from P02116071A0000 IN O
asthmatic P02116071A0000 JJ O
attacks P02116071A0000 NNS O
because P02116071A0000 IN O
of P02116071A0000 IN O
the P02116071A0000 DT O
reduction P02116071A0000 NN O
in P02116071A0000 IN O
the P02116071A0000 DT O
amount P02116071A0000 NN O
of P02116071A0000 IN O
mite P02116071A0000 JJ O
antigen P02116071A0000 NN O
in P02116071A0000 IN O
the P02116071A0000 DT O
body P02116071A0000 NN O
, P02116071A0000 , O
as P02116071A0000 IN O
shown P02116071A0000 VBN O
by P02116071A0000 IN O
the P02116071A0000 DT O
reduction P02116071A0000 NN O
in P02116071A0000 IN O
the P02116071A0000 DT O
amount P02116071A0000 NN O
of P02116071A0000 IN O
mite P02116071A0000 NN I-UN
specific P02116071A0000 JJ I-UN
IgG P02116071A0000 NNP I-UN
. P02116071A0000 . O
. . O O

Bacterially P08195217A0799 RB O
expressed P08195217A0799 VBN O
protein P08195217A0799 NN O
, P08195217A0799 , O
as P08195217A0799 RB O
well P08195217A0799 RB O
as P08195217A0799 IN O
the P08195217A0799 DT O
in P08195217A0799 IN O
vitro P08195217A0799 JJ O
reticulocyte P08195217A0799 NN O
lysate P08195217A0799 NN O
translation P08195217A0799 NN O
product P08195217A0799 NN O
, P08195217A0799 , O
comigrated P08195217A0799 VBN O
with P08195217A0799 IN O
the P08195217A0799 DT O
purified P08195217A0799 JJ O
37-kDa P08195217A0799 JJ O
protein P08195217A0799 NN O
on P08195217A0799 IN O
sodium P08195217A0799 NN O
dodecyl P08195217A0799 NN O
sulfate-polyacrylamide P08195217A0799 JJ O
gels P08195217A0799 NNS O
. P08195217A0799 . O
. . O O

TRAF2 P10477597A0126 NNP I-UN
is P10477597A0126 VBZ O
a P10477597A0126 DT O
potent P10477597A0126 JJ O
activator P10477597A0126 NN O
of P10477597A0126 IN O
a P10477597A0126 DT O
95-kDa P10477597A0126 JJ I-UN
serine P10477597A0126 NN I-UN
/ P10477597A0126 NNP I-UN
threonine P10477597A0126 NN I-UN
kinase P10477597A0126 NN I-UN
termed P10477597A0126 VBD O
germinal P10477597A0126 JJ I-UN
center P10477597A0126 NN I-UN
kinase P10477597A0126 NN I-UN
related P10477597A0126 VBN I-UN
( P10477597A0126 ( O
GCKR P10477597A0126 NNP I-UN
, P10477597A0126 , O
also P10477597A0126 RB O
referred P10477597A0126 VBD O
to P10477597A0126 TO O
as P10477597A0126 IN O
KHS1 P10477597A0126 NNP I-UN
) P10477597A0126 ) O
, P10477597A0126 , O
which P10477597A0126 WDT O
signals P10477597A0126 VBZ O
activation P10477597A0126 NN O
of P10477597A0126 IN O
the P10477597A0126 DT O
SAPK P10477597A0126 NNP I-UN
pathway P10477597A0126 NN O
. P10477597A0126 . O
. . O O

A P07590268A0740 DT O
2.4-kb P07590268A0740 JJ I-UN
MAPKAPK-2 P07590268A0740 JJ I-UN
message P07590268A0740 NN I-UN
is P07590268A0740 VBZ O
expressed P07590268A0740 VBN O
throughout P07590268A0740 IN O
development P07590268A0740 NN O
, P07590268A0740 , O
while P07590268A0740 IN O
two P07590268A0740 CD O
shorter P07590268A0740 JJR O
transcripts P07590268A0740 NNS O
of P07590268A0740 IN O
2.3 P07590268A0740 CD O
and P07590268A0740 CC O
1.8 P07590268A0740 CD O
kb P07590268A0740 NN O
appear P07590268A0740 NN O
to P07590268A0740 TO O
be P07590268A0740 VB O
specifically P07590268A0740 RB O
expressed P07590268A0740 VBN O
in P07590268A0740 IN O
the P07590268A0740 DT O
germline P07590268A0740 NN O
. P07590268A0740 . O
. . O O

The P09632785A0000 DT O
pre-mRNA P09632785A0000 JJ O
splicing P09632785A0000 NN O
factor P09632785A0000 NN O
U2AF P09632785A0000 NNP I-UN
( P09632785A0000 ( O
U2 P09632785A0000 NNP I-UN
small P09632785A0000 JJ I-UN
nuclear P09632785A0000 JJ I-UN
ribonucleoprotein P09632785A0000 NN I-UN
particle P09632785A0000 NN I-UN
[ P09632785A0000 NNP I-UN
snRNP P09632785A0000 NN I-UN
] P09632785A0000 NNP I-UN
auxiliary P09632785A0000 JJ I-UN
factor P09632785A0000 NN I-UN
) P09632785A0000 ) O
plays P09632785A0000 VBZ O
a P09632785A0000 DT O
critical P09632785A0000 JJ O
role P09632785A0000 NN O
in P09632785A0000 IN O
3 P09632785A0000 CD O
' P09632785A0000 POS O
splice P09632785A0000 NN O
site P09632785A0000 NN O
selection P09632785A0000 NN O
. P09632785A0000 . O
. . O O

In P09067577A0721 IN O
untransformed P09067577A0721 JJ O
cells P09067577A0721 NNS O
, P09067577A0721 , O
three P09067577A0721 CD O
major P09067577A0721 JJ O
proteins P09067577A0721 NNS O
coprecipitated P09067577A0721 VBN O
with P09067577A0721 IN O
CRKL P09067577A0721 NNP I-UN
, P09067577A0721 , O
identified P09067577A0721 VBD O
as P09067577A0721 IN O
C3G P09067577A0721 NNP I-UN
, P09067577A0721 , O
SOS P09067577A0721 NNP I-UN
and P09067577A0721 CC O
c-ABL P09067577A0721 NN I-UN
. P09067577A0721 . O
. . O O

Semidominant P08756636T0000 JJ O
mutations P08756636T0000 NNS O
in P08756636T0000 IN O
the P08756636T0000 DT O
yeast P08756636T0000 NN I-UN
Rad51 P08756636T0000 NNP I-UN
protein P08756636T0000 NN I-UN
and P08756636T0000 CC O
their P08756636T0000 PRP$ O
relationships P08756636T0000 NNS O
with P08756636T0000 IN O
the P08756636T0000 DT O
Srs2 P08756636T0000 NNP I-UN
helicase P08756636T0000 NN I-UN
. P08756636T0000 . O
. . O O

The P07678695A0604 DT O
ectopic P07678695A0604 JJ O
expression P07678695A0604 NN O
of P07678695A0604 IN O
Oct-3 P07678695A0604 NNP I-UN
/ P07678695A0604 NNP I-UN
4 P07678695A0604 CD I-UN
in P07678695A0604 IN O
hybrid P07678695A0604 JJ O
cells P07678695A0604 NNS O
under P07678695A0604 IN O
a P07678695A0604 DT O
constitutive P07678695A0604 JJ O
promoter P07678695A0604 NN O
is P07678695A0604 VBZ O
sufficient P07678695A0604 JJ O
for P07678695A0604 IN O
transcriptional P07678695A0604 JJ O
activation P07678695A0604 NN O
of P07678695A0604 IN O
an P07678695A0604 DT O
octamer-dependent P07678695A0604 JJ O
promoter P07678695A0604 NN O
. P07678695A0604 . O
. . O O

This P09815578A1245 DT O
study P09815578A1245 NN O
demonstrates P09815578A1245 VBZ O
that P09815578A1245 IN O
alteration P09815578A1245 NN O
of P09815578A1245 IN O
CDKN2 P09815578A1245 NNP I-UN
is P09815578A1245 VBZ O
one P09815578A1245 CD O
of P09815578A1245 IN O
the P09815578A1245 DT O
most P09815578A1245 RBS O
frequent P09815578A1245 JJ O
genetic P09815578A1245 JJ O
abnormalities P09815578A1245 NNS O
in P09815578A1245 IN O
prostate P09815578A1245 NN O
cancer P09815578A1245 NN O
and P09815578A1245 CC O
may P09815578A1245 MD O
contribute P09815578A1245 VB O
to P09815578A1245 TO O
prostate P09815578A1245 VB O
carcinogenesis P09815578A1245 NN O
. P09815578A1245 . O
. . O O

Amounts P03073091A0449 NNS O
of P03073091A0449 IN O
glucose P03073091A0449 NN O
infused P03073091A0449 VBN O
during P03073091A0449 IN O
the P03073091A0449 DT O
last P03073091A0449 JJ O
20 P03073091A0449 CD O
min P03073091A0449 NN O
of P03073091A0449 IN O
each P03073091A0449 DT O
2 P03073091A0449 CD O
hour P03073091A0449 NN O
insulin P03073091A0449 NN I-UN
infusion P03073091A0449 NN O
were P03073091A0449 VBD O
( P03073091A0449 ( O
at P03073091A0449 IN O
1 P03073091A0449 CD O
and P03073091A0449 CC O
10 P03073091A0449 CD O
m P03073091A0449 NN O
/ P03073091A0449 NNP O
kg P03073091A0449 NNP O
/ P03073091A0449 NNP O
min P03073091A0449 NNP O
respectively P03073091A0449 RB O
) P03073091A0449 ) O
: P03073091A0449 : O
before P03073091A0449 IN O
treatment P03073091A0449 NN O
( P03073091A0449 ( O
K+ P03073091A0449 NNP O
= P03073091A0449 VBZ O
2.7 P03073091A0449 CD O
mmol P03073091A0449 NN O
/ P03073091A0449 NNP O
l P03073091A0449 NN O
) P03073091A0449 ) O
: P03073091A0449 : O
2.4 P03073091A0449 CD O
and P03073091A0449 CC O
8.4 P03073091A0449 CD O
mg P03073091A0449 NN O
/ P03073091A0449 NNP O
kg P03073091A0449 NNP O
/ P03073091A0449 NNP O
min P03073091A0449 NN O
; P03073091A0449 : O
after P03073091A0449 IN O
spironolactone P03073091A0449 NN O
( P03073091A0449 ( O
K+ P03073091A0449 NNP O
= P03073091A0449 VBZ O
3.9 P03073091A0449 CD O
mmol P03073091A0449 NN O
/ P03073091A0449 NNP O
l P03073091A0449 NN O
) P03073091A0449 ) O
: P03073091A0449 : O
3.3 P03073091A0449 CD O
and P03073091A0449 CC O
15.4 P03073091A0449 CD O
mg P03073091A0449 NN O
/ P03073091A0449 NNP O
kg P03073091A0449 NNP O
/ P03073091A0449 NNP O
min P03073091A0449 NN O
; P03073091A0449 : O
after P03073091A0449 IN O
indomethacine P03073091A0449 NN O
( P03073091A0449 ( O
K+ P03073091A0449 NNP O
= P03073091A0449 VBZ O
3.7 P03073091A0449 CD O
mmol P03073091A0449 NN O
/ P03073091A0449 NNP O
l P03073091A0449 NN O
) P03073091A0449 ) O
: P03073091A0449 : O
5 P03073091A0449 CD O
and P03073091A0449 CC O
19 P03073091A0449 CD O
mg P03073091A0449 NN O
/ P03073091A0449 NNP O
kg P03073091A0449 NNP O
/ P03073091A0449 NNP O
min P03073091A0449 NN O
after P03073091A0449 IN O
stopping P03073091A0449 VBG O
drugs P03073091A0449 NNS O
( P03073091A0449 ( O
K+ P03073091A0449 NNP O
= P03073091A0449 VBZ O
2.9 P03073091A0449 CD O
mmol P03073091A0449 NN O
/ P03073091A0449 NNP O
l P03073091A0449 NN O
) P03073091A0449 ) O
: P03073091A0449 : O
2.5 P03073091A0449 CD O
and P03073091A0449 CC O
5.3 P03073091A0449 CD O
mg P03073091A0449 NN O
/ P03073091A0449 NNP O
kg P03073091A0449 NNP O
/ P03073091A0449 NNP O
min P03073091A0449 NN O
. P03073091A0449 . O
. . O O

The P08021177A0000 DT O
fepA-entD P08021177A0000 JJ O
and P08021177A0000 CC O
fes-entF P08021177A0000 JJ O
operons P08021177A0000 NNS O
in P08021177A0000 IN O
the P08021177A0000 DT O
enterobactin P08021177A0000 JJ O
synthesis P08021177A0000 NN O
and P08021177A0000 CC O
transport P08021177A0000 NN O
system P08021177A0000 NN O
are P08021177A0000 VBP O
divergently P08021177A0000 RB O
transcribed P08021177A0000 VBN O
from P08021177A0000 IN O
overlapping P08021177A0000 VBG O
promoters P08021177A0000 NNS O
, P08021177A0000 , O
and P08021177A0000 CC O
both P08021177A0000 DT O
are P08021177A0000 VBP O
inhibited P08021177A0000 VBN O
by P08021177A0000 IN O
the P08021177A0000 DT O
Fur P08021177A0000 NNP I-UN
repressor P08021177A0000 NN I-UN
protein P08021177A0000 NN I-UN
under P08021177A0000 IN O
iron-replete P08021177A0000 JJ O
conditions P08021177A0000 NNS O
. P08021177A0000 . O
. . O O

Moreover P08754840A0793 RB O
, P08754840A0793 , O
glucan P08754840A0793 JJ I-UN
synthase P08754840A0793 NN I-UN
activity P08754840A0793 NN O
, P08754840A0793 , O
which P08754840A0793 WDT O
is P08754840A0793 VBZ O
activated P08754840A0793 VBN O
by P08754840A0793 IN O
Rho1p P08754840A0793 NNP I-UN
, P08754840A0793 , O
was P08754840A0793 VBD O
significantly P08754840A0793 RB O
reduced P08754840A0793 VBN O
in P08754840A0793 IN O
the P08754840A0793 DT O
deltabem4 P08754840A0793 NN I-UN
mutant P08754840A0793 NN I-UN
. P08754840A0793 . O
. . O O

Most P09989339A0968 JJS O
recently P09989339A0968 RB O
, P09989339A0968 , O
the P09989339A0968 DT O
use P09989339A0968 NN O
of P09989339A0968 IN O
the P09989339A0968 DT O
product P09989339A0968 NN O
of P09989339A0968 IN O
brain P09989339A0968 NN O
weight P09989339A0968 NN O
and P09989339A0968 CC O
clearance P09989339A0968 NN O
has P09989339A0968 VBZ O
been P09989339A0968 VBN O
proposed P09989339A0968 VBN O
. P09989339A0968 . O
. . O O

In P02147223A1047 IN O
contrast P02147223A1047 NN O
, P02147223A1047 , O
the P02147223A1047 DT O
CRE P02147223A1047 NNP O
of P02147223A1047 IN O
the P02147223A1047 DT O
human P02147223A1047 JJ I-UN
c-fos P02147223A1047 JJ I-UN
promoter P02147223A1047 NN I-UN
located P02147223A1047 VBN O
at P02147223A1047 IN O
-60 P02147223A1047 NNP O
was P02147223A1047 VBD O
weakly P02147223A1047 RB O
induced P02147223A1047 VBN O
by P02147223A1047 IN O
cAMP P02147223A1047 NN O
and P02147223A1047 CC O
E1a P02147223A1047 NNP I-UN
in P02147223A1047 IN O
both P02147223A1047 DT O
HeLa P02147223A1047 NNP O
and P02147223A1047 CC O
PC12 P02147223A1047 NNP O
cells P02147223A1047 NNS O
. P02147223A1047 . O
. . O O

Immunofixation P11367523A1684 NN O
experiments P11367523A1684 NNS O
of P11367523A1684 IN O
C4A P11367523A1684 NNP I-UN
and P11367523A1684 CC O
C4B P11367523A1684 NNP I-UN
demonstrate P11367523A1684 VBP O
> P11367523A1684 $ O
41 P11367523A1684 CD O
allotypes P11367523A1684 NNS O
in P11367523A1684 IN O
the P11367523A1684 DT O
two P11367523A1684 CD O
classes P11367523A1684 NNS O
of P11367523A1684 IN O
proteins P11367523A1684 NNS O
. P11367523A1684 . O
. . O O

Deletion P09315631A1064 NN O
of P09315631A1064 IN O
the P09315631A1064 DT O
POR2 P09315631A1064 NNP I-UN
gene P09315631A1064 NN I-UN
alone P09315631A1064 RB O
had P09315631A1064 VBD O
no P09315631A1064 DT O
detectable P09315631A1064 JJ O
phenotype P09315631A1064 NN O
, P09315631A1064 , O
while P09315631A1064 IN O
yeasts P09315631A1064 NNS O
with P09315631A1064 IN O
deletions P09315631A1064 NNS O
of P09315631A1064 IN O
both P09315631A1064 DT O
the P09315631A1064 DT O
POR1 P09315631A1064 NNP I-UN
and P09315631A1064 CC O
POR2 P09315631A1064 NNP I-UN
genes P09315631A1064 NNS I-UN
were P09315631A1064 VBD O
viable P09315631A1064 JJ O
and P09315631A1064 CC O
able P09315631A1064 JJ O
to P09315631A1064 TO O
grow P09315631A1064 VB O
on P09315631A1064 IN O
glycerol P09315631A1064 NN O
at P09315631A1064 IN O
30 P09315631A1064 CD O
degrees P09315631A1064 NNS O
C P09315631A1064 NNP O
, P09315631A1064 , O
albeit P09315631A1064 IN O
more P09315631A1064 RBR O
slowly P09315631A1064 RB O
than P09315631A1064 IN O
delta P09315631A1064 JJ I-UN
por1 P09315631A1064 NN I-UN
single P09315631A1064 JJ I-UN
mutants P09315631A1064 NNS I-UN
. P09315631A1064 . O
. . O O

Quantitative P02839488A1314 JJ O
assays P02839488A1314 NNS O
in P02839488A1314 IN O
which P02839488A1314 WDT O
the P02839488A1314 DT O
activity P02839488A1314 NN O
of P02839488A1314 IN O
the P02839488A1314 DT O
synthetic P02839488A1314 JJ I-UN
alpha P02839488A1314 NN I-UN
s-1 P02839488A1314 NN I-UN
was P02839488A1314 VBD O
compared P02839488A1314 VBN O
to P02839488A1314 TO O
that P02839488A1314 DT O
of P02839488A1314 IN O
native P02839488A1314 JJ O
purified P02839488A1314 JJ O
human P02839488A1314 JJ I-UN
erythrocyte P02839488A1314 NN I-UN
type-1 P02839488A1314 NN I-UN
Gs P02839488A1314 NNP I-UN
, P02839488A1314 , O
indicated P02839488A1314 VBD O
that P02839488A1314 IN O
the P02839488A1314 DT O
two P02839488A1314 CD O
products P02839488A1314 NNS O
are P02839488A1314 VBP O
equipotent P02839488A1314 JJ O
within P02839488A1314 IN O
a P02839488A1314 DT O
2-fold P02839488A1314 JJ O
margin P02839488A1314 NN O
of P02839488A1314 IN O
error P02839488A1314 NN O
. P02839488A1314 . O
. . O O

These P02384265A0947 DT O
results P02384265A0947 NNS O
suggest P02384265A0947 VBP O
an P02384265A0947 DT O
increased P02384265A0947 VBN O
risk P02384265A0947 NN O
of P02384265A0947 IN O
developing P02384265A0947 VBG O
cancer P02384265A0947 NN O
among P02384265A0947 IN O
polyp P02384265A0947 JJ O
patients P02384265A0947 NNS O
and P02384265A0947 CC O
the P02384265A0947 DT O
possibility P02384265A0947 NN O
of P02384265A0947 IN O
prophylactic P02384265A0947 JJ O
effect P02384265A0947 NN O
of P02384265A0947 IN O
polypectomy P02384265A0947 NN O
against P02384265A0947 IN O
subsequent P02384265A0947 JJ O
cancer P02384265A0947 NN O
. P02384265A0947 . O
. . O O

However P09041123A0195 RB O
, P09041123A0195 , O
the P09041123A0195 DT O
action P09041123A0195 NN O
of P09041123A0195 IN O
each P09041123A0195 DT O
cognate P09041123A0195 NN O
ligand P09041123A0195 NN O
and P09041123A0195 CC O
the P09041123A0195 DT O
accessory P09041123A0195 JJ O
cellular P09041123A0195 JJ O
factors P09041123A0195 NNS O
that P09041123A0195 WDT O
can P09041123A0195 MD O
differentially P09041123A0195 RB O
regulate P09041123A0195 VB O
the P09041123A0195 DT O
transcriptional P09041123A0195 JJ O
responses P09041123A0195 NNS O
of P09041123A0195 IN O
a P09041123A0195 DT O
heterodimer-DNA P09041123A0195 NN O
complex P09041123A0195 NN O
are P09041123A0195 VBP O
not P09041123A0195 RB O
well P09041123A0195 RB O
understood P09041123A0195 RB O
. P09041123A0195 . O
. . O O

All P07665633A0284 DT O
clinical P07665633A0284 JJ O
isolates P07665633A0284 NNS O
were P07665633A0284 VBD O
concomitantly P07665633A0284 RB O
tested P07665633A0284 VBN O
by P07665633A0284 IN O
disk P07665633A0284 NN O
diffusion P07665633A0284 NN O
and P07665633A0284 CC O
agar P07665633A0284 JJ O
dilution P07665633A0284 NN O
procedures P07665633A0284 NNS O
as P07665633A0284 IN O
outlined P07665633A0284 VBN O
by P07665633A0284 IN O
the P07665633A0284 DT O
National P07665633A0284 NNP O
Committee P07665633A0284 NNP O
for P07665633A0284 IN O
Clinical P07665633A0284 NNP O
Laboratory P07665633A0284 NNP O
Standards P07665633A0284 NNP O
. P07665633A0284 . O
. . O O

The P01123658A0000 DT O
authors P01123658A0000 NNS O
describe P01123658A0000 VBP O
the P01123658A0000 DT O
technique P01123658A0000 NN O
of P01123658A0000 IN O
transverse P01123658A0000 JJ O
axial P01123658A0000 JJ O
tomography P01123658A0000 NN O
of P01123658A0000 IN O
the P01123658A0000 DT O
spine P01123658A0000 NN O
and P01123658A0000 CC O
give P01123658A0000 VB O
a P01123658A0000 DT O
detailed P01123658A0000 JJ O
description P01123658A0000 NN O
of P01123658A0000 IN O
the P01123658A0000 DT O
axial P01123658A0000 JJ O
anatomy P01123658A0000 NN O
of P01123658A0000 IN O
the P01123658A0000 DT O
normal P01123658A0000 JJ O
lumbar P01123658A0000 NN O
spine P01123658A0000 NN O
from P01123658A0000 IN O
L-4 P01123658A0000 NNP O
to P01123658A0000 TO O
the P01123658A0000 DT O
sacrum P01123658A0000 NN O
. P01123658A0000 . O
. . O O

Liver P03733563A0820 NNP O
TG P03733563A0820 NNP O
and P03733563A0820 CC O
serum P03733563A0820 VB O
NEFA P03733563A0820 NNP O
concentrations P03733563A0820 NNS O
were P03733563A0820 VBD O
positively P03733563A0820 RB O
correlated P03733563A0820 VBN O
. P03733563A0820 . O
. . O O

Data P11898018T0000 NNP O
management P11898018T0000 NN O
in P11898018T0000 IN O
practice-based P11898018T0000 JJ O
research P11898018T0000 NN O
. P11898018T0000 . O
. . O O

In P10543949A0686 IN O
particular P10543949A0686 JJ O
, P10543949A0686 , O
the P10543949A0686 DT O
S1 P10543949A0686 NNP I-UN
' P10543949A0686 POS I-UN
specificity P10543949A0686 NN I-UN
site P10543949A0686 NN I-UN
is P10543949A0686 VBZ O
a P10543949A0686 DT O
deep P10543949A0686 JJ O
and P10543949A0686 CC O
highly P10543949A0686 RB O
hydrophobic P10543949A0686 JJ O
cavity P10543949A0686 NN O
. P10543949A0686 . O
. . O O

All P09229595A0618 DT O
corneal P09229595A0618 JJ O
buttons P09229595A0618 NNS O
were P09229595A0618 VBD O
processed P09229595A0618 VBN O
for P09229595A0618 IN O
histopathologic P09229595A0618 NN O
and P09229595A0618 CC O
electron P09229595A0618 NN O
microscopic P09229595A0618 NN O
studies P09229595A0618 NNS O
. P09229595A0618 . O
. . O O

In P04002667A0181 IN O
metastasis-free P04002667A0181 JJ O
patients P04002667A0181 NNS O
, P04002667A0181 , O
the P04002667A0181 DT O
best P04002667A0181 JJS O
results P04002667A0181 NNS O
were P04002667A0181 VBD O
obtained P04002667A0181 VBN O
with P04002667A0181 IN O
tumor P04002667A0181 NN O
diameters P04002667A0181 NNS O
under P04002667A0181 IN O
2 P04002667A0181 CD O
cm P04002667A0181 JJ O
regardless P04002667A0181 NN O
of P04002667A0181 IN O
their P04002667A0181 PRP$ O
localization P04002667A0181 NN O
in P04002667A0181 IN O
lung P04002667A0181 NN O
tissue P04002667A0181 NN O
and P04002667A0181 CC O
with P04002667A0181 IN O
2 P04002667A0181 CD O
-- P04002667A0181 : O
4.9 P04002667A0181 CD O
cm P04002667A0181 NN O
tumors P04002667A0181 NNS O
embedded P04002667A0181 VBD O
in P04002667A0181 IN O
lung P04002667A0181 NN O
parenchyma P04002667A0181 NN O
. P04002667A0181 . O
. . O O

RT-PCR P07680120A1008 JJ O
using P07680120A1008 VBG O
1.D-specific P07680120A1008 JJ O
primers P07680120A1008 NNS O
showed P07680120A1008 VBD O
that P07680120A1008 IN O
kidney P07680120A1008 NN O
, P07680120A1008 , O
brain P07680120A1008 NN O
and P07680120A1008 CC O
prostate P07680120A1008 VB O
do P07680120A1008 VBP O
not P07680120A1008 RB O
express P07680120A1008 VB O
1.D P07680120A1008 CD O
mRNA P07680120A1008 NN O
even P07680120A1008 RB O
though P07680120A1008 IN O
kidney P07680120A1008 NN O
and P07680120A1008 CC O
brain P07680120A1008 NN O
are P07680120A1008 VBP O
the P07680120A1008 DT O
most P07680120A1008 RBS O
abundant P07680120A1008 JJ O
source P07680120A1008 NN O
for P07680120A1008 IN O
aFGF P07680120A1008 JJ I-UN
protein P07680120A1008 NN I-UN
. P07680120A1008 . O
. . O O

Upon P09452444A0450 IN O
analysis P09452444A0450 NN O
of P09452444A0450 IN O
various P09452444A0450 JJ O
deletion P09452444A0450 NN O
and P09452444A0450 CC O
point-mutated P09452444A0450 JJ O
variants P09452444A0450 NNS O
of P09452444A0450 IN O
the P09452444A0450 DT O
human P09452444A0450 JJ I-UN
IL-6 P09452444A0450 NNP I-UN
gene P09452444A0450 NN I-UN
promoter P09452444A0450 NN I-UN
coupled P09452444A0450 VBN O
to P09452444A0450 TO O
a P09452444A0450 DT O
reporter P09452444A0450 NN O
gene P09452444A0450 NN O
, P09452444A0450 , O
we P09452444A0450 PRP O
screened P09452444A0450 VBD O
for P09452444A0450 IN O
possible P09452444A0450 JJ O
cooperating P09452444A0450 VBG O
transcription P09452444A0450 NN O
factors P09452444A0450 NNS O
. P09452444A0450 . O
. . O O

Resources P07620491T0000 NNS O
for P07620491T0000 IN O
helping P07620491T0000 VBG O
patients P07620491T0000 NNS O
to P07620491T0000 TO O
quit P07620491T0000 VB O
smoking P07620491T0000 NN O
. P07620491T0000 . O
. . O O

Our P11403719A1257 PRP$ O
results P11403719A1257 NNS O
indicate P11403719A1257 VBP O
that P11403719A1257 IN O
Gab1 P11403719A1257 NNP I-UN
is P11403719A1257 VBZ O
involved P11403719A1257 VBN O
in P11403719A1257 IN O
the P11403719A1257 DT O
control P11403719A1257 NN O
of P11403719A1257 IN O
egr-1 P11403719A1257 JJ I-UN
expression P11403719A1257 NN O
regulated P11403719A1257 VBN O
by P11403719A1257 IN O
insulin P11403719A1257 NN I-UN
. P11403719A1257 . O
. . O O

Changes P00506649T0000 NNS O
of P00506649T0000 IN O
thirtynine P00506649T0000 NN O
serum P00506649T0000 NN O
protein P00506649T0000 NN O
components P00506649T0000 NNS O
following P00506649T0000 VBG O
surgical P00506649T0000 JJ O
stress P00506649T0000 NN O
. P00506649T0000 . O
. . O O

Mutational P08466864A0878 JJ O
analyses P08466864A0878 NNS O
have P08466864A0878 VBP O
demonstrated P08466864A0878 VBN O
the P08466864A0878 DT O
importance P08466864A0878 NN O
of P08466864A0878 IN O
sequences P08466864A0878 NNS O
within P08466864A0878 IN O
the P08466864A0878 DT O
327 P08466864A0878 CD O
bp P08466864A0878 NN O
segment P08466864A0878 NN O
that P08466864A0878 WDT O
contain P08466864A0878 VBP O
a P08466864A0878 DT O
putative P08466864A0878 JJ O
cyclic P08466864A0878 NN I-UN
AMP P08466864A0878 NNP I-UN
responsive P08466864A0878 JJ I-UN
element P08466864A0878 NN I-UN
binding P08466864A0878 VBG I-UN
protein P08466864A0878 NN I-UN
( P08466864A0878 ( O
CREB P08466864A0878 NNP I-UN
) P08466864A0878 ) O
binding P08466864A0878 VBG O
site P08466864A0878 NN O
for P08466864A0878 IN O
TGF-beta P08466864A0878 NNP I-UN
1 P08466864A0878 CD I-UN
and P08466864A0878 CC O
PMA P08466864A0878 NNP O
responsiveness P08466864A0878 NN O
and P08466864A0878 CC O
putative P08466864A0878 JJ O
PU-1 P08466864A0878 NNP I-UN
and P08466864A0878 CC O
Sp1 P08466864A0878 NNP I-UN
binding P08466864A0878 NN I-UN
sites P08466864A0878 NNS I-UN
for P08466864A0878 IN O
basal P08466864A0878 JJ O
promoter P08466864A0878 NN O
activity P08466864A0878 NN O
. P08466864A0878 . O
. . O O

Overall P10208893A0839 JJ O
, P10208893A0839 , O
our P10208893A0839 PRP$ O
results P10208893A0839 NNS O
suggest P10208893A0839 VBP O
that P10208893A0839 IN O
resistant P10208893A0839 JJ O
genotypes P10208893A0839 NNS O
exist P10208893A0839 VBP O
among P10208893A0839 IN O
the P10208893A0839 DT O
WAD P10208893A0839 NNP O
goat P10208893A0839 NN O
population P10208893A0839 NN O
. P10208893A0839 . O
. . O O

The P10509768A1118 DT O
reduction P10509768A1118 NN O
in P10509768A1118 IN O
saturated P10509768A1118 JJ O
fatty P10509768A1118 JJ O
acids P10509768A1118 NNS O
intake P10509768A1118 VBP O
led P10509768A1118 VBN O
to P10509768A1118 TO O
modest P10509768A1118 JJ O
( P10509768A1118 ( O
but P10509768A1118 CC O
in P10509768A1118 IN O
group P10509768A1118 NN O
1 P10509768A1118 CD O
significant P10509768A1118 JJ O
) P10509768A1118 ) O
0.15 P10509768A1118 CD O
mmol P10509768A1118 NN O
/ P10509768A1118 NN O
l P10509768A1118 NN O
( P10509768A1118 ( O
2.5 P10509768A1118 CD O
% P10509768A1118 NN O
) P10509768A1118 ) O
reduction P10509768A1118 NN O
in P10509768A1118 IN O
total P10509768A1118 JJ O
serum P10509768A1118 NN O
cholesterol P10509768A1118 NN O
level P10509768A1118 NN O
. P10509768A1118 . O
. . O O

Six P00703932A0000 CD O
patients P00703932A0000 NNS O
with P00703932A0000 IN O
glomerulonephritis P00703932A0000 NN O
in P00703932A0000 IN O
association P00703932A0000 NN O
with P00703932A0000 IN O
a P00703932A0000 DT O
ventriculovascular P00703932A0000 JJ O
shunt P00703932A0000 NN O
were P00703932A0000 VBD O
treated P00703932A0000 VBN O
with P00703932A0000 IN O
three P00703932A0000 CD O
basic P00703932A0000 JJ O
modes P00703932A0000 NNS O
of P00703932A0000 IN O
therapy P00703932A0000 NN O
. P00703932A0000 . O
. . O O

Malaria P09653745A0180 NNP O
had P09653745A0180 VBD O
diminished P09653745A0180 VBN O
significantly P09653745A0180 RB O
by P09653745A0180 IN O
the P09653745A0180 DT O
early P09653745A0180 JJ O
1940s P09653745A0180 CD O
, P09653745A0180 , O
and P09653745A0180 CC O
this P09653745A0180 DT O
paper P09653745A0180 NN O
queries P09653745A0180 VBZ O
whether P09653745A0180 IN O
that P09653745A0180 DT O
reduction P09653745A0180 NN O
was P09653745A0180 VBD O
due P09653745A0180 JJ O
to P09653745A0180 TO O
the P09653745A0180 DT O
control P09653745A0180 NN O
projects P09653745A0180 NNS O
of P09653745A0180 IN O
the P09653745A0180 DT O
thirties P09653745A0180 NNS O
, P09653745A0180 , O
and P09653745A0180 CC O
, P09653745A0180 , O
if P09653745A0180 IN O
so P09653745A0180 RB O
, P09653745A0180 , O
whether P09653745A0180 IN O
such P09653745A0180 JJ O
projects P09653745A0180 NNS O
should P09653745A0180 MD O
be P09653745A0180 VB O
a P09653745A0180 DT O
model P09653745A0180 NN O
for P09653745A0180 IN O
the P09653745A0180 DT O
current P09653745A0180 JJ O
developing P09653745A0180 NN O
world P09653745A0180 NN O
, P09653745A0180 , O
where P09653745A0180 WRB O
malaria P09653745A0180 NN O
is P09653745A0180 VBZ O
a P09653745A0180 DT O
growing P09653745A0180 VBG O
problem P09653745A0180 NN O
today P09653745A0180 NN O
. P09653745A0180 . O
. . O O

The P10207049A1001 DT O
results P10207049A1001 NNS O
demonstrate P10207049A1001 VBP O
that P10207049A1001 IN O
the P10207049A1001 DT O
Glc7 P10207049A1001 NNP I-UN
phosphatase P10207049A1001 NN I-UN
and P10207049A1001 CC O
its P10207049A1001 PRP$ O
Gac1 P10207049A1001 NNP I-UN
regulatory P10207049A1001 JJ O
subunit P10207049A1001 NN O
play P10207049A1001 NN O
positive P10207049A1001 JJ O
roles P10207049A1001 NNS O
in P10207049A1001 IN O
HSF P10207049A1001 NNP I-UN
activation P10207049A1001 NN O
of P10207049A1001 IN O
CUP1 P10207049A1001 NNP I-UN
transcription P10207049A1001 NN O
. P10207049A1001 . O
. . O O

O. P10329574A1733 IN I-UN
novo-ulmi P10329574A1733 JJ I-UN
RNA-7 P10329574A1733 NNP I-UN
, P10329574A1733 , O
previously P10329574A1733 RB O
believed P10329574A1733 VBN O
to P10329574A1733 TO O
be P10329574A1733 VB O
a P10329574A1733 DT O
satellite-like P10329574A1733 JJ O
RNA P10329574A1733 NNP O
, P10329574A1733 , O
is P10329574A1733 VBZ O
shown P10329574A1733 VBN O
to P10329574A1733 TO O
be P10329574A1733 VB O
a P10329574A1733 DT O
defective P10329574A1733 JJ O
RNA P10329574A1733 NNP O
, P10329574A1733 , O
derived P10329574A1733 VBD O
from P10329574A1733 IN O
OnuMV4-Ld P10329574A1733 NNP I-UN
RNA P10329574A1733 NNP I-UN
by P10329574A1733 IN O
multiple P10329574A1733 JJ O
internal P10329574A1733 JJ O
deletions P10329574A1733 NNS O
. P10329574A1733 . O
. . O O

Tissue-specific P07666414A0614 JJ O
expression P07666414A0614 NN O
of P07666414A0614 IN O
the P07666414A0614 DT O
tmy-1 P07666414A0614 JJ I-UN
gene P07666414A0614 NN I-UN
was P07666414A0614 VBD O
determined P07666414A0614 VBN O
by P07666414A0614 IN O
microinjection P07666414A0614 NN O
of P07666414A0614 IN O
a P07666414A0614 DT O
promoter P07666414A0614 NN I-UN
/ P07666414A0614 NNP I-UN
lacZ P07666414A0614 VBZ I-UN
fusion P07666414A0614 NN I-UN
gene P07666414A0614 NN I-UN
and P07666414A0614 CC O
with P07666414A0614 IN O
immunohistochemistry P07666414A0614 NN O
by P07666414A0614 IN O
using P07666414A0614 VBG O
affinity-purified P07666414A0614 JJ O
tissue-specific P07666414A0614 JJ I-UN
anti-tropomyosins P07666414A0614 NNS I-UN
. P07666414A0614 . O
. . O O

Thrombophlebitis P03923976T0001 NN O
and P03923976T0001 CC O
pulmonary P03923976T0001 JJ O
embolism P03923976T0001 NN O
in P03923976T0001 IN O
congenital P03923976T0001 JJ O
factor P03923976T0001 NN I-UN
XII P03923976T0001 NNP I-UN
deficiency P03923976T0001 NN O
. P03923976T0001 . O
. . O O

The P09065768A0862 DT O
second P09065768A0862 JJ O
class P09065768A0862 NN O
of P09065768A0862 IN O
cDNA P09065768A0862 NN O
hybridized P09065768A0862 VBN O
to P09065768A0862 TO O
a P09065768A0862 DT O
13 P09065768A0862 CD O
kb P09065768A0862 NN O
transcript P09065768A0862 NN O
, P09065768A0862 , O
which P09065768A0862 WDT O
was P09065768A0862 VBD O
approximately P09065768A0862 RB O
twice P09065768A0862 RB O
as P09065768A0862 RB O
large P09065768A0862 JJ O
as P09065768A0862 IN O
the P09065768A0862 DT O
mammalian P09065768A0862 JJ I-UN
lactase P09065768A0862 NN I-UN
mRNA P09065768A0862 NN I-UN
. P09065768A0862 . O
. . O O

We P09252397A0081 PRP O
had P09252397A0081 VBD O
previously P09252397A0081 RB O
analyzed P09252397A0081 VBN O
repair P09252397A0081 NN O
rates P09252397A0081 NNS O
of P09252397A0081 IN O
cyclobutane P09252397A0081 NN O
pyrimidine P09252397A0081 NN O
dimers P09252397A0081 NNS O
at P09252397A0081 IN O
nucleotide P09252397A0081 JJ O
resolution P09252397A0081 NN O
along P09252397A0081 IN O
the P09252397A0081 DT O
human P09252397A0081 JJ I-UN
JUN P09252397A0081 NNP I-UN
gene P09252397A0081 NN I-UN
in P09252397A0081 IN O
normal P09252397A0081 JJ O
fibroblasts P09252397A0081 NNS O
and P09252397A0081 CC O
found P09252397A0081 VBD O
very P09252397A0081 RB O
efficient P09252397A0081 JJ O
repair P09252397A0081 NN O
of P09252397A0081 IN O
sequences P09252397A0081 NNS O
near P09252397A0081 IN O
the P09252397A0081 DT O
transcription P09252397A0081 NN O
initiation P09252397A0081 NN O
site P09252397A0081 NN O
but P09252397A0081 CC O
slow P09252397A0081 JJ O
repair P09252397A0081 NN O
along P09252397A0081 IN O
the P09252397A0081 DT O
promoter P09252397A0081 NN O
. P09252397A0081 . O
. . O O

Low-dose P08747078T0000 JJ O
aspirin P08747078T0000 NN O
and P08747078T0000 CC O
recurrent P08747078T0000 JJ O
miscarriage P08747078T0000 NN O
. P08747078T0000 . O
. . O O

A P07971709A0907 DT O
normal P07971709A0907 JJ O
systemic P07971709A0907 JJ O
response P07971709A0907 NN O
was P07971709A0907 VBD O
obtained P07971709A0907 VBN O
after P07971709A0907 IN O
IF P07971709A0907 NNP O
, P07971709A0907 , O
indicating P07971709A0907 VBG O
that P07971709A0907 IN O
rhG-CSF P07971709A0907 JJ I-UN
retains P07971709A0907 NNS O
activity P07971709A0907 NN O
in P07971709A0907 IN O
the P07971709A0907 DT O
solid P07971709A0907 JJ O
state P07971709A0907 NN O
. P07971709A0907 . O
. . O O

The P02307848A0347 DT O
coding P02307848A0347 NN O
sequences P02307848A0347 NNS O
of P02307848A0347 IN O
the P02307848A0347 DT O
Crry P02307848A0347 NNP I-UN
gene P02307848A0347 NN I-UN
encompass P02307848A0347 NN O
over P02307848A0347 IN O
25 P02307848A0347 CD O
kb P02307848A0347 NNS O
of P02307848A0347 IN O
DNA P02307848A0347 NNP O
, P02307848A0347 , O
whereas P02307848A0347 IN O
the P02307848A0347 DT O
Crry-ps P02307848A0347 JJ O
sequences P02307848A0347 NNS O
are P02307848A0347 VBP O
included P02307848A0347 VBN O
within P02307848A0347 IN O
a P02307848A0347 DT O
single P02307848A0347 JJ O
5.6-kb P02307848A0347 JJ I-UN
Eco-R1 P02307848A0347 JJ I-UN
fragment P02307848A0347 NN I-UN
. P02307848A0347 . O
. . O O

In P10308312A0203 IN O
this P10308312A0203 DT O
paper P10308312A0203 NN O
, P10308312A0203 , O
the P10308312A0203 DT O
current P10308312A0203 JJ O
status P10308312A0203 NN O
of P10308312A0203 IN O
the P10308312A0203 DT O
understanding P10308312A0203 NN O
of P10308312A0203 IN O
the P10308312A0203 DT O
interaction P10308312A0203 NN O
mechanisms P10308312A0203 NN O
of P10308312A0203 IN O
ultrasound P10308312A0203 NN O
with P10308312A0203 IN O
biological P10308312A0203 JJ O
media P10308312A0203 NNS O
and P10308312A0203 CC O
the P10308312A0203 DT O
factors P10308312A0203 NNS O
that P10308312A0203 WDT O
govern P10308312A0203 VBP O
different P10308312A0203 JJ O
biological P10308312A0203 JJ O
effects P10308312A0203 NNS O
are P10308312A0203 VBP O
surveyed P10308312A0203 VBN O
. P10308312A0203 . O
. . O O

However P08289593A1404 RB O
, P08289593A1404 , O
artificially P08289593A1404 RB O
ventilated P08289593A1404 JJ O
rats P08289593A1404 NNS O
, P08289593A1404 , O
pretreated P08289593A1404 VBN O
with P08289593A1404 IN O
MK-801 P08289593A1404 NNP O
, P08289593A1404 , O
were P08289593A1404 VBD O
more P08289593A1404 RBR O
sensitive P08289593A1404 JJ O
( P08289593A1404 ( O
lethal P08289593A1404 JJ O
cocaine P08289593A1404 NN O
dose P08289593A1404 NN O
, P08289593A1404 , O
76.6 P08289593A1404 CD O
+ P08289593A1404 NN O
/ P08289593A1404 NNP O
- P08289593A1404 : O
8.0 P08289593A1404 CD O
mg P08289593A1404 NN O
/ P08289593A1404 NNP O
kg P08289593A1404 NN O
, P08289593A1404 , O
n P08289593A1404 JJ O
= P08289593A1404 NNP O
5 P08289593A1404 CD O
) P08289593A1404 ) O
than P08289593A1404 IN O
vehicle P08289593A1404 NN O
pretreated P08289593A1404 VBN O
rats P08289593A1404 NNS O
( P08289593A1404 ( O
129.4 P08289593A1404 CD O
+ P08289593A1404 NN O
/ P08289593A1404 NNP O
- P08289593A1404 : O
15.8 P08289593A1404 CD O
mg P08289593A1404 NN O
/ P08289593A1404 NNP O
kg P08289593A1404 NN O
, P08289593A1404 , O
n P08289593A1404 JJ O
= P08289593A1404 NNP O
6 P08289593A1404 CD O
) P08289593A1404 ) O
, P08289593A1404 , O
indicating P08289593A1404 VBG O
that P08289593A1404 IN O
MK-801 P08289593A1404 NNP O
may P08289593A1404 MD O
increase P08289593A1404 VB O
both P08289593A1404 DT O
the P08289593A1404 DT O
respiratory P08289593A1404 NN O
and P08289593A1404 CC O
the P08289593A1404 DT O
cardiac P08289593A1404 JJ O
toxicity P08289593A1404 NN O
of P08289593A1404 IN O
cocaine P08289593A1404 NN O
in P08289593A1404 IN O
urethane P08289593A1404 JJ O
anesthetized P08289593A1404 JJ O
rats P08289593A1404 NNS O
. P08289593A1404 . O
. . O O

Nitrofurazone P03446332A0831 NN O
significantly P03446332A0831 RB O
reduced P03446332A0831 VBD O
the P03446332A0831 DT O
rise P03446332A0831 NN O
in P03446332A0831 IN O
LH P03446332A0831 NNP I-UN
induced P03446332A0831 VBN O
by P03446332A0831 IN O
LHRH P03446332A0831 NNP I-UN
. P03446332A0831 . O
. . O O

We P09341193A0362 PRP O
also P09341193A0362 RB O
identified P09341193A0362 VBD O
Sp1 P09341193A0362 NNP I-UN
, P09341193A0362 , O
Sp3 P09341193A0362 NNP I-UN
, P09341193A0362 , O
and P09341193A0362 CC O
NGFI-A P09341193A0362 NNP I-UN
/ P09341193A0362 NNP O
Egr-1 P09341193A0362 NNP I-UN
as P09341193A0362 IN O
the P09341193A0362 DT O
primary P09341193A0362 JJ O
nuclear P09341193A0362 JJ O
transcription P09341193A0362 NN O
factors P09341193A0362 NNS O
binding P09341193A0362 VBG O
to P09341193A0362 TO O
TRE1 P09341193A0362 NNP I-UN
which P09341193A0362 WDT O
mediate P09341193A0362 VBP O
Tax P09341193A0362 NNP I-UN
responsiveness P09341193A0362 NN O
. P09341193A0362 . O
. . O O

We P08624445A0257 PRP O
present P08624445A0257 VBP O
here P08624445A0257 RB O
a P08624445A0257 DT O
detailed P08624445A0257 JJ O
genomic P08624445A0257 JJ O
sequencing P08624445A0257 VBG O
analysis P08624445A0257 NN O
of P08624445A0257 IN O
the P08624445A0257 DT O
cytosine P08624445A0257 NN O
methylation P08624445A0257 NN O
patterns P08624445A0257 NNS O
of P08624445A0257 IN O
the P08624445A0257 DT O
transposase P08624445A0257 NN I-UN
binding P08624445A0257 NN O
sites P08624445A0257 NNS O
within P08624445A0257 IN O
both P08624445A0257 DT O
Ac P08624445A0257 NNP I-UN
ends P08624445A0257 VBZ O
in P08624445A0257 IN O
the P08624445A0257 DT O
wx-m9 P08624445A0257 NN I-UN
: P08624445A0257 : O
:Ac P08624445A0257 NN O
allele P08624445A0257 NN I-UN
, P08624445A0257 , O
where P08624445A0257 WRB O
Ac P08624445A0257 NNP I-UN
is P08624445A0257 VBZ O
inserted P08624445A0257 VBN O
into P08624445A0257 IN O
the P08624445A0257 DT O
tenth P08624445A0257 JJ O
exon P08624445A0257 NN O
of P08624445A0257 IN O
the P08624445A0257 DT O
Waxy P08624445A0257 NNP I-UN
gene P08624445A0257 NN I-UN
. P08624445A0257 . O
. . O O

The P11574088A1687 DT O
mean P11574088A1687 JJ O
waiting P11574088A1687 NN O
time P11574088A1687 NN O
to P11574088A1687 TO O
receive P11574088A1687 VB O
the P11574088A1687 DT O
pancreas P11574088A1687 NNS O
transplant P11574088A1687 NN O
was P11574088A1687 VBD O
244 P11574088A1687 CD O
days P11574088A1687 NNS O
for P11574088A1687 IN O
SPK P11574088A1687 NNP O
and P11574088A1687 CC O
167 P11574088A1687 CD O
days P11574088A1687 NNS O
for P11574088A1687 IN O
PAK P11574088A1687 NNP O
recipients P11574088A1687 NNS O
( P11574088A1687 ( O
P P11574088A1687 NNP O
= P11574088A1687 NNP O
0.001 P11574088A1687 CD O
) P11574088A1687 ) O
. P11574088A1687 . O
. . O O

Total P10231454A0731 JJ O
serum P10231454A0731 NN O
calcium P10231454A0731 NN O
was P10231454A0731 VBD O
7.8 P10231454A0731 CD O
+ P10231454A0731 JJ O
/ P10231454A0731 NNP O
- P10231454A0731 : O
0.8 P10231454A0731 CD O
mg P10231454A0731 NN O
/ P10231454A0731 NNP O
dl P10231454A0731 NN O
, P10231454A0731 , O
whereas P10231454A0731 WP O
ionized P10231454A0731 VBD O
calcium P10231454A0731 NN O
was P10231454A0731 VBD O
5.7 P10231454A0731 CD O
+ P10231454A0731 JJ O
/ P10231454A0731 NNP O
- P10231454A0731 : O
0.7 P10231454A0731 CD O
mg P10231454A0731 NN O
/ P10231454A0731 NNP O
dl P10231454A0731 NN O
, P10231454A0731 , O
phosphorus P10231454A0731 NN O
3.2 P10231454A0731 CD O
+ P10231454A0731 NN O
/ P10231454A0731 NNP O
- P10231454A0731 : O
1.2 P10231454A0731 CD O
mg P10231454A0731 NN O
/ P10231454A0731 NNP O
dl P10231454A0731 NN O
, P10231454A0731 , O
and P10231454A0731 CC O
alkaline P10231454A0731 JJ I-UN
phosphatase P10231454A0731 NN I-UN
149 P10231454A0731 CD O
+ P10231454A0731 NN O
/ P10231454A0731 NNP O
- P10231454A0731 : O
48.6 P10231454A0731 CD O
U P10231454A0731 NNP O
/ P10231454A0731 NNP O
liter P10231454A0731 NN O
. P10231454A0731 . O
. . O O

The P01829060A0649 DT O
ED30 P01829060A0649 NNP O
values P01829060A0649 NNS O
were P01829060A0649 VBD O
2.4 P01829060A0649 CD O
and P01829060A0649 CC O
2.2 P01829060A0649 CD O
mg P01829060A0649 NN O
/ P01829060A0649 NNP O
kg P01829060A0649 NN O
and P01829060A0649 CC O
similar P01829060A0649 JJ O
to P01829060A0649 TO O
the P01829060A0649 DT O
respective P01829060A0649 JJ O
values P01829060A0649 NNS O
of P01829060A0649 IN O
nifedipine P01829060A0649 NN O
( P01829060A0649 ( O
ED P01829060A0649 NNP O
30:2.4,2.1 P01829060A0649 CD O
mg P01829060A0649 NN O
/ P01829060A0649 NNP O
kg P01829060A0649 NN O
) P01829060A0649 ) O
. P01829060A0649 . O
. . O O

The P02046202A0625 DT O
remainder P02046202A0625 NN O
( P02046202A0625 ( O
18.4 P02046202A0625 CD O
% P02046202A0625 NN O
) P02046202A0625 ) O
was P02046202A0625 VBD O
with P02046202A0625 IN O
IgA P02046202A0625 NNP I-UN
nephropathy P02046202A0625 NN O
, P02046202A0625 , O
which P02046202A0625 WDT O
was P02046202A0625 VBD O
histologically P02046202A0625 RB O
mild P02046202A0625 JJ O
. P02046202A0625 . O
. . O O

The P01285807A0365 DT O
mean P01285807A0365 NN O
( P01285807A0365 ( O
+ P01285807A0365 JJ O
/ P01285807A0365 NNP O
- P01285807A0365 : O
SD P01285807A0365 NN O
) P01285807A0365 ) O
PaO2 P01285807A0365 NNP O
increased P01285807A0365 VBD O
from P01285807A0365 IN O
80.8 P01285807A0365 CD O
+ P01285807A0365 NNS O
/ P01285807A0365 SYM O
- P01285807A0365 : O
26.9 P01285807A0365 CD O
mmHg P01285807A0365 NN O
before P01285807A0365 IN O
to P01285807A0365 TO O
89.8 P01285807A0365 CD O
+ P01285807A0365 NNS O
/ P01285807A0365 SYM O
- P01285807A0365 : O
27.3 P01285807A0365 CD O
mmHg P01285807A0365 NN O
after P01285807A0365 IN O
the P01285807A0365 DT O
infusion P01285807A0365 NN O
( P01285807A0365 ( O
P P01285807A0365 NNP O
< P01285807A0365 NNP O
0.05 P01285807A0365 CD O
) P01285807A0365 ) O
and P01285807A0365 CC O
the P01285807A0365 DT O
PaCO2 P01285807A0365 NNP O
decreased P01285807A0365 VBD O
from P01285807A0365 IN O
42.4 P01285807A0365 CD O
+ P01285807A0365 NNS O
/ P01285807A0365 SYM O
- P01285807A0365 : O
8.3 P01285807A0365 CD O
to P01285807A0365 TO O
39.6 P01285807A0365 CD O
+ P01285807A0365 NNS O
/ P01285807A0365 SYM O
- P01285807A0365 : O
7.9 P01285807A0365 CD O
mmHg P01285807A0365 NN O
( P01285807A0365 ( O
P P01285807A0365 NNP O
< P01285807A0365 NNP O
0.05 P01285807A0365 CD O
) P01285807A0365 ) O
. P01285807A0365 . O
. . O O

Elevated P02853922A0596 VBN O
IOP P02853922A0596 NNP O
developed P02853922A0596 VBD O
in P02853922A0596 IN O
35 P02853922A0596 CD O
patients P02853922A0596 NNS O
( P02853922A0596 ( O
44 P02853922A0596 CD O
eyes P02853922A0596 NNS O
) P02853922A0596 ) O
during P02853922A0596 IN O
the P02853922A0596 DT O
study P02853922A0596 NN O
. P02853922A0596 . O
. . O O

To P10722661A0406 TO O
determine P10722661A0406 VB O
if P10722661A0406 IN O
CYC2 P10722661A0406 NNP I-UN
is P10722661A0406 VBZ O
found P10722661A0406 VBN O
in P10722661A0406 IN O
a P10722661A0406 DT O
complex P10722661A0406 JJ O
with P10722661A0406 IN O
previously P10722661A0406 RB O
identified P10722661A0406 VBN O
trypanosome P10722661A0406 JJ I-UN
cdc2-related P10722661A0406 JJ I-UN
kinases P10722661A0406 NNS I-UN
( P10722661A0406 ( O
CRKs P10722661A0406 NNP I-UN
) P10722661A0406 ) O
, P10722661A0406 , O
the P10722661A0406 DT O
CYC2 P10722661A0406 NNP I-UN
gene P10722661A0406 NN I-UN
was P10722661A0406 VBD O
fused P10722661A0406 VBN O
to P10722661A0406 TO O
the P10722661A0406 DT O
TY P10722661A0406 NNP I-UN
epitope P10722661A0406 NN I-UN
tag P10722661A0406 NN O
, P10722661A0406 , O
integrated P10722661A0406 VBN O
into P10722661A0406 IN O
the P10722661A0406 DT O
trypanosome P10722661A0406 JJ O
genome P10722661A0406 NN O
, P10722661A0406 , O
and P10722661A0406 CC O
expressed P10722661A0406 VBD O
under P10722661A0406 IN O
inducible P10722661A0406 JJ O
control P10722661A0406 NN O
. P10722661A0406 . O
. . O O

The P02217741T0001 DT O
interrelation P02217741T0001 NN O
of P02217741T0001 IN O
the P02217741T0001 DT O
levels P02217741T0001 NNS O
of P02217741T0001 IN O
glucocorticoids P02217741T0001 NNS O
and P02217741T0001 CC O
insulin P02217741T0001 NN I-UN
in P02217741T0001 IN O
the P02217741T0001 DT O
blood P02217741T0001 NN O
of P02217741T0001 IN O
irradiated P02217741T0001 JJ O
animals P02217741T0001 NNS O
. P02217741T0001 . O
. . O O

A P09092675A0283 DT O
P22 P09092675A0283 NNP O
R17 P09092675A0283 NNP O
derivative P09092675A0283 NN O
with P09092675A0283 IN O
an P09092675A0283 DT O
OcRNA P09092675A0283 NNP O
site P09092675A0283 NN O
( P09092675A0283 ( O
P22 P09092675A0283 NNP O
R17 P09092675A0283 NNP O
[ P09092675A0283 VBZ O
A P09092675A0283 NNP O
( P09092675A0283 ( O
-10 P09092675A0283 NNP O
) P09092675A0283 ) O
U P09092675A0283 NNP O
] P09092675A0283 NNP O
) P09092675A0283 ) O
develops P09092675A0283 VBZ O
lytically P09092675A0283 RB O
following P09092675A0283 JJ O
infection P09092675A0283 NN O
of P09092675A0283 IN O
these P09092675A0283 DT O
strains P09092675A0283 NNS O
. P09092675A0283 . O
. . O O

We P08628284A0181 PRP O
constructed P08628284A0181 VBD O
a P08628284A0181 DT O
yeast P08628284A0181 NN O
reporter P08628284A0181 NN O
strain P08628284A0181 NN O
containing P08628284A0181 VBG O
the P08628284A0181 DT O
lacZ P08628284A0181 JJ I-UN
gene P08628284A0181 NN I-UN
under P08628284A0181 IN O
the P08628284A0181 DT O
control P08628284A0181 NN O
of P08628284A0181 IN O
the P08628284A0181 DT O
CYC1 P08628284A0181 NNP I-UN
promoter P08628284A0181 NN I-UN
associated P08628284A0181 VBN O
with P08628284A0181 IN O
three P08628284A0181 CD O
copies P08628284A0181 NNS O
of P08628284A0181 IN O
TRE-1 P08628284A0181 NNP I-UN
. P08628284A0181 . O
. . O O

Liver P08975532T0001 NNP O
injuries P08975532T0001 NNS O
. P08975532T0001 . O
. . O O

Their P11295523A0218 PRP$ O
numbers P11295523A0218 NNS O
have P11295523A0218 VBP O
regularly P11295523A0218 RB O
increased P11295523A0218 VBN O
since P11295523A0218 IN O
the P11295523A0218 DT O
mid-1970s P11295523A0218 NNS O
. P11295523A0218 . O
. . O O

Two P02026491A0399 CD O
patients P02026491A0399 NNS O
had P02026491A0399 VBD O
immediate P02026491A0399 JJ O
adverse P02026491A0399 JJ O
effects P02026491A0399 NNS O
from P02026491A0399 IN O
NMF P02026491A0399 NNP O
; P02026491A0399 : O
one P02026491A0399 CD O
had P02026491A0399 VBD O
a P02026491A0399 DT O
grand P02026491A0399 JJ O
mal P02026491A0399 JJ O
seizure P02026491A0399 NN O
and P02026491A0399 CC O
the P02026491A0399 DT O
other P02026491A0399 JJ O
developed P02026491A0399 VBD O
severe P02026491A0399 JJ O
abdominal P02026491A0399 JJ O
pain P02026491A0399 NN O
. P02026491A0399 . O
. . O O

CONCLUSION P11472523A0535 NN O
: P11472523A0535 : O
Extrusion P11472523A0535 NN O
cooking P11472523A0535 NN O
is P11472523A0535 VBZ O
effective P11472523A0535 JJ O
for P11472523A0535 IN O
the P11472523A0535 DT O
inactivation P11472523A0535 NN O
of P11472523A0535 IN O
DON P11472523A0535 NNP O
but P11472523A0535 CC O
is P11472523A0535 VBZ O
of P11472523A0535 IN O
limited P11472523A0535 JJ O
value P11472523A0535 NN O
for P11472523A0535 IN O
AFB1 P11472523A0535 NNP I-UN
, P11472523A0535 , O
even P11472523A0535 RB O
if P11472523A0535 IN O
metabisulphite P11472523A0535 NN O
is P11472523A0535 VBZ O
added P11472523A0535 VBN O
. P11472523A0535 . O
. . O O

In P10071761A2374 IN O
addition P10071761A2374 NN O
, P10071761A2374 , O
mapping P10071761A2374 NN O
of P10071761A2374 IN O
the P10071761A2374 DT O
promoter P10071761A2374 NN O
region P10071761A2374 NN O
and P10071761A2374 CC O
the P10071761A2374 DT O
identification P10071761A2374 NN O
of P10071761A2374 IN O
putative P10071761A2374 JJ O
promoter P10071761A2374 NN O
regulatory P10071761A2374 JJ O
sequences P10071761A2374 NNS O
should P10071761A2374 MD O
give P10071761A2374 VB O
insight P10071761A2374 NN O
into P10071761A2374 IN O
the P10071761A2374 DT O
transcriptional P10071761A2374 JJ O
regulation P10071761A2374 NN O
of P10071761A2374 IN O
UCP2 P10071761A2374 NNP I-UN
expression P10071761A2374 NN O
-- P10071761A2374 : O
in P10071761A2374 IN O
particular P10071761A2374 JJ O
by P10071761A2374 IN O
anyone P10071761A2374 NN O
of P10071761A2374 IN O
the P10071761A2374 DT O
above P10071761A2374 NN O
mentioned P10071761A2374 VBD O
factors P10071761A2374 NNS O
-- P10071761A2374 : O
in P10071761A2374 IN O
vitro P10071761A2374 NN O
and P10071761A2374 CC O
in P10071761A2374 IN O
vivo P10071761A2374 NN O
. P10071761A2374 . O
. . O O

CD4 P09819110A0703 NNP I-UN
lymphocyte P09819110A0703 NN O
and P09819110A0703 CC O
viral P09819110A0703 JJ O
load P09819110A0703 NN O
levels P09819110A0703 NNS O
suggested P09819110A0703 VBD O
an P09819110A0703 DT O
optimal P09819110A0703 JJ O
response P09819110A0703 NN O
to P09819110A0703 TO O
ARV P09819110A0703 NNP O
therapy P09819110A0703 NN O
at P09819110A0703 IN O
the P09819110A0703 DT O
time P09819110A0703 NN O
LD P09819110A0703 NNP O
developed P09819110A0703 VBD O
. P09819110A0703 . O
. . O O

Effects P04878680T0000 NNS O
of P04878680T0000 IN O
ionizing P04878680T0000 VBG O
radiation P04878680T0000 NN O
in P04878680T0000 IN O
the P04878680T0000 DT O
human P04878680T0000 JJ O
oral P04878680T0000 JJ O
cavity P04878680T0000 NN O
and P04878680T0000 CC O
oropharynx P04878680T0000 NN O
: P04878680T0000 : O
results P04878680T0000 NNS O
of P04878680T0000 IN O
a P04878680T0000 DT O
survey P04878680T0000 NN O
. P04878680T0000 . O
. . O O

An P03789052A0527 DT O
exaggerated P03789052A0527 JJ O
tissue P03789052A0527 NN O
response P03789052A0527 NN O
adjacent P03789052A0527 NN O
to P03789052A0527 TO O
the P03789052A0527 DT O
cyanoacrylate P03789052A0527 NN O
site P03789052A0527 NN O
suggested P03789052A0527 VBD O
a P03789052A0527 DT O
potential P03789052A0527 JJ O
toxic P03789052A0527 NN O
chemical P03789052A0527 NN O
or P03789052A0527 CC O
thermal P03789052A0527 JJ O
reaction P03789052A0527 NN O
, P03789052A0527 , O
or P03789052A0527 CC O
both P03789052A0527 DT O
, P03789052A0527 , O
to P03789052A0527 TO O
the P03789052A0527 DT O
tissue P03789052A0527 NN O
adhesive P03789052A0527 JJ O
, P03789052A0527 , O
but P03789052A0527 CC O
there P03789052A0527 EX O
was P03789052A0527 VBD O
no P03789052A0527 DT O
evidence P03789052A0527 NN O
of P03789052A0527 IN O
any P03789052A0527 DT O
distant P03789052A0527 JJ O
ocular P03789052A0527 JJ O
effects P03789052A0527 NNS O
. P03789052A0527 . O
. . O O

Near P00910823A0196 IN O
term P00910823A0196 NN O
, P00910823A0196 , O
under P00910823A0196 IN O
experimental P00910823A0196 JJ O
conditions P00910823A0196 NNS O
, P00910823A0196 , O
maternal P00910823A0196 JJ O
and P00910823A0196 CC O
fetal P00910823A0196 JJ O
blood P00910823A0196 NN O
gases P00910823A0196 NNS O
, P00910823A0196 , O
pH P00910823A0196 NN O
, P00910823A0196 , O
uterine P00910823A0196 JJ O
and P00910823A0196 CC O
umbilical P00910823A0196 JJ O
blood P00910823A0196 NN O
flows P00910823A0196 NNS O
were P00910823A0196 VBD O
measured P00910823A0196 VBN O
or P00910823A0196 CC O
calculated P00910823A0196 VBN O
. P00910823A0196 . O
. . O O

STAT5A P11413148A0573 NNP I-UN
mutations P11413148A0573 NNS O
in P11413148A0573 IN O
the P11413148A0573 DT O
Src P11413148A0573 NNP I-UN
homology P11413148A0573 NN I-UN
2 P11413148A0573 CD I-UN
( P11413148A0573 ( O
SH2 P11413148A0573 NNP I-UN
) P11413148A0573 ) O
and P11413148A0573 CC O
SH3 P11413148A0573 NNP I-UN
domains P11413148A0573 NNS I-UN
did P11413148A0573 VBD O
not P11413148A0573 RB O
alter P11413148A0573 VB O
the P11413148A0573 DT O
BTK-mediated P11413148A0573 JJ O
tyrosine P11413148A0573 NN O
phosphorylation P11413148A0573 NN O
. P11413148A0573 . O
. . O O

Diary P11029262T0000 NNP O
. P11029262T0000 . O
. . O O

Workers P00222827A0000 NNS O
with P00222827A0000 IN O
`` P00222827A0000 `` O
sensitivity P00222827A0000 NN O
'' P00222827A0000 '' O
to P00222827A0000 TO O
toluene P00222827A0000 VB O
diisocyanate P00222827A0000 NN O
( P00222827A0000 ( O
TDI P00222827A0000 NNP O
) P00222827A0000 ) O
studied P00222827A0000 VBD O
in P00222827A0000 IN O
depth P00222827A0000 NN O
in P00222827A0000 IN O
an P00222827A0000 DT O
attempt P00222827A0000 NN O
to P00222827A0000 TO O
determine P00222827A0000 VB O
mechanisms P00222827A0000 NNS O
of P00222827A0000 IN O
bronchial P00222827A0000 JJ O
hyperreactivity P00222827A0000 NN O
. P00222827A0000 . O
. . O O

To P08101839A0000 TO O
investigate P08101839A0000 VB O
the P08101839A0000 DT O
regulation P08101839A0000 NN O
of P08101839A0000 IN O
expression P08101839A0000 NN O
of P08101839A0000 IN O
the P08101839A0000 DT O
human P08101839A0000 JJ I-UN
mdr1 P08101839A0000 NN I-UN
gene P08101839A0000 NN I-UN
, P08101839A0000 , O
the P08101839A0000 DT O
response P08101839A0000 NN O
of P08101839A0000 IN O
the P08101839A0000 DT O
mdr1 P08101839A0000 NN I-UN
promoter P08101839A0000 NN I-UN
to P08101839A0000 TO O
signals P08101839A0000 NNS O
involved P08101839A0000 VBN O
in P08101839A0000 IN O
cell P08101839A0000 NN O
proliferation P08101839A0000 NN O
was P08101839A0000 VBD O
examined P08101839A0000 VBN O
. P08101839A0000 . O
. . O O

Recognition P09077437T0000 NNP O
mechanisms P09077437T0000 NNS O
of P09077437T0000 IN O
the P09077437T0000 DT O
minus-strand P09077437T0000 JJ O
origin P09077437T0000 NN O
of P09077437T0000 IN O
phage P09077437T0000 NN O
f1 P09077437T0000 NN O
by P09077437T0000 IN O
Escherichia P09077437T0000 NNP I-UN
coli P09077437T0000 NNS I-UN
RNA P09077437T0000 NNP I-UN
polymerase P09077437T0000 NN I-UN
. P09077437T0000 . O
. . O O

Four P08240170A0000 CD O
forms P08240170A0000 NNS O
of P08240170A0000 IN O
salmonellosis P08240170A0000 NN O
were P08240170A0000 VBD O
recognised P08240170A0000 VBN O
in P08240170A0000 IN O
feedlots P08240170A0000 NNS O
and P08240170A0000 CC O
during P08240170A0000 IN O
transport P08240170A0000 NN O
by P08240170A0000 IN O
sea P08240170A0000 NN O
: P08240170A0000 : O
septicaemic P08240170A0000 JJ O
, P08240170A0000 , O
and P08240170A0000 CC O
acute P08240170A0000 NN O
, P08240170A0000 , O
subacute P08240170A0000 NN O
and P08240170A0000 CC O
chronic P08240170A0000 JJ O
enteric P08240170A0000 NN O
. P08240170A0000 . O
. . O O

The P09570952A0000 DT O
complete P09570952A0000 JJ O
exon-intron P09570952A0000 JJ O
organization P09570952A0000 NN O
of P09570952A0000 IN O
the P09570952A0000 DT O
murine P09570952A0000 NN O
gene P09570952A0000 NN O
encoding P09570952A0000 VBG O
M-protein P09570952A0000 NNP I-UN
, P09570952A0000 , O
a P09570952A0000 DT O
structural P09570952A0000 JJ O
protein P09570952A0000 NN O
of P09570952A0000 IN O
sarcomeric P09570952A0000 JJ O
myofibrils P09570952A0000 NNS O
, P09570952A0000 , O
was P09570952A0000 VBD O
determined P09570952A0000 VBN O
. P09570952A0000 . O
. . O O

Partial P09826434T0000 JJ O
characterization P09826434T0000 NN O
of P09826434T0000 IN O
the P09826434T0000 DT O
active P09826434T0000 JJ O
site P09826434T0000 NN O
human P09826434T0000 JJ I-UN
platelet P09826434T0000 NN I-UN
cAMP P09826434T0000 NN I-UN
phosphodiesterase P09826434T0000 NN I-UN
, P09826434T0000 , O
PDE3A P09826434T0000 NNP I-UN
, P09826434T0000 , O
by P09826434T0000 IN O
site-directed P09826434T0000 JJ O
mutagenesis P09826434T0000 NN O
. P09826434T0000 . O
. . O O

BACKGROUND P08994825A0000 NN O
: P08994825A0000 : O
Mitosis P08994825A0000 NN O
is P08994825A0000 VBZ O
regulated P08994825A0000 VBN O
by P08994825A0000 IN O
MPF P08994825A0000 NNP I-UN
( P08994825A0000 ( O
maturation P08994825A0000 NN I-UN
promoting P08994825A0000 VBG I-UN
factor P08994825A0000 NN I-UN
) P08994825A0000 ) O
, P08994825A0000 , O
the P08994825A0000 DT O
active P08994825A0000 JJ O
form P08994825A0000 NN O
of P08994825A0000 IN O
Cdc2 P08994825A0000 NNP I-UN
/ P08994825A0000 NNP I-UN
28-cyclin P08994825A0000 JJ O
B P08994825A0000 NNP I-UN
complexes P08994825A0000 NN O
. P08994825A0000 . O
. . O O

Biometric P00701144T0000 JJ O
analysis P00701144T0000 NN O
of P00701144T0000 IN O
intraocular P00701144T0000 JJ O
lens P00701144T0000 NNS O
power P00701144T0000 NN O
required P00701144T0000 VBN O
to P00701144T0000 TO O
produce P00701144T0000 VB O
emmetropia P00701144T0000 NNS O
: P00701144T0000 : O
results P00701144T0000 NNS O
of P00701144T0000 IN O
450 P00701144T0000 CD O
implants P00701144T0000 NNS O
. P00701144T0000 . O
. . O O

A P06835516A0000 DT O
case P06835516A0000 NN O
of P06835516A0000 IN O
a P06835516A0000 DT O
dense P06835516A0000 NN O
epidermoid P06835516A0000 JJ O
cyst P06835516A0000 NN O
of P06835516A0000 IN O
the P06835516A0000 DT O
suprasellar P06835516A0000 JJ O
cistern P06835516A0000 NN O
is P06835516A0000 VBZ O
presented P06835516A0000 VBN O
. P06835516A0000 . O
. . O O

We P10319955A0941 PRP O
calculated P10319955A0941 VBD O
differences P10319955A0941 NNS O
in P10319955A0941 IN O
late P10319955A0941 JJ O
occlusion P10319955A0941 NN O
rates P10319955A0941 NNS O
by P10319955A0941 IN O
the P10319955A0941 DT O
chi2 P10319955A0941 NN O
( P10319955A0941 ( O
chi-square P10319955A0941 NN O
) P10319955A0941 ) O
test P10319955A0941 NN O
, P10319955A0941 , O
and P10319955A0941 CC O
found P10319955A0941 VBD O
these P10319955A0941 DT O
differences P10319955A0941 NNS O
were P10319955A0941 VBD O
significant P10319955A0941 JJ O
( P10319955A0941 ( O
P=.04 P10319955A0941 NNP O
) P10319955A0941 ) O
. P10319955A0941 . O
. . O O

Functional P07749461A1022 JJ O
analysis P07749461A1022 NN O
of P07749461A1022 IN O
the P07749461A1022 DT O
sGTH P07749461A1022 NN I-UN
alpha P07749461A1022 NN I-UN
subunit P07749461A1022 NN I-UN
promoter P07749461A1022 NN I-UN
by P07749461A1022 IN O
the P07749461A1022 DT O
transient P07749461A1022 JJ O
transfection P07749461A1022 NN O
of P07749461A1022 IN O
several P07749461A1022 JJ O
sGTH P07749461A1022 NNS I-UN
alpha P07749461A1022 VBP I-UN
/ P07749461A1022 JJ O
CAT P07749461A1022 NNP I-UN
chimeric P07749461A1022 NN O
plasmids P07749461A1022 NNS O
into P07749461A1022 IN O
rainbow P07749461A1022 NN O
trout P07749461A1022 IN O
pituitary P07749461A1022 JJ O
cells P07749461A1022 NNS O
suggests P07749461A1022 VBZ O
that P07749461A1022 IN O
its P07749461A1022 PRP$ O
pituitary-specific P07749461A1022 JJ O
expression P07749461A1022 NN O
is P07749461A1022 VBZ O
GSE-dependent P07749461A1022 NNP O
. P07749461A1022 . O
. . O O

NGF P11150315A0844 NNP I-UN
elicits P11150315A0844 VBZ O
a P11150315A0844 DT O
more P11150315A0844 RBR O
delayed P11150315A0844 JJ O
and P11150315A0844 CC O
sustained P11150315A0844 JJ O
ERK P11150315A0844 NNP I-UN
phosphorylation P11150315A0844 NN O
than P11150315A0844 IN O
EGF P11150315A0844 NNP I-UN
, P11150315A0844 , O
consistent P11150315A0844 NN O
with P11150315A0844 IN O
previous P11150315A0844 JJ O
reports P11150315A0844 NNS O
. P11150315A0844 . O
. . O O

These P07592337A0891 DT O
results P07592337A0891 NNS O
suggested P07592337A0891 VBD O
that P07592337A0891 IN O
NfxB P07592337A0891 NNP I-UN
negatively P07592337A0891 RB O
autoregulates P07592337A0891 VBZ O
the P07592337A0891 DT O
expression P07592337A0891 NN O
of P07592337A0891 IN O
nfxB P07592337A0891 JJ I-UN
itself P07592337A0891 PRP O
. P07592337A0891 . O
. . O O

Another P10656802A1724 DT O
long P10656802A1724 JJ O
insertion P10656802A1724 NN O
in P10656802A1724 IN O
the P10656802A1724 DT O
cathepsin P10656802A1724 NN I-UN
X P10656802A1724 NNP I-UN
amino P10656802A1724 NN I-UN
acid P10656802A1724 JJ I-UN
sequence P10656802A1724 NN I-UN
forms P10656802A1724 NNS O
a P10656802A1724 DT O
beta-hairpin P10656802A1724 JJ O
pointing P10656802A1724 VBG O
away P10656802A1724 RB O
from P10656802A1724 IN O
the P10656802A1724 DT O
active P10656802A1724 JJ O
site P10656802A1724 NN O
. P10656802A1724 . O
. . O O

The P09426239A0386 DT O
cglIM P09426239A0386 NN I-UN
gene P09426239A0386 NN I-UN
is P09426239A0386 VBZ O
organized P09426239A0386 VBN O
in P09426239A0386 IN O
an P09426239A0386 DT O
unusual P09426239A0386 JJ O
operon P09426239A0386 NN O
which P09426239A0386 WDT O
contains P09426239A0386 VBZ O
, P09426239A0386 , O
in P09426239A0386 IN O
addition P09426239A0386 NN O
, P09426239A0386 , O
two P09426239A0386 CD O
genes P09426239A0386 NNS O
encoding P09426239A0386 VBG O
stress-sensitive P09426239A0386 JJ O
restriction P09426239A0386 NN O
enzymes P09426239A0386 NNS O
. P09426239A0386 . O
. . O O

The P07775428A0172 DT O
other P07775428A0172 JJ O
two P07775428A0172 CD O
clones P07775428A0172 NNS O
, P07775428A0172 , O
Ash-m P07775428A0172 NNP I-UN
and P07775428A0172 CC I-UN
-s P07775428A0172 NNP I-UN
, P07775428A0172 , O
had P07775428A0172 VBD O
nucleotide P07775428A0172 JJ O
sequences P07775428A0172 NNS O
identical P07775428A0172 JJ O
with P07775428A0172 IN O
Ash-l P07775428A0172 NNP I-UN
cDNA P07775428A0172 NN O
in P07775428A0172 IN O
the P07775428A0172 DT O
amino-terminal P07775428A0172 JJ O
region P07775428A0172 NN O
. P07775428A0172 . O
. . O O

Envelope-function P09945838T0000 NN O
matching P09945838T0000 JJ O
conditions P09945838T0000 NNS O
for P09945838T0000 IN O
GaAs P09945838T0000 NNP O
/ P09945838T0000 NNP O
( P09945838T0000 ( O
Al P09945838T0000 NNP O
, P09945838T0000 , O
Ga P09945838T0000 NNP O
) P09945838T0000 ) O
As P09945838T0000 IN O
heterojunctions P09945838T0000 NNS O
. P09945838T0000 . O
. . O O

Treatment P08621384A0935 NN O
of P08621384A0935 IN O
keratinocytes P08621384A0935 NNS O
expressing P08621384A0935 VBG O
a P08621384A0935 DT O
normal P08621384A0935 JJ O
epidermal P08621384A0935 JJ I-UN
growth P08621384A0935 NN I-UN
factor P08621384A0935 NN I-UN
receptor P08621384A0935 NN I-UN
( P08621384A0935 ( O
EGFR P08621384A0935 NNP I-UN
) P08621384A0935 ) O
with P08621384A0935 IN O
TGFalpha P08621384A0935 NNP I-UN
or P08621384A0935 CC O
epidermal P08621384A0935 JJ I-UN
growth P08621384A0935 NN I-UN
factor P08621384A0935 NN I-UN
for P08621384A0935 IN O
5 P08621384A0935 CD O
min P08621384A0935 NN O
induced P08621384A0935 VBD O
PKCdelta P08621384A0935 NNP I-UN
tyrosine P08621384A0935 JJ O
phosphorylation P08621384A0935 NN O
. P08621384A0935 . O
. . O O

By P07693975A1418 IN O
contrast P07693975A1418 NN O
, P07693975A1418 , O
all P07693975A1418 DT O
proteins P07693975A1418 NNS O
initiated P07693975A1418 VBN O
with P07693975A1418 IN O
a P07693975A1418 DT O
methionine P07693975A1418 NN O
placed P07693975A1418 VBD O
one P07693975A1418 CD O
residue P07693975A1418 JJ O
upstream P07693975A1418 NN O
of P07693975A1418 IN O
the P07693975A1418 DT O
natural P07693975A1418 JJ O
N P07693975A1418 NNP O
terminus P07693975A1418 NN O
of P07693975A1418 IN O
PR P07693975A1418 NNP I-UN
failed P07693975A1418 VBD O
to P07693975A1418 TO O
show P07693975A1418 VB O
specific P07693975A1418 JJ O
proteolysis P07693975A1418 NN O
. P07693975A1418 . O
. . O O

Efficacy P00478714T0000 NN O
of P00478714T0000 IN O
a P00478714T0000 DT O
three- P00478714T0000 JJ O
versus P00478714T0000 NN O
a P00478714T0000 DT O
five-week P00478714T0000 JJ O
alcohol P00478714T0000 NN O
treatment P00478714T0000 NN O
program P00478714T0000 NN O
. P00478714T0000 . O
. . O O

Acquired P11167778T0000 NNP O
antithrombin P11167778T0000 JJ I-UN
deficiency P11167778T0000 NN O
in P11167778T0000 IN O
sepsis P11167778T0000 NN O
. P11167778T0000 . O
. . O O

Accumulated P09382924A0131 VBN O
evidence P09382924A0131 NN O
indicates P09382924A0131 VBZ O
that P09382924A0131 IN O
, P09382924A0131 , O
upon P09382924A0131 IN O
stimulation P09382924A0131 NN O
with P09382924A0131 IN O
interferon-gamma P09382924A0131 JJ I-UN
( P09382924A0131 ( O
IFN-gamma P09382924A0131 NNP I-UN
) P09382924A0131 ) O
, P09382924A0131 , O
three P09382924A0131 CD O
beta-type P09382924A0131 JJ O
subunits P09382924A0131 NNS O
, P09382924A0131 , O
designated P09382924A0131 VBN O
LMP2 P09382924A0131 NNP I-UN
, P09382924A0131 , O
LMP7 P09382924A0131 NNP I-UN
, P09382924A0131 , O
and P09382924A0131 CC O
PSMB10 P09382924A0131 NNP I-UN
, P09382924A0131 , O
are P09382924A0131 VBP O
incorporated P09382924A0131 VBN O
into P09382924A0131 IN O
the P09382924A0131 DT O
20S P09382924A0131 CD I-UN
proteasome P09382924A0131 NN I-UN
by P09382924A0131 IN O
displacing P09382924A0131 VBG O
the P09382924A0131 DT O
housekeeping P09382924A0131 VBG O
beta-type P09382924A0131 JJ O
subunits P09382924A0131 NNS O
designated P09382924A0131 VBN O
PSMB6 P09382924A0131 NNP I-UN
, P09382924A0131 , O
PSMB5 P09382924A0131 NNP I-UN
, P09382924A0131 , O
and P09382924A0131 CC O
PSMB7 P09382924A0131 NNP I-UN
, P09382924A0131 , O
respectively P09382924A0131 RB O
. P09382924A0131 . O
. . O O

The P10467004A0683 DT O
intron P10467004A0683 NN O
is P10467004A0683 VBZ O
capable P10467004A0683 JJ O
of P10467004A0683 IN O
splicing P10467004A0683 VBG O
despite P10467004A0683 IN O
the P10467004A0683 DT O
fact P10467004A0683 NN O
that P10467004A0683 IN O
both P10467004A0683 DT O
the P10467004A0683 DT O
EBS1 P10467004A0683 NNP I-UN
/ P10467004A0683 NNP O
IBS1 P10467004A0683 NNP I-UN
and P10467004A0683 CC O
the P10467004A0683 DT O
EBS2 P10467004A0683 NNP I-UN
/ P10467004A0683 NNP O
IBS2 P10467004A0683 NNP I-UN
sequence P10467004A0683 NN O
motifs P10467004A0683 NNS O
, P10467004A0683 , O
thought P10467004A0683 VBN O
to P10467004A0683 TO O
be P10467004A0683 VB O
necessary P10467004A0683 JJ O
for P10467004A0683 IN O
correct P10467004A0683 JJ O
splicing P10467004A0683 NN O
, P10467004A0683 , O
extend P10467004A0683 VBP O
over P10467004A0683 IN O
5 P10467004A0683 CD O
instead P10467004A0683 RB O
of P10467004A0683 IN O
6 P10467004A0683 CD O
bp P10467004A0683 NN O
. P10467004A0683 . O
. . O O

Nucleotide P11125151T0000 NNP O
sequence P11125151T0000 NN O
, P11125151T0000 , O
genome P11125151T0000 JJ O
organization P11125151T0000 NN O
and P11125151T0000 CC O
phylogenetic P11125151T0000 JJ O
analysis P11125151T0000 NN O
of P11125151T0000 IN O
pineapple P11125151T0000 JJ O
mealybug P11125151T0000 JJ O
wilt-associated P11125151T0000 JJ O
virus-2 P11125151T0000 NN O
. P11125151T0000 . O
. . O O

The P02179052A1044 DT O
characterized P02179052A1044 JJ O
Y P02179052A1044 NNP I-UN
' P02179052A1044 POS I-UN
repeated P02179052A1044 VBD I-UN
sequence P02179052A1044 NN I-UN
families P02179052A1044 NNS I-UN
provide P02179052A1044 VBP O
an P02179052A1044 DT O
experimental P02179052A1044 JJ O
system P02179052A1044 NN O
in P02179052A1044 IN O
which P02179052A1044 WDT O
repeated P02179052A1044 VBD O
sequence P02179052A1044 NN O
interactions P02179052A1044 NNS O
and P02179052A1044 CC O
subsequent P02179052A1044 JJ O
evolution P02179052A1044 NN O
can P02179052A1044 MD O
be P02179052A1044 VB O
studied P02179052A1044 VBN O
. P02179052A1044 . O
. . O O

From P02711167A0818 IN O
day P02711167A0818 NN O
30 P02711167A0818 CD O
after P02711167A0818 IN O
turnout P02711167A0818 NN O
, P02711167A0818 , O
the P02711167A0818 DT O
PFB-group P02711167A0818 NNP O
had P02711167A0818 VBD O
significantly P02711167A0818 RB O
lower P02711167A0818 JJR O
serum P02711167A0818 NN I-UN
pepsinogen P02711167A0818 NN I-UN
levels P02711167A0818 NNS O
, P02711167A0818 , O
which P02711167A0818 WDT O
reflects P02711167A0818 VBZ O
the P02711167A0818 DT O
low P02711167A0818 JJ O
degree P02711167A0818 NN O
of P02711167A0818 IN O
abomasal P02711167A0818 JJ O
damage P02711167A0818 NN O
in P02711167A0818 IN O
these P02711167A0818 DT O
animals P02711167A0818 NNS O
. P02711167A0818 . O
. . O O

We P03553149A0299 PRP O
used P03553149A0299 VBD O
oligonucleotide-directed P03553149A0299 JJ O
mutagenesis P03553149A0299 NN O
to P03553149A0299 TO O
alter P03553149A0299 VB O
a P03553149A0299 DT O
site P03553149A0299 NN O
in P03553149A0299 IN O
MucA P03553149A0299 NNP I-UN
homologous P03553149A0299 JJ O
to P03553149A0299 TO O
the P03553149A0299 DT O
Ala-Gly P03553149A0299 NNP O
cleavage P03553149A0299 NN O
site P03553149A0299 NN O
of P03553149A0299 IN O
LexA P03553149A0299 NNP I-UN
. P03553149A0299 . O
. . O O

High P07511496A1511 JJ O
plasma P07511496A1511 NN O
concentrations P07511496A1511 NNS O
of P07511496A1511 IN O
soluble P07511496A1511 JJ O
E-selectin P07511496A1511 NNP I-UN
were P07511496A1511 VBD O
closely P07511496A1511 RB O
associated P07511496A1511 VBN O
with P07511496A1511 IN O
multiple-organ P07511496A1511 JJ O
dysfunction P07511496A1511 NN O
and P07511496A1511 CC O
death P07511496A1511 NN O
. P07511496A1511 . O
. . O O

It P00599601A0260 PRP O
was P00599601A0260 VBD O
concluded P00599601A0260 VBN O
that P00599601A0260 IN O
both P00599601A0260 DT O
of P00599601A0260 IN O
these P00599601A0260 DT O
surgical P00599601A0260 JJ O
procedures P00599601A0260 NNS O
were P00599601A0260 VBD O
as P00599601A0260 RB O
effective P00599601A0260 JJ O
as P00599601A0260 IN O
pinealectomy P00599601A0260 NN O
in P00599601A0260 IN O
reversing P00599601A0260 VBG O
the P00599601A0260 DT O
pineal-induced P00599601A0260 JJ O
alterations P00599601A0260 NNS O
in P00599601A0260 IN O
the P00599601A0260 DT O
reproductive P00599601A0260 JJ O
physiology P00599601A0260 NN O
of P00599601A0260 IN O
the P00599601A0260 DT O
blind-anosmic P00599601A0260 JJ O
female P00599601A0260 JJ O
rat P00599601A0260 NN O
. P00599601A0260 . O
. . O O

The P10330134A0765 DT O
mRNA P10330134A0765 JJ O
expression P10330134A0765 NN O
of P10330134A0765 IN O
RFX1 P10330134A0765 NNP I-UN
, P10330134A0765 , O
RFX2 P10330134A0765 NNP I-UN
, P10330134A0765 , O
and P10330134A0765 CC O
RFX3 P10330134A0765 NNP I-UN
was P10330134A0765 VBD O
detected P10330134A0765 VBN O
ubiquitously P10330134A0765 RB O
, P10330134A0765 , O
but P10330134A0765 CC O
in P10330134A0765 IN O
transient-transfection P10330134A0765 NN O
assays P10330134A0765 NNS O
, P10330134A0765 , O
multimerized P10330134A0765 VBN I-UN
RFX P10330134A0765 NNP I-UN
binding P10330134A0765 VBG I-UN
sites P10330134A0765 NNS I-UN
in P10330134A0765 IN O
front P10330134A0765 NN O
of P10330134A0765 IN O
a P10330134A0765 DT O
basal P10330134A0765 NN O
promoter P10330134A0765 NN O
efficiently P10330134A0765 RB O
functioned P10330134A0765 VBN O
in P10330134A0765 IN O
a P10330134A0765 DT O
tissue- P10330134A0765 JJ O
and P10330134A0765 CC O
lineage-specific P10330134A0765 JJ O
manner P10330134A0765 NN O
. P10330134A0765 . O
. . O O

Dimerization P01582413A0759 NN O
of P01582413A0759 IN O
Myf-5 P01582413A0759 NNP I-UN
with P01582413A0759 IN O
the P01582413A0759 DT O
ubiquitously P01582413A0759 RB O
expressed P01582413A0759 VBN O
bHLH P01582413A0759 NN O
protein P01582413A0759 NN O
E12 P01582413A0759 NNP I-UN
not P01582413A0759 RB O
only P01582413A0759 RB O
increases P01582413A0759 VBZ O
the P01582413A0759 DT O
affinity P01582413A0759 NN O
for P01582413A0759 IN O
DNA P01582413A0759 NN O
but P01582413A0759 CC O
also P01582413A0759 RB O
stimulates P01582413A0759 VBZ O
transactivation P01582413A0759 NN O
independently P01582413A0759 RB O
of P01582413A0759 IN O
DNA P01582413A0759 NNP O
binding P01582413A0759 NN O
. P01582413A0759 . O
. . O O

Cyclins P11314046A0000 NNS I-UN
are P11314046A0000 VBP O
one P11314046A0000 CD O
of P11314046A0000 IN O
the P11314046A0000 DT O
pivotal P11314046A0000 JJ O
determinants P11314046A0000 NNS O
regulating P11314046A0000 VBG O
cell P11314046A0000 NN O
cycle P11314046A0000 NN O
progression P11314046A0000 NN O
. P11314046A0000 . O
. . O O

Abbreviations P11069756A2618 NNS O
: P11069756A2618 : O
CAS P11069756A2618 NNP I-UN
, P11069756A2618 , O
CRK-associated P11069756A2618 NNP I-UN
substrate P11069756A2618 NN I-UN
; P11069756A2618 : O
CH P11069756A2618 NNP I-UN
, P11069756A2618 , O
calponin-homology P11069756A2618 NN I-UN
domain P11069756A2618 NN I-UN
; P11069756A2618 : O
CSK P11069756A2618 NNP I-UN
, P11069756A2618 , O
C-terminal P11069756A2618 NNP I-UN
SRC P11069756A2618 NNP I-UN
kinase P11069756A2618 NN I-UN
; P11069756A2618 : O
E6 P11069756A2618 NNP I-UN
, P11069756A2618 , O
Papillomavirus P11069756A2618 NNP I-UN
E6 P11069756A2618 NNP I-UN
protein P11069756A2618 NN I-UN
; P11069756A2618 : O
FAK P11069756A2618 NNP I-UN
, P11069756A2618 , O
focal P11069756A2618 JJ I-UN
adhesion P11069756A2618 NN I-UN
kinase P11069756A2618 NN I-UN
; P11069756A2618 : O
GIT P11069756A2618 NNP I-UN
, P11069756A2618 , O
GRK P11069756A2618 NNP I-UN
interacter P11069756A2618 NN I-UN
; P11069756A2618 : O
GPCR P11069756A2618 NNP I-UN
, P11069756A2618 , O
heterotrimeric-G-protein-coupled P11069756A2618 JJ I-UN
receptor P11069756A2618 NN I-UN
; P11069756A2618 : O
GRK P11069756A2618 NNP I-UN
, P11069756A2618 , O
G-protein-coupled-receptor P11069756A2618 NNP I-UN
kinase P11069756A2618 NN I-UN
; P11069756A2618 : O
MAPK P11069756A2618 NNP I-UN
, P11069756A2618 , O
mitogen-activated P11069756A2618 JJ I-UN
protein P11069756A2618 NN I-UN
kinase P11069756A2618 NN I-UN
( P11069756A2618 ( O
ERK P11069756A2618 NNP I-UN
, P11069756A2618 , O
p38 P11069756A2618 NN I-UN
, P11069756A2618 , O
JNK P11069756A2618 NNP I-UN
) P11069756A2618 ) O
; P11069756A2618 : O
PAK P11069756A2618 NNP I-UN
, P11069756A2618 , O
p21-activated P11069756A2618 JJ I-UN
kinase P11069756A2618 NN I-UN
; P11069756A2618 : O
PBS P11069756A2618 NNP I-UN
, P11069756A2618 , O
paxillin-binding P11069756A2618 JJ I-UN
subdomain P11069756A2618 NN I-UN
; P11069756A2618 : O
PIX P11069756A2618 NNP I-UN
, P11069756A2618 , O
PAK-interacting P11069756A2618 NNP I-UN
exchange P11069756A2618 NN I-UN
factor P11069756A2618 NN I-UN
; P11069756A2618 : O
PKL P11069756A2618 NNP I-UN
, P11069756A2618 , O
paxillin P11069756A2618 NN I-UN
kinase P11069756A2618 NN I-UN
linker P11069756A2618 NN I-UN
; P11069756A2618 : O
POR1 P11069756A2618 NNP I-UN
, P11069756A2618 , O
partner P11069756A2618 NN I-UN
of P11069756A2618 IN I-UN
Rac P11069756A2618 NNP I-UN
; P11069756A2618 : O
PS P11069756A2618 NNP O
, P11069756A2618 , O
phosphoserine P11069756A2618 NN O
; P11069756A2618 : O
PT P11069756A2618 NNP O
, P11069756A2618 , O
phosphothreonine P11069756A2618 NN O
; P11069756A2618 : O
PY P11069756A2618 NNP O
, P11069756A2618 , O
phosphotyrosine P11069756A2618 NN O
; P11069756A2618 : O
RTK P11069756A2618 NNP I-UN
, P11069756A2618 , O
growth P11069756A2618 NN I-UN
factor P11069756A2618 NN I-UN
receptor P11069756A2618 NN I-UN
tyrosine P11069756A2618 JJ I-UN
kinase P11069756A2618 NN I-UN
; P11069756A2618 : O
SH P11069756A2618 NNP I-UN
, P11069756A2618 , O
SRC-homology P11069756A2618 NNP I-UN
domain P11069756A2618 NN I-UN
. P11069756A2618 . O
. . O O

Electromobility P09369482A0690 NNP O
shift P09369482A0690 NN O
and P09369482A0690 CC O
cotransfection P09369482A0690 NN O
assays P09369482A0690 NNS O
demonstrated P09369482A0690 VBD O
that P09369482A0690 IN O
HNF1alpha P09369482A0690 NNP I-UN
, P09369482A0690 , O
but P09369482A0690 CC O
not P09369482A0690 RB O
HNF4 P09369482A0690 NNP I-UN
, P09369482A0690 , O
bound P09369482A0690 NN O
to P09369482A0690 TO O
its P09369482A0690 PRP$ O
cognate P09369482A0690 NN O
site P09369482A0690 NN O
and P09369482A0690 CC O
transactivated P09369482A0690 JJ O
G6Pase P09369482A0690 NNP I-UN
gene P09369482A0690 NN I-UN
expression P09369482A0690 NN O
. P09369482A0690 . O
. . O O

The P00842406A0771 DT O
psychological P00842406A0771 JJ O
tests P00842406A0771 NNS O
consisted P00842406A0771 VBD O
of P00842406A0771 IN O
a P00842406A0771 DT O
free-recall P00842406A0771 JJ O
task P00842406A0771 NN O
, P00842406A0771 , O
a P00842406A0771 DT O
test P00842406A0771 NN O
for P00842406A0771 IN O
visuomotor P00842406A0771 NN O
coordination P00842406A0771 NN O
and P00842406A0771 CC O
a P00842406A0771 DT O
recognition P00842406A0771 NN O
task P00842406A0771 NN O
. P00842406A0771 . O
. . O O

Since P02196565A0606 IN O
general P02196565A0606 JJ I-UN
regulatory P02196565A0606 JJ I-UN
factor P02196565A0606 NN I-UN
I P02196565A0606 PRP I-UN
( P02196565A0606 ( O
GRFI P02196565A0606 NNP I-UN
) P02196565A0606 ) O
/ P02196565A0606 NN O
repressor P02196565A0606 NN I-UN
/ P02196565A0606 NNP I-UN
activator P02196565A0606 NN I-UN
site P02196565A0606 NN I-UN
binding P02196565A0606 VBG I-UN
protein P02196565A0606 JJ I-UN
1 P02196565A0606 CD I-UN
( P02196565A0606 ( O
RAP1 P02196565A0606 NNP I-UN
) P02196565A0606 ) O
/ P02196565A0606 VBZ O
translation P02196565A0606 NN I-UN
upstream P02196565A0606 JJ I-UN
factor P02196565A0606 NN I-UN
( P02196565A0606 ( O
TUF P02196565A0606 NNP I-UN
) P02196565A0606 ) O
is P02196565A0606 VBZ O
believed P02196565A0606 VBN O
to P02196565A0606 TO O
be P02196565A0606 VB O
an P02196565A0606 DT O
activator P02196565A0606 NN O
of P02196565A0606 IN O
MAT P02196565A0606 NNP I-UN
alpha P02196565A0606 JJ I-UN
expression P02196565A0606 NN O
, P02196565A0606 , O
we P02196565A0606 PRP O
examined P02196565A0606 VBD O
whether P02196565A0606 IN O
PYK1 P02196565A0606 NNP I-UN
, P02196565A0606 , O
which P02196565A0606 WDT O
is P02196565A0606 VBZ O
known P02196565A0606 VBN O
to P02196565A0606 TO O
be P02196565A0606 VB O
regulated P02196565A0606 VBN O
by P02196565A0606 IN O
GRFI P02196565A0606 NNP I-UN
/ P02196565A0606 NNP O
RAP1 P02196565A0606 NNP I-UN
/ P02196565A0606 NNP O
TUF P02196565A0606 NNP I-UN
, P02196565A0606 , O
is P02196565A0606 VBZ O
also P02196565A0606 RB O
affected P02196565A0606 VBN O
by P02196565A0606 IN O
the P02196565A0606 DT O
gal11 P02196565A0606 JJ I-UN
mutation P02196565A0606 NN I-UN
. P02196565A0606 . O
. . O O

Structural P00516545T0001 JJ O
characteristics P00516545T0001 NNS O
of P00516545T0001 IN O
the P00516545T0001 DT O
erythrocyte P00516545T0001 NN O
membrane P00516545T0001 NN O
, P00516545T0001 , O
peroxidation P00516545T0001 NN O
processes P00516545T0001 NNS O
and P00516545T0001 CC O
antioxidant P00516545T0001 JJ O
function P00516545T0001 NN O
in P00516545T0001 IN O
children P00516545T0001 NNS O
with P00516545T0001 IN O
diffuse P00516545T0001 NN O
glomerulonephritis P00516545T0001 NN O
. P00516545T0001 . O
. . O O

To P06582285A0222 TO O
evaluate P06582285A0222 VB O
the P06582285A0222 DT O
comparative P06582285A0222 JJ O
safety P06582285A0222 NN O
of P06582285A0222 IN O
U-P P06582285A0222 NNP O
and P06582285A0222 CC O
D P06582285A0222 NNP O
& P06582285A0222 CC O
E P06582285A0222 NNP O
, P06582285A0222 , O
we P06582285A0222 PRP O
analyzed P06582285A0222 VBD O
2,805 P06582285A0222 CD O
U-P P06582285A0222 JJ O
and P06582285A0222 CC O
9,572 P06582285A0222 CD O
D P06582285A0222 NNP O
& P06582285A0222 CC O
E P06582285A0222 NNP O
abortions P06582285A0222 NNS O
at P06582285A0222 IN O
13 P06582285A0222 CD O
to P06582285A0222 TO O
24 P06582285A0222 CD O
menstrual P06582285A0222 JJ O
weeks P06582285A0222 NNS O
' P06582285A0222 POS O
gestation P06582285A0222 NN O
. P06582285A0222 . O
. . O O

Thus P11564893A1068 RB O
, P11564893A1068 , O
through P11564893A1068 IN O
a P11564893A1068 DT O
change P11564893A1068 NN O
in P11564893A1068 IN O
conformation P11564893A1068 NN O
upon P11564893A1068 IN O
repair P11564893A1068 NN O
of P11564893A1068 IN O
the P11564893A1068 DT O
6RG P11564893A1068 CD O
lesion P11564893A1068 NN O
, P11564893A1068 , O
MGMT P11564893A1068 NNP I-UN
switches P11564893A1068 VBZ O
from P11564893A1068 IN O
a P11564893A1068 DT O
DNA P11564893A1068 NNP O
repair P11564893A1068 NN O
factor P11564893A1068 NN O
to P11564893A1068 TO O
a P11564893A1068 DT O
transcription P11564893A1068 NN O
regulator P11564893A1068 NN O
( P11564893A1068 ( O
R-MGMT P11564893A1068 NNP I-UN
) P11564893A1068 ) O
, P11564893A1068 , O
enabling P11564893A1068 VBG O
the P11564893A1068 DT O
cell P11564893A1068 NN O
to P11564893A1068 TO O
sense P11564893A1068 NN O
as P11564893A1068 RB O
well P11564893A1068 RB O
as P11564893A1068 IN O
respond P11564893A1068 NN O
to P11564893A1068 TO O
mutagens P11564893A1068 NNS O
. P11564893A1068 . O
. . O O

Potentiation P03146150T0000 NN O
of P03146150T0000 IN O
the P03146150T0000 DT O
thrombolytic P03146150T0000 JJ O
efficacy P03146150T0000 NN O
of P03146150T0000 IN O
single-chain P03146150T0000 JJ I-UN
urokinase P03146150T0000 NN I-UN
( P03146150T0000 ( O
Pro-urokinase P03146150T0000 NNP I-UN
) P03146150T0000 ) O
by P03146150T0000 IN O
heparin P03146150T0000 NN O
. P03146150T0000 . O
. . O O

CONCLUSIONS P11832019A0668 NN O
: P11832019A0668 : O
AMVT P11832019A0668 NNP O
is P11832019A0668 VBZ O
rare P11832019A0668 JJ O
but P11832019A0668 CC O
a P11832019A0668 DT O
potentially P11832019A0668 RB O
lethal P11832019A0668 JJ O
emergency P11832019A0668 NN O
disease P11832019A0668 NN O
. P11832019A0668 . O
. . O O

BACKGROUND P10645921A0000 NN O
: P10645921A0000 : O
Left P10645921A0000 NNP O
ventricular P10645921A0000 JJ O
hypertrophy P10645921A0000 NN O
is P10645921A0000 VBZ O
a P10645921A0000 DT O
heterogeneous P10645921A0000 JJ O
disorder P10645921A0000 NN O
with P10645921A0000 IN O
distinct P10645921A0000 JJ O
morphologies P10645921A0000 NNS O
. P10645921A0000 . O
. . O O

Cloning P09171081T0000 VBG O
and P09171081T0000 CC O
characterization P09171081T0000 NN O
of P09171081T0000 IN O
a P09171081T0000 DT O
cDNA P09171081T0000 NN O
encoding P09171081T0000 VBG O
a P09171081T0000 DT O
bacteriophage-type P09171081T0000 JJ I-UN
RNA P09171081T0000 NNP I-UN
polymerase P09171081T0000 NN I-UN
from P09171081T0000 IN O
the P09171081T0000 DT O
higher P09171081T0000 JJR O
plant P09171081T0000 NN O
Chenopodium P09171081T0000 NNP O
album P09171081T0000 NN O
. P09171081T0000 . O
. . O O

As P07455042A0457 IN O
high-speed P07455042A0457 NN O
, P07455042A0457 , O
volumetric P07455042A0457 JJ O
imaging P07455042A0457 NN O
, P07455042A0457 , O
computed P07455042A0457 VBD O
tomographic P07455042A0457 JJ O
scan P07455042A0457 JJ O
machines P07455042A0457 NNS O
such P07455042A0457 JJ O
as P07455042A0457 IN O
the P07455042A0457 DT O
Dynamic P07455042A0457 NNP O
Spatial P07455042A0457 NNP O
Reconstructor P07455042A0457 NNP O
become P07455042A0457 VBD O
available P07455042A0457 JJ O
with P07455042A0457 IN O
higher P07455042A0457 JJR O
density P07455042A0457 NN O
resolution P07455042A0457 NN O
, P07455042A0457 , O
perhaps P07455042A0457 RB O
a P07455042A0457 DT O
single P07455042A0457 JJ O
injection P07455042A0457 NN O
of P07455042A0457 IN O
contrast P07455042A0457 NN O
agent P07455042A0457 NN O
into P07455042A0457 IN O
the P07455042A0457 DT O
right P07455042A0457 JJ O
atrium P07455042A0457 NN O
or P07455042A0457 CC O
even P07455042A0457 RB O
a P07455042A0457 DT O
peripheral P07455042A0457 JJ O
vein P07455042A0457 NN O
may P07455042A0457 MD O
be P07455042A0457 VB O
adequate P07455042A0457 JJ O
to P07455042A0457 TO O
obtain P07455042A0457 VB O
all P07455042A0457 PDT O
these P07455042A0457 DT O
measurements P07455042A0457 NNS O
. P07455042A0457 . O
. . O O

Assays P09309457A0680 NNS O
of P09309457A0680 IN O
total P09309457A0680 JJ O
cholesterol P09309457A0680 NN O
as P09309457A0680 RB O
well P09309457A0680 RB O
as P09309457A0680 IN O
the P09309457A0680 DT O
HDL P09309457A0680 NNP I-UN
, P09309457A0680 , O
HDL2 P09309457A0680 NNP I-UN
, P09309457A0680 , O
LDL P09309457A0680 NNP I-UN
, P09309457A0680 , O
triglycerides P09309457A0680 NNS O
, P09309457A0680 , O
endothelin-1 P09309457A0680 JJ I-UN
, P09309457A0680 , O
lipoprotein P09309457A0680 FW I-UN
( P09309457A0680 ( I-UN
a P09309457A0680 DT I-UN
) P09309457A0680 ) I-UN
, P09309457A0680 , O
estradiol P09309457A0680 FW O
and P09309457A0680 CC O
FSH P09309457A0680 NNP I-UN
were P09309457A0680 VBD O
also P09309457A0680 RB O
obtained P09309457A0680 VBN O
at P09309457A0680 IN O
baseline P09309457A0680 NN O
before P09309457A0680 IN O
receiving P09309457A0680 VBG O
ERT P09309457A0680 NNP O
and P09309457A0680 CC O
after P09309457A0680 IN O
3 P09309457A0680 CD O
months P09309457A0680 NNS O
of P09309457A0680 IN O
ERT P09309457A0680 NNP O
. P09309457A0680 . O
. . O O

A P01247475A0000 DT O
late P01247475A0000 JJ O
diagnosis P01247475A0000 NN O
of P01247475A0000 IN O
retinoblastoma P01247475A0000 NN O
is P01247475A0000 VBZ O
an P01247475A0000 DT O
unquestionable P01247475A0000 JJ O
fact P01247475A0000 NN O
that P01247475A0000 WDT O
allows P01247475A0000 VBZ O
its P01247475A0000 PRP$ O
growth P01247475A0000 NN O
and P01247475A0000 CC O
leads P01247475A0000 VBZ O
to P01247475A0000 TO O
a P01247475A0000 DT O
deterioration P01247475A0000 NN O
in P01247475A0000 IN O
the P01247475A0000 DT O
outlook P01247475A0000 NN O
. P01247475A0000 . O
. . O O

Purified P07616563A0532 NNP O
CarP P07616563A0532 NNP I-UN
binds P07616563A0532 VBZ O
in P07616563A0532 IN O
vitro P07616563A0532 NN O
to P07616563A0532 TO O
the P07616563A0532 DT O
carAB P07616563A0532 NN I-UN
control P07616563A0532 NN I-UN
region P07616563A0532 NN I-UN
and P07616563A0532 CC O
protects P07616563A0532 NNS O
against P07616563A0532 IN O
DNase P07616563A0532 NNP I-UN
I P07616563A0532 PRP I-UN
two P07616563A0532 CD O
approximately P07616563A0532 RB O
25 P07616563A0532 CD O
bp P07616563A0532 NNS O
long P07616563A0532 JJ O
stretches P07616563A0532 NNS O
, P07616563A0532 , O
one P07616563A0532 CD O
of P07616563A0532 IN O
which P07616563A0532 WDT O
is P07616563A0532 VBZ O
located P07616563A0532 VBN O
just P07616563A0532 RB O
downstream P07616563A0532 NN O
of P07616563A0532 IN O
the P07616563A0532 DT O
GATC P07616563A0532 NNP O
sequence P07616563A0532 NN O
. P07616563A0532 . O
. . O O

The P11686239A0464 DT O
5 P11686239A0464 CD O
' P11686239A0464 POS O
flanking P11686239A0464 VBG O
sequence P11686239A0464 NN O
of P11686239A0464 IN O
the P11686239A0464 DT O
3B P11686239A0464 CD I-UN
gene P11686239A0464 NN I-UN
is P11686239A0464 VBZ O
extremely P11686239A0464 RB O
A P11686239A0464 NNP O
+ P11686239A0464 NNP O
T P11686239A0464 NNP O
rich P11686239A0464 JJ O
but P11686239A0464 CC O
contains P11686239A0464 VBZ O
five P11686239A0464 CD O
G P11686239A0464 NNP O
/ P11686239A0464 NNP O
C P11686239A0464 NNP O
rich P11686239A0464 JJ O
stretches P11686239A0464 NNS O
, P11686239A0464 , O
each P11686239A0464 DT O
approximately P11686239A0464 RB O
7bp P11686239A0464 CD O
long P11686239A0464 NNS O
, P11686239A0464 , O
which P11686239A0464 WDT O
have P11686239A0464 VBP O
strong P11686239A0464 JJ O
sequence P11686239A0464 NN O
similarity P11686239A0464 NN O
to P11686239A0464 TO O
the P11686239A0464 DT O
G P11686239A0464 NNP O
boxes P11686239A0464 NNS O
found P11686239A0464 VBD O
upstream P11686239A0464 RB O
of P11686239A0464 IN O
other P11686239A0464 JJ O
developmentally P11686239A0464 RB O
regulated P11686239A0464 VBN O
Dictyostelium P11686239A0464 NNP O
genes P11686239A0464 NNS O
. P11686239A0464 . O
. . O O

More P02209540A1362 RBR O
generally P02209540A1362 RB O
, P02209540A1362 , O
Ets1 P02209540A1362 NNP I-UN
and P02209540A1362 CC O
Ets2 P02209540A1362 NNP I-UN
could P02209540A1362 MD O
regulate P02209540A1362 VB O
transcription P02209540A1362 NN O
of P02209540A1362 IN O
cellular P02209540A1362 JJ O
genes P02209540A1362 NNS O
. P02209540A1362 . O
. . O O

When P01771593A1232 WRB O
examined P01771593A1232 VBN O
as P01771593A1232 IN O
adults P01771593A1232 NNS O
( P01771593A1232 ( O
8 P01771593A1232 CD O
weeks P01771593A1232 NNS O
old P01771593A1232 JJ O
) P01771593A1232 ) O
, P01771593A1232 , O
the P01771593A1232 DT O
external P01771593A1232 JJ O
genitalia P01771593A1232 NN O
of P01771593A1232 IN O
TA-exposed P01771593A1232 JJ O
offspring P01771593A1232 VBG O
were P01771593A1232 VBD O
normal P01771593A1232 JJ O
. P01771593A1232 . O
. . O O

We P09852136A0174 PRP O
have P09852136A0174 VBP O
introduced P09852136A0174 VBN O
a P09852136A0174 DT O
mutation P09852136A0174 NN O
( P09852136A0174 ( O
Ser36 P09852136A0174 NNP O
-- P09852136A0174 : O
> P09852136A0174 NNP O
Asn P09852136A0174 NNP O
) P09852136A0174 ) O
into P09852136A0174 IN O
this P09852136A0174 DT O
domain P09852136A0174 NN O
of P09852136A0174 IN O
p190 P09852136A0174 NN I-UN
that P09852136A0174 WDT O
decreased P09852136A0174 VBD O
its P09852136A0174 PRP$ O
ability P09852136A0174 NN O
to P09852136A0174 TO O
bind P09852136A0174 VB O
guanine P09852136A0174 JJ O
nucleotide P09852136A0174 NN O
when P09852136A0174 WRB O
expressed P09852136A0174 VBN O
as P09852136A0174 IN O
a P09852136A0174 DT O
hemagglutinin P09852136A0174 NN I-UN
( P09852136A0174 ( O
HA P09852136A0174 NNP I-UN
) P09852136A0174 ) O
-tagged P09852136A0174 VBD O
protein P09852136A0174 NN O
in P09852136A0174 IN O
COS P09852136A0174 NNP O
cells P09852136A0174 NNS O
. P09852136A0174 . O
. . O O

DESIGN P10416429A0221 NN O
: P10416429A0221 : O
Comparison P10416429A0221 NN O
of P10416429A0221 IN O
number P10416429A0221 NN O
of P10416429A0221 IN O
women P10416429A0221 NNS O
with P10416429A0221 IN O
PKU P10416429A0221 NNP O
aged P10416429A0221 VBD O
15-44 P10416429A0221 CD O
years P10416429A0221 NNS O
on P10416429A0221 IN O
the P10416429A0221 DT O
NSW P10416429A0221 NNP O
PKU P10416429A0221 NNP O
database P10416429A0221 NN O
( P10416429A0221 ( O
observed P10416429A0221 JJ O
number P10416429A0221 NN O
) P10416429A0221 ) O
with P10416429A0221 IN O
expected P10416429A0221 VBN O
number P10416429A0221 NN O
derived P10416429A0221 VBN O
from P10416429A0221 IN O
population P10416429A0221 NN O
data P10416429A0221 NNS O
. P10416429A0221 . O
. . O O

Rat P07961958T0000 NNP I-UN
kidney P07961958T0000 NN I-UN
carboxylesterase P07961958T0000 NN I-UN
. P07961958T0000 . O
. . O O

Update P08797362T0037 NN O
: P08797362T0037 : O
diphtheria P08797362T0037 NN O
epidemic P08797362T0037 NN O
in P08797362T0037 IN O
the P08797362T0037 DT O
newly P08797362T0037 RB O
independent P08797362T0037 JJ O
states P08797362T0037 NNS O
of P08797362T0037 IN O
the P08797362T0037 DT O
former P08797362T0037 JJ O
USSR P08797362T0037 NNP O
, P08797362T0037 , O
January P08797362T0037 NNP O
1995-March P08797362T0037 JJ O
1996 P08797362T0037 CD O
. P08797362T0037 . O
. . O O

We P07068496A0000 PRP O
compared P07068496A0000 VBN O
the P07068496A0000 DT O
volume P07068496A0000 NN O
of P07068496A0000 IN O
the P07068496A0000 DT O
pulmonary P07068496A0000 JJ O
extravascular P07068496A0000 NN O
, P07068496A0000 , O
extracellular P07068496A0000 JJ O
water P07068496A0000 NN O
space P07068496A0000 NN O
using P07068496A0000 VBG O
sodium P07068496A0000 NN O
and P07068496A0000 CC O
sucrose P07068496A0000 JJ O
indicators P07068496A0000 NNS O
in P07068496A0000 IN O
8 P07068496A0000 CD O
normal P07068496A0000 JJ O
and P07068496A0000 CC O
11 P07068496A0000 CD O
edematous P07068496A0000 JJ O
rabbit P07068496A0000 NN O
lungs P07068496A0000 NNS O
by P07068496A0000 IN O
steady-state P07068496A0000 JJ O
techniques P07068496A0000 NNS O
. P07068496A0000 . O
. . O O

This P09164856A0980 DT O
region P09164856A0980 NN O
does P09164856A0980 VBZ O
not P09164856A0980 RB O
contain P09164856A0980 VB O
an P09164856A0980 DT O
identifiable P09164856A0980 JJ O
TATA P09164856A0980 NNP O
element P09164856A0980 NN O
, P09164856A0980 , O
indicating P09164856A0980 VBG O
that P09164856A0980 IN O
transcription P09164856A0980 NN O
of P09164856A0980 IN O
the P09164856A0980 DT O
glutaminase P09164856A0980 NN I-UN
gene P09164856A0980 NN I-UN
is P09164856A0980 VBZ O
driven P09164856A0980 VBN O
by P09164856A0980 IN O
a P09164856A0980 DT O
TATA-less P09164856A0980 JJ O
promoter P09164856A0980 NN O
. P09164856A0980 . O
. . O O

Exchanging P11278594A0618 VBG O
the P11278594A0618 DT O
human P11278594A0618 JJ O
propeptide P11278594A0618 NN O
in P11278594A0618 IN O
this P11278594A0618 DT O
chimera P11278594A0618 NN O
with P11278594A0618 IN O
either P11278594A0618 CC O
the P11278594A0618 DT O
murine P11278594A0618 JJ I-UN
MIC-1 P11278594A0618 NNP I-UN
or P11278594A0618 CC O
TGF-beta1 P11278594A0618 NNP I-UN
propeptide P11278594A0618 NN I-UN
resulted P11278594A0618 VBD O
in P11278594A0618 IN O
secretion P11278594A0618 NN O
of P11278594A0618 IN O
the P11278594A0618 DT O
unprocessed P11278594A0618 JJ O
, P11278594A0618 , O
monomeric P11278594A0618 JJ O
chimera P11278594A0618 NN O
, P11278594A0618 , O
suggesting P11278594A0618 VBG O
a P11278594A0618 DT O
specific P11278594A0618 JJ O
interaction P11278594A0618 NN O
between P11278594A0618 IN O
the P11278594A0618 DT O
human P11278594A0618 JJ I-UN
MIC-1 P11278594A0618 NNP I-UN
propeptide P11278594A0618 NN I-UN
and P11278594A0618 CC O
mature P11278594A0618 NN O
peptide P11278594A0618 NN O
. P11278594A0618 . O
. . O O

Both P11278400A0668 DT O
pancreatic P11278400A0668 JJ O
and P11278400A0668 CC O
intestinal P11278400A0668 JJ O
cell P11278400A0668 NN O
lines P11278400A0668 NNS O
were P11278400A0668 VBD O
found P11278400A0668 VBN O
to P11278400A0668 TO O
express P11278400A0668 VB O
a P11278400A0668 DT O
number P11278400A0668 NN O
of P11278400A0668 IN O
POU P11278400A0668 NNP I-UN
( P11278400A0668 ( O
OCT P11278400A0668 NNP I-UN
binding P11278400A0668 VBG O
) P11278400A0668 ) O
homeodomain P11278400A0668 NN O
proteins P11278400A0668 NNS O
examined P11278400A0668 VBN O
by P11278400A0668 IN O
electrophoretic P11278400A0668 JJ O
mobility P11278400A0668 NN O
shift P11278400A0668 NN O
assay P11278400A0668 NN O
. P11278400A0668 . O
. . O O

Propagation P05552642T0000 NN O
and P05552642T0000 CC O
hormone P05552642T0000 NN O
production P05552642T0000 NN O
by P05552642T0000 IN O
human P05552642T0000 JJ O
normal P05552642T0000 JJ O
and P05552642T0000 CC O
malignant P05552642T0000 JJ O
trophoblast P05552642T0000 NN O
in P05552642T0000 IN O
rats P05552642T0000 NNS O
. P05552642T0000 . O
. . O O

The P00172199A0270 DT O
matrix P00172199A0270 NN O
surrounding P00172199A0270 VBG O
the P00172199A0270 DT O
clusters P00172199A0270 NNS O
either P00172199A0270 CC O
showed P00172199A0270 VBD O
a P00172199A0270 DT O
normal P00172199A0270 JJ O
morphology P00172199A0270 NN O
or P00172199A0270 CC O
a P00172199A0270 DT O
homogeneous P00172199A0270 JJ O
appearance P00172199A0270 NN O
, P00172199A0270 , O
within P00172199A0270 IN O
which P00172199A0270 WDT O
faint P00172199A0270 NN O
cross P00172199A0270 NN O
striations P00172199A0270 NNS O
but P00172199A0270 CC O
no P00172199A0270 DT O
distinctly P00172199A0270 RB O
fibrillar P00172199A0270 JJ O
outlines P00172199A0270 NNS O
could P00172199A0270 MD O
be P00172199A0270 VB O
identified P00172199A0270 VBN O
. P00172199A0270 . O
. . O O

Analysis P09786197A0322 NN O
of P09786197A0322 IN O
chromosomal P09786197A0322 JJ O
DNA P09786197A0322 NNP O
sequence P09786197A0322 NN O
immediately P09786197A0322 RB O
downstream P09786197A0322 NN O
of P09786197A0322 IN O
the P09786197A0322 DT O
transposon P09786197A0322 NN O
insertion P09786197A0322 NN O
identified P09786197A0322 VBD O
two P09786197A0322 CD O
open P09786197A0322 JJ O
reading P09786197A0322 VBG O
frames P09786197A0322 NNS O
, P09786197A0322 , O
designated P09786197A0322 VBN O
csrR P09786197A0322 NN I-UN
and P09786197A0322 CC O
csrS P09786197A0322 NN I-UN
, P09786197A0322 , O
which P09786197A0322 WDT O
exhibited P09786197A0322 VBD O
sequence P09786197A0322 NN O
similarity P09786197A0322 NN O
to P09786197A0322 TO O
bacterial P09786197A0322 JJ O
two-component P09786197A0322 JJ O
regulatory P09786197A0322 JJ O
systems P09786197A0322 NNS O
. P09786197A0322 . O
. . O O

The P09426907A0391 DT O
purpose P09426907A0391 NN O
of P09426907A0391 IN O
this P09426907A0391 DT O
investigation P09426907A0391 NN O
was P09426907A0391 VBD O
to P09426907A0391 TO O
describe P09426907A0391 VB O
a P09426907A0391 DT O
new P09426907A0391 JJ O
formulation P09426907A0391 NN O
of P09426907A0391 IN O
silver P09426907A0391 NN O
sulfadiazine P09426907A0391 NN O
in P09426907A0391 IN O
a P09426907A0391 DT O
water P09426907A0391 NN O
soluble P09426907A0391 JJ O
gel P09426907A0391 NN O
, P09426907A0391 , O
poloxamer P09426907A0391 NN O
188 P09426907A0391 CD O
. P09426907A0391 . O
. . O O

Skeletal P01934378T0000 JJ O
muscle P01934378T0000 NN O
metaboreceptor P01934378T0000 NN O
exercise P01934378T0000 NN O
responses P01934378T0000 NNS O
are P01934378T0000 VBP O
attenuated P01934378T0000 VBN O
in P01934378T0000 IN O
heart P01934378T0000 NN O
failure P01934378T0000 NN O
. P01934378T0000 . O
. . O O

The P08910567A2269 DT O
human P08910567A2269 JJ O
gene P08910567A2269 NN O
fragment P08910567A2269 NN O
ligated P08910567A2269 VBN O
to P08910567A2269 TO O
the P08910567A2269 DT O
minimal P08910567A2269 JJ O
rat P08910567A2269 NN O
liver P08910567A2269 NN O
glucokinase P08910567A2269 NN I-UN
promoter P08910567A2269 NN O
was P08910567A2269 VBD O
shown P08910567A2269 VBN O
to P08910567A2269 TO O
work P08910567A2269 VB O
as P08910567A2269 IN O
an P08910567A2269 DT O
enhancer P08910567A2269 NN O
in P08910567A2269 IN O
the P08910567A2269 DT O
hepatocyte P08910567A2269 NN O
transfection P08910567A2269 NN O
system P08910567A2269 NN O
. P08910567A2269 . O
. . O O

Effect P09823014T0000 NN O
of P09823014T0000 IN O
enteral P09823014T0000 JJ O
nutritional P09823014T0000 JJ O
products P09823014T0000 NNS O
differing P09823014T0000 VBG O
in P09823014T0000 IN O
carbohydrate P09823014T0000 NN O
and P09823014T0000 CC O
fat P09823014T0000 NN O
on P09823014T0000 IN O
indices P09823014T0000 NNS O
of P09823014T0000 IN O
carbohydrate P09823014T0000 NN O
and P09823014T0000 CC O
lipid P09823014T0000 JJ O
metabolism P09823014T0000 NN O
in P09823014T0000 IN O
patients P09823014T0000 NNS O
with P09823014T0000 IN O
NIDDM P09823014T0000 NNP O
. P09823014T0000 . O
. . O O

S6K2 P11108720A0124 NNP I-UN
is P11108720A0124 VBZ O
highly P11108720A0124 RB O
homologous P11108720A0124 JJ O
to P11108720A0124 TO O
S6K1 P11108720A0124 NNP I-UN
in P11108720A0124 IN O
the P11108720A0124 DT O
core P11108720A0124 NN O
kinase P11108720A0124 NN O
and P11108720A0124 CC O
linker P11108720A0124 NN O
regulatory P11108720A0124 JJ O
domains P11108720A0124 NNS O
but P11108720A0124 CC O
differs P11108720A0124 NNS O
from P11108720A0124 IN O
S6K1 P11108720A0124 NNP I-UN
in P11108720A0124 IN O
the P11108720A0124 DT O
N- P11108720A0124 NNP O
and P11108720A0124 CC O
C-terminal P11108720A0124 JJ O
regions P11108720A0124 NNS O
and P11108720A0124 CC O
is P11108720A0124 VBZ O
differently P11108720A0124 RB O
localized P11108720A0124 VBN O
primarily P11108720A0124 RB O
to P11108720A0124 TO O
the P11108720A0124 DT O
nucleus P11108720A0124 NN O
because P11108720A0124 IN O
of P11108720A0124 IN O
a P11108720A0124 DT O
C-terminal P11108720A0124 JJ O
nuclear P11108720A0124 JJ O
localization P11108720A0124 NN O
signal P11108720A0124 NN O
unique P11108720A0124 NN O
to P11108720A0124 TO O
S6K2 P11108720A0124 NNP I-UN
. P11108720A0124 . O
. . O O

Interestingly P09763522A2545 RB O
, P09763522A2545 , O
an P09763522A2545 DT O
antibody P09763522A2545 NN O
against P09763522A2545 IN O
N-SMase P09763522A2545 NNP I-UN
can P09763522A2545 MD O
abrogate P09763522A2545 VB O
Ox-LDL- P09763522A2545 NNP O
and P09763522A2545 CC O
TNF-alpha-induced P09763522A2545 NNP O
apoptosis P09763522A2545 NN O
and P09763522A2545 CC O
therefore P09763522A2545 NN O
may P09763522A2545 MD O
be P09763522A2545 VB O
useful P09763522A2545 JJ O
for P09763522A2545 IN O
in P09763522A2545 IN O
vivo P09763522A2545 JJ O
studies P09763522A2545 NNS O
of P09763522A2545 IN O
apoptosis P09763522A2545 NN O
in P09763522A2545 IN O
experimental P09763522A2545 JJ O
animals P09763522A2545 NNS O
. P09763522A2545 . O
. . O O

To P07528772A0616 TO O
further P07528772A0616 RBR O
define P07528772A0616 VB O
the P07528772A0616 DT O
structural P07528772A0616 JJ O
requirements P07528772A0616 NNS O
for P07528772A0616 IN O
ZAP-70 P07528772A0616 JJ I-UN
interaction P07528772A0616 NN O
with P07528772A0616 IN O
the P07528772A0616 DT O
TCR P07528772A0616 NNP I-UN
, P07528772A0616 , O
we P07528772A0616 PRP O
developed P07528772A0616 VBD O
a P07528772A0616 DT O
binding P07528772A0616 NN O
assay P07528772A0616 NN O
using P07528772A0616 VBG O
immobilized P07528772A0616 JJ O
glutathione P07528772A0616 NN I-UN
S-transferase P07528772A0616 NNP I-UN
fusion P07528772A0616 NN I-UN
proteins P07528772A0616 VBZ I-UN
containing P07528772A0616 VBG O
the P07528772A0616 DT O
NH2- P07528772A0616 NNP O
and P07528772A0616 CC O
/ P07528772A0616 NNP O
or P07528772A0616 CC O
COOH-terminal P07528772A0616 JJ I-UN
SH2 P07528772A0616 NNP I-UN
domains P07528772A0616 NNS I-UN
of P07528772A0616 IN O
ZAP-70 P07528772A0616 NNP I-UN
, P07528772A0616 , O
and P07528772A0616 CC O
soluble P07528772A0616 JJ O
synthetic P07528772A0616 JJ O
peptides P07528772A0616 NNS O
with P07528772A0616 IN O
the P07528772A0616 DT O
sequence P07528772A0616 NN O
of P07528772A0616 IN O
the P07528772A0616 DT O
cytoplasmic P07528772A0616 JJ O
region P07528772A0616 NN O
of P07528772A0616 IN O
the P07528772A0616 DT O
TCR P07528772A0616 NNP I-UN
zeta P07528772A0616 NN I-UN
chain P07528772A0616 NN I-UN
( P07528772A0616 ( O
TCR P07528772A0616 NNP I-UN
zeta P07528772A0616 NNP I-UN
cyt P07528772A0616 NN I-UN
) P07528772A0616 ) O
or P07528772A0616 CC O
individual P07528772A0616 JJ O
TCR P07528772A0616 NNP I-UN
zeta P07528772A0616 NN I-UN
and P07528772A0616 CC O
CD3 P07528772A0616 NNP I-UN
epsilon P07528772A0616 VBP I-UN
TAM P07528772A0616 NNP I-UN
motifs P07528772A0616 NNS I-UN
. P07528772A0616 . O
. . O O

Influence P02119530T0000 NN O
of P02119530T0000 IN O
metoprolol P02119530T0000 NN O
treatment P02119530T0000 NN O
on P02119530T0000 IN O
sympatho-adrenal P02119530T0000 JJ O
activation P02119530T0000 NN O
of P02119530T0000 IN O
fibrinolysis P02119530T0000 NN O
. P02119530T0000 . O
. . O O

Chirality-glass P10000253T0000 NN O
and P10000253T0000 CC O
spin-glass P10000253T0000 NN O
correlations P10000253T0000 NNS O
in P10000253T0000 IN O
the P10000253T0000 DT O
two-dimensional P10000253T0000 JJ O
random-bond P10000253T0000 NN O
XY P10000253T0000 NNP O
model P10000253T0000 NN O
. P10000253T0000 . O
. . O O

Transcription P09804779A0000 NN O
factors P09804779A0000 NNS O
of P09804779A0000 IN O
the P09804779A0000 DT O
Stat P09804779A0000 NNP I-UN
family P09804779A0000 NN I-UN
are P09804779A0000 VBP O
controlled P09804779A0000 VBN O
by P09804779A0000 IN O
protein P09804779A0000 NN O
kinases P09804779A0000 NNS O
. P09804779A0000 . O
. . O O

The P11250196A0455 DT O
( P11250196A0455 ( O
two-motif P11250196A0455 JJ O
) P11250196A0455 ) O
domain P11250196A0455 NN O
fold P11250196A0455 JJ O
contains P11250196A0455 VBZ O
a P11250196A0455 DT O
pair P11250196A0455 NN O
of P11250196A0455 IN O
calcium P11250196A0455 NN O
binding P11250196A0455 VBG O
sites P11250196A0455 NNS O
very P11250196A0455 RB O
similar P11250196A0455 JJ O
to P11250196A0455 TO O
those P11250196A0455 DT O
found P11250196A0455 VBN O
in P11250196A0455 IN O
a P11250196A0455 DT O
two-domain P11250196A0455 JJ I-UN
prokaryotic P11250196A0455 JJ I-UN
betagamma-crystallin P11250196A0455 NN I-UN
fold P11250196A0455 JJ I-UN
family P11250196A0455 NN I-UN
member P11250196A0455 NN I-UN
, P11250196A0455 , O
Protein P11250196A0455 NNP I-UN
S P11250196A0455 NNP I-UN
. P11250196A0455 . O
. . O O

A P02727909A0383 DT O
raised P02727909A0383 JJ O
amplitude P02727909A0383 NN O
of P02727909A0383 IN O
the P02727909A0383 DT O
aggregation P02727909A0383 NN O
of P02727909A0383 IN O
plates P02727909A0383 NNS O
and P02727909A0383 CC O
a P02727909A0383 DT O
decrease P02727909A0383 NN O
in P02727909A0383 IN O
the P02727909A0383 DT O
threshold P02727909A0383 NN O
of P02727909A0383 IN O
their P02727909A0383 PRP$ O
sensitivity P02727909A0383 NN O
to P02727909A0383 TO O
ADP P02727909A0383 NNP O
were P02727909A0383 VBD O
established P02727909A0383 VBN O
in P02727909A0383 IN O
the P02727909A0383 DT O
persons P02727909A0383 NNS O
with P02727909A0383 IN O
types P02727909A0383 NNS O
IIa P02727909A0383 NNP O
and P02727909A0383 CC O
IIb P02727909A0383 NNP O
HLP P02727909A0383 NNP O
and P02727909A0383 CC O
in P02727909A0383 IN O
CHD P02727909A0383 NNP O
without P02727909A0383 IN O
HLP P02727909A0383 NNP O
. P02727909A0383 . O
. . O O

In P09135149A0000 IN O
Schizosaccharomyces P09135149A0000 NNP O
pombe P09135149A0000 NN O
, P09135149A0000 , O
the P09135149A0000 DT O
activity P09135149A0000 NN O
of P09135149A0000 IN O
the P09135149A0000 DT O
M-phase-inducing P09135149A0000 NNP O
Cdc2 P09135149A0000 NNP I-UN
/ P09135149A0000 NNP O
Cdc13 P09135149A0000 NNP I-UN
cyclin-dependent P09135149A0000 JJ O
kinase P09135149A0000 NN O
is P09135149A0000 VBZ O
inhibited P09135149A0000 VBN O
by P09135149A0000 IN O
Wee1 P09135149A0000 NNP I-UN
and P09135149A0000 CC O
Mik1 P09135149A0000 NNP I-UN
tyrosine P09135149A0000 NN I-UN
kinases P09135149A0000 NNS I-UN
, P09135149A0000 , O
and P09135149A0000 CC O
activated P09135149A0000 VBN O
by P09135149A0000 IN O
Cdc25 P09135149A0000 NNP I-UN
and P09135149A0000 CC O
Pyp3 P09135149A0000 NNP I-UN
tyrosine P09135149A0000 NN I-UN
phosphatases P09135149A0000 NNS I-UN
. P09135149A0000 . O
. . O O

The P05471866T0000 DT O
plasma P05471866T0000 NN I-UN
growth P05471866T0000 NN I-UN
hormone P05471866T0000 CD I-UN
concentration P05471866T0000 NN O
of P05471866T0000 IN O
the P05471866T0000 DT O
foetal P05471866T0000 JJ O
lamb P05471866T0000 NN O
. P05471866T0000 . O
. . O O

Zinc P08444344A0000 JJ O
fingers P08444344A0000 NNS O
( P08444344A0000 ( O
Zf P08444344A0000 NNP O
) P08444344A0000 ) O
are P08444344A0000 VBP O
a P08444344A0000 DT O
common P08444344A0000 JJ O
structural P08444344A0000 JJ O
motif P08444344A0000 NN O
found P08444344A0000 VBD O
in P08444344A0000 IN O
many P08444344A0000 JJ O
nucleic P08444344A0000 JJ O
acid-binding P08444344A0000 JJ O
proteins P08444344A0000 NNS O
. P08444344A0000 . O
. . O O

Current P01092248T0000 JJ O
status P01092248T0000 NN O
of P01092248T0000 IN O
zinc P01092248T0000 NN O
deficiency P01092248T0000 NN O
in P01092248T0000 IN O
the P01092248T0000 DT O
pathogenesis P01092248T0000 NN O
of P01092248T0000 IN O
neurological P01092248T0000 JJ O
, P01092248T0000 , O
dermatological P01092248T0000 JJ O
and P01092248T0000 CC O
musculoskeletal P01092248T0000 JJ O
disorders P01092248T0000 NNS O
. P01092248T0000 . O
. . O O

Effect P01009739T0001 NN O
of P01009739T0001 IN O
indomethacin P01009739T0001 NN O
on P01009739T0001 IN O
coronary P01009739T0001 JJ O
circulation P01009739T0001 NN O
: P01009739T0001 : O
effect P01009739T0001 NN O
on P01009739T0001 IN O
ECG P01009739T0001 NNP O
tracing P01009739T0001 NN O
. P01009739T0001 . O
. . O O

Incidental P00681571T0028 JJ O
findings P00681571T0028 NNS O
in P00681571T0028 IN O
the P00681571T0028 DT O
epidermis P00681571T0028 NN O
and P00681571T0028 CC O
in P00681571T0028 IN O
the P00681571T0028 DT O
intraepidermal P00681571T0028 JJ O
eccrine P00681571T0028 NN O
sweat P00681571T0028 NN O
duct P00681571T0028 NN O
units P00681571T0028 NNS O
. P00681571T0028 . O
. . O O

Specific P02159470A1432 JJ O
binding P02159470A1432 NN O
of P02159470A1432 IN O
the P02159470A1432 DT O
protein P02159470A1432 NN O
factors P02159470A1432 NNS O
to P02159470A1432 TO O
the P02159470A1432 DT O
sites P02159470A1432 NNS O
, P02159470A1432 , O
possibly P02159470A1432 RB O
to P02159470A1432 TO O
the P02159470A1432 DT O
three P02159470A1432 CD O
Mt P02159470A1432 NNP O
sequences P02159470A1432 NNS O
, P02159470A1432 , O
may P02159470A1432 MD O
play P02159470A1432 VB O
an P02159470A1432 DT O
important P02159470A1432 JJ O
role P02159470A1432 NN O
in P02159470A1432 IN O
the P02159470A1432 DT O
coordinate P02159470A1432 NN O
regulation P02159470A1432 NN O
of P02159470A1432 IN O
the P02159470A1432 DT O
transcription P02159470A1432 NN O
of P02159470A1432 IN O
nuclear P02159470A1432 JJ O
genes P02159470A1432 NNS O
encoding P02159470A1432 VBG O
subunits P02159470A1432 NNS O
responsible P02159470A1432 JJ O
for P02159470A1432 IN O
mitochondrial P02159470A1432 JJ O
oxidative P02159470A1432 JJ O
phosphorylation P02159470A1432 NN O
. P02159470A1432 . O
. . O O

5 P11027027A0061 CD O
( P11027027A0061 ( O
Sunset P11027027A0061 NNP O
Yellow P11027027A0061 NNP O
FCF P11027027A0061 NNP O
) P11027027A0061 ) O
were P11027027A0061 VBD O
determined P11027027A0061 VBN O
using P11027027A0061 VBG O
liquid P11027027A0061 JJ O
chromatography P11027027A0061 NN O
/ P11027027A0061 NNP O
mass P11027027A0061 NN O
spectrometry P11027027A0061 NN O
( P11027027A0061 ( O
LC P11027027A0061 NNP O
/ P11027027A0061 NNP O
MS P11027027A0061 NNP O
) P11027027A0061 ) O
with P11027027A0061 IN O
electrospray P11027027A0061 JJ O
ionization P11027027A0061 NN O
. P11027027A0061 . O
. . O O

Transfecting P01649835A0822 VBG O
the P01649835A0822 DT O
cloned P01649835A0822 JJ O
bovine P01649835A0822 NN O
PBR P01649835A0822 NNP I-UN
/ P01649835A0822 NNP O
IBP P01649835A0822 NNP I-UN
cDNA P01649835A0822 NN O
into P01649835A0822 IN O
COS-7 P01649835A0822 NNP O
cells P01649835A0822 NNS O
resulted P01649835A0822 VBD O
in P01649835A0822 IN O
an P01649835A0822 DT O
11-fold P01649835A0822 JJ O
increase P01649835A0822 NN O
in P01649835A0822 IN O
the P01649835A0822 DT O
density P01649835A0822 NN O
of P01649835A0822 IN O
high P01649835A0822 JJ O
affinity P01649835A0822 NN O
[ P01649835A0822 VBP O
3H P01649835A0822 CD O
] P01649835A0822 NNP O
PK P01649835A0822 NNP O
11195 P01649835A0822 CD O
binding P01649835A0822 NN O
sites P01649835A0822 NNS O
which P01649835A0822 WDT O
had P01649835A0822 VBD O
only P01649835A0822 RB O
low P01649835A0822 JJ O
affinity P01649835A0822 NN O
for P01649835A0822 IN O
Ro5-4864 P01649835A0822 NNP O
. P01649835A0822 . O
. . O O

REM P08915559A0366 NNP O
sleep P08915559A0366 JJ O
deprivation P08915559A0366 NN O
was P08915559A0366 VBD O
performed P08915559A0366 VBN O
using P08915559A0366 VBG O
the P08915559A0366 DT O
platform P08915559A0366 NN O
technique P08915559A0366 NN O
. P08915559A0366 . O
. . O O

Induction P09893913A0656 NN O
of P09893913A0656 IN O
anaesthesia P09893913A0656 NN O
was P09893913A0656 VBD O
standardised P09893913A0656 VBN O
: P09893913A0656 : O
fentanyl P09893913A0656 NN O
( P09893913A0656 ( O
3 P09893913A0656 CD O
micrograms P09893913A0656 NNS O
/ P09893913A0656 NNP O
kg P09893913A0656 NN O
) P09893913A0656 ) O
, P09893913A0656 , O
thiopentone P09893913A0656 NN O
( P09893913A0656 ( O
5 P09893913A0656 CD O
mg P09893913A0656 NN O
/ P09893913A0656 NNP O
kg P09893913A0656 NN O
) P09893913A0656 ) O
, P09893913A0656 , O
atracurium P09893913A0656 NN O
( P09893913A0656 ( O
0.4 P09893913A0656 CD O
mg P09893913A0656 NN O
/ P09893913A0656 NNP O
kg P09893913A0656 NN O
) P09893913A0656 ) O
. P09893913A0656 . O
. . O O

Among P08648665A0956 IN O
the P08648665A0956 DT O
LE6 P08648665A0956 NNP I-UN
deletions P08648665A0956 NNS O
, P08648665A0956 , O
only P08648665A0956 RB O
one P08648665A0956 CD O
had P08648665A0956 VBD O
a P08648665A0956 DT O
reduced P08648665A0956 VBN O
transformation P08648665A0956 NN O
efficiency P08648665A0956 NN O
, P08648665A0956 , O
while P08648665A0956 IN O
seven P08648665A0956 CD O
transformed P08648665A0956 VBD O
cells P08648665A0956 NNS O
at P08648665A0956 IN O
least P08648665A0956 JJS O
as P08648665A0956 RB O
efficiently P08648665A0956 RB O
as P08648665A0956 IN O
wild-type P08648665A0956 JJ I-UN
LE6 P08648665A0956 NNP I-UN
. P08648665A0956 . O
. . O O

The P08199878T0000 DT O
effects P08199878T0000 NNS O
of P08199878T0000 IN O
systemic P08199878T0000 JJ O
glucose P08199878T0000 JJ O
concentration P08199878T0000 NN O
on P08199878T0000 IN O
brain P08199878T0000 NN O
metabolism P08199878T0000 NN O
following P08199878T0000 VBG O
repeated P08199878T0000 VBD O
brain P08199878T0000 NN O
ischemia P08199878T0000 NN O
. P08199878T0000 . O
. . O O

Antiviral P05091970T0000 JJ O
agents P05091970T0000 NNS O
. P05091970T0000 . O
. . O O

Our P09701609A0116 PRP$ O
laboratory P09701609A0116 NN O
has P09701609A0116 VBZ O
recently P09701609A0116 RB O
identified P09701609A0116 VBN O
two P09701609A0116 CD O
phosducin-like P09701609A0116 JJ I-UN
orphan P09701609A0116 JJ I-UN
proteins P09701609A0116 NNS I-UN
( P09701609A0116 ( O
PhLOP1 P09701609A0116 NNP I-UN
and P09701609A0116 CC O
PhLOP2 P09701609A0116 NNP I-UN
) P09701609A0116 ) O
that P09701609A0116 WDT O
lack P09701609A0116 VBP O
the P09701609A0116 DT O
ability P09701609A0116 NN O
to P09701609A0116 TO O
interact P09701609A0116 VB O
with P09701609A0116 IN O
Gbetagamma P09701609A0116 NNP I-UN
. P09701609A0116 . O
. . O O

Crohn P08140847X0001 NNP O
's P08140847X0001 POS O
disease P08140847X0001 NN O
in P08140847X0001 IN O
prolonged P08140847X0001 JJ O
remission P08140847X0001 NN O
: P08140847X0001 : O
should P08140847X0001 MD O
one P08140847X0001 CD O
augment P08140847X0001 NN O
protein-calorie P08140847X0001 JJ O
intake P08140847X0001 NN O
as P08140847X0001 IN O
compared P08140847X0001 VBN O
to P08140847X0001 TO O
healthy P08140847X0001 JJ O
subjects P08140847X0001 NNS O
? P08140847X0001 . O
] P08140847X0001 NN O
The P08140847X0001 DT O
aim P08140847X0001 NN O
of P08140847X0001 IN O
our P08140847X0001 PRP$ O
two P08140847X0001 CD O
year P08140847X0001 NN O
prospective P08140847X0001 JJ O
study P08140847X0001 NN O
was P08140847X0001 VBD O
to P08140847X0001 TO O
evaluate P08140847X0001 VB O
whether P08140847X0001 IN O
adult P08140847X0001 NN O
Crohn P08140847X0001 NNP O
's P08140847X0001 POS O
disease P08140847X0001 NN O
patients P08140847X0001 NNS O
in P08140847X0001 IN O
prolonged P08140847X0001 JJ O
remission P08140847X0001 NN O
( P08140847X0001 ( O
CDAI P08140847X0001 NNP O
< P08140847X0001 NNP O
150 P08140847X0001 CD O
) P08140847X0001 ) O
, P08140847X0001 , O
in P08140847X0001 IN O
order P08140847X0001 NN O
to P08140847X0001 TO O
maintain P08140847X0001 VB O
their P08140847X0001 PRP$ O
body P08140847X0001 NN O
weight P08140847X0001 VBD O
as P08140847X0001 RB O
close P08140847X0001 RB O
as P08140847X0001 IN O
possible P08140847X0001 JJ O
to P08140847X0001 TO O
the P08140847X0001 DT O
ideal P08140847X0001 NN O
one P08140847X0001 CD O
, P08140847X0001 , O
need P08140847X0001 VBP O
a P08140847X0001 DT O
protein-calorie P08140847X0001 JJ O
intake P08140847X0001 NN O
higher P08140847X0001 JJR O
than P08140847X0001 IN O
the P08140847X0001 DT O
predicted P08140847X0001 JJ O
one P08140847X0001 CD O
and P08140847X0001 CC O
that P08140847X0001 IN O
of P08140847X0001 IN O
healthy P08140847X0001 JJ O
controls P08140847X0001 NNS O
. P08140847X0001 . O
. . O O

These P09092580A1354 DT O
studies P09092580A1354 NNS O
point P09092580A1354 VBP O
to P09092580A1354 TO O
the P09092580A1354 DT O
involvement P09092580A1354 NN O
of P09092580A1354 IN O
the P09092580A1354 DT O
MAP P09092580A1354 NNP I-UN
kinase P09092580A1354 VB I-UN
pathway P09092580A1354 NN O
in P09092580A1354 IN O
the P09092580A1354 DT O
activation P09092580A1354 NN O
of P09092580A1354 IN O
monocytic P09092580A1354 JJ O
cells P09092580A1354 NNS O
during P09092580A1354 IN O
transmigration P09092580A1354 NN O
to P09092580A1354 TO O
inflammatory P09092580A1354 VB O
sites P09092580A1354 NNS O
. P09092580A1354 . O
. . O O

Detection P00331936T0000 NN O
of P00331936T0000 IN O
anti-lymphocyte P00331936T0000 JJ O
antibodies P00331936T0000 NNS O
using P00331936T0000 VBG O
the P00331936T0000 DT O
immunoperoxidase P00331936T0000 NN I-UN
antiglobulin P00331936T0000 NN I-UN
technic P00331936T0000 NN O
. P00331936T0000 . O
. . O O

The P02489753A0581 DT O
results P02489753A0581 NNS O
were P02489753A0581 VBD O
as P02489753A0581 IN O
follows P02489753A0581 VBZ O
: P02489753A0581 : O
1 P02489753A0581 CD O
) P02489753A0581 ) O
Total P02489753A0581 NN O
integrated P02489753A0581 JJ O
EMG P02489753A0581 NNP O
activity P02489753A0581 NN O
of P02489753A0581 IN O
FB P02489753A0581 NNP O
group P02489753A0581 NN O
was P02489753A0581 VBD O
approximately P02489753A0581 RB O
equal P02489753A0581 JJ O
in P02489753A0581 IN O
any P02489753A0581 DT O
occluded P02489753A0581 JJ O
position P02489753A0581 NN O
, P02489753A0581 , O
whereas P02489753A0581 IN O
that P02489753A0581 DT O
of P02489753A0581 IN O
CG P02489753A0581 NNP O
and P02489753A0581 CC O
GF P02489753A0581 NNP O
group P02489753A0581 NN O
varied P02489753A0581 VBD O
from P02489753A0581 IN O
position P02489753A0581 NN O
to P02489753A0581 TO O
position P02489753A0581 NN O
. P02489753A0581 . O
. . O O

However P08428952A0399 RB O
, P08428952A0399 , O
L-plastin P08428952A0399 NNP I-UN
has P08428952A0399 VBZ O
been P08428952A0399 VBN O
found P08428952A0399 VBN O
in P08428952A0399 IN O
many P08428952A0399 JJ O
types P08428952A0399 NNS O
of P08428952A0399 IN O
malignant P08428952A0399 JJ O
human P08428952A0399 JJ O
cells P08428952A0399 NNS O
of P08428952A0399 IN O
non-hemopoietic P08428952A0399 JJ O
origin P08428952A0399 NN O
suggesting P08428952A0399 VBG O
that P08428952A0399 IN O
its P08428952A0399 PRP$ O
expression P08428952A0399 NN O
is P08428952A0399 VBZ O
induced P08428952A0399 VBN O
accompanying P08428952A0399 VBG O
tumorigenesis P08428952A0399 NN O
in P08428952A0399 IN O
solid P08428952A0399 JJ O
tissues P08428952A0399 NNS O
. P08428952A0399 . O
. . O O

STUDY P11449014A0000 NNP O
OBJECTIVE P11449014A0000 NNP O
: P11449014A0000 : O
This P11449014A0000 DT O
study P11449014A0000 NN O
assessed P11449014A0000 VBD O
several P11449014A0000 JJ O
methodological P11449014A0000 JJ O
aspects P11449014A0000 NNS O
related P11449014A0000 VBN O
to P11449014A0000 TO O
the P11449014A0000 DT O
quality P11449014A0000 NN O
of P11449014A0000 IN O
published P11449014A0000 VBN O
controlled P11449014A0000 JJ O
clinical P11449014A0000 JJ O
trials P11449014A0000 NNS O
( P11449014A0000 ( O
CCTs P11449014A0000 NNP O
) P11449014A0000 ) O
in P11449014A0000 IN O
relation P11449014A0000 NN O
to P11449014A0000 TO O
the P11449014A0000 DT O
participation P11449014A0000 NN O
of P11449014A0000 IN O
an P11449014A0000 DT O
epidemiologist P11449014A0000 NN O
/ P11449014A0000 NN O
biostatistician P11449014A0000 NN O
( P11449014A0000 ( O
E P11449014A0000 NNP O
/ P11449014A0000 NNP O
B P11449014A0000 NNP O
) P11449014A0000 ) O
. P11449014A0000 . O
. . O O

The P06310608A0749 DT O
mutants P06310608A0749 NNS O
were P06310608A0749 VBD O
obtained P06310608A0749 VBN O
by P06310608A0749 IN O
substitution P06310608A0749 NN O
into P06310608A0749 IN O
a P06310608A0749 DT O
molecular P06310608A0749 JJ O
clone P06310608A0749 NN O
of P06310608A0749 IN O
M-MuLV P06310608A0749 NNP O
DNA P06310608A0749 NNP O
by P06310608A0749 IN O
DNA P06310608A0749 NNP O
from P06310608A0749 IN O
two P06310608A0749 CD O
acutely P06310608A0749 RB O
transforming P06310608A0749 VBG O
viruses P06310608A0749 NNS O
, P06310608A0749 , O
Ableson P06310608A0749 NNP O
MuLV P06310608A0749 NNP O
( P06310608A0749 ( O
Ab-MuLV P06310608A0749 NNP O
) P06310608A0749 ) O
and P06310608A0749 CC O
Moloney P06310608A0749 NNP O
murine P06310608A0749 NN O
sarcoma P06310608A0749 NN O
virus P06310608A0749 NN O
( P06310608A0749 ( O
M-MSV P06310608A0749 NNP O
) P06310608A0749 ) O
. P06310608A0749 . O
. . O O

The P11107637X0001 DT O
determination P11107637X0001 NN O
of P11107637X0001 IN O
the P11107637X0001 DT O
double P11107637X0001 JJ O
bounds P11107637X0001 NNS O
in P11107637X0001 IN O
blood P11107637X0001 NN O
serum P11107637X0001 NN O
lipids P11107637X0001 NNS O
by P11107637X0001 IN O
titration P11107637X0001 NN O
with P11107637X0001 IN O
ozone P11107637X0001 NN O
: P11107637X0001 : O
the P11107637X0001 DT O
pathophysiology P11107637X0001 NN O
and P11107637X0001 CC O
diagnostic P11107637X0001 JJ O
significance P11107637X0001 NN O
] P11107637X0001 NN O
In P11107637X0001 IN O
this P11107637X0001 DT O
article P11107637X0001 NN O
the P11107637X0001 DT O
method P11107637X0001 NN O
of P11107637X0001 IN O
definition P11107637X0001 NN O
of P11107637X0001 IN O
double P11107637X0001 JJ O
binders P11107637X0001 NNS O
in P11107637X0001 IN O
lipids P11107637X0001 NNS O
of P11107637X0001 IN O
blood P11107637X0001 NN O
serum P11107637X0001 NN O
in P11107637X0001 IN O
patients P11107637X0001 NNS O
with P11107637X0001 IN O
different P11107637X0001 JJ O
diseases P11107637X0001 NNS O
basically P11107637X0001 RB O
atherosclerosis P11107637X0001 VBP O
and P11107637X0001 CC O
ischemic P11107637X0001 JJ O
heart P11107637X0001 NN O
disease P11107637X0001 NN O
, P11107637X0001 , O
with P11107637X0001 IN O
use P11107637X0001 NN O
titration P11107637X0001 NN O
by P11107637X0001 IN O
ozone P11107637X0001 NN O
is P11107637X0001 VBZ O
given P11107637X0001 VBN O
. P11107637X0001 . O
. . O O

The P11732417A0571 DT O
cut-off P11732417A0571 JJ O
percentage P11732417A0571 NN O
positivity P11732417A0571 NN O
value P11732417A0571 NN O
was P11732417A0571 VBD O
established P11732417A0571 VBN O
using P11732417A0571 VBG O
500 P11732417A0571 CD O
brucellosis-positive P11732417A0571 JJ O
and P11732417A0571 CC O
500 P11732417A0571 CD O
brucellosis-negative P11732417A0571 JJ O
serum P11732417A0571 NN O
samples P11732417A0571 NNS O
, P11732417A0571 , O
confirmed P11732417A0571 VBN O
with P11732417A0571 IN O
reference P11732417A0571 NN O
to P11732417A0571 TO O
the P11732417A0571 DT O
sample P11732417A0571 NN O
data P11732417A0571 NNS O
using P11732417A0571 VBG O
the P11732417A0571 DT O
indirect P11732417A0571 JJ O
ELISA P11732417A0571 NNP O
kit P11732417A0571 NN O
. P11732417A0571 . O
. . O O

In P08025074A0000 IN O
an P08025074A0000 DT O
in P08025074A0000 IN O
vitro P08025074A0000 NN O
study P08025074A0000 NN O
, P08025074A0000 , O
10 P08025074A0000 CD O
/ P08025074A0000 NN O
0 P08025074A0000 CD O
nylon P08025074A0000 NN O
was P08025074A0000 VBD O
found P08025074A0000 VBN O
to P08025074A0000 TO O
require P08025074A0000 VB O
a P08025074A0000 DT O
significantly P08025074A0000 RB O
lower P08025074A0000 JJR O
laser P08025074A0000 NN O
energy P08025074A0000 NN O
density P08025074A0000 NN O
to P08025074A0000 TO O
produce P08025074A0000 VB O
suture P08025074A0000 JJ O
lysis P08025074A0000 NN O
following P08025074A0000 VBG O
a P08025074A0000 DT O
single P08025074A0000 JJ O
shot P08025074A0000 NN O
than P08025074A0000 IN O
either P08025074A0000 DT O
10 P08025074A0000 CD O
/ P08025074A0000 VBD O
0 P08025074A0000 CD O
Dacron P08025074A0000 NNP O
or P08025074A0000 CC O
10 P08025074A0000 CD O
/ P08025074A0000 JJ O
0 P08025074A0000 CD O
prolene P08025074A0000 NN O
. P08025074A0000 . O
. . O O

In P03608916A0790 IN O
cases P03608916A0790 NNS O
of P03608916A0790 IN O
1 P03608916A0790 CD O
degrees P03608916A0790 NNS O
HPT P03608916A0790 NNP O
, P03608916A0790 , O
the P03608916A0790 DT O
plasma P03608916A0790 JJ O
1,25- P03608916A0790 JJ O
( P03608916A0790 ( O
OH P03608916A0790 NNP O
) P03608916A0790 ) O
2D P03608916A0790 CD O
level P03608916A0790 NN O
rose P03608916A0790 VBD O
significantly P03608916A0790 RB O
in P03608916A0790 IN O
all P03608916A0790 DT O
cases P03608916A0790 NNS O
( P03608916A0790 ( O
P P03608916A0790 NNP O
less P03608916A0790 JJR O
than P03608916A0790 IN O
0.05 P03608916A0790 CD O
) P03608916A0790 ) O
, P03608916A0790 , O
although P03608916A0790 IN O
the P03608916A0790 DT O
pattern P03608916A0790 NN O
of P03608916A0790 IN O
the P03608916A0790 DT O
increase P03608916A0790 NN O
was P03608916A0790 VBD O
not P03608916A0790 RB O
uniform P03608916A0790 JJ O
. P03608916A0790 . O
. . O O

Furthermore P01618027A1108 RB O
, P01618027A1108 , O
no P01618027A1108 DT O
transcripts P01618027A1108 NNS O
of P01618027A1108 IN O
the P01618027A1108 DT O
same P01618027A1108 JJ O
size P01618027A1108 NN O
and P01618027A1108 CC O
having P01618027A1108 VBG O
the P01618027A1108 DT O
same P01618027A1108 JJ O
developmental P01618027A1108 JJ O
profile P01618027A1108 NN O
as P01618027A1108 IN O
those P01618027A1108 DT O
generated P01618027A1108 VBN O
by P01618027A1108 IN O
the P01618027A1108 DT O
wild-type P01618027A1108 JJ I-UN
E10 P01618027A1108 NNP I-UN
fragment P01618027A1108 NN I-UN
were P01618027A1108 VBD O
identified P01618027A1108 VBN O
by P01618027A1108 IN O
probes P01618027A1108 NNS O
covering P01618027A1108 VBG O
the P01618027A1108 DT O
remainder P01618027A1108 NN O
of P01618027A1108 IN O
the P01618027A1108 DT O
cloned P01618027A1108 JJ O
region P01618027A1108 NN O
. P01618027A1108 . O
. . O O

Lung P10392710A1000 NNP O
mesenchyme P10392710A1000 NN O
serves P10392710A1000 VBZ O
as P10392710A1000 IN O
a P10392710A1000 DT O
'compleat P10392710A1000 NN O
' P10392710A1000 POS O
inducer P10392710A1000 NN O
of P10392710A1000 IN O
lung P10392710A1000 NN O
morphogenesis P10392710A1000 NN O
by P10392710A1000 IN O
secreting P10392710A1000 VBG O
soluble P10392710A1000 JJ O
peptide P10392710A1000 JJ O
growth P10392710A1000 NN O
factors P10392710A1000 NNS O
. P10392710A1000 . O
. . O O

On P10065684A0916 IN O
the P10065684A0916 DT O
other P10065684A0916 JJ O
hand P10065684A0916 NN O
, P10065684A0916 , O
subjects P10065684A0916 NNS O
with P10065684A0916 IN O
air P10065684A0916 NN O
trapping P10065684A0916 VBG O
( P10065684A0916 ( O
residual P10065684A0916 JJ O
volume P10065684A0916 NN O
( P10065684A0916 ( O
RV P10065684A0916 NNP O
) P10065684A0916 ) O
/ P10065684A0916 VBP O
total P10065684A0916 JJ O
lung P10065684A0916 NN O
capacity P10065684A0916 NN O
( P10065684A0916 ( O
TLC P10065684A0916 NNP O
) P10065684A0916 ) O
> P10065684A0916 VBD O
37 P10065684A0916 CD O
% P10065684A0916 NN O
) P10065684A0916 ) O
disclosed P10065684A0916 VBD O
not P10065684A0916 RB O
only P10065684A0916 RB O
a P10065684A0916 DT O
higher P10065684A0916 JJR O
n P10065684A0916 NN O
( P10065684A0916 ( O
mit P10065684A0916 NN O
) P10065684A0916 ) O
( P10065684A0916 ( O
0.63+ P10065684A0916 CD O
/ P10065684A0916 NNP O
-0.17 P10065684A0916 NNP O
versus P10065684A0916 VBD O
0.43+ P10065684A0916 CD O
/ P10065684A0916 NNP O
-0.07 P10065684A0916 NNP O
mt P10065684A0916 NN O
x P10065684A0916 NN O
microm P10065684A0916 NN O
( P10065684A0916 ( O
-2 P10065684A0916 NNP O
) P10065684A0916 ) O
, P10065684A0916 , O
p P10065684A0916 JJ O
< P10065684A0916 NNP O
0.05 P10065684A0916 CD O
) P10065684A0916 ) O
but P10065684A0916 CC O
shorter P10065684A0916 JJR O
sarcomeres P10065684A0916 NNS O
( P10065684A0916 ( O
L P10065684A0916 NNP O
( P10065684A0916 ( O
sar P10065684A0916 NN O
) P10065684A0916 ) O
) P10065684A0916 ) O
than P10065684A0916 IN O
subjects P10065684A0916 NNS O
without P10065684A0916 IN O
this P10065684A0916 DT O
functional P10065684A0916 JJ O
abnormality P10065684A0916 NN O
( P10065684A0916 ( O
2.08+ P10065684A0916 CD O
/ P10065684A0916 RB O
-0.16 P10065684A0916 NN O
to P10065684A0916 TO O
2.27+ P10065684A0916 CD O
/ P10065684A0916 NNS O
-0.15 P10065684A0916 JJ O
microm P10065684A0916 NN O
, P10065684A0916 , O
p P10065684A0916 NN O
< P10065684A0916 NNP O
0.05 P10065684A0916 CD O
) P10065684A0916 ) O
. P10065684A0916 . O
. . O O

Methyl P04718233T0000 NNP O
mercury P04718233T0000 NN O
intoxication P04718233T0000 NN O
in P04718233T0000 IN O
rat P04718233T0000 NN O
kidneys P04718233T0000 NNS O
. P04718233T0000 . O
. . O O

Pretreatment P11108720A1130 NN O
of P11108720A1130 IN O
cells P11108720A1130 NNS O
with P11108720A1130 IN O
the P11108720A1130 DT O
mitogen-activated P11108720A1130 JJ I-UN
protein-extracellular P11108720A1130 JJ I-UN
signal-regulated P11108720A1130 JJ I-UN
kinase P11108720A1130 NN I-UN
kinase P11108720A1130 NN I-UN
( P11108720A1130 ( O
MEK P11108720A1130 NNP I-UN
) P11108720A1130 ) O
inhibitor P11108720A1130 NN O
U0126 P11108720A1130 NNP O
inhibited P11108720A1130 VBD O
S6K2 P11108720A1130 NNP I-UN
activation P11108720A1130 NN O
to P11108720A1130 TO O
a P11108720A1130 DT O
greater P11108720A1130 JJR O
extent P11108720A1130 NN O
than P11108720A1130 IN O
S6K1 P11108720A1130 NNP I-UN
. P11108720A1130 . O
. . O O

Delayed P03180595A1040 VBN O
gallbladder P03180595A1040 NN O
visualization P03180595A1040 NN O
and P03180595A1040 CC O
reduction P03180595A1040 NN O
in P03180595A1040 IN O
ejection P03180595A1040 NN O
fraction P03180595A1040 NN O
were P03180595A1040 VBD O
sensitive P03180595A1040 JJ O
but P03180595A1040 CC O
nonspecific P03180595A1040 JJ O
indicators P03180595A1040 NNS O
of P03180595A1040 IN O
biliary P03180595A1040 JJ O
disease P03180595A1040 NN O
. P03180595A1040 . O
. . O O

The P09153010A0499 DT O
main P09153010A0499 JJ O
advantages P09153010A0499 NNS O
of P09153010A0499 IN O
Multi-MUP P09153010A0499 NNP O
analysis P09153010A0499 NN O
are P09153010A0499 VBP O
: P09153010A0499 : O
( P09153010A0499 ( O
1 P09153010A0499 CD O
) P09153010A0499 ) O
quick P09153010A0499 JJ O
acquisition P09153010A0499 NN O
of P09153010A0499 IN O
many P09153010A0499 JJ O
MUPs P09153010A0499 NNP O
; P09153010A0499 : O
( P09153010A0499 ( O
2 P09153010A0499 CD O
) P09153010A0499 ) O
simultaneous P09153010A0499 JJ O
collection P09153010A0499 NN O
of P09153010A0499 IN O
several P09153010A0499 JJ O
MUPs P09153010A0499 NNP O
at P09153010A0499 IN O
one P09153010A0499 CD O
recording P09153010A0499 VBG O
site P09153010A0499 NN O
; P09153010A0499 : O
( P09153010A0499 ( O
3 P09153010A0499 CD O
) P09153010A0499 ) O
possibility P09153010A0499 NN O
to P09153010A0499 TO O
analyze P09153010A0499 VB O
not P09153010A0499 RB O
only P09153010A0499 RB O
low P09153010A0499 JJ O
threshold P09153010A0499 JJ O
MUPs P09153010A0499 NNP O
; P09153010A0499 : O
( P09153010A0499 ( O
4 P09153010A0499 CD O
) P09153010A0499 ) O
less P09153010A0499 JJR O
bias P09153010A0499 NN O
in P09153010A0499 IN O
the P09153010A0499 DT O
selection P09153010A0499 NN O
of P09153010A0499 IN O
MUPs P09153010A0499 NNP O
and P09153010A0499 CC O
( P09153010A0499 ( O
5 P09153010A0499 CD O
) P09153010A0499 ) O
the P09153010A0499 DT O
reproducibility P09153010A0499 NN O
of P09153010A0499 IN O
the P09153010A0499 DT O
results P09153010A0499 NNS O
that P09153010A0499 WDT O
allow P09153010A0499 VBP O
the P09153010A0499 DT O
same P09153010A0499 JJ O
reference P09153010A0499 NN O
values P09153010A0499 NNS O
to P09153010A0499 TO O
be P09153010A0499 VB O
used P09153010A0499 VBN O
in P09153010A0499 IN O
different P09153010A0499 JJ O
laboratories P09153010A0499 NNS O
. P09153010A0499 . O
. . O O

The P03428084A0430 DT O
4 P03428084A0430 CD O
degrees P03428084A0430 NNS O
stimuli P03428084A0430 NNS O
were P03428084A0430 VBD O
found P03428084A0430 VBN O
to P03428084A0430 TO O
elicit P03428084A0430 VB O
scalp P03428084A0430 JJ O
distributions P03428084A0430 NNS O
for P03428084A0430 IN O
the P03428084A0430 DT O
pattern P03428084A0430 NN O
reversal P03428084A0430 NN O
P100 P03428084A0430 NNP O
and P03428084A0430 CC O
the P03428084A0430 DT O
pattern P03428084A0430 NN O
onset P03428084A0430 VBN O
C1 P03428084A0430 NNP O
consistent P03428084A0430 JJ O
with P03428084A0430 IN O
striate P03428084A0430 NN O
and P03428084A0430 CC O
extrastriate P03428084A0430 VB O
visual P03428084A0430 JJ O
cortical P03428084A0430 JJ O
origins P03428084A0430 NNS O
respectively P03428084A0430 RB O
. P03428084A0430 . O
. . O O

The P07179412A1131 DT O
average P07179412A1131 JJ O
annual P07179412A1131 JJ O
cost P07179412A1131 NN O
per P07179412A1131 IN O
head P07179412A1131 NN O
of P07179412A1131 IN O
population P07179412A1131 NN O
was P07179412A1131 VBD O
US+0 P07179412A1131 NNP O
X P07179412A1131 NNP O
46 P07179412A1131 CD O
. P07179412A1131 . O
. . O O

Another P11044105A0616 DT O
cis-acting P11044105A0616 JJ O
element P11044105A0616 NN O
, P11044105A0616 , O
exonic P11044105A0616 JJ O
splicing P11044105A0616 NN O
suppressor P11044105A0616 NN O
1 P11044105A0616 CD O
( P11044105A0616 ( O
ESS1 P11044105A0616 NNP O
) P11044105A0616 ) O
, P11044105A0616 , O
represses P11044105A0616 VBZ O
use P11044105A0616 NN O
of P11044105A0616 IN O
the P11044105A0616 DT O
nt P11044105A0616 JJ O
3225 P11044105A0616 CD O
3 P11044105A0616 CD O
' P11044105A0616 POS O
splice P11044105A0616 NN O
site P11044105A0616 NN O
. P11044105A0616 . O
. . O O

The P03031602A1001 DT O
second P03031602A1001 JJ O
group P03031602A1001 NN O
of P03031602A1001 IN O
homologous P03031602A1001 JJ O
elements P03031602A1001 NNS O
is P03031602A1001 VBZ O
present P03031602A1001 JJ O
in P03031602A1001 IN O
the P03031602A1001 DT O
upstream P03031602A1001 JJ O
region P03031602A1001 NN O
of P03031602A1001 IN O
both P03031602A1001 DT O
genes P03031602A1001 NNS O
. P03031602A1001 . O
. . O O

In P11258906A0743 IN O
DNA P11258906A0743 NNP O
strand P11258906A0743 VBP O
exchange P11258906A0743 NN O
reactions P11258906A0743 NNS O
using P11258906A0743 VBG O
oligonucleotides P11258906A0743 NNS O
, P11258906A0743 , O
we P11258906A0743 PRP O
found P11258906A0743 VBD O
that P11258906A0743 IN O
Rec2 P11258906A0743 NNP I-UN
exhibited P11258906A0743 VBD O
a P11258906A0743 DT O
pairing P11258906A0743 NN O
bias P11258906A0743 NN O
that P11258906A0743 WDT O
is P11258906A0743 VBZ O
opposite P11258906A0743 JJ O
that P11258906A0743 IN O
of P11258906A0743 IN O
RecA P11258906A0743 NNP I-UN
. P11258906A0743 . O
. . O O

We P09291098A0452 PRP O
established P09291098A0452 VBD O
that P09291098A0452 IN O
the P09291098A0452 DT O
2.6 P09291098A0452 CD O
kb P09291098A0452 NN O
mRNA P09291098A0452 RBS O
V-1 P09291098A0452 NNP O
and P09291098A0452 CC O
the P09291098A0452 DT O
2.3 P09291098A0452 CD O
kb P09291098A0452 NN O
GGT P09291098A0452 NNP I-UN
mRNA P09291098A0452 VBZ O
V-2 P09291098A0452 NNP O
derive P09291098A0452 NN O
, P09291098A0452 , O
by P09291098A0452 IN O
alternate P09291098A0452 NN O
splicing P09291098A0452 NN O
, P09291098A0452 , O
from P09291098A0452 IN O
a P09291098A0452 DT O
primary P09291098A0452 JJ O
transcript P09291098A0452 NN O
initiated P09291098A0452 VBN O
on P09291098A0452 IN O
a P09291098A0452 DT O
distal P09291098A0452 JJ O
promoter P09291098A0452 NN O
on P09291098A0452 IN O
the P09291098A0452 DT O
rat P09291098A0452 NN I-UN
GGT P09291098A0452 NNP I-UN
gene P09291098A0452 NN I-UN
. P09291098A0452 . O
. . O O

Here P10556046A0328 RB O
, P10556046A0328 , O
we P10556046A0328 PRP O
propose P10556046A0328 VBP O
that P10556046A0328 IN O
an P10556046A0328 DT O
antagonistic P10556046A0328 JJ O
, P10556046A0328 , O
BMP P10556046A0328 NNP I-UN
/ P10556046A0328 NNP O
ALK2 P10556046A0328 NNP I-UN
/ P10556046A0328 NNP O
Smad-mediated P10556046A0328 NNP O
signaling P10556046A0328 VBG O
pathway P10556046A0328 NN O
is P10556046A0328 VBZ O
active P10556046A0328 JJ O
on P10556046A0328 IN O
the P10556046A0328 DT O
right P10556046A0328 JJ O
side P10556046A0328 NN O
of P10556046A0328 IN O
the P10556046A0328 DT O
Xenopus P10556046A0328 NNP O
embryo P10556046A0328 NN O
. P10556046A0328 . O
. . O O

Four P02675492A0806 CD O
out P02675492A0806 IN O
of P02675492A0806 IN O
10 P02675492A0806 CD O
patients P02675492A0806 NNS O
showed P02675492A0806 VBD O
clinical P02675492A0806 JJ O
improvement P02675492A0806 NN O
according P02675492A0806 VBG O
to P02675492A0806 TO O
Ritchie-Index P02675492A0806 NNP O
, P02675492A0806 , O
pain P02675492A0806 NN O
score P02675492A0806 NN O
, P02675492A0806 , O
ESR P02675492A0806 NNP O
and P02675492A0806 CC O
CRP P02675492A0806 NNP I-UN
. P02675492A0806 . O
. . O O

However P10652324A0177 RB O
, P10652324A0177 , O
its P10652324A0177 PRP$ O
participation P10652324A0177 NN O
in P10652324A0177 IN O
collagen P10652324A0177 NN I-UN
binding P10652324A0177 NN O
has P10652324A0177 VBZ O
not P10652324A0177 RB O
been P10652324A0177 VBN O
shown P10652324A0177 VBN O
. P10652324A0177 . O
. . O O

Mutation P09259315A0809 NN O
of P09259315A0809 IN O
Enh4 P09259315A0809 NNP I-UN
, P09259315A0809 , O
an P09259315A0809 DT O
essential P09259315A0809 JJ O
GT-IIC-like P09259315A0809 NNP I-UN
enhanson P09259315A0809 NN I-UN
in P09259315A0809 IN O
the P09259315A0809 DT O
context P09259315A0809 NN O
of P09259315A0809 IN O
the P09259315A0809 DT O
intact P09259315A0809 JJ O
enhancer P09259315A0809 NN O
, P09259315A0809 , O
abolishes P09259315A0809 VBZ O
silencer P09259315A0809 NN O
activity P09259315A0809 NN O
, P09259315A0809 , O
and P09259315A0809 CC O
multimerized P09259315A0809 VBD O
GT-IIC P09259315A0809 NNP I-UN
enhansons P09259315A0809 NNS I-UN
mimic P09259315A0809 VBP O
the P09259315A0809 DT O
intact P09259315A0809 JJ O
CSEn P09259315A0809 NNP I-UN
enhancer P09259315A0809 NN I-UN
/ P09259315A0809 NNP I-UN
silencer P09259315A0809 NN I-UN
activities P09259315A0809 NNS O
in P09259315A0809 IN O
BeWo P09259315A0809 NNP O
and P09259315A0809 CC O
GC P09259315A0809 NNP O
cells P09259315A0809 NNS O
, P09259315A0809 , O
respectively P09259315A0809 RB O
. P09259315A0809 . O
. . O O

The P02456827A0899 DT O
4-AP P02456827A0899 JJ O
( P02456827A0899 ( O
4-20 P02456827A0899 JJ O
mM P02456827A0899 NN O
) P02456827A0899 ) O
effect P02456827A0899 NN O
resulted P02456827A0899 VBD O
in P02456827A0899 IN O
a P02456827A0899 DT O
decrease P02456827A0899 NN O
of P02456827A0899 IN O
the P02456827A0899 DT O
sensory P02456827A0899 JJ O
activity P02456827A0899 NN O
, P02456827A0899 , O
which P02456827A0899 WDT O
was P02456827A0899 VBD O
fully P02456827A0899 RB O
restored P02456827A0899 VBN O
by P02456827A0899 IN O
TEA P02456827A0899 NNP O
or P02456827A0899 CC O
Ba2+ P02456827A0899 NNP O
. P02456827A0899 . O
. . O O

Effect P00473249T0000 NN O
of P00473249T0000 IN O
intraventricular P00473249T0000 JJ O
administration P00473249T0000 NN O
of P00473249T0000 IN O
streptolysin P00473249T0000 JJ I-UN
O P00473249T0000 NNP I-UN
on P00473249T0000 IN O
the P00473249T0000 DT O
electroencephalogram P00473249T0000 NN O
of P00473249T0000 IN O
rabbits P00473249T0000 NNS O
. P00473249T0000 . O
. . O O

Comprising P09186507A0882 VBG O
a P09186507A0882 DT O
126-nucleotide P09186507A0882 JJ O
5 P09186507A0882 CD O
' P09186507A0882 POS O
untranscribed P09186507A0882 JJ O
genomic P09186507A0882 JJ O
sequence P09186507A0882 NN O
and P09186507A0882 CC O
a P09186507A0882 DT O
466-nucleotide P09186507A0882 JJ O
5 P09186507A0882 CD O
' P09186507A0882 POS O
noncoding P09186507A0882 JJ O
cDNA P09186507A0882 NN O
sequence P09186507A0882 NN O
, P09186507A0882 , O
the P09186507A0882 DT O
592-nucleotide P09186507A0882 JJ O
5 P09186507A0882 CD O
' P09186507A0882 POS O
CpG P09186507A0882 NNP O
island P09186507A0882 NN O
lacked P09186507A0882 VBD O
TATA P09186507A0882 NNP O
and P09186507A0882 CC O
CAAT P09186507A0882 NNP O
boxes P09186507A0882 NNS O
but P09186507A0882 CC O
displayed P09186507A0882 VBD O
a P09186507A0882 DT O
high P09186507A0882 JJ O
G+C P09186507A0882 NNP O
content P09186507A0882 NN O
, P09186507A0882 , O
was P09186507A0882 VBD O
enriched P09186507A0882 VBN O
for P09186507A0882 IN O
CpG P09186507A0882 NNP O
dinucleotides P09186507A0882 NNS O
, P09186507A0882 , O
and P09186507A0882 CC O
contained P09186507A0882 VBD O
a P09186507A0882 DT O
potential P09186507A0882 JJ O
Sp1-binding P09186507A0882 NNP I-UN
site P09186507A0882 NN I-UN
, P09186507A0882 , O
i.e. P09186507A0882 FW O
, P09186507A0882 , O
features P09186507A0882 NNS O
compatible P09186507A0882 VBP O
with P09186507A0882 IN O
a P09186507A0882 DT O
housekeeping P09186507A0882 NN O
gene P09186507A0882 NN O
. P09186507A0882 . O
. . O O

This P09396796A1173 DT O
emphasizes P09396796A1173 VBZ O
the P09396796A1173 DT O
conclusion P09396796A1173 NN O
that P09396796A1173 IN O
CDF-1 P09396796A1173 NNP I-UN
is P09396796A1173 VBZ O
not P09396796A1173 RB O
an P09396796A1173 DT O
E2F P09396796A1173 NNP I-UN
family P09396796A1173 NN I-UN
member P09396796A1173 NN I-UN
and P09396796A1173 CC O
points P09396796A1173 NNS O
to P09396796A1173 TO O
profound P09396796A1173 VB O
differences P09396796A1173 NNS O
in P09396796A1173 IN O
the P09396796A1173 DT O
cell P09396796A1173 NN O
cycle P09396796A1173 NN O
regulation P09396796A1173 NN O
of P09396796A1173 IN O
CDF-1 P09396796A1173 NNP I-UN
and P09396796A1173 CC O
E2F P09396796A1173 NNP I-UN
. P09396796A1173 . O
. . O O

These P11433018A0756 DT O
data P11433018A0756 NNS O
suggest P11433018A0756 VBP O
that P11433018A0756 IN O
proper P11433018A0756 JJ O
direct P11433018A0756 JJ O
binding P11433018A0756 NN O
of P11433018A0756 IN O
Nhp2p P11433018A0756 NNP I-UN
to P11433018A0756 TO O
H P11433018A0756 NNP I-UN
/ P11433018A0756 NNP I-UN
ACA P11433018A0756 NNP I-UN
snoRNAs P11433018A0756 NN I-UN
is P11433018A0756 VBZ O
required P11433018A0756 VBN O
for P11433018A0756 IN O
the P11433018A0756 DT O
assembly P11433018A0756 NN O
of P11433018A0756 IN O
H P11433018A0756 NNP I-UN
/ P11433018A0756 NNP I-UN
ACA P11433018A0756 NNP I-UN
snoRNPs P11433018A0756 NN I-UN
and P11433018A0756 CC O
hence P11433018A0756 NN O
for P11433018A0756 IN O
the P11433018A0756 DT O
stability P11433018A0756 NN O
of P11433018A0756 IN O
some P11433018A0756 DT O
of P11433018A0756 IN O
their P11433018A0756 PRP$ O
components P11433018A0756 NNS O
. P11433018A0756 . O
. . O O

The P05823624T0031 DT O
need P05823624T0031 NN O
in P05823624T0031 IN O
the P05823624T0031 DT O
small P05823624T0031 JJ O
hospital P05823624T0031 NN O
. P05823624T0031 . O
. . O O

The P07080496A0097 DT O
differential P07080496A0097 JJ O
investigation P07080496A0097 NN O
of P07080496A0097 IN O
lipoproteins P07080496A0097 NNS O
, P07080496A0097 , O
however P07080496A0097 RB O
, P07080496A0097 , O
showed P07080496A0097 VBD O
that P07080496A0097 IN O
the P07080496A0097 DT O
high-density P07080496A0097 NN I-UN
lipoprotein P07080496A0097 NN I-UN
( P07080496A0097 ( O
HDL P07080496A0097 NNP I-UN
) P07080496A0097 ) O
fractions P07080496A0097 NNS O
are P07080496A0097 VBP O
absolutely P07080496A0097 RB O
or P07080496A0097 CC O
relatively P07080496A0097 RB O
decreased P07080496A0097 JJ O
with P07080496A0097 IN O
respect P07080496A0097 NN O
to P07080496A0097 TO O
low-density P07080496A0097 NN I-UN
lipoproteins P07080496A0097 NNS I-UN
( P07080496A0097 ( O
LDL P07080496A0097 NNP I-UN
) P07080496A0097 ) O
in P07080496A0097 IN O
cerebral P07080496A0097 JJ O
infarcts P07080496A0097 NNS O
and P07080496A0097 CC O
in P07080496A0097 IN O
transient P07080496A0097 JJ O
ischaemic P07080496A0097 JJ O
attacks P07080496A0097 NNS O
. P07080496A0097 . O
. . O O

The P01601181A0842 DT O
60A P01601181A0842 CD I-UN
transcripts P01601181A0842 NNS I-UN
and P01601181A0842 CC O
protein P01601181A0842 NNS O
are P01601181A0842 VBP O
first P01601181A0842 RB O
detected P01601181A0842 VBN O
at P01601181A0842 IN O
the P01601181A0842 DT O
onset P01601181A0842 NN O
of P01601181A0842 IN O
gastrulation P01601181A0842 NN O
, P01601181A0842 , O
primarily P01601181A0842 RB O
in P01601181A0842 IN O
the P01601181A0842 DT O
mesoderm P01601181A0842 NN O
of P01601181A0842 IN O
the P01601181A0842 DT O
extending P01601181A0842 VBG O
germ P01601181A0842 JJ O
band P01601181A0842 NN O
. P01601181A0842 . O
. . O O

They P08406419A0155 PRP O
were P08406419A0155 VBD O
found P08406419A0155 VBN O
to P08406419A0155 TO O
be P08406419A0155 VB O
seropositive P08406419A0155 JJ O
for P08406419A0155 IN O
antibodies P08406419A0155 NNS O
to P08406419A0155 TO O
hepatitis P08406419A0155 VB O
C P08406419A0155 NNP O
virus P08406419A0155 NN O
by P08406419A0155 IN O
second-generation P08406419A0155 NN O
testing P08406419A0155 NN O
( P08406419A0155 ( O
RIBA P08406419A0155 NNP O
2 P08406419A0155 CD O
, P08406419A0155 , O
Ortho P08406419A0155 NNP O
Diagnostic P08406419A0155 NNP O
Systems P08406419A0155 NNPS O
Inc P08406419A0155 NNP O
, P08406419A0155 , O
Westwood P08406419A0155 NNP O
, P08406419A0155 , O
MA P08406419A0155 NNP O
) P08406419A0155 ) O
. P08406419A0155 . O
. . O O

Two P09267431A0000 CD O
soybean P09267431A0000 JJ O
cDNA P09267431A0000 NN O
clones P09267431A0000 NNS O
, P09267431A0000 , O
SPK-3 P09267431A0000 NNP I-UN
and P09267431A0000 CC O
SPK-4 P09267431A0000 NNP I-UN
, P09267431A0000 , O
encoding P09267431A0000 VBG O
putative P09267431A0000 JJ O
protein P09267431A0000 NN O
kinases P09267431A0000 NNS O
were P09267431A0000 VBD O
isolated P09267431A0000 VBN O
and P09267431A0000 CC O
characterized P09267431A0000 VBN O
. P09267431A0000 . O
. . O O

HANYS P10120952T0000 NNP O
criticizes P10120952T0000 VBZ O
laparoscopic P10120952T0000 FW O
gall P10120952T0000 JJ O
bladder P10120952T0000 NN O
guidelines P10120952T0000 NNS O
. P10120952T0000 . O
. . O O

To P08654983A0000 TO O
determine P08654983A0000 VB O
the P08654983A0000 DT O
signal P08654983A0000 JJ I-UN
recognition P08654983A0000 NN I-UN
particle P08654983A0000 NN I-UN
( P08654983A0000 ( O
SRP P08654983A0000 NNP I-UN
) P08654983A0000 ) O
-SRP P08654983A0000 NN O
receptor P08654983A0000 NN I-UN
( P08654983A0000 ( O
Srb P08654983A0000 NNP I-UN
) P08654983A0000 ) O
system P08654983A0000 NN O
in P08654983A0000 IN O
Bacillus P08654983A0000 NN O
subtilis P08654983A0000 NNS O
( P08654983A0000 ( O
Bs P08654983A0000 NNP O
) P08654983A0000 ) O
, P08654983A0000 , O
we P08654983A0000 PRP O
cloned P08654983A0000 VBD O
the P08654983A0000 DT O
Bs P08654983A0000 NNP I-UN
srb P08654983A0000 NN I-UN
gene P08654983A0000 NN I-UN
, P08654983A0000 , O
which P08654983A0000 WDT O
encodes P08654983A0000 VBZ O
a P08654983A0000 DT O
homologue P08654983A0000 NN O
of P08654983A0000 IN O
the P08654983A0000 DT O
mammalian P08654983A0000 JJ I-UN
SRP P08654983A0000 NNP I-UN
receptor P08654983A0000 NN I-UN
alpha-subunit P08654983A0000 JJ I-UN
[ P08654983A0000 NNP O
Oguro P08654983A0000 NNP O
et P08654983A0000 FW O
al. P08654983A0000 NN O
, P08654983A0000 , O
DNA P08654983A0000 NNP O
Res P08654983A0000 NNP O
. P08654983A0000 . O
. . O O

Kinetics P04428981T0000 NNS O
of P04428981T0000 IN O
calcium P04428981T0000 NN O
metabolism P04428981T0000 NN O
. P04428981T0000 . O
. . O O

We P09832099A0000 PRP O
evaluated P09832099A0000 VBD O
regional P09832099A0000 JJ O
right P09832099A0000 NN O
ventricular P09832099A0000 NN O
wall P09832099A0000 NN O
motion P09832099A0000 NN O
during P09832099A0000 IN O
systole P09832099A0000 NN O
in P09832099A0000 IN O
patients P09832099A0000 NNS O
with P09832099A0000 IN O
surgically P09832099A0000 RB O
repaired P09832099A0000 VBN O
tetralogy P09832099A0000 NN O
of P09832099A0000 IN O
Fallot P09832099A0000 NNP O
( P09832099A0000 ( O
TOF P09832099A0000 NNP O
) P09832099A0000 ) O
using P09832099A0000 VBG O
color P09832099A0000 NN O
kinesis P09832099A0000 NN O
imaging P09832099A0000 NN O
. P09832099A0000 . O
. . O O

Molecular P11368911T0000 JJ O
identification P11368911T0000 NN O
of P11368911T0000 IN O
smg-4 P11368911T0000 JJ I-UN
, P11368911T0000 , O
required P11368911T0000 VBN O
for P11368911T0000 IN O
mRNA P11368911T0000 JJ O
surveillance P11368911T0000 NN O
in P11368911T0000 IN O
C. P11368911T0000 NNP O
elegans P11368911T0000 NNS O
. P11368911T0000 . O
. . O O

Transcriptional P08546707T0000 JJ O
activation P08546707T0000 NN O
of P08546707T0000 IN O
the P08546707T0000 DT O
chicken P08546707T0000 NN I-UN
lysozyme P08546707T0000 NN I-UN
gene P08546707T0000 NN I-UN
by P08546707T0000 IN O
NF-kappa P08546707T0000 NNP I-UN
Bp65 P08546707T0000 NNP I-UN
( P08546707T0000 ( O
RelA P08546707T0000 NNP I-UN
) P08546707T0000 ) O
and P08546707T0000 CC O
c-Rel P08546707T0000 JJ I-UN
, P08546707T0000 , O
but P08546707T0000 CC O
not P08546707T0000 RB O
by P08546707T0000 IN O
NF-kappa P08546707T0000 NNP I-UN
Bp50 P08546707T0000 NNP I-UN
. P08546707T0000 . O
. . O O

Clb2 P08649372A0501 NNP I-UN
/ P08649372A0501 NNP O
Cdc28 P08649372A0501 NNP I-UN
kinase P08649372A0501 NN O
is P08649372A0501 VBZ O
not P08649372A0501 RB O
required P08649372A0501 VBN O
for P08649372A0501 IN O
the P08649372A0501 DT O
repression P08649372A0501 NN O
of P08649372A0501 IN O
MCB-binding P08649372A0501 NNP I-UN
factor P08649372A0501 NN I-UN
transcriptional P08649372A0501 JJ O
activity P08649372A0501 NN O
in P08649372A0501 IN O
G2 P08649372A0501 NNP O
and P08649372A0501 CC O
M P08649372A0501 NNP O
phase P08649372A0501 NN O
. P08649372A0501 . O
. . O O

Both P09523551A0367 DT O
variants P09523551A0367 NNS O
display P09523551A0367 VBP O
the P09523551A0367 DT O
seven-transmembrane P09523551A0367 JJ O
topology P09523551A0367 NN O
that P09523551A0367 WDT O
is P09523551A0367 VBZ O
typical P09523551A0367 JJ O
for P09523551A0367 IN O
G P09523551A0367 NNP I-UN
protein-coupled P09523551A0367 JJ I-UN
receptors P09523551A0367 NNS I-UN
. P09523551A0367 . O
. . O O

The P09629449A0540 DT O
results P09629449A0540 NNS O
show P09629449A0540 VBP O
that P09629449A0540 IN O
ROS P09629449A0540 NNP O
production P09629449A0540 NN O
by P09629449A0540 IN O
viable P09629449A0540 JJ O
spermatozoa P09629449A0540 NN O
is P09629449A0540 VBZ O
highly P09629449A0540 RB O
correlated P09629449A0540 VBN O
with P09629449A0540 IN O
the P09629449A0540 DT O
concentration P09629449A0540 NN O
of P09629449A0540 IN O
PMN P09629449A0540 NNP I-UN
elastase P09629449A0540 NN I-UN
and P09629449A0540 CC O
the P09629449A0540 DT O
number P09629449A0540 NN O
of P09629449A0540 IN O
both P09629449A0540 DT O
peroxidase-positive P09629449A0540 JJ O
and P09629449A0540 CC O
round P09629449A0540 JJ O
cells P09629449A0540 NNS O
. P09629449A0540 . O
. . O O

Expense P01532914A0067 NN O
limits P01532914A0067 VBZ O
the P01532914A0067 DT O
use P01532914A0067 NN O
of P01532914A0067 IN O
hepatitis P01532914A0067 NN O
B P01532914A0067 NNP O
vaccines P01532914A0067 NNS O
, P01532914A0067 , O
but P01532914A0067 CC O
low-dose P01532914A0067 JJ O
intradermal P01532914A0067 JJ O
immunization P01532914A0067 NN O
has P01532914A0067 VBZ O
been P01532914A0067 VBN O
evaluated P01532914A0067 VBN O
as P01532914A0067 IN O
a P01532914A0067 DT O
cost-saving P01532914A0067 JJ O
strategy P01532914A0067 NN O
in P01532914A0067 IN O
numerous P01532914A0067 JJ O
studies P01532914A0067 NNS O
. P01532914A0067 . O
. . O O

The P06732946A0281 DT O
measurement P06732946A0281 NN O
of P06732946A0281 IN O
the P06732946A0281 DT O
areas P06732946A0281 NNS O
of P06732946A0281 IN O
fibrin P06732946A0281 NN I-UN
, P06732946A0281 , O
of P06732946A0281 IN O
tissue P06732946A0281 NN O
and P06732946A0281 CC O
fibrinolysis P06732946A0281 NN O
, P06732946A0281 , O
at P06732946A0281 IN O
the P06732946A0281 DT O
above P06732946A0281 NN O
mentioned P06732946A0281 VBD O
times P06732946A0281 NNS O
, P06732946A0281 , O
has P06732946A0281 VBZ O
been P06732946A0281 VBN O
effected P06732946A0281 VBN O
at P06732946A0281 IN O
standard P06732946A0281 JJ O
magnification P06732946A0281 NN O
( P06732946A0281 ( O
15 P06732946A0281 CD O
X P06732946A0281 NN O
) P06732946A0281 ) O
by P06732946A0281 IN O
an P06732946A0281 DT O
image P06732946A0281 NN O
analyser P06732946A0281 NN O
( P06732946A0281 ( O
Videoplan P06732946A0281 NNP O
) P06732946A0281 ) O
scale P06732946A0281 NN O
1:8 P06732946A0281 CD O
. P06732946A0281 . O
. . O O

The P09815948A1065 DT O
pharmacokinetic P09815948A1065 JJ O
parameters P09815948A1065 NNS O
which P09815948A1065 WDT O
helped P09815948A1065 VBD O
predict P09815948A1065 VB O
these P09815948A1065 DT O
toxicities P09815948A1065 NNS O
included P09815948A1065 VBD O
area P09815948A1065 NN O
under P09815948A1065 IN O
the P09815948A1065 DT O
curve P09815948A1065 NN O
and P09815948A1065 CC O
peak P09815948A1065 JJ O
plasma P09815948A1065 NN O
level P09815948A1065 NN O
. P09815948A1065 . O
. . O O

Variations P04546974T0000 NNS O
of P04546974T0000 IN O
the P04546974T0000 DT O
timing P04546974T0000 NN O
of P04546974T0000 IN O
deflections P04546974T0000 NNS O
in P04546974T0000 IN O
the P04546974T0000 DT O
His P04546974T0000 PRP$ O
bundle P04546974T0000 NN O
recordings P04546974T0000 NNS O
. P04546974T0000 . O
. . O O

Measurements P10591976A0317 NNS O
in P10591976A0317 IN O
the P10591976A0317 DT O
LWS P10591976A0317 NNP O
p.a P10591976A0317 NN O
. P10591976A0317 . O
, P10591976A0317 , O
LWS P10591976A0317 NNP O
lat P10591976A0317 NN O
. P10591976A0317 . O
and P10591976A0317 CC O
at P10591976A0317 IN O
Ward P10591976A0317 NNP O
's P10591976A0317 POS O
triangle P10591976A0317 NN O
were P10591976A0317 VBD O
made P10591976A0317 VBN O
in P10591976A0317 IN O
a P10591976A0317 DT O
total P10591976A0317 NN O
of P10591976A0317 IN O
100 P10591976A0317 CD O
patients P10591976A0317 NNS O
. P10591976A0317 . O
. . O O

They P04143528A0394 PRP O
also P04143528A0394 RB O
discuss P04143528A0394 VBP O
the P04143528A0394 DT O
existing P04143528A0394 VBG O
nomenclature P04143528A0394 NN O
. P04143528A0394 . O
. . O O

Interestingly P01316680A0643 RB O
, P01316680A0643 , O
the P01316680A0643 DT O
IR5 P01316680A0643 NNP I-UN
ORF P01316680A0643 NNP I-UN
of P01316680A0643 IN O
EHV-1 P01316680A0643 NNP O
possesses P01316680A0643 VBZ O
a P01316680A0643 DT O
sequence P01316680A0643 NN O
of P01316680A0643 IN O
13 P01316680A0643 CD O
amino P01316680A0643 JJ O
acids P01316680A0643 NNS O
( P01316680A0643 ( O
CAYWCCLGHAFAC P01316680A0643 NNP O
) P01316680A0643 ) O
that P01316680A0643 WDT O
is P01316680A0643 VBZ O
a P01316680A0643 DT O
perfect P01316680A0643 JJ O
match P01316680A0643 NN O
to P01316680A0643 TO O
the P01316680A0643 DT O
consensus P01316680A0643 NN O
zinc P01316680A0643 NN O
finger P01316680A0643 NN O
motif P01316680A0643 NN O
( P01316680A0643 ( O
C-X2-4-C-X2-15-C P01316680A0643 JJ O
/ P01316680A0643 NNP O
H-X2-4-C P01316680A0643 NNP O
/ P01316680A0643 NNP O
H P01316680A0643 NNP O
) P01316680A0643 ) O
. P01316680A0643 . O
. . O O

One P09015543A0210 CD O
possible P09015543A0210 JJ O
solution P09015543A0210 NN O
is P09015543A0210 VBZ O
a P09015543A0210 DT O
thin P09015543A0210 JJ O
radial P09015543A0210 JJ O
forearm P09015543A0210 NN O
free P09015543A0210 JJ O
flap P09015543A0210 NN O
. P09015543A0210 . O
. . O O

Campomelic P10364523T0000 NNP O
dysplasia P10364523T0000 NN O
translocation P10364523T0000 NN O
breakpoints P10364523T0000 NNS O
are P10364523T0000 VBP O
scattered P10364523T0000 VBN O
over P10364523T0000 IN O
1 P10364523T0000 CD O
Mb P10364523T0000 NNP O
proximal P10364523T0000 NN O
to P10364523T0000 TO O
SOX9 P10364523T0000 NNP I-UN
: P10364523T0000 : O
evidence P10364523T0000 NN O
for P10364523T0000 IN O
an P10364523T0000 DT O
extended P10364523T0000 JJ O
control P10364523T0000 NN O
region P10364523T0000 NN O
. P10364523T0000 . O
. . O O

Negative-staining P07571953T0000 NN O
, P07571953T0000 , O
refractile P07571953T0000 JJ O
mycobacteria P07571953T0000 NN O
in P07571953T0000 IN O
Romanowsky-stained P07571953T0000 JJ O
smears P07571953T0000 NNS O
. P07571953T0000 . O
. . O O

In P11379106A0372 IN O
the P11379106A0372 DT O
meantime P11379106A0372 NN O
, P11379106A0372 , O
one P11379106A0372 CD O
has P11379106A0372 VBZ O
succeeded P11379106A0372 VBN O
to P11379106A0372 TO O
establish P11379106A0372 VB O
the P11379106A0372 DT O
deammonification P11379106A0372 NN O
processes P11379106A0372 VBZ O
in P11379106A0372 IN O
a P11379106A0372 DT O
continuous P11379106A0372 JJ O
flow P11379106A0372 JJ O
moving-bed P11379106A0372 JJ O
pilot P11379106A0372 NN O
plant P11379106A0372 NN O
. P11379106A0372 . O
. . O O

Acute P11072388T0000 NNP O
feasibility P11072388T0000 NN O
and P11072388T0000 CC O
safety P11072388T0000 NN O
of P11072388T0000 IN O
a P11072388T0000 DT O
smoking P11072388T0000 NN O
reduction P11072388T0000 NN O
strategy P11072388T0000 NN O
for P11072388T0000 IN O
smokers P11072388T0000 NNS O
with P11072388T0000 IN O
schizophrenia P11072388T0000 NN O
. P11072388T0000 . O
. . O O

Losses P11804510A0730 NNS O
of P11804510A0730 IN O
dichlofluanid P11804510A0730 NN O
( P11804510A0730 ( O
54 P11804510A0730 CD O
% P11804510A0730 NN O
) P11804510A0730 ) O
, P11804510A0730 , O
chlozolinate P11804510A0730 NN O
( P11804510A0730 ( O
22 P11804510A0730 CD O
% P11804510A0730 NN O
) P11804510A0730 ) O
, P11804510A0730 , O
and P11804510A0730 CC O
etridiazole P11804510A0730 NN O
( P11804510A0730 ( O
40 P11804510A0730 CD O
% P11804510A0730 NN O
) P11804510A0730 ) O
, P11804510A0730 , O
previously P11804510A0730 RB O
reported P11804510A0730 VBN O
to P11804510A0730 TO O
occur P11804510A0730 VB O
during P11804510A0730 IN O
ambient P11804510A0730 JJ O
processing P11804510A0730 NN O
of P11804510A0730 IN O
apples P11804510A0730 NNS O
, P11804510A0730 , O
were P11804510A0730 VBD O
reduced P11804510A0730 VBN O
to P11804510A0730 TO O
barely P11804510A0730 RB O
significant P11804510A0730 JJ O
levels P11804510A0730 NNS O
( P11804510A0730 ( O
10 P11804510A0730 CD O
, P11804510A0730 , O
17 P11804510A0730 CD O
, P11804510A0730 , O
and P11804510A0730 CC O
14 P11804510A0730 CD O
% P11804510A0730 NN O
, P11804510A0730 , O
respectively P11804510A0730 RB O
) P11804510A0730 ) O
by P11804510A0730 IN O
cryogenic P11804510A0730 JJ O
processing P11804510A0730 NN O
. P11804510A0730 . O
. . O O

Most P09030781A0734 JJS O
kinases P09030781A0734 NNS O
are P09030781A0734 VBP O
not P09030781A0734 RB O
significantly P09030781A0734 RB O
inhibited P09030781A0734 VBN O
by P09030781A0734 IN O
roscovitine P09030781A0734 NN O
. P09030781A0734 . O
cdc2 P09030781A0734 NN I-UN
/ P09030781A0734 NNP O
cyclin P09030781A0734 NN I-UN
B P09030781A0734 NNP I-UN
, P09030781A0734 , O
cdk2 P09030781A0734 NN I-UN
/ P09030781A0734 NNP O
cyclin P09030781A0734 VBZ I-UN
A P09030781A0734 NNP I-UN
, P09030781A0734 , O
cdk2 P09030781A0734 NN I-UN
/ P09030781A0734 NNP O
cyclin P09030781A0734 NN I-UN
E P09030781A0734 NNP I-UN
and P09030781A0734 CC O
cdk5 P09030781A0734 VB I-UN
/ P09030781A0734 NNP O
p35 P09030781A0734 IN I-UN
only P09030781A0734 RB O
are P09030781A0734 VBP O
substantially P09030781A0734 RB O
inhibited P09030781A0734 VBN O
( P09030781A0734 ( O
IC50 P09030781A0734 NNP O
values P09030781A0734 NNS O
of P09030781A0734 IN O
0.65 P09030781A0734 CD O
, P09030781A0734 , O
0.7 P09030781A0734 CD O
, P09030781A0734 , O
0.7 P09030781A0734 CD O
and P09030781A0734 CC O
0.2 P09030781A0734 CD O
microM P09030781A0734 NN O
, P09030781A0734 , O
respectively P09030781A0734 RB O
) P09030781A0734 ) O
. P09030781A0734 . O
cdk4 P09030781A0734 NN I-UN
/ P09030781A0734 NNP O
cyclin P09030781A0734 NN I-UN
D1 P09030781A0734 NNP I-UN
and P09030781A0734 CC O
cdk6 P09030781A0734 VB I-UN
/ P09030781A0734 NNP O
cyclin P09030781A0734 NN I-UN
D2 P09030781A0734 NNP I-UN
are P09030781A0734 VBP O
very P09030781A0734 RB O
poorly P09030781A0734 RB O
inhibited P09030781A0734 VBN O
by P09030781A0734 IN O
roscovitine P09030781A0734 NN O
( P09030781A0734 ( O
IC50 P09030781A0734 NNP O
> P09030781A0734 VBZ O
100 P09030781A0734 CD O
microM P09030781A0734 NN O
) P09030781A0734 ) O
. P09030781A0734 . O
. . O O

The P09579789A0974 DT O
present P09579789A0974 JJ O
results P09579789A0974 NNS O
demonstrate P09579789A0974 VBP O
that P09579789A0974 IN O
rats P09579789A0974 NNS O
with P09579789A0974 IN O
relatively P09579789A0974 RB O
small P09579789A0974 JJ O
remnants P09579789A0974 NNS O
of P09579789A0974 IN O
one P09579789A0974 CD O
olfactory P09579789A0974 NN O
bulb P09579789A0974 NN O
can P09579789A0974 MD O
perform P09579789A0974 VB O
a P09579789A0974 DT O
variety P09579789A0974 NN O
of P09579789A0974 IN O
odor P09579789A0974 JJ O
detection P09579789A0974 NN O
and P09579789A0974 CC O
discrimination P09579789A0974 NN O
tasks P09579789A0974 NNS O
as P09579789A0974 RB O
well P09579789A0974 RB O
or P09579789A0974 CC O
nearly P09579789A0974 RB O
as P09579789A0974 RB O
well P09579789A0974 RB O
as P09579789A0974 IN O
controls P09579789A0974 NNS O
. P09579789A0974 . O
. . O O

Sample P08014228A0278 NNP O
treatment P08014228A0278 NN O
was P08014228A0278 VBD O
optimized P08014228A0278 VBN O
in P08014228A0278 IN O
order P08014228A0278 NN O
to P08014228A0278 TO O
achieve P08014228A0278 VB O
a P08014228A0278 DT O
complete P08014228A0278 JJ O
extraction P08014228A0278 NN O
of P08014228A0278 IN O
labetalol P08014228A0278 JJ O
diastereoisomers P08014228A0278 NNS O
and P08014228A0278 CC O
to P08014228A0278 TO O
avoid P08014228A0278 VB O
racemization P08014228A0278 NN O
during P08014228A0278 IN O
extraction P08014228A0278 NN O
. P08014228A0278 . O
. . O O

Characterization P11069075T0000 NN O
of P11069075T0000 IN O
a P11069075T0000 DT O
Xenopus P11069075T0000 NNP I-UN
laevis P11069075T0000 NN I-UN
CXC P11069075T0000 NNP I-UN
chemokine P11069075T0000 NN I-UN
receptor P11069075T0000 NN I-UN
4 P11069075T0000 CD I-UN
: P11069075T0000 : O
implications P11069075T0000 NNS O
for P11069075T0000 IN O
hematopoietic P11069075T0000 JJ O
cell P11069075T0000 NN O
development P11069075T0000 NN O
in P11069075T0000 IN O
the P11069075T0000 DT O
vertebrate P11069075T0000 NN O
embryo P11069075T0000 NN O
. P11069075T0000 . O
. . O O

In P08024139A0393 IN O
addition P08024139A0393 NN O
, P08024139A0393 , O
we P08024139A0393 PRP O
sought P08024139A0393 VBD O
to P08024139A0393 TO O
test P08024139A0393 VB O
the P08024139A0393 DT O
hypothesis P08024139A0393 NN O
that P08024139A0393 IN O
, P08024139A0393 , O
when P08024139A0393 WRB O
equal P08024139A0393 JJ O
volumes P08024139A0393 NNS O
are P08024139A0393 VBP O
administered P08024139A0393 VBN O
intrathecally P08024139A0393 RB O
, P08024139A0393 , O
significant P08024139A0393 JJ O
differences P08024139A0393 NNS O
exist P08024139A0393 VBP O
in P08024139A0393 IN O
the P08024139A0393 DT O
potential P08024139A0393 NN O
to P08024139A0393 TO O
three P08024139A0393 CD O
commonly P08024139A0393 RB O
used P08024139A0393 VBN O
anesthetic P08024139A0393 JJ O
solutions P08024139A0393 NNS O
to P08024139A0393 TO O
induce P08024139A0393 VB O
sensory P08024139A0393 JJ O
impairment P08024139A0393 NN O
. P08024139A0393 . O
. . O O

To P09480831A0272 TO O
elucidate P09480831A0272 VB O
the P09480831A0272 DT O
regulatory P09480831A0272 JJ O
mechanism P09480831A0272 NN O
of P09480831A0272 IN O
human P09480831A0272 JJ I-UN
AM P09480831A0272 NNP I-UN
gene P09480831A0272 NN I-UN
expression P09480831A0272 NN O
, P09480831A0272 , O
functional P09480831A0272 JJ O
elements P09480831A0272 NNS O
of P09480831A0272 IN O
5'-flanking P09480831A0272 JJ O
region P09480831A0272 NN O
of P09480831A0272 IN O
AM P09480831A0272 NNP I-UN
gene P09480831A0272 NN I-UN
were P09480831A0272 VBD O
studied P09480831A0272 VBN O
in P09480831A0272 IN O
human P09480831A0272 JJ O
aortic P09480831A0272 JJ O
endothelial P09480831A0272 NN O
cells P09480831A0272 NNS O
( P09480831A0272 ( O
HAEC P09480831A0272 NNP O
) P09480831A0272 ) O
. P09480831A0272 . O
. . O O

4 P09388201A1027 CD O
) P09388201A1027 ) O
PU P09388201A1027 NNP I-UN
and P09388201A1027 CC O
PD P09388201A1027 NNP I-UN
lacked P09388201A1027 VBD O
the P09388201A1027 DT O
canonical P09388201A1027 JJ O
TATA P09388201A1027 NNP O
or P09388201A1027 CC O
CAAT P09388201A1027 NNP O
motifs P09388201A1027 NNS O
, P09388201A1027 , O
and P09388201A1027 CC O
are P09388201A1027 VBP O
AT-rich P09388201A1027 NNP O
. P09388201A1027 . O
. . O O

Examples P03777398A0156 NNS O
of P03777398A0156 IN O
its P03777398A0156 PRP$ O
use P03777398A0156 NN O
in P03777398A0156 IN O
the P03777398A0156 DT O
intensive P03777398A0156 JJ O
therapy P03777398A0156 NN O
unit P03777398A0156 NN O
are P03777398A0156 VBP O
described P03777398A0156 VBN O
. P03777398A0156 . O
. . O O

Interestingly P10908317A1459 RB O
, P10908317A1459 , O
although P10908317A1459 IN O
E P10908317A1459 NNP O
domains P10908317A1459 NNS O
of P10908317A1459 IN O
these P10908317A1459 DT O
two P10908317A1459 CD O
receptors P10908317A1459 NNS O
are P10908317A1459 VBP O
much P10908317A1459 RB O
less P10908317A1459 JJR O
conserved P10908317A1459 JJ O
, P10908317A1459 , O
replacement P10908317A1459 NN O
of P10908317A1459 IN O
this P10908317A1459 DT O
domain P10908317A1459 NN O
in P10908317A1459 IN O
rtER P10908317A1459 NN I-UN
by P10908317A1459 IN O
its P10908317A1459 PRP$ O
human P10908317A1459 JJ O
counterpart P10908317A1459 NN O
resulted P10908317A1459 VBD O
in P10908317A1459 IN O
higher P10908317A1459 JJR O
estradiol P10908317A1459 NN O
sensitivity P10908317A1459 NN O
but P10908317A1459 CC O
no P10908317A1459 DT O
increase P10908317A1459 NN O
in P10908317A1459 IN O
the P10908317A1459 DT O
magnitude P10908317A1459 NN O
of P10908317A1459 IN O
transactivation P10908317A1459 NN O
. P10908317A1459 . O
. . O O

Samples P07105635A0412 NNS O
obtained P07105635A0412 VBN O
from P07105635A0412 IN O
normal P07105635A0412 JJ O
volunteers P07105635A0412 NNS O
and P07105635A0412 CC O
from P07105635A0412 IN O
the P07105635A0412 DT O
great P07105635A0412 JJ O
majority P07105635A0412 NN O
of P07105635A0412 IN O
the P07105635A0412 DT O
patients P07105635A0412 NNS O
, P07105635A0412 , O
excluding P07105635A0412 VBG O
those P07105635A0412 DT O
with P07105635A0412 IN O
asthma P07105635A0412 NN O
, P07105635A0412 , O
had P07105635A0412 VBD O
no P07105635A0412 DT O
effect P07105635A0412 NN O
on P07105635A0412 IN O
ciliary P07105635A0412 JJ O
beating P07105635A0412 NN O
. P07105635A0412 . O
. . O O

Therefore P01661369A0825 RB O
, P01661369A0825 , O
the P01661369A0825 DT O
strD P01661369A0825 NN I-UN
and P01661369A0825 CC O
strE P01661369A0825 NN I-UN
genes P01661369A0825 NNS I-UN
could P01661369A0825 MD O
serve P01661369A0825 VB O
as P01661369A0825 IN O
universal P01661369A0825 JJ O
probes P01661369A0825 NNS O
indicative P01661369A0825 NN O
of P01661369A0825 IN O
the P01661369A0825 DT O
presence P01661369A0825 NN O
of P01661369A0825 IN O
biosynthetic P01661369A0825 JJ O
capacity P01661369A0825 NN O
for P01661369A0825 IN O
6-deoxyhexose P01661369A0825 JJ O
moieties P01661369A0825 NNS O
. P01661369A0825 . O
. . O O

In P07557387A0241 IN O
this P07557387A0241 DT O
study P07557387A0241 NN O
we P07557387A0241 PRP O
have P07557387A0241 VBP O
investigated P07557387A0241 VBN O
the P07557387A0241 DT O
role P07557387A0241 NN O
of P07557387A0241 IN O
C P07557387A0241 NNP I-UN
/ P07557387A0241 NNP I-UN
EBP P07557387A0241 NNP I-UN
beta P07557387A0241 NN I-UN
in P07557387A0241 IN O
initiating P07557387A0241 VBG O
the P07557387A0241 DT O
adipogenic P07557387A0241 JJ O
program P07557387A0241 NN O
by P07557387A0241 IN O
overexpressing P07557387A0241 VBG O
C P07557387A0241 NNP I-UN
/ P07557387A0241 NNP I-UN
EBP P07557387A0241 NNP I-UN
beta P07557387A0241 NN I-UN
in P07557387A0241 IN O
multipotential P07557387A0241 JJ O
NIH-3T3 P07557387A0241 JJ O
fibroblasts P07557387A0241 NNS O
. P07557387A0241 . O
. . O O

Yeast P09630245A0102 NNP I-UN
U1 P09630245A0102 NNP I-UN
snRNP P09630245A0102 NN I-UN
is P09630245A0102 VBZ O
considerably P09630245A0102 RB O
more P09630245A0102 RBR O
complex P09630245A0102 JJ O
than P09630245A0102 IN O
its P09630245A0102 PRP$ O
metazoan P09630245A0102 NN O
counterpart P09630245A0102 NN O
, P09630245A0102 , O
which P09630245A0102 WDT O
suggests P09630245A0102 VBZ O
possible P09630245A0102 JJ O
differences P09630245A0102 NNS O
between P09630245A0102 IN O
yeast P09630245A0102 NN O
and P09630245A0102 CC O
metazoa P09630245A0102 NN O
in P09630245A0102 IN O
early P09630245A0102 JJ O
splicing P09630245A0102 NN O
events P09630245A0102 NNS O
. P09630245A0102 . O
. . O O

The P07808210A1510 DT O
negative P07808210A1510 JJ O
predictive P07808210A1510 JJ O
value P07808210A1510 NN O
is P07808210A1510 VBZ O
92 P07808210A1510 CD O
% P07808210A1510 NN O
, P07808210A1510 , O
vs P07808210A1510 RB O
80 P07808210A1510 CD O
% P07808210A1510 NN O
for P07808210A1510 IN O
the P07808210A1510 DT O
NCEP P07808210A1510 NNP O
I P07808210A1510 PRP O
. P07808210A1510 . O
. . O O

In P09710599A0310 IN O
the P09710599A0310 DT O
former P09710599A0310 JJ O
cells P09710599A0310 NNS O
, P09710599A0310 , O
ets-2 P09710599A0310 NN I-UN
was P09710599A0310 VBD O
a P09710599A0310 DT O
CSF-1 P09710599A0310 JJ I-UN
immediate-early P09710599A0310 JJ O
response P09710599A0310 NN O
gene P09710599A0310 NN O
, P09710599A0310 , O
and P09710599A0310 CC O
phosphorylated P09710599A0310 VBD O
ets-2 P09710599A0310 NN I-UN
was P09710599A0310 VBD O
detected P09710599A0310 VBN O
after P09710599A0310 IN O
2 P09710599A0310 CD O
to P09710599A0310 TO O
4 P09710599A0310 CD O
h P09710599A0310 NN O
, P09710599A0310 , O
coincident P09710599A0310 NN O
with P09710599A0310 IN O
expression P09710599A0310 NN O
of P09710599A0310 IN O
ets-2 P09710599A0310 JJ I-UN
protein P09710599A0310 NN I-UN
. P09710599A0310 . O
. . O O

Recent P03373755T0001 JJ O
developments P03373755T0001 NNS O
in P03373755T0001 IN O
drugs P03373755T0001 NNS O
antagonistic P03373755T0001 JJ O
to P03373755T0001 TO O
factors P03373755T0001 NNS O
causing P03373755T0001 VBG O
peptic P03373755T0001 JJ O
ulcer P03373755T0001 NN O
-- P03373755T0001 : O
clinical P03373755T0001 JJ O
efficacy P03373755T0001 NN O
and P03373755T0001 CC O
problems P03373755T0001 NNS O
; P03373755T0001 : O
gastrin P03373755T0001 VB I-UN
receptor P03373755T0001 NN I-UN
blockaders P03373755T0001 NNS O
. P03373755T0001 . O
. . O O

Interestingly P08100765A0361 RB O
, P08100765A0361 , O
in P08100765A0361 IN O
the P08100765A0361 DT O
adult P08100765A0361 NN O
, P08100765A0361 , O
transgene P08100765A0361 JJ O
expression P08100765A0361 NN O
patterns P08100765A0361 NNS O
within P08100765A0361 IN O
the P08100765A0361 DT O
cerebellum P08100765A0361 NN O
in P08100765A0361 IN O
two P08100765A0361 CD O
lines P08100765A0361 NNS O
appeared P08100765A0361 VBD O
to P08100765A0361 TO O
mark P08100765A0361 VB O
distinct P08100765A0361 JJ O
anterior-posterior P08100765A0361 JJ O
compartments P08100765A0361 NNS O
. P08100765A0361 . O
. . O O

METHODS P11176098A0342 NN O
: P11176098A0342 : O
Sixteen P11176098A0342 JJ O
pigs P11176098A0342 NNS O
were P11176098A0342 VBD O
assigned P11176098A0342 VBN O
randomly P11176098A0342 RB O
to P11176098A0342 TO O
control P11176098A0342 VB O
and P11176098A0342 CC O
shock P11176098A0342 VB O
groups P11176098A0342 NNS O
. P11176098A0342 . O
. . O O

The P08387994A0980 DT O
orf61 P08387994A0980 JJ I-UN
gene P08387994A0980 NN I-UN
product P08387994A0980 NN I-UN
, P08387994A0980 , O
when P08387994A0980 WRB O
expressed P08387994A0980 VBN O
from P08387994A0980 IN O
an P08387994A0980 DT O
exogenous P08387994A0980 JJ O
promoter P08387994A0980 NN O
, P08387994A0980 , O
inhibited P08387994A0980 VBD O
int-mediated P08387994A0980 JJ O
integration P08387994A0980 NN O
at P08387994A0980 IN O
the P08387994A0980 DT O
chromosomal P08387994A0980 JJ I-UN
attB P08387994A0980 NN I-UN
site P08387994A0980 NN I-UN
. P08387994A0980 . O
. . O O

In P06412385A0356 IN O
the P06412385A0356 DT O
37 P06412385A0356 CD O
patients P06412385A0356 NNS O
without P06412385A0356 IN O
lung P06412385A0356 NN O
disease P06412385A0356 NN O
respiratory P06412385A0356 NN O
muscle P06412385A0356 NN O
weakness P06412385A0356 NN O
was P06412385A0356 VBD O
accompanied P06412385A0356 VBN O
by P06412385A0356 IN O
significant P06412385A0356 JJ O
decreases P06412385A0356 NNS O
in P06412385A0356 IN O
vital P06412385A0356 JJ O
capacity P06412385A0356 NN O
, P06412385A0356 , O
total P06412385A0356 JJ O
lung P06412385A0356 NN O
capacity P06412385A0356 NN O
, P06412385A0356 , O
and P06412385A0356 CC O
maximum P06412385A0356 JJ O
voluntary P06412385A0356 JJ O
ventilation P06412385A0356 NN O
; P06412385A0356 : O
by P06412385A0356 IN O
significant P06412385A0356 JJ O
increases P06412385A0356 NNS O
in P06412385A0356 IN O
residual P06412385A0356 JJ O
volume P06412385A0356 NN O
and P06412385A0356 CC O
arterial P06412385A0356 JJ O
carbon P06412385A0356 NN O
dioxide P06412385A0356 NN O
tension P06412385A0356 NN O
( P06412385A0356 ( O
PaCO2 P06412385A0356 NNP O
) P06412385A0356 ) O
; P06412385A0356 : O
and P06412385A0356 CC O
greater P06412385A0356 JJR O
likelihood P06412385A0356 NN O
of P06412385A0356 IN O
dependence P06412385A0356 NN O
on P06412385A0356 IN O
ventilators P06412385A0356 NNS O
, P06412385A0356 , O
atelectasis P06412385A0356 NN O
, P06412385A0356 , O
and P06412385A0356 CC O
pneumonia P06412385A0356 NN O
. P06412385A0356 . O
. . O O

These P08931991A1026 DT O
data P08931991A1026 NNS O
provide P08931991A1026 VBP O
strong P08931991A1026 JJ O
evidence P08931991A1026 NN O
that P08931991A1026 IN O
E2F P08931991A1026 NNP I-UN
or P08931991A1026 CC O
an P08931991A1026 DT O
E2F-related P08931991A1026 JJ I-UN
transcription P08931991A1026 NN I-UN
factor P08931991A1026 NN I-UN
is P08931991A1026 VBZ O
involved P08931991A1026 VBN O
in P08931991A1026 IN O
the P08931991A1026 DT O
regulation P08931991A1026 NN O
of P08931991A1026 IN O
nonmuscle P08931991A1026 NN I-UN
myosin P08931991A1026 NN I-UN
expression P08931991A1026 NN O
. P08931991A1026 . O
. . O O

The P10852460A0170 DT O
relationships P10852460A0170 NNS O
among P10852460A0170 IN O
blood P10852460A0170 NN O
concentrations P10852460A0170 NNS O
of P10852460A0170 IN O
thyroid P10852460A0170 JJ O
hormones P10852460A0170 NNS O
and P10852460A0170 CC O
selenium P10852460A0170 NN O
, P10852460A0170 , O
zinc P10852460A0170 NN O
, P10852460A0170 , O
retinol P10852460A0170 NN O
, P10852460A0170 , O
and P10852460A0170 CC O
alpha-tocopherol P10852460A0170 NN O
were P10852460A0170 VBD O
studied P10852460A0170 VBN O
in P10852460A0170 IN O
44 P10852460A0170 CD O
healthy P10852460A0170 JJ O
Northern P10852460A0170 NNP O
Italian P10852460A0170 NNP O
oldest-old P10852460A0170 JJ O
subjects P10852460A0170 NNS O
( P10852460A0170 ( O
age P10852460A0170 NN O
range P10852460A0170 NN O
, P10852460A0170 , O
90-107 P10852460A0170 CD O
yr P10852460A0170 NN O
) P10852460A0170 ) O
, P10852460A0170 , O
selected P10852460A0170 VBN O
by P10852460A0170 IN O
the P10852460A0170 DT O
criteria P10852460A0170 NNS O
of P10852460A0170 IN O
the P10852460A0170 DT O
SENIEUR P10852460A0170 NNP O
protocol P10852460A0170 NN O
. P10852460A0170 . O
. . O O

Implications P07418829A0191 NNS O
of P07418829A0191 IN O
this P07418829A0191 DT O
observation P07418829A0191 NN O
for P07418829A0191 IN O
pediatrics P07418829A0191 NNS O
are P07418829A0191 VBP O
discussed P07418829A0191 VBN O
. P07418829A0191 . O
. . O O

Characterization P01982061T0000 NN O
of P01982061T0000 IN O
the P01982061T0000 DT O
5 P01982061T0000 CD O
' P01982061T0000 POS O
end P01982061T0000 NN O
of P01982061T0000 IN O
the P01982061T0000 DT O
growth-regulated P01982061T0000 JJ O
Syrian P01982061T0000 JJ I-UN
hamster P01982061T0000 NN I-UN
CAD P01982061T0000 NNP I-UN
gene P01982061T0000 NN I-UN
. P01982061T0000 . O
. . O O

G P08278480T0002 NNP O
. P08278480T0002 . O
. . O O

We P10206152A1024 PRP O
found P10206152A1024 VBD O
that P10206152A1024 IN O
the P10206152A1024 DT O
expression P10206152A1024 NN O
of P10206152A1024 IN O
the P10206152A1024 DT O
protein P10206152A1024 NN O
was P10206152A1024 VBD O
maximum P10206152A1024 JJ O
in P10206152A1024 IN O
mitosis P10206152A1024 NN O
and P10206152A1024 CC O
minimum P10206152A1024 NN O
in P10206152A1024 IN O
G1 P10206152A1024 NNP O
, P10206152A1024 , O
which P10206152A1024 WDT O
correlated P10206152A1024 VBD O
with P10206152A1024 IN O
the P10206152A1024 DT O
expression P10206152A1024 NN O
of P10206152A1024 IN O
its P10206152A1024 PRP$ O
messenger P10206152A1024 NN O
RNA P10206152A1024 NNP O
. P10206152A1024 . O
. . O O

Interestingly P01348508A0313 RB O
, P01348508A0313 , O
the P01348508A0313 DT O
positions P01348508A0313 NNS O
of P01348508A0313 IN O
these P01348508A0313 DT O
introns P01348508A0313 NNS O
have P01348508A0313 VBP O
been P01348508A0313 VBN O
conserved P01348508A0313 VBN O
in P01348508A0313 IN O
comparison P01348508A0313 NN O
with P01348508A0313 IN O
the P01348508A0313 DT O
genes P01348508A0313 NNS O
of P01348508A0313 IN O
two P01348508A0313 CD O
other P01348508A0313 JJ O
transglutaminase-like P01348508A0313 JJ O
activities P01348508A0313 NNS O
described P01348508A0313 VBN O
in P01348508A0313 IN O
the P01348508A0313 DT O
literature P01348508A0313 NN O
, P01348508A0313 , O
but P01348508A0313 CC O
the P01348508A0313 DT O
TGM1 P01348508A0313 NNP I-UN
gene P01348508A0313 NN I-UN
is P01348508A0313 VBZ O
by P01348508A0313 IN O
far P01348508A0313 RB O
the P01348508A0313 DT O
smallest P01348508A0313 JJS O
characterized P01348508A0313 VBN O
to P01348508A0313 TO O
date P01348508A0313 NN O
because P01348508A0313 IN O
its P01348508A0313 PRP$ O
introns P01348508A0313 NNS O
are P01348508A0313 VBP O
relatively P01348508A0313 RB O
smaller P01348508A0313 JJR O
. P01348508A0313 . O
. . O O

The P02372712A0002 DT O
effects P02372712A0002 NNS O
of P02372712A0002 IN O
tap P02372712A0002 NN O
( P02372712A0002 ( O
TW P02372712A0002 NNP O
) P02372712A0002 ) O
or P02372712A0002 CC O
carbonated P02372712A0002 VBN O
( P02372712A0002 ( O
CW P02372712A0002 NNP O
) P02372712A0002 ) O
water P02372712A0002 NN O
on P02372712A0002 IN O
arterial P02372712A0002 JJ O
pH P02372712A0002 NN O
, P02372712A0002 , O
partial P02372712A0002 JJ O
pressure P02372712A0002 NN O
of P02372712A0002 IN O
carbon P02372712A0002 NN O
dioxide P02372712A0002 NN O
( P02372712A0002 ( O
PCO2 P02372712A0002 NNP O
) P02372712A0002 ) O
and P02372712A0002 CC O
plasma P02372712A0002 JJ O
lactate P02372712A0002 NN O
were P02372712A0002 VBD O
determined P02372712A0002 VBN O
in P02372712A0002 IN O
heat-stressed P02372712A0002 JJ O
broilers P02372712A0002 NNS O
. P02372712A0002 . O
. . O O

A P02607766A0000 DT O
protocol P02607766A0000 NN O
is P02607766A0000 VBZ O
elaborated P02607766A0000 VBN O
for P02607766A0000 IN O
the P02607766A0000 DT O
preparation P02607766A0000 NN O
and P02607766A0000 CC O
characterization P02607766A0000 NN O
of P02607766A0000 IN O
a P02607766A0000 DT O
quality P02607766A0000 NN O
control P02607766A0000 NN O
material P02607766A0000 NN O
( P02607766A0000 ( O
QCM P02607766A0000 NNP O
) P02607766A0000 ) O
containing P02607766A0000 VBG O
intrinsic P02607766A0000 JJ O
concentration P02607766A0000 NN O
of P02607766A0000 IN O
cadmium P02607766A0000 NN O
( P02607766A0000 ( O
Cd P02607766A0000 NNP O
) P02607766A0000 ) O
( P02607766A0000 ( O
0.8 P02607766A0000 CD O
microgram P02607766A0000 NN O
/ P02607766A0000 NNP O
L P02607766A0000 NNP O
) P02607766A0000 ) O
and P02607766A0000 CC O
lead P02607766A0000 JJ O
( P02607766A0000 ( O
Pb P02607766A0000 NNP O
) P02607766A0000 ) O
( P02607766A0000 ( O
13.4 P02607766A0000 CD O
micrograms P02607766A0000 NNS O
/ P02607766A0000 NNP O
dL P02607766A0000 NN O
) P02607766A0000 ) O
from P02607766A0000 IN O
bovine P02607766A0000 NN O
blood P02607766A0000 NN O
and P02607766A0000 CC O
an P02607766A0000 DT O
elevated P02607766A0000 JJ O
QCM P02607766A0000 NNP O
containing P02607766A0000 VBG O
Cd P02607766A0000 NNP O
( P02607766A0000 ( O
5.0 P02607766A0000 CD O
micrograms P02607766A0000 NNS O
/ P02607766A0000 NNP O
L P02607766A0000 NNP O
) P02607766A0000 ) O
, P02607766A0000 , O
mercury P02607766A0000 NN O
( P02607766A0000 ( O
Hg P02607766A0000 NNP O
) P02607766A0000 ) O
( P02607766A0000 ( O
11.2 P02607766A0000 CD O
micrograms P02607766A0000 NNS O
/ P02607766A0000 NNP O
L P02607766A0000 NNP O
) P02607766A0000 ) O
, P02607766A0000 , O
and P02607766A0000 CC O
Pb P02607766A0000 NNP O
( P02607766A0000 ( O
34.5 P02607766A0000 CD O
micrograms P02607766A0000 NNS O
/ P02607766A0000 NNP O
dL P02607766A0000 NN O
) P02607766A0000 ) O
from P02607766A0000 IN O
bovine P02607766A0000 NN O
blood P02607766A0000 NN O
spiked P02607766A0000 VBN O
with P02607766A0000 IN O
aqueous P02607766A0000 JJ O
spiking-solutions P02607766A0000 NNS O
prepared P02607766A0000 VBN O
with P02607766A0000 IN O
salts P02607766A0000 NNS O
of P02607766A0000 IN O
Cd P02607766A0000 NNP O
, P02607766A0000 , O
Hg P02607766A0000 NNP O
, P02607766A0000 , O
and P02607766A0000 CC O
Pb P02607766A0000 NNP O
. P02607766A0000 . O
. . O O

PFK-A P11137296A1216 JJ I-UN
mRNA P11137296A1216 NN O
was P11137296A1216 VBD O
more P11137296A1216 RBR O
abundantly P11137296A1216 RB O
expressed P11137296A1216 VBN O
in P11137296A1216 IN O
all P11137296A1216 DT O
tissues P11137296A1216 NNS O
than P11137296A1216 IN O
were P11137296A1216 VBD O
the P11137296A1216 DT O
PFK-B P11137296A1216 JJ I-UN
and P11137296A1216 CC O
PFK-C P11137296A1216 JJ I-UN
genes P11137296A1216 NNS I-UN
. P11137296A1216 . O
. . O O

Two P10669594A0000 CD O
distinct P10669594A0000 JJ O
Salmonella P10669594A0000 NNP I-UN
fimbrins P10669594A0000 NNS I-UN
, P10669594A0000 , O
AgfA P10669594A0000 NNP I-UN
and P10669594A0000 CC O
SefA P10669594A0000 NNP I-UN
, P10669594A0000 , O
comprising P10669594A0000 VBG O
thin P10669594A0000 JJ O
aggregative P10669594A0000 JJ O
fimbriae P10669594A0000 NN O
SEF17 P10669594A0000 NNP I-UN
and P10669594A0000 CC O
SEF14 P10669594A0000 NNP I-UN
, P10669594A0000 , O
respectively P10669594A0000 RB O
, P10669594A0000 , O
were P10669594A0000 VBD O
each P10669594A0000 DT O
genetically P10669594A0000 RB O
engineered P10669594A0000 VBN O
to P10669594A0000 TO O
carry P10669594A0000 VB O
PT3 P10669594A0000 NNP I-UN
, P10669594A0000 , O
an P10669594A0000 DT O
alpha-helical P10669594A0000 JJ O
16-amino P10669594A0000 JJ O
acid P10669594A0000 NN O
Leishmania P10669594A0000 NNP O
T-cell P10669594A0000 NNP O
epitope P10669594A0000 NN O
derived P10669594A0000 VBN O
from P10669594A0000 IN O
the P10669594A0000 DT O
metalloprotease P10669594A0000 NN I-UN
gp63 P10669594A0000 NN I-UN
. P10669594A0000 . O
. . O O

Parathyroid P10980416T0000 NNP I-UN
hormone P10980416T0000 NN I-UN
regulation P10980416T0000 NN O
of P10980416T0000 IN O
bone P10980416T0000 NN I-UN
sialoprotein P10980416T0000 NN I-UN
( P10980416T0000 ( O
BSP P10980416T0000 NNP I-UN
) P10980416T0000 ) O
gene P10980416T0000 NN O
transcription P10980416T0000 NN O
is P10980416T0000 VBZ O
mediated P10980416T0000 VBN O
through P10980416T0000 IN O
a P10980416T0000 DT O
pituitary-specific P10980416T0000 JJ I-UN
transcription P10980416T0000 NN I-UN
factor-1 P10980416T0000 NN I-UN
( P10980416T0000 ( O
Pit-1 P10980416T0000 NNP I-UN
) P10980416T0000 ) O
motif P10980416T0000 NN O
in P10980416T0000 IN O
the P10980416T0000 DT O
rat P10980416T0000 NN I-UN
BSP P10980416T0000 NNP I-UN
gene P10980416T0000 NN I-UN
promoter P10980416T0000 NN I-UN
. P10980416T0000 . O
. . O O

Definite P02765001A0105 NNP O
JPsA P02765001A0105 NNP O
( P02765001A0105 ( O
24 P02765001A0105 CD O
patients P02765001A0105 NNS O
) P02765001A0105 ) O
was P02765001A0105 VBD O
defined P02765001A0105 VBN O
as P02765001A0105 IN O
arthritis P02765001A0105 NN O
associated P02765001A0105 VBN O
, P02765001A0105 , O
but P02765001A0105 CC O
not P02765001A0105 RB O
necessarily P02765001A0105 RB O
coincident P02765001A0105 NN O
, P02765001A0105 , O
with P02765001A0105 IN O
a P02765001A0105 DT O
typical P02765001A0105 JJ O
psoriatic P02765001A0105 JJ O
rash P02765001A0105 NN O
, P02765001A0105 , O
or P02765001A0105 CC O
arthritis P02765001A0105 NN O
plus P02765001A0105 CC O
at P02765001A0105 IN O
least P02765001A0105 JJS O
3 P02765001A0105 CD O
of P02765001A0105 IN O
4 P02765001A0105 CD O
minor P02765001A0105 JJ O
criteria P02765001A0105 NNS O
: P02765001A0105 : O
dactylitis P02765001A0105 NN O
, P02765001A0105 , O
nail P02765001A0105 JJ O
pitting P02765001A0105 NN O
, P02765001A0105 , O
psoriasis-like P02765001A0105 JJ O
rash P02765001A0105 NN O
, P02765001A0105 , O
or P02765001A0105 CC O
family P02765001A0105 NN O
history P02765001A0105 NN O
of P02765001A0105 IN O
psoriasis P02765001A0105 NN O
. P02765001A0105 . O
. . O O

In P08971835A1057 IN O
Group P08971835A1057 NNP O
IV P08971835A1057 NNP O
dogs P08971835A1057 VBZ O
that P08971835A1057 IN O
received P08971835A1057 VBD O
alpha-MSH P08971835A1057 JJ I-UN
only P08971835A1057 RB O
during P08971835A1057 IN O
reperfusion P08971835A1057 NN O
, P08971835A1057 , O
BAEPs P08971835A1057 NNP O
were P08971835A1057 VBD O
increased P08971835A1057 VBN O
approximately P08971835A1057 RB O
10 P08971835A1057 CD O
to P08971835A1057 TO O
14 P08971835A1057 CD O
% P08971835A1057 NN O
more P08971835A1057 JJR O
than P08971835A1057 IN O
in P08971835A1057 IN O
Group P08971835A1057 NNP O
II P08971835A1057 NNP O
during P08971835A1057 IN O
the P08971835A1057 DT O
late P08971835A1057 JJ O
reperfusion P08971835A1057 NN O
period P08971835A1057 NN O
. P08971835A1057 . O
. . O O

Moreover P11029700A0746 RB O
, P11029700A0746 , O
an P11029700A0746 DT O
in P11029700A0746 IN O
vitro P11029700A0746 JJ O
pull-down P11029700A0746 JJ O
assay P11029700A0746 NN O
showed P11029700A0746 VBD O
that P11029700A0746 IN O
Os P11029700A0746 NNP I-UN
; P11029700A0746 : I-UN
CycH P11029700A0746 NNP I-UN
; P11029700A0746 : I-UN
1 P11029700A0746 CD I-UN
specifically P11029700A0746 RB O
bound P11029700A0746 VBN O
to P11029700A0746 TO O
R2 P11029700A0746 NNP I-UN
but P11029700A0746 CC O
not P11029700A0746 RB O
to P11029700A0746 TO O
other P11029700A0746 JJ O
rice P11029700A0746 NN I-UN
CDKs P11029700A0746 NNP I-UN
. P11029700A0746 . O
. . O O

Further P10942599A1298 JJ O
characterization P10942599A1298 NN O
of P10942599A1298 IN O
these P10942599A1298 DT O
putative P10942599A1298 JJ O
Hoxa-1 P10942599A1298 NNP I-UN
target P10942599A1298 NN I-UN
genes P10942599A1298 NNS I-UN
will P10942599A1298 MD O
aid P10942599A1298 VB O
in P10942599A1298 IN O
delineating P10942599A1298 VBG O
the P10942599A1298 DT O
functions P10942599A1298 NNS O
of P10942599A1298 IN O
the P10942599A1298 DT O
Hoxa-1 P10942599A1298 NNP I-UN
protein P10942599A1298 NN I-UN
in P10942599A1298 IN O
the P10942599A1298 DT O
differentiation P10942599A1298 NN O
processes P10942599A1298 VBZ O
which P10942599A1298 WDT O
occur P10942599A1298 VBP O
during P10942599A1298 IN O
embryogenesis P10942599A1298 NN O
. P10942599A1298 . O
. . O O

The P08163183T0000 DT O
xylose P08163183T0000 JJ I-UN
isomerase-encoding P08163183T0000 JJ I-UN
gene P08163183T0000 NN I-UN
( P08163183T0000 ( O
xylA P08163183T0000 NNP I-UN
) P08163183T0000 ) O
of P08163183T0000 IN O
Clostridium P08163183T0000 NNP O
thermosaccharolyticum P08163183T0000 NN O
: P08163183T0000 : O
cloning P08163183T0000 NN O
, P08163183T0000 , O
sequencing P08163183T0000 VBG O
and P08163183T0000 CC O
phylogeny P08163183T0000 NN O
of P08163183T0000 IN O
XylA P08163183T0000 NNP I-UN
enzymes P08163183T0000 NNS I-UN
. P08163183T0000 . O
. . O O

The P10556033A0000 DT O
RFX P10556033A0000 NNP I-UN
protein P10556033A0000 VBD I-UN
family P10556033A0000 NN I-UN
includes P10556033A0000 VBZ O
members P10556033A0000 NNS O
from P10556033A0000 IN O
yeast P10556033A0000 NN O
to P10556033A0000 TO O
humans P10556033A0000 NNS O
, P10556033A0000 , O
which P10556033A0000 WDT O
function P10556033A0000 NN O
in P10556033A0000 IN O
various P10556033A0000 JJ O
biological P10556033A0000 JJ O
systems P10556033A0000 NNS O
, P10556033A0000 , O
and P10556033A0000 CC O
share P10556033A0000 NN O
a P10556033A0000 DT O
DNA-binding P10556033A0000 JJ O
domain P10556033A0000 NN O
and P10556033A0000 CC O
a P10556033A0000 DT O
conserved P10556033A0000 JJ O
C-terminal P10556033A0000 JJ O
region P10556033A0000 NN O
. P10556033A0000 . O
. . O O

The P01549123A0480 DT O
MET4 P01549123A0480 NNP I-UN
gene P01549123A0480 NN O
was P01549123A0480 VBD O
cloned P01549123A0480 VBN O
, P01549123A0480 , O
and P01549123A0480 CC O
its P01549123A0480 PRP$ O
sequence P01549123A0480 NN O
reveals P01549123A0480 NNS O
that P01549123A0480 IN O
it P01549123A0480 PRP O
encodes P01549123A0480 VBZ O
a P01549123A0480 DT O
protein P01549123A0480 NN O
related P01549123A0480 VBN O
to P01549123A0480 TO O
the P01549123A0480 DT O
family P01549123A0480 NN O
of P01549123A0480 IN O
the P01549123A0480 DT O
bZIP P01549123A0480 JJ I-UN
transcriptional P01549123A0480 JJ I-UN
activators P01549123A0480 NNS I-UN
. P01549123A0480 . O
. . O O

The P09715278A1526 DT O
histopathology P09715278A1526 NN O
and P09715278A1526 CC O
neovascularization P09715278A1526 NN O
did P09715278A1526 VBD O
not P09715278A1526 RB O
appreciably P09715278A1526 RB O
differ P09715278A1526 VBP O
between P09715278A1526 IN O
xenograft P09715278A1526 NN O
tumors P09715278A1526 NNS O
derived P09715278A1526 VBD O
from P09715278A1526 IN O
FGF4 P09715278A1526 NNP I-UN
over-expressing P09715278A1526 JJ O
versus P09715278A1526 NN O
control P09715278A1526 NN O
transfectants P09715278A1526 NNS O
. P09715278A1526 . O
. . O O

Activation P08097732A0000 NN O
of P08097732A0000 IN O
the P08097732A0000 DT O
aboral P08097732A0000 JJ O
ectoderm-specific P08097732A0000 JJ I-UN
Spec2a P08097732A0000 NNP I-UN
gene P08097732A0000 NN I-UN
in P08097732A0000 IN O
blastula-stage P08097732A0000 JJ O
sea P08097732A0000 NN O
urchin P08097732A0000 JJ O
embryos P08097732A0000 NN O
requires P08097732A0000 VBZ O
an P08097732A0000 DT O
upstream P08097732A0000 JJ O
regulatory P08097732A0000 JJ O
region P08097732A0000 NN O
that P08097732A0000 WDT O
is P08097732A0000 VBZ O
part P08097732A0000 NN O
of P08097732A0000 IN O
a P08097732A0000 DT O
repetitive P08097732A0000 JJ O
sequence P08097732A0000 NN O
element P08097732A0000 NN O
( P08097732A0000 ( O
RSR P08097732A0000 NNP O
) P08097732A0000 ) O
associated P08097732A0000 VBN O
with P08097732A0000 IN O
all P08097732A0000 DT O
Spec1 P08097732A0000 NNP I-UN
/ P08097732A0000 NNP O
Spec2 P08097732A0000 NNP I-UN
genes P08097732A0000 NNS O
. P08097732A0000 . O
. . O O

In P09346621A1181 IN O
the P09346621A1181 DT O
context P09346621A1181 NN O
of P09346621A1181 IN O
liver P09346621A1181 NN O
allograft P09346621A1181 NN O
shortage P09346621A1181 NN O
, P09346621A1181 , O
our P09346621A1181 PRP$ O
results P09346621A1181 NNS O
suggest P09346621A1181 VBP O
that P09346621A1181 IN O
an P09346621A1181 DT O
ELT P09346621A1181 NNP O
should P09346621A1181 MD O
not P09346621A1181 RB O
be P09346621A1181 VB O
performed P09346621A1181 VBN O
in P09346621A1181 IN O
patients P09346621A1181 NNS O
with P09346621A1181 IN O
cardiac P09346621A1181 JJ O
failure P09346621A1181 NN O
, P09346621A1181 , O
more P09346621A1181 JJR O
than P09346621A1181 IN O
two P09346621A1181 CD O
OSF P09346621A1181 NNP O
, P09346621A1181 , O
or P09346621A1181 CC O
an P09346621A1181 DT O
APACHE P09346621A1181 NNP O
II P09346621A1181 NNP O
score P09346621A1181 VBD O
higher P09346621A1181 JJR O
than P09346621A1181 IN O
30 P09346621A1181 CD O
. P09346621A1181 . O
. . O O

Mutating P08999857A0801 VBG O
the P08999857A0801 DT O
E-box P08999857A0801 NNP O
in P08999857A0801 IN O
the P08999857A0801 DT O
context P08999857A0801 NN O
of P08999857A0801 IN O
the P08999857A0801 DT O
3'-flanking P08999857A0801 JJ O
region P08999857A0801 NN O
confirmed P08999857A0801 VBD O
that P08999857A0801 IN O
it P08999857A0801 PRP O
contributes P08999857A0801 VBZ O
to P08999857A0801 TO O
the P08999857A0801 DT O
enhancement P08999857A0801 NN O
of P08999857A0801 IN O
transcriptional P08999857A0801 JJ O
activity P08999857A0801 NN O
of P08999857A0801 IN O
the P08999857A0801 DT O
alpha1 P08999857A0801 NN I-UN
( P08999857A0801 ( I-UN
I P08999857A0801 PRP I-UN
) P08999857A0801 ) I-UN
collagen P08999857A0801 NN I-UN
gene P08999857A0801 NN I-UN
promoter P08999857A0801 NN I-UN
. P08999857A0801 . O
. . O O

The P10601606A0152 DT O
rhabdomyosarcoma P10601606A0152 NN O
R1H P10601606A0152 NNP O
growing P10601606A0152 VBG O
on P10601606A0152 IN O
the P10601606A0152 DT O
right P10601606A0152 JJ O
flank P10601606A0152 NN O
of P10601606A0152 IN O
male P10601606A0152 JJ O
WAG P10601606A0152 NNP O
/ P10601606A0152 NNP O
Rij P10601606A0152 NNP O
rats P10601606A0152 NN O
was P10601606A0152 VBD O
clamped P10601606A0152 VBN O
for P10601606A0152 IN O
2 P10601606A0152 CD O
or P10601606A0152 CC O
4 P10601606A0152 CD O
h P10601606A0152 NN O
at P10601606A0152 IN O
20 P10601606A0152 CD O
degrees P10601606A0152 NNS O
C P10601606A0152 NNP O
or P10601606A0152 CC O
37 P10601606A0152 CD O
degrees P10601606A0152 NNS O
C P10601606A0152 NNP O
. P10601606A0152 . O
. . O O

Visual P01363080A0710 JJ O
acuity P01363080A0710 NN O
may P01363080A0710 MD O
be P01363080A0710 VB O
decreased P01363080A0710 VBN O
by P01363080A0710 IN O
transient P01363080A0710 NN O
changes P01363080A0710 NNS O
in P01363080A0710 IN O
refractive P01363080A0710 JJ O
error P01363080A0710 NN O
caused P01363080A0710 VBN O
by P01363080A0710 IN O
sulfonamides P01363080A0710 NNS O
, P01363080A0710 , O
the P01363080A0710 DT O
antifungal P01363080A0710 JJ O
agent P01363080A0710 NN O
metronidazole P01363080A0710 NN O
, P01363080A0710 , O
thiazide P01363080A0710 IN O
diuretics P01363080A0710 NNS O
, P01363080A0710 , O
and P01363080A0710 CC O
carbonic P01363080A0710 JJ I-UN
anhydrase P01363080A0710 NN I-UN
inhibitors P01363080A0710 NNS O
. P01363080A0710 . O
. . O O

For P10850849A0730 IN O
oral P10850849A0730 JJ O
administration P10850849A0730 NN O
, P10850849A0730 , O
AUC0-infinity P10850849A0730 NNP O
was P10850849A0730 VBD O
58.47 P10850849A0730 CD O
+ P10850849A0730 JJ O
/ P10850849A0730 NNP O
- P10850849A0730 : O
16.37 P10850849A0730 CD O
microg P10850849A0730 NN O
x P10850849A0730 NN O
h P10850849A0730 NN O
/ P10850849A0730 NNP O
ml P10850849A0730 NN O
, P10850849A0730 , O
t1 P10850849A0730 EX O
/ P10850849A0730 $ O
2beta P10850849A0730 CD O
was P10850849A0730 VBD O
18.39 P10850849A0730 CD O
+ P10850849A0730 JJ O
/ P10850849A0730 NNP O
- P10850849A0730 : O
0.06 P10850849A0730 CD O
hours P10850849A0730 NNS O
, P10850849A0730 , O
maximum P10850849A0730 JJ O
concentration P10850849A0730 NN O
( P10850849A0730 ( O
Cmax P10850849A0730 NNP O
) P10850849A0730 ) O
was P10850849A0730 VBD O
2.12 P10850849A0730 CD O
+ P10850849A0730 JJ O
/ P10850849A0730 NNP O
- P10850849A0730 : O
00.51 P10850849A0730 CD O
microg P10850849A0730 NN O
/ P10850849A0730 NNP O
ml P10850849A0730 NN O
, P10850849A0730 , O
time P10850849A0730 NN O
to P10850849A0730 TO O
Cmax P10850849A0730 NNP O
was P10850849A0730 VBD O
2.20 P10850849A0730 CD O
+ P10850849A0730 JJ O
/ P10850849A0730 NNP O
- P10850849A0730 : O
2.17 P10850849A0730 CD O
hours P10850849A0730 NNS O
, P10850849A0730 , O
mean P10850849A0730 JJ O
absorption P10850849A0730 NN O
time P10850849A0730 NN O
was P10850849A0730 VBD O
2.09 P10850849A0730 CD O
+ P10850849A0730 JJ O
/ P10850849A0730 NNP O
- P10850849A0730 : O
0.51 P10850849A0730 CD O
hours P10850849A0730 NNS O
, P10850849A0730 , O
and P10850849A0730 CC O
bioavailability P10850849A0730 NN O
was P10850849A0730 VBD O
42 P10850849A0730 CD O
+ P10850849A0730 JJ O
/ P10850849A0730 NNP O
- P10850849A0730 : O
0.42 P10850849A0730 CD O
% P10850849A0730 NN O
. P10850849A0730 . O
. . O O

The P01615182A0206 DT O
present P01615182A0206 JJ O
study P01615182A0206 NN O
highlights P01615182A0206 VBD O
the P01615182A0206 DT O
improvement P01615182A0206 NN O
in P01615182A0206 IN O
sputum P01615182A0206 NN O
amoxycillin P01615182A0206 NN O
( P01615182A0206 ( O
amoxy P01615182A0206 JJ O
) P01615182A0206 ) O
levels P01615182A0206 NNS O
when P01615182A0206 WRB O
a P01615182A0206 DT O
combination P01615182A0206 NN O
tablet P01615182A0206 NN O
, P01615182A0206 , O
amoxy P01615182A0206 JJ O
500 P01615182A0206 CD O
mg P01615182A0206 NN O
plus P01615182A0206 CC O
bromhexeine P01615182A0206 JJ O
8 P01615182A0206 CD O
mg P01615182A0206 NN O
, P01615182A0206 , O
is P01615182A0206 VBZ O
administered P01615182A0206 VBN O
as P01615182A0206 IN O
compared P01615182A0206 VBN O
to P01615182A0206 TO O
plain P01615182A0206 VB O
amoxy P01615182A0206 JJ O
500 P01615182A0206 CD O
mg P01615182A0206 NN O
. P01615182A0206 . O
. . O O

Ultrastructure P03999219A0463 NN O
of P03999219A0463 IN O
the P03999219A0463 DT O
tumor P03999219A0463 NN O
in P03999219A0463 IN O
1 P03999219A0463 CD O
patient P03999219A0463 NN O
in P03999219A0463 IN O
whom P03999219A0463 WP O
transurethral P03999219A0463 JJ O
resection P03999219A0463 NN O
was P03999219A0463 VBD O
performed P03999219A0463 VBN O
2 P03999219A0463 CD O
weeks P03999219A0463 NNS O
after P03999219A0463 IN O
alum P03999219A0463 JJ O
irrigation P03999219A0463 NN O
revealed P03999219A0463 VBD O
well P03999219A0463 RB O
preserved P03999219A0463 VBN O
nuclear P03999219A0463 JJ O
chromatin P03999219A0463 NN O
, P03999219A0463 , O
thus P03999219A0463 RB O
, P03999219A0463 , O
suggesting P03999219A0463 VBG O
that P03999219A0463 IN O
whatever P03999219A0463 WDT O
changes P03999219A0463 NNS O
occur P03999219A0463 VBP O
after P03999219A0463 IN O
alum P03999219A0463 NN O
irrigation P03999219A0463 NN O
are P03999219A0463 VBP O
short-lived P03999219A0463 JJ O
. P03999219A0463 . O
. . O O

This P09098066A0119 DT O
locus P09098066A0119 NN O
maps P09098066A0119 VBZ O
approximately P09098066A0119 RB O
160 P09098066A0119 CD O
kbp P09098066A0119 NNS O
from P09098066A0119 IN O
the P09098066A0119 DT O
genes P09098066A0119 NNS O
encoding P09098066A0119 VBG O
cytadherence-associated P09098066A0119 JJ O
proteins P09098066A0119 NNS O
HMW1 P09098066A0119 NNP I-UN
and P09098066A0119 CC O
HMW3 P09098066A0119 NNP I-UN
, P09098066A0119 , O
and P09098066A0119 CC O
yet P09098066A0119 RB O
insertions P09098066A0119 NNS O
therein P09098066A0119 VBP O
result P09098066A0119 NN O
in P09098066A0119 IN O
loss P09098066A0119 NN O
of P09098066A0119 IN O
these P09098066A0119 DT O
proteins P09098066A0119 NNS O
and P09098066A0119 CC O
a P09098066A0119 DT O
hemadsorption-negative P09098066A0119 JJ O
( P09098066A0119 ( O
HA- P09098066A0119 NNP O
) P09098066A0119 ) O
phenotype P09098066A0119 NN O
, P09098066A0119 , O
prompting P09098066A0119 VBG O
the P09098066A0119 DT O
designation P09098066A0119 NN O
cytadherence-regulatory P09098066A0119 JJ I-UN
locus P09098066A0119 NN I-UN
( P09098066A0119 ( O
crl P09098066A0119 NN I-UN
) P09098066A0119 ) O
. P09098066A0119 . O
. . O O

Truncated P07592711T0000 VBN O
forms P07592711T0000 NNS O
of P07592711T0000 IN O
a P07592711T0000 DT O
novel P07592711T0000 JJ O
yeast P07592711T0000 NN O
protein P07592711T0000 NN O
suppress P07592711T0000 VBD O
the P07592711T0000 DT O
lethality P07592711T0000 NN O
of P07592711T0000 IN O
a P07592711T0000 DT O
G P07592711T0000 NNP I-UN
protein P07592711T0000 NN I-UN
alpha P07592711T0000 NN I-UN
subunit P07592711T0000 NN I-UN
deficiency P07592711T0000 NN O
by P07592711T0000 IN O
interacting P07592711T0000 VBG O
with P07592711T0000 IN O
the P07592711T0000 DT O
beta P07592711T0000 NN O
subunit P07592711T0000 NN O
. P07592711T0000 . O
. . O O

Gastrointestinal P05532854T0001 JJ O
manifestations P05532854T0001 NNS O
of P05532854T0001 IN O
systemic P05532854T0001 JJ O
sclerosis P05532854T0001 NN O
. P05532854T0001 . O
. . O O

Elimination P05460466T0001 NN O
of P05460466T0001 IN O
gamma-irradiation P05460466T0001 NN O
induced P05460466T0001 JJ O
oxidation P05460466T0001 NN O
in P05460466T0001 IN O
aqueous P05460466T0001 JJ O
drug P05460466T0001 NN O
preparations P05460466T0001 NNS O
. P05460466T0001 . O
. . O O

Both P09710131A0374 DT O
methods P09710131A0374 NNS O
were P09710131A0374 VBD O
employed P09710131A0374 VBN O
for P09710131A0374 IN O
various P09710131A0374 JJ O
focal-film P09710131A0374 JJ O
distances P09710131A0374 NNS O
, P09710131A0374 , O
image P09710131A0374 NN O
intensifier P09710131A0374 NN O
tube P09710131A0374 NN O
modes P09710131A0374 NNS O
and P09710131A0374 CC O
laser P09710131A0374 NN O
printer P09710131A0374 NN O
formats P09710131A0374 NNS O
. P09710131A0374 . O
. . O O

Of P02124433A0235 IN O
848 P02124433A0235 CD O
patients P02124433A0235 NNS O
, P02124433A0235 , O
819 P02124433A0235 CD O
cases P02124433A0235 NNS O
with P02124433A0235 IN O
complete P02124433A0235 JJ O
description P02124433A0235 NN O
of P02124433A0235 IN O
patient P02124433A0235 NN O
's P02124433A0235 POS O
background P02124433A0235 NN O
were P02124433A0235 VBD O
evaluable P02124433A0235 JJ O
: P02124433A0235 : O
Group P02124433A0235 NNP O
A P02124433A0235 NNP O
( P02124433A0235 ( O
surgery P02124433A0235 NN O
+ P02124433A0235 RB O
MMC P02124433A0235 NNP O
+ P02124433A0235 VBD O
5-FU P02124433A0235 JJ O
: P02124433A0235 : O
chemotherapy P02124433A0235 NN O
) P02124433A0235 ) O
253 P02124433A0235 CD O
cases P02124433A0235 NNS O
, P02124433A0235 , O
group P02124433A0235 NN O
B P02124433A0235 NNP O
( P02124433A0235 ( O
surgery P02124433A0235 NN O
+ P02124433A0235 RB O
MMC P02124433A0235 NNP O
+ P02124433A0235 NNP O
5-FU P02124433A0235 JJ O
+ P02124433A0235 NNP O
OK-432 P02124433A0235 NNP O
or P02124433A0235 CC O
PSK P02124433A0235 NNP O
: P02124433A0235 : O
immunochemotherapy P02124433A0235 NN O
) P02124433A0235 ) O
282 P02124433A0235 CD O
and P02124433A0235 CC O
group P02124433A0235 NN O
C P02124433A0235 NNP O
( P02124433A0235 ( O
surgery P02124433A0235 VB O
alone P02124433A0235 RB O
) P02124433A0235 ) O
284 P02124433A0235 CD O
. P02124433A0235 . O
. . O O

Both P09851988A0085 DT O
the P09851988A0085 DT O
presence P09851988A0085 NN O
of P09851988A0085 IN O
arginine P09851988A0085 NN O
and P09851988A0085 CC O
anaerobiosis P09851988A0085 NN O
are P09851988A0085 VBP O
needed P09851988A0085 VBN O
to P09851988A0085 TO O
trigger P09851988A0085 VB O
induction P09851988A0085 NN O
of P09851988A0085 IN O
the P09851988A0085 DT O
pathway P09851988A0085 NN O
. P09851988A0085 . O
. . O O

Histopathological P03395249A1044 JJ O
examination P03395249A1044 NN O
revealed P03395249A1044 VBD O
dose-related P03395249A1044 JJ O
proliferation P03395249A1044 NN O
of P03395249A1044 IN O
type P03395249A1044 NN O
II P03395249A1044 NNP O
pneumocytes P03395249A1044 VBZ O
in P03395249A1044 IN O
dams P03395249A1044 NNS O
and P03395249A1044 CC O
proliferation P03395249A1044 NN O
of P03395249A1044 IN O
interstitial P03395249A1044 JJ O
cells P03395249A1044 NNS O
and P03395249A1044 CC O
delayed P03395249A1044 JJ O
septal P03395249A1044 NN O
/ P03395249A1044 NNP O
capillary P03395249A1044 NN O
development P03395249A1044 NN O
in P03395249A1044 IN O
neonates P03395249A1044 NNS O
. P03395249A1044 . O
( P03395249A1044 ( O
ABSTRACT P03395249A1044 NNP O
TRUNCATED P03395249A1044 NNP O
AT P03395249A1044 NNP O
250 P03395249A1044 CD O
WORDS P03395249A1044 NNP O
) P03395249A1044 ) O
. P03395249A1044 . O
. . O O

For P02928376A0312 IN O
the P02928376A0312 DT O
present P02928376A0312 JJ O
work P02928376A0312 NN O
we P02928376A0312 PRP O
used P02928376A0312 VBD O
water P02928376A0312 NN O
saturated P02928376A0312 VBN O
with P02928376A0312 IN O
a P02928376A0312 DT O
50 P02928376A0312 CD O
/ P02928376A0312 NN O
50 P02928376A0312 CD O
mixture P02928376A0312 NN O
of P02928376A0312 IN O
H2 P02928376A0312 NNP O
and P02928376A0312 CC O
O2 P02928376A0312 NNP O
gases P02928376A0312 NNS O
, P02928376A0312 , O
for P02928376A0312 IN O
which P02928376A0312 WDT O
the P02928376A0312 DT O
heat P02928376A0312 NN O
defect P02928376A0312 NN O
is P02928376A0312 VBZ O
calculated P02928376A0312 VBN O
to P02928376A0312 TO O
be P02928376A0312 VB O
-2.1 P02928376A0312 JJ O
% P02928376A0312 NN O
. P02928376A0312 . O
. . O O

The P08668142A1048 DT O
introduction P08668142A1048 NN O
of P08668142A1048 IN O
hARF4 P08668142A1048 NN I-UN
to P08668142A1048 TO O
the P08668142A1048 DT O
cells P08668142A1048 NNS O
maintained P08668142A1048 VBD O
the P08668142A1048 DT O
balance P08668142A1048 NN O
between P08668142A1048 IN O
cytosolic P08668142A1048 JJ O
and P08668142A1048 CC O
membrane-associated P08668142A1048 JJ O
Sec7p P08668142A1048 NNP I-UN
pools P08668142A1048 NNS O
. P08668142A1048 . O
. . O O

If P00838152A0863 IN O
, P00838152A0863 , O
however P00838152A0863 RB O
, P00838152A0863 , O
the P00838152A0863 DT O
mean P00838152A0863 JJ O
temperature P00838152A0863 NN O
rise P00838152A0863 NN O
was P00838152A0863 VBD O
higher P00838152A0863 JJR O
( P00838152A0863 ( O
0.57 P00838152A0863 CD O
degrees P00838152A0863 NNS O
C P00838152A0863 NNP O
or P00838152A0863 CC O
0.69 P00838152A0863 CD O
degrees P00838152A0863 NNS O
C P00838152A0863 NNP O
) P00838152A0863 ) O
, P00838152A0863 , O
such P00838152A0863 PDT O
a P00838152A0863 DT O
selection P00838152A0863 NN O
practically P00838152A0863 RB O
resulted P00838152A0863 VBD O
in P00838152A0863 IN O
the P00838152A0863 DT O
disappearance P00838152A0863 NN O
of P00838152A0863 IN O
'passable P00838152A0863 JJ O
' P00838152A0863 POS O
qualifications P00838152A0863 NNS O
in P00838152A0863 IN O
the P00838152A0863 DT O
triplet P00838152A0863 NN O
groups P00838152A0863 NNS O
and P00838152A0863 CC O
a P00838152A0863 DT O
great P00838152A0863 JJ O
predominance P00838152A0863 NN O
of P00838152A0863 IN O
'to P00838152A0863 NN O
be P00838152A0863 VB O
rejected P00838152A0863 VBN O
' P00838152A0863 '' O
qualifications P00838152A0863 NNS O
in P00838152A0863 IN O
the P00838152A0863 DT O
large P00838152A0863 JJ O
groups P00838152A0863 NNS O
. P00838152A0863 . O
. . O O

We P01386210A0293 PRP O
report P01386210A0293 VBP O
the P01386210A0293 DT O
successful P01386210A0293 JJ O
use P01386210A0293 NN O
of P01386210A0293 IN O
electroconvulsive P01386210A0293 JJ O
therapy P01386210A0293 NN O
for P01386210A0293 IN O
treatment P01386210A0293 NN O
of P01386210A0293 IN O
severe P01386210A0293 JJ O
depression P01386210A0293 NN O
in P01386210A0293 IN O
a P01386210A0293 DT O
young P01386210A0293 JJ O
man P01386210A0293 NN O
with P01386210A0293 IN O
adult P01386210A0293 JJ O
GM2 P01386210A0293 NNP O
gangliosidosis P01386210A0293 NN O
. P01386210A0293 . O
. . O O

This P11382701A0688 DT O
partial P11382701A0688 JJ O
transection P11382701A0688 NN O
could P11382701A0688 MD O
permit P11382701A0688 VB O
vasopressin P11382701A0688 NN I-UN
to P11382701A0688 TO O
be P11382701A0688 VB O
secreted P11382701A0688 VBN O
in P11382701A0688 IN O
response P11382701A0688 NN O
to P11382701A0688 TO O
a P11382701A0688 DT O
larger P11382701A0688 JJR O
rise P11382701A0688 NN O
in P11382701A0688 IN O
plasma P11382701A0688 JJ O
sodium P11382701A0688 NN O
concentration P11382701A0688 NN O
. P11382701A0688 . O
. . O O

BACKGROUND P10874151A0000 NN O
: P10874151A0000 : O
Gamma P10874151A0000 NNP O
knife P10874151A0000 VB O
radiosurgery P10874151A0000 NN O
( P10874151A0000 ( O
GKR P10874151A0000 NNP O
) P10874151A0000 ) O
is P10874151A0000 VBZ O
a P10874151A0000 DT O
safe P10874151A0000 JJ O
and P10874151A0000 CC O
effective P10874151A0000 JJ O
alternative P10874151A0000 NN O
to P10874151A0000 TO O
surgery P10874151A0000 NN O
for P10874151A0000 IN O
intracranial P10874151A0000 JJ O
lesions P10874151A0000 NNS O
. P10874151A0000 . O
. . O O

The P01352113A0002 DT O
pulmonary P01352113A0002 JJ O
toxic P01352113A0002 NN O
events P01352113A0002 NNS O
induced P01352113A0002 VBN O
by P01352113A0002 IN O
acute P01352113A0002 JJ O
nitrogen P01352113A0002 NN O
dioxide P01352113A0002 NN O
( P01352113A0002 ( O
NO P01352113A0002 NNP O
) P01352113A0002 ) O
2 P01352113A0002 CD O
exposure P01352113A0002 NN O
were P01352113A0002 VBD O
studied P01352113A0002 VBN O
in P01352113A0002 IN O
the P01352113A0002 DT O
rat P01352113A0002 NN O
to P01352113A0002 TO O
develop P01352113A0002 VB O
an P01352113A0002 DT O
inhalation P01352113A0002 NN O
model P01352113A0002 NN O
to P01352113A0002 TO O
investigate P01352113A0002 VB O
therapeutic P01352113A0002 JJ O
measures P01352113A0002 NNS O
. P01352113A0002 . O
. . O O

Self P07836364A0000 NNP O
or P07836364A0000 CC O
foreign P07836364A0000 JJ O
cellular P07836364A0000 JJ O
proteins P07836364A0000 NNS O
provide P07836364A0000 VBP O
peptides P07836364A0000 NNS O
for P07836364A0000 IN O
presentation P07836364A0000 NN O
by P07836364A0000 IN O
major P07836364A0000 JJ I-UN
histocompatibility P07836364A0000 NN I-UN
complex P07836364A0000 NN I-UN
( P07836364A0000 ( I-UN
MHC P07836364A0000 NNP I-UN
) P07836364A0000 ) I-UN
class P07836364A0000 NN I-UN
I P07836364A0000 PRP I-UN
molecules P07836364A0000 VBP I-UN
on P07836364A0000 IN O
the P07836364A0000 DT O
surface P07836364A0000 NN O
of P07836364A0000 IN O
antigen P07836364A0000 NN O
presenting P07836364A0000 VBG O
cells P07836364A0000 NNS O
( P07836364A0000 ( O
APC P07836364A0000 NNP O
) P07836364A0000 ) O
. P07836364A0000 . O
. . O O

The P11384880A0719 DT O
mechanism P11384880A0719 NN O
of P11384880A0719 IN O
the P11384880A0719 DT O
induction P11384880A0719 NN O
of P11384880A0719 IN O
3beta-HSD P11384880A0719 JJ I-UN
type P11384880A0719 NN I-UN
1 P11384880A0719 CD I-UN
gene P11384880A0719 NN I-UN
expression P11384880A0719 NN O
was P11384880A0719 VBD O
further P11384880A0719 JJ O
characterized P11384880A0719 VBN O
in P11384880A0719 IN O
ZR-75-1 P11384880A0719 NNP O
human P11384880A0719 JJ O
breast P11384880A0719 NN O
cancer P11384880A0719 NN O
cells P11384880A0719 NNS O
. P11384880A0719 . O
. . O O

The P02020082A0356 DT O
disturbance P02020082A0356 NN O
of P02020082A0356 IN O
pulmonary P02020082A0356 JJ O
gas P02020082A0356 NN O
exchange P02020082A0356 NN O
, P02020082A0356 , O
as P02020082A0356 IN O
revealed P02020082A0356 VBN O
by P02020082A0356 IN O
the P02020082A0356 DT O
high P02020082A0356 JJ O
value P02020082A0356 NN O
of P02020082A0356 IN O
AaDO2 P02020082A0356 NNP O
, P02020082A0356 , O
existed P02020082A0356 VBD O
without P02020082A0356 IN O
left P02020082A0356 JJ O
ventricular P02020082A0356 JJ O
dysfunction P02020082A0356 NN O
, P02020082A0356 , O
and P02020082A0356 CC O
AaDO2 P02020082A0356 NNP O
had P02020082A0356 VBD O
no P02020082A0356 DT O
significant P02020082A0356 JJ O
relationship P02020082A0356 NN O
with P02020082A0356 IN O
any P02020082A0356 DT O
of P02020082A0356 IN O
the P02020082A0356 DT O
hemodynamic P02020082A0356 JJ O
parameters P02020082A0356 NNS O
including P02020082A0356 VBG O
the P02020082A0356 DT O
difference P02020082A0356 NN O
between P02020082A0356 IN O
plasma P02020082A0356 NN O
colloid P02020082A0356 NN O
osmotic P02020082A0356 JJ O
pressure P02020082A0356 NN O
and P02020082A0356 CC O
PCW P02020082A0356 NNP O
. P02020082A0356 . O
. . O O

The P05733953T0001 DT O
effect P05733953T0001 NN O
of P05733953T0001 IN O
a P05733953T0001 DT O
constant P05733953T0001 JJ O
magnetic P05733953T0001 JJ O
field P05733953T0001 NN O
on P05733953T0001 IN O
the P05733953T0001 DT O
phagocytic P05733953T0001 JJ O
activity P05733953T0001 NN O
of P05733953T0001 IN O
Paramecia P05733953T0001 NNP O
. P05733953T0001 . O
. . O O

Using P09259320A0830 VBG O
lectin-affinity P09259320A0830 NN O
chromatography P09259320A0830 NN O
, P09259320A0830 , O
discordance P09259320A0830 NN O
between P09259320A0830 IN O
the P09259320A0830 DT O
pattern P09259320A0830 NN O
of P09259320A0830 IN O
O-glycosylation P09259320A0830 NNP O
of P09259320A0830 IN O
SSBP P09259320A0830 NNP I-UN
and P09259320A0830 CC O
DSBP P09259320A0830 NNP I-UN
was P09259320A0830 VBD O
demonstrated P09259320A0830 VBN O
. P09259320A0830 . O
. . O O

All P10331276A0298 DT O
of P10331276A0298 IN O
the P10331276A0298 DT O
elements P10331276A0298 NNS O
exhibited P10331276A0298 VBD O
a P10331276A0298 DT O
uniform P10331276A0298 JJ O
structure P10331276A0298 NN O
. P10331276A0298 . O
. . O O

Activated P08576179A0126 VBN O
PKR P08576179A0126 NNP I-UN
may P08576179A0126 MD O
exist P08576179A0126 VB O
as P08576179A0126 IN O
a P08576179A0126 DT O
dimer P08576179A0126 NN O
and P08576179A0126 CC O
phosphorylates P08576179A0126 VBZ O
the P08576179A0126 DT O
eukaryotic P08576179A0126 JJ I-UN
translation P08576179A0126 NN I-UN
initiation P08576179A0126 NN I-UN
factor P08576179A0126 NN I-UN
2 P08576179A0126 CD I-UN
alpha P08576179A0126 NN I-UN
subunit P08576179A0126 NN I-UN
( P08576179A0126 ( O
cIF-2 P08576179A0126 JJ I-UN
alpha P08576179A0126 NN I-UN
) P08576179A0126 ) O
to P08576179A0126 TO O
inhibit P08576179A0126 VB O
polypeptide P08576179A0126 JJ O
chain P08576179A0126 NN O
initiation P08576179A0126 NN O
. P08576179A0126 . O
. . O O

AGO1 P11016954A0438 NNP I-UN
is P11016954A0438 VBZ O
similar P11016954A0438 JJ O
to P11016954A0438 TO O
QDE-2 P11016954A0438 NNP I-UN
required P11016954A0438 VBN O
for P11016954A0438 IN O
quelling P11016954A0438 VBG O
and P11016954A0438 CC O
RDE-1 P11016954A0438 NNP I-UN
required P11016954A0438 VBD O
for P11016954A0438 IN O
RNAi P11016954A0438 NNP O
. P11016954A0438 . O
. . O O

The P08534217A0402 DT O
subjects P08534217A0402 NNS O
from P08534217A0402 IN O
the P08534217A0402 DT O
two P08534217A0402 CD O
regions P08534217A0402 NNS O
with P08534217A0402 IN O
a P08534217A0402 DT O
higher P08534217A0402 JJR O
pollution P08534217A0402 NN O
level P08534217A0402 NN O
had P08534217A0402 VBD O
lower P08534217A0402 JJR O
FVC P08534217A0402 NNP O
and P08534217A0402 CC O
FEV1 P08534217A0402 NNP O
values P08534217A0402 NNS O
than P08534217A0402 IN O
those P08534217A0402 DT O
from P08534217A0402 IN O
the P08534217A0402 DT O
Viskovo P08534217A0402 NNP O
region P08534217A0402 NN O
. P08534217A0402 . O
. . O O

The P02875967A0377 DT O
sensitivity P02875967A0377 NN O
of P02875967A0377 IN O
the P02875967A0377 DT O
vas P02875967A0377 NN O
deferens P02875967A0377 VBZ O
to P02875967A0377 TO O
adrenaline P02875967A0377 VB O
was P02875967A0377 VBD O
also P02875967A0377 RB O
reduced P02875967A0377 VBN O
in P02875967A0377 IN O
scorbutic P02875967A0377 JJ O
guinea P02875967A0377 NN O
pigs P02875967A0377 NNS O
, P02875967A0377 , O
thus P02875967A0377 RB O
decreasing P02875967A0377 VBG O
their P02875967A0377 PRP$ O
fertility P02875967A0377 NN O
rate P02875967A0377 NN O
. P02875967A0377 . O
. . O O

Sequence P01917943A0621a NNP O
analysis P01917943A0621a NN O
of P01917943A0621a IN O
the P01917943A0621a DT O
sMtCK P01917943A0621a JJ I-UN
genomic P01917943A0621a JJ I-UN
upstream P01917943A0621a NN I-UN
sequences P01917943A0621a NNS I-UN
reveals P01917943A0621a VBZ O
a P01917943A0621a DT O
typical P01917943A0621a JJ O
TATAA P01917943A0621a NNP O
box P01917943A0621a NN O
within P01917943A0621a IN O
the P01917943A0621a DT O
80 P01917943A0621a CD O
base P01917943A0621a NN O
pairs P01917943A0621a NN O
( P01917943A0621a ( O
bp P01917943A0621a NN O
) P01917943A0621a ) O
that P01917943A0621a IN O
, P01917943A0621a , O
by P01917943A0621a IN O
transfection P01917943A0621a NN O
experiments P01917943A0621a NNS O
, P01917943A0621a , O
are P01917943A0621a VBP O
sufficient P01917943A0621a JJ O
to P01917943A0621a TO O
promote P01917943A0621a VB O
expression P01917943A0621a NN O
of P01917943A0621a IN O
chimeric P01917943A0621a JJ O
plasmids P01917943A0621a NNS O
with P01917943A0621a IN O
the P01917943A0621a DT O
chloramphenicol P01917943A0621a NN I-UN
acetyltransferase P01917943A0621a NN I-UN
reporter P01917943A0621a NN I-UN
. P01917943A0621a . O
. . O O

The P11791853A0532 DT O
experimental P11791853A0532 JJ O
results P11791853A0532 NNS O
showed P11791853A0532 VBD O
that P11791853A0532 IN O
the P11791853A0532 DT O
coagulation-electrooxidation P11791853A0532 NN O
process P11791853A0532 NN O
could P11791853A0532 MD O
efficiently P11791853A0532 RB O
remove P11791853A0532 VB O
the P11791853A0532 DT O
color P11791853A0532 NN O
and P11791853A0532 CC O
the P11791853A0532 DT O
COD P11791853A0532 NNP O
from P11791853A0532 IN O
the P11791853A0532 DT O
simulated P11791853A0532 JJ O
dye P11791853A0532 NN O
wastewater P11791853A0532 NN O
. P11791853A0532 . O
. . O O

In P07919540A1119 IN O
addition P07919540A1119 NN O
, P07919540A1119 , O
both P07919540A1119 CC O
the P07919540A1119 DT O
exon P07919540A1119 JJ O
1- P07919540A1119 JJ O
and P07919540A1119 CC O
exon P07919540A1119 JJ O
2-initiated P07919540A1119 JJ O
forms P07919540A1119 NNS O
of P07919540A1119 IN O
the P07919540A1119 DT O
c-Myc P07919540A1119 JJ I-UN
protein P07919540A1119 NN I-UN
stimulated P07919540A1119 VBD O
transcription P07919540A1119 NN O
of P07919540A1119 IN O
a P07919540A1119 DT O
Myc P07919540A1119 NNP I-UN
/ P07919540A1119 NNP O
Max-responsive P07919540A1119 JJ O
reporter P07919540A1119 NN O
construct P07919540A1119 NN O
to P07919540A1119 TO O
a P07919540A1119 DT O
similar P07919540A1119 JJ O
level P07919540A1119 NN O
. P07919540A1119 . O
. . O O

Synergistic P01309587A0715 JJ O
transactivation P01309587A0715 NN O
of P01309587A0715 IN O
the P01309587A0715 DT O
BMRF1 P01309587A0715 NNP I-UN
promoter P01309587A0715 NN I-UN
by P01309587A0715 IN O
the P01309587A0715 DT O
Z P01309587A0715 NNP I-UN
/ P01309587A0715 NNP O
c-myb P01309587A0715 JJ I-UN
combination P01309587A0715 NN O
appears P01309587A0715 VBZ O
to P01309587A0715 TO O
involve P01309587A0715 VB O
direct P01309587A0715 JJ O
binding P01309587A0715 NN O
by P01309587A0715 IN O
the P01309587A0715 DT O
Z P01309587A0715 NNP I-UN
protein P01309587A0715 NN I-UN
but P01309587A0715 CC O
not P01309587A0715 RB O
the P01309587A0715 DT O
c-myb P01309587A0715 JJ I-UN
protein P01309587A0715 NN I-UN
. P01309587A0715 . O
. . O O

Hospital P10187317T0000 NN O
hit P10187317T0000 VBD O
for P10187317T0000 IN O
hiring P10187317T0000 VBG O
AHERF P10187317T0000 NNP O
physicians P10187317T0000 NNS O
. P10187317T0000 . O
. . O O

Effect P09340641T0001 NN O
of P09340641T0001 IN O
alcohol P09340641T0001 NN O
on P09340641T0001 IN O
minimal P09340641T0001 JJ O
effective P09340641T0001 JJ O
nCPAP P09340641T0001 JJ O
pressure P09340641T0001 NN O
. P09340641T0001 . O
. . O O

In P07548425A0000 IN O
4 P07548425A0000 CD O
spinalized P07548425A0000 JJ O
cats P07548425A0000 NNS O
, P07548425A0000 , O
the P07548425A0000 DT O
effects P07548425A0000 NNS O
of P07548425A0000 IN O
afferent P07548425A0000 NN O
inputs P07548425A0000 NNS O
from P07548425A0000 IN O
hindlimb P07548425A0000 NN O
cutaneous P07548425A0000 JJ O
nerves P07548425A0000 NNS O
( P07548425A0000 ( O
sural P07548425A0000 JJ O
cutaneous P07548425A0000 JJ O
nerve P07548425A0000 NN O
: P07548425A0000 : O
Sur P07548425A0000 NNP O
) P07548425A0000 ) O
on P07548425A0000 IN O
mono-and P07548425A0000 NN O
poly-synaptic P07548425A0000 JJ O
reflex P07548425A0000 NN O
recorded P07548425A0000 VBN O
from P07548425A0000 IN O
tail P07548425A0000 NN O
muscle P07548425A0000 NN O
motoneurons P07548425A0000 NNS O
were P07548425A0000 VBD O
studied P07548425A0000 VBN O
before P07548425A0000 IN O
and P07548425A0000 CC O
after P07548425A0000 IN O
spinal P07548425A0000 JJ O
lesioning P07548425A0000 NN O
at P07548425A0000 IN O
S2-3 P07548425A0000 NNP O
level P07548425A0000 NN O
. P07548425A0000 . O
. . O O

Tests P07372928A0105 NNS O
of P07372928A0105 IN O
the P07372928A0105 DT O
method P07372928A0105 NN O
indicate P07372928A0105 NN O
( P07372928A0105 ( O
1 P07372928A0105 CD O
) P07372928A0105 ) O
the P07372928A0105 DT O
Mossbauer P07372928A0105 NNP O
source P07372928A0105 NN O
can P07372928A0105 MD O
be P07372928A0105 VB O
placed P07372928A0105 VBN O
on P07372928A0105 IN O
the P07372928A0105 DT O
basilar P07372928A0105 JJ O
membrane P07372928A0105 NN O
without P07372928A0105 IN O
altering P07372928A0105 VBG O
the P07372928A0105 DT O
signal-transmission P07372928A0105 NN O
properties P07372928A0105 NNS O
of P07372928A0105 IN O
the P07372928A0105 DT O
cochlea P07372928A0105 NN O
, P07372928A0105 , O
and P07372928A0105 CC O
( P07372928A0105 ( O
2 P07372928A0105 CD O
) P07372928A0105 ) O
the P07372928A0105 DT O
source P07372928A0105 NN O
adheres P07372928A0105 VBZ O
to P07372928A0105 TO O
the P07372928A0105 DT O
basilar P07372928A0105 JJ O
membrane P07372928A0105 NN O
. P07372928A0105 . O
. . O O

Clinical P03463537T0001 JJ O
method P03463537T0001 NN O
for P03463537T0001 IN O
the P03463537T0001 DT O
treatment P03463537T0001 NN O
of P03463537T0001 IN O
Class P03463537T0001 NNP O
II P03463537T0001 NNP O
occlusal P03463537T0001 NN O
anomalies P03463537T0001 NNS O
with P03463537T0001 IN O
open P03463537T0001 JJ O
bite P03463537T0001 NN O
. P03463537T0001 . O
. . O O

Studied P11083432A0332 VBN O
groups P11083432A0332 NNS O
were P11083432A0332 VBD O
( P11083432A0332 ( O
1 P11083432A0332 CD O
) P11083432A0332 ) O
untreated P11083432A0332 VBD O
control P11083432A0332 NN O
, P11083432A0332 , O
n P11083432A0332 JJ O
= P11083432A0332 VBP O
12 P11083432A0332 CD O
; P11083432A0332 : O
( P11083432A0332 ( O
2 P11083432A0332 CD O
) P11083432A0332 ) O
FK-1 P11083432A0332 CD O
, P11083432A0332 , O
n P11083432A0332 FW O
= P11083432A0332 FW O
8 P11083432A0332 CD O
; P11083432A0332 : O
( P11083432A0332 ( O
3 P11083432A0332 CD O
) P11083432A0332 ) O
FK-3 P11083432A0332 CD O
, P11083432A0332 , O
n P11083432A0332 FW O
= P11083432A0332 FW O
8 P11083432A0332 CD O
. P11083432A0332 . O
. . O O

UGA P09774484T0000 NNP O
codon P09774484T0000 VBZ O
position P09774484T0000 NN O
affects P09774484T0000 VBZ O
the P09774484T0000 DT O
efficiency P09774484T0000 NN O
of P09774484T0000 IN O
selenocysteine P09774484T0000 JJ O
incorporation P09774484T0000 NN O
into P09774484T0000 IN O
glutathione P09774484T0000 JJ I-UN
peroxidase-1 P09774484T0000 NN I-UN
. P09774484T0000 . O
. . O O

The P09952378A0529 DT O
odds P09952378A0529 NNS O
ratio P09952378A0529 NN O
for P09952378A0529 IN O
CHD P09952378A0529 NNP O
was P09952378A0529 VBD O
1.21 P09952378A0529 CD O
( P09952378A0529 ( O
95 P09952378A0529 CD O
% P09952378A0529 NN O
confidence P09952378A0529 NN O
interval P09952378A0529 NN O
, P09952378A0529 , O
0.84-1.75 P09952378A0529 JJ O
) P09952378A0529 ) O
given P09952378A0529 VBN O
a P09952378A0529 DT O
positive P09952378A0529 JJ O
serostatus P09952378A0529 NN O
of P09952378A0529 IN O
specific P09952378A0529 JJ O
IgG P09952378A0529 NNP I-UN
antibodies P09952378A0529 NNS O
after P09952378A0529 IN O
adjustment P09952378A0529 NN O
for P09952378A0529 IN O
covariates P09952378A0529 NNS O
. P09952378A0529 . O
. . O O

Down-regulation P09849961A0387 NN O
of P09849961A0387 IN O
IRS-1 P09849961A0387 NNP I-UN
is P09849961A0387 VBZ O
linked P09849961A0387 VBN O
to P09849961A0387 TO O
its P09849961A0387 PRP$ O
serine P09849961A0387 JJ O
phosphorylation P09849961A0387 NN O
dependent P09849961A0387 NN O
on P09849961A0387 IN O
PI P09849961A0387 NNP I-UN
3-kinase P09849961A0387 JJ I-UN
activity P09849961A0387 NN O
and P09849961A0387 CC O
appears P09849961A0387 VBZ O
required P09849961A0387 VBN O
for P09849961A0387 IN O
differentiation P09849961A0387 NN O
to P09849961A0387 TO O
occur P09849961A0387 VB O
, P09849961A0387 , O
as P09849961A0387 IN O
IRS-1 P09849961A0387 NNP I-UN
is P09849961A0387 VBZ O
not P09849961A0387 RB O
modified P09849961A0387 VBN O
and P09849961A0387 CC O
continues P09849961A0387 VBZ O
to P09849961A0387 TO O
accumulate P09849961A0387 VB O
in P09849961A0387 IN O
a P09849961A0387 DT O
nondifferentiating P09849961A0387 JJ O
myoblast P09849961A0387 NN O
cell P09849961A0387 NN O
line P09849961A0387 NN O
. P09849961A0387 . O
. . O O

We P09064659A1055 PRP O
have P09064659A1055 VBP O
thus P09064659A1055 RB O
identified P09064659A1055 VBN O
the P09064659A1055 DT O
first P09064659A1055 JJ O
mammalian P09064659A1055 JJ I-UN
homolog P09064659A1055 NN I-UN
of P09064659A1055 IN I-UN
yeast P09064659A1055 NN I-UN
UPF1 P09064659A1055 NNP I-UN
, P09064659A1055 , O
a P09064659A1055 DT O
protein P09064659A1055 NN O
that P09064659A1055 WDT O
regulates P09064659A1055 VBZ O
levels P09064659A1055 NNS O
of P09064659A1055 IN O
nonsense P09064659A1055 NN O
mRNA P09064659A1055 NN O
, P09064659A1055 , O
and P09064659A1055 CC O
we P09064659A1055 PRP O
tentatively P09064659A1055 RB O
name P09064659A1055 VBP O
this P09064659A1055 DT O
protein P09064659A1055 NN O
human P09064659A1055 JJ I-UN
HUPF1 P09064659A1055 NNP I-UN
( P09064659A1055 ( O
for P09064659A1055 IN O
human P09064659A1055 JJ I-UN
homolog P09064659A1055 NN I-UN
of P09064659A1055 IN I-UN
UPF1 P09064659A1055 NNP I-UN
) P09064659A1055 ) O
. P09064659A1055 . O
. . O O

Evidence P08856132T0000 NN O
for P08856132T0000 IN O
the P08856132T0000 DT O
promoting P08856132T0000 JJ O
role P08856132T0000 NN O
of P08856132T0000 IN O
the P08856132T0000 DT O
intra-uterine P08856132T0000 JJ I-UN
kinin P08856132T0000 NN I-UN
release P08856132T0000 NN O
in P08856132T0000 IN O
the P08856132T0000 DT O
development P08856132T0000 NN O
of P08856132T0000 IN O
late P08856132T0000 JJ O
hypertonic P08856132T0000 JJ O
saline-induced P08856132T0000 JJ O
abortion P08856132T0000 NN O
. P08856132T0000 . O
. . O O

They P08921865A1293 PRP O
lack P08921865A1293 VBP O
a P08921865A1293 DT O
predicted P08921865A1293 JJ O
single P08921865A1293 JJ O
stranded P08921865A1293 VBN O
( P08921865A1293 ( O
ss P08921865A1293 NN O
) P08921865A1293 ) O
DNA P08921865A1293 NN O
binding P08921865A1293 VBG O
motif P08921865A1293 NN O
that P08921865A1293 WDT O
is P08921865A1293 VBZ O
unique P08921865A1293 JJ O
the P08921865A1293 DT O
large P08921865A1293 JJ O
terminase P08921865A1293 NN I-UN
proteins P08921865A1293 NNS I-UN
in P08921865A1293 IN O
T4 P08921865A1293 NNP I-UN
gp17 P08921865A1293 NN I-UN
, P08921865A1293 , O
and P08921865A1293 CC O
that P08921865A1293 DT O
has P08921865A1293 VBZ O
been P08921865A1293 VBN O
implicated P08921865A1293 VBN O
in P08921865A1293 IN O
recognizing P08921865A1293 VBG O
ssDNA P08921865A1293 NN O
regions P08921865A1293 NNS O
in P08921865A1293 IN O
replicating P08921865A1293 VBG O
and P08921865A1293 CC O
recombining P08921865A1293 VBG O
T4DNA P08921865A1293 NNP O
destined P08921865A1293 VBD O
to P08921865A1293 TO O
be P08921865A1293 VB O
packaged P08921865A1293 VBN O
. P08921865A1293 . O
. . O O

Furthermore P02689439A0402 RB O
, P02689439A0402 , O
the P02689439A0402 DT O
3'-untranslated P02689439A0402 JJ O
regions P02689439A0402 NNS O
of P02689439A0402 IN O
pmGT10 P02689439A0402 NN I-UN
display P02689439A0402 NN O
a P02689439A0402 DT O
marked P02689439A0402 JJ O
degree P02689439A0402 NN O
of P02689439A0402 IN O
homology P02689439A0402 NN O
to P02689439A0402 TO O
the P02689439A0402 DT O
3 P02689439A0402 CD O
' P02689439A0402 POS O
region P02689439A0402 NN O
of P02689439A0402 IN O
the P02689439A0402 DT O
rat P02689439A0402 NN I-UN
Yb1 P02689439A0402 NNP I-UN
gene P02689439A0402 NN I-UN
, P02689439A0402 , O
while P02689439A0402 IN O
this P02689439A0402 DT O
region P02689439A0402 NN O
of P02689439A0402 IN O
pmGT2 P02689439A0402 NN I-UN
displays P02689439A0402 NNS O
marked P02689439A0402 VBD O
homology P02689439A0402 NN O
to P02689439A0402 TO O
the P02689439A0402 DT O
corresponding P02689439A0402 JJ O
region P02689439A0402 NN O
of P02689439A0402 IN O
the P02689439A0402 DT O
rat P02689439A0402 NN I-UN
Yb2 P02689439A0402 NNP I-UN
gene P02689439A0402 NN I-UN
. P02689439A0402 . O
. . O O

Acquired P10885708T0000 VBN O
bile P10885708T0000 JJ O
duct P10885708T0000 NN O
blockage P10885708T0000 NN O
: P10885708T0000 : O
entry P10885708T0000 NN O
of P10885708T0000 IN O
hepatobiliary P10885708T0000 JJ O
agent P10885708T0000 NN O
into P10885708T0000 IN O
an P10885708T0000 DT O
intrahepatic P10885708T0000 JJ O
abscess P10885708T0000 NN O
. P10885708T0000 . O
. . O O

Among P06251469A0830 IN O
six P06251469A0830 CD O
different P06251469A0830 JJ O
library P06251469A0830 JJ O
isolates P06251469A0830 NNS O
containing P06251469A0830 VBG O
6.5- P06251469A0830 JJ I-UN
to P06251469A0830 TO I-UN
7-kb P06251469A0830 JJ I-UN
IAP P06251469A0830 NNP I-UN
units P06251469A0830 NNS I-UN
, P06251469A0830 , O
some P06251469A0830 DT O
restriction P06251469A0830 NN O
sites P06251469A0830 NNS O
were P06251469A0830 VBD O
highly P06251469A0830 RB O
conserved P06251469A0830 VBN O
whereas P06251469A0830 JJ O
others P06251469A0830 NNS O
varied P06251469A0830 VBN O
in P06251469A0830 IN O
both P06251469A0830 DT O
occurrence P06251469A0830 NN O
and P06251469A0830 CC O
position P06251469A0830 NN O
. P06251469A0830 . O
. . O O

In P10850942A0989 IN O
experiment P10850942A0989 JJ O
2 P10850942A0989 CD O
, P10850942A0989 , O
no P10850942A0989 DT O
difference P10850942A0989 NN O
in P10850942A0989 IN O
gastric P10850942A0989 JJ O
emptying P10850942A0989 NN O
of P10850942A0989 IN O
40 P10850942A0989 CD O
% P10850942A0989 NN O
peptone P10850942A0989 NN O
or P10850942A0989 CC O
25 P10850942A0989 CD O
% P10850942A0989 NN O
glucose P10850942A0989 NN O
was P10850942A0989 VBD O
found P10850942A0989 VBN O
between P10850942A0989 IN O
rats P10850942A0989 NNS O
receiving P10850942A0989 VBG O
TPN P10850942A0989 NNP O
and P10850942A0989 CC O
those P10850942A0989 DT O
receiving P10850942A0989 VBG O
intragastric P10850942A0989 JJ O
nutrition P10850942A0989 NN O
for P10850942A0989 IN O
10 P10850942A0989 CD O
to P10850942A0989 TO O
12 P10850942A0989 CD O
days P10850942A0989 NNS O
. P10850942A0989 . O
. . O O

20 P09359844A0674 CD O
% P09359844A0674 NN O
of P09359844A0674 IN O
total P09359844A0674 JJ O
HSL P09359844A0674 NNP I-UN
transcripts P09359844A0674 NNS I-UN
in P09359844A0674 IN O
human P09359844A0674 JJ O
subcutaneous P09359844A0674 JJ O
adipocytes P09359844A0674 NNS O
. P09359844A0674 . O
. . O O

Molecular P09832436T0000 JJ O
cloning P09832436T0000 NN O
and P09832436T0000 CC O
characterization P09832436T0000 NN O
of P09832436T0000 IN O
a P09832436T0000 DT O
new P09832436T0000 JJ O
member P09832436T0000 NN O
of P09832436T0000 IN O
the P09832436T0000 DT O
rat P09832436T0000 NN I-UN
placental P09832436T0000 JJ I-UN
prolactin P09832436T0000 NN I-UN
( P09832436T0000 ( O
PRL P09832436T0000 NNP I-UN
) P09832436T0000 ) O
family P09832436T0000 NN O
, P09832436T0000 , O
PRL-like P09832436T0000 NNP O
protein P09832436T0000 NN I-UN
H P09832436T0000 NNP I-UN
. P09832436T0000 . O
. . O O

Efficacy P06864837T0000 NN O
of P06864837T0000 IN O
cervical P06864837T0000 JJ O
spine P06864837T0000 NN O
immobilization P06864837T0000 NN O
methods P06864837T0000 NNS O
. P06864837T0000 . O
. . O O

The P08873063A0493 DT O
deduced P08873063A0493 JJ O
amino P08873063A0493 NN O
acid P08873063A0493 JJ O
sequence P08873063A0493 NN O
of P08873063A0493 IN O
LvUSF2 P08873063A0493 NNP I-UN
is P08873063A0493 VBZ O
nearly P08873063A0493 RB O
identical P08873063A0493 JJ O
to P08873063A0493 TO O
LvUSF1 P08873063A0493 NNP I-UN
except P08873063A0493 IN O
at P08873063A0493 IN O
the P08873063A0493 DT O
amino P08873063A0493 JJ O
end P08873063A0493 NN O
, P08873063A0493 , O
where P08873063A0493 WRB O
they P08873063A0493 PRP O
are P08873063A0493 VBP O
sharply P08873063A0493 RB O
divergent P08873063A0493 JJ O
. P08873063A0493 . O
. . O O

Deletion P09529156A1238 NN O
of P09529156A1238 IN O
the P09529156A1238 DT O
last P09529156A1238 JJ O
two P09529156A1238 CD O
Ser P09529156A1238 NNP O
residues P09529156A1238 NNS O
, P09529156A1238 , O
including P09529156A1238 VBG O
one P09529156A1238 CD O
PKC P09529156A1238 NNP I-UN
consensus P09529156A1238 NN O
site P09529156A1238 NN O
in P09529156A1238 IN O
the P09529156A1238 DT O
receptor P09529156A1238 NN O
tail P09529156A1238 NN O
, P09529156A1238 , O
prevented P09529156A1238 VBD O
only P09529156A1238 RB O
phorbol P09529156A1238 JJ O
12-myristate P09529156A1238 JJ O
13-acetate-induced P09529156A1238 JJ O
desensitization P09529156A1238 NN O
by P09529156A1238 IN O
30 P09529156A1238 CD O
% P09529156A1238 NN O
. P09529156A1238 . O
. . O O

Thus P11038366A1417 RB O
, P11038366A1417 , O
methylation P11038366A1417 NN O
of P11038366A1417 IN O
Pph21p P11038366A1417 NNP I-UN
is P11038366A1417 VBZ O
important P11038366A1417 JJ O
for P11038366A1417 IN O
formation P11038366A1417 NN O
of P11038366A1417 IN O
PP2A P11038366A1417 NNP I-UN
trimeric P11038366A1417 NN I-UN
and P11038366A1417 CC I-UN
dimeric P11038366A1417 NN I-UN
complexes P11038366A1417 NNS I-UN
, P11038366A1417 , O
and P11038366A1417 CC O
consequently P11038366A1417 RB O
, P11038366A1417 , O
for P11038366A1417 IN O
PP2A P11038366A1417 NNP I-UN
function P11038366A1417 NN O
. P11038366A1417 . O
. . O O

A P01674369A0417 DT O
third P01674369A0417 JJ O
is P01674369A0417 VBZ O
a P01674369A0417 DT O
partial P01674369A0417 JJ O
element P01674369A0417 NN O
terminating P01674369A0417 VBG O
at P01674369A0417 IN O
a P01674369A0417 DT O
probable P01674369A0417 JJ O
internal P01674369A0417 JJ O
restriction P01674369A0417 NN O
site P01674369A0417 NN O
used P01674369A0417 VBN O
for P01674369A0417 IN O
cloning P01674369A0417 VBG O
. P01674369A0417 . O
. . O O

Based P11842037A0327 VBN O
on P11842037A0327 IN O
analytic P11842037A0327 JJ O
precisions P11842037A0327 NNS O
, P11842037A0327 , O
a P11842037A0327 DT O
+ P11842037A0327 NN O
/ P11842037A0327 SYM O
- P11842037A0327 : O
2 P11842037A0327 CD O
% P11842037A0327 NN O
urine-plasma P11842037A0327 JJ O
difference P11842037A0327 NN O
was P11842037A0327 VBD O
set P11842037A0327 VBN O
as P11842037A0327 IN O
the P11842037A0327 DT O
cut-off P11842037A0327 NN O
value P11842037A0327 NN O
. P11842037A0327 . O
. . O O

Synthetic P08592713T0001 JJ O
enantiomers P08592713T0001 NNS O
of P08592713T0001 IN O
drugs P08592713T0001 NNS O
. P08592713T0001 . O
. . O O

No P03194410A0771 DT O
UOxase P03194410A0771 NNP I-UN
mRNA P03194410A0771 NN I-UN
was P03194410A0771 VBD O
detected P03194410A0771 VBN O
in P03194410A0771 IN O
11 P03194410A0771 CD O
nonhepatic P03194410A0771 JJ O
tissues P03194410A0771 NNS O
of P03194410A0771 IN O
rat P03194410A0771 NN O
, P03194410A0771 , O
suggesting P03194410A0771 VBG O
tissue P03194410A0771 NN O
specificity P03194410A0771 NN O
of P03194410A0771 IN O
expression P03194410A0771 NN O
of P03194410A0771 IN O
this P03194410A0771 DT O
UOxase P03194410A0771 NNP I-UN
gene P03194410A0771 NN I-UN
. P03194410A0771 . O
. . O O

Regulation P08063775T0000 NN O
of P08063775T0000 IN O
parathyroid P08063775T0000 JJ I-UN
hormone-related P08063775T0000 JJ I-UN
protein P08063775T0000 NN I-UN
( P08063775T0000 ( O
PTHrP P08063775T0000 NNP I-UN
) P08063775T0000 ) O
gene P08063775T0000 NN O
expression P08063775T0000 NN O
. P08063775T0000 . O
. . O O

Engagement P11133830A0174 NN O
of P11133830A0174 IN O
human P11133830A0174 JJ I-UN
CD2 P11133830A0174 NNP I-UN
by P11133830A0174 IN O
mitogenic P11133830A0174 JJ O
pairs P11133830A0174 NNS O
of P11133830A0174 IN O
anti-CD2 P11133830A0174 JJ I-UN
mAb P11133830A0174 NN I-UN
induces P11133830A0174 NNS O
tyrosine P11133830A0174 VBP O
phosphorylation P11133830A0174 NN O
of P11133830A0174 IN O
a P11133830A0174 DT O
number P11133830A0174 NN O
of P11133830A0174 IN O
intracellular P11133830A0174 JJ O
proteins P11133830A0174 NNS O
including P11133830A0174 VBG O
a P11133830A0174 DT O
120 P11133830A0174 CD O
kDa P11133830A0174 NN O
phosphoprotein P11133830A0174 NN O
that P11133830A0174 IN O
we P11133830A0174 PRP O
identify P11133830A0174 VBP O
as P11133830A0174 IN O
the P11133830A0174 DT O
proto-oncogene P11133830A0174 JJ I-UN
c-Cbl P11133830A0174 NN I-UN
. P11133830A0174 . O
. . O O

Morphine P06744024A0000 NNP O
injected P06744024A0000 VBD O
into P06744024A0000 IN O
the P06744024A0000 DT O
lateral P06744024A0000 JJ O
ventricle P06744024A0000 NN O
of P06744024A0000 IN O
the P06744024A0000 DT O
rat P06744024A0000 NN O
produced P06744024A0000 VBD O
unilateral P06744024A0000 JJ O
analgesia P06744024A0000 NN O
in P06744024A0000 IN O
the P06744024A0000 DT O
formalin P06744024A0000 JJ O
test P06744024A0000 NN O
, P06744024A0000 , O
which P06744024A0000 WDT O
involves P06744024A0000 VBZ O
continuous P06744024A0000 JJ O
, P06744024A0000 , O
moderate P06744024A0000 JJ O
pain P06744024A0000 NN O
. P06744024A0000 . O
. . O O

Cdc2 P09115279A0345 NNP I-UN
co-precipitates P09115279A0345 NNS O
with P09115279A0345 IN O
Pch1 P09115279A0345 NNP I-UN
in P09115279A0345 IN O
S. P09115279A0345 NNP O
pombe P09115279A0345 NN O
cell P09115279A0345 NN O
lysates P09115279A0345 VBZ O
, P09115279A0345 , O
although P09115279A0345 IN O
Cdc2 P09115279A0345 NNP I-UN
may P09115279A0345 MD O
not P09115279A0345 RB O
be P09115279A0345 VB O
the P09115279A0345 DT O
major P09115279A0345 JJ O
catalytic P09115279A0345 JJ O
partner P09115279A0345 NN O
of P09115279A0345 IN O
a P09115279A0345 DT O
Pch1 P09115279A0345 NNP I-UN
kinase P09115279A0345 NN I-UN
in P09115279A0345 IN O
vivo P09115279A0345 NN O
. P09115279A0345 . O
. . O O

An P08532967A0364 DT O
infectious P08532967A0364 JJ O
origin P08532967A0364 NN O
should P08532967A0364 MD O
always P08532967A0364 RB O
be P08532967A0364 VB O
excluded P08532967A0364 VBN O
since P08532967A0364 IN O
specific P08532967A0364 JJ O
etiologic P08532967A0364 JJ O
therapy P08532967A0364 NN O
may P08532967A0364 MD O
be P08532967A0364 VB O
implemented P08532967A0364 VBN O
. P08532967A0364 . O
. . O O

Marrow P10784393A0000 NNP O
dysplasia P10784393A0000 NN O
is P10784393A0000 VBZ O
a P10784393A0000 DT O
major P10784393A0000 JJ O
characteristic P10784393A0000 NN O
of P10784393A0000 IN O
patients P10784393A0000 NNS O
with P10784393A0000 IN O
myelodysplastic P10784393A0000 JJ O
syndrome P10784393A0000 NN O
( P10784393A0000 ( O
MDS P10784393A0000 NNP O
) P10784393A0000 ) O
, P10784393A0000 , O
along P10784393A0000 IN O
with P10784393A0000 IN O
marrow P10784393A0000 JJ O
blastosis P10784393A0000 NN O
, P10784393A0000 , O
cytopenia P10784393A0000 NN O
and P10784393A0000 CC O
cytogenetic P10784393A0000 JJ O
anomalies P10784393A0000 NNS O
. P10784393A0000 . O
. . O O

Preheparin P10428294A0227 NNP O
LPL P10428294A0227 NNP I-UN
mass P10428294A0227 NNP O
level P10428294A0227 NN O
did P10428294A0227 VBD O
not P10428294A0227 RB O
significantly P10428294A0227 RB O
differ P10428294A0227 VB O
in P10428294A0227 IN O
individuals P10428294A0227 NNS O
from P10428294A0227 IN O
19 P10428294A0227 CD O
to P10428294A0227 TO O
70 P10428294A0227 CD O
years P10428294A0227 NNS O
old P10428294A0227 JJ O
, P10428294A0227 , O
for P10428294A0227 IN O
both P10428294A0227 DT O
men P10428294A0227 NNS O
and P10428294A0227 CC O
women P10428294A0227 NNS O
. P10428294A0227 . O
. . O O

Serum P07174122A0000 NNP I-UN
creatine P07174122A0000 NN I-UN
kinase P07174122A0000 NN I-UN
( P07174122A0000 ( O
SCK P07174122A0000 NNP I-UN
) P07174122A0000 ) O
was P07174122A0000 VBD O
measured P07174122A0000 VBN O
in P07174122A0000 IN O
ten P07174122A0000 JJ O
subjects P07174122A0000 NNS O
in P07174122A0000 IN O
the P07174122A0000 DT O
laboratory P07174122A0000 NN O
before P07174122A0000 IN O
and P07174122A0000 CC O
after P07174122A0000 IN O
the P07174122A0000 DT O
performance P07174122A0000 NN O
of P07174122A0000 IN O
bicycle P07174122A0000 NN O
ergometry P07174122A0000 NN O
and P07174122A0000 CC O
a P07174122A0000 DT O
lifting P07174122A0000 NN O
task P07174122A0000 NN O
. P07174122A0000 . O
. . O O

Genetic P09858713A1174 NNP O
and P09858713A1174 CC O
molecular P09858713A1174 JJ O
data P09858713A1174 NNS O
indicate P09858713A1174 VBP O
that P09858713A1174 IN O
wild-type P09858713A1174 JJ I-UN
Pan P09858713A1174 NNP I-UN
and P09858713A1174 CC O
CiD P09858713A1174 NNP I-UN
compete P09858713A1174 VBP O
for P09858713A1174 IN O
binding P09858713A1174 VBG O
to P09858713A1174 TO O
Arm P09858713A1174 NNP I-UN
, P09858713A1174 , O
leading P09858713A1174 VBG O
to P09858713A1174 TO O
a P09858713A1174 DT O
compromised P09858713A1174 JJ O
transduction P09858713A1174 NN O
of P09858713A1174 IN O
the P09858713A1174 DT O
Wg P09858713A1174 NNP I-UN
signal P09858713A1174 NN O
in P09858713A1174 IN O
heterozygous P09858713A1174 JJ O
ciD P09858713A1174 NN I-UN
/ P09858713A1174 NNP I-UN
+ P09858713A1174 NNP I-UN
animals P09858713A1174 NNS O
and P09858713A1174 CC O
to P09858713A1174 TO O
a P09858713A1174 DT O
dramatic P09858713A1174 JJ O
enhancement P09858713A1174 NN O
of P09858713A1174 IN O
the P09858713A1174 DT O
gain-of-function P09858713A1174 NN O
activity P09858713A1174 NN O
of P09858713A1174 IN O
CiD P09858713A1174 NNP I-UN
in P09858713A1174 IN O
homozygous P09858713A1174 JJ O
mutants P09858713A1174 NNS O
. P09858713A1174 . O
. . O O

The P11353392A1127 DT O
frameshift P11353392A1127 NN O
initiated P11353392A1127 VBN O
by P11353392A1127 IN O
ADEx2 P11353392A1127 NNP O
is P11353392A1127 VBZ O
believed P11353392A1127 VBN O
to P11353392A1127 TO O
alter P11353392A1127 VB O
the P11353392A1127 DT O
regular P11353392A1127 JJ O
coding P11353392A1127 NN O
sequence P11353392A1127 NN O
, P11353392A1127 , O
acting P11353392A1127 VBG O
as P11353392A1127 IN O
a P11353392A1127 DT O
loss-of-function P11353392A1127 NN O
ASIP P11353392A1127 NNP I-UN
mutation P11353392A1127 NN I-UN
. P11353392A1127 . O
. . O O

The P09188699A1388 DT O
extended P09188699A1388 JJ O
rat P09188699A1388 NN I-UN
SP-A P09188699A1388 JJ I-UN
isoforms P09188699A1388 NNS I-UN
were P09188699A1388 VBD O
enriched P09188699A1388 VBN O
in P09188699A1388 IN O
the P09188699A1388 DT O
more P09188699A1388 RBR O
fully P09188699A1388 RB O
glycosylated P09188699A1388 VBN O
and P09188699A1388 CC O
multimeric P09188699A1388 JJ O
SP-A P09188699A1388 NNP I-UN
species P09188699A1388 NNS O
separated P09188699A1388 VBD O
on P09188699A1388 IN O
SDS-PAGE P09188699A1388 NNP O
gels P09188699A1388 NNS O
. P09188699A1388 . O
. . O O

She P11479104A0446 PRP O
has P11479104A0446 VBZ O
since P11479104A0446 IN O
developed P11479104A0446 VBN O
a P11479104A0446 DT O
positive P11479104A0446 JJ O
anti-cardiolipin P11479104A0446 NN I-UN
antibody P11479104A0446 NN I-UN
but P11479104A0446 CC O
does P11479104A0446 VBZ O
not P11479104A0446 RB O
meet P11479104A0446 VB O
diagnostic P11479104A0446 JJ O
criteria P11479104A0446 NNS O
for P11479104A0446 IN O
systemic P11479104A0446 JJ O
lupus P11479104A0446 NN O
erythematosis P11479104A0446 NN O
. P11479104A0446 . O
CONCLUSION P11479104A0446 NN O
: P11479104A0446 : O
The P11479104A0446 DT O
presence P11479104A0446 NN O
of P11479104A0446 IN O
known P11479104A0446 VBN O
autoimmune P11479104A0446 JJ O
disease P11479104A0446 NN O
in P11479104A0446 IN O
a P11479104A0446 DT O
woman P11479104A0446 NN O
with P11479104A0446 IN O
POF P11479104A0446 NNP O
should P11479104A0446 MD O
not P11479104A0446 RB O
dissuade P11479104A0446 VB O
the P11479104A0446 DT O
clinician P11479104A0446 NN O
from P11479104A0446 IN O
evaluating P11479104A0446 VBG O
for P11479104A0446 IN O
a P11479104A0446 DT O
potential P11479104A0446 JJ O
genetic P11479104A0446 JJ O
cause P11479104A0446 NN O
. P11479104A0446 . O
. . O O

During P08421897A0000 IN O
the P08421897A0000 DT O
past P08421897A0000 JJ O
decade P08421897A0000 NN O
, P08421897A0000 , O
different P08421897A0000 JJ O
types P08421897A0000 NNS O
of P08421897A0000 IN O
endogenous P08421897A0000 JJ O
retroviral P08421897A0000 JJ O
sequences P08421897A0000 NNS O
have P08421897A0000 VBP O
been P08421897A0000 VBN O
defined P08421897A0000 VBN O
in P08421897A0000 IN O
the P08421897A0000 DT O
human P08421897A0000 JJ O
genome P08421897A0000 NN O
usually P08421897A0000 RB O
by P08421897A0000 IN O
low P08421897A0000 JJ O
stringency P08421897A0000 NN O
hybridization P08421897A0000 NN O
employing P08421897A0000 VBG O
DNA P08421897A0000 NNP O
probes P08421897A0000 NNS O
of P08421897A0000 IN O
evolutionary P08421897A0000 JJ O
conserved P08421897A0000 VBN O
animal P08421897A0000 JJ O
retrovirus P08421897A0000 NN O
genes P08421897A0000 NNS O
. P08421897A0000 . O
. . O O

This P11335710A0320 DT O
was P11335710A0320 VBD O
most P11335710A0320 RBS O
pronounced P11335710A0320 JJ O
during P11335710A0320 IN O
the P11335710A0320 DT O
initial P11335710A0320 JJ O
phase P11335710A0320 NN O
of P11335710A0320 IN O
Erk P11335710A0320 NNP I-UN
activation P11335710A0320 NN O
. P11335710A0320 . O
. . O O

Furthermore P08388543A1263 RB O
, P08388543A1263 , O
a P08388543A1263 DT O
mutant P08388543A1263 JJ O
receptor P08388543A1263 NN O
( P08388543A1263 ( O
Y977F P08388543A1263 NNP O
/ P08388543A1263 NNP O
Y989F P08388543A1263 NNP O
[ P08388543A1263 NNP O
PLC P08388543A1263 NNP I-UN
gamma-binding P08388543A1263 NN O
sites P08388543A1263 NNS O
] P08388543A1263 VBP O
) P08388543A1263 ) O
could P08388543A1263 MD O
fully P08388543A1263 RB O
activate P08388543A1263 VB O
Ras P08388543A1263 NNP I-UN
, P08388543A1263 , O
and P08388543A1263 CC O
the P08388543A1263 DT O
direct P08388543A1263 JJ O
activation P08388543A1263 NN O
of P08388543A1263 IN O
protein P08388543A1263 JJ I-UN
kinase P08388543A1263 NN I-UN
C P08388543A1263 NNP I-UN
and P08388543A1263 CC O
calcium P08388543A1263 NN O
mobilization P08388543A1263 NN O
had P08388543A1263 VBD O
almost P08388543A1263 RB O
no P08388543A1263 DT O
effect P08388543A1263 NN O
on P08388543A1263 IN O
the P08388543A1263 DT O
GDP P08388543A1263 NNP O
/ P08388543A1263 NNP O
GTP P08388543A1263 NNP O
state P08388543A1263 NN O
of P08388543A1263 IN O
Ras P08388543A1263 NNP I-UN
in P08388543A1263 IN O
this P08388543A1263 DT O
cell P08388543A1263 NN O
line P08388543A1263 NN O
. P08388543A1263 . O
. . O O

We P10705380A0629 PRP O
also P10705380A0629 RB O
show P10705380A0629 VBP O
that P10705380A0629 IN O
zygotically P10705380A0629 RB O
activated P10705380A0629 VBN O
Xretpos P10705380A0629 NN O
transcripts P10705380A0629 NNS O
are P10705380A0629 VBP O
restricted P10705380A0629 VBN O
to P10705380A0629 TO O
ventro-posterior P10705380A0629 JJ O
specific P10705380A0629 JJ O
regions P10705380A0629 NNS O
and P10705380A0629 CC O
induced P10705380A0629 VBN O
by P10705380A0629 IN O
UV-irradiation P10705380A0629 NNP O
and P10705380A0629 CC O
BMP-4 P10705380A0629 NNP I-UN
overexpression P10705380A0629 NN O
in P10705380A0629 IN O
cycloheximide-dependent P10705380A0629 JJ O
way P10705380A0629 NN O
. P10705380A0629 . O
genesis P10705380A0629 NN O
26:198-207 P10705380A0629 CD O
, P10705380A0629 , O
2000 P10705380A0629 CD O
. P10705380A0629 . O
. . O O

Inspired P02113901A0000 NNP O
CO2 P02113901A0000 NNP O
causing P02113901A0000 VBG O
changes P02113901A0000 NNS O
from P02113901A0000 IN O
hypo- P02113901A0000 NN O
to P02113901A0000 TO O
normocapnia P02113901A0000 VB O
has P02113901A0000 VBZ O
previously P02113901A0000 RB O
been P02113901A0000 VBN O
shown P02113901A0000 VBN O
to P02113901A0000 TO O
improve P02113901A0000 VB O
arterial P02113901A0000 JJ O
O2 P02113901A0000 NNP O
tension P02113901A0000 NN O
( P02113901A0000 ( O
PaO2 P02113901A0000 NNP O
) P02113901A0000 ) O
and P02113901A0000 CC O
to P02113901A0000 TO O
reduce P02113901A0000 VB O
alveolar-arterial P02113901A0000 JJ O
O2 P02113901A0000 NNP O
difference P02113901A0000 NN O
. P02113901A0000 . O
. . O O

SRE P09165004A1700 NNP O
activity P09165004A1700 NN O
is P09165004A1700 VBZ O
dependent P09165004A1700 JJ O
upon P09165004A1700 IN O
the P09165004A1700 DT O
activation P09165004A1700 NN O
by P09165004A1700 IN O
phosphorylation P09165004A1700 NN O
of P09165004A1700 IN O
a P09165004A1700 DT O
ternary P09165004A1700 JJ O
complex P09165004A1700 JJ O
factor P09165004A1700 NN O
; P09165004A1700 : O
included P09165004A1700 VBN O
among P09165004A1700 IN O
the P09165004A1700 DT O
ternary P09165004A1700 JJ O
complex P09165004A1700 JJ O
factors P09165004A1700 NNS O
is P09165004A1700 VBZ O
Elk-1 P09165004A1700 NNP I-UN
. P09165004A1700 . O
. . O O

Two P03029111A0155 CD O
mutants P03029111A0155 NNS O
, P03029111A0155 , O
each P03029111A0155 DT O
representative P03029111A0155 NN O
of P03029111A0155 IN O
a P03029111A0155 DT O
separate P03029111A0155 JJ O
pet P03029111A0155 JJ I-UN
complementation P03029111A0155 NN O
group P03029111A0155 NN O
, P03029111A0155 , O
have P03029111A0155 VBP O
been P03029111A0155 VBN O
analyzed P03029111A0155 VBN O
. P03029111A0155 . O
. . O O

Fasting P07426101A0124 VBG O
plasma P07426101A0124 NN O
and P07426101A0124 CC O
lipoprotein P07426101A0124 NN O
lipid P07426101A0124 JJ O
concentrations P07426101A0124 NNS O
, P07426101A0124 , O
adipose P07426101A0124 JJ I-UN
tissue P07426101A0124 NN I-UN
lipoprotein P07426101A0124 JJ I-UN
lipase P07426101A0124 NN I-UN
activity P07426101A0124 NN O
, P07426101A0124 , O
anthropometric P07426101A0124 JJ O
data P07426101A0124 NNS O
, P07426101A0124 , O
alcohol P07426101A0124 NN O
consumption P07426101A0124 NN O
, P07426101A0124 , O
smoking P07426101A0124 VBG O
habits P07426101A0124 NNS O
, P07426101A0124 , O
weekly P07426101A0124 JJ O
mileage P07426101A0124 NN O
run P07426101A0124 NN O
and P07426101A0124 CC O
performance P07426101A0124 NN O
on P07426101A0124 IN O
a P07426101A0124 DT O
bicycle P07426101A0124 NN O
ergometer P07426101A0124 NN O
were P07426101A0124 VBD O
recorded P07426101A0124 VBN O
before P07426101A0124 IN O
and P07426101A0124 CC O
after P07426101A0124 IN O
the P07426101A0124 DT O
training P07426101A0124 NN O
period P07426101A0124 NN O
. P07426101A0124 . O
. . O O

Neuronal P09425676A0000 JJ O
mechanisms P09425676A0000 NNS O
underlying P09425676A0000 VBG O
stimulus-response P09425676A0000 JJ O
( P09425676A0000 ( O
S-R P09425676A0000 NNP O
) P09425676A0000 ) O
associations P09425676A0000 NNS O
in P09425676A0000 IN O
S-R P09425676A0000 NNP O
compatibility P09425676A0000 NN O
tasks P09425676A0000 NNS O
were P09425676A0000 VBD O
identified P09425676A0000 VBN O
in P09425676A0000 IN O
2 P09425676A0000 CD O
experiments P09425676A0000 NNS O
with P09425676A0000 IN O
monkeys P09425676A0000 NNS O
. P09425676A0000 . O
. . O O

Expression P11145563A0303 NN O
of P11145563A0303 IN O
SREBP-1a P11145563A0303 NNP I-UN
stimulated P11145563A0303 VBD O
StAR P11145563A0303 NNP I-UN
promoter P11145563A0303 NN I-UN
activity P11145563A0303 NN O
in P11145563A0303 IN O
the P11145563A0303 DT O
context P11145563A0303 NN O
of P11145563A0303 IN O
COS-1 P11145563A0303 NNP O
cells P11145563A0303 NNS O
and P11145563A0303 CC O
human P11145563A0303 JJ O
granulosa-lutein P11145563A0303 JJ O
cells P11145563A0303 NNS O
. P11145563A0303 . O
. . O O

We P09840943A0144 PRP O
have P09840943A0144 VBP O
isolated P09840943A0144 VBN O
a P09840943A0144 DT O
novel P09840943A0144 JJ O
human P09840943A0144 JJ I-UN
cyclin P09840943A0144 NN I-UN
, P09840943A0144 , O
cyclin P09840943A0144 NN I-UN
E2 P09840943A0144 NNP I-UN
, P09840943A0144 , O
that P09840943A0144 WDT O
contains P09840943A0144 VBZ O
significant P09840943A0144 JJ O
homology P09840943A0144 NN O
to P09840943A0144 TO O
cyclin P09840943A0144 VB I-UN
E P09840943A0144 NNP I-UN
. P09840943A0144 . O
. . O O

The P07730337A1439 DT O
Ng P07730337A1439 NNP I-UN
/ P07730337A1439 NNP I-UN
RC3 P07730337A1439 NNP I-UN
and P07730337A1439 CC O
PKC-gamma P07730337A1439 NNP I-UN
genes P07730337A1439 NNS I-UN
have P07730337A1439 VBP O
a P07730337A1439 DT O
similar P07730337A1439 JJ O
expression P07730337A1439 NN O
pattern P07730337A1439 NN O
in P07730337A1439 IN O
the P07730337A1439 DT O
brain P07730337A1439 NN O
during P07730337A1439 IN O
development P07730337A1439 NN O
. P07730337A1439 . O
. . O O

In P10918599A0071 IN O
contrast P10918599A0071 NN O
to P10918599A0071 TO O
full-length P10918599A0071 JJ I-UN
E2F-3 P10918599A0071 NNP I-UN
, P10918599A0071 , O
which P10918599A0071 WDT O
is P10918599A0071 VBZ O
expressed P10918599A0071 VBN O
only P10918599A0071 RB O
at P10918599A0071 IN O
the P10918599A0071 DT O
G1 P10918599A0071 NNP O
/ P10918599A0071 NNP O
S P10918599A0071 NNP O
boundary P10918599A0071 JJ O
, P10918599A0071 , O
E2F-3B P10918599A0071 NNP I-UN
is P10918599A0071 VBZ O
detected P10918599A0071 VBN O
throughout P10918599A0071 IN O
the P10918599A0071 DT O
cell P10918599A0071 NN O
cycle P10918599A0071 NN O
with P10918599A0071 IN O
peak P10918599A0071 NN O
levels P10918599A0071 NNS O
in P10918599A0071 IN O
GO P10918599A0071 NNP O
where P10918599A0071 WRB O
it P10918599A0071 PRP O
is P10918599A0071 VBZ O
associated P10918599A0071 VBN O
with P10918599A0071 IN O
Rb P10918599A0071 NNP I-UN
. P10918599A0071 . O
. . O O

Areas P09084621A2567 NNS O
with P09084621A2567 IN O
significantly P09084621A2567 RB O
greater P09084621A2567 JJR O
rCBF P09084621A2567 NN O
for P09084621A2567 IN O
targeting P09084621A2567 VBG O
were P09084621A2567 VBD O
the P09084621A2567 DT O
left P09084621A2567 JJ O
motor P09084621A2567 NN O
cortex P09084621A2567 NN O
, P09084621A2567 , O
left P09084621A2567 VBD O
intraparietal P09084621A2567 JJ O
sulcus P09084621A2567 NN O
, P09084621A2567 , O
and P09084621A2567 CC O
left P09084621A2567 VBD O
caudate P09084621A2567 NN O
. P09084621A2567 . O
. . O O

We P07596697A0971 PRP O
conclude P07596697A0971 VBP O
that P07596697A0971 IN O
pancreatic P07596697A0971 JJ O
polypeptide P07596697A0971 NN O
and P07596697A0971 CC O
motilin P07596697A0971 NN I-UN
responses P07596697A0971 NNS O
to P07596697A0971 TO O
a P07596697A0971 DT O
meal P07596697A0971 NN O
are P07596697A0971 VBP O
different P07596697A0971 JJ O
in P07596697A0971 IN O
encopretic P07596697A0971 JJ O
children P07596697A0971 NNS O
than P07596697A0971 IN O
in P07596697A0971 IN O
children P07596697A0971 NNS O
in P07596697A0971 IN O
the P07596697A0971 DT O
control P07596697A0971 NN O
group P07596697A0971 NN O
. P07596697A0971 . O
. . O O

These P10722737A1726 DT O
findings P10722737A1726 NNS O
indicate P10722737A1726 VBP O
the P10722737A1726 DT O
involvement P10722737A1726 NN O
of P10722737A1726 IN O
Sp1 P10722737A1726 NNP I-UN
and P10722737A1726 CC O
an P10722737A1726 DT O
Inr P10722737A1726 NNP O
in P10722737A1726 IN O
non-cell-specific P10722737A1726 JJ O
regulation P10722737A1726 NN O
and P10722737A1726 CC O
a P10722737A1726 DT O
Kruppel-like P10722737A1726 JJ I-UN
transcription P10722737A1726 NN I-UN
factor P10722737A1726 NN I-UN
and P10722737A1726 CC O
Sp1 P10722737A1726 NNP I-UN
in P10722737A1726 IN O
the P10722737A1726 DT O
cell-specific P10722737A1726 JJ O
regulation P10722737A1726 NN O
of P10722737A1726 IN O
the P10722737A1726 DT O
LTC P10722737A1726 NNP I-UN
( P10722737A1726 ( I-UN
4 P10722737A1726 CD I-UN
) P10722737A1726 ) I-UN
S P10722737A1726 NNP I-UN
gene P10722737A1726 NN I-UN
. P10722737A1726 . O
. . O O

The P07125238T0000 DT O
pia P07125238T0000 NN O
mater P07125238T0000 NN O
at P07125238T0000 IN O
the P07125238T0000 DT O
site P07125238T0000 NN O
of P07125238T0000 IN O
the P07125238T0000 DT O
entry P07125238T0000 NN O
of P07125238T0000 IN O
blood P07125238T0000 NN O
vessels P07125238T0000 NNS O
into P07125238T0000 IN O
the P07125238T0000 DT O
central P07125238T0000 JJ O
nervous P07125238T0000 JJ O
system P07125238T0000 NN O
. P07125238T0000 . O
. . O O

At P07463294A1216 IN O
4 P07463294A1216 CD O
wk P07463294A1216 NN O
however P07463294A1216 RB O
, P07463294A1216 , O
tumor P07463294A1216 NN O
relapse P07463294A1216 NN O
was P07463294A1216 VBD O
noted P07463294A1216 VBN O
in P07463294A1216 IN O
6 P07463294A1216 CD O
of P07463294A1216 IN O
7 P07463294A1216 CD O
group P07463294A1216 NN O
4 P07463294A1216 CD O
responders P07463294A1216 NNS O
, P07463294A1216 , O
10 P07463294A1216 CD O
of P07463294A1216 IN O
12 P07463294A1216 CD O
in P07463294A1216 IN O
group P07463294A1216 NN O
5 P07463294A1216 CD O
, P07463294A1216 , O
13 P07463294A1216 CD O
of P07463294A1216 IN O
16 P07463294A1216 CD O
in P07463294A1216 IN O
group P07463294A1216 NN O
7 P07463294A1216 CD O
, P07463294A1216 , O
but P07463294A1216 CC O
only P07463294A1216 RB O
4 P07463294A1216 CD O
of P07463294A1216 IN O
19 P07463294A1216 CD O
group P07463294A1216 NN O
8 P07463294A1216 CD O
responders P07463294A1216 NNS O
( P07463294A1216 ( O
p P07463294A1216 NN O
less P07463294A1216 JJR O
than P07463294A1216 IN O
.001 P07463294A1216 NNP O
group P07463294A1216 NN O
8 P07463294A1216 CD O
versus P07463294A1216 NN O
4 P07463294A1216 CD O
, P07463294A1216 , O
5 P07463294A1216 CD O
, P07463294A1216 , O
7 P07463294A1216 CD O
) P07463294A1216 ) O
. P07463294A1216 . O
. . O O

Transactivation P08164679A0809 NN O
domain P08164679A0809 NN O
is P08164679A0809 VBZ O
located P08164679A0809 VBN O
downstream P08164679A0809 NN O
of P08164679A0809 IN O
the P08164679A0809 DT O
128-amino-acid P08164679A0809 JJ I-UN
runt P08164679A0809 NN I-UN
homology P08164679A0809 NN I-UN
region P08164679A0809 NN I-UN
, P08164679A0809 , O
referred P08164679A0809 VBD O
to P08164679A0809 TO O
as P08164679A0809 IN O
the P08164679A0809 DT O
Runt P08164679A0809 NNP I-UN
domain P08164679A0809 NN I-UN
. P08164679A0809 . O
. . O O

Skeletal P01934378A1219 JJ O
muscle P01934378A1219 NN O
metaboreceptor P01934378A1219 NN O
responses P01934378A1219 NNS O
are P01934378A1219 VBP O
impaired P01934378A1219 VBN O
in P01934378A1219 IN O
heart P01934378A1219 NN O
failure P01934378A1219 NN O
. P01934378A1219 . O
. . O O

JPEG P10654032A1133 NNP O
53 P10654032A1133 CD O
, P10654032A1133 , O
resulting P10654032A1133 VBG O
in P10654032A1133 IN O
a P10654032A1133 DT O
compression P10654032A1133 NN O
ratio P10654032A1133 NN O
of P10654032A1133 IN O
1:21 P10654032A1133 CD O
, P10654032A1133 , O
does P10654032A1133 VBZ O
not P10654032A1133 RB O
compromise P10654032A1133 VB O
the P10654032A1133 DT O
diagnostic P10654032A1133 JJ O
performance P10654032A1133 NN O
in P10654032A1133 IN O
general P10654032A1133 JJ O
. P10654032A1133 . O
. . O O

Potential P02642976A1474 JJ O
consensus P02642976A1474 NN O
sequences P02642976A1474 NNS O
for P02642976A1474 IN O
early P02642976A1474 RB O
and P02642976A1474 CC O
late P02642976A1474 JJ O
regulatory P02642976A1474 JJ O
elements P02642976A1474 NNS O
were P02642976A1474 VBD O
identified P02642976A1474 VBN O
. P02642976A1474 . O
. . O O

Several P07228955A0000 JJ O
authors P07228955A0000 NNS O
have P07228955A0000 VBP O
recently P07228955A0000 RB O
reported P07228955A0000 VBN O
interference P07228955A0000 NN O
in P07228955A0000 IN O
theophylline P07228955A0000 JJ O
analysis P07228955A0000 NN O
by P07228955A0000 IN O
paraxanthine P07228955A0000 NN O
( P07228955A0000 ( O
1,7-dimethylxanthine P07228955A0000 JJ O
) P07228955A0000 ) O
, P07228955A0000 , O
an P07228955A0000 DT O
important P07228955A0000 JJ O
metabolite P07228955A0000 NN O
of P07228955A0000 IN O
caffeine P07228955A0000 NN O
. P07228955A0000 . O
. . O O

The P10629035A0827 DT O
single P10629035A0827 JJ O
strandedness P10629035A0827 NN O
is P10629035A0827 VBZ O
manifested P10629035A0827 VBN O
as P10629035A0827 IN O
a P10629035A0827 DT O
terminal P10629035A0827 JJ O
extension P10629035A0827 NN O
of P10629035A0827 IN O
the P10629035A0827 DT O
G-rich P10629035A0827 NNP O
strand P10629035A0827 NN O
( P10629035A0827 ( O
G P10629035A0827 NNP O
tails P10629035A0827 NNS O
) P10629035A0827 ) O
that P10629035A0827 WDT O
can P10629035A0827 MD O
occur P10629035A0827 VB O
independently P10629035A0827 RB O
of P10629035A0827 IN O
telomerase P10629035A0827 NN I-UN
, P10629035A0827 , O
suggesting P10629035A0827 VBG O
that P10629035A0827 IN O
cdc17 P10629035A0827 NN I-UN
/ P10629035A0827 NNP O
pol1 P10629035A0827 NN I-UN
mutants P10629035A0827 NNS O
exhibit P10629035A0827 NN O
defects P10629035A0827 NNS O
in P10629035A0827 IN O
telomeric P10629035A0827 JJ O
lagging-strand P10629035A0827 JJ O
synthesis P10629035A0827 NN O
. P10629035A0827 . O
. . O O

The P03278829A0082 DT O
indications P03278829A0082 NNS O
for P03278829A0082 IN O
its P03278829A0082 PRP$ O
use P03278829A0082 NN O
include P03278829A0082 VBP O
every P03278829A0082 DT O
primary P03278829A0082 JJ O
and P03278829A0082 CC O
secondary P03278829A0082 JJ O
rhinoplasty P03278829A0082 NN O
candidate P03278829A0082 NN O
unless P03278829A0082 IN O
tip P03278829A0082 JJ O
grafts P03278829A0082 NNS O
are P03278829A0082 VBP O
going P03278829A0082 VBG O
to P03278829A0082 TO O
be P03278829A0082 VB O
under P03278829A0082 IN O
tension P03278829A0082 NN O
or P03278829A0082 CC O
if P03278829A0082 IN O
the P03278829A0082 DT O
deformity P03278829A0082 NN O
is P03278829A0082 VBZ O
minor P03278829A0082 JJ O
. P03278829A0082 . O
. . O O

These P10799501A1391 DT O
studies P10799501A1391 NNS O
suggest P10799501A1391 VBP O
an P10799501A1391 DT O
additional P10799501A1391 JJ O
component P10799501A1391 NN O
or P10799501A1391 CC O
cellular P10799501A1391 JJ O
environment P10799501A1391 NN O
is P10799501A1391 VBZ O
required P10799501A1391 VBN O
for P10799501A1391 IN O
SPRK P10799501A1391 NNP I-UN
activation P10799501A1391 NN O
by P10799501A1391 IN O
Cdc42 P10799501A1391 NNP I-UN
. P10799501A1391 . O
. . O O

The P04032716A0299 DT O
mean P04032716A0299 NN O
transfer P04032716A0299 NN O
ratios P04032716A0299 NNS O
of P04032716A0299 IN O
the P04032716A0299 DT O
drug P04032716A0299 NN O
into P04032716A0299 IN O
the P04032716A0299 DT O
genital P04032716A0299 JJ O
tissues P04032716A0299 NNS O
to P04032716A0299 TO O
the P04032716A0299 DT O
concentration P04032716A0299 NN O
in P04032716A0299 IN O
the P04032716A0299 DT O
uterine P04032716A0299 JJ O
arterial P04032716A0299 JJ O
blood P04032716A0299 NN O
were P04032716A0299 VBD O
such P04032716A0299 JJ O
that P04032716A0299 IN O
the P04032716A0299 DT O
transfer P04032716A0299 NN O
ratio P04032716A0299 NN O
into P04032716A0299 IN O
the P04032716A0299 DT O
portio P04032716A0299 NN O
vaginalis P04032716A0299 NN O
was P04032716A0299 VBD O
the P04032716A0299 DT O
highest P04032716A0299 JJS O
, P04032716A0299 , O
followed P04032716A0299 VBN O
by P04032716A0299 IN O
the P04032716A0299 DT O
uterine P04032716A0299 JJ O
cervix P04032716A0299 NN O
and P04032716A0299 CC O
the P04032716A0299 DT O
myometrium P04032716A0299 NN O
, P04032716A0299 , O
and P04032716A0299 CC O
that P04032716A0299 DT O
into P04032716A0299 IN O
the P04032716A0299 DT O
oviduct P04032716A0299 NN O
was P04032716A0299 VBD O
the P04032716A0299 DT O
lowest P04032716A0299 JJS O
with P04032716A0299 IN O
about P04032716A0299 RB O
1 P04032716A0299 CD O
/ P04032716A0299 NNS O
2 P04032716A0299 CD O
that P04032716A0299 WDT O
into P04032716A0299 IN O
the P04032716A0299 DT O
portio P04032716A0299 NN O
vaginalis P04032716A0299 NN O
. P04032716A0299 . O
. . O O

Molecular P07680629T0000 JJ O
cloning P07680629T0000 NN O
and P07680629T0000 CC O
characterization P07680629T0000 NN O
of P07680629T0000 IN O
two P07680629T0000 CD O
genes P07680629T0000 NNS I-UN
encoding P07680629T0000 VBG I-UN
gp138 P07680629T0000 NN I-UN
, P07680629T0000 , O
a P07680629T0000 DT O
cell P07680629T0000 NN O
surface P07680629T0000 NN O
glycoprotein P07680629T0000 NN O
involved P07680629T0000 VBN O
in P07680629T0000 IN O
the P07680629T0000 DT O
sexual P07680629T0000 JJ O
cell P07680629T0000 NN O
fusion P07680629T0000 NN O
of P07680629T0000 IN O
Dictyostelium P07680629T0000 NNP O
discoideum P07680629T0000 NN O
. P07680629T0000 . O
. . O O

Our P02164604A0399 PRP$ O
studies P02164604A0399 NNS O
extend P02164604A0399 VBP O
these P02164604A0399 DT O
findings P02164604A0399 NNS O
and P02164604A0399 CC O
show P02164604A0399 NN O
that P02164604A0399 IN O
the P02164604A0399 DT O
E2 P02164604A0399 NNP I-UN
transactivation P02164604A0399 NN I-UN
gene P02164604A0399 NN I-UN
is P02164604A0399 VBZ O
expressed P02164604A0399 VBN O
from P02164604A0399 IN O
multiple P02164604A0399 JJ O
promoters P02164604A0399 NNS O
. P02164604A0399 . O
. . O O

The P03346210A0000 DT O
epidermal P03346210A0000 JJ I-UN
growth P03346210A0000 NN I-UN
factor P03346210A0000 NN I-UN
( P03346210A0000 ( I-UN
EGF P03346210A0000 NNP I-UN
) P03346210A0000 ) I-UN
receptor P03346210A0000 NN I-UN
, P03346210A0000 , O
which P03346210A0000 WDT O
exhibits P03346210A0000 VBZ O
intrinsic P03346210A0000 JJ O
protein P03346210A0000 NN I-UN
tyrosine P03346210A0000 JJ I-UN
kinase P03346210A0000 NN I-UN
activity P03346210A0000 NN O
, P03346210A0000 , O
undergoes P03346210A0000 VBZ O
a P03346210A0000 DT O
rapid P03346210A0000 JJ O
, P03346210A0000 , O
intramolecular P03346210A0000 JJ O
self-phosphorylation P03346210A0000 NN O
reaction P03346210A0000 NN O
following P03346210A0000 VBG O
EGF P03346210A0000 NNP I-UN
activation P03346210A0000 NN O
. P03346210A0000 . O
. . O O

A P08204403A0000 DT O
total P08204403A0000 NN O
of P08204403A0000 IN O
7 P08204403A0000 CD O
( P08204403A0000 ( O
4 P08204403A0000 CD O
males P08204403A0000 NNS O
and P08204403A0000 CC O
3 P08204403A0000 CD O
females P08204403A0000 NNS O
) P08204403A0000 ) O
patients P08204403A0000 NNS O
were P08204403A0000 VBD O
included P08204403A0000 VBN O
in P08204403A0000 IN O
this P08204403A0000 DT O
retrospective P08204403A0000 JJ O
study P08204403A0000 NN O
to P08204403A0000 TO O
determine P08204403A0000 VB O
the P08204403A0000 DT O
sensitivity P08204403A0000 NN O
of P08204403A0000 IN O
radioimmunoscintigraphy P08204403A0000 NN O
with P08204403A0000 IN O
I-131 P08204403A0000 NNP O
labeled P08204403A0000 VBD O
anti P08204403A0000 RP I-UN
CEA P08204403A0000 NNP I-UN
/ P08204403A0000 NNP O
CA P08204403A0000 NNP I-UN
19-9 P08204403A0000 JJ I-UN
monoclonal P08204403A0000 JJ O
antibodies P08204403A0000 NNS O
. P08204403A0000 . O
. . O O

Consistent P11331613A0827 JJ O
effects P11331613A0827 NNS O
on P11331613A0827 IN O
pVHL P11331613A0827 NN I-UN
function P11331613A0827 NN O
were P11331613A0827 VBD O
observed P11331613A0827 VBN O
for P11331613A0827 IN O
all P11331613A0827 DT O
mutations P11331613A0827 NNS O
within P11331613A0827 IN O
each P11331613A0827 DT O
subclass P11331613A0827 NN O
. P11331613A0827 . O
. . O O

The P08383129A0776 DT O
low P08383129A0776 JJ O
molecular P08383129A0776 JJ O
mass P08383129A0776 NN O
polypeptide P08383129A0776 NN O
complex P08383129A0776 NN O
is P08383129A0776 VBZ O
assumed P08383129A0776 VBN O
to P08383129A0776 TO O
be P08383129A0776 VB O
involved P08383129A0776 VBN O
in P08383129A0776 IN O
antigen P08383129A0776 NN O
presentation P08383129A0776 NN O
, P08383129A0776 , O
generating P08383129A0776 VBG O
peptides P08383129A0776 NNS O
from P08383129A0776 IN O
cytosolic P08383129A0776 JJ O
protein P08383129A0776 NN O
antigens P08383129A0776 NNS O
, P08383129A0776 , O
which P08383129A0776 WDT O
are P08383129A0776 VBP O
subsequently P08383129A0776 RB O
presented P08383129A0776 VBN O
to P08383129A0776 TO O
cytotoxic P08383129A0776 VB O
T-lymphocytes P08383129A0776 NNS O
on P08383129A0776 IN O
the P08383129A0776 DT O
cell P08383129A0776 NN O
surface P08383129A0776 NN O
. P08383129A0776 . O
. . O O

After P07595221A0733 IN O
cells P07595221A0733 NNS O
were P07595221A0733 VBD O
stably P07595221A0733 RB O
transfected P07595221A0733 VBN O
with P07595221A0733 IN O
CIITA P07595221A0733 NNP I-UN
, P07595221A0733 , O
endogenous P07595221A0733 JJ O
MHC P07595221A0733 NNP I-UN
class P07595221A0733 NN I-UN
II P07595221A0733 NNP I-UN
genes P07595221A0733 NNS I-UN
were P07595221A0733 VBD O
constitutively P07595221A0733 RB O
expressed P07595221A0733 VBN O
, P07595221A0733 , O
and P07595221A0733 CC O
MHC P07595221A0733 NNP I-UN
class P07595221A0733 NN I-UN
II P07595221A0733 NNP I-UN
promoters P07595221A0733 NNS I-UN
, P07595221A0733 , O
delivered P07595221A0733 VBN O
by P07595221A0733 IN O
transfection P07595221A0733 NN O
, P07595221A0733 , O
were P07595221A0733 VBD O
actively P07595221A0733 RB O
transcribed P07595221A0733 VBN O
in P07595221A0733 IN O
CIITA-expressing P07595221A0733 NNP O
cells P07595221A0733 NNS O
. P07595221A0733 . O
. . O O

This P10899128A0661 DT O
is P10899128A0661 VBZ O
the P10899128A0661 DT O
first P10899128A0661 JJ O
example P10899128A0661 NN O
of P10899128A0661 IN O
a P10899128A0661 DT O
eukaryotic P10899128A0661 JJ O
transcription P10899128A0661 NN O
factor P10899128A0661 NN O
complex P10899128A0661 JJ O
containing P10899128A0661 VBG O
both P10899128A0661 DT O
a P10899128A0661 DT O
MADS-box P10899128A0661 NNP I-UN
and P10899128A0661 CC O
a P10899128A0661 DT O
forkhead P10899128A0661 JJ I-UN
protein P10899128A0661 NN I-UN
, P10899128A0661 , O
and P10899128A0661 CC O
it P10899128A0661 PRP O
has P10899128A0661 VBZ O
important P10899128A0661 JJ O
implications P10899128A0661 NNS O
for P10899128A0661 IN O
the P10899128A0661 DT O
regulation P10899128A0661 NN O
of P10899128A0661 IN O
mammalian P10899128A0661 JJ O
gene P10899128A0661 NN O
expression P10899128A0661 NN O
. P10899128A0661 . O
. . O O

The P01723962A0165 DT O
activity P01723962A0165 NN O
of P01723962A0165 IN O
serum P01723962A0165 NN I-UN
lipase P01723962A0165 NN I-UN
and P01723962A0165 CC O
amylase P01723962A0165 NN I-UN
distinctly P01723962A0165 RB O
increased P01723962A0165 VBD O
at P01723962A0165 IN O
3 P01723962A0165 CD O
h P01723962A0165 NN O
and P01723962A0165 CC O
went P01723962A0165 VBD O
up P01723962A0165 RB O
to P01723962A0165 TO O
the P01723962A0165 DT O
maximum P01723962A0165 NN O
at P01723962A0165 IN O
12 P01723962A0165 CD O
h P01723962A0165 NN O
after P01723962A0165 IN O
injection P01723962A0165 NN O
of P01723962A0165 IN O
Na-Tc P01723962A0165 NNP O
. P01723962A0165 . O
. . O O

In P11500377A0518 IN O
mammals P11500377A0518 NNS O
, P11500377A0518 , O
the P11500377A0518 DT O
transcriptional P11500377A0518 JJ O
repressors P11500377A0518 NNS O
in P11500377A0518 IN O
the P11500377A0518 DT O
Wnt P11500377A0518 NNP I-UN
pathway P11500377A0518 NN O
are P11500377A0518 VBP O
not P11500377A0518 RB O
well P11500377A0518 RB O
defined P11500377A0518 VBN O
. P11500377A0518 . O
. . O O

This P09358055A0590 DT O
sequence P09358055A0590 NN O
possessed P09358055A0590 VBD O
homology P09358055A0590 NN O
with P09358055A0590 IN O
a P09358055A0590 DT O
methylation-sensitive P09358055A0590 JJ O
promoter P09358055A0590 NN O
element P09358055A0590 NN O
, P09358055A0590 , O
Enh2 P09358055A0590 NNP O
, P09358055A0590 , O
present P09358055A0590 NN O
in P09358055A0590 IN O
the P09358055A0590 DT O
LTR P09358055A0590 NNP O
of P09358055A0590 IN O
mouse P09358055A0590 NNP O
intractisternal P09358055A0590 JJ O
A-particles P09358055A0590 NNS O
. P09358055A0590 . O
. . O O

In P01211754A0192 IN O
about P01211754A0192 RB O
one P01211754A0192 CD O
third P01211754A0192 NN O
of P01211754A0192 IN O
the P01211754A0192 DT O
cases P01211754A0192 NNS O
this P01211754A0192 DT O
operation P01211754A0192 NN O
results P01211754A0192 NNS O
in P01211754A0192 IN O
tonal P01211754A0192 JJ O
and P01211754A0192 CC O
vocal P01211754A0192 JJ O
improvement P01211754A0192 NN O
for P01211754A0192 IN O
patients P01211754A0192 NNS O
suffering P01211754A0192 VBG O
from P01211754A0192 IN O
progressive P01211754A0192 JJ O
perceptive P01211754A0192 JJ O
deafness P01211754A0192 NN O
. P01211754A0192 . O
. . O O

Otte P07791771A0183 NNP O
, P07791771A0183 , O
Mol P07791771A0183 NNP O
. P07791771A0183 . O
. . O O

SIT P11433379A0000 NNP I-UN
( P11433379A0000 ( O
SHP2-interacting P11433379A0000 NNP I-UN
transmembrane P11433379A0000 NN I-UN
adaptor P11433379A0000 NN I-UN
protein P11433379A0000 NN I-UN
) P11433379A0000 ) O
is P11433379A0000 VBZ O
a P11433379A0000 DT O
recently P11433379A0000 RB O
identified P11433379A0000 VBN O
transmembrane P11433379A0000 NN O
adaptor P11433379A0000 NN O
protein P11433379A0000 NN O
, P11433379A0000 , O
which P11433379A0000 WDT O
is P11433379A0000 VBZ O
expressed P11433379A0000 VBN O
in P11433379A0000 IN O
lymphocytes P11433379A0000 NNS O
. P11433379A0000 . O
. . O O

In P04025179A0955 IN O
group P04025179A0955 NN O
I P04025179A0955 PRP O
adults P04025179A0955 VBP O
both P04025179A0955 DT O
of P04025179A0955 IN O
these P04025179A0955 DT O
variables P04025179A0955 NNS O
increased P04025179A0955 VBD O
. P04025179A0955 . O
. . O O

Comparison P00001606T0076 NNP O
with P00001606T0076 IN O
alkaline P00001606T0076 JJ I-UN
phosphatases P00001606T0076 NNS I-UN
and P00001606T0076 CC O
5-nucleotidase P00001606T0076 NN I-UN
. P00001606T0076 . O
. . O O

Molecular P11099377T0000 JJ O
cloning P11099377T0000 NN O
and P11099377T0000 CC O
expression P11099377T0000 NN O
of P11099377T0000 IN O
human P11099377T0000 JJ I-UN
UDP-d-Xylose P11099377T0000 JJ I-UN
: P11099377T0000 : I-UN
proteoglycan P11099377T0000 JJ I-UN
core P11099377T0000 NN I-UN
protein P11099377T0000 NN I-UN
beta-d-xylosyltransferase P11099377T0000 NN I-UN
and P11099377T0000 CC O
its P11099377T0000 PRP$ O
first P11099377T0000 JJ O
isoform P11099377T0000 JJ I-UN
XT-II P11099377T0000 NN I-UN
. P11099377T0000 . O
. . O O

BACKGROUND P10717612A0000 NN O
: P10717612A0000 : O
The P10717612A0000 DT O
aim P10717612A0000 NN O
of P10717612A0000 IN O
this P10717612A0000 DT O
study P10717612A0000 NN O
was P10717612A0000 VBD O
to P10717612A0000 TO O
determine P10717612A0000 VB O
the P10717612A0000 DT O
response P10717612A0000 NN O
rates P10717612A0000 NNS O
and P10717612A0000 CC O
toxicity P10717612A0000 NN O
of P10717612A0000 IN O
two P10717612A0000 CD O
regimens P10717612A0000 NNS O
containing P10717612A0000 VBG O
granulocyte-macrophage-colony P10717612A0000 JJ I-UN
stimulating P10717612A0000 JJ I-UN
factor P10717612A0000 NN I-UN
( P10717612A0000 ( O
GM-CSF P10717612A0000 NNP I-UN
) P10717612A0000 ) O
in P10717612A0000 IN O
combination P10717612A0000 NN O
with P10717612A0000 IN O
interleukin-2 P10717612A0000 JJ I-UN
( P10717612A0000 ( O
IL-2 P10717612A0000 NNP I-UN
) P10717612A0000 ) O
in P10717612A0000 IN O
the P10717612A0000 DT O
treatment P10717612A0000 NN O
of P10717612A0000 IN O
patients P10717612A0000 NNS O
with P10717612A0000 IN O
metastatic P10717612A0000 JJ O
renal P10717612A0000 NN O
cell P10717612A0000 NN O
carcinoma P10717612A0000 NN O
. P10717612A0000 . O
. . O O

Association P01172734T0035 NNP O
with P01172734T0035 IN O
HL-A P01172734T0035 NNP I-UN
W-27 P01172734T0035 NNP I-UN
. P01172734T0035 . O
. . O O

These P08089834A0561 DT O
mutants P08089834A0561 NNS O
had P08089834A0561 VBD O
deletions P08089834A0561 NNS O
of P08089834A0561 IN O
the P08089834A0561 DT O
extreme P08089834A0561 JJ O
amino-terminal P08089834A0561 JJ O
residues P08089834A0561 NNS O
as P08089834A0561 RB O
far P08089834A0561 RB O
as P08089834A0561 IN O
amino P08089834A0561 JJ O
acid P08089834A0561 NN O
residue P08089834A0561 JJ O
30 P08089834A0561 CD O
. P08089834A0561 . O
. . O O

CONCLUSIONS P07735833A1078 NN O
: P07735833A1078 : O
A P07735833A1078 DT O
comparison P07735833A1078 NN O
of P07735833A1078 IN O
the P07735833A1078 DT O
LysU P07735833A1078 NNP I-UN
crystal P07735833A1078 NN O
structure P07735833A1078 NN O
with P07735833A1078 IN O
the P07735833A1078 DT O
structures P07735833A1078 NNS O
of P07735833A1078 IN O
seryl- P07735833A1078 JJ I-UN
and P07735833A1078 CC I-UN
aspartyl-tRNA P07735833A1078 JJ I-UN
synthetases P07735833A1078 NNS I-UN
enables P07735833A1078 VBZ O
a P07735833A1078 DT O
conserved P07735833A1078 JJ O
core P07735833A1078 NN O
to P07735833A1078 TO O
be P07735833A1078 VB O
identified P07735833A1078 VBN O
. P07735833A1078 . O
. . O O

In P08390747A0586 IN O
this P08390747A0586 DT O
report P08390747A0586 NN O
, P08390747A0586 , O
we P08390747A0586 PRP O
focus P08390747A0586 VBP O
on P08390747A0586 IN O
the P08390747A0586 DT O
genetics P08390747A0586 NNS O
of P08390747A0586 IN O
the P08390747A0586 DT O
region P08390747A0586 NN O
of P08390747A0586 IN O
the P08390747A0586 DT O
17 P08390747A0586 CD I-UN
hep P08390747A0586 NN I-UN
syn P08390747A0586 NN I-UN
gB P08390747A0586 NN I-UN
gene P08390747A0586 NN I-UN
that P08390747A0586 WDT O
conferred P08390747A0586 VBD O
both P08390747A0586 DT O
the P08390747A0586 DT O
syncytial P08390747A0586 NN O
and P08390747A0586 CC O
pathogenic P08390747A0586 JJ O
phenotypes P08390747A0586 NNS O
to P08390747A0586 TO O
17 P08390747A0586 CD I-UN
syn+ P08390747A0586 NN I-UN
. P08390747A0586 . O
. . O O

MED1 P11056019A0926 NNP I-UN
has P11056019A0926 VBZ O
a P11056019A0926 DT O
weak P11056019A0926 JJ O
glycosylase P11056019A0926 NN I-UN
activity P11056019A0926 NN O
on P11056019A0926 IN O
the P11056019A0926 DT O
mutagenic P11056019A0926 JJ O
adduct P11056019A0926 NN O
3 P11056019A0926 CD O
, P11056019A0926 , O
N P11056019A0926 NNP O
( P11056019A0926 ( O
4 P11056019A0926 CD O
) P11056019A0926 ) O
-ethenocytosine P11056019A0926 NN O
, P11056019A0926 , O
a P11056019A0926 DT O
metabolite P11056019A0926 NN O
of P11056019A0926 IN O
vinyl P11056019A0926 JJ O
chloride P11056019A0926 NN O
and P11056019A0926 CC O
ethyl P11056019A0926 JJ O
carbamate P11056019A0926 NN O
. P11056019A0926 . O
. . O O

CCAAT P07629103T0000 NNP I-UN
/ P07629103T0000 NNP I-UN
enhancer-binding P07629103T0000 JJ I-UN
protein P07629103T0000 NN I-UN
isoforms P07629103T0000 NNS I-UN
beta P07629103T0000 NN I-UN
and P07629103T0000 CC I-UN
delta P07629103T0000 NN I-UN
are P07629103T0000 VBP O
expressed P07629103T0000 VBN O
in P07629103T0000 IN O
mammary P07629103T0000 JJ O
epithelial P07629103T0000 JJ O
cells P07629103T0000 NNS O
and P07629103T0000 CC O
bind P07629103T0000 NN O
to P07629103T0000 TO O
multiple P07629103T0000 VB O
sites P07629103T0000 NNS O
in P07629103T0000 IN O
the P07629103T0000 DT O
beta-casein P07629103T0000 JJ I-UN
gene P07629103T0000 NN I-UN
promoter P07629103T0000 NN I-UN
. P07629103T0000 . O
. . O O

Photopic P05021912T0000 NNP O
spectral P05021912T0000 JJ O
sensitivity P05021912T0000 NN O
determined P05021912T0000 VBD O
electroretinographically P05021912T0000 RB O
for P05021912T0000 IN O
the P05021912T0000 DT O
pigeon P05021912T0000 NN O
eye P05021912T0000 NN O
. P05021912T0000 . O
. . O O

The P02206789A0002 DT O
efficacy P02206789A0002 NN O
and P02206789A0002 CC O
safety P02206789A0002 NN O
of P02206789A0002 IN O
a P02206789A0002 DT O
novel P02206789A0002 JJ O
percutaneous P02206789A0002 JJ O
anaesthetic P02206789A0002 JJ O
preparation P02206789A0002 NN O
based P02206789A0002 VBN O
on P02206789A0002 IN O
amethocaine P02206789A0002 NN O
has P02206789A0002 VBZ O
been P02206789A0002 VBN O
investigated P02206789A0002 VBN O
in P02206789A0002 IN O
the P02206789A0002 DT O
paediatric P02206789A0002 JJ O
clinical P02206789A0002 JJ O
environment P02206789A0002 NN O
. P02206789A0002 . O
. . O O

The P02054754A0919 DT O
standard P02054754A0919 JJ O
principles P02054754A0919 NNS O
of P02054754A0919 IN O
surgical P02054754A0919 JJ O
management P02054754A0919 NN O
must P02054754A0919 MD O
be P02054754A0919 VB O
adhered P02054754A0919 VBN O
to P02054754A0919 TO O
when P02054754A0919 WRB O
using P02054754A0919 VBG O
Sandostatin P02054754A0919 NNP O
to P02054754A0919 TO O
treat P02054754A0919 VB O
patients P02054754A0919 NNS O
with P02054754A0919 IN O
these P02054754A0919 DT O
disorders P02054754A0919 NNS O
. P02054754A0919 . O
. . O O

How P10785668A0000 WRB O
plants P10785668A0000 NNS O
respond P10785668A0000 VBP O
to P10785668A0000 TO O
attack P10785668A0000 VB O
by P10785668A0000 IN O
the P10785668A0000 DT O
range P10785668A0000 NN O
of P10785668A0000 IN O
herbivores P10785668A0000 NNS O
and P10785668A0000 CC O
pathogens P10785668A0000 NNS O
that P10785668A0000 WDT O
confront P10785668A0000 VBP O
them P10785668A0000 PRP O
in P10785668A0000 IN O
the P10785668A0000 DT O
field P10785668A0000 NN O
is P10785668A0000 VBZ O
the P10785668A0000 DT O
subject P10785668A0000 NN O
of P10785668A0000 IN O
considerable P10785668A0000 JJ O
research P10785668A0000 NN O
by P10785668A0000 IN O
both P10785668A0000 DT O
molecular P10785668A0000 JJ O
biologists P10785668A0000 NNS O
and P10785668A0000 CC O
ecologists P10785668A0000 NNS O
. P10785668A0000 . O
. . O O

Multiresistant P06755986A0382 JJ O
strains P06755986A0382 NNS O
isolated P06755986A0382 VBN O
from P06755986A0382 IN O
humans P06755986A0382 NNS O
in P06755986A0382 IN O
enteral P06755986A0382 JJ O
toxico-infections P06755986A0382 NNS O
kill P06755986A0382 MD O
orally P06755986A0382 RB O
infected P06755986A0382 JJ O
mice P06755986A0382 NN O
more P06755986A0382 RBR O
frequently P06755986A0382 RB O
than P06755986A0382 IN O
strains P06755986A0382 NNS O
isolated P06755986A0382 VBN O
in P06755986A0382 IN O
hospital P06755986A0382 JJ O
infections P06755986A0382 NNS O
. P06755986A0382 . O
. . O O

Polypeptides P07768848A1880 NNS O
of P07768848A1880 IN O
the P07768848A1880 DT O
same P07768848A1880 JJ O
apparent P07768848A1880 JJ O
sizes P07768848A1880 NNS O
are P07768848A1880 VBP O
detected P07768848A1880 VBN O
in P07768848A1880 IN O
spores P07768848A1880 NNS O
of P07768848A1880 IN O
a P07768848A1880 DT O
cotE P07768848A1880 NN I-UN
null P07768848A1880 NN O
mutant P07768848A1880 NN O
, P07768848A1880 , O
on P07768848A1880 IN O
which P07768848A1880 WDT O
basis P07768848A1880 NN O
we P07768848A1880 PRP O
infer P07768848A1880 VBP O
that P07768848A1880 IN O
the P07768848A1880 DT O
products P07768848A1880 NNS O
of P07768848A1880 IN O
the P07768848A1880 DT O
cotJ P07768848A1880 NN I-UN
operon P07768848A1880 NN I-UN
are P07768848A1880 VBP O
required P07768848A1880 VBN O
for P07768848A1880 IN O
the P07768848A1880 DT O
normal P07768848A1880 JJ O
formation P07768848A1880 NN O
of P07768848A1880 IN O
the P07768848A1880 DT O
inner P07768848A1880 JJ O
layers P07768848A1880 NNS O
of P07768848A1880 IN O
the P07768848A1880 DT O
coat P07768848A1880 NN O
or P07768848A1880 CC O
are P07768848A1880 VBP O
themselves P07768848A1880 PRP O
structural P07768848A1880 JJ O
components P07768848A1880 NNS O
of P07768848A1880 IN O
the P07768848A1880 DT O
coat P07768848A1880 NN O
. P07768848A1880 . O
. . O O

The P10760109A1050 DT O
prevalence P10760109A1050 NN O
of P10760109A1050 IN O
malnutrition P10760109A1050 NN O
was P10760109A1050 VBD O
30 P10760109A1050 CD O
% P10760109A1050 NN O
in P10760109A1050 IN O
the P10760109A1050 DT O
47 P10760109A1050 CD O
patients P10760109A1050 NNS O
without P10760109A1050 IN O
CVD P10760109A1050 NNP O
and P10760109A1050 CC O
was P10760109A1050 VBD O
significantly P10760109A1050 RB O
higher P10760109A1050 JJR O
( P10760109A1050 ( O
70 P10760109A1050 CD O
% P10760109A1050 NN O
, P10760109A1050 , O
P P10760109A1050 NNP O
< P10760109A1050 NNP O
0.001 P10760109A1050 CD O
) P10760109A1050 ) O
in P10760109A1050 IN O
the P10760109A1050 DT O
70 P10760109A1050 CD O
patients P10760109A1050 NNS O
with P10760109A1050 IN O
CVD P10760109A1050 NNP O
, P10760109A1050 , O
who P10760109A1050 WP O
also P10760109A1050 RB O
had P10760109A1050 VBD O
lower P10760109A1050 JJR O
tHcy P10760109A1050 NN O
, P10760109A1050 , O
SAlb P10760109A1050 NNP O
, P10760109A1050 , O
plasma P10760109A1050 JJ I-UN
IGF-1 P10760109A1050 NNP I-UN
, P10760109A1050 , O
serum P10760109A1050 NN O
creatinine P10760109A1050 NN O
( P10760109A1050 ( O
SCr P10760109A1050 NNP O
) P10760109A1050 ) O
, P10760109A1050 , O
and P10760109A1050 CC O
blood P10760109A1050 NN I-UN
hemoglobin P10760109A1050 NN I-UN
. P10760109A1050 . O
. . O O

The P08990194A0000 DT O
syndrome P08990194A0000 NN O
of P08990194A0000 IN O
resistance P08990194A0000 NN O
to P08990194A0000 TO O
thyroid P08990194A0000 VB O
hormone P08990194A0000 NN O
is P08990194A0000 VBZ O
characterized P08990194A0000 VBN O
by P08990194A0000 IN O
elevated P08990194A0000 JJ O
serum P08990194A0000 NN O
free P08990194A0000 JJ O
thyroid P08990194A0000 NN O
hormones P08990194A0000 NNS O
, P08990194A0000 , O
failure P08990194A0000 NN O
to P08990194A0000 TO O
suppress P08990194A0000 VB O
pituitary P08990194A0000 JJ I-UN
thyrotropin P08990194A0000 NN I-UN
secretion P08990194A0000 NN O
, P08990194A0000 , O
and P08990194A0000 CC O
variable P08990194A0000 JJ O
peripheral P08990194A0000 JJ O
refractoriness P08990194A0000 NN O
to P08990194A0000 TO O
hormone P08990194A0000 VB O
action P08990194A0000 NN O
. P08990194A0000 . O
. . O O

Interestingly P09343208A1405 RB O
, P09343208A1405 , O
segment P09343208A1405 NN O
nesting P09343208A1405 VBG O
differentially P09343208A1405 RB O
increases P09343208A1405 VBZ O
the P09343208A1405 DT O
copy P09343208A1405 NN O
number P09343208A1405 NN O
of P09343208A1405 IN O
genes P09343208A1405 NNS O
encoded P09343208A1405 VBN O
by P09343208A1405 IN O
segment P09343208A1405 NN O
W P09343208A1405 NNP O
, P09343208A1405 , O
suggesting P09343208A1405 VBG O
that P09343208A1405 IN O
the P09343208A1405 DT O
unusual P09343208A1405 JJ O
genomic P09343208A1405 JJ O
organization P09343208A1405 NN O
of P09343208A1405 IN O
PDVs P09343208A1405 NNP O
may P09343208A1405 MD O
be P09343208A1405 VB O
directly P09343208A1405 RB O
linked P09343208A1405 VBN O
to P09343208A1405 TO O
the P09343208A1405 DT O
unique P09343208A1405 JJ O
functions P09343208A1405 NNS O
of P09343208A1405 IN O
this P09343208A1405 DT O
virus P09343208A1405 NN O
in P09343208A1405 IN O
its P09343208A1405 PRP$ O
obligate P09343208A1405 NN O
mutualistic P09343208A1405 JJ O
association P09343208A1405 NN O
with P09343208A1405 IN O
parasitic P09343208A1405 JJ O
wasps P09343208A1405 NN O
. P09343208A1405 . O
. . O O

Nutritional P07328000T0000 JJ O
cataracts P07328000T0000 NNS O
in P07328000T0000 IN O
timber P07328000T0000 NN O
wolves P07328000T0000 NNS O
. P07328000T0000 . O
. . O O

Disturbance P09206968A0000 NN O
of P09206968A0000 IN O
regeneration P09206968A0000 NN O
in P09206968A0000 IN O
the P09206968A0000 DT O
above P09206968A0000 JJ O
pathological P09206968A0000 JJ O
condition P09206968A0000 NN O
results P09206968A0000 NNS O
from P09206968A0000 IN O
the P09206968A0000 DT O
damage P09206968A0000 NN O
to P09206968A0000 TO O
tunica P09206968A0000 VB O
propria P09206968A0000 NNS O
and P09206968A0000 CC O
loss P09206968A0000 NN O
of P09206968A0000 IN O
its P09206968A0000 PRP$ O
function P09206968A0000 NN O
for P09206968A0000 IN O
the P09206968A0000 DT O
support P09206968A0000 NN O
of P09206968A0000 IN O
structural P09206968A0000 JJ O
homeostasis P09206968A0000 NN O
. P09206968A0000 . O
. . O O

Allergenic P01766999A0000 JJ O
activity P01766999A0000 NN O
of P01766999A0000 IN O
allergen P01766999A0000 NN O
extract P01766999A0000 NN O
Ambrosia P01766999A0000 NNP O
elatior P01766999A0000 NN O
( P01766999A0000 ( O
AE P01766999A0000 NNP O
) P01766999A0000 ) O
was P01766999A0000 VBD O
tested P01766999A0000 VBN O
in P01766999A0000 IN O
fifteen P01766999A0000 JJ O
volunteers P01766999A0000 NNS O
extremely P01766999A0000 RB O
sensitive P01766999A0000 JJ O
to P01766999A0000 TO O
the P01766999A0000 DT O
allergen P01766999A0000 NN O
. P01766999A0000 . O
. . O O

Curing P08595836T0000 VBG O
shrinkage P08595836T0000 NN O
and P08595836T0000 CC O
volumetric P08595836T0000 JJ O
changes P08595836T0000 NNS O
of P08595836T0000 IN O
resin-modified P08595836T0000 JJ O
glass P08595836T0000 NN O
ionomer P08595836T0000 NN O
restorative P08595836T0000 JJ O
materials P08595836T0000 NNS O
. P08595836T0000 . O
. . O O

Scratching P07702378A0668 VBG O
during P07702378A0668 IN O
sleep P07702378A0668 NN O
in P07702378A0668 IN O
children P07702378A0668 NNS O
with P07702378A0668 IN O
atopic P07702378A0668 NN O
dermatitis P07702378A0668 NN O
is P07702378A0668 VBZ O
associated P07702378A0668 VBN O
with P07702378A0668 IN O
increased P07702378A0668 JJ O
VO2 P07702378A0668 NNP O
. P07702378A0668 . O
. . O O

The P08497248A0000 DT O
gene P08497248A0000 NN O
encoding P08497248A0000 VBG O
the P08497248A0000 DT O
receptor P08497248A0000 NN O
for P08497248A0000 IN O
macrophage P08497248A0000 NN I-UN
colony-stimulating P08497248A0000 JJ I-UN
factor P08497248A0000 NN I-UN
1 P08497248A0000 CD I-UN
( P08497248A0000 ( O
CSF-1 P08497248A0000 NNP I-UN
) P08497248A0000 ) O
, P08497248A0000 , O
the P08497248A0000 DT O
c-fms P08497248A0000 JJ I-UN
protooncogene P08497248A0000 NN I-UN
, P08497248A0000 , O
is P08497248A0000 VBZ O
selectively P08497248A0000 RB O
expressed P08497248A0000 VBN O
in P08497248A0000 IN O
immature P08497248A0000 NN O
and P08497248A0000 CC O
mature P08497248A0000 NN O
mononuclear P08497248A0000 VBP O
phagocytes P08497248A0000 NNS O
and P08497248A0000 CC O
trophoblasts P08497248A0000 NNS O
. P08497248A0000 . O
. . O O

Overlapping P08449986A0455 VBG O
clones P08449986A0455 NNS O
representing P08449986A0455 VBG O
full-length P08449986A0455 JJ O
cDNAs P08449986A0455 NN O
for P08449986A0455 IN O
MMI P08449986A0455 NNP I-UN
alpha P08449986A0455 NN I-UN
were P08449986A0455 VBD O
obtained P08449986A0455 VBN O
from P08449986A0455 IN O
mouse P08449986A0455 NN O
brain P08449986A0455 NN O
. P08449986A0455 . O
. . O O

The P09396823T0000 DT O
proofreading P09396823T0000 VBG O
domain P09396823T0000 NN O
of P09396823T0000 IN O
Escherichia P09396823T0000 NNP I-UN
coli P09396823T0000 NNS I-UN
DNA P09396823T0000 NNP I-UN
polymerase P09396823T0000 NN I-UN
I P09396823T0000 PRP I-UN
and P09396823T0000 CC O
other P09396823T0000 JJ O
DNA P09396823T0000 NNP I-UN
and P09396823T0000 CC I-UN
/ P09396823T0000 NNP I-UN
or P09396823T0000 CC I-UN
RNA P09396823T0000 NNP I-UN
exonuclease P09396823T0000 NN I-UN
domains P09396823T0000 NNS I-UN
. P09396823T0000 . O
. . O O

Development P03550444T0000 NNP O
of P03550444T0000 IN O
a P03550444T0000 DT O
yeast P03550444T0000 NN O
system P03550444T0000 NN O
to P03550444T0000 TO O
assay P03550444T0000 VB O
mutational P03550444T0000 JJ O
specificity P03550444T0000 NN O
. P03550444T0000 . O
. . O O

All P07967725A0262 DT O
nuclear P07967725A0262 JJ O
receptors P07967725A0262 NNS O
have P07967725A0262 VBP O
several P07967725A0262 JJ O
well-characterized P07967725A0262 JJ O
structural P07967725A0262 JJ O
domains P07967725A0262 NNS O
, P07967725A0262 , O
including P07967725A0262 VBG O
a P07967725A0262 DT O
conserved P07967725A0262 JJ O
DNA-binding P07967725A0262 JJ O
domain P07967725A0262 NN O
, P07967725A0262 , O
and P07967725A0262 CC O
a P07967725A0262 DT O
ligand P07967725A0262 NN O
binding P07967725A0262 VBG O
domain P07967725A0262 NN O
at P07967725A0262 IN O
the P07967725A0262 DT O
carboxyl P07967725A0262 JJ O
terminus P07967725A0262 NN O
of P07967725A0262 IN O
the P07967725A0262 DT O
receptor P07967725A0262 NN O
. P07967725A0262 . O
. . O O

Although P08833653A0783 IN O
isl-1 P08833653A0783 JJ I-UN
binds P08833653A0783 NNS O
to P08833653A0783 TO O
both P08833653A0783 DT O
the P08833653A0783 DT O
insulin P08833653A0783 NN I-UN
and P08833653A0783 CC O
amylin P08833653A0783 JJ I-UN
gene P08833653A0783 NN I-UN
promoter P08833653A0783 NN I-UN
elements P08833653A0783 NNS I-UN
in P08833653A0783 IN O
vitro P08833653A0783 NN O
, P08833653A0783 , O
these P08833653A0783 DT O
sequences P08833653A0783 NNS O
display P08833653A0783 VBP O
marked P08833653A0783 JJ O
differences P08833653A0783 NNS O
in P08833653A0783 IN O
their P08833653A0783 PRP$ O
relative P08833653A0783 JJ O
transcriptional P08833653A0783 NN O
properties P08833653A0783 NNS O
when P08833653A0783 WRB O
ligated P08833653A0783 VBN O
adjacent P08833653A0783 NN O
to P08833653A0783 TO O
a P08833653A0783 DT O
heterologous P08833653A0783 JJ O
promoter P08833653A0783 NN O
and P08833653A0783 CC O
transfected P08833653A0783 VBD O
into P08833653A0783 IN O
InR1 P08833653A0783 NNP O
-G9 P08833653A0783 NNP O
islet P08833653A0783 NN O
cells P08833653A0783 NNS O
. P08833653A0783 . O
. . O O

However P09882334A0822 RB O
, P09882334A0822 , O
serial P09882334A0822 JJ O
passages P09882334A0822 NNS O
of P09882334A0822 IN O
fetal P09882334A0822 JJ O
lamb P09882334A0822 NN O
kidney P09882334A0822 NN O
( P09882334A0822 ( O
FLK P09882334A0822 NNP O
) P09882334A0822 ) O
cells P09882334A0822 NNS O
, P09882334A0822 , O
which P09882334A0822 WDT O
are P09882334A0822 VBP O
sensitive P09882334A0822 JJ O
to P09882334A0822 TO O
infection P09882334A0822 VB O
with P09882334A0822 IN O
BLV P09882334A0822 NNP O
, P09882334A0822 , O
after P09882334A0822 IN O
transient P09882334A0822 JJ O
transfection P09882334A0822 NN O
revealed P09882334A0822 VBD O
that P09882334A0822 IN O
mutation P09882334A0822 NN O
of P09882334A0822 IN O
a P09882334A0822 DT O
second P09882334A0822 JJ O
tyrosine P09882334A0822 NN O
residue P09882334A0822 NN O
in P09882334A0822 IN O
the P09882334A0822 DT O
N-terminal P09882334A0822 JJ O
motif P09882334A0822 NN O
completely P09882334A0822 RB O
prevented P09882334A0822 VBD O
the P09882334A0822 DT O
propagation P09882334A0822 NN O
of P09882334A0822 IN O
the P09882334A0822 DT O
virus P09882334A0822 NN O
. P09882334A0822 . O
. . O O

A P09106057A0000 DT O
method P09106057A0000 NN O
for P09106057A0000 IN O
the P09106057A0000 DT O
simultaneous P09106057A0000 JJ O
determination P09106057A0000 NN O
of P09106057A0000 IN O
de P09106057A0000 FW O
( P09106057A0000 ( O
N-methyl P09106057A0000 NNP O
) P09106057A0000 ) O
-N-ethyl-8,9 P09106057A0000 VBZ O
-anhydroerythromycin P09106057A0000 $ O
A P09106057A0000 DT O
6,9-hemiacetal P09106057A0000 JJ O
( P09106057A0000 ( O
EM523 P09106057A0000 NNP O
, P09106057A0000 , O
I P09106057A0000 PRP O
) P09106057A0000 ) O
and P09106057A0000 CC O
its P09106057A0000 PRP$ O
three P09106057A0000 CD O
metabolites P09106057A0000 NNS O
in P09106057A0000 IN O
human P09106057A0000 JJ O
plasma P09106057A0000 NN O
and P09106057A0000 CC O
urine P09106057A0000 NN O
has P09106057A0000 VBZ O
been P09106057A0000 VBN O
developed P09106057A0000 VBN O
using P09106057A0000 VBG O
high-performance P09106057A0000 NN O
liquid P09106057A0000 NN O
chromatography P09106057A0000 NN O
( P09106057A0000 ( O
HPLC P09106057A0000 NNP O
) P09106057A0000 ) O
with P09106057A0000 IN O
chemiluminescence P09106057A0000 NN O
( P09106057A0000 ( O
CL P09106057A0000 NNP O
) P09106057A0000 ) O
detection P09106057A0000 NN O
. P09106057A0000 . O
. . O O

New P07988945T0000 NNP O
diagnostic P07988945T0000 JJ O
strategies P07988945T0000 NNS O
for P07988945T0000 IN O
lupus P07988945T0000 JJ O
anticoagulants P07988945T0000 NNS O
and P07988945T0000 CC O
antiphospholipid P07988945T0000 JJ O
antibodies P07988945T0000 NNS O
. P07988945T0000 . O
. . O O

Deletion P10446206A0000 NNP O
mapping P10446206A0000 NN O
of P10446206A0000 IN O
the P10446206A0000 DT O
human P10446206A0000 JJ I-UN
presenilin-1 P10446206A0000 NN I-UN
( P10446206A0000 ( O
PS1 P10446206A0000 NNP I-UN
) P10446206A0000 ) O
promoter P10446206A0000 NN O
delineated P10446206A0000 VBN O
the P10446206A0000 DT O
most P10446206A0000 RBS O
active P10446206A0000 JJ O
fragment P10446206A0000 NN O
from P10446206A0000 IN O
-118 P10446206A0000 NN O
to P10446206A0000 TO O
+178 P10446206A0000 VB O
in P10446206A0000 IN O
relation P10446206A0000 NN O
to P10446206A0000 TO O
the P10446206A0000 DT O
transcription P10446206A0000 NN O
start P10446206A0000 NN O
site P10446206A0000 NN O
mapped P10446206A0000 VBN O
in P10446206A0000 IN O
this P10446206A0000 DT O
study P10446206A0000 NN O
, P10446206A0000 , O
in P10446206A0000 IN O
both P10446206A0000 DT O
human P10446206A0000 JJ O
neuroblastoma P10446206A0000 NN O
SK-N-SH P10446206A0000 NNP O
and P10446206A0000 CC O
hepatoma P10446206A0000 NN O
HepG2 P10446206A0000 NNP O
cells P10446206A0000 NNS O
. P10446206A0000 . O
. . O O

This P11327292A0190 DT O
unique P11327292A0190 JJ O
location P11327292A0190 NN O
of P11327292A0190 IN O
cavernous P11327292A0190 JJ O
malformation P11327292A0190 NN O
is P11327292A0190 VBZ O
associated P11327292A0190 VBN O
with P11327292A0190 IN O
a P11327292A0190 DT O
risk P11327292A0190 NN O
of P11327292A0190 IN O
permanent P11327292A0190 JJ O
loss P11327292A0190 NN O
of P11327292A0190 IN O
the P11327292A0190 DT O
vision P11327292A0190 NN O
. P11327292A0190 . O
. . O O

SvO2 P08373972A0335 NN O
can P08373972A0335 MD O
be P08373972A0335 VB O
determined P08373972A0335 VBN O
in P08373972A0335 IN O
vitro P08373972A0335 NN O
and P08373972A0335 CC O
in P08373972A0335 IN O
vivo P08373972A0335 NN O
. P08373972A0335 . O
. . O O

By P07601827A0778 IN O
using P07601827A0778 VBG O
lacZ P07601827A0778 JJ I-UN
fusions P07601827A0778 NNS I-UN
, P07601827A0778 , O
it P07601827A0778 PRP O
was P07601827A0778 VBD O
possible P07601827A0778 JJ O
to P07601827A0778 TO O
localize P07601827A0778 VB O
the P07601827A0778 DT O
DNA P07601827A0778 NNP O
sequences P07601827A0778 NNS O
required P07601827A0778 VBD O
to P07601827A0778 TO O
mediate P07601827A0778 VB O
nitrate P07601827A0778 JJ O
repression P07601827A0778 NN O
to P07601827A0778 TO O
the P07601827A0778 DT O
pfl P07601827A0778 JJ I-UN
promoter-regulatory P07601827A0778 JJ I-UN
region P07601827A0778 NN I-UN
. P07601827A0778 . O
. . O O

Analysis P11278870A0123 NN O
of P11278870A0123 IN O
regulatory P11278870A0123 JJ O
regions P11278870A0123 NNS O
in P11278870A0123 IN O
the P11278870A0123 DT O
promoter P11278870A0123 NN O
of P11278870A0123 IN O
the P11278870A0123 DT O
ctr4 P11278870A0123 NN I-UN
( P11278870A0123 ( I-UN
+ P11278870A0123 NNP I-UN
) P11278870A0123 ) I-UN
copper P11278870A0123 NN I-UN
transporter P11278870A0123 NN I-UN
gene P11278870A0123 NN I-UN
in P11278870A0123 IN O
fission P11278870A0123 NN O
yeast P11278870A0123 NN O
Schizosaccharomyces P11278870A0123 NNP O
pombe P11278870A0123 NN O
reveals P11278870A0123 VBZ O
the P11278870A0123 DT O
identity P11278870A0123 NN O
of P11278870A0123 IN O
a P11278870A0123 DT O
conserved P11278870A0123 JJ O
copper-signaling P11278870A0123 JJ O
element P11278870A0123 NN O
( P11278870A0123 ( O
CuSE P11278870A0123 NNP O
) P11278870A0123 ) O
, P11278870A0123 , O
which P11278870A0123 WDT O
is P11278870A0123 VBZ O
recognized P11278870A0123 VBN O
by P11278870A0123 IN O
the P11278870A0123 DT O
transcription P11278870A0123 NN I-UN
factor P11278870A0123 NN I-UN
Cuf1 P11278870A0123 NNP I-UN
. P11278870A0123 . O
. . O O

A P01084413A0271 DT O
range P01084413A0271 NN O
of P01084413A0271 IN O
normal P01084413A0271 JJ O
ventricular P01084413A0271 JJ O
measurements P01084413A0271 NNS O
for P01084413A0271 IN O
the P01084413A0271 DT O
EMI P01084413A0271 NNP O
scan P01084413A0271 NN O
is P01084413A0271 VBZ O
suggested P01084413A0271 VBN O
. P01084413A0271 . O
. . O O

Early P07463465A0297 JJ O
infection P07463465A0297 NN O
was P07463465A0297 VBD O
detected P07463465A0297 VBN O
in P07463465A0297 IN O
one P07463465A0297 CD O
of P07463465A0297 IN O
50 P07463465A0297 CD O
control P07463465A0297 NN O
women P07463465A0297 NNS O
who P07463465A0297 WP O
gave P07463465A0297 VBD O
birth P07463465A0297 NN O
to P07463465A0297 TO O
a P07463465A0297 DT O
healthy P07463465A0297 JJ O
infant P07463465A0297 NN O
. P07463465A0297 . O
. . O O

Oligonucleotide-directed P03036817A0213 JJ O
mutagenesis P03036817A0213 NN O
was P03036817A0213 VBD O
used P03036817A0213 VBN O
to P03036817A0213 TO O
create P03036817A0213 VB O
an P03036817A0213 DT O
NdeI P03036817A0213 NNP I-UN
restriction P03036817A0213 NN I-UN
site P03036817A0213 NN I-UN
at P03036817A0213 IN O
the P03036817A0213 DT O
natural P03036817A0213 JJ O
ATG P03036817A0213 NNP O
of P03036817A0213 IN O
the P03036817A0213 DT O
yeast P03036817A0213 NN O
R P03036817A0213 NNP O
. P03036817A0213 . O
. . O O

Two P02498322A0226 CD O
specific P02498322A0226 JJ O
DNA-protein P02498322A0226 NNP O
complexes P02498322A0226 NNS O
were P02498322A0226 VBD O
identified P02498322A0226 VBN O
in P02498322A0226 IN O
gel P02498322A0226 JJ O
retardation P02498322A0226 NN O
assays P02498322A0226 NNS O
using P02498322A0226 VBG O
HeLa P02498322A0226 NNP O
cell P02498322A0226 NN O
nuclear P02498322A0226 JJ O
extracts P02498322A0226 NNS O
and P02498322A0226 CC O
an P02498322A0226 DT O
oligonucleotide P02498322A0226 JJ O
probe P02498322A0226 NN O
spanning P02498322A0226 VBG O
the P02498322A0226 DT O
footprinted P02498322A0226 JJ O
region P02498322A0226 NN O
. P02498322A0226 . O
. . O O

These P09819414A1103 DT O
sorting P09819414A1103 VBG I-UN
nexins P09819414A1103 NNS I-UN
also P09819414A1103 RB O
associated P09819414A1103 VBN O
with P09819414A1103 IN O
the P09819414A1103 DT O
long P09819414A1103 JJ O
isoform P09819414A1103 NN O
of P09819414A1103 IN O
the P09819414A1103 DT O
leptin P09819414A1103 JJ I-UN
receptor P09819414A1103 NN I-UN
but P09819414A1103 CC O
not P09819414A1103 RB O
with P09819414A1103 IN O
the P09819414A1103 DT O
short P09819414A1103 JJ O
and P09819414A1103 CC O
medium P09819414A1103 JJ O
isoforms P09819414A1103 NNS O
. P09819414A1103 . O
. . O O

Transcriptional P08660892A1044 NNP O
blockade P08660892A1044 NN O
was P08660892A1044 VBD O
reversed P08660892A1044 VBN O
by P08660892A1044 IN O
co-transfections P08660892A1044 NNS O
of P08660892A1044 IN O
a P08660892A1044 DT O
wild-type P08660892A1044 JJ I-UN
SRF P08660892A1044 NNP I-UN
expression P08660892A1044 NN O
vector P08660892A1044 NN O
, P08660892A1044 , O
but P08660892A1044 CC O
was P08660892A1044 VBD O
not P08660892A1044 RB O
rescued P08660892A1044 VBN O
by P08660892A1044 IN O
the P08660892A1044 DT O
expression P08660892A1044 NN O
of P08660892A1044 IN O
other P08660892A1044 JJ O
myogenic P08660892A1044 JJ O
factors P08660892A1044 NNS O
, P08660892A1044 , O
such P08660892A1044 JJ O
as P08660892A1044 IN O
MyoD P08660892A1044 NNP I-UN
and P08660892A1044 CC O
Mef-2C P08660892A1044 NNP I-UN
. P08660892A1044 . O
. . O O

Immunogenicity P05005311T0000 NN O
of P05005311T0000 IN O
various P05005311T0000 JJ O
mycobacteria P05005311T0000 NNS O
and P05005311T0000 CC O
the P05005311T0000 DT O
corresponding P05005311T0000 JJ O
levels P05005311T0000 NNS O
of P05005311T0000 IN O
cross-protection P05005311T0000 NN O
developed P05005311T0000 NN O
between P05005311T0000 IN O
species P05005311T0000 NNS O
. P05005311T0000 . O
. . O O

On P08933487A0325 IN O
the P08933487A0325 DT O
third P08933487A0325 JJ O
occasion P08933487A0325 NN O
water P08933487A0325 NN O
( P08933487A0325 ( O
W P08933487A0325 NNP O
) P08933487A0325 ) O
was P08933487A0325 VBD O
ingested P08933487A0325 VBN O
throughout P08933487A0325 IN O
the P08933487A0325 DT O
run P08933487A0325 NN O
. P08933487A0325 . O
. . O O

Combined P01985301T0000 VBN O
therapy P01985301T0000 NN O
with P01985301T0000 IN O
MK-801 P01985301T0000 NNP O
and P01985301T0000 CC O
nimodipine P01985301T0000 NN O
for P01985301T0000 IN O
protection P01985301T0000 NN O
of P01985301T0000 IN O
ischemic P01985301T0000 JJ O
brain P01985301T0000 NN O
damage P01985301T0000 NN O
. P01985301T0000 . O
. . O O

Sequencing P08454591A0692 VBG O
of P08454591A0692 IN O
a P08454591A0692 DT O
1.3-kilobase P08454591A0692 JJ O
fragment P08454591A0692 NN O
of P08454591A0692 IN O
the P08454591A0692 DT O
5'-flanking P08454591A0692 JJ O
region P08454591A0692 NN O
of P08454591A0692 IN O
the P08454591A0692 DT O
TSG6 P08454591A0692 NNP I-UN
gene P08454591A0692 NN I-UN
identified P08454591A0692 VBD O
TATA-like P08454591A0692 NNP O
and P08454591A0692 CC O
CAAT P08454591A0692 NNP O
sequences P08454591A0692 NNS O
near P08454591A0692 IN O
the P08454591A0692 DT O
transcription P08454591A0692 NN O
start P08454591A0692 NN O
site P08454591A0692 NN O
. P08454591A0692 . O
. . O O

Lack P07859739T0000 NN O
of P07859739T0000 IN O
cyclin P07859739T0000 JJ I-UN
D-Cdk P07859739T0000 NNP O
complexes P07859739T0000 NNS O
in P07859739T0000 IN O
Rb-negative P07859739T0000 JJ O
cells P07859739T0000 NNS O
correlates P07859739T0000 VBZ O
with P07859739T0000 IN O
high P07859739T0000 JJ O
levels P07859739T0000 NNS O
of P07859739T0000 IN O
p16INK4 P07859739T0000 NN I-UN
/ P07859739T0000 NNP O
MTS1 P07859739T0000 NNP I-UN
tumour P07859739T0000 NN O
suppressor P07859739T0000 NN O
gene P07859739T0000 NN O
product P07859739T0000 NN O
. P07859739T0000 . O
. . O O

The P08096066A0623 DT O
RFLP P08096066A0623 NNP O
patterns P08096066A0623 NNS O
of P08096066A0623 IN O
the P08096066A0623 DT O
isolates P08096066A0623 NNS O
from P08096066A0623 IN O
six P08096066A0623 CD O
of P08096066A0623 IN O
these P08096066A0623 DT O
patients P08096066A0623 NNS O
remained P08096066A0623 VBD O
essentially P08096066A0623 RB O
unchanged P08096066A0623 JJ O
( P08096066A0623 ( O
two P08096066A0623 CD O
strains P08096066A0623 NNS O
showed P08096066A0623 VBD O
one P08096066A0623 CD O
additional P08096066A0623 JJ O
band P08096066A0623 NN O
) P08096066A0623 ) O
despite P08096066A0623 IN O
the P08096066A0623 DT O
development P08096066A0623 NN O
of P08096066A0623 IN O
drug P08096066A0623 NN O
resistance P08096066A0623 NN O
. P08096066A0623 . O
. . O O

Results P10777499A0883 NNS O
from P10777499A0883 IN O
transient P10777499A0883 JJ O
assays P10777499A0883 NNS O
using P10777499A0883 VBG O
these P10777499A0883 DT O
mutants P10777499A0883 NNS O
showed P10777499A0883 VBD O
that P10777499A0883 IN O
the P10777499A0883 DT O
DE1 P10777499A0883 NNP O
received P10777499A0883 VBD O
signals P10777499A0883 NNS O
from P10777499A0883 IN O
phytochromes P10777499A0883 NNS I-UN
A P10777499A0883 NNP I-UN
and P10777499A0883 CC I-UN
B P10777499A0883 NNP I-UN
, P10777499A0883 , O
demonstrating P10777499A0883 VBG O
that P10777499A0883 IN O
this P10777499A0883 DT O
element P10777499A0883 NN O
is P10777499A0883 VBZ O
indeed P10777499A0883 RB O
a P10777499A0883 DT O
light-responsive P10777499A0883 JJ O
element P10777499A0883 NN O
. P10777499A0883 . O
. . O O

Expression P09371431T0000 NN O
of P09371431T0000 IN O
thiamin P09371431T0000 JJ O
biosynthetic P09371431T0000 JJ O
genes P09371431T0000 NNS O
( P09371431T0000 ( O
thiCOGE P09371431T0000 NN I-UN
) P09371431T0000 ) O
and P09371431T0000 CC O
production P09371431T0000 NN O
of P09371431T0000 IN O
symbiotic P09371431T0000 JJ I-UN
terminal P09371431T0000 JJ I-UN
oxidase P09371431T0000 NN I-UN
cbb3 P09371431T0000 NN I-UN
in P09371431T0000 IN O
Rhizobium P09371431T0000 NNP O
etli P09371431T0000 NN O
. P09371431T0000 . O
. . O O

These P09372950A1283 DT O
results P09372950A1283 NNS O
implicate P09372950A1283 VBP O
a P09372950A1283 DT O
precursor-specific P09372950A1283 JJ O
base-paired P09372950A1283 JJ O
structure P09372950A1283 NN O
involving P09372950A1283 VBG O
sequences P09372950A1283 NNS O
on P09372950A1283 IN O
both P09372950A1283 DT O
sides P09372950A1283 NNS O
of P09372950A1283 IN O
the P09372950A1283 DT O
mature P09372950A1283 NN O
cleavage P09372950A1283 NN O
site P09372950A1283 NN O
in P09372950A1283 IN O
the P09372950A1283 DT O
3 P09372950A1283 CD O
' P09372950A1283 POS O
processing P09372950A1283 NN O
of P09372950A1283 IN O
human P09372950A1283 JJ I-UN
U2 P09372950A1283 NNP I-UN
RNA P09372950A1283 NNP I-UN
. P09372950A1283 . O
. . O O

The P10073947A1110 DT O
corresponding P10073947A1110 JJ O
differences P10073947A1110 NNS O
in P10073947A1110 IN O
FVIIa P10073947A1110 NNP I-UN
and P10073947A1110 CC O
PAI-1 P10073947A1110 NNP I-UN
were P10073947A1110 VBD O
not P10073947A1110 RB O
statistically P10073947A1110 RB O
significant P10073947A1110 JJ O
. P10073947A1110 . O
. . O O

Because P01512259A0867 IN O
of P01512259A0867 IN O
this P01512259A0867 DT O
latter P01512259A0867 JJ O
phenomenon P01512259A0867 NN O
, P01512259A0867 , O
we P01512259A0867 PRP O
were P01512259A0867 VBD O
able P01512259A0867 JJ O
to P01512259A0867 TO O
identify P01512259A0867 VB O
a P01512259A0867 DT O
particular P01512259A0867 JJ O
cysteine P01512259A0867 NN O
motif P01512259A0867 NN O
that P01512259A0867 WDT O
was P01512259A0867 VBD O
repeated P01512259A0867 VBN O
multiple P01512259A0867 JJ O
times P01512259A0867 NNS O
in P01512259A0867 IN O
Dfurin2 P01512259A0867 NNP I-UN
but P01512259A0867 CC O
present P01512259A0867 JJ O
only P01512259A0867 RB O
twice P01512259A0867 RB O
in P01512259A0867 IN O
mammalian P01512259A0867 JJ I-UN
furin P01512259A0867 NN I-UN
. P01512259A0867 . O
. . O O

The P07836390A1152 DT O
characteristics P07836390A1152 NNS O
of P07836390A1152 IN O
the P07836390A1152 DT O
VirD1 P07836390A1152 NNP I-UN
/ P07836390A1152 NNP O
VirD2-mediated P07836390A1152 NNP O
cleavage P07836390A1152 NN O
reaction P07836390A1152 NN O
strongly P07836390A1152 RB O
resemble P07836390A1152 JJ O
those P07836390A1152 DT O
observed P07836390A1152 VBN O
with P07836390A1152 IN O
relaxosomes P07836390A1152 NNS O
of P07836390A1152 IN O
IncP P07836390A1152 NNP O
plasmids P07836390A1152 NNS O
involved P07836390A1152 VBN O
in P07836390A1152 IN O
initiation P07836390A1152 NN O
of P07836390A1152 IN O
transfer P07836390A1152 NN O
DNA P07836390A1152 NNP O
replication P07836390A1152 NN O
during P07836390A1152 IN O
bacterial P07836390A1152 JJ O
conjugation P07836390A1152 NN O
. P07836390A1152 . O
. . O O

A P08289342A0931 DT O
mutant P08289342A0931 NN O
in P08289342A0931 IN O
the P08289342A0931 DT O
AAV P08289342A0931 NNP O
terminal P08289342A0931 JJ O
resolution P08289342A0931 NN O
site P08289342A0931 NN O
( P08289342A0931 ( O
trs P08289342A0931 NN O
) P08289342A0931 ) O
was P08289342A0931 VBD O
defective P08289342A0931 JJ O
for P08289342A0931 IN O
DNA P08289342A0931 NNP O
replication P08289342A0931 NN O
in P08289342A0931 IN O
the P08289342A0931 DT O
in P08289342A0931 IN O
vitro P08289342A0931 JJ O
assay P08289342A0931 NN O
. P08289342A0931 . O
. . O O

The P08262067A1608 DT O
functional P08262067A1608 JJ O
homology P08262067A1608 NN O
of P08262067A1608 IN O
Cwg2 P08262067A1608 NNP I-UN
with P08262067A1608 IN O
Cdc43 P08262067A1608 NNP I-UN
, P08262067A1608 , O
which P08262067A1608 WDT O
has P08262067A1608 VBZ O
been P08262067A1608 VBN O
implicated P08262067A1608 VBN O
in P08262067A1608 IN O
the P08262067A1608 DT O
control P08262067A1608 NN O
of P08262067A1608 IN O
cell P08262067A1608 NN O
polarity P08262067A1608 NN O
, P08262067A1608 , O
suggests P08262067A1608 VBZ O
a P08262067A1608 DT O
link P08262067A1608 NN O
between P08262067A1608 IN O
two P08262067A1608 CD O
morphogenetic P08262067A1608 JJ O
events P08262067A1608 NNS O
such P08262067A1608 JJ O
as P08262067A1608 IN O
establishment P08262067A1608 NN O
of P08262067A1608 IN O
cell P08262067A1608 NN O
polarity P08262067A1608 NN O
and P08262067A1608 CC O
cell P08262067A1608 NN O
wall P08262067A1608 NN O
biosynthesis P08262067A1608 NN O
. P08262067A1608 . O
. . O O

Induction P10224289T0000 NN O
of P10224289T0000 IN O
Fas P10224289T0000 NNP I-UN
ligand P10224289T0000 NN I-UN
expression P10224289T0000 NN O
by P10224289T0000 IN O
HIV P10224289T0000 NNP O
involves P10224289T0000 VBZ O
the P10224289T0000 DT O
interaction P10224289T0000 NN O
of P10224289T0000 IN O
Nef P10224289T0000 NNP I-UN
with P10224289T0000 IN O
the P10224289T0000 DT O
T P10224289T0000 NNP I-UN
cell P10224289T0000 NN I-UN
receptor P10224289T0000 NN I-UN
zeta P10224289T0000 NN I-UN
chain P10224289T0000 NN I-UN
. P10224289T0000 . O
. . O O

We P08922385A0622 PRP O
infer P08922385A0622 VBP O
that P08922385A0622 IN O
the P08922385A0622 DT O
dominant P08922385A0622 JJ O
negative P08922385A0622 JJ O
inhibition P08922385A0622 NN O
results P08922385A0622 NNS O
from P08922385A0622 IN O
both P08922385A0622 DT O
direct P08922385A0622 JJ O
proteolysis P08922385A0622 NN O
of P08922385A0622 IN O
the P08922385A0622 DT O
beta-galactosidase P08922385A0622 JJ I-UN
tetramer P08922385A0622 NN I-UN
by P08922385A0622 IN O
the P08922385A0622 DT O
fusion P08922385A0622 NN O
subunit P08922385A0622 NN O
and P08922385A0622 CC O
detour P08922385A0622 NN O
of P08922385A0622 IN O
the P08922385A0622 DT O
tetramer P08922385A0622 NN O
to P08922385A0622 TO O
the P08922385A0622 DT O
lysosome P08922385A0622 NN O
. P08922385A0622 . O
. . O O

Deletion P10918059A0569 NN O
of P10918059A0569 IN O
the P10918059A0569 DT O
RVH P10918059A0569 NNP I-UN
domain P10918059A0569 NN I-UN
resulted P10918059A0569 VBD O
in P10918059A0569 IN O
loss P10918059A0569 NN O
of P10918059A0569 IN O
Ca P10918059A0569 NNP O
( P10918059A0569 ( O
2+ P10918059A0569 CD O
) P10918059A0569 ) O
-dependent P10918059A0569 NN O
activation P10918059A0569 NN O
. P10918059A0569 . O
. . O O

Isolated P00479246T0000 VBN O
calcaneal P00479246T0000 NN O
tuberculous P00479246T0000 JJ O
osteomyelitis P00479246T0000 NN O
. P00479246T0000 . O
. . O O

Eight-four P08879080A0265 JJ O
ACOAs P08879080A0265 NNP O
were P08879080A0265 VBD O
tested P08879080A0265 VBN O
in P08879080A0265 IN O
order P08879080A0265 NN O
to P08879080A0265 TO O
examine P08879080A0265 VB O
the P08879080A0265 DT O
fit P08879080A0265 NN O
of P08879080A0265 IN O
the P08879080A0265 DT O
model P08879080A0265 NN O
to P08879080A0265 TO O
the P08879080A0265 DT O
data P08879080A0265 NNS O
by P08879080A0265 IN O
path P08879080A0265 NN O
analysis P08879080A0265 NN O
with P08879080A0265 IN O
LISREL P08879080A0265 NNP O
VII P08879080A0265 NNP O
. P08879080A0265 . O
. . O O

OBJECTIVE P10205588A0000 NN O
: P10205588A0000 : O
To P10205588A0000 TO O
follow-up P10205588A0000 VB O
prospectively P10205588A0000 JJ O
patients P10205588A0000 NNS O
with P10205588A0000 IN O
arthritis P10205588A0000 NN O
after P10205588A0000 IN O
infection P10205588A0000 NN O
with P10205588A0000 IN O
beta-haemolytic P10205588A0000 JJ O
streptococci P10205588A0000 NN O
of P10205588A0000 IN O
Lancefield P10205588A0000 NNP O
group P10205588A0000 NN O
A P10205588A0000 NNP O
( P10205588A0000 ( O
beta P10205588A0000 JJ O
HSA P10205588A0000 NNP O
) P10205588A0000 ) O
, P10205588A0000 , O
with P10205588A0000 IN O
emphasis P10205588A0000 NN O
on P10205588A0000 IN O
clinical P10205588A0000 JJ O
characteristics P10205588A0000 NNS O
and P10205588A0000 CC O
serological P10205588A0000 JJ O
features P10205588A0000 NNS O
. P10205588A0000 . O
. . O O

An P02521217A1035 DT O
immunologically P02521217A1035 RB O
related P02521217A1035 JJ O
protein P02521217A1035 NN O
was P02521217A1035 VBD O
detected P02521217A1035 VBN O
in P02521217A1035 IN O
ribosome P02521217A1035 NN O
and P02521217A1035 CC O
membrane P02521217A1035 NN O
fractions P02521217A1035 NNS O
of P02521217A1035 IN O
mitochondria P02521217A1035 NN O
from P02521217A1035 IN O
Saccharomyces P02521217A1035 NNP O
cerevisiae P02521217A1035 NN O
. P02521217A1035 . O
. . O O

Second P05285978T0076 JJ O
report P05285978T0076 NN O
of P05285978T0076 IN O
the P05285978T0076 DT O
Norwegian P05285978T0076 JJ O
Cancer P05285978T0076 NNP O
Society P05285978T0076 NNP O
. P05285978T0076 . O
. . O O

The P09840822A0462 DT O
method P09840822A0462 NN O
also P09840822A0462 RB O
eliminates P09840822A0462 VBZ O
tagging P09840822A0462 VBG O
of P09840822A0462 IN O
venous P09840822A0462 JJ O
spins P09840822A0462 NNS O
and P09840822A0462 CC O
concern P09840822A0462 NN O
about P09840822A0462 IN O
asymmetric P09840822A0462 JJ O
magnetization P09840822A0462 NN O
transfer P09840822A0462 NN O
effects P09840822A0462 NNS O
. P09840822A0462 . O
. . O O

We P11134508A0317 PRP O
produced P11134508A0317 VBD O
transgenic P11134508A0317 JJ O
plants P11134508A0317 NNS O
expressing P11134508A0317 VBG O
the P11134508A0317 DT O
antisense P11134508A0317 JJ I-UN
Arabidopsis P11134508A0317 NNP I-UN
HD P11134508A0317 NNP I-UN
( P11134508A0317 ( O
AtHD1 P11134508A0317 NNP I-UN
) P11134508A0317 ) O
gene P11134508A0317 NN O
. P11134508A0317 . O
. . O O

The P08900296A0000 DT O
up-regulation P08900296A0000 NN O
of P08900296A0000 IN O
E-selectin P08900296A0000 NNP I-UN
, P08900296A0000 , O
one P08900296A0000 CD O
of P08900296A0000 IN O
the P08900296A0000 DT O
adhesion P08900296A0000 NN O
molecules P08900296A0000 NNS O
on P08900296A0000 IN O
the P08900296A0000 DT O
endothelium P08900296A0000 NN O
, P08900296A0000 , O
is P08900296A0000 VBZ O
an P08900296A0000 DT O
important P08900296A0000 JJ O
event P08900296A0000 NN O
in P08900296A0000 IN O
the P08900296A0000 DT O
mediation P08900296A0000 NN O
of P08900296A0000 IN O
the P08900296A0000 DT O
inflammatory P08900296A0000 JJ O
response P08900296A0000 NN O
. P08900296A0000 . O
. . O O

155 P08654946A0475 CD O
aa P08654946A0475 NN O
, P08654946A0475 , O
shares P08654946A0475 NNS O
78 P08654946A0475 CD O
% P08654946A0475 NN O
identity P08654946A0475 NN O
with P08654946A0475 IN O
the P08654946A0475 DT O
analogous P08654946A0475 JJ O
region P08654946A0475 NN O
of P08654946A0475 IN O
Xenopus P08654946A0475 NNP O
laevis P08654946A0475 FW O
FGF3 P08654946A0475 NNP I-UN
and P08654946A0475 CC O
72 P08654946A0475 CD O
% P08654946A0475 NN O
identity P08654946A0475 NN O
with P08654946A0475 IN O
the P08654946A0475 DT O
product P08654946A0475 NN O
of P08654946A0475 IN O
the P08654946A0475 DT O
more P08654946A0475 RBR O
distantly P08654946A0475 RB O
related P08654946A0475 VBN O
human P08654946A0475 JJ O
gene P08654946A0475 NN O
. P08654946A0475 . O
. . O O

The P10906999T0000 DT O
measurement P10906999T0000 NN O
of P10906999T0000 IN O
NO P10906999T0000 NNP O
in P10906999T0000 IN O
biological P10906999T0000 JJ O
systems P10906999T0000 NNS O
using P10906999T0000 VBG O
chemiluminescence P10906999T0000 NN O
. P10906999T0000 . O
. . O O

A P01961747A0000 DT O
herpesvirus P01961747A0000 JJ O
proteinase P01961747A0000 NN O
activity P01961747A0000 NN O
has P01961747A0000 VBZ O
been P01961747A0000 VBN O
identified P01961747A0000 VBN O
and P01961747A0000 CC O
partially P01961747A0000 RB O
characterized P01961747A0000 VBN O
by P01961747A0000 IN O
using P01961747A0000 VBG O
the P01961747A0000 DT O
cloned P01961747A0000 VBN O
enzyme P01961747A0000 NN O
and P01961747A0000 CC O
substrate P01961747A0000 NN O
genes P01961747A0000 NNS O
in P01961747A0000 IN O
transient P01961747A0000 JJ O
transfection P01961747A0000 NN O
assays P01961747A0000 NNS O
. P01961747A0000 . O
. . O O

The P09219526A0383 DT O
Man9-mannosidase P09219526A0383 NNP I-UN
specificity P09219526A0383 NN O
of P09219526A0383 IN O
the P09219526A0383 DT O
cDNA P09219526A0383 NN O
construct P09219526A0383 NN O
was P09219526A0383 VBD O
verified P09219526A0383 VBN O
by P09219526A0383 IN O
the P09219526A0383 DT O
observation P09219526A0383 NN O
that P09219526A0383 IN O
all P09219526A0383 DT O
peptide P09219526A0383 JJ O
sequences P09219526A0383 NNS O
derived P09219526A0383 VBN O
from P09219526A0383 IN O
a P09219526A0383 DT O
previously P09219526A0383 RB O
purified P09219526A0383 VBN O
, P09219526A0383 , O
catalytically P09219526A0383 RB O
active P09219526A0383 JJ O
49-kDa P09219526A0383 JJ O
fragment P09219526A0383 NN O
were P09219526A0383 VBD O
found P09219526A0383 VBN O
within P09219526A0383 IN O
the P09219526A0383 DT O
coding P09219526A0383 VBG O
region P09219526A0383 NN O
. P09219526A0383 . O
. . O O

Number P09883639A0000 NNP O
of P09883639A0000 IN O
patients P09883639A0000 NNS O
infected P09883639A0000 VBN O
with P09883639A0000 IN O
nontuberculous P09883639A0000 JJ O
mycobacteria P09883639A0000 NNS O
( P09883639A0000 ( O
NTM P09883639A0000 NNP O
) P09883639A0000 ) O
is P09883639A0000 VBZ O
increasing P09883639A0000 VBG O
world-wide P09883639A0000 NN O
in P09883639A0000 IN O
recent P09883639A0000 JJ O
years P09883639A0000 NNS O
. P09883639A0000 . O
. . O O

2:121-133 P01705541A0273 CD O
, P01705541A0273 , O
1988 P01705541A0273 CD O
) P01705541A0273 ) O
. P01705541A0273 . O
. . O O

The P03119227A0079 DT O
DNA P03119227A0079 NNP O
sequence P03119227A0079 NN O
encodes P03119227A0079 VBZ O
a P03119227A0079 DT O
protein P03119227A0079 NN O
of P03119227A0079 IN O
1520 P03119227A0079 CD O
amino P03119227A0079 NN O
acids P03119227A0079 NNS O
with P03119227A0079 IN O
sequence P03119227A0079 NN O
homology P03119227A0079 NN O
to P03119227A0079 TO O
the P03119227A0079 DT O
human P03119227A0079 JJ I-UN
c-abl P03119227A0079 JJ I-UN
proto-oncogene P03119227A0079 JJ I-UN
product P03119227A0079 NN I-UN
, P03119227A0079 , O
beginning P03119227A0079 VBG O
at P03119227A0079 IN O
the P03119227A0079 DT O
amino P03119227A0079 NN O
terminus P03119227A0079 NN O
and P03119227A0079 CC O
extending P03119227A0079 VBG O
656 P03119227A0079 CD O
amino P03119227A0079 JJ O
acids P03119227A0079 NNS O
through P03119227A0079 IN O
the P03119227A0079 DT O
region P03119227A0079 NN O
essential P03119227A0079 JJ O
for P03119227A0079 IN O
tyrosine P03119227A0079 JJ I-UN
kinase P03119227A0079 NN I-UN
activity P03119227A0079 NN O
. P03119227A0079 . O
. . O O

Treatment P00580106T0000 NN O
of P00580106T0000 IN O
Graves P00580106T0000 NNP O
' P00580106T0000 POS O
disease P00580106T0000 NN O
. P00580106T0000 . O
. . O O

Its P06890622A0067 PRP$ O
vasodilatory P06890622A0067 NN O
, P06890622A0067 , O
anti-vasopressor P06890622A0067 NN O
, P06890622A0067 , O
and P06890622A0067 CC O
platelet P06890622A0067 NN O
stabilizing P06890622A0067 NN O
effects P06890622A0067 NNS O
could P06890622A0067 MD O
be P06890622A0067 VB O
expected P06890622A0067 VBN O
to P06890622A0067 TO O
counteract P06890622A0067 VB O
the P06890622A0067 DT O
placental P06890622A0067 JJ O
ischemia P06890622A0067 NN O
, P06890622A0067 , O
hypertension P06890622A0067 NN O
and P06890622A0067 CC O
excessive P06890622A0067 JJ O
coagulation P06890622A0067 NN O
that P06890622A0067 WDT O
are P06890622A0067 VBP O
seen P06890622A0067 VBN O
in P06890622A0067 IN O
pre-eclampsia P06890622A0067 NN O
. P06890622A0067 . O
. . O O

One P09209312A0968 CD O
RNA P09209312A0968 NNP O
construct P09209312A0968 NN O
which P09209312A0968 WDT O
consisted P09209312A0968 VBD O
of P09209312A0968 IN O
112 P09209312A0968 CD O
nucleotides P09209312A0968 NNS O
( P09209312A0968 ( O
nt P09209312A0968 NN O
) P09209312A0968 ) O
from P09209312A0968 IN O
nt P09209312A0968 $ O
639 P09209312A0968 CD O
to P09209312A0968 TO O
nt P09209312A0968 VB O
750 P09209312A0968 CD O
formed P09209312A0968 VBD O
a P09209312A0968 DT O
heterodimeric P09209312A0968 JJ O
complex P09209312A0968 NN O
with P09209312A0968 IN O
the P09209312A0968 DT O
RNA P09209312A0968 NNP O
which P09209312A0968 WDT O
consisted P09209312A0968 VBD O
of P09209312A0968 IN O
200 P09209312A0968 CD O
nucleotides P09209312A0968 NNS O
from P09209312A0968 IN O
nt P09209312A0968 JJ O
551 P09209312A0968 CD O
to P09209312A0968 TO O
nt P09209312A0968 VB O
750 P09209312A0968 CD O
. P09209312A0968 . O
. . O O

Five P03515840A0000 CD O
out P03515840A0000 IN O
of P03515840A0000 IN O
eight P03515840A0000 CD O
consecutive P03515840A0000 JJ O
cases P03515840A0000 NNS O
with P03515840A0000 IN O
initial P03515840A0000 JJ O
symptoms P03515840A0000 NNS O
of P03515840A0000 IN O
a P03515840A0000 DT O
'midline P03515840A0000 JJ O
granuloma P03515840A0000 NN O
' P03515840A0000 POS O
were P03515840A0000 VBD O
identified P03515840A0000 VBN O
as P03515840A0000 IN O
malignant P03515840A0000 JJ O
histiocytosis P03515840A0000 NN O
( P03515840A0000 ( O
histiocytic P03515840A0000 JJ O
sarcoma P03515840A0000 NN O
) P03515840A0000 ) O
which P03515840A0000 WDT O
within P03515840A0000 IN O
5 P03515840A0000 CD O
months P03515840A0000 NNS O
to P03515840A0000 TO O
4 P03515840A0000 CD O
years P03515840A0000 NNS O
led P03515840A0000 VBD O
to P03515840A0000 TO O
generalization P03515840A0000 NN O
and P03515840A0000 CC O
death P03515840A0000 NN O
. P03515840A0000 . O
. . O O

Endogenous P02459309T0000 JJ O
release P02459309T0000 NN O
of P02459309T0000 IN O
neuronal P02459309T0000 JJ O
serotonin P02459309T0000 NN O
and P02459309T0000 CC O
5-hydroxyindoleacetic P02459309T0000 JJ O
acid P02459309T0000 NN O
in P02459309T0000 IN O
the P02459309T0000 DT O
caudate-putamen P02459309T0000 NNS O
of P02459309T0000 IN O
the P02459309T0000 DT O
rat P02459309T0000 NN O
as P02459309T0000 IN O
revealed P02459309T0000 VBN O
by P02459309T0000 IN O
intracerebral P02459309T0000 JJ O
dialysis P02459309T0000 NN O
coupled P02459309T0000 VBN O
to P02459309T0000 TO O
high-performance P02459309T0000 NN O
liquid P02459309T0000 NN O
chromatography P02459309T0000 NN O
with P02459309T0000 IN O
fluorimetric P02459309T0000 JJ O
detection P02459309T0000 NN O
. P02459309T0000 . O
. . O O

SRC-1 P09792627A0441 JJ I-UN
can P09792627A0441 MD O
relieve P09792627A0441 VB O
the P09792627A0441 DT O
NF-kappaB-mediated P09792627A0441 JJ O
repression P09792627A0441 NN O
of P09792627A0441 IN O
GR P09792627A0441 NNP I-UN
activity P09792627A0441 NN O
. P09792627A0441 . O
. . O O

We P10930526A0174 PRP O
recently P10930526A0174 RB O
reported P10930526A0174 VBD O
the P10930526A0174 DT O
molecular P10930526A0174 JJ O
cloning P10930526A0174 NN O
of P10930526A0174 IN O
a P10930526A0174 DT O
PL P10930526A0174 NNP I-UN
scramblase P10930526A0174 NN I-UN
of P10930526A0174 IN O
human P10930526A0174 JJ O
( P10930526A0174 ( O
HuPLSCR1 P10930526A0174 NNP I-UN
) P10930526A0174 ) O
and P10930526A0174 CC O
mouse P10930526A0174 $ O
origin P10930526A0174 NN O
, P10930526A0174 , O
respectively P10930526A0174 RB O
. P10930526A0174 . O
. . O O

Preventive P02959089T0000 JJ O
effect P02959089T0000 NN O
of P02959089T0000 IN O
ONO-3708 P02959089T0000 NNP O
on P02959089T0000 IN O
thrombosis P02959089T0000 NN O
and P02959089T0000 CC O
vasospasms P02959089T0000 NNS O
in P02959089T0000 IN O
vitro P02959089T0000 NN O
and P02959089T0000 CC O
in P02959089T0000 IN O
vivo P02959089T0000 NN O
. P02959089T0000 . O
. . O O

A P10477748A1076 DT O
portion P10477748A1076 NN O
of P10477748A1076 IN O
p193 P10477748A1076 NN I-UN
is P10477748A1076 VBZ O
nuclear P10477748A1076 JJ O
and P10477748A1076 CC O
localizes P10477748A1076 VBZ O
to P10477748A1076 TO O
the P10477748A1076 DT O
mitotic P10477748A1076 JJ O
spindle P10477748A1076 NN O
. P10477748A1076 . O
. . O O

The P09346953A0000 DT O
cellular P09346953A0000 JJ O
rate P09346953A0000 NN O
of P09346953A0000 IN O
anticoagulant P09346953A0000 JJ I-UN
heparan P09346953A0000 NN I-UN
sulfate P09346953A0000 NN I-UN
proteoglycan P09346953A0000 NN I-UN
( P09346953A0000 ( O
HSPGact P09346953A0000 NNP I-UN
) P09346953A0000 ) O
generation P09346953A0000 NN O
is P09346953A0000 VBZ O
determined P09346953A0000 VBN O
by P09346953A0000 IN O
the P09346953A0000 DT O
level P09346953A0000 NN O
of P09346953A0000 IN O
a P09346953A0000 DT O
kinetically P09346953A0000 RB O
limiting P09346953A0000 VBG O
microsomal P09346953A0000 JJ O
activity P09346953A0000 NN O
, P09346953A0000 , O
HSact P09346953A0000 NNP O
conversion P09346953A0000 NN O
activity P09346953A0000 NN O
, P09346953A0000 , O
which P09346953A0000 WDT O
is P09346953A0000 VBZ O
predominantly P09346953A0000 RB O
composed P09346953A0000 VBN O
of P09346953A0000 IN O
the P09346953A0000 DT O
long P09346953A0000 JJ O
sought P09346953A0000 NN O
heparan P09346953A0000 NN I-UN
sulfate P09346953A0000 VB I-UN
D-glucosaminyl P09346953A0000 NNP I-UN
3-O-sulfotransferase P09346953A0000 JJ I-UN
( P09346953A0000 ( O
3-OST P09346953A0000 JJ I-UN
) P09346953A0000 ) O
( P09346953A0000 ( O
Shworak P09346953A0000 NNP O
, P09346953A0000 , O
N P09346953A0000 NNP O
. P09346953A0000 . O
. . O O

We P03046931A0247 PRP O
also P03046931A0247 RB O
found P03046931A0247 VBD O
an P03046931A0247 DT O
eIF-4A P03046931A0247 JJ I-UN
intronless P03046931A0247 NN O
retroposon P03046931A0247 NN O
which P03046931A0247 WDT O
, P03046931A0247 , O
when P03046931A0247 WRB O
compared P03046931A0247 VBN O
to P03046931A0247 TO O
the P03046931A0247 DT O
cDNA P03046931A0247 NN O
, P03046931A0247 , O
contains P03046931A0247 VBZ O
a P03046931A0247 DT O
single P03046931A0247 JJ O
nucleotide P03046931A0247 NN O
difference P03046931A0247 NN O
. P03046931A0247 . O
. . O O

The P09686344T0000 DT O
biochemical P09686344T0000 JJ O
and P09686344T0000 CC O
molecular P09686344T0000 JJ O
spectrum P09686344T0000 NN O
of P09686344T0000 IN O
ornithine P09686344T0000 JJ I-UN
transcarbamylase P09686344T0000 NN I-UN
deficiency P09686344T0000 NN O
. P09686344T0000 . O
. . O O

Uses P02117799T0000a NNS O
of P02117799T0000a IN O
orthoclone P02117799T0000a NN O
OKT3 P02117799T0000a NNP I-UN
for P02117799T0000a IN O
prophylaxis P02117799T0000a NN O
of P02117799T0000a IN O
rejection P02117799T0000a NN O
and P02117799T0000a CC O
induction P02117799T0000a NN O
in P02117799T0000a IN O
initial P02117799T0000a JJ O
nonfunction P02117799T0000a NN O
in P02117799T0000a IN O
kidney P02117799T0000a NN O
transplantation P02117799T0000a NN O
. P02117799T0000a . O
. . O O

The P07562775A0596 DT O
range P07562775A0596 NN O
of P07562775A0596 IN O
eosinophils P07562775A0596 NNS O
was P07562775A0596 VBD O
22-56 P07562775A0596 JJ O
% P07562775A0596 NN O
of P07562775A0596 IN O
the P07562775A0596 DT O
number P07562775A0596 NN O
of P07562775A0596 IN O
peripheral P07562775A0596 JJ O
white P07562775A0596 JJ O
blood P07562775A0596 NN O
cells P07562775A0596 NNS O
( P07562775A0596 ( O
mean P07562775A0596 JJ O
nadir P07562775A0596 RB O
33 P07562775A0596 CD O
% P07562775A0596 NN O
) P07562775A0596 ) O
. P07562775A0596 . O
. . O O

Myocardial P10448902A0921 JJ O
antioxidant P10448902A0921 NN O
enzymes P10448902A0921 NNS O
, P10448902A0921 , O
catalase P10448902A0921 NN I-UN
, P10448902A0921 , O
glutathione P10448902A0921 NN I-UN
peroxidase P10448902A0921 NN I-UN
and P10448902A0921 CC O
superoxide P10448902A0921 JJ I-UN
dismutase P10448902A0921 NN I-UN
, P10448902A0921 , O
in P10448902A0921 IN O
the P10448902A0921 DT O
MCT-treated P10448902A0921 JJ O
rats P10448902A0921 NNS O
were P10448902A0921 VBD O
not P10448902A0921 RB O
different P10448902A0921 JJ O
compared P10448902A0921 VBN O
to P10448902A0921 TO O
control P10448902A0921 VB O
rats P10448902A0921 NNS O
. P10448902A0921 . O
. . O O

Baseline P11239184A1340 NNP O
variables P11239184A1340 NNS O
associated P11239184A1340 VBN O
with P11239184A1340 IN O
CD P11239184A1340 NNP O
included P11239184A1340 VBD O
a P11239184A1340 DT O
less P11239184A1340 RBR O
frequent P11239184A1340 JJ O
use P11239184A1340 NN O
of P11239184A1340 IN O
prestroke P11239184A1340 NN O
aspirin P11239184A1340 NN O
and P11239184A1340 CC O
a P11239184A1340 DT O
higher P11239184A1340 JJR O
incidence P11239184A1340 NN O
of P11239184A1340 IN O
early P11239184A1340 JJ O
CT P11239184A1340 NNP O
changes P11239184A1340 NNS O
of P11239184A1340 IN O
edema P11239184A1340 NN O
or P11239184A1340 CC O
mass P11239184A1340 NN O
effect P11239184A1340 NN O
or P11239184A1340 CC O
dense P11239184A1340 NN O
middle P11239184A1340 JJ O
cerebral P11239184A1340 JJ O
artery P11239184A1340 NN O
sign P11239184A1340 NN O
. P11239184A1340 . O
. . O O

In P06092048A1111 IN O
these P06092048A1111 DT O
cases P06092048A1111 NNS O
, P06092048A1111 , O
asbestos P06092048A1111 NN O
or P06092048A1111 CC O
erionite-tissue P06092048A1111 NN O
burden P06092048A1111 NN O
followed P06092048A1111 VBN O
by P06092048A1111 IN O
fibrosis P06092048A1111 NN O
was P06092048A1111 VBD O
frequently P06092048A1111 RB O
observed P06092048A1111 VBN O
. P06092048A1111 . O
. . O O

Interspecific P01774063A0161 NNP O
backcross P01774063A0161 NN O
analysis P01774063A0161 NN O
using P01774063A0161 VBG O
progeny P01774063A0161 NNS O
derived P01774063A0161 VBN O
from P01774063A0161 IN O
matings P01774063A0161 NNS O
of P01774063A0161 IN O
( P01774063A0161 ( O
C57BL P01774063A0161 NNP O
/ P01774063A0161 VBZ O
6J P01774063A0161 CD O
x P01774063A0161 NN O
Mus P01774063A0161 NNP O
spretus P01774063A0161 NN O
) P01774063A0161 ) O
F1 P01774063A0161 NNP O
x P01774063A0161 NNP O
C57BL P01774063A0161 NNP O
/ P01774063A0161 VBD O
6J P01774063A0161 CD O
mice P01774063A0161 NN O
indicates P01774063A0161 VBZ O
that P01774063A0161 IN O
the P01774063A0161 DT O
thrombospondin P01774063A0161 JJ I-UN
gene P01774063A0161 NN I-UN
is P01774063A0161 VBZ O
tightly P01774063A0161 RB O
linked P01774063A0161 VBN O
to P01774063A0161 TO O
the P01774063A0161 DT O
Fshb P01774063A0161 NNP I-UN
, P01774063A0161 , O
Actcl P01774063A0161 NNP I-UN
, P01774063A0161 , O
Ltk P01774063A0161 NNP I-UN
, P01774063A0161 , O
and P01774063A0161 CC O
B2M P01774063A0161 NNP I-UN
loci P01774063A0161 VBP I-UN
on P01774063A0161 IN O
murine P01774063A0161 NN O
chromosome P01774063A0161 NN O
2 P01774063A0161 CD O
. P01774063A0161 . O
. . O O

The P09524259A0301 DT O
hp55 P09524259A0301 NN I-UN
gamma P09524259A0301 NN I-UN
protein P09524259A0301 NN I-UN
interacts P09524259A0301 VBZ O
strongly P09524259A0301 RB O
with P09524259A0301 IN O
the P09524259A0301 DT O
activated P09524259A0301 JJ O
IGFIR P09524259A0301 NNP I-UN
but P09524259A0301 CC O
not P09524259A0301 RB O
with P09524259A0301 IN O
the P09524259A0301 DT O
kinase-negative P09524259A0301 JJ O
mutant P09524259A0301 JJ O
receptor P09524259A0301 NN O
. P09524259A0301 . O
hp55 P09524259A0301 NN I-UN
gamma P09524259A0301 NN I-UN
also P09524259A0301 RB O
interacts P09524259A0301 VBZ O
with P09524259A0301 IN O
the P09524259A0301 DT O
insulin P09524259A0301 NN I-UN
receptor P09524259A0301 NN I-UN
( P09524259A0301 ( O
IR P09524259A0301 NNP I-UN
) P09524259A0301 ) O
in P09524259A0301 IN O
the P09524259A0301 DT O
yeast P09524259A0301 NN O
two-hybrid P09524259A0301 JJ O
system P09524259A0301 NN O
. P09524259A0301 . O
. . O O

Controlled P02919530A0000 VBN O
versus P02919530A0000 NN O
uncontrolled P02919530A0000 JJ O
reperfusion P02919530A0000 NN O
of P02919530A0000 IN O
ischemic P02919530A0000 JJ O
myocardium P02919530A0000 NN O
after P02919530A0000 IN O
experimental P02919530A0000 JJ O
coronary P02919530A0000 JJ O
artery P02919530A0000 NN O
occlusion P02919530A0000 NN O
was P02919530A0000 VBD O
studied P02919530A0000 VBN O
to P02919530A0000 TO O
determine P02919530A0000 VB O
the P02919530A0000 DT O
effect P02919530A0000 NN O
on P02919530A0000 IN O
regional P02919530A0000 JJ O
ventricular P02919530A0000 NN O
wall P02919530A0000 NN O
motion P02919530A0000 NN O
and P02919530A0000 CC O
associated P02919530A0000 JJ O
biochemical P02919530A0000 JJ O
alterations P02919530A0000 NNS O
. P02919530A0000 . O
. . O O

The P01392012A0228 DT O
neurohypophysial P01392012A0228 JJ O
vasopressin P01392012A0228 NN I-UN
and P01392012A0228 CC O
oxytocin P01392012A0228 JJ I-UN
content P01392012A0228 NN O
was P01392012A0228 VBD O
bioassayed P01392012A0228 VBN O
by P01392012A0228 IN O
pressor P01392012A0228 NN O
effect P01392012A0228 NN O
following P01392012A0228 VBG O
Dekanski P01392012A0228 NNP O
or P01392012A0228 CC O
milk-ejection P01392012A0228 NN O
activity P01392012A0228 NN O
in P01392012A0228 IN O
vitro P01392012A0228 NN O
following P01392012A0228 VBG O
van P01392012A0228 NN O
Dongen P01392012A0228 NNP O
and P01392012A0228 CC O
Hays P01392012A0228 NNP O
, P01392012A0228 , O
respectively P01392012A0228 RB O
. P01392012A0228 . O
. . O O

The P08442384T0000 DT O
SCH9 P08442384T0000 NNP I-UN
protein P08442384T0000 NN I-UN
kinase P08442384T0000 NN I-UN
mRNA P08442384T0000 NN I-UN
contains P08442384T0000 VBZ O
a P08442384T0000 DT O
long P08442384T0000 JJ O
5 P08442384T0000 CD O
' P08442384T0000 POS O
leader P08442384T0000 NN O
with P08442384T0000 IN O
a P08442384T0000 DT O
small P08442384T0000 JJ O
open P08442384T0000 JJ O
reading P08442384T0000 NN O
frame P08442384T0000 NN O
. P08442384T0000 . O
. . O O

We P01648530A0000 PRP O
identify P01648530A0000 VBP O
the P01648530A0000 DT O
`` P01648530A0000 `` O
M P01648530A0000 NNP O
region P01648530A0000 NN O
'' P01648530A0000 '' O
of P01648530A0000 IN O
the P01648530A0000 DT O
muscle-specific P01648530A0000 JJ I-UN
Xenopus P01648530A0000 NNP I-UN
cardiac P01648530A0000 NN I-UN
actin P01648530A0000 NN I-UN
gene P01648530A0000 NN I-UN
promoter P01648530A0000 NN I-UN
from P01648530A0000 IN O
-282 P01648530A0000 NN O
to P01648530A0000 TO O
-348 P01648530A0000 VB O
as P01648530A0000 IN O
necessary P01648530A0000 JJ O
for P01648530A0000 IN O
the P01648530A0000 DT O
embryonic P01648530A0000 JJ O
expression P01648530A0000 NN O
of P01648530A0000 IN O
a P01648530A0000 DT O
cardiac P01648530A0000 JJ O
actin-beta-globin P01648530A0000 JJ O
reporter P01648530A0000 NN O
gene P01648530A0000 NN O
injected P01648530A0000 VBD O
into P01648530A0000 IN O
fertilized P01648530A0000 VBN O
eggs P01648530A0000 NNS O
. P01648530A0000 . O
. . O O

Since P01050144A0297 IN O
1968 P01050144A0297 CD O
, P01050144A0297 , O
a P01050144A0297 DT O
steep P01050144A0297 JJ O
decrease P01050144A0297 NN O
in P01050144A0297 IN O
the P01050144A0297 DT O
number P01050144A0297 NN O
of P01050144A0297 IN O
strains P01050144A0297 NNS O
resistant P01050144A0297 JJ O
to P01050144A0297 TO O
three P01050144A0297 CD O
or P01050144A0297 CC O
more P01050144A0297 JJR O
antibiotics P01050144A0297 NNS O
( P01050144A0297 ( O
multiple-resistant P01050144A0297 JJ O
) P01050144A0297 ) O
and P01050144A0297 CC O
in P01050144A0297 IN O
strains P01050144A0297 NNS O
of P01050144A0297 IN O
the P01050144A0297 DT O
83A P01050144A0297 CD O
complex P01050144A0297 NN O
was P01050144A0297 VBD O
noticed P01050144A0297 VBN O
. P01050144A0297 . O
. . O O

The P01325386A0766 DT O
hit1-1 P01325386A0766 JJ I-UN
mutation P01325386A0766 NN O
caused P01325386A0766 VBD O
a P01325386A0766 DT O
defect P01325386A0766 NN O
in P01325386A0766 IN O
synthesis P01325386A0766 NN O
of P01325386A0766 IN O
a P01325386A0766 DT O
74-kD P01325386A0766 JJ I-UN
heat P01325386A0766 NN I-UN
shock P01325386A0766 NN I-UN
protein P01325386A0766 NN I-UN
. P01325386A0766 . O
. . O O

DESIGN P11443509A0293 NN O
: P11443509A0293 : O
Prospective P11443509A0293 JJ O
cohort P11443509A0293 NN O
study P11443509A0293 NN O
with P11443509A0293 IN O
a P11443509A0293 DT O
20 P11443509A0293 CD O
y P11443509A0293 JJ O
follow-up P11443509A0293 JJ O
period P11443509A0293 NN O
, P11443509A0293 , O
the P11443509A0293 DT O
First P11443509A0293 NNP O
National P11443509A0293 NNP O
Health P11443509A0293 NNP O
and P11443509A0293 CC O
Examination P11443509A0293 NNP O
Survey P11443509A0293 NNP O
( P11443509A0293 ( O
NHANES P11443509A0293 NNP O
1 P11443509A0293 CD O
) P11443509A0293 ) O
Epidemiologic P11443509A0293 NNP O
Follow-up P11443509A0293 NNP O
Study P11443509A0293 NNP O
( P11443509A0293 ( O
NHEFS P11443509A0293 NNP O
) P11443509A0293 ) O
. P11443509A0293 . O
. . O O

A P11298326A0677 DT O
comparison P11298326A0677 NN O
of P11298326A0677 IN O
the P11298326A0677 DT O
duplicated P11298326A0677 JJ O
Vkappa P11298326A0677 NNP I-UN
genes P11298326A0677 NNS I-UN
suggests P11298326A0677 VBZ O
positive P11298326A0677 JJ O
selection P11298326A0677 NN O
on P11298326A0677 IN O
the P11298326A0677 DT O
complementarity-determining P11298326A0677 JJ O
regions P11298326A0677 NNS O
of P11298326A0677 IN O
the P11298326A0677 DT O
duplicated P11298326A0677 VBN O
genes P11298326A0677 NNS O
by P11298326A0677 IN O
point P11298326A0677 NN O
mutations P11298326A0677 NNS O
. P11298326A0677 . O
. . O O

Hyperprolactinaemia P03285764A0675 NNP O
, P03285764A0675 , O
moderate P03285764A0675 JJ O
hypogonadism P03285764A0675 NN O
, P03285764A0675 , O
infraclinical P03285764A0675 JJ O
neuropathies P03285764A0675 NNS O
, P03285764A0675 , O
arterial P03285764A0675 JJ O
stenoses P03285764A0675 NNS O
and P03285764A0675 CC O
moderate P03285764A0675 JJ O
venous P03285764A0675 JJ O
leakages P03285764A0675 NNS O
seem P03285764A0675 VBP O
to P03285764A0675 TO O
play P03285764A0675 VB O
a P03285764A0675 DT O
partial P03285764A0675 JJ O
role P03285764A0675 NN O
of P03285764A0675 IN O
organic P03285764A0675 JJ O
starter P03285764A0675 NN O
or P03285764A0675 CC O
cofactor P03285764A0675 NN O
, P03285764A0675 , O
the P03285764A0675 DT O
sexual P03285764A0675 JJ O
consequences P03285764A0675 NNS O
of P03285764A0675 IN O
which P03285764A0675 WDT O
are P03285764A0675 VBP O
amplified P03285764A0675 VBN O
by P03285764A0675 IN O
psychological P03285764A0675 JJ O
factors P03285764A0675 NNS O
, P03285764A0675 , O
partly P03285764A0675 RB O
secondary P03285764A0675 JJ O
to P03285764A0675 TO O
the P03285764A0675 DT O
initial P03285764A0675 JJ O
sexual P03285764A0675 JJ O
failures P03285764A0675 NNS O
. P03285764A0675 . O
. . O O

Transcriptional P01752441A0000 JJ O
activation P01752441A0000 NN O
by P01752441A0000 IN O
the P01752441A0000 DT O
HIV-1 P01752441A0000 NNP I-UN
Tat P01752441A0000 NNP I-UN
protein P01752441A0000 NN I-UN
requires P01752441A0000 VBZ O
specific P01752441A0000 JJ O
residues P01752441A0000 NNS O
in P01752441A0000 IN O
the P01752441A0000 DT O
hexanucleotide P01752441A0000 NN O
loop P01752441A0000 NN O
and P01752441A0000 CC O
trinucleotide P01752441A0000 JJ O
bulge P01752441A0000 NN O
of P01752441A0000 IN O
the P01752441A0000 DT O
TAR P01752441A0000 NNP I-UN
RNA P01752441A0000 NNP O
stem-loop P01752441A0000 JJ O
structure P01752441A0000 NN O
found P01752441A0000 VBN O
in P01752441A0000 IN O
the P01752441A0000 DT O
5'-untranslated P01752441A0000 JJ O
leader P01752441A0000 NN O
of P01752441A0000 IN O
all P01752441A0000 DT O
viral P01752441A0000 JJ O
transcripts P01752441A0000 NNS O
. P01752441A0000 . O
. . O O

Three P06607427A0000 CD O
experiments P06607427A0000 NNS O
contrasted P06607427A0000 VBD O
the P06607427A0000 DT O
effects P06607427A0000 NNS O
of P06607427A0000 IN O
6-hydroxydopamine-induced P06607427A0000 JJ O
lesions P06607427A0000 NNS O
of P06607427A0000 IN O
the P06607427A0000 DT O
ventral P06607427A0000 JJ O
noradrenergic P06607427A0000 NN O
and P06607427A0000 CC O
dorsal P06607427A0000 NN O
noradrenergic P06607427A0000 JJ O
projections P06607427A0000 NNS O
, P06607427A0000 , O
predominantly P06607427A0000 RB O
to P06607427A0000 TO O
hypothalamus P06607427A0000 VB O
and P06607427A0000 CC O
cortex P06607427A0000 VB O
, P06607427A0000 , O
respectively P06607427A0000 RB O
, P06607427A0000 , O
upon P06607427A0000 IN O
body P06607427A0000 NN O
weight P06607427A0000 JJ O
changes P06607427A0000 NNS O
and P06607427A0000 CC O
food-related P06607427A0000 JJ O
behaviour P06607427A0000 NN O
in P06607427A0000 IN O
the P06607427A0000 DT O
rat P06607427A0000 NN O
. P06607427A0000 . O
. . O O

This P09888994A0858 DT O
Tbx6-subfamily P09888994A0858 JJ I-UN
gene P09888994A0858 NN I-UN
is P09888994A0858 VBZ O
likely P09888994A0858 JJ O
to P09888994A0858 TO O
participate P09888994A0858 VB O
in P09888994A0858 IN O
paraxial P09888994A0858 JJ O
mesoderm P09888994A0858 NN O
formation P09888994A0858 NN O
and P09888994A0858 CC O
somitogenesis P09888994A0858 NN O
in P09888994A0858 IN O
human P09888994A0858 JJ O
embryo P09888994A0858 NN O
. P09888994A0858 . O
. . O O

However P07623844A0639 RB O
, P07623844A0639 , O
unlike P07623844A0639 IN O
Bcl-2 P07623844A0639 NNP I-UN
and P07623844A0639 CC O
the P07623844A0639 DT O
E1B P07623844A0639 NNP I-UN
19K P07623844A0639 CD I-UN
proteins P07623844A0639 NNS I-UN
, P07623844A0639 , O
which P07623844A0639 WDT O
completely P07623844A0639 RB O
block P07623844A0639 VBP O
apoptosis P07623844A0639 NN O
but P07623844A0639 CC O
not P07623844A0639 RB O
p53-dependent P07623844A0639 JJ O
growth P07623844A0639 NN O
arrest P07623844A0639 NN O
, P07623844A0639 , O
H-ras P07623844A0639 JJ I-UN
expression P07623844A0639 NN O
permitted P07623844A0639 VBD O
DNA P07623844A0639 NNP O
synthesis P07623844A0639 NN O
and P07623844A0639 CC O
cell P07623844A0639 NN O
proliferation P07623844A0639 NN O
in P07623844A0639 IN O
the P07623844A0639 DT O
presence P07623844A0639 NN O
of P07623844A0639 IN O
high P07623844A0639 JJ O
levels P07623844A0639 NNS O
of P07623844A0639 IN O
wild-type P07623844A0639 JJ I-UN
p53 P07623844A0639 NN I-UN
. P07623844A0639 . O
. . O O

Sequential P10799863T0000 JJ O
cleavage P10799863T0000 NN O
by P10799863T0000 IN O
metallopeptidases P10799863T0000 NNS I-UN
and P10799863T0000 CC O
proteasomes P10799863T0000 NNS O
is P10799863T0000 VBZ O
involved P10799863T0000 VBN O
in P10799863T0000 IN O
processing P10799863T0000 VBG O
HIV-1 P10799863T0000 NNP I-UN
ENV P10799863T0000 NNP I-UN
epitope P10799863T0000 NN I-UN
for P10799863T0000 IN O
endogenous P10799863T0000 JJ O
MHC P10799863T0000 NNP I-UN
class P10799863T0000 NN I-UN
I P10799863T0000 PRP I-UN
antigen P10799863T0000 VBP I-UN
presentation P10799863T0000 NN O
. P10799863T0000 . O
. . O O

Collectively P08662617A2051 RB O
, P08662617A2051 , O
these P08662617A2051 DT O
data P08662617A2051 NNS O
indicate P08662617A2051 VBP O
that P08662617A2051 IN O
HIP P08662617A2051 NNP I-UN
is P08662617A2051 VBZ O
a P08662617A2051 DT O
membrane-associated P08662617A2051 JJ O
HP-binding P08662617A2051 NNP I-UN
protein P08662617A2051 NN I-UN
expressed P08662617A2051 VBD O
on P08662617A2051 IN O
the P08662617A2051 DT O
surface P08662617A2051 NN O
of P08662617A2051 IN O
normal P08662617A2051 JJ O
human P08662617A2051 JJ O
uterine P08662617A2051 NN O
epithelia P08662617A2051 NN O
and P08662617A2051 CC O
uterine P08662617A2051 JJ O
epithelial P08662617A2051 NN O
cell P08662617A2051 NN O
lines P08662617A2051 NNS O
. P08662617A2051 . O
. . O O

RNase P07678006A0472 NNP I-UN
protection P07678006A0472 NN O
analyses P07678006A0472 NNS O
indicate P07678006A0472 VBP O
that P07678006A0472 IN O
either P07678006A0472 DT O
61-kDa P07678006A0472 JJ I-UN
CaM P07678006A0472 NNP I-UN
PDE P07678006A0472 NNP I-UN
mRNA P07678006A0472 NN I-UN
or P07678006A0472 CC O
structurally P07678006A0472 RB O
related P07678006A0472 JJ O
transcripts P07678006A0472 NNS O
encoding P07678006A0472 VBG O
different P07678006A0472 JJ O
CaM P07678006A0472 NNP I-UN
PDE P07678006A0472 NNP I-UN
isoforms P07678006A0472 NNS I-UN
are P07678006A0472 VBP O
expressed P07678006A0472 VBN O
in P07678006A0472 IN O
a P07678006A0472 DT O
tissue-specific P07678006A0472 JJ O
manner P07678006A0472 NN O
. P07678006A0472 . O
. . O O

Diclofenac P06734713T0000 NNP O
sodium-chlormezanone P06734713T0000 NN O
poisoning P06734713T0000 NN O
. P06734713T0000 . O
. . O O

These P00954819A1041 DT O
data P00954819A1041 NNS O
suggest P00954819A1041 VBP O
that P00954819A1041 IN O
spontaneous P00954819A1041 JJ O
recovery P00954819A1041 NN O
of P00954819A1041 IN O
central P00954819A1041 JJ O
respiratory P00954819A1041 NN O
function P00954819A1041 NN O
after P00954819A1041 IN O
intoxication P00954819A1041 NN O
with P00954819A1041 IN O
Soman P00954819A1041 NNP O
or P00954819A1041 CC O
Sarin P00954819A1041 NNP O
may P00954819A1041 MD O
not P00954819A1041 RB O
be P00954819A1041 VB O
related P00954819A1041 VBN O
to P00954819A1041 TO O
the P00954819A1041 DT O
return P00954819A1041 NN O
of P00954819A1041 IN O
AChE P00954819A1041 NNP I-UN
activity P00954819A1041 NN O
. P00954819A1041 . O
. . O O

These P02200736A1003 DT O
factors P02200736A1003 NNS O
belong P02200736A1003 VBP O
to P02200736A1003 TO O
a P02200736A1003 DT O
set P02200736A1003 NN O
of P02200736A1003 IN O
genetically P02200736A1003 RB O
distinct P02200736A1003 JJ O
molecules P02200736A1003 NNS O
, P02200736A1003 , O
including P02200736A1003 VBG O
AP-4 P02200736A1003 NNP I-UN
and P02200736A1003 CC O
MLTF P02200736A1003 NNP I-UN
, P02200736A1003 , O
that P02200736A1003 WDT O
bind P02200736A1003 VBZ O
to P02200736A1003 TO O
the P02200736A1003 DT O
CACCTGTC P02200736A1003 NNP O
motif P02200736A1003 NN O
or P02200736A1003 CC O
related P02200736A1003 JJ O
sequences P02200736A1003 NNS O
. P02200736A1003 . O
. . O O

Three P10370778A0000 CD O
new P10370778A0000 JJ O
aromatase P10370778A0000 NN I-UN
inhibitors P10370778A0000 NNS O
have P10370778A0000 VBP O
recently P10370778A0000 RB O
completed P10370778A0000 VBN O
phase P10370778A0000 NN O
III P10370778A0000 NNP O
evaluation P10370778A0000 NN O
as P10370778A0000 IN O
treatment P10370778A0000 NN O
of P10370778A0000 IN O
metastatic P10370778A0000 JJ O
breast P10370778A0000 NN O
cancer P10370778A0000 NN O
in P10370778A0000 IN O
post-menopausal P10370778A0000 JJ O
women P10370778A0000 NNS O
whose P10370778A0000 WP$ O
disease P10370778A0000 NN O
has P10370778A0000 VBZ O
progressed P10370778A0000 VBN O
despite P10370778A0000 IN O
tamoxifen P10370778A0000 JJ O
therapy P10370778A0000 NN O
: P10370778A0000 : O
anastrozole P10370778A0000 NN O
( P10370778A0000 ( O
ARIMIDEX P10370778A0000 NNP O
, P10370778A0000 , O
Zeneca P10370778A0000 NNP O
) P10370778A0000 ) O
, P10370778A0000 , O
letrozole P10370778A0000 JJ O
( P10370778A0000 ( O
FEMARA P10370778A0000 NNP O
, P10370778A0000 , O
Novartis P10370778A0000 NNP O
) P10370778A0000 ) O
and P10370778A0000 CC O
vorozole P10370778A0000 JJ O
( P10370778A0000 ( O
RIVIZOR P10370778A0000 NNP O
, P10370778A0000 , O
Janssen P10370778A0000 NNP O
) P10370778A0000 ) O
. P10370778A0000 . O
. . O O

This P08387155A1248 DT O
stimulatory P08387155A1248 JJ O
effect P08387155A1248 NN O
could P08387155A1248 MD O
also P08387155A1248 RB O
be P08387155A1248 VB O
elicited P08387155A1248 VBN O
by P08387155A1248 IN O
c-Jun P08387155A1248 NN I-UN
, P08387155A1248 , O
which P08387155A1248 WDT O
interacts P08387155A1248 VBZ O
with P08387155A1248 IN O
topo P08387155A1248 NN I-UN
II P08387155A1248 NNP I-UN
, P08387155A1248 , O
but P08387155A1248 CC O
not P08387155A1248 RB O
by P08387155A1248 IN O
c-Fos P08387155A1248 NN I-UN
, P08387155A1248 , O
which P08387155A1248 WDT O
does P08387155A1248 VBZ O
not P08387155A1248 RB O
bind P08387155A1248 VB O
topo P08387155A1248 JJ I-UN
II P08387155A1248 NNP I-UN
in P08387155A1248 IN O
our P08387155A1248 PRP$ O
in P08387155A1248 IN O
vitro P08387155A1248 NN O
assay P08387155A1248 NN O
. P08387155A1248 . O
. . O O

The P10908462A3159 DT O
effectiveness P10908462A3159 NN O
of P10908462A3159 IN O
NRT P10908462A3159 NNP O
appears P10908462A3159 VBZ O
to P10908462A3159 TO O
be P10908462A3159 VB O
largely P10908462A3159 RB O
independent P10908462A3159 JJ O
of P10908462A3159 IN O
the P10908462A3159 DT O
intensity P10908462A3159 NN O
of P10908462A3159 IN O
additional P10908462A3159 JJ O
support P10908462A3159 NN O
provided P10908462A3159 VBD O
to P10908462A3159 TO O
the P10908462A3159 DT O
smoker P10908462A3159 NN O
. P10908462A3159 . O
. . O O

Importance P07385543T0001 NN O
of P07385543T0001 IN O
determining P07385543T0001 VBG O
the P07385543T0001 DT O
blood P07385543T0001 NN O
sulfhydryl P07385543T0001 NN O
groups P07385543T0001 NNS O
in P07385543T0001 IN O
fractures P07385543T0001 NNS O
of P07385543T0001 IN O
the P07385543T0001 DT O
long P07385543T0001 JJ O
tubular P07385543T0001 JJ O
bones P07385543T0001 NNS O
complicated P07385543T0001 VBN O
by P07385543T0001 IN O
infection P07385543T0001 NN O
. P07385543T0001 . O
. . O O

Once P10955913A0827 RB O
HIT P10955913A0827 NNP O
II P10955913A0827 NNP O
is P10955913A0827 VBZ O
suspected P10955913A0827 VBN O
, P10955913A0827 , O
heparin P10955913A0827 NN O
( P10955913A0827 ( O
and P10955913A0827 CC O
low-molecular-weight P10955913A0827 JJ O
heparins P10955913A0827 NNS O
) P10955913A0827 ) O
should P10955913A0827 MD O
be P10955913A0827 VB O
stopped P10955913A0827 VBN O
immediately P10955913A0827 RB O
. P10955913A0827 . O
. . O O

Cardiac P02919832A0144 JJ O
disease P02919832A0144 NN O
was P02919832A0144 VBD O
not P02919832A0144 RB O
detected P02919832A0144 VBN O
with P02919832A0144 IN O
M-mode P02919832A0144 NNP O
, P02919832A0144 , O
2-dimensional P02919832A0144 JJ O
real-time P02919832A0144 NN O
or P02919832A0144 CC O
pulsed-wave P02919832A0144 JJ O
Doppler P02919832A0144 NNP O
echocardiography P02919832A0144 NN O
. P02919832A0144 . O
. . O O

Immunostaining P01734020A1318 NN O
of P01734020A1318 IN O
cells P01734020A1318 NNS O
transfected P01734020A1318 VBN O
with P01734020A1318 IN O
these P01734020A1318 DT O
constructs P01734020A1318 NNS O
revealed P01734020A1318 VBD O
that P01734020A1318 IN O
both P01734020A1318 DT O
the P01734020A1318 DT O
myristoylated P01734020A1318 VBN O
and P01734020A1318 CC O
nonmyristoylated P01734020A1318 VBN O
mutants P01734020A1318 NNS O
were P01734020A1318 VBD O
localized P01734020A1318 VBN O
in P01734020A1318 IN O
nuclei P01734020A1318 NN O
, P01734020A1318 , O
whereas P01734020A1318 IN O
wild-type P01734020A1318 JJ I-UN
PKC P01734020A1318 NNP I-UN
alpha P01734020A1318 NN I-UN
was P01734020A1318 VBD O
primarily P01734020A1318 RB O
cytoplasmic P01734020A1318 JJ O
and P01734020A1318 CC O
perinuclear P01734020A1318 JJ O
. P01734020A1318 . O
. . O O

The P07456774A0448 DT O
potentially P07456774A0448 RB O
SLE-inducing P07456774A0448 JJ O
drugs P07456774A0448 NNS O
are P07456774A0448 VBP O
reviewed P07456774A0448 VBN O
. P07456774A0448 . O
. . O O

In P08621453A0815 IN O
addition P08621453A0815 NN O
, P08621453A0815 , O
anti-phosphotyrosine P08621453A0815 JJ I-UN
antibodies P08621453A0815 NNS I-UN
immunoprecipitated P08621453A0815 VBN O
80K-H P08621453A0815 CD I-UN
from P08621453A0815 IN O
cell P08621453A0815 NN O
lysates P08621453A0815 NNS O
of P08621453A0815 IN O
FGF-stimulated P08621453A0815 NNP O
but P08621453A0815 CC O
not P08621453A0815 RB O
from P08621453A0815 IN O
control P08621453A0815 NN O
fibroblasts P08621453A0815 NNS O
. P08621453A0815 . O
. . O O

Serum P07760790A0327 NNP O
induction P07760790A0327 NN O
of P07760790A0327 IN O
a P07760790A0327 DT O
MEF2 P07760790A0327 NNP I-UN
reporter P07760790A0327 NN I-UN
gene P07760790A0327 NN I-UN
was P07760790A0327 VBD O
not P07760790A0327 RB O
observed P07760790A0327 VBN O
in P07760790A0327 IN O
a P07760790A0327 DT O
line P07760790A0327 NN O
of P07760790A0327 IN O
NIH P07760790A0327 NNP O
3T3 P07760790A0327 CD O
cells P07760790A0327 NNS O
which P07760790A0327 WDT O
contain P07760790A0327 VBP O
low P07760790A0327 JJ O
MEF2 P07760790A0327 NNP I-UN
site P07760790A0327 NN I-UN
binding P07760790A0327 NN O
activity P07760790A0327 NN O
. P07760790A0327 . O
. . O O

We P06542918A1131 PRP O
propose P06542918A1131 VBP O
that P06542918A1131 IN O
the P06542918A1131 DT O
ambiguous P06542918A1131 JJ O
discrimination P06542918A1131 NN O
required P06542918A1131 VBD O
a P06542918A1131 DT O
greater P06542918A1131 JJR O
time P06542918A1131 NN O
for P06542918A1131 IN O
simulus P06542918A1131 JJ O
evaluation P06542918A1131 NN O
and P06542918A1131 CC O
that P06542918A1131 IN O
this P06542918A1131 DT O
was P06542918A1131 VBD O
reflected P06542918A1131 VBN O
in P06542918A1131 IN O
the P06542918A1131 DT O
delayed P06542918A1131 JJ O
P3 P06542918A1131 NNP O
latencies P06542918A1131 NNS O
. P06542918A1131 . O
. . O O

Identical P09605930A1428 JJ O
results P09605930A1428 NNS O
were P09605930A1428 VBD O
obtained P09605930A1428 VBN O
when P09605930A1428 WRB O
transfections P09605930A1428 NNS O
and P09605930A1428 CC O
mobility P09605930A1428 NN O
shift P09605930A1428 NN O
assays P09605930A1428 NNS O
were P09605930A1428 VBD O
performed P09605930A1428 VBN O
in P09605930A1428 IN O
primary P09605930A1428 JJ O
rat P09605930A1428 NN O
hepatocytes P09605930A1428 NNS O
in P09605930A1428 IN O
which P09605930A1428 WDT O
the P09605930A1428 DT O
endogenous P09605930A1428 JJ O
ALS P09605930A1428 NNP I-UN
gene P09605930A1428 NN I-UN
is P09605930A1428 VBZ O
expressed P09605930A1428 VBN O
. P09605930A1428 . O
. . O O

These P01711041A0348 DT O
clones P01711041A0348 NNS O
overlapped P01711041A0348 VBD O
and P01711041A0348 CC O
contained P01711041A0348 VBD O
the P01711041A0348 DT O
structural P01711041A0348 JJ O
gene P01711041A0348 NN O
encoding P01711041A0348 VBG O
the P01711041A0348 DT O
complete P01711041A0348 JJ O
C5 P01711041A0348 NNP I-UN
alpha-chain P01711041A0348 NN I-UN
and P01711041A0348 CC O
90 P01711041A0348 CD O
% P01711041A0348 NN O
of P01711041A0348 IN O
the P01711041A0348 DT O
beta-chain P01711041A0348 NN O
. P01711041A0348 . O
. . O O

This P09719636A1134 DT O
hypothesis P09719636A1134 NN O
was P09719636A1134 VBD O
tested P09719636A1134 VBN O
by P09719636A1134 IN O
introducing P09719636A1134 VBG O
mutations P09719636A1134 NNS O
at P09719636A1134 IN O
each P09719636A1134 DT O
of P09719636A1134 IN O
the P09719636A1134 DT O
three P09719636A1134 CD O
histidine P09719636A1134 NN O
pairs P09719636A1134 NNS O
, P09719636A1134 , O
the P09719636A1134 DT O
H382-X2-H385 P09719636A1134 NNP O
pair P09719636A1134 NN O
, P09719636A1134 , O
the P09719636A1134 DT O
H411-X2-H414 P09719636A1134 NNP O
pair P09719636A1134 NN O
and P09719636A1134 CC O
the P09719636A1134 DT O
H430-X5-H436 P09719636A1134 NNP O
pair P09719636A1134 NN O
, P09719636A1134 , O
which P09719636A1134 WDT O
constitute P09719636A1134 VBP O
the P09719636A1134 DT O
histidine-rich P09719636A1134 JJ O
region P09719636A1134 NN O
near P09719636A1134 IN O
the P09719636A1134 DT O
C P09719636A1134 NNP O
terminus P09719636A1134 NN O
of P09719636A1134 IN O
gp17 P09719636A1134 NN I-UN
. P09719636A1134 . O
. . O O

Serine P08798443A0660 JJ O
528 P08798443A0660 CD O
is P08798443A0660 VBZ O
phosphorylated P08798443A0660 VBN O
in P08798443A0660 IN O
vivo P08798443A0660 NN O
in P08798443A0660 IN O
several P08798443A0660 JJ O
cell P08798443A0660 NN O
lines P08798443A0660 NNS O
, P08798443A0660 , O
and P08798443A0660 CC O
substitution P08798443A0660 NN O
of P08798443A0660 IN O
serine P08798443A0660 NN O
528 P08798443A0660 CD O
to P08798443A0660 TO O
alanine P08798443A0660 VB O
( P08798443A0660 ( O
S528A P08798443A0660 NNP O
) P08798443A0660 ) O
resulted P08798443A0660 VBD O
in P08798443A0660 IN O
an P08798443A0660 DT O
increased P08798443A0660 JJ O
ability P08798443A0660 NN O
of P08798443A0660 IN O
Myb P08798443A0660 NNP I-UN
to P08798443A0660 TO O
transactivate P08798443A0660 VB O
a P08798443A0660 DT O
synthetic P08798443A0660 JJ O
promoter P08798443A0660 NN O
containing P08798443A0660 VBG O
five P08798443A0660 CD O
copies P08798443A0660 NNS O
of P08798443A0660 IN O
the P08798443A0660 DT O
mim-1A P08798443A0660 JJ I-UN
Myb-responsive P08798443A0660 JJ O
element P08798443A0660 NN O
and P08798443A0660 CC O
a P08798443A0660 DT O
minimal P08798443A0660 JJ O
herpes P08798443A0660 NNS I-UN
tk P08798443A0660 VBP I-UN
promoter P08798443A0660 NN I-UN
. P08798443A0660 . O
. . O O

A P01844878A0000 DT O
vector P01844878A0000 NN O
containing P01844878A0000 VBG O
a P01844878A0000 DT O
transcriptionally P01844878A0000 RB O
inactive P01844878A0000 JJ O
neomycin P01844878A0000 NN I-UN
phosphotransferase P01844878A0000 NN I-UN
II P01844878A0000 NNP I-UN
gene P01844878A0000 NN I-UN
was P01844878A0000 VBD O
used P01844878A0000 VBN O
to P01844878A0000 TO O
select P01844878A0000 VB O
promoter P01844878A0000 NN O
sequences P01844878A0000 NNS O
from P01844878A0000 IN O
a P01844878A0000 DT O
pool P01844878A0000 NN O
of P01844878A0000 IN O
random P01844878A0000 JJ O
genomic P01844878A0000 JJ O
DNA P01844878A0000 NN O
fragments P01844878A0000 NNS O
. P01844878A0000 . O
. . O O

Our P11457139A0604 PRP$ O
results P11457139A0604 NNS O
show P11457139A0604 VBP O
that P11457139A0604 IN O
CVN P11457139A0604 NNP I-UN
specifically P11457139A0604 RB O
recognizes P11457139A0604 VBZ O
with P11457139A0604 IN O
nanomolar P11457139A0604 JJ O
affinity P11457139A0604 NN O
Man P11457139A0604 NNP O
( P11457139A0604 ( O
9 P11457139A0604 CD O
) P11457139A0604 ) O
GlcNAc P11457139A0604 NNP O
( P11457139A0604 ( O
2 P11457139A0604 CD O
) P11457139A0604 ) O
and P11457139A0604 CC O
the P11457139A0604 DT O
D1D3 P11457139A0604 NNP O
isomer P11457139A0604 NN O
of P11457139A0604 IN O
Man P11457139A0604 NNP O
( P11457139A0604 ( O
8 P11457139A0604 CD O
) P11457139A0604 ) O
GlcNAc P11457139A0604 NNP O
( P11457139A0604 ( O
2 P11457139A0604 CD O
) P11457139A0604 ) O
. P11457139A0604 . O
. . O O

Antibodies P01324172A0880 NNS O
against P01324172A0880 IN O
this P01324172A0880 DT O
purified P01324172A0880 JJ O
protein P01324172A0880 NN O
localize P01324172A0880 VB O
RIM1 P01324172A0880 NNP I-UN
to P01324172A0880 TO O
mitochondria P01324172A0880 VB O
. P01324172A0880 . O
. . O O

Structure-function P09889202T0000 JJ O
analysis P09889202T0000 NN O
of P09889202T0000 IN O
the P09889202T0000 DT O
Z-DNA-binding P09889202T0000 NNP O
domain P09889202T0000 NN O
Zalpha P09889202T0000 NNP O
of P09889202T0000 IN O
dsRNA P09889202T0000 JJ I-UN
adenosine P09889202T0000 JJ I-UN
deaminase P09889202T0000 NN I-UN
type P09889202T0000 NN I-UN
I P09889202T0000 PRP I-UN
reveals P09889202T0000 VBP O
similarity P09889202T0000 NN O
to P09889202T0000 TO O
the P09889202T0000 DT O
( P09889202T0000 ( I-UN
alpha P09889202T0000 JJ I-UN
+ P09889202T0000 NNP I-UN
beta P09889202T0000 NN I-UN
) P09889202T0000 ) I-UN
family P09889202T0000 NN I-UN
of P09889202T0000 IN O
helix-turn-helix P09889202T0000 JJ I-UN
proteins P09889202T0000 NNS I-UN
. P09889202T0000 . O
. . O O

The P09515921A1662 DT O
spontaneous P09515921A1662 JJ O
mutation P09515921A1662 NN O
blocking P09515921A1662 VBG O
pca P09515921A1662 JJ I-UN
gene P09515921A1662 NN I-UN
expression P09515921A1662 NN O
was P09515921A1662 VBD O
located P09515921A1662 VBN O
in P09515921A1662 IN O
the P09515921A1662 DT O
promoter P09515921A1662 NN O
for P09515921A1662 IN O
the P09515921A1662 DT O
pca P09515921A1662 NN I-UN
operon P09515921A1662 NN I-UN
. P09515921A1662 . O
. . O O

Taking P08538483A0207 VBG O
into P08538483A0207 IN O
consideration P08538483A0207 NN O
weight P08538483A0207 NN O
and P08538483A0207 CC O
seasonal P08538483A0207 JJ O
changes P08538483A0207 NNS O
in P08538483A0207 IN O
bone P08538483A0207 NN O
mass P08538483A0207 NN O
, P08538483A0207 , O
total P08538483A0207 JJ O
( P08538483A0207 ( O
TBBMC P08538483A0207 NNP O
) P08538483A0207 ) O
and P08538483A0207 CC O
regional P08538483A0207 JJ O
body P08538483A0207 NN O
bone P08538483A0207 JJ O
mineral P08538483A0207 JJ O
content P08538483A0207 NN O
were P08538483A0207 VBD O
measured P08538483A0207 VBN O
in P08538483A0207 IN O
38 P08538483A0207 CD O
women P08538483A0207 NNS O
treated P08538483A0207 VBN O
with P08538483A0207 IN O
GnRH P08538483A0207 NNP I-UN
agonists P08538483A0207 NNS O
for P08538483A0207 IN O
6 P08538483A0207 CD O
months P08538483A0207 NNS O
for P08538483A0207 IN O
endometriosis P08538483A0207 NN O
or P08538483A0207 CC O
leiomyomata P08538483A0207 NN O
. P08538483A0207 . O
. . O O

Moreover P02528730A1073 RB O
, P02528730A1073 , O
exons P02528730A1073 NNS O
2a P02528730A1073 CD O
and P02528730A1073 CC O
2b P02528730A1073 CD O
share P02528730A1073 NN O
the P02528730A1073 DT O
same P02528730A1073 JJ O
5 P02528730A1073 CD O
' P02528730A1073 POS O
sequence P02528730A1073 NN O
but P02528730A1073 CC O
differ P02528730A1073 VBP O
from P02528730A1073 IN O
each P02528730A1073 DT O
other P02528730A1073 JJ O
by P02528730A1073 IN O
the P02528730A1073 DT O
use P02528730A1073 NN O
of P02528730A1073 IN O
two P02528730A1073 CD O
distinct P02528730A1073 JJ O
donor P02528730A1073 NN O
splice P02528730A1073 NN O
sites P02528730A1073 VBZ O
171 P02528730A1073 CD O
bp P02528730A1073 JJ O
apart P02528730A1073 RB O
in P02528730A1073 IN O
the P02528730A1073 DT O
gene P02528730A1073 NN O
. P02528730A1073 . O
. . O O

The P00696680A0000 DT O
authors P00696680A0000 NNS O
report P00696680A0000 VBP O
the P00696680A0000 DT O
clinicopathologic P00696680A0000 JJ O
findings P00696680A0000 NNS O
in P00696680A0000 IN O
four P00696680A0000 CD O
cases P00696680A0000 NNS O
of P00696680A0000 IN O
adult P00696680A0000 JJ O
women P00696680A0000 NNS O
with P00696680A0000 IN O
rhabdomyosarcomas P00696680A0000 NN O
that P00696680A0000 WDT O
originated P00696680A0000 VBD O
in P00696680A0000 IN O
the P00696680A0000 DT O
endometrium P00696680A0000 NN O
or P00696680A0000 CC O
cervix P00696680A0000 NN O
, P00696680A0000 , O
or P00696680A0000 CC O
both P00696680A0000 DT O
. P00696680A0000 . O
. . O O

This P08636124A0410 DT O
protein P08636124A0410 NN O
encoded P08636124A0410 VBN O
by P08636124A0410 IN O
this P08636124A0410 DT O
cDNA P08636124A0410 NN O
, P08636124A0410 , O
which P08636124A0410 WDT O
we P08636124A0410 PRP O
have P08636124A0410 VBP O
termed P08636124A0410 VBN O
p150TSP P08636124A0410 NN I-UN
( P08636124A0410 ( O
for P08636124A0410 IN O
TPR-containing P08636124A0410 NNP O
, P08636124A0410 , O
SH2-binding P08636124A0410 NNP I-UN
phosphoprotein P08636124A0410 NN I-UN
) P08636124A0410 ) O
, P08636124A0410 , O
is P08636124A0410 VBZ O
located P08636124A0410 VBN O
predominantly P08636124A0410 RB O
in P08636124A0410 IN O
the P08636124A0410 DT O
nucleus P08636124A0410 NN O
and P08636124A0410 CC O
is P08636124A0410 VBZ O
highly P08636124A0410 RB O
conserved P08636124A0410 VBN O
in P08636124A0410 IN O
evolution P08636124A0410 NN O
. P08636124A0410 . O
. . O O

Yeast P09630245A0903 NNP I-UN
U1 P09630245A0903 NNP I-UN
snRNP P09630245A0903 VBD I-UN
therefore P09630245A0903 RB O
contains P09630245A0903 VBZ O
16 P09630245A0903 CD O
different P09630245A0903 JJ O
proteins P09630245A0903 NNS O
, P09630245A0903 , O
including P09630245A0903 VBG O
seven P09630245A0903 CD O
snRNP P09630245A0903 JJ I-UN
core P09630245A0903 NN I-UN
proteins P09630245A0903 NNS I-UN
, P09630245A0903 , O
three P09630245A0903 CD O
homologues P09630245A0903 NNS O
of P09630245A0903 IN O
the P09630245A0903 DT O
metazoan P09630245A0903 NN I-UN
U1 P09630245A0903 NNP I-UN
snRNP-specific P09630245A0903 JJ I-UN
proteins P09630245A0903 NNS I-UN
, P09630245A0903 , O
and P09630245A0903 CC O
six P09630245A0903 CD O
yeast-specific P09630245A0903 JJ I-UN
U1 P09630245A0903 NNP I-UN
snRNP P09630245A0903 NN I-UN
proteins P09630245A0903 NNS I-UN
. P09630245A0903 . O
. . O O

Thus P09628821A1194 RB O
, P09628821A1194 , O
included P09628821A1194 VBD O
in P09628821A1194 IN O
the P09628821A1194 DT O
KG1a P09628821A1194 NNP O
EST P09628821A1194 NNP O
dataset P09628821A1194 NN O
are P09628821A1194 VBP O
candidates P09628821A1194 NNS O
for P09628821A1194 IN O
new P09628821A1194 JJ O
human P09628821A1194 JJ O
genes P09628821A1194 NNS O
that P09628821A1194 WDT O
may P09628821A1194 MD O
play P09628821A1194 VB O
roles P09628821A1194 NNS O
in P09628821A1194 IN O
hematopoietic P09628821A1194 JJ O
differentiative P09628821A1194 JJ O
progression P09628821A1194 NN O
and P09628821A1194 CC O
lineage P09628821A1194 NN O
commitment P09628821A1194 NN O
. P09628821A1194 . O
. . O O

These P09679066A1352 DT O
results P09679066A1352 NNS O
provide P09679066A1352 VBP O
the P09679066A1352 DT O
first P09679066A1352 JJ O
demonstration P09679066A1352 NN O
that P09679066A1352 IN O
an P09679066A1352 DT O
SR P09679066A1352 NNP I-UN
protein P09679066A1352 NN I-UN
can P09679066A1352 MD O
influence P09679066A1352 VB O
splicing P09679066A1352 NN O
of P09679066A1352 IN O
specific P09679066A1352 JJ O
pre-mRNAs P09679066A1352 NN O
in P09679066A1352 IN O
vivo P09679066A1352 NN O
. P09679066A1352 . O
. . O O

The P11727209A0502 DT O
patients P11727209A0502 NNS O
and P11727209A0502 CC O
their P11727209A0502 PRP$ O
families P11727209A0502 NNS O
were P11727209A0502 VBD O
closely P11727209A0502 RB O
questioned P11727209A0502 VBN O
, P11727209A0502 , O
and P11727209A0502 CC O
full P11727209A0502 JJ O
clinical P11727209A0502 JJ O
examination P11727209A0502 NN O
included P11727209A0502 VBD O
a P11727209A0502 DT O
test P11727209A0502 NN O
for P11727209A0502 IN O
orthostasia P11727209A0502 NN O
. P11727209A0502 . O
. . O O

Effect P04246054T0028 NN O
of P04246054T0028 IN O
immune P04246054T0028 NN O
lymphocytes P04246054T0028 NNS O
and P04246054T0028 CC O
of P04246054T0028 IN O
rabbit-anti-lymphocyte P04246054T0028 JJ I-UN
globulin P04246054T0028 NN I-UN
( P04246054T0028 ( O
RAMLG P04246054T0028 NNP I-UN
) P04246054T0028 ) O
on P04246054T0028 IN O
infected P04246054T0028 VBN O
macrophages P04246054T0028 NNS O
exposed P04246054T0028 VBN O
to P04246054T0028 TO O
increased P04246054T0028 VBN O
incubation P04246054T0028 NN O
temperature P04246054T0028 NN O
in P04246054T0028 IN O
vitro P04246054T0028 NN O
. P04246054T0028 . O
. . O O

Those P10029860A0605 DT O
radiological P10029860A0605 JJ O
aspects P10029860A0605 NNS O
were P10029860A0605 VBD O
distributed P10029860A0605 VBN O
in P10029860A0605 IN O
two P10029860A0605 CD O
categories P10029860A0605 NNS O
: P10029860A0605 : O
1 P10029860A0605 CD O
) P10029860A0605 ) O
type P10029860A0605 NN O
I-presenting P10029860A0605 NNP O
variable P10029860A0605 JJ O
sinusoidal P10029860A0605 NN O
filling P10029860A0605 NN O
. P10029860A0605 . O
. . O O

We P09360956A0840 PRP O
have P09360956A0840 VBP O
now P09360956A0840 RB O
shown P09360956A0840 VBN O
that P09360956A0840 IN O
in P09360956A0840 IN O
vivo P09360956A0840 JJ O
phosphorylation P09360956A0840 NN O
of P09360956A0840 IN O
14-3-3 P09360956A0840 JJ I-UN
zeta P09360956A0840 NN I-UN
at P09360956A0840 IN O
the P09360956A0840 DT O
CKIalpha P09360956A0840 NNP I-UN
site P09360956A0840 NN I-UN
( P09360956A0840 ( I-UN
Thr-233 P09360956A0840 NNP I-UN
) P09360956A0840 ) I-UN
negatively P09360956A0840 RB O
regulates P09360956A0840 VBZ O
its P09360956A0840 PRP$ O
binding P09360956A0840 NN O
to P09360956A0840 TO O
c-Raf P09360956A0840 NN I-UN
, P09360956A0840 , O
and P09360956A0840 CC O
may P09360956A0840 MD O
be P09360956A0840 VB O
important P09360956A0840 JJ O
in P09360956A0840 IN O
Raf-mediated P09360956A0840 JJ O
signal P09360956A0840 JJ O
transduction P09360956A0840 NN O
. P09360956A0840 . O
. . O O

Two P09990060A0803 CD O
of P09990060A0803 IN O
these P09990060A0803 DT O
motifs P09990060A0803 NNS O
are P09990060A0803 VBP O
part P09990060A0803 NN O
of P09990060A0803 IN O
a P09990060A0803 DT O
highly P09990060A0803 RB O
conserved P09990060A0803 VBN O
and P09990060A0803 CC O
inducible P09990060A0803 JJ O
dyad P09990060A0803 NN O
symmetry P09990060A0803 NN O
element P09990060A0803 VBD O
shown P09990060A0803 VBN O
previously P09990060A0803 RB O
to P09990060A0803 TO O
control P09990060A0803 VB O
a P09990060A0803 DT O
remote P09990060A0803 JJ O
IL-2 P09990060A0803 JJ I-UN
enhancer P09990060A0803 NN I-UN
and P09990060A0803 CC O
the P09990060A0803 DT O
CD18 P09990060A0803 NNP I-UN
promoter P09990060A0803 NN I-UN
. P09990060A0803 . O
. . O O

Hisako P03848527T0020 NNP O
Minowa P03848527T0020 NNP O
who P03848527T0020 WP O
has P03848527T0020 VBZ O
worked P03848527T0020 VBN O
as P03848527T0020 IN O
a P03848527T0020 DT O
psychiatric P03848527T0020 JJ O
counsellor P03848527T0020 NN O
in P03848527T0020 IN O
industry P03848527T0020 NN O
for P03848527T0020 IN O
the P03848527T0020 DT O
past P03848527T0020 JJ O
20 P03848527T0020 CD O
years P03848527T0020 NNS O
. P03848527T0020 . O
. . O O

This P00821833A0000 DT O
report P00821833A0000 NN O
presents P00821833A0000 VBZ O
an P00821833A0000 DT O
analysis P00821833A0000 NN O
of P00821833A0000 IN O
the P00821833A0000 DT O
vocal P00821833A0000 JJ O
repertoire P00821833A0000 NN O
of P00821833A0000 IN O
howler P00821833A0000 NN O
monkeys P00821833A0000 NNS O
( P00821833A0000 ( O
Alouatta P00821833A0000 NNP O
palliata P00821833A0000 NN O
) P00821833A0000 ) O
observed P00821833A0000 VBD O
during P00821833A0000 IN O
a P00821833A0000 DT O
field P00821833A0000 NN O
study P00821833A0000 NN O
in P00821833A0000 IN O
southwestern P00821833A0000 JJ O
Panama P00821833A0000 NNP O
. P00821833A0000 . O
. . O O

The P02182618A0168 DT O
promoter P02182618A0168 NN O
activity P02182618A0168 NN O
was P02182618A0168 VBD O
measured P02182618A0168 VBN O
by P02182618A0168 IN O
a P02182618A0168 DT O
transient P02182618A0168 JJ O
expression P02182618A0168 NN O
of P02182618A0168 IN O
a P02182618A0168 DT O
chloramphenicol P02182618A0168 NN I-UN
acetyltransferase P02182618A0168 NN I-UN
( P02182618A0168 ( O
CAT P02182618A0168 NNP I-UN
) P02182618A0168 ) O
gene P02182618A0168 NN O
connected P02182618A0168 VBN O
with P02182618A0168 IN O
various P02182618A0168 JJ O
5'-deletion P02182618A0168 JJ O
mutants P02182618A0168 NNS O
of P02182618A0168 IN O
the P02182618A0168 DT O
5'-flanking P02182618A0168 JJ O
region P02182618A0168 NN O
. P02182618A0168 . O
. . O O

99Tcm-DMP-HSA P09061698A0177 CD O
showed P09061698A0177 VBD O
an P09061698A0177 DT O
almost P09061698A0177 RB O
identical P09061698A0177 JJ O
behaviour P09061698A0177 NN O
to P09061698A0177 TO O
in P09061698A0177 IN O
vitro P09061698A0177 NN O
labelled P09061698A0177 VBN O
red P09061698A0177 JJ O
blood P09061698A0177 NN O
cells P09061698A0177 NNS O
( P09061698A0177 ( O
RBCs P09061698A0177 NNP O
) P09061698A0177 ) O
, P09061698A0177 , O
which P09061698A0177 WDT O
are P09061698A0177 VBP O
generally P09061698A0177 RB O
considered P09061698A0177 VBN O
the P09061698A0177 DT O
reference P09061698A0177 NN O
standard P09061698A0177 NN O
for P09061698A0177 IN O
blood P09061698A0177 NN O
pool P09061698A0177 NN O
agents P09061698A0177 NNS O
. P09061698A0177 . O
. . O O

These P08324280A0098 DT O
lesions P08324280A0098 NNS O
were P08324280A0098 VBD O
asymptomatic P08324280A0098 JJ O
, P08324280A0098 , O
but P08324280A0098 CC O
both P08324280A0098 DT O
were P08324280A0098 VBD O
characterized P08324280A0098 VBN O
clinically P08324280A0098 RB O
by P08324280A0098 IN O
central P08324280A0098 JJ O
ulceration P08324280A0098 NN O
. P08324280A0098 . O
. . O O

TPBF P07499409A0367 NNP I-UN
has P07499409A0367 VBZ O
two P07499409A0367 CD O
potential P07499409A0367 JJ O
coiled-coil P07499409A0367 NN O
regions P07499409A0367 NNS O
, P07499409A0367 , O
a P07499409A0367 DT O
basic P07499409A0367 JJ O
region P07499409A0367 NN O
, P07499409A0367 , O
a P07499409A0367 DT O
proline-rich P07499409A0367 JJ O
region P07499409A0367 NN O
, P07499409A0367 , O
a P07499409A0367 DT O
histidine-rich P07499409A0367 JJ O
N P07499409A0367 NNP O
terminus P07499409A0367 NN O
, P07499409A0367 , O
and P07499409A0367 CC O
a P07499409A0367 DT O
nuclear P07499409A0367 JJ O
targeting P07499409A0367 NN O
sequence P07499409A0367 NN O
. P07499409A0367 . O
. . O O

Children P11103472A0802 NNP O
with P11103472A0802 IN O
ADD P11103472A0802 NNP O
showed P11103472A0802 VBD O
an P11103472A0802 DT O
attenuated P11103472A0802 JJ O
frontal P11103472A0802 JJ O
CNV-1 P11103472A0802 JJ O
amplitude P11103472A0802 NN O
and P11103472A0802 CC O
a P11103472A0802 DT O
trend P11103472A0802 NN O
towards P11103472A0802 NNS O
increased P11103472A0802 VBD O
CNV-1 P11103472A0802 NNP O
and P11103472A0802 CC O
CNV-2 P11103472A0802 NNP O
occipital P11103472A0802 JJ O
amplitudes P11103472A0802 NNS O
. P11103472A0802 . O
. . O O

Antihistamines P02574551T0000 NNS O
in P02574551T0000 IN O
asthma P02574551T0000 NN O
. P02574551T0000 . O
. . O O

The P09590540A0513 DT O
bZP2 P09590540A0513 NN I-UN
cDNA P09590540A0513 NN I-UN
( P09590540A0513 ( I-UN
115-1914 P09590540A0513 JJ I-UN
nt P09590540A0513 NN I-UN
, P09590540A0513 , I-UN
1.8 P09590540A0513 CD I-UN
kb P09590540A0513 NN I-UN
) P09590540A0513 ) I-UN
, P09590540A0513 , O
excluding P09590540A0513 VBG O
sequences P09590540A0513 NNS O
coding P09590540A0513 VBG O
for P09590540A0513 IN O
N-terminal P09590540A0513 NNP O
signal P09590540A0513 JJ O
sequence P09590540A0513 NN O
and P09590540A0513 CC O
C-terminal P09590540A0513 JJ O
transmembranelike P09590540A0513 NN O
domain P09590540A0513 NN O
, P09590540A0513 , O
was P09590540A0513 VBD O
PCR P09590540A0513 NNP O
amplified P09590540A0513 VBD O
and P09590540A0513 CC O
Sac1-Sal1 P09590540A0513 NNP O
restricted P09590540A0513 VBD O
fragment P09590540A0513 NN O
cloned P09590540A0513 VBN O
in P09590540A0513 IN O
frame P09590540A0513 JJ O
downstream P09590540A0513 NN O
of P09590540A0513 IN O
the P09590540A0513 DT O
T5 P09590540A0513 NNP O
promoter P09590540A0513 NN O
under P09590540A0513 IN O
the P09590540A0513 DT O
lac P09590540A0513 NN I-UN
operator P09590540A0513 NN I-UN
control P09590540A0513 NN O
in P09590540A0513 IN O
a P09590540A0513 DT O
pQE-30 P09590540A0513 JJ O
vector P09590540A0513 NN O
. P09590540A0513 . O
. . O O

Discrimination P08874631A1133 NN O
between P08874631A1133 IN O
HIV-1 P08874631A1133 NNP O
and P08874631A1133 CC O
HIV-2 P08874631A1133 NNP O
showed P08874631A1133 VBD O
evidence P08874631A1133 NN O
for P08874631A1133 IN O
the P08874631A1133 DT O
presence P08874631A1133 NN O
of P08874631A1133 IN O
HIV-1 P08874631A1133 NNP O
only P08874631A1133 RB O
. P08874631A1133 . O
. . O O

However P09486890A0234 RB O
, P09486890A0234 , O
laparoscopy P09486890A0234 NN O
failed P09486890A0234 VBD O
to P09486890A0234 TO O
establish P09486890A0234 VB O
inoperability P09486890A0234 NN O
in P09486890A0234 IN O
any P09486890A0234 DT O
cases P09486890A0234 NNS O
of P09486890A0234 IN O
carcinoma P09486890A0234 NN O
spread P09486890A0234 NN O
to P09486890A0234 TO O
areas P09486890A0234 NNS O
not P09486890A0234 RB O
accessible P09486890A0234 JJ O
to P09486890A0234 TO O
laparoscopic P09486890A0234 VB O
visualization P09486890A0234 NN O
. P09486890A0234 . O
. . O O

Sixty-nine P09061697A0629 NNP O
( P09061697A0629 ( O
44 P09061697A0629 CD O
% P09061697A0629 NN O
) P09061697A0629 ) O
patients P09061697A0629 NNS O
were P09061697A0629 VBD O
administered P09061697A0629 VBN O
250 P09061697A0629 CD O
MBq P09061697A0629 NNP O
( P09061697A0629 ( O
7 P09061697A0629 CD O
mCi P09061697A0629 NN O
) P09061697A0629 ) O
99Tcm-tetrofosmin P09061697A0629 CD O
at P09061697A0629 IN O
rest P09061697A0629 NN O
followed P09061697A0629 VBD O
4 P09061697A0629 CD O
h P09061697A0629 NN O
later P09061697A0629 RB O
by P09061697A0629 IN O
750 P09061697A0629 CD O
MBq P09061697A0629 NNP O
( P09061697A0629 ( O
21 P09061697A0629 CD O
mCi P09061697A0629 NN O
) P09061697A0629 ) O
during P09061697A0629 IN O
stress P09061697A0629 NN O
( P09061697A0629 ( O
the P09061697A0629 DT O
1 P09061697A0629 CD O
day P09061697A0629 NN O
protocol P09061697A0629 NN O
) P09061697A0629 ) O
, P09061697A0629 , O
whereas P09061697A0629 $ O
88 P09061697A0629 CD O
( P09061697A0629 ( O
56 P09061697A0629 CD O
% P09061697A0629 NN O
) P09061697A0629 ) O
patients P09061697A0629 NNS O
had P09061697A0629 VBD O
rest P09061697A0629 NN O
and P09061697A0629 CC O
stress P09061697A0629 NN O
imaging P09061697A0629 VBG O
studies P09061697A0629 NNS O
on P09061697A0629 IN O
two P09061697A0629 CD O
separate P09061697A0629 JJ O
days P09061697A0629 NNS O
, P09061697A0629 , O
receiving P09061697A0629 VBG O
a P09061697A0629 DT O
500 P09061697A0629 CD O
MBq P09061697A0629 NNP O
( P09061697A0629 ( O
14 P09061697A0629 CD O
mCi P09061697A0629 NN O
) P09061697A0629 ) O
dose P09061697A0629 NN O
of P09061697A0629 IN O
99Tcm-tetrofosmin P09061697A0629 JJ O
on P09061697A0629 IN O
each P09061697A0629 DT O
occasion P09061697A0629 NN O
( P09061697A0629 ( O
the P09061697A0629 DT O
2 P09061697A0629 CD O
day P09061697A0629 NN O
protocol P09061697A0629 NN O
) P09061697A0629 ) O
. P09061697A0629 . O
. . O O

Carboxy-terminal P08603921A1346 JJ O
Spc110p P08603921A1346 NNP I-UN
truncations P08603921A1346 NNS O
lacking P08603921A1346 VBG O
the P08603921A1346 DT O
calmodulin P08603921A1346 NN I-UN
binding P08603921A1346 VBG O
site P08603921A1346 NN O
can P08603921A1346 MD O
support P08603921A1346 VB O
growth P08603921A1346 NN O
and P08603921A1346 CC O
are P08603921A1346 VBP O
also P08603921A1346 RB O
phosphorylated P08603921A1346 VBN O
in P08603921A1346 IN O
a P08603921A1346 DT O
cell P08603921A1346 NN O
cycle-specific P08603921A1346 JJ O
manner P08603921A1346 NN O
. P08603921A1346 . O
. . O O

Transcriptional P10893243T0000 JJ O
regulation P10893243T0000 NN O
of P10893243T0000 IN O
the P10893243T0000 DT O
mouse P10893243T0000 NN I-UN
cytosolic P10893243T0000 JJ I-UN
chaperonin P10893243T0000 NN I-UN
subunit P10893243T0000 NN I-UN
gene P10893243T0000 NN I-UN
Ccta P10893243T0000 NNP I-UN
/ P10893243T0000 NNP I-UN
t-complex P10893243T0000 JJ I-UN
polypeptide P10893243T0000 NN I-UN
1 P10893243T0000 CD I-UN
by P10893243T0000 IN O
selenocysteine P10893243T0000 NN I-UN
tRNA P10893243T0000 NN I-UN
gene P10893243T0000 NN I-UN
transcription P10893243T0000 NN I-UN
activating P10893243T0000 VBG I-UN
factor P10893243T0000 NN I-UN
family P10893243T0000 NN I-UN
zinc P10893243T0000 NN I-UN
finger P10893243T0000 NN I-UN
proteins P10893243T0000 NNS I-UN
. P10893243T0000 . O
. . O O

Biol P01851756A0743 NNP O
. P01851756A0743 . O
. . O O

This P01977856A1036 DT O
study P01977856A1036 NN O
suggests P01977856A1036 VBZ O
that P01977856A1036 IN O
BSPMs P01977856A1036 NNP O
are P01977856A1036 VBP O
useful P01977856A1036 JJ O
in P01977856A1036 IN O
the P01977856A1036 DT O
assessment P01977856A1036 NN O
of P01977856A1036 IN O
AMI P01977856A1036 NNP O
in P01977856A1036 IN O
terms P01977856A1036 NNS O
of P01977856A1036 IN O
diagnosis P01977856A1036 NN O
, P01977856A1036 , O
location P01977856A1036 NN O
and P01977856A1036 CC O
extent P01977856A1036 NN O
of P01977856A1036 IN O
myocardial P01977856A1036 JJ O
infarct P01977856A1036 NN O
. P01977856A1036 . O
. . O O

Electrophoretic P06073427T0001 JJ O
characteriaztion P06073427T0001 NN O
of P06073427T0001 IN O
virus-induced P06073427T0001 JJ O
interferon P06073427T0001 NN I-UN
of P06073427T0001 IN O
the P06073427T0001 DT O
blood P06073427T0001 NN O
and P06073427T0001 CC O
urine P06073427T0001 NN O
in P06073427T0001 IN O
rabbits P06073427T0001 NNS O
. P06073427T0001 . O
. . O O

After P07663138A0835 IN O
nadolol P07663138A0835 NN O
, P07663138A0835 , O
heart P07663138A0835 NN O
rate P07663138A0835 NN O
decreased P07663138A0835 VBN O
( P07663138A0835 ( O
-22 P07663138A0835 JJ O
+ P07663138A0835 NNP O
/ P07663138A0835 NNP O
- P07663138A0835 : O
8 P07663138A0835 CD O
% P07663138A0835 NN O
) P07663138A0835 ) O
, P07663138A0835 , O
and P07663138A0835 CC O
so P07663138A0835 RB O
did P07663138A0835 VBD O
PBV P07663138A0835 NNP O
and P07663138A0835 CC O
PBF P07663138A0835 NNP O
( P07663138A0835 ( O
8.8 P07663138A0835 CD O
+ P07663138A0835 NN O
/ P07663138A0835 NNP O
- P07663138A0835 : O
3.4 P07663138A0835 CD O
vs P07663138A0835 NN O
. P07663138A0835 . O
. . O O

The P01613640A0158 DT O
coating P01613640A0158 NN O
materials P01613640A0158 NNS O
were P01613640A0158 VBD O
poloxamine P01613640A0158 JJ O
904 P01613640A0158 CD O
, P01613640A0158 , O
poloxamine P01613640A0158 NN O
908 P01613640A0158 CD O
, P01613640A0158 , O
poloxamine P01613640A0158 NN O
1508 P01613640A0158 CD O
, P01613640A0158 , O
poloxamer P01613640A0158 VBZ O
338 P01613640A0158 CD O
, P01613640A0158 , O
and P01613640A0158 CC O
Brij P01613640A0158 NNP O
35 P01613640A0158 CD O
. P01613640A0158 . O
. . O O

In P01125117A0183 IN O
none P01125117A0183 NN O
of P01125117A0183 IN O
the P01125117A0183 DT O
44 P01125117A0183 CD O
type P01125117A0183 NN O
I P01125117A0183 PRP O
attacks P01125117A0183 NNS O
and P01125117A0183 CC O
29 P01125117A0183 CD O
type P01125117A0183 NN O
II P01125117A0183 NNP O
attacks P01125117A0183 NNS O
which P01125117A0183 WDT O
were P01125117A0183 VBD O
recorded P01125117A0183 VBN O
did P01125117A0183 VBD O
circulatory P01125117A0183 JJ O
changes P01125117A0183 NNS O
; P01125117A0183 : O
the P01125117A0183 DT O
latter P01125117A0183 NN O
were P01125117A0183 VBD O
different P01125117A0183 JJ O
in P01125117A0183 IN O
the P01125117A0183 DT O
two P01125117A0183 CD O
groups P01125117A0183 NNS O
. P01125117A0183 . O
. . O O

Maternal P02113015A0295 JJ O
seizures P02113015A0295 NNS O
had P02113015A0295 VBD O
occurred P02113015A0295 VBN O
during P02113015A0295 IN O
pregnancy P02113015A0295 NN O
in P02113015A0295 IN O
52 P02113015A0295 CD O
per P02113015A0295 IN O
cent P02113015A0295 NN O
. P02113015A0295 . O
. . O O

Supershift P10574982A1075 NNP O
EMSAs P10574982A1075 NNP O
identified P10574982A1075 VBD O
that P10574982A1075 IN O
upstream P10574982A1075 JJ I-UN
stimulatory P10574982A1075 NN I-UN
factor-1 P10574982A1075 NN I-UN
and P10574982A1075 CC I-UN
-2 P10574982A1075 NNP I-UN
( P10574982A1075 ( O
USF-1 P10574982A1075 NNP I-UN
and P10574982A1075 CC I-UN
-2 P10574982A1075 NNP I-UN
) P10574982A1075 ) O
were P10574982A1075 VBD O
part P10574982A1075 NN O
of P10574982A1075 IN O
these P10574982A1075 DT O
complexes P10574982A1075 NNS O
. P10574982A1075 . O
. . O O

These P08970352A0880 DT O
data P08970352A0880 NNS O
do P08970352A0880 VBP O
not P08970352A0880 RB O
support P08970352A0880 VB O
the P08970352A0880 DT O
use P08970352A0880 NN O
of P08970352A0880 IN O
LDD P08970352A0880 NNP O
to P08970352A0880 TO O
reduce P08970352A0880 VB O
risk P08970352A0880 NN O
of P08970352A0880 IN O
progression P08970352A0880 NN O
to P08970352A0880 TO O
MSOF P08970352A0880 NNP O
in P08970352A0880 IN O
sepsis P08970352A0880 NN O
. P08970352A0880 . O
. . O O

One P01903841A0125 CD O
of P01903841A0125 IN O
its P01903841A0125 PRP$ O
lysine P01903841A0125 NN O
residues P01903841A0125 NNS O
is P01903841A0125 VBZ O
modified P01903841A0125 VBN O
by P01903841A0125 IN O
spermidine P01903841A0125 NN O
to P01903841A0125 TO O
form P01903841A0125 VB O
hypusine P01903841A0125 NN O
, P01903841A0125 , O
a P01903841A0125 DT O
posttranslational P01903841A0125 JJ O
modification P01903841A0125 NN O
unique P01903841A0125 NN O
to P01903841A0125 TO O
eIF-5A P01903841A0125 NN I-UN
. P01903841A0125 . O
. . O O

The P09202147A0866 DT O
data P09202147A0866 NN O
suggest P09202147A0866 NN O
that P09202147A0866 IN O
like P09202147A0866 IN O
in P09202147A0866 IN O
yeast P09202147A0866 NN O
, P09202147A0866 , O
in P09202147A0866 IN O
plants P09202147A0866 NNS O
a P09202147A0866 DT O
certain P09202147A0866 JJ O
subfamily P09202147A0866 NN O
of P09202147A0866 IN O
UBC P09202147A0866 NNP I-UN
is P09202147A0866 VBZ O
specifically P09202147A0866 RB O
involved P09202147A0866 VBN O
in P09202147A0866 IN O
the P09202147A0866 DT O
proteolytic P09202147A0866 JJ O
degradation P09202147A0866 NN O
of P09202147A0866 IN O
abnormal P09202147A0866 JJ O
proteins P09202147A0866 NNS O
as P09202147A0866 IN O
result P09202147A0866 NN O
of P09202147A0866 IN O
stress P09202147A0866 NN O
. P09202147A0866 . O
. . O O

Glutamic P06151518A0000 NNP O
acid P06151518A0000 NN O
in P06151518A0000 IN O
a P06151518A0000 DT O
dose P06151518A0000 NN O
of P06151518A0000 IN O
1 P06151518A0000 CD O
/ P06151518A0000 JJ O
100 P06151518A0000 CD O
of P06151518A0000 IN O
the P06151518A0000 DT O
LD50 P06151518A0000 NNP O
was P06151518A0000 VBD O
injected P06151518A0000 VBN O
in P06151518A0000 IN O
the P06151518A0000 DT O
form P06151518A0000 NN O
of P06151518A0000 IN O
sodium P06151518A0000 NN O
salt P06151518A0000 NN O
into P06151518A0000 IN O
male P06151518A0000 NN O
and P06151518A0000 CC O
female P06151518A0000 JJ O
Wistar P06151518A0000 NNP O
rats P06151518A0000 NNS O
for P06151518A0000 IN O
7 P06151518A0000 CD O
days P06151518A0000 NNS O
after P06151518A0000 IN O
8- P06151518A0000 JJ O
and P06151518A0000 CC O
12-day P06151518A0000 JJ O
injections P06151518A0000 NNS O
of P06151518A0000 IN O
dexazone P06151518A0000 NN O
. P06151518A0000 . O
. . O O

Hovenitin P09084227A0833 NNP O
I P09084227A0833 PRP O
and P09084227A0833 CC O
( P09084227A0833 ( O
+ P09084227A0833 NNP O
) P09084227A0833 ) O
-ampelopsin P09084227A0833 NN O
, P09084227A0833 , O
both P09084227A0833 DT O
of P09084227A0833 IN O
which P09084227A0833 WDT O
were P09084227A0833 VBD O
principal P09084227A0833 JJ O
ingredients P09084227A0833 NNS O
of P09084227A0833 IN O
the P09084227A0833 DT O
active P09084227A0833 JJ O
fractions P09084227A0833 NNS O
from P09084227A0833 IN O
this P09084227A0833 DT O
natural P09084227A0833 JJ O
medicine P09084227A0833 NN O
, P09084227A0833 , O
were P09084227A0833 VBD O
found P09084227A0833 VBN O
to P09084227A0833 TO O
show P09084227A0833 VB O
an P09084227A0833 DT O
inhibitory P09084227A0833 JJ O
activity P09084227A0833 NN O
on P09084227A0833 IN O
the P09084227A0833 DT O
ethanol-induced P09084227A0833 JJ O
muscle P09084227A0833 NN O
relaxation P09084227A0833 NN O
in P09084227A0833 IN O
rats P09084227A0833 NNS O
. P09084227A0833 . O
. . O O

The P04001490T0001 DT O
POEMS P04001490T0001 NNP O
syndrome P04001490T0001 NN O
( P04001490T0001 ( O
Polyneuropathy P04001490T0001 NNP O
, P04001490T0001 , O
Organomegaly P04001490T0001 NNP O
, P04001490T0001 , O
Endocrinopathy P04001490T0001 NNP O
, P04001490T0001 , O
Monoclonal P04001490T0001 NNP O
component P04001490T0001 NN O
, P04001490T0001 , O
Skin P04001490T0001 NNP O
) P04001490T0001 ) O
. P04001490T0001 . O
. . O O

We P09763607A0521 PRP O
found P09763607A0521 VBD O
that P09763607A0521 IN O
virulent P09763607A0521 JJ O
Ngo P09763607A0521 NNP O
strains P09763607A0521 VBZ O
induce P09763607A0521 VB O
phosphorylation P09763607A0521 NN O
and P09763607A0521 CC O
activation P09763607A0521 NN O
of P09763607A0521 IN O
JNK P09763607A0521 NNP I-UN
but P09763607A0521 CC O
not P09763607A0521 RB O
of P09763607A0521 IN O
p38 P09763607A0521 JJ I-UN
kinase P09763607A0521 NN O
. P09763607A0521 . O
. . O O

DNase P08093616A1214 NNP I-UN
I P08093616A1214 PRP I-UN
footprinting P08093616A1214 VBG O
analysis P08093616A1214 NN O
indicated P08093616A1214 VBD O
that P08093616A1214 IN O
DREF P08093616A1214 NNP I-UN
binds P08093616A1214 VBZ O
to P08093616A1214 TO O
the P08093616A1214 DT O
24-bp P08093616A1214 JJ O
DRE P08093616A1214 NNP O
region P08093616A1214 NN O
of P08093616A1214 IN O
the P08093616A1214 DT O
DNA P08093616A1214 NNP I-UN
polymerase P08093616A1214 NN I-UN
alpha P08093616A1214 NN I-UN
gene P08093616A1214 NN I-UN
in P08093616A1214 IN O
which P08093616A1214 WDT O
8-bp P08093616A1214 JJ O
palindromic P08093616A1214 NN O
sequences P08093616A1214 NNS O
are P08093616A1214 VBP O
centered P08093616A1214 VBN O
. P08093616A1214 . O
. . O O

The P03144705A0859 DT O
distribution P03144705A0859 NN O
of P03144705A0859 IN O
the P03144705A0859 DT O
sites P03144705A0859 NNS O
of P03144705A0859 IN O
recombinational P03144705A0859 JJ O
resolution P03144705A0859 NN O
is P03144705A0859 VBZ O
inversely P03144705A0859 RB O
correlated P03144705A0859 VBN O
with P03144705A0859 IN O
that P03144705A0859 DT O
of P03144705A0859 IN O
the P03144705A0859 DT O
gradient P03144705A0859 NN O
of P03144705A0859 IN O
sequence P03144705A0859 NN O
divergence P03144705A0859 NN O
, P03144705A0859 , O
with P03144705A0859 IN O
only P03144705A0859 RB O
approximately P03144705A0859 RB O
7 P03144705A0859 CD O
% P03144705A0859 NN O
of P03144705A0859 IN O
the P03144705A0859 DT O
X P03144705A0859 NNP O
recombinants P03144705A0859 NNS O
resolved P03144705A0859 VBD O
within P03144705A0859 IN O
the P03144705A0859 DT O
3 P03144705A0859 CD O
' P03144705A0859 POS O
third P03144705A0859 NN O
of P03144705A0859 IN O
the P03144705A0859 DT O
X P03144705A0859 NN O
blocks P03144705A0859 NNS O
where P03144705A0859 WRB O
two P03144705A0859 CD O
diverged P03144705A0859 VBD O
Alu P03144705A0859 NNP I-UN
family P03144705A0859 NN O
repeats P03144705A0859 NNS O
reside P03144705A0859 VBP O
. P03144705A0859 . O
. . O O

Gemfibrozil P02076620T0000 NNP O
in P02076620T0000 IN O
hyperlipidaemic P02076620T0000 JJ O
patients P02076620T0000 NNS O
with P02076620T0000 IN O
peripheral P02076620T0000 JJ O
arterial P02076620T0000 JJ O
disease P02076620T0000 NN O
: P02076620T0000 : O
some P02076620T0000 DT O
undiscovered P02076620T0000 JJ O
actions P02076620T0000 NNS O
. P02076620T0000 . O
. . O O

The P09733854A0198 DT O
only P09733854A0198 JJ O
abundant P09733854A0198 JJ O
viral P09733854A0198 JJ O
transcript P09733854A0198 NN O
expressed P09733854A0198 VBN O
during P09733854A0198 IN O
latency P09733854A0198 NN O
is P09733854A0198 VBZ O
the P09733854A0198 DT O
latency-related P09733854A0198 JJ I-UN
( P09733854A0198 ( O
LR P09733854A0198 NNP I-UN
) P09733854A0198 ) O
RNA P09733854A0198 NNP O
. P09733854A0198 . O
. . O O

By P02293664A0946 IN O
introducing P02293664A0946 VBG O
a P02293664A0946 DT O
series P02293664A0946 NN O
of P02293664A0946 IN O
deletions P02293664A0946 NNS O
in P02293664A0946 IN O
the P02293664A0946 DT O
vimentin P02293664A0946 NN I-UN
promoter P02293664A0946 NN O
, P02293664A0946 , O
we P02293664A0946 PRP O
further P02293664A0946 VBP O
restrict P02293664A0946 VB O
these P02293664A0946 DT O
sequences P02293664A0946 NNS O
to P02293664A0946 TO O
30 P02293664A0946 CD O
base P02293664A0946 NN O
pairs P02293664A0946 NNS O
, P02293664A0946 , O
located P02293664A0946 VBN O
between P02293664A0946 IN O
241 P02293664A0946 CD O
and P02293664A0946 CC O
210 P02293664A0946 CD O
base P02293664A0946 NN O
pairs P02293664A0946 NNS O
upstream P02293664A0946 NN O
of P02293664A0946 IN O
the P02293664A0946 DT O
mRNA P02293664A0946 NN O
cap P02293664A0946 NN O
site P02293664A0946 NN O
. P02293664A0946 . O
. . O O

Therefore P11834476A1187 RB O
, P11834476A1187 , O
in P11834476A1187 IN O
a P11834476A1187 DT O
large P11834476A1187 JJ O
animal P11834476A1187 JJ O
model P11834476A1187 NN O
of P11834476A1187 IN O
permanent P11834476A1187 JJ O
focal P11834476A1187 JJ O
ischemia P11834476A1187 NN O
in P11834476A1187 IN O
which P11834476A1187 WDT O
transfusion P11834476A1187 NN O
starts P11834476A1187 VBZ O
30 P11834476A1187 CD O
min P11834476A1187 NN O
after P11834476A1187 IN O
ischemia P11834476A1187 NN O
, P11834476A1187 , O
tetrameric P11834476A1187 JJ O
cross-linked P11834476A1187 JJ O
hemoglobin P11834476A1187 NN I-UN
transfusion P11834476A1187 NN O
can P11834476A1187 MD O
augment P11834476A1187 VB O
oxygen P11834476A1187 NN O
transport P11834476A1187 NN O
to P11834476A1187 TO O
the P11834476A1187 DT O
ischemic P11834476A1187 JJ O
cortex P11834476A1187 NN O
, P11834476A1187 , O
but P11834476A1187 CC O
the P11834476A1187 DT O
increase P11834476A1187 NN O
can P11834476A1187 MD O
be P11834476A1187 VB O
delayed P11834476A1187 VBN O
and P11834476A1187 CC O
not P11834476A1187 RB O
necessarily P11834476A1187 RB O
provide P11834476A1187 VB O
protection P11834476A1187 NN O
. P11834476A1187 . O
. . O O

Oral P03914875T0001 JJ O
candidiasis P03914875T0001 NN O
. P03914875T0001 . O
. . O O

We P09212063A0425 PRP O
isolated P09212063A0425 VBD O
several P09212063A0425 JJ O
overlapping P09212063A0425 VBG O
A-phage P09212063A0425 NN O
and P09212063A0425 CC O
cosmid P09212063A0425 NN O
clones P09212063A0425 NNS O
that P09212063A0425 WDT O
cover P09212063A0425 VBP O
more P09212063A0425 JJR O
than P09212063A0425 IN O
100 P09212063A0425 CD O
kb P09212063A0425 NN O
of P09212063A0425 IN O
human P09212063A0425 JJ O
DNA P09212063A0425 NNP O
and P09212063A0425 CC O
contained P09212063A0425 VBD O
the P09212063A0425 DT O
entire P09212063A0425 JJ O
VDR P09212063A0425 NNP I-UN
gene P09212063A0425 NN I-UN
. P09212063A0425 . O
. . O O

In P10423292A0782 IN O
about P10423292A0782 RB O
770 P10423292A0782 CD O
bp P10423292A0782 NN O
upstream P10423292A0782 JJ O
region P10423292A0782 NN O
of P10423292A0782 IN O
Spam1 P10423292A0782 NNP I-UN
that P10423292A0782 WDT O
has P10423292A0782 VBZ O
been P10423292A0782 VBN O
cloned P10423292A0782 VBN O
and P10423292A0782 CC O
sequenced P10423292A0782 VBN O
, P10423292A0782 , O
multiple P10423292A0782 JJ O
transcription P10423292A0782 NN O
factor P10423292A0782 NN O
binding P10423292A0782 VBG O
sites P10423292A0782 NNS O
including P10423292A0782 VBG O
a P10423292A0782 DT O
CRE P10423292A0782 NNP O
( P10423292A0782 ( O
cAMP-responsive P10423292A0782 JJ O
element P10423292A0782 NN O
) P10423292A0782 ) O
were P10423292A0782 VBD O
found P10423292A0782 VBN O
. P10423292A0782 . O
. . O O

Longitudinal P07372433A0000 JJ O
force-length P07372433A0000 JJ O
relationships P07372433A0000 NNS O
of P07372433A0000 IN O
guinea P07372433A0000 NN O
pig P07372433A0000 NNS O
ureter P07372433A0000 NN O
were P07372433A0000 VBD O
studied P07372433A0000 VBN O
in P07372433A0000 IN O
vitro P07372433A0000 NN O
in P07372433A0000 IN O
animals P07372433A0000 NNS O
3 P07372433A0000 CD O
weeks P07372433A0000 NNS O
, P07372433A0000 , O
3 P07372433A0000 CD O
months P07372433A0000 NNS O
, P07372433A0000 , O
and P07372433A0000 CC O
3 P07372433A0000 CD O
years P07372433A0000 NNS O
of P07372433A0000 IN O
age P07372433A0000 NN O
. P07372433A0000 . O
. . O O

These P07891709A1542 DT O
observations P07891709A1542 NNS O
indicate P07891709A1542 VBP O
that P07891709A1542 IN O
there P07891709A1542 EX O
are P07891709A1542 VBP O
multiple P07891709A1542 JJ O
mechanisms P07891709A1542 NNS O
by P07891709A1542 IN O
which P07891709A1542 WDT O
an P07891709A1542 DT O
individual P07891709A1542 NN O
transcript P07891709A1542 NN O
can P07891709A1542 MD O
be P07891709A1542 VB O
degraded P07891709A1542 VBN O
following P07891709A1542 VBG O
deadenylation P07891709A1542 NN O
. P07891709A1542 . O
. . O O

Also P06085839A0721 RB O
discussed P06085839A0721 VBN O
is P06085839A0721 VBZ O
the P06085839A0721 DT O
possibility P06085839A0721 NN O
of P06085839A0721 IN O
a P06085839A0721 DT O
combined P06085839A0721 JJ O
genetic P06085839A0721 JJ O
and P06085839A0721 CC O
environmental P06085839A0721 JJ O
etiology P06085839A0721 NN O
. P06085839A0721 . O
. . O O

Thus P09705324A1602 RB O
, P09705324A1602 , O
these P09705324A1602 DT O
studies P09705324A1602 NNS O
on P09705324A1602 IN O
rat P09705324A1602 NN I-UN
Std P09705324A1602 NNP I-UN
promoter P09705324A1602 NN I-UN
function P09705324A1602 NN O
indicate P09705324A1602 VBP O
that P09705324A1602 IN O
( P09705324A1602 ( O
i P09705324A1602 NN O
) P09705324A1602 ) O
HNF1 P09705324A1602 NNP I-UN
and P09705324A1602 CC O
C P09705324A1602 NNP I-UN
/ P09705324A1602 NNP I-UN
EBP P09705324A1602 NNP I-UN
are P09705324A1602 VBP O
responsible P09705324A1602 JJ O
for P09705324A1602 IN O
liver P09705324A1602 JJ O
specificity P09705324A1602 NN O
of P09705324A1602 IN O
the P09705324A1602 DT O
rat P09705324A1602 NN I-UN
Std P09705324A1602 NNP I-UN
gene P09705324A1602 NN I-UN
; P09705324A1602 : O
( P09705324A1602 ( O
ii P09705324A1602 NN O
) P09705324A1602 ) O
androgenic P09705324A1602 JJ O
repression P09705324A1602 NN O
of P09705324A1602 IN O
the P09705324A1602 DT O
gene P09705324A1602 NN O
requires P09705324A1602 VBZ O
the P09705324A1602 DT O
presence P09705324A1602 NN O
of P09705324A1602 IN O
all P09705324A1602 DT O
of P09705324A1602 IN O
the P09705324A1602 DT O
OCT-1 P09705324A1602 NNP I-UN
and P09705324A1602 CC O
C P09705324A1602 NNP I-UN
/ P09705324A1602 NNP I-UN
EBP P09705324A1602 NNP I-UN
elements P09705324A1602 NNS I-UN
between P09705324A1602 IN O
positions P09705324A1602 NNS O
-231 P09705324A1602 NNP O
and P09705324A1602 CC O
-292 P09705324A1602 NNP O
; P09705324A1602 : O
and P09705324A1602 CC O
( P09705324A1602 ( O
iii P09705324A1602 NN O
) P09705324A1602 ) O
AR P09705324A1602 NNP I-UN
may P09705324A1602 MD O
exert P09705324A1602 VB O
its P09705324A1602 PRP$ O
negative P09705324A1602 JJ O
regulatory P09705324A1602 JJ O
effect P09705324A1602 NN O
indirectly P09705324A1602 RB O
through P09705324A1602 IN O
transcriptional P09705324A1602 JJ O
interference P09705324A1602 NN O
of P09705324A1602 IN O
OCT-1 P09705324A1602 NNP I-UN
and P09705324A1602 CC O
C P09705324A1602 NNP I-UN
/ P09705324A1602 NNP I-UN
EBP P09705324A1602 NNP I-UN
rather P09705324A1602 RB O
than P09705324A1602 IN O
through P09705324A1602 IN O
a P09705324A1602 DT O
direct P09705324A1602 JJ O
DNA-AR P09705324A1602 JJ I-UN
interaction P09705324A1602 NN O
. P09705324A1602 . O
. . O O

Following P00540707A0255 VBG O
the P00540707A0255 DT O
satisfactory P00540707A0255 JJ O
results P00540707A0255 NNS O
and P00540707A0255 CC O
taking P00540707A0255 VBG O
into P00540707A0255 IN O
account P00540707A0255 NN O
that P00540707A0255 IN O
the P00540707A0255 DT O
complications P00540707A0255 NNS O
had P00540707A0255 VBD O
reduced P00540707A0255 VBN O
to P00540707A0255 TO O
a P00540707A0255 DT O
very P00540707A0255 RB O
low P00540707A0255 JJ O
rate P00540707A0255 NN O
( P00540707A0255 ( O
in P00540707A0255 IN O
2 P00540707A0255 CD O
cases P00540707A0255 NNS O
lead P00540707A0255 JJ O
tip P00540707A0255 JJ O
displacement P00540707A0255 NN O
and P00540707A0255 CC O
pouch P00540707A0255 JJ O
haematoma P00540707A0255 NN O
occurred P00540707A0255 VBD O
respectively P00540707A0255 RB O
) P00540707A0255 ) O
, P00540707A0255 , O
the P00540707A0255 DT O
Authors P00540707A0255 NNS O
consider P00540707A0255 VBP O
the P00540707A0255 DT O
adopted P00540707A0255 VBN O
method P00540707A0255 NN O
an P00540707A0255 DT O
useful P00540707A0255 JJ O
approach P00540707A0255 NN O
for P00540707A0255 IN O
PMK P00540707A0255 NNP O
implantation P00540707A0255 NN O
particularly P00540707A0255 RB O
when P00540707A0255 WRB O
the P00540707A0255 DT O
use P00540707A0255 NN O
of P00540707A0255 IN O
the P00540707A0255 DT O
vena P00540707A0255 NN O
cephalica P00540707A0255 NN O
is P00540707A0255 VBZ O
deemed P00540707A0255 VBN O
impossible P00540707A0255 JJ O
. P00540707A0255 . O
. . O O

The P09727046A0784 DT O
CBF1 P09727046A0784 NNP I-UN
site P09727046A0784 NN I-UN
within P09727046A0784 IN O
HS2 P09727046A0784 NNP O
resides P09727046A0784 NNS O
near P09727046A0784 IN O
sites P09727046A0784 NNS O
for P09727046A0784 IN O
hematopoietic P09727046A0784 JJ O
regulators P09727046A0784 NNS O
such P09727046A0784 JJ O
as P09727046A0784 IN O
GATA-1 P09727046A0784 NNP I-UN
, P09727046A0784 , O
NF-E2 P09727046A0784 NNP I-UN
, P09727046A0784 , O
and P09727046A0784 CC O
TAL1 P09727046A0784 NNP I-UN
. P09727046A0784 . O
. . O O

To P02476030A0000 TO O
study P02476030A0000 VB O
the P02476030A0000 DT O
retinal P02476030A0000 JJ O
surface P02476030A0000 NN O
in P02476030A0000 IN O
the P02476030A0000 DT O
human P02476030A0000 JJ O
eye P02476030A0000 NN O
in P02476030A0000 IN O
normal P02476030A0000 JJ O
and P02476030A0000 CC O
diseased P02476030A0000 JJ O
states P02476030A0000 NNS O
we P02476030A0000 PRP O
used P02476030A0000 VBD O
laser P02476030A0000 RBR O
scanning P02476030A0000 VBG O
tomography P02476030A0000 NN O
. P02476030A0000 . O
. . O O

IgG P02200315A0278 NNP I-UN
and P02200315A0278 CC O
IgM P02200315A0278 NNP I-UN
antibody P02200315A0278 NN O
activity P02200315A0278 NN O
was P02200315A0278 VBD O
determined P02200315A0278 VBN O
by P02200315A0278 IN O
adding P02200315A0278 VBG O
a P02200315A0278 DT O
1:100 P02200315A0278 CD O
dilution P02200315A0278 NN O
of P02200315A0278 IN O
serum P02200315A0278 NN O
to P02200315A0278 TO O
plates P02200315A0278 NNS O
coated P02200315A0278 VBN O
with P02200315A0278 IN O
A60 P02200315A0278 NNP I-UN
antigen P02200315A0278 NN I-UN
. P02200315A0278 . O
. . O O

For P10407184A0520 IN O
functional P10407184A0520 JJ O
studies P10407184A0520 NNS O
, P10407184A0520 , O
two P10407184A0520 CD O
promoter P10407184A0520 NN O
regions P10407184A0520 NNS O
were P10407184A0520 VBD O
cloned P10407184A0520 VBN O
upstream P10407184A0520 NN O
of P10407184A0520 IN O
the P10407184A0520 DT O
reporter P10407184A0520 NN O
gene P10407184A0520 NN O
, P10407184A0520 , O
chloramphenicol P10407184A0520 JJ I-UN
acetyl P10407184A0520 NN I-UN
transferase P10407184A0520 NN I-UN
( P10407184A0520 ( O
CAT P10407184A0520 NNP I-UN
) P10407184A0520 ) O
: P10407184A0520 : O
( P10407184A0520 ( O
i P10407184A0520 NN O
) P10407184A0520 ) O
phbetaE-B P10407184A0520 NN O
- P10407184A0520 : O
the P10407184A0520 DT O
plasmid P10407184A0520 NN O
that P10407184A0520 WDT O
contains P10407184A0520 VBZ O
the P10407184A0520 DT O
human P10407184A0520 JJ O
( P10407184A0520 ( O
h P10407184A0520 NN O
) P10407184A0520 ) O
promoter P10407184A0520 NN O
region P10407184A0520 NN O
( P10407184A0520 ( O
-2832 P10407184A0520 UH O
to P10407184A0520 TO O
+101 P10407184A0520 VB O
) P10407184A0520 ) O
including P10407184A0520 VBG O
URE P10407184A0520 NNP O
, P10407184A0520 , O
and P10407184A0520 CC O
( P10407184A0520 ( O
ii P10407184A0520 NN O
) P10407184A0520 ) O
prhbetaE-B P10407184A0520 NN O
- P10407184A0520 : O
the P10407184A0520 DT O
plasmid P10407184A0520 NN O
that P10407184A0520 WDT O
contains P10407184A0520 VBZ O
the P10407184A0520 DT O
rhesus P10407184A0520 NN O
( P10407184A0520 ( O
rh P10407184A0520 NN O
) P10407184A0520 ) O
promoter P10407184A0520 NN O
region P10407184A0520 NN O
excluding P10407184A0520 VBG O
URE P10407184A0520 NNP O
as P10407184A0520 IN O
it P10407184A0520 PRP O
lacks P10407184A0520 VBZ O
a P10407184A0520 DT O
270 P10407184A0520 CD O
bp P10407184A0520 JJ O
region P10407184A0520 NN O
of P10407184A0520 IN O
the P10407184A0520 DT O
hbetaAPP P10407184A0520 NN I-UN
promoter P10407184A0520 NN I-UN
( P10407184A0520 ( O
-2435 P10407184A0520 UH O
to P10407184A0520 TO O
-2165 P10407184A0520 VB O
) P10407184A0520 ) O
. P10407184A0520 . O
. . O O

The P09427551A0501 DT O
gene P09427551A0501 NN O
contains P09427551A0501 VBZ O
six P09427551A0501 CD O
exons P09427551A0501 NNS O
separated P09427551A0501 VBN O
by P09427551A0501 IN O
1.1-5.8 P09427551A0501 JJ O
kb P09427551A0501 NN O
introns P09427551A0501 NNS O
and P09427551A0501 CC O
has P09427551A0501 VBZ O
been P09427551A0501 VBN O
localized P09427551A0501 VBN O
to P09427551A0501 TO O
the P09427551A0501 DT O
murine P09427551A0501 NN O
chromosome P09427551A0501 NN O
2 P09427551A0501 CD O
by P09427551A0501 IN O
linkage P09427551A0501 NN O
analysis P09427551A0501 NN O
. P09427551A0501 . O
. . O O

Automatic P05769307T0000 NNP O
view P05769307T0000 NN O
box P05769307T0000 NN O
. P05769307T0000 . O
. . O O

Herein P11287611A0802 NNP O
PPARgamma P11287611A0802 NNP I-UN
, P11287611A0802 , O
liganded P11287611A0802 VBN O
by P11287611A0802 IN O
either P11287611A0802 DT O
natural P11287611A0802 JJ O
( P11287611A0802 ( O
15d-PGJ P11287611A0802 JJ O
( P11287611A0802 ( O
2 P11287611A0802 CD O
) P11287611A0802 ) O
and P11287611A0802 CC O
PGD P11287611A0802 NNP O
( P11287611A0802 ( O
2 P11287611A0802 CD O
) P11287611A0802 ) O
) P11287611A0802 ) O
or P11287611A0802 CC O
synthetic P11287611A0802 JJ O
ligands P11287611A0802 NNS O
( P11287611A0802 ( O
BRL49653 P11287611A0802 NNP O
and P11287611A0802 CC O
troglitazone P11287611A0802 NN O
) P11287611A0802 ) O
, P11287611A0802 , O
selectively P11287611A0802 RB O
inhibited P11287611A0802 JJ O
expression P11287611A0802 NN O
of P11287611A0802 IN O
the P11287611A0802 DT O
cyclin P11287611A0802 NN I-UN
D1 P11287611A0802 NNP I-UN
gene P11287611A0802 NN I-UN
. P11287611A0802 . O
. . O O

Consistent P01907265A0670 JJ O
with P01907265A0670 IN O
the P01907265A0670 DT O
in P01907265A0670 IN O
vivo P01907265A0670 NN O
result P01907265A0670 NN O
, P01907265A0670 , O
the P01907265A0670 DT O
pseudorevertant P01907265A0670 NN O
endonucleases P01907265A0670 VBZ O
in P01907265A0670 IN O
the P01907265A0670 DT O
crude P01907265A0670 NN O
cell P01907265A0670 NN O
extract P01907265A0670 JJ O
display P01907265A0670 NN O
site-specific P01907265A0670 JJ O
partial P01907265A0670 JJ O
DNA P01907265A0670 NNP O
cleavage P01907265A0670 NN O
activity P01907265A0670 NN O
. P01907265A0670 . O
. . O O

All P08534848A0188a DT O
three P08534848A0188a CD O
NR P08534848A0188a NNP I-UN
isoforms P08534848A0188a NNS I-UN
are P08534848A0188a VBP O
expressed P08534848A0188a VBN O
in P08534848A0188a IN O
cv P08534848A0188a NN O
. P08534848A0188a . O
. . O O

Herceptin P11830544A0335 NNP O
, P11830544A0335 , O
which P11830544A0335 WDT O
recognizes P11830544A0335 VBZ O
the P11830544A0335 DT O
HER-2 P11830544A0335 NNP I-UN
/ P11830544A0335 NNP O
neu P11830544A0335 MD I-UN
antigen P11830544A0335 VB O
and P11830544A0335 CC O
has P11830544A0335 VBZ O
similar P11830544A0335 JJ O
size P11830544A0335 NN O
( P11830544A0335 ( O
10 P11830544A0335 CD O
nm P11830544A0335 RB O
) P11830544A0335 ) O
to P11830544A0335 TO O
G6- P11830544A0335 NNP O
( P11830544A0335 ( O
1B4M-Gd P11830544A0335 CD O
) P11830544A0335 ) O
( P11830544A0335 ( O
256 P11830544A0335 CD O
) P11830544A0335 ) O
, P11830544A0335 , O
accumulated P11830544A0335 VBN O
and P11830544A0335 CC O
internalized P11830544A0335 VBN O
in P11830544A0335 IN O
the P11830544A0335 DT O
WIBC-9 P11830544A0335 JJ O
tumors P11830544A0335 NNS O
more P11830544A0335 RBR O
quickly P11830544A0335 RB O
than P11830544A0335 IN O
in P11830544A0335 IN O
the P11830544A0335 DT O
control P11830544A0335 NN O
MC-5 P11830544A0335 NNP O
tumors P11830544A0335 NNS O
that P11830544A0335 IN O
progress P11830544A0335 NN O
with P11830544A0335 IN O
normal P11830544A0335 JJ O
angiogenesis P11830544A0335 NN O
. P11830544A0335 . O
. . O O

Members P08506317A0000 NNS O
of P08506317A0000 IN O
the P08506317A0000 DT O
C P08506317A0000 NNP I-UN
/ P08506317A0000 NNP I-UN
EBP P08506317A0000 NNP I-UN
family P08506317A0000 NN I-UN
of P08506317A0000 IN O
basic-leucine P08506317A0000 JJ I-UN
zipper P08506317A0000 NN I-UN
( P08506317A0000 ( I-UN
bZip P08506317A0000 NN I-UN
) P08506317A0000 ) I-UN
transcription P08506317A0000 NN I-UN
factors P08506317A0000 NNS I-UN
form P08506317A0000 VBP O
heterodimers P08506317A0000 NNS O
and P08506317A0000 CC O
bind P08506317A0000 NN O
to P08506317A0000 TO O
the P08506317A0000 DT O
CAAT P08506317A0000 NNP O
box P08506317A0000 NN O
and P08506317A0000 CC O
other P08506317A0000 JJ O
sequence-related P08506317A0000 JJ O
enhancer P08506317A0000 NN O
motifs P08506317A0000 NNS O
. P08506317A0000 . O
. . O O

In P07708488A0151 IN O
contrast P07708488A0151 NN O
to P07708488A0151 TO O
some P07708488A0151 DT O
results P07708488A0151 NNS O
previously P07708488A0151 RB O
published P07708488A0151 VBN O
for P07708488A0151 IN O
a P07708488A0151 DT O
very P07708488A0151 RB O
close P07708488A0151 JJ O
sequence P07708488A0151 NN O
variant P07708488A0151 NN O
( P07708488A0151 ( O
see P07708488A0151 VB O
ref P07708488A0151 NN O
. P07708488A0151 . O
. . O O

The P05781385T0000 DT O
significance P05781385T0000 NN O
of P05781385T0000 IN O
the P05781385T0000 DT O
phenolphthalein P05781385T0000 NN I-UN
sulphatase P05781385T0000 NN I-UN
test P05781385T0000 NN O
for P05781385T0000 IN O
the P05781385T0000 DT O
differentiation P05781385T0000 NN O
and P05781385T0000 CC O
identification P05781385T0000 NN O
of P05781385T0000 IN O
Nocardia P05781385T0000 NNP O
species P05781385T0000 NNS O
. P05781385T0000 . O
. . O O

A P07219297T0000 DT O
unified P07219297T0000 JJ O
approach P07219297T0000 NN O
to P07219297T0000 TO O
the P07219297T0000 DT O
standardization P07219297T0000 NN O
of P07219297T0000 IN O
allergens P07219297T0000 NNS O
. P07219297T0000 . O
. . O O

The P03042778A0643 DT O
gene P03042778A0643 NN O
is P03042778A0643 VBZ O
essential P03042778A0643 JJ O
for P03042778A0643 IN O
yeast P03042778A0643 JJ O
vegetative P03042778A0643 JJ O
growth P03042778A0643 NN O
. P03042778A0643 . O
. . O O

Mitochondrial P08163528T0000 JJ I-UN
Mas70p P08163528T0000 NNP I-UN
signal P08163528T0000 NN I-UN
anchor P08163528T0000 NN I-UN
sequence P08163528T0000 NN I-UN
. P08163528T0000 . O
. . O O

Downstream P10637149A0806 NN O
of P10637149A0806 IN O
the P10637149A0806 DT O
G-A P10637149A0806 NNP O
anastomosis P10637149A0806 NN O
, P10637149A0806 , O
the P10637149A0806 DT O
RD P10637149A0806 NNP O
, P10637149A0806 , O
CC P10637149A0806 NNP O
, P10637149A0806 , O
E P10637149A0806 NNP O
( P10637149A0806 ( O
p P10637149A0806 NN O
) P10637149A0806 ) O
and P10637149A0806 CC O
loop P10637149A0806 JJ O
areas P10637149A0806 NNS O
were P10637149A0806 VBD O
significantly P10637149A0806 RB O
different P10637149A0806 JJ O
from P10637149A0806 IN O
REF P10637149A0806 NNP O
, P10637149A0806 , O
but P10637149A0806 CC O
significantly P10637149A0806 RB O
different P10637149A0806 JJ O
from P10637149A0806 IN O
A-A P10637149A0806 NNP O
. P10637149A0806 . O
. . O O

Recombinant P10585463A0859 JJ I-UN
prenylcysteine P10585463A0859 NN I-UN
lyase P10585463A0859 NN I-UN
was P10585463A0859 VBD O
produced P10585463A0859 VBN O
in P10585463A0859 IN O
a P10585463A0859 DT O
baculovirus-Sf9 P10585463A0859 JJ O
expression P10585463A0859 NN O
system P10585463A0859 NN O
. P10585463A0859 . O
. . O O

In P11082185A0415 IN O
addition P11082185A0415 NN O
, P11082185A0415 , O
we P11082185A0415 PRP O
identified P11082185A0415 VBD O
a P11082185A0415 DT O
novel P11082185A0415 JJ O
type P11082185A0415 NN O
of P11082185A0415 IN O
inhibitory P11082185A0415 NN O
domain P11082185A0415 NN O
in P11082185A0415 IN O
the P11082185A0415 DT O
N-terminal P11082185A0415 JJ O
60 P11082185A0415 CD O
amino P11082185A0415 JJ O
acids P11082185A0415 NNS O
of P11082185A0415 IN O
IRF-1 P11082185A0415 NNP I-UN
which P11082185A0415 WDT O
strongly P11082185A0415 RB O
inhibits P11082185A0415 VBZ O
its P11082185A0415 PRP$ O
transcriptional P11082185A0415 JJ O
activity P11082185A0415 NN O
. P11082185A0415 . O
. . O O

The P10417331A1008 DT O
enzyme P10417331A1008 NN O
displays P10417331A1008 VBZ O
optimal P10417331A1008 JJ O
activity P10417331A1008 NN O
at P10417331A1008 IN O
about P10417331A1008 RB O
0.5 P10417331A1008 CD O
mM P10417331A1008 NNS O
pantoate P10417331A1008 NN O
( P10417331A1008 ( O
k P10417331A1008 NN O
( P10417331A1008 ( O
cat P10417331A1008 NN O
) P10417331A1008 ) O
0.63 P10417331A1008 CD O
s P10417331A1008 NN O
( P10417331A1008 ( O
-1 P10417331A1008 NNP O
) P10417331A1008 ) O
) P10417331A1008 ) O
and P10417331A1008 CC O
at P10417331A1008 IN O
pH P10417331A1008 JJ O
7.8 P10417331A1008 CD O
. P10417331A1008 . O
. . O O

Male P07704730T0000 JJ O
contraception P07704730T0000 NN O
: P07704730T0000 : O
ideas P07704730T0000 NNS O
for P07704730T0000 IN O
the P07704730T0000 DT O
future P07704730T0000 NN O
. P07704730T0000 . O
. . O O

When P06895663A0810 WRB O
O2 P06895663A0810 NNP O
therapy P06895663A0810 NN O
was P06895663A0810 VBD O
controlled P06895663A0810 VBN O
for P06895663A0810 IN O
, P06895663A0810 , O
the P06895663A0810 DT O
association P06895663A0810 NN O
between P06895663A0810 IN O
RBT P06895663A0810 NNP O
and P06895663A0810 CC O
RLF P06895663A0810 NNP O
did P06895663A0810 VBD O
not P06895663A0810 RB O
achieve P06895663A0810 VB O
statistical P06895663A0810 JJ O
significance P06895663A0810 NN O
( P06895663A0810 ( O
P P06895663A0810 NNP O
= P06895663A0810 NNP O
.07 P06895663A0810 NNP O
) P06895663A0810 ) O
. P06895663A0810 . O
. . O O

C P07959011A0379b NNP I-UN
/ P07959011A0379b NNP I-UN
EBP P07959011A0379b NNP I-UN
alpha P07959011A0379b NN I-UN
also P07959011A0379b RB O
activates P07959011A0379b VBZ O
the P07959011A0379b DT O
promoter P07959011A0379b NN O
of P07959011A0379b IN O
the P07959011A0379b DT O
rat P07959011A0379b NN I-UN
class-I P07959011A0379b JJ I-UN
ADH P07959011A0379b NNP I-UN
gene P07959011A0379b NN I-UN
in P07959011A0379b IN O
a P07959011A0379b DT O
sequence-specific P07959011A0379b JJ O
manner P07959011A0379b NN O
[ P07959011A0379b JJ O
Potter P07959011A0379b NNP O
et P07959011A0379b NN O
al. P07959011A0379b NN O
, P07959011A0379b , O
Arch P07959011A0379b NNP O
. P07959011A0379b . O
. . O O

Transcriptional P09364750T0000 JJ O
regulation P09364750T0000 NN O
of P09364750T0000 IN O
SUP35 P09364750T0000 NNP I-UN
and P09364750T0000 CC O
SUP45 P09364750T0000 NNP I-UN
in P09364750T0000 IN I-UN
Saccharomyces P09364750T0000 NNP I-UN
cerevisiae P09364750T0000 NN I-UN
. P09364750T0000 . O
. . O O

In P08035498A0833 IN O
addition P08035498A0833 NN O
, P08035498A0833 , O
computer P08035498A0833 NN O
analysis P08035498A0833 NN O
suggests P08035498A0833 VBZ O
that P08035498A0833 IN O
sequences P08035498A0833 NNS O
similar P08035498A0833 JJ O
to P08035498A0833 TO O
the P08035498A0833 DT O
A P08035498A0833 NNP O
stem P08035498A0833 NN O
element P08035498A0833 NN O
are P08035498A0833 VBP O
present P08035498A0833 JJ O
within P08035498A0833 IN O
the P08035498A0833 DT O
three P08035498A0833 CD O
AAV P08035498A0833 NNP I-UN
promoter P08035498A0833 NN I-UN
regions P08035498A0833 NNS O
. P08035498A0833 . O
. . O O

EIAV P10544113A0293 NNP I-UN
LTR P10544113A0293 NNP I-UN
sequence P10544113A0293 NN I-UN
variability P10544113A0293 NN O
is P10544113A0293 VBZ O
confined P10544113A0293 VBN O
mostly P10544113A0293 RB O
to P10544113A0293 TO O
a P10544113A0293 DT O
small P10544113A0293 JJ O
portion P10544113A0293 NN O
of P10544113A0293 IN O
the P10544113A0293 DT O
enhancer P10544113A0293 NN O
within P10544113A0293 IN O
the P10544113A0293 DT O
U3 P10544113A0293 NNP O
segment P10544113A0293 NN O
of P10544113A0293 IN O
the P10544113A0293 DT O
LTR P10544113A0293 NNP O
. P10544113A0293 . O
. . O O

Relations P05740389T0001 NNS O
between P05740389T0001 IN O
adrenergic P05740389T0001 JJ O
mechanisms P05740389T0001 NNS O
and P05740389T0001 CC O
analgesic P05740389T0001 JJ O
effects P05740389T0001 NNS O
. P05740389T0001 . O
. . O O

If P08628302A0683 IN O
hnRNP P08628302A0683 JJ I-UN
K P08628302A0683 NNP I-UN
is P08628302A0683 VBZ O
a P08628302A0683 DT O
transcription P08628302A0683 NN O
factor P08628302A0683 NN O
, P08628302A0683 , O
then P08628302A0683 RB O
interactions P08628302A0683 NNS O
with P08628302A0683 IN O
the P08628302A0683 DT O
RNA P08628302A0683 NNP I-UN
polymerase P08628302A0683 NN I-UN
II P08628302A0683 NNP I-UN
transcription P08628302A0683 NN O
apparatus P08628302A0683 NN O
are P08628302A0683 VBP O
predicted P08628302A0683 VBN O
. P08628302A0683 . O
. . O O

Therefore P09243385A1314 RB O
, P09243385A1314 , O
use P09243385A1314 NN O
of P09243385A1314 IN O
presaturation P09243385A1314 NN O
is P09243385A1314 VBZ O
recommended P09243385A1314 VBN O
for P09243385A1314 IN O
myocardial P09243385A1314 JJ O
motion P09243385A1314 NN O
studies P09243385A1314 NNS O
using P09243385A1314 VBG O
cine P09243385A1314 JJ O
PC P09243385A1314 NN O
velocity P09243385A1314 NN O
data P09243385A1314 NNS O
. P09243385A1314 . O
. . O O

CONCLUSIONS P09389982A1383 NNS O
: P09389982A1383 : O
While P09389982A1383 IN O
INR P09389982A1383 NNP O
correction P09389982A1383 NN O
may P09389982A1383 MD O
be P09389982A1383 VB O
achieved P09389982A1383 VBN O
by P09389982A1383 IN O
all P09389982A1383 PDT O
the P09389982A1383 DT O
above P09389982A1383 JJ O
methods P09389982A1383 NNS O
, P09389982A1383 , O
that P09389982A1383 IN O
relating P09389982A1383 VBG O
log P09389982A1383 NN O
reference P09389982A1383 NN O
INR P09389982A1383 NNP O
to P09389982A1383 TO O
log P09389982A1383 VB O
local P09389982A1383 JJ O
prothrombin P09389982A1383 NN I-UN
time P09389982A1383 NN O
by P09389982A1383 IN O
linear P09389982A1383 JJ O
regression P09389982A1383 NN O
analysis P09389982A1383 NN O
is P09389982A1383 VBZ O
the P09389982A1383 DT O
simplest P09389982A1383 JJS O
to P09389982A1383 TO O
perform P09389982A1383 VB O
. P09389982A1383 . O
. . O O

Local P04598670T0000 JJ O
graft P04598670T0000 NN O
irradiation P04598670T0000 NN O
as P04598670T0000 IN O
an P04598670T0000 DT O
adjunct P04598670T0000 NN O
to P04598670T0000 TO O
pharmacologic P04598670T0000 VB O
immunosuppression P04598670T0000 NN O
. P04598670T0000 . O
. . O O

We P08051074A0000 PRP O
have P08051074A0000 VBP O
examined P08051074A0000 VBN O
by P08051074A0000 IN O
in P08051074A0000 IN O
vitro P08051074A0000 NN O
footprinting P08051074A0000 VBG O
a P08051074A0000 DT O
region P08051074A0000 NN O
located P08051074A0000 VBN O
downstream P08051074A0000 NN O
of P08051074A0000 IN O
the P08051074A0000 DT O
human P08051074A0000 JJ O
immunodeficiency P08051074A0000 NN O
virus P08051074A0000 NN O
, P08051074A0000 , O
type P08051074A0000 NN O
1 P08051074A0000 CD O
( P08051074A0000 ( O
HIV-1 P08051074A0000 NNP O
) P08051074A0000 ) O
promoter P08051074A0000 NN O
found P08051074A0000 VBD O
to P08051074A0000 TO O
be P08051074A0000 VB O
hypersensitive P08051074A0000 JJ O
to P08051074A0000 TO O
DNase P08051074A0000 NNP I-UN
I P08051074A0000 PRP I-UN
digestion P08051074A0000 VBP O
in P08051074A0000 IN O
vivo P08051074A0000 NN O
. P08051074A0000 . O
. . O O

Glucose-6-phosphate P01158512T0000 JJ I-UN
dehydrogenase P01158512T0000 NN I-UN
( P01158512T0000 ( O
G-6-PD P01158512T0000 NNP I-UN
) P01158512T0000 ) O
deficiency P01158512T0000 NN O
in P01158512T0000 IN O
the P01158512T0000 DT O
newborn P01158512T0000 NN O
. P01158512T0000 . O
. . O O

While P11011139A0000 IN O
this P11011139A0000 DT O
Saccharomyces P11011139A0000 VBZ O
cerevisiae P11011139A0000 JJ O
SIN4 P11011139A0000 NNP I-UN
gene P11011139A0000 NN I-UN
product P11011139A0000 NN I-UN
is P11011139A0000 VBZ O
a P11011139A0000 DT O
component P11011139A0000 NN O
of P11011139A0000 IN O
a P11011139A0000 DT O
mediator P11011139A0000 NN O
complex P11011139A0000 NN O
associated P11011139A0000 VBN O
with P11011139A0000 IN O
RNA P11011139A0000 NNP I-UN
polymerase P11011139A0000 NN I-UN
II P11011139A0000 NNP I-UN
, P11011139A0000 , O
various P11011139A0000 JJ O
studies P11011139A0000 NNS O
suggest P11011139A0000 VBP O
the P11011139A0000 DT O
involvement P11011139A0000 NN O
of P11011139A0000 IN O
Sin4 P11011139A0000 NNP I-UN
in P11011139A0000 IN O
the P11011139A0000 DT O
alteration P11011139A0000 NN O
of P11011139A0000 IN O
higher-order P11011139A0000 JJ O
chromatin P11011139A0000 NN O
structure P11011139A0000 NN O
. P11011139A0000 . O
. . O O

Assay P07276210T0000 NNP O
of P07276210T0000 IN O
serum P07276210T0000 NN I-UN
immunoreactive P07276210T0000 JJ I-UN
trypsin P07276210T0000 NN I-UN
in P07276210T0000 IN O
dried P07276210T0000 JJ O
blood P07276210T0000 NN O
spots P07276210T0000 NNS O
and P07276210T0000 CC O
the P07276210T0000 DT O
early P07276210T0000 JJ O
detection P07276210T0000 NN O
of P07276210T0000 IN O
cystic P07276210T0000 JJ O
fibrosis P07276210T0000 NN O
. P07276210T0000 . O
. . O O

The P10350484A0346 DT O
kinetics P10350484A0346 NNS O
of P10350484A0346 IN O
kinase P10350484A0346 NN O
activity P10350484A0346 NN O
within P10350484A0346 IN O
these P10350484A0346 DT O
complexes P10350484A0346 NNS O
compared P10350484A0346 VBN O
to P10350484A0346 TO O
CheA P10350484A0346 NNP I-UN
alone P10350484A0346 RB O
indicate P10350484A0346 VBP O
approximately P10350484A0346 RB O
a P10350484A0346 DT O
50 P10350484A0346 CD O
% P10350484A0346 NN O
decrease P10350484A0346 NN O
in P10350484A0346 IN O
the P10350484A0346 DT O
KM P10350484A0346 NNP O
for P10350484A0346 IN O
ATP P10350484A0346 NNP O
and P10350484A0346 CC O
a P10350484A0346 DT O
100-fold P10350484A0346 JJ O
increase P10350484A0346 NN O
in P10350484A0346 IN O
the P10350484A0346 DT O
Vmax P10350484A0346 NNP O
. P10350484A0346 . O
. . O O

Plasmids P07929431A0949 NNS O
were P07929431A0949 VBD O
constructed P07929431A0949 VBN O
with P07929431A0949 IN O
the P07929431A0949 DT O
mouse P07929431A0949 NN O
promoter P07929431A0949 NN O
region P07929431A0949 NN O
linked P07929431A0949 VBN O
to P07929431A0949 TO O
the P07929431A0949 DT O
reporter P07929431A0949 NN I-UN
gene P07929431A0949 NN I-UN
chloramphenicol P07929431A0949 NN I-UN
acetyltransferase P07929431A0949 NN I-UN
( P07929431A0949 ( O
CAT P07929431A0949 NNP I-UN
) P07929431A0949 ) O
, P07929431A0949 , O
and P07929431A0949 CC O
transiently P07929431A0949 RB O
and P07929431A0949 CC O
stably P07929431A0949 RB O
transfected P07929431A0949 VBN O
in P07929431A0949 IN O
the P07929431A0949 DT O
INS-1 P07929431A0949 NNP O
cells P07929431A0949 NNS O
. P07929431A0949 . O
. . O O

Only P11251276A0793 RB O
nine P11251276A0793 CD O
patients P11251276A0793 NNS O
were P11251276A0793 VBD O
offered P11251276A0793 VBN O
surgery P11251276A0793 NN O
( P11251276A0793 ( O
six P11251276A0793 CD O
were P11251276A0793 VBD O
resected P11251276A0793 VBN O
and P11251276A0793 CC O
three P11251276A0793 CD O
were P11251276A0793 VBD O
found P11251276A0793 VBN O
inoperable P11251276A0793 JJ O
) P11251276A0793 ) O
. P11251276A0793 . O
. . O O

Hops P08408963A0048 NNP O
, P08408963A0048 , O
and P08408963A0048 CC O
L P08408963A0048 NNP O
. P08408963A0048 . O
. . O O

Basal P07826625X0000 NNP O
components P07826625X0000 NNS O
of P07826625X0000 IN O
the P07826625X0000 DT O
transcription P07826625X0000 NN O
apparatus P07826625X0000 NN O
( P07826625X0000 ( O
RNA P07826625X0000 NNP I-UN
polymerase P07826625X0000 NN I-UN
II P07826625X0000 NNP I-UN
, P07826625X0000 , O
TATA-binding P07826625X0000 NNP I-UN
protein P07826625X0000 NN I-UN
) P07826625X0000 ) O
contain P07826625X0000 NN O
activation P07826625X0000 NN O
domains P07826625X0000 NNS O
: P07826625X0000 : O
is P07826625X0000 VBZ O
the P07826625X0000 DT O
repetitive P07826625X0000 JJ O
C-terminal P07826625X0000 JJ O
domain P07826625X0000 NN O
( P07826625X0000 ( O
CTD P07826625X0000 NNP O
) P07826625X0000 ) O
of P07826625X0000 IN O
RNA P07826625X0000 NNP I-UN
polymerase P07826625X0000 NN I-UN
II P07826625X0000 NNP I-UN
a P07826625X0000 DT O
`` P07826625X0000 `` O
portable P07826625X0000 JJ O
enhancer P07826625X0000 NN O
domain P07826625X0000 NN O
'' P07826625X0000 '' O
? P07826625X0000 . O
Regions P07826625X0000 NNS O
rich P07826625X0000 VBP O
in P07826625X0000 IN O
serine P07826625X0000 NN O
, P07826625X0000 , O
threonine P07826625X0000 NN O
, P07826625X0000 , O
and P07826625X0000 CC O
proline P07826625X0000 NN O
residues P07826625X0000 NNS O
can P07826625X0000 MD O
be P07826625X0000 VB O
found P07826625X0000 VBN O
in P07826625X0000 IN O
transcriptional P07826625X0000 JJ O
activation P07826625X0000 NN O
domains P07826625X0000 NNS O
, P07826625X0000 , O
as P07826625X0000 RB O
well P07826625X0000 RB O
as P07826625X0000 IN O
in P07826625X0000 IN O
the P07826625X0000 DT O
N-terminal P07826625X0000 JJ O
parts P07826625X0000 NNS O
of P07826625X0000 IN O
mammalian P07826625X0000 JJ I-UN
TATA-binding P07826625X0000 NNP I-UN
proteins P07826625X0000 NNS I-UN
, P07826625X0000 , O
where P07826625X0000 WRB O
they P07826625X0000 PRP O
are P07826625X0000 VBP O
interrupted P07826625X0000 VBN O
by P07826625X0000 IN O
polyglutamine P07826625X0000 NN O
stretches P07826625X0000 NNS O
. P07826625X0000 . O
. . O O

Two-way P09873291A0620 JJ O
analysis P09873291A0620 NN O
of P09873291A0620 IN O
variance P09873291A0620 NN O
was P09873291A0620 VBD O
used P09873291A0620 VBN O
to P09873291A0620 TO O
determine P09873291A0620 VB O
whether P09873291A0620 IN O
composite P09873291A0620 JJ O
knowledge P09873291A0620 NN O
score P09873291A0620 RB O
differed P09873291A0620 VBD O
among P09873291A0620 IN O
patient P09873291A0620 JJ O
groups P09873291A0620 NNS O
. P09873291A0620 . O
. . O O

The P06856306T0000 DT O
Tullio P06856306T0000 NNP O
phenomenon P06856306T0000 NN O
, P06856306T0000 , O
fistula P06856306T0000 JJ O
test P06856306T0000 NN O
, P06856306T0000 , O
and P06856306T0000 CC O
Hennebert P06856306T0000 NNP O
's P06856306T0000 POS O
sign P06856306T0000 NN O
: P06856306T0000 : O
clinical P06856306T0000 JJ O
significance P06856306T0000 NN O
. P06856306T0000 . O
. . O O

Analysis P07483276A0139 NN O
of P07483276A0139 IN O
the P07483276A0139 DT O
sequence P07483276A0139 NN O
identified P07483276A0139 VBD O
four P07483276A0139 CD O
open P07483276A0139 JJ O
reading P07483276A0139 VBG O
frames P07483276A0139 NNS O
( P07483276A0139 ( O
ORFs P07483276A0139 NNP O
) P07483276A0139 ) O
which P07483276A0139 WDT O
are P07483276A0139 VBP O
designated P07483276A0139 VBN O
UL1 P07483276A0139 NNP I-UN
, P07483276A0139 , O
UL2 P07483276A0139 NNP I-UN
, P07483276A0139 , O
UL3 P07483276A0139 NNP I-UN
, P07483276A0139 , O
and P07483276A0139 CC O
UL3.5 P07483276A0139 NNP I-UN
based P07483276A0139 VBN O
on P07483276A0139 IN O
their P07483276A0139 PRP$ O
homology P07483276A0139 NN O
with P07483276A0139 IN O
proteins P07483276A0139 NNS O
of P07483276A0139 IN O
herpes P07483276A0139 NNS O
simplex P07483276A0139 JJ O
virus-1 P07483276A0139 JJ O
( P07483276A0139 ( O
HSV-1 P07483276A0139 NNP O
) P07483276A0139 ) O
, P07483276A0139 , O
pseudorabies P07483276A0139 NNS O
virus P07483276A0139 VBP O
( P07483276A0139 ( O
PRV P07483276A0139 NNP O
) P07483276A0139 ) O
, P07483276A0139 , O
equine P07483276A0139 JJ O
herpesvirus-1 P07483276A0139 NN O
, P07483276A0139 , O
and P07483276A0139 CC O
varicella-zoster P07483276A0139 JJ O
virus P07483276A0139 NN O
. P07483276A0139 . O
. . O O

A P07585559A0000 DT O
pyrazolo-quinoline P07585559A0000 JJ O
compound P07585559A0000 NN O
, P07585559A0000 , O
6-methoxy-4- P07585559A0000 JJ O
[ P07585559A0000 JJ O
2- P07585559A0000 JJ O
[ P07585559A0000 NN O
( P07585559A0000 ( O
2-hydroxyethoxyl P07585559A0000 JJ O
) P07585559A0000 ) O
-ethyl P07585559A0000 FW O
] P07585559A0000 NNP O
amino P07585559A0000 NN O
] P07585559A0000 NNP O
-3-methyl-1M-pyrazo P07585559A0000 NNP O
lo P07585559A0000 VBD O
[ P07585559A0000 JJ O
3,4-b P07585559A0000 JJ O
] P07585559A0000 NN O
quinoline P07585559A0000 NN O
( P07585559A0000 ( O
SCH P07585559A0000 NNP O
51344 P07585559A0000 CD O
) P07585559A0000 ) O
, P07585559A0000 , O
was P07585559A0000 VBD O
identified P07585559A0000 VBN O
based P07585559A0000 VBN O
on P07585559A0000 IN O
its P07585559A0000 PRP$ O
ability P07585559A0000 NN O
to P07585559A0000 TO O
derepress P07585559A0000 VB O
human P07585559A0000 JJ O
smooth P07585559A0000 JJ O
muscle P07585559A0000 NN O
alpha-actin P07585559A0000 JJ I-UN
promoter P07585559A0000 NN I-UN
activity P07585559A0000 NN O
in P07585559A0000 IN O
ras-transformed P07585559A0000 JJ O
cells P07585559A0000 NNS O
. P07585559A0000 . O
. . O O

INTERVENTIONS P10205099A0377 NN O
: P10205099A0377 : O
Study P10205099A0377 NN O
patients P10205099A0377 NNS O
were P10205099A0377 VBD O
randomly P10205099A0377 RB O
divided P10205099A0377 VBN O
into P10205099A0377 IN O
four P10205099A0377 CD O
parallel P10205099A0377 NN O
groups P10205099A0377 NNS O
to P10205099A0377 TO O
receive P10205099A0377 VB O
either P10205099A0377 DT O
terbinafine P10205099A0377 NN O
250 P10205099A0377 CD O
mg P10205099A0377 NN O
a P10205099A0377 DT O
day P10205099A0377 NN O
for P10205099A0377 IN O
12 P10205099A0377 CD O
or P10205099A0377 CC O
16 P10205099A0377 CD O
weeks P10205099A0377 NNS O
( P10205099A0377 ( O
groups P10205099A0377 NNS O
T12 P10205099A0377 NNP O
and P10205099A0377 CC O
T16 P10205099A0377 NNP O
) P10205099A0377 ) O
or P10205099A0377 CC O
itraconazole P10205099A0377 JJ O
400 P10205099A0377 CD O
mg P10205099A0377 NN O
a P10205099A0377 DT O
day P10205099A0377 NN O
for P10205099A0377 IN O
1 P10205099A0377 CD O
week P10205099A0377 NN O
in P10205099A0377 IN O
every P10205099A0377 DT O
4 P10205099A0377 CD O
weeks P10205099A0377 NNS O
for P10205099A0377 IN O
12 P10205099A0377 CD O
or P10205099A0377 CC O
16 P10205099A0377 CD O
weeks P10205099A0377 NNS O
( P10205099A0377 ( O
groups P10205099A0377 NNS O
I3 P10205099A0377 NNP O
and P10205099A0377 CC O
I4 P10205099A0377 NNP O
) P10205099A0377 ) O
. P10205099A0377 . O
. . O O

The P01394200A0592 DT O
treatment P01394200A0592 NN O
group P01394200A0592 NN O
also P01394200A0592 RB O
showed P01394200A0592 VBD O
in P01394200A0592 IN O
vivo P01394200A0592 JJ O
T-cell P01394200A0592 NNP O
activation P01394200A0592 NN O
with P01394200A0592 IN O
an P01394200A0592 DT O
initial P01394200A0592 JJ O
lymphopenia P01394200A0592 NN O
followed P01394200A0592 VBN O
by P01394200A0592 IN O
a P01394200A0592 DT O
rebound P01394200A0592 NN O
lymphocytosis P01394200A0592 NN O
and P01394200A0592 CC O
upregulation P01394200A0592 NN O
of P01394200A0592 IN O
the P01394200A0592 DT O
subset P01394200A0592 NN O
markers P01394200A0592 NNS O
CD25 P01394200A0592 NNP I-UN
( P01394200A0592 ( O
interleukin P01394200A0592 JJ I-UN
2 P01394200A0592 CD I-UN
receptor P01394200A0592 NN I-UN
) P01394200A0592 ) O
and P01394200A0592 CC O
CD45RO P01394200A0592 NNP I-UN
( P01394200A0592 ( O
T-memory P01394200A0592 NNP O
cells P01394200A0592 NNS O
) P01394200A0592 ) O
. P01394200A0592 . O
. . O O

The P03020001A0781 DT O
smallest P03020001A0781 JJS O
of P03020001A0781 IN O
the P03020001A0781 DT O
mini-Mu P03020001A0781 JJ O
elements P03020001A0781 NNS O
is P03020001A0781 VBZ O
only P03020001A0781 RB O
7.9 P03020001A0781 CD O
kilobase P03020001A0781 NN O
pairs P03020001A0781 NNS O
long P03020001A0781 RB O
, P03020001A0781 , O
allowing P03020001A0781 VBG O
the P03020001A0781 DT O
cloning P03020001A0781 NN O
of P03020001A0781 IN O
DNA P03020001A0781 NNP O
fragments P03020001A0781 NNS O
of P03020001A0781 IN O
up P03020001A0781 IN O
to P03020001A0781 TO O
31.1 P03020001A0781 CD O
kilobase P03020001A0781 NN O
pairs P03020001A0781 NNS O
, P03020001A0781 , O
and P03020001A0781 CC O
the P03020001A0781 DT O
largest P03020001A0781 JJS O
of P03020001A0781 IN O
them P03020001A0781 PRP O
is P03020001A0781 VBZ O
21.7 P03020001A0781 CD O
kilobase P03020001A0781 NN O
pairs P03020001A0781 NNS O
, P03020001A0781 , O
requiring P03020001A0781 VBG O
that P03020001A0781 IN O
clones P03020001A0781 NNS O
carry P03020001A0781 VBP O
insertions P03020001A0781 NNS O
of P03020001A0781 IN O
less P03020001A0781 JJR O
than P03020001A0781 IN O
17.3 P03020001A0781 CD O
kilobase P03020001A0781 NN O
pairs P03020001A0781 NNS O
. P03020001A0781 . O
. . O O

Transcription P07665172A0000 NN O
factors P07665172A0000 NNS O
containing P07665172A0000 VBG O
a P07665172A0000 DT O
basic P07665172A0000 JJ O
helix-loop-helix P07665172A0000 NN O
( P07665172A0000 ( O
bHLH P07665172A0000 NN O
) P07665172A0000 ) O
motif P07665172A0000 NN O
regulate P07665172A0000 VBP O
the P07665172A0000 DT O
expression P07665172A0000 NN O
of P07665172A0000 IN O
tissue-specific P07665172A0000 JJ O
genes P07665172A0000 NNS O
in P07665172A0000 IN O
a P07665172A0000 DT O
number P07665172A0000 NN O
of P07665172A0000 IN O
mammalian P07665172A0000 JJ O
and P07665172A0000 CC O
insect P07665172A0000 JJ O
systems P07665172A0000 NNS O
. P07665172A0000 . O
. . O O

Potscoital P01027644T0001 JJ O
test P01027644T0001 NN O
. P01027644T0001 . O
. . O O

Both P09239635A0477 DT O
of P09239635A0477 IN O
these P09239635A0477 DT O
dogs P09239635A0477 NNS O
had P09239635A0477 VBD O
low P09239635A0477 JJ O
serum P09239635A0477 NN O
IgG P09239635A0477 NNP I-UN
( P09239635A0477 ( O
3.5 P09239635A0477 CD O
to P09239635A0477 TO O
7.2 P09239635A0477 CD O
mg P09239635A0477 NNS O
/ P09239635A0477 NNP O
ml P09239635A0477 NN O
) P09239635A0477 ) O
and P09239635A0477 CC O
the P09239635A0477 DT O
second P09239635A0477 JJ O
littermate P09239635A0477 NN O
also P09239635A0477 RB O
had P09239635A0477 VBD O
reduced P09239635A0477 VBN O
serum P09239635A0477 JJ O
IgA P09239635A0477 NNP I-UN
( P09239635A0477 ( O
< P09239635A0477 $ O
0.1 P09239635A0477 CD O
to P09239635A0477 TO O
0.15 P09239635A0477 CD O
mg P09239635A0477 NNS O
/ P09239635A0477 NNP O
ml P09239635A0477 NN O
) P09239635A0477 ) O
. P09239635A0477 . O
. . O O

The P07854130A1387 DT O
requirement P07854130A1387 NN O
of P07854130A1387 IN O
PilE P07854130A1387 NNP I-UN
in P07854130A1387 IN O
pilus P07854130A1387 JJ O
biogenesis P07854130A1387 NN O
was P07854130A1387 VBD O
confirmed P07854130A1387 VBN O
by P07854130A1387 IN O
demonstrating P07854130A1387 VBG O
that P07854130A1387 IN O
chromosomal P07854130A1387 JJ I-UN
pilE P07854130A1387 NN I-UN
insertion P07854130A1387 NN I-UN
mutants P07854130A1387 NNS I-UN
were P07854130A1387 VBD O
pilus- P07854130A1387 JJ O
and P07854130A1387 CC O
twitching-motility P07854130A1387 JJ O
deficient P07854130A1387 NN O
. P07854130A1387 . O
. . O O

These P11158326A1032 DT O
effects P11158326A1032 NNS O
were P11158326A1032 VBD O
not P11158326A1032 RB O
seen P11158326A1032 VBN O
with P11158326A1032 IN O
SHIP2 P11158326A1032 NNP I-UN
possessing P11158326A1032 VBG O
a P11158326A1032 DT O
mutation P11158326A1032 NN O
in P11158326A1032 IN O
the P11158326A1032 DT O
SH2 P11158326A1032 NNP I-UN
domain P11158326A1032 NN I-UN
( P11158326A1032 ( O
R47G P11158326A1032 NNP I-UN
) P11158326A1032 ) O
. P11158326A1032 . O
. . O O

The P01725622A0292 DT O
first P01725622A0292 JJ O
transfusion P01725622A0292 NN O
resulted P01725622A0292 VBD O
in P01725622A0292 IN O
a P01725622A0292 DT O
platelet P01725622A0292 NN O
increment P01725622A0292 NN O
to P01725622A0292 TO O
32 P01725622A0292 CD O
Gpt P01725622A0292 NNP O
/ P01725622A0292 NNP O
l P01725622A0292 NN O
( P01725622A0292 ( O
CCI P01725622A0292 NNP O
11 P01725622A0292 CD O
) P01725622A0292 ) O
. P01725622A0292 . O
. . O O

Competition P09852005A1287 NN O
with P09852005A1287 IN O
a P09852005A1287 DT O
putative P09852005A1287 JJ O
MADS P09852005A1287 NNP I-UN
box P09852005A1287 NN I-UN
consensus P09852005A1287 NN O
binding P09852005A1287 VBG O
site P09852005A1287 NN O
from P09852005A1287 IN O
the P09852005A1287 DT O
promoter P09852005A1287 NN O
of P09852005A1287 IN O
the P09852005A1287 DT O
coordinately P09852005A1287 RB O
regulated P09852005A1287 VBN O
opaque-phase-specific P09852005A1287 JJ I-UN
gene P09852005A1287 NN I-UN
PEP1 P09852005A1287 NNP I-UN
( P09852005A1287 ( O
SAP1 P09852005A1287 NNP I-UN
) P09852005A1287 ) O
and P09852005A1287 CC O
the P09852005A1287 DT O
human P09852005A1287 JJ I-UN
MADS P09852005A1287 NNP I-UN
box P09852005A1287 NN I-UN
consensus P09852005A1287 NN I-UN
binding P09852005A1287 VBG I-UN
site P09852005A1287 NN I-UN
for P09852005A1287 IN O
serum P09852005A1287 JJ I-UN
response P09852005A1287 NN I-UN
factor P09852005A1287 NN I-UN
demonstrated P09852005A1287 VBD O
that P09852005A1287 IN O
one P09852005A1287 CD O
of P09852005A1287 IN O
the P09852005A1287 DT O
three P09852005A1287 CD O
complexes P09852005A1287 NNS O
formed P09852005A1287 VBN O
was P09852005A1287 VBD O
specific P09852005A1287 JJ O
to P09852005A1287 TO O
the P09852005A1287 DT O
OP4 P09852005A1287 NNP I-UN
sequence P09852005A1287 NN I-UN
. P09852005A1287 . O
. . O O

Histochemistry P05839844T0000 NN O
and P05839844T0000 CC O
electron P05839844T0000 NN O
microscopy P05839844T0000 NN O
of P05839844T0000 IN O
acute P05839844T0000 JJ O
liver P05839844T0000 NN O
lesions P05839844T0000 NNS O
induced P05839844T0000 VBN O
by P05839844T0000 IN O
Aflatoxin P05839844T0000 NNP O
B1 P05839844T0000 NNP O
in P05839844T0000 IN O
ducklings P05839844T0000 NNS O
. P05839844T0000 . O
. . O O

Some P09784192A1027 DT O
of P09784192A1027 IN O
the P09784192A1027 DT O
peptide P09784192A1027 NN I-UN
: P09784192A1027 : I-UN
MBP P09784192A1027 JJ I-UN
fusions P09784192A1027 NNS I-UN
were P09784192A1027 VBD O
also P09784192A1027 RB O
analyzed P09784192A1027 VBN O
using P09784192A1027 VBG O
surface P09784192A1027 NN O
plasmon P09784192A1027 NN O
resonance P09784192A1027 NN O
. P09784192A1027 . O
. . O O

The P10378989A0000 DT O
aim P10378989A0000 NN O
of P10378989A0000 IN O
this P10378989A0000 DT O
study P10378989A0000 NN O
was P10378989A0000 VBD O
to P10378989A0000 TO O
investigate P10378989A0000 VB O
the P10378989A0000 DT O
spontaneous P10378989A0000 JJ O
reports P10378989A0000 NNS O
of P10378989A0000 IN O
suspected P10378989A0000 JJ O
adverse P10378989A0000 JJ O
drug P10378989A0000 NN O
reactions P10378989A0000 NNS O
, P10378989A0000 , O
observed P10378989A0000 VBN O
in P10378989A0000 IN O
elderly P10378989A0000 JJ O
patients P10378989A0000 NNS O
( P10378989A0000 ( O
over P10378989A0000 IN O
65 P10378989A0000 CD O
years P10378989A0000 NNS O
of P10378989A0000 IN O
age P10378989A0000 NN O
) P10378989A0000 ) O
in P10378989A0000 IN O
Sicily P10378989A0000 NNP O
( P10378989A0000 ( O
Italy P10378989A0000 NNP O
) P10378989A0000 ) O
during P10378989A0000 IN O
the P10378989A0000 DT O
period P10378989A0000 NN O
from P10378989A0000 IN O
1 P10378989A0000 CD O
January P10378989A0000 NNP O
1995 P10378989A0000 CD O
to P10378989A0000 TO O
31 P10378989A0000 CD O
December P10378989A0000 NNP O
1997 P10378989A0000 CD O
. P10378989A0000 . O
. . O O

Expression P09792702A0754 NN O
of P09792702A0754 IN O
a P09792702A0754 DT O
dominant-negative P09792702A0754 JJ O
mutant P09792702A0754 NN O
of P09792702A0754 IN O
JNK1 P09792702A0754 NNP I-UN
also P09792702A0754 RB O
suppressed P09792702A0754 VBD O
glucose P09792702A0754 JJ O
deprivation-induced P09792702A0754 JJ O
JNK1 P09792702A0754 NNP I-UN
activation P09792702A0754 NN O
as P09792702A0754 RB O
well P09792702A0754 RB O
as P09792702A0754 IN O
HSP70 P09792702A0754 NNP I-UN
gene P09792702A0754 NN I-UN
expression P09792702A0754 NN O
. P09792702A0754 . O
. . O O

We P03649340A1119 PRP O
conclude P03649340A1119 VBP O
that P03649340A1119 DT O
for P03649340A1119 IN O
mono-intronic P03649340A1119 JJ O
precursors P03649340A1119 NNS O
in P03649340A1119 IN O
which P03649340A1119 WDT O
there P03649340A1119 EX O
is P03649340A1119 VBZ O
only P03649340A1119 RB O
one P03649340A1119 CD O
choice P03649340A1119 NN O
of P03649340A1119 IN O
splice P03649340A1119 NN O
sites P03649340A1119 NNS O
, P03649340A1119 , O
most P03649340A1119 JJS O
of P03649340A1119 IN O
the P03649340A1119 DT O
exon P03649340A1119 NN O
sequences P03649340A1119 NNS O
are P03649340A1119 VBP O
not P03649340A1119 RB O
mechanistically P03649340A1119 RB O
involved P03649340A1119 VBN O
in P03649340A1119 IN O
the P03649340A1119 DT O
splicing P03649340A1119 NN O
process P03649340A1119 NN O
. P03649340A1119 . O
. . O O

Reverse P09701616A0108 JJ I-UN
transcriptase-polymerase P09701616A0108 NN O
chain P09701616A0108 NN O
reaction P09701616A0108 NN O
( P09701616A0108 ( O
RT-PCR P09701616A0108 NNP O
) P09701616A0108 ) O
was P09701616A0108 VBD O
performed P09701616A0108 VBN O
using P09701616A0108 VBG O
eyestalk P09701616A0108 NN O
complementary P09701616A0108 JJ O
DNA P09701616A0108 NN O
of P09701616A0108 IN O
the P09701616A0108 DT O
sand P09701616A0108 NN O
shrimp P09701616A0108 NN O
Metapenaeus P09701616A0108 NNP O
ensis P09701616A0108 NN O
. P09701616A0108 . O
. . O O

USA P06328504A0161 NNP O
80 P06328504A0161 CD O
, P06328504A0161 , O
802-806 P06328504A0161 JJ O
] P06328504A0161 NN O
was P06328504A0161 VBD O
used P06328504A0161 VBN O
to P06328504A0161 TO O
isolate P06328504A0161 VB O
a P06328504A0161 DT O
genomic P06328504A0161 JJ O
clone P06328504A0161 NN O
lambda P06328504A0161 VBD O
PGK-1 P06328504A0161 NNP I-UN
containing P06328504A0161 VBG O
a P06328504A0161 DT O
portion P06328504A0161 NN O
of P06328504A0161 IN O
an P06328504A0161 DT O
autosomal P06328504A0161 JJ O
locus P06328504A0161 NN O
for P06328504A0161 IN O
phosphoglycerate P06328504A0161 JJ I-UN
kinase P06328504A0161 NN I-UN
( P06328504A0161 ( O
PGK P06328504A0161 NNP I-UN
) P06328504A0161 ) O
. P06328504A0161 . O
. . O O

The P08119958A0273 DT O
lack P08119958A0273 NN O
of P08119958A0273 IN O
the P08119958A0273 DT O
C2 P08119958A0273 NNP I-UN
domain P08119958A0273 NN O
of P08119958A0273 IN O
the P08119958A0273 DT O
Ca P08119958A0273 NNP I-UN
( P08119958A0273 ( I-UN
2+ P08119958A0273 CD I-UN
) P08119958A0273 ) I-UN
-dependent P08119958A0273 NN I-UN
PKCs P08119958A0273 NNP I-UN
and P08119958A0273 CC O
the P08119958A0273 DT O
presence P08119958A0273 NN O
of P08119958A0273 IN O
a P08119958A0273 DT O
unique P08119958A0273 JJ O
NH2-terminal P08119958A0273 JJ O
sequence P08119958A0273 NN O
with P08119958A0273 IN O
a P08119958A0273 DT O
potential P08119958A0273 JJ O
signal P08119958A0273 NN O
peptide P08119958A0273 NN O
and P08119958A0273 CC O
a P08119958A0273 DT O
transmembrane P08119958A0273 NN O
domain P08119958A0273 NN O
suggest P08119958A0273 VBP O
that P08119958A0273 IN O
PKC P08119958A0273 NNP I-UN
mu P08119958A0273 NN I-UN
is P08119958A0273 VBZ O
a P08119958A0273 DT O
novel P08119958A0273 JJ O
member P08119958A0273 NN O
of P08119958A0273 IN O
the P08119958A0273 DT O
subgroup P08119958A0273 NN O
of P08119958A0273 IN O
atypical P08119958A0273 JJ O
PKCs P08119958A0273 NNP I-UN
. P08119958A0273 . O
. . O O

In P02347655A0193 IN O
the P02347655A0193 DT O
artificial P02347655A0193 JJ O
lung P02347655A0193 NN O
, P02347655A0193 , O
like P02347655A0193 IN O
in P02347655A0193 IN O
the P02347655A0193 DT O
natural P02347655A0193 JJ O
lung P02347655A0193 NN O
and P02347655A0193 CC O
peripheral P02347655A0193 JJ O
tissues P02347655A0193 NNS O
, P02347655A0193 , O
gas P02347655A0193 NN O
exchanges P02347655A0193 NNS O
depend P02347655A0193 VBP O
on P02347655A0193 IN O
several P02347655A0193 JJ O
parameters P02347655A0193 NNS O
: P02347655A0193 : O
blood P02347655A0193 NN O
inlet P02347655A0193 NN O
conditions P02347655A0193 NNS O
, P02347655A0193 , O
blood P02347655A0193 NN O
flow P02347655A0193 NN O
rate P02347655A0193 NN O
, P02347655A0193 , O
temperature P02347655A0193 NN O
, P02347655A0193 , O
composition P02347655A0193 NN O
of P02347655A0193 IN O
the P02347655A0193 DT O
gas P02347655A0193 NN O
mixture P02347655A0193 NN O
used P02347655A0193 VBN O
for P02347655A0193 IN O
ventilation P02347655A0193 NN O
, P02347655A0193 , O
blood P02347655A0193 NN O
tissue P02347655A0193 NN O
perfusion P02347655A0193 NN O
, P02347655A0193 , O
O2 P02347655A0193 NNP O
consumption P02347655A0193 NN O
, P02347655A0193 , O
etc P02347655A0193 FW O
. P02347655A0193 . O
. . O O

The P08573637A0434 DT O
method P08573637A0434 NN O
has P08573637A0434 VBZ O
been P08573637A0434 VBN O
satisfactorily P08573637A0434 RB O
applied P08573637A0434 VBN O
to P08573637A0434 TO O
the P08573637A0434 DT O
determination P08573637A0434 NN O
of P08573637A0434 IN O
paracetamol P08573637A0434 NN O
in P08573637A0434 IN O
pharmaceutical P08573637A0434 JJ O
formulations P08573637A0434 NNS O
and P08573637A0434 CC O
biological P08573637A0434 JJ O
fluids P08573637A0434 NNS O
. P08573637A0434 . O
. . O O

At P08660866A0504 IN O
cuticular P08660866A0504 JJ O
positions P08660866A0504 NNS O
exhibiting P08660866A0504 VBG O
the P08660866A0504 DT O
Brd P08660866A0504 NNP I-UN
bristle P08660866A0504 JJ I-UN
loss P08660866A0504 NN I-UN
phenotype P08660866A0504 NN I-UN
, P08660866A0504 , O
we P08660866A0504 PRP O
have P08660866A0504 VBP O
found P08660866A0504 VBN O
that P08660866A0504 IN O
the P08660866A0504 DT O
progeny P08660866A0504 NN O
of P08660866A0504 IN O
the P08660866A0504 DT O
multiplied P08660866A0504 JJ O
SOPs P08660866A0504 NNP O
develop P08660866A0504 NN O
aberrantly P08660866A0504 RB O
, P08660866A0504 , O
in P08660866A0504 IN O
that P08660866A0504 DT O
neurons P08660866A0504 NNS O
and P08660866A0504 CC O
thecogen P08660866A0504 NN O
( P08660866A0504 ( O
sheath P08660866A0504 NN O
) P08660866A0504 ) O
cells P08660866A0504 NNS O
appear P08660866A0504 VBP O
but P08660866A0504 CC O
not P08660866A0504 RB O
trichogen P08660866A0504 NN O
( P08660866A0504 ( O
shaft P08660866A0504 NN O
) P08660866A0504 ) O
and P08660866A0504 CC O
tormogen P08660866A0504 NN O
( P08660866A0504 ( O
socket P08660866A0504 NN O
) P08660866A0504 ) O
cells P08660866A0504 NNS O
. P08660866A0504 . O
. . O O

Atorvastatin P10907971A0806 NNP O
was P10907971A0806 VBD O
the P10907971A0806 DT O
most P10907971A0806 RBS O
cost-effective P10907971A0806 JJ O
HMG-CoA P10907971A0806 JJ I-UN
reductase P10907971A0806 NN I-UN
inhibitor P10907971A0806 NN O
. P10907971A0806 . O
. . O O

Stat P10810294A0730 NNP I-UN
activation P10810294A0730 NN O
in P10810294A0730 IN O
response P10810294A0730 NN O
to P10810294A0730 TO O
GH P10810294A0730 NNP I-UN
and P10810294A0730 CC O
IL-6 P10810294A0730 NNP I-UN
was P10810294A0730 VBD O
determined P10810294A0730 VBN O
by P10810294A0730 IN O
reporter P10810294A0730 NN O
gene P10810294A0730 NN O
induction P10810294A0730 NN O
. P10810294A0730 . O
. . O O

Zhu P11462024A0306 NNP O
, P11462024A0306 , O
V P11462024A0306 NNP O
. P11462024A0306 . O
. . O O

Badcock P09749988A0000 NNP O
and P09749988A0000 CC O
Westheimer P09749988A0000 NNP O
( P09749988A0000 ( O
Spatial P09749988A0000 NNP O
Vision P09749988A0000 NNP O
1 P09749988A0000 CD O
( P09749988A0000 ( O
1 P09749988A0000 CD O
) P09749988A0000 ) O
, P09749988A0000 , O
3-11 P09749988A0000 CD O
, P09749988A0000 , O
1985 P09749988A0000 CD O
) P09749988A0000 ) O
showed P09749988A0000 VBD O
that P09749988A0000 IN O
a P09749988A0000 DT O
thin P09749988A0000 JJ O
vertical P09749988A0000 JJ O
line P09749988A0000 NN O
induces P09749988A0000 NNS O
nearby P09749988A0000 JJ O
zones P09749988A0000 NNS O
of P09749988A0000 IN O
attraction P09749988A0000 NN O
and P09749988A0000 CC O
repulsion P09749988A0000 NN O
; P09749988A0000 : O
this P09749988A0000 DT O
study P09749988A0000 NN O
extends P09749988A0000 VBZ O
those P09749988A0000 DT O
results P09749988A0000 NNS O
by P09749988A0000 IN O
more P09749988A0000 RBR O
closely P09749988A0000 RB O
examining P09749988A0000 VBG O
the P09749988A0000 DT O
horizontal P09749988A0000 NN O
and P09749988A0000 CC O
vertical P09749988A0000 JJ O
extents P09749988A0000 NNS O
of P09749988A0000 IN O
the P09749988A0000 DT O
repulsion P09749988A0000 NN O
zone P09749988A0000 NN O
and P09749988A0000 CC O
by P09749988A0000 IN O
using P09749988A0000 VBG O
an P09749988A0000 DT O
illusory P09749988A0000 JJ O
contour P09749988A0000 NN O
to P09749988A0000 TO O
induce P09749988A0000 VB O
repulsion P09749988A0000 NN O
. P09749988A0000 . O
. . O O

OBJECTIVE P10845522A0000 NN O
: P10845522A0000 : O
This P10845522A0000 DT O
study P10845522A0000 NN O
was P10845522A0000 VBD O
conducted P10845522A0000 VBN O
to P10845522A0000 TO O
assess P10845522A0000 VB O
the P10845522A0000 DT O
relative P10845522A0000 JJ O
roles P10845522A0000 NNS O
of P10845522A0000 IN O
99mTc-sestamibi P10845522A0000 JJ O
scintimammography P10845522A0000 NN O
and P10845522A0000 CC O
sonography P10845522A0000 NN O
in P10845522A0000 IN O
the P10845522A0000 DT O
evaluation P10845522A0000 NN O
of P10845522A0000 IN O
breast P10845522A0000 NN O
lesions P10845522A0000 NNS O
that P10845522A0000 WDT O
are P10845522A0000 VBP O
indeterminate P10845522A0000 JJ O
or P10845522A0000 CC O
suspicious P10845522A0000 JJ O
on P10845522A0000 IN O
mammography P10845522A0000 NN O
or P10845522A0000 CC O
clinical P10845522A0000 JJ O
examination P10845522A0000 NN O
. P10845522A0000 . O
. . O O

Proteins P10026211A0136 NNS O
known P10026211A0136 VBN O
to P10026211A0136 TO O
bind P10026211A0136 VB O
the P10026211A0136 DT O
PEPCK P10026211A0136 NNP I-UN
CRE P10026211A0136 NNP O
include P10026211A0136 VBP O
the P10026211A0136 DT O
CRE-binding P10026211A0136 JJ I-UN
protein P10026211A0136 NN I-UN
( P10026211A0136 ( O
CREB P10026211A0136 NNP I-UN
) P10026211A0136 ) O
and P10026211A0136 CC O
members P10026211A0136 NNS O
of P10026211A0136 IN O
the P10026211A0136 DT O
CCAAT P10026211A0136 NNP I-UN
/ P10026211A0136 NNP I-UN
enhancer-binding P10026211A0136 JJ I-UN
protein P10026211A0136 NN I-UN
( P10026211A0136 ( O
C P10026211A0136 NNP I-UN
/ P10026211A0136 NNP I-UN
EBP P10026211A0136 NNP I-UN
) P10026211A0136 ) O
family P10026211A0136 NN O
. P10026211A0136 . O
. . O O

Ninety-four P08913974A0533 JJ O
percent P08913974A0533 NN O
of P08913974A0533 IN O
the P08913974A0533 DT O
EPs P08913974A0533 NNP O
were P08913974A0533 VBD O
tubal P08913974A0533 JJ O
, P08913974A0533 , O
and P08913974A0533 CC O
90 P08913974A0533 CD O
% P08913974A0533 NN O
of P08913974A0533 IN O
the P08913974A0533 DT O
tubes P08913974A0533 NNS O
exhibited P08913974A0533 VBD O
some P08913974A0533 DT O
pathologic P08913974A0533 JJ O
changes P08913974A0533 NNS O
, P08913974A0533 , O
including P08913974A0533 VBG O
chronic P08913974A0533 JJ O
salpingitis P08913974A0533 NN O
( P08913974A0533 ( O
49.5 P08913974A0533 CD O
% P08913974A0533 NN O
) P08913974A0533 ) O
and P08913974A0533 CC O
follicular P08913974A0533 JJ O
salpingitis P08913974A0533 NN O
( P08913974A0533 ( O
10 P08913974A0533 CD O
% P08913974A0533 NN O
) P08913974A0533 ) O
, P08913974A0533 , O
among P08913974A0533 IN O
others P08913974A0533 NNS O
. P08913974A0533 . O
. . O O

The P06098828A0352 DT O
results P06098828A0352 NNS O
presented P06098828A0352 VBN O
in P06098828A0352 IN O
this P06098828A0352 DT O
report P06098828A0352 NN O
suggest P06098828A0352 VBP O
that P06098828A0352 IN O
the P06098828A0352 DT O
SV40 P06098828A0352 NNP O
G-C-rich P06098828A0352 NNP O
sequences P06098828A0352 NNS O
can P06098828A0352 MD O
function P06098828A0352 VB O
as P06098828A0352 IN O
independent P06098828A0352 JJ O
RNA P06098828A0352 NNP I-UN
polymerase P06098828A0352 NN I-UN
II P06098828A0352 NNP I-UN
transcriptional-control P06098828A0352 NN O
elements P06098828A0352 NNS O
. P06098828A0352 . O
. . O O

BACKGROUND P11454190A0000 NNP O
/ P11454190A0000 NNP O
AIMS P11454190A0000 NNP O
: P11454190A0000 : O
Hepatitis P11454190A0000 NNP O
C P11454190A0000 NNP O
and P11454190A0000 CC O
nonalcoholic P11454190A0000 JJ O
fatty P11454190A0000 NN O
liver P11454190A0000 NN O
disease P11454190A0000 NN O
( P11454190A0000 ( O
NAFL P11454190A0000 NNP O
) P11454190A0000 ) O
are P11454190A0000 VBP O
the P11454190A0000 DT O
two P11454190A0000 CD O
most P11454190A0000 JJS O
common P11454190A0000 JJ O
forms P11454190A0000 NNS O
of P11454190A0000 IN O
liver P11454190A0000 JJ O
disease P11454190A0000 NN O
in P11454190A0000 IN O
the P11454190A0000 DT O
United P11454190A0000 NNP O
States P11454190A0000 NNPS O
. P11454190A0000 . O
. . O O

A P09064868T0001 DT O
miracle P09064868T0001 NN O
cure P09064868T0001 NN O
and P09064868T0001 CC O
its P09064868T0001 PRP$ O
solution P09064868T0001 NN O
. P09064868T0001 . O
. . O O

Morphological P07234974T0000 JJ O
features P07234974T0000 NNS O
of P07234974T0000 IN O
Jat P07234974T0000 NNP O
dentition P07234974T0000 NN O
. P07234974T0000 . O
. . O O

In P08202546A1206 IN O
addition P08202546A1206 NN O
, P08202546A1206 , O
we P08202546A1206 PRP O
observe P08202546A1206 VBP O
that P08202546A1206 IN O
the P08202546A1206 DT O
hUBF-promoter P08202546A1206 JJ I-UN
interaction P08202546A1206 NN O
is P08202546A1206 VBZ O
highly P08202546A1206 RB O
sensitive P08202546A1206 JJ O
to P08202546A1206 TO O
the P08202546A1206 DT O
antagonistic P08202546A1206 JJ O
effects P08202546A1206 NNS O
of P08202546A1206 IN O
cisplatin-DNA P08202546A1206 JJ O
adducts P08202546A1206 NNS O
. P08202546A1206 . O
. . O O

It P03709191A0125 PRP O
was P03709191A0125 VBD O
found P03709191A0125 VBN O
that P03709191A0125 IN O
the P03709191A0125 DT O
primary P03709191A0125 JJ O
visual P03709191A0125 JJ O
cortex P03709191A0125 NN O
of P03709191A0125 IN O
the P03709191A0125 DT O
rat P03709191A0125 NN O
is P03709191A0125 VBZ O
asymmetrical P03709191A0125 JJ O
in P03709191A0125 IN O
volume P03709191A0125 NN O
, P03709191A0125 , O
and P03709191A0125 CC O
that P03709191A0125 IN O
the P03709191A0125 DT O
asymmetry P03709191A0125 NN O
reflects P03709191A0125 VBZ O
side P03709191A0125 JJ O
differences P03709191A0125 NNS O
in P03709191A0125 IN O
the P03709191A0125 DT O
number P03709191A0125 NN O
of P03709191A0125 IN O
neurons P03709191A0125 NNS O
. P03709191A0125 . O
. . O O

Infect P07966580A0518 NNP O
. P07966580A0518 . O
. . O O

Umweltchem P08521780A0485 NNP O
. P08521780A0485 . O
. . O O

Retinoid-dependent P08626785A0674 JJ O
activation P08626785A0674 NN O
of P08626785A0674 IN O
the P08626785A0674 DT O
tissue P08626785A0674 NN I-UN
transglutaminase P08626785A0674 NN I-UN
promoter P08626785A0674 NN I-UN
depends P08626785A0674 VBZ O
on P08626785A0674 IN O
both P08626785A0674 DT O
a P08626785A0674 DT O
proximal P08626785A0674 JJ O
regulatory P08626785A0674 JJ O
region P08626785A0674 NN O
containing P08626785A0674 VBG O
sequences P08626785A0674 NNS O
highly P08626785A0674 RB O
conserved P08626785A0674 VBD O
between P08626785A0674 IN O
the P08626785A0674 DT O
human P08626785A0674 JJ O
and P08626785A0674 CC O
the P08626785A0674 DT O
mouse P08626785A0674 NN I-UN
tissue P08626785A0674 NN I-UN
transglutaminase P08626785A0674 NN I-UN
promoters P08626785A0674 NNS I-UN
and P08626785A0674 CC O
a P08626785A0674 DT O
distal P08626785A0674 JJ O
region P08626785A0674 NN O
that P08626785A0674 WDT O
includes P08626785A0674 VBZ O
a P08626785A0674 DT O
30-base P08626785A0674 JJ O
pair P08626785A0674 NN O
retinoid P08626785A0674 JJ O
response P08626785A0674 NN O
element P08626785A0674 NN O
( P08626785A0674 ( O
mTGRRE1 P08626785A0674 NN O
) P08626785A0674 ) O
. P08626785A0674 . O
mTGRRE1 P08626785A0674 NN O
contains P08626785A0674 NNS O
three P08626785A0674 CD O
hexanucleotide P08626785A0674 IN O
half-sites P08626785A0674 NNS O
( P08626785A0674 ( O
two P08626785A0674 CD O
canonical P08626785A0674 NN O
and P08626785A0674 CC O
one P08626785A0674 CD O
non-canonical P08626785A0674 JJ O
) P08626785A0674 ) O
in P08626785A0674 IN O
a P08626785A0674 DT O
DR7 P08626785A0674 NNP I-UN
/ P08626785A0674 NNP O
DR5 P08626785A0674 NNP I-UN
motif P08626785A0674 NN O
that P08626785A0674 WDT O
bind P08626785A0674 VBZ O
both P08626785A0674 DT O
RAR*RXR P08626785A0674 NNP O
heterodimers P08626785A0674 NNS O
and P08626785A0674 CC O
RXR P08626785A0674 NNP I-UN
homodimers P08626785A0674 NNS I-UN
. P08626785A0674 . O
. . O O

The P09580563A0331 DT O
predicted P09580563A0331 VBN O
amino P09580563A0331 NN O
acid P09580563A0331 NN O
sequence P09580563A0331 NN O
is P09580563A0331 VBZ O
78.0 P09580563A0331 CD O
% P09580563A0331 NN O
identical P09580563A0331 JJ O
to P09580563A0331 TO O
the P09580563A0331 DT O
cytoplasmic P09580563A0331 JJ I-UN
dynein P09580563A0331 NN I-UN
heavy P09580563A0331 JJ I-UN
chain P09580563A0331 NN I-UN
of P09580563A0331 IN I-UN
Neurospora P09580563A0331 NNP I-UN
crassa P09580563A0331 NN I-UN
, P09580563A0331 , O
70.2 P09580563A0331 CD O
% P09580563A0331 NN O
identical P09580563A0331 JJ O
to P09580563A0331 TO O
that P09580563A0331 DT O
of P09580563A0331 IN O
Aspergillus P09580563A0331 NNP O
nidulans P09580563A0331 NNS O
and P09580563A0331 CC O
24.8 P09580563A0331 CD O
% P09580563A0331 NN O
identical P09580563A0331 JJ O
to P09580563A0331 TO O
that P09580563A0331 DT O
of P09580563A0331 IN O
Saccharomyces P09580563A0331 NNP O
cerevisiae P09580563A0331 NN O
. P09580563A0331 . O
. . O O

The P08063108A0109 DT O
acfD P08063108A0109 JJ I-UN
gene P08063108A0109 NN I-UN
encompasses P08063108A0109 VBZ O
254 P08063108A0109 CD O
nt P08063108A0109 NN O
that P08063108A0109 WDT O
are P08063108A0109 VBP O
predicted P08063108A0109 VBN O
to P08063108A0109 TO O
encode P08063108A0109 VB O
an P08063108A0109 DT O
88-amino-acid P08063108A0109 JJ O
( P08063108A0109 ( O
aa P08063108A0109 NN O
) P08063108A0109 ) O
protein P08063108A0109 NN O
. P08063108A0109 . O
. . O O

Pregnant P03420324A0178 JJ O
rats P03420324A0178 NNS O
were P03420324A0178 VBD O
exposed P03420324A0178 VBN O
to P03420324A0178 TO O
one P03420324A0178 CD O
of P03420324A0178 IN O
the P03420324A0178 DT O
following P03420324A0178 NN O
: P03420324A0178 : O
( P03420324A0178 ( O
1 P03420324A0178 CD O
) P03420324A0178 ) O
10 P03420324A0178 CD O
% P03420324A0178 NN O
O2 P03420324A0178 NNP O
in P03420324A0178 IN O
N2 P03420324A0178 NNP O
or P03420324A0178 CC O
100 P03420324A0178 CD O
% P03420324A0178 NN O
O2 P03420324A0178 NNP O
for P03420324A0178 IN O
2 P03420324A0178 CD O
days P03420324A0178 NNS O
beginning P03420324A0178 VBG O
at P03420324A0178 IN O
day P03420324A0178 NN O
7 P03420324A0178 CD O
, P03420324A0178 , O
11 P03420324A0178 CD O
, P03420324A0178 , O
14 P03420324A0178 CD O
, P03420324A0178 , O
or P03420324A0178 CC O
18 P03420324A0178 CD O
of P03420324A0178 IN O
pregnancy P03420324A0178 NN O
; P03420324A0178 : O
( P03420324A0178 ( O
2 P03420324A0178 CD O
) P03420324A0178 ) O
10 P03420324A0178 CD O
% P03420324A0178 NN O
O2 P03420324A0178 NNP O
in P03420324A0178 IN O
N2 P03420324A0178 NNP O
or P03420324A0178 CC O
100 P03420324A0178 CD O
% P03420324A0178 NN O
O2 P03420324A0178 NNP O
for P03420324A0178 IN O
10 P03420324A0178 CD O
h P03420324A0178 JJ O
/ P03420324A0178 JJ O
day P03420324A0178 NN O
beginning P03420324A0178 VBG O
at P03420324A0178 IN O
day P03420324A0178 NN O
7 P03420324A0178 CD O
; P03420324A0178 : O
or P03420324A0178 CC O
( P03420324A0178 ( O
3 P03420324A0178 CD O
) P03420324A0178 ) O
14-11 P03420324A0178 CD O
% P03420324A0178 NN O
O2 P03420324A0178 NNP O
in P03420324A0178 IN O
N2 P03420324A0178 NNP O
continuously P03420324A0178 RB O
beginning P03420324A0178 VBG O
at P03420324A0178 IN O
day P03420324A0178 NN O
14 P03420324A0178 CD O
till P03420324A0178 NN O
day P03420324A0178 NN O
21 P03420324A0178 CD O
when P03420324A0178 WRB O
they P03420324A0178 PRP O
were P03420324A0178 VBD O
sacrificed P03420324A0178 VBN O
. P03420324A0178 . O
. . O O

To P02052592A0000 TO O
determine P02052592A0000 VB O
whether P02052592A0000 IN O
mononuclear P02052592A0000 JJ O
cell P02052592A0000 NN O
secretory P02052592A0000 NN O
products P02052592A0000 NNS O
contribute P02052592A0000 VBP O
to P02052592A0000 TO O
the P02052592A0000 DT O
changes P02052592A0000 NNS O
in P02052592A0000 IN O
bone P02052592A0000 NN O
turnover P02052592A0000 NN O
that P02052592A0000 WDT O
characterize P02052592A0000 VBZ O
the P02052592A0000 DT O
development P02052592A0000 NN O
of P02052592A0000 IN O
postmenopausal P02052592A0000 NN O
osteoporosis P02052592A0000 NN O
, P02052592A0000 , O
we P02052592A0000 PRP O
evaluated P02052592A0000 VBD O
the P02052592A0000 DT O
effects P02052592A0000 NNS O
of P02052592A0000 IN O
oophorectomy P02052592A0000 NN O
and P02052592A0000 CC O
subsequent P02052592A0000 JJ O
estrogen P02052592A0000 NN O
replacement P02052592A0000 NN O
on P02052592A0000 IN O
the P02052592A0000 DT O
spontaneous P02052592A0000 JJ O
secretion P02052592A0000 NN O
of P02052592A0000 IN O
interleukin P02052592A0000 JJ I-UN
1 P02052592A0000 CD I-UN
( P02052592A0000 ( O
IL-1 P02052592A0000 NNP I-UN
) P02052592A0000 ) O
and P02052592A0000 CC O
tumor P02052592A0000 JJ I-UN
necrosis P02052592A0000 NN I-UN
factor P02052592A0000 NN I-UN
alpha P02052592A0000 NN I-UN
( P02052592A0000 ( O
TNF-alpha P02052592A0000 NNP I-UN
) P02052592A0000 ) O
and P02052592A0000 CC O
on P02052592A0000 IN O
the P02052592A0000 DT O
phytohemagglutinin P02052592A0000 NN I-UN
A-induced P02052592A0000 NNP O
secretion P02052592A0000 NN O
of P02052592A0000 IN O
granulocyte-macrophage P02052592A0000 JJ I-UN
colony-stimulating P02052592A0000 JJ I-UN
factor P02052592A0000 NN I-UN
( P02052592A0000 ( O
GM-CSF P02052592A0000 NNP I-UN
) P02052592A0000 ) O
from P02052592A0000 IN O
peripheral P02052592A0000 JJ O
blood P02052592A0000 NN O
mononuclear P02052592A0000 NN O
cells P02052592A0000 NNS O
. P02052592A0000 . O
. . O O

To P11169113A0555 TO O
study P11169113A0555 VB O
the P11169113A0555 DT O
in P11169113A0555 IN O
vivo P11169113A0555 JJ O
role P11169113A0555 NN O
of P11169113A0555 IN O
p16.7 P11169113A0555 NN I-UN
, P11169113A0555 , O
a P11169113A0555 DT O
phi29 P11169113A0555 NN O
mutant P11169113A0555 NN O
containing P11169113A0555 VBG O
a P11169113A0555 DT O
suppressible P11169113A0555 JJ O
mutation P11169113A0555 NN O
in P11169113A0555 IN O
gene P11169113A0555 NN I-UN
16.7 P11169113A0555 CD I-UN
was P11169113A0555 VBD O
constructed P11169113A0555 VBN O
. P11169113A0555 . O
. . O O

Judge P10119827T0000 NNP O
OKs P10119827T0000 NNP O
docs P10119827T0000 NN O
' P10119827T0000 '' O
bid P10119827T0000 NN O
for P10119827T0000 IN O
Chicago P10119827T0000 NNP O
hospital P10119827T0000 NN O
. P10119827T0000 . O
. . O O

Acetoin P11274109A0129 NNP O
can P11274109A0129 MD O
be P11274109A0129 VB O
reused P11274109A0129 VBN O
by P11274109A0129 IN O
the P11274109A0129 DT O
bacteria P11274109A0129 NNS O
during P11274109A0129 IN O
stationary P11274109A0129 JJ O
phase P11274109A0129 NN O
when P11274109A0129 WRB O
other P11274109A0129 JJ O
carbon P11274109A0129 NN O
sources P11274109A0129 NNS O
have P11274109A0129 VBP O
been P11274109A0129 VBN O
depleted P11274109A0129 VBN O
. P11274109A0129 . O
. . O O

Natural P04392584T0000 NNP O
and P04392584T0000 CC O
induced P04392584T0000 VBD O
malarias P04392584T0000 NNS O
in P04392584T0000 IN O
western P04392584T0000 JJ O
hemisphere P04392584T0000 JJ O
monkeys P04392584T0000 NNS O
. P04392584T0000 . O
. . O O

SELECTION P10908478A0717 NNP O
CRITERIA P10908478A0717 NNP O
: P10908478A0717 : O
All P10908478A0717 DT O
controlled P10908478A0717 VBN O
trials P10908478A0717 NNS O
where P10908478A0717 WRB O
adults P10908478A0717 NNS O
with P10908478A0717 IN O
schizophrenia P10908478A0717 NN O
or P10908478A0717 CC O
similar P10908478A0717 JJ O
illnesses P10908478A0717 NNS O
were P10908478A0717 VBD O
randomised P10908478A0717 VBN O
to P10908478A0717 TO O
quetiapine P10908478A0717 VB O
, P10908478A0717 , O
placebo P10908478A0717 NN O
or P10908478A0717 CC O
other P10908478A0717 JJ O
neuroleptic P10908478A0717 JJ O
drugs P10908478A0717 NNS O
and P10908478A0717 CC O
where P10908478A0717 WRB O
clinically P10908478A0717 RB O
relevant P10908478A0717 JJ O
outcomes P10908478A0717 NNS O
were P10908478A0717 VBD O
reported P10908478A0717 VBN O
. P10908478A0717 . O
. . O O

Histochemical P08443339A1374 JJ O
localization P08443339A1374 NN O
of P08443339A1374 IN O
GUS P08443339A1374 NNP I-UN
revealed P08443339A1374 VBD O
promoter P08443339A1374 NN O
function P08443339A1374 NN O
in P08443339A1374 IN O
leaf P08443339A1374 NN O
epidermis P08443339A1374 NN O
, P08443339A1374 , O
mesophyll P08443339A1374 NN O
and P08443339A1374 CC O
vascular P08443339A1374 JJ O
bundles P08443339A1374 NNS O
, P08443339A1374 , O
in P08443339A1374 IN O
the P08443339A1374 DT O
cortex P08443339A1374 NN O
and P08443339A1374 CC O
vascular P08443339A1374 JJ O
cylinder P08443339A1374 NN O
of P08443339A1374 IN O
the P08443339A1374 DT O
root P08443339A1374 NN O
. P08443339A1374 . O
. . O O

It P07112654A0388 PRP O
was P07112654A0388 VBD O
also P07112654A0388 RB O
found P07112654A0388 VBN O
that P07112654A0388 IN O
there P07112654A0388 EX O
is P07112654A0388 VBZ O
no P07112654A0388 DT O
significant P07112654A0388 JJ O
difference P07112654A0388 NN O
between P07112654A0388 IN O
the P07112654A0388 DT O
prevalence P07112654A0388 NN O
of P07112654A0388 IN O
nasal P07112654A0388 JJ O
carriage P07112654A0388 NN O
of P07112654A0388 IN O
S. P07112654A0388 NNP O
aureus P07112654A0388 NN O
amongst P07112654A0388 VBD O
the P07112654A0388 DT O
hospital P07112654A0388 JJ O
staff P07112654A0388 NN O
and P07112654A0388 CC O
the P07112654A0388 DT O
patients P07112654A0388 NNS O
. P07112654A0388 . O
. . O O

Mutations P08887659A0753 NNS O
at P08887659A0753 IN O
two P08887659A0753 CD O
neighboring P08887659A0753 VBG O
sites P08887659A0753 NNS O
, P08887659A0753 , O
serine P08887659A0753 VBP O
242 P08887659A0753 CD O
and P08887659A0753 CC O
threonine P08887659A0753 VB O
255 P08887659A0753 CD O
, P08887659A0753 , O
exacerbated P08887659A0753 VBD O
the P08887659A0753 DT O
effect P08887659A0753 NN O
. P08887659A0753 . O
. . O O

Plasma P08403245A1234 NNP O
thromboxane P08403245A1234 NN O
B2 P08403245A1234 NNP O
levels P08403245A1234 NNS O
in P08403245A1234 IN O
the P08403245A1234 DT O
older P08403245A1234 JJR O
group P08403245A1234 NN O
were P08403245A1234 VBD O
about P08403245A1234 RB O
double P08403245A1234 JJ O
those P08403245A1234 DT O
in P08403245A1234 IN O
younger P08403245A1234 JJR O
piglets P08403245A1234 NNS O
. P08403245A1234 . O
. . O O

Congruent P09149929A0750 NN O
with P09149929A0750 IN O
empirical P09149929A0750 JJ O
predictions P09149929A0750 NNS O
, P09149929A0750 , O
the P09149929A0750 DT O
most P09149929A0750 RBS O
homesick P09149929A0750 JJ O
children P09149929A0750 NNS O
perceived P09149929A0750 VBD O
low P09149929A0750 JJ O
control P09149929A0750 NN O
over P09149929A0750 IN O
homesickness P09149929A0750 NN O
and P09149929A0750 CC O
separation P09149929A0750 NN O
, P09149929A0750 , O
and P09149929A0750 CC O
coped P09149929A0750 VBN O
by P09149929A0750 IN O
relinquishing P09149929A0750 VBG O
control P09149929A0750 NN O
. P09149929A0750 . O
. . O O

Using P07883754A0993 VBG O
gel P07883754A0993 JJ O
retardation P07883754A0993 NN O
assays P07883754A0993 NNS O
with P07883754A0993 IN O
HepG2 P07883754A0993 NNP O
nuclear P07883754A0993 JJ O
extract P07883754A0993 NN O
, P07883754A0993 , O
we P07883754A0993 PRP O
demonstrated P07883754A0993 VBD O
the P07883754A0993 DT O
presence P07883754A0993 NN O
of P07883754A0993 IN O
a P07883754A0993 DT O
specific P07883754A0993 NN O
protein P07883754A0993 NN O
which P07883754A0993 WDT O
bound P07883754A0993 NN O
to P07883754A0993 TO O
the P07883754A0993 DT O
NRE P07883754A0993 NNP O
fragment P07883754A0993 NN O
. P07883754A0993 . O
. . O O

Whereas P01702972A0613 NNP O
cDNA P01702972A0613 NN O
hybridization P01702972A0613 NN O
to P01702972A0613 TO O
genomic P01702972A0613 VB O
DNA P01702972A0613 NNP O
blots P01702972A0613 NNS O
indicated P01702972A0613 VBD O
a P01702972A0613 DT O
small P01702972A0613 JJ O
subfamily P01702972A0613 NN O
of P01702972A0613 IN O
G0S19 P01702972A0613 NNP I-UN
genes P01702972A0613 NNS I-UN
, P01702972A0613 , O
simple P01702972A0613 JJ O
patterns P01702972A0613 NNS O
of P01702972A0613 IN O
bands P01702972A0613 NNS O
indicated P01702972A0613 VBN O
that P01702972A0613 IN O
most P01702972A0613 JJS O
cDNAs P01702972A0613 NNS O
, P01702972A0613 , O
including P01702972A0613 VBG O
G0S30 P01702972A0613 NNP I-UN
cDNA P01702972A0613 NN I-UN
, P01702972A0613 , O
corresponded P01702972A0613 VBD O
to P01702972A0613 TO O
single-copy P01702972A0613 JJ O
genes P01702972A0613 NNS O
. P01702972A0613 . O
. . O O

Patients P10728945A0233 NNS O
enrolled P10728945A0233 VBN O
in P10728945A0233 IN O
the P10728945A0233 DT O
Integrilin P10728945A0233 NNP O
to P10728945A0233 TO O
Minimize P10728945A0233 VB O
Platelet P10728945A0233 NNP O
Aggregation P10728945A0233 NNP O
and P10728945A0233 CC O
Coronary P10728945A0233 NNP O
Thrombosis-II P10728945A0233 NNP O
( P10728945A0233 ( O
IMPACT-II P10728945A0233 NNP O
) P10728945A0233 ) O
trial P10728945A0233 NN O
were P10728945A0233 VBD O
analyzed P10728945A0233 VBN O
. P10728945A0233 . O
. . O O

Ultrasound P04328746T0073 NNP O
effect P04328746T0073 NN O
on P04328746T0073 IN O
the P04328746T0073 DT O
cytochrome P04328746T0073 JJ I-UN
oxidase P04328746T0073 NN I-UN
activity P04328746T0073 NN O
. P04328746T0073 . O
. . O O

LY290181 P08621017A1186 NNP O
appears P08621017A1186 VBZ O
to P08621017A1186 TO O
inhibit P08621017A1186 VB O
uPA P08621017A1186 JJ I-UN
promoter P08621017A1186 NN I-UN
activation P08621017A1186 NN O
by P08621017A1186 IN O
blocking P08621017A1186 VBG O
phorbol P08621017A1186 JJ O
ester-stimulated P08621017A1186 JJ O
binding P08621017A1186 NN O
of P08621017A1186 IN O
nuclear P08621017A1186 JJ O
proteins P08621017A1186 NNS O
to P08621017A1186 TO O
the P08621017A1186 DT O
uPA P08621017A1186 JJ I-UN
PEA3 P08621017A1186 NNP I-UN
/ P08621017A1186 NNP O
12-0-tetradecanoylphorbol P08621017A1186 JJ O
13-acetate P08621017A1186 JJ O
responsive P08621017A1186 JJ O
element P08621017A1186 NN O
( P08621017A1186 ( O
TRE P08621017A1186 NNP O
) P08621017A1186 ) O
. P08621017A1186 . O
. . O O

Clear P10622576A0552 JJ O
and P10622576A0552 CC O
evidenced-based P10622576A0552 JJ O
information P10622576A0552 NN O
should P10622576A0552 MD O
be P10622576A0552 VB O
provided P10622576A0552 VBN O
to P10622576A0552 TO O
patients P10622576A0552 NNS O
as P10622576A0552 IN O
to P10622576A0552 TO O
the P10622576A0552 DT O
means P10622576A0552 NNS O
of P10622576A0552 IN O
prevention P10622576A0552 NN O
with P10622576A0552 IN O
special P10622576A0552 JJ O
attention P10622576A0552 NN O
to P10622576A0552 TO O
individual P10622576A0552 JJ O
risk P10622576A0552 NN O
groups P10622576A0552 NNS O
such P10622576A0552 JJ O
as P10622576A0552 IN O
IV P10622576A0552 NNP O
drug P10622576A0552 NN O
abusers P10622576A0552 NNS O
. P10622576A0552 . O
. . O O

This P01004298A0744 DT O
up-grading P01004298A0744 NN O
of P01004298A0744 IN O
the P01004298A0744 DT O
final P01004298A0744 JJ O
score P01004298A0744 NN O
by P01004298A0744 IN O
the P01004298A0744 DT O
CA P01004298A0744 NNP O
component P01004298A0744 NN O
is P01004298A0744 VBZ O
greater P01004298A0744 JJR O
( P01004298A0744 ( O
3-8 P01004298A0744 CD O
% P01004298A0744 NN O
) P01004298A0744 ) O
in P01004298A0744 IN O
the P01004298A0744 DT O
less P01004298A0744 RBR O
able P01004298A0744 JJ O
students P01004298A0744 NNS O
with P01004298A0744 IN O
scores P01004298A0744 NNS O
below P01004298A0744 IN O
the P01004298A0744 DT O
mean P01004298A0744 JJ O
level P01004298A0744 NN O
. P01004298A0744 . O
. . O O

We P11737900A0700 PRP O
found P11737900A0700 VBD O
no P11737900A0700 DT O
correlation P11737900A0700 NN O
between P11737900A0700 IN O
plasma P11737900A0700 NN O
COP P11737900A0700 NNP O
and P11737900A0700 CC O
body P11737900A0700 NN O
weight P11737900A0700 NN O
at P11737900A0700 IN O
the P11737900A0700 DT O
same P11737900A0700 JJ O
age P11737900A0700 NN O
( P11737900A0700 ( O
r2 P11737900A0700 JJ O
= P11737900A0700 NN O
0.05 P11737900A0700 CD O
, P11737900A0700 , O
P P11737900A0700 NNP O
= P11737900A0700 NNP O
0.155 P11737900A0700 CD O
) P11737900A0700 ) O
. P11737900A0700 . O
. . O O

METHODS P08124785A0445 NNP O
AND P08124785A0445 CC O
RESULTS P08124785A0445 NNP O
: P08124785A0445 : O
In P08124785A0445 IN O
25 P08124785A0445 CD O
open-chest P08124785A0445 JJ O
, P08124785A0445 , O
anesthetized P08124785A0445 JJ O
dogs P08124785A0445 NNS O
, P08124785A0445 , O
progressive P08124785A0445 JJ O
circumflex P08124785A0445 NN O
artery P08124785A0445 NN O
stenosis P08124785A0445 NN O
led P08124785A0445 VBD O
to P08124785A0445 TO O
a P08124785A0445 DT O
concordant P08124785A0445 JJ O
decrease P08124785A0445 NN O
of P08124785A0445 IN O
circumflex P08124785A0445 JJ O
artery P08124785A0445 NN O
resting P08124785A0445 NN O
and P08124785A0445 CC O
hyperemic P08124785A0445 JJ O
flow P08124785A0445 NN O
, P08124785A0445 , O
coronary P08124785A0445 JJ O
flow P08124785A0445 NN O
reserve P08124785A0445 NN O
, P08124785A0445 , O
and P08124785A0445 CC O
inverse P08124785A0445 JJ O
angiographic P08124785A0445 JJ O
mean P08124785A0445 JJ O
transit P08124785A0445 NN O
time P08124785A0445 NN O
Tmicro-1 P08124785A0445 NNP O
( P08124785A0445 ( O
P P08124785A0445 NNP O
< P08124785A0445 NNP O
.01 P08124785A0445 NNP O
) P08124785A0445 ) O
. P08124785A0445 . O
. . O O

To P02958204A0175 TO O
investigate P02958204A0175 VB O
the P02958204A0175 DT O
effects P02958204A0175 NNS O
of P02958204A0175 IN O
isotretinoin P02958204A0175 NN O
on P02958204A0175 IN O
HDL P02958204A0175 NNP I-UN
, P02958204A0175 , O
we P02958204A0175 PRP O
measured P02958204A0175 VBD O
HDL-C P02958204A0175 NNP I-UN
, P02958204A0175 , O
HDL P02958204A0175 NNP I-UN
phospholipids P02958204A0175 NNS O
( P02958204A0175 ( O
HDL-PL P02958204A0175 NNP I-UN
) P02958204A0175 ) O
, P02958204A0175 , O
apoprotein P02958204A0175 JJ I-UN
A1 P02958204A0175 NNP I-UN
( P02958204A0175 ( O
apo P02958204A0175 IN I-UN
A-1 P02958204A0175 NNP I-UN
) P02958204A0175 ) O
, P02958204A0175 , O
and P02958204A0175 CC O
HDL-C P02958204A0175 NNP I-UN
subfractions P02958204A0175 NNS O
( P02958204A0175 ( O
HDL2-C P02958204A0175 NNP I-UN
and P02958204A0175 CC O
HDL3-C P02958204A0175 NNP I-UN
) P02958204A0175 ) O
in P02958204A0175 IN O
24 P02958204A0175 CD O
healthy P02958204A0175 JJ O
, P02958204A0175 , O
male P02958204A0175 JJ O
patients P02958204A0175 NNS O
receiving P02958204A0175 VBG O
a P02958204A0175 DT O
16-week P02958204A0175 JJ O
course P02958204A0175 NN O
of P02958204A0175 IN O
isotretinoin P02958204A0175 NN O
( P02958204A0175 ( O
1.0 P02958204A0175 CD O
mg P02958204A0175 NN O
/ P02958204A0175 NNP O
kg P02958204A0175 NN O
/ P02958204A0175 NNP O
day P02958204A0175 NN O
) P02958204A0175 ) O
for P02958204A0175 IN O
treatment P02958204A0175 NN O
of P02958204A0175 IN O
severe P02958204A0175 JJ O
acne P02958204A0175 JJ O
vulgaris P02958204A0175 NN O
. P02958204A0175 . O
. . O O

Contractile P06993660A0000 JJ O
responses P06993660A0000 NNS O
to P06993660A0000 TO O
norepinephrine P06993660A0000 VB O
, P06993660A0000 , O
serotonin P06993660A0000 NN O
and P06993660A0000 CC O
potassium P06993660A0000 NN O
( P06993660A0000 ( O
K+ P06993660A0000 NNP O
) P06993660A0000 ) O
and P06993660A0000 CC O
relaxant P06993660A0000 JJ O
responses P06993660A0000 NNS O
to P06993660A0000 TO O
isoproterenol P06993660A0000 VB O
and P06993660A0000 CC O
papaverine P06993660A0000 VB O
were P06993660A0000 VBD O
studied P06993660A0000 VBN O
in P06993660A0000 IN O
vitro P06993660A0000 NN O
with P06993660A0000 IN O
spirally P06993660A0000 RB O
cut P06993660A0000 VBN O
thoracic P06993660A0000 JJ O
aortic P06993660A0000 JJ O
strips P06993660A0000 NNS O
from P06993660A0000 IN O
aortic P06993660A0000 JJ O
coarcted P06993660A0000 VBN O
hypertensive P06993660A0000 JJ O
rats P06993660A0000 NNS O
( P06993660A0000 ( O
AHR P06993660A0000 NNP O
) P06993660A0000 ) O
2 P06993660A0000 CD O
, P06993660A0000 , O
6 P06993660A0000 CD O
, P06993660A0000 , O
14 P06993660A0000 CD O
and P06993660A0000 CC O
28 P06993660A0000 CD O
days P06993660A0000 NNS O
postoperatively P06993660A0000 RB O
and P06993660A0000 CC O
compared P06993660A0000 VBN O
to P06993660A0000 TO O
time-matched P06993660A0000 JJ O
, P06993660A0000 , O
sham-operated P06993660A0000 JJ O
normotensive P06993660A0000 JJ O
controls P06993660A0000 NNS O
. P06993660A0000 . O
. . O O

In P09566871A0343 IN O
fus3 P09566871A0343 JJ I-UN
mutants P09566871A0343 NNS I-UN
, P09566871A0343 , O
the P09566871A0343 DT O
levels P09566871A0343 NNS O
of P09566871A0343 IN O
Ty1 P09566871A0343 NNP I-UN
RNA P09566871A0343 NNP I-UN
, P09566871A0343 , O
protein P09566871A0343 NN O
synthesis P09566871A0343 NN O
, P09566871A0343 , O
and P09566871A0343 CC O
proteolytic P09566871A0343 JJ O
processing P09566871A0343 NN O
were P09566871A0343 VBD O
not P09566871A0343 RB O
altered P09566871A0343 VBN O
relative P09566871A0343 JJ O
to P09566871A0343 TO O
those P09566871A0343 DT O
in P09566871A0343 IN O
FUS3 P09566871A0343 NNP I-UN
strains P09566871A0343 NNS O
but P09566871A0343 CC O
steady-state P09566871A0343 JJ O
levels P09566871A0343 NNS O
of P09566871A0343 IN O
TyA P09566871A0343 NNP I-UN
, P09566871A0343 , O
integrase P09566871A0343 NN I-UN
, P09566871A0343 , O
and P09566871A0343 CC O
reverse P09566871A0343 VB I-UN
transcriptase P09566871A0343 NN I-UN
proteins P09566871A0343 NNS O
and P09566871A0343 CC O
Ty1 P09566871A0343 NNP I-UN
cDNA P09566871A0343 NN I-UN
were P09566871A0343 VBD O
all P09566871A0343 DT O
increased P09566871A0343 VBN O
. P09566871A0343 . O
. . O O

1 P00619948A0000 CD O
The P00619948A0000 DT O
effects P00619948A0000 NNS O
in P00619948A0000 IN O
normal P00619948A0000 JJ O
subjects P00619948A0000 NNS O
of P00619948A0000 IN O
a P00619948A0000 DT O
single P00619948A0000 JJ O
oral P00619948A0000 JJ O
dose P00619948A0000 NN O
of P00619948A0000 IN O
Motival P00619948A0000 NNP O
( P00619948A0000 ( O
one P00619948A0000 CD O
tablet P00619948A0000 NN O
, P00619948A0000 , O
containing P00619948A0000 VBG O
fluphenazine P00619948A0000 NN O
0.5 P00619948A0000 CD O
mg P00619948A0000 NN O
and P00619948A0000 CC O
nortriptyline P00619948A0000 JJ O
10 P00619948A0000 CD O
mg P00619948A0000 NN O
) P00619948A0000 ) O
on P00619948A0000 IN O
the P00619948A0000 DT O
contingent P00619948A0000 NN O
negative P00619948A0000 JJ O
variation P00619948A0000 NN O
( P00619948A0000 ( O
CNV P00619948A0000 NNP O
) P00619948A0000 ) O
, P00619948A0000 , O
reaction P00619948A0000 NN O
time P00619948A0000 NN O
, P00619948A0000 , O
heart P00619948A0000 NN O
rate P00619948A0000 NN O
, P00619948A0000 , O
blood P00619948A0000 NN O
pressure P00619948A0000 NN O
and P00619948A0000 CC O
self-rating P00619948A0000 JJ O
scales P00619948A0000 NNS O
for P00619948A0000 IN O
alertness P00619948A0000 NN O
, P00619948A0000 , O
anxiety P00619948A0000 NN O
, P00619948A0000 , O
tension P00619948A0000 NN O
, P00619948A0000 , O
detachment P00619948A0000 NN O
and P00619948A0000 CC O
depression P00619948A0000 NN O
were P00619948A0000 VBD O
compared P00619948A0000 VBN O
with P00619948A0000 IN O
those P00619948A0000 DT O
of P00619948A0000 IN O
diazepam P00619948A0000 NN O
( P00619948A0000 ( O
5 P00619948A0000 CD O
mg P00619948A0000 NN O
and P00619948A0000 CC O
7.5 P00619948A0000 CD O
mg P00619948A0000 NN O
) P00619948A0000 ) O
and P00619948A0000 CC O
placebo P00619948A0000 NN O
or P00619948A0000 CC O
propranolol P00619948A0000 NN O
( P00619948A0000 ( O
60 P00619948A0000 CD O
mg P00619948A0000 NN O
) P00619948A0000 ) O
. P00619948A0000 . O
. . O O

Current P00847967T0000 JJ O
diagnostic P00847967T0000 JJ O
uses P00847967T0000 NNS O
of P00847967T0000 IN O
computerized P00847967T0000 JJ O
tomography P00847967T0000 NN O
in P00847967T0000 IN O
clinical P00847967T0000 JJ O
medicine P00847967T0000 NN O
. P00847967T0000 . O
. . O O

We P11015197A0310 PRP O
have P11015197A0310 VBP O
mutated P11015197A0310 VBN O
to P11015197A0310 TO O
cysteine P11015197A0310 VB O
, P11015197A0310 , O
one P11015197A0310 CD O
at P11015197A0310 IN O
a P11015197A0310 DT O
time P11015197A0310 NN O
, P11015197A0310 , O
21 P11015197A0310 CD O
consecutive P11015197A0310 JJ O
residues P11015197A0310 NNS O
in P11015197A0310 IN O
the P11015197A0310 DT O
fourth P11015197A0310 JJ O
TMS P11015197A0310 NNP O
( P11015197A0310 ( O
TM4 P11015197A0310 NNP O
) P11015197A0310 ) O
. P11015197A0310 . O
. . O O

Here P11361338A0447 RB O
, P11361338A0447 , O
the P11361338A0447 DT O
PEX5-TPR P11361338A0447 NNP O
domains P11361338A0447 NNS O
from P11361338A0447 IN O
human P11361338A0447 JJ O
, P11361338A0447 , O
tobacco P11361338A0447 NN O
, P11361338A0447 , O
and P11361338A0447 CC O
nematode P11361338A0447 NNS O
were P11361338A0447 VBD O
inserted P11361338A0447 VBN O
into P11361338A0447 IN O
a P11361338A0447 DT O
TPR-less P11361338A0447 JJ O
yeast P11361338A0447 NN O
Pex5p P11361338A0447 NNP I-UN
construct P11361338A0447 NN O
to P11361338A0447 TO O
generate P11361338A0447 VB O
Pex5p P11361338A0447 NNP I-UN
chimaeras P11361338A0447 NNS O
. P11361338A0447 . O
. . O O

STK P08918464A0225 NNP I-UN
/ P08918464A0225 NNP O
RON-expressing P08918464A0225 NNP O
Ba P08918464A0225 NNP O
/ P08918464A0225 NNP O
F3 P08918464A0225 NNP O
pro-B P08918464A0225 JJ O
cells P08918464A0225 NNS O
( P08918464A0225 ( O
BaF P08918464A0225 NNP O
/ P08918464A0225 NNP O
STK P08918464A0225 NNP I-UN
) P08918464A0225 ) O
exhibited P08918464A0225 VBD O
MSP-dependent P08918464A0225 JJ O
growth P08918464A0225 NN O
, P08918464A0225 , O
whereas P08918464A0225 WP O
STK P08918464A0225 NNP I-UN
/ P08918464A0225 VBD O
RON-expressing P08918464A0225 NNP O
mouse P08918464A0225 NN O
erythroleukaemia P08918464A0225 NN O
cells P08918464A0225 NNS O
( P08918464A0225 ( O
MEL P08918464A0225 NNP O
/ P08918464A0225 NNP O
STK P08918464A0225 NNP I-UN
) P08918464A0225 ) O
displayed P08918464A0225 VBD O
MSP-induced P08918464A0225 JJ O
apoptosis P08918464A0225 NN O
. P08918464A0225 . O
. . O O

Comparative P09596638T0000 JJ O
mapping P09596638T0000 NN O
of P09596638T0000 IN O
the P09596638T0000 DT O
Brassica P09596638T0000 NNP I-UN
S P09596638T0000 NNP I-UN
locus P09596638T0000 POS I-UN
region P09596638T0000 NN I-UN
and P09596638T0000 CC O
its P09596638T0000 PRP$ O
homeolog P09596638T0000 NN O
in P09596638T0000 IN O
Arabidopsis P09596638T0000 NNP O
. P09596638T0000 . O
. . O O

Preceptorship P01559209T0000 NN O
of P01559209T0000 IN O
CNS P01559209T0000 JJ O
students P01559209T0000 NNS O
: P01559209T0000 : O
an P01559209T0000 DT O
exploratory P01559209T0000 NN O
study P01559209T0000 NN O
. P01559209T0000 . O
. . O O

The P01429724A0664 DT O
data P01429724A0664 NN O
indicate P01429724A0664 NN O
that P01429724A0664 IN O
the P01429724A0664 DT O
minimal P01429724A0664 JJ O
catalytic P01429724A0664 JJ O
domain P01429724A0664 NN O
of P01429724A0664 IN O
Nmt1p P01429724A0664 NNP I-UN
is P01429724A0664 VBZ O
located P01429724A0664 VBN O
between P01429724A0664 IN O
Ile59 P01429724A0664 NNP O
-- P01429724A0664 : O
> P01429724A0664 JJ O
Phe96 P01429724A0664 NNP O
and P01429724A0664 CC O
Gly451 P01429724A0664 NNP O
-- P01429724A0664 : O
> P01429724A0664 JJ O
Leu455 P01429724A0664 NNP O
. P01429724A0664 . O
. . O O

Marked P10572866A0481 VBN O
hemolysis P10572866A0481 NN O
significantly P10572866A0481 RB O
increased P10572866A0481 VBD O
plasma P10572866A0481 JJ O
values P10572866A0481 NNS O
of P10572866A0481 IN O
potassium P10572866A0481 NN O
, P10572866A0481 , O
phosphorus P10572866A0481 NN O
, P10572866A0481 , O
total P10572866A0481 JJ O
protein P10572866A0481 NN O
, P10572866A0481 , O
and P10572866A0481 CC O
aspartate P10572866A0481 JJ I-UN
aminotransferase P10572866A0481 NN I-UN
. P10572866A0481 . O
. . O O

Urease P01394655A0615b NNP I-UN
activity P01394655A0615b NN O
, P01394655A0615b , O
judged P01394655A0615b VBN O
as P01394655A0615b IN O
the P01394655A0615b DT O
amount P01394655A0615b NN O
of P01394655A0615b IN O
ammonia P01394655A0615b JJ O
production P01394655A0615b NN O
from P01394655A0615b IN O
urea P01394655A0615b JJ O
, P01394655A0615b , O
could P01394655A0615b MD O
be P01394655A0615b VB O
measured P01394655A0615b VBN O
at P01394655A0615b IN O
25 P01394655A0615b CD O
ng P01394655A0615b JJ O
per P01394655A0615b IN O
tube P01394655A0615b NN O
( P01394655A0615b ( O
S P01394655A0615b NNP O
/ P01394655A0615b NNP O
N P01394655A0615b NNP O
= P01394655A0615b NNP O
1.5 P01394655A0615b CD O
) P01394655A0615b ) O
with P01394655A0615b IN O
Jack P01394655A0615b NNP I-UN
bean P01394655A0615b JJ I-UN
meal P01394655A0615b NN I-UN
urease P01394655A0615b NN I-UN
. P01394655A0615b . O
. . O O

The P06609166A0209 DT O
method P06609166A0209 NN O
involved P06609166A0209 VBN O
deproteinizing P06609166A0209 VBG O
samples P06609166A0209 NNS O
with P06609166A0209 IN O
two P06609166A0209 CD O
volumes P06609166A0209 NNS O
of P06609166A0209 IN O
acetonitrile P06609166A0209 NN O
followed P06609166A0209 VBN O
by P06609166A0209 IN O
injection P06609166A0209 NN O
of P06609166A0209 IN O
5 P06609166A0209 CD O
microliters P06609166A0209 NNS O
of P06609166A0209 IN O
deproteinized P06609166A0209 JJ O
supernatant P06609166A0209 NN O
onto P06609166A0209 IN O
a P06609166A0209 DT O
C18 P06609166A0209 NNP O
reversed-phase P06609166A0209 JJ O
column P06609166A0209 NN O
. P06609166A0209 . O
. . O O

Only P00092689A0352 RB O
17 P00092689A0352 CD O
% P00092689A0352 NN O
of P00092689A0352 IN O
all P00092689A0352 DT O
patients P00092689A0352 NNS O
admitted P00092689A0352 VBD O
it P00092689A0352 PRP O
at P00092689A0352 IN O
all P00092689A0352 DT O
times P00092689A0352 NNS O
. P00092689A0352 . O
. . O O

Resistance P09460171T0000 NN O
to P09460171T0000 TO O
thyroid P09460171T0000 VB O
hormone P09460171T0000 NN O
: P09460171T0000 : O
implications P09460171T0000 NNS O
for P09460171T0000 IN O
neurodevelopmental P09460171T0000 JJ O
research P09460171T0000 NN O
on P09460171T0000 IN O
the P09460171T0000 DT O
effects P09460171T0000 NNS O
of P09460171T0000 IN O
thyroid P09460171T0000 JJ O
hormone P09460171T0000 NN O
disruptors P09460171T0000 NNS O
. P09460171T0000 . O
. . O O

A P11687869A0000 DT O
38-year-old P11687869A0000 JJ O
woman P11687869A0000 NN O
with P11687869A0000 IN O
ulcerative P11687869A0000 JJ O
colitis P11687869A0000 NN O
subsequently P11687869A0000 RB O
developed P11687869A0000 VBD O
sarcoidosis P11687869A0000 NN O
. P11687869A0000 . O
. . O O

At P08035499A0941 IN O
least P08035499A0941 JJS O
some P08035499A0941 DT O
of P08035499A0941 IN O
the P08035499A0941 DT O
difference P08035499A0941 NN O
in P08035499A0941 IN O
stability P08035499A0941 NN O
of P08035499A0941 IN O
the P08035499A0941 DT O
two P08035499A0941 CD O
kinds P08035499A0941 NNS O
of P08035499A0941 IN O
complexes P08035499A0941 NNS O
was P08035499A0941 VBD O
due P08035499A0941 JJ O
to P08035499A0941 TO O
the P08035499A0941 DT O
fact P08035499A0941 NN O
that P08035499A0941 IN O
the P08035499A0941 DT O
dissociation P08035499A0941 NN O
rate P08035499A0941 NN O
of P08035499A0941 IN O
the P08035499A0941 DT O
A P08035499A0941 NNP O
stem P08035499A0941 NN O
substrate P08035499A0941 NN O
from P08035499A0941 IN O
the P08035499A0941 DT O
protein-DNA P08035499A0941 NN O
complexes P08035499A0941 NN O
was P08035499A0941 VBD O
approximately P08035499A0941 RB O
fourfold P08035499A0941 JJ O
faster P08035499A0941 JJR O
than P08035499A0941 IN O
that P08035499A0941 DT O
of P08035499A0941 IN O
the P08035499A0941 DT O
complete P08035499A0941 JJ O
TR P08035499A0941 NNP I-UN
. P08035499A0941 . O
. . O O

During P09077108A0458 IN O
the P09077108A0458 DT O
febrile P09077108A0458 JJ O
period P09077108A0458 NN O
, P09077108A0458 , O
pleocytosis P09077108A0458 NN O
was P09077108A0458 VBD O
associated P09077108A0458 VBN O
with P09077108A0458 IN O
high P09077108A0458 JJ O
levels P09077108A0458 NNS O
of P09077108A0458 IN O
IgG P09077108A0458 NNP I-UN
, P09077108A0458 , O
IL-6 P09077108A0458 NNP I-UN
, P09077108A0458 , O
TNF-alpha P09077108A0458 NNP I-UN
, P09077108A0458 , O
and P09077108A0458 CC O
PGE2 P09077108A0458 NNP O
in P09077108A0458 IN O
the P09077108A0458 DT O
cerebrospinal P09077108A0458 JJ O
fluid P09077108A0458 NN O
. P09077108A0458 . O
. . O O

Furthermore P09431828A1472 RB O
the P09431828A1472 DT O
median P09431828A1472 JJ O
increase P09431828A1472 NN O
in P09431828A1472 IN O
cyclosporine P09431828A1472 JJ O
DR P09431828A1472 NNP O
/ P09431828A1472 NNP O
C P09431828A1472 NNP O
( P09431828A1472 ( O
SS P09431828A1472 NNP O
trough P09431828A1472 RB O
) P09431828A1472 ) O
was P09431828A1472 VBD O
18 P09431828A1472 CD O
l P09431828A1472 JJ O
h-1 P09431828A1472 NN O
( P09431828A1472 ( O
-3.1 P09431828A1472 UH O
to P09431828A1472 TO O
42.1 P09431828A1472 CD O
l P09431828A1472 NN O
h-1 P09431828A1472 NN O
, P09431828A1472 , O
interquartile P09431828A1472 JJ O
range P09431828A1472 NN O
) P09431828A1472 ) O
. P09431828A1472 . O
. . O O

Piperacillin-tazobactam P07606587A0266 NN O
can P07606587A0266 MD O
be P07606587A0266 VB O
used P07606587A0266 VBN O
for P07606587A0266 IN O
the P07606587A0266 DT O
treatment P07606587A0266 NN O
of P07606587A0266 IN O
infections P07606587A0266 NNS O
caused P07606587A0266 VBN O
by P07606587A0266 IN O
gram-negative P07606587A0266 JJ O
, P07606587A0266 , O
gram-positive P07606587A0266 JJ O
, P07606587A0266 , O
aerobic P07606587A0266 JJ O
, P07606587A0266 , O
and P07606587A0266 CC O
anaerobic P07606587A0266 JJ O
bacteria P07606587A0266 NNS O
. P07606587A0266 . O
. . O O

In P08754852A0960 IN O
gel P08754852A0960 JJ O
retardation P08754852A0960 NN O
assays P08754852A0960 NNS O
, P08754852A0960 , O
an P08754852A0960 DT O
RCS P08754852A0960 NNP O
cell-specific P08754852A0960 JJ O
protein P08754852A0960 NN O
and P08754852A0960 CC O
another P08754852A0960 DT O
closely P08754852A0960 RB O
related P08754852A0960 VBN O
protein P08754852A0960 NN O
expressed P08754852A0960 VBN O
only P08754852A0960 RB O
in P08754852A0960 IN O
RCS P08754852A0960 NNP O
cells P08754852A0960 NNS O
and P08754852A0960 CC O
primary P08754852A0960 JJ O
chondrocytes P08754852A0960 NNS O
bound P08754852A0960 IN O
to P08754852A0960 TO O
a P08754852A0960 DT O
10-bp P08754852A0960 JJ O
sequence P08754852A0960 NN O
within P08754852A0960 IN O
the P08754852A0960 DT O
18-mer P08754852A0960 JJ O
. P08754852A0960 . O
. . O O

The P11356214A0794 DT O
difference P11356214A0794 NN O
of P11356214A0794 IN O
hardness P11356214A0794 NN O
over P11356214A0794 IN O
time P11356214A0794 NN O
of P11356214A0794 IN O
composite P11356214A0794 JJ O
specimens P11356214A0794 NNS O
was P11356214A0794 VBD O
measured P11356214A0794 VBN O
using P11356214A0794 VBG O
Knoop P11356214A0794 NNP O
hardness P11356214A0794 NN O
measurements P11356214A0794 NNS O
taken P11356214A0794 VBN O
at P11356214A0794 IN O
the P11356214A0794 DT O
top P11356214A0794 JJ O
and P11356214A0794 CC O
bottom P11356214A0794 JJ O
surfaces P11356214A0794 NNS O
of P11356214A0794 IN O
resin P11356214A0794 NN O
specimens P11356214A0794 NNS O
made P11356214A0794 VBN O
in P11356214A0794 IN O
a P11356214A0794 DT O
Teflon P11356214A0794 NNP O
mold P11356214A0794 VBD O
the P11356214A0794 DT O
same P11356214A0794 JJ O
dimensions P11356214A0794 NNS O
as P11356214A0794 IN O
the P11356214A0794 DT O
cavity P11356214A0794 NN O
prepared P11356214A0794 VBN O
in P11356214A0794 IN O
dentin P11356214A0794 NN O
. P11356214A0794 . O
. . O O

Magnetic P08915051T0000 JJ O
resonance P08915051T0000 NN O
imaging P08915051T0000 NN O
in P08915051T0000 IN O
coccidioidal P08915051T0000 JJ O
arthritis P08915051T0000 NN O
. P08915051T0000 . O
. . O O

Detection P06854957T0066 NN O
of P06854957T0066 IN O
exercise-induced P06854957T0066 JJ O
asynergy P06854957T0066 NN O
by P06854957T0066 IN O
M-mode P06854957T0066 NNP O
echocardiography P06854957T0066 NN O
. P06854957T0066 . O
. . O O

The P09950394A0336 DT O
history P09950394A0336 NN O
of P09950394A0336 IN O
exposure P09950394A0336 NN O
and P09950394A0336 CC O
carboxyhemoglobin P09950394A0336 NN I-UN
levels P09950394A0336 NNS O
should P09950394A0336 MD O
alert P09950394A0336 VB O
the P09950394A0336 DT O
physician P09950394A0336 NN O
to P09950394A0336 TO O
this P09950394A0336 DT O
diagnosis P09950394A0336 NN O
. P09950394A0336 . O
. . O O

We P02789062A0000 PRP O
have P02789062A0000 VBP O
utilized P02789062A0000 VBN O
the P02789062A0000 DT O
human P02789062A0000 JJ I-UN
4F2 P02789062A0000 CD I-UN
heavy P02789062A0000 NN I-UN
chain P02789062A0000 NN I-UN
( P02789062A0000 ( O
4F2HC P02789062A0000 CD I-UN
) P02789062A0000 ) O
gene P02789062A0000 NN O
as P02789062A0000 IN O
a P02789062A0000 DT O
model P02789062A0000 NN O
system P02789062A0000 NN O
in P02789062A0000 IN O
studies P02789062A0000 NNS O
designed P02789062A0000 VBN O
to P02789062A0000 TO O
elucidate P02789062A0000 VB O
the P02789062A0000 DT O
molecular P02789062A0000 JJ O
events P02789062A0000 NNS O
involved P02789062A0000 VBN O
in P02789062A0000 IN O
regulating P02789062A0000 VBG O
inducible P02789062A0000 JJ O
gene P02789062A0000 NN O
expression P02789062A0000 NN O
during P02789062A0000 IN O
normal P02789062A0000 JJ O
human P02789062A0000 JJ O
T-cell P02789062A0000 NNP O
activation P02789062A0000 NN O
. P02789062A0000 . O
. . O O

That P07487908A0230 DT O
sequence P07487908A0230 NN O
strongly P07487908A0230 RB O
promoted P07487908A0230 VBD O
the P07487908A0230 DT O
transcription P07487908A0230 NN O
of P07487908A0230 IN O
the P07487908A0230 DT O
promotorless P07487908A0230 NN O
chloramphenicol P07487908A0230 NN I-UN
acetyltranferase P07487908A0230 NN I-UN
( P07487908A0230 ( O
CAT P07487908A0230 NNP I-UN
) P07487908A0230 ) O
gene P07487908A0230 NN O
in P07487908A0230 IN O
cells P07487908A0230 NNS O
of P07487908A0230 IN O
pancreatic P07487908A0230 JJ O
origin P07487908A0230 NN O
( P07487908A0230 ( O
AR-42J P07487908A0230 NNP O
) P07487908A0230 ) O
but P07487908A0230 CC O
not P07487908A0230 RB O
in P07487908A0230 IN O
cells P07487908A0230 NNS O
of P07487908A0230 IN O
non-pancreatic P07487908A0230 JJ O
origin P07487908A0230 NN O
( P07487908A0230 ( O
Rat P07487908A0230 NNP O
2 P07487908A0230 CD O
and P07487908A0230 CC O
IEC P07487908A0230 NNP O
6 P07487908A0230 CD O
) P07487908A0230 ) O
. P07487908A0230 . O
. . O O

Histopathology P05364951T0001 NNP O
and P05364951T0001 CC O
pathogenesis P05364951T0001 NN O
of P05364951T0001 IN O
exanthematous P05364951T0001 JJ O
viroses P05364951T0001 NNS O
. P05364951T0001 . O
. . O O

Plasma P03027905A0632 NNP I-UN
renin P03027905A0632 NN I-UN
activity P03027905A0632 NN O
rose P03027905A0632 VBD O
and P03027905A0632 CC O
the P03027905A0632 DT O
plasma P03027905A0632 NN O
aldosterone P03027905A0632 NN O
level P03027905A0632 NN O
fell P03027905A0632 VBD O
after P03027905A0632 IN O
taking P03027905A0632 VBG O
lisinopril P03027905A0632 NN O
. P03027905A0632 . O
. . O O

NF-HB P08497273T0000 NNP I-UN
( P08497273T0000 ( O
BSAP P08497273T0000 NNP I-UN
) P08497273T0000 ) O
is P08497273T0000 VBZ O
a P08497273T0000 DT O
repressor P08497273T0000 NN O
of P08497273T0000 IN O
the P08497273T0000 DT O
murine P08497273T0000 JJ I-UN
immunoglobulin P08497273T0000 NN I-UN
heavy-chain P08497273T0000 NN I-UN
3 P08497273T0000 CD I-UN
' P08497273T0000 POS I-UN
alpha P08497273T0000 JJ I-UN
enhancer P08497273T0000 NN I-UN
at P08497273T0000 IN O
early P08497273T0000 JJ O
stages P08497273T0000 NNS O
of P08497273T0000 IN O
B-cell P08497273T0000 NNP O
differentiation P08497273T0000 NN O
. P08497273T0000 . O
. . O O

The P03159903A0352 DT O
5 P03159903A0352 CD O
' P03159903A0352 POS O
end P03159903A0352 NN O
of P03159903A0352 IN O
the P03159903A0352 DT O
coding P03159903A0352 VBG O
region P03159903A0352 NN O
was P03159903A0352 VBD O
located P03159903A0352 VBN O
precisely P03159903A0352 RB O
by P03159903A0352 IN O
comparing P03159903A0352 VBG O
the P03159903A0352 DT O
deduced P03159903A0352 JJ O
amino P03159903A0352 NN O
acid P03159903A0352 NN O
sequence P03159903A0352 NN O
to P03159903A0352 TO O
the P03159903A0352 DT O
actual P03159903A0352 JJ O
N-terminal P03159903A0352 NNP O
amino P03159903A0352 NN O
acid P03159903A0352 NN O
sequence P03159903A0352 NN O
of P03159903A0352 IN O
IHF P03159903A0352 NNP I-UN
. P03159903A0352 . O
. . O O

Reporter P09478971A1896 NNP O
constructs P09478971A1896 NNS O
function P09478971A1896 NN O
in P09478971A1896 IN O
a P09478971A1896 DT O
parallel P09478971A1896 JJ O
manner P09478971A1896 NN O
, P09478971A1896 , O
demonstrating P09478971A1896 VBG O
the P09478971A1896 DT O
key P09478971A1896 JJ O
role P09478971A1896 NN O
of P09478971A1896 IN O
the P09478971A1896 DT O
AhR P09478971A1896 NNP I-UN
in P09478971A1896 IN O
constitutive P09478971A1896 NN O
as P09478971A1896 RB O
well P09478971A1896 RB O
as P09478971A1896 IN O
TCDD-induced P09478971A1896 NNP O
expression P09478971A1896 NN O
of P09478971A1896 IN O
Cyp1B1 P09478971A1896 NNP I-UN
in P09478971A1896 IN O
mouse P09478971A1896 NN O
embryo P09478971A1896 NN O
fibroblasts P09478971A1896 NNS O
. P09478971A1896 . O
. . O O

Twenty-three P08307564A0233 JJ O
sequence-tagged P08307564A0233 JJ O
sites P08307564A0233 NNS O
( P08307564A0233 ( O
STSs P08307564A0233 NNP O
) P08307564A0233 ) O
were P08307564A0233 VBD O
mapped P08307564A0233 VBN O
within P08307564A0233 IN O
the P08307564A0233 DT O
contig P08307564A0233 NN O
, P08307564A0233 , O
a P08307564A0233 DT O
density P08307564A0233 NN O
of P08307564A0233 IN O
approximately P08307564A0233 RB O
1 P08307564A0233 CD O
per P08307564A0233 IN O
200 P08307564A0233 CD O
kb P08307564A0233 NN O
. P08307564A0233 . O
. . O O

The P03765552A0582 DT O
mechanism P03765552A0582 NN O
of P03765552A0582 IN O
action P03765552A0582 NN O
is P03765552A0582 VBZ O
explored P03765552A0582 VBN O
in P03765552A0582 IN O
some P03765552A0582 DT O
detail P03765552A0582 NN O
, P03765552A0582 , O
specifically P03765552A0582 RB O
as P03765552A0582 IN O
it P03765552A0582 PRP O
relates P03765552A0582 VBZ O
to P03765552A0582 TO O
reticuloendothelial P03765552A0582 VB O
system P03765552A0582 NN O
( P03765552A0582 ( O
RES P03765552A0582 NNP O
) P03765552A0582 ) O
Fc P03765552A0582 NNP I-UN
receptor P03765552A0582 NN I-UN
blockade P03765552A0582 NN O
and P03765552A0582 CC O
suppression P03765552A0582 NN O
of P03765552A0582 IN O
antiplatelet P03765552A0582 NN O
antibody P03765552A0582 NN O
synthesis P03765552A0582 NN O
. P03765552A0582 . O
. . O O

The P11769229A0357 DT O
sorption P11769229A0357 NN O
mechanisms P11769229A0357 NNS O
changed P11769229A0357 VBD O
from P11769229A0357 IN O
adsorption P11769229A0357 NN O
to P11769229A0357 TO O
partition P11769229A0357 NN O
in P11769229A0357 IN O
the P11769229A0357 DT O
process P11769229A0357 NN O
of P11769229A0357 IN O
repetitious P11769229A0357 JJ O
sorption P11769229A0357 NN O
. P11769229A0357 . O
. . O O

Hu-Met-1 P08245461A0700 NNP I-UN
mRNA P08245461A0700 NN I-UN
expression P08245461A0700 NN O
in P08245461A0700 IN O
a P08245461A0700 DT O
small P08245461A0700 JJ O
number P08245461A0700 NN O
of P08245461A0700 IN O
human P08245461A0700 JJ O
T P08245461A0700 NNP O
cell P08245461A0700 NN O
tumor P08245461A0700 NN O
lines P08245461A0700 NNS O
did P08245461A0700 VBD O
not P08245461A0700 RB O
correlate P08245461A0700 VB O
with P08245461A0700 IN O
any P08245461A0700 DT O
particular P08245461A0700 JJ O
phenotype P08245461A0700 NN O
or P08245461A0700 CC O
stage P08245461A0700 NN O
of P08245461A0700 IN O
development P08245461A0700 NN O
. P08245461A0700 . O
. . O O

AMY-1 P09797456A0883 NNP I-UN
was P09797456A0883 VBD O
localized P09797456A0883 VBN O
in P09797456A0883 IN O
the P09797456A0883 DT O
cytoplasm P09797456A0883 NN O
in P09797456A0883 IN O
cells P09797456A0883 NNS O
expressing P09797456A0883 VBG O
c-myc P09797456A0883 NN I-UN
at P09797456A0883 IN O
low P09797456A0883 JJ O
levels P09797456A0883 NNS O
, P09797456A0883 , O
but P09797456A0883 CC O
in P09797456A0883 IN O
the P09797456A0883 DT O
nucleus P09797456A0883 NN O
in P09797456A0883 IN O
the P09797456A0883 DT O
cells P09797456A0883 NNS O
of P09797456A0883 IN O
a P09797456A0883 DT O
high P09797456A0883 JJ O
c-myc P09797456A0883 JJ I-UN
expression P09797456A0883 NN O
in P09797456A0883 IN O
transiently P09797456A0883 RB O
transfected P09797456A0883 VBN O
cells P09797456A0883 NNS O
. P09797456A0883 . O
. . O O

Exons P09038166A0818 NNS O
A1a P09038166A0818 NNP O
and P09038166A0818 CC O
A1b P09038166A0818 NNP O
are P09038166A0818 VBP O
separated P09038166A0818 VBN O
from P09038166A0818 IN O
each P09038166A0818 DT O
other P09038166A0818 JJ O
by P09038166A0818 IN O
a P09038166A0818 DT O
124-nucleotide P09038166A0818 JJ O
intron P09038166A0818 NN O
. P09038166A0818 . O
. . O O

Thus P11545594A1556 RB O
, P11545594A1556 , O
while P11545594A1556 IN O
the P11545594A1556 DT O
folds P11545594A1556 NNS O
of P11545594A1556 IN O
all P11545594A1556 DT O
Myb P11545594A1556 NNP I-UN
domains P11545594A1556 NNS I-UN
resemble P11545594A1556 JJ O
each P11545594A1556 DT O
other P11545594A1556 JJ O
closely P11545594A1556 RB O
, P11545594A1556 , O
the P11545594A1556 DT O
function P11545594A1556 NN O
of P11545594A1556 IN O
each P11545594A1556 DT O
Myb P11545594A1556 NNP I-UN
domain P11545594A1556 NN I-UN
depends P11545594A1556 VBZ O
on P11545594A1556 IN O
the P11545594A1556 DT O
amino P11545594A1556 NN O
acid P11545594A1556 NN O
residues P11545594A1556 NNS O
that P11545594A1556 WDT O
are P11545594A1556 VBP O
located P11545594A1556 VBN O
on P11545594A1556 IN O
the P11545594A1556 DT O
surface P11545594A1556 NN O
of P11545594A1556 IN O
each P11545594A1556 DT O
protein P11545594A1556 NN O
. P11545594A1556 . O
. . O O

Gel-shift P09414287A0637 NNP O
assays P09414287A0637 NNS O
identified P09414287A0637 VBD O
two P09414287A0637 CD O
Sp1 P09414287A0637 NNP I-UN
binding P09414287A0637 VBG I-UN
sites P09414287A0637 NNS I-UN
within P09414287A0637 IN O
this P09414287A0637 DT O
element P09414287A0637 NN O
. P09414287A0637 . O
. . O O

Glomerular P08284227A0336 JJ O
mesangial P08284227A0336 JJ O
cells P08284227A0336 NNS O
expressed P08284227A0336 VBD O
an P08284227A0336 DT O
abundant P08284227A0336 JJ O
1.1 P08284227A0336 CD O
kb P08284227A0336 NN O
mRNA P08284227A0336 NN O
transcript P08284227A0336 NN O
for P08284227A0336 IN O
Id1 P08284227A0336 NNP I-UN
, P08284227A0336 , O
but P08284227A0336 CC O
in P08284227A0336 IN O
contrast P08284227A0336 NN O
to P08284227A0336 TO O
other P08284227A0336 JJ O
cell P08284227A0336 NN O
types P08284227A0336 NNS O
Id1 P08284227A0336 NNP I-UN
mRNA P08284227A0336 NN I-UN
was P08284227A0336 VBD O
expressed P08284227A0336 VBN O
in P08284227A0336 IN O
both P08284227A0336 DT O
randomly P08284227A0336 RB O
cycling P08284227A0336 NN O
cells P08284227A0336 NNS O
and P08284227A0336 CC O
in P08284227A0336 IN O
serum-deprived P08284227A0336 JJ O
, P08284227A0336 , O
quiescent P08284227A0336 JJ O
cultures P08284227A0336 NNS O
. P08284227A0336 . O
. . O O

We P02026147A0000 PRP O
purified P02026147A0000 VBD O
a P02026147A0000 DT O
Ca2+ P02026147A0000 NNP I-UN
/ P02026147A0000 NNP I-UN
calmodulin P02026147A0000 NN I-UN
( P02026147A0000 ( I-UN
CaM P02026147A0000 NNP I-UN
) P02026147A0000 ) I-UN
-dependent P02026147A0000 NN I-UN
protein P02026147A0000 NN I-UN
kinase P02026147A0000 NN I-UN
( P02026147A0000 ( O
CaM P02026147A0000 NNP I-UN
kinase P02026147A0000 NN I-UN
) P02026147A0000 ) O
from P02026147A0000 IN O
the P02026147A0000 DT O
yeast P02026147A0000 NN O
Saccharomyces P02026147A0000 NNP O
cerevisiae P02026147A0000 NN O
with P02026147A0000 IN O
properties P02026147A0000 NNS O
similar P02026147A0000 JJ O
to P02026147A0000 TO O
mammalian P02026147A0000 JJ I-UN
type P02026147A0000 NN I-UN
II P02026147A0000 NNP I-UN
CaM P02026147A0000 NNP I-UN
kinases P02026147A0000 NNS I-UN
. P02026147A0000 . O
. . O O

TFEC P08336698T0000 NNP I-UN
, P08336698T0000 , O
a P08336698T0000 DT O
basic P08336698T0000 JJ I-UN
helix-loop-helix P08336698T0000 NN I-UN
protein P08336698T0000 NN I-UN
, P08336698T0000 , O
forms P08336698T0000 VBZ O
heterodimers P08336698T0000 NNS O
with P08336698T0000 IN O
TFE3 P08336698T0000 NNP I-UN
and P08336698T0000 CC O
inhibits P08336698T0000 VBZ O
TFE3-dependent P08336698T0000 JJ O
transcription P08336698T0000 NN O
activation P08336698T0000 NN O
. P08336698T0000 . O
. . O O

Here P09263856A0563 RB O
, P09263856A0563 , O
we P09263856A0563 PRP O
report P09263856A0563 VBP O
theoretical P09263856A0563 JJ O
models P09263856A0563 NNS O
for P09263856A0563 IN O
the P09263856A0563 DT O
Gla P09263856A0563 NNP O
and P09263856A0563 CC O
EGF-1 P09263856A0563 NNP I-UN
modules P09263856A0563 NNS I-UN
of P09263856A0563 IN O
human P09263856A0563 JJ I-UN
PS P09263856A0563 NNP I-UN
constructed P09263856A0563 VBD O
using P09263856A0563 VBG O
prothrombin P09263856A0563 NN I-UN
and P09263856A0563 CC O
factor P09263856A0563 NN I-UN
X P09263856A0563 NNP I-UN
experimental P09263856A0563 JJ O
structures P09263856A0563 NNS O
. P09263856A0563 . O
. . O O

The P08749393A0783 DT O
PI3K_68D P08749393A0783 NNP I-UN
cDNA P08749393A0783 NN I-UN
encodes P08749393A0783 VBZ O
a P08749393A0783 DT O
protein P08749393A0783 NN O
of P08749393A0783 IN O
210 P08749393A0783 CD O
kDa P08749393A0783 NNS O
, P08749393A0783 , O
which P08749393A0783 WDT O
lacks P08749393A0783 VBZ O
sequences P08749393A0783 NNS O
implicated P08749393A0783 VBN O
in P08749393A0783 IN O
linking P08749393A0783 VBG O
p110 P08749393A0783 JJ I-UN
PI P08749393A0783 NNP I-UN
3-kinases P08749393A0783 NNS I-UN
to P08749393A0783 TO O
p85 P08749393A0783 VB I-UN
adaptor P08749393A0783 NN I-UN
proteins P08749393A0783 NNS I-UN
, P08749393A0783 , O
but P08749393A0783 CC O
contains P08749393A0783 VBZ O
an P08749393A0783 DT O
amino-terminal P08749393A0783 JJ O
proline-rich P08749393A0783 JJ O
sequence P08749393A0783 NN O
, P08749393A0783 , O
which P08749393A0783 WDT O
could P08749393A0783 MD O
bind P08749393A0783 VB O
to P08749393A0783 TO O
SH3 P08749393A0783 NNP I-UN
domains P08749393A0783 NNS I-UN
, P08749393A0783 , O
and P08749393A0783 CC O
a P08749393A0783 DT O
carboxy-terminal P08749393A0783 JJ O
C2 P08749393A0783 NNP I-UN
domain P08749393A0783 NN O
. P08749393A0783 . O
. . O O

To P11416012A2511 TO O
investigate P11416012A2511 VB O
the P11416012A2511 DT O
convergent P11416012A2511 JJ O
role P11416012A2511 NN O
of P11416012A2511 IN O
the P11416012A2511 DT O
insulin P11416012A2511 NN I-UN
/ P11416012A2511 NNP O
IGF-I P11416012A2511 NNP I-UN
effector P11416012A2511 NN O
pathway P11416012A2511 NN O
mediating P11416012A2511 VBG O
bihormonal P11416012A2511 JJ O
stimulation P11416012A2511 NN O
of P11416012A2511 IN O
LDL P11416012A2511 NNP I-UN
receptor P11416012A2511 NN I-UN
promoter P11416012A2511 NN I-UN
expression P11416012A2511 NN O
, P11416012A2511 , O
transfected P11416012A2511 VBD O
granulosa-luteal P11416012A2511 JJ O
cells P11416012A2511 NNS O
were P11416012A2511 VBD O
pretreated P11416012A2511 VBN O
for P11416012A2511 IN O
30 P11416012A2511 CD O
min P11416012A2511 NNS O
with P11416012A2511 IN O
two P11416012A2511 CD O
specific P11416012A2511 JJ O
inhibitors P11416012A2511 NNS O
of P11416012A2511 IN O
phophatidylinositol P11416012A2511 JJ I-UN
3-kinase P11416012A2511 JJ I-UN
, P11416012A2511 , O
wortmannin P11416012A2511 NN O
( P11416012A2511 ( O
100 P11416012A2511 CD O
nM P11416012A2511 NN O
) P11416012A2511 ) O
and P11416012A2511 CC O
LY P11416012A2511 $ O
294002 P11416012A2511 CD O
( P11416012A2511 ( O
10 P11416012A2511 CD O
microM P11416012A2511 NN O
) P11416012A2511 ) O
, P11416012A2511 , O
or P11416012A2511 CC O
of P11416012A2511 IN O
mitogen-activated P11416012A2511 JJ I-UN
protein P11416012A2511 NN I-UN
kinase P11416012A2511 NN I-UN
kinase P11416012A2511 NN I-UN
, P11416012A2511 , O
PD P11416012A2511 NNP O
98059 P11416012A2511 CD O
( P11416012A2511 ( O
50 P11416012A2511 CD O
microM P11416012A2511 NN O
) P11416012A2511 ) O
, P11416012A2511 , O
U0126 P11416012A2511 NNP O
( P11416012A2511 ( O
10 P11416012A2511 CD O
microM P11416012A2511 NN O
) P11416012A2511 ) O
, P11416012A2511 , O
or P11416012A2511 CC O
the P11416012A2511 DT O
latter P11416012A2511 NN O
's P11416012A2511 POS O
inactive P11416012A2511 JJ O
derivative P11416012A2511 NN O
, P11416012A2511 , O
U0124 P11416012A2511 NNP O
( P11416012A2511 ( O
10 P11416012A2511 CD O
microM P11416012A2511 NN O
) P11416012A2511 ) O
. P11416012A2511 . O
. . O O

Blood P04082592T0000 NNP O
eosinophils P04082592T0000 NNS O
in P04082592T0000 IN O
patients P04082592T0000 NNS O
with P04082592T0000 IN O
Taenia P04082592T0000 NNP O
saginata P04082592T0000 NN O
taeniasis P04082592T0000 NN O
. P04082592T0000 . O
. . O O

Multidrug P11191208A0000 NNP O
resistance P11191208A0000 NN O
in P11191208A0000 IN O
Saccharomyces P11191208A0000 NNP O
cerevisiae P11191208A0000 NN O
mainly P11191208A0000 RB O
results P11191208A0000 NNS O
from P11191208A0000 IN O
the P11191208A0000 DT O
overexpression P11191208A0000 NN O
of P11191208A0000 IN O
genes P11191208A0000 NNS O
coding P11191208A0000 VBG O
for P11191208A0000 IN O
the P11191208A0000 DT O
membrane P11191208A0000 NN O
efflux P11191208A0000 NN O
pumps P11191208A0000 NNS O
, P11191208A0000 , O
the P11191208A0000 DT O
major P11191208A0000 JJ O
facilitators P11191208A0000 NNS O
and P11191208A0000 CC O
the P11191208A0000 DT O
ABC P11191208A0000 NNP I-UN
binding P11191208A0000 NN I-UN
cassette P11191208A0000 NN I-UN
transporters P11191208A0000 NNS I-UN
, P11191208A0000 , O
under P11191208A0000 IN O
the P11191208A0000 DT O
control P11191208A0000 NN O
of P11191208A0000 IN O
key P11191208A0000 JJ O
transcription P11191208A0000 NN O
regulators P11191208A0000 NNS O
encoded P11191208A0000 VBN O
by P11191208A0000 IN O
the P11191208A0000 DT O
PDR1 P11191208A0000 NNP I-UN
and P11191208A0000 CC O
PDR3 P11191208A0000 NNP I-UN
genes P11191208A0000 NNS I-UN
. P11191208A0000 . O
. . O O

This P07607342A0703 DT O
paper P07607342A0703 NN O
summarises P07607342A0703 VBZ O
the P07607342A0703 DT O
experimental P07607342A0703 JJ O
evidence P07607342A0703 NN O
upon P07607342A0703 IN O
which P07607342A0703 WDT O
the P07607342A0703 DT O
clinical P07607342A0703 JJ O
trials P07607342A0703 NNS O
of P07607342A0703 IN O
aldose P07607342A0703 JJ I-UN
reductase P07607342A0703 NN I-UN
inhibitors P07607342A0703 NNS O
in P07607342A0703 IN O
diabetic P07607342A0703 JJ O
patients P07607342A0703 NNS O
have P07607342A0703 VBP O
been P07607342A0703 VBN O
initiated P07607342A0703 VBN O
and P07607342A0703 CC O
the P07607342A0703 DT O
results P07607342A0703 NNS O
of P07607342A0703 IN O
published P07607342A0703 JJ O
drug P07607342A0703 NN O
trials P07607342A0703 NNS O
in P07607342A0703 IN O
these P07607342A0703 DT O
patients P07607342A0703 NNS O
. P07607342A0703 . O
. . O O

Viscosity P10460171A0842 NNP O
experiments P10460171A0842 NNS O
on P10460171A0842 IN O
the P10460171A0842 DT O
catalytic P10460171A0842 JJ O
fragment P10460171A0842 NN O
kinase P10460171A0842 NN O
reaction P10460171A0842 NN O
demonstrated P10460171A0842 VBD O
that P10460171A0842 IN O
the P10460171A0842 DT O
chemical P10460171A0842 NN O
( P10460171A0842 ( O
phosphoryl P10460171A0842 JJ O
transfer P10460171A0842 NN O
) P10460171A0842 ) O
step P10460171A0842 NN O
had P10460171A0842 VBD O
a P10460171A0842 DT O
reduced P10460171A0842 VBN O
rate P10460171A0842 NN O
. P10460171A0842 . O
. . O O

The P10823961A0664 DT O
C P10823961A0664 NNP O
terminus P10823961A0664 NN O
of P10823961A0664 IN O
TRBP P10823961A0664 NNP I-UN
binds P10823961A0664 NNS O
to P10823961A0664 TO O
CBP P10823961A0664 NNP I-UN
/ P10823961A0664 NNP O
p300 P10823961A0664 NN I-UN
and P10823961A0664 CC O
DRIP130 P10823961A0664 NNP I-UN
, P10823961A0664 , O
a P10823961A0664 DT O
component P10823961A0664 NN O
of P10823961A0664 IN O
the P10823961A0664 DT O
DRIP P10823961A0664 NNP I-UN
/ P10823961A0664 NNP O
TRAP P10823961A0664 NNP I-UN
/ P10823961A0664 NNP O
ARC P10823961A0664 NNP I-UN
complex P10823961A0664 NN O
, P10823961A0664 , O
which P10823961A0664 WDT O
suggests P10823961A0664 VBZ O
that P10823961A0664 IN O
TRBP P10823961A0664 NNP I-UN
may P10823961A0664 MD O
activate P10823961A0664 VB O
transcription P10823961A0664 NN O
by P10823961A0664 IN O
means P10823961A0664 NNS O
of P10823961A0664 IN O
such P10823961A0664 JJ O
interactions P10823961A0664 NNS O
. P10823961A0664 . O
. . O O

Indeed P08332495A0408 RB O
, P08332495A0408 , O
significant P08332495A0408 JJ O
level P08332495A0408 NN O
of P08332495A0408 IN O
CAT P08332495A0408 NNP I-UN
activity P08332495A0408 NN O
was P08332495A0408 VBD O
observed P08332495A0408 VBN O
in P08332495A0408 IN O
human P08332495A0408 JJ O
lung P08332495A0408 NN O
adenocarcinoma P08332495A0408 NN O
( P08332495A0408 ( O
A549-1 P08332495A0408 NNP O
) P08332495A0408 ) O
cells P08332495A0408 NNS O
which P08332495A0408 WDT O
had P08332495A0408 VBD O
been P08332495A0408 VBN O
incubated P08332495A0408 VBN O
with P08332495A0408 IN O
a P08332495A0408 DT O
complex P08332495A0408 NN O
of P08332495A0408 IN O
T7 P08332495A0408 NNP I-UN
RNA P08332495A0408 NNP I-UN
polymerase P08332495A0408 NN I-UN
, P08332495A0408 , O
pT7-EMC-CAT P08332495A0408 JJ I-UN
DNA P08332495A0408 NN I-UN
and P08332495A0408 CC O
DC-chol P08332495A0408 NNP O
cationic P08332495A0408 JJ O
liposomes P08332495A0408 NNS O
. P08332495A0408 . O
. . O O

Concordance P08299896A0626 NN O
of P08299896A0626 IN O
IBDQ P08299896A0626 NNP O
scores P08299896A0626 NNS O
was P08299896A0626 VBD O
tested P08299896A0626 VBN O
in P08299896A0626 IN O
280 P08299896A0626 CD O
stable P08299896A0626 JJ O
subjects P08299896A0626 NNS O
. P08299896A0626 . O
. . O O

Identification P10074520T0000 NN O
and P10074520T0000 CC O
characterization P10074520T0000 NN O
of P10074520T0000 IN O
IS2404 P10074520T0000 NNP I-UN
and P10074520T0000 CC O
IS2606 P10074520T0000 NNP I-UN
: P10074520T0000 : O
two P10074520T0000 CD O
distinct P10074520T0000 NN O
repeated P10074520T0000 VBD O
sequences P10074520T0000 NNS O
for P10074520T0000 IN O
detection P10074520T0000 NN O
of P10074520T0000 IN O
Mycobacterium P10074520T0000 NNP O
ulcerans P10074520T0000 NNS O
by P10074520T0000 IN O
PCR P10074520T0000 NNP O
. P10074520T0000 . O
. . O O

This P11118712A1296 DT O
sensitivity P11118712A1296 NN O
analysis P11118712A1296 NN O
showed P11118712A1296 VBD O
that P11118712A1296 IN O
the P11118712A1296 DT O
practical P11118712A1296 JJ O
limits P11118712A1296 NNS O
of P11118712A1296 IN O
the P11118712A1296 DT O
accuracy P11118712A1296 NN O
of P11118712A1296 IN O
the P11118712A1296 DT O
used P11118712A1296 JJ O
screening P11118712A1296 NN O
test P11118712A1296 NN O
jeopardize P11118712A1296 NN O
the P11118712A1296 DT O
estimation P11118712A1296 NN O
of P11118712A1296 IN O
the P11118712A1296 DT O
true P11118712A1296 JJ O
herd P11118712A1296 NN O
prevalence P11118712A1296 NN O
within P11118712A1296 IN O
reasonable P11118712A1296 JJ O
confidence P11118712A1296 NN O
limits P11118712A1296 NNS O
, P11118712A1296 , O
because P11118712A1296 IN O
the P11118712A1296 DT O
within-herd P11118712A1296 JJ O
PTB P11118712A1296 NNP O
true P11118712A1296 JJ O
prevalence P11118712A1296 NN O
was P11118712A1296 VBD O
low.For P11118712A1296 RBR O
this P11118712A1296 DT O
reason P11118712A1296 NN O
we P11118712A1296 PRP O
augmented P11118712A1296 VBD O
the P11118712A1296 DT O
herd P11118712A1296 NN O
specificity P11118712A1296 NN O
for P11118712A1296 IN O
herds P11118712A1296 NNS O
with P11118712A1296 IN O
larger P11118712A1296 JJR O
adult P11118712A1296 NN O
herd P11118712A1296 NN O
size P11118712A1296 NN O
( P11118712A1296 ( O
> P11118712A1296 $ O
5 P11118712A1296 CD O
) P11118712A1296 ) O
. P11118712A1296 . O
. . O O

All P07568865A0305 DT O
carcasses P07568865A0305 NNS O
resulted P07568865A0305 VBD O
in P07568865A0305 IN O
contamination P07568865A0305 NN O
with P07568865A0305 IN O
aerobic P07568865A0305 JJ O
mesophilic P07568865A0305 JJ O
bacteria P07568865A0305 NNS O
in P07568865A0305 IN O
the P07568865A0305 DT O
range P07568865A0305 NN O
from P07568865A0305 IN O
6 P07568865A0305 CD O
x P07568865A0305 NNS O
10 P07568865A0305 CD O
( P07568865A0305 ( O
3 P07568865A0305 CD O
) P07568865A0305 ) O
to P07568865A0305 TO O
1.2 P07568865A0305 CD O
x P07568865A0305 NNS O
10 P07568865A0305 CD O
( P07568865A0305 ( O
6 P07568865A0305 CD O
) P07568865A0305 ) O
CFU P07568865A0305 NNP O
/ P07568865A0305 NNP O
ml P07568865A0305 NN O
liquid P07568865A0305 NN O
washed P07568865A0305 VBD O
, P07568865A0305 , O
and P07568865A0305 CC O
94 P07568865A0305 CD O
% P07568865A0305 NN O
them P07568865A0305 PRP O
with P07568865A0305 IN O
sporulate P07568865A0305 NN O
bacteria P07568865A0305 NNS O
, P07568865A0305 , O
the P07568865A0305 DT O
threshold P07568865A0305 NN O
being P07568865A0305 VBG O
under P07568865A0305 IN O
100 P07568865A0305 CD O
CFU P07568865A0305 NNP O
/ P07568865A0305 NNP O
ml P07568865A0305 NN O
( P07568865A0305 ( O
Figure P07568865A0305 NNP O
1 P07568865A0305 CD O
) P07568865A0305 ) O
. P07568865A0305 . O
. . O O

( P09311810A0814 ( O
iv P09311810A0814 NN O
) P09311810A0814 ) O
The P09311810A0814 DT O
accumulation P09311810A0814 NN O
of P09311810A0814 IN O
cyclin P09311810A0814 NN I-UN
D3 P09311810A0814 NNP I-UN
protein P09311810A0814 NN I-UN
in P09311810A0814 IN O
Vero P09311810A0814 NNP O
cells P09311810A0814 NNS O
infected P09311810A0814 VBN O
with P09311810A0814 IN O
an P09311810A0814 DT O
alpha0 P09311810A0814 JJ I-UN
deletion P09311810A0814 NN I-UN
mutant P09311810A0814 NN I-UN
was P09311810A0814 VBD O
reduced P09311810A0814 VBN O
relative P09311810A0814 JJ O
to P09311810A0814 TO O
that P09311810A0814 DT O
of P09311810A0814 IN O
cells P09311810A0814 NNS O
infected P09311810A0814 VBN O
with P09311810A0814 IN O
wild-type P09311810A0814 JJ O
virus P09311810A0814 NN O
or P09311810A0814 CC O
a P09311810A0814 DT O
recombinant P09311810A0814 JJ O
virus P09311810A0814 NN O
in P09311810A0814 IN O
which P09311810A0814 WDT O
the P09311810A0814 DT O
deleted P09311810A0814 VBN O
alpha0 P09311810A0814 NN I-UN
sequences P09311810A0814 NNS I-UN
were P09311810A0814 VBD O
restored P09311810A0814 VBN O
. P09311810A0814 . O
. . O O

The P10892300A0268 DT O
first P10892300A0268 JJ O
symptoms P10892300A0268 NNS O
of P10892300A0268 IN O
enzootic P10892300A0268 JJ O
calcinosis P10892300A0268 NN O
were P10892300A0268 VBD O
noted P10892300A0268 VBN O
in P10892300A0268 IN O
March P10892300A0268 NNP O
1998 P10892300A0268 CD O
, P10892300A0268 , O
when P10892300A0268 WRB O
some P10892300A0268 DT O
of P10892300A0268 IN O
the P10892300A0268 DT O
cows P10892300A0268 NNS O
developed P10892300A0268 VBD O
locomotor P10892300A0268 NN O
abnormalities P10892300A0268 NNS O
. P10892300A0268 . O
. . O O

The P09268631A0316 DT O
position P09268631A0316 NN O
, P09268631A0316 , O
transcription P09268631A0316 NN O
orientation P09268631A0316 NN O
, P09268631A0316 , O
and P09268631A0316 CC O
imprinted P09268631A0316 VBD O
status P09268631A0316 NN O
of P09268631A0316 IN O
the P09268631A0316 DT O
genes P09268631A0316 NNS O
immediately P09268631A0316 RB O
flanking P09268631A0316 VBG O
Igf2r P09268631A0316 NNP I-UN
have P09268631A0316 VBP O
been P09268631A0316 VBN O
assessed P09268631A0316 VBN O
. P09268631A0316 . O
. . O O

When P08360180A1041 WRB O
comparing P08360180A1041 VBG O
the P08360180A1041 DT O
barley P08360180A1041 NN I-UN
PSI-K P08360180A1041 NNP I-UN
and P08360180A1041 CC O
PSI-G P08360180A1041 NNP I-UN
with P08360180A1041 IN O
the P08360180A1041 DT O
reported P08360180A1041 VBN O
PSI-K P08360180A1041 NNP I-UN
sequence P08360180A1041 NN I-UN
from P08360180A1041 IN I-UN
Synechococcus P08360180A1041 NNP I-UN
vulcanus P08360180A1041 NN I-UN
, P08360180A1041 , O
the P08360180A1041 DT O
degree P08360180A1041 NN O
of P08360180A1041 IN O
similarity P08360180A1041 NN O
is P08360180A1041 VBZ O
equal P08360180A1041 JJ O
, P08360180A1041 , O
suggesting P08360180A1041 VBG O
that P08360180A1041 IN O
an P08360180A1041 DT O
ancestral P08360180A1041 JJ O
gene P08360180A1041 NN O
has P08360180A1041 VBZ O
been P08360180A1041 VBN O
duplicated P08360180A1041 VBN O
in P08360180A1041 IN O
a P08360180A1041 DT O
chloroplast P08360180A1041 NN O
progenitor P08360180A1041 NN O
but P08360180A1041 CC O
not P08360180A1041 RB O
in P08360180A1041 IN O
a P08360180A1041 DT O
cyanobacterial P08360180A1041 NN O
. P08360180A1041 . O
. . O O

Gene P01285009A0000 NNP O
constructs P01285009A0000 NNS O
consisting P01285009A0000 VBG O
of P01285009A0000 IN O
human P01285009A0000 JJ I-UN
growth P01285009A0000 NN I-UN
hormone P01285009A0000 NN I-UN
( P01285009A0000 ( O
hGH P01285009A0000 NN I-UN
) P01285009A0000 ) O
gene P01285009A0000 NN O
driven P01285009A0000 VBN O
by P01285009A0000 IN O
promoter P01285009A0000 NN O
/ P01285009A0000 NNP O
regulatory P01285009A0000 JJ O
sequence P01285009A0000 NN O
of P01285009A0000 IN O
mouse P01285009A0000 NN I-UN
metallothionein P01285009A0000 NN I-UN
( P01285009A0000 ( O
mMT P01285009A0000 NN I-UN
) P01285009A0000 ) O
, P01285009A0000 , O
viral P01285009A0000 JJ I-UN
thymidine P01285009A0000 NN I-UN
kinase P01285009A0000 NN I-UN
( P01285009A0000 ( O
vTK P01285009A0000 NN I-UN
) P01285009A0000 ) O
, P01285009A0000 , O
rat P01285009A0000 FW I-UN
cholecystokinin P01285009A0000 NN I-UN
( P01285009A0000 ( O
rCCK P01285009A0000 NN I-UN
) P01285009A0000 ) O
, P01285009A0000 , O
or P01285009A0000 CC O
chicken P01285009A0000 VB I-UN
beta-actin P01285009A0000 NN I-UN
( P01285009A0000 ( O
cBA P01285009A0000 NN I-UN
) P01285009A0000 ) O
gene P01285009A0000 NN O
were P01285009A0000 VBD O
injected P01285009A0000 VBN O
into P01285009A0000 IN O
the P01285009A0000 DT O
cytoplasm P01285009A0000 NN O
of P01285009A0000 IN O
fertilized P01285009A0000 JJ O
medaka P01285009A0000 NN O
eggs P01285009A0000 NNS O
via P01285009A0000 IN O
the P01285009A0000 DT O
micropyle P01285009A0000 NN O
. P01285009A0000 . O
. . O O

Our P03102289A0786 PRP$ O
data P03102289A0786 NNS O
suggest P03102289A0786 VBP O
that P03102289A0786 IN O
it P03102289A0786 PRP O
may P03102289A0786 MD O
be P03102289A0786 VB O
possible P03102289A0786 JJ O
to P03102289A0786 TO O
individualize P03102289A0786 VB O
hCG P03102289A0786 JJ I-UN
administration P03102289A0786 NN O
at P03102289A0786 IN O
midcycle P03102289A0786 NN O
by P03102289A0786 IN O
determining P03102289A0786 VBG O
the P03102289A0786 DT O
number P03102289A0786 NN O
of P03102289A0786 IN O
follicles P03102289A0786 NNS O
greater P03102289A0786 JJR O
than P03102289A0786 IN O
1 P03102289A0786 CD O
cm P03102289A0786 NN O
by P03102289A0786 IN O
ultrasound P03102289A0786 NN O
on P03102289A0786 IN O
cycle P03102289A0786 NN O
day P03102289A0786 NN O
12 P03102289A0786 CD O
or P03102289A0786 CC O
13 P03102289A0786 CD O
and P03102289A0786 CC O
giving P03102289A0786 VBG O
hCG P03102289A0786 NN I-UN
when P03102289A0786 WRB O
serum P03102289A0786 NN O
E2 P03102289A0786 NNP O
levels P03102289A0786 NNS O
reach P03102289A0786 VBP O
1100 P03102289A0786 CD O
to P03102289A0786 TO O
1200 P03102289A0786 CD O
pmol P03102289A0786 NN O
/ P03102289A0786 NNP O
l P03102289A0786 NN O
per P03102289A0786 IN O
follicle P03102289A0786 NN O
. P03102289A0786 . O
. . O O

The P07565720A0256 DT O
DNA P07565720A0256 NN O
binding P07565720A0256 VBG O
domain P07565720A0256 NN O
of P07565720A0256 IN O
NirA P07565720A0256 NNP I-UN
was P07565720A0256 VBD O
expressed P07565720A0256 VBN O
as P07565720A0256 IN O
a P07565720A0256 DT O
fusion P07565720A0256 NN O
protein P07565720A0256 NN O
with P07565720A0256 IN O
the P07565720A0256 DT O
glutathione P07565720A0256 NN I-UN
S-transferase P07565720A0256 NNP I-UN
of P07565720A0256 IN O
Schistosoma P07565720A0256 NNP O
japonicum P07565720A0256 NN O
. P07565720A0256 . O
. . O O

The P10694511A0570 DT O
expression P10694511A0570 NN O
of P10694511A0570 IN O
the P10694511A0570 DT O
yam8 P10694511A0570 NN I-UN
( P10694511A0570 ( I-UN
+ P10694511A0570 NNP I-UN
) P10694511A0570 ) I-UN
cDNA P10694511A0570 NN I-UN
in P10694511A0570 IN O
the P10694511A0570 DT O
mid1 P10694511A0570 NN I-UN
mutant P10694511A0570 JJ I-UN
cells P10694511A0570 NNS O
partially P10694511A0570 RB O
remediated P10694511A0570 VBD O
the P10694511A0570 DT O
mid P10694511A0570 NN O
phenotype P10694511A0570 NN O
and P10694511A0570 CC O
resulted P10694511A0570 VBD O
in P10694511A0570 IN O
a P10694511A0570 DT O
slight P10694511A0570 JJ O
increase P10694511A0570 NN O
in P10694511A0570 IN O
Ca P10694511A0570 NNP O
( P10694511A0570 ( O
2+ P10694511A0570 CD O
) P10694511A0570 ) O
uptake P10694511A0570 NN O
activity P10694511A0570 NN O
. P10694511A0570 . O
. . O O

In P09268387A0293 IN O
this P09268387A0293 DT O
report P09268387A0293 NN O
, P09268387A0293 , O
we P09268387A0293 PRP O
identify P09268387A0293 VBP O
and P09268387A0293 CC O
characterize P09268387A0293 VBP O
two P09268387A0293 CD O
overlapping P09268387A0293 VBG O
ELL P09268387A0293 NNP I-UN
functional P09268387A0293 JJ I-UN
domains P09268387A0293 NNS I-UN
that P09268387A0293 WDT O
govern P09268387A0293 VBP O
its P09268387A0293 PRP$ O
interaction P09268387A0293 NN O
with P09268387A0293 IN O
RNA P09268387A0293 NNP I-UN
polymerase P09268387A0293 NN I-UN
II P09268387A0293 NNP I-UN
and P09268387A0293 CC O
the P09268387A0293 DT O
ternary P09268387A0293 JJ O
elongation P09268387A0293 NN O
complex P09268387A0293 NN O
. P09268387A0293 . O
. . O O

We P09601007A0223 PRP O
provide P09601007A0223 VBP O
community P09601007A0223 NN O
metabolic P09601007A0223 JJ O
data P09601007A0223 NNS O
that P09601007A0223 WDT O
indicate P09601007A0223 VBP O
that P09601007A0223 IN O
large P09601007A0223 JJ O
changes P09601007A0223 NNS O
in P09601007A0223 IN O
CO2 P09601007A0223 NNP O
concentration P09601007A0223 NN O
can P09601007A0223 MD O
occur P09601007A0223 VB O
in P09601007A0223 IN O
coral P09601007A0223 JJ O
reef P09601007A0223 NN O
waters P09601007A0223 NNS O
via P09601007A0223 IN O
biogeochemical P09601007A0223 JJ O
processes P09601007A0223 NNS O
not P09601007A0223 RB O
directly P09601007A0223 RB O
associated P09601007A0223 VBN O
with P09601007A0223 IN O
photosynthesis P09601007A0223 NN O
, P09601007A0223 , O
respiration P09601007A0223 NN O
, P09601007A0223 , O
calcification P09601007A0223 NN O
, P09601007A0223 , O
and P09601007A0223 CC O
CaCO3 P09601007A0223 NNP O
dissolution P09601007A0223 NN O
. P09601007A0223 . O
. . O O

A P03429306T0000 DT O
Golgi P03429306T0000 NNP O
study P03429306T0000 NN O
of P03429306T0000 IN O
the P03429306T0000 DT O
sixth P03429306T0000 JJ O
layer P03429306T0000 NN O
of P03429306T0000 IN O
the P03429306T0000 DT O
cerebral P03429306T0000 JJ O
cortex P03429306T0000 NN O
. P03429306T0000 . O
. . O O

Botulinum P08348919T0000 NNP I-UN
toxin P08348919T0000 NN I-UN
: P08348919T0000 : O
preferred P08348919T0000 JJ O
treatment P08348919T0000 NN O
for P08348919T0000 IN O
hemifacial P08348919T0000 JJ O
spasm P08348919T0000 NN O
. P08348919T0000 . O
. . O O

In P08702517A0000 IN O
a P08702517A0000 DT O
screen P08702517A0000 NN O
for P08702517A0000 IN O
genes P08702517A0000 NNS O
with P08702517A0000 IN O
oncogenic P08702517A0000 JJ O
potential P08702517A0000 NN O
expressed P08702517A0000 VBN O
by P08702517A0000 IN O
the P08702517A0000 DT O
murine P08702517A0000 NN O
B6SUtA1 P08702517A0000 NNP O
myeloid P08702517A0000 NN O
progenitor P08702517A0000 NN O
cell P08702517A0000 NN O
line P08702517A0000 NN O
, P08702517A0000 , O
we P08702517A0000 PRP O
isolated P08702517A0000 VBD O
a P08702517A0000 DT O
2 P08702517A0000 CD O
. P08702517A0000 . O
. . O O

This P08516301A0080 DT O
gene P08516301A0080 NN O
spans P08516301A0080 VBZ O
23 P08516301A0080 CD O
kb P08516301A0080 NN O
and P08516301A0080 CC O
is P08516301A0080 VBZ O
composed P08516301A0080 VBN O
of P08516301A0080 IN O
five P08516301A0080 CD O
exons P08516301A0080 NNS O
and P08516301A0080 CC O
four P08516301A0080 CD O
introns P08516301A0080 NNS O
. P08516301A0080 . O
. . O O

Significance P06801778T0001 NN O
of P06801778T0001 IN O
the P06801778T0001 DT O
pulmonary P06801778T0001 JJ O
gas P06801778T0001 NN O
exchange P06801778T0001 NN O
reaction P06801778T0001 NN O
to P06801778T0001 TO O
physical P06801778T0001 JJ O
loading P06801778T0001 NN O
in P06801778T0001 IN O
evaluating P06801778T0001 VBG O
the P06801778T0001 DT O
effectiveness P06801778T0001 NN O
of P06801778T0001 IN O
mitral P06801778T0001 JJ O
commissurotomy P06801778T0001 NN O
. P06801778T0001 . O
. . O O

TREB7 P02196176A0749 NNP I-UN
and P02196176A0749 CC O
TREB36 P02196176A0749 NNP I-UN
protected P02196176A0749 VBD O
all P02196176A0749 DT O
three P02196176A0749 CD O
repeats P02196176A0749 NNS O
of P02196176A0749 IN O
the P02196176A0749 DT O
21 P02196176A0749 CD O
bp P02196176A0749 NN O
, P02196176A0749 , O
but P02196176A0749 CC O
TREB5 P02196176A0749 NNP I-UN
protected P02196176A0749 VBD O
only P02196176A0749 RB O
the P02196176A0749 DT O
second P02196176A0749 JJ O
repeat P02196176A0749 NN O
. P02196176A0749 . O
. . O O

Neutron P09947191T0000 NNP O
scattering P09947191T0000 VBG O
measurements P09947191T0000 NNS O
of P09947191T0000 IN O
critical P09947191T0000 JJ O
exponents P09947191T0000 NNS O
in P09947191T0000 IN O
CsMnBr3 P09947191T0000 NNP O
: P09947191T0000 : O
A P09947191T0000 NNP O
Z2 P09947191T0000 NNP O
& P09947191T0000 CC O
gt P09947191T0000 NN O
; P09947191T0000 : O
= P09947191T0000 CC O
1 P09947191T0000 CD O
antiferromagnet P09947191T0000 NN O
. P09947191T0000 . O
. . O O

Variable P06493655A0415 JJ O
FHR P06493655A0415 NNP O
decelerations P06493655A0415 NNS O
or P06493655A0415 CC O
bradycardias P06493655A0415 NNS O
were P06493655A0415 VBD O
encountered P06493655A0415 VBN O
on P06493655A0415 IN O
95 P06493655A0415 CD O
nonstress P06493655A0415 JJ O
tests P06493655A0415 NNS O
( P06493655A0415 ( O
18.8 P06493655A0415 CD O
% P06493655A0415 NN O
) P06493655A0415 ) O
in P06493655A0415 IN O
80 P06493655A0415 CD O
( P06493655A0415 ( O
33.5 P06493655A0415 CD O
% P06493655A0415 NN O
) P06493655A0415 ) O
postdate P06493655A0415 NN O
patients P06493655A0415 NNS O
. P06493655A0415 . O
. . O O

Salivary P07685874A0258 JJ O
sodium P07685874A0258 NN O
, P07685874A0258 , O
calcium P07685874A0258 NN O
, P07685874A0258 , O
and P07685874A0258 CC O
magnesium P07685874A0258 NN O
concentrations P07685874A0258 NNS O
were P07685874A0258 VBD O
significantly P07685874A0258 RB O
higher P07685874A0258 JJR O
in P07685874A0258 IN O
the P07685874A0258 DT O
SLE P07685874A0258 NNP O
patients P07685874A0258 NNS O
with P07685874A0258 IN O
systemic P07685874A0258 JJ O
lupus P07685874A0258 NN O
erythematosus P07685874A0258 NN O
, P07685874A0258 , O
whereas P07685874A0258 JJ O
potassium P07685874A0258 NN O
and P07685874A0258 CC O
total P07685874A0258 JJ O
protein P07685874A0258 NN O
concentrations P07685874A0258 NNS O
and P07685874A0258 CC O
amylase P07685874A0258 NN I-UN
activity P07685874A0258 NN O
did P07685874A0258 VBD O
not P07685874A0258 RB O
differ P07685874A0258 VB O
significantly P07685874A0258 RB O
from P07685874A0258 IN O
the P07685874A0258 DT O
controls P07685874A0258 NNS O
. P07685874A0258 . O
. . O O

The P01777841A0744 DT O
possible P01777841A0744 JJ O
mechanisms P01777841A0744 NNS O
underlying P01777841A0744 VBG O
differences P01777841A0744 NNS O
in P01777841A0744 IN O
post-tetanic P01777841A0744 JJ O
effects P01777841A0744 NNS O
from P01777841A0744 IN O
muscle P01777841A0744 NN O
and P01777841A0744 CC O
cutaneous P01777841A0744 JJ O
afferents P01777841A0744 NNS O
in P01777841A0744 IN O
adults P01777841A0744 NNS O
and P01777841A0744 CC O
neonates P01777841A0744 NNS O
are P01777841A0744 VBP O
discussed P01777841A0744 VBN O
. P01777841A0744 . O
. . O O

The P10542281A0382 DT O
expressed P10542281A0382 VBN O
G1-G2 P10542281A0382 NNP O
bound P10542281A0382 NN O
to P10542281A0382 TO O
both P10542281A0382 DT O
hyaluronan P10542281A0382 NN O
and P10542281A0382 CC O
link P10542281A0382 NN I-UN
protein P10542281A0382 NN I-UN
indicating P10542281A0382 VBG O
that P10542281A0382 IN O
the P10542281A0382 DT O
immunoglobulin-fold P10542281A0382 JJ I-UN
motif P10542281A0382 NN I-UN
and P10542281A0382 CC O
proteoglycan P10542281A0382 JJ O
tandem P10542281A0382 NN O
repeat P10542281A0382 NN O
loops P10542281A0382 NNS O
of P10542281A0382 IN O
the P10542281A0382 DT O
G1 P10542281A0382 NNP I-UN
domain P10542281A0382 NN I-UN
were P10542281A0382 VBD O
correctly P10542281A0382 RB O
folded P10542281A0382 VBN O
. P10542281A0382 . O
. . O O

Snail P10606664A0000 NNP I-UN
family P10606664A0000 NN I-UN
proteins P10606664A0000 NNS I-UN
are P10606664A0000 VBP O
zinc P10606664A0000 JJ O
finger P10606664A0000 JJ O
transcriptional P10606664A0000 JJ O
regulators P10606664A0000 NNS O
first P10606664A0000 RB O
identified P10606664A0000 VBN O
in P10606664A0000 IN O
Drosophila P10606664A0000 NNP O
which P10606664A0000 WDT O
play P10606664A0000 VBP O
critical P10606664A0000 JJ O
roles P10606664A0000 NNS O
in P10606664A0000 IN O
cell P10606664A0000 NN O
fate P10606664A0000 NN O
determination P10606664A0000 NN O
. P10606664A0000 . O
. . O O

Krox-20 P08625806A0263 NNP I-UN
, P08625806A0263 , O
a P08625806A0263 DT O
zinc P08625806A0263 NN I-UN
finger P08625806A0263 NN I-UN
gene P08625806A0263 NN I-UN
, P08625806A0263 , O
has P08625806A0263 VBZ O
a P08625806A0263 DT O
highly P08625806A0263 RB O
conserved P08625806A0263 JJ O
pattern P08625806A0263 NN O
of P08625806A0263 IN O
expression P08625806A0263 NN O
in P08625806A0263 IN O
r3 P08625806A0263 NN O
and P08625806A0263 CC O
r5 P08625806A0263 NN O
and P08625806A0263 CC O
is P08625806A0263 VBZ O
functionally P08625806A0263 RB O
required P08625806A0263 VBN O
for P08625806A0263 IN O
their P08625806A0263 PRP$ O
maintenance P08625806A0263 NN O
in P08625806A0263 IN O
mouse P08625806A0263 NN O
embryos P08625806A0263 NN O
. P08625806A0263 . O
. . O O

Incorporation P03235487A0404 NN O
of P03235487A0404 IN O
0.1 P03235487A0404 CD O
or P03235487A0404 CC O
0.2 P03235487A0404 CD O
M P03235487A0404 NNP O
sodium P03235487A0404 NN O
dihydrogen P03235487A0404 NN O
phosphate P03235487A0404 NN O
in P03235487A0404 IN O
the P03235487A0404 DT O
sugar P03235487A0404 NN O
solutions P03235487A0404 NNS O
resulted P03235487A0404 VBD O
in P03235487A0404 IN O
a P03235487A0404 DT O
decrease P03235487A0404 NN O
in P03235487A0404 IN O
the P03235487A0404 DT O
shelf-life P03235487A0404 NN O
of P03235487A0404 IN O
diltiazem P03235487A0404 NN O
. P03235487A0404 . O
. . O O

Furthermore P08668158A1252 RB O
, P08668158A1252 , O
strains P08668158A1252 NNS O
with P08668158A1252 IN O
mutant P08668158A1252 JJ I-UN
RPM1 P08668158A1252 NNP I-UN
genes P08668158A1252 NNS I-UN
also P08668158A1252 RB O
accumulate P08668158A1252 VBP O
precursor P08668158A1252 NN I-UN
Rpm1r P08668158A1252 NNP I-UN
, P08668158A1252 , O
suggesting P08668158A1252 VBG O
that P08668158A1252 IN O
mutations P08668158A1252 NNS O
in P08668158A1252 IN O
either P08668158A1252 DT O
gene P08668158A1252 NN O
can P08668158A1252 MD O
lead P08668158A1252 VB O
to P08668158A1252 TO O
similar P08668158A1252 JJ O
biogenesis P08668158A1252 NN O
defects P08668158A1252 NNS O
. P08668158A1252 . O
. . O O

An P08656672A0678 DT O
apparent P08656672A0678 JJ O
ufo P08656672A0678 JJ I-UN
mRNA P08656672A0678 NN I-UN
overexpression P08656672A0678 NN O
was P08656672A0678 VBD O
not P08656672A0678 RB O
found P08656672A0678 VBN O
in P08656672A0678 IN O
any P08656672A0678 DT O
of P08656672A0678 IN O
the P08656672A0678 DT O
positive P08656672A0678 JJ O
leukemia P08656672A0678 NN O
cell P08656672A0678 NN O
lines P08656672A0678 NNS O
, P08656672A0678 , O
but P08656672A0678 CC O
was P08656672A0678 VBD O
identified P08656672A0678 VBN O
in P08656672A0678 IN O
the P08656672A0678 DT O
drug-resistant P08656672A0678 JJ O
subclones P08656672A0678 NNS O
of P08656672A0678 IN O
the P08656672A0678 DT O
cervix P08656672A0678 NN O
carcinoma P08656672A0678 NN O
cell P08656672A0678 NN O
line P08656672A0678 NN O
HeLa P08656672A0678 NNP O
. P08656672A0678 . O
. . O O

Measurements P09916786A0811 NNS O
included P09916786A0811 VBD O
bone P09916786A0811 JJ O
mineral P09916786A0811 JJ O
density P09916786A0811 NN O
of P09916786A0811 IN O
the P09916786A0811 DT O
lumbar P09916786A0811 NN O
spine P09916786A0811 NN O
and P09916786A0811 CC O
proximal P09916786A0811 JJ O
femur P09916786A0811 NN O
( P09916786A0811 ( O
by P09916786A0811 IN O
dual-energy P09916786A0811 JJ O
X-ray P09916786A0811 JJ O
absorptiometry P09916786A0811 NN O
) P09916786A0811 ) O
and P09916786A0811 CC O
biochemical P09916786A0811 JJ O
markers P09916786A0811 NNS O
of P09916786A0811 IN O
bone P09916786A0811 NN O
remodeling P09916786A0811 NN O
( P09916786A0811 ( O
serum P09916786A0811 JJ O
bone-specific P09916786A0811 JJ O
alkaline P09916786A0811 NN I-UN
phosphatase P09916786A0811 NN I-UN
by P09916786A0811 IN O
immunoassay P09916786A0811 NN O
and P09916786A0811 CC O
urine P09916786A0811 JJ O
deoxypyridinoline P09916786A0811 NN O
by P09916786A0811 IN O
high-pressure P09916786A0811 NN O
liquid P09916786A0811 NN O
chromatography P09916786A0811 NN O
) P09916786A0811 ) O
. P09916786A0811 . O
. . O O

The P08125949A1162 DT O
previously P08125949A1162 RB O
described P08125949A1162 VBN O
enhanced P08125949A1162 JJ O
translation P08125949A1162 NN O
of P08125949A1162 IN O
spinach P08125949A1162 NN O
L12 P08125949A1162 NNP I-UN
mRNA P08125949A1162 NN I-UN
from P08125949A1162 IN O
its P08125949A1162 PRP$ O
two P08125949A1162 CD O
tandem P08125949A1162 NN O
AUG P08125949A1162 NNP O
codons P08125949A1162 NNS O
and P08125949A1162 CC O
the P08125949A1162 DT O
two P08125949A1162 CD O
functional P08125949A1162 JJ O
rpl12 P08125949A1162 NN I-UN
genes P08125949A1162 NNS I-UN
in P08125949A1162 IN O
Arabidopsis P08125949A1162 NNP O
probably P08125949A1162 RB O
provide P08125949A1162 VBP O
two P08125949A1162 CD O
mechanisms P08125949A1162 NNS O
for P08125949A1162 IN O
generating P08125949A1162 VBG O
the P08125949A1162 DT O
four P08125949A1162 CD O
copies P08125949A1162 NNS O
of P08125949A1162 IN O
L12 P08125949A1162 NNP I-UN
/ P08125949A1162 NNP I-UN
chloroplast P08125949A1162 VBD I-UN
ribosome P08125949A1162 NN I-UN
, P08125949A1162 , O
qualitatively P08125949A1162 RB O
different P08125949A1162 JJ O
from P08125949A1162 IN O
those P08125949A1162 DT O
attempted P08125949A1162 VBN O
in P08125949A1162 IN O
eubacteria P08125949A1162 NN O
. P08125949A1162 . O
. . O O

Hypoxic P02064119A1172 NNP O
ventilatory P02064119A1172 NN O
responses P02064119A1172 NNS O
were P02064119A1172 VBD O
-1.99 P02064119A1172 JJ O
+ P02064119A1172 NNP O
/ P02064119A1172 NNP O
- P02064119A1172 : O
0.37 P02064119A1172 CD O
L P02064119A1172 NNP O
/ P02064119A1172 NNP O
min P02064119A1172 NNP O
/ P02064119A1172 NNP O
% P02064119A1172 NN O
SaO2 P02064119A1172 NNP O
in P02064119A1172 IN O
the P02064119A1172 DT O
relatives P02064119A1172 NNS O
and P02064119A1172 CC O
-1.54 P02064119A1172 NNP O
+ P02064119A1172 NNP O
/ P02064119A1172 NNP O
- P02064119A1172 : O
0.25 P02064119A1172 CD O
L P02064119A1172 NNP O
/ P02064119A1172 NNP O
min P02064119A1172 NNP O
/ P02064119A1172 NNP O
% P02064119A1172 NN O
SaO2 P02064119A1172 NNP O
in P02064119A1172 IN O
the P02064119A1172 DT O
control P02064119A1172 NN O
subjects P02064119A1172 VBZ O
. P02064119A1172 . O
( P02064119A1172 ( O
ABSTRACT P02064119A1172 NNP O
TRUNCATED P02064119A1172 NNP O
AT P02064119A1172 NNP O
250 P02064119A1172 CD O
WORDS P02064119A1172 NNP O
) P02064119A1172 ) O
. P02064119A1172 . O
. . O O

Evaluation P04123662T0000 NN O
of P04123662T0000 IN O
thyroid P04123662T0000 JJ O
function P04123662T0000 NN O
. P04123662T0000 . O
. . O O

For P11844812A0915 IN O
the P11844812A0915 DT O
2.5 P11844812A0915 CD O
to P11844812A0915 TO O
4 P11844812A0915 CD O
ng P11844812A0915 NNS O
/ P11844812A0915 JJ O
mL P11844812A0915 JJ O
model P11844812A0915 NN O
, P11844812A0915 , O
the P11844812A0915 DT O
AUC P11844812A0915 NNP O
of P11844812A0915 IN O
the P11844812A0915 DT O
ANN P11844812A0915 NNP O
ROC P11844812A0915 NNP O
curve P11844812A0915 NN O
was P11844812A0915 VBD O
significantly P11844812A0915 RB O
higher P11844812A0915 JJR O
than P11844812A0915 IN O
the P11844812A0915 DT O
AUCs P11844812A0915 NNP O
for P11844812A0915 IN O
percentage P11844812A0915 NN O
of P11844812A0915 IN O
free P11844812A0915 JJ O
PSA P11844812A0915 NNP I-UN
( P11844812A0915 ( O
P P11844812A0915 NNP O
=.0239 P11844812A0915 NNP O
) P11844812A0915 ) O
, P11844812A0915 , O
PSA-TZ P11844812A0915 NNP O
( P11844812A0915 ( O
P P11844812A0915 NNP O
=.0204 P11844812A0915 NNP O
) P11844812A0915 ) O
, P11844812A0915 , O
and P11844812A0915 CC O
PSA P11844812A0915 NNP I-UN
density P11844812A0915 NN O
and P11844812A0915 CC O
total P11844812A0915 JJ O
prostate P11844812A0915 NN O
volume P11844812A0915 NN O
( P11844812A0915 ( O
P P11844812A0915 NNP O
< P11844812A0915 NNP O
.01 P11844812A0915 NNP O
for P11844812A0915 IN O
both P11844812A0915 DT O
) P11844812A0915 ) O
. P11844812A0915 . O
. . O O

IMPLICATIONS P08847723A2351 NN O
: P08847723A2351 : O
Given P08847723A2351 VBN O
the P08847723A2351 DT O
small P08847723A2351 JJ O
size P08847723A2351 NN O
of P08847723A2351 IN O
this P08847723A2351 DT O
study P08847723A2351 NN O
and P08847723A2351 CC O
the P08847723A2351 DT O
inconsistency P08847723A2351 NN O
of P08847723A2351 IN O
results P08847723A2351 NNS O
among P08847723A2351 IN O
the P08847723A2351 DT O
few P08847723A2351 JJ O
prospective P08847723A2351 JJ O
studies P08847723A2351 NNS O
of P08847723A2351 IN O
ovarian P08847723A2351 JJ O
cancer P08847723A2351 NN O
conducted P08847723A2351 VBN O
to P08847723A2351 TO O
test P08847723A2351 VB O
these P08847723A2351 DT O
associations P08847723A2351 NNS O
, P08847723A2351 , O
replications P08847723A2351 NNS O
of P08847723A2351 IN O
these P08847723A2351 DT O
findings P08847723A2351 NNS O
are P08847723A2351 VBP O
highly P08847723A2351 RB O
desirable P08847723A2351 JJ O
. P08847723A2351 . O
. . O O

Serum P07555373A0000 NNP O
magnesium P07555373A0000 NN O
in P07555373A0000 IN O
79 P07555373A0000 CD O
patients P07555373A0000 NNS O
of P07555373A0000 IN O
gynecologic P07555373A0000 JJ O
neoplasms P07555373A0000 NNS O
treated P07555373A0000 VBN O
with P07555373A0000 IN O
cisplatin P07555373A0000 NN O
and P07555373A0000 CC O
their P07555373A0000 PRP$ O
controls P07555373A0000 NNS O
was P07555373A0000 VBD O
measured P07555373A0000 VBN O
. P07555373A0000 . O
. . O O

Because P07854324A0281 IN O
of P07854324A0281 IN O
the P07854324A0281 DT O
functional P07854324A0281 JJ O
conservation P07854324A0281 NN O
of P07854324A0281 IN O
cell P07854324A0281 NN O
cycle P07854324A0281 NN O
control P07854324A0281 NN O
elements P07854324A0281 NNS O
, P07854324A0281 , O
the P07854324A0281 DT O
expression P07854324A0281 NN O
of P07854324A0281 IN O
a P07854324A0281 DT O
vertebrate P07854324A0281 NN I-UN
wee1 P07854324A0281 NN I-UN
or P07854324A0281 CC O
mik1 P07854324A0281 NN I-UN
homolog P07854324A0281 NN I-UN
would P07854324A0281 MD O
be P07854324A0281 VB O
expected P07854324A0281 VBN O
to P07854324A0281 TO O
rescue P07854324A0281 VB O
such P07854324A0281 JJ O
lethal P07854324A0281 JJ O
mutations P07854324A0281 NNS O
in P07854324A0281 IN O
yeast P07854324A0281 NN O
. P07854324A0281 . O
. . O O

Drosophila P11223240A0655 NNP I-UN
Menin1 P11223240A0655 NNP I-UN
gene P11223240A0655 NN I-UN
transcripts P11223240A0655 NNS I-UN
use P11223240A0655 VBP O
alternative P11223240A0655 JJ O
polyadenylation P11223240A0655 NN O
sites P11223240A0655 NNS O
resulting P11223240A0655 VBG O
in P11223240A0655 IN O
4.3 P11223240A0655 CD O
and P11223240A0655 CC O
5-kb P11223240A0655 JJ O
messages P11223240A0655 NNS O
. P11223240A0655 . O
. . O O

The P10405635A0374 DT O
transcriptional P10405635A0374 JJ O
activities P10405635A0374 NNS O
of P10405635A0374 IN O
the P10405635A0374 DT O
full-length P10405635A0374 JJ O
promoter P10405635A0374 NN O
( P10405635A0374 ( O
-295 P10405635A0374 UH O
to P10405635A0374 TO O
+85 P10405635A0374 VB O
) P10405635A0374 ) O
and P10405635A0374 CC O
of P10405635A0374 IN O
three P10405635A0374 CD O
deletion P10405635A0374 NN O
constructs P10405635A0374 NNS O
( P10405635A0374 ( O
-197 P10405635A0374 NN O
, P10405635A0374 , O
-154 P10405635A0374 NNP O
and P10405635A0374 CC O
-74 P10405635A0374 NNP O
to P10405635A0374 TO O
+85 P10405635A0374 VB O
) P10405635A0374 ) O
were P10405635A0374 VBD O
significantly P10405635A0374 RB O
down-regulated P10405635A0374 VBN O
in P10405635A0374 IN O
resistant P10405635A0374 JJ O
cells P10405635A0374 NNS O
. P10405635A0374 . O
. . O O

Methisergide P07260389A0221 NNP O
( P07260389A0221 ( O
0.5 P07260389A0221 CD O
mg P07260389A0221 NN O
/ P07260389A0221 NNP O
kg P07260389A0221 NN O
, P07260389A0221 , O
i.p P07260389A0221 NN O
. P07260389A0221 . O
) P07260389A0221 ) O
, P07260389A0221 , O
a P07260389A0221 DT O
blocker P07260389A0221 NN O
of P07260389A0221 IN O
serotonin P07260389A0221 NN I-UN
receptors P07260389A0221 NNS I-UN
, P07260389A0221 , O
prevented P07260389A0221 VBD O
the P07260389A0221 DT O
development P07260389A0221 NN O
of P07260389A0221 IN O
the P07260389A0221 DT O
antinociceptive P07260389A0221 JJ O
effect P07260389A0221 NN O
of P07260389A0221 IN O
serotonin P07260389A0221 NN O
. P07260389A0221 . O
. . O O

A P08474438A0000 DT O
variety P08474438A0000 NN O
of P08474438A0000 IN O
nuclear P08474438A0000 JJ O
ribonucleoproteins P08474438A0000 NNS O
are P08474438A0000 VBP O
believed P08474438A0000 VBN O
to P08474438A0000 TO O
associate P08474438A0000 VB O
directly P08474438A0000 RB O
with P08474438A0000 IN O
nascent P08474438A0000 JJ O
RNA P08474438A0000 NNP I-UN
polymerase P08474438A0000 NN I-UN
II P08474438A0000 NNP I-UN
transcripts P08474438A0000 NNS I-UN
and P08474438A0000 CC O
remain P08474438A0000 VBP O
associated P08474438A0000 JJ O
during P08474438A0000 IN O
subsequent P08474438A0000 JJ O
nuclear P08474438A0000 JJ O
RNA P08474438A0000 NNP O
processing P08474438A0000 NN O
reactions P08474438A0000 NNS O
, P08474438A0000 , O
including P08474438A0000 VBG O
pre-mRNA P08474438A0000 JJ O
polyadenylation P08474438A0000 NN O
and P08474438A0000 CC O
splicing P08474438A0000 NN O
as P08474438A0000 RB O
well P08474438A0000 RB O
as P08474438A0000 IN O
nucleocytoplasmic P08474438A0000 JJ O
mRNA P08474438A0000 NN O
transport P08474438A0000 NN O
. P08474438A0000 . O
. . O O

The P00512215A0000 DT O
present P00512215A0000 JJ O
study P00512215A0000 NN O
examined P00512215A0000 VBD O
the P00512215A0000 DT O
dependence P00512215A0000 NN O
of P00512215A0000 IN O
difference P00512215A0000 NN O
tone P00512215A0000 NN O
level P00512215A0000 NN O
[ P00512215A0000 NNP O
L P00512215A0000 NNP O
( P00512215A0000 ( O
f2-f1 P00512215A0000 JJ O
) P00512215A0000 ) O
] P00512215A0000 NN O
on P00512215A0000 IN O
the P00512215A0000 DT O
following P00512215A0000 JJ O
parameters P00512215A0000 NNS O
of P00512215A0000 IN O
the P00512215A0000 DT O
two-tone P00512215A0000 JJ O
input P00512215A0000 NN O
: P00512215A0000 : O
f1 P00512215A0000 NN O
, P00512215A0000 , O
f2 P00512215A0000 JJ O
/ P00512215A0000 NN O
f1 P00512215A0000 NN O
( P00512215A0000 ( O
f2 P00512215A0000 JJ O
greater P00512215A0000 JJR O
than P00512215A0000 IN O
f1 P00512215A0000 NN O
) P00512215A0000 ) O
, P00512215A0000 , O
L1 P00512215A0000 NNP O
, P00512215A0000 , O
L2 P00512215A0000 NNP O
, P00512215A0000 , O
and P00512215A0000 CC O
L1 P00512215A0000 NNP O
= P00512215A0000 NNP O
L2 P00512215A0000 NNP O
. P00512215A0000 . O
. . O O

RESULTS P09776293A0777 NN O
: P09776293A0777 : O
The P09776293A0777 DT O
binding P09776293A0777 NN O
of P09776293A0777 IN O
99mTc P09776293A0777 CD O
d P09776293A0777 NN O
, P09776293A0777 , O
1-HMPAO P09776293A0777 JJ O
to P09776293A0777 TO O
human P09776293A0777 JJ O
placenta P09776293A0777 NNS O
ranged P09776293A0777 VBD O
from P09776293A0777 IN O
2.95 P09776293A0777 CD O
% P09776293A0777 NN O
+ P09776293A0777 NNP O
/ P09776293A0777 NNP O
- P09776293A0777 : O
1.5 P09776293A0777 CD O
% P09776293A0777 NN O
to P09776293A0777 TO O
5.82 P09776293A0777 CD O
% P09776293A0777 NN O
+ P09776293A0777 NNP O
/ P09776293A0777 NNP O
- P09776293A0777 : O
0.3 P09776293A0777 CD O
% P09776293A0777 NN O
per P09776293A0777 IN O
1 P09776293A0777 CD O
ml P09776293A0777 JJ O
standard P09776293A0777 JJ O
solution P09776293A0777 NN O
. P09776293A0777 . O
. . O O

Dsh P11036939A2149 NNP I-UN
is P11036939A2149 VBZ O
required P11036939A2149 VBN O
for P11036939A2149 IN O
two P11036939A2149 CD O
different P11036939A2149 JJ O
pathways P11036939A2149 NNS O
, P11036939A2149 , O
the P11036939A2149 DT O
Wnt P11036939A2149 NNP I-UN
pathway P11036939A2149 NN O
and P11036939A2149 CC O
planar P11036939A2149 NN O
polarity P11036939A2149 NN O
pathway P11036939A2149 NN O
in P11036939A2149 IN O
Drosophila P11036939A2149 NNP O
. P11036939A2149 . O
. . O O

Growth P11706949T0000 NNP I-UN
hormone P11706949T0000 NN I-UN
and P11706949T0000 CC O
insulin-like P11706949T0000 JJ I-UN
growth P11706949T0000 NN I-UN
factor P11706949T0000 NN I-UN
I P11706949T0000 PRP I-UN
receptors P11706949T0000 NNS I-UN
in P11706949T0000 IN O
the P11706949T0000 DT O
temporomandibular P11706949T0000 JJ O
joint P11706949T0000 NN O
of P11706949T0000 IN O
the P11706949T0000 DT O
rat P11706949T0000 NN O
. P11706949T0000 . O
. . O O

Cloning P09484463T0000 VBG O
and P09484463T0000 CC O
expression P09484463T0000 NN O
of P09484463T0000 IN O
two P09484463T0000 CD O
genes P09484463T0000 NNS O
encoding P09484463T0000 VBG O
auxin-binding P09484463T0000 JJ I-UN
proteins P09484463T0000 NNS I-UN
from P09484463T0000 IN O
tobacco P09484463T0000 NN O
. P09484463T0000 . O
. . O O

Mutations P07828824A0307 NNS O
that P07828824A0307 WDT O
alter P07828824A0307 VBP O
photoreceptor P07828824A0307 NN O
cell P07828824A0307 NN O
structure P07828824A0307 NN O
and P07828824A0307 CC O
development P07828824A0307 NN O
were P07828824A0307 VBD O
isolated P07828824A0307 VBN O
that P07828824A0307 IN O
fail P07828824A0307 NN O
to P07828824A0307 TO O
complement P07828824A0307 VB O
these P07828824A0307 DT O
deletions P07828824A0307 NNS O
. P07828824A0307 . O
. . O O

Previous P01279696A0862 JJ O
studies P01279696A0862 NNS O
have P01279696A0862 VBP O
shown P01279696A0862 VBN O
[ P01279696A0862 NNP O
Hisanaga P01279696A0862 NNP O
, P01279696A0862 , O
S. P01279696A0862 NNP O
, P01279696A0862 , O
Kusubata P01279696A0862 NNP O
, P01279696A0862 , O
M. P01279696A0862 NNP O
, P01279696A0862 , O
Okumura P01279696A0862 NNP O
, P01279696A0862 , O
E. P01279696A0862 NNP O
& P01279696A0862 CC O
Kishimoto P01279696A0862 NNP O
, P01279696A0862 , O
T P01279696A0862 NNP O
. P01279696A0862 . O
. . O O

Positional P09159160A0000 NNP O
cloning P09159160A0000 NN O
has P09159160A0000 VBZ O
already P09159160A0000 RB O
produced P09159160A0000 VBN O
the P09159160A0000 DT O
sequences P09159160A0000 NNS O
of P09159160A0000 IN O
more P09159160A0000 JJR O
than P09159160A0000 IN O
70 P09159160A0000 CD O
human P09159160A0000 JJ O
genes P09159160A0000 NNS O
associated P09159160A0000 VBN O
with P09159160A0000 IN O
specific P09159160A0000 JJ O
diseases P09159160A0000 NNS O
. P09159160A0000 . O
. . O O

The P02483210A0000 DT O
diagnostic P02483210A0000 JJ O
value P02483210A0000 NN O
of P02483210A0000 IN O
blood P02483210A0000 NN O
serum P02483210A0000 NN O
and P02483210A0000 CC O
urinary P02483210A0000 JJ I-UN
amylase P02483210A0000 NN I-UN
, P02483210A0000 , O
lipase P02483210A0000 NN I-UN
, P02483210A0000 , O
and P02483210A0000 CC O
trypsin P02483210A0000 NN I-UN
in P02483210A0000 IN O
exacerbations P02483210A0000 NNS O
of P02483210A0000 IN O
chronic P02483210A0000 JJ O
relapsing P02483210A0000 VBG O
pancreatitis P02483210A0000 NN O
is P02483210A0000 VBZ O
discussed P02483210A0000 VBN O
. P02483210A0000 . O
. . O O

Finally P09786926A1372 RB O
, P09786926A1372 , O
using P09786926A1372 VBG O
in P09786926A1372 IN O
vitro P09786926A1372 NN O
binding P09786926A1372 NN O
studies P09786926A1372 NNS O
, P09786926A1372 , O
we P09786926A1372 PRP O
showed P09786926A1372 VBD O
that P09786926A1372 IN O
SREBP2 P09786926A1372 NNP I-UN
was P09786926A1372 VBD O
able P09786926A1372 JJ O
to P09786926A1372 TO O
displace P09786926A1372 VB O
ADD1 P09786926A1372 NNP I-UN
/ P09786926A1372 NNP O
SREBP1 P09786926A1372 NNP I-UN
binding P09786926A1372 VBG O
from P09786926A1372 IN O
the P09786926A1372 DT O
sterol P09786926A1372 NN O
regulatory P09786926A1372 JJ O
element P09786926A1372 NN O
( P09786926A1372 ( O
SRE P09786926A1372 NNP O
) P09786926A1372 ) O
site P09786926A1372 NN O
. P09786926A1372 . O
. . O O

We P11844591A0329 PRP O
also P11844591A0329 RB O
studied P11844591A0329 VBD O
a P11844591A0329 DT O
new P11844591A0329 JJ O
parameter P11844591A0329 NN O
: P11844591A0329 : O
the P11844591A0329 DT O
angle P11844591A0329 NN O
to P11844591A0329 TO O
maximal P11844591A0329 VB O
peak P11844591A0329 JJ O
torque P11844591A0329 NN O
( P11844591A0329 ( O
APT P11844591A0329 NNP O
) P11844591A0329 ) O
. P11844591A0329 . O
. . O O

In P08783666A0957 IN O
addition P08783666A0957 NN O
, P08783666A0957 , O
the P08783666A0957 DT O
time P08783666A0957 NN O
to P08783666A0957 TO O
engraftment P08783666A0957 VB O
was P08783666A0957 VBD O
significantly P08783666A0957 RB O
shorter P08783666A0957 JJR O
in P08783666A0957 IN O
the P08783666A0957 DT O
amifostine P08783666A0957 NN O
arm P08783666A0957 NN O
in P08783666A0957 IN O
both P08783666A0957 DT O
cohorts P08783666A0957 NNS O
. P08783666A0957 . O
. . O O

We P02002051A0276 PRP O
report P02002051A0276 VBP O
here P02002051A0276 RB O
the P02002051A0276 DT O
isolation P02002051A0276 NN O
of P02002051A0276 IN O
a P02002051A0276 DT O
full-length P02002051A0276 JJ O
cDNA P02002051A0276 NN O
clone P02002051A0276 NN O
coding P02002051A0276 VBG O
for P02002051A0276 IN O
a P02002051A0276 DT O
hitherto P02002051A0276 NN O
undiscovered P02002051A0276 JJ O
isoform P02002051A0276 NN O
of P02002051A0276 IN O
the P02002051A0276 DT O
bovine P02002051A0276 JJ I-UN
C-subunit P02002051A0276 NNP I-UN
. P02002051A0276 . O
. . O O

In P00488534A0308 IN O
addition P00488534A0308 NN O
a P00488534A0308 DT O
significant P00488534A0308 JJ O
Treatment P00488534A0308 NNP O
X P00488534A0308 NNP O
Strain P00488534A0308 NNP O
interaction P00488534A0308 NN O
was P00488534A0308 VBD O
due P00488534A0308 JJ O
to P00488534A0308 TO O
the P00488534A0308 DT O
larger P00488534A0308 JJR O
defecation P00488534A0308 NN O
numbers P00488534A0308 NNS O
displayed P00488534A0308 VBN O
by P00488534A0308 IN O
the P00488534A0308 DT O
taurine-injected P00488534A0308 JJ O
MR P00488534A0308 NNP O
rats P00488534A0308 NNS O
relative P00488534A0308 VBP O
to P00488534A0308 TO O
the P00488534A0308 DT O
saline-injected P00488534A0308 JJ O
MR P00488534A0308 NNP O
rats P00488534A0308 NNS O
. P00488534A0308 . O
. . O O

Increase P07814717A0669 NNP O
in P07814717A0669 IN O
blood P07814717A0669 NN O
NEFA P07814717A0669 NNP O
was P07814717A0669 VBD O
further P07814717A0669 RBR O
augmented P07814717A0669 VBN O
by P07814717A0669 IN O
fat P07814717A0669 JJ O
plus P07814717A0669 CC O
AA P07814717A0669 NNP O
supplementation P07814717A0669 NN O
, P07814717A0669 , O
but P07814717A0669 CC O
no P07814717A0669 DT O
changes P07814717A0669 NNS O
in P07814717A0669 IN O
concentrations P07814717A0669 NNS O
of P07814717A0669 IN O
Lys P07814717A0669 NNP O
or P07814717A0669 CC O
Met P07814717A0669 NNP O
in P07814717A0669 IN O
blood P07814717A0669 NN O
were P07814717A0669 VBD O
found P07814717A0669 VBN O
. P07814717A0669 . O
. . O O

A P00201881A0487 DT O
striking P00201881A0487 JJ O
finding P00201881A0487 NN O
in P00201881A0487 IN O
all P00201881A0487 DT O
of P00201881A0487 IN O
the P00201881A0487 DT O
studies P00201881A0487 NNS O
was P00201881A0487 VBD O
a P00201881A0487 DT O
positive P00201881A0487 JJ O
correlation P00201881A0487 NN O
between P00201881A0487 IN O
PI P00201881A0487 NNP O
ACTH P00201881A0487 NNP I-UN
and P00201881A0487 CC O
MSH P00201881A0487 NNP I-UN
contents P00201881A0487 NNS O
. P00201881A0487 . O
. . O O

Surprisingly P09456312A1064 RB O
, P09456312A1064 , O
the P09456312A1064 DT O
COOH-terminal P09456312A1064 JJ O
domain P09456312A1064 NN O
of P09456312A1064 IN O
RanGAP1 P09456312A1064 NNP I-UN
was P09456312A1064 VBD O
also P09456312A1064 RB O
found P09456312A1064 VBN O
to P09456312A1064 TO O
harbor P09456312A1064 VB O
a P09456312A1064 DT O
nuclear P09456312A1064 JJ O
localization P09456312A1064 NN O
signal P09456312A1064 NN O
. P09456312A1064 . O
. . O O

Until P09730413A0642 IN O
such P09730413A0642 JJ O
investigations P09730413A0642 NNS O
are P09730413A0642 VBP O
performed P09730413A0642 VBN O
, P09730413A0642 , O
we P09730413A0642 PRP O
conclude P09730413A0642 VBP O
that P09730413A0642 IN O
the P09730413A0642 DT O
role P09730413A0642 NN O
for P09730413A0642 IN O
adjuvant P09730413A0642 JJ O
treatment P09730413A0642 NN O
is P09730413A0642 VBZ O
questionable P09730413A0642 JJ O
and P09730413A0642 CC O
that P09730413A0642 DT O
TME P09730413A0642 NNP O
surgery P09730413A0642 NN O
is P09730413A0642 VBZ O
preferred P09730413A0642 VBN O
as P09730413A0642 IN O
the P09730413A0642 DT O
treatment P09730413A0642 NN O
option P09730413A0642 NN O
for P09730413A0642 IN O
Stage P09730413A0642 NNP O
T1-T3 P09730413A0642 NNP O
rectal P09730413A0642 JJ O
cancers P09730413A0642 NNS O
. P09730413A0642 . O
. . O O

The P03064811A0485 DT O
amino P03064811A0485 NN O
acid P03064811A0485 JJ O
sequence P03064811A0485 NN O
of P03064811A0485 IN O
the P03064811A0485 DT O
S. P03064811A0485 NNP O
aureus P03064811A0485 NN O
peptide P03064811A0485 NN O
carrying P03064811A0485 VBG O
the P03064811A0485 DT O
phosphoryl P03064811A0485 NN O
group P03064811A0485 NN O
was P03064811A0485 VBD O
found P03064811A0485 VBN O
to P03064811A0485 TO O
be P03064811A0485 VB O
Gln-Val-Val-Ser-Thr-Phe-Met-Gly-Asn-Gly-Leu-Ala-Ile-Pro-His-Gly-Thr-Asp- P03064811A0485 JJ O
Asp P03064811A0485 NNP O
. P03064811A0485 . O
. . O O

To P02033062A1169 TO O
test P02033062A1169 VB O
promotor P02033062A1169 NN O
function P02033062A1169 NN O
, P02033062A1169 , O
chimeric P02033062A1169 JJ O
genes P02033062A1169 NNS O
were P02033062A1169 VBD O
constructed P02033062A1169 VBN O
linking P02033062A1169 VBG O
fragments P02033062A1169 NNS O
of P02033062A1169 IN O
chicken P02033062A1169 JJ O
IGF-I P02033062A1169 JJ I-UN
5'-flanking P02033062A1169 JJ O
DNA P02033062A1169 NN O
to P02033062A1169 TO O
a P02033062A1169 DT O
promoterless P02033062A1169 NN O
reporter P02033062A1169 NN O
plasmid P02033062A1169 NN O
. P02033062A1169 . O
. . O O

Here P09121424A0296 RB O
we P09121424A0296 PRP O
characterize P09121424A0296 VBP O
an P09121424A0296 DT O
S. P09121424A0296 NNP I-UN
cerevisiae P09121424A0296 NN I-UN
Swi3 P09121424A0296 NNP I-UN
homolog P09121424A0296 NN I-UN
( P09121424A0296 ( O
Swh3 P09121424A0296 NNP I-UN
) P09121424A0296 ) O
and P09121424A0296 CC O
present P09121424A0296 JJ O
evidence P09121424A0296 NN O
that P09121424A0296 IN O
it P09121424A0296 PRP O
associates P09121424A0296 VBZ O
in P09121424A0296 IN O
a P09121424A0296 DT O
complex P09121424A0296 JJ O
with P09121424A0296 IN O
a P09121424A0296 DT O
Snf2 P09121424A0296 NNP I-UN
homolog P09121424A0296 NN I-UN
, P09121424A0296 , O
Sthl P09121424A0296 NNP I-UN
. P09121424A0296 . O
. . O O

Human P08824798A0761 NNP O
ESP1 P08824798A0761 NNP I-UN
/ P08824798A0761 NNP O
CRP2 P08824798A0761 NNP I-UN
protein P08824798A0761 NN O
has P08824798A0761 VBZ O
two P08824798A0761 CD O
LIM P08824798A0761 NNP I-UN
domains P08824798A0761 NNS O
, P08824798A0761 , O
and P08824798A0761 CC O
each P08824798A0761 DT O
shares P08824798A0761 NNS O
35.1 P08824798A0761 CD O
% P08824798A0761 NN O
and P08824798A0761 CC O
77 P08824798A0761 CD O
or P08824798A0761 CC O
79 P08824798A0761 CD O
% P08824798A0761 NN O
identical P08824798A0761 JJ O
residues P08824798A0761 NNS O
with P08824798A0761 IN O
human P08824798A0761 JJ I-UN
cysteine-rich P08824798A0761 JJ I-UN
protein P08824798A0761 NN I-UN
( P08824798A0761 ( O
CRP P08824798A0761 NNP I-UN
) P08824798A0761 ) O
and P08824798A0761 CC O
rat P08824798A0761 JJ I-UN
CRIP P08824798A0761 NNP I-UN
, P08824798A0761 , O
respectively P08824798A0761 RB O
. P08824798A0761 . O
. . O O

The P01936348A0155 DT O
examinations P01936348A0155 NNS O
were P01936348A0155 VBD O
performed P01936348A0155 VBN O
on P01936348A0155 IN O
two P01936348A0155 CD O
groups P01936348A0155 NNS O
of P01936348A0155 IN O
20 P01936348A0155 CD O
( P01936348A0155 ( O
using P01936348A0155 VBG O
AmF P01936348A0155 NNP O
/ P01936348A0155 NNP O
SnF2 P01936348A0155 NNP O
) P01936348A0155 ) O
- P01936348A0155 : O
, P01936348A0155 , O
resp P01936348A0155 NN O
. P01936348A0155 . O
. . O O

Serine P10347203A0832 NNP O
phosphorylation P10347203A0832 NN O
of P10347203A0832 IN O
STAT3 P10347203A0832 NNP I-UN
was P10347203A0832 VBD O
only P10347203A0832 RB O
apparent P10347203A0832 JJ O
after P10347203A0832 IN O
somatostatin P10347203A0832 JJ I-UN
treatment P10347203A0832 NN O
and P10347203A0832 CC O
was P10347203A0832 VBD O
abolished P10347203A0832 VBN O
by P10347203A0832 IN O
pertussis P10347203A0832 NN I-UN
toxin P10347203A0832 NN I-UN
or P10347203A0832 CC O
PD P10347203A0832 NNP O
98059 P10347203A0832 CD O
, P10347203A0832 , O
together P10347203A0832 RB O
with P10347203A0832 IN O
the P10347203A0832 DT O
associated P10347203A0832 JJ O
increases P10347203A0832 NNS O
in P10347203A0832 IN O
proliferation P10347203A0832 NN O
. P10347203A0832 . O
. . O O

These P07501992A0125 DT O
incisors P07501992A0125 NNS O
were P07501992A0125 VBD O
studied P07501992A0125 VBN O
by P07501992A0125 IN O
scanning P07501992A0125 VBG O
electron P07501992A0125 JJ O
microscopy-energy P07501992A0125 JJ O
dispersive P07501992A0125 JJ O
spectroscopy P07501992A0125 NN O
analysis P07501992A0125 NN O
( P07501992A0125 ( O
SEM-EDS P07501992A0125 NNP O
) P07501992A0125 ) O
and P07501992A0125 CC O
light P07501992A0125 JJ O
microscopy P07501992A0125 NN O
to P07501992A0125 TO O
examine P07501992A0125 VB O
the P07501992A0125 DT O
calciotraumatic P07501992A0125 JJ O
lines P07501992A0125 NNS O
of P07501992A0125 IN O
strontium P07501992A0125 NN O
in P07501992A0125 IN O
the P07501992A0125 DT O
rat P07501992A0125 NN O
incisor P07501992A0125 NN O
labial P07501992A0125 JJ O
dentin P07501992A0125 NN O
. P07501992A0125 . O
. . O O

The P09858577A1186 DT O
loss P09858577A1186 NN O
of P09858577A1186 IN O
SKO1 P09858577A1186 NNP I-UN
completely P09858577A1186 RB O
restored P09858577A1186 VBD O
ENA1 P09858577A1186 NNP I-UN
expression P09858577A1186 NN O
in P09858577A1186 IN O
a P09858577A1186 DT O
hog1 P09858577A1186 NN I-UN
mutant P09858577A1186 NN I-UN
and P09858577A1186 CC O
partially P09858577A1186 RB O
suppressed P09858577A1186 VBD O
the P09858577A1186 DT O
osmotic P09858577A1186 JJ O
stress P09858577A1186 NN O
sensitivity P09858577A1186 NN O
, P09858577A1186 , O
qualifying P09858577A1186 VBG O
Sko1p P09858577A1186 NNP I-UN
as P09858577A1186 IN O
a P09858577A1186 DT O
downstream P09858577A1186 NN O
effector P09858577A1186 NN O
of P09858577A1186 IN O
the P09858577A1186 DT O
HOG P09858577A1186 NNP I-UN
pathway P09858577A1186 NN O
. P09858577A1186 . O
. . O O

Cbf3 P07957085A0207 NNP I-UN
contains P07957085A0207 VBZ O
three P07957085A0207 CD O
proteins P07957085A0207 NNS O
, P07957085A0207 , O
Cbf3a P07957085A0207 NNP I-UN
, P07957085A0207 , O
Cbf3b P07957085A0207 NNP I-UN
and P07957085A0207 CC O
Cbf3c P07957085A0207 NNP I-UN
. P07957085A0207 . O
. . O O

Activation P10679065A1217 NN O
of P10679065A1217 IN O
a P10679065A1217 DT O
CRE-dependent P10679065A1217 JJ O
junB P10679065A1217 NN I-UN
promoter P10679065A1217 NN I-UN
/ P10679065A1217 NNP O
chloramphenicol P10679065A1217 NN I-UN
acetyltransferase P10679065A1217 NN I-UN
( P10679065A1217 ( O
CAT P10679065A1217 NNP I-UN
) P10679065A1217 ) O
reporter P10679065A1217 NN O
gene P10679065A1217 NN O
by P10679065A1217 IN O
the P10679065A1217 DT O
BCR P10679065A1217 NNP I-UN
was P10679065A1217 VBD O
also P10679065A1217 RB O
blocked P10679065A1217 VBN O
by P10679065A1217 IN O
SB203580 P10679065A1217 NNP O
. P10679065A1217 . O
. . O O

These P07504712A0843 DT O
observations P07504712A0843 NNS O
link P07504712A0843 VBP O
actin P07504712A0843 JJ I-UN
plaque P07504712A0843 NN O
assembly P07504712A0843 NN O
to P07504712A0843 TO O
increased P07504712A0843 VBN O
cell P07504712A0843 NN O
substrate P07504712A0843 NN O
adhesion P07504712A0843 NN O
. P07504712A0843 . O
. . O O

Body P02882893A0301 NN O
temperature P02882893A0301 NN O
and P02882893A0301 CC O
overall P02882893A0301 JJ O
conductance P02882893A0301 NN O
in P02882893A0301 IN O
the P02882893A0301 DT O
cold P02882893A0301 JJ O
appear P02882893A0301 NN O
to P02882893A0301 TO O
be P02882893A0301 VB O
more P02882893A0301 RBR O
variable P02882893A0301 JJ O
in P02882893A0301 IN O
P. P02882893A0301 NNP O
s. P02882893A0301 NN O
campbelli P02882893A0301 NN O
than P02882893A0301 IN O
in P02882893A0301 IN O
nominative P02882893A0301 JJ O
sp P02882893A0301 NN O
. P02882893A0301 . O
. . O O

Sestamibi P08678959A0640 NNP O
scintigraphy P08678959A0640 NN O
, P08678959A0640 , O
performed P08678959A0640 VBN O
in P08678959A0640 IN O
70 P08678959A0640 CD O
patients P08678959A0640 NNS O
, P08678959A0640 , O
was P08678959A0640 VBD O
less P08678959A0640 RBR O
sensitive P08678959A0640 JJ O
than P08678959A0640 IN O
ultrasonography P08678959A0640 NN O
( P08678959A0640 ( O
80 P08678959A0640 CD O
% P08678959A0640 NN O
) P08678959A0640 ) O
. P08678959A0640 . O
. . O O

GN101 P02586485A0511 NNP O
, P02586485A0511 , O
YC819-9 P02586485A0511 NNP O
, P02586485A0511 , O
and P02586485A0511 CC O
SB3 P02586485A0511 NNP O
. P02586485A0511 . O
. . O O

The P09299696A1074 DT O
distribution P09299696A1074 NN O
of P09299696A1074 IN O
cryptosporidia P09299696A1074 NN O
in P09299696A1074 IN O
the P09299696A1074 DT O
intestine P09299696A1074 NN O
and P09299696A1074 CC O
number P09299696A1074 NN O
of P09299696A1074 IN O
cryptosporidia P09299696A1074 JJ O
per P09299696A1074 IN O
ileal P09299696A1074 NN O
villus P09299696A1074 NN O
on P09299696A1074 IN O
different P09299696A1074 JJ O
DPI P09299696A1074 NNP O
were P09299696A1074 VBD O
also P09299696A1074 RB O
estimated P09299696A1074 VBN O
for P09299696A1074 IN O
detailed P09299696A1074 JJ O
characterization P09299696A1074 NN O
of P09299696A1074 IN O
the P09299696A1074 DT O
infection P09299696A1074 NN O
in P09299696A1074 IN O
kids P09299696A1074 NNS O
as P09299696A1074 IN O
a P09299696A1074 DT O
model P09299696A1074 NN O
for P09299696A1074 IN O
experimental P09299696A1074 JJ O
cryptosporidiosis P09299696A1074 NN O
. P09299696A1074 . O
. . O O

Individual P07565775A1265 JJ O
mutations P07565775A1265 NNS O
in P07565775A1265 IN O
motifs P07565775A1265 JJ O
III P07565775A1265 NNP O
, P07565775A1265 , O
IV P07565775A1265 NNP O
, P07565775A1265 , O
and P07565775A1265 CC O
V P07565775A1265 NNP O
had P07565775A1265 VBD O
distinctive P07565775A1265 JJ O
effects P07565775A1265 NNS O
on P07565775A1265 IN O
the P07565775A1265 DT O
affinity P07565775A1265 NN O
of P07565775A1265 IN O
enzyme P07565775A1265 NN O
for P07565775A1265 IN O
GTP P07565775A1265 NNP O
, P07565775A1265 , O
the P07565775A1265 DT O
rate P07565775A1265 NN O
of P07565775A1265 IN O
covalent P07565775A1265 NN O
catalysis P07565775A1265 NN O
( P07565775A1265 ( O
EpG P07565775A1265 NNP O
formation P07565775A1265 NN O
) P07565775A1265 ) O
, P07565775A1265 , O
or P07565775A1265 CC O
the P07565775A1265 DT O
transfer P07565775A1265 NN O
of P07565775A1265 IN O
GMP P07565775A1265 NNP O
from P07565775A1265 IN O
enzyme P07565775A1265 NN O
to P07565775A1265 TO O
RNA P07565775A1265 NNP O
. P07565775A1265 . O
. . O O

We P08778700A0476 PRP O
present P08778700A0476 VBP O
this P08778700A0476 DT O
case P08778700A0476 NN O
because P08778700A0476 IN O
of P08778700A0476 IN O
the P08778700A0476 DT O
rarity P08778700A0476 NN O
of P08778700A0476 IN O
left P08778700A0476 JJ O
ventricular P08778700A0476 JJ O
involvement P08778700A0476 NN O
associated P08778700A0476 VBN O
with P08778700A0476 IN O
ARVD P08778700A0476 NNP O
. P08778700A0476 . O
. . O O

Seven P01986360A0000 NNP O
clones P01986360A0000 NNS O
encoding P01986360A0000 VBG O
interferon P01986360A0000 NN I-UN
response P01986360A0000 NN I-UN
element P01986360A0000 NN I-UN
binding P01986360A0000 VBG I-UN
factors P01986360A0000 NNS I-UN
have P01986360A0000 VBP O
been P01986360A0000 VBN O
isolated P01986360A0000 VBN O
from P01986360A0000 IN O
a P01986360A0000 DT O
mouse P01986360A0000 NN O
fibroblast P01986360A0000 NN O
lambda P01986360A0000 NN O
gt11 P01986360A0000 NN O
cDNA P01986360A0000 NN O
library P01986360A0000 NN O
by P01986360A0000 IN O
using P01986360A0000 VBG O
a P01986360A0000 DT O
32P P01986360A0000 CD O
end-labeled P01986360A0000 JJ O
tandem P01986360A0000 JJ O
trimer P01986360A0000 NN O
of P01986360A0000 IN O
the P01986360A0000 DT O
mouse P01986360A0000 NN I-UN
( P01986360A0000 ( I-UN
2'-5 P01986360A0000 JJ I-UN
' P01986360A0000 '' I-UN
) P01986360A0000 ) I-UN
oligoadenylate P01986360A0000 VBP I-UN
synthetase P01986360A0000 JJ I-UN
gene P01986360A0000 NN I-UN
interferon P01986360A0000 NN O
response P01986360A0000 NN O
element P01986360A0000 NN O
as P01986360A0000 IN O
a P01986360A0000 DT O
probe P01986360A0000 NN O
. P01986360A0000 . O
. . O O

Egd1p P08522175A0306 NNP I-UN
is P08522175A0306 VBZ O
homologous P08522175A0306 JJ O
to P08522175A0306 TO O
human P08522175A0306 JJ I-UN
BTF3b P08522175A0306 NNP I-UN
, P08522175A0306 , O
recently P08522175A0306 RB O
identified P08522175A0306 VBN O
as P08522175A0306 IN O
the P08522175A0306 DT O
beta P08522175A0306 NN O
subunit P08522175A0306 NN O
of P08522175A0306 IN O
the P08522175A0306 DT O
heterodimeric P08522175A0306 JJ I-UN
nascent-polypeptide-associated P08522175A0306 JJ I-UN
complex P08522175A0306 NN I-UN
( P08522175A0306 ( O
NAC P08522175A0306 NNP I-UN
) P08522175A0306 ) O
involved P08522175A0306 VBN O
in P08522175A0306 IN O
ensuring P08522175A0306 VBG O
signal-sequence-specific P08522175A0306 JJ O
protein P08522175A0306 NN O
sorting P08522175A0306 NN O
and P08522175A0306 CC O
translocation P08522175A0306 NN O
[ P08522175A0306 NNP O
Wiedmann P08522175A0306 NNP O
et P08522175A0306 FW O
al. P08522175A0306 NN O
, P08522175A0306 , O
Nature P08522175A0306 NNP O
370 P08522175A0306 CD O
( P08522175A0306 ( O
1994 P08522175A0306 CD O
) P08522175A0306 ) O
434-440 P08522175A0306 JJ O
] P08522175A0306 NN O
. P08522175A0306 . O
. . O O

In P03023859A0000 IN O
the P03023859A0000 DT O
DNAs P03023859A0000 NNP O
of P03023859A0000 IN O
all P03023859A0000 DT O
Ph1-positive P03023859A0000 JJ O
chronic P03023859A0000 JJ O
myelocytic P03023859A0000 JJ O
leukemia P03023859A0000 NN O
patients P03023859A0000 NNS O
studied P03023859A0000 VBN O
to P03023859A0000 TO O
date P03023859A0000 NN O
, P03023859A0000 , O
a P03023859A0000 DT O
breakpoint P03023859A0000 NN O
on P03023859A0000 IN O
chromosome P03023859A0000 NN O
22 P03023859A0000 CD O
( P03023859A0000 ( O
the P03023859A0000 DT O
Ph1 P03023859A0000 NNP O
chromosome P03023859A0000 NN O
) P03023859A0000 ) O
can P03023859A0000 MD O
be P03023859A0000 VB O
demonstrated P03023859A0000 VBN O
with P03023859A0000 IN O
a P03023859A0000 DT O
probe P03023859A0000 NN O
from P03023859A0000 IN O
the P03023859A0000 DT O
bcr P03023859A0000 NN I-UN
( P03023859A0000 ( O
breakpoint P03023859A0000 JJ I-UN
cluster P03023859A0000 NN I-UN
region P03023859A0000 NN I-UN
) P03023859A0000 ) O
. P03023859A0000 . O
. . O O

There P11444762A0373 EX O
are P11444762A0373 VBP O
many P11444762A0373 JJ O
different P11444762A0373 JJ O
proposals P11444762A0373 NNS O
for P11444762A0373 IN O
the P11444762A0373 DT O
statistical P11444762A0373 JJ O
analysis P11444762A0373 NN O
of P11444762A0373 IN O
data P11444762A0373 NNS O
to P11444762A0373 TO O
determine P11444762A0373 VB O
early P11444762A0373 JJ O
onset P11444762A0373 NN O
of P11444762A0373 IN O
action P11444762A0373 NN O
. P11444762A0373 . O
. . O O

Sequence P10607899A0605 NNP O
analysis P10607899A0605 NN O
of P10607899A0605 IN O
the P10607899A0605 DT O
promoter P10607899A0605 NN O
region P10607899A0605 NN O
showed P10607899A0605 VBD O
no P10607899A0605 DT O
TATA P10607899A0605 NNP O
box P10607899A0605 NN O
but P10607899A0605 CC O
identified P10607899A0605 VBD O
consensus P10607899A0605 NN O
binding P10607899A0605 NN O
motifs P10607899A0605 NNS O
for P10607899A0605 IN O
Sp1 P10607899A0605 NNP I-UN
, P10607899A0605 , O
CREB P10607899A0605 NNP I-UN
, P10607899A0605 , O
and P10607899A0605 CC O
half P10607899A0605 NN O
sites P10607899A0605 NNS O
of P10607899A0605 IN O
the P10607899A0605 DT O
estrogen P10607899A0605 NN I-UN
receptor P10607899A0605 NN I-UN
binding P10607899A0605 VBG I-UN
site P10607899A0605 NN I-UN
. P10607899A0605 . O
. . O O

Chemical P04712626T0000 NNP O
constituents P04712626T0000 NNS O
of P04712626T0000 IN O
the P04712626T0000 DT O
gentianaceae P04712626T0000 NN O
V P04712626T0000 NNP O
: P04712626T0000 : O
tetraoxygenated P04712626T0000 JJ O
xanthones P04712626T0000 NNS O
of P04712626T0000 IN O
Swertia P04712626T0000 NNP O
chirata P04712626T0000 VBD O
Buch.-Ham P04712626T0000 NNP O
. P04712626T0000 . O
. . O O

Thus P07668009A0172 RB O
, P07668009A0172 , O
endemic P07668009A0172 JJ O
cumlations P07668009A0172 NNS O
of P07668009A0172 IN O
hepatitis P07668009A0172 NN O
A P07668009A0172 NNP O
diseases P07668009A0172 NNS O
are P07668009A0172 VBP O
possible P07668009A0172 JJ O
. P07668009A0172 . O
. . O O

This P02473693A0174 DT O
approach P02473693A0174 NN O
was P02473693A0174 VBD O
examined P02473693A0174 VBN O
utilizing P02473693A0174 VBG O
the P02473693A0174 DT O
fetal P02473693A0174 JJ O
protein P02473693A0174 NN O
, P02473693A0174 , O
HGB P02473693A0174 NNP I-UN
F P02473693A0174 NNP I-UN
. P02473693A0174 . O
. . O O

Small P07891713T0000 JJ I-UN
Maf P07891713T0000 NNP I-UN
proteins P07891713T0000 NNS I-UN
heterodimerize P07891713T0000 VB O
with P07891713T0000 IN O
Fos P07891713T0000 NNP I-UN
and P07891713T0000 CC O
may P07891713T0000 MD O
act P07891713T0000 VB O
as P07891713T0000 IN O
competitive P07891713T0000 JJ O
repressors P07891713T0000 NNS O
of P07891713T0000 IN O
the P07891713T0000 DT O
NF-E2 P07891713T0000 NNP I-UN
transcription P07891713T0000 NN I-UN
factor P07891713T0000 NN I-UN
. P07891713T0000 . O
. . O O

Blood P06341139A0213 NNP O
glucose P06341139A0213 NN O
and P06341139A0213 CC O
plasma P06341139A0213 JJ O
insulin P06341139A0213 NN I-UN
were P06341139A0213 VBD O
measured P06341139A0213 VBN O
at P06341139A0213 IN O
zero P06341139A0213 CD O
time P06341139A0213 NN O
and P06341139A0213 CC O
then P06341139A0213 RB O
at P06341139A0213 IN O
15 P06341139A0213 CD O
, P06341139A0213 , O
30 P06341139A0213 CD O
, P06341139A0213 , O
60 P06341139A0213 CD O
, P06341139A0213 , O
90 P06341139A0213 CD O
and P06341139A0213 CC O
120 P06341139A0213 CD O
min P06341139A0213 NN O
after P06341139A0213 IN O
ingestion P06341139A0213 NN O
of P06341139A0213 IN O
25 P06341139A0213 CD O
g P06341139A0213 NNS O
glucose P06341139A0213 RB O
, P06341139A0213 , O
fructose P06341139A0213 VBD O
or P06341139A0213 CC O
lactose P06341139A0213 JJ O
, P06341139A0213 , O
or P06341139A0213 CC O
30 P06341139A0213 CD O
g P06341139A0213 JJ O
honey P06341139A0213 NN O
, P06341139A0213 , O
50 P06341139A0213 CD O
g P06341139A0213 JJ O
white P06341139A0213 JJ O
bread P06341139A0213 NN O
, P06341139A0213 , O
125 P06341139A0213 CD O
g P06341139A0213 NN O
white P06341139A0213 JJ O
rice P06341139A0213 NN O
or P06341139A0213 CC O
potatoes P06341139A0213 NNS O
, P06341139A0213 , O
150 P06341139A0213 CD O
g P06341139A0213 NN O
apples P06341139A0213 NNS O
or P06341139A0213 CC O
260 P06341139A0213 CD O
g P06341139A0213 JJ O
carrots P06341139A0213 NNS O
. P06341139A0213 . O
. . O O

Additional P11374051A0437 JJ O
factors P11374051A0437 NNS O
such P11374051A0437 JJ O
as P11374051A0437 IN O
advanced P11374051A0437 JJ O
age P11374051A0437 NN O
, P11374051A0437 , O
concomitant P11374051A0437 JJ O
use P11374051A0437 NN O
of P11374051A0437 IN O
corticosteroids P11374051A0437 NNS O
or P11374051A0437 CC O
anticoagulants P11374051A0437 NNS O
, P11374051A0437 , O
prior P11374051A0437 JJ O
ulcer P11374051A0437 JJ O
complications P11374051A0437 NNS O
and P11374051A0437 CC O
co-morbid P11374051A0437 JJ O
diseases P11374051A0437 NNS O
may P11374051A0437 MD O
further P11374051A0437 RB O
increase P11374051A0437 VB O
the P11374051A0437 DT O
risk P11374051A0437 NN O
of P11374051A0437 IN O
bleeding P11374051A0437 NN O
. P11374051A0437 . O
. . O O

Evidence P05792868T0000 NN O
forthe P05792868T0000 JJ O
electroosmosis P05792868T0000 NN O
theory P05792868T0000 NN O
of P05792868T0000 IN O
transport P05792868T0000 NN O
in P05792868T0000 IN O
the P05792868T0000 DT O
phloem P05792868T0000 NN O
. P05792868T0000 . O
. . O O

Our P07546293A0968 PRP$ O
results P07546293A0968 NNS O
suggest P07546293A0968 VBP O
that P07546293A0968 IN O
protein P07546293A0968 NN O
binding P07546293A0968 VBG O
to P07546293A0968 TO O
the P07546293A0968 DT O
E2F-like P07546293A0968 JJ I-UN
sequences P07546293A0968 NNS I-UN
may P07546293A0968 MD O
act P07546293A0968 VB O
to P07546293A0968 TO O
reduce P07546293A0968 VB O
expression P07546293A0968 NN O
. P07546293A0968 . O
. . O O

Thus P10750020A0843 RB O
, P10750020A0843 , O
growth P10750020A0843 NN O
factor P10750020A0843 NN O
activation P10750020A0843 NN O
of P10750020A0843 IN O
ER P10750020A0843 NNP I-UN
can P10750020A0843 MD O
mediate P10750020A0843 VB O
transactivation P10750020A0843 NN O
vs P10750020A0843 FW O
ER P10750020A0843 NNP I-UN
/ P10750020A0843 NNP O
Sp1 P10750020A0843 NNP I-UN
binding P10750020A0843 VBG O
to P10750020A0843 TO O
GC-rich P10750020A0843 NNP O
sites P10750020A0843 NNS O
and P10750020A0843 CC O
represents P10750020A0843 VBZ O
a P10750020A0843 DT O
novel P10750020A0843 JJ O
pathway P10750020A0843 NN O
for P10750020A0843 IN O
ligand-independent P10750020A0843 JJ O
ER P10750020A0843 NNP I-UN
action P10750020A0843 NN O
. P10750020A0843 . O
. . O O

Of P10372627A0530 IN O
those P10372627A0530 DT O
injuries P10372627A0530 NNS O
, P10372627A0530 , O
143 P10372627A0530 CD O
cases P10372627A0530 NNS O
were P10372627A0530 VBD O
snowboard P10372627A0530 RB O
related P10372627A0530 VBN O
and P10372627A0530 CC O
158 P10372627A0530 CD O
cases P10372627A0530 NNS O
were P10372627A0530 VBD O
ski P10372627A0530 JJ O
related P10372627A0530 VBN O
. P10372627A0530 . O
. . O O

The P10226074A0637 DT O
5 P10226074A0637 CD O
' P10226074A0637 POS O
untranslated P10226074A0637 JJ O
and P10226074A0637 CC O
coding P10226074A0637 JJ O
regions P10226074A0637 NNS O
are P10226074A0637 VBP O
contained P10226074A0637 VBN O
within P10226074A0637 IN O
12 P10226074A0637 CD O
exons P10226074A0637 NNS O
, P10226074A0637 , O
with P10226074A0637 IN O
the P10226074A0637 DT O
translation P10226074A0637 NN O
start P10226074A0637 NN O
site P10226074A0637 NN O
located P10226074A0637 VBN O
within P10226074A0637 IN O
the P10226074A0637 DT O
first P10226074A0637 JJ O
exon P10226074A0637 NN O
. P10226074A0637 . O
. . O O

Conversely P09556557A1238 RB O
, P09556557A1238 , O
the P09556557A1238 DT O
central P09556557A1238 JJ O
regions P09556557A1238 NNS O
are P09556557A1238 VBP O
highly P09556557A1238 RB O
variable P09556557A1238 JJ O
. P09556557A1238 . O
. . O O

It P06230499A0128 PRP O
has P06230499A0128 VBZ O
been P06230499A0128 VBN O
established P06230499A0128 VBN O
that P06230499A0128 IN O
preoperative P06230499A0128 JJ O
irradiation P06230499A0128 NN O
in P06230499A0128 IN O
the P06230499A0128 DT O
form P06230499A0128 NN O
of P06230499A0128 IN O
the P06230499A0128 DT O
fractionation P06230499A0128 NN O
of P06230499A0128 IN O
a P06230499A0128 DT O
single P06230499A0128 JJ O
focal P06230499A0128 JJ O
dose P06230499A0128 NN O
of P06230499A0128 IN O
6 P06230499A0128 CD O
Gy P06230499A0128 NNP O
every P06230499A0128 DT O
other P06230499A0128 JJ O
day P06230499A0128 NN O
, P06230499A0128 , O
the P06230499A0128 DT O
summary P06230499A0128 JJ O
dose P06230499A0128 NN O
of P06230499A0128 IN O
24 P06230499A0128 CD O
Gy P06230499A0128 NNP O
within P06230499A0128 IN O
8-10 P06230499A0128 JJ O
days P06230499A0128 NNS O
followed P06230499A0128 VBN O
by P06230499A0128 IN O
surgery P06230499A0128 NN O
1-3 P06230499A0128 JJ O
days P06230499A0128 NNS O
after P06230499A0128 IN O
irradiation P06230499A0128 NN O
does P06230499A0128 VBZ O
not P06230499A0128 RB O
either P06230499A0128 VB O
complicate P06230499A0128 VB O
its P06230499A0128 PRP$ O
performance P06230499A0128 NN O
or P06230499A0128 CC O
the P06230499A0128 DT O
course P06230499A0128 NN O
of P06230499A0128 IN O
the P06230499A0128 DT O
postoperative P06230499A0128 JJ O
period P06230499A0128 NN O
, P06230499A0128 , O
and P06230499A0128 CC O
by P06230499A0128 IN O
the P06230499A0128 DT O
short- P06230499A0128 JJ O
and P06230499A0128 CC O
long-term P06230499A0128 JJ O
results P06230499A0128 NNS O
it P06230499A0128 PRP O
is P06230499A0128 VBZ O
no P06230499A0128 DT O
worse P06230499A0128 JJR O
than P06230499A0128 IN O
the P06230499A0128 DT O
routine P06230499A0128 JJ O
dose P06230499A0128 NN O
fractionation P06230499A0128 NN O
. P06230499A0128 . O
. . O O

Autopsy P01407286A0427 NNP O
demonstrated P01407286A0427 VBD O
good P01407286A0427 JJ O
survival P01407286A0427 NN O
of P01407286A0427 IN O
the P01407286A0427 DT O
transplanted P01407286A0427 JJ O
cells P01407286A0427 NNS O
with P01407286A0427 IN O
good P01407286A0427 JJ O
integration P01407286A0427 NN O
with P01407286A0427 IN O
the P01407286A0427 DT O
brain P01407286A0427 NN O
of P01407286A0427 IN O
the P01407286A0427 DT O
recipient P01407286A0427 NN O
and P01407286A0427 CC O
traces P01407286A0427 NNS O
of P01407286A0427 IN O
positive P01407286A0427 JJ O
immunocytochemical P01407286A0427 JJ O
reaction P01407286A0427 NN O
for P01407286A0427 IN O
tyrosine P01407286A0427 JJ I-UN
hydroxylase P01407286A0427 NN I-UN
. P01407286A0427 . O
. . O O

Whether P02154474A1504 NNP O
or P02154474A1504 CC O
not P02154474A1504 RB O
there P02154474A1504 EX O
are P02154474A1504 VBP O
sequences P02154474A1504 NNS O
conferring P02154474A1504 VBG O
cAMP P02154474A1504 NN O
responsiveness P02154474A1504 NN O
which P02154474A1504 WDT O
are P02154474A1504 VBP O
common P02154474A1504 JJ O
both P02154474A1504 DT O
to P02154474A1504 TO O
P-450scc P02154474A1504 NNP I-UN
and P02154474A1504 CC O
the P02154474A1504 DT O
other P02154474A1504 JJ O
steroidogenic P02154474A1504 JJ O
P-450 P02154474A1504 NNP I-UN
genes P02154474A1504 NNS I-UN
remains P02154474A1504 VBZ O
to P02154474A1504 TO O
be P02154474A1504 VB O
established P02154474A1504 VBN O
. P02154474A1504 . O
. . O O

Thus P08643557A0259 RB O
, P08643557A0259 , O
a P08643557A0259 DT O
critical P08643557A0259 JJ O
question P08643557A0259 NN O
is P08643557A0259 VBZ O
how P08643557A0259 WRB O
HOX P08643557A0259 JJ I-UN
proteins P08643557A0259 NNS I-UN
select P08643557A0259 VBP O
the P08643557A0259 DT O
correct P08643557A0259 JJ O
sets P08643557A0259 NNS O
of P08643557A0259 IN O
target P08643557A0259 NN O
genes P08643557A0259 NNS O
in P08643557A0259 IN O
vivo P08643557A0259 NN O
. P08643557A0259 . O
. . O O

Albumin P10604583T0000 JJ I-UN
dialysis P10604583T0000 NN O
: P10604583T0000 : O
effective P10604583T0000 JJ O
removal P10604583T0000 NN O
of P10604583T0000 IN O
copper P10604583T0000 NN O
in P10604583T0000 IN O
a P10604583T0000 DT O
patient P10604583T0000 NN O
with P10604583T0000 IN O
fulminant P10604583T0000 JJ O
Wilson P10604583T0000 NNP O
disease P10604583T0000 NN O
and P10604583T0000 CC O
successful P10604583T0000 JJ O
bridging P10604583T0000 NN O
to P10604583T0000 TO O
liver P10604583T0000 VB O
transplantation P10604583T0000 NN O
: P10604583T0000 : O
a P10604583T0000 DT O
new P10604583T0000 JJ O
possibility P10604583T0000 NN O
for P10604583T0000 IN O
the P10604583T0000 DT O
elimination P10604583T0000 NN O
of P10604583T0000 IN O
protein-bound P10604583T0000 NN O
toxins P10604583T0000 NNS O
. P10604583T0000 . O
. . O O

In P10601410A0977 IN O
conclusion P10601410A0977 NN O
, P10601410A0977 , O
our P10601410A0977 PRP$ O
data P10601410A0977 NNS O
do P10601410A0977 VBP O
not P10601410A0977 RB O
support P10601410A0977 VB O
a P10601410A0977 DT O
role P10601410A0977 NN O
for P10601410A0977 IN O
IVIg P10601410A0977 NNP I-UN
in P10601410A0977 IN O
the P10601410A0977 DT O
remyelination P10601410A0977 NN O
of P10601410A0977 IN O
stable P10601410A0977 JJ O
multiple P10601410A0977 JJ O
sclerosis P10601410A0977 NN O
lesions P10601410A0977 NNS O
as P10601410A0977 IN O
measured P10601410A0977 VBN O
by P10601410A0977 IN O
central P10601410A0977 JJ O
conduction P10601410A0977 NN O
time P10601410A0977 NN O
. P10601410A0977 . O
. . O O

We P09786926A0095 PRP O
previously P09786926A0095 RB O
delineated P09786926A0095 VBD O
a P09786926A0095 DT O
region P09786926A0095 NN O
in P09786926A0095 IN O
the P09786926A0095 DT O
fatty-acid P09786926A0095 JJ I-UN
synthase P09786926A0095 NN I-UN
promoter P09786926A0095 NN I-UN
, P09786926A0095 , O
which P09786926A0095 WDT O
was P09786926A0095 VBD O
responsible P09786926A0095 JJ O
for P09786926A0095 IN O
obesity-related P09786926A0095 JJ O
overexpression P09786926A0095 NN O
of P09786926A0095 IN O
the P09786926A0095 DT O
fatty-acid P09786926A0095 JJ I-UN
synthase P09786926A0095 NN I-UN
( P09786926A0095 ( O
FAS P09786926A0095 NNP I-UN
) P09786926A0095 ) O
gene P09786926A0095 NN O
, P09786926A0095 , O
by P09786926A0095 IN O
negatively P09786926A0095 RB O
regulating P09786926A0095 VBG O
the P09786926A0095 DT O
activity P09786926A0095 NN O
of P09786926A0095 IN O
the P09786926A0095 DT O
downstream P09786926A0095 NN O
promoter P09786926A0095 NN O
in P09786926A0095 IN O
lean P09786926A0095 JJ O
but P09786926A0095 CC O
not P09786926A0095 RB O
obese P09786926A0095 JJ O
rat P09786926A0095 NNS O
fat P09786926A0095 JJ O
cells P09786926A0095 NNS O
. P09786926A0095 . O
. . O O

These P09508377A0863 DT O
results P09508377A0863 NNS O
would P09508377A0863 MD O
suggest P09508377A0863 VB O
that P09508377A0863 IN O
a P09508377A0863 DT O
high P09508377A0863 JJ O
UV P09508377A0863 NNP O
sensitivity P09508377A0863 NN O
is P09508377A0863 VBZ O
associated P09508377A0863 VBN O
with P09508377A0863 IN O
high P09508377A0863 JJ O
phaeomelanin P09508377A0863 NN O
and P09508377A0863 CC O
low P09508377A0863 JJ O
eumelanin P09508377A0863 NN O
levels P09508377A0863 NNS O
, P09508377A0863 , O
and P09508377A0863 CC O
point P09508377A0863 NN O
to P09508377A0863 TO O
the P09508377A0863 DT O
eumelanin P09508377A0863 NN O
/ P09508377A0863 NNP O
phaeomelanin P09508377A0863 NN O
ratio P09508377A0863 NN O
as P09508377A0863 IN O
a P09508377A0863 DT O
novel P09508377A0863 JJ O
chemical P09508377A0863 NN O
parameter P09508377A0863 NN O
that P09508377A0863 WDT O
could P09508377A0863 MD O
be P09508377A0863 VB O
used P09508377A0863 VBN O
for P09508377A0863 IN O
predicting P09508377A0863 VBG O
individuals P09508377A0863 NNS O
at P09508377A0863 IN O
high P09508377A0863 JJ O
risk P09508377A0863 NN O
for P09508377A0863 IN O
skin P09508377A0863 JJ O
cancer P09508377A0863 NN O
and P09508377A0863 CC O
melanoma P09508377A0863 NN O
. P09508377A0863 . O
. . O O

Mitomycin-C P01906166A0119 NNP O
can P01906166A0119 MD O
cause P01906166A0119 VB O
severe P01906166A0119 JJ O
necrosis P01906166A0119 NN O
and P01906166A0119 CC O
ulceration P01906166A0119 NN O
when P01906166A0119 WRB O
extravasated P01906166A0119 VBN O
inadvertently P01906166A0119 RB O
into P01906166A0119 IN O
skin P01906166A0119 NN O
and P01906166A0119 CC O
soft P01906166A0119 JJ O
tissues P01906166A0119 NNS O
following P01906166A0119 VBG O
IV P01906166A0119 NNP O
drug P01906166A0119 NN O
administration P01906166A0119 NN O
. P01906166A0119 . O
. . O O

A P07309562T0000 DT O
simplified P07309562T0000 JJ O
thin-layer P07309562T0000 JJ O
chromatographic P07309562T0000 JJ O
determination P07309562T0000 NN O
of P07309562T0000 IN O
hippuric P07309562T0000 JJ O
acid P07309562T0000 NN O
and P07309562T0000 CC O
methylhippuric P07309562T0000 JJ O
acids P07309562T0000 NNS O
. P07309562T0000 . O
. . O O

Hemodynamic P02920591A0251 NNP O
assessment P02920591A0251 NN O
was P02920591A0251 VBD O
obtained P02920591A0251 VBN O
before P02920591A0251 IN O
and P02920591A0251 CC O
following P02920591A0251 VBG O
administration P02920591A0251 NN O
of P02920591A0251 IN O
digoxin P02920591A0251 NN O
10 P02920591A0251 CD O
micrograms P02920591A0251 NNS O
/ P02920591A0251 VBP O
kg P02920591A0251 JJ O
IV P02920591A0251 NNP O
or P02920591A0251 CC O
dopamine P02920591A0251 NN O
, P02920591A0251 , O
5 P02920591A0251 CD O
to P02920591A0251 TO O
12 P02920591A0251 CD O
micrograms P02920591A0251 NNS O
/ P02920591A0251 VBP O
kg P02920591A0251 JJ O
/ P02920591A0251 NNP O
min P02920591A0251 NN O
IV P02920591A0251 NNP O
. P02920591A0251 . O
. . O O

MEK P08131746A0140 NNP I-UN
itself P08131746A0140 PRP O
is P08131746A0140 VBZ O
activated P08131746A0140 VBN O
via P08131746A0140 IN O
serine P08131746A0140 JJ O
phosphorylation P08131746A0140 NN O
by P08131746A0140 IN O
upstream P08131746A0140 JJ I-UN
activator P08131746A0140 NN I-UN
kinases P08131746A0140 NNS I-UN
, P08131746A0140 , O
including P08131746A0140 VBG O
c-raf P08131746A0140 NN I-UN
, P08131746A0140 , O
mos P08131746A0140 NN I-UN
and P08131746A0140 CC O
MEK P08131746A0140 NNP I-UN
kinase P08131746A0140 NN I-UN
. P08131746A0140 . O
. . O O

Eleven P03861687A0000 RB O
healthy P03861687A0000 JJ O
, P03861687A0000 , O
normotensive P03861687A0000 JJ O
males P03861687A0000 NNS O
undergoing P03861687A0000 VBG O
routine P03861687A0000 JJ O
restorative P03861687A0000 JJ O
dental P03861687A0000 NN O
care P03861687A0000 NN O
were P03861687A0000 VBD O
evaluated P03861687A0000 VBN O
during P03861687A0000 IN O
treatment P03861687A0000 NN O
for P03861687A0000 IN O
possible P03861687A0000 JJ O
hemodynamic P03861687A0000 JJ O
alterations P03861687A0000 NNS O
in P03861687A0000 IN O
response P03861687A0000 NN O
to P03861687A0000 TO O
potential P03861687A0000 JJ O
sympathetic P03861687A0000 JJ O
nervous P03861687A0000 JJ O
system P03861687A0000 NN O
stimulation P03861687A0000 NN O
. P03861687A0000 . O
. . O O

The P03491190A0233 DT O
detectability P03491190A0233 NN O
of P03491190A0233 IN O
the P03491190A0233 DT O
defects P03491190A0233 NNS O
in P03491190A0233 IN O
RCA P03491190A0233 NNP O
or P03491190A0233 CC O
LAD P03491190A0233 NNP O
region P03491190A0233 NN O
was P03491190A0233 VBD O
80 P03491190A0233 CD O
% P03491190A0233 NN O
in P03491190A0233 IN O
single-position P03491190A0233 NN O
scans P03491190A0233 NNS O
in P03491190A0233 IN O
stress P03491190A0233 NN O
studies P03491190A0233 NNS O
. P03491190A0233 . O
. . O O

The P10653400A0000 DT O
applicability P10653400A0000 NN O
of P10653400A0000 IN O
laparoscopic P10653400A0000 NN O
donor P10653400A0000 NN O
nephrectomy P10653400A0000 NN O
( P10653400A0000 ( O
LDN P10653400A0000 NNP O
) P10653400A0000 ) O
has P10653400A0000 VBZ O
not P10653400A0000 RB O
been P10653400A0000 VBN O
assessed P10653400A0000 VBN O
in P10653400A0000 IN O
the P10653400A0000 DT O
obese P10653400A0000 JJ O
donor P10653400A0000 NN O
. P10653400A0000 . O
. . O O

Evaluating P05642051T0000 VBG O
dietary P05642051T0000 JJ O
department P05642051T0000 NN O
management P05642051T0000 NN O
. P05642051T0000 . O
. . O O

The P00517890A0468 DT O
enteric P00517890A0468 JJ O
route P00517890A0468 NN O
is P00517890A0468 VBZ O
the P00517890A0468 DT O
principal P00517890A0468 JJ O
mode P00517890A0468 NN O
of P00517890A0468 IN O
transmission P00517890A0468 NN O
for P00517890A0468 IN O
hepatitis P00517890A0468 NN O
A P00517890A0468 NNP O
, P00517890A0468 , O
but P00517890A0468 CC O
maximal P00517890A0468 JJ O
levels P00517890A0468 NNS O
of P00517890A0468 IN O
hepatitis P00517890A0468 NN O
A P00517890A0468 NNP O
virus P00517890A0468 NN O
excretion P00517890A0468 NN O
occur P00517890A0468 NN O
before P00517890A0468 IN O
the P00517890A0468 DT O
onset P00517890A0468 NN O
of P00517890A0468 IN O
jaundice P00517890A0468 NN O
. P00517890A0468 . O
. . O O

Testing P10881275T0000 VBG O
for P10881275T0000 IN O
serum P10881275T0000 NN I-UN
IgM P10881275T0000 NNP I-UN
binding P10881275T0000 NN O
to P10881275T0000 TO O
GM1 P10881275T0000 NNP O
ganglioside P10881275T0000 NN O
in P10881275T0000 IN O
clinical P10881275T0000 JJ O
practice P10881275T0000 NN O
. P10881275T0000 . O
. . O O

From P03009366A0438 IN O
our P03009366A0438 PRP$ O
ultrastructural P03009366A0438 JJ O
and P03009366A0438 CC O
biochemical P03009366A0438 JJ O
studies P03009366A0438 NNS O
, P03009366A0438 , O
it P03009366A0438 PRP O
is P03009366A0438 VBZ O
evident P03009366A0438 JJ O
that P03009366A0438 IN O
Type P03009366A0438 NNP O
II P03009366A0438 NNP O
pneumocytes P03009366A0438 NNS O
are P03009366A0438 VBP O
an P03009366A0438 DT O
early P03009366A0438 JJ O
target P03009366A0438 NN O
of P03009366A0438 IN O
radiation P03009366A0438 NN O
and P03009366A0438 CC O
the P03009366A0438 DT O
release P03009366A0438 NN O
of P03009366A0438 IN O
surfactant P03009366A0438 NN O
into P03009366A0438 IN O
the P03009366A0438 DT O
alveolus P03009366A0438 NN O
shortly P03009366A0438 RB O
after P03009366A0438 IN O
exposure P03009366A0438 NN O
persists P03009366A0438 VBZ O
for P03009366A0438 IN O
days P03009366A0438 NNS O
and P03009366A0438 CC O
weeks P03009366A0438 NNS O
. P03009366A0438 . O
. . O O

The P04942414T0000 DT O
metabolism P04942414T0000 NN O
and P04942414T0000 CC O
pharmacology P04942414T0000 NN O
of P04942414T0000 IN O
5-fluorouracil P04942414T0000 JJ O
. P04942414T0000 . O
. . O O

These P00622556A0111 DT O
show P00622556A0111 NN O
that P00622556A0111 IN O
the P00622556A0111 DT O
collagen P00622556A0111 NN I-UN
in P00622556A0111 IN O
this P00622556A0111 DT O
tissue P00622556A0111 NN O
is P00622556A0111 VBZ O
modified P00622556A0111 VBN O
compared P00622556A0111 VBN O
with P00622556A0111 IN O
that P00622556A0111 DT O
in P00622556A0111 IN O
tendon P00622556A0111 NN O
. P00622556A0111 . O
. . O O

This P11274368A0469 DT O
effect P11274368A0469 NN O
was P11274368A0469 VBD O
observed P11274368A0469 VBN O
in P11274368A0469 IN O
the P11274368A0469 DT O
absence P11274368A0469 NN O
of P11274368A0469 IN O
de P11274368A0469 FW O
novo P11274368A0469 FW O
protein P11274368A0469 CC O
synthesis P11274368A0469 NN O
and P11274368A0469 CC O
was P11274368A0469 VBD O
independent P11274368A0469 JJ O
of P11274368A0469 IN O
histone P11274368A0469 JJ I-UN
deacetylase P11274368A0469 NN I-UN
activity P11274368A0469 NN O
. P11274368A0469 . O
. . O O

The P08395004A0141 DT O
ability P08395004A0141 NN O
of P08395004A0141 IN O
spt2 P08395004A0141 JJ I-UN
mutations P08395004A0141 NNS I-UN
to P08395004A0141 TO O
suppress P08395004A0141 VB O
the P08395004A0141 DT O
transcriptional P08395004A0141 JJ O
interference P08395004A0141 NN O
caused P08395004A0141 VBN O
by P08395004A0141 IN O
the P08395004A0141 DT O
delta P08395004A0141 NN I-UN
promoter P08395004A0141 NN I-UN
insertion P08395004A0141 NN I-UN
his-4-912 P08395004A0141 JJ I-UN
delta P08395004A0141 NN I-UN
correlates P08395004A0141 NNS O
with P08395004A0141 IN O
an P08395004A0141 DT O
increase P08395004A0141 NN O
in P08395004A0141 IN O
wild-type P08395004A0141 JJ I-UN
HIS4 P08395004A0141 NNP I-UN
mRNA P08395004A0141 NN I-UN
levels P08395004A0141 NNS O
. P08395004A0141 . O
. . O O

Serum P01285358A0396 NNP O
gastrin P01285358A0396 NN I-UN
and P01285358A0396 CC O
AFP P01285358A0396 NNP I-UN
levels P01285358A0396 NNS O
had P01285358A0396 VBD O
the P01285358A0396 DT O
same P01285358A0396 JJ O
evolution P01285358A0396 NN O
and P01285358A0396 CC O
appear P01285358A0396 VBP O
to P01285358A0396 TO O
have P01285358A0396 VB O
the P01285358A0396 DT O
same P01285358A0396 JJ O
interest P01285358A0396 NN O
to P01285358A0396 TO O
follow P01285358A0396 VB O
the P01285358A0396 DT O
course P01285358A0396 NN O
of P01285358A0396 IN O
the P01285358A0396 DT O
disease P01285358A0396 NN O
. P01285358A0396 . O
. . O O

The P01744042A1355 DT O
csbA P01744042A1355 NN I-UN
fusion P01744042A1355 NN I-UN
was P01744042A1355 VBD O
maximally P01744042A1355 RB O
expressed P01744042A1355 VBN O
during P01744042A1355 IN O
early P01744042A1355 JJ O
stationary P01744042A1355 JJ O
phase P01744042A1355 NN O
in P01744042A1355 IN O
cells P01744042A1355 NNS O
grown P01744042A1355 VBN O
in P01744042A1355 IN O
Luria P01744042A1355 NNP O
broth P01744042A1355 CC O
containing P01744042A1355 VBG O
5 P01744042A1355 CD O
% P01744042A1355 NN O
glucose P01744042A1355 NN O
and P01744042A1355 CC O
0.2 P01744042A1355 CD O
% P01744042A1355 NN O
glutamine P01744042A1355 NN O
. P01744042A1355 . O
. . O O

FZD4 P10544037A0617 NNP I-UN
is P10544037A0617 VBZ O
homologous P10544037A0617 JJ O
to P10544037A0617 TO O
FZD9 P10544037A0617 NNP I-UN
and P10544037A0617 CC O
FZD10 P10544037A0617 NNP I-UN
, P10544037A0617 , O
and P10544037A0617 CC O
overall P10544037A0617 JJ O
amino P10544037A0617 NN O
acid P10544037A0617 NN O
identity P10544037A0617 NN O
is P10544037A0617 VBZ O
as P10544037A0617 IN O
follows P10544037A0617 VBZ O
: P10544037A0617 : O
FZD4 P10544037A0617 NNP I-UN
vs P10544037A0617 NN O
FZD9 P10544037A0617 NNP I-UN
, P10544037A0617 , O
51.6 P10544037A0617 CD O
% P10544037A0617 NN O
; P10544037A0617 : O
FZD4 P10544037A0617 NNP I-UN
vs P10544037A0617 FW O
FZD10 P10544037A0617 NNP I-UN
, P10544037A0617 , O
51.2 P10544037A0617 CD O
% P10544037A0617 NN O
; P10544037A0617 : O
FZD9 P10544037A0617 NNP I-UN
vs P10544037A0617 FW O
FZD10 P10544037A0617 NNP I-UN
, P10544037A0617 , O
65.7 P10544037A0617 CD O
% P10544037A0617 NN O
. P10544037A0617 . O
. . O O

Four P07567980T0000 CD O
p53 P07567980T0000 NN I-UN
DNA-binding P07567980T0000 NNP I-UN
domain P07567980T0000 NN I-UN
peptides P07567980T0000 NNS I-UN
bind P07567980T0000 IN O
natural P07567980T0000 JJ O
p53-response P07567980T0000 JJ I-UN
elements P07567980T0000 NNS I-UN
and P07567980T0000 CC O
bend P07567980T0000 VB O
the P07567980T0000 DT O
DNA P07567980T0000 NN O
. P07567980T0000 . O
. . O O

To P08207795A0409 TO O
identify P08207795A0409 VB O
the P08207795A0409 DT O
precise P08207795A0409 JJ O
location P08207795A0409 NN O
of P08207795A0409 IN O
the P08207795A0409 DT O
phosphorylation P08207795A0409 NN O
site P08207795A0409 NN O
on P08207795A0409 IN O
the P08207795A0409 DT O
64-kDa P08207795A0409 JJ O
protein P08207795A0409 NN O
, P08207795A0409 , O
a P08207795A0409 DT O
step-by-step P08207795A0409 JJ O
mutagenesis P08207795A0409 NN O
procedures P08207795A0409 NNS O
was P08207795A0409 VBD O
followed P08207795A0409 VBN O
. P08207795A0409 . O
. . O O

Alanine P01992953T0000 NNP I-UN
aminotransferase P01992953T0000 NN I-UN
in P01992953T0000 IN O
clinical P01992953T0000 JJ O
practice P01992953T0000 NN O
. P01992953T0000 . O
. . O O

We P10458905A0000 PRP O
report P10458905A0000 VBP O
the P10458905A0000 DT O
construction P10458905A0000 NN O
of P10458905A0000 IN O
an P10458905A0000 DT O
approximately P10458905A0000 RB O
1.7-Mb P10458905A0000 JJ O
sequence-ready P10458905A0000 JJ O
YAC P10458905A0000 NNP O
/ P10458905A0000 NNP O
BAC P10458905A0000 NNP O
clone P10458905A0000 NN O
contig P10458905A0000 NN O
of P10458905A0000 IN O
8p22-p23 P10458905A0000 JJ O
. P10458905A0000 . O
. . O O

The P02167467T0000 DT O
26S P02167467T0000 CD I-UN
rRNA P02167467T0000 NN I-UN
binding P02167467T0000 VBG I-UN
ribosomal P02167467T0000 JJ I-UN
protein P02167467T0000 NN I-UN
equivalent P02167467T0000 NN O
to P02167467T0000 TO O
bacterial P02167467T0000 JJ I-UN
protein P02167467T0000 NN I-UN
L11 P02167467T0000 NNP I-UN
is P02167467T0000 VBZ O
encoded P02167467T0000 VBN O
by P02167467T0000 IN O
unspliced P02167467T0000 JJ O
duplicated P02167467T0000 VBN O
genes P02167467T0000 NNS O
in P02167467T0000 IN O
Saccharomyces P02167467T0000 NNP O
cerevisiae P02167467T0000 NN O
. P02167467T0000 . O
. . O O

Overexpression P09713996A0262 NN O
of P09713996A0262 IN O
MDR1 P09713996A0262 NNP I-UN
has P09713996A0262 VBZ O
been P09713996A0262 VBN O
demonstrated P09713996A0262 VBN O
in P09713996A0262 IN O
many P09713996A0262 JJ O
cancers P09713996A0262 NNS O
, P09713996A0262 , O
both P09713996A0262 DT O
in P09713996A0262 IN O
patient P09713996A0262 NN O
tumors P09713996A0262 NNS O
and P09713996A0262 CC O
in P09713996A0262 IN O
cell P09713996A0262 NN O
lines P09713996A0262 NNS O
selected P09713996A0262 VBN O
with P09713996A0262 IN O
a P09713996A0262 DT O
variety P09713996A0262 NN O
of P09713996A0262 IN O
chemotherapeutic P09713996A0262 JJ O
agents P09713996A0262 NNS O
. P09713996A0262 . O
. . O O

We P08090767A0000 PRP O
present P08090767A0000 JJ O
evidence P08090767A0000 NN O
that P08090767A0000 IN O
DNA P08090767A0000 NNP I-UN
polymerase P08090767A0000 VBD I-UN
delta P08090767A0000 NN I-UN
of P08090767A0000 IN I-UN
Saccharomyces P08090767A0000 NNP I-UN
cerevisiae P08090767A0000 NN I-UN
, P08090767A0000 , O
an P08090767A0000 DT O
enzyme P08090767A0000 NN O
that P08090767A0000 WDT O
is P08090767A0000 VBZ O
essential P08090767A0000 JJ O
for P08090767A0000 IN O
viability P08090767A0000 NN O
and P08090767A0000 CC O
chromosomal P08090767A0000 JJ O
replication P08090767A0000 NN O
, P08090767A0000 , O
is P08090767A0000 VBZ O
also P08090767A0000 RB O
required P08090767A0000 VBN O
for P08090767A0000 IN O
base P08090767A0000 JJ O
excision P08090767A0000 NN O
repair P08090767A0000 NN O
of P08090767A0000 IN O
exogenous P08090767A0000 JJ O
DNA P08090767A0000 NNP O
methylation P08090767A0000 NN O
damage P08090767A0000 NN O
. P08090767A0000 . O
. . O O

Cicatricial P01424674A0000 JJ O
pemphigoid P01424674A0000 NN O
is P01424674A0000 VBZ O
an P01424674A0000 DT O
autoimmune P01424674A0000 JJ O
systemic P01424674A0000 JJ O
disease P01424674A0000 NN O
characterized P01424674A0000 VBN O
by P01424674A0000 IN O
chronic P01424674A0000 JJ O
conjunctival P01424674A0000 NN O
cicatrization P01424674A0000 NN O
. P01424674A0000 . O
. . O O

Platelet P01695314T0000 NNP O
aggregation P01695314T0000 NN O
and P01695314T0000 CC O
metabolic P01695314T0000 JJ O
control P01695314T0000 NN O
are P01695314T0000 VBP O
not P01695314T0000 RB O
affected P01695314T0000 VBN O
by P01695314T0000 IN O
calcium P01695314T0000 JJ O
antagonist P01695314T0000 NN O
treatment P01695314T0000 NN O
in P01695314T0000 IN O
type P01695314T0000 NN O
II P01695314T0000 NNP O
diabetes P01695314T0000 VBZ O
mellitus P01695314T0000 NN O
. P01695314T0000 . O
. . O O

Transient P08474456A1041 JJ O
transfection P08474456A1041 NN O
analysis P08474456A1041 NN O
with P08474456A1041 IN O
these P08474456A1041 DT O
mutations P08474456A1041 NNS O
revealed P08474456A1041 VBD O
that P08474456A1041 IN O
only P08474456A1041 RB O
a P08474456A1041 DT O
10-bp P08474456A1041 JJ O
region P08474456A1041 NN O
, P08474456A1041 , O
containing P08474456A1041 VBG O
precisely P08474456A1041 RB O
the P08474456A1041 DT O
Ets P08474456A1041 NNP I-UN
and P08474456A1041 CC O
proximal P08474456A1041 JJ O
LyF-1 P08474456A1041 NNP I-UN
binding P08474456A1041 NN I-UN
sites P08474456A1041 NNS I-UN
, P08474456A1041 , O
was P08474456A1041 VBD O
needed P08474456A1041 VBN O
for P08474456A1041 IN O
D P08474456A1041 NNP O
' P08474456A1041 POS O
activity P08474456A1041 NN O
. P08474456A1041 . O
. . O O

This P10555285A1065 DT O
organization P10555285A1065 NN O
suggests P10555285A1065 VBZ O
that P10555285A1065 IN O
duplication P10555285A1065 NN O
events P10555285A1065 NNS O
that P10555285A1065 WDT O
have P10555285A1065 VBP O
generated P10555285A1065 VBN O
the P10555285A1065 DT O
primate P10555285A1065 JJ O
FUT3-FUT5-FUT6 P10555285A1065 NNP O
cluster P10555285A1065 NN O
might P10555285A1065 MD O
have P10555285A1065 VB O
occurred P10555285A1065 VBN O
through P10555285A1065 IN O
a P10555285A1065 DT O
long-interspersed-nuclear-element-based P10555285A1065 JJ O
mechanism P10555285A1065 NN O
of P10555285A1065 IN O
unequal P10555285A1065 JJ O
crossing P10555285A1065 NN O
over P10555285A1065 RB O
, P10555285A1065 , O
as P10555285A1065 IN O
described P10555285A1065 VBN O
for P10555285A1065 IN O
the P10555285A1065 DT O
globin P10555285A1065 NN I-UN
cluster P10555285A1065 NN I-UN
. P10555285A1065 . O
. . O O

V P05544291T0031 NNP O
. P05544291T0031 . O
. . O O

Treatment P11177686A0243 NN O
includes P11177686A0243 VBZ O
both P11177686A0243 DT O
medical P11177686A0243 JJ O
and P11177686A0243 CC O
surgical P11177686A0243 JJ O
options P11177686A0243 NNS O
, P11177686A0243 , O
with P11177686A0243 IN O
medical P11177686A0243 JJ O
therapy P11177686A0243 NN O
further P11177686A0243 RBR O
subclassified P11177686A0243 VBD O
into P11177686A0243 IN O
pharmacologic P11177686A0243 NN O
and P11177686A0243 CC O
pneumatic P11177686A0243 JJ O
dilation P11177686A0243 NN O
. P11177686A0243 . O
. . O O

National P09518808T0000 NNP O
certification P09518808T0000 NN O
: P09518808T0000 : O
a P09518808T0000 DT O
vital P09518808T0000 JJ O
component P09518808T0000 NN O
of P09518808T0000 IN O
quality P09518808T0000 NN O
assurance P09518808T0000 NN O
. P09518808T0000 . O
. . O O

An P10712618A0181 DT O
amino-acid P10712618A0181 JJ O
sequence P10712618A0181 NN O
comparison P10712618A0181 NN O
revealed P10712618A0181 VBD O
that P10712618A0181 IN O
Bacillus P10712618A0181 NNP I-UN
YM55-1 P10712618A0181 NNP I-UN
aspartase P10712618A0181 NN I-UN
shared P10712618A0181 VBD O
71 P10712618A0181 CD O
% P10712618A0181 NN O
homology P10712618A0181 NN O
with P10712618A0181 IN O
Bacillus P10712618A0181 NNP I-UN
subtilis P10712618A0181 NNS I-UN
aspartase P10712618A0181 NN I-UN
and P10712618A0181 CC O
49 P10712618A0181 CD O
% P10712618A0181 NN O
with P10712618A0181 IN O
Escherichia P10712618A0181 NNP O
coli P10712618A0181 NNS O
and P10712618A0181 CC O
Pseudomonas P10712618A0181 NNP I-UN
fluorescens P10712618A0181 VBZ I-UN
aspartases P10712618A0181 NNS I-UN
. P10712618A0181 . O
. . O O

Therefore P01428513A0440 RB O
, P01428513A0440 , O
it P01428513A0440 PRP O
would P01428513A0440 MD O
be P01428513A0440 VB O
advantageous P01428513A0440 JJ O
to P01428513A0440 TO O
identify P01428513A0440 VB O
such P01428513A0440 JJ O
persons P01428513A0440 NNS O
and P01428513A0440 CC O
treat P01428513A0440 VB O
them P01428513A0440 PRP O
preferentially P01428513A0440 RB O
. P01428513A0440 . O
. . O O

Eucaryotic P02398897A0000 JJ O
transcription P02398897A0000 NN O
factors P02398897A0000 NNS O
that P02398897A0000 WDT O
stimulate P02398897A0000 VBP O
RNA P02398897A0000 NNP I-UN
polymerase P02398897A0000 NN I-UN
II P02398897A0000 NNP I-UN
by P02398897A0000 IN O
increasing P02398897A0000 VBG O
the P02398897A0000 DT O
efficiency P02398897A0000 NN O
of P02398897A0000 IN O
elongation P02398897A0000 NN O
of P02398897A0000 IN O
specifically P02398897A0000 RB O
or P02398897A0000 CC O
randomly P02398897A0000 RB O
initiated P02398897A0000 VBN O
RNA P02398897A0000 NNP O
chains P02398897A0000 NNS O
have P02398897A0000 VBP O
been P02398897A0000 VBN O
isolated P02398897A0000 VBN O
and P02398897A0000 CC O
characterized P02398897A0000 VBN O
. P02398897A0000 . O
. . O O

We P08614403A0989 PRP O
then P08614403A0989 RB O
demonstrated P08614403A0989 VBD O
that P08614403A0989 IN O
1 P08614403A0989 CD O
) P08614403A0989 ) O
GAL4-REV-erbA P08614403A0989 NNP O
alpha P08614403A0989 NN I-UN
chimeras P08614403A0989 NNS O
that P08614403A0989 WDT O
contain P08614403A0989 VBP O
the P08614403A0989 DT O
'AB P08614403A0989 NNP O
' P08614403A0989 POS O
region P08614403A0989 NN O
and P08614403A0989 CC O
lack P08614403A0989 VB O
the P08614403A0989 DT O
'E P08614403A0989 NNP O
' P08614403A0989 POS O
region P08614403A0989 NN O
activated P08614403A0989 VBD O
transcription P08614403A0989 NN O
of P08614403A0989 IN O
GAL4 P08614403A0989 NNP I-UN
response P08614403A0989 NN I-UN
elements P08614403A0989 NNS I-UN
in P08614403A0989 IN O
the P08614403A0989 DT O
presence P08614403A0989 NN O
of P08614403A0989 IN O
8-Br-cAMP P08614403A0989 JJ O
and P08614403A0989 CC O
2 P08614403A0989 CD O
) P08614403A0989 ) O
the P08614403A0989 DT O
ligand-binding P08614403A0989 JJ O
domain P08614403A0989 NN O
( P08614403A0989 ( O
LBD P08614403A0989 NNP O
) P08614403A0989 ) O
contains P08614403A0989 VBZ O
an P08614403A0989 DT O
active P08614403A0989 JJ O
transcriptional P08614403A0989 JJ O
silencer P08614403A0989 NN O
. P08614403A0989 . O
. . O O

The P10782640A0444 DT O
method P10782640A0444 NN O
is P10782640A0444 VBZ O
applied P10782640A0444 VBN O
to P10782640A0444 TO O
determine P10782640A0444 VB O
aberration P10782640A0444 NN O
constants P10782640A0444 NNS O
of P10782640A0444 IN O
a P10782640A0444 DT O
CM300 P10782640A0444 NNP O
FEG P10782640A0444 NNP O
/ P10782640A0444 NNP O
UT P10782640A0444 NNP O
microscope P10782640A0444 NN O
with P10782640A0444 IN O
correction P10782640A0444 NN O
of P10782640A0444 IN O
the P10782640A0444 DT O
three-fold P10782640A0444 JJ O
astigmatism P10782640A0444 NN O
. P10782640A0444 . O
. . O O

Deregulation P01833716A0990 NN O
of P01833716A0990 IN O
their P01833716A0990 PRP$ O
expression P01833716A0990 NN O
may P01833716A0990 MD O
contribute P01833716A0990 VB O
to P01833716A0990 TO O
malignant P01833716A0990 JJ O
transformation P01833716A0990 NN O
associated P01833716A0990 VBN O
with P01833716A0990 IN O
HTLV-1 P01833716A0990 NNP O
infection P01833716A0990 NN O
. P01833716A0990 . O
. . O O

Control P09005609A0299 NNP O
examination P09005609A0299 NN O
was P09005609A0299 VBD O
performed P09005609A0299 VBN O
at P09005609A0299 IN O
the P09005609A0299 DT O
end P09005609A0299 NN O
of P09005609A0299 IN O
each P09005609A0299 DT O
period P09005609A0299 NN O
. P09005609A0299 . O
. . O O

The P01713213A0000 DT O
protein P01713213A0000 NN O
predicted P01713213A0000 VBN O
by P01713213A0000 IN O
the P01713213A0000 DT O
sequence P01713213A0000 NN O
of P01713213A0000 IN O
the P01713213A0000 DT O
human P01713213A0000 JJ I-UN
pim-1 P01713213A0000 JJ I-UN
proto-oncogene P01713213A0000 JJ I-UN
shares P01713213A0000 NNS O
extensive P01713213A0000 JJ O
homology P01713213A0000 NN O
with P01713213A0000 IN O
known P01713213A0000 JJ O
serine P01713213A0000 NN I-UN
/ P01713213A0000 NNP I-UN
threonine P01713213A0000 NN I-UN
protein P01713213A0000 NN I-UN
kinases P01713213A0000 NNS I-UN
, P01713213A0000 , O
and P01713213A0000 CC O
yet P01713213A0000 RB O
the P01713213A0000 DT O
human P01713213A0000 JJ I-UN
Pim-1 P01713213A0000 NNP I-UN
enzyme P01713213A0000 NN I-UN
has P01713213A0000 VBZ O
previously P01713213A0000 RB O
been P01713213A0000 VBN O
reported P01713213A0000 VBN O
to P01713213A0000 TO O
exhibit P01713213A0000 VB O
protein P01713213A0000 JJ I-UN
tyrosine P01713213A0000 JJ I-UN
kinase P01713213A0000 NN I-UN
activity P01713213A0000 NN O
both P01713213A0000 DT O
in P01713213A0000 IN O
vitro P01713213A0000 NN O
and P01713213A0000 CC O
in P01713213A0000 IN O
vivo P01713213A0000 NN O
. P01713213A0000 . O
. . O O

Marker P01551568A1476 NNP O
rescue P01551568A1476 NN O
analysis P01551568A1476 NN O
has P01551568A1476 VBZ O
localized P01551568A1476 VBN O
ts8 P01551568A1476 NN I-UN
to P01551568A1476 TO O
a P01551568A1476 DT O
910-bp P01551568A1476 JJ O
internal P01551568A1476 JJ O
segment P01551568A1476 NN O
of P01551568A1476 IN O
rpoB P01551568A1476 NN I-UN
that P01551568A1476 WDT O
encodes P01551568A1476 VBZ O
the P01551568A1476 DT O
Rif P01551568A1476 NNP I-UN
domain P01551568A1476 NN I-UN
. P01551568A1476 . O
. . O O

Subdural P06200300A0409 NNP O
electrodes P06200300A0409 NNS O
may P06200300A0409 MD O
yield P06200300A0409 VB O
larger P06200300A0409 JJR O
VEP P06200300A0409 NNP O
amplitudes P06200300A0409 NNS O
than P06200300A0409 IN O
skull P06200300A0409 NN O
or P06200300A0409 CC O
scalp P06200300A0409 NN O
electrodes P06200300A0409 NNS O
. P06200300A0409 . O
. . O O

Treatment P11605207T0001 NN O
of P11605207T0001 IN O
ischemic P11605207T0001 JJ O
heart P11605207T0001 NN O
disease P11605207T0001 NN O
in P11605207T0001 IN O
the P11605207T0001 DT O
elderly P11605207T0001 JJ O
. P11605207T0001 . O
. . O O

The P02163394T0000 DT O
sacT P02163394T0000 JJ I-UN
gene P02163394T0000 NN I-UN
regulating P02163394T0000 VBG O
the P02163394T0000 DT O
sacPA P02163394T0000 NN I-UN
operon P02163394T0000 NN I-UN
in P02163394T0000 IN I-UN
Bacillus P02163394T0000 NNP I-UN
subtilis P02163394T0000 NNS I-UN
shares P02163394T0000 NNS O
strong P02163394T0000 JJ O
homology P02163394T0000 NN O
with P02163394T0000 IN O
transcriptional P02163394T0000 JJ O
antiterminators P02163394T0000 NNS O
. P02163394T0000 . O
. . O O

The P03110746A0146 DT O
mean P03110746A0146 JJ O
percentage P03110746A0146 NN O
of P03110746A0146 IN O
linoleic P03110746A0146 JJ O
acid P03110746A0146 NN O
in P03110746A0146 IN O
the P03110746A0146 DT O
triglycerides P03110746A0146 NNS O
of P03110746A0146 IN O
the P03110746A0146 DT O
subcutaneous P03110746A0146 JJ O
adipose P03110746A0146 JJ O
tissue P03110746A0146 NN O
( P03110746A0146 ( O
PLASAT P03110746A0146 NNP O
) P03110746A0146 ) O
of P03110746A0146 IN O
these P03110746A0146 DT O
subjects P03110746A0146 NNS O
was P03110746A0146 VBD O
substantially P03110746A0146 RB O
higher P03110746A0146 JJR O
than P03110746A0146 IN O
that P03110746A0146 DT O
in P03110746A0146 IN O
a P03110746A0146 DT O
similar P03110746A0146 JJ O
group P03110746A0146 NN O
examined P03110746A0146 VBD O
in P03110746A0146 IN O
1975-1976 P03110746A0146 JJ O
. P03110746A0146 . O
. . O O

A P01766876A0000 DT O
method P01766876A0000 NN O
is P01766876A0000 VBZ O
described P01766876A0000 VBN O
for P01766876A0000 IN O
detecting P01766876A0000 VBG O
targeted P01766876A0000 JJ O
events P01766876A0000 NNS O
at P01766876A0000 IN O
the P01766876A0000 DT O
mu P01766876A0000 NN I-UN
heavy P01766876A0000 NN I-UN
chain P01766876A0000 NN I-UN
gene P01766876A0000 NN I-UN
which P01766876A0000 WDT O
relies P01766876A0000 VBZ O
on P01766876A0000 IN O
co-conversion P01766876A0000 NN O
( P01766876A0000 ( O
or P01766876A0000 CC O
co-exchange P01766876A0000 NN O
) P01766876A0000 ) O
of P01766876A0000 IN O
a P01766876A0000 DT O
point P01766876A0000 NN O
mutation P01766876A0000 NN O
with P01766876A0000 IN O
a P01766876A0000 DT O
selectable P01766876A0000 JJ O
marker P01766876A0000 NN O
contained P01766876A0000 VBN O
on P01766876A0000 IN O
a P01766876A0000 DT O
replacement P01766876A0000 NN O
vector P01766876A0000 NN O
. P01766876A0000 . O
. . O O

Overall P03713187A0691 JJ O
, P03713187A0691 , O
lesions P03713187A0691 NNS O
infiltrating P03713187A0691 VBG O
the P03713187A0691 DT O
deep P03713187A0691 JJ O
lamina P03713187A0691 NN O
propria P03713187A0691 NNS O
do P03713187A0691 VBP O
not P03713187A0691 RB O
exhibit P03713187A0691 VB O
a P03713187A0691 DT O
reduced P03713187A0691 JJ O
frequency P03713187A0691 NN O
of P03713187A0691 IN O
occurrence P03713187A0691 NN O
compared P03713187A0691 VBN O
to P03713187A0691 TO O
lesions P03713187A0691 NNS O
infiltrating P03713187A0691 VBG O
the P03713187A0691 DT O
skeletal P03713187A0691 JJ O
muscle P03713187A0691 NN O
; P03713187A0691 : O
however P03713187A0691 RB O
, P03713187A0691 , O
carcinomas P03713187A0691 VBP O
affecting P03713187A0691 VBG O
other P03713187A0691 JJ O
oral P03713187A0691 JJ O
sites P03713187A0691 NNS O
showed P03713187A0691 VBD O
a P03713187A0691 DT O
reduced P03713187A0691 JJ O
frequency P03713187A0691 NN O
of P03713187A0691 IN O
deeply P03713187A0691 NN O
infiltrating P03713187A0691 VBG O
lesions P03713187A0691 NNS O
in P03713187A0691 IN O
comparison P03713187A0691 NN O
to P03713187A0691 TO O
more P03713187A0691 RBR O
superficial P03713187A0691 JJ O
lesions P03713187A0691 NNS O
. P03713187A0691 . O
. . O O

The P01710979T0000 DT O
SH2 P01710979T0000 NNP I-UN
and P01710979T0000 CC O
SH3 P01710979T0000 NNP I-UN
domains P01710979T0000 NNS I-UN
of P01710979T0000 IN O
pp60src P01710979T0000 NN I-UN
direct P01710979T0000 JJ O
stable P01710979T0000 JJ O
association P01710979T0000 NN O
with P01710979T0000 IN O
tyrosine P01710979T0000 NN O
phosphorylated P01710979T0000 VBN O
proteins P01710979T0000 NNS O
p130 P01710979T0000 NNS I-UN
and P01710979T0000 CC O
p110 P01710979T0000 NN I-UN
. P01710979T0000 . O
. . O O

There P06452461A0930 EX O
was P06452461A0930 VBD O
significant P06452461A0930 JJ O
correlation P06452461A0930 NN O
of P06452461A0930 IN O
LVM P06452461A0930 NNP O
/ P06452461A0930 NNP O
M2 P06452461A0930 NNP O
and P06452461A0930 CC O
PWVn P06452461A0930 NNP O
for P06452461A0930 IN O
pre-AVR P06452461A0930 NN O
and P06452461A0930 CC O
post P06452461A0930 NN O
AVR P06452461A0930 NNP O
studies P06452461A0930 NNS O
. P06452461A0930 . O
. . O O

Finally P08980533A1160 RB O
, P08980533A1160 , O
the P08980533A1160 DT O
C-terminal P08980533A1160 JJ O
region P08980533A1160 NN O
of P08980533A1160 IN O
ENBP1 P08980533A1160 NNP I-UN
shows P08980533A1160 VBZ O
strong P08980533A1160 JJ O
homology P08980533A1160 NN O
to P08980533A1160 TO O
a P08980533A1160 DT O
protein P08980533A1160 NN O
from P08980533A1160 IN O
rat P08980533A1160 NN O
that P08980533A1160 WDT O
is P08980533A1160 VBZ O
specifically P08980533A1160 RB O
expressed P08980533A1160 VBN O
in P08980533A1160 IN O
testis P08980533A1160 NN O
tissue P08980533A1160 NN O
. P08980533A1160 . O
. . O O

A P01721884A0962 DT O
second P01721884A0962 JJ O
even P01721884A0962 RB O
more P01721884A0962 RBR O
significant P01721884A0962 JJ O
match P01721884A0962 NN O
to P01721884A0962 TO O
this P01721884A0962 DT O
E. P01721884A0962 NNP O
coli P01721884A0962 JJ O
region P01721884A0962 NN O
was P01721884A0962 VBD O
found P01721884A0962 VBN O
in P01721884A0962 IN O
the P01721884A0962 DT O
retroviral P01721884A0962 JJ I-UN
ribonuclease P01721884A0962 NN I-UN
H P01721884A0962 NNP I-UN
( P01721884A0962 ( O
RNase P01721884A0962 NNP I-UN
H P01721884A0962 NNP I-UN
) P01721884A0962 ) O
domain P01721884A0962 NN O
, P01721884A0962 , O
and P01721884A0962 CC O
corresponds P01721884A0962 VBZ O
precisely P01721884A0962 RB O
to P01721884A0962 TO O
a P01721884A0962 DT O
region P01721884A0962 NN O
that P01721884A0962 WDT O
has P01721884A0962 VBZ O
been P01721884A0962 VBN O
aligned P01721884A0962 VBN O
by P01721884A0962 IN O
previous P01721884A0962 JJ O
investigators P01721884A0962 NNS O
with P01721884A0962 IN O
the P01721884A0962 DT O
E. P01721884A0962 NNP I-UN
coli P01721884A0962 NNS I-UN
RNase P01721884A0962 NNP I-UN
H P01721884A0962 NNP I-UN
, P01721884A0962 , O
suggesting P01721884A0962 VBG O
that P01721884A0962 IN O
Pol P01721884A0962 NNP I-UN
I P01721884A0962 PRP I-UN
helices P01721884A0962 VBP O
O P01721884A0962 NNP O
and P01721884A0962 CC O
P P01721884A0962 NNP O
are P01721884A0962 VBP O
homologous P01721884A0962 JJ O
to P01721884A0962 TO O
helices P01721884A0962 VB O
A P01721884A0962 NNP O
and P01721884A0962 CC O
D P01721884A0962 NNP O
of P01721884A0962 IN O
the P01721884A0962 DT O
RNase P01721884A0962 NNP I-UN
H P01721884A0962 NNP I-UN
crystal P01721884A0962 JJ O
structure P01721884A0962 NN O
, P01721884A0962 , O
respectively P01721884A0962 RB O
. P01721884A0962 . O
. . O O

Mutations P08816483A0869 NNS O
in P08816483A0869 IN O
three P08816483A0869 CD O
loci P08816483A0869 NN O
( P08816483A0869 ( O
SIC1 P08816483A0869 NNP I-UN
, P08816483A0869 , O
SWI5 P08816483A0869 NNP I-UN
, P08816483A0869 , O
and P08816483A0869 CC O
RIC3 P08816483A0869 NNP I-UN
) P08816483A0869 ) O
were P08816483A0869 VBD O
identified P08816483A0869 VBN O
. P08816483A0869 . O
. . O O

4.26 P09135928A0912 CD O
+ P09135928A0912 JJ O
/ P09135928A0912 NNP O
- P09135928A0912 : O
1.54 P09135928A0912 CD O
mmol P09135928A0912 NN O
/ P09135928A0912 NNP O
l P09135928A0912 NN O
, P09135928A0912 , O
P P09135928A0912 NNP O
< P09135928A0912 NNP O
0.01 P09135928A0912 CD O
) P09135928A0912 ) O
, P09135928A0912 , O
and P09135928A0912 CC O
systolic P09135928A0912 JJ O
BP P09135928A0912 NNP O
responses P09135928A0912 NNS O
to P09135928A0912 TO O
intravenous P09135928A0912 JJ O
norepinephrine P09135928A0912 NN O
and P09135928A0912 CC O
angiotensin P09135928A0912 NN I-UN
II P09135928A0912 NNP I-UN
were P09135928A0912 VBD O
significantly P09135928A0912 RB O
higher P09135928A0912 JJR O
on P09135928A0912 IN O
glibenclamide P09135928A0912 NN O
than P09135928A0912 IN O
on P09135928A0912 IN O
metformin P09135928A0912 NN O
( P09135928A0912 ( O
P P09135928A0912 NNP O
< P09135928A0912 NNP O
0.02 P09135928A0912 CD O
and P09135928A0912 CC O
P P09135928A0912 NNP O
< P09135928A0912 NNP O
0.05 P09135928A0912 CD O
, P09135928A0912 , O
respectively P09135928A0912 RB O
) P09135928A0912 ) O
. P09135928A0912 . O
. . O O

Some P07913891A0174 DT O
of P07913891A0174 IN O
these P07913891A0174 DT O
targets P07913891A0174 NNS O
were P07913891A0174 VBD O
reported P07913891A0174 VBN O
to P07913891A0174 TO O
code P07913891A0174 VB O
for P07913891A0174 IN O
molecules P07913891A0174 NNS O
involved P07913891A0174 VBN O
in P07913891A0174 IN O
cell-cell P07913891A0174 JJ O
interactions P07913891A0174 NNS O
, P07913891A0174 , O
whereas P07913891A0174 IN O
no P07913891A0174 DT O
relationship P07913891A0174 NN O
has P07913891A0174 VBZ O
yet P07913891A0174 RB O
been P07913891A0174 VBN O
demonstrated P07913891A0174 VBN O
between P07913891A0174 IN O
Hox P07913891A0174 NNP I-UN
genes P07913891A0174 NNS I-UN
and P07913891A0174 CC O
other P07913891A0174 JJ O
transcription P07913891A0174 NN O
factors P07913891A0174 NNS O
involved P07913891A0174 VBN O
in P07913891A0174 IN O
determining P07913891A0174 VBG O
and P07913891A0174 CC O
/ P07913891A0174 NNP O
or P07913891A0174 CC O
maintaining P07913891A0174 VBG O
tissue P07913891A0174 NN O
specificity P07913891A0174 NN O
. P07913891A0174 . O
. . O O

Cardiac P06113084T0000 NNP O
taurine P06113084T0000 NN O
levels P06113084T0000 NNS O
and P06113084T0000 CC O
sarcolemmal P06113084T0000 JJ O
calcium P06113084T0000 NN O
binding P06113084T0000 NN O
activity P06113084T0000 NN O
in P06113084T0000 IN O
furazolidone-induced P06113084T0000 JJ O
cardiomyopathy P06113084T0000 NN O
. P06113084T0000 . O
. . O O

The P06599282T0001 DT O
invasive P06599282T0001 JJ O
pattern P06599282T0001 NN O
of P06599282T0001 IN O
squamous P06599282T0001 JJ O
cell P06599282T0001 NN O
carcinoma P06599282T0001 NN O
in P06599282T0001 IN O
the P06599282T0001 DT O
mandibular P06599282T0001 JJ O
gingiva P06599282T0001 NN O
. P06599282T0001 . O
. . O O

We P01771593A1152 PRP O
conclude P01771593A1152 VBP O
that P01771593A1152 IN O
TA P01771593A1152 NNP O
caused P01771593A1152 VBD O
a P01771593A1152 DT O
specific P01771593A1152 JJ O
decrease P01771593A1152 NN O
in P01771593A1152 IN O
AGD P01771593A1152 NNP O
on P01771593A1152 IN O
GD P01771593A1152 NNP O
20 P01771593A1152 CD O
that P01771593A1152 WDT O
was P01771593A1152 VBD O
largely P01771593A1152 RB O
reversed P01771593A1152 VBN O
by P01771593A1152 IN O
PCD P01771593A1152 NNP O
23 P01771593A1152 CD O
. P01771593A1152 . O
. . O O

Effects P02544059A0377 NNS O
of P02544059A0377 IN O
nitrogen P02544059A0377 NN O
( P02544059A0377 ( O
PN2 P02544059A0377 NNP O
: P02544059A0377 : O
5 P02544059A0377 CD O
and P02544059A0377 CC O
14 P02544059A0377 CD O
MPa P02544059A0377 NNP O
) P02544059A0377 ) O
and P02544059A0377 CC O
helium P02544059A0377 NN O
( P02544059A0377 ( O
PHe P02544059A0377 NNP O
: P02544059A0377 : O
13 P02544059A0377 CD O
and P02544059A0377 CC O
14 P02544059A0377 CD O
MPa P02544059A0377 NNP O
) P02544059A0377 ) O
were P02544059A0377 VBD O
also P02544059A0377 RB O
tested P02544059A0377 VBN O
. P02544059A0377 . O
. . O O

CONCLUSION P10831972A1091 NN O
: P10831972A1091 : O
Our P10831972A1091 PRP$ O
findings P10831972A1091 NNS O
suggest P10831972A1091 VBP O
that P10831972A1091 IN O
endometriosis P10831972A1091 NN O
increases P10831972A1091 NNS O
soluble P10831972A1091 JJ O
CD23 P10831972A1091 NNP I-UN
levels P10831972A1091 NNS O
, P10831972A1091 , O
which P10831972A1091 WDT O
can P10831972A1091 MD O
be P10831972A1091 VB O
suppressed P10831972A1091 VBN O
with P10831972A1091 IN O
either P10831972A1091 DT O
danazol P10831972A1091 NN O
or P10831972A1091 CC O
leuprolide P10831972A1091 JJ O
acetate P10831972A1091 JJ O
injection P10831972A1091 NN O
. P10831972A1091 . O
. . O O

Thrombocyte P06482318A0117 NNP O
function P06482318A0117 NN O
was P06482318A0117 VBD O
impaired P06482318A0117 VBN O
in P06482318A0117 IN O
all P06482318A0117 DT O
patients P06482318A0117 NNS O
, P06482318A0117 , O
characterized P06482318A0117 VBN O
by P06482318A0117 IN O
a P06482318A0117 DT O
diminished P06482318A0117 JJ O
platelet P06482318A0117 NN O
shape P06482318A0117 NN O
change P06482318A0117 NN O
. P06482318A0117 . O
. . O O

In P11755894A0466 IN O
the P11755894A0466 DT O
treatment P11755894A0466 NN O
of P11755894A0466 IN O
opioid P11755894A0466 JJ O
naive P11755894A0466 JJ O
patients P11755894A0466 NNS O
who P11755894A0466 WP O
underwent P11755894A0466 VBP O
surgery P11755894A0466 NN O
and P11755894A0466 CC O
received P11755894A0466 VBD O
opioids P11755894A0466 NNS O
for P11755894A0466 IN O
acute P11755894A0466 NN O
pain P11755894A0466 NN O
, P11755894A0466 , O
oral P11755894A0466 JJ O
ADL P11755894A0466 NNP O
8-2698 P11755894A0466 NN O
( P11755894A0466 ( O
6.0 P11755894A0466 CD O
mg P11755894A0466 NN O
) P11755894A0466 ) O
improved P11755894A0466 VBD O
the P11755894A0466 DT O
management P11755894A0466 NN O
of P11755894A0466 IN O
postoperative P11755894A0466 JJ O
ileus P11755894A0466 NN O
( P11755894A0466 ( O
POI P11755894A0466 NNP O
) P11755894A0466 ) O
by P11755894A0466 IN O
shortening P11755894A0466 VBG O
the P11755894A0466 DT O
time P11755894A0466 NN O
to P11755894A0466 TO O
achieve P11755894A0466 VB O
normal P11755894A0466 JJ O
bowel P11755894A0466 NN O
function P11755894A0466 NN O
and P11755894A0466 CC O
, P11755894A0466 , O
ultimately P11755894A0466 RB O
, P11755894A0466 , O
hospital P11755894A0466 JJ O
stay P11755894A0466 NN O
. P11755894A0466 . O
. . O O

Although P09767593A0130 IN O
YopH P09767593A0130 NNP I-UN
is P09767593A0130 VBZ O
a P09767593A0130 DT O
highly P09767593A0130 RB O
active P09767593A0130 JJ O
PTP P09767593A0130 NNP I-UN
, P09767593A0130 , O
it P09767593A0130 PRP O
preferentially P09767593A0130 RB O
targets P09767593A0130 VBZ O
a P09767593A0130 DT O
subset P09767593A0130 NN O
of P09767593A0130 IN O
tyrosine-phosphorylated P09767593A0130 JJ O
proteins P09767593A0130 NNS O
in P09767593A0130 IN O
host P09767593A0130 NN O
cells P09767593A0130 NNS O
, P09767593A0130 , O
including P09767593A0130 VBG O
p130Cas P09767593A0130 NN I-UN
. P09767593A0130 . O
. . O O

Recent P00926751A0000 JJ O
studies P00926751A0000 NNS O
have P00926751A0000 VBP O
shown P00926751A0000 VBN O
the P00926751A0000 DT O
rat P00926751A0000 NN O
larynx P00926751A0000 NN O
to P00926751A0000 TO O
be P00926751A0000 VB O
an P00926751A0000 DT O
important P00926751A0000 JJ O
organ P00926751A0000 NN O
in P00926751A0000 IN O
the P00926751A0000 DT O
evaluation P00926751A0000 NN O
of P00926751A0000 IN O
irritancy P00926751A0000 NN O
of P00926751A0000 IN O
inhaled P00926751A0000 JJ O
materials P00926751A0000 NNS O
. P00926751A0000 . O
. . O O

In P07327097A0647 IN O
PB P07327097A0647 NNP O
mice P07327097A0647 NN O
, P07327097A0647 , O
there P07327097A0647 EX O
was P07327097A0647 VBD O
only P07327097A0647 RB O
a P07327097A0647 DT O
small P07327097A0647 JJ O
deficit P07327097A0647 NN O
in P07327097A0647 IN O
the P07327097A0647 DT O
number P07327097A0647 NN O
of P07327097A0647 IN O
the P07327097A0647 DT O
hippocampal P07327097A0647 JJ O
pyramidal P07327097A0647 NN O
neurons P07327097A0647 NNS O
compared P07327097A0647 VBN O
to P07327097A0647 TO O
controls P07327097A0647 NNS O
( P07327097A0647 ( O
15 P07327097A0647 CD O
% P07327097A0647 NN O
, P07327097A0647 , O
p P07327097A0647 NN O
less P07327097A0647 JJR O
than P07327097A0647 IN O
0.01 P07327097A0647 CD O
) P07327097A0647 ) O
, P07327097A0647 , O
and P07327097A0647 CC O
no P07327097A0647 DT O
deficit P07327097A0647 NN O
in P07327097A0647 IN O
the P07327097A0647 DT O
granule P07327097A0647 NN O
cells P07327097A0647 NNS O
. P07327097A0647 . O
. . O O

We P09445056A0215 PRP O
have P09445056A0215 VBP O
used P09445056A0215 VBN O
mutation-directed P09445056A0215 JJ O
chemical P09445056A0215 JJ O
cross-linking P09445056A0215 NN O
with P09445056A0215 IN O
bis P09445056A0215 NN O
( P09445056A0215 ( O
sulfosuccinimidyl P09445056A0215 NN O
) P09445056A0215 ) O
suberate P09445056A0215 NN O
( P09445056A0215 ( O
BS3 P09445056A0215 NNP O
) P09445056A0215 ) O
to P09445056A0215 TO O
investigate P09445056A0215 VB O
the P09445056A0215 DT O
architecture P09445056A0215 NN O
of P09445056A0215 IN O
the P09445056A0215 DT O
gp41 P09445056A0215 NN I-UN
oligomer P09445056A0215 NN I-UN
. P09445056A0215 . O
. . O O

OBJECTIVE P09739401A0000 NN O
: P09739401A0000 : O
The P09739401A0000 DT O
purpose P09739401A0000 NN O
of P09739401A0000 IN O
this P09739401A0000 DT O
article P09739401A0000 NN O
is P09739401A0000 VBZ O
to P09739401A0000 TO O
review P09739401A0000 VB O
balance P09739401A0000 NN O
instruments P09739401A0000 NNS O
developed P09739401A0000 VBD O
within P09739401A0000 IN O
the P09739401A0000 DT O
past P09739401A0000 JJ O
10 P09739401A0000 CD O
years P09739401A0000 NNS O
that P09739401A0000 WDT O
can P09739401A0000 MD O
be P09739401A0000 VB O
used P09739401A0000 VBN O
in P09739401A0000 IN O
the P09739401A0000 DT O
clinic P09739401A0000 NN O
or P09739401A0000 CC O
home P09739401A0000 NN O
environment P09739401A0000 NN O
. P09739401A0000 . O
. . O O

Low P03673640A0533 JJ O
MAO P03673640A0533 NNP I-UN
subjects P03673640A0533 NNS O
showed P03673640A0533 VBD O
a P03673640A0533 DT O
pattern P03673640A0533 NN O
of P03673640A0533 IN O
higher P03673640A0533 JJR O
scores P03673640A0533 NNS O
in P03673640A0533 IN O
KSP P03673640A0533 NNP O
Impulsiveness P03673640A0533 NNP O
, P03673640A0533 , O
EPQ P03673640A0533 NNP O
Neuroticism P03673640A0533 NNP O
, P03673640A0533 , O
and P03673640A0533 CC O
KSP P03673640A0533 NNP O
Somatic P03673640A0533 NNP O
Anxiety P03673640A0533 NNP O
and P03673640A0533 CC O
Irritability P03673640A0533 NNP O
and P03673640A0533 CC O
lower P03673640A0533 JJR O
scores P03673640A0533 NNS O
in P03673640A0533 IN O
KSP P03673640A0533 NNP O
Socialization P03673640A0533 NNP O
, P03673640A0533 , O
in P03673640A0533 IN O
line P03673640A0533 NN O
with P03673640A0533 IN O
personality P03673640A0533 NN O
profiles P03673640A0533 NNS O
found P03673640A0533 VBN O
in P03673640A0533 IN O
alcoholics P03673640A0533 NNS O
, P03673640A0533 , O
psychopaths P03673640A0533 NNS O
, P03673640A0533 , O
and P03673640A0533 CC O
suicide P03673640A0533 JJ O
attempters P03673640A0533 NNS O
who P03673640A0533 WP O
also P03673640A0533 RB O
tend P03673640A0533 VBP O
to P03673640A0533 TO O
have P03673640A0533 VB O
low P03673640A0533 JJ O
platelet P03673640A0533 NN O
MAO P03673640A0533 NNP I-UN
activity P03673640A0533 NN O
. P03673640A0533 . O
. . O O

Functional P09058373A1620 JJ O
tests P09058373A1620 NNS O
using P09058373A1620 VBG O
a P09058373A1620 DT O
reporter P09058373A1620 NN O
gene P09058373A1620 NN O
, P09058373A1620 , O
containing P09058373A1620 VBG O
Stat5-binding P09058373A1620 JJ I-UN
elements P09058373A1620 NNS I-UN
, P09058373A1620 , O
confirmed P09058373A1620 VBD O
that P09058373A1620 IN O
while P09058373A1620 IN O
the P09058373A1620 DT O
variant P09058373A1620 JJ O
form P09058373A1620 NN O
was P09058373A1620 VBD O
inactive P09058373A1620 JJ O
by P09058373A1620 IN O
itself P09058373A1620 PRP O
, P09058373A1620 , O
it P09058373A1620 PRP O
could P09058373A1620 MD O
inhibit P09058373A1620 VB O
the P09058373A1620 DT O
function P09058373A1620 NN O
of P09058373A1620 IN O
the P09058373A1620 DT O
full-length P09058373A1620 JJ O
receptor P09058373A1620 NN O
. P09058373A1620 . O
. . O O

A P00851041A0000 DT O
follow-up P00851041A0000 JJ O
study P00851041A0000 NN O
of P00851041A0000 IN O
22 P00851041A0000 CD O
patients P00851041A0000 NNS O
with P00851041A0000 IN O
Ebstein P00851041A0000 NNP O
's P00851041A0000 POS O
anomaly P00851041A0000 NN O
has P00851041A0000 VBZ O
been P00851041A0000 VBN O
performed P00851041A0000 VBN O
. P00851041A0000 . O
. . O O

A P07504171A0715 DT O
platelet-derived P07504171A0715 JJ I-UN
growth P07504171A0715 NN I-UN
factor P07504171A0715 NN I-UN
receptor P07504171A0715 NN I-UN
( P07504171A0715 ( O
PDGF-R P07504171A0715 NNP I-UN
) P07504171A0715 ) O
phosphopeptide P07504171A0715 IN O
containing P07504171A0715 VBG O
Tyr-857 P07504171A0715 NNP O
does P07504171A0715 VBZ O
not P07504171A0715 RB O
bind P07504171A0715 VB O
appreciably P07504171A0715 RB O
to P07504171A0715 TO O
the P07504171A0715 DT O
Src P07504171A0715 NNP I-UN
SH2 P07504171A0715 NNP I-UN
domain P07504171A0715 NN I-UN
, P07504171A0715 , O
suggesting P07504171A0715 VBG O
it P07504171A0715 PRP O
is P07504171A0715 VBZ O
not P07504171A0715 RB O
the P07504171A0715 DT O
PDGF-R P07504171A0715 NNP I-UN
binding P07504171A0715 NN O
site P07504171A0715 NN O
for P07504171A0715 IN O
Src P07504171A0715 NNP I-UN
as P07504171A0715 IN O
previously P07504171A0715 RB O
reported P07504171A0715 VBN O
. P07504171A0715 . O
. . O O

By P02934891A0845 IN O
adapting P02934891A0845 VBG O
a P02934891A0845 DT O
method P02934891A0845 NN O
for P02934891A0845 IN O
DNA-footprinting P02934891A0845 NNP O
using P02934891A0845 VBG O
impure P02934891A0845 JJ O
extracts P02934891A0845 NNS O
of P02934891A0845 IN O
ner P02934891A0845 NN I-UN
overproducing P02934891A0845 VBG O
cells P02934891A0845 NNS O
, P02934891A0845 , O
we P02934891A0845 PRP O
were P02934891A0845 VBD O
able P02934891A0845 JJ O
to P02934891A0845 TO O
determine P02934891A0845 VB O
that P02934891A0845 IN O
the P02934891A0845 DT O
ner-binding P02934891A0845 JJ I-UN
sites P02934891A0845 NNS I-UN
are P02934891A0845 VBP O
located P02934891A0845 VBN O
between P02934891A0845 IN O
nucleotides P02934891A0845 NNS O
1026 P02934891A0845 CD O
and P02934891A0845 CC O
1058 P02934891A0845 CD O
from P02934891A0845 IN O
the P02934891A0845 DT O
Mu P02934891A0845 NNP O
left P02934891A0845 VBD O
end P02934891A0845 NN O
. P02934891A0845 . O
. . O O

Since P07683375A0000 IN O
we P07683375A0000 PRP O
have P07683375A0000 VBP O
observed P07683375A0000 VBN O
effects P07683375A0000 NNS O
of P07683375A0000 IN O
growth P07683375A0000 NN O
factors P07683375A0000 NNS O
and P07683375A0000 CC O
cAMP P07683375A0000 NN O
as P07683375A0000 RB O
well P07683375A0000 RB O
as P07683375A0000 IN O
estradiol P07683375A0000 NN O
( P07683375A0000 ( O
E2 P07683375A0000 NNP O
) P07683375A0000 ) O
on P07683375A0000 IN O
regulation P07683375A0000 NN O
of P07683375A0000 IN O
expression P07683375A0000 NN O
of P07683375A0000 IN O
some P07683375A0000 DT O
genes P07683375A0000 NNS O
stimulated P07683375A0000 VBN O
by P07683375A0000 IN O
the P07683375A0000 DT O
estrogen P07683375A0000 NN I-UN
receptor P07683375A0000 NN I-UN
( P07683375A0000 ( O
ER P07683375A0000 NNP I-UN
) P07683375A0000 ) O
, P07683375A0000 , O
we P07683375A0000 PRP O
have P07683375A0000 VBP O
undertaken P07683375A0000 VBN O
studies P07683375A0000 NNS O
to P07683375A0000 TO O
examine P07683375A0000 VB O
directly P07683375A0000 RB O
whether P07683375A0000 IN O
activators P07683375A0000 NNS O
of P07683375A0000 IN O
protein P07683375A0000 NN O
kinases P07683375A0000 NNS O
can P07683375A0000 MD O
modulate P07683375A0000 VB O
transcriptional P07683375A0000 JJ O
activity P07683375A0000 NN O
of P07683375A0000 IN O
the P07683375A0000 DT O
ER P07683375A0000 NNP I-UN
. P07683375A0000 . O
. . O O

Of P02358975A0709 IN O
the P02358975A0709 DT O
remaining P02358975A0709 VBG O
seven P02358975A0709 CD O
, P02358975A0709 , O
five P02358975A0709 CD O
reacted P02358975A0709 VBD O
either P02358975A0709 CC O
with P02358975A0709 IN O
immediate P02358975A0709 JJ O
and P02358975A0709 CC O
strong P02358975A0709 JJ O
symptoms P02358975A0709 NNS O
or P02358975A0709 CC O
had P02358975A0709 VBD O
spontaneously P02358975A0709 RB O
reduced P02358975A0709 VBN O
gluten P02358975A0709 JJ I-UN
intake P02358975A0709 NN O
, P02358975A0709 , O
or P02358975A0709 CC O
had P02358975A0709 VBD O
an P02358975A0709 DT O
acquired P02358975A0709 VBN O
IgA P02358975A0709 NNP I-UN
deficiency P02358975A0709 NN O
. P02358975A0709 . O
. . O O

This P10406462A1127 DT O
constitutes P10406462A1127 VBZ O
evidence P10406462A1127 NN O
for P10406462A1127 IN O
an P10406462A1127 DT O
in P10406462A1127 IN O
vivo P10406462A1127 JJ O
role P10406462A1127 NN O
of P10406462A1127 IN O
SRC-1 P10406462A1127 NNP I-UN
in P10406462A1127 IN O
dimerization-induced P10406462A1127 JJ O
activation P10406462A1127 NN O
by P10406462A1127 IN O
OR1 P10406462A1127 NNP I-UN
/ P10406462A1127 NNP O
RXRalpha P10406462A1127 NNP I-UN
. P10406462A1127 . O
. . O O

However P06602580A0664 RB O
, P06602580A0664 , O
the P06602580A0664 DT O
history P06602580A0664 NN O
of P06602580A0664 IN O
acute P06602580A0664 NN O
severe P06602580A0664 JJ O
complications P06602580A0664 NNS O
from P06602580A0664 IN O
otitis P06602580A0664 JJ O
media P06602580A0664 NNS O
revealed P06602580A0664 VBD O
a P06602580A0664 DT O
higher P06602580A0664 JJR O
frequency P06602580A0664 NN O
in P06602580A0664 IN O
those P06602580A0664 DT O
individuals P06602580A0664 NNS O
with P06602580A0664 IN O
alpha P06602580A0664 JJ I-UN
1-antitrypsin P06602580A0664 JJ I-UN
deficiency P06602580A0664 NN O
as P06602580A0664 IN O
compared P06602580A0664 VBN O
to P06602580A0664 TO O
normals P06602580A0664 NNS O
. P06602580A0664 . O
. . O O

All P07784199A0000 DT O
ribosomal P07784199A0000 JJ I-UN
protein P07784199A0000 NN I-UN
( P07784199A0000 ( O
rp P07784199A0000 NN I-UN
) P07784199A0000 ) O
gene P07784199A0000 NN O
promoters P07784199A0000 NNS O
from P07784199A0000 IN O
Saccharomyces P07784199A0000 NNP O
cerevisiae P07784199A0000 NN O
studied P07784199A0000 VBD O
so P07784199A0000 RB O
far P07784199A0000 RB O
contain P07784199A0000 NN O
either P07784199A0000 CC O
( P07784199A0000 ( O
usually P07784199A0000 RB O
two P07784199A0000 CD O
) P07784199A0000 ) O
binding P07784199A0000 NN O
sites P07784199A0000 NNS O
for P07784199A0000 IN O
the P07784199A0000 DT O
global P07784199A0000 JJ O
gene P07784199A0000 NN O
regulator P07784199A0000 NN O
Rap1p P07784199A0000 NNP I-UN
or P07784199A0000 CC O
one P07784199A0000 CD O
binding P07784199A0000 NN O
site P07784199A0000 NN O
for P07784199A0000 IN O
another P07784199A0000 DT O
global P07784199A0000 JJ O
factor P07784199A0000 NN O
, P07784199A0000 , O
Abf1p P07784199A0000 NNP I-UN
. P07784199A0000 . O
. . O O

Sequence P07747462A0332 NNP O
comparisons P07747462A0332 NNS O
of P07747462A0332 IN O
prokaryotic P07747462A0332 JJ I-UN
RCR P07747462A0332 NNP I-UN
initiators P07747462A0332 NNS I-UN
has P07747462A0332 VBZ O
revealed P07747462A0332 VBN O
a P07747462A0332 DT O
set P07747462A0332 NN O
of P07747462A0332 IN O
three P07747462A0332 CD O
common P07747462A0332 JJ O
motifs P07747462A0332 NNS O
, P07747462A0332 , O
two P07747462A0332 CD O
of P07747462A0332 IN O
which P07747462A0332 WDT O
, P07747462A0332 , O
a P07747462A0332 DT O
putative P07747462A0332 JJ O
metal P07747462A0332 NN O
coordination P07747462A0332 NN O
site P07747462A0332 NN O
and P07747462A0332 CC O
a P07747462A0332 DT O
downstream P07747462A0332 NN O
active-site P07747462A0332 JJ O
tyrosine P07747462A0332 NN O
motif P07747462A0332 NN O
, P07747462A0332 , O
could P07747462A0332 MD O
be P07747462A0332 VB O
tentatively P07747462A0332 RB O
identified P07747462A0332 VBN O
in P07747462A0332 IN O
parvoviral P07747462A0332 JJ I-UN
replicator P07747462A0332 NN I-UN
proteins P07747462A0332 NNS I-UN
. P07747462A0332 . O
. . O O

One P08370275A0290 CD O
chimpanzee P08370275A0290 NN O
reliably P08370275A0290 RB O
selected P08370275A0290 VBD O
the P08370275A0290 DT O
larger P08370275A0290 JJR O
numeral P08370275A0290 JJ O
4 P08370275A0290 CD O
during P08370275A0290 IN O
testing P08370275A0290 VBG O
with P08370275A0290 IN O
a P08370275A0290 DT O
nonadjacent P08370275A0290 JJ O
pair P08370275A0290 NN O
( P08370275A0290 ( O
2-4 P08370275A0290 JJ O
) P08370275A0290 ) O
, P08370275A0290 , O
and P08370275A0290 CC O
2 P08370275A0290 CD O
chimps P08370275A0290 NNS O
showed P08370275A0290 VBD O
no P08370275A0290 DT O
preference P08370275A0290 NN O
. P08370275A0290 . O
. . O O

One P08248246A0838 CD O
complex P08248246A0838 NN O
most P08248246A0838 RBS O
likely P08248246A0838 JJ O
contained P08248246A0838 VBN O
Sp1 P08248246A0838 NNP I-UN
, P08248246A0838 , O
and P08248246A0838 CC O
another P08248246A0838 DT O
complex P08248246A0838 JJ O
showed P08248246A0838 VBD O
S-phase-specific P08248246A0838 JJ O
binding P08248246A0838 NN O
, P08248246A0838 , O
suggesting P08248246A0838 VBG O
a P08248246A0838 DT O
direct P08248246A0838 JJ O
role P08248246A0838 NN O
in P08248246A0838 IN O
the P08248246A0838 DT O
cell-cycle-dependent P08248246A0838 JJ O
R1 P08248246A0838 NNP I-UN
gene P08248246A0838 NN I-UN
expression P08248246A0838 NN O
. P08248246A0838 . O
. . O O

Vitrectomy P01147502T0000 NNP O
with P01147502T0000 IN O
an P01147502T0000 DT O
alternative P01147502T0000 JJ O
instrument P01147502T0000 NN O
system P01147502T0000 NN O
. P01147502T0000 . O
. . O O

On P04429269T0000 IN O
the P04429269T0000 DT O
transport P04429269T0000 NN O
of P04429269T0000 IN O
mucus P04429269T0000 NN O
and P04429269T0000 CC O
its P04429269T0000 PRP$ O
rheologic P04429269T0000 JJ O
simulants P04429269T0000 NNS O
in P04429269T0000 IN O
ciliated P04429269T0000 JJ O
systems P04429269T0000 NNS O
. P04429269T0000 . O
. . O O

By P02906027A0553 IN O
sequence P02906027A0553 NN O
comparison P02906027A0553 NN O
, P02906027A0553 , O
42 P02906027A0553 CD O
blocks P02906027A0553 NNS O
of P02906027A0553 IN O
homology P02906027A0553 NN O
are P02906027A0553 VBP O
defined P02906027A0553 VBN O
in P02906027A0553 IN O
the P02906027A0553 DT O
5'-terminal P02906027A0553 JJ O
region P02906027A0553 NN O
, P02906027A0553 , O
of P02906027A0553 IN O
which P02906027A0553 WDT O
36 P02906027A0553 CD O
appear P02906027A0553 NN O
in P02906027A0553 IN O
the P02906027A0553 DT O
CpG P02906027A0553 NNP O
island P02906027A0553 NN O
and P02906027A0553 CC O
contain P02906027A0553 VBP O
numerous P02906027A0553 JJ O
conserved P02906027A0553 VBN O
CpG P02906027A0553 NNP O
dinucleotides P02906027A0553 NNS O
. P02906027A0553 . O
. . O O

Similarities P09402139A1121 NNS O
between P09402139A1121 IN O
the P09402139A1121 DT O
hIGFBP-1 P09402139A1121 NN I-UN
and P09402139A1121 CC O
phosphoenolpyruvate P09402139A1121 NN I-UN
kinase P09402139A1121 NN I-UN
( P09402139A1121 ( O
PEPCK P09402139A1121 NNP I-UN
) P09402139A1121 ) O
promoters P09402139A1121 NNS O
, P09402139A1121 , O
including P09402139A1121 VBG O
regions P09402139A1121 NNS O
conferring P09402139A1121 VBG O
insulin P09402139A1121 NN I-UN
, P09402139A1121 , O
glucocorticoid P09402139A1121 NN O
, P09402139A1121 , O
and P09402139A1121 CC O
cyclic P09402139A1121 JJ O
adenosine-monophosphate P09402139A1121 JJ O
responses P09402139A1121 NNS O
, P09402139A1121 , O
are P09402139A1121 VBP O
consistent P09402139A1121 JJ O
with P09402139A1121 IN O
our P09402139A1121 PRP$ O
previous P09402139A1121 JJ O
hypothesis P09402139A1121 NN O
that P09402139A1121 IN O
IGFBP-1 P09402139A1121 NNP I-UN
is P09402139A1121 VBZ O
involved P09402139A1121 VBN O
in P09402139A1121 IN O
regulation P09402139A1121 NN O
of P09402139A1121 IN O
glucose P09402139A1121 JJ O
metabolism P09402139A1121 NN O
. P09402139A1121 . O
. . O O

Activities P03992022A0330 NNS O
of P03992022A0330 IN O
hepatic P03992022A0330 JJ O
cytochrome P03992022A0330 JJ I-UN
P-450-dependent P03992022A0330 JJ O
metabolizing P03992022A0330 VBG O
enzymes P03992022A0330 NNS O
such P03992022A0330 JJ O
as P03992022A0330 IN O
aminopyrine- P03992022A0330 JJ I-UN
and P03992022A0330 CC I-UN
TMO P03992022A0330 NNP I-UN
N-demethylase P03992022A0330 NNP I-UN
and P03992022A0330 CC O
aniline P03992022A0330 JJ I-UN
hydroxylase P03992022A0330 NN I-UN
activity P03992022A0330 NN O
were P03992022A0330 VBD O
decreased P03992022A0330 VBN O
by P03992022A0330 IN O
pretreatment P03992022A0330 NN O
of P03992022A0330 IN O
rats P03992022A0330 NNS O
with P03992022A0330 IN O
cimetidine P03992022A0330 NN O
, P03992022A0330 , O
whereas P03992022A0330 NNS O
in P03992022A0330 IN O
the P03992022A0330 DT O
rats P03992022A0330 NNS O
pretreated P03992022A0330 VBD O
with P03992022A0330 IN O
ranitidine P03992022A0330 NN O
, P03992022A0330 , O
these P03992022A0330 DT O
enzyme P03992022A0330 JJ O
activities P03992022A0330 NNS O
were P03992022A0330 VBD O
not P03992022A0330 RB O
changed P03992022A0330 VBN O
. P03992022A0330 . O
. . O O

In P10492127A0914 IN O
another P10492127A0914 DT O
study P10492127A0914 NN O
, P10492127A0914 , O
intravenous P10492127A0914 JJ O
administration P10492127A0914 NN O
of P10492127A0914 IN O
devazepide P10492127A0914 NN O
, P10492127A0914 , O
a P10492127A0914 DT O
specific P10492127A0914 JJ O
cholecystokinin-A P10492127A0914 JJ I-UN
receptor P10492127A0914 NN I-UN
antagonist P10492127A0914 NN O
, P10492127A0914 , O
at P10492127A0914 IN O
a P10492127A0914 DT O
dose P10492127A0914 NN O
of P10492127A0914 IN O
0.1 P10492127A0914 CD O
mg P10492127A0914 NNS O
/ P10492127A0914 JJ O
kg P10492127A0914 FW O
/ P10492127A0914 FW O
hr P10492127A0914 NN O
was P10492127A0914 VBD O
begun P10492127A0914 VBN O
15 P10492127A0914 CD O
min P10492127A0914 NN O
before P10492127A0914 IN O
postprandial P10492127A0914 JJ O
saline P10492127A0914 NN O
intake P10492127A0914 NN O
and P10492127A0914 CC O
continued P10492127A0914 VBD O
for P10492127A0914 IN O
1 P10492127A0914 CD O
hr P10492127A0914 NN O
. P10492127A0914 . O
. . O O

Analysis P07608968A0836 NN O
of P07608968A0836 IN O
several P07608968A0836 JJ O
Tat P07608968A0836 NNP I-UN
mutants P07608968A0836 NNS I-UN
indicated P07608968A0836 VBD O
that P07608968A0836 IN O
both P07608968A0836 DT O
the P07608968A0836 DT O
cysteine-rich P07608968A0836 JJ O
and P07608968A0836 CC O
the P07608968A0836 DT O
core P07608968A0836 NN O
domains P07608968A0836 NNS O
of P07608968A0836 IN O
this P07608968A0836 DT O
transactivator P07608968A0836 NN O
are P07608968A0836 VBP O
necessary P07608968A0836 JJ O
and P07608968A0836 CC O
sufficient P07608968A0836 JJ O
to P07608968A0836 TO O
activate P07608968A0836 VB O
transcription P07608968A0836 NN O
when P07608968A0836 WRB O
TBP P07608968A0836 NNP I-UN
is P07608968A0836 VBZ O
overexpressed P07608968A0836 VBN O
. P07608968A0836 . O
. . O O

Thus P07864652A1901 RB O
, P07864652A1901 , O
we P07864652A1901 PRP O
have P07864652A1901 VBP O
produced P07864652A1901 VBN O
lipoyl P07864652A1901 JJ O
domain P07864652A1901 NN O
constructs P07864652A1901 NNS O
that P07864652A1901 WDT O
can P07864652A1901 MD O
be P07864652A1901 VB O
employed P07864652A1901 VBN O
in P07864652A1901 IN O
sorting P07864652A1901 VBG O
the P07864652A1901 DT O
specific P07864652A1901 JJ O
roles P07864652A1901 NNS O
of P07864652A1901 IN O
E2L1 P07864652A1901 NNP I-UN
and P07864652A1901 CC O
E2L2 P07864652A1901 NNP I-UN
in P07864652A1901 IN O
facilitating P07864652A1901 VBG O
catalytic P07864652A1901 JJ O
and P07864652A1901 CC O
regulatory P07864652A1901 JJ O
processes P07864652A1901 NNS O
. P07864652A1901 . O
. . O O

Surprisingly P01378506A0884 RB O
, P01378506A0884 , O
the P01378506A0884 DT O
full-deletion P01378506A0884 NN O
mutant P01378506A0884 NN O
showed P01378506A0884 VBD O
a P01378506A0884 DT O
strong P01378506A0884 JJ O
block P01378506A0884 NN O
in P01378506A0884 IN O
virus P01378506A0884 NN O
release P01378506A0884 NN O
, P01378506A0884 , O
suggesting P01378506A0884 VBG O
that P01378506A0884 IN O
NC P01378506A0884 NNP I-UN
is P01378506A0884 VBZ O
involved P01378506A0884 VBN O
in P01378506A0884 IN O
virus P01378506A0884 NN O
assembly P01378506A0884 NN O
. P01378506A0884 . O
. . O O

A P08569680A0636 DT O
mutant P08569680A0636 JJ I-UN
areA P08569680A0636 JJ I-UN
product P08569680A0636 NN I-UN
truncated P08569680A0636 VBD O
immediately P08569680A0636 RB O
after P08569680A0636 IN O
the P08569680A0636 DT O
last P08569680A0636 JJ O
residue P08569680A0636 NN O
of P08569680A0636 IN O
the P08569680A0636 DT O
highly P08569680A0636 RB O
conserved P08569680A0636 VBN O
GATA P08569680A0636 NNP I-UN
( P08569680A0636 ( I-UN
DNA-binding P08569680A0636 NNP I-UN
) P08569680A0636 ) I-UN
domain P08569680A0636 NN I-UN
retains P08569680A0636 VBZ O
partial P08569680A0636 JJ O
function P08569680A0636 NN O
. P08569680A0636 . O
. . O O

Transcriptional P08657157A0000 JJ O
regulators P08657157A0000 NNS O
utilizing P08657157A0000 VBG O
the P08657157A0000 DT O
POU P08657157A0000 NNP I-UN
domain P08657157A0000 NN I-UN
DNA-binding P08657157A0000 NNP I-UN
motif P08657157A0000 NN I-UN
have P08657157A0000 VBP O
been P08657157A0000 VBN O
shown P08657157A0000 VBN O
to P08657157A0000 TO O
form P08657157A0000 VB O
multi-protein P08657157A0000 JJ O
complexes P08657157A0000 NNS O
dependent P08657157A0000 NN O
on P08657157A0000 IN O
the P08657157A0000 DT O
POU P08657157A0000 NNP I-UN
domain P08657157A0000 NN I-UN
itself P08657157A0000 PRP O
and P08657157A0000 CC O
its P08657157A0000 PRP$ O
flexible P08657157A0000 JJ O
recognition P08657157A0000 NN O
of P08657157A0000 IN O
various P08657157A0000 JJ O
octamer P08657157A0000 JJ O
sequence P08657157A0000 NN O
elements P08657157A0000 NNS O
. P08657157A0000 . O
. . O O

These P07937841A0790 DT O
results P07937841A0790 NNS O
provide P07937841A0790 VBP O
evidence P07937841A0790 NN O
of P07937841A0790 IN O
a P07937841A0790 DT O
bypass P07937841A0790 NN O
of P07937841A0790 IN O
p53-induced P07937841A0790 JJ O
Waf1 P07937841A0790 NNP I-UN
/ P07937841A0790 NNP O
Cip1-mediated P07937841A0790 NNP O
cell P07937841A0790 NN O
cycle P07937841A0790 NN O
regulatory P07937841A0790 JJ O
pathways P07937841A0790 NNS O
by P07937841A0790 IN O
a P07937841A0790 DT O
member P07937841A0790 NN O
of P07937841A0790 IN O
the P07937841A0790 DT O
myb P07937841A0790 NN I-UN
oncogene P07937841A0790 JJ I-UN
family P07937841A0790 NN I-UN
. P07937841A0790 . O
. . O O

